The	O
Physiological	B-MED
Role	O
and	O
Regulation	B-MED
of	O
Aquaporins	B-MED
in	O
Teleost	B-MED
Germ	B-MED
Cells	I-MED
The	O
unicellular	O
germ	B-MED
cells	I-MED
and	O
gametes	B-MED
of	O
oviparous	B-MED
teleosts	B-MED
lack	O
the	O
osmoregulatory	B-MED
organs	B-MED
present	O
in	O
juveniles	B-MED
and	O
adults	B-MED
,	O
yet	O
during	O
development	B-MED
and	O
particularly	O
at	O
spawning	B-MED
,	O
they	O
face	O
tremendous	O
osmotic	B-MED
challenges	B-MED
when	O
released	O
into	O
the	O
external	B-MED
aquatic	B-MED
environment	I-MED
.	O
Increasing	O
evidence	O
suggests	O
that	O
transmembrane	B-MED
water	I-MED
channels	I-MED
(	O
aquaporins	B-MED
)	O
evolved	O
to	O
play	O
vital	O
adaptive	O
roles	O
that	O
mitigate	B-MED
the	O
osmotic	B-MED
and	O
oxidative	B-MED
stress	I-MED
problems	B-MED
of	O
the	O
developing	B-MED
oocytes	B-MED
,	O
embryos	B-MED
and	O
spermatozoa	B-MED
.	O
In	O
this	O
chapter	O
,	O
we	O
provide	O
a	O
short	O
overview	O
of	O
the	O
diversity	B-MED
of	O
the	O
aquaporin	B-MED
superfamily	O
in	O
teleosts	B-MED
,	O
and	O
summarize	O
the	O
findings	O
that	O
uncovered	O
a	O
highly	O
specific	O
molecular	B-MED
regulation	I-MED
of	O
aquaporins	B-MED
during	O
oogenesis	B-MED
and	O
spermatogenesis	B-MED
.	O
We	O
further	O
review	O
the	O
multiple	O
functions	O
that	O
these	O
channels	B-MED
play	O
during	O
the	O
establishment	O
of	O
egg	B-MED
buoyancy	B-MED
and	O
the	O
activation	B-MED
and	O
detoxification	B-MED
of	O
spermatozoa	B-MED
in	O
the	O
marine	B-MED
environment	B-MED
.	O
A	O
Double	B-MED
-	I-MED
Blind	I-MED
Randomized	B-MED
Controlled	I-MED
Trial	I-MED
of	O
Maternal	B-MED
Postpartum	I-MED
Deworming	B-MED
to	O
Improve	O
Infant	B-MED
Weight	B-MED
Gain	I-MED
in	O
the	O
Peruvian	B-MED
Amazon	O
Nutritional	B-MED
interventions	I-MED
targeting	O
the	O
critical	B-MED
growth	B-MED
and	I-MED
development	I-MED
period	I-MED
before	O
two	O
years	O
of	O
age	B-MED
can	O
have	O
the	O
greatest	O
impact	O
on	O
health	B-MED
trajectories	B-MED
over	O
the	O
life	B-MED
course	I-MED
.	O
Compelling	O
evidence	B-MED
has	O
demonstrated	O
that	O
interventions	B-MED
investing	O
in	O
maternal	B-MED
health	I-MED
in	O
the	O
first	O
1000	O
days	B-MED
of	O
life	B-MED
are	O
beneficial	O
for	O
both	O
mothers	B-MED
and	O
their	O
children	B-MED
.	O
One	O
such	O
potential	O
intervention	B-MED
is	O
deworming	B-MED
integrated	O
into	O
maternal	B-MED
postpartum	I-MED
care	I-MED
in	O
areas	B-MED
where	O
soil	B-MED
-	O
transmitted	B-MED
helminth	B-MED
(	O
STH	B-MED
)	O
infections	B-MED
are	O
endemic	B-MED
.	O
From	O
February	B-MED
to	O
August	B-MED
2014	O
,	O
1010	O
mother	B-MED
-	O
infant	B-MED
pairs	O
were	O
recruited	O
into	O
a	O
trial	B-MED
aimed	O
at	O
assessing	B-MED
the	O
effectiveness	B-MED
of	O
maternal	B-MED
postpartum	I-MED
deworming	B-MED
on	O
infant	B-MED
and	O
maternal	B-MED
health	I-MED
outcomes	B-MED
.	O
Following	B-MED
delivery	B-MED
,	O
mothers	B-MED
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
single-	O
dose	B-MED
400	O
mg	O
albendazole	B-MED
or	O
placebo	B-MED
.	O
Participants	B-MED
were	O
followed	B-MED
-	I-MED
up	I-MED
at	O
1	B-MED
and	O
6	B-MED
months	I-MED
postpartum	B-MED
.	O
There	O
was	O
no	B-MED
statistically	I-MED
significant	I-MED
difference	B-MED
in	O
mean	O
weight	B-MED
gain	I-MED
between	O
infants	B-MED
in	O
the	O
experimental	B-MED
and	O
control	B-MED
groups	I-MED
(	O
mean	B-MED
difference	I-MED
:	O
-0.02	O
;	O
95	O
%	O
CI	B-MED
:	O
-0.1	O
,	O
0.08	O
)	O
at	O
6	B-MED
months	I-MED
of	O
age	B-MED
.	O
Further	O
,	O
deworming	B-MED
had	O
no	B-MED
effect	I-MED
on	O
measured	O
infant	B-MED
morbidity	I-MED
indicators	B-MED
.	O
However	O
,	O
ad	B-MED
hoc	I-MED
analyses	I-MED
restricted	O
to	O
mothers	B-MED
who	O
tested	O
positive	B-MED
for	O
STHs	B-MED
at	O
baseline	B-MED
suggest	O
that	O
infants	B-MED
of	O
mothers	B-MED
in	O
the	O
experimental	O
group	O
had	O
greater	O
mean	O
length	B-MED
gain	B-MED
in	O
cm	O
(	O
mean	B-MED
difference	I-MED
:	O
0.8	O
;	O
95	O
%	O
CI	B-MED
:	O
0.1	O
,	O
1.4	O
)	O
and	O
length	B-MED
-	I-MED
for	I-MED
-	I-MED
age	I-MED
z	I-MED
-	I-MED
score	I-MED
(	O
mean	B-MED
difference	I-MED
:	O
0.5	O
;	O
95	O
%	O
CI	B-MED
:	O
0.2	O
,	O
0.8	O
)	O
at	O
6	B-MED
months	I-MED
of	O
age	B-MED
.	O
In	O
a	O
study	B-MED
population	I-MED
composed	O
of	O
both	O
STH	B-MED
-	I-MED
infected	I-MED
and	O
uninfected	B-MED
mothers	B-MED
,	O
maternal	B-MED
postpartum	I-MED
deworming	B-MED
was	O
insufficient	B-MED
to	O
impact	O
infant	B-MED
growth	B-MED
and	O
morbidity	B-MED
indicators	B-MED
up	O
to	O
6	B-MED
months	I-MED
postpartum	B-MED
.	O
Among	O
STH	B-MED
-	I-MED
infected	I-MED
mothers	B-MED
,	O
however	O
,	O
important	O
improvements	O
in	O
infant	B-MED
length	O
gain	O
and	O
length	B-MED
-	I-MED
for	I-MED
-	I-MED
age	I-MED
were	O
observed	O
.	O
The	O
benefits	O
of	O
maternal	B-MED
postpartum	I-MED
deworming	B-MED
should	O
be	O
further	O
investigated	O
in	O
study	B-MED
populations	I-MED
having	O
higher	O
overall	O
prevalences	B-MED
and	O
intensities	B-MED
of	O
STH	B-MED
infections	I-MED
and	O
,	O
in	O
particular	O
,	O
where	O
whipworm	B-MED
and	O
hookworm	B-MED
infections	I-MED
are	O
of	O
public	B-MED
health	I-MED
concern	I-MED
.	O
ClinicalTrials.gov	O
(	O
NCT01748929	O
)	O
.	O
Agglomeration	B-MED
of	O
Luminescent	B-MED
Porous	B-MED
Silicon	B-MED
Nanoparticles	B-MED
in	O
Colloidal	B-MED
Solutions	I-MED
We	O
have	O
prepared	B-MED
colloidal	B-MED
solutions	I-MED
of	O
clusters	B-MED
composed	O
from	O
porous	B-MED
silicon	B-MED
nanoparticles	B-MED
in	O
methanol	B-MED
,	O
water	B-MED
and	O
phosphate	B-MED
-	I-MED
buffered	I-MED
saline	I-MED
(	O
PBS	B-MED
)	O
.	O
Even	O
if	O
the	O
size	B-MED
of	O
the	O
nanoclusters	B-MED
is	O
between	O
60	O
and	O
500	O
nm	O
,	O
due	O
to	O
their	O
highly	B-MED
porous	B-MED
"	B-MED
cauliflower"-like	I-MED
structure	I-MED
,	O
the	O
porous	B-MED
silicon	B-MED
nanoparticles	B-MED
are	O
composed	O
of	O
interconnected	B-MED
nanocrystals	B-MED
having	O
around	O
2.5	O
nm	O
in	O
size	B-MED
and	O
showing	O
strong	B-MED
visible	B-MED
luminescence	B-MED
in	O
the	O
orange	B-MED
-	O
red	B-MED
spectral	B-MED
region	B-MED
(	O
centred	O
at	O
600	O
-	O
700	O
nm	O
)	O
.	O
Hydrophilic	B-MED
behaviour	I-MED
and	O
good	B-MED
solubility	B-MED
of	O
the	O
nanoclusters	B-MED
in	O
water	B-MED
and	O
water	B-MED
-	O
based	B-MED
solutions	B-MED
were	O
obtained	B-MED
by	O
adding	O
hydrogen	B-MED
peroxide	I-MED
into	O
the	O
etching	B-MED
solution	B-MED
during	O
preparation	B-MED
and	O
16	O
min	O
long	O
after	B-MED
-	I-MED
bath	I-MED
in	O
hydrogen	B-MED
peroxide	I-MED
.	O
By	O
simple	B-MED
filtration	B-MED
of	O
the	O
solutions	B-MED
with	O
syringe	B-MED
filters	I-MED
,	O
we	O
have	O
extracted	B-MED
smaller	B-MED
nanoclusters	B-MED
with	O
sizes	B-MED
of	O
approx	B-MED
.	O
60	O
-	O
70	O
nm	O
;	O
however	O
,	O
these	O
nanoclusters	B-MED
in	O
water	B-MED
and	O
PBS	B-MED
solution	I-MED
(	O
pH	B-MED
neutral	I-MED
)	O
are	O
prone	B-MED
to	O
agglomeration	B-MED
,	O
as	O
was	O
confirmed	B-MED
by	O
zeta	B-MED
potential	I-MED
measurements	B-MED
.	O
When	O
the	O
samples	B-MED
were	O
left	O
at	O
ambient	B-MED
conditions	I-MED
for	O
several	B-MED
weeks	O
,	O
the	O
typical	B-MED
nanocluster	B-MED
size	B-MED
increased	B-MED
to	O
approx	B-MED
.	O
330	O
-	O
400	O
nm	O
and	O
then	O
remained	O
stable	B-MED
.	O
However	O
,	O
both	O
freshly	B-MED
filtered	B-MED
and	O
aged	B-MED
samples	B-MED
(	O
with	O
agglomerated	B-MED
porous	B-MED
silicon	B-MED
nanoparticles	B-MED
)	O
of	O
porous	B-MED
silicon	B-MED
in	O
water	B-MED
and	O
PBS	B-MED
solutions	I-MED
can	O
be	O
further	O
used	O
for	O
biological	B-MED
studies	B-MED
or	O
as	O
luminescent	B-MED
markers	B-MED
in	O
living	B-MED
cells	I-MED
.	O
Strategies	B-MED
for	O
Successful	B-MED
Clinical	B-MED
Teaching	B-MED
This	O
article	B-MED
is	O
one	O
in	O
a	O
series	O
on	O
the	O
roles	B-MED
of	O
adjunct	B-MED
clinical	I-MED
faculty	I-MED
and	O
preceptors	B-MED
,	O
who	O
teach	B-MED
nursing	B-MED
students	I-MED
and	O
new	B-MED
graduates	B-MED
to	O
apply	B-MED
knowledge	B-MED
in	O
clinical	B-MED
settings	I-MED
.	O
This	O
article	B-MED
describes	O
teaching	B-MED
strategies	I-MED
as	O
well	O
as	O
the	O
importance	O
of	O
the	O
learning	B-MED
environment	I-MED
.	O
Is	O
Total	B-MED
Elbow	I-MED
Arthroplasty	I-MED
Safe	B-MED
as	O
an	O
Outpatient	B-MED
Procedure	I-MED
?	O
Ambulatory	B-MED
surgery	I-MED
centers	I-MED
are	O
the	O
preferred	B-MED
setting	I-MED
for	O
many	O
procedures	B-MED
formerly	O
performed	B-MED
in	O
a	O
hospital	B-MED
setting	B-MED
.	O
This	O
study	B-MED
sought	O
to	O
determine	O
whether	O
outpatient	B-MED
total	B-MED
elbow	I-MED
arthroplasty	I-MED
(	O
TEA	B-MED
)	O
is	O
as	O
safe	B-MED
as	O
inpatient	B-MED
TEA	B-MED
.	O
A	O
retrospective	B-MED
analysis	I-MED
was	O
performed	B-MED
of	O
inpatient	B-MED
(	O
IP	B-MED
)	O
versus	O
outpatient	B-MED
(	O
OP	B-MED
)	O
TEA	B-MED
by	O
a	O
single	B-MED
surgeon	B-MED
over	O
a	O
period	O
of	O
18	O
years	B-MED
.	O
Demographic	B-MED
,	O
social	B-MED
,	O
and	O
comorbidity	B-MED
measures	I-MED
as	O
well	O
as	O
complication	B-MED
rates	B-MED
were	O
analyzed	B-MED
and	O
stratified	B-MED
by	O
IP	B-MED
or	O
OP	B-MED
status	B-MED
.	O
Bivariate	B-MED
comparison	I-MED
showed	O
increased	B-MED
prevalence	B-MED
of	O
coronary	B-MED
artery	I-MED
disease	I-MED
in	O
the	O
OP	B-MED
group	B-MED
(	O
32	O
%	O
vs.	O
7	O
%	O
)	O
and	O
increased	B-MED
age	B-MED
in	O
the	O
IP	B-MED
group	B-MED
(	O
68	O
years	B-MED
vs.	O
58	O
years	B-MED
)	O
.	O
All	O
other	O
demographic	B-MED
,	O
social	B-MED
,	O
and	O
comorbidity	B-MED
factors	I-MED
were	O
comparable	B-MED
between	O
the	O
IP	B-MED
and	O
OP	B-MED
groups	B-MED
,	O
although	O
more	B-MED
infections	B-MED
were	O
seen	B-MED
in	O
the	O
IP	B-MED
group	B-MED
.	O
The	O
surgeons	B-MED
'	I-MED
initial	B-MED
learning	I-MED
curve	I-MED
occurred	B-MED
mostly	O
within	O
the	O
IP	B-MED
group	B-MED
.	O
Most	O
important	O
,	O
no	B-MED
difference	I-MED
in	O
complication	B-MED
rate	B-MED
was	O
observed	B-MED
between	O
the	O
IP	B-MED
and	O
OP	B-MED
groups	B-MED
.	O
Structural	B-MED
Basis	B-MED
for	O
Simvastatin	B-MED
Competitive	B-MED
Antagonism	I-MED
of	O
Complement	B-MED
Receptor	I-MED
3	I-MED
The	O
complement	B-MED
system	I-MED
is	O
an	O
important	O
part	O
of	O
the	O
innate	B-MED
immune	I-MED
response	I-MED
to	O
infection	B-MED
but	O
may	O
also	O
cause	O
severe	B-MED
complications	I-MED
during	O
inflammation	B-MED
.	O
Small	B-MED
molecule	I-MED
antagonists	B-MED
to	O
complement	B-MED
receptor	I-MED
3	I-MED
(	O
CR3	B-MED
)	O
have	O
been	O
widely	O
sought	O
,	O
but	O
a	O
structural	B-MED
basis	B-MED
for	O
their	O
mode	B-MED
of	I-MED
action	I-MED
is	O
not	O
available	O
.	O
We	O
report	B-MED
here	O
on	O
the	O
structure	B-MED
of	O
the	O
human	B-MED
CR3	B-MED
ligand	B-MED
-	I-MED
binding	I-MED
I	I-MED
domain	I-MED
in	O
complex	B-MED
with	O
simvastatin	B-MED
.	O
Simvastatin	B-MED
targets	B-MED
the	O
metal	B-MED
ion	B-MED
-	I-MED
dependent	I-MED
adhesion	B-MED
site	I-MED
of	O
the	O
open	O
,	O
ligand	B-MED
-	I-MED
binding	I-MED
conformation	B-MED
of	O
the	O
CR3	B-MED
I	B-MED
domain	I-MED
by	O
direct	O
contact	B-MED
with	I-MED
the	O
chelated	B-MED
Mg(2	I-MED
+	I-MED
)	I-MED
ion	I-MED
.	O
Simvastatin	B-MED
antagonizes	B-MED
I	B-MED
domain	I-MED
binding	I-MED
to	O
the	O
complement	B-MED
fragments	I-MED
iC3b	B-MED
and	O
C3d	B-MED
but	O
not	O
to	O
intercellular	B-MED
adhesion	I-MED
molecule-1	I-MED
.	O
By	O
virtue	B-MED
of	O
the	O
I	B-MED
domain	I-MED
's	I-MED
wide	O
distribution	B-MED
in	O
binding	B-MED
kinetics	I-MED
to	O
ligands	B-MED
,	O
it	O
was	O
possible	B-MED
to	O
identify	O
ligand	B-MED
binding	I-MED
kinetics	B-MED
as	O
discriminator	O
for	O
simvastatin	B-MED
antagonism	B-MED
.	O
In	O
static	B-MED
cellular	B-MED
experiments	B-MED
,	O
15	O
-	O
25	O
μm	O
simvastatin	B-MED
reduced	B-MED
adhesion	B-MED
by	O
K562	B-MED
cells	I-MED
expressing	B-MED
recombinant	B-MED
CR3	B-MED
and	O
by	O
primary	B-MED
human	B-MED
monocytes	B-MED
,	O
with	O
an	O
endogenous	B-MED
expression	B-MED
of	O
this	O
receptor	B-MED
.	O
Application	B-MED
of	O
force	B-MED
to	O
adhering	B-MED
monocytes	B-MED
potentiated	O
the	O
effects	B-MED
of	I-MED
simvastatin	B-MED
where	O
only	O
a	O
50	O
-	O
100	O
nm	O
concentration	B-MED
of	O
the	O
drug	B-MED
reduced	B-MED
the	O
adhesion	B-MED
by	O
20	O
-	O
40	O
%	O
compared	B-MED
with	O
untreated	B-MED
cells	B-MED
.	O
The	O
ability	B-MED
of	O
simvastatin	B-MED
to	O
target	B-MED
CR3	B-MED
in	O
its	O
ligand	B-MED
binding	I-MED
-	O
activated	B-MED
conformation	B-MED
is	O
a	O
novel	B-MED
mechanism	B-MED
to	O
explain	O
the	O
known	O
anti	B-MED
-	I-MED
inflammatory	I-MED
effects	I-MED
of	O
this	O
compound	B-MED
,	O
in	O
particular	O
because	O
this	O
CR3	B-MED
conformation	B-MED
is	O
found	O
in	O
pro	B-MED
-	I-MED
inflammatory	I-MED
environments	B-MED
.	O
Our	O
report	B-MED
points	O
to	O
new	O
designs	B-MED
of	O
CR3	B-MED
antagonists	B-MED
and	O
opens	O
new	O
perspectives	O
and	O
identifies	B-MED
druggable	B-MED
receptors	B-MED
from	O
characterization	B-MED
of	O
the	O
ligand	B-MED
binding	I-MED
kinetics	B-MED
in	O
the	O
presence	B-MED
of	O
antagonists	B-MED
.	O
Network	B-MED
analysis	B-MED
reveals	B-MED
why	O
Xylella	B-MED
fastidiosa	I-MED
will	O
persist	O
in	O
Europe	B-MED
The	O
insect	B-MED
vector	I-MED
borne	O
bacterium	B-MED
Xylella	B-MED
fastidiosa	I-MED
was	O
first	O
detected	O
in	O
olive	B-MED
trees	I-MED
in	O
Southern	B-MED
Italy	I-MED
in	O
2013	O
,	O
and	O
identified	O
as	O
the	O
main	O
culprit	O
behind	O
the	O
'	O
olive	B-MED
quick	I-MED
decline	I-MED
syndrome	I-MED
'	O
.	O
Since	O
then	O
,	O
the	O
disease	B-MED
has	O
spread	O
rapidly	O
through	O
Italy	B-MED
's	I-MED
main	O
olive	B-MED
oil	I-MED
producing	O
region	B-MED
.	O
The	O
epidemiology	B-MED
of	O
the	O
outbreak	B-MED
is	O
largely	O
unstudied	O
,	O
with	O
the	O
list	O
of	O
X.	B-MED
fastidiosa	I-MED
hosts	B-MED
and	O
vectors	B-MED
in	O
Europe	B-MED
likely	O
incomplete	O
,	O
and	O
the	O
role	O
humans	B-MED
play	O
in	O
dispersal	B-MED
unknown	B-MED
.	O
These	O
knowledge	B-MED
gaps	B-MED
have	O
led	O
to	O
management	B-MED
strategies	I-MED
based	O
on	O
general	O
assumptions	O
that	O
require	O
,	O
among	O
others	O
,	O
local	O
vector	B-MED
control	I-MED
and	O
,	O
in	O
certain	O
areas	B-MED
,	O
the	O
destruction	B-MED
of	O
infected	B-MED
plants	I-MED
and	O
healthy	B-MED
ones	O
around	O
them	O
in	O
an	O
attempt	O
to	O
eradicate	B-MED
or	O
halt	B-MED
the	O
spreading	B-MED
pest	B-MED
.	O
Here	O
we	O
show	O
that	O
,	O
regardless	O
of	O
epidemiological	B-MED
uncertainties	B-MED
,	O
the	O
mere	O
distribution	O
of	O
olive	B-MED
olive	B-MED
orchards	I-MED
in	O
Southern	B-MED
Italy	I-MED
makes	O
the	O
chances	O
of	O
eradicating	B-MED
X.	B-MED
fastidiosa	I-MED
from	O
the	O
region	B-MED
extremely	O
slim	O
.	O
Our	O
results	B-MED
imply	O
that	O
Southern	B-MED
Italy	I-MED
is	O
becoming	O
a	O
reservoir	B-MED
for	O
X.	B-MED
fastidiosa	I-MED
.	O
As	O
a	O
consequence	O
,	O
management	B-MED
strategies	I-MED
should	O
keep	O
the	O
prevalence	B-MED
of	O
X.	B-MED
fastidiosa	I-MED
in	O
the	O
region	B-MED
as	O
low	O
as	O
possible	O
,	O
primarily	O
through	O
vector	B-MED
control	I-MED
,	O
lest	B-MED
the	O
pathogen	B-MED
,	O
that	O
has	O
also	O
been	O
detected	O
in	O
southern	B-MED
France	I-MED
and	O
the	O
island	B-MED
of	I-MED
Mallorca	I-MED
(	O
Spain	B-MED
)	O
,	O
continues	O
spreading	B-MED
through	O
Italy	B-MED
and	O
Europe	B-MED
.	O
Effect	B-MED
of	O
constitutive	B-MED
inactivation	I-MED
of	O
the	O
myostatin	B-MED
gene	I-MED
on	O
the	O
gain	B-MED
in	O
muscle	B-MED
strength	I-MED
during	O
postnatal	B-MED
growth	I-MED
in	O
two	O
murine	B-MED
models	B-MED
The	O
effect	B-MED
of	O
constitutive	B-MED
inactivation	I-MED
of	O
the	O
gene	B-MED
encoding	I-MED
myostatin	I-MED
on	O
the	O
gain	B-MED
in	O
muscle	B-MED
performance	I-MED
during	O
postnatal	B-MED
growth	I-MED
has	O
not	O
been	O
well	O
characterized	O
.	O
We	O
analyzed	O
2	O
murine	B-MED
myostatin	B-MED
knockout	B-MED
(	I-MED
KO	I-MED
)	I-MED
models	I-MED
,	O
(	O
i	O
)	O
the	O
Lee	B-MED
model	I-MED
(	O
KO(Lee	B-MED
)	O
)	O
and	O
(	O
ii	O
)	O
the	O
Grobet	B-MED
model	I-MED
(	O
KO(Grobet	B-MED
)	I-MED
)	O
,	O
and	O
measured	B-MED
the	O
contraction	B-MED
of	O
tibialis	B-MED
anterior	I-MED
muscle	I-MED
in	B-MED
situ	I-MED
.	O
Absolute	B-MED
maximal	I-MED
isometric	I-MED
force	I-MED
was	O
increased	B-MED
in	O
6	O
-	O
month	O
-	O
old	O
KO(Lee	B-MED
)	I-MED
and	O
KO(Grobet	B-MED
)	I-MED
mice	I-MED
,	O
as	O
compared	B-MED
to	O
wild	B-MED
-	I-MED
type	I-MED
mice	I-MED
.	O
Similarly	O
,	O
absolute	B-MED
maximal	I-MED
power	I-MED
was	O
increased	B-MED
in	O
6	O
-	O
month	O
-	O
old	O
KO(Lee	B-MED
)	I-MED
mice	I-MED
.	O
In	O
contrast	O
,	O
specific	B-MED
maximal	B-MED
force	I-MED
(	O
relative	B-MED
maximal	B-MED
force	I-MED
per	O
unit	O
of	O
muscle	B-MED
mass	B-MED
was	O
decreased	B-MED
in	O
all	O
6	O
-	O
month	O
-	O
old	O
male	B-MED
and	O
female	B-MED
KO	B-MED
mice	I-MED
,	O
except	B-MED
in	O
6	B-MED
-	I-MED
month	I-MED
-old	O
female	B-MED
KO(Grobet	B-MED
)	I-MED
mice	I-MED
,	O
whereas	O
specific	B-MED
maximal	B-MED
power	I-MED
was	O
reduced	B-MED
only	O
in	O
male	B-MED
KO(Lee	B-MED
)	I-MED
mice	I-MED
.	O
Genetic	B-MED
inactivation	I-MED
of	O
myostatin	B-MED
increases	B-MED
maximal	B-MED
force	I-MED
and	O
power	B-MED
,	O
but	O
in	O
return	B-MED
it	O
reduces	B-MED
muscle	B-MED
quality	B-MED
,	O
particularly	O
in	O
male	B-MED
mice	B-MED
.	O
Muscle	O
Nerve	O
55	O
:	O
254	O
-	O
261	O
,	O
2017	O
.	O
Concordant	O
but	O
Varied	O
Phenotypes	B-MED
among	O
Duchenne	B-MED
Muscular	I-MED
Dystrophy	I-MED
Patient	B-MED
-Specific	O
Myoblasts	B-MED
Derived	O
using	O
a	O
Human	B-MED
iPSC	B-MED
-Based	O
Model	B-MED
Duchenne	B-MED
muscular	I-MED
dystrophy	I-MED
(	O
DMD	B-MED
)	O
remains	O
an	O
intractable	O
genetic	B-MED
disease	I-MED
.	O
Althogh	O
there	O
are	O
several	O
animal	B-MED
models	I-MED
of	O
DMD	B-MED
,	O
there	O
is	O
no	O
human	B-MED
cell	I-MED
model	O
that	O
carries	O
patient	B-MED
-specific	O
DYSTROPHIN	B-MED
mutations	B-MED
.	O
Here	O
,	O
we	O
present	O
a	O
human	B-MED
DMD	B-MED
model	B-MED
using	O
human	B-MED
induced	I-MED
pluripotent	I-MED
stem	I-MED
cells	I-MED
(	O
hiPSCs	B-MED
)	O
.	O
Our	O
model	O
reveals	O
concordant	O
disease	B-MED
-	O
related	B-MED
phenotypes	B-MED
with	O
patient	B-MED
-	O
dependent	B-MED
variation	B-MED
,	O
which	O
are	O
partially	O
reversed	O
by	O
genetic	B-MED
and	O
pharmacological	B-MED
approaches	O
.	O
Our	O
"	O
chemical	B-MED
-	I-MED
compound	I-MED
-based	O
"	O
strategy	B-MED
successfully	O
directs	O
hiPSCs	B-MED
into	O
expandable	O
myoblasts	B-MED
,	O
which	O
exhibit	O
a	O
myogenic	B-MED
transcriptional	I-MED
program	B-MED
,	O
forming	O
striated	B-MED
contractile	B-MED
myofibers	B-MED
and	O
participating	O
in	O
muscle	B-MED
regeneration	I-MED
in	B-MED
vivo	I-MED
.	O
DMD	B-MED
-	O
hiPSC	B-MED
-derived	O
myoblasts	B-MED
show	O
disease	B-MED
-	O
related	B-MED
phenotypes	B-MED
with	O
patient	B-MED
-to-	O
patient	B-MED
variability	B-MED
,	O
including	O
aberrant	B-MED
expression	O
of	O
inflammation	B-MED
or	O
immune	B-MED
-	I-MED
response	I-MED
genes	I-MED
and	O
collagens	B-MED
,	O
increased	O
BMP	B-MED
/	O
TGFβ	B-MED
signaling	I-MED
,	O
and	O
reduced	O
fusion	O
competence	O
.	O
Furthermore	O
,	O
by	O
genetic	B-MED
correction	B-MED
and	O
pharmacological	B-MED
"	O
dual-	O
SMAD	B-MED
"	O
inhibition	B-MED
,	O
the	O
DMD	B-MED
-	O
hiPSC	B-MED
-derived	O
myoblasts	B-MED
and	O
genetically	B-MED
corrected	O
isogenic	B-MED
myoblasts	B-MED
form	O
"	O
rescued	O
"	O
multi	B-MED
-	O
nucleated	B-MED
myotubes	B-MED
.	O
In	O
conclusion	O
,	O
our	O
findings	O
demonstrate	O
the	O
feasibility	O
of	O
establishing	O
a	O
human	B-MED
"	O
DMD	B-MED
-in	O
-	O
a	O
-	O
dish	O
"	O
model	B-MED
using	O
hiPSC	B-MED
-based	O
disease	B-MED
modeling	I-MED
.	O
Effects	O
of	O
Binge	B-MED
-	I-MED
Like	I-MED
Ethanol	B-MED
Exposure	I-MED
During	O
Adolescence	B-MED
on	O
the	O
Febrile	B-MED
Response	B-MED
in	O
Rats	B-MED
Ethanol	B-MED
(	I-MED
EtOH	I-MED
)	I-MED
exposure	I-MED
during	O
different	O
phases	B-MED
of	O
life	B-MED
may	O
increase	O
the	O
risk	B-MED
of	I-MED
infections	I-MED
and	O
cause	O
alterations	B-MED
in	O
the	O
central	B-MED
nervous	I-MED
system	I-MED
.	O
The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
binge	B-MED
-	I-MED
like	I-MED
EtOH	B-MED
exposure	I-MED
in	O
adolescent	B-MED
rats	B-MED
on	O
the	O
febrile	B-MED
response	B-MED
that	O
was	O
induced	O
by	O
lipopolysaccharide	B-MED
(	O
LPS	B-MED
)	O
and	O
interleukin-1β	B-MED
(	O
IL-1β	B-MED
)	O
.	O
Male	O
rats	B-MED
were	O
exposed	B-MED
to	I-MED
EtOH	I-MED
from	O
postnatal	B-MED
days	I-MED
25	O
to	O
38	O
in	O
a	O
binge	B-MED
-	I-MED
like	I-MED
pattern	O
.	O
Fever	B-MED
was	O
induced	O
by	O
LPS	B-MED
(	O
5	O
and	O
50	O
μg	O
/	O
kg	O
,	O
intraperitoneally	B-MED
)	O
and	O
evaluated	O
on	O
postnatal	B-MED
days	I-MED
51	O
and	O
63	O
,	O
or	O
by	O
IL	B-MED
-	I-MED
β	I-MED
(	O
3	O
ng	O
)	O
and	O
evaluated	O
on	O
postnatal	B-MED
day	I-MED
51	O
.	O
Hematological	B-MED
parameters	O
,	O
the	O
status	O
of	O
peritoneal	B-MED
macrophages	I-MED
,	O
and	O
plasma	B-MED
and	O
cerebrospinal	B-MED
IL-1β	B-MED
levels	B-MED
were	O
also	O
evaluated	O
on	O
postnatal	B-MED
day	I-MED
51	O
.	O
EtOH	B-MED
exposure	I-MED
during	O
adolescence	B-MED
did	O
not	O
alter	O
normal	B-MED
body	I-MED
temperature	I-MED
.	O
However	O
,	O
a	O
significant	O
reduction	O
in	O
the	O
febrile	B-MED
response	B-MED
that	O
was	O
induced	O
by	O
LPS	B-MED
at	O
both	O
doses	O
was	O
observed	O
on	O
postnatal	B-MED
day	O
51	O
.	O
However	O
,	O
no	O
changes	O
in	O
the	O
febrile	B-MED
response	B-MED
were	O
observed	O
on	O
postnatal	B-MED
day	I-MED
63	O
in	O
EtOH	B-MED
-	I-MED
exposed	I-MED
animals	B-MED
.	O
The	O
febrile	B-MED
response	B-MED
that	O
was	O
induced	O
by	O
intracerebroventricular	B-MED
IL-1β	B-MED
also	O
significantly	O
decreased	O
in	O
animals	B-MED
that	O
received	O
binge	B-MED
-	I-MED
like	I-MED
EtOH	B-MED
exposure	I-MED
during	O
adolescence	B-MED
.	O
Acute	B-MED
oral	I-MED
treatment	I-MED
with	O
EtOH	B-MED
24	O
h	O
prior	O
to	O
LPS	B-MED
administration	B-MED
did	O
not	O
alter	O
the	O
febrile	B-MED
response	B-MED
that	O
was	O
induced	O
by	O
LPS	B-MED
.	O
Binge	B-MED
-	I-MED
like	I-MED
EtOH	B-MED
exposure	I-MED
during	O
adolescence	B-MED
did	O
not	O
alter	O
hematological	B-MED
parameters	O
or	O
the	O
number	O
or	O
viability	B-MED
of	O
peritoneal	B-MED
macrophages	I-MED
.	O
Binge	B-MED
-	I-MED
like	I-MED
EtOH	B-MED
exposure	I-MED
did	O
not	O
alter	O
plasma	B-MED
IL-1β	B-MED
levels	B-MED
but	O
reduced	O
the	O
cerebrospinal	B-MED
fluid	I-MED
levels	B-MED
of	O
this	O
cytokine	B-MED
.	O
These	O
results	O
suggest	O
that	O
binge	B-MED
-	I-MED
like	I-MED
EtOH	B-MED
exposure	I-MED
during	O
adolescence	B-MED
causes	O
changes	O
in	O
the	O
central	B-MED
nervous	I-MED
system	I-MED
that	O
can	O
impair	O
the	O
febrile	B-MED
response	B-MED
that	O
can	O
be	O
observed	O
after	O
the	O
cessation	B-MED
of	O
EtOH	B-MED
exposure	I-MED
.	O
These	O
changes	O
were	O
reversible	O
and	O
appeared	O
to	O
involve	O
the	O
LPS	B-MED
/	O
IL-1β	B-MED
system	O
.	O
Advanced	B-MED
interlocking	B-MED
systems	I-MED
to	O
improve	B-MED
heavy	B-MED
-	O
load	B-MED
-	I-MED
bearing	I-MED
characteristics	B-MED
of	O
flexible	B-MED
intramedullary	B-MED
nailing	I-MED
Flexible	B-MED
intramedullary	B-MED
nailing	I-MED
(	O
FIN	B-MED
)	O
is	O
a	O
minimally	B-MED
invasive	I-MED
and	O
widespread	B-MED
standard	B-MED
method	B-MED
for	O
osteosynthesis	B-MED
of	O
pediatric	B-MED
long	B-MED
bone	I-MED
fractures	I-MED
.	O
In	O
the	O
case	O
of	O
unstable	B-MED
fractures	I-MED
of	O
the	O
lower	B-MED
extremity	I-MED
,	O
interlocking	B-MED
systems	I-MED
need	O
to	O
be	O
used	O
to	O
prevent	O
axial	B-MED
shortening	B-MED
and	O
subsequent	B-MED
perforation	B-MED
of	O
the	O
nail	B-MED
at	O
its	O
insertion	B-MED
site	I-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
four	O
different	O
screw	B-MED
-fixed	O
interlocking	B-MED
systems	I-MED
for	O
FINs	B-MED
(	O
Hofer	B-MED
TwinPlug	I-MED
with	O
two	O
3	O
-	O
mm	O
titanium	B-MED
interlocking	B-MED
screws	I-MED
,	O
Hofer	B-MED
FixPlug	I-MED
with	O
3	O
-	O
mm	O
titanium	B-MED
interlocking	B-MED
screw	I-MED
,	O
Hofer	B-MED
Plug	I-MED
with	O
3.5	O
-	O
mm	O
titanium	B-MED
interlocking	B-MED
screw	I-MED
,	O
and	O
Hofer	B-MED
Plug	I-MED
with	O
3	O
-	O
mm	O
titanium	B-MED
interlocking	B-MED
screw	I-MED
)	O
in	O
comparison	B-MED
with	O
the	O
commonly	O
used	O
Ender	O
stainless	B-MED
steel	I-MED
nails	B-MED
(	O
locked	O
with	O
3.5	O
-	O
mm	O
screw	B-MED
)	O
were	O
experimentally	B-MED
investigated	I-MED
in	O
cadaveric	B-MED
lamb	B-MED
tibiae	B-MED
,	O
regarding	O
their	O
load	B-MED
characteristics	B-MED
and	O
failure	B-MED
modes	B-MED
in	O
the	O
case	O
of	O
heavy	B-MED
loading	B-MED
.	O
The	O
specimens	B-MED
were	O
subjected	O
to	O
sequential	B-MED
axial	B-MED
cyclic	B-MED
loading	B-MED
of	O
5000	O
cycles	B-MED
with	O
stepwise	B-MED
increase	I-MED
of	O
the	O
load	B-MED
amplitude	B-MED
until	O
failure	B-MED
.	O
Migration	B-MED
of	O
locking	B-MED
screws	I-MED
and	O
internal	B-MED
damage	B-MED
of	O
bone	B-MED
tissue	I-MED
was	O
quantified	O
by	O
micro	B-MED
-	I-MED
computed	I-MED
tomography	I-MED
(	I-MED
CT	I-MED
)	I-MED
imaging	I-MED
.	O
Ender	B-MED
nails	I-MED
failed	B-MED
on	O
average	B-MED
at	O
a	O
peak	B-MED
load	B-MED
of	O
800	O
N	O
,	O
TwinPlugs	B-MED
at	O
1367	O
N	O
,	O
FixPlugs	B-MED
at	O
1222	O
N	O
,	O
Plugs	B-MED
3.5	O
mm	O
at	O
1225	O
N	O
and	O
Plugs	B-MED
3.0	O
mm	O
at	O
971	O
N.	O
TwinPlugs	B-MED
,	O
FixPlugs	B-MED
,	O
and	O
Plugs	B-MED
3.5	O
mm	O
failed	B-MED
in	O
a	O
slow	O
manner	O
over	O
several	O
hundred	O
loading	B-MED
cycles	B-MED
,	O
whereas	O
Ender	B-MED
nails	I-MED
and	O
Plugs	B-MED
3.0	O
mm	O
exhibited	O
abrupt	B-MED
failure	B-MED
without	O
any	O
prior	B-MED
indication	B-MED
.	O
Our	O
results	O
confirm	O
that	O
axial	B-MED
stability	B-MED
of	O
FIN	B-MED
can	O
be	O
further	O
improved	B-MED
by	O
screw	B-MED
-fixed	O
plugs	B-MED
by	O
simultaneously	B-MED
avoiding	O
shortcomings	O
of	O
an	O
eye	B-MED
-	I-MED
locked	I-MED
system	I-MED
,	O
which	O
the	O
Ender	B-MED
nails	I-MED
are	O
.	O
Considering	O
biomechanical	B-MED
results	B-MED
,	O
plug	B-MED
interlocking	B-MED
systems	I-MED
with	O
3.5	O
-	O
mm	O
screws	B-MED
should	O
be	O
favored	O
over	O
conventional	B-MED
Ender	B-MED
nails	I-MED
and	O
plugs	B-MED
with	O
3	O
-	O
mm	O
screws	B-MED
.	O
FGF21	B-MED
is	O
a	O
biomarker	B-MED
for	O
mitochondrial	B-MED
translation	I-MED
and	O
mtDNA	B-MED
maintenance	B-MED
disorders	B-MED
To	O
validate	O
new	O
mitochondrial	B-MED
myopathy	I-MED
serum	B-MED
biomarkers	B-MED
for	O
diagnostic	B-MED
use	I-MED
.	O
We	O
analyzed	B-MED
serum	B-MED
FGF21	B-MED
(	O
S	B-MED
-	I-MED
FGF21	I-MED
)	O
and	O
GDF15	B-MED
from	O
patients	B-MED
with	O
(	O
1	O
)	O
mitochondrial	B-MED
diseases	I-MED
and	O
(	O
2	O
)	O
nonmitochondrial	B-MED
disorders	I-MED
partially	B-MED
overlapping	B-MED
with	O
mitochondrial	B-MED
disorder	I-MED
phenotypes	B-MED
.	O
We	O
(	O
3	O
)	O
did	O
a	O
meta	B-MED
-	I-MED
analysis	I-MED
of	O
S	B-MED
-	I-MED
FGF21	I-MED
in	O
mitochondrial	B-MED
disease	I-MED
and	O
(	O
4	O
)	O
analyzed	B-MED
S	B-MED
-	I-MED
Fgf21	I-MED
and	O
skeletal	B-MED
muscle	I-MED
Fgf21	B-MED
expression	B-MED
in	O
6	O
mouse	B-MED
models	B-MED
with	O
different	B-MED
muscle	B-MED
-	O
manifesting	B-MED
mitochondrial	B-MED
dysfunctions	I-MED
.	O
We	O
report	O
that	O
S	B-MED
-	I-MED
FGF21	I-MED
consistently	O
increases	B-MED
in	O
primary	B-MED
mitochondrial	B-MED
myopathy	I-MED
,	O
especially	O
in	O
patients	B-MED
with	O
mitochondrial	B-MED
translation	I-MED
defects	B-MED
or	O
mitochondrial	B-MED
DNA	I-MED
(	I-MED
mtDNA	I-MED
)	I-MED
deletions	I-MED
(	O
675	O
and	O
347	O
pg	O
/	O
mL	O
,	O
respectively	O
;	O
controls	B-MED
:	O
66	O
pg	O
/	O
mL	O
,	O
p	O
<	O
0.0001	O
for	O
both	O
)	O
.	O
This	O
is	O
corroborated	O
in	O
mice	B-MED
(	O
mtDNA	B-MED
deletions	I-MED
1,163	O
vs	O
379	O
pg	O
/	O
mL	O
,	O
p	O
<	O
0.0001	O
)	O
.	O
However	O
,	O
patients	B-MED
and	O
mice	B-MED
with	O
structural	B-MED
respiratory	I-MED
chain	I-MED
subunit	I-MED
or	I-MED
assembly	I-MED
factor	I-MED
defects	I-MED
showed	O
low	B-MED
induction	B-MED
(	O
human	B-MED
335	O
pg	O
/	O
mL	O
,	O
p	O
<	O
0.05	O
;	O
mice	B-MED
335	O
pg	O
/	O
mL	O
,	O
not	B-MED
significant	I-MED
)	O
.	O
Overall	B-MED
specificities	B-MED
of	O
FGF21	B-MED
and	O
GDF15	B-MED
to	O
find	O
patients	B-MED
with	O
mitochondrial	B-MED
myopathy	I-MED
were	O
89.3	O
%	O
vs	O
86.4	O
%	O
,	O
and	O
sensitivities	B-MED
67.3	O
%	O
and	O
76.0	O
%	O
,	O
respectively	O
.	O
However	O
,	O
GDF15	B-MED
was	O
increased	B-MED
also	O
in	O
a	O
wide	O
range	O
of	O
nonmitochondrial	B-MED
conditions	I-MED
.	O
S	B-MED
-	I-MED
FGF21	I-MED
is	O
a	O
specific	B-MED
biomarker	B-MED
for	O
muscle	B-MED
-	O
manifesting	B-MED
defects	B-MED
of	O
mitochondrial	B-MED
translation	I-MED
,	O
including	O
mitochondrial	B-MED
transfer	B-MED
-	I-MED
RNA	I-MED
mutations	B-MED
and	O
primary	B-MED
and	O
secondary	B-MED
mtDNA	B-MED
deletions	I-MED
,	O
the	O
most	O
common	O
causes	B-MED
of	O
mitochondrial	B-MED
disease	I-MED
.	O
However	O
,	O
normal	B-MED
S	B-MED
-	I-MED
FGF21	I-MED
does	O
not	B-MED
exclude	B-MED
structural	B-MED
respiratory	I-MED
chain	I-MED
complex	I-MED
or	I-MED
assembly	I-MED
factor	I-MED
defects	I-MED
,	O
important	O
to	O
acknowledge	O
in	O
diagnostics	B-MED
.	O
This	O
study	B-MED
provides	O
Class	B-MED
III	I-MED
evidence	B-MED
that	O
elevated	B-MED
S	B-MED
-	I-MED
FGF21	I-MED
accurately	O
distinguishes	O
patients	B-MED
with	O
mitochondrial	B-MED
myopathies	I-MED
from	O
patients	B-MED
with	O
other	O
conditions	B-MED
,	O
and	O
FGF21	B-MED
and	O
GDF15	B-MED
mitochondrial	B-MED
myopathy	I-MED
from	O
other	O
myopathies	B-MED
.	O
Habitual	B-MED
physical	I-MED
activity	I-MED
is	O
associated	B-MED
with	I-MED
improved	O
anthropometric	B-MED
and	O
androgenic	B-MED
profile	B-MED
in	O
PCOS	B-MED
:	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
To	O
examine	O
the	O
effect	B-MED
of	O
habitual	B-MED
physical	I-MED
activity	I-MED
(	O
PA	B-MED
)	O
on	O
the	O
metabolic	B-MED
and	O
hormonal	B-MED
profiles	I-MED
of	O
women	B-MED
with	O
polycystic	B-MED
ovary	I-MED
syndrome	I-MED
.	O
Anthropometric	B-MED
,	O
metabolic	B-MED
and	O
hormonal	B-MED
assessment	I-MED
and	O
determination	O
of	O
habitual	B-MED
PA	I-MED
levels	O
with	O
a	O
digital	B-MED
pedometer	I-MED
were	O
evaluated	O
in	O
84	O
women	B-MED
with	O
PCOS	B-MED
and	O
67	O
age-	O
and	O
body	B-MED
mass	I-MED
index	I-MED
BMI	B-MED
(	O
BMI)-matched	O
controls	B-MED
.	O
PA	B-MED
status	O
was	O
defined	O
according	O
to	O
number	B-MED
of	I-MED
steps	I-MED
(	O
≥7500	O
steps	O
,	O
active	O
,	O
or	O
<	O
7500	O
steps	O
,	O
sedentary	B-MED
)	O
.	O
BMI	B-MED
was	O
lower	O
in	O
active	O
women	B-MED
from	O
both	O
groups	O
.	O
Active	O
PCOS	B-MED
women	B-MED
presented	O
lower	O
waist	B-MED
circumference	I-MED
(	O
WC	B-MED
)	O
and	O
lipid	B-MED
accumulation	I-MED
product	I-MED
(	O
LAP	B-MED
)	O
values	O
versus	O
sedentary	B-MED
PCOS	B-MED
women	B-MED
.	O
In	O
the	O
control	B-MED
group	I-MED
,	O
active	O
women	B-MED
also	O
had	O
lower	O
WC	B-MED
,	O
lower	O
values	O
for	O
fasting	O
and	O
120	O
-	O
min	O
insulin	B-MED
,	O
and	O
lower	O
LAP	B-MED
than	O
sedentary	B-MED
controls	I-MED
.	O
In	O
the	O
PCOS	B-MED
group	O
,	O
androgen	B-MED
levels	O
were	O
lower	O
in	O
active	O
versus	O
sedentary	B-MED
women	I-MED
(	O
p	O
=	O
0.001	O
)	O
.	O
In	O
the	O
control	B-MED
group	I-MED
,	O
free	B-MED
androgen	I-MED
index	I-MED
(	O
FAI	B-MED
)	O
was	O
also	O
lower	O
in	O
active	O
versus	O
sedentary	B-MED
women	I-MED
(	O
p	O
=	O
0.018	O
)	O
.	O
Homeostasis	B-MED
model	I-MED
assessment	I-MED
of	O
insulin	B-MED
resistance	I-MED
and	O
2000	O
daily	O
step	O
increments	O
were	O
independent	O
predictors	B-MED
of	O
FAI	B-MED
.	O
Each	O
2000	O
daily	O
step	O
increment	O
was	O
associated	B-MED
with	I-MED
a	O
decrease	O
of	O
1.07	O
in	O
FAI	B-MED
.	O
Habitual	B-MED
PA	I-MED
was	O
associated	B-MED
with	I-MED
a	O
better	O
anthropometric	B-MED
and	O
androgenic	B-MED
profile	B-MED
in	O
PCOS	B-MED
.	O
New	B-MED
metabolites	B-MED
from	O
the	O
sponge	B-MED
-derived	O
fungus	B-MED
Aspergillus	B-MED
sydowii	I-MED
J05B-7F-4	I-MED
Two	O
new	B-MED
metabolites	B-MED
,	O
diorcinolic	B-MED
acid	I-MED
(	O
1	O
)	O
and	O
β	B-MED
-	I-MED
d	I-MED
-	I-MED
glucopyranosyl	I-MED
aspergillusene	I-MED
A	I-MED
(	O
8)	O
,	O
together	O
with	O
six	O
diphenylethers	B-MED
(	O
2	O
-	O
7	O
)	O
,	O
a	O
diketopiperazine	B-MED
(	O
9	O
)	O
,	O
a	O
chromone	B-MED
(	O
10	O
)	O
and	O
a	O
xanthone	B-MED
(	O
11	O
)	O
were	O
isolated	B-MED
from	O
the	O
fungus	B-MED
Aspergillus	B-MED
sydowii	I-MED
derived	O
from	O
the	O
marine	B-MED
sponge	I-MED
Stelletta	B-MED
sp	I-MED
.	O
The	O
planar	O
structures	O
and	O
their	O
relative	O
configurations	B-MED
were	O
elucidated	O
by	O
analysing	O
1D	B-MED
,	I-MED
2D	I-MED
NMR	I-MED
and	O
HRESIMS	B-MED
data	B-MED
.	O
Compound	B-MED
8	O
is	O
the	O
first	O
glycoside	B-MED
of	O
phenolic	B-MED
bisabolane	B-MED
sesquiterpenes	I-MED
.	O
Compounds	B-MED
1	I-MED
and	I-MED
8	I-MED
exhibited	O
mild	B-MED
cytotoxicity	B-MED
against	O
KB	B-MED
(	O
human	B-MED
nasopharyngeal	I-MED
carcinoma	I-MED
cells	I-MED
)	O
,	O
HepG2	B-MED
(	O
human	B-MED
liver	I-MED
cancer	I-MED
cells	I-MED
)	O
and	O
HCT	B-MED
116	I-MED
(	O
human	B-MED
colon	I-MED
cancer	I-MED
cells	I-MED
)	O
.	O
All	O
compounds	B-MED
were	O
evaluated	B-MED
for	O
antibacterial	B-MED
activity	I-MED
and	O
their	O
abilities	O
to	O
suppress	B-MED
LPS	B-MED
-induced	O
nitric	B-MED
oxide	I-MED
(	O
NO	B-MED
)	O
production	O
.	O
Compounds	B-MED
2	I-MED
and	I-MED
4	I-MED
-	I-MED
7	I-MED
showed	O
mild	B-MED
antibacterial	B-MED
activity	I-MED
against	O
human	B-MED
pathogen	B-MED
Staphylococcus	B-MED
aureus	I-MED
and	O
fish	B-MED
pathogens	B-MED
Streptococcus	B-MED
iniae	I-MED
and	O
Vibrio	B-MED
ichthyoenteri	I-MED
,	O
and	O
compounds	B-MED
4	I-MED
and	I-MED
7	I-MED
weakly	O
suppressed	B-MED
NO	B-MED
production	O
.	O
Neurotrophins	B-MED
and	O
specific	B-MED
receptors	I-MED
in	O
the	O
oviduct	B-MED
tracts	I-MED
of	O
Japanese	B-MED
quail	I-MED
(	O
Coturnix	B-MED
coturnix	I-MED
japonica	I-MED
)	O
Neurotrophins	B-MED
(	O
NGF	B-MED
,	O
BDNF	B-MED
and	O
NT-3	B-MED
)	O
and	O
their	O
specific	B-MED
receptors	I-MED
(	O
TrkA	B-MED
,	O
TrkB	B-MED
and	O
TrkC	B-MED
)	O
were	O
studied	B-MED
in	O
the	O
oviduct	B-MED
of	O
egg	B-MED
laying	I-MED
quails	B-MED
.	O
Neurotrophins	B-MED
(	O
NTs	B-MED
)	O
are	O
mainly	O
involved	O
in	O
the	O
development	B-MED
and	O
maintenance	B-MED
of	O
neuronal	B-MED
populations	I-MED
in	O
the	O
central	B-MED
and	O
peripheral	B-MED
nervous	I-MED
system	I-MED
,	O
but	O
also	O
in	O
reproductive	B-MED
system	I-MED
.	O
In	O
this	O
survey	O
,	O
we	O
first	O
studied	B-MED
the	O
morphological	B-MED
organization	B-MED
of	O
the	O
quail	B-MED
oviduct	B-MED
,	O
distinguished	O
in	O
infundibulum	B-MED
,	O
magnum	B-MED
,	O
isthmus	B-MED
,	O
uterus	B-MED
and	O
vagina	B-MED
,	O
and	O
then	O
we	O
analyzed	B-MED
the	O
expression	B-MED
and	O
localization	B-MED
of	O
NTs	B-MED
and	O
Trks	B-MED
receptors	I-MED
in	O
the	O
whole	O
tracts	B-MED
.	O
By	O
western	B-MED
blotting	I-MED
we	O
detected	O
that	O
the	O
investigated	B-MED
NTs	B-MED
and	O
Trks	B-MED
receptors	I-MED
are	O
expressed	B-MED
in	O
all	O
oviductal	B-MED
tracts	I-MED
.	O
By	O
immunohistochemistry	B-MED
we	O
were	O
able	O
to	O
define	O
the	O
distribution	B-MED
of	O
NTs	B-MED
and	O
Trks	B-MED
.	O
Specifically	O
,	O
NGF	B-MED
,	O
BDNF	B-MED
and	O
NT3	B-MED
were	O
localized	O
in	O
lining	B-MED
and	O
ductal	B-MED
epithelial	I-MED
cells	I-MED
,	O
and	O
NGF	B-MED
was	O
also	O
detected	O
in	O
secretory	B-MED
cells	I-MED
of	O
tubular	B-MED
glands	I-MED
and	O
in	O
nervous	B-MED
fibers	I-MED
of	O
vessel	B-MED
wall	I-MED
.	O
TrkA	B-MED
and	O
TrkB	B-MED
were	O
present	O
in	O
the	O
lining	B-MED
and	O
ductal	B-MED
epithelium	I-MED
;	O
TrkA	B-MED
and	O
TrkC	B-MED
were	O
present	O
in	O
nervous	B-MED
fibers	I-MED
of	O
vessel	B-MED
wall	I-MED
in	O
all	O
oviductal	B-MED
tracts	I-MED
.	O
Furthermore	O
,	O
we	O
also	O
observed	O
NGF	B-MED
and	O
BDNF	B-MED
co	O
-	O
localized	O
with	O
TrkA	B-MED
and	O
TrkB	B-MED
in	O
cells	B-MED
of	O
the	O
lining	B-MED
and	O
ductal	B-MED
epithelium	I-MED
,	O
suggesting	O
an	O
autocrine	B-MED
mechanism	I-MED
of	O
action	B-MED
.	O
Knocking	B-MED
down	I-MED
TCF8	B-MED
inhibits	O
high	B-MED
glucose	I-MED
-	O
and	O
angiotensin	B-MED
II	I-MED
-	O
induced	B-MED
epithelial	B-MED
to	I-MED
mesenchymal	I-MED
transition	I-MED
in	O
podocytes	B-MED
Epithelial	B-MED
to	I-MED
mesenchymal	I-MED
transition	I-MED
(	O
EMT	B-MED
)	O
is	O
a	O
physiological	B-MED
phenomenon	I-MED
in	O
mammalian	B-MED
embryogenesis	B-MED
by	O
which	O
epithelial	B-MED
cells	I-MED
become	O
mesenchymal	B-MED
stem	I-MED
cells	I-MED
.	O
Studies	O
have	O
indicated	O
that	O
an	O
inappropriate	O
EMT	B-MED
plays	O
a	O
key	O
role	O
in	O
a	O
variety	O
of	O
pathogenic	B-MED
processes	B-MED
such	O
as	O
embryonic	B-MED
development	I-MED
and	O
tumor	B-MED
metastasis	I-MED
.	O
Moreover	O
,	O
recent	O
studies	O
have	O
indicated	O
EMT	B-MED
also	O
plays	O
an	O
important	O
role	O
in	O
renal	B-MED
fibrosis	I-MED
.	O
In	O
the	O
current	O
study	O
,	O
glucose	B-MED
and	O
angiotensin	B-MED
II	I-MED
promoted	O
EMT	B-MED
in	O
podocytes	B-MED
as	O
well	O
as	O
changes	O
in	O
the	O
cellular	B-MED
morphology	I-MED
of	O
podocytes	B-MED
.	O
A	O
high	B-MED
concentration	B-MED
of	O
glucose	B-MED
and	O
angiotensin	B-MED
II	I-MED
also	O
promoted	O
podocyte	B-MED
movement	B-MED
and	O
migration	B-MED
.	O
Moreover	O
,	O
a	O
high	B-MED
concentration	B-MED
of	O
glucose	B-MED
and	O
angiotensin	B-MED
II	I-MED
promoted	O
TCF8	B-MED
expression	B-MED
.	O
Inhibiting	B-MED
TCF8	B-MED
expression	B-MED
with	O
siRNA	B-MED
reversed	O
EMT	B-MED
in	O
podocytes	B-MED
in	O
the	O
presence	O
of	O
a	O
high	B-MED
concentration	B-MED
of	O
glucose	B-MED
and	O
angiotensin	B-MED
.	O
Inhibiting	B-MED
TCF8	B-MED
expression	B-MED
also	O
reversed	O
changes	O
in	O
cellular	B-MED
morphology	I-MED
and	O
podocyte	B-MED
movement	B-MED
and	O
migration	B-MED
.	O
Therefore	O
,	O
glucose	B-MED
and	O
angiotensin	B-MED
II	I-MED
may	O
promote	O
EMT	B-MED
in	O
podocytes	B-MED
via	O
TCF8	B-MED
.	O
Reduction	B-MED
in	O
Hospital	B-MED
-	I-MED
Wide	I-MED
Clinical	B-MED
Laboratory	I-MED
Specimen	I-MED
Identification	I-MED
Errors	B-MED
following	O
Process	B-MED
Interventions	I-MED
:	O
A	O
10-	O
Year	B-MED
Retrospective	B-MED
Observational	I-MED
Study	I-MED
Accurate	B-MED
patient	B-MED
identification	I-MED
and	O
specimen	B-MED
labeling	I-MED
at	O
the	O
time	O
of	O
collection	O
are	O
crucial	B-MED
steps	I-MED
in	O
the	O
prevention	B-MED
of	O
medical	B-MED
errors	I-MED
,	O
thereby	O
improving	B-MED
patient	B-MED
safety	I-MED
.	O
All	O
patient	B-MED
specimen	I-MED
identification	B-MED
errors	B-MED
that	O
occurred	B-MED
in	O
the	O
outpatient	B-MED
department	I-MED
(	O
OPD	B-MED
)	O
,	O
emergency	B-MED
department	I-MED
(	O
ED	B-MED
)	O
,	O
and	O
inpatient	B-MED
department	I-MED
(	O
IPD	B-MED
)	O
of	O
a	O
3,800-	O
bed	B-MED
academic	B-MED
medical	I-MED
center	I-MED
in	O
Taiwan	B-MED
were	O
documented	B-MED
and	O
analyzed	B-MED
retrospectively	O
from	O
2005	O
to	O
2014	O
.	O
To	O
reduce	B-MED
such	O
errors	B-MED
,	O
the	O
following	O
series	B-MED
of	O
strategies	B-MED
were	O
implemented	O
:	O
a	O
restrictive	B-MED
specimen	I-MED
acceptance	I-MED
policy	I-MED
for	O
the	O
ED	B-MED
and	O
IPD	B-MED
in	O
2006	O
;	O
a	O
computer	B-MED
-	I-MED
assisted	I-MED
barcode	B-MED
positive	B-MED
patient	I-MED
identification	I-MED
system	I-MED
for	O
the	O
ED	B-MED
and	O
IPD	B-MED
in	O
2007	O
and	O
2010	O
,	O
and	O
automated	B-MED
sample	B-MED
labeling	I-MED
combined	B-MED
with	O
electronic	B-MED
identification	I-MED
systems	I-MED
introduced	B-MED
to	O
the	O
OPD	B-MED
in	O
2009	O
.	O
Of	O
the	O
2000345	O
specimens	B-MED
collected	B-MED
in	O
2005	O
,	O
1023	O
(	O
0.0511	O
%	O
)	O
were	O
identified	B-MED
as	O
having	O
patient	B-MED
identification	I-MED
errors	B-MED
,	O
compared	O
with	O
58	O
errors	B-MED
(	O
0.0015	O
%	O
)	O
among	O
3761238	O
specimens	B-MED
collected	B-MED
in	O
2014	O
,	O
after	O
serial	O
interventions	B-MED
;	O
this	O
represents	O
a	O
97	O
%	O
relative	B-MED
reduction	B-MED
.	O
The	O
total	B-MED
number	I-MED
(	O
rate	B-MED
)	O
of	O
institutional	B-MED
identification	I-MED
errors	B-MED
contributed	O
from	O
the	O
ED	B-MED
,	O
IPD	B-MED
,	O
and	O
OPD	B-MED
over	O
a	O
10-	O
year	B-MED
period	B-MED
were	O
423	O
(	O
0.1058	O
%	O
)	O
,	O
556	O
(	O
0.0587	O
%	O
)	O
,	O
and	O
44	O
(	O
0.0067	O
%	O
)	O
errors	B-MED
before	B-MED
the	O
interventions	B-MED
,	O
and	O
3	O
(	O
0.0007	O
%	O
)	O
,	O
52	O
(	O
0.0045	O
%	O
)	O
and	O
3	O
(	O
0.0001	O
%	O
)	O
after	B-MED
interventions	B-MED
,	O
representing	O
relative	B-MED
99	O
%	O
,	O
92	O
%	O
and	O
98	O
%	O
reductions	B-MED
,	O
respectively	O
.	O
Accurate	B-MED
patient	B-MED
identification	I-MED
is	O
a	O
challenge	O
of	O
patient	B-MED
safety	I-MED
in	O
different	O
health	B-MED
settings	B-MED
.	O
The	O
data	B-MED
collected	I-MED
in	O
our	O
study	B-MED
indicate	O
that	O
a	O
restrictive	B-MED
specimen	I-MED
acceptance	I-MED
policy	I-MED
,	O
computer	B-MED
-	I-MED
generated	I-MED
positive	B-MED
identification	I-MED
systems	I-MED
,	O
and	O
interdisciplinary	O
cooperation	O
can	O
significantly	O
reduce	B-MED
patient	B-MED
identification	I-MED
errors	B-MED
.	O
Cultivation	B-MED
of	O
four	O
microalgae	B-MED
species	B-MED
in	O
the	O
effluent	B-MED
of	O
anaerobic	B-MED
digester	I-MED
for	O
biodiesel	B-MED
production	B-MED
This	O
study	B-MED
investigated	B-MED
if	O
an	O
effluent	B-MED
from	O
anaerobic	B-MED
digestion	I-MED
(	I-MED
AD	I-MED
)	I-MED
system	I-MED
can	O
be	O
used	B-MED
as	O
a	O
nutrients	B-MED
source	B-MED
for	O
the	O
microalgae	B-MED
cultivation	B-MED
,	O
and	O
in	O
so	O
doing	O
,	O
if	O
the	O
effluent	B-MED
can	O
be	O
properly	O
treated	B-MED
.	O
Nitrogen	B-MED
and	O
phosphorus	B-MED
in	O
the	O
AD	B-MED
AD	B-MED
effluent	B-MED
well	O
supported	O
microalgal	B-MED
growth	B-MED
,	O
and	O
their	O
removal	B-MED
efficiency	B-MED
reached	O
>	O
97.9	O
%	O
and	O
99.2	O
%	O
,	O
respectively	O
.	O
Among	O
four	O
different	B-MED
algal	B-MED
species	B-MED
tested	B-MED
,	O
Micractinium	B-MED
inermum	I-MED
particularly	O
stood	B-MED
out	I-MED
,	O
showing	O
the	O
highest	B-MED
biomass	B-MED
and	O
FAME	B-MED
productivity	B-MED
:	O
0.16gL(-1)d(-1	O
)	O
with	O
3.23gL(-1	O
)	O
of	O
dry	B-MED
cell	B-MED
weight	B-MED
,	O
and	O
0.04gL(-1)d(-1	O
)	O
with	O
27.54	O
%	O
(	O
w	O
/	O
w	O
)	O
of	O
FAME	B-MED
contents	B-MED
,	O
respectively	O
.	O
As	O
the	O
concentrations	B-MED
of	O
the	O
nutrients	B-MED
decreased	B-MED
over	B-MED
time	B-MED
,	O
the	O
FAME	B-MED
contents	B-MED
were	O
increased	B-MED
and	O
its	O
quality	B-MED
as	O
well	B-MED
,	O
satisfying	O
several	B-MED
biodiesel	B-MED
quality	B-MED
standards	B-MED
.	O
This	O
study	B-MED
supports	O
that	O
the	O
AD	B-MED
effluent	B-MED
can	O
indeed	O
serve	O
as	O
a	O
cheap	B-MED
and	O
nutrient	B-MED
-	O
rich	B-MED
medium	B-MED
for	O
microalgae	B-MED
cultivation	B-MED
,	O
and	O
equally	B-MED
importantly	B-MED
,	O
microalgae	B-MED
can	O
be	O
a	O
workable	O
treatment	B-MED
option	B-MED
for	O
it	O
.	O
Enhancing	O
Doctors	B-MED
'	I-MED
Competencies	B-MED
in	O
Communication	B-MED
With	O
and	O
Activation	B-MED
of	O
Older	B-MED
Patients	B-MED
:	O
The	O
Promoting	B-MED
Active	B-MED
Aging	B-MED
(	O
PRACTA	B-MED
)	O
Computer	B-MED
-	I-MED
Based	I-MED
Intervention	I-MED
Study	I-MED
Demographic	B-MED
changes	B-MED
over	O
the	O
past	O
decades	B-MED
call	O
for	O
the	O
promotion	B-MED
of	I-MED
health	I-MED
and	I-MED
disease	I-MED
prevention	I-MED
for	O
older	B-MED
patients	B-MED
,	O
as	O
well	O
as	O
strategies	O
to	O
enhance	O
their	O
independence	B-MED
,	O
productivity	B-MED
,	O
and	O
quality	B-MED
of	I-MED
life	I-MED
.	O
Our	O
objective	O
was	O
to	O
examine	O
the	O
effects	O
of	O
a	O
computer	B-MED
-	I-MED
based	I-MED
educational	I-MED
intervention	I-MED
designed	O
for	O
general	B-MED
practitioners	I-MED
(	O
GPs	B-MED
)	O
to	O
promote	O
active	B-MED
aging	B-MED
.	O
The	O
Promoting	B-MED
Active	O
Aging	B-MED
(	O
PRACTA	B-MED
)	O
study	O
consisted	O
of	O
a	O
baseline	B-MED
questionnaire	I-MED
,	O
implementation	B-MED
of	O
an	O
intervention	B-MED
,	O
and	O
a	O
follow	B-MED
-	I-MED
up	I-MED
questionnaire	I-MED
that	O
was	O
administered	B-MED
1	O
month	O
after	O
the	O
intervention	B-MED
.	O
A	O
total	O
of	O
151	O
primary	B-MED
care	I-MED
facilities	I-MED
(	O
response	B-MED
rate	I-MED
151/767	O
,	O
19.7	O
%	O
)	O
and	O
503	O
GPs	B-MED
(	O
response	B-MED
rate	I-MED
503/996	O
,	O
50.5	O
%	O
)	O
agreed	O
to	O
participate	B-MED
in	O
the	O
baseline	B-MED
assessment	I-MED
.	O
At	O
the	O
follow	B-MED
-	I-MED
up	I-MED
,	O
393	O
GPs	B-MED
filled	O
in	O
the	O
questionnaires	B-MED
(	O
response	B-MED
rate	I-MED
,	O
393/503	O
,	O
78.1	O
%	O
)	O
,	O
but	O
not	O
all	O
of	O
them	O
took	O
part	O
in	O
the	O
intervention	B-MED
.	O
The	O
final	O
study	B-MED
group	I-MED
of	O
225	O
GPs	B-MED
participated	O
in	O
3	O
study	O
conditions	O
:	O
e	B-MED
-	I-MED
learning	I-MED
(	O
knowledge	B-MED
plus	O
skills	B-MED
modelling	B-MED
,	O
n=42	O
)	O
,	O
a	O
pdf	B-MED
article	I-MED
(	O
knowledge	B-MED
only	O
,	O
n=89	O
)	O
,	O
and	O
control	B-MED
(	O
no	B-MED
intervention	B-MED
,	O
n=94	O
)	O
.	O
We	O
measured	O
the	O
outcome	O
as	O
scores	B-MED
on	O
the	O
Patients	B-MED
Expectations	B-MED
Scale	I-MED
,	O
Communication	B-MED
Scale	I-MED
,	O
Attitude	B-MED
Toward	I-MED
Treatment	I-MED
and	I-MED
Health	I-MED
Scale	I-MED
,	O
and	O
Self	B-MED
-	I-MED
Efficacy	I-MED
Scale	I-MED
.	O
GPs	B-MED
participating	O
in	O
e	B-MED
-	I-MED
learning	I-MED
demonstrated	O
a	O
significant	B-MED
rise	O
in	O
their	O
perception	B-MED
of	O
older	B-MED
patients	B-MED
'	O
expectations	B-MED
for	O
disease	B-MED
explanation	I-MED
(	O
Wald	O
χ(2)=19.7	O
,	O
P<.001	O
)	O
and	O
in	O
perception	B-MED
of	O
motivational	B-MED
aspect	O
of	O
older	B-MED
patients	B-MED
'	O
attitude	O
toward	O
treatment	B-MED
and	O
health	B-MED
(	O
Wald	O
χ(2)=8.9	O
,	O
P=.03	O
)	O
in	O
comparison	O
with	O
both	O
the	O
control	B-MED
and	O
pdf	B-MED
article	I-MED
groups	I-MED
.	O
We	O
observed	O
additional	O
between-	O
group	B-MED
differences	O
at	O
the	O
level	B-MED
of	O
statistical	B-MED
trend	O
.	O
GPs	B-MED
participating	O
in	O
the	O
pdf	B-MED
article	I-MED
intervention	B-MED
demonstrated	O
a	O
decline	O
in	O
self	O
-	O
assessed	O
communication	B-MED
,	O
both	O
at	O
the	O
level	B-MED
of	O
global	B-MED
scoring	I-MED
(	O
Wald	O
χ(2)=34.5	O
,	O
P<.001	O
)	O
and	O
at	O
the	O
level	B-MED
of	O
20	O
of	O
26	O
specific	B-MED
behaviors	I-MED
(	O
all	O
P<.05	O
)	O
.	O
Factors	O
moderating	O
the	O
effects	B-MED
of	I-MED
the	O
intervention	B-MED
were	O
the	O
number	O
of	O
patients	B-MED
per	O
GP	B-MED
and	O
the	O
facility	O
's	O
organizational	B-MED
structure	I-MED
.	O
Both	O
methods	O
were	O
suitable	O
,	O
but	O
in	O
different	O
areas	B-MED
and	O
under	O
different	O
conditions	B-MED
.	O
The	O
key	O
benefit	O
of	O
the	O
pdf	B-MED
article	I-MED
intervention	B-MED
was	O
raising	O
doctors	B-MED
'	O
reflection	O
on	O
limitations	B-MED
in	O
their	O
communication	B-MED
skills	I-MED
,	O
whereas	O
e	B-MED
-	I-MED
learning	I-MED
was	O
more	O
effective	B-MED
in	O
changing	O
their	O
perception	O
of	O
older	B-MED
patients	B-MED
'	O
proactive	O
attitude	O
,	O
especially	O
among	O
GPs	B-MED
working	O
in	O
privately	B-MED
owned	I-MED
facilities	I-MED
and	O
having	O
a	O
greater	O
number	O
of	O
assigned	B-MED
patients	B-MED
.	O
Although	O
we	O
did	O
not	O
achieve	O
all	O
expected	O
effects	B-MED
of	I-MED
the	O
PRACTA	B-MED
intervention	I-MED
,	O
both	O
its	O
forms	O
seem	O
promising	O
in	O
terms	O
of	O
enhancing	O
the	O
competencies	B-MED
of	O
doctors	B-MED
in	O
communication	B-MED
with	O
and	O
activation	O
of	O
older	B-MED
patients	B-MED
.	O
Biochemical	B-MED
and	O
proteomic	B-MED
analyses	B-MED
of	O
the	O
physiological	B-MED
response	I-MED
induced	O
by	O
individual	O
housing	B-MED
in	O
gilts	B-MED
provide	O
new	O
potential	B-MED
stress	B-MED
markers	B-MED
The	O
objective	B-MED
assessment	B-MED
of	O
animal	B-MED
stress	B-MED
and	O
welfare	O
requires	O
proper	O
laboratory	B-MED
biomarkers	B-MED
.	O
In	O
this	O
work	O
,	O
we	O
have	O
analyzed	O
the	O
changes	O
in	O
serum	B-MED
composition	B-MED
in	O
gilts	B-MED
after	O
switching	O
their	O
housing	B-MED
,	O
from	O
pen	O
to	O
individual	O
stalls	B-MED
,	O
which	O
is	O
generally	O
accepted	O
to	O
cause	O
animal	B-MED
discomfort	B-MED
.	O
Blood	B-MED
and	O
saliva	B-MED
samples	I-MED
were	O
collected	O
a	O
day	O
before	O
and	O
up	O
to	O
four	O
days	O
after	O
changing	O
the	O
housing	B-MED
system	O
.	O
Biochemical	B-MED
analyses	B-MED
showed	O
adaptive	B-MED
changes	O
in	O
lipid	B-MED
and	O
protein	B-MED
metabolism	I-MED
after	O
the	O
housing	B-MED
switch	O
,	O
whereas	O
cortisol	B-MED
and	O
muscular	B-MED
markers	B-MED
showed	O
a	O
large	O
variability	B-MED
between	O
animals	B-MED
.	O
2D	B-MED
-	I-MED
DIGE	I-MED
and	O
iTRAQ	B-MED
proteomic	B-MED
approaches	B-MED
revealed	O
variations	O
in	O
serum	B-MED
protein	I-MED
composition	B-MED
after	O
changing	O
housing	B-MED
and	O
diet	O
of	O
gilts	B-MED
.	O
Both	O
techniques	B-MED
showed	O
alterations	B-MED
in	O
two	O
main	O
homeostatic	B-MED
mechanisms	I-MED
:	O
the	O
innate	B-MED
immune	I-MED
and	O
redox	B-MED
systems	O
.	O
The	O
acute	B-MED
phase	I-MED
proteins	I-MED
haptoglobin	B-MED
,	O
apolipoprotein	B-MED
A	I-MED
-	I-MED
I	I-MED
and	O
α1	O
-	O
antichymotrypsin	O
3	O
,	O
and	O
the	O
antioxidant	B-MED
enzyme	O
peroxiredoxin	B-MED
2	I-MED
were	O
found	O
differentially	O
expressed	O
by	O
2D	B-MED
-	I-MED
DIGE	I-MED
.	O
Other	O
proteins	B-MED
related	O
to	O
the	O
innate	B-MED
immune	I-MED
system	I-MED
,	O
including	O
lactotransferrin	B-MED
,	O
protegrin	B-MED
3	I-MED
and	O
galectin	B-MED
1	I-MED
were	O
also	O
identified	O
by	O
iTRAQ	B-MED
,	O
as	O
well	O
as	O
oxidative	B-MED
stress	I-MED
enzymes	B-MED
such	O
as	O
peroxiredoxin	B-MED
2	I-MED
and	O
glutathione	B-MED
peroxidase	I-MED
3	I-MED
.	O
Proteomics	B-MED
also	O
revealed	O
the	O
decrease	B-MED
of	O
apolipoproteins	B-MED
,	O
and	O
the	O
presence	O
of	O
intracellular	B-MED
proteins	B-MED
in	O
serum	B-MED
,	O
which	O
may	O
indicate	O
physical	B-MED
injury	I-MED
to	O
tissues	B-MED
.	O
Housing	B-MED
of	O
gilts	B-MED
in	O
individual	O
stalls	B-MED
and	O
diet	O
change	O
increase	O
lipid	B-MED
and	O
protein	B-MED
catabolism	I-MED
,	O
oxidative	B-MED
stress	I-MED
,	O
activate	O
the	O
innate	B-MED
immune	I-MED
system	I-MED
and	O
cause	O
a	O
certain	O
degree	O
of	O
tissue	B-MED
damage	I-MED
.	O
We	O
propose	O
that	O
valuable	O
assays	O
for	O
stress	B-MED
assessment	I-MED
in	O
gilts	B-MED
may	O
be	O
based	O
on	O
a	O
score	B-MED
composed	O
by	O
a	O
combination	O
of	O
salivary	O
cortisol	O
,	O
lipid	B-MED
metabolites	B-MED
,	O
innate	B-MED
immunity	I-MED
and	O
oxidative	B-MED
stress	I-MED
markers	B-MED
and	O
intracellular	B-MED
proteins	B-MED
.	O
Potentiation	B-MED
of	O
LPS	B-MED
-	O
Induced	B-MED
Apoptotic	B-MED
Cell	I-MED
Death	I-MED
in	O
Human	B-MED
Hepatoma	I-MED
HepG2	I-MED
Cells	I-MED
by	O
Aspirin	B-MED
via	O
ROS	B-MED
and	O
Mitochondrial	B-MED
Dysfunction	I-MED
:	O
Protection	B-MED
by	O
N	B-MED
-	I-MED
Acetyl	I-MED
Cysteine	I-MED
Cytotoxicity	B-MED
and	O
inflammation	B-MED
-	O
associated	B-MED
toxic	B-MED
responses	B-MED
have	O
been	O
observed	B-MED
to	O
be	O
induced	B-MED
by	O
bacterial	B-MED
lipopolysaccharides	B-MED
(	O
LPS	B-MED
)	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
respectively	O
.	O
Use	O
of	O
nonsteroidal	B-MED
anti	I-MED
-	I-MED
inflammatory	I-MED
drugs	I-MED
(	O
NSAIDs	B-MED
)	O
,	O
such	O
as	O
aspirin	B-MED
,	O
has	O
been	O
reported	B-MED
to	O
be	O
beneficial	O
in	O
inflammation	B-MED
-	O
associated	B-MED
diseases	I-MED
like	O
cancer	B-MED
,	O
diabetes	B-MED
and	O
cardiovascular	B-MED
disorders	I-MED
.	O
Their	O
precise	O
molecular	B-MED
mechanisms	B-MED
,	O
however	O
,	O
are	O
not	O
clearly	O
understood	O
.	O
Our	O
previous	O
studies	B-MED
on	O
aspirin	B-MED
treated	B-MED
HepG2	B-MED
cells	I-MED
strongly	O
suggest	O
cell	B-MED
cycle	I-MED
arrest	I-MED
and	O
induction	B-MED
of	O
apoptosis	B-MED
associated	B-MED
with	I-MED
mitochondrial	B-MED
dysfunction	I-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
we	O
have	O
further	O
demonstrated	O
that	O
HepG2	B-MED
cells	I-MED
treated	B-MED
with	I-MED
LPS	B-MED
alone	O
or	O
in	O
combination	B-MED
with	O
aspirin	B-MED
induces	B-MED
subcellular	B-MED
toxic	B-MED
responses	I-MED
which	O
are	O
accompanied	O
by	O
increase	B-MED
in	O
reactive	B-MED
oxygen	I-MED
species	I-MED
(	O
ROS	B-MED
)	O
production	O
,	O
oxidative	B-MED
stress	I-MED
,	O
mitochondrial	B-MED
respiratory	I-MED
dysfunction	I-MED
and	O
apoptosis	B-MED
.	O
The	O
LPS	B-MED
/	O
Aspirin	B-MED
induced	B-MED
toxicity	B-MED
was	O
attenuated	B-MED
by	O
pre	B-MED
-	I-MED
treatment	I-MED
of	O
cells	B-MED
with	O
N	B-MED
-	I-MED
acetyl	I-MED
cysteine	I-MED
(	O
NAC	B-MED
)	O
.	O
Alterations	O
in	O
oxidative	B-MED
stress	I-MED
and	O
glutathione	B-MED
-	O
dependent	B-MED
redox	B-MED
-	I-MED
homeostasis	I-MED
were	O
more	O
pronounced	O
in	O
mitochondria	B-MED
compared	B-MED
to	O
extra	B-MED
-	O
mitochondrial	B-MED
cellular	B-MED
compartments	I-MED
.	O
Pre	B-MED
-	I-MED
treatment	I-MED
of	O
HepG2	B-MED
cells	I-MED
with	O
NAC	B-MED
exhibited	O
a	O
selective	O
protection	B-MED
in	O
redox	B-MED
homeostasis	I-MED
and	O
mitochondrial	B-MED
dysfunction	I-MED
.	O
Our	O
results	B-MED
suggest	O
that	O
the	O
altered	B-MED
redox	B-MED
metabolism	I-MED
,	O
oxidative	B-MED
stress	I-MED
and	O
mitochondrial	B-MED
function	B-MED
in	O
HepG2	B-MED
cells	I-MED
play	O
a	O
critical	O
role	O
in	O
LPS	B-MED
/	O
aspirin	B-MED
-	O
induced	B-MED
cytotoxicity	B-MED
.	O
These	O
results	B-MED
may	O
help	O
in	O
better	O
understanding	O
the	O
pharmacological	B-MED
,	O
toxicological	B-MED
and	O
therapeutic	B-MED
properties	I-MED
of	O
NSAIDs	B-MED
in	O
cancer	B-MED
cells	I-MED
exposed	B-MED
to	O
bacterial	B-MED
endotoxins	I-MED
.	O
Variation	B-MED
analysis	I-MED
of	O
PRIM1	B-MED
gene	I-MED
in	O
Chinese	B-MED
patients	B-MED
with	O
primary	B-MED
ovarian	I-MED
insufficiency	I-MED
Insights	O
into	O
common	O
genetic	B-MED
susceptibility	I-MED
between	O
primary	B-MED
ovarian	I-MED
insufficiency	I-MED
(	O
POI	B-MED
)	O
and	O
natural	B-MED
or	O
early	B-MED
menopause	I-MED
have	O
delivered	B-MED
an	O
innovative	O
way	O
of	O
assessing	O
the	O
genetic	B-MED
mechanisms	I-MED
involved	O
in	O
POI	B-MED
.	O
PRIM1	B-MED
plays	O
a	O
crucial	O
role	O
in	O
DNA	B-MED
replication	I-MED
by	O
synthesizing	B-MED
RNA	B-MED
primers	I-MED
for	O
Okazaki	B-MED
fragments	I-MED
.	O
It	O
is	O
closely	O
associated	B-MED
with	I-MED
age	B-MED
at	O
natural	B-MED
menopause	I-MED
,	O
early	B-MED
menopause	I-MED
and	O
POI	B-MED
in	O
European	B-MED
women	B-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
aimed	O
to	O
investigate	B-MED
whether	O
mutations	B-MED
in	O
PRIM1	B-MED
contribute	O
to	O
POI	B-MED
in	O
Chinese	B-MED
women	B-MED
.	O
All	O
exons	B-MED
and	O
exon	B-MED
-	I-MED
intron	I-MED
boundaries	I-MED
of	O
PRIM1	B-MED
gene	I-MED
were	O
sequenced	B-MED
in	O
192	O
Han	B-MED
Chinese	I-MED
women	B-MED
with	O
non	O
-	O
syndromic	O
POI	B-MED
.	O
No	O
plausible	O
mutations	B-MED
were	O
identified	B-MED
.	O
The	O
results	O
suggest	O
that	O
the	O
perturbations	B-MED
in	O
PRIM1	B-MED
gene	I-MED
are	O
not	O
a	O
common	O
explanation	O
for	O
POI	B-MED
in	O
Chinese	B-MED
women	B-MED
.	O
Correlations	B-MED
between	O
physical	B-MED
activity	I-MED
and	O
neurocognitive	B-MED
domain	I-MED
functions	I-MED
in	O
patients	B-MED
with	O
schizophrenia	B-MED
:	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
Neurocognitive	B-MED
dysfunction	I-MED
is	O
a	O
critical	O
target	O
symptom	B-MED
of	O
schizophrenia	B-MED
treatment	B-MED
.	O
A	O
positive	O
correlation	B-MED
between	O
physical	B-MED
activity	I-MED
level	O
and	O
neurocognitive	B-MED
function	I-MED
has	O
been	O
reported	O
in	O
healthy	B-MED
individuals	I-MED
,	O
but	O
it	O
is	O
unclear	O
whether	O
such	O
a	O
correlation	B-MED
exists	O
in	O
patients	B-MED
with	O
schizophrenia	B-MED
and	O
whether	O
the	O
relationship	B-MED
is	O
different	O
according	O
to	O
inpatients	B-MED
or	O
outpatients	B-MED
.	O
This	O
study	B-MED
aimed	O
to	O
examine	B-MED
the	O
differences	O
in	O
the	O
correlations	B-MED
between	O
physical	B-MED
activity	I-MED
and	O
multiple	O
neurocognitive	B-MED
domains	I-MED
in	O
inpatients	B-MED
and	O
outpatients	B-MED
with	O
schizophrenia	B-MED
and	O
obtain	O
suggestions	B-MED
for	O
further	O
study	B-MED
to	O
facilitate	O
this	O
field	O
.	O
Twenty	O
-	O
nine	O
patients	B-MED
with	O
schizophrenia	B-MED
were	O
examined	B-MED
(	O
16	O
inpatients	B-MED
and	O
13	O
outpatients	B-MED
,	O
56.0	O
±	O
11.4	O
years	B-MED
of	O
age	B-MED
)	O
.	O
Current	O
symptoms	B-MED
were	O
assessed	B-MED
using	O
the	O
Positive	B-MED
and	O
Negative	B-MED
Symptom	B-MED
Scale	I-MED
and	O
neurocognitive	B-MED
functions	I-MED
using	O
Cognitrax	B-MED
,	O
which	O
yields	O
a	O
composite	O
neurocognitive	B-MED
index	I-MED
(	O
NCI	B-MED
)	O
and	O
11	O
domain	O
scores	B-MED
.	O
After	O
testing	O
,	O
participants	B-MED
wore	O
an	O
HJA-750C	B-MED
accelerometer	I-MED
for	O
one	B-MED
week	I-MED
to	O
measure	B-MED
physical	B-MED
activity	I-MED
levels	O
and	O
durations	B-MED
.	O
Partial	B-MED
correlation	I-MED
analyses	I-MED
were	O
performed	O
between	O
exercise	B-MED
and	O
cognitive	B-MED
parameters	B-MED
.	O
In	O
the	O
outpatient	B-MED
group	O
,	O
higher	B-MED
physical	B-MED
activity	I-MED
was	O
associated	O
with	O
faster	O
Motor	B-MED
and	O
Psychomotor	B-MED
Speeds	B-MED
in	O
outpatients	B-MED
.	O
However	O
,	O
higher	B-MED
physical	B-MED
activity	I-MED
was	O
associated	B-MED
with	I-MED
lower	B-MED
overall	O
NCI	B-MED
,	O
Attention	B-MED
score	B-MED
,	O
and	O
Memory	B-MED
scores	B-MED
in	O
inpatients	B-MED
.	O
Although	O
higher	B-MED
physical	B-MED
activity	I-MED
was	O
associated	B-MED
with	I-MED
better	O
neurocognitive	B-MED
functions	I-MED
of	O
outpatients	B-MED
,	O
in	O
inpatients	B-MED
with	O
non	O
-	O
remitted	O
schizophrenia	B-MED
,	O
higher	B-MED
physical	B-MED
activity	I-MED
was	O
associated	B-MED
with	I-MED
worsening	O
of	O
several	O
cognitive	B-MED
domains	I-MED
.	O
In	O
a	O
future	O
study	B-MED
examining	B-MED
the	O
relationship	B-MED
between	O
physical	B-MED
activity	I-MED
and	O
neurocognitive	B-MED
function	I-MED
for	O
facilitating	O
this	O
research	O
field	O
,	O
separation	O
between	O
inpatients	B-MED
and	O
outpatients	B-MED
are	O
needed	O
because	O
the	O
relationship	B-MED
is	O
different	O
between	O
inpatients	B-MED
and	O
outpatients	B-MED
.	O
Comparison	O
of	O
a	O
new	O
visual	B-MED
stylet	I-MED
(	I-MED
Discopo)-guided	I-MED
laryngeal	B-MED
mask	I-MED
airway	I-MED
placement	I-MED
vs	O
conventional	B-MED
blind	I-MED
technique	I-MED
:	O
a	O
prospective	O
randomized	B-MED
study	O
To	O
compare	O
the	O
ease	O
of	O
laryngeal	B-MED
mask	I-MED
airway	I-MED
(	I-MED
LMA	I-MED
)	I-MED
insertion	I-MED
and	O
fiberoptic	B-MED
view	I-MED
of	O
LMA	B-MED
after	O
placement	B-MED
using	O
the	O
Discopo	B-MED
visual	I-MED
stylet	I-MED
-	I-MED
guided	I-MED
insertion	I-MED
and	O
conventional	B-MED
blind	I-MED
technique	I-MED
.	O
Prospective	O
,	O
randomized	B-MED
controlled	B-MED
study	I-MED
.	O
Operating	B-MED
room	I-MED
in	O
a	O
university	B-MED
hospital	I-MED
.	O
One	O
hundred	O
adult	B-MED
patients	B-MED
scheduled	O
for	O
elective	B-MED
surgery	I-MED
under	O
LMA	B-MED
general	B-MED
anesthesia	I-MED
were	O
enrolled	O
.	O
Patients	B-MED
were	O
randomly	B-MED
allocated	O
to	O
2	O
groups	B-MED
:	O
GLMA	B-MED
group	I-MED
using	O
a	O
visual	B-MED
stylet	I-MED
-	I-MED
guided	I-MED
technique	I-MED
(	O
n=50	O
)	O
and	O
BLMA	B-MED
group	I-MED
using	O
standard	O
blind	B-MED
technique	I-MED
(	O
n=50	O
)	O
.	O
Correct	O
placement	B-MED
of	O
the	O
LMA	B-MED
was	O
confirmed	O
using	O
clinical	B-MED
test	I-MED
along	O
with	O
fiberoptic	B-MED
assessment	B-MED
.	O
Unblinded	B-MED
data	I-MED
were	O
collected	O
about	O
the	O
insertion	B-MED
time	O
,	O
the	O
first	O
attempt	O
success	B-MED
rate	I-MED
,	O
the	O
LMA	B-MED
position	B-MED
adjustment	O
rate	O
,	O
fiberoptic	B-MED
view	I-MED
of	O
LMA	B-MED
anatomical	B-MED
position	I-MED
,	O
hemodynamic	B-MED
responses	I-MED
,	O
and	O
the	O
adverse	B-MED
insertion	B-MED
responses	B-MED
(	O
bucking	B-MED
,	O
breathholding	B-MED
,	O
and	O
laryngospasm	B-MED
)	O
.	O
Blinded	B-MED
data	I-MED
were	O
recorded	O
about	O
postoperative	B-MED
airway	B-MED
morbidity	I-MED
(	O
visible	O
blood	B-MED
staining	I-MED
on	O
LMA	B-MED
at	O
removal	O
,	O
sore	B-MED
throat	I-MED
,	O
and	O
hoarseness	B-MED
)	O
.	O
Insertion	B-MED
was	O
more	O
frequently	O
successful	O
at	O
the	O
first	O
attempt	O
in	O
GLMA	B-MED
than	O
that	O
in	O
BLMA	B-MED
group	I-MED
(	O
100	O
%	O
vs	O
92	O
%	O
;	O
P=.041	O
)	O
.	O
The	O
time	O
taken	O
for	O
establishing	O
effective	O
airway	O
was	O
shorter	O
in	O
GLMA	B-MED
than	O
that	O
in	O
BLMA	B-MED
(	O
54.8	O
vs	O
62.9	O
seconds	O
;	O
P=.001	O
)	O
.	O
The	O
patients	B-MED
in	O
BLMA	B-MED
group	I-MED
required	O
more	O
readjustment	O
and	O
reinsertion	B-MED
than	O
those	O
in	O
GLMA	B-MED
group	I-MED
(	O
38	O
%	O
vs	O
0	O
%	O
;	O
P=.000	O
)	O
.	O
The	O
fiberoptic	B-MED
view	I-MED
was	O
significantly	O
better	O
in	O
GLMA	B-MED
group	I-MED
(	O
P<.001	O
)	O
.	O
No	O
difference	O
between	O
the	O
2	O
groups	B-MED
existed	O
regarding	O
hemodynamic	B-MED
stress	I-MED
responses	I-MED
,	O
incidences	B-MED
of	O
adverse	B-MED
insertion	B-MED
responses	O
,	O
and	O
postoperative	B-MED
airway	B-MED
morbidity	I-MED
.	O
By	O
direct	O
visualizing	O
the	O
whole	O
process	O
of	O
LMA	B-MED
insertion	B-MED
,	O
the	O
Discopo	B-MED
visual	I-MED
stylet	I-MED
increases	O
the	O
success	B-MED
rate	I-MED
and	O
accuracy	B-MED
rate	I-MED
of	O
LMA	B-MED
placement	B-MED
without	O
increasing	O
hemodynamic	B-MED
stress	I-MED
response	I-MED
or	O
incidences	B-MED
of	O
adverse	B-MED
events	I-MED
.	O
Flexible	B-MED
Coordination	B-MED
of	O
Stationary	B-MED
and	O
Mobile	B-MED
Conversations	B-MED
with	O
Gaze	B-MED
:	O
Resource	B-MED
Allocation	I-MED
among	O
Multiple	B-MED
Joint	I-MED
Activities	I-MED
Gaze	B-MED
is	O
instrumental	O
in	O
coordinating	B-MED
face	B-MED
-	I-MED
to	I-MED
-	I-MED
face	I-MED
social	B-MED
interactions	I-MED
.	O
But	O
little	O
is	O
known	O
about	O
gaze	B-MED
use	O
when	O
social	B-MED
interactions	I-MED
co	B-MED
-	I-MED
occur	I-MED
with	O
other	O
joint	B-MED
activities	I-MED
.	O
We	O
investigated	B-MED
the	O
case	O
of	O
walking	B-MED
while	O
talking	B-MED
.	O
We	O
assessed	B-MED
how	O
gaze	B-MED
gets	O
allocated	B-MED
among	O
various	O
targets	B-MED
in	O
mobile	B-MED
conversations	B-MED
,	O
whether	O
allocation	B-MED
of	O
gaze	B-MED
to	O
other	O
targets	B-MED
affects	B-MED
conversational	B-MED
coordination	B-MED
,	O
and	O
whether	O
reduced	B-MED
availability	B-MED
of	I-MED
gaze	B-MED
for	O
conversational	B-MED
coordination	B-MED
affects	B-MED
conversational	B-MED
performance	B-MED
and	O
content	B-MED
.	O
In	O
an	O
experimental	B-MED
study	I-MED
,	O
pairs	O
were	O
videotaped	B-MED
in	O
four	O
conditions	B-MED
of	O
mobility	B-MED
(	O
standing	B-MED
still	I-MED
,	O
talking	B-MED
while	O
walking	B-MED
along	I-MED
a	I-MED
straight	I-MED
-	I-MED
line	I-MED
itinerary	I-MED
,	O
talking	B-MED
while	O
walking	B-MED
along	O
a	O
complex	B-MED
itinerary	I-MED
,	O
or	O
walking	B-MED
along	O
a	O
complex	B-MED
itinerary	I-MED
with	O
no	B-MED
conversational	I-MED
task	B-MED
)	O
.	O
Gaze	B-MED
to	O
partners	B-MED
was	O
substantially	B-MED
reduced	I-MED
in	O
mobile	B-MED
conversations	B-MED
,	O
but	O
gaze	B-MED
was	O
still	O
used	O
to	O
coordinate	B-MED
conversation	B-MED
via	O
displays	B-MED
of	O
mutual	B-MED
orientation	B-MED
,	O
and	O
conversational	B-MED
performance	B-MED
and	O
content	B-MED
was	O
not	O
different	B-MED
between	O
stationary	B-MED
and	O
mobile	B-MED
conditions	B-MED
.	O
Results	B-MED
expand	O
the	O
phenomena	B-MED
of	O
multitasking	O
to	O
joint	B-MED
activities	I-MED
.	O
Low	B-MED
-	I-MED
intensity	I-MED
pulsed	I-MED
ultrasound	I-MED
reduces	O
periodontal	B-MED
atrophy	I-MED
in	O
occlusal	B-MED
hypofunctional	B-MED
teeth	B-MED
To	O
clarify	O
whether	O
low	B-MED
-	I-MED
intensity	I-MED
pulsed	I-MED
ultrasound	I-MED
(	O
LIPUS	B-MED
)	O
exposure	O
has	O
recovery	O
effects	O
on	O
the	O
hypofunctional	B-MED
periodontal	B-MED
ligament	I-MED
(	O
PDL	B-MED
)	O
and	O
interradicular	B-MED
alveolar	I-MED
bone	I-MED
(	O
IRAB	B-MED
)	O
.	O
Twelve-	O
week	B-MED
-old	O
male	B-MED
Sprague	B-MED
-	I-MED
Dawley	I-MED
rats	I-MED
were	O
divided	O
into	O
three	O
groups	B-MED
(	O
n	O
=	O
5	O
each	O
):	O
a	O
normal	B-MED
occlusion	I-MED
(	O
C	O
)	O
group	B-MED
,	O
an	O
occlusal	B-MED
hypofunction	B-MED
(	O
H	O
)	O
group	B-MED
,	O
and	O
an	O
occlusal	B-MED
hypofunction	I-MED
group	I-MED
subjected	O
to	O
LIPUS	B-MED
(	O
HL	O
)	O
treatment	B-MED
.	O
Hypofunctional	B-MED
occlusion	B-MED
of	O
the	O
maxillary	B-MED
first	I-MED
molar	I-MED
(	O
M1	B-MED
)	O
of	O
the	O
H	B-MED
and	O
HL	B-MED
groups	I-MED
was	O
induced	O
by	O
the	O
bite	B-MED
-	I-MED
raising	I-MED
technique	I-MED
.	O
Only	O
the	O
HL	B-MED
group	I-MED
was	O
irradiated	O
with	O
LIPUS	B-MED
for	O
5	O
days	B-MED
.	O
The	O
IRAB	B-MED
and	O
PDL	B-MED
of	O
M1	B-MED
were	O
examined	O
by	O
microcomputed	B-MED
tomography	I-MED
(	O
micro	B-MED
-	I-MED
CT	I-MED
)	O
analysis	B-MED
.	O
To	O
quantify	O
mRNA	B-MED
expression	B-MED
of	O
cytokines	B-MED
involved	O
in	O
PDL	B-MED
proliferation	B-MED
and	O
development	B-MED
,	O
real	B-MED
-	I-MED
time	I-MED
reverse	I-MED
transcription	I-MED
quantitative	I-MED
PCR	I-MED
(	O
qRT	B-MED
-	I-MED
PCR	I-MED
)	O
was	O
performed	O
for	O
twist	B-MED
family	I-MED
bHLH	I-MED
transcription	I-MED
factor	I-MED
1	I-MED
(	O
Twist1	B-MED
)	O
,	O
periostin	B-MED
,	O
and	O
connective	B-MED
tissue	I-MED
growth	I-MED
factor	I-MED
(	O
CTGF	B-MED
)	O
in	O
the	O
PDL	B-MED
samples	B-MED
.	O
Micro	B-MED
-	I-MED
CT	I-MED
analysis	B-MED
showed	O
that	O
the	O
PDL	B-MED
volume	B-MED
was	O
decreased	O
in	O
the	O
H	B-MED
group	I-MED
compared	O
with	O
that	O
of	O
the	O
C	B-MED
and	O
HL	B-MED
groups	I-MED
.	O
Both	O
bone	B-MED
volume	I-MED
per	O
tissue	B-MED
volume	I-MED
(	O
BV	B-MED
/	O
TV	B-MED
)	O
of	O
IRAB	B-MED
was	O
decreased	O
in	O
the	O
H	B-MED
group	I-MED
compared	O
with	O
that	O
in	O
the	O
C	B-MED
group	I-MED
.	O
LIPUS	B-MED
exposure	O
restored	O
BV	B-MED
/	O
TV	B-MED
in	O
the	O
IRAB	B-MED
of	O
the	O
HL	B-MED
group	I-MED
.	O
qRT	B-MED
-	I-MED
PCR	I-MED
analysis	B-MED
showed	O
that	O
Twist1	B-MED
,	O
periostin	B-MED
,	O
and	O
CTGF	B-MED
mRNA	B-MED
levels	B-MED
were	O
decreased	O
in	O
the	O
H	B-MED
group	I-MED
and	O
increased	O
in	O
the	O
HL	B-MED
group	I-MED
.	O
LIPUS	B-MED
exposure	O
reduced	O
the	O
atrophic	B-MED
changes	B-MED
of	O
alveolar	B-MED
bone	I-MED
by	O
inducing	B-MED
the	O
upregulation	B-MED
of	O
periostin	B-MED
and	O
CTGF	B-MED
expression	B-MED
to	O
promote	O
PDL	B-MED
healing	B-MED
after	O
induction	B-MED
of	O
occlusal	B-MED
hypofunction	B-MED
.	O
LDL	B-MED
particle	B-MED
number	I-MED
and	O
size	B-MED
and	O
cardiovascular	B-MED
risk	B-MED
:	O
anything	O
new	O
under	O
the	O
sun	O
?	O
We	O
provide	O
here	O
an	O
up	O
-	O
to	O
-	O
date	O
perspective	O
on	O
the	O
potential	B-MED
use	B-MED
of	O
LDL	B-MED
particle	B-MED
number	I-MED
and	O
size	B-MED
as	O
complementary	O
risk	B-MED
factors	I-MED
to	O
predict	O
and	O
manage	O
cardiovascular	B-MED
disease	I-MED
(	O
CVD	B-MED
)	O
risk	B-MED
in	O
the	O
clinical	B-MED
realm	O
.	O
Studies	B-MED
show	O
that	O
a	O
significant	B-MED
proportion	B-MED
of	O
the	O
population	B-MED
has	O
discordant	B-MED
LDL	B-MED
particle	B-MED
number	I-MED
and	O
cholesterol	B-MED
indices	B-MED
[	O
non	B-MED
-	I-MED
HDL	I-MED
cholesterol	I-MED
(	O
HDL	B-MED
-	I-MED
C	I-MED
)	O
]	O
.	O
Data	O
also	O
show	O
that	O
risk	O
prediction	O
may	O
be	O
improved	O
when	O
using	O
information	B-MED
on	O
LDL	B-MED
particle	B-MED
number	I-MED
in	O
patients	B-MED
with	O
discordant	B-MED
particle	B-MED
number	I-MED
and	O
cholesterol	B-MED
data	O
.	O
Yet	O
,	O
most	O
of	O
the	O
current	O
CVD	B-MED
guidelines	B-MED
conclude	O
that	O
LDL	B-MED
particle	B-MED
number	I-MED
is	O
not	O
superior	O
to	O
cholesterol	B-MED
indices	B-MED
,	O
including	O
non	B-MED
-	I-MED
HDL	I-MED
-	I-MED
C	I-MED
concentrations	B-MED
,	O
in	O
predicting	O
CVD	B-MED
risk	B-MED
.	O
LDL	B-MED
particle	B-MED
size	I-MED
,	O
on	O
the	O
other	O
hand	O
,	O
has	O
not	O
been	O
independently	O
associated	B-MED
with	I-MED
CVD	B-MED
risk	B-MED
after	O
adjustment	B-MED
for	O
other	O
risk	B-MED
factors	I-MED
such	O
as	O
LDL	B-MED
cholesterol	I-MED
,	O
triglycerides	B-MED
,	O
and	O
HDL	B-MED
-	I-MED
C	I-MED
and	O
that	O
routine	O
use	O
of	O
information	B-MED
pertaining	O
to	O
particle	B-MED
size	I-MED
to	O
determine	O
and	O
manage	O
patients	B-MED
'	I-MED
risk	B-MED
is	O
not	O
yet	O
justified	O
.	O
Additional	B-MED
studies	B-MED
are	O
required	O
to	O
settle	O
the	O
debate	B-MED
on	O
which	O
of	O
cholesterol	B-MED
indices	B-MED
and	O
LDL	B-MED
particle	B-MED
number	I-MED
is	O
the	O
best	O
predictor	O
of	O
CVD	B-MED
risk	B-MED
,	O
and	O
if	O
such	O
measures	B-MED
should	O
be	O
integrated	O
in	O
clinical	B-MED
practice	I-MED
.	O
Identification	B-MED
of	O
In	B-MED
-	I-MED
Chain	I-MED
-	I-MED
Functionalized	I-MED
Compounds	I-MED
and	O
Methyl	B-MED
-	I-MED
Branched	I-MED
Alkanes	I-MED
in	O
Cuticular	B-MED
Waxes	B-MED
of	O
Triticum	B-MED
aestivum	I-MED
cv	I-MED
.	I-MED
Bethlehem	I-MED
In	O
this	O
work	O
,	O
cuticular	B-MED
waxes	B-MED
from	O
flag	B-MED
leaf	I-MED
blades	B-MED
and	O
peduncles	B-MED
of	O
Triticum	B-MED
aestivum	I-MED
cv	I-MED
.	I-MED
Bethlehem	I-MED
were	O
investigated	B-MED
in	O
search	O
for	O
novel	B-MED
wax	B-MED
compounds	I-MED
.	O
Seven	O
wax	B-MED
compound	I-MED
classes	B-MED
were	O
detected	B-MED
that	O
had	O
previously	O
not	O
been	O
reported	O
,	O
and	O
their	O
structures	B-MED
were	O
elucidated	O
using	O
gas	B-MED
chromatography	I-MED
-	I-MED
mass	I-MED
spectrometry	I-MED
of	O
various	O
derivatives	B-MED
.	O
Six	O
of	O
the	O
classes	O
were	O
identified	O
as	O
series	B-MED
of	I-MED
homologs	I-MED
differing	B-MED
by	O
two	B-MED
methylene	I-MED
units	I-MED
,	O
while	O
the	O
seventh	O
was	O
a	O
homologous	B-MED
series	I-MED
with	O
homologs	B-MED
with	I-MED
single	I-MED
methylene	I-MED
unit	I-MED
differences	O
.	O
In	O
the	O
waxes	B-MED
of	O
flag	B-MED
leaf	I-MED
blades	B-MED
,	O
secondary	B-MED
alcohols	I-MED
(	O
predominantly	B-MED
C27	B-MED
and	O
C33	B-MED
)	O
,	O
primary	B-MED
/	O
secondary	B-MED
diols	I-MED
(	O
predominantly	B-MED
C28	B-MED
)	O
and	O
esters	B-MED
of	I-MED
primary	I-MED
/	O
secondary	B-MED
diols	I-MED
(	O
predominantly	B-MED
C50	B-MED
,	O
combining	O
C28	B-MED
diol	I-MED
with	O
C22	B-MED
acid	I-MED
)	O
were	O
found	O
,	O
all	O
sharing	O
similar	O
secondary	B-MED
hydroxyl	I-MED
group	I-MED
positions	I-MED
at	O
and	O
around	O
C-12	O
or	O
ω-12	O
.	O
7-	B-MED
and	O
8	B-MED
-	I-MED
hydroxy-2	I-MED
-	I-MED
alkanol	I-MED
esters	I-MED
(	O
predominantly	B-MED
C35	B-MED
)	O
,	O
7-	B-MED
and	O
8	B-MED
-	I-MED
oxo-2	I-MED
-	I-MED
alkanol	I-MED
esters	I-MED
(	O
predominantly	B-MED
C35	B-MED
)	O
,	O
and	O
4	B-MED
-	I-MED
alkylbutan-4	I-MED
-	I-MED
olides	I-MED
(	O
predominantly	B-MED
C28	B-MED
)	O
were	O
found	O
both	O
in	O
flag	B-MED
leaf	I-MED
and	O
peduncle	B-MED
wax	B-MED
mixtures	O
.	O
Finally	O
,	O
a	O
series	B-MED
of	O
even	B-MED
-	O
and	O
odd	B-MED
-	I-MED
numbered	I-MED
alkane	I-MED
homologs	I-MED
was	O
identified	O
in	O
both	O
leaf	B-MED
and	O
peduncle	B-MED
waxes	B-MED
,	O
with	O
an	O
internal	B-MED
methyl	I-MED
branch	I-MED
preferentially	O
on	O
C-11	B-MED
and	O
C-13	B-MED
of	I-MED
homologs	I-MED
with	I-MED
even	I-MED
total	I-MED
carbon	I-MED
number	I-MED
and	O
on	O
C-12	B-MED
of	I-MED
odd	I-MED
-	I-MED
numbered	I-MED
homologs	I-MED
.	O
Biosynthetic	B-MED
pathways	I-MED
are	O
suggested	O
for	O
all	O
compounds	B-MED
,	O
based	O
on	O
common	O
structural	B-MED
features	B-MED
and	O
matching	O
chain	B-MED
length	I-MED
profiles	B-MED
with	O
other	O
wheat	B-MED
wax	B-MED
compound	I-MED
classes	O
.	O
Adenoviral	B-MED
Delivery	B-MED
of	O
Tumor	B-MED
Necrosis	I-MED
Factor	I-MED
-	I-MED
α	I-MED
and	O
Interleukin-2	B-MED
Enables	O
Successful	O
Adoptive	B-MED
Cell	I-MED
Therapy	I-MED
of	O
Immunosuppressive	B-MED
Melanoma	B-MED
Adoptive	B-MED
T	I-MED
-	I-MED
cell	I-MED
transfer	I-MED
is	O
a	O
promising	O
treatment	B-MED
approach	I-MED
for	O
metastatic	B-MED
cancer	I-MED
,	O
but	O
efficacy	B-MED
in	O
solid	B-MED
tumors	I-MED
has	O
only	O
been	O
achieved	O
with	O
toxic	B-MED
pre-	O
and	O
postconditioning	O
regimens	O
.	O
Thus	O
,	O
adoptive	B-MED
T	I-MED
-	I-MED
cell	I-MED
therapies	I-MED
would	O
benefit	B-MED
from	O
complementary	O
modalities	B-MED
that	O
enable	O
their	O
full	B-MED
potential	B-MED
without	O
excessive	B-MED
toxicity	B-MED
.	O
We	O
aimed	B-MED
to	O
improve	B-MED
the	O
efficacy	B-MED
and	O
safety	B-MED
of	O
adoptive	B-MED
T	I-MED
-	I-MED
cell	I-MED
transfer	I-MED
by	O
using	O
adenoviral	B-MED
vectors	I-MED
for	O
direct	O
delivery	B-MED
of	O
immunomodulatory	B-MED
murine	B-MED
cytokines	B-MED
into	O
B16.OVA	B-MED
melanoma	B-MED
tumors	I-MED
tumors	B-MED
with	O
concomitant	B-MED
T	B-MED
-	I-MED
cell	I-MED
receptor	I-MED
transgenic	B-MED
OT	I-MED
-	I-MED
I	I-MED
transgenic	B-MED
OT	I-MED
-	I-MED
I	I-MED
T	I-MED
-	I-MED
cell	I-MED
transfer	I-MED
.	O
Armed	O
adenoviruses	B-MED
expressed	O
high	O
local	O
and	O
low	O
systemic	O
levels	O
of	O
cytokine	B-MED
when	O
injected	B-MED
into	O
B16.OVA	B-MED
tumors	B-MED
,	O
suggesting	O
safety	B-MED
of	O
virus	B-MED
-	I-MED
mediated	I-MED
virus	B-MED
-	I-MED
mediated	I-MED
cytokine	I-MED
delivery	I-MED
cytokine	B-MED
.	O
Antitumor	B-MED
efficacy	B-MED
was	O
significantly	O
enhanced	B-MED
with	O
adenoviruses	B-MED
coding	O
for	O
murine	B-MED
interleukin-2	B-MED
(	O
mIL-2	B-MED
)	O
and	O
tumor	B-MED
necrosis	I-MED
factor	I-MED
-	I-MED
α	I-MED
(	O
mTNFα	B-MED
)	O
when	O
compared	O
with	O
T	B-MED
-	I-MED
cell	I-MED
transfer	I-MED
alone	O
or	O
viruses	B-MED
alone	O
.	O
Further	O
improvement	B-MED
in	O
efficacy	B-MED
was	O
achieved	O
with	O
a	O
triple	B-MED
combination	B-MED
of	O
mIL-2	B-MED
,	O
mTNFα	B-MED
,	O
and	O
OT	B-MED
-	I-MED
I	I-MED
T	I-MED
-	I-MED
cells	I-MED
.	O
Mechanistic	B-MED
studies	I-MED
suggest	O
that	O
mIL-2	B-MED
has	O
an	O
important	B-MED
role	B-MED
in	O
activating	B-MED
T	B-MED
-	I-MED
cells	I-MED
at	O
the	O
tumor	B-MED
,	O
while	O
mTNFα	B-MED
induces	O
chemokine	B-MED
expression	B-MED
.	O
Furthermore	O
,	O
adenovirus	B-MED
treatments	B-MED
enhanced	B-MED
tumor	B-MED
-	O
infiltration	O
of	O
OT	B-MED
-	I-MED
I	I-MED
T	I-MED
-	I-MED
cells	I-MED
as	O
demonstrated	B-MED
by	O
SPECT	B-MED
/	I-MED
CT	I-MED
imaging	I-MED
of	O
(	B-MED
111)In	I-MED
-	I-MED
labeled	I-MED
cells	I-MED
.	O
Our	O
results	B-MED
suggest	B-MED
the	O
utility	O
of	O
cytokine	B-MED
-	I-MED
coding	I-MED
adenoviruses	B-MED
for	O
improving	B-MED
the	O
efficacy	B-MED
of	O
adoptive	B-MED
T	I-MED
-	I-MED
cell	I-MED
therapies	I-MED
.	O
Sleep	B-MED
Loss	I-MED
Promotes	B-MED
Astrocytic	B-MED
Phagocytosis	B-MED
and	O
Microglial	B-MED
Activation	I-MED
in	O
Mouse	B-MED
Cerebral	I-MED
Cortex	I-MED
We	O
previously	O
found	O
that	O
Mertk	B-MED
and	O
its	O
ligand	B-MED
Gas6	I-MED
,	O
astrocytic	B-MED
genes	B-MED
involved	O
in	O
phagocytosis	B-MED
,	O
are	O
upregulated	B-MED
after	B-MED
acute	B-MED
sleep	B-MED
deprivation	I-MED
.	O
These	O
results	O
suggested	O
that	O
astrocytes	B-MED
may	O
engage	O
in	O
phagocytic	B-MED
activity	I-MED
during	B-MED
extended	B-MED
wake	B-MED
,	O
but	O
direct	B-MED
evidence	B-MED
was	O
lacking	B-MED
.	O
Studies	B-MED
in	O
humans	B-MED
and	O
rodents	B-MED
also	O
found	B-MED
that	O
sleep	B-MED
loss	I-MED
increases	B-MED
peripheral	B-MED
markers	B-MED
of	O
inflammation	B-MED
,	O
but	O
whether	O
these	O
changes	B-MED
are	O
associated	B-MED
with	I-MED
neuroinflammation	B-MED
and/or	O
activation	B-MED
of	O
microglia	B-MED
,	O
the	O
brain	B-MED
's	I-MED
resident	O
innate	B-MED
immune	I-MED
cells	I-MED
,	O
was	O
unknown	B-MED
.	O
Here	O
we	O
used	B-MED
serial	B-MED
block	I-MED
-	I-MED
face	I-MED
scanning	I-MED
electron	I-MED
microscopy	I-MED
to	O
obtain	O
3D	O
volume	B-MED
measurements	B-MED
of	O
synapses	B-MED
and	O
surrounding	B-MED
astrocytic	B-MED
processes	B-MED
in	O
mouse	B-MED
frontal	B-MED
cortex	I-MED
after	B-MED
6	O
-	O
8	O
h	O
of	O
sleep	B-MED
,	O
spontaneous	B-MED
wake	B-MED
,	O
or	O
sleep	B-MED
deprivation	I-MED
(	O
SD	B-MED
)	O
and	O
after	B-MED
chronic	B-MED
(	I-MED
∼5	I-MED
d	I-MED
)	I-MED
sleep	I-MED
restriction	I-MED
(	O
CSR	B-MED
)	O
.	O
Astrocytic	B-MED
phagocytosis	B-MED
,	O
mainly	O
of	O
presynaptic	B-MED
components	I-MED
of	I-MED
large	I-MED
synapses	I-MED
,	O
increased	B-MED
after	B-MED
both	B-MED
acute	B-MED
and	O
chronic	B-MED
sleep	B-MED
loss	I-MED
relative	B-MED
to	O
sleep	B-MED
and	O
wake	B-MED
.	O
MERTK	B-MED
expression	B-MED
and	O
lipid	B-MED
peroxidation	I-MED
in	O
synaptoneurosomes	B-MED
also	O
increased	B-MED
to	O
a	O
similar	B-MED
extent	B-MED
after	B-MED
short	B-MED
and	O
long	B-MED
sleep	B-MED
loss	I-MED
,	O
suggesting	O
that	O
astrocytic	B-MED
phagocytosis	B-MED
may	O
represent	B-MED
the	O
brain	B-MED
's	I-MED
response	B-MED
to	O
the	O
increase	B-MED
in	O
synaptic	B-MED
activity	I-MED
associated	B-MED
with	I-MED
prolonged	B-MED
wake	B-MED
,	O
clearing	B-MED
worn	O
components	O
of	O
heavily	O
used	B-MED
synapses	B-MED
.	O
Using	B-MED
confocal	B-MED
microscopy	I-MED
,	O
we	O
then	O
found	B-MED
that	O
CSR	B-MED
but	O
not	B-MED
SD	B-MED
mice	B-MED
show	O
morphological	B-MED
signs	B-MED
of	O
microglial	B-MED
activation	I-MED
and	O
enhanced	B-MED
microglial	B-MED
phagocytosis	B-MED
of	O
synaptic	B-MED
elements	I-MED
,	O
without	B-MED
obvious	O
signs	B-MED
of	O
neuroinflammation	B-MED
in	O
the	O
CSF	B-MED
.	O
Because	O
low	B-MED
-	O
level	B-MED
sustained	B-MED
microglia	B-MED
activation	I-MED
can	O
lead	O
to	O
abnormal	B-MED
responses	B-MED
to	O
a	O
secondary	B-MED
insult	B-MED
,	O
these	O
results	B-MED
suggest	B-MED
that	O
chronic	B-MED
sleep	B-MED
loss	I-MED
,	O
through	B-MED
microglia	B-MED
priming	B-MED
,	O
may	O
predispose	O
the	O
brain	B-MED
to	O
further	B-MED
damage	B-MED
.SIGNIFICANCE	O
STATEMENT	O
We	O
find	B-MED
that	O
astrocytic	B-MED
phagocytosis	B-MED
of	O
synaptic	B-MED
elements	I-MED
,	O
mostly	O
of	O
presynaptic	B-MED
origin	I-MED
and	O
in	O
large	B-MED
synapses	B-MED
,	O
is	O
upregulated	B-MED
already	O
after	B-MED
a	O
few	B-MED
hours	B-MED
of	O
sleep	B-MED
deprivation	I-MED
and	O
shows	O
a	O
further	B-MED
significant	B-MED
increase	B-MED
after	B-MED
prolonged	B-MED
and	O
severe	B-MED
sleep	B-MED
loss	I-MED
,	O
suggesting	O
that	O
it	O
may	O
promote	B-MED
the	O
housekeeping	B-MED
of	O
heavily	O
used	B-MED
and	O
strong	B-MED
synapses	B-MED
in	O
response	B-MED
to	O
the	O
increased	B-MED
neuronal	B-MED
activity	B-MED
of	O
extended	B-MED
wake	B-MED
.	O
By	O
contrast	B-MED
,	O
chronic	B-MED
sleep	I-MED
restriction	I-MED
but	O
not	B-MED
acute	B-MED
sleep	B-MED
loss	I-MED
activates	B-MED
microglia	B-MED
,	O
promotes	B-MED
their	O
phagocytic	B-MED
activity	I-MED
,	O
and	O
does	O
so	O
in	O
the	O
absence	B-MED
of	O
overt	O
signs	B-MED
of	O
neuroinflammation	B-MED
,	O
suggesting	O
that	O
like	O
many	O
other	B-MED
stressors	B-MED
,	O
extended	B-MED
sleep	B-MED
disruption	I-MED
may	O
lead	O
to	O
a	O
state	B-MED
of	O
sustained	B-MED
microglia	B-MED
activation	I-MED
,	O
perhaps	O
increasing	B-MED
the	O
brain	B-MED
's	I-MED
susceptibility	B-MED
to	O
other	B-MED
forms	B-MED
of	O
damage	B-MED
.	O
P	B-MED
-	I-MED
glycoprotein	I-MED
traffics	B-MED
from	O
the	O
nucleus	B-MED
to	O
the	O
plasma	B-MED
membrane	I-MED
in	O
rat	B-MED
brain	I-MED
endothelium	B-MED
during	O
inflammatory	B-MED
pain	I-MED
P	B-MED
-	I-MED
glycoprotein	I-MED
(	O
PgP	B-MED
)	O
,	O
a	O
drug	B-MED
efflux	B-MED
pump	I-MED
in	O
blood	B-MED
-	I-MED
brain	I-MED
barrier	I-MED
endothelial	B-MED
cells	I-MED
,	O
is	O
a	O
major	O
clinical	B-MED
obstacle	B-MED
for	O
effective	O
central	B-MED
nervous	I-MED
system	I-MED
drug	B-MED
delivery	I-MED
.	O
Identifying	B-MED
PgP	B-MED
regulatory	B-MED
pathways	I-MED
that	O
can	O
be	O
exploited	O
clinically	O
is	O
critical	O
for	O
improving	O
central	B-MED
nervous	I-MED
system	I-MED
drug	B-MED
delivery	I-MED
.	O
We	O
previously	O
found	O
that	O
PgP	B-MED
activity	I-MED
increases	B-MED
in	O
rat	B-MED
brain	I-MED
microvessels	B-MED
concomitant	B-MED
with	O
decreased	B-MED
central	B-MED
nervous	I-MED
system	I-MED
drug	B-MED
delivery	I-MED
in	O
response	O
to	O
acute	B-MED
peripheral	B-MED
inflammatory	B-MED
pain	I-MED
.	O
In	O
the	O
current	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
PgP	B-MED
traffics	B-MED
to	O
the	O
luminal	B-MED
plasma	B-MED
membrane	I-MED
of	O
the	O
microvessel	B-MED
endothelial	B-MED
cells	I-MED
from	O
intracellular	B-MED
stores	B-MED
during	O
peripheral	B-MED
inflammatory	B-MED
pain	I-MED
.	O
Using	O
immunofluorescence	B-MED
microscopy	I-MED
,	O
we	O
detected	B-MED
PgP	B-MED
in	O
endothelial	B-MED
cell	I-MED
nuclei	B-MED
and	O
in	O
the	O
luminal	B-MED
plasma	B-MED
membrane	I-MED
in	O
control	B-MED
animals	I-MED
.	O
Following	O
peripheral	B-MED
inflammatory	B-MED
pain	I-MED
,	O
luminal	B-MED
PgP	B-MED
staining	B-MED
increased	B-MED
while	O
staining	B-MED
in	O
the	O
nucleus	B-MED
decreased	B-MED
.	O
Biochemical	B-MED
analysis	I-MED
of	O
nuclear	B-MED
PgP	B-MED
content	B-MED
confirmed	O
our	O
visual	B-MED
observations	I-MED
.	O
Peripheral	B-MED
inflammatory	B-MED
pain	I-MED
also	O
increased	B-MED
endothelial	B-MED
cell	I-MED
luminal	B-MED
staining	B-MED
of	O
polymerase	B-MED
1	I-MED
and	I-MED
transcript	I-MED
release	I-MED
factor	I-MED
/	O
cavin1	B-MED
and	O
serum	B-MED
deprivation	I-MED
response	I-MED
protein	I-MED
/	O
cavin2	B-MED
,	O
two	O
caveolar	B-MED
scaffold	I-MED
proteins	I-MED
,	O
without	O
changing	O
caveolin1	B-MED
or	O
protein	B-MED
kinase	I-MED
C	I-MED
delta	I-MED
binding	I-MED
protein	I-MED
/	O
cavin3	B-MED
location	B-MED
.	O
Our	O
data	B-MED
(	O
a	O
)	O
indicate	O
that	O
PgP	B-MED
traffics	B-MED
from	O
stores	B-MED
in	O
the	O
nucleus	B-MED
to	O
the	O
endothelial	B-MED
cell	I-MED
luminal	B-MED
membrane	I-MED
in	O
response	O
to	O
peripheral	B-MED
inflammatory	B-MED
pain	I-MED
;	O
(	O
b	O
)	O
provide	O
an	O
explanation	O
for	O
our	O
previous	O
observation	B-MED
that	O
peripheral	B-MED
inflammatory	B-MED
pain	I-MED
inhibits	B-MED
central	B-MED
nervous	I-MED
system	I-MED
drug	B-MED
uptake	B-MED
;	O
and	O
(	O
c	O
)	O
suggest	O
a	O
novel	B-MED
regulatory	B-MED
mechanism	I-MED
for	O
PgP	B-MED
activity	I-MED
in	O
rat	B-MED
brain	I-MED
.	O
A	O
completely	B-MED
calcified	B-MED
prostate	B-MED
Prostatic	B-MED
calcification	I-MED
and	O
prostatic	B-MED
calculus	I-MED
formation	B-MED
is	O
commonly	O
seen	O
in	O
adult	B-MED
population	B-MED
with	O
chronic	B-MED
prostatitis	I-MED
,	O
however	O
,	O
gross	O
prostatic	B-MED
calcification	I-MED
which	O
involves	O
more	O
than	O
3	O
cm(2	O
)	O
of	O
the	O
gland	B-MED
is	O
quite	O
rare	B-MED
.	O
We	O
are	O
presenting	B-MED
here	O
one	O
such	O
case	B-MED
in	O
which	O
almost	O
whole	O
glandular	B-MED
prostate	I-MED
was	O
converted	B-MED
into	O
stone	B-MED
which	O
is	O
never	O
reported	O
so	O
far	O
.	O
Antenatal	B-MED
Stressful	B-MED
Life	I-MED
Events	I-MED
and	O
Postpartum	B-MED
Depressive	B-MED
Symptoms	I-MED
in	O
the	O
United	B-MED
States	I-MED
:	O
The	O
Role	O
of	O
Women	B-MED
's	I-MED
Socioeconomic	B-MED
Status	I-MED
Indices	B-MED
at	O
the	O
State	B-MED
Level	I-MED
Approximately	O
10%-20	O
%	O
of	O
women	B-MED
suffer	B-MED
from	O
postpartum	B-MED
depression	I-MED
(	O
PPD	B-MED
)	O
,	O
important	O
predictors	B-MED
of	O
which	O
are	O
antenatal	B-MED
stressful	B-MED
life	I-MED
event	I-MED
(	O
SLE	B-MED
)	O
experiences	B-MED
.	O
The	O
association	B-MED
between	O
women	B-MED
's	I-MED
state	B-MED
-	I-MED
level	I-MED
socioeconomic	B-MED
status	I-MED
(	O
SES	B-MED
)	O
and	O
PPD	B-MED
has	O
not	O
been	O
explored	O
.	O
This	O
study	B-MED
aimed	O
to	O
examine	O
whether	O
the	O
association	B-MED
between	O
antenatal	B-MED
SLE	B-MED
and	O
PPD	B-MED
symptoms	B-MED
was	O
moderated	B-MED
by	O
women	B-MED
's	I-MED
state	B-MED
-	I-MED
level	I-MED
SES	B-MED
.	O
Data	B-MED
from	O
the	O
2009	O
-	O
2011	O
Pregnancy	B-MED
Risk	I-MED
Assessment	I-MED
Monitoring	I-MED
System	I-MED
(	O
PRAMS	B-MED
)	O
were	O
used	O
.	O
State	B-MED
-	I-MED
level	I-MED
women	B-MED
's	I-MED
employment	B-MED
/	O
earnings	B-MED
and	O
social	B-MED
/	O
economic	B-MED
autonomy	B-MED
indices	B-MED
were	O
computed	O
from	O
indicators	B-MED
published	O
by	O
the	O
Institute	B-MED
of	I-MED
Women	I-MED
's	I-MED
Policy	I-MED
Research	I-MED
(	O
IWPR	B-MED
)	O
.	O
Multilevel	B-MED
multivariable	I-MED
logistic	I-MED
regression	I-MED
analyses	I-MED
were	O
performed	O
.	O
Among	O
91,253	O
women	B-MED
with	O
valid	B-MED
responses	B-MED
,	O
11.3	O
%	O
had	O
PPD	B-MED
symptoms	B-MED
,	O
prevalence	B-MED
ranging	O
from	O
7.1	O
%	O
in	O
Illinois	B-MED
to	O
17.1	O
%	O
in	O
Arkansas	B-MED
.	O
Women	B-MED
who	O
experienced	O
all	O
four	O
stressor	B-MED
categories	B-MED
,	O
including	O
partner	B-MED
related	B-MED
,	O
traumatic	B-MED
,	O
emotional	B-MED
,	O
and	O
financial	B-MED
,	O
had	O
the	O
highest	O
odds	B-MED
(	O
adjusted	B-MED
odds	I-MED
ratio	I-MED
[	O
aOR	B-MED
]	O
:	O
5.43	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
:	O
5.36	O
-	O
5.51	O
)	O
of	O
PPD	B-MED
symptoms	B-MED
.	O
The	O
odds	B-MED
of	O
experiencing	O
PPD	B-MED
symptoms	B-MED
decreased	B-MED
with	O
an	O
increase	B-MED
in	O
the	O
state	B-MED
-	I-MED
level	I-MED
social	B-MED
/	O
economic	B-MED
autonomy	B-MED
index	B-MED
(	O
aOR	B-MED
:	O
0.75	O
;	O
95	O
%	O
CI	B-MED
:	O
0.64	O
-	O
0.88	O
)	O
.	O
There	O
was	O
significant	O
cross	B-MED
-	I-MED
level	I-MED
interaction	I-MED
between	O
number	O
of	O
stressor	B-MED
categories	B-MED
experienced	O
and	O
state	B-MED
-	I-MED
level	I-MED
index	B-MED
.	O
Screening	B-MED
for	O
antenatal	B-MED
SLEs	B-MED
can	O
help	O
identify	O
women	B-MED
at	B-MED
risk	I-MED
for	O
PPD	B-MED
symptoms	B-MED
.	O
That	O
the	O
odds	B-MED
of	O
having	O
PPD	B-MED
symptoms	B-MED
decreased	B-MED
with	O
increasing	B-MED
state	B-MED
-	I-MED
level	I-MED
social	B-MED
/	O
economic	B-MED
autonomy	B-MED
and	O
women	B-MED
residing	O
in	O
states	B-MED
with	O
lower	O
indices	B-MED
were	O
more	B-MED
vulnerable	I-MED
to	O
the	O
impacts	O
of	O
antenatal	B-MED
stressors	B-MED
,	O
could	O
have	O
policy	B-MED
implications	I-MED
related	O
to	O
improving	O
the	O
SES	B-MED
of	O
women	B-MED
in	O
these	O
states	B-MED
.	O
Interprofessional	B-MED
Barriers	I-MED
:	O
A	O
Study	O
of	O
Quality	B-MED
Improvement	I-MED
Work	I-MED
Among	O
Nurses	B-MED
and	O
Physicians	B-MED
This	O
article	O
studies	O
interprofessional	B-MED
barriers	I-MED
between	O
nurses	B-MED
and	O
physicians	B-MED
in	O
the	O
context	B-MED
of	O
quality	B-MED
improvement	I-MED
work	I-MED
.	O
A	O
total	O
of	O
17	O
nurses	B-MED
and	O
10	O
physicians	B-MED
were	O
interviewed	B-MED
at	O
2	O
hospitals	B-MED
in	O
Sweden	B-MED
.	O
The	O
study	B-MED
uncovered	I-MED
a	O
number	B-MED
of	I-MED
barriers	I-MED
relating	O
to	O
both	O
the	O
relative	O
status	O
of	O
each	B-MED
group	I-MED
and	O
their	O
defined	O
areas	B-MED
of	I-MED
responsibility	I-MED
.	O
Draft	B-MED
Genome	I-MED
Sequence	I-MED
of	O
Bacillus	B-MED
cereus	I-MED
LA2007	I-MED
,	O
a	O
Human	B-MED
-	I-MED
Pathogenic	I-MED
Isolate	I-MED
Harboring	O
Anthrax	B-MED
Anthrax	B-MED
-Like	I-MED
Plasmids	I-MED
We	O
present	O
the	O
genome	B-MED
sequence	I-MED
of	O
Bacillus	B-MED
cereus	I-MED
LA2007	I-MED
,	O
a	O
strain	B-MED
isolated	B-MED
in	O
2007	O
from	O
a	O
fatal	B-MED
pneumonia	I-MED
case	B-MED
in	O
Louisiana	B-MED
.	O
Sequence	B-MED
-	I-MED
based	I-MED
genome	I-MED
analysis	I-MED
revealed	B-MED
that	O
LA2007	B-MED
carries	B-MED
a	O
plasmid	B-MED
highly	O
similar	O
to	O
Bacillus	B-MED
anthracis	I-MED
pXO1	I-MED
,	O
including	O
the	O
genes	B-MED
responsible	O
for	O
the	O
production	B-MED
and	O
regulation	B-MED
of	O
anthrax	B-MED
toxin	I-MED
.	O
Psychological	B-MED
Distress	I-MED
Is	O
More	O
Prevalent	O
in	O
Fertile	B-MED
Age	B-MED
and	O
Premenopausal	B-MED
Women	B-MED
with	O
PCOS	B-MED
Symptoms	B-MED
-15	O
-	O
yr	O
Follow	B-MED
-	I-MED
up	I-MED
Polycystic	B-MED
ovary	I-MED
syndrome	I-MED
(	O
PCOS	B-MED
)	O
is	O
associated	O
with	O
increased	O
psychological	B-MED
distress	I-MED
;	O
obesity	B-MED
and	O
hyperandrogenism	B-MED
being	O
suggested	O
as	O
key	O
promoters	B-MED
.	O
To	O
investigate	B-MED
the	O
prevalence	B-MED
of	O
anxiety	B-MED
/	O
depression	B-MED
and	O
their	O
coexistence	O
in	O
women	B-MED
with	O
PCOS	B-MED
/	O
PCOS	B-MED
symptoms	B-MED
at	O
age	B-MED
s	O
31	O
and	O
46	O
.	O
The	O
roles	O
of	O
obesity	B-MED
,	O
hyperandrogenism	B-MED
and	O
awareness	B-MED
of	O
PCOS	B-MED
on	O
psychological	B-MED
distress	I-MED
were	O
also	O
assessed	B-MED
.	O
Population	B-MED
based	I-MED
follow	I-MED
-	I-MED
up	I-MED
.	O
Northern	B-MED
Finland	I-MED
Birth	B-MED
Cohort	I-MED
1966	O
with	O
15-	O
year	B-MED
follow	B-MED
-	I-MED
up	I-MED
.	O
At	O
age	B-MED
31	O
a	O
questionnaire	B-MED
-	I-MED
based	I-MED
screening	I-MED
for	O
oligoamenorrhea	B-MED
(	O
OA	B-MED
)	O
and	O
hirsutism	B-MED
(	O
H	B-MED
):	O
2188	O
asymptomatic	B-MED
(	O
controls	B-MED
)	O
,	O
331	O
OA	B-MED
,	O
323	O
H	B-MED
,	O
125	O
OA	B-MED
+	O
H	B-MED
(	O
PCOS	B-MED
)	O
.	O
46	O
year	B-MED
old	O
follow	B-MED
-	I-MED
up	I-MED
:	O
1576	O
controls	B-MED
,	O
239	O
OA	B-MED
,	O
231	O
H	B-MED
and	O
85	O
PCOS	B-MED
.	O
Questionnaire	B-MED
-	I-MED
based	I-MED
screening	I-MED
for	O
anxiety	B-MED
and	O
depression	B-MED
symptoms	I-MED
(	O
Hopkins	B-MED
Symptom	I-MED
Checklist-25	I-MED
)	O
and	O
previously	O
diagnosed	B-MED
/	O
treated	B-MED
depression	B-MED
at	O
age	B-MED
31	O
and	O
46	O
.	O
BMI	B-MED
,	O
serum	B-MED
testosterone	I-MED
/	O
free	B-MED
androgen	I-MED
index	I-MED
(	O
FAI	B-MED
)	O
and	O
awareness	B-MED
of	O
polycystic	B-MED
ovaries	I-MED
/	O
PCOS	B-MED
on	O
psychological	B-MED
distress	I-MED
were	O
also	O
assessed	B-MED
.	O
Population	B-MED
-	I-MED
based	I-MED
prevalence	I-MED
of	O
anxiety	B-MED
and/or	O
depression	B-MED
in	O
women	B-MED
with	O
PCOS	B-MED
/	O
PCOS	B-MED
symptoms	B-MED
at	O
age	B-MED
s	O
31	O
and	O
46	O
.	O
Anxiety	B-MED
and/or	O
depression	B-MED
symptoms	I-MED
,	O
their	O
coexistence	O
and	O
rate	O
of	O
depression	B-MED
were	O
increased	O
at	O
age	B-MED
31	O
and	O
46	O
in	O
women	B-MED
with	O
PCOS	B-MED
or	O
isolated	O
H	B-MED
compared	O
with	O
controls	B-MED
.	O
High	O
BMI	B-MED
or	O
hyperandrogenism	B-MED
did	O
not	O
associate	O
with	O
increased	O
anxiety	B-MED
or	O
depression	B-MED
symptoms	I-MED
.	O
The	O
awareness	B-MED
of	O
PCOS	B-MED
was	O
associated	O
with	O
increased	O
anxiety	B-MED
.	O
Women	B-MED
with	O
PCOS	B-MED
or	O
isolated	O
H	B-MED
present	O
more	O
often	O
with	O
anxiety	B-MED
and/or	O
depression	B-MED
symptoms	I-MED
and	O
their	O
coexistence	O
compared	O
with	O
controls	B-MED
.	O
High	O
BMI	B-MED
or	O
hyperandrogenism	B-MED
did	O
not	O
provoke	O
psychological	B-MED
distress	I-MED
in	O
PCOS	B-MED
.	O
The	O
awareness	B-MED
of	O
PCOS	B-MED
increased	O
anxiety	B-MED
but	O
did	O
not	O
associate	O
with	O
severe	O
anxiety	B-MED
or	O
depression	B-MED
.	O
Medication	B-MED
regimen	I-MED
complexity	B-MED
and	O
prevalence	B-MED
of	O
potentially	B-MED
inappropriate	I-MED
medicines	I-MED
in	O
older	B-MED
patients	B-MED
after	O
hospitalisation	B-MED
Background	O
There	O
is	O
a	O
relative	B-MED
paucity	O
of	O
information	B-MED
to	O
characterise	O
potential	B-MED
changes	B-MED
in	O
medication	B-MED
regimen	I-MED
complexity	B-MED
and	O
prevalence	B-MED
of	O
prescribing	B-MED
of	O
potentially	B-MED
inappropriate	I-MED
medications	I-MED
after	O
hospitalisation	B-MED
,	O
both	O
in	O
Australia	B-MED
and	O
elsewhere	O
.	O
Objective	B-MED
To	O
evaluate	B-MED
medication	B-MED
regimen	I-MED
complexity	B-MED
and	O
the	O
prevalence	B-MED
of	O
potentially	B-MED
inappropriate	I-MED
medications	I-MED
before	B-MED
and	O
after	O
admission	B-MED
to	I-MED
hospital	I-MED
.	O
Setting	O
General	B-MED
medical	I-MED
units	I-MED
of	O
a	O
tertiary	B-MED
care	I-MED
hospital	I-MED
in	O
Australia	B-MED
.	O
Methods	O
Retrospective	B-MED
cohort	I-MED
study	I-MED
of	O
patients	B-MED
aged	B-MED
65	O
years	O
and	O
above	O
.	O
Medication	B-MED
complexity	B-MED
was	O
measured	B-MED
by	O
using	O
the	O
Medication	B-MED
Regimen	I-MED
Complexity	I-MED
Index	I-MED
(	O
MRCI	B-MED
)	O
.	O
Main	B-MED
outcome	I-MED
measure	I-MED
The	O
primary	B-MED
outcome	I-MED
was	O
the	O
change	B-MED
in	O
the	O
Medication	B-MED
Regimen	I-MED
Complexity	I-MED
Index	I-MED
for	O
all	O
prescribed	B-MED
medications	I-MED
after	O
hospitalization	B-MED
.	O
Results	B-MED
A	O
convenience	B-MED
sample	I-MED
of	O
100	O
patients	B-MED
was	O
included	B-MED
in	O
the	O
study	B-MED
.	O
There	O
was	O
a	O
significant	B-MED
change	B-MED
in	O
the	O
mean	B-MED
medication	B-MED
complexity	B-MED
score	B-MED
(	O
as	O
measured	B-MED
using	O
the	O
MRCI	B-MED
)	O
,	O
increasing	B-MED
from	O
29	O
at	O
the	O
time	B-MED
of	I-MED
admission	I-MED
to	O
32	O
at	O
the	O
time	B-MED
of	I-MED
discharge	I-MED
(	O
p	O
<	O
0.05	O
)	O
.	O
Factors	B-MED
such	O
as	O
baseline	B-MED
medication	B-MED
regimen	I-MED
complexity	B-MED
(	O
pre	B-MED
-	I-MED
admission	I-MED
MRCI	B-MED
)	O
and	O
length	B-MED
of	I-MED
stay	I-MED
in	I-MED
the	I-MED
hospitals	I-MED
appear	B-MED
to	O
influence	B-MED
the	O
change	B-MED
in	O
medication	B-MED
complexity	B-MED
.	O
However	O
,	O
the	O
proportion	B-MED
of	O
patients	B-MED
prescribed	B-MED
at	O
least	O
one	O
potentially	B-MED
inappropriate	I-MED
medicine	I-MED
(	O
PIM	B-MED
)	O
decreased	B-MED
significantly	I-MED
,	O
from	O
52	O
%	O
pre	B-MED
-	I-MED
hospitalization	I-MED
to	O
42	O
%	O
at	B-MED
discharge	I-MED
(	O
p	O
=	O
0.04	O
)	O
.	O
Conclusions	O
Relative	B-MED
to	O
the	O
time	B-MED
of	I-MED
admission	I-MED
,	O
overall	B-MED
medication	B-MED
complexity	B-MED
increased	B-MED
and	O
the	O
proportion	B-MED
of	O
patients	B-MED
who	O
were	O
prescribed	B-MED
PIMs	B-MED
decreased	B-MED
after	O
hospitalisation	B-MED
.	O
The	O
role	O
of	O
the	O
hippocampus	B-MED
and	O
the	O
function	O
of	O
calcitonin	B-MED
gene	I-MED
-	I-MED
related	I-MED
peptide	I-MED
in	O
the	O
mechanism	O
of	O
traumatic	B-MED
brain	I-MED
injury	I-MED
accelerating	O
fracture	B-MED
-	I-MED
healing	I-MED
This	O
research	O
attempts	O
to	O
identify	O
the	O
part	O
the	O
hippocampus	B-MED
plays	O
in	O
accelerated	O
fracture	B-MED
-	I-MED
healing	I-MED
after	O
traumatic	B-MED
brain	I-MED
injury	I-MED
as	O
well	O
as	O
to	O
test	O
functions	O
of	O
calcitonin	B-MED
gene	I-MED
-	I-MED
related	I-MED
peptide	I-MED
(	O
CGRP	B-MED
)	O
during	O
this	O
process	O
.	O
Experiments	O
were	O
carried	O
out	O
on	O
Male	O
Sprague	B-MED
-	I-MED
Dawley	I-MED
rats	I-MED
that	O
were	O
split	O
into	O
four	O
groups	B-MED
at	O
random	O
:	O
TBI	B-MED
-	O
fracture	B-MED
group	B-MED
,	O
fracture	B-MED
-	O
only	B-MED
group	B-MED
,	O
TBI	B-MED
-	O
only	B-MED
group	B-MED
,	O
and	O
control	B-MED
group	I-MED
.	O
In	O
the	O
first	O
week	O
,	O
blood	B-MED
specimen	I-MED
would	O
be	O
drawn	O
from	O
rats	B-MED
among	O
the	O
groups	B-MED
except	O
those	O
of	O
the	O
control	B-MED
group	I-MED
at	O
three	O
-	O
time	O
points	O
(	O
24	O
,	O
72	O
and	O
168	O
hours	O
)	O
post	B-MED
-	O
damage	B-MED
.	O
These	O
rats	B-MED
would	O
be	O
assessed	O
from	O
the	O
neurological	B-MED
perspective	O
based	O
on	O
their	O
grades	O
of	O
performance	O
in	O
a	O
sequence	O
of	O
tests	O
24	O
hours	O
before	O
and	O
12	O
hours	O
after	O
brain	B-MED
injury	I-MED
.	O
Blood	B-MED
samples	I-MED
were	O
also	O
taken	O
from	O
the	O
control	B-MED
group	I-MED
24	O
hours	O
before	O
the	O
injury	B-MED
,	O
and	O
whole	O
brain	B-MED
tissues	I-MED
in	O
the	O
injured	B-MED
groups	B-MED
were	O
harvested	B-MED
at	O
72	O
and	O
168	O
hours	O
post	B-MED
-	O
injury	B-MED
.	O
We	O
compared	O
the	O
serum	B-MED
CGRP	B-MED
concentration	B-MED
,	O
the	O
distribution	O
of	O
CGRP	B-MED
,	O
the	O
CGRP	B-MED
expression	B-MED
,	O
and	O
the	O
expression	B-MED
of	O
CGRP	B-MED
in	O
the	O
hippocampus	B-MED
,	O
the	O
expression	B-MED
of	O
CGRP	B-MED
in	O
the	O
hippocampus	B-MED
,	O
the	O
expression	B-MED
of	O
CGRP	B-MED
in	O
the	O
hippocampus	B-MED
,	O
and	O
the	O
expression	B-MED
of	O
CGRP	B-MED
in	O
the	O
brain	B-MED
by	O
immunohistochemistry	B-MED
,	O
Western	B-MED
blotting	I-MED
,	O
RT	B-MED
-	O
Of	O
CGRP	B-MED
RNA	B-MED
expression	I-MED
levels	O
.	O
Neurological	B-MED
examinations	I-MED
suggested	O
that	O
the	O
functions	O
of	O
the	O
cerebral	B-MED
cortex	I-MED
,	O
cerebellum	B-MED
,	O
and	O
brain	B-MED
stem	I-MED
showed	O
significant	O
differences	O
pre	B-MED
-	O
and	O
post	B-MED
-	O
injury	B-MED
(	O
p	O
<	O
0.001	O
)	O
.	O
ELISA	B-MED
analysis	I-MED
indicated	O
a	O
great	O
density	O
of	O
CGRP	B-MED
in	O
TBI	B-MED
-	O
fracture	B-MED
group	B-MED
at	O
different	O
time	O
points	O
.	O
Furthermore	O
,	O
in	O
the	O
TBI	B-MED
-	O
fracture	B-MED
group	B-MED
,	O
CGRP	B-MED
in	O
both	O
hippocampus	B-MED
and	O
the	O
whole	B-MED
brain	I-MED
showed	O
a	O
noticeable	O
augment	O
in	O
RT	B-MED
-	I-MED
PCR	I-MED
and	O
western	B-MED
blot	I-MED
analysis	I-MED
at	O
72	O
and	O
168	O
h	O
post	B-MED
-	O
injury	B-MED
,	O
and	O
only	B-MED
in	O
this	O
group	O
,	O
immunohistochemistry	B-MED
analysis	I-MED
indicated	O
that	O
CGRP	B-MED
was	O
present	O
in	O
the	O
hippocampus	B-MED
at	O
168	O
hours	O
post	B-MED
-	O
injury	B-MED
.	O
We	O
observed	O
that	O
the	O
hippocampus	B-MED
and	O
CGRP	B-MED
were	O
responsible	O
for	O
quick	O
bone	B-MED
-	I-MED
healing	I-MED
mechanisms	O
.	O
We	O
suggest	O
a	O
role	O
for	O
the	O
hippocampus	B-MED
in	O
accelerated	O
fracture	B-MED
healing	I-MED
.	O
CGRP	B-MED
expression	B-MED
,	O
as	O
determined	O
by	O
IHC	B-MED
,	O
can	O
not	O
be	O
observed	O
in	O
other	O
groups	B-MED
,	O
indicating	O
that	O
the	O
hippocampus	B-MED
may	O
be	O
the	O
specific	O
component	O
of	O
the	O
brain	B-MED
that	O
responds	O
to	O
"	O
big	B-MED
stress	I-MED
"	O
.	O
Acute	B-MED
Complicated	I-MED
Sinusitis	I-MED
:	O
Ten	O
Years	B-MED
Experience	B-MED
from	O
the	O
University	B-MED
Hospital	I-MED
of	O
the	O
West	B-MED
Indies	I-MED
Complicated	B-MED
sinusitis	I-MED
is	O
rare	B-MED
.	O
It	O
might	O
not	O
be	O
identified	O
early	O
and	O
might	O
expose	O
the	O
patient	B-MED
to	O
an	O
unfavourable	B-MED
outcome	I-MED
.	O
There	O
is	O
a	O
paucity	O
of	O
data	B-MED
regarding	O
this	O
condition	B-MED
in	O
the	O
Caribbean	B-MED
.	O
This	O
study	B-MED
was	O
undertaken	O
to	O
describe	O
the	O
clinical	B-MED
characteristics	I-MED
and	O
treatment	B-MED
outcomes	I-MED
of	O
patients	B-MED
admitted	B-MED
with	O
this	O
condition	B-MED
.	O
A	O
retrospective	B-MED
chart	B-MED
review	I-MED
was	O
performed	O
on	O
patients	B-MED
admitted	B-MED
to	O
the	O
University	B-MED
Hospital	I-MED
of	I-MED
the	I-MED
West	I-MED
Indies	I-MED
(	O
UHWI	B-MED
)	O
with	O
complicated	B-MED
sinusitis	I-MED
between	O
1999	O
to	O
2011	O
.	O
The	O
data	B-MED
was	O
analysed	B-MED
using	O
SPSS	B-MED
statistics	I-MED
22	I-MED
software	I-MED
.	O
There	O
were	O
30	O
patients	B-MED
(	O
23	O
males	B-MED
and	O
7	O
females	B-MED
)	O
.	O
The	O
mean	B-MED
(	O
SD	B-MED
)	O
age	B-MED
was	O
19	O
(	O
13.96	O
)	O
years	B-MED
.	O
Twenty	O
-	O
two	O
had	O
orbital	B-MED
complications	B-MED
,	O
two	O
had	O
intracranial	B-MED
complications	B-MED
and	O
one	O
had	O
both	O
.	O
The	O
most	O
common	B-MED
organisms	B-MED
isolated	B-MED
were	O
streptococcus	B-MED
and	O
the	O
most	O
common	B-MED
sensitivity	B-MED
was	O
to	O
amoxicillin	B-MED
and	O
clavulinic	B-MED
acid	I-MED
.	O
Sixteen	O
patients	B-MED
who	O
had	O
an	O
external	B-MED
surgical	B-MED
approach	I-MED
had	O
a	O
mean	B-MED
(	O
SD	B-MED
)	O
hospital	B-MED
stay	I-MED
of	O
8.8	O
(	O
3.71	O
)	O
days	B-MED
compared	O
to	O
three	O
patients	B-MED
who	O
had	O
a	O
purely	O
endoscopic	B-MED
approach	I-MED
who	O
had	O
a	O
mean	B-MED
(	O
SD	B-MED
)	O
hospital	B-MED
stay	I-MED
of	O
7.67	O
(	O
0.577	O
)	O
days	B-MED
.	O
There	O
was	O
no	B-MED
statistical	B-MED
difference	I-MED
in	O
mean	B-MED
hospital	B-MED
stay	I-MED
between	O
these	O
two	O
groups	B-MED
(	O
95	O
%	O
CI,-3.49	O
-	O
5.78	O
;	O
p	O
=	O
0.609	O
)	O
.	O
The	O
mean	B-MED
duration	B-MED
of	O
hospital	B-MED
stay	I-MED
for	O
those	O
treated	B-MED
medically	I-MED
was	O
six	O
days	B-MED
versus	O
ten	O
days	B-MED
for	O
the	O
surgical	B-MED
group	B-MED
.	O
The	O
mean	B-MED
difference	B-MED
was	O
three	O
days	B-MED
(	O
95	O
%	O
CI	O
,	O
0.193	O
-	O
6.595	O
;	O
p	O
=	O
0.039	O
)	O
.	O
Acute	B-MED
complicated	I-MED
sinusitis	I-MED
is	O
seen	O
more	O
commonly	B-MED
in	O
adolescent	B-MED
males	I-MED
.	O
The	O
most	O
common	B-MED
complication	B-MED
was	O
orbital	B-MED
.	O
Surgical	B-MED
treatment	I-MED
is	O
indicated	O
for	O
those	O
patients	B-MED
who	O
fail	B-MED
medical	B-MED
management	B-MED
and	O
should	O
consist	O
of	O
an	O
endoscopic	B-MED
approach	I-MED
which	O
may	O
be	O
combined	O
with	O
open	O
approaches	O
if	O
indicated	O
.	O
Nitrogen	B-MED
utilization	I-MED
efficiency	B-MED
and	O
prediction	B-MED
of	O
nitrogen	B-MED
excretion	B-MED
in	O
sheep	B-MED
offered	B-MED
fresh	B-MED
perennial	I-MED
ryegrass	I-MED
(	O
)	O
Nitrogen	B-MED
excretion	B-MED
from	O
sheep	B-MED
production	B-MED
systems	I-MED
is	O
an	O
important	O
source	O
of	O
nitrate	B-MED
,	O
ammonia	B-MED
,	O
and	O
nitrous	B-MED
oxide	I-MED
responsible	O
for	O
groundwater	B-MED
pollution	B-MED
and	O
global	B-MED
warming	I-MED
.	O
The	O
present	O
study	B-MED
aimed	O
to	O
identify	B-MED
key	B-MED
parameters	I-MED
influencing	O
N	B-MED
utilization	I-MED
efficiency	B-MED
and	O
develop	O
prediction	B-MED
equations	B-MED
for	O
manure	B-MED
N	B-MED
,	O
feces	B-MED
N	B-MED
,	O
and	O
urine	B-MED
N	B-MED
outputs	B-MED
in	O
sheep	B-MED
.	O
Data	B-MED
used	O
were	O
collected	O
from	O
82	O
sheep	B-MED
offered	B-MED
fresh	B-MED
perennial	I-MED
ryegrass	I-MED
(	O
)	O
as	O
the	O
sole	B-MED
diet	I-MED
in	O
6	O
metabolism	B-MED
experiments	B-MED
(	O
data	B-MED
from	O
non	B-MED
-	I-MED
grass	I-MED
-	I-MED
only	I-MED
diets	I-MED
were	O
not	B-MED
used	I-MED
)	O
.	O
Sheep	B-MED
were	O
from	O
breeds	B-MED
of	O
Highlander	B-MED
,	O
Texel	B-MED
,	O
Scottish	B-MED
Blackface	I-MED
,	O
and	O
Swaledale	B-MED
at	O
the	O
age	B-MED
of	O
5	O
to	O
18	O
mo	B-MED
and	O
weighing	O
from	O
24.5	O
to	O
62.7	O
kg	O
.	O
Herbage	B-MED
was	O
harvested	B-MED
daily	B-MED
from	O
6	O
swards	B-MED
of	O
contrasting	O
harvest	B-MED
dates	B-MED
(	O
May	O
to	O
December	O
)	O
,	O
offering	B-MED
wide	O
variation	B-MED
in	O
feed	O
value	O
to	O
cover	O
the	O
range	B-MED
that	O
would	O
be	O
offered	B-MED
in	O
most	O
practical	O
farm	B-MED
situations	I-MED
.	O
Before	O
the	O
commencement	O
of	O
each	O
study	B-MED
,	O
the	O
experimental	B-MED
sward	B-MED
was	O
harvested	B-MED
at	O
a	O
residual	B-MED
height	I-MED
of	O
4	O
cm	O
and	O
allowed	O
to	O
grow	B-MED
for	O
2	O
to	O
4	O
wk	B-MED
to	O
target	B-MED
an	O
average	O
pregrazing	O
sward	B-MED
height	B-MED
in	O
a	O
range	B-MED
of	O
8	O
to	O
15	O
cm	O
depending	B-MED
on	O
the	O
time	B-MED
of	I-MED
year	I-MED
.	O
Sheep	B-MED
were	O
housed	B-MED
in	O
individual	O
pens	O
for	O
14	O
d	B-MED
and	O
then	O
transferred	B-MED
to	I-MED
individual	O
metabolism	B-MED
crates	O
for	O
4	O
d	B-MED
with	O
feed	B-MED
intake	B-MED
and	O
feces	B-MED
and	O
urine	B-MED
outputs	B-MED
measured	O
.	O
Data	B-MED
were	O
analyzed	B-MED
using	O
the	O
linear	B-MED
mixed	I-MED
model	I-MED
procedure	I-MED
to	O
develop	O
prediction	B-MED
equations	B-MED
for	O
feces	B-MED
N	O
,	O
urine	B-MED
N	O
,	O
and	O
manure	B-MED
N	B-MED
outputs	B-MED
using	O
N	B-MED
intake	I-MED
,	O
herbage	B-MED
chemical	B-MED
composition	I-MED
,	O
and	O
digestibility	B-MED
with	O
effects	B-MED
of	I-MED
sex	B-MED
,	O
breed	B-MED
,	O
and	O
experimental	O
periods	B-MED
removed	B-MED
.	O
Nitrogen	B-MED
intake	B-MED
was	O
the	O
best	B-MED
single	B-MED
predictor	I-MED
for	O
N	B-MED
output	B-MED
in	O
feces	B-MED
,	O
urine	B-MED
,	O
and	O
manure	B-MED
,	O
and	O
the	O
value	O
for	O
prediction	B-MED
of	O
manure	B-MED
N	B-MED
output	B-MED
was	O
greater	B-MED
than	O
those	O
for	O
feces	B-MED
N	B-MED
and	O
urine	B-MED
N	B-MED
(	O
0.86	O
vs.	O
0.70	O
and	O
0.77	O
,	O
respectively	O
;	O
<	O
0.001	O
)	O
.	O
Animal	B-MED
BW	B-MED
and	O
herbage	B-MED
DM	B-MED
,	O
ether	B-MED
extract	I-MED
,	O
NDF	B-MED
,	O
ADF	B-MED
,	O
water	B-MED
soluble	I-MED
carbohydrate	I-MED
,	O
and	O
DE	O
concentrations	O
and	O
N	B-MED
digestibility	B-MED
were	O
also	O
used	O
to	O
predict	B-MED
N	B-MED
outputs	B-MED
because	O
N	B-MED
intake	B-MED
may	O
not	B-MED
be	I-MED
available	I-MED
in	O
commercial	B-MED
practice	I-MED
.	O
The	O
prediction	B-MED
equations	B-MED
for	O
N	B-MED
utilizatio	I-MED
n	O
efficiency	B-MED
indicated	O
that	O
increasing	B-MED
feeding	B-MED
level	B-MED
and	O
ME	B-MED
concentration	B-MED
and	O
reducing	B-MED
N	B-MED
concentration	I-MED
could	O
improve	B-MED
N	B-MED
utilization	I-MED
efficiency	B-MED
and	O
shift	O
N	B-MED
excretion	B-MED
into	O
feces	B-MED
rather	B-MED
than	I-MED
urine	B-MED
(	O
<	O
0.001	O
)	O
.	O
The	O
equations	B-MED
developed	O
in	O
the	O
current	O
study	B-MED
provide	O
an	O
approach	B-MED
for	O
sheep	B-MED
producers	B-MED
to	O
quantify	B-MED
N	B-MED
excretion	B-MED
against	O
production	B-MED
and	O
,	O
consequently	O
,	O
to	O
develop	O
their	O
own	O
mitigation	B-MED
strategies	I-MED
to	O
reduce	B-MED
the	O
environmental	B-MED
impact	I-MED
of	O
sheep	B-MED
production	B-MED
systems	I-MED
.	O
DRG1	B-MED
is	O
a	O
potential	O
oncogene	B-MED
in	O
lung	B-MED
adenocarcinoma	I-MED
and	O
promotes	B-MED
tumor	B-MED
progression	I-MED
via	O
spindle	B-MED
checkpoint	I-MED
signaling	I-MED
regulation	B-MED
Developmentally	O
regulated	O
GTP	B-MED
binding	I-MED
protein	I-MED
1	I-MED
(	O
DRG1	B-MED
)	O
,	O
a	O
member	O
of	O
the	O
DRG	B-MED
family	I-MED
,	O
plays	O
important	O
roles	O
in	O
regulating	B-MED
cell	I-MED
growth	I-MED
.	O
However	O
,	O
the	O
molecular	B-MED
basis	I-MED
of	O
DRG1	B-MED
in	O
cell	B-MED
proliferation	I-MED
regulation	I-MED
and	O
the	O
relationship	O
between	O
DRG1	B-MED
and	O
tumor	B-MED
progression	I-MED
remain	O
poorly	O
understood	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
DRG1	B-MED
is	O
elevated	O
in	O
lung	B-MED
adenocarcinomas	I-MED
while	O
weakly	O
expressed	B-MED
in	O
adjacent	O
lung	B-MED
tissues	B-MED
.	O
DRG1	B-MED
knockdown	B-MED
causes	O
growth	B-MED
inhibition	I-MED
of	O
tumor	B-MED
cells	I-MED
by	O
significantly	O
increasing	O
the	O
proportion	O
of	O
cells	B-MED
in	O
M	B-MED
phase	I-MED
.	O
Overexpression	B-MED
of	O
DRG1	B-MED
leads	O
to	O
chromosome	B-MED
missegregation	B-MED
which	O
is	O
an	O
important	O
index	O
for	O
tumorigenesis	B-MED
.	O
Interestingly	O
,	O
ectopic	B-MED
of	O
DRG1	B-MED
reduces	O
taxol	B-MED
induced	B-MED
apoptosis	B-MED
of	O
lung	B-MED
adenocarcinoma	I-MED
cells	B-MED
.	O
Mechanistic	B-MED
analyses	B-MED
confirm	O
that	O
DRG1	B-MED
localizes	B-MED
at	O
mitotic	B-MED
spindles	I-MED
in	O
dividing	B-MED
cells	I-MED
and	O
binds	B-MED
to	O
spindle	B-MED
checkpoint	I-MED
signaling	I-MED
proteins	B-MED
in	B-MED
vivo	I-MED
.	O
These	O
studies	B-MED
highlight	O
the	O
expanding	O
role	O
of	O
DRG1	B-MED
in	O
tumorigenesis	B-MED
and	O
reveal	O
a	O
mechanism	B-MED
of	O
DRG1	B-MED
in	O
taxol	B-MED
resistance	O
.	O
Influence	B-MED
of	O
Different	B-MED
Levels	B-MED
of	O
Lipoic	B-MED
Acid	I-MED
Synthase	I-MED
Gene	B-MED
Expression	I-MED
on	O
Diabetic	B-MED
Nephropathy	I-MED
Oxidative	B-MED
stress	I-MED
is	O
implicated	O
in	O
the	O
pathogenesis	B-MED
of	O
diabetic	B-MED
nephropathy	I-MED
(	O
DN	B-MED
)	O
but	O
outcomes	B-MED
of	O
many	O
clinical	B-MED
trials	I-MED
are	O
controversial	O
.	O
To	O
define	O
the	O
role	B-MED
of	O
antioxidants	B-MED
in	O
kidney	B-MED
protection	O
during	B-MED
the	O
development	B-MED
of	O
diabetic	B-MED
nephropathy	I-MED
,	O
we	O
have	O
generated	B-MED
a	O
novel	B-MED
genetic	B-MED
antioxidant	I-MED
mouse	I-MED
model	I-MED
with	O
over-	B-MED
or	I-MED
under	I-MED
-	I-MED
expression	I-MED
of	O
lipoic	B-MED
acid	I-MED
synthase	I-MED
gene	I-MED
(	O
Lias	B-MED
)	O
.	O
These	O
models	B-MED
have	O
been	O
mated	B-MED
with	O
Ins2Akita/+	B-MED
mice	I-MED
,	O
a	O
type	B-MED
I	I-MED
diabetic	I-MED
mouse	B-MED
model	I-MED
.	O
We	O
compare	B-MED
the	O
major	B-MED
pathologic	B-MED
changes	I-MED
and	O
oxidative	B-MED
stress	I-MED
status	B-MED
in	O
two	O
new	O
strains	O
of	O
the	O
mice	B-MED
with	O
controls	O
.	O
Our	O
results	B-MED
show	O
that	O
Ins2Akita/+	B-MED
mice	I-MED
with	O
under	B-MED
-	I-MED
expressed	I-MED
Lias	B-MED
gene	I-MED
,	O
exhibit	O
higher	B-MED
oxidative	B-MED
stress	I-MED
and	O
more	B-MED
severe	B-MED
DN	B-MED
features	B-MED
(	O
albuminuria	B-MED
,	O
glomerular	B-MED
basement	I-MED
membrane	I-MED
thickening	I-MED
and	O
mesangial	B-MED
matrix	I-MED
expansion	I-MED
)	O
.	O
In	O
contrast	O
,	O
Ins2Akita/+	B-MED
mice	I-MED
with	O
highly	B-MED
-	O
expressed	B-MED
Lias	B-MED
gene	I-MED
display	B-MED
lower	B-MED
oxidative	B-MED
stress	I-MED
and	O
less	B-MED
DN	B-MED
pathologic	B-MED
changes	I-MED
.	O
Our	O
study	B-MED
demonstrates	B-MED
that	O
strengthening	O
endogenous	B-MED
antioxidant	B-MED
capacity	B-MED
could	O
be	O
an	O
effective	B-MED
strategy	I-MED
for	I-MED
prevention	I-MED
and	O
treatment	B-MED
of	O
DN	B-MED
.	O
Alcohol	B-MED
brief	I-MED
intervention	I-MED
in	O
primary	B-MED
care	I-MED
:	O
Blood	B-MED
pressure	I-MED
outcomes	B-MED
in	O
hypertensive	B-MED
patients	B-MED
In	O
clinical	B-MED
trials	I-MED
alcohol	B-MED
brief	I-MED
intervention	I-MED
(	O
BI	B-MED
)	O
in	O
adult	B-MED
primary	B-MED
care	I-MED
has	O
been	O
efficacious	B-MED
in	O
reducing	B-MED
alcohol	B-MED
consumption	I-MED
,	O
but	O
we	O
know	O
little	O
about	O
its	O
impact	B-MED
on	O
health	B-MED
outcomes	I-MED
.	O
Hypertension	B-MED
is	O
a	O
prevalent	O
and	O
costly	O
chronic	B-MED
condition	I-MED
in	O
the	O
U.S.	B-MED
and	O
worldwide	B-MED
,	O
and	O
alcohol	B-MED
use	I-MED
is	O
a	O
modifiable	O
hypertension	B-MED
risk	B-MED
factor	I-MED
.	O
To	O
evaluate	O
the	O
effect	B-MED
of	O
receiving	O
BI	B-MED
for	O
unhealthy	B-MED
drinking	I-MED
on	O
blood	B-MED
pressure	I-MED
(	I-MED
BP	I-MED
)	I-MED
control	I-MED
among	O
adult	B-MED
hypertensive	B-MED
patients	B-MED
by	O
analyzing	B-MED
secondary	I-MED
data	I-MED
from	O
a	O
clustered	B-MED
,	O
randomized	B-MED
controlled	I-MED
trial	I-MED
on	O
alcohol	B-MED
screening	I-MED
,	O
brief	B-MED
intervention	I-MED
and	O
referral	B-MED
to	I-MED
treatment	I-MED
(	O
SBIRT	B-MED
)	O
implementation	B-MED
by	O
primary	B-MED
care	I-MED
physicians	I-MED
(	O
PCP	B-MED
intervention	I-MED
arm	I-MED
)	O
and	O
non	B-MED
-	I-MED
physician	I-MED
providers	I-MED
and	O
medical	B-MED
assistants	I-MED
(	O
NPP	B-MED
&	O
MA	B-MED
intervention	I-MED
arm	I-MED
)	O
in	O
a	O
large	O
,	O
integrated	B-MED
health	I-MED
care	I-MED
delivery	I-MED
system	I-MED
.	O
Observational	B-MED
,	O
prospective	B-MED
cohort	I-MED
study	I-MED
.	O
3811	O
adult	B-MED
hypertensive	B-MED
primary	B-MED
care	I-MED
patients	I-MED
screening	B-MED
positive	O
for	O
past	B-MED
-	I-MED
year	I-MED
heavy	B-MED
drinking	I-MED
at	O
baseline	B-MED
,	O
of	O
which	O
1422	O
(	O
37	O
%	O
)	O
had	O
an	O
electronic	B-MED
health	I-MED
record	I-MED
BP	B-MED
measure	O
at	O
baseline	B-MED
and	O
18	B-MED
-	I-MED
month	I-MED
follow	B-MED
-	I-MED
up	I-MED
.	O
Change	B-MED
in	I-MED
BP	I-MED
and	O
controlled	B-MED
BP	I-MED
(	O
systolic	B-MED
/	I-MED
diastolic	I-MED
BP	I-MED
<	O
140/90	O
mmHg	B-MED
)	O
.	O
Overall	O
no	O
significant	O
associations	B-MED
were	O
found	O
between	O
alcohol	B-MED
BI	I-MED
and	O
BP	B-MED
change	I-MED
at	O
18	B-MED
-	I-MED
month	I-MED
follow	B-MED
-	I-MED
up	I-MED
when	O
analyzing	O
the	O
combined	O
sample	O
of	O
subjects	B-MED
in	O
both	O
intervention	B-MED
arms	I-MED
.	O
However	O
,	O
moderation	O
analyses	O
found	O
that	O
receiving	O
BI	B-MED
for	O
positive	O
past	B-MED
-	I-MED
year	I-MED
unhealthy	B-MED
drinking	I-MED
was	O
positively	O
associated	B-MED
with	I-MED
better	O
BP	B-MED
control	I-MED
at	O
18months	B-MED
in	O
the	O
PCP	B-MED
intervention	I-MED
arm	I-MED
,	O
and	O
for	O
those	O
with	O
lower	O
heavy	B-MED
drinking	I-MED
frequency	B-MED
and	O
poor	O
BP	B-MED
control	I-MED
at	O
the	O
index	B-MED
screening	I-MED
.	O
Our	O
findings	O
suggest	O
that	O
hypertensive	B-MED
patients	B-MED
may	O
benefit	B-MED
from	O
receiving	O
physician	B-MED
brief	B-MED
intervention	I-MED
for	O
unhealthy	B-MED
alcohol	I-MED
use	I-MED
in	O
primary	B-MED
care	I-MED
.	O
Findings	O
also	O
highlight	O
potential	O
population	B-MED
-	I-MED
level	I-MED
benefits	I-MED
of	O
alcohol	B-MED
BI	I-MED
if	O
widely	O
applied	O
,	O
suggesting	O
a	O
need	O
for	O
the	O
development	O
of	O
innovative	O
strategies	O
to	O
facilitate	O
SBIRT	B-MED
delivery	I-MED
in	O
primary	B-MED
care	I-MED
settings	O
.	O
Pharmacological	B-MED
Actions	I-MED
of	O
Glucagon	B-MED
-	I-MED
Like	I-MED
Peptide-1	I-MED
,	O
Gastric	B-MED
Inhibitory	I-MED
Polypeptide	I-MED
,	O
and	O
Glucagon	B-MED
Glucagon	B-MED
family	I-MED
of	O
peptide	B-MED
hormones	I-MED
is	O
a	O
group	O
of	O
structurally	O
related	O
brain	B-MED
-	I-MED
gut	I-MED
peptides	I-MED
that	O
exert	O
their	O
pleiotropic	B-MED
actions	I-MED
through	O
interactions	B-MED
with	O
unique	B-MED
members	I-MED
of	I-MED
class	I-MED
B1	I-MED
G	B-MED
protein	I-MED
-	I-MED
coupled	I-MED
receptors	I-MED
(	O
GPCRs	B-MED
)	O
.	O
They	O
are	O
key	O
regulators	B-MED
of	O
hormonal	B-MED
homeostasis	B-MED
and	O
are	O
important	O
drug	B-MED
targets	I-MED
for	O
metabolic	B-MED
disorders	I-MED
such	O
as	O
type-2	B-MED
diabetes	I-MED
mellitus	I-MED
(	O
T2DM	B-MED
)	O
,	O
obesity	B-MED
,	O
and	O
dysregulations	B-MED
of	I-MED
the	I-MED
nervous	I-MED
systems	I-MED
such	O
as	O
migraine	B-MED
,	O
anxiety	B-MED
,	O
depression	B-MED
,	O
neurodegeneration	B-MED
,	O
psychiatric	B-MED
disorders	I-MED
,	O
and	O
cardiovascular	B-MED
diseases	I-MED
.	O
The	O
current	O
review	O
aims	O
to	O
provide	O
a	O
detailed	O
overview	B-MED
of	O
the	O
current	O
understanding	O
of	O
the	O
pharmacological	B-MED
actions	I-MED
and	O
therapeutic	B-MED
advances	I-MED
of	O
three	O
members	O
within	O
this	O
family	O
including	O
glucagon	B-MED
-	I-MED
like	I-MED
peptide-1	I-MED
(	O
GLP-1	B-MED
)	O
,	O
gastric	B-MED
inhibitory	I-MED
polypeptide	I-MED
(	O
GIP	B-MED
)	O
,	O
and	O
glucagon	B-MED
.	O
Fairness	B-MED
:	O
the	O
hidden	O
challenge	B-MED
for	O
competency	B-MED
-	I-MED
based	I-MED
postgraduate	I-MED
medical	I-MED
education	I-MED
programs	I-MED
Competency	B-MED
-	I-MED
based	I-MED
medical	I-MED
education	I-MED
systems	I-MED
allow	O
institutions	B-MED
to	O
individualize	B-MED
teaching	B-MED
practices	I-MED
to	O
meet	B-MED
the	O
needs	B-MED
of	O
diverse	B-MED
learners	I-MED
.	O
Yet	O
,	O
the	O
focus	O
on	O
continuous	O
improvement	B-MED
and	O
individualization	B-MED
of	O
curricula	B-MED
does	O
not	O
exempt	O
programs	B-MED
from	O
treating	O
learners	B-MED
in	O
a	O
fair	B-MED
manner	I-MED
.	O
When	O
learners	B-MED
fail	O
to	O
meet	O
key	O
competencies	B-MED
and	O
are	O
placed	O
on	O
probation	B-MED
or	O
dismissed	B-MED
from	O
training	B-MED
programs	I-MED
,	O
issues	B-MED
of	O
fairness	B-MED
may	O
form	O
the	O
basis	O
of	O
their	O
legal	B-MED
claims	I-MED
.	O
In	O
a	O
literature	O
search	O
,	O
we	O
found	O
no	O
in	O
-	O
depth	O
examination	B-MED
of	O
fairness	B-MED
.	O
In	O
this	O
paper	O
,	O
we	O
utilize	O
a	O
systems	O
lens	O
to	O
examine	B-MED
fairness	B-MED
within	O
postgraduate	B-MED
medical	I-MED
education	I-MED
contexts	B-MED
,	O
focusing	O
on	O
educational	B-MED
opportunities	I-MED
,	O
assessment	B-MED
practices	I-MED
,	O
decision	B-MED
-	I-MED
making	I-MED
processes	I-MED
,	O
fairness	B-MED
from	O
a	O
legal	B-MED
standpoint	I-MED
,	O
and	O
fairness	B-MED
in	O
the	O
context	B-MED
of	O
the	O
learning	B-MED
environment	I-MED
.	O
While	O
we	O
provide	O
examples	O
of	O
fairness	B-MED
issues	B-MED
within	O
US	B-MED
training	B-MED
programs	I-MED
,	O
concerns	O
regarding	O
fairness	B-MED
are	O
relevant	O
in	O
any	O
medical	B-MED
education	I-MED
system	I-MED
which	O
utilizes	O
a	O
competency	B-MED
-	I-MED
based	I-MED
education	I-MED
framework	I-MED
.	O
Assessment	B-MED
oversight	O
committees	B-MED
and	O
annual	B-MED
programmatic	I-MED
evaluations	I-MED
,	O
while	O
recommended	O
,	O
will	O
not	O
guarantee	O
fairness	B-MED
within	O
postgraduate	B-MED
medical	I-MED
education	I-MED
programs	I-MED
,	O
but	O
they	O
can	O
provide	O
a	O
window	O
into	O
'	O
hidden	O
'	O
threats	O
to	O
fairness	B-MED
,	O
as	O
everything	O
from	O
training	B-MED
experiences	I-MED
to	O
assessment	B-MED
practices	I-MED
may	O
be	O
examined	B-MED
by	O
these	O
committees	B-MED
.	O
One	O
of	O
the	O
first	O
steps	O
programs	B-MED
can	O
take	O
is	O
to	O
recognize	O
that	O
threats	O
to	O
fairness	B-MED
may	O
exist	O
in	O
any	O
educational	B-MED
program	I-MED
,	O
including	O
their	O
own	O
,	O
and	O
begin	O
conversations	B-MED
about	O
how	O
to	O
address	O
these	O
issues	B-MED
.	O
Mesenchymal	B-MED
stromal	I-MED
cells	I-MED
in	O
clinical	B-MED
kidney	B-MED
transplantation	I-MED
:	O
how	O
tolerant	B-MED
can	O
it	O
be	O
?	O
Progress	B-MED
in	O
the	O
improvement	B-MED
of	O
short	B-MED
-	I-MED
term	I-MED
and	O
long	B-MED
-	I-MED
term	I-MED
outcomes	B-MED
of	O
kidney	B-MED
transplantation	I-MED
seems	O
to	O
have	O
reached	O
a	O
plateau	B-MED
,	O
partially	O
due	O
to	O
consequences	B-MED
of	I-MED
very	O
efficient	B-MED
,	O
but	O
nonspecific	B-MED
immunosuppressive	B-MED
drugs	I-MED
.	O
In	O
recent	O
years	O
,	O
various	O
forms	O
of	O
cell	B-MED
therapy	I-MED
,	O
including	O
the	O
use	O
of	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
,	O
have	O
been	O
put	O
forward	O
as	O
an	O
alternative	B-MED
strategy	B-MED
for	O
more	O
defined	O
therapy	B-MED
.	O
It	O
is	O
thought	O
that	O
these	O
therapies	B-MED
will	O
not	O
only	O
allow	O
controlled	B-MED
tapering	B-MED
of	O
immunosuppressive	B-MED
medication	I-MED
,	O
but	O
might	O
bring	O
us	O
also	O
closer	O
to	O
the	O
ambition	B-MED
of	O
generating	B-MED
donor	B-MED
-specific	O
immune	B-MED
regulation	I-MED
and	O
tolerance	B-MED
.	O
Different	O
forms	O
of	O
alloimmunity	B-MED
,	O
including	O
direct	B-MED
,	O
indirect	B-MED
and	O
semi	B-MED
-	I-MED
direct	I-MED
alloantigen	B-MED
presentation	O
have	O
to	O
be	O
controlled	O
before	O
donor	B-MED
-specific	O
immune	B-MED
regulation	I-MED
can	O
be	O
reached	O
.	O
Several	O
mechanisms	B-MED
have	O
been	O
described	O
how	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
can	O
affect	O
alloimmunity	B-MED
.	O
Especially	O
,	O
the	O
interaction	B-MED
with	O
professional	O
antigen	B-MED
presenting	I-MED
cells	I-MED
,	O
like	O
dendritic	B-MED
cells	I-MED
,	O
is	O
of	O
critical	B-MED
importance	B-MED
.	O
This	O
review	O
will	O
discuss	O
the	O
current	B-MED
status	B-MED
of	O
ongoing	O
clinical	B-MED
trials	I-MED
with	O
mesenchymal	B-MED
stromal	I-MED
cells	I-MED
in	O
kidney	B-MED
transplantation	I-MED
and	O
specifically	O
concentrate	O
on	O
the	O
possibilities	O
and	O
impossibilities	O
of	O
how	O
these	O
therapeutic	B-MED
strategies	I-MED
can	O
contribute	B-MED
to	O
control	B-MED
of	O
the	O
different	O
forms	O
of	O
alloreactivity	B-MED
operation	O
in	O
organ	B-MED
transplantation	I-MED
.	O
Total	B-MED
Arsenic	B-MED
,	O
Cadmium	B-MED
,	O
and	O
Lead	B-MED
Determination	B-MED
in	O
Brazilian	B-MED
Rice	I-MED
Samples	B-MED
Using	O
ICP	B-MED
-	I-MED
MS	I-MED
This	O
study	B-MED
is	O
aimed	O
at	O
investigating	B-MED
a	O
suitable	O
method	B-MED
for	O
rice	B-MED
sample	B-MED
preparation	B-MED
as	O
well	O
as	O
validating	B-MED
and	O
applying	B-MED
the	O
method	B-MED
for	O
monitoring	B-MED
the	O
concentration	B-MED
of	O
total	B-MED
arsenic	B-MED
,	O
cadmium	B-MED
,	O
and	O
lead	B-MED
in	O
rice	B-MED
by	O
using	O
Inductively	B-MED
Coupled	I-MED
Plasma	I-MED
Mass	I-MED
Spectrometry	I-MED
(	O
ICP	B-MED
-	I-MED
MS	I-MED
)	O
.	O
Various	O
rice	B-MED
sample	B-MED
preparation	B-MED
procedures	B-MED
were	O
evaluated	O
.	O
The	O
analytical	B-MED
method	I-MED
was	O
validated	B-MED
by	O
measuring	B-MED
several	O
parameters	B-MED
including	O
limit	B-MED
of	I-MED
detection	I-MED
(	O
LOD	B-MED
)	O
,	O
limit	B-MED
of	I-MED
quantification	I-MED
(	O
LOQ	B-MED
)	O
,	O
linearity	B-MED
,	O
relative	B-MED
bias	I-MED
,	O
and	O
repeatability	B-MED
.	O
Regarding	O
the	O
sample	B-MED
preparation	B-MED
,	O
recoveries	B-MED
of	O
spiked	B-MED
samples	I-MED
were	O
within	O
the	O
acceptable	B-MED
range	I-MED
from	O
89.3	O
to	O
98.2	O
%	O
for	O
muffle	B-MED
furnace	I-MED
,	O
94.2	O
to	O
103.3	O
%	O
for	O
heating	B-MED
block	I-MED
,	O
81.0	O
to	O
115.0	O
%	O
for	O
hot	B-MED
plate	I-MED
,	O
and	O
92.8	O
to	O
108.2	O
%	O
for	O
microwave	B-MED
.	O
Validation	B-MED
parameters	B-MED
showed	O
that	O
the	O
method	B-MED
fits	O
for	O
its	O
purpose	O
,	O
being	O
the	O
total	B-MED
arsenic	B-MED
,	O
cadmium	B-MED
,	O
and	O
lead	B-MED
within	O
the	O
Brazilian	O
Legislation	O
limits	O
.	O
The	O
method	B-MED
was	O
applied	O
for	O
analyzing	B-MED
37	O
rice	B-MED
samples	B-MED
(	O
including	O
polished	B-MED
,	O
brown	B-MED
,	O
and	O
parboiled	B-MED
)	O
,	O
consumed	O
by	O
the	O
Brazilian	B-MED
population	I-MED
.	O
The	O
total	B-MED
arsenic	B-MED
,	O
cadmium	B-MED
,	O
and	O
lead	B-MED
contents	B-MED
were	O
lower	O
than	O
the	O
established	O
legislative	B-MED
values	B-MED
,	O
except	O
for	O
total	B-MED
arsenic	B-MED
in	O
one	O
brown	B-MED
rice	I-MED
sample	B-MED
.	O
This	O
study	B-MED
indicated	O
the	O
need	O
to	O
establish	O
monitoring	B-MED
programs	B-MED
for	O
emphasizing	O
the	O
study	B-MED
on	O
this	O
type	B-MED
of	O
cereal	B-MED
,	O
aiming	O
at	O
promoting	O
the	O
Public	B-MED
Health	I-MED
.	O
Meta	B-MED
-	I-MED
Analysis	I-MED
of	O
29	O
Experiments	B-MED
Evaluating	B-MED
the	O
Effects	B-MED
of	I-MED
Rapamycin	B-MED
on	O
Life	B-MED
Span	I-MED
in	O
the	O
Laboratory	B-MED
Mouse	I-MED
Rapamycin	B-MED
has	O
favorable	O
effects	B-MED
on	O
aging	B-MED
in	O
mice	B-MED
and	O
may	O
eventually	O
be	O
applied	B-MED
to	O
encourage	O
"	O
healthy	B-MED
aging	B-MED
"	O
in	O
humans	B-MED
.	O
This	O
study	B-MED
analyzed	B-MED
raw	B-MED
data	B-MED
from	O
29	O
survival	B-MED
studies	I-MED
of	O
rapamycin	B-MED
-	O
and	O
control	B-MED
-	O
treated	B-MED
mice	B-MED
,	O
with	O
the	O
goals	B-MED
of	O
estimating	B-MED
summary	B-MED
statistics	B-MED
and	O
identifying	B-MED
factors	B-MED
associated	B-MED
with	I-MED
effect	B-MED
size	I-MED
heterogeneity	B-MED
.	O
Meta	B-MED
-	I-MED
analysis	I-MED
demonstrated	B-MED
significant	B-MED
heterogeneity	B-MED
across	O
studies	B-MED
,	O
with	O
hazard	B-MED
ratio	I-MED
(	B-MED
HR	I-MED
)	I-MED
estimates	B-MED
ranging	B-MED
from	O
0.22	O
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	B-MED
CI	I-MED
]	I-MED
:	O
0.06	O
-	O
0.82	O
)	O
to	O
0.92	O
(	O
95	O
%	O
CI	B-MED
:	O
0.65	O
-	O
1.28	O
)	O
.	O
Sex	B-MED
was	O
the	O
major	B-MED
factor	B-MED
accounting	B-MED
for	O
effect	B-MED
size	I-MED
variation	B-MED
,	O
and	O
mortality	B-MED
was	O
decreased	B-MED
more	B-MED
in	O
females	B-MED
(	O
HR	B-MED
=	O
0.41	O
;	O
95	O
%	O
CI	B-MED
:	O
0.35	O
-	O
0.48	O
)	O
as	O
compared	B-MED
with	O
males	B-MED
(	O
HR	B-MED
=	O
0.63	O
;	O
95	O
%	O
CI	B-MED
:	O
0.55	O
-	O
0.71	O
)	O
.	O
Rapamycin	B-MED
effects	B-MED
were	O
also	O
genotype	B-MED
dependent	B-MED
,	O
however	O
,	O
with	O
stronger	B-MED
survivorship	B-MED
increases	B-MED
in	O
hybrid	B-MED
mice	B-MED
(	O
14.4	O
%	O
;	O
95	O
%	O
CI	B-MED
:	O
12.5	O
-	O
16.3	O
%	O
)	O
relative	B-MED
to	O
pure	B-MED
inbred	B-MED
strains	I-MED
(	O
8.8	O
%	O
;	O
95	O
%	O
CI	B-MED
:	O
6.2	O
-	O
11.6	O
%	O
)	O
.	O
Number	B-MED
needed	B-MED
to	O
treat	B-MED
was	O
applied	B-MED
as	O
an	O
effect	B-MED
size	I-MED
metric	B-MED
,	O
which	O
consistently	O
identified	B-MED
early	O
senescence	B-MED
as	O
the	O
age	B-MED
of	O
peak	B-MED
treatment	B-MED
benefit	B-MED
.	O
These	O
results	B-MED
provide	B-MED
synthesis	B-MED
of	O
existing	B-MED
data	B-MED
to	O
support	B-MED
the	O
potential	O
translation	B-MED
of	O
findings	B-MED
from	O
mouse	B-MED
to	O
primate	B-MED
species	I-MED
.	O
Because	O
rapamycin	B-MED
's	I-MED
effect	B-MED
on	O
survival	B-MED
depends	B-MED
on	O
sex	B-MED
and	O
genotype	B-MED
,	O
further	O
work	O
is	O
justified	O
to	O
understand	O
how	O
these	O
factors	B-MED
shape	O
treatment	B-MED
response	B-MED
.	O
Inhibition	B-MED
of	O
STEP61	B-MED
ameliorates	B-MED
deficits	B-MED
in	O
mouse	B-MED
and	O
hiPSC	B-MED
-based	O
schizophrenia	B-MED
models	B-MED
The	O
brain	B-MED
-	O
specific	B-MED
tyrosine	B-MED
phosphatase	I-MED
,	O
STEP	B-MED
(	O
STriatal	B-MED
-	I-MED
Enriched	I-MED
protein	I-MED
tyrosine	I-MED
Phosphatase	I-MED
)	O
is	O
an	O
important	O
regulator	B-MED
of	O
synaptic	B-MED
function	I-MED
.	O
STEP	B-MED
normally	O
opposes	O
synaptic	B-MED
strengthening	B-MED
by	O
increasing	B-MED
N	B-MED
-	I-MED
methyl	I-MED
D	I-MED
-	I-MED
aspartate	I-MED
glutamate	I-MED
receptor	I-MED
(	O
NMDAR	B-MED
)	O
internalization	B-MED
through	O
dephosphorylation	B-MED
of	O
GluN2B	B-MED
and	O
inactivation	B-MED
of	O
the	O
kinases	B-MED
extracellular	B-MED
signal	I-MED
-	I-MED
regulated	I-MED
kinase	I-MED
1	I-MED
/	O
2	B-MED
and	O
Fyn	B-MED
.	O
Here	O
we	O
show	O
that	O
STEP61	B-MED
is	O
elevated	B-MED
in	O
the	O
cortex	B-MED
in	O
the	O
Nrg1(+/-	B-MED
)	I-MED
knockout	B-MED
mouse	B-MED
model	I-MED
of	O
schizophrenia	B-MED
(	O
SZ	B-MED
)	O
.	O
Genetic	B-MED
reduction	B-MED
or	O
pharmacological	B-MED
inhibition	B-MED
of	O
STEP	B-MED
prevents	B-MED
the	O
loss	O
of	O
NMDARs	B-MED
from	O
synaptic	B-MED
membranes	I-MED
and	O
reverses	O
behavioral	B-MED
deficits	I-MED
in	O
Nrg1(+/-	B-MED
)	I-MED
mice	B-MED
.	O
STEP61	B-MED
protein	I-MED
is	O
also	O
increased	B-MED
in	O
cortical	B-MED
lysates	B-MED
from	O
the	O
central	B-MED
nervous	I-MED
system	I-MED
-	O
specific	B-MED
ErbB2	B-MED
/	O
4	B-MED
mouse	B-MED
model	I-MED
of	O
SZ	B-MED
,	O
as	O
well	O
as	O
in	O
human	B-MED
induced	I-MED
pluripotent	I-MED
stem	I-MED
cell	I-MED
hiPSC	B-MED
(	O
hiPSC)-derived	O
forebrain	B-MED
neurons	B-MED
and	O
Ngn2	B-MED
-	O
induced	B-MED
excitatory	B-MED
neurons	I-MED
,	O
from	O
two	O
independent	B-MED
SZ	B-MED
patient	B-MED
cohorts	B-MED
.	O
In	O
these	O
selected	B-MED
SZ	B-MED
models	B-MED
,	O
increased	B-MED
STEP61	B-MED
protein	B-MED
levels	I-MED
likely	O
reflect	O
reduced	B-MED
ubiquitination	B-MED
and	O
degradation	B-MED
.	O
These	O
convergent	B-MED
findings	B-MED
from	O
mouse	B-MED
and	O
hiPSC	B-MED
SZ	B-MED
models	B-MED
provide	B-MED
evidence	B-MED
for	O
STEP61	B-MED
dysfunction	B-MED
in	O
SZ	B-MED
.Molecular	O
Psychiatry	O
advance	O
online	O
publication	O
,	O
18	O
October	O
2016	O
;	O
doi:10.1038	O
/	O
mp.2016.163	O
.	O
The	O
Maternal	B-MED
Legacy	B-MED
:	O
Female	B-MED
Identity	B-MED
Predicts	O
Offspring	B-MED
Sex	B-MED
Ratio	I-MED
in	O
the	O
Loggerhead	B-MED
Sea	I-MED
Turtle	I-MED
In	O
organisms	B-MED
with	O
temperature	B-MED
-	I-MED
dependent	I-MED
sex	B-MED
determination	I-MED
,	O
the	O
incubation	B-MED
environment	I-MED
plays	O
a	O
key	O
role	O
in	O
determining	O
offspring	B-MED
sex	B-MED
ratios	I-MED
.	O
Given	O
that	O
global	B-MED
temperatures	B-MED
have	O
warmed	B-MED
approximately	O
0.6	O
°	O
C	O
in	O
the	O
last	O
century	O
,	O
it	O
is	O
necessary	O
to	O
consider	O
how	O
organisms	B-MED
will	O
adjust	B-MED
to	O
climate	B-MED
change	I-MED
.	O
To	O
better	O
understand	O
the	O
degree	B-MED
to	O
which	O
mothers	B-MED
influence	B-MED
the	O
sex	B-MED
ratios	I-MED
of	O
their	O
offspring	B-MED
,	O
we	O
use	O
24	O
years	B-MED
of	O
nesting	B-MED
data	I-MED
for	O
individual	B-MED
female	B-MED
loggerhead	B-MED
sea	I-MED
turtles	I-MED
(	O
Caretta	B-MED
caretta	I-MED
)	O
observed	O
on	O
Bald	B-MED
Head	I-MED
Island	I-MED
,	O
North	B-MED
Carolina	I-MED
.	O
We	O
find	O
that	O
maternal	B-MED
identity	B-MED
is	O
the	O
best	O
predictor	O
of	O
nest	B-MED
sex	B-MED
ratio	I-MED
in	O
univariate	B-MED
and	O
multivariate	B-MED
predictive	I-MED
models	I-MED
.	O
We	O
find	O
significant	O
variability	B-MED
in	O
estimated	O
nest	B-MED
sex	B-MED
ratios	I-MED
among	O
mothers	B-MED
,	O
but	O
a	O
high	O
degree	O
of	O
consistency	B-MED
within	O
mothers	B-MED
,	O
despite	O
substantial	O
spatial	B-MED
and	O
temporal	B-MED
thermal	B-MED
variation	I-MED
.	O
Our	O
results	O
suggest	O
that	O
individual	B-MED
differences	O
in	O
nesting	B-MED
preferences	I-MED
are	O
the	O
main	O
driver	O
behind	O
divergences	B-MED
in	O
nest	B-MED
sex	B-MED
ratios	I-MED
.	O
As	O
such	O
,	O
a	O
female	B-MED
's	I-MED
ability	O
to	O
plastically	O
adjust	O
her	O
nest	B-MED
sex	B-MED
ratios	I-MED
in	O
response	O
to	O
environmental	B-MED
conditions	B-MED
is	O
constrained	B-MED
,	O
potentially	O
limiting	O
how	O
individuals	B-MED
behaviorally	O
mitigate	B-MED
the	O
effects	O
of	O
environmental	B-MED
change	I-MED
.	O
Given	O
that	O
many	O
loggerhead	B-MED
populations	B-MED
already	O
show	O
female	B-MED
-	I-MED
biased	I-MED
offspring	B-MED
sex	B-MED
ratios	I-MED
,	O
understanding	O
maternal	B-MED
behavioral	I-MED
responses	O
is	O
critical	B-MED
for	O
predicting	O
the	O
future	O
of	O
long	O
-	O
lived	O
species	B-MED
vulnerable	B-MED
to	O
extinction	B-MED
.	O
Using	B-MED
melanopsin	B-MED
to	O
study	B-MED
G	B-MED
protein	I-MED
signaling	I-MED
in	O
cortical	B-MED
neurons	B-MED
Our	O
understanding	B-MED
of	O
G	B-MED
protein	I-MED
-	I-MED
coupled	I-MED
receptors	I-MED
(	O
GPCRs	B-MED
)	O
in	O
the	O
central	B-MED
nervous	I-MED
system	I-MED
(	O
CNS	B-MED
)	O
has	O
been	O
hampered	O
by	O
the	O
limited	O
availability	O
of	O
tools	B-MED
allowing	O
for	O
the	O
study	B-MED
of	O
their	O
signaling	B-MED
with	O
precise	B-MED
temporal	I-MED
control	B-MED
.	O
To	O
overcome	B-MED
this	O
,	O
we	O
tested	B-MED
the	O
utility	O
of	O
the	O
bistable	B-MED
mammalian	B-MED
opsin	B-MED
melanopsin	B-MED
to	O
examine	O
G	B-MED
protein	I-MED
signaling	I-MED
in	O
CNS	B-MED
neurons	B-MED
.	O
Specifically	O
,	O
we	O
used	B-MED
biolistic	B-MED
(	O
gene	B-MED
gun	I-MED
)	O
approaches	O
to	O
transfect	B-MED
melanopsin	I-MED
into	O
cortical	B-MED
pyramidal	B-MED
cells	I-MED
maintained	B-MED
in	O
organotypic	B-MED
slice	I-MED
culture	I-MED
.	O
Whole	B-MED
cell	I-MED
recordings	I-MED
from	O
transfected	B-MED
neurons	I-MED
indicated	O
that	O
application	O
of	O
blue	B-MED
light	I-MED
effectively	B-MED
activated	B-MED
the	O
transfected	B-MED
melanopsin	I-MED
to	O
elicit	B-MED
the	O
canonical	O
biphasic	B-MED
modulation	B-MED
of	O
membrane	B-MED
excitability	B-MED
previously	O
associated	B-MED
with	I-MED
the	O
activation	B-MED
of	O
GPCRs	B-MED
coupling	B-MED
to	O
Gαq-11	B-MED
Remarkably	O
,	O
full	O
mimicry	O
of	O
exogenous	B-MED
agonist	B-MED
concentration	B-MED
could	O
be	O
obtained	B-MED
with	O
pulses	B-MED
as	O
short	O
as	O
a	O
few	B-MED
milliseconds	B-MED
,	O
suggesting	O
that	O
their	O
triggering	B-MED
required	O
a	O
single	B-MED
melanopsin	B-MED
activation	B-MED
-	I-MED
deactivation	I-MED
cycle	I-MED
.	O
The	O
resulting	B-MED
temporal	B-MED
control	I-MED
over	O
melanopsin	B-MED
activation	B-MED
allowed	O
us	O
to	O
compare	B-MED
the	O
activation	B-MED
kinetics	B-MED
of	O
different	O
components	O
of	O
the	O
electrophysiological	B-MED
response	B-MED
.	O
We	O
also	O
replaced	O
the	O
intracellular	B-MED
loops	B-MED
of	O
melanopsin	B-MED
with	O
those	O
of	O
the	O
5	B-MED
-	I-MED
HT2A	I-MED
receptor	I-MED
to	O
create	O
a	O
light	B-MED
-	I-MED
activated	I-MED
GPCR	B-MED
capable	O
of	O
interacting	B-MED
with	O
the	O
5	B-MED
-	I-MED
HT2A	I-MED
receptor	I-MED
interacting	B-MED
proteins	B-MED
.	O
The	O
resulting	B-MED
chimera	B-MED
expressed	B-MED
weak	B-MED
activity	B-MED
but	O
validated	B-MED
the	O
potential	B-MED
usefulness	B-MED
of	O
melanopsin	B-MED
as	O
a	O
tool	B-MED
for	O
the	O
study	B-MED
of	O
G	B-MED
protein	I-MED
signaling	I-MED
in	O
CNS	B-MED
neurons	B-MED
.	O
Laceration	B-MED
of	O
a	O
branch	B-MED
of	I-MED
the	O
profunda	B-MED
femoris	I-MED
artery	I-MED
caused	B-MED
by	O
a	O
spike	B-MED
of	O
the	O
displaced	B-MED
lesser	B-MED
trochanter	I-MED
in	O
an	O
inter	B-MED
-	I-MED
trochanteric	I-MED
femoral	B-MED
fracture	I-MED
.	O
A	O
case	B-MED
report	I-MED
Injury	B-MED
of	O
femoral	B-MED
vessels	I-MED
is	O
an	O
extremely	B-MED
rare	B-MED
complication	B-MED
in	O
intertrochanteric	B-MED
femoral	B-MED
fractures	I-MED
.	O
In	O
most	O
cases	B-MED
reported	B-MED
,	O
the	O
vascular	B-MED
lesion	I-MED
involves	B-MED
the	O
superficial	B-MED
femoral	I-MED
artery	I-MED
,	O
whereas	O
in	O
very	O
few	O
cases	B-MED
does	O
it	O
involve	B-MED
the	O
profunda	B-MED
femoris	I-MED
artery	I-MED
.	O
We	O
report	B-MED
a	O
case	B-MED
of	O
acute	B-MED
bleeding	I-MED
due	O
to	O
laceration	B-MED
of	O
a	O
perforating	B-MED
branch	B-MED
of	I-MED
the	O
profunda	B-MED
femoris	I-MED
artery	I-MED
caused	B-MED
by	O
a	O
sharp	B-MED
fragment	B-MED
of	I-MED
the	O
displaced	B-MED
lesser	B-MED
trochanter	I-MED
in	O
an	O
intertrochanteric	B-MED
femoral	B-MED
fracture	I-MED
;	O
the	O
lesion	B-MED
was	O
treated	B-MED
by	O
transcatheter	B-MED
embolization	I-MED
.	O
The	O
arterial	B-MED
injury	I-MED
may	O
be	O
iatrogenic	B-MED
,	O
occurring	B-MED
during	O
intramedullary	B-MED
internal	B-MED
fixation	I-MED
,	O
or	O
less	O
frequently	B-MED
,	O
the	O
injury	B-MED
may	O
be	O
due	O
to	O
the	O
fracture	B-MED
itself	O
,	O
caused	B-MED
by	O
a	O
sharp	B-MED
bone	B-MED
fragment	I-MED
that	O
damages	B-MED
the	O
profunda	B-MED
femoris	I-MED
artery	I-MED
or	O
one	O
of	O
its	O
perforating	B-MED
branches	B-MED
.	O
We	O
believe	O
that	O
intertrochanteric	B-MED
femoral	B-MED
fractures	I-MED
with	O
avulsed	B-MED
lesser	B-MED
trochanter	I-MED
are	O
at	B-MED
risk	I-MED
for	O
femoral	B-MED
vessel	I-MED
injuries	B-MED
caused	B-MED
by	O
the	O
displaced	B-MED
bone	B-MED
spike	B-MED
,	O
and	O
we	O
advise	O
meticulous	B-MED
clinical	B-MED
and	O
laboratory	B-MED
monitoring	I-MED
pre-	B-MED
and	O
post	B-MED
-	I-MED
operatively	I-MED
to	O
prevent	B-MED
serious	I-MED
complications	I-MED
.	O
Percutaneous	B-MED
coronary	I-MED
intervention	I-MED
and	O
heart	B-MED
surgery	I-MED
learning	B-MED
needs	B-MED
of	I-MED
patients	I-MED
in	O
Jordan	B-MED
This	O
study	O
aimed	O
to	O
identify	O
and	O
prioritize	B-MED
the	O
perceived	B-MED
learning	B-MED
needs	B-MED
of	I-MED
patients	I-MED
who	O
underwent	O
percutaneous	B-MED
coronary	I-MED
intervention	I-MED
or	O
open	B-MED
-	I-MED
heart	I-MED
surgery	I-MED
.	O
Identifying	O
learning	B-MED
needs	O
for	O
post	B-MED
-	I-MED
cardiac	I-MED
intervention	I-MED
patients	B-MED
is	O
essential	O
to	O
establish	O
successful	O
health	B-MED
education	I-MED
programmes	I-MED
based	O
on	O
patient	B-MED
central	B-MED
care	I-MED
.	O
A	O
descriptive	O
comparative	O
design	B-MED
was	O
employed	O
on	O
a	O
convenience	B-MED
sample	B-MED
of	O
260	O
patients	B-MED
who	O
underwent	O
a	O
percutaneous	B-MED
coronary	I-MED
intervention	I-MED
and	O
105	O
patients	B-MED
who	O
underwent	O
open	B-MED
-	I-MED
heart	I-MED
surgery	I-MED
patients	B-MED
.	O
Participants	B-MED
had	O
completed	O
the	O
Patient	B-MED
Learning	B-MED
Needs	I-MED
Scale	I-MED
.	O
Data	B-MED
were	O
collected	O
between	O
1	O
October	O
2014	O
and	O
31	O
June	O
2015	O
.	O
Patients	B-MED
from	O
the	O
two	O
groups	B-MED
highly	O
requesting	O
health	B-MED
and	I-MED
recovery	I-MED
related	I-MED
information	I-MED
.	O
They	O
scored	O
all	O
learning	B-MED
need	I-MED
topics	B-MED
as	O
important	O
or	O
highly	O
important	O
for	O
them	O
.	O
The	O
top	O
priority	B-MED
learning	B-MED
need	O
for	O
both	O
patient	B-MED
groups	I-MED
was	O
'	O
information	B-MED
about	O
wound	B-MED
care	I-MED
'	O
,	O
and	O
the	O
lowest	O
priority	B-MED
learning	B-MED
need	O
topic	B-MED
was	O
'	O
physical	B-MED
activity	I-MED
'	O
.	O
The	O
learning	B-MED
needs	B-MED
of	O
both	O
groups	B-MED
were	O
very	O
close	O
,	O
which	O
indicated	O
that	O
educational	B-MED
secondary	I-MED
prevention	I-MED
programmes	I-MED
'	O
content	O
can	O
be	O
prepared	O
in	O
a	O
unified	O
structure	O
for	O
those	O
patients	B-MED
.	O
Although	O
,	O
specific	O
headings	B-MED
can	O
be	O
used	O
to	O
address	O
the	O
unique	O
needs	B-MED
that	O
emerge	O
from	O
having	O
a	O
specific	O
cardiac	B-MED
interventional	B-MED
procedure	I-MED
.	O
The	O
fact	O
that	O
wound	B-MED
care	I-MED
and	O
medications	B-MED
are	O
areas	O
of	O
highest	O
learning	B-MED
needs	B-MED
for	O
patients	B-MED
requires	O
health	B-MED
policy	I-MED
decision	B-MED
makers	I-MED
to	O
address	O
these	O
topics	B-MED
at	O
the	O
time	B-MED
of	O
hospital	B-MED
discharge	I-MED
.	O
In	O
addition	O
,	O
a	O
policy	B-MED
focus	O
on	O
considering	O
patients	B-MED
'	O
actual	O
learning	B-MED
needs	B-MED
requires	O
establishment	B-MED
and	O
managerial	B-MED
support	I-MED
.	O
As	O
patients	B-MED
'	O
learning	B-MED
needs	B-MED
might	O
change	O
later	O
after	O
discharge	B-MED
,	O
the	O
health	B-MED
services	I-MED
should	O
be	O
proactive	O
and	O
focus	O
on	O
continuous	O
support	B-MED
for	O
patients	B-MED
after	O
hospital	B-MED
discharge	I-MED
.	O
Secondary	B-MED
prevention	I-MED
programmes	I-MED
should	O
incorporate	O
health	B-MED
education	I-MED
topics	B-MED
based	O
on	O
patients	B-MED
'	O
own	O
views	O
.	O
This	O
can	O
be	O
done	O
by	O
giving	O
higher	O
priority	B-MED
to	O
understand	O
patients	B-MED
'	I-MED
needs	I-MED
,	O
put	O
much	O
more	O
effort	O
into	O
how	O
to	O
meet	O
patients	B-MED
'	O
information	B-MED
needs	B-MED
and	O
to	O
create	O
a	O
more	O
engaging	O
learning	B-MED
environment	B-MED
for	O
patients	B-MED
and	O
their	O
families	B-MED
.	O
Fabrication	B-MED
of	O
gelatin	B-MED
methacrylate	I-MED
/	O
nanohydroxyapatite	B-MED
microgel	B-MED
arrays	B-MED
for	O
periodontal	B-MED
tissue	I-MED
regeneration	I-MED
Periodontitis	B-MED
is	O
a	O
chronic	B-MED
infectious	I-MED
disease	I-MED
and	O
is	O
the	O
major	B-MED
cause	I-MED
of	O
tooth	B-MED
loss	I-MED
and	O
other	O
oral	B-MED
health	I-MED
issues	B-MED
around	O
the	O
world	B-MED
.	O
Periodontal	B-MED
tissue	I-MED
regeneration	I-MED
has	O
therefore	O
always	O
been	O
the	O
ultimate	B-MED
goal	I-MED
of	O
dentists	B-MED
and	O
researchers	B-MED
.	O
Existing	O
fabrication	B-MED
methods	B-MED
mainly	O
focused	B-MED
on	O
a	O
top	B-MED
-	I-MED
down	I-MED
tissue	I-MED
engineering	I-MED
strategy	B-MED
in	O
which	O
several	O
drawbacks	B-MED
remain	B-MED
,	O
including	O
low	B-MED
throughput	I-MED
and	O
limited	O
diffusion	B-MED
properties	B-MED
resulting	B-MED
from	O
a	O
large	B-MED
sample	I-MED
size	I-MED
.	O
Gelatin	B-MED
methacrylate	I-MED
(	O
GelMA	B-MED
)	O
is	O
a	O
kind	O
of	O
photocrosslinkable	B-MED
and	O
biocompatible	B-MED
hydrogel	B-MED
,	O
with	O
the	O
capacities	B-MED
of	O
enabling	B-MED
cell	B-MED
encapsulation	I-MED
and	O
regeneration	B-MED
of	I-MED
functional	I-MED
tissues	I-MED
.	O
Here	O
,	O
we	O
developed	O
a	O
novel	B-MED
method	B-MED
to	O
fabricate	B-MED
GelMA	B-MED
/	O
nanohydroxylapatite	B-MED
(	O
nHA	B-MED
)	O
microgel	B-MED
arrays	B-MED
using	O
a	O
photocrosslinkable	B-MED
strategy	B-MED
.	O
The	O
viability	B-MED
,	O
proliferation	B-MED
,	O
and	O
osteogenic	B-MED
differentiation	I-MED
and	O
in	B-MED
vivo	I-MED
osteogenesis	B-MED
of	O
human	B-MED
periodontal	B-MED
ligament	I-MED
stem	B-MED
cells	I-MED
(	O
hPDLSCs	B-MED
)	O
encapsulated	B-MED
in	O
microgels	B-MED
were	O
evaluated	B-MED
.	O
The	O
results	B-MED
suggested	B-MED
that	O
such	O
microgels	B-MED
provide	B-MED
great	O
potential	B-MED
for	O
periodontal	B-MED
tissue	I-MED
repair	I-MED
and	I-MED
regeneration	I-MED
.	O
Microgel	B-MED
arrays	B-MED
were	O
fabricated	B-MED
by	O
blending	B-MED
different	B-MED
weight	B-MED
ratios	I-MED
of	O
GelMA	B-MED
and	O
nHA	B-MED
.	O
hPDLSCs	B-MED
were	O
encapsulated	B-MED
in	O
GelMA	B-MED
/	O
nHA	B-MED
microgels	B-MED
of	O
various	O
ratios	B-MED
for	O
a	O
systematic	B-MED
evaluation	B-MED
of	O
cell	B-MED
viability	I-MED
,	O
proliferation	B-MED
,	O
and	O
osteogenic	B-MED
differentiation	I-MED
.	O
In	B-MED
vivo	I-MED
osteogenesis	B-MED
in	O
nude	B-MED
mice	I-MED
was	O
also	O
studied	O
.	O
The	O
GelMA	B-MED
/	O
nHA	B-MED
microgels	B-MED
exhibited	O
appropriate	B-MED
microarchitecture	B-MED
,	O
mechanical	B-MED
strength	I-MED
,	O
and	O
surface	B-MED
roughness	B-MED
,	O
thus	O
enabling	O
cell	B-MED
adhesion	I-MED
and	O
proliferation	B-MED
.	O
Additionally	O
,	O
the	O
GelMA	B-MED
/	O
nHA	B-MED
microgels	B-MED
(	O
10%/2	O
%	O
w	O
/	O
v	O
)	O
enhanced	B-MED
the	O
osteogenic	B-MED
differentiation	I-MED
of	O
hPDLSCs	B-MED
by	O
elevating	B-MED
the	O
expression	B-MED
levels	I-MED
of	O
osteogenic	B-MED
biomarker	I-MED
genes	B-MED
,	O
such	O
as	O
ALP	B-MED
,	O
BSP	B-MED
,	O
OCN	B-MED
,	O
and	O
RUNX2	B-MED
.	O
In	B-MED
vivo	I-MED
ectopic	B-MED
transplantation	B-MED
results	B-MED
showed	O
that	O
GelMA	B-MED
/	O
nHA	B-MED
microgels	B-MED
(	O
10%/2	O
%	O
w	O
/	O
v	O
)	O
increased	B-MED
mineralized	B-MED
tissue	I-MED
formation	B-MED
with	O
abundant	B-MED
vascularization	B-MED
,	O
compared	B-MED
with	O
the	O
1	O
%	O
,	O
3	O
%	O
,	O
and	O
the	O
pure	O
GelMA	B-MED
group	I-MED
.	O
The	O
GelMA	B-MED
/	O
nHA	B-MED
microgels	B-MED
(	O
10%/2	O
%	O
w	O
/	O
v	O
)	O
facilitated	O
hPDLSCs	B-MED
viability	B-MED
,	O
proliferation	B-MED
,	O
and	O
osteogenic	B-MED
differentiation	I-MED
in	B-MED
vitro	I-MED
and	O
further	B-MED
promoted	B-MED
new	B-MED
bone	B-MED
formation	I-MED
in	B-MED
vivo	I-MED
,	O
suggesting	O
that	O
the	O
GelMA	B-MED
/	O
nHA	B-MED
microgels	B-MED
(	O
10%/2	O
%	O
w	O
/	O
v	O
)	O
provide	B-MED
great	O
potential	B-MED
for	O
periodontal	B-MED
tissue	I-MED
regeneration	I-MED
.	O
Conservation	B-MED
education	I-MED
and	O
habitat	B-MED
restoration	B-MED
for	O
the	O
endangered	B-MED
Sagalla	B-MED
caecilian	I-MED
(	O
Boulengerula	B-MED
niedeni	I-MED
)	O
in	O
Sagalla	B-MED
Hill	I-MED
,	O
Kenya	B-MED
The	O
Sagalla	B-MED
caecilian	I-MED
(	O
Boulengerula	B-MED
niedeni	I-MED
)	O
is	O
an	O
endangered	B-MED
amphibian	B-MED
endemic	B-MED
to	O
Sagalla	B-MED
Hill	I-MED
in	O
the	O
Taita	B-MED
Hills	I-MED
.	O
This	O
burrowing	B-MED
worm	I-MED
-like	O
species	B-MED
prefers	O
soft	B-MED
soil	B-MED
with	O
high	B-MED
moisture	B-MED
and	O
organic	B-MED
matter	I-MED
.	O
The	O
major	B-MED
threats	B-MED
to	O
the	O
Sagalla	B-MED
caecilian	I-MED
are	O
soil	B-MED
erosion	I-MED
caused	B-MED
by	O
steep	B-MED
slopes	I-MED
,	O
bare	O
ground	B-MED
and	O
water	B-MED
siphoning	I-MED
/	O
soil	B-MED
hardening	I-MED
from	O
exotic	B-MED
eucalyptus	I-MED
trees	I-MED
.	O
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
get	O
a	O
better	B-MED
understanding	B-MED
of	O
the	O
local	B-MED
people	B-MED
's	I-MED
attitude	B-MED
towards	O
this	O
species	B-MED
and	O
how	O
they	O
can	O
contribute	B-MED
to	O
its	O
continued	B-MED
conservation	B-MED
through	O
restoration	B-MED
of	O
its	O
remaining	B-MED
habitat	B-MED
.	O
In	O
this	O
study	B-MED
,	O
it	O
was	O
found	B-MED
that	O
96	O
%	O
of	O
Sagalla	B-MED
people	B-MED
are	O
aware	B-MED
of	O
the	O
species	B-MED
,	O
its	O
habits	B-MED
and	O
its	O
association	O
with	O
soils	B-MED
high	B-MED
in	O
organic	B-MED
matter	I-MED
.	O
It	O
was	O
also	O
found	B-MED
that	O
96	O
%	O
of	O
Sagalla	B-MED
people	B-MED
use	O
organic	B-MED
manure	B-MED
from	O
cow	B-MED
dung	B-MED
in	O
their	O
farms	B-MED
.	O
Habitat	B-MED
restoration	B-MED
through	O
planting	B-MED
of	O
indigenous	B-MED
plants	B-MED
was	O
found	B-MED
to	O
be	O
ongoing	B-MED
,	O
especially	B-MED
on	O
compounds	B-MED
of	O
public	B-MED
institutions	I-MED
as	O
well	O
as	O
on	O
private	B-MED
lands	I-MED
.	O
Although	O
drought	B-MED
was	O
found	B-MED
to	O
be	O
a	O
challenge	O
for	O
seedlings	B-MED
development	B-MED
especially	O
on	O
the	O
low	B-MED
elevation	B-MED
sites	B-MED
,	O
destruction	B-MED
by	O
livestock	B-MED
especially	O
during	B-MED
the	O
dry	B-MED
season	B-MED
is	O
also	O
a	O
major	B-MED
threat	B-MED
.	O
In	O
this	O
study	B-MED
,	O
it	O
was	O
recommended	B-MED
that	O
any	O
future	B-MED
habitat	B-MED
restoration	B-MED
initiative	B-MED
should	O
include	B-MED
strong	B-MED
chain	B-MED
-	I-MED
link	I-MED
fencing	B-MED
to	O
protect	O
the	O
seedlings	B-MED
from	O
livestock	B-MED
activity	B-MED
.	O
Recognizing	O
that	O
the	O
preferred	B-MED
habitats	B-MED
for	O
the	O
species	B-MED
are	O
in	O
the	O
valleys	B-MED
,	O
systematic	B-MED
planting	B-MED
of	O
keystone	B-MED
plant	I-MED
species	B-MED
such	O
as	O
fig	B-MED
trees	I-MED
(	O
Ficus	B-MED
)	O
creates	B-MED
the	O
best	O
microhabitats	B-MED
.	O
These	O
are	O
better	B-MED
than	O
general	B-MED
woodlots	B-MED
of	O
indigenous	B-MED
trees	B-MED
.	O
Chemical	B-MED
composition	I-MED
and	O
amino	B-MED
acid	I-MED
digestibility	B-MED
of	O
soybean	B-MED
meal	I-MED
produced	O
in	O
the	O
United	B-MED
States	I-MED
,	O
China	B-MED
,	O
Argentina	B-MED
,	O
Brazil	B-MED
,	O
or	O
India	B-MED
An	O
experiment	O
was	O
conducted	O
to	O
compare	O
nutritional	B-MED
composition	B-MED
of	O
soybean	B-MED
meal	I-MED
(	O
SBM	B-MED
)	O
produced	O
in	O
China	B-MED
,	O
Argentina	B-MED
,	O
Brazil	B-MED
,	O
the	O
U.S	B-MED
.	O
,	O
or	O
India	B-MED
and	O
the	O
apparent	B-MED
ileal	I-MED
digestibility	I-MED
(	O
AID	B-MED
)	O
and	O
the	O
standardized	B-MED
ileal	I-MED
digestibility	I-MED
(	O
SID	B-MED
)	O
of	O
CP	B-MED
and	O
AA	B-MED
in	O
these	O
SBM	B-MED
when	O
fed	O
to	O
growing	O
pigs	B-MED
.	O
Five	O
sources	O
of	O
SBM	B-MED
from	O
China	B-MED
,	O
Argentina	B-MED
,	O
Brazil	B-MED
,	O
and	O
the	O
U.S	B-MED
.	O
,	O
and	O
4	O
sources	O
from	O
India	B-MED
were	O
collected	O
for	O
a	O
total	O
of	O
24	O
sources	O
of	O
SBM	B-MED
.	O
All	O
samples	O
were	O
analyzed	O
for	O
energy	B-MED
,	O
DM	B-MED
,	O
and	O
nutrients	B-MED
,	O
and	O
each	O
source	O
was	O
included	O
in	O
a	O
cornstarch	B-MED
based	I-MED
diet	I-MED
in	O
which	O
SBM	B-MED
was	O
the	O
only	O
AA	B-MED
contributing	O
ingredient	B-MED
.	O
An	O
N	B-MED
-	I-MED
free	I-MED
diet	I-MED
was	O
also	O
formulated	O
.	O
Twenty	O
-	O
five	O
barrows	O
(	O
initial	O
BW	O
:	O
30.53	O
±	O
1.73	O
kg	O
)	O
were	O
equipped	O
with	O
a	O
T	O
-	O
cannula	O
in	O
the	O
distal	B-MED
ileum	I-MED
and	O
randomly	O
allotted	O
to	O
a	O
25	O
×	O
8	O
Youden	B-MED
square	I-MED
design	I-MED
with	O
25	O
diets	B-MED
and	O
8	O
periods	B-MED
.	O
Results	O
indicate	O
that	O
the	O
concentration	B-MED
of	O
CP	B-MED
was	O
greater	O
(	O
<	O
0.05	O
)	O
in	O
SBM	B-MED
from	O
Brazil	B-MED
and	O
India	B-MED
(	O
49.3	O
and	O
49.5	O
%	O
,	O
respectively	O
)	O
than	O
in	O
SBM	B-MED
from	O
China	B-MED
,	O
Argentina	B-MED
U.S	B-MED
,	O
or	O
the	O
U.S.	O
(	O
45.1	O
,	O
46.7	O
,	O
and	O
47.3	O
%	O
,	O
respectively	O
,	O
as	O
-	O
fed	O
basis	O
)	O
.	O
The	O
concentration	B-MED
of	O
most	O
indispensable	O
AA	B-MED
followed	O
the	O
same	O
pattern	O
as	O
CP	B-MED
with	O
the	O
exception	O
that	O
SBM	B-MED
U.S	B-MED
from	O
the	O
U.S.	O
contained	O
more	O
(	O
<	O
0.05	O
)	O
indispensable	O
AA	B-MED
than	O
SBM	B-MED
from	O
China	B-MED
or	O
Argentina	B-MED
.	O
However	O
,	O
SBM	B-MED
from	O
India	B-MED
contained	O
more	O
(	O
<	O
0.05	O
)	O
trypsin	B-MED
inhibitors	I-MED
than	O
SBM	B-MED
from	O
the	O
other	O
countries	B-MED
.	O
A	O
greater	O
(	O
<	O
0.05	O
)	O
AID	B-MED
and	O
SID	B-MED
of	O
CP	B-MED
and	O
most	O
AA	B-MED
was	O
observed	O
in	O
SBM	B-MED
U.S	B-MED
from	O
the	O
U.S.	O
compared	O
with	O
SBM	B-MED
from	O
Brazil	B-MED
,	O
Argentina	B-MED
,	O
and	O
India	B-MED
,	O
but	O
there	O
were	O
no	O
differences	O
between	O
SBM	B-MED
U.S	B-MED
from	O
the	O
U.S.	O
and	O
SBM	B-MED
from	O
China	B-MED
.	O
However	O
,	O
because	O
of	O
the	O
lower	O
concentration	B-MED
of	O
AA	B-MED
in	O
SBM	B-MED
from	O
China	B-MED
,	O
the	O
concentration	B-MED
of	O
standardized	B-MED
ileal	I-MED
digestible	I-MED
AA	B-MED
in	O
SBM	B-MED
from	O
China	B-MED
was	O
less	O
(	O
<	O
0.05	O
)	O
than	O
in	O
SBM	B-MED
U.S	B-MED
U.S	B-MED
from	O
the	O
U.S.	O
Soybean	O
meal	O
from	O
the	O
U.S.	O
or	O
Brazil	B-MED
had	O
less	O
(	O
<	O
0.05	O
)	O
variability	O
in	O
SID	B-MED
values	O
than	O
SBM	B-MED
from	O
Argentina	B-MED
,	O
China	B-MED
,	O
or	O
India	B-MED
.	O
In	O
conclusion	O
,	O
the	O
SID	B-MED
of	O
CP	B-MED
and	O
AA	B-MED
is	O
dependent	O
on	O
the	O
country	B-MED
where	O
the	O
SBM	B-MED
is	O
produced	O
.	O
This	O
difference	O
and	O
the	O
variability	O
within	O
each	O
country	B-MED
should	O
be	O
evaluated	O
when	O
formulating	B-MED
diets	I-MED
for	O
pigs	B-MED
.	O
Preparation	B-MED
and	O
characterization	B-MED
of	O
gastrointestinal	B-MED
wafer	B-MED
formulations	B-MED
Many	O
active	B-MED
pharmaceutical	I-MED
ingredients	I-MED
(	O
API	B-MED
)	O
have	O
a	O
very	O
poor	O
or	O
highly	O
variable	B-MED
bioavailability	B-MED
after	O
oral	B-MED
administration	I-MED
.	O
One	O
possibility	O
to	O
overcome	B-MED
this	O
problem	O
might	O
be	O
found	O
in	O
the	O
application	O
of	O
mucoadhesive	B-MED
dosage	I-MED
forms	I-MED
like	O
gastrointestinal	B-MED
wafers	B-MED
.	O
However	O
,	O
a	O
currently	B-MED
unsolved	B-MED
challenge	O
is	O
the	O
control	B-MED
of	O
the	O
adhesion	B-MED
of	O
the	O
wafer	B-MED
to	O
the	O
intestinal	B-MED
mucus	I-MED
.	O
One	O
suggested	O
solution	O
might	O
be	O
the	O
combination	B-MED
of	O
gastrointestinal	B-MED
wafers	B-MED
and	O
expanding	B-MED
systems	I-MED
.	O
Such	O
a	O
combination	B-MED
requires	O
thin	B-MED
and	I-MED
elastic	I-MED
wafers	I-MED
which	O
are	O
further	O
characterized	B-MED
by	O
an	O
unidirectional	B-MED
drug	I-MED
release	I-MED
.	O
In	O
this	O
study	B-MED
gastrointestinal	B-MED
,	O
twolayered	B-MED
wafers	I-MED
containing	O
a	O
water	B-MED
-	I-MED
insoluble	I-MED
backing	I-MED
layer	I-MED
and	O
a	O
drug	B-MED
-	I-MED
loaded	I-MED
,	O
mucoadhesive	B-MED
layer	I-MED
were	O
fabricated	O
by	O
casting	B-MED
solvent	I-MED
technique	I-MED
.	O
The	O
backing	B-MED
layer	I-MED
consists	O
of	O
Ethocel	B-MED
™	I-MED
Standard	I-MED
10	I-MED
Premium	I-MED
and	O
the	O
mucoadhesive	B-MED
layer	I-MED
was	O
prepared	O
using	O
a	O
mixture	B-MED
of	O
Methocel	B-MED
™	I-MED
E15	I-MED
Premium	I-MED
LV	I-MED
,	O
polyvinyl	B-MED
alcohol	I-MED
and	O
Macrogol	B-MED
400	I-MED
.	O
The	O
wafers	B-MED
were	O
characterized	B-MED
regarding	O
their	O
appearance	B-MED
,	O
mechanical	B-MED
properties	I-MED
and	O
dissolution	B-MED
profiles	I-MED
as	O
well	O
as	O
the	O
influence	B-MED
of	O
backing	B-MED
layer	I-MED
thickness	B-MED
on	O
drug	B-MED
transfer	I-MED
and	O
their	O
ability	O
of	O
unidirectional	B-MED
drug	I-MED
release	I-MED
.	O
The	O
wafers	B-MED
with	O
backing	B-MED
layer	I-MED
thickness	B-MED
of	O
500μg	B-MED
Ethocel	I-MED
™	O
/cm(2	O
)	O
presented	O
adequate	B-MED
mechanical	B-MED
properties	I-MED
,	O
a	O
drug	B-MED
transfer	I-MED
about	O
73	O
%	O
and	O
unidirectional	B-MED
drug	I-MED
release	I-MED
.	O
Patient	B-MED
Satisfaction	I-MED
with	O
Pharmacist	B-MED
-Led	O
Collaborative	B-MED
Follow	B-MED
-	I-MED
Up	I-MED
Care	I-MED
in	O
an	O
Ambulatory	B-MED
Rheumatology	B-MED
Clinic	I-MED
Patient	B-MED
satisfaction	I-MED
is	O
known	O
to	O
increase	O
with	O
pharmacist	B-MED
intervention	B-MED
in	O
general	B-MED
outpatient	I-MED
clinics	I-MED
and	O
with	O
nurse	B-MED
-	I-MED
led	I-MED
care	I-MED
in	O
rheumatology	B-MED
clinics	I-MED
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
describe	O
and	O
compare	O
patient	B-MED
satisfaction	I-MED
with	O
two	O
different	O
types	O
of	O
care	B-MED
:	O
a	O
pharmacist	B-MED
physician	B-MED
collaborative	B-MED
model	I-MED
and	O
a	O
traditional	B-MED
physician	I-MED
model	I-MED
in	O
a	O
rheumatology	B-MED
clinic	I-MED
setting	O
.	O
A	O
cross	B-MED
-	I-MED
sectional	I-MED
survey	I-MED
of	O
inflammatory	B-MED
arthritis	I-MED
patients	B-MED
seen	O
during	O
a	O
follow	B-MED
-	I-MED
up	I-MED
visit	I-MED
in	O
Edmonton	B-MED
,	O
Alberta	B-MED
,	O
Canada	B-MED
,	O
was	O
conducted	O
over	O
a	O
ten	B-MED
-	I-MED
week	I-MED
period	I-MED
.	O
Patient	B-MED
satisfaction	I-MED
was	O
measured	O
using	O
a	O
modified	O
version	O
of	O
the	O
validated	O
Leeds	B-MED
Satisfaction	I-MED
Questionnaire	I-MED
,	O
which	O
uses	O
a	O
five	O
-	O
point	O
Likert	B-MED
scale	I-MED
to	O
measure	O
six	B-MED
dimensions	I-MED
of	O
satisfaction	B-MED
,	O
and	O
compared	O
between	O
the	O
collaborative	B-MED
care	I-MED
and	O
traditional	B-MED
physician	I-MED
models	I-MED
.	O
A	O
total	O
of	O
62	O
patients	B-MED
completed	O
the	O
questionnaire	B-MED
(	O
21	O
collaborative	B-MED
care	I-MED
and	O
41	O
traditional	B-MED
physician	I-MED
model	I-MED
)	O
.	O
The	O
average	O
age	O
of	O
respondents	B-MED
was	O
52	O
years	O
and	O
the	O
majority	O
were	O
female	B-MED
.	O
The	O
mean	B-MED
score	I-MED
for	I-MED
satisfaction	I-MED
across	O
the	O
six	B-MED
dimensions	I-MED
was	O
4.56	O
in	O
the	O
collaborative	B-MED
care	I-MED
group	I-MED
and	O
4.30	O
in	O
the	O
traditional	B-MED
physician	I-MED
group	I-MED
(	O
p	O
=	O
0.02	O
)	O
.	O
Patient	B-MED
satisfaction	I-MED
in	O
the	O
collaborative	B-MED
care	I-MED
group	I-MED
was	O
consistently	O
higher	O
across	O
all	O
dimensions	O
.	O
No	B-MED
difference	I-MED
was	O
noted	O
between	O
participants	B-MED
seen	O
for	O
the	O
first	O
time	O
compared	O
with	O
those	O
seen	O
two	O
or	O
more	O
times	O
by	O
the	O
pharmacist	B-MED
.	O
A	O
collaborative	B-MED
care	I-MED
model	I-MED
can	O
exceed	O
the	O
already	O
high	B-MED
expectations	I-MED
for	O
care	B-MED
of	I-MED
patients	I-MED
with	O
inflammatory	B-MED
arthritis	I-MED
.	O
Our	O
findings	O
support	O
the	O
role	O
of	O
pharmacists	B-MED
using	O
a	O
collaborative	B-MED
care	I-MED
approach	O
to	O
care	B-MED
for	I-MED
patients	I-MED
in	O
rheumatology	B-MED
clinics	I-MED
.	O
Opioids	B-MED
for	O
chronic	B-MED
pain	I-MED
:	O
The	O
CDC	B-MED
's	I-MED
12	O
recommendations	B-MED
The	O
Centers	B-MED
for	I-MED
Disease	I-MED
Control	I-MED
and	I-MED
Prevention	I-MED
has	O
issued	O
12	O
recommendations	B-MED
to	O
help	O
clinicians	B-MED
prescribe	B-MED
an	O
optimal	B-MED
and	O
safe	O
course	O
of	O
treatment	B-MED
for	O
patients	B-MED
.	O
Incidence	B-MED
of	O
environmental	B-MED
and	O
genetic	B-MED
factors	I-MED
causing	O
congenital	B-MED
cataract	I-MED
in	O
Children	B-MED
of	O
Lahore	B-MED
To	O
check	O
the	O
incidence	B-MED
of	O
environmental	B-MED
and	O
genetic	B-MED
factors	I-MED
causing	O
congenital	B-MED
cataract	I-MED
in	O
infants	B-MED
.	O
The	O
descriptive	B-MED
study	I-MED
was	O
conducted	O
at	O
Layton	B-MED
Rahmatullah	I-MED
Benevolent	I-MED
Trust	I-MED
,	O
Lahore	B-MED
,	O
Pakistan	B-MED
,	O
from	O
October	O
2013	O
to	O
April	O
2014	O
,	O
and	O
comprised	O
children	B-MED
under	O
15	O
years	B-MED
of	O
age	B-MED
who	O
had	O
rubella	B-MED
syndrome	I-MED
,	O
herpes	B-MED
simplex	I-MED
,	O
birth	B-MED
trauma	I-MED
,	O
trisomy	B-MED
21	I-MED
,	O
Nance	B-MED
-	I-MED
Horan	I-MED
syndrome	I-MED
or	O
Lowe	B-MED
's	I-MED
syndrome	I-MED
.	O
Of	O
the	O
38,000	O
cases	B-MED
examined	O
,	O
120(0.3	O
%	O
)	O
patients	B-MED
were	O
diagnosed	B-MED
with	O
congenital	B-MED
cataract	I-MED
.	O
Of	O
them	O
,	O
52(43.33%)were	O
aged	B-MED
between	O
2	O
and	O
5	O
years	B-MED
,	O
22(18.33	O
%	O
)	O
<	O
11	O
years	B-MED
and	O
10(8.33	O
%	O
)	O
?	O
15	O
years	B-MED
.	O
Bilateral	B-MED
congenital	I-MED
cataract	I-MED
was	O
observed	O
in	O
91(75.83	O
%	O
)	O
patients	B-MED
and	O
unilateral	B-MED
congenital	I-MED
cataract	I-MED
in	O
29(24.17	O
%	O
)	O
.	O
Environmental	B-MED
factors	I-MED
caused	O
72(62.07	O
%	O
)	O
cases	B-MED
and	O
genetic	B-MED
factors	I-MED
caused	O
44(37.93	O
%	O
)	O
..	O
Congenital	B-MED
cataract	I-MED
predominated	B-MED
in	O
boys	B-MED
compared	O
to	O
girls	B-MED
.	O
Early	O
diagnosis	B-MED
and	O
adequate	O
therapy	B-MED
requires	O
specific	O
technology	B-MED
,	O
as	O
well	O
as	O
long	B-MED
-	I-MED
term	I-MED
and	O
permanent	B-MED
care	B-MED
..	O
Pre	B-MED
-	I-MED
Activation	I-MED
Negativity	I-MED
(	O
PrAN	B-MED
)	O
in	O
Brain	B-MED
Potentials	B-MED
to	O
Unfolding	B-MED
Words	I-MED
We	O
describe	O
an	O
event	B-MED
-	I-MED
related	I-MED
potential	I-MED
(	O
ERP	B-MED
)	O
effect	B-MED
termed	O
the	O
"	O
pre	B-MED
-	I-MED
activation	I-MED
negativity	I-MED
"	O
(	O
PrAN	B-MED
)	O
,	O
which	O
is	O
proposed	O
to	O
index	B-MED
the	O
degree	B-MED
of	I-MED
pre	I-MED
-	I-MED
activation	I-MED
of	O
upcoming	O
word	B-MED
-	O
internal	B-MED
morphemes	B-MED
in	O
speech	B-MED
processing	B-MED
.	O
Using	O
lexical	B-MED
competition	I-MED
measures	B-MED
based	O
on	O
word	B-MED
-	I-MED
initial	I-MED
speech	I-MED
fragments	I-MED
(	O
WIFs	B-MED
)	O
,	O
as	O
well	O
as	O
statistical	B-MED
analyses	I-MED
of	O
ERP	B-MED
data	B-MED
from	O
three	O
experiments	B-MED
,	O
it	O
is	O
shown	O
that	O
the	O
PrAN	B-MED
is	O
sensitive	O
to	O
lexical	B-MED
competition	I-MED
and	O
that	O
it	O
reflects	O
the	O
degree	B-MED
of	O
predictive	B-MED
certainty	B-MED
:	O
the	O
negativity	B-MED
is	O
larger	B-MED
when	O
there	O
are	O
fewer	B-MED
upcoming	O
lexical	B-MED
competitors	B-MED
.	O
Evaluation	B-MED
of	O
Mathisen	B-MED
's	I-MED
technique	I-MED
for	O
ureteral	B-MED
reimplantation	I-MED
in	O
children	B-MED
with	O
primary	B-MED
vesicoureteral	B-MED
reflux	I-MED
Although	O
cross	B-MED
-	I-MED
trigonal	I-MED
ureteral	I-MED
reimplantation	I-MED
(	I-MED
Cohen	I-MED
)	I-MED
is	O
a	O
commonly	O
used	O
technique	B-MED
in	O
children	B-MED
,	O
it	O
represents	O
a	O
non	B-MED
-	I-MED
physiological	I-MED
transfer	I-MED
of	O
the	O
ureteral	B-MED
orifices	I-MED
and	O
may	O
prove	O
challenging	O
with	O
regard	O
to	O
endoscopic	B-MED
ureteral	I-MED
operations	I-MED
in	O
later	B-MED
life	B-MED
.	O
In	O
1964	O
,	O
Mathisen	O
described	B-MED
an	O
alternative	B-MED
method	B-MED
of	O
ureteral	B-MED
reimplantation	I-MED
with	O
lateralization	B-MED
of	O
the	O
neohiatus	B-MED
,	O
creating	O
an	O
orthotopic	B-MED
course	B-MED
of	O
the	O
submucosal	B-MED
ureter	I-MED
.	O
We	O
have	O
evaluated	B-MED
success	B-MED
and	O
complication	B-MED
rates	B-MED
of	O
both	O
techniques	B-MED
that	O
were	O
applied	B-MED
sequentially	B-MED
at	O
our	O
departments	B-MED
.	O
Forty	O
-	O
eight	O
consecutive	B-MED
patients	B-MED
(	O
83	O
ureters	B-MED
,	O
24	O
males	B-MED
/24	O
females	B-MED
)	O
following	O
Mathisen	B-MED
reimplantation	I-MED
were	O
compared	B-MED
with	O
53	O
consecutive	B-MED
patients	B-MED
(	O
98	O
ureters	B-MED
,	O
30	O
males	B-MED
/23	O
females	B-MED
)	O
following	O
Cohen	B-MED
reimplantation	I-MED
.	O
Inclusion	B-MED
criteria	B-MED
were	O
primary	B-MED
vesicoureteral	B-MED
reflux	I-MED
(	O
VUR	B-MED
)	O
and	O
no	O
previous	B-MED
intervention	B-MED
.	O
Reflux	B-MED
grades	B-MED
(	O
Mathisen	O
58	O
ureters	B-MED
/69.9	O
%	O
VUR	B-MED
≥	I-MED
III	I-MED
;	O
Cohen	O
66	O
ureters	B-MED
/66.7	O
%	O
VUR	B-MED
≥	I-MED
III	I-MED
)	O
and	O
the	O
occurence	O
of	O
other	O
complicating	B-MED
factors	B-MED
(	O
ureteroceles	B-MED
,	O
megaureters	B-MED
,	O
posterior	B-MED
urethral	I-MED
valves	I-MED
)	O
in	O
both	O
groups	B-MED
were	O
comparable	B-MED
.	O
After	O
Cohen	B-MED
's	I-MED
reimplantation	I-MED
there	O
were	O
no	O
immediate	B-MED
complications	B-MED
requiring	O
intervention	B-MED
;	O
during	B-MED
follow	B-MED
-	I-MED
up	I-MED
(	O
mean	B-MED
28.2	O
months	B-MED
)	O
three	O
patients	B-MED
(	O
5.6	O
%	O
)	O
suffered	B-MED
febrile	B-MED
urinary	I-MED
tract	I-MED
infections	I-MED
(	O
UTIs	B-MED
)	O
,	O
of	O
which	O
one	O
(	O
1.8	O
%	O
)	O
was	O
diagnosed	B-MED
with	O
a	O
persisting	B-MED
VUR	B-MED
.	O
Persistent	B-MED
hydronephroses	B-MED
(	O
≥II	O
SFU	B-MED
)	O
were	O
recorded	O
in	O
six	O
patients	B-MED
(	O
13.2	O
%	O
)	O
.	O
After	O
reimplantation	B-MED
using	O
Mathisen	B-MED
's	I-MED
technique	I-MED
,	O
two	O
patients	B-MED
(	O
4.1	O
%	O
)	O
suffered	B-MED
significant	B-MED
intravesical	B-MED
bleeding	I-MED
;	O
during	O
follow	B-MED
-	I-MED
up	I-MED
(	O
mean	B-MED
23.06	O
months	B-MED
)	O
four	O
patients	B-MED
(	O
8.3	O
%	O
)	O
suffered	B-MED
febrile	B-MED
UTIs	I-MED
,	O
and	O
seven	O
patients	B-MED
(	O
14.5	O
%	O
)	O
were	O
diagnosed	B-MED
with	O
persisting	B-MED
VUR	B-MED
after	O
a	O
mean	B-MED
follow	B-MED
-	I-MED
up	I-MED
of	O
10.8	O
months	B-MED
.	O
The	O
patients	B-MED
with	O
persistent	B-MED
VUR	B-MED
had	O
more	O
commonly	O
high	B-MED
-	I-MED
grade	I-MED
(	O
IV	O
and	O
V	O
)	O
VUR	B-MED
initially	O
,	O
compared	B-MED
to	O
the	O
whole	B-MED
group	I-MED
.	O
Two	O
patients	B-MED
(	O
4.1	O
%	O
)	O
had	O
persistent	B-MED
hydronephroses	B-MED
(	O
≥II	O
SFU	B-MED
)	O
.	O
Mathisen	B-MED
's	I-MED
technique	I-MED
for	O
ureteral	B-MED
reimplantation	I-MED
yielded	O
a	O
significantly	B-MED
(	O
p	O
=	O
0.0256	O
patients	B-MED
,	O
p	O
=	O
0.006	O
ureterorenal	B-MED
units	I-MED
)	O
lower	B-MED
success	B-MED
rate	B-MED
(	O
85.5	O
%	O
patients	B-MED
,	O
89.2	O
%	O
ureterorenal	B-MED
units	I-MED
)	O
in	O
comparison	B-MED
with	O
Cohen	B-MED
's	I-MED
technique	I-MED
(	O
98.2	O
%	O
patients	B-MED
,	O
99	O
%	O
ureterorenal	B-MED
units	I-MED
)	O
.	O
Although	O
there	O
was	O
no	O
intervention	B-MED
for	O
obstruction	B-MED
,	O
persistent	B-MED
hydronephrosis	B-MED
was	O
more	O
common	O
in	O
the	O
Cohen	B-MED
group	I-MED
(	O
13.2	O
%	O
vs.	O
4.1	O
%	O
,	O
n.s	O
.	O
)	O
.	O
Despite	O
the	O
advantages	O
of	O
an	O
orthotopic	B-MED
ureteral	B-MED
orifice	I-MED
close	O
to	O
the	O
bladder	B-MED
neck	I-MED
,	O
as	O
achieved	O
by	O
Mathisen	B-MED
's	I-MED
reimplantation	I-MED
,	O
cross	B-MED
-	I-MED
trigonal	I-MED
ureteral	I-MED
reimplantation	I-MED
proved	O
more	O
reliable	B-MED
for	O
VUR	B-MED
correction	B-MED
.	O
As	O
regards	O
optimizing	O
the	O
results	O
,	O
patient	B-MED
selection	I-MED
for	O
either	O
technique	B-MED
could	O
prove	B-MED
essential	I-MED
.	O
Nevertheless	O
,	O
as	O
regards	O
the	O
difficulties	B-MED
with	O
ectopic	B-MED
ureteral	B-MED
orifices	I-MED
in	O
the	O
Cohen	B-MED
technique	I-MED
in	O
the	O
long	B-MED
-	I-MED
term	I-MED
follow	B-MED
-	I-MED
up	I-MED
,	O
the	O
concept	B-MED
of	O
anatomic	B-MED
,	O
orthotopic	B-MED
ureteral	B-MED
reimplantation	I-MED
should	O
be	O
pursued	O
and	O
the	O
technique	B-MED
should	O
be	O
further	O
refined	O
.	O
Diabetic	B-MED
nephropathy	I-MED
as	O
the	O
cause	B-MED
of	O
end	B-MED
-	I-MED
stage	I-MED
kidney	I-MED
disease	I-MED
reported	O
on	O
the	O
medical	B-MED
evidence	I-MED
form	I-MED
CMS2728	B-MED
at	O
a	O
single	O
center	B-MED
Background	O
:	O
End	B-MED
-	I-MED
stage	I-MED
renal	I-MED
disease	I-MED
(	O
ESRD	B-MED
)	O
incidence	B-MED
due	O
to	O
Type	B-MED
2	I-MED
diabetic	B-MED
nephropathy	I-MED
(	O
DN	B-MED
)	O
is	O
35	O
-	O
50	O
%	O
,	O
according	O
to	O
the	O
United	B-MED
States	I-MED
Renal	I-MED
Data	I-MED
System	I-MED
.	O
Methods	O
:	O
A	O
single-	O
center	B-MED
,	O
retrospective	B-MED
cohort	I-MED
study	I-MED
to	O
determine	O
incidence	B-MED
and	O
diagnostic	B-MED
accuracy	I-MED
for	O
Type	B-MED
2	I-MED
DN	B-MED
as	O
the	O
primary	B-MED
cause	B-MED
of	O
ESRD	B-MED
(	O
Code	O
250.40	O
)	O
on	O
the	O
Center	B-MED
for	I-MED
Medicare	I-MED
&	I-MED
Medicaid	I-MED
(	O
CMS	B-MED
)	O
Medical	B-MED
Evidence	I-MED
Report	I-MED
form	I-MED
(	O
CMS2728	B-MED
)	O
submitted	B-MED
at	O
renal	B-MED
replacement	I-MED
therapy	I-MED
initiation	O
.	O
All	O
patients	B-MED
≥18	O
years	B-MED
of	O
age	B-MED
with	O
a	O
CMS2728	B-MED
submitted	B-MED
between	O
1	O
March	O
2006	O
and	O
31	O
March	O
2015	O
at	O
a	O
single	O
academic	B-MED
military	I-MED
medical	I-MED
center	I-MED
(	O
ESRD	B-MED
Network	O
5	O
)	O
were	O
included	O
.	O
Medical	B-MED
records	I-MED
of	O
those	O
with	O
a	O
Code	O
250.40	O
diagnosis	B-MED
were	O
reviewed	B-MED
to	O
determine	O
whether	O
they	O
met	O
the	O
Kidney	B-MED
Disease	I-MED
Outcomes	I-MED
Quality	I-MED
Initiative	I-MED
(	O
KDOQI	B-MED
)	O
2007	O
criteria	B-MED
for	O
DN	B-MED
.	O
Results	O
:	O
ESRD	B-MED
incidence	B-MED
secondary	O
to	O
Type	B-MED
2	I-MED
DN	B-MED
was	O
18.7	O
%	O
(	O
56/299	O
individual	B-MED
CMS2728	B-MED
submissions	B-MED
over	O
9.09	O
years	O
)	O
.	O
In	O
all	O
,	O
12/56	O
(	O
21.4	O
%	O
)	O
did	O
not	O
meet	O
KDOQI	B-MED
criteria	I-MED
for	O
Type	B-MED
2	I-MED
DN	B-MED
.	O
Although	O
all	O
had	O
diabetes	B-MED
,	O
those	O
not	B-MED
meeting	I-MED
criteria	I-MED
had	O
shorter	O
disease	B-MED
duration	I-MED
(	O
P	O
=	O
0.007	O
)	O
,	O
were	O
more	O
likely	O
to	O
have	O
active	B-MED
urine	B-MED
sediment	I-MED
(	O
P	O
=	O
0.006	O
)	O
,	O
and	O
were	O
less	O
likely	O
to	O
have	O
macroalbuminuria	B-MED
(	O
P	O
=	O
0.037	O
)	O
or	O
retinopathy	B-MED
(	O
P	O
=	O
0.002	O
)	O
prior	O
to	O
ESRD	B-MED
.	O
On	O
exact	O
logistic	B-MED
regression	I-MED
,	O
retinopathy	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
KDOQI	B-MED
-predicted	O
DN	B-MED
[	O
odds	B-MED
ratio	I-MED
=	O
19.16	O
(	O
confidence	B-MED
interval	I-MED
2.76	O
-	O
223.7	O
)	O
,	O
P	O
=	O
0.0009	O
]	O
.	O
Conclusions	B-MED
:	O
In	O
this	O
single-	O
center	B-MED
cohort	B-MED
,	O
21.4	O
%	O
identified	B-MED
as	O
having	O
Type	B-MED
2	I-MED
DN	B-MED
as	O
the	O
primary	B-MED
cause	B-MED
of	O
ESRD	B-MED
were	O
incorrectly	O
assigned	B-MED
per	O
KDOQI	B-MED
2007	O
clinical	B-MED
criteria	B-MED
.	O
If	O
replicated	B-MED
in	O
larger	B-MED
populations	B-MED
,	O
this	O
could	O
have	O
substantial	O
implications	O
regarding	O
the	O
epidemiology	B-MED
of	O
ESRD	B-MED
in	O
the	O
USA	B-MED
.	O
AAV9	B-MED
-	O
NPC1	B-MED
significantly	B-MED
ameliorates	B-MED
Purkinje	B-MED
cell	I-MED
death	B-MED
and	O
behavioral	B-MED
abnormalities	I-MED
in	O
mouse	B-MED
NPC	B-MED
disease	I-MED
Niemann	B-MED
-	I-MED
Pick	I-MED
type	I-MED
C	I-MED
(	I-MED
NPC	I-MED
)	I-MED
disease	I-MED
is	O
a	O
fatal	B-MED
inherited	B-MED
neurodegenerative	B-MED
disorder	I-MED
caused	O
by	O
loss	B-MED
-	I-MED
of	I-MED
-	I-MED
function	I-MED
mutations	B-MED
in	O
the	O
NPC1	B-MED
or	O
NPC2	B-MED
gene	I-MED
.	O
There	O
is	O
no	O
effective	O
way	O
to	O
treat	B-MED
NPC	B-MED
disease	I-MED
.	O
In	O
this	O
study	O
,	O
we	O
used	O
adeno	B-MED
-	I-MED
associated	I-MED
virus	I-MED
(	O
AAV	B-MED
)	O
serotype	B-MED
9	I-MED
(	O
AAV9	B-MED
)	O
to	O
deliver	O
a	O
functional	B-MED
NPC1	B-MED
gene	I-MED
systemically	B-MED
into	O
NPC1(-/-	B-MED
)	I-MED
mice	B-MED
at	O
postnatal	B-MED
day	I-MED
4	I-MED
.	O
One	O
single	B-MED
AAV9	B-MED
-	I-MED
NPC1	I-MED
injection	I-MED
resulted	O
in	O
robust	B-MED
NPC1	B-MED
expression	B-MED
in	O
various	O
tissues	B-MED
,	O
including	O
brain	B-MED
,	O
heart	B-MED
,	O
and	O
lung	B-MED
.	O
Strikingly	O
,	O
AAV9	B-MED
-	I-MED
mediated	I-MED
NPC1	B-MED
delivery	I-MED
significantly	B-MED
promoted	B-MED
Purkinje	B-MED
cell	I-MED
survival	B-MED
,	O
restored	O
locomotor	B-MED
activity	I-MED
and	O
coordination	B-MED
,	O
and	O
increased	B-MED
the	O
lifespan	B-MED
of	O
NPC1(-/-	B-MED
)	I-MED
mice	B-MED
.	O
Our	O
work	O
suggests	O
that	O
AAV	B-MED
-	I-MED
based	I-MED
gene	I-MED
therapy	I-MED
is	O
a	O
promising	O
means	O
to	O
treat	B-MED
NPC	B-MED
disease	I-MED
.	O
Can	O
inorganic	B-MED
phosphate	I-MED
explain	O
sag	B-MED
during	O
unfused	B-MED
tetanic	B-MED
contractions	I-MED
of	O
skeletal	B-MED
muscle	I-MED
?	O
We	O
test	O
the	O
hypothesis	B-MED
that	O
cytosolic	B-MED
inorganic	B-MED
phosphate	I-MED
(	O
Pi	B-MED
)	O
can	O
account	O
for	O
the	O
contraction	B-MED
-	O
induced	B-MED
reductions	B-MED
in	O
twitch	B-MED
duration	B-MED
which	O
impair	B-MED
summation	O
and	O
cause	O
force	B-MED
to	O
decline	B-MED
(	O
sag	B-MED
)	O
during	O
unfused	B-MED
tetanic	B-MED
contractions	I-MED
of	O
fast	B-MED
-	I-MED
twitch	I-MED
muscle	I-MED
.	O
A	O
five	B-MED
-	I-MED
state	I-MED
model	I-MED
of	O
crossbridge	B-MED
cycling	I-MED
was	O
used	O
to	O
simulate	B-MED
twitch	B-MED
and	O
unfused	B-MED
tetanic	B-MED
contractions	I-MED
.	O
As	O
Pi	B-MED
concentration	B-MED
(	O
[	O
Pi	B-MED
]	O
)	O
was	O
increased	B-MED
from	O
0	O
to	O
30	O
mmol·L(-1	O
)	O
,	O
twitch	B-MED
duration	B-MED
decreased	B-MED
,	O
with	O
progressive	B-MED
reductions	B-MED
in	O
sensitivity	B-MED
to	O
Pi	B-MED
as	O
[	O
Pi	B-MED
]	O
was	O
increased	B-MED
.	O
When	O
unfused	B-MED
tetani	O
were	O
simulated	B-MED
with	O
rising	O
[	O
Pi	B-MED
]	O
,	O
sag	B-MED
was	O
most	O
pronounced	B-MED
when	O
initial	B-MED
[	O
Pi	B-MED
]	O
was	O
low	B-MED
,	O
and	O
when	O
the	O
magnitude	B-MED
of	O
[	O
Pi	B-MED
]	O
increase	B-MED
was	O
large	B-MED
.	O
Fast	B-MED
-	I-MED
twitch	I-MED
extensor	B-MED
digitorum	I-MED
longus	I-MED
(	I-MED
EDL	I-MED
)	I-MED
muscles	I-MED
(	O
sag	B-MED
-	I-MED
prone	I-MED
,	O
typically	O
low	O
basal	O
[	O
Pi	B-MED
]	O
)	O
and	O
slow	B-MED
-	I-MED
twitch	I-MED
soleus	B-MED
muscles	I-MED
(	O
sag	B-MED
-	O
resistant	B-MED
,	O
typically	O
high	O
basal	O
[	O
Pi	B-MED
]	O
)	O
were	O
isolated	B-MED
from	O
14	O
female	B-MED
C57BL/6	B-MED
mice	I-MED
.	O
Muscles	B-MED
were	O
sequentially	O
incubated	B-MED
in	O
solutions	B-MED
containing	O
either	O
glucose	B-MED
or	O
pyruvate	B-MED
to	O
create	O
typical	B-MED
and	O
low	B-MED
Pi	B-MED
environments	B-MED
,	O
respectively	O
.	O
Twitch	B-MED
duration	B-MED
was	O
greater	O
(	O
P	O
<	O
0.05	O
)	O
in	O
pyruvate	B-MED
than	O
glucose	B-MED
in	O
both	O
muscles	B-MED
.	O
Stimuli	B-MED
applied	B-MED
at	O
intervals	B-MED
approximately	O
three	O
times	O
the	O
time	O
to	O
peak	B-MED
twitch	B-MED
tension	B-MED
resulted	O
in	O
sag	B-MED
of	O
35.0	O
±	O
3.7	O
%	O
in	O
glucose	B-MED
and	O
50.5	O
±	O
1.4	O
%	O
in	O
pyruvate	B-MED
in	O
the	O
EDL	B-MED
(	O
pyruvate	B-MED
>	O
glucose	B-MED
;	O
P	O
<	O
0.05	O
)	O
,	O
and	O
3.9	O
±	O
0.3	O
%	O
in	O
glucose	B-MED
and	O
37.8	O
±	O
2.7	O
%	O
in	O
pyruvate	B-MED
in	O
the	O
soleus	B-MED
(	O
pyruvate	B-MED
>	O
glucose	B-MED
;	O
P	O
<	O
0.05	O
)	O
.	O
The	O
influence	O
of	O
Pi	B-MED
on	O
crossbridge	B-MED
cycling	I-MED
provides	O
a	O
tenable	B-MED
mechanism	I-MED
for	O
sag	B-MED
.	O
Moreover	O
,	O
the	O
low	B-MED
basal	I-MED
[	O
Pi	B-MED
]	O
in	O
fast	B-MED
-	I-MED
twitch	I-MED
relative	O
to	O
slow	B-MED
-	I-MED
twitch	I-MED
muscle	I-MED
has	O
promise	O
as	O
an	O
explanation	B-MED
for	O
the	O
fiber	B-MED
-	I-MED
type	I-MED
dependency	O
of	O
sag	B-MED
.	O
Ocular	B-MED
hypotensive	I-MED
effect	B-MED
of	O
the	O
novel	O
EP3	B-MED
/	O
FP	B-MED
agonist	B-MED
ONO-9054	B-MED
versus	O
Xalatan	B-MED
:	O
results	O
of	O
a	O
28-	O
day	B-MED
,	O
double	B-MED
-	I-MED
masked	I-MED
,	O
randomised	B-MED
study	B-MED
ONO-9054	B-MED
is	O
being	O
developed	O
for	O
the	O
reduction	B-MED
of	O
intraocular	B-MED
pressure	I-MED
(	O
IOP	B-MED
)	O
in	O
patients	B-MED
with	O
ocular	B-MED
hypertension	I-MED
(	O
OHT	B-MED
)	O
and	O
open	B-MED
-	I-MED
angle	I-MED
glaucoma	I-MED
(	O
OAG	B-MED
)	O
.	O
This	O
study	B-MED
compared	O
the	O
novel	O
dual	O
EP3	B-MED
/	O
FP	B-MED
agonist	B-MED
ONO-9054	B-MED
with	O
the	O
FP	B-MED
agonist	B-MED
Xalatan	B-MED
.	O
Adults	B-MED
(	O
n=123	O
)	O
with	O
bilateral	O
mild	O
/	O
moderate	O
OAG	B-MED
or	O
OHT	B-MED
,	O
with	O
unmedicated	O
IOP	B-MED
of	O
≥24	O
mm	O
Hg	O
at	O
8:00	O
hours	O
,	O
≥21	O
mm	O
Hg	O
at	O
10:00	O
hours	O
and	O
≤36	O
mm	O
Hg	O
,	O
were	O
randomised	O
1:1	O
to	O
receive	O
ONO-9054	B-MED
(	O
0.003	O
%	O
,	O
30	O
μg	O
/	O
mL	O
)	O
or	O
Xalatan	B-MED
(	O
0.005	O
%	O
,	O
50	O
μg	O
/	O
mL	O
)	O
once	O
daily	B-MED
for	O
28	O
days	B-MED
.	O
Day	B-MED
29	O
mean	O
diurnal	O
IOP	B-MED
was	O
-7.2	O
mm	O
Hg	O
for	O
ONO-9054	B-MED
vs	O
-6.6	O
mm	O
Hg	O
for	O
Xalatan	B-MED
.	O
At	O
08:00	O
hours	O
,	O
the	O
IOPs	B-MED
were	O
comparable	O
,	O
and	O
at	O
all	O
later	O
time	O
points	O
the	O
decrease	B-MED
in	O
IOP	B-MED
was	O
greater	O
for	O
ONO-9054	B-MED
.	O
On	O
day	B-MED
29	O
,	O
the	O
odds	O
of	O
a	O
mean	O
IOP	B-MED
reduction	B-MED
of	O
≤-25	O
%	O
,	O
≤-30	O
%	O
and	O
≤-35	O
%	O
for	O
ONO-9054	B-MED
were	O
2.39	O
,	O
2.37	O
and	O
4.85	O
times	O
more	O
,	O
respectively	O
,	O
than	O
the	O
odds	O
for	O
Xalatan	B-MED
(	O
p<0.05	O
,	O
post	B-MED
hoc	I-MED
analyses	I-MED
)	O
.	O
The	O
percentage	O
of	O
subjects	O
achieving	O
target	O
IOPs	B-MED
on	O
day	B-MED
29	O
(	O
≤17	O
,	O
≤16	O
and	O
≤15	O
mm	O
Hg	O
)	O
was	O
greater	O
for	O
ONO-9054	B-MED
than	O
for	O
Xalatan	B-MED
;	O
the	O
odds	O
of	O
achieving	O
an	O
IOP	B-MED
≤15	O
mm	O
Hg	O
for	O
ONO-9054	B-MED
were	O
2.4	O
times	O
more	O
than	O
the	O
odds	O
for	O
Xalatan	B-MED
(	O
p<0.01	O
,	O
post	B-MED
hoc	I-MED
analysis	I-MED
)	O
.	O
Subjects	O
randomised	O
to	O
receive	O
ONO-9054	B-MED
were	O
more	O
likely	O
to	O
achieve	O
a	O
greater	O
per	O
cent	O
reduction	O
in	O
IOP	B-MED
and	O
were	O
more	O
likely	O
to	O
achieve	O
target	O
IOPs	B-MED
than	O
those	O
receiving	O
Xalatan	B-MED
.	O
The	O
effects	O
of	O
ONO-9054	B-MED
in	O
reducing	O
IOP	B-MED
appear	O
to	O
persist	O
longer	O
than	O
those	O
of	O
Xalatan	B-MED
.	O
NCT02083289	O
,	O
Results	O
.	O
Fabrication	B-MED
and	O
modelling	B-MED
of	O
fractal	B-MED
,	O
biomimetic	B-MED
,	O
micro	B-MED
and	O
nano	B-MED
-	I-MED
topographical	I-MED
surfaces	I-MED
Natural	B-MED
surface	B-MED
topographies	I-MED
are	O
often	O
self	O
-	O
similar	O
with	O
hierarchical	B-MED
features	I-MED
at	O
the	O
micro	B-MED
and	O
nanoscale	B-MED
,	O
which	O
may	O
be	O
mimicked	O
to	O
overcome	O
modern	B-MED
tissue	B-MED
engineering	I-MED
and	O
biomaterial	B-MED
design	B-MED
limitations	B-MED
.	O
Specifically	O
,	O
a	O
cell	B-MED
's	I-MED
microenvironment	I-MED
within	O
the	O
human	B-MED
body	I-MED
contains	O
highly	O
optimised	O
,	O
fractal	B-MED
topographical	I-MED
cues	I-MED
,	O
which	O
directs	O
precise	O
cell	B-MED
behaviour	B-MED
.	O
However	O
,	O
recreating	B-MED
biomimetic	B-MED
,	O
fractal	B-MED
topographies	I-MED
in	B-MED
vitro	I-MED
is	O
not	O
a	O
trivial	B-MED
process	I-MED
and	O
a	O
number	O
of	O
fabrication	B-MED
methods	I-MED
have	O
been	O
proposed	O
but	O
often	O
fail	B-MED
to	O
precisely	O
control	B-MED
the	O
spatial	B-MED
resolution	I-MED
of	O
features	B-MED
at	O
different	B-MED
lengths	B-MED
scales	B-MED
and	O
hence	O
,	O
to	O
provide	O
true	O
biomimetic	B-MED
properties	I-MED
.	O
Here	O
,	O
we	O
propose	O
a	O
method	B-MED
of	O
accurately	B-MED
reproducing	B-MED
the	O
self	O
-	O
similar	O
,	O
micro	B-MED
and	O
nanoscale	B-MED
topography	I-MED
of	O
a	O
human	B-MED
biological	B-MED
tissue	I-MED
into	O
a	O
synthetic	B-MED
polymer	I-MED
through	O
an	O
innovative	O
fabrication	B-MED
process	I-MED
.	O
The	O
biological	B-MED
tissue	I-MED
surface	B-MED
was	O
characterised	B-MED
using	O
atomic	B-MED
force	I-MED
microscopy	I-MED
(	O
AFM	B-MED
)	O
to	O
obtain	O
spatial	B-MED
data	B-MED
in	O
X	O
,	O
Y	O
and	O
Z	O
,	O
which	O
was	O
converted	O
into	O
a	O
grayscale	B-MED
'	I-MED
digital	I-MED
photomask	I-MED
'	I-MED
.	O
As	O
a	O
result	O
of	O
maskless	B-MED
grayscale	I-MED
optical	I-MED
lithography	I-MED
followed	O
by	O
modified	B-MED
deep	I-MED
reactive	I-MED
ion	I-MED
etching	I-MED
and	O
replica	B-MED
molding	I-MED
,	O
we	O
were	O
able	O
to	O
accurately	B-MED
reproduce	O
the	O
fractal	B-MED
topography	I-MED
of	O
acellular	B-MED
dermal	I-MED
matrix	I-MED
(	O
ADM	B-MED
)	O
into	O
polydimethylsiloxane	B-MED
(	O
PDMS	B-MED
)	O
.	O
Characterisation	B-MED
using	O
AFM	B-MED
at	O
three	O
different	B-MED
length	B-MED
scales	B-MED
revealed	O
that	O
the	O
nano	B-MED
and	O
micro	B-MED
-	I-MED
topographical	I-MED
features	B-MED
,	O
in	O
addition	O
to	O
the	O
fractal	B-MED
dimension	I-MED
,	O
of	O
native	B-MED
ADM	B-MED
were	O
reproduced	B-MED
in	O
PDMS	B-MED
.	O
In	O
conclusion	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
fractal	B-MED
topography	I-MED
of	O
biological	B-MED
surfaces	I-MED
can	O
be	O
mimicked	O
in	O
synthetic	B-MED
materials	I-MED
using	O
the	O
novel	B-MED
fabrication	B-MED
process	I-MED
outlined	O
,	O
which	O
may	O
be	O
applied	O
to	O
significantly	O
enhance	O
medical	B-MED
device	I-MED
biocompatibility	B-MED
and	O
performance	B-MED
.	O
Methylation	B-MED
status	B-MED
of	O
the	O
promoter	B-MED
region	I-MED
of	O
the	O
human	B-MED
frizzled	B-MED
9	I-MED
gene	I-MED
in	O
acute	B-MED
myeloid	I-MED
leukemia	I-MED
The	O
FZD9	B-MED
gene	I-MED
is	O
located	O
at	O
chromosome	B-MED
7q11.23	I-MED
,	O
and	O
has	O
been	O
indicated	O
to	O
be	O
a	O
tumor	B-MED
suppressor	I-MED
gene	I-MED
.	O
The	O
present	O
study	B-MED
examined	B-MED
the	O
involvement	B-MED
of	O
FZD9	B-MED
promoter	B-MED
methylation	B-MED
in	O
the	O
downregulation	B-MED
of	O
FZD9	B-MED
expression	B-MED
in	O
leukemia	B-MED
cells	B-MED
.	O
The	O
expression	B-MED
of	O
the	O
FZD9	B-MED
gene	I-MED
was	O
absent	B-MED
in	O
various	O
leukemic	B-MED
cell	B-MED
lines	I-MED
,	O
while	O
it	O
was	O
restored	O
following	O
treatment	B-MED
with	O
DNA	B-MED
demethylating	I-MED
agent	I-MED
5	B-MED
-	I-MED
aza-2'-deoxycytidine	I-MED
.	O
Bisulfite	B-MED
sequencing	I-MED
analysis	I-MED
of	O
the	O
FZD9	B-MED
promoter	B-MED
region	I-MED
showed	O
that	O
it	O
was	O
partially	O
methylated	B-MED
in	O
cell	B-MED
lines	I-MED
in	O
which	O
FZD9	B-MED
gene	I-MED
was	O
not	O
expressed	B-MED
.	O
Thus	O
,	O
DNA	B-MED
methylation	I-MED
in	O
the	O
promoter	B-MED
region	I-MED
may	O
lead	O
to	O
inactivation	B-MED
of	O
the	O
FZD9	B-MED
gene	I-MED
,	O
which	O
may	O
represent	O
and	O
aberration	O
associated	B-MED
with	I-MED
leukemia	B-MED
,	O
since	O
DNA	B-MED
was	O
not	O
methylated	B-MED
in	O
normal	O
peripheral	B-MED
blood	I-MED
mononuclear	I-MED
cells	I-MED
.	O
Methylation	B-MED
-specific	O
polymerase	B-MED
chain	I-MED
reaction	I-MED
analysis	I-MED
revealed	O
that	O
the	O
promoter	B-MED
region	I-MED
of	O
the	O
FZD9	B-MED
gene	I-MED
was	O
frequently	B-MED
methylated	B-MED
in	O
primary	B-MED
or	O
relapse	B-MED
acute	B-MED
myeloid	I-MED
leukemia	I-MED
(	O
52.9	O
%	O
;	O
excluding	O
acute	B-MED
promyelocytic	I-MED
leukemia	I-MED
)	O
;	O
however	O
,	O
methylation	B-MED
was	O
infrequent	O
in	O
B	B-MED
-	I-MED
cell	I-MED
acute	B-MED
lymphocytic	I-MED
leukemia	I-MED
(	O
5.6	O
%	O
)	O
.	O
In	O
conclusion	O
,	O
the	O
present	O
study	B-MED
indicated	O
that	O
the	O
methylation	B-MED
profile	B-MED
of	O
the	O
FZD9	B-MED
gene	I-MED
corresponded	O
to	O
that	O
of	O
a	O
candidate	O
tumor	B-MED
-	I-MED
suppressor	I-MED
gene	I-MED
in	O
acute	B-MED
myeloid	I-MED
leukemia	I-MED
.	O
Role	B-MED
of	O
Oxidative	B-MED
Stress	I-MED
and	O
Inflammatory	B-MED
Factors	B-MED
in	O
Diabetic	B-MED
Kidney	I-MED
Disease	I-MED
Diabetic	B-MED
nephropathy	I-MED
(	O
DN	B-MED
)	O
is	O
a	O
serious	B-MED
complication	B-MED
of	O
diabetes	B-MED
mellitus	I-MED
,	O
and	O
its	O
prevalence	B-MED
has	O
been	O
increasing	B-MED
in	O
developed	B-MED
countries	I-MED
.	O
Diabetic	B-MED
nephropathy	I-MED
has	O
become	O
the	O
most	O
common	B-MED
single	B-MED
cause	O
of	O
end	B-MED
-	I-MED
stage	I-MED
renal	I-MED
disease	I-MED
worldwide	B-MED
.	O
Oxidative	B-MED
stress	I-MED
and	O
inflammation	B-MED
factors	B-MED
are	O
hypothesized	B-MED
to	O
play	B-MED
a	I-MED
role	I-MED
in	O
the	O
development	B-MED
of	O
late	B-MED
diabetes	B-MED
complications	I-MED
.	O
Chronic	B-MED
hyperglycemia	I-MED
increases	B-MED
oxidative	B-MED
stress	I-MED
,	O
significantly	B-MED
modifies	I-MED
the	O
structure	B-MED
and	O
function	B-MED
of	O
proteins	B-MED
and	O
lipids	B-MED
,	O
and	O
induces	B-MED
glycoxidation	B-MED
and	O
peroxidation	B-MED
.	O
Therefore	O
,	O
hyperglycemia	B-MED
causes	O
auto	B-MED
-	I-MED
oxidation	I-MED
of	O
glucose	B-MED
,	O
glycation	B-MED
of	O
proteins	B-MED
,	O
and	O
activation	B-MED
of	O
polyol	B-MED
mechanism	I-MED
.	O
Overproduction	B-MED
of	O
intracellular	B-MED
reactive	B-MED
oxygen	I-MED
species	I-MED
contributes	B-MED
to	O
several	B-MED
microvascular	B-MED
and	O
macrovascular	B-MED
complications	B-MED
of	O
DN	B-MED
.	O
On	O
the	O
other	O
hand	O
,	O
reactive	B-MED
oxygen	I-MED
species	I-MED
modulates	B-MED
signaling	B-MED
cascade	I-MED
of	O
immune	B-MED
factors	I-MED
.	O
An	O
increase	B-MED
in	O
reactive	B-MED
oxygen	I-MED
species	I-MED
can	O
increase	B-MED
the	O
production	B-MED
of	O
inflammatory	B-MED
cytokines	B-MED
,	O
and	O
likewise	O
,	O
an	O
increase	B-MED
in	O
inflammatory	B-MED
cytokines	B-MED
can	O
stimulate	B-MED
the	O
production	B-MED
of	O
free	B-MED
radicals	I-MED
.	O
Some	O
studies	B-MED
have	O
shown	O
that	O
kidney	B-MED
inflammation	I-MED
is	O
serious	B-MED
in	O
promoting	B-MED
the	O
development	B-MED
and	O
progression	B-MED
of	O
DN	B-MED
.	O
Inflammatory	B-MED
factors	B-MED
which	O
are	O
activated	B-MED
by	O
the	O
metabolic	B-MED
,	O
biochemical	B-MED
,	O
and	O
hemodynamic	B-MED
derangements	O
are	O
known	O
to	O
exist	B-MED
in	O
the	O
diabetic	B-MED
kidney	I-MED
.	O
This	O
review	B-MED
discusses	O
facts	O
for	O
oxidative	B-MED
stress	I-MED
and	O
inflammatory	B-MED
factors	B-MED
in	O
DN	B-MED
and	O
encompasses	O
the	O
role	B-MED
of	O
immune	B-MED
and	O
inflammatory	B-MED
cells	I-MED
,	O
inflammatory	B-MED
cytokines	B-MED
,	O
and	O
stress	B-MED
oxidative	I-MED
factors	B-MED
.	O
Challenging	B-MED
some	O
assumptions	O
about	O
empathy	B-MED
In	O
New	B-MED
Zealand	I-MED
little	O
nursing	B-MED
or	O
medical	B-MED
curricula	I-MED
time	B-MED
,	O
if	O
any	O
,	O
is	O
specifically	O
devoted	O
to	O
the	O
enhancement	B-MED
of	O
empathy	B-MED
.	O
If	O
being	O
empathic	B-MED
is	O
important	B-MED
in	O
the	O
context	O
of	O
patient	B-MED
care	I-MED
,	O
it	O
is	O
a	O
quality	O
that	O
is	O
already	O
present	O
in	O
students	B-MED
or	O
is	O
learned	O
by	O
students	B-MED
during	O
their	O
practicum	B-MED
in	O
the	O
company	O
of	O
experienced	B-MED
clinicians	B-MED
.	O
This	O
study	B-MED
aimed	O
to	O
compare	B-MED
self	B-MED
-	I-MED
reported	I-MED
empathy	B-MED
ratings	O
between	O
different	O
groups	B-MED
of	O
medical	B-MED
students	I-MED
and	O
one	O
cohort	B-MED
of	O
nursing	B-MED
students	I-MED
who	O
were	O
either	O
exposed	O
or	O
not	O
exposed	O
to	O
explicit	O
empathy	B-MED
training	B-MED
or	O
learning	B-MED
in	O
clinical	B-MED
settings	I-MED
in	O
the	O
presence	O
of	O
patients	B-MED
.	O
The	O
Jefferson	B-MED
Scale	I-MED
of	I-MED
Physician	I-MED
Empathy	I-MED
(	O
JSPE	B-MED
)	O
was	O
completed	O
before	O
and	O
after	O
groups	O
of	O
medical	B-MED
and	O
nursing	B-MED
students	I-MED
had	O
been	O
exposed	O
to	O
various	O
extended	B-MED
periods	B-MED
of	O
practicum	B-MED
.	O
Some	O
medical	B-MED
student	I-MED
cohorts	B-MED
undertook	O
brief	B-MED
empathy	B-MED
training	B-MED
training	B-MED
,	O
whereas	O
others	O
had	O
no	O
exposure	O
.	O
The	O
nursing	B-MED
student	I-MED
cohort	B-MED
had	O
no	B-MED
formal	I-MED
,	O
explicit	O
empathy	B-MED
training	B-MED
.	O
Irrespective	O
of	O
profession	B-MED
,	O
length	B-MED
of	O
practicum	B-MED
or	O
exposure	O
to	O
specific	O
empathy	B-MED
training	B-MED
,	O
there	O
were	O
no	B-MED
significant	I-MED
differences	I-MED
in	O
the	O
self	B-MED
-	I-MED
reported	I-MED
JSPE	B-MED
scores	I-MED
across	O
the	O
seven	O
different	O
cohorts	B-MED
of	O
students	B-MED
.	O
Empathy	B-MED
is	O
a	O
quality	B-MED
that	O
is	O
already	O
present	B-MED
in	O
students	B-MED
or	O
is	O
learned	B-MED
by	I-MED
students	B-MED
during	O
their	O
practicum	B-MED
DISCUSSION	B-MED
:	O
If	O
empathy	B-MED
is	O
caught	B-MED
rather	O
than	O
taught	B-MED
,	O
then	O
brief	O
efforts	O
to	O
enhance	B-MED
empathy	B-MED
may	O
be	O
futile	B-MED
.	O
To	O
optimise	O
the	O
inherent	B-MED
empathic	I-MED
qualities	I-MED
of	O
aspirant	O
health	B-MED
professionals	I-MED
,	O
explicit	O
consideration	B-MED
should	O
be	O
given	O
to	O
how	O
empathy	B-MED
is	O
influenced	B-MED
by	O
the	O
practicum	B-MED
experience	B-MED
.	O
Intraoperative	B-MED
ketamine	B-MED
reduces	B-MED
immediate	B-MED
postoperative	B-MED
opioid	B-MED
consumption	B-MED
after	O
spinal	B-MED
fusion	I-MED
surgery	I-MED
in	O
chronic	B-MED
pain	I-MED
patients	B-MED
with	O
opioid	B-MED
dependency	B-MED
:	O
a	O
randomized	B-MED
,	O
blinded	B-MED
trial	I-MED
Perioperative	B-MED
handling	B-MED
of	O
surgical	B-MED
patients	I-MED
with	O
opioid	B-MED
dependency	B-MED
represents	O
an	O
important	B-MED
clinical	B-MED
problem	B-MED
.	O
Animal	B-MED
studies	I-MED
suggest	O
that	O
ketamine	B-MED
attenuates	B-MED
central	B-MED
sensitization	I-MED
and	O
hyperalgesia	B-MED
and	O
thereby	O
reduces	B-MED
postoperative	B-MED
opioid	B-MED
opioid	B-MED
tolerance	I-MED
.	O
We	O
hypothesized	B-MED
that	O
intraoperative	B-MED
ketamine	B-MED
would	O
reduce	B-MED
immediate	B-MED
postoperative	B-MED
opioid	B-MED
consumption	B-MED
compared	O
with	O
placebo	B-MED
in	O
chronic	B-MED
pain	I-MED
patients	B-MED
with	O
opioid	B-MED
dependency	B-MED
undergoing	O
lumbar	B-MED
spinal	I-MED
fusion	I-MED
surgery	I-MED
.	O
Primary	B-MED
outcome	I-MED
was	O
morphine	B-MED
consumption	B-MED
0	B-MED
to	I-MED
24	I-MED
hours	I-MED
postoperatively	B-MED
.	O
Secondary	B-MED
outcomes	I-MED
were	O
acute	B-MED
pain	I-MED
at	I-MED
rest	I-MED
and	O
during	O
mobilization	B-MED
2	B-MED
to	I-MED
24	I-MED
hours	I-MED
postoperatively	B-MED
(	O
visual	B-MED
analogue	I-MED
scale	I-MED
)	O
,	O
adverse	B-MED
events	I-MED
,	O
and	O
persistent	B-MED
pain	B-MED
6	O
months	O
postoperatively	B-MED
.	O
One	O
hundred	O
fifty	O
patients	B-MED
were	O
randomly	B-MED
assigned	I-MED
to	O
intraoperative	B-MED
S	B-MED
-	I-MED
ketamine	I-MED
bolus	B-MED
0.5	I-MED
mg	I-MED
/	I-MED
kg	I-MED
and	I-MED
infusion	I-MED
0.25	O
mg·kg·h	O
or	O
placebo	B-MED
.	O
Postoperatively	B-MED
,	O
patients	B-MED
received	O
their	O
usual	O
opioids	B-MED
,	O
paracetamol	B-MED
and	O
IV	O
patient	B-MED
-	I-MED
controlled	I-MED
analgesia	I-MED
with	O
morphine	B-MED
.	O
In	O
the	O
final	B-MED
analyses	I-MED
,	O
147	O
patients	B-MED
were	O
included	O
.	O
Patient	B-MED
-	I-MED
controlled	I-MED
analgesia	I-MED
IV	O
morphine	B-MED
consumption	B-MED
0	O
to	O
24	O
hours	O
postoperatively	B-MED
was	O
significantly	B-MED
reduced	B-MED
in	O
the	O
ketamine	B-MED
group	O
compared	O
with	O
the	O
placebo	B-MED
group	O
:	O
79	O
(	O
47	O
)	O
vs	O
121	O
(	O
53	O
)	O
mg	O
IV	O
,	O
mean	B-MED
difference	B-MED
42	O
mg	O
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
-59	O
to	O
-25	O
)	O
,	O
P	O
<	O
0.001	O
.	O
Sedation	B-MED
was	O
significantly	B-MED
reduced	B-MED
in	O
the	O
ketamine	B-MED
group	O
6	O
and	O
24	O
hours	O
postoperatively	B-MED
.	O
There	O
were	O
no	B-MED
significant	I-MED
differences	I-MED
regarding	O
acute	B-MED
pain	I-MED
,	O
nausea	B-MED
,	O
vomiting	B-MED
,	O
hallucinations	B-MED
,	O
or	O
nightmares	B-MED
.	O
Back	B-MED
pain	I-MED
at	O
6	O
months	O
postoperatively	B-MED
compared	O
with	O
preoperative	B-MED
pain	B-MED
was	O
significantly	B-MED
more	O
improved	B-MED
in	O
the	O
ketamine	B-MED
group	O
compared	O
with	O
the	O
placebo	B-MED
group	O
,	O
P	O
=	O
0.005	O
.	O
In	O
conclusion	O
,	O
intraoperative	B-MED
ketamine	B-MED
significantly	B-MED
reduced	B-MED
morphine	B-MED
consumption	B-MED
0	B-MED
to	I-MED
24	I-MED
hours	I-MED
after	O
lumbar	B-MED
fusion	I-MED
surgery	I-MED
in	O
opioid	B-MED
-	O
dependent	B-MED
patients	B-MED
.	O
The	O
trend	B-MED
regarding	O
less	O
persistent	B-MED
pain	B-MED
6	O
months	O
postoperatively	B-MED
needs	O
further	B-MED
investigation	B-MED
.	O
Two	O
-	O
stage	O
reconstructive	B-MED
overlapping	B-MED
stent	I-MED
LEO+	B-MED
and	O
SILK	B-MED
for	O
treatment	B-MED
of	O
intracranial	B-MED
circumferential	B-MED
fusiform	B-MED
aneurysms	I-MED
in	O
the	O
posterior	B-MED
circulation	B-MED
Intracranial	B-MED
circumferential	B-MED
fusiform	B-MED
aneurysms	I-MED
of	O
the	O
posterior	B-MED
circulation	B-MED
involving	O
arterial	B-MED
branches	I-MED
or	O
perforating	B-MED
vessels	B-MED
vessels	B-MED
are	O
difficult	B-MED
to	O
treat	B-MED
.	O
This	O
article	O
shows	O
an	O
endovascular	B-MED
reconstruction	B-MED
technique	I-MED
not	O
yet	O
described	O
,	O
using	O
a	O
telescoping	B-MED
self	I-MED
-	I-MED
expandable	I-MED
stent	I-MED
(	O
LEO+	B-MED
)	O
and	O
flow	B-MED
-	I-MED
diverter	I-MED
device	I-MED
(	O
SILK	B-MED
)	O
at	O
different	B-MED
surgical	B-MED
times	I-MED
.	O
Two	O
patients	B-MED
with	O
circumferential	B-MED
fusiform	B-MED
aneurysm	I-MED
,	O
one	O
being	O
an	O
aneurysm	B-MED
of	O
the	O
segments	O
P2	O
and	O
P3	O
of	O
the	O
posterior	B-MED
cerebral	I-MED
artery	I-MED
,	O
diagnosed	B-MED
after	O
a	O
headache	B-MED
,	O
and	O
the	O
other	O
a	O
partially	B-MED
thrombosed	B-MED
aneurysm	I-MED
of	O
the	O
lower	B-MED
basilar	B-MED
artery	I-MED
,	O
diagnosed	B-MED
following	O
ischemia	B-MED
of	O
the	O
brain	B-MED
stem	I-MED
.	O
Endovascular	B-MED
treatment	B-MED
was	O
performed	O
by	O
means	O
of	O
a	O
vascular	B-MED
reconstruction	B-MED
technique	I-MED
that	O
used	O
at	O
different	B-MED
surgical	B-MED
times	I-MED
:	O
overlapping	B-MED
;	I-MED
a	I-MED
telescoped	I-MED
self	I-MED
-	I-MED
expandable	I-MED
stent	I-MED
,	O
LEO+	B-MED
;	O
and	O
a	O
flow	B-MED
-	I-MED
diverter	I-MED
device	I-MED
,	O
SILK	B-MED
.	O
Angiographic	B-MED
control	B-MED
was	O
carried	O
out	O
at	O
6	O
and	O
12	O
months	B-MED
,	O
to	O
evaluate	O
arterial	B-MED
patency	I-MED
,	O
flow	B-MED
maintenance	B-MED
in	O
the	O
arterial	B-MED
branches	I-MED
and	O
perforating	B-MED
vessels	B-MED
,	O
and	O
thrombosis	B-MED
of	O
the	O
aneurysm	B-MED
.	O
The	O
combined	B-MED
use	O
at	O
different	B-MED
surgical	B-MED
times	I-MED
of	O
the	O
self	B-MED
-	I-MED
expandable	I-MED
stent	I-MED
and	O
flow	B-MED
-	I-MED
diverter	I-MED
device	I-MED
was	O
technically	O
successful	B-MED
in	O
both	O
patients	B-MED
.	O
There	O
were	O
no	O
complications	B-MED
during	O
the	O
procedure	B-MED
,	O
nor	O
in	O
the	O
long	B-MED
-	I-MED
term	I-MED
follow	B-MED
-	I-MED
up	I-MED
with	O
full	O
arterial	B-MED
vascular	B-MED
reconstruction	B-MED
,	O
maintenance	B-MED
of	O
cerebral	B-MED
perfusion	I-MED
and	O
complete	B-MED
aneurysm	B-MED
occlusion	B-MED
at	O
the	O
6-	O
and	O
12-	O
month	B-MED
angiographic	B-MED
follow	B-MED
-	I-MED
up	I-MED
.	O
There	O
was	O
no	O
aneurysm	B-MED
recanalization	I-MED
nor	O
intra	B-MED
-	I-MED
stent	I-MED
stenosis	I-MED
.	O
Circumferential	B-MED
fusiform	B-MED
aneurysm	I-MED
of	O
the	O
posterior	B-MED
circulation	B-MED
involving	O
arterial	B-MED
branches	I-MED
or	O
perforating	B-MED
vessels	B-MED
to	O
the	O
brain	B-MED
stem	I-MED
may	O
be	O
treated	B-MED
with	O
this	O
arterial	B-MED
reconstruction	B-MED
technique	I-MED
at	O
different	B-MED
surgical	B-MED
times	I-MED
,	O
using	O
the	O
self	B-MED
-	I-MED
expandable	I-MED
stent	I-MED
called	O
LEO+	B-MED
and	O
the	O
flow	B-MED
-	I-MED
diverter	I-MED
device	I-MED
SILK	B-MED
,	O
minimizing	B-MED
the	O
risk	B-MED
of	O
complications	B-MED
and	O
failure	B-MED
of	O
the	O
endovascular	B-MED
technique	B-MED
,	O
with	O
the	O
potential	B-MED
for	O
arterial	B-MED
reconstruction	I-MED
with	O
thrombosis	B-MED
of	O
the	O
aneurysmatic	B-MED
sac	I-MED
,	O
as	O
well	O
as	O
flow	B-MED
maintenance	B-MED
in	O
the	O
eloquent	B-MED
arteries	I-MED
,	O
in	O
this	O
type	O
of	O
cerebral	B-MED
aneurysm	I-MED
.	O
Clinical	B-MED
value	I-MED
of	O
pathologic	B-MED
examination	I-MED
of	O
non	B-MED
-	I-MED
neoplastic	I-MED
kidney	I-MED
in	O
patients	B-MED
with	O
upper	B-MED
urinary	I-MED
tract	I-MED
malignancies	B-MED
While	O
surgical	B-MED
resection	I-MED
remains	O
the	O
standard	O
of	O
care	B-MED
in	O
the	O
treatment	B-MED
of	O
upper	B-MED
urinary	I-MED
tract	I-MED
malignancies	B-MED
,	O
nephrectomy	B-MED
is	O
a	O
risk	B-MED
factor	I-MED
for	O
the	O
development	B-MED
of	O
chronic	B-MED
kidney	I-MED
disease	I-MED
(	O
CKD	B-MED
)	O
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
determine	O
whether	O
histologic	B-MED
evaluation	B-MED
of	O
non	B-MED
-	I-MED
neoplastic	I-MED
kidney	I-MED
could	O
enable	O
early	B-MED
identification	I-MED
of	O
unrecognized	O
kidney	B-MED
disease	I-MED
and	O
could	O
be	O
of	O
prognostic	B-MED
value	O
in	O
predicting	O
postoperative	B-MED
renal	B-MED
outcomes	B-MED
.	O
We	O
retrospectively	B-MED
analyzed	I-MED
51	O
patients	B-MED
with	O
upper	B-MED
urinary	I-MED
tract	I-MED
malignancies	B-MED
who	O
received	O
uninephrectomy	B-MED
or	O
uninephroureterectomy	B-MED
.	O
A	O
thorough	O
pathologic	B-MED
evaluation	B-MED
of	O
non	B-MED
-	I-MED
neoplastic	I-MED
kidney	I-MED
including	O
special	B-MED
stains	I-MED
,	O
immunofluorescence	B-MED
,	O
and	O
electron	B-MED
microscopic	I-MED
studies	I-MED
was	O
performed	O
.	O
The	O
degree	B-MED
of	O
parenchymal	B-MED
changes	B-MED
was	O
graded	O
from	O
0	O
to	O
15	O
.	O
Of	O
51	O
patients	B-MED
,	O
only	O
13	O
showed	O
normal	O
kidney	B-MED
pathology	B-MED
.	O
Fifteen	O
patients	B-MED
showed	O
glomerular	B-MED
abnormalities	I-MED
,	O
14	O
showed	O
diabetic	B-MED
nephropathy	I-MED
,	O
and	O
11	O
showed	O
vascular	B-MED
nephropathy	B-MED
.	O
There	O
was	O
one	O
case	O
each	O
of	O
reflux	B-MED
nephropathy	I-MED
and	O
chronic	B-MED
pyelonephritis	I-MED
.	O
The	O
median	O
histologic	B-MED
score	I-MED
was	O
5	O
points	O
.	O
Only	O
25.4	O
%	O
of	O
patients	B-MED
had	O
≤	O
3	O
points	O
.	O
Score	B-MED
more	O
than	O
5	O
was	O
observed	O
in	O
47.1	O
%	O
of	O
patients	B-MED
.	O
Postoperative	B-MED
estimated	B-MED
glomerular	I-MED
filtration	I-MED
rate	I-MED
(	O
eGFR	B-MED
)	O
at	O
3	O
to	O
36	O
months	B-MED
were	O
obtained	O
from	O
90.2	O
%	O
of	O
patients	B-MED
,	O
and	O
of	O
those	O
,	O
34.8	O
%	O
had	O
de	O
novo	O
CKD	B-MED
.	O
Since	O
no	O
one	O
had	O
CKD	B-MED
in	O
partial	O
nephrectomized	B-MED
patients	I-MED
,	O
we	O
determined	O
risk	B-MED
factors	I-MED
for	O
CKD	B-MED
in	O
radical	O
nephrectomized	B-MED
patients	I-MED
.	O
Cox	B-MED
regression	I-MED
analysis	I-MED
revealed	O
that	O
postoperative	B-MED
AKI	B-MED
,	O
preoperative	B-MED
eGFR	B-MED
,	O
and	O
histologic	B-MED
score	O
of	O
non	B-MED
-	I-MED
neoplastic	I-MED
kidney	I-MED
were	O
the	O
independent	O
predictors	B-MED
for	O
CKD	B-MED
.	O
We	O
conclude	O
that	O
routine	O
pathologic	B-MED
evaluation	B-MED
of	O
non	B-MED
-	I-MED
neoplastic	I-MED
kidney	I-MED
provides	O
valuable	O
diagnostic	B-MED
and	O
prognostic	B-MED
information	O
.	O
Synaptic	B-MED
and	O
Neuronal	B-MED
Autoantibody	B-MED
-	O
Associated	B-MED
Psychiatric	B-MED
Syndromes	I-MED
:	O
Controversies	B-MED
and	O
Hypotheses	B-MED
Autoimmune	B-MED
encephalitis	I-MED
(	O
AE	B-MED
)	O
mediated	O
by	O
antibodies	B-MED
against	O
synaptic	B-MED
and	O
neuronal	B-MED
surface	B-MED
targets	B-MED
frequently	B-MED
presents	B-MED
with	O
a	O
psychiatric	B-MED
syndrome	I-MED
.	O
In	O
these	O
patients	B-MED
,	O
removal	B-MED
of	I-MED
autoantibodies	B-MED
treats	B-MED
the	O
disease	B-MED
and	O
outcomes	B-MED
are	O
closely	O
linked	O
to	O
early	O
intervention	B-MED
.	O
The	O
discovery	B-MED
of	O
these	O
autoantibodies	B-MED
in	O
isolated	B-MED
psychiatric	B-MED
syndromes	I-MED
has	O
raised	B-MED
the	O
possibility	O
that	O
these	O
patients	B-MED
may	O
derive	O
similar	O
benefits	B-MED
from	O
immunotherapy	B-MED
,	O
a	O
potentially	B-MED
transformational	O
approach	B-MED
to	O
the	O
treatment	B-MED
of	O
mental	B-MED
illness	I-MED
.	O
Although	O
open	B-MED
-	I-MED
label	I-MED
case	I-MED
series	I-MED
suggest	O
impressive	O
therapeutic	B-MED
outcomes	I-MED
,	O
the	O
pathological	B-MED
relevance	B-MED
of	O
these	O
autoantibodies	B-MED
outside	O
of	O
canonical	B-MED
presentations	I-MED
is	O
debated	O
.	O
The	O
advent	O
of	O
diagnostic	B-MED
criteria	I-MED
for	O
AE	B-MED
attempts	B-MED
to	O
facilitate	O
its	O
prompt	O
identification	B-MED
but	O
risks	B-MED
prematurely	O
neglecting	O
the	O
potential	B-MED
scientific	B-MED
and	O
clinical	B-MED
significance	I-MED
of	O
isolated	B-MED
syndromes	B-MED
that	O
do	O
not	O
satisfy	O
these	O
criteria	O
.	O
Here	O
,	O
we	O
propose	O
using	O
a	O
syndrome	B-MED
-	O
level	B-MED
taxonomy	B-MED
that	O
has	O
occasional	B-MED
,	O
but	O
not	O
necessary	O
,	O
overlap	B-MED
with	O
AE	B-MED
:	O
synaptic	B-MED
and	O
neuronal	B-MED
autoantibody	B-MED
-	O
associated	B-MED
psychiatric	B-MED
syndromes	I-MED
or	O
"	O
SNAps	B-MED
"	O
.	O
This	O
will	O
prevent	B-MED
confusion	O
with	O
AE	B-MED
and	O
act	B-MED
heuristically	I-MED
to	O
promote	B-MED
active	B-MED
investigation	B-MED
into	O
this	O
rare	B-MED
example	B-MED
of	O
psychopathology	B-MED
defined	B-MED
on	O
a	O
molecular	B-MED
level	I-MED
.	O
We	O
suggest	O
that	O
this	O
concept	B-MED
would	O
have	O
application	O
in	O
other	O
autoantibody	B-MED
-	O
associated	B-MED
syndromes	B-MED
including	B-MED
seizure	B-MED
,	O
cognitive	B-MED
,	O
and	O
movement	B-MED
disorders	I-MED
,	O
in	O
which	O
similar	B-MED
issues	B-MED
arise	O
.	O
We	O
review	B-MED
putative	O
direct	B-MED
and	O
indirect	B-MED
mechanisms	B-MED
and	O
outline	O
experimentally	B-MED
testable	O
hypotheses	B-MED
that	O
would	O
help	O
to	O
determine	O
prospectively	B-MED
in	O
whom	O
autoantibody	B-MED
detection	B-MED
is	O
relevant	B-MED
,	O
and	O
as	O
important	B-MED
,	O
in	O
whom	O
it	O
is	O
not	O
.	O
We	O
summarize	O
a	O
pragmatic	B-MED
approach	O
to	O
autoantibody	B-MED
testing	B-MED
and	O
management	B-MED
in	O
severe	B-MED
mental	B-MED
illness	I-MED
in	O
order	O
to	O
promptly	O
diagnose	B-MED
AE	B-MED
and	O
advocate	O
a	O
research	B-MED
-	O
orientated	B-MED
experimental	B-MED
medicine	B-MED
paradigm	B-MED
for	O
SNAps	B-MED
,	O
where	O
there	O
is	O
greater	B-MED
equipoise	B-MED
.	O
We	O
conclude	O
that	O
SNAps	B-MED
remains	O
a	O
nascent	O
area	O
of	O
clinical	B-MED
neuroscience	B-MED
with	O
great	O
potential	B-MED
and	O
in	O
ongoing	B-MED
need	B-MED
of	O
psychiatry	B-MED
-led	O
basic	O
and	O
clinical	B-MED
research	I-MED
.	O
Ceftaroline	B-MED
fosamil	I-MED
for	O
community	B-MED
-	I-MED
acquired	I-MED
pneumonia	I-MED
and	O
skin	B-MED
and	O
skin	B-MED
structure	I-MED
infections	I-MED
:	O
a	O
systematic	B-MED
review	I-MED
Background	O
Ceftaroline	B-MED
is	O
a	O
parentally	O
administered	B-MED
cephalosporin	B-MED
that	O
has	O
an	O
in	B-MED
vitro	I-MED
expanded	B-MED
spectrum	O
of	O
activity	B-MED
compared	B-MED
with	O
other	O
cephalosporins	B-MED
yet	O
data	B-MED
is	O
conflicting	O
regarding	O
its	O
place	O
in	O
therapy	B-MED
.	O
Aim	O
of	O
the	O
Review	B-MED
To	O
compare	B-MED
the	O
efficacy	B-MED
and	O
safety	B-MED
of	O
ceftaroline	B-MED
against	O
standard	O
antibiotic	B-MED
regimens	B-MED
for	O
community	B-MED
-	I-MED
acquired	I-MED
pneumonia	I-MED
(	O
CAP	B-MED
)	O
and	O
complicated	B-MED
skin	I-MED
and	I-MED
skin	I-MED
structure	I-MED
infections	I-MED
(	O
cSSSIs	B-MED
)	O
.	O
Method	O
The	O
databases	B-MED
of	O
MEDLINE	B-MED
,	O
EBSCO	B-MED
,	O
and	O
Embase	B-MED
were	O
searched	O
up	O
to	O
June	O
2016	O
.	O
Manual	B-MED
review	I-MED
of	I-MED
references	I-MED
was	I-MED
completed	I-MED
and	O
experts	B-MED
in	O
the	O
field	O
were	O
contacted	O
for	O
unpublished	B-MED
data	I-MED
.	O
Randomized	B-MED
controlled	I-MED
trials	I-MED
of	O
ceftaroline	B-MED
in	O
CAP	B-MED
or	O
cSSSI	B-MED
populations	B-MED
were	O
included	O
.	O
Outcomes	B-MED
included	O
clinical	B-MED
cure	I-MED
,	O
mortality	B-MED
,	O
adverse	B-MED
events	I-MED
,	O
serious	B-MED
adverse	I-MED
events	I-MED
,	O
and	O
discontinuation	B-MED
due	O
to	O
adverse	B-MED
events	I-MED
.	O
Meta	B-MED
-	I-MED
analysis	I-MED
was	O
used	O
to	O
pool	O
results	O
for	O
these	O
outcomes	B-MED
.	O
We	O
performed	O
subgroup	B-MED
analyses	B-MED
for	O
gram	B-MED
positive	I-MED
infections	I-MED
in	O
CAP	B-MED
and	O
infections	B-MED
caused	O
by	O
methicillin	B-MED
-	I-MED
resistant	I-MED
Staphylococcus	I-MED
aureus	I-MED
in	O
cSSSIs	B-MED
.	O
Risk	B-MED
of	O
bias	B-MED
was	O
assessed	O
for	O
all	O
studies	B-MED
.	O
Results	O
Six	O
trials	B-MED
(	O
three	O
for	O
each	O
indication	O
)	O
were	O
included	O
,	O
each	O
of	O
which	O
had	O
an	O
unclear	O
or	O
high	O
risk	B-MED
of	O
bias	B-MED
in	O
at	O
least	O
one	O
domain	O
.	O
For	O
CAP	B-MED
,	O
ceftaroline	B-MED
was	O
significantly	O
more	O
efficacious	B-MED
in	O
achieving	O
clinical	B-MED
cure	I-MED
than	O
ceftriaxone	B-MED
[	O
risk	B-MED
ratio	I-MED
(	O
RR	B-MED
)	O
1.11	O
,	O
95	O
%	O
confidence	B-MED
interval	I-MED
(	O
CI	B-MED
)	O
1.04	O
-	O
1.19	O
;	O
I(2	O
)	O
=	O
47	O
%	O
]	O
.	O
For	O
cSSSIs	B-MED
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
clinical	B-MED
cure	I-MED
between	O
ceftaroline	B-MED
and	O
vancomycin	B-MED
plus	O
aztreonam	B-MED
(	O
RR	B-MED
1.01	O
,	O
95	O
%	O
CI	B-MED
0.97	O
-	O
1.05	O
;	O
I(2	O
)	O
=	O
0	O
%	O
)	O
.	O
No	O
differences	O
were	O
found	O
for	O
overall	O
mortality	B-MED
,	O
serious	B-MED
adverse	I-MED
events	I-MED
,	O
discontinuation	B-MED
due	O
to	O
adverse	B-MED
events	I-MED
,	O
and	O
overall	O
adverse	B-MED
events	I-MED
.	O
Conclusion	O
Ceftaroline	B-MED
is	O
a	O
viable	O
therapeutic	B-MED
alternative	I-MED
for	O
patients	B-MED
with	O
CAP	B-MED
and	O
cSSSIs	B-MED
,	O
yet	O
identified	O
risks	B-MED
of	O
bias	B-MED
and	O
poor	B-MED
external	I-MED
validity	I-MED
preclude	O
it	O
from	O
being	O
recommended	O
as	O
a	O
first	B-MED
-	I-MED
line	I-MED
agent	I-MED
.	O
CD84	B-MED
mediates	O
CLL	B-MED
-	O
microenvironment	B-MED
interactions	B-MED
Chronic	B-MED
lymphocytic	I-MED
leukemia	I-MED
(	O
CLL	B-MED
)	O
is	O
a	O
malignant	B-MED
disease	I-MED
of	O
small	O
mature	B-MED
lymphocytes	I-MED
.	O
Signals	B-MED
from	O
the	O
CLL	B-MED
microenvironment	B-MED
promote	B-MED
progression	B-MED
of	I-MED
the	I-MED
disease	I-MED
and	O
induce	B-MED
drug	B-MED
resistance	I-MED
.	O
This	O
phenomenon	B-MED
is	O
largely	O
dependent	B-MED
on	O
direct	O
contact	O
between	O
the	O
malignant	B-MED
B	I-MED
cells	I-MED
and	O
stromal	B-MED
cells	I-MED
.	O
CD84	B-MED
belongs	O
to	O
the	O
signaling	B-MED
lymphocyte	I-MED
activation	I-MED
molecule	I-MED
family	I-MED
of	O
immunoreceptors	B-MED
,	O
which	O
self	B-MED
-	I-MED
associates	I-MED
,	O
forming	O
an	O
orthogonal	B-MED
homophilic	I-MED
dimer	I-MED
.	O
We	O
therefore	O
hypothesized	O
that	O
CD84	B-MED
may	O
bridge	O
between	O
CLL	B-MED
cells	B-MED
and	O
their	O
microenvironment	B-MED
,	O
promoting	B-MED
cell	B-MED
survival	I-MED
.	O
Our	O
in	B-MED
vitro	I-MED
results	B-MED
show	O
that	O
CD84	B-MED
expressed	I-MED
on	O
CLL	B-MED
cells	B-MED
interact	B-MED
with	O
CD84	B-MED
expressed	I-MED
on	O
cells	B-MED
in	O
their	O
microenvironment	B-MED
,	O
inducing	B-MED
cell	B-MED
survival	I-MED
in	O
both	O
sides	O
.	O
Blocking	B-MED
CD84	B-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
disrupt	B-MED
the	O
interaction	B-MED
of	O
CLL	B-MED
cells	B-MED
with	O
their	O
microenvironment	B-MED
,	O
resulting	B-MED
in	I-MED
induced	B-MED
cell	B-MED
death	I-MED
.	O
Thus	O
,	O
our	O
findings	B-MED
suggest	O
novel	B-MED
therapeutic	B-MED
strategies	O
based	O
on	O
the	O
blockade	B-MED
of	O
this	O
CD84	B-MED
-	O
dependent	B-MED
survival	B-MED
pathway	B-MED
.	O
Understanding	B-MED
the	O
interrelationship	B-MED
between	O
the	O
synthesis	B-MED
of	O
urea	B-MED
and	O
gluconeogenesis	B-MED
by	O
formulating	O
an	O
overall	B-MED
balanced	B-MED
equation	I-MED
It	O
is	O
well	O
known	O
that	O
a	O
strong	O
metabolic	B-MED
interrelationship	B-MED
exists	O
between	O
ureagenesis	B-MED
and	O
gluconeogenesis	B-MED
.	O
In	O
this	O
paper	O
,	O
we	O
present	O
a	O
detailed	O
,	O
overall	B-MED
equation	B-MED
,	O
describing	O
a	O
possible	O
metabolic	B-MED
link	B-MED
between	O
ureagenesis	B-MED
and	O
gluconeogenesis	B-MED
.	O
We	O
adopted	O
a	O
guided	B-MED
approach	I-MED
in	O
which	O
we	O
strongly	O
suggest	O
that	O
students	B-MED
,	O
when	O
faced	O
with	O
the	O
problem	B-MED
of	O
obtaining	B-MED
the	O
overall	B-MED
equation	B-MED
of	O
a	O
metabolic	B-MED
pathway	I-MED
,	O
carefully	O
account	O
for	O
all	O
atoms	B-MED
and	O
charges	B-MED
of	O
the	O
single	O
reactions	B-MED
,	O
as	O
well	O
as	O
the	O
cellular	B-MED
localizations	I-MED
of	O
the	O
substrates	B-MED
,	O
and	O
the	O
related	O
transport	B-MED
systems	B-MED
.	O
If	O
this	O
suggestion	O
is	O
always	O
taken	O
into	O
account	O
,	O
a	O
balanced	B-MED
,	O
overall	B-MED
equation	B-MED
of	O
a	O
metabolic	B-MED
pathway	I-MED
will	O
be	O
obtained	O
,	O
which	O
strongly	O
facilitates	O
the	O
discussion	O
of	O
its	O
physiological	B-MED
role	O
.	O
Unfortunately	O
,	O
textbooks	B-MED
often	O
report	B-MED
unbalanced	O
overall	B-MED
equations	B-MED
of	O
metabolic	B-MED
pathways	I-MED
,	O
including	O
ureagenesis	B-MED
and	O
gluconeogenesis	B-MED
.	O
Most	O
likely	O
the	O
reason	O
is	O
that	O
metabolism	B-MED
and	O
enzymology	B-MED
have	O
been	O
neglected	O
for	O
about	O
three	O
decades	O
,	O
owing	O
to	O
the	O
remarkable	O
advances	O
of	O
molecular	B-MED
biology	I-MED
and	O
molecular	B-MED
genetics	I-MED
.	O
In	O
this	O
paper	B-MED
,	O
we	O
strongly	O
suggest	O
that	O
students	B-MED
,	O
when	O
faced	O
with	O
the	O
problem	O
of	O
obtaining	O
the	O
overall	B-MED
reaction	B-MED
of	O
a	O
metabolic	B-MED
pathway	I-MED
,	O
carefully	O
control	O
if	O
the	O
single	O
reactions	B-MED
are	O
properly	O
balanced	B-MED
for	O
atoms	B-MED
and	O
charges	B-MED
.	O
Following	O
this	O
suggestion	B-MED
,	O
we	O
were	O
able	O
to	O
obtain	O
an	O
overall	B-MED
equation	B-MED
describing	O
the	O
metabolic	B-MED
interrelationship	B-MED
between	O
ureagenesis	B-MED
and	O
gluconeogenesis	B-MED
,	O
in	O
which	O
urea	B-MED
and	O
glucose	B-MED
are	O
the	O
final	B-MED
products	B-MED
.	O
The	O
aim	O
is	O
to	O
better	O
rationalize	B-MED
this	O
topic	B-MED
and	O
to	O
convince	O
students	B-MED
and	O
teachers	B-MED
that	O
metabolism	B-MED
is	O
an	O
important	O
and	O
rewarding	O
chapter	B-MED
of	O
human	B-MED
physiology	I-MED
.	O
Sex	B-MED
Life	I-MED
and	O
Impact	B-MED
of	O
Operative	B-MED
Intervention	B-MED
on	O
Sex	B-MED
Life	I-MED
-	I-MED
related	I-MED
Pain	I-MED
in	O
Degenerative	B-MED
Spinal	B-MED
Conditions	O
:	O
An	O
Analysis	B-MED
of	O
the	O
SPORT	B-MED
Study	I-MED
This	O
study	B-MED
is	O
a	O
therapeutic	B-MED
retrospective	I-MED
cohort	I-MED
study	I-MED
OBJECTIVES	O
.	O
:	O
This	O
study	B-MED
aims	O
to	O
determine	O
whether	O
sexual	B-MED
function	I-MED
is	O
relevant	O
for	O
patients	B-MED
with	O
spinal	B-MED
stenosis	I-MED
(	O
SPS	B-MED
)	O
and	O
degenerative	B-MED
spondylolisthesis	I-MED
(	O
DS	B-MED
)	O
and	O
to	O
determine	O
the	O
impact	B-MED
of	O
operative	B-MED
inter	O
vqAvention	O
on	O
sexual	B-MED
function	I-MED
for	O
these	O
patients	B-MED
.	O
The	O
benefits	O
of	O
nonoperative	B-MED
versus	O
operative	B-MED
treatment	B-MED
for	O
patients	B-MED
with	O
SPS	B-MED
and	O
DS	B-MED
with	O
regards	O
to	O
sexual	B-MED
function	I-MED
are	O
unknown	O
.	O
Demographic	B-MED
,	O
treatment	B-MED
,	O
and	O
follow	B-MED
-	I-MED
up	I-MED
data	B-MED
,	O
including	O
the	O
Oswestry	O
Disability	O
Index	O
(	O
ODI	O
)	O
,	O
were	O
obtained	O
on	O
patients	B-MED
enrolled	O
in	O
the	O
SPORT	B-MED
study	I-MED
.	O
Based	O
on	O
the	O
response	O
to	O
question	O
#	O
9	O
in	O
the	O
ODI	O
,	O
patients	B-MED
were	O
classified	O
into	O
a	O
sexual	B-MED
life	I-MED
relevant	I-MED
(	O
SLR	B-MED
)	O
or	O
sexual	B-MED
life	I-MED
not	I-MED
relevant	I-MED
(	I-MED
NR	I-MED
)	I-MED
group	I-MED
.	O
Univariate	B-MED
and	O
multivariate	B-MED
analysis	I-MED
of	O
patient	B-MED
characteristics	B-MED
comparing	O
the	O
NR	B-MED
and	O
SLR	B-MED
group	I-MED
were	O
performed	O
.	O
Operative	B-MED
treatment	B-MED
groups	B-MED
were	O
compared	O
to	O
the	O
nonoperative	B-MED
group	B-MED
with	O
regards	O
to	O
response	O
to	O
ODI	O
question	O
#	O
9	O
to	O
determine	O
the	O
impact	B-MED
of	O
surgery	B-MED
on	O
sexual	B-MED
function	I-MED
.	O
A	O
total	O
of	O
1235	O
patients	B-MED
were	O
included	O
to	O
determine	O
relevance	O
of	O
sex	B-MED
life	I-MED
.	O
Three	O
hundred	O
sixty	O
-	O
six	O
patients	B-MED
(	O
29	O
%	O
)	O
were	O
included	O
in	O
the	O
NR	B-MED
group	I-MED
.	O
Eight	O
hundred	O
sixty	O
-	O
nine	O
patients	B-MED
(	O
71	O
%	O
)	O
were	O
included	O
in	O
the	O
SLR	B-MED
group	I-MED
.	O
Patients	B-MED
that	O
were	O
older	B-MED
,	O
female	B-MED
,	O
unmarried	B-MED
,	O
had	O
three	O
or	O
more	O
stenotic	B-MED
levels	I-MED
,	O
and	O
had	O
central	B-MED
stenosis	I-MED
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
NR	B-MED
group	I-MED
.	O
Eight	O
hundred	O
twenty	O
-	O
five	O
patients	B-MED
were	O
included	O
in	O
the	O
analysis	B-MED
comparing	O
operative	B-MED
versus	O
nonoperative	B-MED
treatment	B-MED
.	O
At	O
all	O
follow	B-MED
-	I-MED
up	I-MED
time	O
points	O
,	O
the	O
operative	B-MED
groups	B-MED
had	O
a	O
lower	O
percentage	B-MED
of	O
patients	B-MED
reporting	O
pain	B-MED
with	O
their	O
sex	B-MED
life	I-MED
compared	O
to	O
the	O
nonoperative	B-MED
group	B-MED
(	O
P	O
<	O
0.05	O
at	O
all	O
time	O
points	O
except	O
between	O
more	O
than	O
one	O
level	O
fusion	O
and	O
nonoperative	B-MED
at	O
4	O
years	B-MED
'	O
follow	B-MED
-	I-MED
up	I-MED
)	O
.	O
Sex	B-MED
life	I-MED
is	O
a	O
relevant	O
consideration	O
for	O
the	O
majority	O
of	O
patients	B-MED
with	O
DS	B-MED
and	O
SPS	B-MED
;	O
operative	B-MED
treatment	B-MED
leads	O
to	O
improved	B-MED
sex	B-MED
life	I-MED
-	I-MED
related	I-MED
pain	I-MED
.	O
3	O
.	O
Esomeprazole	B-MED
-	O
or	O
rabeprazole	B-MED
-based	O
triple	B-MED
therapy	B-MED
eradicated	O
Helicobacter	B-MED
pylori	I-MED
comparably	O
regardless	B-MED
of	O
clarithromycin	B-MED
susceptibility	B-MED
and	O
CYP2C19	B-MED
genotypes	B-MED
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
assess	B-MED
the	O
efficacy	B-MED
of	O
esomeprazole	B-MED
-based	O
triple	B-MED
therapy	B-MED
compared	B-MED
with	O
rabeprazole	B-MED
-based	O
triple	B-MED
therapy	B-MED
according	O
to	O
CYP2C19	B-MED
genotype	B-MED
and	O
clarithromycin	B-MED
susceptibility	B-MED
status	B-MED
for	O
first	O
-	O
line	O
eradication	B-MED
therapy	I-MED
of	I-MED
Helicobacter	I-MED
pylori	I-MED
(	O
H.	B-MED
pylori	I-MED
)	O
in	O
Japan	B-MED
.	O
We	O
enrolled	O
219	O
H.	B-MED
pylori	I-MED
-	O
infected	B-MED
patients	I-MED
,	O
and	O
randomly	B-MED
allocated	B-MED
patients	B-MED
to	O
the	O
EAC	B-MED
group	I-MED
(	O
esomeprazole	B-MED
20	O
mg	O
,	O
clarithromycin	B-MED
200	O
mg	O
,	O
amoxicillin	B-MED
750	O
mg	O
for	O
one	O
week	B-MED
,	O
with	O
all	O
drugs	B-MED
given	B-MED
twice	B-MED
daily	I-MED
)	O
or	O
RAC	B-MED
group	I-MED
(	O
rabeprazole	B-MED
10	O
mg	O
,	O
clarithromycin	B-MED
200	O
mg	O
,	O
amoxicillin	B-MED
750	O
mg	O
for	O
one	O
week	B-MED
,	O
with	O
all	O
drugs	B-MED
given	B-MED
twice	B-MED
daily	I-MED
)	O
.	O
The	O
H.	B-MED
pylori	I-MED
eradication	B-MED
rate	I-MED
according	O
to	O
the	O
PP	B-MED
analyses	I-MED
was	O
75.0	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
65.2	O
-	O
82.8	O
%	O
)	O
in	O
the	O
EAC	B-MED
group	I-MED
and	O
71.4	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
61.4	O
-	O
79.1	O
%	O
)	O
in	O
the	O
RAC	B-MED
group	I-MED
.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	B-MED
.	O
The	O
eradication	B-MED
rates	I-MED
of	O
the	O
clarithromycin	B-MED
clarithromycin	B-MED
-resistant	I-MED
/-	O
sensitive	B-MED
strains	B-MED
were	O
,	O
respectively	O
,	O
45.0	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
30.7	O
-	O
60.2%)/98.0	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
88.7	O
-	O
100	O
%	O
)	O
in	O
the	O
EAC	B-MED
group	I-MED
and	O
39.5	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
25.6	O
-	O
55.3%)/93.5	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
81.9	O
-	O
98.4	O
%	O
)	O
in	O
the	O
RAC	B-MED
group	I-MED
.	O
The	O
eradication	B-MED
rate	I-MED
of	O
the	O
clarithromycin	B-MED
-	O
sensitive	B-MED
strains	B-MED
was	O
significantly	O
higher	B-MED
than	O
that	O
of	O
the	O
resistant	B-MED
strains	I-MED
in	O
both	B-MED
groups	B-MED
.	O
In	O
conclusion	O
,	O
EAC	B-MED
and	O
RAC	B-MED
therapies	B-MED
show	O
a	O
comparable	O
efficacy	B-MED
regardless	B-MED
of	O
the	O
CYP2C19	B-MED
genotype	B-MED
and	O
clarithromycin	B-MED
susceptibility	B-MED
status	B-MED
in	O
Japan	B-MED
.	O
Hospital	B-MED
clowning	I-MED
:	O
a	O
paediatrician	B-MED
's	I-MED
view	B-MED
This	O
study	B-MED
investigates	B-MED
the	O
current	B-MED
position	O
of	O
hospital	B-MED
clowns	I-MED
from	O
the	O
perspective	B-MED
of	O
paediatricians	B-MED
and	O
paediatric	B-MED
residents	I-MED
.	O
A	O
total	B-MED
of	O
14	O
attending	B-MED
paediatricians	I-MED
and	O
paediatric	B-MED
residents	I-MED
participated	B-MED
in	O
two	O
focus	B-MED
group	I-MED
sessions	I-MED
.	O
Data	B-MED
were	O
analysed	B-MED
using	O
Atlas.ti	B-MED
5.0	I-MED
.	O
In	O
general	B-MED
,	O
physicians	B-MED
reported	B-MED
positive	B-MED
experiences	B-MED
regarding	O
the	O
interaction	B-MED
between	O
hospital	B-MED
clowns	I-MED
and	O
paediatric	B-MED
patients	I-MED
on	O
the	O
ward	B-MED
.	O
Physicians	B-MED
were	O
more	O
interested	B-MED
in	O
research	B-MED
on	O
children	B-MED
's	I-MED
perception	I-MED
of	O
hospital	B-MED
clowns	I-MED
than	O
in	O
research	B-MED
on	O
the	O
clinical	B-MED
efficacy	I-MED
of	O
hospital	B-MED
clowning	I-MED
.	O
No	B-MED
direct	I-MED
collaboration	B-MED
between	O
physicians	B-MED
and	O
hospital	B-MED
clowns	I-MED
was	O
reported	B-MED
.	O
However	O
,	O
physicians	B-MED
proposed	B-MED
conditions	B-MED
which	O
may	O
streamline	B-MED
their	O
encounters	B-MED
with	O
hospital	B-MED
clowns	I-MED
such	O
as	O
clear	B-MED
communication	I-MED
prior	B-MED
to	O
hospital	B-MED
clown	I-MED
visits	B-MED
,	O
and	O
the	O
condition	B-MED
that	O
visits	B-MED
do	O
not	O
impede	B-MED
medical	B-MED
interventions	I-MED
.	O
Overall	B-MED
,	O
paediatricians	B-MED
and	O
paediatric	B-MED
residents	I-MED
view	B-MED
the	O
positive	B-MED
impact	B-MED
on	O
paediatric	B-MED
patients	I-MED
as	O
the	O
most	O
important	B-MED
aspect	B-MED
of	O
hospital	B-MED
clown	I-MED
visits	B-MED
,	O
rather	O
than	O
the	O
clinical	B-MED
efficacy	I-MED
of	O
hospital	B-MED
clowning	I-MED
.	O
In	O
light	O
of	O
the	O
growing	O
number	O
of	O
hospital	B-MED
clowns	I-MED
worldwide	B-MED
,	O
this	O
article	B-MED
provides	O
recommendations	B-MED
for	O
arranging	O
their	O
encounters	B-MED
with	O
paediatricians	B-MED
and	O
paediatric	B-MED
residents	I-MED
to	O
maintain	B-MED
optimal	B-MED
health	B-MED
care	I-MED
.	O
What	O
is	O
known	O
:	O
•	O
Previous	B-MED
studies	B-MED
show	O
a	O
clinically	B-MED
significant	I-MED
pain	B-MED
-	O
and	O
anxiety	B-MED
-	O
reducing	B-MED
effect	I-MED
of	O
hospital	B-MED
clowning	I-MED
in	O
paediatric	B-MED
patients	I-MED
admitted	B-MED
to	I-MED
hospitals	I-MED
or	O
undergoing	B-MED
(	O
invasive	B-MED
)	O
medical	B-MED
procedures	I-MED
.	O
•	O
In	O
general	O
,	O
paediatricians	B-MED
have	O
positive	B-MED
ideas	B-MED
about	O
hospital	B-MED
clowns	I-MED
,	O
aside	O
from	O
personal	B-MED
prejudices	I-MED
.	O
What	O
is	O
new	O
:	O
•	O
This	O
novel	B-MED
study	B-MED
gives	O
deeper	O
insight	B-MED
into	O
day	B-MED
-	I-MED
to	I-MED
-	I-MED
day	I-MED
interaction	B-MED
between	O
paediatricians	B-MED
and	O
hospital	B-MED
clowns	I-MED
on	O
the	O
ward	B-MED
.	O
•	O
This	O
study	B-MED
provides	O
recommendations	B-MED
for	O
clinical	B-MED
practice	I-MED
to	O
arrange	O
encounters	B-MED
between	O
physicians	B-MED
and	O
hospital	B-MED
clowns	I-MED
during	O
hospital	B-MED
clown	I-MED
visits	B-MED
.	O
Quo	O
vadis	O
G	B-MED
protein	I-MED
-	I-MED
coupled	I-MED
receptor	I-MED
ligands	I-MED
?	O
A	O
tool	O
for	O
analysis	B-MED
of	O
the	O
emergence	B-MED
of	O
new	O
groups	B-MED
of	O
compounds	B-MED
over	B-MED
time	I-MED
Exponential	B-MED
growth	B-MED
in	O
the	O
number	B-MED
of	O
compounds	B-MED
with	O
experimentally	B-MED
verified	B-MED
activity	B-MED
towards	O
particular	O
target	B-MED
has	O
led	O
to	O
the	O
emergence	B-MED
of	O
various	O
databases	B-MED
gathering	O
data	B-MED
on	O
biological	B-MED
activity	B-MED
.	O
In	O
this	O
study	B-MED
,	O
the	O
ligands	B-MED
of	O
family	B-MED
A	I-MED
of	I-MED
the	I-MED
G	I-MED
Protein	I-MED
-	I-MED
Coupled	I-MED
Receptors	I-MED
that	O
are	O
collected	B-MED
in	O
the	O
ChEMBL	B-MED
database	I-MED
were	O
examined	B-MED
,	O
and	O
special	O
attention	O
was	O
given	O
to	O
serotonin	B-MED
receptors	I-MED
.	O
Sets	B-MED
of	O
compounds	B-MED
were	O
examined	B-MED
in	O
terms	O
of	O
their	O
appearance	B-MED
over	B-MED
time	I-MED
,	O
they	O
were	O
mapped	B-MED
to	O
the	O
chemical	B-MED
space	I-MED
of	O
drugs	B-MED
deposited	O
in	O
DrugBank	B-MED
,	O
and	O
the	O
emergence	B-MED
of	O
structurally	B-MED
new	I-MED
clusters	I-MED
of	I-MED
compounds	I-MED
was	O
indicated	B-MED
.	O
In	O
addition	O
,	O
a	O
tool	O
for	O
detailed	O
analysis	B-MED
of	O
the	O
obtained	B-MED
visualizations	B-MED
was	O
prepared	B-MED
and	O
made	O
available	B-MED
online	B-MED
at	O
http://chem.gmum.net/vischem	B-MED
,	O
which	O
enables	O
the	O
investigation	B-MED
of	O
chemical	B-MED
structures	I-MED
while	O
referring	B-MED
to	O
particular	O
data	B-MED
points	I-MED
depicted	O
in	O
the	O
figures	B-MED
and	O
changes	B-MED
in	O
compounds	B-MED
datasets	B-MED
over	B-MED
time	I-MED
.	O
Abnormal	B-MED
metabolic	B-MED
brain	B-MED
network	B-MED
associated	O
with	O
Parkinson	B-MED
's	I-MED
disease	I-MED
:	O
replication	B-MED
on	O
a	O
new	O
European	B-MED
sample	B-MED
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
identify	B-MED
the	O
specific	O
metabolic	B-MED
brain	B-MED
pattern	B-MED
characteristic	B-MED
for	O
Parkinson	B-MED
's	I-MED
disease	I-MED
(	O
PD	B-MED
):	O
Parkinson	B-MED
's	I-MED
disease	I-MED
-	I-MED
related	I-MED
pattern	I-MED
(	O
PDRP	B-MED
)	O
,	O
using	O
network	B-MED
analysis	O
of	O
[	B-MED
18F]-fluorodeoxyglucose	I-MED
positron	I-MED
emission	I-MED
tomography	I-MED
(	O
FDG	B-MED
-	I-MED
PET	I-MED
)	O
brain	B-MED
images	B-MED
in	O
a	O
cohort	B-MED
of	O
Slovenian	B-MED
PD	B-MED
patients	B-MED
.	O
Twenty	O
PD	B-MED
patients	B-MED
(	O
age	B-MED
70.1	O
±	O
7.8	O
years	B-MED
,	O
Movement	B-MED
Disorder	I-MED
Society	I-MED
Unified	I-MED
Parkinson	I-MED
's	I-MED
Disease	I-MED
Motor	I-MED
Rating	I-MED
Scale	I-MED
(	O
MDS	B-MED
-	I-MED
UPDRS	I-MED
-	I-MED
III	I-MED
)	O
38.3	O
±	O
12.2	O
;	O
disease	B-MED
duration	I-MED
4.3	O
±	O
4.1	O
years	B-MED
)	O
and	O
20	O
age	B-MED
-	O
matched	B-MED
normal	B-MED
controls	I-MED
(	O
NCs	B-MED
)	O
underwent	O
FDG	B-MED
-	I-MED
PET	I-MED
brain	B-MED
imaging	I-MED
.	O
An	O
automatic	B-MED
voxel	I-MED
-	I-MED
based	I-MED
scaled	I-MED
subprofile	I-MED
model	I-MED
/	O
principal	B-MED
component	I-MED
analysis	I-MED
(	O
SSM	B-MED
/	O
PCA	B-MED
)	O
was	O
applied	O
to	O
these	O
scans	B-MED
for	O
PDRP	B-MED
-	O
Slovenia	B-MED
identification	B-MED
.	O
The	O
pattern	B-MED
was	O
characterized	B-MED
by	O
relative	O
hypermetabolism	B-MED
in	O
pallidum	B-MED
,	O
putamen	B-MED
,	O
thalamus	B-MED
,	O
brain	B-MED
stem	I-MED
,	O
and	O
cerebellum	B-MED
associated	O
with	O
hypometabolism	B-MED
in	O
sensorimotor	B-MED
cortex	I-MED
,	O
posterior	B-MED
parietal	I-MED
,	O
occipital	B-MED
,	O
and	O
frontal	B-MED
cortices	I-MED
.	O
The	O
expression	B-MED
of	O
PDRP	B-MED
-	O
Slovenia	B-MED
discriminated	O
PD	B-MED
patients	B-MED
from	O
NCs	B-MED
(	O
p	O
<	O
0.0001	O
)	O
and	O
correlated	B-MED
positively	O
with	O
patients	B-MED
'	O
clinical	B-MED
score	B-MED
(	O
MDS	B-MED
-	I-MED
UPDRS	I-MED
-	I-MED
III	I-MED
,	O
p	O
=	O
0.03	O
)	O
.	O
Additionally	O
,	O
its	O
topography	B-MED
agrees	O
well	O
with	O
the	O
original	O
PDRP	B-MED
(	O
p	O
<	O
0.001	O
)	O
identified	B-MED
in	O
American	B-MED
cohort	B-MED
of	O
PD	B-MED
patients	B-MED
.	O
We	O
validated	O
the	O
PDRP	B-MED
-	O
Slovenia	B-MED
expression	B-MED
on	O
additional	O
FDG	B-MED
-	I-MED
PET	I-MED
scans	B-MED
of	O
20	O
PD	B-MED
patients	B-MED
,	O
20	O
NCs	B-MED
,	O
and	O
25	O
patients	B-MED
with	O
atypical	B-MED
parkinsonism	I-MED
(	O
AP	B-MED
)	O
.	O
We	O
confirmed	O
that	O
the	O
expression	B-MED
of	O
PDRP	B-MED
-	O
Slovenia	B-MED
manifests	O
good	O
diagnostic	B-MED
accuracy	I-MED
with	O
specificity	B-MED
and	O
sensitivity	B-MED
of	O
85	O
-	O
90	O
%	O
at	O
optimal	O
pattern	B-MED
expression	B-MED
cutoff	O
for	O
discrimination	O
of	O
PD	B-MED
patients	B-MED
and	O
NCs	B-MED
and	O
is	O
not	O
expressed	O
in	O
AP	B-MED
.	O
PDRP	B-MED
-	O
Slovenia	B-MED
proves	O
to	O
be	O
a	O
robust	O
and	O
reproducible	O
functional	B-MED
imaging	I-MED
biomarker	B-MED
independent	O
of	O
patient	B-MED
population	B-MED
.	O
It	O
accurately	O
differentiates	O
PD	B-MED
patients	B-MED
from	O
NCs	B-MED
and	O
AP	B-MED
and	O
correlates	O
well	O
with	O
the	O
clinical	B-MED
measure	B-MED
of	O
PD	B-MED
progression	B-MED
.	O
Derivation	B-MED
of	O
a	O
Predictive	B-MED
Score	B-MED
for	O
Hemorrhagic	B-MED
Progression	B-MED
of	O
Cerebral	B-MED
Contusions	I-MED
in	O
Moderate	B-MED
and	O
Severe	B-MED
Traumatic	I-MED
Brain	I-MED
Injury	I-MED
After	O
traumatic	B-MED
brain	I-MED
injury	I-MED
(	O
TBI	B-MED
)	O
,	O
hemorrhagic	B-MED
progression	B-MED
of	O
contusions	B-MED
(	O
HPCs	B-MED
)	O
occurs	O
frequently	B-MED
.	O
However	O
,	O
there	O
is	O
no	O
established	B-MED
predictive	B-MED
score	B-MED
to	O
identify	O
high	B-MED
-	I-MED
risk	I-MED
patients	B-MED
for	O
HPC	B-MED
.	O
Consecutive	B-MED
patients	B-MED
who	O
were	O
hospitalized	B-MED
(	O
2008	O
-	O
2013	O
)	O
with	O
non	O
-	O
penetrating	O
moderate	B-MED
or	O
severe	B-MED
TBI	I-MED
were	O
studied	O
.	O
The	O
primary	B-MED
outcome	I-MED
was	O
HPC	B-MED
,	O
defined	O
by	O
both	O
a	O
relative	O
increase	B-MED
in	O
contusion	B-MED
volume	B-MED
by	O
≥30	O
%	O
and	O
an	O
absolute	B-MED
increase	B-MED
by	O
≥10	O
mL	O
on	O
serial	B-MED
imaging	I-MED
.	O
Logistic	B-MED
regression	I-MED
models	I-MED
were	O
created	B-MED
to	O
identify	O
independent	O
risk	B-MED
factors	I-MED
for	O
HPC	B-MED
.	O
The	O
HPC	B-MED
Score	B-MED
was	O
then	O
derived	B-MED
based	O
on	O
the	O
final	B-MED
model	I-MED
.	O
Among	O
a	O
total	O
of	O
286	O
eligible	O
patients	B-MED
,	O
61	O
(	O
21	O
%	O
)	O
patients	B-MED
developed	O
HPC	B-MED
.	O
On	O
univariate	B-MED
analyses	I-MED
,	O
HPC	B-MED
was	O
associated	B-MED
with	I-MED
older	B-MED
age	I-MED
,	O
higher	B-MED
initial	I-MED
blood	I-MED
pressure	I-MED
,	O
antiplatelet	B-MED
medications	I-MED
,	O
anticoagulants	B-MED
,	O
subarachnoid	B-MED
hemorrhage	I-MED
(	O
SAH	B-MED
)	O
subdural	B-MED
hematoma	I-MED
(	O
SDH	B-MED
)	O
,	O
skull	B-MED
fracture	I-MED
,	O
frontal	B-MED
contusion	B-MED
,	O
larger	B-MED
contusion	B-MED
volume	B-MED
,	O
and	O
shorter	B-MED
interval	I-MED
from	O
injury	B-MED
to	O
initial	B-MED
CT	I-MED
.	O
In	O
the	O
final	B-MED
model	I-MED
,	O
SAH	B-MED
(	O
OR	B-MED
6.33	O
,	O
95	O
%	O
CI	B-MED
,	O
1.80	O
-	O
22.23	O
)	O
,	O
SDH	B-MED
(	O
OR	B-MED
3.46	O
,	O
95	O
%	O
CI	B-MED
,	O
1.39	O
-	O
8.63	O
)	O
,	O
and	O
skull	B-MED
fracture	I-MED
(	O
OR	B-MED
2.67	O
,	O
95	O
%	O
CI	B-MED
,	O
1.28	O
-	O
5.58	O
)	O
were	O
associated	B-MED
with	I-MED
HPC	B-MED
.	O
Based	O
on	O
these	O
factors	B-MED
,	O
the	O
HPC	B-MED
Score	B-MED
was	O
derived	B-MED
(	O
SAH	B-MED
=	O
2	O
points	O
,	O
SDH	B-MED
=	O
1	O
point	O
,	O
and	O
skull	B-MED
fracture	I-MED
=	O
1	O
point	O
)	O
.	O
This	O
score	B-MED
had	O
an	O
area	O
under	O
the	O
receiver	B-MED
operating	I-MED
curve	I-MED
of	O
0.77	O
.	O
Patients	B-MED
with	O
a	O
score	B-MED
of	O
0	O
-	O
2	O
had	O
a	O
4.0	O
%	O
incidence	B-MED
of	O
HPC	B-MED
,	O
while	O
patients	B-MED
with	O
a	O
score	B-MED
of	O
3	O
-	O
4	O
had	O
a	O
34.6	O
%	O
incidence	B-MED
of	O
HPC	B-MED
.	O
A	O
simple	O
HPC	B-MED
Score	B-MED
was	O
developed	O
for	O
early	O
risk	B-MED
stratification	B-MED
of	O
HPC	B-MED
in	O
patients	B-MED
with	O
moderate	B-MED
or	O
severe	B-MED
TBI	I-MED
.	O
Decompression	B-MED
Surgery	I-MED
Alone	O
Versus	O
Decompression	B-MED
Plus	O
Fusion	B-MED
in	O
Symptomatic	B-MED
Lumbar	B-MED
Spinal	I-MED
Stenosis	I-MED
:	O
A	O
Swiss	B-MED
Prospective	B-MED
Multi	I-MED
-	I-MED
center	I-MED
Cohort	I-MED
Study	I-MED
with	O
3	O
Years	B-MED
of	O
Follow	B-MED
-	I-MED
up	I-MED
Retrospective	B-MED
analysis	I-MED
of	O
a	O
prospective	B-MED
,	I-MED
multicenter	I-MED
cohort	I-MED
study	I-MED
.	O
To	O
estimate	O
the	O
added	O
effect	B-MED
of	O
surgical	B-MED
fusion	I-MED
as	O
compared	O
to	O
decompression	B-MED
surgery	I-MED
alone	O
in	O
symptomatic	B-MED
lumbar	B-MED
spinal	I-MED
stenosis	I-MED
patients	B-MED
with	O
spondylolisthesis	B-MED
.	O
The	O
optimal	B-MED
surgical	I-MED
management	I-MED
of	O
lumbar	B-MED
spinal	I-MED
stenosis	I-MED
patients	B-MED
with	O
spondylolisthesis	B-MED
remains	O
controversial	O
.	O
Patients	B-MED
of	O
the	O
LSOS	B-MED
with	O
confirmed	O
DLSS	B-MED
and	O
spondylolisthesis	B-MED
were	O
enrolled	O
in	O
this	O
study	B-MED
.	O
The	O
outcomes	B-MED
of	O
this	O
study	B-MED
were	O
Spinal	B-MED
Stenosis	I-MED
Spinal	B-MED
Stenosis	I-MED
Measure	I-MED
(	O
SSM	B-MED
)	O
symptoms	B-MED
(	O
score	B-MED
range	I-MED
1	O
-	O
5	O
,	O
best	O
-	O
worst	O
)	O
and	O
function	B-MED
(	O
1	O
-	O
4	O
)	O
over	B-MED
time	I-MED
,	O
measured	B-MED
at	O
baseline	B-MED
,	O
6	O
,	O
12	O
,	O
24	O
and	O
36	O
months	B-MED
follow	B-MED
-	I-MED
up	I-MED
.	O
In	O
order	O
to	O
quantify	B-MED
the	O
effect	B-MED
of	O
fusion	B-MED
surgery	I-MED
as	O
compared	O
to	O
decompression	B-MED
alone	O
and	O
number	B-MED
of	I-MED
decompressed	I-MED
levels	I-MED
,	O
we	O
used	O
mixed	O
effects	B-MED
models	B-MED
and	O
accounted	O
for	O
the	O
repeated	B-MED
observations	I-MED
in	O
main	O
outcomes	B-MED
(	O
SSM	B-MED
symptoms	B-MED
and	O
SSM	B-MED
function	B-MED
)	O
over	B-MED
time	I-MED
.	O
In	O
addition	O
to	O
individual	O
patients	B-MED
'	O
random	B-MED
effects	I-MED
,	O
we	O
also	O
fitted	B-MED
random	I-MED
slopes	I-MED
for	O
follow	B-MED
-	I-MED
up	I-MED
time	B-MED
points	I-MED
and	O
compared	O
these	O
two	O
approaches	B-MED
with	O
Akaike	B-MED
's	I-MED
Information	I-MED
Criterion	I-MED
(	O
AIC	B-MED
)	O
and	O
the	O
chi	B-MED
-	I-MED
squared	I-MED
test	I-MED
.	O
Confounders	B-MED
were	O
adjusted	O
with	O
fixed	B-MED
effects	I-MED
for	O
age	B-MED
,	O
gender	B-MED
,	O
BMI	B-MED
,	O
diabetes	B-MED
,	O
CIRS	B-MED
musculoskeletal	B-MED
disorders	I-MED
and	O
duration	B-MED
of	O
symptoms	B-MED
.	O
One	O
hundred	O
and	O
thirty	O
-	O
one	O
patients	B-MED
undergoing	O
decompression	B-MED
surgery	I-MED
alone	O
(	O
n	O
=	O
85	O
)	O
or	O
decompression	B-MED
plus	O
fusion	B-MED
surgery	I-MED
(	O
n	O
=	O
46	O
)	O
were	O
included	O
in	O
this	O
study	B-MED
.	O
In	O
the	O
multiple	B-MED
mixed	I-MED
effects	I-MED
model	B-MED
the	O
adjusted	O
effect	B-MED
of	O
fusion	B-MED
versus	O
decompression	B-MED
alone	I-MED
surgery	I-MED
on	O
SSM	B-MED
symptoms	B-MED
was	O
0.06	O
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
,	O
CI	B-MED
:	O
-0.16	O
to	O
0.27	O
)	O
and	O
-0.07	O
(	O
95	O
%	O
CI	B-MED
:	O
-0.25	O
to	O
0.10	O
)	O
on	O
SSM	B-MED
function	B-MED
,	O
respectively	O
.	O
Among	O
the	O
patients	B-MED
with	O
degenerative	B-MED
lumbar	I-MED
spinal	I-MED
stenosis	I-MED
and	O
spondylolisthesis	B-MED
our	O
study	B-MED
confirms	O
that	O
in	O
the	O
two	O
groups	B-MED
,	O
decompression	B-MED
alone	O
and	O
decompression	B-MED
plus	O
fusion	B-MED
,	O
patients	B-MED
distinctively	O
benefited	O
from	O
surgical	B-MED
treatment	I-MED
.	O
When	O
adjusted	O
for	O
confounders	B-MED
,	O
fusion	B-MED
surgery	I-MED
was	O
not	O
associated	B-MED
with	I-MED
a	O
more	O
favorable	O
outcome	B-MED
in	O
both	O
SSM	B-MED
scores	I-MED
as	O
compared	O
to	O
decompression	B-MED
alone	I-MED
surgery	I-MED
.	O
3	O
.	O
Biogeochemical	B-MED
Controls	B-MED
of	O
Uranium	B-MED
Bioavailability	B-MED
from	O
the	O
Dissolved	B-MED
Phase	I-MED
in	O
Natural	B-MED
Freshwaters	B-MED
To	O
gain	O
insights	O
into	O
the	O
risks	B-MED
associated	B-MED
with	I-MED
uranium	B-MED
(	O
U	B-MED
)	O
mining	B-MED
and	O
processing	B-MED
,	O
we	O
investigated	B-MED
the	O
biogeochemical	B-MED
controls	B-MED
of	O
U	B-MED
bioavailability	B-MED
in	O
the	O
model	O
freshwater	B-MED
species	B-MED
Lymnaea	B-MED
stagnalis	I-MED
(	O
Gastropoda	B-MED
)	O
.	O
Bioavailability	B-MED
of	O
dissolved	B-MED
U(VI	I-MED
)	I-MED
was	O
characterized	B-MED
in	O
controlled	B-MED
laboratory	B-MED
experiments	B-MED
over	O
a	O
range	O
of	O
water	B-MED
hardness	B-MED
,	O
pH	B-MED
,	O
and	O
in	O
the	O
presence	B-MED
of	O
complexing	B-MED
ligands	I-MED
in	O
the	O
form	O
of	O
dissolved	B-MED
natural	I-MED
organic	I-MED
matter	I-MED
(	O
DOM	B-MED
)	O
.	O
Results	B-MED
show	O
that	O
dissolved	B-MED
U	I-MED
is	O
bioavailable	B-MED
under	O
all	O
the	O
geochemical	B-MED
conditions	I-MED
tested	B-MED
.	O
Uranium	B-MED
uptake	B-MED
rates	B-MED
follow	O
first	B-MED
order	I-MED
kinetics	I-MED
over	O
a	O
range	O
encompassing	O
most	O
environmental	B-MED
concentrations	B-MED
.	O
Uranium	B-MED
uptake	B-MED
rates	B-MED
in	O
L.	B-MED
stagnalis	I-MED
ultimately	O
demonstrate	O
saturation	B-MED
uptake	B-MED
kinetics	B-MED
when	O
exposure	B-MED
concentrations	B-MED
exceed	O
100	O
nM	O
,	O
suggesting	B-MED
uptake	B-MED
via	O
a	O
finite	O
number	O
of	O
carriers	O
or	O
ion	B-MED
channels	I-MED
.	O
The	O
lack	O
of	O
a	O
relationship	O
between	O
U	B-MED
uptake	B-MED
rate	O
constants	B-MED
and	O
Ca	B-MED
uptake	B-MED
rates	B-MED
suggest	B-MED
that	O
U	B-MED
does	O
not	O
exclusively	O
use	O
Ca	B-MED
membrane	B-MED
transporters	I-MED
.	O
In	O
general	O
,	O
U	B-MED
bioavailability	B-MED
decreases	B-MED
with	O
increasing	B-MED
pH	B-MED
,	O
increasing	B-MED
Ca	B-MED
and	O
Mg	B-MED
concentrations	B-MED
,	O
and	O
when	O
DOM	B-MED
is	O
present	B-MED
.	O
Competing	O
ions	B-MED
did	O
not	O
affect	O
U	B-MED
uptake	B-MED
rates	B-MED
.	O
Speciation	B-MED
modeling	I-MED
that	O
includes	O
formation	B-MED
constants	B-MED
for	O
U	B-MED
ternary	B-MED
complexes	I-MED
reveals	B-MED
that	O
the	O
aqueous	B-MED
concentration	B-MED
of	O
dicarbonato	B-MED
U	I-MED
species	B-MED
(	O
UO2(CO3)2(-2	O
)	O
)	O
best	O
predicts	O
U	B-MED
bioavailability	B-MED
to	O
L.	B-MED
stagnalis	I-MED
,	O
challenging	O
the	O
free	B-MED
-	I-MED
ion	I-MED
activity	I-MED
model	O
postulate	O
.	O
Wiedemann	B-MED
-	I-MED
Rautenstrauch	I-MED
Syndrome	I-MED
With	O
Bilateral	B-MED
Tarsal	B-MED
Kink	I-MED
:	O
Three	O
Sutures	B-MED
for	O
Correction	B-MED
The	O
authors	O
describe	O
a	O
5-	O
month	B-MED
-	I-MED
old	I-MED
male	B-MED
infant	B-MED
with	O
Wiedemann	B-MED
-	I-MED
Rautenstrauch	I-MED
syndrome	I-MED
,	O
which	O
is	O
an	O
extremely	O
rare	B-MED
condition	B-MED
.	O
He	O
had	O
tarsal	B-MED
kink	I-MED
in	O
upper	B-MED
eyelids	I-MED
in	O
both	B-MED
eyes	I-MED
.	O
The	O
authors	O
treated	B-MED
bilateral	B-MED
tarsal	B-MED
kink	I-MED
with	O
an	O
everting	B-MED
suture	B-MED
via	O
a	O
transconjunctival	B-MED
approach	I-MED
under	O
local	B-MED
anesthesia	I-MED
.	O
Direct	O
effects	B-MED
of	I-MED
glucose	B-MED
,	O
insulin	B-MED
,	O
GLP-1	B-MED
,	O
and	O
GIP	B-MED
on	O
bulbospinal	B-MED
neurons	B-MED
in	O
the	O
rostral	B-MED
ventrolateral	I-MED
medulla	I-MED
in	O
neonatal	B-MED
wistar	B-MED
rats	I-MED
Although	O
patients	B-MED
with	O
diabetes	B-MED
mellitus	I-MED
(	O
DM	B-MED
)	O
often	O
exhibit	O
hypertension	B-MED
,	O
the	O
mechanisms	B-MED
responsible	O
for	O
this	O
correlation	B-MED
are	O
not	O
well	O
known	O
.	O
We	O
hypothesized	O
that	O
the	O
bulbospinal	B-MED
neurons	B-MED
in	O
the	O
rostral	B-MED
ventrolateral	I-MED
medulla	I-MED
(	O
RVLM	B-MED
)	O
are	O
affected	B-MED
by	O
the	O
levels	B-MED
of	O
glucose	B-MED
,	O
insulin	B-MED
,	O
or	O
incretins	B-MED
(	O
glucagon	B-MED
like	I-MED
peptide-1	I-MED
[	O
GLP-1	B-MED
]	O
or	O
glucose	B-MED
-	I-MED
dependent	I-MED
insulinotropic	I-MED
peptide	I-MED
[	O
GIP	B-MED
]	O
)	O
in	O
patients	B-MED
with	O
DM	B-MED
.	O
To	O
investigate	B-MED
whether	O
RVLM	B-MED
neurons	B-MED
are	O
activated	B-MED
by	O
glucose	B-MED
,	O
insulin	B-MED
,	O
GLP-1	B-MED
,	O
or	O
GIP	B-MED
,	O
we	O
examined	O
changes	B-MED
in	O
the	O
membrane	B-MED
potentials	I-MED
of	O
bulbospinal	B-MED
RVLM	B-MED
neurons	B-MED
using	O
whole	B-MED
-	I-MED
cell	I-MED
patch	B-MED
-	I-MED
clamp	I-MED
technique	I-MED
during	O
superfusion	B-MED
with	O
various	O
levels	B-MED
of	O
glucose	B-MED
or	O
these	O
hormones	B-MED
in	O
neonatal	B-MED
Wistar	B-MED
rats	I-MED
.	O
A	O
brainstem	B-MED
-	O
spinal	B-MED
cord	I-MED
preparation	B-MED
was	O
used	O
for	O
the	O
experiments	B-MED
.	O
A	O
low	B-MED
level	B-MED
of	O
glucose	B-MED
stimulated	O
bulbospinal	B-MED
RVLM	B-MED
neurons	B-MED
.	O
During	O
insulin	B-MED
superfusion	B-MED
,	O
almost	O
all	O
the	O
RVLM	B-MED
neurons	B-MED
were	O
depolarized	B-MED
,	O
while	O
during	O
GLP-1	B-MED
or	O
GIP	B-MED
superfusion	B-MED
,	O
almost	O
all	O
the	O
RVLM	B-MED
neurons	B-MED
were	O
hyperpolarized	B-MED
.	O
Next	O
,	O
histological	B-MED
examinations	I-MED
were	O
performed	O
to	O
examine	O
transporters	B-MED
for	I-MED
glucose	I-MED
and	O
receptors	B-MED
for	O
insulin	B-MED
,	O
GLP-1	B-MED
,	O
and	O
GIP	B-MED
on	O
RVLM	B-MED
neurons	B-MED
.	O
Low	B-MED
-	O
level	B-MED
glucose	B-MED
-	O
depolarized	B-MED
RVLM	B-MED
neurons	B-MED
exhibited	O
the	O
presence	B-MED
of	O
glucose	B-MED
transporter	I-MED
3	I-MED
(	O
GLUT3	B-MED
)	O
.	O
Meanwhile	O
,	O
insulin	B-MED
-	O
depolarized	B-MED
,	O
GLP-1	B-MED
-	O
hyperpolarized	B-MED
,	O
and	O
GIP	B-MED
-	O
hyperpolarized	B-MED
RVLM	B-MED
neurons	B-MED
showed	O
each	O
of	O
the	O
respective	O
specific	B-MED
receptor	B-MED
.	O
These	O
results	O
indicate	O
that	O
a	O
low	B-MED
level	B-MED
of	O
glucose	B-MED
stimulates	B-MED
bulbospinal	B-MED
RVLM	B-MED
neurons	B-MED
via	O
specific	B-MED
transporters	B-MED
on	O
these	O
neurons	B-MED
,	O
inducing	B-MED
hypertension	B-MED
.	O
Furthermore	O
,	O
an	O
increase	B-MED
in	O
insulin	B-MED
or	O
a	O
reduction	B-MED
in	O
incretins	B-MED
may	O
also	O
activate	B-MED
the	O
sympathetic	B-MED
nervous	I-MED
system	I-MED
and	O
induce	B-MED
hypertension	B-MED
by	O
activating	B-MED
RVLM	B-MED
neurons	B-MED
via	O
their	O
own	O
receptors	B-MED
.	O
Detection	B-MED
of	O
AMA	B-MED
-	I-MED
M2	I-MED
in	O
human	B-MED
saliva	B-MED
:	O
Potentials	B-MED
in	O
diagnosis	B-MED
and	O
monitoring	B-MED
of	O
primary	B-MED
biliary	I-MED
cholangitis	I-MED
Serum	B-MED
anti	B-MED
-	I-MED
mitochondrial	I-MED
antibody	I-MED
type	I-MED
2	I-MED
(	O
AMA	B-MED
-	I-MED
M2	I-MED
)	O
is	O
considered	O
as	O
a	O
pivotal	O
biomarker	B-MED
for	O
the	O
diagnosis	B-MED
of	O
primary	B-MED
biliary	I-MED
cholangitis	I-MED
(	O
PBC	B-MED
)	O
.	O
However	O
,	O
serological	B-MED
tests	I-MED
have	O
many	O
limitations	B-MED
,	O
including	O
inconvenience	B-MED
,	O
invasiveness	B-MED
,	O
and	O
infection	B-MED
risks	I-MED
.	O
Thus	O
,	O
a	O
less	B-MED
invasive	B-MED
approach	B-MED
to	O
detect	B-MED
AMA	B-MED
-	I-MED
M2	I-MED
titer	I-MED
is	O
desirable	O
.	O
We	O
examined	O
salivary	B-MED
AMA	B-MED
-	I-MED
M2	I-MED
of	O
potential	B-MED
PBC	B-MED
patients	B-MED
and	O
found	O
that	O
AMA	B-MED
-	I-MED
M2	I-MED
could	O
be	O
detected	B-MED
only	O
in	O
saliva	B-MED
of	O
serum	B-MED
AMA	B-MED
-	I-MED
M2	I-MED
-	I-MED
positive	I-MED
PBC	B-MED
patients	B-MED
,	O
but	O
not	O
in	O
saliva	B-MED
of	O
serum	B-MED
AMA	B-MED
-	I-MED
M2	I-MED
-	I-MED
negative	I-MED
PBC	B-MED
patients	B-MED
,	O
oral	B-MED
lichen	I-MED
planus	I-MED
patients	B-MED
(	O
OLP	B-MED
)	O
patients	B-MED
,	O
or	O
healthy	B-MED
controls	I-MED
.	O
Furthermore	O
,	O
the	O
concentration	B-MED
of	O
salivary	B-MED
AMA	B-MED
-	I-MED
M2	I-MED
was	O
positively	B-MED
correlated	I-MED
with	O
the	O
amount	B-MED
of	O
serum	B-MED
AMA	B-MED
-	I-MED
M2	I-MED
in	O
patients	B-MED
.	O
The	O
salivary	B-MED
inflammatory	B-MED
cytokines	I-MED
were	O
increased	B-MED
in	O
the	O
PBC	B-MED
,	O
consistent	B-MED
with	I-MED
the	O
results	B-MED
of	O
serum	B-MED
test	B-MED
.	O
These	O
findings	O
indicated	O
that	O
saliva	B-MED
might	O
be	O
a	O
less	B-MED
invasive	B-MED
and	O
cost	B-MED
-	I-MED
effective	I-MED
medium	B-MED
to	O
accurately	O
test	B-MED
for	O
AMA	B-MED
-	I-MED
M2	I-MED
levels	I-MED
and	O
this	O
is	O
a	O
promising	O
development	B-MED
for	O
the	O
diagnosis	B-MED
and	O
monitoring	B-MED
of	O
PBC	B-MED
.	O
Pyoderma	B-MED
gangrenosum	I-MED
:	O
A	O
clinician	B-MED
's	I-MED
nightmare	B-MED
Pyoderma	B-MED
gangrenosum	I-MED
(	O
PG	B-MED
)	O
is	O
a	O
rare	B-MED
disease	I-MED
and	O
that	O
affecting	O
specifically	O
the	O
sole	B-MED
of	I-MED
the	I-MED
foot	I-MED
,	O
is	O
even	O
rarer	O
.	O
Here	O
,	O
we	O
report	B-MED
the	O
case	O
of	O
a	O
54	O
-	O
year-	O
old	B-MED
female	B-MED
admitted	B-MED
with	O
a	O
painful	B-MED
ulcer	B-MED
on	O
the	O
sole	B-MED
of	I-MED
the	I-MED
right	I-MED
foot	I-MED
which	O
was	O
initially	O
treated	B-MED
with	I-MED
empirical	O
antibiotics	B-MED
and	O
debridement	B-MED
.	O
The	O
disease	B-MED
was	O
found	O
to	O
spread	O
rapidly	B-MED
after	O
each	O
debridement	B-MED
.	O
The	O
culture	B-MED
reports	I-MED
were	O
negative	B-MED
;	O
rheumatology	B-MED
workup	B-MED
and	O
Doppler	B-MED
study	I-MED
were	O
within	O
normal	B-MED
limits	I-MED
.	O
A	O
clinical	B-MED
suspicion	B-MED
of	O
PG	B-MED
was	O
made	O
and	O
was	O
confirmed	O
with	O
tissue	B-MED
biopsy	I-MED
.	O
She	O
was	O
started	B-MED
on	I-MED
oral	I-MED
steroids	I-MED
following	O
which	O
she	O
dramatically	O
improved	B-MED
.	O
Thus	O
,	O
when	O
a	O
patient	B-MED
presents	O
with	O
a	O
rapidly	B-MED
expanding	O
painful	B-MED
ulcer	B-MED
in	O
a	O
vascular	B-MED
limb	I-MED
that	O
is	O
refractory	B-MED
to	O
antibiotic	B-MED
treatment	I-MED
and	O
exacerbating	B-MED
on	O
debridement	B-MED
,	O
it	O
is	O
imperative	O
to	O
consider	O
the	O
possibility	O
of	O
PG	B-MED
.	O
Injury	B-MED
surveillance	I-MED
of	O
female	B-MED
adult	B-MED
Zumba	B-MED
®	O
dancers	B-MED
We	O
sought	O
to	O
describe	O
the	O
patterns	B-MED
of	O
injury	B-MED
and	O
to	O
establish	O
the	O
injury	B-MED
incidence	B-MED
rates	I-MED
associated	B-MED
with	O
Zumba	B-MED
®	O
.	O
Zumba	B-MED
®	O
dancers	B-MED
were	O
invited	O
to	O
complete	O
an	O
anonymous	O
web	B-MED
-	I-MED
based	I-MED
survey	B-MED
containing	O
13	O
demographic	B-MED
background	B-MED
and	O
14	O
(	O
1	O
yr	B-MED
retrospective	B-MED
)	O
injury	B-MED
history	B-MED
questions	B-MED
.	O
Inclusion	B-MED
criteria	B-MED
stated	O
that	O
the	O
respondents	B-MED
had	O
to	O
be	O
aged	B-MED
18	O
-	O
64	O
yr	B-MED
and	O
currently	O
involved	O
in	O
group	B-MED
-based	O
classes	B-MED
of	O
Zumba	B-MED
®	O
,	O
either	O
as	O
a	O
registered	B-MED
instructor	I-MED
or	O
class	B-MED
participant	B-MED
.	O
Binomial	B-MED
logistic	I-MED
regression	I-MED
analysis	I-MED
was	O
used	O
to	O
predict	O
the	O
odds	B-MED
of	O
injury	B-MED
during	O
Zumba	B-MED
®	O
and	O
Mann	B-MED
-	I-MED
Whitney	I-MED
tests	I-MED
were	O
employed	O
to	O
ascertain	O
differences	O
between	O
groups	B-MED
.	O
The	O
survey	B-MED
response	B-MED
rate	I-MED
was	O
74	O
%	O
.	O
The	O
final	O
sample	O
of	O
respondents	B-MED
(	O
N	O
=	O
138	O
;	O
female	B-MED
=	O
100	O
%	O
)	O
included	O
19	O
registered	B-MED
instructors	I-MED
and	O
119	O
class	B-MED
participants	B-MED
,	O
of	O
which	O
58	O
%	O
and	O
16	O
%	O
,	O
respectively	O
,	O
sustained	B-MED
≥	O
1	O
injury	B-MED
during	O
Zumba	B-MED
®	O
in	O
the	O
past	O
year	B-MED
.	O
The	O
odds	B-MED
of	O
injury	B-MED
was	O
7	O
(	O
95	O
%	O
CI	B-MED
2	O
-	O
19	O
)	O
times	O
greater	B-MED
(	O
p	O
<	O
0.01	O
)	O
for	O
registered	B-MED
instructors	I-MED
than	O
for	O
class	B-MED
participants	B-MED
.	O
Zumba	B-MED
®	O
dancers	B-MED
had	O
a	O
17	O
(	O
95	O
%	O
CI	B-MED
7	O
-	O
28	O
)	O
%	O
greater	B-MED
(	O
p	O
<	O
0.01	O
)	O
odds	B-MED
of	O
injury	B-MED
for	O
every	O
1	O
h	B-MED
of	O
non-	O
Zumba	B-MED
®	O
-	O
related	O
moderate	B-MED
to	I-MED
vigorous	I-MED
physical	I-MED
activity	I-MED
(	O
MVPA	B-MED
)	O
engagement	O
per	O
week	B-MED
.	O
The	O
injury	B-MED
incidence	B-MED
rate	I-MED
for	O
registered	B-MED
instructors	I-MED
and	O
class	B-MED
participants	B-MED
was	O
5.7	O
(	O
95	O
%	O
CI	B-MED
3.1	O
-	O
8.2	O
)	O
and	O
3.9	O
(	O
95	O
%	O
CI	B-MED
2.5	O
-	O
5.3	O
)	O
injuries	B-MED
per	O
1000	O
h	B-MED
of	O
exposure	B-MED
,	O
respectively	O
.	O
Zumba	B-MED
®	O
presents	O
a	O
low	B-MED
risk	I-MED
of	O
injury	B-MED
;	O
for	O
registered	B-MED
instructors	I-MED
,	O
the	O
increased	B-MED
risk	I-MED
of	O
injury	B-MED
is	O
likely	O
due	O
to	O
the	O
high	O
total	O
volume	O
of	O
MVPA	B-MED
participated	B-MED
in	O
weekly	B-MED
.	O
Comparison	B-MED
of	O
pulse	B-MED
wave	I-MED
velocity	I-MED
derived	O
from	O
accelerometer	B-MED
and	O
reflective	B-MED
photo	I-MED
-	I-MED
plethysmography	I-MED
signals	I-MED
placed	O
at	O
the	O
carotid	B-MED
and	O
femoral	B-MED
artery	I-MED
Carotid	B-MED
-	O
femoral	B-MED
pulse	B-MED
wave	I-MED
velocity	I-MED
is	O
an	O
established	B-MED
measure	I-MED
to	O
assess	B-MED
cardiovascular	B-MED
risk	I-MED
and	O
an	O
interesting	O
surrogate	B-MED
parameter	I-MED
towards	O
non	B-MED
-	I-MED
invasive	I-MED
continuous	I-MED
blood	I-MED
pressure	I-MED
inference	I-MED
.	O
Due	O
to	O
progress	B-MED
in	O
sensing	O
technologies	O
for	O
wearable	B-MED
wrist	I-MED
worn	I-MED
sensors	I-MED
,	O
there	O
are	O
low	O
cost	O
sensor	O
combinations	O
of	O
photo	B-MED
-	I-MED
plethysmography	I-MED
and	O
high	B-MED
fidelity	I-MED
accelerometer	I-MED
s	I-MED
available	O
offering	O
access	O
to	O
pulse	B-MED
information	I-MED
from	O
larger	B-MED
arteries	I-MED
complemented	O
by	O
blood	B-MED
volume	I-MED
changes	O
in	O
the	O
superficial	B-MED
tissue	I-MED
.	O
In	O
this	O
work	O
we	O
compare	O
pulse	B-MED
wave	I-MED
velocities	I-MED
derived	O
from	O
accelerometer	B-MED
and	O
reflective	B-MED
photo	I-MED
-	I-MED
plethysmography	I-MED
signals	I-MED
placed	O
at	O
the	O
carotid	B-MED
and	O
femoral	B-MED
artery	I-MED
.	O
We	O
discuss	O
the	O
different	O
underlying	O
physiological	B-MED
processes	I-MED
for	O
the	O
two	O
sensing	B-MED
principles	I-MED
and	O
present	O
experimental	B-MED
results	I-MED
obtained	O
in	O
a	O
study	B-MED
with	O
healthy	B-MED
subjects	I-MED
.	O
A	O
rare	B-MED
cause	B-MED
of	O
gastric	B-MED
obstruction	I-MED
:	O
Lighters	B-MED
swallowing	B-MED
The	O
majority	B-MED
of	O
swallowed	B-MED
foreign	I-MED
bodies	I-MED
are	O
thrown	B-MED
spontaneously	B-MED
without	B-MED
causing	B-MED
complications	B-MED
in	O
the	O
digestive	B-MED
system	I-MED
.	O
Multiple	B-MED
number	B-MED
of	O
foreign	B-MED
bodies	I-MED
may	O
be	O
swallowed	B-MED
by	O
psychiatric	B-MED
patients	I-MED
which	O
delay	B-MED
diagnosis	I-MED
and	O
increase	B-MED
the	O
complication	B-MED
rate	B-MED
.	O
Long	B-MED
and	O
hard	B-MED
objects	B-MED
can	O
not	O
pass	O
through	O
the	O
pylorus	B-MED
,	O
and	O
may	O
cause	B-MED
obstruction	B-MED
,	O
ulceration	B-MED
,	O
bleeding	B-MED
and	O
perforation	B-MED
.	O
Endoscopy	B-MED
is	O
used	B-MED
as	O
an	O
effective	B-MED
method	B-MED
in	O
such	O
cases	B-MED
.	O
An	O
exploratory	B-MED
laparatomy	I-MED
was	O
performed	B-MED
after	O
unsuccessful	B-MED
endoscopic	B-MED
foreign	B-MED
object	I-MED
removal	B-MED
in	O
a	O
28	O
-	O
year	O
-	O
old	O
schizophrenic	B-MED
patient	B-MED
with	O
gastric	B-MED
outlet	I-MED
obstruction	I-MED
due	B-MED
to	I-MED
multiple	B-MED
cigarette	B-MED
lighter	I-MED
swallowing	B-MED
.	O
Ten	O
lighters	B-MED
were	O
removed	B-MED
from	O
the	O
stomach	B-MED
through	B-MED
gastrotomy	B-MED
and	O
one	O
more	O
lighter	B-MED
was	O
removed	B-MED
from	O
the	O
descending	B-MED
colon	I-MED
by	O
milking	B-MED
through	B-MED
the	O
anus	B-MED
.	O
The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
discuss	O
encountered	O
difficulties	B-MED
in	O
psychiatric	B-MED
patients	I-MED
who	O
underwent	O
surgery	B-MED
due	B-MED
to	I-MED
intake	B-MED
of	O
foreign	B-MED
bodies	I-MED
.	O
Visualization	B-MED
and	O
targeting	B-MED
of	O
LGR5(+	B-MED
)	I-MED
human	B-MED
colon	B-MED
cancer	B-MED
stem	I-MED
cells	I-MED
The	O
cancer	B-MED
stem	I-MED
cell	I-MED
(	O
CSC	B-MED
)	O
theory	B-MED
highlights	O
a	O
self	B-MED
-	I-MED
renewing	I-MED
subpopulation	B-MED
of	O
cancer	B-MED
cells	I-MED
that	O
fuels	O
tumour	B-MED
growth	I-MED
.	I-MED
The	O
existence	B-MED
of	O
human	B-MED
CSCs	B-MED
is	O
mainly	O
supported	O
by	O
xenotransplantation	B-MED
of	O
prospectively	O
isolated	B-MED
cells	I-MED
,	O
but	O
their	O
clonal	B-MED
dynamics	B-MED
and	O
plasticity	B-MED
remain	O
unclear	O
.	O
Here	O
,	O
we	O
show	O
that	O
human	B-MED
LGR5(+	B-MED
)	I-MED
colorectal	B-MED
cancer	I-MED
cells	I-MED
serve	O
as	O
CSCs	B-MED
in	O
growing	O
cancer	B-MED
tissues	B-MED
.	O
Lineage	B-MED
-	O
tracing	B-MED
experiments	I-MED
with	O
a	O
tamoxifen	B-MED
-inducible	O
Cre	B-MED
knock	B-MED
-	I-MED
in	I-MED
allele	B-MED
of	O
LGR5	B-MED
reveal	O
the	O
self	B-MED
-	I-MED
renewal	I-MED
and	O
differentiation	B-MED
capacity	B-MED
of	O
LGR5(+	B-MED
)	I-MED
tumour	B-MED
cells	I-MED
.	O
Selective	O
ablation	B-MED
of	O
LGR5(+	B-MED
)	I-MED
CSCs	B-MED
in	O
LGR5	B-MED
-i	O
Caspase9	B-MED
knock	B-MED
-	I-MED
in	I-MED
organoids	B-MED
leads	O
to	O
tumour	B-MED
regression	I-MED
,	O
followed	O
by	O
tumour	B-MED
regrowth	I-MED
driven	O
by	O
re	O
-	O
emerging	O
LGR5(+	B-MED
)	I-MED
CSCs	B-MED
.	O
KRT20	B-MED
knock	B-MED
-	I-MED
in	I-MED
reporter	B-MED
marks	O
differentiated	B-MED
cancer	B-MED
cells	I-MED
that	O
constantly	O
diminish	O
in	O
tumour	B-MED
tissues	I-MED
,	O
while	O
reverting	O
to	O
LGR5(+	B-MED
)	I-MED
CSCs	B-MED
and	O
contributing	O
to	O
tumour	B-MED
regrowth	I-MED
after	O
LGR5(+	B-MED
)	I-MED
CSC	B-MED
ablation	B-MED
.	O
We	O
also	O
show	O
that	O
combined	O
chemotherapy	B-MED
potentiates	O
targeting	B-MED
of	O
LGR5(+	B-MED
)	I-MED
CSCs	B-MED
.	O
These	O
data	B-MED
provide	O
insights	O
into	O
the	O
plasticity	B-MED
of	O
CSCs	B-MED
and	O
their	O
potential	B-MED
as	O
a	O
therapeutic	B-MED
target	B-MED
in	O
human	B-MED
colorectal	B-MED
cancer	I-MED
.	O
Identification	B-MED
of	O
mineral	B-MED
-	O
binding	B-MED
peptides	B-MED
that	O
discriminate	B-MED
between	O
chalcopyrite	B-MED
and	O
enargite	B-MED
Innovative	O
approaches	O
to	O
the	O
separation	B-MED
of	O
minerals	B-MED
and	O
subsequent	B-MED
extraction	B-MED
of	O
metals	B-MED
are	O
imperative	B-MED
owing	O
to	O
the	O
increasing	B-MED
mineralogical	B-MED
complexity	B-MED
of	O
ore	B-MED
deposits	I-MED
that	O
are	O
difficult	B-MED
or	O
even	O
impossible	B-MED
to	O
separate	B-MED
into	O
slurries	B-MED
or	O
solutions	B-MED
containing	B-MED
only	O
the	O
minerals	B-MED
or	O
metals	B-MED
of	O
interest	O
.	O
Low	B-MED
recovery	B-MED
of	O
metal	B-MED
is	O
typical	B-MED
for	O
these	O
complex	B-MED
deposits	B-MED
leading	O
to	O
significant	B-MED
losses	B-MED
to	O
tailings	B-MED
.	O
In	B-MED
addition	I-MED
,	O
the	O
minerals	B-MED
often	O
contain	O
impurities	B-MED
,	O
some	O
toxic	B-MED
,	O
which	O
are	O
difficult	B-MED
and	O
costly	B-MED
to	O
control	B-MED
or	O
manage	O
during	O
the	O
processing	B-MED
of	O
a	O
concentrate	B-MED
or	O
other	O
mineral	B-MED
product	B-MED
.	O
One	O
example	B-MED
of	O
this	O
complex	B-MED
situation	O
is	O
the	O
significant	B-MED
economic	B-MED
and	O
environmental	B-MED
costs	B-MED
associated	B-MED
with	I-MED
diluting	B-MED
and	O
processing	B-MED
copper	B-MED
concentrates	B-MED
containing	B-MED
arsenic	B-MED
(	O
in	O
the	O
form	O
of	O
the	O
mineral	B-MED
enargite	I-MED
,	O
Cu3	B-MED
AsS4	I-MED
)	O
in	O
the	O
production	B-MED
of	O
pure	B-MED
copper	B-MED
.	O
To	O
overcome	O
these	O
separation	B-MED
problems	B-MED
,	O
we	O
have	O
utilized	O
phage	B-MED
display	I-MED
to	O
identify	B-MED
peptides	B-MED
that	O
demonstrate	O
selective	B-MED
recognition	B-MED
of	O
enargite	B-MED
and	O
the	O
arsenic	B-MED
-	O
free	B-MED
copper	B-MED
sulfide	I-MED
,	O
chalcopyrite	B-MED
.	O
Screening	O
of	O
two	O
random	B-MED
peptide	B-MED
phage	I-MED
display	I-MED
libraries	I-MED
resulted	O
in	O
the	O
identification	B-MED
of	O
an	O
enargite	B-MED
-	O
selective	B-MED
peptide	B-MED
with	O
the	O
sequence	B-MED
MHKPTVHIKGPT	I-MED
and	O
a	O
chalcopyrite	B-MED
-	O
selective	B-MED
peptide	B-MED
with	O
the	O
sequence	B-MED
RKKKCKGNCCYTPQ	I-MED
.	O
Mineral	B-MED
-	O
binding	B-MED
selectivity	B-MED
was	O
demonstrated	O
by	O
binding	B-MED
studies	B-MED
,	O
zeta	B-MED
potential	I-MED
determination	B-MED
and	O
immunochemistry	B-MED
.	O
Peptides	B-MED
that	O
have	O
the	O
ability	B-MED
to	O
discriminate	B-MED
between	O
enargite	B-MED
and	O
chalcopyrite	B-MED
provide	O
a	O
greener	O
option	B-MED
for	O
the	O
separation	B-MED
of	O
arsenic	B-MED
containing	B-MED
contaminants	B-MED
from	O
copper	B-MED
concentrates	B-MED
.	O
This	O
represents	O
the	O
first	O
step	O
towards	O
a	O
major	B-MED
advance	B-MED
in	O
the	O
replacement	B-MED
or	O
reduction	B-MED
of	O
toxic	B-MED
collectors	B-MED
as	O
well	O
as	O
reducing	B-MED
the	O
level	B-MED
of	O
arsenic	B-MED
-	O
bearing	B-MED
minerals	B-MED
in	O
the	O
early	B-MED
stages	B-MED
of	O
mineral	B-MED
processing	B-MED
.	O
Biotechnol	O
.	O
Bioeng	O
.	O
2016;9999	O
:	O
1	O
-	O
8	O
.	O
©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Involvement	O
of	O
intracellular	B-MED
Zn(2	B-MED
+	I-MED
)	I-MED
signaling	B-MED
in	O
LTP	B-MED
at	O
perforant	B-MED
pathway	I-MED
-	O
CA1	B-MED
pyramidal	I-MED
cell	I-MED
synapse	I-MED
Physiological	B-MED
significance	O
of	O
synaptic	B-MED
Zn(2	I-MED
+	I-MED
)	I-MED
signaling	I-MED
was	O
examined	O
at	O
perforant	B-MED
pathway	I-MED
-	O
CA1	B-MED
pyramidal	I-MED
cell	I-MED
synapses	I-MED
.	O
In	B-MED
vivo	I-MED
long	B-MED
-	I-MED
term	I-MED
potentiation	I-MED
(	O
LTP	B-MED
)	O
at	O
perforant	B-MED
pathway	I-MED
-	O
CA1	B-MED
pyramidal	I-MED
cell	I-MED
synapses	I-MED
was	O
induced	O
using	O
a	O
recording	O
electrode	B-MED
attached	O
to	O
a	O
microdialysis	B-MED
probe	B-MED
and	O
the	O
recording	O
region	O
was	O
locally	O
perfused	B-MED
with	O
artificial	B-MED
cerebrospinal	I-MED
fluid	I-MED
(	O
ACSF	B-MED
)	O
via	O
the	O
microdialysis	B-MED
probe	B-MED
.	O
Perforant	B-MED
pathway	I-MED
LTP	B-MED
was	O
not	O
attenuated	O
under	O
perfusion	B-MED
with	O
CaEDTA	B-MED
(	O
10	O
mM	O
)	O
,	O
an	O
extracellular	B-MED
Zn(2	B-MED
+	I-MED
)	I-MED
chelator	O
,	O
but	O
attenuated	O
under	O
perfusion	B-MED
with	O
ZnAF-2DA	B-MED
(	O
50	O
μM	O
)	O
,	O
an	O
intracellular	B-MED
Zn(2	B-MED
+	I-MED
)	I-MED
chelator	O
,	O
suggesting	O
that	O
intracellular	B-MED
Zn(2	B-MED
+	I-MED
)	I-MED
signaling	B-MED
is	O
required	O
for	O
perforant	B-MED
pathway	I-MED
LTP	B-MED
.	O
Even	O
in	O
rat	B-MED
brain	I-MED
slices	I-MED
bathed	O
in	O
CaEDTA	B-MED
in	O
ACSF	B-MED
,	O
intracellular	B-MED
Zn(2	B-MED
+	I-MED
)	I-MED
level	O
,	O
which	O
was	O
measured	O
with	O
intracellular	B-MED
ZnAF-2	B-MED
,	O
was	O
increased	O
in	O
the	O
stratum	B-MED
lacunosum	I-MED
-	I-MED
moleculare	I-MED
where	O
perforant	B-MED
pathway	I-MED
-	O
CA1	B-MED
pyramidal	I-MED
cell	I-MED
synapses	I-MED
were	O
contained	O
after	O
tetanic	B-MED
stimulation	I-MED
.	O
These	O
results	O
suggest	O
that	O
intracellular	B-MED
Zn(2	B-MED
+	I-MED
)	I-MED
signaling	B-MED
,	O
which	O
originates	O
in	O
internal	O
stores/	O
proteins	B-MED
,	O
is	O
involved	O
in	O
LTP	B-MED
at	O
perforant	B-MED
pathway	I-MED
-	O
CA1	B-MED
pyramidal	I-MED
cell	I-MED
synapses	I-MED
.	O
Because	O
the	O
influx	B-MED
of	O
extracellular	B-MED
Zn(2	B-MED
+	I-MED
)	I-MED
,	O
which	O
originates	O
in	O
presynaptic	B-MED
Zn(2	I-MED
+	I-MED
)	I-MED
release	I-MED
,	O
is	O
involved	O
in	O
LTP	B-MED
at	O
Schaffer	B-MED
collateral	I-MED
-	O
CA1	B-MED
pyramidal	I-MED
cell	I-MED
synapses	I-MED
,	O
synapse	B-MED
-dependent	O
Zn(2	B-MED
+	I-MED
)	I-MED
dynamics	O
may	O
be	O
involved	O
in	O
plasticity	B-MED
of	O
postsynaptic	B-MED
CA1	B-MED
pyramidal	I-MED
cells	I-MED
.	O
A	O
novel	B-MED
combination	O
treatment	B-MED
to	O
stimulate	B-MED
bone	B-MED
healing	I-MED
and	O
regeneration	B-MED
under	O
hypoxic	B-MED
conditions	I-MED
:	O
photobiomodulation	B-MED
and	O
melatonin	B-MED
Melatonin	B-MED
has	O
anabolic	B-MED
effects	I-MED
on	O
the	O
bone	B-MED
,	O
even	O
under	O
hypoxia	B-MED
,	O
and	O
laser	B-MED
irradiation	I-MED
has	O
been	O
shown	O
to	O
improve	O
osteoblastic	B-MED
differentiation	I-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
whether	O
laser	B-MED
irradiation	I-MED
and	O
melatonin	B-MED
would	O
have	O
synergistic	B-MED
effects	B-MED
on	O
osteoblastic	B-MED
differentiation	I-MED
and	O
mineralization	B-MED
under	O
hypoxic	B-MED
conditions	I-MED
.	O
MC3T3	B-MED
-	I-MED
E1	I-MED
cells	I-MED
were	O
exposed	O
to	O
1	O
%	O
oxygen	B-MED
tension	I-MED
for	O
the	O
hypoxia	B-MED
condition	I-MED
.	O
The	O
cells	B-MED
were	O
divided	O
into	O
four	O
groups	B-MED
:	O
G1	B-MED
-	O
osteoblast	B-MED
differentiation	I-MED
medium	B-MED
only	O
(	O
as	O
the	O
hypoxic	B-MED
condition	I-MED
)	O
,	O
G2	B-MED
-	O
treatment	B-MED
with	O
50	O
μM	O
melatonin	B-MED
only	O
,	O
G3	B-MED
-	O
laser	B-MED
irradiation	I-MED
(	O
808	O
nm	O
,	O
80	O
mW	O
,	O
GaAlAs	B-MED
diode	I-MED
)	O
only	O
,	O
and	O
G4	B-MED
-	O
treatment	B-MED
with	O
50	O
μM	O
melatonin	B-MED
and	O
laser	B-MED
irradiation	I-MED
(	O
808	O
nm	O
,	O
80	O
mW	O
,	O
GaAlAs	B-MED
diode	I-MED
)	O
.	O
Immunoblotting	B-MED
showed	O
that	O
osterix	B-MED
expression	B-MED
was	O
markedly	O
increased	B-MED
in	O
the	O
melatonin	B-MED
-	O
treated	B-MED
and	O
laser	B-MED
-	I-MED
irradiated	I-MED
cells	B-MED
at	O
48	O
and	O
72	O
h.	O
In	O
addition	O
,	O
alkaline	B-MED
phosphatase	I-MED
activity	B-MED
significantly	O
increased	B-MED
and	O
continued	B-MED
to	O
rise	O
throughout	O
the	O
experiment	B-MED
.	O
Alizarin	B-MED
Red	I-MED
staining	I-MED
showed	O
markedly	O
increased	B-MED
mineralized	B-MED
nodules	B-MED
as	O
compared	O
with	O
only	O
melatonin	B-MED
-	O
treated	B-MED
or	O
laser	B-MED
-	I-MED
irradiated	I-MED
cells	B-MED
at	O
day	O
7	O
,	O
which	O
significantly	O
increased	B-MED
by	O
day	O
14	O
.	O
Moreover	O
,	O
when	O
melatonin	B-MED
-	O
treated	B-MED
cells	B-MED
were	O
laser	B-MED
-	I-MED
irradiated	I-MED
,	O
the	O
differentiation	B-MED
and	O
mineralization	B-MED
of	O
cells	B-MED
were	O
found	O
to	O
involve	O
p38	B-MED
MAPK	I-MED
and	O
PRKD1	B-MED
signaling	B-MED
mechanisms	I-MED
.	O
However	O
,	O
the	O
enhanced	B-MED
effects	B-MED
of	I-MED
laser	B-MED
irradiation	I-MED
with	O
melatonin	B-MED
were	O
markedly	O
inhibited	B-MED
when	O
the	O
cells	B-MED
were	O
treated	B-MED
with	O
luzindole	B-MED
,	O
a	O
selective	O
melatonin	B-MED
receptor	I-MED
antagonist	I-MED
.	O
Therefore	O
,	O
we	O
concluded	O
that	O
laser	B-MED
irradiation	I-MED
could	O
promote	O
the	O
effect	B-MED
of	I-MED
melatonin	B-MED
on	O
the	O
differentiation	B-MED
and	O
mineralization	B-MED
of	O
MC3T3	B-MED
-	I-MED
E1	I-MED
cells	I-MED
under	O
hypoxic	B-MED
conditions	I-MED
,	O
and	O
that	O
this	O
process	O
is	O
mediated	O
through	O
melatonin	B-MED
1/2	I-MED
receptors	I-MED
and	O
PKRD	B-MED
/	O
p38	B-MED
signaling	B-MED
pathways	I-MED
.	O
Serum	B-MED
C	I-MED
-	I-MED
Reactive	I-MED
Protein	I-MED
in	O
Children	B-MED
with	O
Liver	B-MED
Disease	I-MED
and	O
Ascites	B-MED
The	O
diagnosis	B-MED
of	O
peritonitis	B-MED
as	O
a	O
complication	B-MED
of	O
cirrhosis	B-MED
is	O
an	O
important	O
clinical	O
problem	O
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	O
serum	B-MED
C	I-MED
-	I-MED
reactive	I-MED
protein	I-MED
levels	I-MED
as	O
a	O
diagnostic	B-MED
factor	I-MED
for	O
spontaneous	B-MED
bacterial	I-MED
peritonitis	I-MED
(	O
SBP	B-MED
)	O
in	O
child	B-MED
patients	I-MED
with	O
liver	B-MED
disease	I-MED
.	O
In	O
this	O
study	B-MED
,	O
150	O
children	B-MED
diagnosed	B-MED
with	O
liver	B-MED
disease	I-MED
and	O
ascites	B-MED
upon	O
admission	B-MED
to	O
Nemazee	B-MED
Teaching	I-MED
Hospital	I-MED
(	O
Shiraz	B-MED
,	O
Iran	B-MED
)	O
were	O
examined	B-MED
.	O
Patients	B-MED
were	O
divided	O
into	O
spontaneous	B-MED
bacterial	I-MED
peritonitis	I-MED
and	O
sterile	B-MED
ascetic	I-MED
fluid	I-MED
groups	I-MED
according	O
to	O
the	O
PMN	B-MED
count	I-MED
≥	O
250	O
/	O
mm(3	O
)	O
in	O
the	O
ascetic	B-MED
fluids	I-MED
.	O
Routine	B-MED
laboratory	I-MED
tests	I-MED
were	O
conducted	O
and	O
quantitative	O
C	B-MED
-	I-MED
reactive	I-MED
protein	I-MED
(	I-MED
CRP	I-MED
)	I-MED
levels	I-MED
were	O
measured	O
for	O
all	O
of	O
the	O
patients	B-MED
.	O
Accuracy	B-MED
,	O
sensitivity	B-MED
,	I-MED
and	I-MED
specificity	I-MED
of	O
CRP	B-MED
was	O
evaluated	O
for	O
diagnosis	B-MED
of	O
SBP	B-MED
.	O
Of	O
150	O
cirrhotic	B-MED
patients	B-MED
,	O
109	O
patients	B-MED
presented	O
without	O
SBP	B-MED
(	O
52.29	O
%	O
male	B-MED
,	O
mean	B-MED
age	I-MED
:	O
5.02	O
±	O
4.49	O
years	B-MED
)	O
and	O
41	O
patients	B-MED
presented	O
with	O
SBP	B-MED
(	O
51.21	O
%	O
male	B-MED
,	O
mean	B-MED
age	I-MED
:	O
4.71	O
years	B-MED
)	O
.	O
Cell	B-MED
counts	I-MED
,	O
protein	B-MED
levels	I-MED
,	O
albumin	B-MED
levels	I-MED
,	O
and	O
lactate	B-MED
dehydrogenize	I-MED
(	I-MED
LDH	I-MED
)	I-MED
levels	I-MED
of	O
the	O
ascetic	B-MED
fluid	I-MED
and	O
serum	B-MED
samples	I-MED
in	O
the	O
SBP	B-MED
group	O
were	O
higher	O
than	O
the	O
rates	O
for	O
those	O
without	O
SBP	B-MED
(	O
P	O
<	O
0.05	O
(	O
.	O
The	O
mean	O
±	O
SD	O
of	O
CRP	B-MED
in	O
the	O
SBP	B-MED
group	O
(	O
36.89	O
±	O
23.43	O
)	O
increased	O
significantly	O
compared	O
to	O
the	O
rate	O
among	O
those	O
without	O
SBP	B-MED
(	O
21.59	O
±	O
15.43	O
,	O
P	O
=	O
0.001	O
)	O
.	O
The	O
percentages	O
for	O
sensitivity	B-MED
and	I-MED
specificity	I-MED
of	O
CRP	B-MED
,	O
the	O
diagnosis	B-MED
of	O
SBP	B-MED
based	O
on	O
the	O
PMN	B-MED
count	I-MED
≥	O
250	O
/	O
mm(3	O
)	O
,	O
and	O
cultured	B-MED
ascites	I-MED
were	O
69.23	O
%	O
,	O
90.25	O
%	O
,	O
88.43	O
%	O
,	O
and	O
84.32	O
%	O
,	O
respectively	O
.	O
The	O
areas	O
under	O
the	O
curve	O
of	O
CRP	B-MED
for	O
SBP	B-MED
based	O
on	O
the	O
PMN	B-MED
count	I-MED
≥	O
250	O
/	O
mm(3	O
)	O
and	O
cultured	B-MED
ascites	I-MED
was	O
0.94	O
(	O
CI	O
95	O
%	O
:	O
0.90	O
to	O
0.96	O
)	O
and	O
0.85	O
(	O
CI	O
95	O
%	O
:	O
0.84	O
to	O
0.92	O
)	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Our	O
study	B-MED
showed	O
that	O
CRP	B-MED
is	O
a	O
marker	O
with	O
high	O
sensitivity	B-MED
and	I-MED
specificity	I-MED
for	O
the	O
diagnosis	B-MED
of	O
SBP	B-MED
in	O
cirrhotic	B-MED
children	B-MED
.	O
Epidemiology	B-MED
of	O
polyomavirus	B-MED
BK	I-MED
(	O
BKV	B-MED
)	O
and	O
the	O
emergent	B-MED
African	B-MED
variant	B-MED
in	O
kidney	B-MED
and	O
bone	B-MED
marrow	I-MED
transplant	B-MED
recipients	I-MED
in	O
the	O
Fundacion	B-MED
Valle	I-MED
del	I-MED
Lili	I-MED
in	I-MED
Cali	I-MED
,	O
Colombia	B-MED
To	O
describe	O
the	O
epidemiology	B-MED
of	O
BKV	B-MED
and	O
to	O
assess	B-MED
the	O
presence	B-MED
of	O
the	O
African	B-MED
variant	B-MED
in	O
bone	B-MED
marrow	I-MED
and	O
kidney	B-MED
transplant	I-MED
patients	I-MED
who	O
have	O
suspected	B-MED
BKV	B-MED
reactivation	B-MED
.	O
A	O
descriptive	B-MED
study	I-MED
was	O
conducted	B-MED
,	O
using	O
institutional	B-MED
records	I-MED
,	O
at	O
the	O
Fundación	B-MED
Valle	I-MED
del	I-MED
Lili	I-MED
,	I-MED
Cali	I-MED
-	O
Colombia	B-MED
.	O
The	O
overall	B-MED
prevalence	I-MED
of	O
BKV	B-MED
during	O
the	O
study	O
period	O
was	O
51	O
%	O
.	O
The	O
African	B-MED
variant	B-MED
was	O
identified	B-MED
in	O
49.4	O
%	O
of	O
samples	B-MED
that	O
were	O
positive	B-MED
for	O
BKV	B-MED
.	O
50.6	O
%	O
of	O
the	O
samples	B-MED
were	O
found	O
to	O
have	O
the	O
wild	B-MED
strain	B-MED
of	O
BKV	B-MED
.	O
Among	O
BKV	B-MED
positive	B-MED
patients	B-MED
,	O
57	O
%	O
were	O
kidney	B-MED
transplant	I-MED
recipients	I-MED
and	O
43	O
%	O
were	O
bone	B-MED
marrow	I-MED
transplant	B-MED
recipients	I-MED
.	O
This	O
is	O
the	O
first	O
epidemiological	B-MED
study	I-MED
describing	O
the	O
African	B-MED
variant	B-MED
of	O
BKV	B-MED
in	O
Colombia	B-MED
.	O
A	O
Comparison	B-MED
Between	O
Measured	B-MED
Concentration	B-MED
of	O
3H	B-MED
in	O
Kalpakkam	B-MED
Environment	I-MED
with	O
Predicted	B-MED
Atmospheric	I-MED
Dispersion	I-MED
Model	I-MED
The	O
field	B-MED
measurements	B-MED
of	O
3H	B-MED
in	O
the	O
form	O
of	O
HTO	B-MED
present	O
in	O
air	B-MED
moisture	B-MED
carried	O
out	O
around	O
Madras	B-MED
Atomic	I-MED
Power	I-MED
Station	I-MED
were	O
compared	B-MED
with	O
predicted	O
values	O
using	O
atmospheric	B-MED
dispersion	I-MED
modeling	I-MED
.	O
Air	B-MED
3H	I-MED
samples	I-MED
were	O
collected	B-MED
from	O
different	O
sectors	B-MED
at	O
the	O
site	B-MED
boundary	B-MED
of	O
the	O
operating	B-MED
reactors	B-MED
for	O
the	O
period	B-MED
of	O
2	O
y	B-MED
and	O
compared	B-MED
with	O
Gaussian	B-MED
Plume	I-MED
model	I-MED
.	O
The	O
predictions	B-MED
were	O
comparable	O
with	O
the	O
measured	B-MED
value	B-MED
.	O
The	O
slight	B-MED
variation	B-MED
observed	B-MED
between	O
the	O
two	O
methods	B-MED
is	O
attributed	O
to	O
the	O
uncertainty	B-MED
involved	O
in	O
the	O
measurement	B-MED
of	O
air	B-MED
3H	B-MED
concentration	B-MED
and	O
in	O
the	O
measurement	B-MED
of	O
site	B-MED
-	I-MED
specific	I-MED
meteorological	B-MED
parameters	I-MED
.	O
The	O
radiation	B-MED
dose	I-MED
imparted	B-MED
to	O
members	B-MED
of	I-MED
public	I-MED
due	O
to	O
the	O
levels	B-MED
observed	B-MED
is	O
well	O
within	O
station	B-MED
technical	B-MED
specification	I-MED
limit	I-MED
3H	B-MED
for	O
3H.	O
Effect	B-MED
of	O
Xenotransplantation	B-MED
Site	B-MED
on	O
MicroRNA	B-MED
Expression	B-MED
of	O
Human	B-MED
Colon	B-MED
Cancer	I-MED
Stem	B-MED
Cells	I-MED
Cancer	B-MED
stem	I-MED
cells	I-MED
(	O
CSCs	B-MED
)	O
have	O
a	O
high	B-MED
tumorigenic	B-MED
ability	B-MED
to	O
form	O
patient	B-MED
-	I-MED
derived	I-MED
tumor	I-MED
xenografts	I-MED
(	O
PDXs	B-MED
)	O
.	O
PDXs	B-MED
are	O
an	O
attractive	B-MED
pre	B-MED
-	I-MED
clinical	I-MED
model	I-MED
,	O
but	O
gene	B-MED
expression	I-MED
and	O
biological	B-MED
behavior	I-MED
of	O
cancer	B-MED
cells	I-MED
in	O
the	O
tumor	B-MED
will	O
change	B-MED
during	O
establishment	B-MED
and	O
passage	O
of	O
PDXs	B-MED
.	O
Human	B-MED
colon	B-MED
cancer	I-MED
PDX	B-MED
was	O
established	B-MED
and	O
passaged	B-MED
either	O
subcutaneously	B-MED
or	O
orthotopically	B-MED
into	O
the	O
murine	B-MED
intestine	B-MED
.	O
Histology	B-MED
and	O
flow	B-MED
cytometric	I-MED
profile	B-MED
of	O
the	O
surgical	B-MED
specimen	B-MED
and	O
the	O
PDX	B-MED
were	O
analyzed	B-MED
.	O
CSCs	B-MED
were	O
then	O
isolated	B-MED
from	O
the	O
tumors	B-MED
and	O
their	O
microRNA	B-MED
(	O
miRNA	B-MED
)	O
expression	B-MED
was	O
analyzed	B-MED
by	O
semi	B-MED
-	I-MED
quantitative	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
.	O
The	O
surgical	B-MED
specimens	B-MED
and	O
PDXs	B-MED
were	O
histologically	B-MED
similar	B-MED
.	O
The	O
size	B-MED
of	O
CSC	B-MED
population	B-MED
increased	B-MED
and	O
expression	B-MED
of	O
miRNA	B-MED
s	O
in	O
CSCs	B-MED
changed	B-MED
in	O
the	O
passaged	B-MED
PDXs	B-MED
.	O
Expression	B-MED
of	O
oncogenic	B-MED
miRNAs	B-MED
was	O
highly	B-MED
up	B-MED
-	I-MED
regulated	I-MED
in	O
the	O
CSCs	B-MED
of	O
the	O
orthotopically	B-MED
passaged	B-MED
PDXs	B-MED
.	O
The	O
xenotransplantation	B-MED
site	B-MED
and	O
the	O
number	B-MED
of	O
tumor	B-MED
passages	B-MED
affect	B-MED
the	O
miRNA	B-MED
expression	B-MED
of	O
human	B-MED
colon	B-MED
CSCs	B-MED
.	O
Unusual	B-MED
asymptomatic	B-MED
presentation	I-MED
of	O
bladder	B-MED
cancer	I-MED
metastatic	B-MED
to	I-MED
the	I-MED
penis	I-MED
Penile	B-MED
metastasis	I-MED
is	O
an	O
extremely	B-MED
rare	I-MED
event	I-MED
and	O
mainly	O
originate	O
from	O
primary	O
pelvic	B-MED
tumor	B-MED
sites	I-MED
such	O
us	O
urinary	B-MED
bladder	I-MED
,	O
gastro	B-MED
-	I-MED
intestinal	I-MED
tract	I-MED
and	O
prostate	B-MED
and	O
more	O
rarely	O
from	O
respiratory	B-MED
system	I-MED
,	O
bone	B-MED
tumors	I-MED
and	O
melanoma	B-MED
.	O
Here	O
we	O
describe	O
the	O
unusual	B-MED
presentation	B-MED
of	O
two	O
bladder	B-MED
urothelial	I-MED
cancer	I-MED
metastatic	B-MED
to	I-MED
the	O
penis	B-MED
with	O
no	B-MED
relevant	I-MED
clinical	I-MED
symptoms	I-MED
.	O
Namely	O
,	O
a	O
69	O
years	O
-	O
old	O
man	O
with	O
a	O
warthy	O
lesions	B-MED
of	O
the	O
foreskin	B-MED
and	I-MED
the	I-MED
glans	I-MED
misunderstood	O
for	O
a	O
condylomata	B-MED
that	O
at	O
histological	B-MED
and	O
immunohistochemical	B-MED
analysis	I-MED
showed	O
a	O
bladder	B-MED
urothelial	I-MED
carcinoma	I-MED
;	O
and	O
a	O
71	O
years	O
-	O
old	O
man	O
with	O
reddish	B-MED
skin	B-MED
lesion	I-MED
of	I-MED
the	I-MED
glans	I-MED
,	O
a	O
previous	O
history	B-MED
of	I-MED
bladder	I-MED
and	O
urethral	B-MED
carcinoma	I-MED
and	O
histological	B-MED
pagetoid	I-MED
spread	I-MED
of	O
urothelial	B-MED
cancer	I-MED
to	B-MED
the	I-MED
glans	I-MED
.	O
Recurrent	B-MED
bladder	I-MED
urothelial	I-MED
carcinoma	I-MED
is	O
usually	O
a	O
visceral	B-MED
disease	B-MED
that	O
rarely	O
presents	O
as	O
a	O
superficial	O
asymptomatic	B-MED
skin	B-MED
lesion	I-MED
.	O
The	O
two	O
reported	O
cases	B-MED
were	I-MED
asymptomatic	I-MED
superficial	B-MED
penis	I-MED
metastases	I-MED
with	O
a	O
relatively	O
slow	O
growth	O
and	O
a	O
fairy	B-MED
good	I-MED
prognosis	I-MED
after	O
conservative	B-MED
surgical	I-MED
approach	I-MED
.	O
Accurate	O
clinical	B-MED
examination	I-MED
of	I-MED
the	I-MED
penis	I-MED
is	I-MED
mandatory	I-MED
for	I-MED
males	I-MED
with	O
history	B-MED
of	I-MED
bladder	I-MED
cancer	I-MED
.	O
Visual	B-MED
Analytics	I-MED
for	O
Pattern	B-MED
Discovery	I-MED
in	O
Home	B-MED
Care	I-MED
.	O
Clinical	B-MED
Relevance	I-MED
for	O
Quality	B-MED
Improvement	I-MED
Visualization	B-MED
can	O
reduce	O
the	O
cognitive	B-MED
load	I-MED
of	I-MED
information	I-MED
,	O
allowing	O
users	O
to	O
easily	O
interpret	B-MED
and	O
assess	B-MED
large	I-MED
amounts	I-MED
of	I-MED
data	I-MED
.	O
The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
examine	O
home	B-MED
health	I-MED
data	I-MED
using	O
visual	B-MED
analysis	I-MED
techniques	I-MED
to	O
discover	O
clinically	B-MED
salient	I-MED
associations	B-MED
between	O
patient	B-MED
characteristics	I-MED
with	O
problem	B-MED
-	I-MED
oriented	I-MED
health	I-MED
outcomes	I-MED
of	O
older	B-MED
adult	I-MED
home	I-MED
health	I-MED
patients	I-MED
during	O
the	O
home	B-MED
health	I-MED
service	I-MED
period	O
.	O
Knowledge	B-MED
,	O
Behavior	B-MED
and	O
Status	B-MED
ratings	I-MED
at	O
discharge	B-MED
as	O
well	O
as	O
change	O
from	O
admission	B-MED
to	O
discharge	B-MED
that	O
was	O
coded	O
using	O
the	O
Omaha	B-MED
System	I-MED
was	O
collected	O
from	O
a	O
dataset	B-MED
on	O
988	O
de	O
-	O
identified	O
patient	B-MED
data	I-MED
from	O
15	O
home	B-MED
health	I-MED
agencies	I-MED
.	O
SPSS	B-MED
Visualization	I-MED
Designer	I-MED
v1.0	I-MED
was	O
used	O
to	O
visually	B-MED
analyze	I-MED
patterns	I-MED
between	O
independent	O
and	O
outcome	O
variables	O
using	O
heat	B-MED
maps	I-MED
and	O
histograms	B-MED
.	O
Visualizations	B-MED
suggesting	O
clinical	B-MED
salience	I-MED
were	O
tested	B-MED
for	O
significance	O
using	O
correlation	B-MED
analysis	I-MED
.	O
The	O
mean	O
age	O
of	O
the	O
patients	B-MED
was	O
80	O
years	O
,	O
with	O
the	O
majority	O
female	B-MED
(	O
66	O
%	O
)	O
.	O
Of	O
the	O
150	O
visualizations	B-MED
,	O
69	O
potentially	O
meaningful	B-MED
patterns	I-MED
were	O
statistically	O
evaluated	O
through	O
bivariate	B-MED
associations	I-MED
,	O
revealing	O
21	O
significant	O
associations	B-MED
.	O
Further	O
,	O
14	O
associations	B-MED
between	O
episode	O
length	O
and	O
Charlson	B-MED
co	I-MED
-	I-MED
morbidity	I-MED
index	I-MED
mainly	O
with	O
urinary	B-MED
related	O
diagnoses	B-MED
and	I-MED
problems	I-MED
remained	O
significant	O
after	O
adjustment	O
analyses	O
.	O
Through	O
visual	B-MED
analysis	I-MED
,	O
the	O
adverse	O
association	B-MED
of	O
the	O
longer	O
home	B-MED
health	I-MED
episode	I-MED
length	O
and	O
higher	O
Charlson	B-MED
co	I-MED
-	I-MED
morbidity	I-MED
index	I-MED
with	O
behavior	B-MED
or	I-MED
status	I-MED
outcomes	I-MED
for	O
patients	B-MED
with	O
impaired	B-MED
urinary	I-MED
function	I-MED
was	O
revealed	O
.	O
We	O
have	O
demonstrated	O
the	O
use	O
of	O
visual	B-MED
analysis	I-MED
to	O
discover	O
novel	O
patterns	O
that	O
described	O
high	O
-	O
needs	O
subgroups	B-MED
among	O
the	O
older	B-MED
home	I-MED
health	I-MED
patient	I-MED
population	I-MED
.	O
The	O
effective	O
presentation	O
of	O
these	O
data	B-MED
patterns	I-MED
can	O
allow	O
clinicians	B-MED
to	O
identify	O
areas	O
of	O
patient	B-MED
improvement	I-MED
,	O
and	O
time	O
periods	O
that	O
are	O
most	O
effective	O
for	O
implementing	O
home	B-MED
health	I-MED
interventions	I-MED
to	O
improve	O
patient	B-MED
outcomes	I-MED
.	O
Variety	B-MED
of	O
DNA	B-MED
Replication	I-MED
Activity	I-MED
Among	O
Cyanobacteria	B-MED
Correlates	B-MED
with	O
Distinct	O
Respiration	B-MED
Activity	I-MED
in	O
the	O
Dark	B-MED
Cyanobacteria	B-MED
exhibit	O
light	B-MED
-dependent	O
cell	B-MED
growth	I-MED
since	O
most	O
of	O
their	O
cellular	B-MED
energy	B-MED
is	O
obtained	O
by	O
photosynthesis	B-MED
.	O
In	O
Synechococcus	B-MED
elongatus	I-MED
PCC	I-MED
7942	I-MED
,	O
one	O
of	O
the	O
model	O
cyanobacteria	B-MED
,	O
DNA	B-MED
replication	I-MED
depends	O
on	O
photosynthetic	B-MED
electron	I-MED
transport	I-MED
.	O
However	O
,	O
the	O
critical	B-MED
signal	I-MED
for	O
the	O
regulatory	B-MED
mechanism	B-MED
of	O
DNA	B-MED
replication	I-MED
has	O
not	O
been	O
identified	O
.	O
In	O
addition	O
,	O
conservation	B-MED
of	O
this	O
regulatory	B-MED
mechanism	I-MED
has	O
not	O
been	O
investigated	B-MED
among	O
cyanobacteria	B-MED
.	O
To	O
understand	O
this	O
regulatory	B-MED
signal	B-MED
and	O
its	O
dependence	O
on	O
light	B-MED
,	O
we	O
examined	O
the	O
regulation	B-MED
of	O
DNA	B-MED
replication	I-MED
under	O
both	O
light	B-MED
and	O
dark	B-MED
conditions	O
among	O
three	O
model	B-MED
cyanobacteria	B-MED
,	O
S.	B-MED
elongatus	I-MED
PCC	I-MED
7942	I-MED
,	O
Synechocystis	B-MED
sp	I-MED
.	I-MED
PCC	I-MED
6803	I-MED
and	O
Anabaena	B-MED
sp	I-MED
.	I-MED
PCC	I-MED
7120	I-MED
.	O
Interestingly	O
,	O
DNA	B-MED
replication	I-MED
activity	I-MED
in	O
Synechocystis	B-MED
and	O
Anabaena	B-MED
was	O
retained	B-MED
when	O
cells	B-MED
were	O
transferred	B-MED
to	I-MED
the	O
dark	B-MED
,	O
although	O
it	O
was	O
drastically	O
decreased	B-MED
in	O
S.	B-MED
elongatus	I-MED
.	O
Glycogen	B-MED
metabolism	I-MED
and	O
respiration	B-MED
were	O
higher	O
in	O
Synechocystis	B-MED
and	O
Anabaena	B-MED
than	O
in	O
S.	B-MED
elongatus	I-MED
in	O
the	O
dark	B-MED
.	O
Moreover	O
,	O
DNA	B-MED
replication	I-MED
activity	I-MED
in	O
Synechocystis	B-MED
and	O
Anabaena	B-MED
was	O
reduced	B-MED
to	O
the	O
same	O
level	O
as	O
that	O
in	O
S.	B-MED
elongatus	I-MED
by	O
inhibition	B-MED
of	O
respiratory	B-MED
electron	B-MED
transport	I-MED
after	O
transfer	O
to	O
the	O
dark	B-MED
.	O
These	O
results	O
demonstrate	O
that	O
there	O
is	O
disparity	B-MED
in	O
DNA	B-MED
replication	I-MED
occurring	O
in	O
the	O
dark	B-MED
among	O
cyanobacteria	B-MED
,	O
which	O
is	O
caused	O
by	O
the	O
difference	B-MED
in	O
activity	B-MED
of	O
respiratory	B-MED
electron	B-MED
transport	I-MED
.	O
Kidney	B-MED
transplant	I-MED
recipients	I-MED
after	O
nonrenal	B-MED
solid	I-MED
organ	I-MED
transplantation	I-MED
show	O
low	O
alloreactivity	B-MED
but	O
an	O
increased	O
risk	B-MED
of	O
infection	B-MED
The	O
number	O
of	O
kidney	B-MED
transplant	I-MED
recipients	I-MED
(	O
KTRs	B-MED
)	O
after	O
nonrenal	B-MED
solid	I-MED
organ	I-MED
transplantation	I-MED
(	O
SOT	B-MED
)	O
has	O
increased	O
to	O
almost	O
5	O
%	O
.	O
Knowledge	O
on	O
patient	B-MED
and	O
allograft	B-MED
outcomes	B-MED
,	O
infections	B-MED
,	O
and	O
alloreactivity	B-MED
,	O
however	O
,	O
remains	O
scarce	O
.	O
We	O
studied	B-MED
40	O
KTRs	B-MED
after	O
nonrenal	B-MED
SOT	I-MED
.	O
Seven	O
hundred	O
and	O
twenty	O
primary	O
KTRs	B-MED
and	O
119	O
repeat	O
KTRs	B-MED
were	O
used	O
for	O
comparison	O
.	O
Samples	B-MED
were	O
collected	O
pretransplantation	B-MED
,	O
at	O
+1	O
,	O
+2	O
,	O
and	O
+3	O
months	O
post	B-MED
-	I-MED
transplantation	I-MED
.	O
Alloreactive	B-MED
and	O
CMV	B-MED
-	I-MED
specific	I-MED
T	B-MED
cells	I-MED
were	O
measured	O
by	O
interferon	B-MED
-	I-MED
γ	I-MED
ELISPOT	I-MED
assay	I-MED
.	O
Patient	B-MED
survival	B-MED
in	O
KTRs	B-MED
after	O
SOT	B-MED
,	O
primary	O
and	O
repeat	O
KTRs	B-MED
was	O
comparable	O
.	O
While	O
death	B-MED
-censored	O
allograft	B-MED
survival	B-MED
was	O
comparable	O
between	O
KTRs	B-MED
after	O
SOT	B-MED
and	O
primary	O
KTRs	B-MED
,	O
KTRs	B-MED
after	O
SOT	B-MED
showed	O
superior	O
5	B-MED
-	I-MED
year	I-MED
death	B-MED
-censored	O
allograft	B-MED
survival	B-MED
of	O
92.5	O
%	O
compared	O
to	O
81.2	O
%	O
in	O
repeat	O
KTRs	B-MED
.	O
Interestingly	O
,	O
KTRs	B-MED
after	O
SOT	B-MED
show	O
less	O
preformed	O
panel	B-MED
-	I-MED
reactive	I-MED
antibodies	I-MED
,	O
frequencies	B-MED
of	O
alloreactive	B-MED
T	B-MED
cells	I-MED
,	O
and	O
acute	B-MED
rejections	I-MED
compared	O
to	O
repeat	O
KTRs	B-MED
.	O
KTRs	B-MED
after	O
SOT	B-MED
,	O
however	O
,	O
show	O
higher	O
incidences	B-MED
of	O
EBV	B-MED
viremia	I-MED
and	O
PTLD	B-MED
,	O
sepsis	B-MED
,	O
and	O
death	B-MED
from	O
sepsis	B-MED
.	O
Impaired	O
CMV	B-MED
-	I-MED
specific	I-MED
cellular	B-MED
immunity	I-MED
was	O
associated	B-MED
with	I-MED
more	O
CMV	B-MED
replication	B-MED
compared	O
to	O
repeat	O
KTRs	B-MED
.	O
Our	O
results	O
suggest	O
comparable	O
patient	B-MED
and	O
allograft	B-MED
outcomes	B-MED
in	O
KTRs	B-MED
after	O
SOT	B-MED
and	O
primary	O
KTRs	B-MED
.	O
The	O
observed	O
low	O
alloreactivity	B-MED
may	O
contribute	O
to	O
excellent	O
allograft	B-MED
outcomes	B-MED
.	O
Caution	O
should	O
be	O
taken	O
in	O
KTRs	B-MED
after	O
SOT	B-MED
regarding	O
infectious	B-MED
complications	I-MED
due	O
to	O
overimmunosuppression	B-MED
.	O
Extracorporeal	B-MED
membrane	I-MED
oxygenation	I-MED
outcomes	B-MED
in	O
children	B-MED
with	O
hemophagocytic	B-MED
lymphohistiocytosis	I-MED
Pediatric	B-MED
patients	B-MED
with	O
hemophagocytic	B-MED
lymphohistiocytosis	I-MED
(	O
HLH	B-MED
)	O
may	O
develop	O
refractory	B-MED
respiratory	B-MED
or	O
cardiac	B-MED
failure	I-MED
that	O
warrants	O
consideration	B-MED
for	O
extracorporeal	B-MED
membrane	I-MED
oxygenation	I-MED
(	O
ECMO	B-MED
)	O
support	B-MED
.	O
The	O
purposes	B-MED
of	O
this	O
study	B-MED
were	O
to	O
describe	O
the	O
use	B-MED
and	O
outcomes	B-MED
of	O
ECMO	B-MED
in	O
pediatric	B-MED
HLH	B-MED
patients	B-MED
,	O
to	O
identify	B-MED
risk	B-MED
factors	I-MED
for	O
hospital	B-MED
mortality	I-MED
and	O
to	O
compare	B-MED
their	O
ECMO	B-MED
use	B-MED
and	O
outcomes	B-MED
to	O
the	O
ECMO	B-MED
population	B-MED
as	O
a	O
whole	O
.	O
Pediatric	B-MED
patients	B-MED
(	O
⩽	O
18	O
years	B-MED
)	O
with	O
a	O
diagnosis	B-MED
of	O
HLH	B-MED
in	O
the	O
Extracorporeal	B-MED
Life	I-MED
Support	I-MED
Organization	I-MED
(	O
ELSO	B-MED
)	O
Registry	B-MED
were	O
included	B-MED
.	O
Between	O
1983	O
and	O
2014	O
,	O
data	B-MED
for	O
30	O
children	B-MED
with	O
HLH	B-MED
were	O
available	O
in	O
the	O
ELSO	B-MED
registry	B-MED
and	O
all	O
were	O
included	B-MED
in	O
this	O
study	B-MED
.	O
All	O
cases	B-MED
occurred	B-MED
in	O
the	O
last	B-MED
decade	B-MED
.	O
Of	O
the	O
30	O
HLH	B-MED
patients	B-MED
,	O
24	O
(	O
80	O
%	O
)	O
had	O
a	O
respiratory	B-MED
indication	B-MED
for	O
ECMO	B-MED
and	O
six	O
(	O
20	O
%	O
)	O
had	O
a	O
cardiac	B-MED
indication	B-MED
(	O
of	O
which	O
4	O
were	O
E	B-MED
-	O
CPR	B-MED
and	O
2	O
cardiac	B-MED
failure	I-MED
)	O
.	O
Of	O
the	O
24	O
respiratory	B-MED
ECMO	B-MED
patients	B-MED
,	O
63	O
%	O
were	O
placed	O
on	O
VA	B-MED
ECMO	I-MED
.	O
Compared	B-MED
with	O
all	O
pediatric	B-MED
patients	B-MED
in	O
the	O
ELSO	B-MED
registry	B-MED
during	O
the	O
study	B-MED
period	I-MED
(	O
n=17,007	O
)	O
,	O
HLH	B-MED
patients	B-MED
had	O
worse	O
hospital	B-MED
survival	I-MED
(	O
non	O
-	O
HLH	O
59	O
%	O
vs	O
HLH	B-MED
30	O
%	O
,	O
p	B-MED
=	O
0.001	O
)	O
.	O
In	O
pediatric	B-MED
HLH	B-MED
patients	B-MED
,	O
no	O
pre-	O
ECMO	B-MED
risk	B-MED
factors	I-MED
for	O
mortality	B-MED
were	O
identified	B-MED
.	O
The	O
development	B-MED
of	O
a	O
hemorrhagic	B-MED
complication	B-MED
on	O
ECMO	B-MED
was	O
associated	B-MED
with	I-MED
decreased	B-MED
mortality	B-MED
(	O
p	B-MED
=	O
0.01	O
)	O
.	O
Comparing	B-MED
HLH	B-MED
patients	B-MED
with	O
respiratory	B-MED
failure	I-MED
to	O
patients	B-MED
with	O
other	O
immune	B-MED
compromised	I-MED
conditions	I-MED
,	O
the	O
overall	O
survival	B-MED
rate	I-MED
is	O
similar	O
(	O
HLH	B-MED
38	O
%	O
vs.	O
non	O
-	O
HLH	O
immune	B-MED
compromised	I-MED
31	O
%	O
,	O
p	B-MED
=	O
0.64	O
)	O
.	O
HLH	B-MED
is	O
an	O
uncommon	B-MED
indication	B-MED
for	O
ECMO	B-MED
and	O
these	O
patients	B-MED
have	O
increased	B-MED
mortality	B-MED
compared	B-MED
to	O
the	O
overall	O
pediatric	B-MED
ECMO	B-MED
population	B-MED
.	O
These	O
data	B-MED
should	O
be	O
factored	O
into	O
decision	B-MED
-	I-MED
making	I-MED
when	O
considering	O
ECMO	B-MED
for	O
pediatric	B-MED
HLH	B-MED
patients	B-MED
.	O
Facilitating	B-MED
factors	I-MED
and	O
barriers	B-MED
to	O
malaria	B-MED
research	B-MED
utilization	B-MED
for	O
policy	B-MED
development	I-MED
in	O
Malawi	B-MED
Research	B-MED
on	O
various	O
determinants	B-MED
of	O
health	B-MED
is	O
key	O
in	O
providing	B-MED
evidence	B-MED
for	O
policy	B-MED
development	I-MED
,	O
thereby	O
leading	O
to	O
successful	B-MED
interventions	O
.	O
Utilization	B-MED
of	O
research	B-MED
is	O
an	O
intricate	B-MED
process	B-MED
requiring	O
an	O
understanding	O
of	O
contextual	B-MED
factors	I-MED
.	O
The	O
study	O
was	O
conducted	O
to	O
assess	O
enhancing	B-MED
factors	B-MED
and	O
barriers	B-MED
of	O
research	B-MED
utilization	B-MED
for	O
malaria	B-MED
policy	B-MED
development	I-MED
in	O
Malawi	B-MED
.	O
Qualitative	B-MED
research	B-MED
approach	O
was	O
used	O
through	O
in	O
-	O
depth	O
interviews	B-MED
with	O
39	O
key	O
informants	B-MED
that	O
included	O
malaria	B-MED
researchers	B-MED
,	O
policy	B-MED
makers	I-MED
,	O
programme	B-MED
managers	B-MED
,	O
and	O
key	B-MED
stakeholders	I-MED
.	O
Purposive	B-MED
sampling	I-MED
and	O
snowballing	B-MED
techniques	I-MED
were	O
used	O
in	O
identifying	B-MED
key	O
informants	B-MED
.	O
Interview	B-MED
transcripts	B-MED
were	O
entered	B-MED
in	O
QSR	B-MED
Nvivo	I-MED
11	I-MED
software	I-MED
for	O
coding	O
and	O
analysis	B-MED
.	O
Respondents	B-MED
identified	B-MED
global	B-MED
efforts	B-MED
as	O
key	O
in	O
advancing	O
knowledge	B-MED
translation	I-MED
,	O
while	O
local	B-MED
political	B-MED
will	I-MED
has	O
been	O
conducive	B-MED
for	O
research	B-MED
utilization	B-MED
.	O
Other	O
factors	B-MED
were	O
availability	B-MED
of	I-MED
research	B-MED
,	O
availability	B-MED
of	I-MED
diverse	O
local	B-MED
researchers	B-MED
and	O
stakeholders	B-MED
supporting	B-MED
knowledge	B-MED
translation	I-MED
.	O
While	O
barriers	B-MED
included	O
:	O
lack	B-MED
of	O
platforms	O
for	O
researcher	B-MED
-	O
public	B-MED
engagement	B-MED
,	O
politics	B-MED
,	O
researchers	B-MED
'	I-MED
lack	B-MED
of	O
communication	B-MED
skills	I-MED
,	O
lack	B-MED
of	O
research	B-MED
collaborations	B-MED
,	O
funder	B-MED
driven	I-MED
research	I-MED
,	O
unknown	B-MED
World	B-MED
Health	I-MED
Organization	I-MED
policy	B-MED
position	O
,	O
and	O
the	O
lack	B-MED
of	O
a	O
malaria	B-MED
research	B-MED
repository	B-MED
.	O
Overall	O
,	O
the	O
study	O
identified	B-MED
facilitating	B-MED
factors	I-MED
to	O
malaria	B-MED
research	B-MED
utilization	B-MED
for	O
policy	B-MED
development	I-MED
in	O
Malawi	B-MED
.	O
These	O
factors	B-MED
need	O
to	O
be	O
systematically	B-MED
coordinated	B-MED
to	O
address	O
the	O
identified	B-MED
barriers	B-MED
and	O
improve	B-MED
on	O
malaria	B-MED
research	B-MED
utilization	B-MED
in	O
policy	B-MED
development	I-MED
.	O
Malaria	B-MED
research	B-MED
can	O
be	O
key	O
in	O
the	O
implementation	B-MED
of	O
evidence	B-MED
-	I-MED
based	I-MED
interventions	O
to	O
reduce	B-MED
the	O
malaria	B-MED
burden	B-MED
and	O
assist	O
in	O
the	O
paradigm	B-MED
shift	I-MED
from	O
malaria	B-MED
control	B-MED
to	O
elimination	B-MED
in	O
Malawi	B-MED
.	O
Chronic	B-MED
adiponectin	B-MED
deficiency	I-MED
leads	O
to	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
-like	O
cognitive	B-MED
impairments	I-MED
and	O
pathologies	B-MED
through	O
AMPK	B-MED
inactivation	O
and	O
cerebral	B-MED
insulin	B-MED
resistance	I-MED
in	O
aged	B-MED
mice	B-MED
Insulin	B-MED
resistance	I-MED
is	O
the	O
major	O
pathogenesis	B-MED
underlying	O
type	B-MED
2	I-MED
diabetes	I-MED
mellitus	I-MED
(	O
T2DM	B-MED
)	O
and	O
these	O
patients	B-MED
have	O
doubled	O
risk	B-MED
of	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
(	O
AD	B-MED
)	O
.	O
Increasing	O
evidence	O
suggests	O
that	O
insulin	B-MED
resistance	I-MED
plays	O
an	O
important	O
role	O
in	O
AD	O
pathogenesis	B-MED
,	O
possibly	O
due	O
to	O
abnormal	O
GSK3β	B-MED
activation	B-MED
,	O
causing	O
intra-	B-MED
and	O
extracellular	B-MED
amyloid	B-MED
-	I-MED
beta	I-MED
(	O
Aβ	B-MED
)	O
accumulation	O
.	O
Adiponectin	B-MED
(	O
APN	B-MED
)	O
is	O
an	O
adipokine	B-MED
with	O
insulin	O
-	O
sensitizing	O
and	O
anti	B-MED
-	I-MED
inflammatory	I-MED
effects	I-MED
.	O
Reduced	O
circulatory	O
APN	B-MED
level	O
is	O
associated	O
with	O
insulin	B-MED
resistance	I-MED
and	O
T2DM	B-MED
.	O
The	O
role	O
of	O
APN	B-MED
in	O
AD	B-MED
has	O
not	O
been	O
elucidated	O
.	O
In	O
this	O
study	B-MED
,	O
we	O
aim	O
to	O
examine	O
if	O
adiponectin	B-MED
deficiency	I-MED
adiponectin	B-MED
deficiency	I-MED
would	O
lead	O
to	O
cerebral	B-MED
insulin	B-MED
resistance	I-MED
,	O
cognitive	B-MED
decline	I-MED
and	O
Alzheimer's	B-MED
-	I-MED
like	I-MED
pathology	I-MED
in	O
mice	B-MED
.	O
To	O
study	B-MED
the	O
role	O
of	O
adiponectin	B-MED
in	O
cognitive	B-MED
functions	I-MED
,	O
we	O
employed	O
adiponectin	B-MED
-	I-MED
knockout	I-MED
(	B-MED
APN	I-MED
-	I-MED
KO	I-MED
)	I-MED
mice	I-MED
and	O
demonstrated	O
chronic	B-MED
APN	B-MED
deficiency	I-MED
in	O
their	O
CNS	B-MED
.	O
Behavioral	B-MED
tests	I-MED
were	O
performed	O
to	O
study	B-MED
the	O
cognitions	B-MED
of	O
male	B-MED
APN	B-MED
-	I-MED
KO	I-MED
mice	I-MED
.	O
Brains	B-MED
and	O
tissue	B-MED
lysates	B-MED
were	O
collected	O
to	O
study	B-MED
the	O
pathophysiological	O
and	O
molecular	B-MED
changes	I-MED
in	O
the	O
brain	B-MED
of	O
APN	B-MED
-	I-MED
KO	I-MED
mice	I-MED
.	O
SH	B-MED
-	I-MED
SY5Y	I-MED
neuroblastoma	I-MED
cell	I-MED
line	I-MED
was	O
used	O
to	O
study	B-MED
the	O
molecular	B-MED
mechanism	I-MED
upon	O
APN	B-MED
and	O
insulin	B-MED
treatment	I-MED
.	O
Aged	B-MED
APN	B-MED
-deficient	O
mice	B-MED
displayed	O
spatial	B-MED
memory	I-MED
and	O
learning	B-MED
impairments	B-MED
,	O
fear	B-MED
-	I-MED
conditioned	I-MED
memory	B-MED
deficit	I-MED
as	O
well	O
as	O
anxiety	B-MED
.	O
These	O
mice	B-MED
also	O
developed	O
AD	B-MED
pathologies	B-MED
including	O
increased	O
cerebral	B-MED
Aβ42	B-MED
level	O
,	O
Aβ	B-MED
deposition	O
,	O
hyperphosphorylated	B-MED
Tau	I-MED
proteins	I-MED
,	O
microgliosis	B-MED
and	O
astrogliosis	B-MED
with	O
increased	O
cerebral	B-MED
IL-1β	B-MED
and	O
TNFα	B-MED
levels	O
that	O
associated	O
with	O
increased	O
neuronal	B-MED
apoptosis	I-MED
and	O
reduced	O
synaptic	B-MED
proteins	B-MED
levels	I-MED
,	O
suggesting	O
APN	B-MED
deficiency	I-MED
may	O
lead	O
to	O
neuronal	B-MED
and	O
synaptic	O
loss	O
in	O
the	O
brain	B-MED
.	O
AD	B-MED
pathologies	B-MED
-associated	O
APN	B-MED
-	O
KO	B-MED
mice	I-MED
displayed	O
attenuated	O
AMPK	B-MED
phosphorylation	B-MED
and	O
impaired	O
insulin	B-MED
signaling	I-MED
including	O
decreased	O
Akt	B-MED
induction	O
and	O
increased	O
GSK3β	B-MED
activation	B-MED
in	O
the	O
hippocampus	B-MED
and	O
frontal	B-MED
cortex	I-MED
.	O
Aged	B-MED
APN	B-MED
-KO	O
mice	B-MED
developed	O
hippocampal	B-MED
insulin	B-MED
resistance	I-MED
with	O
reduced	O
pAkt	B-MED
induction	O
upon	O
intracerebral	O
insulin	B-MED
injection	I-MED
.	O
Consistently	O
,	O
APN	B-MED
treatment	B-MED
in	O
SH	B-MED
-	I-MED
SY5Y	I-MED
cells	I-MED
with	O
insulin	B-MED
resistance	I-MED
and	O
overexpressing	B-MED
Aβ	B-MED
induce	O
higher	O
pAkt	B-MED
levels	O
through	O
AdipoR1	B-MED
upon	O
insulin	B-MED
treatment	I-MED
whereas	O
the	O
induction	O
was	O
blocked	B-MED
by	O
compound	B-MED
C	I-MED
,	O
indicating	O
APN	B-MED
can	O
enhance	O
neuronal	B-MED
insulin	B-MED
sensitivity	I-MED
through	O
AMPK	B-MED
activation	O
.	O
Our	O
results	O
indicated	O
that	O
chronic	B-MED
APN	B-MED
deficiency	I-MED
inactivated	O
AMPK	B-MED
causing	O
insulin	O
desensitization	O
and	O
elicited	O
AD	B-MED
-	I-MED
like	I-MED
pathogenesis	I-MED
in	O
aged	B-MED
mice	B-MED
which	O
also	O
developed	O
significant	O
cognitive	B-MED
impairments	I-MED
and	O
psychiatric	B-MED
symptoms	I-MED
.	O
Developing	O
elite	B-MED
Neurospora	B-MED
crassa	I-MED
strains	B-MED
for	O
cellulosic	B-MED
ethanol	B-MED
production	I-MED
using	O
fungal	B-MED
breeding	B-MED
The	O
demand	O
for	O
renewable	B-MED
and	O
sustainable	B-MED
energy	I-MED
has	O
generated	B-MED
considerable	O
interest	B-MED
in	O
the	O
conversion	B-MED
of	O
cellulosic	B-MED
biomass	B-MED
into	O
liquid	B-MED
fuels	B-MED
such	O
as	O
ethanol	B-MED
using	O
a	O
filamentous	B-MED
fungus	I-MED
.	O
While	O
attempts	B-MED
have	O
been	O
made	O
to	O
study	B-MED
cellulose	B-MED
metabolism	I-MED
through	O
the	O
use	B-MED
of	I-MED
knock	B-MED
-	I-MED
out	I-MED
mutants	B-MED
,	O
there	O
have	O
been	O
no	O
systematic	B-MED
effort	O
to	O
characterize	B-MED
natural	B-MED
variation	B-MED
for	O
cellulose	B-MED
metabolism	I-MED
in	O
ecotypes	B-MED
adapted	B-MED
to	O
different	B-MED
habitats	B-MED
.	O
Here	O
,	O
we	O
characterized	B-MED
natural	B-MED
variation	B-MED
in	O
saccharification	B-MED
of	O
cellulose	B-MED
and	O
fermentation	B-MED
in	O
73	O
ecotypes	B-MED
and	O
89	O
laboratory	B-MED
strains	B-MED
of	O
the	O
model	B-MED
fungus	B-MED
Neurospora	B-MED
crassa	I-MED
.	O
We	O
observed	B-MED
significant	B-MED
variation	B-MED
in	O
both	O
traits	B-MED
among	O
natural	B-MED
and	O
laboratory	B-MED
generated	I-MED
populations	B-MED
,	O
with	O
some	O
elite	B-MED
strains	B-MED
performing	B-MED
better	B-MED
than	O
the	O
reference	B-MED
strain	B-MED
.	O
In	O
the	O
F1	B-MED
population	I-MED
N345	I-MED
,	O
15	O
%	O
of	O
the	O
population	B-MED
outperformed	O
both	O
parents	B-MED
with	O
the	O
top	O
performing	B-MED
strain	B-MED
having	O
10	O
%	O
improvement	B-MED
in	O
ethanol	B-MED
production	I-MED
.	O
These	O
results	B-MED
suggest	O
that	O
natural	B-MED
alleles	B-MED
can	O
be	O
exploited	O
through	O
fungal	B-MED
breeding	B-MED
for	O
developing	O
elite	B-MED
industrial	B-MED
strains	B-MED
for	O
bioethanol	B-MED
production	I-MED
.	O
Unaffected	O
twins	B-MED
discordant	I-MED
for	O
affective	B-MED
disorders	I-MED
show	O
changes	O
in	O
anterior	B-MED
callosal	I-MED
white	B-MED
matter	I-MED
microstructure	B-MED
The	O
neurobiological	B-MED
mechanisms	B-MED
mediating	O
an	O
increased	O
risk	B-MED
to	O
develop	O
affective	B-MED
disorders	I-MED
remain	O
poorly	O
understood	O
.	O
In	O
a	O
group	B-MED
of	I-MED
individuals	I-MED
with	O
a	O
family	B-MED
history	I-MED
of	O
major	B-MED
depressive	I-MED
(	O
MDD	B-MED
)	O
or	O
bipolar	B-MED
disorder	I-MED
(	O
BD	B-MED
)	O
,	O
we	O
investigated	O
the	O
microstructural	O
properties	O
of	O
white	B-MED
matter	I-MED
fiber	B-MED
tracts	I-MED
,	O
that	O
is	O
,	O
cingulum	B-MED
bundle	I-MED
,	O
uncinate	B-MED
fasciculus	I-MED
,	O
anterior	B-MED
limb	I-MED
of	I-MED
the	I-MED
internal	I-MED
capsule	I-MED
,	O
and	O
corpus	B-MED
callosum	I-MED
,	O
that	O
facilitate	O
the	O
communication	O
between	O
brain	B-MED
regions	I-MED
implicated	O
in	O
affective	B-MED
disorders	I-MED
.	O
Eighty	O
-	O
nine	O
healthy	O
mono	B-MED
-	O
or	O
dizygotic	B-MED
twins	I-MED
with	O
a	O
co	B-MED
-	I-MED
twin	I-MED
diagnosed	B-MED
with	O
MDD	B-MED
or	O
BD	B-MED
(	O
high	B-MED
-	I-MED
risk	I-MED
)	O
and	O
57	O
healthy	B-MED
twins	B-MED
with	O
a	O
co	B-MED
-	I-MED
twin	I-MED
with	O
no	B-MED
familial	I-MED
history	I-MED
of	I-MED
affective	B-MED
disorders	I-MED
(	O
low	O
-	O
risk	O
)	O
were	O
included	O
in	O
a	O
diffusion	B-MED
tensor	I-MED
imaging	I-MED
study	I-MED
.	O
The	O
high	B-MED
-	I-MED
risk	I-MED
group	I-MED
showed	O
decreased	O
fractional	B-MED
anisotropy	I-MED
(	O
FA	B-MED
)	O
,	O
a	O
measure	O
of	O
water	B-MED
diffusion	B-MED
directionality	B-MED
,	O
and	O
increased	O
radial	B-MED
diffusivity	B-MED
in	O
the	O
anterior	B-MED
region	I-MED
of	I-MED
corpus	I-MED
callosum	I-MED
compared	O
to	O
the	O
low	B-MED
-	I-MED
risk	I-MED
group	I-MED
.	O
This	O
abnormality	B-MED
was	O
not	O
associated	O
with	O
zygosity	B-MED
or	O
type	O
of	O
depressive	B-MED
disorder	I-MED
of	O
co	B-MED
-	I-MED
twin	I-MED
.	O
The	O
observed	O
decreased	O
anterior	B-MED
callosal	I-MED
fiber	I-MED
FA	B-MED
in	O
the	O
high	B-MED
-	I-MED
risk	I-MED
group	I-MED
may	O
be	O
indicative	O
of	O
a	O
compromised	O
interhemispheric	B-MED
communication	I-MED
between	O
left	B-MED
and	O
right	B-MED
frontal	I-MED
regions	I-MED
critically	O
involved	O
in	O
mood	B-MED
regulation	I-MED
.	O
Reduced	O
anterior	B-MED
callosal	I-MED
FA	B-MED
may	O
act	O
as	O
a	O
vulnerability	B-MED
marker	B-MED
for	O
affective	B-MED
disorders	I-MED
in	O
individuals	B-MED
at	O
familial	B-MED
risk	I-MED
.	O
Correlation	B-MED
between	O
the	O
histopathology	B-MED
of	O
chronic	B-MED
urticaria	I-MED
and	O
its	O
clinical	B-MED
picture	I-MED
Chronic	B-MED
urticaria	I-MED
is	O
characterized	O
by	O
transient	B-MED
,	O
pruritic	B-MED
lesions	I-MED
of	O
varying	O
sizes	B-MED
,	O
with	O
central	B-MED
pallor	B-MED
and	O
well	O
-	O
defined	O
edges	O
,	O
with	O
disease	B-MED
duration	O
longer	O
than	O
six	O
weeks	B-MED
.	O
Its	O
cellular	B-MED
infiltrate	I-MED
consists	O
of	O
neutrophils	B-MED
,	O
lymphocytes	B-MED
and	O
eosinophils	B-MED
.	O
There	O
is	O
a	O
subgroup	O
of	O
patients	B-MED
with	O
eosinophilic	B-MED
or	O
neutrophilic	B-MED
urticaria	I-MED
,	O
resistant	O
to	O
the	O
treatment	B-MED
with	O
antihistamines	B-MED
,	O
but	O
that	O
respond	O
to	O
a	O
combination	O
of	O
antihistamine	B-MED
with	O
other	O
drugs	B-MED
.	O
To	O
evaluate	O
the	O
present	O
infiltration	B-MED
in	O
chronic	B-MED
urticaria	I-MED
biopsies	B-MED
and	O
correlate	O
it	O
with	O
the	O
clinical	B-MED
disease	I-MED
activity	I-MED
and	O
response	B-MED
to	I-MED
treatment	I-MED
.	O
Forty	O
-	O
one	O
patients	B-MED
with	O
chronic	B-MED
urticaria	I-MED
were	O
classified	O
according	O
to	O
the	O
score	B-MED
of	I-MED
severity	I-MED
of	O
the	O
disease	B-MED
,	O
response	B-MED
to	I-MED
treatment	I-MED
and	O
type	O
of	O
perivascular	B-MED
infiltrate	I-MED
.	O
Inflammatory	B-MED
infiltrates	I-MED
were	O
divided	O
in	O
eosinophilic	B-MED
(	O
46.30	O
%	O
)	O
,	O
neutrophilic	B-MED
and	O
mixed	O
.	O
An	O
association	B-MED
was	O
found	O
between	O
the	O
eosinophilic	B-MED
infiltrate	I-MED
and	O
clinical	B-MED
scores	I-MED
of	O
greater	O
severity	B-MED
(	O
p	O
=	O
0.002	O
)	O
.	O
This	O
association	B-MED
shows	O
that	O
the	O
eosinophilic	B-MED
inflammatory	I-MED
infiltrates	I-MED
denote	O
high	O
clinical	B-MED
activity	I-MED
,	O
which	O
means	O
more	O
severe	B-MED
and	O
exuberant	O
clinical	B-MED
pictures	I-MED
of	O
the	O
disease	B-MED
.	O
A	O
Case	O
of	O
Acute	B-MED
Hepatitis	B-MED
E	I-MED
Infection	I-MED
in	O
a	O
Patient	B-MED
with	O
Non	B-MED
-	I-MED
Hodgkin	I-MED
Lymphoma	I-MED
Treated	B-MED
Successfully	O
with	O
Ribavirin	B-MED
We	O
present	O
the	O
case	O
of	O
a	O
man	B-MED
who	O
,	O
following	O
immunosuppressive	B-MED
treatment	I-MED
for	O
non	B-MED
-	I-MED
Hodgkin	I-MED
lymphoma	I-MED
,	O
became	O
infected	B-MED
with	O
viral	B-MED
hepatitis	I-MED
E	I-MED
E.	O
Acute	B-MED
hepatitis	B-MED
E	I-MED
virus	I-MED
infection	I-MED
should	O
be	O
considered	O
in	O
patients	B-MED
with	O
deranged	B-MED
liver	B-MED
function	I-MED
on	O
a	O
background	O
of	O
haematological	B-MED
malignancies	I-MED
or	O
immunosuppression	B-MED
,	O
even	O
without	O
travel	O
to	O
endemic	B-MED
regions	I-MED
.	O
Whilst	O
clearance	O
is	O
usually	O
spontaneous	O
in	O
immune	B-MED
-	O
competent	B-MED
individuals	B-MED
,	O
these	O
at	B-MED
-	I-MED
risk	I-MED
groups	I-MED
may	O
develop	O
a	O
more	O
complicated	O
and	O
protracted	B-MED
disease	I-MED
course	I-MED
.	O
Thus	O
awareness	O
is	O
important	O
as	O
additional	O
treatment	B-MED
with	O
ribavirin	B-MED
or	O
pegylated	B-MED
interferon	I-MED
may	O
be	O
required	O
,	O
as	O
in	O
this	O
case	O
,	O
in	O
order	O
to	O
help	O
achieve	O
eradication	B-MED
.	O
Selected	B-MED
flavonoid	B-MED
compounds	I-MED
as	O
promising	O
inhibitors	B-MED
of	O
protein	B-MED
kinase	I-MED
CK2α	B-MED
and	O
CK2α	B-MED
'	I-MED
,	O
the	O
catalytic	B-MED
subunits	I-MED
of	O
CK2	B-MED
CK2	B-MED
is	O
a	O
ubiquitous	O
protein	B-MED
kinase	I-MED
involved	O
in	O
many	O
cell	B-MED
functions	I-MED
.	O
During	O
the	O
last	O
years	B-MED
it	O
became	O
an	O
interesting	O
target	B-MED
in	O
cancer	B-MED
research	I-MED
.	O
A	O
series	O
of	O
flavonoid	B-MED
compounds	I-MED
was	O
tested	B-MED
as	O
inhibitors	B-MED
of	O
protein	B-MED
kinase	I-MED
CK2	B-MED
.	O
Several	O
substances	B-MED
were	O
found	O
to	O
be	O
highly	B-MED
active	B-MED
against	I-MED
both	O
catalytic	B-MED
subunits	I-MED
with	O
IC50	B-MED
values	B-MED
below	O
1	O
μM	O
in	O
case	O
of	O
CK2α	B-MED
'	I-MED
.	O
The	O
most	O
promising	O
inhibitor	B-MED
we	O
identified	B-MED
is	O
chrysoeriol	B-MED
with	O
IC50	B-MED
values	B-MED
of	O
250	O
and	O
34	O
nM	O
for	O
CK2α	B-MED
and	O
CK2α	B-MED
'	I-MED
,	O
respectively	O
.	O
Higher	B-MED
risk	I-MED
of	I-MED
revision	B-MED
for	O
infection	B-MED
using	O
systemic	B-MED
clindamycin	B-MED
prophylaxis	B-MED
than	O
with	O
cloxacillin	B-MED
Background	O
and	O
purpose	O
-	O
Clindamycin	B-MED
has	O
not	O
been	O
compared	O
with	O
other	O
antibiotics	B-MED
for	O
prophylaxis	B-MED
in	O
arthroplasty	B-MED
.	O
Since	O
2009	O
,	O
the	O
Swedish	B-MED
Knee	I-MED
Arthroplasty	I-MED
Register	I-MED
Knee	B-MED
Arthroplasty	I-MED
(	O
SKAR	B-MED
)	O
has	O
been	O
collecting	B-MED
information	B-MED
on	O
the	O
prophylactic	B-MED
antibiotic	I-MED
regime	I-MED
used	O
at	O
every	O
individual	B-MED
operation	B-MED
.	O
In	O
Sweden	B-MED
,	O
when	O
there	O
is	O
allergy	B-MED
to	O
penicillin	B-MED
,	O
clindamycin	B-MED
has	O
been	O
the	O
recommended	B-MED
alternative	B-MED
.	O
We	O
examined	O
whether	O
there	O
were	O
differences	O
in	O
the	O
rate	O
of	O
revision	B-MED
due	O
to	O
infection	B-MED
depending	O
on	O
which	O
antibiotic	B-MED
was	O
used	O
as	O
systemic	B-MED
prophylaxis	B-MED
.	O
Patients	B-MED
and	O
methods	O
-	O
Patients	B-MED
who	O
had	O
a	O
total	B-MED
knee	I-MED
arthroplasty	I-MED
(	O
TKA	B-MED
)	O
performed	O
due	O
to	O
osteoarthritis	B-MED
(	O
OA	B-MED
)	O
during	O
the	O
years	O
2009	O
-	O
2015	O
were	O
included	O
in	O
the	O
study	O
.	O
Information	O
on	O
which	O
antibiotic	B-MED
was	O
used	O
was	O
available	O
for	O
80,018	O
operations	B-MED
(	O
55,530	O
patients	B-MED
)	O
.	O
Survival	B-MED
statistics	I-MED
were	O
used	O
to	O
calculate	O
the	O
rate	O
of	O
revision	B-MED
due	O
to	O
infection	B-MED
until	O
the	O
end	O
of	O
2015	O
,	O
comparing	O
the	O
group	O
of	O
patients	B-MED
who	O
received	O
cloxacillin	B-MED
with	O
those	O
who	O
received	O
clindamycin	B-MED
as	O
systemic	B-MED
prophylaxis	B-MED
.	O
Results	O
-	O
Cloxacillin	B-MED
was	O
used	O
in	O
90	O
%	O
of	O
the	O
cases	O
,	O
clindamycin	B-MED
in	O
7	O
%	O
,	O
and	O
cephalosporins	B-MED
in	O
2	O
%	O
.	O
The	O
risk	O
of	O
being	O
revised	O
due	O
to	O
infection	B-MED
was	O
higher	O
when	O
clindamycin	B-MED
was	O
used	O
than	O
when	O
cloxacillin	B-MED
was	O
used	O
(	O
RR	O
=	O
1.5	O
,	O
95	O
%	O
CI	O
:	O
1.2	O
-	O
2.0	O
;	O
p	O
=	O
0.001	O
)	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
revision	B-MED
rate	O
for	O
other	O
causes	B-MED
(	O
p	O
=	O
0.2	O
)	O
.	O
Interpretation	B-MED
-	O
We	O
advise	O
that	O
patients	B-MED
reporting	O
allergic	B-MED
reaction	I-MED
to	O
penicillin	B-MED
should	O
have	O
their	O
allergic	B-MED
history	I-MED
explored	O
.	O
In	O
the	O
absence	O
of	O
a	O
clear	O
history	B-MED
of	O
type	B-MED
-	I-MED
I	I-MED
allergic	I-MED
reaction	I-MED
(	O
e.g.	O
urticaria	B-MED
,	O
anaphylaxis	B-MED
,	O
or	O
bronchospasm	B-MED
)	O
,	O
we	O
suggest	O
the	O
use	O
of	O
a	O
third	B-MED
-	I-MED
generation	I-MED
cephalosporin	I-MED
instead	O
of	O
clindamycin	B-MED
as	O
perioperative	B-MED
prophylaxis	B-MED
when	O
undergoing	O
a	O
TKR	B-MED
.	O
No	O
recommendation	B-MED
can	O
be	O
given	O
regarding	O
patients	B-MED
with	O
type-1	B-MED
allergy	I-MED
.	O
Interaction	B-MED
of	O
the	O
Antimicrobial	B-MED
Peptides	I-MED
Rhesus	B-MED
θ	I-MED
-	I-MED
Defensin	I-MED
and	O
Porcine	B-MED
Protegrin-1	B-MED
with	O
Anionic	B-MED
Phospholipid	I-MED
Monolayers	I-MED
A	O
combination	O
of	O
Langmuir	B-MED
isotherm	I-MED
,	O
Brewster	B-MED
angle	I-MED
microscopy	I-MED
(	O
BAM	B-MED
)	O
,	O
and	O
neutron	B-MED
reflectivity	I-MED
studies	I-MED
have	O
been	O
performed	O
to	O
gain	O
insight	O
into	O
the	O
effects	O
on	O
model	B-MED
bacterial	B-MED
cell	I-MED
membranes	I-MED
of	O
the	O
antimicrobial	B-MED
peptides	I-MED
,	O
Rhesus	B-MED
θ	I-MED
-	I-MED
defensin	I-MED
1	I-MED
(	O
RTD-1	B-MED
)	O
,	O
and	O
porcine	B-MED
protegrin	B-MED
1	I-MED
(	O
PG-1	B-MED
)	O
.	O
The	O
peptides	B-MED
were	O
interacted	B-MED
with	O
monolayers	B-MED
spread	O
at	O
the	O
air	B-MED
-	O
water	B-MED
interface	O
and	O
prepared	O
from	O
a	O
3:1	O
molar	O
mixture	O
of	O
phosphatidylethanolamine	B-MED
and	O
phosphatidylglycerol	B-MED
used	O
to	O
approximate	B-MED
the	O
cell	B-MED
membranes	I-MED
of	O
Gram	B-MED
positive	I-MED
bacteria	I-MED
.	O
The	O
Langmuir	B-MED
film	I-MED
balance	O
measurements	B-MED
show	O
that	O
both	O
peptides	B-MED
perturb	B-MED
the	O
lipid	B-MED
monolayers	I-MED
causing	O
an	O
increase	O
in	O
surface	B-MED
pressure	I-MED
,	O
and	O
the	O
BAM	B-MED
studies	O
show	O
that	O
each	O
results	O
in	O
the	O
formation	O
of	O
small	B-MED
domains	I-MED
within	O
the	O
lipid	B-MED
films	I-MED
,	O
around	O
5	O
μm	O
diameter	O
.	O
The	O
overall	O
change	O
in	O
monolayer	B-MED
surface	B-MED
pressure	I-MED
caused	O
by	O
PG-1	B-MED
,	O
however	O
,	O
is	O
a	O
little	O
more	O
pronounced	O
than	O
that	O
due	O
to	O
RTD-1	B-MED
(	O
+8.5	O
mN·m(-1	O
)	O
vs	O
+5.5	O
mN·m(-1	O
)	O
)	O
,	O
and	O
the	O
rate	O
of	O
its	O
initial	O
interaction	B-MED
with	O
the	O
monolayer	B-MED
is	O
a	O
little	O
more	O
rapid	O
than	O
that	O
for	O
RTD-1	B-MED
.	O
The	O
neutron	B-MED
reflectivity	I-MED
studies	I-MED
also	O
show	O
differences	O
for	O
PG-1	B-MED
and	O
RTD-1	B-MED
,	O
with	O
the	O
model	B-MED
fits	O
to	O
these	O
data	O
showing	O
that	O
the	O
more	O
amphiphilic	B-MED
PG-1	B-MED
becomes	O
fully	O
embedded	B-MED
within	O
the	O
lipid	B-MED
film	I-MED
-causing	O
an	O
extension	O
of	O
the	O
lipid	B-MED
acyl	I-MED
chains	I-MED
but	O
leaving	O
the	O
thickness	B-MED
of	O
the	O
lipid	B-MED
headgroup	I-MED
layer	I-MED
unaffected	O
-	O
while	O
RTD-1	B-MED
is	O
seen	O
to	O
insert	O
less	O
deeply	O
-	O
causing	O
the	O
same	O
extension	O
of	O
the	O
lipid	B-MED
acyl	I-MED
chains	I-MED
as	O
PG-1	B-MED
but	O
also	O
causing	O
a	O
significant	O
increase	O
in	O
thickness	B-MED
of	O
the	O
lipid	B-MED
headgroup	I-MED
layer	I-MED
.	O
The	O
various	O
differing	O
effects	O
of	O
the	O
two	O
peptides	B-MED
on	O
anionic	B-MED
lipid	I-MED
monolayers	I-MED
are	O
discussed	O
in	O
the	O
context	O
of	O
their	O
differing	O
hemolytic	B-MED
activities	I-MED
,	O
and	O
their	O
proposed	O
differing	B-MED
propensities	I-MED
to	O
form	O
transmembrane	B-MED
pores	B-MED
.	O
Integrating	O
one	B-MED
health	I-MED
in	O
national	B-MED
health	I-MED
policies	I-MED
of	O
developing	B-MED
countries	I-MED
:	O
India	B-MED
's	I-MED
lost	O
opportunities	O
Globally	B-MED
,	O
the	O
threat	B-MED
of	O
infectious	B-MED
diseases	I-MED
,	O
particularly	O
emerging	B-MED
infectious	I-MED
diseases	I-MED
,	O
originating	B-MED
at	O
the	O
human	B-MED
-	O
animal	B-MED
-	O
environment	B-MED
interface	B-MED
,	O
has	O
caught	O
health	B-MED
systems	I-MED
off	O
guard	O
.	O
With	O
forecasts	O
that	O
future	O
pathogen	B-MED
emergence	B-MED
will	O
be	O
centred	O
in	O
hotspots	O
in	O
Asia	B-MED
,	O
Africa	B-MED
,	O
and	O
Latin	B-MED
America	I-MED
,	O
the	O
need	O
to	O
prepare	O
policy	B-MED
frameworks	I-MED
that	O
can	O
combat	O
this	O
threat	B-MED
is	O
urgent	B-MED
.	O
Emergence	B-MED
of	I-MED
diseases	I-MED
such	O
as	O
avian	B-MED
influenza	I-MED
and	O
Ebola	B-MED
virus	I-MED
disease	I-MED
,	O
which	O
threatened	B-MED
social	B-MED
disruption	B-MED
,	O
have	O
established	B-MED
the	O
need	O
for	O
intersectoral	B-MED
coordination	I-MED
/	I-MED
collaboration	I-MED
.	O
These	O
events	B-MED
led	O
to	O
the	O
initiation	B-MED
of	O
establishing	B-MED
institutionalised	B-MED
collaborative	B-MED
frameworks	I-MED
in	O
India	B-MED
to	O
adopt	O
a	O
One	B-MED
Health	I-MED
approach	I-MED
to	O
disease	B-MED
prevention	I-MED
and	I-MED
control	I-MED
.	O
However	O
,	O
the	O
gains	B-MED
made	O
in	O
influenza	B-MED
control	B-MED
could	O
not	O
be	O
adapted	O
to	O
other	O
infectious	B-MED
diseases	I-MED
.	O
Intersectoral	B-MED
coordination	I-MED
was	O
briefly	O
carried	O
out	O
,	O
more	O
as	O
a	O
reactive	B-MED
response	O
to	O
threats	B-MED
.	O
The	O
systemic	B-MED
failure	B-MED
to	O
sustain	B-MED
such	O
efforts	O
have	O
therefore	O
,	O
only	O
undermined	O
a	O
coordinated	B-MED
response	B-MED
.	O
The	O
recent	O
draft	B-MED
National	B-MED
Health	I-MED
Policy	I-MED
,	O
2015	O
,	O
has	O
also	O
failed	B-MED
to	O
establish	B-MED
the	O
need	O
for	O
intersectoral	B-MED
coordination	I-MED
in	O
disease	B-MED
control	I-MED
approaches	I-MED
.	O
Neglecting	O
the	O
need	O
to	O
endorse	O
linkages	B-MED
between	O
human	B-MED
health	B-MED
,	O
animal	B-MED
health	B-MED
and	O
husbandry	B-MED
,	O
agriculture	B-MED
,	O
and	O
environmental	B-MED
sectors	B-MED
,	O
has	O
led	O
to	O
duplicative	B-MED
and	O
weak	B-MED
response	I-MED
systems	I-MED
.	O
The	O
absence	B-MED
of	O
health	B-MED
impact	I-MED
assessment	I-MED
with	O
respect	O
to	O
the	O
development	B-MED
agenda	B-MED
in	O
policies	B-MED
,	O
has	O
cast	O
negative	B-MED
effects	B-MED
on	O
the	O
health	B-MED
and	O
wellbeing	B-MED
of	I-MED
man	I-MED
,	O
animal	B-MED
,	O
and	O
the	O
environment	B-MED
.	O
Lack	B-MED
of	I-MED
attention	I-MED
to	O
building	O
core	O
capacity	B-MED
in	O
these	O
critical	B-MED
sectors	B-MED
has	O
further	O
raised	B-MED
challenges	B-MED
in	O
designing	O
and	O
deploying	B-MED
mitigation	B-MED
strategies	B-MED
.	O
With	O
developing	B-MED
countries	I-MED
like	O
India	B-MED
being	O
home	O
to	O
a	O
major	O
portion	B-MED
of	O
the	O
world	B-MED
's	I-MED
poorest	B-MED
livestock	B-MED
farmers	I-MED
,	O
the	O
absence	B-MED
of	O
a	O
policy	B-MED
discourse	B-MED
that	O
endorses	O
the	O
One	B-MED
Health	I-MED
approach	I-MED
in	O
development	B-MED
and	O
health	B-MED
policies	I-MED
is	O
a	O
major	O
hurdle	B-MED
in	O
eliminating	B-MED
poverty	B-MED
and	O
poverty	B-MED
-	O
related	B-MED
diseases	B-MED
.	O
The	O
adoption	B-MED
of	O
One	B-MED
Health	I-MED
approaches	I-MED
in	O
health	B-MED
and	O
related	O
sectoral	B-MED
policies	B-MED
is	O
a	O
critical	B-MED
policy	B-MED
requirement	O
for	O
India	B-MED
and	O
other	O
developing	B-MED
countries	I-MED
.	O
The	O
goal	O
should	O
be	O
to	O
not	O
just	O
establish	B-MED
preparedness	B-MED
plans	B-MED
,	O
but	O
also	O
to	O
encourage	B-MED
a	O
policy	B-MED
environment	I-MED
where	O
assessment	B-MED
and	O
mitigation	B-MED
of	O
downstream	B-MED
impacts	B-MED
of	O
different	O
agenda	B-MED
are	O
incorporated	B-MED
.	O
Biochemical	B-MED
studies	B-MED
of	O
amylase	B-MED
,	O
lipase	B-MED
and	O
protease	B-MED
in	O
Callosobruchus	B-MED
maculatus	I-MED
(	O
Coleoptera	B-MED
:	O
Chrysomelidae	B-MED
)	O
populations	B-MED
fed	O
with	O
Vigna	B-MED
unguiculata	I-MED
grain	B-MED
cultivated	B-MED
with	O
diazotrophic	B-MED
bacteria	I-MED
strains	I-MED
The	O
objective	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	O
the	O
enzymatic	B-MED
activity	I-MED
of	O
homogenates	B-MED
of	O
insects	B-MED
fed	O
on	O
grain	B-MED
of	O
cowpea	B-MED
,	O
Vigna	B-MED
unguiculata	I-MED
(	I-MED
L.	I-MED
)	I-MED
,	O
cultivars	B-MED
grown	O
with	O
different	O
nitrogen	B-MED
sources	O
.	O
For	O
the	O
experiment	O
we	O
used	O
aliquots	O
of	O
the	O
homogenate	B-MED
of	O
100	O
unsexed	O
adult	B-MED
insects	B-MED
,	O
emerged	O
from	O
10	O
g	O
of	O
grain	B-MED
obtained	O
from	O
four	O
cowpea	B-MED
cultivars	B-MED
:	O
'	O
BRS	B-MED
Acauã	I-MED
'	O
,	O
'	O
BRS	B-MED
Carijó	I-MED
'	O
,	O
'	O
BRS	B-MED
Pujante	I-MED
'	O
,	O
and	O
'	O
BRS	B-MED
Tapaihum	I-MED
'	O
grown	O
under	O
different	O
regimes	O
of	O
nitrogen	B-MED
sources	O
:	O
mineral	B-MED
fertilizer	B-MED
,	O
inoculation	B-MED
with	O
strains	B-MED
of	I-MED
diazotrophs	I-MED
(	O
BR	B-MED
3267	I-MED
,	O
BR	B-MED
3262	I-MED
,	O
BR	B-MED
3299	I-MED
;	O
INPA	B-MED
03	I-MED
-	I-MED
11B	I-MED
,	O
03	B-MED
-	I-MED
84	I-MED
UFLA	I-MED
,	O
as	O
well	O
as	O
the	O
control	B-MED
(	O
with	O
soil	B-MED
nitrogen	B-MED
)	O
.	O
The	O
parameters	O
evaluated	O
were	O
enzymatic	B-MED
activities	I-MED
of	O
insect	B-MED
protease	B-MED
,	O
amylase	B-MED
and	O
lipase	B-MED
and	O
the	O
starch	B-MED
content	O
of	O
the	O
grains	B-MED
.	O
There	O
were	O
differences	O
in	O
the	O
enzymatic	B-MED
activity	I-MED
of	O
amylase	B-MED
,	O
lipase	B-MED
and	O
protease	B-MED
of	O
insect	B-MED
homogenate	B-MED
according	O
to	O
the	O
food	B-MED
source	O
.	O
A	O
lower	O
activity	B-MED
of	I-MED
the	I-MED
enzyme	I-MED
amylase	B-MED
from	O
C.	B-MED
maculatus	I-MED
homogenate	B-MED
was	O
observed	O
when	O
insects	B-MED
were	O
fed	O
grain	B-MED
of	O
the	O
cultivar	B-MED
BRS	I-MED
Carijó	I-MED
.	O
A	O
lower	O
activity	B-MED
of	I-MED
lipase	I-MED
enzyme	I-MED
from	O
C.	B-MED
maculatus	I-MED
homogenate	B-MED
was	O
observed	O
when	O
the	O
insects	B-MED
fed	O
on	O
grain	B-MED
from	O
the	O
interaction	O
of	O
the	O
cultivar	B-MED
Tapaihum	I-MED
inoculated	O
with	O
BR	B-MED
3262	I-MED
diazotrophs	I-MED
.	O
The	O
lowest	O
proteolytic	B-MED
activity	I-MED
was	O
observed	O
in	O
homogenate	B-MED
of	O
insects	B-MED
fed	O
on	O
interaction	O
of	O
'	O
BRS	B-MED
Carijó	I-MED
'	O
inoculated	O
with	O
BR	B-MED
3262	I-MED
diazotroph	I-MED
s.	O
Starch	B-MED
content	O
correlated	O
positively	O
with	O
the	O
amylase	B-MED
activity	I-MED
of	O
C.	B-MED
maculatus	I-MED
homogenate	B-MED
.	O
The	O
cultivar	B-MED
BRS	I-MED
Carijó	I-MED
had	O
a	O
different	O
behavior	O
from	O
the	O
other	O
cultivars	B-MED
,	O
according	O
to	O
the	O
cluster	B-MED
analysis	I-MED
.	O
Conditional	B-MED
Knockdown	B-MED
of	O
Endogenous	B-MED
MicroRNAs	B-MED
in	O
CHO	B-MED
Cells	I-MED
Using	O
TET	B-MED
-	I-MED
ON	I-MED
-	I-MED
SanDI	I-MED
Sponge	I-MED
Vectors	I-MED
MicroRNAs	B-MED
(	O
miRNAs	B-MED
)	O
are	O
small	O
,	O
noncoding	B-MED
RNAs	I-MED
of	O
about	O
22	O
nucleotides	B-MED
in	O
length	O
and	O
have	O
proven	O
to	O
be	O
useful	O
targets	B-MED
for	O
genetic	B-MED
modifications	I-MED
for	O
desirable	O
phenotype	B-MED
in	O
the	O
biotech	B-MED
industry	B-MED
.	O
The	O
use	O
of	O
constitutively	O
expressed	O
"	O
miRNA	B-MED
sponge	I-MED
"	I-MED
vectors	I-MED
in	O
which	O
multiple	O
,	O
tandem	B-MED
miRNA	I-MED
binding	B-MED
sites	I-MED
containing	O
transcripts	B-MED
are	O
transcriptionally	B-MED
regulated	I-MED
by	O
a	O
constitutive	O
promoter	B-MED
for	O
down	B-MED
regulating	I-MED
the	O
levels	O
of	O
endogenous	B-MED
microRNAs	B-MED
in	O
Chinese	B-MED
hamster	I-MED
ovary	I-MED
(	I-MED
CHO	I-MED
)	I-MED
cells	I-MED
has	O
shown	O
to	O
be	O
more	O
advantageous	O
than	O
using	O
synthetic	O
antisense	B-MED
oligonucleotides	I-MED
.	O
The	O
application	O
of	O
miRNA	B-MED
sponges	I-MED
in	O
biotechnological	B-MED
processes	B-MED
,	O
however	O
,	O
could	O
be	O
more	O
effective	B-MED
,	O
if	O
expression	B-MED
of	O
miRNA	B-MED
sponges	I-MED
could	O
be	O
tuned	O
.	O
In	O
this	O
chapter	O
,	O
we	O
present	O
a	O
method	O
for	O
the	O
generation	O
of	O
stable	O
CHO	B-MED
cell	I-MED
lines	I-MED
expressing	B-MED
a	O
TET	B-MED
-	I-MED
ON	I-MED
-	I-MED
SanDI	I-MED
-	I-MED
miRNA	I-MED
-	I-MED
sponge	I-MED
that	O
is	O
in	O
theory	O
expressed	O
only	O
in	O
the	O
presence	O
of	O
an	O
inducer	B-MED
.	O
Multitarget	B-MED
sensing	B-MED
of	I-MED
glucose	I-MED
and	O
cholesterol	B-MED
based	O
on	O
Janus	B-MED
hydrogel	I-MED
microparticles	I-MED
A	O
visualized	B-MED
sensing	B-MED
method	I-MED
for	I-MED
glucose	I-MED
and	O
cholesterol	B-MED
was	O
developed	O
based	O
on	O
the	O
hemispheres	O
of	O
the	O
same	O
Janus	B-MED
hydrogel	I-MED
microparticles	I-MED
.	O
Single	O
-	O
phase	O
and	O
Janus	B-MED
hydrogel	I-MED
microparticles	I-MED
were	O
both	O
generated	O
using	O
a	O
centrifugal	B-MED
microfluidic	B-MED
chip	I-MED
.	O
For	O
glucose	B-MED
sensing	I-MED
,	O
concanavalin	B-MED
A	I-MED
and	O
fluorescein	B-MED
labeled	I-MED
dextran	I-MED
used	O
for	O
competitive	B-MED
binding	I-MED
assay	I-MED
were	O
encapsulated	B-MED
in	O
alginate	B-MED
microparticles	B-MED
,	O
and	O
the	O
fluorescence	B-MED
of	O
the	O
microparticles	B-MED
was	O
positively	B-MED
correlated	B-MED
with	O
glucose	B-MED
concentration	B-MED
.	O
For	O
cholesterol	B-MED
sensing	I-MED
,	O
the	O
microparticles	B-MED
embedded	O
with	O
γ	B-MED
-	I-MED
Fe2O3	I-MED
nanoparticles	I-MED
were	O
used	O
as	O
catalyst	B-MED
for	O
the	O
oxidation	B-MED
of	O
3,3',5,5'-Tetramethylbenzidine	B-MED
by	O
H2O2	B-MED
,	O
an	O
enzymatic	B-MED
hydrolysis	B-MED
product	B-MED
of	O
cholesterol	B-MED
.	O
And	O
the	O
color	B-MED
transition	B-MED
was	O
more	O
sensitive	B-MED
in	O
the	O
microparticles	B-MED
than	O
in	O
solutions	B-MED
,	O
indicating	O
the	O
microparticles	B-MED
are	O
more	O
applicable	B-MED
for	O
visualized	B-MED
determination	B-MED
.	O
Furthermore	O
,	O
Janus	B-MED
microparticles	I-MED
were	O
employed	B-MED
for	O
multitarget	B-MED
sensing	B-MED
in	O
the	O
two	O
hemespheres	O
,	O
and	O
glucose	B-MED
and	O
cholesterol	B-MED
were	O
detected	B-MED
within	O
the	O
same	O
microparticles	B-MED
without	O
obvious	O
interference	B-MED
.	O
Besides	O
,	O
the	O
particles	B-MED
could	O
be	O
manipulated	O
by	O
an	O
external	B-MED
magnetic	B-MED
field	I-MED
.	O
The	O
glucose	B-MED
and	O
cholesterol	B-MED
levels	I-MED
were	O
measured	B-MED
in	O
human	B-MED
serum	B-MED
utilizing	O
the	O
microparticles	B-MED
,	O
which	O
confirmed	B-MED
the	O
potential	B-MED
application	O
of	O
the	O
microparticles	B-MED
in	O
real	O
sample	B-MED
detection	B-MED
.	O
Air	B-MED
tamponade	B-MED
of	O
the	O
heart	B-MED
Pneumopericardium	B-MED
is	O
a	O
rare	B-MED
disease	I-MED
defined	O
as	O
the	O
presence	B-MED
of	O
air	B-MED
or	O
gas	B-MED
in	O
the	O
pericardial	B-MED
sac	I-MED
.	O
Among	O
the	O
etiological	B-MED
factors	I-MED
,	O
the	O
following	O
stand	O
out	O
:	O
chest	B-MED
trauma	I-MED
,	O
barotrauma	B-MED
,	O
air	B-MED
-containing	O
fistulas	B-MED
between	O
the	O
pericardium	B-MED
and	O
the	O
surrounding	B-MED
structures	B-MED
,	O
secondary	B-MED
gas	I-MED
production	I-MED
by	O
microorganisms	B-MED
growing	O
in	O
the	O
pericardial	B-MED
sac	I-MED
,	O
and	O
iatrogenic	B-MED
factors	B-MED
.	O
Until	O
now	O
,	O
spontaneous	B-MED
pneumopericardium	B-MED
has	O
been	O
considered	B-MED
a	O
harmless	B-MED
and	O
temporary	B-MED
state	B-MED
,	O
but	O
a	O
review	B-MED
of	I-MED
clinical	B-MED
cases	I-MED
indicates	O
that	O
the	O
presence	B-MED
of	O
air	B-MED
in	O
the	O
pericardium	B-MED
can	O
lead	O
to	O
cardiac	B-MED
tamponade	I-MED
and	O
life	B-MED
-	I-MED
threatening	I-MED
hemodynamic	B-MED
disturbances	B-MED
.	O
We	O
present	B-MED
the	O
case	O
of	O
an	O
80-	O
year	B-MED
-	I-MED
old	I-MED
patient	B-MED
with	O
a	O
chronic	B-MED
bronchopericardial	B-MED
fistula	B-MED
,	O
who	O
suffered	O
from	O
a	O
cardiac	B-MED
arrest	I-MED
due	O
to	O
air	B-MED
tamponade	B-MED
of	O
the	O
heart	B-MED
.	O
Melatonin	B-MED
and	O
nitric	B-MED
oxide	I-MED
regulate	B-MED
sunflower	B-MED
seedling	B-MED
growth	I-MED
under	O
salt	B-MED
stress	I-MED
accompanying	O
differential	O
expression	B-MED
of	O
Cu	B-MED
/	I-MED
Zn	I-MED
SOD	I-MED
and	O
Mn	B-MED
SOD	I-MED
Salinity	B-MED
results	I-MED
in	O
significant	B-MED
reduction	I-MED
in	O
sunflower	B-MED
(	O
Helianthus	B-MED
annuus	I-MED
L.	I-MED
)	O
seedling	B-MED
growth	I-MED
and	O
excessive	O
generation	O
of	O
reactive	B-MED
oxygen	I-MED
species	I-MED
(	O
ROS	B-MED
)	O
.	O
Present	O
work	O
highlights	O
the	O
possible	O
role	O
of	O
melatonin	B-MED
as	O
an	O
antioxidant	B-MED
through	O
its	O
interaction	O
with	O
nitric	B-MED
oxide	I-MED
(	O
NO	B-MED
)	O
,	O
and	O
as	O
an	O
early	O
and	O
long	O
distance	O
NaCl	B-MED
-	I-MED
stress	I-MED
sensing	O
signaling	B-MED
molecule	I-MED
in	O
seedling	B-MED
cotyledons	B-MED
.	O
Exogenous	B-MED
melatonin	B-MED
(	O
15µM)±	O
NaCl	B-MED
(	O
120mM	O
)	O
inhibit	B-MED
seedling	B-MED
growth	I-MED
,	O
which	O
is	O
also	O
correlated	O
with	O
NO	B-MED
availability	O
,	O
accumulation	O
of	O
potential	B-MED
superoxide	I-MED
anion	I-MED
(	O
O2(•-	B-MED
)	I-MED
)	O
and	O
peroxynitrite	B-MED
anion	I-MED
(	O
ONOO(-	B-MED
)	I-MED
)	O
,	O
extent	O
of	O
tyrosine	B-MED
-	I-MED
nitration	I-MED
of	O
proteins	B-MED
,	O
spatial	B-MED
localization	I-MED
and	O
activity	B-MED
of	I-MED
superoxide	I-MED
dismutase	I-MED
(	O
SOD	B-MED
)	O
isoforms	B-MED
.	O
NO	B-MED
acts	O
as	O
a	O
positive	O
modulator	O
of	O
melatonin	B-MED
accumulation	O
in	O
seedling	B-MED
cotyledons	B-MED
as	O
a	O
long	B-MED
-	I-MED
distance	I-MED
signaling	I-MED
response	I-MED
.	O
Modulation	B-MED
of	I-MED
superoxide	I-MED
anion	I-MED
and	O
peroxynitrite	B-MED
anion	I-MED
content	O
by	O
melatonin	B-MED
highlights	O
its	O
crucial	O
role	O
in	O
combating	O
deleterious	O
effects	O
of	O
ROS	B-MED
and	O
reactive	B-MED
nitrogen	I-MED
species	I-MED
(	O
RNS	O
)	O
.	O
Present	O
findings	O
provide	O
evidence	O
for	O
an	O
interaction	O
between	O
melatonin	B-MED
and	O
NO	B-MED
in	O
their	O
effect	O
on	O
seedling	B-MED
growth	I-MED
under	O
salt	B-MED
stress	I-MED
accompanying	I-MED
differential	O
modulation	O
of	O
two	O
SOD	B-MED
isoforms	B-MED
,	O
i.e.	O
Cu	B-MED
/	I-MED
Zn	I-MED
SOD	I-MED
and	O
Mn	B-MED
SOD	I-MED
.	O
Contralateral	B-MED
Superior	B-MED
Cerebellar	I-MED
Artery	I-MED
Syndrome	I-MED
:	O
A	O
Consequence	B-MED
of	I-MED
Brain	B-MED
Herniation	I-MED
Vascular	B-MED
compromise	B-MED
is	O
a	O
well	O
-	O
known	O
consequence	B-MED
of	I-MED
brain	B-MED
herniation	I-MED
syndromes	B-MED
.	O
Transtentorial	B-MED
brain	B-MED
herniation	I-MED
most	O
often	O
involves	O
posterior	B-MED
cerebral	I-MED
arteries	I-MED
.	O
However	O
,	O
isolated	B-MED
involvement	B-MED
of	O
contralateral	B-MED
superior	B-MED
cerebellar	I-MED
artery	I-MED
(	O
SCA	B-MED
)	O
during	O
unilateral	B-MED
impending	B-MED
brain	B-MED
herniation	I-MED
is	O
reported	B-MED
only	O
once	O
and	O
we	O
present	O
another	O
case	O
of	O
this	O
exceedingly	O
rare	B-MED
entity	B-MED
.	O
A	O
24	O
-	O
year	O
-	O
old	O
man	B-MED
was	O
referred	O
to	O
us	O
with	O
impending	B-MED
herniation	B-MED
due	O
to	O
a	O
multiloculated	B-MED
hydrocephalus	B-MED
,	O
and	O
during	O
the	O
course	B-MED
of	I-MED
illness	I-MED
,	O
he	O
developed	O
an	O
isolated	B-MED
SCA	B-MED
ischemia	B-MED
in	O
the	O
opposite	O
side	O
of	O
the	O
most	O
dilated	B-MED
entrapped	O
horn	B-MED
.	O
In	O
the	O
current	O
article	B-MED
we	O
discuss	O
the	O
probable	O
pathophysiologic	B-MED
mechanisms	B-MED
of	O
this	O
phenomenon	B-MED
,	O
as	O
well	O
as	O
recommending	O
more	O
inclusive	B-MED
brain	B-MED
studies	O
in	O
cases	O
suspected	B-MED
of	O
Kernohan	B-MED
-	I-MED
Woltman	I-MED
notch	I-MED
phenomenon	I-MED
in	O
unilateral	B-MED
brain	B-MED
herniation	I-MED
.	O
The	O
rationale	B-MED
for	O
this	O
commentary	B-MED
is	O
that	O
contralateral	B-MED
SCA	B-MED
transient	B-MED
ischemia	I-MED
or	O
infarct	B-MED
might	O
be	O
the	O
underdiagnosed	B-MED
underlying	O
pathomechanism	B-MED
of	O
ipsilateral	B-MED
hemiparesis	B-MED
occurring	O
in	O
many	O
cases	O
of	O
this	O
somehow	O
vague	B-MED
phenomenon	B-MED
.	O
Vaccination	B-MED
of	O
piglets	B-MED
at	O
2	O
and	O
3	O
weeks	O
of	O
age	O
with	O
Ingelvac	B-MED
PRRSFLEX	I-MED
®	I-MED
EU	I-MED
provides	O
protection	B-MED
against	O
heterologous	B-MED
field	O
challenge	O
in	O
the	O
face	O
of	O
homologous	B-MED
maternally	B-MED
derived	I-MED
antibodies	I-MED
Due	O
to	O
difficulties	O
in	O
eradicating	B-MED
porcine	B-MED
reproductive	I-MED
and	I-MED
respiratory	I-MED
syndrome	I-MED
(	O
PRRS	B-MED
)	O
linked	O
to	O
biosecurity	O
challenges	O
,	O
transmission	B-MED
of	I-MED
the	I-MED
virus	I-MED
and	O
the	O
lack	O
of	O
efficient	B-MED
DIVA	B-MED
vaccines	I-MED
,	O
successful	B-MED
control	B-MED
of	O
PRRS	B-MED
requires	O
a	O
combination	O
of	O
strict	O
management	B-MED
measures	I-MED
and	O
vaccination	B-MED
of	O
both	O
sows	B-MED
and	O
piglets	B-MED
.	O
The	O
present	O
study	B-MED
aimed	O
to	O
assess	B-MED
the	O
efficacy	B-MED
of	O
a	O
recently	O
developed	O
MLV	B-MED
vaccine	I-MED
(	O
Ingelvac	B-MED
PRRSFLEX	I-MED
®	I-MED
EU	I-MED
)	O
in	O
piglets	B-MED
at	O
2	O
and	O
3	O
-	O
weeks	O
of	O
age	O
in	O
the	O
presence	B-MED
of	O
homologous	B-MED
maternally	B-MED
derived	I-MED
antibodies	I-MED
as	O
the	O
dams	O
were	O
vaccinated	B-MED
with	O
the	O
same	O
vaccine	B-MED
strain	I-MED
(	O
ReproCyc	B-MED
®	I-MED
PRRS	I-MED
EU	I-MED
)	O
.	O
The	O
study	B-MED
was	O
carried	O
out	O
on	O
a	O
Hungarian	B-MED
farrow	I-MED
to	O
finish	O
farm	B-MED
naturally	B-MED
infected	I-MED
with	O
PRRSv	B-MED
.	O
The	O
study	B-MED
was	O
designed	O
as	O
a	O
blind	B-MED
,	O
placebo	B-MED
controlled	I-MED
side	O
by	O
side	O
trial	O
.	O
ORF5	B-MED
sequence	B-MED
similarity	I-MED
of	O
the	O
vaccine	B-MED
strain	I-MED
and	O
the	O
resident	B-MED
field	I-MED
strain	I-MED
was	O
87.8	O
%	O
.	O
PRRS	B-MED
specific	O
real	B-MED
-	I-MED
time	I-MED
quantitative	I-MED
PCR	I-MED
was	O
performed	O
from	O
serum	B-MED
samples	I-MED
to	O
measure	B-MED
both	O
the	O
viral	B-MED
load	I-MED
and	O
the	O
frequency	O
of	O
virus	B-MED
positive	I-MED
animals	B-MED
.	O
At	O
the	O
time	O
of	O
the	O
natural	B-MED
infection	I-MED
observed	B-MED
in	O
the	O
control	B-MED
group	I-MED
at	O
10	O
-	O
12	O
weeks	O
of	O
age	O
,	O
the	O
number	O
of	O
viraemic	B-MED
animals	B-MED
did	O
not	O
increase	O
significantly	O
in	O
the	O
vaccinated	B-MED
group	O
.	O
To	O
understand	O
the	O
infection	B-MED
dynamics	B-MED
,	O
positive	B-MED
PCR	B-MED
samples	B-MED
with	O
low	O
Ct	O
values	O
were	O
sequenced	O
(	O
ORF5	B-MED
)	O
and	O
the	O
data	B-MED
analysis	I-MED
indicated	B-MED
the	O
circulation	B-MED
of	O
wild	O
type	O
virus	O
in	O
both	O
groups	O
,	O
however	O
wild	O
type	O
virus	B-MED
was	O
only	O
found	O
in	O
non	O
-	O
vaccinated	O
animals	O
.	O
Our	O
data	B-MED
indicate	O
that	O
piglets	B-MED
vaccinated	B-MED
at	O
as	O
early	O
as	O
2	O
weeks	O
of	O
age	O
with	O
Ingelvac	B-MED
PRRSFLEX	I-MED
®	I-MED
EU	I-MED
were	O
protected	O
both	O
in	O
terms	O
of	O
proportion	B-MED
of	O
viraemic	B-MED
animals	B-MED
and	O
viraemia	B-MED
levels	O
.	O
It	O
has	O
to	O
be	O
highlighted	O
that	O
these	O
results	O
were	O
achieved	O
in	O
piglets	B-MED
with	O
high	O
levels	O
of	O
homologous	B-MED
maternally	B-MED
derived	I-MED
antibodies	I-MED
(	O
MDA	B-MED
)	O
at	O
the	O
time	O
of	O
vaccination	B-MED
.	O
Effects	O
of	O
display	B-MED
curvature	B-MED
,	O
display	B-MED
zone	B-MED
,	O
and	O
task	B-MED
duration	B-MED
on	O
legibility	B-MED
and	O
visual	B-MED
fatigue	I-MED
during	O
visual	B-MED
search	I-MED
task	I-MED
This	O
study	O
examined	O
the	O
effects	O
of	O
display	B-MED
curvature	B-MED
(	O
400	O
,	O
600	O
,	O
1200	O
mm	O
,	O
and	O
flat	B-MED
)	O
,	O
display	B-MED
zone	B-MED
(	O
5	O
zones	B-MED
)	O
,	O
and	O
task	B-MED
duration	B-MED
(	O
15	O
and	O
30	O
min	O
)	O
on	O
legibility	B-MED
and	O
visual	B-MED
fatigue	I-MED
.	O
Each	O
participant	B-MED
completed	O
two	O
15	O
-	O
min	O
visual	B-MED
search	I-MED
task	I-MED
sets	O
at	O
each	O
curvature	B-MED
setting	B-MED
.	O
The	O
600	O
-	O
mm	O
and	O
1200	O
-	O
mm	O
settings	B-MED
yielded	O
better	O
results	O
than	O
the	O
flat	B-MED
setting	B-MED
in	O
terms	O
of	O
legibility	B-MED
and	O
perceived	O
visual	B-MED
fatigue	I-MED
.	O
Relative	O
to	O
the	O
corresponding	O
centre	B-MED
zone	B-MED
,	O
the	O
outermost	O
zones	B-MED
of	O
the	O
1200	O
-	O
mm	O
and	O
flat	B-MED
settings	B-MED
showed	O
a	O
decrease	O
of	O
8%-37	O
%	O
in	O
legibility	B-MED
,	O
whereas	O
those	O
of	O
the	O
flat	B-MED
setting	B-MED
showed	O
an	O
increase	B-MED
of	O
26%-45	O
%	O
in	O
perceived	B-MED
visual	B-MED
fatigue	I-MED
.	O
Across	O
curvature	B-MED
s	O
,	O
legibility	B-MED
decreased	B-MED
by	O
2%-8	O
%	O
,	O
whereas	O
perceived	B-MED
visual	B-MED
fatigue	I-MED
increased	B-MED
by	O
22	O
%	O
during	O
the	O
second	O
task	B-MED
set	I-MED
.	O
The	O
two	O
task	B-MED
sets	I-MED
induced	O
an	O
increase	B-MED
of	O
102	O
%	O
in	O
the	O
eye	B-MED
complaint	I-MED
score	I-MED
and	O
a	O
decrease	O
of	O
0.3	O
Hz	O
in	O
the	O
critical	B-MED
fusion	I-MED
frequency	I-MED
,	O
both	O
of	O
which	O
indicated	O
an	O
increase	B-MED
in	O
visual	B-MED
fatigue	I-MED
.	O
In	O
summary	O
,	O
a	O
curvature	B-MED
of	O
around	O
600	O
mm	O
,	O
central	B-MED
display	B-MED
zones	B-MED
,	O
and	O
frequent	O
breaks	B-MED
are	O
recommended	O
to	O
improve	B-MED
legibility	B-MED
and	O
reduce	O
visual	B-MED
fatigue	I-MED
.	O
Socioeconomic	B-MED
Predictors	B-MED
of	O
Adherence	B-MED
Behavior	I-MED
Among	O
HIV	B-MED
-	I-MED
Positive	I-MED
Patients	B-MED
Receiving	B-MED
Antiretroviral	B-MED
Therapy	I-MED
in	O
Selangor	B-MED
,	O
Malaysia	B-MED
Medication	B-MED
adherence	I-MED
remains	O
a	O
critical	B-MED
link	O
between	O
the	O
prescribed	B-MED
ART	B-MED
regimen	B-MED
and	O
treatment	B-MED
outcome	I-MED
.	O
Several	B-MED
factors	B-MED
may	O
influence	B-MED
adherence	B-MED
behavior	I-MED
.	O
This	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
aimed	B-MED
to	O
highlight	O
socioeconomic	B-MED
predictors	B-MED
of	O
adherence	B-MED
behavior	I-MED
among	O
a	O
cohort	B-MED
of	O
242	O
adult	B-MED
Malaysian	B-MED
patients	B-MED
receiving	B-MED
antiretroviral	B-MED
therapy	I-MED
in	O
Hospital	B-MED
Sungai	I-MED
Buloh	I-MED
,	O
Malaysia	B-MED
,	O
where	O
they	O
were	O
enrolled	O
in	O
a	O
parent	O
study	O
(	O
single	B-MED
-	I-MED
blinded	I-MED
randomized	B-MED
controlled	I-MED
trial	I-MED
)	O
between	O
January	B-MED
and	O
December	B-MED
2014	O
.	O
Statistical	B-MED
analysis	I-MED
of	O
secondary	B-MED
data	I-MED
on	O
adherence	B-MED
behavior	I-MED
and	O
sociodemographic	B-MED
characteristics	I-MED
of	O
the	O
patients	B-MED
revealed	B-MED
mean	B-MED
age	I-MED
of	O
33.4	O
years	B-MED
and	O
ranged	B-MED
from	O
18	O
to	O
64	O
years	B-MED
;	O
88.8	O
%	O
were	O
males	B-MED
.	O
A	O
total	O
of	O
224	O
(	O
93	O
%	O
)	O
patients	B-MED
who	O
completed	O
6	O
months	O
'	O
adherence	B-MED
assessment	I-MED
were	O
included	B-MED
in	O
the	O
model	O
.	O
Of	O
these	O
,	O
135	O
(	O
60.3	O
%	O
)	O
achieved	B-MED
optimal	B-MED
adherence	B-MED
.	O
Multivariate	B-MED
binary	I-MED
logistic	I-MED
regression	I-MED
analysis	I-MED
revealed	B-MED
that	O
patient	B-MED
's	I-MED
income	B-MED
and	O
ethnicity	B-MED
were	O
significant	B-MED
predictors	B-MED
of	O
adherence	B-MED
behavior	I-MED
.	O
This	O
may	O
be	O
valuable	O
for	O
targeted	B-MED
programmatic	B-MED
interventions	I-MED
to	O
further	O
enhance	B-MED
successful	B-MED
treatment	I-MED
outcomes	B-MED
among	O
the	O
target	B-MED
population	I-MED
.	O
Structural	B-MED
and	I-MED
tribometric	I-MED
characterization	I-MED
of	O
biomimetically	O
inspired	O
synthetic	O
"	O
insect	B-MED
adhesives	B-MED
"	O
Background	O
:	O
Based	O
on	O
previous	O
chemical	B-MED
analyses	I-MED
of	O
insect	B-MED
tarsal	B-MED
adhesives	B-MED
,	O
we	O
prepared	O
12	O
heterogeneous	B-MED
synthetic	B-MED
emulsions	B-MED
mimicking	O
the	O
polar	B-MED
/	I-MED
non	I-MED
-	I-MED
polar	I-MED
principle	I-MED
,	O
analysed	O
their	O
microscopical	B-MED
structure	I-MED
and	O
tested	O
their	O
adhesive	B-MED
,	O
frictional	B-MED
,	O
and	O
rheological	B-MED
properties	I-MED
.	O
Results	O
:	O
The	O
prepared	B-MED
emulsions	B-MED
varied	O
in	O
their	O
consistency	B-MED
from	O
solid	B-MED
rubber	B-MED
-	I-MED
like	I-MED
,	O
over	O
soft	B-MED
elastic	B-MED
,	O
to	O
fluid	B-MED
(	O
watery	B-MED
or	O
oily	B-MED
)	O
.	O
With	O
droplet	B-MED
sizes	I-MED
>	O
100	O
nm	O
,	O
all	O
the	O
emulsions	B-MED
belonged	O
to	O
the	O
common	O
type	O
of	O
macroemulsions	B-MED
.	O
The	O
emulsions	B-MED
of	O
the	O
first	B-MED
generation	I-MED
generally	O
showed	O
broader	O
droplet	B-MED
-	I-MED
size	I-MED
ranges	O
compared	O
with	O
the	O
second	B-MED
generation	I-MED
,	O
especially	O
when	O
less	O
defined	O
components	B-MED
such	O
as	O
petrolatum	B-MED
or	O
waxes	B-MED
were	O
present	O
in	O
the	O
lipophilic	B-MED
fraction	B-MED
of	O
the	O
first	B-MED
generation	I-MED
of	O
emulsions	B-MED
.	O
Some	O
of	O
the	O
prepared	B-MED
emulsions	B-MED
showed	O
a	O
yield	B-MED
point	I-MED
and	O
were	O
Bingham	B-MED
fluids	I-MED
.	O
Tribometric	B-MED
adhesion	I-MED
was	O
tested	O
via	O
probe	B-MED
tack	I-MED
tests	I-MED
.	O
Compared	O
with	O
the	O
"	O
second	B-MED
generation	I-MED
"	O
(	O
containing	O
less	O
viscous	B-MED
components	B-MED
)	O
,	O
the	O
"	O
first	B-MED
generation	I-MED
"	O
emulsions	B-MED
were	O
much	O
more	B-MED
adhesive	I-MED
(	O
31	O
-	O
93	O
mN	O
)	O
,	O
a	O
finding	O
attributable	O
to	O
their	O
highly	O
viscous	B-MED
components	B-MED
,	O
i.e.	O
,	O
wax	B-MED
,	O
petrolatum	B-MED
,	O
gelatin	B-MED
and	O
poly(vinyl	B-MED
alcohol	I-MED
)	I-MED
.	O
In	O
the	O
second	B-MED
generation	I-MED
emulsions	B-MED
,	O
we	O
attained	O
much	O
lower	O
adhesivenesses	B-MED
,	O
ranging	O
between	O
1	O
-	O
18	O
mN.	O
The	O
adhesive	B-MED
performance	B-MED
was	O
drastically	O
reduced	B-MED
in	O
the	O
emulsions	B-MED
that	O
contained	O
albumin	B-MED
as	O
the	O
protein	B-MED
component	I-MED
or	O
that	O
lacked	O
protein	B-MED
.	O
Tribometric	B-MED
shear	I-MED
tests	I-MED
were	O
performed	O
at	O
moderate	O
normal	B-MED
loads	I-MED
.	O
Our	O
measured	O
friction	B-MED
forces	I-MED
(	O
4	O
-	O
93	O
mN	O
in	O
the	O
first	O
and	O
0.1	O
-	O
5.8	O
mN	O
in	O
the	O
second	B-MED
generation	I-MED
emulsions	B-MED
)	O
were	O
comparatively	O
low	O
.	O
Differences	B-MED
in	O
shear	B-MED
performance	B-MED
were	O
related	O
to	O
the	O
chemical	B-MED
composition	I-MED
and	O
emulsion	B-MED
structure	B-MED
.	O
Conclusion	O
:	O
By	O
varying	O
their	O
chemical	B-MED
composition	I-MED
,	O
synthetic	O
heterogeneous	B-MED
adhesive	B-MED
emulsions	B-MED
can	O
be	O
adjusted	O
to	O
have	O
diverse	O
consistencies	B-MED
and	O
are	O
able	O
to	O
mimic	O
certain	O
rheological	B-MED
and	O
tribological	B-MED
properties	I-MED
of	O
natural	B-MED
tarsal	B-MED
insect	B-MED
adhesives	B-MED
.	O
Gelsolin	B-MED
in	O
Onychophora	B-MED
and	O
Tardigrada	B-MED
with	O
notes	O
on	O
its	O
variability	B-MED
in	O
the	O
Ecdysozoa	B-MED
Rearrangements	B-MED
of	O
the	O
filamentous	B-MED
actin	I-MED
network	I-MED
involve	O
a	O
broad	O
range	B-MED
of	O
actin	B-MED
binding	I-MED
proteins	I-MED
.	O
Among	O
these	O
,	O
the	O
gelsolin	B-MED
proteins	I-MED
sever	O
actin	B-MED
filaments	I-MED
,	O
cap	O
their	O
fast	B-MED
growing	I-MED
end	O
and	O
nucleate	B-MED
actin	B-MED
assembly	I-MED
in	O
a	O
calcium	B-MED
-	O
dependent	B-MED
manner	O
.	O
Here	O
,	O
we	O
focus	O
on	O
the	O
gelsolin	B-MED
of	O
the	O
onychophoran	B-MED
Peripatoides	B-MED
novaezealandiae	I-MED
and	O
the	O
eutardigrade	B-MED
Hypsibius	B-MED
dujardini	I-MED
.	O
From	O
the	O
cDNA	B-MED
of	O
P.	B-MED
novaezealandiae	I-MED
we	O
obtained	B-MED
the	O
complete	O
coding	B-MED
sequence	I-MED
with	O
an	O
open	B-MED
reading	I-MED
frame	I-MED
of	O
2178	O
bp	B-MED
.	O
It	O
encodes	B-MED
a	O
protein	B-MED
of	O
726	O
amino	B-MED
acids	I-MED
with	O
a	O
calculated	B-MED
molecular	B-MED
mass	I-MED
of	O
82,610.9Da	O
and	O
a	O
pI	O
of	O
5.57	O
.	O
This	O
sequence	B-MED
is	O
comprised	B-MED
of	O
six	O
segments	B-MED
(	O
S1	O
-	O
S6	O
)	O
.	O
However	O
,	O
analysis	B-MED
of	O
data	B-MED
from	O
TardiBase	B-MED
reveals	B-MED
that	O
the	O
gelsolin	B-MED
of	O
the	O
eutardigrade	B-MED
Hypsibius	B-MED
dujardini	I-MED
has	O
only	O
three	O
segments	B-MED
(	O
S1	O
-	O
S3	O
)	O
.	O
The	O
coding	B-MED
sequence	I-MED
consist	O
of	O
1119	O
bp	B-MED
for	O
373	O
amino	B-MED
acids	I-MED
with	O
a	O
calculated	B-MED
molecular	B-MED
mass	I-MED
of	O
42,440.95Da	O
and	O
a	O
pI	O
of	O
6.17	O
.	O
The	O
Peripatoides	B-MED
and	O
Hypsibius	B-MED
gelsolin	B-MED
revealed	B-MED
both	O
conserved	B-MED
binding	B-MED
motifs	I-MED
for	O
G	B-MED
-	I-MED
actin	I-MED
,	O
F	B-MED
-	I-MED
actin	I-MED
and	O
phosphatidylinositol	B-MED
4,5	I-MED
-	I-MED
bisphosphate	I-MED
(	O
PIP2	B-MED
)	O
,	O
along	O
with	O
a	O
full	O
set	O
of	O
type-1	B-MED
and	O
type-2	B-MED
Ca(2	B-MED
+	I-MED
)	I-MED
-	O
binding	B-MED
sites	I-MED
which	O
could	O
result	B-MED
in	O
the	O
binding	B-MED
of	O
eight	O
and	O
four	O
calcium	B-MED
ions	I-MED
,	O
respectively	O
.	O
Both	O
gelsolin	B-MED
proteins	I-MED
lack	B-MED
a	O
C	B-MED
-	I-MED
terminal	I-MED
latch	B-MED
-	I-MED
helix	I-MED
indicating	O
a	O
more	O
rapid	B-MED
activation	B-MED
in	O
the	O
submicromolar	O
Ca(2	B-MED
+	I-MED
)	I-MED
range	I-MED
.	O
We	O
suggest	O
that	O
a	O
gelsolin	B-MED
with	O
three	O
segments	B-MED
was	O
present	B-MED
in	O
the	O
last	O
common	O
ancestor	B-MED
of	O
the	O
ecdysozoan	B-MED
clade	O
Panarthropoda	B-MED
(	O
Onychophora	B-MED
,	O
Tardigrada	B-MED
,	O
Arthropoda	B-MED
)	O
,	O
primarily	B-MED
because	O
the	O
gelsolin	B-MED
of	O
all	O
non	O
-	O
Ecdysozoa	O
studied	B-MED
so	O
far	O
(	O
except	O
Chordata	B-MED
)	O
reveals	B-MED
this	O
number	O
of	O
segments	B-MED
.	O
Mapping	B-MED
of	O
our	O
molecular	B-MED
data	I-MED
onto	O
a	O
well	B-MED
-	I-MED
established	I-MED
phylogeny	B-MED
revealed	B-MED
that	O
the	O
number	O
of	O
gelsolin	B-MED
segments	B-MED
does	O
not	O
correlate	B-MED
with	O
the	O
phylogenetic	B-MED
lineage	B-MED
but	O
rather	O
with	O
particular	O
functional	B-MED
demands	O
to	O
alter	B-MED
the	O
kinetics	B-MED
of	O
actin	B-MED
polymerization	I-MED
.	O
Zebrafish	B-MED
akt2	B-MED
is	O
essential	B-MED
for	O
survival	B-MED
,	O
growth	B-MED
,	O
bone	B-MED
development	I-MED
,	O
and	O
glucose	B-MED
homeostasis	I-MED
As	O
one	O
of	O
three	O
akt	B-MED
isoforms	B-MED
,	O
akt2	B-MED
plays	O
a	O
key	O
role	B-MED
in	O
the	O
regulation	B-MED
of	O
widely	O
divergent	O
cellular	B-MED
processes	I-MED
in	O
mammals	B-MED
.	O
However	O
,	O
its	O
role	B-MED
and	O
underlying	O
mechanisms	B-MED
in	O
zebrafish	B-MED
remain	O
largely	O
unknown	B-MED
.	O
To	O
elucidate	O
the	O
function	B-MED
of	O
akt2	B-MED
in	O
zebrafish	B-MED
,	O
we	O
generated	B-MED
zebrafish	B-MED
lacking	B-MED
akt2	B-MED
gene	I-MED
via	O
CRISPR	B-MED
/	I-MED
Cas9	I-MED
technology	B-MED
.	O
Akt2	B-MED
-	O
null	B-MED
zebrafish	B-MED
exhibit	O
partial	O
lethality	B-MED
and	O
severe	B-MED
growth	B-MED
deficiency	B-MED
,	O
which	O
is	O
different	O
from	O
those	O
observed	O
in	O
akt2	B-MED
-	O
null	B-MED
mice	B-MED
.	O
Furthermore	O
,	O
akt2	B-MED
-	O
null	B-MED
zebrafish	B-MED
display	B-MED
deficiency	B-MED
in	O
fin	B-MED
ray	I-MED
development	I-MED
,	O
but	O
their	O
cartilage	B-MED
is	O
not	B-MED
affected	I-MED
.	O
Similar	O
to	O
observations	B-MED
in	O
akt2	B-MED
-	O
null	B-MED
mice	B-MED
,	O
akt2	B-MED
-	O
null	B-MED
zebrafish	B-MED
display	B-MED
impaired	B-MED
glucose	B-MED
homeostasis	I-MED
.	O
However	O
,	O
in	O
contrast	O
to	O
that	O
in	O
akt2	B-MED
-	O
null	B-MED
mice	B-MED
,	O
insulin	B-MED
level	I-MED
is	O
lower	B-MED
in	O
akt2	B-MED
-	O
null	B-MED
zebrafish	B-MED
,	O
implicating	O
the	O
symptoms	B-MED
of	O
type	B-MED
I	I-MED
diabetes	I-MED
exhibited	O
in	O
akt2	B-MED
-	O
null	B-MED
zebrafish	B-MED
.	O
In	O
addition	O
,	O
transcriptome	B-MED
analysis	I-MED
reveals	B-MED
that	O
the	O
genes	B-MED
involved	O
in	O
metabolism	B-MED
and	O
osteogenesis	B-MED
are	O
disturbed	O
in	O
akt2	B-MED
-	O
null	B-MED
zebrafish	B-MED
.	O
Taken	O
together	O
,	O
these	O
data	B-MED
not	O
only	O
support	O
an	O
important	O
role	B-MED
of	O
akt2	B-MED
in	O
zebrafish	B-MED
survival	B-MED
,	O
growth	B-MED
,	O
bone	B-MED
development	I-MED
and	O
glucose	B-MED
homeostasis	I-MED
,	O
but	O
also	O
suggest	O
that	O
akt2	B-MED
has	O
divergent	O
functions	B-MED
between	O
mice	B-MED
and	O
zebrafish	B-MED
,	O
even	O
though	O
they	O
are	O
evolutionarily	B-MED
conserved	B-MED
.	O
Quantitative	B-MED
assessment	I-MED
of	O
fluorescent	B-MED
proteins	I-MED
The	O
advent	O
of	O
fluorescent	B-MED
proteins	I-MED
(	O
FPs	B-MED
)	O
for	O
genetic	B-MED
labeling	I-MED
of	O
molecules	B-MED
and	O
cells	B-MED
has	O
revolutionized	O
fluorescence	B-MED
microscopy	I-MED
.	O
Genetic	B-MED
manipulations	I-MED
have	O
created	O
a	O
vast	O
array	O
of	O
bright	O
and	O
stable	O
FPs	B-MED
spanning	O
blue	B-MED
to	I-MED
red	I-MED
spectral	I-MED
regions	I-MED
.	O
Common	O
to	O
autofluorescent	B-MED
FPs	B-MED
is	O
their	O
tight	O
β	B-MED
-	I-MED
barrel	I-MED
structure	I-MED
,	O
which	O
provides	O
the	O
rigidity	B-MED
and	O
chemical	B-MED
environment	B-MED
needed	O
for	O
effectual	O
fluorescence	B-MED
.	O
Despite	O
the	O
common	O
structure	B-MED
,	O
each	O
FP	B-MED
has	O
unique	O
properties	B-MED
.	O
Thus	O
,	O
there	O
is	O
no	O
single	O
'	O
best	O
'	O
FP	B-MED
for	O
every	O
circumstance	O
,	O
and	O
each	O
FP	B-MED
has	O
advantages	O
and	O
disadvantages	O
.	O
To	O
guide	O
decisions	O
about	O
which	O
FP	B-MED
is	O
right	O
for	O
a	O
given	O
application	O
,	O
we	O
have	O
quantitatively	B-MED
characterized	O
the	O
brightness	B-MED
,	O
photostability	B-MED
,	O
pH	B-MED
stability	B-MED
and	O
monomeric	B-MED
properties	B-MED
of	O
more	O
than	O
40	O
FPs	B-MED
to	O
enable	O
straightforward	B-MED
and	O
direct	O
comparison	B-MED
between	O
them	O
.	O
We	O
focus	O
on	O
popular	O
and/or	O
top	O
-	O
performing	O
FPs	B-MED
in	O
each	O
spectral	B-MED
region	I-MED
.	O
Medial	B-MED
Patellofemoral	I-MED
Ligament	I-MED
Reconstruction	B-MED
Femoral	B-MED
Tunnel	B-MED
Accuracy	B-MED
:	O
Relationship	O
to	O
Disease	B-MED
-	O
Specific	B-MED
Quality	B-MED
of	I-MED
Life	I-MED
Medial	B-MED
patellofemoral	I-MED
ligament	I-MED
(	O
MPFL	B-MED
)	O
reconstruction	B-MED
is	O
a	O
procedure	O
aimed	O
to	O
reestablish	O
the	O
checkrein	O
to	O
lateral	B-MED
patellar	I-MED
translation	I-MED
in	O
patients	B-MED
with	O
symptomatic	B-MED
patellofemoral	I-MED
instability	I-MED
.	O
Correct	O
femoral	B-MED
tunnel	B-MED
position	B-MED
is	O
thought	O
to	O
be	O
crucial	O
to	O
successful	O
MPFL	B-MED
reconstruction	B-MED
,	O
but	O
the	O
accuracy	B-MED
of	O
this	O
statement	O
in	O
terms	O
of	O
patient	B-MED
outcomes	I-MED
has	O
not	O
been	O
tested	O
.	O
To	O
assess	O
the	O
accuracy	B-MED
of	O
femoral	B-MED
tunnel	B-MED
placement	B-MED
in	O
an	O
MPFL	B-MED
reconstruction	B-MED
cohort	B-MED
and	O
to	O
determine	O
the	O
correlation	B-MED
between	O
tunnel	B-MED
accuracy	B-MED
and	O
a	O
validated	B-MED
disease	B-MED
-	O
specific	B-MED
,	O
patient	B-MED
-reported	O
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
life	I-MED
outcome	B-MED
measure	I-MED
.	O
Case	O
series	O
;	O
Level	O
of	O
evidence	O
,	O
4	O
.	O
Between	O
June	B-MED
2008	O
and	O
February	B-MED
2014	O
,	O
a	O
total	O
of	O
206	O
subjects	B-MED
underwent	O
an	O
MPFL	B-MED
reconstruction	B-MED
.	O
Lateral	B-MED
radiographs	B-MED
were	O
measured	O
to	O
determine	O
the	O
accuracy	B-MED
of	O
the	O
femoral	B-MED
tunnel	B-MED
by	O
measuring	O
the	O
distance	O
from	O
the	O
center	O
of	O
the	O
femoral	B-MED
tunnel	B-MED
to	O
the	O
Schöttle	B-MED
point	I-MED
.	O
Banff	B-MED
Patella	I-MED
Instability	I-MED
Instrument	I-MED
(	I-MED
BPII	I-MED
)	I-MED
scores	I-MED
were	O
collected	O
a	O
mean	B-MED
24	O
months	B-MED
postoperatively	B-MED
.	O
A	O
total	O
of	O
155	O
(	O
79.5	O
%	O
)	O
subjects	O
had	O
adequate	O
postoperative	B-MED
lateral	B-MED
radiographs	B-MED
and	O
complete	O
BPII	B-MED
scores	I-MED
.	O
The	O
mean	B-MED
duration	B-MED
of	O
follow	B-MED
-	I-MED
up	I-MED
(	O
±	O
SD	B-MED
)	O
was	O
24.4	O
±	O
8.2	O
months	B-MED
(	O
range	O
,	O
12	O
-	O
74	O
months	B-MED
)	O
.	O
Measurement	B-MED
from	O
the	O
center	B-MED
of	O
the	O
femoral	B-MED
tunnel	B-MED
to	O
the	O
Schöttle	B-MED
point	I-MED
resulted	O
in	O
143	O
(	O
92.3	O
%	O
)	O
tunnel	B-MED
s	O
being	O
categorized	O
as	O
"	O
good	B-MED
"	O
or	O
"	O
ideal	B-MED
.	O
"	O
There	O
were	O
8	O
failures	B-MED
in	O
the	O
cohort	B-MED
,	O
none	O
of	O
which	O
occurred	O
in	O
malpositioned	B-MED
tunnels	B-MED
.	O
The	O
mean	B-MED
distance	O
from	O
the	O
center	B-MED
of	O
the	O
MPFL	B-MED
tunnel	B-MED
to	O
the	O
center	B-MED
of	O
the	O
Schöttle	B-MED
point	I-MED
was	O
5.9	O
±	O
4.2	O
mm	O
(	O
range	O
,	O
0.5	O
-	O
25.9	O
mm	O
)	O
.	O
The	O
mean	B-MED
postoperative	B-MED
BPII	B-MED
score	I-MED
was	O
65.2	O
±	O
22.5	O
(	O
range	O
,	O
9.2	O
-	O
100	O
)	O
.	O
Pearson	B-MED
r	I-MED
correlation	I-MED
demonstrated	O
no	B-MED
statistically	I-MED
significant	I-MED
relationship	B-MED
between	O
accuracy	B-MED
of	O
femoral	B-MED
tunnel	B-MED
position	B-MED
and	O
BPII	B-MED
score	I-MED
(	O
r	O
=	O
-0.08	O
;	O
95	O
%	O
CI	O
,	O
-0.24	O
to	O
0.08	O
)	O
.	O
There	O
was	O
no	B-MED
evidence	I-MED
of	I-MED
a	O
correlation	B-MED
between	O
the	O
accuracy	B-MED
of	O
MPFL	B-MED
reconstruction	B-MED
femoral	B-MED
tunnel	B-MED
in	O
relation	O
to	O
the	O
Schöttle	B-MED
point	I-MED
and	O
disease	B-MED
-	O
specific	B-MED
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
life	I-MED
scores	I-MED
.	O
Graft	B-MED
failure	I-MED
was	O
not	O
related	O
to	O
femoral	B-MED
tunnel	B-MED
placement	B-MED
.	O
The	O
patellofemoral	B-MED
instability	I-MED
population	O
is	O
complex	O
,	O
and	O
patients	B-MED
present	O
with	O
multiple	O
risk	B-MED
factors	I-MED
that	O
,	O
in	O
addition	O
to	O
the	O
accuracy	B-MED
of	O
femoral	O
tunnel	B-MED
position	B-MED
,	O
contribute	O
to	O
quality	B-MED
of	I-MED
life	I-MED
and	O
warrant	O
further	O
investigation	B-MED
.	O
Evaluation	O
of	O
nutraceutical	B-MED
and	O
antinutritional	B-MED
properties	I-MED
in	O
barnyard	B-MED
and	O
finger	B-MED
millet	I-MED
varieties	B-MED
grown	O
in	O
Himalayan	B-MED
region	I-MED
Five	O
elite	O
varieties	B-MED
of	O
barnyard	B-MED
(	O
Echinochloa	B-MED
frumentacea	I-MED
)	O
and	O
finger	B-MED
(	O
Eleusine	B-MED
coracana	I-MED
)	O
growing	O
at	O
northwestern	B-MED
Himalaya	I-MED
were	O
investigated	B-MED
for	O
nutraceutical	B-MED
and	O
antinutritional	B-MED
properties	I-MED
.	O
Barnyard	B-MED
millet	I-MED
contained	O
higher	O
amount	B-MED
of	O
crude	B-MED
fiber	I-MED
,	O
total	B-MED
dietary	I-MED
fiber	I-MED
,	O
tryptophan	B-MED
content	B-MED
,	O
total	B-MED
carotenoids	I-MED
,	O
α	B-MED
-	I-MED
tocopherol	I-MED
compared	O
to	O
the	O
finger	B-MED
millet	I-MED
whereas	O
the	O
finger	B-MED
millet	I-MED
contains	O
higher	O
amount	B-MED
of	O
methionine	B-MED
and	O
ascorbic	B-MED
acid	I-MED
as	O
compared	O
to	O
the	O
barnyard	B-MED
millet	I-MED
.	O
The	O
secondary	B-MED
metabolites	I-MED
of	O
biological	B-MED
functions	I-MED
were	O
analyzed	O
and	O
found	O
that	O
barnyard	B-MED
millet	I-MED
contained	O
the	O
higher	O
amount	B-MED
of	O
polyphenols	B-MED
,	O
tannins	B-MED
and	O
ortho	B-MED
-	I-MED
dihydroxy	I-MED
phenol	I-MED
content	B-MED
compared	O
to	O
finger	B-MED
millet	I-MED
.	O
Among	O
antinutitional	B-MED
compounds	I-MED
barnyard	B-MED
millet	I-MED
contained	O
lower	O
phytic	B-MED
acid	I-MED
content	B-MED
compare	O
to	O
finger	B-MED
millet	I-MED
whereas	O
no	B-MED
significant	I-MED
difference	I-MED
in	O
trypsin	B-MED
inhibition	I-MED
activity	I-MED
of	O
barnyard	B-MED
millet	I-MED
and	O
finger	B-MED
millet	I-MED
varieties	B-MED
were	O
found	O
.	O
Barnyard	B-MED
millet	I-MED
contained	O
higher	O
acid	B-MED
phosphatase	I-MED
,	O
α	B-MED
-	I-MED
galactosidase	I-MED
and	O
α	B-MED
-	I-MED
amylase	I-MED
inhibitor	I-MED
activity	I-MED
compared	O
to	O
finger	B-MED
millet	I-MED
.	O
Finger	B-MED
millet	I-MED
seeds	I-MED
contained	O
about	O
10	O
-	O
13	O
folds	O
higher	O
calcium	B-MED
content	B-MED
and	O
double	O
amount	B-MED
of	O
manganese	B-MED
content	B-MED
in	O
comparison	O
to	O
barnyard	B-MED
millet	I-MED
seeds	I-MED
.	O
Present	O
study	O
suggests	O
that	O
barnyard	B-MED
millet	I-MED
varieties	B-MED
studied	O
under	O
present	O
investigation	O
were	O
found	O
nutritionally	O
superior	O
compared	O
to	O
finger	B-MED
millet	I-MED
varieties	B-MED
.	O
Recovery	B-MED
from	O
alcohol	B-MED
dependence	I-MED
:	O
Do	O
smoking	B-MED
indicators	B-MED
predict	O
abstinence	B-MED
?	O
There	O
is	O
inconsistent	B-MED
evidence	B-MED
about	O
the	O
potential	B-MED
influence	B-MED
of	O
smoking	B-MED
on	O
recovery	B-MED
from	O
alcohol	B-MED
dependence	I-MED
.	O
Our	O
study	B-MED
aimed	O
at	O
assessing	B-MED
the	O
impact	B-MED
of	O
smoking	B-MED
-	I-MED
behavior	I-MED
on	O
relapse	B-MED
during	O
a	O
12	O
months	B-MED
follow	B-MED
-	I-MED
up	I-MED
period	B-MED
following	O
a	O
detoxification	B-MED
in	O
patients	B-MED
with	O
Alcohol	B-MED
Use	I-MED
Disorder	I-MED
(	O
AUD	B-MED
)	O
.	O
Three	O
hundred	O
Patients	B-MED
with	O
AUD	B-MED
(	O
74.9	O
%	O
smoking	B-MED
)	O
were	O
recruited	O
from	O
two	O
inpatient	B-MED
detoxification	B-MED
units	I-MED
in	O
psychiatric	B-MED
hospitals	I-MED
in	O
Germany	B-MED
and	O
their	O
alcohol	B-MED
consumption	I-MED
was	O
prospectively	O
followed	O
for	O
1	O
year	B-MED
.	O
Data	B-MED
on	O
different	O
indicators	B-MED
of	O
smoking	B-MED
behavior	I-MED
was	O
gathered	O
.	O
Cox	B-MED
regression	I-MED
model	I-MED
was	O
used	O
to	O
evaluate	B-MED
potential	B-MED
risk	B-MED
factors	I-MED
on	O
time	O
to	O
relapse	B-MED
of	O
alcohol	B-MED
consumption	I-MED
.	O
Two	O
hundred	O
seventy	O
-	O
nine	O
participants	B-MED
(	O
n	O
=	O
279	O
)	O
were	O
included	O
in	O
the	O
final	B-MED
analysis	B-MED
.	O
Smoking	B-MED
increased	B-MED
the	O
risk	B-MED
for	O
alcohol	B-MED
relapse	I-MED
(	O
hazard	B-MED
ratio	I-MED
=	O
3.962	O
,	O
95	O
%	O
CI	B-MED
1.582	O
-	O
9.921	O
)	O
.	O
However	O
,	O
this	O
increased	B-MED
risk	B-MED
is	O
slightly	O
reduced	B-MED
with	O
higher	O
numbers	O
of	O
daily	B-MED
consumed	B-MED
cigarettes	I-MED
(	O
hazard	B-MED
ratio	I-MED
per	B-MED
cigarette	B-MED
=	O
.986	O
,	O
95	O
%	O
CI	B-MED
.976-.995	O
)	O
.	O
Smoking	B-MED
reduced	I-MED
the	O
probability	B-MED
of	O
maintaining	B-MED
alcohol	B-MED
abstinence	I-MED
significantly	B-MED
,	O
whereas	O
higher	B-MED
number	O
of	O
cigarettes	B-MED
smoked	I-MED
daily	B-MED
diminished	B-MED
the	O
increased	B-MED
risk	B-MED
of	O
alcohol	B-MED
relapse	I-MED
in	O
alcohol	B-MED
-	I-MED
dependent	I-MED
patients	B-MED
.	O
Coordinated	B-MED
psychiatric	B-MED
and	O
substance	B-MED
abuse	I-MED
interventions	B-MED
for	O
different	O
subgroups	B-MED
of	O
patients	B-MED
with	O
AUD	B-MED
in	O
the	O
post	B-MED
-	I-MED
acute	I-MED
treatment	I-MED
phase	I-MED
are	O
necessary	O
.	O
Individualized	B-MED
treatment	B-MED
planning	O
is	O
especially	O
important	O
in	O
smoking	B-MED
patients	B-MED
with	O
AUD	B-MED
who	O
are	O
vulnerable	O
for	O
a	O
relapse	B-MED
to	I-MED
alcohol	I-MED
drinking	I-MED
and	O
for	O
somatic	B-MED
complications	B-MED
.	O
Our	O
findings	B-MED
might	O
support	O
individualized	B-MED
treatment	B-MED
plans	I-MED
.(Am	O
J	O
Addict	O
2017;XX:1	O
-	O
8)	O
.	O
Potassium	B-MED
depletion	I-MED
stimulates	B-MED
Na	B-MED
-	I-MED
Cl	I-MED
cotransporter	I-MED
via	O
phosphorylation	B-MED
and	O
inactivation	B-MED
of	O
the	O
ubiquitin	B-MED
ligase	I-MED
Kelch	B-MED
-	I-MED
like	I-MED
3	I-MED
Kelch	B-MED
-	I-MED
like	I-MED
3	I-MED
(	O
KLHL3	B-MED
)	O
is	O
a	O
component	B-MED
of	O
an	O
E3	B-MED
ubiquitin	I-MED
ligase	I-MED
complex	I-MED
that	O
regulates	B-MED
blood	B-MED
pressure	I-MED
by	O
targeting	B-MED
With	B-MED
-	I-MED
No	I-MED
-	I-MED
Lysine	I-MED
(	I-MED
WNK	I-MED
)	I-MED
kinases	I-MED
for	O
degradation	B-MED
.	O
Mutations	B-MED
in	O
KLHL3	B-MED
cause	O
constitutively	O
increased	B-MED
renal	I-MED
salt	I-MED
reabsorption	I-MED
and	O
impaired	B-MED
K(+	B-MED
)	I-MED
secretion	B-MED
,	O
resulting	O
in	O
hypertension	B-MED
and	O
hyperkalemia	B-MED
.	O
Although	O
clinical	B-MED
studies	I-MED
have	O
shown	O
that	O
dietary	B-MED
K(+	I-MED
)	I-MED
intake	B-MED
affects	B-MED
blood	B-MED
pressure	I-MED
,	O
the	O
mechanisms	B-MED
have	O
been	O
obscure	B-MED
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
KLHL3	B-MED
ubiquitin	B-MED
ligase	I-MED
complex	B-MED
is	O
involved	O
in	O
the	O
low-	O
K(+	B-MED
)	I-MED
-mediated	O
activation	B-MED
of	O
Na	B-MED
-	I-MED
Cl	I-MED
cotransporter	I-MED
(	O
NCC	B-MED
)	O
in	O
the	O
kidney	B-MED
.	O
In	O
the	O
distal	B-MED
convoluted	I-MED
tubules	I-MED
of	O
mice	B-MED
eating	B-MED
a	O
low	B-MED
-	I-MED
K(+	I-MED
)	I-MED
diet	I-MED
,	O
we	O
found	O
increased	O
KLHL3	B-MED
phosphorylation	B-MED
at	O
S433	B-MED
(	B-MED
KLHL3(S433	I-MED
-	I-MED
P	I-MED
)	I-MED
)	I-MED
,	O
a	O
modification	B-MED
that	O
impairs	B-MED
WNK	B-MED
binding	B-MED
,	O
and	O
also	O
reduced	O
total	O
KLHL3	B-MED
levels	B-MED
.	O
These	O
changes	O
are	O
accompanied	O
by	O
the	O
accumulation	B-MED
of	O
the	O
target	B-MED
substrate	B-MED
WNK4	B-MED
,	O
and	O
activation	B-MED
of	O
the	O
downstream	B-MED
kinases	B-MED
SPAK	I-MED
(	O
STE20	B-MED
/	O
SPS1	B-MED
-related	O
proline	B-MED
-	I-MED
alanine	I-MED
-	I-MED
rich	I-MED
protein	I-MED
kinase	I-MED
)	O
and	O
OSR1	B-MED
(	O
oxidative	B-MED
stress	I-MED
-	I-MED
responsive	I-MED
1	I-MED
)	O
,	O
resulting	O
in	O
NCC	B-MED
phosphorylation	B-MED
and	O
its	O
accumulation	B-MED
at	O
the	O
plasma	B-MED
membrane	I-MED
.	O
Increased	O
phosphorylation	B-MED
of	O
S433	B-MED
was	O
explained	O
by	O
increased	O
levels	B-MED
of	O
active	B-MED
,	O
phosphorylated	O
protein	B-MED
kinase	I-MED
C	I-MED
(	O
but	O
not	O
protein	B-MED
kinase	I-MED
A	I-MED
)	O
,	O
which	O
directly	O
phosphorylates	B-MED
S433	B-MED
.	O
Moreover	O
,	O
in	O
HEK	B-MED
cells	I-MED
expressing	B-MED
KLHL3	B-MED
and	O
WNK4	B-MED
,	O
we	O
showed	O
that	O
the	O
activation	B-MED
of	O
protein	B-MED
kinase	I-MED
C	I-MED
by	O
phorbol	B-MED
12	I-MED
-	I-MED
myristate	I-MED
13	I-MED
-	I-MED
acetate	I-MED
induces	B-MED
KLHL3(S433	B-MED
-	I-MED
P	I-MED
)	I-MED
and	O
increases	O
WNK4	B-MED
levels	B-MED
by	O
abrogating	O
its	O
ubiquitination	B-MED
.	O
These	O
data	B-MED
demonstrate	O
the	O
role	B-MED
of	O
KLHL3	B-MED
in	O
low-	O
K(+	B-MED
)	I-MED
-mediated	O
induction	B-MED
of	O
NCC	B-MED
;	O
this	O
physiologic	B-MED
adaptation	I-MED
reduces	O
distal	B-MED
electrogenic	B-MED
Na(+	B-MED
)	I-MED
reabsorption	I-MED
,	O
preventing	B-MED
further	O
renal	B-MED
K(+	B-MED
)	I-MED
loss	B-MED
but	O
promoting	B-MED
increased	O
blood	B-MED
pressure	I-MED
.	O
Predicting	O
changes	O
in	O
adaptive	B-MED
functioning	B-MED
and	O
behavioral	B-MED
adjustment	B-MED
following	O
treatment	B-MED
for	O
a	O
pediatric	B-MED
brain	I-MED
tumor	I-MED
:	O
A	O
report	B-MED
from	O
the	O
Brain	B-MED
Radiation	B-MED
Investigative	I-MED
Study	I-MED
Consortium	I-MED
Children	B-MED
are	O
at	O
risk	B-MED
for	O
behavioral	B-MED
and	O
adaptive	B-MED
difficulties	B-MED
following	O
pediatric	B-MED
brain	I-MED
tumor	I-MED
.	O
This	O
study	B-MED
explored	O
whether	O
familial	B-MED
/	O
demographic	B-MED
,	O
developmental	B-MED
,	O
diagnostic	B-MED
,	O
or	O
treatment	B-MED
-related	O
variables	B-MED
best	O
predict	O
posttreatment	B-MED
behavioral	B-MED
and	O
adaptive	B-MED
functioning	B-MED
.	O
Participants	B-MED
included	O
40	O
children	B-MED
(	O
mean	B-MED
age	B-MED
=	O
12.76	O
years	O
,	O
SD	B-MED
=	O
4.01	O
)	O
posttreatment	B-MED
(	O
mean	B-MED
time	B-MED
since	O
diagnosis	B-MED
=	O
1.99	O
years	O
,	O
SD	B-MED
=	O
0.21	O
)	O
for	O
pediatric	B-MED
brain	I-MED
tumor	I-MED
.	O
Parents	B-MED
rated	O
children	B-MED
's	O
behavioral	B-MED
adjustment	B-MED
and	O
adaptive	B-MED
functioning	B-MED
and	O
provided	O
demographic	B-MED
and	O
developmental	B-MED
histories	B-MED
.	O
Diagnostic	B-MED
and	O
treatment	B-MED
-related	O
information	B-MED
was	O
abstracted	O
from	O
medical	B-MED
records	I-MED
.	O
Ratings	B-MED
of	O
adaptive	B-MED
and	O
behavioral	B-MED
functioning	B-MED
approximately	O
2	O
years	O
postdiagnosis	B-MED
were	O
within	O
the	O
average	B-MED
range	B-MED
,	O
although	O
the	O
percentage	B-MED
of	O
children	B-MED
exceeding	O
clinical	B-MED
cutoffs	B-MED
for	O
impairment	B-MED
in	O
adaptive	B-MED
skills	B-MED
exceeded	O
expectation	B-MED
,	O
particularly	O
practical	O
skills	B-MED
.	O
Premorbid	B-MED
behavior	I-MED
problems	B-MED
and	O
tumor	B-MED
size	I-MED
predicted	O
posttreatment	B-MED
adaptive	B-MED
functioning	B-MED
.	O
After	O
accounting	O
for	O
adaptive	B-MED
functioning	B-MED
near	O
diagnosis	B-MED
,	O
premorbid	B-MED
behavior	I-MED
problems	B-MED
predicted	O
declines	O
in	O
adaptive	B-MED
functioning	B-MED
2	O
years	O
postdiagnosis	B-MED
.	O
After	O
accounting	O
for	O
adjustment	B-MED
near	O
diagnosis	B-MED
,	O
no	O
variables	B-MED
predicted	O
declines	O
in	O
behavioral	B-MED
adjustment	B-MED
.	O
Children	B-MED
may	O
be	O
vulnerable	B-MED
to	O
reduced	O
adaptive	B-MED
functioning	B-MED
following	O
pediatric	B-MED
brain	I-MED
tumor	I-MED
treatment	B-MED
,	O
especially	O
in	O
practical	O
skills	O
.	O
Assessing	O
prediagnosis	B-MED
functioning	B-MED
and	O
diagnostic	B-MED
and	O
treatment	B-MED
-related	O
variables	B-MED
may	O
improve	B-MED
our	O
ability	B-MED
to	O
predict	O
those	O
at	O
greatest	O
risk	B-MED
,	O
although	O
those	O
factors	B-MED
may	O
be	O
less	O
helpful	B-MED
in	O
identifying	B-MED
children	B-MED
likely	O
to	O
develop	O
behavioral	B-MED
difficulties	B-MED
.	O
Screening	B-MED
of	O
these	O
factors	B-MED
in	O
tertiary	B-MED
care	I-MED
and	O
long	B-MED
-	I-MED
term	I-MED
follow	B-MED
-	I-MED
up	I-MED
settings	O
may	O
improve	B-MED
identification	B-MED
of	O
those	O
at	O
greatest	O
need	B-MED
for	O
support	B-MED
services	I-MED
.	O
Interaction	B-MED
of	I-MED
lifestyle	I-MED
,	O
behaviour	B-MED
or	O
systemic	B-MED
diseases	I-MED
with	O
dental	B-MED
caries	I-MED
and	O
periodontal	B-MED
diseases	I-MED
:	O
consensus	B-MED
report	I-MED
of	I-MED
group	I-MED
2	I-MED
of	I-MED
the	I-MED
joint	I-MED
EFP	I-MED
/	I-MED
ORCA	I-MED
workshop	I-MED
on	O
the	O
boundaries	O
between	O
caries	B-MED
and	O
periodontal	B-MED
diseases	I-MED
Periodontal	B-MED
diseases	I-MED
and	O
dental	B-MED
caries	I-MED
are	O
the	O
most	O
common	B-MED
diseases	I-MED
of	O
humans	O
and	O
the	O
main	O
cause	O
of	O
tooth	B-MED
loss	I-MED
.	O
Both	O
diseases	B-MED
can	O
lead	O
to	O
nutritional	B-MED
compromise	I-MED
and	O
negative	O
impacts	O
upon	O
self	B-MED
-	I-MED
esteem	I-MED
and	O
quality	B-MED
of	I-MED
life	I-MED
.	O
As	O
complex	B-MED
chronic	I-MED
diseases	I-MED
,	O
they	O
share	O
common	B-MED
risk	I-MED
factors	I-MED
,	O
such	O
as	O
a	O
requirement	O
for	O
a	O
pathogenic	B-MED
plaque	I-MED
biofilm	I-MED
,	O
yet	O
they	O
exhibit	O
distinct	B-MED
pathophysiologies	I-MED
.	O
Multiple	B-MED
exposures	I-MED
contribute	O
to	O
their	O
causal	O
pathways	O
,	O
and	O
susceptibility	B-MED
involves	I-MED
risk	B-MED
factors	I-MED
that	O
are	O
inherited	B-MED
(	O
e.g.	O
genetic	B-MED
variants	I-MED
)	O
,	O
and	O
those	O
that	O
are	O
acquired	O
(	O
e.g.	O
socio	B-MED
-	I-MED
economic	I-MED
factors	I-MED
,	O
biofilm	B-MED
load	O
or	O
composition	O
,	O
smoking	B-MED
,	O
carbohydrate	B-MED
intake	I-MED
)	O
.	O
Identification	O
of	O
these	O
factors	O
is	O
crucial	O
in	O
the	O
prevention	B-MED
of	I-MED
both	I-MED
diseases	I-MED
as	O
well	O
as	O
in	O
their	B-MED
management	I-MED
.	O
To	O
systematically	O
appraise	O
the	O
scientific	B-MED
literature	I-MED
to	O
identify	O
potential	B-MED
risk	I-MED
factors	I-MED
for	O
caries	B-MED
and	O
periodontal	B-MED
diseases	I-MED
.	O
One	O
systematic	B-MED
review	I-MED
(	O
genetic	B-MED
risk	I-MED
factors	I-MED
)	O
,	O
one	O
narrative	B-MED
review	I-MED
(	O
role	B-MED
of	I-MED
diet	I-MED
and	I-MED
nutrition	I-MED
)	O
and	O
reference	B-MED
documentation	I-MED
for	O
modifiable	B-MED
acquired	I-MED
risk	I-MED
factors	I-MED
common	O
to	O
both	O
disease	O
groups	O
,	O
formed	O
the	O
basis	O
of	O
the	O
report	O
.	O
There	O
is	O
moderately	O
strong	O
evidence	O
for	O
a	O
genetic	B-MED
contribution	I-MED
to	O
periodontal	B-MED
diseases	I-MED
and	O
caries	B-MED
susceptibility	I-MED
,	O
with	O
an	O
attributable	B-MED
risk	I-MED
estimated	O
to	O
be	O
up	O
to	O
50	O
%	O
.	O
The	O
genetics	B-MED
literature	I-MED
for	O
periodontal	B-MED
disease	I-MED
is	O
more	O
substantial	O
than	O
for	O
caries	B-MED
and	O
genes	B-MED
associated	B-MED
with	I-MED
chronic	B-MED
periodontitis	I-MED
are	O
the	O
vitamin	B-MED
D	I-MED
receptor	I-MED
(	O
VDR	B-MED
)	O
,	O
Fc	B-MED
gamma	I-MED
receptor	I-MED
IIA	I-MED
(	O
Fc	B-MED
-	I-MED
γRIIA	I-MED
)	O
and	O
Interleukin	B-MED
10	I-MED
(	I-MED
IL10	I-MED
)	I-MED
genes	I-MED
IL10	B-MED
.	O
For	O
caries	B-MED
,	O
genes	B-MED
involved	O
in	O
enamel	B-MED
formation	I-MED
(	O
AMELX	B-MED
,	O
AMBN	B-MED
,	O
ENAM	B-MED
,	O
TUFT	B-MED
,	O
MMP20	B-MED
,	O
and	O
KLK4	B-MED
)	O
,	O
salivary	B-MED
characteristics	I-MED
(	O
AQP5	B-MED
)	O
,	O
immune	B-MED
regulation	I-MED
and	O
dietary	B-MED
preferences	I-MED
had	O
the	O
largest	B-MED
impact	I-MED
.	O
No	O
common	O
genetic	O
variants	O
were	O
found	O
.	O
Fermentable	B-MED
carbohydrates	I-MED
(	O
sugars	B-MED
and	I-MED
starches	I-MED
)	O
were	O
the	O
most	O
relevant	O
common	O
dietary	O
risk	B-MED
factor	I-MED
for	I-MED
both	I-MED
diseases	I-MED
,	O
but	O
associated	O
mechanisms	O
differed	O
.	O
In	O
caries	B-MED
,	O
the	O
fermentation	B-MED
process	I-MED
leads	O
to	O
acid	O
production	O
and	O
the	O
generation	B-MED
of	I-MED
biofilm	I-MED
components	O
such	O
as	O
Glucans	B-MED
.	O
In	O
periodontitis	B-MED
,	O
glycaemia	B-MED
drives	I-MED
oxidative	B-MED
stress	I-MED
and	O
advanced	B-MED
glycation	I-MED
end	O
-	O
products	O
may	O
also	O
trigger	O
a	O
hyper	B-MED
inflammatory	I-MED
state	O
.	O
Micronutrient	B-MED
deficiencies	I-MED
,	O
such	O
as	O
for	O
vitamin	B-MED
C	I-MED
,	O
vitamin	B-MED
D	I-MED
or	O
vitamin	B-MED
B12	I-MED
,	O
may	O
be	O
related	O
to	O
the	O
onset	B-MED
and	O
progression	B-MED
of	I-MED
both	I-MED
diseases	I-MED
.	O
Functional	B-MED
foods	I-MED
or	O
probiotics	B-MED
could	O
be	O
helpful	O
in	O
caries	B-MED
prevention	I-MED
and	O
periodontal	B-MED
disease	I-MED
management	B-MED
,	O
although	O
evidence	O
is	O
limited	O
and	O
biological	B-MED
mechanisms	I-MED
not	O
fully	O
elucidated	O
.	O
Hyposalivation	B-MED
,	O
rheumatoid	B-MED
arthritis	I-MED
,	O
smoking	B-MED
/	I-MED
tobacco	I-MED
use	I-MED
,	O
undiagnosed	B-MED
or	O
sub	B-MED
-	I-MED
optimally	I-MED
controlled	I-MED
diabetes	B-MED
and	O
obesity	B-MED
are	O
common	O
acquired	O
risk	B-MED
factors	I-MED
for	O
both	O
caries	B-MED
and	O
periodontal	B-MED
diseases	I-MED
.	O
Expressed	B-MED
microRNA	B-MED
associated	B-MED
with	I-MED
high	B-MED
rate	B-MED
of	O
egg	B-MED
production	I-MED
in	O
chicken	B-MED
ovarian	B-MED
follicles	I-MED
MicroRNA	B-MED
(	O
miRNA	B-MED
)	O
is	O
a	O
highly	O
conserved	O
class	O
of	O
small	O
noncoding	B-MED
RNA	I-MED
about	O
19	O
-	O
24	O
nucleotides	B-MED
in	O
length	B-MED
that	O
function	B-MED
in	O
a	O
specific	O
manner	O
to	O
post	B-MED
-	I-MED
transcriptionally	I-MED
regulate	I-MED
gene	B-MED
expression	I-MED
in	O
organisms	B-MED
.	O
Tissue	B-MED
miRNA	B-MED
expression	B-MED
studies	B-MED
have	O
discovered	O
a	O
myriad	O
of	O
functions	B-MED
for	O
miRNAs	B-MED
in	O
various	O
aspects	O
,	O
but	O
a	O
role	O
for	O
miRNAs	B-MED
in	O
chicken	B-MED
ovarian	B-MED
tissue	I-MED
at	O
300	O
days	B-MED
of	O
age	B-MED
has	O
not	O
hitherto	O
been	O
reported	O
.	O
In	O
this	O
study	O
,	O
we	O
performed	O
the	O
first	O
miRNA	B-MED
analysis	B-MED
of	O
ovarian	B-MED
tissues	I-MED
in	O
chickens	B-MED
with	O
low	B-MED
and	O
high	B-MED
rates	B-MED
of	O
egg	B-MED
production	I-MED
using	O
high	B-MED
-	I-MED
throughput	I-MED
sequencing	I-MED
.	O
By	O
comparing	O
low	B-MED
rate	B-MED
of	O
egg	B-MED
production	I-MED
chickens	B-MED
with	O
high	B-MED
rate	B-MED
of	O
egg	B-MED
production	I-MED
chickens	B-MED
,	O
17	O
significantly	O
differentially	O
expressed	B-MED
miRNAs	B-MED
were	O
found	O
(	O
P	O
<	O
0.05	O
)	O
,	O
including	O
11	O
known	O
and	O
six	O
novel	O
miRNAs	B-MED
.	O
We	O
found	O
that	O
all	O
11	O
known	O
miRNAs	B-MED
were	O
involved	O
mainly	O
in	O
pathways	B-MED
of	O
reproduction	B-MED
regulation	B-MED
,	O
such	O
as	O
steroid	B-MED
hormone	I-MED
biosynthesis	I-MED
and	O
dopaminergic	B-MED
synapse	I-MED
.	O
Additionally	O
,	O
expression	B-MED
profiling	O
of	O
six	O
randomly	O
selected	O
differentially	O
regulated	B-MED
miRNAs	B-MED
were	O
validated	O
by	O
quantitative	B-MED
real	I-MED
-	I-MED
time	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
(	O
RT	B-MED
-	I-MED
qPCR	I-MED
)	O
.	O
Some	O
miRNAs	B-MED
,	O
such	O
as	O
gga	B-MED
-	I-MED
miR-34b	I-MED
,	O
gga	B-MED
-	I-MED
miR-34c	I-MED
and	O
gga	B-MED
-	I-MED
miR-216b	I-MED
,	O
were	O
reported	O
to	O
regulate	B-MED
processes	O
such	O
as	O
proliferation	B-MED
,	O
cell	B-MED
cycle	I-MED
,	O
apoptosis	B-MED
and	O
metastasis	B-MED
and	O
were	O
expressed	B-MED
differentially	O
in	O
ovaries	B-MED
of	O
chickens	B-MED
with	O
high	B-MED
rates	B-MED
of	O
egg	B-MED
production	I-MED
,	O
suggesting	O
that	O
these	O
miRNAs	B-MED
have	O
an	O
important	O
role	O
in	O
ovary	B-MED
development	B-MED
and	O
reproductive	B-MED
management	I-MED
of	O
chicken	B-MED
.	O
Furthermore	O
,	O
we	O
uncovered	O
that	O
a	O
significantly	O
up	B-MED
-	I-MED
regulated	I-MED
miRNA	B-MED
-	O
gga	B-MED
-	I-MED
miR-200a-3p	I-MED
-is	O
ubiquitous	O
in	O
reproduction	B-MED
-	O
regulation	B-MED
-related	O
pathways	B-MED
.	O
This	O
miRNA	B-MED
may	O
play	O
a	O
special	O
central	O
role	O
in	O
the	O
reproductive	B-MED
management	I-MED
of	O
chicken	B-MED
,	O
and	O
needs	O
to	O
be	O
further	O
studied	O
for	O
confirmation	O
.	O
Consumption	B-MED
of	I-MED
fruits	I-MED
and	I-MED
vegetables	I-MED
associated	B-MED
with	I-MED
other	O
risk	B-MED
behaviors	I-MED
among	O
adolescents	B-MED
in	O
Northeast	B-MED
Brazil	I-MED
To	O
determine	O
the	O
prevalence	B-MED
of	O
consumption	B-MED
of	I-MED
fruits	I-MED
and	I-MED
vegetables	I-MED
and	O
identify	O
the	O
association	B-MED
with	I-MED
low	B-MED
level	B-MED
of	O
physical	B-MED
activity	I-MED
,	O
exposure	B-MED
to	I-MED
sedentary	B-MED
behavior	I-MED
,	O
consumption	B-MED
of	O
soft	B-MED
drinks	I-MED
and	O
overweight	B-MED
/	O
obesity	B-MED
in	O
adolescents	B-MED
.	O
This	O
is	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
school	I-MED
-	I-MED
based	I-MED
study	I-MED
with	O
a	O
representative	O
sample	B-MED
of	O
3992	O
students	B-MED
aged	O
14	O
-	O
19	O
years	B-MED
from	O
the	O
state	B-MED
of	I-MED
Sergipe	I-MED
,	O
Brazil	B-MED
.	O
The	O
outcome	B-MED
was	O
low	B-MED
consumption	B-MED
of	I-MED
fruits	I-MED
and	I-MED
vegetables	I-MED
(	O
<	O
5	O
servings	B-MED
/	I-MED
day	I-MED
)	O
.	O
Independent	B-MED
variables	I-MED
were	O
:	O
level	B-MED
of	O
physical	B-MED
activity	I-MED
,	O
sedentary	B-MED
behavior	I-MED
,	O
consumption	B-MED
of	O
soft	B-MED
drinks	I-MED
,	O
and	O
overweight	B-MED
/	O
obesity	B-MED
.	O
Global	B-MED
Student	I-MED
Health	I-MED
Survey	I-MED
questionnaire	I-MED
and	O
body	B-MED
mass	I-MED
and	O
height	B-MED
measurements	B-MED
were	O
used	O
,	O
as	O
well	O
as	O
chi	B-MED
-	I-MED
square	I-MED
test	I-MED
and	O
crude	B-MED
and	I-MED
adjusted	I-MED
binary	I-MED
logistic	I-MED
regression	I-MED
.	O
The	O
significance	B-MED
level	I-MED
adopted	O
was	O
5	O
%	O
.	O
The	O
prevalence	B-MED
of	O
inadequate	B-MED
consumption	B-MED
of	I-MED
fruits	I-MED
and	I-MED
vegetables	I-MED
was	O
high	B-MED
-	O
88.6	O
%	O
(	O
95	O
%	O
CI	B-MED
=	O
87.6	O
-	O
89.5	O
)	O
.	O
Higher	B-MED
likelihood	O
of	O
low	B-MED
consumption	B-MED
of	I-MED
fruits	I-MED
and	I-MED
vegetables	I-MED
was	O
verified	O
among	O
boys	B-MED
who	O
were	O
exposed	B-MED
to	I-MED
sedentary	B-MED
behavior	I-MED
(	O
OR	B-MED
=	O
1.63	O
;	O
95	O
%	O
CI	B-MED
=	O
1.18	O
-	O
2.24	O
)	O
,	O
who	O
consumed	B-MED
soft	B-MED
drinks	I-MED
(	O
OR	B-MED
=	O
3.04	O
;	O
95	O
%	O
CI	B-MED
=	O
2.10	O
-	O
4.40	O
)	O
,	O
with	O
insufficiently	B-MED
physical	B-MED
activity	I-MED
(	O
OR	B-MED
=	O
1.98	O
;	O
95	O
%	O
CI	B-MED
=	O
1.43	O
-	O
2.73	O
)	O
and	O
girls	B-MED
who	O
consumed	B-MED
soft	B-MED
drinks	I-MED
(	O
OR	B-MED
=	O
1.88	O
;	O
95	O
%	O
CI	B-MED
=	O
1.43	O
-	O
2.47	O
)	O
and	O
those	O
with	O
overweight	B-MED
/	O
obesity	B-MED
(	O
OR	B-MED
=	O
1.63	O
;	O
95	O
%	O
CI	B-MED
=	O
1.19	O
-	O
2.23	O
)	O
.	O
There	O
is	O
a	O
need	O
of	O
public	B-MED
policies	I-MED
aimed	O
at	O
encouraging	O
the	O
consumption	B-MED
of	I-MED
healthy	I-MED
foods	I-MED
among	O
adolescents	B-MED
.	O
The	O
emerging	B-MED
contribution	I-MED
of	O
social	B-MED
wasps	I-MED
to	O
grape	B-MED
rot	I-MED
disease	I-MED
ecology	B-MED
Grape	B-MED
sour	I-MED
(	I-MED
bunch	I-MED
)	I-MED
rot	I-MED
is	O
a	O
polymicrobial	B-MED
disease	I-MED
of	O
vineyards	B-MED
that	O
causes	O
millions	B-MED
of	O
dollars	B-MED
in	O
lost	B-MED
revenue	I-MED
per	B-MED
year	I-MED
due	O
to	O
decreased	B-MED
quality	B-MED
of	O
grapes	B-MED
and	O
resultant	B-MED
wine	I-MED
.	O
The	O
disease	B-MED
is	O
associated	B-MED
with	I-MED
damaged	B-MED
berries	B-MED
infected	B-MED
with	O
a	O
community	B-MED
of	O
acetic	B-MED
acid	I-MED
bacteria	I-MED
,	O
yeasts	B-MED
,	O
and	O
filamentous	B-MED
fungi	I-MED
that	O
results	O
in	O
rotting	B-MED
berries	B-MED
with	O
high	B-MED
amounts	B-MED
of	O
undesirable	O
volatile	B-MED
acidity	B-MED
.	O
Many	O
insect	B-MED
species	B-MED
cause	O
the	O
initial	B-MED
grape	B-MED
berry	B-MED
damage	B-MED
that	O
can	O
lead	O
to	O
this	O
disease	B-MED
,	O
but	O
most	O
studies	B-MED
have	O
focused	B-MED
on	O
the	O
role	B-MED
of	O
fruit	B-MED
flies	I-MED
in	O
facilitating	O
symptoms	B-MED
and	O
vectoring	B-MED
the	O
microorganisms	B-MED
of	O
this	O
disease	B-MED
complex	B-MED
.	O
Like	O
fruit	B-MED
flies	I-MED
,	O
social	B-MED
wasps	I-MED
are	O
abundant	B-MED
in	O
vineyards	B-MED
where	O
they	O
feed	O
on	O
ripe	B-MED
berries	I-MED
and	O
cause	O
significant	B-MED
damage	B-MED
,	O
while	O
also	O
dispersing	B-MED
yeasts	B-MED
involved	B-MED
in	O
wine	B-MED
fermentation	B-MED
.	O
Despite	O
this	O
,	O
their	O
possible	O
role	B-MED
in	O
disease	B-MED
facilitation	O
and	O
dispersal	B-MED
of	I-MED
grape	I-MED
rots	I-MED
has	O
not	O
been	O
explored	O
.	O
We	O
tested	B-MED
the	O
hypothesis	B-MED
that	O
the	O
paper	B-MED
wasp	I-MED
Polistes	B-MED
dominulus	I-MED
could	O
facilitate	O
grape	B-MED
sour	I-MED
rot	I-MED
in	O
the	O
absence	B-MED
of	O
other	O
insect	B-MED
vectors	I-MED
.	O
Using	O
marker	B-MED
gene	I-MED
sequencing	I-MED
we	O
characterized	B-MED
the	O
bacterial	B-MED
and	O
fungal	B-MED
community	B-MED
of	O
wild	B-MED
-	I-MED
caught	I-MED
adults	I-MED
.	O
We	O
used	O
a	O
sterilized	O
foraging	B-MED
arena	I-MED
to	O
determine	O
if	O
these	O
wasps	B-MED
transfer	O
viable	B-MED
microorganisms	B-MED
when	O
foraging	B-MED
.	O
We	O
then	O
tested	B-MED
if	O
wasps	B-MED
harboring	O
their	O
native	B-MED
microbial	B-MED
community	B-MED
,	O
or	O
those	O
inoculated	B-MED
with	O
sour	B-MED
rot	I-MED
,	O
had	O
an	O
effect	B-MED
on	O
grape	B-MED
sour	I-MED
rot	I-MED
incidence	B-MED
and	O
severity	B-MED
using	O
a	O
laboratory	B-MED
foraging	I-MED
arena	I-MED
.	O
We	O
found	O
that	O
all	O
wasps	B-MED
harbor	O
some	O
portion	O
of	O
the	O
sour	B-MED
rot	I-MED
microbial	B-MED
community	B-MED
and	O
that	O
they	O
have	O
the	O
ability	B-MED
to	O
transfer	O
viable	B-MED
microorganisms	B-MED
when	O
foraging	B-MED
.	O
Foraging	B-MED
by	O
inoculated	B-MED
and	O
uninoculated	B-MED
wasps	I-MED
led	O
to	O
an	O
increase	B-MED
in	O
berry	B-MED
rot	I-MED
disease	I-MED
symptom	B-MED
severity	B-MED
and	O
incidence	B-MED
.	O
Our	O
results	B-MED
indicate	O
that	O
paper	B-MED
wasps	I-MED
can	O
facilitate	O
sour	B-MED
rot	I-MED
diseases	I-MED
in	O
the	O
absence	B-MED
of	O
other	B-MED
vectors	I-MED
and	O
that	O
the	O
mechanism	B-MED
of	O
this	O
facilitation	O
may	O
include	O
both	O
increasing	B-MED
host	B-MED
susceptibility	B-MED
and	O
transmitting	B-MED
these	O
microbial	B-MED
communities	B-MED
to	O
the	O
grapes	B-MED
.	O
Social	B-MED
wasps	I-MED
are	O
understudied	O
but	O
relevant	B-MED
players	I-MED
in	O
the	O
sour	B-MED
rot	I-MED
ecology	B-MED
of	O
vineyards	B-MED
.	O
Detection	B-MED
and	O
Characterization	O
of	O
Flat	B-MED
Aberrant	I-MED
Crypt	I-MED
Foci	I-MED
(	I-MED
Flat	I-MED
ACF	I-MED
)	I-MED
in	O
the	O
Novel	O
A	B-MED
/	I-MED
J	I-MED
Min/+	I-MED
Mouse	I-MED
Flat	B-MED
aberrant	I-MED
crypt	I-MED
foci	I-MED
(	O
flat	B-MED
ACF	I-MED
)	O
and	O
mucin	B-MED
-	I-MED
depleted	I-MED
foci	I-MED
(	O
MDF	B-MED
)	O
have	O
previously	O
been	O
described	O
as	O
preneoplastic	B-MED
colonic	I-MED
lesions	I-MED
.	O
We	O
used	O
the	O
novel	O
A	B-MED
/	I-MED
J	I-MED
Min/+	I-MED
mouse	I-MED
model	I-MED
,	O
that	O
demonstrates	O
extensive	O
spontaneous	O
colon	B-MED
carcinogenesis	I-MED
to	O
refine	O
the	O
method	O
of	O
detection	B-MED
of	O
flat	B-MED
ACF	I-MED
and	O
further	O
characterize	O
and	O
define	O
them	O
as	O
early	O
lesions	B-MED
by	O
histological	B-MED
examination	I-MED
and	O
comparison	O
with	O
MDF	B-MED
.	O
Colons	B-MED
were	O
stained	B-MED
with	I-MED
methylene	I-MED
blue	I-MED
(	O
MB	B-MED
)	O
for	O
flat	B-MED
ACF	I-MED
detection	B-MED
and	O
restained	B-MED
with	O
high	B-MED
-	I-MED
iron	I-MED
diamine	I-MED
-	I-MED
alcian	I-MED
blue	I-MED
(	O
HID	B-MED
-	I-MED
AB	I-MED
)	O
for	O
MDF	B-MED
detection	B-MED
.	O
Optimal	O
flat	B-MED
ACF	I-MED
recognition	O
required	O
at	O
least	O
24	O
h	O
of	O
storage	O
post-	O
MB	B-MED
staining	I-MED
and	O
adherence	O
to	O
a	O
set	O
of	O
characteristics	O
.	O
The	O
fraction	B-MED
of	I-MED
flat	B-MED
ACF	I-MED
corresponding	O
with	O
MDF	B-MED
was	O
93	O
%	O
.	O
Flat	B-MED
ACF	I-MED
/	O
MDF	B-MED
displayed	O
the	O
same	O
picture	O
of	O
severe	B-MED
dysplasia	I-MED
,	O
lack	B-MED
of	I-MED
mucus	B-MED
and	O
goblet	B-MED
cells	I-MED
and	O
accumulation	B-MED
of	O
cytoplasmic	B-MED
β	B-MED
-	I-MED
catenin	I-MED
.	O
The	O
easily	O
detectable	O
flat	B-MED
ACF	I-MED
are	O
reliable	O
surface	B-MED
biomarkers	B-MED
of	O
Apc	B-MED
-driven	O
colon	B-MED
carcinogenesis	I-MED
.	O
Assessment	B-MED
of	O
Vascular	B-MED
Stent	I-MED
Heating	B-MED
with	O
Repetitive	B-MED
Transcranial	I-MED
Magnetic	I-MED
Stimulation	I-MED
A	O
high	O
proportion	O
of	O
patients	B-MED
with	O
stroke	B-MED
do	O
not	O
qualify	O
for	O
repetitive	B-MED
transcranial	I-MED
magnetic	I-MED
stimulation	I-MED
(	O
rTMS	B-MED
)	O
clinical	B-MED
studies	I-MED
due	O
to	O
the	O
presence	O
of	O
metallic	B-MED
stents	I-MED
.	O
The	O
ultimate	O
concern	O
is	O
that	O
any	O
metal	B-MED
could	O
become	O
heated	B-MED
due	O
to	O
eddy	B-MED
currents	I-MED
.	O
However	O
,	O
to	O
date	O
,	O
no	O
clinical	B-MED
safety	I-MED
data	I-MED
are	O
available	O
regarding	O
the	O
risk	B-MED
of	O
metallic	B-MED
stents	I-MED
heating	B-MED
with	O
rTMS	B-MED
.	O
We	O
tested	B-MED
the	O
safety	B-MED
of	O
common	O
rTMS	B-MED
protocols	B-MED
(	O
1	O
Hz	O
and	O
10	O
Hz	O
)	O
with	O
stents	B-MED
used	O
commonly	O
in	O
stroke	B-MED
,	O
nitinol	B-MED
and	O
elgiloy	B-MED
.	O
In	O
our	O
method	O
,	O
stents	B-MED
were	O
tested	B-MED
in	O
gelled	B-MED
saline	B-MED
at	O
2	O
different	O
locations	B-MED
:	O
at	B-MED
the	I-MED
center	I-MED
and	O
at	O
the	O
lobe	B-MED
of	O
the	O
coil	B-MED
.	O
In	O
addition	O
,	O
at	O
each	O
location	B-MED
,	O
stent	B-MED
heating	B-MED
was	O
evaluated	B-MED
in	O
3	O
different	O
orientations	B-MED
:	O
parallel	B-MED
to	O
the	O
long	B-MED
axis	I-MED
of	O
coil	B-MED
,	O
parallel	B-MED
to	O
the	O
short	B-MED
axis	I-MED
of	O
the	O
coil	B-MED
,	O
and	O
perpendicular	B-MED
to	O
the	O
plane	O
of	O
the	O
coil	B-MED
.	O
We	O
found	O
that	O
stents	B-MED
did	O
not	O
heat	B-MED
to	O
more	O
than	O
1	O
°	O
C	O
with	O
either	O
1	O
Hz	O
rTMS	B-MED
or	O
10	O
Hz	O
rTMS	B-MED
in	O
any	O
configuration	O
or	O
orientation	B-MED
.	O
Heating	B-MED
in	O
general	O
was	O
greater	B-MED
at	O
the	O
lobe	B-MED
when	O
the	O
stent	B-MED
was	O
oriented	B-MED
perpendicularly	B-MED
.	O
Our	O
study	O
represents	O
a	O
new	O
method	O
for	O
ex	B-MED
vivo	I-MED
quantification	B-MED
of	O
stent	B-MED
heating	B-MED
.	O
We	O
have	O
found	O
that	O
heating	B-MED
of	O
stents	B-MED
was	O
well	O
below	O
the	O
Food	B-MED
and	I-MED
Drug	I-MED
Administration	I-MED
standards	B-MED
of	O
2	O
°	O
C	O
.	O
Thus	O
,	O
our	O
study	O
paves	O
the	O
way	O
for	O
in	B-MED
vivo	I-MED
testing	B-MED
of	O
rTMS	B-MED
(	O
≤10	O
Hz	O
)	O
in	O
the	O
presence	O
of	O
implanted	B-MED
magnetic	B-MED
resonance	I-MED
imaging	I-MED
-	O
compatible	B-MED
stents	B-MED
in	O
animal	B-MED
studies	I-MED
.	O
When	O
planning	O
human	B-MED
safety	B-MED
studies	I-MED
though	O
,	O
geometry	B-MED
,	O
orientation	B-MED
,	O
and	O
location	B-MED
relative	O
to	O
the	O
coil	B-MED
would	O
be	O
important	O
to	O
consider	O
as	O
well	O
.	O
Primitive	B-MED
Neuroectodermal	I-MED
Tumors	I-MED
of	O
the	O
Female	B-MED
Genital	I-MED
Tract	I-MED
:	O
A	O
Morphologic	B-MED
,	O
Immunohistochemical	B-MED
,	O
and	O
Molecular	B-MED
Study	B-MED
of	O
19	O
Cases	B-MED
Primary	B-MED
primitive	I-MED
neuroectodermal	I-MED
tumor	I-MED
(	O
PNET	B-MED
)	O
of	O
the	O
female	B-MED
genital	I-MED
tract	I-MED
is	O
rare	O
,	O
and	O
its	O
proper	O
classification	B-MED
remains	O
unclear	O
.	O
The	O
clinical	B-MED
,	O
histologic	B-MED
,	O
and	O
immunophenotypic	B-MED
features	B-MED
as	O
well	O
as	O
EWSR1	B-MED
rearrangement	B-MED
status	O
of	O
19	O
gynecologic	B-MED
PNETs	B-MED
,	O
including	O
10	O
ovarian	B-MED
,	O
8	O
uterine	B-MED
,	O
and	O
1	O
vulvar	B-MED
tumors	B-MED
,	O
are	O
herein	O
reported	B-MED
.	O
Patient	B-MED
age	B-MED
ranged	B-MED
from	O
12	O
to	O
68	O
years	B-MED
,	O
with	O
a	O
median	O
age	B-MED
of	O
20	O
and	O
51	O
years	B-MED
among	O
those	O
with	O
ovarian	B-MED
and	O
uterine	B-MED
PNETs	B-MED
,	O
respectively	O
.	O
Morphologic	B-MED
features	B-MED
of	O
central	B-MED
nervous	I-MED
system	I-MED
(	O
CNS	B-MED
)	O
tumors	B-MED
were	O
seen	O
in	O
15	O
PNETs	B-MED
,	O
including	O
9	O
medulloblastomas	B-MED
,	O
3	O
ependymomas	B-MED
,	O
2	O
medulloepitheliomas	B-MED
,	O
and	O
1	O
glioblastoma	B-MED
,	O
consistent	O
with	O
central	B-MED
PNET	I-MED
.	O
The	O
remaining	O
4	O
PNETs	B-MED
were	O
composed	O
entirely	O
of	O
undifferentiated	B-MED
small	B-MED
round	I-MED
blue	I-MED
cells	I-MED
and	O
were	O
classified	O
as	O
Ewing	B-MED
sarcoma	I-MED
/	I-MED
peripheral	I-MED
PNET	I-MED
.	O
Eight	O
PNETs	B-MED
were	O
associated	O
with	O
another	O
tumor	B-MED
type	O
,	O
including	O
5	O
ovarian	B-MED
mature	B-MED
cystic	I-MED
teratomas	I-MED
,	O
2	O
endometrial	B-MED
low	I-MED
-	I-MED
grade	I-MED
endometrioid	B-MED
carcinomas	I-MED
,	O
and	O
a	O
uterine	B-MED
carcinosarcoma	I-MED
.	O
By	O
immunohistochemistry	B-MED
,	O
17	O
PNETs	B-MED
expressed	O
at	O
least	O
1	O
marker	B-MED
of	O
neuronal	B-MED
differentiation	I-MED
,	O
including	O
synaptophysin	B-MED
,	O
NSE	B-MED
,	O
CD56	B-MED
,	O
S100	B-MED
,	O
and	O
chromogranin	B-MED
in	O
10	O
,	O
8	O
,	O
14	O
,	O
8	O
,	O
and	O
1	O
tumors	B-MED
,	O
respectively	O
.	O
GFAP	B-MED
was	O
positive	O
in	O
4	O
PNETs	B-MED
,	O
all	O
of	O
which	O
were	O
of	O
central	O
type	O
.	O
Membranous	B-MED
CD99	B-MED
and	O
nuclear	B-MED
Fli-1	B-MED
staining	B-MED
was	O
seen	O
in	O
10	O
and	O
16	O
tumors	B-MED
,	O
respectively	O
,	O
and	O
concurrent	O
expression	B-MED
of	O
both	O
markers	B-MED
was	O
seen	O
in	O
both	O
central	B-MED
and	O
Ewing	B-MED
sarcoma	I-MED
/	I-MED
peripheral	I-MED
PNET	I-MED
s.	O
All	O
tumors	B-MED
expressed	B-MED
vimentin	B-MED
,	O
whereas	O
keratin	B-MED
cocktail	O
(	O
CAM5.2	B-MED
,	O
AE1	B-MED
/	I-MED
AE3	I-MED
)	O
staining	B-MED
was	O
only	O
focally	O
present	O
in	O
4	O
PNETs	B-MED
.	O
Fluorescence	B-MED
in	I-MED
situ	I-MED
hybridization	I-MED
was	O
successful	O
in	O
all	O
cases	B-MED
and	O
confirmed	O
EWSR1	B-MED
rearrangement	B-MED
in	O
2	O
of	O
4	O
tumors	B-MED
demonstrating	O
morphologic	B-MED
features	B-MED
of	O
Ewing	B-MED
sarcoma	I-MED
/	I-MED
peripheral	I-MED
PNET	I-MED
and	O
concurrent	O
CD99	B-MED
and	O
Fli-1	B-MED
expression	B-MED
.	O
In	O
conclusion	O
,	O
central	B-MED
and	O
Ewing	B-MED
sarcoma	I-MED
/	I-MED
peripheral	I-MED
PNETs	I-MED
may	O
be	O
encountered	O
in	O
the	O
female	B-MED
genital	I-MED
tract	I-MED
with	O
central	B-MED
PNETs	I-MED
being	O
more	O
common	O
.	O
Central	B-MED
PNETs	I-MED
show	O
a	O
spectrum	B-MED
of	O
morphologic	B-MED
features	B-MED
that	O
overlaps	O
with	O
CNS	B-MED
tumors	B-MED
but	O
lack	O
EWSR1	B-MED
rearrangement	B-MED
s.	O
GFAP	B-MED
expression	B-MED
supports	O
a	O
morphologic	B-MED
impression	O
of	O
central	B-MED
PNET	I-MED
and	O
is	O
absent	O
in	O
Ewing	O
sarcoma	B-MED
/	I-MED
peripheral	I-MED
PNET	I-MED
.	O
Ewing	B-MED
sarcoma	I-MED
/	I-MED
peripheral	I-MED
PNETs	I-MED
lack	O
morphologic	B-MED
features	B-MED
of	O
CNS	B-MED
tumors	B-MED
.	O
Vascular	B-MED
smooth	I-MED
muscle	I-MED
cell	I-MED
peroxisome	B-MED
proliferator	I-MED
-	I-MED
activated	I-MED
receptor	I-MED
γ	I-MED
protects	O
against	O
endothelin-1	B-MED
-	O
induced	B-MED
oxidative	B-MED
stress	I-MED
and	O
inflammation	B-MED
Peroxisome	B-MED
proliferator	I-MED
-	I-MED
activated	I-MED
receptor	I-MED
γ	I-MED
(	O
PPARγ	B-MED
)	O
agonists	B-MED
reduce	B-MED
blood	B-MED
pressure	I-MED
and	O
vascular	B-MED
injury	I-MED
in	O
hypertensive	B-MED
rodents	B-MED
.	O
Pparγ	B-MED
inactivation	B-MED
in	O
vascular	B-MED
smooth	I-MED
muscle	I-MED
cells	I-MED
(	O
VSMC	B-MED
)	O
enhances	B-MED
vascular	B-MED
injury	I-MED
.	O
Transgenic	B-MED
mice	I-MED
overexpressing	B-MED
endothelin	B-MED
(	I-MED
ET)-1	I-MED
selectively	O
in	O
the	O
endothelium	B-MED
(	B-MED
eET-1	I-MED
)	I-MED
exhibit	O
endothelial	B-MED
dysfunction	I-MED
,	O
increased	B-MED
oxidative	B-MED
stress	I-MED
and	O
inflammation	B-MED
.	O
We	O
hypothesized	B-MED
that	O
inactivation	B-MED
of	O
the	O
Pparγ	B-MED
gene	I-MED
in	O
VSMC	B-MED
(	O
smPparγ	B-MED
)	O
would	O
exaggerate	B-MED
ET-1	B-MED
-	O
induced	B-MED
vascular	B-MED
injury	I-MED
.	O
eET-1	B-MED
,	O
smPparγ	B-MED
and	O
eET-1	B-MED
/	O
smPparγ	B-MED
mice	B-MED
were	O
treated	B-MED
with	O
tamoxifen	B-MED
for	O
5	O
days	O
and	O
studied	B-MED
4	O
weeks	O
later	O
.	O
SBP	B-MED
was	O
higher	B-MED
in	O
eET-1	B-MED
and	O
unaffected	B-MED
by	O
smPparγ	B-MED
inactivation	B-MED
.	O
Mesenteric	B-MED
artery	I-MED
vasodilatory	B-MED
responses	B-MED
to	O
acetylcholine	B-MED
were	O
impaired	B-MED
only	O
in	O
smPparγ	B-MED
.	O
N	B-MED
-	I-MED
Nitro	I-MED
-	I-MED
L	I-MED
-	I-MED
arginine	I-MED
methyl	I-MED
ester	I-MED
abrogated	B-MED
relaxation	B-MED
responses	B-MED
,	O
and	O
the	O
Ednra	B-MED
/	O
Ednrb	B-MED
mRNA	B-MED
ratio	B-MED
was	O
decreased	B-MED
in	O
eET-1	B-MED
/	O
smPparγ	B-MED
,	O
which	O
could	O
indicate	B-MED
that	O
nitric	B-MED
oxide	I-MED
production	B-MED
was	O
enhanced	B-MED
by	O
ET-1	B-MED
stimulation	B-MED
of	O
endothelin	B-MED
type	I-MED
B	I-MED
receptors	I-MED
.	O
Mesenteric	B-MED
artery	I-MED
media	B-MED
/	O
lumen	B-MED
was	O
greater	B-MED
only	O
in	O
eET-1	B-MED
/	O
smPparγ	B-MED
.	O
Mesenteric	B-MED
artery	I-MED
reactive	B-MED
oxygen	I-MED
species	I-MED
increased	B-MED
in	O
smPparγ	B-MED
and	O
were	O
further	O
enhanced	B-MED
in	O
eET-1	B-MED
/	O
smPparγ	B-MED
.	O
Perivascular	B-MED
fat	B-MED
monocyte	I-MED
/	O
macrophage	B-MED
infiltration	B-MED
was	O
higher	B-MED
in	O
eET-1	B-MED
and	O
smPparγ	B-MED
and	O
increased	B-MED
further	O
in	O
eET-1	B-MED
/	O
smPparγ	B-MED
.	O
Spleen	B-MED
CD11b	B-MED
cells	I-MED
were	O
increased	B-MED
in	O
smPparγ	B-MED
and	O
further	O
enhance	B-MED
d	O
in	O
eET-1	B-MED
/	O
smPparγ	B-MED
,	O
whereas	O
Ly-6C	B-MED
monocytes	I-MED
increased	B-MED
in	O
eET-1	B-MED
and	O
smPparγ	B-MED
but	O
not	O
in	O
eET-1	B-MED
/	O
smPparγ	B-MED
.	O
Spleen	B-MED
T	B-MED
regulatory	I-MED
lymphocytes	I-MED
increased	B-MED
in	O
smPparγ	B-MED
and	O
decreased	B-MED
in	O
eET-1	B-MED
,	O
and	O
decreased	B-MED
further	O
in	O
eET-1	B-MED
/	O
smPparγ	B-MED
.	O
VSMC	B-MED
Pparγ	B-MED
inactivation	B-MED
exaggerates	B-MED
ET-1	B-MED
-	O
induced	B-MED
vascular	B-MED
injury	I-MED
,	O
supporting	O
a	O
protective	O
role	B-MED
for	O
PPARγ	B-MED
in	O
hypertension	B-MED
through	O
modulation	B-MED
of	O
pro	B-MED
-	I-MED
oxidant	I-MED
and	O
proinflammatory	B-MED
pathways	B-MED
.	O
Paradoxically	O
,	O
ET-1	B-MED
overexpression	B-MED
preserved	O
endothelial	B-MED
function	B-MED
in	O
smPparγ	B-MED
mice	B-MED
,	O
presumably	O
by	O
enhancing	B-MED
nitric	B-MED
oxide	I-MED
through	O
stimulation	B-MED
of	O
endothelin	B-MED
type	I-MED
B	I-MED
receptors	I-MED
.	O
Endemic	B-MED
hydrothermal	B-MED
vent	I-MED
species	B-MED
identified	B-MED
in	O
the	O
open	O
ocean	B-MED
seed	B-MED
bank	I-MED
Hydrothermal	B-MED
vent	I-MED
systems	B-MED
host	O
microbial	B-MED
communities	B-MED
among	O
which	O
several	B-MED
microorganisms	B-MED
have	O
been	O
considered	B-MED
endemic	B-MED
to	O
this	O
type	O
of	O
habitat	B-MED
.	O
It	O
is	O
still	O
unclear	B-MED
how	O
these	O
organisms	B-MED
colonize	B-MED
geographically	B-MED
distant	B-MED
hydrothermal	B-MED
environments	B-MED
.	O
Based	O
on	O
16S	B-MED
rRNA	I-MED
gene	B-MED
sequences	I-MED
,	O
we	O
compare	B-MED
the	O
bacterial	B-MED
communities	B-MED
of	O
sixteen	O
Atlantic	B-MED
hydrothermal	B-MED
vent	I-MED
samples	B-MED
with	O
our	O
own	O
and	O
publicly	O
available	B-MED
global	B-MED
open	O
ocean	B-MED
samples	B-MED
.	O
Analysing	B-MED
sequences	B-MED
obtained	B-MED
from	O
63	O
million	O
16S	B-MED
rRNA	I-MED
genes	B-MED
,	O
the	O
genera	B-MED
we	O
could	O
identify	O
in	O
the	O
open	O
ocean	B-MED
waters	I-MED
contained	B-MED
99.9	O
%	O
of	O
the	O
vent	B-MED
reads	O
.	O
This	O
suggests	B-MED
that	O
previously	B-MED
observed	B-MED
vent	B-MED
exclusiveness	B-MED
is	O
,	O
in	O
most	O
cases	B-MED
,	O
probably	B-MED
an	O
artefact	B-MED
of	O
lower	B-MED
sequencing	B-MED
depth	B-MED
.	O
These	O
findings	B-MED
are	O
a	O
further	O
step	O
towards	O
elucidating	O
the	O
role	B-MED
of	O
the	O
open	O
ocean	B-MED
as	O
a	O
seed	B-MED
bank	I-MED
.	O
They	O
can	O
explain	O
the	O
predicament	B-MED
of	O
how	O
species	B-MED
expected	B-MED
to	O
be	O
endemic	B-MED
to	O
vent	B-MED
systems	B-MED
are	O
able	B-MED
to	O
colonize	B-MED
geographically	B-MED
distant	B-MED
hydrothermal	B-MED
habitats	B-MED
and	O
contribute	B-MED
to	O
our	O
understanding	B-MED
of	O
whether	O
'	O
everything	O
is	O
really	O
everywhere	O
'	O
.	O
Evaluation	B-MED
of	O
the	O
VIDAS	B-MED
Anti	I-MED
-	I-MED
HCV	I-MED
Assay	I-MED
for	O
Detection	B-MED
of	O
Hepatitis	B-MED
C	I-MED
Virus	I-MED
Infection	I-MED
Anti	B-MED
-	I-MED
hepatitis	I-MED
C	I-MED
virus	I-MED
antibody	I-MED
(	O
anti	B-MED
-	I-MED
HCV	I-MED
)	O
assays	B-MED
are	O
recommended	O
for	O
screening	B-MED
HCV	B-MED
HCV	B-MED
-infected	I-MED
persons	I-MED
.	O
The	O
VIDAS	B-MED
Anti	I-MED
-	I-MED
HCV	I-MED
Assay	I-MED
(	O
bioMérieux	O
,	O
France	B-MED
)	O
,	O
based	O
on	O
the	O
enzyme	B-MED
-	I-MED
linked	I-MED
fluorescence	I-MED
test	I-MED
principle	B-MED
,	O
was	O
recently	O
introduced	O
in	O
Korea	B-MED
.	O
We	O
evaluated	O
the	O
clinical	B-MED
performance	B-MED
of	O
the	O
VIDAS	B-MED
assay	I-MED
.	O
One	O
hundred	O
HCV	B-MED
-	I-MED
positive	I-MED
and	O
1,002	O
HCV	B-MED
-	I-MED
negative	I-MED
blood	B-MED
samples	I-MED
confirmed	O
by	O
Architect	B-MED
anti	I-MED
-	I-MED
HCV	I-MED
(	O
Abbott	B-MED
Laboratories	I-MED
,	O
USA	B-MED
)	O
and	O
COBAS	B-MED
TaqMan	I-MED
HCV	I-MED
real	I-MED
-	I-MED
time	I-MED
PCR	I-MED
(	O
Roche	B-MED
Diagnostics	I-MED
,	O
USA	B-MED
)	O
or	O
the	O
Procleix	B-MED
Ultrio	I-MED
Plus	I-MED
Assay	I-MED
(	O
Gen	O
-	O
Probe	O
Incorporated	O
,	O
USA	B-MED
)	O
were	O
obtained	O
from	O
the	O
Human	B-MED
Serum	I-MED
Bank	I-MED
(	O
HSB	B-MED
)	O
and	O
tested	O
by	O
VIDAS	B-MED
.	O
In	O
case	O
of	O
discrepant	B-MED
results	I-MED
,	O
we	O
conducted	O
a	O
recombinant	B-MED
immunoblot	I-MED
assay	I-MED
(	O
RIBA	B-MED
)	O
.	O
The	O
agreement	B-MED
rates	I-MED
for	O
known	O
HCV	B-MED
-	I-MED
positive	I-MED
and	O
HCV	B-MED
-	I-MED
negative	I-MED
samples	B-MED
between	O
the	O
VIDAS	B-MED
assay	I-MED
and	O
the	O
HSB	B-MED
testing	O
were	O
100	O
%	O
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
:	O
96.4	O
-	O
100	O
%	O
)	O
and	O
99.5	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
98.8	O
-	O
99.8	O
%	O
)	O
,	O
respectively	O
.	O
One	O
of	O
the	O
five	O
discrepant	B-MED
samples	B-MED
was	O
positive	B-MED
for	O
Core	B-MED
2	I-MED
+	I-MED
and	O
NS3	B-MED
-	I-MED
2	I-MED
2	I-MED
+	I-MED
reactivity	O
,	O
two	O
samples	B-MED
were	O
negative	B-MED
,	O
and	O
the	O
other	O
two	O
were	O
indeterminate	O
regarding	O
NS4	B-MED
2	I-MED
+	I-MED
reactivity	O
in	O
RIBA	B-MED
.	O
We	O
observed	O
a	O
significant	O
but	O
weak	O
positive	O
correlation	B-MED
between	O
the	O
titers	B-MED
of	O
VIDAS	B-MED
and	O
Architect	B-MED
assays	I-MED
(	O
r=0.315	O
,	O
P<0.001	O
)	O
.	O
The	O
VIDAS	B-MED
anti	I-MED
-	I-MED
HCV	I-MED
assay	I-MED
,	O
developed	O
on	O
the	O
VIDAS	B-MED
automated	B-MED
immunoassay	I-MED
platform	I-MED
based	O
on	O
the	O
ready	O
-	O
to	O
-	O
use	O
,	O
single	O
-	O
sample	O
test	O
concept	O
may	O
be	O
useful	O
in	O
small	O
-	O
to	O
-	O
medium	O
-	O
sized	O
laboratories	B-MED
.	O
It	O
showed	O
good	O
agreement	O
with	O
Architect	B-MED
anti	I-MED
-	I-MED
HCV	I-MED
and	O
COBAS	B-MED
PCR	I-MED
assays	I-MED
and	O
is	O
therefore	O
useful	O
for	O
detection	O
of	O
HCV	B-MED
infection	I-MED
.	O
Weakly	B-MED
test	I-MED
-	I-MED
positive	I-MED
(	I-MED
ambiguous	I-MED
)	I-MED
samples	B-MED
require	O
additional	O
testing	O
by	O
another	O
anti	B-MED
-	I-MED
HCV	I-MED
,	O
RIBA	B-MED
,	O
or	O
HCV	B-MED
RNA	I-MED
assay	I-MED
.	O
Ultra	B-MED
-	I-MED
low	I-MED
activities	I-MED
of	O
a	O
common	O
radioisotope	B-MED
for	O
permission	B-MED
-free	O
tracking	B-MED
of	O
a	O
drosophilid	B-MED
fly	I-MED
in	O
its	O
natural	B-MED
habitat	I-MED
Knowledge	O
of	O
a	O
species	B-MED
'	O
ecology	B-MED
,	O
including	O
its	O
movement	B-MED
in	O
time	B-MED
and	O
space	B-MED
,	O
is	O
key	O
for	O
many	O
questions	O
in	O
biology	B-MED
and	O
conservation	B-MED
.	O
While	O
numerous	O
tools	B-MED
for	O
tracking	B-MED
larger	O
animals	B-MED
are	O
available	O
,	O
millimetre	B-MED
-	I-MED
sized	I-MED
insects	I-MED
are	O
averse	O
to	O
standard	O
tracking	B-MED
and	O
labelling	B-MED
procedures	I-MED
.	O
Here	O
,	O
we	O
evaluated	O
the	O
applicability	O
of	O
ultra	B-MED
-	I-MED
low	I-MED
,	O
permission	B-MED
-	O
exempt	B-MED
activities	I-MED
of	O
the	O
metastable	B-MED
isomer	I-MED
of	O
the	O
radionuclide	B-MED
Technetium-99	B-MED
for	O
labelling	B-MED
and	O
field	B-MED
detection	I-MED
of	O
the	O
mountain	B-MED
fly	B-MED
Drosophila	B-MED
nigrosparsa	I-MED
.	O
We	O
demonstrate	O
that	O
an	O
activity	B-MED
of	O
less	O
than	O
10	O
MBq	O
is	O
sufficient	O
to	O
label	B-MED
dozens	O
of	O
flies	B-MED
and	O
detect	B-MED
single	I-MED
individuals	I-MED
using	O
standard	O
radiation	B-MED
protection	I-MED
monitors	B-MED
.	O
The	O
methodology	B-MED
presented	O
here	O
is	O
applicable	O
to	O
many	O
small	B-MED
-	I-MED
sized	I-MED
,	O
low	B-MED
-	I-MED
mobility	I-MED
animals	B-MED
as	O
well	O
as	O
independent	O
from	O
light	B-MED
and	O
weather	B-MED
conditions	B-MED
and	O
visual	B-MED
contact	I-MED
with	O
the	O
target	B-MED
organism	B-MED
.	O
Risk	B-MED
of	I-MED
cancer	I-MED
in	O
patients	B-MED
with	O
heart	B-MED
failure	I-MED
who	O
use	O
digoxin	B-MED
:	O
a	O
10	O
-	O
year	O
follow	B-MED
-	I-MED
up	I-MED
study	I-MED
and	O
cell	B-MED
-based	O
verification	B-MED
Heart	B-MED
failure	I-MED
(	O
HF	B-MED
)	O
is	O
the	O
leading	O
cause	B-MED
of	I-MED
death	I-MED
in	O
the	O
world	B-MED
and	O
digoxin	B-MED
remains	O
one	O
of	O
the	O
oldest	O
therapies	B-MED
for	O
HF	B-MED
.	O
However	O
,	O
its	O
safety	B-MED
and	O
efficacy	B-MED
have	O
been	O
controversial	O
since	O
its	O
initial	O
use	B-MED
and	O
there	O
is	O
uncertainty	B-MED
about	O
its	O
long	B-MED
-	I-MED
term	I-MED
efficacy	B-MED
and	O
safety	B-MED
.	O
Recently	O
,	O
the	O
repositioning	B-MED
of	O
cardiac	B-MED
glycosides	I-MED
is	O
to	O
function	B-MED
in	O
anti	B-MED
-	I-MED
tumor	I-MED
activity	I-MED
via	O
multiple	B-MED
working	B-MED
pathways	I-MED
.	O
It	O
is	O
interesting	O
to	O
compare	B-MED
the	O
potential	B-MED
effects	B-MED
of	O
digoxin	B-MED
in	O
clinical	B-MED
patients	B-MED
and	O
cell	B-MED
lines	I-MED
.	O
First	O
,	O
we	O
analyze	O
patient	B-MED
information	I-MED
retrieved	O
from	O
the	O
National	B-MED
Health	I-MED
Insurance	I-MED
Research	I-MED
database	I-MED
of	O
Taiwan	B-MED
between	O
January	O
1	O
,	O
2000	O
and	O
December	O
31	O
,	O
2000	O
.	O
This	O
retrospective	B-MED
study	I-MED
included	O
a	O
study	O
cohort	B-MED
(	O
1,219	O
patients	B-MED
)	O
and	O
a	O
comparison	B-MED
cohort	B-MED
.	O
Our	O
analytical	B-MED
data	I-MED
suggested	O
that	O
patients	B-MED
taking	O
digoxin	B-MED
are	O
at	O
an	O
increased	B-MED
risk	B-MED
of	I-MED
cancers	I-MED
,	O
including	O
breast	B-MED
,	O
liver	B-MED
,	O
and	O
lung	B-MED
cancers	I-MED
,	O
during	O
the	O
10	O
-	O
year	O
follow	B-MED
-	I-MED
up	I-MED
period	I-MED
.	O
In	O
contrast	O
to	O
the	O
anti	B-MED
-	I-MED
tumor	I-MED
function	I-MED
of	O
digoxin	B-MED
,	O
we	O
further	O
examined	O
the	O
potential	B-MED
pathway	B-MED
of	O
digoxin	B-MED
via	O
the	O
cell	B-MED
-based	O
strategy	B-MED
using	O
several	O
breast	B-MED
cancer	I-MED
cell	B-MED
lines	I-MED
,	O
including	O
MCF-7	B-MED
,	O
BT-474	B-MED
,	O
MAD	B-MED
-	I-MED
MB-231	I-MED
,	O
and	O
ZR-75	B-MED
-	I-MED
1	I-MED
.	O
Digoxin	B-MED
consistently	O
exerted	O
its	O
cytotoxicity	B-MED
to	O
these	O
four	O
cell	B-MED
lines	I-MED
with	O
various	O
range	O
of	O
concentration	B-MED
.	O
However	O
,	O
the	O
proliferation	B-MED
of	O
ZR-75	B-MED
-	I-MED
1	I-MED
cells	I-MED
was	O
the	O
only	O
cell	B-MED
lines	I-MED
induced	O
by	O
digoxin	B-MED
and	O
the	O
others	O
were	O
dramatically	O
suppressed	B-MED
by	O
digoxin	B-MED
.	O
The	O
responsiveness	B-MED
of	O
SRSF3	B-MED
to	O
digoxin	B-MED
might	O
be	O
involved	O
with	O
cell	B-MED
-	I-MED
type	I-MED
differences	B-MED
.	O
In	O
summary	O
,	O
we	O
combined	O
a	O
cohort	B-MED
study	I-MED
for	O
digoxin	B-MED
treatment	B-MED
for	O
HF	B-MED
patients	B-MED
with	O
a	O
cell	B-MED
-based	O
strategy	B-MED
that	O
addresses	O
the	O
translation	O
issue	O
,	O
which	O
revealed	O
the	O
complexity	B-MED
of	O
personalized	B-MED
medicine	I-MED
.	O
An	O
Analysis	B-MED
of	O
Systematic	B-MED
Elemental	B-MED
Changes	B-MED
in	O
Decomposing	B-MED
Bone	I-MED
The	O
aim	B-MED
of	O
this	O
pilot	B-MED
study	I-MED
was	O
to	O
investigate	B-MED
compositional	B-MED
changes	B-MED
in	O
bone	B-MED
during	O
decomposition	B-MED
.	O
Elemental	B-MED
concentrations	B-MED
of	O
barium	B-MED
,	O
calcium	B-MED
,	O
iron	B-MED
,	O
potassium	B-MED
,	O
magnesium	B-MED
,	O
zinc	B-MED
and	O
phosphorus	B-MED
in	O
porcine	B-MED
bone	B-MED
(	O
as	O
an	O
experimental	B-MED
analog	B-MED
for	O
human	B-MED
bone	B-MED
)	O
were	O
analyzed	B-MED
by	O
inductively	B-MED
coupled	I-MED
plasma	I-MED
optical	I-MED
emission	I-MED
spectroscopy	I-MED
(	O
ICP	B-MED
-	I-MED
OES	I-MED
)	O
.	O
The	O
samples	B-MED
were	O
taken	O
from	O
porcine	B-MED
bone	B-MED
subjected	B-MED
to	O
shallow	B-MED
burial	I-MED
and	O
surface	B-MED
depositions	B-MED
at	O
28-	O
day	B-MED
intervals	B-MED
for	O
a	O
period	B-MED
of	O
140	O
days	B-MED
.	O
Results	B-MED
indicated	B-MED
that	O
ICP	B-MED
-	I-MED
OES	I-MED
elemental	B-MED
profiling	B-MED
has	O
potential	B-MED
to	O
be	O
developed	B-MED
as	O
a	O
forensic	B-MED
test	I-MED
for	O
determining	B-MED
whether	O
a	O
bone	B-MED
sample	I-MED
originates	O
from	O
the	O
early	B-MED
stages	B-MED
of	O
soft	B-MED
tissue	I-MED
putrefaction	B-MED
.	O
Significant	B-MED
changes	I-MED
in	O
iron	B-MED
,	O
sodium	B-MED
and	O
potassium	B-MED
concentrations	B-MED
were	O
found	B-MED
over	B-MED
140	O
days	B-MED
.	O
These	O
elements	B-MED
are	O
known	B-MED
to	O
be	O
primarily	B-MED
associated	B-MED
with	I-MED
proteins	B-MED
and/or	O
tissue	B-MED
fluids	I-MED
within	O
the	O
bone	B-MED
.	O
Changes	B-MED
in	O
their	O
respective	O
concentrations	B-MED
may	O
therefore	O
be	O
linked	O
to	O
dehydration	B-MED
over	O
time	B-MED
and	O
in	O
turn	O
may	O
be	O
indicative	O
of	O
time	B-MED
since	B-MED
deposition	B-MED
.	O
Vitamin	B-MED
D	I-MED
Receptor	I-MED
Activator	I-MED
Use	O
and	O
Cause	B-MED
-	I-MED
specific	I-MED
Death	I-MED
among	O
dialysis	B-MED
Patients	B-MED
:	O
a	O
Nationwide	B-MED
Cohort	I-MED
Study	I-MED
using	O
Coarsened	B-MED
Exact	I-MED
Matching	I-MED
Vitamin	B-MED
D	I-MED
receptor	I-MED
activators	I-MED
(	O
VDRA	B-MED
)	O
may	O
exert	O
pleiotropic	B-MED
effects	I-MED
on	O
cardiovascular	B-MED
disease	I-MED
,	O
malignancy	B-MED
,	O
and	O
infections	B-MED
among	O
dialysis	B-MED
patients	B-MED
,	O
but	O
recent	O
studies	O
have	O
mainly	O
focused	O
on	O
cardiovascular	B-MED
outcomes	I-MED
.	O
Among	O
8,675	O
patients	B-MED
who	O
started	O
dialysis	B-MED
in	O
2007	O
and	O
who	B-MED
survived	I-MED
until	O
January	O
1	O
,	O
2010	O
,	O
listed	O
in	O
the	O
Renal	B-MED
Data	I-MED
Registry	I-MED
of	O
the	O
Japanese	B-MED
Society	I-MED
for	O
Dialysis	B-MED
Therapy	I-MED
,	O
5,365	O
VDRA	B-MED
users	O
were	O
matched	O
to	O
3,203	O
non	O
-	O
users	O
based	O
on	O
clinically	B-MED
relevant	I-MED
variables	I-MED
at	O
the	O
end	O
of	O
2009	O
using	O
the	O
coarsened	B-MED
exact	I-MED
matching	I-MED
procedure	I-MED
.	O
Until	O
December	O
31	O
,	O
2011	O
,	O
a	O
total	O
of	O
1,128	O
deaths	B-MED
occurred	O
,	O
of	O
which	O
468	O
(	O
42	O
%	O
)	O
were	O
cardiovascular	B-MED
deaths	I-MED
,	O
229	O
(	O
20	O
%	O
)	O
were	O
infection	B-MED
-	I-MED
related	I-MED
deaths	I-MED
,	O
and	O
141	O
(	O
12	O
%	O
)	O
were	O
malignancy	B-MED
-	I-MED
related	I-MED
deaths	I-MED
.	O
Multivariable	B-MED
survival	I-MED
analyses	I-MED
accounting	O
for	O
intra	B-MED
-	I-MED
region	I-MED
correlation	I-MED
revealed	O
that	O
VDRA	B-MED
use	O
was	O
significantly	O
associated	O
with	O
lower	B-MED
rates	I-MED
of	O
infection	B-MED
-	O
and	O
malignancy	B-MED
-related	O
deaths	B-MED
[	O
subhazard	B-MED
ratio	I-MED
0.62	O
(	O
95	O
%	O
CI	B-MED
,	O
0.52	O
-	O
0.73	O
)	O
and	O
0.70	O
(	O
95	O
%	O
CI	B-MED
,	O
0.50	O
-	O
0.97	O
)	O
,	O
respectively	O
]	O
but	O
not	O
with	O
cardiovascular	B-MED
death	I-MED
[	O
subhazard	B-MED
ratio	I-MED
0.86	O
(	O
95	O
%	O
CI	B-MED
,	O
0.72	O
-	O
1.04	O
)	O
]	O
.	O
Future	O
randomized	B-MED
clinical	I-MED
trials	I-MED
with	O
a	O
sufficient	O
sample	B-MED
size	I-MED
and	O
an	O
adequate	O
follow	B-MED
-	I-MED
up	I-MED
period	O
are	O
warranted	O
to	O
test	O
the	O
clinical	B-MED
effectiveness	I-MED
of	O
VDRA	B-MED
on	O
infection	B-MED
and	O
malignancy	B-MED
,	O
rather	O
than	O
cardiovascular	B-MED
disease	I-MED
,	O
among	O
dialysis	B-MED
patients	B-MED
.	O
Altered	B-MED
pH	I-MED
gradient	I-MED
at	O
the	O
plasma	B-MED
membrane	I-MED
of	O
osteosarcoma	B-MED
cells	B-MED
is	O
a	O
key	O
mechanism	B-MED
of	O
drug	B-MED
resistance	I-MED
Current	O
therapy	B-MED
of	O
osteosarcoma	B-MED
(	O
OS	B-MED
)	O
,	O
the	O
most	O
common	O
primary	B-MED
bone	I-MED
malignancy	I-MED
,	O
is	O
based	O
on	O
a	O
combination	B-MED
of	I-MED
surgery	I-MED
and	I-MED
chemotherapy	I-MED
.	O
Multidrug	B-MED
resistance	I-MED
mediated	O
by	O
P	B-MED
-	I-MED
glycoprotein	I-MED
(	O
P	B-MED
-	I-MED
gp	I-MED
)	O
overexpression	B-MED
has	O
been	O
previously	O
associated	O
with	O
treatment	B-MED
failure	I-MED
and	O
progression	B-MED
of	O
OS	B-MED
,	O
although	O
other	O
mechanisms	B-MED
may	O
also	O
play	O
a	O
role	O
.	O
We	O
considered	O
the	O
typical	O
acidic	B-MED
extracellular	I-MED
pH	I-MED
(	O
pHe	B-MED
)	O
of	O
sarcomas	B-MED
,	O
and	O
found	O
that	O
doxorubicin	B-MED
(	O
DXR	B-MED
)	O
cytotoxicity	B-MED
is	O
reduced	B-MED
in	O
P	B-MED
-	I-MED
gp	I-MED
negative	O
OS	B-MED
cells	B-MED
cultured	I-MED
at	O
pHe	B-MED
6.5	O
compared	O
to	O
standard	O
7.4	O
.	O
Short	B-MED
-	I-MED
time	I-MED
(	O
24	O
-	O
48	O
hours	O
)	O
exposure	B-MED
to	I-MED
low	O
pHe	B-MED
significantly	B-MED
increased	I-MED
the	O
number	O
and	O
acidity	B-MED
of	O
lysosomes	B-MED
,	O
and	O
the	O
combination	B-MED
of	O
DXR	B-MED
with	O
omeprazole	B-MED
,	O
a	O
proton	B-MED
pump	I-MED
inhibitor	I-MED
targeting	O
lysosomal	B-MED
acidity	I-MED
,	O
significantly	B-MED
enhanced	I-MED
DXR	B-MED
cytotoxicity	B-MED
.	O
In	O
OS	B-MED
xenografts	B-MED
,	O
the	O
combination	B-MED
treatment	I-MED
of	O
DXR	B-MED
and	O
omeprazole	B-MED
significantly	B-MED
reduced	I-MED
tumor	B-MED
volume	I-MED
and	O
body	B-MED
weight	I-MED
loss	I-MED
.	O
The	O
impaired	B-MED
toxicity	I-MED
of	O
DXR	B-MED
at	O
low	O
pHe	B-MED
was	O
not	O
associated	O
with	O
increased	B-MED
autophagy	B-MED
or	O
lysosomal	B-MED
acidification	I-MED
,	O
but	O
rather	O
,	O
as	O
shown	O
by	O
SNARF	B-MED
staining	B-MED
,	O
with	O
a	O
reversal	B-MED
of	O
the	O
pH	B-MED
gradient	I-MED
at	O
the	O
plasma	B-MED
membrane	I-MED
(	O
ΔpHcm	B-MED
)	O
,	O
eventually	O
leading	O
to	O
a	O
reduced	B-MED
DXR	B-MED
intracellular	B-MED
accumulation	B-MED
.	O
Finally	O
,	O
the	O
reversal	B-MED
of	O
ΔpHcm	B-MED
in	O
OS	B-MED
cells	B-MED
promoted	O
resistance	B-MED
not	O
only	O
to	O
DXR	B-MED
,	O
but	O
also	O
to	O
cisplatin	B-MED
and	O
methotrexate	B-MED
,	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
to	O
vincristine	B-MED
.	O
Altogether	O
,	O
our	O
findings	O
show	O
that	O
,	O
in	O
OS	B-MED
cells	B-MED
,	O
short	B-MED
-	I-MED
term	I-MED
acidosis	B-MED
induces	O
resistance	B-MED
to	O
different	O
chemotherapeutic	B-MED
drugs	I-MED
by	O
a	O
reversal	B-MED
of	O
ΔpHcm	B-MED
,	O
suggesting	O
that	O
buffer	B-MED
therapies	B-MED
or	O
regimens	B-MED
including	O
proton	B-MED
pump	I-MED
inhibitors	I-MED
in	O
combination	B-MED
to	O
low	O
concentrations	B-MED
of	O
conventional	O
anticancer	B-MED
agents	I-MED
may	O
offer	O
novel	B-MED
solutions	O
to	O
overcome	B-MED
drug	B-MED
resistance	I-MED
.	O
Consecutive	B-MED
Endovascular	B-MED
Treatment	I-MED
of	O
20	O
Ruptured	B-MED
Very	O
Small	B-MED
(	O
<3	O
mm	O
)	O
Anterior	B-MED
Communicating	I-MED
Artery	I-MED
Aneurysms	I-MED
Small	B-MED
aneurysms	B-MED
located	O
at	O
the	O
anterior	B-MED
communicating	I-MED
artery	I-MED
carry	O
significant	O
procedural	O
challenges	O
due	O
to	O
a	O
complex	O
anatomy	B-MED
.	O
Recent	O
advances	O
in	O
endovascular	B-MED
technologies	I-MED
have	O
expanded	O
the	O
use	O
of	O
coil	B-MED
embolization	I-MED
for	O
small	B-MED
aneurysm	B-MED
treatment	B-MED
.	O
However	O
,	O
limited	O
reports	O
describe	O
their	O
safety	B-MED
and	O
efficacy	B-MED
profiles	O
in	O
very	O
small	B-MED
anterior	B-MED
communicating	I-MED
artery	I-MED
aneurysms	I-MED
.	O
We	O
sought	O
to	O
review	O
and	O
report	O
the	O
immediate	O
and	O
long	B-MED
-	I-MED
term	I-MED
clinical	I-MED
as	O
well	O
as	O
radiographic	B-MED
outcomes	I-MED
of	O
consecutive	B-MED
patients	B-MED
with	O
ruptured	B-MED
very	O
small	B-MED
anterior	B-MED
communicating	I-MED
artery	I-MED
aneurysms	I-MED
treated	O
with	O
current	O
endovascular	B-MED
coil	I-MED
embolization	I-MED
techniques	I-MED
.	O
A	O
prospectively	O
maintained	O
single	O
-	O
institution	O
neuroendovascular	B-MED
database	I-MED
was	O
accessed	O
to	O
identify	O
consecutive	O
cases	O
of	O
very	O
small	B-MED
(	O
<3	O
mm	O
)	O
ruptured	B-MED
anterior	B-MED
communicating	I-MED
artery	I-MED
aneurysms	I-MED
treated	O
endovascularly	O
between	O
2006	O
and	O
2013	O
.	O
A	O
total	O
of	O
20	O
patients	B-MED
with	O
ruptured	B-MED
very	O
small	B-MED
(	O
<3	O
mm	O
)	O
anterior	B-MED
communicating	I-MED
artery	I-MED
aneurysms	I-MED
were	O
consecutively	B-MED
treated	O
with	O
coil	B-MED
embolization	I-MED
.	O
The	O
average	O
maximum	O
diameter	B-MED
was	O
2.66	O
±	O
0.41	O
mm	O
.	O
Complete	O
aneurysm	B-MED
occlusion	I-MED
was	O
achieved	O
for	O
17	O
(	O
85	O
%	O
)	O
aneurysms	B-MED
and	O
near	O
-	O
complete	O
aneurysm	B-MED
occlusion	I-MED
for	O
3	O
(	O
15	O
%	O
)	O
aneurysms	B-MED
.	O
Intraoperative	B-MED
perforation	B-MED
was	O
seen	O
in	O
2	O
(	O
10	O
%	O
)	O
patients	B-MED
without	O
any	O
clinical	B-MED
worsening	I-MED
or	O
need	O
for	O
an	O
external	B-MED
ventricular	I-MED
drain	I-MED
.	O
A	O
thromboembolic	B-MED
event	I-MED
occurred	O
in	O
1	O
(	O
5	O
%	O
)	O
patient	B-MED
without	O
clinical	B-MED
worsening	I-MED
or	O
radiologic	B-MED
infarct	I-MED
.	O
Median	O
clinical	O
follow	B-MED
-	I-MED
up	I-MED
was	O
12	O
(	O
±14.1	O
)	O
months	B-MED
and	O
median	O
imaging	O
follow	B-MED
-	I-MED
up	I-MED
was	O
12	O
(	O
±18.4	O
)	O
months	B-MED
.	O
This	O
report	O
describes	O
the	O
largest	O
series	O
of	O
consecutive	B-MED
endovascular	B-MED
treatments	I-MED
of	O
ruptured	B-MED
very	O
small	B-MED
anterior	B-MED
communicating	I-MED
artery	I-MED
aneurysms	I-MED
.	O
These	O
findings	O
suggest	O
that	O
coil	B-MED
embolization	I-MED
of	O
very	O
small	B-MED
aneurysms	B-MED
in	O
this	O
location	B-MED
can	O
be	O
performed	O
with	O
acceptable	O
rates	O
of	O
complications	B-MED
and	O
recanalization	B-MED
.	O
Vestibular	B-MED
-dependent	O
inter	B-MED
-	I-MED
stimulus	I-MED
interval	I-MED
effects	B-MED
on	O
sound	B-MED
evoked	I-MED
potentials	I-MED
of	O
central	B-MED
origin	B-MED
Todd	O
et	O
al	O
.	O
(	O
2014ab	O
)	O
have	O
recently	O
demonstrated	O
the	O
presence	B-MED
of	O
vestibular	B-MED
-dependent	O
contributions	B-MED
to	O
auditory	B-MED
evoked	I-MED
potentials	I-MED
(	O
AEPs	B-MED
)	O
when	O
passing	O
through	O
the	O
vestibular	B-MED
threshold	B-MED
as	O
determined	O
by	O
vestibular	B-MED
evoked	I-MED
myogenic	I-MED
potentials	I-MED
(	O
VEMPs	B-MED
)	O
,	O
including	O
a	O
particular	O
deflection	B-MED
labeled	B-MED
as	O
an	O
N42	O
/	O
P52	O
prior	B-MED
to	O
the	O
long	B-MED
-	O
latency	B-MED
AEPs	B-MED
N1	O
and	O
P2	O
.	O
In	O
this	O
paper	O
we	O
report	B-MED
the	O
results	B-MED
of	O
an	O
experiment	B-MED
to	O
determine	O
the	O
effect	B-MED
of	I-MED
inter	B-MED
-	I-MED
stimulus	I-MED
interval	I-MED
(	O
ISI	B-MED
)	O
and	O
regularity	B-MED
on	O
potentials	B-MED
recorded	O
above	B-MED
and	O
below	B-MED
VEMP	B-MED
threshold	B-MED
.	O
Five	O
healthy	B-MED
,	O
right	B-MED
-	I-MED
handed	I-MED
subjects	B-MED
were	O
recruited	O
and	O
evoked	B-MED
potentials	I-MED
were	O
recorded	O
to	O
binaurally	O
presented	O
sound	B-MED
stimulation	I-MED
,	O
above	B-MED
and	O
below	B-MED
vestibular	B-MED
threshold	B-MED
,	O
at	O
seven	O
stimulus	B-MED
rates	B-MED
with	O
ISIs	B-MED
of	O
212	O
,	O
300	O
,	O
424	O
,	O
600	O
,	O
848	O
,	O
1200	O
and	O
1696	O
ms	O
.	O
The	O
inner	O
five	O
intervals	B-MED
,	O
i.e.	O
300	O
,	O
424	O
,	O
600	O
,	O
848	O
,	O
1200	O
ms	O
,	O
were	O
presented	B-MED
twice	O
in	O
both	O
regular	B-MED
and	O
irregular	B-MED
conditions	O
.	O
ANOVA	B-MED
on	O
the	O
global	B-MED
field	I-MED
power	I-MED
(	O
GFP	B-MED
)	O
were	O
conducted	O
for	O
each	O
of	O
four	O
waves	O
,	O
N42	O
,	O
P52	O
,	O
N1	O
and	O
P2	O
with	O
factors	O
of	O
intensity	B-MED
,	O
ISI	B-MED
and	O
regularity	B-MED
.	O
Both	O
N42	O
and	O
P52	O
waves	O
showed	O
significant	B-MED
ANOVA	B-MED
effects	B-MED
of	I-MED
intensity	B-MED
but	O
no	O
other	O
main	O
effects	B-MED
or	O
interactions	B-MED
.	O
In	O
contrast	O
both	O
N1	O
and	O
P2	O
showed	O
additional	B-MED
effects	B-MED
of	I-MED
ISI	B-MED
,	O
as	O
well	O
as	O
intensity	B-MED
,	O
and	O
evidence	B-MED
of	I-MED
non	B-MED
-	O
linear	B-MED
interactions	B-MED
between	O
ISI	B-MED
and	O
intensity	B-MED
.	O
A	O
source	B-MED
analysis	I-MED
was	O
carried	O
out	O
consistent	B-MED
with	I-MED
prior	B-MED
work	O
suggesting	O
that	O
when	O
above	B-MED
vestibular	B-MED
threshold	B-MED
,	O
in	B-MED
addition	I-MED
to	I-MED
bilateral	B-MED
superior	B-MED
temporal	B-MED
cortex	I-MED
,	O
ocular	B-MED
,	O
cerebellar	B-MED
and	O
cingulate	B-MED
sources	B-MED
are	O
recruited	O
.	O
Further	O
statistical	B-MED
analysis	I-MED
of	O
the	O
source	B-MED
currents	B-MED
indicated	O
that	O
the	O
origin	O
of	O
the	O
interactions	B-MED
with	O
intensity	B-MED
may	O
be	O
the	O
ISI	B-MED
sensitivity	B-MED
of	O
the	O
vestibular	B-MED
-dependent	O
sources	B-MED
.	O
This	O
in	O
turn	O
may	O
reflect	O
a	O
specific	B-MED
vestibular	B-MED
preference	B-MED
for	O
stimulus	B-MED
rates	B-MED
associated	B-MED
with	I-MED
locomotion	B-MED
,	O
i.e.	O
rates	B-MED
close	O
to	O
2	O
Hz	O
,	O
or	O
ISIs	B-MED
close	O
to	O
500	O
ms	O
,	O
where	O
saccular	B-MED
afferents	B-MED
show	O
increased	B-MED
gain	B-MED
and	O
the	O
corresponding	O
reflexes	B-MED
are	O
most	O
sensitive	B-MED
.	O
Mucosal	B-MED
IgM	B-MED
Antibody	I-MED
with	O
d	B-MED
-	I-MED
Mannose	I-MED
Affinity	B-MED
in	O
Fugu	B-MED
Takifugu	I-MED
rubripes	I-MED
Is	O
Utilized	O
by	O
a	O
Monogenean	B-MED
Parasite	B-MED
Heterobothrium	B-MED
okamotoi	I-MED
for	O
Host	B-MED
Recognition	I-MED
How	O
parasites	B-MED
recognize	B-MED
their	O
definitive	B-MED
hosts	B-MED
is	O
a	O
mystery	O
;	O
however	O
,	O
parasitism	B-MED
is	O
reportedly	O
initiated	O
by	O
recognition	B-MED
of	O
certain	O
molecules	B-MED
on	O
host	B-MED
surfaces	I-MED
.	O
Fish	B-MED
ectoparasites	B-MED
make	O
initial	B-MED
contact	I-MED
with	O
their	O
hosts	B-MED
at	O
body	B-MED
surfaces	I-MED
,	O
such	O
as	O
skin	B-MED
and	O
gills	B-MED
,	O
which	O
are	O
covered	B-MED
with	O
mucosa	B-MED
that	O
are	O
similar	O
to	O
those	O
of	O
mammalian	B-MED
guts	I-MED
.	O
Fish	B-MED
are	O
among	O
the	O
most	O
primitive	B-MED
vertebrates	I-MED
with	O
immune	B-MED
systems	I-MED
that	O
are	O
equivalent	O
to	O
those	O
in	O
mammals	B-MED
,	O
and	O
they	O
produce	O
and	O
secrete	B-MED
IgM	B-MED
into	O
mucus	B-MED
.	O
In	O
this	O
study	O
,	O
we	O
showed	O
that	O
the	O
monogenean	B-MED
parasite	B-MED
Heterobothrium	B-MED
okamotoi	I-MED
utilizes	O
IgM	B-MED
to	O
recognize	B-MED
its	O
host	B-MED
,	O
fugu	B-MED
Takifugu	I-MED
rubripes	I-MED
Oncomiracidia	I-MED
are	O
infective	B-MED
larvae	I-MED
of	O
H.	B-MED
okamotoi	I-MED
that	O
shed	O
their	O
cilia	B-MED
and	O
metamorphose	B-MED
into	O
juveniles	B-MED
when	O
exposed	O
to	O
purified	B-MED
d	B-MED
-	I-MED
mannose	I-MED
-	O
binding	B-MED
fractions	B-MED
from	O
fugu	B-MED
fugu	B-MED
mucus	B-MED
.	O
Using	O
liquid	B-MED
chromatography	I-MED
-	I-MED
tandem	I-MED
mass	I-MED
spectrometry	I-MED
analysis	I-MED
,	O
proteins	B-MED
contained	O
in	O
the	O
fraction	B-MED
were	O
identified	B-MED
as	O
d	B-MED
-	I-MED
mannose	I-MED
-specific	O
IgM	B-MED
with	O
two	O
d	B-MED
-	I-MED
mannose	I-MED
d	B-MED
-	I-MED
mannose	I-MED
-binding	I-MED
lectins	B-MED
.	O
However	O
,	O
although	O
deciliation	B-MED
was	O
significantly	O
induced	B-MED
by	O
IgM	B-MED
and	O
was	O
inhibited	B-MED
by	O
d	B-MED
-	I-MED
mannose	I-MED
or	O
a	O
specific	O
Ab	B-MED
against	O
fugu	B-MED
IgM	B-MED
,	O
other	O
lectins	B-MED
had	O
no	B-MED
effect	I-MED
,	O
and	O
IgM	B-MED
without	O
d	B-MED
-	I-MED
mannose	I-MED
affinity	B-MED
induced	B-MED
deciliation	B-MED
to	O
a	O
limited	O
degree	O
.	O
Subsequent	O
immunofluorescent	B-MED
staining	I-MED
experiments	I-MED
showed	O
that	O
fugu	B-MED
d	B-MED
-	I-MED
mannose	I-MED
-specific	O
IgM	B-MED
binds	B-MED
ciliated	B-MED
epidermal	I-MED
cells	I-MED
of	O
oncomiracidium	B-MED
.	O
These	O
observations	B-MED
suggest	O
that	O
deciliation	B-MED
is	O
triggered	B-MED
by	I-MED
binding	B-MED
of	O
fugu	B-MED
IgM	B-MED
to	O
cell	B-MED
surface	I-MED
Ags	I-MED
via	O
Ag	B-MED
binding	I-MED
sites	I-MED
.	O
Moreover	O
,	O
concentrations	B-MED
of	O
d	B-MED
-	I-MED
mannose	I-MED
-	O
binding	B-MED
IgM	B-MED
in	O
gill	B-MED
mucus	I-MED
were	O
sufficient	O
to	O
induce	B-MED
deciliation	B-MED
in	B-MED
vitro	I-MED
,	O
indicating	B-MED
that	O
H.	B-MED
okamotoi	I-MED
parasites	I-MED
initially	O
use	B-MED
host	B-MED
Abs	B-MED
to	O
colonize	B-MED
host	B-MED
gills	B-MED
.	O
Experience	B-MED
is	O
Instrumental	B-MED
in	O
Tuning	B-MED
a	O
Link	B-MED
Between	O
Language	B-MED
and	O
Cognition	B-MED
:	O
Evidence	B-MED
from	O
6-	B-MED
to	I-MED
7-	I-MED
Month	I-MED
-	I-MED
Old	I-MED
Infants	B-MED
'	O
Object	O
Categorization	B-MED
At	B-MED
birth	I-MED
,	O
infants	B-MED
not	O
only	O
prefer	O
listening	B-MED
to	O
human	B-MED
vocalizations	B-MED
,	O
but	O
also	O
have	O
begun	B-MED
to	O
link	B-MED
these	O
vocalizations	B-MED
to	O
cognition	B-MED
:	O
For	O
infants	B-MED
as	O
young	B-MED
as	O
three	B-MED
months	I-MED
of	O
age	B-MED
,	O
listening	B-MED
to	O
human	B-MED
language	B-MED
supports	O
object	O
categorization	B-MED
,	O
a	O
core	B-MED
cognitive	B-MED
capacity	B-MED
.	O
This	O
precocious	B-MED
link	B-MED
is	O
initially	B-MED
broad	B-MED
:	O
At	O
3	O
and	O
4	O
months	O
,	O
vocalizations	B-MED
of	O
both	B-MED
humans	B-MED
and	O
nonhuman	B-MED
primates	I-MED
support	O
categorization	B-MED
.	O
But	O
by	O
6	B-MED
months	I-MED
,	O
infants	B-MED
have	O
narrowed	B-MED
the	O
link	B-MED
:	O
Only	O
human	B-MED
vocalizations	B-MED
support	O
object	O
categorization	B-MED
.	O
Here	O
we	O
ask	O
what	O
guides	O
infants	B-MED
as	O
they	O
tune	B-MED
their	O
initially	B-MED
broad	B-MED
link	B-MED
to	O
a	O
more	O
precise	B-MED
one	O
,	O
engaged	O
only	O
by	O
the	O
vocalizations	B-MED
of	O
our	O
species	B-MED
.	O
Across	O
three	O
studies	B-MED
,	O
we	O
use	O
a	O
novel	B-MED
exposure	B-MED
paradigm	B-MED
to	O
examine	O
the	O
effects	B-MED
of	O
experience	B-MED
.	O
We	O
document	O
that	O
merely	O
exposing	B-MED
infants	B-MED
to	O
nonhuman	B-MED
primate	I-MED
vocalizations	B-MED
enables	B-MED
infants	B-MED
to	O
preserve	O
the	O
early	B-MED
-	O
established	B-MED
link	B-MED
between	O
this	O
signal	B-MED
and	O
categorization	B-MED
.	O
In	O
contrast	O
,	O
exposing	B-MED
infants	B-MED
to	O
backward	B-MED
speech	B-MED
-	O
a	O
signal	B-MED
that	O
fails	B-MED
to	O
support	B-MED
categorization	B-MED
at	O
any	O
age	B-MED
-	O
offers	O
no	O
such	O
advantage	O
.	O
Our	O
findings	B-MED
reveal	B-MED
the	O
power	B-MED
of	O
early	B-MED
experience	B-MED
as	O
infants	B-MED
specify	O
which	O
signals	B-MED
,	O
from	O
an	O
initially	B-MED
broad	B-MED
set	O
,	O
they	O
will	O
continue	B-MED
to	O
link	B-MED
to	O
cognition	B-MED
.	O
The	O
influence	O
of	O
liposomal	B-MED
formulation	B-MED
on	O
the	O
incorporation	B-MED
and	O
retention	B-MED
of	O
PNA	B-MED
oligomers	I-MED
Liposomal	B-MED
formulations	B-MED
composed	O
of	O
phospholipids	B-MED
with	O
different	O
unsaturation	B-MED
degrees	I-MED
,	O
head	B-MED
groups	I-MED
and	O
at	O
different	O
cholesterol	B-MED
content	I-MED
have	I-MED
been	I-MED
tested	I-MED
for	O
the	O
encapsulation	B-MED
of	O
Peptide	B-MED
Nucleic	I-MED
Acid	I-MED
(	I-MED
PNA	I-MED
)	I-MED
oligomers	I-MED
.	O
The	O
best	B-MED
loading	I-MED
capability	I-MED
(	O
177μg	O
,	O
ER	B-MED
%	O
=	O
87.2	O
)	O
was	O
obtained	O
for	O
pure	O
liposomes	B-MED
of	O
phosphatidylglycerol	B-MED
(	O
DOPG	B-MED
)	O
with	O
negatively	B-MED
charged	I-MED
head	B-MED
group	I-MED
.	O
The	O
insertion	B-MED
of	O
a	O
10	O
-	O
20	O
%	O
of	O
cholesterol	B-MED
in	O
DOPG	B-MED
based	O
liposomes	B-MED
provides	O
a	O
slight	O
decrease	B-MED
(	O
∼160μg	O
)	O
of	O
the	O
PNA	B-MED
loading	B-MED
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
cholesterol	B-MED
addition	B-MED
(	O
20	O
-	O
30	O
%	O
)	O
slows	O
down	O
the	O
PNA	B-MED
's	I-MED
release	B-MED
(	O
∼27	O
%	O
)	O
in	O
fetal	B-MED
bovine	I-MED
serum	I-MED
from	O
the	O
liposomal	B-MED
formulation	B-MED
.	O
Based	O
on	O
the	O
encapsulation	B-MED
and	O
the	O
release	B-MED
properties	I-MED
,	O
PEGylated	B-MED
DOPG	B-MED
liposomes	B-MED
with	O
a	O
percentage	O
of	O
cholesterol	B-MED
of	O
10	O
-	O
20	O
%	O
are	O
the	O
optimal	B-MED
formulation	I-MED
for	O
the	O
loading	B-MED
of	O
PNA	B-MED
-	I-MED
a210	I-MED
.	O
The	O
Psychometric	B-MED
Costs	I-MED
of	O
Applicants	B-MED
'	O
Faking	B-MED
:	O
Examining	O
Measurement	B-MED
Invariance	O
and	O
Retest	B-MED
Correlations	I-MED
Across	O
Response	B-MED
Conditions	I-MED
This	O
study	O
examines	B-MED
the	I-MED
stability	I-MED
of	O
the	O
response	B-MED
process	I-MED
and	O
the	O
rank	B-MED
-	I-MED
order	I-MED
of	O
respondents	B-MED
responding	B-MED
to	O
3	O
personality	B-MED
scales	I-MED
in	O
4	O
different	O
response	B-MED
conditions	I-MED
.	O
Applicants	B-MED
to	O
the	O
University	B-MED
College	I-MED
of	I-MED
Teacher	I-MED
Education	I-MED
Styria	B-MED
(	O
N	O
=	O
243	O
)	O
completed	O
personality	B-MED
scales	I-MED
as	O
part	O
of	O
their	O
college	B-MED
admission	I-MED
process	I-MED
.	O
Half	O
a	O
year	O
later	O
,	O
they	O
retook	O
the	O
same	O
personality	B-MED
scales	I-MED
in	O
1	O
of	O
3	O
randomly	B-MED
assigned	I-MED
experimental	O
response	B-MED
conditions	I-MED
:	O
honest	B-MED
,	O
faking	B-MED
-	I-MED
good	I-MED
,	O
or	O
reproduce	O
.	O
Longitudinal	B-MED
means	I-MED
and	O
covariance	B-MED
structure	I-MED
analyses	I-MED
showed	O
that	O
applicants	B-MED
'	O
response	B-MED
processes	I-MED
could	O
be	O
partially	O
reproduced	O
after	O
half	O
a	O
year	O
,	O
and	O
respondents	B-MED
seemed	O
to	O
rely	O
on	O
an	O
honest	B-MED
response	B-MED
behavior	I-MED
as	O
a	O
frame	B-MED
of	I-MED
reference	I-MED
.	O
Additionally	O
,	O
applicants	B-MED
'	O
faking	B-MED
behavior	I-MED
and	O
instructed	O
faking	B-MED
(	O
faking	B-MED
-	I-MED
good	I-MED
)	O
caused	O
differences	O
in	O
the	O
latent	B-MED
retest	B-MED
correlations	I-MED
and	O
consistently	O
affected	O
measurement	B-MED
properties	O
.	O
The	O
varying	O
latent	B-MED
retest	B-MED
correlations	I-MED
indicated	B-MED
that	O
faking	B-MED
can	O
distort	B-MED
respondents	B-MED
'	O
rank	B-MED
-	I-MED
order	I-MED
and	O
thus	O
the	O
fairness	B-MED
of	O
subsequent	O
selection	B-MED
decisions	I-MED
,	O
depending	O
on	O
the	O
kind	O
of	O
faking	B-MED
behavior	I-MED
.	O
Instructed	O
faking	B-MED
(	O
faking	B-MED
-	I-MED
good	I-MED
)	O
even	O
affected	O
weak	O
measurement	B-MED
invariance	O
,	O
whereas	O
applicants	B-MED
'	O
faking	B-MED
behavior	I-MED
did	O
not	O
.	O
Consequently	O
,	O
correlations	B-MED
with	O
personality	B-MED
scales	I-MED
-which	O
can	O
be	O
utilized	O
for	O
predictive	B-MED
validity	I-MED
-may	O
be	O
readily	O
interpreted	B-MED
for	O
applicants	B-MED
.	O
Faking	B-MED
behavior	I-MED
also	O
introduced	O
a	O
uniform	B-MED
bias	I-MED
,	O
implying	O
that	O
the	O
classically	O
observed	O
mean	B-MED
raw	I-MED
score	I-MED
differences	O
may	O
not	O
be	O
readily	O
interpreted	B-MED
.	O
Dry	B-MED
skin	I-MED
conditions	O
are	O
related	B-MED
to	O
the	O
recovery	B-MED
rate	I-MED
of	O
skin	B-MED
temperature	I-MED
after	O
cold	B-MED
stress	B-MED
rather	O
than	O
to	O
blood	B-MED
flow	I-MED
Cutaneous	B-MED
blood	B-MED
flow	I-MED
plays	O
an	O
important	B-MED
role	O
in	O
the	O
thermoregulation	B-MED
,	O
oxygen	B-MED
supply	I-MED
,	O
and	O
nutritional	B-MED
support	I-MED
necessary	O
to	O
maintain	B-MED
the	O
skin	B-MED
.	O
However	O
,	O
there	O
is	O
little	O
evidence	B-MED
for	O
a	O
link	O
between	O
blood	B-MED
flow	I-MED
and	O
skin	B-MED
physiology	I-MED
.	O
Therefore	O
,	O
we	O
conducted	O
surveys	B-MED
of	O
healthy	B-MED
volunteers	I-MED
to	O
determine	O
the	O
relationship	B-MED
(	O
s	O
)	O
between	O
dry	B-MED
skin	I-MED
properties	O
and	O
cutaneous	B-MED
vascular	B-MED
function	I-MED
.	O
Water	O
content	O
of	O
the	O
stratum	B-MED
corneum	I-MED
,	O
transepidermal	B-MED
water	I-MED
loss	I-MED
,	O
and	O
visual	B-MED
dryness	I-MED
score	I-MED
were	O
investigated	B-MED
as	O
dry	B-MED
skin	I-MED
parameters	B-MED
.	O
Cutaneous	B-MED
blood	B-MED
flow	I-MED
in	O
the	O
resting	B-MED
state	I-MED
,	O
the	O
recovery	B-MED
rate	I-MED
(	O
RR	B-MED
)	O
of	O
skin	B-MED
temperature	I-MED
on	O
the	O
hand	B-MED
after	O
a	O
cold	B-MED
-	I-MED
stress	I-MED
test	I-MED
,	O
and	O
the	O
responsiveness	B-MED
of	O
facial	B-MED
skin	I-MED
blood	B-MED
flow	I-MED
to	O
local	B-MED
cooling	I-MED
were	O
examined	B-MED
as	O
indices	B-MED
of	O
cutaneous	B-MED
vascular	B-MED
functions	I-MED
.	O
The	O
relationships	B-MED
between	O
dry	B-MED
skin	I-MED
parameters	B-MED
and	O
cutaneous	B-MED
vascular	B-MED
functions	I-MED
were	O
assessed	B-MED
.	O
The	O
RR	B-MED
correlated	B-MED
negatively	O
with	O
the	O
visual	B-MED
dryness	I-MED
score	I-MED
of	O
skin	B-MED
on	O
the	O
leg	B-MED
but	O
correlated	B-MED
positively	O
with	O
water	O
content	O
of	O
the	O
stratum	B-MED
corneum	I-MED
on	O
the	O
arm	O
.	O
No	O
significant	O
correlation	B-MED
between	O
the	O
resting	B-MED
state	I-MED
of	O
blood	B-MED
flow	I-MED
and	O
dry	B-MED
skin	I-MED
parameters	B-MED
was	O
observed	B-MED
.	O
In	O
both	O
the	O
face	B-MED
and	O
the	O
body	B-MED
,	O
deterioration	B-MED
in	O
skin	B-MED
dryness	I-MED
from	O
summer	B-MED
to	O
winter	B-MED
was	O
significant	B-MED
in	O
subjects	O
with	O
low	O
RR	B-MED
.	O
The	O
RR	B-MED
correlated	B-MED
well	O
with	O
the	O
responsiveness	B-MED
of	O
facial	B-MED
skin	I-MED
blood	B-MED
flow	I-MED
to	O
local	B-MED
cooling	I-MED
,	O
indicating	B-MED
that	O
the	O
RR	B-MED
affects	O
systemic	O
dry	B-MED
skin	I-MED
conditions	O
.	O
These	O
results	O
suggest	O
that	O
the	O
RR	B-MED
but	O
not	O
blood	B-MED
flow	I-MED
at	O
the	O
resting	B-MED
state	I-MED
is	O
associated	O
with	O
dry	B-MED
skin	I-MED
conditions	O
and	O
is	O
involved	O
in	O
skin	O
homeostasis	B-MED
during	O
seasonal	B-MED
environmental	B-MED
changes	I-MED
.	O
Optogenetic	B-MED
Demonstration	B-MED
of	O
Functional	B-MED
Innervation	B-MED
of	O
Mouse	B-MED
Colon	B-MED
by	O
Neurons	B-MED
Derived	O
From	O
Transplanted	B-MED
Neural	B-MED
Cells	I-MED
Cell	B-MED
therapy	I-MED
offers	O
the	O
potential	O
to	O
treat	B-MED
gastrointestinal	B-MED
motility	I-MED
disorders	I-MED
caused	O
by	O
diseased	B-MED
or	O
absent	B-MED
enteric	B-MED
neurons	B-MED
.	O
We	O
examined	O
whether	O
neurons	B-MED
generated	O
from	O
transplanted	B-MED
enteric	B-MED
neural	B-MED
cells	I-MED
provide	O
a	O
functional	B-MED
innervation	B-MED
of	O
bowel	B-MED
smooth	B-MED
muscle	I-MED
in	O
mice	B-MED
.	O
Enteric	B-MED
neural	B-MED
cells	I-MED
expressing	O
the	O
light	B-MED
-	I-MED
sensitive	I-MED
ion	I-MED
channel	I-MED
,	O
channelrhodopsin	B-MED
,	O
were	O
isolated	B-MED
from	O
the	O
fetal	B-MED
or	O
postnatal	B-MED
mouse	B-MED
bowel	B-MED
and	O
transplanted	B-MED
into	O
the	O
distal	B-MED
colon	I-MED
of	O
3-	O
to	O
4-	O
week	B-MED
-old	O
wild	B-MED
-	I-MED
type	I-MED
recipient	B-MED
mice	I-MED
.	O
Intracellular	B-MED
electrophysiological	B-MED
recordings	I-MED
of	O
responses	B-MED
to	O
light	B-MED
stimulation	I-MED
of	O
the	O
transplanted	B-MED
cells	B-MED
were	O
made	O
from	O
colonic	B-MED
smooth	B-MED
muscle	I-MED
cells	I-MED
in	O
recipient	B-MED
mice	I-MED
.	O
Electrical	B-MED
stimulation	I-MED
of	O
endogenous	B-MED
enteric	B-MED
neurons	B-MED
was	O
used	O
as	O
a	O
control	B-MED
.	O
The	O
axons	B-MED
of	O
graft	B-MED
-derived	O
neurons	B-MED
formed	O
a	O
plexus	B-MED
in	O
the	O
circular	B-MED
muscle	I-MED
layer	I-MED
.	O
Selective	B-MED
stimulation	I-MED
of	O
graft	B-MED
-derived	O
cells	B-MED
by	O
light	B-MED
resulted	O
in	O
excitatory	B-MED
and	O
inhibitory	B-MED
junction	I-MED
potentials	I-MED
,	O
the	O
electrical	B-MED
events	B-MED
underlying	O
contraction	B-MED
and	O
relaxation	B-MED
,	O
respectively	O
,	O
in	O
colonic	B-MED
muscle	B-MED
cells	I-MED
.	O
Graft	B-MED
-derived	O
excitatory	B-MED
and	O
inhibitory	B-MED
motor	I-MED
neurons	I-MED
released	O
the	O
same	O
neurotransmitters	B-MED
as	O
endogenous	B-MED
motor	B-MED
neurons	I-MED
-	O
acetylcholine	B-MED
and	O
a	O
combination	O
of	O
adenosine	B-MED
triphosphate	I-MED
and	O
nitric	B-MED
oxide	I-MED
,	O
respectively	O
.	O
Graft	B-MED
-derived	O
neurons	B-MED
also	O
included	O
interneurons	B-MED
that	O
provided	O
synaptic	O
inputs	O
to	O
motor	O
neurons	B-MED
,	O
but	O
the	O
pharmacologic	B-MED
properties	I-MED
of	O
interneurons	B-MED
varied	O
with	O
the	O
age	B-MED
of	O
the	O
donors	B-MED
from	O
which	O
enteric	B-MED
neural	B-MED
cells	I-MED
were	O
obtained	O
.	O
Enteric	B-MED
neural	B-MED
cells	I-MED
transplanted	B-MED
into	O
the	O
bowel	B-MED
give	O
rise	O
to	O
multiple	B-MED
functional	B-MED
types	B-MED
of	O
neurons	B-MED
that	O
integrate	O
and	O
provide	O
a	O
functional	B-MED
innervation	B-MED
of	O
the	O
smooth	B-MED
muscle	I-MED
of	O
the	O
bowel	B-MED
wall	I-MED
.	O
Circuits	B-MED
composed	O
of	O
both	O
motor	B-MED
neurons	I-MED
and	O
interneurons	B-MED
were	O
established	O
,	O
but	O
the	O
age	B-MED
at	O
which	O
cells	B-MED
are	O
isolated	O
influences	O
the	O
neurotransmitter	B-MED
phenotype	B-MED
of	O
interneurons	B-MED
that	O
are	O
generated	O
.	O
Closing	B-MED
the	I-MED
Loop	I-MED
in	O
Adults	B-MED
,	O
Children	B-MED
and	O
Adolescents	B-MED
With	O
Suboptimally	B-MED
Controlled	I-MED
Type	I-MED
1	I-MED
Diabetes	I-MED
Under	O
Free	B-MED
Living	B-MED
Conditions	I-MED
:	O
A	O
Psychosocial	B-MED
Substudy	B-MED
The	O
objective	O
was	O
to	O
explore	O
psychosocial	B-MED
experiences	I-MED
of	O
closed	B-MED
loop	I-MED
technology	I-MED
for	O
adults	B-MED
,	O
children	B-MED
,	O
and	O
adolescents	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
and	O
their	O
parents	B-MED
taking	O
part	O
in	O
two	O
multicenter	B-MED
,	O
free	B-MED
-	O
living	B-MED
,	O
randomized	B-MED
crossover	B-MED
home	I-MED
studies	I-MED
.	O
Participants	B-MED
using	O
insulin	B-MED
pump	I-MED
therapy	B-MED
were	O
randomized	B-MED
to	O
either	O
12	O
weeks	B-MED
of	O
automated	B-MED
closed	B-MED
-	I-MED
loop	I-MED
glucose	B-MED
control	I-MED
,	O
then	O
12	O
weeks	B-MED
of	O
sensor	B-MED
augmented	B-MED
insulin	B-MED
pump	I-MED
therapy	B-MED
(	O
open	B-MED
loop	I-MED
)	O
,	O
or	O
vice	O
versa	O
.	O
Closed	B-MED
loop	I-MED
was	O
used	O
for	O
24	O
hours	B-MED
by	O
adults	B-MED
and	O
overnight	B-MED
only	O
by	O
children	B-MED
and	O
adolescents	B-MED
.	O
Participants	B-MED
completed	O
the	O
Diabetes	B-MED
Technology	I-MED
Questionnaire	I-MED
(	O
DTQ	B-MED
)	O
periodically	B-MED
and	O
shared	O
their	O
views	B-MED
in	O
semistructured	B-MED
interviews	I-MED
.	O
This	O
analysis	B-MED
characterizes	B-MED
the	O
impact	B-MED
of	O
the	O
technology	B-MED
,	O
positive	B-MED
and	O
negative	B-MED
aspects	O
of	O
living	B-MED
with	O
the	O
device	B-MED
,	O
alongside	O
participants	B-MED
'	O
expectations	B-MED
,	O
hopes	B-MED
,	O
and	O
anxieties	B-MED
.	O
Participants	B-MED
were	O
32	O
adults	B-MED
,	O
age	O
38.6	O
±	O
9.6	O
years	B-MED
,	O
55	O
%	O
male	B-MED
,	O
and	O
26	O
children	B-MED
,	O
mean	O
age	B-MED
12	O
years	B-MED
(	O
range	O
6	O
-	O
18	O
years	B-MED
)	O
,	O
54	O
%	O
male	B-MED
.	O
DTQ	B-MED
results	B-MED
indicated	O
moderately	B-MED
favorable	I-MED
impact	I-MED
of	O
,	O
and	O
satisfaction	O
with	O
,	O
both	O
open	B-MED
and	O
closed	B-MED
loop	I-MED
interventions	B-MED
,	O
but	O
little	O
evidence	B-MED
of	O
a	O
comparative	B-MED
advantage	I-MED
of	O
either	O
.	O
Key	O
positive	B-MED
themes	I-MED
included	O
perceived	O
improved	B-MED
blood	I-MED
glucose	I-MED
control	I-MED
,	O
improved	B-MED
general	I-MED
well	I-MED
-	I-MED
being	I-MED
,	O
particularly	O
on	O
waking	B-MED
,	O
improved	B-MED
sleep	I-MED
,	O
reduced	B-MED
burden	B-MED
of	O
diabetes	B-MED
,	O
and	O
visibility	B-MED
of	O
data	B-MED
.	O
Key	O
negative	B-MED
themes	I-MED
included	O
having	O
to	O
carry	O
around	O
the	O
equipment	B-MED
and	O
dislike	B-MED
of	O
the	O
pump	B-MED
and	O
second	O
cannula	B-MED
(	O
ie	O
,	O
sensor	B-MED
)	O
inserted	O
.	O
Overall	O
,	O
participants	B-MED
reported	O
a	O
positive	B-MED
experience	B-MED
of	O
the	O
closed	B-MED
loop	I-MED
technology	I-MED
.	O
Results	B-MED
are	O
consistent	B-MED
with	I-MED
previous	O
research	O
with	O
size	B-MED
of	O
equipment	B-MED
continuing	O
to	O
be	O
a	O
problem	B-MED
.	O
Progress	O
is	O
being	O
made	O
in	O
the	O
usability	B-MED
of	O
the	O
closed	B-MED
-	I-MED
loop	I-MED
system	I-MED
.	O
DEPRESSION	B-MED
,	O
ANXIETY	B-MED
,	O
STRESS	B-MED
,	O
AND	O
THEIR	O
ASSOCIATED	B-MED
FACTORS	B-MED
AMONG	O
CORPS	B-MED
MEMBERS	I-MED
SERVING	O
IN	O
KEBBI	B-MED
STATE	I-MED
Depression	B-MED
,	O
anxiety	B-MED
and	O
stress	B-MED
,	O
are	O
not	O
only	O
health	B-MED
problems	I-MED
by	O
themselves	O
,	O
but	O
also	O
associated	B-MED
with	I-MED
other	O
negative	B-MED
health	B-MED
consequences	B-MED
.	O
The	O
national	B-MED
youth	I-MED
service	I-MED
is	O
usually	O
characterized	B-MED
by	O
a	O
number	O
of	O
new	O
challenges	O
and	O
experiences	B-MED
which	O
may	O
require	O
life	B-MED
style	I-MED
adjustments	B-MED
by	O
the	O
corps	B-MED
member	I-MED
.	O
However	O
,	O
no	O
previous	O
study	O
on	O
psychological	B-MED
factors	I-MED
has	O
been	O
conducted	O
among	O
corps	B-MED
members	I-MED
.	O
This	O
study	B-MED
was	O
conducted	O
to	O
determine	O
the	O
prevalence	B-MED
of	O
depression	B-MED
,	O
anxiety	B-MED
and	O
,	O
stress	B-MED
and	O
their	O
associated	B-MED
factors	B-MED
among	O
corps	B-MED
members	I-MED
serving	O
in	O
Kebbi	B-MED
state	I-MED
.	O
A	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
was	O
conducted	O
among	O
264	O
corps	B-MED
members	I-MED
from	O
four	O
local	B-MED
government	I-MED
areas	I-MED
of	O
the	O
state	B-MED
.	O
Selection	O
of	O
the	O
local	B-MED
government	I-MED
areas	I-MED
and	O
the	O
individual	O
participants	B-MED
was	O
by	O
simple	B-MED
random	I-MED
sampling	I-MED
.	O
Data	B-MED
was	O
collected	O
from	O
May	B-MED
to	O
June	B-MED
2014	O
using	O
a	O
self	B-MED
-	I-MED
administered	I-MED
questionnaire	I-MED
.	O
Data	B-MED
analysis	I-MED
used	O
chi	B-MED
-	I-MED
square	I-MED
test	I-MED
to	O
identify	O
the	O
relationship	B-MED
between	O
categorical	B-MED
variables	I-MED
and	O
multivariate	B-MED
logistic	I-MED
regression	I-MED
to	O
identify	O
the	O
independent	O
factors	B-MED
for	O
depression	B-MED
,	O
anxiety	B-MED
and	O
stress	B-MED
each	O
.	O
The	O
response	B-MED
rate	I-MED
was	O
97	O
%	O
.	O
Most	O
of	O
the	O
respondents	B-MED
were	O
males	B-MED
(	O
63.6	O
%	O
)	O
,	O
single	B-MED
(	O
85.5	O
%	O
)	O
,	O
and	O
above	O
20	O
years	B-MED
of	O
age	B-MED
(	O
71.6	O
%	O
)	O
.	O
The	O
overall	O
prevalences	B-MED
of	O
depression	B-MED
,	O
anxiety	B-MED
and	O
stress	B-MED
among	O
the	O
respondents	B-MED
were	O
36.4	O
%	O
,	O
54.5	O
%	O
and	O
18.2	O
%	O
respectively	O
.	O
The	O
independent	O
factors	B-MED
for	O
depression	B-MED
were	O
;	O
being	O
from	O
the	O
North	B-MED
central	I-MED
(	O
OR	B-MED
=	O
5.99	O
;	O
95	O
%	O
CI	B-MED
:	O
2.194	O
-	O
16.354	O
)	O
or	O
South	B-MED
-	I-MED
south	I-MED
;	O
and	O
the	O
perception	B-MED
of	O
earning	B-MED
enough	O
income	B-MED
(	O
OR	B-MED
=	O
2.987	O
;	O
95	O
%	O
CI	B-MED
CI	B-MED
:	O
1.062	O
-	O
8.400	O
)	O
.	O
For	O
anxiety	B-MED
,	O
male	B-MED
gender	I-MED
(	O
OR	B-MED
=	O
0.411	O
;	O
95	O
%	O
CI	B-MED
:	O
0.169	O
-	O
0.999	O
)	O
;	O
and	O
being	O
from	O
the	O
North	B-MED
central	I-MED
were	O
significant	O
risk	B-MED
factors	I-MED
(	O
OR	B-MED
=	O
3.731	O
;	O
95	O
%	O
CI	B-MED
:	O
1.450	O
-	O
9.599	O
)	O
.	O
Being	O
above	O
26	O
years	B-MED
of	O
age	B-MED
was	O
an	O
independent	O
risk	B-MED
factor	I-MED
for	O
stress	B-MED
(	O
OR	B-MED
=	O
0.083	O
;	O
95	O
%	O
CI	B-MED
:	O
0.018	O
-	O
0.381	O
)	O
.	O
Also	O
,	O
those	O
who	O
had	O
ever	O
schooled	B-MED
outside	O
their	O
towns	B-MED
of	O
residence	B-MED
were	O
less	O
likely	O
to	O
be	O
stressed	B-MED
compared	O
to	O
those	O
who	O
had	O
never	O
(	O
OR	B-MED
=	O
0.30	O
;	O
95	O
%	O
CI	B-MED
:	O
0.110	O
-	O
0.855	O
)	O
.	O
All	O
other	O
factors	B-MED
did	O
not	O
show	O
any	O
significant	B-MED
association	I-MED
with	O
any	O
of	O
the	O
outcome	B-MED
variables	I-MED
in	O
multivariate	B-MED
analysis	I-MED
.	O
In	O
conclusion	B-MED
,	O
the	O
prevalences	B-MED
of	O
depression	B-MED
,	O
anxiety	B-MED
and	O
stress	B-MED
are	O
high	B-MED
among	O
corps	B-MED
members	I-MED
serving	O
in	O
Kebbi	B-MED
state	I-MED
.	O
There	O
is	O
need	O
to	O
expand	O
the	O
scope	O
of	O
this	O
study	B-MED
to	O
a	O
national	B-MED
level	I-MED
so	O
as	O
to	O
get	O
a	O
bigger	O
picture	O
of	O
the	O
problem	B-MED
.	O
Constructive	B-MED
and	I-MED
Unproductive	I-MED
Processing	I-MED
of	O
Traumatic	B-MED
Experiences	I-MED
in	O
Trauma	B-MED
-	I-MED
Focused	I-MED
Cognitive	I-MED
-	I-MED
Behavioral	I-MED
Therapy	I-MED
for	O
Youth	B-MED
Although	O
there	O
is	O
substantial	O
evidence	B-MED
to	O
support	O
the	O
efficacy	B-MED
of	O
cognitive	B-MED
-	I-MED
behavioral	I-MED
treatments	I-MED
(	O
CBT	B-MED
)	O
for	O
posttraumatic	B-MED
stress	I-MED
disorder	I-MED
(	O
PTSD	B-MED
)	O
,	O
there	O
is	O
some	O
debate	O
about	O
how	O
these	O
treatments	B-MED
have	O
their	O
effects	O
.	O
Modern	O
learning	B-MED
theory	I-MED
and	O
cognitive	B-MED
and	I-MED
emotional	I-MED
processing	I-MED
theories	I-MED
highlight	O
the	O
importance	O
of	O
reducing	O
avoidance	B-MED
,	O
facilitating	O
the	O
constructive	B-MED
processing	I-MED
of	I-MED
feared	I-MED
experiences	I-MED
,	O
and	O
strengthening	O
new	O
inhibitory	B-MED
learning	I-MED
.	O
We	O
examined	O
variables	O
thought	O
to	O
be	O
associated	O
with	O
unproductive	B-MED
and	I-MED
constructive	I-MED
processing	I-MED
of	O
traumatic	B-MED
experiences	I-MED
in	O
a	O
sample	O
of	O
81	O
youth	O
with	O
elevated	O
PTSD	B-MED
symptoms	B-MED
,	O
who	O
received	O
Trauma	B-MED
-	I-MED
Focused	I-MED
Cognitive	I-MED
Behavioral	I-MED
Therapy	I-MED
(	O
TF	B-MED
-	I-MED
CBT	I-MED
)	O
for	O
abuse	B-MED
or	O
traumatic	B-MED
interpersonal	B-MED
loss	I-MED
.	O
Sessions	B-MED
during	O
the	O
trauma	B-MED
narrative	I-MED
phase	I-MED
of	O
TF	B-MED
-	I-MED
CBT	I-MED
were	O
coded	O
for	O
indicators	O
of	O
unproductive	B-MED
processing	I-MED
(	O
overgeneralization	B-MED
,	O
rumination	B-MED
,	O
avoidance	B-MED
)	O
and	O
constructive	B-MED
processing	I-MED
(	O
decentering	B-MED
,	O
accommodation	B-MED
of	I-MED
corrective	I-MED
information	I-MED
)	O
,	O
as	O
well	O
as	O
levels	B-MED
of	I-MED
negative	I-MED
emotion	I-MED
.	O
In	O
previous	B-MED
analyses	O
of	O
this	O
trial	O
(	O
Ready	O
et	O
al	O
.	O
,	O
2015	O
)	O
,	O
more	O
overgeneralization	B-MED
during	O
the	O
narrative	B-MED
phase	I-MED
predicted	O
less	O
improvement	O
in	O
internalizing	B-MED
symptoms	I-MED
at	O
posttreatment	B-MED
and	O
a	O
worsening	B-MED
of	O
externalizing	B-MED
symptoms	I-MED
over	O
the	O
12	O
-	O
month	O
follow	B-MED
-	I-MED
up	I-MED
.	O
In	O
contrast	O
,	O
more	O
accommodation	B-MED
predicted	I-MED
improvement	I-MED
in	O
internalizing	B-MED
symptoms	I-MED
and	O
also	O
moderated	B-MED
the	O
negative	B-MED
effects	B-MED
of	I-MED
overgeneralization	B-MED
on	O
internalizing	B-MED
and	I-MED
externalizing	I-MED
symptoms	I-MED
.	O
The	O
current	O
study	O
examined	O
correlates	O
of	O
overgeneralization	B-MED
and	O
accommodation	B-MED
.	O
Overgeneralization	B-MED
was	O
associated	B-MED
with	I-MED
more	O
rumination	B-MED
,	O
less	O
decentering	O
,	O
and	O
more	O
negative	B-MED
emotion	I-MED
,	O
suggesting	B-MED
immersion	B-MED
in	O
trauma	B-MED
-related	O
material	O
.	O
Accommodation	B-MED
was	O
associated	B-MED
with	I-MED
less	O
avoidance	B-MED
and	O
more	O
decentering	B-MED
,	O
suggesting	O
a	O
healthy	B-MED
distance	O
from	O
trauma	B-MED
-related	O
material	O
that	O
might	O
allow	O
for	O
processing	O
and	O
cognitive	B-MED
change	I-MED
.	O
Decentering	O
also	O
predicted	B-MED
improvement	B-MED
in	O
externalizing	B-MED
symptoms	I-MED
at	O
posttreatment	B-MED
.	O
Rumination	B-MED
and	O
avoidance	B-MED
showed	O
important	O
associations	O
with	O
overgeneralization	B-MED
and	O
accommodation	B-MED
,	O
respectively	O
,	O
but	O
did	O
not	O
predict	O
treatment	B-MED
outcomes	I-MED
.	O
This	O
study	O
identifies	O
correlates	O
of	O
overgeneralization	B-MED
and	O
accommodation	B-MED
that	O
might	O
shed	O
light	O
on	O
how	O
these	O
variables	O
relate	O
to	O
unproductive	B-MED
and	I-MED
constructive	I-MED
processing	I-MED
of	O
traumatic	B-MED
experiences	I-MED
.	O
Reduced	B-MED
haemodynamic	B-MED
coupling	I-MED
and	O
exercise	B-MED
are	O
associated	B-MED
with	I-MED
vascular	B-MED
stiffening	I-MED
in	O
pulmonary	B-MED
arterial	I-MED
hypertension	I-MED
Inadequate	B-MED
right	B-MED
ventricular	I-MED
(	O
RV	B-MED
)	O
and	O
pulmonary	B-MED
arterial	I-MED
(	O
PA	B-MED
)	O
functional	B-MED
responses	B-MED
to	O
exercise	B-MED
are	O
important	O
yet	O
poorly	O
understood	O
features	O
of	O
pulmonary	B-MED
arterial	I-MED
hypertension	I-MED
(	O
PAH	B-MED
)	O
.	O
This	O
study	B-MED
combined	O
invasive	B-MED
catheterisation	B-MED
with	O
echocardiography	B-MED
to	O
assess	B-MED
RV	B-MED
afterload	O
,	O
RV	B-MED
function	I-MED
and	O
ventricular	B-MED
-	O
vascular	B-MED
coupling	B-MED
in	O
subjects	B-MED
with	O
PAH	B-MED
.	O
Twenty	O
-	O
six	O
subjects	B-MED
with	O
PAH	B-MED
were	O
prospectively	O
recruited	O
to	O
undergo	O
right	B-MED
heart	I-MED
catheterisation	B-MED
and	O
Doppler	B-MED
echocardiography	I-MED
at	O
rest	B-MED
and	O
during	O
incremental	B-MED
exercise	B-MED
,	O
and	O
cardiac	B-MED
MRI	I-MED
at	O
rest	B-MED
.	O
Measurements	B-MED
at	O
rest	B-MED
included	O
basic	O
haemodynamics	B-MED
,	O
RV	B-MED
function	I-MED
and	O
coupling	B-MED
efficiency	I-MED
(	O
η	B-MED
)	O
.	O
Measurements	B-MED
during	O
incremental	B-MED
exercise	B-MED
included	O
pulmonary	B-MED
vascular	I-MED
resistance	I-MED
(	O
Z0	B-MED
)	O
,	O
characteristic	B-MED
impedance	I-MED
(	O
ZC	B-MED
,	O
a	O
measure	B-MED
of	O
proximal	B-MED
PA	B-MED
stiffness	B-MED
)	O
and	O
proximal	B-MED
and	O
distal	B-MED
PA	O
compliance	O
(	O
CPA	O
)	O
.	O
In	O
patients	B-MED
with	O
PAH	B-MED
,	O
the	O
proximal	B-MED
PAs	B-MED
were	O
significantly	B-MED
stiffer	B-MED
at	O
maximum	B-MED
exercise	B-MED
(	O
ZC	B-MED
=	O
2.31±0.38	O
vs	O
1.33±0.15	O
WU×m(2	O
)	O
at	O
rest	B-MED
;	O
p=0.003	O
)	O
and	O
PA	O
compliance	O
was	O
decreased	B-MED
(	O
CPA	O
=	O
0.88±0.10	O
vs	O
1.32±0.17	O
mL	O
/	O
mm	O
Hg	O
/	O
m(2	O
)	O
at	O
rest	B-MED
;	O
p=0.0002	O
)	O
.	O
Z0	B-MED
did	O
not	O
change	O
with	O
exercise	B-MED
.	O
As	O
a	O
result	O
,	O
the	O
resistance	B-MED
-	I-MED
compliance	I-MED
(	I-MED
RC	I-MED
)	I-MED
time	I-MED
decreased	B-MED
with	O
exercise	B-MED
(	O
0.67±0.05	O
vs	O
1.00±0.07	O
s	O
at	O
rest	B-MED
;	O
p<10(-6	O
)	O
)	O
.	O
When	O
patients	B-MED
were	O
grouped	O
according	O
to	O
resting	B-MED
coupling	B-MED
efficiency	I-MED
,	O
those	O
with	O
poorer	O
η	B-MED
exhibited	O
stiffer	B-MED
proximal	B-MED
PAs	B-MED
at	O
rest	B-MED
,	O
a	O
lower	O
maximum	B-MED
exercise	B-MED
level	B-MED
,	O
and	O
more	O
limited	O
CPA	O
reduction	B-MED
at	O
maximum	B-MED
exercise	B-MED
.	O
In	O
PAH	B-MED
,	O
exercise	B-MED
causes	O
proximal	B-MED
and	O
distal	B-MED
PA	B-MED
stiffening	B-MED
,	O
which	O
combined	O
with	O
preserved	O
Z0	B-MED
results	O
in	O
decreased	B-MED
RC	B-MED
time	I-MED
with	O
exercise	B-MED
.	O
Stiff	B-MED
PAs	I-MED
at	O
rest	B-MED
may	O
also	O
contribute	O
to	O
poor	O
haemodynamic	B-MED
coupling	I-MED
,	O
reflecting	O
reduced	B-MED
pulmonary	B-MED
vascular	I-MED
reserve	O
that	O
contributes	B-MED
to	O
limit	O
the	O
maximum	B-MED
exercise	B-MED
level	B-MED
tolerated	O
.	O
A	O
standardized	O
approach	O
for	O
the	O
assessment	B-MED
and	O
treatment	B-MED
of	O
internationally	B-MED
adopted	B-MED
children	I-MED
with	O
a	O
previously	O
repaired	O
anorectal	B-MED
malformation	I-MED
(	O
ARM	B-MED
)	O
A	O
significant	O
number	O
of	O
internationally	B-MED
adopted	B-MED
children	I-MED
have	O
congenital	B-MED
birth	I-MED
defects	I-MED
.	O
As	O
a	O
specialist	O
center	O
for	O
colorectal	B-MED
diagnoses	B-MED
,	O
we	O
evaluate	O
such	O
children	B-MED
with	O
an	O
anorectal	B-MED
malformation	I-MED
(	O
ARM	B-MED
)	O
and	O
have	O
found	O
that	O
a	O
significant	O
number	O
need	O
a	O
reoperation	B-MED
.	O
Knowledge	B-MED
of	O
the	O
common	O
complications	B-MED
following	O
ARM	B-MED
surgery	B-MED
has	O
led	O
us	O
to	O
develop	O
treatment	B-MED
algorithms	B-MED
for	O
patients	B-MED
with	O
unknown	O
past	B-MED
medical	I-MED
and	O
surgical	B-MED
history	I-MED
,	O
a	O
situation	O
typically	O
encountered	O
in	O
the	O
adopted	B-MED
population	B-MED
.	O
The	O
results	O
of	O
investigations	B-MED
,	O
indications	B-MED
,	O
and	O
rate	B-MED
of	O
reoperation	B-MED
were	O
assessed	O
for	O
adopted	B-MED
children	I-MED
with	O
an	O
ARM	B-MED
evaluated	O
between	O
2014	O
and	O
2016	O
.	O
56	O
patients	B-MED
(	O
28	O
males	B-MED
)	O
were	O
identified	O
.	O
76.8	O
%	O
required	O
reoperative	B-MED
surgery	I-MED
.	O
Mislocation	O
of	O
the	O
anus	B-MED
outside	B-MED
the	O
sphincter	B-MED
complex	O
was	O
seen	O
in	O
50	O
%	O
of	O
males	B-MED
and	O
39.3	O
%	O
of	O
females	B-MED
.	O
Anal	B-MED
stricture	I-MED
,	O
rectal	B-MED
prolapse	I-MED
,	O
retained	B-MED
vaginal	B-MED
septum	I-MED
,	O
and	O
a	O
strictured	B-MED
vaginal	B-MED
introitus	I-MED
were	O
also	O
common	O
.	O
The	O
reoperative	B-MED
surgery	I-MED
rate	B-MED
in	O
the	O
internationally	B-MED
adopted	B-MED
child	I-MED
with	O
an	O
ARM	B-MED
is	O
high	O
.	O
Complete	O
,	O
systematic	O
evaluation	O
of	O
these	O
children	B-MED
is	O
required	O
to	O
identify	O
complications	B-MED
following	O
initial	O
repair	B-MED
.	O
Development	O
of	O
mechanisms	O
to	O
improve	O
the	O
primary	O
surgical	B-MED
care	I-MED
these	O
children	B-MED
receive	O
is	O
needed	O
.	O
Medulloblastoma	B-MED
:	O
molecular	B-MED
pathways	I-MED
and	O
histopathological	B-MED
classification	B-MED
Malignant	B-MED
brain	I-MED
tumors	I-MED
are	O
the	O
leading	B-MED
cause	B-MED
of	O
cancer	B-MED
death	B-MED
among	O
pediatric	B-MED
patients	B-MED
,	O
and	O
medulloblastoma	B-MED
constitutes	O
20	O
%	O
of	O
them	O
.	O
Currently	O
,	O
the	O
treatment	B-MED
is	O
risk	O
-	O
adapted	O
.	O
Maximum	O
surgical	B-MED
resection	I-MED
is	O
recommended	B-MED
,	O
always	O
followed	O
by	O
chemotherapy	B-MED
and	O
neuroaxis	B-MED
radiotherapy	B-MED
.	O
In	O
spite	O
of	O
the	O
improving	B-MED
survival	B-MED
rate	I-MED
,	O
survivors	B-MED
succumb	O
to	O
treatment	B-MED
-	O
induced	B-MED
side	B-MED
effects	I-MED
.	O
To	O
reduce	B-MED
toxic	B-MED
effects	I-MED
,	O
molecular	B-MED
-	I-MED
targeted	I-MED
treatment	I-MED
is	O
proposed	O
.	O
Medulloblastoma	B-MED
research	B-MED
is	O
very	O
robust	B-MED
,	O
and	O
new	O
articles	B-MED
on	O
the	O
subject	O
are	O
published	B-MED
daily	O
.	O
In	O
the	O
current	O
review	B-MED
we	O
have	O
tried	O
to	O
bring	O
together	O
molecular	B-MED
pathophysiology	B-MED
of	O
the	O
neoplasm	B-MED
and	O
current	O
pathological	B-MED
classification	B-MED
,	O
thus	O
making	O
an	O
effort	O
to	O
relate	O
tumor	B-MED
biology	I-MED
and	O
the	O
histological	B-MED
picture	I-MED
.	O
Penetrating	B-MED
Craniomaxillofacial	B-MED
Injury	I-MED
Craniomaxillofacial	B-MED
Injury	I-MED
Caused	I-MED
by	I-MED
a	I-MED
Pneumatic	I-MED
Nail	I-MED
Gun	I-MED
Pneumatic	B-MED
Nail	I-MED
Gun	I-MED
Craniomaxillofacial	O
injuries	O
can	O
be	O
complex	O
,	O
requiring	O
a	O
multidisciplinary	O
approach	O
.	O
The	O
primary	O
survey	O
is	O
always	O
the	O
first	O
step	O
in	O
trauma	O
management	O
prior	O
to	O
proceeding	O
with	O
further	O
evaluation	O
and	O
treatment	B-MED
.	O
A	O
26-	O
year	O
-old	O
man	O
presented	O
with	O
a	O
penetrating	B-MED
nail	O
gun	O
injury	O
through	O
the	O
oral	B-MED
and	O
nasal	B-MED
cavities	I-MED
.	O
He	O
did	O
not	O
present	O
in	O
extremis	O
but	O
required	O
elective	O
endotracheal	O
intubation	O
for	O
intraoperative	O
assessment	O
and	O
treatment	B-MED
.	O
Airway	O
management	O
was	O
enhanced	B-MED
by	O
the	O
use	O
of	O
lingual	B-MED
nerve	I-MED
and	O
inferior	B-MED
alveolar	I-MED
nerve	I-MED
blocks	I-MED
via	O
the	O
Vazirani	O
-	O
Akinosi	O
technique	O
to	O
maintain	B-MED
spontaneous	B-MED
respiration	I-MED
while	O
the	O
tongue	B-MED
was	O
distracted	B-MED
from	O
the	O
palate	B-MED
.	O
The	O
nail	O
was	O
removed	O
and	O
rapid	O
sequence	O
induction	O
initiated	O
for	O
orotracheal	O
intubation	O
.	O
Local	O
nerve	O
blocks	O
can	O
be	O
an	O
effective	O
tool	O
in	O
the	O
armamentarium	O
of	O
the	O
craniomaxillofacial	O
trauma	O
surgeon	O
in	O
managing	O
blunt	O
and	O
penetrating	O
injuries	O
.	O
We	O
demonstrate	O
its	O
utility	O
in	O
airway	O
management	O
when	O
a	O
penetrating	O
foreign	O
body	O
in	O
the	O
upper	B-MED
airway	I-MED
precludes	O
orotracheal	O
or	O
nasotracheal	O
intubation	O
.	O
The	O
role	O
of	O
catheter	B-MED
ablation	I-MED
in	O
the	O
management	B-MED
of	O
atrial	B-MED
fibrillation	I-MED
Atrial	B-MED
fibrillation	I-MED
is	O
driven	O
by	O
spontaneous	O
electrical	B-MED
activation	I-MED
emerging	O
from	O
the	O
pulmonary	B-MED
veins	I-MED
.	O
Catheter	B-MED
ablation	I-MED
using	O
either	O
radiofrequency	B-MED
or	O
cryothermal	B-MED
energy	I-MED
electrically	B-MED
isolates	B-MED
these	O
veins	B-MED
from	O
the	O
left	B-MED
atrium	I-MED
,	O
both	O
reducing	B-MED
the	O
burden	B-MED
of	O
atrial	B-MED
fibrillation	I-MED
episodes	B-MED
and	O
improving	O
the	O
patient	B-MED
's	I-MED
symptoms	B-MED
.	O
Catheter	B-MED
ablation	I-MED
is	O
superior	O
to	O
antiarryhthmic	B-MED
drugs	I-MED
when	O
patients	B-MED
are	O
carefully	O
selected	O
.	O
Underlying	O
medical	B-MED
problems	I-MED
-	O
including	O
obesity	B-MED
,	O
hypertension	B-MED
and	O
obstructive	B-MED
sleep	I-MED
apnoea	I-MED
-	O
should	O
be	O
optimally	O
treated	B-MED
before	O
considering	O
ablation	B-MED
.	O
Although	O
this	O
treatment	B-MED
has	O
the	O
potential	B-MED
to	O
cure	B-MED
patients	B-MED
of	O
their	O
symptoms	B-MED
,	O
they	O
should	O
be	O
aware	O
of	O
the	O
important	O
associated	O
procedural	B-MED
complications	I-MED
.	O
Promoting	B-MED
Healthy	B-MED
Growth	B-MED
or	O
Feeding	B-MED
Obesity	B-MED
?	O
The	O
Need	B-MED
for	O
Evidence	B-MED
-Based	O
Oversight	O
of	O
Infant	B-MED
Nutritional	B-MED
Supplement	I-MED
Claims	O
The	O
Developmental	B-MED
Origins	I-MED
of	I-MED
Health	I-MED
and	I-MED
Disease	I-MED
(	O
DOHaD	B-MED
)	O
model	O
recognizes	O
growth	B-MED
in	O
infancy	B-MED
and	O
childhood	B-MED
as	O
a	O
fundamental	O
determinant	O
of	O
lifespan	B-MED
health	B-MED
.	O
Evidence	B-MED
of	I-MED
long	B-MED
-	I-MED
term	I-MED
health	B-MED
risks	B-MED
among	O
small	B-MED
neonates	B-MED
who	O
subsequently	O
grow	B-MED
rapidly	B-MED
poses	O
a	O
challenge	O
for	O
interventions	B-MED
aiming	O
to	O
support	O
healthy	B-MED
growth	B-MED
,	O
not	O
merely	O
drive	O
weight	B-MED
gain	I-MED
.	O
Defining	O
healthy	B-MED
growth	B-MED
beyond	O
"	O
getting	O
bigger	O
"	O
is	O
essential	B-MED
as	O
infant	B-MED
and	O
young	B-MED
child	B-MED
feeding	B-MED
industries	B-MED
expand	O
.	O
Liquid	B-MED
-based	O
nutritional	B-MED
supplements	I-MED
,	O
originally	O
formulated	B-MED
for	O
undernourished	B-MED
children	B-MED
,	O
are	O
increasingly	B-MED
marketed	B-MED
for	O
and	O
consumed	B-MED
by	O
children	B-MED
generally	O
.	O
Clarifying	B-MED
the	O
nature	O
of	O
the	O
evidentiary	O
base	O
on	O
which	O
structure	O
/	O
function	O
claims	O
promoting	B-MED
"	O
healthy	B-MED
growth	B-MED
"	O
are	O
constructed	O
is	O
important	B-MED
to	O
curb	O
invalid	O
generalizations	O
.	O
Evidence	B-MED
points	O
to	O
changing	O
social	B-MED
beliefs	B-MED
and	O
cultural	B-MED
practices	B-MED
surrounding	O
supplementary	B-MED
feeding	I-MED
,	O
raising	O
specific	B-MED
concerns	B-MED
about	O
the	O
long	B-MED
-	I-MED
term	I-MED
health	B-MED
consequences	B-MED
of	I-MED
an	O
associated	B-MED
altered	B-MED
feeding	B-MED
culture	B-MED
,	O
including	O
reduced	B-MED
dietary	B-MED
variety	B-MED
and	O
weight	B-MED
gain	I-MED
.	O
Reassessing	B-MED
the	O
evidence	B-MED
for	I-MED
and	O
relevance	B-MED
of	O
dietary	B-MED
supplements	I-MED
'	I-MED
"	O
promoting	B-MED
healthy	B-MED
growth	B-MED
"	O
claims	O
for	O
otherwise	O
healthy	B-MED
children	B-MED
is	O
both	O
needed	B-MED
in	O
a	O
time	O
of	O
global	B-MED
obesity	B-MED
and	O
an	O
opportunity	B-MED
to	O
refine	O
intervention	B-MED
approaches	I-MED
among	O
small	B-MED
children	B-MED
for	O
whom	O
rapid	B-MED
subsequent	O
growth	B-MED
in	O
early	O
life	O
augments	O
risk	B-MED
for	O
chronic	B-MED
disease	I-MED
.	O
Scientific	B-MED
and	O
health	B-MED
care	I-MED
partnerships	B-MED
are	O
needed	B-MED
to	O
consider	O
current	O
governmental	B-MED
oversight	O
shortfalls	O
in	O
protecting	O
vulnerable	O
populations	B-MED
from	O
overconsumption	B-MED
.	O
This	O
is	O
important	B-MED
because	O
we	O
may	O
be	O
doing	O
more	O
harm	O
than	O
good	O
.	O
Silk	B-MED
I	I-MED
and	O
Silk	B-MED
II	I-MED
studied	B-MED
by	O
fast	B-MED
scanning	I-MED
calorimetry	I-MED
Using	O
fast	B-MED
scanning	I-MED
calorimetry	I-MED
(	O
FSC	B-MED
)	O
,	O
we	O
investigated	B-MED
the	O
glass	B-MED
transition	I-MED
and	O
crystal	B-MED
melting	B-MED
of	O
samples	B-MED
of	O
B.	B-MED
mori	I-MED
silk	B-MED
fibroin	I-MED
containing	O
Silk	B-MED
I	I-MED
and/or	O
Silk	B-MED
II	I-MED
crystal	B-MED
s.	O
Due	O
to	O
the	O
very	O
short	B-MED
residence	B-MED
times	B-MED
at	O
high	B-MED
temperatures	B-MED
during	O
such	O
measurements	B-MED
,	O
thermal	B-MED
decomposition	B-MED
of	O
silk	B-MED
protein	I-MED
can	O
be	O
significantly	B-MED
suppressed	B-MED
.	O
FSC	B-MED
was	O
performed	B-MED
at	O
2000K	O
/	O
s	O
using	O
the	O
Mettler	B-MED
Flash	I-MED
DSC1	I-MED
on	O
fibroin	B-MED
films	B-MED
with	O
masses	B-MED
around	O
130	O
-	O
270ng	O
.	O
Films	B-MED
were	O
prepared	O
with	O
different	B-MED
crystalline	B-MED
fractions	B-MED
(	O
ranging	O
from	O
0.26	O
to	O
0.50	O
)	O
and	O
with	O
different	B-MED
crystal	B-MED
structures	I-MED
(	O
Silk	B-MED
I	I-MED
,	O
Silk	B-MED
II	I-MED
,	O
or	O
mixed	O
)	O
by	O
varying	O
the	O
processing	B-MED
conditions	B-MED
.	O
These	O
included	O
water	B-MED
annealing	B-MED
at	O
different	B-MED
temperatures	B-MED
,	O
exposure	B-MED
to	I-MED
50	O
%	O
MeOH	B-MED
in	O
water	B-MED
,	O
or	O
autoclaving	B-MED
.	O
The	O
resulting	B-MED
crystal	B-MED
structure	I-MED
was	O
examined	O
using	O
wide	B-MED
angle	I-MED
X	B-MED
-	I-MED
ray	I-MED
scattering	I-MED
.	O
Degree	B-MED
of	O
crystallinity	B-MED
was	O
evaluated	B-MED
from	O
Fourier	B-MED
transform	I-MED
infrared	I-MED
(	I-MED
FTIR	I-MED
)	I-MED
spectroscopy	I-MED
and	O
from	O
analysis	B-MED
of	O
the	O
heat	B-MED
capacity	I-MED
increment	B-MED
at	O
the	O
glass	B-MED
transition	I-MED
temperature	I-MED
.	O
Silk	B-MED
fibroin	I-MED
films	B-MED
prepared	O
by	O
water	B-MED
annealing	B-MED
at	O
25	O
°	O
C	O
were	O
the	O
least	O
crystalline	B-MED
and	O
had	O
Silk	B-MED
I	I-MED
structure	B-MED
.	O
FTIR	B-MED
and	O
FSC	B-MED
studies	B-MED
showed	O
that	O
films	B-MED
prepared	O
by	O
autoclaving	B-MED
or	O
50	O
%	O
MeOH	B-MED
exposure	B-MED
were	O
the	O
most	O
crystalline	B-MED
and	O
had	O
Silk	B-MED
II	I-MED
structure	B-MED
.	O
Intermediate	B-MED
crystalline	B-MED
fraction	B-MED
and	O
mixed	O
Silk	B-MED
I	I-MED
/	O
Silk	B-MED
II	I-MED
structure	B-MED
s	O
were	O
found	O
in	O
films	B-MED
prepared	O
by	O
water	B-MED
annealing	B-MED
at	O
37	O
°	O
C	O
.	O
FSC	B-MED
results	B-MED
indicate	O
that	O
Silk	B-MED
I	I-MED
Silk	B-MED
I	I-MED
I	I-MED
crystals	B-MED
exhibit	O
endotherms	B-MED
of	O
narrower	B-MED
width	I-MED
and	O
have	O
higher	B-MED
mean	B-MED
melting	B-MED
temperature	I-MED
Tm(II)=351±2.6	O
°	O
C	O
,	O
compared	B-MED
to	O
Silk	B-MED
I	I-MED
crystals	B-MED
which	O
melt	B-MED
at	O
Tm(I)=292±3.8	O
°	O
C	O
.	O
Films	B-MED
containing	O
mixed	O
Silk	B-MED
I	I-MED
/	O
Silk	B-MED
II	I-MED
structure	B-MED
showed	O
two	O
clearly	B-MED
separated	B-MED
endothermic	B-MED
peaks	B-MED
.	O
Evidence	B-MED
suggests	O
that	O
the	O
two	O
types	O
of	O
crystal	B-MED
s	O
melt	B-MED
separately	B-MED
and	O
do	O
not	O
thermal	B-MED
ly	O
interconvert	B-MED
on	O
the	O
extremely	B-MED
short	B-MED
time	B-MED
scale	I-MED
(	O
0.065s	O
between	O
onset	O
and	O
end	O
of	O
melting	B-MED
)	O
of	O
the	O
FSC	B-MED
experiment	I-MED
.	O
Silkworm	B-MED
silk	B-MED
is	O
a	O
naturally	B-MED
occurring	O
biomaterial	B-MED
.	O
The	O
fibroin	B-MED
component	I-MED
of	O
silk	B-MED
forms	I-MED
two	O
types	O
of	O
crystals	B-MED
.	O
Silk	B-MED
properties	B-MED
depend	O
upon	O
the	O
amount	B-MED
and	O
type	O
of	O
crystals	B-MED
,	O
and	O
their	O
stability	B-MED
.	O
One	O
measure	B-MED
of	O
stability	B-MED
is	O
crystal	B-MED
melting	B-MED
temperature	I-MED
.	O
Crystal	B-MED
s	O
which	O
are	O
more	O
stable	B-MED
have	O
a	O
higher	B-MED
melting	B-MED
temperature	I-MED
.	O
Until	O
now	O
,	O
it	O
has	O
been	O
challenging	O
to	O
study	B-MED
thermal	B-MED
behavior	B-MED
of	O
silk	B-MED
crystal	B-MED
s	O
because	O
they	O
degrade	B-MED
at	O
high	B-MED
temperature	B-MED
.	O
To	O
avoid	O
degradation	B-MED
,	O
and	O
study	B-MED
the	O
melting	B-MED
properties	B-MED
of	O
silk	B-MED
biomaterial	B-MED
,	O
we	O
heated	B-MED
silk	B-MED
at	O
a	O
very	O
fast	O
rate	O
of	O
2000K	O
/	O
s	O
using	O
a	O
special	B-MED
calorimeter	I-MED
.	O
We	O
have	O
shown	O
that	O
the	O
two	O
crystal	B-MED
types	O
have	O
very	O
different	B-MED
melting	B-MED
temperature	I-MED
s	O
,	O
indicating	O
that	O
one	O
crystal	B-MED
type	B-MED
is	O
much	O
more	O
stable	B-MED
than	O
the	O
other	O
.	O
Comparison	O
of	O
methods	O
for	O
isolating	B-MED
primary	B-MED
hepatocytes	B-MED
from	O
mini	B-MED
pigs	I-MED
Successful	O
porcine	B-MED
hepatocyte	B-MED
isolation	B-MED
is	O
crucial	O
for	O
the	O
development	B-MED
of	O
bioartificial	B-MED
liver	I-MED
devices	I-MED
and	O
hepatocyte	B-MED
transplantation	I-MED
.	O
Serva	B-MED
collagenase	I-MED
NB	I-MED
grades	I-MED
are	O
formulated	O
collagenases	B-MED
that	O
are	O
suitable	O
for	O
various	O
tissue	B-MED
isolation	B-MED
applications	O
.	O
N	B-MED
-	I-MED
acetylcysteine	I-MED
(	O
NAC	B-MED
)	O
can	O
improve	O
the	O
viability	B-MED
of	O
human	B-MED
hepatocytes	B-MED
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effectiveness	B-MED
of	O
two	O
collagenases	B-MED
and	O
effect	B-MED
of	I-MED
NAC	B-MED
on	O
hepatocyte	B-MED
isolation	B-MED
from	O
porcine	B-MED
liver	B-MED
tissue	I-MED
.	O
Porcine	B-MED
hepatocytes	B-MED
were	O
isolated	B-MED
using	O
the	O
perfusion	B-MED
method	I-MED
from	O
Bama	O
mini	B-MED
pigs	I-MED
assigned	O
to	O
the	O
Serva	B-MED
NB	I-MED
4	I-MED
group	B-MED
(	O
n=6	O
)	O
,	O
the	O
Serva	B-MED
NB	I-MED
8	I-MED
group	B-MED
(	O
n=6	O
)	O
,	O
or	O
the	O
NB	B-MED
8	I-MED
+	O
NAC	B-MED
group	B-MED
(	O
n=6	O
)	O
.	O
Viability	B-MED
and	O
yield	O
were	O
defined	O
as	O
fresh	O
hepatocytes	B-MED
and	O
their	O
spheroids	B-MED
formation	I-MED
after	O
24	O
-	O
hour	O
rocker	B-MED
culture	I-MED
in	O
serum	B-MED
-	I-MED
free	I-MED
medium	I-MED
.	O
Metabolic	B-MED
function	I-MED
was	O
assessed	O
by	O
gene	B-MED
expression	I-MED
,	O
albumin	B-MED
,	O
and	O
urea	B-MED
synthesis	B-MED
.	O
All	O
procedures	O
resulted	O
in	O
successful	O
hepatocyte	B-MED
isolation	B-MED
.	O
Cells	B-MED
from	O
the	O
NB	B-MED
8	I-MED
+	O
NAC	B-MED
group	B-MED
had	O
(	O
97.8±1.9)%	O
viability	B-MED
,	O
which	O
was	O
higher	O
than	O
the	O
NB	B-MED
8	I-MED
group	B-MED
with	O
(	O
94.4±2.4)%	O
and	O
the	O
NB	B-MED
4	I-MED
group	B-MED
with	O
(	O
94.5±3.2)%	O
(	O
P<.001	O
)	O
.	O
The	O
final	O
cell	B-MED
yield	O
reached	O
(	O
11.8±1.0)×10(9	O
)	O
cells	B-MED
in	O
the	O
NB	B-MED
8	I-MED
+	O
NAC	B-MED
group	B-MED
,	O
compared	O
to	O
(	O
9.5±2.1)×10(9	O
)	O
cells	B-MED
in	O
the	O
NB	B-MED
8	I-MED
group	B-MED
(	O
P<.01	O
)	O
and	O
(	O
9.1±1.1	O
)	O
×10(9	O
)	O
cells	B-MED
in	O
the	O
NB	B-MED
4	I-MED
group	B-MED
(	O
P<.001	O
)	O
.	O
The	O
secretion	B-MED
of	O
albumin	B-MED
was	O
superior	O
in	O
the	O
NB	B-MED
8	I-MED
+	O
NAC	B-MED
group	B-MED
at	O
a	O
concentration	O
of	O
(	O
425.8±35.3	O
)	O
ng	O
/	O
mL	O
compared	O
to	O
the	O
NB	B-MED
8	I-MED
group	B-MED
(	O
339.1±32.6	O
)	O
ng	O
/	O
mL	O
(	O
P	O
<	O
.001	O
)	O
and	O
NB	B-MED
4	I-MED
group	B-MED
(	O
293.6±43.3	O
)	O
ng	O
/	O
mL	O
(	O
P	O
<	O
.01	O
)	O
.	O
The	O
injury	B-MED
of	O
hepatocytes	B-MED
also	O
decreased	O
in	O
the	O
NB	B-MED
8	I-MED
+	O
NAC	B-MED
group	B-MED
(	O
P<.01	O
)	O
.	O
The	O
data	O
are	O
presented	O
as	O
means	B-MED
±	I-MED
SD	I-MED
.	O
Formulated	O
collagenase	B-MED
Serva	I-MED
NB	I-MED
8	I-MED
and	O
NAC	B-MED
could	O
improve	O
the	O
porcine	B-MED
hepatocyte	B-MED
isolation	B-MED
,	O
resulting	O
in	O
higher	O
yields	O
of	O
viable	B-MED
cells	I-MED
.	O
Loss	B-MED
of	O
Snf5	B-MED
Induces	B-MED
Formation	B-MED
of	O
an	O
Aberrant	B-MED
SWI	B-MED
/	I-MED
SNF	I-MED
Complex	I-MED
The	O
SWI	B-MED
/	I-MED
SNF	I-MED
chromatin	B-MED
remodeling	I-MED
complex	I-MED
is	O
highly	O
conserved	O
from	O
yeast	B-MED
to	O
human	B-MED
,	O
and	O
aberrant	B-MED
SWI	B-MED
/	I-MED
SNF	I-MED
complexes	I-MED
contribute	O
to	O
human	B-MED
disease	B-MED
.	O
The	O
Snf5	B-MED
/	I-MED
SMARCB1	I-MED
/	I-MED
INI1	I-MED
subunit	B-MED
of	O
SWI	B-MED
/	I-MED
SNF	I-MED
is	O
a	O
tumor	B-MED
suppressor	I-MED
frequently	O
lost	B-MED
in	O
pediatric	B-MED
rhabdoid	B-MED
cancers	I-MED
.	O
We	O
examined	O
the	O
effects	B-MED
of	I-MED
Snf5	B-MED
loss	B-MED
on	O
the	O
composition	B-MED
,	O
nucleosome	B-MED
binding	I-MED
,	O
recruitment	O
,	O
and	O
remodeling	O
activities	O
of	O
yeast	B-MED
SWI	B-MED
/	I-MED
SNF	I-MED
.	O
The	O
Snf5	B-MED
subunit	B-MED
is	O
shown	O
by	O
crosslinking	B-MED
-	I-MED
mass	I-MED
spectrometry	I-MED
(	O
CX	B-MED
-	I-MED
MS	I-MED
)	O
and	O
subunit	B-MED
deletion	B-MED
analysis	I-MED
to	O
interact	O
with	O
the	O
ATPase	B-MED
domain	I-MED
of	O
Snf2	B-MED
and	O
to	O
form	O
a	O
submodule	B-MED
consisting	O
of	O
Snf5	B-MED
,	O
Swp82	B-MED
,	O
and	O
Taf14	B-MED
.	O
Snf5	B-MED
promotes	O
binding	B-MED
of	O
the	O
Snf2	B-MED
ATPase	B-MED
domain	I-MED
to	O
nucleosomal	B-MED
DNA	I-MED
and	O
enhances	O
the	O
catalytic	O
and	O
nucleosome	O
remodeling	O
activities	O
of	O
SWI	B-MED
/	I-MED
SNF	I-MED
.	O
Snf5	B-MED
is	O
also	O
required	O
for	O
SWI	B-MED
/	I-MED
SNF	I-MED
recruitment	O
by	O
acidic	B-MED
transcription	I-MED
factors	I-MED
.	O
RNA	B-MED
-	I-MED
seq	I-MED
analysis	I-MED
suggests	O
that	O
both	O
the	O
recruitment	O
and	O
remodeling	O
functions	O
of	O
Snf5	B-MED
are	O
required	O
in	B-MED
vivo	I-MED
for	O
SWI	B-MED
/	I-MED
SNF	I-MED
regulation	B-MED
of	I-MED
gene	I-MED
expression	I-MED
.	O
Thus	O
,	O
loss	B-MED
of	O
SNF5	B-MED
alters	O
the	O
structure	B-MED
and	O
function	B-MED
of	O
SWI	B-MED
/	I-MED
SNF	I-MED
.	O
Folate	B-MED
-	O
conjugated	B-MED
gene	B-MED
-	O
carrying	B-MED
microbubbles	B-MED
with	O
focused	B-MED
ultrasound	I-MED
for	O
concurrent	B-MED
blood	B-MED
-	I-MED
brain	I-MED
barrier	I-MED
opening	B-MED
and	O
local	B-MED
gene	B-MED
delivery	I-MED
Previous	B-MED
studies	B-MED
have	O
demonstrated	O
that	O
circulating	B-MED
DNA	B-MED
-	O
encapsulated	B-MED
microbubbles	B-MED
(	O
MBs	B-MED
)	O
combined	B-MED
with	O
focused	B-MED
ultrasound	I-MED
(	O
FUS	B-MED
)	O
can	O
be	O
used	B-MED
for	O
local	B-MED
blood	B-MED
-	I-MED
brain	I-MED
barrier	I-MED
(	O
BBB	B-MED
)	O
opening	B-MED
and	O
gene	B-MED
delivery	I-MED
.	O
However	O
,	O
few	O
studies	B-MED
focused	B-MED
on	O
how	O
to	O
increase	B-MED
the	O
efficiency	B-MED
of	O
gene	B-MED
delivery	I-MED
to	O
brain	B-MED
tumors	I-MED
after	O
the	O
released	B-MED
gene	B-MED
penetrating	B-MED
the	O
BBB	B-MED
.	O
Here	O
,	O
we	O
proposed	O
the	O
use	B-MED
of	I-MED
folate	B-MED
-	O
conjugated	O
DNA	O
-	O
loaded	O
cationic	B-MED
MBs	I-MED
(	O
FCMBs	B-MED
)	O
.	O
When	O
combined	B-MED
with	O
FUS	B-MED
as	O
a	O
trigger	B-MED
for	O
BBB	B-MED
opening	O
,	O
FCMBs	B-MED
were	O
converted	O
into	O
nanometer	B-MED
-	O
sized	B-MED
vesicles	B-MED
that	O
were	O
transported	B-MED
to	O
the	O
brain	B-MED
parenchyma	B-MED
.	O
The	O
FCMBs	B-MED
can	O
selectively	O
aggregate	B-MED
around	O
tumor	B-MED
cells	I-MED
that	O
overexpressed	B-MED
the	O
folate	B-MED
receptor	I-MED
,	O
thus	O
enhancing	B-MED
gene	B-MED
delivery	I-MED
via	O
folate	B-MED
-	O
stimulated	B-MED
endocytosis	B-MED
.	O
Our	O
results	B-MED
confirmed	B-MED
that	O
FCMBs	B-MED
can	O
carry	B-MED
DNA	B-MED
on	O
the	O
surface	B-MED
of	O
the	O
MB	B-MED
shell	B-MED
and	O
have	O
good	B-MED
targeting	B-MED
ability	B-MED
on	O
C6	B-MED
glioma	I-MED
cells	I-MED
.	O
In	O
addition	O
,	O
the	O
optimized	O
FUS	B-MED
parameters	B-MED
for	O
FCMBs	B-MED
-	O
enhanced	B-MED
gene	B-MED
delivery	I-MED
were	O
confirmed	B-MED
by	I-MED
cell	B-MED
experiments	B-MED
(	O
center	B-MED
frequency	I-MED
=	O
1	O
MHz	O
;	O
acoustic	B-MED
pressure	I-MED
=	O
700	O
kPa	O
;	O
pulse	B-MED
repetition	B-MED
frequency	B-MED
=	O
5	O
Hz	O
;	O
cycle	B-MED
number	B-MED
=	O
10000	O
;	O
exposure	B-MED
time	B-MED
=	O
1	O
min	O
;	O
FCMBs	B-MED
concentration	B-MED
=	O
4	O
×	O
10(7	O
)	O
MB	O
/	O
mL	O
)	O
.	O
In	B-MED
vivo	I-MED
data	B-MED
also	O
indicated	B-MED
that	O
FCMBs	B-MED
show	O
better	B-MED
gene	B-MED
transfection	B-MED
efficiency	B-MED
than	O
MBs	B-MED
without	B-MED
folate	B-MED
conjugation	B-MED
and	O
the	O
traditional	B-MED
approach	B-MED
of	O
directly	B-MED
injecting	B-MED
the	O
gene	B-MED
.	O
This	O
study	B-MED
described	O
our	O
novel	B-MED
development	B-MED
of	O
multifunctional	B-MED
MBs	B-MED
for	O
FUS	B-MED
-	O
triggered	B-MED
gene	B-MED
delivery	I-MED
/	O
therapy	B-MED
.	O
A	O
fast	B-MED
small	I-MED
-	I-MED
sample	I-MED
kernel	I-MED
independence	I-MED
test	I-MED
for	O
microbiome	B-MED
community	B-MED
-	O
level	B-MED
association	I-MED
analysis	I-MED
To	O
fully	O
understand	O
the	O
role	B-MED
of	O
microbiome	B-MED
in	O
human	B-MED
health	B-MED
and	O
diseases	B-MED
,	O
researchers	B-MED
are	O
increasingly	O
interested	O
in	O
assessing	B-MED
the	O
relationship	B-MED
between	O
microbiome	B-MED
composition	I-MED
and	O
host	B-MED
genomic	B-MED
data	B-MED
.	O
The	O
dimensionality	B-MED
of	O
the	O
data	B-MED
as	O
well	O
as	O
complex	B-MED
relationships	B-MED
between	O
microbiota	B-MED
and	O
host	B-MED
genomics	B-MED
pose	O
considerable	O
challenges	B-MED
for	O
analysis	B-MED
.	O
In	O
this	O
article	O
,	O
we	O
apply	O
a	O
kernel	B-MED
RV	I-MED
coefficient	I-MED
(	I-MED
KRV	I-MED
)	I-MED
test	I-MED
to	O
evaluate	O
the	O
overall	B-MED
association	B-MED
between	O
host	B-MED
gene	B-MED
expression	I-MED
and	O
microbiome	B-MED
composition	I-MED
.	O
The	O
KRV	B-MED
statistic	I-MED
can	O
capture	O
nonlinear	B-MED
correlations	I-MED
and	O
complex	B-MED
relationships	B-MED
among	O
the	O
individual	O
data	B-MED
types	I-MED
and	O
between	O
gene	B-MED
expression	I-MED
and	O
microbiome	B-MED
composition	I-MED
through	O
measuring	O
general	O
dependency	B-MED
.	O
Testing	B-MED
proceeds	O
via	O
a	O
similar	O
route	O
as	O
existing	O
tests	B-MED
of	O
the	O
generalized	O
RV	B-MED
coefficients	I-MED
and	O
allows	O
for	O
rapid	O
p	B-MED
-	I-MED
value	I-MED
calculation	B-MED
.	O
Strategies	B-MED
to	O
allow	O
adjustment	O
for	O
confounding	B-MED
effects	I-MED
,	O
which	O
is	O
crucial	O
for	O
avoiding	O
misleading	O
results	B-MED
,	O
and	O
to	O
alleviate	O
the	O
problem	B-MED
of	O
selecting	O
the	O
most	O
favorable	O
kernel	B-MED
are	O
considered	O
.	O
Simulation	B-MED
studies	I-MED
show	O
that	O
KRV	B-MED
is	O
useful	O
in	O
testing	B-MED
statistical	B-MED
independence	I-MED
with	O
finite	O
samples	O
given	O
the	O
kernels	B-MED
are	O
appropriately	O
chosen	O
,	O
and	O
can	O
powerfully	O
identify	O
existing	O
associations	B-MED
between	O
microbiome	B-MED
composition	I-MED
and	O
host	B-MED
genomic	B-MED
data	B-MED
while	O
protecting	O
type	B-MED
I	I-MED
error	B-MED
.	O
We	O
apply	O
the	O
KRV	B-MED
to	O
a	O
microbiome	B-MED
study	B-MED
examining	O
the	O
relationship	B-MED
between	O
host	B-MED
transcriptome	B-MED
and	O
microbiome	B-MED
composition	I-MED
within	O
the	O
context	B-MED
of	O
inflammatory	B-MED
bowel	I-MED
disease	I-MED
and	O
are	O
able	O
to	O
derive	O
new	O
biological	O
insights	O
and	O
provide	O
formal	O
inference	O
on	O
prior	O
qualitative	B-MED
observations	I-MED
.	O
Basal	B-MED
ryanodine	B-MED
receptor	I-MED
activity	I-MED
suppresses	B-MED
autophagic	B-MED
flux	B-MED
The	O
inositol	B-MED
1,4,5	I-MED
-	I-MED
trisphosphate	I-MED
receptors	I-MED
(	O
IP3Rs	B-MED
)	O
and	O
intracellular	B-MED
Ca(2	I-MED
+	I-MED
)	I-MED
signaling	I-MED
are	O
critically	B-MED
involved	B-MED
in	O
regulating	B-MED
different	B-MED
steps	B-MED
of	O
autophagy	B-MED
,	O
a	O
lysosomal	B-MED
degradation	B-MED
pathway	I-MED
.	O
The	O
ryanodine	B-MED
receptors	I-MED
(	O
RyR	B-MED
)	O
,	O
intracellular	B-MED
Ca(2+)-release	I-MED
channels	I-MED
mainly	O
expressed	B-MED
in	O
excitable	B-MED
cell	B-MED
types	I-MED
including	B-MED
muscle	B-MED
and	O
neurons	B-MED
,	O
have	O
however	O
not	O
yet	O
been	O
extensively	B-MED
studied	B-MED
in	O
relation	O
to	O
autophagy	B-MED
.	O
Yet	O
,	O
aberrant	B-MED
expression	B-MED
and	O
excessive	B-MED
activity	B-MED
of	O
RyRs	B-MED
in	O
these	O
tissues	B-MED
has	O
been	O
implicated	B-MED
in	O
the	O
onset	B-MED
of	I-MED
several	B-MED
diseases	B-MED
including	B-MED
Alzheimer	B-MED
's	I-MED
disease	I-MED
,	O
where	O
impaired	B-MED
autophagy	B-MED
regulation	B-MED
contributes	B-MED
to	O
the	O
pathology	B-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
determined	B-MED
whether	O
pharmacological	B-MED
RyR	B-MED
inhibition	B-MED
could	O
modulate	B-MED
autophagic	B-MED
flux	B-MED
in	O
ectopic	B-MED
RyR	B-MED
-	O
expressing	B-MED
models	B-MED
,	O
like	O
HEK293	B-MED
cells	I-MED
and	O
in	O
cell	B-MED
types	I-MED
that	O
endogenously	B-MED
express	B-MED
RyR	B-MED
s	O
,	O
like	O
C2C12	B-MED
myoblasts	I-MED
and	O
primary	B-MED
hippocampal	B-MED
neurons	B-MED
.	O
Importantly	B-MED
,	O
RyR3	B-MED
overexpression	B-MED
in	O
HEK293	B-MED
cells	I-MED
impaired	B-MED
the	O
autophagic	B-MED
flux	B-MED
.	O
Conversely	O
,	O
in	O
all	O
cell	B-MED
models	B-MED
tested	B-MED
,	O
pharmacological	B-MED
inhibition	B-MED
of	O
endogenous	B-MED
or	O
ectopically	B-MED
expressed	B-MED
RyRs	B-MED
,	O
using	O
dantrolene	B-MED
or	O
ryanodine	B-MED
,	O
augmented	B-MED
autophagic	B-MED
flux	B-MED
by	O
increasing	B-MED
lysosomal	B-MED
turn	B-MED
-	I-MED
over	I-MED
(	O
number	B-MED
of	O
autophagosomes	B-MED
and	O
autolysosomes	B-MED
measured	B-MED
as	O
mCherry	B-MED
-	O
LC3	B-MED
punctae	I-MED
/	O
cell	B-MED
increased	B-MED
from	O
70.37±7.81	O
in	O
control	B-MED
HEK	B-MED
RyR3	I-MED
cells	I-MED
to	O
111.18±7.72	O
and	O
98.14±7.31	O
after	O
dantrolene	B-MED
and	O
ryanodine	B-MED
treatments	B-MED
,	O
respectively	O
)	O
.	O
Moreover	O
,	O
in	O
differentiated	B-MED
C2C12	B-MED
cells	I-MED
,	O
transmission	B-MED
electron	I-MED
microscopy	I-MED
demonstrated	B-MED
that	O
dantrolene	B-MED
treatment	B-MED
decreased	B-MED
the	O
number	B-MED
of	O
early	O
autophagic	B-MED
vacuoles	B-MED
from	O
5.9±2.97	O
to	O
1.8±1.03	O
per	O
cellular	B-MED
cross	B-MED
section	I-MED
.	O
The	O
modulation	B-MED
of	O
the	O
autophagic	B-MED
flux	B-MED
could	O
be	O
linked	O
to	O
the	O
functional	B-MED
inhibition	B-MED
of	O
RyR	B-MED
channels	I-MED
as	O
both	O
RyR	B-MED
inhibitors	B-MED
efficiently	B-MED
diminished	O
the	O
number	B-MED
of	O
cells	B-MED
showing	O
spontaneous	B-MED
RyR3	B-MED
activity	B-MED
in	O
the	O
HEK293	B-MED
cell	I-MED
model	B-MED
(	O
from	O
41.14%±2.12	O
in	O
control	B-MED
cells	B-MED
to	O
18.70%±2.25	O
and	O
9.74%±2.67	O
after	O
dantrolene	B-MED
and	O
ryanodine	B-MED
treatments	B-MED
,	O
respectively	O
)	O
.	O
In	O
conclusion	B-MED
,	O
basal	B-MED
RyR	B-MED
-mediated	O
Ca(2+)-release	B-MED
events	I-MED
suppress	B-MED
autophagic	B-MED
flux	B-MED
at	O
the	O
level	B-MED
of	O
the	O
lysosomes	B-MED
.	O
High	B-MED
-	I-MED
Throughput	I-MED
Analysis	I-MED
of	O
the	O
IgG	B-MED
N	I-MED
-	I-MED
Glycome	I-MED
by	O
UPLC	B-MED
-	O
FLR	B-MED
As	O
biological	B-MED
and	O
clinical	B-MED
relevance	B-MED
of	O
glycosylation	B-MED
is	O
becoming	O
more	O
apparent	B-MED
,	O
interest	O
in	O
large	B-MED
scale	I-MED
studies	I-MED
of	O
the	O
glycome	B-MED
is	O
growing	O
.	O
Glycans	B-MED
attached	O
to	O
immunoglobulin	B-MED
G	I-MED
(	O
IgG	B-MED
)	O
were	O
shown	O
to	O
be	O
essential	B-MED
for	O
its	O
function	B-MED
and	O
IgG	B-MED
glycosylation	B-MED
was	O
shown	O
to	O
change	B-MED
with	O
various	O
processes	B-MED
,	O
making	O
IgG	B-MED
one	O
of	O
the	O
most	O
studied	O
glycoproteins	B-MED
.	O
Many	O
approaches	B-MED
including	O
liquid	B-MED
chromatography	I-MED
,	O
capillary	B-MED
gel	I-MED
electrophoresis	I-MED
,	O
and	O
mass	B-MED
spectrometry	I-MED
were	O
developed	O
to	O
study	B-MED
IgG	B-MED
glycosylation	B-MED
.	O
Generation	B-MED
of	O
high	B-MED
-	I-MED
quality	I-MED
glycomics	B-MED
data	B-MED
in	O
a	O
high	B-MED
-	I-MED
throughput	I-MED
fashion	O
requires	O
reproducible	B-MED
and	O
robust	B-MED
sample	B-MED
preparation	I-MED
and	O
accurate	B-MED
and	O
reliable	O
quantitative	B-MED
analysis	I-MED
.	O
This	O
chapter	B-MED
presents	O
a	O
protocol	B-MED
for	O
an	O
optimized	O
and	O
high	B-MED
-	I-MED
throughput	I-MED
IgG	B-MED
N	I-MED
-	I-MED
glycan	I-MED
release	B-MED
,	O
fluorescent	B-MED
labeling	I-MED
and	O
cleanup	B-MED
,	O
and	O
analysis	B-MED
of	O
fluorescently	B-MED
labeled	I-MED
IgG	B-MED
N	I-MED
-	I-MED
glycans	I-MED
by	O
hydrophilic	B-MED
interaction	I-MED
liquid	I-MED
chromatography	I-MED
(	O
HILIC	B-MED
)	O
on	O
an	O
ultra	B-MED
performance	I-MED
liquid	I-MED
chromatography	I-MED
(	O
UPLC	B-MED
)	O
system	O
with	O
fluorescence	B-MED
(	O
FLR	B-MED
)	O
detection	B-MED
.	O
A	O
comparison	O
of	O
outcomes	B-MED
in	O
morbidly	B-MED
obese	I-MED
,	O
obese	B-MED
and	O
non	B-MED
-	I-MED
obese	I-MED
patients	B-MED
undergoing	O
primary	B-MED
total	I-MED
knee	I-MED
and	O
total	B-MED
hip	I-MED
arthroplasty	I-MED
Obesity	B-MED
is	O
a	O
growing	O
public	B-MED
health	B-MED
issue	I-MED
with	O
the	O
prevalence	B-MED
of	O
morbid	B-MED
obesity	I-MED
,	I-MED
(	I-MED
Body	I-MED
Mass	I-MED
Index	I-MED
(	I-MED
BMI	I-MED
)	I-MED
≥	I-MED
40	I-MED
kg	I-MED
/	I-MED
m(2	I-MED
)	I-MED
)	I-MED
increasing	B-MED
.	O
There	O
is	O
some	O
evidence	B-MED
these	O
patients	B-MED
have	O
more	O
peri-	B-MED
and	I-MED
post	I-MED
-	I-MED
operative	I-MED
complications	I-MED
and	O
poorer	B-MED
outcomes	I-MED
when	O
undergoing	O
arthroplasty	B-MED
procedures	I-MED
.	O
This	O
audit	O
aimed	O
to	O
determine	O
and	O
compare	O
the	O
outcomes	B-MED
of	O
non	B-MED
-	I-MED
obese	I-MED
,	O
obese	B-MED
and	O
morbidly	B-MED
obese	I-MED
patients	B-MED
undergoing	O
arthroplasty	B-MED
at	O
our	O
institution	B-MED
.	O
This	O
was	O
a	O
retrospective	B-MED
audit	I-MED
of	O
patients	B-MED
from	O
our	O
institution	B-MED
who	O
had	O
undergone	O
total	B-MED
knee	I-MED
(	O
TKA	B-MED
)	O
or	O
total	B-MED
hip	I-MED
arthroplasty	I-MED
(	O
THA	B-MED
)	O
in	O
2009	O
.	O
Data	B-MED
collected	B-MED
were	O
:	O
age	B-MED
,	O
gender	B-MED
,	O
BMI	B-MED
,	O
length	B-MED
of	I-MED
stay	I-MED
(	O
LOS	B-MED
)	O
,	O
Oxford	B-MED
knee	I-MED
or	O
hip	B-MED
score	I-MED
(	O
OKS	B-MED
/	O
OHS	B-MED
)	O
,	O
satisfaction	B-MED
and	O
complications	B-MED
up	O
to	O
two	O
years	B-MED
post	B-MED
operation	I-MED
.	O
Patients	B-MED
were	O
divided	O
into	O
three	O
groups	B-MED
:	O
BMI	B-MED
<	I-MED
30	I-MED
,	O
BMI	B-MED
30	I-MED
-	I-MED
40	I-MED
and	O
BMI	B-MED
>	I-MED
40	I-MED
.	O
Outcomes	B-MED
for	O
each	O
BMI	B-MED
group	B-MED
were	O
compared	O
.	O
1014	O
TKA	B-MED
and	O
906	O
THA	B-MED
operations	B-MED
were	O
included	O
.	O
When	O
compared	O
to	O
obese	B-MED
and	O
non	B-MED
-	I-MED
obese	I-MED
patients	B-MED
,	O
morbidly	B-MED
obese	I-MED
patients	B-MED
undergoing	O
TKA	B-MED
had	O
a	O
mean	O
LOS	B-MED
one	O
day	B-MED
longer	O
,	O
a	O
mean	B-MED
OKS	I-MED
four	O
points	O
lower	O
and	O
higher	O
rates	O
of	O
postoperative	B-MED
problems	I-MED
,	O
37	O
%	O
vs.	O
21	O
%	O
.	O
For	O
THA	B-MED
patients	B-MED
there	O
was	O
no	B-MED
difference	I-MED
in	O
LOS	B-MED
,	O
OHS	B-MED
score	I-MED
was	O
two	O
points	O
lower	O
for	O
each	O
increasing	B-MED
BMI	B-MED
category	B-MED
and	O
postoperative	B-MED
problems	I-MED
increase	B-MED
from	O
25	O
%	O
for	O
non	B-MED
-	I-MED
obese	I-MED
to	O
31	O
%	O
for	O
obese	B-MED
and	O
38	O
%	O
for	O
morbidly	B-MED
obese	I-MED
patients	B-MED
.	O
These	O
results	O
will	O
be	O
useful	O
in	O
informing	O
obese	B-MED
patients	B-MED
of	O
their	O
potential	O
outcomes	B-MED
following	O
TKA	B-MED
or	O
THA	B-MED
.	O
These	O
patients	B-MED
can	O
then	O
make	O
a	O
more	O
informed	O
choice	O
before	O
proceeding	O
with	O
arthroplasty	B-MED
.	O
Design	O
of	O
a	O
candidate	O
vibrational	B-MED
signal	I-MED
for	O
mating	B-MED
disruption	B-MED
against	O
the	O
glassy	B-MED
-	I-MED
winged	I-MED
sharpshooter	I-MED
,	O
Homalodisca	B-MED
vitripennis	I-MED
The	O
glassy	B-MED
-	I-MED
winged	I-MED
sharpshooter	I-MED
(	O
GWSS	B-MED
)	O
,	O
Homalodisca	B-MED
vitripennis	I-MED
,	O
is	O
an	O
important	O
pest	B-MED
of	O
grapevines	B-MED
due	O
to	O
its	O
ability	O
to	O
transmit	B-MED
Xylella	B-MED
fastidiosa	I-MED
,	O
the	O
causal	B-MED
agent	I-MED
of	O
Pierce	B-MED
's	I-MED
disease	I-MED
.	O
GWSS	B-MED
mating	B-MED
communication	B-MED
is	O
based	O
on	O
vibrational	B-MED
signals	I-MED
;	O
therefore	O
,	O
vibrational	B-MED
mating	B-MED
disruption	B-MED
could	O
be	O
an	O
alternative	B-MED
to	O
insecticides	B-MED
for	O
suppression	B-MED
of	O
GWSS	B-MED
population	B-MED
.	O
Our	O
objectives	B-MED
were	O
to	O
identify	O
spectral	B-MED
features	B-MED
of	O
female	B-MED
signal	B-MED
that	O
elicit	O
male	B-MED
signaling	B-MED
,	O
design	O
disruptive	B-MED
signals	B-MED
able	O
to	O
alter	B-MED
male	B-MED
perception	B-MED
and	O
acceptance	B-MED
of	O
a	O
female	B-MED
,	O
and	O
determine	O
the	O
signal	B-MED
intensity	I-MED
required	O
for	O
future	O
field	O
applications	O
.	O
Results	B-MED
showed	O
that	O
male	B-MED
responses	B-MED
to	O
playback	B-MED
of	O
modified	B-MED
female	B-MED
signals	B-MED
were	O
significantly	B-MED
reduced	B-MED
by	O
60	O
-	O
75%when	O
part	O
of	O
the	O
female	B-MED
signal	B-MED
spectral	I-MED
components	I-MED
above	O
or	O
below	O
400	O
Hz	O
were	O
deleted	O
.	O
Playback	B-MED
bioassays	B-MED
showed	O
that	O
transmission	B-MED
of	O
an	O
80	O
Hz	O
pure	O
frequency	B-MED
tone	I-MED
to	O
plants	B-MED
completely	O
suppressed	B-MED
male	B-MED
signaling	B-MED
to	O
female	B-MED
signal	B-MED
playback	I-MED
,	O
even	O
if	O
the	O
disruptive	B-MED
signal	B-MED
amplitude	I-MED
was	O
10	O
dB	O
lower	O
than	O
the	O
female	B-MED
signal	B-MED
playback	I-MED
.	O
Although	O
the	O
mechanism	B-MED
underlying	O
cessation	B-MED
of	O
male	B-MED
signaling	B-MED
activity	O
in	O
the	O
presence	B-MED
of	O
disruption	B-MED
is	O
not	O
yet	O
understood	O
,	O
results	B-MED
suggest	O
that	O
an	O
80	O
Hz	O
vibrational	B-MED
signal	I-MED
should	O
be	O
tested	O
in	O
laboratory	B-MED
and	O
field	B-MED
experiments	I-MED
to	O
assess	B-MED
its	O
efficacy	B-MED
in	O
disrupting	O
mating	B-MED
of	O
GWSS	B-MED
.	O
Increased	B-MED
acute	B-MED
mortality	B-MED
with	O
chemoradiotherapy	B-MED
for	O
locally	B-MED
advanced	I-MED
head	I-MED
and	I-MED
neck	I-MED
cancer	I-MED
in	O
patients	B-MED
≥70	O
years	B-MED
Concurrent	B-MED
chemoradiotherapy	I-MED
(	O
CRT	B-MED
)	O
is	O
the	O
standard	B-MED
of	I-MED
care	I-MED
for	O
many	O
sites	B-MED
of	O
locally	B-MED
advanced	I-MED
head	I-MED
and	I-MED
neck	I-MED
squamous	I-MED
cell	I-MED
carcinomas	I-MED
(	O
LAHNC	B-MED
)	O
.	O
However	O
,	O
on	O
meta	B-MED
-	I-MED
analysis	I-MED
,	O
the	O
addition	O
of	O
chemotherapy	B-MED
did	O
not	O
improve	O
survival	B-MED
for	O
patients	B-MED
>	O
70	O
years	B-MED
.	O
We	O
hypothesized	O
that	O
elderly	B-MED
patients	B-MED
treated	B-MED
with	O
CRT	B-MED
would	O
have	O
increased	B-MED
toxicity	B-MED
without	O
similar	O
improvements	B-MED
in	O
survival	B-MED
.	O
A	O
single	B-MED
-	I-MED
institution	I-MED
,	O
IRB	B-MED
-	I-MED
approved	I-MED
retrospective	B-MED
study	I-MED
took	O
place	O
from	O
2005	O
to	O
2012	O
including	O
369	O
patients	B-MED
treated	B-MED
with	O
CRT	B-MED
for	O
LAHNC	B-MED
.	O
Multivariate	B-MED
models	I-MED
for	O
death	B-MED
at	O
3	O
months	B-MED
and	O
death	B-MED
over	O
time	B-MED
were	O
developed	O
using	O
logistic	B-MED
regression	I-MED
and	O
Cox	B-MED
modeling	I-MED
,	O
respectively	O
.	O
Patients	B-MED
≥70	O
years	B-MED
were	O
treated	B-MED
less	O
often	O
with	O
concurrent	B-MED
cisplatin	B-MED
dosed	O
every	O
3	O
weeks	B-MED
(	O
25.5	O
%	O
vs.	O
71.4	O
%	O
,	O
respectively	O
)	O
and	O
more	O
often	O
with	O
weekly	B-MED
carboplatin	B-MED
(	O
31.9	O
%	O
vs.	O
3.4	O
%	O
)	O
than	O
patients	B-MED
<	O
70	O
years	B-MED
(	O
n=322	O
;	O
p<0.001	O
)	O
.	O
Patients	B-MED
≥70	O
years	B-MED
experienced	O
increased	B-MED
toxicity	B-MED
during	O
treatment	B-MED
with	O
more	O
frequently	O
hospitalizations	B-MED
(	O
36.2	O
%	O
vs.	O
21.1	O
%	O
;	O
p=0.02	O
)	O
and	O
a	O
lower	O
rate	O
of	O
PEG	B-MED
removal	I-MED
at	O
last	O
follow	B-MED
-	I-MED
up	I-MED
or	O
death	B-MED
(	O
77.1	O
%	O
vs.	O
92.9	O
%	O
;	O
p=0.004	O
)	O
.	O
A	O
higher	O
proportion	B-MED
of	O
patients	B-MED
≥70	O
years	B-MED
died	O
within	O
3	O
months	B-MED
(	O
12.8	O
%	O
vs.	O
2.8	O
%	O
;	O
p=0.001	O
)	O
following	O
CRT	B-MED
.	O
Patients	B-MED
≥70	O
had	O
an	O
increased	B-MED
risk	B-MED
of	O
death	B-MED
at	O
3	O
months	B-MED
following	O
CRT	B-MED
(	O
odds	B-MED
ratio	I-MED
5.19	O
,	O
95	O
%	O
CI	B-MED
1.64	O
-	O
16.41	O
;	O
p=0.005	O
)	O
and	O
worse	O
survival	B-MED
over	O
time	B-MED
(	O
hazard	B-MED
ratio	I-MED
2.30	O
,	O
95	O
%	O
CI	B-MED
1.34	O
-	O
3.93	O
;	O
p=0.002	O
)	O
.	O
Patients	B-MED
≥70	O
years	B-MED
were	O
more	O
often	O
treated	B-MED
with	O
less	O
toxic	B-MED
chemotherapy	B-MED
,	O
yet	O
experienced	O
higher	O
rates	B-MED
of	O
hospitalization	B-MED
during	O
treatment	B-MED
and	O
increased	B-MED
rates	B-MED
of	O
acute	B-MED
mortality	B-MED
following	O
CRT	B-MED
.	O
The	O
efficacy	B-MED
of	O
chemoradiotherapy	B-MED
for	O
elderly	B-MED
patients	B-MED
should	O
be	O
evaluated	O
in	O
a	O
prospective	B-MED
setting	I-MED
.	O
Entrapment	B-MED
of	O
the	O
posterior	B-MED
femoral	I-MED
cutaneous	I-MED
nerve	I-MED
and	O
its	O
inferior	B-MED
cluneal	I-MED
branches	I-MED
:	O
anatomical	B-MED
basis	I-MED
of	O
surgery	B-MED
for	O
inferior	B-MED
cluneal	I-MED
neuralgia	I-MED
The	O
apparent	O
failure	O
of	O
pudendal	B-MED
nerve	I-MED
surgery	B-MED
in	O
some	O
patients	B-MED
has	O
led	O
us	O
to	O
suggest	O
the	O
possibility	O
of	O
entrapment	B-MED
of	O
other	O
adjacent	B-MED
nerve	I-MED
structures	I-MED
,	O
leading	O
to	O
the	O
concept	O
of	O
inferior	B-MED
cluneal	I-MED
neuralgia	I-MED
.	O
Via	O
its	O
numerous	O
collateral	B-MED
branches	I-MED
,	O
the	O
posterior	B-MED
femoral	I-MED
cutaneous	I-MED
nerve	I-MED
innervates	O
a	O
very	O
extensive	O
territory	O
including	O
the	O
posterior	B-MED
surface	I-MED
of	I-MED
the	I-MED
thigh	I-MED
,	O
the	O
infragluteal	B-MED
fold	I-MED
,	O
the	O
skin	B-MED
over	O
the	O
ischial	B-MED
tuberosity	I-MED
,	O
but	O
also	O
the	O
lateral	B-MED
anal	I-MED
region	I-MED
,	O
scrotum	B-MED
or	O
labium	B-MED
majus	I-MED
via	O
its	O
perineal	B-MED
branch	I-MED
.	O
We	O
described	O
the	O
pathophysiological	B-MED
features	B-MED
of	O
cluneal	B-MED
neuralgia	I-MED
,	O
the	O
surgical	B-MED
technique	I-MED
and	O
our	O
preliminary	B-MED
results	I-MED
.	O
We	O
performed	O
a	O
transmuscular	B-MED
approach	I-MED
leading	O
to	O
the	O
fat	B-MED
of	O
the	O
deep	O
gluteal	B-MED
region	I-MED
.	O
Exploration	B-MED
was	O
continued	O
cranially	O
underneath	O
the	O
piriformis	B-MED
,	O
looking	O
for	O
potential	O
entrapments	B-MED
affecting	O
the	O
posterior	B-MED
femoral	I-MED
cutaneous	I-MED
nerve	I-MED
and	O
the	O
sciatic	B-MED
nerve	I-MED
.	O
Nerve	B-MED
decompression	I-MED
on	O
the	O
lateral	B-MED
surface	I-MED
of	O
the	O
ischial	B-MED
tuberosity	I-MED
was	O
then	O
performed	O
.	O
A	O
constant	O
anatomical	B-MED
finding	I-MED
must	O
be	O
highlighted	O
:	O
the	O
presence	O
of	O
a	O
lateral	B-MED
fibrous	I-MED
expansion	B-MED
from	O
the	O
ischium	B-MED
passing	O
behind	O
the	O
nerves	B-MED
and	O
vessels	B-MED
,	O
especially	O
the	O
posterior	B-MED
femoral	I-MED
cutaneous	I-MED
nerve	I-MED
and	O
its	O
perineal	B-MED
branches	I-MED
.	O
In	O
our	O
patients	B-MED
,	O
release	O
of	O
this	O
expansion	B-MED
allowed	O
decompression	B-MED
of	O
the	O
nerve	B-MED
trapped	I-MED
by	O
this	O
expansion	B-MED
.	O
Cluneal	B-MED
neuralgia	I-MED
constitutes	O
a	O
distinct	O
entity	O
of	O
perineal	B-MED
pain	I-MED
,	O
which	O
must	O
be	O
identified	O
and	O
distinguished	O
from	O
pudendal	B-MED
neuralgia	I-MED
.	O
Surgery	B-MED
should	O
be	O
performed	O
via	O
a	O
transgluteal	B-MED
approach	I-MED
.	O
A	O
lateral	B-MED
ischial	I-MED
obstacle	O
must	O
be	O
investigated	B-MED
,	O
in	O
the	O
form	O
of	O
a	O
constant	O
fibrous	B-MED
expansion	B-MED
,	O
which	O
,	O
like	O
a	O
retinaculum	B-MED
,	O
can	O
cause	O
nerve	B-MED
entrapment	I-MED
.	O
The	O
lost	O
art	O
of	O
the	O
splenorrhaphy	B-MED
In	O
the	O
case	O
of	O
the	O
hemodynamically	B-MED
unstable	I-MED
child	B-MED
,	O
splenorrhaphy	B-MED
is	O
preferred	O
to	O
splenectomy	B-MED
to	O
avert	O
postsplenectomy	B-MED
sepsis	B-MED
.	O
However	O
,	O
successful	O
splenorrhaphy	B-MED
requires	O
familiarity	B-MED
with	O
the	O
procedure	B-MED
.	O
We	O
sought	O
to	O
determine	O
how	O
many	O
splenectomies	B-MED
or	O
splenorrhaphies	B-MED
for	O
trauma	B-MED
the	O
average	O
pediatric	B-MED
surgeon	I-MED
can	O
be	O
expected	O
to	O
perform	B-MED
during	O
their	O
career	B-MED
.	O
The	O
Pediatric	B-MED
Health	I-MED
Information	I-MED
System	I-MED
(	I-MED
PHIS	I-MED
)	I-MED
Database	I-MED
was	O
queried	O
for	O
patients	B-MED
≤18	O
years	B-MED
coded	O
with	O
an	O
International	B-MED
Classification	I-MED
of	I-MED
Diseases	I-MED
9th	I-MED
Edition	I-MED
diagnosis	B-MED
code	I-MED
of	O
a	O
splenic	B-MED
injury	I-MED
from	O
2004	O
to	O
2013	O
.	O
Age	B-MED
,	O
gender	B-MED
,	O
grade	B-MED
of	O
splenic	B-MED
injury	I-MED
,	O
and	O
operations	B-MED
performed	B-MED
were	O
extracted	B-MED
.	O
Numbers	O
of	O
pediatric	B-MED
surgeons	I-MED
per	O
hospital	B-MED
were	O
obtained	O
.	O
9567	O
children	B-MED
were	O
identified	B-MED
.	O
2.1	O
%	O
underwent	O
a	O
splenectomy	B-MED
and	O
0.8	O
%	O
underwent	O
a	O
splenorrhaphy	B-MED
.	O
The	O
average	O
surgeon	B-MED
performed	B-MED
0.6	O
(	O
SD=0.6	O
)	O
splenectomies	B-MED
and	O
0.2	O
(	O
SD=0.4	O
)	O
splenorrhaphies	B-MED
for	O
trauma	B-MED
.	O
If	O
these	O
rates	B-MED
remain	O
constant	B-MED
over	O
time	O
,	O
the	O
average	O
surgeon	B-MED
would	O
perform	B-MED
1.8	O
(	O
SD	O
=	O
1.7	O
)	O
splenectomies	B-MED
and	O
0.6	O
(	O
SD	O
=	O
1.1	O
)	O
splenorrhaphies	B-MED
for	O
trauma	B-MED
over	O
a	O
30-	O
year	B-MED
surgical	B-MED
career	I-MED
.	O
Nonoperative	B-MED
management	I-MED
is	O
associated	O
with	O
a	O
host	O
of	O
benefits	O
,	O
but	O
has	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
experience	B-MED
level	I-MED
of	O
the	O
pediatric	B-MED
surgeons	I-MED
expected	O
to	O
perform	B-MED
an	O
emergency	O
splenectomy	B-MED
or	O
splenorrhaphy	B-MED
when	O
the	O
unusual	O
occasion	O
arises	O
.	O
Correlation	B-MED
between	O
preoperative	B-MED
physical	B-MED
signs	I-MED
and	O
functional	B-MED
outcomes	B-MED
after	O
laminoplasty	B-MED
for	O
ossification	B-MED
of	I-MED
the	I-MED
posterior	I-MED
longitudinal	I-MED
ligament	I-MED
Ossification	B-MED
of	I-MED
the	I-MED
posterior	I-MED
longitudinal	I-MED
ligament	I-MED
(	O
OPLL	B-MED
)	O
can	O
cause	O
myelopathy	B-MED
that	O
is	O
often	B-MED
managed	B-MED
surgically	B-MED
.	O
Knowledge	B-MED
of	O
predictors	B-MED
of	O
surgical	B-MED
outcomes	B-MED
can	O
provide	B-MED
decision	B-MED
support	I-MED
to	O
surgeons	B-MED
.	O
The	O
aims	B-MED
of	O
this	O
study	B-MED
were	O
to	O
investigate	B-MED
the	O
relationships	B-MED
between	O
preoperative	B-MED
physical	B-MED
signs	I-MED
and	O
postoperative	B-MED
functional	B-MED
outcomes	B-MED
in	O
patients	B-MED
with	O
OPLL	B-MED
and	O
to	O
clarify	B-MED
whether	O
physical	B-MED
signs	I-MED
could	O
predict	B-MED
functional	B-MED
outcomes	B-MED
.	O
Fifty	O
-	O
five	O
patients	B-MED
with	O
OPLL	B-MED
who	O
had	O
undergone	O
cervical	B-MED
laminoplasty	I-MED
were	O
included	B-MED
in	O
this	O
study	B-MED
.	O
Six	O
physical	B-MED
signs	I-MED
including	O
hyperreflexia	B-MED
,	O
Babinski	B-MED
sign	I-MED
,	O
sensory	B-MED
disturbance	I-MED
,	O
grip	B-MED
strength	I-MED
,	O
10	B-MED
-	I-MED
s	I-MED
grip	I-MED
and	I-MED
release	I-MED
test	I-MED
,	O
and	O
bladder	B-MED
dysfunction	I-MED
,	O
and	O
four	O
other	O
factors	B-MED
including	O
age	B-MED
,	O
duration	B-MED
of	I-MED
symptoms	I-MED
,	O
history	O
of	O
minor	B-MED
trauma	I-MED
and	O
preoperative	B-MED
Japanese	B-MED
Orthopaedic	I-MED
Association	I-MED
(	I-MED
JOA	I-MED
)	I-MED
score	I-MED
were	O
investigated	B-MED
as	O
potential	B-MED
predictive	B-MED
prognostic	B-MED
factors	I-MED
using	O
both	O
univariate	B-MED
and	O
multivariate	B-MED
analyses	I-MED
.	O
The	O
mean	B-MED
recovery	B-MED
rate	I-MED
of	O
JOA	B-MED
score	I-MED
was	O
62.5	O
±	O
32.5	O
%	O
.	O
The	O
neurological	B-MED
recovery	B-MED
rate	I-MED
was	O
negatively	B-MED
associated	B-MED
with	I-MED
age	B-MED
(	O
P	O
=	O
0.002	O
)	O
,	O
the	O
duration	B-MED
of	I-MED
symptoms	I-MED
(	O
P	O
=	O
0.002	O
)	O
and	O
Babinski	B-MED
sign	I-MED
(	O
P	O
=	O
0.007	O
)	O
,	O
whereas	O
it	O
was	O
positively	B-MED
correlated	B-MED
with	O
grip	B-MED
strength	I-MED
(	O
P	O
=	O
0.011	O
)	O
.	O
Multiple	B-MED
logistic	I-MED
regression	I-MED
analyses	I-MED
revealed	B-MED
that	O
age	B-MED
(	O
Odds	B-MED
ratio	I-MED
:	O
0.89	O
,	O
95	O
%	O
CI	B-MED
:	O
0.81	O
-	O
0.99	O
)	O
and	O
Babinski	B-MED
sign	I-MED
(	O
Odds	B-MED
ratio	I-MED
:	O
0.18	O
,	O
95	O
%	O
CI	B-MED
:	O
0.04	O
-	O
0.89	O
)	O
were	O
factors	B-MED
associated	B-MED
with	I-MED
functional	B-MED
outcomes	B-MED
.	O
Satisfactory	B-MED
functional	B-MED
outcomes	B-MED
could	O
be	O
expected	B-MED
for	O
patients	B-MED
who	O
are	O
young	B-MED
and	O
do	O
not	O
exhibit	O
the	O
Babinski	B-MED
sign	I-MED
,	O
showing	O
that	O
the	O
Babinski	B-MED
sign	I-MED
could	O
be	O
useful	B-MED
as	O
an	O
indicator	B-MED
of	O
the	O
window	B-MED
of	I-MED
opportunity	I-MED
for	O
achieving	B-MED
satisfactory	B-MED
functional	B-MED
outcomes	B-MED
.	O
Decreased	B-MED
Frequencies	I-MED
of	O
Peripheral	B-MED
Blood	I-MED
CD4+CD25+CD127	B-MED
-	I-MED
Foxp3	I-MED
+	I-MED
in	O
Patients	B-MED
with	O
Graves	B-MED
'	I-MED
Disease	I-MED
and	O
Graves	B-MED
'	I-MED
Orbitopathy	I-MED
:	O
Enhancing	B-MED
Effect	I-MED
of	O
Insulin	B-MED
Growth	I-MED
Factor-1	I-MED
on	O
Treg	B-MED
Cells	I-MED
Graves	B-MED
'	I-MED
orbitopathy	I-MED
(	O
GO	B-MED
)	O
is	O
characterized	B-MED
by	O
orbital	B-MED
T	I-MED
cell	I-MED
infiltration	B-MED
.	O
We	O
evaluated	B-MED
the	O
regulatory	B-MED
T	I-MED
(	I-MED
Treg	I-MED
)	I-MED
cell	I-MED
fractions	B-MED
induced	B-MED
with	O
IGF-1	B-MED
in	O
Graves	B-MED
'	I-MED
disease	I-MED
(	O
GD	B-MED
)	O
with	O
and	O
without	O
GO	B-MED
.	O
Peripheral	B-MED
blood	I-MED
mononuclear	I-MED
cells	I-MED
(	O
PBMCs	B-MED
)	O
were	O
obtained	O
from	O
13	O
patients	B-MED
with	O
GD	B-MED
without	O
eye	B-MED
manifestations	I-MED
;	O
10	O
patients	B-MED
with	O
active	B-MED
GO	B-MED
;	O
and	O
12	O
patients	B-MED
with	O
nodular	B-MED
goiter	I-MED
(	O
NG	B-MED
)	O
.	O
All	O
the	O
patients	B-MED
from	O
GD	B-MED
,	O
GO	B-MED
,	O
and	O
NG	B-MED
were	O
subclinical	B-MED
hyperthyroid	I-MED
.	O
We	O
analyzed	B-MED
the	O
expression	B-MED
of	I-MED
Treg	I-MED
cell	I-MED
markers	I-MED
(	O
CD4	B-MED
,	O
CD25	B-MED
,	O
CD127(-	B-MED
)	I-MED
,	O
Foxp3	B-MED
)	O
on	O
T	B-MED
cells	I-MED
and	O
their	O
ability	O
to	O
respond	B-MED
to	I-MED
IGF-1	B-MED
stimulation	B-MED
.	O
In	O
patients	B-MED
with	O
GD	B-MED
without	O
GO	B-MED
,	O
we	O
found	O
lowered	B-MED
percentages	I-MED
of	O
CD4(+	B-MED
)	I-MED
Foxp3(+	I-MED
)	I-MED
cells	I-MED
,	O
as	O
compared	O
to	O
nodular	B-MED
goiter	I-MED
1.77	O
vs.	O
5.42	O
%	O
(	O
p=0.0276	O
)	O
.	O
Similarly	O
,	O
significantly	B-MED
reduced	I-MED
frequencies	I-MED
of	O
CD4(+)CD25(+)CD127(-)Foxp3(+	B-MED
)	I-MED
and	O
CD4(+)CD25(+)CD127(-	B-MED
)	I-MED
cells	I-MED
were	O
observed	B-MED
in	O
GD	B-MED
patients	B-MED
as	O
compared	O
to	O
nodular	B-MED
goiter	I-MED
patients	B-MED
with	O
hyperthyreosis	B-MED
,	O
(	O
0.7	O
vs.	O
1.48	O
%	O
)	O
(	O
p=0.0071	O
)	O
and	O
(	O
14.5	O
vs.	O
37.2	O
%	O
)	O
(	O
p=0.0051	O
)	O
,	O
respectively	O
.	O
In	O
GO	B-MED
with	O
active	B-MED
GO	B-MED
,	O
only	O
the	O
percentage	B-MED
of	O
CD4(+)CD25(+)CD127(-	B-MED
)	I-MED
cells	I-MED
was	O
found	O
to	O
be	O
decreased	B-MED
versus	O
nodular	B-MED
goiter	I-MED
(	O
9.35	O
vs.	O
37.2	O
)	O
(	O
p=0.0275	O
)	O
.	O
Stimulation	B-MED
of	O
PBMC	B-MED
derived	O
from	O
GO	B-MED
patients	B-MED
with	O
IGF-1	B-MED
resulted	O
in	O
significant	B-MED
increase	I-MED
of	I-MED
frequency	I-MED
of	O
both	O
CD4(+	B-MED
)	I-MED
Foxp3(+	I-MED
)	I-MED
and	O
CD4(+)CD25(+)CD127(-	B-MED
)	I-MED
Foxp3	I-MED
cells	I-MED
.	O
Decreased	B-MED
frequencies	I-MED
of	O
peripheral	B-MED
blood	I-MED
CD4(+)CD25(+)CD127(-)Foxp3(+	B-MED
)	I-MED
in	O
patients	B-MED
with	O
GD	B-MED
and	O
GO	B-MED
could	O
be	O
an	O
useful	B-MED
marker	I-MED
of	O
autoimmune	B-MED
process	I-MED
and	O
perhaps	O
a	O
possible	O
target	O
for	O
future	B-MED
therapies	I-MED
.	O
This	O
is	O
the	O
first	O
study	B-MED
demonstrating	O
Treg	B-MED
-	O
enhancing	B-MED
effects	I-MED
of	O
IGF-1	B-MED
.	O
Thus	O
IGF-1	B-MED
can	O
be	O
accounted	O
for	O
modulating	B-MED
Treg	B-MED
cell	I-MED
-related	O
action	B-MED
in	O
GO	B-MED
.	O
Twisting	B-MED
method	I-MED
for	O
reducing	B-MED
friction	B-MED
during	O
insertion	B-MED
of	O
a	O
sheath	B-MED
introducer	B-MED
and	O
a	O
sheathless	B-MED
guiding	I-MED
catheter	I-MED
A	O
sheathless	B-MED
system	I-MED
that	O
inserts	B-MED
a	O
catheter	B-MED
directly	B-MED
into	O
the	O
artery	B-MED
can	O
reduce	B-MED
puncture	B-MED
site	B-MED
-related	O
complications	B-MED
through	O
a	O
2	B-MED
-	I-MED
Fr	I-MED
reduction	I-MED
of	O
the	O
outer	B-MED
diameter	I-MED
.	O
However	O
,	O
the	O
gap	B-MED
between	O
the	O
dilator	B-MED
and	O
the	O
guiding	B-MED
catheter	I-MED
of	O
the	O
sheathless	B-MED
system	I-MED
is	O
larger	B-MED
than	O
the	O
gap	B-MED
between	O
the	O
dilator	B-MED
and	O
sheath	B-MED
of	O
the	O
introducer	B-MED
system	I-MED
,	O
resulting	O
in	O
stronger	O
insertion	B-MED
resistance	B-MED
.	O
A	O
twisting	B-MED
method	I-MED
with	O
rapid	B-MED
alternating	B-MED
rotation	B-MED
of	O
a	O
device	B-MED
to	O
the	O
left	O
and	O
right	O
during	O
insertion	B-MED
insertion	B-MED
can	O
reduce	B-MED
the	O
insertion	B-MED
resistance	B-MED
.	O
This	O
method	O
can	O
be	O
effective	B-MED
with	O
the	O
sheathless	B-MED
system	I-MED
which	O
has	O
a	O
larger	B-MED
gap	B-MED
.	O
To	O
examine	O
the	O
effect	B-MED
of	I-MED
size	B-MED
reduction	B-MED
on	O
the	O
sheathless	B-MED
system	I-MED
and	O
the	O
effect	B-MED
of	I-MED
insertion	B-MED
resistance	B-MED
reduction	B-MED
using	O
the	O
twisting	B-MED
method	I-MED
,	O
we	O
developed	O
an	O
insertion	B-MED
simulator	B-MED
and	O
compared	B-MED
insertion	B-MED
resistance	B-MED
to	O
a	O
5	B-MED
-	I-MED
Fr	I-MED
sheath	I-MED
introducer	B-MED
and	O
a	O
5	B-MED
-	I-MED
Fr	I-MED
sheathless	I-MED
system	I-MED
,	O
with	O
and	O
without	O
the	O
twisting	B-MED
method	I-MED
.	O
The	O
insertion	B-MED
simulator	B-MED
pushed	O
a	O
sheath	B-MED
introducer	B-MED
or	O
a	O
sheathless	B-MED
system	I-MED
toward	O
a	O
mock	B-MED
artery	B-MED
consisted	O
with	O
a	O
5	B-MED
-	I-MED
mm	I-MED
urethane	I-MED
and	O
a	O
1	B-MED
-	I-MED
mm	I-MED
rubber	I-MED
sheet	I-MED
by	O
an	O
electrical	B-MED
motor	I-MED
with	O
or	O
without	O
twisting	B-MED
motion	B-MED
generated	O
by	O
a	O
crank	B-MED
shaft	I-MED
.	O
Insertion	B-MED
resistance	B-MED
during	O
the	O
penetration	B-MED
was	O
measured	B-MED
by	O
a	O
tension	B-MED
meter	I-MED
.	O
The	O
insertion	B-MED
resistance	B-MED
was	O
less	O
with	O
the	O
5	B-MED
-	I-MED
Fr	I-MED
sheathless	I-MED
system	I-MED
than	O
with	O
the	O
5	B-MED
-	I-MED
Fr	I-MED
sheath	I-MED
introducer	B-MED
.	O
The	O
resistance	B-MED
reduced	B-MED
further	O
with	O
use	O
of	O
twisting	B-MED
for	O
both	O
the	O
sheathed	B-MED
and	O
sheathless	B-MED
catheters	I-MED
.	O
In	O
conclusion	B-MED
,	O
the	O
experiment	O
suggests	O
the	O
benefits	B-MED
of	O
twisting	B-MED
insertion	B-MED
of	O
a	O
sheathless	B-MED
guiding	I-MED
catheter	I-MED
for	O
reduction	B-MED
of	O
puncture	B-MED
site	B-MED
-related	O
complications	B-MED
.	O
Physicochemical	O
characterization	O
of	O
chitosan	B-MED
-	O
hyaluronan	B-MED
-coated	O
solid	O
lipid	B-MED
nanoparticles	I-MED
for	O
the	O
targeted	O
delivery	B-MED
of	O
paclitaxel	B-MED
:	O
a	O
proof	B-MED
-	I-MED
of	I-MED
-	I-MED
concept	I-MED
study	I-MED
in	O
breast	B-MED
cancer	I-MED
cells	I-MED
To	O
investigate	O
the	O
potential	O
of	O
modified	O
solid	B-MED
lipid	I-MED
nanoparticles	I-MED
(	O
SLN	B-MED
)	O
for	O
the	O
delivery	O
of	O
paclitaxel	B-MED
(	O
PAX	B-MED
)	O
.	O
SLN	B-MED
loaded	I-MED
with	I-MED
PAX	I-MED
were	O
prepared	O
via	O
modified	O
high	B-MED
-	I-MED
pressure	I-MED
hot	I-MED
homogenization	I-MED
.	O
Formulation	B-MED
parameters	I-MED
were	O
optimized	O
to	O
obtain	O
a	O
high	B-MED
-	I-MED
quality	I-MED
delivery	I-MED
system	I-MED
.	O
SLN	B-MED
cores	O
were	O
coated	B-MED
,	I-MED
layer	I-MED
-	I-MED
by	I-MED
-	I-MED
layer	I-MED
,	O
with	O
a	O
chitosan	B-MED
and	O
hyaluronan	B-MED
(	O
HA	B-MED
)	O
shell	O
.	O
Selectivity	O
toward	O
HA	B-MED
receptors	B-MED
was	O
tested	O
in	O
a	O
breast	B-MED
cancer	I-MED
cell	I-MED
line	I-MED
,	O
MCF-7	B-MED
.	O
Stable	B-MED
and	I-MED
reproducible	I-MED
nano	B-MED
-	I-MED
sized	I-MED
and	O
negatively	B-MED
charged	I-MED
nanoparticles	I-MED
resulted	O
.	O
Findings	O
reveal	O
that	O
chitosan	B-MED
-	O
HA	B-MED
-coated	O
SLN	B-MED
facilitated	O
the	O
targeting	B-MED
,	O
cellular	B-MED
uptake	I-MED
and	O
the	O
time-/dose	B-MED
-	I-MED
controlled	I-MED
delivery	I-MED
and	I-MED
release	I-MED
of	O
PAX	B-MED
,	O
enhancing	O
intrinsic	B-MED
chemotherapeutic	I-MED
activities	I-MED
.	O
SLN	B-MED
are	O
suitable	O
carrier	B-MED
candidates	I-MED
for	O
nano	B-MED
-	I-MED
oncology	I-MED
given	O
their	O
localized	O
,	O
and	O
potent	O
cytotoxic	B-MED
potential	I-MED
overcoming	B-MED
multidrug	B-MED
-	I-MED
resistant	I-MED
cancer	I-MED
cells	I-MED
.	O
Risk	B-MED
Factors	I-MED
for	O
Infection	B-MED
After	O
Knee	B-MED
Arthroscopy	I-MED
:	O
Analysis	B-MED
of	O
595,083	O
Cases	B-MED
From	O
3	O
United	B-MED
States	I-MED
Databases	B-MED
To	O
identify	B-MED
and	O
quantify	B-MED
patient-	B-MED
and	O
procedure	B-MED
-	I-MED
related	I-MED
risk	I-MED
factors	I-MED
for	O
post	B-MED
-	I-MED
arthroscopic	I-MED
knee	B-MED
infections	I-MED
using	O
a	O
large	O
dataset	B-MED
.	O
An	O
administrative	B-MED
health	I-MED
care	I-MED
database	I-MED
including	O
8	O
years	B-MED
of	O
records	O
from	O
2	O
large	O
commercial	O
insurers	B-MED
and	O
Medicare	B-MED
(	O
a	O
5	O
%	O
random	B-MED
sample	I-MED
)	O
was	O
queried	O
to	O
identify	O
all	O
knee	B-MED
arthroscopies	I-MED
performed	B-MED
on	O
patients	B-MED
aged	B-MED
at	O
least	O
15	O
years	B-MED
using	O
Current	B-MED
Procedural	I-MED
Terminology	I-MED
(	I-MED
CPT	I-MED
)	I-MED
codes	I-MED
.	O
Each	O
CPT	B-MED
code	I-MED
was	O
designated	O
as	O
a	O
high-	B-MED
or	O
low	B-MED
-	I-MED
complexity	I-MED
procedure	I-MED
,	O
with	O
the	O
former	O
typically	O
requiring	O
accessory	O
incisions	B-MED
or	O
increased	O
operative	B-MED
time	I-MED
.	O
Deep	O
infections	B-MED
were	O
identified	O
by	O
a	O
CPT	B-MED
code	I-MED
for	O
incision	B-MED
and	O
drainage	B-MED
within	O
90	O
days	B-MED
of	O
surgery	B-MED
.	O
Superficial	B-MED
infections	I-MED
were	O
identified	O
by	O
International	B-MED
Classification	I-MED
of	I-MED
Diseases	I-MED
,	I-MED
Ninth	I-MED
Revision	I-MED
infection	I-MED
codes	I-MED
without	O
any	O
record	B-MED
of	O
incision	B-MED
and	O
drainage	B-MED
.	O
Patients	B-MED
were	O
compared	O
based	O
on	O
age	B-MED
,	O
sex	B-MED
,	O
body	B-MED
mass	I-MED
index	I-MED
,	O
tobacco	B-MED
use	I-MED
,	O
presence	B-MED
of	O
diabetes	B-MED
,	O
and	O
Charlson	B-MED
Comorbidity	I-MED
Index	I-MED
.	O
A	O
total	O
of	O
526,537	O
patients	B-MED
underwent	O
595,083	O
arthroscopic	B-MED
knee	I-MED
procedures	I-MED
.	O
Deep	O
postoperative	B-MED
infections	I-MED
occurred	O
at	O
a	O
rate	O
of	O
0.22	O
%	O
.	O
Superficial	B-MED
infections	I-MED
occurred	O
at	O
a	O
rate	O
of	O
0.29	O
%	O
.	O
Tobacco	B-MED
use	I-MED
and	O
morbid	B-MED
obesity	I-MED
were	O
the	O
largest	O
risk	B-MED
factors	I-MED
for	O
deep	B-MED
and	O
superficial	B-MED
infections	I-MED
,	O
respectively	O
(	O
P	O
<	O
.001	O
;	O
relative	B-MED
risk	I-MED
of	O
1.90	O
and	O
2.19	O
,	O
respectively	O
)	O
.	O
There	O
were	O
also	O
higher	O
infection	B-MED
rates	I-MED
among	O
patients	B-MED
undergoing	O
relatively	O
high	B-MED
-	I-MED
complexity	I-MED
arthroscopies	I-MED
,	O
men	B-MED
,	O
obese	B-MED
patients	B-MED
,	O
diabetic	B-MED
patients	B-MED
,	O
and	O
younger	B-MED
patients	B-MED
(	O
in	O
order	O
of	O
decreasing	O
relative	B-MED
risk	I-MED
)	O
.	O
Increased	O
Charlson	B-MED
Comorbidity	I-MED
Index	I-MED
was	O
associated	B-MED
with	I-MED
superficial	B-MED
and	O
total	B-MED
infections	I-MED
(	O
P	O
<	O
.001	O
)	O
.	O
Post	B-MED
-	I-MED
arthroscopic	I-MED
knee	B-MED
infections	I-MED
were	O
more	O
frequent	O
among	O
morbidly	B-MED
obese	I-MED
patients	B-MED
,	O
tobacco	B-MED
users	I-MED
,	O
patients	B-MED
undergoing	O
relatively	O
complex	B-MED
procedures	I-MED
,	O
men	B-MED
,	O
obese	B-MED
patients	I-MED
,	O
diabetic	B-MED
patients	I-MED
,	O
relatively	O
young	B-MED
patients	I-MED
,	O
and	O
patients	B-MED
with	O
increased	O
comorbidity	B-MED
burdens	O
in	O
this	O
study	O
population	B-MED
.	O
This	O
knowledge	O
may	O
allow	O
more	O
informed	O
preoperative	B-MED
counseling	I-MED
,	O
aid	B-MED
surgeons	I-MED
in	O
patient	B-MED
selection	I-MED
,	O
and	O
facilitate	O
infection	B-MED
prevention	I-MED
by	O
targeting	O
individuals	B-MED
with	O
higher	O
inherent	B-MED
risk	I-MED
.	O
Level	O
IV	O
,	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
.	O
Fibrinogen	B-MED
:	O
A	O
Marker	B-MED
in	O
Predicting	O
Diabetic	B-MED
Foot	I-MED
Ulcer	I-MED
Severity	B-MED
Aims	O
.	O
To	O
examine	B-MED
whether	O
fibrinogen	B-MED
levels	I-MED
are	O
a	O
valuable	O
biomarker	B-MED
for	O
assessing	B-MED
disease	B-MED
severity	I-MED
and	O
monitoring	B-MED
disease	B-MED
progression	I-MED
in	O
patients	B-MED
with	O
diabetic	B-MED
foot	I-MED
ulcer	I-MED
(	O
DFU	B-MED
)	O
.	O
Methods	O
.	O
A	O
retrospective	B-MED
study	I-MED
was	O
designed	O
to	O
examine	O
the	O
utility	B-MED
of	O
fibrinogen	B-MED
in	O
estimating	O
disease	B-MED
severity	I-MED
in	O
patients	B-MED
with	O
DFU	B-MED
admitted	B-MED
to	O
our	O
hospital	B-MED
between	O
January	B-MED
2015	O
and	O
January	B-MED
2016	O
.	O
In	O
total	O
,	O
152	O
patients	B-MED
with	O
DFU	B-MED
were	O
enrolled	O
in	O
the	O
study	B-MED
group	I-MED
,	O
and	O
52	O
age	O
and	O
gender	B-MED
matched	O
people	B-MED
with	O
diabetes	B-MED
but	O
no	O
DFU	B-MED
were	O
included	O
as	O
the	O
control	B-MED
group	I-MED
.	O
DFU	B-MED
severity	B-MED
was	O
assessed	O
using	O
Wagner	O
criteria	O
.	O
Results	O
.	O
Patients	B-MED
with	O
DFU	B-MED
were	O
divided	O
into	O
2	O
subgroups	B-MED
based	O
on	O
the	O
Wagner	O
criteria	O
.	O
Mean	O
fibrinogen	B-MED
values	I-MED
were	O
significantly	B-MED
higher	I-MED
in	O
patients	B-MED
with	O
DFU	B-MED
grade	B-MED
≧	O
3	O
compared	O
to	O
those	O
with	O
DFU	B-MED
grades	B-MED
1	O
-	O
2	O
(	O
5.23	O
±	O
1.37	O
g	O
/	O
L	O
versus	O
3.61	O
±	O
1.04	O
g	O
/	O
L	O
)	O
.	O
Using	O
ROC	B-MED
statistic	I-MED
,	O
a	O
cut	B-MED
-	I-MED
off	I-MED
value	I-MED
of	O
5.13	O
g	O
/	O
L	O
indicated	O
the	O
possible	O
amputation	B-MED
with	O
a	O
sensitivity	B-MED
of	O
81.8	O
%	O
and	O
a	O
specificity	B-MED
of	O
78.9	O
%	O
(	O
positive	B-MED
predictive	I-MED
value	I-MED
[	O
PPV	B-MED
]	O
78.6	O
%	O
,	O
negative	B-MED
predictive	I-MED
value	I-MED
[	O
89.0	O
%	O
]	O
)	O
.	O
Fibrinogen	B-MED
values	I-MED
were	O
found	O
to	O
be	O
correlated	O
with	O
CRP	B-MED
levels	I-MED
,	O
neutrophil	B-MED
,	O
and	O
WBC	B-MED
count	I-MED
.	O
Conclusions	O
.	O
Fibrinogen	B-MED
levels	I-MED
might	O
be	O
a	O
valuable	O
tool	O
for	O
assessing	B-MED
the	O
disease	B-MED
severity	I-MED
and	O
monitoring	B-MED
the	O
disease	B-MED
progression	I-MED
in	O
patients	B-MED
with	O
DFU	B-MED
.	O
Evaluation	B-MED
and	O
Treatment	B-MED
of	O
Anemia	B-MED
in	O
Premature	B-MED
Infants	I-MED
Anemia	B-MED
in	O
preterm	B-MED
infants	I-MED
is	O
the	O
pathophysiological	B-MED
process	B-MED
with	O
greater	O
and	O
more	O
rapid	O
decline	B-MED
in	O
hemoglobin	B-MED
compared	B-MED
to	O
the	O
physiological	B-MED
anemia	B-MED
in	O
infants	B-MED
.	O
There	O
is	O
a	O
need	O
for	O
transfusions	B-MED
and	O
administration	B-MED
of	O
human	B-MED
recombinant	I-MED
erythropoietin	I-MED
.	O
To	O
determine	B-MED
the	O
frequency	B-MED
of	O
anemia	B-MED
in	O
premature	B-MED
infants	I-MED
at	O
the	O
Pediatric	B-MED
Clinic	I-MED
,	I-MED
University	I-MED
Clinical	I-MED
Center	I-MED
Sarajevo	I-MED
,	O
as	O
well	O
as	O
parameter	B-MED
values	I-MED
in	O
the	O
blood	B-MED
count	I-MED
of	O
premature	B-MED
infants	I-MED
and	O
to	O
explore	O
a	O
relationship	B-MED
between	O
blood	B-MED
transfusions	I-MED
with	O
the	O
advent	O
of	O
intraventricular	B-MED
hemorrhage	I-MED
(	O
determine	B-MED
treatment	B-MED
outcome	O
in	O
preterm	B-MED
infants	I-MED
)	O
.	O
Research	B-MED
is	O
retrospective	B-MED
study	I-MED
and	O
it	O
included	O
the	O
period	B-MED
of	O
six	O
months	B-MED
in	O
year	B-MED
2014	O
.	O
Research	B-MED
included	O
100	O
patients	B-MED
,	O
gestational	B-MED
age	I-MED
<	O
37	O
weeks	B-MED
(	O
premature	B-MED
infants	I-MED
)	O
.	O
Data	B-MED
were	O
collected	B-MED
by	O
examining	B-MED
the	O
medical	B-MED
records	I-MED
of	O
patients	B-MED
at	O
the	O
Pediatric	B-MED
Clinic	I-MED
,	I-MED
UCCS	I-MED
.	O
The	O
first	B-MED
group	B-MED
of	O
patients	B-MED
were	O
premature	B-MED
infants	I-MED
of	O
gestational	B-MED
age	I-MED
≤	O
32	O
weeks	B-MED
(	O
62/100	O
)	O
and	O
the	O
second	B-MED
group	B-MED
were	O
premature	B-MED
infants	I-MED
of	O
gestational	B-MED
age	I-MED
33	O
-	O
37	O
weeks	B-MED
(	O
38/100	O
)	O
.	O
Among	O
the	O
patients	B-MED
,	O
5	O
%	O
were	O
boys	B-MED
and	O
46	O
%	O
girls	B-MED
.	O
There	O
was	O
significant	B-MED
difference	I-MED
in	O
birth	B-MED
weight	I-MED
and	O
APGAR	B-MED
score	I-MED
among	O
the	O
groups	B-MED
.	O
In	O
the	O
first	B-MED
group	B-MED
,	O
there	O
were	O
27.42	O
%	O
of	O
deaths	B-MED
,	O
while	O
in	O
the	O
second	B-MED
group	B-MED
,	O
there	O
were	O
only	O
10.53	O
%	O
of	O
deaths	B-MED
.	O
There	O
was	O
a	O
significant	B-MED
difference	I-MED
in	O
the	O
length	O
of	O
treatment	B-MED
.	O
There	O
was	O
a	O
statistically	B-MED
significant	I-MED
difference	B-MED
in	O
the	O
need	O
for	O
transfusion	B-MED
among	O
the	O
groups	B-MED
.	O
18	O
patients	B-MED
in	O
the	O
first	B-MED
group	B-MED
required	O
a	O
transfusion	B-MED
,	O
while	O
in	O
the	O
second	B-MED
group	B-MED
only	O
3	O
patients	B-MED
.	O
Preterm	B-MED
infants	I-MED
of	O
gestational	B-MED
age	I-MED
≤	O
32	O
weeks	B-MED
are	O
likely	O
candidates	B-MED
for	O
blood	B-MED
transfusion	I-MED
during	O
treatment	B-MED
.	O
Preterm	B-MED
infants	I-MED
of	O
gestational	B-MED
age	I-MED
≤	O
32	O
weeks	B-MED
have	O
the	O
risk	B-MED
of	O
intracranial	B-MED
bleeding	I-MED
associated	B-MED
with	I-MED
the	O
application	B-MED
of	O
blood	B-MED
transfusion	I-MED
in	O
the	O
first	O
week	B-MED
of	O
life	B-MED
.	O
A	O
Window	O
on	O
the	O
Study	B-MED
of	I-MED
Aversive	I-MED
Instrumental	B-MED
Learning	I-MED
:	O
Strains	B-MED
,	O
Performance	B-MED
,	O
Neuroendocrine	B-MED
,	O
and	O
Immunologic	B-MED
Systems	I-MED
The	O
avoidance	B-MED
response	B-MED
is	O
present	O
in	O
pathological	B-MED
anxiety	B-MED
and	O
interferes	O
with	O
normal	B-MED
daily	I-MED
functions	I-MED
.	O
The	O
aim	O
of	O
this	O
article	O
is	O
to	O
shed	O
light	O
on	O
performance	B-MED
markers	O
of	O
active	B-MED
avoidance	I-MED
(	O
AA	B-MED
)	O
using	O
two	O
different	O
rat	B-MED
strains	I-MED
,	O
Sprague	B-MED
-	I-MED
Dawley	I-MED
(	O
SD	B-MED
)	O
and	O
Wistar	B-MED
.	O
Specifically	O
,	O
good	O
and	O
poor	O
performers	B-MED
were	O
evaluated	B-MED
regarding	O
anxiety	B-MED
traits	B-MED
exhibited	O
in	O
the	O
elevated	B-MED
plus	I-MED
maze	I-MED
(	O
EPM	B-MED
)	O
and	O
corticosterone	B-MED
levels	I-MED
and	O
motor	B-MED
activity	I-MED
in	O
the	O
open	B-MED
field	I-MED
test	I-MED
.	O
In	O
addition	O
,	O
the	O
plasma	B-MED
levels	I-MED
of	O
Interleukin-6	B-MED
(	O
IL-6	B-MED
)	O
,	O
Interleukin-1Beta	B-MED
(	O
IL-1beta	B-MED
)	O
,	O
Nerve	B-MED
Growth	I-MED
Factor	I-MED
Beta	I-MED
(	O
NGF	B-MED
-	I-MED
beta	I-MED
)	O
,	O
Tumor	B-MED
Necrosis	I-MED
Factor	I-MED
-	I-MED
Alpha	I-MED
(	O
TNF	B-MED
-	I-MED
alpha	I-MED
)	O
and	O
cytokine	B-MED
-	I-MED
induced	I-MED
neutrophil	I-MED
chemoattractant	I-MED
1	I-MED
(	O
CINC-1	B-MED
)	O
were	O
compared	O
in	O
the	O
good	O
and	O
poor	O
performers	B-MED
to	O
better	O
understand	O
the	O
role	O
of	O
the	O
immunologic	B-MED
system	I-MED
in	O
aversive	B-MED
learning	I-MED
.	O
Behavioral	B-MED
criteria	I-MED
were	O
employed	O
to	O
identify	O
subpopulations	B-MED
of	O
SD	B-MED
and	O
Wistar	B-MED
rats	I-MED
based	O
on	O
their	O
behavioral	B-MED
scores	I-MED
during	O
a	O
two	O
-	O
way	O
AA	B-MED
test	B-MED
.	O
The	O
animals	B-MED
were	O
tested	B-MED
for	O
anxiety	B-MED
-like	O
behavior	B-MED
in	O
the	O
EPM	B-MED
and	O
motor	B-MED
activity	I-MED
in	O
the	O
open	B-MED
-	I-MED
field	I-MED
test	I-MED
.	O
Plasma	B-MED
corticosterone	I-MED
levels	I-MED
were	O
measured	B-MED
at	O
the	O
end	O
of	O
the	O
avoidance	B-MED
test	B-MED
.	O
Cytokine	B-MED
levels	I-MED
of	O
IL-6	B-MED
,	O
IL-1beta	B-MED
,	O
NGF	B-MED
-	I-MED
beta	I-MED
,	O
TNF	B-MED
-	I-MED
alpha	I-MED
,	O
and	O
CINC-1	B-MED
were	O
measured	B-MED
in	O
the	O
plasma	B-MED
of	O
the	O
Wistar	B-MED
rats	I-MED
.	O
Sixty	O
-	O
six	O
percent	O
of	O
the	O
Wistar	B-MED
rats	I-MED
and	O
35	O
%	O
of	O
the	O
SD	B-MED
rats	I-MED
exhibited	O
a	O
poor	O
performance	B-MED
.	O
This	O
feature	O
was	O
associated	B-MED
with	I-MED
a	O
decrease	O
in	O
anxiety	B-MED
-like	O
behavior	B-MED
in	O
the	O
EPM	B-MED
.	O
The	O
poor	O
and	O
good	O
performers	B-MED
exhibited	O
lower	O
levels	B-MED
of	I-MED
corticosterone	I-MED
compared	O
with	O
the	O
control	B-MED
animals	I-MED
,	O
which	O
suggests	O
that	O
training	O
alters	O
corticosterone	B-MED
levels	I-MED
,	O
thereby	O
leading	O
to	O
hypocortisolism	B-MED
,	O
independent	O
of	O
the	O
performance	B-MED
.	O
The	O
CINC-1	B-MED
levels	B-MED
were	O
increased	O
in	O
the	O
poor	O
performers	B-MED
,	O
which	O
reinforces	O
the	O
role	O
of	O
immunologic	B-MED
system	I-MED
activation	B-MED
in	O
learning	B-MED
deficits	I-MED
.	O
Our	O
study	O
provides	O
a	O
better	O
understanding	O
of	O
the	O
complex	B-MED
interactions	B-MED
that	O
underlie	O
neuroimmune	B-MED
consequences	B-MED
and	O
their	O
implications	O
for	O
performance	B-MED
.	O
Assessment	B-MED
and	O
classification	B-MED
of	O
protocol	B-MED
deviations	I-MED
Deviations	B-MED
from	O
the	O
approved	O
trial	B-MED
protocol	I-MED
are	O
common	O
during	O
clinical	B-MED
trials	I-MED
.	O
They	O
have	O
been	O
conventionally	O
classified	B-MED
as	O
deviations	B-MED
or	O
violations	B-MED
,	O
depending	O
on	O
their	O
impact	B-MED
on	O
the	O
trial	B-MED
.	O
A	O
new	O
method	O
has	O
been	O
proposed	O
by	O
which	O
deviations	B-MED
are	O
classified	B-MED
in	O
five	O
grades	B-MED
from	I-MED
1	I-MED
to	I-MED
5	I-MED
.	O
A	O
deviation	B-MED
of	O
Grade	B-MED
1	I-MED
has	O
no	B-MED
impact	B-MED
on	O
the	O
subjects	B-MED
'	I-MED
well	B-MED
-	I-MED
being	I-MED
or	O
on	O
the	O
quality	B-MED
of	I-MED
data	I-MED
.	O
At	O
the	O
maximum	O
,	O
a	O
deviation	B-MED
Grade	B-MED
5	I-MED
leads	O
to	O
the	O
death	B-MED
of	O
the	O
subject	B-MED
.	O
This	O
method	O
of	O
classification	B-MED
was	O
applied	O
to	O
deviations	B-MED
noted	O
in	O
the	O
center	O
over	O
the	O
last	O
3	O
years	O
.	O
It	O
was	O
observed	O
that	O
most	O
deviations	B-MED
were	O
of	O
Grades	B-MED
1	I-MED
and	I-MED
2	I-MED
,	O
with	O
fewer	O
falling	O
in	O
Grades	B-MED
3	I-MED
and	I-MED
4	I-MED
.	O
There	O
were	O
no	O
deviations	B-MED
that	O
led	O
to	O
the	O
death	B-MED
of	I-MED
the	I-MED
subject	I-MED
(	O
Grade	O
5	O
)	O
.	O
This	O
method	O
of	O
classification	B-MED
would	O
help	O
trial	B-MED
managers	B-MED
decide	O
on	O
the	O
action	O
to	O
be	O
taken	O
on	O
the	O
occurrence	B-MED
of	O
deviations	B-MED
,	O
which	O
would	O
be	O
based	O
on	O
their	O
impact	B-MED
.	O
A	O
Wnt	B-MED
Pathway	I-MED
Activator	B-MED
Induces	B-MED
Apoptosis	I-MED
and	O
Cell	B-MED
Death	I-MED
in	O
Mouse	B-MED
Monocytic	I-MED
Leukemia	I-MED
Cells	B-MED
A	O
Wnt	B-MED
agonist	I-MED
,	I-MED
2	B-MED
-	I-MED
amino-4-[3,4-(methylenedioxy)benzylamino]-6-(3	I-MED
-	I-MED
methoxyphenyl	I-MED
)	I-MED
pyrimidine	I-MED
,	O
is	O
a	O
cell	B-MED
-	I-MED
permeable	I-MED
pyrimidine	B-MED
compound	I-MED
that	O
has	O
been	O
shown	O
to	O
mimic	O
the	O
effect	O
of	O
Wnt	B-MED
.	O
In	O
this	O
study	O
,	O
leukemic	B-MED
mouse	I-MED
cell	I-MED
lines	I-MED
,	O
RAW	B-MED
264.7	I-MED
and	O
J774.1	B-MED
,	O
were	O
incubated	O
with	O
the	O
Wnt	B-MED
agonist	I-MED
.	O
The	O
Wnt	B-MED
agonist	I-MED
showed	O
cell	B-MED
death	I-MED
in	O
the	O
concentration	O
of	O
1	O
-	O
10	O
μM.	O
The	O
Wnt	B-MED
agonist	I-MED
did	O
not	O
show	O
inhibition	B-MED
of	O
GSK-3β	B-MED
activity	B-MED
but	O
induced	B-MED
β	B-MED
-	I-MED
catenin	I-MED
accumulation	I-MED
in	O
the	O
nucleus	B-MED
.	O
The	O
Wnt	B-MED
agonist	I-MED
showed	O
caspase	B-MED
-	I-MED
independent	I-MED
cell	I-MED
death	I-MED
,	O
but	O
no	O
further	O
involvement	O
in	O
cell	B-MED
death	I-MED
ER	I-MED
stress	I-MED
signaling	I-MED
.	O
Here	O
we	O
discuss	O
the	O
possible	O
mechanism	O
of	O
Wnt	B-MED
agonist	I-MED
-	O
induced	B-MED
apoptotic	I-MED
cell	I-MED
death	I-MED
in	O
RAW	B-MED
264.7	I-MED
cells	I-MED
.	O
Tyrphostin	B-MED
AG	I-MED
-	I-MED
related	I-MED
compounds	I-MED
attenuate	O
H2O2	B-MED
-	O
induced	B-MED
TRPM2	B-MED
-	O
dependent	B-MED
and	O
-	O
independent	B-MED
cellular	B-MED
responses	B-MED
TRPM2	B-MED
is	O
a	O
Ca(2+)-permeable	B-MED
channel	I-MED
that	O
is	O
activated	B-MED
by	O
H2O2	B-MED
.	O
TRPM2	B-MED
-mediated	O
Ca(2	B-MED
+	I-MED
)	I-MED
signaling	I-MED
has	O
been	O
implicated	O
in	O
the	O
aggravation	B-MED
of	O
inflammatory	B-MED
diseases	I-MED
.	O
Therefore	O
,	O
the	O
development	B-MED
of	O
TRPM2	B-MED
inhibitors	B-MED
to	O
prevent	O
the	O
aggravation	B-MED
of	O
these	O
diseases	B-MED
is	O
expected	O
.	O
We	O
recently	O
reported	O
that	O
some	O
Tyrphostin	B-MED
AG	I-MED
-	I-MED
related	I-MED
compounds	I-MED
inhibited	B-MED
the	O
H2O2	B-MED
-	O
induced	B-MED
activation	B-MED
of	O
TRPM2	B-MED
by	O
scavenging	B-MED
the	I-MED
intracellular	I-MED
hydroxyl	I-MED
radical	I-MED
.	O
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effects	B-MED
of	I-MED
AG	B-MED
-	I-MED
related	I-MED
compounds	I-MED
on	O
H2O2	B-MED
-	O
induced	B-MED
cellular	B-MED
responses	B-MED
in	O
human	B-MED
monocytic	B-MED
U937	B-MED
cells	I-MED
,	O
which	O
functionally	B-MED
express	B-MED
TRPM2	B-MED
.	O
The	O
effects	B-MED
of	I-MED
AG	B-MED
-	I-MED
related	I-MED
compounds	I-MED
on	O
H2O2	B-MED
-	O
induced	B-MED
changes	B-MED
in	O
intracellular	B-MED
Ca(2	B-MED
+	I-MED
)	I-MED
concentrations	B-MED
,	O
extracellular	B-MED
signal	I-MED
-	I-MED
regulated	I-MED
kinase	I-MED
(	O
ERK	B-MED
)	O
activation	B-MED
,	O
and	O
CXCL8	B-MED
secretion	B-MED
were	O
assessed	O
using	O
U937	B-MED
cells	I-MED
.	O
Ca(2	B-MED
+	I-MED
)	I-MED
influxes	I-MED
via	O
TRPM2	B-MED
in	O
response	O
to	O
H2O2	B-MED
were	O
blocked	B-MED
by	O
AG	B-MED
-	I-MED
related	I-MED
compounds	I-MED
.	O
AG	B-MED
-	I-MED
related	I-MED
compounds	I-MED
also	O
inhibited	B-MED
the	O
H2O2	B-MED
-	O
induced	B-MED
activation	B-MED
of	O
ERK	B-MED
,	O
and	O
subsequent	O
secretion	B-MED
of	O
CXCL8	B-MED
mediated	O
by	O
TRPM2	B-MED
-	O
dependent	B-MED
and	O
-	O
independent	B-MED
mechanisms	B-MED
.	O
Our	O
results	O
show	O
that	O
AG	B-MED
-	I-MED
related	I-MED
compounds	I-MED
inhibit	B-MED
H2O2	B-MED
-	O
induced	B-MED
CXCL8	B-MED
secretion	B-MED
following	O
ERK	B-MED
activation	B-MED
,	O
which	O
is	O
mediated	O
by	O
TRPM2	B-MED
-	O
dependent	B-MED
and	O
-	O
independent	B-MED
mechanisms	B-MED
in	O
U937	B-MED
cells	I-MED
.	O
We	O
previously	O
reported	O
that	O
AG	B-MED
-	I-MED
related	I-MED
compounds	I-MED
blocked	B-MED
H2O2	B-MED
-	O
induced	B-MED
TRPM2	B-MED
activation	B-MED
by	O
scavenging	B-MED
the	I-MED
hydroxyl	I-MED
radical	I-MED
.	O
The	O
inhibitory	B-MED
effects	B-MED
of	O
AG	B-MED
-	I-MED
related	I-MED
compounds	I-MED
on	O
TRPM2	B-MED
-	O
independent	B-MED
responses	B-MED
may	O
be	O
due	O
to	O
scavenging	B-MED
of	I-MED
the	I-MED
hydroxyl	I-MED
radical	I-MED
.	O
Effect	O
of	O
magnesium	B-MED
supplementation	I-MED
on	O
depression	B-MED
status	B-MED
in	O
depressed	B-MED
patients	B-MED
with	O
magnesium	B-MED
deficiency	I-MED
:	O
A	O
randomized	B-MED
,	O
double	B-MED
-	I-MED
blind	I-MED
,	O
placebo	B-MED
-	I-MED
controlled	I-MED
trial	I-MED
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	B-MED
of	O
magnesium	B-MED
supplementation	I-MED
on	O
the	O
depression	B-MED
status	B-MED
of	O
depressed	B-MED
patients	B-MED
suffering	B-MED
from	O
magnesium	B-MED
deficiency	I-MED
.	O
Sixty	B-MED
depressed	I-MED
people	I-MED
suffering	B-MED
from	O
hypomagnesemia	B-MED
participated	O
in	O
this	B-MED
trial	I-MED
.	O
The	O
individuals	B-MED
were	O
randomly	B-MED
categorized	I-MED
into	O
two	O
groups	B-MED
of	O
30	O
members	O
;	O
one	O
receiving	O
two	O
250	O
-	O
mg	O
tablets	B-MED
of	I-MED
magnesium	I-MED
oxide	I-MED
(	O
MG	B-MED
)	O
daily	O
and	O
the	O
other	O
receiving	O
placebo	B-MED
(	O
PG	B-MED
)	O
for	O
8	O
wk	O
.	O
The	O
Beck	B-MED
Depression	I-MED
Inventory	I-MED
-	I-MED
II	I-MED
was	O
conducted	O
and	O
the	O
concentration	O
of	O
serum	B-MED
magnesium	I-MED
was	I-MED
measured	I-MED
.	O
At	O
the	O
end	O
of	O
intervention	O
,	O
88.5	O
%	O
of	O
the	O
MG	B-MED
and	O
48.1	O
%	O
of	O
the	O
PG	B-MED
(	O
P	O
=	O
0.002	O
)	O
had	O
a	O
normal	B-MED
level	I-MED
of	I-MED
magnesium	I-MED
.	O
The	O
mean	O
changes	B-MED
of	I-MED
serum	I-MED
magnesium	I-MED
were	O
significantly	O
different	O
across	O
the	O
two	O
groups	B-MED
.	O
After	O
the	O
intervention	O
,	O
the	O
mean	B-MED
Beck	I-MED
score	I-MED
significantly	B-MED
declined	I-MED
.	O
However	O
,	O
in	O
the	O
MG	B-MED
,	O
this	O
reduction	O
was	O
more	B-MED
significant	I-MED
than	O
in	O
the	O
PG	B-MED
(	O
P	O
=	O
0.02	O
)	O
,	O
so	O
that	O
the	O
mean	O
changes	O
in	O
this	O
group	B-MED
experienced	O
15.65	O
±	O
8.9	O
reduction	O
,	O
but	O
in	O
the	O
PG	B-MED
,	O
it	O
declined	O
by	O
10.40	O
±	O
7.9	O
.	O
Daily	B-MED
consumption	I-MED
of	O
500	O
mg	O
magnesium	B-MED
oxide	I-MED
tablets	I-MED
for	O
≥8	O
wk	O
by	O
depressed	B-MED
patients	B-MED
suffering	B-MED
from	O
magnesium	B-MED
deficiency	I-MED
leads	O
to	O
improvements	O
in	O
depression	B-MED
status	B-MED
and	O
magnesium	B-MED
levels	I-MED
.	O
Therefore	O
,	O
assessment	B-MED
of	I-MED
the	I-MED
magnesium	I-MED
serum	I-MED
and	O
resolving	O
this	O
deficiency	B-MED
positively	O
influence	O
the	O
treatment	B-MED
of	O
depressed	B-MED
patients	B-MED
.	O
Resistance	B-MED
Exercise	B-MED
in	O
Pregnancy	B-MED
and	O
Outcome	B-MED
As	O
the	O
health	B-MED
benefits	I-MED
of	O
exercise	B-MED
are	O
increasingly	O
recognized	O
,	O
the	O
traditional	B-MED
advice	I-MED
to	O
rest	B-MED
during	O
pregnancy	B-MED
has	O
changed	B-MED
toward	O
a	O
more	O
healthy	B-MED
and	O
active	B-MED
pregnancy	B-MED
,	O
therefore	O
different	O
forms	O
of	O
exercise	B-MED
have	O
been	O
integrated	O
into	O
the	O
life	B-MED
of	O
the	O
pregnant	B-MED
woman	I-MED
.	O
Although	O
the	O
benefits	B-MED
of	O
using	O
a	O
combination	B-MED
of	O
resistance	B-MED
and	O
aerobic	B-MED
exercises	I-MED
are	O
not	O
yet	O
determined	O
,	O
studies	B-MED
about	O
resistance	B-MED
and	O
strengthen	O
training	B-MED
programs	I-MED
are	O
few	O
although	O
no	B-MED
adverse	I-MED
outcomes	B-MED
were	O
reported	O
.	O
Biochemical	B-MED
characteristics	B-MED
of	O
AtFAR2	B-MED
,	O
a	O
fatty	B-MED
acid	I-MED
reductase	I-MED
from	O
Arabidopsis	B-MED
thaliana	I-MED
that	O
reduces	O
fatty	B-MED
acyl	I-MED
-	I-MED
CoA	I-MED
and	O
-	O
ACP	B-MED
substrates	I-MED
into	O
fatty	B-MED
alcohols	I-MED
Fatty	B-MED
alcohols	I-MED
and	O
derivatives	B-MED
are	O
important	B-MED
for	O
proper	O
deposition	B-MED
of	O
a	O
functional	B-MED
pollen	B-MED
wall	I-MED
.	O
Mutations	B-MED
in	O
specific	O
genes	B-MED
encoding	O
fatty	B-MED
acid	I-MED
reductases	I-MED
(	O
FAR	B-MED
)	O
responsible	O
for	O
fatty	B-MED
alcohol	I-MED
production	B-MED
cause	O
abnormal	B-MED
development	B-MED
of	O
pollen	B-MED
.	O
A	O
disrupted	B-MED
AtFAR2	B-MED
(	I-MED
MS2	I-MED
)	I-MED
gene	I-MED
in	O
Arabidopsis	B-MED
thaliana	I-MED
results	B-MED
in	O
pollen	B-MED
developing	B-MED
an	O
abnormal	B-MED
exine	B-MED
layer	I-MED
and	O
a	O
reduced	B-MED
fertility	I-MED
phenotype	B-MED
.	O
AtFAR2	B-MED
has	O
been	O
shown	O
to	O
be	O
targeted	B-MED
to	O
chloroplasts	B-MED
and	O
in	O
a	O
purified	B-MED
form	I-MED
to	O
be	O
specific	B-MED
for	O
acyl	B-MED
-	I-MED
ACP	I-MED
substrates	I-MED
.	O
Here	O
,	O
we	O
present	O
data	B-MED
on	O
the	O
in	B-MED
vitro	I-MED
and	O
in	O
planta	B-MED
characterizations	B-MED
of	O
AtFAR2	B-MED
from	O
A.	B-MED
thaliana	I-MED
and	O
show	O
that	O
this	O
enzyme	B-MED
has	O
the	O
ability	O
to	O
use	O
both	O
,	O
C16:0	B-MED
-	I-MED
ACP	I-MED
and	O
C16:0	B-MED
-	I-MED
CoA	I-MED
,	O
as	O
substrates	B-MED
to	O
produce	O
C16:0	B-MED
-	I-MED
alcohol	I-MED
.	O
Our	O
results	O
further	O
show	O
that	O
AtFAR2	B-MED
is	O
highly	O
similar	O
in	O
properties	B-MED
and	O
substrate	B-MED
specificity	B-MED
to	O
AtFAR6	B-MED
for	O
which	O
in	B-MED
vitro	I-MED
data	B-MED
has	O
been	O
published	O
,	O
and	O
which	O
is	O
also	O
a	O
chloroplast	B-MED
localized	B-MED
enzyme	B-MED
.	O
This	O
suggests	O
that	O
although	O
AtFAR2	B-MED
is	O
the	O
major	O
enzyme	B-MED
responsible	O
for	O
exine	B-MED
layer	I-MED
functionality	B-MED
,	O
AtFAR6	B-MED
might	O
provide	O
functional	B-MED
redundancy	B-MED
to	O
AtFAR2	B-MED
.	O
The	O
Use	O
of	O
a	O
Software	B-MED
-	O
Assisted	B-MED
Method	B-MED
to	O
Estimate	B-MED
Fetal	B-MED
Weight	I-MED
at	O
and	O
Near	O
Term	B-MED
Using	O
Magnetic	B-MED
Resonance	I-MED
Imaging	I-MED
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
apply	O
a	O
semi	B-MED
-	I-MED
automated	I-MED
calculation	B-MED
method	B-MED
of	O
fetal	B-MED
body	B-MED
volume	I-MED
and	O
,	O
thus	O
,	O
of	O
magnetic	B-MED
resonance	I-MED
-	I-MED
estimated	I-MED
fetal	I-MED
weight	I-MED
(	O
MR	B-MED
-	I-MED
EFW	I-MED
)	O
prior	O
to	O
planned	B-MED
delivery	B-MED
and	O
to	O
evaluate	B-MED
whether	O
the	O
technique	B-MED
of	O
measurement	B-MED
could	O
be	O
simplified	B-MED
while	O
remaining	B-MED
accurate	B-MED
.	O
MR	B-MED
-	I-MED
EFW	I-MED
was	O
calculated	B-MED
using	O
a	O
semi	B-MED
-	I-MED
automated	I-MED
method	B-MED
at	O
38.6	O
weeks	B-MED
of	O
gestation	B-MED
in	O
36	O
patients	B-MED
and	O
compared	O
to	O
the	O
picture	B-MED
archiving	I-MED
and	I-MED
communication	I-MED
system	I-MED
(	O
PACS	B-MED
)	O
.	O
Per	O
patient	B-MED
,	O
8	O
sequences	B-MED
were	O
acquired	B-MED
with	O
a	O
slice	B-MED
thickness	I-MED
of	O
4	O
-	O
8	O
mm	O
and	O
an	O
intersection	B-MED
gap	I-MED
of	O
0	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
or	O
20	O
mm	O
.	O
The	O
median	B-MED
absolute	B-MED
relative	B-MED
errors	I-MED
for	O
MR	B-MED
-	I-MED
EFW	I-MED
and	O
the	O
time	B-MED
of	O
planimetric	B-MED
measurements	I-MED
were	O
calculated	B-MED
for	O
all	O
8	O
sequences	B-MED
and	O
for	O
each	O
method	B-MED
(	O
assisted	B-MED
vs.	O
PACS	B-MED
)	O
,	O
and	O
the	O
difference	O
between	O
the	O
methods	B-MED
was	O
calculated	B-MED
.	O
The	O
median	B-MED
delivery	O
weight	O
was	O
3,280	O
g.	O
The	O
overall	O
median	B-MED
relative	B-MED
error	I-MED
for	O
all	O
288	O
MR	B-MED
-	I-MED
EFW	I-MED
calculations	B-MED
was	O
2.4	O
%	O
using	O
the	O
semi	B-MED
-	I-MED
automated	I-MED
method	B-MED
and	O
2.2	O
%	O
for	O
the	O
PACS	B-MED
method	B-MED
.	O
Measurements	B-MED
did	O
not	O
differ	O
between	O
the	O
8	O
sequences	B-MED
using	O
the	O
assisted	B-MED
method	B-MED
(	O
p	O
=	O
0.313	O
)	O
or	O
the	O
PACS	B-MED
(	O
p	O
=	O
0.118	O
)	O
,	O
while	O
the	O
time	B-MED
of	O
planimetric	B-MED
measurement	I-MED
decreased	B-MED
significantly	O
with	O
a	O
larger	O
gap	B-MED
(	O
p	O
<	O
0.001	O
)	O
and	O
in	O
the	O
assisted	B-MED
method	B-MED
compared	O
to	O
the	O
PACS	B-MED
method	B-MED
(	O
p	O
<	O
0.01	O
)	O
.	O
Our	O
simplified	B-MED
MR	B-MED
-	I-MED
EFW	I-MED
measurement	B-MED
showed	O
a	O
dramatic	B-MED
decrease	I-MED
in	O
time	B-MED
of	O
planimetric	B-MED
measurement	I-MED
without	O
a	O
decrease	B-MED
in	O
the	O
accuracy	B-MED
of	O
weight	B-MED
estimates	B-MED
.	O
Multisensory	B-MED
Integration	I-MED
in	O
the	O
Virtual	B-MED
Hand	I-MED
Illusion	I-MED
with	O
Active	B-MED
Movement	I-MED
Improving	O
the	O
sense	B-MED
of	I-MED
sense	B-MED
of	I-MED
immersion	I-MED
is	O
one	O
of	O
the	O
core	O
issues	O
in	O
virtual	B-MED
reality	I-MED
.	O
Perceptual	B-MED
illusions	I-MED
of	O
ownership	O
can	O
be	O
perceived	B-MED
over	O
a	O
virtual	B-MED
body	I-MED
in	O
a	O
multisensory	B-MED
virtual	B-MED
reality	I-MED
environment	O
.	O
Rubber	B-MED
Hand	I-MED
and	O
Virtual	B-MED
Hand	I-MED
Illusions	I-MED
showed	O
that	O
body	O
ownership	O
can	O
be	O
manipulated	O
by	O
applying	O
suitable	O
visual	B-MED
and	O
tactile	B-MED
stimulation	I-MED
.	O
In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
effects	O
of	O
multisensory	B-MED
integration	I-MED
in	O
the	O
Virtual	B-MED
Hand	I-MED
Illusion	I-MED
with	O
active	B-MED
movement	I-MED
.	O
A	O
virtual	B-MED
xylophone	I-MED
playing	I-MED
system	O
which	O
can	O
interactively	O
provide	O
synchronous	B-MED
visual	B-MED
,	O
tactile	B-MED
,	O
and	O
auditory	B-MED
stimulation	I-MED
was	O
constructed	O
.	O
We	O
conducted	O
two	O
experiments	O
regarding	O
different	O
movement	O
conditions	O
and	O
different	O
sensory	B-MED
stimulations	I-MED
.	O
Our	O
results	O
demonstrate	O
that	O
multisensory	B-MED
integration	I-MED
with	O
free	O
active	B-MED
movement	I-MED
can	O
improve	O
the	O
sense	B-MED
of	I-MED
immersion	B-MED
in	I-MED
virtual	I-MED
reality	I-MED
.	O
Genotyping	B-MED
of	O
German	B-MED
and	O
Austrian	B-MED
Taylorella	B-MED
equigenitalis	I-MED
isolates	B-MED
using	O
repetitive	B-MED
extragenic	I-MED
palindromic	I-MED
(	I-MED
REP	I-MED
)	I-MED
PCR	I-MED
and	O
pulsed	B-MED
-	I-MED
field	I-MED
gel	I-MED
electrophoresis	I-MED
(	O
PFGE	B-MED
)	O
A	O
total	B-MED
of	O
124	O
Taylorella	B-MED
(	I-MED
T.	I-MED
)	I-MED
equigenitalis	I-MED
and	O
five	O
T.	B-MED
asinigenitalis	I-MED
field	B-MED
isolates	B-MED
collected	B-MED
between	O
2002	O
and	O
2014	O
were	O
available	B-MED
for	O
genotyping	B-MED
using	O
REP-	B-MED
(	I-MED
repetitive	I-MED
extragenic	I-MED
palindromic	I-MED
)	I-MED
PCR	I-MED
and	O
PFGE	B-MED
(	O
pulsed	B-MED
-	I-MED
field	I-MED
gel	I-MED
electrophoresis	I-MED
)	O
.	O
The	O
study	B-MED
comprised	O
79	O
T.	B-MED
equigenitalis	I-MED
field	B-MED
isolates	B-MED
originating	O
from	O
ten	O
defined	O
breeds	B-MED
of	O
German	B-MED
horses	I-MED
and	O
revealed	B-MED
a	O
spectrum	B-MED
of	O
five	O
REP	B-MED
(	O
rep	B-MED
-	I-MED
E1	I-MED
-	I-MED
E4	I-MED
,	O
rep	B-MED
-	I-MED
E3a	I-MED
)	O
and	O
15	O
PFGE	B-MED
(	O
TE	B-MED
-	I-MED
A1	I-MED
-	I-MED
A9	I-MED
,	O
TE	B-MED
-	I-MED
B1	I-MED
-	I-MED
B3	I-MED
,	O
TE	B-MED
-	I-MED
C	I-MED
,	O
TE	B-MED
-	I-MED
E1	I-MED
,	O
and	O
TE	B-MED
-	I-MED
E2	I-MED
)	O
genotypes	B-MED
.	O
T.	B-MED
equigenitalis	I-MED
field	B-MED
isolates	B-MED
(	O
n=40	O
)	O
obtained	B-MED
from	O
Austrian	B-MED
Lipizzaner	I-MED
horses	I-MED
were	O
differentiated	B-MED
into	O
three	O
REP	B-MED
(	O
rep	B-MED
-	I-MED
E1	I-MED
,	O
rep	B-MED
-	I-MED
E3a	I-MED
,	O
and	O
rep	B-MED
-	I-MED
E4	I-MED
)	O
and	O
three	O
PFGE	B-MED
genotypes	B-MED
(	O
TE	B-MED
-	I-MED
A2	I-MED
,	O
TE	B-MED
-	I-MED
A5	I-MED
,	O
and	O
TE	B-MED
-	I-MED
D	I-MED
)	O
;	O
those	O
isolated	B-MED
from	O
four	O
Austrian	B-MED
Trotters	I-MED
belonged	O
to	O
the	O
REP	B-MED
/	O
PFGE	B-MED
genotype	B-MED
rep	B-MED
-	I-MED
E2	I-MED
/	I-MED
TE	I-MED
-	I-MED
A1	I-MED
.	O
Interestingly	O
,	O
a	O
T.	B-MED
equigenitalis	I-MED
isolate	B-MED
recovered	B-MED
from	I-MED
a	O
Holsteiner	B-MED
stallion	I-MED
living	B-MED
in	O
South	B-MED
Africa	I-MED
revealed	B-MED
the	O
REP	B-MED
/	O
PFGE	B-MED
genotype	B-MED
rep	B-MED
-	I-MED
E1	I-MED
/	I-MED
TE	I-MED
-	I-MED
A5	I-MED
which	O
was	O
otherwise	O
exclusively	B-MED
present	B-MED
in	O
the	O
majority	B-MED
of	O
Austrian	B-MED
Lipizzaner	I-MED
horses	I-MED
in	O
our	O
study	B-MED
.	O
The	O
type	O
strain	B-MED
included	O
in	O
this	O
study	B-MED
revealed	B-MED
the	O
genotype	B-MED
REP	B-MED
/	O
PFGE	B-MED
rep	B-MED
-	I-MED
E1	I-MED
/	I-MED
TE	I-MED
-	I-MED
F	I-MED
F.	O
Six	O
strains	B-MED
of	O
T.	B-MED
asinigenitalis	I-MED
including	O
the	O
type	O
strain	B-MED
were	O
separated	B-MED
into	O
three	O
REP	B-MED
(	O
rep	B-MED
-	I-MED
A1	I-MED
-	I-MED
A3	I-MED
)	O
and	O
six	O
PFGE	B-MED
genotypes	B-MED
(	O
TA	B-MED
-	I-MED
A1	I-MED
,	O
TA	B-MED
-	I-MED
A2	I-MED
,	O
TA	B-MED
-	I-MED
A3	I-MED
,	O
TA	B-MED
-	I-MED
B	I-MED
,	O
TA	B-MED
-	I-MED
C	I-MED
,	O
TA	B-MED
-	I-MED
D	I-MED
)	O
.	O
Overall	B-MED
,	I-MED
the	O
generated	B-MED
REP	B-MED
and	O
PFGE	B-MED
genotypes	B-MED
showed	O
a	O
good	B-MED
correlation	B-MED
,	O
whereas	O
REP	B-MED
-	I-MED
PCR	I-MED
proved	O
to	O
be	O
a	O
suitable	B-MED
method	I-MED
for	O
molecular	B-MED
epidemiological	I-MED
screening	I-MED
of	O
T.	B-MED
equigenitalis	I-MED
and	O
T.	B-MED
asinigenitalis	I-MED
isolates	B-MED
that	O
should	O
be	O
differentiated	B-MED
in	O
detail	B-MED
by	O
genotyping	B-MED
using	O
PFGE	B-MED
.	O
The	O
impact	B-MED
on	O
productivity	B-MED
of	O
a	O
hypothetical	B-MED
tax	I-MED
on	O
sugar	B-MED
-	I-MED
sweetened	I-MED
beverages	I-MED
To	O
quantify	O
the	O
potential	B-MED
impact	B-MED
of	O
an	O
additional	B-MED
20	O
%	O
tax	B-MED
on	O
sugar	B-MED
-	I-MED
sweetened	I-MED
beverages	I-MED
(	O
SSBs	B-MED
)	O
on	O
productivity	B-MED
in	O
Australia	B-MED
.	O
We	O
used	O
a	O
multi	B-MED
-	I-MED
state	I-MED
lifetable	I-MED
Markov	I-MED
model	I-MED
to	O
examine	B-MED
the	O
potential	B-MED
impact	B-MED
of	O
an	O
additional	B-MED
20	O
%	O
tax	B-MED
on	O
SSBs	B-MED
on	O
total	B-MED
lifetime	I-MED
productivity	B-MED
in	O
the	O
paid	B-MED
and	I-MED
unpaid	I-MED
sectors	I-MED
of	O
the	O
economy	B-MED
.	O
The	O
study	B-MED
population	I-MED
consisted	O
of	O
Australians	B-MED
aged	B-MED
20	O
years	B-MED
or	O
older	B-MED
in	O
2010	O
,	O
whose	O
health	B-MED
and	O
other	O
relevant	B-MED
outcomes	B-MED
were	O
modelled	B-MED
over	O
their	O
remaining	B-MED
lifetime	B-MED
.	O
The	O
SSBs	B-MED
tax	B-MED
was	O
estimated	B-MED
to	O
reduce	B-MED
the	O
number	B-MED
of	O
people	B-MED
with	O
obesity	B-MED
by	O
1.96	O
%	O
of	O
the	O
entire	O
population	B-MED
(	O
437,000	O
fewer	O
persons	B-MED
with	O
obesity	B-MED
)	O
,	O
and	O
reduce	B-MED
the	O
number	B-MED
of	O
employees	B-MED
with	O
obesity	B-MED
by	O
317,000	O
persons	B-MED
.	O
These	O
effects	B-MED
translated	O
into	O
productivity	B-MED
gains	B-MED
in	O
the	O
paid	B-MED
sector	I-MED
of	O
AU$751	O
million	B-MED
for	O
the	O
working	B-MED
-	O
age	B-MED
population	B-MED
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
:	O
AU$565	O
million	B-MED
to	O
AU$954	O
million	B-MED
)	O
,	O
using	O
the	O
human	B-MED
capital	I-MED
approach	B-MED
.	O
In	O
the	O
unpaid	B-MED
sector	I-MED
,	O
the	O
potential	B-MED
productivity	B-MED
gains	B-MED
amounted	B-MED
to	O
AU$1172	O
million	B-MED
(	O
AU$929	O
million	B-MED
to	O
AU$1435	O
million	B-MED
)	O
using	O
the	O
replacement	B-MED
cost	I-MED
method	I-MED
.	O
These	O
productivity	B-MED
benefits	B-MED
are	O
in	O
addition	O
to	O
the	O
health	B-MED
benefits	I-MED
of	O
35,000	O
life	B-MED
years	I-MED
gained	B-MED
and	O
a	O
reduction	B-MED
in	O
healthcare	B-MED
costs	I-MED
of	O
AU$425	O
million	B-MED
.	O
An	O
additional	B-MED
20	O
%	O
tax	B-MED
on	O
SSBs	B-MED
not	O
only	O
improves	B-MED
health	B-MED
outcomes	I-MED
and	O
reduces	B-MED
healthcare	B-MED
costs	I-MED
,	O
but	O
provides	O
productivity	B-MED
gains	B-MED
in	O
both	O
the	O
paid	B-MED
and	I-MED
unpaid	I-MED
sectors	I-MED
of	O
the	O
economy	B-MED
.	O
Tooth	B-MED
wear	I-MED
as	O
a	O
means	O
to	O
quantify	B-MED
intra	B-MED
-	I-MED
specific	I-MED
variations	B-MED
in	O
diet	B-MED
and	O
chewing	B-MED
movements	B-MED
In	O
mammals	B-MED
,	O
tooth	B-MED
function	B-MED
,	O
and	O
its	O
efficiency	B-MED
,	O
depends	O
both	O
on	O
the	O
mechanical	B-MED
properties	B-MED
of	O
the	O
food	B-MED
and	O
on	O
chewing	B-MED
dynamics	B-MED
.	O
These	O
aspects	B-MED
have	O
rarely	O
been	O
studied	B-MED
in	O
combination	O
and/or	O
at	O
the	O
intra	B-MED
-	I-MED
specific	I-MED
level	O
.	O
Here	O
we	O
applied	O
3D	B-MED
dental	B-MED
surface	B-MED
texture	B-MED
analysis	B-MED
to	O
a	O
sample	B-MED
of	O
field	B-MED
voles	I-MED
(	O
Microtus	B-MED
agrestis	I-MED
)	O
trapped	O
from	O
Finnish	B-MED
Lapland	I-MED
at	O
different	O
seasons	B-MED
and	O
localities	B-MED
to	O
test	B-MED
for	O
inter	B-MED
-	I-MED
population	I-MED
variations	B-MED
.	O
We	O
also	O
explored	O
intra	B-MED
-	I-MED
individual	I-MED
variation	B-MED
in	O
chewing	B-MED
dynamics	B-MED
by	O
analysing	B-MED
two	O
facets	B-MED
on	O
the	O
second	B-MED
upper	I-MED
molars	I-MED
.	O
Our	O
results	B-MED
confirm	O
that	O
the	O
two	O
localities	B-MED
have	O
similar	O
environments	B-MED
and	O
that	O
the	O
voles	B-MED
feed	B-MED
on	O
the	O
same	O
items	O
there	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
texture	B-MED
data	B-MED
suggest	O
that	O
diets	B-MED
are	O
seasonally	O
variable	B-MED
,	O
probably	O
due	O
to	O
varying	O
concentrations	B-MED
of	O
abrasives	B-MED
.	O
Lastly	O
,	O
the	O
textures	B-MED
on	O
the	O
buccal	B-MED
facets	I-MED
are	O
more	O
isotropic	B-MED
and	O
their	O
direction	B-MED
deviates	B-MED
more	O
from	O
the	O
mesial	B-MED
chewing	B-MED
direction	B-MED
than	O
the	O
lingual	B-MED
facets	B-MED
.	O
We	O
interpret	B-MED
these	O
results	B-MED
as	O
reflecting	O
food	B-MED
,	O
rather	O
than	O
chewing	B-MED
,	O
movements	B-MED
,	O
where	O
food	B-MED
particles	I-MED
are	O
more	O
guided	O
on	O
the	O
lingual	B-MED
side	O
of	O
the	O
molars	B-MED
.	O
This	O
has	O
implications	O
for	O
the	O
application	O
of	O
dental	B-MED
microwear	I-MED
analysis	B-MED
to	O
fossils	B-MED
:	O
only	O
homologous	B-MED
facets	B-MED
can	O
be	O
compared	O
,	O
even	O
when	O
the	O
molar	B-MED
row	O
seems	O
to	O
constitute	O
a	O
functional	B-MED
unit	I-MED
.	O
Physical	B-MED
activity	I-MED
limits	B-MED
the	O
effects	B-MED
of	I-MED
age	B-MED
and	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
on	O
postural	B-MED
control	I-MED
The	O
aim	B-MED
was	O
to	O
study	O
the	O
possible	O
influence	B-MED
of	O
physical	B-MED
activity	I-MED
on	O
the	O
postural	B-MED
performance	B-MED
of	O
subjects	B-MED
with	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
(	O
AD	B-MED
)	O
.	O
The	O
postural	B-MED
performance	B-MED
(	O
i.e.	O
surface	B-MED
area	I-MED
of	O
the	O
center	B-MED
of	I-MED
foot	I-MED
pressure	I-MED
displacement	I-MED
)	O
of	O
3	O
groups	B-MED
was	O
compared	B-MED
:	O
Alzheimer	B-MED
active	I-MED
group	I-MED
(	O
AA	B-MED
)	O
,	O
Alzheimer	B-MED
non	I-MED
-	I-MED
active	I-MED
group	I-MED
(	O
ANA	B-MED
)	O
and	O
healthy	B-MED
non	I-MED
-	I-MED
active	I-MED
group	I-MED
(	O
HNA	B-MED
)	O
.	O
The	O
AA	B-MED
group	I-MED
's	I-MED
postural	B-MED
performance	B-MED
was	O
superior	B-MED
to	O
that	O
of	O
the	O
ANA	B-MED
and	O
HNA	B-MED
groups	I-MED
.	O
AD	B-MED
disturbed	O
postural	B-MED
performance	B-MED
but	O
participation	B-MED
in	O
regular	B-MED
physical	B-MED
activity	I-MED
made	O
it	O
possible	O
to	O
limit	B-MED
the	O
disturbing	B-MED
effects	I-MED
of	O
AD	B-MED
to	O
a	O
surprising	O
extent	O
,	O
since	O
the	O
postural	B-MED
performance	B-MED
of	O
active	B-MED
AD	I-MED
subjects	I-MED
was	O
also	O
superior	B-MED
to	O
that	O
of	O
healthy	B-MED
subjects	I-MED
.	O
Bacteria	B-MED
from	O
Wheat	B-MED
and	O
Cucurbit	B-MED
Plant	B-MED
Roots	I-MED
Metabolize	B-MED
PAHs	B-MED
and	O
Aromatic	B-MED
Root	B-MED
Exudates	B-MED
:	O
Implications	B-MED
for	O
Rhizodegradation	B-MED
The	O
chemical	B-MED
interaction	I-MED
between	O
plants	B-MED
and	O
bacteria	B-MED
in	O
the	O
root	B-MED
zone	B-MED
can	O
lead	O
to	O
soil	B-MED
decontamination	B-MED
.	O
Bacteria	B-MED
which	O
degrade	B-MED
PAHs	B-MED
have	O
been	O
isolated	B-MED
from	O
the	O
rhizospheres	B-MED
of	O
plant	B-MED
species	B-MED
with	O
varied	O
biological	B-MED
traits	B-MED
,	O
however	O
,	O
it	O
is	O
not	O
known	O
what	O
phytochemicals	B-MED
promote	O
contaminant	B-MED
degradation	B-MED
.	O
One	O
monocot	B-MED
and	O
two	O
dicotyledon	B-MED
plants	I-MED
were	O
grown	B-MED
in	O
PAH	B-MED
-	O
contaminated	B-MED
soil	B-MED
from	O
a	O
manufactured	B-MED
gas	I-MED
plant	I-MED
(	O
MGP	B-MED
)	O
site	B-MED
.	O
A	O
phytotoxicity	B-MED
assay	I-MED
confirmed	O
greater	O
soil	B-MED
decontamination	B-MED
in	O
rhizospheres	B-MED
when	O
compared	B-MED
to	O
bulk	O
soil	B-MED
controls	B-MED
.	O
Bacteria	B-MED
were	O
isolated	B-MED
from	O
plant	B-MED
roots	I-MED
(	O
rhizobacteria	B-MED
)	O
and	O
selected	B-MED
for	O
growth	B-MED
on	O
anthracene	B-MED
and	O
chrysene	B-MED
on	O
PAH	B-MED
-	O
amended	B-MED
plates	B-MED
.	O
Rhizosphere	B-MED
isolates	B-MED
metabolized	B-MED
3-	O
and	O
4	O
-	O
ring	O
PAHs	B-MED
and	O
PAH	B-MED
catabolic	B-MED
intermediates	O
in	O
liquid	B-MED
incubations	I-MED
.	O
Aromatic	B-MED
root	B-MED
exudate	B-MED
compounds	I-MED
,	O
namely	O
flavonoids	B-MED
and	O
simple	B-MED
phenols	I-MED
,	O
were	O
also	O
substrates	B-MED
for	O
isolated	B-MED
rhizobacteria	B-MED
.	O
In	O
particular	O
,	O
the	O
phenolic	B-MED
compounds	I-MED
-	O
morin	B-MED
,	O
caffeic	B-MED
acid	I-MED
,	O
and	O
protocatechuic	B-MED
acid	I-MED
-	O
appear	O
to	O
be	O
linked	O
to	O
bacterial	B-MED
degradation	B-MED
of	O
3-	O
and	O
4-	O
ring	O
PAHs	B-MED
in	O
the	O
rhizosphere	B-MED
.	O
Mismatch	B-MED
Repair	I-MED
Incompatibilities	B-MED
in	O
Diverse	B-MED
Yeast	B-MED
Populations	B-MED
An	O
elevated	B-MED
mutation	B-MED
rate	I-MED
can	O
provide	O
cells	B-MED
with	O
a	O
source	B-MED
of	O
mutations	B-MED
to	O
adapt	O
to	O
changing	B-MED
environments	B-MED
.	O
We	O
identified	B-MED
a	O
negative	B-MED
epistatic	B-MED
interaction	I-MED
involving	B-MED
naturally	O
occurring	O
variants	B-MED
in	O
the	O
MLH1	B-MED
and	O
PMS1	B-MED
mismatch	B-MED
repair	I-MED
(	O
MMR	B-MED
)	O
genes	B-MED
of	O
Saccharomyces	B-MED
cerevisiae	I-MED
We	O
hypothesized	O
that	O
this	O
MMR	B-MED
incompatibility	B-MED
,	O
created	O
through	O
mating	B-MED
between	O
divergent	O
S.	B-MED
cerevisiae	I-MED
,	O
yields	O
mutator	O
progeny	B-MED
that	O
can	O
rapidly	B-MED
but	O
transiently	O
adapt	O
to	O
an	O
environmental	B-MED
stress	I-MED
.	O
Here	O
we	O
analyzed	B-MED
the	O
MLH1	B-MED
and	O
PMS1	B-MED
genes	I-MED
across	O
1010	O
S.	B-MED
cerevisiae	I-MED
natural	B-MED
isolates	B-MED
spanning	O
a	O
wide	O
range	B-MED
of	O
ecological	B-MED
sources	B-MED
(	O
tree	B-MED
exudates	B-MED
,	O
Drosophila	B-MED
,	O
fruits	B-MED
,	O
and	O
various	O
fermentation	B-MED
and	O
clinical	B-MED
isolates	B-MED
)	O
and	O
geographical	B-MED
sources	B-MED
(	O
Europe	B-MED
,	O
America	B-MED
,	O
Africa	B-MED
,	O
and	O
Asia	B-MED
)	O
.	O
We	O
identified	B-MED
one	O
homozygous	B-MED
clinical	B-MED
isolate	B-MED
and	O
18	O
heterozygous	B-MED
isolates	B-MED
containing	B-MED
the	O
incompatible	O
MMR	B-MED
genotype	B-MED
.	O
The	O
MLH1	B-MED
-	O
PMS1	B-MED
gene	I-MED
combination	B-MED
isolated	B-MED
from	O
the	O
homozygous	B-MED
clinical	B-MED
isolate	B-MED
conferred	O
a	O
mutator	O
phenotype	B-MED
when	O
expressed	B-MED
in	O
the	O
S288c	O
laboratory	B-MED
background	B-MED
.	O
Using	O
a	O
novel	O
reporter	B-MED
to	O
measure	B-MED
mutation	B-MED
rates	I-MED
,	O
we	O
showed	O
that	O
the	O
overall	B-MED
mutation	B-MED
rate	I-MED
in	O
the	O
homozygous	B-MED
incompatible	O
background	B-MED
was	O
similar	O
to	O
that	O
seen	O
in	O
compatible	B-MED
strains	B-MED
,	O
indicating	O
the	O
presence	O
of	O
suppressor	B-MED
mutations	I-MED
in	O
the	O
clinical	B-MED
isolate	B-MED
that	O
lowered	O
its	O
mutation	B-MED
rate	I-MED
.	O
This	O
observation	B-MED
and	O
the	O
identification	B-MED
of	O
18	O
heterozygous	B-MED
isolates	B-MED
isolates	B-MED
,	O
which	O
can	O
lead	O
to	O
MMR	B-MED
incompatible	O
genotypes	B-MED
in	O
the	O
offspring	B-MED
,	O
are	O
consistent	B-MED
with	I-MED
an	O
elevated	B-MED
mutation	B-MED
rate	I-MED
rapidly	O
but	O
transiently	O
facilitating	O
adaptation	B-MED
.	O
To	O
avoid	O
long	B-MED
-	I-MED
term	I-MED
fitness	B-MED
costs	B-MED
,	O
the	O
incompatibility	B-MED
is	O
apparently	O
buffered	B-MED
by	O
mating	B-MED
or	O
by	O
acquiring	O
suppressors	B-MED
.	O
These	O
observations	B-MED
highlight	O
effective	B-MED
strategies	O
in	O
eukaryotes	B-MED
to	O
avoid	O
long	B-MED
-	I-MED
term	I-MED
fitness	B-MED
costs	B-MED
associated	B-MED
with	I-MED
elevated	B-MED
mutation	B-MED
rates	I-MED
.	O
Fluoride	B-MED
concentration	B-MED
in	O
saliva	B-MED
and	O
biofilm	B-MED
fluid	I-MED
following	O
the	O
application	B-MED
of	O
three	O
fluoride	B-MED
varnishes	I-MED
Most	O
of	O
the	O
commercially	O
available	O
fluoride	B-MED
varnishes	I-MED
(	O
FV	B-MED
)	O
have	O
not	O
been	O
evaluated	B-MED
for	O
their	O
cariostatic	B-MED
properties	I-MED
.	O
Consequently	B-MED
,	O
the	O
aim	B-MED
of	O
this	O
in	B-MED
vivo	I-MED
study	B-MED
was	O
to	O
investigate	B-MED
intra	B-MED
-	O
oral	B-MED
fluoride	B-MED
retention	B-MED
and	O
clearance	B-MED
patterns	I-MED
from	O
three	O
different	O
FV	B-MED
.	O
Eighteen	O
subjects	B-MED
(	O
7	O
-	O
11	O
years	B-MED
)	O
participated	O
in	O
a	O
laboratory	B-MED
analyst	B-MED
-	O
blinded	B-MED
,	O
randomized	B-MED
,	O
crossover	B-MED
study	I-MED
comparing	B-MED
the	O
ability	B-MED
of	O
5	O
%	O
sodium	B-MED
fluoride	I-MED
varnishes	I-MED
(	O
CavityShield	B-MED
-	I-MED
CS	I-MED
,	O
Enamel	B-MED
Pro	I-MED
-	I-MED
EP	I-MED
,	O
Vanish	B-MED
-	I-MED
V	I-MED
)	O
to	O
enhance	B-MED
fluoride	B-MED
concentrations	B-MED
in	O
biofilm	B-MED
fluid	I-MED
,	O
centrifuged	B-MED
and	O
whole	B-MED
saliva	B-MED
over	O
a	O
period	B-MED
of	O
48h	O
after	O
a	O
single	O
FV	B-MED
application	O
.	O
Similar	O
fluoride	B-MED
concentration	B-MED
×	O
time	B-MED
patterns	I-MED
were	O
noted	B-MED
for	O
all	O
investigated	B-MED
FV	B-MED
and	O
studied	B-MED
variables	B-MED
,	O
with	O
the	O
highest	B-MED
fluoride	B-MED
concentrations	B-MED
observed	B-MED
for	O
the	O
first	O
biological	B-MED
sample	I-MED
collected	B-MED
after	O
FV	B-MED
application	O
(	O
30min	O
)	O
.	O
Mean±SE	B-MED
(	O
area	B-MED
under	I-MED
fluoride	I-MED
clearance	I-MED
curve	I-MED
)	O
values	B-MED
were	O
(	O
μg	O
F	O
/	O
g	O
or	O
ml×min	O
):	O
biofilm	B-MED
fluid	I-MED
-	O
CS	B-MED
(	O
472±191	O
)	O
,	O
EP	B-MED
(	O
423±75	O
)	O
,	O
V	B-MED
(	O
1264±279	O
)	O
;	O
centrifuged	B-MED
saliva	B-MED
-	O
CS	B-MED
(	O
42±7	O
)	O
,	O
EP	B-MED
(	O
19±3	O
)	O
,	O
V	B-MED
(	O
41±8	O
)	O
;	O
whole	B-MED
saliva	B-MED
-	O
CS	B-MED
(	O
68±11	O
)	O
,	O
EP	B-MED
(	O
64±10	O
)	O
,	O
V	B-MED
(	O
60±7	O
)	O
.	O
V	B-MED
delivered	O
more	O
fluoride	B-MED
to	O
biofilm	B-MED
fluid	I-MED
than	O
CS	B-MED
(	O
p=0.0116	O
)	O
and	O
EP	B-MED
(	O
p=0.0065	O
)	O
,	O
which	O
did	O
not	O
differ	O
(	O
p=0.27	O
)	O
.	O
For	O
centrifuged	B-MED
saliva	B-MED
,	O
CS	B-MED
and	O
V	B-MED
were	O
not	O
significantly	B-MED
different	O
(	O
p=0.86	O
)	O
,	O
but	O
resulted	B-MED
in	O
higher	B-MED
fluoride	B-MED
retention	B-MED
than	O
EP	B-MED
(	O
p<0.0008	O
)	O
.	O
No	O
significant	B-MED
differences	O
among	O
FV	B-MED
were	O
observed	B-MED
for	O
whole	B-MED
saliva	B-MED
(	O
p=0.79	O
)	O
.	O
The	O
present	B-MED
study	B-MED
has	O
shown	O
that	O
FV	B-MED
vary	O
in	O
their	O
ability	B-MED
to	O
deliver	O
fluoride	B-MED
intra	B-MED
-	O
orally	B-MED
potentially	B-MED
related	B-MED
to	O
formulation	O
differences	B-MED
.	O
To	O
what	O
extent	B-MED
the	O
present	B-MED
findings	B-MED
relate	B-MED
to	O
clinical	B-MED
efficacy	I-MED
remains	O
,	O
however	O
,	O
to	O
be	O
determined	B-MED
.	O
Clinical	B-MED
research	I-MED
that	O
investigates	B-MED
fluoride	B-MED
release	B-MED
patterns	B-MED
into	O
saliva	B-MED
and	O
biofilm	B-MED
fluid	I-MED
from	O
different	O
FV	B-MED
products	I-MED
is	O
insufficient	B-MED
.	O
More	O
research	B-MED
is	O
needed	O
to	O
investigate	B-MED
different	O
FV	B-MED
formulations	I-MED
for	O
their	O
efficacy	B-MED
in	O
order	O
to	O
help	O
clinicians	B-MED
make	O
better	B-MED
evidence	B-MED
based	O
treatment	B-MED
choices	O
.	O
CDF	B-MED
-	O
quantile	B-MED
distributions	B-MED
for	O
modelling	B-MED
random	B-MED
variables	I-MED
on	O
the	O
unit	B-MED
interval	I-MED
This	O
paper	O
introduces	O
a	O
two	B-MED
-	I-MED
parameter	I-MED
family	O
of	O
distributions	B-MED
for	O
modelling	B-MED
random	B-MED
variables	I-MED
on	O
the	O
(	O
0,1	O
)	O
interval	B-MED
by	O
applying	O
the	O
cumulative	B-MED
distribution	I-MED
function	I-MED
of	O
one	O
'	O
parent	B-MED
'	I-MED
distribution	I-MED
to	O
the	O
quantile	B-MED
function	B-MED
of	O
another	O
.	O
Family	O
members	O
have	O
explicit	O
probability	B-MED
density	I-MED
functions	B-MED
,	O
cumulative	B-MED
distribution	I-MED
functions	I-MED
and	O
quantile	B-MED
s	O
in	O
a	O
location	B-MED
parameter	B-MED
and	O
a	O
dispersion	B-MED
parameter	B-MED
.	O
They	O
capture	O
a	O
wide	O
variety	B-MED
of	O
shapes	B-MED
that	O
the	O
beta	B-MED
and	O
Kumaraswamy	B-MED
distributions	I-MED
can	B-MED
not	I-MED
.	O
They	O
are	O
amenable	B-MED
to	O
likelihood	B-MED
inference	I-MED
,	O
and	O
enable	O
a	O
wide	O
variety	B-MED
of	O
quantile	B-MED
regression	B-MED
models	I-MED
,	O
with	O
predictors	B-MED
for	O
both	O
the	O
location	B-MED
and	O
dispersion	B-MED
parameters	B-MED
.	O
We	O
demonstrate	O
their	O
applicability	O
to	O
psychological	B-MED
research	B-MED
problems	I-MED
and	O
their	O
utility	B-MED
in	O
modelling	B-MED
real	B-MED
data	I-MED
.	O
Hemodynamic	B-MED
correlates	O
of	O
transient	B-MED
cognitive	I-MED
impairment	I-MED
after	O
transient	B-MED
ischemic	I-MED
attack	I-MED
and	O
minor	B-MED
stroke	I-MED
:	O
A	O
transcranial	B-MED
Doppler	I-MED
study	I-MED
Transient	B-MED
cognitive	I-MED
impairment	I-MED
(	O
TCI	B-MED
)	O
on	O
the	O
Mini	B-MED
Mental	I-MED
State	I-MED
Evaluation	I-MED
score	B-MED
is	O
common	O
after	O
transient	B-MED
ischemic	I-MED
attack	I-MED
/	O
minor	B-MED
stroke	I-MED
and	O
might	O
identify	B-MED
patients	B-MED
at	O
increased	O
risk	B-MED
of	O
dementia	B-MED
.	O
We	O
aimed	B-MED
to	O
replicate	B-MED
TCI	B-MED
using	O
the	O
Montreal	B-MED
Cognitive	I-MED
Assessment	I-MED
(	O
MoCA	B-MED
)	O
,	O
compare	B-MED
it	O
with	O
persistent	B-MED
Mild	I-MED
Cognitive	I-MED
Impairment	I-MED
(	O
PMCI	B-MED
)	O
,	O
and	O
to	O
determine	O
whether	O
global	B-MED
cerebral	B-MED
hemodynamic	B-MED
changes	B-MED
could	O
explain	O
transient	B-MED
impairment	B-MED
.	O
Consecutive	O
patients	B-MED
with	O
transient	B-MED
ischemic	I-MED
attack	I-MED
/	O
minor	B-MED
stroke	I-MED
(	O
NIHSS	O
≤	O
3	O
)	O
were	O
assessed	B-MED
with	O
the	O
MoCA	B-MED
and	O
transcranial	B-MED
Doppler	I-MED
ultrasound	I-MED
acutely	B-MED
and	O
at	O
1	O
month	O
.	O
We	O
compared	B-MED
patients	B-MED
with	O
TCI	B-MED
(	O
baseline	B-MED
MoCA	B-MED
<	O
26	O
with	O
≥	O
2	O
points	B-MED
increase	B-MED
at	O
1	O
month	O
)	O
,	O
PMCI	B-MED
(	O
MoCA	B-MED
<	O
26	O
with	O
<	O
2	O
points	B-MED
increase	B-MED
)	O
,	O
and	O
no	B-MED
cognitive	I-MED
impairment	I-MED
(	O
NCI	B-MED
;	O
MoCA	B-MED
≥	O
26	O
)	O
.	O
Of	O
326	O
patients	B-MED
,	O
46	O
(	O
14.1	O
%	O
)	O
had	O
PMCI	B-MED
,	O
98	O
(	O
30.1	O
%	O
)	O
TCI	B-MED
,	O
and	O
182	O
(	O
55.8	O
%	O
)	O
NCI	B-MED
.	O
At	O
baseline	B-MED
,	O
TCI	B-MED
patients	B-MED
had	O
higher	B-MED
systolic	I-MED
blood	I-MED
pressure	I-MED
(	O
150.95	O
±	O
21.52	O
vs	O
144.86	O
±	O
22.44	O
mmHg	O
,	O
p	O
=	O
0.02	O
)	O
and	O
lower	B-MED
cerebral	B-MED
blood	I-MED
flow	I-MED
velocities	I-MED
,	O
particularly	O
end	B-MED
-	I-MED
diastolic	I-MED
velocity	I-MED
(	O
30.16	O
±	O
9.63	O
vs	O
35.02	O
±	O
9.01	O
cm	O
/	O
s	O
,	O
p	O
<	O
0.001	O
)	O
and	O
mean	B-MED
flow	I-MED
velocity	I-MED
(	O
48.95	O
±	O
12.72	O
vs	O
54	O
±	O
12.46	O
cm	O
/	O
s	O
,	O
p	O
=	O
0.001	O
)	O
than	O
those	O
with	O
NCI	B-MED
,	O
but	O
similar	O
clinical	B-MED
and	O
hemodynamic	B-MED
profiles	B-MED
to	O
those	O
with	O
PMCI	B-MED
.	O
Systolic	B-MED
BP	I-MED
fell	I-MED
between	O
baseline	B-MED
and	O
1	O
month	O
(	O
mean	B-MED
reduction	B-MED
=	O
14.01	O
±	O
21.26	O
mmHg	O
)	O
and	O
end	B-MED
-	I-MED
diastolic	I-MED
velocity	I-MED
and	O
mean	B-MED
flow	I-MED
velocity	I-MED
increased	B-MED
(	O
mean	B-MED
increase	B-MED
=	O
+	O
2.42	O
±	O
6.41	O
and	O
1.89	O
±	O
8.77	O
cm	O
/	O
s	O
,	O
respectively	O
)	O
,	O
but	O
these	O
changes	B-MED
did	O
not	B-MED
differ	I-MED
between	O
patients	B-MED
with	O
TCI	B-MED
,	O
PMCI	B-MED
,	O
and	O
NCI	B-MED
.	O
TCI	B-MED
is	O
detectable	B-MED
with	O
the	O
MoCA	B-MED
after	O
transient	B-MED
ischemic	I-MED
attack	I-MED
and	O
minor	B-MED
stroke	I-MED
and	O
has	O
similar	O
clinical	B-MED
and	O
hemodynamic	B-MED
profile	B-MED
to	O
PMCI	B-MED
.	O
However	O
,	O
TCI	B-MED
does	O
not	B-MED
appear	I-MED
to	O
be	O
due	O
to	O
exaggerated	B-MED
acute	B-MED
reversible	B-MED
global	B-MED
hemodynamic	B-MED
changes	B-MED
.	O
Direct	B-MED
anterior	I-MED
approach	I-MED
for	O
total	B-MED
hip	I-MED
arthroplasty	I-MED
with	O
a	O
novel	O
mobile	B-MED
traction	I-MED
table	I-MED
-a	O
prospective	B-MED
cohort	I-MED
study	I-MED
The	O
purpose	O
of	O
this	O
prospective	B-MED
cohort	I-MED
study	I-MED
was	O
to	O
clarify	O
the	O
safety	O
and	O
efficacy	O
of	O
total	B-MED
hip	I-MED
arthroplasty	I-MED
via	O
the	O
direct	B-MED
anterior	I-MED
approach	I-MED
in	O
the	O
supine	B-MED
position	I-MED
with	O
a	O
novel	O
mobile	B-MED
traction	I-MED
table	I-MED
.	O
The	O
first	O
experience	O
of	O
consecutive	B-MED
surgeries	I-MED
by	O
a	O
single	B-MED
surgeon	I-MED
using	O
the	O
direct	B-MED
anterior	I-MED
approach	I-MED
with	O
a	O
traction	B-MED
table	I-MED
is	O
described	O
with	O
a	O
two	O
-	O
year	O
follow	B-MED
-	I-MED
up	I-MED
period	O
.	O
Of	O
121	O
patients	B-MED
,	O
100	O
patients	B-MED
without	O
previous	B-MED
hip	I-MED
surgeries	I-MED
,	O
severe	B-MED
deformity	I-MED
,	O
or	O
cemented	B-MED
implants	I-MED
were	O
divided	O
into	O
two	O
groups	B-MED
comprising	O
the	O
first	O
50	O
patients	B-MED
and	O
the	O
second	O
50	O
patients	B-MED
.	O
The	O
implant	B-MED
survival	I-MED
rate	I-MED
was	O
99	O
%	O
at	O
the	O
two	O
-	O
year	O
follow	B-MED
-	I-MED
up	I-MED
.	O
Revision	B-MED
surgery	I-MED
was	O
required	O
for	O
periprosthetic	B-MED
femoral	B-MED
fracture	I-MED
in	O
one	O
patient	B-MED
.	O
The	O
complication	B-MED
rate	B-MED
possibly	O
related	O
to	O
the	O
traction	B-MED
table	I-MED
was	O
5	O
%	O
(	O
5	O
patients	B-MED
):	O
three	O
anterior	B-MED
dislocations	I-MED
,	O
one	O
periprosthetic	B-MED
femoral	B-MED
fracture	I-MED
,	O
and	O
one	O
intraoperative	B-MED
perforation	I-MED
caused	O
by	O
femoral	B-MED
rasping	I-MED
.	O
The	O
complication	B-MED
rate	B-MED
tended	O
to	O
decrease	B-MED
in	O
the	O
second	O
group	B-MED
compared	O
to	O
the	O
first	O
group	O
(	O
4	O
%	O
versus	O
6	O
%	O
)	O
.	O
Mean	B-MED
surgical	I-MED
time	I-MED
(	O
72.0	O
minutes	O
versus	O
82.5	O
min	O
,	O
p	O
=	O
0.027	O
)	O
,	O
rate	B-MED
of	O
allogeneic	B-MED
blood	I-MED
transfusion	I-MED
(	O
2	O
%	O
versus	O
24	O
%	O
,	O
p	O
=	O
0.001	O
)	O
,	O
and	O
cup	B-MED
alignment	I-MED
in	O
the	O
safe	B-MED
zone	I-MED
(	O
100	O
%	O
versus	O
88	O
%	O
,	O
p	O
=	O
0.027	O
)	O
were	O
significantly	O
improved	O
in	O
the	O
second	O
group	B-MED
compared	O
to	O
the	O
first	O
group	B-MED
.	O
The	O
direct	B-MED
anterior	I-MED
approach	I-MED
with	O
a	O
novel	O
mobile	B-MED
traction	I-MED
table	I-MED
showed	O
a	O
positive	B-MED
learning	I-MED
curve	I-MED
for	O
surgical	B-MED
time	I-MED
,	O
rate	B-MED
of	O
allogeneic	B-MED
blood	I-MED
transfusion	I-MED
,	O
and	O
cup	B-MED
alignment	I-MED
in	O
the	O
safe	B-MED
zone	I-MED
.	O
PROTECTIVE	B-MED
EFFECTS	I-MED
OF	I-MED
DIPEPTIDYL	B-MED
PEPTIDASE-4	I-MED
INHIBITORS	I-MED
ON	O
PROGRESSION	B-MED
OF	O
DIABETIC	B-MED
RETINOPATHY	I-MED
IN	O
PATIENTS	B-MED
WITH	O
TYPE	B-MED
2	I-MED
DIABETES	I-MED
To	O
investigate	B-MED
the	O
effects	B-MED
of	I-MED
dipeptidyl	B-MED
peptidase-4	I-MED
inhibitors	I-MED
(	O
DPP4	B-MED
)	O
on	O
the	O
progression	B-MED
of	O
diabetic	B-MED
retinopathy	I-MED
(	O
DR	B-MED
)	O
in	O
patients	B-MED
with	O
Type	B-MED
2	I-MED
diabetes	I-MED
based	O
on	O
the	O
DR	B-MED
severity	B-MED
scale	I-MED
.	O
The	O
medical	B-MED
records	I-MED
of	O
82	O
patients	B-MED
with	O
Type	B-MED
2	I-MED
diabetes	I-MED
enrolled	O
from	O
2005	O
to	O
2015	O
were	O
retrospectively	B-MED
reviewed	B-MED
.	O
Fundus	B-MED
photographs	I-MED
were	O
graded	B-MED
using	O
Early	B-MED
Treatment	I-MED
Diabetic	I-MED
Retinopathy	I-MED
Study	I-MED
methods	I-MED
.	O
The	O
associations	B-MED
between	O
baseline	B-MED
risk	B-MED
factors	I-MED
and	O
progression	B-MED
of	O
DR	B-MED
were	O
investigated	B-MED
.	O
Seven	O
of	O
28	O
patients	B-MED
treated	B-MED
with	O
DPP4	B-MED
inhibitors	I-MED
and	O
26	O
of	O
54	O
treated	B-MED
with	O
other	O
hypoglycemic	B-MED
agents	I-MED
showed	O
progression	B-MED
of	O
retinopathy	B-MED
,	O
defined	O
as	O
one	O
or	O
more	O
steps	O
on	O
the	O
Early	B-MED
Treatment	I-MED
Diabetic	I-MED
Retinopathy	I-MED
Study	I-MED
scale	I-MED
(	O
P	O
=	O
0.043	O
)	O
.	O
Only	O
treatment	B-MED
with	O
DPP4	B-MED
inhibitors	I-MED
significantly	O
reduced	B-MED
the	O
progression	B-MED
of	O
DR	B-MED
in	O
patients	B-MED
after	O
propensity	B-MED
score	I-MED
matching	O
(	O
P	O
=	O
0.009	O
)	O
.	O
Treatment	B-MED
with	O
DPP4	B-MED
inhibitors	I-MED
was	O
associated	B-MED
with	I-MED
a	O
lower	B-MED
risk	B-MED
of	O
DR	B-MED
progression	B-MED
(	O
P	O
=	O
0.011	O
)	O
.	O
Treatment	B-MED
with	O
DPP4	B-MED
inhibitors	I-MED
was	O
the	O
independent	B-MED
protective	B-MED
factor	I-MED
against	O
the	O
progression	B-MED
of	O
DR	B-MED
,	O
aside	O
from	O
improving	B-MED
glycemic	I-MED
control	I-MED
.	O
This	O
is	O
the	O
first	O
study	O
to	O
show	O
the	O
benefits	B-MED
of	O
DPP4	B-MED
inhibitors	I-MED
in	O
reducing	B-MED
DR	B-MED
progression	B-MED
,	O
and	O
provides	O
encouraging	O
preliminary	B-MED
data	B-MED
for	O
further	O
evaluation	B-MED
of	O
DPP4	B-MED
inhibitors	I-MED
in	O
the	O
progression	B-MED
of	O
DR	B-MED
in	O
a	O
randomized	B-MED
,	O
double	B-MED
-	I-MED
blind	I-MED
,	O
placebo	B-MED
-	I-MED
controlled	I-MED
trial	I-MED
.	O
Bone	B-MED
Degeneration	I-MED
and	O
Its	O
Recovery	O
in	O
SMP30	B-MED
/	I-MED
GNL	I-MED
-	O
Knockout	B-MED
Mice	I-MED
Senescence	B-MED
marker	I-MED
protein-30	I-MED
(	O
SMP30	B-MED
)	O
decreases	O
androgen	B-MED
-independently	O
with	O
aging	B-MED
and	O
is	O
a	O
lactone	B-MED
-	O
hydrolyzing	B-MED
enzyme	I-MED
gluconolactonase	B-MED
(	O
GNL	B-MED
)	O
that	O
is	O
involved	O
in	O
vitamin	B-MED
C	I-MED
biosynthesis	B-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
bone	B-MED
properties	O
of	O
SMP30	B-MED
/	I-MED
GNL	I-MED
knockout	B-MED
(	I-MED
KO	I-MED
)	I-MED
mice	I-MED
with	O
deficiency	B-MED
in	O
vitamin	B-MED
C	I-MED
synthesis	B-MED
were	O
investigated	O
to	O
reveal	O
the	O
effects	O
of	O
SMP30	B-MED
/	I-MED
GNL	I-MED
and	O
exogenous	B-MED
vitamin	B-MED
C	I-MED
supplementation	B-MED
on	O
bone	B-MED
formation	I-MED
.	O
Mineral	B-MED
content	I-MED
(	O
BMC	B-MED
)	O
and	O
mineral	B-MED
density	I-MED
(	O
BMD	B-MED
)	O
of	O
the	O
mandible	B-MED
and	O
femur	B-MED
of	O
SMP30	B-MED
/	I-MED
GNL	I-MED
KO	B-MED
and	O
wild	B-MED
-	I-MED
type	I-MED
mice	I-MED
at	O
2	O
and	O
3	O
months	B-MED
of	O
age	B-MED
with	O
or	O
without	O
vitamin	B-MED
C	I-MED
supplementation	B-MED
were	O
measured	O
by	O
dual	B-MED
-	I-MED
energy	I-MED
X	I-MED
-	I-MED
ray	I-MED
absorptiometry	I-MED
.	O
Body	B-MED
and	O
bone	B-MED
weight	B-MED
of	O
both	O
age	B-MED
groups	I-MED
decreased	O
and	O
became	O
significantly	O
lower	O
than	O
those	O
of	O
wild	B-MED
-	I-MED
type	I-MED
mice	I-MED
.	O
The	O
bones	B-MED
of	O
SMP30	B-MED
/	I-MED
GNL	I-MED
KO	B-MED
mice	I-MED
were	O
rough	O
and	O
porous	O
,	O
with	O
BMC	B-MED
and	O
BMD	B-MED
significantly	O
below	O
wild	B-MED
-	I-MED
type	I-MED
.	O
Oral	B-MED
supplementation	B-MED
with	O
vitamin	B-MED
C	I-MED
eliminated	O
differences	O
in	O
body	B-MED
weight	I-MED
,	O
bone	B-MED
weight	O
,	O
BMC	B-MED
,	O
and	O
BMD	B-MED
between	O
SMP30	B-MED
/	I-MED
GNL	I-MED
KO	B-MED
and	O
wild	B-MED
-	I-MED
type	I-MED
mice	I-MED
at	O
each	O
age	B-MED
.	O
These	O
results	O
indicate	O
that	O
bone	B-MED
degeneration	I-MED
in	O
SMP30	B-MED
/	I-MED
GNL	I-MED
KO	B-MED
mice	I-MED
was	O
caused	O
by	O
lack	O
of	O
vitamin	B-MED
C	I-MED
,	O
and	O
that	O
this	O
mouse	B-MED
strain	I-MED
is	O
an	O
appropriate	O
model	B-MED
for	O
bone	B-MED
metabolism	I-MED
in	O
humans	B-MED
,	O
which	O
have	O
no	O
ability	O
to	O
synthesize	B-MED
vitamin	B-MED
C	I-MED
C.	O
Association	B-MED
of	O
kidney	B-MED
disease	I-MED
with	O
obstructive	B-MED
sleep	I-MED
apnea	I-MED
in	O
a	O
population	B-MED
study	I-MED
of	O
men	B-MED
To	O
determine	B-MED
the	O
relationship	B-MED
between	O
obstructive	B-MED
sleep	I-MED
apnea	I-MED
(	O
OSA	B-MED
)	O
and	O
chronic	B-MED
kidney	I-MED
disease	I-MED
(	O
CKD	B-MED
)	O
.	O
Previous	O
population	B-MED
studies	I-MED
of	O
the	O
association	B-MED
are	O
sparse	B-MED
,	O
conflicting	B-MED
and	O
confined	B-MED
largely	O
to	O
studies	B-MED
of	O
administrative	B-MED
data	B-MED
.	O
Cross	B-MED
-	I-MED
sectional	I-MED
analysis	I-MED
in	O
unselected	O
participants	B-MED
of	O
the	O
Men	B-MED
Androgens	I-MED
Inflammation	I-MED
Lifestyle	I-MED
Environment	I-MED
and	I-MED
Stress	I-MED
(	I-MED
MAILES	I-MED
)	I-MED
study	I-MED
,	O
aged	B-MED
>	O
40	O
y.	O
Renal	B-MED
data	B-MED
were	O
available	O
on	O
812	O
men	B-MED
without	O
a	O
prior	B-MED
OSA	B-MED
diagnosis	B-MED
who	O
underwent	O
full	O
in	B-MED
-	I-MED
home	I-MED
polysomnography	B-MED
(	O
Embletta	B-MED
X100	I-MED
)	O
in	O
2010	O
-	O
2011	O
.	O
CKD	B-MED
was	O
defined	O
as	O
an	O
estimated	B-MED
glomerular	I-MED
filtration	I-MED
rate	I-MED
(	O
eGFR	B-MED
)	O
<	O
60	O
mL	O
/	O
min/1.73m2	O
or	O
eGFR	B-MED
≥60	O
and	O
albuminuria	B-MED
(	O
albumin	B-MED
creatinine	I-MED
ratio	I-MED
≥3.0	O
mg	O
/	O
mmol	O
)	O
.	O
CKD	B-MED
[	O
10.5	O
%	O
,	O
n=85	O
(	O
Stage	B-MED
1	O
-	O
3	O
,	O
9.7	O
%	O
;	O
Stage	B-MED
4	O
-	O
5	O
,	O
0.7	O
%	O
)	O
]	O
of	O
predominantly	B-MED
mild	B-MED
severity	I-MED
showed	O
significant	B-MED
association	B-MED
s	O
with	O
OSA	B-MED
(	O
AHI≥10	O
):	O
odds	B-MED
ratio	I-MED
OR	B-MED
(	O
OR)=1.9	O
,	O
95	O
%	O
confidence	B-MED
interval	I-MED
CI	B-MED
(	O
CI):1.02	O
-	O
3.5	O
,	O
severe	B-MED
OSA	B-MED
(	O
AHI	O
≥30	O
/	O
h	O
):	O
OR	B-MED
=	O
2.6	O
,	O
95	O
%	O
CI:1.1	O
-	O
6.2	O
,	O
and	O
respiratory	B-MED
related	O
arousal	B-MED
index	B-MED
:	O
≥7.6	O
/	O
h	O
OR	B-MED
=	O
2.3	O
,	O
95%CI	O
:	O
1.1	O
-	O
4.7	O
,	O
but	O
not	O
measures	B-MED
of	O
hypoxemia	B-MED
after	O
adjustment	B-MED
for	O
age	B-MED
,	O
hypertension	B-MED
,	O
diabetes	B-MED
,	O
smoking	B-MED
,	O
obesity	B-MED
,	O
and	O
NSAID	B-MED
use	B-MED
.	O
There	O
was	O
no	O
association	B-MED
of	O
CKD	B-MED
with	O
daytime	B-MED
sleepiness	I-MED
.	O
In	O
men	B-MED
with	O
CKD	B-MED
,	O
those	O
with	O
OSA	B-MED
were	O
not	B-MED
significantly	I-MED
more	B-MED
likely	B-MED
to	O
report	B-MED
symptoms	B-MED
(	O
sleepiness	B-MED
,	O
snoring	B-MED
,	O
apneas	B-MED
)	O
or	O
be	O
identified	B-MED
with	O
the	O
STOP	B-MED
OSA	I-MED
screening	I-MED
questionnaire	I-MED
,	O
compared	O
to	O
men	B-MED
without	O
OSA	B-MED
.	O
Predominantly	B-MED
mild	B-MED
CKD	B-MED
is	O
associated	B-MED
with	I-MED
severe	B-MED
OSA	B-MED
and	O
arousals	B-MED
.	O
Further	O
population	B-MED
studies	I-MED
examining	B-MED
the	O
longitudinal	B-MED
relationship	B-MED
between	O
CKD	B-MED
and	O
OSA	B-MED
are	O
warranted	B-MED
.	O
Better	O
methods	B-MED
are	O
needed	B-MED
to	O
identify	B-MED
OSA	B-MED
in	O
CKD	B-MED
which	O
may	O
have	O
few	B-MED
symptoms	B-MED
.	O
Is	O
UV	B-MED
-	O
Induced	B-MED
Electron	B-MED
-	I-MED
Driven	I-MED
Proton	I-MED
Transfer	I-MED
Active	B-MED
in	O
a	O
Chemically	B-MED
Modified	I-MED
A	B-MED
·	O
T	B-MED
DNA	B-MED
Base	B-MED
Pair	I-MED
?	O
Transient	B-MED
electronic	I-MED
and	I-MED
vibrational	I-MED
absorption	I-MED
spectroscopies	I-MED
have	O
been	O
used	O
to	O
investigate	B-MED
whether	O
UV	B-MED
-	O
induced	B-MED
electron	B-MED
-	I-MED
driven	I-MED
proton	I-MED
transfer	I-MED
(	O
EDPT	B-MED
)	O
mechanisms	B-MED
are	O
active	B-MED
in	O
a	O
chemically	B-MED
modified	I-MED
adenine	B-MED
-	O
thymine	B-MED
(	O
A	B-MED
·	O
T	B-MED
)	O
DNA	B-MED
base	B-MED
pair	I-MED
.	O
To	O
enhance	O
the	O
fraction	B-MED
of	I-MED
biologically	B-MED
relevant	I-MED
Watson	B-MED
-	I-MED
Crick	I-MED
(	I-MED
WC	I-MED
)	I-MED
hydrogen	I-MED
-	I-MED
bonding	I-MED
motifs	B-MED
and	O
eliminate	O
undesired	O
Hoogsteen	B-MED
structures	I-MED
,	O
a	O
chemically	B-MED
modified	I-MED
derivative	B-MED
of	I-MED
A	I-MED
A	B-MED
was	O
synthesized	B-MED
,	O
8-(tert	B-MED
-	I-MED
butyl)-9	I-MED
-	I-MED
ethyladenine	I-MED
(	O
8tBA	B-MED
)	O
.	O
Equimolar	B-MED
solutions	I-MED
of	O
8tBA	B-MED
and	O
silyl	B-MED
-	I-MED
protected	I-MED
T	I-MED
nucleosides	B-MED
in	O
chloroform	B-MED
yield	B-MED
a	O
mixture	B-MED
of	O
WC	B-MED
pairs	I-MED
,	O
reverse	B-MED
WC	I-MED
pairs	I-MED
,	O
and	O
residual	B-MED
monomers	I-MED
.	O
Unlike	O
previous	O
transient	B-MED
absorption	I-MED
studies	I-MED
of	O
WC	O
guanine	B-MED
-	O
cytosin	B-MED
e	O
(	O
G	B-MED
·	O
C	B-MED
)	O
pairs	B-MED
,	O
no	O
clear	O
spectroscopic	B-MED
or	I-MED
kinetic	I-MED
evidence	I-MED
was	O
identified	B-MED
for	O
the	O
participation	B-MED
of	O
EDPT	B-MED
in	O
the	O
excited	B-MED
-	I-MED
state	I-MED
relaxation	I-MED
dynamics	I-MED
of	O
8tBA	B-MED
·	O
T	B-MED
pairs	B-MED
,	O
although	O
ultrafast	B-MED
(	O
sub-100	O
fs	O
)	O
EDPT	B-MED
can	O
not	O
be	O
discounted	O
.	O
Monomer	B-MED
-	I-MED
like	I-MED
dynamics	I-MED
are	O
proposed	O
to	O
dominate	O
in	O
8tBA	B-MED
T	B-MED
·	O
T.	O
Gene	B-MED
-based	O
genome	B-MED
-	I-MED
wide	I-MED
association	I-MED
study	I-MED
identified	B-MED
19p13.3	B-MED
for	O
lean	B-MED
body	I-MED
mass	I-MED
Lean	B-MED
body	I-MED
mass	I-MED
(	O
LBM	B-MED
)	O
is	O
a	O
complex	O
trait	B-MED
for	O
human	B-MED
health	B-MED
.	O
To	O
identify	O
genomic	B-MED
loci	I-MED
underlying	O
LBM	B-MED
,	O
we	O
performed	O
a	O
gene	B-MED
-based	O
genome	B-MED
-	I-MED
wide	I-MED
association	I-MED
study	I-MED
of	O
lean	B-MED
mass	I-MED
index	I-MED
(	O
LMI	B-MED
)	O
in	O
1000	O
unrelated	B-MED
Caucasian	B-MED
subjects	B-MED
,	O
and	O
replicated	B-MED
in	O
2283	O
unrelated	B-MED
Caucasians	B-MED
subjects	B-MED
.	O
Gene	B-MED
-based	O
association	B-MED
analyses	I-MED
highlighted	O
the	O
significant	O
associations	B-MED
of	O
three	O
genes	B-MED
UQCR	B-MED
,	O
TCF3	B-MED
and	O
MBD3	B-MED
in	O
one	O
single	B-MED
locus	B-MED
19p13.3	B-MED
(	O
discovery	B-MED
p	O
=	O
6.10	O
×	O
10(-5	O
)	O
,	O
1.65	O
×	O
10(-4	O
)	O
and	O
1.10	O
×	O
10(-4	O
)	O
;	O
replication	B-MED
p	O
=	O
2.21	O
×	O
10(-3	O
)	O
,	O
1.84	O
×	O
10(-3	O
)	O
and	O
6.95	O
×	O
10(-3	O
)	O
;	O
combined	O
p	O
=	O
2.26	O
×	O
10(-6	O
)	O
,	O
4.86	O
×	O
10(-6	O
)	O
and	O
1.15	O
×	O
10(-5	O
)	O
,	O
respectively	O
)	O
.	O
These	O
results	O
,	O
together	O
with	O
the	O
known	O
functional	B-MED
relevance	B-MED
of	O
the	O
three	O
genes	B-MED
to	O
LMI	B-MED
,	O
suggested	O
that	O
the	O
19p13.3	B-MED
region	B-MED
containing	O
UQCR	B-MED
,	O
TCF3	B-MED
and	O
MBD3	B-MED
genes	I-MED
was	O
a	O
novel	O
locus	B-MED
underlying	O
lean	B-MED
mass	I-MED
variation	B-MED
.	O
Anatomic	B-MED
assessment	B-MED
of	O
the	O
left	B-MED
main	I-MED
bifurcation	I-MED
and	O
dynamic	B-MED
bifurcation	I-MED
angles	I-MED
using	O
computed	B-MED
tomography	I-MED
angiography	I-MED
An	O
understanding	O
of	O
the	O
left	B-MED
main	I-MED
coronary	I-MED
artery	I-MED
(	O
LMCA	B-MED
)	O
anatomy	B-MED
is	O
important	O
for	O
accurate	O
diagnosis	B-MED
and	O
therapeutic	B-MED
.	O
We	O
aimed	O
to	O
investigate	B-MED
LMCA	B-MED
anatomy	B-MED
via	O
128	B-MED
-	I-MED
multisliced	I-MED
coronary	I-MED
computed	I-MED
-	I-MED
tomography	I-MED
-	I-MED
angiography	I-MED
(	O
CCTA	B-MED
)	O
in	O
patients	B-MED
with	O
normal	O
LMCA	B-MED
.	O
A	O
total	O
of	O
201	O
CCTA	B-MED
studies	B-MED
were	O
included	O
in	O
this	O
study	B-MED
.	O
Anatomical	B-MED
features	I-MED
of	O
LMCA	B-MED
including	O
cross	B-MED
-	I-MED
sectional	I-MED
areas	I-MED
of	O
the	O
LMCA	B-MED
ostial	B-MED
,	O
LMCA	B-MED
distal	B-MED
,	O
LAD	B-MED
ostial	I-MED
and	O
LCX	B-MED
ostial	B-MED
,	O
and	O
degree	O
of	O
tapering	O
and	O
LMCA	B-MED
bifurcation	B-MED
angles	I-MED
(	O
BA	B-MED
)	O
in	O
the	O
form	O
of	O
LMCA	B-MED
-	O
LCX	B-MED
BA	B-MED
,	O
LMCA	B-MED
-	O
LAD	B-MED
BA	B-MED
,	O
LAD	B-MED
-	O
LCX	B-MED
BA	B-MED
at	O
end	B-MED
-	I-MED
diastole	I-MED
and	O
end	B-MED
-	I-MED
systole	I-MED
.	O
The	O
mean	O
age	B-MED
was	O
55	O
±	O
11	O
with	O
55.7	O
%	O
males	B-MED
.	O
RCA	B-MED
was	O
dominant	B-MED
in	O
173	O
(	O
86.1	O
%	O
)	O
patients	B-MED
.	O
Mean	O
LMCA	B-MED
length	B-MED
was	O
10.0±4.5	O
mm	O
.	O
The	O
mean	O
values	O
of	O
LMCA	B-MED
ostial	B-MED
,	O
LMCA	B-MED
distal	B-MED
,	O
LAD	B-MED
ostial	I-MED
and	O
LCX	B-MED
ostial	B-MED
areas	B-MED
were	O
18.2±5.1	O
mm²	O
,	O
13.2±4.0	O
,	O
9.0±3.2	O
mm²	O
and	O
7.6±2.8	O
mm²	O
,	O
respectively	O
.	O
LMCA	B-MED
ostial	B-MED
-	O
distal	B-MED
area	B-MED
,	O
LMCA	B-MED
distal	B-MED
-	O
LAD	B-MED
ostial	I-MED
area	B-MED
and	O
LMCA	B-MED
distal	B-MED
-	O
LCX	B-MED
ostial	B-MED
area	B-MED
ratios	I-MED
were	O
≥1.44	O
-	O
<	O
1.69	O
in	O
47	O
(	O
23.4	O
%	O
)	O
,	O
53	O
(	O
26.4	O
%	O
)	O
,	O
47	O
(	O
23.4	O
%	O
)	O
patients	B-MED
,	O
respectively	O
,	O
and	O
were	O
≥1.69-<1.96	O
in	O
19	O
(	O
9.5	O
%	O
)	O
,	O
24(11.9	O
%	O
)	O
,	O
40(19.9	O
%	O
)	O
patients	B-MED
respectively	O
.	O
Systolic	B-MED
motion	I-MED
modifies	O
LMCA	B-MED
BAs	B-MED
;	O
systolic	B-MED
motion	I-MED
begets	O
an	O
increment	O
of	O
LMCA	B-MED
-	O
LAD	B-MED
angle	O
in	O
72.6	O
%	O
of	O
patients	B-MED
and	O
decrement	O
of	O
LAD	B-MED
-	O
LCX	B-MED
angle	O
in	O
75.6	O
%	O
of	O
the	O
patients	B-MED
.	O
Patients	B-MED
with	O
T	O
-	O
shaped	O
LAD	B-MED
-	O
LCX	B-MED
BA	B-MED
was	O
shown	O
to	O
have	O
significantly	O
longer	O
LMCA	B-MED
,	O
larger	O
LAD	B-MED
ostial	I-MED
area	B-MED
,	O
larger	O
LCX	B-MED
ostial	B-MED
area	B-MED
and	O
higher	O
diastolic	B-MED
-	I-MED
to	I-MED
-	I-MED
systolic	I-MED
range	I-MED
(	O
DSR	B-MED
)	O
of	O
LAD	B-MED
-	O
LCX	B-MED
BA	B-MED
compared	O
to	O
patients	B-MED
with	O
Y	O
-	O
shaped	O
LAD	B-MED
-	O
LCX	B-MED
BA	B-MED
.	O
LMCA	B-MED
with	O
T	B-MED
-	I-MED
shaped	I-MED
distal	I-MED
BA	B-MED
was	O
found	O
to	O
have	O
significantly	O
longer	O
LMCA	B-MED
,	O
larger	O
LAD	B-MED
ostial	I-MED
area	B-MED
,	O
larger	O
LCX	B-MED
ostial	B-MED
area	B-MED
and	O
higher	O
DSR	B-MED
of	O
distal	B-MED
BA	B-MED
compared	O
to	O
patients	B-MED
with	O
Y	B-MED
-	I-MED
shaped	I-MED
distal	I-MED
BA	B-MED
.	O
These	O
findings	B-MED
may	O
provide	O
useful	O
information	O
for	O
LMCA	B-MED
bifurcation	B-MED
stenting	I-MED
or	O
designing	O
dedicated	O
stents	B-MED
for	O
LMCA	B-MED
.	O
Fully	B-MED
Endoscope	B-MED
-	O
Controlled	B-MED
Clipping	B-MED
Bilateral	B-MED
Middle	I-MED
Cerebral	I-MED
Artery	I-MED
Aneurysm	I-MED
Via	O
Unilateral	B-MED
Supraorbital	I-MED
Keyhole	I-MED
Approach	I-MED
Clipping	B-MED
bilateral	B-MED
middle	I-MED
cerebral	I-MED
artery	I-MED
(	I-MED
bMCA	I-MED
)	I-MED
aneurysms	I-MED
via	O
unilateral	B-MED
approach	I-MED
in	O
a	O
single	B-MED
-	I-MED
stage	I-MED
operation	I-MED
is	O
considered	O
as	O
a	O
challenge	O
procedure	O
.	O
To	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
study	O
in	O
surgical	B-MED
management	I-MED
of	O
patients	B-MED
with	O
bMCA	B-MED
aneurysms	I-MED
by	O
fully	O
endoscope	B-MED
-	O
controlled	B-MED
techniques	B-MED
.	O
The	O
author	O
reported	O
a	O
patient	B-MED
with	O
bMCA	B-MED
aneurysms	I-MED
who	O
underwent	O
aneurysms	B-MED
clipping	I-MED
via	O
a	O
unilateral	B-MED
supraorbital	I-MED
keyhole	I-MED
approach	I-MED
by	O
endoscope	B-MED
-	O
controlled	B-MED
microneurosurgery	B-MED
,	O
and	O
the	O
patient	B-MED
had	O
an	O
uneventful	O
postoperative	B-MED
course	I-MED
without	B-MED
neurologic	B-MED
impairment	B-MED
and	O
complication	B-MED
.	O
Furthermore	O
,	O
the	O
author	O
discussed	O
the	O
advantages	O
and	O
adaptation	B-MED
of	O
endoscope	B-MED
-	O
controlled	B-MED
clipping	B-MED
bMCA	B-MED
aneurysms	I-MED
via	O
unilateral	B-MED
supraorbital	I-MED
keyhole	I-MED
approach	I-MED
.	O
Ankaflavin	B-MED
and	O
Monascin	B-MED
Induce	B-MED
Apoptosis	B-MED
in	O
Activated	B-MED
Hepatic	B-MED
Stellate	I-MED
Cells	I-MED
through	O
Suppression	B-MED
of	O
the	O
Akt	B-MED
/	O
NF	B-MED
-	I-MED
κB	I-MED
/	O
p38	B-MED
Signaling	B-MED
Pathway	I-MED
The	O
increased	B-MED
proliferation	B-MED
of	O
activated	B-MED
hepatic	B-MED
stellate	I-MED
cells	I-MED
(	O
HSCs	B-MED
)	O
is	O
associated	B-MED
with	I-MED
hepatic	B-MED
fibrosis	I-MED
and	O
excessive	B-MED
extracellular	B-MED
matrix	I-MED
ECM	B-MED
(	O
ECM)-	O
protein	B-MED
production	O
.	O
We	O
examined	O
the	O
inhibitory	B-MED
effects	B-MED
of	I-MED
the	O
Monascus	B-MED
purpureus	I-MED
-fermented	O
metabolites	B-MED
,	O
ankaflavin	B-MED
and	O
monascin	B-MED
(	O
15	O
and	O
30	O
μM	O
)	O
,	O
on	O
the	O
Akt	B-MED
/	O
nuclear	B-MED
factor	I-MED
(	I-MED
NF)-κB	I-MED
and	O
p38	B-MED
mitogen	I-MED
-	I-MED
activated	I-MED
protein	I-MED
kinase	I-MED
(	O
MAPK	B-MED
)	O
signaling	B-MED
pathways	I-MED
in	O
HSC	B-MED
-	I-MED
T6	I-MED
(	O
activated	B-MED
hepatic	I-MED
stellate	I-MED
cell	I-MED
line	I-MED
)	O
.	O
Ankaflavin	B-MED
and	O
monascin	B-MED
(	O
30	O
μM	O
)	O
induced	B-MED
apoptosis	B-MED
and	O
significantly	B-MED
inhibited	B-MED
cell	B-MED
growth	I-MED
(	O
cell	B-MED
viabilities	I-MED
:	O
80.2	O
±	O
5.43	O
%	O
and	O
62.8	O
±	O
8.20	O
%	O
,	O
respectively	O
,	O
versus	O
control	B-MED
cells	I-MED
;	O
P	O
<	O
0.05	O
)	O
.	O
Apoptosis	B-MED
and	O
G1	B-MED
phase	I-MED
arrest	I-MED
(	O
G1	B-MED
phase	I-MED
percentages	B-MED
:	O
76.1	O
±	O
2.85	O
%	O
and	O
79.9	O
±	O
1.80	O
%	O
,	O
respectively	O
,	O
versus	O
control	B-MED
cells	I-MED
65.9	O
±	O
4.94	O
%	O
;	O
P	O
<	O
0.05	O
)	O
correlated	B-MED
with	O
increased	B-MED
p53	B-MED
and	O
p21	B-MED
levels	B-MED
and	O
caspase	B-MED
3	I-MED
activity	I-MED
and	O
decreased	B-MED
cyclin	B-MED
D1	I-MED
and	O
Bcl-2	B-MED
-	I-MED
family	I-MED
protein	I-MED
levels	B-MED
(	O
P	O
<	O
0.05	O
,	O
all	O
cases	O
)	O
.	O
The	O
apoptotic	B-MED
effects	B-MED
of	I-MED
ankaflavin	B-MED
and	O
monascin	B-MED
were	O
HSC	B-MED
-	I-MED
T6	I-MED
-	O
specific	B-MED
,	O
suggesting	O
their	O
potential	B-MED
in	O
treating	B-MED
liver	B-MED
fibrosis	I-MED
.	O
Effects	B-MED
of	O
Transplanted	B-MED
Human	B-MED
Cord	B-MED
Blood	I-MED
-	O
Mononuclear	B-MED
Cells	I-MED
on	O
Pulmonary	B-MED
Hypertension	I-MED
in	O
Immunodeficient	B-MED
Mice	I-MED
and	O
Their	O
Distribution	B-MED
To	O
investigate	B-MED
the	O
effects	B-MED
of	O
human	B-MED
umbilical	B-MED
cord	I-MED
blood	I-MED
-derived	O
mononuclear	B-MED
cell	I-MED
(	O
hUCB	B-MED
-	O
MNC	B-MED
)	O
transplantation	B-MED
on	O
pulmonary	B-MED
hypertension	I-MED
(	O
PH	B-MED
)	O
induced	B-MED
by	O
monocrotaline	B-MED
(	O
MCT	B-MED
)	O
in	O
immunodeficient	B-MED
mice	I-MED
and	O
their	O
distribution	B-MED
.	O
MCT	B-MED
was	O
administered	B-MED
to	O
BALB	B-MED
/	I-MED
c	I-MED
Slc	I-MED
-	I-MED
nu	I-MED
/	I-MED
nu	I-MED
mice	I-MED
,	O
and	O
PH	B-MED
was	O
induced	B-MED
in	O
mice	B-MED
4	O
weeks	O
later	O
.	O
Fresh	B-MED
hUCB	B-MED
-	O
MNCs	B-MED
harvested	B-MED
from	O
a	O
human	B-MED
donor	B-MED
after	O
her	O
delivery	B-MED
were	O
injected	B-MED
intravenously	I-MED
into	O
those	O
PH	B-MED
mice	B-MED
.	O
The	O
medial	B-MED
thickness	B-MED
of	O
pulmonary	B-MED
arterioles	I-MED
,	O
ratio	B-MED
of	O
right	B-MED
ventricular	I-MED
to	O
septum	B-MED
plus	B-MED
left	B-MED
ventricular	I-MED
weight	B-MED
(	O
RV	B-MED
/	O
S	B-MED
+	O
LV	B-MED
)	O
,	O
and	O
ratio	B-MED
of	O
acceleration	B-MED
time	I-MED
to	O
ejection	B-MED
time	I-MED
of	O
pulmonary	B-MED
blood	I-MED
flow	I-MED
waveform	B-MED
(	O
AT	B-MED
/	O
ET	B-MED
)	O
were	O
determined	B-MED
4	O
weeks	O
after	O
hUCB	B-MED
-	O
MNC	B-MED
transplantation	B-MED
.	O
To	O
reveal	B-MED
the	O
incorporation	B-MED
into	O
the	O
lung	B-MED
,	O
CMTMR	B-MED
-	O
labeled	B-MED
hUCB	B-MED
-	O
MNCs	B-MED
were	O
observed	B-MED
in	O
the	O
lung	B-MED
by	O
fluorescent	B-MED
microscopy	I-MED
.	O
DiR	B-MED
-	I-MED
labeled	I-MED
hUCB	B-MED
-	O
MNCs	B-MED
were	O
detected	B-MED
in	O
the	O
lung	B-MED
and	O
other	O
organs	B-MED
by	O
bioluminescence	B-MED
images	I-MED
.	O
Medial	B-MED
thickness	B-MED
,	O
RV	B-MED
/	O
S	B-MED
+	O
LV	B-MED
and	O
AT	B-MED
/	O
ET	B-MED
were	O
significantly	B-MED
improved	B-MED
4	O
weeks	O
after	O
hUCB	B-MED
-	O
MNC	B-MED
transplantation	B-MED
compared	B-MED
with	O
those	O
in	O
mice	B-MED
without	O
hUCB	B-MED
-	O
MNC	B-MED
transplantation	B-MED
.	O
CMTMR	B-MED
-	O
positive	B-MED
hUCB	B-MED
-	O
MNCs	B-MED
were	O
observed	B-MED
in	O
the	O
lung	B-MED
3	O
hours	O
after	O
transplantation	B-MED
.	O
Bioluminescence	B-MED
signals	B-MED
were	O
detected	B-MED
more	O
strongly	B-MED
in	O
the	O
lung	B-MED
than	O
in	O
other	O
organs	B-MED
for	O
24	O
hours	O
after	O
transplantation	B-MED
.	O
The	O
results	B-MED
indicate	B-MED
that	O
hUCB	B-MED
-	O
MNCs	B-MED
are	O
incorporated	B-MED
into	O
the	O
lung	B-MED
early	B-MED
after	O
hUCB	B-MED
-	O
MNC	B-MED
transplantation	B-MED
and	O
improve	B-MED
MCT	B-MED
-	O
induced	B-MED
PH	B-MED
.	O
J.	O
Med	O
.	O
Invest	O
.	O
64	O
:	O
43	O
-	O
49	O
,	O
February	O
,	O
2017	O
.	O
Characterization	B-MED
of	O
Phytochrome	B-MED
Interacting	I-MED
Factors	I-MED
from	O
the	O
Moss	B-MED
Physcomitrella	B-MED
patens	I-MED
Illustrates	O
Conservation	B-MED
of	O
Phytochrome	B-MED
Signaling	I-MED
Modules	I-MED
in	O
Land	B-MED
Plants	I-MED
Across	O
the	O
plant	B-MED
kingdom	I-MED
,	O
phytochrome	B-MED
(	O
PHY	B-MED
)	O
photoreceptors	B-MED
play	O
an	O
important	O
role	O
during	O
adaptive	B-MED
and	O
developmental	O
responses	B-MED
to	I-MED
light	I-MED
.	O
In	O
Arabidopsis	B-MED
thaliana	I-MED
,	O
light	O
-	O
activated	O
PHYs	B-MED
accumulate	O
in	O
the	O
nucleus	B-MED
,	O
where	O
they	O
regulate	O
downstream	B-MED
signaling	I-MED
components	I-MED
,	O
such	O
as	O
phytochrome	B-MED
interacting	I-MED
factors	I-MED
(	O
PIFs	B-MED
)	O
.	O
PIFs	B-MED
are	O
transcription	B-MED
factors	I-MED
that	O
act	O
as	O
repressors	B-MED
of	O
photomorphogenesis	B-MED
;	O
their	O
inhibition	B-MED
by	O
PHYs	B-MED
leads	O
to	O
substantial	O
changes	O
in	O
gene	B-MED
expression	I-MED
.	O
The	O
nuclear	B-MED
function	I-MED
of	O
PHYs	B-MED
,	O
however	O
,	O
has	O
so	O
far	O
been	O
investigated	O
in	O
only	O
a	O
few	O
non	B-MED
-	I-MED
seed	I-MED
plants	I-MED
.	O
Here	O
,	O
we	O
identified	O
putative	O
target	O
genes	B-MED
of	O
PHY	B-MED
signaling	B-MED
in	O
the	O
moss	B-MED
Physcomitrella	B-MED
patens	I-MED
and	O
found	O
light	B-MED
-	I-MED
regulated	I-MED
genes	I-MED
that	O
are	O
putative	O
orthologs	B-MED
of	O
PIF	B-MED
-	I-MED
controlled	I-MED
genes	I-MED
in	O
Arabidopsis	B-MED
.	O
Phylogenetic	B-MED
analyses	I-MED
revealed	O
that	O
an	O
ancestral	O
PIF	B-MED
-	I-MED
like	I-MED
gene	I-MED
was	O
already	O
present	O
in	O
streptophyte	B-MED
algae	I-MED
,	O
i.e.	O
,	O
before	O
the	O
water	B-MED
-	I-MED
to	I-MED
-	I-MED
land	I-MED
transition	I-MED
of	O
plants	B-MED
.	O
The	O
PIF	B-MED
homologs	I-MED
in	O
the	O
genome	B-MED
of	O
P.	B-MED
patens	I-MED
resemble	O
Arabidopsis	B-MED
PIFs	B-MED
in	O
their	O
protein	B-MED
domain	I-MED
structure	I-MED
,	O
molecular	B-MED
properties	I-MED
,	O
and	O
physiological	B-MED
effects	I-MED
,	O
albeit	O
with	O
notable	O
differences	O
in	O
the	O
motif	O
-	O
dependent	O
PHY	B-MED
interaction	B-MED
.	O
Our	O
results	O
suggest	O
that	O
P.	B-MED
patens	I-MED
PIFs	B-MED
are	O
involved	O
in	O
PHY	B-MED
signaling	B-MED
.	O
The	O
PHY	B-MED
-	I-MED
PIF	I-MED
signaling	I-MED
node	I-MED
that	O
relays	O
light	B-MED
signals	I-MED
to	O
target	O
genes	B-MED
has	O
been	O
largely	O
conserved	O
during	O
land	B-MED
plant	I-MED
evolution	B-MED
,	O
with	O
evidence	O
of	O
lineage	B-MED
-	I-MED
specific	I-MED
diversification	I-MED
.	O
Surface	B-MED
mediated	O
cooperative	O
interactions	B-MED
of	I-MED
drugs	I-MED
enhance	B-MED
mechanical	B-MED
forces	I-MED
for	O
antibiotic	B-MED
action	B-MED
The	O
alarming	B-MED
increase	I-MED
of	O
pathogenic	B-MED
bacteria	I-MED
that	O
are	O
resistant	B-MED
to	I-MED
multiple	I-MED
antibiotics	I-MED
is	O
now	O
recognized	O
as	O
a	O
major	B-MED
health	I-MED
issue	I-MED
fuelling	O
demand	B-MED
for	O
new	O
drugs	B-MED
.	O
Bacterial	B-MED
resistance	I-MED
is	O
often	O
caused	O
by	O
molecular	B-MED
changes	I-MED
at	O
the	O
bacterial	B-MED
surface	I-MED
,	O
which	O
alter	O
the	O
nature	O
of	O
specific	O
drug	B-MED
-	I-MED
target	I-MED
interactions	I-MED
.	O
Here	O
,	O
we	O
identify	O
a	O
novel	O
mechanism	B-MED
by	O
which	O
drug	B-MED
-	I-MED
target	I-MED
interactions	I-MED
in	O
resistant	B-MED
bacteria	I-MED
can	O
be	O
enhanced	B-MED
.	O
We	O
examined	O
the	O
surface	B-MED
surface	B-MED
forces	B-MED
generated	O
by	O
four	O
antibiotics	B-MED
;	O
vancomycin	B-MED
,	O
ristomycin	B-MED
,	O
chloroeremomycin	B-MED
and	O
oritavancin	B-MED
against	O
drug	B-MED
-	I-MED
susceptible	I-MED
and	O
drug	B-MED
-	I-MED
resistant	I-MED
targets	I-MED
on	O
a	O
cantilever	O
and	O
demonstrated	O
significant	B-MED
differences	O
in	O
mechanical	B-MED
response	B-MED
when	O
drug	B-MED
-	I-MED
resistant	I-MED
targets	I-MED
are	O
challenged	O
with	O
different	O
antibiotics	B-MED
although	O
no	O
significant	O
differences	O
were	O
observed	B-MED
when	O
using	O
susceptible	B-MED
targets	I-MED
.	O
Remarkably	O
,	O
the	O
binding	B-MED
affinity	I-MED
for	O
oritavancin	B-MED
against	O
drug	B-MED
-	I-MED
resistant	I-MED
targets	I-MED
(	O
70	O
nM	O
)	O
was	O
found	O
to	O
be	O
11,000	O
times	O
stronger	O
than	O
for	O
vancomycin	B-MED
(	O
800	O
μM	O
)	O
,	O
a	O
powerful	O
antibiotic	B-MED
used	O
as	O
the	O
last	O
resort	B-MED
treatment	I-MED
for	O
streptococcal	B-MED
and	O
staphylococcal	B-MED
bacteria	I-MED
including	O
methicillin	B-MED
-	I-MED
resistant	I-MED
Staphylococcus	I-MED
aureus	I-MED
(	O
MRSA	B-MED
)	O
.	O
Using	O
an	O
exactly	B-MED
solvable	I-MED
model	I-MED
,	O
which	O
takes	O
into	O
account	O
the	O
solvent	B-MED
and	O
membrane	B-MED
effects	B-MED
,	O
we	O
demonstrate	O
that	O
drug	B-MED
-	I-MED
target	I-MED
interactions	I-MED
are	O
strengthened	O
by	O
pronounced	B-MED
polyvalent	I-MED
interactions	I-MED
catalyzed	B-MED
by	O
the	O
surface	B-MED
itself	O
.	O
These	O
findings	O
further	O
enhance	B-MED
our	O
understanding	B-MED
of	O
antibiotic	B-MED
mode	I-MED
of	I-MED
action	I-MED
and	O
will	O
enable	O
development	B-MED
of	O
more	O
effective	O
therapies	B-MED
.	O
A	O
pilot	B-MED
study	I-MED
of	O
intraocular	B-MED
lens	I-MED
explantation	I-MED
in	O
69	O
eyes	B-MED
in	O
Chinese	B-MED
patients	I-MED
To	O
study	O
the	O
effects	O
of	O
intraocular	B-MED
lens	I-MED
(	I-MED
IOL	I-MED
)	I-MED
explantation	I-MED
and	O
demographic	B-MED
characteristics	I-MED
.	O
Retrospective	B-MED
non	B-MED
-	I-MED
comparative	I-MED
case	I-MED
series	I-MED
.	O
Clinical	B-MED
data	I-MED
recorded	O
from	O
patient	B-MED
charts	I-MED
included	O
the	O
following	O
:	O
demographic	B-MED
,	O
preoperative	B-MED
and	O
postoperative	B-MED
characteristics	B-MED
;	O
complications	B-MED
;	O
surgical	B-MED
methods	I-MED
,	O
and	O
changes	O
in	O
visual	B-MED
acuity	I-MED
.	O
A	O
total	O
of	O
69	O
eyes	B-MED
in	O
67	O
Chinese	B-MED
patients	B-MED
who	O
received	O
IOL	B-MED
explants	I-MED
were	O
studied	O
.	O
The	O
patients	B-MED
'	O
mean	O
age	B-MED
at	O
the	O
time	B-MED
of	I-MED
explantation	I-MED
was	O
46.1	O
years	O
old	O
[	O
SD	O
22.5	O
(	O
6	O
-	O
85	O
)	O
]	O
,	O
and	O
37	O
patients	B-MED
were	I-MED
female	I-MED
(	O
55.2	O
%	O
)	O
.	O
Regarding	O
employment	B-MED
,	O
47.8	O
%	O
were	O
farmers	B-MED
,	O
23.9	O
%	O
were	O
retired	B-MED
,	O
16.4	O
%	O
were	O
students	B-MED
,	O
4.5	O
%	O
were	O
unemployed	B-MED
,	O
3	O
%	O
were	O
workers	B-MED
,	O
and	O
4.5	O
%	O
were	O
other	O
(	O
including	O
staff	B-MED
members	I-MED
,	O
teachers	B-MED
and	O
officers	B-MED
)	O
.	O
The	O
main	O
reasons	O
for	O
explantation	B-MED
were	O
dislocation	B-MED
/	O
decentration	B-MED
in	O
41	O
cases	O
(	O
59.4	O
%	O
)	O
and	O
retinal	B-MED
detachment	I-MED
in	O
10	O
cases	O
(	O
14.5	O
%	O
)	O
.	O
The	O
third	O
most	O
prevalent	B-MED
cause	I-MED
was	O
incorrect	B-MED
lens	I-MED
power	I-MED
in	O
7	O
eyes	B-MED
(	O
10.1	O
%	O
)	O
.	O
The	O
remaining	O
reasons	O
were	O
endophthalmitis	B-MED
in	O
6	O
cases	O
(	O
8.7	O
%	O
)	O
,	O
posterior	B-MED
capsular	I-MED
opacity	I-MED
in	O
3	O
eyes	B-MED
(	O
4.3	O
%	O
)	O
,	O
and	O
impacting	B-MED
retinal	B-MED
surgery	I-MED
operation	I-MED
in	O
2	O
cases	O
(	O
2.9	O
%	O
)	O
.	O
The	O
main	O
comorbidities	B-MED
were	O
high	B-MED
myopia	I-MED
in	O
18	O
eyes	B-MED
(	O
26.1	O
%	O
)	O
,	O
trauma	B-MED
in	O
8	O
eyes	B-MED
(	O
11.6	O
%	O
)	O
,	O
retinal	B-MED
detachment	I-MED
in	O
6	O
eyes	B-MED
(	O
8.7	O
%	O
)	O
,	O
congenital	B-MED
cataracts	I-MED
in	O
8	O
eyes	B-MED
(	O
11.6	O
%	O
)	O
,	O
and	O
Marfan	B-MED
's	I-MED
syndrome	I-MED
in	O
2	O
eyes	B-MED
(	O
2.9	O
%	O
)	O
.	O
The	O
mean	B-MED
time	I-MED
from	I-MED
implantation	I-MED
to	I-MED
explantation	I-MED
was	O
4.0y	O
[	O
SD	O
4.2	O
(	O
0.005	O
-	O
15	O
)	O
]	O
.	O
Treatment	B-MED
after	I-MED
explantation	I-MED
included	O
posterior	B-MED
chamber	I-MED
IOL	I-MED
implantation	I-MED
in	O
44	O
eyes	B-MED
(	O
63.8	O
%	O
)	O
and	O
aphakia	B-MED
in	O
25	O
eyes	B-MED
(	O
36.2	O
%	O
)	O
.	O
After	B-MED
surgery	I-MED
,	O
the	O
best	B-MED
corrected	I-MED
visual	I-MED
ability	I-MED
(	O
BCVA	B-MED
)	O
was	O
improved	O
in	O
50	O
cases	O
(	O
72.5	O
%	O
)	O
,	O
including	O
28	O
patients	B-MED
(	O
40.6	O
%	O
)	O
in	O
whom	O
visual	B-MED
ability	I-MED
was	O
improved	O
by	O
more	O
than	O
two	O
lines	O
.	O
Dislocation	B-MED
/	O
decentration	B-MED
is	O
the	O
main	B-MED
cause	I-MED
for	O
explantation	B-MED
,	O
and	O
high	B-MED
myopia	I-MED
is	O
a	O
main	B-MED
risk	I-MED
factor	I-MED
.	O
Posterior	B-MED
chamber	I-MED
IOL	I-MED
implantation	I-MED
remains	O
the	O
most	O
elected	O
treatment	B-MED
after	I-MED
explantation	I-MED
.	O
Whole	B-MED
-	I-MED
body	I-MED
strength	I-MED
training	I-MED
with	O
Huber	B-MED
Motion	I-MED
Lab	I-MED
and	O
traditional	B-MED
strength	I-MED
training	I-MED
in	O
cardiac	B-MED
rehabilitation	I-MED
:	O
A	O
randomized	B-MED
controlled	I-MED
study	I-MED
Isometric	B-MED
strengthening	I-MED
has	O
been	O
rarely	O
studied	O
in	O
patients	B-MED
with	O
coronary	B-MED
heart	I-MED
disease	I-MED
(	O
CHD	B-MED
)	O
,	O
mainly	O
because	O
of	O
possible	O
potential	B-MED
side	I-MED
effects	I-MED
and	O
lack	B-MED
of	O
appropriate	B-MED
and	O
reliable	B-MED
devices	B-MED
.	O
We	O
aimed	O
to	O
compare	O
2	O
different	O
modes	B-MED
of	O
resistance	B-MED
training	I-MED
,	O
an	O
isometric	O
mode	B-MED
with	O
the	O
Huber	B-MED
Motion	I-MED
Lab	I-MED
(	O
HML	B-MED
)	O
and	O
traditional	B-MED
strength	I-MED
training	I-MED
(	O
TST	B-MED
)	O
,	O
in	O
CHD	B-MED
patients	B-MED
undergoing	O
a	O
cardiac	B-MED
rehabilitation	I-MED
program	O
.	O
We	O
randomly	O
assigned	O
50	O
patients	B-MED
to	O
HML	B-MED
or	O
TST	B-MED
.	O
Patients	B-MED
underwent	O
complete	O
blinded	B-MED
evaluation	B-MED
before	O
and	O
after	O
the	O
rehabilitation	B-MED
program	I-MED
,	O
including	O
testing	B-MED
for	I-MED
cardiopulmonary	I-MED
exercise	I-MED
,	O
maximal	B-MED
isometric	I-MED
voluntary	I-MED
contraction	I-MED
,	O
endothelial	B-MED
function	B-MED
and	O
body	B-MED
composition	I-MED
.	O
After	O
4	O
weeks	B-MED
of	O
training	B-MED
(	O
16	O
sessions	O
)	O
,	O
the	O
groups	B-MED
did	O
not	O
differ	O
in	O
body	B-MED
composition	I-MED
,	O
anthropometric	B-MED
characteristics	B-MED
,	O
or	O
endothelial	B-MED
function	B-MED
.	O
With	O
HML	B-MED
,	O
peak	B-MED
power	B-MED
output	I-MED
(	O
P=0.035	O
)	O
,	O
maximal	B-MED
heart	B-MED
rate	I-MED
(	O
P<0.01	O
)	O
and	O
gain	B-MED
of	O
force	B-MED
measured	B-MED
in	O
the	O
chest	O
press	O
position	O
(	O
P<0.02	O
)	O
were	O
greater	B-MED
after	O
versus	O
before	O
training	B-MED
.	O
Both	O
protocols	B-MED
appeared	O
to	O
be	O
well	O
tolerated	O
,	O
safe	O
and	O
feasible	O
for	O
these	O
CHD	B-MED
patients	B-MED
.	O
A	O
training	B-MED
protocol	I-MED
involving	O
6s	O
phases	O
of	O
isometric	B-MED
contractions	I-MED
with	O
10s	O
of	O
passive	B-MED
recovery	B-MED
on	O
an	O
HML	B-MED
device	O
could	O
be	O
safely	O
implemented	O
in	O
rehabilitation	B-MED
programs	I-MED
for	O
patients	B-MED
with	O
CHD	B-MED
and	O
improve	O
functional	B-MED
outcomes	I-MED
.	O
Adequacy	B-MED
criteria	B-MED
for	O
thyroid	B-MED
FNA	I-MED
evaluated	B-MED
by	O
ThinPrep	B-MED
slides	I-MED
only	O
Adequacy	B-MED
criteria	B-MED
for	O
thyroid	B-MED
fine	I-MED
-	I-MED
needle	I-MED
aspiration	I-MED
(	O
FNA	B-MED
)	O
recommended	B-MED
by	O
The	O
Bethesda	B-MED
System	I-MED
for	I-MED
Reporting	I-MED
Thyroid	I-MED
Cytopathology	I-MED
(	O
TBS	B-MED
)	O
were	O
developed	O
with	O
smears	B-MED
,	O
but	O
they	O
are	O
commonly	O
applied	B-MED
to	O
ThinPreps	B-MED
(	O
TPs	B-MED
)	O
.	O
This	O
study	O
evaluated	B-MED
adequacy	B-MED
in	O
TPs	B-MED
at	O
different	O
diagnostic	B-MED
thresholds	B-MED
.	O
All	O
FNA	B-MED
procedures	I-MED
performed	B-MED
between	O
2010	O
and	O
2015	O
with	O
matched	B-MED
surgical	B-MED
specimens	I-MED
were	O
analyzed	B-MED
.	O
Cell	B-MED
counts	I-MED
and	O
cytological	B-MED
features	B-MED
were	O
evaluated	B-MED
in	O
all	O
initially	O
nondiagnostic	B-MED
(	O
ND	B-MED
)	O
cases	B-MED
.	O
ND	B-MED
cases	B-MED
were	O
reclassified	B-MED
into	O
TBS	B-MED
categories	B-MED
by	O
2	O
pathologists	B-MED
,	O
and	O
the	O
results	B-MED
were	O
compared	B-MED
with	O
surgical	B-MED
outcomes	I-MED
.	O
One	O
hundred	B-MED
forty	I-MED
-	I-MED
six	I-MED
of	O
the	O
151	O
cases	B-MED
initially	O
classified	B-MED
as	O
ND	B-MED
were	O
available	B-MED
for	O
review	B-MED
,	O
and	O
they	O
had	O
a	O
mean	B-MED
cell	B-MED
count	I-MED
of	O
60.5	O
(	O
standard	B-MED
deviation	I-MED
,	O
71.4	O
)	O
.	O
Interobserver	B-MED
agreement	I-MED
on	O
the	O
reclassification	B-MED
of	O
ND	B-MED
cases	B-MED
was	O
moderate	B-MED
(	O
k	O
=	O
0.57	O
)	O
,	O
and	O
consensus	B-MED
yielded	B-MED
48	O
ND	B-MED
cases	B-MED
(	O
33	O
%	O
)	O
,	O
72	O
benign	B-MED
cases	B-MED
(	O
49	O
%	O
)	O
,	O
24	O
cases	B-MED
of	O
atypia	B-MED
of	O
undetermined	B-MED
significance	I-MED
(	O
16	O
%	O
)	O
,	O
and	O
2	O
cases	B-MED
suspicious	B-MED
for	I-MED
malignancy	I-MED
(	O
1	O
%	O
)	O
.	O
Lowering	B-MED
the	O
diagnostic	B-MED
threshold	B-MED
to	O
any	O
follicular	B-MED
cells	B-MED
yielded	B-MED
a	O
sensitivity	B-MED
of	O
92	O
%	O
,	O
a	O
specificity	B-MED
of	O
60	O
%	O
,	O
a	O
positive	B-MED
predictive	I-MED
value	I-MED
of	O
59	O
%	O
,	O
a	O
negative	B-MED
predictive	I-MED
value	I-MED
of	O
92	O
%	O
,	O
and	O
a	O
false	B-MED
-	I-MED
negative	I-MED
rate	B-MED
of	O
7.7	O
%	O
,	O
whereas	O
the	O
values	O
for	O
the	O
initially	O
diagnostic	B-MED
cases	B-MED
were	O
93	O
%	O
,	O
58	O
%	O
,	O
59	O
%	O
,	O
93	O
%	O
,	O
and	O
7.7	O
%	O
,	O
respectively	O
.	O
Including	O
cases	B-MED
with	O
>	O
60	O
cells	B-MED
but	O
lacking	B-MED
6	O
groups	B-MED
containing	B-MED
at	O
least	O
10	O
cells	B-MED
did	O
not	O
affect	O
test	B-MED
performance	I-MED
.	O
Nuclear	B-MED
enlargement	I-MED
,	O
pallor	B-MED
,	O
grooves	B-MED
,	O
and	O
the	O
presence	B-MED
of	O
histiocytoid	B-MED
cells	I-MED
in	O
initially	O
ND	B-MED
FNA	B-MED
correlated	B-MED
with	O
malignancy	B-MED
.	O
In	O
thyroid	B-MED
FNA	I-MED
examined	B-MED
with	O
TP	B-MED
only	O
,	O
lowering	B-MED
the	O
adequacy	B-MED
threshold	B-MED
and	O
eliminating	O
the	O
requirement	B-MED
of	O
6	O
groups	B-MED
of	O
at	O
least	O
10	O
cells	B-MED
did	O
not	O
significantly	B-MED
affect	O
test	B-MED
performance	I-MED
if	O
cytological	B-MED
features	B-MED
associated	B-MED
with	I-MED
malignancy	B-MED
were	O
absent	B-MED
.	O
Cancer	O
Cytopathol	O
2017	O
.	O
©	O
2017	O
American	O
Cancer	O
Society	O
.	O
Collecting	B-MED
and	O
Reporting	B-MED
Safety	I-MED
Data	I-MED
and	O
Monitoring	B-MED
Trial	I-MED
Conduct	I-MED
In	O
Pragmatic	B-MED
Trials	I-MED
Pragmatic	B-MED
trials	I-MED
offer	O
the	O
opportunity	B-MED
to	O
obtain	O
real	B-MED
-	I-MED
life	I-MED
data	B-MED
on	O
the	O
relative	O
effectiveness	B-MED
and	O
safety	B-MED
of	O
a	O
treatment	B-MED
before	O
or	O
after	O
market	B-MED
authorisation	I-MED
.	O
This	O
is	O
the	O
penultimate	B-MED
paper	I-MED
in	O
a	O
series	O
of	O
eight	O
,	O
describing	O
the	O
impact	O
of	O
design	B-MED
choices	B-MED
on	O
the	O
practical	O
implementation	B-MED
of	O
pragmatic	B-MED
trials	I-MED
.	O
This	O
paper	B-MED
focuses	O
on	O
the	O
practical	O
challenges	O
of	O
collecting	B-MED
and	O
reporting	B-MED
safety	I-MED
data	I-MED
and	O
of	O
monitoring	B-MED
trial	I-MED
conduct	I-MED
while	O
maintaining	O
routine	O
clinical	B-MED
care	I-MED
practice	I-MED
.	O
Current	O
ICH	B-MED
guidance	O
recommends	O
that	O
,	O
all	O
serious	B-MED
adverse	I-MED
events	I-MED
(	O
SAEs	B-MED
)	O
and	O
all	O
drug	B-MED
-related	O
events	O
must	O
be	O
reported	O
in	O
an	O
interventional	B-MED
trial	B-MED
.	O
In	O
line	O
with	O
current	O
guidance	O
,	O
we	O
propose	O
a	O
risk	B-MED
based	O
approach	B-MED
to	O
the	O
collection	B-MED
of	O
non	B-MED
-	O
drug	B-MED
related	O
non	B-MED
-	I-MED
serious	I-MED
AEs	I-MED
,	O
and	O
even	O
serious	B-MED
events	I-MED
not	O
related	O
to	O
treatment	B-MED
based	O
on	O
the	O
risk	B-MED
profile	B-MED
of	O
the	O
medicine	B-MED
/class	O
in	O
the	O
patient	B-MED
population	B-MED
of	O
interest	O
.	O
Different	O
options	O
available	O
to	O
support	O
the	O
collection	B-MED
and	O
reporting	B-MED
of	I-MED
safety	I-MED
data	I-MED
whilst	O
minimizing	O
study	B-MED
-related	O
follow	B-MED
-	I-MED
up	I-MED
visits	I-MED
are	O
discussed	O
.	O
A	O
risk	B-MED
-based	O
approach	B-MED
to	O
monitoring	B-MED
trial	I-MED
conduct	I-MED
is	O
also	O
discussed	O
,	O
highlighting	O
the	O
difference	O
in	O
the	O
balance	O
of	O
risks	B-MED
likely	O
to	O
occur	O
in	O
a	O
pragmatic	B-MED
trial	I-MED
compared	O
to	O
traditional	O
clinical	B-MED
trials	I-MED
,	O
and	O
the	O
careful	O
consideration	O
that	O
must	O
be	O
given	O
to	O
the	O
mitigation	B-MED
and	O
management	B-MED
of	I-MED
these	I-MED
risks	I-MED
in	O
order	O
to	O
maintain	O
routine	O
care	B-MED
.	O
Improvement	B-MED
of	O
older	B-MED
-	O
person	B-MED
-	O
specific	B-MED
QOL	B-MED
after	O
hearing	B-MED
aid	I-MED
fitting	B-MED
and	O
its	O
relation	B-MED
to	O
social	B-MED
interaction	I-MED
This	O
study	B-MED
aimed	B-MED
to	O
investigate	B-MED
whether	O
hearing	B-MED
aids	I-MED
use	O
is	O
associated	B-MED
with	I-MED
improvement	B-MED
of	O
older	B-MED
-	O
person	B-MED
-	O
specific	B-MED
QOL	B-MED
and	O
whether	O
social	B-MED
interactions	I-MED
modify	B-MED
the	O
association	B-MED
.	O
The	O
WHOQOL	B-MED
-	I-MED
OLD	I-MED
questionnaire	I-MED
was	O
answered	B-MED
by	O
105	O
older	B-MED
adults	I-MED
aged	B-MED
60	O
to	O
90	O
years	O
who	O
were	O
newly	B-MED
fitted	B-MED
hearing	B-MED
aids	I-MED
on	O
the	O
day	O
of	O
fitting	B-MED
and	O
at	O
2	O
-	O
6	O
months	O
afterward	B-MED
.	O
The	O
associations	B-MED
between	O
the	O
daily	O
hours	O
of	O
hearing	B-MED
aid	I-MED
usage	B-MED
and	O
social	B-MED
relations	I-MED
with	O
changes	B-MED
in	O
the	O
WHOQOL	B-MED
-	I-MED
OLD	I-MED
total	B-MED
score	I-MED
after	O
hearing	B-MED
aids	I-MED
fitting	B-MED
were	O
estimated	B-MED
adjusting	B-MED
for	O
possible	B-MED
confounders	B-MED
.	O
Older	B-MED
persons	B-MED
with	O
hearing	B-MED
loss	I-MED
experienced	B-MED
significant	B-MED
increases	B-MED
in	O
WHOQOL	B-MED
-	I-MED
OLD	I-MED
total	B-MED
score	I-MED
after	O
hearing	B-MED
aid	I-MED
fitting	B-MED
.	O
Regular	B-MED
use	B-MED
of	I-MED
hearing	B-MED
aid	I-MED
was	O
associated	B-MED
with	I-MED
a	O
greater	B-MED
increase	B-MED
in	O
the	O
total	B-MED
score	I-MED
.	O
The	O
combined	B-MED
categorical	B-MED
variable	B-MED
of	O
social	B-MED
relations	I-MED
and	O
hearing	B-MED
aid	I-MED
usage	B-MED
revealed	B-MED
no	O
separate	B-MED
effects	B-MED
of	O
these	O
two	O
variables	B-MED
,	O
but	O
a	O
combined	B-MED
effect	B-MED
;	O
only	O
those	O
with	O
frequent	B-MED
social	B-MED
interactions	I-MED
who	O
used	O
their	O
hearing	B-MED
aid	I-MED
regularly	B-MED
had	O
a	O
significantly	B-MED
greater	B-MED
increase	B-MED
in	O
WHOQOL	B-MED
-	I-MED
OLD	I-MED
total	B-MED
score	I-MED
.	O
This	O
study	B-MED
's	I-MED
findings	B-MED
indicate	B-MED
that	O
hearing	B-MED
aid	I-MED
fitting	B-MED
may	O
be	O
associated	B-MED
with	I-MED
a	O
subsequent	B-MED
improvement	B-MED
in	O
older	B-MED
-	O
person	B-MED
-	O
specific	B-MED
QOL	B-MED
by	O
improvements	B-MED
in	O
hearing	B-MED
due	O
to	O
the	O
hearing	B-MED
aid	I-MED
,	O
and	O
possibly	B-MED
enhanced	B-MED
communication	B-MED
opportunities	B-MED
.	O
Effects	B-MED
of	O
Environmental	B-MED
Factors	B-MED
and	O
Metallic	B-MED
Electrodes	B-MED
on	O
AC	B-MED
Electrical	B-MED
Conduction	I-MED
Through	O
DNA	B-MED
Molecule	I-MED
Deoxyribonucleic	B-MED
acid	I-MED
(	I-MED
DNA	I-MED
)	I-MED
is	O
one	O
of	O
the	O
best	O
candidate	O
materials	O
for	O
various	O
device	B-MED
applications	B-MED
such	O
as	O
in	O
electrodes	B-MED
for	O
rechargeable	B-MED
batteries	I-MED
,	O
biosensors	B-MED
,	O
molecular	B-MED
electronics	I-MED
,	O
medical	B-MED
-	O
and	O
biomedical	B-MED
-	O
applications	B-MED
etc	O
.	O
Hence	O
,	O
it	O
is	O
worthwhile	O
to	O
examine	O
the	O
mechanism	O
of	O
charge	B-MED
transport	I-MED
in	O
the	O
DNA	B-MED
molecule	I-MED
,	O
however	O
,	O
still	O
a	O
question	O
without	O
a	O
clear	O
answer	O
is	O
DNA	B-MED
a	O
molecular	B-MED
conducting	B-MED
material	B-MED
(	O
wire	B-MED
)	O
,	O
semiconductor	B-MED
,	O
or	O
insulator	B-MED
?	O
The	O
answer	O
,	O
after	O
the	O
published	O
data	O
,	O
is	O
still	O
ambiguous	O
without	O
any	O
confirmed	O
and	O
clear	O
scientific	O
answer	O
.	O
DNA	B-MED
is	O
found	O
to	O
be	O
always	O
surrounded	O
with	O
different	O
electric	B-MED
charges	I-MED
,	O
ions	B-MED
,	O
and	O
dipoles	B-MED
.	O
These	O
surrounding	O
charges	B-MED
and	O
electric	B-MED
barrier(s	I-MED
)	I-MED
due	O
to	O
metallic	B-MED
electrodes	B-MED
(	O
as	O
environmental	B-MED
factors	B-MED
(	O
EFs	B-MED
)	O
)	O
play	O
a	O
substantial	O
role	O
when	O
measuring	B-MED
measuring	B-MED
the	O
electrical	B-MED
conductivity	I-MED
through	O
λ	B-MED
-	I-MED
double	I-MED
helix	I-MED
(	I-MED
DNA	I-MED
)	I-MED
molecule	I-MED
suspended	O
between	O
metallic	B-MED
electrodes	B-MED
.	O
We	O
found	O
that	O
strong	B-MED
frequency	B-MED
dependence	O
of	O
AC	B-MED
-	O
complex	B-MED
conductivity	B-MED
comes	O
from	O
the	O
electrical	B-MED
conduction	I-MED
of	O
EFs	B-MED
.	O
This	O
leads	O
to	O
superimposing	O
serious	O
incorrect	O
experimental	B-MED
data	O
to	O
measured	B-MED
ones	O
.	O
At	O
1	O
MHz	O
,	O
we	O
carried	O
out	O
a	O
first	O
control	O
experiment	B-MED
on	O
electrical	B-MED
conductivity	I-MED
with	O
and	O
without	O
the	O
presence	O
of	O
DNA	B-MED
molecule	I-MED
.	O
If	O
there	O
are	O
possible	O
electrical	B-MED
conduction	I-MED
due	O
to	O
stray	O
ions	B-MED
and	O
contribution	O
of	O
substrate	O
,	O
we	O
will	O
detected	O
them	O
.	O
This	O
control	O
experiment	B-MED
revealed	O
that	O
there	O
is	O
an	O
important	O
role	O
played	O
by	O
the	O
environmental	B-MED
-	O
charges	B-MED
around	O
DNA	B-MED
molecule	I-MED
and	O
any	O
experiment	B-MED
should	O
consider	O
this	O
role	O
.	O
We	O
have	O
succeeded	O
to	O
measure	B-MED
both	O
electrical	B-MED
conductivity	I-MED
due	O
to	O
EFs	B-MED
(	O
σ	O
ENV	O
)	O
and	O
electrical	B-MED
conductivity	I-MED
due	O
to	O
DNA	B-MED
molecule	I-MED
(	O
σ	B-MED
DNA	I-MED
)	O
independently	O
by	O
carrying	O
the	O
measurements	B-MED
at	O
different	O
DNA	B-MED
-	O
lengths	B-MED
and	O
subtracting	O
the	O
data	O
.	O
We	O
carried	O
out	O
measurements	B-MED
as	O
a	O
function	O
of	O
frequency	B-MED
(	I-MED
f	I-MED
)	I-MED
and	O
temperature	B-MED
(	I-MED
T	I-MED
)	I-MED
in	O
the	O
ranges	O
0.1	O
Hz	O
<	O
f	O
<	O
1	O
MHz	O
and	O
288	O
K	O
<	O
T	O
<	O
343	O
K.	O
The	O
measured	B-MED
conductivity	B-MED
(	O
σ	O
MES	O
)	O
portrays	O
a	O
metal	B-MED
-like	O
behavior	O
at	O
high	B-MED
frequencies	I-MED
near	O
1	O
MHz	O
.	O
However	O
,	O
we	O
found	O
that	O
σ	B-MED
DNA	I-MED
was	O
far	O
from	O
this	O
behavior	O
because	O
the	O
conduction	B-MED
due	O
to	O
EFs	B-MED
superimposes	O
σ	B-MED
DNA	I-MED
,	O
in	O
particular	O
at	O
low	B-MED
frequencies	I-MED
.	O
By	O
measuring	B-MED
the	O
electrical	B-MED
conductivity	I-MED
at	O
different	O
lengths	B-MED
:	O
40	O
,	O
60	O
,	O
80	O
,	O
and	O
100	O
nm	O
,	O
we	O
have	O
succeeded	O
not	O
only	O
to	O
separate	O
the	O
electrical	B-MED
conduction	I-MED
of	O
the	O
DNA	B-MED
molecule	I-MED
from	O
all	O
EFs	B-MED
effects	O
that	O
surround	O
the	O
molecule	B-MED
,	O
but	O
also	O
to	O
present	O
accurate	O
values	O
of	O
σ	B-MED
DNA	I-MED
and	O
the	O
dielectric	B-MED
constant	I-MED
of	O
the	O
molecule	O
ε'DNA	B-MED
as	O
a	O
function	O
of	O
temperature	O
and	O
frequency	O
.	O
Furthermore	O
,	O
in	O
order	O
to	O
explain	O
these	O
data	O
,	O
we	O
present	O
a	O
model	O
describing	O
the	O
electrical	B-MED
conduction	I-MED
through	O
DNA	B-MED
molecule	I-MED
:	O
DNA	B-MED
is	O
a	O
classical	O
semiconductor	B-MED
with	O
charges	B-MED
,	O
dipoles	B-MED
and	O
ions	B-MED
that	O
result	O
in	O
creation	O
of	O
localized	B-MED
energy	B-MED
-	O
states	B-MED
(	O
LESs	O
)	O
in	O
the	O
extended	O
bands	O
and	O
in	O
the	O
energy	B-MED
gap	I-MED
of	O
the	O
DNA	B-MED
molecule	I-MED
.	O
This	O
model	O
explains	O
clearly	O
the	O
mechanism	O
of	O
charge	B-MED
transfer	I-MED
mechanism	I-MED
in	O
the	O
DNA	B-MED
,	O
and	O
it	O
sheds	O
light	O
on	O
why	O
the	O
charge	B-MED
transfer	I-MED
through	O
the	O
DNA	B-MED
can	O
lead	O
to	O
insulating	B-MED
,	O
semiconducting	B-MED
,	O
or	O
metallic	B-MED
behavior	O
on	O
the	O
same	O
time	O
.	O
The	O
model	O
considers	O
charges	B-MED
on	O
DNA	B-MED
,	O
in	O
the	O
extended	O
bands	O
,	O
either	O
could	O
be	O
free	O
to	O
move	O
under	O
electric	B-MED
field	I-MED
or	O
localized	O
in	O
potential	B-MED
wells	I-MED
/	I-MED
hills	I-MED
.	O
Localization	B-MED
of	O
charges	B-MED
in	O
DNA	B-MED
is	O
an	O
intrinsic	B-MED
structural	B-MED
-	O
property	B-MED
of	O
this	O
solitaire	O
molecule	O
.	O
At	O
all	O
temperatures	O
,	O
the	O
expected	O
increase	O
in	O
thermal	B-MED
-	O
induced	B-MED
charge	B-MED
is	O
attributed	O
to	O
the	O
delocalization	B-MED
of	I-MED
holes	I-MED
(	O
or	O
/	O
and	O
electrons	B-MED
)	O
in	O
potential	B-MED
hills	I-MED
(	O
or	O
/	O
and	O
potential	B-MED
wells	I-MED
)	I-MED
which	O
accurately	O
accounts	O
for	O
the	O
total	O
electric	B-MED
and	O
dielectric	B-MED
behavior	I-MED
through	O
DNA	B-MED
molecule	I-MED
.	O
We	O
succeeded	O
to	O
fit	O
the	O
experiment	B-MED
al	O
data	O
to	O
the	O
proposed	O
model	O
with	O
reasonable	O
magnitudes	O
of	O
potential	B-MED
hills	I-MED
/	I-MED
wells	I-MED
that	O
are	O
in	O
the	O
energy	B-MED
range	O
from	O
0.068	O
eV.	O
Cross	O
-	O
Species	O
Rhesus	B-MED
Cytomegalovirus	B-MED
Infection	I-MED
of	O
Cynomolgus	B-MED
Macaques	I-MED
Cytomegaloviruses	B-MED
(	O
CMV	B-MED
)	O
are	O
highly	O
species	O
-	O
specific	O
due	O
to	O
millennia	O
of	O
co	B-MED
-	I-MED
evolution	I-MED
and	O
adaptation	B-MED
to	O
their	O
host	B-MED
,	O
with	O
no	O
successful	O
experimental	O
cross-	O
species	B-MED
infection	B-MED
in	O
primates	B-MED
reported	O
to	O
date	O
.	O
Accordingly	O
,	O
full	O
genome	B-MED
phylogenetic	B-MED
analysis	I-MED
of	O
multiple	O
new	O
CMV	B-MED
field	O
isolates	B-MED
derived	O
from	O
two	O
closely	O
related	O
nonhuman	B-MED
primate	I-MED
species	B-MED
,	O
Indian	B-MED
-	I-MED
origin	I-MED
rhesus	B-MED
macaques	I-MED
(	O
RM	B-MED
)	O
and	O
Mauritian	B-MED
-origin	O
cynomolgus	B-MED
macaques	I-MED
(	O
MCM	B-MED
)	O
,	O
revealed	O
distinct	O
and	O
tight	O
lineage	B-MED
clustering	O
according	O
to	O
the	O
species	B-MED
of	I-MED
origin	I-MED
,	O
with	O
MCM	B-MED
CMV	B-MED
isolates	B-MED
mirroring	O
the	O
limited	O
genetic	B-MED
diversity	I-MED
of	O
their	O
primate	B-MED
host	B-MED
that	O
underwent	O
a	O
population	O
bottleneck	O
400	O
years	O
ago	O
.	O
Despite	O
the	O
ability	B-MED
of	O
Rhesus	B-MED
CMV	B-MED
(	O
RhCMV	B-MED
)	O
laboratory	B-MED
strain	I-MED
68	O
-	O
1	O
to	O
replicate	B-MED
efficiently	O
in	O
MCM	B-MED
fibroblasts	B-MED
and	O
potently	O
inhibit	B-MED
antigen	I-MED
presentation	I-MED
to	O
MCM	B-MED
T	B-MED
cells	I-MED
in	B-MED
vitro	I-MED
,	O
RhCMV	B-MED
68	O
-	O
1	O
failed	O
to	O
productively	O
infect	B-MED
MCM	B-MED
in	B-MED
vivo	I-MED
,	O
even	O
in	O
the	O
absence	O
of	O
host	B-MED
CD8	B-MED
+	I-MED
T	I-MED
and	O
NK	B-MED
cells	I-MED
.	O
In	O
contrast	O
,	O
RhCMV	B-MED
clone	B-MED
68	O
-	O
1.2	O
,	O
genetically	B-MED
repaired	B-MED
to	O
express	B-MED
the	O
homologues	B-MED
of	O
the	O
HCMV	B-MED
anti	B-MED
-	I-MED
apoptosis	I-MED
gene	B-MED
UL36	I-MED
and	O
epithelial	B-MED
cell	I-MED
tropism	I-MED
genes	B-MED
UL128	I-MED
and	O
UL130	B-MED
absent	O
in	O
68	O
-	O
1	O
,	O
efficiently	O
infected	B-MED
MCM	B-MED
as	O
evidenced	O
by	O
the	O
induction	B-MED
of	O
transgene	B-MED
-specific	O
T	B-MED
cells	I-MED
and	O
virus	B-MED
shedding	I-MED
.	O
Recombinant	B-MED
variants	I-MED
of	O
RhCMV	B-MED
68	O
-	O
1	O
and	O
68	O
-	O
1.2	O
revealed	O
that	O
expression	B-MED
of	O
either	O
UL36	B-MED
or	O
UL128	B-MED
together	O
with	O
UL130	B-MED
enabled	O
productive	O
MCM	B-MED
infection	B-MED
,	O
indicating	O
that	O
multiple	O
layers	O
of	O
cross-	O
species	B-MED
restriction	B-MED
operate	O
even	O
between	O
closely	O
related	O
hosts	B-MED
.	O
Cumulatively	O
,	O
these	O
results	O
implicate	O
cell	B-MED
tropism	I-MED
and	O
evasion	O
of	O
apoptosis	B-MED
as	O
critical	O
determinants	B-MED
of	O
CMV	B-MED
transmission	B-MED
across	O
primate	B-MED
species	B-MED
barriers	O
,	O
and	O
extend	O
the	O
macaque	B-MED
model	B-MED
of	O
human	B-MED
CMV	B-MED
infection	B-MED
and	O
immunology	B-MED
to	O
MCM	B-MED
,	O
a	O
nonhuman	B-MED
primate	I-MED
species	B-MED
with	O
uniquely	O
simplified	O
host	B-MED
immunogenetics	B-MED
.	O
In	B-MED
Vivo	I-MED
3	B-MED
-	I-MED
Dimensional	I-MED
Strain	B-MED
Mapping	I-MED
Confirms	B-MED
Large	B-MED
Optic	B-MED
Nerve	I-MED
Head	I-MED
Deformations	B-MED
Following	B-MED
Horizontal	B-MED
Eye	I-MED
Movements	I-MED
To	O
measure	B-MED
lamina	B-MED
cribrosa	I-MED
(	O
LC	B-MED
)	O
strains	B-MED
(	O
deformations	B-MED
)	O
following	B-MED
abduction	B-MED
and	O
adduction	B-MED
in	O
healthy	B-MED
subjects	I-MED
and	O
to	O
compare	B-MED
them	O
with	O
those	O
resulting	B-MED
from	O
a	O
relatively	B-MED
high	B-MED
acute	B-MED
intraocular	B-MED
pressure	I-MED
(	O
IOP	B-MED
)	O
elevation	B-MED
.	O
A	O
total	B-MED
of	O
16	O
eyes	B-MED
from	O
8	O
healthy	B-MED
subjects	I-MED
were	O
included	B-MED
.	O
Among	O
the	O
16	O
eyes	B-MED
,	O
11	O
had	O
peripapillary	B-MED
atrophy	I-MED
(	O
PPA	B-MED
)	O
.	O
For	O
each	B-MED
subject	B-MED
,	O
both	O
optic	B-MED
nerve	I-MED
heads	I-MED
(	O
ONHs	B-MED
)	O
were	O
imaged	B-MED
using	O
optical	B-MED
coherence	I-MED
tomography	I-MED
(	O
OCT	B-MED
)	O
at	O
baseline	B-MED
(	O
twice	B-MED
)	O
,	O
in	O
different	B-MED
gaze	B-MED
positions	B-MED
(	O
adduction	B-MED
and	O
abduction	B-MED
of	O
20	O
°	O
)	O
and	O
following	B-MED
an	O
acute	B-MED
IOP	B-MED
elevation	B-MED
of	O
approximately	B-MED
20	O
mm	O
Hg	B-MED
from	O
baseline	B-MED
(	O
via	O
ophthalmodynamometry	B-MED
)	O
.	O
Strains	B-MED
of	O
LC	B-MED
for	O
all	O
loading	B-MED
scenarios	I-MED
were	O
mapped	B-MED
using	O
a	O
three	B-MED
-	I-MED
dimensional	I-MED
tracking	B-MED
algorithm	B-MED
.	O
In	O
all	O
16	O
eyes	B-MED
,	O
LC	B-MED
strains	B-MED
induced	B-MED
by	O
adduction	B-MED
and	O
abduction	B-MED
were	O
5.83	O
%	O
±	O
3.78	O
%	O
and	O
3.93	O
%	O
±	O
2.57	O
%	O
,	O
respectively	O
,	O
and	O
both	O
significantly	B-MED
higher	I-MED
than	O
the	O
control	B-MED
strains	B-MED
measured	B-MED
from	O
the	O
repeated	B-MED
baseline	B-MED
acquisitions	B-MED
(	O
P	O
<	O
0.01	O
)	O
.	O
Strains	B-MED
of	O
LC	B-MED
in	O
adduction	B-MED
were	O
on	O
average	B-MED
higher	B-MED
than	O
those	O
in	O
abduction	B-MED
,	O
but	O
the	O
difference	B-MED
was	O
not	O
statistically	B-MED
significant	I-MED
(	O
P	O
=	O
0.07	O
)	O
.	O
Strains	B-MED
of	O
LC	B-MED
induced	B-MED
by	O
IOP	B-MED
elevations	B-MED
(	O
on	O
average	B-MED
21.13	O
±	O
7.61	O
mm	O
Hg	B-MED
)	O
were	O
6.41	O
%	O
±	O
3.21	O
%	O
and	O
significantly	B-MED
higher	I-MED
than	O
the	O
control	B-MED
strains	B-MED
(	O
P	O
<	O
0.0005	O
)	O
.	O
Gaze	B-MED
-	O
induced	B-MED
LC	B-MED
strains	B-MED
in	O
the	O
PPA	B-MED
group	B-MED
were	O
on	O
average	B-MED
larger	B-MED
than	O
those	O
in	O
the	O
non	B-MED
-	I-MED
PPA	I-MED
group	I-MED
;	O
however	O
,	O
the	O
relationship	B-MED
was	O
not	O
statistically	B-MED
significant	I-MED
.	O
Our	O
results	B-MED
confirm	B-MED
that	O
horizontal	B-MED
eye	I-MED
movements	I-MED
generate	B-MED
significant	B-MED
ONH	B-MED
strains	B-MED
,	O
which	O
is	O
consistent	B-MED
with	I-MED
our	O
previous	B-MED
estimations	B-MED
using	O
finite	B-MED
element	I-MED
analysis	I-MED
.	O
Further	B-MED
studies	I-MED
are	O
needed	O
to	O
explore	O
a	O
possible	B-MED
link	O
between	O
ONH	B-MED
strains	B-MED
induced	B-MED
by	O
eye	B-MED
movements	I-MED
and	O
axonal	B-MED
loss	I-MED
in	O
optic	B-MED
neuropathies	I-MED
.	O
Heterogeneous	B-MED
depression	B-MED
trajectories	B-MED
in	O
multiple	B-MED
sclerosis	I-MED
patients	B-MED
Trajectories	B-MED
of	O
depression	B-MED
over	O
time	O
may	O
be	O
heterogeneous	B-MED
in	O
Multiple	B-MED
Sclerosis	I-MED
(	O
MS	B-MED
)	O
patients	B-MED
.	O
Describing	O
these	O
trajectories	B-MED
will	O
help	O
clinicians	B-MED
understand	O
better	O
the	O
progression	B-MED
of	O
depression	B-MED
in	O
MS	B-MED
patients	B-MED
to	O
aid	O
in	O
patient	O
care	O
decisions	O
.	O
Latent	B-MED
class	I-MED
growth	I-MED
analysis	I-MED
(	O
LCGA	B-MED
)	O
was	O
applied	O
to	O
3507	O
MS	B-MED
patients	B-MED
using	O
an	O
electronic	B-MED
health	I-MED
records	I-MED
(	I-MED
EHR	I-MED
)	I-MED
data	I-MED
base	I-MED
to	O
identify	O
subgroups	B-MED
of	O
MS	B-MED
patients	B-MED
based	O
on	O
self	O
-	O
reported	O
depression	B-MED
screening	I-MED
(	O
PHQ-9	B-MED
)	O
.	O
Latent	B-MED
trajectory	B-MED
classes	O
were	O
used	O
for	O
group	B-MED
comparisons	O
based	O
on	O
baseline	B-MED
clinical	B-MED
characteristics	I-MED
.	O
Three	O
subgroups	B-MED
were	O
found	O
characterized	O
by	O
high	B-MED
(	O
10.0	O
%	O
[	O
of	O
participants	B-MED
]	O
)	O
,	O
wavering	O
above	O
and	O
below	O
moderate	B-MED
(	O
26.2	O
%	O
)	O
and	O
low	B-MED
and	O
variable	B-MED
(	O
63.8	O
%	O
)	O
depression	B-MED
level	I-MED
trajectories	B-MED
.	O
The	O
subpopulation	B-MED
trajectories	B-MED
,	O
respectively	O
,	O
were	O
also	O
characterized	O
by	O
high	B-MED
,	O
moderate	B-MED
and	O
low	B-MED
MS	B-MED
disability	B-MED
at	O
baseline	B-MED
.	O
In	O
contrast	O
,	O
the	O
overall	O
average	O
trajectory	B-MED
was	O
slightly	O
declining	O
and	O
below	O
the	O
moderate	B-MED
depression	B-MED
threshold	B-MED
.	O
The	O
LCGA	B-MED
approach	O
described	O
in	O
this	O
paper	O
and	O
applied	O
to	O
MS	B-MED
patients	B-MED
provides	O
a	O
template	B-MED
for	O
improved	O
use	O
of	O
an	O
EHR	B-MED
data	I-MED
base	I-MED
for	O
understanding	O
heterogeneous	B-MED
depression	B-MED
screening	I-MED
trajectories	B-MED
.	O
Clinicians	B-MED
may	O
use	O
such	O
information	B-MED
to	O
more	O
closely	O
monitor	B-MED
patients	I-MED
that	O
are	O
expected	O
to	O
maintain	O
high	B-MED
or	O
unstable	B-MED
depression	B-MED
levels	I-MED
.	O
The	O
PLA2	B-MED
gene	I-MED
mediates	O
the	O
humoral	B-MED
immune	I-MED
responses	I-MED
in	O
Bactrocera	B-MED
dorsalis	I-MED
(	I-MED
Hendel	I-MED
)	I-MED
The	O
phospholipase	B-MED
A2	I-MED
(	I-MED
PLA2	I-MED
)	I-MED
gene	I-MED
encodes	B-MED
the	O
enzyme	B-MED
that	O
catalyzes	B-MED
the	O
hydrolysis	B-MED
of	O
phospholipids	B-MED
(	O
PLs	B-MED
)	O
from	O
the	O
sn-2	B-MED
position	I-MED
.	O
However	O
,	O
little	O
is	O
known	O
about	O
its	O
role	B-MED
in	O
humoral	B-MED
immune	I-MED
responses	I-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
investigated	B-MED
the	O
expression	B-MED
profile	I-MED
of	O
PLA2	B-MED
in	O
different	B-MED
tissues	B-MED
and	O
developmental	B-MED
stages	I-MED
in	O
Bactrocera	B-MED
dorsalis	I-MED
(	I-MED
Hendel	I-MED
)	I-MED
,	O
and	O
the	O
results	O
showed	O
that	O
the	O
transcriptional	B-MED
level	B-MED
of	O
PLA2	B-MED
was	O
high	B-MED
in	O
the	O
egg	B-MED
and	O
mature	B-MED
stage	I-MED
and	O
in	O
the	O
testis	B-MED
tissue	B-MED
.	O
Bacterial	B-MED
infection	I-MED
increased	O
the	O
expression	B-MED
of	O
PLA2	B-MED
,	O
and	O
the	O
highest	O
degree	O
of	O
up	B-MED
-	I-MED
regulation	I-MED
appeared	O
in	O
the	O
fat	B-MED
body	I-MED
.	O
Silencing	B-MED
PLA2	B-MED
influenced	B-MED
the	O
expression	B-MED
of	O
immune	B-MED
-	I-MED
related	I-MED
genes	I-MED
,	O
including	O
MyD88	B-MED
and	O
defensin	B-MED
in	O
the	O
Toll	B-MED
pathway	I-MED
and	O
relish	B-MED
and	O
diptericin	B-MED
in	O
the	O
Imd	B-MED
pathway	I-MED
.	O
Moreover	O
,	O
the	O
expression	B-MED
of	O
MyD88	B-MED
and	O
defensin	B-MED
was	O
down	B-MED
-	I-MED
regulated	I-MED
significantly	O
in	O
the	O
ds	B-MED
-	I-MED
PLA2	I-MED
group	B-MED
compared	O
with	O
those	O
in	O
the	O
ds	B-MED
-	I-MED
egfp	I-MED
group	B-MED
when	O
B.	B-MED
dorsalis	I-MED
was	O
infected	B-MED
with	O
L.	B-MED
monocytogenes	I-MED
and	O
S.	B-MED
aureus	I-MED
,	O
indicating	O
that	O
PLA2	B-MED
was	O
involved	O
in	O
the	O
activation	B-MED
of	O
the	O
Toll	B-MED
pathway	I-MED
.	O
Meanwhile	O
,	O
infection	B-MED
with	O
L.	B-MED
monocytogenes	I-MED
and	O
E.	B-MED
coli	I-MED
,	O
which	O
activate	B-MED
the	O
Imd	B-MED
pathway	I-MED
,	O
does	O
not	O
increase	B-MED
the	O
mRNA	B-MED
levels	B-MED
of	O
relish	B-MED
and	O
diptericin	B-MED
in	O
the	O
ds	B-MED
-	I-MED
PLA2	I-MED
group	B-MED
as	O
severely	O
as	O
it	O
increases	B-MED
those	O
in	O
the	O
ds	B-MED
-	I-MED
egfp	I-MED
group	B-MED
,	O
indicating	O
that	O
the	O
Imd	B-MED
pathway	I-MED
was	O
also	O
repressed	B-MED
after	O
silencing	B-MED
PLA2	B-MED
.	O
Notably	O
,	O
the	O
development	B-MED
of	O
lipid	B-MED
droplets	I-MED
in	O
fat	B-MED
body	I-MED
cells	B-MED
was	O
influenced	B-MED
by	O
silencing	B-MED
PLA2	B-MED
,	O
implying	O
that	O
PLA2	B-MED
affects	O
the	O
function	B-MED
of	O
fat	B-MED
body	I-MED
tissue	B-MED
.	O
These	O
results	O
suggest	O
that	O
the	O
PLA2	B-MED
PLA2	B-MED
gene	I-MED
may	O
mediate	O
humoral	B-MED
immune	I-MED
responses	I-MED
by	O
reducing	B-MED
lipid	B-MED
storage	I-MED
in	O
fat	B-MED
body	I-MED
cells	B-MED
in	O
B.	B-MED
dorsalis	I-MED
.	O
Feasibility	B-MED
of	O
a	O
transition	B-MED
intervention	B-MED
aimed	B-MED
at	O
adolescents	B-MED
with	O
chronic	B-MED
illness	I-MED
International	B-MED
guidelines	B-MED
recommend	O
planned	O
and	O
structured	O
transition	B-MED
programmes	B-MED
for	O
adolescents	B-MED
with	O
chronic	B-MED
illness	I-MED
because	O
inadequate	B-MED
transition	B-MED
may	O
lead	O
to	O
poor	B-MED
disease	I-MED
control	I-MED
and	O
risk	B-MED
of	O
lacking	B-MED
outpatient	B-MED
follow	I-MED
-	I-MED
up	I-MED
.	O
To	O
investigate	B-MED
the	O
feasibility	B-MED
of	O
a	O
transition	B-MED
intervention	B-MED
aimed	B-MED
at	O
adolescents	B-MED
with	O
chronic	B-MED
illness	I-MED
focusing	B-MED
on	O
declines	B-MED
,	O
drop	B-MED
-	I-MED
outs	I-MED
,	O
no	B-MED
-	I-MED
shows	I-MED
and	O
advantages	B-MED
and	O
disadvantages	B-MED
of	O
participating	B-MED
.	O
We	O
invited	O
236	O
adolescents	B-MED
(	O
12	O
-	O
20	O
years	O
)	O
with	O
juvenile	B-MED
idiopathic	I-MED
arthritis	I-MED
(	O
JIA	B-MED
)	O
to	O
participate	B-MED
in	O
a	O
randomised	B-MED
controlled	I-MED
trial	I-MED
(	O
RCT	B-MED
)	O
transition	B-MED
intervention	B-MED
.	O
Reasons	B-MED
for	O
decline	B-MED
and	O
drop	B-MED
-	I-MED
outs	I-MED
were	O
calculated	B-MED
.	O
Adolescents	B-MED
'	O
experiences	B-MED
of	O
advantages	B-MED
and	O
disadvantages	B-MED
of	O
participating	B-MED
and	O
reasons	B-MED
for	O
no	B-MED
-	I-MED
shows	I-MED
were	O
investigated	B-MED
through	O
focus	B-MED
groups	I-MED
and	O
telephone	B-MED
interviews	I-MED
,	O
which	O
were	O
analysed	B-MED
using	O
thematic	B-MED
analysis	B-MED
.	O
One	O
hundred	O
and	O
twenty	O
of	O
the	O
236	O
eligible	O
patients	B-MED
declined	B-MED
to	I-MED
participate	I-MED
in	O
the	O
intervention	B-MED
and	O
20	O
%	O
dropped	B-MED
out	I-MED
during	O
the	O
intervention	B-MED
.	O
Unspecified	B-MED
declines	B-MED
and	O
practical	B-MED
issues	I-MED
were	O
the	O
most	O
common	B-MED
reason	B-MED
to	O
decline	B-MED
,	O
and	O
'	O
do	B-MED
not	I-MED
wish	I-MED
to	I-MED
continue	I-MED
'	O
was	O
the	O
most	O
common	B-MED
reason	B-MED
to	O
drop	B-MED
-	I-MED
out	I-MED
.	O
Reasons	B-MED
for	O
no	B-MED
-	I-MED
shows	I-MED
were	O
forgetting	B-MED
and	O
being	O
too	O
busy	O
.	O
Advantages	B-MED
of	O
participating	B-MED
were	O
stated	O
as	O
'	O
participating	B-MED
without	B-MED
parents	B-MED
'	O
,	O
'	O
trust	B-MED
and	O
confidentiality	B-MED
'	O
,	O
'	O
being	O
able	O
to	O
set	O
the	O
agenda	B-MED
'	O
and	O
'	O
responsiveness	B-MED
'	O
.	O
Disadvantages	B-MED
were	O
'	O
unclear	B-MED
aim	B-MED
of	O
the	O
study	B-MED
'	O
,	O
'	O
meeting	O
others	O
with	O
JIA	B-MED
'	O
,	O
'	O
too	O
few	O
conversations	B-MED
'	O
and	O
'	O
transport	B-MED
issues	B-MED
'	O
.	O
Many	O
adolescents	B-MED
had	O
difficulties	B-MED
understanding	B-MED
the	O
aim	B-MED
of	O
the	O
intervention	B-MED
.	O
However	O
,	O
most	O
participants	B-MED
appreciated	O
the	O
conversations	B-MED
about	O
identity	O
as	O
well	O
as	O
the	O
trust	B-MED
and	O
confidentiality	B-MED
in	O
the	O
communication	B-MED
.	O
In	O
the	O
future	O
,	O
adolescents	B-MED
should	O
be	O
offered	O
more	O
individually	O
organised	O
programmes	B-MED
according	O
to	O
their	O
preferences	B-MED
and	O
needs	O
in	O
cooperation	B-MED
with	O
parents	B-MED
and	O
health	B-MED
care	I-MED
providers	I-MED
.	O
Emergency	B-MED
department	I-MED
use	B-MED
and	O
barriers	B-MED
to	O
wellness	B-MED
:	O
a	O
survey	B-MED
of	O
emergency	B-MED
department	I-MED
frequent	B-MED
users	B-MED
There	O
is	O
no	O
common	O
understanding	O
of	O
how	O
needs	B-MED
of	O
emergency	B-MED
department	I-MED
(	O
ED	B-MED
)	O
frequent	B-MED
users	B-MED
differ	O
from	O
other	O
patients	B-MED
.	O
This	O
study	B-MED
sought	O
to	O
examine	O
how	O
to	O
best	O
serve	O
this	O
population	B-MED
.	O
Examinations	B-MED
of	O
why	O
ED	B-MED
frequent	B-MED
users	B-MED
present	B-MED
to	O
the	O
ED	B-MED
,	O
what	O
barriers	B-MED
to	O
care	B-MED
exist	B-MED
,	O
and	O
what	O
service	B-MED
offerings	O
may	O
help	O
these	O
patients	B-MED
achieve	O
an	O
optimal	B-MED
level	B-MED
of	O
health	B-MED
were	O
conducted	O
.	O
We	O
performed	O
a	O
prospective	B-MED
study	I-MED
of	O
frequent	B-MED
ED	B-MED
users	B-MED
in	O
an	O
adult	B-MED
only	O
,	O
level	B-MED
1	I-MED
trauma	I-MED
center	I-MED
with	O
approximately	B-MED
90,000	O
visits	B-MED
per	B-MED
year	I-MED
.	O
Frequent	B-MED
ED	B-MED
users	B-MED
were	O
defined	O
as	O
those	O
who	O
make	O
four	O
or	O
more	O
ED	B-MED
visits	I-MED
in	O
a	O
12	O
month	B-MED
period	B-MED
.	O
Participants	B-MED
were	O
administered	B-MED
a	O
piloted	B-MED
structured	I-MED
interview	I-MED
by	O
a	O
trained	B-MED
researcher	I-MED
querying	B-MED
demographics	B-MED
,	O
ED	B-MED
usage	B-MED
,	O
perceived	B-MED
barriers	I-MED
to	O
care	B-MED
,	O
and	O
potential	O
aids	B-MED
to	O
maintaining	B-MED
health	I-MED
.	O
Of	O
1,523	O
screened	B-MED
patients	B-MED
,	O
297	O
were	O
identified	B-MED
as	O
frequent	B-MED
ED	B-MED
users	B-MED
.	O
One	O
hundred	O
frequent	B-MED
ED	B-MED
users	B-MED
were	O
enrolled	O
.	O
The	O
mean	B-MED
age	I-MED
was	O
48	O
years	B-MED
(	O
95	O
%	O
CI	B-MED
45	O
-	O
51	O
)	O
.	O
The	O
majority	O
of	O
subjects	B-MED
were	O
female	B-MED
(	O
64	O
%	O
,	O
64/100	O
,	O
95	O
%	O
CI	B-MED
55	O
-	O
73	O
%	O
)	O
,	O
white	B-MED
(	O
61	O
%	O
,	O
60/98	O
,	O
95	O
%	O
CI	B-MED
52	O
-	O
71	O
%	O
)	O
and	O
insured	B-MED
by	O
Medicaid	B-MED
(	O
55	O
%	O
,	O
47/86	O
,	O
95	O
%	O
CI	B-MED
44	O
-	O
65	O
%	O
)	O
or	O
Medicare	B-MED
(	O
23	O
%	O
,	O
20/86	O
,	O
95	O
%	O
CI	B-MED
14	O
-	O
32	O
%	O
)	O
.	O
Subjects	B-MED
had	O
a	O
median	B-MED
of	O
6	O
ED	B-MED
visits	I-MED
,	O
and	O
2	O
inpatient	B-MED
admissions	I-MED
in	O
the	O
past	B-MED
12	O
months	B-MED
at	O
this	O
hospital	B-MED
.	O
Most	O
frequent	B-MED
ED	B-MED
users	B-MED
(	O
61	O
%	O
,	O
59/96	O
,	O
95	O
%	O
CI	B-MED
52	O
-	O
71	O
%	O
)	O
stated	O
the	O
primary	B-MED
reason	I-MED
for	O
their	O
visit	B-MED
was	O
that	O
they	O
felt	O
that	O
their	O
health	B-MED
problem	I-MED
could	O
only	O
be	O
treated	B-MED
in	O
an	O
ED	B-MED
.	O
Transportation	B-MED
presented	O
as	O
a	O
major	B-MED
barrier	B-MED
to	O
few	B-MED
patients	B-MED
(	O
7	O
%	O
,	O
7/95	O
,	O
95	O
%	O
CI	B-MED
3	O
-	O
14	O
%	O
)	O
.	O
Subjects	B-MED
stated	O
that	O
"	O
after	B-MED
-	I-MED
hours	I-MED
options	I-MED
,	O
besides	O
the	O
ED	B-MED
for	O
minor	B-MED
health	B-MED
issues	I-MED
"	O
(	O
63	O
%	O
,	O
60/95	O
,	O
95	O
%	O
CI	B-MED
53	O
-	O
73	O
%	O
)	O
and	O
having	O
"	O
a	O
nurse	B-MED
to	O
work	B-MED
with	O
you	O
one	B-MED
-	I-MED
on	I-MED
-	I-MED
one	I-MED
to	O
help	O
manage	B-MED
health	B-MED
care	I-MED
needs	B-MED
"	O
(	O
53	O
%	O
,	O
50/95	O
,	O
95	O
%	O
CI	B-MED
43	O
-	O
63	O
%	O
)	O
would	O
be	O
most	O
helpful	O
in	O
achieving	O
optimal	B-MED
health	B-MED
.	O
This	O
study	B-MED
characterized	B-MED
ED	B-MED
frequent	B-MED
users	B-MED
and	O
identified	B-MED
several	B-MED
opportunities	B-MED
to	O
better	O
serve	O
this	O
population	B-MED
.	O
By	O
understanding	O
barriers	B-MED
to	O
care	B-MED
from	O
the	O
patient	B-MED
perspective	O
,	O
health	B-MED
systems	I-MED
can	O
potentially	O
address	O
unmet	O
needs	B-MED
that	O
prevent	B-MED
wellness	B-MED
in	O
this	O
population	B-MED
.	O
Neurological	B-MED
Decline	I-MED
in	O
an	O
Elderly	B-MED
with	O
Repaired	B-MED
Myelomeningocele	B-MED
Complicated	B-MED
with	O
Lumbar	B-MED
Canal	I-MED
Stenosis	I-MED
:	O
a	O
case	B-MED
report	I-MED
Tethered	B-MED
cord	I-MED
syndrome	I-MED
is	O
a	O
well	O
-	O
known	O
complication	B-MED
after	O
myelomeningocele	B-MED
(	O
MMC	B-MED
)	O
repair	B-MED
in	O
childhood	B-MED
.	O
However	O
,	O
late	O
complications	B-MED
in	O
adults	B-MED
with	O
a	O
repaired	B-MED
MMC	B-MED
are	O
not	O
well	O
understood	O
.	O
In	O
particular	O
,	O
the	O
influence	B-MED
of	O
a	O
degenerative	B-MED
spinal	I-MED
deformity	I-MED
on	O
a	O
sustained	B-MED
tethered	B-MED
cord	I-MED
is	O
still	O
unclear	O
.	O
A	O
63	B-MED
-	I-MED
year	I-MED
-	I-MED
old	I-MED
man	B-MED
with	O
a	O
repaired	B-MED
MMC	B-MED
presented	O
with	O
a	O
progressive	B-MED
gait	I-MED
disturbance	I-MED
and	O
numbness	B-MED
in	O
both	O
lower	B-MED
limbs	I-MED
.	O
Magnetic	B-MED
resonance	I-MED
images	I-MED
demonstrated	O
that	O
the	O
tethered	B-MED
spinal	I-MED
cord	I-MED
was	O
compressed	B-MED
by	O
severe	B-MED
canal	B-MED
stenosis	I-MED
along	O
the	O
entire	B-MED
lumbar	I-MED
spine	I-MED
.	O
After	O
a	O
multi	B-MED
-	I-MED
level	I-MED
lumbar	I-MED
decompression	I-MED
surgery	B-MED
,	O
the	O
patient	B-MED
recovered	I-MED
to	O
baseline	B-MED
neurological	B-MED
status	O
.	O
In	O
adults	B-MED
with	O
a	O
repaired	B-MED
MMC	B-MED
,	O
lumbar	B-MED
canal	I-MED
stenosis	I-MED
should	O
be	O
investigated	B-MED
as	O
a	O
possible	O
cause	O
of	O
late	O
neurological	B-MED
decline	I-MED
.	O
Clinical	O
manifestations	O
may	O
be	O
complicated	B-MED
by	O
the	O
coexistence	O
of	O
both	O
the	O
original	O
and	O
subsequent	O
neurological	B-MED
disorders	I-MED
.	O
Because	O
these	O
additional	O
disorders	B-MED
result	O
from	O
compressive	B-MED
myelopathy	I-MED
,	O
early	O
surgical	B-MED
decompression	I-MED
is	O
indicated	O
to	O
avoid	O
irreversible	O
spinal	B-MED
cord	I-MED
dysfunction	I-MED
.	O
Description	O
of	O
the	O
first	O
species	B-MED
of	O
Fiorianteon	B-MED
Olmi	I-MED
(	O
Hymenoptera	B-MED
,	O
Dryinidae	B-MED
)	O
from	O
the	O
Afrotropical	B-MED
region	I-MED
Fiorianteon	B-MED
sulcatumsp	I-MED
.	O
n.	O
is	O
described	O
from	O
Fianarantsoa	B-MED
Province	I-MED
(	O
Madagascar	B-MED
)	O
.	O
It	O
is	O
the	O
first	O
species	B-MED
of	O
Fiorianteon	B-MED
found	O
in	O
the	O
Afrotropical	B-MED
region	I-MED
.	O
The	O
genus	B-MED
Fiorianteon	B-MED
can	O
be	O
distinguished	O
from	O
the	O
closely	O
related	O
genus	B-MED
Conganteon	B-MED
by	O
the	O
distal	B-MED
part	O
of	O
the	O
stigmal	B-MED
vein	I-MED
,	O
which	O
is	O
as	O
long	B-MED
as	O
,	O
or	O
shorter	B-MED
than	O
the	O
proximal	B-MED
part	O
of	O
the	O
stigmal	B-MED
vein	I-MED
(	O
longer	O
than	O
the	O
proximal	B-MED
part	O
of	O
the	O
vein	B-MED
in	O
Conganteon	B-MED
)	O
.	O
Polymeric	B-MED
Nanostructure	B-MED
Compiled	O
with	O
Multifunctional	B-MED
Components	I-MED
To	O
Exert	O
Tumor	B-MED
-	O
Targeted	B-MED
Delivery	I-MED
of	O
Antiangiogenic	B-MED
Gene	B-MED
for	O
Tumor	B-MED
Growth	I-MED
Suppression	B-MED
Nucleic	B-MED
acid	I-MED
-	I-MED
based	I-MED
therapy	B-MED
has	O
emerged	O
as	O
a	O
revolutionary	B-MED
methodology	I-MED
for	O
treatment	B-MED
of	O
the	O
diseases	B-MED
related	O
to	O
protein	B-MED
dysfunction	B-MED
;	O
however	O
,	O
lack	B-MED
of	I-MED
systemically	B-MED
applicable	B-MED
synthetic	B-MED
delivery	I-MED
systems	I-MED
limits	O
its	O
current	O
usage	O
in	O
local	B-MED
applications	I-MED
,	O
particularly	O
for	O
DNA	B-MED
-	I-MED
based	I-MED
therapy	B-MED
with	O
regard	O
to	O
the	O
poor	B-MED
bioavailability	I-MED
in	O
the	O
systemic	B-MED
administrations	I-MED
.	O
To	O
overcome	O
this	O
obstacle	O
,	O
we	O
compiled	O
multiple	B-MED
chemistry	B-MED
-	I-MED
based	I-MED
strategies	I-MED
into	O
the	O
manufacture	B-MED
of	O
the	O
gene	B-MED
delivery	I-MED
formulations	I-MED
to	O
pursue	O
improved	B-MED
tolerability	B-MED
of	O
DNA	B-MED
to	O
the	O
enzymatic	B-MED
degradation	B-MED
in	O
the	O
biological	B-MED
milieu	B-MED
and	O
prolonged	B-MED
retention	I-MED
in	O
the	O
systemic	O
circulation	O
.	O
Here	O
,	O
we	O
constructed	O
a	O
distinctive	B-MED
multilayered	I-MED
functional	B-MED
architecture	B-MED
:	O
plasmid	B-MED
DNA	I-MED
(	O
pDNA	B-MED
)	O
was	O
electrostatically	B-MED
complexed	I-MED
with	O
cationic	B-MED
poly(lysine	B-MED
)	I-MED
(	O
polyplex	B-MED
)	O
as	O
the	O
interior	B-MED
pDNA	B-MED
reservoir	B-MED
,	O
which	O
was	O
further	O
cross	B-MED
-	I-MED
linked	I-MED
by	O
redox	B-MED
-	O
responsive	B-MED
disulfide	B-MED
cross	B-MED
-	I-MED
linking	I-MED
to	O
minimize	O
the	O
occurrence	B-MED
of	O
polyplex	B-MED
disassembly	B-MED
through	O
exchange	B-MED
reaction	I-MED
with	O
the	O
biological	B-MED
charged	B-MED
components	I-MED
.	O
Still	O
,	O
the	O
pDNA	B-MED
reservoir	B-MED
was	O
spatially	O
protected	O
by	O
a	O
sequential	B-MED
thermoresponsive	B-MED
poly(N	B-MED
-	I-MED
isopropylacrylamide	I-MED
)	I-MED
palisade	B-MED
as	O
the	O
intermediate	B-MED
barrier	I-MED
and	O
a	O
biocompatible	B-MED
hydrophilic	B-MED
poly(ethylene	B-MED
glycol	I-MED
)	I-MED
(	O
PEG	B-MED
)	O
shell	B-MED
with	O
the	O
aim	O
of	O
preventing	O
the	O
accessibility	B-MED
of	O
the	O
biological	B-MED
species	B-MED
,	O
particularly	O
the	O
nuclease	B-MED
degradation	B-MED
to	O
the	O
pDNA	B-MED
payload	O
.	O
Subsequent	O
investigations	B-MED
validated	O
the	O
utilities	O
of	O
these	O
strategies	B-MED
in	O
accomplishing	O
prolonged	O
blood	B-MED
retention	B-MED
.	O
In	O
an	O
attempt	O
to	O
apply	O
this	O
method	B-MED
for	O
tumor	O
therapy	B-MED
,	O
ligand	B-MED
cyclic	I-MED
(	I-MED
Arg	I-MED
-	I-MED
Gly	I-MED
-	I-MED
Asp	I-MED
)	I-MED
peptide	I-MED
was	O
attached	O
at	O
the	O
distal	O
end	O
of	O
PEG	B-MED
,	O
validating	O
prompted	O
tumor	B-MED
-	O
targeted	B-MED
delivery	B-MED
and	O
gene	B-MED
expression	I-MED
of	O
the	O
loaded	O
antiangiogenic	B-MED
gene	B-MED
at	O
the	O
targeted	B-MED
tumor	B-MED
cells	I-MED
and	O
accordingly	O
exerting	B-MED
antiangiogenesis	B-MED
of	O
the	O
tumors	B-MED
for	O
abrogation	B-MED
of	O
tumor	B-MED
growth	I-MED
.	O
Together	O
with	O
its	O
excellent	O
safe	O
profile	O
,	O
the	O
proposed	O
formulation	O
suggests	O
potential	B-MED
utility	O
as	O
a	O
practical	O
gene	B-MED
delivery	I-MED
system	I-MED
for	O
treatment	B-MED
of	O
intractable	B-MED
diseases	B-MED
.	O
Renieramycin	B-MED
M	I-MED
Attenuates	O
Cancer	B-MED
Stem	I-MED
Cell	I-MED
-like	O
Phenotypes	B-MED
in	O
H460	B-MED
Lung	B-MED
Cancer	B-MED
Cells	I-MED
Cancer	B-MED
stem	I-MED
cells	I-MED
(	O
CSCs	B-MED
)	O
are	O
a	O
subpopulation	O
of	O
cancer	B-MED
cells	I-MED
that	O
possess	O
self	B-MED
-	I-MED
renewal	I-MED
and	O
differentiation	B-MED
capacities	O
.	O
CSCs	B-MED
contribute	O
to	O
drug	B-MED
-	I-MED
resistance	I-MED
,	O
cancer	B-MED
recurrence	I-MED
and	O
metastasis	B-MED
,	O
thus	O
development	B-MED
of	O
CSC	B-MED
-targeted	O
therapeutic	B-MED
strategies	I-MED
has	O
recently	O
received	O
significant	O
attention	O
in	O
cancer	B-MED
research	I-MED
.	O
In	O
this	O
study	B-MED
,	O
the	O
potential	O
efficacy	B-MED
of	O
renieramycin	B-MED
M	I-MED
(	O
RM	B-MED
)	O
isolated	O
from	O
the	O
sponge	B-MED
Xestospongia	B-MED
species	I-MED
,	O
was	O
examined	B-MED
against	O
lung	B-MED
CSCs	B-MED
.	O
Colony	B-MED
and	I-MED
spheroid	I-MED
formation	I-MED
assays	I-MED
,	O
as	O
well	O
as	O
western	B-MED
blotting	I-MED
analysis	I-MED
of	O
lung	B-MED
CSC	B-MED
protein	B-MED
markers	B-MED
were	O
employed	O
to	O
determine	O
the	O
CSC	B-MED
-like	O
phenotypes	B-MED
of	O
H460	B-MED
lung	B-MED
cancer	B-MED
cells	I-MED
after	O
treatment	B-MED
with	O
RM	B-MED
at	O
non	B-MED
-	I-MED
toxic	I-MED
concentrations	I-MED
.	O
RM	B-MED
treatment	B-MED
reduced	O
significantly	O
colony	B-MED
and	I-MED
spheroid	I-MED
formation	I-MED
of	O
H460	B-MED
cells	I-MED
.	O
Moreover	O
,	O
the	O
CSC	B-MED
markers	B-MED
CD133	B-MED
,	O
CD44	B-MED
and	O
ALDH1A1	B-MED
of	O
CSC	B-MED
-enriched	O
H460	B-MED
cells	I-MED
were	O
reduced	O
significantly	O
following	O
RM	B-MED
treatment	B-MED
.	O
RM	B-MED
could	O
be	O
a	O
potent	O
anti	B-MED
-	I-MED
metastatic	I-MED
agent	I-MED
by	O
suppressing	O
lung	B-MED
CSC	B-MED
-like	O
phenotypes	B-MED
in	O
H460	B-MED
cells	I-MED
.	O
Spine	B-MED
fracture	I-MED
prevalence	B-MED
in	O
a	O
nationally	B-MED
representative	I-MED
sample	O
of	O
US	B-MED
women	B-MED
and	O
men	B-MED
aged	B-MED
≥40	O
years	O
:	O
results	O
from	O
the	O
National	B-MED
Health	I-MED
and	I-MED
Nutrition	I-MED
Examination	I-MED
Survey	I-MED
(	O
NHANES	B-MED
)	O
2013	O
-	O
2014	O
Spine	B-MED
fracture	I-MED
prevalence	B-MED
is	O
similar	O
in	O
men	B-MED
and	O
women	B-MED
,	O
increasing	O
from	O
<	O
5	O
%	O
in	O
those	O
<	O
60	O
to	O
11	O
%	O
in	O
those	O
70	O
-	O
79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years	O
.	O
Prevalence	B-MED
was	O
higher	B-MED
with	O
age	B-MED
age	B-MED
,	O
lower	B-MED
bone	B-MED
mineral	I-MED
density	I-MED
(	O
BMD	B-MED
)	O
,	O
and	O
in	O
those	O
meeting	O
criteria	B-MED
for	O
spine	B-MED
imaging	I-MED
.	O
Most	O
subjects	B-MED
with	O
spine	B-MED
fractures	I-MED
were	O
unaware	B-MED
of	O
them	O
.	O
Spine	B-MED
fractures	I-MED
have	O
substantial	O
medical	B-MED
significance	O
but	O
are	O
seldom	B-MED
recognized	O
.	O
This	O
study	O
collected	O
contemporary	O
nationally	B-MED
representative	I-MED
spine	B-MED
fracture	I-MED
prevalence	B-MED
data	O
.	O
Cross	B-MED
-	I-MED
sectional	I-MED
analysis	I-MED
of	O
3330	O
US	B-MED
adults	B-MED
aged	B-MED
≥40	O
years	O
participating	O
in	O
NHANES	B-MED
2013	O
-	O
2014	O
with	O
evaluable	O
Vertebral	B-MED
Fracture	I-MED
Assessment	O
(	O
VFA	B-MED
)	O
.	O
VFA	B-MED
was	O
graded	O
by	O
semiquantitative	O
measurement	O
.	O
BMD	B-MED
and	O
an	O
osteoporosis	B-MED
questionnaire	B-MED
were	O
collected	O
.	O
Overall	O
spine	B-MED
fracture	I-MED
prevalence	B-MED
was	O
5.4	O
%	O
and	O
similar	O
in	O
men	B-MED
and	O
women	B-MED
.	O
Prevalence	B-MED
increased	O
with	O
age	B-MED
from	O
<	O
5	O
%	O
in	O
those	O
<	O
60	O
to	O
11	O
%	O
in	O
those	O
70	O
-	O
79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years	O
.	O
Fractures	B-MED
were	O
more	O
common	O
in	O
non	B-MED
-	I-MED
Hispanic	I-MED
whites	I-MED
and	O
in	O
people	O
with	O
lower	B-MED
body	B-MED
mass	I-MED
index	I-MED
and	O
BMD	B-MED
.	O
Among	O
subjects	B-MED
with	O
spine	B-MED
fracture	I-MED
,	O
26	O
%	O
met	O
BMD	B-MED
criteria	B-MED
for	O
osteoporosis	B-MED
.	O
Prevalence	B-MED
was	O
higher	B-MED
in	O
subjects	B-MED
who	O
met	O
National	B-MED
Osteoporosis	I-MED
Foundation	I-MED
(	O
NOF	B-MED
)	O
criteria	B-MED
for	O
spine	B-MED
imaging	I-MED
(	O
14	O
vs	O
4.7	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O
Only	O
8	O
%	O
of	O
people	O
with	O
a	O
spine	B-MED
fracture	I-MED
diagnosed	B-MED
by	O
VFA	B-MED
had	O
a	O
self	B-MED
-	I-MED
reported	I-MED
fracture	B-MED
,	O
and	O
among	O
those	O
who	O
self	B-MED
-	I-MED
reported	I-MED
a	O
spine	B-MED
fracture	I-MED
,	O
only	O
21	O
%	O
were	O
diagnosed	B-MED
with	O
fracture	B-MED
by	O
VFA	B-MED
.	O
Spine	B-MED
fracture	I-MED
prevalence	B-MED
is	O
similar	O
in	O
women	B-MED
and	O
men	B-MED
and	O
increases	O
with	O
age	B-MED
and	O
lower	B-MED
BMD	B-MED
,	O
although	O
most	O
subjects	B-MED
with	O
spine	B-MED
fracture	I-MED
do	O
not	O
meet	O
BMD	B-MED
criteria	O
for	O
osteoporosis	B-MED
.	O
Since	O
most	O
(	O
>	O
90	O
%	O
)	O
individuals	B-MED
were	O
unaware	B-MED
of	O
their	O
spine	B-MED
fractures	I-MED
,	O
lateral	B-MED
spine	B-MED
imaging	I-MED
is	O
needed	O
to	O
identify	O
these	O
women	B-MED
and	O
men	B-MED
.	O
Spine	B-MED
fracture	I-MED
prevalence	B-MED
was	O
threefold	O
higher	B-MED
in	O
individuals	B-MED
meeting	O
NOF	B-MED
criteria	B-MED
for	O
spine	B-MED
imaging	I-MED
(	O
∼1	O
in	O
7	O
undergoing	O
VFA	B-MED
)	O
.	O
Identifying	O
spine	B-MED
fractures	I-MED
as	O
part	O
of	O
comprehensive	B-MED
risk	B-MED
assessment	I-MED
may	O
improve	B-MED
clinical	B-MED
decision	I-MED
making	I-MED
.	O
Successful	B-MED
Fetal	B-MED
Tele	I-MED
-	I-MED
Echo	I-MED
at	O
a	O
Small	B-MED
Regional	I-MED
Hospital	I-MED
Prenatal	B-MED
diagnosis	I-MED
of	O
complex	B-MED
congenital	B-MED
heart	I-MED
disease	I-MED
(	O
CHD	B-MED
)	O
has	O
been	O
shown	O
to	O
improve	B-MED
newborn	B-MED
outcomes	B-MED
.	O
The	O
rate	O
of	O
prenatal	B-MED
diagnosis	I-MED
and	O
access	B-MED
to	O
fetal	B-MED
echocardiography	I-MED
vary	O
widely	O
across	O
the	O
United	B-MED
States	I-MED
.	O
A	O
clinical	B-MED
fetal	I-MED
tele	I-MED
-	I-MED
echo	I-MED
service	O
was	O
established	O
at	O
King	B-MED
's	I-MED
Daughters	I-MED
Medical	I-MED
Center	I-MED
(	O
KDMC	B-MED
)	O
in	O
Ashland	B-MED
,	O
KY	B-MED
,	O
a	O
region	O
in	O
eastern	B-MED
Kentucky	I-MED
that	O
is	O
3	O
h	O
from	O
the	O
nearest	O
congenital	B-MED
heart	I-MED
surgeon	I-MED
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
determine	O
if	O
fetal	B-MED
tele	I-MED
-	I-MED
echo	I-MED
utilizing	O
local	B-MED
sonographers	I-MED
at	O
a	O
small	B-MED
regional	I-MED
hospital	I-MED
can	O
accurately	B-MED
and	O
efficiently	B-MED
identify	O
fetuses	B-MED
with	O
complex	B-MED
CHD	B-MED
.	O
Medical	B-MED
records	I-MED
were	O
reviewed	B-MED
for	O
all	O
mother	B-MED
-	I-MED
infant	I-MED
pairs	I-MED
who	O
had	O
fetal	B-MED
tele	I-MED
-	I-MED
echoes	I-MED
performed	B-MED
at	O
KDMC	B-MED
and	O
interpreted	B-MED
by	O
University	B-MED
of	I-MED
Louisville	I-MED
pediatric	I-MED
cardiology	I-MED
between	O
March	O
2011	O
and	O
December	O
2013	O
.	O
Findings	B-MED
on	O
fetal	B-MED
tele	I-MED
-	I-MED
echo	I-MED
were	O
compared	O
to	O
newborn	B-MED
newborn	B-MED
echo	B-MED
and	O
clinical	B-MED
course	I-MED
,	O
and	O
divided	O
into	O
four	O
groups	O
:	O
(	O
1	O
)	O
Correct	B-MED
-	O
no	B-MED
difference	I-MED
between	O
fetal	B-MED
tele	I-MED
-	I-MED
echo	I-MED
and	O
newborn	B-MED
echo	B-MED
,	O
(	O
2	O
)	O
Likely	O
Correct	O
-	O
normal	O
fetal	B-MED
tele	I-MED
-	I-MED
echo	I-MED
and	O
benign	O
newborn	B-MED
course	O
,	O
(	O
3	O
)	O
Major	B-MED
Difference	I-MED
-one	O
that	O
affected	B-MED
newborn	B-MED
newborn	B-MED
clinical	B-MED
course	I-MED
,	O
and	O
(	O
4	O
)	O
Minor	B-MED
Difference	I-MED
-did	O
not	O
affect	O
clinical	B-MED
course	I-MED
.	O
Seventy	O
-	O
five	O
mother	B-MED
-	I-MED
infant	I-MED
pairs	I-MED
were	O
analyzed	B-MED
.	O
Fetal	B-MED
tele	I-MED
-	I-MED
echoes	I-MED
were	O
Correct	B-MED
in	O
21	O
%	O
,	O
Likely	O
Correct	B-MED
in	O
56	O
%	O
,	O
showed	O
Major	B-MED
Differences	I-MED
in	O
0	O
%	O
,	O
and	O
showed	O
Minor	B-MED
Differences	I-MED
in	O
23	O
%	O
.	O
For	O
identifying	O
complex	B-MED
CHD	B-MED
,	O
fetal	B-MED
tele	I-MED
-	I-MED
echo	I-MED
had	O
a	O
sensitivity	B-MED
and	O
specificity	B-MED
of	O
100	O
%	O
.	O
The	O
average	O
number	O
of	O
fetal	B-MED
echocardiograms	I-MED
per	O
mother	B-MED
-	I-MED
infant	I-MED
pair	I-MED
was	O
1.1	O
.	O
Fetal	B-MED
tele	I-MED
-	I-MED
echocardiography	I-MED
performed	B-MED
by	O
local	B-MED
sonographers	I-MED
at	O
a	O
small	B-MED
regional	I-MED
hospital	I-MED
can	O
accurately	B-MED
and	O
efficiently	B-MED
identify	O
fetuses	B-MED
with	O
complex	B-MED
CHD	B-MED
.	O
Determination	B-MED
of	O
volatile	B-MED
organic	I-MED
compounds	I-MED
exhaled	B-MED
by	O
cell	B-MED
lines	I-MED
derived	B-MED
from	O
hematological	B-MED
malignancies	I-MED
Background	O
:	O
The	O
gas	B-MED
human	B-MED
exhaled	B-MED
contains	O
many	O
volatile	B-MED
organic	I-MED
compounds	I-MED
(	O
VOCs	B-MED
)	O
,	O
which	O
is	O
related	O
to	O
the	O
health	B-MED
status	I-MED
of	O
body	B-MED
.	O
Analysis	B-MED
of	O
VOCs	B-MED
has	O
been	O
proposed	O
as	O
a	O
noninvasive	B-MED
diagnostic	B-MED
tool	I-MED
for	O
certain	O
cancers	B-MED
.	O
Detailed	O
research	O
on	O
the	O
VOCs	B-MED
in	O
gas	B-MED
exhaled	B-MED
by	O
cell	B-MED
can	O
characterize	O
cell	B-MED
type	I-MED
specific	O
metabolites	B-MED
and	O
may	O
be	O
helpful	O
to	O
detect	O
the	O
cancer	B-MED
markers	I-MED
in	O
clinical	B-MED
practice	I-MED
.	O
Methods	O
:	O
Solid	B-MED
phase	I-MED
microextraction	I-MED
-	O
gas	B-MED
chromatography	I-MED
-	O
mass	B-MED
spectrometry	I-MED
was	O
used	O
to	O
detect	O
VOCs	B-MED
in	O
the	O
headspace	O
of	O
tissue	B-MED
culture	I-MED
flask	I-MED
in	O
non	B-MED
-	I-MED
Hodgkin	I-MED
's	I-MED
lymphoma	I-MED
cell	B-MED
line	I-MED
JEKO	I-MED
and	O
acute	B-MED
mononuclear	I-MED
leukemia	I-MED
cell	B-MED
line	I-MED
SHI-1	I-MED
,	O
to	O
elaborate	O
the	O
characteristic	O
gaseous	B-MED
biomarkers	B-MED
of	O
hematological	B-MED
malignancies	I-MED
.	O
While	O
macrophage	B-MED
cells	I-MED
and	O
lymphocytic	B-MED
cells	I-MED
were	O
acted	O
as	O
control	B-MED
.	O
The	O
blank	B-MED
group	I-MED
was	O
only	O
the	O
RPMI	B-MED
1640	I-MED
medium	I-MED
containing	O
10	O
%	O
fetal	B-MED
calf	I-MED
serum	I-MED
that	O
without	O
cells	B-MED
.	O
Results	O
:	O
Comparing	O
to	O
control	B-MED
group	I-MED
,	O
the	O
concentration	B-MED
of	O
dimethyl	B-MED
sulphide	I-MED
,	O
2,4	B-MED
-	I-MED
dimethyl	I-MED
-	I-MED
heptane	I-MED
,	O
methylbenzene	B-MED
,	O
o	B-MED
-	I-MED
xylene	I-MED
,	O
dodecane	B-MED
and	O
1,3	B-MED
-	I-MED
ditert	I-MED
-	I-MED
butylbenzene	I-MED
in	O
JEKO	B-MED
cells	I-MED
were	O
relatively	O
higher	O
,	O
while	O
the	O
concentration	O
of	O
ethanol	B-MED
,	O
hexanal	B-MED
and	O
benzaldehyde	B-MED
was	O
lower	O
.	O
In	O
SHI-1	B-MED
cells	I-MED
,	O
the	O
levels	O
of	O
2,4	B-MED
-	I-MED
dimethyl	I-MED
-	I-MED
heptane	I-MED
,	O
benzene	B-MED
,	O
4	B-MED
-	I-MED
methyldecane	I-MED
,	O
chloroform	B-MED
,	O
3,7	B-MED
-	I-MED
dimethyl	I-MED
dodecane	I-MED
and	O
hexadecane	B-MED
were	O
significantly	O
elevated	O
,	O
but	O
the	O
levels	O
of	O
hexanol	B-MED
and	O
cyclohexanol	B-MED
were	O
distinctly	O
reduced	O
.	O
Conclusions	O
:	O
This	O
pilot	B-MED
study	I-MED
revealed	O
that	O
the	O
malignant	B-MED
hematological	I-MED
cells	B-MED
could	O
change	O
the	O
components	O
of	O
VOCs	B-MED
in	O
the	O
cell	B-MED
culture	I-MED
flask	I-MED
in	O
a	O
cell	B-MED
type	I-MED
specific	O
pattern	O
.	O
The	O
traits	O
of	O
VOCs	B-MED
in	O
our	O
setting	O
offered	O
new	O
strategy	O
for	O
hematological	B-MED
malignancies	I-MED
tracing	O
,	O
and	O
would	O
act	O
as	O
potential	O
biomarkers	B-MED
in	O
diagnosis	B-MED
of	O
malignant	B-MED
hematological	B-MED
diseases	I-MED
.	O
Differential	B-MED
regulation	I-MED
of	O
spontaneous	B-MED
and	O
evoked	B-MED
inhibitory	B-MED
synaptic	I-MED
transmission	I-MED
in	O
somatosensory	B-MED
cortex	I-MED
by	O
retinoic	B-MED
acid	I-MED
Retinoic	B-MED
acid	I-MED
(	O
RA	B-MED
)	O
,	O
a	O
developmental	B-MED
morphogen	B-MED
,	O
has	O
emerged	O
in	O
recent	O
studies	O
as	O
a	O
novel	B-MED
synaptic	B-MED
signaling	B-MED
molecule	I-MED
that	O
acts	O
in	O
mature	B-MED
hippocampal	B-MED
neurons	B-MED
to	O
modulate	B-MED
excitatory	B-MED
and	O
inhibitory	B-MED
synaptic	I-MED
transmission	I-MED
in	O
the	O
context	O
of	O
homeostatic	B-MED
synaptic	B-MED
plasticity	I-MED
.	O
However	O
,	O
it	O
is	O
unclear	O
whether	O
RA	B-MED
is	O
capable	O
of	O
modulating	B-MED
neural	B-MED
circuits	I-MED
outside	B-MED
of	O
the	O
hippocampus	B-MED
,	O
and	O
if	O
so	O
,	O
whether	O
the	O
mode	B-MED
of	I-MED
RA	I-MED
's	I-MED
action	I-MED
at	O
synapses	B-MED
is	O
similar	B-MED
to	O
that	O
within	B-MED
the	O
hippocampal	B-MED
network	O
.	O
Here	O
we	O
explore	O
for	O
the	O
first	O
time	O
RA	B-MED
's	O
synaptic	B-MED
function	I-MED
outside	B-MED
the	O
hippocampus	B-MED
and	O
uncover	O
a	O
novel	B-MED
function	B-MED
of	O
all	B-MED
-	I-MED
trans	I-MED
retinoic	I-MED
acid	I-MED
at	O
inhibitory	B-MED
synapses	I-MED
.	O
Acute	B-MED
RA	B-MED
treatment	B-MED
increases	B-MED
spontaneous	B-MED
inhibitory	B-MED
synaptic	I-MED
transmission	I-MED
in	O
L2/3	B-MED
pyramidal	I-MED
neurons	I-MED
of	O
the	O
somatosensory	B-MED
cortex	I-MED
,	O
and	O
this	O
effect	B-MED
requires	O
expression	B-MED
of	O
RA	B-MED
's	I-MED
receptor	I-MED
RARα	B-MED
both	O
pre-	B-MED
and	I-MED
post	I-MED
-	I-MED
synaptically	I-MED
.	O
Intriguingly	O
,	O
RA	B-MED
does	O
not	O
seem	O
to	O
affect	O
evoked	B-MED
inhibitory	B-MED
transmission	I-MED
assayed	O
with	O
either	O
extracellular	B-MED
stimulation	O
or	O
direct	O
activation	B-MED
of	I-MED
action	I-MED
potentials	I-MED
in	O
presynaptic	B-MED
interneurons	B-MED
at	O
connected	O
pairs	O
of	O
interneurons	B-MED
and	O
pyramidal	B-MED
neurons	I-MED
.	O
Taken	O
together	O
,	O
these	O
results	B-MED
suggest	O
that	O
RA	B-MED
's	I-MED
action	B-MED
at	O
synapses	B-MED
is	O
not	O
monotonous	O
,	O
but	O
is	O
diverse	B-MED
depending	O
on	O
the	O
type	O
of	O
synaptic	B-MED
connection	I-MED
(	O
excitatory	B-MED
versus	O
inhibitory	B-MED
)	O
and	O
circuit	B-MED
(	O
hippocampal	B-MED
versus	O
cortical	B-MED
)	I-MED
.	O
Thus	O
,	O
synaptic	B-MED
signaling	I-MED
of	O
RA	B-MED
may	O
mediate	O
multi	O
-	O
faceted	O
regulation	B-MED
of	I-MED
synaptic	I-MED
plasticity	I-MED
.	O
In	O
addition	O
to	O
its	O
classic	B-MED
roles	I-MED
in	O
brain	B-MED
development	I-MED
,	O
retinoic	B-MED
acid	I-MED
(	O
RA	B-MED
)	O
has	O
recently	O
been	O
shown	O
to	O
regulate	B-MED
excitatory	B-MED
and	O
inhibitory	B-MED
transmission	I-MED
in	O
the	O
adult	B-MED
brain	B-MED
.	O
Here	O
,	O
the	O
authors	B-MED
show	O
that	O
in	O
layer	B-MED
2/3	I-MED
(	O
L2/3	B-MED
)	O
of	O
the	O
somatosensory	B-MED
cortex	I-MED
(	O
S1	B-MED
)	O
,	O
acute	B-MED
RA	B-MED
induces	B-MED
increases	B-MED
in	O
spontaneous	B-MED
but	O
not	O
action	B-MED
-	I-MED
potential	I-MED
evoked	B-MED
transmission	B-MED
,	O
and	O
that	O
this	O
requires	O
retinoic	B-MED
acid	I-MED
receptor	I-MED
(	O
RARα	B-MED
)	O
both	O
in	O
presynaptic	B-MED
PV	B-MED
-positive	O
interneurons	B-MED
and	O
postsynaptic	B-MED
pyramidal	B-MED
(	I-MED
PN	I-MED
)	I-MED
neurons	I-MED
.	O
Midodrine	B-MED
and	O
tolvaptan	B-MED
in	O
patients	B-MED
with	O
cirrhosis	B-MED
and	O
refractory	B-MED
or	O
recurrent	B-MED
ascites	I-MED
:	O
a	O
randomised	B-MED
pilot	B-MED
study	I-MED
Splanchnic	B-MED
arterial	I-MED
vasodilatation	I-MED
and	O
subsequent	O
sodium	B-MED
and	O
water	B-MED
retention	I-MED
play	O
an	O
important	O
role	O
in	O
cirrhotic	B-MED
ascites	I-MED
.	O
Midodrine	B-MED
and	O
tolvaptan	B-MED
have	O
been	O
used	O
separately	O
in	O
these	O
patients	B-MED
.	O
However	O
,	O
there	O
are	O
no	O
reports	O
on	O
the	O
use	O
of	O
combination	B-MED
of	O
midodrine	B-MED
and	O
tolvaptan	B-MED
in	O
the	O
control	O
of	O
ascites	B-MED
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	B-MED
the	O
safety	B-MED
and	O
efficacy	B-MED
of	O
midodrine	B-MED
,	O
tolvaptan	B-MED
and	O
their	O
combination	B-MED
in	O
control	O
of	O
refractory	B-MED
or	O
recurrent	B-MED
ascites	I-MED
in	O
cirrhotics	B-MED
.	O
Fifty	O
cirrhotic	B-MED
patients	B-MED
with	O
refractory	B-MED
or	O
recurrent	B-MED
ascites	I-MED
were	O
randomised	B-MED
to	O
receive	O
midodrine	B-MED
(	O
n=13	O
)	O
,	O
tolvaptan	B-MED
(	O
n=12	O
)	O
or	O
both	O
(	O
n=13	O
)	O
plus	O
standard	O
medical	B-MED
therapy	I-MED
(	O
SMT	B-MED
)	O
or	O
SMT	B-MED
alone	O
(	O
n=12	O
)	O
.	O
A	O
significant	B-MED
increase	I-MED
in	I-MED
urinary	I-MED
volume	I-MED
and	O
urinary	B-MED
sodium	I-MED
at	O
1	O
and	O
3	O
months	B-MED
(	O
P<.05	O
)	O
was	O
observed	O
in	O
all	O
groups	B-MED
except	O
SMT	B-MED
.	O
There	O
was	O
no	O
worsening	B-MED
of	O
renal	B-MED
or	O
hepatic	B-MED
function	I-MED
in	O
any	O
group	B-MED
.	O
There	O
was	O
deterioration	B-MED
of	O
model	B-MED
for	I-MED
end	I-MED
-	I-MED
stage	I-MED
liver	I-MED
disease	I-MED
(	O
MELD	B-MED
)	O
in	O
SMT	O
.	O
Midodrine	B-MED
as	O
well	O
as	O
combination	B-MED
of	O
midodrine	B-MED
and	O
tolvaptan	B-MED
but	O
not	O
tolvaptan	B-MED
alone	O
was	O
superior	O
to	O
SMT	B-MED
in	O
control	O
of	O
ascites	B-MED
at	O
3	O
months	B-MED
(	O
P<.05	O
)	O
.	O
The	O
combination	B-MED
therapy	I-MED
was	O
also	O
superior	O
to	O
midodrine	B-MED
in	O
the	O
control	O
of	O
ascites	B-MED
at	O
1	O
month	B-MED
.	O
The	O
morbidity	B-MED
and	O
mortality	B-MED
were	O
similar	O
in	O
all	O
the	O
groups	B-MED
except	O
SMT	B-MED
.	O
The	O
results	O
of	O
this	O
pilot	B-MED
study	I-MED
suggest	O
that	O
midodrine	B-MED
and	O
combination	B-MED
with	O
tolvaptan	B-MED
better	O
controls	O
ascites	B-MED
without	O
any	O
renal	B-MED
or	O
hepatic	B-MED
dysfunction	I-MED
.	O
The	O
combination	B-MED
therapy	I-MED
rapidly	O
controls	O
ascites	B-MED
as	O
compared	O
to	O
midodrine	B-MED
or	O
tolvaptan	B-MED
alone	O
.	O
Omega	B-MED
3	I-MED
Fatty	I-MED
Acids	I-MED
Reduce	B-MED
Bone	B-MED
Resorption	I-MED
While	O
Promoting	B-MED
Bone	I-MED
Generation	I-MED
in	O
Rat	B-MED
Apical	B-MED
Periodontitis	I-MED
This	O
study	O
evaluated	B-MED
the	O
effects	B-MED
of	I-MED
the	O
dietary	B-MED
supplement	I-MED
omega	B-MED
3	I-MED
polyunsaturated	I-MED
fatty	I-MED
acids	I-MED
(	O
ω-3	B-MED
PUFAs	I-MED
)	O
on	O
pulp	B-MED
exposure	I-MED
-induced	O
apical	B-MED
periodontitis	I-MED
(	O
AP	B-MED
)	O
in	O
rats	B-MED
.	O
Twenty	O
-	O
eight	O
male	B-MED
rats	B-MED
were	O
divided	O
into	O
groups	B-MED
:	O
control	O
untreated	B-MED
rats	B-MED
(	O
C	O
)	O
,	O
control	O
rats	B-MED
treated	B-MED
with	I-MED
ω-3	B-MED
PUFAs	I-MED
alone	O
(	O
C	O
-	O
O	O
)	O
,	O
rats	B-MED
with	O
pulp	B-MED
exposure	I-MED
-induced	O
AP	B-MED
,	O
and	O
rats	B-MED
with	O
pulp	B-MED
exposure	I-MED
-induced	O
AP	B-MED
treated	B-MED
with	I-MED
ω-3	B-MED
PUFAs	I-MED
(	O
AP	B-MED
-O	O
)	O
.	O
The	O
ω-3	B-MED
PUFAs	I-MED
were	O
administered	B-MED
orally	I-MED
,	O
once	O
a	O
day	O
,	O
for	O
15	O
days	O
before	O
pulp	B-MED
exposure	I-MED
and	O
,	O
subsequently	O
,	O
30	O
days	O
after	O
pulp	B-MED
exposure	I-MED
.	O
Rats	B-MED
were	O
killed	B-MED
30	O
days	O
after	O
pulp	B-MED
exposure	I-MED
,	O
and	O
jaws	B-MED
were	O
subjected	O
to	O
histologic	B-MED
and	O
immunohistochemical	B-MED
analyses	B-MED
.	O
Immunohistochemical	B-MED
analyses	B-MED
were	O
performed	O
to	O
detect	O
tartrate	B-MED
-	I-MED
resistant	I-MED
acid	I-MED
phosphatase	I-MED
-	O
positive	B-MED
osteoclasts	B-MED
and	O
osteocalcin	B-MED
-	O
positive	B-MED
osteoblasts	B-MED
on	O
the	O
bone	B-MED
surface	I-MED
of	O
periapical	B-MED
area	I-MED
.	O
Results	O
were	O
statistically	O
evaluated	B-MED
by	O
using	O
analysis	B-MED
of	I-MED
variance	I-MED
and	O
Tukey	B-MED
honestly	I-MED
significant	I-MED
difference	I-MED
,	O
and	O
P	O
<	O
.05	O
was	O
considered	O
statistically	B-MED
significant	I-MED
.	O
The	O
bone	B-MED
resorption	I-MED
lesion	B-MED
was	O
significantly	B-MED
larger	I-MED
in	O
the	O
AP	B-MED
group	O
compared	O
with	O
AP	B-MED
-O	O
,	O
C	O
,	O
and	O
C	O
-	O
O	O
groups	B-MED
(	O
P	O
<	O
.05	O
)	O
.	O
The	O
level	B-MED
of	O
inflammatory	B-MED
cell	I-MED
infiltration	I-MED
was	O
significantly	O
elevated	O
,	O
and	O
the	O
number	O
of	O
tartrate	B-MED
-	I-MED
resistant	I-MED
acid	I-MED
phosphatase	I-MED
-	O
positive	B-MED
osteoclasts	B-MED
was	O
significantly	B-MED
higher	I-MED
in	O
the	O
periapical	B-MED
lesions	B-MED
of	O
the	O
AP	B-MED
group	O
compared	O
with	O
AP	B-MED
-O	O
,	O
C	O
,	O
and	O
C	O
-	O
O	O
groups	B-MED
(	O
P	O
<	O
.05	O
)	O
.	O
The	O
number	O
of	O
osteocalcin	B-MED
-	O
positive	B-MED
osteoblasts	B-MED
was	O
significantly	O
increased	B-MED
in	O
the	O
AP	B-MED
-O	O
group	O
compared	O
with	O
the	O
AP	B-MED
group	O
(	O
P	O
>	O
.05	O
)	O
.	O
Supplementation	B-MED
with	O
ω-3	B-MED
PUFAs	I-MED
not	O
only	O
suppresses	B-MED
bone	B-MED
resorption	I-MED
but	O
also	O
promotes	B-MED
new	I-MED
bone	I-MED
formation	I-MED
in	O
the	O
periapical	B-MED
area	I-MED
of	O
rats	B-MED
with	O
AP	B-MED
in	O
conjunction	B-MED
with	O
downregulation	B-MED
of	O
inflammatory	B-MED
cell	I-MED
infiltration	I-MED
into	O
the	O
lesion	B-MED
.	O
Early	O
hippocampal	B-MED
volume	B-MED
loss	I-MED
as	O
a	O
marker	B-MED
of	O
eventual	O
memory	B-MED
deficits	I-MED
caused	O
by	O
repeated	B-MED
stress	I-MED
Exposure	B-MED
to	I-MED
severe	B-MED
and	O
prolonged	B-MED
stress	B-MED
has	O
detrimental	B-MED
effects	I-MED
on	O
the	O
hippocampus	B-MED
.	O
However	O
,	O
relatively	B-MED
little	B-MED
is	O
known	B-MED
about	O
the	O
gradual	B-MED
changes	B-MED
in	O
hippocampal	B-MED
structure	I-MED
,	O
and	O
its	O
behavioral	B-MED
consequences	B-MED
,	O
over	O
the	O
course	O
of	O
repeated	B-MED
stress	I-MED
.	O
Behavioral	B-MED
analyses	I-MED
during	O
10	O
days	O
of	O
chronic	B-MED
stress	I-MED
pointed	O
to	O
a	O
delayed	O
decline	B-MED
in	O
spatial	B-MED
memory	I-MED
,	O
the	O
full	O
impact	B-MED
of	O
which	O
is	O
evident	O
only	O
after	O
the	O
end	O
of	O
stress	B-MED
.	O
In	O
contrast	O
,	O
concurrent	B-MED
volumetric	B-MED
measurements	I-MED
in	O
the	O
same	O
animals	B-MED
revealed	O
significant	O
reduction	B-MED
in	O
hippocampal	B-MED
volumes	B-MED
in	O
stressed	B-MED
animals	B-MED
relative	O
to	O
their	O
unstressed	B-MED
counterparts	I-MED
,	O
as	O
early	O
as	O
the	O
third	O
day	O
of	O
stress	B-MED
.	O
Notably	O
,	O
animals	B-MED
that	O
were	O
behaviorally	B-MED
the	O
worst	B-MED
affected	B-MED
at	O
the	O
end	O
of	O
chronic	B-MED
stress	I-MED
suffered	B-MED
the	O
most	O
pronounced	O
early	B-MED
loss	I-MED
in	I-MED
hippocampal	I-MED
volume	I-MED
.	O
Together	O
,	O
these	O
findings	O
support	O
the	O
view	O
that	O
not	O
only	O
is	O
smaller	O
hippocampal	B-MED
volume	B-MED
linked	O
to	O
stress	B-MED
-	O
induced	B-MED
memory	B-MED
deficits	I-MED
,	O
but	O
it	O
may	O
also	O
act	O
as	O
an	O
early	O
risk	B-MED
factor	I-MED
for	O
the	O
eventual	O
development	O
of	O
cognitive	B-MED
impairments	I-MED
seen	O
in	O
stress	B-MED
-	I-MED
related	I-MED
psychiatric	I-MED
disorders	I-MED
.	O
De	B-MED
Ritis	I-MED
Ratio	I-MED
(	I-MED
AST	I-MED
/	I-MED
ALT	I-MED
)	I-MED
as	O
a	O
Significant	B-MED
Prognostic	I-MED
Factor	I-MED
in	O
Patients	B-MED
With	O
Upper	B-MED
Tract	I-MED
Urothelial	I-MED
Cancer	I-MED
Treated	B-MED
With	O
Surgery	B-MED
We	O
investigated	B-MED
the	O
clinical	B-MED
prognostic	I-MED
value	I-MED
of	O
preoperative	B-MED
De	B-MED
Ritis	I-MED
ratio	I-MED
(	I-MED
aspartate	I-MED
aminotransferase	I-MED
[	I-MED
AST]/alanine	I-MED
aminotransferase	I-MED
[	I-MED
ALT	I-MED
]	I-MED
)	I-MED
on	O
postsurgical	B-MED
survival	B-MED
outcomes	B-MED
in	O
patients	B-MED
with	O
upper	B-MED
tract	I-MED
urothelial	I-MED
cancer	I-MED
(	O
UTUC	B-MED
)	O
.	O
We	O
retrospectively	B-MED
analyzed	I-MED
the	O
data	B-MED
of	O
623	O
patients	B-MED
who	O
underwent	O
radical	B-MED
nephrouretectomy	I-MED
for	O
UTUC	B-MED
.	O
Multivariate	B-MED
regression	I-MED
tests	B-MED
were	O
performed	O
to	O
identify	O
possible	B-MED
associations	I-MED
between	O
adverse	B-MED
pathologic	I-MED
events	I-MED
and	O
AST	B-MED
/	I-MED
ALT	I-MED
.	O
The	O
risk	O
of	O
postoperative	B-MED
progression	B-MED
and	O
survival	B-MED
were	O
tested	B-MED
using	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
analyses	I-MED
and	O
Cox	B-MED
proportional	I-MED
hazards	I-MED
models	I-MED
.	O
According	O
to	O
the	O
receiver	B-MED
operator	I-MED
characteristic	I-MED
curve	I-MED
of	O
AST	B-MED
/	I-MED
ALT	I-MED
for	O
cancer	B-MED
-	I-MED
specific	I-MED
mortality	I-MED
,	O
patients	B-MED
with	O
AST	B-MED
/	I-MED
ALT	I-MED
value	O
≥1.5	O
were	O
regarded	O
as	O
the	O
high	O
AST	B-MED
/	I-MED
ALT	I-MED
group	O
,	O
and	O
the	O
remaining	O
patients	B-MED
formed	O
the	O
low	O
AST	B-MED
/	I-MED
ALT	I-MED
group	O
.	O
In	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
analyses	I-MED
,	O
the	O
high	O
AST	B-MED
/	I-MED
ALT	I-MED
group	O
showed	O
worse	O
progression	B-MED
-	I-MED
free	I-MED
survival	I-MED
(	O
PFS	B-MED
)	O
,	O
cancer	B-MED
-	I-MED
specific	I-MED
survival	I-MED
(	O
CSS	B-MED
)	O
,	O
and	O
overall	B-MED
survival	I-MED
(	O
all	O
P	O
<	O
.001	O
)	O
.	O
Elevated	O
AST	B-MED
/	I-MED
ALT	I-MED
was	O
associated	B-MED
with	I-MED
higher	O
T	B-MED
stage	I-MED
(	O
hazard	B-MED
ratio	I-MED
[	O
HR	B-MED
]	O
,	O
1.577	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
,	O
1.077	O
-	O
2.311	O
;	O
P	O
=	O
.033	O
)	O
and	O
higher	B-MED
cellular	I-MED
grade	I-MED
(	O
HR	B-MED
,	O
1.538	O
;	O
95	O
%	O
CI	B-MED
,	O
1.034	O
-	O
2.287	O
;	O
P	O
=	O
.041	O
)	O
in	O
multivariate	B-MED
regression	I-MED
tests	B-MED
.	O
In	O
multivariate	B-MED
Cox	I-MED
analyses	I-MED
,	O
high	O
AST	B-MED
/	I-MED
ALT	I-MED
was	O
revealed	O
as	O
an	O
independent	B-MED
predictor	I-MED
of	O
PFS	B-MED
(	O
HR	B-MED
,	O
2.335	O
;	O
95	O
%	O
CI	B-MED
,	O
1.633	O
-	O
3.340	O
;	O
P	O
<	O
.001	O
)	O
,	O
CSS	B-MED
(	O
HR	B-MED
,	O
2.550	O
;	O
1.689	O
-	O
3.851	O
;	O
P	O
<	O
.001	O
)	O
,	O
and	O
overall	B-MED
survival	I-MED
(	O
HR	B-MED
,	O
2.069	O
;	O
95	O
%	O
CI	B-MED
,	O
1.409	O
-	O
3.038	O
;	O
P	O
<	O
.001	O
)	O
.	O
Elevated	O
preoperative	B-MED
AST	B-MED
/	I-MED
ALT	I-MED
was	O
a	O
significant	B-MED
predictor	I-MED
of	O
worse	B-MED
postoperative	B-MED
survival	B-MED
in	O
patients	B-MED
surgically	B-MED
treated	I-MED
for	O
UTUC	B-MED
.	O
Further	O
large	O
prospective	B-MED
studies	I-MED
are	O
needed	O
for	O
better	O
understanding	O
of	O
the	O
prognostic	B-MED
value	I-MED
of	O
preoperative	B-MED
AST	B-MED
/	I-MED
ALT	I-MED
.	O
Neonatal	B-MED
infections	I-MED
:	O
Case	B-MED
definition	I-MED
and	O
guidelines	B-MED
for	O
data	B-MED
collection	I-MED
,	O
analysis	B-MED
,	O
and	O
presentation	B-MED
of	O
immunisation	B-MED
safety	B-MED
data	I-MED
Maternal	B-MED
vaccination	B-MED
is	O
an	O
important	O
area	O
of	O
research	B-MED
and	O
requires	O
appropriate	O
and	O
internationally	O
comparable	O
definitions	B-MED
and	O
safety	B-MED
standards	I-MED
.	O
The	O
GAIA	B-MED
group	I-MED
,	O
part	O
of	O
the	O
Brighton	B-MED
Collaboration	I-MED
was	O
created	O
with	O
the	O
mandate	O
of	O
proposing	O
standardised	O
definitions	B-MED
applicable	O
to	O
maternal	B-MED
vaccine	B-MED
research	B-MED
.	O
This	O
study	B-MED
proposes	O
international	O
definitions	B-MED
for	O
neonatal	B-MED
infections	I-MED
.	O
The	O
neonatal	B-MED
infections	I-MED
GAIA	B-MED
working	B-MED
group	I-MED
performed	O
a	O
literature	B-MED
review	B-MED
using	O
Medline	B-MED
,	O
EMBASE	B-MED
and	O
the	O
Cochrane	B-MED
collaboration	I-MED
and	O
collected	O
definitions	B-MED
in	O
use	O
in	O
neonatal	B-MED
and	O
public	B-MED
health	I-MED
networks	I-MED
.	O
The	O
common	O
criteria	B-MED
derived	B-MED
from	O
the	O
extensive	O
search	O
formed	O
the	O
basis	O
for	O
a	O
consensus	B-MED
process	I-MED
that	O
resulted	O
in	O
three	O
separate	O
definitions	B-MED
for	O
neonatal	B-MED
blood	B-MED
stream	I-MED
infections	I-MED
(	O
BSI	B-MED
)	O
,	O
meningitis	B-MED
and	O
lower	B-MED
respiratory	I-MED
tract	I-MED
infections	I-MED
(	O
LRTI	B-MED
)	O
.	O
For	O
each	O
definition	B-MED
three	O
levels	O
of	O
evidence	O
are	O
proposed	O
to	O
ensure	O
the	O
applicability	O
of	O
the	O
definitions	B-MED
to	O
different	O
settings	O
.	O
Recommendations	O
about	O
data	B-MED
collection	I-MED
,	O
analysis	B-MED
and	O
presentation	B-MED
are	O
presented	O
and	O
harmonized	B-MED
with	O
the	O
Brighton	B-MED
Collaboration	I-MED
and	O
GAIA	B-MED
format	B-MED
and	O
other	O
existing	O
international	B-MED
standards	I-MED
for	O
study	B-MED
reporting	B-MED
.	O
Vestibular	B-MED
disorders	I-MED
and	O
nausea	B-MED
during	O
head	B-MED
and	O
neck	B-MED
intensity	B-MED
-	I-MED
modulated	I-MED
radiation	I-MED
therapy	I-MED
We	O
studied	O
whether	O
there	O
is	O
a	O
relationship	B-MED
between	O
nausea	B-MED
and	O
vestibular	B-MED
disorders	I-MED
in	O
patients	B-MED
treated	B-MED
with	I-MED
intensity	B-MED
modulated	I-MED
radiation	I-MED
therapy	I-MED
(	O
IMRT	B-MED
)	O
for	O
head	B-MED
and	O
neck	B-MED
cancer	I-MED
.	O
We	O
performed	O
a	O
prospective	B-MED
single	I-MED
-	I-MED
centre	I-MED
study	I-MED
that	O
enrolled	B-MED
31	O
patients	B-MED
.	O
A	O
videonystagmography	B-MED
was	O
carried	O
out	O
before	O
and	O
within	O
15	O
days	O
after	O
radiation	B-MED
therapy	I-MED
for	O
each	O
patient	B-MED
.	O
Nausea	B-MED
was	O
assessed	O
at	O
baseline	B-MED
,	O
every	O
week	O
,	O
and	O
at	O
the	O
post	B-MED
-	I-MED
radiotherapy	I-MED
videonystagmography	B-MED
visit	O
.	O
Twenty	O
-	O
six	O
patients	B-MED
had	O
benefited	O
from	O
a	O
complete	O
interpretable	O
videonystagmography	B-MED
.	O
For	O
14	O
of	O
these	O
patients	B-MED
vestibular	B-MED
damage	I-MED
was	O
diagnosed	B-MED
post	B-MED
-	I-MED
radiotherapy	I-MED
.	O
During	O
irradiation	B-MED
,	O
six	O
patients	B-MED
felt	O
nauseous	B-MED
,	O
but	O
without	O
dizziness	B-MED
.	O
In	O
univariate	B-MED
analysis	I-MED
,	O
we	O
found	O
a	O
relationship	B-MED
statistically	B-MED
significant	I-MED
between	O
the	O
average	O
dose	B-MED
received	O
by	O
the	O
vestibules	B-MED
and	O
vestibular	B-MED
disorder	I-MED
videonystagmography	B-MED
(	O
P=0.001	O
,	O
odds	B-MED
ratio	I-MED
[	O
OR	B-MED
]	O
:	O
1.08	O
[	O
1.025-.138	O
]	O
)	O
,	O
but	O
there	O
was	O
no	B-MED
relationship	B-MED
between	O
vestibular	B-MED
disorder	I-MED
videonystagmography	B-MED
and	O
nausea	B-MED
(	O
P=0.701	O
)	O
.	O
Irradiation	B-MED
of	O
the	O
vestibular	B-MED
system	I-MED
during	O
IMRT	B-MED
does	O
not	O
seem	O
to	O
explain	O
the	O
nausea	B-MED
.	O
The	O
Chinese	B-MED
Herbal	I-MED
Mixture	B-MED
Tien	B-MED
-	I-MED
Hsien	I-MED
Liquid	I-MED
Augments	B-MED
the	O
Anticancer	B-MED
Immunity	B-MED
in	O
Tumor	B-MED
Cell	I-MED
-	O
Vaccinated	B-MED
Mice	B-MED
Background	O
The	O
Chinese	B-MED
herbal	I-MED
mixture	B-MED
,	O
Tien	B-MED
-	I-MED
Hsien	I-MED
liquid	I-MED
(	O
THL	B-MED
)	O
,	O
has	O
been	O
used	O
as	O
an	O
anticancer	B-MED
dietary	B-MED
supplement	I-MED
for	O
more	O
than	O
20	O
years	B-MED
.	O
Our	O
previous	B-MED
studies	B-MED
have	O
shown	O
that	O
THL	B-MED
can	O
modulate	B-MED
immune	B-MED
response	I-MED
and	O
inhibit	B-MED
tumor	B-MED
growth	I-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
further	O
evaluated	B-MED
the	O
effect	B-MED
of	O
THL	B-MED
on	O
anticancer	B-MED
immune	B-MED
response	I-MED
in	O
mice	B-MED
vaccinated	B-MED
with	O
γ	B-MED
-	I-MED
ray	I-MED
-	O
irradiated	B-MED
tumor	B-MED
cells	I-MED
.	O
Methods	O
The	O
antitumor	B-MED
effect	B-MED
of	O
THL	B-MED
was	O
determined	B-MED
in	O
mice	B-MED
vaccinated	B-MED
with	O
low	B-MED
-	I-MED
tumorigenic	I-MED
CT-26	I-MED
-	I-MED
low	I-MED
colon	I-MED
cancer	I-MED
cells	I-MED
or	O
γ	B-MED
-	I-MED
ray	I-MED
-	I-MED
irradiated	I-MED
high	B-MED
-	I-MED
tumorigenic	I-MED
CT-26	I-MED
-	I-MED
high	I-MED
colon	I-MED
cancer	I-MED
cells	I-MED
.	O
The	O
number	B-MED
of	O
natural	B-MED
killer	I-MED
(	I-MED
NK	I-MED
)	I-MED
cells	I-MED
and	O
T	B-MED
lymphocytes	I-MED
in	O
the	O
spleen	B-MED
was	O
analyzed	B-MED
by	O
flow	B-MED
cytometry	I-MED
.	O
The	O
tumor	B-MED
-	O
killing	B-MED
activities	B-MED
of	O
NK	B-MED
cells	I-MED
and	O
cytotoxic	B-MED
T	I-MED
lymphocytes	I-MED
(	O
CTLs	B-MED
)	O
were	O
analyzed	B-MED
by	O
flow	B-MED
cytometry	I-MED
using	O
YAC-1	B-MED
and	O
CT-26	B-MED
-	I-MED
high	I-MED
cells	I-MED
,	O
respectively	O
,	O
as	O
target	B-MED
cells	B-MED
.	O
The	O
levels	B-MED
of	O
IFN	B-MED
-	I-MED
γ	I-MED
,	O
IL-2	B-MED
,	O
and	O
TNF	B-MED
-	I-MED
α	I-MED
were	O
determined	B-MED
by	I-MED
ELISA	B-MED
.	O
Results	O
THL	B-MED
suppressed	B-MED
the	O
growth	B-MED
of	O
CT-26	B-MED
-	I-MED
high	I-MED
tumor	I-MED
in	O
mice	B-MED
previously	O
vaccinated	B-MED
with	O
low	B-MED
-	I-MED
tumorigenic	I-MED
CT-26	I-MED
-	I-MED
low	I-MED
cells	I-MED
or	O
γ	B-MED
-	I-MED
irradiated	I-MED
CT-26	B-MED
-	I-MED
high	I-MED
cells	I-MED
.	O
THL	B-MED
increased	B-MED
the	O
populations	O
of	O
NK	B-MED
cells	I-MED
and	O
CD4	B-MED
+	I-MED
T	I-MED
lymphocytes	I-MED
in	O
the	O
spleen	B-MED
and	O
enhanced	B-MED
the	O
tumor	B-MED
-	O
killing	B-MED
activities	B-MED
of	O
NK	B-MED
cells	I-MED
and	O
CTL	B-MED
in	O
mice	B-MED
vaccinated	B-MED
with	O
γ	B-MED
-	I-MED
irradiated	I-MED
CT-26	B-MED
-	I-MED
high	I-MED
cells	I-MED
.	O
THL	B-MED
increased	B-MED
the	O
production	B-MED
of	O
IFN	B-MED
-	I-MED
γ	I-MED
,	O
IL-2	B-MED
,	O
and	O
TNF	B-MED
-	I-MED
α	I-MED
in	O
mice	B-MED
vaccinated	B-MED
with	O
γ	B-MED
-	I-MED
irradiated	I-MED
CT-26	B-MED
-	I-MED
high	I-MED
cells	I-MED
.	O
Conclusion	O
THL	B-MED
can	O
enhance	B-MED
the	O
antitumor	B-MED
immune	B-MED
responses	I-MED
in	O
mice	B-MED
vaccinated	B-MED
with	O
killed	B-MED
tumor	B-MED
cells	I-MED
.	O
These	O
results	B-MED
suggest	O
that	O
THL	B-MED
may	O
be	O
used	O
as	O
a	O
complementary	B-MED
medicine	I-MED
for	O
cancer	B-MED
patients	B-MED
previously	B-MED
treated	B-MED
with	O
killed	B-MED
tumor	I-MED
cell	I-MED
vaccines	I-MED
,	O
radiotherapy	B-MED
,	O
or	O
chemotherapy	B-MED
.	O
Maf1	B-MED
-mediated	O
regulation	B-MED
of	O
yeast	B-MED
RNA	B-MED
polymerase	I-MED
III	I-MED
is	O
correlated	B-MED
with	O
CCA	B-MED
addition	I-MED
at	I-MED
the	I-MED
3	I-MED
'	I-MED
end	I-MED
of	I-MED
tRNA	I-MED
tRNA	B-MED
precursors	I-MED
In	O
eukaryotic	B-MED
cells	I-MED
tRNA	B-MED
synthesis	I-MED
is	O
negatively	B-MED
regulated	B-MED
by	O
the	O
protein	B-MED
Maf1	I-MED
,	O
conserved	O
from	O
yeast	B-MED
to	O
humans	B-MED
.	O
Maf1	B-MED
from	O
yeast	B-MED
Saccharomyces	B-MED
cerevisiae	I-MED
mediates	O
repression	B-MED
of	O
trna	B-MED
transcription	I-MED
when	O
cells	B-MED
are	O
transferred	O
from	O
medium	B-MED
with	O
glucose	B-MED
to	O
medium	B-MED
with	O
glycerol	B-MED
,	O
a	O
non	B-MED
-	I-MED
fermentable	I-MED
carbon	B-MED
source	B-MED
.	O
The	O
strain	B-MED
with	O
deleted	B-MED
gene	B-MED
encoding	B-MED
Maf1	B-MED
(	O
maf1Δ	B-MED
)	O
is	O
viable	B-MED
but	O
accumulates	O
tRNA	B-MED
precursors	I-MED
.	O
In	O
this	O
study	B-MED
tRNA	B-MED
precursors	I-MED
were	O
analysed	B-MED
by	O
RNA	B-MED
-	I-MED
Seq	I-MED
and	O
Northern	B-MED
hybridization	I-MED
in	O
wild	B-MED
type	I-MED
strain	B-MED
and	O
maf1Δ	B-MED
mutant	B-MED
grown	O
in	O
glucose	B-MED
medium	B-MED
or	O
upon	O
shift	O
to	O
repressive	B-MED
conditions	I-MED
.	O
A	O
negative	B-MED
effect	B-MED
of	O
maf1Δ	B-MED
mutant	B-MED
on	O
the	O
addition	B-MED
of	I-MED
the	I-MED
auxiliary	I-MED
CCA	I-MED
nucleotides	I-MED
to	I-MED
the	I-MED
3	I-MED
'	I-MED
end	I-MED
of	I-MED
pre	I-MED
-	I-MED
tRNAs	I-MED
was	O
observed	O
in	O
cells	B-MED
shifted	O
to	O
unfavourable	O
growth	B-MED
conditions	B-MED
.	O
This	O
effect	B-MED
was	O
reduced	B-MED
by	O
overexpression	B-MED
of	O
the	O
yeast	B-MED
CCA1	B-MED
gene	I-MED
encoding	B-MED
ATP(CTP):tRNA	B-MED
nucleotidyltransferase	I-MED
.	O
The	O
CCA	B-MED
sequence	I-MED
at	O
the	O
3	O
'	O
end	O
is	O
important	O
for	O
export	B-MED
of	O
tRNA	B-MED
precursors	I-MED
from	O
the	O
nucleus	B-MED
and	O
essential	O
for	O
tRNA	B-MED
charging	I-MED
with	O
amino	B-MED
acids	I-MED
.	O
Data	B-MED
presented	O
here	O
indicate	O
that	O
CCA	B-MED
-	I-MED
addition	I-MED
to	I-MED
intron	I-MED
-containing	I-MED
end	I-MED
-	I-MED
processed	I-MED
tRNA	I-MED
precursors	I-MED
intron	B-MED
is	O
a	O
limiting	B-MED
step	I-MED
in	O
tRNA	B-MED
maturation	I-MED
when	O
there	O
is	O
no	O
Maf1	B-MED
mediated	O
RNA	B-MED
polymerase	I-MED
III	I-MED
(	O
Pol	B-MED
III	I-MED
)	O
repression	B-MED
.	O
The	O
correlation	B-MED
between	O
CCA	B-MED
synthesis	B-MED
and	O
Pol	B-MED
III	I-MED
regulation	B-MED
by	O
Maf1	B-MED
could	O
be	O
important	O
in	O
coordination	B-MED
of	O
tRNA	B-MED
transcription	I-MED
,	O
processing	B-MED
and	O
regulation	B-MED
of	I-MED
translation	I-MED
.	O
MESOTHELIAL	B-MED
CELL	I-MED
ADHERENCE	B-MED
TO	O
VASCULAR	B-MED
PROSTHESES	I-MED
AND	O
THEIR	O
SUBSEQUENT	B-MED
GROWTH	B-MED
IN	B-MED
VITRO	I-MED
Cell	B-MED
seeding	B-MED
may	O
decrease	B-MED
the	O
thrombogenicity	B-MED
of	O
implanted	B-MED
vascular	B-MED
grafts	I-MED
,	O
but	O
its	O
application	O
is	O
hampered	O
by	O
the	O
limited	O
availability	B-MED
of	I-MED
autologous	B-MED
endothelial	B-MED
cells	I-MED
.	O
Human	B-MED
peritoneal	B-MED
mesothelial	B-MED
cells	I-MED
have	O
blood	B-MED
flow	I-MED
supporting	B-MED
qualities	I-MED
and	O
are	O
readily	B-MED
available	I-MED
.	O
This	O
study	O
investigated	B-MED
the	O
adherence	B-MED
of	O
mesothelial	B-MED
cells	I-MED
to	O
vascular	B-MED
prostheses	I-MED
and	O
their	O
subsequent	B-MED
growth	B-MED
in	B-MED
vitro	I-MED
.	O
Circular	B-MED
pieces	B-MED
of	O
various	O
vascular	B-MED
prosthetic	B-MED
materials	I-MED
were	O
seeded	B-MED
with	O
51Chromium	B-MED
-	I-MED
labeled	I-MED
mesothelial	B-MED
and	O
endothelial	B-MED
cells	I-MED
and	O
left	O
for	O
either	O
5	O
,	O
15	O
,	O
30	O
,	O
60	O
,	O
and	O
120	O
minutes	B-MED
.	O
The	O
unattached	B-MED
cells	B-MED
were	O
removed	B-MED
and	O
the	O
degree	B-MED
of	O
cell	B-MED
attachment	B-MED
was	O
measured	B-MED
.	O
The	O
number	B-MED
of	O
mesothelial	B-MED
cells	I-MED
to	O
Dacron	B-MED
increased	B-MED
during	O
the	O
first	O
60	O
min	B-MED
up	O
to	O
35.2	O
%	O
of	O
the	O
seeded	B-MED
inoculum	B-MED
where	O
after	O
a	O
plateau	B-MED
was	O
reached	B-MED
.	O
Scanning	B-MED
electron	I-MED
microscopy	I-MED
showed	O
spreaded	B-MED
mesothelial	B-MED
cells	I-MED
adherent	B-MED
to	O
the	O
Dacron	B-MED
fibers	I-MED
.	O
A	O
significant	B-MED
increase	B-MED
in	O
adherence	B-MED
was	O
observed	B-MED
after	O
preincubation	B-MED
of	O
Dacron	B-MED
with	O
10	O
μg	O
/	O
mL	O
fibronectin	B-MED
,	O
but	O
no	B-MED
improvement	I-MED
was	O
found	B-MED
after	O
preincubation	B-MED
with	O
human	B-MED
serum	B-MED
albumin	I-MED
or	O
gelatin	B-MED
.	O
Mesothelial	B-MED
cells	I-MED
adhered	B-MED
better	O
to	O
Gelcoated	B-MED
than	O
to	O
Gelsealed	B-MED
or	O
plain	B-MED
Dacron	I-MED
.	O
The	O
adherence	B-MED
of	O
mesothelial	B-MED
cells	I-MED
to	O
ePTFE	B-MED
(	O
Teflon	B-MED
)	O
was	O
significantly	B-MED
poorer	B-MED
.	O
No	B-MED
significant	I-MED
differences	B-MED
in	O
adherence	B-MED
were	O
found	B-MED
between	O
mesothelial	B-MED
and	O
endothelial	B-MED
cells	I-MED
.	O
Mesothelial	B-MED
cell	I-MED
growth	B-MED
on	O
Dacron	B-MED
resulted	B-MED
in	O
a	O
modest	B-MED
increase	I-MED
in	O
the	O
number	B-MED
of	O
viable	B-MED
cells	I-MED
during	O
27	O
days	B-MED
,	O
which	O
implies	O
biocompatibility	B-MED
of	O
Dacron	B-MED
and	O
mesothelial	B-MED
cells	I-MED
in	B-MED
vitro	I-MED
.	O
Clinical	B-MED
Observation	I-MED
of	O
Treatment	B-MED
of	O
Chronic	B-MED
Subdural	I-MED
Hematoma	I-MED
With	O
Novel	B-MED
Double	I-MED
Needle	I-MED
Minimally	I-MED
Invasive	I-MED
Aspiration	I-MED
Technology	I-MED
The	O
aim	B-MED
of	O
the	O
present	O
study	B-MED
was	O
to	O
explore	O
the	O
clinical	B-MED
effects	I-MED
,	O
including	O
the	O
prevention	O
of	O
complications	B-MED
,	O
of	O
the	O
treatment	B-MED
of	O
chronic	B-MED
subdural	I-MED
hematoma	I-MED
with	O
double	B-MED
needle	I-MED
aspiration	I-MED
.	O
The	O
clinical	B-MED
data	I-MED
of	O
31	O
patients	B-MED
with	O
chronic	B-MED
subdural	I-MED
hematoma	I-MED
treated	B-MED
by	O
double	B-MED
YL-1	I-MED
needle	I-MED
double	O
skull	B-MED
drilling	I-MED
and	O
31	O
controls	O
treated	B-MED
by	O
traditional	O
drilling	B-MED
and	O
drainage	B-MED
were	O
analyzed	O
retrospectively	O
.	O
In	O
the	O
YL-1	B-MED
needle	I-MED
group	B-MED
,	O
only	O
1	O
patient	B-MED
was	O
with	O
hematoma	B-MED
recurrence	B-MED
,	O
1	O
patient	B-MED
was	O
with	O
intracranial	B-MED
pneumocephalus	I-MED
,	O
and	O
the	O
remaining	O
patients	B-MED
who	O
were	O
followed	O
up	O
for	O
3	O
months	B-MED
achieved	O
a	O
clinical	B-MED
cure	I-MED
.	O
In	O
the	O
traditional	B-MED
drilling	I-MED
and	O
drainage	B-MED
group	B-MED
,	O
13	O
patients	B-MED
were	O
with	O
hematoma	B-MED
recurrence	B-MED
within	O
3	O
months	B-MED
after	O
the	O
operation	B-MED
and	O
7	O
patients	B-MED
were	O
with	O
postoperative	B-MED
intracranial	B-MED
pneumocephalus	I-MED
.	O
The	O
method	B-MED
of	O
double	B-MED
YL-1	I-MED
needle	I-MED
is	O
better	O
than	O
the	O
traditional	B-MED
drilling	I-MED
and	O
drainage	B-MED
method	I-MED
for	O
the	O
treatment	B-MED
of	O
chronic	B-MED
subdural	I-MED
hematoma	I-MED
because	O
it	O
reduces	O
the	O
postoperative	B-MED
recurrence	B-MED
rate	O
and	O
complications	B-MED
.	O
Reimbursement	B-MED
Based	O
on	O
Value	O
in	O
Knee	B-MED
Surgery	I-MED
:	O
What	O
You	O
Need	O
to	O
Know	O
about	O
the	O
Medicare	B-MED
Access	I-MED
and	I-MED
Children	I-MED
's	I-MED
Health	I-MED
Insurance	I-MED
Program	I-MED
Reauthorization	I-MED
Act	I-MED
of	I-MED
2015	I-MED
Health	B-MED
care	I-MED
cost	I-MED
is	O
consuming	O
a	O
large	O
portion	O
of	O
the	O
nation	B-MED
's	I-MED
gross	B-MED
domestic	I-MED
product	I-MED
while	O
placing	O
added	O
economic	B-MED
burdens	I-MED
on	O
physicians	B-MED
and	O
their	O
patients	B-MED
.	O
With	O
total	B-MED
joint	I-MED
replacement	I-MED
being	O
one	O
of	O
the	O
early	O
-	O
targeted	O
procedures	B-MED
in	O
the	O
evolving	O
health	B-MED
care	I-MED
environment	I-MED
,	O
knee	B-MED
surgeons	I-MED
will	O
benefit	O
from	O
developing	O
a	O
critical	O
knowledge	O
on	O
health	B-MED
care	I-MED
reforms	I-MED
and	O
their	O
financial	O
implications	O
.	O
The	O
Medicare	B-MED
Access	I-MED
and	I-MED
Children	I-MED
's	I-MED
Health	I-MED
Insurance	I-MED
Program	I-MED
Reauthorization	I-MED
Act	I-MED
represents	O
a	O
cohesive	O
movement	O
toward	O
value	B-MED
-	I-MED
based	I-MED
payment	I-MED
reform	I-MED
and	O
contains	O
several	O
unchartered	O
rulings	O
that	O
require	O
detailed	O
attention	O
by	O
knee	B-MED
surgeons	I-MED
.	O
In	O
this	O
article	O
,	O
we	O
provide	O
a	O
contextual	B-MED
framework	I-MED
of	O
health	B-MED
care	I-MED
legislation	I-MED
that	O
has	O
led	O
to	O
the	O
formation	O
of	O
the	O
current	O
health	B-MED
policy	I-MED
,	O
and	O
present	O
a	O
comprehensive	B-MED
summary	B-MED
and	O
update	O
on	O
the	O
Merit	B-MED
-	I-MED
Based	I-MED
Incentive	I-MED
Payment	I-MED
Systems	I-MED
and	O
Alternative	B-MED
Payment	I-MED
Models	I-MED
reimbursement	I-MED
models	I-MED
.	O
Comparison	B-MED
between	O
magnetic	B-MED
resonance	I-MED
imaging	I-MED
and	O
B	B-MED
-	I-MED
mode	I-MED
ultrasound	I-MED
in	O
detecting	B-MED
and	O
estimating	B-MED
the	O
extent	B-MED
of	O
human	B-MED
carotid	B-MED
atherosclerosis	I-MED
In	O
MRI	B-MED
studies	I-MED
of	O
carotid	B-MED
plaques	I-MED
,	O
ultrasound	B-MED
is	O
used	O
to	O
find	B-MED
plaques	B-MED
,	O
which	O
are	O
later	O
imaged	B-MED
using	O
MRI	B-MED
.	O
The	O
performance	B-MED
in	O
plaque	B-MED
detection	B-MED
has	O
not	O
been	O
compared	B-MED
between	O
the	O
modalities	B-MED
.	O
The	O
aim	O
of	O
the	O
current	O
study	B-MED
was	O
to	O
compare	B-MED
the	O
performance	B-MED
of	O
MRI	B-MED
and	O
ultrasound	B-MED
in	O
detecting	B-MED
carotid	B-MED
artery	I-MED
plaques	I-MED
and	O
measuring	B-MED
extent	B-MED
of	O
atherosclerosis	B-MED
.	O
Subjects	B-MED
with	O
at	O
least	O
one	O
plaque	B-MED
(	O
height	B-MED
≥2·5	O
mm	O
)	O
on	O
ultrasound	B-MED
were	O
imaged	B-MED
using	O
MRI	B-MED
.	O
The	O
number	B-MED
of	O
plaques	B-MED
and	O
their	O
height	B-MED
was	O
measured	B-MED
in	O
both	O
modalities	B-MED
;	O
plaque	B-MED
area	B-MED
and	O
volume	B-MED
were	O
analysed	B-MED
on	O
ultrasound	B-MED
and	O
MRI	B-MED
,	O
respectively	O
.	O
Thirty	B-MED
-	I-MED
eight	I-MED
subjects	B-MED
were	O
included	B-MED
.	O
MRI	B-MED
detected	B-MED
plaques	B-MED
in	O
95	O
%	O
of	O
carotid	B-MED
arteries	I-MED
with	O
a	O
plaque	B-MED
height	B-MED
of	O
≥2·5	O
mm	O
on	O
ultrasound	B-MED
and	O
in	O
all	O
carotid	B-MED
arteries	I-MED
with	O
a	O
plaque	B-MED
exceeding	O
2·5	O
mm	O
.	O
MRI	B-MED
detected	B-MED
53	O
%	O
of	O
the	O
plaques	B-MED
with	O
a	O
height	B-MED
below	O
2·5	O
mm	O
.	O
The	O
plaque	B-MED
height	B-MED
measured	B-MED
with	O
both	O
techniques	B-MED
correlated	B-MED
significantly	O
,	O
0·59	O
,	O
P<0·0001	O
.	O
Ultrasound	B-MED
-derived	O
plaque	B-MED
height	B-MED
and	O
plaque	B-MED
area	B-MED
correlated	B-MED
similarly	B-MED
to	O
MRI	B-MED
-derived	O
plaque	B-MED
volume	B-MED
,	O
r	O
=	O
0·52	O
;	O
P<0·0001	O
and	O
r	O
=	O
0·47	O
;	O
P	O
=	O
0·001	O
,	O
respectively	O
.	O
We	O
conclude	O
that	O
MRI	B-MED
has	O
a	O
similar	B-MED
sensitivity	B-MED
to	O
ultrasound	B-MED
in	O
finding	B-MED
carotid	B-MED
artery	I-MED
plaques	I-MED
that	O
are	O
2·5	O
mm	O
or	O
higher	B-MED
.	O
In	O
smaller	B-MED
plaques	B-MED
,	O
MRI	B-MED
detects	B-MED
fewer	B-MED
plaques	B-MED
.	O
Multiple	B-MED
carotid	I-MED
plaques	I-MED
seen	O
on	O
ultrasound	B-MED
most	O
often	O
are	O
a	O
misinterpretation	O
of	O
the	O
anatomy	B-MED
and	O
correspond	O
to	O
a	O
single	B-MED
plaque	I-MED
.	O
Plaque	B-MED
height	B-MED
on	O
ultrasound	B-MED
is	O
comparable	O
to	O
plaque	B-MED
height	B-MED
on	O
MRI	B-MED
and	O
correlates	B-MED
fairly	O
well	O
with	O
plaque	B-MED
volume	B-MED
on	O
MRI	B-MED
making	O
it	O
an	O
interesting	O
proxy	O
for	O
plaque	B-MED
burden	B-MED
.	O
Preliminary	O
Randomized	B-MED
Controlled	I-MED
Trial	I-MED
of	O
Habit	B-MED
Reversal	I-MED
Training	I-MED
for	O
Treatment	B-MED
of	O
Hair	B-MED
Pulling	I-MED
in	O
Youth	B-MED
This	O
study	B-MED
evaluated	B-MED
the	O
treatment	B-MED
efficacy	B-MED
of	O
habit	B-MED
reversal	I-MED
training	I-MED
(	O
HRT	B-MED
)	O
relative	O
to	O
treatment	B-MED
as	I-MED
usual	I-MED
(	O
TAU	B-MED
)	O
for	O
children	B-MED
and	O
adolescents	B-MED
aged	B-MED
7	O
-	O
17	O
years	B-MED
with	O
a	O
primary	O
diagnosis	B-MED
of	O
trichotillomania	B-MED
(	O
TTM	B-MED
)	O
.	O
An	O
initial	O
assessment	B-MED
consisting	O
of	O
semistructured	O
interviews	B-MED
and	O
rating	B-MED
scales	I-MED
was	O
conducted	O
.	O
Participants	B-MED
(	O
N	O
=	O
40	O
,	O
85	O
%	O
female	B-MED
)	O
meeting	O
diagnostic	B-MED
criteria	I-MED
for	O
TTM	B-MED
were	O
randomized	B-MED
to	O
either	O
8	O
weekly	B-MED
sessions	O
of	O
HRT	B-MED
by	O
trained	O
therapists	B-MED
or	O
8	O
weeks	B-MED
of	O
TAU	B-MED
.	O
One	O
week	B-MED
after	O
the	O
final	O
HRT	B-MED
session	O
or	O
final	O
TAU	B-MED
week	B-MED
,	O
patients	B-MED
completed	O
a	O
posttreatment	B-MED
assessment	I-MED
,	O
followed	O
by	O
1-	O
and	O
3-	O
month	B-MED
follow	B-MED
-	I-MED
up	I-MED
assessments	B-MED
.	O
All	O
assessments	B-MED
were	O
conducted	O
by	O
a	O
trained	O
rater	B-MED
who	O
was	O
blinded	B-MED
to	O
treatment	B-MED
condition	B-MED
.	O
The	O
group	O
by	O
time	O
analysis	B-MED
of	I-MED
variance	I-MED
yielded	O
a	O
significant	B-MED
interaction	O
on	O
the	O
National	B-MED
Institute	I-MED
of	I-MED
Mental	I-MED
Health	I-MED
-	O
Trichotillomania	B-MED
Severity	I-MED
Scale	I-MED
Total	I-MED
Score	I-MED
(	O
F1,38	O
=	O
16.47	O
,	O
p	O
<	O
0.001	O
,	O
η(2)p	O
=	O
0.30	O
)	O
.	O
The	O
mean	B-MED
score	I-MED
decreased	O
from	O
12.67	O
±	O
4.60	O
at	O
baseline	B-MED
to	O
5.62	O
±	O
4.38	O
at	O
posttreatment	B-MED
in	O
the	O
HRT	B-MED
group	B-MED
(	O
t20	O
=	O
5.99	O
,	O
p	O
<	O
0.001	O
,	O
d	O
=	O
1.31	O
)	O
,	O
whereas	O
the	O
TAU	B-MED
group	B-MED
changed	O
from	O
10.42	O
±	O
4.35	O
to	O
9.32	O
±	O
4.11	O
(	O
t18	O
=	O
1.34	O
,	O
p	O
=	O
0.20	O
,	O
d	O
=	O
0.31	O
)	O
.	O
The	B-MED
Massachusetts	I-MED
General	I-MED
Hospital	I-MED
-	I-MED
Hair	I-MED
Pulling	I-MED
Scale	I-MED
Total	I-MED
Score	I-MED
decreased	O
from	O
15.14	O
±	O
3.86	O
at	O
baseline	B-MED
to	O
7.14	O
±	O
5.54	O
at	O
posttreatment	B-MED
in	O
the	O
HRT	B-MED
group	B-MED
(	O
t20	O
=	O
6.16	O
,	O
p	O
<	O
0.001	O
,	O
d	O
=	O
1.34	O
)	O
;	O
the	O
TAU	B-MED
group	B-MED
changed	O
from	O
14.16	O
±	O
4.51	O
to	O
12.26	O
±	O
4.34	O
(	O
t18	O
=	O
1.50	O
,	O
p	O
=	O
0.15	O
,	O
d	O
=	O
0.34	O
)	O
.	O
On	O
the	O
Clinical	B-MED
Global	I-MED
Impressions	I-MED
-	I-MED
Improvement	I-MED
,	O
16/21	O
participants	B-MED
(	O
76	O
%	O
)	O
were	O
rated	O
as	O
treatment	B-MED
responders	B-MED
in	O
the	O
HRT	B-MED
group	B-MED
versus	O
4/19	O
(	O
21	O
%	O
)	O
in	O
the	O
TAU	B-MED
group	B-MED
(	O
χ(2	O
)	O
=	O
12.13	O
,	O
p	O
<	O
0.001	O
,	O
V	O
=	O
0.55	O
)	O
.	O
At	O
1-	O
month	B-MED
follow	B-MED
-	I-MED
up	I-MED
,	O
10	O
-	O
12	O
treatment	B-MED
responders	B-MED
who	O
completed	O
the	O
assessment	B-MED
maintained	O
improvement	B-MED
.	O
At	O
3-	O
month	B-MED
follow	B-MED
-	I-MED
up	I-MED
,	O
six	O
of	O
eight	O
maintained	O
improvement	B-MED
.	O
HRT	B-MED
can	O
be	O
an	O
effective	O
treatment	B-MED
for	O
TTM	B-MED
in	O
youth	B-MED
.	O
Cobalamin	B-MED
Protection	B-MED
against	O
Oxidative	B-MED
Stress	I-MED
in	O
the	O
Acidophilic	B-MED
Iron	B-MED
-	I-MED
oxidizing	I-MED
Bacterium	I-MED
Leptospirillum	B-MED
Group	I-MED
II	I-MED
CF-1	I-MED
Members	O
of	O
the	O
genus	O
Leptospirillum	B-MED
are	O
aerobic	B-MED
iron	B-MED
-	I-MED
oxidizing	I-MED
bacteria	I-MED
belonging	O
to	O
the	O
phylum	B-MED
Nitrospira	I-MED
.	O
They	O
are	O
important	O
members	O
of	O
microbial	B-MED
communities	B-MED
that	O
catalyze	B-MED
the	O
biomining	B-MED
of	O
sulfidic	B-MED
ores	I-MED
,	O
thereby	O
solubilizing	O
metal	B-MED
ions	I-MED
.	O
These	O
microorganisms	B-MED
live	O
under	O
extremely	O
acidic	O
and	O
metal	B-MED
-loaded	O
environments	B-MED
and	O
thus	O
must	O
tolerate	O
high	O
concentrations	B-MED
of	O
reactive	B-MED
oxygen	I-MED
species	I-MED
(	O
ROS	B-MED
)	O
.	O
Cobalamin	B-MED
(	O
vitamin	B-MED
B12	I-MED
)	O
is	O
a	O
cobalt	B-MED
-containing	O
tetrapyrrole	B-MED
cofactor	B-MED
involved	O
in	O
intramolecular	B-MED
rearrangement	I-MED
reactions	I-MED
and	O
has	O
recently	O
been	O
suggested	O
to	O
be	O
an	O
intracellular	B-MED
antioxidant	B-MED
.	O
In	O
this	O
work	O
,	O
we	O
investigated	B-MED
the	O
effect	B-MED
of	O
the	O
exogenous	B-MED
addition	O
of	O
cobalamin	B-MED
on	O
oxidative	B-MED
stress	I-MED
parameters	B-MED
in	O
Leptospirillum	B-MED
group	I-MED
II	I-MED
strain	I-MED
CF-1	I-MED
.	O
Our	O
results	O
revealed	B-MED
that	O
the	O
external	B-MED
supplementation	I-MED
of	O
cobalamin	B-MED
reduces	O
the	O
levels	O
of	O
intracellular	B-MED
ROSs	B-MED
and	O
the	O
damage	B-MED
to	O
biomolecules	B-MED
,	O
and	O
also	O
stimulates	B-MED
the	O
growth	B-MED
and	O
survival	B-MED
of	I-MED
cells	I-MED
exposed	O
to	O
oxidative	B-MED
stress	I-MED
exerted	O
by	O
ferric	B-MED
ion	I-MED
,	O
hydrogen	B-MED
peroxide	I-MED
,	O
chromate	B-MED
and	O
diamide	B-MED
.	O
Furthermore	O
,	O
exposure	O
of	O
strain	B-MED
CF-1	I-MED
to	O
oxidative	B-MED
stress	I-MED
elicitors	O
resulted	O
in	O
the	O
transcriptional	B-MED
activation	I-MED
of	O
the	O
cbiA	B-MED
gene	I-MED
encoding	O
CbiA	B-MED
of	O
the	O
cobalamin	B-MED
biosynthetic	B-MED
pathway	I-MED
.	O
Altogether	O
,	O
these	O
data	B-MED
suggest	O
that	O
cobalamin	B-MED
plays	O
an	O
important	O
role	O
in	O
redox	B-MED
protection	B-MED
of	O
Leptospirillum	B-MED
strain	I-MED
CF-1	I-MED
,	O
supporting	O
survival	O
of	O
this	O
microorganism	B-MED
under	O
extremely	O
oxidative	B-MED
environmental	B-MED
conditions	I-MED
.	O
Understanding	O
the	O
mechanisms	B-MED
underlying	O
the	O
protective	B-MED
effect	B-MED
of	O
cobalamin	B-MED
against	O
oxidative	B-MED
stress	I-MED
may	O
help	O
to	O
develop	O
strategies	O
to	O
make	O
biomining	B-MED
processes	B-MED
more	O
effective	B-MED
.	O
Temporal	B-MED
and	O
Spatial	B-MED
Variability	B-MED
of	O
Fungal	B-MED
Structures	I-MED
and	O
Host	B-MED
Responses	I-MED
in	O
an	O
Incompatible	B-MED
Rust	I-MED
-	I-MED
Wheat	I-MED
Interaction	I-MED
Information	B-MED
about	O
temporal	B-MED
and	O
spatial	B-MED
variability	B-MED
of	O
fungal	B-MED
structures	I-MED
and	O
host	B-MED
responses	I-MED
is	O
scarce	B-MED
in	O
comparison	B-MED
to	O
the	O
vast	O
amount	B-MED
of	O
genetic	B-MED
,	O
biochemical	B-MED
,	O
and	O
physiological	B-MED
studies	B-MED
of	O
host	B-MED
-	I-MED
pathogen	I-MED
interactions	I-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
used	B-MED
avirulent	B-MED
wild	B-MED
type	I-MED
and	O
virulent	B-MED
mutant	B-MED
isolates	B-MED
of	O
Puccinia	B-MED
striiformis	I-MED
to	O
characterize	B-MED
the	O
interactions	B-MED
in	O
wheat	B-MED
carrying	B-MED
yellow	B-MED
rust	I-MED
Yr2	B-MED
resistance	B-MED
.	O
Both	O
conventional	B-MED
and	O
advanced	B-MED
microscopic	B-MED
techniques	B-MED
were	O
used	B-MED
for	O
a	O
detailed	B-MED
study	B-MED
of	O
morphology	B-MED
and	O
growth	B-MED
of	O
fungal	B-MED
colonies	B-MED
and	O
associated	B-MED
host	B-MED
cell	I-MED
responses	I-MED
.	O
The	O
growth	B-MED
of	O
the	O
wild	B-MED
type	I-MED
isolates	B-MED
was	O
highly	B-MED
restricted	B-MED
due	O
to	O
hypersensitive	B-MED
response	I-MED
(	O
HR	B-MED
,	O
plant	B-MED
cell	B-MED
death	I-MED
)	O
indicated	B-MED
by	O
autofluorescence	B-MED
and	O
change	B-MED
in	O
the	O
shape	B-MED
of	O
the	O
affected	B-MED
plant	B-MED
cells	I-MED
.	O
The	O
host	B-MED
response	I-MED
appeared	B-MED
post	B-MED
-	O
haustorial	B-MED
,	O
but	O
large	B-MED
variation	B-MED
in	O
the	O
time	B-MED
and	O
stage	B-MED
of	O
arrest	B-MED
was	O
observed	B-MED
for	O
individual	B-MED
fungal	B-MED
colonies	B-MED
,	O
probably	B-MED
due	O
to	O
a	O
delay	B-MED
between	B-MED
detection	B-MED
and	O
response	B-MED
.	O
Some	O
colonies	B-MED
were	O
stopped	B-MED
right	B-MED
after	I-MED
the	O
formation	B-MED
of	O
the	O
primary	B-MED
infection	I-MED
hyphae	B-MED
whereas	O
others	O
formed	B-MED
highly	B-MED
branched	B-MED
mycelia	B-MED
.	O
HR	B-MED
was	O
first	O
observed	B-MED
in	O
host	B-MED
cells	I-MED
in	O
direct	B-MED
contact	B-MED
with	O
fungal	B-MED
structures	I-MED
,	O
after	O
which	O
the	O
defense	B-MED
responses	I-MED
spread	B-MED
to	O
adjacent	B-MED
host	B-MED
cells	I-MED
,	O
and	O
eventually	O
led	O
to	O
encasement	B-MED
of	O
the	O
fungal	B-MED
colony	B-MED
.	O
Several	B-MED
cells	B-MED
with	O
HR	B-MED
contained	B-MED
haustoria	B-MED
,	O
which	O
were	O
small	B-MED
and	O
underdeveloped	B-MED
,	O
but	O
some	B-MED
cells	B-MED
contained	B-MED
normal	B-MED
sized	B-MED
haustoria	B-MED
without	O
signs	B-MED
of	O
hypersensitivity	B-MED
.	O
The	O
growth	B-MED
of	O
the	O
virulent	B-MED
mutants	B-MED
in	O
the	O
resistant	B-MED
plants	B-MED
was	O
similar	B-MED
to	O
the	O
growth	B-MED
in	O
plants	B-MED
without	O
Yr2	B-MED
resistance	B-MED
,	O
which	O
is	O
a	O
strong	B-MED
indication	B-MED
that	O
the	O
incompatible	B-MED
phenotype	B-MED
was	O
associated	B-MED
with	O
Yr2	B-MED
.	O
The	O
interaction	B-MED
between	B-MED
P.	B-MED
striiformis	I-MED
and	O
wheat	B-MED
with	O
Yr2	B-MED
resistance	B-MED
was	O
highly	B-MED
variable	B-MED
in	O
time	B-MED
and	O
space	B-MED
,	O
which	O
demonstrate	B-MED
that	O
histological	B-MED
studies	B-MED
are	O
important	B-MED
for	O
a	O
deeper	B-MED
understanding	I-MED
of	O
host	B-MED
-	I-MED
pathogen	I-MED
interactions	I-MED
and	O
plant	B-MED
defense	B-MED
mechanisms	B-MED
in	O
general	B-MED
.	O
Comparison	B-MED
of	O
Occlusive	B-MED
and	O
Open	B-MED
Application	B-MED
in	O
a	O
Psoriasis	B-MED
Plaque	I-MED
Test	I-MED
Design	I-MED
,	O
Exemplarily	O
Using	O
Investigations	B-MED
of	O
Mapracorat	B-MED
0.1	O
%	O
Ointment	B-MED
versus	O
Vehicle	B-MED
and	O
Reference	B-MED
Drugs	B-MED
Psoriasis	B-MED
plaque	I-MED
tests	I-MED
(	O
PPTs	B-MED
)	O
are	O
important	O
tools	O
in	O
the	O
early	O
phases	O
of	O
antipsoriatic	B-MED
drug	B-MED
development	I-MED
.	O
Two	O
distinct	O
PPT	B-MED
design	I-MED
variants	O
(	O
open	B-MED
vs.	O
occluded	B-MED
drug	I-MED
application	I-MED
)	O
are	O
commonly	O
used	O
,	O
but	O
no	O
previous	O
work	O
has	O
aimed	O
to	O
directly	O
compare	O
and	O
contrast	O
their	O
performance	O
.	O
We	O
compared	O
the	O
antipsoriatic	B-MED
efficacy	O
of	O
mapracorat	B-MED
0.1	O
%	O
ointment	B-MED
and	O
reference	B-MED
drugs	B-MED
reported	O
in	O
2	O
separate	O
studies	B-MED
,	O
representing	O
open	B-MED
and	O
occluded	B-MED
PPT	I-MED
designs	I-MED
.	O
The	O
drug	B-MED
effect	I-MED
size	O
was	O
measured	O
by	O
sonography	B-MED
(	O
mean	O
change	O
in	O
echo	O
-	O
poor	O
band	O
thickness	B-MED
)	O
,	O
chromametry	B-MED
,	O
and	O
standardized	O
clinical	B-MED
assessment	I-MED
.	O
Antipsoriatic	B-MED
effects	B-MED
were	O
detectable	O
for	O
the	O
study	B-MED
drugs	B-MED
in	O
both	O
occluded	B-MED
and	O
open	B-MED
PPTs	I-MED
.	O
Differences	O
between	O
the	O
potency	B-MED
of	O
antipsoriatic	B-MED
drugs	I-MED
and	O
vehicle	B-MED
were	O
observable	O
.	O
The	O
total	O
antipsoriatic	B-MED
effect	B-MED
size	O
appeared	O
to	O
be	O
higher	O
in	O
the	O
occluded	B-MED
PPT	I-MED
than	O
the	O
open	B-MED
PPT	I-MED
,	O
despite	O
the	O
shorter	O
treatment	B-MED
duration	I-MED
(	O
2	O
vs.	O
4	O
weeks	B-MED
)	O
.	O
Effect	B-MED
dynamics	B-MED
over	O
time	B-MED
revealed	O
greater	O
differences	O
between	O
some	O
study	B-MED
drugs	B-MED
in	O
the	O
open	B-MED
PPT	I-MED
compared	O
to	O
the	O
occluded	B-MED
PPT	I-MED
.	O
Taking	O
the	O
higher	O
technical	B-MED
challenges	I-MED
for	O
the	O
open	B-MED
PPT	I-MED
into	O
account	O
,	O
we	O
recommend	O
the	O
occluded	B-MED
PPT	I-MED
as	O
a	O
standard	O
screening	B-MED
setting	O
in	O
early	B-MED
drug	B-MED
development	I-MED
.	O
In	O
special	O
cases	O
,	O
considering	O
certain	O
drug	B-MED
aspects	B-MED
or	O
study	B-MED
objectives	O
that	O
would	O
require	O
procedural	O
adaptations	O
,	O
an	O
open	B-MED
PPT	I-MED
could	O
be	O
the	O
better	O
-	O
suited	O
design	O
.	O
Finally	O
,	O
both	O
PPT	B-MED
models	O
show	O
clear	O
advantages	O
:	O
classification	B-MED
as	O
phase	B-MED
I	I-MED
studies	I-MED
,	O
small	O
number	O
of	O
psoriatic	O
subjects	O
,	O
relatively	O
short	O
study	B-MED
duration	B-MED
,	O
excellent	O
discrimination	O
between	O
compounds	B-MED
and	O
concentrations	B-MED
,	O
parallel	O
measurement	B-MED
of	O
treatment	B-MED
response	I-MED
,	O
and	O
go	O
/	O
no	O
go	O
decisions	O
very	O
early	B-MED
in	O
clinical	B-MED
development	I-MED
.	O
The	O
Experience	B-MED
of	O
Women	B-MED
Veterans	B-MED
Coming	O
Back	O
from	O
War	B-MED
Issues	B-MED
surrounding	I-MED
mental	I-MED
health	I-MED
are	O
common	O
for	O
women	B-MED
veterans	B-MED
who	O
have	O
served	O
in	O
Iraq	B-MED
and	O
Afghanistan	B-MED
wars	B-MED
.	O
The	O
goal	O
of	O
this	O
phenomenological	B-MED
study	B-MED
was	O
to	O
document	B-MED
themes	B-MED
in	O
the	O
stories	B-MED
gathered	O
from	O
eight	O
women	B-MED
veterans	B-MED
who	O
had	O
come	O
back	O
from	O
war	B-MED
.	O
Themes	B-MED
in	O
the	O
stories	B-MED
were	O
:	O
arriving	O
with	O
mixed	O
sentiments	B-MED
;	O
evolving	O
to	O
a	O
changed	B-MED
view	B-MED
of	I-MED
self	I-MED
;	O
permeating	B-MED
aggravation	I-MED
;	O
confounding	B-MED
broken	I-MED
relationships	I-MED
,	O
frequent	B-MED
deployments	I-MED
,	O
and	O
change	B-MED
in	I-MED
military	I-MED
status	I-MED
;	O
remembering	B-MED
war	B-MED
experiences	B-MED
;	O
and	O
seeking	B-MED
opportunity	I-MED
for	I-MED
what	I-MED
is	I-MED
possible	I-MED
.	O
Mental	B-MED
health	I-MED
issues	I-MED
can	O
be	O
observed	O
in	O
the	O
themes	B-MED
.	O
Including	O
story	B-MED
as	O
part	O
of	O
the	O
mental	B-MED
health	I-MED
visit	O
with	O
veterans	B-MED
may	O
be	O
beneficial	O
to	O
veterans	B-MED
as	O
they	O
deal	O
with	O
the	O
transition	B-MED
of	I-MED
coming	I-MED
back	I-MED
.	O
The	O
clinical	B-MED
prognosis	I-MED
of	O
implants	B-MED
that	O
are	O
placed	O
against	O
super	B-MED
-	I-MED
erupted	I-MED
opposing	O
dentition	B-MED
If	O
teeth	B-MED
are	O
missing	B-MED
,	O
super	B-MED
-	I-MED
eruption	I-MED
of	I-MED
teeth	I-MED
in	O
the	O
opposing	B-MED
arch	I-MED
can	O
occur	O
in	O
the	O
area	B-MED
and	O
can	O
change	O
the	O
occlusal	B-MED
plane	I-MED
.	O
When	O
missing	B-MED
teeth	I-MED
are	O
replaced	O
with	O
implants	B-MED
,	O
the	O
oral	B-MED
surgeon	I-MED
must	O
determine	O
whether	O
or	O
not	O
the	O
super	B-MED
-	I-MED
erupted	I-MED
teeth	I-MED
need	O
to	O
be	O
treated	B-MED
in	O
order	O
to	O
normalize	B-MED
the	O
occlusal	B-MED
plane	I-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
evaluated	B-MED
the	O
clinical	B-MED
prognosis	I-MED
of	O
dentition	B-MED
after	O
implant	B-MED
placement	I-MED
and	O
prosthetic	B-MED
treatment	I-MED
were	O
completed	B-MED
in	O
an	O
occlusal	B-MED
plane	I-MED
altered	O
by	O
super	B-MED
-	I-MED
erupted	I-MED
teeth	I-MED
in	O
the	O
opposing	B-MED
arch	I-MED
without	O
additional	O
treatment	B-MED
of	O
the	O
super	B-MED
-	I-MED
erupted	I-MED
teeth	I-MED
.	O
Twenty	O
-	O
two	O
patients	B-MED
(	O
9	O
males	B-MED
,	O
13	O
females	B-MED
)	O
were	O
treated	B-MED
with	O
implants	B-MED
and	O
prosthetics	B-MED
without	O
addressing	O
the	O
super	B-MED
-	I-MED
erupted	I-MED
opposing	O
dentition	B-MED
from	O
April	O
2004	O
to	O
August	O
2012	O
at	O
Seoul	B-MED
National	B-MED
University	I-MED
Bundang	I-MED
Hospital	I-MED
.	O
A	O
total	O
of	O
33	O
implants	B-MED
were	O
placed	O
.	O
Values	O
of	O
crestal	B-MED
bone	I-MED
loss	I-MED
,	O
survival	B-MED
rates	I-MED
,	O
and	O
surgical	B-MED
and	O
prosthetic	B-MED
complications	I-MED
for	O
an	O
average	O
of	O
29.6	O
months	B-MED
after	O
prosthetic	B-MED
loading	I-MED
were	O
recorded	O
.	O
In	O
one	O
case	B-MED
,	O
the	O
cover	B-MED
screw	I-MED
was	O
exposed	O
after	O
implant	B-MED
surgery	I-MED
.	O
The	O
mean	O
crestal	B-MED
bone	I-MED
loss	I-MED
was	O
0.09±0.30	O
mm	O
.	O
Of	O
the	O
33	O
implants	B-MED
,	O
31	O
survived	B-MED
,	O
a	O
survival	B-MED
rate	I-MED
of	O
93.94	O
%	O
.	O
A	O
prosthetic	B-MED
complication	I-MED
occurred	O
in	O
one	O
case	B-MED
but	O
functioned	O
well	O
after	O
correction	O
.	O
Favorable	O
clinical	B-MED
results	I-MED
from	O
prosthetic	B-MED
complications	I-MED
,	O
crestal	B-MED
bone	I-MED
loss	I-MED
,	O
and	O
implant	B-MED
survival	B-MED
rates	I-MED
were	O
exhibited	O
in	O
implants	B-MED
next	O
to	O
a	O
super	B-MED
-	I-MED
erupted	I-MED
opposing	I-MED
tooth	I-MED
.	O
Monitoring	B-MED
proteolytic	B-MED
processing	I-MED
events	B-MED
by	O
quantitative	B-MED
mass	I-MED
spectrometry	I-MED
Protease	B-MED
activity	I-MED
plays	O
a	O
key	O
role	B-MED
in	O
a	O
wide	O
variety	O
of	O
biological	B-MED
processes	I-MED
including	B-MED
gene	B-MED
expression	I-MED
,	O
protein	B-MED
turnover	I-MED
and	O
development	B-MED
.	O
misregulation	B-MED
of	O
these	O
proteins	B-MED
has	O
been	O
associated	B-MED
with	I-MED
many	O
cancer	B-MED
types	I-MED
such	O
as	O
prostate	B-MED
,	O
breast	B-MED
,	O
and	O
skin	B-MED
cancer	I-MED
.	O
thus	O
,	O
the	O
identification	B-MED
of	O
protease	B-MED
substrates	B-MED
will	O
provide	B-MED
key	O
information	B-MED
to	O
understand	B-MED
proteolysis	B-MED
-related	O
pathologies	B-MED
.	O
Areas	O
covered	B-MED
:	O
Proteomics	B-MED
-based	O
methods	B-MED
to	O
investigate	B-MED
proteolysis	B-MED
activity	I-MED
,	I-MED
focusing	O
on	O
substrate	B-MED
identification	B-MED
,	O
protease	B-MED
specificity	B-MED
and	O
their	O
applications	B-MED
in	O
systems	B-MED
biology	I-MED
are	O
reviewed	B-MED
.	O
Their	O
quantification	B-MED
strategies	O
,	O
challenges	B-MED
and	O
pitfalls	B-MED
are	O
underlined	O
and	O
the	O
biological	B-MED
implications	O
of	O
protease	B-MED
malfunction	B-MED
are	O
highlighted	O
.	O
Expert	B-MED
commentary	I-MED
:	O
Dysregulated	B-MED
protease	B-MED
activity	I-MED
is	O
a	O
hallmark	B-MED
for	O
some	O
disease	B-MED
pathologies	B-MED
such	O
as	O
cancer	B-MED
.	O
Current	B-MED
biochemical	B-MED
approaches	B-MED
are	O
low	B-MED
throughput	B-MED
and	O
some	O
are	O
limited	B-MED
by	O
the	O
amount	B-MED
of	O
sample	B-MED
required	B-MED
to	O
obtain	B-MED
reliable	O
results	B-MED
.	O
Mass	B-MED
spectrometry	I-MED
based	O
proteomics	B-MED
provides	B-MED
a	O
suitable	B-MED
platform	B-MED
to	O
investigate	B-MED
protease	B-MED
activity	I-MED
,	O
providing	B-MED
information	B-MED
about	O
substrate	B-MED
specificity	I-MED
and	O
mapping	B-MED
cleavage	B-MED
sites	I-MED
.	O
Clinical	B-MED
Features	B-MED
of	O
Smokers	B-MED
With	O
Radiological	B-MED
Emphysema	B-MED
But	O
Without	O
Airway	B-MED
Limitation	B-MED
The	O
clinical	B-MED
characteristics	I-MED
of	O
patients	B-MED
with	O
emphysema	B-MED
but	O
without	O
airway	B-MED
limitations	B-MED
remain	O
unknown	B-MED
.	O
The	O
goal	B-MED
of	O
this	O
study	B-MED
was	O
to	O
compare	B-MED
the	O
clinical	B-MED
features	B-MED
of	O
current	B-MED
and	O
former	B-MED
smokers	I-MED
without	O
airflow	B-MED
limitation	B-MED
who	O
have	O
radiologic	B-MED
emphysema	B-MED
on	O
chest	B-MED
CT	I-MED
scans	I-MED
vs	O
a	O
control	B-MED
group	I-MED
of	O
current	B-MED
and	O
ex	B-MED
-	I-MED
smokers	I-MED
without	O
emphysema	B-MED
.	O
Subjects	B-MED
enrolled	O
had	O
anthropometric	B-MED
characteristics	I-MED
recorded	O
,	O
provided	B-MED
a	O
medical	B-MED
history	I-MED
,	O
and	O
underwent	O
low	B-MED
-	I-MED
dose	I-MED
chest	B-MED
CT	I-MED
scanning	I-MED
.	O
The	O
following	O
parameters	B-MED
were	O
also	O
evaluated	O
:	O
pulmonary	B-MED
function	I-MED
tests	I-MED
including	O
diffusion	B-MED
capacity	I-MED
for	I-MED
carbon	I-MED
monoxide	I-MED
(	O
Dlco	B-MED
)	O
,	O
the	O
modified	O
Medical	B-MED
Research	I-MED
Council	I-MED
dyspnea	I-MED
score	I-MED
,	O
COPD	B-MED
assessment	I-MED
test	I-MED
(	O
CAT	B-MED
)	O
,	O
and	O
6	B-MED
-	I-MED
min	I-MED
walk	I-MED
test	I-MED
(	O
6MWT	B-MED
)	O
.	O
A	O
comparison	B-MED
was	O
conducted	O
between	O
those	O
with	O
and	O
without	O
CT	B-MED
-	O
confirmed	B-MED
emphysema	B-MED
.	O
Of	O
the	O
203	O
subjects	B-MED
,	O
154	O
had	O
emphysema	B-MED
,	O
and	O
49	O
did	O
not	O
.	O
Adjusted	O
group	B-MED
comparisons	B-MED
revealed	B-MED
that	O
a	O
higher	O
proportion	B-MED
of	O
patients	B-MED
with	O
emphysema	B-MED
according	O
to	O
low	B-MED
-	I-MED
dose	I-MED
chest	B-MED
CT	I-MED
scanning	I-MED
had	O
an	O
abnormal	B-MED
Dlco	I-MED
value	B-MED
(	O
<	O
80	O
%	O
)	O
(	O
46	O
%	O
vs	O
19	O
%	O
;	O
P	O
=	O
.02	O
)	O
,	O
a	O
decrease	B-MED
in	O
percentage	B-MED
of	O
oxygen	B-MED
saturation	I-MED
>	O
4	O
%	O
during	O
the	O
6MWT	B-MED
(	O
8.5	O
%	O
vs	O
0	O
;	O
P	O
=	O
.04	O
)	O
,	O
and	O
an	O
altered	B-MED
quality	B-MED
of	I-MED
life	I-MED
(	O
CAT	B-MED
score	B-MED
≥	O
10	O
)	O
(	O
32	O
%	O
vs	O
14	O
%	O
;	O
P	O
=	O
.01	O
)	O
.	O
A	O
detailed	O
analysis	B-MED
of	O
the	O
CAT	B-MED
questionnaire	I-MED
items	O
revealed	B-MED
that	O
more	O
patients	B-MED
with	O
emphysema	B-MED
had	O
a	O
score	B-MED
≥	O
1	O
in	O
the	O
"	O
chest	B-MED
tightness	I-MED
"	O
(	O
P	O
=	O
.05	O
)	O
and	O
"	O
limitation	B-MED
when	O
doing	O
activities	B-MED
at	O
home	B-MED
"	O
(	O
P	O
<	O
.01	O
)	O
items	O
compared	B-MED
with	O
those	O
with	O
no	B-MED
emphysema	I-MED
.	O
They	O
also	O
experienced	O
significantly	O
more	O
exacerbations	B-MED
in	O
the	O
previous	O
year	B-MED
(	O
0.19	O
vs	O
0.04	O
;	O
P	O
=	O
.02	O
)	O
.	O
A	O
significant	B-MED
proportion	B-MED
of	O
smokers	B-MED
with	O
emphysema	B-MED
according	O
to	O
low	B-MED
-	I-MED
dose	I-MED
chest	B-MED
CT	I-MED
scanning	I-MED
but	O
without	O
airway	B-MED
limitation	B-MED
had	O
alterations	B-MED
in	O
their	O
quality	B-MED
of	I-MED
life	I-MED
,	O
number	O
of	O
exacerbations	B-MED
,	O
Dlco	B-MED
values	B-MED
,	O
and	O
oxygen	B-MED
saturation	I-MED
during	O
the	O
6MWT	B-MED
test	I-MED
.	O
Comparison	O
and	O
Outcome	O
Analysis	B-MED
of	I-MED
Patients	I-MED
with	O
Takotsubo	B-MED
Cardiomyopathy	I-MED
Triggered	B-MED
by	I-MED
Emotional	B-MED
Stress	I-MED
or	O
Physical	B-MED
Stress	I-MED
Background	O
:	O
Previous	O
studies	O
revealed	O
that	O
takotsubo	B-MED
cardiomyopathy	I-MED
(	O
TTC	B-MED
)	O
is	O
triggered	B-MED
by	I-MED
physical	B-MED
and	O
emotional	B-MED
stresses	I-MED
.	O
This	O
study	O
was	O
performed	O
to	O
determine	O
the	O
short-	B-MED
and	O
long	B-MED
-	I-MED
term	I-MED
prognostic	O
impact	O
of	O
emotional-	B-MED
and	O
physical	B-MED
stress	I-MED
associated	B-MED
with	I-MED
TTC	B-MED
.	O
Methods	O
and	O
results	O
:	O
Our	O
institutional	B-MED
database	I-MED
constituted	O
a	O
collective	O
of	O
84	O
patients	B-MED
diagnosed	B-MED
with	O
TTC	B-MED
between	O
2003	O
and	O
2015	O
.	O
The	O
patients	B-MED
were	O
divided	O
into	O
two	O
groups	B-MED
as	O
per	O
the	O
presence	O
of	O
emotional	B-MED
stress	I-MED
(	O
n	O
=	O
24	O
,	O
21	O
%	O
)	O
or	O
physical	B-MED
stress	I-MED
(	O
n	O
=	O
60	O
,	O
52.6	O
%	O
)	O
.	O
The	O
endpoint	B-MED
was	O
a	O
composite	B-MED
of	O
in	B-MED
-	I-MED
hospital	I-MED
events	I-MED
(	O
thromboembolic	B-MED
events	I-MED
and	O
life	B-MED
-	I-MED
threatening	I-MED
arrhythmias	B-MED
)	O
,	O
myocardial	B-MED
infarction	I-MED
,	O
all-	O
cause	B-MED
of	I-MED
mortality	I-MED
,	O
re	B-MED
-	I-MED
hospitalization	I-MED
due	O
to	O
heart	B-MED
failure	I-MED
,	O
stroke	B-MED
,	O
and	O
recurrence	B-MED
of	O
TTC	B-MED
.	O
A	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
analysis	I-MED
indicated	O
a	O
significantly	O
lower	O
event	O
-	O
free	O
survival	B-MED
rate	I-MED
over	O
a	O
mean	O
follow	B-MED
-	I-MED
up	I-MED
of	O
5	O
years	O
in	O
the	O
emotional	B-MED
group	B-MED
than	O
the	O
physical	B-MED
stress	I-MED
group	B-MED
(	O
log	O
-	O
rank	O
,	O
p	O
<	O
0.01	O
)	O
.	O
Multivariate	B-MED
Cox	I-MED
regression	I-MED
analysis	I-MED
revealed	O
only	O
emotional	B-MED
stress	I-MED
(	O
HR	O
0.4	O
,	O
95	O
%	O
CI	O
:	O
0.2	O
-	O
0.9	O
,	O
p	O
<	O
0.05	O
)	O
as	O
a	O
negative	B-MED
independent	I-MED
predictor	I-MED
of	O
the	O
primary	O
endpoint	B-MED
.	O
Conclusion	O
:	O
Rates	O
of	O
in	B-MED
-	I-MED
hospital	I-MED
events	I-MED
and	O
short-	B-MED
as	O
well	O
as	O
long	B-MED
-	I-MED
term	I-MED
events	O
were	O
significantly	O
lower	O
in	O
TTC	B-MED
patients	B-MED
suffering	B-MED
from	O
emotional	B-MED
stress	I-MED
as	O
compared	O
to	O
patients	B-MED
with	O
physical	B-MED
stress	I-MED
.	O
CHOROIDAL	B-MED
VASCULARITY	I-MED
INDEX	I-MED
:	O
A	O
Novel	O
Optical	B-MED
Coherence	I-MED
Tomography	I-MED
Based	O
Parameter	B-MED
in	O
Patients	B-MED
With	O
Exudative	B-MED
Age	I-MED
-	I-MED
Related	I-MED
Macular	I-MED
Degeneration	I-MED
To	O
evaluate	O
choroidal	B-MED
structural	B-MED
changes	O
in	O
exudative	B-MED
age	I-MED
-	I-MED
related	I-MED
macular	I-MED
degeneration	I-MED
(	O
AMD	B-MED
)	O
using	O
choroidal	B-MED
vascularity	I-MED
index	I-MED
computed	B-MED
from	O
image	O
binarization	O
on	O
spectral	B-MED
domain	I-MED
optical	I-MED
coherence	I-MED
tomography	I-MED
with	O
enhanced	O
depth	B-MED
imaging	I-MED
.	O
This	O
prospective	O
case	B-MED
series	I-MED
included	O
42	O
consecutive	B-MED
patients	B-MED
with	O
unilateral	B-MED
exudative	B-MED
AMD	I-MED
.	O
Choroidal	B-MED
images	B-MED
were	O
segmented	O
into	O
luminal	B-MED
area	B-MED
and	O
stromal	O
area	O
.	O
Choroidal	B-MED
vascularity	I-MED
index	I-MED
was	O
defined	O
as	O
the	O
ratio	B-MED
of	O
luminal	B-MED
area	B-MED
to	O
total	O
choroid	O
area	B-MED
.	O
Mean	B-MED
choroidal	B-MED
vascularity	I-MED
index	I-MED
and	O
mean	B-MED
choroidal	B-MED
thickness	I-MED
between	O
study	B-MED
and	O
fellow	O
eyes	B-MED
of	O
the	O
same	O
patient	B-MED
with	O
dry	O
AMD	B-MED
were	O
compared	O
using	O
Student	B-MED
's	I-MED
t	I-MED
-	I-MED
test	I-MED
.	O
There	O
was	O
a	O
significantly	B-MED
lower	I-MED
choroidal	B-MED
vascularity	I-MED
index	I-MED
in	O
eyes	B-MED
with	O
exudative	B-MED
AMD	I-MED
(	O
60.14	O
±	O
4.55	O
vs.	O
62.75	O
±	O
4.82	O
,	O
P	O
<	O
0.01	O
)	O
.	O
Luminal	B-MED
area	I-MED
(	O
P	O
<	O
0.01	O
)	O
was	O
decreased	B-MED
in	O
eyes	B-MED
with	O
exudative	B-MED
AMD	I-MED
but	O
there	O
was	O
no	B-MED
significant	I-MED
difference	I-MED
in	O
total	O
choroid	O
area	B-MED
(	O
P	O
=	O
0.05	O
)	O
and	O
choroidal	O
thickness	O
(	O
P	O
=	O
0.93	O
)	O
between	O
study	B-MED
and	O
fellow	O
eyes	B-MED
.	O
Eyes	B-MED
with	O
exudative	B-MED
AMD	I-MED
demonstrated	O
reduced	B-MED
choroidal	B-MED
vascularity	I-MED
index	I-MED
but	O
insignificant	O
differences	B-MED
in	O
choroidal	O
thickness	O
compared	O
with	O
their	O
fellow	O
eyes	B-MED
.	O
Choroidal	B-MED
vascularity	I-MED
index	I-MED
may	O
be	O
a	O
potential	B-MED
noninvasive	B-MED
tool	I-MED
for	O
studying	B-MED
structural	B-MED
changes	O
in	O
choroid	B-MED
and	O
monitoring	O
choroidal	B-MED
disease	I-MED
in	O
exudative	B-MED
AMD	I-MED
.	O
Human	B-MED
cathelicidin	I-MED
LL-37	I-MED
enhance	O
the	O
antibiofilm	B-MED
effect	I-MED
of	O
EGCG	B-MED
on	O
Streptococcus	B-MED
mutans	I-MED
Streptococcus	B-MED
mutans	I-MED
forms	O
biofilms	B-MED
as	O
a	O
resistance	B-MED
mechanism	B-MED
against	O
antimicrobial	B-MED
agents	I-MED
in	O
the	O
human	B-MED
oral	B-MED
cavity	I-MED
.	O
We	O
recently	O
showed	O
that	O
human	B-MED
cathelicidin	I-MED
LL-37	I-MED
exhibits	O
inhibitory	B-MED
effects	I-MED
on	O
biofilm	B-MED
formation	I-MED
of	O
S.	B-MED
mutans	I-MED
through	O
interaction	B-MED
with	O
lipoteichoic	B-MED
acid	I-MED
(	O
LTA	B-MED
)	O
,	O
but	O
without	O
antibacterial	B-MED
or	O
biofilm	B-MED
dispersal	B-MED
abilities	I-MED
.	O
(	B-MED
-)-Epigallocatechin	I-MED
gallate	I-MED
(	O
EGCG	B-MED
)	O
is	O
the	O
most	O
abundant	O
constituent	O
of	O
tea	B-MED
catechins	B-MED
that	O
has	O
the	O
greatest	O
anti	B-MED
-	I-MED
infective	I-MED
potential	I-MED
to	O
inhibit	B-MED
the	I-MED
growth	I-MED
of	O
various	O
microorganisms	B-MED
and	O
biofilm	B-MED
formation	I-MED
.	O
Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
evaluated	B-MED
whether	O
LL-37	B-MED
interacts	O
with	O
EGCG	B-MED
to	O
enhance	O
the	O
antibiofilm	B-MED
effect	I-MED
of	O
EGCG	B-MED
on	O
S.	B-MED
mutans	I-MED
biofilm	B-MED
formation	I-MED
.	O
Clinical	O
S.	B-MED
mutans	I-MED
strains	B-MED
(	O
n	O
=	O
10	O
)	O
isolated	O
from	O
children	B-MED
's	I-MED
saliva	B-MED
were	O
tested	B-MED
in	O
a	O
biofilm	B-MED
formation	I-MED
assay	B-MED
.	O
The	O
antibiofilm	B-MED
effect	I-MED
of	O
EGCG	B-MED
with	O
and	O
without	O
LL-37	B-MED
was	O
analyzed	B-MED
by	O
the	O
minimum	O
biofilm	B-MED
eradication	B-MED
concentration	B-MED
assay	B-MED
and	O
confirmed	O
using	O
field	O
emission	B-MED
-	I-MED
scanning	I-MED
electron	I-MED
microscopy	I-MED
.	O
In	O
addition	O
,	O
the	O
interaction	B-MED
among	O
EGCG	B-MED
,	O
LL-37	B-MED
,	O
and	O
LTA	B-MED
of	O
S.	B-MED
mutans	I-MED
was	O
determined	O
using	O
quartz	B-MED
crystal	I-MED
microbalance	I-MED
analysis	I-MED
.	O
EGCG	B-MED
killed	O
100	O
%	O
of	O
planktonic	B-MED
S.	B-MED
mutans	I-MED
within	O
5	O
h	O
,	O
inhibited	O
biofilm	B-MED
formation	I-MED
within	O
24	O
h	O
,	O
and	O
reduced	O
bacteria	B-MED
cells	I-MED
in	O
preformed	O
biofilms	B-MED
within	O
3	O
h	O
at	O
a	O
concentration	B-MED
of	O
0.2	O
mg	O
/	O
mL.	O
However	O
,	O
EGCG	B-MED
did	O
not	O
appear	O
to	O
interact	O
with	O
LTA	B-MED
.	O
LL-37	B-MED
effectively	O
enhanced	O
the	O
bactericidal	B-MED
activity	I-MED
of	O
EGCG	B-MED
against	O
biofilm	B-MED
formation	I-MED
and	O
preformed	O
biofilms	B-MED
as	O
determined	O
by	O
quantitative	B-MED
crystal	B-MED
violet	I-MED
staining	B-MED
and	O
field	O
emission	B-MED
-	I-MED
scanning	I-MED
electron	I-MED
microscopy	I-MED
.	O
In	O
addition	O
,	O
quartz	B-MED
crystal	I-MED
microbalance	I-MED
analysis	I-MED
revealed	O
that	O
LL-37	B-MED
interacted	B-MED
with	O
EGCG	B-MED
and	O
promoted	O
binding	B-MED
between	O
EGCG	B-MED
and	O
LTA	B-MED
of	O
S.	B-MED
mutans	I-MED
.	O
We	O
show	O
that	O
LL-37	B-MED
enhances	O
the	O
antibiofilm	B-MED
effect	I-MED
of	O
EGCG	B-MED
on	O
S.	B-MED
mutans	I-MED
.	O
This	O
finding	O
provides	O
new	O
knowledge	O
for	O
dental	B-MED
treatment	I-MED
by	O
using	O
LL-37	B-MED
as	O
a	O
potential	O
antibiofilm	B-MED
compound	I-MED
.	O
Efficient	O
genome	B-MED
editing	I-MED
of	O
differentiated	B-MED
renal	B-MED
epithelial	B-MED
cells	I-MED
Recent	O
advances	O
in	O
genome	B-MED
editing	I-MED
technologies	I-MED
have	O
enabled	O
the	O
rapid	O
and	O
precise	O
manipulation	B-MED
of	I-MED
genomes	I-MED
,	O
including	O
the	O
targeted	B-MED
introduction	I-MED
,	O
alteration	B-MED
,	O
and	O
removal	B-MED
of	I-MED
genomic	I-MED
sequences	I-MED
.	O
However	O
,	O
respective	O
methods	B-MED
have	O
been	O
described	O
mainly	O
in	O
non	B-MED
-	I-MED
differentiated	I-MED
or	O
haploid	B-MED
cell	B-MED
types	I-MED
.	O
Genome	B-MED
editing	I-MED
of	O
well	B-MED
-	I-MED
differentiated	I-MED
renal	B-MED
epithelial	B-MED
cells	I-MED
has	O
been	O
hampered	O
by	O
a	O
range	O
of	O
technological	B-MED
issues	I-MED
,	O
including	O
optimal	B-MED
design	B-MED
,	O
efficient	B-MED
expression	B-MED
of	I-MED
multiple	I-MED
genome	I-MED
editing	I-MED
constructs	I-MED
,	O
attainable	B-MED
mutation	B-MED
rates	I-MED
,	O
and	O
best	O
screening	B-MED
strategies	I-MED
.	O
Here	O
,	O
we	O
present	O
an	O
easily	O
implementable	O
workflow	B-MED
for	O
the	O
rapid	B-MED
generation	B-MED
of	I-MED
targeted	I-MED
heterozygous	I-MED
and	I-MED
homozygous	I-MED
genomic	I-MED
sequence	I-MED
alterations	I-MED
in	O
renal	B-MED
cells	B-MED
using	O
transcription	B-MED
activator	I-MED
-	I-MED
like	I-MED
effector	I-MED
nucleases	I-MED
(	O
TALENs	B-MED
)	O
and	O
the	O
clustered	B-MED
regularly	I-MED
interspaced	I-MED
short	I-MED
palindromic	I-MED
repeat	I-MED
(	I-MED
CRISPR	I-MED
)	I-MED
system	I-MED
.	O
We	O
demonstrate	O
the	O
versatility	O
of	O
established	O
protocols	B-MED
by	O
generating	B-MED
novel	B-MED
cellular	B-MED
models	I-MED
for	O
studying	B-MED
autosomal	B-MED
dominant	I-MED
polycystic	I-MED
kidney	I-MED
disease	I-MED
(	O
ADPKD	B-MED
)	O
.	O
Furthermore	O
,	O
we	O
show	O
that	O
cell	B-MED
culture	I-MED
-	I-MED
validated	I-MED
genetic	I-MED
modifications	I-MED
can	O
be	O
readily	O
applied	O
to	O
mouse	B-MED
embryonic	I-MED
stem	I-MED
cells	I-MED
(	O
mESCs	B-MED
)	O
for	O
the	O
generation	B-MED
of	O
corresponding	O
mouse	B-MED
models	B-MED
.	O
The	O
described	O
procedure	B-MED
for	O
efficient	O
genome	B-MED
editing	I-MED
can	O
be	O
applied	O
to	O
any	O
cell	B-MED
type	I-MED
to	O
study	B-MED
physiological	B-MED
and	O
pathophysiological	B-MED
functions	I-MED
in	O
the	O
context	O
of	O
precisely	O
engineered	B-MED
genotypes	I-MED
.	O
Recombinant	B-MED
MHC	B-MED
Tetramers	I-MED
for	O
Isolation	B-MED
of	O
Virus	B-MED
-	O
Specific	B-MED
CD8(+	B-MED
)	I-MED
Cells	I-MED
from	O
Healthy	B-MED
Donors	I-MED
:	O
Potential	B-MED
Approach	O
for	O
Cell	B-MED
Therapy	I-MED
of	O
Posttransplant	B-MED
Cytomegalovirus	I-MED
Infection	I-MED
Patients	B-MED
undergoing	O
allogeneic	B-MED
hematopoietic	B-MED
stem	I-MED
cell	I-MED
transplantation	I-MED
have	O
a	O
high	O
risk	O
of	O
cytomegalovirus	B-MED
reactivation	I-MED
,	O
which	O
in	O
the	O
absence	O
of	O
T	B-MED
-	I-MED
cell	I-MED
immunity	I-MED
can	O
result	O
in	O
the	O
development	O
of	O
an	O
acute	B-MED
inflammatory	I-MED
reaction	I-MED
and	O
damage	B-MED
of	I-MED
internal	I-MED
organs	I-MED
.	O
Transfusion	B-MED
of	O
the	O
virus	B-MED
-	I-MED
specific	I-MED
donor	B-MED
T	I-MED
-	I-MED
lymphocytes	I-MED
represents	O
an	O
alternative	O
to	O
a	O
highly	B-MED
toxic	I-MED
and	O
often	O
ineffective	B-MED
antiviral	B-MED
therapy	I-MED
.	O
Potentially	B-MED
promising	O
cell	B-MED
therapy	I-MED
approach	O
comprises	O
transfusion	B-MED
of	O
cytotoxic	B-MED
T	I-MED
-	I-MED
lymphocytes	I-MED
,	O
specific	B-MED
to	O
the	O
viral	B-MED
antigens	I-MED
,	O
immediately	O
after	O
their	O
isolation	B-MED
from	O
the	O
donor	B-MED
's	I-MED
blood	I-MED
circulation	I-MED
without	O
any	O
in	B-MED
vitro	I-MED
expansion	I-MED
.	O
Specific	B-MED
T	B-MED
-	I-MED
cells	I-MED
could	O
be	O
separated	O
from	O
potentially	B-MED
alloreactive	B-MED
lymphocytes	I-MED
using	O
recombinant	B-MED
major	B-MED
histocompatibility	I-MED
complex	I-MED
(	O
MHC	B-MED
)	O
multimers	B-MED
,	O
carrying	O
synthetic	B-MED
viral	I-MED
peptides	I-MED
.	O
Rapid	O
transfusion	B-MED
of	O
virus	B-MED
-	O
specific	B-MED
T	B-MED
-	I-MED
cells	I-MED
to	O
patients	B-MED
has	O
several	O
crucial	O
advantages	O
in	O
comparison	O
with	O
methods	O
based	O
on	O
the	O
in	B-MED
vitro	I-MED
expansion	I-MED
of	O
the	O
cells	B-MED
.	O
About	O
30	O
%	O
of	O
hematopoietic	B-MED
stem	B-MED
cell	I-MED
donors	I-MED
and	O
46	O
%	O
of	O
transplant	B-MED
recipients	I-MED
at	O
the	O
National	B-MED
Research	I-MED
Center	I-MED
for	I-MED
Hematology	I-MED
were	O
carriers	O
of	O
the	O
HLA	B-MED
-	I-MED
A*02	I-MED
allele	I-MED
.	O
Moreover	O
,	O
94	O
%	O
of	O
Russian	B-MED
donors	B-MED
have	O
an	O
immune	B-MED
response	I-MED
against	O
the	O
cytomegalovirus	B-MED
(	O
CMV	B-MED
)	O
.	O
Using	O
recombinant	B-MED
HLA	B-MED
-	I-MED
A*02	I-MED
multimers	B-MED
carrying	O
an	O
immunodominant	B-MED
cytomegalovirus	B-MED
peptide	I-MED
(	O
NLV	B-MED
)	O
,	O
we	O
have	O
shown	O
that	O
the	O
majority	O
of	O
healthy	B-MED
donors	I-MED
have	O
pronounced	O
T	B-MED
-	I-MED
cell	I-MED
immunity	I-MED
against	O
this	O
antigen	B-MED
,	O
whereas	O
shortly	O
after	O
the	O
transplantation	B-MED
the	O
patients	B-MED
do	O
not	O
have	O
specific	B-MED
T	B-MED
-	I-MED
lymphocytes	I-MED
.	O
The	O
donor	B-MED
cells	I-MED
have	O
the	O
immune	B-MED
phenotype	I-MED
of	O
memory	B-MED
cells	I-MED
and	O
can	O
be	O
activated	B-MED
and	O
proliferate	B-MED
after	O
stimulation	O
with	O
the	O
specific	B-MED
antigen	B-MED
.	O
Donor	B-MED
lymphocytes	I-MED
can	O
be	O
substantially	O
enriched	B-MED
to	O
significant	O
purity	B-MED
by	O
magnetic	B-MED
separation	I-MED
with	O
recombinant	B-MED
MHC	B-MED
multimers	B-MED
and	O
are	O
not	O
activated	B-MED
upon	O
cocultivation	B-MED
with	O
the	O
antigen	B-MED
-presenting	O
cells	B-MED
from	O
HLA	B-MED
-	O
incompatible	B-MED
donors	I-MED
without	O
addition	O
of	O
the	O
specific	B-MED
antigen	B-MED
.	O
This	O
study	B-MED
demonstrated	O
that	O
strong	O
immune	B-MED
response	I-MED
to	O
CMV	B-MED
of	O
healthy	B-MED
donors	I-MED
and	O
prevalence	O
of	O
HLA	B-MED
-	I-MED
A*02	I-MED
allele	I-MED
in	O
the	O
Russian	B-MED
population	I-MED
make	O
it	O
possible	O
to	O
isolate	O
a	O
significant	O
number	O
of	O
virus	B-MED
-	I-MED
specific	I-MED
cells	B-MED
using	O
HLA	B-MED
-	I-MED
A*02	I-MED
-	I-MED
NLV	I-MED
multimers	B-MED
.	O
After	O
the	O
transfusion	B-MED
,	O
these	O
cells	B-MED
should	O
protect	O
patients	B-MED
from	O
CMV	B-MED
without	O
development	O
of	O
allogeneic	B-MED
immune	B-MED
response	I-MED
.	O
A	O
prime	B-MED
a	O
day	O
keeps	O
calories	B-MED
away	O
:	O
The	O
effects	B-MED
of	I-MED
supraliminal	B-MED
priming	I-MED
on	O
food	B-MED
consumption	I-MED
and	O
the	O
moderating	B-MED
role	I-MED
of	O
gender	B-MED
and	O
eating	B-MED
restraint	I-MED
The	O
link	O
between	O
intentions	B-MED
and	O
action	B-MED
in	O
weight	B-MED
control	I-MED
is	O
weaker	O
than	O
previously	O
thought	O
,	O
so	O
recent	O
research	B-MED
has	O
called	O
for	O
further	O
investigation	O
of	O
ways	O
to	O
improve	O
weight	B-MED
control	I-MED
that	O
bypass	O
conscious	B-MED
intentions	B-MED
.	O
Priming	B-MED
has	O
been	O
shown	O
to	O
have	O
effects	O
on	O
individual	O
behavior	O
in	O
a	O
variety	O
of	O
contexts	O
by	O
influencing	O
subconscious	B-MED
cognition	B-MED
.	O
This	O
paper	O
investigates	O
the	O
effects	B-MED
of	I-MED
semantic	B-MED
priming	I-MED
using	O
healthy	B-MED
body	B-MED
image	I-MED
,	O
goal	B-MED
-	I-MED
oriented	I-MED
words	I-MED
on	O
food	B-MED
consumption	I-MED
.	O
The	O
moderating	B-MED
role	I-MED
of	O
both	O
restrained	B-MED
eating	I-MED
and	O
gender	B-MED
is	O
investigated	O
.	O
161	O
participants	B-MED
were	O
involved	O
in	O
an	O
experiment	B-MED
using	O
a	O
novel	O
version	O
of	O
a	O
scrambled	O
sentence	B-MED
priming	B-MED
game	B-MED
.	O
The	O
outcome	O
measure	O
was	O
the	O
number	O
of	O
kilocalories	B-MED
consumed	B-MED
,	O
examined	O
using	O
a	O
between	O
subjects	O
ANCOVA	B-MED
with	O
priming	B-MED
,	O
gender	B-MED
,	O
restrained	B-MED
eating	I-MED
index	I-MED
,	O
self	B-MED
-	I-MED
reported	I-MED
BMI	B-MED
,	O
and	O
two	O
interaction	B-MED
terms	O
(	O
priming	B-MED
x	O
gender	B-MED
,	O
and	O
priming	B-MED
x	O
restrained	B-MED
eating	I-MED
index	I-MED
)	O
.	O
There	O
was	O
no	O
main	O
effect	B-MED
of	I-MED
priming	B-MED
but	O
there	O
was	O
an	O
interaction	B-MED
of	O
priming	B-MED
with	O
gender	B-MED
.	O
Females	B-MED
consumed	O
significantly	O
fewer	O
kilocalories	B-MED
after	O
being	O
exposed	O
to	O
priming	B-MED
words	B-MED
related	O
to	O
a	O
healthy	B-MED
body	B-MED
image	I-MED
(	O
i.e.	O
"	O
slim	O
"	O
,	O
"	O
fit	O
,	O
"	O
)	O
compared	O
to	O
females	B-MED
receiving	O
the	O
neutral	O
prime	B-MED
,	O
with	O
a	O
medium	O
effect	O
size	O
(	O
d	O
=	O
0.58	O
)	O
.	O
The	O
body	B-MED
image	I-MED
prime	B-MED
did	O
not	O
significantly	O
affect	O
food	B-MED
intake	I-MED
for	O
males	B-MED
,	O
nor	O
did	O
it	O
have	O
a	O
differential	O
effect	O
on	O
restrained	B-MED
eaters	I-MED
.	O
This	O
study	O
shows	O
that	O
priming	B-MED
can	O
be	O
an	O
effective	O
method	O
for	O
influencing	O
females	B-MED
to	O
reduce	O
food	B-MED
intake	I-MED
,	O
regardless	O
of	O
whether	O
they	O
are	O
restrained	B-MED
or	O
unrestrained	B-MED
eaters	I-MED
.	O
Future	O
studies	O
could	O
investigate	O
whether	O
different	O
priming	B-MED
words	B-MED
related	O
to	O
a	O
male	B-MED
's	I-MED
healthy	B-MED
body	B-MED
image	I-MED
goal	O
(	O
i.e.	O
"	O
buff	O
,	O
"	O
"	O
muscles	B-MED
,	O
"	O
etc	O
.	O
)	O
would	O
similarly	O
reduce	O
food	B-MED
intake	I-MED
for	O
males	B-MED
.	O
Demonstration	O
and	O
validation	B-MED
of	O
a	O
new	O
pressure	B-MED
-based	O
MRI	B-MED
-safe	O
pain	B-MED
tolerance	I-MED
device	B-MED
One	O
of	O
the	O
barriers	O
to	O
studying	O
the	O
behavioral	B-MED
and	O
emotional	B-MED
effects	B-MED
of	O
pain	B-MED
using	O
functional	B-MED
Magnetic	I-MED
Resonance	I-MED
Imaging	I-MED
(	O
fMRI	B-MED
)	O
is	O
the	O
absence	O
of	O
a	O
commercially	O
available	O
,	O
MRI	B-MED
-	O
compatible	B-MED
,	O
pressure	B-MED
-based	O
algometer	B-MED
to	O
elicit	B-MED
pain	B-MED
.	O
The	O
present	O
study	O
sought	O
to	O
address	O
this	O
barrier	O
through	O
creation	O
and	O
validation	O
of	O
a	O
novel	O
MRI	B-MED
-safe	O
apparatus	B-MED
capable	O
of	O
delivering	O
incremental	B-MED
,	O
measurable	B-MED
amounts	O
of	O
pressure	B-MED
inside	O
a	O
scanning	B-MED
bore	I-MED
.	O
We	O
introduced	O
an	O
MR	O
-	O
safe	O
device	B-MED
used	O
to	O
administer	O
pressure	B-MED
-based	O
pain	B-MED
.	O
To	O
test	B-MED
against	O
a	O
commercially	O
available	O
,	O
MRI	B-MED
-	O
incompatible	B-MED
algometer	B-MED
(	O
AlgoMed	B-MED
)	O
,	O
199	O
participants	O
reported	O
their	O
pain	B-MED
tolerance	I-MED
for	O
both	O
devices	O
.	O
A	O
second	O
experiment	O
tested	B-MED
the	O
validity	O
of	O
pressure	B-MED
-based	O
pain	B-MED
in	O
an	O
MRI	B-MED
environment	B-MED
by	O
comparing	O
brain	B-MED
activation	B-MED
with	O
established	O
neural	B-MED
networks	I-MED
for	O
pain	B-MED
.	O
10	O
participants	O
performed	O
an	O
identical	O
procedure	O
to	O
test	B-MED
for	O
pain	B-MED
tolerance	O
while	O
being	O
scanned	B-MED
in	O
a	O
7	O
T	O
MRI	B-MED
scanner	I-MED
.	O
Results	O
support	O
the	O
validity	B-MED
and	I-MED
reliability	I-MED
of	O
our	O
novel	O
device	B-MED
.	O
In	O
Study	O
1	O
,	O
pain	B-MED
tolerance	I-MED
with	O
this	O
device	B-MED
was	O
strongly	O
correlated	O
with	O
pain	B-MED
tolerance	I-MED
as	O
measured	O
by	O
a	O
commercially	O
available	O
algometer	B-MED
(	O
r=0.78	O
)	O
.	O
In	O
Study	O
2	O
,	O
this	O
device	B-MED
yielded	O
BOLD	B-MED
activation	O
within	O
the	O
insula	B-MED
(	O
BA	B-MED
13	I-MED
)	O
and	O
anterior	B-MED
cingulate	I-MED
gyrus	I-MED
(	O
BA	B-MED
24	I-MED
)	O
;	O
as	O
pressure	B-MED
increased	B-MED
,	O
activation	O
in	O
these	O
areas	O
parametrically	B-MED
increased	B-MED
.	O
These	O
findings	O
correspond	O
to	O
other	O
studies	O
using	O
thermal	B-MED
,	O
electrical	B-MED
,	O
or	O
mechanical	B-MED
pain	B-MED
applications	I-MED
.	O
Behavioral	B-MED
and	O
functional	B-MED
data	B-MED
demonstrate	O
that	O
this	O
new	O
device	B-MED
is	O
a	O
valid	O
method	O
of	O
administering	B-MED
pressure	B-MED
-related	O
pain	B-MED
in	O
MRI	B-MED
environments	B-MED
.	O
Our	O
novel	O
MRI	B-MED
-safe	O
device	B-MED
is	O
a	O
valid	O
instrument	B-MED
to	O
measure	B-MED
and	O
administer	B-MED
pressure	B-MED
-based	O
pain	B-MED
.	O
Famous	B-MED
faces	I-MED
and	O
voices	B-MED
:	O
Differential	B-MED
profiles	B-MED
in	O
early	B-MED
right	B-MED
and	O
left	B-MED
semantic	B-MED
dementia	I-MED
and	O
in	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
Famous	B-MED
face	I-MED
and	O
voice	B-MED
recognition	I-MED
is	O
reported	O
to	O
be	O
impaired	B-MED
both	O
in	O
semantic	B-MED
dementia	I-MED
(	O
SD	B-MED
)	O
and	O
in	O
Alzheimer	B-MED
's	I-MED
Disease	I-MED
(	O
AD	B-MED
)	O
,	O
although	O
more	O
severely	B-MED
in	O
the	O
former	O
.	O
In	O
AD	B-MED
a	O
coexistence	O
of	O
perceptual	B-MED
impairment	B-MED
in	O
face	B-MED
and	O
voice	B-MED
processing	B-MED
has	O
also	O
been	O
reported	O
and	O
this	O
could	O
contribute	O
to	O
the	O
altered	O
performance	B-MED
in	O
complex	B-MED
semantic	B-MED
tasks	B-MED
.	O
On	O
the	O
other	O
hand	O
,	O
in	O
SD	B-MED
both	O
face	B-MED
and	O
voice	B-MED
recognition	I-MED
disorders	B-MED
could	O
be	O
related	O
to	O
the	O
prevalence	B-MED
of	O
atrophy	B-MED
in	O
the	O
right	B-MED
temporal	I-MED
lobe	I-MED
(	O
RTL	B-MED
)	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	B-MED
was	O
twofold	O
:	O
(	O
1	O
)	O
to	O
investigate	B-MED
famous	B-MED
faces	I-MED
and	O
voices	B-MED
recognition	I-MED
in	O
SD	B-MED
and	O
AD	B-MED
to	O
verify	O
if	O
the	O
two	O
diseases	B-MED
show	O
a	O
differential	B-MED
pattern	B-MED
of	O
impairment	B-MED
,	O
resulting	O
from	O
disruption	B-MED
of	O
different	O
cognitive	B-MED
mechanisms	B-MED
;	O
(	O
2	O
)	O
to	O
check	O
if	O
face	B-MED
and	O
voice	B-MED
recognition	I-MED
disorders	B-MED
prevail	O
in	O
patients	B-MED
with	O
atrophy	B-MED
mainly	O
affecting	O
the	O
RTL	B-MED
.	O
To	O
avoid	O
the	O
potential	B-MED
influence	B-MED
of	O
primary	B-MED
perceptual	B-MED
problems	B-MED
in	O
face	B-MED
and	O
voice	B-MED
recognition	I-MED
,	O
a	O
pool	O
of	O
patients	B-MED
suffering	O
from	O
early	B-MED
SD	B-MED
and	O
AD	B-MED
were	O
administered	B-MED
a	O
detailed	O
set	O
of	O
tests	B-MED
exploring	O
face	B-MED
and	O
voice	B-MED
perception	B-MED
.	O
Thirteen	O
SD	B-MED
(	O
8	O
with	O
prevalence	B-MED
of	O
right	B-MED
and	O
5	O
with	O
prevalence	B-MED
of	O
left	B-MED
temporal	I-MED
atrophy	B-MED
)	O
and	O
25	O
CE	O
patients	B-MED
,	O
who	O
did	O
not	O
show	O
visual	B-MED
and	O
auditory	B-MED
perceptual	B-MED
impairment	B-MED
,	O
were	O
finally	O
selected	O
and	O
were	O
administered	B-MED
an	O
experimental	B-MED
battery	B-MED
exploring	O
famous	B-MED
face	I-MED
and	O
voice	B-MED
recognition	I-MED
and	O
naming	B-MED
.	O
Twelve	O
SD	B-MED
patients	B-MED
underwent	O
cerebral	B-MED
PET	B-MED
imaging	I-MED
and	O
were	O
classified	O
in	O
right	B-MED
and	O
left	B-MED
SD	B-MED
according	O
to	O
the	O
onset	O
modality	B-MED
and	O
to	O
the	O
prevalent	O
decrease	B-MED
in	O
FDG	B-MED
uptake	I-MED
in	O
right	B-MED
or	O
left	B-MED
temporal	I-MED
lobe	I-MED
respectively	O
.	O
Correlation	B-MED
of	O
PET	B-MED
imaging	I-MED
and	O
famous	B-MED
face	I-MED
and	O
voice	B-MED
recognition	I-MED
was	O
performed	O
.	O
Results	B-MED
showed	O
a	O
differential	B-MED
performance	B-MED
profile	B-MED
in	O
the	O
two	O
diseases	B-MED
,	O
because	O
AD	B-MED
patients	B-MED
were	O
significantly	O
impaired	B-MED
in	O
the	O
naming	B-MED
tests	I-MED
,	O
but	O
showed	O
preserved	O
recognition	B-MED
,	O
whereas	O
SD	B-MED
patients	B-MED
were	O
profoundly	O
impaired	B-MED
both	O
in	O
naming	B-MED
and	O
in	O
recognition	B-MED
of	I-MED
famous	I-MED
faces	I-MED
and	O
voices	B-MED
.	O
Furthermore	O
,	O
face	B-MED
and	O
voice	B-MED
recognition	I-MED
disorders	B-MED
prevailed	O
in	O
SD	B-MED
patients	B-MED
with	O
RTL	B-MED
atrophy	B-MED
,	O
who	O
also	O
showed	O
a	O
conceptual	B-MED
impairment	B-MED
on	O
the	O
Pyramids	B-MED
and	I-MED
Palm	I-MED
Trees	I-MED
test	I-MED
more	O
important	O
in	O
the	O
pictorial	O
than	O
in	O
the	O
verbal	B-MED
modality	B-MED
.	O
Finally	O
,	O
in	O
12	O
SD	B-MED
patients	B-MED
in	O
whom	O
PET	B-MED
was	O
available	O
,	O
a	O
strong	O
correlation	B-MED
between	O
FDG	B-MED
uptake	I-MED
and	O
face	B-MED
-	I-MED
to	I-MED
-	I-MED
name	I-MED
and	O
voice	B-MED
-	I-MED
to	I-MED
-	I-MED
name	I-MED
matching	I-MED
data	B-MED
was	O
found	O
in	O
the	O
right	B-MED
but	O
not	O
in	O
the	O
left	B-MED
temporal	I-MED
lobe	I-MED
.	O
The	O
data	B-MED
support	O
the	O
hypothesis	B-MED
of	O
a	O
different	O
cognitive	B-MED
basis	O
for	O
impairment	B-MED
of	O
face	B-MED
and	O
voice	B-MED
recognition	I-MED
in	O
the	O
two	O
dementias	B-MED
and	O
suggest	O
that	O
the	O
pattern	B-MED
of	O
impairment	B-MED
in	O
SD	B-MED
may	O
be	O
due	O
to	O
a	O
loss	O
of	O
semantic	B-MED
representations	B-MED
,	O
while	O
a	O
defect	O
of	O
semantic	B-MED
control	B-MED
,	O
with	O
impaired	B-MED
naming	B-MED
and	O
preserved	B-MED
recognition	I-MED
might	O
be	O
hypothesized	O
in	O
AD	B-MED
.	O
Furthermore	O
,	O
the	O
correlation	B-MED
between	O
face	B-MED
and	O
voice	B-MED
recognition	I-MED
disorders	B-MED
and	O
RTL	B-MED
damage	B-MED
are	O
consistent	O
with	O
the	O
hypothesis	B-MED
assuming	O
that	O
in	O
the	O
RTL	B-MED
person	B-MED
-specific	O
knowledge	B-MED
may	O
be	O
mainly	O
based	O
upon	O
non	B-MED
-	I-MED
verbal	I-MED
representations	I-MED
.	O
Well	O
,	O
I	O
Would	O
n't	O
be	O
Any	O
Worse	O
Off	O
,	O
Would	O
I	O
,	O
Than	O
I	O
am	O
Now	O
?	O
A	O
Qualitative	B-MED
Study	I-MED
of	O
Decision	B-MED
-	I-MED
Making	I-MED
,	O
Hopes	B-MED
,	O
and	O
Realities	B-MED
of	O
Adults	B-MED
With	O
Type	B-MED
1	I-MED
Diabetes	I-MED
Undergoing	O
Islet	B-MED
Cell	I-MED
Transplantation	I-MED
For	O
selected	O
individuals	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
,	O
pancreatic	B-MED
islet	I-MED
transplantation	I-MED
(	O
IT	B-MED
)	O
prevents	O
recurrent	O
severe	O
hypoglycemia	B-MED
and	O
optimizes	B-MED
glycemia	I-MED
,	O
although	O
ongoing	O
systemic	B-MED
immunosuppression	I-MED
is	O
needed	O
.	O
Our	O
aim	O
was	O
to	O
explore	O
candidates	B-MED
and	O
recipients	B-MED
'	O
expectations	O
of	O
transplantation	B-MED
,	O
their	O
experience	O
of	O
being	O
on	O
the	O
waiting	B-MED
list	I-MED
,	O
and	O
(	O
for	O
recipients	B-MED
)	O
the	O
procedure	O
and	O
life	O
posttransplant	B-MED
.	O
Cross	O
-	O
sectional	O
qualitative	B-MED
research	B-MED
design	I-MED
using	O
semistructured	O
interviews	B-MED
with	O
16	O
adults	B-MED
(	O
8	O
pretransplant	B-MED
,	O
8	O
posttransplant	B-MED
;	O
from	O
4	O
UK	B-MED
centers	B-MED
(	O
n	O
=	O
13	O
)	O
and	O
1	O
Canadian	B-MED
center	B-MED
(	O
n	O
=	O
3	O
)	O
)	O
.	O
Interviews	B-MED
were	O
audio	B-MED
-	I-MED
recorded	I-MED
,	O
transcribed	O
,	O
and	O
underwent	O
inductive	B-MED
thematic	I-MED
analysis	I-MED
.	O
Interviewees	B-MED
were	O
aged	O
(	O
mean	O
±	O
SD	O
)	O
52	O
±	O
10	O
years	B-MED
(	O
range	O
,	O
30	O
-	O
64	O
)	O
;	O
duration	B-MED
of	O
diabetes	B-MED
,	O
36	O
±	O
9	O
years	B-MED
(	O
range	O
,	O
21	O
-	O
56	O
)	O
;	O
12	O
(	O
75	O
%	O
)	O
were	O
women	B-MED
.	O
Narrative	O
accounts	O
centered	O
on	O
expectations	B-MED
,	O
hopes	B-MED
,	O
and	O
realities	B-MED
;	O
decision	B-MED
-	I-MED
making	I-MED
;	O
waiting	O
and	O
uncertainty	O
;	O
the	O
procedure	O
,	O
hospital	B-MED
stay	I-MED
,	O
and	O
follow	B-MED
-	I-MED
up	I-MED
.	O
Expected	O
benefits	O
included	O
fewer	O
severe	O
hypoglycemic	B-MED
episodes	I-MED
,	O
reduced	B-MED
need	O
for	O
insulin	B-MED
,	O
preventing	O
onset	O
/	O
progression	O
of	O
complications	B-MED
and	O
improved	O
psychological	B-MED
well	I-MED
-	I-MED
being	I-MED
.	O
These	O
were	O
realized	O
for	O
most	O
,	O
at	O
least	O
in	O
the	O
short	O
term	O
.	O
Most	O
interviewees	B-MED
described	O
well	O
-	O
informed	O
,	O
shared	O
decision	B-MED
-	I-MED
making	I-MED
with	O
clinicians	B-MED
and	O
family	B-MED
,	O
and	O
managing	O
their	O
expectations	O
.	O
Although	O
life	O
"	O
on	O
the	O
list	O
"	O
could	O
be	O
stressful	B-MED
,	O
and	O
immunosuppressant	B-MED
side	B-MED
effects	I-MED
were	O
severe	B-MED
,	O
interviewees	B-MED
reported	O
"	O
no	B-MED
regrets	B-MED
.	O
"	O
Posttransplant	B-MED
,	O
interviewees	B-MED
experienced	O
increased	O
confidence	B-MED
,	O
through	O
freedom	B-MED
from	I-MED
hypoglycemia	I-MED
and	O
regained	O
glycemic	B-MED
control	I-MED
,	O
which	O
tempered	O
any	O
disappointment	O
about	O
continued	O
reliance	O
on	O
insulin	B-MED
.	O
Most	O
viewed	O
their	O
transplant	B-MED
as	O
a	O
success	O
,	O
though	O
several	O
reflected	O
upon	O
setbacks	O
and	O
hidden	O
hopes	B-MED
for	O
becoming	O
"	O
insulin	B-MED
-	I-MED
free	I-MED
.	O
"	O
Independently	O
undertaken	O
interviews	B-MED
demonstrated	O
realistic	O
and	O
balanced	O
expectations	O
of	O
IT	B-MED
and	O
indicate	O
how	O
to	O
optimize	O
the	O
process	O
and	O
support	O
for	O
future	O
IT	B-MED
candidates	B-MED
.	O
Clinicopathological	B-MED
relevance	O
of	O
kinesin	B-MED
family	I-MED
member	I-MED
18A	I-MED
expression	B-MED
in	O
invasive	B-MED
breast	I-MED
cancer	I-MED
Recently	O
,	O
kinesin	B-MED
motor	B-MED
proteins	I-MED
have	O
been	O
focused	O
on	O
as	O
targets	B-MED
for	O
cancer	B-MED
therapy	I-MED
.	O
Kinesins	B-MED
are	O
microtubule	B-MED
-based	O
motor	B-MED
proteins	I-MED
that	O
mediate	O
diverse	B-MED
functions	I-MED
within	O
the	O
cell	B-MED
,	O
including	O
the	O
transport	B-MED
of	O
vesicles	B-MED
,	O
organelles	B-MED
,	O
chromosomes	B-MED
and	O
protein	B-MED
complexes	I-MED
,	O
as	O
well	O
as	O
the	O
movement	B-MED
of	I-MED
microtubules	I-MED
.	O
In	O
the	O
current	O
study	O
,	O
the	O
expression	B-MED
of	O
kinesin	B-MED
family	I-MED
member	I-MED
18A	I-MED
(	O
KIF18A	B-MED
)	O
,	O
a	O
member	B-MED
of	I-MED
kinesin	I-MED
superfamily	I-MED
,	O
was	O
investigated	B-MED
in	O
breast	B-MED
cancer	I-MED
using	O
immunohistochemistry	B-MED
,	O
and	O
its	O
effect	O
on	O
breast	B-MED
cancer	I-MED
prognosis	O
was	O
examined	O
.	O
KIF18A	B-MED
expression	B-MED
level	I-MED
was	O
significantly	O
associated	B-MED
with	I-MED
lymph	B-MED
node	I-MED
metastasis	I-MED
(	O
P=0.047	O
)	O
.	O
In	O
patients	B-MED
with	O
high	O
levels	O
of	O
KIF18A	B-MED
expression	B-MED
,	O
survival	B-MED
was	O
significantly	O
poorer	O
compared	O
to	O
patients	B-MED
with	O
low	O
levels	O
of	O
KIF18A	B-MED
expression	B-MED
(	O
disease	B-MED
-	I-MED
free	I-MED
survival	I-MED
,	O
P=0.030	O
)	O
.	O
Multivariate	B-MED
analysis	I-MED
revealed	O
that	O
venous	B-MED
invasion	I-MED
(	O
hazard	B-MED
ratio	I-MED
,	O
9.22	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
,	O
3.90	O
-	O
23.66	O
;	O
P<0.001	O
)	O
and	O
KIF18A	B-MED
expression	B-MED
(	O
hazard	B-MED
ratio	I-MED
,	O
3.20	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
,	O
1.34	O
-	O
6.09	O
;	O
P=0.010	O
)	O
were	O
independent	O
predictive	B-MED
factors	I-MED
for	O
lymph	B-MED
node	I-MED
metastasis	I-MED
.	O
KIF18A	B-MED
may	O
be	O
a	O
useful	O
predictive	B-MED
marker	B-MED
for	O
lymph	B-MED
node	I-MED
metastasis	I-MED
in	O
breast	B-MED
cancer	I-MED
,	O
which	O
could	O
facilitate	O
curative	B-MED
adjuvant	I-MED
treatment	B-MED
.	O
Encaged	B-MED
Chironomus	B-MED
riparius	I-MED
larvae	B-MED
in	O
assessment	B-MED
of	O
trace	B-MED
metal	I-MED
bioavailability	B-MED
and	O
transfer	B-MED
in	O
a	O
landfill	B-MED
leachate	I-MED
collection	B-MED
pond	B-MED
Household	B-MED
wastes	B-MED
may	O
constitute	B-MED
a	O
vector	B-MED
of	O
environmental	B-MED
contamination	I-MED
when	O
buried	B-MED
,	O
in	O
particular	O
through	O
degradation	B-MED
and	O
production	O
of	O
leachates	B-MED
containing	B-MED
significant	B-MED
trace	B-MED
metal	I-MED
(	O
TM	B-MED
)	O
concentrations	B-MED
that	O
may	O
constitute	B-MED
a	O
serious	O
risk	B-MED
to	O
biota	B-MED
.	O
The	O
objectives	B-MED
of	O
this	O
study	B-MED
were	O
to	O
assess	B-MED
the	O
bioavailability	B-MED
and	O
transfer	B-MED
potential	B-MED
of	O
various	O
TMs	B-MED
present	B-MED
in	O
water	B-MED
and	O
sediments	B-MED
in	O
a	O
reservoir	B-MED
receiving	B-MED
landfill	B-MED
leachates	I-MED
.	O
An	O
active	B-MED
biomonitoring	B-MED
approach	O
was	O
adopted	O
consisting	O
of	O
exposing	B-MED
naive	O
laboratory	B-MED
organisms	I-MED
in	O
cages	B-MED
deployed	B-MED
in	B-MED
the	I-MED
field	I-MED
.	O
Aquatic	B-MED
insects	I-MED
such	O
as	O
Chironomus	B-MED
riparius	I-MED
larvae	B-MED
are	O
good	O
candidates	O
since	O
they	O
represent	B-MED
key	O
organisms	B-MED
in	O
the	O
trophic	B-MED
functioning	B-MED
of	O
aquatic	B-MED
ecosystems	I-MED
.	O
The	O
results	B-MED
show	O
that	O
water	B-MED
,	O
suspended	B-MED
particles	B-MED
,	O
and	O
sediments	B-MED
were	O
significant	B-MED
ly	O
contaminated	B-MED
by	O
various	O
TMs	B-MED
(	O
As	B-MED
,	O
Cd	B-MED
,	O
Cu	B-MED
,	O
Ni	B-MED
,	O
Pb	B-MED
,	O
and	O
Zn	B-MED
)	O
.	O
Their	O
contribution	B-MED
to	O
the	O
transfer	B-MED
of	O
TMs	B-MED
depends	O
,	O
however	O
,	O
on	O
the	O
specific	B-MED
element	B-MED
considered	B-MED
,	O
e.g.	O
,	O
Cd	B-MED
in	O
sediments	B-MED
or	O
Pb	B-MED
in	O
both	O
suspended	B-MED
particles	B-MED
and	O
sediments	B-MED
.	O
The	O
internal	O
fate	O
of	O
TMs	B-MED
was	O
investigated	B-MED
according	O
to	O
their	O
fractionation	B-MED
between	O
an	O
insoluble	B-MED
and	O
a	O
cytosolic	B-MED
fraction	B-MED
.	O
This	O
approach	O
revealed	B-MED
different	O
detoxification	B-MED
strategies	B-MED
capable	O
of	O
preventing	B-MED
the	O
induction	B-MED
of	O
deleterious	B-MED
effects	I-MED
at	O
the	O
individual	B-MED
scale	B-MED
.	O
However	O
,	O
the	O
accumulation	B-MED
of	O
several	O
TMs	B-MED
in	O
C.	B-MED
riparius	I-MED
larvae	B-MED
tissues	B-MED
may	O
also	O
represent	B-MED
a	O
significant	B-MED
load	O
potentially	B-MED
transferable	B-MED
to	O
higher	B-MED
trophic	B-MED
levels	B-MED
.	O
γ	B-MED
-	I-MED
Butenolide	I-MED
and	O
furanone	B-MED
derivatives	I-MED
from	O
the	O
soil	B-MED
-derived	O
fungus	B-MED
Aspergillus	B-MED
sclerotiorum	I-MED
PSU	B-MED
-	I-MED
RSPG178	I-MED
Chromatographic	B-MED
separation	I-MED
of	O
the	O
broth	B-MED
extract	B-MED
of	O
the	O
soil	B-MED
-derived	O
fungus	B-MED
Aspergillus	B-MED
sclerotiorum	I-MED
PSU	B-MED
-	I-MED
RSPG178	I-MED
resulted	O
in	O
isolation	B-MED
of	O
four	O
γ	B-MED
-	I-MED
butenolide	I-MED
-	I-MED
furanone	I-MED
dimers	I-MED
,	O
aspersclerotiorones	B-MED
A	I-MED
-	I-MED
D	I-MED
,	O
a	O
furanone	B-MED
derivative	I-MED
,	O
aspersclerotiorone	B-MED
E	I-MED
,	O
and	O
two	O
γ	B-MED
-	I-MED
butenolide	I-MED
derivatives	I-MED
,	O
aspersclerotiorones	B-MED
F	I-MED
and	O
G	B-MED
,	O
together	O
with	O
six	O
known	O
compounds	O
,	O
penicillic	B-MED
acid	I-MED
,	O
dihydropenicillic	B-MED
acid	I-MED
,	O
5,6	B-MED
-	I-MED
dihydro-6	I-MED
-	I-MED
hydroxypenicillic	I-MED
acid	I-MED
,	O
6	B-MED
-	I-MED
methoxy-5,6	I-MED
-	I-MED
dihydropenicillic	I-MED
acid	I-MED
,	O
coculnol	B-MED
and	O
(	B-MED
4R,5R)-4,5	I-MED
-	I-MED
dihydroxy-3	I-MED
-	I-MED
methoxy-5	I-MED
-	I-MED
methylcyclohex-2	I-MED
-	I-MED
en-1	I-MED
-	I-MED
one	I-MED
.	O
Their	O
structures	B-MED
were	O
determined	O
by	O
spectroscopic	B-MED
evidence	I-MED
.	O
For	O
aspersclerotiorones	B-MED
A	I-MED
and	O
B	B-MED
,	O
the	O
structures	B-MED
were	O
confirmed	O
by	O
single	B-MED
-	I-MED
crystal	I-MED
X	I-MED
-	I-MED
ray	I-MED
diffraction	I-MED
crystallography	I-MED
.	O
Penicillic	O
acid	O
displayed	O
weak	O
antibacterial	B-MED
activity	I-MED
against	O
Staphylococcus	B-MED
aureus	I-MED
and	O
Escherichia	B-MED
coli	I-MED
with	O
equal	O
MIC	B-MED
values	I-MED
of	O
128	O
μg	O
/	O
mL	O
,	O
and	O
it	O
was	O
noncytotoxic	B-MED
towards	O
African	B-MED
green	I-MED
monkey	I-MED
kidney	B-MED
fibroblast	B-MED
cells	I-MED
.	O
Comparative	O
kinematic	B-MED
gait	I-MED
analysis	I-MED
in	O
young	B-MED
and	O
old	B-MED
Beagle	B-MED
dogs	I-MED
Age	B-MED
-	I-MED
related	I-MED
involution	B-MED
in	O
dogs	B-MED
involves	O
loss	B-MED
of	I-MED
muscle	I-MED
mass	I-MED
and	O
changes	O
in	O
connective	B-MED
tissue	I-MED
and	O
articular	B-MED
cartilage	I-MED
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	B-MED
whether	O
an	O
age	B-MED
-	I-MED
related	I-MED
influence	O
on	O
joint	B-MED
mobility	I-MED
can	O
be	O
detected	B-MED
in	O
the	O
absence	B-MED
of	O
diseases	B-MED
.	O
Five	O
young	B-MED
(	O
Ø	O
2.0	O
years	B-MED
)	O
and	O
five	O
old	B-MED
(	O
Ø	O
10.4	O
years	B-MED
)	O
healthy	B-MED
and	O
sound	B-MED
Beagle	I-MED
dogs	I-MED
were	O
measured	B-MED
during	O
locomotion	B-MED
on	O
a	O
treadmill	B-MED
by	O
computer	B-MED
-	I-MED
assisted	I-MED
gait	B-MED
analysis	I-MED
.	O
Angles	B-MED
of	O
the	O
shoulder	B-MED
,	O
elbow	B-MED
,	O
carpal	B-MED
,	O
hip	B-MED
,	O
stifle	B-MED
and	O
tarsal	B-MED
joints	I-MED
were	O
analyzed	B-MED
,	O
including	O
joint	B-MED
angle	I-MED
progression	I-MED
curves	I-MED
,	O
minimum	B-MED
and	O
maximum	B-MED
joint	B-MED
angles	B-MED
and	O
range	B-MED
of	I-MED
motion	I-MED
(	O
ROM	B-MED
)	O
.	O
The	O
old	B-MED
group	B-MED
showed	O
a	O
smaller	O
maximum	O
joint	B-MED
angle	B-MED
(	O
p	O
=	O
0.037	O
)	O
and	O
ROM	B-MED
(	O
p	O
=	O
0.037	O
)	O
of	O
the	O
carpal	B-MED
joint	I-MED
and	O
similar	O
tendencies	O
in	O
the	O
shoulder	B-MED
,	O
elbow	B-MED
and	O
carpal	B-MED
joint	I-MED
.	O
The	O
descriptive	B-MED
analysis	I-MED
of	O
the	O
progression	B-MED
curves	I-MED
revealed	O
less	B-MED
flexion	I-MED
and	O
extension	B-MED
of	O
the	O
joints	B-MED
of	O
the	O
forelimb	B-MED
.	O
This	O
indicates	O
restricted	B-MED
joint	B-MED
mobility	I-MED
of	O
the	O
forelimb	B-MED
but	O
primarily	O
of	O
the	O
carpal	B-MED
joint	I-MED
.	O
Findings	B-MED
in	O
the	O
joints	B-MED
of	O
the	O
hindlimb	B-MED
were	O
not	O
consistent	B-MED
;	O
contrasting	O
alterations	B-MED
may	O
be	O
due	O
to	O
a	O
compensatory	B-MED
mechanism	B-MED
.	O
As	O
most	O
alterations	B-MED
were	O
found	B-MED
in	O
the	O
distal	B-MED
joints	I-MED
,	O
these	O
should	O
receive	O
particular	B-MED
attention	I-MED
when	O
examining	O
elderly	B-MED
dogs	I-MED
.	O
Improving	B-MED
the	O
Sexual	B-MED
Health	I-MED
of	O
Young	B-MED
People	I-MED
With	O
Mobility	B-MED
Impairments	I-MED
:	O
Challenges	B-MED
and	O
Recommendations	B-MED
This	O
mixed	B-MED
-	I-MED
method	I-MED
study	I-MED
(	O
a	O
)	O
describes	O
challenges	B-MED
to	O
providing	B-MED
sexual	B-MED
health	I-MED
services	B-MED
to	O
youth	B-MED
with	O
mobility	B-MED
impairments	I-MED
from	O
the	O
perspective	B-MED
of	O
health	B-MED
care	I-MED
providers	I-MED
and	O
experts	B-MED
and	O
(	O
b	O
)	O
describes	O
and	O
compares	B-MED
sexual	B-MED
health	I-MED
-related	O
experiences	B-MED
of	O
youth	B-MED
with	O
mobility	B-MED
impairments	I-MED
.	O
Secondary	B-MED
data	I-MED
analysis	I-MED
of	I-MED
My	I-MED
Path	I-MED
,	O
a	O
study	B-MED
focused	B-MED
on	O
the	O
transition	B-MED
to	O
adulthood	B-MED
for	O
youth	B-MED
with	O
mobility	B-MED
impairments	I-MED
.	O
Using	O
an	O
exploratory	B-MED
sequential	I-MED
design	I-MED
,	O
qualitative	B-MED
data	I-MED
(	O
n	O
=	O
10	O
)	O
were	O
analyzed	B-MED
using	O
systematic	B-MED
content	B-MED
analysis	I-MED
followed	O
by	O
quantitative	B-MED
analysis	I-MED
of	I-MED
survey	I-MED
data	I-MED
(	O
N	O
=	O
337	O
)	O
.	O
Challenges	B-MED
included	B-MED
not	B-MED
talking	I-MED
about	O
sex	B-MED
,	O
managing	O
sexual	B-MED
development	I-MED
,	O
adaptation	B-MED
and	O
instruction	B-MED
,	O
parent	B-MED
roles	I-MED
,	O
and	O
safety	B-MED
.	O
Survey	B-MED
data	B-MED
showed	O
that	O
youth	B-MED
with	O
mobility	B-MED
impairments	I-MED
are	O
diverse	B-MED
in	O
their	O
experiences	B-MED
with	O
sexual	B-MED
behavior	I-MED
and	O
sources	B-MED
of	O
sexual	B-MED
health	I-MED
information	B-MED
.	O
Although	O
connected	B-MED
with	O
primary	B-MED
care	I-MED
providers	I-MED
,	O
few	O
received	B-MED
information	B-MED
about	O
sexual	B-MED
health	I-MED
.	O
Interventions	B-MED
to	O
improve	B-MED
youths	B-MED
'	O
well	B-MED
-	I-MED
being	I-MED
should	O
include	B-MED
comprehensive	B-MED
care	I-MED
and	O
education	B-MED
that	O
promotes	B-MED
and	O
supports	B-MED
healthy	B-MED
sexual	B-MED
development	I-MED
.	O
Co	B-MED
-	I-MED
delivery	I-MED
of	O
pemetrexed	B-MED
and	O
miR-21	B-MED
antisense	I-MED
oligonucleotide	I-MED
by	O
lipid	B-MED
-	O
polymer	B-MED
hybrid	B-MED
nanoparticles	I-MED
and	O
effects	B-MED
on	O
glioblastoma	B-MED
cells	B-MED
Combination	B-MED
therapy	I-MED
using	O
anticancer	B-MED
drugs	I-MED
and	O
nucleic	B-MED
acid	I-MED
is	O
a	O
more	O
promising	O
strategy	O
to	O
overcome	O
multidrug	B-MED
resistance	I-MED
in	O
cancer	B-MED
and	O
to	O
enhance	O
apoptosis	B-MED
.	O
In	O
this	O
study	B-MED
,	O
lipid	B-MED
-	O
polymer	B-MED
hybrid	B-MED
nanoparticles	I-MED
(	O
LPNs	B-MED
)	O
,	O
which	O
contain	O
both	O
pemetrexed	B-MED
and	O
miR-21	B-MED
antisense	I-MED
oligonucleotide	I-MED
(	O
anti	B-MED
-	I-MED
miR-21	I-MED
)	O
,	O
have	O
been	O
developed	O
for	O
treatment	B-MED
of	O
glioblastoma	B-MED
,	O
the	O
most	O
aggressive	B-MED
type	O
of	O
brain	B-MED
tumor	I-MED
.	O
Prepared	O
LPNs	B-MED
have	O
been	O
well	O
characterized	O
by	O
particle	B-MED
size	I-MED
distribution	B-MED
and	O
zeta	B-MED
potential	I-MED
measurements	B-MED
,	O
determination	O
of	O
encapsulation	B-MED
efficiency	B-MED
,	O
and	O
in	B-MED
vitro	I-MED
release	B-MED
experiments	I-MED
.	O
Morphology	B-MED
of	O
LPNs	B-MED
was	O
determined	O
by	O
transmission	B-MED
electron	I-MED
microscopy	I-MED
.	O
LPNs	B-MED
had	O
a	O
hydrodynamic	B-MED
size	B-MED
below	O
100	O
nm	O
and	O
exhibited	O
sustained	B-MED
release	I-MED
of	O
pemetrexed	B-MED
up	O
to	O
10	O
h.	O
Encapsulation	B-MED
of	O
pemetrexed	B-MED
in	O
LPNs	B-MED
increased	O
cellular	B-MED
uptake	I-MED
from	O
6	O
%	O
to	O
78	O
%	O
.	O
Results	O
of	O
confocal	B-MED
microscopy	I-MED
analysis	I-MED
have	O
shown	O
that	O
co	B-MED
-	I-MED
delivery	I-MED
of	O
anti	B-MED
-	I-MED
miR-21	I-MED
significantly	O
improved	O
accumulation	B-MED
of	O
LPNs	B-MED
in	O
the	O
nucleus	B-MED
of	O
U87MG	B-MED
cells	I-MED
.	O
Nevertheless	O
,	O
more	O
effective	O
cytotoxicity	B-MED
results	B-MED
could	O
not	O
be	O
obtained	O
due	O
to	O
low	O
concentration	B-MED
of	O
anti	B-MED
-	I-MED
miR-21	I-MED
,	O
loaded	O
in	O
LPNs	B-MED
.	O
We	O
expect	O
that	O
the	O
effective	O
drug	B-MED
delivery	I-MED
systems	I-MED
can	O
be	O
obtained	O
with	O
higher	O
concentration	B-MED
of	O
anti	B-MED
-	I-MED
miR-21	I-MED
for	O
the	O
treatment	B-MED
of	O
glioblastoma	B-MED
.	O
MiR-424	B-MED
-	I-MED
5p	I-MED
participates	B-MED
in	O
esophageal	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
invasion	B-MED
and	O
metastasis	B-MED
via	O
SMAD7	B-MED
pathway	B-MED
mediated	O
EMT	B-MED
ESCC	B-MED
is	O
a	O
life	B-MED
-	I-MED
threatening	I-MED
disease	B-MED
due	O
to	O
invasion	B-MED
and	O
metastasis	B-MED
in	O
the	O
early	B-MED
stage	I-MED
.	O
Great	O
efforts	O
had	O
been	O
made	O
to	O
detect	B-MED
the	O
molecular	B-MED
mechanisms	B-MED
which	O
led	O
to	O
the	O
invasion	B-MED
and	O
metastasis	B-MED
in	O
ESCC	B-MED
.	O
Recent	O
evidence	B-MED
had	O
suggested	O
that	O
deregulation	B-MED
of	O
miR-424	B-MED
-	I-MED
5p	I-MED
took	O
an	O
important	O
role	B-MED
in	O
cancers	B-MED
.	O
However	O
,	O
its	O
role	B-MED
and	O
functional	B-MED
mechanism	B-MED
in	O
ESCC	B-MED
had	O
seldom	B-MED
been	O
elucidated	O
.	O
The	O
expression	B-MED
levels	I-MED
of	O
miR-424	B-MED
-	I-MED
5p	I-MED
were	O
detected	B-MED
in	O
ESCC	B-MED
tissues	B-MED
and	O
cell	B-MED
lines	I-MED
by	O
real	B-MED
-	I-MED
time	I-MED
PCR	I-MED
methods	I-MED
.	O
Then	O
,	O
the	O
invasion	B-MED
,	O
metastasis	B-MED
and	O
proliferation	B-MED
ability	O
of	O
ESCC	B-MED
cell	B-MED
lines	I-MED
transfected	B-MED
with	O
miR-424	B-MED
-	I-MED
5p	I-MED
mimics	O
were	O
analyzed	B-MED
separately	O
by	O
transwell	B-MED
invasion	I-MED
assay	I-MED
,	O
wound	B-MED
healing	I-MED
assay	I-MED
and	O
cell	B-MED
proliferation	I-MED
assay	I-MED
.	O
Finally	O
,	O
the	O
target	B-MED
gene	I-MED
of	O
miR-424	B-MED
-	I-MED
5p	I-MED
was	O
studied	O
and	O
verified	B-MED
by	O
luciferase	B-MED
activity	I-MED
assay	I-MED
.	O
And	O
the	O
role	B-MED
of	O
miR-424	B-MED
-	I-MED
5p	I-MED
in	O
EMT	B-MED
was	O
also	O
investigated	B-MED
by	O
real	B-MED
-	I-MED
time	I-MED
PCR	I-MED
and	O
western	B-MED
blot	I-MED
assay	I-MED
.	O
We	O
showed	O
that	O
the	O
expression	B-MED
levels	I-MED
of	O
miR-424	B-MED
-	I-MED
5p	I-MED
were	O
decreased	B-MED
both	O
in	O
ESCC	B-MED
tissues	B-MED
and	O
cell	B-MED
lines	I-MED
.	O
Furthermore	O
,	O
the	O
expression	B-MED
levels	I-MED
of	O
miR-424	B-MED
-	I-MED
5p	I-MED
were	O
negatively	O
linked	O
to	O
lymph	B-MED
node	I-MED
metastasis	B-MED
in	O
ESCC	B-MED
tissues	B-MED
.	O
Restoration	O
of	O
miR-424	B-MED
-	I-MED
5p	I-MED
in	O
EC-1	B-MED
cells	I-MED
by	O
using	O
miR-424	B-MED
-	I-MED
5p	I-MED
mimics	O
could	O
decrease	B-MED
the	O
invasion	B-MED
,	O
metastasis	B-MED
and	O
proliferation	B-MED
of	O
EC-1	B-MED
cells	I-MED
,	O
indicating	O
its	O
role	B-MED
in	O
inhibition	B-MED
on	O
the	O
invasion	B-MED
and	O
metastasis	B-MED
ability	O
of	O
ESCC	B-MED
cells	B-MED
and	O
tissues	B-MED
.	O
In	O
addition	O
,	O
we	O
demonstrated	O
that	O
SMAD7	B-MED
was	O
a	O
specific	O
target	B-MED
gene	I-MED
for	O
miR-424	B-MED
-	I-MED
5p	I-MED
by	O
luciferase	B-MED
activity	I-MED
assay	I-MED
and	O
miR-424	B-MED
-	I-MED
5p	I-MED
could	O
not	O
only	O
negatively	B-MED
regulate	B-MED
SMAD7	B-MED
expression	B-MED
but	O
also	O
participate	O
in	O
EMT	B-MED
via	O
SMAD7	B-MED
,	O
because	O
overexpression	B-MED
of	O
SMAD7	B-MED
could	O
partly	O
enhance	B-MED
the	O
miR-424	B-MED
-	I-MED
5p	I-MED
anti	B-MED
-	I-MED
EMT	I-MED
function	B-MED
.	O
Our	O
results	B-MED
described	O
that	O
miR-424	B-MED
-	I-MED
5p	I-MED
-	O
SMAD7	B-MED
pathway	B-MED
contributed	O
to	O
ESCC	B-MED
invasion	B-MED
and	O
metastasis	B-MED
and	O
up	B-MED
-	I-MED
regulation	I-MED
of	O
miR-424	B-MED
-	I-MED
5p	I-MED
perhaps	O
provided	O
a	O
strategy	O
for	O
preventing	B-MED
tumor	B-MED
invasion	I-MED
,	O
metastasis	B-MED
.	O
Insurance	B-MED
Coverage	I-MED
and	O
Utilization	B-MED
at	O
a	O
Sexually	B-MED
Transmitted	I-MED
Disease	I-MED
Clinic	I-MED
in	O
a	O
Medicaid	B-MED
Expansion	O
State	B-MED
In	O
Rhode	B-MED
Island	I-MED
,	O
the	O
Patient	B-MED
Protection	I-MED
and	I-MED
Affordable	I-MED
Care	I-MED
Act	I-MED
has	O
led	O
to	O
over	O
95	O
%	O
of	O
the	O
state	B-MED
's	I-MED
population	B-MED
being	O
insured	B-MED
.	O
We	O
evaluated	B-MED
insurance	B-MED
coverage	I-MED
and	O
barriers	B-MED
to	O
insurance	B-MED
use	O
among	O
patients	B-MED
presenting	O
for	O
services	B-MED
at	O
the	O
Rhode	B-MED
Island	I-MED
sexually	B-MED
transmitted	I-MED
disease	I-MED
(	I-MED
STD	I-MED
)	I-MED
clinic	I-MED
.	O
We	O
analyzed	B-MED
factors	B-MED
associated	B-MED
with	I-MED
insurance	B-MED
coverage	I-MED
and	O
utilization	B-MED
among	O
patients	B-MED
presenting	O
for	O
STD	B-MED
services	B-MED
between	O
July	B-MED
and	O
December	B-MED
2015	O
.	O
A	O
total	O
of	O
692	O
patients	B-MED
had	O
insurance	B-MED
information	I-MED
available	B-MED
;	O
of	O
those	O
,	O
40	O
%	O
were	O
uninsured	B-MED
.	O
Patients	B-MED
without	B-MED
insurance	I-MED
were	O
more	O
likely	O
than	O
those	O
with	O
insurance	B-MED
to	O
be	O
nonwhite	O
(	O
50	O
%	O
among	O
uninsured	B-MED
,	O
compared	O
with	O
40	O
%	O
among	O
insured	B-MED
;	O
P	O
=	O
0.014	O
)	O
and	O
Hispanic	B-MED
or	O
Latino	B-MED
/	I-MED
a	I-MED
(	O
25	O
%	O
,	O
compared	O
with	O
16	O
%	O
;	O
P	O
=	O
0.006	O
)	O
,	O
and	O
less	O
likely	O
to	O
be	O
men	B-MED
who	O
have	O
sex	B-MED
with	O
men	B-MED
(	O
27	O
%	O
,	O
compared	O
with	O
39	O
%	O
;	O
P	O
=	O
0.001	O
)	O
.	O
Of	O
those	O
with	O
health	B-MED
insurance	I-MED
,	O
26	O
%	O
obtained	O
coverage	B-MED
as	O
a	O
result	B-MED
of	O
the	O
Affordable	B-MED
Care	I-MED
Act	I-MED
,	O
and	O
56	O
%	O
of	O
those	O
were	O
previously	O
uninsured	B-MED
.	O
Among	O
uninsured	B-MED
individuals	I-MED
,	O
barriers	B-MED
to	O
obtaining	O
health	B-MED
insurance	I-MED
included	O
cost	B-MED
and	O
unemployment	B-MED
.	O
Among	O
those	O
with	B-MED
insurance	I-MED
,	O
43	O
%	O
reported	O
willingness	B-MED
to	O
use	O
insurance	B-MED
for	O
STD	B-MED
services	B-MED
.	O
Barriers	B-MED
to	O
insurance	B-MED
use	O
included	O
concerns	O
about	O
anonymity	B-MED
and	O
out	B-MED
-	I-MED
of	I-MED
-	I-MED
pocket	I-MED
costs	I-MED
.	O
Despite	O
expanded	O
insurance	B-MED
access	B-MED
,	O
many	O
individuals	B-MED
presenting	O
to	O
the	O
Rhode	B-MED
Island	I-MED
STD	B-MED
Clinic	I-MED
were	O
uninsured	B-MED
.	O
Among	O
those	O
who	O
were	O
insured	B-MED
,	O
significant	O
barriers	B-MED
still	O
existed	O
to	O
using	O
insurance	B-MED
.	O
STD	B-MED
clinics	I-MED
continue	O
to	O
play	O
an	O
important	O
role	O
in	O
providing	O
safety	B-MED
-	I-MED
net	I-MED
STD	B-MED
services	B-MED
in	O
states	B-MED
with	O
low	O
uninsured	B-MED
rates	B-MED
.	O
Both	O
public	B-MED
and	O
private	B-MED
insurers	B-MED
are	O
needed	O
to	O
address	O
financial	B-MED
barriers	I-MED
and	O
optimize	B-MED
payment	B-MED
structures	B-MED
for	O
services	B-MED
.	O
Crocetin	B-MED
improves	B-MED
the	O
quality	B-MED
of	O
in	B-MED
vitro	I-MED
-	O
produced	B-MED
bovine	B-MED
embryos	B-MED
:	O
Implications	O
for	O
blastocyst	B-MED
development	I-MED
,	O
cryotolerance	B-MED
,	O
and	O
apoptosis	B-MED
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
assess	B-MED
the	O
effect	B-MED
of	O
supplementation	B-MED
of	O
bovine	B-MED
culture	B-MED
medium	I-MED
with	O
the	O
natural	B-MED
antioxidant	I-MED
crocetin	B-MED
on	O
in	B-MED
vitro	I-MED
blastocyst	B-MED
development	I-MED
and	O
quality	B-MED
.	O
This	O
was	O
evaluated	B-MED
as	O
cryotolerance	B-MED
,	O
apoptosis	B-MED
index	I-MED
,	O
and	O
total	B-MED
cells	I-MED
number	I-MED
and	O
allocation	B-MED
.	O
Abattoir	B-MED
-derived	O
oocytes	B-MED
were	O
matured	B-MED
and	O
fertilized	B-MED
in	B-MED
vitro	I-MED
according	O
to	O
standard	B-MED
procedure	I-MED
.	O
Twenty	O
hours	B-MED
after	O
IVF	B-MED
,	O
presumptive	B-MED
zygotes	B-MED
were	O
cultured	B-MED
in	O
synthetic	B-MED
oviduct	I-MED
fluid	B-MED
medium	I-MED
,	O
supplemented	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μM	O
crocetin	B-MED
(	O
experiment	O
1	O
)	O
at	O
39	O
°	O
C	O
under	O
humidified	B-MED
air	I-MED
with	O
5	O
%	O
CO2	B-MED
,	O
7	O
%	O
O2	B-MED
,	O
and	O
88	O
%	O
N2	B-MED
.	O
On	O
Day	B-MED
7	O
,	O
embryo	B-MED
yields	I-MED
were	O
assessed	B-MED
and	O
the	O
blastocysts	B-MED
were	O
vitrified	O
by	O
Cryotop	B-MED
method	I-MED
in	O
16.5	O
%	O
ethylene	B-MED
glycol	I-MED
,	O
16.5	O
%	O
DMSO	B-MED
,	O
and	O
0.5	O
M	O
sucrose	B-MED
.	O
Finally	O
,	O
blastocysts	B-MED
produced	O
on	O
Day	B-MED
8	O
in	O
the	O
absence	B-MED
(	O
control	B-MED
)	O
and	O
presence	B-MED
of	O
1	O
μM	O
crocetin	B-MED
were	O
used	O
for	O
terminal	B-MED
deoxynucleotidyl	I-MED
transferase	I-MED
-	I-MED
mediated	I-MED
dUTP	I-MED
nick	I-MED
end	I-MED
labelling	I-MED
and	O
differential	B-MED
staining	I-MED
to	O
evaluate	B-MED
,	O
respectively	O
,	O
the	O
apoptotic	B-MED
rate	I-MED
and	O
the	O
allocation	B-MED
of	O
cells	B-MED
into	O
inner	B-MED
cell	I-MED
mass	I-MED
(	O
ICM	B-MED
)	O
and	O
trophectoderm	B-MED
(	O
TE	B-MED
)	O
lineages	B-MED
(	O
experiment	O
2	O
)	O
.	O
Embryo	B-MED
development	I-MED
was	O
higher	O
in	O
the	O
1	O
μM	O
crocetin	B-MED
group	I-MED
compared	O
to	O
the	O
control	B-MED
,	O
both	O
in	O
terms	O
of	O
total	B-MED
embryo	B-MED
output	B-MED
(	O
37.7	O
±	O
4.2	O
%	O
,	O
52.9	O
±	O
6.3	O
%	O
,	O
40.9	O
±	O
7.6	O
%	O
,	O
and	O
42.4	O
±	O
8.7	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0.01	O
)	O
and	O
grade	B-MED
1	I-MED
and	O
2	B-MED
blastocysts	B-MED
(	O
33.6	O
±	O
4.9	O
%	O
,	O
46.1	O
±	O
7.3	O
%	O
,	O
37.8	O
±	O
7.9	O
%	O
,	O
and	O
39.4	O
±	O
7.9	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0.05	O
)	O
.	O
Moreover	O
,	O
the	O
percentage	B-MED
of	O
fast	B-MED
-	I-MED
developing	I-MED
embryos	I-MED
increased	B-MED
in	O
1	O
μM	O
crocetin	B-MED
group	I-MED
compared	O
to	O
the	O
control	B-MED
(	O
23.4	O
±	O
4.7	O
%	O
,	O
32.7	O
±	O
6.6	O
%	O
,	O
27.2	O
±	O
6.6	O
%	O
,	O
and	O
30.1	O
±	O
7.2	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0.05	O
)	O
.	O
In	O
addition	O
,	O
the	O
enrichment	B-MED
of	I-MED
culture	I-MED
medium	I-MED
with	O
1	O
μM	O
crocetin	B-MED
improved	B-MED
embryo	B-MED
cryotolerance	B-MED
compared	O
to	O
the	O
control	B-MED
,	O
as	O
indicated	O
by	O
higher	O
hatching	B-MED
rates	B-MED
recorded	O
after	O
48	O
hours	B-MED
postwarming	B-MED
culture	I-MED
(	O
46.5	O
%	O
vs.	O
60.4	O
%	O
;	O
P	O
<	O
0.05	O
)	O
.	O
Furthermore	O
,	O
1	O
μM	O
crocetin	B-MED
decreased	B-MED
both	O
the	O
average	O
number	O
(	O
9.9	O
±	O
0.4	O
vs.	O
7.1	O
±	O
0.3	O
)	O
and	O
the	O
percentage	B-MED
of	O
apoptotic	B-MED
cells	B-MED
(	O
7.1	O
±	O
0.4	O
vs.	O
4.2	O
±	O
0.2	O
)	O
in	O
blastocysts	B-MED
compared	O
to	O
the	O
control	B-MED
(	O
P	O
<	O
0.01	O
)	O
.	O
However	O
,	O
no	O
differences	O
were	O
recorded	O
in	O
the	O
average	O
number	O
of	O
ICM	B-MED
,	O
TE	B-MED
,	O
and	O
total	B-MED
total	B-MED
cells	B-MED
between	O
1	O
μM	O
crocetin	B-MED
and	O
control	B-MED
groups	O
.	O
In	O
conclusion	O
,	O
the	O
enrichment	B-MED
of	I-MED
bovine	I-MED
culture	I-MED
medium	I-MED
with	O
1	O
μM	O
crocetin	B-MED
increased	B-MED
both	O
blastocyst	B-MED
yield	I-MED
and	O
quality	B-MED
,	O
as	O
indicated	O
by	O
the	O
improved	B-MED
chronology	B-MED
of	O
embryo	B-MED
development	I-MED
,	O
increased	B-MED
resistance	B-MED
to	O
cryopreservation	B-MED
,	O
and	O
reduced	B-MED
incidence	I-MED
of	O
apoptosis	B-MED
.	O
Addressing	B-MED
holistic	B-MED
health	I-MED
and	O
work	B-MED
empowerment	B-MED
through	B-MED
a	O
body	B-MED
-	I-MED
mind	I-MED
-	I-MED
spirit	I-MED
intervention	I-MED
program	I-MED
among	O
helping	B-MED
professionals	B-MED
in	O
continuous	B-MED
education	B-MED
:	O
A	O
pilot	B-MED
study	I-MED
To	O
examine	O
the	O
effectiveness	B-MED
of	O
a	O
body	B-MED
-	I-MED
mind	I-MED
-	I-MED
spirit	I-MED
(	I-MED
BMS	I-MED
)	I-MED
intervention	I-MED
program	I-MED
in	O
improving	B-MED
the	O
holistic	B-MED
well	I-MED
-	I-MED
being	I-MED
and	O
work	B-MED
empowerment	B-MED
among	O
helping	B-MED
professionals	B-MED
in	O
continuous	B-MED
education	B-MED
.	O
Forty	O
-	O
four	O
helping	B-MED
professionals	B-MED
,	O
who	O
were	O
in	O
their	O
first	O
-	O
year	O
part	O
-	O
time	O
postgraduate	B-MED
study	I-MED
,	O
participated	O
in	O
the	O
present	O
study	O
.	O
All	O
participants	B-MED
attended	B-MED
a	O
3	O
-	O
day	O
BMS	B-MED
intervention	I-MED
program	I-MED
which	O
emphasized	O
a	O
holistic	B-MED
approach	I-MED
to	O
health	B-MED
and	O
well	B-MED
-	I-MED
being	I-MED
.	O
Ratings	O
on	O
their	O
levels	B-MED
of	O
physical	B-MED
distress	I-MED
,	O
daily	B-MED
functioning	I-MED
,	O
affect	B-MED
,	O
spirituality	B-MED
,	O
and	O
psychologica	B-MED
l	O
empowerment	B-MED
at	O
work	B-MED
were	O
compared	O
before	O
and	O
immediately	O
after	O
the	O
intervention	B-MED
.	O
Participants	B-MED
reported	O
significantly	O
lower	O
levels	B-MED
of	O
negative	B-MED
affect	I-MED
and	O
physical	B-MED
distress	I-MED
,	O
and	O
were	O
less	O
spiritually	B-MED
disoriented	I-MED
after	O
the	O
intervention	B-MED
.	O
Enhanced	B-MED
levels	B-MED
of	O
daily	B-MED
functioning	I-MED
,	O
positive	B-MED
affect	I-MED
,	O
spiritual	B-MED
resilience	I-MED
,	O
and	O
tranquility	B-MED
were	O
also	O
reported	O
.	O
Results	O
also	O
suggested	O
that	O
participants	B-MED
were	O
empowered	B-MED
at	O
work	B-MED
,	O
and	O
specifically	O
felt	O
more	O
able	O
to	O
make	O
an	O
impact	O
on	O
work	B-MED
outcomes	O
.	O
The	O
3	O
-	O
day	O
BMS	B-MED
intervention	I-MED
program	I-MED
produced	O
a	O
positive	B-MED
and	O
measurable	B-MED
effec	B-MED
t	O
on	O
participants	B-MED
'	O
holistic	B-MED
well	I-MED
-	I-MED
being	I-MED
and	O
empowerment	B-MED
at	O
work	B-MED
.	O
Educators	B-MED
in	O
related	O
fields	B-MED
could	O
incorporate	O
holistic	B-MED
practices	B-MED
into	O
the	O
curriculum	B-MED
to	O
better	O
prepare	O
the	O
future	O
practitioners	B-MED
,	O
leading	O
to	O
better	O
outcomes	O
both	O
to	O
the	O
professionals	B-MED
themselves	O
and	O
their	O
clients	B-MED
or	O
patients	B-MED
.	O
Similar	O
patterns	B-MED
of	O
neural	B-MED
activity	I-MED
predict	O
memory	B-MED
function	I-MED
during	O
encoding	B-MED
and	O
retrieval	B-MED
Neural	B-MED
networks	I-MED
that	O
span	B-MED
the	O
medial	B-MED
temporal	I-MED
lobe	I-MED
(	O
MTL	B-MED
)	O
,	O
prefrontal	B-MED
cortex	I-MED
,	O
and	O
posterior	B-MED
cortical	I-MED
regions	I-MED
are	O
essential	O
to	O
episodic	B-MED
memory	I-MED
function	I-MED
in	O
humans	B-MED
.	O
Encoding	B-MED
and	O
retrieval	B-MED
are	O
supported	O
by	O
the	O
engagement	O
of	O
both	O
distinct	O
neural	B-MED
pathways	I-MED
across	O
the	O
cortex	B-MED
and	O
common	O
structures	B-MED
within	O
the	O
medial	B-MED
temporal	I-MED
lobes	I-MED
.	O
However	O
,	O
the	O
degree	O
to	O
which	O
memory	B-MED
performance	I-MED
can	O
be	O
determined	O
by	O
neural	B-MED
processing	I-MED
that	O
is	O
common	O
to	O
encoding	B-MED
and	O
retrieval	B-MED
remains	O
to	O
be	O
determined	O
.	O
To	O
identify	O
neural	B-MED
signatures	I-MED
of	O
successful	O
memory	B-MED
function	I-MED
,	O
we	O
administered	O
a	O
delayed	O
free	B-MED
-	I-MED
recall	I-MED
task	I-MED
to	O
187	O
neurosurgical	B-MED
patients	B-MED
implanted	B-MED
with	O
subdural	B-MED
or	O
intraparenchymal	B-MED
depth	B-MED
electrodes	I-MED
.	O
We	O
developed	O
multivariate	B-MED
classifiers	I-MED
to	O
identify	O
patterns	B-MED
of	O
spectral	O
power	O
across	O
the	O
brain	B-MED
that	O
independently	O
predicted	O
successful	O
episodic	B-MED
encoding	I-MED
and	O
retrieval	B-MED
.	O
During	O
encoding	B-MED
and	O
retrieval	B-MED
,	O
patterns	B-MED
of	O
increased	O
high	B-MED
frequency	I-MED
activity	B-MED
in	O
prefrontal	B-MED
,	O
MTL	B-MED
,	O
and	O
inferior	B-MED
parietal	I-MED
cortices	I-MED
,	O
accompanied	O
by	O
widespread	O
decreases	O
in	O
low	B-MED
frequency	I-MED
power	O
across	O
the	O
brain	B-MED
predicted	O
successful	O
memory	B-MED
function	I-MED
.	O
Using	O
a	O
cross	B-MED
-	I-MED
decoding	I-MED
approach	I-MED
,	O
we	O
demonstrate	O
the	O
ability	O
to	O
predict	O
memory	B-MED
function	I-MED
across	O
distinct	O
phases	O
of	O
the	O
free	B-MED
-	I-MED
recall	I-MED
task	I-MED
.	O
Furthermore	O
,	O
we	O
demonstrate	O
that	O
classifiers	B-MED
that	O
combine	O
information	O
from	O
both	O
encoding	B-MED
and	O
retrieval	B-MED
states	I-MED
can	O
outperform	O
task	B-MED
-	I-MED
independent	I-MED
models	I-MED
.	O
These	O
findings	O
suggest	O
that	O
the	O
engagement	O
of	O
a	O
core	O
memory	B-MED
network	I-MED
during	O
either	O
encoding	B-MED
or	O
retrieval	B-MED
shapes	B-MED
the	O
ability	B-MED
to	I-MED
remember	I-MED
the	I-MED
past	I-MED
,	O
despite	O
distinct	O
neural	B-MED
interactions	I-MED
that	O
facilitate	O
encoding	B-MED
and	O
retrieval	B-MED
.	O
Beyond	O
neutral	B-MED
and	O
forbidden	B-MED
links	I-MED
:	O
morphological	B-MED
matches	B-MED
and	O
the	O
assembly	B-MED
of	O
mutualistic	B-MED
hawkmoth	B-MED
-	O
plant	B-MED
networks	B-MED
A	O
major	O
challenge	O
in	O
evolutionary	B-MED
ecology	I-MED
is	O
to	O
understand	O
how	O
co	B-MED
-	I-MED
evolutionary	I-MED
processes	I-MED
shape	O
patterns	B-MED
of	O
interactions	B-MED
between	O
species	B-MED
at	O
community	B-MED
level	B-MED
.	O
Pollination	B-MED
of	O
flowers	B-MED
with	O
long	B-MED
corolla	I-MED
tubes	I-MED
by	O
long	B-MED
-	I-MED
tongued	I-MED
hawkmoths	I-MED
has	O
been	O
invoked	O
as	O
a	O
showcase	O
model	B-MED
of	O
co	B-MED
-	I-MED
evolution	I-MED
.	O
Recently	O
,	O
optimal	O
foraging	O
models	B-MED
have	O
predicted	O
that	O
there	O
might	O
be	O
a	O
close	O
association	B-MED
between	O
mouthparts	B-MED
'	I-MED
length	I-MED
and	O
the	O
corolla	B-MED
depth	B-MED
of	O
the	O
visited	O
flowers	B-MED
,	O
thus	O
favouring	O
trait	B-MED
convergence	B-MED
and	O
specialization	B-MED
at	O
community	B-MED
level	O
.	O
Here	O
,	O
we	O
assessed	B-MED
whether	O
hawkmoths	B-MED
more	O
frequently	O
pollinate	B-MED
plants	I-MED
with	O
floral	B-MED
tube	I-MED
lengths	B-MED
similar	O
to	O
their	O
proboscis	B-MED
lengths	B-MED
(	O
morphological	B-MED
match	B-MED
hypothesis	B-MED
)	O
against	O
abundance	B-MED
-based	O
processes	B-MED
(	O
neutral	B-MED
hypothesis	I-MED
)	O
and	O
ecological	B-MED
trait	I-MED
mismatches	B-MED
constraints	B-MED
(	O
forbidden	B-MED
links	I-MED
hypothesis	B-MED
)	O
,	O
and	O
how	O
these	O
processes	B-MED
structure	B-MED
hawkmoth	B-MED
-	O
plant	B-MED
mutualistic	B-MED
networks	I-MED
from	O
five	O
communities	B-MED
in	O
four	O
biogeographical	B-MED
regions	I-MED
of	O
South	B-MED
America	I-MED
.	O
We	O
found	O
convergence	B-MED
in	O
morphological	B-MED
traits	B-MED
across	O
the	O
five	O
communities	B-MED
and	O
that	O
the	O
distribution	B-MED
of	O
morphological	B-MED
differences	O
between	O
hawkmoths	B-MED
and	O
plants	B-MED
is	O
consistent	O
with	O
expectations	O
under	O
the	O
morphological	B-MED
match	B-MED
hypothesis	B-MED
in	O
three	O
of	O
the	O
five	O
communities	B-MED
.	O
In	O
the	O
two	O
remaining	O
communities	B-MED
,	O
which	O
are	O
ecotones	O
between	O
two	O
distinct	O
biogeographical	B-MED
areas	I-MED
,	O
interactions	B-MED
are	O
better	O
predicted	O
by	O
the	O
neutral	B-MED
hypothesis	I-MED
.	O
Our	O
findings	B-MED
are	O
consistent	O
with	O
the	O
idea	O
that	O
diffuse	O
co	B-MED
-	I-MED
evolution	I-MED
drives	O
the	O
evolution	B-MED
of	O
extremely	O
long	B-MED
proboscises	I-MED
and	O
flower	B-MED
tubes	I-MED
,	O
and	O
highlight	O
the	O
importance	O
of	O
morphological	B-MED
traits	B-MED
,	O
beyond	O
the	O
forbidden	B-MED
links	I-MED
hypothesis	B-MED
,	O
in	O
structuring	O
interactions	B-MED
between	O
mutualistic	B-MED
partners	I-MED
,	O
revealing	O
that	O
the	O
role	B-MED
of	O
niche	B-MED
-	I-MED
based	I-MED
processes	I-MED
can	O
be	O
much	O
more	O
complex	O
than	O
previously	O
known	O
.	O
Central	B-MED
Corneal	I-MED
Thickness	I-MED
Reproducibility	B-MED
among	O
Ten	O
Different	O
Instruments	B-MED
To	O
assess	B-MED
agreement	O
between	O
one	O
ultrasonic	B-MED
(	O
US	B-MED
)	O
and	O
nine	O
optical	B-MED
instruments	I-MED
for	O
the	O
measurement	B-MED
of	O
central	B-MED
corneal	I-MED
thickness	I-MED
(	O
CCT	B-MED
)	O
,	O
and	O
to	O
evaluate	B-MED
intra-	B-MED
and	I-MED
inter	I-MED
-	I-MED
operator	I-MED
reproducibility	I-MED
.	O
In	O
this	O
observational	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
,	O
two	O
masked	O
operators	O
measured	O
CCT	B-MED
thickness	O
twice	O
in	O
28	O
healthy	B-MED
eyes	B-MED
.	O
We	O
used	O
seven	O
spectral	B-MED
-	I-MED
domain	I-MED
optical	I-MED
coherence	I-MED
tomography	I-MED
(	I-MED
SD	I-MED
-	I-MED
OCT	I-MED
)	I-MED
devices	I-MED
,	O
one	B-MED
time	I-MED
-	I-MED
domain	I-MED
OCT	I-MED
,	O
one	O
Scheimpflug	B-MED
camera	I-MED
,	O
and	O
one	O
US	B-MED
-	I-MED
based	I-MED
instrument	I-MED
.	O
Inter-	B-MED
and	I-MED
intra	I-MED
-	I-MED
operator	I-MED
reproducibility	I-MED
was	O
evaluated	B-MED
by	O
intraclass	B-MED
correlation	I-MED
coefficient	I-MED
(	O
ICC	B-MED
)	O
,	O
coefficient	B-MED
of	I-MED
variation	I-MED
(	O
CV	B-MED
)	O
,	O
and	O
Bland	B-MED
-	I-MED
Altman	I-MED
test	I-MED
analysis	B-MED
.	O
Instrument	B-MED
-to-	O
instrument	B-MED
reproducibility	B-MED
was	O
determined	O
by	O
ANOVA	B-MED
for	O
repeated	O
measurements	O
.	O
We	O
also	O
tested	B-MED
how	O
the	O
devices	B-MED
disagreed	O
regarding	O
systemic	B-MED
bias	B-MED
and	O
random	B-MED
error	B-MED
using	O
a	O
structural	B-MED
equation	I-MED
model	I-MED
.	O
Mean	O
CCT	B-MED
of	O
all	O
instruments	B-MED
ranged	O
from	O
536	O
±	O
42	O
μm	O
to	O
577	O
±	O
40	O
μm	O
.	O
An	O
instrument	B-MED
-to-	O
instrument	B-MED
correlation	B-MED
test	I-MED
showed	O
high	B-MED
values	B-MED
among	O
the	O
10	O
investigated	B-MED
devices	B-MED
(	O
correlation	B-MED
coefficient	I-MED
range	B-MED
0.852	O
-	O
0.995	O
;	O
p	B-MED
values	I-MED
<	O
0.0001	O
in	O
all	O
cases	O
)	O
.	O
The	O
highest	O
correlation	O
coefficient	O
values	O
were	O
registered	O
between	O
3D	O
OCT-2000	O
Topcon	B-MED
-	I-MED
Spectral	I-MED
OCT	I-MED
/	I-MED
SLO	I-MED
Opko	I-MED
(	O
0.995	O
)	O
and	O
Cirrus	B-MED
HD	I-MED
-	I-MED
OCT	I-MED
Zeiss	I-MED
-	I-MED
RS-3000	I-MED
Nidek	I-MED
(	O
0.995	O
)	O
,	O
whereas	O
the	O
lowest	O
were	O
seen	O
between	O
SS-1000	B-MED
CASIA	I-MED
and	O
Spectral	B-MED
OCT	I-MED
/	I-MED
SLO	I-MED
Opko	I-MED
(	O
0.852	O
)	O
.	O
ICC	B-MED
and	O
CV	B-MED
showed	O
excellent	O
inter-	B-MED
and	I-MED
intra	I-MED
-	I-MED
operator	I-MED
reproducibility	I-MED
for	O
all	O
optic	B-MED
-based	O
devices	B-MED
,	O
except	O
for	O
the	O
US	B-MED
-based	O
device	B-MED
.	O
Bland	B-MED
-	I-MED
Altman	I-MED
analysis	B-MED
demonstrated	O
low	O
mean	O
biases	B-MED
between	O
operators	O
.	O
Despite	O
highlighting	O
good	O
intra-	B-MED
and	I-MED
inter	I-MED
-	I-MED
operator	I-MED
reproducibility	I-MED
,	O
we	O
found	O
that	O
a	O
scale	B-MED
bias	B-MED
between	O
instruments	B-MED
might	O
interfere	B-MED
with	I-MED
thorough	O
CCT	B-MED
monitoring	B-MED
.	O
We	O
suggest	O
that	O
optimal	B-MED
monitoring	B-MED
is	O
achieved	O
with	O
the	O
same	O
operator	O
and	O
the	O
same	O
device	B-MED
.	O
Medicare	B-MED
claims	B-MED
indicators	B-MED
of	O
healthcare	B-MED
utilization	B-MED
differences	B-MED
after	O
hospitalization	B-MED
for	O
ischemic	B-MED
stroke	I-MED
:	O
Race	B-MED
,	O
gender	B-MED
,	O
and	O
caregiving	B-MED
effects	B-MED
Background	B-MED
Differences	B-MED
in	O
healthcare	B-MED
utilization	B-MED
after	O
stroke	B-MED
may	O
partly	O
explain	O
race	B-MED
or	O
gender	B-MED
differences	B-MED
in	O
stroke	B-MED
outcomes	O
and	O
identify	O
factors	B-MED
that	O
might	O
reduce	B-MED
post	B-MED
-	O
acute	B-MED
stroke	I-MED
care	B-MED
costs	I-MED
.	O
Aim	O
To	O
examine	O
systematic	B-MED
differences	B-MED
in	O
Medicare	B-MED
claims	B-MED
for	O
healthcare	B-MED
utilization	B-MED
after	O
hospitalization	B-MED
for	O
ischemic	B-MED
stroke	I-MED
in	O
a	O
US	B-MED
population	B-MED
-based	O
sample	B-MED
.	O
Methods	O
Claims	B-MED
were	O
examined	B-MED
over	O
a	O
six	B-MED
-	I-MED
month	I-MED
period	B-MED
after	O
hospitalization	B-MED
for	O
279	O
ischemic	B-MED
stroke	I-MED
survivors	B-MED
65	O
years	B-MED
or	O
older	B-MED
from	O
the	O
REasons	B-MED
for	O
Geographic	B-MED
And	O
Racial	B-MED
Differences	I-MED
in	O
Stroke	B-MED
(	O
REGARDS	B-MED
)	O
study	O
.	O
Statistical	B-MED
analyses	I-MED
examined	B-MED
differences	B-MED
in	O
post	B-MED
-	O
acute	B-MED
healthcare	I-MED
utilization	B-MED
,	O
adjusted	O
for	O
pre	B-MED
-	O
stroke	B-MED
utilization	B-MED
,	O
as	O
a	O
function	B-MED
of	O
race	B-MED
(	O
African	B-MED
-	I-MED
American	I-MED
vs.	O
White	B-MED
)	O
,	O
gender	B-MED
,	O
age	B-MED
,	O
stroke	B-MED
belt	I-MED
residence	B-MED
,	O
income	B-MED
,	O
Medicaid	B-MED
dual	I-MED
-	I-MED
eligibility	I-MED
,	O
Charlson	B-MED
comorbidity	I-MED
index	I-MED
,	O
and	O
whether	O
the	O
person	B-MED
lived	B-MED
with	O
an	O
available	B-MED
caregiver	B-MED
.	O
Results	O
After	O
adjusting	O
for	O
covariates	O
,	O
women	B-MED
were	O
more	O
likely	O
than	O
men	B-MED
to	O
receive	B-MED
home	B-MED
health	I-MED
care	I-MED
and	O
to	O
use	O
emergency	B-MED
department	I-MED
services	I-MED
during	O
the	O
post	B-MED
-	O
acute	B-MED
care	I-MED
period	B-MED
.	O
These	O
effects	B-MED
were	O
maintained	B-MED
even	O
after	O
further	B-MED
adjustment	B-MED
for	O
acute	B-MED
stroke	I-MED
severity	B-MED
.	O
African	B-MED
-	I-MED
Americans	I-MED
had	O
more	O
home	B-MED
health	I-MED
care	I-MED
visits	B-MED
than	O
Whites	B-MED
among	O
patients	B-MED
who	O
received	B-MED
some	O
home	B-MED
health	I-MED
care	I-MED
.	O
Having	O
a	O
co	B-MED
-	I-MED
residing	I-MED
caregiver	B-MED
was	O
associated	B-MED
with	I-MED
reduced	B-MED
acute	B-MED
hospitalization	I-MED
length	B-MED
of	I-MED
stay	I-MED
and	O
fewer	O
post	B-MED
-	O
acute	B-MED
emergency	I-MED
department	I-MED
and	O
primary	B-MED
care	I-MED
physician	I-MED
visits	I-MED
.	O
Conclusions	O
Underutilization	B-MED
of	I-MED
healthcare	I-MED
after	O
stroke	B-MED
does	O
not	O
appear	O
to	O
explain	O
poorer	O
long	B-MED
-	I-MED
term	I-MED
stroke	B-MED
outcomes	O
for	O
women	B-MED
and	O
African	B-MED
-	I-MED
Americans	I-MED
in	O
this	O
epidemiologically	B-MED
-derived	O
sample	B-MED
.	O
Caregiver	B-MED
availability	B-MED
may	O
contribute	B-MED
to	O
reduced	B-MED
formal	B-MED
care	I-MED
and	O
cost	B-MED
during	O
the	O
post	B-MED
-	O
acute	B-MED
period	B-MED
.	O
Comparative	O
proteomic	B-MED
analysis	I-MED
reveals	O
alterations	B-MED
in	O
development	B-MED
and	O
photosynthesis	B-MED
-related	O
proteins	B-MED
in	O
diploid	B-MED
and	O
triploid	B-MED
rice	B-MED
Polyploidy	B-MED
has	O
pivotal	O
influences	B-MED
on	O
rice	B-MED
(	O
Oryza	B-MED
sativa	I-MED
L.	I-MED
)	O
morphology	B-MED
and	O
physiology	B-MED
,	O
and	O
is	O
very	O
important	O
for	O
understanding	O
rice	B-MED
domestication	B-MED
and	O
improving	O
agricultural	B-MED
traits	I-MED
.	O
Diploid	B-MED
(	O
DP	B-MED
)	O
and	O
triploid	B-MED
(	O
TP	B-MED
)	O
rice	B-MED
shows	O
differences	B-MED
in	O
morphological	B-MED
parameters	B-MED
,	O
such	O
as	O
plant	B-MED
height	B-MED
,	O
leaf	B-MED
length	B-MED
,	O
leaf	B-MED
width	B-MED
and	O
the	O
physiological	B-MED
index	B-MED
of	O
chlorophyll	B-MED
content	B-MED
.	O
However	O
,	O
the	O
underlying	O
mechanisms	B-MED
determining	O
these	O
morphological	B-MED
differences	B-MED
are	O
remain	O
to	O
be	O
defined	O
.	O
To	O
better	O
understand	O
the	O
proteomic	B-MED
changes	B-MED
between	O
DP	B-MED
and	O
TP	B-MED
,	O
tandem	B-MED
mass	I-MED
tags	I-MED
(	I-MED
TMT	I-MED
)	I-MED
mass	I-MED
spectrometry	I-MED
(	I-MED
MS	I-MED
)	I-MED
/	O
MS	B-MED
was	O
used	O
to	O
detect	O
the	O
significant	O
changes	B-MED
to	O
protein	B-MED
expression	I-MED
between	O
DP	B-MED
and	O
TP	B-MED
.	O
Results	O
indicated	O
that	O
both	O
photosynthesis	B-MED
and	O
metabolic	B-MED
pathways	I-MED
were	O
highly	O
significantly	O
associated	B-MED
with	I-MED
proteomic	B-MED
alteration	I-MED
between	O
DP	B-MED
and	O
TP	B-MED
based	O
on	O
biological	B-MED
process	I-MED
and	O
pathway	B-MED
enrichment	I-MED
analysis	I-MED
,	O
and	O
13	O
higher	O
abundance	B-MED
chloroplast	B-MED
proteins	I-MED
involving	O
in	O
these	O
two	O
pathways	B-MED
were	O
identified	B-MED
in	O
TP	B-MED
.	O
Quantitative	B-MED
real	I-MED
-	I-MED
time	I-MED
PCR	I-MED
analysis	I-MED
demonstrated	O
that	O
5	O
of	O
the	O
13	O
chloroplast	B-MED
proteins	I-MED
ATPF	B-MED
,	O
PSAA	B-MED
,	O
PSAB	B-MED
,	O
PSBB	B-MED
and	O
RBL	B-MED
in	O
TP	B-MED
were	O
higher	O
abundance	B-MED
compared	O
with	O
those	O
in	O
DP	B-MED
.	O
This	O
study	B-MED
integrates	O
morphology	B-MED
,	O
physiology	B-MED
and	O
proteomic	B-MED
profiling	I-MED
alteration	B-MED
of	O
DP	B-MED
and	O
TP	B-MED
to	O
address	O
their	O
underlying	O
different	O
molecular	B-MED
mechanisms	I-MED
.	O
Our	O
finding	O
revealed	O
that	O
ATPF	B-MED
,	O
PSAA	B-MED
,	O
PSAB	B-MED
,	O
PSBB	B-MED
and	O
RBL	B-MED
can	O
induce	O
considerable	O
expression	B-MED
changes	B-MED
in	O
TP	B-MED
and	O
may	O
affect	O
the	O
development	B-MED
and	O
growth	B-MED
of	O
rice	B-MED
through	O
photosynthesis	B-MED
and	O
metabolic	B-MED
pathways	I-MED
.	O
Placental	B-MED
Pathologic	B-MED
Associations	B-MED
with	O
Morbidly	B-MED
Adherent	I-MED
Placenta	I-MED
:	O
Potential	O
insights	O
into	O
Pathogenesis	B-MED
The	O
pathology	B-MED
that	O
underlies	O
morbidly	B-MED
adherent	I-MED
placenta	I-MED
(	O
MAP	B-MED
)	O
is	O
poorly	O
understood	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
placental	B-MED
pathology	B-MED
,	O
especially	O
implantation	B-MED
site	I-MED
pathology	B-MED
,	O
associated	B-MED
with	I-MED
MAP	B-MED
.	O
This	O
was	O
a	O
single	B-MED
institution	B-MED
,	O
retrospective	B-MED
case	I-MED
-	I-MED
control	I-MED
study	I-MED
design	O
examining	O
placentas	B-MED
of	O
patients	B-MED
who	O
delivered	B-MED
between	O
January	O
2008	O
and	O
September	O
2013	O
.	O
MAP	B-MED
cases	B-MED
were	O
defined	O
by	O
the	O
need	O
for	O
clinical	B-MED
intervention	B-MED
at	O
delivery	B-MED
beyond	O
spontaneous	B-MED
placental	B-MED
delivery	I-MED
or	O
simple	O
manual	B-MED
extraction	I-MED
of	O
the	O
placenta	B-MED
.	O
Controls	B-MED
consisted	O
of	O
patients	B-MED
with	O
placentas	B-MED
sent	O
for	O
examination	B-MED
due	O
to	O
a	O
history	B-MED
of	O
maternal	B-MED
malignancy	B-MED
with	O
no	B-MED
clinical	B-MED
suspicion	B-MED
of	O
accreta	B-MED
.	O
Placental	B-MED
pathologic	B-MED
findings	I-MED
of	O
maternal	B-MED
vascular	I-MED
underperfusion	I-MED
(	O
MVU	B-MED
)	O
,	O
acute	B-MED
inflammation	I-MED
,	O
chronic	B-MED
inflammation	I-MED
,	O
fetal	B-MED
vascular	B-MED
obstruction	I-MED
and	O
hemorrhage	B-MED
were	O
recorded	O
and	O
compared	O
using	O
bivariable	B-MED
and	I-MED
multivariable	I-MED
analyses	I-MED
.	O
Three	O
categories	B-MED
of	O
pathologic	B-MED
changes	B-MED
were	O
seen	O
more	O
commonly	O
in	O
MAP	B-MED
placentas	B-MED
(	O
N=101	O
)	O
than	O
control	B-MED
placentas	B-MED
(	O
N=110	O
):	O
chronic	B-MED
basal	I-MED
inflammation	I-MED
,	O
villous	O
changes	B-MED
of	O
MVU	B-MED
and	O
retromembranous	O
and	O
retromembranous	B-MED
/	O
intervillous	B-MED
hemorrhage	I-MED
.	O
In	O
multivariable	B-MED
analyses	I-MED
adjusted	O
for	O
confounders	B-MED
,	O
chronic	B-MED
basal	I-MED
villitis	I-MED
(	O
aOR	B-MED
5.6	O
,	O
1.73	O
-	O
18.18	O
)	O
,	O
plasma	B-MED
cell	I-MED
deciduitis	I-MED
(	O
aOR	B-MED
2.63	O
,	O
1.08	O
-	O
6.39	O
)	O
,	O
increased	B-MED
syncytial	I-MED
knots	I-MED
(	O
aOR	B-MED
3.92	O
,	O
1.57	O
-	O
9.75	O
)	O
,	O
villous	O
agglutination	O
(	O
aOR	B-MED
24.85	O
,	O
2.78	O
-	O
221.75	O
)	O
,	O
increased	B-MED
perivillous	I-MED
fibrin	I-MED
(	O
aOR	B-MED
5.08	O
,	O
1.49	O
-	O
17.34	O
)	O
,	O
and	O
the	O
presence	O
of	O
subchorionic	B-MED
/	O
intervillous	B-MED
thrombi	I-MED
(	O
aOR	B-MED
4.01	O
,	O
1.63	O
-	O
9.86	O
)	O
remained	O
associated	B-MED
with	I-MED
MAP	B-MED
.	O
MAP	B-MED
is	O
highly	O
associated	B-MED
with	I-MED
evidence	O
of	O
intraparenchymal	B-MED
placental	I-MED
hemorrhage	I-MED
villous	B-MED
changes	B-MED
of	O
MVU	B-MED
,	O
and	O
a	O
lymphoplasmacytic	B-MED
infiltrate	I-MED
at	O
the	O
implantation	B-MED
site	I-MED
.	O
The	O
contribution	O
of	O
this	O
basal	B-MED
chronic	I-MED
inflammatory	I-MED
infiltrate	I-MED
to	O
MAP	B-MED
requires	O
further	O
investigation	O
.	O
Effects	B-MED
of	I-MED
high	B-MED
-	I-MED
intensity	I-MED
training	I-MED
on	O
cardiovascular	B-MED
risk	I-MED
factors	I-MED
in	O
premenopausal	B-MED
and	O
postmenopausal	B-MED
women	B-MED
Menopause	B-MED
is	O
associated	B-MED
with	I-MED
increased	B-MED
risk	O
of	O
cardiovascular	B-MED
disease	I-MED
and	O
the	O
causal	O
factors	B-MED
have	O
been	O
proposed	O
to	O
be	O
the	O
loss	B-MED
of	O
estrogen	B-MED
and	O
the	O
subsequent	O
alterations	O
of	O
the	O
hormonal	B-MED
milieu	I-MED
.	O
However	O
,	O
which	O
factors	B-MED
contribute	B-MED
to	O
the	O
deterioration	B-MED
of	O
cardiometabolic	B-MED
health	I-MED
in	O
postmenopausal	B-MED
women	B-MED
is	O
debated	O
as	O
the	O
menopausal	B-MED
transition	B-MED
is	O
also	O
associated	B-MED
with	I-MED
increased	B-MED
age	B-MED
and	O
fat	B-MED
mass	I-MED
.	O
Furthermore	O
,	O
indications	B-MED
of	O
reduced	B-MED
cardiometabolic	B-MED
adaptations	B-MED
to	O
exercise	B-MED
in	O
postmenopausal	B-MED
women	B-MED
add	O
to	O
the	O
adverse	B-MED
health	B-MED
profile	I-MED
.	O
We	O
sought	O
to	O
evaluate	B-MED
risk	B-MED
factors	I-MED
for	O
type	B-MED
2	I-MED
diabetes	I-MED
and	O
cardiovascular	B-MED
disease	I-MED
in	O
late	B-MED
premenopausal	B-MED
and	O
early	B-MED
postmenopausal	B-MED
women	B-MED
,	O
matched	O
by	O
age	B-MED
and	O
body	B-MED
composition	I-MED
,	O
and	O
investigate	B-MED
the	O
effect	O
of	O
high	B-MED
-	I-MED
intensity	I-MED
training	I-MED
.	O
A	O
3	O
-	O
month	O
high	B-MED
-	I-MED
intensity	I-MED
aerobic	I-MED
training	I-MED
intervention	B-MED
,	O
involving	O
healthy	B-MED
,	O
nonobese	B-MED
,	O
late	B-MED
premenopausal	B-MED
(	O
n	O
=	O
40	O
)	O
and	O
early	B-MED
postmenopausal	B-MED
(	O
n	O
=	O
39	O
)	O
women	B-MED
was	O
conducted	O
and	O
anthropometrics	B-MED
,	O
body	B-MED
composition	I-MED
,	O
blood	B-MED
pressure	I-MED
,	O
lipid	B-MED
profile	I-MED
,	O
glucose	B-MED
tolerance	I-MED
,	O
and	O
maximal	B-MED
oxygen	I-MED
consumption	I-MED
were	O
determined	O
at	O
baseline	B-MED
and	O
after	O
the	O
intervention	B-MED
.	O
At	O
baseline	B-MED
,	O
the	O
groups	B-MED
matched	O
in	O
anthropometrics	B-MED
and	O
body	B-MED
composition	I-MED
,	O
and	O
only	O
differed	O
by	O
4.2	O
years	O
in	O
age	B-MED
(	O
mean	O
[	O
95	O
%	O
confidence	B-MED
limits	I-MED
]	O
49.2	O
[	O
48.5	O
-	O
49.9	O
]	O
vs	O
53.4	O
[	O
52.4	O
-	O
54.4	O
]	O
years	O
)	O
.	O
Time	O
since	O
last	O
menstrual	B-MED
period	I-MED
for	O
the	O
postmenopausal	B-MED
women	B-MED
was	O
(	O
mean	O
[	O
95	O
%	O
confidecnce	B-MED
limits	I-MED
]	O
3.1	O
[	O
2.6	O
-	O
3.7	O
]	O
years	O
)	O
.	O
Hormonal	B-MED
levels	I-MED
(	O
estrogen	B-MED
,	O
follicle	B-MED
stimulation	I-MED
hormone	I-MED
,	O
luteinizing	B-MED
hormone	I-MED
)	O
confirmed	O
menopausal	B-MED
status	I-MED
.	O
At	O
baseline	B-MED
the	O
postmenopausal	B-MED
women	B-MED
had	O
higher	O
total	B-MED
cholesterol	I-MED
(	O
P	O
<	O
.001	O
)	O
,	O
low	B-MED
-	I-MED
density	I-MED
lipoprotein	I-MED
-	I-MED
cholesterol	I-MED
(	O
P	O
<	O
.05	O
)	O
,	O
and	O
high	B-MED
-	I-MED
density	I-MED
lipoprotein	I-MED
-	I-MED
cholesterol	I-MED
(	O
P	O
<	O
.001	O
)	O
than	O
the	O
premenopausal	B-MED
women	B-MED
.	O
The	O
training	O
intervention	B-MED
reduced	B-MED
body	B-MED
weight	I-MED
(	O
P	O
<	O
.01	O
)	O
,	O
waist	B-MED
circumference	I-MED
(	O
P	O
<	O
.01	O
)	O
,	O
and	O
improved	B-MED
body	B-MED
composition	I-MED
by	O
increasing	B-MED
lean	B-MED
body	I-MED
mass	I-MED
(	O
P	O
<	O
.001	O
)	O
and	O
decreasing	B-MED
fat	B-MED
mass	I-MED
(	O
P	O
<	O
.001	O
)	O
similarly	O
in	O
both	O
groups	B-MED
.	O
Moreover	O
,	O
training	O
resulted	O
in	O
lower	B-MED
diastolic	I-MED
blood	I-MED
pressure	I-MED
(	O
P	O
<	O
.05	O
)	O
,	O
resting	B-MED
heart	I-MED
rate	I-MED
(	O
P	O
<	O
.001	O
)	O
,	O
total	B-MED
cholesterol	I-MED
(	O
P	O
<	O
.01	O
)	O
,	O
low	B-MED
-	I-MED
density	I-MED
lipoprotein	I-MED
-	I-MED
cholesterol	I-MED
(	O
P	O
<	O
.01	O
)	O
,	O
total	B-MED
cholesterol	I-MED
/	O
high	B-MED
-	I-MED
density	I-MED
lipoprotein	I-MED
-	I-MED
cholesterol	I-MED
index	O
(	O
P	O
<	O
.01	O
)	O
,	O
and	O
improved	B-MED
plasma	B-MED
insulin	I-MED
concentration	I-MED
during	O
the	O
oral	B-MED
glucose	I-MED
tolerance	I-MED
test	I-MED
(	O
P	O
<	O
.05	O
)	O
in	O
both	O
groups	B-MED
.	O
Cardiovascular	B-MED
risk	I-MED
factors	I-MED
are	O
similar	O
in	O
late	B-MED
premenopausal	B-MED
and	O
early	B-MED
postmenopausal	B-MED
women	B-MED
,	O
matched	O
by	O
age	B-MED
and	O
body	B-MED
composition	I-MED
,	O
with	O
the	O
exception	O
that	O
postmenopausal	B-MED
women	B-MED
have	O
higher	O
high-	B-MED
and	O
low	B-MED
-	I-MED
density	I-MED
lipoprotein	I-MED
-	I-MED
cholesterol	I-MED
levels	I-MED
.	O
A	O
3	O
-	O
month	O
intervention	B-MED
of	O
high	B-MED
-	I-MED
intensity	I-MED
aerobic	I-MED
training	I-MED
reduces	O
risk	B-MED
factors	I-MED
for	O
type	B-MED
2	I-MED
.diabetes	I-MED
and	O
cardiovascular	B-MED
disease	I-MED
to	O
a	O
similar	O
extent	O
in	O
late	B-MED
premenopausal	B-MED
and	O
early	B-MED
postmenopausal	B-MED
women	B-MED
.	O
Clinical	B-MED
characteristics	I-MED
of	O
genital	B-MED
chlamydia	I-MED
infection	I-MED
in	O
pelvic	B-MED
inflammatory	I-MED
disease	I-MED
Chlamydia	B-MED
infection	I-MED
in	O
acute	B-MED
pelvic	I-MED
inflammatory	I-MED
disease	I-MED
(	O
PID	B-MED
)	O
is	O
associated	O
with	O
serious	O
complications	B-MED
including	O
ectopic	B-MED
pregnancy	I-MED
,	O
tubal	B-MED
infertility	I-MED
,	O
Fitz	B-MED
-	I-MED
Hugh	I-MED
-	I-MED
Curtis	I-MED
syndrome	I-MED
and	O
tubo	B-MED
-	I-MED
ovarian	I-MED
abscess	I-MED
(	O
TOA	B-MED
)	O
.	O
This	O
study	B-MED
compared	O
clinical	B-MED
and	O
laboratory	B-MED
data	I-MED
between	O
PID	B-MED
with	O
and	O
without	O
chlamydia	B-MED
infection	I-MED
.	O
The	O
medical	B-MED
records	I-MED
of	O
497	O
women	B-MED
who	O
were	O
admitted	O
with	O
PID	B-MED
between	O
2002	O
and	O
2011	O
were	O
reviewed	O
.	O
The	O
patients	B-MED
were	O
divided	O
into	O
two	O
groups	B-MED
(	O
PID	B-MED
with	O
and	O
without	O
chlamydia	B-MED
infection	I-MED
)	O
,	O
which	O
were	O
compared	O
in	O
terms	O
of	O
the	O
patients	B-MED
'	I-MED
characteristics	I-MED
,	O
clinical	B-MED
presentation	I-MED
,	O
and	O
laboratory	B-MED
findings	I-MED
,	O
including	O
inflammatory	B-MED
markers	B-MED
.	O
The	O
chlamydia	B-MED
and	O
non	B-MED
-	I-MED
chlamydia	I-MED
groups	I-MED
comprised	O
175	O
and	O
322	O
women	B-MED
,	O
respectively	O
.	O
The	O
patients	B-MED
in	O
the	O
chlamydia	B-MED
group	I-MED
were	O
younger	B-MED
and	O
had	O
a	O
higher	O
rate	O
of	O
TOA	B-MED
,	O
a	O
longer	O
mean	B-MED
hospital	B-MED
stay	I-MED
,	O
and	O
had	O
undergone	O
more	O
surgeries	B-MED
than	O
the	O
patients	B-MED
in	O
the	O
non-	B-MED
chlamydia	I-MED
group	I-MED
.	O
The	O
erythrocyte	B-MED
sedimentation	I-MED
rate	I-MED
(	O
ESR	B-MED
)	O
,	O
C	B-MED
-	I-MED
reactive	I-MED
protein	I-MED
(	O
CRP	B-MED
)	O
,	O
and	O
CA-125	B-MED
level	B-MED
were	O
higher	O
in	O
the	O
chlamydia	B-MED
group	I-MED
than	O
in	O
the	O
non	B-MED
-	I-MED
chlamydia	I-MED
group	I-MED
,	O
but	O
there	O
was	O
no	O
significant	B-MED
difference	O
in	O
the	O
white	B-MED
blood	I-MED
cell	I-MED
count	I-MED
between	O
the	O
two	O
groups	B-MED
.	O
The	O
CA-125	B-MED
level	B-MED
was	O
the	O
strongest	O
predictor	B-MED
of	O
chlamydia	B-MED
infection	I-MED
,	O
followed	O
by	O
the	O
ESR	B-MED
and	O
CRP	B-MED
level	B-MED
.	O
The	O
area	B-MED
under	O
the	O
receiving	B-MED
operating	I-MED
curve	I-MED
for	O
CA-125	B-MED
,	O
ESR	B-MED
,	O
and	O
CRP	B-MED
was	O
0.804	O
,	O
0.755	O
,	O
and	O
0.663	O
,	O
respectively	O
.	O
Chlamydia	B-MED
infection	I-MED
in	O
acute	B-MED
PID	I-MED
is	O
associated	O
with	O
increased	O
level	B-MED
of	O
inflammatory	B-MED
markers	B-MED
,	O
such	O
as	O
CA-125	B-MED
,	O
ESR	B-MED
and	O
CRP	B-MED
,	O
incidence	O
of	O
TOA	B-MED
,	O
operation	B-MED
risk	B-MED
,	O
and	O
longer	O
hospitalization	B-MED
.	O
Glycated	B-MED
Hemoglobin	I-MED
(	O
HbA1c	B-MED
)	O
Correlation	B-MED
with	O
Severity	B-MED
of	O
Coronary	B-MED
Artery	I-MED
Disease	I-MED
in	O
Non	B-MED
-	I-MED
diabetic	I-MED
Patients	B-MED
-	O
A	O
Hospital	B-MED
based	I-MED
Study	B-MED
from	O
North	B-MED
-	I-MED
Eastern	I-MED
India	I-MED
Glycated	B-MED
Hemoglobin	I-MED
(	I-MED
HbA1c	I-MED
)	I-MED
levels	I-MED
are	O
predictive	B-MED
of	O
cardiovascular	B-MED
disease	I-MED
and	O
mortality	B-MED
in	O
patients	B-MED
with	O
diabetes	B-MED
mellitus	I-MED
,	O
however	O
,	O
association	O
of	O
HbA1c	B-MED
with	O
Coronary	B-MED
Artery	I-MED
Disease	I-MED
(	O
CAD	B-MED
)	O
in	O
non	B-MED
-	I-MED
diabetics	I-MED
is	O
inconsistent	B-MED
.	O
To	O
evaluate	B-MED
the	O
correlation	B-MED
between	O
HbA1c	B-MED
level	I-MED
and	O
severity	B-MED
of	O
CAD	B-MED
in	O
non	B-MED
-	I-MED
diabetic	I-MED
patients	I-MED
using	O
SYNTAX	B-MED
score	I-MED
in	O
a	O
cohort	B-MED
of	O
proven	O
CAD	B-MED
on	O
angiography	B-MED
at	O
Gauhati	B-MED
Medical	I-MED
College	I-MED
,	O
Guwahati	B-MED
,	I-MED
Assam	I-MED
,	O
India	B-MED
,	O
which	O
is	O
a	O
major	O
tertiary	B-MED
care	I-MED
hospital	I-MED
of	O
North	B-MED
-	I-MED
Eastern	I-MED
India	I-MED
.	O
We	O
prospectively	O
collected	O
data	B-MED
of	O
non	B-MED
-	I-MED
diabetic	I-MED
patients	I-MED
with	O
proven	O
CAD	B-MED
on	O
angiography	B-MED
from	O
June	O
2014	O
to	O
June	O
2015	O
.	O
Patients	B-MED
were	O
divided	O
into	O
four	O
groups	B-MED
(	O
interquartiles	B-MED
)	O
according	O
to	O
HbA1c	B-MED
levels	I-MED
,	O
less	O
than	O
4.8	O
%	O
,	O
4.8	O
%	O
to	O
5.1	O
%	O
,	O
5.1	O
%	O
to	O
5.6	O
%	O
,	O
and	O
5.6	O
%	O
to	O
6.5	O
%	O
.	O
Severity	B-MED
of	O
CAD	B-MED
was	O
assessed	B-MED
using	O
SYNTAX	B-MED
score	I-MED
and	O
the	O
number	B-MED
of	I-MED
coronary	I-MED
vessels	I-MED
diseased	I-MED
.	O
We	O
compared	O
different	O
quartiles	B-MED
of	O
HbA1c	B-MED
with	O
regard	O
to	O
SYNTAX	B-MED
score	I-MED
and	O
number	O
of	O
diseased	B-MED
vessels	I-MED
.	O
A	O
total	O
of	O
346	O
patients	B-MED
were	O
included	O
in	O
the	O
study	B-MED
.	O
Mean	O
age	B-MED
was	O
58.1±10.4	O
years	O
.	O
Of	O
the	O
total	O
91.9	O
%	O
(	O
318	O
)	O
were	O
males	B-MED
,	O
44.8	O
%	O
(	O
155	O
)	O
were	O
hypertensives	B-MED
,	O
29.2	O
%	O
(	O
101	O
)	O
were	O
smokers	B-MED
and	O
34.7	O
%	O
(	O
120	O
)	O
were	O
dyslipidemic	B-MED
.	O
We	O
found	O
that	O
CAD	B-MED
severity	B-MED
by	O
SYNTAX	B-MED
score	I-MED
as	O
well	O
as	O
number	O
of	O
vessels	B-MED
involved	O
was	O
significantly	O
different	O
among	O
quartiles	B-MED
(	O
p	B-MED
-	I-MED
values	I-MED
<	O
0.001	O
and	O
<	O
0.001	O
respectively	O
)	O
.	O
Increase	B-MED
in	O
HbA1c	B-MED
level	I-MED
was	O
strongly	O
correlated	B-MED
with	O
disease	B-MED
severity	I-MED
and	O
higher	O
SYNTAX	B-MED
score	I-MED
.	O
A	O
significant	O
increase	B-MED
was	O
noted	O
in	O
the	O
mean	O
number	O
of	O
diseased	B-MED
vessels	I-MED
(	O
p	B-MED
-	I-MED
value	I-MED
<	O
0.001	O
)	O
as	O
HbA1c	B-MED
level	I-MED
increases	B-MED
.	O
Age	B-MED
,	O
gender	B-MED
,	O
hypertension	B-MED
and	O
dyslipidemia	B-MED
did	O
not	O
show	O
significant	O
difference	O
among	O
quartiles	B-MED
however	O
smoking	B-MED
was	O
found	O
to	O
be	O
an	O
independent	O
predictor	B-MED
of	O
severity	B-MED
of	O
CAD	B-MED
by	O
SYNTAX	B-MED
score	I-MED
(	O
p	O
<	O
0.05	O
)	O
.	O
From	O
this	O
clinical	B-MED
study	I-MED
,	O
we	O
can	O
conclude	O
that	O
a	O
significant	O
correlation	B-MED
exists	O
between	O
HbA1c	B-MED
and	O
severity	B-MED
of	O
CAD	B-MED
by	O
SYNTAX	B-MED
score	I-MED
as	O
well	O
as	O
number	O
of	O
vessels	B-MED
involved	O
in	O
non-	B-MED
diabetes	I-MED
.	O
Integrating	B-MED
Palliative	B-MED
Care	I-MED
in	O
Pediatric	B-MED
Oncology	I-MED
:	O
Evidence	O
for	O
an	O
Evolving	B-MED
Paradigm	B-MED
for	O
Comprehensive	B-MED
Cancer	B-MED
Care	I-MED
The	O
demonstrated	O
benefit	O
of	O
integrating	B-MED
palliative	B-MED
care	I-MED
(	O
PC	B-MED
)	O
into	O
cancer	B-MED
treatment	I-MED
has	O
triggered	O
an	O
increased	B-MED
need	O
for	O
PC	B-MED
services	O
.	O
The	O
trajectory	O
of	O
integrating	B-MED
PC	B-MED
in	O
comprehensive	B-MED
cancer	B-MED
centers	I-MED
,	I-MED
particularly	O
pediatric	B-MED
centers	I-MED
,	O
is	O
unknown	O
.	O
We	O
describe	O
our	O
8-	O
year	B-MED
experience	O
of	O
initiating	O
and	O
establishing	B-MED
PC	B-MED
with	O
the	O
Quality	B-MED
of	I-MED
Life	I-MED
Service	I-MED
(	O
QoLS	B-MED
)	O
at	O
St.	B-MED
Jude	I-MED
Children	I-MED
's	I-MED
Research	I-MED
Hospital	I-MED
.	O
We	O
retrospectively	O
reviewed	O
records	B-MED
of	I-MED
patients	I-MED
seen	O
by	O
the	O
QoLS	B-MED
(	O
n=615	O
)	O
from	O
March	B-MED
2007	O
to	O
December	B-MED
2014	O
.	O
Variables	B-MED
analyzed	O
for	O
each	O
year	B-MED
,	O
using	O
descriptive	O
statistics	B-MED
,	O
included	O
diagnostic	B-MED
groups	I-MED
,	O
QoLS	B-MED
encounters	B-MED
,	O
goals	B-MED
of	I-MED
care	I-MED
,	O
duration	B-MED
of	I-MED
survival	I-MED
,	O
and	O
location	B-MED
of	I-MED
death	I-MED
.	O
Total	O
QoLS	B-MED
patient	B-MED
encounters	B-MED
increased	B-MED
from	O
58	O
(	O
2007	O
)	O
to	O
1,297	O
(	O
2014	O
)	O
,	O
new	O
consults	B-MED
increased	B-MED
from	O
17	O
(	O
2007	O
)	O
to	O
115	O
(	O
2014	O
)	O
,	O
and	O
mean	O
encounters	B-MED
per	O
patient	B-MED
increased	B-MED
from	O
5.06	O
(	O
2007	O
)	O
to	O
16.11	O
(	O
2014	O
)	O
.	O
Goal	B-MED
of	I-MED
care	I-MED
at	O
initial	B-MED
consultation	I-MED
shifted	O
from	O
primarily	O
comfort	B-MED
to	O
an	O
increasing	B-MED
goal	B-MED
of	I-MED
cure	I-MED
.	O
The	O
median	O
number	O
of	O
days	O
from	O
initial	B-MED
consult	I-MED
to	O
death	B-MED
increased	B-MED
from	O
52	O
days	O
(	O
2008	O
)	O
to	O
223	O
days	O
(	O
2014	O
)	O
.	O
A	O
trend	O
toward	O
increased	B-MED
outpatient	B-MED
location	B-MED
of	I-MED
death	I-MED
was	O
noted	O
with	O
42	O
%	O
outpatient	B-MED
deaths	B-MED
in	O
2007	O
,	O
increasing	B-MED
to	O
a	O
majority	B-MED
in	O
each	O
subsequent	O
year	B-MED
(	O
range	O
,	O
51%-74	O
%	O
)	O
.	O
Hospital	B-MED
-	I-MED
wide	I-MED
,	O
patients	B-MED
receiving	O
PC	B-MED
services	O
before	O
death	B-MED
increased	B-MED
from	O
approximately	B-MED
50	O
%	O
to	O
nearly	O
100	O
%	O
.	O
Since	O
its	O
inception	O
,	O
the	O
QoLS	B-MED
experienced	O
a	O
dramatic	O
increase	B-MED
in	O
referrals	B-MED
and	O
encounters	B-MED
per	O
patient	B-MED
,	O
increased	B-MED
use	O
by	O
all	O
clinical	B-MED
services	I-MED
,	O
a	O
trend	O
toward	O
earlier	B-MED
consultation	B-MED
and	O
longer	B-MED
term	I-MED
follow	B-MED
-	I-MED
up	I-MED
,	O
increasing	B-MED
outpatient	B-MED
location	B-MED
of	I-MED
death	I-MED
,	O
and	O
near-	O
universal	B-MED
PC	B-MED
involvement	O
at	O
the	O
end	B-MED
-	I-MED
of	I-MED
-	I-MED
life	I-MED
.	O
The	O
successful	O
integration	B-MED
of	O
PC	B-MED
in	O
a	O
comprehensive	B-MED
cancer	B-MED
center	I-MED
,	O
and	O
the	O
resulting	O
potential	O
for	O
improved	O
care	B-MED
provision	I-MED
over	O
time	B-MED
,	O
can	O
serve	O
as	O
a	O
model	B-MED
for	O
other	O
programs	B-MED
on	O
a	O
broad	O
scale	O
.	O
Validating	B-MED
Signs	B-MED
and	I-MED
Symptoms	I-MED
From	O
An	O
Actual	O
Mass	B-MED
Casualty	I-MED
Incident	I-MED
to	O
Characterize	B-MED
An	O
Irritant	B-MED
Gas	I-MED
Syndrome	I-MED
Agent	I-MED
(	O
IGSA	B-MED
)	O
Exposure	O
:	O
A	O
First	O
Step	O
in	O
The	O
Development	B-MED
of	O
a	O
Novel	B-MED
IGSA	B-MED
Triage	B-MED
Algorithm	B-MED
Chemical	B-MED
exposures	I-MED
can	O
pose	O
a	O
significant	B-MED
threat	B-MED
to	O
life	B-MED
.	O
Rapid	O
assessment	B-MED
by	O
first	B-MED
responders	I-MED
/	O
emergency	B-MED
nurses	I-MED
is	O
required	B-MED
to	O
reduce	B-MED
death	B-MED
and	O
disability	B-MED
.	O
Currently	O
,	O
no	B-MED
informatics	B-MED
tools	I-MED
for	O
irritant	B-MED
gas	I-MED
syndrome	I-MED
agent	I-MED
s	O
(	O
IGSA	B-MED
)	O
exposures	B-MED
exist	B-MED
to	O
process	B-MED
victims	B-MED
efficiently	B-MED
,	O
continuously	B-MED
monitor	B-MED
for	O
latent	B-MED
signs	B-MED
/	I-MED
symptoms	I-MED
,	O
or	O
make	O
triage	B-MED
recommendations	B-MED
.	O
This	O
study	B-MED
describes	O
the	O
first	O
step	O
in	O
developing	O
ED	B-MED
informatics	B-MED
tools	I-MED
for	O
chemical	B-MED
incidents	I-MED
:	O
validation	B-MED
of	O
signs	B-MED
/	I-MED
symptoms	I-MED
that	O
characterize	B-MED
an	O
IGSA	B-MED
syndrome	B-MED
.	O
Data	B-MED
abstracted	I-MED
from	O
146	O
patients	B-MED
treated	B-MED
for	O
chlorine	B-MED
exposure	I-MED
in	O
one	O
emergency	B-MED
department	I-MED
during	B-MED
a	O
2005	O
train	B-MED
derailment	I-MED
and	O
152	O
patients	B-MED
not	B-MED
exposed	B-MED
to	I-MED
chlorine	I-MED
(	O
a	O
comparison	B-MED
group	I-MED
)	O
were	O
mapped	B-MED
to	O
93	O
possible	O
signs	B-MED
/	I-MED
symptoms	I-MED
within	O
2	O
tools	B-MED
(	O
WISER	B-MED
and	O
CHEMM	B-MED
-	I-MED
IST	I-MED
)	O
designed	B-MED
to	O
assist	B-MED
emergency	B-MED
responders	I-MED
/	O
emergency	B-MED
nurses	I-MED
with	O
managing	O
hazardous	B-MED
material	I-MED
exposures	B-MED
.	O
Inferential	B-MED
statistics	I-MED
(	O
χ(2)/	O
Fisher	B-MED
's	I-MED
exact	I-MED
test	I-MED
)	O
and	O
diagnostics	B-MED
tests	I-MED
were	O
used	B-MED
to	O
examine	O
mapped	B-MED
signs	B-MED
/	I-MED
symptoms	I-MED
of	O
persons	B-MED
who	O
were	O
and	O
were	O
not	O
exposed	B-MED
to	I-MED
chlorine	I-MED
.	O
Three	O
clusters	B-MED
of	O
signs	B-MED
/	I-MED
symptoms	I-MED
are	O
statistically	B-MED
associated	B-MED
with	I-MED
an	O
IGSA	B-MED
syndrome	B-MED
(	O
P	O
<	O
.01	O
):	O
respiratory	B-MED
(	O
shortness	B-MED
of	I-MED
breath	I-MED
,	O
wheezing	B-MED
,	O
coughing	B-MED
,	O
and	O
choking	B-MED
)	O
;	O
chest	B-MED
discomfort	I-MED
(	O
tightness	B-MED
,	O
pain	B-MED
,	O
and	O
burning	B-MED
)	O
,	O
and	O
eye	B-MED
,	O
nose	B-MED
and/or	O
throat	B-MED
(	O
pain	B-MED
,	O
irritation	B-MED
,	O
and	O
burning	B-MED
)	O
.	O
The	O
syndrome	B-MED
requires	O
the	O
presence	B-MED
of	O
signs	B-MED
/	I-MED
symptoms	I-MED
from	O
at	O
least	O
2	O
of	O
these	O
clusters	B-MED
.	O
The	O
latency	B-MED
period	I-MED
must	O
also	O
be	O
considered	B-MED
for	O
exposed	B-MED
/	O
potentially	B-MED
exposed	B-MED
persons	I-MED
.	O
This	O
study	B-MED
uses	B-MED
actual	O
patient	B-MED
data	I-MED
from	O
a	O
chemical	B-MED
incident	I-MED
to	O
characterize	B-MED
and	O
validate	B-MED
signs	B-MED
/	I-MED
symptoms	I-MED
of	O
an	O
IGSA	B-MED
syndrome	B-MED
.	O
Validating	B-MED
signs	B-MED
/	I-MED
symptoms	I-MED
is	O
the	O
first	O
step	O
in	O
developing	O
new	B-MED
ED	B-MED
informatics	B-MED
tools	I-MED
with	O
the	O
potential	B-MED
to	O
revolutionize	O
the	O
process	B-MED
by	O
which	O
emergency	B-MED
nurses	I-MED
manage	O
triage	B-MED
victims	B-MED
of	O
chemical	B-MED
incidents	I-MED
.	O
Low	B-MED
-	I-MED
Volume	I-MED
vs	O
High	B-MED
-	I-MED
Volume	I-MED
Centers	I-MED
and	O
Management	B-MED
of	I-MED
Fournier	I-MED
's	I-MED
Gangrene	I-MED
Fournier	B-MED
's	I-MED
Gangrene	I-MED
in	O
Washington	B-MED
State	I-MED
Fournier	B-MED
's	I-MED
gangrene	I-MED
(	O
FG	B-MED
)	O
is	O
a	O
life	B-MED
-	I-MED
threatening	I-MED
infection	I-MED
affecting	B-MED
the	O
perineum	B-MED
and	O
genitals	B-MED
.	O
Complex	B-MED
patient	B-MED
management	I-MED
often	O
necessitates	O
transfer	O
to	O
tertiary	B-MED
centers	I-MED
.	O
We	O
aimed	O
to	O
characterize	O
hospital	B-MED
transfer	I-MED
patterns	B-MED
and	O
assess	O
morbidity	B-MED
among	O
patients	B-MED
with	O
FG	B-MED
in	O
Washington	B-MED
State	I-MED
.	O
The	O
Washington	B-MED
State	I-MED
Comprehensive	B-MED
Hospital	O
Abstract	B-MED
Reporting	I-MED
System	O
includes	O
claims	O
from	O
all	O
hospital	B-MED
discharges	I-MED
in	O
Washington	B-MED
.	O
We	O
identified	O
patients	B-MED
with	O
FG	B-MED
between	O
2007	O
and	O
2013	O
,	O
based	O
on	O
diagnosis	B-MED
and	I-MED
treatment	I-MED
codes	I-MED
.	O
Analyses	O
were	O
stratified	B-MED
by	O
center	O
volume	O
(	O
low	B-MED
-	I-MED
volume	I-MED
centers	I-MED
[	O
LVCs	B-MED
]	O
or	O
high	B-MED
-	I-MED
volume	I-MED
centers	I-MED
[	O
HVCs	B-MED
]	O
)	O
,	O
and	O
transfer	B-MED
status	I-MED
.	O
Variables	O
of	O
interest	O
included	O
number	O
of	O
debridements	B-MED
,	O
septic	B-MED
shock	I-MED
,	O
acute	B-MED
renal	I-MED
failure	I-MED
,	O
acute	B-MED
respiratory	I-MED
failure	I-MED
,	O
length	B-MED
of	I-MED
hospitalization	I-MED
,	O
and	O
death	B-MED
.	O
We	O
identified	O
165	O
FG	B-MED
patients	B-MED
.	O
Only	O
1	O
HVC	B-MED
treated	B-MED
more	O
than	O
2	O
FG	B-MED
patients	B-MED
per	O
year	O
.	O
Overall	B-MED
mortality	I-MED
was	O
6.7	O
%	O
.	O
Most	O
patients	B-MED
(	O
57	O
%	O
)	O
were	O
treated	B-MED
entirely	O
at	O
LVCs	B-MED
;	O
87	O
%	O
of	O
patients	B-MED
treated	B-MED
at	O
the	O
HVC	B-MED
were	O
transferred	O
from	O
an	O
LVC	B-MED
.	O
High	B-MED
-	I-MED
volume	I-MED
center	I-MED
-treated	O
patients	B-MED
had	O
similar	O
baseline	O
comorbidities	B-MED
(	O
p	O
=	O
0.77	O
)	O
and	O
similar	O
mortality	B-MED
(	O
p	O
=	O
0.87	O
)	O
,	O
despite	O
higher	O
rates	O
of	O
septic	B-MED
shock	I-MED
(	O
p	O
<	O
0.01	O
)	O
and	O
respiratory	B-MED
failure	I-MED
(	O
p	O
=	O
0.01	O
)	O
compared	O
with	O
LVC	B-MED
patients	B-MED
.	O
Among	O
HVC	B-MED
-	O
transferred	B-MED
patients	I-MED
,	O
immediate	B-MED
compared	O
with	O
delayed	B-MED
transfer	O
was	O
associated	B-MED
with	I-MED
fewer	O
debridements	B-MED
(	O
p	O
<	O
0.01	O
)	O
,	O
lower	O
rates	O
of	O
septic	B-MED
shock	I-MED
(	O
p	O
=	O
0.05	O
)	O
,	O
and	O
acute	B-MED
renal	I-MED
failure	I-MED
(	O
p	O
=	O
0.04	O
)	O
.	O
Patients	B-MED
treated	B-MED
at	O
the	O
HVC	B-MED
were	O
more	O
acutely	B-MED
ill	I-MED
,	O
yet	O
mortality	B-MED
was	O
similar	O
compared	O
with	O
patients	B-MED
treated	B-MED
solely	O
at	O
LVCs	B-MED
,	O
suggesting	O
a	O
benefit	O
to	O
transfer	O
of	O
high	O
acuity	B-MED
patients	I-MED
.	O
Immediate	B-MED
vs	O
delayed	B-MED
transfer	O
may	O
benefit	O
FG	B-MED
health	B-MED
outcomes	I-MED
;	O
however	O
,	O
this	O
may	O
also	O
reflect	O
greater	O
disease	B-MED
acuity	B-MED
of	I-MED
patients	I-MED
with	O
delayed	O
transfer	B-MED
status	I-MED
.	O
Cobalt-60	B-MED
Machines	I-MED
and	O
Medical	B-MED
Linear	I-MED
Accelerators	I-MED
:	O
Competing	B-MED
Technologies	I-MED
for	O
External	B-MED
Beam	I-MED
Radiotherapy	I-MED
Medical	B-MED
linear	I-MED
accelerators	I-MED
(	O
linacs	B-MED
)	O
and	O
cobalt-60	B-MED
machines	I-MED
are	O
both	O
mature	O
technologies	B-MED
for	O
external	B-MED
beam	I-MED
radiotherapy	I-MED
.	O
A	O
comparison	B-MED
is	O
made	O
between	O
these	O
two	O
technologies	B-MED
in	O
terms	O
of	O
infrastructure	B-MED
and	O
maintenance	B-MED
,	O
dosimetry	B-MED
,	O
shielding	B-MED
requirements	B-MED
,	O
staffing	B-MED
,	O
costs	B-MED
,	O
security	B-MED
,	O
patient	B-MED
throughput	B-MED
and	O
clinical	B-MED
use	I-MED
.	O
Infrastructure	B-MED
and	O
maintenance	B-MED
are	O
more	O
demanding	B-MED
for	O
linacs	B-MED
due	O
to	O
the	O
complex	B-MED
electric	I-MED
componentry	I-MED
.	O
In	O
dosimetry	B-MED
,	O
a	O
higher	B-MED
beam	B-MED
energy	I-MED
,	O
modulated	B-MED
dose	B-MED
rate	I-MED
and	O
smaller	B-MED
focal	B-MED
spot	I-MED
size	I-MED
mean	O
that	O
it	O
is	O
easier	B-MED
to	O
create	B-MED
an	O
optimised	B-MED
treatment	B-MED
with	O
a	O
linac	B-MED
for	O
conformal	O
dose	B-MED
coverage	B-MED
of	O
the	O
tumour	B-MED
while	O
sparing	O
healthy	B-MED
organs	I-MED
at	O
risk	B-MED
.	O
In	O
shielding	B-MED
,	O
the	O
requirements	B-MED
for	O
a	O
concrete	B-MED
bunker	I-MED
are	O
similar	O
for	O
cobalt-60	B-MED
machines	I-MED
and	O
linacs	B-MED
but	O
extra	O
shielding	B-MED
and	O
protection	B-MED
from	O
neutrons	B-MED
are	O
required	O
for	O
linacs	B-MED
.	O
Staffing	B-MED
levels	I-MED
can	O
be	O
higher	B-MED
for	O
linacs	B-MED
and	O
more	O
staff	B-MED
training	I-MED
is	O
required	O
for	O
linacs	B-MED
.	O
Life	B-MED
cycle	I-MED
costs	I-MED
are	O
higher	B-MED
for	O
linacs	B-MED
,	O
especially	O
multi	B-MED
-	I-MED
energy	I-MED
linacs	I-MED
.	O
Security	B-MED
is	O
more	O
complex	B-MED
for	O
cobalt-60	B-MED
machines	I-MED
because	O
of	O
the	O
high	B-MED
activity	B-MED
radioactive	B-MED
source	I-MED
.	O
Patient	B-MED
throughput	B-MED
can	O
be	O
affected	B-MED
by	O
source	B-MED
decay	B-MED
for	O
cobalt-60	B-MED
machines	I-MED
but	O
poor	B-MED
maintenance	B-MED
and	O
breakdowns	B-MED
can	O
severely	O
affect	B-MED
patient	B-MED
throughput	B-MED
for	O
linacs	B-MED
.	O
In	O
clinical	B-MED
use	I-MED
,	O
more	O
complex	B-MED
treatment	B-MED
techniques	B-MED
are	O
easier	B-MED
to	O
achieve	O
with	O
linacs	B-MED
,	O
and	O
the	O
availability	B-MED
of	I-MED
electron	B-MED
beams	I-MED
on	O
high	B-MED
-	O
energy	B-MED
linacs	B-MED
can	O
be	O
useful	O
for	O
certain	O
treatments	B-MED
.	O
In	O
summary	O
,	O
there	O
is	O
no	O
simple	O
answer	O
to	O
the	O
question	O
of	O
the	O
choice	O
of	O
either	O
cobalt-60	B-MED
machines	I-MED
or	O
linacs	B-MED
for	O
radiotherapy	B-MED
in	O
low-	B-MED
and	O
middle	B-MED
-	I-MED
income	I-MED
countries	B-MED
.	O
In	O
fact	O
a	O
radiotherapy	B-MED
department	I-MED
with	O
a	O
combination	B-MED
of	O
technologies	B-MED
,	O
including	O
orthovoltage	B-MED
X	I-MED
-	I-MED
ray	I-MED
units	I-MED
,	O
may	O
be	O
an	O
option	B-MED
.	O
Local	B-MED
needs	B-MED
,	O
conditions	B-MED
and	O
resources	B-MED
will	O
have	O
to	O
be	O
factored	O
into	O
any	O
decision	B-MED
on	O
technology	B-MED
taking	O
into	O
account	O
the	O
characteristics	B-MED
of	O
both	O
forms	O
of	O
teletherapy	B-MED
,	O
with	O
the	O
primary	O
goal	B-MED
being	O
the	O
sustainability	B-MED
of	O
the	O
radiotherapy	B-MED
service	I-MED
over	O
the	O
useful	O
lifetime	B-MED
of	O
the	O
equipment	B-MED
.	O
Ontology	B-MED
-Based	O
High	B-MED
-	O
Level	B-MED
Context	B-MED
Inference	B-MED
for	O
Human	B-MED
Behavior	I-MED
Identification	B-MED
Recent	O
years	O
have	O
witnessed	O
a	O
huge	O
progress	B-MED
in	O
the	O
automatic	B-MED
identification	B-MED
of	O
individual	B-MED
primitives	B-MED
of	O
human	B-MED
behavior	I-MED
,	O
such	O
as	O
activities	B-MED
or	O
locations	B-MED
.	O
However	O
,	O
the	O
complex	B-MED
nature	B-MED
of	O
human	B-MED
behavior	I-MED
demands	O
more	O
abstract	O
contextual	B-MED
information	B-MED
for	O
its	O
analysis	O
.	O
This	O
work	O
presents	O
an	O
ontology	B-MED
-based	O
method	B-MED
that	O
combines	O
low	B-MED
-	O
level	B-MED
primitives	B-MED
of	O
behavior	B-MED
,	O
namely	O
activity	B-MED
,	O
locations	B-MED
and	O
emotions	B-MED
,	O
unprecedented	B-MED
to	O
date	B-MED
,	O
to	O
intelligently	O
derive	O
more	O
meaningful	O
high	B-MED
-	O
level	B-MED
context	B-MED
information	B-MED
.	O
The	O
paper	O
contributes	B-MED
with	O
a	O
new	O
open	O
ontology	B-MED
describing	O
both	O
low	B-MED
-	O
level	B-MED
and	O
high	B-MED
-	O
level	B-MED
context	B-MED
information	B-MED
,	O
as	O
well	O
as	O
their	O
relationships	B-MED
.	O
Furthermore	O
,	O
a	O
framework	B-MED
building	O
on	O
the	O
developed	O
ontology	B-MED
and	O
reasoning	O
models	B-MED
is	O
presented	O
and	O
evaluated	O
.	O
The	O
proposed	O
method	O
proves	O
to	O
be	O
robust	O
while	O
identifying	O
high	B-MED
-	O
level	B-MED
contexts	B-MED
even	O
in	O
the	O
event	B-MED
of	O
erroneously	B-MED
-	O
detected	B-MED
low	B-MED
-l	O
evel	B-MED
context	B-MED
s.	O
Despite	O
reasonable	O
inference	B-MED
times	O
being	O
obtained	O
for	O
a	O
relevant	B-MED
set	B-MED
of	O
users	B-MED
and	O
instances	B-MED
,	O
additional	O
work	O
is	O
required	O
to	O
scale	O
to	O
long	O
-	O
term	O
scenarios	B-MED
with	O
a	O
large	O
number	O
of	O
users	B-MED
.	O
A	O
Systematic	B-MED
Review	I-MED
of	O
the	O
Diagnostic	B-MED
and	O
Prognostic	B-MED
Value	I-MED
of	O
Urinary	B-MED
Protein	B-MED
Biomarkers	B-MED
in	O
Urothelial	B-MED
Bladder	I-MED
Cancer	I-MED
For	O
over	O
80	O
years	O
,	O
cystoscopy	B-MED
has	O
remained	O
the	O
gold	B-MED
-	I-MED
standard	I-MED
for	O
detecting	B-MED
tumours	B-MED
of	O
the	O
urinary	B-MED
bladder	I-MED
.	O
Since	O
bladder	B-MED
tumours	I-MED
have	O
a	O
tendency	O
to	O
recur	B-MED
and	O
progress	B-MED
,	O
many	O
patients	B-MED
are	O
subjected	O
to	O
repeated	O
cystoscopies	B-MED
during	O
long	B-MED
-	I-MED
term	I-MED
surveillance	B-MED
,	O
with	O
the	O
procedure	B-MED
being	O
both	O
unpleasant	O
for	O
the	O
patient	B-MED
and	O
expensive	O
for	O
healthcare	B-MED
providers	I-MED
.	O
The	O
identification	B-MED
and	O
validation	B-MED
of	O
bladder	B-MED
tumour	I-MED
specific	O
molecular	B-MED
markers	I-MED
in	O
urine	B-MED
could	O
enable	O
tumour	B-MED
detection	B-MED
and	O
reduce	O
reliance	B-MED
on	O
cystoscopy	B-MED
,	O
and	O
numerous	O
classes	O
of	O
biomarkers	B-MED
have	O
been	O
studied	O
.	O
Proteins	B-MED
represent	O
the	O
most	O
intensively	O
studied	B-MED
class	I-MED
of	I-MED
biomolecule	I-MED
in	O
this	O
setting	O
.	O
As	O
an	O
aid	O
to	O
researchers	B-MED
searching	O
for	O
better	O
urinary	B-MED
biomarkers	B-MED
,	O
we	O
report	O
a	O
comprehensive	B-MED
systematic	I-MED
review	I-MED
of	O
the	O
literature	B-MED
and	O
a	O
searchable	O
database	B-MED
of	O
proteins	B-MED
that	O
have	O
been	O
investigated	B-MED
to	O
date	O
.	O
Our	O
objective	O
was	O
to	O
classify	O
these	O
proteins	B-MED
as	O
:	O
1	O
)	O
those	O
with	O
robustly	O
characterised	O
sensitivity	B-MED
and	I-MED
specificity	I-MED
for	O
bladder	B-MED
cancer	I-MED
detection	B-MED
;	O
2	O
)	O
those	O
that	O
show	O
potential	O
but	O
further	O
investigation	B-MED
is	O
required	O
;	O
3	O
)	O
those	O
unlikely	O
to	O
warrant	O
further	O
investigation	B-MED
;	O
and	O
4	O
)	O
those	O
investigated	B-MED
as	O
prognostic	B-MED
markers	I-MED
.	O
This	O
work	O
should	O
help	O
to	O
prioritise	O
certain	O
biomarkers	B-MED
for	O
rigorous	B-MED
validation	I-MED
,	O
whilst	O
preventing	B-MED
wasted	O
effort	O
on	O
proteins	B-MED
that	O
have	O
shown	O
no	O
association	O
whatsoever	O
with	O
the	O
disease	B-MED
,	O
or	O
only	O
modest	O
biomarker	B-MED
performance	O
despite	O
large	B-MED
-	I-MED
scale	I-MED
efforts	I-MED
at	O
validation	B-MED
.	O
Anterior	B-MED
single	I-MED
implants	I-MED
with	O
different	O
neck	B-MED
designs	B-MED
:	O
5	O
Year	B-MED
results	O
of	O
a	O
randomized	B-MED
clinical	I-MED
trial	I-MED
The	O
design	B-MED
of	O
the	O
implant	B-MED
neck	I-MED
might	O
be	O
significant	O
for	O
preservation	B-MED
of	O
marginal	B-MED
bone	B-MED
.	O
To	O
compare	O
the	O
5	B-MED
-	I-MED
year	I-MED
radiographic	B-MED
and	O
clinical	B-MED
outcome	B-MED
of	O
single	B-MED
anterior	I-MED
implants	I-MED
provided	O
with	O
a	O
smooth	B-MED
smooth	B-MED
neck	I-MED
,	O
a	O
rough	B-MED
neck	I-MED
or	O
a	O
scalloped	O
rough	B-MED
neck	I-MED
.	O
93	O
Patients	B-MED
with	O
a	O
missing	O
anterior	B-MED
tooth	B-MED
in	O
the	O
maxilla	B-MED
were	O
included	O
.	O
At	O
random	O
,	O
patients	B-MED
received	O
an	O
implant	B-MED
with	O
a	O
1.5	O
mm	O
smooth	B-MED
neck	B-MED
(	O
"	O
smooth	B-MED
group	I-MED
"	O
)	O
,	O
a	O
rough	B-MED
neck	I-MED
with	O
grooves	O
(	O
"	O
rough	B-MED
group	I-MED
"	O
)	O
or	O
a	O
scalloped	O
rough	B-MED
neck	I-MED
with	O
grooves	O
(	O
"	O
scalloped	B-MED
group	I-MED
"	O
)	O
.	O
Implants	B-MED
were	O
installed	O
in	O
healed	B-MED
sites	I-MED
.	O
Follow	B-MED
-	I-MED
up	I-MED
visits	I-MED
were	O
conducted	O
after	O
final	O
crown	B-MED
delivery	I-MED
and	O
1	O
year	B-MED
and	O
5	O
years	B-MED
later	O
.	O
Scalloped	O
implants	B-MED
showed	O
significantly	O
more	O
initial	O
marginal	B-MED
bone	B-MED
resorption	I-MED
.	O
The	O
total	O
amount	O
of	O
bone	B-MED
loss	I-MED
was	O
1.26	O
±	O
0.90	O
mm	O
in	O
the	O
smooth	B-MED
group	I-MED
,	O
1.20	O
±	O
1.1	O
mm	O
in	O
the	O
rough	B-MED
group	I-MED
and	O
2.28	O
±	O
0.97	O
mm	O
in	O
the	O
scalloped	B-MED
group	I-MED
(	O
P	O
<	O
.05	O
)	O
.	O
Survival	B-MED
rates	I-MED
were	O
96.2	O
%	O
for	O
the	O
smooth	B-MED
and	O
scalloped	B-MED
group	I-MED
and	O
100	O
%	O
for	O
the	O
rough	B-MED
group	I-MED
.	O
Scalloped	O
implants	B-MED
showed	O
deeper	B-MED
pocket	I-MED
depths	I-MED
,	O
more	O
bleeding	B-MED
and	O
more	O
technical	O
complications	B-MED
.	O
There	O
were	O
no	O
differences	O
in	O
esthetic	B-MED
outcome	I-MED
nor	O
in	O
patient	B-MED
satisfaction	I-MED
.	O
For	O
anterior	B-MED
single	O
tooth	B-MED
replacements	I-MED
,	O
scalloped	O
implants	B-MED
show	O
less	O
favorable	O
radiographic	B-MED
and	O
clinical	B-MED
outcome	B-MED
compared	O
to	O
regular	O
implants	B-MED
with	O
a	O
smooth	B-MED
neck	B-MED
or	O
rough	B-MED
neck	I-MED
.	O
The	O
relationships	B-MED
between	O
rugby	B-MED
players	B-MED
'	I-MED
tackle	B-MED
training	B-MED
attitudes	B-MED
and	O
behaviour	B-MED
and	O
their	O
match	B-MED
tackle	I-MED
attitudes	I-MED
and	O
behaviour	B-MED
The	O
tackle	B-MED
event	O
in	O
rugby	B-MED
is	O
a	O
technical	B-MED
and	O
physical	B-MED
contest	B-MED
between	O
opposing	O
players	B-MED
.	O
A	O
player	B-MED
's	I-MED
ability	O
to	O
tolerate	B-MED
and	O
contest	B-MED
during	O
a	O
tackle	B-MED
is	O
a	O
prerequisite	B-MED
for	O
safe	B-MED
participation	B-MED
and	O
success	B-MED
in	O
rugby	B-MED
.	O
Little	O
is	O
known	O
about	O
the	O
relationship	B-MED
between	O
tackle	B-MED
training	I-MED
and	O
tackling	B-MED
in	O
matches	B-MED
in	O
rugby	B-MED
union	I-MED
.	O
Therefore	O
,	O
we	O
investigated	B-MED
the	O
relationships	B-MED
between	O
players	B-MED
'	I-MED
training	B-MED
attitudes	I-MED
and	O
behaviour	B-MED
and	O
their	O
match	B-MED
attitudes	I-MED
and	O
behaviour	B-MED
for	O
tackling	B-MED
in	O
rugby	B-MED
union	I-MED
.	O
A	O
questionnaire	B-MED
was	O
designed	O
to	O
assess	B-MED
attitude	B-MED
(	O
importance	O
)	O
and	O
behaviours	B-MED
(	O
frequency	B-MED
and	O
quantity	B-MED
)	O
among	O
junior	B-MED
(	O
under	O
19	O
)	O
players	B-MED
on	O
a	O
5	B-MED
-	I-MED
point	I-MED
Likert	I-MED
Scale	I-MED
.	O
Questionnaires	B-MED
were	O
handed	O
out	O
to	O
220	O
players	B-MED
(	O
10	O
schools	B-MED
)	O
at	O
a	O
tournament	B-MED
and	O
75	O
%	O
(	O
9	O
schools	B-MED
,	O
n=164	O
)	O
were	O
returned	O
for	O
analysis	B-MED
.	O
Associations	B-MED
between	O
training	B-MED
attitudes	I-MED
and	O
behaviours	B-MED
were	O
tested	B-MED
using	O
the	O
χ(2	B-MED
)	I-MED
test	I-MED
,	I-MED
Cramer	I-MED
's	I-MED
V	I-MED
and	I-MED
τ	I-MED
-	I-MED
b	I-MED
b.	O
The	O
more	O
time	O
spent	O
on	O
emphasising	O
proper	O
technique	B-MED
to	O
prevent	B-MED
injuries	B-MED
in	O
training	B-MED
,	O
the	O
more	O
important	O
players	B-MED
rated	O
'	O
own	O
safety	O
'	O
(	O
τ	O
-	O
b=0.21	O
,	O
moderate	B-MED
,	O
z=3.1	O
,	O
p<0.01	O
)	O
,	O
'	O
going	O
for	O
the	O
ball	B-MED
only	O
'	O
(	O
τ	O
-	O
b=0.27	O
,	O
moderate	B-MED
,	O
z=4.6	O
,	O
p<0.001	O
)	O
and	O
'	O
staying	O
on	O
feet	O
'	O
(	O
τ	O
-	O
b=0.23	O
,	O
moderate	B-MED
,	O
z=3.6	O
,	O
p<0.001	O
)	O
in	O
match	B-MED
play	I-MED
.	O
The	O
more	O
time	O
spent	O
on	O
emphasising	O
proper	O
technique	B-MED
to	O
improve	B-MED
performance	B-MED
in	O
training	B-MED
,	O
the	O
more	O
important	O
players	B-MED
rated	O
actions	O
'	O
going	O
for	O
ball	B-MED
only	O
'	O
(	O
τ	O
-	O
b=0.23	O
,	O
moderate	B-MED
,	O
z=3.7	O
,	O
p<0.001	O
)	O
and	O
'	O
preventing	B-MED
the	O
ball	B-MED
carrier	O
from	O
retaining	B-MED
position	B-MED
'	O
(	O
τ	O
-	O
b=0.20	O
,	O
moderate	B-MED
,	O
z=3.1	O
,	O
p<0.01	O
)	O
in	O
match	B-MED
play	I-MED
.	O
This	O
is	O
the	O
first	O
study	B-MED
to	O
report	O
on	O
the	O
relationships	B-MED
between	O
players	B-MED
'	O
training	B-MED
attitudes	I-MED
and	O
behaviour	B-MED
and	O
their	O
match	B-MED
attitudes	I-MED
and	O
behaviour	B-MED
s	O
for	O
tackling	B-MED
in	O
rugby	B-MED
union	I-MED
.	O
The	O
importance	O
of	O
tackle	B-MED
training	B-MED
to	O
prevent	B-MED
injury	B-MED
,	O
and	O
the	O
amount	O
of	O
time	O
spent	O
on	O
technique	B-MED
to	O
prevent	B-MED
injuries	B-MED
,	O
was	O
associated	B-MED
with	I-MED
behaviours	B-MED
that	O
reduce	B-MED
the	O
risk	B-MED
of	I-MED
injury	I-MED
in	O
matches	B-MED
.	O
Exposure	B-MED
to	I-MED
suicidal	I-MED
behaviors	I-MED
:	O
A	O
common	O
suicide	B-MED
risk	B-MED
factor	I-MED
or	O
a	O
personal	B-MED
negative	B-MED
life	I-MED
event	I-MED
?	O
Numerous	B-MED
suicide	B-MED
risk	B-MED
factors	I-MED
have	O
been	O
proposed	O
but	O
not	O
adequately	O
validated	B-MED
for	I-MED
epidemiology	I-MED
,	O
treatment	B-MED
and	O
prevention	B-MED
efforts	I-MED
.	O
Exposures	B-MED
to	I-MED
suicidal	I-MED
behaviors	I-MED
(	O
ESB	B-MED
)	O
,	O
from	O
family	B-MED
and	O
friend	B-MED
suicide	B-MED
attempts	I-MED
and	O
completions	B-MED
,	O
were	O
tested	O
for	O
validity	B-MED
as	O
a	O
suicidal	B-MED
risk	B-MED
factor	I-MED
and	O
also	O
for	O
measurement	B-MED
and	O
construct	O
adequacy	B-MED
.	O
An	O
anonymous	B-MED
online	B-MED
survey	B-MED
yielded	O
713	O
participants	B-MED
(	O
aged	B-MED
18	O
-	O
71	O
)	O
,	O
who	O
reported	O
ESB	B-MED
,	O
completed	O
the	O
Suicidal	B-MED
Affect	I-MED
-	I-MED
Behavior	I-MED
-	I-MED
Cognition	I-MED
Scale	I-MED
(	O
SABCS	B-MED
)	O
,	O
and	O
comprised	O
a	O
broad	O
spectrum	O
on	O
those	O
variables	B-MED
.	O
Tests	B-MED
of	O
dimensionality	B-MED
and	O
internal	B-MED
consistency	I-MED
showed	O
the	O
four	O
ESB	B-MED
variables	B-MED
(	O
attempts	B-MED
/	O
completions	B-MED
through	O
family	B-MED
/	O
friends	B-MED
)	O
were	O
independent	B-MED
and	O
did	O
not	O
form	O
a	O
common	O
factor	O
or	O
an	O
identifiable	O
ESB	B-MED
latent	B-MED
trait	B-MED
.	O
ESB	B-MED
variables	B-MED
were	O
,	O
however	O
,	O
associated	O
with	O
demographic	B-MED
and	O
psychiatric	B-MED
histories	I-MED
.	O
A	O
battery	O
of	O
tests	B-MED
revealed	O
no	O
meaningful	O
associations	B-MED
between	O
ESB	B-MED
and	O
total	O
suicidality	B-MED
or	O
suicide	B-MED
risk	B-MED
factors	I-MED
(	O
social	B-MED
support	I-MED
,	O
depression	B-MED
,	O
anxiety	B-MED
,	O
stress	B-MED
,	O
satisfaction	B-MED
with	I-MED
life	I-MED
and	O
emotional	B-MED
stability	I-MED
)	O
.	O
In	O
addition	O
,	O
in	O
contrast	O
to	O
previous	O
reports	B-MED
,	O
young	B-MED
adults	I-MED
(	O
n	O
=	O
200	O
;	O
aged	B-MED
18	O
-	O
20	O
)	O
showed	O
no	O
increased	B-MED
suicidality	B-MED
due	O
to	O
ESB	B-MED
.	O
Results	B-MED
showed	O
no	O
validity	B-MED
for	O
ESB	B-MED
as	O
a	O
common	O
risk	B-MED
factor	I-MED
for	O
suicidality	B-MED
or	O
other	O
psychopathology	B-MED
,	O
or	O
as	O
a	O
latent	B-MED
trait	B-MED
.	O
ESB	B-MED
showed	O
evidence	B-MED
as	O
a	O
personal	B-MED
negative	B-MED
life	I-MED
event	I-MED
with	O
individual	B-MED
effects	B-MED
and	O
interpretations	B-MED
.	O
Comparative	O
Epidemiologic	B-MED
Characteristics	B-MED
of	O
Pertussis	B-MED
in	O
10	O
Central	B-MED
and	O
Eastern	B-MED
European	I-MED
Countries	I-MED
,	O
2000	O
-	O
2013	O
We	O
undertook	O
an	O
epidemiological	B-MED
survey	I-MED
of	O
the	O
annual	B-MED
incidence	B-MED
of	O
pertussis	B-MED
reported	B-MED
from	O
2000	O
to	O
2013	O
in	O
ten	O
Central	B-MED
and	O
Eastern	B-MED
European	I-MED
countries	I-MED
to	O
ascertain	O
whether	O
increased	O
pertussis	B-MED
reports	B-MED
in	O
some	O
countries	B-MED
share	O
common	O
underlying	O
drivers	O
or	O
whether	O
there	O
are	O
specific	O
features	B-MED
in	O
each	O
country	B-MED
.	O
The	O
annual	B-MED
incidence	B-MED
of	O
pertussis	B-MED
in	O
the	O
participating	O
countries	B-MED
was	O
obtained	O
from	O
relevant	O
government	B-MED
institutions	I-MED
and/or	O
national	B-MED
surveillance	I-MED
systems	I-MED
.	O
We	O
reviewed	B-MED
the	O
changes	B-MED
in	O
the	O
pertussis	B-MED
incidence	B-MED
rates	I-MED
in	O
each	O
country	B-MED
to	O
explore	O
differences	B-MED
and/or	O
similarities	B-MED
between	O
countries	B-MED
in	O
relation	O
to	O
pertussis	B-MED
surveillance	B-MED
;	O
case	B-MED
definitions	I-MED
for	O
detection	B-MED
and	O
confirmation	B-MED
of	O
pertussis	B-MED
;	O
incidence	B-MED
and	O
number	B-MED
of	I-MED
cases	I-MED
of	O
pertussis	B-MED
by	O
year	B-MED
,	O
overall	O
and	O
by	O
age	B-MED
group	I-MED
;	O
population	B-MED
by	O
year	B-MED
,	O
overall	O
and	O
by	O
age	B-MED
group	I-MED
;	O
pertussis	B-MED
immunization	B-MED
schedule	I-MED
and	O
coverage	B-MED
,	O
and	O
switch	O
from	O
whole	B-MED
-	I-MED
cell	I-MED
pertussis	I-MED
vaccines	I-MED
(	O
wP	B-MED
)	O
to	O
acellular	B-MED
pertussis	I-MED
vaccines	I-MED
(	O
aP	B-MED
)	O
.	O
There	O
was	O
heterogeneity	B-MED
in	O
the	O
reported	B-MED
annual	B-MED
incidence	B-MED
rates	I-MED
and	O
trends	O
observed	O
across	O
countries	B-MED
.	O
Reported	B-MED
pertussis	B-MED
incidence	B-MED
rates	I-MED
varied	O
considerably	O
,	O
ranging	O
from	O
0.01	O
to	O
96	O
per	O
100,000	O
population	B-MED
,	O
with	O
the	O
highest	B-MED
rates	B-MED
generally	O
reported	B-MED
in	O
Estonia	B-MED
and	O
the	O
lowest	B-MED
in	O
Hungary	B-MED
and	O
Serbia	B-MED
.	O
The	O
greatest	O
burden	B-MED
appears	O
for	O
the	O
most	O
part	O
in	O
infants	B-MED
(	O
<	O
1	O
year	B-MED
)	O
in	O
Bulgaria	B-MED
,	O
Hungary	B-MED
,	O
Latvia	B-MED
,	O
Romania	B-MED
,	O
and	O
Serbia	B-MED
,	O
but	O
not	O
in	O
the	O
other	O
participating	O
countries	B-MED
where	O
the	O
burden	B-MED
may	O
have	O
shifted	O
to	O
older	B-MED
children	I-MED
,	O
though	O
surveillance	B-MED
of	O
adults	B-MED
may	O
be	O
inappropriate	O
.	O
There	O
was	O
no	O
consistent	O
pattern	O
associated	B-MED
with	I-MED
the	O
switch	O
from	O
wP	B-MED
to	O
aP	B-MED
vaccines	I-MED
on	O
reported	B-MED
pertussis	B-MED
incidence	B-MED
rates	I-MED
.	O
The	O
heterogeneity	B-MED
in	O
reported	B-MED
data	B-MED
may	O
be	O
related	O
to	O
a	O
number	O
of	O
factors	B-MED
including	O
surveillance	B-MED
system	B-MED
characteristics	B-MED
or	O
capabilities	B-MED
,	O
different	O
case	B-MED
definitions	I-MED
,	O
type	B-MED
of	O
pertussis	B-MED
confirmation	B-MED
tests	I-MED
used	O
,	O
public	B-MED
awareness	B-MED
of	O
the	O
disease	B-MED
,	O
as	O
well	O
as	O
real	O
differences	B-MED
in	O
the	O
magnitude	B-MED
of	O
the	O
disease	B-MED
,	O
or	O
a	O
combination	O
of	O
these	O
factors	B-MED
.	O
Our	O
study	O
highlights	O
the	O
need	O
to	O
standardize	O
pertussis	B-MED
detection	B-MED
and	O
confirmation	B-MED
in	O
surveillance	B-MED
programs	I-MED
across	O
Europe	B-MED
,	O
complemented	O
with	O
carefully	O
-	O
designed	O
seroprevalence	B-MED
studies	I-MED
using	O
the	O
same	O
protocols	B-MED
and	O
methodologies	B-MED
.	O
Neuro	B-MED
-	I-MED
Behcet	I-MED
disease	I-MED
presenting	B-MED
as	O
a	O
solitary	O
cerebellar	B-MED
hemorrhagic	I-MED
lesion	B-MED
:	O
a	O
case	B-MED
report	I-MED
and	O
review	B-MED
of	I-MED
the	I-MED
literature	I-MED
Behcet	B-MED
's	I-MED
disease	I-MED
is	O
a	O
heterogeneous	B-MED
,	O
multisystem	B-MED
,	O
inflammatory	B-MED
disorder	I-MED
of	O
unknown	B-MED
etiology	I-MED
.	O
The	O
classic	O
triad	O
of	O
oral	B-MED
and	O
genital	B-MED
ulcerations	I-MED
in	O
conjunction	B-MED
with	O
uveitis	B-MED
was	O
originally	O
described	B-MED
by	O
the	O
Turkish	B-MED
dermatologist	B-MED
Hulusi	O
Behcet	O
in	O
1937	O
,	O
but	O
associated	B-MED
symptoms	I-MED
of	O
the	O
cardiovascular	B-MED
,	O
central	B-MED
nervous	I-MED
,	O
pulmonary	B-MED
,	O
and	O
gastrointestinal	B-MED
systems	I-MED
were	O
later	O
identified	B-MED
.	O
In	O
fact	O
,	O
Behcet	B-MED
's	I-MED
disease	I-MED
with	O
neurological	B-MED
involvement	I-MED
(	O
neuro	B-MED
-	I-MED
Behcet	I-MED
's	I-MED
disease	I-MED
)	O
is	O
not	O
uncommon	O
.	O
Patients	B-MED
with	O
neuro	B-MED
-	I-MED
Behcet	I-MED
's	I-MED
disease	I-MED
typically	O
exhibit	O
a	O
diverse	O
array	O
of	O
symptoms	B-MED
,	O
most	B-MED
commonly	B-MED
in	O
the	O
brainstem	B-MED
and	O
diencephalic	B-MED
regions	B-MED
.	O
Herein	O
,	O
we	O
report	B-MED
an	O
unusual	B-MED
case	B-MED
of	O
neuro	B-MED
-	I-MED
Behcet	I-MED
's	I-MED
disease	I-MED
in	O
a	O
patient	B-MED
who	O
presented	B-MED
with	O
a	O
solitary	O
cerebellar	B-MED
hemorrhage	I-MED
.	O
A	O
39	B-MED
-	I-MED
year	I-MED
-	I-MED
old	I-MED
Asian	B-MED
woman	B-MED
was	O
admitted	B-MED
to	O
our	O
hospital	B-MED
with	O
complaints	B-MED
of	O
a	O
sudden	B-MED
speech	B-MED
difficulty	I-MED
that	O
had	O
manifested	B-MED
the	O
same	B-MED
morning	B-MED
,	O
and	O
dizziness	B-MED
and	O
mild	B-MED
vomiting	B-MED
experienced	O
over	B-MED
the	O
previous	B-MED
3	O
days	B-MED
.	O
Magnetic	B-MED
resonance	I-MED
images	I-MED
revealed	B-MED
target	O
-	O
like	O
hemorrhagic	B-MED
lesions	B-MED
in	O
the	O
right	B-MED
hemisphere	I-MED
of	I-MED
the	I-MED
cerebellum	I-MED
.	O
Risk	B-MED
factors	I-MED
that	O
may	O
result	B-MED
in	O
cerebellar	B-MED
hemorrhage	I-MED
,	O
such	O
as	O
high	B-MED
blood	I-MED
pressure	I-MED
or	O
bleeding	B-MED
diathesis	I-MED
,	O
were	O
ruled	B-MED
out	I-MED
,	O
and	O
subsequent	B-MED
brain	B-MED
angiograms	B-MED
were	O
normal	B-MED
.	O
These	O
findings	B-MED
suggest	B-MED
that	O
the	O
patient	B-MED
's	I-MED
cerebellar	B-MED
hemorrhage	I-MED
could	O
have	O
been	O
due	B-MED
to	I-MED
intracranial	B-MED
vasculitis	B-MED
in	O
a	O
rare	B-MED
,	O
if	O
not	O
unique	O
,	O
complication	B-MED
of	O
neuro	B-MED
-	I-MED
Behcet	I-MED
's	I-MED
disease	I-MED
.	O
Mechanisms	B-MED
of	O
ear	B-MED
trauma	B-MED
and	O
reconstructive	B-MED
techniques	B-MED
in	O
105	O
consecutive	B-MED
patients	B-MED
Acquired	B-MED
auricular	B-MED
deformities	B-MED
may	O
diminish	B-MED
facial	B-MED
esthetics	I-MED
and	O
cause	O
psychological	B-MED
distress	I-MED
.	O
The	O
aim	O
of	O
this	O
article	O
is	O
to	O
provide	O
an	O
overview	O
of	O
the	O
type	O
of	O
injuries	B-MED
and	O
applied	B-MED
reconstructive	I-MED
techniques	B-MED
in	O
a	O
large	O
academic	B-MED
hospital	I-MED
in	O
The	O
Netherlands	B-MED
.	O
A	O
retrospective	B-MED
chart	B-MED
review	I-MED
was	O
conducted	O
for	O
the	O
last	O
105	O
patients	B-MED
who	O
underwent	O
auricular	B-MED
reconstruction	B-MED
for	O
an	O
acquired	B-MED
deformity	I-MED
.	O
Data	B-MED
concerning	O
gender	B-MED
,	O
affected	B-MED
side	I-MED
,	O
cause	B-MED
of	I-MED
injury	I-MED
,	O
anatomical	B-MED
region	I-MED
,	O
the	O
previous	O
and	O
further	O
surgeries	B-MED
,	O
type	O
of	O
cartilage	B-MED
,	O
and	O
skin	B-MED
cover	I-MED
used	I-MED
were	O
collected	O
and	O
analyzed	B-MED
.	O
105	O
patients	B-MED
were	O
included	O
.	O
Acquired	B-MED
auricular	B-MED
deformities	B-MED
were	O
mainly	O
caused	O
by	O
bite	B-MED
injuries	I-MED
(	O
22	O
%	O
)	O
,	O
traffic	B-MED
accidents	I-MED
(	O
17	O
%	O
)	O
,	O
burns	B-MED
(	O
9.5	O
%	O
)	O
,	O
and	O
post	B-MED
-	I-MED
otoplasty	I-MED
complications	B-MED
(	O
9.5	O
%	O
)	O
.	O
The	O
upper	B-MED
third	I-MED
of	I-MED
the	I-MED
auricle	I-MED
was	O
most	O
often	O
injured	B-MED
(	O
41	O
%	O
)	O
,	O
followed	O
by	O
the	O
entire	B-MED
auricle	I-MED
(	O
19	O
%	O
)	O
.	O
70	O
%	O
of	O
cases	B-MED
required	O
reconstruction	B-MED
with	O
costal	B-MED
cartilage	I-MED
.	O
The	O
most	O
common	O
form	O
of	O
cutaneous	B-MED
cover	I-MED
was	O
a	O
postauricular	B-MED
skin	I-MED
flap	I-MED
(	O
40	O
%	O
of	O
cases	B-MED
)	O
.	O
This	O
study	B-MED
gives	O
a	O
complete	O
overview	O
of	O
causes	O
and	O
treatment	B-MED
of	O
acquired	B-MED
auricular	B-MED
deformities	B-MED
.	O
The	O
results	O
are	O
comparable	O
with	O
the	O
results	B-MED
of	O
similar	O
studies	B-MED
found	O
in	O
literature	B-MED
.	O
Bite	B-MED
wounds	I-MED
are	O
the	O
leading	O
cause	O
of	O
acquired	B-MED
auricular	B-MED
injuries	B-MED
.	O
The	O
upper	B-MED
third	I-MED
is	O
most	O
commonly	O
affected	O
.	O
In	O
the	O
largest	O
percentage	O
of	O
reconstructions	B-MED
,	O
costal	B-MED
cartilage	I-MED
and	O
a	O
postauricular	B-MED
flap	I-MED
were	O
used	O
to	O
correct	O
the	O
deformity	B-MED
.	O
Absorption	B-MED
Characteristics	I-MED
of	O
Vertebrate	B-MED
Non	B-MED
-	O
Visual	B-MED
Opsin	B-MED
,	I-MED
Opn3	I-MED
Most	O
animals	B-MED
possess	B-MED
multiple	B-MED
opsins	B-MED
which	O
sense	B-MED
light	B-MED
for	O
visual	B-MED
and	O
non	B-MED
-	O
visual	B-MED
functions	I-MED
.	O
Here	O
,	O
we	O
show	O
spectral	B-MED
characteristics	B-MED
of	O
non	B-MED
-	O
visual	B-MED
opsins	B-MED
,	O
vertebrate	B-MED
Opn3s	B-MED
,	O
which	O
are	O
widely	O
distributed	B-MED
among	O
vertebrates	B-MED
.	O
We	O
successfully	B-MED
expressed	B-MED
zebrafish	B-MED
Opn3	B-MED
in	O
mammalian	B-MED
cultured	B-MED
cells	I-MED
and	O
measured	B-MED
its	O
absorption	B-MED
spectrum	I-MED
spectroscopically	I-MED
.	O
When	O
incubated	B-MED
with	O
11	B-MED
-	I-MED
cis	I-MED
retinal	I-MED
,	O
zebrafish	B-MED
Opn3	B-MED
formed	O
a	O
blue	B-MED
-	I-MED
sensitive	I-MED
photopigment	I-MED
with	O
an	O
absorption	B-MED
maximum	B-MED
around	O
465	O
nm	O
.	O
The	O
Opn3	B-MED
converts	B-MED
to	O
an	O
all	B-MED
-	I-MED
trans	I-MED
retinal	I-MED
-	I-MED
bearing	I-MED
photoproduct	B-MED
with	O
an	O
absorption	B-MED
spectrum	I-MED
similar	B-MED
to	O
the	O
dark	B-MED
state	I-MED
following	O
brief	B-MED
blue	B-MED
-	I-MED
light	I-MED
irradiation	B-MED
.	O
The	O
photoproduct	B-MED
experienced	O
a	O
remarkable	O
blue	B-MED
-	I-MED
shift	I-MED
,	O
with	O
changes	O
in	B-MED
position	I-MED
of	O
the	O
isosbestic	B-MED
point	I-MED
,	O
during	O
further	O
irradiation	B-MED
.	O
We	O
then	O
used	O
a	O
cAMP	B-MED
-	O
dependent	B-MED
luciferase	B-MED
reporter	B-MED
assay	B-MED
to	O
investigate	B-MED
light	B-MED
-	O
dependent	B-MED
cAMP	B-MED
responses	B-MED
in	O
cultured	B-MED
cells	I-MED
expressing	B-MED
zebrafish	B-MED
,	O
pufferfish	B-MED
,	O
anole	B-MED
and	O
chicken	B-MED
Opn3	B-MED
.	O
The	O
wild	B-MED
type	I-MED
opsins	B-MED
did	O
not	O
produce	O
responses	B-MED
,	O
but	O
cells	B-MED
expressing	B-MED
chimera	B-MED
mutants	B-MED
(	O
WT	B-MED
Opn3s	I-MED
in	O
which	O
the	O
third	B-MED
intracellular	I-MED
loops	B-MED
were	O
replaced	B-MED
with	O
the	O
third	B-MED
intracellular	I-MED
loop	B-MED
of	O
a	O
Gs	B-MED
-	I-MED
coupled	I-MED
jellyfish	B-MED
opsin	B-MED
)	O
displayed	B-MED
light	B-MED
-	O
dependent	B-MED
changes	B-MED
in	O
cAMP	B-MED
.	O
The	O
results	O
suggest	O
that	O
Opn3	B-MED
is	O
capable	O
of	O
activating	B-MED
G	B-MED
protein(s	I-MED
)	I-MED
in	O
a	O
light	B-MED
-	O
dependent	B-MED
manner	O
.	O
Finally	O
,	O
we	O
used	O
this	O
assay	B-MED
to	O
measure	B-MED
the	O
relative	B-MED
wavelength	B-MED
-	O
dependent	B-MED
response	B-MED
of	O
cells	B-MED
expressing	B-MED
Opn3	B-MED
chimeras	B-MED
to	O
multiple	B-MED
quantally	B-MED
-	O
matched	B-MED
stimuli	B-MED
.	O
The	O
inferred	B-MED
spectral	B-MED
sensitivity	I-MED
curve	B-MED
of	O
zebrafish	B-MED
Opn3	B-MED
accurately	B-MED
matched	B-MED
the	O
measured	B-MED
absorption	B-MED
spectrum	I-MED
.	O
We	O
were	O
unable	O
to	O
estimate	O
the	O
spectral	B-MED
sensitivity	I-MED
curve	B-MED
of	O
mouse	B-MED
or	O
anole	B-MED
Opn3	B-MED
,	O
but	O
,	O
like	O
zebrafish	B-MED
Opn3	B-MED
,	O
the	O
chicken	B-MED
and	O
pufferfish	B-MED
Opn3	B-MED
-	I-MED
JiL3	I-MED
chimeras	B-MED
also	O
formed	O
blue	B-MED
-	I-MED
sensitive	I-MED
pigments	I-MED
.	O
These	O
findings	O
suggest	O
that	O
vertebrate	B-MED
Opn3s	B-MED
may	O
form	O
blue	B-MED
-	I-MED
sensitive	I-MED
G	I-MED
protein	I-MED
-	I-MED
coupled	I-MED
pigments	I-MED
.	O
Further	O
,	O
we	O
suggest	O
that	O
the	O
method	O
described	O
here	O
,	O
combining	O
a	O
cAMP	B-MED
-	O
dependent	B-MED
luciferase	B-MED
reporter	B-MED
assay	B-MED
with	O
chimeric	B-MED
opsins	B-MED
possessing	O
the	O
third	B-MED
intracellular	I-MED
loop	B-MED
of	O
jellyfish	B-MED
opsin	B-MED
,	O
is	O
a	O
versatile	O
approach	O
for	O
estimating	B-MED
absorption	B-MED
spectra	I-MED
of	O
opsins	B-MED
with	O
unknown	O
signaling	B-MED
cascades	I-MED
or	O
for	O
which	O
absorption	B-MED
spectra	I-MED
are	O
difficult	B-MED
to	O
obtain	O
.	O
Passive	B-MED
case	I-MED
detection	I-MED
of	O
malaria	B-MED
in	O
Ratanakiri	B-MED
Province	I-MED
(	O
Cambodia	B-MED
)	O
to	O
detect	B-MED
villages	B-MED
at	B-MED
higher	I-MED
risk	I-MED
for	O
malaria	B-MED
Cambodia	B-MED
reduced	B-MED
malaria	B-MED
incidence	B-MED
by	O
more	O
than	O
75	O
%	O
between	O
2000	O
and	O
2015	O
,	O
a	O
target	B-MED
of	O
the	O
Millennium	B-MED
Development	I-MED
Goal	I-MED
6	I-MED
.	O
The	O
Cambodian	B-MED
Government	B-MED
aims	B-MED
to	O
eliminate	B-MED
all	O
forms	O
of	O
malaria	B-MED
by	O
2025	O
.	O
The	O
country	B-MED
's	I-MED
malaria	B-MED
incidence	B-MED
is	O
highly	B-MED
variable	B-MED
at	O
provincial	B-MED
level	B-MED
,	O
but	O
less	O
is	O
known	O
at	O
village	B-MED
level	B-MED
.	O
This	O
study	B-MED
used	O
passive	B-MED
case	I-MED
detection	I-MED
(	O
PCD	B-MED
)	O
data	O
at	O
village	B-MED
level	B-MED
in	O
Ratanakiri	B-MED
Province	I-MED
from	O
2010	O
to	O
2014	O
to	O
describe	O
incidence	B-MED
trends	B-MED
and	O
identify	B-MED
high	B-MED
-	I-MED
risk	I-MED
areas	I-MED
of	I-MED
malaria	B-MED
to	O
be	O
primarily	B-MED
targeted	B-MED
towards	O
malaria	B-MED
elimination	B-MED
.	O
In	O
2010	O
,	O
the	O
Cambodian	B-MED
malaria	B-MED
programme	B-MED
created	O
a	O
Malaria	B-MED
Information	I-MED
System	I-MED
(	O
MIS	B-MED
)	O
to	O
capture	O
malaria	B-MED
information	B-MED
at	O
village	B-MED
level	B-MED
through	O
PCD	B-MED
by	O
village	B-MED
malaria	B-MED
workers	I-MED
and	O
health	B-MED
facilities	I-MED
.	O
The	O
MIS	B-MED
data	B-MED
of	O
Ratanakiri	B-MED
Province	I-MED
2010	O
-	O
2014	O
were	O
used	O
to	O
calculate	B-MED
annual	B-MED
incidence	B-MED
rates	I-MED
by	O
Plasmodium	B-MED
species	I-MED
at	O
province	B-MED
and	O
commune	B-MED
levels	B-MED
.	O
For	O
estimating	B-MED
the	O
trend	B-MED
at	O
provincial	B-MED
level	B-MED
only	O
villages	B-MED
reporting	B-MED
each	O
year	B-MED
were	O
selected	O
.	O
The	O
communal	B-MED
incidences	B-MED
and	O
the	O
number	O
of	O
cases	B-MED
per	B-MED
village	B-MED
were	O
visualized	O
on	O
a	O
map	B-MED
per	O
Plasmodium	B-MED
species	I-MED
and	O
per	B-MED
year	I-MED
.	O
Analysis	B-MED
of	I-MED
spatial	I-MED
clustering	I-MED
of	O
village	B-MED
malaria	B-MED
cases	B-MED
by	O
Plasmodium	B-MED
species	I-MED
was	O
performed	B-MED
by	O
year	B-MED
.	O
Overall	O
,	O
malaria	B-MED
annual	B-MED
incidence	B-MED
rates	I-MED
per	O
1000	O
inhabitants	B-MED
decreased	B-MED
from	O
86	O
(	O
2010	O
)	O
to	O
30	O
(	O
2014	O
)	O
.	O
Falciparum	B-MED
incidence	B-MED
decreased	B-MED
(	O
by	O
79	O
%	O
in	O
2014	O
compared	B-MED
to	O
2010	O
;	O
CI	B-MED
95	O
%	O
76	O
-	O
82	O
%	O
)	O
more	O
rapidly	B-MED
than	O
vivax	B-MED
incidence	B-MED
(	O
by	O
19	O
%	O
in	O
2014	O
compared	B-MED
to	O
2010	O
;	O
CI	B-MED
95	O
%	O
5	O
-	O
32	O
%	O
)	O
.	O
There	O
were	O
ten	O
to	O
16	O
significant	B-MED
spatial	B-MED
clusters	I-MED
each	O
year	B-MED
.	O
Big	B-MED
clusters	I-MED
tended	O
to	O
extend	B-MED
along	O
the	O
Cambodian	B-MED
-	I-MED
Vietnamese	I-MED
border	I-MED
and	O
along	O
the	O
Sesan	B-MED
River	I-MED
.	O
Three	O
clusters	B-MED
appeared	O
throughout	O
all	O
years	B-MED
(	O
2010	O
-	O
2014	O
):	O
one	O
with	O
21	O
villages	B-MED
appeared	O
each	O
year	B-MED
,	O
the	O
second	O
shrunk	B-MED
progressively	B-MED
from	O
2012	O
to	O
2014	O
and	O
the	O
third	O
was	O
split	B-MED
into	O
two	O
smaller	O
clusters	B-MED
in	O
2013	O
and	O
2014	O
.	O
The	O
decline	B-MED
of	O
malaria	B-MED
burden	B-MED
can	O
be	O
attributed	O
to	O
intensive	B-MED
malaria	B-MED
control	I-MED
activities	I-MED
implemented	B-MED
in	O
the	O
areas	B-MED
:	O
distribution	B-MED
of	O
a	O
long	B-MED
-	I-MED
lasting	I-MED
insecticidal	B-MED
net	I-MED
per	O
person	B-MED
and	O
early	B-MED
diagnosis	I-MED
and	O
prompt	B-MED
treatment	B-MED
.	O
Dihydro	B-MED
-	I-MED
artemisinin	I-MED
piperaquine	B-MED
was	O
the	O
only	O
first	B-MED
-	I-MED
line	I-MED
treatment	I-MED
for	O
all	O
malaria	B-MED
cases	B-MED
.	O
No	O
radical	B-MED
treatment	B-MED
with	O
primaquine	B-MED
was	O
provided	O
for	O
Plasmodium	B-MED
vivax	I-MED
cases	B-MED
,	O
which	O
could	O
explain	O
the	O
slow	B-MED
decrease	B-MED
of	O
P.	B-MED
vivax	I-MED
due	O
to	O
relapses	B-MED
.	O
To	O
achieve	B-MED
malaria	B-MED
elimination	B-MED
by	O
2025	O
,	O
priority	B-MED
should	O
be	O
given	O
to	O
the	O
control	O
of	O
stable	B-MED
malaria	B-MED
clusters	I-MED
appearing	O
over	O
time	O
.	O
Parental	B-MED
perceptions	B-MED
of	O
children´s	B-MED
agency	I-MED
:	O
Parental	B-MED
warmth	I-MED
,	O
school	B-MED
achievement	I-MED
and	O
adjustment	B-MED
The	O
present	O
study	B-MED
examined	O
Swedish	B-MED
mothers	B-MED
'	I-MED
and	O
fathers	B-MED
'	I-MED
warmth	B-MED
towards	O
their	O
children	B-MED
in	O
relation	O
to	O
their	O
children´s	B-MED
agency	I-MED
.	O
It	O
also	O
examined	O
the	O
longitudinal	O
relation	O
between	O
agency	B-MED
and	O
children	B-MED
's	I-MED
externalizing	O
,	O
internalizing	O
,	O
and	O
school	B-MED
achievement	I-MED
.	O
Swedish	B-MED
children	B-MED
's	I-MED
mothers	B-MED
and	O
fathers	B-MED
(	O
N	O
=	O
103	O
)	O
were	O
interviewed	B-MED
at	O
three	O
time	B-MED
points	I-MED
(	O
when	O
children	B-MED
were	O
8	O
,	O
9	O
,	O
and	O
10	O
years	B-MED
old	O
)	O
about	O
their	O
warmth	B-MED
towards	O
their	O
children	B-MED
,	O
children	B-MED
's	I-MED
agency	I-MED
,	O
and	O
children	B-MED
's	I-MED
externalizing	O
and	O
internalizing	O
behaviors	O
and	O
school	B-MED
achievement	I-MED
.	O
Parental	B-MED
warmth	I-MED
at	O
Time	B-MED
1	O
was	O
significantly	O
correlated	B-MED
with	O
child	B-MED
agency	I-MED
at	O
Time	B-MED
2	O
,	O
which	O
was	O
significantly	O
correlated	B-MED
with	O
child	B-MED
externalizing	O
and	O
internalizing	O
behaviors	O
and	O
academic	B-MED
achievement	I-MED
at	O
Time	B-MED
3	O
.	O
There	O
were	O
no	O
differences	O
between	O
girls	B-MED
and	O
boys	B-MED
.	O
Results	O
from	O
this	O
study	B-MED
indicate	O
that	O
Swedish	B-MED
parents	B-MED
'	I-MED
warmth	I-MED
is	O
directly	O
related	O
to	O
subsequent	O
perceptions	B-MED
of	O
children	B-MED
's	I-MED
agency	I-MED
,	O
which	O
in	O
turn	O
are	O
related	O
to	O
subsequently	O
lower	O
child	B-MED
externalizing	O
and	O
internalizing	O
problems	B-MED
and	O
higher	O
academic	B-MED
achievement	I-MED
.	O
These	O
findings	B-MED
held	O
in	O
the	O
context	O
of	O
a	O
three-	O
year	B-MED
longitudinal	B-MED
study	I-MED
and	O
for	O
both	O
boys	B-MED
and	O
girls	B-MED
,	O
suggesting	O
the	O
importance	O
of	O
child	B-MED
agency	I-MED
in	O
the	O
link	O
between	O
parental	B-MED
warmth	I-MED
and	O
children	B-MED
's	I-MED
adjustment	B-MED
.	O
Effects	B-MED
of	O
obesity	B-MED
on	O
IL-33	B-MED
/	O
ST2	B-MED
system	B-MED
in	O
heart	B-MED
,	O
adipose	B-MED
tissue	I-MED
and	O
liver	B-MED
:	O
study	B-MED
in	O
the	O
experimental	B-MED
model	I-MED
of	O
Zucker	B-MED
rats	I-MED
Suppression	B-MED
of	I-MED
tumorigenicity	I-MED
2	I-MED
(	O
ST2	B-MED
)	O
mediates	O
the	O
effect	B-MED
of	O
Interleukin-33	B-MED
(	O
IL-33	B-MED
)	O
.	O
Few	O
data	O
are	O
reported	O
on	O
the	O
relationship	B-MED
between	O
IL-33	B-MED
/	O
ST2	B-MED
and	O
obesity	B-MED
.	O
We	O
aimed	O
to	O
investigate	O
effects	B-MED
of	O
obesity	B-MED
on	O
IL-33	B-MED
/	O
ST2	B-MED
system	B-MED
in	O
heart	B-MED
,	O
adipose	B-MED
tissue	I-MED
and	O
liver	B-MED
in	O
a	O
rodent	B-MED
model	I-MED
of	O
obesity	B-MED
.	O
The	O
relationship	B-MED
of	O
cardiac	B-MED
expression	B-MED
of	O
IL-33	B-MED
/	O
ST2	B-MED
system	B-MED
with	O
natriuretic	B-MED
peptides	I-MED
(	O
NPs	B-MED
)	O
system	B-MED
and	O
inflammatory	B-MED
mediators	I-MED
was	O
also	O
studied	O
.	O
mRNA	B-MED
expression	I-MED
of	O
IL-33	B-MED
/	O
ST2	B-MED
system	B-MED
was	O
evaluated	O
in	O
cardiac	B-MED
,	O
adipose	B-MED
and	O
hepatic	B-MED
biopsies	I-MED
from	O
obese	B-MED
Zucker	I-MED
rats	I-MED
(	O
O	B-MED
)	O
and	O
controls	B-MED
(	O
CO	B-MED
)	O
.	O
Expression	B-MED
levels	O
of	O
sST2	B-MED
was	O
significantly	O
lower	O
in	O
O	B-MED
rats	I-MED
compared	O
with	O
CO	B-MED
(	O
p<0.05	O
)	O
in	O
all	O
tissues	B-MED
.	O
Besides	O
,	O
the	O
mRNA	B-MED
levels	O
of	O
IL-33	B-MED
decreased	O
significant	O
in	O
fat	O
of	O
O	B-MED
respect	O
to	O
CO	B-MED
,	O
while	O
,	O
expression	B-MED
levels	O
of	O
ST2L	B-MED
was	O
significantly	O
higher	O
in	O
liver	B-MED
of	O
CO	B-MED
O	B-MED
than	O
in	O
O.	O
A	O
strong	O
relationship	B-MED
of	O
IL-33	B-MED
/	O
ST2	B-MED
with	O
NPs	B-MED
and	O
classical	O
inflammatory	B-MED
mediators	I-MED
was	O
observed	O
in	O
cardiac	B-MED
tissue	I-MED
.	O
Expression	B-MED
of	O
sST2	B-MED
in	O
cardiac	B-MED
,	O
adipose	B-MED
and	O
liver	B-MED
tissue	I-MED
decreased	O
in	O
O	B-MED
compared	O
with	O
controls	B-MED
,	O
suggesting	O
an	O
involvement	O
for	O
IL-33	B-MED
/	O
ST2	B-MED
system	B-MED
in	O
molecular	B-MED
mechanisms	I-MED
of	O
obesity	B-MED
.	O
The	O
strong	O
relationships	B-MED
with	O
NP	B-MED
systems	B-MED
and	O
inflammatory	B-MED
mediators	I-MED
could	O
suggest	O
an	O
involvement	O
for	O
IL-33	B-MED
/	O
ST2	B-MED
in	O
molecular	B-MED
pathways	I-MED
leading	O
to	O
cardiac	B-MED
dysfunction	I-MED
and	O
inflammation	B-MED
associated	O
with	O
obesity	B-MED
.	O
The	O
Multi	B-MED
-	I-MED
center	I-MED
Evaluation	I-MED
of	I-MED
the	I-MED
Accuracy	I-MED
of	I-MED
the	I-MED
Contrast	I-MED
MEdium	I-MED
INduced	I-MED
Pd	I-MED
/	I-MED
Pa	I-MED
RaTiO	I-MED
in	O
Predicting	O
FFR	B-MED
(	O
MEMENTO	B-MED
-	O
FFR	B-MED
)	O
Study	B-MED
Adenosine	B-MED
administration	B-MED
is	O
needed	O
for	O
the	O
achievement	O
of	O
maximal	B-MED
hyperaemia	B-MED
fractional	B-MED
flow	I-MED
reserve	I-MED
(	O
FFR	B-MED
)	O
assessment	B-MED
.	O
The	O
objective	O
was	O
to	O
test	O
the	O
accuracy	B-MED
of	O
Pd	B-MED
/	O
Pa	B-MED
ratio	B-MED
registered	O
during	O
submaximal	B-MED
hyperaemia	B-MED
induced	O
by	O
non	B-MED
-	I-MED
ionic	I-MED
contrast	I-MED
medium	I-MED
(	O
contrast	B-MED
FFR	I-MED
[	O
cFFR	B-MED
]	O
)	O
in	O
predicting	O
FFR	B-MED
and	O
comparing	O
it	O
to	O
the	O
performance	O
of	O
resting	B-MED
Pd	B-MED
/	O
Pa	B-MED
in	O
a	O
collaborative	B-MED
registry	O
of	O
926	O
patients	B-MED
enrolled	O
in	O
10	O
hospitals	B-MED
from	O
four	B-MED
European	B-MED
countries	I-MED
(	O
Italy	B-MED
,	O
Spain	B-MED
,	O
France	B-MED
and	O
Portugal	B-MED
)	O
.	O
Resting	B-MED
Pd	B-MED
/	O
Pa	B-MED
,	O
cFFR	B-MED
and	O
FFR	B-MED
were	O
measured	O
in	O
1,026	O
coronary	B-MED
stenoses	I-MED
functionally	B-MED
evaluated	O
using	O
commercially	O
available	O
pressure	B-MED
wires	I-MED
.	O
cFFR	B-MED
was	O
obtained	O
after	O
intracoronary	B-MED
injection	I-MED
of	O
contrast	B-MED
medium	I-MED
,	O
while	O
FFR	B-MED
was	O
measured	O
after	O
administration	B-MED
of	O
adenosine	B-MED
.	O
Resting	B-MED
Pd	B-MED
/	O
Pa	B-MED
and	O
cFFR	B-MED
were	O
significantly	O
higher	B-MED
than	O
FFR	B-MED
(	O
0.93±0.05	O
vs.	O
0.87±0.08	O
vs.	O
0.84±0.08	O
,	O
p<0.001	O
)	O
.	O
A	O
strong	O
correlation	B-MED
and	O
a	O
close	O
agreement	O
at	O
Bland	B-MED
-	I-MED
Altman	I-MED
analysis	I-MED
between	O
cFFR	B-MED
and	O
FFR	B-MED
were	O
observed	O
(	O
r=0.90	O
,	O
p<0.001	O
and	O
95	O
%	O
CI	B-MED
of	O
disagreement	O
:	O
from	O
-0.042	O
to	O
0.11	O
)	O
.	O
ROC	B-MED
curve	I-MED
analysis	B-MED
showed	O
an	O
excellent	O
accuracy	B-MED
(	O
89	O
%	O
)	O
of	O
the	O
cFFR	B-MED
cut	O
-	O
off	O
of	O
≤0.85	O
in	O
predicting	O
an	O
FFR	B-MED
value	O
≤0.80	O
(	O
AUC	O
0.95	O
[	O
95	O
%	O
CI	B-MED
:	O
0.94	O
-	O
0.96	O
]	O
)	O
,	O
significantly	O
better	O
than	O
that	O
observed	O
using	O
resting	B-MED
Pd	B-MED
/	O
Pa	B-MED
(	O
AUC	O
:	O
0.90	O
,	O
95	O
%	O
CI	B-MED
:	O
0.88	O
-	O
0.91	O
;	O
p<0.001	O
)	O
.	O
A	O
cFFR	B-MED
/	O
FFR	B-MED
hybrid	B-MED
approach	I-MED
showed	O
a	O
significantly	O
lower	B-MED
number	O
of	O
lesions	B-MED
requiring	O
adenosine	B-MED
than	O
a	O
resting	B-MED
Pd	B-MED
/	O
Pa	B-MED
/	O
FFR	B-MED
hybrid	B-MED
approach	I-MED
(	O
22	O
%	O
vs.	O
44	O
%	O
,	O
p<0.0001	O
)	O
.	O
cFFR	B-MED
is	O
accurate	B-MED
in	O
predicting	O
the	O
functional	B-MED
significance	O
of	O
coronary	B-MED
stenosis	I-MED
.	O
This	O
could	O
allow	O
limiting	O
the	O
use	O
of	O
adenosine	B-MED
to	O
obtain	O
FFR	B-MED
to	O
a	O
minority	O
of	O
stenoses	B-MED
with	O
considerable	O
savings	O
of	O
time	B-MED
and	O
costs	B-MED
.	O
The	O
Effects	B-MED
of	I-MED
Messages	B-MED
about	O
the	O
Causes	B-MED
of	O
Obesity	B-MED
on	O
Disciplinary	B-MED
Action	I-MED
Decisions	B-MED
for	O
Overweight	B-MED
Employees	B-MED
We	O
investigated	B-MED
the	O
impact	B-MED
of	O
messages	B-MED
about	O
the	O
causes	B-MED
of	O
obesity	B-MED
(	O
controllable	B-MED
or	O
uncontrollable	B-MED
)	O
on	O
the	O
disciplinary	B-MED
action	I-MED
consequences	B-MED
selected	O
for	O
obese	B-MED
employees	B-MED
in	O
response	B-MED
to	O
a	O
work	B-MED
-	I-MED
related	I-MED
mistake	B-MED
.	O
Participants	B-MED
read	O
about	O
either	O
the	O
controllable	B-MED
or	O
uncontrollable	B-MED
causes	B-MED
of	O
obesity	B-MED
before	O
reviewing	B-MED
an	O
ostensible	B-MED
employee	B-MED
file	B-MED
that	O
included	O
a	O
description	O
of	O
an	O
employee	B-MED
mistake	B-MED
.	O
Depending	O
on	O
condition	O
,	O
the	O
file	B-MED
contained	O
a	O
photo	B-MED
of	O
the	O
employee	B-MED
that	O
either	O
depicted	O
them	O
as	O
obese	B-MED
or	O
average	B-MED
weight	B-MED
.	O
Participants	B-MED
were	O
more	O
willing	O
to	O
withhold	B-MED
a	O
raise	O
or	O
promotion	B-MED
from	O
an	O
obese	B-MED
employee	B-MED
than	O
from	O
an	O
average	B-MED
-	O
weight	B-MED
employee	B-MED
.	O
Further	O
,	O
there	O
was	O
little	O
evidence	B-MED
that	O
the	O
messages	B-MED
about	O
the	O
causes	B-MED
of	O
obesity	B-MED
affected	B-MED
participants	B-MED
'	O
perceived	B-MED
control	I-MED
and	O
self	B-MED
-	I-MED
efficacy	I-MED
for	O
healthy	B-MED
behaviors	B-MED
.	O
AMPK	B-MED
-	O
autophagy	B-MED
inhibition	B-MED
sensitizes	O
icaritin	B-MED
-	O
induced	B-MED
anti	B-MED
-	I-MED
colorectal	I-MED
cancer	I-MED
cell	B-MED
activity	I-MED
The	O
current	B-MED
research	B-MED
studied	O
the	O
potential	B-MED
effect	I-MED
of	O
autophagy	B-MED
on	O
icaritin	B-MED
-	O
induced	B-MED
anti	B-MED
-	I-MED
colorectal	I-MED
cancer	I-MED
(	O
CRC	B-MED
)	O
cell	B-MED
activity	I-MED
.	O
Treatment	B-MED
of	O
icaritin	B-MED
in	O
both	O
primary	B-MED
and	O
established	B-MED
(	O
HT-29	B-MED
)	O
CRC	B-MED
cells	B-MED
induced	B-MED
feedback	B-MED
activation	I-MED
of	O
autophagy	B-MED
,	O
evidenced	O
by	O
p62	B-MED
degradation	B-MED
,	O
Beclin-1	B-MED
and	O
autophagy	B-MED
-	I-MED
related	I-MED
gene-5	I-MED
(	O
ATG-5	B-MED
)	O
upregulation	B-MED
,	O
as	O
well	O
as	O
light	B-MED
chain	I-MED
3B	I-MED
LC3B	B-MED
(	O
LC3B)-	O
GFP	B-MED
puncta	O
formation	B-MED
.	O
Pharmacological	B-MED
inhibiting	B-MED
of	O
autophagy	B-MED
dramatically	O
potentiated	O
icaritin	B-MED
-	O
induced	B-MED
CRC	B-MED
cell	B-MED
death	I-MED
and	O
apoptosis	B-MED
.	O
Meanwhile	O
,	O
shRNA	B-MED
-mediated	O
knockdown	B-MED
of	O
Beclin-1	B-MED
or	O
ATG-5	B-MED
also	O
sensitized	O
icaritin	B-MED
-	O
induced	B-MED
CRC	B-MED
cell	B-MED
death	I-MED
and	O
apoptosis	B-MED
.	O
Icaritin	B-MED
activated	B-MED
AMP	B-MED
-	I-MED
activated	I-MED
protein	I-MED
kinase	I-MED
(	O
AMPK	B-MED
)	O
signaling	B-MED
in	O
CRC	B-MED
cells	B-MED
,	O
functioning	B-MED
as	O
the	O
upstream	O
signaling	B-MED
for	O
autophagy	B-MED
activation	B-MED
.	O
shRNA	B-MED
/	O
siRNA	B-MED
-mediated	O
knockdown	B-MED
of	O
AMPKα1	B-MED
inhibited	B-MED
icaritin	B-MED
-	O
induced	B-MED
autophagy	B-MED
activation	B-MED
,	O
but	O
exacerbated	B-MED
CRC	B-MED
cell	B-MED
death	I-MED
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
AMPK	B-MED
activator	O
compound	B-MED
13	I-MED
(	O
C13	B-MED
)	O
or	O
the	O
autophagy	B-MED
activator	O
MHY1485	B-MED
attenuated	B-MED
icaritin	B-MED
-	O
induced	B-MED
cytotoxicity	B-MED
.	O
In	O
nude	B-MED
mice	I-MED
,	O
icaritin	B-MED
(	O
oral	B-MED
administration	I-MED
administration)-	O
induced	B-MED
HT-29	B-MED
tumor	B-MED
growth	I-MED
inhibition	B-MED
was	O
potentiated	O
when	O
combined	O
with	O
AMPKα1	B-MED
shRNA	B-MED
knockdown	B-MED
in	O
tumors	B-MED
.	O
We	O
conclude	O
that	O
feedback	B-MED
activation	I-MED
of	O
AMPK	B-MED
-	O
autophagy	B-MED
pathway	B-MED
could	O
be	O
a	O
primary	O
resistance	B-MED
factor	B-MED
of	O
icaritin	B-MED
.	O
A	O
miniature	O
bird	B-MED
-borne	O
passive	B-MED
air	I-MED
sampler	I-MED
for	O
monitoring	B-MED
halogenated	B-MED
flame	I-MED
retardants	I-MED
Birds	B-MED
have	O
been	O
used	O
intensively	O
as	O
biomonitors	B-MED
of	O
halogenated	B-MED
flame	I-MED
retardants	I-MED
(	O
HFRs	B-MED
)	O
,	O
and	O
several	O
studies	B-MED
have	O
reported	O
elevated	O
tissue	B-MED
concentrations	B-MED
and	O
inter-	O
individual	B-MED
variability	B-MED
for	O
these	O
contaminants	B-MED
.	O
While	O
diet	B-MED
is	O
known	O
to	O
be	O
an	O
important	O
exposure	B-MED
pathway	B-MED
for	O
HFRs	B-MED
in	O
birds	B-MED
,	O
it	O
has	O
been	O
suggested	B-MED
that	O
exposure	B-MED
through	O
air	B-MED
may	O
represent	B-MED
an	O
underestimated	O
source	B-MED
of	O
HFRs	B-MED
for	O
certain	O
species	B-MED
.	O
However	O
,	O
a	O
method	B-MED
was	O
not	B-MED
available	I-MED
for	O
measuring	B-MED
the	O
atmospheric	B-MED
exposure	B-MED
of	O
individual	B-MED
birds	B-MED
to	O
HFRs	B-MED
or	O
other	O
semi	B-MED
-	I-MED
volatile	I-MED
contaminants	B-MED
.	O
The	O
goal	B-MED
of	O
this	O
study	B-MED
was	O
to	O
develop	O
a	O
bird	B-MED
-borne	O
passive	B-MED
air	I-MED
sampler	I-MED
(	O
PAS	B-MED
)	O
enabling	O
the	O
determination	B-MED
of	O
individual	B-MED
atmospheric	B-MED
exposure	B-MED
to	O
gas	B-MED
-	O
and	O
particle	B-MED
-	I-MED
phase	I-MED
HFRs	B-MED
using	O
the	O
ring	B-MED
-	I-MED
billed	I-MED
gull	I-MED
(	O
Larus	B-MED
delawarensis	I-MED
)	O
nesting	B-MED
in	O
the	O
Montreal	B-MED
area	I-MED
(	O
QC	B-MED
,	O
Canada	B-MED
)	O
.	O
The	O
new	O
miniaturized	O
elliptical	B-MED
-	I-MED
shaped	I-MED
PAS	B-MED
(	O
mean	B-MED
weight	I-MED
:	O
2.72	O
g	O
)	O
was	O
tested	B-MED
using	O
two	B-MED
sorbent	I-MED
types	I-MED
during	O
three	O
exposure	B-MED
periods	I-MED
(	O
one	O
,	O
two	O
and	O
three	O
weeks	O
)	O
.	O
Results	B-MED
showed	O
that	O
PAS	B-MED
using	O
polyurethane	B-MED
foam	I-MED
(	O
PUF	B-MED
)	O
combined	O
with	O
a	O
glass	B-MED
fiber	I-MED
filter	B-MED
collected	I-MED
all	O
major	O
polybrominated	B-MED
diphenyl	I-MED
ethers	I-MED
(	O
PBDEs	B-MED
)	O
and	O
exhibited	O
better	B-MED
performance	I-MED
for	O
collecting	B-MED
highly	B-MED
hydrophobic	I-MED
DecaBDE	B-MED
mixture	B-MED
congeners	B-MED
compared	B-MED
to	I-MED
the	O
PAS	B-MED
using	O
polydimethylsiloxane	B-MED
(	O
PDMS	B-MED
)	O
.	O
Emerging	O
HFRs	B-MED
including	O
hexabromobenzene	B-MED
,	O
Dechlorane	B-MED
604	I-MED
Component	I-MED
B	I-MED
,	O
and	O
Dechlorane	B-MED
plus	I-MED
(	O
DP	B-MED
)	O
isomers	B-MED
also	O
were	O
sampled	B-MED
by	O
the	O
PUF	B-MED
-based	O
PAS	B-MED
.	O
Sampling	B-MED
rates	B-MED
for	O
most	O
HFRs	B-MED
were	O
comparable	B-MED
between	O
the	O
three	O
exposure	B-MED
periods	I-MED
.	O
This	O
novel	O
bird	B-MED
-borne	O
PAS	B-MED
provides	O
valuable	B-MED
information	I-MED
on	O
the	O
non	B-MED
-	I-MED
dietary	I-MED
exposure	I-MED
of	O
free	B-MED
-	I-MED
ranging	I-MED
birds	B-MED
to	O
HFRs	B-MED
.	O
The	O
use	B-MED
of	I-MED
Oxford	B-MED
Nanopore	I-MED
native	B-MED
barcoding	B-MED
for	O
complete	B-MED
genome	B-MED
assembly	I-MED
The	O
Oxford	B-MED
Nanopore	I-MED
Technologies	I-MED
MinION(TM	B-MED
)	I-MED
is	O
a	O
mobile	B-MED
DNA	O
sequencer	O
that	O
can	O
produce	O
long	B-MED
read	I-MED
sequences	I-MED
with	O
a	O
short	O
turn	B-MED
-	I-MED
around	I-MED
time	I-MED
.	O
Here	O
we	O
report	B-MED
the	O
first	O
demonstration	O
of	O
single	B-MED
contig	I-MED
genome	I-MED
assembly	I-MED
using	B-MED
Oxford	B-MED
Nanopore	I-MED
native	B-MED
barcoding	B-MED
when	O
applied	B-MED
to	O
a	O
multiplexed	B-MED
library	I-MED
of	O
12	O
samples	B-MED
and	O
combined	B-MED
with	O
existing	B-MED
Illumina	O
short	B-MED
-	I-MED
read	I-MED
data	I-MED
.	O
This	O
paves	O
the	O
way	O
for	O
the	O
closure	B-MED
of	O
multiple	B-MED
bacterial	B-MED
genomes	I-MED
from	O
a	O
single	B-MED
MinION(TM	B-MED
)	I-MED
sequencing	B-MED
run	B-MED
,	O
given	O
the	O
availability	B-MED
of	I-MED
existing	B-MED
short	B-MED
-	I-MED
read	I-MED
data	I-MED
.	O
The	O
strain	B-MED
we	O
used	B-MED
,	O
MHO_001	B-MED
,	O
represents	O
the	O
important	O
community	O
-	O
acquired	O
methicillin	B-MED
resistant	I-MED
Staphylococcus	B-MED
aureus	I-MED
lineage	O
USA300	B-MED
.	O
Using	B-MED
a	O
hybrid	O
assembly	B-MED
of	O
existing	B-MED
short	B-MED
read	I-MED
and	O
barcoded	B-MED
long	I-MED
read	I-MED
sequences	I-MED
from	O
multiplexed	B-MED
data	I-MED
,	O
we	O
completed	O
a	O
genome	B-MED
of	O
the	O
S.	B-MED
aureus	I-MED
USA300	B-MED
strain	I-MED
MHO_001	I-MED
.	O
The	O
long	B-MED
-	I-MED
read	I-MED
data	I-MED
represented	O
only	O
~5	O
-	O
10	O
%	O
of	O
an	O
average	B-MED
MinION(TM	B-MED
)	I-MED
run	B-MED
(	O
~7x	O
genomic	B-MED
coverage	B-MED
)	O
,	O
but	O
,	O
using	B-MED
standard	B-MED
tools	B-MED
,	O
this	O
was	O
sufficient	B-MED
to	O
complete	B-MED
the	O
circular	B-MED
chromosome	I-MED
of	O
S.	B-MED
aureus	I-MED
strain	B-MED
MHO_001	I-MED
(	O
2.86	O
Mb	O
)	O
and	O
two	O
complete	B-MED
plasmids	B-MED
(	O
27	O
Kb	O
and	O
3	O
Kb	O
)	O
.	O
Minor	B-MED
differences	B-MED
were	O
noted	B-MED
when	O
compared	B-MED
to	O
USA300	B-MED
reference	O
genome	B-MED
,	O
USA300_FPR3757	B-MED
,	O
including	B-MED
the	O
translocation	B-MED
,	O
loss	B-MED
and	O
gain	B-MED
of	O
mobile	B-MED
genetic	I-MED
elements	I-MED
.	O
Here	O
we	O
demonstrate	O
that	O
MinION(TM	B-MED
)	I-MED
reads	B-MED
,	O
multiplexed	B-MED
using	B-MED
native	B-MED
barcoding	B-MED
,	O
can	O
be	O
used	B-MED
in	O
combination	B-MED
with	O
short	B-MED
-	I-MED
read	I-MED
data	I-MED
,	O
to	O
fully	O
complete	B-MED
a	O
bacterial	B-MED
genome	I-MED
.	O
The	O
ability	O
to	O
complete	B-MED
multiple	B-MED
genomes	B-MED
,	O
for	O
which	O
short	B-MED
-	I-MED
read	I-MED
data	I-MED
is	O
already	O
available	B-MED
,	O
from	O
a	O
single	B-MED
MinION(TM	B-MED
)	I-MED
run	B-MED
is	O
set	O
to	O
impact	B-MED
on	O
our	O
understanding	B-MED
of	O
accessory	B-MED
genome	B-MED
content	I-MED
,	O
plasmid	B-MED
diversity	B-MED
and	O
genome	B-MED
rearrangements	B-MED
.	O
Risk	B-MED
factors	I-MED
for	O
hepatitis	B-MED
C	I-MED
virus	I-MED
infection	I-MED
in	O
the	O
Colombian	B-MED
Caribbean	B-MED
coast	I-MED
:	O
A	O
case	B-MED
-	I-MED
control	I-MED
study	I-MED
An	O
estimated	O
6.8	O
-	O
8.9	O
million	B-MED
people	B-MED
are	O
infected	B-MED
with	O
hepatitis	B-MED
C	I-MED
virus	I-MED
in	O
Latin	B-MED
America	I-MED
,	O
of	O
which	O
less	B-MED
than	I-MED
1	O
%	O
receives	O
antiviral	B-MED
treatment	I-MED
.	O
Studies	B-MED
so	O
far	O
in	O
Colombia	B-MED
have	O
attempted	B-MED
to	O
determine	O
the	O
prevalence	B-MED
of	O
the	O
disease	B-MED
in	O
some	O
risk	B-MED
groups	B-MED
,	O
thus	O
preventing	B-MED
the	O
identification	B-MED
of	O
other	O
factors	B-MED
potentially	B-MED
involved	O
in	O
the	O
spread	O
of	O
the	O
infection	B-MED
.	O
To	O
identify	B-MED
traditional	O
and	O
non	O
-	O
traditional	O
risk	B-MED
factors	I-MED
for	O
chronic	B-MED
hepatitis	I-MED
C	I-MED
in	O
the	O
Colombian	B-MED
Caribbean	B-MED
coast	I-MED
.	O
This	O
was	O
a	O
case	B-MED
-	I-MED
control	I-MED
study	I-MED
(	O
1:3	O
)	O
matched	O
by	O
health	B-MED
care	I-MED
provider	I-MED
and	O
age	B-MED
(	O
±	O
10	O
years	B-MED
)	O
conducted	O
at	O
the	O
primary	B-MED
care	I-MED
level	I-MED
of	O
gastroenterology	B-MED
and	O
hepatology	B-MED
outpatient	B-MED
services	I-MED
.	O
All	O
patients	B-MED
with	O
a	O
positive	B-MED
ELISA	B-MED
underwent	O
a	O
confirmatory	B-MED
viral	B-MED
load	I-MED
test	I-MED
.	O
A	O
multivariate	B-MED
logistic	I-MED
regression	I-MED
analysis	I-MED
identified	B-MED
the	O
independent	B-MED
predictors	I-MED
of	O
infection	B-MED
.	O
Blood	B-MED
transfusion	I-MED
(	O
OR	B-MED
=	O
159.2	O
;	O
95	O
%	O
CI	B-MED
:	O
35.4	O
-	O
715	O
;	O
p<0.001	O
)	O
and	O
history	B-MED
of	I-MED
hospitalization	I-MED
before	O
1994	O
(	O
OR	B-MED
=	O
4.7	O
;	O
95	O
%	O
CI	B-MED
:	O
1.3	O
-	O
17.1	O
;	O
p=0.018	O
)	O
were	O
identified	B-MED
as	O
the	O
only	O
two	O
independent	B-MED
predictors	I-MED
of	O
infection	B-MED
.	O
It	O
is	O
necessary	O
to	O
check	O
the	O
reproducibility	B-MED
of	I-MED
these	I-MED
results	I-MED
and	O
to	O
conduct	O
cost	B-MED
-	I-MED
effectiveness	I-MED
studies	B-MED
before	O
recommending	B-MED
their	O
use	B-MED
in	O
the	O
design	B-MED
of	O
new	B-MED
screening	I-MED
strategies	I-MED
.	O
Acute	B-MED
Kidney	I-MED
Injury	I-MED
Severity	B-MED
and	O
Long	B-MED
-	I-MED
Term	I-MED
Readmission	B-MED
and	O
Mortality	B-MED
After	O
Cardiac	B-MED
Surgery	I-MED
Acute	B-MED
kidney	I-MED
injury	I-MED
(	O
AKI	B-MED
)	O
is	O
a	O
common	O
complication	B-MED
after	O
cardiac	B-MED
surgery	I-MED
.	O
While	O
AKI	B-MED
severity	B-MED
is	O
known	O
to	O
be	O
associated	B-MED
with	I-MED
increased	O
risk	B-MED
of	O
short	B-MED
-	I-MED
term	I-MED
outcomes	O
,	O
its	O
long	B-MED
-	I-MED
term	I-MED
impact	O
is	O
less	O
well	O
understood	O
.	O
Adult	O
patients	B-MED
undergoing	O
isolated	O
coronary	B-MED
artery	I-MED
bypass	I-MED
graft	I-MED
surgery	I-MED
at	O
eight	O
centers	O
were	O
enrolled	O
into	O
the	O
Northern	B-MED
New	I-MED
England	I-MED
biomarker	I-MED
registry	I-MED
(	O
n	O
=	O
1,610	O
)	O
.	O
Patients	B-MED
were	O
excluded	O
if	O
they	O
had	O
renal	B-MED
failure	I-MED
(	O
n	O
=	O
15	O
)	O
or	O
died	B-MED
during	O
index	B-MED
admission	I-MED
(	O
n	O
=	O
38	O
)	O
.	O
Severity	B-MED
of	O
AKI	B-MED
was	O
defined	O
using	O
the	O
Acute	B-MED
Kidney	I-MED
Injury	I-MED
Network	I-MED
(	O
AKIN	B-MED
)	O
.	O
We	O
linked	O
our	O
cohort	B-MED
to	O
national	B-MED
Medicare	I-MED
and	O
state	B-MED
all	I-MED
-	I-MED
payer	I-MED
claims	I-MED
to	O
ascertain	O
readmissions	B-MED
and	O
to	O
the	O
National	B-MED
Death	I-MED
Index	I-MED
to	O
ascertain	O
survival	B-MED
.	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
and	O
multivariate	B-MED
Cox	I-MED
proportional	I-MED
hazards	I-MED
modeling	I-MED
was	O
conducted	O
for	O
time	O
to	O
readmission	B-MED
and	O
death	B-MED
over	O
5	O
years	O
.	O
Within	O
5	O
years	O
,	O
513	O
patients	B-MED
(	O
33.8	O
%	O
)	O
had	O
AKI	B-MED
with	O
AKIN	B-MED
stage	O
1	O
(	O
29.9	O
%	O
)	O
and	O
stage	O
2	O
to	O
3	O
(	O
3.9	O
%	O
)	O
.	O
There	O
were	O
620	O
readmissions	B-MED
(	O
39.9	O
%	O
)	O
and	O
370	O
deaths	B-MED
(	O
23.8	O
%	O
)	O
.	O
After	O
adjustment	O
,	O
stage	O
1	O
AKI	B-MED
patients	B-MED
had	O
a	O
31	O
%	O
increased	O
risk	B-MED
of	O
readmission	B-MED
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
:	O
1.10	O
to	O
1.57	O
)	O
,	O
whereas	O
stage	O
2	O
or	O
3	O
patients	B-MED
had	O
a	O
98	O
%	O
increased	O
risk	B-MED
(	O
95	O
%	O
CI	B-MED
:	O
1.41	O
to	O
2.78	O
)	O
compared	O
with	O
patients	B-MED
having	O
no	B-MED
AKI	B-MED
.	O
Relative	O
to	O
patients	B-MED
without	O
AKI	B-MED
,	O
stage	O
1	O
patients	B-MED
had	O
a	O
56	O
%	O
increased	O
risk	B-MED
of	O
mortality	B-MED
(	O
95	O
%	O
CI	B-MED
:	O
1.14	O
to	O
2.13	O
)	O
,	O
whereas	O
stage	O
2	O
or	O
3	O
patients	B-MED
had	O
a	O
3.5	O
times	O
higher	O
risk	B-MED
(	O
95	O
%	O
CI	B-MED
:	O
2.16	O
to	O
5.60	O
)	O
.	O
Severity	B-MED
of	O
AKI	B-MED
using	O
the	O
AKIN	B-MED
stage	O
criteria	O
is	O
associated	B-MED
with	I-MED
a	O
significantly	O
increased	O
risk	B-MED
of	O
5	O
-	O
year	O
readmission	B-MED
and	O
mortality	B-MED
.	O
Our	O
findings	O
suggest	O
that	O
efforts	O
to	O
reduce	O
AKI	B-MED
in	O
the	O
perioperative	B-MED
period	I-MED
may	O
have	O
a	O
significant	O
long	B-MED
-	I-MED
term	I-MED
impact	O
on	O
patients	B-MED
and	O
payers	O
in	O
reducing	O
mortality	B-MED
and	O
health	B-MED
care	I-MED
utilization	I-MED
.	O
Punch	B-MED
injury	B-MED
self	B-MED
-	I-MED
harm	I-MED
in	O
young	B-MED
people	I-MED
Punch	B-MED
injuries	B-MED
are	O
a	O
form	B-MED
of	O
self	B-MED
-	I-MED
harm	I-MED
characterised	B-MED
by	O
the	O
intentional	B-MED
act	B-MED
of	I-MED
striking	I-MED
an	O
object	B-MED
with	O
a	O
closed	B-MED
fist	B-MED
.	O
We	O
aimed	B-MED
to	O
describe	O
the	O
characteristics	B-MED
and	O
trends	B-MED
in	O
young	B-MED
people	I-MED
presenting	B-MED
with	O
injuries	B-MED
sustained	B-MED
via	O
the	O
punch	B-MED
mechanism	B-MED
.	O
A	O
comprehensive	B-MED
retrospective	B-MED
review	I-MED
of	O
medical	B-MED
records	I-MED
was	O
completed	B-MED
of	O
all	O
young	B-MED
people	I-MED
aged	B-MED
10	O
-	O
18	O
years	B-MED
presenting	B-MED
to	O
our	O
Central	B-MED
London	I-MED
Emergency	I-MED
Department	I-MED
over	O
a	O
12	B-MED
-	I-MED
month	I-MED
period	I-MED
.	O
A	O
subset	B-MED
of	I-MED
the	I-MED
total	I-MED
group	I-MED
was	O
identified	B-MED
as	O
the	O
punch	B-MED
injury	B-MED
subgroup	B-MED
.	O
A	O
total	O
of	O
78	O
punch	B-MED
injury	B-MED
presentations	B-MED
were	O
identified	B-MED
.	O
In	O
this	O
subgroup	B-MED
,	O
the	O
male	B-MED
:	O
female	B-MED
ratio	B-MED
is	O
4.57:1	O
;	O
37.18	O
%	O
of	O
presentations	B-MED
were	O
associated	B-MED
with	I-MED
a	O
fracture	B-MED
(	O
n	O
=	O
29	O
)	O
and	O
35.90	O
%	O
(	O
n	O
=	O
28	O
)	O
of	O
patients	B-MED
re	B-MED
-	I-MED
presented	I-MED
following	O
another	O
punch	B-MED
injury	B-MED
,	O
as	O
a	O
victim	B-MED
of	I-MED
violence	I-MED
,	O
or	O
by	O
other	O
psychiatric	B-MED
presentation	B-MED
.	O
In	O
conclusion	B-MED
,	O
a	O
male	B-MED
preponderance	I-MED
was	O
observed	B-MED
,	O
with	O
frequent	B-MED
re	B-MED
-	I-MED
presentations	I-MED
,	O
often	O
in	O
high	B-MED
-	I-MED
risk	I-MED
circumstances	B-MED
.	O
An	O
opportunity	O
for	O
screening	B-MED
,	O
including	O
mental	B-MED
health	I-MED
,	O
social	B-MED
and	O
substance	B-MED
misuse	I-MED
,	O
was	O
identified	B-MED
.	O
Further	O
research	B-MED
is	O
needed	B-MED
to	O
enable	O
targeted	B-MED
effective	B-MED
interventions	B-MED
in	O
this	O
group	B-MED
.	O
Measure	B-MED
Up	I-MED
Pressure	I-MED
Down	I-MED
:	I-MED
Provider	I-MED
Toolkit	I-MED
to	O
Improve	B-MED
Hypertension	B-MED
Control	B-MED
Hypertension	B-MED
is	O
one	O
of	O
the	O
most	O
important	O
risk	B-MED
factors	I-MED
for	O
heart	B-MED
disease	I-MED
,	O
stroke	B-MED
,	O
kidney	B-MED
failure	I-MED
,	O
and	O
diabetes	B-MED
complications	I-MED
.	O
Nearly	O
one	O
in	O
three	O
Americans	B-MED
adults	B-MED
has	O
high	B-MED
blood	I-MED
pressure	I-MED
,	O
and	O
the	O
cost	B-MED
associated	B-MED
with	I-MED
treating	B-MED
this	O
condition	B-MED
is	O
staggering	O
.	O
The	O
Measure	B-MED
Up	I-MED
Pressure	I-MED
Down	I-MED
:	I-MED
Provider	I-MED
Toolkit	I-MED
to	O
Improve	B-MED
Hypertension	B-MED
Control	B-MED
is	O
a	O
resource	B-MED
developed	B-MED
by	O
the	O
American	B-MED
Medical	I-MED
Group	I-MED
Foundation	I-MED
in	O
partnership	B-MED
with	O
the	O
American	B-MED
Medical	I-MED
Group	I-MED
Association	I-MED
.	O
The	O
goal	B-MED
of	O
this	O
toolkit	B-MED
is	O
to	O
mobilize	O
health	B-MED
care	I-MED
practitioners	I-MED
to	O
work	B-MED
together	B-MED
through	O
team	B-MED
-based	O
approaches	O
to	O
achieve	O
an	O
80	O
%	O
control	B-MED
rate	B-MED
of	O
high	B-MED
blood	I-MED
pressure	I-MED
among	O
their	O
patient	B-MED
population	I-MED
.	O
The	O
toolkit	B-MED
can	O
be	O
used	O
by	O
health	B-MED
educators	I-MED
,	O
clinic	B-MED
administrators	I-MED
,	O
physicians	B-MED
,	O
students	B-MED
,	O
and	O
other	O
clinic	B-MED
staff	I-MED
as	O
a	O
step	O
-	O
by	O
-	O
step	O
resource	B-MED
for	O
developing	B-MED
the	O
infrastructure	B-MED
needed	O
to	O
better	O
identify	O
and	O
treat	B-MED
individuals	B-MED
with	O
high	B-MED
blood	I-MED
pressure	I-MED
or	O
other	O
chronic	B-MED
conditions	I-MED
.	I-MED
Leonurine	B-MED
Attenuates	B-MED
Hyperalgesia	B-MED
in	O
Mice	B-MED
with	O
Induced	B-MED
Adenomyosis	B-MED
BACKGROUND	O
Adenomyosis	B-MED
,	O
defined	O
as	O
the	O
invasion	B-MED
of	O
endometrial	B-MED
glands	I-MED
and	O
stroma	B-MED
into	O
the	O
myometrium	B-MED
,	O
is	O
a	O
common	B-MED
gynecological	B-MED
disorder	I-MED
.	O
In	O
the	O
present	O
study	O
we	O
report	B-MED
on	O
the	O
effect	B-MED
of	O
leonurine	B-MED
on	O
ICR	B-MED
mice	I-MED
with	O
adenomyosis	B-MED
induced	B-MED
by	O
neonatal	B-MED
tamoxifen	B-MED
.	O
MATERIAL	O
AND	O
METHODS	O
After	O
being	O
treated	B-MED
with	O
tamoxifen	B-MED
for	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
,	O
we	O
assessed	B-MED
body	B-MED
weight	I-MED
and	O
pain	B-MED
modulation	O
in	O
mice	B-MED
in	O
hotplate	B-MED
tests	B-MED
.	O
The	O
mice	B-MED
were	O
divided	B-MED
into	O
5	O
groups	B-MED
:	O
a	O
low	B-MED
-	I-MED
dose	I-MED
leonurine	B-MED
treatment	B-MED
group	B-MED
,	O
a	O
high	B-MED
-	I-MED
dose	I-MED
leonurine	B-MED
treatment	B-MED
group	B-MED
,	O
a	O
valproic	B-MED
acid	I-MED
(	O
VPA	B-MED
)	O
treatment	B-MED
group	B-MED
,	O
a	O
vehicle	B-MED
only	B-MED
treatment	B-MED
group	B-MED
,	O
and	O
a	O
blank	B-MED
control	B-MED
group	I-MED
.	O
We	O
evaluated	B-MED
body	B-MED
weight	I-MED
,	O
pain	O
modulation	O
in	O
hotplate	B-MED
tests	B-MED
,	O
and	O
the	O
depth	B-MED
of	O
myometrial	B-MED
infiltration	B-MED
.	O
Immunoreactivity	B-MED
staining	B-MED
of	O
progesterone	B-MED
receptor	I-MED
(	O
PR	B-MED
)	O
,	O
nuclear	B-MED
factor	I-MED
-	I-MED
κB	I-MED
phosphorylated	I-MED
-	I-MED
p65	I-MED
(	O
p	B-MED
-	I-MED
p65	I-MED
)	O
,	O
cyclooxygenase-2	B-MED
(	O
COX-2	B-MED
)	O
,	O
and	O
oxytocin	B-MED
receptor	I-MED
(	O
OTR	B-MED
)	O
was	O
evaluated	B-MED
by	O
immunohistochemistry	B-MED
.	O
RESULTS	O
The	O
measurement	B-MED
of	O
the	O
body	B-MED
weight	I-MED
,	O
myometrial	B-MED
infiltration	B-MED
,	O
and	O
pain	O
modulation	O
showed	O
that	O
neonatal	B-MED
tamoxifen	B-MED
treatment	B-MED
led	O
to	O
adenomyosis	B-MED
.	O
Leonurine	B-MED
treatment	B-MED
appeared	O
to	O
decrease	B-MED
hyperalgesia	B-MED
and	O
myometrial	B-MED
infiltration	B-MED
.	O
Immunoreactivity	B-MED
staining	B-MED
showed	O
decreased	B-MED
p	B-MED
-	I-MED
p65	I-MED
,	O
COX-2	B-MED
,	O
and	O
OTR	B-MED
protein	B-MED
expressions	I-MED
.	O
CONCLUSIONS	O
Our	O
results	O
indicate	O
that	O
leonurine	B-MED
attenuates	B-MED
hyperalgesia	B-MED
in	O
mice	B-MED
with	O
induced	B-MED
adenomyosis	B-MED
via	O
down	B-MED
-	I-MED
regulating	I-MED
expressions	B-MED
of	O
p	B-MED
-	I-MED
P65	I-MED
,	O
COX-2	B-MED
,	O
and	O
OTR	B-MED
,	O
and	O
could	O
be	O
beneficial	O
for	O
treating	B-MED
adenomyosis	B-MED
.	O
Zebrafish	B-MED
adult	B-MED
pigment	I-MED
stem	I-MED
cells	I-MED
are	O
multipotent	B-MED
and	O
form	B-MED
pigment	I-MED
cells	I-MED
by	O
a	O
progressive	B-MED
fate	B-MED
restriction	I-MED
process	I-MED
:	O
Clonal	B-MED
analysis	I-MED
identifies	B-MED
shared	O
origin	O
of	O
all	O
pigment	B-MED
cell	I-MED
types	I-MED
Skin	B-MED
pigment	I-MED
pattern	B-MED
formation	I-MED
is	O
a	O
paradigmatic	B-MED
example	O
of	O
pattern	B-MED
formation	I-MED
.	O
In	O
zebrafish	B-MED
,	O
the	O
adult	B-MED
body	B-MED
stripes	I-MED
are	O
generated	B-MED
by	O
coordinated	B-MED
rearrangement	B-MED
of	O
three	B-MED
distinct	O
pigment	B-MED
cell	I-MED
-	I-MED
types	I-MED
,	O
black	B-MED
melanocytes	B-MED
,	O
shiny	B-MED
iridophores	B-MED
and	O
yellow	B-MED
xanthophores	B-MED
.	O
A	O
stem	B-MED
cell	I-MED
origin	I-MED
of	O
melanocytes	B-MED
and	O
iridophores	B-MED
has	O
been	O
proposed	O
although	O
the	O
potency	B-MED
of	O
those	O
stem	B-MED
cells	I-MED
has	O
remained	B-MED
unclear	B-MED
.	O
Xanthophores	B-MED
,	O
however	O
,	O
seemed	O
to	O
originate	O
predominantly	B-MED
from	O
proliferation	B-MED
of	O
embryonic	B-MED
xanthophores	B-MED
.	O
Now	O
,	O
data	B-MED
from	O
Singh	O
et	O
al	O
.	O
shows	O
that	O
all	O
three	B-MED
cell	B-MED
-	I-MED
types	I-MED
derive	B-MED
from	O
shared	O
stem	B-MED
cells	I-MED
,	O
and	O
that	O
these	O
cells	B-MED
generate	B-MED
peripheral	B-MED
neural	B-MED
cell	I-MED
-	I-MED
types	I-MED
too	O
.	O
Furthermore	O
,	O
clonal	B-MED
compositions	B-MED
are	O
best	O
explained	O
by	O
a	O
progressive	B-MED
fate	B-MED
restriction	I-MED
model	I-MED
generating	B-MED
the	O
individual	B-MED
cell	B-MED
-	I-MED
types	I-MED
.	O
The	O
numbers	B-MED
of	O
adult	B-MED
pigment	I-MED
stem	I-MED
cells	I-MED
associated	B-MED
with	I-MED
the	O
dorsal	B-MED
root	I-MED
ganglia	I-MED
remain	B-MED
low	B-MED
,	O
but	O
progenitor	B-MED
numbers	B-MED
increase	B-MED
significantly	O
during	B-MED
larval	B-MED
development	I-MED
up	O
to	O
metamorphosis	B-MED
,	O
likely	O
via	O
production	O
of	O
partially	B-MED
restricted	B-MED
progenitors	B-MED
on	O
the	O
spinal	B-MED
nerves	I-MED
.	O
Trump	B-MED
's	I-MED
got	O
the	O
right	B-MED
idea	I-MED
I	O
am	O
a	O
US	B-MED
nursing	B-MED
student	I-MED
and	O
feel	B-MED
that	O
Obamacare	B-MED
is	O
a	O
bad	B-MED
idea	I-MED
.	O
I	O
'm	O
disappointed	B-MED
that	O
President	B-MED
Trump	B-MED
was	O
not	B-MED
able	I-MED
to	I-MED
get	I-MED
rid	I-MED
of	I-MED
it	O
last	B-MED
month	I-MED
.	O
Evidence	O
that	O
vitronectin	B-MED
is	O
a	O
potent	O
migration	B-MED
-	I-MED
enhancing	I-MED
factor	I-MED
for	O
cancer	B-MED
cells	I-MED
chaperoned	B-MED
by	O
fibrinogen	B-MED
:	O
a	O
novel	O
view	O
of	O
the	O
metastasis	B-MED
of	O
cancer	B-MED
cells	I-MED
to	O
low-	O
fibrinogen	B-MED
lymphatics	B-MED
and	O
body	B-MED
cavities	I-MED
Diluted	B-MED
(	O
1	O
%	O
)	O
plasma	B-MED
induces	O
migration	B-MED
of	O
malignant	B-MED
cell	I-MED
lines	I-MED
much	O
more	O
strongly	O
than	O
potent	O
pro	B-MED
-	I-MED
metastatic	I-MED
factors	I-MED
.	O
To	O
characterize	O
the	O
factor(s	B-MED
)	I-MED
present	O
in	O
diluted	B-MED
plasma	B-MED
responsible	O
for	O
this	O
phenomenon	B-MED
we	O
performed	O
i	O
)	O
heat	B-MED
inactivation	B-MED
,	O
ii	O
)	O
dialysis	B-MED
,	O
iii	O
)	O
proteinase	B-MED
K	I-MED
treatment	B-MED
,	O
and	O
iv	O
)	O
molecular	B-MED
size	I-MED
filtration	I-MED
studies	I-MED
.	O
We	O
found	O
that	O
this	O
remarkable	O
pro	B-MED
-	I-MED
migratory	I-MED
activity	I-MED
of	O
diluted	B-MED
normal	O
plasma	B-MED
is	O
associated	O
with	O
a	O
~50	O
-	O
100	O
-	O
kD	O
protein	B-MED
that	O
interacts	O
with	O
GαI	B-MED
protein	I-MED
-	I-MED
coupled	I-MED
receptors	I-MED
and	O
activates	O
p42/44	B-MED
MAPK	I-MED
and	O
AKT	B-MED
signaling	I-MED
in	O
target	O
cells	B-MED
.	O
Since	O
this	O
pro	B-MED
-	I-MED
migratory	I-MED
activity	I-MED
of	O
1	O
%	O
plasma	B-MED
decreases	O
at	O
higher	O
plasma	B-MED
concentrations	I-MED
(	O
>	O
20	O
%	O
)	O
,	O
but	O
is	O
retained	O
in	O
serum	B-MED
,	O
we	O
hypothesized	O
that	O
fibrinogen	B-MED
may	O
be	O
involved	O
as	O
a	O
chaperone	B-MED
of	O
the	O
protein(s	B-MED
)	I-MED
.	O
To	O
identify	O
the	O
pro	B-MED
-	I-MED
migratory	I-MED
protein(s	I-MED
)	I-MED
present	O
in	O
diluted	B-MED
plasma	B-MED
and	O
fibrinogen	B-MED
-depleted	O
serum	B-MED
,	O
we	O
performed	O
gel	B-MED
filtration	I-MED
and	O
hydrophobic	B-MED
interaction	I-MED
chromatography	I-MED
followed	O
by	O
mass	B-MED
spectrometry	I-MED
analysis	I-MED
.	O
We	O
identified	O
several	O
putative	O
protein	B-MED
candidates	O
that	O
were	O
further	O
tested	O
in	O
in	B-MED
vitro	I-MED
experiments	B-MED
.	O
We	O
found	O
that	O
this	O
pro	B-MED
-	I-MED
migratory	I-MED
factor	I-MED
chaperoned	B-MED
by	O
fibrinogen	B-MED
is	O
vitronectin	B-MED
,	O
which	O
activates	O
uPAR	O
,	O
and	O
that	O
this	O
effect	O
can	O
be	O
inhibited	O
by	O
fibrinogen	B-MED
.	O
These	O
results	O
provide	O
a	O
novel	O
mechanism	B-MED
for	O
the	O
metastasis	B-MED
of	O
cancer	B-MED
cells	I-MED
to	O
lymphatics	B-MED
and	O
body	B-MED
cavities	I-MED
,	O
in	O
which	O
the	O
concentration	B-MED
of	O
fibrinogen	B-MED
is	O
low	O
,	O
and	O
thus	O
suggests	O
that	O
free	O
vitronectin	B-MED
stimulates	O
migration	B-MED
of	O
tumor	B-MED
cells	I-MED
.	O
Methylation	B-MED
Analysis	I-MED
of	O
BRCA1	B-MED
and	O
APC	B-MED
in	O
Breast	B-MED
Cancer	I-MED
and	O
It	O
's	O
Relationship	B-MED
to	O
Clinicopathological	B-MED
Features	B-MED
Promoter	B-MED
methylation	I-MED
of	O
tumor	B-MED
suppressor	I-MED
genes	I-MED
is	O
an	O
important	O
epigenetic	B-MED
alteration	I-MED
that	O
occurs	O
in	O
the	O
primary	B-MED
stages	B-MED
of	O
human	B-MED
tumors	B-MED
,	O
including	O
breast	B-MED
cancer	I-MED
.	O
Identification	O
of	O
methylated	B-MED
genes	I-MED
and	O
their	O
relationship	B-MED
to	O
clinical	B-MED
features	B-MED
can	O
contribute	O
to	O
the	O
prognosis	B-MED
and	O
early	B-MED
detection	I-MED
of	O
tumors	B-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
explored	O
the	O
methylation	B-MED
status	B-MED
of	O
APC	B-MED
and	O
BRCA1	B-MED
genes	I-MED
and	O
their	O
relationship	B-MED
to	O
clinical	B-MED
factors	B-MED
in	O
breast	B-MED
cancer	I-MED
patients	B-MED
.	O
BRCA1	B-MED
and	O
APC	B-MED
promoter	B-MED
methylation	I-MED
was	O
examined	O
by	O
methylation	B-MED
-	O
specific	B-MED
multiplex	I-MED
ligation	I-MED
-	I-MED
dependent	I-MED
probe	I-MED
amplification	I-MED
(	O
MS	B-MED
-	I-MED
MLPA	I-MED
)	O
assay	B-MED
in	O
formalin	B-MED
-	I-MED
fixed	I-MED
paraffin	I-MED
embedded	I-MED
(	I-MED
FFPE	I-MED
)	I-MED
breast	I-MED
tissue	I-MED
from	O
75	O
patients	B-MED
.	O
APC	B-MED
promoter	B-MED
methylation	I-MED
was	O
detected	B-MED
in	O
30.67	O
%	O
breast	B-MED
cancer	I-MED
tissues	B-MED
and	O
BRCA1	B-MED
was	O
methylated	B-MED
in	O
9.33	O
%	O
of	O
breast	B-MED
tumors	I-MED
.	O
Methylation	B-MED
of	O
APC	B-MED
was	O
associated	B-MED
with	I-MED
low	O
histological	B-MED
grade	I-MED
(	O
p	O
=	O
0.006	O
)	O
and	O
methylation	B-MED
of	O
BRCA1	B-MED
was	O
related	O
with	O
lymph	B-MED
node	I-MED
metastasis	B-MED
(	O
p	O
=	O
0.017	O
)	O
.	O
These	O
findings	B-MED
suggest	O
that	O
the	O
methylation	B-MED
status	B-MED
of	O
APC	B-MED
and	O
BRCA1	B-MED
can	O
be	O
a	O
predictive	B-MED
marker	I-MED
for	O
early	B-MED
detection	I-MED
and	O
better	O
management	B-MED
of	O
breast	B-MED
cancer	I-MED
patients	B-MED
.	O
Next	B-MED
-	I-MED
Generation	I-MED
Sequencing	I-MED
Approaches	B-MED
to	O
Define	O
the	O
Role	B-MED
of	O
the	O
Autophagy	B-MED
Lysosomal	I-MED
Pathway	I-MED
in	O
Human	B-MED
Disease	B-MED
:	O
The	O
Example	B-MED
of	O
LysoPlex	B-MED
Next	B-MED
-	I-MED
Generation	I-MED
Sequencing	I-MED
(	I-MED
NGS	I-MED
)	I-MED
technologies	I-MED
have	O
deeply	O
changed	O
the	O
throughput	B-MED
of	O
genetic	B-MED
testing	I-MED
allowing	O
analyzing	O
millions	O
of	O
DNA	B-MED
fragments	I-MED
in	O
parallel	B-MED
.	O
One	O
key	O
application	B-MED
is	O
the	O
understanding	O
of	O
genetically	B-MED
heterogeneous	B-MED
and	O
complex	B-MED
diseases	I-MED
where	O
50	O
-	O
100	O
different	O
genes	B-MED
may	O
converge	O
to	O
control	B-MED
the	O
same	O
pathways	B-MED
.	O
These	O
disorders	B-MED
can	O
not	O
be	O
studied	O
using	O
traditional	B-MED
approaches	B-MED
,	O
based	O
on	O
gene	B-MED
-	I-MED
by	I-MED
-	I-MED
gene	I-MED
Sanger	I-MED
sequencing	I-MED
.	O
We	O
have	O
set	O
up	O
an	O
NGS	B-MED
protocol	B-MED
based	O
on	O
a	O
specific	O
selection	B-MED
of	O
DNA	B-MED
regions	I-MED
belonging	O
to	O
about	O
900	O
genes	B-MED
of	O
the	O
autophagy	B-MED
-	I-MED
lysosomal	I-MED
(	I-MED
ALP	I-MED
)	I-MED
pathway	I-MED
.	O
We	O
here	O
specify	O
all	O
the	O
technical	B-MED
steps	I-MED
and	O
challenges	B-MED
of	O
our	O
protocol	B-MED
,	O
named	O
LysoPlex	B-MED
.	O
This	O
is	O
based	O
on	O
the	O
Haloplex	O
technology	O
and	O
together	O
with	O
high	B-MED
-	I-MED
coverage	I-MED
sequencing	I-MED
empowers	O
a	O
high	O
and	O
uniform	O
coverage	O
of	O
ALP	B-MED
genes	I-MED
.	O
LysoPlex	B-MED
outplays	O
other	O
NGS	B-MED
applications	B-MED
in	O
sensitivity	B-MED
and	I-MED
specificity	I-MED
,	O
providing	O
an	O
accurate	O
picture	O
of	O
all	O
variations	B-MED
in	O
ALP	B-MED
genes	I-MED
.	O
Joint	B-MED
model	I-MED
imputation	I-MED
to	O
estimate	B-MED
the	O
treatment	B-MED
effect	I-MED
on	O
long	B-MED
-	I-MED
term	I-MED
survival	B-MED
using	O
auxiliary	B-MED
events	I-MED
Clinical	B-MED
trial	I-MED
duration	B-MED
may	O
be	O
a	O
concern	O
in	O
clinical	B-MED
research	I-MED
,	O
especially	O
in	O
cancer	B-MED
trials	I-MED
where	O
the	O
endpoint	B-MED
is	O
overall	B-MED
survival	I-MED
.	O
A	O
surrogate	B-MED
endpoint	I-MED
can	O
be	O
used	O
as	O
an	O
auxiliary	B-MED
variable	I-MED
to	O
analyze	B-MED
the	O
treatment	B-MED
effect	I-MED
earlier	O
.	O
At	O
an	O
early	O
time	O
point	O
,	O
the	O
high	O
number	O
of	O
censored	B-MED
observations	B-MED
can	O
be	O
compensated	B-MED
by	O
the	O
imputation	B-MED
of	O
the	O
unobserved	B-MED
deaths	B-MED
times	O
.	O
We	O
propose	O
to	O
use	O
predictions	B-MED
of	O
the	O
risk	B-MED
of	O
death	B-MED
from	O
a	O
joint	B-MED
model	I-MED
for	O
a	O
recurrent	B-MED
event	B-MED
and	O
a	O
terminal	B-MED
event	B-MED
,	O
which	O
account	O
for	O
disease	B-MED
relapse	I-MED
information	B-MED
.	O
Two	O
imputation	B-MED
methods	I-MED
were	O
compared	B-MED
:	O
sampling	B-MED
from	O
the	O
estimated	B-MED
parametric	I-MED
distribution	I-MED
of	O
the	O
survival	B-MED
time	I-MED
and	O
sampling	B-MED
using	O
its	O
nonparametric	B-MED
estimation	I-MED
.	O
The	O
treatment	B-MED
effect	I-MED
and	O
its	O
standard	B-MED
error	I-MED
were	O
estimated	B-MED
via	O
multiple	B-MED
imputations	I-MED
.	O
The	O
performances	B-MED
of	O
the	O
two	O
methods	B-MED
were	O
compared	B-MED
in	O
terms	O
of	O
bias	B-MED
in	O
the	O
estimates	B-MED
,	O
standard	B-MED
errors	I-MED
,	O
and	O
coverage	B-MED
probability	B-MED
.	O
Both	O
methods	B-MED
were	O
then	O
retrospectively	B-MED
applied	B-MED
to	O
two	O
randomized	B-MED
clinical	I-MED
trials	I-MED
studying	O
the	O
effect	B-MED
of	O
adjuvant	B-MED
chemotherapy	B-MED
in	O
breast	B-MED
cancer	I-MED
patients	B-MED
.	O
Quantifying	B-MED
Nonlinear	O
Contributions	B-MED
to	O
Cortical	B-MED
Responses	I-MED
Evoked	I-MED
by	O
Continuous	B-MED
Wrist	I-MED
Manipulation	I-MED
Cortical	B-MED
responses	I-MED
to	O
continuous	B-MED
stimuli	I-MED
as	O
recorded	O
using	O
either	O
magneto-	B-MED
or	O
electroencephalography	B-MED
(	O
EEG	B-MED
)	O
have	O
shown	O
power	O
at	O
harmonics	O
of	O
the	O
stimulated	B-MED
frequency	I-MED
,	O
indicating	O
nonlinear	B-MED
behavior	I-MED
.	O
Even	O
though	O
the	O
selection	O
of	O
analysis	B-MED
techniques	B-MED
depends	O
on	O
the	O
linearity	B-MED
of	O
the	O
system	O
under	O
study	O
,	O
the	O
importance	O
of	O
nonlinear	O
contributions	B-MED
to	O
cortical	B-MED
responses	I-MED
has	O
not	O
been	O
formally	O
addressed	O
.	O
The	O
goal	B-MED
of	I-MED
this	I-MED
paper	I-MED
is	O
to	O
quantify	B-MED
the	O
nonlinear	O
contributions	B-MED
to	O
the	O
cortical	B-MED
response	I-MED
obtained	O
from	O
continuous	B-MED
sensory	B-MED
stimulation	I-MED
.	O
EEG	B-MED
was	O
used	O
to	O
record	O
the	O
cortical	B-MED
response	I-MED
evoked	I-MED
by	O
continuous	B-MED
movement	I-MED
of	I-MED
the	I-MED
wrist	I-MED
joint	I-MED
of	O
healthy	O
subjects	O
applied	O
with	O
a	O
robotic	B-MED
manipulator	I-MED
.	O
Multisine	O
stimulus	B-MED
signals	I-MED
(	O
i.e.	O
,	O
the	O
sum	O
of	O
several	B-MED
sinusoids	B-MED
)	O
elicit	O
a	O
periodic	B-MED
cortical	B-MED
response	I-MED
and	O
allow	O
to	O
assess	B-MED
the	O
nonlinear	O
contributions	B-MED
to	O
the	O
response	O
.	O
Wrist	B-MED
dynamics	I-MED
(	O
relation	O
between	O
joint	B-MED
angle	I-MED
and	O
torque	B-MED
)	O
were	O
successfully	O
linearized	B-MED
,	O
explaining	O
99	O
%	O
of	O
the	O
response	O
.	O
In	O
contrast	O
,	O
the	O
cortical	B-MED
response	I-MED
revealed	O
a	O
highly	O
nonlinear	O
relation	O
;	O
where	O
most	O
power	O
(	O
∼	O
80	O
%	O
)	O
occurred	O
at	O
non	O
-	O
stimulated	O
frequencies	O
.	O
Moreover	O
,	O
only	O
10	O
%	O
of	O
the	O
response	O
could	O
be	O
explained	O
using	O
a	O
nonparametric	B-MED
linear	I-MED
model	I-MED
.	O
These	O
results	B-MED
indicate	O
that	O
the	O
recorded	O
evoked	B-MED
cortical	I-MED
responses	I-MED
are	O
governed	O
by	O
nonlinearities	O
and	O
that	O
linear	B-MED
methods	O
do	O
not	O
suffice	O
when	O
describing	O
the	O
relation	O
between	O
mechanical	B-MED
stimulus	I-MED
and	O
cortical	B-MED
response	I-MED
.	O
Worldwide	B-MED
Occurrence	B-MED
of	O
Mycotoxins	B-MED
in	O
Cereals	B-MED
and	O
Cereal	B-MED
-	O
Derived	B-MED
Food	B-MED
Products	I-MED
:	O
Public	B-MED
Health	B-MED
Perspectives	B-MED
of	O
Their	O
Co	O
-	O
occurrence	O
Cereal	B-MED
grains	I-MED
and	O
their	O
processed	B-MED
food	B-MED
products	I-MED
are	O
frequently	O
contaminated	B-MED
with	O
mycotoxins	B-MED
.	O
Among	O
many	O
,	O
five	B-MED
major	B-MED
mycotoxins	B-MED
of	O
aflatoxins	B-MED
,	O
ochratoxins	B-MED
,	O
fumonisins	B-MED
,	O
deoxynivalenol	B-MED
,	O
and	O
zearalenone	B-MED
are	O
of	O
significant	O
public	B-MED
health	B-MED
concern	B-MED
as	O
they	O
can	O
cause	B-MED
adverse	B-MED
effects	I-MED
in	O
humans	B-MED
.	O
Being	O
airborne	B-MED
or	O
soilborne	B-MED
,	O
the	O
cosmopolitan	O
nature	B-MED
of	O
mycotoxigenic	B-MED
fungi	I-MED
contribute	O
to	O
the	O
worldwide	B-MED
occurrence	B-MED
of	O
mycotoxins	B-MED
.	O
On	O
the	O
basis	B-MED
of	O
the	O
global	B-MED
occurrence	B-MED
data	B-MED
reported	B-MED
during	O
the	O
past	O
10	O
years	O
,	O
the	O
incidences	B-MED
and	O
maximum	B-MED
levels	B-MED
in	O
raw	B-MED
cereal	B-MED
grains	I-MED
were	O
55	O
%	O
and	O
1642	O
μg	O
/	O
kg	O
for	O
aflatoxins	B-MED
,	O
29	O
%	O
and	O
1164	O
μg	O
/	O
kg	O
for	O
ochratoxin	B-MED
A	I-MED
,	O
61	O
%	O
and	O
71,121	O
μg	O
/	O
kg	O
for	O
fumonisins	B-MED
,	O
58	O
%	O
and	O
41,157	O
μg	O
/	O
kg	O
,	O
for	O
deoxynivalenol	B-MED
,	O
and	O
46	O
%	O
and	O
3049	O
μg	O
/	O
kg	O
for	O
zearalenone	B-MED
.	O
The	O
concentrations	B-MED
of	O
mycotoxins	B-MED
tend	O
to	O
be	O
lower	B-MED
in	O
processed	B-MED
food	B-MED
products	I-MED
;	O
the	O
incidences	B-MED
varied	O
depending	O
on	O
the	O
individual	O
mycotoxins	B-MED
,	O
possibly	O
due	B-MED
to	I-MED
the	O
varying	B-MED
stability	B-MED
during	B-MED
processing	B-MED
and	O
distribution	B-MED
of	O
mycotoxins	B-MED
.	O
It	O
should	O
be	O
noted	O
that	O
more	O
than	O
one	O
mycotoxin	B-MED
,	O
produced	B-MED
by	O
a	O
single	B-MED
or	O
several	B-MED
fungal	B-MED
species	B-MED
,	O
may	O
occur	O
in	O
various	B-MED
combinations	B-MED
in	O
a	O
given	O
sample	B-MED
or	O
food	B-MED
.	O
Most	O
studies	B-MED
reported	B-MED
additive	B-MED
or	O
synergistic	B-MED
effects	B-MED
,	O
suggesting	B-MED
that	O
these	O
mixtures	B-MED
may	O
pose	O
a	O
significant	B-MED
threat	B-MED
to	O
public	B-MED
health	B-MED
,	O
particularly	O
to	O
infants	B-MED
and	O
young	B-MED
children	I-MED
.	O
Therefore	O
,	O
information	B-MED
on	O
the	O
co	O
-	O
occurrence	O
of	O
mycotoxins	B-MED
and	O
their	O
interactive	B-MED
toxicity	B-MED
is	O
summarized	B-MED
in	O
this	O
paper	O
.	O
A	O
primer	O
on	O
intraosseous	B-MED
access	I-MED
:	O
History	B-MED
,	O
clinical	B-MED
considerations	I-MED
,	O
and	O
current	B-MED
devices	I-MED
Intraosseous	B-MED
(	I-MED
IO	I-MED
)	I-MED
access	I-MED
is	O
a	O
method	B-MED
recommended	O
by	O
the	O
American	B-MED
Heart	I-MED
Association	I-MED
and	O
the	O
European	B-MED
Resuscitation	I-MED
Council	I-MED
to	O
administer	B-MED
resuscitative	B-MED
drugs	I-MED
and	O
fluids	B-MED
when	O
intravenous	B-MED
(	I-MED
IV	I-MED
)	I-MED
access	I-MED
can	O
not	O
be	O
rapidly	O
or	O
easily	O
obtained	O
.	O
Many	O
clinicians	B-MED
have	O
limited	B-MED
knowledge	I-MED
or	O
experience	B-MED
with	O
the	O
IO	B-MED
route	I-MED
.	O
The	O
purpose	O
of	O
this	O
review	B-MED
was	O
to	O
provide	O
the	O
reader	O
with	O
a	O
succinct	B-MED
review	I-MED
of	O
the	O
history	B-MED
,	O
clinical	B-MED
considerations	I-MED
,	O
and	O
devices	B-MED
associated	B-MED
with	I-MED
IO	B-MED
access	I-MED
.	O
Narrative	O
review	O
.	O
University	O
-	O
based	O
academic	O
research	O
cell	O
.	O
Not	O
applicable	O
.	O
Not	O
applicable	O
.	O
IO	B-MED
access	I-MED
IO	B-MED
access	I-MED
is	O
a	O
lifesaving	B-MED
bridge	I-MED
to	O
definitive	B-MED
vascular	I-MED
access	I-MED
that	O
may	O
be	O
considered	O
when	O
an	O
IV	B-MED
can	O
not	O
be	O
rapidly	O
attained	O
and	O
the	O
patient	B-MED
's	I-MED
outcome	I-MED
may	O
be	O
negatively	B-MED
affected	I-MED
without	O
prompt	B-MED
circulatory	I-MED
access	I-MED
.	O
The	O
IO	B-MED
route	I-MED
has	O
few	O
contraindications	B-MED
for	O
use	O
and	O
a	O
low	O
rate	O
of	O
serious	B-MED
complications	I-MED
.	O
Multiple	O
manual	B-MED
and	O
powered	B-MED
devices	I-MED
that	O
may	O
be	O
placed	O
in	O
several	B-MED
anatomic	I-MED
sites	I-MED
are	O
commercially	O
available	O
.	O
All	O
clinicians	B-MED
who	O
provide	O
acute	B-MED
care	I-MED
or	O
respond	O
to	O
cardiovascular	B-MED
emergencies	B-MED
should	O
obtain	O
training	B-MED
and	O
maintain	O
proficiency	B-MED
in	O
placing	O
and	O
using	O
IO	B-MED
devices	B-MED
as	O
the	O
IO	B-MED
route	I-MED
is	O
recommended	O
by	O
the	O
major	O
resuscitation	B-MED
organizations	I-MED
as	O
the	O
preferred	B-MED
route	I-MED
of	I-MED
infusion	I-MED
when	O
rapid	O
,	O
reliable	O
IV	B-MED
access	I-MED
is	O
unavailable	O
.	O
Us3	B-MED
and	O
Us9	B-MED
proteins	B-MED
contribute	O
to	O
the	O
stromal	B-MED
invasion	I-MED
of	O
bovine	B-MED
herpesvirus	I-MED
1	I-MED
in	O
the	O
respiratory	B-MED
mucosa	I-MED
Bovine	B-MED
herpesvirus	I-MED
1	I-MED
(	I-MED
BHV-1	I-MED
)	I-MED
infection	I-MED
may	O
lead	O
to	O
conjunctivitis	B-MED
,	O
upper	B-MED
respiratory	I-MED
tract	I-MED
problems	B-MED
,	O
pneumonia	B-MED
,	O
genital	B-MED
disorders	I-MED
and	O
abortion	B-MED
.	O
BHV-1	B-MED
is	O
able	O
to	O
spread	B-MED
quickly	O
in	O
a	O
plaque	B-MED
-wise	O
manner	B-MED
and	O
invade	B-MED
by	O
breaching	B-MED
the	O
basement	B-MED
membrane	I-MED
(	B-MED
BM	I-MED
)	I-MED
barrier	B-MED
in	O
the	O
respiratory	B-MED
mucosa	I-MED
.	O
BHV-1	B-MED
Us3	B-MED
,	O
a	O
serine	B-MED
/	I-MED
threonine	I-MED
kinase	I-MED
,	O
induces	B-MED
a	O
dramatic	O
cytoskeletal	B-MED
reorganization	I-MED
and	O
BHV-1	B-MED
Us9	B-MED
,	O
a	O
tail	B-MED
-	I-MED
anchored	I-MED
membrane	I-MED
protein	I-MED
,	O
is	O
required	O
for	O
axonal	B-MED
transport	I-MED
of	O
viruses	B-MED
in	O
neurons	B-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
investigated	B-MED
the	O
role	B-MED
of	O
Us3	B-MED
and	O
Us9	B-MED
during	O
BHV-1	B-MED
infection	I-MED
in	O
the	O
respiratory	B-MED
mucosa	I-MED
.	O
First	O
,	O
we	O
constructed	O
and	O
characterized	B-MED
BHV-1	B-MED
Us3	B-MED
null	B-MED
,	O
Us9	B-MED
null	B-MED
and	O
revertant	B-MED
viruses	I-MED
.	O
Then	O
,	O
we	O
analysed	B-MED
the	O
viral	B-MED
replication	I-MED
and	O
plaque	B-MED
size	B-MED
(	O
latitude	O
)	O
in	O
Madin	B-MED
-	I-MED
Darby	I-MED
bovine	I-MED
kidney	I-MED
(	O
MDBK	B-MED
)	O
cells	B-MED
and	O
the	O
respiratory	B-MED
mucosa	I-MED
as	O
well	O
as	O
viral	B-MED
penetration	I-MED
depth	O
underneath	O
the	O
BM	B-MED
of	O
the	O
respiratory	B-MED
mucosa	I-MED
when	O
inoculated	B-MED
with	O
these	O
recombinant	B-MED
viruses	I-MED
.	O
Knockout	B-MED
of	O
Us3	B-MED
resulted	O
in	O
a	O
1	O
log10	O
reduction	B-MED
in	O
viral	B-MED
titre	I-MED
and	O
plaque	B-MED
size	B-MED
(	O
latitude	B-MED
)	O
in	O
MDBK	B-MED
cells	I-MED
and	O
the	O
trachea	B-MED
mucosa	I-MED
.	O
There	O
were	O
no	B-MED
defects	B-MED
in	O
the	O
cell	B-MED
-	I-MED
to	I-MED
-	I-MED
cell	I-MED
spread	I-MED
observed	B-MED
for	O
BHV-1	B-MED
Us9	B-MED
null	B-MED
virus	I-MED
.	O
Both	O
BHV-1	B-MED
Us3	B-MED
null	B-MED
and	O
Us9	B-MED
null	B-MED
viruses	I-MED
showed	O
a	O
significant	B-MED
reduction	B-MED
of	O
plaque	B-MED
penetration	B-MED
underneath	O
the	O
BM	B-MED
;	O
however	O
,	O
penetration	B-MED
was	O
not	O
completely	O
inhibited	B-MED
.	O
In	O
conclusion	B-MED
,	O
the	O
current	O
findings	B-MED
demonstrated	O
that	O
Us3	B-MED
and	O
Us9	B-MED
play	O
an	O
important	O
role	B-MED
in	O
the	O
invasion	B-MED
of	O
BHV-1	B-MED
through	O
the	O
BM	B-MED
of	O
the	O
respiratory	B-MED
mucosa	I-MED
,	O
which	O
shows	O
the	O
way	O
forward	O
for	O
research	B-MED
-based	O
attenuation	B-MED
of	O
viruses	B-MED
in	O
order	O
to	O
make	O
safer	O
and	O
better	B-MED
-	O
performing	B-MED
vaccines	B-MED
.	O
Determination	O
of	O
the	O
Mutant	B-MED
Prevention	I-MED
Concentration	I-MED
and	O
the	O
Mutant	B-MED
Selection	I-MED
Window	I-MED
of	O
Topical	B-MED
Antimicrobial	I-MED
Agents	I-MED
against	O
Propionibacterium	B-MED
acnes	I-MED
Determination	O
of	O
the	O
mutant	B-MED
prevention	I-MED
concentration	I-MED
(	O
MPC	B-MED
)	O
and	O
the	O
mutant	B-MED
selection	I-MED
window	I-MED
(	O
MSW	B-MED
)	O
of	O
antimicrobial	B-MED
agents	I-MED
used	O
to	O
treat	O
pathogenic	B-MED
bacteria	B-MED
is	O
important	O
in	O
order	O
to	O
apply	O
effective	O
antimicrobial	B-MED
therapies	B-MED
.	O
Here	O
,	O
we	O
determined	O
the	O
MPCs	B-MED
of	O
the	O
major	O
topical	B-MED
antimicrobial	I-MED
agents	I-MED
against	O
Propionibacterium	B-MED
acnes	I-MED
and	O
Staphylococcus	B-MED
aureus	I-MED
which	O
cause	O
skin	B-MED
infections	I-MED
and	O
compared	O
their	O
MSWs	B-MED
.	O
Among	O
the	O
MPCs	B-MED
of	O
nadifloxacin	B-MED
and	O
clindamycin	B-MED
,	O
the	O
clindamycin	B-MED
MPC	B-MED
was	O
determined	O
to	O
be	O
the	O
lowest	B-MED
against	O
P.	B-MED
acnes	I-MED
.	O
In	O
contrast	O
,	O
the	O
nadifloxacin	B-MED
MPC	B-MED
was	O
the	O
lowest	B-MED
against	O
S.	B-MED
aureus	I-MED
.	O
Calculations	B-MED
based	O
on	O
the	O
minimum	B-MED
inhibitory	I-MED
concentrations	I-MED
and	O
MPCs	B-MED
showed	O
that	O
clindamycin	B-MED
has	O
the	O
lowest	B-MED
MSW	B-MED
against	O
both	O
P.	B-MED
acnes	I-MED
and	O
S.	B-MED
aureus	I-MED
.	O
Nadifloxacin	B-MED
MSWs	B-MED
were	O
4	O
-	O
fold	O
higher	B-MED
against	O
P.	B-MED
acnes	I-MED
than	O
against	O
S.	B-MED
aureus	I-MED
.	O
It	O
is	O
more	O
likely	O
for	O
P.	B-MED
acnes	I-MED
to	O
acquire	O
resistance	B-MED
to	O
fluoroquinolones	B-MED
than	O
S.	B-MED
aureus	I-MED
.	O
Therefore	O
,	O
topical	B-MED
application	I-MED
of	O
clindamycin	B-MED
contributes	O
very	O
little	O
to	O
the	O
emergence	O
of	O
resistant	B-MED
P.	B-MED
acnes	I-MED
and	O
S.	B-MED
aureus	I-MED
strains	O
.	O
Altered	B-MED
interregional	B-MED
correlations	B-MED
between	O
serotonin	B-MED
transporter	I-MED
availability	B-MED
and	O
cerebral	B-MED
glucose	I-MED
glucose	B-MED
metabolism	I-MED
in	O
schizophrenia	B-MED
:	O
A	O
high	B-MED
-	I-MED
resolution	I-MED
PET	I-MED
study	O
using	O
[	B-MED
(	I-MED
11)C]DASB	I-MED
and	O
[	B-MED
(	I-MED
18)F]FDG	I-MED
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
patterns	O
of	O
interregional	B-MED
correlations	B-MED
of	O
serotonin	B-MED
transporter	I-MED
(	O
SERT	B-MED
)	O
availability	B-MED
with	O
glucose	B-MED
metabolism	I-MED
using	O
7	B-MED
-	I-MED
Tesla	I-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
(	O
MRI	B-MED
)	O
and	O
high	B-MED
-	I-MED
resolution	I-MED
positron	I-MED
emission	I-MED
tomography	I-MED
(	O
PET	B-MED
)	O
with	O
(	B-MED
11)C-3	I-MED
-	I-MED
amino-4-(2	I-MED
-	I-MED
dimethylaminomethylphenylthio)benzonitrile	I-MED
(	O
[	B-MED
(	I-MED
11)C]DASB	I-MED
)	O
and	O
[	B-MED
(	I-MED
18)F]fluorodeoxyglucose	I-MED
(	O
[	B-MED
(	I-MED
18)F]FDG	I-MED
)	O
in	O
antipsychotic	B-MED
-	I-MED
free	I-MED
patients	I-MED
with	O
schizophrenia	B-MED
in	O
order	O
to	O
shed	O
new	O
light	O
on	O
the	O
disrupted	B-MED
functional	B-MED
connectivity	I-MED
in	O
schizophrenia	B-MED
.	O
Nineteen	O
patients	B-MED
with	O
schizophrenia	B-MED
and	O
18	O
healthy	B-MED
controls	I-MED
underwent	O
high	B-MED
-	I-MED
resolution	I-MED
PET	I-MED
and	O
MRI	B-MED
.	O
The	O
binding	B-MED
potential	I-MED
(	O
BPND	B-MED
)	O
of	O
[	B-MED
(	I-MED
11)C]DASB	I-MED
and	O
standardized	B-MED
uptake	I-MED
value	I-MED
ratio	I-MED
(	O
SUVR	B-MED
)	O
of	O
[	B-MED
(	I-MED
18)F]FDG	I-MED
were	O
obtained	O
.	O
In	O
SERT	B-MED
availability	B-MED
,	O
the	O
region	B-MED
of	I-MED
interest	I-MED
ROI	B-MED
(	O
ROI)-based	O
analyses	B-MED
showed	O
no	O
significant	O
group	O
differences	O
in	O
any	O
region	B-MED
,	O
except	O
for	O
the	O
anterior	B-MED
hippocampus	B-MED
where	O
the	O
SERT	B-MED
availability	B-MED
was	O
lower	O
in	O
patients	B-MED
with	O
schizophrenia	B-MED
than	O
in	O
controls	B-MED
.	O
The	O
ROI	B-MED
-	O
and	O
voxel	B-MED
-based	O
analyses	B-MED
revealed	O
that	O
the	O
[	B-MED
(	I-MED
18)F]FDG	I-MED
SUVR	B-MED
values	I-MED
were	O
significantly	O
lower	O
in	O
patients	B-MED
than	O
in	O
controls	B-MED
in	O
the	O
right	B-MED
superior	I-MED
frontal	I-MED
gyrus	I-MED
and	O
medial	B-MED
part	I-MED
of	O
the	O
left	B-MED
superior	I-MED
frontal	I-MED
gyrus	I-MED
.	O
Regarding	O
the	O
interregional	B-MED
correlations	B-MED
of	O
[	B-MED
(	I-MED
11)C]DASB	I-MED
BPND	B-MED
with	O
[	B-MED
(	I-MED
18)F]FDG	I-MED
SUVR	B-MED
,	O
more	O
widespread	O
positive	B-MED
correlations	B-MED
across	O
the	O
brain	B-MED
regions	I-MED
were	O
observed	O
in	O
control	B-MED
subjects	I-MED
than	O
in	O
patients	B-MED
with	O
schizophrenia	B-MED
.	O
Notably	O
,	O
the	O
patients	B-MED
and	O
control	B-MED
subjects	I-MED
showed	O
statistically	O
significant	O
differences	O
in	O
correlations	B-MED
between	O
the	O
SERT	B-MED
availability	B-MED
in	O
the	O
parietal	B-MED
and	O
temporal	B-MED
cortices	I-MED
and	O
the	O
glucose	B-MED
metabolism	I-MED
in	O
the	O
posterior	B-MED
cingulate	I-MED
cortex	I-MED
.	O
These	O
results	O
suggest	O
abnormal	B-MED
functional	B-MED
connectivity	I-MED
between	O
the	O
higher	B-MED
-	I-MED
order	I-MED
cortical	I-MED
regions	I-MED
in	O
schizophrenia	B-MED
and	O
a	O
possible	O
important	O
role	B-MED
of	O
the	O
posterior	B-MED
cingulate	I-MED
gyrus	I-MED
and	O
its	O
related	O
circuitry	B-MED
in	O
the	O
pathophysiology	B-MED
of	O
schizophrenia	B-MED
.	O
Surviving	B-MED
moment	B-MED
to	O
moment	B-MED
:	O
The	O
experience	B-MED
of	O
living	B-MED
in	O
a	O
state	B-MED
of	O
ambivalence	B-MED
for	O
those	O
with	O
recurrent	B-MED
suicide	B-MED
attempts	I-MED
This	O
qualitative	B-MED
study	I-MED
aimed	O
to	O
capture	O
the	O
experience	B-MED
of	O
living	B-MED
in	O
the	O
ambivalent	B-MED
space	I-MED
between	O
life	B-MED
and	O
death	B-MED
for	O
adults	B-MED
with	O
recurrent	B-MED
suicide	B-MED
attempts	I-MED
(	O
RSA	B-MED
)	O
.	O
It	O
sought	O
to	O
expand	B-MED
upon	O
an	O
earlier	O
study	B-MED
that	O
explored	O
the	O
processes	B-MED
involved	B-MED
in	O
transitioning	B-MED
away	O
from	O
RSA	B-MED
among	O
adults	B-MED
,	O
which	O
revealed	B-MED
that	O
occupying	O
this	O
ambivalent	B-MED
space	I-MED
is	O
a	O
crucial	O
part	O
of	O
this	O
process	B-MED
.	O
Interpretive	B-MED
phenomenological	I-MED
analysis	I-MED
(	O
IPA	B-MED
)	O
was	O
used	O
.	O
This	O
methodology	B-MED
was	O
designed	B-MED
to	O
explore	O
the	O
lived	B-MED
experiences	I-MED
and	O
meaning	B-MED
making	I-MED
and	O
enabled	O
interpretation	B-MED
of	O
the	O
multidimensional	B-MED
subjective	B-MED
experiences	B-MED
of	O
RSA	B-MED
participants	B-MED
.	O
In	O
-	O
depth	O
semi	B-MED
-	I-MED
structured	I-MED
interviews	I-MED
were	O
conducted	B-MED
with	O
eight	O
adult	B-MED
women	I-MED
with	O
a	O
history	B-MED
of	O
RSA	B-MED
who	O
had	O
participated	B-MED
in	O
a	O
therapeutic	B-MED
intervention	I-MED
at	O
the	O
research	B-MED
site	B-MED
(	O
Skills	B-MED
for	O
Safer	B-MED
Living	I-MED
:	O
A	O
Psychosocial	B-MED
/	O
Psychoeducational	B-MED
Intervention	I-MED
for	O
People	B-MED
with	O
Recurrent	B-MED
Suicide	B-MED
Attempts	I-MED
[	O
SfSL	B-MED
/	O
PISA	B-MED
]	O
)	O
.	O
The	O
six	O
stages	B-MED
of	O
IPA	B-MED
were	O
followed	O
to	O
analyse	B-MED
the	O
interview	B-MED
data	B-MED
.	O
Analysis	B-MED
revealed	B-MED
the	O
superordinate	B-MED
theme	I-MED
,	O
'	O
surviving	B-MED
moment	B-MED
to	O
moment	B-MED
'	O
,	O
which	O
refers	O
to	O
a	O
precarious	B-MED
state	I-MED
of	O
making	B-MED
decisions	I-MED
about	O
one	O
's	O
life	B-MED
and	O
destiny	B-MED
on	O
a	O
moment	B-MED
-to-	O
moment	B-MED
basis	O
without	O
clear	O
commitment	B-MED
to	O
either	O
life	B-MED
or	O
death	B-MED
.	O
Two	O
subordinate	B-MED
themes	I-MED
were	O
identified	B-MED
:	O
'	O
deciding	B-MED
not	O
to	O
die	B-MED
in	O
the	O
moment	B-MED
'	O
when	O
the	O
participants	B-MED
were	O
more	O
invested	B-MED
in	O
dying	B-MED
than	O
living	B-MED
and	O
'	O
deciding	B-MED
to	O
live	B-MED
in	O
the	O
moment	B-MED
'	O
when	O
they	O
were	O
more	O
invested	B-MED
in	O
living	B-MED
than	O
dying	B-MED
.	O
The	O
study	B-MED
illuminated	O
the	O
complex	B-MED
process	B-MED
of	O
making	B-MED
decisions	I-MED
about	O
ones	O
'	O
destiny	B-MED
on	O
a	O
moment	B-MED
-to-	O
moment	B-MED
basis	O
.	O
It	O
revealed	B-MED
the	O
torment	O
experienced	B-MED
when	O
occupying	O
this	O
state	B-MED
,	O
while	O
paradoxically	B-MED
,	O
also	O
revealing	O
how	O
indecision	B-MED
about	O
life	B-MED
and	O
death	B-MED
provided	B-MED
a	O
lifeline	B-MED
opportunity	B-MED
for	O
those	O
with	O
RSA	B-MED
.	O
Clinicians	B-MED
who	O
recognize	O
the	O
subtle	O
distinctions	O
associated	B-MED
with	I-MED
this	O
in	O
-	O
between	O
state	B-MED
can	O
tailor	O
their	O
interventions	B-MED
accordingly	O
.	O
Surviving	B-MED
moment	B-MED
to	O
moment	B-MED
is	O
characterized	B-MED
by	O
a	O
state	B-MED
of	O
emotional	B-MED
flux	I-MED
and	O
uncertainty	B-MED
about	O
one	O
's	O
destiny	B-MED
,	O
where	O
the	O
person	B-MED
has	O
not	O
fully	O
committed	O
to	O
either	O
life	B-MED
or	O
death	B-MED
.	O
Within	O
this	O
state	B-MED
,	O
there	O
are	O
two	O
interlinked	B-MED
subprocesses	I-MED
,	O
whereby	O
the	O
person	B-MED
is	O
leaning	B-MED
more	O
towards	O
death	B-MED
or	O
life	B-MED
.	O
A	O
critical	O
feature	B-MED
in	O
working	B-MED
with	O
this	O
client	B-MED
group	I-MED
is	O
to	O
recognize	O
their	O
ambiguity	B-MED
and	O
the	O
fragility	B-MED
and	O
temporality	B-MED
of	O
their	O
decisions	B-MED
about	O
their	O
destiny	B-MED
.	O
The	O
practitioner	B-MED
has	O
an	O
opportunity	B-MED
to	O
be	O
a	O
catalyst	O
in	O
the	O
momentum	O
towards	O
life	B-MED
by	O
demonstrating	O
understanding	B-MED
of	O
this	O
survival	B-MED
struggle	B-MED
and	O
tailoring	B-MED
intervention	I-MED
to	O
fit	O
with	O
the	O
nuanced	B-MED
processes	I-MED
within	O
this	O
state	B-MED
.	O
Committee	B-MED
Opinion	O
No	O
.	O
701	O
Summary	O
:	O
Choosing	O
The	O
Route	B-MED
Of	O
Hysterectomy	B-MED
For	O
Benign	B-MED
Disease	B-MED
Hysterectomy	B-MED
is	O
one	O
of	O
the	O
most	O
frequently	O
performed	O
surgical	B-MED
procedures	I-MED
in	O
the	O
United	B-MED
States	I-MED
.	O
Selection	B-MED
of	O
the	O
route	B-MED
of	O
hysterectomy	B-MED
for	O
benign	B-MED
causes	O
can	O
be	O
influenced	O
by	O
the	O
size	B-MED
and	O
shape	B-MED
of	O
the	O
vagina	B-MED
and	O
uterus	B-MED
;	O
accessibility	O
to	O
the	O
uterus	B-MED
;	O
extent	O
of	O
extrauterine	B-MED
disease	I-MED
;	O
the	O
need	O
for	O
concurrent	O
procedures	O
;	O
surgeon	B-MED
training	B-MED
and	O
experience	B-MED
;	O
average	O
case	B-MED
volume	I-MED
;	O
available	O
hospital	B-MED
technology	B-MED
,	O
devices	B-MED
,	O
and	O
support	O
;	O
whether	O
the	O
case	O
is	O
emergent	O
or	O
scheduled	O
;	O
and	O
preference	O
of	O
the	O
informed	O
patient	B-MED
.	O
Vaginal	B-MED
and	O
laparoscopic	B-MED
procedures	I-MED
are	O
considered	O
"	O
minimally	B-MED
invasive	I-MED
"	O
surgical	B-MED
approaches	I-MED
because	O
they	O
do	O
not	O
require	O
a	O
large	O
abdominal	B-MED
incision	I-MED
and	O
,	O
thus	O
,	O
typically	O
are	O
associated	O
with	O
shortened	O
hospitalization	B-MED
and	O
postoperative	B-MED
recovery	I-MED
times	I-MED
compared	O
with	O
open	O
abdominal	B-MED
hysterectomy	I-MED
.	O
Minimally	B-MED
invasive	I-MED
approaches	I-MED
to	O
hysterectomy	B-MED
should	O
be	O
performed	O
,	O
whenever	O
feasible	O
,	O
based	O
on	O
their	O
well	O
-	O
documented	O
advantages	O
over	O
abdominal	B-MED
hysterectomy	I-MED
.	O
The	O
vaginal	B-MED
approach	I-MED
is	O
preferred	O
among	O
the	O
minimally	B-MED
invasive	I-MED
approaches	I-MED
.	O
Laparoscopic	B-MED
hysterectomy	I-MED
is	O
a	O
preferable	O
alternative	O
to	O
open	O
abdominal	B-MED
hysterectomy	I-MED
for	O
those	O
patients	B-MED
in	O
whom	O
a	O
vaginal	B-MED
hysterectomy	I-MED
is	O
not	O
indicated	O
or	O
feasible	O
.	O
Although	O
minimally	B-MED
invasive	I-MED
approaches	I-MED
to	O
hysterectomy	B-MED
are	O
the	O
preferred	O
route	B-MED
,	O
open	B-MED
abdominal	B-MED
hysterectomy	I-MED
remains	O
an	O
important	O
surgical	O
option	O
for	O
some	O
patients	B-MED
.	O
The	O
obstetrician	B-MED
-	O
gynecologist	B-MED
should	O
discuss	O
the	O
options	O
with	O
patients	B-MED
and	O
make	O
clear	O
recommendations	O
on	O
which	O
route	B-MED
of	O
hysterectomy	B-MED
will	O
maximize	O
benefits	B-MED
and	O
minimize	O
risks	B-MED
given	O
the	O
specific	O
clinical	O
situation	O
.	O
The	O
relative	O
advantages	O
and	O
disadvantages	O
of	O
the	O
approaches	B-MED
to	O
hysterectomy	B-MED
should	O
be	O
discussed	O
in	O
the	O
context	O
of	O
the	O
patient	B-MED
's	O
values	O
and	O
preferences	B-MED
,	O
and	O
the	O
patient	B-MED
and	O
health	B-MED
care	I-MED
provider	I-MED
should	O
together	O
determine	O
the	O
best	O
course	O
of	O
action	O
after	O
this	O
discussion	O
.	O
Psychogenic	B-MED
non	I-MED
-	I-MED
epileptic	I-MED
seizure	I-MED
in	O
patients	B-MED
with	O
intellectual	B-MED
disability	I-MED
with	O
special	O
focus	O
on	O
choice	B-MED
of	O
therapeutic	B-MED
intervention	I-MED
There	O
have	O
been	O
a	O
number	O
of	O
studies	B-MED
exploring	O
treatments	B-MED
for	O
psychogenic	B-MED
non	I-MED
-	I-MED
epileptic	I-MED
seizure	I-MED
(	O
PNES	B-MED
)	O
but	O
largely	O
neglecting	B-MED
the	O
sizable	O
subgroup	B-MED
of	O
patients	B-MED
with	O
intellectual	B-MED
disability	I-MED
(	O
ID	B-MED
)	O
.	O
In	O
the	O
present	B-MED
study	B-MED
,	O
we	O
attempted	B-MED
to	O
demonstrate	B-MED
effects	B-MED
and	O
preferred	B-MED
modes	O
of	O
therapeutic	B-MED
intervention	I-MED
in	O
PNES	B-MED
patients	B-MED
with	O
ID	B-MED
being	O
treated	B-MED
at	O
a	O
Japanese	B-MED
municipal	I-MED
center	I-MED
with	O
a	O
short	B-MED
referral	B-MED
chain	I-MED
.	O
We	O
examined	B-MED
46	O
PNES	B-MED
patients	B-MED
with	O
ID	B-MED
(	O
ID	B-MED
group	B-MED
)	O
and	O
106	O
PNES	B-MED
patients	B-MED
without	O
ID	B-MED
(	O
non	B-MED
-	I-MED
ID	I-MED
group	B-MED
)	O
retrospectively	B-MED
in	O
case	B-MED
charts	I-MED
.	O
In	B-MED
addition	I-MED
to	I-MED
examining	B-MED
basic	O
demographic	B-MED
and	O
clinical	B-MED
data	I-MED
,	O
effects	B-MED
of	I-MED
different	B-MED
therapeutic	B-MED
intervention	I-MED
were	O
examined	B-MED
as	O
a	O
function	B-MED
of	O
decrease	B-MED
or	O
disappearance	B-MED
of	O
PNES	B-MED
attacks	O
in	O
the	O
ID	B-MED
group	B-MED
.	O
Age	B-MED
at	O
the	O
first	O
visit	B-MED
as	O
well	O
as	O
PNES	B-MED
onset	B-MED
was	O
younger	B-MED
in	O
the	O
ID	B-MED
than	O
in	O
the	O
non	B-MED
-	I-MED
ID	I-MED
group	B-MED
(	O
t=2.651	O
,	O
p=0.009	O
;	O
t=3.528	O
,	O
p=0.001	O
,	O
respectively	O
)	O
.	O
PNES	B-MED
-free	O
ratio	B-MED
at	O
the	O
last	O
visit	B-MED
tended	O
to	O
be	O
higher	B-MED
in	O
the	O
non	B-MED
-	I-MED
ID	I-MED
group	B-MED
group	B-MED
(	O
chi	B-MED
square	I-MED
=	O
3.455	O
;	O
p=0.063	O
)	O
.	O
Psychosis	B-MED
was	O
more	O
often	O
encountered	O
in	O
the	O
ID	B-MED
group	B-MED
(	O
chi	B-MED
square	I-MED
=	O
13.443	O
;	O
p=0.001	O
)	O
.	O
Although	O
cognitive	B-MED
therapy	I-MED
and	O
pharmaco	B-MED
-	I-MED
therapeutic	I-MED
approaches	O
were	O
quite	O
similarly	B-MED
distributed	B-MED
in	O
both	O
groups	B-MED
,	O
environmental	B-MED
adjustment	B-MED
was	O
often	O
introduced	B-MED
in	O
the	O
ID	B-MED
group	B-MED
(	O
44	O
%	O
)	O
as	O
compared	B-MED
to	O
the	O
non	B-MED
-	I-MED
ID	I-MED
group	B-MED
(	O
15	O
%	O
)	O
(	O
chi	B-MED
square	I-MED
=	O
14.299	O
;	O
p=0.001	O
)	O
.	O
Brief	B-MED
weekly	B-MED
visit	B-MED
service	I-MED
is	O
also	O
more	O
often	O
utilized	B-MED
by	O
the	O
patients	B-MED
with	O
ID	B-MED
(	O
54	O
%	O
)	O
than	O
by	O
those	O
without	O
ID	B-MED
(	O
35	O
%	O
)	O
(	O
chi	B-MED
square	I-MED
=	O
5.021	O
,	O
p=0.025	O
)	O
.	O
Optimal	B-MED
treatment	B-MED
approaches	O
in	O
this	O
sizable	O
patient	B-MED
subgroup	B-MED
should	O
be	O
the	O
subject	B-MED
of	O
future	B-MED
prospective	B-MED
studies	I-MED
.	O
Hypovitaminosis	B-MED
D	I-MED
and	O
Associated	O
Cardiometabolic	B-MED
Risk	I-MED
in	O
Women	B-MED
with	O
PCOS	B-MED
Women	B-MED
with	O
Polycystic	B-MED
Ovary	I-MED
Syndrome	I-MED
(	O
PCOS	B-MED
)	O
frequently	O
suffer	O
from	O
metabolic	B-MED
disturbances	I-MED
like	O
insulin	B-MED
resistance	I-MED
,	O
hypertension	B-MED
and	O
atherogenic	B-MED
dyslipidemia	I-MED
.	O
Accumulating	B-MED
evidences	O
suggest	O
that	O
Vitamin	B-MED
D	I-MED
deficiency	I-MED
is	O
common	O
in	O
PCOS	B-MED
and	O
may	O
be	O
associated	B-MED
with	I-MED
metabolic	B-MED
and	O
endocrinal	B-MED
dysfunctions	I-MED
in	O
PCOS	B-MED
.	O
Thus	O
women	B-MED
with	O
PCOS	B-MED
may	O
be	O
at	O
elevated	O
risk	B-MED
of	O
cardiovascular	B-MED
disease	I-MED
.	O
Present	O
study	B-MED
aims	O
to	O
evaluate	O
Vitamin	B-MED
D	I-MED
status	O
and	O
to	O
assess	O
its	O
association	O
with	O
metabolic	B-MED
and	O
endocrinal	B-MED
dysregulations	I-MED
in	O
women	B-MED
with	O
PCOS	B-MED
,	O
which	O
might	O
help	O
in	O
early	B-MED
identification	I-MED
and	O
prevention	B-MED
of	O
future	O
symptomatic	B-MED
cardiac	B-MED
disease	I-MED
.	O
A	O
total	O
of	O
44	O
women	B-MED
with	O
PCOS	B-MED
,	O
diagnosed	O
by	O
Rotterdam	B-MED
criteria	I-MED
and	O
45	O
healthy	B-MED
control	I-MED
without	O
PCOS	B-MED
,	O
were	O
evaluated	O
for	O
Vitamin	B-MED
D	I-MED
and	O
cardiometabolic	B-MED
risk	I-MED
factors	I-MED
,	O
including	O
fasting	B-MED
plasma	I-MED
glucose	I-MED
,	O
insulin	B-MED
resistance	I-MED
,	O
dyslipidemia	B-MED
,	O
hs	B-MED
-	I-MED
CRP	I-MED
.	O
That	O
apart	O
,	O
several	O
endocrinal	B-MED
parameters	B-MED
of	O
hyperandrogenism	B-MED
were	O
also	O
examined	O
.	O
Several	O
correlation	B-MED
studies	I-MED
were	O
determined	O
to	O
establish	O
the	O
role	O
of	O
Vitamin	B-MED
D	I-MED
as	O
a	O
cardiometabolic	B-MED
risk	I-MED
factor	I-MED
in	O
PCOS	B-MED
.	O
Results	O
were	O
expressed	O
as	O
mean±SD	O
and	O
were	O
statistically	B-MED
analysed	I-MED
using	O
SPSS	B-MED
software	I-MED
version	I-MED
16	I-MED
,	O
unpaired	B-MED
student	I-MED
's	I-MED
t	I-MED
-	I-MED
test	I-MED
and	O
Pearson	B-MED
's	I-MED
correlation	I-MED
coefficient	I-MED
.	O
We	O
found	O
lower	O
levels	O
of	O
Vitamin	B-MED
D	I-MED
,	O
which	O
was	O
statistically	O
significant	O
as	O
compared	O
to	O
healthy	B-MED
controls	I-MED
.	O
Hyperinsulinemia	B-MED
,	O
rise	O
in	O
insulin	B-MED
resistance	I-MED
and	O
marked	O
dyslipidemia	B-MED
was	O
observed	O
in	O
the	O
present	O
study	B-MED
.	O
Another	O
relevant	O
finding	O
was	O
significant	O
correlation	O
of	O
Vitamin	B-MED
D	I-MED
with	O
insulin	B-MED
and	O
Homeostatic	B-MED
Model	I-MED
of	I-MED
Assessment-	I-MED
Insulin	I-MED
Resistance	I-MED
Index	I-MED
(	O
HOMA	B-MED
-	I-MED
IR	I-MED
)	O
.	O
Hypovitaminosis	B-MED
D	I-MED
was	O
prevalent	O
in	O
PCOS	B-MED
.	O
This	O
was	O
related	O
to	O
metabolic	B-MED
and	O
hormonal	B-MED
disorders	I-MED
in	O
PCOS	B-MED
.	O
Possibly	O
this	O
combined	O
with	O
impaired	B-MED
fasting	I-MED
glucose	I-MED
,	O
IR	B-MED
and	O
dyslipidemia	B-MED
,	O
could	O
account	O
for	O
Cardio	B-MED
vascular	I-MED
risks	I-MED
in	O
PCOS	B-MED
.	O
Further	O
prospective	O
observational	B-MED
studies	I-MED
and	O
randomized	B-MED
control	I-MED
trials	I-MED
are	O
required	O
to	O
explore	O
the	O
above	O
hypothesis	B-MED
.	O
Development	B-MED
of	O
the	O
four	B-MED
-	I-MED
item	I-MED
Letter	I-MED
and	I-MED
Shape	I-MED
Drawing	I-MED
test	I-MED
(	O
LSD-4	B-MED
):	O
A	O
brief	O
bedside	B-MED
test	I-MED
of	O
visuospatial	B-MED
function	I-MED
Conventional	B-MED
bedside	B-MED
tests	I-MED
of	O
visuospatial	B-MED
function	I-MED
such	O
as	O
the	O
Clock	B-MED
Drawing	I-MED
(	O
CDT	B-MED
)	O
and	O
Intersecting	B-MED
Pentagons	I-MED
(	O
IPT	B-MED
)	O
lack	B-MED
consistency	B-MED
in	O
delivery	O
and	O
interpretation	B-MED
.	O
We	O
compared	B-MED
performance	B-MED
on	O
a	O
novel	O
test	O
of	O
visuospatial	B-MED
ability	I-MED
-	O
the	O
LSD	B-MED
-	O
with	O
the	O
IPT	B-MED
,	O
CDT	B-MED
and	O
MMSE	B-MED
in	O
180	O
acute	B-MED
elderly	B-MED
medical	B-MED
inpatients	B-MED
[	O
mean	B-MED
age	B-MED
79.7±7.1	O
(	O
range	B-MED
62	O
-	O
96	O
)	O
;	O
91	O
females	B-MED
(	O
50.6	O
%	O
)	O
]	O
.	O
124	O
(	O
69	O
%	O
)	O
scored	B-MED
≤23	O
on	O
the	O
MMSE	B-MED
;	O
60	O
with	O
mild	B-MED
(	O
score	B-MED
18	O
-	O
23	O
)	O
and	O
64	O
with	O
severe	B-MED
(	O
score	B-MED
≤17	O
)	O
impairment	B-MED
.	O
78	O
(	O
43	O
%	O
)	O
scored	B-MED
≥6	O
on	O
the	O
CDT	B-MED
,	O
while	O
for	O
the	O
IPT	B-MED
,	O
87	O
(	O
47	O
%	O
)	O
scored	B-MED
≥4	O
.	O
The	O
CDT	B-MED
and	O
IPT	B-MED
agreed	B-MED
on	O
the	O
classification	B-MED
of	O
138	O
patients	B-MED
(	O
77	O
%	O
)	O
with	O
modest-	O
strong	B-MED
agreement	O
with	O
the	O
MMSE	B-MED
categories	B-MED
.	O
Correlation	B-MED
between	O
the	O
LSD	B-MED
and	O
visuospatial	B-MED
tests	I-MED
was	O
high	B-MED
.	O
A	O
four	B-MED
-	I-MED
item	I-MED
version	I-MED
of	O
the	O
LSD	B-MED
incorporating	O
items	B-MED
1,10,12,15	O
had	O
high	B-MED
correlation	B-MED
with	O
the	O
LSD-15	B-MED
and	O
strong	B-MED
association	B-MED
with	I-MED
MMSE	B-MED
categories	B-MED
.	O
The	O
LSD-4	B-MED
provides	O
a	O
brief	O
and	O
easily	B-MED
interpreted	B-MED
bedside	B-MED
test	I-MED
of	O
visuospatial	B-MED
function	I-MED
that	O
has	O
high	B-MED
coverage	B-MED
of	O
elderly	B-MED
patients	B-MED
with	O
neurocognitive	B-MED
impairment	I-MED
,	O
good	O
agreement	O
with	O
conventional	B-MED
tests	O
of	O
visuospatial	B-MED
ability	I-MED
and	O
favourable	O
ability	O
to	O
identify	B-MED
significant	B-MED
cognitive	B-MED
impairment	I-MED
.	O
[	O
181	O
words	O
]	O
.	O
High	B-MED
-	I-MED
density	I-MED
lipoprotein	I-MED
-associated	O
sphingosine-1	B-MED
-	I-MED
phosphate	I-MED
activity	O
in	O
heterozygous	B-MED
familial	I-MED
hypercholesterolaemia	I-MED
Patients	B-MED
with	O
heterozygous	B-MED
familial	I-MED
hypercholesterolaemia	I-MED
(	O
FH	B-MED
)	O
suffer	B-MED
from	O
high	B-MED
plasma	I-MED
cholesterol	I-MED
and	O
an	O
environment	B-MED
of	O
increased	O
oxidative	B-MED
stress	I-MED
.	O
We	O
examined	O
its	O
potential	O
effects	O
on	O
high	B-MED
-	I-MED
density	I-MED
lipoprotein	I-MED
HDL	B-MED
(	O
HDL)-associated	O
sphingosine-1	B-MED
-	I-MED
phosphate	I-MED
(	O
S1P	B-MED
)	O
content	O
(	O
HDL	B-MED
-	O
S1P	B-MED
)	O
and	O
HDL	B-MED
-mediated	O
protection	B-MED
against	I-MED
oxidative	I-MED
stress	I-MED
,	O
both	O
with	O
and	O
without	O
statin	B-MED
treatment	I-MED
.	O
In	O
a	O
case	B-MED
-	I-MED
control	I-MED
study	I-MED
,	O
HDL	B-MED
was	O
isolated	B-MED
from	O
12	O
FH	B-MED
patients	B-MED
with	O
and	O
without	O
statin	B-MED
treatment	I-MED
and	O
from	O
12	O
healthy	B-MED
controls	I-MED
.	O
The	O
HDL	B-MED
-	O
S1P	B-MED
content	O
and	O
the	O
capacity	O
of	O
HDL	B-MED
to	O
protect	B-MED
cardiomyocytes	B-MED
against	O
oxidative	B-MED
stress	I-MED
in	B-MED
vitro	I-MED
were	O
measured	O
.	O
HDL	B-MED
-associated	O
S1P	B-MED
was	O
significantly	O
correlated	O
with	O
cell	B-MED
protection	I-MED
,	O
but	O
not	O
with	O
HDL	B-MED
-	I-MED
cholesterol	I-MED
or	O
apolipoprotein	B-MED
AI	I-MED
.	O
The	O
latter	O
did	O
not	O
correlate	O
with	O
HDL	B-MED
-mediated	O
cell	B-MED
protection	I-MED
.	O
Neither	O
the	O
HDL	B-MED
-	O
S1P	B-MED
content	O
nor	O
HDL	B-MED
protective	O
capacity	O
differed	O
between	O
nontreated	O
FH	B-MED
patients	B-MED
and	O
controls	O
.	O
The	O
relative	O
amounts	O
of	O
apolipoprotein	B-MED
AI	I-MED
and	O
apolipoprotein	B-MED
M	I-MED
were	O
similar	O
between	O
controls	O
and	O
FH	B-MED
patients	B-MED
.	O
Statin	B-MED
treatment	I-MED
had	O
no	O
effect	O
on	O
any	O
of	O
these	O
measures	O
.	O
The	O
FH	B-MED
environment	B-MED
is	O
not	O
detrimental	O
to	O
HDL	B-MED
-	O
S1P	B-MED
content	O
or	O
HDL	B-MED
-	O
S1P	B-MED
-mediated	O
cell	B-MED
protection	I-MED
.	O
Statin	B-MED
treatment	I-MED
does	O
not	O
modulate	O
HDL	B-MED
function	O
in	O
this	O
regard	O
.	O
Simvastatin	B-MED
Promotes	O
Hematoma	B-MED
Absorption	B-MED
and	O
Reduces	O
Hydrocephalus	B-MED
Following	O
Intraventricular	B-MED
Hemorrhage	I-MED
in	O
Part	O
by	O
Upregulating	B-MED
CD36	B-MED
We	O
previously	O
found	O
that	O
hematoma	B-MED
worsens	B-MED
hydrocephalus	B-MED
after	O
intraventricular	B-MED
hemorrhage	I-MED
(	O
IVH	B-MED
)	O
via	O
increasing	B-MED
iron	B-MED
deposition	I-MED
and	O
aggravating	O
ependymal	B-MED
cilia	B-MED
injury	B-MED
;	O
therefore	O
,	O
promoting	O
hematoma	B-MED
absorption	B-MED
may	O
be	O
a	O
promising	O
strategy	O
for	O
IVH	B-MED
.	O
Recently	O
,	O
some	O
investigations	O
imply	O
that	O
simvastatin	B-MED
has	O
the	O
ability	O
of	O
accelerating	O
hematoma	B-MED
absorption	B-MED
.	O
Thus	O
,	O
this	O
study	O
was	O
designed	O
to	O
examine	O
the	O
efficacy	B-MED
of	O
simvastatin	B-MED
for	O
IVH	B-MED
in	O
rats	B-MED
.	O
Intracerebral	B-MED
hemorrhage	I-MED
with	O
ventricular	O
extension	O
was	O
induced	O
in	O
adult	B-MED
male	I-MED
Sprague	B-MED
-	I-MED
Dawley	I-MED
rats	I-MED
after	O
autologous	B-MED
blood	I-MED
injection	I-MED
.	O
Simvastatin	B-MED
or	O
vehicle	B-MED
was	O
administered	B-MED
orally	I-MED
at	O
1	O
day	O
after	O
IVH	B-MED
and	O
then	O
daily	O
for	O
1	O
week	O
.	O
MRI	B-MED
studies	I-MED
were	O
performed	O
to	O
measure	B-MED
the	O
volumes	B-MED
of	O
intracranial	B-MED
hematoma	B-MED
and	O
lateral	B-MED
ventricle	I-MED
at	O
days	O
1	O
,	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
28	O
after	O
IVH	B-MED
.	O
Motor	B-MED
and	O
neurocognitive	B-MED
functions	I-MED
were	O
assessed	B-MED
at	O
days	O
1	O
to	O
7	O
and	O
23	O
to	O
28	O
,	O
respectively	O
.	O
Iron	B-MED
deposition	I-MED
,	O
iron	B-MED
-related	O
protein	B-MED
expression	I-MED
,	O
ependymal	B-MED
damage	I-MED
,	O
and	O
histology	B-MED
were	O
detected	B-MED
at	O
day	O
28	O
.	O
Expression	B-MED
of	O
CD36	B-MED
scavenger	B-MED
receptor	I-MED
(	O
facilitating	O
phagocytosis	B-MED
)	O
was	O
examined	B-MED
at	O
day	O
3	O
after	O
IVH	B-MED
using	O
western	B-MED
blotting	I-MED
and	O
immunofluorescence	B-MED
.	O
Simvastatin	B-MED
significantly	O
increased	B-MED
hematoma	B-MED
absorption	B-MED
ratio	B-MED
,	O
reduced	B-MED
ventricular	B-MED
volume	I-MED
,	O
and	O
attenuated	B-MED
neurological	I-MED
dysfunction	I-MED
post-	O
IVH	B-MED
.	O
In	O
addition	O
,	O
less	B-MED
iron	I-MED
accumulation	I-MED
and	O
more	O
cilia	B-MED
survival	B-MED
was	O
observed	O
in	O
the	O
simvastatin	B-MED
group	O
when	O
compared	O
with	O
the	O
control	B-MED
.	O
What	O
's	O
more	O
,	O
higher	B-MED
expression	B-MED
of	O
CD36	B-MED
was	O
detected	B-MED
around	O
the	O
hematoma	B-MED
after	O
simvastatin	B-MED
administration	B-MED
.	O
Simvastatin	B-MED
significantly	O
enhanced	O
brain	B-MED
hematoma	B-MED
absorption	B-MED
,	O
alleviated	B-MED
hydrocephalus	I-MED
,	O
and	O
improved	B-MED
neurological	B-MED
recovery	B-MED
after	O
experimental	B-MED
IVH	B-MED
,	O
which	O
may	O
in	O
part	O
by	O
upregulating	B-MED
CD36	B-MED
expression	B-MED
.	O
Our	O
data	B-MED
suggest	O
that	O
early	O
simvastatin	B-MED
use	O
may	O
be	O
a	O
novel	B-MED
therapy	B-MED
for	O
IVH	B-MED
patients	B-MED
.	O
The	O
correlation	B-MED
of	I-MED
the	I-MED
results	I-MED
of	O
the	O
survey	B-MED
SNOT-20	I-MED
of	O
objective	B-MED
studies	I-MED
of	O
nasal	B-MED
obstruction	I-MED
and	O
the	O
geometry	O
of	O
the	O
nasal	B-MED
cavities	I-MED
In	O
this	O
paper	O
were	O
verified	O
the	O
correlation	B-MED
between	I-MED
the	I-MED
results	I-MED
of	O
the	O
survey	B-MED
SNOT-20	I-MED
and	O
the	O
results	B-MED
of	I-MED
the	I-MED
objective	I-MED
tests	I-MED
of	O
nasal	B-MED
obstruction	I-MED
which	O
are	O
rhinomanometry	B-MED
and	O
acoustic	B-MED
rhinometry	I-MED
before	O
and	O
after	O
surgical	B-MED
treatment	I-MED
,	O
such	O
as	O
septoplasty	B-MED
,	O
septoconchoplasty	B-MED
,	O
ethmoidectomy	B-MED
and	O
septoethmoidectomy	B-MED
.	O
The	O
material	O
used	O
in	O
this	O
study	O
was	O
233	O
patients	B-MED
diagnosed	B-MED
routinely	O
in	O
the	O
Rhinomanometry	B-MED
Laboratory	B-MED
of	O
the	O
Department	B-MED
of	I-MED
Otolaryngology	I-MED
at	O
the	O
Medical	B-MED
University	I-MED
of	O
Warsaw	B-MED
,	O
reporting	O
rhinological	B-MED
problems	I-MED
.	O
Data	B-MED
were	O
obtained	O
from	O
70	O
women	B-MED
(	O
31,4	O
%	O
)	O
ranging	O
in	O
ages	O
from	O
18	O
to	O
81	O
years	O
of	O
age	O
and	O
153	O
men	B-MED
(	O
68,6	O
%	O
)	O
ranging	O
in	O
ages	O
from	O
16	O
to	O
81	O
years	O
of	O
age	O
.	O
The	O
researches	O
presented	O
in	O
the	O
study	O
were	O
made	O
using	O
the	O
device	O
RhinoMetrics	B-MED
SRE	I-MED
2100	I-MED
which	O
combines	O
the	O
Rhinomanometer	B-MED
(	O
RhinoStream	B-MED
)	O
and	O
Acoustic	B-MED
Rhinometer	I-MED
(	O
RhinoScan	B-MED
)	O
Interacoustics	B-MED
AS	I-MED
(	O
Denmark	B-MED
)	O
.	O
Survey	B-MED
SNOT-20	I-MED
(	O
Sino	B-MED
-	I-MED
Nasal	I-MED
Outcome	I-MED
Test-20	I-MED
)	O
in	O
Polish	B-MED
was	O
completed	O
by	O
patients	B-MED
before	B-MED
surgery	I-MED
and	O
during	B-MED
the	I-MED
postoperative	I-MED
control	I-MED
visits	I-MED
.	O
The	O
calculated	O
correlations	O
between	O
the	O
objective	B-MED
parameter	I-MED
,	O
which	O
was	O
the	O
resistance	B-MED
to	O
the	O
flow	B-MED
of	I-MED
air	I-MED
through	I-MED
the	I-MED
nasal	I-MED
cavity	I-MED
,	O
and	O
the	O
subjective	B-MED
feelings	I-MED
of	I-MED
respondents	I-MED
expressed	O
in	O
the	O
survey	B-MED
SNOT-20	I-MED
were	O
generally	B-MED
weak	I-MED
,	O
and	O
statistical	B-MED
significance	I-MED
was	O
achieved	O
with	O
respect	O
to	O
the	O
first	B-MED
question	I-MED
survey	I-MED
(	O
the	O
severity	B-MED
of	I-MED
the	I-MED
nose	I-MED
obstruction	I-MED
)	O
for	O
all	O
components	O
of	O
resistance	B-MED
flow	I-MED
.	O
The	O
feeling	O
of	O
nasal	B-MED
obstruction	I-MED
is	O
the	O
most	O
reproducible	O
and	O
reliable	O
complaint	O
reported	O
by	O
the	O
patient	B-MED
with	O
rhinological	B-MED
problems	I-MED
.	O
Novel	B-MED
and	O
Lost	B-MED
Forests	B-MED
in	O
the	O
Upper	B-MED
Midwestern	I-MED
United	I-MED
States	I-MED
,	O
from	O
New	B-MED
Estimates	B-MED
of	O
Settlement	B-MED
-	I-MED
Era	I-MED
Composition	O
,	O
Stem	B-MED
Density	B-MED
,	O
and	O
Biomass	B-MED
EuroAmerican	B-MED
land	B-MED
-	I-MED
use	I-MED
and	O
its	O
legacies	B-MED
have	O
transformed	B-MED
forest	B-MED
structure	I-MED
and	O
composition	O
across	O
the	O
United	B-MED
States	I-MED
(	O
US	B-MED
)	O
.	O
More	B-MED
accurate	B-MED
reconstructions	B-MED
of	O
historical	B-MED
states	I-MED
are	O
critical	B-MED
to	O
understanding	O
the	O
processes	B-MED
governing	B-MED
past	B-MED
,	O
current	B-MED
,	O
and	O
future	B-MED
forest	B-MED
dynamics	B-MED
.	O
Here	O
we	O
present	O
new	O
gridded	O
(	O
8x8	O
km	O
)	O
reconstructions	B-MED
of	O
pre	B-MED
-	I-MED
settlement	I-MED
(	O
1800s	O
)	O
forest	B-MED
composition	O
and	O
structure	O
from	O
the	O
upper	B-MED
Midwestern	I-MED
US	I-MED
(	O
Minnesota	B-MED
,	O
Wisconsin	B-MED
,	O
and	O
most	O
of	O
Michigan	B-MED
)	O
,	O
using	O
19th	O
Century	B-MED
Public	I-MED
Land	I-MED
Survey	I-MED
System	I-MED
(	O
PLSS	B-MED
)	O
,	O
with	O
estimates	B-MED
of	O
relative	B-MED
composition	O
,	O
above	B-MED
-	I-MED
ground	I-MED
biomass	B-MED
,	O
stem	B-MED
density	B-MED
,	O
and	O
basal	B-MED
area	I-MED
for	O
28	O
tree	B-MED
types	B-MED
.	O
This	O
mapping	B-MED
is	O
more	O
robust	B-MED
than	O
past	B-MED
efforts	B-MED
,	O
using	O
spatially	O
varying	O
correction	B-MED
factors	I-MED
to	O
accommodate	O
sampling	B-MED
design	I-MED
,	O
azimuthal	B-MED
censoring	I-MED
,	O
and	O
biases	B-MED
in	O
tree	B-MED
selection	B-MED
.	O
We	O
compare	O
pre	B-MED
-	I-MED
settlement	I-MED
to	O
modern	B-MED
forests	B-MED
using	O
US	B-MED
Forest	B-MED
Service	B-MED
Forest	B-MED
Inventory	I-MED
and	I-MED
Analysis	I-MED
(	I-MED
FIA	I-MED
)	I-MED
data	I-MED
to	O
show	O
the	O
prevalence	B-MED
of	O
lost	B-MED
forests	B-MED
(	O
pre	B-MED
-	I-MED
settlement	I-MED
forests	B-MED
with	O
no	B-MED
current	B-MED
analog	B-MED
)	O
,	O
and	O
novel	B-MED
forests	B-MED
(	O
modern	B-MED
forests	B-MED
with	O
no	B-MED
past	B-MED
analogs	B-MED
)	O
.	O
Differences	O
between	O
pre	B-MED
-	I-MED
settlement	I-MED
and	O
modern	B-MED
forests	B-MED
are	O
spatially	O
structured	O
owing	O
to	O
differences	O
in	O
land	B-MED
-	I-MED
use	I-MED
impacts	B-MED
and	O
accompanying	O
ecological	B-MED
responses	I-MED
.	O
Modern	B-MED
forests	B-MED
are	O
more	O
homogeneous	B-MED
,	O
and	O
ecotonal	B-MED
gradients	B-MED
are	O
more	O
diffuse	B-MED
today	O
than	O
in	B-MED
the	I-MED
past	I-MED
.	O
Novel	B-MED
forest	B-MED
assemblages	B-MED
represent	O
28	O
%	O
of	O
all	O
FIA	B-MED
cells	O
,	O
and	O
28	O
%	O
of	O
pre	B-MED
-	I-MED
settlement	I-MED
forests	B-MED
no	B-MED
longer	I-MED
exist	B-MED
in	O
a	O
modern	B-MED
context	B-MED
.	O
Lost	B-MED
forests	B-MED
include	O
tamarack	B-MED
forests	B-MED
in	O
northeastern	B-MED
Minnesota	B-MED
,	O
hemlock	B-MED
and	O
cedar	B-MED
dominated	O
forests	B-MED
in	O
north	B-MED
-	I-MED
central	I-MED
Wisconsin	I-MED
and	O
along	O
the	O
Upper	B-MED
Peninsula	I-MED
of	I-MED
Michigan	I-MED
,	O
and	O
elm	B-MED
,	O
oak	B-MED
,	O
basswood	B-MED
and	O
ironwood	B-MED
forests	B-MED
along	O
the	O
forest	B-MED
-	O
prairie	B-MED
boundary	I-MED
in	O
south	B-MED
central	I-MED
Minnesota	I-MED
and	O
eastern	B-MED
Wisconsin	B-MED
.	O
Novel	B-MED
FIA	B-MED
forest	B-MED
assemblages	B-MED
are	O
distributed	O
evenly	O
across	O
the	O
region	B-MED
,	O
but	O
novelty	B-MED
shows	O
a	O
strong	B-MED
relationship	B-MED
to	O
spatial	B-MED
distance	I-MED
from	O
remnant	B-MED
forests	B-MED
in	O
the	O
upper	B-MED
Midwest	I-MED
,	O
with	O
novelty	B-MED
predicted	B-MED
at	O
between	O
20	O
to	O
60	O
km	O
from	O
remnants	B-MED
,	O
depending	O
on	O
historical	B-MED
forest	B-MED
type	I-MED
.	O
The	O
spatial	B-MED
relationships	B-MED
between	O
remnant	B-MED
and	O
novel	B-MED
forests	B-MED
,	O
shifts	B-MED
in	O
ecotone	B-MED
structure	I-MED
and	O
the	O
loss	B-MED
of	O
historic	B-MED
forest	B-MED
types	I-MED
point	O
to	O
significant	B-MED
challenges	O
for	O
land	B-MED
managers	B-MED
if	O
landscape	B-MED
restoration	O
is	O
a	O
priority	B-MED
.	O
The	O
spatial	O
signals	O
of	O
novelty	B-MED
and	O
ecological	B-MED
change	B-MED
also	O
point	O
to	O
potential	B-MED
challenges	O
in	O
using	O
modern	B-MED
spatial	B-MED
distributions	I-MED
of	O
species	B-MED
and	O
communities	B-MED
and	O
their	O
relationship	B-MED
to	O
underlying	O
geophysical	B-MED
and	O
climatic	B-MED
attributes	I-MED
in	O
understanding	O
potential	B-MED
responses	O
to	O
changing	B-MED
climate	B-MED
.	O
The	O
signal	B-MED
of	O
human	B-MED
settlement	B-MED
on	O
modern	B-MED
forests	B-MED
is	O
broad	B-MED
,	O
spatially	O
varying	O
and	O
acts	O
to	O
homogenize	B-MED
modern	B-MED
forests	B-MED
relative	B-MED
to	O
their	O
historic	B-MED
counterparts	O
,	O
with	O
significant	B-MED
implications	O
for	O
future	B-MED
management	B-MED
.	O
Investigation	B-MED
on	O
evaluation	B-MED
criteria	B-MED
of	O
backwashing	B-MED
effects	B-MED
for	O
a	O
pilot	B-MED
-	I-MED
scale	I-MED
BAF	B-MED
treating	B-MED
petrochemical	B-MED
wastewater	B-MED
Parameters	B-MED
for	O
evaluation	B-MED
criteria	B-MED
of	O
air	B-MED
-	O
water	B-MED
backwashing	B-MED
effect	B-MED
s	O
of	O
a	O
pilot	B-MED
-	I-MED
scale	I-MED
biological	B-MED
aerated	I-MED
filter	I-MED
(	O
BAF	B-MED
)	O
treating	B-MED
petrochemical	B-MED
wastewater	B-MED
were	O
investigated	B-MED
.	O
The	O
parameters	B-MED
included	O
the	O
suspended	B-MED
solids	B-MED
(	O
SS	B-MED
)	O
and	O
specific	B-MED
oxygen	I-MED
uptake	I-MED
rate	I-MED
(	O
SOUR	B-MED
)	O
of	O
the	O
backwashing	B-MED
effluent	B-MED
,	O
recovery	B-MED
of	O
the	O
BAF	B-MED
after	O
backwashing	B-MED
,	O
and	O
the	O
removal	B-MED
of	O
the	O
biomass	B-MED
/	O
bioactivity	B-MED
attached	B-MED
on	O
the	O
filter	B-MED
media	B-MED
after	O
backwashing	B-MED
.	O
Results	B-MED
showed	O
that	O
the	O
weight	B-MED
of	O
the	O
total	B-MED
sludge	B-MED
produced	O
in	O
the	O
backwashing	B-MED
effluent	B-MED
increased	B-MED
with	O
the	O
increase	B-MED
in	O
water	B-MED
-	O
backwashing	B-MED
intensity	B-MED
,	O
while	O
the	O
total	B-MED
SOUR	B-MED
of	O
backwashing	B-MED
effluent	B-MED
rose	O
notably	B-MED
with	O
the	O
increase	B-MED
of	O
air	B-MED
-	O
backwashing	B-MED
intensity	B-MED
.	O
The	O
optimal	B-MED
backwashing	B-MED
intensity	B-MED
of	O
14	O
L/(m(2)·s	O
)	O
for	O
air	B-MED
and	O
4	O
L/(m(2)·s	O
)	O
for	O
water	B-MED
were	O
obtained	B-MED
.	O
When	O
the	O
BAF	B-MED
was	O
backwashed	B-MED
on	O
this	O
condition	O
,	O
the	O
BAF	B-MED
recovered	B-MED
with	O
high	B-MED
average	B-MED
removal	B-MED
of	O
chemical	B-MED
oxygen	I-MED
demand	I-MED
(	O
COD	B-MED
)	O
and	O
ammonia	B-MED
nitrogen	I-MED
[	O
Formula	O
:	O
see	O
text	O
]	O
of	O
14.3	O
%	O
and	O
50.3	O
%	O
,	O
respectively	O
.	O
High	B-MED
amount	B-MED
of	O
biomass	B-MED
removal	B-MED
at	O
15.8	O
%	O
and	O
low	B-MED
level	B-MED
of	O
bioactivity	B-MED
removal	B-MED
at	O
8.8	O
%	O
attached	B-MED
on	O
the	O
filter	B-MED
media	B-MED
were	O
also	O
found	O
.	O
Concentrations	B-MED
of	O
the	O
benzene	B-MED
,	O
toluene	B-MED
,	O
ethylbenzene	B-MED
and	O
(	B-MED
o-	I-MED
,	I-MED
m-	I-MED
,	I-MED
p-	I-MED
)	I-MED
xylenes	I-MED
(	O
BTEX	B-MED
)	O
and	O
phenol	B-MED
in	O
the	O
backwashed	B-MED
sludge	B-MED
were	O
analyzed	B-MED
,	O
showing	O
that	O
the	O
backwashing	B-MED
was	O
essential	B-MED
to	O
remove	B-MED
some	O
aromatic	B-MED
compounds	I-MED
adsorbed	B-MED
in	O
the	O
microorganisms	B-MED
.	O
Zika	B-MED
Virus	I-MED
Disrupts	B-MED
Phospho	B-MED
-	I-MED
TBK1	I-MED
Localization	B-MED
and	O
Mitosis	B-MED
in	O
Human	B-MED
Neuroepithelial	B-MED
Stem	B-MED
Cells	I-MED
and	O
Radial	B-MED
Glia	I-MED
The	O
mechanisms	B-MED
underlying	O
Zika	B-MED
virus	I-MED
ZIKV	B-MED
(	O
ZIKV)-related	O
microcephaly	B-MED
and	O
other	O
neurodevelopment	B-MED
defects	B-MED
remain	O
poorly	B-MED
understood	B-MED
.	O
Here	O
,	O
we	O
describe	O
the	O
derivation	B-MED
and	O
characterization	B-MED
,	O
including	O
single	B-MED
-	I-MED
cell	I-MED
RNA	I-MED
-	I-MED
seq	I-MED
,	O
of	O
neocortical	B-MED
and	O
spinal	B-MED
cord	I-MED
neuroepithelial	B-MED
stem	B-MED
(	I-MED
NES	I-MED
)	I-MED
cells	I-MED
to	O
model	O
early	B-MED
human	B-MED
neurodevelopment	B-MED
and	O
ZIKV	B-MED
-related	O
neuropathogenesis	B-MED
.	O
By	O
analyzing	O
human	B-MED
NES	B-MED
cells	I-MED
,	O
organotypic	B-MED
fetal	B-MED
brain	B-MED
slices	B-MED
,	O
and	O
a	O
ZIKV	B-MED
-	O
infected	B-MED
micrencephalic	B-MED
brain	B-MED
,	O
we	O
show	O
that	O
ZIKV	B-MED
infects	B-MED
both	O
neocortical	B-MED
and	O
spinal	B-MED
NES	B-MED
cells	I-MED
as	O
well	O
as	O
their	O
fetal	B-MED
homolog	O
,	O
radial	B-MED
glial	I-MED
cells	I-MED
(	O
RGCs	B-MED
)	O
,	O
causing	O
disrupted	B-MED
mitoses	B-MED
,	O
supernumerary	B-MED
centrosomes	B-MED
,	O
structural	B-MED
disorganization	B-MED
,	O
and	O
cell	B-MED
death	I-MED
.	O
ZIKV	B-MED
infection	I-MED
of	O
NES	B-MED
cells	I-MED
and	O
RGCs	B-MED
causes	O
centrosomal	B-MED
depletion	B-MED
and	O
mitochondrial	B-MED
sequestration	B-MED
of	O
phospho	B-MED
-	I-MED
TBK1	I-MED
during	O
mitosis	B-MED
.	O
We	O
also	O
found	O
that	O
nucleoside	B-MED
analogs	I-MED
inhibit	B-MED
ZIKV	B-MED
replication	B-MED
in	O
NES	B-MED
cells	I-MED
,	O
protecting	O
them	O
from	O
ZIKV	B-MED
-	O
induced	B-MED
pTBK1	B-MED
relocalization	B-MED
and	O
cell	B-MED
death	I-MED
.	O
We	O
established	B-MED
a	O
model	B-MED
system	I-MED
of	O
human	B-MED
neural	B-MED
stem	I-MED
cells	I-MED
to	O
reveal	O
cellular	B-MED
and	O
molecular	B-MED
mechanisms	B-MED
underlying	O
neurodevelopmental	B-MED
defects	B-MED
associated	B-MED
with	I-MED
ZIKV	B-MED
infection	I-MED
and	O
its	O
potential	B-MED
treatment	B-MED
.	O
Assessment	B-MED
of	O
genetic	B-MED
relationship	B-MED
among	O
Rhododendron	B-MED
cultivars	B-MED
using	O
amplified	B-MED
fragment	I-MED
length	I-MED
polymorphism	I-MED
and	O
inter	B-MED
-	I-MED
simple	I-MED
sequence	I-MED
repeat	I-MED
markers	B-MED
Genetic	B-MED
relationships	B-MED
of	O
17	O
Rhododendron	B-MED
cultivars	B-MED
,	O
China	B-MED
,	O
were	O
assessed	B-MED
using	O
inter	B-MED
-	I-MED
simple	I-MED
sequence	I-MED
repeat	I-MED
(	O
ISSR	B-MED
)	O
and	O
amplified	B-MED
fragment	I-MED
length	I-MED
polymorphism	I-MED
(	O
AFLP	B-MED
)	O
markers	B-MED
.	O
A	O
total	O
of	O
133	O
bands	O
were	O
obtained	O
using	O
nine	O
selected	O
ISSR	B-MED
primers	B-MED
,	O
129	O
(	O
96.99	O
%	O
)	O
of	O
which	O
were	O
polymorphic	B-MED
;	O
267	O
bands	O
were	O
amplified	O
by	O
four	O
AFLP	B-MED
primer	B-MED
pairs	I-MED
,	O
251	O
(	O
94.01	O
%	O
)	O
of	O
which	O
exhibited	O
polymorphism	B-MED
.	O
Based	O
on	O
these	O
polymorphic	B-MED
products	B-MED
,	O
a	O
cluster	B-MED
analysis	I-MED
revealed	O
similarities	B-MED
between	O
the	O
results	B-MED
of	O
the	O
ISSR	B-MED
and	O
AFLP	B-MED
.	O
All	O
of	O
the	O
cultivars	B-MED
were	O
clustered	B-MED
into	O
two	O
major	O
branches	B-MED
;	O
one	O
branch	B-MED
contained	O
the	O
same	O
four	O
cultivars	B-MED
,	O
and	O
the	O
other	O
cultivars	B-MED
were	O
separated	O
into	O
different	O
groups	B-MED
in	O
the	O
other	O
branch	B-MED
.	O
The	O
cluster	B-MED
results	B-MED
showed	O
that	O
the	O
genetic	B-MED
relationships	B-MED
of	O
the	O
17	O
cultivars	B-MED
were	O
partly	O
related	B-MED
to	O
their	O
morphological	B-MED
characteristics	B-MED
,	O
particularly	O
the	O
flowering	B-MED
phase	B-MED
.	O
Therefore	O
,	O
the	O
results	B-MED
of	O
this	O
study	B-MED
support	O
the	O
classification	B-MED
of	O
Rhododendron	B-MED
cultivars	B-MED
according	O
to	O
flowering	B-MED
phase	B-MED
.	O
In	O
addition	O
,	O
the	O
cluster	B-MED
results	B-MED
can	O
be	O
used	O
to	O
select	B-MED
suitable	O
parents	O
for	O
breeding	B-MED
.	O
Recombinant	B-MED
fibrinogen	B-MED
reveals	O
the	O
differential	B-MED
roles	O
of	O
α-	B-MED
and	O
γ	B-MED
-	I-MED
chain	I-MED
cross	B-MED
-	I-MED
linking	I-MED
and	O
molecular	B-MED
heterogeneity	B-MED
in	O
fibrin	B-MED
clot	I-MED
strain	B-MED
-	I-MED
stiffening	I-MED
Essentials	O
Fibrinogen	B-MED
circulates	B-MED
in	O
human	B-MED
plasma	B-MED
as	O
a	O
complex	B-MED
mixture	B-MED
of	O
heterogeneous	B-MED
molecular	B-MED
variants	B-MED
.	O
We	O
measured	B-MED
strain	B-MED
-	I-MED
stiffening	I-MED
of	O
recombinantly	B-MED
produced	O
fibrinogen	B-MED
upon	O
clotting	B-MED
.	O
Factor	B-MED
XIII	I-MED
and	O
molecular	B-MED
heterogeneity	B-MED
alter	O
clot	B-MED
elasticity	B-MED
at	O
the	O
protofibril	B-MED
and	O
fiber	B-MED
level	O
.	O
This	O
highlights	O
the	O
hitherto	O
unknown	O
role	O
of	O
molecular	B-MED
composition	B-MED
in	O
fibrin	B-MED
clot	I-MED
mechanics	B-MED
.	O
Background	O
Fibrin	B-MED
plays	O
a	O
crucial	O
role	O
in	O
haemostasis	B-MED
and	O
wound	B-MED
healing	I-MED
by	O
forming	O
strain	B-MED
-	I-MED
stiffening	I-MED
fibrous	B-MED
networks	I-MED
that	O
reinforce	O
blood	B-MED
clots	I-MED
.	O
The	O
molecular	B-MED
origin	O
of	O
fibrin	B-MED
's	I-MED
strain	B-MED
-	I-MED
stiffening	I-MED
behavior	O
remains	O
poorly	O
understood	O
,	O
primarily	O
because	O
plasma	B-MED
fibrinogen	B-MED
is	O
a	O
complex	B-MED
mixture	B-MED
of	O
heterogeneous	B-MED
molecular	B-MED
variants	B-MED
and	O
is	O
often	O
contaminated	O
by	O
plasma	B-MED
factors	I-MED
that	O
affect	O
clot	B-MED
properties	B-MED
.	O
Objectives	O
and	O
methods	O
To	O
facilitate	O
mechanistic	B-MED
dissection	I-MED
of	O
fibrin	B-MED
nonlinear	B-MED
elasticity	I-MED
,	O
we	O
produced	O
a	O
homogeneous	B-MED
recombinant	B-MED
fibrinogen	B-MED
corresponding	O
to	O
the	O
main	O
variant	B-MED
in	O
human	B-MED
plasma	B-MED
,	O
termed	O
rFib610	B-MED
.	O
We	O
characterized	O
the	O
structure	B-MED
of	O
rFib610	B-MED
clots	B-MED
using	O
turbidimetry	B-MED
,	O
microscopy	B-MED
and	O
X	B-MED
-	I-MED
ray	I-MED
scattering	I-MED
.	O
We	O
used	O
rheology	B-MED
to	O
measure	B-MED
the	O
strain	B-MED
-	I-MED
stiffening	I-MED
behavior	O
of	O
the	O
clots	B-MED
and	O
determined	O
the	O
fiber	B-MED
properties	B-MED
by	O
modeling	B-MED
the	O
clots	B-MED
as	O
semi	B-MED
-	I-MED
flexible	I-MED
polymer	I-MED
networks	I-MED
.	O
Results	O
We	O
show	O
that	O
addition	O
of	O
FXIII	B-MED
to	O
rFib610	B-MED
clots	B-MED
causes	O
a	O
dose	B-MED
-	I-MED
dependent	I-MED
stiffness	I-MED
increase	O
at	O
small	O
deformations	B-MED
and	O
renders	O
the	O
strain	B-MED
-	I-MED
stiffening	I-MED
response	O
reversible	O
.	O
We	O
find	O
that	O
γ	B-MED
-	I-MED
chain	I-MED
cross	B-MED
-	I-MED
linking	I-MED
contributes	O
to	O
clot	B-MED
elasticity	B-MED
by	O
changing	O
the	O
force	B-MED
-	I-MED
extension	I-MED
behavior	I-MED
of	O
the	O
protofibrils	B-MED
,	O
whereas	O
α	B-MED
-	I-MED
chain	I-MED
cross	B-MED
-	I-MED
linking	I-MED
stiffens	O
the	O
fibers	B-MED
,	O
as	O
a	O
consequence	O
of	O
tighter	B-MED
coupling	I-MED
between	O
the	O
constituent	O
protofibrils	B-MED
.	O
Interestingly	O
,	O
rFib610	B-MED
protofibrils	B-MED
have	O
a	O
25	O
%	O
larger	O
bending	B-MED
rigidity	I-MED
than	O
plasma	B-MED
-purified	O
fibrin	B-MED
protofibrils	B-MED
and	O
a	O
delayed	O
strain	B-MED
-	I-MED
stiffening	I-MED
,	O
indicating	O
that	O
molecular	B-MED
heterogeneity	B-MED
influences	B-MED
clot	B-MED
mechanics	B-MED
at	O
the	O
protofibril	B-MED
scale	I-MED
.	O
Conclusions	O
Fibrinogen	B-MED
molecular	B-MED
heterogeneity	B-MED
and	O
FXIII	B-MED
affect	O
the	O
mechanical	B-MED
function	I-MED
of	O
fibrin	B-MED
clots	I-MED
by	O
altering	O
the	O
nonlinear	B-MED
viscoelastic	I-MED
properties	I-MED
at	O
the	O
protofibril	B-MED
and	O
fiber	B-MED
scale	I-MED
.	O
This	O
work	O
provides	O
a	O
starting	O
point	O
to	O
investigate	B-MED
the	O
role	O
of	O
molecular	B-MED
heterogeneity	B-MED
of	O
plasma	B-MED
fibrinogen	B-MED
in	O
fibrin	B-MED
clot	I-MED
mechanics	B-MED
and	O
haemostasis	B-MED
.	O
Low	B-MED
intensity	B-MED
sprint	B-MED
training	I-MED
with	O
blood	B-MED
flow	I-MED
restriction	I-MED
improves	O
100	O
m	O
dash	O
We	O
investigated	B-MED
the	O
effects	B-MED
of	I-MED
practical	B-MED
blood	I-MED
flow	I-MED
restriction	I-MED
(	O
pBFR	B-MED
)	O
of	O
leg	B-MED
muscles	I-MED
during	O
sprint	B-MED
training	I-MED
on	O
the	O
100	O
m	O
dash	O
time	B-MED
in	O
well	B-MED
-	I-MED
trained	I-MED
sport	I-MED
students	I-MED
.	O
Participants	B-MED
performed	O
6x100	O
m	O
sprints	B-MED
at	O
60	O
-	O
70	O
%	O
of	O
their	O
maximal	O
100	O
m	O
sprinting	B-MED
speed	I-MED
twice	B-MED
a	I-MED
week	I-MED
for	O
6	O
weeks	B-MED
,	O
either	O
with	O
(	O
IG	B-MED
;	O
n=12	O
)	O
or	O
without	O
pBFR	B-MED
(	O
CG	B-MED
;	O
n=12	O
)	O
.	O
The	O
100	O
m	O
dash	O
time	B-MED
significantly	O
decreased	B-MED
more	O
in	O
the	O
IG	B-MED
(	O
-0.38±0.24	O
s	O
)	O
than	O
in	O
the	O
CG	B-MED
(	O
-0.16±0.17	O
s	O
)	O
.	O
The	O
muscle	B-MED
thickness	B-MED
of	O
the	O
rectus	B-MED
femoris	I-MED
increased	B-MED
only	O
in	O
the	O
IG	B-MED
,	O
while	O
no	O
group	B-MED
by	O
time	B-MED
interactions	B-MED
were	O
found	O
for	O
the	O
muscle	B-MED
thickness	B-MED
of	O
the	O
biceps	B-MED
femoris	I-MED
and	O
the	O
biceps	B-MED
brachii	I-MED
.	O
The	O
maximal	B-MED
isometric	I-MED
force	I-MED
,	O
measured	O
using	O
a	O
leg	B-MED
press	I-MED
,	O
did	O
not	B-MED
change	I-MED
in	O
either	O
group	B-MED
.	O
However	O
,	O
the	O
rate	B-MED
of	I-MED
force	I-MED
development	I-MED
improved	O
in	O
the	O
IG	B-MED
.	O
Growth	B-MED
hormone	I-MED
,	O
testosterone	B-MED
,	O
insulin	B-MED
-	I-MED
like	I-MED
growth	I-MED
factor	I-MED
1	I-MED
,	O
and	O
cortisol	B-MED
concentrations	B-MED
did	O
not	B-MED
significantly	I-MED
differ	I-MED
between	O
both	O
groups	B-MED
at	O
any	O
measurement	B-MED
time	B-MED
point	I-MED
(	O
pre	O
,	O
1	O
min	O
,	O
20	O
min	O
,	O
120	O
min	O
,	O
and	O
24	O
h	O
after	O
the	O
six	O
all	O
-	O
out	O
sprints	B-MED
of	O
the	O
first	O
training	B-MED
session	B-MED
)	O
.	O
The	O
muscle	B-MED
damage	I-MED
marker	B-MED
h	B-MED
-	I-MED
FABP	I-MED
increased	B-MED
significantly	O
more	O
in	O
the	O
CG	B-MED
than	O
in	O
the	O
IG	B-MED
.	O
The	O
pBFR	B-MED
improved	O
the	O
100	O
m	O
dash	O
time	B-MED
significantly	O
more	O
than	O
low	B-MED
-	O
intensity	B-MED
sprint	B-MED
interval	I-MED
training	I-MED
alone	O
.	O
Other	O
noted	O
benefits	B-MED
of	O
training	B-MED
with	O
pBFR	B-MED
were	O
a	O
decreased	B-MED
level	B-MED
of	O
muscle	B-MED
damage	I-MED
,	O
a	O
greater	O
increase	B-MED
of	O
the	O
rectus	B-MED
femoris	I-MED
muscle	I-MED
thickness	B-MED
,	O
and	O
a	O
higher	B-MED
rate	B-MED
of	I-MED
force	I-MED
development	I-MED
.	O
However	O
,	O
the	O
tested	B-MED
hormones	B-MED
were	O
unable	O
to	O
explain	O
the	O
additional	O
beneficial	B-MED
effects	I-MED
.	O
Acute	B-MED
kidney	I-MED
injury	I-MED
and	O
fluid	B-MED
overload	I-MED
in	O
infants	B-MED
and	O
children	B-MED
after	O
cardiac	B-MED
surgery	I-MED
Acute	B-MED
kidney	I-MED
injury	I-MED
is	O
a	O
common	O
and	O
serious	B-MED
complication	B-MED
after	O
congenital	B-MED
heart	I-MED
surgery	I-MED
,	O
particularly	O
among	O
infants	B-MED
.	O
This	O
comorbidity	B-MED
has	O
been	O
independently	O
associated	B-MED
with	I-MED
adverse	B-MED
outcomes	I-MED
including	O
an	O
increase	B-MED
in	O
mortality	B-MED
.	O
Postoperative	B-MED
acute	B-MED
kidney	I-MED
injury	I-MED
has	O
a	O
complex	O
pathophysiology	B-MED
with	O
many	O
risk	B-MED
factors	I-MED
,	O
and	O
therefore	O
no	B-MED
single	I-MED
medication	I-MED
or	O
therapy	B-MED
has	O
been	O
demonstrated	O
to	O
be	O
effective	B-MED
for	O
treatment	B-MED
or	O
prevention	B-MED
.	O
However	O
,	O
it	O
has	O
been	O
established	O
that	O
the	O
associated	O
fluid	B-MED
overload	I-MED
is	O
one	O
of	O
the	O
major	O
determinants	B-MED
of	O
morbidity	B-MED
,	O
particularly	O
in	O
infants	B-MED
after	O
cardiac	B-MED
surgery	I-MED
.	O
Therefore	O
,	O
in	O
the	O
absence	B-MED
of	O
an	O
intervention	B-MED
to	O
prevent	O
acute	B-MED
kidney	I-MED
injury	I-MED
,	O
much	O
of	O
the	O
effort	O
to	O
improve	B-MED
outcomes	B-MED
has	O
focused	O
on	O
treating	B-MED
and	O
preventing	B-MED
fluid	B-MED
overload	I-MED
.	O
Early	B-MED
renal	B-MED
replacement	I-MED
therapy	I-MED
,	O
often	O
in	O
the	O
form	O
of	O
peritoneal	B-MED
dialysis	I-MED
,	O
has	O
been	O
shown	O
to	O
be	O
safe	B-MED
and	O
beneficial	B-MED
in	O
infants	B-MED
with	O
oliguria	B-MED
after	O
heart	B-MED
surgery	I-MED
.	O
As	O
understanding	O
of	O
the	O
pathophysiology	B-MED
of	O
acute	B-MED
kidney	I-MED
injury	I-MED
and	O
the	O
ability	O
to	O
confidently	O
diagnose	B-MED
it	O
earlier	O
continues	O
to	O
evolve	O
,	O
it	O
is	O
likely	O
that	O
novel	O
preventative	B-MED
and	O
therapeutic	B-MED
interventions	I-MED
will	O
be	O
available	O
in	O
the	O
future	O
.	O
Tailor	B-MED
-	I-MED
made	I-MED
drug	I-MED
carrier	I-MED
:	O
Comparison	B-MED
of	O
formation	O
-	O
dependent	O
physicochemical	B-MED
properties	I-MED
within	O
self	B-MED
-	I-MED
assembled	I-MED
aggregates	B-MED
for	O
an	O
optimal	B-MED
drug	B-MED
carrier	I-MED
Self	B-MED
-	I-MED
assembled	I-MED
surfactant	B-MED
aggregates	B-MED
,	O
such	O
as	O
micelles	B-MED
and	O
vesicles	B-MED
,	O
have	O
been	O
investigated	O
for	O
their	O
application	B-MED
as	O
drug	B-MED
carriers	I-MED
in	O
the	O
treatment	B-MED
of	O
various	O
diseases	B-MED
.	O
However	O
,	O
the	O
characteristics	B-MED
that	O
decide	O
which	O
aggregate	B-MED
is	O
the	O
best	B-MED
drug	B-MED
carrier	I-MED
for	O
each	O
disease	B-MED
have	O
not	O
yet	O
been	O
clarified	O
.	O
In	O
order	O
to	O
design	B-MED
an	O
optimal	B-MED
drug	B-MED
carrier	I-MED
for	O
each	O
disease	B-MED
,	O
various	O
kinds	O
of	O
self	B-MED
-	I-MED
assembled	I-MED
aggregates	B-MED
,	O
such	O
as	O
spherical	B-MED
micelles	I-MED
,	O
lens	B-MED
-	I-MED
like	I-MED
vesicles	I-MED
,	O
and	O
tube	B-MED
-	I-MED
like	I-MED
vesicles	I-MED
,	O
were	O
evaluated	O
by	O
"	O
multiple	B-MED
techniques	I-MED
"	O
including	O
dynamic	B-MED
light	I-MED
scattering	I-MED
,	O
differential	B-MED
scanning	I-MED
calorimetry	I-MED
,	O
nuclear	B-MED
magnetic	I-MED
resonance	I-MED
spectroscopy	I-MED
,	O
and	O
fluorescence	B-MED
measurement	I-MED
using	O
the	O
Laurdan	B-MED
probe	B-MED
.	O
These	O
studies	B-MED
led	O
to	O
the	O
compilation	O
of	O
a	O
database	B-MED
on	O
the	O
formation	O
-	O
dependent	O
properties	O
of	O
self	B-MED
-	I-MED
assembled	I-MED
aggregates	B-MED
.	O
As	O
the	O
relationship	B-MED
between	O
physicochemical	B-MED
properties	I-MED
of	O
self	B-MED
-	I-MED
assembled	I-MED
aggregates	B-MED
and	O
their	O
functions	B-MED
as	O
drug	B-MED
carriers	I-MED
have	O
been	O
extensively	O
reported	O
,	O
this	O
database	B-MED
can	O
be	O
utilized	O
for	O
designing	O
an	O
optimal	B-MED
drug	B-MED
carrier	I-MED
,	O
i.e.	O
,	O
a	O
tailor	B-MED
-	I-MED
made	I-MED
drug	I-MED
carrier	I-MED
.	O
Effects	B-MED
of	I-MED
heat	B-MED
treatment	B-MED
on	O
conformation	B-MED
and	O
cell	B-MED
growth	I-MED
activity	O
of	O
alpha-	B-MED
lactalbumin	I-MED
and	O
beta	B-MED
-	I-MED
lactoglobulin	I-MED
from	O
market	B-MED
milk	B-MED
Heat	B-MED
processes	B-MED
,	O
low	B-MED
temperature	B-MED
for	O
long	B-MED
time	B-MED
(	O
LTLT	B-MED
)	O
pasteurization	B-MED
and	O
ultra	B-MED
-	I-MED
heat	I-MED
treatment	I-MED
(	I-MED
UHT	I-MED
)	I-MED
sterilization	I-MED
,	O
are	O
essential	O
for	O
commercial	O
market	B-MED
milk	B-MED
to	O
improve	O
the	O
shelf	B-MED
life	I-MED
of	O
raw	B-MED
milk	I-MED
milk	B-MED
and	O
ensure	O
microbial	B-MED
safety	B-MED
.	O
We	O
evaluated	O
the	O
effects	B-MED
of	I-MED
heat	B-MED
experience	O
on	O
the	O
molecular	B-MED
properties	B-MED
of	O
α	B-MED
-	I-MED
lactalbumin	I-MED
(	O
α	B-MED
-	I-MED
LA	I-MED
)	O
and	O
β	B-MED
-	I-MED
lactoglobulin	I-MED
(	O
β	B-MED
-	I-MED
LG	I-MED
)	O
isolated	O
from	O
four	O
types	O
of	O
market	B-MED
milk	B-MED
such	O
as	O
LTLT	B-MED
-	I-MED
A	I-MED
(	O
66	O
°	O
C	O
for	O
30	O
min	O
)	O
,	O
LTLT	B-MED
-	I-MED
B	I-MED
(	O
65	O
°	O
C	O
for	O
30	O
min	O
)	O
,	O
UHT	B-MED
-	I-MED
I	I-MED
(	O
130	O
°	O
C	O
for	O
2	O
s	O
,	O
indirect	B-MED
heating	B-MED
)	O
and	O
UHT	B-MED
-	I-MED
D	I-MED
(	O
135	O
°	O
C	O
for	O
2	O
s	O
,	O
direct	B-MED
heating	B-MED
)	O
samples	O
.	O
We	O
examined	O
molecular	B-MED
conformations	I-MED
using	O
circular	B-MED
dichroism	I-MED
spectrum	I-MED
measurement	I-MED
and	O
cell	B-MED
growth	I-MED
activity	O
using	O
the	O
WST-1	B-MED
method	I-MED
for	O
the	O
proteins	B-MED
.	O
α	B-MED
-	I-MED
LA	I-MED
isolated	O
from	O
each	O
of	O
these	O
four	O
types	O
of	O
market	B-MED
milk	B-MED
displayed	O
no	B-MED
significant	I-MED
structural	B-MED
difference	B-MED
as	O
compared	O
to	O
raw	B-MED
milk	I-MED
α	B-MED
-	I-MED
LA	I-MED
,	O
while	O
α	B-MED
-	I-MED
LA	I-MED
of	O
UHT	B-MED
-	I-MED
I	I-MED
only	O
inhibited	B-MED
cell	B-MED
growth	I-MED
of	O
an	O
intestinal	B-MED
epithelial	B-MED
cell	I-MED
line	I-MED
more	O
potently	O
than	O
raw	B-MED
milk	I-MED
α	B-MED
-	I-MED
LA	I-MED
.	O
In	O
the	O
case	O
of	O
β	B-MED
-	I-MED
LG	I-MED
,	O
only	O
the	O
UHT	B-MED
-	I-MED
I	I-MED
sample	O
demonstrated	O
a	O
drastic	O
change	B-MED
in	O
structure	B-MED
,	O
while	O
it	O
did	B-MED
not	I-MED
exhibit	I-MED
any	O
cytotoxicity	B-MED
.	O
We	O
found	O
that	O
cell	B-MED
viability	I-MED
effects	B-MED
of	I-MED
α	B-MED
-	I-MED
LA	I-MED
and	O
β	B-MED
-	I-MED
LG	I-MED
are	O
attributable	O
to	O
the	O
type	O
of	O
UHT	B-MED
;	O
indirect	B-MED
and	O
direct	B-MED
.	O
These	O
findings	B-MED
indicate	O
that	O
the	O
effect	B-MED
of	I-MED
heat	B-MED
treatment	B-MED
on	O
whey	B-MED
proteins	I-MED
should	O
carefully	O
be	O
investigated	B-MED
further	O
.	O
Expressions	B-MED
of	O
CD8	B-MED
+	O
TILs	B-MED
,	O
PD	B-MED
-	I-MED
L1	I-MED
and	O
Foxp3	B-MED
+	O
TILs	B-MED
in	O
stage	B-MED
I	I-MED
NSCLC	I-MED
guiding	O
adjuvant	B-MED
chemotherapy	I-MED
decisions	B-MED
Currently	O
,	O
adjuvant	B-MED
chemotherapy	I-MED
is	O
recommended	B-MED
for	O
patients	B-MED
with	O
high	B-MED
risk	I-MED
stage	B-MED
I	I-MED
non	I-MED
-	I-MED
small	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
(	O
NSCLC	B-MED
)	O
.	O
However	O
,	O
identifying	B-MED
high	B-MED
risk	I-MED
patients	B-MED
remains	O
a	O
challenge	O
.	O
This	O
study	B-MED
aims	B-MED
to	O
identify	B-MED
the	O
patient	B-MED
cohorts	B-MED
more	O
likely	O
to	O
benefit	O
from	O
adjuvant	B-MED
chemotherapy	I-MED
based	O
on	O
the	O
tumor	B-MED
micro	B-MED
-	I-MED
immune	I-MED
environment	B-MED
.	O
CD8	B-MED
+	O
TILs	B-MED
significantly	B-MED
associated	I-MED
with	I-MED
disease	B-MED
-	I-MED
free	I-MED
survival	I-MED
(	O
DFS	B-MED
)	O
and	O
overall	B-MED
survial	I-MED
(	O
OS	B-MED
)	O
(	O
p=0.002	O
;	O
0.040	O
)	O
.	O
Patients	B-MED
with	O
high	B-MED
risk	I-MED
factors	I-MED
may	O
also	O
predict	O
shorter	O
DFS	B-MED
(	O
P=0.056	O
)	O
.	O
When	O
compared	B-MED
together	O
,	O
patients	B-MED
with	O
high	B-MED
-	O
CD8	B-MED
+	O
TILs	B-MED
showed	O
better	O
DFS	B-MED
than	O
patients	B-MED
with	O
low	B-MED
-	O
CD8	B-MED
+	O
TILs	B-MED
,	O
no	O
matter	O
their	O
risk	B-MED
factors	I-MED
status	O
.	O
There	O
's	O
no	B-MED
correlation	I-MED
between	O
PD	B-MED
-	I-MED
L1	I-MED
expressions	B-MED
and	O
survival	B-MED
.	O
PD	B-MED
-	I-MED
L1	I-MED
was	O
highly	B-MED
expressed	B-MED
in	O
men	B-MED
,	O
squamous	B-MED
and	O
well	B-MED
differentiated	I-MED
carcinoma	B-MED
.	O
In	O
addition	O
,	O
Foxp3	B-MED
+	O
TILs	B-MED
alone	O
did	O
n't	O
show	O
any	O
prognostic	O
effects	O
,	O
but	O
low	B-MED
-	O
Foxp3	B-MED
/	O
high	B-MED
-	O
CD8	B-MED
+	O
TILs	B-MED
were	O
associated	B-MED
with	I-MED
prolonged	B-MED
DFS	B-MED
(	O
p=0.031	O
)	O
.	O
A	O
total	O
of	O
126	O
patients	B-MED
with	O
surgically	B-MED
resected	I-MED
stage	B-MED
I	I-MED
NSCLC	I-MED
were	O
included	B-MED
to	O
perform	O
immunohistochemistry	B-MED
of	O
CD8	B-MED
+	O
tumor	B-MED
infiltrating	I-MED
lymphocytes	I-MED
(	O
TILs	B-MED
)	O
,	O
programmed	B-MED
death	I-MED
ligand-1	I-MED
(	O
PD	B-MED
-	I-MED
L1	I-MED
)	O
and	O
forkhead	B-MED
box	I-MED
P3	I-MED
Foxp3	B-MED
(	O
Foxp3)+	O
TILs	B-MED
.	O
CD8	B-MED
+	O
TILs	B-MED
are	O
effective	B-MED
prognostic	O
predictors	O
.	O
Patients	B-MED
with	O
surgically	B-MED
resected	I-MED
stage	B-MED
I	I-MED
NSCLC	I-MED
showing	O
low	O
CD8	B-MED
+	O
TILs	B-MED
could	O
be	O
considered	O
for	O
adjuvant	B-MED
chemotherapy	I-MED
,	O
even	O
if	O
they	O
have	O
no	O
high	B-MED
risk	I-MED
features	O
.	O
Synchronous	B-MED
vitellogenin	B-MED
expression	B-MED
and	O
sexual	B-MED
maturation	I-MED
during	O
migration	B-MED
are	O
negatively	B-MED
correlated	B-MED
with	O
juvenile	B-MED
hormone	I-MED
levels	B-MED
in	O
Mythimna	B-MED
separata	I-MED
Annual	O
migration	B-MED
of	O
pests	B-MED
between	O
different	B-MED
seasonal	B-MED
habitats	B-MED
can	O
lead	B-MED
to	O
serious	O
crop	B-MED
damage	B-MED
.	O
Reproductive	B-MED
immaturity	B-MED
is	O
generally	O
associated	O
with	O
the	O
migratory	B-MED
process	I-MED
(	O
oogenesis	B-MED
-	O
flight	B-MED
syndrome	I-MED
)	O
,	O
but	O
the	O
mechanism	B-MED
of	O
reproductive	B-MED
development	I-MED
during	O
migration	B-MED
migration	B-MED
varies	O
unpredictably	B-MED
.	O
Here	O
,	O
the	O
vitellogenin	B-MED
gene	I-MED
(	O
MsVg	B-MED
)	O
and	O
three	O
key	B-MED
regulatory	B-MED
enzyme	I-MED
genes	I-MED
(	O
MsJhamt	B-MED
,	O
MsJheh	B-MED
and	O
MsJhe	B-MED
)	O
related	O
to	O
juvenile	B-MED
hormone	I-MED
(	O
JH	B-MED
)	O
synthesis	B-MED
and	O
degradation	B-MED
were	O
identified	B-MED
and	O
characterized	B-MED
in	O
Mythimna	B-MED
separata	I-MED
.	O
The	O
relative	B-MED
expression	I-MED
of	O
MsVg	B-MED
varied	O
significantly	O
in	O
response	B-MED
to	O
seasonal	B-MED
changes	B-MED
and	O
was	O
significantly	O
correlated	B-MED
with	O
stages	B-MED
of	O
ovarian	B-MED
development	I-MED
.	O
The	O
relatively	O
low	B-MED
levels	I-MED
of	O
JH	B-MED
titer	B-MED
did	O
not	B-MED
differ	I-MED
significantly	O
in	O
male	B-MED
moths	B-MED
but	O
slightly	O
increased	B-MED
in	O
female	B-MED
adults	I-MED
during	O
the	O
migratory	B-MED
season	I-MED
,	O
which	O
was	O
consistent	B-MED
with	I-MED
changes	B-MED
in	O
mRNA	B-MED
levels	B-MED
for	O
MsJhamt	B-MED
,	O
MsJheh	B-MED
and	O
MsJhe	B-MED
.	O
JH	B-MED
titer	B-MED
was	O
negatively	B-MED
associated	O
with	O
relative	O
seasonal	B-MED
levels	B-MED
of	O
vitellogenin	B-MED
mRNA	B-MED
transcripts	B-MED
and	O
with	O
ovarian	B-MED
development	I-MED
in	O
migrating	B-MED
M.	B-MED
separata	I-MED
.	O
The	O
synchrony	B-MED
of	O
MsVg	B-MED
expression	I-MED
with	O
sexual	B-MED
maturation	I-MED
highlighted	O
the	O
potential	B-MED
of	O
MsVg	B-MED
transcript	B-MED
levels	B-MED
to	O
serve	O
as	O
an	O
index	B-MED
to	O
monitor	O
the	O
adult	B-MED
reproductive	B-MED
status	B-MED
.	O
In	O
addition	O
,	O
the	O
level	B-MED
of	O
JH	B-MED
and	O
sexual	B-MED
maturity	I-MED
were	O
correlated	B-MED
with	O
the	O
extent	O
of	O
JH	B-MED
in	O
regulating	B-MED
the	O
MsVg	B-MED
expression	I-MED
and	O
reproduction	B-MED
during	O
seasonal	B-MED
northern	B-MED
and	I-MED
southern	I-MED
migration	I-MED
migration	B-MED
.	O
Surgical	B-MED
Excision	I-MED
of	O
Heterotopic	B-MED
Ossification	I-MED
Leads	O
to	O
Re	B-MED
-	I-MED
Emergence	I-MED
of	O
Mesenchymal	B-MED
Stem	I-MED
Cell	I-MED
Populations	I-MED
Responsible	O
for	O
Recurrence	B-MED
Trauma	O
-	O
induced	O
heterotopic	B-MED
ossification	I-MED
(	O
HO	B-MED
)	O
occurs	O
after	O
severe	B-MED
musculoskeletal	B-MED
injuries	I-MED
and	O
burns	B-MED
,	O
and	O
presents	O
a	O
significant	B-MED
barrier	O
to	O
patient	B-MED
rehabilitation	B-MED
.	O
Interestingly	O
,	O
the	O
incidence	B-MED
of	O
HO	B-MED
significantly	O
increases	B-MED
with	O
repeated	B-MED
operations	I-MED
and	O
after	O
resection	B-MED
of	O
previous	O
HO	B-MED
.	O
Treatment	B-MED
of	O
established	O
heterotopic	B-MED
ossification	I-MED
is	O
challenging	O
because	O
surgical	B-MED
excision	I-MED
is	O
often	O
incomplete	B-MED
,	O
with	O
evidence	B-MED
of	I-MED
persistent	B-MED
heterotopic	B-MED
bone	I-MED
.	O
As	O
a	O
result	O
,	O
patients	B-MED
may	O
continue	B-MED
to	O
report	O
the	O
signs	B-MED
or	I-MED
symptoms	I-MED
of	O
HO	B-MED
,	O
including	O
chronic	B-MED
pain	I-MED
,	O
nonhealing	B-MED
wounds	B-MED
,	O
and	O
joint	B-MED
restriction	I-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
designed	O
a	O
model	B-MED
of	O
recurrent	B-MED
HO	B-MED
that	O
occurs	O
after	O
surgical	B-MED
excision	I-MED
of	O
mature	B-MED
HO	B-MED
in	O
a	O
mouse	B-MED
model	I-MED
of	O
hind	B-MED
-	I-MED
limb	I-MED
Achilles	I-MED
'	I-MED
tendon	I-MED
transection	B-MED
with	O
dorsal	B-MED
burn	B-MED
injury	I-MED
.	O
We	O
first	O
demonstrated	O
that	O
key	B-MED
signaling	B-MED
mediators	B-MED
of	O
HO	B-MED
,	O
including	O
bone	B-MED
morphogenetic	I-MED
protein	I-MED
signaling	I-MED
,	O
are	O
diminished	O
in	O
mature	B-MED
bone	I-MED
.	O
However	O
,	O
upon	O
surgical	B-MED
excision	I-MED
,	O
we	O
have	O
noted	O
upregulation	B-MED
of	O
downstream	B-MED
mediators	B-MED
of	O
osteogenic	B-MED
differentiation	B-MED
,	O
including	O
pSMAD	B-MED
1	I-MED
/	O
5	B-MED
.	O
Additionally	O
,	O
surgical	B-MED
excision	I-MED
resulted	O
in	O
re	B-MED
-	I-MED
emergence	I-MED
of	O
a	O
mesenchymal	B-MED
cell	I-MED
population	I-MED
marked	O
by	O
expression	B-MED
of	O
platelet	B-MED
-	I-MED
derived	I-MED
growth	I-MED
factor	I-MED
receptor	I-MED
-	I-MED
α	I-MED
(	O
PDGFRα	B-MED
)	O
and	O
present	B-MED
in	O
the	O
initial	B-MED
developing	O
HO	B-MED
lesion	B-MED
but	O
absent	B-MED
in	O
mature	B-MED
HO	B-MED
.	O
In	O
the	O
recurrent	B-MED
lesion	B-MED
,	O
these	O
PDGFRα	B-MED
+	O
mesenchymal	B-MED
cells	I-MED
are	O
also	O
highly	O
proliferative	B-MED
,	O
similar	O
to	O
the	O
initial	B-MED
developing	O
HO	B-MED
lesion	B-MED
.	O
These	O
findings	O
indicate	O
that	O
surgical	B-MED
excision	I-MED
of	O
HO	B-MED
results	B-MED
in	O
recurrence	B-MED
through	O
similar	O
mesenchymal	B-MED
cell	I-MED
populations	I-MED
and	O
signaling	B-MED
mechanisms	B-MED
that	O
are	O
present	B-MED
in	O
the	O
initial	B-MED
developing	O
HO	B-MED
lesion	B-MED
.	O
These	O
results	B-MED
are	O
consistent	B-MED
with	I-MED
findings	B-MED
in	O
patients	B-MED
that	O
new	O
foci	B-MED
of	O
ectopic	B-MED
bone	I-MED
can	O
develop	O
in	O
excision	B-MED
sites	B-MED
and	O
are	O
likely	O
related	O
to	O
de	B-MED
novo	I-MED
formation	B-MED
rather	O
than	O
extension	B-MED
of	O
unresected	B-MED
bone	B-MED
.	O
Stem	O
Cells	O
Translational	O
Medicine	O
2017;6:799	O
-	O
806	O
.	O
A	O
novel	O
quantitative	B-MED
PCR	I-MED
detects	O
Babesia	B-MED
infection	B-MED
in	O
patients	B-MED
not	O
identified	O
by	O
currently	O
available	O
non	B-MED
-	I-MED
nucleic	I-MED
acid	I-MED
amplification	I-MED
tests	I-MED
Ticks	B-MED
transmit	B-MED
Babesia	B-MED
microti	I-MED
,	O
the	O
causative	B-MED
agents	I-MED
of	O
babesiosis	B-MED
in	O
North	B-MED
America	I-MED
and	O
Europe	B-MED
.	O
Babesiosis	B-MED
is	O
now	O
endemic	B-MED
in	O
Northeastern	B-MED
USA	B-MED
and	O
affects	O
people	B-MED
of	O
all	O
ages	B-MED
.	O
Babesia	B-MED
species	I-MED
infect	O
erythrocytes	B-MED
and	O
can	O
be	O
transmitted	B-MED
through	O
blood	B-MED
transfusion	I-MED
.	O
Whole	B-MED
blood	I-MED
and	O
blood	B-MED
products	I-MED
,	O
which	O
are	O
not	O
tested	O
for	O
Babesia	B-MED
,	O
can	O
cause	O
transfusion	B-MED
-	O
transmitted	B-MED
babesiosis	B-MED
(	O
TTB	B-MED
)	O
resulting	O
in	O
severe	B-MED
consequences	B-MED
in	O
the	O
immuno	B-MED
-	I-MED
compromised	I-MED
patients	B-MED
.	O
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
epidemiological	B-MED
evaluation	I-MED
of	O
babesiosis	B-MED
in	O
a	O
tick	B-MED
-	I-MED
infested	I-MED
state	I-MED
.	O
We	O
examined	B-MED
blood	B-MED
samples	I-MED
from	O
192	O
patients	B-MED
who	O
visited	O
clinics	B-MED
during	O
the	O
active	O
tick	B-MED
-	I-MED
borne	I-MED
diseases	I-MED
season	B-MED
,	O
using	O
a	O
newly	O
developed	O
qPCR	B-MED
assay	I-MED
that	O
uses	O
the	O
specific	O
molecular	B-MED
beacon	I-MED
probe	I-MED
.	O
Due	O
to	O
the	O
absence	B-MED
of	O
clear	O
symptomology	B-MED
,	O
clinical	B-MED
laboratories	I-MED
did	O
not	O
test	O
131	O
samples	B-MED
by	O
IFA	B-MED
,	O
FISH	B-MED
or	O
microscopic	B-MED
examination	I-MED
of	O
Giemsa	B-MED
-	I-MED
stained	I-MED
blood	B-MED
smears	I-MED
.	O
Babesia	B-MED
infection	B-MED
was	O
detected	O
in	O
all	O
age	B-MED
groups	I-MED
by	O
FISH	B-MED
and	O
microscopy	B-MED
;	O
notably	O
patients	B-MED
>	O
40	O
years	B-MED
of	O
age	B-MED
represented	O
64	O
%	O
of	O
tested	O
samples	B-MED
and	O
13	O
%	O
were	O
younger	B-MED
patients	B-MED
.	O
We	O
tested	O
all	O
samples	B-MED
using	O
qPCR	B-MED
and	O
found	O
that	O
38	O
%	O
were	O
positive	B-MED
for	O
Babesia	B-MED
.	O
Of	O
28	O
samples	B-MED
that	O
were	O
positive	B-MED
by	O
FISH	B-MED
,	O
27	O
(	O
96	O
%	O
)	O
were	O
also	O
positive	B-MED
by	O
qPCR	B-MED
indicating	O
high	O
congruency	O
between	O
nucleic	B-MED
acid	I-MED
based	I-MED
tests	I-MED
.	O
Interestingly	O
,	O
of	O
78	O
asymptomatic	B-MED
samples	B-MED
not	O
tested	O
by	O
FISH	B-MED
,	O
22	O
were	O
positive	B-MED
by	O
our	O
qPCR	B-MED
.	O
Direct	O
detection	B-MED
of	O
Babesia	B-MED
relies	O
upon	O
microscopic	B-MED
examination	I-MED
of	O
patient	B-MED
blood	B-MED
smears	I-MED
,	O
which	O
is	O
labor	O
intensive	O
,	O
difficult	O
to	O
scale	O
up	O
,	O
requires	O
specific	O
expertise	O
and	O
is	O
hence	O
,	O
often	O
not	O
performed	O
.	O
In	O
fact	O
,	O
a	O
clinical	B-MED
laboratory	I-MED
examined	B-MED
only	O
23	O
of	O
86	O
blood	B-MED
samples	I-MED
obtained	O
from	O
two	O
different	O
counties	B-MED
by	O
microscopy	B-MED
.	O
By	O
considering	O
individuals	B-MED
positive	B-MED
for	O
Babesia	B-MED
infection	B-MED
when	O
results	O
from	O
currently	O
available	O
microscopy	B-MED
,	O
FISH	B-MED
or	O
serological	B-MED
tests	I-MED
were	O
positive	B-MED
,	O
we	O
found	O
that	O
our	O
qPCR	B-MED
is	O
highly	O
sensitive	B-MED
(	O
96.2	O
%	O
)	O
and	O
showed	O
a	O
specificity	B-MED
of	O
70.5	O
%	O
for	O
Babesia	B-MED
.	O
Robust	O
qPCR	B-MED
using	O
specific	O
probes	B-MED
can	O
be	O
highly	O
useful	O
for	O
efficient	O
and	O
appropriate	O
diagnosis	B-MED
of	O
babesiosis	B-MED
in	O
patients	B-MED
in	O
conjunction	O
with	O
conventional	O
diagnostics	B-MED
,	O
or	O
as	O
a	O
stand	O
-	O
alone	O
test	O
,	O
especially	O
for	O
donated	O
blood	B-MED
screening	I-MED
.	O
The	O
use	O
of	O
a	O
nucleic	B-MED
acid	I-MED
amplification	I-MED
test	I-MED
based	O
screening	B-MED
of	I-MED
blood	I-MED
and	O
blood	B-MED
products	I-MED
could	O
prevent	O
TTB	B-MED
.	O
Bi	B-MED
-	I-MED
layered	I-MED
constructs	I-MED
of	O
poly(glycerol	B-MED
-	I-MED
sebacate	I-MED
)	I-MED
-	O
β	B-MED
-	I-MED
tricalcium	I-MED
phosphate	I-MED
for	O
bone	B-MED
-	I-MED
soft	I-MED
tissue	I-MED
interface	B-MED
applications	I-MED
This	O
study	B-MED
aims	O
to	O
establish	O
a	O
facile	O
protocol	B-MED
for	O
the	O
preparation	B-MED
of	O
a	O
bi	B-MED
-	I-MED
layered	I-MED
poly(glycerol	B-MED
-	I-MED
sebacate	I-MED
)	I-MED
PGS	B-MED
(	O
PGS)/	O
β	B-MED
-	I-MED
tricalcium	I-MED
phosphate	I-MED
(	O
β	B-MED
-	I-MED
TCP	I-MED
)	O
construct	B-MED
and	O
to	O
investigate	B-MED
its	O
potential	O
for	O
bone	B-MED
-	I-MED
soft	I-MED
tissue	I-MED
engineering	B-MED
applications	B-MED
.	O
The	O
layered	B-MED
structure	I-MED
was	O
prepared	O
by	O
distributing	B-MED
the	O
ceramic	B-MED
particles	B-MED
within	O
a	O
prepolymer	B-MED
synthesized	B-MED
in	O
a	O
microwave	B-MED
reactor	I-MED
followed	O
by	O
a	O
cross	B-MED
-	I-MED
linking	I-MED
of	O
the	O
final	O
construct	B-MED
in	O
vacuum	B-MED
(	O
<	O
10	O
mbar	O
)	O
.	O
The	O
vacuum	B-MED
stage	B-MED
led	O
to	O
the	O
separation	B-MED
of	O
cross	B-MED
-	I-MED
linked	I-MED
elastomer	B-MED
(	O
top	B-MED
)	O
and	O
ceramic	B-MED
(	O
bottom	B-MED
)	O
phases	B-MED
.	O
Results	O
showed	O
that	O
addition	O
of	O
β	B-MED
-	I-MED
TCP	I-MED
particles	B-MED
to	O
the	O
elastomer	B-MED
matrix	I-MED
after	O
the	O
polymerization	B-MED
led	O
to	O
an	O
increase	B-MED
in	O
compression	B-MED
strength	I-MED
(	O
up	O
to	O
14±2.3MPa	O
)	O
.	O
Tensile	B-MED
strength	I-MED
(	O
σ	O
)	O
,	O
Young	B-MED
's	I-MED
modulus	I-MED
(	O
E	O
)	O
,	O
and	O
elongation	B-MED
at	I-MED
break	I-MED
(	O
%	O
)	O
values	O
were	O
calculated	O
as	O
0.29±0.03MPa	O
and	O
0.21±0.03	O
;	O
0.38±0.02	O
and	O
1.95±0.4	O
;	O
and	O
240±50	O
%	O
and	O
24±2	O
%	O
for	O
PGS	B-MED
and	O
PGS	B-MED
/	O
β	B-MED
-	I-MED
TCP	I-MED
bi	B-MED
-	I-MED
layered	I-MED
constructs	I-MED
,	O
respectively	O
.	O
Morphology	B-MED
was	O
characterized	O
by	O
using	O
Scanning	B-MED
Electron	I-MED
Microscopy	I-MED
(	O
SEM	B-MED
)	O
and	O
micro	B-MED
-	I-MED
computed	I-MED
tomography	I-MED
(	O
μ	B-MED
-	I-MED
CT	I-MED
)	O
.	O
Tomography	B-MED
data	B-MED
revealed	O
an	O
open	B-MED
porosity	I-MED
of	O
35	O
%	O
for	O
the	O
construct	B-MED
,	O
mostly	O
contributed	O
from	O
the	O
ceramic	B-MED
phase	I-MED
since	O
the	O
elastomer	B-MED
side	B-MED
has	O
no	O
pore	B-MED
.	O
Homogeneous	B-MED
β	B-MED
-	I-MED
TCP	I-MED
distribution	B-MED
within	O
the	O
elastomeric	B-MED
structure	I-MED
was	O
observed	O
.	O
Cell	B-MED
culture	I-MED
studies	I-MED
confirmed	O
biocompatibility	B-MED
with	O
poor	O
elastomer	B-MED
-	O
side	B-MED
and	O
good	O
bone	B-MED
-	O
side	B-MED
cell	B-MED
attachment	I-MED
.	O
In	O
a	O
further	O
study	O
to	O
investigate	B-MED
the	O
osteogenic	B-MED
properties	B-MED
,	O
the	O
construct	B-MED
were	O
loaded	O
with	O
BMP-2	B-MED
and/or	O
TGF	B-MED
-	I-MED
β1	I-MED
.	O
The	O
PGS	B-MED
/	O
β	B-MED
-	I-MED
TCP	I-MED
bi	B-MED
-	I-MED
layered	I-MED
constructs	I-MED
with	O
improved	O
mechanical	B-MED
and	O
biological	B-MED
properties	B-MED
have	O
the	O
potential	O
to	O
be	O
used	O
in	O
bone	B-MED
-	I-MED
soft	I-MED
tissue	I-MED
interface	B-MED
applications	I-MED
where	O
soft	B-MED
tissue	I-MED
penetration	B-MED
is	O
a	O
problem	B-MED
.	O
Air	B-MED
pollution	I-MED
,	O
neighbourhood	B-MED
and	O
maternal	B-MED
-	O
level	B-MED
factors	B-MED
modify	B-MED
the	O
effect	B-MED
of	O
smoking	B-MED
on	O
birth	B-MED
weight	I-MED
:	O
a	O
multilevel	B-MED
analysis	I-MED
in	O
British	B-MED
Columbia	I-MED
,	O
Canada	B-MED
Maternal	B-MED
smoking	B-MED
during	O
pregnancy	B-MED
negatively	B-MED
impacts	B-MED
fetal	B-MED
growth	I-MED
,	O
but	O
the	O
effect	B-MED
is	O
not	O
homogenous	B-MED
across	O
the	O
population	B-MED
.	O
We	O
sought	O
to	O
determine	O
how	O
the	O
relationship	B-MED
between	O
cigarette	B-MED
use	I-MED
and	O
fetal	B-MED
growth	I-MED
is	O
modified	B-MED
by	O
the	O
social	B-MED
and	O
physical	B-MED
environment	I-MED
.	O
Birth	B-MED
records	I-MED
with	O
covariates	O
were	O
obtained	O
from	O
the	O
BC	B-MED
Perinatal	I-MED
Database	I-MED
Registry	I-MED
(	O
N	O
=	O
232,291	O
)	O
.	O
Maternal	B-MED
smoking	B-MED
status	I-MED
was	O
self	B-MED
-	I-MED
reported	I-MED
as	O
the	O
number	B-MED
of	O
cigarettes	B-MED
smoked	B-MED
per	B-MED
day	I-MED
usually	O
at	O
the	O
first	B-MED
prenatal	I-MED
care	I-MED
visit	I-MED
.	O
Census	B-MED
dissemination	B-MED
areas	B-MED
(	O
DAs	B-MED
)	O
were	O
used	O
as	O
neighbourhood	B-MED
-	O
level	B-MED
units	B-MED
and	O
linked	O
to	O
individual	B-MED
births	B-MED
using	O
residential	B-MED
postal	I-MED
codes	I-MED
to	O
assign	B-MED
exposure	B-MED
to	I-MED
particulate	B-MED
air	B-MED
pollution	I-MED
(	O
PM2.5	O
)	O
and	O
neighbourhood	B-MED
-	O
level	B-MED
attributes	B-MED
such	O
as	O
socioeconomic	B-MED
status	I-MED
(	O
SES	B-MED
)	O
,	O
proportion	B-MED
of	O
post	B-MED
-	I-MED
secondary	I-MED
education	I-MED
,	O
immigrant	B-MED
density	B-MED
and	O
living	B-MED
in	O
a	O
rural	B-MED
place	I-MED
.	O
Random	B-MED
coefficient	B-MED
models	B-MED
were	O
used	O
with	O
cigarettes	B-MED
/day	B-MED
modeled	B-MED
with	O
a	O
random	B-MED
slope	B-MED
to	O
estimate	B-MED
its	O
between-	O
DA	B-MED
variability	B-MED
and	O
test	B-MED
cross	B-MED
-	I-MED
level	I-MED
interactions	B-MED
with	O
the	O
neighbourhood	B-MED
-	O
level	B-MED
variables	B-MED
on	O
continuous	B-MED
birth	B-MED
weight	I-MED
.	O
A	O
significant	B-MED
negative	B-MED
and	O
non	O
-	O
linear	O
association	B-MED
was	O
found	O
between	O
maternal	B-MED
smoking	B-MED
and	O
birth	B-MED
weight	I-MED
.	O
There	O
was	O
significant	B-MED
between-	O
DA	B-MED
intercept	B-MED
variability	B-MED
in	O
birth	B-MED
weight	I-MED
as	O
well	O
as	O
between-	O
DA	B-MED
slope	B-MED
variability	B-MED
of	O
maternal	B-MED
smoking	B-MED
on	O
birth	B-MED
weight	I-MED
of	O
which	O
68	O
and	O
30	O
%	O
respectively	O
was	O
explained	O
with	O
the	O
inclusion	B-MED
of	O
DA	B-MED
-	O
level	B-MED
variables	B-MED
and	O
their	O
cross	B-MED
-	I-MED
level	I-MED
interactions	B-MED
.	O
High	B-MED
DA	B-MED
-	O
level	B-MED
SES	B-MED
had	O
a	O
strong	B-MED
positive	B-MED
association	B-MED
with	O
birth	B-MED
weight	I-MED
but	O
the	O
effect	B-MED
was	O
moderated	B-MED
with	O
increased	B-MED
cigarettes	B-MED
/day	B-MED
.	O
Conversely	O
,	O
heavy	B-MED
smokers	I-MED
showed	O
the	O
largest	B-MED
increases	B-MED
in	O
birth	B-MED
weight	I-MED
with	O
rising	B-MED
neighbourhood	B-MED
education	B-MED
levels	I-MED
.	O
Increased	B-MED
levels	B-MED
of	O
PM2.5	B-MED
and	O
immigrant	B-MED
density	B-MED
were	O
negatively	B-MED
associated	B-MED
with	I-MED
birth	B-MED
weight	I-MED
,	O
but	O
showed	O
positive	B-MED
interactions	B-MED
with	O
increased	B-MED
levels	B-MED
of	O
smoking	B-MED
.	O
Older	O
maternal	B-MED
age	I-MED
and	O
suspected	B-MED
drug	B-MED
or	O
alcohol	B-MED
use	I-MED
both	O
had	O
negative	B-MED
interactions	B-MED
with	O
increased	B-MED
levels	B-MED
of	O
maternal	B-MED
smoking	B-MED
.	O
Maternal	B-MED
smoking	B-MED
had	O
a	O
negative	B-MED
and	O
non	O
-	O
linear	O
dose	B-MED
-	I-MED
response	I-MED
association	I-MED
with	O
birth	B-MED
weight	I-MED
which	O
was	O
highly	B-MED
variable	B-MED
between	O
neighbourhood	B-MED
s	O
and	O
evidence	B-MED
of	O
effect	B-MED
modification	B-MED
with	O
neighbourhood	B-MED
-	O
level	B-MED
factors	B-MED
.	O
These	O
results	B-MED
suggest	B-MED
that	O
focusing	O
exclusively	O
on	O
individual	B-MED
behaviours	B-MED
may	O
have	O
limited	B-MED
success	B-MED
in	O
improving	B-MED
outcomes	B-MED
without	B-MED
addressing	O
the	O
contextual	B-MED
influences	B-MED
at	O
the	O
neighbourhood	B-MED
-	O
level	B-MED
.	O
Further	O
studies	B-MED
are	O
needed	O
to	O
corroborate	B-MED
our	O
findings	B-MED
and	O
to	O
understand	B-MED
how	O
neighbourhood	B-MED
-	O
level	B-MED
attributes	B-MED
interact	B-MED
with	O
smoking	B-MED
to	O
affect	B-MED
birth	B-MED
outcomes	I-MED
.	O
Differing	O
rates	O
of	O
antibody	B-MED
acquisition	B-MED
to	O
merozoite	B-MED
antigens	B-MED
in	O
malaria	B-MED
:	O
implications	O
for	O
immunity	B-MED
and	O
surveillance	B-MED
Antibodies	B-MED
play	O
a	O
key	O
role	O
in	O
acquired	B-MED
human	I-MED
immunity	I-MED
to	O
Plasmodium	B-MED
falciparum	I-MED
(	I-MED
Pf	I-MED
)	I-MED
malaria	I-MED
and	O
target	O
merozoites	B-MED
to	O
reduce	O
or	O
prevent	O
blood	B-MED
-stage	O
replication	B-MED
and	O
the	O
development	O
of	O
disease	B-MED
.	O
Merozoites	B-MED
present	O
a	O
complex	O
array	O
of	O
antigens	B-MED
to	O
the	O
immune	B-MED
system	I-MED
,	O
and	O
currently	O
,	O
there	O
is	O
only	O
a	O
partial	O
understanding	O
of	O
the	O
targets	O
of	O
protective	O
antibodies	B-MED
and	O
how	O
responses	B-MED
to	O
different	O
antigens	B-MED
are	O
acquired	B-MED
and	O
boosted	B-MED
.	O
We	O
hypothesized	O
that	O
there	O
would	O
be	O
differences	O
in	O
the	O
rate	O
of	O
acquisition	B-MED
of	O
antibodies	B-MED
to	O
different	O
antigens	B-MED
and	O
how	O
well	O
they	O
are	O
boosted	O
by	O
infection	B-MED
,	O
which	O
impacts	O
the	O
acquisition	B-MED
of	O
immunity	B-MED
.	O
We	O
examined	O
responses	B-MED
to	O
a	O
range	O
of	O
merozoite	B-MED
antigens	B-MED
in	O
2	O
different	O
cohorts	O
of	O
children	B-MED
and	O
adults	B-MED
with	O
different	O
age	B-MED
structures	O
and	O
levels	O
of	O
malaria	B-MED
exposure	O
.	O
Overall	O
,	O
antibodies	B-MED
were	O
associated	O
with	O
age	B-MED
,	O
exposure	O
,	O
and	O
active	O
infection	B-MED
,	O
and	O
the	O
repertoire	O
of	O
responses	B-MED
increased	O
with	O
age	B-MED
and	O
active	O
infection	B-MED
.	O
However	O
,	O
rates	O
of	O
antibody	B-MED
acquisition	B-MED
varied	O
between	O
antigens	B-MED
and	O
different	O
regions	O
within	O
an	O
antigen	B-MED
following	O
exposure	O
to	O
malaria	B-MED
,	O
supporting	O
our	O
hypothesis	B-MED
.	O
Antigen	B-MED
-specific	O
responses	B-MED
could	O
be	O
broadly	O
classified	O
into	O
early	O
response	B-MED
types	O
in	O
which	O
antibodies	B-MED
were	O
acquired	B-MED
early	O
in	O
childhood	B-MED
exposure	O
and	O
late	B-MED
response	I-MED
response	B-MED
types	O
that	O
appear	O
to	O
require	O
substantially	O
more	O
exposure	O
for	O
the	O
development	O
of	O
substantial	O
levels	O
.	O
We	O
identified	O
antigen	B-MED
-specific	O
responses	B-MED
that	O
were	O
effectively	O
boosted	O
after	O
recent	O
infection	B-MED
,	O
whereas	O
other	O
responses	B-MED
were	O
not	O
.	O
These	O
findings	O
advance	O
our	O
understanding	O
of	O
the	O
acquisition	B-MED
of	O
human	B-MED
immunity	B-MED
to	O
malaria	B-MED
and	O
are	O
relevant	O
to	O
the	O
development	O
of	O
malaria	B-MED
vaccines	I-MED
targeting	O
merozoite	B-MED
antigens	B-MED
and	O
the	O
selection	O
of	O
antigens	B-MED
for	O
use	O
in	O
malaria	B-MED
surveillance	B-MED
.	O
MiR	B-MED
221	I-MED
/	O
222	B-MED
as	O
new	O
players	O
in	O
tamoxifen	B-MED
resistance	B-MED
Breast	B-MED
cancer	I-MED
is	O
the	O
most	O
frequent	O
cancer	B-MED
in	O
women	B-MED
.	O
Despite	O
advances	O
in	O
early	B-MED
detection	I-MED
and	O
treatment	B-MED
,	O
it	O
has	O
the	O
second	O
highest	O
mortality	B-MED
rate	I-MED
after	O
lung	B-MED
cancer	I-MED
.	O
Around	O
85	O
%	O
of	O
breast	B-MED
carcinomas	I-MED
are	O
ER+	B-MED
;	O
thus	O
,	O
antiestrogens	B-MED
like	O
tamoxifen	B-MED
are	O
beneficial	O
.	O
Although	O
,	O
tamoxifen	B-MED
is	O
useful	O
for	O
many	O
patients	B-MED
,	O
plenty	O
of	O
patients	B-MED
respond	B-MED
poorly	I-MED
to	O
initial	O
therapy	B-MED
or	O
recurrence	B-MED
occurs	O
in	O
about	O
30	O
%	O
of	O
cases	O
,	O
because	O
tamoxifen	B-MED
resistance	B-MED
happens	O
.	O
Drug	B-MED
resistance	I-MED
remains	O
a	O
major	O
clinical	B-MED
obstacle	O
to	O
successful	B-MED
treatment	I-MED
of	O
breast	B-MED
cancer	I-MED
and	O
more	O
than	O
90	O
%	O
of	O
unsuccessful	B-MED
treatments	I-MED
are	O
because	O
of	O
acquired	B-MED
resistance	B-MED
and	O
MultiDrug	B-MED
Resistance	I-MED
(	B-MED
MDR	I-MED
)	I-MED
is	O
a	O
major	O
contributor	O
.	O
MicroRNAs	B-MED
are	O
members	O
of	O
a	O
novel	O
class	O
of	O
short	O
noncoding	B-MED
RNAs	I-MED
.	O
Besides	O
to	O
their	O
various	O
roles	O
in	O
gene	B-MED
expression	I-MED
,	O
miRNAs	B-MED
are	O
considered	O
as	O
important	O
cancer	B-MED
therapeutic	B-MED
targets	I-MED
and	O
biomarkers	B-MED
.	O
Since	O
2005	O
,	O
when	O
miRNA	B-MED
deregulation	B-MED
was	O
first	O
reported	O
in	O
breast	B-MED
cancer	I-MED
,	O
more	O
than	O
1000	O
reports	B-MED
have	O
been	O
published	O
about	O
miRNAs	B-MED
.	O
Increasing	O
number	O
of	O
studies	B-MED
showed	O
the	O
importance	O
of	O
miRNAs	B-MED
in	O
antiestrogen	B-MED
therapy	I-MED
,	O
especially	O
on	O
tamoxifen	B-MED
;	O
thus	O
,	O
it	O
is	O
not	O
surprising	O
that	O
these	O
tiny	O
molecules	B-MED
are	O
involved	O
in	O
drug	B-MED
resistance	I-MED
.	O
Due	O
to	O
the	O
pivotal	O
role	O
of	O
these	O
known	O
RNA	B-MED
molecules	I-MED
,	O
in	O
this	O
review	O
,	O
we	O
tried	O
to	O
illustrate	O
the	O
importance	O
of	O
the	O
miRNAs	B-MED
as	O
a	O
new	O
player	O
in	O
breast	B-MED
cancer	I-MED
pathogenesis	B-MED
.	O
We	O
have	O
also	O
focused	O
on	O
cancer	B-MED
drug	B-MED
resistance	I-MED
mechanisms	B-MED
highlighting	O
the	O
role	O
of	O
important	O
oncomirs	B-MED
,	O
miR	B-MED
221	I-MED
/	O
222	B-MED
,	O
involved	O
in	O
cell	B-MED
cycle	I-MED
deregulation	I-MED
in	O
breast	B-MED
cancer	I-MED
.	O
The	O
relationship	O
between	O
these	O
oncomiRs	B-MED
with	O
resistance	B-MED
to	O
tamoxifen	B-MED
is	O
also	O
emphasized	B-MED
.	O
Neospora	B-MED
caninum	I-MED
in	O
Axis	B-MED
Deer	I-MED
(	O
Axis	B-MED
axis	I-MED
)	O
and	O
Fallow	B-MED
Deer	I-MED
(	O
Dama	B-MED
dama	I-MED
)	O
in	O
Northern	B-MED
Mexico	B-MED
Serum	B-MED
samples	I-MED
from	O
18	O
axis	B-MED
deer	I-MED
(	O
Axis	B-MED
axis	I-MED
)	O
and	O
19	O
fallow	B-MED
deer	I-MED
(	O
Dama	B-MED
dama	I-MED
)	O
were	O
analyzed	O
with	O
an	O
enzyme	B-MED
-	I-MED
linked	I-MED
immunosorbent	I-MED
assay	I-MED
for	O
Neospora	B-MED
caninum	I-MED
antibodies	I-MED
.	O
Two	O
axis	B-MED
(	O
11	O
%	O
)	O
and	O
two	O
fallow	B-MED
deer	I-MED
(	O
11	O
%	O
)	O
were	O
positive	B-MED
for	O
N.	B-MED
caninum	I-MED
antibodies	I-MED
.	O
Quality	B-MED
Improvement	I-MED
of	O
Liver	B-MED
Ultrasound	B-MED
Images	B-MED
Using	O
Fuzzy	B-MED
Techniques	B-MED
Liver	B-MED
ultrasound	B-MED
images	B-MED
are	O
so	O
common	O
and	O
are	O
applied	O
so	O
often	O
to	O
diagnose	B-MED
diffuse	B-MED
liver	I-MED
diseases	I-MED
like	O
fatty	B-MED
liver	I-MED
.	O
However	O
,	O
the	O
low	B-MED
quality	B-MED
of	O
such	O
images	B-MED
makes	O
it	O
difficult	O
to	O
analyze	B-MED
them	O
and	O
diagnose	B-MED
diseases	B-MED
.	O
The	O
purpose	O
of	O
this	O
study	B-MED
,	O
therefore	O
,	O
is	O
to	O
improve	O
the	O
contrast	B-MED
and	O
quality	B-MED
of	O
liver	B-MED
ultrasound	B-MED
images	B-MED
.	O
In	O
this	O
study	B-MED
,	O
a	O
number	O
of	O
image	B-MED
contrast	B-MED
enhancement	B-MED
algorithms	I-MED
which	O
are	O
based	O
on	O
fuzzy	B-MED
logic	I-MED
were	O
applied	O
to	O
liver	B-MED
ultrasound	B-MED
images	B-MED
-	O
in	O
which	O
the	O
view	O
of	O
kidney	B-MED
is	O
observable	O
-	O
using	O
Matlab2013b	B-MED
to	O
improve	O
the	O
image	B-MED
contrast	B-MED
and	O
quality	B-MED
which	O
has	O
a	O
fuzzy	B-MED
definition	B-MED
;	O
just	O
like	O
image	B-MED
contrast	B-MED
improvement	B-MED
algorithms	B-MED
using	O
a	O
fuzzy	B-MED
intensification	B-MED
operator	I-MED
,	O
contrast	B-MED
improvement	B-MED
algorithms	B-MED
applying	O
fuzzy	B-MED
image	B-MED
histogram	B-MED
hyperbolization	I-MED
,	O
and	O
contrast	B-MED
improvement	B-MED
algorithms	B-MED
by	O
fuzzy	B-MED
IF	B-MED
-	I-MED
THEN	I-MED
rules	I-MED
.	O
With	O
the	O
measurement	B-MED
of	O
Mean	B-MED
Squared	I-MED
Error	I-MED
and	O
Peak	B-MED
Signal	B-MED
to	I-MED
Noise	I-MED
Ratio	I-MED
obtained	O
from	O
different	O
images	B-MED
,	O
fuzzy	B-MED
methods	B-MED
provided	O
better	O
results	B-MED
,	O
and	O
their	O
implementation	B-MED
-	O
compared	B-MED
with	O
histogram	B-MED
equalization	I-MED
method	I-MED
-	O
led	O
both	O
to	O
the	O
improvement	B-MED
of	O
contrast	B-MED
and	O
visual	B-MED
quality	I-MED
of	O
images	B-MED
and	O
to	O
the	O
improvement	B-MED
of	O
liver	B-MED
segmentation	B-MED
algorithms	I-MED
results	O
in	O
images	B-MED
.	O
Comparison	B-MED
of	O
the	O
four	O
algorithms	B-MED
revealed	O
the	O
power	O
of	O
fuzzy	B-MED
logic	I-MED
in	O
improving	O
image	B-MED
contrast	B-MED
compared	B-MED
with	O
traditional	O
image	B-MED
processing	I-MED
algorithms	B-MED
.	O
Moreover	O
,	O
contrast	B-MED
improvement	B-MED
algorithm	O
based	O
on	O
a	O
fuzzy	B-MED
intensification	B-MED
operator	I-MED
was	O
selected	O
as	O
the	O
strongest	O
algorithm	B-MED
considering	O
the	O
measured	O
indicators	O
.	O
This	O
method	B-MED
can	O
also	O
be	O
used	O
in	O
future	O
studies	B-MED
on	O
other	O
ultrasound	B-MED
images	B-MED
for	O
quality	B-MED
improvement	I-MED
and	O
other	O
image	B-MED
processing	I-MED
and	O
analysis	B-MED
applications	B-MED
.	O
Developing	B-MED
understanding	B-MED
of	O
object	B-MED
fall	B-MED
:	O
Going	O
beyond	O
inhibitory	B-MED
processes	B-MED
A	O
study	B-MED
is	O
reported	B-MED
where	O
118	O
participants	B-MED
aged	B-MED
between	O
10	O
years	O
and	O
early	B-MED
20s	O
drew	O
the	O
trajectories	B-MED
they	O
expected	B-MED
objects	B-MED
to	O
follow	B-MED
as	O
they	O
fell	B-MED
.	O
The	O
younger	B-MED
participants	B-MED
typically	B-MED
anticipated	B-MED
backward	B-MED
trajectories	B-MED
during	O
fall	B-MED
from	O
moving	B-MED
carriers	B-MED
while	O
forward	B-MED
but	O
non	B-MED
-	I-MED
parabolic	I-MED
trajectories	I-MED
were	O
relatively	B-MED
more	B-MED
frequent	B-MED
amongst	O
the	O
older	B-MED
participants	I-MED
.	O
Both	O
patterns	B-MED
suggest	B-MED
strong	B-MED
sociocultural	B-MED
influences	B-MED
,	O
with	O
implications	B-MED
for	O
models	B-MED
that	O
regard	O
development	B-MED
in	O
this	O
area	B-MED
as	O
purely	B-MED
the	O
inhibition	B-MED
of	O
principles	B-MED
established	B-MED
in	O
infancy	B-MED
.	O
Statement	B-MED
of	O
contribution	B-MED
What	O
is	O
already	O
known	B-MED
on	O
this	O
subject	B-MED
?	O
Research	B-MED
with	O
infants	B-MED
demonstrates	B-MED
an	O
early	B-MED
-	O
established	B-MED
belief	B-MED
that	O
dropped	B-MED
objects	B-MED
fall	B-MED
straight	B-MED
down	B-MED
.	O
The	O
erroneous	B-MED
expectations	B-MED
that	O
pre	B-MED
-	I-MED
schoolers	I-MED
hold	B-MED
about	O
object	B-MED
fall	B-MED
are	O
consistent	B-MED
with	I-MED
failure	B-MED
to	O
inhibit	B-MED
the	O
presumption	B-MED
of	O
straight	B-MED
-	O
down	B-MED
fall	B-MED
,	O
in	O
contexts	B-MED
where	O
it	O
is	O
inappropriate	B-MED
.	O
What	O
does	O
this	O
study	B-MED
add	O
?	O
The	O
research	B-MED
replicates	B-MED
and	O
extends	B-MED
research	B-MED
with	O
older	B-MED
participants	I-MED
,	O
which	O
indicates	B-MED
errors	B-MED
that	O
can	O
not	O
be	O
explained	B-MED
via	O
failed	B-MED
inhibition	B-MED
of	O
straight	B-MED
-	O
down	B-MED
fall	B-MED
.	O
It	O
is	O
the	O
first	O
study	B-MED
to	O
trace	O
patterns	B-MED
of	O
errors	B-MED
across	O
late	B-MED
childhood	B-MED
,	O
adolescence	B-MED
and	O
early	B-MED
adulthood	B-MED
.	O
A	O
consequence	B-MED
of	I-MED
the	O
findings	B-MED
is	O
that	O
adequate	B-MED
modelling	B-MED
in	O
developmental	B-MED
psychology	I-MED
must	O
consider	B-MED
multilayered	B-MED
interactions	B-MED
between	O
prior	B-MED
representations	B-MED
and	O
sociocultural	B-MED
experiences	B-MED
.	O
Dental	B-MED
enamel	B-MED
defects	I-MED
in	O
German	B-MED
medieval	B-MED
and	O
early	B-MED
-	I-MED
modern	I-MED
-	I-MED
age	I-MED
populations	B-MED
Aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
the	O
frequency	B-MED
and	O
type	B-MED
of	O
developmental	B-MED
defects	I-MED
of	I-MED
enamel	I-MED
(	O
DDE	B-MED
)	O
in	O
a	O
medieval	B-MED
and	O
an	O
early	B-MED
-	I-MED
modern	I-MED
-	I-MED
age	I-MED
population	B-MED
from	O
Thuringia	B-MED
,	I-MED
Germany	I-MED
.	O
Sixty	O
-	O
six	O
skeletons	B-MED
subdivided	B-MED
into	O
31	O
single	B-MED
burials	B-MED
(	O
12(th)/13(th	O
)	O
c.	O
)	O
and	O
35	O
individuals	B-MED
buried	B-MED
in	O
groups	B-MED
(	O
15(th)/16(th	O
)	O
c.	O
)	O
were	O
examined	B-MED
.	O
DDE	B-MED
were	O
classified	B-MED
on	O
1,246	O
teeth	B-MED
according	O
to	O
the	O
DDE	B-MED
index	B-MED
.	O
Molar	B-MED
-	I-MED
incisor	I-MED
-	I-MED
hypomineralisation	I-MED
(	O
MIH	B-MED
)	O
,	O
a	O
special	O
type	B-MED
of	O
DDE	B-MED
,	O
was	O
recorded	B-MED
according	O
to	O
the	O
European	B-MED
Academy	I-MED
of	I-MED
Paediatric	I-MED
Dentistry	I-MED
(	O
EAPD	B-MED
)	O
criteria	B-MED
.	O
DDE	B-MED
was	O
found	O
in	O
89.4	O
%	O
of	O
the	O
individuals	B-MED
(	O
single	B-MED
burials	B-MED
90.3	O
%	O
and	O
group	B-MED
burials	B-MED
88.6	O
%	O
)	O
.	O
Hypoplastic	B-MED
pits	B-MED
were	O
the	O
most	O
frequent	B-MED
defect	B-MED
in	O
primary	B-MED
teeth	I-MED
and	O
linear	B-MED
enamel	I-MED
hypoplasia	I-MED
(	O
LEH	B-MED
)	O
in	O
permanent	B-MED
teeth	I-MED
.	O
13	O
individuals	B-MED
(	O
24.1	O
%	O
)	O
showed	O
at	O
least	O
one	O
hypomineralised	B-MED
permanent	B-MED
tooth	I-MED
,	O
12.2	O
%	O
had	O
MIH	B-MED
on	O
at	O
least	O
one	O
first	O
permanent	B-MED
molar	I-MED
and	O
10.0	O
%	O
in	O
permanent	B-MED
incisors	I-MED
.	O
Second	B-MED
primary	I-MED
molars	I-MED
were	O
affected	B-MED
in	O
8.0	O
%	O
of	O
the	O
children	B-MED
and	O
juveniles	B-MED
.	O
No	O
individual	B-MED
suffered	O
from	O
affected	B-MED
molars	B-MED
and	O
incisors	B-MED
in	O
combination	B-MED
.	O
Endogenous	B-MED
factors	B-MED
like	O
nutritional	B-MED
deficiencies	I-MED
and	O
health	B-MED
problems	I-MED
in	O
early	B-MED
childhood	B-MED
could	O
have	O
been	O
aetiological	B-MED
reasons	B-MED
of	O
DDE	B-MED
and	O
MIH	B-MED
.	O
The	O
frequency	B-MED
of	O
DDE	B-MED
and	O
MIH	B-MED
might	O
have	O
been	O
masked	B-MED
by	O
extended	B-MED
carious	B-MED
lesions	I-MED
,	O
dental	B-MED
wear	I-MED
and	O
ante	B-MED
-	I-MED
mortem	I-MED
tooth	B-MED
loss	I-MED
.	O
The	O
consummatory	B-MED
and	O
motivational	B-MED
behaviors	B-MED
for	O
natural	B-MED
rewards	B-MED
following	O
long	O
-	O
term	O
withdrawal	B-MED
from	O
morphine	B-MED
:	O
no	O
anhedonia	B-MED
but	O
persistent	O
maladaptive	B-MED
behaviors	I-MED
for	O
high	O
-	O
value	O
rewards	B-MED
The	O
negative	O
affective	O
state	O
,	O
e.g.	O
,	O
anhedonia	B-MED
,	O
emerges	O
after	O
abstinence	B-MED
from	O
abused	B-MED
drugs	I-MED
may	O
be	O
linked	O
to	O
the	O
motivational	B-MED
processes	B-MED
of	O
drug	B-MED
craving	I-MED
and	O
relapse	B-MED
.	O
Although	O
anhedonia	B-MED
diminishes	O
over	O
time	O
with	O
drug	B-MED
abstinence	I-MED
,	O
it	O
is	O
not	O
yet	O
rather	O
explicit	O
whether	O
anhedonia	B-MED
exists	O
or	O
not	O
following	O
protracted	O
withdrawal	B-MED
.	O
The	O
behavioral	B-MED
responses	B-MED
to	O
natural	B-MED
rewards	B-MED
were	O
examined	O
after	O
2	O
to	O
3	O
weeks	B-MED
withdrawal	B-MED
from	O
morphine	B-MED
.	O
Male	B-MED
rats	B-MED
were	O
pretreated	O
with	O
either	O
a	O
binge	O
-	O
like	O
morphine	B-MED
paradigm	B-MED
or	O
daily	B-MED
saline	B-MED
injection	I-MED
for	O
5	O
days	B-MED
.	O
The	O
consummatory	B-MED
and	O
motivational	B-MED
behaviors	B-MED
for	O
three	O
natural	B-MED
rewards	B-MED
(	O
sucrose	B-MED
solutions	I-MED
4	O
,	O
15	O
,	O
and	O
60	O
%	O
,	O
social	B-MED
stimulus	B-MED
:	O
male	B-MED
rat	B-MED
,	O
and	O
sexual	B-MED
stimulus	B-MED
:	O
estrous	B-MED
female	B-MED
rat	B-MED
)	O
were	O
examined	O
under	O
varied	O
testing	B-MED
conditions	I-MED
.	O
The	O
morphine	B-MED
-	O
withdrawn	B-MED
rats	B-MED
significantly	O
increased	O
their	O
intake	O
of	O
15	O
%	O
sucrose	B-MED
solution	I-MED
during	O
the	O
1	O
-	O
h	O
consumption	B-MED
test	I-MED
and	O
their	O
operant	B-MED
responding	I-MED
for	O
15	O
%	O
sucrose	B-MED
solution	I-MED
under	O
a	O
progressive	B-MED
ratio	I-MED
(	I-MED
PR	I-MED
)	I-MED
schedule	I-MED
of	I-MED
reinforcement	I-MED
.	O
When	O
obtaining	O
a	O
reinforcer	B-MED
was	O
associated	O
with	O
a	O
0.5	O
mA	O
foot	B-MED
shock	B-MED
under	O
a	O
PR	B-MED
-	I-MED
punishment	I-MED
schedule	I-MED
,	O
the	O
morphine	B-MED
-	O
withdrawn	B-MED
rats	B-MED
showed	O
a	O
higher	O
performance	O
for	O
60	O
%	O
sucrose	B-MED
solution	I-MED
.	O
Meanwhile	O
,	O
the	O
morphine	B-MED
-	O
withdrawn	B-MED
rats	B-MED
displayed	O
a	O
higher	O
motivation	B-MED
to	O
sexual	B-MED
stimulus	B-MED
during	O
the	O
free	B-MED
-	I-MED
approach	I-MED
test	I-MED
and	O
more	O
approaching	O
behaviors	B-MED
towards	O
sexual	B-MED
stimulus	B-MED
in	O
a	O
conflict	B-MED
-	I-MED
based	I-MED
approach	I-MED
test	I-MED
(	O
concurrent	O
presence	O
of	O
reward	B-MED
and	O
aversive	B-MED
stimulus	I-MED
)	O
.	O
No	B-MED
anhedonia	B-MED
-like	O
behavior	B-MED
but	O
sensitized	B-MED
behaviors	B-MED
for	O
natural	B-MED
rewards	B-MED
were	O
found	O
after	O
long	O
-	O
term	O
morphine	B-MED
withdrawal	B-MED
.	O
Notably	O
,	O
the	O
morphine	B-MED
-	O
withdrawn	B-MED
rats	B-MED
displayed	O
persistent	O
motivated	B-MED
behaviors	B-MED
for	O
high	O
-	O
value	O
rewards	B-MED
(	O
60	O
%	O
sucrose	B-MED
and	O
sexual	B-MED
stimulus	B-MED
)	O
in	O
the	O
conflict	B-MED
tests	I-MED
suggesting	O
impairments	O
in	O
inhibitory	O
control	O
in	O
morphine	B-MED
-	O
treated	B-MED
rats	B-MED
.	O
Selection	B-MED
of	O
an	O
Artificial	B-MED
Diet	B-MED
for	O
Laboratory	B-MED
Rearing	B-MED
of	O
Opogona	B-MED
sacchari	I-MED
(	O
Lepidoptera	B-MED
:	O
Tineidae	B-MED
)	O
(	O
Bojer	O
,	O
1856	O
)	O
The	O
banana	B-MED
moth	I-MED
Opogona	I-MED
sacchari	I-MED
(	O
Bojer	B-MED
)	O
(	O
Lepidoptera	B-MED
:	O
Tineidae	B-MED
)	O
is	O
a	O
polyphagous	B-MED
pest	I-MED
that	O
can	O
cause	O
serious	B-MED
damage	B-MED
,	O
in	O
particular	O
to	O
banana	B-MED
crops	B-MED
in	O
southern	B-MED
Brazil	B-MED
.	O
The	O
insect	B-MED
is	O
a	O
quarantine	O
pest	B-MED
in	O
several	O
countries	B-MED
,	O
including	O
Argentina	B-MED
,	O
the	O
main	O
consumer	B-MED
market	B-MED
for	O
bananas	B-MED
from	O
southern	B-MED
Brazil	B-MED
.	O
Little	O
information	B-MED
is	O
available	O
about	O
the	O
biology	B-MED
and	O
ecology	B-MED
of	O
this	O
moth	B-MED
,	O
such	O
as	O
a	O
suitable	O
diet	B-MED
for	O
laboratory	B-MED
rearing	B-MED
.	O
In	O
order	O
to	O
provide	O
support	O
for	O
integrated	O
pest	B-MED
management	I-MED
of	O
the	O
pest	B-MED
,	O
this	O
study	B-MED
furnished	O
data	B-MED
for	O
selecting	O
two	O
diets	B-MED
suitable	O
for	O
continuous	O
laboratory	B-MED
rearing	B-MED
of	O
O.	B-MED
sacchari	I-MED
,	O
one	O
based	O
on	O
dried	B-MED
beans	B-MED
,	O
wheat	B-MED
germ	I-MED
,	O
soy	B-MED
bran	I-MED
,	O
brewer	B-MED
's	I-MED
yeast	I-MED
,	O
and	O
casein	B-MED
and	O
another	O
diet	B-MED
with	O
wheat	B-MED
germ	I-MED
and	O
casein	B-MED
as	O
protein	B-MED
sources	B-MED
.	O
With	O
both	O
diets	B-MED
,	O
the	O
viability	B-MED
of	O
the	O
egg	B-MED
-	O
adult	B-MED
period	B-MED
exceeded	O
68	O
%	O
,	O
with	O
fertility	B-MED
over	O
338	O
eggs	B-MED
per	O
female	B-MED
.	O
A	O
corrected	O
biotic	B-MED
potential	B-MED
analysis	B-MED
gave	O
similar	O
values	B-MED
for	O
the	O
two	O
diets	B-MED
.	O
Implementation	B-MED
of	O
infrared	B-MED
and	O
Raman	B-MED
modalities	B-MED
for	O
glycosaminoglycan	B-MED
characterization	B-MED
in	O
complex	B-MED
systems	B-MED
Glycosaminoglycans	B-MED
(	O
GAGs	B-MED
)	O
are	O
natural	B-MED
,	O
linear	B-MED
and	O
negatively	B-MED
charged	I-MED
heteropolysaccharides	B-MED
which	O
are	O
incident	B-MED
in	O
every	O
mammalian	B-MED
tissue	B-MED
.	O
They	O
consist	O
of	O
repeating	O
disaccharide	B-MED
units	B-MED
,	O
which	O
are	O
composed	O
of	O
either	O
sulfated	B-MED
or	O
non	B-MED
-	I-MED
sulfated	I-MED
monosaccharides	I-MED
.	O
Depending	O
on	O
tissue	B-MED
types	B-MED
,	O
GAGs	B-MED
exhibit	O
structural	B-MED
heterogeneity	B-MED
such	O
as	O
the	O
position	B-MED
and	O
degree	B-MED
of	O
sulfation	B-MED
or	O
within	O
their	O
disaccharide	B-MED
units	B-MED
composition	B-MED
being	O
heparin	B-MED
,	O
heparan	B-MED
sulfate	I-MED
,	O
chondroitine	B-MED
sulfate	I-MED
,	O
dermatan	B-MED
sulfate	I-MED
,	O
keratan	B-MED
sulfate	I-MED
,	O
and	O
hyaluronic	B-MED
acid	I-MED
.	O
They	O
are	O
covalently	B-MED
linked	I-MED
to	O
a	O
core	B-MED
protein	B-MED
(	O
proteoglycans	B-MED
)	O
or	O
as	O
free	B-MED
chains	B-MED
(	O
hyaluronan	B-MED
)	O
.	O
GAGs	B-MED
affect	O
cell	B-MED
properties	B-MED
and	O
functions	B-MED
either	O
by	O
direct	B-MED
interaction	B-MED
with	O
cell	B-MED
receptors	I-MED
or	O
by	O
sequestration	B-MED
of	O
growth	B-MED
factors	I-MED
.	O
These	O
evidences	B-MED
of	I-MED
divert	B-MED
biological	B-MED
roles	B-MED
of	O
GAGs	B-MED
make	O
their	O
characterization	B-MED
at	O
cell	B-MED
and	O
tissue	B-MED
levels	B-MED
of	O
importance	O
.	O
Thus	O
,	O
non	B-MED
-	I-MED
invasive	I-MED
techniques	B-MED
are	O
interesting	O
to	O
investigate	B-MED
,	O
to	O
qualitatively	B-MED
and	O
quantitatively	B-MED
characterize	O
GAGs	B-MED
in	B-MED
vitro	I-MED
in	O
order	O
to	O
use	O
them	O
as	O
diagnostic	B-MED
biomarkers	B-MED
and/or	O
as	O
therapeutic	B-MED
targets	B-MED
in	O
several	O
human	B-MED
diseases	B-MED
including	O
cancer	B-MED
.	O
Infrared	B-MED
and	O
Raman	B-MED
microspectroscopies	I-MED
and	O
imaging	B-MED
are	O
sensitive	B-MED
enough	O
to	O
differentiate	O
and	O
classify	B-MED
GAG	B-MED
types	B-MED
and	O
subtypes	B-MED
in	O
spite	O
of	O
their	O
close	O
molecular	B-MED
structures	I-MED
.	O
Spectroscopic	B-MED
markers	B-MED
characteristic	O
of	O
reference	O
GAG	B-MED
molecules	B-MED
were	O
identified	B-MED
.	O
Beyond	O
these	O
investigations	B-MED
of	O
the	O
standard	O
GAG	B-MED
spectral	O
signature	O
,	O
infrared	B-MED
and	O
Raman	B-MED
spectral	O
signatures	O
of	O
GAG	B-MED
were	O
searched	O
in	O
complex	B-MED
biological	B-MED
systems	B-MED
like	O
cells	B-MED
.	O
The	O
aim	O
of	O
the	O
present	O
review	O
is	O
to	O
describe	O
the	O
implementation	B-MED
of	O
these	O
complementary	O
vibrational	B-MED
spectroscopy	I-MED
techniques	I-MED
,	O
and	O
to	O
discuss	O
their	O
potentials	O
,	O
advantages	O
and	O
disadvantages	O
for	O
GAG	B-MED
analysis	B-MED
.	O
In	O
addition	O
,	O
this	O
review	O
presents	O
new	O
data	O
as	O
we	O
show	O
for	O
the	O
first	O
time	O
GAG	B-MED
infrared	B-MED
and	O
Raman	B-MED
spectral	O
signatures	O
from	O
conditioned	B-MED
media	I-MED
and	O
live	B-MED
cells	I-MED
,	O
respectively	O
.	O
Homocysteine	B-MED
as	O
a	O
peripheral	B-MED
biomarker	B-MED
in	O
bipolar	B-MED
disorder	I-MED
:	O
A	O
meta	B-MED
-	I-MED
analysis	I-MED
Bipolar	B-MED
disorder	I-MED
(	O
BD	B-MED
)	O
is	O
a	O
psychiatric	B-MED
disorder	I-MED
with	O
an	O
uncertain	B-MED
aetiology	B-MED
.	O
Recently	O
,	O
special	O
attention	O
has	O
been	O
given	O
to	O
homocysteine	B-MED
(	O
Hcy	B-MED
)	O
,	O
as	O
it	O
has	O
been	O
suggested	O
that	O
alterations	B-MED
in	O
1	B-MED
-	I-MED
carbon	I-MED
metabolism	I-MED
might	O
be	O
implicated	O
in	O
diverse	O
psychiatric	B-MED
disorders	I-MED
.	O
However	O
,	O
there	O
is	O
uncertainty	B-MED
regarding	O
possible	O
alterations	B-MED
in	O
peripheral	B-MED
Hcy	B-MED
levels	O
in	O
BD	B-MED
.	O
This	O
study	O
comprises	O
a	O
meta	B-MED
-	I-MED
analysis	I-MED
comparing	O
serum	B-MED
and	O
plasma	B-MED
Hcy	I-MED
levels	I-MED
in	O
persons	B-MED
with	O
BD	B-MED
and	O
healthy	B-MED
controls	I-MED
.	O
We	O
conducted	O
a	O
systematic	B-MED
search	B-MED
for	O
all	O
eligible	B-MED
English	O
and	O
non	O
-	O
English	O
peer	B-MED
-	I-MED
reviewed	I-MED
articles	I-MED
.	O
Nine	O
cross	B-MED
-	I-MED
sectional	I-MED
studies	I-MED
were	O
included	B-MED
in	O
the	O
meta	B-MED
-	I-MED
analyses	I-MED
,	O
providing	B-MED
data	B-MED
on	O
1547	O
participants	B-MED
.	O
Random	B-MED
-	I-MED
effects	I-MED
meta	B-MED
-	I-MED
analysis	I-MED
showed	O
that	O
serum	B-MED
and	O
plasma	B-MED
levels	I-MED
of	I-MED
Hcy	I-MED
were	O
increased	B-MED
in	O
subjects	B-MED
with	O
BD	B-MED
in	O
either	O
mania	B-MED
or	O
euthymia	B-MED
when	O
compared	B-MED
to	O
healthy	B-MED
controls	I-MED
,	O
with	O
a	O
large	O
effect	B-MED
size	I-MED
in	O
the	O
mania	B-MED
group	B-MED
(	O
g=0.98	O
,	O
95	O
%	O
CI	B-MED
:	O
0.8	O
-	O
1.17	O
,	O
P<0.001	O
,	O
n=495	O
)	O
and	O
a	O
small	O
effect	B-MED
in	O
the	O
euthymia	B-MED
group	B-MED
(	O
g=0.3	O
,	O
95	O
%	O
CI	B-MED
:	O
0.11	O
-	O
0.48	O
,	O
P=0.002	O
,	O
n=1052	O
)	O
.	O
Our	O
meta	B-MED
-	I-MED
analysis	I-MED
provides	O
evidence	O
that	O
Hcy	B-MED
levels	I-MED
are	I-MED
elevated	I-MED
in	O
persons	B-MED
with	O
BD	B-MED
during	O
mania	B-MED
and	O
euthymia	B-MED
.	O
Peripheral	B-MED
Hcy	B-MED
could	O
be	O
considered	B-MED
as	O
a	O
potential	B-MED
biomarker	B-MED
in	O
BD	B-MED
,	O
both	O
of	O
trait	B-MED
(	O
since	O
it	O
is	O
increased	B-MED
in	O
euthymia	B-MED
)	O
,	O
and	O
also	O
of	O
state	B-MED
(	O
since	O
its	O
increase	B-MED
is	O
more	O
accentuated	B-MED
in	O
mania	B-MED
)	O
.	O
Longitudinal	B-MED
studies	I-MED
are	O
needed	O
to	O
clarify	O
the	O
relationship	B-MED
between	O
bipolar	B-MED
disorder	I-MED
and	O
Hcy	B-MED
,	O
as	O
well	O
as	O
the	O
usefulness	B-MED
of	O
peripheral	B-MED
Hcy	B-MED
as	O
both	O
a	O
trait	B-MED
and	O
state	B-MED
biomarker	B-MED
in	O
BD	B-MED
.	O
Commissioning	B-MED
through	O
competition	B-MED
and	O
cooperation	B-MED
in	O
the	O
English	B-MED
NHS	B-MED
under	O
the	O
Health	B-MED
and	I-MED
Social	I-MED
Care	I-MED
Act	I-MED
2012	I-MED
:	O
evidence	O
from	O
a	O
qualitative	B-MED
study	I-MED
of	O
four	O
clinical	B-MED
commissioning	I-MED
groups	I-MED
The	O
Health	B-MED
and	I-MED
Social	I-MED
Care	I-MED
Act	I-MED
2012	I-MED
(	O
'	O
HSCA	B-MED
2012	I-MED
'	O
)	O
introduced	O
a	O
new	O
,	O
statutory	O
,	O
form	O
of	O
regulation	B-MED
of	O
competition	B-MED
into	O
the	O
National	B-MED
Health	I-MED
Service	I-MED
(	O
NHS	B-MED
)	O
,	O
while	O
at	O
the	O
same	O
time	O
recognising	O
that	O
cooperation	B-MED
was	O
necessary	O
.	O
NHS	B-MED
England	B-MED
's	I-MED
policy	I-MED
document	I-MED
,	O
The	O
Five	B-MED
Year	I-MED
Forward	I-MED
View	I-MED
(	O
'	O
5YFV	B-MED
'	O
)	O
of	O
2014	O
placed	O
less	O
emphasis	O
on	O
competition	B-MED
without	O
altering	O
the	O
legislation	B-MED
.	O
We	O
explored	O
how	O
commissioners	B-MED
and	O
providers	B-MED
understand	O
the	O
complex	B-MED
regulatory	B-MED
framework	I-MED
,	O
and	O
how	O
they	O
behave	O
in	O
relation	O
to	O
competition	B-MED
and	O
cooperation	B-MED
.	O
We	O
carried	O
out	O
detailed	O
case	B-MED
studies	I-MED
in	O
four	O
clinical	B-MED
commissioning	I-MED
groups	I-MED
,	O
using	O
interviews	B-MED
and	O
documentary	B-MED
analysis	I-MED
to	O
explore	O
the	O
commissioners	B-MED
'	O
and	O
providers	B-MED
'	O
understanding	O
and	O
experience	O
of	O
competition	B-MED
and	O
cooperation	B-MED
.	O
We	O
conducted	O
42	O
interviews	B-MED
with	O
senior	B-MED
managers	I-MED
in	O
commissioning	B-MED
organisations	B-MED
and	O
senior	B-MED
managers	I-MED
in	O
NHS	B-MED
and	O
independent	B-MED
provider	I-MED
organisations	I-MED
(	O
acute	B-MED
and	I-MED
community	I-MED
services	I-MED
)	O
.	O
Neither	O
commissioners	B-MED
nor	O
providers	B-MED
fully	O
understand	O
the	O
regulatory	B-MED
regime	I-MED
in	O
respect	O
of	O
competition	B-MED
in	O
the	O
NHS	B-MED
,	O
and	O
have	O
not	O
found	O
that	O
the	O
regulatory	B-MED
authorities	I-MED
have	O
provided	O
adequate	O
guidance	B-MED
.	O
Despite	O
the	O
HSCA	B-MED
2012	I-MED
promoting	B-MED
competition	B-MED
,	O
commissioners	B-MED
chose	O
mainly	O
to	O
use	O
collaborative	B-MED
strategies	I-MED
to	O
effect	O
major	O
service	B-MED
reconfigurations	O
,	O
which	O
is	O
endorsed	O
as	O
a	O
suitable	O
approach	O
by	O
providers	B-MED
.	O
Nevertheless	O
,	O
commissioners	B-MED
are	O
using	O
competitive	B-MED
tendering	O
in	O
respect	O
of	O
more	O
peripheral	B-MED
services	I-MED
in	O
order	O
to	O
improve	O
quality	B-MED
of	I-MED
care	I-MED
and	O
value	B-MED
for	I-MED
money	I-MED
.	O
Commissioners	B-MED
regard	O
the	O
use	O
of	O
competition	B-MED
and	O
cooperation	B-MED
as	O
appropriate	O
in	O
the	O
NHS	B-MED
currently	O
,	O
although	O
collaborative	B-MED
strategies	I-MED
appear	O
more	O
helpful	O
in	O
respect	O
of	O
large	B-MED
-	I-MED
scale	I-MED
changes	I-MED
.	O
However	O
,	O
the	O
current	O
regulatory	B-MED
framework	I-MED
contained	O
in	O
the	O
HSCA	B-MED
2012	I-MED
,	O
particularly	O
since	O
the	O
publication	B-MED
of	O
the	O
5YFV	B-MED
,	O
is	O
not	O
clear	O
.	O
Better	O
guidance	B-MED
should	O
be	O
issued	O
by	O
the	O
regulatory	B-MED
authorities	I-MED
.	O
Characterization	B-MED
of	O
exposure	B-MED
in	O
epidemiological	B-MED
studies	I-MED
on	O
air	B-MED
pollution	I-MED
from	O
biodegradable	B-MED
wastes	B-MED
:	O
Misclassification	B-MED
and	O
comparison	B-MED
of	O
exposure	B-MED
assessment	B-MED
strategies	B-MED
The	O
assignment	O
of	O
exposure	B-MED
is	O
one	O
of	O
the	O
main	O
challenges	O
faced	O
by	O
environmental	B-MED
epidemiologists	B-MED
.	O
However	O
,	O
misclassification	B-MED
of	O
exposures	B-MED
has	O
not	O
been	O
explored	O
in	O
population	B-MED
epidemiological	B-MED
studies	I-MED
on	O
air	B-MED
pollution	I-MED
from	O
biodegradable	B-MED
wastes	B-MED
.	O
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
the	O
use	O
of	O
different	O
approaches	O
for	O
assessing	O
exposure	B-MED
to	O
air	B-MED
pollution	I-MED
from	O
biodegradable	B-MED
wastes	B-MED
by	O
analyzing	B-MED
(	O
1	O
)	O
the	O
misclassification	B-MED
of	O
exposure	B-MED
that	O
is	O
committed	O
by	O
using	O
these	O
surrogates	B-MED
,	O
(	O
2	O
)	O
the	O
existence	O
of	O
differentia	B-MED
l	O
misclassification	B-MED
(	O
3	O
)	O
the	O
effects	B-MED
that	O
misclassification	B-MED
may	O
have	O
on	O
health	B-MED
effect	B-MED
estimates	B-MED
and	O
the	O
interpretation	B-MED
of	O
epidemiological	B-MED
results	B-MED
,	O
and	O
(	O
4	O
)	O
the	O
ability	O
of	O
the	O
exposure	B-MED
measures	O
to	O
predict	O
health	B-MED
outcomes	I-MED
using	O
10	O
-	O
fold	O
cross	B-MED
validation	I-MED
.	O
Four	O
different	O
exposure	B-MED
assessment	B-MED
approaches	O
were	O
studied	B-MED
:	O
ammonia	B-MED
concentrations	B-MED
at	O
the	O
residence	B-MED
(	O
Metric	B-MED
I	I-MED
)	O
,	O
distance	B-MED
to	O
the	O
closest	O
source	B-MED
(	O
Metric	B-MED
II	I-MED
)	O
,	O
number	O
of	O
sources	B-MED
within	O
certain	O
distances	B-MED
from	O
the	O
residence	B-MED
(	O
Metric	B-MED
IIIa	I-MED
,	O
b	B-MED
)	O
and	O
location	B-MED
in	O
a	O
specific	O
region	B-MED
(	O
Metric	B-MED
IV	I-MED
)	O
.	O
Exposure	B-MED
-	I-MED
response	I-MED
models	I-MED
based	O
on	O
Metric	B-MED
I	I-MED
provided	O
the	O
highest	O
predictive	O
ability	O
(	O
72.3	O
%	O
)	O
and	O
goodness	B-MED
-	I-MED
of	I-MED
-	I-MED
fit	I-MED
,	O
followed	O
by	O
IV	B-MED
,	O
III	B-MED
and	O
II	B-MED
.	O
When	O
compared	O
to	O
Metric	B-MED
I	I-MED
,	O
Metric	B-MED
IV	I-MED
yielded	O
the	O
best	O
results	B-MED
for	O
exposure	B-MED
misclassification	B-MED
analysis	B-MED
and	O
interpretation	B-MED
of	O
health	B-MED
effect	B-MED
estimates	B-MED
,	O
followed	O
by	O
Metric	B-MED
IIIb	I-MED
,	O
IIIa	B-MED
and	O
II	B-MED
.	O
The	O
study	B-MED
showed	O
that	O
modelled	O
NH3	B-MED
concentrations	B-MED
provide	O
more	O
accurate	O
estimations	B-MED
of	O
true	O
exposure	B-MED
than	O
distances	O
-	O
based	O
surrogates	B-MED
,	O
and	O
that	O
distance	O
-	O
based	O
surrogates	B-MED
(	O
especially	O
those	O
based	O
on	O
distance	B-MED
to	O
the	O
closest	O
point	O
source	B-MED
)	O
are	O
imprecise	O
methods	O
to	O
identify	O
exposed	O
populations	B-MED
,	O
although	O
they	O
may	O
be	O
useful	O
for	O
initial	O
studies	B-MED
.	O
Lycopene	B-MED
and	O
risk	B-MED
of	O
cardiovascular	B-MED
diseases	I-MED
:	O
A	O
meta	B-MED
-	I-MED
analysis	I-MED
of	O
observational	B-MED
studies	I-MED
The	O
aim	O
of	O
current	O
meta	B-MED
-	I-MED
analysis	I-MED
was	O
to	O
investigate	B-MED
the	O
relation	O
between	O
lycopene	B-MED
and	O
risk	B-MED
of	O
cardiovascular	B-MED
diseases	I-MED
(	O
CVD	B-MED
)	O
.	O
Studies	B-MED
concerning	O
about	O
the	O
association	O
between	O
lycopene	B-MED
and	O
risk	B-MED
of	O
CVD	B-MED
were	O
searched	O
on	O
Pubmed	B-MED
,	O
Embase	B-MED
,	O
and	O
Web	B-MED
of	I-MED
Science	I-MED
from	O
inception	O
to	O
October	O
2016	O
.	O
A	O
total	O
of	O
14	O
eligible	B-MED
studies	I-MED
were	O
identified	B-MED
.	O
A	O
significantly	O
inverse	B-MED
association	I-MED
with	O
a	O
pooled	O
risk	B-MED
ratio	I-MED
(	O
RR	B-MED
)	O
of	O
0.83	O
(	O
95	O
%	O
CI	B-MED
:	O
0.76	O
-	O
0.90	O
)	O
was	O
shown	O
between	O
lycopene	B-MED
exposure	B-MED
and	O
risk	B-MED
of	O
CVD	B-MED
.	O
Findings	B-MED
were	O
similar	O
restricting	O
to	O
dietary	B-MED
studies	B-MED
(	O
RR	B-MED
=	O
0.87	O
,	O
95	O
%	O
CI	B-MED
=	O
0.79	O
-	O
0.96	O
)	O
and	O
biomarker	B-MED
studies	B-MED
(	O
RR	B-MED
=	O
0.74	O
,	O
95	O
%	O
CI	B-MED
=	O
0	O
.	O
62	O
-	O
0.87	O
)	O
.	O
Dietary	B-MED
lycopene	B-MED
intake	B-MED
was	O
statistically	B-MED
significant	I-MED
for	O
coronary	B-MED
heart	I-MED
disease	I-MED
(	O
CHD	B-MED
)	O
(	O
RR	B-MED
:	O
0.87	O
;	O
95	O
%	O
CI	B-MED
:	O
0.76	O
-	O
0.98	O
)	O
and	O
stroke	B-MED
(	O
RR	B-MED
:	O
0.83	O
;	O
95	O
%	O
CI	B-MED
:	O
0.69	O
-	O
0.96).The	O
pooled	O
risk	B-MED
estimate	I-MED
was	O
generally	O
similar	O
for	O
lycopene	B-MED
biomarker	B-MED
concentrations	O
,	O
but	O
the	O
association	O
was	O
only	O
statistically	B-MED
significant	I-MED
for	O
stroke	B-MED
(	O
RR	B-MED
:	O
0.65	O
;	O
95	O
%	O
CI	B-MED
:	O
0.42	O
-	O
0.87	O
)	O
.	O
Subgroup	B-MED
analyses	B-MED
showed	O
that	O
retrospective	B-MED
and	O
low	O
quality	O
studies	B-MED
were	O
statistically	B-MED
significant	I-MED
sources	O
of	O
heterogeneity	B-MED
.	O
Higher	O
lycopene	B-MED
exposure	B-MED
is	O
inversely	B-MED
associated	I-MED
with	O
a	O
lower	O
risk	B-MED
of	O
CVD	B-MED
.	O
Further	O
well	O
-	O
designed	O
randomized	B-MED
clinical	I-MED
trials	I-MED
are	O
required	O
to	O
assess	O
the	O
role	O
of	O
lycopene	B-MED
on	O
CVD	B-MED
.	O
The	O
Abundance	B-MED
of	O
Endofungal	B-MED
Bacterium	I-MED
Rhizobium	B-MED
radiobacter	I-MED
(	O
syn	O
.	O
Agrobacterium	B-MED
tumefaciens	I-MED
)	O
Increases	B-MED
in	O
Its	O
Fungal	B-MED
Host	B-MED
Piriformospora	B-MED
indica	I-MED
during	O
the	O
Tripartite	O
Sebacinalean	B-MED
Symbiosis	B-MED
with	O
Higher	B-MED
Plants	I-MED
Rhizobium	B-MED
radiobacter	I-MED
(	O
syn	O
.	O
Agrobacterium	B-MED
tumefaciens	I-MED
,	O
syn	O
.	O
"	O
Agrobacterium	B-MED
fabrum	I-MED
"	O
)	O
is	O
an	O
endofungal	B-MED
bacterium	I-MED
of	O
the	O
fungal	B-MED
mutualist	B-MED
Piriformospora	B-MED
(	O
syn	O
.	O
Serendipita	B-MED
)	O
indica	B-MED
(	O
Basidiomycota	B-MED
)	O
,	O
which	O
together	O
form	O
a	O
tripartite	O
Sebacinalean	B-MED
symbiosis	B-MED
with	O
a	O
broad	O
range	O
of	O
plants	B-MED
.	O
R.	B-MED
radiobacter	I-MED
strain	B-MED
F4	I-MED
(	O
RrF4	B-MED
)	O
,	O
isolated	O
from	O
P.	B-MED
indica	I-MED
DSM	I-MED
11827	I-MED
,	O
induces	B-MED
growth	B-MED
promotion	B-MED
and	O
systemic	B-MED
resistance	I-MED
in	O
cereal	B-MED
crops	B-MED
,	O
including	O
barley	B-MED
and	O
wheat	B-MED
,	O
suggesting	O
that	O
R.	B-MED
radiobacter	I-MED
contributes	O
to	O
a	O
successful	O
symbiosis	B-MED
.	O
Here	O
,	O
we	O
studied	O
the	O
impact	B-MED
of	O
endobacteria	B-MED
on	O
the	O
morphology	B-MED
and	O
the	O
beneficial	O
activity	O
of	O
P.	B-MED
indica	I-MED
during	O
interactions	B-MED
with	O
plants	B-MED
.	O
Low	O
numbers	O
of	O
endobacteria	B-MED
were	O
detected	B-MED
in	O
the	O
axenically	B-MED
grown	I-MED
P.	B-MED
indica	I-MED
(	O
long	B-MED
term	I-MED
lab	B-MED
-	I-MED
cultured	I-MED
,	O
lcPiri	B-MED
)	O
whereas	O
mycelia	B-MED
colonizing	B-MED
the	O
plant	B-MED
root	I-MED
contained	O
increased	B-MED
numbers	O
of	O
bacteria	B-MED
.	O
Higher	O
numbers	O
of	O
endobacteria	B-MED
were	O
also	O
found	O
in	O
axenic	B-MED
cultures	I-MED
of	O
P.	B-MED
indica	I-MED
that	O
was	O
freshly	O
re	B-MED
-	I-MED
isolated	I-MED
(	O
riPiri	B-MED
)	O
from	O
plant	B-MED
roots	I-MED
,	O
though	O
numbers	O
dropped	O
during	O
repeated	O
axenic	B-MED
re	I-MED
-	I-MED
cultivation	I-MED
.	O
Prolonged	B-MED
treatments	B-MED
of	O
P.	B-MED
indica	I-MED
cultures	B-MED
with	O
various	O
antibiotics	B-MED
could	O
not	O
completely	O
eliminate	O
the	O
bacterium	B-MED
,	O
though	O
the	O
number	O
of	O
detectable	B-MED
endobacteria	B-MED
decreased	B-MED
significantly	B-MED
,	O
resulting	O
in	O
partial	B-MED
-	I-MED
cured	I-MED
P.	B-MED
indica	I-MED
(	O
pcPiri	B-MED
)	O
.	O
pcPiri	B-MED
showed	O
reduced	B-MED
growth	B-MED
in	O
axenic	B-MED
cultures	I-MED
and	O
poor	B-MED
sporulation	B-MED
.	O
Consistent	B-MED
with	I-MED
this	O
,	O
pcPiri	B-MED
also	O
showed	O
reduced	B-MED
plant	B-MED
growth	I-MED
promotion	B-MED
and	O
reduced	B-MED
systemic	B-MED
resistanc	I-MED
e	O
against	O
powdery	B-MED
mildew	I-MED
infection	B-MED
as	O
compared	O
with	O
riPiri	B-MED
and	O
lcPiri	B-MED
.	O
These	O
results	B-MED
are	O
consistent	B-MED
with	I-MED
the	O
assumption	O
that	O
the	O
endobacterium	B-MED
R.	B-MED
radiobacter	I-MED
improves	B-MED
P.	B-MED
indica	I-MED
's	I-MED
fitness	B-MED
and	O
thus	O
contributes	O
to	O
the	O
success	O
of	O
the	O
tripartite	O
Sebacinalean	B-MED
symbiosis	B-MED
.	O
The	O
bachelorette	O
:	O
Female	B-MED
Siamese	B-MED
fighting	I-MED
fish	I-MED
avoid	B-MED
males	B-MED
exposed	B-MED
to	I-MED
an	O
estrogen	B-MED
mimic	B-MED
Due	O
to	O
improper	B-MED
disposal	B-MED
and	O
a	O
lack	B-MED
of	O
removal	B-MED
during	O
the	O
wastewater	B-MED
treatment	B-MED
process	I-MED
,	O
endocrine	B-MED
disrupting	B-MED
chemicals	B-MED
enter	O
aquatic	B-MED
ecosystems	I-MED
where	O
they	O
exert	O
detrimental	O
effects	B-MED
on	O
fish	B-MED
behavior	B-MED
and	O
physiology	B-MED
.	O
Perhaps	O
the	O
most	O
well	O
-	O
studied	O
and	O
prevalent	B-MED
EDC	B-MED
is	O
17α	B-MED
-	I-MED
ethinylestradiol	I-MED
(	O
EE2	B-MED
)	O
,	O
an	O
active	O
ingredient	B-MED
in	O
oral	B-MED
contraceptives	I-MED
,	O
which	O
is	O
known	O
to	O
cause	O
dramatic	O
reductions	B-MED
in	O
male	B-MED
-typical	O
behaviors	B-MED
.	O
While	O
it	O
is	O
likely	O
that	O
alterations	B-MED
in	O
male	B-MED
courtship	B-MED
behavior	B-MED
decrease	B-MED
reproductive	B-MED
fitness	I-MED
,	O
this	O
is	O
rarely	O
explicitly	O
examined	O
.	O
To	O
this	O
end	O
,	O
whether	O
EE2	B-MED
exposure	B-MED
reduces	B-MED
male	B-MED
attractiveness	B-MED
to	O
female	B-MED
Siamese	B-MED
fighting	I-MED
fish	I-MED
,	O
Betta	B-MED
splendens	I-MED
,	O
was	O
investigated	B-MED
by	O
showing	O
females	B-MED
video	B-MED
images	B-MED
of	O
exposed	B-MED
and	O
unexposed	B-MED
males	B-MED
.	O
Females	B-MED
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
exposure	B-MED
conditions	B-MED
(	O
exposed	B-MED
to	I-MED
EE2	B-MED
,	O
control	B-MED
)	O
and	O
each	O
subject	B-MED
then	O
viewed	O
four	B-MED
different	B-MED
video	B-MED
combinations	B-MED
of	O
male	B-MED
conspecifics	B-MED
(	O
courting	B-MED
exposed	B-MED
+	O
exposed	B-MED
;	O
courting	B-MED
unexposed	B-MED
+	O
unexposed	B-MED
;	O
courting	B-MED
unexposed	B-MED
+	O
exposed	B-MED
;	O
swimming	B-MED
unexposed	B-MED
+	O
exposed	B-MED
)	O
.	O
Females	B-MED
,	O
regardless	O
of	O
whether	O
or	O
not	O
they	O
were	O
exposed	B-MED
to	I-MED
EE2	B-MED
,	O
directed	O
markedly	O
less	O
behavior	B-MED
towards	O
exposed	B-MED
males	B-MED
,	O
especially	O
when	O
they	O
viewed	O
an	O
exposed	B-MED
male	B-MED
and	O
an	O
unexposed	B-MED
male	B-MED
simultaneously	B-MED
.	O
These	O
findings	O
demonstrate	O
that	O
EE2	B-MED
can	O
have	O
significant	B-MED
individual	B-MED
-	O
and	O
population	B-MED
-	I-MED
level	I-MED
consequences	B-MED
on	O
fitness	B-MED
by	O
disrupting	B-MED
sexual	B-MED
selection	I-MED
and	O
,	O
ultimately	O
,	O
the	O
success	B-MED
of	O
exposed	B-MED
males	B-MED
males	B-MED
.	O
Thaw	B-MED
-and	O
-	O
use	O
target	B-MED
cells	I-MED
pre	B-MED
-	I-MED
labeled	I-MED
with	O
calcein	B-MED
AM	I-MED
for	O
antibody	B-MED
-	I-MED
dependent	I-MED
cell	I-MED
-	I-MED
mediated	I-MED
cytotoxicity	I-MED
assays	I-MED
In	B-MED
vitro	I-MED
antibody	B-MED
-	I-MED
dependent	I-MED
cell	I-MED
-	I-MED
mediated	I-MED
cytotoxicity	I-MED
(	I-MED
ADCC	I-MED
)	I-MED
assays	I-MED
are	O
routinely	O
performed	O
to	O
support	O
the	O
research	O
and	O
development	O
of	O
therapeutic	B-MED
antibodies	I-MED
.	O
In	O
ADCC	B-MED
assays	I-MED
,	O
target	B-MED
cells	I-MED
bound	O
by	O
the	O
antibodies	B-MED
are	O
lysed	B-MED
by	O
activated	B-MED
effector	B-MED
cells	I-MED
following	O
interactions	O
between	O
the	O
Fc	B-MED
region	I-MED
of	O
the	O
bound	O
antibody	B-MED
and	O
Fcγ	B-MED
receptors	I-MED
on	O
effector	B-MED
cells	I-MED
.	O
Target	B-MED
cell	I-MED
lysis	B-MED
is	O
typically	O
measured	O
by	O
quantification	B-MED
of	O
released	O
endogenous	B-MED
enzymes	B-MED
,	O
e.g.	O
,	O
lactate	B-MED
dehydrogenase	I-MED
,	O
or	O
measurement	O
of	O
released	O
exogenous	B-MED
labels	B-MED
,	O
e.g.	O
,	O
(	B-MED
51)Cr	I-MED
,	O
europium	B-MED
or	O
calcein	B-MED
.	O
ADCC	B-MED
assays	I-MED
based	O
on	O
the	O
detection	O
of	O
exogenous	B-MED
labels	B-MED
released	O
from	O
lysed	B-MED
target	B-MED
cells	I-MED
generally	O
show	O
higher	O
sensitivity	O
and	O
require	O
shorter	O
incubation	B-MED
times	I-MED
.	O
However	O
,	O
target	B-MED
cells	I-MED
are	O
usually	O
labeled	B-MED
immediately	O
prior	O
to	O
assay	B-MED
,	O
which	O
inadvertently	O
introduces	O
additional	O
assay	B-MED
variations	B-MED
due	O
to	O
differences	O
in	O
target	B-MED
cell	I-MED
conditions	O
and	O
labeling	B-MED
/	O
handling	B-MED
processes	I-MED
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
the	O
use	O
of	O
thaw	B-MED
-and	O
-	O
use	O
pre	B-MED
-	I-MED
labeled	I-MED
target	B-MED
cells	I-MED
for	O
ADCC	B-MED
assays	I-MED
.	O
Thaw	B-MED
-and	O
-	O
use	O
target	B-MED
cells	I-MED
in	O
our	O
experiments	O
were	O
pre	B-MED
-	I-MED
labeled	I-MED
with	O
the	O
fluorescent	B-MED
dye	I-MED
calcein	I-MED
AM	I-MED
,	O
cryopreserved	B-MED
in	O
single	O
-	O
use	O
aliquots	O
and	O
used	O
directly	O
in	O
assays	B-MED
after	O
thawing	B-MED
.	O
Upon	O
thaw	B-MED
,	O
the	O
pre	B-MED
-	I-MED
labeled	I-MED
cells	B-MED
displayed	O
viability	B-MED
and	O
label	B-MED
retention	B-MED
comparable	O
to	O
freshly	O
labeled	B-MED
cells	B-MED
,	O
responded	O
to	O
ADCC	B-MED
mediated	O
by	O
both	O
peripheral	B-MED
blood	I-MED
mononuclear	I-MED
cells	I-MED
and	O
engineered	B-MED
natural	I-MED
killer	I-MED
cells	I-MED
,	O
performed	O
stably	O
for	O
at	O
least	O
3	O
years	O
and	O
provided	O
favorable	O
precision	O
and	O
accuracy	O
to	O
ADCC	B-MED
assays	I-MED
.	O
Implementation	O
of	O
thaw	B-MED
-and	O
-	O
use	O
pre	B-MED
-	I-MED
labeled	I-MED
target	B-MED
cells	I-MED
in	O
ADCC	B-MED
assays	I-MED
can	O
help	O
to	O
alleviate	O
both	O
cell	B-MED
culture	I-MED
and	O
dye	B-MED
labeling	I-MED
derived	O
variability	O
,	O
increase	O
the	O
flexibility	O
of	O
assay	B-MED
scheduling	O
and	O
improve	O
assay	B-MED
consistency	I-MED
and	O
robustness	B-MED
.	O
Effectiveness	B-MED
of	O
offloading	B-MED
methods	B-MED
in	O
preventing	B-MED
primary	B-MED
diabetic	B-MED
foot	I-MED
ulcers	I-MED
in	O
adults	B-MED
with	O
diabetes	B-MED
:	O
a	O
systematic	B-MED
review	I-MED
The	O
incidence	B-MED
of	O
foot	B-MED
ulceration	I-MED
related	O
to	O
diabetes	B-MED
is	O
increasing	B-MED
.	O
Many	O
foot	B-MED
care	I-MED
professionals	B-MED
recommend	O
offloading	B-MED
measures	O
as	O
part	O
of	O
management	B-MED
strategies	I-MED
for	O
modulating	O
excess	B-MED
pressure	B-MED
to	O
prevent	B-MED
development	O
of	O
diabetic	B-MED
foot	I-MED
ulcers	I-MED
(	O
DFUs	B-MED
)	O
.	O
These	O
measures	B-MED
may	O
include	O
padding	B-MED
,	O
insoles	B-MED
/	O
orthotic	B-MED
devices	I-MED
and	O
footwear	B-MED
.	O
There	O
is	O
a	O
lack	O
of	O
evidence	B-MED
-based	O
guidance	O
on	O
the	O
effectiveness	B-MED
of	O
the	O
different	O
offloading	B-MED
options	O
for	O
preventing	B-MED
primary	B-MED
ulceration	B-MED
in	O
those	O
with	O
diabetes	B-MED
.	O
To	O
identify	O
,	O
critically	O
appraise	O
and	O
synthesize	O
the	O
best	O
available	O
evidence	B-MED
on	O
methods	B-MED
of	O
offloading	B-MED
to	O
prevent	B-MED
the	O
development	B-MED
,	O
and	O
reduce	B-MED
the	O
risk	B-MED
,	O
of	O
primary	B-MED
foot	B-MED
ulceration	I-MED
in	O
adults	B-MED
with	O
diabetes	B-MED
.The	O
question	B-MED
addressed	B-MED
by	O
the	O
review	B-MED
was	O
:	O
what	O
is	O
the	O
effectiveness	B-MED
of	O
methods	B-MED
of	O
offloading	B-MED
in	O
preventing	B-MED
primary	B-MED
DFUs	B-MED
in	O
adults	B-MED
with	O
diabetes	B-MED
?	O
Adults	B-MED
18	O
years	B-MED
and	O
older	O
with	O
diabetes	B-MED
mellitus	I-MED
,	O
regardless	O
of	O
age	B-MED
,	O
gender	B-MED
,	O
ethnicity	B-MED
,	O
duration	B-MED
or	O
type	B-MED
of	O
diabetes	B-MED
,	O
with	O
no	O
history	B-MED
of	O
DFUs	B-MED
and	O
in	O
any	O
clinical	B-MED
setting	I-MED
will	O
be	O
included	O
.	O
Interventions	B-MED
will	O
include	O
all	O
external	O
methods	B-MED
of	O
offloading	B-MED
.	O
All	O
comparators	O
will	O
be	O
considered	O
.	O
Studies	B-MED
that	O
utilize	O
interventions	B-MED
not	O
considered	O
usual	B-MED
practice	B-MED
in	O
the	O
prevention	B-MED
of	O
DFUs	B-MED
will	O
be	O
excluded	B-MED
.	O
The	O
primary	B-MED
outcome	B-MED
will	O
be	O
primary	B-MED
foot	B-MED
ulceration	I-MED
.	O
The	O
secondary	B-MED
outcome	B-MED
will	O
be	O
indications	O
of	O
changes	O
in	O
plantar	B-MED
pressure	B-MED
.	O
This	O
review	B-MED
will	O
consider	O
all	O
quantitative	B-MED
study	B-MED
designs	I-MED
.	O
A	O
three	O
-	O
step	O
strategy	O
for	O
published	O
and	O
unpublished	O
literature	B-MED
will	O
be	O
used	O
.	O
Fourteen	O
databases	B-MED
will	O
be	O
searched	O
for	O
studies	B-MED
in	O
English	B-MED
up	O
to	O
November	O
2013	O
.	O
The	O
JBI	B-MED
-	I-MED
MAStARI	I-MED
extraction	I-MED
tool	I-MED
was	O
used	O
to	O
extract	O
relevant	O
data	B-MED
.	O
Results	B-MED
were	O
summarized	B-MED
using	O
narrative	B-MED
and	O
tables	B-MED
.	O
Three	O
studies	B-MED
which	O
examined	O
the	O
effectiveness	B-MED
of	O
four	O
different	O
offloading	B-MED
interventions	B-MED
met	O
the	O
inclusion	B-MED
criteria	I-MED
.	O
There	O
is	O
limited	O
evidence	B-MED
that	O
use	O
of	O
a	O
footwear	B-MED
system	O
(	O
prototype	B-MED
shoe	I-MED
plus	I-MED
polyurethane	I-MED
or	O
cork	B-MED
insole	I-MED
)	O
may	O
prevent	B-MED
a	O
break	O
in	O
the	O
skin	B-MED
;	O
use	O
of	O
customized	O
rigid	O
orthotic	B-MED
devices	I-MED
may	O
contribute	O
to	O
a	O
reduction	B-MED
in	O
the	O
grade	B-MED
and	O
number	B-MED
of	O
calluses	B-MED
;	O
and	O
a	O
manufactured	O
shoe	B-MED
plus	I-MED
customized	O
insole	B-MED
may	O
reduce	O
plantar	B-MED
pressure	B-MED
and	O
therefore	O
reduce	O
the	O
potential	O
risk	B-MED
of	O
skin	B-MED
ulceration	I-MED
.	O
There	O
is	O
limited	O
and	O
low	O
-	O
quality	O
evidence	B-MED
that	O
in	O
a	O
population	B-MED
of	O
adults	B-MED
with	O
diabetes	B-MED
with	O
no	O
history	B-MED
of	O
DFU	B-MED
,	O
the	O
use	O
of	O
footwear	B-MED
with	O
customized	O
or	O
prefabricated	O
orthotic	B-MED
devices	I-MED
may	O
provide	O
some	O
reduction	O
in	O
plantar	B-MED
pressure	B-MED
and	O
therefore	O
help	O
to	O
prevent	B-MED
a	O
primary	B-MED
DFU	B-MED
.	O
There	O
is	O
a	O
lack	O
of	O
evidence	B-MED
on	O
the	O
relative	O
effectiveness	B-MED
of	O
different	O
offloading	B-MED
options	O
.	O
Scutellaria	B-MED
barbata	I-MED
D.	I-MED
Don	I-MED
extract	I-MED
inhibits	B-MED
the	O
tumor	B-MED
growth	I-MED
through	O
down	B-MED
-	I-MED
regulating	I-MED
of	O
Treg	B-MED
cells	I-MED
and	O
manipulating	B-MED
Th1	B-MED
/	O
Th17	B-MED
immune	I-MED
response	I-MED
in	O
hepatoma	B-MED
H22	I-MED
-bearing	O
mice	B-MED
Previous	O
studies	O
showed	O
Scutellaria	B-MED
barbata	I-MED
D.	I-MED
Don	I-MED
extract	I-MED
(	O
SBE	B-MED
)	O
is	O
a	O
potent	O
inhibitor	B-MED
in	O
hepatoma	B-MED
and	O
could	O
improve	O
immune	B-MED
function	I-MED
of	O
hepatoma	B-MED
H22	I-MED
-bearing	O
mice	B-MED
.	O
However	O
,	O
the	O
immunomodulatory	B-MED
function	I-MED
of	O
SBE	B-MED
on	O
the	O
tumor	B-MED
growth	I-MED
of	O
hepatoma	B-MED
remains	O
unclear	B-MED
.	O
This	O
study	B-MED
aimed	O
to	O
investigate	B-MED
the	O
anti	B-MED
-	I-MED
tumor	I-MED
effects	B-MED
of	O
SBE	B-MED
on	O
hepatoma	B-MED
H22	I-MED
-bearing	O
mice	B-MED
and	O
explore	O
the	O
underlying	O
immunomodulatory	B-MED
function	I-MED
.	O
The	O
hepatoma	B-MED
H22	I-MED
-bearing	O
mice	B-MED
were	O
treated	B-MED
by	O
SBE	B-MED
for	O
30	O
days	B-MED
.	O
The	O
effect	B-MED
of	I-MED
SBE	B-MED
on	O
the	O
proliferation	B-MED
of	O
HepG2	B-MED
cells	I-MED
in	B-MED
vitro	I-MED
,	O
the	O
growth	B-MED
of	I-MED
transplanted	I-MED
tumor	I-MED
,	O
the	O
cytotoxicity	B-MED
of	I-MED
natural	I-MED
killer	I-MED
(	I-MED
NK	I-MED
)	I-MED
cells	I-MED
in	O
spleen	B-MED
,	O
the	O
amount	B-MED
of	O
CD4(+)CD25(+)Foxp3(+	B-MED
)	I-MED
Treg	I-MED
cells	I-MED
and	O
Th17	B-MED
cells	I-MED
in	O
tumor	B-MED
tissue	I-MED
,	O
and	O
the	O
levels	B-MED
of	O
IL-10	B-MED
,	O
TGF	B-MED
-	I-MED
β	I-MED
,	O
IL-17A	B-MED
,	O
IL-2	B-MED
,	O
and	O
IFN	B-MED
-	I-MED
γ	I-MED
in	O
serum	B-MED
of	O
the	O
hepatoma	B-MED
H22	I-MED
-bearing	O
mice	B-MED
was	O
observered	O
.	O
IL-17A	B-MED
was	O
injected	B-MED
to	O
the	O
SBE	B-MED
treated	B-MED
mice	B-MED
from	O
day	B-MED
9	O
post	B-MED
H22	B-MED
inoculation	B-MED
to	O
examine	O
its	O
effect	B-MED
on	O
tumor	B-MED
growth	I-MED
.	O
SBE	B-MED
treatment	B-MED
inhibited	B-MED
the	O
proliferation	B-MED
of	O
HepG2	B-MED
cells	I-MED
in	B-MED
vitro	I-MED
with	O
a	O
dose	B-MED
-	I-MED
dependent	I-MED
manner	I-MED
and	O
significantly	O
suppressed	B-MED
the	O
tumor	B-MED
growth	I-MED
of	O
hepatoma	B-MED
H22	I-MED
-bearing	O
mice	B-MED
.	O
Meanwhile	O
,	O
it	O
increased	B-MED
NK	B-MED
cells	I-MED
'	I-MED
cytotoxicity	I-MED
in	O
spleen	B-MED
,	O
down	B-MED
-	I-MED
regulated	I-MED
the	O
amount	B-MED
of	O
CD4(+)CD25(+)Foxp3(+	B-MED
)	I-MED
Treg	I-MED
cells	I-MED
and	O
Th17	B-MED
cells	I-MED
in	O
tumor	B-MED
tissue	I-MED
,	O
and	O
decreased	B-MED
IL-10	B-MED
,	O
TGF	B-MED
-	I-MED
β	I-MED
,	O
and	O
IL-17A	B-MED
levels	B-MED
(	O
P	O
<	O
0.01	O
)	O
whereas	O
increased	B-MED
IL-2	B-MED
and	O
IFN	B-MED
-	I-MED
γ	I-MED
levels	B-MED
(	O
P	O
<	O
0.01	O
)	O
in	O
the	O
serum	B-MED
of	O
hepatoma	B-MED
H22	I-MED
-bearing	O
mice	B-MED
.	O
Moreover	O
,	O
administration	B-MED
of	O
recombinant	B-MED
mouse	I-MED
IL-17A	B-MED
reversed	B-MED
the	O
anti	B-MED
-	I-MED
tumor	I-MED
effects	B-MED
of	O
SBE	B-MED
.	O
SBE	B-MED
could	O
inhibit	B-MED
the	O
proliferation	B-MED
of	O
HepG2	B-MED
cells	I-MED
in	B-MED
vitro	I-MED
.	O
Meanwhile	O
,	O
SBE	B-MED
also	O
could	O
inhibit	B-MED
the	O
growth	B-MED
of	O
H22	B-MED
implanted	B-MED
tumor	I-MED
in	O
hepatoma	B-MED
H22	I-MED
-bearing	O
mice	B-MED
,	O
and	O
this	O
function	B-MED
might	O
be	O
associated	B-MED
with	I-MED
immunomodulatory	B-MED
activity	I-MED
through	O
down	B-MED
-	I-MED
regulating	I-MED
of	O
Treg	B-MED
cells	I-MED
and	O
manipulating	B-MED
Th1	B-MED
/	O
Th17	B-MED
immune	I-MED
response	I-MED
.	O
Assessing	O
the	O
benefits	B-MED
of	O
targeted	B-MED
drug	B-MED
delivery	I-MED
by	O
nanocarriers	B-MED
:	O
A	O
partico	B-MED
/	I-MED
pharmacokinetic	I-MED
framework	I-MED
An	O
in	B-MED
vivo	I-MED
kinetic	B-MED
framework	I-MED
is	O
introduced	O
to	O
analyze	B-MED
and	O
predict	O
the	O
quantitative	B-MED
advantage	O
of	O
using	O
nanocarriers	B-MED
to	O
deliver	B-MED
drugs	I-MED
,	O
especially	O
anticancer	B-MED
agents	I-MED
,	O
compared	B-MED
to	O
administering	B-MED
the	O
same	O
drugs	B-MED
in	O
their	O
free	O
form	O
.	O
This	O
framework	B-MED
recognizes	O
three	O
levels	B-MED
of	O
kinetics	B-MED
.	O
First	O
is	O
the	O
particokinetics	B-MED
associated	B-MED
with	I-MED
deposition	B-MED
of	O
nanocarriers	B-MED
into	O
tissues	B-MED
associated	B-MED
with	I-MED
drug	B-MED
effect	I-MED
and	O
toxicity	B-MED
,	O
their	O
residence	B-MED
inside	O
those	O
tissues	B-MED
,	O
and	O
elimination	B-MED
of	O
the	O
nanocarriers	B-MED
from	O
the	O
body	B-MED
.	O
Second	O
is	O
the	O
release	B-MED
pattern	I-MED
in	O
time	O
of	O
free	B-MED
drug	I-MED
from	O
the	O
nanocarriers	B-MED
.	O
Third	O
is	O
the	O
pharmacokinetics	B-MED
of	O
free	B-MED
drug	I-MED
,	O
as	O
it	O
relates	O
to	O
deposition	B-MED
and	O
elimination	B-MED
processes	I-MED
in	O
the	O
target	B-MED
and	O
toxicity	B-MED
associated	B-MED
tissues	B-MED
,	O
and	O
total	B-MED
body	I-MED
clearance	I-MED
.	O
A	O
figure	O
of	O
merit	O
,	O
the	O
drug	B-MED
targeting	I-MED
index	I-MED
(	O
DTI	B-MED
)	O
,	O
is	O
used	O
to	O
quantitate	B-MED
the	O
benefit	O
of	O
nanocarrier	B-MED
based	O
drug	B-MED
delivery	I-MED
by	O
considering	O
the	O
effects	B-MED
of	O
preferential	O
deposition	B-MED
of	O
nanoparticles	B-MED
into	O
target	B-MED
tissues	B-MED
and	O
relative	O
avoidance	O
of	O
tissues	B-MED
associated	B-MED
with	I-MED
drug	B-MED
toxicity	I-MED
,	O
compared	B-MED
to	O
drug	B-MED
that	O
is	O
administered	B-MED
in	O
its	O
free	O
form	O
.	O
General	O
methods	B-MED
are	O
derived	O
for	O
calculating	B-MED
DTI	B-MED
when	O
appropriate	O
particokinetic	B-MED
,	O
pharmacokinetic	B-MED
,	O
and	O
drug	B-MED
release	I-MED
rate	I-MED
information	O
is	O
available	O
,	O
and	O
it	O
is	O
shown	O
that	O
relatively	O
simple	O
algebraic	O
forms	O
result	B-MED
when	O
some	O
common	O
assumptions	O
are	O
made	O
.	O
This	O
approach	O
may	O
find	O
use	O
in	O
developing	B-MED
and	O
selecting	O
nanocarrier	B-MED
formulations	B-MED
,	O
either	O
for	O
populations	B-MED
or	O
for	O
individuals	B-MED
.	O
Aquaporin-2	B-MED
excretion	B-MED
in	O
hospitalized	B-MED
patients	I-MED
with	O
cirrhosis	B-MED
:	O
Relation	O
to	O
development	B-MED
of	O
renal	B-MED
insufficiency	I-MED
and	O
mortality	B-MED
Urinary	B-MED
aquaporin-2	B-MED
(	O
AQP2	B-MED
)	O
is	O
a	O
parameter	O
of	O
water	B-MED
transport	I-MED
in	O
the	O
principal	B-MED
cells	I-MED
in	O
the	O
distal	B-MED
part	I-MED
of	O
the	O
nephron	B-MED
and	O
involved	O
in	O
water	B-MED
retention	I-MED
in	O
cirrhosis	B-MED
and	O
may	O
be	O
a	O
marker	B-MED
of	O
renal	B-MED
function	I-MED
.	O
The	O
aim	B-MED
of	O
the	O
study	B-MED
was	O
to	O
evaluate	O
AQP2	B-MED
as	O
a	O
predictor	B-MED
of	O
renal	B-MED
insufficiency	I-MED
and	O
death	B-MED
in	O
patients	B-MED
with	O
cirrhosis	B-MED
.	O
Urine	B-MED
samples	I-MED
from	O
199	O
patients	B-MED
(	O
90	O
patients	B-MED
without	O
organ	B-MED
failure	I-MED
[	O
Group	B-MED
1	I-MED
]	O
,	O
58	O
patients	B-MED
with	O
organ	B-MED
failure	I-MED
excluding	O
renal	B-MED
failure	I-MED
[	O
Group	B-MED
2	I-MED
]	O
,	O
and	O
51	O
patients	B-MED
with	O
organ	B-MED
failure	I-MED
including	O
renal	B-MED
failure	I-MED
[	O
Group	B-MED
3	I-MED
]	O
)	O
from	O
the	O
CANONIC	B-MED
study	I-MED
were	O
analyzed	O
for	O
urine	B-MED
AQP2	B-MED
and	O
urine	B-MED
osmolality	I-MED
.	O
There	O
was	O
no	B-MED
difference	I-MED
in	O
AQP2	B-MED
between	O
the	O
three	O
groups	B-MED
.	O
Urine	B-MED
osmolality	I-MED
was	O
significantly	B-MED
lower	I-MED
in	O
patients	B-MED
in	O
Group	B-MED
3	I-MED
versus	O
Group	B-MED
1	I-MED
and	O
Group	B-MED
2	I-MED
(	O
P	O
=	O
0.0004	O
)	O
.	O
No	B-MED
relation	I-MED
was	O
found	O
between	O
AQP2	B-MED
and	O
glomerular	B-MED
filtration	I-MED
rate	I-MED
or	O
creatinine	B-MED
;	O
however	O
,	O
AQP2	B-MED
was	O
a	O
significant	O
predictor	B-MED
of	O
the	O
development	B-MED
of	O
renal	B-MED
insufficiency	I-MED
(	O
P	O
=	O
0.0485	O
)	O
.	O
In	O
a	O
univariate	B-MED
analysis	I-MED
,	O
AQP2	B-MED
was	O
a	O
significant	O
predictor	B-MED
of	O
14	O
and	O
28	O
-	O
day	O
survival	B-MED
,	O
but	O
this	O
was	O
not	O
confirmed	O
in	O
multivariate	B-MED
analysis	I-MED
.	O
Aquaporin-2	B-MED
was	O
not	O
associated	O
with	O
disease	B-MED
severity	I-MED
or	O
markers	B-MED
of	O
renal	B-MED
function	I-MED
but	O
was	O
a	O
predictor	B-MED
for	O
the	O
development	B-MED
of	O
renal	B-MED
insufficiency	I-MED
and	O
death	B-MED
.	O
Therefore	O
,	O
its	O
future	O
use	O
as	O
marker	B-MED
of	O
renal	B-MED
insufficiency	I-MED
could	O
be	O
promising	O
,	O
but	O
further	O
research	B-MED
is	O
needed	O
before	O
it	O
can	O
be	O
considered	O
a	O
clinical	B-MED
useful	O
tool	O
.	O
The	O
Complete	B-MED
Chloroplast	B-MED
Genome	I-MED
Sequence	B-MED
of	O
the	O
Medicinal	B-MED
Plant	I-MED
Swertia	B-MED
mussotii	I-MED
Using	O
the	O
PacBio	B-MED
RS	I-MED
II	I-MED
Platform	I-MED
Swertia	B-MED
mussotii	I-MED
is	O
an	O
important	O
medicinal	B-MED
plant	I-MED
that	O
has	O
great	B-MED
economic	B-MED
and	O
medicinal	B-MED
value	I-MED
and	O
is	O
found	O
on	O
the	O
Qinghai	B-MED
Tibetan	I-MED
Plateau	I-MED
.	O
The	O
complete	B-MED
chloroplast	B-MED
(	I-MED
cp	I-MED
)	I-MED
genome	I-MED
of	O
S.	B-MED
mussotii	I-MED
is	O
153,431	O
bp	O
in	O
size	B-MED
,	O
with	O
a	O
pair	B-MED
of	O
inverted	B-MED
repeat	I-MED
(	I-MED
IR	I-MED
)	I-MED
regions	I-MED
of	O
25,761	O
bp	O
each	O
that	O
separate	B-MED
an	O
large	B-MED
single	I-MED
-	I-MED
copy	I-MED
(	I-MED
LSC	I-MED
)	I-MED
region	I-MED
of	O
83,567	O
bp	O
and	O
an	O
a	O
small	B-MED
single	I-MED
-	I-MED
copy	I-MED
(	I-MED
SSC	I-MED
)	I-MED
region	I-MED
of	O
18,342	O
bp	O
.	O
The	O
S.	B-MED
mussotii	I-MED
cp	B-MED
genome	I-MED
encodes	B-MED
84	O
protein	B-MED
-	I-MED
coding	I-MED
genes	I-MED
,	O
37	O
transfer	B-MED
RNA	I-MED
(	O
tRNA	B-MED
)	O
genes	B-MED
,	O
and	O
eight	O
ribosomal	B-MED
RNA	I-MED
(	I-MED
rRNA	I-MED
)	I-MED
genes	I-MED
.	O
The	O
identity	O
,	O
number	O
,	O
and	O
GC	B-MED
content	I-MED
of	O
S.	B-MED
mussotii	I-MED
cp	B-MED
genes	I-MED
were	O
similar	O
to	O
those	O
in	O
the	O
genomes	B-MED
of	O
other	O
Gentianales	B-MED
species	B-MED
.	O
Via	O
analysis	B-MED
of	O
the	O
repeat	B-MED
structure	I-MED
,	O
11	O
forward	O
repeats	B-MED
,	O
eight	O
palindromic	B-MED
repeats	I-MED
,	O
and	O
one	O
reverse	O
repeat	O
were	O
detected	B-MED
in	O
the	O
S.	B-MED
mussotii	I-MED
cp	B-MED
genome	I-MED
.	O
There	O
are	O
45	O
SSRs	B-MED
in	O
the	O
S.	B-MED
mussotii	I-MED
cp	B-MED
genome	I-MED
,	O
the	O
majority	B-MED
of	O
which	O
are	O
mononucleotides	B-MED
found	O
in	O
all	O
other	O
Gentianales	B-MED
species	B-MED
.	O
An	O
entire	B-MED
cp	B-MED
genome	I-MED
comparison	B-MED
study	I-MED
of	O
S.	B-MED
mussotii	I-MED
and	O
two	O
other	O
species	B-MED
in	O
Gentianaceae	B-MED
was	O
conducted	O
.	O
The	O
complete	B-MED
cp	B-MED
genome	I-MED
sequence	B-MED
provides	O
intragenic	B-MED
information	B-MED
for	O
the	O
cp	B-MED
genetic	B-MED
engineering	I-MED
of	O
this	O
medicinal	B-MED
plant	I-MED
.	O
Design	B-MED
and	O
characteristics	B-MED
of	O
cytotoxic	B-MED
fibroblast	B-MED
growth	I-MED
factor	I-MED
1	I-MED
conjugate	B-MED
for	O
fibroblast	B-MED
growth	I-MED
factor	I-MED
receptor	I-MED
-	O
targeted	B-MED
cancer	I-MED
therapy	I-MED
Fibroblast	B-MED
growth	I-MED
factor	I-MED
receptors	I-MED
(	O
FGFRs	B-MED
)	O
are	O
attractive	O
candidate	O
cancer	B-MED
therapy	I-MED
targets	B-MED
as	O
they	O
are	O
overexpressed	B-MED
in	O
multiple	B-MED
types	O
of	O
tumors	B-MED
,	O
such	O
as	O
breast	B-MED
,	O
prostate	B-MED
,	O
bladder	B-MED
,	O
and	O
lung	B-MED
cancer	I-MED
.	O
In	O
this	O
study	O
,	O
a	O
natural	B-MED
ligand	I-MED
of	O
FGFR	B-MED
,	O
an	O
engineered	B-MED
variant	I-MED
of	O
fibroblast	B-MED
growth	I-MED
factor	I-MED
1	I-MED
(	O
FGF1V	B-MED
)	O
,	O
was	O
conjugated	B-MED
to	O
a	O
potent	B-MED
cytotoxic	I-MED
drug	I-MED
,	O
monomethyl	B-MED
auristatin	I-MED
E	I-MED
(	O
MMAE	B-MED
)	O
,	O
and	O
used	O
as	O
a	O
targeting	B-MED
agent	I-MED
for	O
cancer	B-MED
cells	I-MED
overexpressing	B-MED
FGFRs	B-MED
,	O
similar	O
to	O
antibodies	B-MED
in	O
antibody	B-MED
-	I-MED
drug	I-MED
conjugates	I-MED
.	O
The	O
FGF1V	B-MED
-	I-MED
valine	I-MED
-	I-MED
citrulline	I-MED
-	I-MED
MMAE	I-MED
conjugate	I-MED
showed	O
a	O
favorable	O
stability	B-MED
profile	I-MED
,	O
bound	B-MED
FGFRs	B-MED
on	O
the	O
cell	B-MED
surface	I-MED
specifically	B-MED
,	O
and	O
efficiently	B-MED
released	B-MED
the	O
drug	B-MED
(	I-MED
MMAE	I-MED
)	I-MED
upon	O
cleavage	B-MED
by	O
the	O
lysosomal	B-MED
protease	I-MED
cathepsin	I-MED
B	I-MED
B.	O
Importantly	O
,	O
the	O
conjugate	B-MED
showed	O
a	O
prominent	B-MED
cytotoxic	B-MED
effect	I-MED
toward	O
cell	B-MED
lines	I-MED
expressing	B-MED
FGFR	B-MED
.	O
FGF1V	B-MED
-	I-MED
vcMMAE	I-MED
was	O
highly	O
cytotoxic	B-MED
at	O
concentrations	B-MED
even	O
an	O
order	O
of	O
magnitude	O
lower	B-MED
than	O
those	O
found	O
for	O
free	O
MMAE	B-MED
.	O
This	O
effect	O
was	O
FGFR	B-MED
-specific	O
as	O
cells	B-MED
lacking	B-MED
FGFR	B-MED
did	B-MED
not	I-MED
show	I-MED
any	O
increased	B-MED
mortality	B-MED
.	O
The	O
influence	B-MED
of	O
cognitive	B-MED
load	I-MED
on	O
metabolic	B-MED
cost	B-MED
of	O
transport	B-MED
during	O
overground	B-MED
walking	I-MED
in	O
healthy	B-MED
,	O
young	B-MED
adults	I-MED
Our	O
aim	O
was	O
to	O
examine	O
whether	O
cognitive	B-MED
processing	I-MED
during	O
walking	B-MED
increases	B-MED
the	O
metabolic	B-MED
cost	B-MED
of	O
transport	B-MED
in	O
healthy	B-MED
young	B-MED
adults	I-MED
.	O
Twenty	O
healthy	B-MED
,	O
young	B-MED
adults	I-MED
completed	O
five	O
conditions	B-MED
:	O
(	O
1	O
)	O
walking	B-MED
at	O
a	O
self	B-MED
-	O
selected	B-MED
speed	B-MED
(	O
spontaneous	B-MED
single	B-MED
-	I-MED
task	I-MED
)	O
,	O
(	O
2	O
)	O
seated	B-MED
resting	B-MED
(	O
baseline	B-MED
)	O
,	O
(	O
3	O
)	O
performing	O
cognitive	B-MED
task	B-MED
while	O
seated	B-MED
(	O
cognitive	B-MED
single	B-MED
-	I-MED
task	I-MED
)	O
,	O
(	O
4	O
)	O
walking	B-MED
while	O
simultaneously	B-MED
performing	B-MED
the	O
cognitive	B-MED
task	B-MED
(	O
dual	B-MED
-	I-MED
task	I-MED
)	O
,	O
and	O
(	O
5	O
)	O
single	B-MED
-	I-MED
task	I-MED
walking	B-MED
at	O
a	O
speed	B-MED
that	O
matched	B-MED
the	O
participant	B-MED
's	I-MED
dual	B-MED
-	I-MED
task	I-MED
gait	B-MED
speed	I-MED
(	O
matched	B-MED
single	B-MED
-	I-MED
task	I-MED
)	O
.	O
Rate	B-MED
of	I-MED
oxygen	I-MED
consumption	I-MED
(	O
V̇O2	B-MED
)	O
was	O
recorded	O
during	O
all	O
conditions	B-MED
.	O
Gait	B-MED
speed	I-MED
and	O
cost	B-MED
of	O
walking	B-MED
(	O
Cw	B-MED
;	O
oxygen	B-MED
consumed	I-MED
per	I-MED
distance	I-MED
traveled	I-MED
)	O
were	O
recorded	O
during	O
all	O
walking	B-MED
conditions	B-MED
.	O
Reaction	B-MED
time	I-MED
and	O
accuracy	B-MED
of	O
responses	B-MED
in	O
the	O
cognitive	B-MED
task	B-MED
were	O
recorded	O
during	O
all	O
cognitive	B-MED
task	B-MED
conditions	B-MED
.	O
Data	B-MED
from	O
the	O
fifth	O
minute	B-MED
of	O
each	O
5-	O
min	B-MED
condition	B-MED
were	O
analyzed	B-MED
.	O
There	O
was	O
no	O
difference	O
in	O
V̇O2	B-MED
between	O
the	O
dual	B-MED
-	I-MED
task	I-MED
and	O
matched	B-MED
single	B-MED
-	I-MED
task	I-MED
walking	B-MED
conditions	B-MED
.	O
V̇O2	B-MED
in	O
the	O
seated	B-MED
cognitive	B-MED
condition	B-MED
was	O
significantly	O
smaller	O
than	O
both	O
walking	B-MED
conditions	B-MED
,	O
but	O
was	O
not	O
significantly	O
different	O
than	O
zero	O
.	O
Cw	B-MED
was	O
significantly	O
greater	O
during	O
the	O
matched	B-MED
single	B-MED
-	I-MED
task	I-MED
walking	B-MED
condition	B-MED
than	O
during	O
the	O
dual	B-MED
-	I-MED
task	I-MED
walking	B-MED
condition	B-MED
.	O
However	O
,	O
the	O
difference	O
in	O
Cw	B-MED
was	O
so	O
small	O
that	O
it	O
is	O
unlikely	O
to	O
be	O
clinically	B-MED
significant	B-MED
(	O
0.008	O
mLO2	O
/	O
kg	O
/	O
m	O
,	O
95	O
%	O
CI	O
0.002	O
-	O
0.014	O
)	O
.	O
Cognitive	B-MED
processing	I-MED
while	O
walking	B-MED
may	O
not	O
increase	B-MED
energy	B-MED
demands	O
of	O
walking	B-MED
in	O
healthy	B-MED
young	B-MED
adults	I-MED
.	O
Maintaining	O
non	O
-	O
preferred	O
gait	B-MED
speed	I-MED
(	O
matched	B-MED
speed	B-MED
)	O
overground	O
continuously	O
for	O
5	O
min	B-MED
may	O
require	O
attentional	B-MED
resources	B-MED
,	O
and	O
thereby	O
increase	B-MED
metabolic	B-MED
costs	B-MED
relative	O
to	O
walking	B-MED
at	O
habitual	B-MED
speed	B-MED
.	O
Biomimetic	B-MED
whitlockite	B-MED
inorganic	B-MED
nanoparticles	B-MED
-mediated	O
in	B-MED
situ	I-MED
remodeling	B-MED
and	O
rapid	O
bone	B-MED
regeneration	I-MED
Bone	B-MED
remodeling	I-MED
process	O
relies	O
on	O
complex	B-MED
signaling	B-MED
pathway	I-MED
between	O
osteoblasts	B-MED
and	O
osteoclasts	B-MED
and	O
control	O
mechanisms	B-MED
to	O
achieve	O
homeostasis	B-MED
of	O
their	O
growth	B-MED
and	O
differentiation	B-MED
.	O
Despite	O
previous	O
achievements	O
in	O
understanding	O
complicated	O
signaling	B-MED
pathways	I-MED
between	O
cells	B-MED
and	O
bone	B-MED
extracellular	B-MED
matrices	I-MED
during	O
bone	B-MED
remodeling	I-MED
process	O
,	O
a	O
role	O
of	O
local	O
ionic	B-MED
concentration	B-MED
remains	O
to	O
be	O
elucidated	B-MED
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
synthetic	B-MED
whitlockite	B-MED
(	O
WH	B-MED
:	I-MED
Ca18Mg2(HPO4)2(PO4)12	I-MED
)	I-MED
nanoparticles	B-MED
can	O
recapitulate	B-MED
early	O
-	O
stage	O
of	O
bone	B-MED
regeneration	I-MED
through	O
stimulating	B-MED
osteogenic	B-MED
differentiation	I-MED
,	O
prohibiting	B-MED
osteoclastic	B-MED
activity	B-MED
,	O
and	O
transforming	B-MED
into	O
mechanically	O
enhanced	O
hydroxyapatite	B-MED
HAP	B-MED
(	O
HAP)-	O
neo	B-MED
bone	I-MED
tissues	I-MED
by	O
continuous	O
supply	O
of	O
PO4(3-	B-MED
)	I-MED
and	O
Mg(2	B-MED
+	I-MED
)	I-MED
under	O
physiological	B-MED
conditions	B-MED
.	O
In	O
addition	O
,	O
based	O
on	O
their	O
structural	B-MED
analysis	I-MED
,	O
the	O
dynamic	O
phase	B-MED
transformation	B-MED
from	O
WH	B-MED
into	O
HAP	B-MED
contributed	O
as	O
a	O
key	O
factor	B-MED
for	O
rapid	O
bone	B-MED
regeneration	I-MED
with	O
denser	B-MED
hierarchical	B-MED
neo	B-MED
-	I-MED
bone	I-MED
structure	B-MED
.	O
Our	O
findings	B-MED
suggest	O
a	O
groundbreaking	O
concept	O
of	O
'	O
living	B-MED
bone	B-MED
minerals	B-MED
'	O
that	O
actively	B-MED
communicate	B-MED
with	O
the	O
surrounding	O
system	O
to	O
induce	B-MED
self	B-MED
-	I-MED
healing	I-MED
,	O
while	O
previous	O
notions	O
about	O
bone	B-MED
minerals	B-MED
have	O
been	O
limited	O
to	O
passive	B-MED
products	O
of	O
cellular	B-MED
mineralization	B-MED
.	O
Novel	O
biomarkers	B-MED
for	O
patients	B-MED
with	O
idiopathic	B-MED
acute	B-MED
anterior	I-MED
uveitis	I-MED
:	O
neutrophil	B-MED
to	O
lymphocyte	B-MED
ratio	B-MED
and	O
platelet	B-MED
to	O
lymphocyte	B-MED
ratio	B-MED
To	O
assess	B-MED
the	O
levels	B-MED
of	O
the	O
neutrophil	B-MED
to	O
lymphocyte	B-MED
ratio	B-MED
(	O
N	B-MED
/	O
L	B-MED
)	O
and	O
the	O
platelet	B-MED
to	O
lymphocyte	B-MED
ratio	B-MED
(	O
P	B-MED
/	O
L	B-MED
)	O
in	O
patients	B-MED
with	O
idiopathic	B-MED
acute	B-MED
anterior	I-MED
uveitis	I-MED
(	O
AAU	B-MED
)	O
and	O
to	O
compare	B-MED
with	O
healthy	B-MED
controls	I-MED
.	O
Thirty	O
-	O
six	O
male	B-MED
patients	B-MED
with	O
idiopathic	B-MED
AAU	B-MED
and	O
36	O
male	B-MED
healthy	B-MED
subjects	B-MED
were	O
enrolled	O
in	O
this	O
retrospective	B-MED
study	I-MED
.	O
Complete	B-MED
ophthalmological	B-MED
examination	I-MED
and	O
complete	O
blood	B-MED
count	I-MED
measurements	I-MED
results	B-MED
of	O
all	O
subjects	B-MED
were	O
evaluated	B-MED
.	O
There	O
was	O
a	O
significant	B-MED
difference	O
in	O
N	B-MED
/	O
L	B-MED
and	O
P	B-MED
/	O
L	B-MED
between	O
idiopathic	B-MED
AAU	B-MED
and	O
control	B-MED
groups	I-MED
(	O
P=0.006	O
,	O
P=0.022	O
)	O
.	O
Also	O
,	O
correlation	B-MED
analysis	I-MED
revealed	O
a	O
significant	B-MED
correlation	B-MED
between	O
C	B-MED
-	I-MED
reactive	I-MED
protein	I-MED
(	O
CRP	B-MED
)	O
and	O
N	B-MED
/	O
L	B-MED
(	O
P=0.002	O
;	O
r=0.461	O
)	O
.	O
Our	O
study	B-MED
for	O
the	O
first	O
time	O
provides	O
evidence	B-MED
of	I-MED
N	B-MED
/	O
L	B-MED
and	O
P	B-MED
/	O
L	B-MED
may	O
be	O
useful	B-MED
biomarkers	B-MED
in	O
patients	B-MED
with	O
idiopathic	B-MED
AAU	B-MED
.	O
N	B-MED
/	O
L	B-MED
is	O
correlated	B-MED
with	O
CRP	B-MED
,	O
so	O
it	O
can	O
be	O
a	O
useful	B-MED
biomarker	B-MED
to	O
predict	O
the	O
prognosis	B-MED
in	O
idiopathic	B-MED
AAU	B-MED
.	O
Structured	B-MED
Instruction	B-MED
With	O
Modified	B-MED
Storybooks	B-MED
to	O
Teach	B-MED
Morphosyntax	B-MED
and	O
Vocabulary	B-MED
to	O
Preschoolers	B-MED
Who	O
are	O
Deaf	B-MED
/	O
Hard	B-MED
of	I-MED
Hearing	I-MED
Children	B-MED
who	O
are	O
deaf	B-MED
/	O
hard	B-MED
of	I-MED
hearing	I-MED
(	O
D	B-MED
/	O
HH	B-MED
)	O
are	O
at	B-MED
risk	I-MED
for	O
diminished	B-MED
morphosyntactical	B-MED
and	O
vocabulary	B-MED
development	B-MED
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	B-MED
of	I-MED
repeated	B-MED
reading	B-MED
combined	B-MED
with	O
structured	B-MED
instruction	B-MED
.	O
Targets	B-MED
were	O
a	O
morphosyntactical	B-MED
form	I-MED
and	O
novel	O
vocabulary	B-MED
words	I-MED
.	O
Participants	B-MED
were	O
3	O
preschoolers	B-MED
who	O
are	O
D	B-MED
/	O
HH	B-MED
who	O
were	O
receiving	B-MED
instruction	B-MED
with	O
an	O
oral	B-MED
approach	O
.	O
Data	B-MED
from	O
a	O
multiple	B-MED
baseline	B-MED
design	I-MED
indicated	O
that	O
all	O
children	B-MED
acquired	B-MED
the	O
targeted	B-MED
skills	B-MED
and	O
demonstrated	O
high	O
levels	O
of	O
generalization	B-MED
of	O
these	O
skills	B-MED
to	O
untrained	B-MED
context	B-MED
.	O
Implications	B-MED
for	O
teaching	B-MED
young	B-MED
children	B-MED
who	O
are	O
D	B-MED
/	O
HH	B-MED
using	B-MED
repeated	B-MED
storybook	B-MED
reading	B-MED
are	O
discussed	O
.	O
Altered	O
expression	B-MED
of	O
the	O
Olr59	B-MED
,	O
Ethe1	B-MED
,	O
and	O
Slc10a2	B-MED
genes	I-MED
in	O
the	O
liver	B-MED
of	O
F344	B-MED
rats	I-MED
by	O
neonatal	B-MED
thyroid	B-MED
hormone	I-MED
disruption	I-MED
Many	O
concerns	O
have	O
been	O
expressed	O
regarding	O
the	O
possible	O
adverse	O
effects	O
of	O
thyroid	B-MED
hormone	I-MED
-	I-MED
disrupting	I-MED
chemicals	B-MED
in	O
the	O
environment	B-MED
.	O
The	O
disruption	B-MED
of	I-MED
thyroid	I-MED
hormones	I-MED
in	O
the	O
neonatal	B-MED
period	I-MED
may	O
lead	O
to	O
permanent	B-MED
effects	I-MED
on	O
thyroid	B-MED
hormone	I-MED
homeostasis	B-MED
as	O
well	O
as	O
related	O
developmental	B-MED
disorders	I-MED
,	O
as	O
thyroid	B-MED
hormones	I-MED
are	O
essential	O
for	O
regulating	B-MED
the	I-MED
growth	I-MED
and	O
differentiation	B-MED
of	I-MED
many	I-MED
tissues	I-MED
.	O
To	O
understand	O
the	O
long	O
-	O
term	O
alteration	O
in	O
gene	B-MED
expressions	I-MED
by	O
neonatal	B-MED
administration	B-MED
of	I-MED
thyroid	I-MED
hormone	I-MED
-like	O
chemicals	O
in	O
general	O
,	O
we	O
identified	O
genes	B-MED
whose	I-MED
expression	I-MED
was	O
altered	B-MED
in	O
the	O
liver	B-MED
,	O
an	O
important	O
component	O
of	O
the	O
thyroid	B-MED
hormone	I-MED
axis	O
,	O
by	O
neonatal	B-MED
exposure	B-MED
to	I-MED
triiodothyronine	B-MED
(	O
T3	B-MED
)	O
.	O
T3	B-MED
was	O
administered	B-MED
to	O
male	B-MED
F344	I-MED
rats	I-MED
on	O
postnatal	B-MED
days	I-MED
1	O
,	O
3	O
,	O
and	O
5	O
(	O
week	O
0	O
)	O
.	O
At	O
8	O
weeks	O
of	O
age	O
,	O
cDNA	B-MED
microarray	I-MED
analysis	I-MED
was	O
used	O
to	O
identify	O
hepatic	B-MED
genes	B-MED
whose	O
expression	B-MED
was	O
altered	O
by	O
neonatal	B-MED
exposure	B-MED
to	I-MED
T3	B-MED
.	O
Among	O
the	O
up	B-MED
-	I-MED
regulated	I-MED
genes	I-MED
that	O
were	O
identified	O
,	O
the	O
expression	B-MED
of	O
Olr59	B-MED
,	O
Ethe1	B-MED
,	O
and	O
Slc10a2	B-MED
increased	O
specifically	O
in	O
rats	B-MED
neonatally	B-MED
exposed	B-MED
to	I-MED
T3	B-MED
.	O
Interestingly	O
,	O
altered	O
hepatic	B-MED
expression	B-MED
of	I-MED
these	I-MED
genes	I-MED
indeed	O
increased	O
when	O
a	O
hydroxylated	B-MED
polybrominated	I-MED
diphenyl	I-MED
ether	I-MED
(	O
PBDE	B-MED
)	O
,	O
OH	B-MED
-	I-MED
BDE42	I-MED
,	O
which	O
is	O
capable	O
of	O
binding	B-MED
to	I-MED
the	I-MED
TR	I-MED
,	O
was	O
given	O
neonatally	B-MED
.	O
Our	O
data	O
demonstrated	O
that	O
neonatal	B-MED
exposure	O
to	O
thyroid	B-MED
hormones	I-MED
could	O
affect	O
the	O
long	O
-	O
term	O
expression	B-MED
of	I-MED
the	I-MED
genes	I-MED
,	O
which	O
could	O
be	O
useful	O
markers	O
for	O
neonatal	B-MED
effects	I-MED
by	O
thyroid	B-MED
hormone	I-MED
-	O
disrupting	B-MED
chemicals	I-MED
.	O
Copyright	O
©	O
2017	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
Historical	B-MED
relationships	I-MED
of	O
three	O
enigmatic	B-MED
phasianid	B-MED
genera	I-MED
(	O
Aves	B-MED
:	O
Galliformes	B-MED
)	O
inferred	O
using	O
phylogenomic	B-MED
and	I-MED
mitogenomic	I-MED
data	I-MED
The	O
phylogeny	B-MED
of	O
the	O
Phasianidae	B-MED
(	O
pheasants	B-MED
,	O
partridges	B-MED
,	O
and	O
allies	B-MED
)	O
has	O
been	O
studied	O
extensively	O
.	O
However	O
,	O
these	O
studies	O
have	O
largely	O
ignored	O
three	O
enigmatic	B-MED
genera	I-MED
because	O
of	O
scarce	B-MED
DNA	B-MED
source	B-MED
material	I-MED
and	O
limited	O
overlapping	O
phylogenetic	B-MED
data	I-MED
:	O
blood	B-MED
pheasants	I-MED
(	O
Ithaginis	B-MED
)	O
,	O
snow	B-MED
partridges	I-MED
(	O
Lerwa	B-MED
)	O
,	O
and	O
long	B-MED
-	I-MED
billed	I-MED
partridges	I-MED
(	O
Rhizothera	B-MED
)	O
.	O
Thus	O
,	O
phylogenetic	B-MED
positions	I-MED
of	O
these	O
three	O
genera	O
remain	O
uncertain	O
in	O
what	O
is	O
otherwise	O
a	O
well	O
-	O
resolved	O
phylogeny	B-MED
.	O
Previous	O
studies	O
using	O
different	O
data	B-MED
types	O
place	O
Lerwa	B-MED
and	O
Ithaginis	B-MED
in	O
similar	O
positions	O
,	O
but	O
the	O
absence	O
of	O
overlapping	B-MED
data	I-MED
means	O
the	O
relationship	B-MED
between	O
them	O
could	O
not	O
be	O
inferred	O
.	O
Rhizothera	B-MED
was	O
originally	O
described	O
in	O
the	O
genus	O
Perdix	B-MED
(	O
true	B-MED
partridges	I-MED
)	O
,	O
although	O
a	O
partial	O
cytochrome	B-MED
b	I-MED
(	O
CYB	B-MED
)	O
sequence	O
suggests	O
it	O
is	O
sister	B-MED
to	O
Pucrasia	B-MED
(	O
koklass	B-MED
pheasant	I-MED
)	O
.	O
To	O
identify	O
robust	O
relationships	B-MED
among	O
Ithaginis	B-MED
,	O
Lerwa	B-MED
,	O
Rhizothera	B-MED
,	O
and	O
their	O
phasianid	B-MED
relatives	I-MED
,	O
we	O
used	O
3692	O
ultra	B-MED
-	I-MED
conserved	I-MED
element	I-MED
(	I-MED
UCE	I-MED
)	I-MED
loci	I-MED
and	O
complete	O
mitogenomes	B-MED
from	O
19	O
species	B-MED
including	O
previously	O
hypothesized	B-MED
relatives	B-MED
of	O
the	O
three	O
focal	O
genera	O
and	O
representatives	O
from	O
all	O
major	O
phasianid	B-MED
clades	I-MED
.	O
We	O
used	O
DNA	B-MED
extracted	I-MED
from	O
historical	O
specimen	B-MED
toepads	I-MED
for	O
species	O
that	O
lacked	B-MED
fresh	I-MED
tissue	I-MED
in	O
museum	B-MED
collections	I-MED
.	O
Maximum	O
likelihood	O
and	O
multispecies	B-MED
coalescent	I-MED
UCE	I-MED
analyses	I-MED
strongly	O
supported	O
Lerwa	B-MED
sister	B-MED
to	O
a	O
large	B-MED
clade	I-MED
which	O
included	O
Ithaginis	B-MED
at	O
its	O
base	O
,	O
and	O
also	O
including	O
turkey	B-MED
,	O
grouse	B-MED
,	O
typical	O
pheasants	B-MED
,	O
tragopans	B-MED
,	O
Pucrasia	B-MED
,	O
and	O
Perdix	B-MED
.	O
Rhizothera	B-MED
was	O
also	O
in	O
this	O
clade	B-MED
,	O
sister	B-MED
to	O
a	O
diverse	O
group	O
comprising	O
Perdix	B-MED
,	O
typical	O
pheasants	B-MED
,	O
Pucrasia	B-MED
,	O
turkey	B-MED
and	O
grouse	B-MED
.	O
Mitogenomic	B-MED
genealogies	I-MED
differed	O
from	O
UCEs	B-MED
topologies	I-MED
,	O
supporting	O
a	O
sister	B-MED
relationship	I-MED
between	O
Ithaginis	B-MED
and	O
Lerwa	B-MED
rather	O
than	O
a	O
grade	O
.	O
The	O
position	O
of	O
Rhizothera	B-MED
using	O
mitogenomes	B-MED
depended	O
on	O
analytical	B-MED
choices	I-MED
.	O
Unpartitioned	O
and	O
codon	B-MED
-	I-MED
based	I-MED
analyses	I-MED
placed	O
Rhizothera	B-MED
sister	B-MED
to	O
a	O
tragopan	B-MED
clade	I-MED
,	O
whereas	O
a	O
partitioned	O
DNA	B-MED
model	I-MED
of	O
the	O
mitogenome	B-MED
was	O
congruent	B-MED
with	O
UCE	B-MED
results	I-MED
.	O
In	O
all	O
mitogenome	B-MED
analyses	I-MED
,	O
Pucrasia	B-MED
was	O
sister	B-MED
to	O
a	O
clade	B-MED
including	O
Perdix	B-MED
and	O
the	O
typical	O
pheasants	B-MED
with	O
high	O
support	O
,	O
in	O
contrast	O
to	O
UCEs	O
and	O
published	B-MED
nuclear	I-MED
intron	I-MED
data	I-MED
.	O
Due	O
to	O
the	O
strong	O
support	O
and	O
consistent	O
topology	B-MED
provided	O
by	O
all	O
UCE	B-MED
analyses	I-MED
,	O
we	O
have	O
identified	O
phylogenetic	B-MED
relationships	B-MED
of	O
these	O
three	O
enigmatic	B-MED
,	O
poorly	O
-	O
studied	O
,	O
phasianid	B-MED
taxa	I-MED
.	O
Hif-1α	B-MED
Overexpression	B-MED
Improves	B-MED
Transplanted	B-MED
Bone	I-MED
Mesenchymal	I-MED
Stem	I-MED
Cells	I-MED
Survival	B-MED
in	O
Rat	B-MED
MCAO	I-MED
Stroke	I-MED
Model	I-MED
Bone	B-MED
mesenchymal	I-MED
stem	I-MED
cells	I-MED
(	O
BMSCs	B-MED
)	O
death	B-MED
after	O
transplantation	B-MED
is	O
a	O
serious	O
obstacle	O
impacting	O
on	O
the	O
outcome	O
of	O
cell	B-MED
therapy	I-MED
for	O
cerebral	B-MED
infarction	I-MED
.	O
This	O
study	B-MED
was	O
aimed	B-MED
to	O
investigate	B-MED
whether	O
modification	B-MED
of	O
BMSCs	B-MED
with	O
hypoxia	B-MED
-	I-MED
inducible	I-MED
factor	I-MED
1α	I-MED
(	O
Hif-1α	B-MED
)	O
could	O
enhance	B-MED
the	O
survival	B-MED
of	O
the	O
implanted	B-MED
BMSCs	I-MED
.	O
BMSCs	B-MED
were	O
isolated	B-MED
from	O
Wistar	B-MED
rats	I-MED
,	O
and	O
were	O
infected	B-MED
with	O
Hif-1α	B-MED
-	I-MED
GFP	I-MED
lentiviral	I-MED
vector	I-MED
or	O
Hif-1α	B-MED
siRNA	I-MED
.	O
The	O
modified	B-MED
BMSCs	B-MED
were	O
exposed	O
to	O
oxygen	B-MED
-	I-MED
glucose	I-MED
deprivation	I-MED
(	I-MED
OGD	I-MED
)	I-MED
condition	I-MED
,	O
cellular	B-MED
viability	I-MED
and	O
apoptosis	B-MED
were	O
then	O
assessed	B-MED
.	O
An	O
inhibitor	B-MED
of	O
AMPK	B-MED
(	O
compound	B-MED
C	I-MED
)	O
was	O
used	O
to	O
detect	B-MED
whether	O
AMPK	B-MED
and	O
mTOR	B-MED
were	O
implicated	O
in	O
the	O
functions	O
of	O
Hif-1α	B-MED
on	O
BMSCs	B-MED
survival	I-MED
.	O
Besides	O
,	O
ultrastructure	O
of	O
BMSCs	B-MED
was	O
observed	O
and	O
the	O
expression	B-MED
of	I-MED
autophagy	I-MED
markers	I-MED
was	O
measured	O
.	O
The	O
modified	B-MED
BMSCs	B-MED
were	O
transplanted	B-MED
into	O
middle	B-MED
cerebral	I-MED
artery	I-MED
occlusion	I-MED
(	O
MCAO	B-MED
)	O
model	B-MED
of	I-MED
rats	I-MED
,	O
and	O
the	O
cerebral	B-MED
infarction	I-MED
volume	B-MED
and	O
neurological	B-MED
function	I-MED
was	O
assessed	B-MED
.	O
The	O
results	O
indicated	O
that	O
Hif-1α	B-MED
overexpression	I-MED
protected	O
OGD	B-MED
induced	B-MED
injury	B-MED
by	O
promoting	O
cellular	B-MED
viability	I-MED
and	O
inhibiting	B-MED
apoptosis	B-MED
.	O
AMPK	B-MED
was	O
activated	O
while	O
mTOR	B-MED
was	O
inactivated	B-MED
by	O
Hif-1α	B-MED
overexpression	I-MED
,	O
and	O
that	O
might	O
be	O
through	O
which	O
Hif-1α	B-MED
functioned	O
BMSCs	B-MED
survival	I-MED
.	O
Hif-1α	B-MED
overexpression	I-MED
promoted	O
autophagy	B-MED
;	O
more	O
important	O
,	O
compound	B-MED
C	I-MED
abolished	O
the	O
induction	B-MED
of	I-MED
Hif-1α	I-MED
on	O
autophagy	B-MED
.	O
Transplantation	B-MED
of	I-MED
the	I-MED
overexpressed	I-MED
Hif-1α	I-MED
of	I-MED
BMSCs	I-MED
into	O
the	O
MCAO	B-MED
rats	I-MED
reduced	O
brain	B-MED
infarct	I-MED
volume	B-MED
and	O
improved	B-MED
neurobehavioral	B-MED
outcome	I-MED
;	O
besides	O
,	O
it	O
inhibited	O
pro	B-MED
-	I-MED
inflammatory	I-MED
cytokines	I-MED
generation	O
while	O
promoted	O
neurotrophin	B-MED
secretion	B-MED
.	O
In	O
conclusion	O
,	O
Hif-1α	B-MED
might	O
be	O
contributed	O
in	O
the	O
survival	B-MED
of	I-MED
BMSCs	I-MED
by	O
regulating	O
the	O
activation	B-MED
of	I-MED
AMPK	I-MED
and	I-MED
mTOR	I-MED
,	O
as	O
well	O
as	O
by	O
promoting	O
autophagy	B-MED
.	O
The	O
antineoplastic	B-MED
drug	I-MED
,	O
trastuzumab	B-MED
,	O
dysregulates	B-MED
metabolism	B-MED
in	O
iPSC	B-MED
-derived	O
cardiomyocytes	B-MED
The	O
targeted	B-MED
ERBB2	I-MED
therapy	I-MED
,	O
trastuzumab	B-MED
,	O
has	O
had	O
a	O
tremendous	O
impact	B-MED
on	O
management	B-MED
of	O
patients	B-MED
with	O
HER2	B-MED
+	I-MED
breast	I-MED
cancer	I-MED
,	O
leading	O
to	O
development	B-MED
and	O
increased	B-MED
use	O
of	O
further	O
HER2	B-MED
targeted	B-MED
therapies	I-MED
.	O
The	O
major	O
clinical	B-MED
side	B-MED
effect	I-MED
is	O
cardiotoxicity	B-MED
but	O
the	O
mechanism	B-MED
is	O
largely	O
unknown	O
.	O
On	O
the	O
basis	O
that	O
gene	B-MED
expression	I-MED
is	O
known	O
to	O
be	O
altered	B-MED
in	O
multiple	B-MED
models	B-MED
of	O
heart	B-MED
failure	I-MED
,	O
we	O
examined	O
differential	B-MED
gene	I-MED
expression	I-MED
of	O
iPSC	B-MED
-derived	O
cardiomyocytes	B-MED
treated	B-MED
at	O
day	B-MED
11	O
with	O
the	O
ERBB2	B-MED
targeted	O
monoclonal	B-MED
antibody	I-MED
,	O
trastuzumab	B-MED
for	O
48	O
h	O
and	O
the	O
small	B-MED
molecule	I-MED
tyrosine	I-MED
kinase	I-MED
inhibitor	I-MED
of	O
EGFR	B-MED
and	O
ERBB2	B-MED
.	O
Transcriptome	B-MED
sequencing	I-MED
was	O
performed	B-MED
on	O
four	O
replicates	B-MED
from	O
each	O
group	B-MED
(	O
48	O
h	O
untreated	O
,	O
48	O
h	O
trastuzumab	B-MED
and	O
48	O
h	O
lapatinib	B-MED
)	O
and	O
differential	B-MED
gene	I-MED
expression	I-MED
analyses	B-MED
were	O
performed	B-MED
on	O
each	O
treatment	B-MED
group	B-MED
relative	O
to	O
untreated	O
cardiomyocytes	B-MED
.	O
517	O
and	O
1358	O
genes	B-MED
were	O
differentially	B-MED
expressed	I-MED
,	O
p	O
<	O
0.05	O
,	O
respectively	O
in	O
cardiomyocytes	B-MED
treated	B-MED
with	O
trastuzumab	B-MED
and	O
lapatinib	B-MED
.	O
Gene	B-MED
ontology	I-MED
analyses	B-MED
revealed	O
in	O
cardiomyocytes	B-MED
treated	B-MED
with	O
trastuzumab	B-MED
,	O
significant	B-MED
down	B-MED
-	I-MED
regulation	I-MED
of	O
genes	B-MED
involved	O
in	O
small	B-MED
molecule	I-MED
metabolism	I-MED
(	O
p	O
=	O
3.22	O
�	O
—	O
10(-9	O
)	O
)	O
and	O
cholesterol	B-MED
(	O
p	O
=	O
0.01	O
)	O
and	O
sterol	B-MED
(	O
p	O
=	O
0.03	O
)	O
processing	O
.	O
We	O
next	O
measured	B-MED
glucose	B-MED
uptake	I-MED
and	O
lactate	B-MED
production	B-MED
in	O
iPSC	B-MED
-derived	O
cardiomyocytes	B-MED
13	O
days	B-MED
post	O
-	O
plating	O
,	O
treated	B-MED
with	O
trastuzumab	B-MED
up	O
to	O
96	O
h.	O
We	O
observed	B-MED
significantly	B-MED
decreased	B-MED
glucose	B-MED
uptake	I-MED
from	O
the	O
media	B-MED
of	O
iPSC	B-MED
-derived	O
cardiomyocytes	B-MED
treated	B-MED
with	O
trastuzumab	B-MED
as	O
early	O
as	O
24	O
h	O
(	O
p	O
=	O
0.001	O
)	O
and	O
consistently	B-MED
up	O
to	O
96	O
h	O
(	O
p	O
=	O
0.03	O
)	O
.	O
Our	O
study	B-MED
suggests	O
dysregulation	B-MED
of	O
cardiac	B-MED
gene	B-MED
expression	I-MED
and	O
metabolism	B-MED
as	O
key	O
elements	O
of	O
ERBB2	B-MED
signaling	B-MED
that	O
could	O
potentially	B-MED
be	O
early	O
biomarkers	B-MED
of	O
cardiotoxicity	B-MED
.	O
Incidence	B-MED
and	O
effect	B-MED
of	I-MED
variant	B-MED
histology	B-MED
on	O
oncological	B-MED
outcomes	I-MED
in	O
patients	B-MED
with	O
bladder	B-MED
cancer	I-MED
treated	B-MED
with	O
radical	B-MED
cystectomy	I-MED
We	O
sought	O
to	O
describe	O
incidence	B-MED
of	O
histological	B-MED
variants	B-MED
after	O
radical	B-MED
cystectomy	I-MED
(	O
RC	B-MED
)	O
due	O
to	O
bladder	B-MED
cancer	I-MED
(	O
BCa	B-MED
)	O
.	O
Moreover	O
,	O
we	O
investigated	O
survival	B-MED
outcomes	B-MED
accounting	O
for	O
this	O
parameter	O
.	O
We	O
retrospectively	B-MED
evaluated	B-MED
data	B-MED
from	O
1,067	O
patients	B-MED
with	O
BCa	B-MED
treated	B-MED
with	O
RC	B-MED
between	O
1990	O
and	O
2013	O
at	O
a	O
single	B-MED
tertiary	I-MED
care	I-MED
referral	I-MED
center	I-MED
.	O
All	O
specimen	B-MED
were	O
evaluated	B-MED
by	O
dedicated	O
uropathologists	B-MED
.	O
Univariable	B-MED
and	I-MED
multivariable	I-MED
Cox	I-MED
regression	I-MED
analyses	I-MED
tested	O
the	O
effect	B-MED
of	I-MED
different	O
histopathological	B-MED
variant	B-MED
on	O
recurrence	B-MED
,	O
cancer	B-MED
-	I-MED
specific	I-MED
mortality	I-MED
(	O
CSM	B-MED
)	O
,	O
and	O
overall	B-MED
mortality	I-MED
(	O
OM	B-MED
)	O
after	O
accounting	O
for	O
all	O
available	O
confounders	B-MED
.	O
Of	O
1,067	O
patients	B-MED
,	O
729	O
(	O
68.3	O
%	O
)	O
harbored	O
pure	B-MED
urothelial	I-MED
BCa	I-MED
while	O
338	O
(	O
31.7	O
%	O
)	O
were	O
found	O
to	O
have	O
a	O
variant	B-MED
.	O
Considering	O
uncommon	O
variants	B-MED
,	O
21	O
(	O
2.0	O
%	O
)	O
were	O
sarcomatoid	B-MED
,	O
10	O
(	O
0.9	O
%	O
)	O
lymphoepitelial	B-MED
,	O
19	O
(	O
1.8	O
%	O
)	O
small	B-MED
cell	I-MED
,	O
109	O
(	O
10.2	O
%	O
)	O
squamous	B-MED
,	O
89	O
(	O
8.3	O
%	O
)	O
micropapillary	B-MED
,	O
23	O
(	O
2.2	O
%	O
)	O
glandular	B-MED
,	O
34	O
(	O
3.2	O
%	O
)	O
mixed	O
variants	B-MED
,	O
and	O
33	O
(	O
3.1	O
%	O
)	O
were	O
found	O
with	O
other	O
types	O
of	O
variants	B-MED
.	O
With	O
a	O
median	B-MED
follow	B-MED
-	I-MED
up	I-MED
of	O
6.2	O
years	B-MED
,	O
343	O
recurrence	B-MED
,	O
365	O
CSM	B-MED
,	O
and	O
451	O
OM	B-MED
were	O
recorded	O
,	O
respectively	O
.	O
At	O
multivariable	B-MED
Cox	I-MED
regression	I-MED
analyses	I-MED
,	O
the	O
presence	O
of	O
small	B-MED
cell	I-MED
variant	I-MED
was	O
associated	B-MED
with	I-MED
higher	O
recurrence	B-MED
(	O
hazard	B-MED
ratio	I-MED
[	O
HR	B-MED
]	O
=	O
3.47	O
,	O
P<0.001	O
)	O
,	O
CSM	B-MED
(	O
HR	B-MED
=	O
3.30	O
,	O
P<0.04	O
)	O
,	O
and	O
OM	B-MED
(	O
HR	B-MED
=	O
2.97	O
,	O
P<0.003	O
)	O
as	O
compared	O
with	O
pure	O
urothelial	B-MED
cancer	I-MED
.	O
Conversely	O
,	O
no	B-MED
survival	I-MED
differences	I-MED
were	O
recorded	O
considering	O
other	O
histological	B-MED
variants	B-MED
(	O
all	O
P	O
>	O
0.1	O
)	O
.	O
Our	O
study	B-MED
confirms	O
that	O
histological	B-MED
variant	B-MED
is	O
not	O
an	O
infrequent	O
event	O
at	O
RC	B-MED
specimen	B-MED
.	O
However	O
,	O
in	O
our	O
single	B-MED
-	I-MED
center	I-MED
series	I-MED
,	O
only	O
patients	B-MED
found	O
with	O
small	B-MED
cell	I-MED
variant	I-MED
were	O
associated	B-MED
with	I-MED
a	O
negative	B-MED
effect	B-MED
on	O
survival	B-MED
after	O
RC	B-MED
.	O
Does	O
a	O
policy	B-MED
of	O
earlier	B-MED
induction	I-MED
affect	O
labour	B-MED
outcomes	B-MED
in	O
women	B-MED
induced	B-MED
for	O
postmaturity	B-MED
?	O
A	O
retrospective	B-MED
analysis	B-MED
in	O
a	O
tertiary	B-MED
hospital	I-MED
in	O
the	O
North	B-MED
of	O
England	B-MED
to	O
investigate	B-MED
whether	O
a	O
change	B-MED
in	O
the	O
management	B-MED
of	O
postmature	B-MED
pregnancy	I-MED
to	O
earlier	B-MED
induction	I-MED
affects	O
the	O
length	B-MED
of	I-MED
labour	I-MED
and	O
the	O
induction	B-MED
process	I-MED
.	O
Secondly	O
,	O
to	O
assess	B-MED
the	O
feasibility	B-MED
of	O
the	O
research	B-MED
process	I-MED
to	O
inform	O
a	O
future	B-MED
larger	B-MED
study	I-MED
.	O
a	O
change	B-MED
in	O
management	B-MED
of	O
postmature	B-MED
pregnancy	I-MED
in	O
an	O
NHS	B-MED
hospital	B-MED
in	O
October	B-MED
2013	O
,	O
from	O
induction	B-MED
at	O
42	O
weeks	B-MED
gestation	B-MED
to	O
induction	B-MED
between	O
41	O
-	O
42	O
weeks	B-MED
,	O
provided	B-MED
an	O
opportunity	B-MED
to	O
conduct	O
a	O
retrospective	B-MED
analysis	B-MED
.	O
Pre	B-MED
-	I-MED
existing	I-MED
data	B-MED
from	O
the	O
maternity	B-MED
database	B-MED
and	O
casenotes	B-MED
were	O
collected	B-MED
and	O
primary	B-MED
outcomes	I-MED
analysed	B-MED
using	O
the	O
Mann	B-MED
-	I-MED
Whitney	I-MED
test	I-MED
and	O
the	O
Hodges	B-MED
-	I-MED
Lehman	I-MED
confidence	I-MED
interval	I-MED
for	O
differences	B-MED
in	O
medians	B-MED
.	O
a	O
large	B-MED
city	I-MED
based	O
tertiary	B-MED
referral	I-MED
hospital	I-MED
in	O
the	O
North	B-MED
of	O
England	B-MED
.	O
125	O
women	B-MED
induced	B-MED
before	O
the	O
change	B-MED
in	O
policy	B-MED
were	O
compared	B-MED
with	O
309	O
women	B-MED
induced	B-MED
after	O
the	O
change	B-MED
.	O
primary	B-MED
outcomes	I-MED
were	O
length	B-MED
of	O
1st	B-MED
and	O
2nd	B-MED
stage	I-MED
of	I-MED
labour	I-MED
,	O
overall	O
length	B-MED
of	I-MED
labour	I-MED
,	O
length	B-MED
of	O
induction	B-MED
to	O
established	B-MED
labour	B-MED
and	O
length	B-MED
of	O
induction	B-MED
to	O
birth	B-MED
.	O
the	O
median	B-MED
overall	O
length	B-MED
of	I-MED
labour	I-MED
for	O
women	B-MED
induced	B-MED
at	O
42	O
weeks	B-MED
was	O
6.5	O
hours	B-MED
,	O
while	O
for	O
women	B-MED
induced	B-MED
at	O
41	O
-	O
42	O
weeks	B-MED
this	O
was	O
5.2	O
hours	B-MED
.	O
The	O
difference	B-MED
was	O
not	O
statistically	B-MED
significant	I-MED
(	O
p=0.15	O
,	O
95	O
%	O
CI	B-MED
for	O
median	B-MED
difference	B-MED
-0.27	O
to	O
1.93	O
hours	B-MED
)	O
with	O
a	O
small	B-MED
effect	I-MED
size	I-MED
(	O
Pearson	B-MED
's	I-MED
r=-0.08	O
)	O
.	O
The	O
median	B-MED
length	B-MED
of	O
induction	B-MED
to	O
birth	B-MED
was	O
13.6	O
hours	B-MED
for	O
women	B-MED
induced	B-MED
at	O
42	O
weeks	B-MED
and	O
16.5	O
hours	B-MED
for	O
women	B-MED
induced	B-MED
at	O
41	O
-	O
42	O
weeks	B-MED
.	O
This	O
difference	B-MED
was	O
also	O
not	O
statistically	B-MED
significant	I-MED
(	O
p=0.14	O
,	O
95	O
%	O
CI	B-MED
for	O
median	B-MED
difference	B-MED
-7.25	O
to	O
1.20	O
hours	B-MED
)	O
with	O
a	O
small	B-MED
effect	I-MED
size	I-MED
(	O
Pearson	B-MED
's	I-MED
r=-0.13	O
)	O
.	O
This	O
study	B-MED
demonstrated	O
no	O
statistically	B-MED
significant	I-MED
difference	B-MED
s	O
in	O
length	B-MED
of	I-MED
labour	I-MED
and	O
induction	B-MED
following	O
a	O
change	B-MED
in	O
the	O
management	B-MED
of	O
postmature	B-MED
pregnancy	I-MED
to	O
earlier	B-MED
induction	I-MED
.	O
A	O
large	B-MED
study	I-MED
is	O
needed	O
to	O
establish	B-MED
definitively	O
the	O
effects	B-MED
of	I-MED
earlier	B-MED
induction	I-MED
on	O
labour	B-MED
outcomes	B-MED
.	O
Interleukin-1β	B-MED
induced	O
Stress	B-MED
Granules	I-MED
Sequester	B-MED
COX-2	B-MED
mRNA	B-MED
and	O
Regulates	B-MED
its	O
Stability	B-MED
and	O
Translation	B-MED
in	O
Human	B-MED
OA	B-MED
Chondrocytes	B-MED
Enhanced	B-MED
and	O
immediate	O
expression	B-MED
of	O
cyclooxygenase-2	B-MED
(	O
COX-2	B-MED
)	O
mRNA	B-MED
is	O
observed	O
in	O
IL-1β	B-MED
-	O
stimulated	B-MED
OA	B-MED
chondrocytes	B-MED
but	O
the	O
synthesis	B-MED
of	I-MED
protein	I-MED
found	O
significantly	O
delayed	B-MED
.	O
Here	O
we	O
investigated	O
the	O
role	O
of	O
stress	B-MED
granules	I-MED
(	O
SGs	B-MED
)	O
,	O
ribonucleoprotein	B-MED
complexes	I-MED
that	O
regulate	B-MED
mRNA	B-MED
translation	I-MED
,	O
in	O
the	O
delayed	B-MED
translation	B-MED
of	O
COX-2	B-MED
mRNAs	B-MED
in	O
IL-1β	B-MED
-	O
stimulated	B-MED
OA	B-MED
chondrocytes	B-MED
.	O
Stimulation	B-MED
of	O
human	B-MED
chondrocytes	B-MED
with	O
IL-1β	B-MED
activated	O
the	O
stress	B-MED
response	I-MED
genes	B-MED
and	O
the	O
phosphorylation	B-MED
of	O
eIF2α	B-MED
that	O
triggered	B-MED
the	O
assembly	B-MED
of	I-MED
SGs	I-MED
.	O
Using	O
combined	O
immunofluorescence	B-MED
staining	I-MED
of	O
SGs	B-MED
markers	B-MED
and	O
COX-2	B-MED
protein	I-MED
,	O
RNA	B-MED
fluorescence	B-MED
in	I-MED
situ	I-MED
hybridization	I-MED
and	O
RNA	B-MED
immunoprecipitation	B-MED
,	O
the	O
COX-2	B-MED
mRNAs	B-MED
were	O
found	O
sequestered	B-MED
in	O
SGs	B-MED
in	O
IL-1β	B-MED
-	O
stimulated	B-MED
OA	B-MED
chondrocytes	B-MED
.	O
No	B-MED
increase	B-MED
in	O
COX-2	B-MED
protein	B-MED
expression	I-MED
was	O
observed	O
during	O
the	O
persistence	B-MED
of	O
SGs	B-MED
but	O
enhanced	B-MED
expression	B-MED
of	O
COX-2	B-MED
protein	I-MED
was	O
noted	O
upon	O
clearance	B-MED
of	O
the	O
SGs	B-MED
.	O
Inhibition	B-MED
of	O
SGs	B-MED
clearance	B-MED
blocked	B-MED
COX-2	B-MED
mRNA	B-MED
translation	B-MED
whereas	O
blocking	B-MED
the	O
assembly	B-MED
of	I-MED
SGs	I-MED
by	O
TIA-1	B-MED
depletion	B-MED
resulted	O
in	O
rapid	O
and	O
increased	B-MED
production	B-MED
of	O
COX-2	B-MED
and	O
PGE2	B-MED
.	O
Our	O
findings	O
show	O
for	O
the	O
first	O
time	O
assembly	B-MED
of	I-MED
SGs	I-MED
and	O
sequestration	B-MED
of	O
COX-2	B-MED
mRNAs	B-MED
in	O
human	B-MED
OA	B-MED
chondrocytes	B-MED
under	O
pathological	B-MED
conditions	I-MED
.	O
Post	B-MED
-	I-MED
transcriptional	I-MED
regulation	I-MED
of	O
COX-2	B-MED
mRNAs	B-MED
translation	I-MED
by	O
SGs	B-MED
indicates	O
a	O
role	O
in	O
IL-1β	B-MED
-mediated	O
catabolic	B-MED
response	B-MED
that	O
could	O
be	O
therapeutically	B-MED
targeted	O
in	O
OA	B-MED
.	O
Structural	B-MED
Modification	I-MED
of	O
Lipopolysaccharide	B-MED
Conferred	O
by	O
mcr-1	B-MED
in	O
Gram	B-MED
-	I-MED
Negative	I-MED
ESKAPE	I-MED
Pathogens	B-MED
mcr-1	B-MED
was	O
initially	O
reported	O
as	O
the	O
first	O
plasmid	B-MED
-mediated	O
colistin	B-MED
resistance	B-MED
gene	I-MED
in	O
clinical	B-MED
isolates	I-MED
of	O
Escherichia	B-MED
coli	I-MED
and	O
Klebsiella	B-MED
pneumoniae	I-MED
in	O
China	B-MED
and	O
has	O
subsequently	O
been	O
identified	O
worldwide	O
in	O
various	O
species	B-MED
of	O
the	O
family	B-MED
Enterobacteriaceae	I-MED
mcr-1	B-MED
encodes	O
a	O
phosphoethanolamine	B-MED
transferase	I-MED
,	O
and	O
its	O
expression	B-MED
has	O
been	O
shown	O
to	O
generate	O
phosphoethanolamine	B-MED
-modified	O
bis	B-MED
-	I-MED
phosphorylated	I-MED
hexa	I-MED
-	I-MED
acylated	I-MED
lipid	I-MED
A	I-MED
in	O
E.	B-MED
coli	I-MED
Here	O
,	O
we	O
investigated	O
the	O
effects	B-MED
of	I-MED
mcr-1	B-MED
on	O
colistin	B-MED
susceptibility	B-MED
and	O
on	O
lipopolysaccharide	B-MED
structures	B-MED
in	O
laboratory	B-MED
and	O
clinical	B-MED
strains	B-MED
of	O
the	O
Gram	B-MED
-	I-MED
negative	I-MED
ESKAPE	I-MED
(	O
Enterococcus	B-MED
faecium	I-MED
,	O
Staphylococcus	B-MED
aureus	I-MED
,	O
K.	B-MED
pneumoniae	I-MED
K.	B-MED
pneumoniae	I-MED
,	O
Acinetobacter	B-MED
baumannii	I-MED
,	O
Pseudomonas	B-MED
aeruginosa	I-MED
,	O
and	O
Enterobacter	B-MED
species	I-MED
)	O
pathogens	B-MED
,	O
which	O
are	O
often	O
treated	B-MED
clinically	B-MED
by	O
colistin	B-MED
.	O
The	O
effects	B-MED
of	I-MED
mcr-1	B-MED
on	O
colistin	B-MED
resistance	B-MED
were	O
determined	O
using	O
MIC	B-MED
assays	I-MED
of	O
laboratory	B-MED
and	O
clinical	B-MED
strains	B-MED
of	O
E.	B-MED
coli	I-MED
,	O
K.	B-MED
pneumoniae	I-MED
,	O
A.	B-MED
baumannii	I-MED
,	O
and	O
P.	B-MED
aeruginosa	I-MED
Lipid	B-MED
A	I-MED
structural	B-MED
changes	O
resulting	O
from	O
MCR-1	B-MED
were	O
analyzed	O
by	O
mass	B-MED
spectrometry	I-MED
.	O
The	O
introduction	O
of	O
mcr-1	B-MED
led	O
to	O
colistin	B-MED
resistance	B-MED
in	O
E.	B-MED
coli	I-MED
,	O
K.	B-MED
pneumoniae	I-MED
,	O
and	O
A.	B-MED
baumannii	I-MED
but	O
only	O
moderately	O
reduced	B-MED
susceptibility	B-MED
in	O
P.	B-MED
aeruginosa	I-MED
Phosphoethanolamine	B-MED
modification	B-MED
of	O
lipid	B-MED
A	I-MED
was	O
observed	O
consistently	O
for	O
all	O
four	O
species	B-MED
.	O
These	O
findings	B-MED
highlight	O
the	O
risk	B-MED
of	O
colistin	B-MED
resistance	B-MED
as	O
a	O
consequence	B-MED
of	I-MED
mcr-1	B-MED
expression	B-MED
among	O
ESKAPE	B-MED
pathogens	B-MED
,	O
especially	O
in	O
K.	B-MED
pneumoniae	I-MED
and	O
A.	B-MED
baumannii	I-MED
Furthermore	O
,	O
the	O
observation	O
that	O
lipid	B-MED
A	I-MED
structures	B-MED
were	O
modified	O
despite	O
only	O
modest	O
increases	B-MED
in	O
colistin	B-MED
MICs	B-MED
in	O
some	O
instances	O
suggests	O
more	O
sophisticated	O
surveillance	B-MED
methods	I-MED
may	O
need	O
to	O
be	O
developed	O
to	O
track	O
the	O
dissemination	B-MED
of	O
mcr-1	B-MED
or	O
plasmid	B-MED
plasmid	B-MED
-mediated	O
phosphoethanolamine	B-MED
transferases	I-MED
in	O
general	O
.	O
CS	B-MED
-	O
PEG	B-MED
decorated	O
PLGA	B-MED
nano	I-MED
-	I-MED
prototype	I-MED
for	O
delivery	B-MED
of	O
bioactive	B-MED
compounds	I-MED
:	O
A	O
novel	B-MED
approach	B-MED
for	O
induction	B-MED
of	O
apoptosis	B-MED
in	O
HepG2	B-MED
cell	I-MED
line	I-MED
Polymer	B-MED
-	O
based	B-MED
nanoparticles	B-MED
are	O
used	B-MED
as	O
vectors	B-MED
for	O
cancer	B-MED
drug	B-MED
delivery	I-MED
.	O
The	O
bioactive	B-MED
compounds	I-MED
(	O
quercetin	B-MED
,	O
ellagic	B-MED
acid	I-MED
and	O
gallic	B-MED
acid	I-MED
)	O
are	O
well	O
known	O
to	O
be	O
not	O
only	O
antioxidants	B-MED
but	O
also	O
chemopreventive	B-MED
candidates	I-MED
against	B-MED
various	B-MED
types	B-MED
of	O
cancers	B-MED
.	O
To	O
circumvent	O
the	O
low	B-MED
bioavailability	B-MED
and	O
the	O
short	B-MED
half	B-MED
-	I-MED
life	I-MED
time	B-MED
obstacles	B-MED
,	O
we	O
hypothesized	O
a	O
novel	B-MED
PLGA	B-MED
nano	I-MED
-	I-MED
platform	I-MED
functionalized	B-MED
with	O
CS	B-MED
and	O
PEG	B-MED
to	O
encapsulate	B-MED
these	O
phytochemicals	B-MED
.	O
This	O
encapsulation	B-MED
will	O
protect	B-MED
the	O
compounds	B-MED
from	O
the	O
phagocytic	B-MED
uptake	I-MED
and	O
deliver	B-MED
PLGA	B-MED
-	I-MED
CS	I-MED
-	I-MED
PEG	I-MED
nano	I-MED
-	I-MED
prototype	I-MED
with	O
high	O
biodegradability	B-MED
and	O
biosafety	B-MED
.	O
Three	O
consequent	O
types	B-MED
of	O
PLGA	B-MED
-	I-MED
based	I-MED
nanocomposites	I-MED
were	O
prepared	B-MED
and	O
characterized	B-MED
.	O
Furthermore	O
,	O
we	O
investigated	B-MED
the	O
newly	O
synthesized	B-MED
nano	B-MED
-	I-MED
formulations	I-MED
against	B-MED
human	B-MED
hepatocellular	B-MED
carcinoma	I-MED
(	O
HepG2	B-MED
)	O
and	O
colorectal	B-MED
cancer	I-MED
(	O
HCT	B-MED
116	I-MED
)	O
cell	B-MED
lines	I-MED
using	B-MED
cell	B-MED
growth	I-MED
inhibition	I-MED
assays	B-MED
,	O
followed	B-MED
by	I-MED
apoptosis	B-MED
and	O
necrosis	B-MED
assays	B-MED
using	B-MED
flow	B-MED
cytometry	I-MED
to	O
detect	B-MED
the	O
underlying	O
mechanism	B-MED
of	O
HepG2	B-MED
cell	B-MED
death	I-MED
.	O
Through	O
Malvern	O
Zeta	O
Sizer	O
,	O
we	O
recorded	O
that	O
the	O
average	B-MED
diameters	B-MED
of	O
the	O
nano	B-MED
-	I-MED
prototypes	I-MED
ranged	O
from	O
150	O
to	O
300	O
nm	O
.	O
The	O
cytotoxic	B-MED
activity	I-MED
of	O
quercetin	B-MED
,	O
ellagic	B-MED
acid	I-MED
,	O
and	O
gallic	B-MED
acid	I-MED
-	O
encapsulated	B-MED
PLGA	B-MED
,	O
PLGA	B-MED
-	I-MED
CS	I-MED
,	O
and	O
PLGA	B-MED
-	I-MED
CS	I-MED
-	I-MED
PEG	I-MED
nano	I-MED
-	I-MED
prototypes	I-MED
it	O
has	O
been	O
found	B-MED
that	O
they	O
reduce	B-MED
the	O
IC50s	B-MED
of	O
the	O
HepG2	B-MED
cells	I-MED
values	B-MED
by	O
2.2	O
,	O
2.9	O
,	O
2.8-	O
folds	B-MED
,	O
1	O
,	O
1.5	O
,	O
2.7-	O
folds	B-MED
,	O
and	O
0.9	O
,	O
0.7	O
,	O
1.5-	O
folds	B-MED
,	O
respectively	O
.	O
Mechanistically	O
,	O
the	O
nano	O
-	O
platforms	O
of	O
quercetin	B-MED
seem	O
to	O
be	O
dependent	B-MED
on	O
both	O
apoptosis	B-MED
and	O
necrosis	B-MED
,	O
while	O
those	O
of	O
ellagic	B-MED
acid	I-MED
and	O
gallic	B-MED
acid	I-MED
are	O
mainly	O
dependent	B-MED
on	O
apoptosis	B-MED
.	O
CS	B-MED
-	O
PEG	B-MED
-blended	O
PLGA	B-MED
nano	B-MED
-	I-MED
delivery	I-MED
system	I-MED
of	O
quercetin	B-MED
,	O
ellagic	B-MED
acid	I-MED
and	O
gallic	B-MED
acid	I-MED
can	O
potentiate	B-MED
apoptosis	B-MED
-	I-MED
mediated	I-MED
cell	B-MED
death	I-MED
in	O
HepG2	B-MED
cell	I-MED
line	I-MED
.	O
Fragment	B-MED
-Based	O
Discovery	B-MED
of	O
5	B-MED
-	I-MED
Arylisatin	I-MED
-Based	O
Inhibitors	B-MED
of	O
Matrix	B-MED
Metalloproteinases	I-MED
2	I-MED
and	O
13	B-MED
Matrix	B-MED
metalloproteinases	I-MED
(	O
MMPs	B-MED
)	O
are	O
well	O
-	O
established	O
targets	O
for	O
several	O
pathologies	B-MED
.	O
In	O
particular	O
,	O
MMP-2	B-MED
and	O
MMP-13	B-MED
play	O
a	O
prominent	O
role	O
in	O
cancer	B-MED
progression	I-MED
.	O
In	O
this	O
study	B-MED
,	O
a	O
structure	B-MED
-	I-MED
based	I-MED
screening	I-MED
campaign	O
was	O
applied	O
to	O
prioritize	O
metalloproteinase	B-MED
-oriented	O
fragments	B-MED
.	O
This	O
computational	B-MED
model	I-MED
was	O
applied	O
to	O
a	O
representative	O
fragment	B-MED
set	B-MED
from	O
the	O
publically	O
available	O
EDASA	B-MED
Scientific	I-MED
compound	I-MED
library	I-MED
.	O
These	O
fragments	B-MED
were	O
prioritized	O
,	O
and	O
the	O
top	O
-	O
ranking	O
hits	O
were	O
tested	O
in	O
a	O
biological	B-MED
assay	I-MED
to	O
validate	B-MED
the	O
model	B-MED
.	O
Two	O
scaffolds	B-MED
showed	O
consistent	O
activity	B-MED
in	O
the	O
assay	B-MED
,	O
and	O
the	O
isatin	B-MED
-	I-MED
based	I-MED
compounds	I-MED
were	O
the	O
most	O
interesting	O
.	O
These	O
latter	O
fragments	B-MED
have	O
significant	O
potential	O
as	O
tools	O
for	O
the	O
design	B-MED
and	O
realization	O
of	O
novel	O
MMP	B-MED
inhibitors	I-MED
.	O
In	O
addition	O
to	O
their	O
micromolar	B-MED
activity	I-MED
,	O
the	O
chemical	B-MED
synthesis	I-MED
affords	O
flexible	B-MED
and	O
creative	B-MED
access	I-MED
to	O
their	O
analogues	B-MED
.	O
Transfusion	B-MED
medicine	I-MED
in	O
medical	B-MED
education	I-MED
:	O
an	O
analysis	B-MED
of	O
curricular	B-MED
grids	I-MED
in	O
Brazil	B-MED
and	O
a	O
review	B-MED
of	O
the	O
current	B-MED
literature	I-MED
Blood	B-MED
transfusions	I-MED
are	O
one	O
of	O
the	O
most	O
performed	O
medical	B-MED
procedures	I-MED
in	O
the	O
world	B-MED
.	O
Thus	O
,	O
as	O
education	B-MED
in	O
transfusion	B-MED
medicine	I-MED
is	O
vital	B-MED
to	O
medical	B-MED
care	I-MED
,	O
it	O
should	O
aim	O
to	O
promote	B-MED
a	O
responsible	O
practice	B-MED
with	O
the	O
rational	O
use	O
of	O
blood	B-MED
by	O
doctors	B-MED
.	O
This	O
study	O
aims	O
to	O
investigate	B-MED
the	O
situation	O
of	O
the	O
teaching	B-MED
of	O
transfusion	B-MED
medicine	I-MED
in	O
medical	B-MED
schools	I-MED
in	O
Brazil	B-MED
.	O
The	O
websites	B-MED
of	O
the	O
249	O
Brazilian	B-MED
medical	B-MED
schools	I-MED
in	O
operation	B-MED
in	O
June	O
2015	O
were	O
visited	O
and	O
the	O
curricula	B-MED
of	O
the	O
medical	B-MED
courses	I-MED
were	O
investigated	B-MED
in	O
respect	O
to	O
the	O
presence	O
or	O
absence	O
of	O
a	O
transfusion	B-MED
medicine	I-MED
discipline	I-MED
.	O
When	O
available	O
,	O
the	O
subject	O
grids	O
were	O
analyzed	B-MED
to	O
verify	O
whether	O
a	O
description	B-MED
of	I-MED
content	I-MED
regarding	O
transfusion	B-MED
medicine	I-MED
was	O
given	O
within	O
other	O
disciplines	B-MED
.	O
Of	O
the	O
249	O
medical	B-MED
school	I-MED
sites	O
visited	O
,	O
information	B-MED
on	O
the	O
curriculum	B-MED
was	O
obtained	O
from	O
178	O
.	O
Of	O
the	O
medical	B-MED
schools	I-MED
that	O
published	B-MED
their	O
curriculum	B-MED
,	O
132	O
(	O
74.1	O
%	O
)	O
did	O
not	O
have	O
disciplines	B-MED
of	I-MED
transfusion	I-MED
medicine	I-MED
or	O
hematology	B-MED
and	O
only	O
seven	O
(	O
3.9	O
%	O
)	O
had	O
a	O
discipline	B-MED
of	I-MED
transfusion	I-MED
medicine	I-MED
in	O
the	O
curricular	B-MED
grid	I-MED
.	O
Education	B-MED
on	O
transfusion	B-MED
medicine	I-MED
is	O
of	O
fundamental	B-MED
importance	I-MED
for	O
safe	B-MED
and	I-MED
efficient	I-MED
transfusion	I-MED
practices	I-MED
.	O
Deficiencies	B-MED
in	O
medical	B-MED
knowledge	B-MED
of	O
this	O
subject	O
have	O
been	O
found	O
worldwide	O
.	O
The	O
results	O
of	O
this	O
study	O
indicate	O
a	O
possible	O
deficiency	B-MED
in	O
teaching	B-MED
the	O
basics	B-MED
of	O
this	O
specialty	O
.	O
Thus	O
,	O
additional	O
prospective	B-MED
studies	I-MED
to	O
assess	B-MED
the	O
knowledge	B-MED
and	O
practice	O
of	O
transfusion	B-MED
medicine	I-MED
in	O
Brazilian	B-MED
medical	B-MED
schools	I-MED
are	O
warranted	O
,	O
which	O
could	O
prompt	O
a	O
discussion	O
on	O
the	O
importance	B-MED
of	O
offering	O
training	B-MED
in	O
transfusion	B-MED
medicine	I-MED
to	O
medical	B-MED
students	I-MED
.	O
Progressive	B-MED
Occlusion	I-MED
and	O
Recanalization	B-MED
after	O
Endovascular	B-MED
Treatment	I-MED
for	O
287	O
Unruptured	B-MED
Small	I-MED
Aneurysms	I-MED
(	O
<	O
5	O
mm	O
):	O
A	O
Single	B-MED
-	I-MED
Center	I-MED
6	B-MED
-	I-MED
Year	I-MED
Experience	B-MED
We	O
aimed	O
to	O
investigate	O
the	O
effect	B-MED
of	O
coiling	B-MED
for	O
small	O
unruptured	B-MED
intracranial	I-MED
aneurysms	I-MED
UIAs	B-MED
(	O
UIAs)﹤5	O
mm	O
)	O
on	O
progressive	B-MED
occlusio	I-MED
n	O
and	O
recanalization	B-MED
,	O
and	O
the	O
dubious	O
factors	O
related	O
to	O
progressive	B-MED
occlusion	I-MED
and	O
recanalization	B-MED
among	O
UIAs	B-MED
without	O
complete	O
occlusion	B-MED
.	O
A	O
total	O
of	O
264	O
patients	B-MED
with	O
287	O
small	O
UIAs	B-MED
were	O
coiled	O
in	O
our	O
institute	B-MED
between	O
June	O
2009	O
and	O
December	O
2014	O
.	O
All	O
UIAs	B-MED
enrolled	O
were	O
divided	O
into	O
small	O
(	O
3	O
-	O
5	O
mm	O
)	O
and	O
very	O
small	O
(	O
<3	O
mm	O
)	O
group	B-MED
s	O
,	O
and	O
UIAs	B-MED
without	O
initial	O
complete	O
occlusion	B-MED
were	O
divided	O
into	O
progressive	B-MED
,	O
stable	B-MED
and	O
recanalization	B-MED
groups	B-MED
.	O
Baseline	B-MED
characteristics	B-MED
,	O
procedure	B-MED
-related	O
complications	B-MED
,	O
angiographic	B-MED
follow	B-MED
-	I-MED
up	I-MED
results	I-MED
,	O
and	O
clinical	B-MED
outcomes	I-MED
were	O
statistically	B-MED
analyzed	I-MED
.	O
Among	O
287	O
aneurysms	B-MED
,	O
211	O
aneurysms	B-MED
(	O
73.5	O
%	O
)	O
were	O
completely	O
coiled	O
,	O
three	O
(	O
1.2	O
%	O
)	O
intraoperative	B-MED
ruptures	B-MED
and	O
12	O
(	O
4.2	O
%	O
)	O
perioperative	B-MED
thromboembolic	B-MED
events	I-MED
occurred	O
.	O
Angiographic	B-MED
follow	B-MED
-	I-MED
up	I-MED
was	O
available	O
for	O
174	O
patients	B-MED
(	O
65.9	O
%	O
)	O
,	O
the	O
incidence	B-MED
of	O
recanalization	B-MED
was	O
5.7	O
%	O
.	O
Among	O
56	O
aneurysms	B-MED
without	O
complete	O
occlusion	B-MED
,	O
43	O
(	O
76.8	O
%	O
)	O
had	O
progressive	B-MED
occlusion	I-MED
and	O
6(10.7	O
%	O
)	O
had	O
recanalization	B-MED
.	O
Anatomic	B-MED
results	I-MED
of	O
initial	O
and	O
follow	B-MED
-	I-MED
up	I-MED
between	O
small	O
and	O
very	O
small	O
groups	B-MED
were	O
similar	O
in	O
both	O
groups	B-MED
.	O
On	O
logistic	B-MED
regression	I-MED
analysis	I-MED
,	O
smaller	O
size	B-MED
(	O
<3	O
mm	O
)	O
without	O
complete	O
occlusion	B-MED
related	O
to	O
recanalization	B-MED
(	O
OR	O
,	O
8.0	O
,	O
95	O
%	O
CI	O
,	O
1.3	O
-	O
50.0	O
,	O
P=0.026	O
)	O
.	O
Our	O
study	B-MED
suggested	O
that	O
coil	B-MED
embolization	I-MED
of	O
small	O
UIAs	B-MED
can	O
achieve	O
a	O
high	O
rate	O
of	O
progressive	B-MED
occlusion	I-MED
and	O
low	O
rate	O
of	O
recanalization	B-MED
during	O
follow	B-MED
-	I-MED
up	I-MED
.	O
Anatomic	B-MED
results	I-MED
of	O
initial	O
and	O
follow	B-MED
-	I-MED
up	I-MED
between	O
small	O
(	O
3	O
-	O
5	O
mm	O
)	O
and	O
very	O
small	O
(	O
<3	O
mm	O
)	O
groups	B-MED
were	O
similar	O
in	O
both	O
groups	B-MED
.	O
What	O
's	O
more	O
,	O
smaller	O
size	O
(	O
<3	O
mm	O
)	O
without	O
complete	O
occlusion	B-MED
may	O
relate	O
to	O
recanalization	B-MED
.	O
Metacarpophalangeal	B-MED
Joint	I-MED
Arthrodesis	I-MED
of	O
the	O
Thumb	B-MED
-	O
Minimum	O
of	O
Eight	O
Months	B-MED
Follow	B-MED
-	I-MED
up	I-MED
Disorders	B-MED
of	O
the	O
thumb	B-MED
metacarpophalangeal	I-MED
(	I-MED
MCP	I-MED
)	I-MED
joint	I-MED
can	O
lead	O
to	O
significant	O
loss	B-MED
of	O
function	B-MED
and	O
pain	B-MED
.	O
Thumb	B-MED
MCP	I-MED
arthrodesis	B-MED
following	O
traumatic	B-MED
injuries	I-MED
is	O
inadequately	O
described	B-MED
and	O
recent	O
studies	B-MED
have	O
questioned	O
the	O
outcome	B-MED
of	O
this	O
treatment	B-MED
.	O
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
report	B-MED
outcome	B-MED
and	O
disability	B-MED
following	O
thumb	B-MED
MCP	I-MED
joint	I-MED
arthrodesis	B-MED
in	O
the	O
treatment	B-MED
of	O
chronic	B-MED
instability	I-MED
after	O
traumatic	B-MED
injuries	I-MED
.	O
A	O
retrospective	B-MED
review	B-MED
of	O
26	O
patients	B-MED
operated	B-MED
on	O
with	O
MCP	B-MED
joint	I-MED
arthrodesis	B-MED
,	O
median	O
follow	B-MED
-	I-MED
up	I-MED
42	O
months	B-MED
(	O
8	O
-	O
104	O
months	B-MED
)	O
.	O
Subjective	O
outcome	B-MED
was	O
assessed	B-MED
using	O
the	O
disabilities	B-MED
of	I-MED
the	I-MED
Arm	I-MED
,	I-MED
Shoulder	I-MED
,	I-MED
and	I-MED
Hand	I-MED
-	I-MED
questionnaire	I-MED
(	O
DASH	B-MED
)	O
.	O
In	O
addition	O
,	O
patient	B-MED
satisfaction	I-MED
,	O
pain	B-MED
,	O
stiffness	B-MED
,	O
and	O
impairment	B-MED
of	O
activities	B-MED
of	I-MED
daily	I-MED
living	I-MED
were	O
assessed	B-MED
on	O
a	O
Visual	B-MED
Analogue	I-MED
Scale	I-MED
(	O
VAS	B-MED
)	O
followed	O
by	O
a	O
question	O
stating	O
whether	O
they	O
would	O
undergo	O
the	O
same	O
procedure	B-MED
again	O
.	O
Two	O
patients	B-MED
(	O
7.7	O
%	O
)	O
needed	O
re	B-MED
-	I-MED
operation	I-MED
due	O
to	O
nonunion	B-MED
.	O
Four	O
patients	B-MED
(	O
15.4	O
%	O
)	O
needed	O
hardware	B-MED
removal	I-MED
.	O
Median	B-MED
DASH	B-MED
-	O
score	B-MED
was	O
18	O
(	O
25	O
-	O
75	O
%	O
range	B-MED
6	O
-	O
47	O
)	O
,	O
with	O
lower	O
DASH	B-MED
score	B-MED
s	I-MED
being	O
better	O
.	O
Score	B-MED
s	I-MED
were	O
significantly	O
worse	O
in	O
gender	B-MED
and	O
age	B-MED
matched	O
individuals	B-MED
(	O
p<0.05	O
)	O
.	O
Median	B-MED
VAS	B-MED
for	O
pain	B-MED
was	O
3.7	O
(	O
range	B-MED
0	O
-	O
8)	O
.	O
More	O
than	O
50	O
%	O
of	O
patients	B-MED
reported	O
mild	B-MED
,	O
moderate	B-MED
or	O
severe	B-MED
pain	I-MED
,	O
but	O
all	O
patients	B-MED
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	B-MED
again	O
.	O
Our	O
data	B-MED
suggest	O
,	O
that	O
patients	B-MED
with	O
post	B-MED
-	I-MED
traumatic	I-MED
thumb	B-MED
injuries	I-MED
managed	O
with	O
thumb	B-MED
MCP	I-MED
joint	I-MED
arthrodesis	B-MED
perform	O
worse	O
than	O
gender	B-MED
and	O
age	B-MED
matched	O
individuals	B-MED
.	O
Many	O
lived	O
with	O
pain	B-MED
,	O
but	O
all	O
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	B-MED
again	O
.	O
We	O
suggest	O
that	O
the	O
disability	B-MED
scale	I-MED
by	O
the	O
National	B-MED
Board	I-MED
of	I-MED
Industrial	I-MED
Injuries	I-MED
should	O
be	O
reconsidered	O
for	O
patients	B-MED
operated	B-MED
on	O
with	O
thumb	B-MED
MCP	I-MED
arthrodesis	B-MED
.	O
Epidemiology	B-MED
and	O
risk	B-MED
factors	I-MED
associated	B-MED
with	I-MED
surgical	B-MED
site	I-MED
infection	I-MED
after	O
different	O
types	B-MED
of	O
hepatobiliary	B-MED
and	I-MED
pancreatic	I-MED
surgery	I-MED
Surgical	B-MED
site	I-MED
infection	I-MED
(	O
SSI	B-MED
)	O
is	O
one	O
of	O
the	O
most	O
common	O
healthcare	B-MED
-	I-MED
associated	I-MED
infections	I-MED
(	O
HAIs	B-MED
)	O
;	O
however	O
,	O
SSI	B-MED
after	O
hepatobiliary	B-MED
and	I-MED
pancreatic	I-MED
surgery	I-MED
(	O
HBPS	B-MED
)	O
has	O
not	O
been	O
well	O
investigated	B-MED
in	O
a	O
large	B-MED
cohort	B-MED
of	O
patients	B-MED
.	O
This	O
study	O
analyzed	O
the	O
factors	B-MED
associated	B-MED
with	I-MED
SSI	B-MED
following	O
HBPS	B-MED
in	O
Japan	B-MED
,	O
using	O
a	O
Japanese	B-MED
national	I-MED
database	I-MED
.	O
Data	B-MED
on	O
HBPS	B-MED
performed	B-MED
between	O
2012	O
and	O
2014	O
were	O
extracted	B-MED
from	O
a	O
national	B-MED
monitoring	I-MED
system	I-MED
for	O
HAI	B-MED
:	O
The	O
Japan	B-MED
Nosocomial	I-MED
Infections	I-MED
Surveillance	I-MED
.	O
Using	O
multivariate	B-MED
logistic	I-MED
regression	I-MED
,	O
I	O
assessed	B-MED
the	O
factors	B-MED
associated	B-MED
with	I-MED
SSI	B-MED
.	O
The	O
cumulative	B-MED
incidence	B-MED
of	O
SSI	B-MED
following	O
HBPS	B-MED
was	O
15.6	O
%	O
(	O
2873/18,398	O
)	O
.	O
The	O
incidence	B-MED
of	O
SSI	B-MED
after	O
pancreatoduodenectomy	B-MED
was	O
28.0	O
%	O
,	O
which	O
was	O
significantly	B-MED
higher	I-MED
than	O
that	O
after	O
liver	B-MED
resection	I-MED
and	O
other	O
types	B-MED
of	O
HBPS	B-MED
(	O
8.8	O
and	O
15.5	O
%	O
,	O
respectively	O
)	O
.	O
Among	O
the	O
four	O
traditional	B-MED
risk	B-MED
factors	I-MED
,	O
the	O
American	B-MED
Society	I-MED
of	I-MED
Anesthesiologists	I-MED
score	B-MED
was	O
ineffective	B-MED
for	O
predicting	B-MED
SSI	B-MED
in	O
the	O
final	O
model	B-MED
of	O
all	O
three	O
types	B-MED
of	O
surgery	B-MED
.	O
Additional	O
risk	B-MED
factors	I-MED
were	O
identified	B-MED
,	O
including	O
age	B-MED
and	O
male	B-MED
gender	I-MED
.	O
The	O
incidence	B-MED
of	O
and	O
factors	B-MED
associated	B-MED
with	I-MED
SSI	B-MED
after	O
the	O
three	O
types	B-MED
of	O
HBPS	B-MED
analyzed	O
differed	O
significantly	O
.	O
To	O
accurately	B-MED
compare	B-MED
hospital	B-MED
performance	B-MED
in	O
relation	B-MED
to	O
SSI	B-MED
following	O
HBPS	B-MED
,	O
the	O
operative	B-MED
procedure	I-MED
category	B-MED
in	O
the	O
surveillance	B-MED
system	I-MED
must	O
be	O
divided	B-MED
into	O
three	O
types	B-MED
.	O
Shared	B-MED
decision	I-MED
making	I-MED
in	O
the	O
UK	B-MED
:	O
Moving	O
towards	O
wider	O
uptake	O
Shared	B-MED
decision	I-MED
making	I-MED
(	O
SDM	B-MED
)	O
is	O
firmly	O
on	O
the	O
policy	B-MED
agenda	B-MED
in	O
the	O
UK	B-MED
and	O
a	O
recent	O
legal	B-MED
ruling	B-MED
has	O
confirmed	O
its	O
importance	O
.	O
Policymakers	B-MED
,	O
ethicists	B-MED
,	O
professional	B-MED
regulators	I-MED
and	O
societies	B-MED
,	O
patient	B-MED
organisations	I-MED
and	O
now	O
the	O
courts	B-MED
are	O
committed	O
to	O
ensuring	O
that	O
SDM	B-MED
becomes	O
the	O
norm	B-MED
throughout	O
the	O
NHS	B-MED
,	O
but	O
an	O
unfavourable	O
economic	B-MED
climate	I-MED
makes	O
this	O
especially	O
challenging	O
.	O
Considerable	O
progress	B-MED
has	O
been	O
made	O
over	O
the	O
last	O
few	O
years	B-MED
,	O
with	O
new	O
learning	B-MED
from	O
demonstration	B-MED
sites	B-MED
,	O
various	O
initiatives	B-MED
in	O
capacity	B-MED
building	I-MED
and	O
training	B-MED
,	O
wider	O
availability	O
of	O
patient	B-MED
decision	B-MED
aids	I-MED
,	O
and	O
important	O
leadership	B-MED
initiatives	B-MED
.	O
Enthusiasm	B-MED
for	O
this	O
way	O
of	O
working	B-MED
is	O
growing	O
among	O
clinicians	B-MED
,	O
patients	B-MED
and	O
managers	B-MED
,	O
but	O
it	O
could	O
be	O
undermined	O
if	O
SDM	B-MED
comes	O
to	O
be	O
seen	O
primarily	O
as	O
a	O
means	B-MED
of	O
cost	B-MED
control	I-MED
.	O
The	O
Silorane	B-MED
-	I-MED
based	I-MED
Resin	I-MED
Composites	I-MED
:	O
A	O
Review	B-MED
This	O
article	B-MED
aims	O
to	O
review	B-MED
the	O
research	B-MED
done	O
on	O
the	O
silorane	B-MED
-	I-MED
based	I-MED
resin	I-MED
composites	I-MED
(	O
SBRC	B-MED
)	O
regarding	O
polymerization	B-MED
shrinkage	B-MED
and	O
contraction	B-MED
stresses	I-MED
and	O
their	O
ability	O
to	O
improve	O
the	O
shortcomings	O
of	O
the	O
methacrylate	B-MED
-	I-MED
based	I-MED
resin	I-MED
composites	I-MED
(	O
MRBC	B-MED
)	O
.	O
Special	O
attention	O
is	O
given	O
to	O
their	O
physical	B-MED
and	O
mechanical	B-MED
properties	I-MED
,	O
bond	B-MED
strength	I-MED
,	O
marginal	B-MED
adaptation	I-MED
,	O
and	O
cusp	B-MED
deflection	I-MED
.	O
The	O
clinical	B-MED
significance	I-MED
of	O
this	O
material	B-MED
is	O
critically	O
appraised	O
with	O
a	O
focus	O
on	O
the	O
ability	O
of	O
SBRC	B-MED
to	O
strengthen	O
the	O
tooth	B-MED
structure	I-MED
as	O
a	O
direct	B-MED
restorative	I-MED
material	I-MED
.	O
A	O
search	O
of	O
English	B-MED
peer	B-MED
-	I-MED
reviewed	I-MED
dental	I-MED
literature	I-MED
(	O
2003	O
-	O
2015	O
)	O
from	O
PubMed	B-MED
and	O
MEDLINE	B-MED
databases	B-MED
was	O
conducted	O
with	O
the	O
terms	O
"	O
low	B-MED
shrinkage	B-MED
"	O
and	O
"	O
silorane	B-MED
composites	I-MED
.	O
"	O
The	O
list	O
was	O
screened	O
,	O
and	O
70	O
articles	B-MED
that	O
were	O
relevant	O
to	O
the	O
objectives	B-MED
of	O
this	O
work	O
were	O
included	O
.	O
Modulation	B-MED
of	O
Interleukins	B-MED
in	O
Sepsis	B-MED
-	O
Associated	B-MED
Clotting	B-MED
Disorders	I-MED
:	O
Interplay	O
With	O
Hemostatic	B-MED
Derangement	I-MED
Interleukins	B-MED
play	O
a	O
central	B-MED
role	B-MED
in	O
the	O
immune	B-MED
system	I-MED
and	O
are	O
involved	B-MED
in	O
a	O
variety	O
of	O
immunological	B-MED
,	O
inflammatory	B-MED
,	O
and	O
infectious	B-MED
disease	I-MED
states	B-MED
including	O
sepsis	B-MED
syndrome	I-MED
.	O
Levels	B-MED
of	O
interleukins	B-MED
may	O
correlate	B-MED
with	O
overall	B-MED
survival	I-MED
and	O
may	O
directly	B-MED
or	O
indirectly	B-MED
affect	B-MED
some	O
of	O
the	O
regulators	B-MED
of	O
coagulation	B-MED
and	O
fibrinolysis	B-MED
,	O
thereby	O
disrupting	O
hemostasis	B-MED
and	O
thrombosis	B-MED
.	O
Our	O
hypothesis	B-MED
is	O
that	O
in	O
sepsis	B-MED
-	I-MED
associated	I-MED
coagulopathies	I-MED
(	O
SACs	B-MED
)	O
,	O
interleukins	B-MED
may	O
be	O
upregulated	B-MED
,	O
leading	O
to	O
hemostatic	B-MED
imbalance	I-MED
by	O
generating	O
thrombogenic	B-MED
mediators	I-MED
.	O
We	O
profiled	B-MED
the	O
levels	B-MED
of	O
interleukins	B-MED
IL-1α	B-MED
,	O
IL-1β	B-MED
,	O
IL-2	B-MED
,	O
IL-4	B-MED
,	O
IL-6	B-MED
,	O
IL-8	B-MED
,	O
and	O
IL-10	B-MED
in	B-MED
addition	I-MED
to	I-MED
d	B-MED
-	I-MED
dimer	I-MED
(	O
DD	B-MED
)	O
in	O
patients	B-MED
with	O
SAC	B-MED
and	O
in	O
normal	B-MED
donors	B-MED
.	O
We	O
observed	B-MED
the	O
highest	B-MED
increase	B-MED
in	O
interleukins	B-MED
IL-6	B-MED
(	O
322	B-MED
-	I-MED
fold	I-MED
)	O
,	O
IL-8	B-MED
(	O
48	B-MED
-	I-MED
fold	I-MED
)	O
,	O
IL-10	B-MED
(	O
72	B-MED
-	I-MED
fold	I-MED
)	O
,	O
and	O
DD	B-MED
(	O
18	B-MED
-	I-MED
fold	I-MED
)	O
.	O
This	O
suggests	B-MED
that	O
interleukins	B-MED
such	O
as	O
IL-6	B-MED
and	O
IL-10	B-MED
have	O
a	O
close	O
association	B-MED
with	I-MED
coagulopathy	B-MED
and	O
fibrinolytic	B-MED
dysregulation	I-MED
in	O
sepsis	B-MED
and	O
can	O
be	O
considered	B-MED
as	O
candidates	B-MED
for	O
potential	B-MED
therapeutic	B-MED
targets	B-MED
in	O
SAC	B-MED
.	O
Transcriptome	B-MED
and	O
Metabolome	B-MED
Analyses	B-MED
of	O
Glucosinolates	B-MED
in	O
Two	O
Broccoli	B-MED
Cultivars	I-MED
Following	O
Jasmonate	B-MED
Treatment	B-MED
for	O
the	O
Induction	B-MED
of	O
Glucosinolate	B-MED
Defense	B-MED
to	O
Trichoplusia	B-MED
ni	I-MED
(	O
Hübner	B-MED
)	O
Lepidopteran	B-MED
larvae	B-MED
growth	B-MED
is	O
influenced	B-MED
by	O
host	B-MED
plant	B-MED
glucosinolate	B-MED
(	O
GS	B-MED
)	O
concentrations	B-MED
,	O
which	O
are	O
,	O
in	O
turn	O
,	O
influenced	B-MED
by	O
the	O
phytohormone	B-MED
jasmonate	B-MED
(	O
JA	B-MED
)	O
.	O
In	O
order	O
to	O
elucidate	O
insect	B-MED
resistance	B-MED
biomarkers	B-MED
to	O
lepidopteran	B-MED
pests	B-MED
,	O
transcriptome	B-MED
and	O
metabolome	B-MED
analyses	B-MED
following	O
JA	B-MED
treatments	B-MED
were	O
conducted	O
with	O
two	O
broccoli	B-MED
cultivars	I-MED
,	O
Green	B-MED
Magic	I-MED
and	O
VI-158	B-MED
,	O
which	O
have	O
differentially	O
induced	B-MED
indole	B-MED
GSs	I-MED
,	O
neoglucobrassicin	B-MED
and	O
glucobrassicin	B-MED
,	O
respectively	O
.	O
To	O
test	B-MED
these	O
two	O
inducible	B-MED
GSs	B-MED
on	O
growth	B-MED
of	O
cabbage	B-MED
looper	I-MED
(	O
Trichoplusia	B-MED
ni	I-MED
)	O
,	O
eight	O
neonate	O
cabbage	B-MED
looper	I-MED
larvae	I-MED
were	O
placed	O
onto	O
each	O
of	O
three	O
plants	B-MED
per	O
JA	B-MED
treatments	B-MED
(	O
0	O
,	O
100	O
,	O
200	O
,	O
400	O
µM	O
)	O
three	O
days	B-MED
after	O
treatment	B-MED
.	O
After	O
five	O
days	B-MED
of	O
feeding	B-MED
,	O
weight	B-MED
of	O
larvae	B-MED
and	O
their	O
survival	B-MED
rate	I-MED
was	O
found	O
to	O
decrease	B-MED
with	O
increasing	B-MED
JA	B-MED
concentrations	B-MED
in	O
both	O
broccoli	B-MED
cultivars	I-MED
.	O
JA	B-MED
-	O
inducible	B-MED
GSs	B-MED
were	O
measured	B-MED
by	O
high	B-MED
performance	I-MED
liquid	I-MED
chromatography	I-MED
.	O
Neoglucobrassicin	B-MED
in	O
Green	B-MED
Magic	I-MED
and	O
glucobrassicin	B-MED
in	O
VI-158	B-MED
leaves	B-MED
were	O
increased	B-MED
in	O
a	O
dose	B-MED
-	I-MED
dependent	I-MED
manner	O
.	O
One	O
or	O
both	O
of	O
these	O
glucosinolates	B-MED
and/or	O
their	O
hydrolysis	B-MED
products	B-MED
showed	O
significant	O
inverse	B-MED
correlations	B-MED
with	O
larval	B-MED
weight	B-MED
and	O
survival	B-MED
(	O
five	O
days	B-MED
after	O
treatment	B-MED
)	O
while	O
being	O
positively	B-MED
correlated	B-MED
with	O
the	O
number	O
of	O
days	B-MED
to	O
pupation	B-MED
.	O
This	O
implies	O
that	O
these	O
two	O
JA	B-MED
-	O
inducible	B-MED
glucosinolates	B-MED
can	O
influence	B-MED
the	O
growth	B-MED
and	O
survival	B-MED
of	O
cabbage	B-MED
looper	I-MED
larvae	I-MED
.	O
Transcriptome	B-MED
profiling	I-MED
supported	O
the	O
observed	O
changes	B-MED
in	O
glucosinolate	B-MED
and	O
their	O
hydrolysis	B-MED
product	B-MED
concentrations	B-MED
following	O
JA	B-MED
treatments	B-MED
.	O
Several	O
genes	B-MED
related	O
to	O
GS	B-MED
metabolism	B-MED
differentiate	B-MED
the	O
two	O
broccoli	B-MED
cultivars	I-MED
in	O
their	O
pattern	B-MED
of	O
transcriptional	B-MED
response	B-MED
to	O
JA	B-MED
treatments	B-MED
.	O
Indicative	O
of	O
the	O
corresponding	O
change	B-MED
in	O
indole	B-MED
GS	I-MED
concentrations	B-MED
,	O
transcripts	B-MED
of	O
the	O
transcription	B-MED
factor	I-MED
MYB122	B-MED
,	O
core	O
structure	O
biosynthesis	B-MED
genes	B-MED
(	O
CYP79B2	B-MED
,	O
UGT74B1	B-MED
,	O
SUR1	B-MED
,	O
SOT16	B-MED
,	O
SOT17	B-MED
,	O
and	O
SOT18	B-MED
)	O
,	O
an	O
indole	B-MED
glucosinolate	I-MED
side	O
chain	O
modification	B-MED
gene	B-MED
(	O
IGMT1	B-MED
)	O
,	O
and	O
several	O
glucosinolate	B-MED
hydrolysis	B-MED
genes	O
(	O
TGG1	B-MED
,	O
TGG2	B-MED
,	O
and	O
ESM1	B-MED
)	O
were	O
significantly	O
increased	B-MED
in	O
Green	B-MED
Magic	I-MED
(	O
statistically	O
significant	O
in	O
most	O
cases	O
at	O
400	O
µM	O
)	O
while	O
UGT74B1	B-MED
and	O
MYB122	B-MED
were	O
significantly	O
increased	B-MED
in	O
VI-158	B-MED
.	O
Therefore	O
,	O
these	O
metabolite	B-MED
and	O
transcript	B-MED
biomarker	B-MED
results	O
indicate	O
that	O
transcriptome	B-MED
profiling	I-MED
can	O
identify	B-MED
genes	B-MED
associated	O
with	O
the	O
formation	B-MED
of	O
two	O
different	O
indole	B-MED
GS	I-MED
and	O
their	O
hydrolysis	B-MED
products	B-MED
.	O
Therefore	O
,	O
these	O
metabolite	B-MED
and	O
transcript	B-MED
biomarkers	B-MED
could	O
be	O
useful	O
in	O
an	O
effective	B-MED
marker	B-MED
-	O
assisted	B-MED
breeding	B-MED
strategy	O
for	O
resistance	B-MED
to	O
generalist	O
lepidopteran	B-MED
pests	B-MED
in	O
broccoli	B-MED
and	O
potentially	O
other	O
Brassica	B-MED
vegetables	I-MED
.	O
Association	B-MED
of	O
prenatal	B-MED
and	O
early	O
life	O
exposure	B-MED
to	I-MED
tetrachloroethylene	B-MED
(	O
PCE	B-MED
)	O
with	O
polycystic	B-MED
ovary	I-MED
syndrome	I-MED
and	O
other	O
reproductive	B-MED
disorders	I-MED
in	O
the	O
cape	B-MED
cod	I-MED
health	B-MED
study	I-MED
:	O
A	O
retrospective	B-MED
cohort	I-MED
study	I-MED
Tetrachloroethylene	B-MED
(	O
PCE	B-MED
)	O
is	O
an	O
organic	B-MED
lipophilic	B-MED
solvent	B-MED
with	O
possible	O
neuroendocrine	B-MED
toxicity	B-MED
.	O
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	O
the	O
association	B-MED
of	O
prenatal	B-MED
and	O
early	B-MED
childhood	I-MED
exposure	B-MED
to	I-MED
PCE	B-MED
-	O
contaminated	B-MED
drinking	B-MED
water	I-MED
and	O
development	B-MED
of	O
adult	B-MED
-	I-MED
onset	I-MED
Polycystic	B-MED
Ovary	I-MED
Syndrome	I-MED
(	O
PCOS	B-MED
)	O
,	O
endometriosis	B-MED
,	O
difficulty	B-MED
conceiving	I-MED
and	O
miscarriage	B-MED
.	O
Five	O
-	O
hundred	O
exposed	B-MED
and	O
331	O
unexposed	B-MED
female	B-MED
participants	B-MED
born	O
between	O
1969	O
and	O
1983	O
completed	B-MED
questionnaires	B-MED
on	O
demographic	B-MED
and	O
lifestyle	B-MED
characteristics	B-MED
,	O
and	O
reproductive	B-MED
disorders	I-MED
.	O
Residential	B-MED
locations	I-MED
from	O
the	O
prenatal	B-MED
period	B-MED
through	O
five	O
years	O
of	O
age	B-MED
were	O
used	O
to	O
estimate	B-MED
early	O
life	O
PCE	B-MED
exposure	B-MED
with	O
water	B-MED
modeling	I-MED
software	I-MED
.	O
For	O
any	O
early	O
life	O
exposure	B-MED
to	I-MED
PCE	B-MED
,	O
the	O
adjusted	B-MED
risk	I-MED
ratio	I-MED
for	O
PCOS	B-MED
was	O
0.9	O
(	O
95	O
%	O
CI	B-MED
:	O
0.5	O
-	O
1.6	O
)	O
.	O
No	O
statistically	B-MED
significan	I-MED
t	O
associations	B-MED
were	O
observed	B-MED
for	O
increasing	B-MED
levels	B-MED
of	O
exposure	B-MED
with	O
PCOS	B-MED
or	O
the	O
other	O
reproductive	B-MED
disorders	I-MED
.	O
No	O
meaningful	O
associations	B-MED
were	O
found	B-MED
among	O
adult	B-MED
women	B-MED
with	O
early	O
life	O
exposure	B-MED
to	I-MED
PCE	B-MED
-	O
contaminated	B-MED
drinking	B-MED
water	I-MED
and	O
adult	B-MED
-	I-MED
onset	I-MED
reproductive	B-MED
disorders	I-MED
.	O
Association	B-MED
of	O
abdominal	B-MED
fat	I-MED
with	O
serum	B-MED
amylase	B-MED
in	O
an	O
older	B-MED
cohort	B-MED
:	O
The	O
Baltimore	B-MED
Longitudinal	B-MED
Study	I-MED
of	O
Aging	B-MED
Abdominal	B-MED
fat	I-MED
is	O
a	O
major	O
determinant	B-MED
of	O
metabolic	B-MED
diseases	I-MED
in	O
older	B-MED
individuals	B-MED
.	O
Obesity	B-MED
and	O
diabetes	B-MED
are	O
associated	B-MED
with	I-MED
low	B-MED
serum	B-MED
amylase	I-MED
(	I-MED
SA	I-MED
)	I-MED
levels	I-MED
,	O
but	O
the	O
association	B-MED
between	O
SA	B-MED
and	O
metabolic	B-MED
disease	I-MED
is	O
poorly	O
understood	O
.	O
We	O
investigated	B-MED
the	O
association	B-MED
of	O
low	B-MED
SA	B-MED
with	O
diabetes	B-MED
and	O
sex	B-MED
-	O
specific	B-MED
associations	B-MED
of	O
serum	B-MED
amylase	B-MED
with	O
abdominal	B-MED
fat	I-MED
in	O
older	B-MED
adults	I-MED
.	O
In	O
community	B-MED
-	I-MED
dwelling	I-MED
volunteers	B-MED
from	O
the	O
Baltimore	B-MED
Longitudinal	B-MED
Study	I-MED
of	O
Aging	B-MED
(	O
778	O
participants	B-MED
,	O
age	B-MED
66.8±13.6	O
years	B-MED
)	O
,	O
we	O
assessed	B-MED
abdominal	B-MED
fat	I-MED
by	O
computed	B-MED
tomography	I-MED
and	O
diabetes	B-MED
status	I-MED
using	O
the	O
American	B-MED
Diabetes	I-MED
Association	I-MED
criteria	B-MED
.	O
Linear	B-MED
regression	I-MED
analyses	I-MED
assessed	B-MED
the	O
cross	B-MED
-	I-MED
sectional	I-MED
associations	I-MED
between	O
abdominal	B-MED
fat	I-MED
and	O
SA	B-MED
,	O
and	O
logistic	B-MED
regression	I-MED
assessed	B-MED
the	O
odds	B-MED
of	O
diabetes	B-MED
,	O
given	O
low	B-MED
SA	B-MED
.	O
In	O
unadjusted	B-MED
analyses	I-MED
,	O
individuals	B-MED
in	O
the	O
lowest	B-MED
SA	B-MED
quartile	B-MED
(	O
<	O
48μ	O
/	O
L	O
)	O
had	O
1.97	O
greater	O
odds	B-MED
of	O
diabetes	B-MED
,	O
(	O
95	O
%	O
CI	B-MED
,	O
1.01	O
-	O
3.83	O
)	O
than	O
those	O
in	O
the	O
highest	O
quartile	B-MED
(	O
⩾80μ	O
/	O
L	O
)	O
.	O
This	O
association	B-MED
was	O
no	O
longer	O
significant	B-MED
after	O
adjusting	O
for	O
visceral	B-MED
adipose	I-MED
tissue	I-MED
area	I-MED
(	O
VAT	B-MED
,	O
dm(2	O
)	O
)	O
,	O
abdominal	B-MED
subcutaneous	I-MED
adipose	I-MED
tissue	I-MED
(	O
SAT	B-MED
,	O
dm(2	O
)	O
)	O
or	O
BMI	B-MED
.	O
In	O
adjusted	B-MED
analyses	I-MED
,	O
VAT	B-MED
and	O
SAT	B-MED
were	O
significantly	B-MED
associated	B-MED
with	I-MED
SA	B-MED
in	O
both	O
sexes	B-MED
.	O
Among	O
women	B-MED
,	O
SA	B-MED
was	O
more	O
strongly	O
associated	B-MED
with	I-MED
VAT	B-MED
than	O
with	O
SAT	B-MED
or	O
BMI	B-MED
;	O
VAT	B-MED
(	O
β=-0.117±0.048	O
,	O
P<0.001	O
)	O
,	O
SAT	B-MED
(	O
β=-0.023±0.025	O
,	O
P=0.346	O
)	O
and	O
BMI	B-MED
(	O
β=-0.0052±0.075	O
,	O
P=0.49	O
)	O
.	O
The	O
association	B-MED
between	O
SA	B-MED
and	O
diabetes	B-MED
was	O
explained	O
mainly	O
by	O
abdominal	B-MED
visceral	I-MED
fat	I-MED
.	O
In	O
women	B-MED
,	O
SA	B-MED
was	O
more	O
strongly	O
associated	B-MED
with	I-MED
VAT	B-MED
than	O
with	O
BMI	B-MED
or	O
SAT	B-MED
.	O
These	O
findings	O
provide	O
motivation	O
for	O
future	O
mechanistic	B-MED
studies	I-MED
on	O
SA	B-MED
's	I-MED
role	O
in	O
metabolic	B-MED
diseases	I-MED
.	O
Modified	B-MED
frailty	B-MED
index	I-MED
predicts	B-MED
postoperative	B-MED
outcomes	B-MED
in	O
older	B-MED
gastrointestinal	B-MED
cancer	I-MED
patients	B-MED
Frailty	B-MED
disproportionately	B-MED
impacts	B-MED
older	B-MED
patients	B-MED
with	O
gastrointestinal	B-MED
cancer	I-MED
,	O
rendering	B-MED
them	O
at	O
increased	B-MED
risk	I-MED
for	I-MED
poor	I-MED
outcomes	I-MED
.	O
A	O
frailty	B-MED
index	I-MED
may	O
aid	O
in	O
preoperative	B-MED
risk	B-MED
stratification	B-MED
.	O
We	O
hypothesized	B-MED
that	O
high	O
modified	B-MED
frailty	I-MED
index	I-MED
(	I-MED
mFI	I-MED
)	I-MED
scores	I-MED
are	O
associated	B-MED
with	I-MED
adverse	B-MED
outcomes	I-MED
after	O
tumor	B-MED
resection	B-MED
in	O
older	B-MED
,	O
gastrointestinal	B-MED
cancer	I-MED
patients	B-MED
.	O
Patients	B-MED
(	O
60	B-MED
-	I-MED
90	I-MED
years	I-MED
old	I-MED
)	O
who	O
underwent	B-MED
gastrointestinal	B-MED
tumor	I-MED
resection	I-MED
were	O
identified	B-MED
in	O
the	O
2005	O
-	O
2012	O
NSQIP	B-MED
Participant	B-MED
Use	O
File	O
.	O
mFI	B-MED
was	O
defined	O
by	O
11	O
previously	B-MED
described	B-MED
,	O
preoperative	B-MED
variables	B-MED
.	O
Frailty	B-MED
was	O
defined	O
by	O
an	O
mFI	B-MED
score	I-MED
>	O
0.27	O
.	O
The	O
postoperative	B-MED
course	I-MED
was	O
evaluated	B-MED
using	O
univariate	B-MED
and	O
multivariate	B-MED
analysis	I-MED
.	O
41	O
455	O
patients	B-MED
(	O
mean	O
age	O
72.4	O
years	O
,	O
47.4	O
%	O
female	B-MED
)	O
were	O
identified	B-MED
.	O
The	O
most	O
prevalent	B-MED
form	I-MED
of	O
cancer	B-MED
was	O
colorectal	B-MED
(	O
69.3	O
%	O
,	O
n	O
=	O
28	O
708	O
)	O
and	O
2.8	O
%	O
of	O
patients	B-MED
were	O
frail	B-MED
(	O
n	O
=	O
1,164	O
)	O
.	O
Frail	B-MED
patients	B-MED
were	O
significantly	B-MED
more	B-MED
likely	I-MED
to	O
have	O
increased	B-MED
length	I-MED
of	I-MED
stay	I-MED
(	O
11.7	O
vs	O
9.0	O
days	O
)	O
,	O
major	B-MED
complications	B-MED
(	O
29.1	O
%	O
vs	O
17.9	O
%	O
)	O
,	O
and	O
30	O
-	O
day	O
mortality	B-MED
(	O
5.6	O
%	O
vs	O
2.5	O
%	O
)	O
,	O
(	O
all	O
P	O
<	O
0.001	O
)	O
.	O
Multivariate	B-MED
analysis	I-MED
identified	B-MED
mFI	B-MED
as	O
an	O
independent	B-MED
predictor	B-MED
of	O
major	B-MED
complications	B-MED
(	O
OR	O
1.52	O
,	O
95%CI	O
1.39	O
-	O
1.65	O
,	O
P	O
<	O
0.001	O
)	O
and	O
30	O
-	O
day	O
mortality	B-MED
(	O
OR	O
1.48	O
,	O
95%CI	O
1.24	O
-	O
1.75	O
,	O
P	O
<	O
0.001	O
)	O
.	O
mFI	B-MED
was	O
associated	B-MED
with	I-MED
the	O
incidence	B-MED
of	O
postoperative	B-MED
complications	B-MED
and	O
mortality	B-MED
in	O
older	B-MED
surgical	B-MED
patients	I-MED
with	O
gastrointestinal	B-MED
cancer	I-MED
.	O
A	O
Novel	B-MED
Insulin	B-MED
/	I-MED
Glucose	I-MED
Model	B-MED
after	O
a	O
Mixed	B-MED
-	I-MED
Meal	I-MED
Test	I-MED
in	O
Patients	B-MED
with	O
Type	B-MED
1	I-MED
Diabetes	I-MED
on	O
Insulin	B-MED
Pump	I-MED
Therapy	B-MED
Current	B-MED
closed	B-MED
-	I-MED
loop	I-MED
insulin	I-MED
delivery	I-MED
methods	I-MED
stem	O
from	O
sophisticated	O
models	O
of	O
the	O
glucose	B-MED
-	I-MED
insulin	I-MED
(	I-MED
G	I-MED
/	I-MED
I	I-MED
)	I-MED
system	I-MED
,	O
mostly	B-MED
based	O
on	O
complex	B-MED
studies	B-MED
employing	B-MED
glucose	B-MED
tracer	I-MED
technology	I-MED
.	O
We	O
tested	B-MED
the	O
performance	B-MED
of	O
a	O
new	O
minimal	B-MED
model	I-MED
(	O
GLUKINSLOOP	B-MED
2.0	I-MED
)	O
of	O
the	O
G	B-MED
/	I-MED
I	I-MED
system	I-MED
to	O
characterize	B-MED
the	O
glucose	B-MED
and	I-MED
insulin	I-MED
dynamics	B-MED
during	O
multiple	B-MED
mixed	B-MED
meal	I-MED
tests	I-MED
(	O
MMT	B-MED
)	O
of	O
different	B-MED
sizes	B-MED
in	O
patients	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
(	O
T1D	B-MED
)	O
on	O
insulin	B-MED
pump	I-MED
therapy	B-MED
(	O
continuous	B-MED
subcutaneous	I-MED
insulin	I-MED
infusion	I-MED
,	O
CSII	B-MED
)	O
.	O
The	O
GLUKINSLOOP	B-MED
2.0	I-MED
identified	B-MED
the	O
G	B-MED
/	I-MED
I	I-MED
system	I-MED
,	O
provided	B-MED
a	O
close	O
fit	O
of	O
the	O
G	B-MED
/	I-MED
I	I-MED
time	B-MED
-	I-MED
courses	I-MED
and	O
showed	O
acceptable	B-MED
reproducibility	B-MED
of	O
the	O
G	B-MED
/	I-MED
I	I-MED
system	I-MED
parameters	B-MED
in	O
repeated	B-MED
studies	B-MED
of	O
identical	B-MED
and	O
double	B-MED
-	I-MED
sized	I-MED
MMTs	B-MED
.	O
This	O
model	B-MED
can	O
provide	B-MED
a	O
fairly	O
good	O
and	O
reproducible	O
description	B-MED
of	O
the	O
G	B-MED
/	I-MED
I	I-MED
system	I-MED
in	O
T1D	B-MED
patients	B-MED
on	O
CSII	B-MED
,	O
and	O
it	O
may	O
be	O
applied	B-MED
to	O
create	O
a	O
bank	O
of	O
"	B-MED
virtual	I-MED
"	I-MED
patients	I-MED
.	O
Our	O
results	B-MED
might	O
be	O
relevant	B-MED
at	O
improving	B-MED
the	O
architecture	O
of	O
upcoming	O
closed	B-MED
-	I-MED
loop	I-MED
CSII	B-MED
systems	O
.	O
A	O
Tractable	B-MED
Method	B-MED
for	O
Measuring	B-MED
Nanomaterial	B-MED
Risk	B-MED
Using	O
Bayesian	B-MED
Networks	I-MED
While	O
control	O
banding	B-MED
has	O
been	O
identified	O
as	O
a	O
suitable	O
framework	O
for	O
the	O
evaluation	B-MED
and	O
the	O
determination	O
of	O
potential	B-MED
human	B-MED
health	B-MED
risks	I-MED
associated	O
with	O
exposure	B-MED
to	I-MED
nanomaterials	B-MED
(	O
NMs	B-MED
)	O
,	O
the	O
approach	O
currently	O
lacks	O
any	O
implementation	B-MED
that	O
enjoys	O
widespread	O
support	O
.	O
Large	O
inconsistencies	O
in	O
characterisation	O
data	B-MED
,	O
toxicological	B-MED
measurements	B-MED
and	O
exposure	O
scenarios	O
make	O
it	O
difficult	O
to	O
map	O
and	O
compare	O
the	O
risk	B-MED
associated	O
with	O
NMs	B-MED
based	O
on	O
physicochemical	B-MED
data	B-MED
,	O
concentration	B-MED
and	O
exposure	B-MED
route	I-MED
.	O
Here	O
we	O
demonstrate	O
the	O
use	O
of	O
Bayesian	B-MED
networks	I-MED
as	O
a	O
reliable	O
tool	B-MED
for	O
NM	B-MED
risk	B-MED
estimation	O
.	O
This	O
tool	B-MED
is	O
tractable	B-MED
,	O
accessible	B-MED
and	O
scalable	B-MED
.	O
Most	O
importantly	O
,	O
it	O
captures	O
a	O
broad	O
span	O
of	O
data	B-MED
types	O
,	O
from	O
complete	O
,	O
high	O
quality	B-MED
data	B-MED
sets	I-MED
through	O
to	O
data	B-MED
sets	I-MED
with	O
missing	O
data	B-MED
and/or	O
values	B-MED
with	O
a	O
relatively	O
high	O
spread	O
of	O
probability	B-MED
distribution	I-MED
.	O
The	O
tool	B-MED
is	O
able	O
to	O
learn	O
iteratively	O
in	O
order	O
to	O
further	O
refine	O
forecasts	O
as	O
the	O
quality	B-MED
of	O
data	B-MED
available	O
improves	O
.	O
We	O
demonstrate	O
how	O
this	O
risk	B-MED
measurement	B-MED
approach	O
works	O
on	O
NMs	B-MED
with	O
varying	O
degrees	O
of	O
risk	B-MED
potential	B-MED
,	O
namely	O
,	O
carbon	B-MED
nanotubes	I-MED
,	O
silver	B-MED
and	O
titanium	B-MED
dioxide	I-MED
.	O
The	O
results	O
afford	O
even	O
non	B-MED
-	I-MED
experts	I-MED
an	O
accurate	O
picture	O
of	O
the	O
occupational	O
risk	B-MED
probabilities	O
associated	O
with	O
these	O
NMs	B-MED
and	O
,	O
in	O
doing	O
so	O
,	O
demonstrated	O
how	O
NM	B-MED
risk	B-MED
can	O
be	O
evaluated	B-MED
into	O
a	O
tractable	B-MED
,	O
quantitative	B-MED
risk	B-MED
comparator	O
.	O
Synchronisms	B-MED
between	O
bud	B-MED
and	O
cambium	B-MED
phenology	B-MED
in	O
black	B-MED
spruce	I-MED
:	O
early	B-MED
-	O
flushing	B-MED
provenances	B-MED
exhibit	O
early	B-MED
xylem	B-MED
formation	B-MED
Bud	B-MED
and	O
cambial	B-MED
phenology	B-MED
represent	B-MED
the	O
adaptation	B-MED
of	O
species	B-MED
to	O
the	O
local	B-MED
environment	B-MED
that	O
allows	O
the	O
growing	B-MED
season	I-MED
to	O
be	O
maximized	B-MED
while	O
minimizing	B-MED
the	O
risk	B-MED
of	O
frost	B-MED
for	O
the	O
developing	B-MED
tissues	B-MED
.	O
The	O
temporal	B-MED
relationship	B-MED
between	O
the	O
apical	B-MED
and	O
radial	B-MED
meristems	B-MED
can	O
help	O
in	O
the	O
understanding	O
of	O
tree	B-MED
growth	B-MED
growth	B-MED
as	O
a	O
whole	B-MED
process	B-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
compare	B-MED
cambial	B-MED
phenology	B-MED
in	O
black	B-MED
spruce	I-MED
(	O
Picea	B-MED
mariana	I-MED
(	O
Mill	O
.	O
)	O
B.S.P.	O
)	O
provenances	B-MED
classified	B-MED
as	O
early	B-MED
and	O
late	B-MED
bud	B-MED
flushing	B-MED
.	O
The	O
different	B-MED
phases	B-MED
of	O
cambial	B-MED
phenology	B-MED
were	O
assessed	B-MED
on	O
wood	B-MED
microcores	B-MED
sampled	B-MED
weekly	B-MED
from	O
April	O
to	O
October	O
in	O
2014	O
and	O
2015	O
from	O
61	O
trees	B-MED
growing	B-MED
in	O
a	O
provenance	B-MED
trial	I-MED
in	O
Quebec	B-MED
,	O
Canada	B-MED
.	O
Trees	B-MED
showing	O
an	O
early	B-MED
bud	B-MED
flush	B-MED
also	O
exhibited	O
early	B-MED
reactivation	B-MED
of	O
xylem	B-MED
differentiation	B-MED
,	O
although	O
an	O
average	B-MED
difference	B-MED
of	O
12	O
days	B-MED
for	O
buds	B-MED
corresponded	O
to	O
small	B-MED
although	O
significant	B-MED
differences	B-MED
of	O
4	O
days	B-MED
for	O
xylem	B-MED
.	O
Provenances	B-MED
with	O
early	B-MED
bud	B-MED
flush	B-MED
had	O
an	O
early	B-MED
bud	B-MED
set	O
and	O
completed	B-MED
xylem	B-MED
formation	B-MED
earlier	B-MED
than	O
late	B-MED
bud	B-MED
flush	B-MED
provenances	B-MED
.	O
No	B-MED
significant	I-MED
difference	B-MED
in	O
the	O
period	B-MED
of	O
xylem	B-MED
formation	B-MED
and	O
total	B-MED
growth	B-MED
growth	B-MED
was	O
observed	B-MED
between	O
the	O
flushing	B-MED
classes	O
.	O
Our	O
results	B-MED
demonstrate	O
that	O
the	O
ecotype	B-MED
differentiation	B-MED
of	O
black	B-MED
spruce	I-MED
provenances	B-MED
represented	O
by	O
the	O
phenological	B-MED
adaptation	B-MED
of	O
buds	B-MED
to	O
the	O
local	B-MED
climate	B-MED
corresponds	O
to	O
specific	B-MED
growth	B-MED
dynamics	B-MED
of	O
the	O
xylem	B-MED
.	O
Avulsions	B-MED
of	O
Triceps	B-MED
Brachii	I-MED
:	O
associated	O
injuries	B-MED
and	O
surgical	B-MED
treatment	I-MED
;	O
a	O
case	O
series	O
This	O
study	B-MED
reports	O
the	O
clinical	B-MED
presentations	I-MED
,	O
intra	B-MED
-operative	I-MED
findings	B-MED
,	O
type	O
of	O
the	O
treatments	B-MED
,	O
outcome	B-MED
of	O
the	O
treatment	B-MED
and	O
specially	O
associated	O
injuries	B-MED
in	O
patients	B-MED
with	O
the	O
avulsion	B-MED
of	O
the	O
distal	B-MED
end	I-MED
of	O
the	O
triceps	B-MED
brachii	I-MED
(	I-MED
TB	I-MED
)	I-MED
tendon	I-MED
.	O
We	O
studied	O
6	O
patients	B-MED
with	O
rupture	B-MED
or	O
avulsion	B-MED
of	O
the	O
distal	B-MED
end	I-MED
of	O
the	O
TB	B-MED
tendon	I-MED
.	O
The	O
medical	B-MED
records	I-MED
,	O
imaging	B-MED
files	I-MED
,	O
clinical	B-MED
outcomes	B-MED
at	O
the	O
final	O
follow	B-MED
up	I-MED
visit	I-MED
were	O
reviewed	O
.	O
The	O
clinical	B-MED
outcomes	B-MED
were	O
assessed	O
by	O
Mayo	B-MED
Elbow	I-MED
Score	I-MED
at	O
the	O
final	O
follow	B-MED
-	I-MED
up	I-MED
visit	I-MED
.	O
All	O
patients	B-MED
were	O
male	B-MED
,	O
4	O
of	O
them	O
having	O
injury	B-MED
in	O
the	O
left	B-MED
hand	I-MED
as	O
the	O
non	O
-	O
dominant	O
hand	B-MED
.	O
Mean	O
age	B-MED
of	O
them	O
was	O
34.5	O
years	B-MED
.	O
All	O
cases	O
had	O
small	O
bony	B-MED
fleck	B-MED
in	O
the	O
posterior	O
of	O
elbow	B-MED
in	O
lateral	B-MED
radiograph	I-MED
.	O
Three	O
patients	B-MED
had	O
associated	O
injuries	B-MED
-including	O
intra	B-MED
-	I-MED
articular	I-MED
fractures	B-MED
and	O
medial	B-MED
collateral	I-MED
ligament	I-MED
rupture	I-MED
.	O
In	O
one	O
case	O
V	B-MED
-	I-MED
Y	I-MED
plasty	I-MED
of	O
the	O
distal	B-MED
TB	B-MED
was	O
done	O
.	O
In	O
4	O
patients	B-MED
the	O
results	O
of	O
surgery	B-MED
were	O
excellent	O
,	O
one	O
was	O
good	O
and	O
one	O
was	O
fair	O
.	O
Although	O
TB	B-MED
tendon	I-MED
rupture	B-MED
is	O
rare	O
,	O
it	O
should	O
be	O
-considered	O
in	O
differential	O
diagnosis	B-MED
of	O
the	O
upper	B-MED
-extremity	I-MED
trauma	I-MED
and	O
its	O
associated	O
injuries	B-MED
should	O
be	O
addressed	O
properly	O
.	O
Serum	B-MED
levels	B-MED
of	O
genomic	B-MED
DNA	I-MED
of	O
α1(I	B-MED
)	I-MED
collagen	I-MED
are	O
elevated	B-MED
in	O
scleroderma	B-MED
patients	B-MED
Recent	O
studies	O
have	O
indicated	O
that	O
various	O
nucleic	B-MED
acids	I-MED
are	O
present	O
in	O
human	B-MED
sera	B-MED
,	O
and	O
attracted	O
attention	O
for	O
their	O
potential	O
as	O
novel	O
disease	B-MED
markers	I-MED
in	O
many	O
human	B-MED
diseases	B-MED
.	O
In	O
this	O
study	O
,	O
we	O
tried	O
to	O
evaluate	O
the	O
possibility	O
that	O
DNA	B-MED
and	O
RNA	B-MED
of	O
collagens	B-MED
exist	O
in	O
human	B-MED
sera	B-MED
,	O
and	O
determined	O
whether	O
their	O
serum	B-MED
levels	B-MED
can	O
be	O
useful	O
biomarkers	B-MED
in	O
scleroderma	B-MED
patients	B-MED
.	O
The	O
RNA	B-MED
or	O
DNA	B-MED
of	O
collagens	B-MED
were	O
purified	B-MED
from	O
sera	B-MED
,	O
and	O
detected	B-MED
by	O
polymerase	B-MED
chain	I-MED
reaction	I-MED
or	O
quantitated	B-MED
by	O
real	B-MED
-	I-MED
time	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
.	O
Among	O
approximately	O
18	O
360	B-MED
bases	I-MED
of	I-MED
full	I-MED
-	I-MED
length	I-MED
α1(I	I-MED
)	I-MED
collagen	I-MED
DNA	B-MED
,	O
various	O
regions	B-MED
were	O
detected	B-MED
by	O
polymerase	B-MED
chain	I-MED
reaction	I-MED
in	O
human	B-MED
sera	B-MED
.	O
However	O
,	O
α2(I	B-MED
)	I-MED
collagen	I-MED
DNA	B-MED
,	O
α1(I	B-MED
)	I-MED
collagen	I-MED
RNA	B-MED
or	O
α2(I	B-MED
)	I-MED
collagen	I-MED
RNA	B-MED
were	O
not	B-MED
detectable	I-MED
.	O
α1(I	B-MED
)	I-MED
Collagen	I-MED
DNA	B-MED
in	O
sera	B-MED
was	O
quantitative	B-MED
using	O
our	O
method	O
.	O
The	O
levels	B-MED
of	O
serum	B-MED
α1(I	B-MED
)	I-MED
collagen	I-MED
DNA	B-MED
were	O
significantly	O
increased	B-MED
in	O
scleroderma	B-MED
patients	B-MED
compared	O
with	O
healthy	B-MED
control	I-MED
subjects	B-MED
or	O
systemic	B-MED
lupus	I-MED
erythematosus	I-MED
patients	B-MED
.	O
According	O
to	O
the	O
receiver	B-MED
-	I-MED
operator	I-MED
curve	I-MED
analysis	I-MED
,	O
serum	B-MED
α1(I	B-MED
)	I-MED
collagen	I-MED
DNA	B-MED
levels	B-MED
were	O
shown	O
to	O
be	O
effective	O
as	O
a	O
diagnostic	B-MED
marker	I-MED
of	O
scleroderma	B-MED
.	O
Furthermore	O
,	O
when	O
we	O
determined	O
the	O
association	B-MED
of	O
serum	B-MED
α1(I	B-MED
)	I-MED
collagen	I-MED
DNA	B-MED
levels	B-MED
with	O
clinical	B-MED
/	O
laboratory	B-MED
features	B-MED
in	O
scleroderma	B-MED
patients	B-MED
,	O
those	O
with	O
elevated	B-MED
α1(I	B-MED
)	I-MED
collagen	I-MED
DNA	B-MED
levels	B-MED
showed	O
significantly	O
higher	O
prevalence	B-MED
of	O
pitting	B-MED
scars	I-MED
/	O
ulcers	B-MED
.	O
In	O
summary	O
,	O
elevation	B-MED
of	O
serum	B-MED
α1(I	B-MED
)	I-MED
collagen	I-MED
DNA	B-MED
levels	B-MED
in	O
scleroderma	B-MED
patients	B-MED
may	O
be	O
useful	O
as	O
the	O
diagnostic	B-MED
marker	I-MED
,	O
reflecting	O
the	O
presence	O
of	O
vasculopathy	B-MED
.	O
Jou	O
rna	B-MED
Intrinsic	B-MED
rifamycin	B-MED
resistance	B-MED
of	O
Mycobacterium	B-MED
abscessus	I-MED
is	O
mediated	O
by	O
ADP	B-MED
-	I-MED
ribosyltransferase	I-MED
MAB_0591	B-MED
Rifampicin	B-MED
,	O
a	O
potent	O
first	O
-	O
line	O
TB	B-MED
drug	I-MED
of	O
the	O
rifamycin	B-MED
group	I-MED
,	O
shows	O
only	O
little	O
activity	B-MED
against	O
the	O
emerging	O
pathogen	B-MED
Mycobacterium	B-MED
abscessus	I-MED
.	O
Reportedly	O
,	O
bacterial	B-MED
resistance	I-MED
to	O
rifampicin	B-MED
is	O
associated	O
with	O
polymorphisms	B-MED
in	O
the	O
target	O
gene	B-MED
rpoB	I-MED
or	O
the	O
presence	O
of	O
enzymes	B-MED
that	O
modify	O
and	O
thereby	O
inactivate	O
rifampicin	B-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
the	O
MAB_0591	B-MED
arrMab	B-MED
(	O
arrMab)-encoded	O
rifampicin	B-MED
ADP	B-MED
-	I-MED
ribosyltransferase	I-MED
(	O
Arr_Mab	B-MED
)	O
in	O
innate	O
high	O
-	O
level	O
rifampicin	B-MED
resistance	B-MED
in	O
M.	B-MED
abscessus	I-MED
.	O
Recombinant	B-MED
Escherichia	B-MED
coli	I-MED
and	O
Mycobacterium	B-MED
tuberculosis	I-MED
strains	B-MED
expressing	B-MED
MAB_0591	B-MED
were	O
generated	O
,	O
as	O
was	O
an	O
M.	B-MED
abscessus	I-MED
deletion	B-MED
mutant	I-MED
deficient	B-MED
for	O
MAB_0591	B-MED
.	O
MIC	B-MED
assays	I-MED
were	O
used	O
to	O
study	O
susceptibility	B-MED
to	O
rifampicin	B-MED
and	O
C25	B-MED
carbamate	I-MED
-modified	O
rifamycin	B-MED
derivatives	I-MED
.	O
Heterologous	B-MED
expression	B-MED
of	O
MAB_0591	B-MED
conferred	O
rifampicin	B-MED
resistance	B-MED
to	O
E.	B-MED
coli	I-MED
and	O
M.	B-MED
tuberculosis	I-MED
Rifamycin	B-MED
MIC	B-MED
values	I-MED
were	O
consistently	O
lower	O
for	O
the	O
M.	B-MED
abscessus	I-MED
ΔarrMab	B-MED
mutant	I-MED
as	O
compared	B-MED
with	O
the	O
M.	B-MED
abscessus	I-MED
ATCC	I-MED
19977	I-MED
parental	B-MED
type	I-MED
strain	I-MED
.	O
The	O
rifamycin	B-MED
WT	B-MED
phenotype	B-MED
was	O
restored	O
after	O
complementation	B-MED
of	O
the	O
M.	B-MED
abscessus	I-MED
ΔarrMab	B-MED
mutant	I-MED
with	O
arrMab	B-MED
Further	O
MIC	B-MED
data	I-MED
demonstrated	O
that	O
a	O
C25	B-MED
modification	B-MED
increases	O
rifamycin	B-MED
activity	B-MED
in	O
WT	B-MED
M.	B-MED
abscessus	I-MED
However	O
,	O
MIC	B-MED
studies	I-MED
in	O
the	O
M.	B-MED
abscessus	I-MED
ΔarrMab	B-MED
mutant	I-MED
suggest	O
that	O
C25	B-MED
modified	O
rifamycins	B-MED
are	O
still	O
subject	O
to	O
modification	B-MED
by	O
Arr_Mab	B-MED
CONCLUSIONS	O
:	O
Our	O
findings	O
identify	O
Arr_Mab	B-MED
as	O
the	O
major	O
innate	O
rifamycin	B-MED
resistance	B-MED
determinant	O
of	O
M.	B-MED
abscessus	I-MED
.	O
Our	O
data	O
also	O
indicate	O
that	O
Arr_Mab	B-MED
-mediated	O
rifamycin	B-MED
resistance	B-MED
in	O
M.	B-MED
abscessus	I-MED
can	O
only	O
in	O
part	O
be	O
overcome	O
by	O
C25	B-MED
carbamate	I-MED
modification	B-MED
.	O
Development	O
of	O
a	O
novel	B-MED
near	B-MED
-	I-MED
infrared	I-MED
fluorescent	B-MED
theranostic	B-MED
combretastain	B-MED
A-4	I-MED
analogue	B-MED
,	O
YK-5	B-MED
-	I-MED
252	I-MED
,	O
to	O
target	O
triple	B-MED
negative	I-MED
breast	I-MED
cancer	I-MED
The	O
treatment	B-MED
of	O
triple	B-MED
negative	I-MED
breast	I-MED
cancer	I-MED
(	O
TNBC	B-MED
)	O
is	O
a	O
significant	O
challenge	O
to	O
cancer	B-MED
research	I-MED
.	O
The	O
lack	O
of	O
hormone	B-MED
receptors	I-MED
limits	O
the	O
treatment	B-MED
options	O
available	O
to	O
patients	B-MED
with	O
this	O
diagnosis	B-MED
,	O
forcing	O
them	O
to	O
endure	O
prolonged	O
radiation	B-MED
and	O
chemotherapy	B-MED
.	O
Anti	B-MED
-	I-MED
angiogenesis	I-MED
is	O
a	O
chemotherapeutic	O
strategy	O
that	O
targets	O
the	O
vasculature	B-MED
of	O
tumors	B-MED
.	O
Combretastatin	B-MED
A-4	I-MED
(	O
CA-4	B-MED
)	O
is	O
a	O
well	O
-	O
known	O
vasculature	B-MED
-	O
disrupting	O
agent	O
,	O
which	O
has	O
been	O
shown	O
to	O
effectively	O
kill	O
a	O
variety	O
of	O
cancers	B-MED
through	O
inhibition	B-MED
of	O
tubulin	B-MED
polymerization	B-MED
.	O
Due	O
to	O
its	O
toxicity	B-MED
,	O
small	O
molecule	O
analogues	B-MED
of	O
CA-4	B-MED
have	O
been	O
sought	O
out	O
.	O
We	O
have	O
designed	O
a	O
novel	B-MED
dual	O
action	O
CA-4	B-MED
prodrug	B-MED
,	O
YK-5	B-MED
-	I-MED
252	I-MED
,	O
which	O
releases	O
the	O
drug	B-MED
through	O
a	O
disulfide	B-MED
bond	I-MED
cleavage	B-MED
mechanism	B-MED
and	O
contains	O
a	O
near	B-MED
-	I-MED
infrared	I-MED
(	O
NIR	B-MED
)	O
fluorophore	B-MED
,	O
which	O
allows	O
fluorescence	B-MED
monitoring	O
of	O
cleavage	B-MED
.	O
This	O
disulfide	B-MED
linkage	I-MED
causes	O
CA-4	B-MED
to	O
become	O
effective	O
only	O
when	O
released	O
by	O
glutathione	B-MED
(	O
GSH	B-MED
)	O
reducing	O
the	O
toxicity	B-MED
of	O
the	O
drug	B-MED
while	O
simultaneously	O
releasing	O
the	O
NIR	B-MED
fluorophore	B-MED
.	O
Therefore	O
the	O
prodrug	B-MED
,	O
YK-5	B-MED
-	I-MED
252	I-MED
,	O
represents	O
a	O
novel	B-MED
CA-4	B-MED
analogue	B-MED
which	O
has	O
reduced	O
toxicity	B-MED
and	O
can	O
be	O
used	O
for	O
theranostics	B-MED
imaging	B-MED
.	O
MagR	B-MED
Alone	O
Is	O
Insufficient	B-MED
to	O
Confer	O
Cellular	B-MED
Calcium	I-MED
Responses	I-MED
to	O
Magnetic	B-MED
Stimulation	B-MED
Magnetic	B-MED
manipulation	B-MED
of	O
cell	B-MED
activity	I-MED
offers	O
advantages	B-MED
over	O
optical	B-MED
manipulation	I-MED
but	O
an	O
ideal	O
tool	O
remains	O
elusive	O
.	O
The	O
MagR	B-MED
protein	I-MED
was	O
found	O
through	O
its	O
interaction	B-MED
with	O
cryptochrome	B-MED
(	O
Cry	B-MED
)	O
and	O
the	O
protein	B-MED
in	O
solution	B-MED
appeared	O
to	O
respond	B-MED
to	O
magnetic	B-MED
stimulation	B-MED
(	O
MS	B-MED
)	O
.	O
After	O
we	O
initiated	O
an	O
investigation	B-MED
on	O
the	O
specific	O
role	B-MED
of	O
MagR	B-MED
in	O
cellular	B-MED
response	I-MED
to	O
MS	B-MED
,	O
a	O
subsequent	O
study	B-MED
claimed	O
that	O
MagR	B-MED
expression	B-MED
alone	O
could	O
achieve	O
cellular	B-MED
activation	I-MED
by	O
MS	B-MED
.	O
Here	O
we	O
report	O
that	O
despite	O
systematically	B-MED
testing	B-MED
different	O
ways	O
of	O
measuring	B-MED
intracellular	B-MED
calcium	B-MED
and	O
different	O
MS	B-MED
protocols	B-MED
,	O
it	O
was	O
not	O
possible	O
to	O
detect	B-MED
any	O
cellular	B-MED
or	O
neuronal	B-MED
responses	B-MED
to	O
MS	B-MED
in	O
MagR	B-MED
-	O
expressing	B-MED
HEK	B-MED
cells	I-MED
or	O
primary	B-MED
neurons	B-MED
from	O
the	O
dorsal	B-MED
root	B-MED
ganglion	I-MED
and	O
the	O
hippocampus	B-MED
.	O
By	O
contrast	O
,	O
in	O
neurons	B-MED
co	B-MED
-	I-MED
expressing	I-MED
MagR	B-MED
and	O
channelrhodopin	B-MED
,	O
optical	B-MED
but	O
not	O
MS	B-MED
increased	B-MED
calcium	B-MED
influx	I-MED
in	O
hippocampal	B-MED
neurons	B-MED
.	O
Our	O
results	O
indicate	O
that	O
MagR	B-MED
alone	O
is	O
not	B-MED
sufficient	I-MED
to	O
confer	O
cellular	B-MED
magnetic	B-MED
responses	I-MED
.	O
Pulmonary	B-MED
function	I-MED
and	O
health	B-MED
-	I-MED
related	I-MED
quality	I-MED
of	I-MED
life	I-MED
1-	O
year	B-MED
follow	B-MED
up	I-MED
after	O
cardiac	B-MED
surgery	I-MED
Pulmonary	B-MED
function	I-MED
is	O
severely	B-MED
reduced	B-MED
in	O
the	O
early	B-MED
period	B-MED
after	O
cardiac	B-MED
surgery	I-MED
,	O
and	O
impairments	B-MED
have	O
been	O
described	O
up	O
to	O
4	O
-	O
6	O
months	B-MED
after	B-MED
surgery	I-MED
.	O
Evaluation	B-MED
of	O
pulmonary	B-MED
function	I-MED
in	O
a	O
longer	O
perspective	O
is	O
lacking	B-MED
.	O
In	O
this	O
prospective	B-MED
study	I-MED
pulmonary	B-MED
function	I-MED
and	O
health	B-MED
-	I-MED
related	I-MED
quality	I-MED
of	I-MED
life	I-MED
were	O
investigated	B-MED
1	O
year	B-MED
after	O
cardiac	B-MED
surgery	I-MED
.	O
Pulmonary	B-MED
function	I-MED
measurements	B-MED
,	O
health	B-MED
-	I-MED
related	I-MED
quality	I-MED
of	I-MED
life	I-MED
(	O
SF-36	B-MED
)	O
,	O
dyspnoea	B-MED
,	O
subjective	B-MED
breathing	B-MED
and	O
coughing	B-MED
ability	B-MED
and	O
pain	B-MED
were	O
evaluated	B-MED
before	B-MED
and	O
1	O
year	B-MED
after	B-MED
surgery	I-MED
in	O
150	O
patients	B-MED
undergoing	O
coronary	B-MED
artery	I-MED
bypass	I-MED
grafting	I-MED
,	O
valve	B-MED
surgery	I-MED
or	O
combined	O
surgery	B-MED
.	O
One	O
year	B-MED
after	B-MED
surgery	I-MED
the	O
forced	B-MED
vital	I-MED
capacity	I-MED
and	O
forced	B-MED
expiratory	I-MED
volume	I-MED
in	O
1	O
s	O
were	O
significantly	O
decreased	B-MED
(	O
by	O
4	O
-	O
5	O
%	O
)	O
compared	B-MED
to	O
preoperative	B-MED
values	B-MED
(	O
p	O
<	O
0.05	O
)	O
.	O
Saturation	B-MED
of	I-MED
peripheral	I-MED
oxygen	I-MED
was	O
unchanged	B-MED
1	O
year	B-MED
postoperatively	B-MED
compared	B-MED
to	O
baseline	B-MED
.	O
A	O
significantly	O
improved	B-MED
health	B-MED
-	I-MED
related	I-MED
quality	I-MED
of	I-MED
life	I-MED
was	O
found	O
1	O
year	B-MED
after	B-MED
surgery	I-MED
,	O
with	O
improvements	B-MED
in	O
all	O
eight	O
aspects	B-MED
of	O
SF-36	B-MED
(	O
p	O
<	O
0.001	O
)	O
.	O
Sternotomy	B-MED
-related	O
pain	B-MED
was	O
low	B-MED
1	O
year	B-MED
postoperatively	B-MED
at	B-MED
rest	I-MED
(	O
median	O
0	O
[	O
min	O
-	O
max	O
;	O
0	O
-	O
7	O
]	O
)	O
,	O
while	O
taking	O
a	O
deep	B-MED
breath	I-MED
(	O
0	O
[	O
0	O
-	O
4	O
]	O
)	O
and	O
while	O
coughing	B-MED
(	O
0	O
[	O
0	O
-	O
8	O
]	O
)	O
.	O
A	O
more	O
pronounced	O
decrease	O
in	O
pulmonary	B-MED
function	I-MED
was	O
associated	B-MED
with	I-MED
dyspnoea	B-MED
limitations	B-MED
and	O
impaired	B-MED
subjective	B-MED
breathing	B-MED
and	O
coughing	B-MED
ability	B-MED
.	O
One	O
year	B-MED
after	O
cardiac	B-MED
surgery	I-MED
static	B-MED
and	O
dynamic	B-MED
lung	B-MED
function	I-MED
measurements	I-MED
were	O
slightly	O
decreased	B-MED
,	O
while	O
health	B-MED
-	I-MED
related	I-MED
quality	I-MED
of	I-MED
life	I-MED
was	O
improved	B-MED
in	O
comparison	B-MED
to	O
preoperative	B-MED
values	B-MED
.	O
Measured	B-MED
levels	B-MED
of	O
pain	B-MED
were	O
low	B-MED
and	O
saturation	B-MED
of	I-MED
peripheral	I-MED
oxygen	I-MED
was	O
same	B-MED
as	O
preoperatively	B-MED
.	O
A	O
systematic	B-MED
review	I-MED
investigating	B-MED
psychosocial	B-MED
aspects	I-MED
of	O
egg	B-MED
sharing	I-MED
in	O
the	O
United	B-MED
Kingdom	I-MED
and	O
their	O
potential	B-MED
effects	B-MED
on	O
egg	B-MED
donation	I-MED
numbers	B-MED
This	O
review	B-MED
aims	O
to	O
provide	O
an	O
up	O
-	O
to	O
-	O
date	O
knowledge	B-MED
of	O
the	O
psychosocial	B-MED
aspects	I-MED
of	O
egg	B-MED
donation	I-MED
from	O
the	O
perspectives	O
of	O
the	O
egg	B-MED
share	I-MED
donor	I-MED
and	O
their	O
recipient	B-MED
.	O
It	O
explores	O
the	O
motives	B-MED
,	O
experiences	B-MED
and	O
attitudes	B-MED
of	O
egg	B-MED
sharers	I-MED
and	O
their	O
views	O
towards	O
donor	B-MED
anonymity	B-MED
and	O
disclosure	B-MED
.	O
Conclusions	B-MED
are	O
made	O
on	O
how	O
these	O
findings	B-MED
can	O
guide	B-MED
clinical	I-MED
practice	I-MED
and	O
improve	O
egg	B-MED
sharing	I-MED
numbers	B-MED
.	O
A	O
systematic	B-MED
search	B-MED
of	O
peer	B-MED
-	I-MED
reviewed	I-MED
journals	I-MED
of	O
four	O
computerized	B-MED
databases	I-MED
was	O
undertaken	O
.	O
Eleven	O
studies	B-MED
were	O
included	O
in	O
the	O
review	B-MED
.	O
Psychosocial	B-MED
aspects	I-MED
towards	O
donation	B-MED
were	O
positive	B-MED
from	O
the	O
egg	B-MED
share	I-MED
donor	I-MED
and	O
recipient	B-MED
.	O
Concerns	B-MED
raised	B-MED
were	O
whether	O
participating	B-MED
in	O
the	O
egg	B-MED
sharing	I-MED
scheme	B-MED
would	O
impact	B-MED
on	O
their	O
success	B-MED
rates	B-MED
,	O
as	O
well	O
as	O
frustration	B-MED
expressed	B-MED
by	O
a	O
minority	B-MED
regarding	O
the	O
lack	B-MED
of	I-MED
knowledge	I-MED
of	O
egg	B-MED
sharing	I-MED
outside	O
of	O
fertility	B-MED
clinics	B-MED
.	O
The	O
2005	O
legislative	B-MED
changes	B-MED
in	O
the	O
UK	B-MED
have	O
not	O
caused	O
the	O
anticipated	O
dramatic	O
decrease	B-MED
in	O
egg	B-MED
donation	I-MED
;	O
however	O
,	O
oocyte	B-MED
donation	I-MED
still	O
falls	O
short	O
of	O
demand	B-MED
.	O
Egg	B-MED
sharing	I-MED
provides	O
a	O
practical	B-MED
option	I-MED
for	O
more	O
patients	B-MED
to	O
access	B-MED
IVF	B-MED
,	O
whilst	O
also	O
providing	O
more	O
donor	B-MED
oocytes	I-MED
.	O
Improved	O
information	B-MED
provision	I-MED
will	O
result	B-MED
in	O
greater	O
awareness	B-MED
of	O
egg	B-MED
sharing	I-MED
,	O
with	O
the	O
potential	B-MED
to	O
recruit	B-MED
more	O
donors	O
and	O
meet	B-MED
the	O
needs	O
of	O
recipients	B-MED
currently	B-MED
on	O
long	O
waiting	B-MED
lists	I-MED
.	O
Incontinence	B-MED
-associated	O
dermatitis	B-MED
:	O
reducing	B-MED
adverse	B-MED
events	I-MED
Incontinence	B-MED
-associated	O
dermatitis	B-MED
(	O
IAD	B-MED
)	O
is	O
a	O
common	O
problem	B-MED
in	O
patients	B-MED
with	O
faecal	B-MED
and/or	O
urinary	B-MED
incontinence	I-MED
.	O
Urine	B-MED
alters	O
the	O
normal	O
skin	B-MED
flora	B-MED
and	O
increases	O
permeability	B-MED
of	O
the	O
stratum	B-MED
corneum	I-MED
and	O
faecal	B-MED
enzymes	B-MED
on	O
the	O
skin	B-MED
contribute	O
to	O
skin	B-MED
damage	I-MED
.	O
Faecal	B-MED
bacteria	B-MED
can	O
then	O
penetrate	B-MED
the	O
skin	B-MED
,	O
increasing	O
the	O
risk	B-MED
of	O
secondary	B-MED
infection	I-MED
.	O
However	O
,	O
IAD	B-MED
can	O
be	O
prevented	B-MED
and	O
healed	B-MED
with	O
timely	O
and	O
appropriate	B-MED
skin	B-MED
cleansing	I-MED
and	O
skin	B-MED
protection	I-MED
.	O
This	O
includes	O
appropriate	B-MED
use	O
of	O
containment	B-MED
devices	I-MED
.	O
This	O
article	O
also	O
looks	O
at	O
HARTMANN	B-MED
incontinence	I-MED
pads	I-MED
that	O
have	O
been	O
developed	O
to	O
absorb	O
the	O
fluids	B-MED
that	O
cause	O
IAD	B-MED
and	O
maintain	O
the	O
skin	B-MED
's	I-MED
acidic	B-MED
pH	I-MED
pH.	O
The	O
acidic	B-MED
pH	I-MED
of	O
the	O
skin	B-MED
contributes	O
to	O
its	O
barrier	B-MED
function	I-MED
and	O
defence	O
against	O
infection	B-MED
.	O
Therefore	O
,	O
maintaining	O
an	O
acidic	B-MED
pH	I-MED
will	O
help	O
protect	O
the	O
skin	B-MED
from	O
damage	B-MED
.	O
Physiological	B-MED
Properties	B-MED
and	O
Behavioral	B-MED
Correlates	B-MED
of	O
Hippocampal	B-MED
Granule	B-MED
Cells	I-MED
and	O
Mossy	B-MED
Cells	I-MED
The	O
hippocampal	B-MED
dentate	B-MED
gyrus	I-MED
is	O
often	O
viewed	O
as	O
a	O
segregator	B-MED
of	O
upstream	B-MED
information	I-MED
.	O
Physiological	B-MED
support	I-MED
for	O
such	O
function	B-MED
has	O
been	O
hampered	O
by	O
a	O
lack	B-MED
of	O
well	B-MED
-	I-MED
defined	I-MED
characteristics	B-MED
that	O
can	O
identify	O
granule	B-MED
cells	I-MED
and	O
mossy	B-MED
cells	I-MED
.	O
We	O
developed	O
an	O
electrophysiology	B-MED
-based	O
classification	B-MED
of	O
dentate	B-MED
granule	B-MED
cells	I-MED
and	O
mossy	B-MED
cells	I-MED
in	O
mice	B-MED
that	O
we	O
validated	O
by	O
optogenetic	B-MED
tagging	I-MED
of	O
mossy	B-MED
cells	I-MED
.	O
Granule	B-MED
cells	I-MED
exhibited	O
sparse	O
firing	B-MED
,	O
had	O
a	O
single	B-MED
place	B-MED
field	I-MED
,	O
and	O
showed	O
only	O
modest	O
changes	B-MED
when	O
the	O
mouse	B-MED
was	O
tested	B-MED
in	O
different	O
mazes	B-MED
in	O
the	O
same	O
room	B-MED
.	O
In	O
contrast	O
,	O
mossy	B-MED
cells	I-MED
were	O
more	O
active	B-MED
,	O
had	O
multiple	B-MED
place	B-MED
fields	I-MED
and	O
showed	O
stronger	O
remapping	O
of	O
place	B-MED
fields	I-MED
under	O
the	O
same	O
conditions	B-MED
.	O
Although	O
the	O
granule	B-MED
cell	I-MED
-	O
mossy	B-MED
cell	I-MED
synapse	B-MED
was	O
strong	O
and	O
facilitating	O
,	O
mossy	B-MED
cells	I-MED
rarely	O
"	O
inherited	O
"	O
place	B-MED
fields	I-MED
from	O
single	B-MED
granule	B-MED
cells	I-MED
.	O
Our	O
findings	B-MED
suggest	O
that	O
the	O
granule	B-MED
cells	I-MED
and	O
mossy	B-MED
cells	I-MED
could	O
be	O
modulated	B-MED
separately	O
and	O
their	O
joint	O
action	B-MED
may	O
be	O
critical	O
for	O
pattern	B-MED
separation	I-MED
.	O
The	O
2016	O
Infusion	B-MED
Therapy	I-MED
Standards	B-MED
of	O
Practice	B-MED
Approximately	O
every	O
5	O
years	O
,	O
the	O
Infusion	B-MED
Nurses	I-MED
Society	I-MED
publishes	B-MED
evidence	B-MED
-	I-MED
based	I-MED
practice	I-MED
standards	B-MED
.	O
This	O
article	B-MED
provides	O
an	O
overview	O
of	O
the	O
process	B-MED
used	B-MED
in	O
standards	B-MED
development	B-MED
,	O
describes	O
the	O
format	B-MED
of	O
the	O
standards	B-MED
,	O
and	O
provides	B-MED
a	O
short	O
summary	B-MED
of	O
selected	B-MED
standards	B-MED
as	O
applied	B-MED
to	O
home	B-MED
care	I-MED
.	O
The	O
Standards	B-MED
are	O
an	O
important	B-MED
document	B-MED
that	O
should	O
be	O
available	B-MED
to	O
every	B-MED
home	B-MED
care	I-MED
organization	B-MED
that	O
provides	B-MED
home	B-MED
infusion	I-MED
therapy	I-MED
.	O
Executive	B-MED
functions	I-MED
deficits	B-MED
impair	B-MED
extinction	B-MED
of	O
generalization	B-MED
of	O
fear	B-MED
of	O
movement	B-MED
-	I-MED
related	I-MED
pain	I-MED
Generalization	B-MED
of	O
fear	B-MED
of	O
movement	B-MED
-	I-MED
related	I-MED
pain	I-MED
across	O
novel	O
but	O
similar	O
movements	B-MED
can	O
lead	O
to	O
fear	B-MED
responses	I-MED
to	O
movements	B-MED
that	O
are	O
actually	O
not	O
associated	B-MED
with	I-MED
pain	B-MED
.	O
The	O
peak	B-MED
-	I-MED
shift	I-MED
effect	I-MED
describes	O
a	O
phenomenon	B-MED
whereby	O
particular	O
novel	O
movements	B-MED
elicit	B-MED
even	O
greater	O
fear	B-MED
responses	I-MED
than	O
the	O
original	O
pain	B-MED
-	I-MED
provoking	I-MED
movement	B-MED
(	O
CS+	B-MED
)	O
,	O
because	O
they	O
represent	O
a	O
more	O
extreme	O
version	O
of	O
the	O
CS+	B-MED
.	O
There	O
is	O
great	O
variance	B-MED
in	O
the	O
propensity	O
to	O
generalize	B-MED
as	O
well	O
as	O
the	O
speed	O
of	O
extinction	B-MED
learning	I-MED
when	O
these	O
novel	O
movements	B-MED
are	O
not	O
followed	O
by	O
pain	B-MED
.	O
It	O
can	O
be	O
argued	O
that	O
this	O
variance	B-MED
may	O
be	O
associated	B-MED
with	I-MED
executive	B-MED
function	I-MED
capacity	I-MED
,	O
as	O
individuals	B-MED
may	O
be	O
unable	O
to	O
intentionally	O
inhibit	B-MED
fear	I-MED
responses	I-MED
.	O
This	O
study	O
examined	B-MED
whether	O
executive	B-MED
function	I-MED
capacity	I-MED
contributes	O
to	O
generalization	B-MED
and	O
extinction	B-MED
of	O
generalization	B-MED
as	O
well	O
as	O
peak	B-MED
-	I-MED
shift	I-MED
of	O
conditioned	B-MED
fear	I-MED
of	O
movement	B-MED
-	I-MED
related	I-MED
pain	I-MED
and	O
expectancy	B-MED
.	O
Healthy	B-MED
participants	I-MED
performed	O
a	O
proprioceptive	B-MED
fear	B-MED
conditioning	I-MED
task	I-MED
.	O
Executive	B-MED
function	I-MED
tests	I-MED
assessing	O
updating	B-MED
,	O
switching	O
,	O
and	O
inhibition	B-MED
were	O
used	O
to	O
predict	O
changes	O
in	O
(	O
extinction	B-MED
of	O
)	O
fear	B-MED
of	O
movement	B-MED
-	I-MED
related	I-MED
pain	I-MED
and	O
pain	B-MED
expectancy	B-MED
generalization	B-MED
.	O
Low	B-MED
inhibitory	I-MED
capacity	I-MED
was	O
associated	B-MED
with	I-MED
slower	O
extinction	B-MED
of	O
generalized	B-MED
fear	I-MED
of	O
movement	B-MED
-	I-MED
related	I-MED
pain	I-MED
and	O
pain	B-MED
expectancy	B-MED
.	O
Evidence	O
was	O
found	O
in	O
favor	O
of	O
an	O
area	B-MED
-	I-MED
shift	I-MED
,	O
rather	O
than	O
a	O
peak	B-MED
-	I-MED
shift	I-MED
effect	I-MED
,	O
which	O
implies	O
that	O
the	O
peak	B-MED
conditioned	B-MED
fear	I-MED
response	I-MED
extended	O
to	O
,	O
but	O
did	O
not	O
shift	O
to	O
a	O
novel	O
stimulus	B-MED
.	O
Participants	B-MED
with	O
low	O
inhibitory	B-MED
capacity	I-MED
may	O
have	O
difficulties	O
withholding	O
fear	B-MED
responses	I-MED
,	O
leading	O
to	O
a	O
slower	O
decrease	O
of	O
generalized	B-MED
fear	I-MED
over	O
time	B-MED
.	O
The	O
findings	B-MED
may	O
be	O
relevant	O
to	O
inform	O
treatments	B-MED
.	O
Low	B-MED
inhibitory	I-MED
capacity	I-MED
is	O
not	O
associated	B-MED
with	I-MED
slower	O
generalization	B-MED
,	O
but	O
extinction	B-MED
of	O
fear	B-MED
generalization	B-MED
.	O
Fear	B-MED
elicited	B-MED
by	I-MED
a	O
novel	O
safe	O
movement	B-MED
,	O
situated	O
outside	O
the	O
CS+/-	B-MED
continuum	O
on	O
the	O
CS+	B-MED
side	O
,	O
can	O
be	O
as	O
strong	O
as	O
to	O
the	O
original	O
stimulus	B-MED
predicting	O
the	O
pain	B-MED
-	I-MED
onset	I-MED
.	O
Chronic	B-MED
exposure	I-MED
to	I-MED
haloperidol	B-MED
and	O
olanzapine	B-MED
leads	O
to	O
common	O
and	O
divergent	O
shape	B-MED
changes	I-MED
in	O
the	O
rat	B-MED
hippocampus	B-MED
in	O
the	O
absence	O
of	O
grey	B-MED
-	I-MED
matter	I-MED
volume	B-MED
loss	I-MED
One	O
of	O
the	O
most	O
consistently	O
reported	O
brain	B-MED
abnormalities	I-MED
in	O
schizophrenia	B-MED
(	O
SCZ	B-MED
)	O
is	O
decreased	O
volume	B-MED
and	I-MED
shape	I-MED
deformation	I-MED
of	O
the	O
hippocampus	B-MED
.	O
However	O
,	O
the	O
potential	O
contribution	O
of	O
chronic	B-MED
antipsychotic	I-MED
medication	I-MED
exposure	B-MED
to	O
these	O
phenomena	O
remains	O
unclear	O
.	O
We	O
examined	O
the	O
effect	O
of	O
chronic	B-MED
exposure	I-MED
(	O
8	O
weeks	O
)	O
to	O
clinically	O
relevant	B-MED
doses	I-MED
of	O
either	O
haloperidol	B-MED
(	O
HAL	B-MED
)	O
or	O
olanzapine	B-MED
(	O
OLZ	B-MED
)	O
on	O
adult	O
rat	B-MED
hippocampal	B-MED
volume	B-MED
and	I-MED
shape	I-MED
using	O
ex	B-MED
vivo	I-MED
structural	B-MED
MRI	I-MED
with	O
the	O
brain	B-MED
retained	I-MED
inside	I-MED
the	I-MED
cranium	I-MED
to	O
prevent	O
distortions	B-MED
due	O
to	O
dissection	B-MED
,	O
followed	O
by	O
tensor	B-MED
-	I-MED
based	I-MED
morphometry	I-MED
(	O
TBM	B-MED
)	O
and	O
elastic	B-MED
surface	I-MED
-	I-MED
based	I-MED
shape	I-MED
deformation	I-MED
analysis	I-MED
.	O
The	O
volume	O
of	O
the	O
hippocampus	B-MED
was	O
also	O
measured	O
post	B-MED
-	I-MED
mortem	I-MED
from	O
brain	B-MED
tissue	I-MED
sections	O
in	O
each	O
group	O
.	O
Chronic	B-MED
exposure	I-MED
to	O
either	O
HAL	B-MED
or	O
OLZ	B-MED
had	O
no	O
effect	O
on	O
the	O
volume	O
of	O
the	O
hippocampus	B-MED
,	O
even	O
at	O
exploratory	B-MED
thresholds	I-MED
,	O
which	O
was	O
confirmed	O
post	B-MED
-	I-MED
mortem	I-MED
.	O
In	O
contrast	O
,	O
shape	B-MED
deformation	I-MED
analysis	I-MED
revealed	O
that	O
chronic	O
HAL	B-MED
and	O
OLZ	B-MED
exposure	B-MED
lead	O
to	O
both	O
common	O
and	O
divergent	B-MED
shape	I-MED
deformations	I-MED
(	O
q	O
=	O
0.05	O
,	O
FDR	O
-	O
corrected	O
)	O
in	O
the	O
rat	B-MED
hippocampus	B-MED
.	O
In	O
particular	O
,	O
in	O
the	O
dorsal	B-MED
hippocampus	I-MED
,	O
HAL	B-MED
exposure	B-MED
led	O
to	O
inward	B-MED
shape	I-MED
deformation	I-MED
,	O
whereas	O
OLZ	B-MED
exposure	B-MED
led	O
to	O
outward	B-MED
shape	I-MED
deformation	I-MED
.	O
Interestingly	O
,	O
outward	B-MED
shape	I-MED
deformations	I-MED
that	O
were	O
common	O
to	O
both	O
drugs	B-MED
occurred	O
in	O
the	O
ventral	B-MED
hippocampus	I-MED
.	O
These	O
effects	O
remained	O
significant	O
after	O
controlling	O
for	O
hippocampal	B-MED
volume	O
suggesting	O
true	O
shape	B-MED
changes	I-MED
.	O
Chronic	B-MED
exposure	I-MED
to	O
either	O
HAL	B-MED
or	O
OLZ	B-MED
leads	O
to	O
both	O
common	O
and	O
divergent	O
effects	O
on	O
rat	B-MED
hippocampal	B-MED
shape	I-MED
in	O
the	O
absence	O
of	O
volume	O
change	O
.	O
The	O
implications	O
of	O
these	O
findings	O
for	O
the	O
clinic	O
are	O
discussed	O
.	O
Short	B-MED
-	I-MED
term	I-MED
Variability	I-MED
of	O
Vitamin	B-MED
D	I-MED
-Related	O
Biomarkers	B-MED
Quantifying	B-MED
the	O
variability	B-MED
of	O
biomarkers	B-MED
is	O
important	B-MED
,	O
as	O
high	O
within	O
-	O
person	O
variability	B-MED
can	O
lead	O
to	O
misclassification	B-MED
of	O
individuals	B-MED
.	O
Short	O
-	O
term	O
variability	B-MED
of	O
important	B-MED
markers	B-MED
of	O
vitamin	B-MED
D	I-MED
metabolism	I-MED
is	O
relatively	O
unknown	O
.	O
A	O
repeatability	B-MED
study	I-MED
was	O
conducted	O
in	O
160	O
Atherosclerosis	B-MED
Risk	B-MED
in	O
Communities	B-MED
study	I-MED
participants	I-MED
(	O
60	O
%	O
female	B-MED
,	O
28	O
%	O
black	B-MED
,	O
mean	O
age	B-MED
76	O
years	O
)	O
.	O
Fasting	B-MED
serum	B-MED
was	O
drawn	O
at	O
2	O
time	O
points	O
,	O
a	O
median	O
of	O
6	O
(	O
range	O
3	O
-	O
13	O
)	O
weeks	B-MED
apart	O
.	O
Vitamin	B-MED
D	I-MED
binding	I-MED
protein	I-MED
(	O
VDBP	B-MED
)	O
and	O
25	B-MED
-	I-MED
hydroxyvitamin	I-MED
D	I-MED
[	O
25(OH)D	B-MED
]	O
were	O
measured	B-MED
by	O
LC	B-MED
-	I-MED
MS	I-MED
,	O
fibroblast	B-MED
growth	I-MED
factor	I-MED
(	O
FGF23	B-MED
)	O
and	O
parathyroid	B-MED
hormone	I-MED
(	O
PTH	B-MED
)	O
by	O
enzyme	B-MED
-	I-MED
linked	I-MED
immunoassay	I-MED
,	O
and	O
calcium	B-MED
and	O
phosphorus	B-MED
by	O
Roche	B-MED
Cobas	I-MED
6000	I-MED
.	O
Free	B-MED
and	O
bioavailable	B-MED
25(OH)D	B-MED
were	O
calculated	B-MED
.	O
We	O
calculated	B-MED
the	O
within	B-MED
-	I-MED
person	I-MED
CV	I-MED
(	O
CVW	B-MED
)	O
,	O
intraclass	B-MED
correlation	I-MED
coefficient	I-MED
(	O
ICC	B-MED
)	O
,	O
Spearman	B-MED
rank	I-MED
correlation	I-MED
coefficient	I-MED
(	O
r	B-MED
)	O
,	O
and	O
percent	B-MED
reclassified	B-MED
.	O
The	O
CVW	B-MED
was	O
lowest	B-MED
for	O
calcium	B-MED
(	O
2.0	O
%	O
)	O
,	O
albumin	B-MED
(	O
3.6	O
%	O
)	O
,	O
25(OH)D	B-MED
(	O
6.9	O
%	O
)	O
,	O
VDBP	B-MED
(	O
7.0	O
%	O
)	O
and	O
phosphorus	B-MED
(	O
7.6	O
%	O
)	O
;	O
intermediate	B-MED
for	O
free	B-MED
25(OH)D	B-MED
(	O
9.0	O
%	O
)	O
and	O
bioavailable	B-MED
25(OH)D	B-MED
(	O
9.9	O
%	O
)	O
;	O
and	O
highest	B-MED
for	O
PTH	B-MED
(	O
16.7	O
%	O
)	O
and	O
FGF23	B-MED
(	O
17.8	O
%	O
)	O
.	O
Reclassification	B-MED
was	O
highest	B-MED
for	O
PTH	B-MED
,	O
VDBP	B-MED
,	O
and	O
phosphorus	B-MED
(	O
all	O
7.5	O
%	O
)	O
.	O
The	O
ICC	B-MED
and	O
r	B-MED
were	O
highest	B-MED
(	O
≥0.80	O
)	O
for	O
25(OH)D	B-MED
,	O
free	B-MED
25(OH)D	B-MED
,	O
bioavailable	B-MED
25(OH)D	B-MED
and	O
PTH	B-MED
,	O
but	O
somewhat	O
lower	B-MED
(	O
approximately	B-MED
0.60	O
-	O
0.75	O
)	O
for	O
the	O
other	O
biomarkers	B-MED
.	O
Six-	O
week	B-MED
short	B-MED
-	I-MED
term	I-MED
variability	I-MED
,	O
as	O
assessed	B-MED
by	O
CVW	B-MED
,	O
was	O
quite	B-MED
low	I-MED
for	O
VDBP	B-MED
,	O
calcium	B-MED
and	O
phosphorus	B-MED
,	O
but	O
fairly	B-MED
high	I-MED
for	O
FGF23	B-MED
and	O
PTH	B-MED
.	O
As	O
such	O
,	O
multiple	B-MED
measurements	I-MED
of	O
FGF23	B-MED
and	O
PTH	B-MED
may	O
be	O
needed	O
to	O
minimize	B-MED
misclassification	B-MED
.	O
These	O
results	B-MED
provide	O
insight	B-MED
into	O
the	O
extent	O
of	O
potential	B-MED
misclassification	B-MED
of	O
vitamin	B-MED
D	I-MED
markers	B-MED
in	O
research	B-MED
and	O
clinical	B-MED
settings	I-MED
.	O
Sepsis	B-MED
Clinical	B-MED
Criteria	I-MED
in	O
Emergency	B-MED
Department	I-MED
Patients	B-MED
Admitted	B-MED
to	O
an	O
Intensive	B-MED
Care	I-MED
Unit	I-MED
:	O
An	O
External	B-MED
Validation	I-MED
Study	I-MED
of	O
Quick	B-MED
Sequential	I-MED
Organ	I-MED
Failure	I-MED
Assessment	I-MED
Quick	B-MED
Sequential	I-MED
Organ	I-MED
Failure	I-MED
Assessment	I-MED
(	O
qSOFA	B-MED
)	O
is	O
a	O
prognostic	B-MED
score	I-MED
for	O
patients	B-MED
with	O
sepsis	B-MED
.	O
Our	O
aim	B-MED
was	O
to	O
compare	O
the	O
area	B-MED
under	I-MED
the	I-MED
receiver	I-MED
operating	I-MED
curve	I-MED
(	O
AUROC	B-MED
)	O
,	O
sensitivity	B-MED
,	O
specificity	B-MED
,	O
and	O
likelihood	B-MED
ratios	I-MED
of	O
qSOFA	B-MED
vs.	O
systemic	B-MED
inflammation	I-MED
response	I-MED
syndrome	I-MED
(	O
SIRS	B-MED
)	O
in	O
predicting	O
in	B-MED
-	I-MED
hospital	I-MED
mortality	I-MED
among	O
emergency	B-MED
department	I-MED
(	O
ED	B-MED
)	O
patients	B-MED
with	O
suspected	B-MED
infection	I-MED
admitted	B-MED
to	O
intensive	B-MED
care	I-MED
units	I-MED
(	O
ICUs	B-MED
)	O
.	O
We	O
conducted	O
a	O
retrospective	B-MED
cohort	I-MED
chart	I-MED
review	I-MED
study	I-MED
of	O
ED	B-MED
patients	B-MED
admitted	B-MED
to	O
an	O
ICU	B-MED
with	O
suspected	B-MED
infection	I-MED
from	O
August	B-MED
1	O
,	O
2012	O
to	O
February	B-MED
28	O
,	O
2015	O
.	O
We	O
included	O
all	O
patients	B-MED
with	O
body	B-MED
fluid	I-MED
cultures	I-MED
sampled	I-MED
either	O
during	O
their	O
ED	B-MED
stay	O
without	O
antibiotic	B-MED
administration	I-MED
or	O
within	O
24	O
h	O
of	O
antibiotics	B-MED
administered	I-MED
in	O
the	O
ED	B-MED
.	O
Trained	B-MED
chart	I-MED
abstractors	I-MED
blinded	O
to	O
the	O
study	B-MED
hypothesis	O
double	B-MED
-	I-MED
entered	I-MED
data	I-MED
from	O
each	O
patient	B-MED
's	I-MED
electronic	B-MED
medical	I-MED
record	I-MED
including	O
demographic	B-MED
characteristics	I-MED
,	O
vital	B-MED
signs	I-MED
,	O
laboratory	B-MED
study	I-MED
results	I-MED
,	O
physical	B-MED
examination	I-MED
findings	B-MED
,	O
and	O
in	B-MED
-	I-MED
hospital	I-MED
mortality	I-MED
.	O
We	O
then	O
calculated	O
the	O
AUROC	B-MED
,	O
sensitivity	B-MED
,	O
specificity	B-MED
,	O
and	O
likelihood	B-MED
ratios	I-MED
for	O
qSOFA	B-MED
and	O
SIRS	B-MED
for	O
predicting	O
in	B-MED
-	I-MED
hospital	I-MED
mortality	I-MED
.	O
Of	O
214	O
patients	B-MED
admitted	B-MED
to	O
an	O
ICU	B-MED
with	O
presumed	B-MED
sepsis	I-MED
,	O
39	O
(	O
18.2	O
%	O
)	O
died	B-MED
during	I-MED
hospitalization	I-MED
.	O
The	O
AUROC	B-MED
value	O
was	O
0.65	O
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
[	O
CI	B-MED
]	O
0.56	O
-	O
0.74	O
)	O
for	O
SIRS	B-MED
vs.	O
0.66	O
(	O
95	O
%	O
CI	B-MED
0.57	O
-	O
0.76	O
)	O
for	O
qSOFA	B-MED
;	O
2	O
+	O
qSOFA	B-MED
criteria	O
predicted	O
in	B-MED
-	I-MED
hospital	I-MED
mortality	I-MED
with	O
89.7	O
%	O
sensitivity	B-MED
,	O
27.4	O
%	O
specificity	B-MED
,	O
1.2	O
positive	B-MED
likelihood	I-MED
ratio	I-MED
,	O
and	O
0.4	O
negative	B-MED
likelihood	I-MED
ratio	I-MED
.	O
Among	O
ED	B-MED
patients	B-MED
admitted	B-MED
to	O
an	O
ICU	B-MED
,	O
the	O
SIRS	B-MED
and	O
qSOFA	B-MED
criteria	O
had	O
comparable	O
prognostic	B-MED
value	I-MED
for	O
predicting	O
in	B-MED
-	I-MED
hospital	I-MED
mortality	I-MED
.	O
These	O
prognostic	B-MED
values	I-MED
are	O
similar	O
to	O
those	O
reported	O
by	O
the	O
Sepsis-3	B-MED
guidelines	I-MED
for	O
ICU	B-MED
encounters	B-MED
.	O
The	O
nanocomposite	B-MED
nature	O
of	O
bone	B-MED
drives	O
its	O
strength	B-MED
and	O
damage	B-MED
resistance	B-MED
In	O
human	B-MED
bone	I-MED
,	O
an	O
amorphous	B-MED
mineral	B-MED
serves	O
as	O
a	O
precursor	B-MED
to	O
the	O
formation	B-MED
of	O
a	O
highly	O
substituted	O
nanocrystalline	B-MED
apatite	B-MED
.	O
However	O
,	O
the	O
precise	O
role	O
of	O
this	O
amorphous	B-MED
mineral	B-MED
remains	O
unknown	O
.	O
Here	O
,	O
we	O
show	O
by	O
using	O
transmission	B-MED
electron	I-MED
microscopy	I-MED
that	O
100	O
-	O
300	O
nm	O
amorphous	B-MED
calcium	B-MED
phosphate	I-MED
regions	B-MED
are	O
present	O
in	O
the	O
disordered	B-MED
phase	I-MED
of	O
trabecular	B-MED
bone	I-MED
.	O
Nanomechanical	B-MED
experiments	I-MED
on	O
cylindrical	B-MED
samples	B-MED
,	O
with	O
diameters	B-MED
between	O
250	O
nm	O
and	O
3,000	O
nm	O
,	O
of	O
the	O
bone	B-MED
's	I-MED
ordered	B-MED
and	O
disordered	B-MED
phases	I-MED
revealed	O
a	O
transition	B-MED
from	O
plastic	B-MED
deformation	B-MED
to	O
brittle	B-MED
failure	B-MED
and	O
at	O
least	O
a	O
factor	O
-	O
of-2	O
higher	O
strength	B-MED
in	O
the	O
smaller	B-MED
samples	B-MED
.	O
We	O
postulate	O
that	O
this	O
transition	B-MED
in	O
failure	B-MED
mechanism	B-MED
is	O
caused	O
by	O
the	O
suppression	B-MED
of	O
extrafibrillar	B-MED
shearing	B-MED
in	O
the	O
smaller	O
samples	B-MED
,	O
and	O
that	O
the	O
emergent	O
smaller	B-MED
-is-	O
stronger	B-MED
size	B-MED
effect	I-MED
is	O
related	O
to	O
the	O
sample	B-MED
-	I-MED
size	I-MED
scaling	B-MED
of	O
the	O
distribution	O
of	O
flaws	O
.	O
Our	O
findings	B-MED
should	O
help	O
in	O
the	O
understanding	O
of	O
the	O
multi	B-MED
-	I-MED
scale	I-MED
nature	I-MED
of	O
bone	B-MED
and	O
provide	O
insights	O
into	O
the	O
biomineralization	B-MED
process	B-MED
.	O
Adverse	B-MED
outcomes	I-MED
in	O
older	B-MED
adults	I-MED
attending	B-MED
emergency	B-MED
departments	I-MED
:	O
a	O
systematic	B-MED
review	I-MED
and	O
meta	B-MED
-	I-MED
analysis	I-MED
of	O
the	O
Identification	B-MED
of	I-MED
Seniors	I-MED
At	I-MED
Risk	I-MED
(	I-MED
ISAR	I-MED
)	I-MED
screening	I-MED
tool	I-MED
older	B-MED
adults	I-MED
are	O
frequent	B-MED
users	O
of	O
emergency	B-MED
services	I-MED
and	O
demonstrate	O
high	B-MED
rates	B-MED
of	O
adverse	B-MED
outcomes	I-MED
following	O
emergency	B-MED
care	I-MED
.	O
to	O
perform	O
a	O
systematic	B-MED
review	I-MED
and	O
meta	B-MED
-	I-MED
analysis	I-MED
of	O
the	O
Identification	B-MED
of	I-MED
Seniors	I-MED
At	I-MED
Risk	I-MED
(	I-MED
ISAR	I-MED
)	I-MED
screening	I-MED
tool	I-MED
,	O
to	O
determine	O
its	O
predictive	B-MED
value	I-MED
in	O
identifying	O
adults	B-MED
≥65	O
years	B-MED
at	O
risk	B-MED
of	O
functional	B-MED
decline	I-MED
,	O
unplanned	O
emergency	B-MED
department	I-MED
(	I-MED
ED	I-MED
)	I-MED
readmission	I-MED
,	O
emergency	B-MED
hospitalisation	B-MED
or	O
death	B-MED
within	O
180	O
days	B-MED
after	O
index	O
ED	B-MED
visit	I-MED
/	O
hospitalisation	B-MED
.	O
a	O
systematic	B-MED
literature	B-MED
search	B-MED
was	O
conducted	O
in	O
PubMed	B-MED
,	O
EMBASE	B-MED
,	O
CINAHL	B-MED
,	O
EBSCO	B-MED
and	O
the	O
Cochrane	B-MED
Library	I-MED
to	O
identify	O
validation	B-MED
and	O
impact	B-MED
analysis	B-MED
studies	O
of	O
the	O
ISAR	B-MED
tool	I-MED
.	O
A	O
pre	B-MED
-	I-MED
specified	I-MED
ISAR	B-MED
score	B-MED
of	O
≥2	O
(	O
maximum	O
score	B-MED
6	O
points	O
)	O
was	O
used	O
to	O
identify	O
patients	B-MED
at	O
high	B-MED
risk	I-MED
of	I-MED
adverse	B-MED
outcomes	I-MED
.	O
A	O
bivariate	B-MED
random	I-MED
effects	I-MED
model	I-MED
generated	O
pooled	B-MED
estimates	B-MED
of	O
sensitivity	B-MED
and	I-MED
specificity	I-MED
.	O
Statistical	B-MED
heterogeneity	I-MED
was	O
explored	O
and	O
methodological	B-MED
quality	I-MED
was	O
assessed	O
using	O
validated	B-MED
criteria	I-MED
.	O
thirty	O
-	O
two	O
validation	B-MED
studies	I-MED
(	O
n	O
=	O
12,939	O
)	O
are	O
included	B-MED
.	O
At	O
≥2	O
,	O
the	O
pooled	B-MED
sensitivity	B-MED
of	O
the	O
ISAR	B-MED
for	O
predicting	O
ED	B-MED
return	B-MED
,	O
emergency	B-MED
hospitalisation	B-MED
and	O
mortality	B-MED
at	O
6	O
months	B-MED
is	O
0.80	O
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
(	O
CI	B-MED
)	O
0.70	O
-	O
0.87	O
)	O
,	O
0.82	O
(	O
95	O
%	O
CI	B-MED
0.74	O
-	O
0.88	O
)	O
and	O
0.87	O
(	O
95	O
%	O
CI	B-MED
0.75	O
-	O
0.94	O
)	O
,	O
respectively	O
,	O
with	O
a	O
pooled	B-MED
specificity	B-MED
of	O
0.31	O
(	O
95	O
%	O
CI	B-MED
0.24	O
-	O
0.38	O
)	O
,	O
0.32	O
(	O
95	O
%	O
CI	B-MED
0.24	O
-	O
0.41	O
)	O
and	O
0.35	O
(	O
95	O
%	O
CI	B-MED
0.26	O
-	O
0.44	O
)	O
.	O
Similar	O
values	B-MED
are	O
demonstrated	O
at	O
30	O
and	O
90	O
days	B-MED
.	O
Three	O
heterogeneous	B-MED
impact	B-MED
analysis	B-MED
studies	O
examined	B-MED
the	O
clinical	B-MED
implementation	B-MED
of	O
the	O
ISAR	B-MED
and	O
reported	O
mixed	B-MED
findings	I-MED
across	O
patient	B-MED
and	O
process	B-MED
outcomes	B-MED
.	O
the	O
ISAR	B-MED
has	O
modest	O
predictive	B-MED
accuracy	B-MED
and	O
may	O
serve	O
as	O
a	O
decision	B-MED
-	I-MED
making	I-MED
adjunct	B-MED
when	O
determining	O
which	O
older	B-MED
adults	I-MED
can	O
be	O
safely	O
discharged	B-MED
.	O
Defining	B-MED
,	O
Describing	B-MED
,	O
and	O
Categorizing	B-MED
Public	B-MED
Health	I-MED
Infrastructure	I-MED
Priorities	B-MED
for	O
Tropical	B-MED
Cyclone	I-MED
,	O
Flood	B-MED
,	O
Storm	B-MED
,	O
Tornado	B-MED
,	O
and	O
Tsunami	B-MED
-	I-MED
Related	I-MED
Disasters	I-MED
The	O
study	B-MED
aim	O
was	O
to	O
undertake	O
a	O
qualitative	O
research	O
literature	B-MED
review	I-MED
to	O
analyze	O
available	O
databases	B-MED
to	O
define	B-MED
,	O
describe	B-MED
,	O
and	O
categorize	B-MED
public	B-MED
health	I-MED
infrastructure	I-MED
(	O
PHI	B-MED
)	O
priorities	B-MED
for	O
tropical	B-MED
cyclone	I-MED
,	O
flood	B-MED
,	O
storm	B-MED
,	O
tornado	B-MED
,	O
and	O
tsunami	B-MED
-	I-MED
related	I-MED
disasters	I-MED
.	O
Five	O
electronic	O
publication	B-MED
databases	I-MED
were	O
searched	O
to	O
define	B-MED
,	O
describe	B-MED
,	O
or	O
categorize	B-MED
PHI	B-MED
and	O
discuss	B-MED
tropical	B-MED
cyclone	I-MED
,	O
flood	B-MED
,	O
storm	B-MED
,	O
tornado	B-MED
,	O
and	O
tsunami	B-MED
-	I-MED
related	I-MED
disasters	I-MED
and	O
their	O
impact	B-MED
on	O
PHI	B-MED
.	O
The	O
data	B-MED
were	O
analyzed	O
through	O
aggregation	B-MED
of	O
individual	O
articles	B-MED
to	O
create	O
an	O
overall	O
data	O
description	O
.	O
The	O
data	B-MED
were	O
grouped	B-MED
into	O
PHI	B-MED
themes	B-MED
,	O
which	O
were	O
then	O
prioritized	B-MED
on	O
the	O
basis	O
of	O
degree	O
of	O
interdependency	O
.	O
Sixty	O
-	O
seven	O
relevant	O
articles	B-MED
were	O
identified	O
.	O
PHI	B-MED
was	O
categorized	B-MED
into	O
13	O
themes	B-MED
with	O
a	O
total	O
of	O
158	O
descriptors	B-MED
.	O
The	O
highest	O
priority	B-MED
PHI	B-MED
identified	O
was	O
workforce	B-MED
.	O
This	O
was	O
followed	O
by	O
water	B-MED
,	O
sanitation	B-MED
,	O
equipment	B-MED
,	O
communication	B-MED
,	O
physical	B-MED
structure	I-MED
,	O
power	B-MED
,	O
governance	B-MED
,	O
prevention	B-MED
,	O
supplies	B-MED
,	O
service	B-MED
,	O
transport	B-MED
,	O
and	O
surveillance	B-MED
.	O
This	O
review	B-MED
identified	O
workforce	B-MED
as	O
the	O
most	O
important	O
of	O
the	O
13	O
thematic	B-MED
areas	I-MED
related	O
to	O
PHI	B-MED
and	O
disasters	B-MED
.	O
If	O
its	O
functionality	O
fails	O
,	O
workforce	B-MED
has	O
the	O
greatest	O
impact	O
on	O
the	O
performance	O
of	O
health	B-MED
services	I-MED
.	O
If	O
addressed	O
post	B-MED
-	I-MED
disaster	I-MED
,	O
the	O
remaining	O
forms	O
of	O
PHI	B-MED
will	O
then	O
be	O
progressively	O
addressed	O
.	O
These	O
findings	O
are	O
a	O
step	O
toward	O
providing	O
an	O
evidence	O
base	O
to	O
inform	O
PHI	B-MED
priorities	B-MED
in	O
the	O
disaster	B-MED
setting	O
.	O
(	O
Disaster	O
Med	O
Public	O
Health	O
Preparedness	O
.	O
2016;10:598	O
-	O
610	O
)	O
.	O
Endothermal	B-MED
venous	I-MED
ablation	I-MED
of	O
the	O
saphenous	B-MED
vein	I-MED
on	O
patients	B-MED
who	O
are	O
on	O
anticoagulation	B-MED
therapy	I-MED
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	O
the	O
risks	B-MED
of	O
bleeding	B-MED
,	O
deep	B-MED
venous	I-MED
thrombosis	I-MED
(	O
DVT	B-MED
)	O
,	O
endovenous	B-MED
heat	I-MED
induced	I-MED
thrombosis	I-MED
(	O
EHIT	B-MED
)	O
and	O
failure	B-MED
of	O
ablation	B-MED
on	O
patients	B-MED
who	O
undergo	O
ablation	B-MED
while	O
on	O
oral	B-MED
anticoagulation	I-MED
.	O
We	O
compared	B-MED
378	O
(	O
3.4	O
%	O
)	O
out	O
of	O
11252	O
patients	B-MED
(	O
group	B-MED
A	I-MED
)	O
who	O
had	O
undergone	O
724	O
endovenous	B-MED
ablation	I-MED
of	O
the	O
saphenous	B-MED
veins	I-MED
from	O
January	O
1	O
,	O
2011	O
to	O
September	O
30	O
,	O
2014	O
while	O
on	O
oral	B-MED
anticoagulation	I-MED
to	O
a	O
randomly	O
selected	O
375	O
patients	B-MED
(	O
group	B-MED
B	I-MED
)	O
who	O
underwent	O
641	O
endovenous	B-MED
ablation	I-MED
in	O
the	O
same	O
time	B-MED
period	I-MED
but	O
were	O
not	O
on	O
anticoagulation	B-MED
.	O
The	O
demographic	B-MED
data	I-MED
,	O
history	B-MED
of	I-MED
DVT	B-MED
,	O
the	O
Clinical	B-MED
,	O
Etiologic	B-MED
,	O
Anatomic	B-MED
,	O
Pathologic	B-MED
(	O
CEAP	B-MED
)	O
classification	B-MED
and	O
the	O
VCSS	B-MED
(	O
Venous	B-MED
Clinical	I-MED
Severity	I-MED
Score	I-MED
)	O
scores	O
were	O
analyzed	O
.	O
The	O
indications	B-MED
for	O
anticoagulation	B-MED
,	O
the	O
anticoagulants	B-MED
used	O
were	O
recorded	O
.	O
The	O
primary	O
endpoints	O
were	O
bleeding	B-MED
,	O
development	O
of	O
DVT	B-MED
or	O
EHIT	B-MED
,	O
and	O
failure	B-MED
of	O
ablation	B-MED
.	O
Patients	B-MED
in	O
group	B-MED
A	I-MED
were	O
older	B-MED
,	O
had	O
more	O
men	B-MED
,	O
more	O
history	O
of	O
DVT	B-MED
and	O
PE	B-MED
,	O
had	O
higher	O
CEAP	B-MED
and	O
VCSS	B-MED
scores	O
compared	O
to	O
group	B-MED
B	I-MED
B.	O
The	O
type	O
of	O
anticoagulation	B-MED
used	O
was	O
warfarin	B-MED
in	O
77.2	O
%	O
direct	B-MED
oral	I-MED
inhibitors	I-MED
(	O
DOIs	B-MED
)	O
in	O
22.8	O
%	O
.	O
The	O
rate	B-MED
of	O
failure	B-MED
of	O
ablation	B-MED
at	O
3	O
days	B-MED
was	O
39	O
(	O
5.6	O
%	O
)	O
for	O
Group	B-MED
A	I-MED
and	O
3	O
(	O
0.5	O
%	O
)	O
for	O
Group	B-MED
B	I-MED
(	O
P<0.0001	O
)	O
and	O
at	O
one	B-MED
month	I-MED
it	O
was	O
46	O
(	O
10.1	O
%	O
)	O
vs.	O
27	O
(	O
6.7	O
%	O
)	O
(	O
P=0.086	O
)	O
.	O
The	O
number	O
of	O
EHIT	B-MED
cases	B-MED
in	O
group	B-MED
A	I-MED
at	O
3	O
days	B-MED
was	O
2	O
(	O
0.3	O
%	O
)	O
,	O
compared	O
to	O
6	O
(	O
0.9	O
%	O
)	O
in	O
group	B-MED
B	I-MED
(	O
P=0.016	O
)	O
and	O
at	O
1	B-MED
month	I-MED
it	O
was	O
0	O
compared	O
to	O
4	O
(	O
1.0	O
%	O
)	O
(	O
P=0.0483	O
)	O
.	O
The	O
DVT	B-MED
,	O
SVT	B-MED
,	O
hematoma	B-MED
and	O
wound	B-MED
infection	I-MED
rates	B-MED
were	O
similar	O
in	O
the	O
two	O
groups	B-MED
.	O
Ablation	B-MED
of	O
the	O
saphenous	B-MED
veins	I-MED
in	O
patients	B-MED
who	O
are	O
on	O
oral	B-MED
anticoagulation	I-MED
is	O
safe	O
and	O
does	O
not	O
increase	O
the	O
risk	B-MED
of	O
bleeding	B-MED
or	O
hematoma	B-MED
,	O
but	O
it	O
may	O
slightly	O
lower	O
the	O
incidence	B-MED
of	O
EHIT	B-MED
and	O
increase	O
the	O
incidence	B-MED
of	O
failure	B-MED
of	O
ablation	B-MED
.	O
Stalk	B-MED
versus	O
base	B-MED
invasion	B-MED
in	O
pT1	B-MED
papillary	B-MED
cancers	I-MED
of	I-MED
the	I-MED
bladder	I-MED
:	O
improved	O
substaging	O
system	O
predicting	O
risk	B-MED
of	O
progression	B-MED
Pathologic	B-MED
stage	I-MED
T1	I-MED
(	O
pT1	B-MED
)	O
bladder	B-MED
cancers	I-MED
are	O
a	O
clinically	B-MED
heterogeneous	B-MED
group	I-MED
.	O
However	O
,	O
current	O
staging	B-MED
guidelines	O
for	O
superficially	B-MED
invasive	B-MED
cancers	I-MED
do	O
not	O
acknowledge	O
the	O
variability	B-MED
in	O
type	O
and	O
extent	O
of	O
lamina	B-MED
propria	I-MED
invasion	I-MED
in	O
papillary	B-MED
urothelial	I-MED
carcinomas	I-MED
(	O
PUC	B-MED
)	O
,	O
and	O
historically	O
proposed	O
substaging	O
systems	O
showed	O
either	O
high	O
inter	B-MED
-	I-MED
observer	I-MED
variation	I-MED
or	O
limited	B-MED
value	I-MED
in	O
predicting	O
patient	B-MED
outcomes	I-MED
.	O
Herein	O
we	O
reappraise	B-MED
pT1	B-MED
PUC	B-MED
substaging	O
,	O
aiming	B-MED
to	O
identify	B-MED
a	O
novel	B-MED
scheme	B-MED
which	O
is	O
reproducible	B-MED
and	O
prognostically	B-MED
meaningful	O
.	O
Stage	B-MED
pT1	I-MED
PUC	B-MED
diagnosed	B-MED
during	O
years	B-MED
1999	O
-	O
2015	O
were	O
retrospectively	B-MED
reviewed	I-MED
and	O
characterized	B-MED
as	O
focal	B-MED
invasion	B-MED
confined	O
to	O
papillary	B-MED
stalk	I-MED
,	O
focal	B-MED
invasion	B-MED
of	O
tumor	B-MED
base	B-MED
,	O
or	O
extensive	O
invasion	B-MED
of	O
tumor	B-MED
base	B-MED
.	O
Cases	B-MED
with	O
concurrent	B-MED
flat	B-MED
carcinoma	I-MED
in	I-MED
-	I-MED
situ	I-MED
,	O
angiolymphatic	B-MED
invasion	I-MED
,	O
absent	B-MED
muscularis	B-MED
propria	I-MED
,	O
or	O
clinically	B-MED
advanced	B-MED
disease	I-MED
were	O
excluded	B-MED
.	O
We	O
calculated	O
cumulative	B-MED
incidence	B-MED
of	O
recurrence	B-MED
,	O
progression	B-MED
,	O
and	O
death	B-MED
by	O
tumor	B-MED
subtype	I-MED
and	O
evaluated	B-MED
differential	B-MED
risks	I-MED
using	O
log	B-MED
-	I-MED
rank	I-MED
tests	I-MED
and	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
curves	I-MED
stratified	B-MED
by	O
type	B-MED
and	O
extent	B-MED
of	I-MED
invasion	I-MED
.	O
Among	O
62	O
patients	B-MED
satisfying	O
inclusion	B-MED
criteria	B-MED
,	O
22	O
of	O
29	O
patients	B-MED
with	O
base	B-MED
extensive	B-MED
invasion	B-MED
progressed	B-MED
while	O
4	O
of	O
13	O
with	O
base	B-MED
focal	B-MED
and	O
0	O
of	O
20	O
with	O
stalk	B-MED
only	O
invasion	B-MED
progressed	B-MED
.	O
There	O
was	O
strong	O
evidence	O
that	O
base	B-MED
extensive	O
patients	B-MED
had	O
higher	O
risk	B-MED
of	O
progression	B-MED
and	O
death	B-MED
due	O
to	O
bladder	B-MED
cancer	I-MED
than	O
base	B-MED
focal	B-MED
or	O
stalk	B-MED
only	O
counterparts	O
(	O
P<0.0001	O
)	O
.	O
However	O
,	O
tumor	B-MED
subtype	I-MED
was	O
not	O
significantly	O
associated	O
with	O
risk	B-MED
of	O
recurrence	B-MED
(	O
P=0.21	O
)	O
.	O
We	O
propose	O
an	O
innovative	O
substaging	O
approach	O
for	O
reporting	O
site	O
and	O
extent	O
of	O
lamina	B-MED
propria	I-MED
invasion	I-MED
in	O
patients	B-MED
with	O
pT1	B-MED
PUC	B-MED
allowing	O
patient	B-MED
stratification	B-MED
for	O
risk	B-MED
of	O
progression	B-MED
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
Evaluation	B-MED
of	O
the	O
Effects	B-MED
of	I-MED
Intravenous	B-MED
and	O
Percutaneous	B-MED
Low	B-MED
Level	I-MED
Laser	I-MED
Therapy	I-MED
in	O
the	O
Management	B-MED
of	O
Shoulder	B-MED
Myofascial	B-MED
Pain	I-MED
Syndrome	I-MED
Myofascial	B-MED
pain	I-MED
syndrome	I-MED
(	O
MPS	B-MED
)	O
treatment	B-MED
is	O
challenging	O
with	O
a	O
high	O
recurrence	O
rate	O
and	O
still	O
lacks	O
a	O
clear	O
treatment	B-MED
frame	I-MED
.	O
Therefore	O
research	O
on	O
new	O
,	O
more	O
efficient	B-MED
and	O
long	O
lasting	O
effect	O
treatment	B-MED
modalities	B-MED
is	O
necessary	O
.	O
This	O
study	O
looked	O
at	O
the	O
effects	B-MED
of	I-MED
intravenous	B-MED
laser	B-MED
therapy	I-MED
(	O
IVL	B-MED
)	O
and	O
percutaneous	B-MED
low	B-MED
level	I-MED
laser	I-MED
(	O
PLLL	B-MED
)	O
in	O
the	O
management	B-MED
of	O
shoulder	B-MED
MPS	B-MED
.	O
In	O
this	O
randomized	B-MED
controlled	I-MED
trial	I-MED
,	O
30	O
patients	B-MED
fulfilling	O
inclusion	B-MED
criteria	I-MED
were	O
randomly	O
equally	O
allocated	O
to	O
3	O
groups	O
,	O
control	B-MED
,	O
IVL	B-MED
and	O
PLLL	B-MED
.	O
Control	B-MED
group	I-MED
received	O
12	O
sessions	O
of	O
placebo	B-MED
low	B-MED
level	I-MED
laser	I-MED
,	O
IVL	B-MED
group	I-MED
received	O
12	O
sessions	O
of	O
IVL	B-MED
therapy	I-MED
,	O
and	O
PLLL	B-MED
group	I-MED
received	O
12	O
sessions	O
of	O
PLLL	B-MED
therapy	I-MED
.	O
All	O
patients	B-MED
were	O
trained	O
for	O
better	B-MED
body	B-MED
posture	I-MED
,	O
body	B-MED
mechanics	I-MED
,	O
gentle	B-MED
massage	I-MED
of	O
trigger	B-MED
points	I-MED
,	O
stretching	B-MED
exercises	I-MED
of	O
affected	B-MED
muscle	B-MED
(	O
trapezius	B-MED
)	O
,	O
and	O
received	O
10	O
mg	O
of	O
oral	B-MED
nortriptyline	B-MED
regimen	B-MED
every	O
night	O
for	O
3	O
months	O
.	O
Outcomes	O
included	O
pain	B-MED
severity	I-MED
,	O
functional	B-MED
disability	I-MED
,	O
and	O
quality	B-MED
of	I-MED
life	I-MED
.	O
Patients	B-MED
were	O
assessed	O
using	O
Numeric	B-MED
Rating	I-MED
Scale	I-MED
(	O
NRS	B-MED
)	O
,	O
Pain	B-MED
Disability	I-MED
Index	I-MED
(	O
PDI	B-MED
)	O
,	O
and	O
Short	B-MED
Form	I-MED
Health	I-MED
Survey	I-MED
(	O
SF-12	B-MED
)	O
.	O
Data	B-MED
collected	I-MED
were	O
analyzed	B-MED
using	O
analysis	B-MED
of	I-MED
variance	I-MED
(	O
ANOVA	B-MED
)	O
,	O
Mann	B-MED
-	I-MED
Whitney	I-MED
and	O
t	B-MED
tests	I-MED
.	O
The	O
mean	O
of	O
PDI	B-MED
and	O
maximum	O
pain	B-MED
intensity	I-MED
during	O
day	O
and	O
night	O
significantly	O
reduced	B-MED
in	O
both	O
PLLL	B-MED
and	O
IVL	B-MED
groups	I-MED
compared	O
to	O
control	B-MED
group	I-MED
.	O
Although	O
pain	O
severity	O
and	O
PDI	B-MED
reduction	O
was	O
more	O
pronounced	O
in	O
IVL	B-MED
group	I-MED
compared	O
to	O
PLLL	B-MED
group	I-MED
,	O
the	O
differences	O
were	O
not	O
statistically	B-MED
significant	I-MED
.	O
Also	O
,	O
quality	B-MED
of	I-MED
life	I-MED
statistically	B-MED
significantly	I-MED
improved	O
in	O
both	O
IVL	B-MED
and	O
PLLL	B-MED
groups	I-MED
compared	O
to	O
control	B-MED
group	I-MED
was	O
more	O
,	O
and	O
although	O
higher	O
in	O
IVL	B-MED
group	I-MED
,	O
the	O
difference	O
was	O
not	O
statistically	B-MED
significant	I-MED
when	O
compared	O
to	O
PLLL	B-MED
group	I-MED
.	O
No	B-MED
side	I-MED
effects	I-MED
were	O
observed	O
in	O
the	O
intervention	B-MED
groups	I-MED
.	O
Intravenous	B-MED
laser	B-MED
and	O
PLLL	B-MED
therapy	I-MED
had	O
a	O
positive	O
effect	B-MED
on	O
pain	B-MED
severity	I-MED
and	O
PDI	B-MED
reduction	O
,	O
and	O
quality	B-MED
of	I-MED
life	I-MED
in	O
this	O
study	O
.	O
Also	O
no	B-MED
adverse	I-MED
event	I-MED
was	O
recorded	O
.	O
Thus	O
,	O
intravenous	B-MED
lasers	B-MED
and	O
PLLL	B-MED
therapy	I-MED
seem	O
to	O
be	O
effective	B-MED
complementary	O
modalities	B-MED
in	O
managing	B-MED
patients	B-MED
with	O
shoulder	B-MED
MPS	B-MED
.	O
Quantitative	B-MED
regulation	B-MED
of	O
histone	B-MED
variant	I-MED
H2A.Z	I-MED
during	B-MED
cell	B-MED
cycle	I-MED
by	O
ubiquitin	B-MED
proteasome	I-MED
system	I-MED
and	O
SUMO	B-MED
-	I-MED
targeted	I-MED
ubiquitin	I-MED
ligases	I-MED
Quantitative	B-MED
control	B-MED
of	O
histones	B-MED
and	O
histone	B-MED
variants	I-MED
during	B-MED
cell	B-MED
cycle	I-MED
is	O
relevant	B-MED
to	O
their	O
epigenetic	B-MED
functions	I-MED
.	O
We	O
found	O
that	O
the	O
level	B-MED
of	O
yeast	B-MED
histone	I-MED
variant	I-MED
H2A.Z	I-MED
in	O
the	O
G2	B-MED
/	I-MED
M	I-MED
-	I-MED
phase	I-MED
is	O
actively	B-MED
kept	O
low	O
by	O
the	O
ubiquitin	B-MED
proteasome	I-MED
system	I-MED
and	O
SUMO	B-MED
-	I-MED
targeted	I-MED
ubiquitin	I-MED
ligases	I-MED
.	O
Overexpression	B-MED
of	O
H2A.Z	B-MED
induced	B-MED
defects	I-MED
in	I-MED
mitotic	I-MED
progression	I-MED
,	O
suggesting	B-MED
functional	B-MED
importance	B-MED
of	O
this	O
quantitative	B-MED
control	B-MED
.	O
Identifying	O
research	B-MED
priorities	I-MED
with	O
nurses	B-MED
at	O
a	O
tertiary	O
children	B-MED
's	I-MED
hospital	B-MED
in	O
the	O
United	B-MED
Kingdom	I-MED
The	O
objective	O
of	O
this	O
study	B-MED
was	O
to	O
undertake	O
a	O
research	B-MED
priority	I-MED
setting	O
exercise	O
with	O
the	O
aim	O
of	O
maximizing	O
efficiency	B-MED
and	O
impact	B-MED
in	O
research	B-MED
activity	I-MED
undertaken	O
by	O
nurses	B-MED
at	O
one	O
children	B-MED
's	I-MED
tertiary	O
healthcare	B-MED
institution	I-MED
by	O
ensuring	O
the	O
clinical	B-MED
staff	I-MED
directly	O
shaped	O
a	O
coherent	B-MED
,	O
transparent	B-MED
and	O
consensus	B-MED
driven	O
nurse	B-MED
-	I-MED
led	I-MED
research	I-MED
agenda	I-MED
.	O
In	O
Round	O
1	O
,	O
the	O
research	B-MED
topics	I-MED
of	O
147	O
nurses	B-MED
were	O
elicited	O
using	O
a	O
modified	B-MED
nominal	I-MED
group	I-MED
technique	I-MED
as	O
the	O
consensus	B-MED
method	I-MED
.	O
The	O
number	O
of	O
participants	B-MED
in	O
the	O
24	O
separate	O
discussions	O
ranged	O
from	O
3	O
to	O
21	O
,	O
generating	O
lists	O
of	O
between	O
6	O
and	O
23	O
topics	O
.	O
In	O
Round	O
2	O
,	O
nurses	B-MED
from	O
the	O
clinical	B-MED
areas	I-MED
ranked	B-MED
topics	O
of	O
importance	O
resulting	O
in	O
a	O
set	O
of	O
four	O
to	O
five	O
priorities	B-MED
.	O
In	O
Round	O
3	O
,	O
the	O
divisional	B-MED
heads	I-MED
of	O
nursing	B-MED
consulted	O
with	O
staff	B-MED
in	O
all	O
of	O
their	O
clinical	B-MED
areas	I-MED
to	O
each	O
finalize	O
their	O
five	O
divisional	B-MED
priorities	I-MED
.	O
The	O
Nursing	B-MED
Research	I-MED
Working	I-MED
Group	I-MED
discussed	O
and	O
refined	O
the	O
divisions	B-MED
'	I-MED
priorities	I-MED
and	O
voted	B-MED
on	O
the	O
final	O
list	O
to	O
agree	O
the	O
top	O
five	O
research	B-MED
priorities	I-MED
for	O
the	O
organization	B-MED
.	O
A	O
total	O
of	O
269	O
research	B-MED
topics	I-MED
were	O
initially	O
generated	O
.	O
Following	O
three	O
rounds	O
of	O
ranking	B-MED
and	O
prioritizing	O
,	O
five	O
priorities	B-MED
were	O
agreed	O
at	O
Divisional	B-MED
level	I-MED
,	O
and	O
from	O
these	O
,	O
the	O
five	O
top	O
organizational	B-MED
priorities	I-MED
were	O
selected	O
.	O
These	O
were	O
(	O
i	O
)	O
understanding	O
and	O
improving	O
all	O
aspects	O
of	O
the	O
patient	B-MED
journey	O
through	O
the	O
hospital	B-MED
system	I-MED
;	O
(	O
ii	O
)	O
play	B-MED
;	O
(	O
iii	O
)	O
staff	B-MED
wellbeing	I-MED
,	O
patient	B-MED
care	I-MED
and	O
productivity	B-MED
;	O
(	O
iv	O
)	O
team	B-MED
work	I-MED
-	O
linking	O
to	O
a	O
more	O
efficient	O
service	B-MED
;	O
and	O
(	O
v	O
)	O
supporting	B-MED
parents	I-MED
/	O
parent	B-MED
pathway	O
.	O
Divisional	O
priorities	B-MED
have	O
been	O
disseminated	O
widely	O
to	O
clinical	B-MED
teams	I-MED
to	O
inform	O
a	O
patient	B-MED
-	I-MED
specific	I-MED
nurse	I-MED
-	I-MED
led	I-MED
research	I-MED
agenda	I-MED
.	O
Organizational	B-MED
priorities	I-MED
agreed	O
upon	O
have	O
been	O
disseminated	O
through	O
management	B-MED
structures	I-MED
and	O
processes	O
to	O
ensure	O
engagement	O
at	O
all	O
levels	O
.	O
A	O
subgroup	B-MED
of	O
the	O
Nursing	B-MED
Research	I-MED
Working	I-MED
Group	I-MED
has	O
been	O
delegated	O
to	O
take	O
this	O
work	O
forward	O
so	O
that	O
the	O
agreed	O
priorities	B-MED
continue	O
to	O
contribute	O
towards	O
shaping	O
nurse	B-MED
-	I-MED
led	I-MED
research	I-MED
activity	I-MED
,	O
thereby	O
going	O
some	O
way	O
to	O
inform	O
and	O
embed	O
an	O
evidence	O
-	O
based	O
culture	O
of	O
inquiry	B-MED
.	O
ITPR3	B-MED
gene	I-MED
haplotype	B-MED
is	O
associated	O
with	O
cervical	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
risk	B-MED
in	O
Taiwanese	B-MED
women	B-MED
Host	B-MED
immunogenetic	I-MED
background	O
plays	O
an	O
important	O
role	O
in	O
human	B-MED
papillomavirus	I-MED
(	I-MED
HPV	I-MED
)	I-MED
infection	I-MED
and	O
cervical	B-MED
cancer	I-MED
development	I-MED
.	O
Inositol	B-MED
1,4,5	I-MED
-	I-MED
triphosphate	I-MED
receptor	I-MED
type	I-MED
3	I-MED
(	O
ITPR3	B-MED
)	O
is	O
essential	O
for	O
both	O
immune	B-MED
activation	I-MED
and	O
cancer	B-MED
pathogenesis	B-MED
.	O
We	O
aim	O
to	O
investigate	O
if	O
ITPR3	B-MED
genetic	B-MED
polymorphisms	I-MED
are	O
associated	O
with	O
the	O
risk	B-MED
of	I-MED
cervical	I-MED
cancer	I-MED
in	O
Taiwanese	B-MED
women	B-MED
.	O
ITPR3	B-MED
rs3748079	B-MED
A	I-MED
/	I-MED
G	I-MED
and	O
rs2229634	B-MED
C	I-MED
/	I-MED
T	I-MED
polymorphisms	I-MED
were	O
genotyped	B-MED
in	O
a	O
hospital	B-MED
-	I-MED
based	I-MED
study	I-MED
of	O
462	O
women	B-MED
with	O
cervical	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
(	O
CSCC	B-MED
)	O
and	O
921	O
age	O
-	O
matched	O
healthy	B-MED
control	I-MED
women	B-MED
.	O
The	O
presence	O
and	O
genotypes	B-MED
of	O
HPV	B-MED
in	O
CSCC	B-MED
was	O
determined	O
.	O
No	O
significant	O
association	O
of	O
individual	O
ITPR3	B-MED
variants	B-MED
were	O
found	O
among	O
controls	O
,	O
CSCC	B-MED
,	O
and	O
HPV-16	B-MED
positive	I-MED
CSCC	B-MED
.	O
However	O
,	O
we	O
found	O
a	O
significant	O
association	O
of	O
haplotype	B-MED
AT	I-MED
between	O
CSCC	B-MED
and	O
controls	O
(	O
OR	B-MED
=	O
2.28	O
,	O
95	O
%	O
CI	B-MED
1.31	O
-	O
3.97	O
,	O
P	O
=	O
2.83	O
×	O
10	O
-	O
3	O
)	O
and	O
the	O
OR	B-MED
increased	O
further	O
in	O
CSCC	B-MED
patients	B-MED
infected	I-MED
with	O
HPV-16	B-MED
(	O
OR	B-MED
=	O
2.89	O
,	O
95	O
%	O
CI	B-MED
1.55	O
-	O
5.37	O
,	O
P	O
=	O
4.54	O
×	O
10	O
-	O
4	O
)	O
.	O
The	O
linkage	B-MED
disequilibrium	I-MED
analysis	I-MED
demonstrated	O
that	O
ITPR3	B-MED
association	B-MED
with	O
CSCC	B-MED
was	O
independent	O
of	O
HLA	B-MED
-	I-MED
DRB1	I-MED
alleles	B-MED
.	O
In	O
conclusion	O
,	O
these	O
findings	O
suggest	O
that	O
AT	B-MED
haplotype	I-MED
in	O
the	O
ITPR3	B-MED
gene	I-MED
may	O
serve	O
as	O
a	O
potential	B-MED
marker	I-MED
for	O
genetic	B-MED
susceptibility	I-MED
to	O
CSCC	B-MED
.	O
Remote	B-MED
Ischemic	B-MED
Conditioning	I-MED
and	O
Renal	B-MED
Protection	B-MED
Over	O
the	O
course	O
of	O
the	O
last	O
2	O
decades	O
,	O
the	O
concept	O
of	O
remote	B-MED
ischemic	B-MED
conditioning	I-MED
(	O
RIC	B-MED
)	O
has	O
attracted	O
considerable	O
research	B-MED
interest	B-MED
,	O
because	O
RIC	B-MED
,	O
in	O
most	O
of	O
its	O
embodiments	O
offers	O
an	O
inexpensive	O
way	O
of	O
protecting	B-MED
tissues	B-MED
against	O
ischemic	B-MED
damage	B-MED
inflicted	O
by	O
a	O
number	O
of	O
medical	B-MED
conditions	B-MED
or	O
procedures	B-MED
.	O
Acute	B-MED
kidney	I-MED
injury	I-MED
(	O
AKI	B-MED
)	O
is	O
a	O
common	O
side	B-MED
effect	I-MED
in	O
the	O
context	O
of	O
various	O
medical	B-MED
procedures	I-MED
,	O
and	O
RIC	B-MED
has	O
been	O
suggested	O
as	O
a	O
means	O
of	O
reducing	O
its	O
incidence	O
.	O
Outcomes	B-MED
regarding	O
kidney	B-MED
function	I-MED
have	O
been	O
reported	O
in	O
numerous	O
studies	B-MED
that	O
evaluated	O
the	O
effects	B-MED
of	I-MED
RIC	B-MED
in	O
a	O
variety	O
of	O
settings	O
(	O
eg	O
,	O
cardiac	B-MED
surgery	I-MED
,	O
interventions	B-MED
requiring	O
intravenous	B-MED
administration	I-MED
of	O
contrast	B-MED
media	I-MED
)	O
.	O
Although	O
several	O
individual	O
studies	B-MED
have	O
implied	O
a	O
beneficial	O
effect	B-MED
of	I-MED
RIC	B-MED
in	O
preserving	O
kidney	B-MED
function	I-MED
,	O
3	O
recently	O
published	O
randomized	B-MED
controlled	I-MED
trials	I-MED
evaluating	O
more	O
than	O
1000	O
patients	B-MED
each	O
(	O
Effect	B-MED
of	I-MED
Remote	B-MED
Ischemic	I-MED
Preconditioning	I-MED
in	O
the	O
Cardiac	B-MED
Surgery	I-MED
,	O
Remote	B-MED
Ischaemic	I-MED
Preconditioning	I-MED
for	O
Heart	B-MED
Surgery	I-MED
,	O
and	O
E	B-MED
RIC	I-MED
CA	I-MED
RIC	B-MED
)	O
were	O
negative	B-MED
.	O
However	O
,	O
AKI	B-MED
or	O
any	O
other	O
index	O
of	O
renal	B-MED
function	I-MED
was	O
not	O
a	O
stand	O
-	O
alone	O
primary	O
end	O
point	O
in	O
any	O
of	O
these	O
trials	B-MED
.	O
On	O
the	O
other	O
hand	O
,	O
a	O
range	O
of	O
meta	B-MED
-	I-MED
analyses	I-MED
(	O
each	O
including	O
thousands	O
of	O
participants	B-MED
)	O
have	O
reported	O
mixed	O
results	B-MED
,	O
with	O
the	O
most	O
recent	O
among	O
them	O
showing	O
benefit	O
from	O
RIC	B-MED
,	O
pinpointing	O
at	O
the	O
same	O
time	O
a	O
number	O
of	O
shortcomings	O
in	O
published	B-MED
studies	B-MED
,	O
adversely	B-MED
affecting	I-MED
the	O
quality	B-MED
of	O
available	B-MED
data	I-MED
.	O
The	O
present	O
review	B-MED
provides	O
a	O
critical	O
appraisal	O
of	O
the	O
current	O
state	O
of	O
this	O
field	O
of	O
research	B-MED
.	O
It	O
is	O
the	O
opinion	O
of	O
the	O
authors	B-MED
of	O
this	O
review	B-MED
that	O
there	O
is	O
a	O
clear	O
need	O
for	O
a	O
common	O
clinical	B-MED
trial	I-MED
framework	O
for	O
ischemic	B-MED
conditioning	I-MED
studies	B-MED
.	O
If	O
the	O
current	O
babel	O
of	O
definitions	B-MED
,	O
procedures	B-MED
,	O
outcomes	B-MED
,	O
and	O
goals	B-MED
persists	I-MED
,	O
it	O
is	O
most	O
likely	O
that	O
soon	O
ischemic	B-MED
conditioning	I-MED
will	O
be	O
"	O
yesterday	O
's	O
news	O
"	O
with	O
no	O
definitive	O
conclusions	O
having	O
been	O
reached	O
in	O
terms	O
of	O
its	O
real	O
clinical	B-MED
utility	I-MED
.	O
An	O
influenza	B-MED
A	I-MED
virus	I-MED
(	I-MED
H7N9	I-MED
)	I-MED
anti	B-MED
-	I-MED
neuraminidase	I-MED
monoclonal	B-MED
antibody	I-MED
with	O
prophylactic	B-MED
and	I-MED
therapeutic	I-MED
activity	I-MED
in	B-MED
vivo	I-MED
Zoonotic	B-MED
A(H7N9	B-MED
)	I-MED
avian	I-MED
influenza	I-MED
viruses	I-MED
emerged	O
in	O
China	B-MED
in	O
2013	O
and	O
continue	O
to	O
be	O
a	O
threat	B-MED
to	O
human	B-MED
public	B-MED
health	I-MED
,	O
having	O
infected	B-MED
over	O
800	O
individuals	B-MED
with	O
a	O
mortality	B-MED
rate	I-MED
approaching	O
40	O
%	O
.	O
Treatment	B-MED
options	I-MED
for	O
people	O
infected	B-MED
with	O
A(H7N9	B-MED
)	I-MED
include	O
the	O
use	O
of	O
neuraminidase	B-MED
(	I-MED
NA	I-MED
)	I-MED
inhibitors	I-MED
.	O
However	O
,	O
like	O
other	O
influenza	B-MED
viruses	I-MED
,	O
A(H7N9	B-MED
)	I-MED
can	O
become	O
resistant	B-MED
to	O
these	O
drugs	B-MED
.	O
The	O
use	O
of	O
monoclonal	B-MED
antibodies	I-MED
is	O
a	O
rapidly	O
developing	O
strategy	B-MED
for	O
controlling	O
influenza	B-MED
virus	I-MED
infection	B-MED
.	O
Here	O
we	O
generated	O
a	O
murine	B-MED
monoclonal	B-MED
antibody	I-MED
(	O
3c10	B-MED
-	I-MED
3	I-MED
)	O
directed	O
against	O
the	O
NA	B-MED
of	O
A(H7N9	B-MED
)	I-MED
and	O
show	O
that	O
prophylactic	B-MED
systemic	B-MED
administration	I-MED
of	O
3c10	B-MED
-	I-MED
3	I-MED
fully	O
protected	O
mice	O
from	O
lethal	O
challenge	O
with	O
wild	B-MED
-	I-MED
type	I-MED
A	B-MED
/	I-MED
Anhui/1/2013	I-MED
(	O
H7N9	B-MED
)	O
.	O
Further	O
,	O
post-	O
infection	B-MED
treatment	B-MED
with	O
a	O
single	O
systemic	B-MED
dose	B-MED
of	O
3c10	B-MED
-	I-MED
3	I-MED
at	O
either	O
24	O
,	O
48	O
or	O
72	O
h	O
post	O
A(H7N9	B-MED
)	I-MED
challenge	O
resulted	O
in	O
both	O
dose	B-MED
-	O
and	O
time	B-MED
-	O
dependent	B-MED
protection	B-MED
of	O
up	O
to	O
100	O
%	O
of	O
mice	B-MED
,	O
demonstrating	O
therapeutic	B-MED
potential	B-MED
for	O
3c10	B-MED
-	I-MED
3	I-MED
.	O
Epitope	B-MED
mapping	I-MED
revealed	O
that	O
3c10	B-MED
-	I-MED
3	I-MED
binds	B-MED
near	O
the	O
enzyme	B-MED
active	B-MED
site	I-MED
of	O
NA	B-MED
,	O
and	O
functional	B-MED
characterization	O
showed	O
that	O
3c10	B-MED
-	I-MED
3	I-MED
inhibits	O
the	O
enzyme	B-MED
activity	I-MED
of	O
NA	B-MED
and	O
restricts	O
the	O
cell	O
-to-	O
cell	O
spread	B-MED
of	O
the	O
virus	B-MED
in	O
cultured	B-MED
cells	I-MED
.	O
Affinity	B-MED
analysis	B-MED
also	O
revealed	O
that	O
3c10	B-MED
-	I-MED
3	I-MED
binds	B-MED
equally	O
well	O
to	O
recombinant	B-MED
NA	B-MED
of	O
wild	B-MED
-	I-MED
type	I-MED
A	B-MED
/	I-MED
Anhui/1/2013	I-MED
and	O
to	O
a	O
variant	B-MED
NA	B-MED
carrying	O
a	O
R289	O
K	O
mutation	B-MED
known	O
to	O
infer	O
NAI	B-MED
resistance	B-MED
.	O
These	O
results	O
suggest	O
that	O
3c10	B-MED
-	I-MED
3	I-MED
has	O
the	O
potential	B-MED
to	O
be	O
used	O
as	O
a	O
therapeutic	B-MED
to	O
treat	O
A(H7N9	B-MED
)	I-MED
infections	B-MED
either	O
as	O
an	O
alternative	B-MED
to	O
,	O
or	O
in	O
combination	B-MED
with	O
,	O
current	O
NA	B-MED
antiviral	B-MED
inhibitors	I-MED
.	O
A	O
three	B-MED
perspective	B-MED
study	I-MED
of	O
the	O
sense	O
of	O
home	B-MED
of	O
nursing	B-MED
home	I-MED
residents	I-MED
:	O
the	O
views	O
of	O
residents	B-MED
,	O
care	B-MED
professionals	I-MED
and	O
relatives	B-MED
The	O
sense	O
of	O
home	B-MED
of	O
nursing	B-MED
home	I-MED
residents	I-MED
is	O
a	O
multifactorial	B-MED
phenomenon	B-MED
which	O
is	O
important	B-MED
for	O
the	O
quality	B-MED
of	O
living	B-MED
.	O
The	O
purpose	B-MED
of	O
this	O
study	B-MED
is	O
to	O
investigate	B-MED
the	O
factors	B-MED
influencing	B-MED
the	O
sense	O
of	O
home	B-MED
of	O
older	B-MED
adults	I-MED
residing	B-MED
in	O
the	O
nursing	B-MED
home	I-MED
from	O
the	O
perspective	O
of	O
residents	B-MED
,	O
relatives	B-MED
and	O
care	B-MED
professionals	I-MED
.	O
A	O
total	O
of	O
78	O
participants	B-MED
(	O
n	O
=	O
24	O
residents	B-MED
,	O
n	O
=	O
18	O
relatives	B-MED
and	O
n	O
=	O
26	O
care	B-MED
professionals	I-MED
)	O
from	O
4	O
nursing	B-MED
homes	I-MED
in	O
the	O
Netherlands	B-MED
engaged	O
in	O
a	O
qualitative	B-MED
study	I-MED
,	O
in	O
which	O
photography	O
was	O
as	O
a	O
supportive	O
tool	O
for	O
subsequent	B-MED
interviews	B-MED
and	O
focus	B-MED
groups	I-MED
.	O
The	O
data	B-MED
were	O
analyzed	O
based	O
on	O
open	B-MED
ended	I-MED
coding	I-MED
,	O
axial	B-MED
coding	I-MED
and	O
selective	B-MED
coding	I-MED
.	O
The	O
sense	O
of	O
home	B-MED
of	O
nursing	B-MED
home	I-MED
residents	I-MED
is	O
influenced	B-MED
by	O
a	O
number	O
of	O
jointly	O
identified	O
factors	B-MED
,	O
including	O
the	O
building	B-MED
and	O
interior	B-MED
design	I-MED
;	O
eating	B-MED
and	O
drinking	B-MED
;	O
autonomy	B-MED
and	O
control	B-MED
;	O
involvement	B-MED
of	O
relatives	B-MED
;	O
engagement	O
with	O
others	O
and	O
activities	B-MED
;	O
quality	B-MED
of	I-MED
care	I-MED
are	O
shared	O
themes	O
.	O
Residents	B-MED
and	O
relatives	B-MED
stressed	O
the	O
importance	B-MED
of	O
having	O
a	O
connection	O
with	O
nature	B-MED
and	O
the	O
outdoors	B-MED
,	O
as	O
well	O
as	O
coping	B-MED
strategies	I-MED
.	O
Relatives	B-MED
and	O
care	B-MED
professionals	I-MED
emphasized	O
the	O
role	O
the	O
organization	B-MED
of	O
facilitation	B-MED
of	O
care	B-MED
played	O
,	O
as	O
well	O
as	O
making	O
residents	B-MED
feel	O
like	O
they	O
still	O
matter	O
.	O
The	O
sense	O
of	O
home	B-MED
of	O
nursing	B-MED
home	I-MED
residents	I-MED
is	O
influenced	B-MED
by	O
a	O
multitude	B-MED
of	O
factors	B-MED
related	O
to	O
the	O
psychology	B-MED
of	O
the	O
residents	B-MED
,	O
and	O
the	O
social	B-MED
and	I-MED
built	I-MED
environmental	I-MED
contexts	I-MED
.	O
A	O
holistic	B-MED
understanding	O
of	O
which	O
factors	B-MED
influence	B-MED
the	O
sense	O
of	O
home	B-MED
of	O
residents	B-MED
can	O
lead	O
to	O
strategies	O
to	O
optimize	B-MED
this	O
sense	O
of	O
home	B-MED
.	O
This	O
study	B-MED
also	O
indicated	O
that	O
the	O
nursing	B-MED
home	I-MED
has	O
a	O
dual	O
nature	B-MED
as	O
a	O
place	O
of	O
residence	B-MED
and	O
a	O
place	B-MED
where	O
people	B-MED
are	O
supported	O
through	O
numerous	B-MED
care	O
strategies	O
.	O
Primary	B-MED
Management	B-MED
and	O
Outcome	B-MED
-	O
Open	B-MED
Laryngotracheal	I-MED
Trauma	I-MED
Acute	B-MED
external	B-MED
injury	I-MED
to	O
the	O
larynx	B-MED
is	O
both	O
life	B-MED
threatening	I-MED
and	O
a	O
potential	O
long	B-MED
term	I-MED
management	B-MED
challenge	O
.	O
As	O
Otorhinolaryngologist	B-MED
we	O
must	O
be	O
prepared	O
and	O
well	O
versed	O
to	O
manage	O
these	O
patients	B-MED
.	O
In	O
our	O
study	O
seven	O
patients	B-MED
of	O
open	B-MED
laryngeal	I-MED
traumas	I-MED
were	O
managed	O
by	O
primary	B-MED
closure	I-MED
.	O
In	O
five	O
patients	B-MED
nature	B-MED
of	I-MED
injury	I-MED
was	O
known	O
in	O
other	O
two	O
patients	B-MED
exact	O
nature	B-MED
of	I-MED
injury	I-MED
was	O
not	O
known	O
.	O
After	O
primary	B-MED
closure	I-MED
five	O
patients	B-MED
with	O
known	O
injury	B-MED
survived	B-MED
and	O
two	O
patients	B-MED
with	O
unknown	O
injury	B-MED
died	B-MED
.	O
As	O
per	O
our	O
experience	B-MED
,	O
we	O
recommend	O
primary	B-MED
closure	I-MED
,	O
if	O
the	O
exact	O
nature	B-MED
of	I-MED
injury	I-MED
is	O
known	O
as	O
the	O
outcome	B-MED
is	O
definitely	O
favourable	B-MED
.	O
Persistent	B-MED
Organic	I-MED
Pollutants	I-MED
(	O
POPs	B-MED
)	O
in	O
the	O
atmosphere	B-MED
of	O
three	O
Chilean	B-MED
cities	B-MED
using	O
passive	B-MED
air	B-MED
samplers	I-MED
In	O
this	O
study	B-MED
passive	B-MED
air	B-MED
samplers	I-MED
containing	O
polyurethane	B-MED
foam	I-MED
(	O
PUF	B-MED
)	O
disks	B-MED
were	O
deployed	B-MED
in	O
three	O
cities	B-MED
across	O
Chile	B-MED
;	O
Santiago	B-MED
(	O
STG	B-MED
)	O
(	O
n=5	O
,	O
sampling	B-MED
sites	I-MED
)	O
,	O
Concepciόn	B-MED
(	O
CON	B-MED
)	O
(	O
n=6	O
)	O
and	O
Temuco	B-MED
(	O
TEM	B-MED
)	O
(	O
n=6	O
)	O
from	O
2008	O
to	O
2009	O
.	O
Polychlorinated	B-MED
biphenyls	I-MED
(	O
PCBs	B-MED
)	O
(	O
7	O
indicator	B-MED
congeners	B-MED
)	O
,	O
chlorinated	B-MED
pesticides	I-MED
hexachlorocyclohexanes	B-MED
(	O
HCHs	B-MED
)	O
,	O
dichlorodiphenyl	B-MED
trichloroethanes	I-MED
(	O
DDTs	B-MED
)	O
and	O
flame	B-MED
retardants	I-MED
such	O
as	O
polybrominated	B-MED
diphenyl	I-MED
ethers	I-MED
(	O
PBDEs	B-MED
)	O
were	O
determined	B-MED
by	I-MED
gas	B-MED
chromatography	I-MED
coupled	I-MED
mass	I-MED
spectrometry	I-MED
(	O
GC	B-MED
/	I-MED
MS	I-MED
)	O
.	O
A	O
sampling	B-MED
rate	B-MED
(	O
R	B-MED
)	O
typical	O
of	O
urban	B-MED
sites	I-MED
(	O
4m(3)/day	O
)	O
was	O
used	O
to	O
estimate	B-MED
the	O
atmospheric	B-MED
concentrations	B-MED
of	O
individual	B-MED
compounds	B-MED
.	O
PCB	B-MED
concentrations	B-MED
in	O
the	O
air	B-MED
(	O
pg	O
/	O
m(3	O
)	O
)	O
ranged	B-MED
from	O
~1	O
-	O
10	O
(	O
TEM	B-MED
)	O
,	O
~1	O
-	O
40	O
(	O
STG	B-MED
)	O
and	O
4	O
-	O
30	O
(	O
CON	B-MED
)	O
.	O
Higher	B-MED
molecular	I-MED
weight	I-MED
PCBs	B-MED
(	O
PCB	B-MED
-153	O
,	O
-180	O
)	O
were	O
detected	B-MED
at	O
industrial	B-MED
sites	I-MED
(	O
in	O
Concepción	B-MED
)	O
.	O
The	O
HCHs	B-MED
showed	O
a	O
prevalence	B-MED
of	O
γ	B-MED
-	I-MED
HCH	I-MED
across	O
all	O
sites	B-MED
,	O
indicative	B-MED
of	O
inputs	B-MED
from	O
the	O
use	O
of	O
lindane	B-MED
but	O
a	O
limited	B-MED
use	O
of	O
technical	B-MED
HCHs	B-MED
in	O
Chile	B-MED
.	O
DDTs	B-MED
were	O
detected	B-MED
with	O
a	O
prevalence	B-MED
of	O
p	B-MED
,	I-MED
p'-DDE	I-MED
accounting	B-MED
for	O
~50	O
%	O
of	O
the	O
total	O
DDTs	B-MED
.	O
PBDE	B-MED
concentrations	B-MED
in	O
air	B-MED
(	O
pg	O
/	O
m(3	O
)	O
)	O
ranged	B-MED
from	O
1	O
to	O
55	O
(	O
STG	B-MED
)	O
,	O
0.5	O
to	O
20	O
(	O
CON	B-MED
)	O
and	O
from	O
0.4	O
to	O
10	O
(	O
TEM	B-MED
)	O
,	O
and	O
were	O
generally	O
similar	B-MED
to	O
those	O
reported	B-MED
for	O
many	O
other	O
urban	B-MED
areas	I-MED
globally	B-MED
.	O
The	O
pattern	B-MED
of	O
PBDEs	B-MED
was	O
different	O
among	O
the	O
three	O
cities	B-MED
;	O
however	O
,	O
PBDE	B-MED
-209	O
was	O
dominant	B-MED
at	O
most	O
of	O
the	O
sites	B-MED
.	O
These	O
results	B-MED
represent	O
one	O
of	O
the	O
few	O
assessments	B-MED
of	O
air	B-MED
concentrations	B-MED
of	O
POPs	B-MED
across	O
different	O
urban	B-MED
areas	I-MED
within	O
the	O
same	O
country	B-MED
.	O
These	O
data	B-MED
will	O
support	B-MED
Chilean	B-MED
commitments	B-MED
as	O
a	O
signatory	B-MED
to	O
the	O
Stockholm	B-MED
Convention	I-MED
on	O
POPs	B-MED
and	O
for	O
reporting	B-MED
as	O
a	O
member	B-MED
country	B-MED
of	O
the	O
Group	B-MED
of	I-MED
Latin	I-MED
America	I-MED
and	I-MED
Caribbean	I-MED
Countries	I-MED
(	I-MED
GRULAC	I-MED
)	I-MED
region	I-MED
.	O
Comparison	B-MED
of	O
270	B-MED
Versus	O
320	B-MED
mg	I-MED
I	I-MED
/	I-MED
mL	I-MED
of	I-MED
Iodixanol	I-MED
in	O
1	O
Image	B-MED
Assessment	I-MED
of	O
Both	O
Renal	B-MED
Arteries	I-MED
and	O
Veins	B-MED
With	O
Dual	B-MED
-	I-MED
Energy	I-MED
Spectral	I-MED
CT	I-MED
Imaging	I-MED
in	O
Late	B-MED
Arterial	I-MED
Phase	I-MED
and	O
Their	O
Influence	B-MED
on	O
Renal	B-MED
Function	I-MED
The	O
objective	O
of	O
this	O
study	B-MED
was	O
to	O
compare	B-MED
the	O
image	B-MED
quality	I-MED
of	O
renal	B-MED
arteries	I-MED
and	O
veins	B-MED
with	O
dual	B-MED
-	I-MED
energy	I-MED
spectral	I-MED
computed	I-MED
tomography	I-MED
(	I-MED
CT	I-MED
)	I-MED
imaging	I-MED
in	O
late	B-MED
arterial	I-MED
phase	I-MED
using	O
270	B-MED
and	O
320	B-MED
mg	I-MED
I	I-MED
/	I-MED
mL	I-MED
of	I-MED
iodixanol	I-MED
and	O
their	O
influence	B-MED
on	O
renal	B-MED
function	I-MED
.	O
A	O
total	O
of	O
1062	O
patients	B-MED
underwent	O
renal	B-MED
CT	I-MED
angiography	I-MED
with	O
270	B-MED
or	O
320	B-MED
mg	I-MED
I	I-MED
/	I-MED
mL	I-MED
of	I-MED
iodixanol	I-MED
with	O
dual	B-MED
-	I-MED
energy	I-MED
spectral	I-MED
CT	I-MED
imaging	I-MED
in	O
late	B-MED
arterial	I-MED
phase	I-MED
.	O
Image	B-MED
quality	I-MED
and	O
their	O
influence	B-MED
on	O
renal	B-MED
function	I-MED
were	O
compared	B-MED
.	O
There	O
were	O
no	O
significant	O
differences	O
of	O
CT	B-MED
value	I-MED
,	O
signal	B-MED
-	I-MED
to	I-MED
-	I-MED
noise	I-MED
ratio	I-MED
,	O
contrast	B-MED
-	I-MED
to	I-MED
-	I-MED
noise	I-MED
ratio	I-MED
,	O
and	O
subjective	O
score	B-MED
of	O
renal	B-MED
vessels	I-MED
between	O
2	O
groups	O
(	O
all	O
P	O
>	O
0.05	O
)	O
.	O
The	O
incidence	B-MED
of	O
contrast	B-MED
-	I-MED
induced	I-MED
nephropathy	I-MED
in	O
patients	B-MED
with	O
abnormal	B-MED
renal	I-MED
function	I-MED
using	O
320	B-MED
mg	I-MED
I	I-MED
/	I-MED
mL	I-MED
of	I-MED
iodixanol	I-MED
was	O
significantly	O
higher	O
than	O
using	O
270	B-MED
mg	I-MED
I	I-MED
/	I-MED
mL	I-MED
of	I-MED
iodixanol	I-MED
(	O
P	O
=	O
0.043	O
)	O
.	O
The	O
renal	B-MED
arteries	I-MED
and	O
veins	B-MED
can	O
be	O
fully	O
assessed	O
in	O
late	B-MED
arterial	I-MED
phase	I-MED
with	O
270	B-MED
mg	I-MED
I	I-MED
/	I-MED
mL	I-MED
of	I-MED
iodixanol	I-MED
using	O
dual	B-MED
-	I-MED
energy	I-MED
spectral	I-MED
CT	I-MED
scan	I-MED
with	O
better	O
preserved	O
renal	B-MED
function	I-MED
.	O
Inhibitory	B-MED
effects	B-MED
of	I-MED
Lactobacillus	B-MED
rhamnosus	I-MED
and	O
Lactobacillus	B-MED
casei	I-MED
on	O
Candida	B-MED
biofilm	B-MED
of	O
denture	B-MED
surface	I-MED
Candida	B-MED
albicans	I-MED
biofilm	B-MED
is	O
associated	B-MED
with	I-MED
denture	B-MED
-	I-MED
related	I-MED
stomatitis	I-MED
and	O
oral	B-MED
candidiasis	I-MED
of	O
elderly	B-MED
.	O
Probiotics	B-MED
are	O
beneficial	O
bacteria	B-MED
and	O
have	O
antibacterial	B-MED
activity	I-MED
against	O
pathogenic	B-MED
bacteria	I-MED
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	B-MED
the	O
antifungal	B-MED
activity	I-MED
of	O
various	O
probiotics	B-MED
against	O
C.	B-MED
albicans	I-MED
and	O
the	O
inhibitory	B-MED
effects	B-MED
of	I-MED
probiotics	B-MED
on	O
Candida	B-MED
biofilm	B-MED
on	O
the	O
denture	B-MED
surface	I-MED
.	O
The	O
spent	B-MED
culture	I-MED
media	I-MED
of	O
various	O
probiotics	B-MED
were	O
investigated	O
the	O
antifungal	B-MED
efficacy	I-MED
against	O
C.	B-MED
albicans	I-MED
.	O
Candida	B-MED
biofilm	B-MED
was	O
formed	O
on	O
a	O
denture	B-MED
base	I-MED
resin	I-MED
and	O
was	O
then	O
treated	B-MED
with	O
Lactobacillus	B-MED
rhamnosus	I-MED
and	O
Lactobacillus	B-MED
casei	I-MED
.	O
Also	O
,	O
the	O
biofilm	B-MED
s	O
of	O
L.	B-MED
rhamnosus	I-MED
and	O
L.	B-MED
casei	I-MED
were	O
formed	O
and	O
were	O
sequentially	O
treated	B-MED
with	O
C.	B-MED
albicans	I-MED
.	O
Colony	B-MED
-	I-MED
forming	I-MED
units	I-MED
of	O
C.	B-MED
albicans	I-MED
on	O
the	O
denture	B-MED
surface	I-MED
were	O
counted	O
after	O
spreading	B-MED
on	O
agar	B-MED
plate	B-MED
.	O
The	O
denture	B-MED
base	I-MED
resin	I-MED
was	O
treated	B-MED
with	O
the	O
spent	B-MED
culture	I-MED
media	I-MED
for	O
30	O
days	B-MED
,	O
after	O
which	O
the	O
denture	B-MED
surface	I-MED
roughness	B-MED
was	O
analyzed	O
with	O
an	O
atomic	B-MED
force	I-MED
microscope	I-MED
.	O
L.	B-MED
rhamnosus	I-MED
and	O
L.	B-MED
casei	I-MED
exhibited	O
stronger	O
antifungal	B-MED
activity	I-MED
than	O
other	O
probiotics	B-MED
.	O
The	O
spent	B-MED
culture	I-MED
medium	I-MED
of	O
L.	B-MED
rhamnosus	I-MED
and	O
L.	B-MED
casei	I-MED
exhibited	O
the	O
antifungal	B-MED
activity	I-MED
against	O
blastoconidia	B-MED
and	O
biofilm	B-MED
of	O
C.	B-MED
albicans	I-MED
.	O
L.	B-MED
rhamnosus	I-MED
and	O
L.	B-MED
casei	I-MED
showed	O
the	O
antifungal	B-MED
activity	I-MED
against	O
Candida	B-MED
biofilm	B-MED
,	O
and	O
the	O
biofilm	B-MED
of	O
L.	B-MED
rhamnosus	I-MED
and	O
L.	B-MED
casei	I-MED
inhibited	B-MED
formation	B-MED
of	O
Candida	B-MED
biofilm	B-MED
on	O
denture	B-MED
surface	I-MED
.	O
Neither	O
of	O
the	O
probiotics	B-MED
affected	O
the	O
surface	B-MED
roughness	I-MED
of	O
the	O
denture	B-MED
base	I-MED
resin	I-MED
.	O
L.	B-MED
rhamnosus	I-MED
and	O
L.	B-MED
casei	I-MED
may	O
be	O
the	O
ideal	O
probiotics	B-MED
for	O
the	O
prevention	B-MED
and	O
treatment	B-MED
of	O
denture	B-MED
-	I-MED
related	I-MED
stomatitis	I-MED
.	O
Giant	B-MED
Antrochoanal	B-MED
Polyp	I-MED
-A	O
Rare	B-MED
Presentation	B-MED
Antrochoanal	B-MED
polyp	I-MED
(	O
ACP	B-MED
)	O
,	O
also	O
called	O
as	O
Killian	B-MED
polyp	I-MED
,	O
is	O
an	O
infrequent	O
,	O
benign	B-MED
lesion	I-MED
of	O
maxillary	B-MED
origin	O
in	O
non	O
-	O
atopic	O
patients	B-MED
.	O
The	O
antrochoanal	B-MED
polyp	I-MED
is	O
shaped	O
according	O
to	O
the	O
anatomical	B-MED
constraints	O
of	O
the	O
lateral	B-MED
nasal	I-MED
wall	I-MED
,	O
particularly	O
the	O
middle	B-MED
meatus	I-MED
and	O
antrum	B-MED
,	O
resembling	O
typically	O
a	O
dumbbell	B-MED
.	O
Here	O
presenting	O
a	O
common	O
problem	B-MED
with	O
unusual	B-MED
presentation	B-MED
.	O
Forensic	B-MED
characteristics	I-MED
and	O
phylogenetic	B-MED
analyses	I-MED
of	O
the	O
Chinese	B-MED
Yi	B-MED
population	I-MED
via	O
19	O
X	B-MED
-	I-MED
chromosomal	I-MED
STR	B-MED
loci	B-MED
The	O
demographic	B-MED
characteristics	I-MED
and	O
genetic	B-MED
polymorphism	I-MED
data	B-MED
of	O
56	O
Chinese	B-MED
nationalities	B-MED
or	O
31	O
administrative	B-MED
divisions	I-MED
in	O
Chinese	B-MED
mainland	I-MED
have	O
repeatedly	O
been	O
the	O
genetic	B-MED
research	I-MED
hotspots	B-MED
.	O
While	O
most	O
genetic	B-MED
studies	I-MED
focused	O
on	O
some	O
particular	O
Chinese	B-MED
populations	B-MED
based	O
on	O
autosomal	B-MED
or	O
Y	B-MED
-	I-MED
chromosomal	I-MED
genetic	B-MED
markers	I-MED
,	O
the	O
forensic	B-MED
characteristics	I-MED
and	O
phylogenetic	B-MED
analyses	I-MED
of	O
the	O
seventh	O
largest	O
Chinese	B-MED
population	B-MED
(	O
Yi	B-MED
ethnicity	I-MED
)	O
on	O
the	O
X	B-MED
-	I-MED
chromosomal	I-MED
genetic	B-MED
markers	I-MED
are	O
scarce	O
.	O
Here	O
,	O
allele	B-MED
frequencies	I-MED
and	O
forensic	B-MED
statistical	I-MED
parameters	I-MED
for	O
19	O
X	B-MED
-	I-MED
chromosomal	I-MED
short	B-MED
tandem	I-MED
repeat	I-MED
loci	B-MED
(	O
DXS7424	B-MED
-	I-MED
DXS101	I-MED
,	O
DXS6789	B-MED
-	I-MED
DXS6809	I-MED
,	O
DXS7423	B-MED
-	I-MED
DXS10134	I-MED
,	O
DXS10103	B-MED
-	I-MED
HPRTB	I-MED
-	I-MED
DXS10101	I-MED
,	O
DXS10159	B-MED
-	I-MED
DXS10162	I-MED
-	I-MED
DXS10164	I-MED
,	O
DXS10148	B-MED
-	I-MED
DXS10135	I-MED
-	I-MED
DXS8378	I-MED
,	O
and	O
DXS7132	B-MED
-	I-MED
DXS10079	I-MED
-	I-MED
DXS10074	I-MED
-	I-MED
DXS10075	I-MED
)	O
of	O
331	O
Chinese	B-MED
Yi	B-MED
individuals	I-MED
were	O
obtained	O
.	O
All	O
19	O
X	B-MED
-	I-MED
chromosomal	I-MED
short	B-MED
tandem	I-MED
repeat	I-MED
(	O
STR	B-MED
)	O
loci	B-MED
in	O
females	B-MED
were	O
consistent	O
with	O
the	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
test	O
.	O
A	O
total	O
of	O
214	O
alleles	B-MED
were	O
identified	B-MED
with	O
the	O
corresponding	O
allele	B-MED
frequencies	I-MED
spanned	O
from	O
0.0019	O
to	O
0.6106	O
.	O
The	O
combined	O
PE	B-MED
,	O
PDF	B-MED
,	O
and	O
PDM	B-MED
were	O
0.9999999214	O
,	O
0.9999999999999999999993	O
,	O
and	O
0.9999999999998	O
,	O
respectively	O
.	O
The	O
high	O
combined	O
MECKrüger	B-MED
,	O
MECKishida	B-MED
,	O
MECDesmarais	B-MED
,	O
and	O
MECDesmarais	B-MED
Duo	I-MED
were	O
achieved	O
as	O
0.9999999617638	O
,	O
0.9999999999971	O
,	O
0.9999999999971	O
,	O
and	O
0.9999999931538	O
,	O
respectively	O
.	O
The	O
findings	B-MED
suggested	O
that	O
the	O
panel	B-MED
of	O
19	O
X	B-MED
-	I-MED
STR	I-MED
loci	B-MED
is	O
highly	O
polymorphic	B-MED
and	O
informative	B-MED
in	O
the	O
Yi	B-MED
ethnic	I-MED
population	I-MED
and	O
can	O
be	O
considered	O
to	O
be	O
a	O
powerful	O
tool	B-MED
in	O
forensic	B-MED
complex	I-MED
kinship	I-MED
identification	I-MED
.	O
Population	B-MED
differentiation	I-MED
analyses	I-MED
among	O
12	O
populations	B-MED
indicated	O
that	O
significant	O
differences	B-MED
in	O
genetic	B-MED
structure	I-MED
were	O
observed	O
in	O
between	O
the	O
Yi	B-MED
ethnicity	I-MED
and	O
the	O
Chinese	B-MED
Uyghur	B-MED
as	O
well	O
as	O
Kazakh	B-MED
,	O
and	O
genetic	B-MED
homogeneity	I-MED
existed	O
in	O
similar	O
ethno	B-MED
-	I-MED
origin	I-MED
or	O
geographic	B-MED
origin	I-MED
populations	I-MED
.	O
Association	B-MED
of	O
CKIP-1	B-MED
P21A	I-MED
polymorphism	B-MED
with	O
risk	B-MED
of	O
chronic	B-MED
heart	I-MED
failure	I-MED
in	O
a	O
Chinese	B-MED
population	I-MED
Pathological	B-MED
cardiac	B-MED
hypertrophy	I-MED
is	O
an	O
independent	O
risk	B-MED
factor	I-MED
for	O
chronic	B-MED
heart	I-MED
failure	I-MED
.	O
Casein	B-MED
kinase-2	I-MED
interacting	I-MED
protein-1	I-MED
(	O
CKIP-1	B-MED
)	O
can	O
inhibit	O
pathological	B-MED
cardiac	B-MED
hypertrophy	I-MED
.	O
Therefore	O
,	O
we	O
investigated	B-MED
whether	O
CKIP-1	B-MED
nonsynonymous	B-MED
polymorphism	I-MED
rs2306235	I-MED
(	O
Pro21Ala	B-MED
)	O
contributes	O
to	O
risk	B-MED
and	O
prognosis	B-MED
of	O
chronic	B-MED
heart	I-MED
failure	I-MED
in	O
a	O
Chinese	B-MED
population	I-MED
.	O
A	O
total	O
of	O
923	O
adult	B-MED
patients	B-MED
with	O
chronic	B-MED
heart	I-MED
failure	I-MED
and	O
1020	O
age	B-MED
-	O
and	O
gender	B-MED
-matched	O
healthy	B-MED
controls	I-MED
were	O
recruited	O
.	O
CKIP-1	B-MED
rs2306235	I-MED
polymorphism	B-MED
was	O
genotyped	B-MED
using	O
PCR	B-MED
-	O
restriction	B-MED
fragment	I-MED
length	I-MED
polymorphism	I-MED
.	O
Additional	O
follow	B-MED
-	I-MED
up	I-MED
data	B-MED
for	O
140	O
chronic	B-MED
heart	I-MED
failure	I-MED
patients	B-MED
was	O
evaluated	B-MED
.	O
The	O
rs2306235	B-MED
G	B-MED
allele	I-MED
was	O
associated	O
with	O
an	O
increased	B-MED
risk	B-MED
of	O
chronic	B-MED
heart	I-MED
failure	I-MED
(	O
OR	B-MED
=	O
1.38	O
,	O
95	O
%	O
CI	B-MED
=	O
1.09	O
-	O
1.75	O
,	O
p	B-MED
=	O
0.007	O
)	O
,	O
especially	O
in	O
patients	B-MED
with	O
hypertension	B-MED
(	O
OR	B-MED
=	O
1.45	O
,	O
95	O
%	O
CI	B-MED
=	O
1.09	O
-	O
1.75	O
,	O
p	O
=	O
0.006	O
)	O
and	O
coronary	B-MED
heart	I-MED
disease	I-MED
(	O
OR	B-MED
=	O
1.41	O
,	O
95	O
%	O
CI	B-MED
=	O
1.09	O
-	O
1.83	O
,	O
p	B-MED
=	O
0.010	O
)	O
after	O
adjustment	O
for	O
multiple	B-MED
cardiovascular	I-MED
risk	B-MED
factors	I-MED
.	O
However	O
,	O
rs2306235	B-MED
polymorphism	B-MED
was	O
not	O
associated	O
with	O
cardiovascular	B-MED
mortality	I-MED
in	O
chronic	B-MED
heart	I-MED
failure	I-MED
(	O
p	O
=	O
0.875	O
)	O
.	O
CKIP-1	B-MED
rs2306235	I-MED
polymorphism	B-MED
may	O
be	O
a	O
risk	B-MED
factor	I-MED
for	O
chronic	B-MED
heart	I-MED
failure	I-MED
in	O
a	O
Chinese	B-MED
Han	I-MED
population	I-MED
.	O
Isolation	B-MED
and	O
prebiotic	B-MED
activity	B-MED
of	O
water	B-MED
-	I-MED
soluble	I-MED
polysaccharides	B-MED
fractions	B-MED
from	O
the	O
bamboo	B-MED
shoots	I-MED
(	O
Phyllostachys	B-MED
praecox	I-MED
)	O
The	O
water	B-MED
-	I-MED
soluble	I-MED
polysaccharides	B-MED
from	O
bamboo	B-MED
shoots	I-MED
(	O
Phyllostachys	B-MED
praecox	I-MED
)	O
(	O
WBP	B-MED
)	O
were	O
isolated	B-MED
,	O
and	O
the	O
characterizations	B-MED
as	O
well	O
as	O
prebiotic	B-MED
activities	B-MED
were	O
investigated	B-MED
.	O
The	O
yield	B-MED
of	O
WBP	B-MED
was	O
7.58±0.31	O
%	O
under	O
optimal	O
hot	B-MED
-	I-MED
water	I-MED
extraction	B-MED
conditions	O
.	O
Two	O
fractions	B-MED
,	O
i.e.	O
,	O
WBP-1	B-MED
and	O
WBP-2	B-MED
with	O
molecular	B-MED
weight	I-MED
of	O
83.50kDa	O
and	O
80.08kDa	O
,	O
respectively	O
,	O
were	O
purified	O
by	O
chromatography	B-MED
.	O
Both	O
the	O
polysaccharides	B-MED
fractions	B-MED
were	O
identified	O
as	O
heteropolysaccharides	B-MED
-	I-MED
protein	I-MED
complexes	I-MED
composed	O
of	O
15	O
kinds	O
of	O
common	O
amino	B-MED
acids	I-MED
in	O
protein	B-MED
part	O
and	O
rhamnose	B-MED
,	O
arabinose	B-MED
,	O
xylose	B-MED
,	O
mannose	B-MED
,	O
glucose	B-MED
and	O
galactose	B-MED
in	O
different	O
molar	B-MED
ratios	I-MED
in	O
polysaccharide	B-MED
part	O
.	O
The	O
existence	O
of	O
α-	B-MED
and	O
β	B-MED
-	I-MED
glycosidic	I-MED
linkages	I-MED
between	O
the	O
sugar	B-MED
units	O
was	O
confirmed	O
by	O
FTIR	B-MED
and	O
NMR	B-MED
spectra	I-MED
.	O
Compared	O
with	O
the	O
blank	O
control	O
and	O
the	O
reference	O
of	O
FOS	O
,	O
WBP-1	B-MED
and	O
WBP-2	B-MED
significantly	O
increased	O
the	O
numbers	O
of	O
Bifidobacterium	B-MED
adolescentis	I-MED
and	O
Bifidobacterium	B-MED
bifidum	I-MED
(	O
P<0.05	O
)	O
,	O
which	O
contributed	O
to	O
the	O
production	B-MED
of	O
organic	B-MED
acids	I-MED
,	O
suggesting	O
that	O
the	O
polysaccharides	B-MED
have	O
potential	B-MED
prebiotic	B-MED
properties	B-MED
.	O
Impact	B-MED
of	O
Soil	B-MED
Salinity	B-MED
on	O
the	O
Structure	B-MED
of	O
the	O
Bacterial	B-MED
Endophytic	B-MED
Community	B-MED
Identified	B-MED
from	O
the	O
Roots	B-MED
of	O
Caliph	B-MED
Medic	I-MED
(	O
Medicago	B-MED
truncatula	I-MED
)	O
In	O
addition	O
to	O
being	O
a	O
forage	B-MED
crop	I-MED
,	O
Caliph	B-MED
medic	I-MED
(	O
Medicago	B-MED
truncatula	I-MED
)	O
is	O
also	O
a	O
model	B-MED
legume	I-MED
plant	I-MED
and	O
is	O
used	O
for	O
research	O
focusing	O
on	O
the	O
molecular	B-MED
characterization	I-MED
of	O
the	O
interaction	B-MED
between	O
rhizobia	B-MED
and	O
plants	B-MED
.	O
However	O
,	O
the	O
endophytic	B-MED
microbiome	I-MED
in	O
this	O
plant	B-MED
is	O
poorly	O
defined	O
.	O
Endophytic	B-MED
bacteria	B-MED
play	O
a	O
role	O
in	O
supplying	O
plants	B-MED
with	O
the	O
basic	O
requirements	B-MED
necessary	O
for	O
growth	B-MED
and	O
development	B-MED
.	O
Moreover	O
,	O
these	O
bacteria	B-MED
also	O
play	O
a	O
role	O
in	O
the	O
mechanism	B-MED
of	O
salinity	B-MED
stress	I-MED
adaptation	B-MED
in	O
plants	B-MED
.	O
As	O
a	O
prelude	O
to	O
the	O
isolation	B-MED
and	O
utilization	B-MED
of	O
these	O
bacteria	B-MED
in	O
Caliph	B-MED
medic	I-MED
farming	B-MED
,	O
41	O
bacterial	B-MED
OTUs	B-MED
were	O
identified	B-MED
in	O
this	O
project	O
from	O
within	O
the	O
interior	B-MED
of	O
the	O
roots	B-MED
of	O
this	O
plant	B-MED
by	O
pyrosequencing	B-MED
of	O
the	O
small	B-MED
ribosomal	I-MED
subunit	I-MED
gene	I-MED
(	O
16S	B-MED
rDNA	I-MED
)	O
using	O
a	O
cultivation	B-MED
-	I-MED
independent	I-MED
approach	I-MED
.	O
In	O
addition	O
,	O
the	O
differential	B-MED
abundance	B-MED
of	O
these	O
bacteria	B-MED
was	O
studied	O
following	O
exposure	O
of	O
the	O
plants	B-MED
to	O
salinity	B-MED
stress	I-MED
.	O
About	O
29,064	O
high	B-MED
-	I-MED
quality	I-MED
reads	I-MED
were	O
obtained	O
from	O
the	O
sequencing	B-MED
of	O
six	O
libraries	B-MED
prepared	O
from	O
control	B-MED
and	O
salinity	B-MED
-	I-MED
treated	I-MED
tissues	I-MED
.	O
Statistical	B-MED
analysis	I-MED
revealed	O
that	O
the	O
abundance	B-MED
of	O
~70	O
%	O
of	O
the	O
OTUs	B-MED
was	O
significantly	O
(	O
p	O
≤	O
0.05	O
)	O
altered	O
in	O
roots	B-MED
that	O
were	O
exposed	B-MED
to	I-MED
salinity	B-MED
stress	I-MED
.	O
Sequence	B-MED
analysis	I-MED
showed	O
a	O
similarity	O
between	O
some	O
of	O
the	O
identified	B-MED
species	B-MED
and	O
other	O
,	O
known	O
,	O
growth	B-MED
-	I-MED
promoting	I-MED
bacteria	I-MED
,	O
marine	B-MED
and	O
salt	B-MED
-	I-MED
stressed	I-MED
soil	I-MED
-	I-MED
borne	I-MED
bacteria	I-MED
,	O
and	O
nitrogen	B-MED
-	I-MED
fixing	I-MED
bacterial	I-MED
isolates	B-MED
.	O
Determination	O
of	O
the	O
amendments	O
to	O
the	O
bacteria	B-MED
l	O
community	B-MED
due	O
to	O
salinity	B-MED
stress	I-MED
in	O
Caliph	B-MED
medic	I-MED
provides	O
a	O
crucial	O
step	O
toward	O
developing	O
an	O
understanding	O
of	O
the	O
association	B-MED
of	O
these	O
endophytes	B-MED
,	O
under	O
salt	B-MED
stress	I-MED
conditions	I-MED
,	O
in	O
this	O
model	B-MED
plant	I-MED
.	O
To	O
provide	O
direct	O
evidence	B-MED
regarding	O
their	O
growth	B-MED
promoting	I-MED
activity	I-MED
,	O
a	O
group	B-MED
of	O
endophytic	B-MED
bacteria	B-MED
were	O
isolated	B-MED
from	O
inside	O
of	O
plant	B-MED
roots	I-MED
using	O
a	O
cultivation	B-MED
-	I-MED
dependent	I-MED
approach	I-MED
.	O
Several	O
of	O
these	O
isolates	B-MED
were	O
able	O
to	O
produce	O
ACC	B-MED
-	I-MED
deaminase	I-MED
,	O
ammonia	B-MED
and	O
IAA	B-MED
;	O
and	O
to	O
solubilize	B-MED
Zn+2	B-MED
and	O
PO4	B-MED
-	I-MED
3	I-MED
.	O
This	O
data	B-MED
is	O
consistent	O
with	O
the	O
predicted	O
occurrence	B-MED
(	O
based	O
on	O
cultivation	B-MED
-	I-MED
independent	I-MED
techniques	I-MED
)	O
of	O
these	O
bacteria	B-MED
and	O
provides	O
some	O
insight	O
into	O
the	O
importance	O
of	O
the	O
endophytic	B-MED
bacteria	B-MED
in	O
Caliph	B-MED
medic	I-MED
when	O
grown	O
under	O
normal	B-MED
and	O
saline	B-MED
conditions	B-MED
.	O
Bilirubin	B-MED
and	O
atherosclerotic	B-MED
diseases	B-MED
Bilirubin	B-MED
is	O
the	O
final	O
product	B-MED
of	O
heme	B-MED
catabolism	I-MED
in	O
the	O
systemic	B-MED
circulation	I-MED
.	O
For	O
decades	B-MED
,	O
increased	B-MED
serum	B-MED
/	O
plasma	B-MED
bilirubin	B-MED
levels	B-MED
were	O
considered	O
an	O
ominous	O
sign	B-MED
of	O
an	O
underlying	O
liver	B-MED
disease	I-MED
.	O
However	O
,	O
data	B-MED
from	O
recent	O
years	B-MED
convincingly	O
suggest	O
that	O
mildly	O
elevated	B-MED
bilirubin	B-MED
concentrations	B-MED
are	O
associated	B-MED
with	O
protection	B-MED
against	O
various	O
oxidative	B-MED
stress	I-MED
-mediated	O
diseases	B-MED
diseases	B-MED
,	O
atherosclerotic	B-MED
conditions	O
being	O
the	O
most	O
clinically	B-MED
relevant	B-MED
.	O
Although	O
scarce	O
data	B-MED
on	O
beneficial	B-MED
effects	B-MED
of	O
bilirubin	B-MED
had	O
been	O
published	B-MED
also	O
in	O
the	O
past	O
,	O
it	O
took	O
until	O
1994	O
when	O
the	O
first	O
clinical	B-MED
study	I-MED
demonstrated	O
an	O
increased	B-MED
risk	B-MED
of	O
coronary	B-MED
heart	I-MED
disease	I-MED
in	O
subjects	O
with	O
low	B-MED
serum	B-MED
bilirubin	B-MED
levels	B-MED
,	O
and	O
bilirubin	B-MED
was	O
found	O
to	O
be	O
a	O
risk	B-MED
factor	I-MED
for	O
atherosclerotic	B-MED
diseases	B-MED
independent	O
of	O
standard	O
risk	B-MED
factors	I-MED
.	O
Consistent	O
with	O
these	O
results	B-MED
,	O
we	O
proved	O
in	O
our	O
own	O
studies	B-MED
,	O
that	O
subjects	O
with	O
mild	B-MED
elevation	I-MED
of	I-MED
serum	I-MED
levels	I-MED
of	I-MED
unconjugated	I-MED
bilirubin	I-MED
(	O
benign	B-MED
hyperbilirubinemia	B-MED
,	O
Gilbert	B-MED
syndrome	I-MED
)	O
have	O
much	O
lower	O
prevalence	B-MED
/	O
incidence	B-MED
of	O
coronary	B-MED
heart	I-MED
as	O
well	O
as	O
peripheral	B-MED
vascular	I-MED
disease	I-MED
.	O
We	O
have	O
also	O
demonstrated	O
that	O
this	O
association	B-MED
is	O
even	O
more	O
general	O
,	O
with	O
serum	B-MED
bilirubin	B-MED
being	O
a	O
biomarker	B-MED
of	O
numerous	O
other	O
diseases	B-MED
diseases	B-MED
,	O
often	O
associated	B-MED
with	O
increased	B-MED
risk	B-MED
of	O
atherosclerosis	B-MED
.	O
In	O
addition	O
,	O
very	O
recent	O
data	B-MED
have	O
demonstrated	O
biological	B-MED
pathways	I-MED
modulated	O
by	O
bilirubin	B-MED
,	O
which	O
are	O
responsible	O
for	O
observed	O
strong	O
clinical	B-MED
associations	B-MED
.	O
Visual	B-MED
outcome	B-MED
,	O
endocrine	B-MED
function	I-MED
and	O
tumor	B-MED
control	B-MED
after	O
fractionated	B-MED
stereotactic	I-MED
radiation	I-MED
therapy	I-MED
of	O
craniopharyngiomas	B-MED
in	I-MED
adults	I-MED
:	O
findings	O
in	O
a	O
prospective	B-MED
cohort	I-MED
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
examine	B-MED
visual	B-MED
outcome	B-MED
,	O
endocrine	B-MED
function	I-MED
and	O
tumor	B-MED
control	B-MED
in	O
a	O
prospective	B-MED
cohort	I-MED
of	O
craniopharyngioma	B-MED
patients	B-MED
,	O
treated	B-MED
with	I-MED
fractionated	B-MED
stereotactic	I-MED
radiation	I-MED
therapy	I-MED
(	O
FSRT	B-MED
)	O
.	O
Sixteen	O
adult	B-MED
patients	B-MED
with	O
craniopharyngiomas	B-MED
were	O
eligible	B-MED
for	O
analysis	B-MED
.	O
They	O
were	O
treated	B-MED
with	I-MED
linear	B-MED
accelerator	I-MED
-	I-MED
based	I-MED
FSRT	B-MED
during	O
1999	O
-	O
2015	O
.	O
In	O
all	O
cases	B-MED
,	O
diagnosis	B-MED
was	O
confirmed	O
by	O
histological	B-MED
analysis	B-MED
.	O
The	O
prescription	B-MED
dose	B-MED
to	O
the	O
tumor	B-MED
was	O
54	O
Gy	B-MED
(	O
median	B-MED
,	O
range	B-MED
48	O
-	O
54	O
)	O
in	O
1.8	O
or	O
2.0	O
Gy	B-MED
per	O
fraction	B-MED
,	O
and	O
the	O
maximum	O
radiation	B-MED
dose	I-MED
to	O
the	O
optic	B-MED
nerves	I-MED
and	O
chiasm	B-MED
was	O
54.2	O
Gy	B-MED
(	O
median	B-MED
,	O
range	B-MED
48.6	O
-	O
60.0	O
)	O
for	O
the	O
cohort	B-MED
.	O
Serial	O
ophthalmological	B-MED
and	O
endocrine	B-MED
evaluations	I-MED
and	O
magnetic	B-MED
resonance	I-MED
imaging	I-MED
(	O
MRI	B-MED
)	O
scans	B-MED
were	O
performed	O
at	O
regular	O
intervals	O
.	O
Median	B-MED
follow	B-MED
-	I-MED
up	I-MED
was	O
3.3	O
years	B-MED
(	O
range	B-MED
1.1	O
-	O
14.1	O
)	O
,	O
3.7	O
years	B-MED
(	O
range	B-MED
0.8	O
-	O
15.2	O
)	O
,	O
and	O
3.6	O
years	B-MED
(	O
range	B-MED
0.7	O
-	O
13.1	O
)	O
for	O
visual	B-MED
outcome	B-MED
,	O
endocrine	B-MED
function	I-MED
,	O
and	O
tumor	B-MED
control	B-MED
,	O
respectively	O
.	O
Visual	B-MED
acuity	I-MED
impairment	B-MED
was	O
present	O
in	O
10	O
patients	B-MED
(	O
62.5	O
%	O
)	O
and	O
visual	B-MED
field	I-MED
defects	I-MED
were	O
present	O
in	O
12	O
patients	B-MED
(	O
75	O
%	O
)	O
before	O
FSRT	B-MED
.	O
One	O
patient	B-MED
developed	O
radiation	B-MED
-	I-MED
induced	I-MED
optic	I-MED
neuropathy	I-MED
at	O
seven	O
years	B-MED
after	O
FSRT	B-MED
.	O
Thirteen	O
of	O
16	O
patients	B-MED
(	O
81.3	O
%	O
)	O
had	O
pituitary	B-MED
deficiency	I-MED
before	O
FSRT	B-MED
,	O
and	O
did	O
not	O
develop	O
further	O
pituitary	B-MED
deficiency	I-MED
after	O
FSRT	B-MED
.	O
Mean	B-MED
tumor	B-MED
volume	I-MED
pre-	O
FSRT	B-MED
was	O
2.72	O
cm(3	O
)	O
(	O
range	B-MED
0.20	O
-	O
9.90	O
)	O
and	O
post-	O
FSRT	B-MED
1.2	O
cm(3	O
)	O
(	O
range	B-MED
0.00	O
-	O
13.10	O
)	O
.	O
Tumor	B-MED
control	B-MED
rate	B-MED
was	O
81.3	O
%	O
at	O
two	O
,	O
five	O
,	O
and	O
10	O
years	B-MED
after	O
FSRT	B-MED
.	O
FSRT	B-MED
was	O
relatively	O
safe	O
in	O
this	O
prospective	O
cohort	B-MED
of	O
craniopharyngiomas	B-MED
,	O
with	O
only	O
one	O
case	B-MED
of	O
radiation	B-MED
-	I-MED
induced	I-MED
optic	I-MED
neuropathy	I-MED
and	O
no	O
case	B-MED
of	O
new	O
endocrinopathy	B-MED
.	O
Tumor	B-MED
control	B-MED
rate	B-MED
was	O
acceptable	O
.	O
TLR9	B-MED
Deficiency	B-MED
Leads	O
to	O
Accelerated	B-MED
Renal	B-MED
Disease	I-MED
and	O
Myeloid	B-MED
Lineage	I-MED
Abnormalities	B-MED
in	O
Pristane	B-MED
-Induced	O
Murine	B-MED
Lupus	B-MED
Systemic	B-MED
lupus	I-MED
erythematosus	I-MED
(	O
SLE	B-MED
)	I-MED
is	O
a	O
chronic	B-MED
,	O
life	B-MED
-	I-MED
threatening	I-MED
autoimmune	B-MED
disorder	I-MED
,	O
leading	O
to	O
multiple	O
organ	B-MED
pathologies	B-MED
and	O
kidney	B-MED
destruction	B-MED
.	O
Analyses	O
of	O
numerous	O
murine	B-MED
models	B-MED
of	O
spontaneous	O
SLE	B-MED
have	O
revealed	O
a	O
critical	O
role	O
for	O
endosomal	B-MED
TLRs	B-MED
in	O
the	O
production	O
of	O
autoantibodies	B-MED
and	O
development	O
of	O
other	O
clinical	B-MED
disease	B-MED
manifestations	B-MED
.	O
Nevertheless	O
,	O
the	O
corresponding	O
TLR9	B-MED
-	O
deficient	B-MED
autoimmune	B-MED
-prone	O
strains	B-MED
consistently	O
develop	O
more	O
severe	O
disease	B-MED
pathology	B-MED
.	O
Injection	B-MED
of	O
BALB	B-MED
/	I-MED
c	I-MED
mice	I-MED
with	O
2,6,10,14	B-MED
-	I-MED
tetramethylpentadecane	I-MED
(	O
TMPD	B-MED
)	O
,	O
commonly	O
known	O
as	O
pristane	B-MED
,	O
also	O
results	O
in	O
the	O
development	O
of	O
SLE	B-MED
-	I-MED
like	I-MED
disease	I-MED
.	O
We	O
now	O
show	O
that	O
Tlr9(-/-	B-MED
)	I-MED
BALB	B-MED
/	I-MED
c	I-MED
mice	I-MED
injected	B-MED
i.p	I-MED
.	I-MED
with	O
TMPD	B-MED
develop	O
more	O
severe	O
autoimmunity	B-MED
than	O
do	O
their	O
TLR	B-MED
-sufficient	O
cohorts	O
.	O
Early	O
indications	O
include	O
an	O
increased	O
accumulation	B-MED
of	O
TLR7	B-MED
-	O
expressing	B-MED
Ly6C(hi	B-MED
)	I-MED
inflammatory	B-MED
monocytes	B-MED
at	O
the	O
site	B-MED
of	I-MED
injection	I-MED
,	O
upregulation	B-MED
of	O
IFN	B-MED
-regulated	O
gene	B-MED
expression	I-MED
in	O
the	O
peritoneal	B-MED
cavity	I-MED
,	O
and	O
an	O
increased	O
production	O
of	O
myeloid	B-MED
lineage	I-MED
precursors	I-MED
(	O
common	B-MED
myeloid	I-MED
progenitors	I-MED
and	O
granulocyte	B-MED
myeloid	B-MED
precursors	I-MED
)	O
in	O
the	O
bone	B-MED
marrow	I-MED
.	O
TMPD	B-MED
-	O
injected	B-MED
Tlr9(-/-	B-MED
)	I-MED
BALB	B-MED
/	I-MED
c	I-MED
mice	I-MED
develop	O
higher	O
autoantibody	B-MED
titers	O
against	O
RNA	B-MED
,	O
neutrophil	B-MED
cytoplasmic	B-MED
Ags	B-MED
,	O
and	O
myeloperoxidase	B-MED
than	O
do	O
TMPD	B-MED
-	O
injected	B-MED
wild	B-MED
-	I-MED
type	I-MED
BALB	I-MED
/	I-MED
c	I-MED
mice	I-MED
.	O
The	O
TMP	B-MED
-	O
injected	B-MED
Tlr9(-/-	B-MED
)	I-MED
mice	B-MED
,	O
and	O
not	O
the	O
wild	B-MED
-	I-MED
type	I-MED
mice	I-MED
,	O
also	O
develop	O
a	O
marked	O
increase	O
in	O
glomerular	B-MED
IgG	I-MED
deposition	B-MED
and	O
infiltrating	O
granulocytes	B-MED
,	O
much	O
more	O
severe	O
glomerulonephritis	B-MED
,	O
and	O
a	O
reduced	B-MED
lifespan	B-MED
.	O
Collectively	O
,	O
the	O
data	O
point	O
to	O
a	O
major	O
role	O
for	O
TLR7	B-MED
in	O
the	O
response	B-MED
to	O
self	B-MED
-	I-MED
antigens	I-MED
in	O
this	O
model	B-MED
of	O
experimental	O
autoimmunity	B-MED
.	O
Therefore	O
,	O
the	O
BALB	B-MED
/	I-MED
c	I-MED
pristane	B-MED
model	B-MED
recapitulates	O
other	O
TLR7	B-MED
-driven	O
spontaneous	O
models	B-MED
of	O
SLE	B-MED
and	O
is	O
negatively	B-MED
regulated	O
by	O
TLR9	B-MED
.	O
Interobserver	B-MED
and	O
Intraobserver	B-MED
Reliability	B-MED
of	O
Clinical	B-MED
Assessments	I-MED
in	O
Knee	B-MED
Osteoarthritis	I-MED
Clinical	B-MED
examination	I-MED
of	O
the	O
knee	B-MED
is	O
subject	O
to	O
measurement	B-MED
error	I-MED
.	O
The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
interobserver	B-MED
and	O
intraobserver	B-MED
reliability	B-MED
of	O
commonly	O
used	O
clinical	O
tests	O
in	O
patients	B-MED
with	O
knee	B-MED
osteoarthritis	I-MED
(	O
OA	B-MED
)	O
.	O
We	O
studied	O
subjects	B-MED
with	O
symptomatic	B-MED
knee	B-MED
OA	I-MED
who	O
were	O
participants	B-MED
in	O
an	O
open	B-MED
-	I-MED
label	I-MED
clinical	I-MED
trial	I-MED
of	O
intraarticular	B-MED
steroid	I-MED
therapy	I-MED
.	O
Following	O
standardization	B-MED
of	O
the	O
clinical	B-MED
test	I-MED
procedures	I-MED
,	O
2	O
clinicians	B-MED
assessed	B-MED
25	O
subjects	B-MED
independently	O
at	O
the	O
same	O
visit	B-MED
,	O
and	O
the	O
same	O
clinician	B-MED
assessed	B-MED
88	O
subjects	B-MED
over	O
an	O
interval	B-MED
period	I-MED
of	O
2	O
-	O
10	O
weeks	O
;	O
in	O
both	O
cases	O
prior	O
to	O
the	O
steroid	B-MED
intervention	B-MED
.	O
Clinical	B-MED
examination	I-MED
included	B-MED
assessment	B-MED
of	O
bony	B-MED
enlargement	I-MED
,	O
crepitus	B-MED
,	O
quadriceps	B-MED
wasting	I-MED
,	O
knee	B-MED
effusion	I-MED
,	O
joint	B-MED
-	I-MED
line	I-MED
and	O
anserine	B-MED
tenderness	B-MED
,	O
and	O
knee	B-MED
range	I-MED
of	I-MED
movement	I-MED
(	O
ROM	B-MED
)	O
.	O
Intraclass	B-MED
correlation	I-MED
coefficients	I-MED
(	O
ICC	B-MED
)	O
,	O
estimated	B-MED
kappa	I-MED
(	O
κ	B-MED
)	O
,	O
weighted	B-MED
kappa	I-MED
(	O
κω	B-MED
)	O
,	O
and	O
Bland	B-MED
-	I-MED
Altman	I-MED
plots	I-MED
were	O
used	O
to	O
determine	O
interobserver	B-MED
and	O
intraobserver	B-MED
levels	B-MED
of	O
agreement	B-MED
.	O
Using	O
Landis	B-MED
and	I-MED
Koch	I-MED
criteria	I-MED
,	O
interobserver	B-MED
κ	I-MED
scores	I-MED
were	O
moderate	B-MED
for	O
patellofemoral	B-MED
joint	I-MED
(	O
κ	B-MED
=	O
0.53	O
)	O
and	O
anserine	B-MED
tenderness	B-MED
(	O
κ	B-MED
=	O
0.48	O
)	O
;	O
good	B-MED
for	O
bony	B-MED
enlargement	I-MED
(	O
κ	B-MED
=	O
0.66	O
)	O
,	O
quadriceps	B-MED
wasting	I-MED
(	O
κ	B-MED
=	O
0.78	O
)	O
,	O
crepitus	B-MED
(	O
κ	B-MED
=	O
0.78	O
)	O
,	O
medial	B-MED
tibiofemoral	B-MED
joint	I-MED
tenderness	B-MED
(	O
κ	B-MED
=	O
0.76	O
)	O
,	O
and	O
effusion	B-MED
assessed	O
by	O
ballottement	B-MED
(	O
κ	B-MED
=	O
0.73	O
)	O
and	O
bulge	B-MED
sign	I-MED
(	O
κω	B-MED
=	O
0.78	O
)	O
;	O
and	O
excellent	B-MED
for	O
lateral	B-MED
tibiofemoral	B-MED
joint	I-MED
tenderness	B-MED
(	O
κ	B-MED
=	O
1.00	O
)	O
,	O
flexion	B-MED
(	O
ICC	B-MED
=	O
0.97	O
)	O
,	O
and	O
extension	B-MED
(	O
ICC	B-MED
=	O
0.87	O
)	O
ROM	B-MED
.	O
Intraobserver	B-MED
κ	I-MED
scores	I-MED
were	O
moderate	B-MED
for	O
lateral	B-MED
tibiofemoral	B-MED
joint	I-MED
tenderness	B-MED
(	O
κ	B-MED
=	O
0.60	O
)	O
;	O
good	O
for	O
crepitus	O
(	O
κ	B-MED
=	O
0.78	O
)	O
,	O
effusion	B-MED
assessed	O
by	O
ballottement	B-MED
test	I-MED
(	O
κ	B-MED
=	O
0.77	O
)	O
,	O
patellofemoral	B-MED
joint	I-MED
(	O
κ	B-MED
=	O
0.66	O
)	O
,	O
medial	B-MED
tibiofemoral	B-MED
joint	I-MED
(	O
κ	B-MED
=	O
0.64	O
)	O
,	O
and	O
anserine	B-MED
tenderness	B-MED
(	O
κ	B-MED
=	O
0.73	O
)	O
;	O
and	O
excellent	B-MED
for	O
effusion	B-MED
assessed	O
by	O
bulge	B-MED
sign	I-MED
(	O
κω	B-MED
=	O
0.83	O
)	O
,	O
bony	B-MED
enlargement	I-MED
(	O
κ	B-MED
=	O
0.98	O
)	O
,	O
quadriceps	B-MED
wasting	I-MED
(	O
κ	B-MED
=	O
0.83	O
)	O
,	O
flexion	B-MED
(	O
ICC	B-MED
=	O
0.99	O
)	O
,	O
and	O
extension	B-MED
(	O
ICC	B-MED
=	O
0.96	O
)	O
ROM	B-MED
.	O
Among	O
individuals	B-MED
with	O
symptomatic	B-MED
knee	B-MED
OA	I-MED
,	O
the	O
reliability	B-MED
of	O
clinical	B-MED
examination	I-MED
of	O
the	O
knee	B-MED
was	O
at	O
least	O
good	O
for	O
the	O
majority	O
of	O
clinical	B-MED
signs	I-MED
of	O
knee	B-MED
OA	I-MED
.	O
Effects	O
of	O
a	O
novel	O
phosphodiesterase	B-MED
10A	I-MED
inhibitor	I-MED
in	O
non	B-MED
-	I-MED
human	I-MED
primates	I-MED
:	O
A	O
therapeutic	B-MED
approach	I-MED
for	O
schizophrenia	B-MED
with	O
improved	O
side	B-MED
effect	I-MED
profile	I-MED
Schizophrenia	B-MED
symptoms	B-MED
are	O
associated	B-MED
with	I-MED
alterations	B-MED
in	I-MED
basal	I-MED
ganglia	I-MED
-	I-MED
cortical	I-MED
networks	I-MED
that	O
include	O
the	O
cyclic	B-MED
nucleotides	I-MED
(	O
cAMP	B-MED
/	O
cGMP	B-MED
)	O
signaling	B-MED
pathways	I-MED
.	O
Phosphodiesterase	B-MED
10A	I-MED
(	I-MED
PDE10A	I-MED
)	I-MED
inhibitors	I-MED
have	O
been	O
considered	O
as	O
therapeutic	B-MED
agents	I-MED
for	O
schizophrenia	B-MED
because	O
the	O
regulation	B-MED
of	I-MED
cAMP	I-MED
and	O
cGMP	B-MED
in	O
the	O
striatum	B-MED
by	O
PDE10A	B-MED
plays	O
an	O
important	O
role	O
in	O
the	O
signaling	B-MED
mechanisms	I-MED
of	O
the	O
striatal	B-MED
-	I-MED
cortical	I-MED
network	I-MED
,	O
and	O
thereby	O
in	O
cognitive	B-MED
function	I-MED
.	O
In	O
the	O
present	O
study	O
we	O
assessed	O
in	O
non	B-MED
-	I-MED
human	I-MED
primates	I-MED
(	O
NHPs	B-MED
)	O
the	O
effects	O
of	O
a	O
novel	O
PDE10A	B-MED
inhibitor	I-MED
(	O
FRM-6308	B-MED
)	O
that	O
has	O
demonstrated	O
high	B-MED
potency	I-MED
and	O
selectivity	O
for	O
human	B-MED
recombinant	I-MED
PDE10A	I-MED
in	B-MED
vitro	I-MED
.	O
The	O
behavioral	B-MED
effects	I-MED
of	O
FRM-6308	B-MED
in	O
a	O
dose	B-MED
range	I-MED
were	O
determined	O
in	O
rhesus	B-MED
monkeys	I-MED
using	O
a	O
standardized	B-MED
motor	I-MED
disability	I-MED
scale	I-MED
for	O
primates	B-MED
,	O
motor	B-MED
tasks	I-MED
,	O
and	O
the	O
"	O
drug	B-MED
effects	I-MED
on	I-MED
the	I-MED
nervous	I-MED
system	I-MED
"	I-MED
(	I-MED
DENS	I-MED
)	I-MED
scale	I-MED
.	O
The	O
neuronal	B-MED
metabolic	B-MED
effects	I-MED
of	O
FRM-6308	B-MED
were	O
determined	O
with	O
[	B-MED
(	I-MED
18)F]-fluorodeoxyglucose	I-MED
PET	I-MED
imaging	I-MED
.	O
Results	O
showed	O
that	O
FRM-6308	B-MED
did	O
not	O
have	O
any	O
specific	O
effects	O
on	O
the	O
motor	B-MED
system	I-MED
at	O
s.c	B-MED
.	I-MED
doses	I-MED
up	O
to	O
0.32	O
mg	O
/	O
kg	O
in	O
NHPs	B-MED
,	O
which	O
induced	O
a	O
significant	O
increase	O
in	O
the	O
FDG	B-MED
-	O
SUV	B-MED
in	O
striatum	B-MED
(	O
F	O
16.069	O
,	O
p	O
<	O
0.05	O
)	O
and	O
cortical	B-MED
(	O
F	O
15.181	O
,	O
p	O
<	O
0.05	O
)	O
regions	O
.	O
Higher	B-MED
doses	I-MED
induced	O
sedation	B-MED
and	O
occasional	B-MED
involuntary	I-MED
movements	I-MED
with	O
clear	O
development	O
of	O
tolerance	B-MED
after	I-MED
repeated	I-MED
exposures	I-MED
.	O
These	O
findings	O
suggest	O
that	O
FRM-6308	B-MED
has	O
the	O
adequate	B-MED
pharmacological	I-MED
profile	I-MED
to	O
advance	O
testing	O
in	O
clinical	B-MED
trials	I-MED
and	O
demonstrate	O
antipsychotic	B-MED
efficacy	I-MED
of	O
PDE10A	B-MED
inhibition	B-MED
for	O
the	O
treatment	B-MED
of	O
schizophrenia	B-MED
patients	B-MED
.	O
Shear	B-MED
and	O
extensional	B-MED
properties	I-MED
of	O
kefiran	B-MED
Kefiran	B-MED
is	O
a	O
neutral	B-MED
polysaccharide	I-MED
constituted	O
by	O
glucose	B-MED
and	O
galactose	B-MED
produced	O
by	O
Lactobacillus	B-MED
kefiranofaciens	I-MED
.	O
It	O
is	O
included	O
into	O
kefir	B-MED
grains	I-MED
and	O
has	O
several	O
health	B-MED
promoting	I-MED
properties	I-MED
.	O
In	O
the	O
present	O
work	O
,	O
shear	B-MED
and	O
extensional	B-MED
properties	I-MED
of	O
different	B-MED
kefiran	B-MED
aqueous	B-MED
dispersions	I-MED
(	O
0.5	O
,	O
1	O
and	O
2	O
%	O
wt	O
.	O
)	O
were	O
assessed	B-MED
and	O
compared	B-MED
to	O
other	O
neutral	B-MED
gums	I-MED
commonly	O
used	O
in	O
food	B-MED
,	O
cosmetic	B-MED
and	O
pharmaceutics	B-MED
industries	I-MED
(	O
methylcellulose	B-MED
,	O
locust	B-MED
bean	I-MED
gum	I-MED
and	O
guar	B-MED
gum	I-MED
)	O
.	O
Kefiran	B-MED
showed	O
shear	B-MED
flow	I-MED
characteristics	I-MED
similar	O
to	O
that	O
displayed	O
by	O
other	O
representative	O
neutral	B-MED
gums	I-MED
,	O
although	O
it	O
always	O
yielded	O
lower	B-MED
viscosities	B-MED
at	O
a	O
given	O
concentration	B-MED
.	O
For	O
each	O
gum	B-MED
system	B-MED
it	O
was	O
possible	O
to	O
find	O
a	O
correlation	B-MED
between	O
dynamic	B-MED
and	I-MED
steady	I-MED
shear	I-MED
properties	I-MED
by	O
a	O
master	B-MED
curve	I-MED
including	O
both	O
the	O
apparent	B-MED
and	O
complex	B-MED
viscosities	B-MED
.	O
When	O
studying	O
extensional	B-MED
properties	I-MED
of	O
selected	O
gums	B-MED
at	O
2	O
%	O
wt	O
.	O
by	O
means	O
of	O
a	O
capillary	B-MED
break	I-MED
-	I-MED
up	I-MED
rheometer	I-MED
,	O
kefiran	B-MED
solutions	B-MED
did	O
not	O
show	O
important	O
extensional	B-MED
properties	I-MED
,	O
displaying	O
a	O
behaviour	B-MED
close	O
the	O
Newtonian	B-MED
.	O
Blood	B-MED
Pressure	I-MED
and	O
All	B-MED
-	I-MED
Cause	I-MED
Mortality	I-MED
by	O
Level	B-MED
of	O
Cognitive	B-MED
Function	I-MED
in	O
the	O
Elderly	B-MED
:	O
Results	B-MED
From	O
a	O
Population	B-MED
-	I-MED
Based	I-MED
Study	I-MED
in	O
Rural	B-MED
Greece	I-MED
This	O
study	B-MED
aimed	B-MED
to	O
investigate	B-MED
whether	O
the	O
effect	B-MED
of	O
blood	B-MED
pressure	I-MED
(	O
BP	B-MED
)	O
on	O
mortality	B-MED
differs	O
by	O
levels	B-MED
of	O
cognitive	B-MED
function	I-MED
.	O
The	O
associations	B-MED
of	O
brachial	B-MED
systolic	B-MED
BP	I-MED
,	O
diastolic	B-MED
BP	I-MED
,	O
mean	B-MED
arterial	I-MED
pressure	I-MED
(	O
MAP	B-MED
)	O
,	O
and	O
pulse	B-MED
pressure	I-MED
with	O
all	B-MED
-	I-MED
cause	I-MED
mortality	I-MED
were	O
prospectively	B-MED
explored	I-MED
(	O
follow	B-MED
-	I-MED
up	I-MED
7.0±2.2	O
years	B-MED
)	O
in	O
660	O
community	B-MED
-	I-MED
dwelling	I-MED
individuals	B-MED
(	O
≥60	B-MED
years	I-MED
)	O
using	O
adjusted	B-MED
Cox	I-MED
models	I-MED
,	O
stratified	B-MED
by	O
cognitive	B-MED
impairment	I-MED
(	O
Mini	B-MED
-	I-MED
Mental	I-MED
State	I-MED
Examination	I-MED
[	O
MMSE	B-MED
]	O
<	O
24	O
)	O
.	O
No	B-MED
association	I-MED
between	O
brachial	B-MED
BP	B-MED
variables	B-MED
and	O
mortality	B-MED
was	O
shown	O
for	O
the	O
total	B-MED
sample	B-MED
in	O
quartiles	B-MED
analysis	I-MED
;	O
however	O
,	O
MAP	B-MED
in	O
the	O
highest	B-MED
quartile	I-MED
,	O
compared	B-MED
with	O
the	O
second	B-MED
,	O
was	O
associated	B-MED
with	I-MED
mortality	B-MED
(	O
hazard	B-MED
ratio	I-MED
,	O
1.85	O
;	O
95	O
%	O
confidence	B-MED
intervals	I-MED
,	O
1.09	O
-	O
3.12	O
)	O
among	O
cognitively	B-MED
impaired	I-MED
individuals	B-MED
.	O
The	O
fractional	B-MED
-	I-MED
polynomials	I-MED
approach	I-MED
for	O
BP	B-MED
confirmed	B-MED
this	O
finding	B-MED
and	O
further	B-MED
showed	O
,	O
solely	B-MED
in	O
the	O
MMSE	B-MED
<	O
24	O
subcohort	B-MED
,	O
U	B-MED
-	I-MED
shaped	I-MED
trends	I-MED
of	O
MAP	B-MED
and	O
systolic	B-MED
BP	I-MED
,	O
with	O
increased	B-MED
mortality	B-MED
risk	I-MED
in	O
extremely	B-MED
low	B-MED
or	I-MED
high	I-MED
values	I-MED
;	O
no	O
such	O
pattern	B-MED
was	O
evident	B-MED
for	O
patients	B-MED
with	O
MMSE	B-MED
≥24	O
.	O
Elderly	B-MED
individuals	B-MED
with	O
cognitive	B-MED
impairment	I-MED
might	O
be	O
more	B-MED
susceptible	B-MED
to	O
the	O
detrimental	B-MED
effects	I-MED
of	O
low	B-MED
and	O
elevated	B-MED
MAP	B-MED
and	O
systolic	B-MED
BP	I-MED
.	O
Chronic	B-MED
Enzyme	I-MED
Replacement	I-MED
to	O
the	O
Brain	B-MED
of	O
a	O
Late	B-MED
Infantile	I-MED
Neuronal	I-MED
Ceroid	I-MED
Lipofuscinosis	I-MED
Mouse	B-MED
Has	O
Differential	O
Effects	B-MED
on	O
Phenotypes	B-MED
of	O
Disease	B-MED
Late	B-MED
infantile	I-MED
neuronal	I-MED
ceroid	I-MED
lipofuscinosis	I-MED
(	O
LINCL	B-MED
)	O
is	O
a	O
fatal	B-MED
inherited	O
neurodegenerative	B-MED
disease	I-MED
caused	O
by	O
loss	O
of	O
lysosomal	B-MED
protease	I-MED
tripeptidyl	I-MED
peptidase	I-MED
1	I-MED
(	O
TPP1	B-MED
)	O
.	O
We	O
have	O
investigated	O
the	O
effects	B-MED
of	O
chronic	B-MED
intrathecal	I-MED
(	I-MED
IT	I-MED
)	I-MED
administration	I-MED
using	O
enzyme	B-MED
replacement	I-MED
therapy	I-MED
(	O
ERT	B-MED
)	O
to	O
the	O
brain	B-MED
of	O
an	O
LINCL	B-MED
mouse	B-MED
model	I-MED
,	O
in	O
which	O
locomotor	B-MED
function	I-MED
declines	O
dramatically	O
prior	O
to	O
early	B-MED
death	I-MED
.	O
Median	O
lifespan	B-MED
was	O
significantly	O
extended	O
from	O
126	O
days	B-MED
to	O
>	O
259	O
days	B-MED
when	O
chronic	B-MED
IT	I-MED
treatment	I-MED
was	O
initiated	O
before	O
the	O
onset	B-MED
of	O
disease	B-MED
.	O
While	O
treated	O
animals	B-MED
lived	O
longer	O
and	O
showed	O
little	O
sign	O
of	O
locomotor	B-MED
dysfunction	I-MED
as	O
measured	O
by	O
stride	O
length	O
,	O
some	O
or	O
all	O
(	O
depending	O
on	O
regimen	O
)	O
still	O
died	B-MED
prematurely	O
.	O
One	O
explanation	O
is	O
that	O
cerebrospinal	B-MED
fluid	I-MED
CSF	B-MED
(	O
CSF)-mediated	O
delivery	B-MED
may	O
not	O
deliver	B-MED
TPP1	B-MED
to	O
all	O
brain	B-MED
regions	I-MED
.	O
Morphological	B-MED
studies	B-MED
support	O
this	O
,	O
showing	O
delivery	B-MED
of	O
TPP1	B-MED
to	O
ventral	B-MED
,	O
but	O
not	O
deeper	O
and	O
dorsal	B-MED
regions	I-MED
.	O
When	O
IT	B-MED
treatment	I-MED
is	O
initiated	O
in	O
severely	B-MED
affected	B-MED
LINCL	B-MED
mice	B-MED
,	O
lifespan	B-MED
was	O
extended	O
modestly	O
in	O
most	O
but	O
dramatically	O
extended	O
in	O
approximately	O
one	O
-	O
third	O
of	O
the	O
cohort	B-MED
.	O
Treatment	B-MED
improved	O
locomotor	B-MED
function	I-MED
in	O
these	O
severely	O
compromised	O
animals	B-MED
after	O
it	O
had	O
declined	O
to	O
the	O
point	O
at	O
which	O
animals	B-MED
normally	O
die	B-MED
.	O
This	O
indicates	O
that	O
some	O
pathology	B-MED
in	O
LINCL	B-MED
is	O
reversible	B-MED
and	O
does	O
not	O
simply	O
reflect	O
neuronal	B-MED
death	I-MED
.	O
Laparoscopic	B-MED
Approach	I-MED
for	O
Thermoablation	B-MED
Microwave	I-MED
in	O
the	O
Treatment	B-MED
of	O
Hepatocellular	B-MED
Carcinoma	I-MED
:	O
A	O
Single	O
Center	O
Experience	B-MED
The	O
surgical	B-MED
therapy	I-MED
of	O
choice	O
for	O
hepatocellular	B-MED
carcinoma	I-MED
(	O
HCC	B-MED
)	O
is	O
liver	B-MED
transplantation	I-MED
(	O
LT	B-MED
)	O
or	O
hepatic	B-MED
resection	I-MED
,	O
although	O
only	O
a	O
small	B-MED
percentage	B-MED
of	O
patients	B-MED
can	O
undergo	O
these	O
procedures	B-MED
.	O
Microwave	B-MED
thermal	I-MED
ablation	I-MED
(	O
MWTA	B-MED
)	O
can	O
be	O
an	O
effective	B-MED
alternative	B-MED
treatment	B-MED
for	O
HCC	B-MED
that	O
complicates	B-MED
a	O
cirrhotic	B-MED
liver	I-MED
disease	I-MED
,	O
either	O
as	O
a	O
final	B-MED
procedure	B-MED
or	O
for	O
downstaging	B-MED
patients	B-MED
on	O
the	O
waiting	O
list	O
for	O
LT	B-MED
,	O
or	O
in	O
combination	B-MED
with	O
resective	B-MED
surgery	B-MED
to	O
achieve	O
oncological	B-MED
radicality	B-MED
.	O
The	O
purpose	O
of	O
this	O
retrospective	B-MED
study	I-MED
was	O
to	O
evaluate	B-MED
experience	B-MED
with	O
the	O
laparoscopic	B-MED
approach	I-MED
of	O
MWTA	B-MED
at	O
our	O
center	O
.	O
In	O
a	O
cohort	B-MED
of	O
35	O
consecutive	B-MED
patients	B-MED
undergoing	O
MWTA	B-MED
with	O
laparoscopic	B-MED
approach	I-MED
between	O
January	O
,	O
2013	O
and	O
May	O
,	O
2016	O
,	O
we	O
reviewed	O
the	O
demographic	B-MED
data	I-MED
,	O
the	O
Barcelona	B-MED
clinic	I-MED
liver	I-MED
cancer	I-MED
stage	I-MED
,	O
the	O
severity	B-MED
of	O
cirrhotic	B-MED
liver	I-MED
disease	I-MED
,	O
the	O
size	B-MED
of	O
the	O
ablated	B-MED
lesion	B-MED
,	O
the	O
duration	B-MED
of	O
the	O
procedure	B-MED
,	O
and	O
complications	B-MED
occurring	O
within	O
90	O
days	B-MED
of	O
surgery	B-MED
.	O
MWTA	B-MED
was	O
performed	O
by	O
applying	O
one	O
to	O
three	O
hepatic	B-MED
parenchymal	B-MED
insertions	B-MED
(	O
mean	B-MED
1.8	O
)	O
per	O
patient	B-MED
.	O
The	O
mean	B-MED
duration	B-MED
of	O
surgery	B-MED
was	O
163	O
±	O
18	O
minutes	B-MED
.	O
There	O
was	O
no	O
blood	B-MED
loss	I-MED
in	O
any	O
of	O
the	O
procedures	B-MED
.	O
Complete	O
necrosis	B-MED
on	O
CT	B-MED
scan	I-MED
was	O
achieved	O
in	O
26/35	O
patients	B-MED
(	O
75	O
%	O
)	O
.	O
The	O
mean	B-MED
hospital	B-MED
stay	I-MED
was	O
4.6	O
(	O
range	O
2	O
-	O
7	O
)	O
days	B-MED
;	O
major	O
complications	B-MED
were	O
postablation	B-MED
syndrome	B-MED
in	O
2/35	O
(	O
5.7	O
%	O
)	O
,	O
peritoneal	B-MED
fluid	I-MED
in	O
4/35	O
(	O
11.4	O
%	O
)	O
,	O
and	O
transient	B-MED
jaundice	B-MED
in	O
1/35	O
(	O
2.8	O
%	O
)	O
patients	B-MED
.	O
There	O
was	O
no	B-MED
mortality	I-MED
.	O
Laparoscopic	B-MED
MWTA	B-MED
is	O
a	O
safe	O
and	O
effective	B-MED
treatment	B-MED
for	O
unresectable	B-MED
HCC	B-MED
and	O
when	O
a	O
percutaneous	B-MED
procedure	B-MED
is	O
not	O
feasible	O
.	O
Lung	B-MED
nodule	I-MED
in	O
French	B-MED
Guiana	I-MED
in	O
a	O
immunocompetent	B-MED
patient	B-MED
We	O
report	O
the	O
case	B-MED
of	O
an	O
immunocompetent	B-MED
French	B-MED
soldier	B-MED
stationed	O
in	O
French	B-MED
Guiana	I-MED
,	O
who	O
developed	O
symptomatic	B-MED
pulmonary	B-MED
histoplasmosis	I-MED
.	O
Typical	O
Skin	B-MED
Injuries	I-MED
in	O
Children	B-MED
With	O
Autism	B-MED
Spectrum	I-MED
Disorder	I-MED
Pediatric	B-MED
skin	B-MED
injuries	I-MED
have	O
primarily	O
been	O
described	O
in	O
typically	O
developing	B-MED
children	I-MED
.	O
Our	O
objectives	B-MED
were	O
to	O
describe	O
the	O
prevalence	B-MED
and	O
pattern	B-MED
of	O
skin	B-MED
injuries	I-MED
of	O
children	B-MED
with	O
autism	B-MED
spectrum	I-MED
disorder	I-MED
(	O
ASD	B-MED
)	O
,	O
to	O
describe	O
how	O
this	O
compared	O
with	O
previously	O
demonstrated	O
skin	B-MED
injury	I-MED
locations	B-MED
in	O
typically	O
developing	B-MED
children	I-MED
,	O
and	O
to	O
identify	O
differences	B-MED
in	O
skin	B-MED
injury	I-MED
frequency	B-MED
and	O
locations	B-MED
between	O
autistic	B-MED
children	I-MED
with	O
and	O
without	O
self	B-MED
-	I-MED
injurious	I-MED
behaviors	I-MED
(	O
SIBs	B-MED
)	O
.	O
Children	B-MED
with	O
ASD	B-MED
were	O
recruited	O
between	O
September	B-MED
of	O
2011	O
and	O
September	B-MED
of	O
2014	O
.	O
Demographic	B-MED
information	I-MED
was	O
obtained	O
from	O
the	O
caregiver	B-MED
.	O
All	O
skin	B-MED
injuries	I-MED
and	O
their	O
locations	B-MED
were	O
documented	B-MED
.	O
Of	O
the	O
41	O
children	B-MED
enrolled	O
,	O
half	O
were	O
reported	O
to	O
have	O
SIBs	B-MED
.	O
The	O
most	O
identified	O
skin	B-MED
injury	I-MED
locations	B-MED
were	O
the	O
legs	B-MED
,	O
knees	B-MED
,	O
and	O
back	B-MED
.	O
Children	B-MED
with	O
autism	B-MED
(	O
1	O
)	O
obtain	O
skin	B-MED
injuries	I-MED
frequently	O
and	O
in	O
similar	O
locations	B-MED
as	O
typically	O
developing	B-MED
children	I-MED
and	O
(	O
2	O
)	O
rarely	O
obtain	O
skin	B-MED
injuries	I-MED
to	O
locations	B-MED
that	O
are	O
considered	O
uncommon	O
for	O
accidental	B-MED
injuries	I-MED
despite	O
reports	O
of	O
SIBs	B-MED
.	O
Assembly	B-MED
of	I-MED
the	I-MED
outermost	I-MED
spore	I-MED
layer	I-MED
:	O
pieces	O
of	O
the	O
puzzle	O
are	O
coming	O
together	O
Certain	O
endospore	B-MED
-	I-MED
forming	I-MED
soil	I-MED
dwelling	I-MED
bacteria	I-MED
are	O
important	O
human	B-MED
,	O
animal	B-MED
or	O
insect	B-MED
pathogens	B-MED
.	O
These	O
organisms	B-MED
produce	O
spores	B-MED
containing	O
an	O
outer	B-MED
layer	I-MED
,	O
the	O
exosporium	B-MED
.	O
The	O
exosporium	B-MED
is	O
the	O
site	B-MED
of	I-MED
interactions	B-MED
between	O
the	O
spore	B-MED
and	O
the	O
soil	B-MED
environment	B-MED
and	O
between	O
the	O
spore	B-MED
and	O
the	O
infected	B-MED
host	B-MED
during	O
the	O
initial	B-MED
stages	B-MED
of	O
infection	B-MED
.	O
The	O
composition	B-MED
and	O
assembly	B-MED
process	I-MED
of	I-MED
the	I-MED
exosporium	I-MED
are	O
poorly	O
understood	O
.	O
This	O
is	O
partly	O
due	O
to	O
the	O
extreme	O
stability	B-MED
of	O
the	O
exosporium	B-MED
that	O
has	O
proven	O
to	O
be	O
refractive	O
to	O
existing	O
methods	B-MED
to	O
deconstruct	O
the	O
intact	B-MED
structure	B-MED
into	O
its	O
component	B-MED
parts	B-MED
.	O
Although	O
more	O
than	O
20	O
proteins	B-MED
have	O
been	O
identified	B-MED
as	O
exosporium	B-MED
-	O
associated	B-MED
,	O
their	O
abundance	B-MED
,	O
relationship	B-MED
to	O
other	O
proteins	B-MED
and	O
the	O
processes	B-MED
by	O
which	O
they	O
are	O
assembled	B-MED
to	I-MED
create	I-MED
the	I-MED
exosporium	I-MED
are	O
largely	O
unknown	O
.	O
In	O
this	O
issue	O
of	O
Molecular	B-MED
Microbiology	I-MED
,	O
Terry	O
,	O
Jiang	O
,	O
and	O
colleagues	O
in	O
Per	O
Bullough	O
's	O
laboratory	B-MED
show	O
that	O
the	O
ExsY	B-MED
protein	I-MED
is	O
a	O
major	O
structural	B-MED
protein	I-MED
of	O
the	O
exosporium	B-MED
basal	I-MED
layer	I-MED
of	O
B.	B-MED
cereus	I-MED
family	I-MED
spores	B-MED
and	O
that	O
it	O
can	O
self	B-MED
-	I-MED
assemble	I-MED
into	O
complex	B-MED
structures	B-MED
that	O
possess	O
many	O
of	O
the	O
structural	B-MED
features	B-MED
characteristic	B-MED
of	O
the	O
exosporium	B-MED
basal	I-MED
layer	I-MED
.	O
The	O
authors	B-MED
refined	O
a	O
model	B-MED
for	O
exosporium	B-MED
assembly	I-MED
.	O
Their	O
findings	B-MED
may	O
have	O
implications	O
for	O
exosporium	B-MED
formation	B-MED
in	O
other	O
spore	B-MED
forming	I-MED
bacteria	I-MED
,	O
including	O
Clostridium	B-MED
species	I-MED
.	O
Pancreatic	B-MED
Cancer	I-MED
:	O
A	O
Survival	B-MED
Analysis	I-MED
Study	B-MED
in	O
Oklahoma	B-MED
Pancreatic	B-MED
cancer	I-MED
is	O
among	O
the	O
most	O
deadly	B-MED
cancers	I-MED
.	O
Risk	B-MED
factors	I-MED
associated	B-MED
with	I-MED
the	O
disease	B-MED
include	O
age	B-MED
,	O
race	B-MED
,	O
sex	B-MED
,	O
smoking	B-MED
status	I-MED
,	O
and	O
diabetes	B-MED
status	I-MED
.	O
We	O
conducted	O
a	O
prospective	B-MED
analysis	I-MED
of	O
risk	B-MED
factors	I-MED
and	O
length	B-MED
of	I-MED
survival	I-MED
among	O
pancreatic	B-MED
cancer	I-MED
patients	I-MED
living	O
in	O
Oklahoma	B-MED
between	O
1997	O
and	O
2012	O
(	O
n=6,291	O
)	O
.	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
survival	I-MED
curves	I-MED
were	O
created	B-MED
followed	O
by	O
the	O
log	B-MED
-	I-MED
rank	I-MED
test	I-MED
to	O
compare	O
difference	B-MED
in	O
the	O
survival	B-MED
time	I-MED
.	O
Cox	B-MED
proportional	I-MED
hazard	I-MED
regression	I-MED
models	I-MED
were	O
used	O
to	O
examine	O
the	O
strength	B-MED
of	I-MED
association	I-MED
through	O
the	O
estimated	B-MED
hazard	B-MED
ratios	I-MED
.	O
The	O
median	B-MED
survival	I-MED
time	I-MED
of	O
the	O
cohort	B-MED
was	O
three	O
months	B-MED
.	O
Significant	B-MED
risk	B-MED
factors	I-MED
for	O
reduced	B-MED
survival	B-MED
times	I-MED
included	O
age	B-MED
,	O
stage	B-MED
at	I-MED
diagnosis	I-MED
,	O
and	O
year	B-MED
of	I-MED
diagnosis	I-MED
.	O
Results	B-MED
are	O
in	O
agreement	O
with	O
previous	O
research	B-MED
findings	I-MED
.	O
There	O
have	O
been	O
small	O
but	O
noteworthy	B-MED
improvements	I-MED
in	O
survival	B-MED
times	I-MED
for	O
pancreatic	B-MED
cancer	I-MED
patients	I-MED
in	O
Oklahoma	B-MED
.	O
Length	B-MED
of	I-MED
survival	I-MED
during	O
the	O
study	B-MED
period	I-MED
was	O
significantly	B-MED
associated	B-MED
with	I-MED
known	O
risk	B-MED
factors	I-MED
such	O
as	O
age	B-MED
and	O
stage	B-MED
of	I-MED
diagnosis	I-MED
.	O
Improving	B-MED
protein	B-MED
complex	I-MED
prediction	B-MED
by	O
reconstructing	B-MED
a	O
high	B-MED
-	I-MED
confidence	I-MED
protein	B-MED
-	I-MED
protein	I-MED
interaction	I-MED
network	I-MED
of	O
Escherichia	B-MED
coli	I-MED
from	O
different	O
physical	B-MED
interaction	I-MED
data	B-MED
sources	I-MED
Although	O
different	O
protein	B-MED
-	I-MED
protein	I-MED
physical	I-MED
interaction	I-MED
(	O
PPI	B-MED
)	O
datasets	B-MED
exist	O
for	O
Escherichia	B-MED
coli	I-MED
,	O
no	O
common	O
methodology	B-MED
exists	O
to	O
integrate	B-MED
these	O
datasets	B-MED
and	O
extract	O
reliable	O
modules	B-MED
reflecting	O
the	O
existing	O
biological	B-MED
process	I-MED
and	O
protein	B-MED
complexes	I-MED
.	O
Naïve	B-MED
Bayesian	I-MED
formula	I-MED
is	O
the	O
highly	O
accepted	O
method	O
to	O
integrate	B-MED
different	O
PPI	B-MED
datasets	B-MED
into	O
a	O
single	O
weighted	B-MED
PPI	B-MED
network	I-MED
,	O
but	O
detecting	O
proper	O
weights	B-MED
in	O
such	O
network	B-MED
is	O
still	O
a	O
major	O
problem	O
.	O
In	O
this	O
paper	O
,	O
we	O
proposed	O
a	O
new	O
methodology	B-MED
to	O
integrate	B-MED
various	O
physical	B-MED
PPI	I-MED
datasets	B-MED
into	O
a	O
single	O
weighted	B-MED
PPI	B-MED
network	I-MED
in	O
a	O
way	O
that	O
the	O
detected	B-MED
modules	B-MED
in	O
PPI	B-MED
network	I-MED
exhibit	O
the	O
highest	O
similarity	O
to	O
available	O
functional	B-MED
modules	B-MED
.	O
We	O
used	O
the	O
co	B-MED
-	I-MED
expression	I-MED
modules	B-MED
as	O
functional	B-MED
modules	B-MED
,	O
and	O
we	O
shown	O
that	O
direct	O
functional	B-MED
modules	B-MED
detected	B-MED
from	O
Gene	B-MED
Ontology	I-MED
terms	B-MED
could	O
be	O
used	O
as	O
an	O
alternative	O
dataset	B-MED
.	O
After	O
running	O
this	O
integrating	B-MED
methodology	B-MED
over	O
six	O
different	O
physical	B-MED
PPI	I-MED
datasets	B-MED
,	O
orthologous	B-MED
high	B-MED
-	I-MED
confidence	I-MED
interactions	B-MED
from	O
a	O
related	O
organism	B-MED
and	O
two	O
AP	B-MED
-	I-MED
MS	I-MED
PPI	B-MED
datasets	B-MED
gained	B-MED
high	I-MED
weights	I-MED
in	O
the	O
integrated	B-MED
networks	B-MED
,	O
while	O
the	O
weights	B-MED
for	O
one	O
AP	B-MED
-	I-MED
MS	I-MED
PPI	B-MED
dataset	B-MED
and	O
two	O
other	O
datasets	B-MED
derived	O
from	O
public	B-MED
databases	I-MED
have	O
converged	O
to	O
zero	O
.	O
The	O
majority	O
of	O
detected	B-MED
modules	B-MED
shaped	O
around	O
one	O
or	O
few	O
hub	B-MED
protein(s	I-MED
)	I-MED
.	O
Still	O
,	O
a	O
large	O
number	O
of	O
highly	O
interacting	O
protein	B-MED
modules	B-MED
were	O
detected	B-MED
which	O
are	O
functionally	B-MED
relevant	B-MED
and	O
are	O
likely	O
to	O
construct	B-MED
protein	B-MED
complexes	I-MED
.	O
We	O
provided	O
a	O
new	O
high	B-MED
confidence	I-MED
protein	B-MED
complex	I-MED
prediction	B-MED
method	O
supported	O
by	O
functional	B-MED
studies	O
and	O
literature	B-MED
mining	O
.	O
A	O
longitudinal	B-MED
study	I-MED
assessing	O
childcare	B-MED
services	B-MED
'	I-MED
adoption	O
of	O
obesity	B-MED
prevention	B-MED
policies	I-MED
and	I-MED
practices	I-MED
Despite	O
ongoing	O
investments	O
to	O
improve	O
the	O
obesogenic	B-MED
environments	B-MED
of	O
childcare	B-MED
settings	O
,	O
little	O
is	O
known	O
regarding	O
how	O
these	O
services	B-MED
have	O
changed	O
their	O
physical	B-MED
activity	I-MED
and	O
nutrition	B-MED
-	I-MED
promoting	I-MED
practices	I-MED
.	O
This	O
study	O
aims	O
to	O
describe	O
changes	O
in	O
the	O
proportion	O
of	O
Australian	B-MED
childcare	B-MED
services	B-MED
that	O
have	O
adopted	O
best	B-MED
-	I-MED
practice	I-MED
healthy	B-MED
eating	I-MED
and	O
physical	B-MED
activity	I-MED
practices	B-MED
between	O
2006	O
and	O
2013	O
and	O
to	O
assess	O
whether	O
adoption	O
varied	O
by	O
socio	B-MED
-	I-MED
economic	I-MED
status	I-MED
and	O
locality	B-MED
.	O
A	O
randomly	B-MED
selected	I-MED
sample	I-MED
of	O
nominated	O
supervisors	B-MED
(	O
n	O
=	O
358	O
)	O
from	O
childcare	B-MED
services	B-MED
located	O
in	O
New	B-MED
South	I-MED
Wales	I-MED
,	O
Australia	B-MED
,	O
participated	O
in	O
a	O
telephone	B-MED
survey	I-MED
in	O
2006	O
,	O
2009	O
,	O
2010	O
and	O
2013	O
.	O
Supervisors	B-MED
reported	O
on	O
their	O
service	B-MED
's	I-MED
adoption	O
of	O
six	O
practices	B-MED
:	O
(	O
i	O
)	O
having	O
written	O
nutrition	B-MED
and	O
physical	B-MED
activity	I-MED
policies	B-MED
;	O
(	O
ii	O
)	O
staff	B-MED
trained	O
in	O
physical	B-MED
activity	I-MED
and	O
nutrition	B-MED
in	O
the	O
past	O
year	O
;	O
(	O
iii	O
)	O
scheduled	O
time	B-MED
for	O
fundamental	O
movement	B-MED
skills	B-MED
and	O
(	O
iv	O
)	O
outdoor	B-MED
play	I-MED
;	O
(	O
v	O
)	O
weekly	B-MED
or	O
less	O
screen	B-MED
time	I-MED
opportunitie	I-MED
s	O
;	O
and	O
(	O
vi	O
)	O
serving	O
only	O
non	B-MED
-	I-MED
sweetened	I-MED
beverages	I-MED
.	O
A	O
significant	O
increase	O
in	O
the	O
prevalence	B-MED
of	O
services	B-MED
adopting	O
all	O
but	O
one	O
practice	B-MED
,	O
between	O
2006	O
and	O
2013	O
was	O
identified	O
.	O
Ninety	O
one	O
percent	O
of	O
services	B-MED
adopted	O
four	O
or	O
more	O
practices	B-MED
,	O
a	O
significant	O
increase	O
from	O
38	O
%	O
in	O
2006	O
.	O
There	O
were	O
no	O
differences	O
in	O
the	O
proportion	O
of	O
services	B-MED
adopting	O
each	O
practice	B-MED
by	O
locality	B-MED
and	O
socio	B-MED
-	I-MED
economic	I-MED
status	I-MED
.	O
Government	B-MED
investment	B-MED
in	O
obesity	B-MED
prevention	B-MED
programmes	I-MED
can	O
equitably	O
improve	O
childcare	B-MED
service	O
's	O
adoption	O
of	O
healthy	B-MED
eating	I-MED
and	O
physical	B-MED
activity	I-MED
promoting	O
practices	B-MED
on	O
a	O
jurisdiction	B-MED
-wide	O
basis	O
.	O
The	O
establishment	O
of	O
a	O
routine	O
system	O
to	O
monitor	O
adoption	O
of	O
a	O
broader	O
range	O
of	O
practices	B-MED
by	O
childcare	B-MED
services	B-MED
is	O
warranted	O
.	O
Moberg	B-MED
Picking	I-MED
-	I-MED
Up	I-MED
Test	I-MED
in	O
patients	B-MED
with	O
hand	B-MED
osteoarthritis	I-MED
Clinical	B-MED
measurement	I-MED
.	O
The	O
Moberg	B-MED
Pick	I-MED
-	I-MED
up	I-MED
Test	I-MED
(	O
MPUT	B-MED
)	O
was	O
previously	O
used	O
to	O
evaluate	O
functional	B-MED
performance	I-MED
in	O
patients	B-MED
with	O
hand	B-MED
inflammatory	B-MED
disease	I-MED
.	O
This	O
is	O
the	O
first	O
study	O
using	O
the	O
MPUT	B-MED
in	O
hand	B-MED
osteoarthritis	I-MED
(	O
OA	B-MED
)	O
.	O
Compare	O
the	O
functional	B-MED
performance	I-MED
(	O
MPUT	B-MED
)	O
in	O
hand	B-MED
OA	I-MED
patients	B-MED
and	O
healthy	B-MED
controls	I-MED
.	O
Fifty	O
hand	B-MED
OA	I-MED
patients	B-MED
and	O
50	O
controls	B-MED
were	O
assessed	O
using	O
the	O
MPUT	B-MED
,	O
AUSCAN	B-MED
and	O
Cochin	B-MED
questionnaires	I-MED
,	O
grip	B-MED
and	O
pinch	B-MED
strength	I-MED
,	O
pain	B-MED
using	O
a	O
visual	B-MED
analog	I-MED
scale	I-MED
and	O
a	O
Likert	B-MED
scale	I-MED
regarding	O
difficulty	O
to	O
perform	O
MPUT	B-MED
.	O
In	O
the	O
MPUT	B-MED
evaluation	B-MED
,	O
the	O
OA	B-MED
group	O
presented	O
a	O
statistically	B-MED
significant	I-MED
difference	O
from	O
the	O
control	B-MED
group	I-MED
.	O
The	O
OA	B-MED
group	O
spent	O
more	B-MED
time	B-MED
executing	O
test	B-MED
.	O
The	O
grip	B-MED
and	O
pinch	B-MED
strength	I-MED
measurements	I-MED
showed	O
higher	O
values	O
for	O
the	O
control	B-MED
group	I-MED
.	O
The	O
OA	B-MED
group	O
reported	O
a	O
greater	O
difficulty	B-MED
than	O
the	O
control	B-MED
group	I-MED
in	O
performing	O
the	O
test	B-MED
.	O
The	O
MPUT	B-MED
is	O
a	O
short	O
and	O
easy	O
to	O
apply	O
test	B-MED
,	O
which	O
can	O
be	O
safely	O
used	O
to	O
assess	O
the	O
functional	B-MED
performance	I-MED
of	O
the	O
hand	B-MED
OA	I-MED
.	O
II	O
.	O
Panitumumab	B-MED
-Associated	O
Encephalopathy	B-MED
after	O
Accidental	O
Intra	B-MED
-	I-MED
arterial	I-MED
Application	B-MED
through	O
Dislocated	B-MED
Central	I-MED
Venous	I-MED
Access	I-MED
Device	I-MED
Acute	B-MED
central	B-MED
nervous	I-MED
system	I-MED
(	O
CNS	B-MED
)	O
toxicity	B-MED
and	O
immune	B-MED
-related	O
side	B-MED
effects	I-MED
are	O
increasingly	O
recognized	O
with	O
the	O
use	O
of	O
monoclonal	B-MED
antibodies	I-MED
for	O
cancer	B-MED
therapy	I-MED
.	O
Here	O
,	O
we	O
report	O
a	O
patient	B-MED
who	O
developed	O
of	O
acute	B-MED
-	I-MED
onset	I-MED
encephalopathy	I-MED
and	O
coma	B-MED
,	O
which	O
began	O
shortly	O
after	O
administration	B-MED
of	O
panitumumab	B-MED
for	O
the	O
treatment	B-MED
of	O
metastatic	B-MED
colorectal	I-MED
cancer	I-MED
.	O
Echocardiography	B-MED
revealed	O
that	O
the	O
drug	B-MED
had	O
been	O
infused	O
into	O
the	O
left	B-MED
cardiac	I-MED
ventricle	I-MED
via	O
a	O
dislocated	B-MED
central	I-MED
venous	I-MED
line	I-MED
.	O
Diffusion	B-MED
-	I-MED
weighted	I-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
disclosed	O
multiple	O
cortical	B-MED
hyperintensities	I-MED
,	O
which	O
were	O
preferentially	O
located	O
in	O
the	O
frontal	B-MED
lobes	I-MED
.	O
While	O
the	O
neurological	B-MED
condition	I-MED
improved	O
within	O
a	O
few	O
days	B-MED
,	O
the	O
patient	B-MED
died	B-MED
4	O
weeks	B-MED
later	O
.	O
It	O
seems	O
likely	O
that	O
the	O
administration	B-MED
of	O
the	O
antibody	B-MED
via	O
the	O
intra	B-MED
-	I-MED
arterial	I-MED
route	I-MED
contributed	O
to	O
the	O
development	O
of	O
this	O
condition	B-MED
.	O
Toxic	B-MED
encephalopathy	I-MED
may	O
be	O
a	O
hitherto	B-MED
unrecognized	O
complication	B-MED
of	O
panitumumab	B-MED
treatment	B-MED
and	O
should	O
be	O
taken	O
into	O
consideration	O
in	O
patients	B-MED
developing	O
CNS	B-MED
symptoms	B-MED
undergoing	O
this	O
therapy	B-MED
.	O
Comparative	B-MED
evaluation	I-MED
of	O
iodine-131	B-MED
metaiodobenzylguanidine	I-MED
and	O
18	B-MED
-	I-MED
fluorodeoxyglucose	I-MED
positron	B-MED
emission	I-MED
tomography	I-MED
in	O
assessing	O
neural	B-MED
crest	I-MED
tumors	I-MED
:	O
Will	O
they	O
play	O
a	O
complementary	O
role	O
?	O
18	B-MED
-	I-MED
Fluorodeoxyglucose	I-MED
positron	B-MED
emission	I-MED
tomography	I-MED
(	O
FDG	B-MED
-	I-MED
PET	I-MED
)	O
has	O
established	O
a	O
role	O
in	O
the	O
evaluation	O
of	O
several	O
malignancies	B-MED
.	O
However	O
,	O
its	O
precise	O
clinical	B-MED
role	I-MED
in	O
the	O
neural	B-MED
crest	I-MED
cell	I-MED
tumors	I-MED
continues	O
to	O
evolve	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
iodine-131	B-MED
metaiodobenzylguanidine	I-MED
(	O
(	B-MED
131)I	I-MED
-	I-MED
MIBG	I-MED
)	O
and	O
FDG	B-MED
-	I-MED
PET	I-MED
of	O
head	O
to	O
head	O
in	O
patients	B-MED
with	O
neural	B-MED
crest	I-MED
tumors	I-MED
both	O
qualitatively	B-MED
and	O
semiquantitatively	B-MED
and	O
to	O
determine	O
their	O
clinical	B-MED
utility	I-MED
in	O
disease	B-MED
status	I-MED
evaluation	I-MED
and	O
further	B-MED
management	I-MED
.	O
A	O
total	O
of	O
32	O
patients	B-MED
who	O
had	O
undergone	O
(	B-MED
131)I	I-MED
-	I-MED
MIBG	I-MED
and	O
FDG	B-MED
-	I-MED
PET	I-MED
prospectively	O
were	O
evaluated	O
and	O
clinicopathologically	B-MED
grouped	O
into	O
three	O
categories	O
:	O
neuroblastoma	B-MED
,	O
pheochromocytoma	B-MED
,	O
and	O
medullary	B-MED
carcinoma	I-MED
thyroid	I-MED
.	O
In	O
18	O
patients	B-MED
of	O
neuroblastoma	B-MED
,	O
FDG	B-MED
PET	I-MED
and	O
(	B-MED
131)I	I-MED
-	I-MED
MIBG	I-MED
showed	O
patient	B-MED
-	I-MED
specific	I-MED
sensitivity	I-MED
of	O
84	O
%	O
and	O
72	O
%	O
,	O
respectively	O
.	O
The	O
mean	O
maximum	B-MED
standardized	I-MED
uptake	I-MED
value	I-MED
(	O
SUVmax	B-MED
)	O
of	O
primary	B-MED
lesions	I-MED
in	O
patients	B-MED
with	O
unfavorable	B-MED
histology	I-MED
was	O
found	O
to	O
be	O
relatively	O
higher	O
than	O
those	O
with	O
favorable	B-MED
histology	I-MED
(	O
5.18	O
±	O
2.38	O
vs.	O
3.21	O
±	O
1.69	O
)	O
.	O
The	O
mean	O
SUVmax	B-MED
of	O
two	O
common	O
sites	O
(	O
posterior	B-MED
superior	I-MED
iliac	I-MED
spine	I-MED
[	O
PSIS	B-MED
]	O
and	O
greater	B-MED
trochanter	I-MED
)	O
was	O
higher	O
in	O
patients	B-MED
with	O
involved	O
marrow	B-MED
than	O
those	O
with	O
uninvolved	O
one	O
(	O
2.36	O
and	O
2.75	O
vs.	O
1.26	O
and	O
1.34	O
,	O
respectively	O
)	O
.	O
The	O
ratio	O
of	O
SUVmax	B-MED
of	O
the	O
involved/	O
contralateral	B-MED
normal	I-MED
sites	I-MED
was	O
2.16	O
±	O
1.9	O
.	O
In	O
equivocal	B-MED
bone	B-MED
marrow	I-MED
results	I-MED
,	O
the	O
uptake	O
pattern	O
with	O
SUV	B-MED
estimation	O
can	O
depict	O
metastatic	B-MED
involvement	I-MED
and	O
help	O
in	O
redirecting	O
the	O
biopsy	B-MED
site	I-MED
.	O
Among	O
seven	O
patients	B-MED
of	O
pheochromocytoma	B-MED
,	O
FDG	B-MED
-	I-MED
PET	I-MED
revealed	O
100	O
%	O
patient	B-MED
-	I-MED
specific	I-MED
sensitivity	I-MED
.	O
FDG	B-MED
-	I-MED
PET	I-MED
detected	O
more	O
metastatic	B-MED
foci	I-MED
than	O
(	B-MED
131)I	I-MED
-	I-MED
MIBG	I-MED
(	O
18	O
vs.	O
13	O
sites	O
)	O
.	O
In	O
seven	O
patients	B-MED
of	O
medullary	B-MED
carcinoma	I-MED
thyroid	I-MED
,	O
FDG	B-MED
-	I-MED
PET	I-MED
localized	O
residual	O
,	O
recurrent	B-MED
,	O
or	O
metastatic	B-MED
disease	I-MED
with	O
much	O
higher	O
sensitivity	O
(	O
32	O
metastatic	B-MED
foci	I-MED
with	O
72	O
%	O
patient	B-MED
specific	I-MED
sensitivity	I-MED
)	O
than	O
(	B-MED
131)I	I-MED
-	I-MED
MIBG	I-MED
,	O
trending	O
along	O
the	O
higher	B-MED
serum	I-MED
calcitonin	I-MED
levels	I-MED
.	O
FDG	B-MED
-	I-MED
PET	I-MED
is	O
not	O
only	O
a	O
good	O
complementary	B-MED
modality	I-MED
in	O
the	O
management	O
of	O
neural	B-MED
crest	I-MED
cell	I-MED
tumors	I-MED
but	O
also	O
it	O
can	O
even	O
be	O
superior	O
,	O
especially	O
in	O
cases	O
of	O
(	B-MED
131)I	I-MED
-	I-MED
MIBG	I-MED
nonavid	B-MED
tumors	I-MED
.	O
Forest	B-MED
protected	B-MED
areas	I-MED
governance	B-MED
in	O
Zimbabwe	B-MED
:	O
Shift	B-MED
needed	O
away	O
from	O
a	O
long	B-MED
history	I-MED
of	O
local	B-MED
community	B-MED
exclusion	B-MED
In	O
this	O
literature	O
review	O
based	O
paper	O
we	O
explored	O
the	O
concept	B-MED
of	O
exclusion	B-MED
of	O
local	B-MED
communities	B-MED
from	O
accessing	B-MED
resources	B-MED
in	O
forest	B-MED
protected	B-MED
areas	I-MED
(	O
FPAs	B-MED
)	O
in	O
Zimbabwe	B-MED
.	O
We	O
discussed	O
the	O
colonial	B-MED
and	O
post	B-MED
-	O
colonial	B-MED
forms	I-MED
,	O
causes	O
and	O
mechanisms	B-MED
of	O
exclusion	B-MED
and	O
their	O
social	B-MED
,	O
economic	B-MED
and	O
ecological	B-MED
outcomes	I-MED
.	O
We	O
examined	B-MED
the	O
range	B-MED
of	O
powers	B-MED
embodied	O
in	O
and	O
exercised	O
through	O
various	O
mechanisms	O
,	O
processes	B-MED
and	O
social	B-MED
relations	I-MED
and	O
their	O
impact	B-MED
on	O
local	B-MED
communities	B-MED
'	O
access	B-MED
to	O
FPA	B-MED
resources	B-MED
and	O
associated	O
benefits	B-MED
along	O
the	O
historical	B-MED
trajectory	B-MED
of	O
forest	B-MED
governance	B-MED
in	O
Zimbabwe	B-MED
.	O
Results	O
showed	O
that	O
the	O
forms	B-MED
and	O
extent	B-MED
of	O
exclusion	B-MED
changed	B-MED
over	B-MED
time	B-MED
in	O
tandem	O
with	O
the	O
shifting	B-MED
political	B-MED
and	O
economic	B-MED
landscape	I-MED
.	O
During	O
the	O
colonial	B-MED
period	I-MED
,	O
it	O
was	O
total	O
exclusion	B-MED
whereby	O
people	B-MED
were	O
evicted	B-MED
from	O
forest	B-MED
land	B-MED
as	O
well	O
as	O
being	O
denied	B-MED
access	B-MED
to	O
basic	B-MED
resources	B-MED
for	O
their	O
livelihoods	O
.	O
Local	B-MED
communities	B-MED
'	O
access	B-MED
to	O
low	B-MED
value	B-MED
FPA	B-MED
resources	B-MED
improved	B-MED
during	O
the	O
post	B-MED
-	I-MED
colonial	I-MED
period	I-MED
but	O
access	B-MED
to	O
high	B-MED
value	B-MED
resources	B-MED
like	O
commercial	B-MED
timber	I-MED
as	O
well	O
as	O
sharing	B-MED
income	B-MED
benefits	B-MED
derived	B-MED
from	O
FPA	B-MED
commercial	B-MED
activities	I-MED
remained	O
a	O
pipe	B-MED
dream	I-MED
.	O
Regulation	B-MED
,	O
legitimation	B-MED
,	O
force	O
and	O
markets	O
constituted	O
the	O
mixture	O
of	O
the	O
power	O
elements	O
that	O
FPA	B-MED
governing	B-MED
authorities	B-MED
used	O
to	O
exclude	B-MED
local	B-MED
communities	B-MED
.	O
These	O
powers	O
remained	O
intact	B-MED
despite	O
attempts	O
at	O
collaborative	B-MED
governance	B-MED
in	O
the	O
1990s	O
.	O
However	O
,	O
from	O
the	O
year	O
2000	O
,	O
local	B-MED
communities	B-MED
expressed	B-MED
their	O
dissatisfaction	B-MED
with	O
the	O
centralised	B-MED
exclusionary	I-MED
governance	I-MED
system	I-MED
by	O
invading	O
the	O
FPAs	B-MED
rendering	O
them	O
ungovernable	B-MED
.	O
There	O
is	O
therefore	O
a	O
need	O
for	O
policy	B-MED
reform	B-MED
within	O
the	O
FPA	B-MED
sector	B-MED
to	O
improve	B-MED
the	O
current	B-MED
dire	B-MED
situation	I-MED
.	O
Bayesian	B-MED
and	O
Phylogenic	B-MED
Approaches	I-MED
for	O
Studying	O
Relationships	B-MED
among	O
Table	B-MED
Olive	I-MED
Cultivars	I-MED
To	O
enhance	O
table	B-MED
olive	I-MED
tree	I-MED
authentication	B-MED
,	O
relationship	B-MED
,	O
and	O
productivity	B-MED
,	O
we	O
consider	O
the	O
analysis	B-MED
of	O
18	O
worldwide	O
table	B-MED
olive	I-MED
cultivars	I-MED
(	O
Olea	B-MED
europaea	I-MED
L.	I-MED
)	O
based	O
on	O
morphological	B-MED
,	O
biological	B-MED
,	O
and	O
physicochemical	B-MED
markers	I-MED
analyzed	O
by	O
bioinformatic	B-MED
and	O
biostatistic	B-MED
tools	I-MED
.	O
Accordingly	O
,	O
we	O
assess	O
the	O
relationships	B-MED
between	O
the	O
studied	O
varieties	B-MED
,	O
on	O
the	O
one	O
hand	O
,	O
and	O
the	O
potential	O
productivity	B-MED
-	O
quantitative	B-MED
parameter	B-MED
links	O
on	O
the	O
other	O
hand	O
.	O
The	O
bioinformatic	B-MED
analysis	B-MED
based	O
on	O
the	O
graphical	B-MED
representation	I-MED
of	O
the	O
matrix	B-MED
of	I-MED
Euclidean	I-MED
distances	I-MED
,	O
the	O
principal	B-MED
components	I-MED
analysis	I-MED
,	O
unweighted	B-MED
pair	I-MED
group	I-MED
method	I-MED
with	O
arithmetic	B-MED
mean	I-MED
,	O
and	O
principal	B-MED
coordinate	I-MED
analysis	I-MED
(	O
PCoA	B-MED
)	O
revealed	O
three	O
major	O
clusters	B-MED
which	O
were	O
not	O
correlated	O
with	O
the	O
geographic	B-MED
origin	B-MED
.	O
The	O
statistical	B-MED
analysis	I-MED
based	O
on	O
Kendall	O
's	O
and	O
Spearman	B-MED
correlation	I-MED
coefficients	I-MED
suggests	O
two	O
highly	O
significant	O
associations	B-MED
with	O
both	O
fruit	B-MED
color	B-MED
and	O
pollinization	B-MED
and	O
the	O
productivity	B-MED
character	O
.	O
These	O
results	B-MED
are	O
confirmed	O
by	O
the	O
multiple	B-MED
linear	I-MED
regression	I-MED
prediction	I-MED
models	I-MED
.	O
In	O
fact	O
,	O
based	O
on	O
the	O
coefficient	B-MED
of	I-MED
determination	I-MED
(	O
R	B-MED
(	I-MED
2	I-MED
)	I-MED
)	O
value	O
,	O
the	O
best	O
model	B-MED
demonstrated	O
the	O
power	B-MED
of	O
the	O
pollinization	B-MED
on	O
the	O
tree	O
productivity	B-MED
(	O
R	B-MED
(	I-MED
2	I-MED
)	I-MED
=	O
0.846	O
)	O
.	O
Moreover	O
,	O
the	O
derived	O
directed	B-MED
acyclic	I-MED
graph	I-MED
showed	O
that	O
only	O
two	O
direct	O
influences	B-MED
are	O
detected	B-MED
:	O
effect	B-MED
of	O
tolerance	B-MED
on	O
fruit	B-MED
and	O
stone	B-MED
symmetry	I-MED
on	O
side	O
and	O
effect	B-MED
of	O
tolerance	B-MED
on	O
stone	B-MED
form	I-MED
and	O
oil	B-MED
content	B-MED
on	O
the	O
other	O
side	O
.	O
This	O
work	O
provides	O
better	O
understanding	O
of	O
the	O
diversity	B-MED
available	O
in	O
worldwide	O
table	B-MED
olive	I-MED
cultivars	I-MED
and	O
supplies	O
an	O
important	O
contribution	O
for	O
olive	B-MED
breeding	B-MED
and	O
authenticity	B-MED
.	O
Cerebral	B-MED
toxoplasmosis	I-MED
in	O
patients	B-MED
with	O
acquired	B-MED
immune	I-MED
deficiency	I-MED
syndrome	I-MED
in	O
the	O
neurological	B-MED
emergency	I-MED
department	I-MED
of	O
a	O
tertiary	B-MED
hospital	I-MED
Cerebral	B-MED
toxoplasmosis	I-MED
is	O
the	O
most	O
common	O
cause	B-MED
of	O
space	B-MED
occupying	O
brain	B-MED
lesion	I-MED
in	O
patients	B-MED
with	O
HIV	B-MED
/	I-MED
AIDS	I-MED
in	O
Brazil	B-MED
.	O
In	O
the	O
post	B-MED
-	I-MED
HAART	I-MED
era	I-MED
,	O
it	O
is	O
responsible	O
for	O
high	B-MED
rates	B-MED
of	O
morbidity	B-MED
and	O
mortality	B-MED
worldwide	O
.	O
This	O
study	B-MED
consists	O
of	O
a	O
case	B-MED
series	I-MED
of	O
56	O
patients	B-MED
diagnosed	B-MED
with	O
cerebral	B-MED
toxoplasmosis	I-MED
whose	O
clinical	B-MED
features	B-MED
,	O
brain	B-MED
imaging	I-MED
and	O
cerebrospinal	B-MED
fluid	I-MED
aspects	B-MED
were	O
analyzed	B-MED
.	O
Cerebral	B-MED
toxoplasmosis	I-MED
led	O
to	O
the	O
diagnosis	B-MED
of	O
infection	B-MED
by	O
the	O
human	B-MED
immunodeficiency	I-MED
virus	I-MED
(	O
HIV	B-MED
)	O
in	O
27	O
(	O
48.2	O
%	O
)	O
of	O
the	O
patients	B-MED
,	O
while	O
29	O
(	O
51.2	O
%	O
)	O
others	O
already	O
knew	O
to	O
be	O
HIV	B-MED
seropositive	I-MED
.	O
However	O
,	O
at	O
the	O
time	B-MED
of	O
diagnosis	B-MED
of	O
cerebral	B-MED
toxoplasmosis	I-MED
,	O
only	O
9	O
(	O
16.6	O
%	O
)	O
reported	B-MED
being	O
under	O
antiretroviral	B-MED
therapy	I-MED
and	O
5	O
(	O
8.9	O
%	O
)	O
were	O
receiving	B-MED
primary	B-MED
prophylaxis	B-MED
for	O
toxoplasmosis	B-MED
.	O
Headache	B-MED
,	O
strength	B-MED
deficit	I-MED
and	O
fever	B-MED
were	O
the	O
most	O
frequent	O
signs	B-MED
and	I-MED
symptoms	I-MED
throughout	O
the	O
study	B-MED
.	O
Fifty	O
-	O
three	O
patients	B-MED
showed	O
changes	B-MED
consistent	B-MED
with	I-MED
toxoplasmosis	B-MED
in	O
CT	B-MED
or	O
MRI	B-MED
.	O
Thirty	O
-	O
four	O
(	O
60.7	O
%	O
)	O
CSF	B-MED
samples	I-MED
were	O
positive	B-MED
in	O
the	O
indirect	B-MED
haemagglutination	I-MED
test	I-MED
and	O
for	O
the	O
reaction	B-MED
of	O
Toxoplasma	B-MED
gondii	I-MED
IgG	I-MED
ELISA	B-MED
,	O
while	O
31	O
(	O
55.4	O
%	O
)	O
were	O
positive	B-MED
in	O
the	O
direct	B-MED
haemagglutination	I-MED
test	I-MED
.	O
Fifty	O
(	O
89.3	O
%	O
)	O
patients	B-MED
underwent	O
first	B-MED
-	I-MED
line	I-MED
treatment	I-MED
for	O
toxoplasmosis	B-MED
.	O
Cerebral	B-MED
toxoplasmosis	I-MED
is	O
still	O
a	O
very	O
relevant	B-MED
neurological	B-MED
disease	I-MED
in	O
individuals	B-MED
with	O
AIDS	B-MED
admitted	B-MED
to	O
neurology	B-MED
emergency	B-MED
departments	I-MED
.	O
Early	B-MED
diagnosis	I-MED
and	O
initiation	B-MED
of	O
empiric	B-MED
treatment	I-MED
and	O
antiretroviral	B-MED
therapy	I-MED
are	O
important	O
for	O
good	O
prognosis	B-MED
.	O
Data	B-MED
set	I-MED
of	O
interactomes	B-MED
and	O
metabolic	B-MED
pathways	I-MED
of	O
proteins	B-MED
differentially	O
expressed	B-MED
in	O
brains	B-MED
with	O
Alzheimer׳s	B-MED
disease	I-MED
Alzheimer׳s	B-MED
disease	I-MED
is	O
one	O
of	O
the	O
main	O
causes	O
of	O
dementia	B-MED
in	O
the	O
elderly	B-MED
and	O
its	O
frequency	B-MED
is	O
on	O
the	O
rise	O
worldwide	B-MED
.	O
It	O
is	O
considered	O
the	O
result	O
of	O
complex	B-MED
interactions	B-MED
between	O
genetic	B-MED
and	O
environmental	B-MED
factors	I-MED
,	O
being	O
many	O
of	O
them	O
unknown	O
.	O
Therefore	O
,	O
there	O
is	O
a	O
dire	O
necessity	O
for	O
the	O
identification	O
of	O
novel	O
molecular	B-MED
players	I-MED
for	O
the	O
understanding	O
of	O
this	O
disease	B-MED
.	O
In	O
this	O
data	B-MED
article	B-MED
we	O
determined	O
the	O
protein	B-MED
expression	I-MED
profiles	O
of	O
whole	O
protein	B-MED
extracts	B-MED
from	O
cortex	B-MED
regions	I-MED
of	I-MED
brains	I-MED
from	O
patients	B-MED
with	O
Alzheimer׳s	B-MED
disease	I-MED
in	O
comparison	O
to	O
a	O
normal	B-MED
brain	I-MED
.	O
We	O
identified	B-MED
721	O
iTRAQ	B-MED
-	I-MED
labeled	I-MED
polypeptides	B-MED
with	O
more	O
than	O
95	O
%	O
in	O
confidence	O
.	O
We	O
analyzed	B-MED
all	O
proteins	B-MED
that	O
changed	O
in	O
their	O
expression	B-MED
level	I-MED
and	O
located	O
them	O
in	O
the	O
KEGG	B-MED
metabolic	I-MED
pathways	I-MED
,	O
as	O
well	O
as	O
in	O
the	O
mitochondrial	B-MED
complexes	I-MED
of	I-MED
the	I-MED
electron	I-MED
transport	I-MED
chain	I-MED
and	O
ATP	B-MED
synthase	I-MED
.	O
In	O
addition	O
,	O
we	O
analyzed	B-MED
the	O
over-	B-MED
and	I-MED
sub	I-MED
-	I-MED
expressed	I-MED
polypeptides	I-MED
through	O
IPA	B-MED
software	I-MED
,	O
specifically	O
Core	B-MED
I	I-MED
and	I-MED
Biomarkers	I-MED
I	I-MED
modules	I-MED
.	O
Data	B-MED
in	O
this	O
article	B-MED
is	O
related	O
to	O
the	O
research	B-MED
article	B-MED
"	O
Identification	O
of	O
proteins	B-MED
that	O
are	O
differentially	O
expressed	B-MED
in	O
brains	B-MED
with	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
using	O
iTRAQ	B-MED
labeling	I-MED
and	O
tandem	B-MED
mass	I-MED
spectrometry	I-MED
"	O
(	O
Minjarez	O
et	O
al	O
.	O
,	O
2016	O
)	O
[	O
1	O
]	O
.	O
Prevalence	B-MED
of	O
HPV	B-MED
genotypes	B-MED
in	O
cervical	B-MED
adenocarcinoma	I-MED
:	O
a	O
study	B-MED
in	O
Greek	B-MED
women	B-MED
To	O
study	B-MED
the	O
prevalence	B-MED
of	O
human	B-MED
papillomavirus	I-MED
(	O
HPV	B-MED
)	O
genotypes	B-MED
among	O
cervical	B-MED
adenocarcinomas	I-MED
in	O
Greek	B-MED
women	B-MED
.	O
The	O
study	B-MED
group	I-MED
comprised	O
78	O
adenocarcinoma	B-MED
cases	B-MED
(	O
20	O
in	B-MED
situ	I-MED
and	O
58	O
invasive	B-MED
)	O
.	O
HPV	B-MED
DNA	I-MED
was	O
amplified	B-MED
using	O
polymerase	B-MED
chain	I-MED
reaction	I-MED
(	O
PCR	B-MED
)	O
and	O
HPV	B-MED
genotypes	B-MED
were	O
identified	B-MED
by	O
reverse	B-MED
hybridization	I-MED
.	O
There	O
was	O
a	O
high	B-MED
prevalence	I-MED
of	O
HPV	B-MED
infection	I-MED
both	O
for	O
in	B-MED
situ	I-MED
(	O
95	O
%	O
)	O
or	O
invasive	B-MED
(	I-MED
94.83	I-MED
%	I-MED
)	I-MED
adenocarcinomas	I-MED
,	O
comprising	O
also	O
cancers	B-MED
of	O
unusual	B-MED
morphology	I-MED
.	O
HPV	B-MED
16	I-MED
was	O
the	O
commonest	B-MED
strain	B-MED
(	O
N=57	O
,	O
73.08	O
%	O
)	O
followed	O
by	O
HPV	B-MED
18	I-MED
(	O
N=28	O
,	O
35.90	O
%	O
)	O
.	O
Interestingly	O
,	O
13	O
cases	B-MED
(	O
16.67	O
%	O
)	O
were	O
also	O
HPV	B-MED
52	I-MED
positive	I-MED
(	O
as	O
co	B-MED
-	I-MED
infection	I-MED
with	O
HPV	B-MED
16	I-MED
or	O
18	B-MED
)	O
.	O
All	O
other	O
strains	B-MED
with	O
the	O
exception	B-MED
of	O
HPV	B-MED
66	I-MED
were	O
found	O
only	O
as	O
co	B-MED
-	I-MED
infections	I-MED
.	O
No	O
significant	O
age	B-MED
difference	I-MED
was	O
noted	O
in	O
terms	O
of	O
any	O
HPV	B-MED
strain	B-MED
positivity	B-MED
.	O
HPV	B-MED
DNA	I-MED
was	O
found	O
in	O
the	O
large	B-MED
majority	I-MED
of	O
cervical	B-MED
adenocarcinomas	I-MED
.	O
As	O
opposed	O
to	O
other	O
studies	B-MED
,	O
HPV	B-MED
52	I-MED
was	O
the	O
third	O
most	O
commonly	B-MED
encountered	B-MED
strain	B-MED
after	O
HPV	B-MED
16	I-MED
and	O
HPV	B-MED
18	I-MED
.	O
The	O
above	O
findings	O
would	O
probably	O
be	O
of	O
help	B-MED
in	O
decision	B-MED
making	I-MED
concerning	O
vaccination	B-MED
policy	B-MED
for	O
the	O
prevention	B-MED
of	O
HPV	B-MED
infection	I-MED
in	O
Greece	B-MED
.	O
Fluorescence-	B-MED
and	O
magnetic	B-MED
-	I-MED
activated	I-MED
cell	I-MED
sorting	I-MED
strategies	B-MED
to	O
separate	B-MED
spermatozoa	B-MED
involving	O
plural	B-MED
contributors	B-MED
from	O
biological	B-MED
mixtures	I-MED
for	O
human	B-MED
identification	I-MED
No	O
effective	O
method	B-MED
has	O
been	O
developed	O
to	O
distinguish	B-MED
sperm	B-MED
cells	I-MED
originating	O
from	O
different	O
men	B-MED
in	O
multi	B-MED
-	I-MED
suspect	I-MED
sexual	B-MED
assault	I-MED
cases	B-MED
.	O
Here	O
we	O
combined	O
MACS	B-MED
and	O
FACS	B-MED
to	O
isolate	B-MED
single	B-MED
donor	B-MED
sperm	B-MED
cells	I-MED
from	O
forensic	B-MED
mixture	I-MED
samples	I-MED
including	O
female	B-MED
vaginal	B-MED
epithelial	B-MED
cells	I-MED
and	O
sperm	B-MED
cells	I-MED
from	O
multiple	B-MED
contributors	B-MED
.	O
Sperms	B-MED
from	O
vaginal	B-MED
swab	I-MED
were	O
isolated	B-MED
by	O
MACS	B-MED
using	O
FITC	B-MED
-conjugated	O
A	B-MED
kinase	I-MED
anchor	I-MED
protein	I-MED
3	I-MED
(	O
AKAP3	B-MED
)	O
antibody	B-MED
;	O
target	B-MED
individual	I-MED
sperm	B-MED
cells	I-MED
involving	O
two	O
or	O
three	O
donors	B-MED
were	O
separated	B-MED
by	O
FACS	B-MED
using	O
FITC	B-MED
-labeled	O
blood	B-MED
group	I-MED
A	I-MED
/	I-MED
B	I-MED
antigen	I-MED
antibody	B-MED
.	O
This	O
procedure	B-MED
was	O
further	O
tested	B-MED
in	O
two	O
mock	B-MED
multi	B-MED
-	I-MED
suspect	I-MED
sexual	B-MED
assault	I-MED
samples	B-MED
and	O
one	O
practical	B-MED
casework	I-MED
sample	B-MED
.	O
Our	O
results	O
showed	O
that	O
complete	B-MED
single	B-MED
donor	B-MED
STR	B-MED
profiles	I-MED
could	O
be	O
successfully	O
obtained	O
from	O
sperm	B-MED
/	O
epithelial	B-MED
cell	I-MED
and	O
sperm	B-MED
mixtures	B-MED
from	O
two	O
contributors	B-MED
.	O
For	O
unbalanced	O
sperm	B-MED
/	O
epithelial	B-MED
cells	I-MED
and	O
sperm	B-MED
cells	I-MED
mixtures	B-MED
,	O
sensitivity	B-MED
results	O
revealed	O
that	O
target	B-MED
cells	I-MED
could	O
be	O
detected	B-MED
at	O
as	O
low	O
as	O
1:32	O
and	O
1:8	O
mixed	O
ratios	O
,	O
respectively	O
.	O
Although	O
highly	O
relies	O
on	O
cell	B-MED
number	I-MED
and	O
blood	B-MED
types	I-MED
or	O
secretor	O
status	O
of	O
the	O
individuals	B-MED
,	O
this	O
procedure	B-MED
would	O
still	O
be	O
useful	O
tools	O
for	O
forensic	B-MED
DNA	I-MED
analysis	I-MED
of	O
multi	B-MED
-	I-MED
suspect	I-MED
sexual	B-MED
assault	I-MED
cases	B-MED
by	O
the	O
combined	O
use	B-MED
of	I-MED
FACS	B-MED
and	O
MACS	B-MED
based	O
on	O
sperm	B-MED
-specific	O
AKAP3	B-MED
antigen	B-MED
and	O
human	B-MED
blood	B-MED
type	I-MED
antigen	I-MED
.	O
Trajectories	B-MED
of	O
Health	B-MED
and	O
Behavioral	B-MED
Health	I-MED
Services	I-MED
Use	B-MED
among	O
Community	B-MED
Corrections	B-MED
-Involved	O
Rural	B-MED
Adults	B-MED
This	O
article	O
seeks	O
to	O
establish	O
time	O
-	O
based	O
trajectories	B-MED
of	O
health	B-MED
and	O
behavioral	B-MED
health	I-MED
services	I-MED
utilization	B-MED
for	O
community	B-MED
corrections	I-MED
-	I-MED
involved	I-MED
(	O
CCI	B-MED
)	O
adults	B-MED
and	O
to	O
examine	O
demographic	B-MED
and	O
clinical	B-MED
correlates	O
associated	O
with	O
these	O
trajectories	B-MED
.	O
To	O
accomplish	O
this	O
aim	O
,	O
the	O
authors	O
applied	O
a	O
latent	B-MED
class	I-MED
growth	I-MED
analysis	I-MED
(	O
LCGA	B-MED
)	O
to	O
services	B-MED
use	O
data	O
from	O
a	O
sample	O
of	O
rural	B-MED
CCI	B-MED
adults	B-MED
who	O
reported	O
their	O
medical	B-MED
,	O
mental	B-MED
health	I-MED
,	O
and	O
substance	B-MED
use	I-MED
treatment	B-MED
utilization	I-MED
behavior	B-MED
every	O
60	O
days	B-MED
for	O
1.5	O
years	B-MED
.	O
LCGA	B-MED
established	O
1.5	B-MED
-	I-MED
year	I-MED
trajectories	B-MED
and	O
demographic	B-MED
correlates	O
of	O
health	B-MED
services	I-MED
among	O
rural	B-MED
CCI	B-MED
adults	B-MED
.	O
For	O
medical	B-MED
services	I-MED
,	O
three	O
classes	O
emerged	O
(	O
stable	O
-	O
low	O
users	B-MED
,	O
13	O
%	O
;	O
stable	O
-	O
intermediate	O
users	B-MED
,	O
40	O
%	O
;	O
and	O
stable	O
-	O
high	O
users	B-MED
,	O
47	O
%	O
)	O
.	O
For	O
mental	B-MED
health	I-MED
and	O
substance	B-MED
use	I-MED
services	B-MED
,	O
three	O
classes	O
emerged	O
(	O
stable	O
-	O
low	O
,	O
69	O
%	O
and	O
61	O
%	O
,	O
respectively	O
;	O
low	O
-	O
baseline	O
-	O
increase	O
,	O
10	O
%	O
and	O
12	O
%	O
,	O
respectively	O
;	O
high	O
-	O
baseline	O
decline	O
,	O
21	O
%	O
and	O
28	O
%	O
,	O
respectively	O
)	O
.	O
Employment	B-MED
,	O
gender	B-MED
,	O
medication	B-MED
usage	I-MED
,	O
and	O
depression	B-MED
severity	B-MED
predicted	O
membership	B-MED
across	O
all	O
services	B-MED
.	O
Results	O
underscore	O
the	O
importance	O
of	O
social	B-MED
workers	I-MED
and	O
other	O
community	B-MED
services	I-MED
providers	B-MED
aligning	O
health	B-MED
services	I-MED
access	O
with	O
the	O
needs	O
of	O
the	O
CCI	B-MED
population	O
,	O
and	O
highlight	O
CCI	B-MED
adults	B-MED
as	O
being	O
at	O
risk	B-MED
of	O
underservice	O
in	O
critical	O
prevention	B-MED
and	O
intervention	B-MED
domains	I-MED
.	O
Grasping	B-MED
At	O
The	O
Moon	B-MED
:	O
Enhancing	B-MED
Access	B-MED
To	O
Careers	B-MED
In	O
The	O
Health	B-MED
Professions	I-MED
A	O
former	B-MED
HHS	B-MED
secretary	B-MED
reflects	B-MED
on	O
what	O
's	O
needed	O
to	O
enable	O
more	O
minorities	B-MED
to	O
become	O
doctors	B-MED
and	O
other	O
health	B-MED
professionals	I-MED
.	O
Metabolomics	B-MED
,	O
Nutrition	B-MED
,	O
and	O
Potential	B-MED
Biomarkers	B-MED
of	O
Food	B-MED
Quality	I-MED
,	O
Intake	B-MED
,	O
and	O
Health	B-MED
Status	I-MED
Diet	B-MED
,	O
dietary	B-MED
patterns	I-MED
,	O
and	O
other	O
environmental	B-MED
factors	I-MED
such	O
as	O
exposure	B-MED
to	I-MED
toxins	B-MED
are	O
playing	O
an	O
important	O
role	B-MED
in	O
the	O
prevention	B-MED
/	O
development	B-MED
of	O
many	O
diseases	B-MED
,	O
like	O
obesity	B-MED
,	O
type	B-MED
2	I-MED
diabetes	I-MED
,	O
and	O
consequently	O
on	O
the	O
health	B-MED
status	I-MED
of	O
individuals	B-MED
.	O
A	O
major	O
challenge	O
nowadays	O
is	O
to	O
identify	B-MED
novel	B-MED
biomarkers	B-MED
to	O
detect	B-MED
as	O
early	B-MED
as	O
possible	O
metabolic	B-MED
dysfunction	B-MED
and	O
to	O
predict	B-MED
evolution	B-MED
of	O
health	B-MED
status	I-MED
in	O
order	O
to	O
refine	O
nutritional	B-MED
advices	I-MED
to	O
specific	O
population	B-MED
groups	I-MED
.	O
Omics	B-MED
technologies	I-MED
such	O
as	O
genomics	B-MED
,	O
transcriptomics	O
,	O
proteomics	B-MED
,	O
and	O
metabolomics	B-MED
coupled	B-MED
with	O
statistical	B-MED
and	O
bioinformatics	B-MED
tools	I-MED
have	O
already	O
shown	O
great	O
potential	B-MED
in	O
this	O
research	B-MED
field	I-MED
even	O
if	O
so	O
far	O
only	O
few	O
biomarkers	B-MED
have	O
been	O
validated	O
.	O
For	O
the	O
past	O
two	O
decades	B-MED
,	O
important	O
analytical	B-MED
techniques	I-MED
have	O
been	O
developed	B-MED
to	O
detect	B-MED
as	O
many	O
metabolites	B-MED
as	O
possible	O
in	O
human	B-MED
biofluids	B-MED
such	O
as	O
urine	B-MED
,	O
blood	B-MED
,	O
and	O
saliva	B-MED
.	O
In	O
the	O
field	O
of	O
food	B-MED
science	I-MED
and	O
nutrition	B-MED
,	O
many	O
studies	B-MED
have	O
been	O
carried	O
out	O
for	O
food	B-MED
authenticity	B-MED
,	O
quality	B-MED
,	O
and	O
safety	B-MED
,	O
as	O
well	O
as	O
for	O
food	B-MED
processing	I-MED
.	O
Furthermore	O
,	O
metabolomic	B-MED
investigations	B-MED
have	O
been	O
carried	O
out	O
to	O
discover	B-MED
new	O
early	B-MED
biomarkers	B-MED
of	O
metabolic	B-MED
dysfunction	B-MED
and	O
predictive	B-MED
biomarkers	B-MED
of	O
developing	O
pathologies	B-MED
(	O
obesity	B-MED
,	O
metabolic	B-MED
syndrome	I-MED
,	O
type-2	B-MED
diabetes	I-MED
,	O
etc	O
.	O
)	O
.	O
Great	O
emphasis	O
is	O
also	O
placed	O
in	O
the	O
development	B-MED
of	O
methodologies	B-MED
to	O
identify	B-MED
and	O
validate	O
biomarkers	B-MED
of	O
nutrients	B-MED
exposure	B-MED
.	O
Transition	B-MED
From	O
Hospital	B-MED
to	O
Home	B-MED
in	O
Preterm	B-MED
Infants	I-MED
and	O
Their	O
Families	B-MED
When	O
the	O
day	B-MED
of	O
discharge	B-MED
from	O
a	O
neonatal	B-MED
intensive	I-MED
care	I-MED
unit	I-MED
(	O
NICU	B-MED
)	O
comes	O
for	O
the	O
parents	B-MED
of	O
newborn	B-MED
infants	I-MED
,	O
they	O
are	O
filled	O
with	O
long	O
-	O
awaited	O
joy	B-MED
and	O
happiness	B-MED
.	O
They	O
go	O
home	B-MED
feeling	B-MED
as	O
parents	B-MED
,	O
away	O
from	O
scheduled	B-MED
routines	I-MED
of	O
the	O
hospital	B-MED
,	O
monitor	B-MED
alarms	I-MED
,	O
clinical	B-MED
rounds	I-MED
,	O
numerous	B-MED
tests	B-MED
,	O
and	O
so	O
on	O
.	O
What	O
do	O
we	O
know	O
about	O
what	O
happens	B-MED
after	O
these	O
little	B-MED
patients	I-MED
and	O
their	O
families	B-MED
leave	B-MED
the	O
NICU	B-MED
?	O
What	O
happens	B-MED
from	O
the	O
point	O
of	O
leaving	B-MED
the	O
hospital	B-MED
until	O
when	O
things	O
get	O
settled	O
and	O
life	B-MED
becomes	O
perceived	B-MED
as	O
normal	B-MED
?	O
This	O
article	B-MED
presents	O
a	O
short	O
summary	B-MED
of	O
research	B-MED
conducted	O
with	O
the	O
vulnerable	B-MED
population	I-MED
of	O
high	B-MED
-	I-MED
risk	I-MED
and	O
preterm	B-MED
infants	I-MED
and	O
their	O
families	B-MED
postdischarge	B-MED
.	O
Available	O
evidence	B-MED
suggests	O
that	O
transition	B-MED
to	O
home	B-MED
after	O
hospital	B-MED
discharge	I-MED
,	O
a	O
phenomenon	B-MED
that	O
many	O
families	B-MED
experience	B-MED
,	O
is	O
challenging	B-MED
and	O
requires	O
attention	B-MED
from	O
clinicians	B-MED
and	O
researchers	B-MED
if	O
we	O
are	O
to	O
provide	O
effective	B-MED
,	O
efficient	B-MED
,	O
and	O
high	B-MED
-	I-MED
quality	I-MED
care	I-MED
.	O
Basal	B-MED
and	O
maximal	B-MED
metabolic	B-MED
rates	I-MED
differ	O
in	O
their	O
response	B-MED
to	O
rapid	O
temperature	B-MED
change	I-MED
among	O
avian	B-MED
species	B-MED
In	O
birds	B-MED
,	O
acclimation	B-MED
and	O
acclimatization	B-MED
to	O
temperature	B-MED
are	O
associated	O
with	O
changes	O
in	O
basal	B-MED
(	O
BMR	B-MED
)	O
,	O
summit	B-MED
(	O
Msum	B-MED
)	O
and	O
maximal	B-MED
(	O
MMR	B-MED
)	O
metabolic	B-MED
rates	I-MED
but	O
little	O
is	O
known	O
about	O
the	O
rate	B-MED
at	O
which	O
species	B-MED
adjust	O
their	O
phenotype	B-MED
to	O
short	B-MED
-	I-MED
term	I-MED
temperature	B-MED
variations	B-MED
.	O
Our	O
aims	B-MED
were	O
(	O
1	O
)	O
to	O
determine	O
the	O
pattern	B-MED
of	O
metabolic	B-MED
adjustments	O
following	O
a	O
rapid	O
temperature	B-MED
change	I-MED
,	O
(	O
2	O
)	O
to	O
determine	O
whether	O
performance	O
varies	O
at	O
similar	O
rates	B-MED
during	O
exposure	B-MED
to	I-MED
warm	B-MED
or	O
cold	B-MED
environments	I-MED
,	O
and	O
(	O
3	O
)	O
to	O
determine	O
if	O
BMR	B-MED
,	O
Msum	B-MED
and	O
MMR	B-MED
change	O
at	O
comparable	O
rates	B-MED
during	O
thermal	B-MED
acclimation	B-MED
.	O
We	O
measured	O
these	O
parameters	O
in	O
white	B-MED
-	I-MED
throated	I-MED
sparrows	I-MED
(	O
Zonotrichia	B-MED
albicollis	I-MED
)	O
,	O
black	B-MED
-	I-MED
capped	I-MED
chickadees	I-MED
(	O
Poecile	B-MED
atricapillus	I-MED
)	O
,	O
and	O
snow	B-MED
buntings	I-MED
(	O
Plectrophenax	B-MED
nivalis	I-MED
)	O
after	O
acclimation	B-MED
to	O
10	O
°	O
C	O
(	O
day	B-MED
0	O
)	O
and	O
on	O
the	O
4th	O
and	O
8th	O
days	B-MED
of	O
acclimation	B-MED
to	O
either	O
-5	O
or	O
28	O
°	O
C	O
.	O
Birds	B-MED
changed	O
their	O
metabolic	B-MED
phenotype	B-MED
within	O
8	O
days	B-MED
with	O
patterns	B-MED
differing	O
among	O
species	B-MED
.	O
Sparrows	B-MED
expressed	O
the	O
expected	O
metabolic	B-MED
increases	B-MED
in	O
the	O
cold	B-MED
and	O
decreases	O
at	O
thermoneutrality	B-MED
while	O
performance	O
in	O
chickadees	B-MED
and	O
buntings	B-MED
was	O
not	O
influenced	B-MED
by	O
temperature	B-MED
but	O
changed	O
over	O
time	O
with	O
inverse	O
patterns	B-MED
.	O
Our	O
results	B-MED
suggest	O
that	O
BMR	B-MED
varies	O
at	O
comparable	O
rates	B-MED
in	O
warm	B-MED
and	O
cold	B-MED
environments	I-MED
but	O
changes	O
faster	O
than	O
Msum	B-MED
and	O
MMR	B-MED
,	O
likely	O
due	O
to	O
limitations	B-MED
in	O
the	O
rate	B-MED
of	O
change	O
in	O
organ	B-MED
size	I-MED
and	O
function	B-MED
.	O
They	O
also	O
suggest	O
that	O
maximal	B-MED
metabolic	B-MED
capacity	B-MED
is	O
lost	B-MED
faster	O
in	O
a	O
warm	B-MED
environment	I-MED
than	O
it	O
is	O
gained	B-MED
in	O
a	O
cold	B-MED
environment	I-MED
.	O
With	O
the	O
expected	O
increase	O
in	O
temperature	B-MED
stochasticity	B-MED
at	O
northern	B-MED
latitudes	I-MED
,	O
a	O
loss	B-MED
of	O
thermogenic	B-MED
capacity	B-MED
during	O
warm	B-MED
winter	B-MED
days	B-MED
could	O
,	O
therefore	O
,	O
be	O
detrimental	O
if	O
birds	B-MED
are	O
slow	O
to	O
readjust	O
their	O
phenotype	B-MED
with	O
the	O
return	O
of	O
cold	B-MED
days	B-MED
.	O
Covalent	B-MED
Modulators	I-MED
of	O
the	O
Vacuolar	B-MED
ATPase	I-MED
The	O
vacuolar	B-MED
H(+	I-MED
)	I-MED
ATPase	I-MED
(	O
V	B-MED
-	I-MED
ATPase	I-MED
)	O
is	O
a	O
complex	B-MED
multisubunit	O
machine	B-MED
that	O
regulates	B-MED
important	O
cellular	B-MED
processes	I-MED
through	O
controlling	B-MED
acidity	B-MED
of	O
intracellular	B-MED
compartments	B-MED
in	O
eukaryotes	B-MED
.	O
Existing	O
small	B-MED
-	I-MED
molecule	I-MED
modulators	B-MED
of	O
V	B-MED
-	I-MED
ATPase	I-MED
either	O
are	O
restricted	B-MED
to	O
targeting	B-MED
one	O
membranous	B-MED
subunit	B-MED
of	O
V	B-MED
-	I-MED
ATPase	I-MED
or	O
have	O
poorly	O
understood	B-MED
mechanisms	B-MED
of	O
action	O
.	O
Small	B-MED
molecules	I-MED
with	O
novel	B-MED
and	O
defined	B-MED
mechanisms	B-MED
of	O
inhibition	B-MED
are	O
thus	O
needed	B-MED
to	O
functionally	B-MED
characterize	B-MED
V	B-MED
-	I-MED
ATPase	I-MED
and	O
to	O
fully	O
evaluate	O
the	O
therapeutic	B-MED
relevance	B-MED
of	O
V	B-MED
-	I-MED
ATPase	I-MED
in	O
human	B-MED
diseases	B-MED
.	O
We	O
have	O
discovered	O
electrophilic	B-MED
quinazolines	B-MED
that	O
covalently	B-MED
modify	I-MED
a	O
soluble	B-MED
catalytic	B-MED
subunit	I-MED
of	O
V	B-MED
-	I-MED
ATPase	I-MED
with	O
high	B-MED
potency	B-MED
and	O
exquisite	O
proteomic	B-MED
selectivity	I-MED
as	O
revealed	B-MED
by	O
fluorescence	B-MED
imaging	I-MED
and	O
chemical	B-MED
proteomic	I-MED
activity	I-MED
-	I-MED
based	I-MED
profiling	I-MED
.	O
The	O
site	B-MED
of	O
covalent	O
modification	B-MED
was	O
mapped	B-MED
to	O
a	O
cysteine	B-MED
residue	B-MED
located	B-MED
in	I-MED
a	O
region	B-MED
of	O
V	B-MED
-	I-MED
ATPase	I-MED
subunit	B-MED
A	I-MED
that	O
is	O
thought	B-MED
to	O
regulate	B-MED
the	O
dissociation	B-MED
of	O
V	B-MED
-	I-MED
ATPase	I-MED
.	O
We	O
further	O
demonstrate	O
that	O
a	O
previously	O
reported	O
V	B-MED
-	I-MED
ATPase	I-MED
inhibitor	I-MED
,	O
3	B-MED
-	I-MED
bromopyruvate	I-MED
,	O
also	O
targets	B-MED
the	O
same	B-MED
cysteine	B-MED
residue	B-MED
and	O
that	O
our	O
electrophilic	B-MED
quinazolines	B-MED
modulate	B-MED
the	O
function	B-MED
of	O
V	B-MED
-	I-MED
ATPase	I-MED
in	O
cells	B-MED
.	O
With	O
their	O
well	B-MED
-	I-MED
defined	I-MED
mechanism	B-MED
of	O
action	B-MED
and	O
high	B-MED
proteomic	B-MED
specificity	I-MED
,	O
the	O
described	O
quinazolines	B-MED
offer	O
a	O
powerful	B-MED
set	B-MED
of	O
chemical	B-MED
probes	I-MED
to	O
investigate	B-MED
the	O
physiological	B-MED
and	O
pathological	B-MED
roles	B-MED
of	O
V	B-MED
-	I-MED
ATPase	I-MED
.	O
Effects	B-MED
of	I-MED
regular	B-MED
water	B-MED
-	O
and	O
land	B-MED
-	I-MED
based	I-MED
exercise	I-MED
on	O
physical	B-MED
function	I-MED
after	O
5	O
years	B-MED
:	O
A	O
long	B-MED
-	I-MED
term	I-MED
study	I-MED
on	O
the	O
well	O
-	O
being	O
of	O
older	B-MED
Japanese	I-MED
adults	B-MED
To	O
investigate	B-MED
the	O
effects	B-MED
of	O
5	O
years	B-MED
of	O
physical	B-MED
exercise	I-MED
on	O
functional	B-MED
parameters	B-MED
among	O
older	B-MED
Japanese	I-MED
adults	B-MED
who	O
carried	O
out	O
water	B-MED
-	O
or	O
land	B-MED
-	I-MED
based	I-MED
exercise	I-MED
.	O
We	O
retrospectively	B-MED
investigated	B-MED
data	B-MED
from	O
5707	O
medical	B-MED
examinations	I-MED
and	O
enrolled	B-MED
77	O
older	B-MED
adults	I-MED
into	O
the	O
study	B-MED
.	O
Eligible	O
participants	B-MED
had	O
to	O
be	O
aged	B-MED
≥60	O
years	B-MED
,	O
and	O
engaged	O
in	O
water	B-MED
-	I-MED
based	I-MED
exercise	I-MED
(	O
n	O
=	O
38	O
)	O
or	O
a	O
combination	B-MED
of	O
water	B-MED
-	O
and	O
land	B-MED
-	I-MED
based	I-MED
exercise	I-MED
(	O
n	O
=	O
39	O
)	O
for	O
at	O
least	O
80	O
%	O
of	O
their	O
total	B-MED
exercise	I-MED
time	I-MED
for	O
over	O
5	O
years	B-MED
at	O
our	O
fitness	B-MED
center	I-MED
.	O
In	O
statistical	B-MED
analysis	I-MED
,	O
a	O
two	B-MED
-	I-MED
way	I-MED
repeated	I-MED
-	I-MED
measures	I-MED
analysis	I-MED
of	I-MED
variance	I-MED
was	O
carried	O
out	O
to	O
examine	B-MED
the	O
effects	B-MED
over	O
time	B-MED
and	O
by	O
exercise	B-MED
type	I-MED
,	O
and	O
the	O
changes	B-MED
in	O
each	O
parameter	B-MED
over	O
5	O
years	B-MED
were	O
also	O
compared	B-MED
between	O
the	O
two	O
groups	B-MED
.	O
We	O
found	B-MED
significant	B-MED
main	B-MED
effects	B-MED
and	O
an	O
interaction	B-MED
between	O
time	B-MED
and	O
exercise	B-MED
type	I-MED
for	O
gait	B-MED
speed	I-MED
,	O
with	O
an	O
early	B-MED
decline	I-MED
in	O
the	O
combined	B-MED
exercise	B-MED
group	I-MED
,	O
as	O
well	O
as	O
significant	B-MED
main	B-MED
effects	B-MED
of	I-MED
time	B-MED
,	O
showing	O
a	O
functional	B-MED
decline	I-MED
in	O
grip	B-MED
strength	I-MED
,	O
one	B-MED
-	I-MED
leg	I-MED
standing	I-MED
time	B-MED
and	O
step	B-MED
/	I-MED
height	I-MED
ratio	B-MED
in	O
both	O
exercise	B-MED
types	I-MED
at	O
the	O
5-	O
year	B-MED
follow	B-MED
up	I-MED
.	O
The	O
5-	O
year	B-MED
changes	B-MED
in	O
each	O
parameter	B-MED
did	O
not	O
differ	O
between	O
the	O
two	O
groups	B-MED
despite	O
the	O
frequency	B-MED
of	I-MED
exercise	I-MED
,	O
even	O
though	O
we	O
found	B-MED
a	O
negative	B-MED
correlation	B-MED
between	O
changes	B-MED
in	O
one	B-MED
-	I-MED
leg	I-MED
standing	I-MED
time	B-MED
and	O
total	B-MED
amount	B-MED
of	O
water	B-MED
-	I-MED
based	I-MED
exercise	I-MED
.	O
Contrary	O
to	O
expectations	B-MED
,	O
these	O
results	B-MED
suggest	B-MED
that	O
regular	B-MED
engagement	O
in	O
water	B-MED
-	I-MED
based	I-MED
exercise	I-MED
,	O
even	O
combined	B-MED
with	O
land	B-MED
-	I-MED
based	I-MED
exercise	I-MED
,	O
might	O
have	O
poor	O
long	B-MED
-	I-MED
term	I-MED
benefits	B-MED
for	O
maintaining	B-MED
physical	B-MED
performance	I-MED
in	O
older	B-MED
adults	I-MED
.	O
Geriatr	O
Gerontol	O
Int	O
2017	O
;	O
••	O
:	O
••-••.	O
Cdc45	B-MED
-	O
induced	B-MED
loading	B-MED
of	O
human	B-MED
RPA	I-MED
onto	O
single	B-MED
-	I-MED
stranded	I-MED
DNA	I-MED
Cell	B-MED
division	I-MED
cycle	I-MED
protein	I-MED
45	I-MED
(	O
Cdc45	B-MED
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
eukaryotic	B-MED
replicative	B-MED
DNA	B-MED
helicase	I-MED
.	O
We	O
found	O
that	O
human	B-MED
Cdc45	I-MED
forms	O
a	O
complex	B-MED
with	O
the	O
single	B-MED
-	I-MED
stranded	I-MED
DNA	I-MED
(	I-MED
ssDNA	I-MED
)	I-MED
binding	I-MED
protein	I-MED
RPA	I-MED
.	O
Moreover	O
,	O
it	O
actively	O
loads	B-MED
RPA	B-MED
onto	O
nascent	O
ssDNA	B-MED
.	O
Pull	B-MED
-	I-MED
down	I-MED
assays	I-MED
and	O
surface	B-MED
plasmon	I-MED
resonance	I-MED
studies	I-MED
revealed	O
that	O
Cdc45	B-MED
-	O
bound	B-MED
RPA	B-MED
complexed	B-MED
with	O
ssDNA	B-MED
in	O
the	O
8	O
-	O
10	O
nucleotide	B-MED
binding	I-MED
mode	O
,	O
but	O
dissociated	B-MED
when	O
RPA	B-MED
covered	O
a	O
30	B-MED
-	I-MED
mer	I-MED
.	O
Real	B-MED
-	I-MED
time	I-MED
analysis	I-MED
of	O
RPA	B-MED
-	O
ssDNA	B-MED
binding	B-MED
demonstrated	O
that	O
Cdc45	B-MED
catalytically	O
loaded	B-MED
RPA	B-MED
onto	O
ssDNA	B-MED
.	O
This	O
placement	B-MED
reaction	B-MED
required	O
physical	B-MED
contacts	I-MED
of	O
Cdc45	B-MED
with	O
the	O
RPA70A	B-MED
subdomain	I-MED
.	O
Our	O
results	O
imply	O
that	O
Cdc45	B-MED
controlled	O
stabilization	B-MED
of	O
the	O
8-	O
nt	B-MED
RPA	B-MED
binding	B-MED
mode	O
,	O
the	O
subsequent	O
RPA	B-MED
transition	O
into	O
30	B-MED
-	I-MED
mer	I-MED
mode	B-MED
and	O
facilitated	O
an	O
ordered	O
binding	B-MED
to	O
ssDNA	B-MED
.	O
We	O
propose	O
that	O
a	O
Cdc45	B-MED
-mediated	O
loading	B-MED
guarantees	O
a	O
seamless	O
deposition	B-MED
of	O
RPA	B-MED
on	O
newly	O
emerging	O
ssDNA	B-MED
at	O
the	O
nascent	O
replication	B-MED
fork	I-MED
.	O
Utility	O
of	O
Post	B-MED
-	I-MED
Mortem	I-MED
Genetic	B-MED
Testing	I-MED
in	O
Cases	O
of	O
Sudden	B-MED
Arrhythmic	I-MED
Death	I-MED
Syndrome	I-MED
Sudden	B-MED
arrhythmic	I-MED
death	I-MED
syndrome	I-MED
(	O
SADS	B-MED
)	O
describes	O
a	O
sudden	B-MED
death	I-MED
with	O
negative	O
autopsy	B-MED
and	O
toxicological	B-MED
analysis	B-MED
.	O
Cardiac	B-MED
genetic	I-MED
disease	I-MED
is	O
a	O
likely	O
etiology	B-MED
.	O
This	O
study	B-MED
investigated	B-MED
the	O
clinical	B-MED
utility	I-MED
and	O
combined	O
yield	O
of	O
post	B-MED
-	I-MED
mortem	I-MED
genetic	B-MED
testing	I-MED
(	O
molecular	B-MED
autopsy	I-MED
)	O
in	O
cases	O
of	O
SADS	B-MED
and	O
comprehensive	B-MED
clinical	B-MED
evaluation	I-MED
of	O
surviving	B-MED
relatives	B-MED
.	O
We	O
evaluated	B-MED
302	O
expertly	O
validated	O
SADS	B-MED
cases	O
with	O
suitable	O
DNA	B-MED
(	O
median	O
age	B-MED
:	O
24	O
years	O
;	O
65	O
%	O
males	B-MED
)	O
who	O
underwent	O
next	B-MED
-	I-MED
generation	I-MED
sequencing	B-MED
using	O
an	O
extended	O
panel	B-MED
of	O
77	O
primary	B-MED
electrical	I-MED
disorder	I-MED
and	O
cardiomyopathy	B-MED
genes	I-MED
.	O
Pathogenic	B-MED
and	O
likely	O
pathogenic	B-MED
variants	I-MED
were	O
classified	O
using	O
American	B-MED
College	I-MED
of	I-MED
Medical	I-MED
Genetics	I-MED
(	O
ACMG	B-MED
)	O
consensus	B-MED
guidelines	I-MED
.	O
The	O
yield	O
of	O
combined	O
molecular	B-MED
autopsy	I-MED
and	O
clinical	B-MED
evaluation	I-MED
in	O
82	O
surviving	B-MED
families	I-MED
was	O
evaluated	B-MED
.	O
A	O
gene	B-MED
-	I-MED
level	I-MED
rare	I-MED
variant	I-MED
association	I-MED
analysis	I-MED
was	O
conducted	O
in	O
SADS	B-MED
cases	O
versus	O
controls	B-MED
.	O
A	O
clinically	B-MED
actionable	I-MED
pathogenic	B-MED
or	O
likely	O
pathogenic	B-MED
variant	I-MED
was	O
identified	O
in	O
40	O
of	O
302	O
cases	O
(	O
13	O
%	O
)	O
.	O
The	O
main	O
etiologies	B-MED
established	O
were	O
catecholaminergic	B-MED
polymorphic	I-MED
ventricular	I-MED
tachycardia	I-MED
and	O
long	B-MED
QT	I-MED
syndrome	I-MED
(	O
17	O
[	O
6	O
%	O
]	O
and	O
11	O
[	O
4	O
%	O
]	O
,	O
respectively	O
)	O
.	O
Gene	B-MED
-	I-MED
based	I-MED
rare	I-MED
variants	I-MED
association	I-MED
analysis	I-MED
showed	O
enrichment	O
of	O
rare	O
predicted	O
deleterious	B-MED
variants	I-MED
in	O
RYR2	B-MED
(	O
p	O
=	O
5	O
×	O
10(-5	O
)	O
)	O
.	O
Combining	O
molecular	B-MED
autopsy	I-MED
with	O
clinical	B-MED
evaluation	I-MED
in	O
surviving	B-MED
families	I-MED
increased	O
diagnostic	B-MED
yield	I-MED
from	O
26	O
%	O
to	O
39	O
%	O
.	O
Molecular	B-MED
autopsy	I-MED
for	O
electrical	B-MED
disorder	I-MED
and	O
cardiomyopathy	B-MED
genes	I-MED
,	O
using	O
ACMG	B-MED
guidelines	B-MED
for	O
variant	B-MED
classification	I-MED
,	O
identified	O
a	O
modest	O
but	O
realistic	O
yield	O
in	O
SADS	B-MED
.	O
Our	O
data	O
highlighted	O
the	O
predominant	O
role	O
of	O
catecholaminergic	B-MED
polymorphic	I-MED
ventricular	I-MED
tachycardia	I-MED
and	O
long	B-MED
QT	I-MED
syndrome	I-MED
,	O
especially	O
the	O
RYR2	B-MED
gene	I-MED
,	O
as	O
well	O
as	O
the	O
minimal	O
yield	O
from	O
other	O
genes	B-MED
.	O
Furthermore	O
,	O
we	O
showed	O
the	O
enhanced	O
utility	O
of	O
combined	O
clinical	B-MED
and	O
genetic	B-MED
evaluation	I-MED
.	O
Quantitative	B-MED
determination	B-MED
of	O
five	O
metabolites	B-MED
of	O
aspirin	B-MED
by	O
UHPLC	B-MED
-	I-MED
MS	I-MED
/	O
MS	B-MED
coupled	B-MED
with	O
enzymatic	B-MED
reaction	I-MED
and	O
its	O
application	O
to	O
evaluate	O
the	O
effects	B-MED
of	O
aspirin	B-MED
dosage	B-MED
on	O
the	O
metabolic	B-MED
profile	I-MED
Acetylsalicylic	B-MED
acid	I-MED
(	O
Aspirin	B-MED
,	O
ASA	B-MED
)	O
is	O
a	O
famous	O
drug	B-MED
for	O
cardiovascular	B-MED
diseases	I-MED
in	O
recent	O
years	B-MED
.	O
Effects	O
of	O
ASA	B-MED
dosage	B-MED
on	O
the	O
metabolic	B-MED
profile	I-MED
have	O
not	O
been	O
fully	O
understood	O
.	O
The	O
purpose	O
of	O
our	O
study	B-MED
is	O
to	O
establish	O
a	O
rapid	B-MED
and	O
reliable	B-MED
method	B-MED
to	O
quantify	B-MED
ASA	B-MED
metabolites	B-MED
in	O
biological	B-MED
matrices	I-MED
,	O
especially	O
for	O
glucuronide	B-MED
metabolites	B-MED
whose	O
standards	O
are	O
not	O
commercially	O
available	O
.	O
Then	O
we	O
applied	O
this	O
method	B-MED
to	O
evaluate	O
the	O
effects	O
of	O
ASA	B-MED
dosage	B-MED
on	O
the	O
metabolic	B-MED
and	O
excretion	B-MED
profile	B-MED
of	O
ASA	B-MED
metabolites	B-MED
in	O
rat	B-MED
urine	B-MED
.	O
Salicylic	B-MED
acid	I-MED
(	O
SA	B-MED
)	O
,	O
gentisic	B-MED
acid	I-MED
(	O
GA	B-MED
)	O
and	O
salicyluric	B-MED
acid	I-MED
(	O
SUA	B-MED
)	O
were	O
determined	O
directly	O
by	O
UHPLC	B-MED
-	I-MED
MS	I-MED
/	O
MS	B-MED
,	O
while	O
salicyl	B-MED
phenolic	I-MED
glucuronide	I-MED
(	O
SAPG	B-MED
)	O
and	O
salicyluric	B-MED
acid	I-MED
phenolic	I-MED
glucuronide	I-MED
(	O
SUAPG	B-MED
)	O
were	O
quantified	B-MED
indirectly	O
by	O
measuring	O
the	O
released	O
SA	B-MED
and	O
SUA	B-MED
from	O
SAPG	B-MED
and	O
SUAPG	B-MED
after	O
β	B-MED
-	I-MED
glucuronidase	I-MED
digestion	B-MED
.	O
SUA	B-MED
and	O
SUAPG	B-MED
were	O
the	O
major	O
metabolites	B-MED
of	O
ASA	B-MED
in	O
rat	B-MED
urine	B-MED
24	O
h	B-MED
after	O
ASA	B-MED
administration	B-MED
,	O
which	O
accounted	O
for	O
50	O
%	O
(	O
SUA	B-MED
)	O
and	O
26	O
%	O
(	O
SUAPG	B-MED
)	O
.	O
When	O
ASA	B-MED
dosage	B-MED
was	O
increased	B-MED
,	O
the	O
contributions	O
dropped	O
to	O
32	O
%	O
and	O
18	O
%	O
,	O
respectively	O
.	O
The	O
excretion	B-MED
of	O
other	O
three	O
metabolites	B-MED
(	O
GA	B-MED
,	O
SA	B-MED
and	O
SAPG	B-MED
)	O
however	O
showed	O
remarkable	O
increases	O
by	O
16	O
%	O
,	O
6	O
%	O
and	O
4	O
%	O
,	O
respectively	O
.	O
In	O
addition	O
,	O
SUA	B-MED
and	O
SUAPG	B-MED
were	O
mainly	O
excreted	B-MED
in	O
the	O
time	B-MED
period	I-MED
of	O
12	O
-	O
24	O
h	B-MED
,	O
while	O
GA	B-MED
was	O
excreted	B-MED
in	O
the	O
earlier	O
time	B-MED
periods	I-MED
(	O
0	O
-	O
4	O
h	B-MED
and	O
4	O
-	O
8	O
h	B-MED
)	O
.	O
SA	B-MED
was	O
mainly	O
excreted	B-MED
in	O
the	O
time	B-MED
period	I-MED
of	O
0	O
-	O
4	O
h	B-MED
h	B-MED
and	O
12	O
-	O
24	O
h.	O
And	O
the	O
excretion	B-MED
of	O
SAPG	B-MED
was	O
equally	O
distributed	O
in	O
the	O
four	O
time	B-MED
periods	I-MED
.	O
We	O
went	O
further	O
to	O
show	O
that	O
the	O
excretion	B-MED
of	O
five	O
metabolites	B-MED
in	O
rat	B-MED
urine	B-MED
was	O
delayed	O
when	O
ASA	B-MED
dosage	B-MED
was	O
increased	B-MED
.	O
In	O
conclusion	O
,	O
we	O
have	O
developed	O
a	O
rapid	B-MED
and	O
sensitive	B-MED
method	B-MED
to	O
determine	O
the	O
five	O
ASA	B-MED
metabolites	B-MED
(	O
SA	B-MED
,	O
GA	B-MED
,	O
SUA	B-MED
,	O
SAPG	B-MED
and	O
SUAPG	B-MED
)	O
in	O
rat	B-MED
urine	B-MED
.	O
We	O
showed	O
that	O
ASA	B-MED
dosage	B-MED
could	O
significantly	O
influence	B-MED
the	O
metabolic	B-MED
and	O
excretion	B-MED
profile	B-MED
of	O
ASA	B-MED
metabolites	B-MED
in	O
rat	B-MED
urine	B-MED
.	O
Gold	B-MED
-	O
Nanosponge	B-MED
-Based	O
Multistimuli	B-MED
-	I-MED
Responsive	I-MED
Drug	I-MED
Vehicles	I-MED
for	O
Targeted	B-MED
Chemo	B-MED
-	I-MED
Photothermal	I-MED
Therapy	I-MED
Gold	B-MED
-	O
nanosponge	B-MED
-based	O
multistimuli	B-MED
-	I-MED
responsive	I-MED
drug	I-MED
vehicles	I-MED
are	O
constructed	O
for	O
combined	O
chemo	B-MED
-	I-MED
photothermal	I-MED
therapy	I-MED
with	O
pinpointed	O
drug	B-MED
delivery	B-MED
and	O
release	B-MED
capabilities	O
and	O
minimized	O
nonspecific	B-MED
systemic	B-MED
spread	B-MED
of	O
drugs	B-MED
,	O
remarkably	O
enhancing	B-MED
the	O
therapeutic	B-MED
efficiency	I-MED
while	O
minimizing	O
acute	B-MED
side	B-MED
effects	I-MED
.	O
Geolocalization	B-MED
of	O
Influenza	B-MED
Outbreak	B-MED
Within	O
an	O
Acute	B-MED
Care	I-MED
Population	B-MED
:	O
A	O
Layered	B-MED
-	I-MED
Surveillance	I-MED
Approach	B-MED
We	O
seek	O
to	O
use	O
a	O
novel	O
layered	B-MED
-	I-MED
surveillance	I-MED
approach	B-MED
to	O
localize	B-MED
influenza	B-MED
clusters	B-MED
within	O
an	O
acute	B-MED
care	I-MED
population	B-MED
.	O
The	O
first	O
layer	O
of	O
this	O
system	B-MED
is	O
a	O
syndromic	B-MED
surveillance	B-MED
screen	I-MED
to	O
guide	O
rapid	B-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
testing	I-MED
.	O
The	O
second	B-MED
layer	O
is	O
geolocalization	B-MED
and	O
cluster	B-MED
analysis	I-MED
of	O
these	O
patients	B-MED
.	O
We	O
posit	O
that	O
any	O
identified	B-MED
clusters	B-MED
could	O
represent	O
at	B-MED
-	I-MED
risk	I-MED
populations	I-MED
who	O
could	O
serve	O
as	O
high	B-MED
-	I-MED
yield	I-MED
targets	B-MED
for	O
preventive	B-MED
medical	I-MED
interventions	I-MED
.	O
This	O
was	O
a	O
prospective	B-MED
observational	I-MED
surveillance	I-MED
study	I-MED
.	O
Patients	B-MED
were	O
screened	B-MED
with	O
a	O
previously	O
derived	O
clinical	B-MED
decision	I-MED
guideline	I-MED
that	O
has	O
a	O
90	O
%	O
sensitivity	B-MED
and	O
30	O
%	O
specificity	B-MED
for	O
influenza	B-MED
.	O
Patients	B-MED
received	O
points	B-MED
for	O
the	O
following	O
signs	B-MED
and	I-MED
symptoms	I-MED
within	O
the	O
past	B-MED
7	O
days	B-MED
:	O
cough	B-MED
(	O
2	O
points	O
)	O
,	O
headache	B-MED
(	O
1	O
point	O
)	O
,	O
subjective	B-MED
fever	I-MED
(	O
1	O
point	O
)	O
,	O
and	O
documented	B-MED
fever	I-MED
at	O
triage	B-MED
(	O
temperature	B-MED
>	O
38	O
°	O
C	O
[	O
100.4	O
°	O
F	O
]	O
)	O
(	O
1	O
point	O
)	O
.	O
Patients	B-MED
scoring	B-MED
3	O
points	O
or	O
higher	O
were	O
indicated	B-MED
for	O
influenza	B-MED
testing	B-MED
.	O
Patients	B-MED
were	O
tested	B-MED
with	O
Xpert	B-MED
Flu	I-MED
(	O
Cepheid	B-MED
,	O
Sunnyvale	B-MED
,	O
CA	B-MED
)	O
,	O
a	O
rapid	B-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
test	I-MED
.	O
Positive	B-MED
results	B-MED
were	O
mapped	B-MED
with	O
ArcGIS	B-MED
(	O
ESRI	B-MED
,	O
Redlands	B-MED
,	O
CA	B-MED
)	O
and	O
analyzed	B-MED
with	O
kernel	B-MED
density	I-MED
estimation	I-MED
to	O
create	O
heat	B-MED
maps	I-MED
.	O
There	O
were	O
1,360	O
patients	B-MED
tested	B-MED
with	O
Xpert	B-MED
Flu	I-MED
with	O
retrievable	B-MED
addresses	B-MED
within	O
the	O
greater	O
Phoenix	B-MED
metro	I-MED
area	I-MED
.	O
One	O
hundred	O
sixty	O
-	O
seven	O
(	O
12	O
%	O
)	O
of	O
them	O
tested	B-MED
positive	B-MED
for	I-MED
influenza	I-MED
A	I-MED
and	O
23	O
(	O
2	O
%	O
)	O
tested	B-MED
positive	B-MED
for	I-MED
influenza	I-MED
B	I-MED
B.	O
The	O
influenza	B-MED
A	I-MED
virus	I-MED
exhibited	O
a	O
clear	B-MED
cluster	I-MED
pattern	B-MED
within	O
this	O
patient	B-MED
population	B-MED
.	O
The	O
densest	B-MED
cluster	I-MED
was	O
located	B-MED
in	O
an	O
approximately	O
1-	O
square	B-MED
-	I-MED
mile	I-MED
region	B-MED
southeast	B-MED
of	O
our	O
hospital	B-MED
.	O
Our	O
layered	B-MED
-	I-MED
surveillance	I-MED
approach	B-MED
was	O
effective	B-MED
in	O
localizing	B-MED
a	O
cluster	B-MED
of	O
influenza	B-MED
A	I-MED
outbreak	B-MED
.	O
This	O
region	B-MED
may	O
house	B-MED
a	O
high	B-MED
-	I-MED
yield	I-MED
target	B-MED
population	B-MED
for	O
public	B-MED
health	I-MED
intervention	I-MED
.	O
Further	O
collaborative	B-MED
efforts	O
will	O
be	O
made	O
between	O
our	O
hospital	B-MED
and	O
the	O
Maricopa	B-MED
County	I-MED
Department	B-MED
of	I-MED
Public	I-MED
Health	I-MED
to	O
perform	B-MED
a	O
series	O
of	O
community	B-MED
vaccination	B-MED
events	B-MED
before	O
the	O
next	O
influenza	B-MED
season	B-MED
.	O
We	O
hope	O
these	O
efforts	O
will	O
ultimately	O
serve	O
to	O
reduce	B-MED
the	O
burden	B-MED
of	O
this	O
disease	B-MED
on	O
our	O
patient	B-MED
population	B-MED
,	O
and	O
that	O
this	O
system	B-MED
will	O
serve	O
as	O
a	O
framework	O
for	O
future	B-MED
investigations	B-MED
locating	O
at	B-MED
-	I-MED
risk	I-MED
populations	I-MED
.	O
Non	B-MED
-	I-MED
pharmacological	I-MED
treatments	B-MED
for	O
pain	B-MED
relief	I-MED
:	O
TENS	B-MED
and	O
acupuncture	B-MED
Acupuncture	B-MED
and	O
transcutaneous	B-MED
electrical	I-MED
nerve	I-MED
stimulation	I-MED
(	O
TENS	B-MED
)	O
are	O
non	B-MED
-	I-MED
pharmacological	I-MED
methods	B-MED
that	O
have	O
been	O
used	O
for	O
millennia	B-MED
to	O
relieve	B-MED
pain	I-MED
.	O
As	O
with	O
all	O
complementary	B-MED
treatments	I-MED
,	O
efficacy	B-MED
evaluations	B-MED
face	O
two	O
hurdles	O
:	O
the	O
non	O
-	O
feasibility	O
of	O
double	B-MED
-	I-MED
blinding	I-MED
and	O
the	O
difficulty	O
in	O
identifying	O
the	O
optimal	B-MED
control	I-MED
population	I-MED
or	O
treatment	B-MED
.	O
Nevertheless	O
,	O
recent	O
studies	O
of	O
good	B-MED
methodological	B-MED
quality	I-MED
have	O
demonstrated	O
benefits	B-MED
in	O
many	O
types	O
of	O
pain	B-MED
compared	O
to	O
conventional	B-MED
treatment	B-MED
.	O
The	O
mechanisms	B-MED
of	I-MED
action	I-MED
of	O
acupuncture	B-MED
and	O
TENS	B-MED
,	O
which	O
are	O
increasingly	B-MED
well	O
understood	O
,	O
involve	O
endogenous	B-MED
pain	B-MED
control	I-MED
systems	I-MED
,	O
cerebral	B-MED
plasticity	I-MED
,	O
and	O
nonspecific	O
effects	B-MED
(	O
e.g.	O
,	O
expectations	B-MED
and	O
placebo	B-MED
effect	I-MED
)	O
.	O
No	O
serious	O
adverse	B-MED
effects	I-MED
have	O
been	O
reported	O
.	O
These	O
data	B-MED
support	O
the	O
more	O
widespread	O
use	O
of	O
non	B-MED
-	I-MED
pharmacological	I-MED
pain	B-MED
management	I-MED
,	O
most	O
notably	O
in	O
patients	B-MED
with	O
chronic	B-MED
pain	I-MED
inadequately	O
relieved	B-MED
by	I-MED
medications	B-MED
alone	O
.	O
Does	O
Video	B-MED
Laryngoscopy	I-MED
Offer	O
Advantages	B-MED
over	O
Direct	B-MED
Laryngoscopy	I-MED
during	B-MED
Cardiopulmonary	B-MED
Resuscitation	I-MED
?	O
Interruption	B-MED
of	O
chest	B-MED
compressions	I-MED
should	O
be	O
minimized	B-MED
because	O
of	O
its	O
negative	B-MED
effects	B-MED
on	O
survival	B-MED
.	O
This	O
randomized	B-MED
,	O
controlled	B-MED
,	O
cross	B-MED
-	I-MED
over	I-MED
study	I-MED
aimed	B-MED
to	O
analyze	B-MED
the	O
effectiveness	B-MED
of	O
Macintosh	B-MED
,	O
Miller	B-MED
,	O
McCoy	B-MED
and	O
McGrath	B-MED
laryngoscopes	I-MED
during	B-MED
with	O
or	O
without	O
chest	B-MED
compressions	I-MED
in	O
the	O
scope	B-MED
of	O
a	O
simulated	O
cardiopulmonary	B-MED
resuscitation	I-MED
scenario	B-MED
.	O
The	O
time	B-MED
required	B-MED
for	O
successful	B-MED
tracheal	B-MED
intubation	I-MED
,	O
number	B-MED
of	I-MED
attempts	I-MED
,	O
dental	B-MED
trauma	I-MED
severity	B-MED
and	O
the	O
need	B-MED
for	O
optimization	B-MED
manoeuvres	B-MED
were	O
recorded	B-MED
during	B-MED
cardiopulmonary	B-MED
resuscitation	I-MED
with	O
and	O
without	O
chest	B-MED
compressions	I-MED
.	O
The	O
experience	B-MED
with	O
computer	B-MED
games	I-MED
during	B-MED
the	O
last	O
10	O
years	B-MED
were	O
asked	O
to	O
the	O
participants	B-MED
and	O
recorded	B-MED
.	O
McCoy	B-MED
laryngoscope	I-MED
yielded	O
the	O
shortest	B-MED
time	I-MED
for	O
successful	B-MED
tracheal	B-MED
intubation	I-MED
both	O
in	O
the	O
presence	B-MED
of	O
and	O
without	O
chest	B-MED
compressions	I-MED
.	O
During	B-MED
the	O
use	B-MED
of	O
McCoy	B-MED
laryngoscopes	I-MED
,	O
fewer	B-MED
tracheal	B-MED
intubation	I-MED
attempts	B-MED
,	O
lower	B-MED
incidence	I-MED
of	O
dental	B-MED
trauma	I-MED
and	O
lower	B-MED
visual	B-MED
analogue	I-MED
scale	I-MED
scores	I-MED
on	O
the	O
ease	O
of	O
intubation	B-MED
were	O
recorded	B-MED
.	O
Participants	B-MED
who	O
are	O
experienced	B-MED
computer	B-MED
game	I-MED
players	B-MED
using	O
Macintosh	B-MED
,	O
McCoy	B-MED
and	O
McGrath	B-MED
achieved	B-MED
successful	B-MED
tracheal	B-MED
intubation	I-MED
in	O
a	O
significantly	B-MED
shorter	B-MED
time	I-MED
during	B-MED
resuscitation	B-MED
without	O
chest	B-MED
compressions	I-MED
.	O
Dental	B-MED
trauma	I-MED
incidence	B-MED
and	O
number	B-MED
of	O
tracheal	B-MED
intubation	I-MED
attempts	B-MED
did	O
not	O
show	O
any	O
significant	B-MED
difference	B-MED
between	O
the	O
four	B-MED
laryngoscopes	B-MED
being	O
related	O
to	O
the	O
rate	B-MED
of	O
playing	B-MED
computer	B-MED
games	I-MED
.	O
McGrath	B-MED
video	I-MED
laryngoscopes	I-MED
do	O
not	O
appear	O
to	O
have	O
advantages	B-MED
over	O
direct	B-MED
laryngoscopes	I-MED
for	O
securing	O
a	O
smooth	B-MED
and	O
successful	B-MED
tracheal	B-MED
intubation	I-MED
during	B-MED
rhythmic	B-MED
chest	I-MED
compressions	I-MED
.	O
We	O
believe	O
that	O
as	O
McCoy	B-MED
laryngoscope	I-MED
provided	B-MED
tracheal	B-MED
intubation	I-MED
in	O
a	O
shorter	B-MED
time	I-MED
and	O
with	O
fewer	B-MED
attempts	B-MED
,	O
this	O
laryngoscope	B-MED
may	O
increase	B-MED
the	O
success	B-MED
rate	I-MED
of	O
resuscitation	B-MED
.	O
Economic	B-MED
Burden	I-MED
of	O
Illness	B-MED
Among	O
Patients	B-MED
with	O
Severe	B-MED
Asthma	I-MED
in	O
a	O
Managed	O
Care	B-MED
Setting	I-MED
Despite	O
intensive	O
pharmacotherapy	B-MED
,	O
a	O
considerable	O
number	B-MED
of	O
patients	B-MED
with	O
severe	B-MED
asthma	I-MED
have	O
inadequate	B-MED
disease	B-MED
control	B-MED
.	O
Patients	B-MED
with	O
severe	B-MED
asthma	I-MED
who	O
experience	B-MED
exacerbations	B-MED
consume	O
significant	O
health	B-MED
care	I-MED
resources	I-MED
.	O
To	O
assess	B-MED
health	B-MED
care	I-MED
resource	I-MED
utilization	B-MED
and	O
associated	O
costs	B-MED
among	O
patients	B-MED
with	O
persistent	B-MED
severe	B-MED
asthma	I-MED
who	O
experienced	B-MED
exacerbations	B-MED
compared	O
with	O
patients	B-MED
with	O
persistent	B-MED
but	O
nonsevere	O
asthma	B-MED
.	O
This	O
retrospective	B-MED
analysis	B-MED
of	O
a	O
national	B-MED
administrative	I-MED
claims	I-MED
database	I-MED
identified	B-MED
patients	B-MED
aged	B-MED
≥	O
12	O
years	B-MED
who	O
had	O
at	O
least	O
1	O
medical	B-MED
claim	I-MED
with	O
an	O
asthma	B-MED
diagnosis	B-MED
in	O
2012	O
and	O
had	O
continuous	O
medical	B-MED
and	O
pharmacy	B-MED
coverage	I-MED
under	O
a	O
commercial	B-MED
or	O
Medicare	B-MED
Advantage	I-MED
plan	I-MED
from	O
January	O
1	O
,	O
2012	O
,	O
to	O
December	O
31	O
,	O
2013	O
.	O
Patients	B-MED
were	O
assigned	B-MED
to	O
1	O
of	O
2	O
mutually	O
exclusive	O
cohorts	B-MED
-	O
persistent	B-MED
asthma	I-MED
(	O
PA	B-MED
)	O
or	O
severe	B-MED
asthma	I-MED
SA	B-MED
(	O
SA)-according	O
to	O
an	O
established	O
algorithm	B-MED
based	O
on	O
asthma	B-MED
-related	O
health	B-MED
care	I-MED
resource	I-MED
use	B-MED
and	O
pharmacy	B-MED
claims	I-MED
for	O
controller	B-MED
medication	I-MED
.	O
SA	B-MED
patients	B-MED
were	O
required	O
to	O
meet	B-MED
PA	B-MED
criteria	B-MED
and	O
also	O
have	O
evidence	B-MED
of	O
≥2	O
asthma	B-MED
exacerbations	I-MED
in	O
2012	O
.	O
Asthma	B-MED
-related	O
health	B-MED
care	I-MED
resource	I-MED
utilization	B-MED
and	O
costs	B-MED
were	O
computed	B-MED
from	O
asthma	B-MED
medication	B-MED
use	B-MED
(	O
rescue	B-MED
and	O
controller	B-MED
therapy	I-MED
)	O
and	O
medical	B-MED
claims	I-MED
with	O
an	O
asthma	B-MED
diagnosis	B-MED
in	O
the	O
primary	B-MED
position	I-MED
in	O
2012	O
and	O
2013	O
.	O
Adherence	B-MED
to	O
controller	B-MED
therapy	I-MED
was	O
assessed	B-MED
over	O
365	O
days	B-MED
by	O
using	O
the	O
proportion	B-MED
of	I-MED
days	I-MED
covered	I-MED
(	O
PDC	B-MED
)	O
,	O
starting	O
with	O
the	O
first	O
claim	B-MED
for	O
controller	B-MED
therapy	I-MED
in	O
2012	O
.	O
Differences	B-MED
between	O
the	O
PA	B-MED
and	O
SA	B-MED
cohorts	B-MED
were	O
analyzed	B-MED
by	O
t	B-MED
-	I-MED
test	I-MED
for	O
continuous	B-MED
variables	I-MED
and	O
chi	B-MED
-	I-MED
square	I-MED
test	I-MED
for	O
categorical	B-MED
variables	I-MED
.	O
Asthma	B-MED
-related	O
costs	B-MED
in	O
2013	O
were	O
also	O
analyzed	B-MED
using	O
a	O
generalized	O
linear	B-MED
model	I-MED
with	O
a	O
gamma	B-MED
distribution	I-MED
and	O
log	B-MED
link	I-MED
,	O
adjusted	B-MED
for	O
patient	B-MED
demographics	B-MED
(	O
age	B-MED
,	O
gender	B-MED
,	O
region	B-MED
,	O
and	O
insurance	B-MED
type	I-MED
)	O
and	O
Quan	B-MED
-	I-MED
Charlson	I-MED
comorbidity	I-MED
score	I-MED
.	O
A	O
total	O
of	O
65,359	O
patients	B-MED
were	O
included	O
:	O
63,597	O
(	O
97.3	O
%	O
)	O
PA	B-MED
patients	B-MED
and	O
1,762	O
SA	B-MED
patients	B-MED
(	O
2.7	O
%	O
)	O
.	O
Compared	B-MED
with	O
the	O
PA	B-MED
cohort	B-MED
,	O
the	O
SA	B-MED
cohort	B-MED
was	O
older	B-MED
(	O
mean	B-MED
age	I-MED
=	O
50.8	O
years	B-MED
vs.	O
46.5	O
years	B-MED
,	O
P	O
<	O
0.001	O
)	O
and	O
had	O
higher	O
mean	O
comorbidity	B-MED
score	I-MED
(	O
1.47	O
vs.	O
1.31	O
,	O
P	O
<	O
0.001	O
)	O
.	O
The	O
mean	O
count	O
of	O
all	O
asthma	B-MED
medications	B-MED
fills	O
was	O
2.2	O
-	O
fold	O
(	O
2012	O
)	O
and	O
2.1	O
-	O
fold	O
(	O
2013	O
)	O
higher	O
in	O
the	O
SA	B-MED
cohort	B-MED
,	I-MED
compared	B-MED
with	O
the	O
PA	B-MED
cohort	B-MED
(	O
P	O
<	O
0.001	O
)	O
.	O
Mean	O
PDC	B-MED
for	O
all	O
oral	B-MED
and	O
inhaled	B-MED
controller	B-MED
therapy	I-MED
was	O
also	O
higher	O
in	O
the	O
SA	B-MED
cohort	B-MED
compared	B-MED
with	O
the	O
PA	B-MED
cohort	B-MED
(	O
0.80	O
vs.	O
0.65	O
,	O
P	O
<	O
0.001	O
)	O
.	O
SA	B-MED
patients	B-MED
had	O
a	O
significantly	O
greater	B-MED
mean	I-MED
count	I-MED
of	O
asthma	B-MED
-related	O
hospitalizations	B-MED
,	O
emergency	B-MED
room	I-MED
visits	I-MED
,	O
and	O
ambulatory	B-MED
visits	I-MED
in	O
2012	O
and	O
2013	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Unadjusted	O
mean	O
annual	O
asthma	B-MED
-related	O
costs	B-MED
in	O
the	O
SA	B-MED
versus	O
PA	B-MED
cohorts	B-MED
were	O
$	O
6,496	O
versus	O
$	O
2,739	O
(	O
P	O
<	O
0.001	O
)	O
in	O
2012	O
and	O
$	O
5,174	O
versus	O
$	O
1,775	O
(	O
P	O
<	O
0.001	O
)	O
in	O
2013	O
.	O
Higher	O
asthma	B-MED
-related	O
costs	B-MED
were	O
driven	O
by	O
greater	O
mean	O
annual	O
asthma	B-MED
medication	B-MED
costs	B-MED
in	O
2012	O
(	O
$	O
4,545	O
vs.	O
$	O
1,738	O
,	O
P	O
<	O
0.001	O
)	O
and	O
2013	O
(	O
$	O
4,068	O
vs.	O
$	O
1,348	O
,	O
P	O
<	O
0.001	O
)	O
.	O
Adjusted	B-MED
mean	O
annual	O
asthma	B-MED
-related	O
costs	B-MED
in	O
2013	O
were	O
$	O
3,336	O
greater	O
(	O
cost	B-MED
ratio	I-MED
=	O
2.878	O
,	O
P	O
<	O
0.001	O
)	O
in	O
the	O
SA	B-MED
cohort	B-MED
,	O
and	O
adjusted	B-MED
mean	O
annual	O
asthma	B-MED
medication	B-MED
costs	B-MED
were	O
$	O
2,672	O
higher	O
(	O
cost	O
ratio=2.982	O
,	O
P	O
<	O
0.001	O
)	O
in	O
the	O
SA	B-MED
cohort	B-MED
.	O
Patients	B-MED
with	O
SA	B-MED
who	O
experienced	B-MED
2	O
or	O
more	O
exacerbations	B-MED
had	O
2.1	O
-	O
fold	O
greater	O
use	B-MED
of	O
controller	B-MED
medications	I-MED
across	O
both	O
study	O
years	B-MED
and	O
were	O
more	O
adherent	B-MED
to	O
controller	B-MED
therapy	I-MED
than	O
patients	B-MED
with	O
PA	B-MED
.	O
Despite	O
more	O
intensive	O
pharmacotherapy	B-MED
,	O
SA	B-MED
patients	B-MED
incurred	O
2.9	O
-	O
fold	O
higher	O
adjusted	B-MED
asthma	B-MED
-related	O
costs	B-MED
and	O
3	O
-	O
fold	O
higher	O
adjusted	B-MED
asthma	B-MED
medication	B-MED
costs	B-MED
than	O
PA	B-MED
patients	B-MED
.	O
Patients	B-MED
with	O
SA	B-MED
consistently	B-MED
demonstrated	O
a	O
higher	O
rate	O
of	O
health	B-MED
care	I-MED
utilization	B-MED
.	O
Funding	B-MED
for	O
this	O
study	B-MED
(	O
HO-14	O
-	O
14443	O
)	O
was	O
provided	O
by	O
GlaxoSmithKline	B-MED
(	O
GSK	B-MED
)	O
.	O
All	O
listed	O
authors	B-MED
meet	B-MED
the	O
criteria	B-MED
for	O
authorship	B-MED
set	O
forth	O
by	O
the	O
International	B-MED
Committee	I-MED
for	I-MED
Medical	I-MED
Journal	I-MED
Editors	I-MED
.	O
Albers	B-MED
,	O
Forshag	B-MED
,	O
and	O
Yancey	B-MED
are	O
employees	B-MED
of	O
GSK	B-MED
and	O
hold	O
stock	O
in	O
GSK	B-MED
.	O
Dalal	B-MED
,	O
Nagar	B-MED
,	O
and	O
Ortega	B-MED
were	O
employees	B-MED
of	O
GSK	B-MED
at	O
the	O
time	B-MED
this	O
research	B-MED
was	O
conducted	O
.	O
Chastek	B-MED
and	O
Korrer	B-MED
are	O
employees	B-MED
of	O
Optum	B-MED
,	O
which	O
received	O
consulting	B-MED
fees	I-MED
from	O
GSK	B-MED
for	O
research	B-MED
related	O
to	O
this	O
study	B-MED
.	O
Study	B-MED
concept	I-MED
and	O
design	B-MED
were	O
contributed	B-MED
by	O
Chastek	B-MED
,	O
Nagar	B-MED
,	O
and	O
Dalal	B-MED
.	O
Korrer	B-MED
took	O
the	O
lead	O
in	O
data	B-MED
collection	I-MED
,	O
along	O
with	O
Chastek	B-MED
,	O
and	O
data	B-MED
interpretation	I-MED
was	O
performed	O
by	O
Chastek	B-MED
,	O
Ortega	B-MED
,	O
Forshag	B-MED
,	O
and	O
Dalal	B-MED
.	O
The	O
manuscript	B-MED
was	O
written	O
by	O
Chastek	B-MED
and	O
Dalal	B-MED
and	O
revised	B-MED
by	O
Albers	B-MED
and	O
Yancy	B-MED
,	O
assisted	B-MED
by	O
the	O
other	O
authors	B-MED
.	O
Genital	B-MED
and	O
Extragenital	B-MED
Gonorrhea	I-MED
and	O
Chlamydia	B-MED
in	O
Children	B-MED
and	O
Adolescents	B-MED
Evaluated	B-MED
for	O
Sexual	B-MED
Abuse	I-MED
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
describe	O
the	O
use	O
of	O
a	O
nucleic	B-MED
acid	I-MED
amplification	I-MED
test	I-MED
in	O
detecting	B-MED
genital	B-MED
and	O
extragenital	B-MED
Neisseria	I-MED
gonorrhoeae	I-MED
(	O
NG	B-MED
)	O
and	O
Chlamydia	B-MED
trachomatis	I-MED
(	O
CT	B-MED
)	O
in	O
children	B-MED
and	O
adolescents	B-MED
assessed	B-MED
for	O
sexual	B-MED
abuse	I-MED
/	O
assault	B-MED
.	O
The	O
charts	O
of	O
children	B-MED
aged	B-MED
0	O
to	O
17	O
years	B-MED
,	O
consecutively	O
evaluated	B-MED
for	O
sexual	B-MED
victimization	I-MED
,	O
in	O
emergency	B-MED
department	I-MED
and	O
outpatient	B-MED
settings	I-MED
were	O
reviewed	O
.	O
Data	B-MED
extracted	O
included	O
age	B-MED
,	O
sex	B-MED
,	O
type	O
of	O
sexual	B-MED
contact	I-MED
,	O
anogenital	B-MED
findings	B-MED
,	O
previous	B-MED
sexual	B-MED
contact	I-MED
,	O
toxicology	B-MED
results	I-MED
,	O
and	O
sites	B-MED
tested	B-MED
for	O
NG	B-MED
and	O
CT	B-MED
.	O
Of	O
the	O
1319	O
patients	B-MED
who	O
were	O
tested	B-MED
,	O
579	O
were	O
tested	B-MED
at	O
more	O
than	O
1	O
site	B-MED
,	O
and	O
120	O
had	O
at	O
least	O
1	O
infected	B-MED
site	B-MED
.	O
Chlamydia	B-MED
trachomatis	I-MED
was	O
identified	O
in	O
104	O
patients	B-MED
,	O
and	O
NG	B-MED
was	O
found	O
in	O
33	O
.	O
In	O
bivariate	B-MED
analysis	I-MED
,	O
a	O
positive	O
test	O
was	O
associated	B-MED
with	I-MED
female	B-MED
sex	I-MED
,	O
age	B-MED
older	O
than	O
11	O
years	B-MED
,	O
previous	B-MED
sexual	B-MED
contact	I-MED
,	O
acute	O
or	O
healed	B-MED
genital	B-MED
injury	I-MED
,	O
drug	B-MED
/	I-MED
alcohol	I-MED
intoxication	I-MED
,	O
and	O
examination	B-MED
within	O
72	O
hours	B-MED
of	O
sexual	B-MED
contact	I-MED
.	O
Fifty	O
-	O
one	O
patients	B-MED
had	O
positive	B-MED
anal	B-MED
tests	B-MED
,	O
and	O
24	O
had	O
positive	B-MED
oral	B-MED
tests	B-MED
.	O
More	O
than	O
75	O
%	O
of	O
patients	B-MED
with	O
positive	B-MED
extragenital	B-MED
tests	I-MED
had	O
additional	O
positive	B-MED
tests	B-MED
or	O
anogenital	B-MED
injury	B-MED
.	O
Most	O
with	O
a	O
positive	B-MED
anal	B-MED
(	O
59	O
%	O
)	O
or	O
oral	B-MED
(	O
77	O
%	O
)	O
test	B-MED
did	O
not	O
report	O
that	O
the	O
assailant	O
's	O
genitals	B-MED
came	O
into	O
contact	O
with	O
that	O
site	B-MED
.	O
Positive	B-MED
tests	B-MED
for	O
NG	B-MED
and	O
CT	B-MED
in	O
patients	B-MED
evaluated	B-MED
for	O
sexual	B-MED
victimization	I-MED
may	O
represent	O
infection	B-MED
from	O
sexual	B-MED
contact	I-MED
,	O
contiguous	B-MED
spread	I-MED
of	O
infection	B-MED
,	O
or	O
the	O
presence	O
of	O
infected	B-MED
assailant	I-MED
secretions	I-MED
.	O
Relying	O
on	O
patient	B-MED
reports	O
of	O
symptoms	B-MED
,	O
or	O
types	O
of	O
sexual	B-MED
contact	I-MED
,	O
to	O
determine	O
need	O
for	O
testing	O
may	O
miss	O
NG	B-MED
and	O
CT	B-MED
infections	I-MED
in	O
patients	B-MED
evaluated	B-MED
for	O
sexual	B-MED
victimization	I-MED
.	O
Repetitive	B-MED
and	O
Prolonged	B-MED
Omega-3	B-MED
Fatty	I-MED
Acid	I-MED
Treatment	B-MED
After	B-MED
Traumatic	B-MED
Brain	I-MED
Injury	I-MED
Enhances	B-MED
Long	B-MED
-	I-MED
Term	I-MED
Tissue	B-MED
Restoration	B-MED
and	O
Cognitive	B-MED
Recovery	I-MED
Traumatic	B-MED
brain	I-MED
injury	I-MED
(	O
TBI	B-MED
)	O
is	O
one	O
of	O
the	O
most	O
disabling	B-MED
clinical	I-MED
conditions	I-MED
that	O
could	O
lead	B-MED
to	O
neurocognitive	B-MED
disorders	I-MED
in	O
survivors	B-MED
.	O
Our	O
group	B-MED
and	O
others	B-MED
previously	O
reported	B-MED
that	O
prophylactic	B-MED
enrichment	I-MED
of	O
dietary	B-MED
omega-3	B-MED
polyunsaturated	I-MED
fatty	I-MED
acids	I-MED
(	O
n-3	B-MED
PUFAs	I-MED
)	O
markedly	O
ameliorate	B-MED
cognitive	B-MED
deficits	I-MED
after	B-MED
TBI	B-MED
.	O
However	O
,	O
it	O
remains	O
unclear	B-MED
whether	O
a	O
clinically	B-MED
relevant	B-MED
therapeutic	B-MED
regimen	I-MED
with	O
n-3	B-MED
PUFAs	I-MED
administered	B-MED
after	B-MED
TBI	B-MED
would	O
still	O
offer	O
significant	O
improvement	B-MED
of	O
long	B-MED
-	I-MED
term	I-MED
cognitive	B-MED
recovery	I-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
we	O
employed	O
the	O
decline	B-MED
of	O
spatial	O
cognitive	B-MED
function	I-MED
as	O
a	O
main	B-MED
outcome	B-MED
after	B-MED
TBI	B-MED
to	O
investigate	B-MED
the	O
therapeutic	B-MED
efficacy	I-MED
of	O
post	B-MED
-	O
TBI	B-MED
n-3	B-MED
PUFA	I-MED
treatment	B-MED
and	O
the	O
underlying	O
mechanisms	B-MED
.	O
Mice	B-MED
were	O
subjected	O
to	O
sham	B-MED
operation	I-MED
or	O
controlled	B-MED
cortical	B-MED
impact	B-MED
,	O
followed	O
by	O
random	B-MED
assignment	I-MED
to	O
receive	B-MED
the	O
following	O
four	B-MED
treatments	B-MED
:	O
(	O
1	O
)	O
vehicle	B-MED
control	B-MED
;	O
(	O
2	O
)	O
daily	B-MED
intraperitoneal	B-MED
injections	I-MED
of	O
n-3	B-MED
PUFAs	I-MED
for	O
2	O
weeks	B-MED
,	O
beginning	B-MED
2	O
h	B-MED
after	B-MED
TBI	B-MED
;	O
(	O
3	O
)	O
fish	B-MED
oil	I-MED
dietary	I-MED
supplementation	B-MED
throughout	O
the	O
study	B-MED
,	O
beginning	B-MED
1	O
day	B-MED
after	B-MED
TBI	B-MED
;	O
or	O
(	O
4	O
)	O
combination	B-MED
of	O
treatments	B-MED
(	O
2	O
)	O
and	O
(	O
3	O
)	O
.	O
Spatial	O
cognitive	O
deficits	O
and	O
chronic	B-MED
brain	B-MED
tissue	I-MED
loss	B-MED
,	O
as	O
well	O
as	O
endogenous	B-MED
brain	B-MED
repair	I-MED
processes	I-MED
such	O
as	O
neurogenesis	B-MED
,	O
angiogenesis	B-MED
,	O
and	O
oligodendrogenesis	B-MED
,	O
were	O
evaluated	O
up	O
to	O
35	O
days	B-MED
after	B-MED
TBI	B-MED
.	O
The	O
results	B-MED
revealed	B-MED
prominent	O
spatial	O
cognitive	B-MED
deficits	I-MED
and	O
massive	B-MED
tissue	B-MED
loss	B-MED
caused	O
by	O
TBI	B-MED
.	O
Among	O
all	O
mice	B-MED
receiving	B-MED
post	B-MED
-	I-MED
TBI	I-MED
n-3	B-MED
PUFA	I-MED
treatments	B-MED
,	O
the	O
combined	B-MED
treatment	B-MED
of	O
fish	B-MED
oil	I-MED
dietary	I-MED
supplement	B-MED
and	O
n-3	B-MED
PUFA	I-MED
injections	B-MED
demonstrated	B-MED
a	O
reproducible	B-MED
beneficial	I-MED
effect	I-MED
in	O
attenuating	O
cognitive	B-MED
deficits	I-MED
although	O
without	O
reducing	B-MED
gross	B-MED
tissue	B-MED
loss	B-MED
.	O
Mechanistically	O
,	O
the	O
combined	O
treatment	B-MED
promoted	B-MED
post	B-MED
-	I-MED
TBI	I-MED
restorative	B-MED
processes	I-MED
in	O
the	O
brain	B-MED
,	O
including	B-MED
generation	O
of	O
immature	B-MED
neurons	I-MED
,	O
microvessels	B-MED
,	O
and	O
oligodendrocytes	B-MED
,	O
each	O
of	O
which	O
was	O
significantly	O
correlated	B-MED
with	O
the	O
improved	B-MED
cognitive	B-MED
recovery	I-MED
.	O
These	O
results	B-MED
indicated	B-MED
that	O
repetitive	B-MED
and	O
prolonged	B-MED
n-3	B-MED
PUFA	I-MED
treatments	B-MED
after	B-MED
TBI	B-MED
are	O
capable	O
of	O
enhancing	B-MED
brain	B-MED
remodeling	B-MED
and	O
could	O
be	O
developed	O
as	O
a	O
potential	B-MED
therapy	B-MED
to	O
treat	O
TBI	B-MED
victims	B-MED
in	O
the	O
clinic	B-MED
.	O
The	O
relationship	B-MED
between	O
thoracic	B-MED
configuration	B-MED
and	O
changes	B-MED
in	O
volumes	B-MED
of	O
hemithoraces	B-MED
in	O
upright	B-MED
sitting	I-MED
[	O
Purpose	O
]	O
Some	O
patients	B-MED
with	O
respiratory	B-MED
disease	I-MED
exhibit	O
asymmetrical	B-MED
movement	I-MED
of	I-MED
the	I-MED
thorax	I-MED
.	O
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
the	O
relationship	B-MED
of	O
thoracic	B-MED
configuration	B-MED
with	O
changes	B-MED
in	O
thoracic	B-MED
volume	I-MED
in	O
13	O
sedentary	B-MED
healthy	B-MED
men	B-MED
.	O
[	O
Subjects	O
and	O
Methods	O
]	O
In	O
upright	B-MED
sitting	I-MED
,	O
84	O
reflective	B-MED
markers	I-MED
were	O
placed	O
on	O
the	O
anterior	B-MED
and	O
posterior	B-MED
aspects	B-MED
of	O
the	O
trunk	B-MED
to	O
record	O
thoracic	B-MED
volume	I-MED
during	O
quiet	B-MED
and	O
volitional	B-MED
deep	B-MED
breathing	I-MED
.	O
Using	O
a	O
three	B-MED
-	I-MED
dimensional	I-MED
motion	I-MED
analyzer	I-MED
,	O
the	O
difference	B-MED
in	O
volume	B-MED
within	O
the	O
upper	B-MED
and	O
lower	B-MED
hemithoraces	B-MED
was	O
measured	B-MED
.	O
For	O
calculation	B-MED
of	O
the	O
thoracic	B-MED
volume	I-MED
six	O
imaginary	B-MED
hexahedra	I-MED
were	O
visualized	O
for	O
the	O
upper	B-MED
and	O
lower	B-MED
thorax	B-MED
using	O
four	O
reflective	B-MED
markers	I-MED
for	O
each	O
on	O
the	O
anterior	B-MED
and	O
posterior	B-MED
aspects	B-MED
of	O
the	O
thorax	B-MED
.	O
Each	O
hexahedron	B-MED
was	O
then	O
divided	O
into	O
three	O
imaginary	B-MED
triangular	I-MED
pyramids	I-MED
to	O
calculate	B-MED
positional	B-MED
vectors	B-MED
.	O
Finally	O
,	O
the	O
volume	B-MED
for	O
both	O
the	O
hexahedra	B-MED
and	O
triangular	B-MED
pyramids	I-MED
was	O
calculated	B-MED
.	O
Four	O
thoracic	B-MED
volumes	I-MED
were	O
obtained	O
.	O
[	O
Results	O
]	O
The	O
findings	B-MED
showed	O
that	O
the	O
left	B-MED
upper	B-MED
and	O
right	B-MED
lower	B-MED
hemithorax	B-MED
yielded	O
significantly	O
larger	B-MED
thoracic	B-MED
volumes	I-MED
.	O
[	O
Conclusion	O
]	O
In	O
conclusion	B-MED
the	O
left	B-MED
upper	B-MED
and	O
right	B-MED
lower	B-MED
hemithoraces	B-MED
were	O
found	O
to	O
expand	B-MED
more	O
than	O
their	O
corresponding	O
sides	B-MED
.	O
Understanding	O
the	O
characteristics	B-MED
of	O
thoracic	B-MED
excursion	B-MED
during	O
quiet	B-MED
and	O
volitional	B-MED
deep	B-MED
breathing	I-MED
could	O
be	O
of	O
value	B-MED
in	O
assessment	B-MED
and	O
instruction	B-MED
of	O
breathing	B-MED
techniques	I-MED
to	O
patients	B-MED
.	O
Extracellular	B-MED
Self	B-MED
-	I-MED
Assembly	I-MED
of	O
Functional	B-MED
and	O
Tunable	B-MED
Protein	I-MED
Conjugates	I-MED
from	O
Bacillus	B-MED
subtilis	I-MED
The	O
ability	O
to	O
stably	B-MED
and	O
specifically	O
conjugate	B-MED
recombinant	B-MED
proteins	I-MED
to	O
one	O
another	O
is	O
a	O
powerful	O
approach	O
for	O
engineering	B-MED
multifunctional	B-MED
enzymes	B-MED
,	O
protein	B-MED
therapeutics	I-MED
,	O
and	O
novel	B-MED
biological	B-MED
materials	I-MED
.	O
While	O
many	O
of	O
these	O
applications	B-MED
have	O
been	O
illustrated	O
through	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
intracellular	B-MED
protein	B-MED
conjugation	I-MED
methods	O
,	O
extracellular	B-MED
self	B-MED
-	I-MED
assembly	I-MED
of	O
protein	B-MED
conjugates	I-MED
offers	O
unique	O
advantages	O
:	O
simplifying	O
purification	B-MED
,	O
reducing	B-MED
toxicity	B-MED
and	O
burden	B-MED
,	O
and	O
enabling	O
tunability	B-MED
.	O
Exploiting	O
the	O
recently	O
described	O
SpyTag	B-MED
-	I-MED
SpyCatcher	I-MED
system	I-MED
,	O
we	O
describe	O
here	O
how	O
enzymes	B-MED
and	O
structural	B-MED
proteins	I-MED
can	O
be	O
genetically	B-MED
encoded	I-MED
to	O
covalently	B-MED
conjugate	B-MED
in	O
culture	B-MED
media	I-MED
following	O
programmable	B-MED
secretion	I-MED
from	O
Bacillus	B-MED
subtilis	I-MED
.	O
Using	O
this	O
approach	O
,	O
we	O
demonstrate	O
how	O
self	B-MED
-	I-MED
conjugation	I-MED
of	O
a	O
secreted	B-MED
industrial	O
enzyme	B-MED
,	O
XynA	B-MED
,	O
dramatically	O
increases	B-MED
its	O
resilience	B-MED
to	O
boiling	B-MED
,	O
and	O
we	O
show	O
that	O
cellular	B-MED
consortia	I-MED
can	O
be	O
engineered	B-MED
to	O
self	B-MED
-	I-MED
assemble	I-MED
functional	B-MED
protein	B-MED
-	I-MED
protein	I-MED
conjugates	I-MED
with	O
tunable	O
composition	O
.	O
This	O
novel	B-MED
genetically	B-MED
encoded	I-MED
modular	B-MED
system	I-MED
provides	O
a	O
flexible	B-MED
strategy	I-MED
for	O
protein	B-MED
conjugation	I-MED
harnessing	O
the	O
substantial	O
advantages	O
of	O
extracellular	B-MED
self	B-MED
-	I-MED
assembly	I-MED
.	O
A	O
closer	O
look	O
at	O
school	B-MED
bonding	B-MED
among	O
African	B-MED
American	I-MED
adolescents	B-MED
in	O
low	B-MED
-	I-MED
income	I-MED
communities	I-MED
:	O
A	O
latent	B-MED
class	I-MED
analysis	I-MED
Positive	B-MED
school	B-MED
bonding	B-MED
is	O
a	O
significant	B-MED
precursor	B-MED
to	O
students	B-MED
'	O
school	B-MED
success	B-MED
.	O
However	O
,	O
African	B-MED
American	I-MED
youth	B-MED
report	O
lower	B-MED
school	B-MED
success	B-MED
compared	O
with	O
their	O
White	B-MED
counterparts	I-MED
.	O
This	O
study	B-MED
examined	O
correlates	B-MED
of	O
school	B-MED
bonding	B-MED
among	O
633	O
African	B-MED
American	I-MED
youth	B-MED
who	O
were	O
recruited	B-MED
from	O
community	B-MED
settings	I-MED
in	O
Chicago	B-MED
.	O
Major	B-MED
findings	B-MED
indicated	O
that	O
negative	B-MED
peer	I-MED
norms	I-MED
,	O
exposure	B-MED
to	I-MED
community	B-MED
violence	I-MED
,	O
and	O
poor	B-MED
mental	B-MED
health	I-MED
were	O
negatively	B-MED
correlated	B-MED
with	O
school	B-MED
bonding	B-MED
,	O
while	O
parental	B-MED
monitoring	I-MED
,	O
positive	B-MED
self	I-MED
-	I-MED
regard	I-MED
,	O
and	O
future	B-MED
orientation	B-MED
were	O
correlated	B-MED
with	O
higher	B-MED
school	B-MED
motivation	B-MED
.	O
Students	B-MED
classified	B-MED
as	O
having	O
high	B-MED
or	O
moderate	B-MED
school	B-MED
bonding	B-MED
were	O
more	O
likely	O
to	O
live	B-MED
with	O
both	O
parents	B-MED
,	O
experience	B-MED
higher	B-MED
levels	B-MED
of	O
parental	B-MED
monitoring	I-MED
,	O
and	O
exhibit	B-MED
positive	I-MED
self	I-MED
-	I-MED
regard	I-MED
.	O
Implications	O
are	O
discussed	O
in	O
view	O
of	O
these	O
findings	B-MED
.	O
Structure	O
of	O
the	O
bacterial	B-MED
plant	B-MED
-	O
ferredoxin	B-MED
receptor	B-MED
FusA	B-MED
Iron	B-MED
is	O
a	O
limiting	O
nutrient	B-MED
in	O
bacterial	B-MED
infection	I-MED
putting	O
it	O
at	O
the	O
centre	O
of	O
an	O
evolutionary	O
arms	O
race	O
between	O
host	B-MED
and	O
pathogen	B-MED
.	O
Gram	B-MED
-	I-MED
negative	I-MED
bacteria	I-MED
utilize	O
TonB	B-MED
-dependent	O
outer	B-MED
membrane	I-MED
receptors	B-MED
to	O
obtain	O
iron	B-MED
during	O
infection	B-MED
.	O
These	O
receptors	B-MED
acquire	O
iron	B-MED
either	O
in	O
concert	O
with	O
soluble	O
iron	B-MED
-	I-MED
scavenging	I-MED
siderophores	I-MED
or	O
through	O
direct	B-MED
interaction	I-MED
and	O
extraction	B-MED
from	O
host	B-MED
proteins	B-MED
.	O
Characterization	B-MED
of	O
these	O
receptors	B-MED
provides	O
invaluable	O
insight	O
into	O
pathogenesis	B-MED
.	O
However	O
,	O
only	O
a	O
subset	O
of	O
virulence	B-MED
-related	O
TonB	B-MED
-dependent	O
receptors	B-MED
have	O
been	O
currently	O
described	O
.	O
Here	O
we	O
report	O
the	O
discovery	B-MED
of	O
FusA	B-MED
,	O
a	O
new	O
class	O
of	O
TonB	B-MED
-dependent	O
receptor	B-MED
,	O
which	O
is	O
utilized	O
by	O
phytopathogenic	B-MED
Pectobacterium	I-MED
spp	I-MED
.	I-MED
to	O
obtain	O
iron	B-MED
from	O
plant	B-MED
ferredoxin	B-MED
.	O
Through	O
the	O
crystal	B-MED
structure	I-MED
of	O
FusA	B-MED
we	O
show	O
that	O
binding	B-MED
of	O
ferredoxin	B-MED
occurs	O
through	O
specialized	O
extracellular	B-MED
loops	I-MED
that	O
form	O
extensive	B-MED
interactions	B-MED
with	O
ferredoxin	B-MED
.	O
The	O
function	B-MED
of	O
FusA	B-MED
and	O
the	O
presence	O
of	O
homologues	B-MED
in	O
clinically	B-MED
important	I-MED
pathogens	B-MED
suggests	O
that	O
small	O
iron	B-MED
-	I-MED
containing	I-MED
proteins	I-MED
represent	O
an	O
iron	B-MED
source	B-MED
for	O
bacterial	B-MED
pathogens	B-MED
.	O
Towards	O
culturally	B-MED
competent	I-MED
paediatric	I-MED
oncology	I-MED
care	I-MED
.	O
A	O
qualitative	B-MED
study	I-MED
from	O
the	O
perspective	B-MED
of	O
care	B-MED
providers	I-MED
In	O
order	O
to	O
gain	O
more	O
insight	O
on	O
the	O
influence	B-MED
of	O
ethnic	B-MED
diversity	B-MED
in	O
paediatric	B-MED
cancer	B-MED
care	I-MED
,	O
the	O
perspectives	B-MED
of	O
care	B-MED
providers	I-MED
were	O
explored	O
.	O
Semi	B-MED
-	I-MED
structured	I-MED
interviews	I-MED
were	O
conducted	O
among	O
12	O
paediatric	B-MED
oncologists	I-MED
and	O
13	O
nurses	B-MED
of	O
two	O
different	O
paediatric	B-MED
oncology	I-MED
wards	I-MED
and	O
were	O
analysed	B-MED
using	O
a	O
framework	B-MED
method	I-MED
.	O
We	O
found	O
that	O
care	B-MED
providers	I-MED
described	O
the	O
contact	O
with	O
Turkish	B-MED
and	O
Moroccan	B-MED
parents	B-MED
as	O
more	O
difficult	O
.	O
They	O
offered	O
two	O
reasons	O
for	O
this	O
:	O
(	O
1	O
)	O
language	B-MED
barriers	I-MED
between	O
care	B-MED
provider	I-MED
and	O
parents	B-MED
hindered	B-MED
the	O
exchange	B-MED
of	I-MED
information	I-MED
;	O
(	O
2	O
)	O
cultural	B-MED
barriers	I-MED
between	O
care	B-MED
provider	I-MED
and	O
parents	B-MED
about	O
sharing	O
the	O
diagnosis	B-MED
and	O
palliative	B-MED
perspective	B-MED
hindered	B-MED
communication	B-MED
.	O
Care	B-MED
providers	I-MED
reported	O
different	O
solutions	B-MED
to	O
deal	O
with	O
these	O
barriers	B-MED
,	O
such	O
as	O
using	O
an	O
interpreter	B-MED
and	O
improving	O
their	O
cultural	B-MED
knowledge	I-MED
about	O
their	O
patients	B-MED
.	O
They	O
,	O
however	O
,	O
were	O
not	O
using	O
interpreters	B-MED
sufficiently	O
and	O
were	O
unaware	O
of	O
the	O
importance	O
of	O
eliciting	B-MED
parents	B-MED
'	O
perspectives	B-MED
.	O
Communication	B-MED
techniques	B-MED
to	O
overcome	O
dilemmas	B-MED
between	O
parents	B-MED
and	O
care	B-MED
providers	I-MED
were	O
not	O
used	O
and	O
care	B-MED
providers	I-MED
were	O
unaware	O
of	O
stereotypes	B-MED
and	O
prejudice	B-MED
.	O
Care	B-MED
providers	I-MED
should	O
be	O
offered	O
insight	O
in	O
cultural	B-MED
barriers	I-MED
they	O
are	O
unaware	O
of	O
.	O
Training	B-MED
in	O
cultural	B-MED
competence	I-MED
might	O
be	O
a	O
possibility	O
to	O
overcome	O
manifest	B-MED
barriers	B-MED
.	O
Lactate	B-MED
induces	O
osteoblast	B-MED
differentiation	I-MED
by	O
stabilization	B-MED
of	O
HIF1α	B-MED
Aerobic	B-MED
glycolysis	I-MED
is	O
involved	O
in	O
osteoblast	B-MED
differentiation	I-MED
induced	O
by	O
Wnt	B-MED
signaling	I-MED
or	O
PTH	B-MED
treatment	B-MED
.	O
However	O
,	O
it	O
is	O
still	O
unclear	O
whether	O
lactate	B-MED
,	O
the	O
end	O
product	O
of	O
aerobic	B-MED
glycolysis	I-MED
,	O
plays	O
any	O
role	O
in	O
osteoblast	B-MED
differentiation	I-MED
.	O
Herein	O
we	O
report	O
that	O
in	O
cultures	B-MED
of	O
osteoblast	B-MED
-	I-MED
lineage	I-MED
cells	I-MED
,	O
lactate	B-MED
promoted	O
alkaline	B-MED
phosphatase	I-MED
-positive	O
cell	B-MED
formation	I-MED
,	O
increased	O
the	O
activity	B-MED
of	O
alkaline	B-MED
phosphatase	I-MED
,	O
and	O
induced	O
the	O
expression	B-MED
of	O
osteocalcin	B-MED
.	O
This	O
osteoblast	B-MED
differentiation	I-MED
-inducing	O
effect	O
of	O
lactate	B-MED
can	O
be	O
inhibited	B-MED
by	O
blocking	B-MED
its	O
entry	O
into	O
cells	B-MED
with	O
MCT1	B-MED
siRNA	B-MED
or	O
inhibitors	B-MED
,	O
and	O
by	O
interfering	O
with	O
its	O
metabolism	B-MED
by	O
using	O
specific	O
siRNAs	B-MED
for	O
LDHB	B-MED
and	O
PDH	B-MED
.	O
Moreover	O
,	O
lactate	B-MED
stabilized	O
HIF1α	B-MED
expression	B-MED
and	O
inhibited	B-MED
HIF1α	B-MED
activity	B-MED
,	O
with	O
BAY87	B-MED
-	I-MED
2243	I-MED
lowering	O
the	O
osteoblast	B-MED
differentiation	I-MED
-inducing	O
effect	O
of	O
lactate	B-MED
.	O
Thus	O
,	O
these	O
findings	B-MED
reveal	O
an	O
unrecognized	O
role	O
for	O
aerobic	B-MED
glycolysis	I-MED
in	O
osteoblast	B-MED
differentiation	I-MED
via	O
its	O
end	O
product	O
,	O
lactate	B-MED
.	O
1	O
in	O
100	O
babies	B-MED
:	O
the	O
fetal	B-MED
alcohol	I-MED
spectrum	I-MED
disorder	I-MED
pathway	B-MED
Alcohol	B-MED
consumed	B-MED
during	O
pregnancy	B-MED
is	O
the	O
nation	B-MED
's	I-MED
leading	O
preventable	B-MED
cause	B-MED
of	O
developmental	B-MED
disabilities	I-MED
and	O
birth	B-MED
defects	I-MED
.	O
One	O
in	O
100	O
babies	B-MED
is	O
estimated	O
to	O
be	O
born	B-MED
with	O
alcohol	B-MED
-	I-MED
related	I-MED
damage	I-MED
,	O
according	O
to	O
the	O
World	B-MED
Health	I-MED
Organization	I-MED
.	O
Fetal	B-MED
alcohol	I-MED
spectrum	I-MED
disorders	I-MED
(	O
FASDs	B-MED
)	O
are	O
more	O
common	O
than	O
autism	B-MED
but	O
are	O
under-	O
diagnosed	B-MED
.	O
The	O
use	O
of	O
Ocimum	B-MED
americanum	I-MED
essential	B-MED
oil	I-MED
against	O
the	O
pathogens	B-MED
Aeromonas	B-MED
hydrophila	I-MED
and	O
Gyrodactylus	B-MED
sp	I-MED
.	I-MED
in	O
silver	B-MED
catfish	I-MED
(	O
Rhamdia	B-MED
quelen	I-MED
)	O
The	O
bactericidal	B-MED
activity	I-MED
(	O
MIC	B-MED
-	I-MED
test	I-MED
)	O
of	O
Ocimum	B-MED
americanum	I-MED
(	O
inflorescences	B-MED
)	O
essential	B-MED
oil	I-MED
(	O
OAEO	B-MED
)	O
against	O
Aeromonas	B-MED
hydrophila	I-MED
was	O
determined	O
in	O
this	O
study	O
.	O
It	O
was	O
also	O
investigated	O
the	O
potential	O
of	O
OAEO	B-MED
and	O
the	O
main	O
compound	B-MED
found	O
in	O
the	O
oil	B-MED
(	O
linalool	B-MED
)	O
at	O
subinhibitory	O
concentrations	O
to	O
be	O
inhibitors	B-MED
of	O
hemolysis	B-MED
caused	O
by	O
Aer	B-MED
.	I-MED
hydrophila	I-MED
in	O
fish	B-MED
erythrocytes	B-MED
.	O
An	O
in	B-MED
vivo	I-MED
experiment	I-MED
was	O
conducted	O
to	O
evaluate	O
survival	B-MED
of	O
fish	B-MED
(	O
Rhamdia	B-MED
quelen	I-MED
)	O
experimentally	B-MED
infected	B-MED
with	O
Aer	B-MED
.	I-MED
hydrophila	I-MED
and	O
exposed	B-MED
to	O
OAEO	B-MED
.	O
A	O
second	O
experiment	B-MED
was	O
conducted	O
to	O
evaluate	O
the	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
activity	O
of	O
OAEO	B-MED
(	O
mix	O
from	O
inflorescences	B-MED
and	O
leaves	B-MED
)	O
against	O
the	O
parasite	B-MED
Gyrodactylus	I-MED
sp	I-MED
.	I-MED
The	O
OAEO	B-MED
showed	O
weak	B-MED
in	B-MED
vitro	I-MED
activity	O
against	O
Aer	B-MED
.	I-MED
hydrophila	I-MED
(	O
6400	O
μg	O
ml(-1	O
)	O
)	O
.	O
At	O
subinhibitory	O
concentrations	O
OAEO	B-MED
(	O
100	O
μg	O
ml(-1	O
)	O
)	O
inhibited	B-MED
hemolysis	B-MED
(	O
90	O
%	O
)	O
caused	O
by	O
Aer	B-MED
.	I-MED
hydrophila	I-MED
in	O
fish	B-MED
erythrocytes	B-MED
,	O
however	O
,	O
linalool	B-MED
did	O
not	B-MED
present	I-MED
hemolysis	B-MED
inhibition	B-MED
activity	I-MED
.	O
At	O
low	O
concentrations	O
(	O
10	O
and	O
20	O
mg	O
l(-1	O
)	O
)	O
added	O
to	O
the	O
water	B-MED
OAEO	B-MED
promoted	B-MED
survival	B-MED
of	O
experimentally	O
infected	B-MED
fish	B-MED
with	O
Aer	B-MED
.	I-MED
hydrophila	I-MED
.	O
Lastly	O
,	O
OAEO	B-MED
-mix	O
(	O
50	O
mg	O
l(-1	O
)	O
)	O
was	O
effective	B-MED
against	O
Gyrodactylus	B-MED
sp	I-MED
.	I-MED
significantly	B-MED
reducing	I-MED
(	O
60	O
%	O
)	O
the	O
number	O
of	O
parasites	B-MED
in	O
the	O
fish	B-MED
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
Propensity	B-MED
Score	I-MED
Matched	O
Comparison	B-MED
of	O
Partial	B-MED
to	O
Whole	B-MED
Gland	B-MED
Cryotherapy	B-MED
for	O
Intermediate	B-MED
-	I-MED
Risk	I-MED
Prostate	B-MED
Cancer	I-MED
:	O
An	O
analysis	B-MED
of	O
the	O
COLD	B-MED
registry	I-MED
data	I-MED
To	O
compare	O
the	O
oncological	B-MED
and	O
functional	B-MED
outcomes	B-MED
of	O
partial	B-MED
versus	O
whole	B-MED
-	O
gland	B-MED
cryotherapy	B-MED
for	O
men	B-MED
with	O
intermediate	B-MED
-	I-MED
risk	I-MED
prostate	B-MED
cancer	I-MED
.	O
Men	B-MED
with	O
intermediate	B-MED
-	I-MED
risk	I-MED
prostate	B-MED
cancer	I-MED
treated	B-MED
with	I-MED
primary	B-MED
prostate	B-MED
cryotherapy	I-MED
from	O
1993	O
-	O
2013	O
were	O
selected	O
from	O
the	O
Cryo	B-MED
On	I-MED
-	I-MED
Line	I-MED
Data	I-MED
Registry	I-MED
for	O
a	O
1:1	O
matched	B-MED
comparison	B-MED
between	O
those	O
undergoing	O
whole	B-MED
-	O
gland	B-MED
and	O
partial	B-MED
prostate	B-MED
cryotherapy	I-MED
(	O
targeted	B-MED
-	I-MED
ablation	I-MED
,	O
unilateral	B-MED
/	I-MED
bilateral	I-MED
nerve	I-MED
-	I-MED
sparing	I-MED
ablations	I-MED
)	O
.	O
A	O
propensity	B-MED
score	I-MED
was	O
developed	O
based	O
on	O
age	B-MED
,	O
pre	B-MED
-	I-MED
biopsy	I-MED
serum	I-MED
PSA	B-MED
,	O
biopsy	B-MED
Gleason	I-MED
score	I-MED
,	O
clinical	B-MED
stage	I-MED
,	O
prostate	B-MED
volume	I-MED
,	O
neoadjuvant	B-MED
androgen	I-MED
deprivation	I-MED
status	B-MED
,	O
year	B-MED
of	O
surgery	B-MED
and	O
pre	B-MED
-	I-MED
treatment	I-MED
potency	O
.	O
Outcomes	B-MED
were	O
biochemical	B-MED
progression	B-MED
-	I-MED
free	I-MED
survival	I-MED
(	O
BPFS	B-MED
)	O
using	O
ASTRO	B-MED
and	O
Phoenix	B-MED
criteria	I-MED
,	O
12	O
-	O
month	O
continence	B-MED
(	O
strictly	O
pad	O
-	O
free	O
)	O
and	O
sexual	B-MED
function	I-MED
(	O
potency	O
sufficient	B-MED
for	O
sexual	B-MED
intercourse	I-MED
)	O
.	O
After	O
propensity	B-MED
score	I-MED
-	O
matching	B-MED
,	O
BPFS	B-MED
was	O
compared	B-MED
using	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
analysis	I-MED
and	O
functional	B-MED
outcomes	B-MED
using	O
chi	B-MED
-	I-MED
square	I-MED
tests	I-MED
.	O
In	O
all	O
,	O
897	O
men	B-MED
were	O
identified	B-MED
(	O
731	O
whole	B-MED
-	O
gland	B-MED
and	O
166	O
partial	B-MED
)	O
.	O
Post	B-MED
-	I-MED
matching	I-MED
,	O
166	O
pairs	O
of	O
men	B-MED
were	O
analysed	B-MED
(	O
mean	O
follow	B-MED
-	I-MED
up	I-MED
31	O
months	O
)	O
.	O
The	O
2/5	O
year	O
BPFS	B-MED
rate	B-MED
was	O
87.2%/76.4	O
%	O
for	O
whole	B-MED
-	O
gland	B-MED
vs.	O
80.7%/70.0	O
%	O
for	O
partial	B-MED
ablation	B-MED
using	O
Phoenix	B-MED
(	O
p=0.26	O
)	O
and	O
72.3%/69.6	O
%	O
for	O
whole	B-MED
gland	B-MED
vs.	O
82.1%/75.0	O
%	O
for	O
partial	B-MED
ablation	B-MED
using	O
ASTRO	B-MED
criteria	O
(	O
p=0.10	O
)	O
.	O
Of	O
164	O
pairs	O
,	O
the	O
12	O
-	O
month	O
continence	B-MED
rate	B-MED
was	O
similar	B-MED
94.1	O
%	O
vs.	O
95.1	O
%	O
(	O
p=0.803	O
)	O
.	O
Of	O
139	O
pairs	O
,	O
the	O
12	O
-	O
month	O
rate	O
of	O
successful	B-MED
intercourse	B-MED
was	O
29.5	O
%	O
for	O
whole	B-MED
-	O
gland	B-MED
and	O
46.8	O
%	O
for	O
partial	B-MED
ablation	B-MED
(	O
OR	O
2.1	O
,	O
p=0.003	O
)	O
.	O
The	O
incidence	B-MED
of	O
post	B-MED
-	I-MED
treatment	I-MED
urinary	B-MED
retention	I-MED
was	O
6.0	O
%	O
and	O
6.6	O
%	O
(	O
p=0.88	O
)	O
following	O
whole	B-MED
-	O
gland	B-MED
and	O
partial	B-MED
ablation	B-MED
respectively	O
and	O
that	O
of	O
rectourethral	B-MED
fistula	I-MED
was	O
1.2	O
%	O
and	O
0	O
%	O
(	O
p=0.50	O
)	O
Conclusion	O
:	O
Partial	B-MED
ablation	B-MED
results	B-MED
in	O
better	B-MED
post	B-MED
-	I-MED
treatment	I-MED
sexual	B-MED
function	I-MED
compared	B-MED
to	O
whole	B-MED
-	O
gland	B-MED
ablation	B-MED
in	O
men	B-MED
with	O
intermediate	B-MED
-	I-MED
risk	I-MED
prostate	B-MED
cancer	I-MED
.	O
We	O
did	O
not	O
observe	O
a	O
difference	O
in	O
early	B-MED
BPFS	B-MED
between	O
the	O
two	O
groups	B-MED
.	O
E3	B-MED
Ligase	I-MED
RNF126	B-MED
Directly	O
Ubiquitinates	B-MED
Frataxin	B-MED
,	O
Promoting	B-MED
Its	O
Degradation	B-MED
:	O
Identification	B-MED
of	O
a	O
Potential	O
Therapeutic	B-MED
Target	B-MED
for	O
Friedreich	B-MED
Ataxia	I-MED
Friedreich	B-MED
ataxia	I-MED
(	O
FRDA	B-MED
)	O
is	O
a	O
severe	O
genetic	B-MED
neurodegenerative	B-MED
disease	I-MED
caused	O
by	O
reduced	O
expression	B-MED
of	O
the	O
mitochondrial	B-MED
protein	I-MED
frataxin	B-MED
.	O
To	O
date	O
,	O
there	O
is	O
no	O
therapy	B-MED
to	O
treat	B-MED
this	O
condition	B-MED
.	O
The	O
amount	O
of	O
residual	B-MED
frataxin	B-MED
critically	O
affects	O
the	O
severity	B-MED
of	O
the	O
disease	B-MED
;	O
thus	O
,	O
attempts	O
to	O
restore	O
physiological	B-MED
frataxin	B-MED
levels	B-MED
are	O
considered	O
therapeutically	B-MED
relevant	B-MED
.	O
Frataxin	B-MED
levels	B-MED
are	O
controlled	B-MED
by	I-MED
the	O
ubiquitin	B-MED
-	I-MED
proteasome	I-MED
system	I-MED
;	O
therefore	O
,	O
inhibition	B-MED
of	O
the	O
frataxin	B-MED
E3	B-MED
ligase	I-MED
may	O
represent	O
a	O
strategy	B-MED
to	O
achieve	O
an	O
increase	O
in	O
frataxin	B-MED
levels	B-MED
.	O
Here	O
,	O
we	O
report	O
the	O
identification	B-MED
of	O
the	O
RING	B-MED
E3	I-MED
ligase	I-MED
RNF126	B-MED
as	O
the	O
enzyme	B-MED
that	O
specifically	O
mediates	O
frataxin	B-MED
ubiquitination	B-MED
and	O
targets	O
it	O
for	O
degradation	B-MED
.	O
RNF126	B-MED
interacts	B-MED
with	O
frataxin	B-MED
and	O
promotes	B-MED
its	O
ubiquitination	B-MED
in	O
a	O
catalytic	B-MED
activity	I-MED
-	O
dependent	B-MED
manner	O
,	O
both	O
in	B-MED
vivo	I-MED
and	O
in	B-MED
vitro	I-MED
.	O
Most	O
importantly	O
,	O
RNF126	B-MED
depletion	B-MED
results	O
in	O
frataxin	B-MED
accumulation	B-MED
in	O
cells	B-MED
derived	O
from	O
FRDA	B-MED
patients	B-MED
,	O
highlighting	O
the	O
relevance	B-MED
of	O
RNF126	B-MED
as	O
a	O
new	O
therapeutic	B-MED
target	B-MED
for	O
Friedreich	B-MED
ataxia	I-MED
.	O
An	O
ion	O
-	O
gating	O
multinanochannel	O
system	O
based	O
on	O
a	O
copper	B-MED
-	O
responsive	B-MED
self	B-MED
-	O
cleaving	B-MED
DNAzyme	B-MED
We	O
developed	O
an	O
ion	O
-	O
gating	O
nanochannel	O
composite	O
system	O
by	O
immobilizing	B-MED
a	O
Cu(2	B-MED
+	I-MED
)	I-MED
-	O
responsive	B-MED
self	B-MED
-	O
cleaving	B-MED
DNAzyme	B-MED
into	O
PET	B-MED
conical	B-MED
multinanochannels	I-MED
,	O
which	O
could	O
control	B-MED
the	O
ion	B-MED
transport	I-MED
by	O
regulating	B-MED
the	O
surface	B-MED
charge	B-MED
density	B-MED
of	O
the	O
channels	B-MED
.	O
Mechanisms	B-MED
of	O
compensation	B-MED
in	O
the	O
gait	B-MED
of	O
patients	B-MED
with	O
drop	B-MED
foot	I-MED
Drop	B-MED
foot	I-MED
is	O
a	O
complex	O
syndrome	B-MED
,	O
with	O
multiple	B-MED
interactions	B-MED
between	O
joints	B-MED
and	O
muscles	B-MED
.	O
Abnormalities	B-MED
in	O
movement	B-MED
patterns	I-MED
can	O
be	O
measured	O
using	O
motion	B-MED
capture	I-MED
techniques	I-MED
,	O
but	O
identifying	O
compensation	B-MED
mechanisms	B-MED
mechanisms	B-MED
remains	O
challenging	O
.	O
In	O
order	O
to	O
identify	O
compensatory	B-MED
mechanisms	B-MED
in	O
patients	B-MED
with	O
drop	B-MED
foot	I-MED
,	O
this	O
study	B-MED
evaluated	O
a	O
sample	O
of	O
15	O
such	O
patients	B-MED
using	O
a	O
computerized	B-MED
gait	B-MED
analysis	I-MED
system	I-MED
,	O
as	O
compared	O
to	O
a	O
group	O
of	O
15	O
healthy	B-MED
subjects	I-MED
.	O
Four	O
classes	O
of	O
parameters	O
were	O
distinguished	O
,	O
falling	B-MED
in	O
differing	O
intervals	B-MED
of	O
percentage	B-MED
differences	B-MED
between	O
the	O
groups	B-MED
in	O
the	O
study	B-MED
.	O
The	O
first	O
class	O
comprised	O
two	O
kinematic	B-MED
parameters	I-MED
for	O
which	O
the	O
values	O
of	O
percentage	O
differences	O
in	O
the	O
control	B-MED
group	I-MED
were	O
more	O
than	O
100	O
%	O
greater	O
than	O
for	O
the	O
patient	B-MED
group	I-MED
.	O
The	O
second	O
class	O
comprised	O
two	O
kinetic	B-MED
parameters	I-MED
falling	B-MED
in	O
the	O
interval	B-MED
of	O
100	O
-	O
49	O
%	O
.	O
In	O
the	O
third	O
class	O
,	O
in	O
the	O
49	O
-	O
20	O
%	O
interval	B-MED
the	O
main	O
differences	O
were	O
observed	O
for	O
spatiotemporal	B-MED
parameters	I-MED
,	O
whereas	O
in	O
the	O
20	O
-	O
4	O
%	O
interval	B-MED
the	O
differences	O
were	O
distributed	O
similarly	O
for	O
kinematic	B-MED
,	O
kinetic	B-MED
and	O
spatiotemporal	B-MED
parameters	I-MED
.	O
These	O
differences	O
in	O
gait	B-MED
pattern	I-MED
between	O
the	O
groups	B-MED
may	O
be	O
related	O
to	O
both	O
primary	O
motor	B-MED
deficits	I-MED
and	O
secondary	O
compensatory	B-MED
mechanisms	B-MED
.	O
Generally	O
,	O
we	O
conclude	O
that	O
drop	B-MED
foot	I-MED
affects	O
the	O
patients	B-MED
'	O
overall	O
kinematic	B-MED
and	O
kinetic	B-MED
gait	B-MED
parameters	O
,	O
with	O
compensation	B-MED
seen	O
as	O
a	O
chain	O
originating	O
from	O
a	O
change	B-MED
of	O
movement	B-MED
within	O
the	O
ankle	B-MED
joint	I-MED
.	O
Targeting	B-MED
brain	B-MED
and	O
peripheral	B-MED
plasticity	I-MED
of	O
the	O
lipidome	B-MED
in	O
acute	B-MED
kainic	B-MED
acid	I-MED
-	O
induced	B-MED
epileptic	B-MED
seizures	I-MED
in	O
mice	B-MED
via	O
quantitative	B-MED
mass	I-MED
spectrometry	I-MED
Epilepsy	B-MED
is	O
a	O
highly	O
common	O
chronic	B-MED
neurological	I-MED
disorder	I-MED
,	O
manifested	B-MED
in	O
many	O
different	O
types	B-MED
,	O
affecting	O
~1	O
%	O
of	O
the	O
worldwide	O
human	B-MED
population	B-MED
.	O
The	O
molecular	B-MED
mechanisms	I-MED
of	O
epileptogenesis	B-MED
have	O
not	O
yet	O
been	O
clarified	O
,	O
and	O
pharmacoresistance	B-MED
exhibited	O
by	O
30	O
-	O
40	O
%	O
of	O
epilepsy	B-MED
patients	B-MED
remains	O
a	O
major	O
obstacle	O
in	O
medical	B-MED
care	B-MED
.	O
Growing	O
evidence	B-MED
indicates	O
a	O
role	O
of	O
lipid	B-MED
signalling	B-MED
pathways	I-MED
in	O
epileptogenesis	B-MED
,	O
thus	O
lipid	B-MED
signals	B-MED
emerge	O
as	O
potential	B-MED
biomarkers	B-MED
for	O
the	O
onset	O
and	O
evolving	O
course	O
of	O
the	O
epileptic	B-MED
disorder	I-MED
,	O
as	O
well	O
as	O
potential	B-MED
therapeutic	B-MED
agents	I-MED
and	O
targets	B-MED
.	O
For	O
this	O
purpose	O
,	O
we	O
applied	O
a	O
lipidomic	B-MED
strategy	B-MED
to	O
unravel	O
lipid	B-MED
alterations	O
in	O
brain	B-MED
regions	I-MED
,	O
periphery	B-MED
tissues	I-MED
and	O
plasma	B-MED
that	O
are	O
specific	B-MED
for	O
acute	B-MED
epileptic	B-MED
seizures	I-MED
in	O
mice	B-MED
at	O
1h	O
after	O
seizure	B-MED
induction	B-MED
by	O
systemic	B-MED
kainic	B-MED
acid	I-MED
injection	B-MED
as	O
compared	B-MED
to	O
vehicle	B-MED
controls	I-MED
.	O
Specifically	O
,	O
levels	B-MED
of	O
(	O
i	O
)	O
selected	O
phospholipids	B-MED
and	O
sphingomyelins	B-MED
,	O
(	O
ii	O
)	O
the	O
endocannabinoids	B-MED
anandamide	B-MED
(	O
AEA	B-MED
)	O
and	O
2	B-MED
-	I-MED
arachidonoyl	I-MED
glycerol	I-MED
(	O
2	B-MED
-	I-MED
AG	I-MED
)	O
,	O
and	O
the	O
endocannabinoid	B-MED
-related	O
compounds	B-MED
oleoylethanolamide	B-MED
(	O
OEA	B-MED
)	O
and	O
palmitoylethanolamide	B-MED
(	O
PEA	B-MED
)	O
,	O
(	O
iii	O
)	O
arachidonic	B-MED
acid	I-MED
(	O
AA	B-MED
)	O
,	O
(	O
iv	O
)	O
selected	O
eicosanoids	B-MED
,	O
and	O
(	O
v	O
)	O
fatty	B-MED
acyl	I-MED
content	O
of	O
lipidome	B-MED
were	O
determined	O
in	O
pulverized	B-MED
tissues	B-MED
from	O
six	O
brain	B-MED
regions	I-MED
of	O
kainic	B-MED
acid	I-MED
induced	B-MED
epileptic	B-MED
seizure	I-MED
models	B-MED
and	O
vehicle	B-MED
controls	I-MED
:	O
hypothalamus	B-MED
,	O
hippocampus	B-MED
,	O
thalamus	B-MED
,	O
striatum	B-MED
,	O
cerebellum	B-MED
and	O
cerebral	B-MED
cortex	I-MED
,	O
and	O
from	O
peripheral	B-MED
organs	B-MED
,	O
such	O
as	O
heart	B-MED
and	O
lungs	B-MED
,	O
and	O
in	O
plasma	B-MED
.	O
Alterations	O
in	O
lipid	B-MED
levels	O
after	O
acute	B-MED
epileptic	B-MED
seizures	I-MED
as	O
compared	B-MED
to	O
non	B-MED
-	I-MED
seizure	I-MED
controls	I-MED
were	O
found	O
to	O
be	O
brain	B-MED
region	I-MED
-	O
and	O
periphery	B-MED
tissue	I-MED
-	O
specific	B-MED
,	O
including	O
specific	B-MED
plasma	B-MED
lipid	B-MED
correlates	O
,	O
highlighting	O
their	O
value	O
as	O
marker	B-MED
candidates	I-MED
in	O
translational	O
research	B-MED
studies	I-MED
,	O
and/or	O
drug	B-MED
discovery	I-MED
and	O
response	B-MED
monitoring	I-MED
.	O
BALB	B-MED
/	I-MED
c	I-MED
mice	I-MED
immunized	B-MED
with	O
a	O
combination	O
of	O
virus	B-MED
-	I-MED
like	I-MED
particles	I-MED
incorporating	O
Kaposi	B-MED
sarcoma	I-MED
-	I-MED
associated	I-MED
herpesvirus	I-MED
(	O
KSHV	B-MED
)	O
envelope	O
glycoproteins	B-MED
gpK8.1	I-MED
,	O
gB	B-MED
,	O
and	O
gH	B-MED
/	O
gL	B-MED
induced	O
comparable	O
serum	B-MED
neutralizing	B-MED
antibody	I-MED
activity	B-MED
to	O
UV	B-MED
-	O
inactivated	B-MED
KSHV	B-MED
Infection	O
with	O
Kaposi	B-MED
sarcoma	I-MED
-	I-MED
associated	I-MED
herpesvirus	I-MED
(	O
KSHV	B-MED
)	O
is	O
estimated	O
to	O
account	O
for	O
over	O
44,000	O
new	O
cases	O
of	O
Kaposi	B-MED
sarcoma	I-MED
annually	O
,	O
with	O
84	O
%	O
occurring	O
in	O
Africa	B-MED
,	O
where	O
the	O
virus	B-MED
is	O
endemic	O
.	O
To	O
date	O
,	O
there	O
is	O
no	O
prophylactic	B-MED
vaccine	I-MED
against	O
KSHV	B-MED
.	O
KSHV	B-MED
gpK8.1	B-MED
,	O
gB	B-MED
,	O
and	O
gH	B-MED
/	O
gL	B-MED
glycoproteins	I-MED
,	O
implicated	O
in	O
the	O
virus	B-MED
entry	O
into	O
host	B-MED
cells	I-MED
,	O
are	O
attractive	O
vaccine	B-MED
targets	B-MED
for	O
eliciting	O
potent	O
neutralizing	B-MED
antibodies	I-MED
(	O
nAbs	B-MED
)	O
against	O
virus	B-MED
infection	I-MED
.	O
We	O
incorporated	O
gpK8.1	B-MED
,	O
gB	B-MED
gB	B-MED
,	O
or	O
gH	B-MED
/	O
gL	B-MED
on	O
the	O
surface	O
of	O
virus	B-MED
-	I-MED
like	I-MED
particles	I-MED
(	O
VLPs	B-MED
)	O
and	O
characterized	O
these	O
VLPs	B-MED
for	O
their	O
composition	O
,	O
size	O
,	O
and	O
functionality	O
.	O
To	O
determine	O
which	O
viral	B-MED
glycoprotein(s	I-MED
)	I-MED
elicit	O
the	O
most	O
effective	O
serum	B-MED
-	O
nAbs	B-MED
,	O
we	O
immunized	B-MED
BALB	B-MED
/	I-MED
c	I-MED
mice	I-MED
with	O
gpK8.1	B-MED
,	O
gB	B-MED
,	O
or	O
gH	B-MED
/	O
gL	B-MED
VLPs	B-MED
individually	O
or	O
in	O
combination	O
.	O
Neutralizing	B-MED
antibody	I-MED
assay	O
revealed	O
that	O
sera	O
from	O
mice	B-MED
immunized	B-MED
with	O
the	O
VLPs	B-MED
inhibited	O
KSHV	B-MED
infection	B-MED
of	O
HEK-293	B-MED
cells	I-MED
in	O
a	O
dose	B-MED
-	I-MED
dependent	I-MED
manner	O
.	O
As	O
a	O
single	O
immunogen	B-MED
,	O
gpK8.1	B-MED
VLPs	B-MED
stimulated	O
comparable	O
nAb	B-MED
activity	O
to	O
that	O
of	O
UV	B-MED
-	O
inactivated	B-MED
KSHV	B-MED
(	O
UV	B-MED
-	I-MED
KSHV	I-MED
)	O
.	O
In	O
contrast	O
,	O
UV	B-MED
-	I-MED
KSHV	I-MED
stimulated	O
higher	O
titers	O
of	O
nAb	O
compared	O
to	O
gB	B-MED
(	O
p	O
=	O
0.0316	O
)	O
or	O
gH	B-MED
/	O
gL	B-MED
(	O
p	O
=	O
0.0486	O
)	O
.	O
Mice	B-MED
immunized	B-MED
with	O
the	O
combination	O
of	O
gB	B-MED
and	O
gH	B-MED
/	O
gL	B-MED
VLPs	B-MED
had	O
a	O
better	O
nAb	O
response	O
than	O
those	O
immunized	B-MED
with	O
either	O
gB	B-MED
(	O
p	O
=	O
0.0268	O
)	O
,	O
or	O
gH	B-MED
/gL	O
(	O
p	O
=	O
0.0397	O
)	O
as	O
single	O
VLP	B-MED
immunogens	B-MED
.	O
Immunization	B-MED
with	O
any	O
VLP	B-MED
combination	O
stimulated	O
comparable	O
nAb	B-MED
activity	O
to	O
UV	B-MED
-	I-MED
KSHV	I-MED
serum	B-MED
.	O
Our	O
data	O
provide	O
the	O
first	O
evidence	O
that	O
KSHV	B-MED
gpK8.1	B-MED
,	O
gB	B-MED
,	O
and	O
gH	B-MED
/	O
gL	B-MED
glycoproteins	I-MED
can	O
be	O
incorporated	O
onto	O
the	O
surface	O
of	O
VLPs	B-MED
and	O
used	O
as	O
prophylactic	B-MED
vaccine	I-MED
candidates	O
,	O
with	O
potential	O
to	O
prevent	O
KSHV	B-MED
infection	B-MED
.	O
Diagnostic	B-MED
utility	B-MED
of	O
additional	O
conventional	B-MED
techniques	B-MED
after	O
endobronchial	B-MED
ultrasonography	I-MED
guidance	B-MED
during	O
transbronchial	B-MED
biopsy	I-MED
Endobronchial	B-MED
ultrasonography	I-MED
with	O
a	O
guide	B-MED
sheath	I-MED
transbronchial	B-MED
biopsy	I-MED
(	O
EBUS	B-MED
-	O
GS	B-MED
TBB	B-MED
)	O
has	O
been	O
used	O
to	O
diagnose	B-MED
peripheral	B-MED
pulmonary	I-MED
lesions	I-MED
(	O
PPLs	B-MED
)	O
.	O
In	O
this	O
study	B-MED
,	O
we	O
evaluated	O
the	O
diagnostic	B-MED
utility	B-MED
of	O
conventional	B-MED
TBB	B-MED
after	O
EBUS	B-MED
-	O
GS	B-MED
TBB	B-MED
.	O
A	O
retrospective	B-MED
analysis	I-MED
of	O
patients	B-MED
who	O
underwent	O
conventional	B-MED
TBB	B-MED
after	O
EBUS	B-MED
-	O
GS	B-MED
TBB	B-MED
for	O
PPL	B-MED
between	O
August	O
1	O
,	O
2012	O
and	O
December	O
31	O
,	O
2014	O
.	O
We	O
performed	O
multivariate	B-MED
analysis	I-MED
to	O
examine	O
the	O
association	B-MED
of	O
various	O
clinical	B-MED
factors	B-MED
,	O
including	O
EBUS	B-MED
probe	B-MED
distance	B-MED
and	O
sample	B-MED
size	I-MED
area	B-MED
,	O
with	O
diagnostic	B-MED
yield	I-MED
.	O
Of	O
88	O
eligible	O
patients	B-MED
,	O
57	O
(	O
65	O
%	O
)	O
were	O
successfully	O
diagnosed	B-MED
by	O
EBUS	B-MED
-	O
GS	B-MED
TBB	B-MED
.	O
In	O
31	O
patients	B-MED
not	O
diagnosed	B-MED
by	O
EBUS	B-MED
-	O
GS	B-MED
TBB	B-MED
,	O
15	O
(	O
48	O
%	O
)	O
were	O
successfully	O
diagnosed	B-MED
by	O
additional	O
conventional	B-MED
TBB	B-MED
.	O
Ground	B-MED
glass	I-MED
opacity	I-MED
(	O
GGO	B-MED
)	O
was	O
a	O
significant	B-MED
factor	B-MED
associated	O
with	O
the	O
diagnostic	B-MED
yield	I-MED
of	O
additional	O
conventional	B-MED
TBB	B-MED
following	O
EBUS	B-MED
-	O
GS	B-MED
TBB	B-MED
.	O
Multivariate	B-MED
analysis	I-MED
and	O
receiver	B-MED
operator	I-MED
curves	I-MED
revealed	O
that	O
distance	B-MED
between	O
the	O
PPL	B-MED
and	O
the	O
EBUS	B-MED
probe	B-MED
of	O
less	O
than	O
2.55	O
mm	O
favored	O
the	O
utility	B-MED
of	O
conventional	B-MED
TBB	B-MED
.	O
Additional	O
conventional	B-MED
TBB	B-MED
after	O
EBUS	B-MED
-	O
GS	B-MED
TBB	B-MED
could	O
be	O
a	O
useful	O
procedure	B-MED
for	O
the	O
diagnosis	B-MED
of	O
ground	B-MED
glass	I-MED
opacity	I-MED
PPLs	B-MED
and	O
in	O
cases	B-MED
of	O
a	O
distance	B-MED
of	O
less	O
than	O
2.55	O
mm	O
between	O
the	O
EBUS	B-MED
probe	B-MED
and	O
the	O
lesion	B-MED
.	O
Prevalence	B-MED
of	O
high	B-MED
-	I-MED
risk	I-MED
human	B-MED
papillomavirus	I-MED
infection	I-MED
among	O
women	B-MED
in	O
Shaanxi	B-MED
province	B-MED
of	O
China	B-MED
:	O
A	O
hospital	B-MED
-based	O
investigation	B-MED
This	O
study	O
aimed	O
to	O
investigate	B-MED
the	O
characteristics	B-MED
of	O
female	B-MED
high	B-MED
-	I-MED
risk	I-MED
human	I-MED
papillomavirus	I-MED
(	I-MED
HR	I-MED
-	I-MED
HPV	I-MED
)	I-MED
infection	I-MED
in	O
Shaanxi	B-MED
province	B-MED
of	O
China	B-MED
.	O
A	O
total	O
of	O
14	O
111	O
women	B-MED
were	O
enrolled	O
for	O
HPV	B-MED
genotyping	B-MED
test	I-MED
,	O
and	O
a	O
cytology	B-MED
,	O
and/or	O
cervix	B-MED
biopsy	I-MED
were	O
performed	O
in	O
partial	O
women	B-MED
.	O
Of	O
these	O
women	B-MED
,	O
the	O
HPV	B-MED
infection	I-MED
rate	B-MED
was	O
30.21	O
%	O
,	O
and	O
26.73	O
%	O
were	O
caused	O
by	O
HR	B-MED
-	I-MED
HPV	I-MED
.	O
The	O
most	O
common	O
HR	B-MED
-	I-MED
HPV	I-MED
genotypes	B-MED
were	O
HPV-16	B-MED
,	O
HPV-58	B-MED
,	O
HPV-52	B-MED
,	O
HPV-18	B-MED
,	O
and	O
HPV-31	B-MED
.	O
The	O
prevalence	B-MED
of	O
HR	B-MED
-	I-MED
HPV	I-MED
among	O
women	B-MED
older	O
than	O
50	O
years	O
was	O
significantly	O
higher	O
than	O
the	O
other	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O
The	O
main	O
carcinogenic	B-MED
genotypes	B-MED
were	O
HPV-16	B-MED
,	O
HPV-18	B-MED
,	O
HPV-58	B-MED
,	O
HPV-52	B-MED
,	O
and	O
HPV-31	B-MED
.	O
HPV-16	B-MED
and	O
HPV-18	B-MED
combined	O
caused	O
80.79	O
%	O
of	O
cervical	B-MED
cancer	I-MED
cases	O
.	O
The	O
infection	B-MED
with	O
multiple	O
HR	B-MED
-	I-MED
HPVs	I-MED
was	O
not	B-MED
a	O
risk	B-MED
factor	I-MED
for	O
cervical	B-MED
lesions	I-MED
.	O
In	O
conclusion	O
,	O
HPV	B-MED
infection	I-MED
was	O
common	O
among	O
women	B-MED
in	O
Shaanxi	B-MED
province	B-MED
.	O
Women	B-MED
older	O
than	O
50	O
years	O
were	O
a	O
high	B-MED
-	I-MED
risk	I-MED
group	I-MED
for	O
HR	B-MED
-	I-MED
HPV	I-MED
infection	I-MED
and	O
cervical	B-MED
cancer	I-MED
.	O
HPV-16	B-MED
and	O
HPV-18	B-MED
were	O
the	O
main	O
carcinogenic	B-MED
genotypes	B-MED
in	O
this	O
region	B-MED
.	O
Muscle	B-MED
synergies	B-MED
after	O
stroke	B-MED
are	O
correlated	O
with	O
perilesional	B-MED
high	B-MED
gamma	I-MED
Movements	B-MED
can	O
be	O
factored	O
into	O
modules	B-MED
termed	O
"	O
muscle	B-MED
synergies	B-MED
"	O
.	O
After	O
stroke	B-MED
,	O
abnormal	B-MED
synergies	B-MED
are	O
linked	O
to	O
impaired	B-MED
movements	B-MED
;	O
however	O
,	O
their	O
neural	B-MED
basis	B-MED
is	O
not	O
understood	O
.	O
In	O
a	O
single	O
subject	O
,	O
we	O
examined	O
how	O
electrocorticography	B-MED
signals	I-MED
from	O
the	O
perilesional	B-MED
cortex	B-MED
were	O
associated	O
with	O
synergies	B-MED
.	O
The	O
measured	O
synergies	B-MED
contained	B-MED
a	O
mix	O
of	O
both	O
normal	B-MED
and	O
abnormal	B-MED
patterns	B-MED
and	O
were	O
remarkably	O
similar	O
to	O
those	O
described	O
in	O
past	O
work	O
.	O
Interestingly	O
,	O
we	O
found	O
that	O
both	O
normal	B-MED
and	O
abnormal	B-MED
synergies	B-MED
were	O
correlated	O
with	O
perilesional	B-MED
high	B-MED
gamma	I-MED
.	O
Given	O
the	O
link	O
between	O
high	B-MED
gamma	I-MED
and	O
cortical	B-MED
spiking	I-MED
,	O
our	O
results	O
suggest	O
that	O
perilesional	B-MED
spiking	I-MED
may	O
organize	O
synergies	B-MED
after	O
stroke	B-MED
.	O
Pembrolizumab	B-MED
for	O
the	O
treatment	B-MED
of	O
non	B-MED
-	I-MED
small	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
In	O
the	O
last	O
years	O
,	O
a	O
spectacular	O
development	B-MED
of	O
immunotherapeutic	B-MED
agents	I-MED
aimed	O
at	O
the	O
PD-1	B-MED
/	O
PD	B-MED
-	I-MED
L1	I-MED
axis	O
has	O
taken	O
place	O
.	O
This	O
development	B-MED
of	O
these	O
checkpoint	B-MED
inhibitors	I-MED
has	O
greatly	O
influenced	O
our	O
approach	O
to	O
the	O
treatment	B-MED
of	O
lung	B-MED
cancer	I-MED
in	O
first	B-MED
and	O
second	B-MED
line	I-MED
.	O
The	O
limited	B-MED
toxicity	B-MED
profile	O
and	O
the	O
ability	O
to	O
treat	B-MED
for	O
prolonged	B-MED
periods	B-MED
,	O
even	O
in	O
smokers	B-MED
,	O
is	O
a	O
welcome	O
expansion	O
of	O
the	O
therapeutic	O
arsenal	O
of	O
the	O
oncologist	B-MED
.	O
Areas	O
covered	O
:	O
This	O
review	B-MED
highlights	O
the	O
results	B-MED
of	O
recent	O
clinical	B-MED
trials	I-MED
on	O
pembrolizumab	B-MED
for	O
the	O
treatment	B-MED
of	O
non	B-MED
-	I-MED
small	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
.	O
The	O
authors	B-MED
discuss	O
both	O
first	B-MED
and	O
second	B-MED
line	I-MED
treatment	I-MED
with	O
pembrolizumab	B-MED
as	O
monotherapy	B-MED
and	O
in	O
combination	B-MED
therapies	I-MED
.	O
Additionally	O
,	O
implications	O
of	O
the	O
PD	B-MED
-	I-MED
L1	I-MED
immunohistochemistry	B-MED
assay	I-MED
with	O
the	O
22C3	B-MED
antibody	I-MED
and	O
its	O
use	B-MED
in	O
clinical	B-MED
practice	I-MED
and	O
trials	B-MED
is	O
discussed	O
.	O
Expert	O
commentary	O
:	O
A	O
higher	B-MED
overall	B-MED
response	I-MED
,	O
overall	B-MED
survival	I-MED
and	O
a	O
moderate	B-MED
toxicity	B-MED
profile	O
is	O
observed	O
with	O
the	O
use	B-MED
of	O
pembrolizumab	B-MED
,	O
compared	O
to	O
chemotherapy	B-MED
,	O
in	O
both	O
first	B-MED
and	O
second	B-MED
line	I-MED
.	O
These	O
promising	O
results	B-MED
have	O
already	O
translated	O
into	O
the	O
registration	B-MED
of	O
pembrolizumab	B-MED
in	O
first	B-MED
and	O
second	B-MED
line	I-MED
in	O
patients	B-MED
with	O
a	O
high	B-MED
expression	B-MED
of	O
PD	B-MED
-	I-MED
L1	I-MED
.	O
However	O
,	O
as	O
PD	B-MED
-	I-MED
L1	I-MED
staining	B-MED
does	O
not	O
sufficiently	O
discriminate	O
responders	B-MED
from	O
non	B-MED
-	I-MED
responders	I-MED
for	O
all	O
checkpoint	B-MED
inhibitors	I-MED
,	O
there	O
still	O
is	O
a	O
need	O
for	O
a	O
better	O
predictive	B-MED
biomarker	B-MED
.	O
Intracameral	B-MED
cefuroxime	B-MED
in	O
the	O
prevention	B-MED
of	O
postoperative	B-MED
endophthalmitis	I-MED
:	O
an	O
experience	B-MED
from	O
Hong	B-MED
Kong	I-MED
The	O
purpose	O
was	O
to	O
study	B-MED
the	O
effect	B-MED
of	O
introducing	B-MED
intracameral	B-MED
cefuroxime	B-MED
,	O
which	O
was	O
compounded	B-MED
by	O
a	O
hospital	B-MED
pharmacy	I-MED
,	O
on	O
postoperative	B-MED
endophthalmitis	I-MED
in	O
a	O
tertiary	B-MED
eye	I-MED
centre	I-MED
in	O
Hong	B-MED
Kong	I-MED
.	O
All	O
cases	O
that	O
underwent	O
cataract	B-MED
surgeries	I-MED
over	O
a	O
12	O
-	O
year	O
period	O
(	O
January	O
2004	O
to	O
December	O
2015	O
)	O
were	O
included	O
.	O
The	O
routine	B-MED
use	B-MED
of	O
intracameral	B-MED
cefuroxime	B-MED
at	O
the	O
end	O
of	O
cataract	B-MED
surgery	I-MED
was	O
introduced	O
at	O
our	O
centre	O
after	O
April	O
2010	O
.	O
All	O
cefuroxime	B-MED
aliquots	B-MED
were	O
prepared	O
by	O
the	O
hospital	B-MED
pharmacy	I-MED
using	O
an	O
aseptic	B-MED
aseptic	B-MED
compounding	I-MED
technique	O
.	O
The	O
rates	B-MED
of	O
postoperative	B-MED
endophthalmitis	I-MED
before	O
April	O
2010	O
(	O
Group	B-MED
1	O
,	O
no	B-MED
intracameral	B-MED
cefuroxime	B-MED
)	O
and	O
after	O
April	O
2010	O
(	O
Group	B-MED
2	O
,	O
routine	O
use	O
of	O
intracameral	B-MED
cefuroxime	B-MED
)	O
were	O
compared	O
.	O
A	O
total	O
of	O
30,428	O
eyes	B-MED
(	O
7,332	O
in	O
Group	B-MED
1	O
and	O
23,096	O
in	O
Group	B-MED
2	O
)	O
were	O
studied	O
.	O
Eight	O
cases	O
developed	O
postoperative	B-MED
endophthalmitis	I-MED
(	O
1.09	O
in	O
1000	O
;	O
0.11	O
%	O
)	O
in	O
Group	B-MED
1	O
whereas	O
no	O
cases	O
developed	O
endophthalmitis	B-MED
(	O
0	O
%	O
)	O
in	O
Group	B-MED
2	O
.	O
The	O
rate	B-MED
of	O
reduction	B-MED
was	O
statistically	B-MED
significant	I-MED
(	O
p	O
<	O
0.0001	O
)	O
.	O
Seven	O
out	O
of	O
eight	O
cases	O
of	O
endophthalmitis	B-MED
were	O
confirmed	O
by	O
positive	B-MED
culture	I-MED
.	O
Organisms	B-MED
identified	O
were	O
Group	B-MED
G	I-MED
Streptococcus	I-MED
(	O
two	O
cases	O
)	O
,	O
Group	B-MED
B	I-MED
Streptococcus	I-MED
,	O
Staphylococcus	B-MED
aureus	I-MED
,	O
Serratia	B-MED
marcescens	I-MED
,	O
and	O
coagulase	B-MED
-	I-MED
negative	I-MED
Staphylococcus	I-MED
(	O
two	O
cases	O
)	O
.	O
Antibiotic	B-MED
susceptibility	I-MED
testing	B-MED
results	I-MED
were	O
available	O
in	O
six	O
cases	O
.	O
Four	O
out	O
of	O
six	O
organisms	B-MED
were	O
susceptible	B-MED
to	O
the	O
penicillin	B-MED
group	I-MED
.	O
No	B-MED
adverse	I-MED
events	I-MED
related	O
to	O
the	O
use	B-MED
of	O
intracameral	B-MED
cefuroxime	B-MED
were	O
encountered	O
.	O
The	O
use	B-MED
of	O
intracameral	B-MED
cefuroxime	B-MED
could	O
significantly	O
reduce	B-MED
the	O
rate	B-MED
of	O
postoperative	B-MED
endophthalmitis	I-MED
in	O
a	O
tertiary	B-MED
centre	I-MED
in	O
Hong	B-MED
Kong	I-MED
.	O
The	O
use	B-MED
of	O
aseptic	B-MED
aseptic	B-MED
compounding	I-MED
to	O
prepare	O
cefuroxime	B-MED
aliquots	B-MED
by	O
hospital	B-MED
pharmacy	I-MED
appeared	O
to	O
be	O
safe	O
and	O
efficacious	O
.	O
Design	B-MED
,	O
Synthesis	B-MED
,	O
and	O
Cytotoxic	B-MED
Evaluation	B-MED
of	O
Certain	O
7	B-MED
-	I-MED
Chloro-4-(piperazin-1	I-MED
-	I-MED
yl)quinoline	I-MED
Derivatives	B-MED
as	O
VEGFR	B-MED
-	I-MED
II	I-MED
Inhibitors	B-MED
Signaling	B-MED
pathway	I-MED
inhibition	B-MED
of	O
VEGFR	B-MED
-	I-MED
II	I-MED
is	O
visualized	O
as	O
valuable	O
tool	O
in	O
cancer	B-MED
management	B-MED
.	O
In	O
the	O
current	B-MED
study	I-MED
,	O
the	O
synthesis	B-MED
of	O
novel	B-MED
1	B-MED
-	I-MED
4-(7	I-MED
-	I-MED
chloroquinolin-4	I-MED
-	I-MED
yl)piperazin-1	I-MED
-	I-MED
yl)-2-(N	I-MED
-	I-MED
substituted	I-MED
-	I-MED
amino)-ethanone	I-MED
derivatives	B-MED
(	O
4a	B-MED
-	I-MED
t	I-MED
)	O
was	O
achieved	O
through	O
the	O
amination	B-MED
of	O
2	B-MED
-	I-MED
chloro-1-(4-(7	I-MED
-	I-MED
chloroquinolin-4	I-MED
-	I-MED
yl)piperazin-1	I-MED
-	I-MED
yl)ethanone	I-MED
(	I-MED
3	I-MED
)	I-MED
with	O
different	O
secondary	B-MED
amines	I-MED
.	I-MED
The	O
structures	B-MED
of	O
the	O
target	B-MED
compounds	B-MED
were	O
confirmed	B-MED
by	I-MED
IR	B-MED
,	O
(	B-MED
1	I-MED
)	I-MED
H	I-MED
-	I-MED
NMR	I-MED
,	O
(	B-MED
13	I-MED
)	I-MED
C	I-MED
-	I-MED
NMR	I-MED
,	O
HRMS	B-MED
,	O
and	O
microanalysis	B-MED
.	O
Compounds	B-MED
4a	B-MED
-	I-MED
t	I-MED
were	O
subjected	O
to	O
in	B-MED
vitro	I-MED
anticancer	B-MED
screening	B-MED
against	O
human	B-MED
breast	I-MED
cancer	I-MED
(	O
MCF-7	B-MED
)	O
and	O
prostate	B-MED
cancer	I-MED
(	O
PC3	B-MED
)	O
cell	B-MED
lines	I-MED
.	O
The	O
highest	O
cytotoxicty	B-MED
against	O
both	O
cell	B-MED
lines	I-MED
was	O
displayed	O
by	O
2-(4-(4	B-MED
-	I-MED
bromobenzyl)piperazin-1	I-MED
-	I-MED
yl)-1-(4-(7	I-MED
-	I-MED
chloroquinolin-4	I-MED
-	I-MED
yl)piperazin-1	I-MED
-	I-MED
yl)ethanone	I-MED
(	I-MED
4q	I-MED
)	I-MED
,	O
with	O
IC50	B-MED
values	I-MED
of	O
6.502	O
and	O
11.751	O
μM	O
against	O
MCF-7	B-MED
and	O
PC3	B-MED
cells	I-MED
,	O
respectively	O
,	O
compared	B-MED
with	O
the	O
standard	B-MED
drug	I-MED
doxorubicin	B-MED
(	O
MCF-7	B-MED
:	O
6.774	O
μM	O
,	O
PC3	B-MED
:	O
7.7316	O
μM	O
)	O
.	O
Due	O
to	O
its	O
notable	O
activity	B-MED
toward	O
MCF-7	B-MED
cells	I-MED
,	O
4q	B-MED
was	O
further	O
evaluated	O
as	O
VEGFR	B-MED
-	I-MED
II	I-MED
inhibitor	B-MED
,	O
showing	O
an	O
IC50	B-MED
of	O
1.38	O
μM	O
compared	O
to	O
sorafenib	B-MED
(	O
0.33	O
μM	O
)	O
.	O
The	O
docking	B-MED
study	O
proved	O
that	O
4q	B-MED
has	O
a	O
binding	B-MED
mode	I-MED
akin	O
to	O
that	O
of	O
VEGFR	B-MED
-	I-MED
II	I-MED
inhibitors	B-MED
.	O
Intrapartum	B-MED
Cervical	B-MED
Laceration	I-MED
and	O
Subsequent	O
Pregnancy	B-MED
Outcomes	I-MED
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
describe	O
pregnancy	B-MED
outcomes	I-MED
,	O
including	O
cervical	B-MED
insufficiency	I-MED
and	O
preterm	B-MED
birth	I-MED
,	O
in	O
the	O
subsequent	O
pregnancy	B-MED
following	B-MED
an	O
intrapartum	B-MED
cervical	B-MED
laceration	I-MED
.	O
Retrospective	O
cohort	B-MED
of	O
women	B-MED
with	O
their	O
first	O
two	O
consecutive	B-MED
singleton	B-MED
pregnancies	I-MED
carried	O
to	O
≥	O
20(0/7	O
)	O
weeks	B-MED
'	O
gestation	B-MED
within	O
a	O
tertiary	B-MED
health	I-MED
care	I-MED
system	I-MED
from	O
2002	O
to	O
2012	O
.	O
Cervical	B-MED
laceration	I-MED
cases	B-MED
were	O
identified	B-MED
by	O
ICD9	B-MED
codes	I-MED
and	O
included	B-MED
if	O
suture	B-MED
repair	I-MED
was	O
required	B-MED
.	O
In	O
this	O
study	B-MED
,	O
55	O
women	B-MED
were	O
confirmed	B-MED
to	O
have	O
a	O
cervical	B-MED
laceration	I-MED
in	O
the	O
first	O
delivery	B-MED
;	O
43	O
lacerations	B-MED
after	O
vaginal	B-MED
delivery	I-MED
(	B-MED
VD	I-MED
)	I-MED
and	O
12	O
after	O
cesarean	B-MED
delivery	I-MED
(	B-MED
CD	I-MED
)	I-MED
.	O
The	O
median	B-MED
gestational	B-MED
age	I-MED
of	O
the	O
first	O
delivery	B-MED
was	O
40(0/7	O
)	O
weeks	B-MED
and	O
the	O
median	B-MED
birth	B-MED
weight	I-MED
3,545	O
g	O
;	O
these	O
did	O
not	O
differ	B-MED
between	O
VD	B-MED
and	O
CD	B-MED
.	O
In	O
the	O
second	O
pregnancy	B-MED
,	O
2	O
of	O
55	O
women	B-MED
(	O
4.6	O
%	O
)	O
had	O
a	O
prophylactic	B-MED
cerclage	B-MED
placed	O
;	O
1	O
carried	B-MED
to	O
term	B-MED
and	O
the	O
other	O
delivered	B-MED
at	O
35(6/7	O
)	O
weeks	B-MED
.	O
In	O
total	B-MED
,	O
four	O
women	B-MED
(	O
9.3	O
%	O
)	O
delivered	B-MED
the	O
second	O
pregnancy	B-MED
<	O
37	O
weeks	B-MED
:	O
three	O
had	O
a	O
prior	B-MED
term	B-MED
VD	B-MED
and	O
one	O
had	O
a	O
prior	B-MED
34	O
weeks	B-MED
VD	B-MED
.	O
There	O
was	O
only	O
one	O
case	B-MED
of	O
recurrent	B-MED
cervical	B-MED
laceration	I-MED
,	O
occurring	B-MED
in	O
the	O
setting	B-MED
of	O
vaginal	B-MED
deliveries	I-MED
.	O
Obstetric	B-MED
cervical	B-MED
lacerations	I-MED
are	O
uncommon	B-MED
.	O
Complications	B-MED
in	O
the	O
following	B-MED
pregnancy	B-MED
were	O
low	B-MED
,	O
despite	O
lack	B-MED
of	O
additional	O
prophylactic	B-MED
cerclage	B-MED
use	O
.	O
The	O
Bindex	B-MED
(	I-MED
®	I-MED
)	I-MED
ultrasound	I-MED
device	I-MED
:	O
reliability	B-MED
of	O
cortical	B-MED
bone	I-MED
thickness	B-MED
measures	B-MED
and	O
their	O
relationship	B-MED
to	O
regional	B-MED
bone	B-MED
mineral	I-MED
density	I-MED
The	O
Bindex	B-MED
(	I-MED
®	I-MED
)	I-MED
quantitative	I-MED
ultrasound	I-MED
(	I-MED
QUS	I-MED
)	I-MED
device	I-MED
is	O
currently	O
available	O
and	O
this	O
study	B-MED
analyzed	B-MED
(	O
I	O
)	O
its	O
relative	B-MED
and	O
absolute	B-MED
intra-	B-MED
and	I-MED
inter	I-MED
-	I-MED
session	I-MED
reliability	I-MED
and	O
(	O
II	O
)	O
the	O
relationship	B-MED
between	O
the	O
data	B-MED
provided	O
by	O
Bindex(	B-MED
®	I-MED
)-QUS	I-MED
and	O
the	O
bone	B-MED
mineral	I-MED
density	I-MED
(	O
BMD	B-MED
)	O
measured	B-MED
by	O
dual	B-MED
-	I-MED
energy	I-MED
x	I-MED
-	I-MED
ray	I-MED
absorptiometry	I-MED
at	O
corresponding	O
skeletal	B-MED
sites	I-MED
in	O
young	B-MED
and	O
healthy	B-MED
subjects	I-MED
(	O
age	B-MED
:	O
25.0	O
±	O
3.6	O
years	B-MED
)	O
.	O
Bindex(	B-MED
®	I-MED
)-QUS	I-MED
calculates	B-MED
a	O
density	B-MED
index	I-MED
on	O
the	O
basis	O
of	O
the	O
thickness	B-MED
of	O
cortical	B-MED
bone	I-MED
measured	B-MED
at	O
the	O
distal	B-MED
radius	I-MED
and	O
the	O
distal	B-MED
plus	O
proximal	B-MED
tibia	I-MED
.	O
The	O
data	B-MED
show	O
a	O
very	O
good	O
relative	B-MED
and	O
absolute	B-MED
intra-	B-MED
(	O
ICC	B-MED
=	O
0.977	O
,	O
CV	B-MED
=	O
1.5	O
%	O
)	O
and	O
inter	B-MED
-	I-MED
session	I-MED
reliability	I-MED
(	O
ICC	B-MED
=	O
0.978	O
,	O
CV	B-MED
=	O
1.4	O
%	O
)	O
for	O
the	O
density	B-MED
index	I-MED
.	O
The	O
highest	B-MED
positive	B-MED
correlations	B-MED
were	O
found	O
between	O
cortical	B-MED
thickness	B-MED
and	O
BMD	B-MED
for	O
the	O
distal	B-MED
radius	I-MED
and	O
distal	B-MED
tibia	I-MED
(	O
r	O
⩾	O
0.71	O
,	O
p	O
<	O
0.001	O
)	O
.	O
The	O
data	B-MED
indicate	O
that	O
the	O
Bindex(	B-MED
®	I-MED
)-QUS	I-MED
parameters	B-MED
are	O
repeatable	O
within	O
and	O
between	O
measurement	B-MED
sessions	B-MED
.	O
Furthermore	O
,	O
the	O
measurements	B-MED
reflect	O
the	O
BMD	B-MED
at	O
specific	B-MED
skeletal	B-MED
sites	I-MED
.	O
Bindex(	B-MED
®	I-MED
)-QUS	I-MED
might	O
be	O
a	O
useful	O
tool	O
for	O
the	O
measurement	B-MED
of	O
skeletal	B-MED
adaptations	I-MED
.	O
Correlation	B-MED
of	O
cardiopulmonary	B-MED
exercise	I-MED
testing	I-MED
parameters	B-MED
with	O
quality	B-MED
of	I-MED
life	I-MED
in	O
stable	B-MED
COPD	B-MED
patients	B-MED
The	O
precise	O
head	O
to	O
head	O
relationships	B-MED
between	O
Cardio	B-MED
-	I-MED
pulmonary	I-MED
exercise	I-MED
testing	I-MED
(	O
CPET	B-MED
)	O
parameters	B-MED
and	O
patients	B-MED
'	O
daily	B-MED
symptoms	I-MED
/	O
activities	B-MED
and	O
the	O
disease	B-MED
social	B-MED
/	O
emotional	B-MED
impact	I-MED
are	O
less	O
well	O
defined	O
.	O
In	O
this	O
study	O
,	O
the	O
correlation	B-MED
of	O
COPD	B-MED
daily	B-MED
symptoms	I-MED
and	O
quality	B-MED
of	I-MED
life	I-MED
[	O
assessed	O
by	O
St.	B-MED
George	I-MED
's	I-MED
Respiratory	I-MED
Questionnaire	I-MED
(	O
SGRQ	B-MED
)	O
]	O
and	O
COPD	B-MED
severity	B-MED
index	I-MED
(	O
BODE	B-MED
-	I-MED
index	I-MED
)	O
with	O
CPET	B-MED
parameters	B-MED
were	O
investigated	O
.	O
Symptom	B-MED
-limited	O
CPET	B-MED
was	O
performed	O
in	O
37	O
consecutive	B-MED
COPD	B-MED
(	O
GOLD	B-MED
I	I-MED
-	I-MED
III	I-MED
)	O
subjects	O
during	O
non-	O
exacerbation	B-MED
phase	B-MED
.	O
The	O
SGRQ	B-MED
was	O
also	O
completed	O
by	O
each	O
patient	B-MED
.	O
SGRQ	B-MED
-	I-MED
score	I-MED
correlated	B-MED
negatively	B-MED
with	O
FEV1	B-MED
(	O
r=-0.49	O
,	O
P<0.01	O
)	O
,	O
predicted	B-MED
maximal	B-MED
work	I-MED
-	I-MED
rate	I-MED
(	O
%	B-MED
WR	I-MED
-	I-MED
max	I-MED
)	O
(	O
r=-0.44	O
,	O
P<0.01	O
)	O
,	O
V'O2	B-MED
/	O
WR	B-MED
(	O
r=-0.52	O
,	O
P<0.01	O
)	O
and	O
breathing	B-MED
reserve	I-MED
(	O
r=-0.50	O
,	O
P<0.01	O
)	O
.	O
However	O
it	O
did	B-MED
not	I-MED
correlate	I-MED
with	O
Peak	B-MED
-	I-MED
V'O2	I-MED
%	O
predicted	O
(	O
r=-0.27	O
,	O
P=0.10	O
)	O
.	O
In	O
20	O
(	O
54.1	O
%	O
)	O
subjects	O
in	O
which	O
leg	B-MED
fatigue	I-MED
was	I-MED
the	I-MED
main	I-MED
cause	I-MED
for	I-MED
stopping	I-MED
the	I-MED
test	I-MED
,	O
Peak	B-MED
-	I-MED
V'O2	I-MED
,	O
%	B-MED
WR	I-MED
-	I-MED
max	I-MED
,	O
HR	B-MED
-	I-MED
Reserve	I-MED
and	O
Breathing	B-MED
reserve	I-MED
were	O
higher	O
(	O
P=0.04	O
,	O
<	O
0.01	O
,	O
0.04	O
and	O
<	O
0.01	O
respectively	O
)	O
than	O
the	O
others	O
.	O
There	O
was	O
also	O
a	O
significant	B-MED
correlation	B-MED
between	O
BODE	B-MED
-	I-MED
index	I-MED
and	O
∆VO2	B-MED
/	O
∆WR	B-MED
(	O
r=-0.64	O
,	O
P<0.001	O
)	O
and	O
breathing	B-MED
-	I-MED
reserve	I-MED
(	O
r=-0.38	O
,	O
P=0.018	O
)	O
.	O
The	O
observed	O
relationships	B-MED
between	O
CPET	B-MED
parameter	B-MED
and	O
daily	B-MED
subjective	B-MED
complaints	I-MED
in	O
COPD	B-MED
were	O
not	O
strong	O
.	O
Those	O
who	O
discontinued	O
the	O
CPET	B-MED
because	B-MED
of	I-MED
leg	I-MED
fatigue	I-MED
were	O
in	O
the	O
earlier	B-MED
stages	I-MED
of	O
COPD	B-MED
.	O
Significant	O
negative	B-MED
correlation	B-MED
between	O
∆VO2	B-MED
/	O
∆WR	B-MED
and	O
BODE	B-MED
-	I-MED
index	I-MED
suggests	O
that	O
along	O
with	O
COPD	B-MED
progression	B-MED
,	O
regardless	O
of	O
negative	B-MED
past	I-MED
history	I-MED
,	O
other	O
comorbidities	B-MED
such	O
as	O
cardiac	B-MED
/	O
musculoskeletal	B-MED
problems	I-MED
should	O
be	O
sought	O
.	O
Acoustic	B-MED
startle	I-MED
response	I-MED
in	O
rats	B-MED
predicts	O
inter	B-MED
-	I-MED
individual	I-MED
variation	B-MED
in	O
fear	B-MED
extinction	B-MED
Although	O
a	O
large	O
portion	O
of	O
the	O
population	B-MED
is	O
exposed	O
to	O
a	O
traumatic	B-MED
event	B-MED
at	O
some	O
point	O
,	O
only	O
a	O
small	O
percentage	B-MED
of	O
the	O
population	B-MED
develops	O
post	B-MED
-	I-MED
traumatic	I-MED
stress	I-MED
disorder	I-MED
(	O
PTSD	B-MED
)	O
,	O
suggesting	O
the	O
presence	O
of	O
predisposing	B-MED
factors	I-MED
.	O
Abnormal	B-MED
acoustic	B-MED
startle	I-MED
response	I-MED
(	O
ASR	B-MED
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
PTSD	B-MED
,	O
implicating	O
it	O
as	O
a	O
potential	B-MED
predictor	B-MED
of	O
the	O
development	B-MED
of	O
PTSD	B-MED
-like	O
behavior	B-MED
.	O
Since	O
poor	O
extinction	B-MED
and	O
retention	O
of	O
extinction	B-MED
learning	I-MED
are	O
characteristic	O
of	O
PTSD	B-MED
patients	B-MED
,	O
it	O
is	O
of	O
interest	O
to	O
determine	O
if	O
abnormal	B-MED
ASR	B-MED
is	O
predictive	O
of	O
development	B-MED
of	O
such	O
deficits	B-MED
.	O
To	O
determine	O
whether	O
baseline	B-MED
ASR	B-MED
has	O
utility	O
in	O
predicting	O
the	O
development	B-MED
of	O
PTSD	B-MED
-like	O
behavior	B-MED
,	O
the	O
relationship	O
between	O
baseline	B-MED
ASR	B-MED
and	O
freezing	B-MED
behavior	I-MED
following	O
Pavlovian	B-MED
fear	I-MED
conditioning	I-MED
was	O
examined	O
in	O
a	O
group	O
of	O
adult	B-MED
,	O
male	B-MED
Sprague	B-MED
-	I-MED
Dawley	I-MED
rats	I-MED
.	O
Baseline	B-MED
acoustic	B-MED
startle	I-MED
response	I-MED
(	O
ASR	B-MED
)	O
was	O
assessed	O
preceding	O
exposure	O
to	O
a	O
Pavlovian	B-MED
fear	I-MED
conditioning	I-MED
paradigm	I-MED
where	O
freezing	B-MED
behavior	I-MED
was	O
measured	O
during	O
fear	B-MED
conditioning	I-MED
,	O
extinction	B-MED
training	B-MED
,	O
and	O
extinction	B-MED
testing	B-MED
.	O
Although	O
there	O
was	O
no	O
relationship	O
between	O
baseline	B-MED
ASR	B-MED
and	O
fear	B-MED
memory	B-MED
following	O
conditioning	B-MED
,	O
rats	B-MED
with	O
low	O
baseline	B-MED
ASR	B-MED
had	O
significantly	O
lower	O
magnitude	O
of	O
retention	B-MED
of	O
the	O
extinction	B-MED
memory	B-MED
than	O
rats	B-MED
with	O
high	O
baseline	B-MED
ASR	B-MED
.	O
The	O
results	O
suggest	O
that	O
baseline	B-MED
ASR	B-MED
has	O
value	O
as	O
a	O
predictive	B-MED
index	B-MED
of	O
the	O
development	B-MED
of	O
a	O
PTSD	B-MED
-like	O
phenotype	B-MED
.	O
The	O
impact	B-MED
of	O
adjunctive	B-MED
guanfacine	B-MED
extended	B-MED
release	I-MED
on	O
stimulant	B-MED
adherence	B-MED
in	O
children	B-MED
/	O
adolescents	B-MED
with	O
attention	B-MED
-	I-MED
deficit	I-MED
/	O
hyperactivity	B-MED
disorder	I-MED
To	O
assess	O
stimulant	B-MED
adherence	B-MED
among	O
children	B-MED
/	O
adolescents	B-MED
with	O
attention	B-MED
-	I-MED
deficit	I-MED
/	O
hyperactivity	B-MED
disorder	I-MED
(	O
ADHD	B-MED
)	O
augmenting	B-MED
stimulants	I-MED
stimulants	B-MED
with	O
guanfacine	B-MED
extended	I-MED
-	I-MED
release	I-MED
(	O
GXR	B-MED
)	O
.	O
Inclusion	B-MED
criteria	I-MED
:	O
6	O
-	O
17	O
years	B-MED
,	O
≥1	O
ADHD	B-MED
diagnosis	B-MED
,	O
≥1	O
long	B-MED
-	I-MED
acting	I-MED
and/or	O
short	B-MED
-	I-MED
acting	I-MED
stimulant	I-MED
with	O
GXR	B-MED
augmentation	B-MED
.	O
Modified	B-MED
medication	I-MED
possession	I-MED
ratio	I-MED
(	O
mMPR	B-MED
;	O
days	B-MED
medication	B-MED
available	B-MED
/	O
days	B-MED
in	O
period	B-MED
,	O
excluding	B-MED
medication	B-MED
holidays	B-MED
)	O
was	O
assessed	O
;	O
mMPR	B-MED
<	O
0.80	O
nonadherent	B-MED
.	O
Regression	B-MED
models	B-MED
assessed	B-MED
change	B-MED
in	O
mMPR	B-MED
adjusting	B-MED
for	O
demographic	B-MED
and	O
clinical	B-MED
characteristics	I-MED
.	O
Among	O
patients	B-MED
nonadherent	B-MED
to	O
stimulants	B-MED
pre	B-MED
-	O
augmentation	B-MED
(	O
n	O
=	O
165	O
)	O
,	O
unadjusted	B-MED
mean	O
(	O
SD	B-MED
)	O
pre	B-MED
-	O
and	O
post	B-MED
-	O
stimulant	B-MED
mMPRs	B-MED
were	O
0.68	O
(	O
0.11	O
)	O
and	O
0.87	O
(	O
0.16	O
)	O
.	O
Adjusted	B-MED
mean	O
change	B-MED
in	O
mMPR	B-MED
was	O
0.20	O
for	O
long	B-MED
-	I-MED
acting	I-MED
versus	O
0.18	O
for	O
short	B-MED
-	I-MED
acting	I-MED
stimulants	I-MED
(	O
p	O
=	O
0.34	O
)	O
.	O
Among	O
patients	B-MED
nonadherent	B-MED
to	O
stimulants	B-MED
,	O
GXR	B-MED
augmentation	B-MED
was	O
associated	B-MED
with	I-MED
increased	B-MED
stimulant	B-MED
adherence	B-MED
.	O
Protein	B-MED
Design	B-MED
for	O
Nanostructural	B-MED
Engineering	I-MED
:	O
Concluding	O
Remarks	B-MED
and	O
Future	O
Directions	O
This	O
final	O
chapter	B-MED
aims	O
to	O
summarize	O
the	O
main	O
conclusions	B-MED
of	O
the	O
book	B-MED
and	O
to	O
point	O
to	O
possible	O
directions	O
for	O
further	O
research	B-MED
in	O
the	O
field	B-MED
of	O
protein	B-MED
design	B-MED
for	O
nanostructural	B-MED
engineering	I-MED
.	O
Even	O
though	O
this	O
research	B-MED
field	I-MED
is	O
still	O
at	O
its	O
infancy	O
,	O
multidisciplinary	B-MED
research	B-MED
efforts	I-MED
in	O
the	O
design	B-MED
of	O
synthetic	B-MED
protein	I-MED
-based	O
nanostructures	B-MED
and	O
functional	B-MED
materials	B-MED
have	O
resulted	O
in	O
significant	O
progress	B-MED
.	O
The	O
chapters	B-MED
in	O
this	O
book	B-MED
cover	O
several	O
selected	O
examples	B-MED
of	O
the	O
most	O
recent	O
advances	B-MED
concerning	O
the	O
use	B-MED
of	I-MED
proteins	B-MED
and	O
peptides	B-MED
as	O
building	B-MED
blocks	I-MED
for	O
the	O
fabrication	B-MED
of	O
architectures	B-MED
and	O
functional	B-MED
nanostructures	B-MED
,	O
assemblies	B-MED
,	O
and	O
materials	B-MED
.	O
Here	O
,	O
we	O
provide	O
a	O
general	O
overview	O
of	O
the	O
strategies	B-MED
that	O
can	O
be	O
employed	O
to	O
prepare	B-MED
functional	B-MED
protein	B-MED
-based	O
nanostructures	B-MED
,	O
and	O
nanostructured	B-MED
materials	I-MED
and	O
devices	B-MED
.	O
Finally	O
,	O
we	O
highlight	O
some	O
of	O
the	O
main	O
aspects	B-MED
to	O
be	O
considered	O
by	O
the	O
research	B-MED
community	B-MED
to	O
set	O
the	O
path	O
for	O
the	O
near	O
future	O
developments	B-MED
.	O
Direct	O
contact	O
with	O
perivascular	B-MED
tumor	B-MED
cells	I-MED
enhances	O
integrin	B-MED
αvβ3	I-MED
signaling	B-MED
and	O
migration	B-MED
of	O
endothelial	B-MED
cells	I-MED
The	O
secretion	B-MED
of	O
soluble	O
pro	B-MED
-	I-MED
angiogenic	I-MED
factors	I-MED
by	O
tumor	B-MED
cells	I-MED
and	O
stromal	B-MED
cells	I-MED
in	O
the	O
perivascular	B-MED
niche	O
promotes	O
the	O
aggressive	B-MED
angiogenesis	I-MED
that	O
is	O
typical	O
of	O
glioblastoma	B-MED
(	O
GBM	B-MED
)	O
.	O
Here	O
,	O
we	O
show	O
that	O
angiogenesis	B-MED
also	O
can	O
be	O
promoted	O
by	O
a	O
direct	O
interaction	O
between	O
brain	B-MED
tumor	B-MED
cells	I-MED
,	O
including	O
tumor	B-MED
cells	I-MED
with	O
cancer	B-MED
stem	I-MED
-like	O
properties	O
(	O
CSCs	B-MED
)	O
,	O
and	O
endothelial	B-MED
cells	I-MED
(	O
ECs	B-MED
)	O
.	O
As	O
shown	O
in	B-MED
vitro	I-MED
,	O
this	O
direct	O
interaction	O
is	O
mediated	O
by	O
binding	B-MED
of	O
integrin	B-MED
αvβ3	I-MED
expressed	B-MED
on	O
ECs	B-MED
to	O
the	O
RGD	B-MED
-	I-MED
peptide	I-MED
in	O
L1CAM	B-MED
expressed	B-MED
on	O
CSCs	B-MED
.	O
It	O
promotes	O
both	O
EC	B-MED
network	B-MED
formation	I-MED
and	O
enhances	O
directed	O
migration	B-MED
toward	O
basic	O
fibroblast	B-MED
growth	I-MED
factor	I-MED
.	O
Activation	B-MED
of	O
αvβ3	B-MED
and	O
bone	B-MED
marrow	I-MED
tyrosine	I-MED
kinase	I-MED
on	I-MED
chromosome	I-MED
X	I-MED
(	O
BMX	B-MED
)	O
is	O
required	O
for	O
migration	B-MED
stimulated	O
by	O
direct	O
binding	B-MED
but	O
not	O
for	O
migration	B-MED
stimulated	O
by	O
soluble	O
factors	O
.	O
RGD	B-MED
-	I-MED
peptide	I-MED
treatment	B-MED
of	O
mice	B-MED
with	O
established	O
intracerebral	B-MED
GBM	B-MED
xenografts	B-MED
significantly	O
reduced	O
the	O
percentage	O
of	O
Sox2	B-MED
-positive	O
tumor	B-MED
cells	I-MED
and	O
CSCs	B-MED
in	O
close	O
proximity	O
to	O
ECs	B-MED
,	O
decreased	O
integrin	B-MED
αvβ3	I-MED
and	O
BMX	B-MED
activation	O
and	O
p130CAS	B-MED
phosphorylation	B-MED
in	O
the	O
ECs	B-MED
,	O
and	O
reduced	O
the	O
vessel	B-MED
surface	B-MED
area	I-MED
.	O
These	O
results	O
reveal	O
a	O
previously	O
unrecognized	O
aspect	O
of	O
the	O
regulation	B-MED
of	O
angiogenesis	B-MED
in	O
GBM	B-MED
that	O
can	O
impact	O
therapeutic	B-MED
anti	B-MED
-	I-MED
angiogenic	I-MED
targeting	O
.	O
Targeted	B-MED
therapy	I-MED
in	O
gastric	B-MED
cancer	I-MED
Gastric	B-MED
cancer	I-MED
is	O
the	O
fourth	O
most	O
common	O
cancer	B-MED
worldwide	O
.	O
Surgery	B-MED
in	O
combination	O
with	O
multimodal	B-MED
therapy	I-MED
provides	O
the	O
only	O
curative	B-MED
therapy	I-MED
until	O
now	O
.	O
The	O
importance	O
of	O
targeted	B-MED
therapy	I-MED
became	O
clear	O
over	O
the	O
last	O
few	O
years	B-MED
.	O
Due	O
to	O
the	O
implication	B-MED
of	O
HER2	B-MED
and	O
angiogenesis	B-MED
-directed	O
targeted	B-MED
therapies	I-MED
major	O
advances	O
in	O
the	O
treatment	B-MED
of	O
gastric	B-MED
cancer	I-MED
could	O
be	O
reached	O
.	O
Nevertheless	O
,	O
benefits	O
in	O
survival	O
remain	O
unsatisfactory	O
and	O
the	O
development	O
of	O
resistance	B-MED
to	O
monoclonal	B-MED
antibodies	I-MED
is	O
arising	O
.	O
A	O
comprehensive	B-MED
and	O
comparative	B-MED
literature	B-MED
research	B-MED
was	O
performed	O
to	O
evaluate	B-MED
the	O
status	O
of	O
HER2	B-MED
and	O
angiogenesis	B-MED
-directed	O
targeted	B-MED
therapy	I-MED
in	O
gastric	B-MED
cancer	I-MED
.	O
Up	O
to	O
now	O
,	O
trastuzumab	B-MED
and	O
ramucirumab	B-MED
are	O
the	O
only	O
agents	B-MED
showing	O
remarkable	O
benefits	O
in	O
the	O
therapy	B-MED
for	O
the	O
patients	B-MED
suffering	O
from	O
gastric	B-MED
cancer	I-MED
.	O
The	O
limitations	O
of	O
targeted	B-MED
therapies	I-MED
in	O
gastric	B-MED
cancer	I-MED
are	O
mainly	O
associated	O
with	O
the	O
development	O
of	O
secondary	O
resistance	B-MED
.	O
Addition	O
of	O
targeted	B-MED
therapy	I-MED
in	O
second	B-MED
-	I-MED
line	I-MED
treatment	I-MED
is	O
beneficial	O
when	O
compared	O
with	O
chemotherapy	B-MED
alone	O
.	O
Nevertheless	O
,	O
results	B-MED
in	O
first	B-MED
-	I-MED
line	I-MED
treatment	I-MED
remain	O
modest	O
.	O
Therefore	O
,	O
new	O
therapeutic	B-MED
agents	I-MED
and	O
combinations	B-MED
in	O
the	O
first	B-MED
-	I-MED
line	I-MED
treatment	I-MED
of	O
gastric	B-MED
cancer	I-MED
are	O
urgently	O
needed	O
and	O
remain	O
to	O
be	O
validated	O
in	O
clinical	B-MED
trials	I-MED
.	O
Role	O
of	O
agonistic	B-MED
autoantibodies	I-MED
against	O
type-1	B-MED
angiotensin	I-MED
II	I-MED
receptor	I-MED
in	O
the	O
pathogenesis	B-MED
of	O
retinopathy	B-MED
in	O
preeclampsia	B-MED
To	O
investigate	B-MED
the	O
mechanism	B-MED
underlying	O
AT1	B-MED
-	I-MED
AA	I-MED
-induced	O
retinopathy	B-MED
in	O
severe	O
preeclampsia	B-MED
by	O
measuring	O
the	O
positive	B-MED
rate	I-MED
and	O
titer	B-MED
of	O
AT1	B-MED
-	I-MED
AA	I-MED
in	O
plasma	B-MED
from	O
women	B-MED
with	O
severe	B-MED
preeclampsia	I-MED
and	O
normal	O
pregnant	B-MED
women	I-MED
to	O
see	O
whether	O
AT1	B-MED
-	I-MED
AA	I-MED
titer	B-MED
was	O
correlated	B-MED
with	O
the	O
grade	O
of	O
retinopathy	B-MED
.	O
A	O
preeclampsia	B-MED
rat	B-MED
model	B-MED
was	O
also	O
established	O
by	O
intravenous	B-MED
injection	I-MED
of	O
AT1	B-MED
-	I-MED
AA	I-MED
extracted	O
from	O
the	O
plasma	B-MED
of	O
patient	B-MED
suffering	O
from	O
severe	B-MED
preeclampsia	I-MED
.	O
The	O
results	O
showed	O
that	O
the	O
plasma	B-MED
titer	B-MED
and	O
positive	B-MED
rate	I-MED
of	O
AT1	B-MED
-	I-MED
AA	I-MED
were	O
significantly	O
higher	O
in	O
women	B-MED
with	O
severe	B-MED
preeclampsia	I-MED
than	O
normal	O
pregnant	B-MED
women	I-MED
.	O
The	O
antibody	B-MED
titer	B-MED
in	O
cases	O
of	O
severe	O
preeclampsia	B-MED
was	O
associated	O
with	O
the	O
grade	O
of	O
retinopathy	B-MED
,	O
and	O
positively	O
correlated	B-MED
with	O
the	O
level	O
of	O
TNF	B-MED
-	I-MED
α	I-MED
and	O
VEGF	B-MED
.	O
The	O
animal	B-MED
experiment	I-MED
results	B-MED
showed	O
that	O
the	O
modeled	B-MED
rats	I-MED
presented	O
symptoms	B-MED
very	O
similar	O
to	O
symptoms	B-MED
of	O
human	B-MED
preeclampsia	B-MED
,	O
including	O
retinopathy	B-MED
.	O
Ocular	B-MED
fundus	I-MED
examination	B-MED
showed	O
retinal	B-MED
microvascular	I-MED
abnormalities	I-MED
,	O
hemorrhaging	B-MED
and	O
leakage	B-MED
in	O
the	O
severe	B-MED
preeclampsia	I-MED
.	O
Morphological	B-MED
changes	I-MED
included	O
edema	B-MED
,	O
thickening	B-MED
of	O
the	O
INL	B-MED
and	O
ONL	B-MED
,	O
and	O
pigment	B-MED
atrophy	I-MED
.	O
TNF	B-MED
-	I-MED
α	I-MED
and	O
VEGF	B-MED
levels	O
were	O
increased	O
in	O
the	O
vitreous	B-MED
humor	I-MED
and	O
retina	B-MED
of	O
the	O
model	B-MED
rats	I-MED
.	O
Our	O
studies	B-MED
results	B-MED
suggest	O
that	O
abnormal	B-MED
expression	I-MED
of	O
AT1	B-MED
-	I-MED
AA	I-MED
could	O
induce	O
damage	B-MED
to	O
retinal	B-MED
capillary	I-MED
endothelial	I-MED
cells	I-MED
and	O
increase	O
vascular	B-MED
permeability	I-MED
,	O
resulting	B-MED
in	I-MED
retinopathy	B-MED
.	O
miR-27b	B-MED
inhibits	B-MED
gastric	B-MED
cancer	I-MED
metastasis	B-MED
by	O
targeting	B-MED
NR2F2	B-MED
Increasing	B-MED
attention	B-MED
is	O
focused	O
on	O
the	O
down	B-MED
-	I-MED
regulation	I-MED
of	O
miRNAs	B-MED
in	O
cancer	B-MED
process	I-MED
.	O
Nuclear	B-MED
receptor	I-MED
subfamily	I-MED
2	I-MED
(	O
NR2F2	B-MED
,	O
also	O
known	O
as	O
COUP	B-MED
-	I-MED
TFII	I-MED
)	O
is	O
involved	B-MED
in	O
the	O
development	B-MED
of	O
many	O
types	B-MED
of	O
cancers	B-MED
,	O
but	O
its	O
role	B-MED
in	O
gastric	B-MED
cancer	I-MED
remains	O
elusive	O
.	O
In	O
this	O
experiment	B-MED
,	O
oncomine	B-MED
and	O
Kaplan	B-MED
-	I-MED
meier	I-MED
database	I-MED
revealed	B-MED
that	O
NR2F2	B-MED
was	O
up	B-MED
-	I-MED
regulated	I-MED
in	O
gastric	B-MED
cancer	I-MED
and	O
that	O
the	O
high	B-MED
NR2F2	B-MED
expression	B-MED
contributed	B-MED
to	O
poor	B-MED
survival	B-MED
.	O
MicroRNA-27b	B-MED
was	O
targeted	B-MED
and	O
down	B-MED
-	I-MED
regulated	I-MED
by	O
NR2F2	B-MED
in	O
human	B-MED
gastric	B-MED
cancer	I-MED
tissues	B-MED
and	O
cells	B-MED
.	O
The	O
ectopic	B-MED
expression	I-MED
of	O
miR-27b	B-MED
inhibited	B-MED
gastric	B-MED
cancer	I-MED
cell	B-MED
proliferation	I-MED
and	O
tumor	B-MED
growth	I-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
Assays	B-MED
suggested	B-MED
that	O
the	O
overexpression	B-MED
of	O
miR-27b	B-MED
could	O
promote	B-MED
MGC-803	B-MED
cells	I-MED
'	O
migration	B-MED
and	O
invasion	B-MED
and	O
retard	B-MED
their	O
metastasis	B-MED
to	O
the	O
liver	B-MED
.	O
In	O
addition	O
,	O
down	B-MED
-	I-MED
regulation	I-MED
of	O
miR-27b	B-MED
enhanced	O
GES-1	B-MED
cells	I-MED
'	O
proliferation	B-MED
and	O
metastasis	B-MED
in	B-MED
vitro	I-MED
.	O
These	O
findings	B-MED
reveal	B-MED
that	O
miR-27b	B-MED
is	O
a	O
tumor	B-MED
suppressor	I-MED
in	O
gastric	B-MED
cancer	I-MED
and	O
a	O
biomarker	B-MED
for	O
improving	B-MED
patients	B-MED
'	O
survival	B-MED
.	O
Vasopressin	B-MED
regulates	B-MED
the	I-MED
growth	I-MED
of	O
the	O
biliary	B-MED
epithelium	I-MED
in	O
polycystic	B-MED
liver	I-MED
disease	I-MED
The	O
neurohypophysial	B-MED
hormone	I-MED
arginine	B-MED
vasopressin	I-MED
(	O
AVP	B-MED
)	O
acts	O
by	O
three	O
distinct	O
receptor	B-MED
subtypes	O
:	O
V1a	B-MED
,	O
V1b	B-MED
,	O
and	O
V2	B-MED
.	O
In	O
the	O
liver	B-MED
,	O
AVP	B-MED
is	O
involved	B-MED
in	O
ureogenesis	B-MED
,	O
glycogenolysis	B-MED
,	O
neoglucogenesis	B-MED
and	O
regeneration	B-MED
.	O
No	O
data	O
exist	O
about	O
the	O
presence	B-MED
of	O
AVP	B-MED
in	O
the	O
biliary	B-MED
epithelium	I-MED
.	O
Cholangiocytes	B-MED
are	O
the	O
target	B-MED
cells	I-MED
in	O
a	O
number	O
of	O
animal	B-MED
models	I-MED
of	O
cholestasis	B-MED
,	O
including	O
bile	B-MED
duct	I-MED
ligation	B-MED
(	O
BDL	B-MED
)	O
,	O
and	O
in	O
several	O
human	B-MED
pathologies	B-MED
,	O
such	O
as	O
polycystic	B-MED
liver	I-MED
disease	I-MED
characterized	B-MED
by	O
the	O
presence	B-MED
of	O
cysts	B-MED
that	O
bud	O
from	O
the	O
biliary	B-MED
epithelium	I-MED
.	O
In	B-MED
vivo	I-MED
,	O
liver	B-MED
fragments	B-MED
from	O
normal	O
and	O
BDL	B-MED
mice	B-MED
and	O
rats	B-MED
as	O
well	O
as	O
liver	B-MED
samples	I-MED
from	O
normal	O
and	O
ADPKD	B-MED
patients	B-MED
were	O
collected	O
to	O
evaluate	O
:	O
(	O
i	O
)	O
intrahepatic	B-MED
bile	B-MED
duct	I-MED
mass	B-MED
by	O
immunohistochemistry	B-MED
for	O
cytokeratin-19	B-MED
;	O
and	O
(	O
ii	O
)	O
expression	B-MED
of	O
V1a	B-MED
,	O
V1b	B-MED
and	O
V2	B-MED
by	O
immunohistochemistry	B-MED
,	O
immunofluorescence	B-MED
and	O
real	B-MED
-	I-MED
time	I-MED
PCR	I-MED
.	O
In	B-MED
vitro	I-MED
,	O
small	O
and	O
large	O
mouse	B-MED
cholangiocytes	B-MED
,	O
H69	B-MED
(	O
non	B-MED
-	I-MED
malignant	I-MED
human	B-MED
cholangiocytes	B-MED
)	O
and	O
LCDE	B-MED
(	O
human	B-MED
cholangiocytes	B-MED
from	O
the	O
cystic	B-MED
epithelium	I-MED
)	O
were	O
stimulated	B-MED
with	O
vasopressin	B-MED
in	O
the	O
absence/	O
presence	B-MED
of	O
AVP	B-MED
antagonists	I-MED
such	O
as	O
OPC-31260	B-MED
and	O
Tolvaptan	B-MED
,	O
before	O
assessing	O
cellular	B-MED
growth	I-MED
by	O
MTT	B-MED
assay	I-MED
and	O
cAMP	B-MED
levels	O
.	O
Cholangiocytes	B-MED
express	O
V2	B-MED
receptor	I-MED
that	O
was	O
upregulated	B-MED
following	O
BDL	B-MED
and	O
in	O
ADPKD	B-MED
liver	B-MED
samples	I-MED
.	O
Administration	B-MED
of	O
AVP	B-MED
increased	B-MED
proliferation	B-MED
and	O
cAMP	B-MED
levels	O
of	O
small	O
cholangiocytes	B-MED
and	O
LCDE	B-MED
cells	I-MED
.	O
We	O
found	O
no	B-MED
effect	I-MED
in	O
the	O
proliferation	B-MED
of	O
large	O
mouse	B-MED
cholangiocytes	B-MED
and	O
H69	B-MED
cells	I-MED
.	O
Increases	B-MED
were	O
blocked	B-MED
by	O
preincubation	B-MED
with	O
the	O
AVP	B-MED
antagonists	I-MED
.	O
These	O
results	B-MED
showed	O
that	O
AVP	B-MED
and	O
its	O
receptors	B-MED
may	O
be	O
important	O
in	O
the	O
modulation	B-MED
of	O
the	O
proliferation	B-MED
rate	I-MED
of	O
the	O
biliary	B-MED
epithelium	I-MED
.	O
HOST	B-MED
IMMUNE	B-MED
RECOGNITION	I-MED
OF	O
THE	O
EPIDEMIC	B-MED
CYSTIC	B-MED
FIBROSIS	I-MED
PATHOGEN	B-MED
BURKHOLDERIA	B-MED
DOLOSA	I-MED
Burkholderia	B-MED
dolosa	I-MED
caused	O
an	O
outbreak	O
in	O
the	O
cystic	B-MED
fibrosis	I-MED
(	O
CF	B-MED
)	O
clinic	O
at	O
Boston	B-MED
Children	I-MED
's	I-MED
Hospital	I-MED
from	O
1998	O
to	O
2005	O
and	O
led	O
to	O
the	O
infection	B-MED
of	O
over	O
40	O
patients	B-MED
,	O
many	O
of	O
whom	O
died	B-MED
due	O
to	O
complications	B-MED
from	O
infection	B-MED
by	O
this	O
organism	B-MED
.	O
To	O
assess	O
whether	O
B.	B-MED
dolosa	I-MED
significantly	O
contributes	O
to	O
disease	B-MED
or	O
is	O
recognized	O
by	O
the	O
host	B-MED
immune	B-MED
response	I-MED
,	O
mice	B-MED
were	O
infected	B-MED
with	O
a	O
sequenced	O
outbreak	O
B.	B-MED
dolosa	I-MED
strain	I-MED
,	O
AU0158	B-MED
,	O
and	O
responses	B-MED
compared	O
to	O
the	O
well	O
-	O
studied	O
CF	B-MED
pathogen	B-MED
,	O
Pseudomonas	B-MED
aeruginosa	I-MED
In	O
parallel	O
,	O
mice	B-MED
were	O
also	O
infected	B-MED
with	O
a	O
polar	O
flagellin	B-MED
mutant	B-MED
of	O
B.	B-MED
dolosa	I-MED
to	O
examine	O
the	O
role	O
of	O
flagella	B-MED
in	O
B.	B-MED
dolosa	I-MED
lung	B-MED
colonization	B-MED
.	O
The	O
results	O
showed	O
a	O
higher	B-MED
persistence	B-MED
in	O
the	O
host	B-MED
by	O
B.	B-MED
dolosa	I-MED
strains	I-MED
and	O
yet	O
neutrophil	B-MED
recruitment	O
and	O
cytokine	B-MED
production	B-MED
were	O
lower	O
compared	O
to	O
P.	B-MED
aeruginosa	I-MED
The	O
ability	O
of	O
host	B-MED
immune	B-MED
cells	I-MED
to	O
recognize	O
B.	B-MED
dolosa	I-MED
was	O
then	O
assessed	O
and	O
B.	B-MED
dolosa	I-MED
induced	O
a	O
robust	O
cytokine	B-MED
response	O
in	O
cultured	B-MED
cells	I-MED
and	O
this	O
effect	O
was	O
dependent	O
on	O
the	O
flagella	B-MED
only	O
when	O
bacteria	B-MED
were	O
dead	B-MED
.	O
Together	O
,	O
these	O
results	O
suggest	O
that	O
B.	B-MED
dolosa	I-MED
can	O
be	O
recognized	O
by	O
host	B-MED
cells	I-MED
in	B-MED
vitro	I-MED
but	O
may	O
avoid	O
or	O
suppress	B-MED
the	O
host	B-MED
immune	B-MED
response	I-MED
in	B-MED
vivo	I-MED
through	O
unknown	O
mechanisms	O
.	O
B.	B-MED
dolosa	I-MED
was	O
then	O
compared	O
to	O
other	O
Burkholderia	B-MED
species	I-MED
and	O
found	O
to	O
induce	O
similar	O
levels	O
of	O
cytokine	B-MED
production	B-MED
despite	O
being	O
internalized	O
by	O
macrophages	B-MED
more	O
than	O
B.	B-MED
cenocepacia	I-MED
strains	I-MED
.	O
These	O
data	B-MED
suggest	O
that	O
B.	B-MED
dolosa	I-MED
AU0158	I-MED
may	O
act	O
differently	O
with	O
host	B-MED
cells	I-MED
and	O
is	O
it	O
recognized	O
differently	O
by	O
immune	B-MED
systems	I-MED
compared	O
other	O
Burkholderia	B-MED
strains	I-MED
or	O
species	B-MED
.	O
Crude	B-MED
4	B-MED
-	I-MED
methylcyclohexanemethanol	I-MED
(	O
MCHM	B-MED
)	O
did	O
not	O
cause	B-MED
skin	B-MED
irritation	I-MED
in	O
humans	B-MED
in	O
48	B-MED
-	I-MED
h	I-MED
patch	B-MED
test	I-MED
Crude	B-MED
4	B-MED
-	I-MED
methylcyclohexanemethanol	I-MED
(	O
MCHM	B-MED
)	O
is	O
an	O
industrial	B-MED
chemical	B-MED
used	O
to	O
wash	B-MED
and	O
clean	B-MED
coal	B-MED
.	O
On	O
January	O
9th	O
,	O
2014	O
approximately	O
10,000	B-MED
gallons	I-MED
of	O
a	O
mixture	B-MED
containing	O
crude	B-MED
MCHM	B-MED
were	O
released	O
into	O
the	O
Elk	B-MED
River	I-MED
near	O
Charleston	B-MED
,	O
West	B-MED
Virginia	I-MED
,	O
contaminating	B-MED
the	O
local	B-MED
water	B-MED
supply	I-MED
.	O
Following	O
the	O
spill	B-MED
,	O
residents	B-MED
reported	B-MED
numerous	B-MED
health	B-MED
complaints	I-MED
,	O
and	O
sought	O
medical	B-MED
attention	I-MED
for	O
ailments	B-MED
including	O
rashes	B-MED
and	O
itching	B-MED
.	O
The	O
relationship	B-MED
between	O
the	O
complaints	B-MED
and	O
the	O
spill	B-MED
were	O
unknown	O
,	O
as	O
such	O
symptoms	B-MED
are	O
reported	B-MED
frequently	B-MED
in	O
the	O
background	O
.	O
In	O
this	O
study	B-MED
,	O
the	O
primary	B-MED
irritation	B-MED
potential	B-MED
of	O
crude	B-MED
MCHM	B-MED
was	O
evaluated	B-MED
in	O
206	O
individuals	B-MED
who	O
underwent	O
48	B-MED
hour	I-MED
semi	B-MED
-	I-MED
occluded	I-MED
patch	B-MED
testing	I-MED
.	O
MCHM	B-MED
concentrations	B-MED
assessed	O
in	O
this	O
study	B-MED
were	O
1	O
,	O
5	O
,	O
15	O
,	O
and	O
100	O
ppm	O
.	O
No	O
appreciable	O
skin	B-MED
reactions	I-MED
were	O
observed	O
in	O
individuals	B-MED
at	O
any	O
concentration	B-MED
.	O
Three	O
of	O
the	O
five	O
concentrations	B-MED
evaluated	B-MED
were	O
above	O
the	O
highest	O
measured	B-MED
concentration	I-MED
of	O
MCHM	B-MED
in	O
the	O
tap	B-MED
water	I-MED
of	O
residents	B-MED
in	O
West	B-MED
Virginia	I-MED
(	O
3.7	O
ppm	O
)	O
.	O
The	O
results	B-MED
of	O
this	O
study	B-MED
suggest	O
that	O
crude	B-MED
MCHM	B-MED
would	O
not	O
be	O
a	O
dermal	B-MED
irritant	B-MED
for	O
the	O
vast	O
majority	O
,	O
if	O
not	O
all	O
,	O
potentially	O
exposed	O
persons	B-MED
at	O
the	O
concentrations	B-MED
in	O
the	O
water	B-MED
reported	B-MED
after	O
the	O
spill	B-MED
.	O
Renal	B-MED
arterial	I-MED
mycotic	I-MED
aneurysm	I-MED
after	O
kidney	B-MED
transplantation	I-MED
Mycotic	B-MED
aneurysm	I-MED
is	O
a	O
rare	O
condition	O
mostly	O
attributable	B-MED
to	O
Candida	B-MED
or	O
Aspergillus	B-MED
species	I-MED
.	O
About	O
20	O
cases	O
of	O
Candida	B-MED
-related	O
arteritis	B-MED
have	O
been	O
reported	O
in	O
kidney	B-MED
transplant	I-MED
patients	B-MED
.	O
Herein	O
,	O
we	O
report	B-MED
the	O
case	O
of	O
a	O
40	O
-	O
year-	O
old	O
man	O
who	O
received	O
a	O
kidney	B-MED
from	O
a	O
deceased	O
donor	B-MED
in	O
whom	O
an	O
accidental	B-MED
digestive	B-MED
wound	I-MED
was	O
made	O
during	O
organ	B-MED
retrieval	I-MED
.	O
He	O
presented	O
with	O
sudden	O
anuria	B-MED
47	O
days	O
after	O
renal	B-MED
transplantation	I-MED
revealing	O
a	O
large	O
mycotic	B-MED
aneurysm	I-MED
of	O
the	O
kidney	B-MED
graft	I-MED
renal	B-MED
artery	I-MED
.	O
Organs	B-MED
derived	O
from	O
donors	B-MED
in	O
whom	O
a	O
digestive	B-MED
breach	I-MED
is	O
noticed	O
should	O
be	O
used	B-MED
with	I-MED
caution	I-MED
.	O
Bone	B-MED
extracellular	B-MED
matrix	I-MED
hydrogel	B-MED
enhances	O
osteogenic	B-MED
differentiation	I-MED
of	O
C2C12	B-MED
myoblasts	I-MED
and	O
mouse	B-MED
primary	O
calvarial	B-MED
cells	B-MED
Hydrogel	B-MED
scaffolds	I-MED
derived	O
from	O
the	O
extracellular	B-MED
matrix	I-MED
(	O
ECM	B-MED
)	O
of	O
mammalian	B-MED
tissues	I-MED
have	O
been	O
successfully	O
used	O
to	O
promote	O
tissue	B-MED
repair	I-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
The	O
objective	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	O
the	O
osteogenic	B-MED
potential	I-MED
of	O
ECM	B-MED
hydrogels	B-MED
prepared	O
from	O
demineralized	B-MED
and	O
decellularized	B-MED
bovine	I-MED
bone	I-MED
in	O
the	O
presence	O
and	O
absence	O
of	O
osteogenic	B-MED
medium	I-MED
.	O
Culture	B-MED
of	O
C2C12	B-MED
and	O
mouse	B-MED
primary	O
calvarial	B-MED
cells	B-MED
(	O
mPCs	B-MED
)	O
on	O
decellularized	B-MED
bone	I-MED
ECM	I-MED
(	O
bECM	B-MED
)	O
and	O
demineralized	B-MED
bone	I-MED
matrix	I-MED
(	O
DBM	B-MED
)	O
gels	B-MED
resulted	O
in	O
increased	O
expression	B-MED
of	O
osteogenic	B-MED
gene	I-MED
markers	I-MED
,	O
including	O
a	O
3.6-	O
and	O
13.4	O
-	O
fold	O
increase	O
in	O
osteopontin	B-MED
and	O
15.7-	O
and	O
27.1	O
-	O
fold	O
increase	O
in	O
osteocalcin	B-MED
when	O
mPCs	B-MED
were	O
cultured	B-MED
upon	O
bECM	B-MED
with	O
basal	B-MED
and	O
osteogenic	B-MED
media	I-MED
,	O
respectively	O
.	O
bECM	B-MED
hydrogels	B-MED
stimulated	O
the	O
osteogenic	B-MED
differentiation	I-MED
of	O
C2C12	B-MED
and	O
mPCs	B-MED
even	O
in	O
the	O
absence	O
of	O
osteogenic	B-MED
medium	I-MED
.	O
These	O
results	O
suggest	O
that	O
bECM	B-MED
hydrogel	B-MED
scaffolds	I-MED
may	O
have	O
great	O
utility	O
in	O
future	O
clinical	B-MED
applications	B-MED
for	O
bone	B-MED
tissue	B-MED
engineering	I-MED
.	O
©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc.	O
J	O
Biomed	O
Mater	O
Res	O
Part	O
B	O
:	O
Appl	O
Biomater	O
,	O
2017	O
.	O
Social	B-MED
capital	I-MED
and	O
healthy	B-MED
ageing	B-MED
in	O
Indonesia	B-MED
A	O
large	B-MED
international	B-MED
literature	B-MED
has	O
found	O
a	O
positive	B-MED
association	B-MED
between	O
social	B-MED
capital	I-MED
and	O
measures	B-MED
of	O
physical	B-MED
and	O
mental	B-MED
health	I-MED
.	O
However	O
,	O
there	O
is	O
a	O
paucity	O
of	O
research	B-MED
on	O
the	O
links	B-MED
between	O
social	B-MED
capital	I-MED
and	O
healthy	B-MED
ageing	B-MED
in	O
a	O
developing	B-MED
country	I-MED
environment	B-MED
,	O
where	O
universal	B-MED
social	I-MED
security	I-MED
coverage	I-MED
is	O
absent	B-MED
and	O
health	B-MED
infrastructure	I-MED
is	O
poor	B-MED
.	O
In	O
this	O
paper	O
,	O
we	O
develop	O
and	O
empirically	O
test	B-MED
a	O
model	B-MED
of	O
the	O
linkages	B-MED
between	O
social	B-MED
capital	I-MED
and	O
the	O
health	B-MED
outcomes	I-MED
for	O
older	B-MED
adults	I-MED
in	O
Indonesia	B-MED
,	O
using	O
data	B-MED
from	O
the	O
Indonesian	B-MED
Family	I-MED
Life	I-MED
Survey	I-MED
-	I-MED
East	I-MED
(	O
IFLS	B-MED
-	I-MED
East	I-MED
)	O
,	O
conducted	O
in	O
2012	O
.	O
Using	O
multivariate	B-MED
regression	I-MED
analysis	I-MED
,	O
we	O
examine	O
whether	O
social	B-MED
capital	I-MED
plays	O
a	O
role	B-MED
in	O
mitigating	B-MED
poor	B-MED
health	I-MED
among	O
older	B-MED
individuals	B-MED
aged	B-MED
50	O
years	B-MED
and	O
above	O
in	O
Indonesia	B-MED
's	O
most	O
vulnerable	B-MED
provinces	I-MED
.	O
We	O
test	B-MED
the	O
robustness	B-MED
of	O
these	O
social	B-MED
capital	I-MED
variables	B-MED
across	O
different	O
health	B-MED
measures	B-MED
(	O
self	B-MED
-	I-MED
assessed	I-MED
health	B-MED
,	O
Activities	B-MED
of	I-MED
Daily	I-MED
Living	I-MED
(	O
ADL	B-MED
)	O
,	O
measures	B-MED
of	O
chronic	B-MED
illness	I-MED
and	O
mental	B-MED
health	I-MED
measures	B-MED
)	O
,	O
as	O
well	O
as	O
across	O
different	O
demographic	B-MED
groups	B-MED
,	O
after	O
controlling	B-MED
for	O
an	O
array	B-MED
of	O
socio	B-MED
-	I-MED
economic	I-MED
,	O
demographic	B-MED
and	O
geographic	B-MED
characteristics	B-MED
.	O
Our	O
findings	B-MED
show	O
that	O
access	B-MED
to	O
better	O
social	B-MED
capital	I-MED
(	O
using	O
measures	B-MED
of	O
neighbourhood	B-MED
trust	B-MED
and	O
community	B-MED
participation	I-MED
)	O
is	O
associated	B-MED
with	I-MED
a	O
higher	B-MED
degree	B-MED
of	O
physical	B-MED
mobility	I-MED
,	O
independence	B-MED
,	O
and	O
mental	B-MED
well	I-MED
-	I-MED
being	I-MED
among	O
older	B-MED
individuals	B-MED
but	O
has	O
no	O
influence	B-MED
on	O
chronic	B-MED
illnesses	I-MED
.	O
These	O
results	B-MED
are	O
consistent	B-MED
when	O
we	O
estimate	B-MED
samples	B-MED
disaggregated	O
by	O
gender	B-MED
,	O
rural	B-MED
/	O
urban	B-MED
residence	B-MED
,	O
and	O
by	O
age	B-MED
categories	B-MED
.	O
From	O
a	O
policy	B-MED
perspective	O
these	O
results	B-MED
point	O
to	O
the	O
importance	O
of	O
social	B-MED
capital	I-MED
measures	B-MED
in	O
moderating	B-MED
the	O
influence	B-MED
of	O
poor	B-MED
health	I-MED
,	O
particularly	O
in	O
the	O
Activities	B-MED
of	I-MED
Daily	I-MED
Living	I-MED
.	O
Comparing	B-MED
Time	B-MED
Perception	I-MED
among	O
Morphine	B-MED
-	O
Derived	B-MED
Drugs	B-MED
Addicts	B-MED
and	O
Controls	B-MED
The	O
aim	B-MED
of	O
the	O
present	O
study	B-MED
is	O
to	O
compare	B-MED
time	B-MED
perception	I-MED
among	O
drug	B-MED
addicts	I-MED
and	O
controls	B-MED
.	O
30	O
drug	B-MED
addicts	I-MED
were	O
selected	B-MED
,	O
and	O
30	O
non	B-MED
-	I-MED
addict	I-MED
individuals	I-MED
were	O
selected	B-MED
as	O
the	O
control	B-MED
group	I-MED
.	O
The	O
two	O
groups	B-MED
performed	O
three	O
tests	B-MED
of	O
time	B-MED
reproduction	B-MED
,	O
time	B-MED
estimation	I-MED
,	O
and	O
time	B-MED
discrimination	B-MED
.	O
There	O
was	O
a	O
significant	B-MED
difference	B-MED
between	O
the	O
addicts	B-MED
group	B-MED
and	O
the	O
control	B-MED
group	I-MED
regarding	O
the	O
error	B-MED
of	O
time	B-MED
reproduction	B-MED
and	O
time	B-MED
estimation	I-MED
.	O
The	O
addict	B-MED
group	B-MED
in	O
comparison	B-MED
to	O
the	O
control	B-MED
group	I-MED
had	O
a	O
lower	B-MED
under-	O
reproduction	B-MED
and	O
a	O
higher	B-MED
over-	O
reproduction	B-MED
error	B-MED
,	O
and	O
also	O
a	O
lower	B-MED
under-	O
estimation	B-MED
and	O
higher	B-MED
over-	O
estimation	B-MED
error	B-MED
.	O
However	O
,	O
regarding	O
time	B-MED
discrimination	B-MED
,	O
no	O
significant	B-MED
difference	B-MED
was	O
observed	O
between	O
the	O
errors	B-MED
committed	O
by	O
both	O
groups	B-MED
.	O
On	O
the	O
other	O
hand	O
,	O
when	O
showing	O
images	B-MED
of	O
drug	B-MED
consumption	I-MED
tools	B-MED
and	O
normal	B-MED
images	B-MED
with	O
same	O
durations	B-MED
,	O
the	O
normal	B-MED
group	B-MED
believed	O
that	O
the	O
images	B-MED
related	O
to	O
drug	B-MED
consumption	I-MED
tools	B-MED
were	O
shown	O
for	O
a	O
shorter	B-MED
period	B-MED
of	O
time	B-MED
.	O
Time	B-MED
perception	I-MED
is	O
different	B-MED
between	O
morphine	B-MED
-	O
derived	B-MED
drugs	B-MED
addicts	B-MED
and	O
controls	B-MED
.	O
Pancreatic	B-MED
neuroendocrine	B-MED
cancer	I-MED
with	O
liver	B-MED
metastases	I-MED
and	O
multiple	B-MED
peritoneal	I-MED
metastases	I-MED
:	O
report	O
of	O
one	O
case	O
Pancreatic	B-MED
neuroendocrine	B-MED
tumor	I-MED
(	O
pNET	B-MED
)	O
is	O
a	O
rare	O
pancreatic	B-MED
tumor	I-MED
,	O
with	O
its	O
incidence	O
showing	O
a	O
rising	O
trend	O
in	O
recent	O
years	O
.	O
Most	O
of	O
its	O
distant	B-MED
metastases	I-MED
are	O
found	B-MED
in	O
the	O
liver	B-MED
.	O
This	O
article	O
describes	O
a	O
59	O
-	O
year	O
-	O
old	O
male	B-MED
patient	I-MED
with	O
pNET	B-MED
with	O
liver	B-MED
metastasis	I-MED
and	O
multiple	B-MED
abdominal	I-MED
metastases	I-MED
,	O
focusing	O
on	O
the	O
management	B-MED
of	O
this	O
tumor	B-MED
in	O
its	O
advanced	B-MED
stage	I-MED
.	O
Intestinal	B-MED
micropatches	B-MED
for	O
oral	B-MED
insulin	B-MED
delivery	I-MED
Diabetes	B-MED
mellitus	I-MED
has	O
become	O
a	O
major	O
public	B-MED
health	I-MED
issue	I-MED
that	O
has	O
almost	O
reached	O
epidemic	B-MED
proportions	I-MED
worldwide	O
.	O
Injectable	B-MED
insulin	I-MED
has	O
been	O
typically	O
utilized	O
for	O
the	O
management	B-MED
of	O
this	O
chronic	B-MED
disease	I-MED
.	O
However	O
,	O
lack	B-MED
of	I-MED
patient	I-MED
compliance	I-MED
with	O
injectable	B-MED
formulations	B-MED
has	O
spurred	O
the	O
development	O
of	O
oral	B-MED
insulin	B-MED
formulations	B-MED
,	O
which	O
although	O
appealing	O
,	O
face	O
several	O
delivery	B-MED
challenges	B-MED
.	O
We	O
have	O
developed	O
novel	O
mucoadhesive	B-MED
intestinal	B-MED
patches	B-MED
,	O
several	O
hundred	O
micrometers	B-MED
in	O
dimension	B-MED
(	O
micropatches	B-MED
)	O
that	O
address	O
the	O
challenges	B-MED
of	O
oral	B-MED
insulin	B-MED
delivery	I-MED
.	O
The	O
micropatches	B-MED
adhere	B-MED
to	O
the	O
intestinal	B-MED
mucosa	I-MED
,	O
release	O
their	O
drug	B-MED
load	O
rapidly	B-MED
within	O
30	O
min	O
and	O
are	O
effective	B-MED
in	O
lowering	B-MED
blood	I-MED
glucose	I-MED
levels	I-MED
in	B-MED
vivo	I-MED
.	O
When	O
insulin	B-MED
-loaded	O
micropatches	B-MED
were	O
administered	B-MED
with	O
a	O
permeation	B-MED
enhancer	I-MED
and	O
protease	B-MED
inhibitor	I-MED
,	O
a	O
peak	B-MED
efficacy	B-MED
of	O
34	O
%	O
drop	B-MED
in	I-MED
blood	I-MED
glucose	I-MED
levels	I-MED
was	O
observed	O
within	O
3	O
h.	O
Efficacy	B-MED
further	O
improved	O
to	O
41	O
%	O
when	O
micropatches	B-MED
were	O
administered	B-MED
in	O
multiple	B-MED
doses	I-MED
.	O
Here	O
,	O
we	O
describe	O
the	O
design	O
of	O
micropatches	B-MED
as	O
an	O
oral	B-MED
insulin	B-MED
formulation	B-MED
and	O
report	O
their	O
in	B-MED
vivo	I-MED
efficacy	B-MED
.	O
Do	O
dynamic	B-MED
global	I-MED
vegetation	I-MED
models	I-MED
capture	O
the	O
seasonality	B-MED
of	O
carbon	B-MED
fluxes	I-MED
in	O
the	O
Amazon	B-MED
basin	I-MED
?	O
A	O
data	B-MED
-	O
model	B-MED
intercomparison	B-MED
To	O
predict	O
forest	B-MED
response	B-MED
to	O
long	B-MED
-	I-MED
term	I-MED
climate	B-MED
change	I-MED
with	O
high	O
confidence	O
requires	O
that	O
dynamic	B-MED
global	I-MED
vegetation	I-MED
models	I-MED
(	O
DGVMs	B-MED
)	O
be	O
successfully	O
tested	O
against	O
ecosystem	B-MED
response	B-MED
to	O
short	B-MED
-	I-MED
term	I-MED
variations	B-MED
in	O
environmental	B-MED
drivers	I-MED
,	O
including	O
regular	O
seasonal	B-MED
patterns	I-MED
.	O
Here	O
,	O
we	O
used	O
an	O
integrated	O
dataset	B-MED
from	O
four	O
forests	B-MED
in	O
the	O
Brasil	B-MED
flux	I-MED
network	I-MED
,	O
spanning	O
a	O
range	O
of	O
dry	B-MED
-	I-MED
season	I-MED
intensities	B-MED
and	O
lengths	B-MED
,	O
to	O
determine	O
how	O
well	O
four	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
models	B-MED
(	O
IBIS	B-MED
,	O
ED2	B-MED
,	O
JULES	B-MED
,	O
and	O
CLM3.5	B-MED
)	O
simulated	O
the	O
seasonality	B-MED
of	O
carbon	B-MED
exchanges	I-MED
in	O
Amazonian	B-MED
tropical	B-MED
forests	I-MED
.	O
We	O
found	O
that	O
most	O
DGVMs	B-MED
poorly	O
represented	O
the	O
annual	O
cycle	O
of	O
gross	B-MED
primary	I-MED
productivity	I-MED
(	O
GPP	B-MED
)	O
,	O
of	O
photosynthetic	B-MED
capacity	I-MED
(	O
Pc	B-MED
)	O
,	O
and	O
of	O
other	O
fluxes	B-MED
and	O
pools	O
.	O
Models	B-MED
simulated	O
consistent	O
dry	B-MED
-	I-MED
season	I-MED
declines	B-MED
in	O
GPP	B-MED
in	O
the	O
equatorial	B-MED
Amazon	I-MED
(	O
Manaus	B-MED
K34	I-MED
,	O
Santarem	B-MED
K67	I-MED
,	O
and	O
Caxiuanã	B-MED
CAX	I-MED
)	O
;	O
a	O
contrast	O
to	O
observed	O
GPP	B-MED
increases	O
.	O
Model	B-MED
simulated	O
dry	B-MED
-	I-MED
season	I-MED
GPP	B-MED
reductions	B-MED
were	O
driven	O
by	O
an	O
external	O
environmental	B-MED
factor	B-MED
,	O
'	O
soil	B-MED
water	I-MED
stress	I-MED
'	O
and	O
consequently	O
by	O
a	O
constant	O
or	O
decreasing	O
photosynthetic	B-MED
infrastructure	I-MED
(	O
Pc	B-MED
)	O
,	O
while	O
observed	O
dry	B-MED
-	I-MED
season	I-MED
GPP	B-MED
resulted	O
from	O
a	O
combination	O
of	O
internal	O
biological	B-MED
(	O
leaf	B-MED
-flush	O
and	O
abscission	B-MED
and	O
increased	O
Pc	B-MED
)	O
and	O
environmental	B-MED
(	O
incoming	O
radiation	B-MED
)	O
causes	O
.	O
Moreover	O
,	O
we	O
found	O
models	B-MED
generally	O
overestimated	O
observed	O
seasonal	O
net	B-MED
ecosystem	I-MED
exchange	I-MED
(	O
NEE	B-MED
)	O
and	O
respiration	B-MED
(	O
Re	B-MED
)	O
at	O
equatorial	O
locations	O
.	O
In	O
contrast	O
,	O
a	O
southern	B-MED
Amazon	I-MED
forest	B-MED
(	O
Jarú	O
RJA	O
)	O
exhibited	O
dry	B-MED
-	I-MED
season	I-MED
declines	B-MED
in	O
GPP	B-MED
and	O
Re	B-MED
consistent	O
with	O
most	O
DGVMs	B-MED
simulations	B-MED
.	O
While	O
water	O
limitation	O
was	O
represented	O
in	O
models	B-MED
and	O
the	O
primary	O
driver	O
of	O
seasonal	O
photosynthesis	B-MED
in	O
southern	B-MED
Amazonia	I-MED
,	O
changes	O
in	O
internal	O
biophysical	B-MED
processes	I-MED
,	O
light	B-MED
-	I-MED
harvesting	I-MED
adaptations	B-MED
(	O
e.g.	O
,	O
variations	O
in	O
leaf	B-MED
area	I-MED
index	I-MED
(	O
LAI	B-MED
)	O
and	O
increasing	O
leaf	B-MED
-level	O
assimilation	B-MED
rate	B-MED
related	O
to	O
leaf	B-MED
demography	I-MED
)	O
,	O
and	O
allocation	O
lags	O
between	O
leaf	B-MED
and	O
wood	B-MED
,	O
dominated	O
equatorial	B-MED
Amazon	I-MED
carbon	B-MED
flux	I-MED
dynamics	O
and	O
were	O
deficient	O
or	O
absent	O
from	O
current	O
model	B-MED
formulations	O
.	O
Correctly	O
simulating	O
flux	B-MED
seasonality	B-MED
at	O
tropical	B-MED
forests	I-MED
requires	O
a	O
greater	O
understanding	O
and	O
the	O
incorporation	O
of	O
internal	O
biophysical	B-MED
mechanisms	I-MED
in	O
future	O
model	B-MED
developments	I-MED
.	O
Stem	B-MED
cell	I-MED
registry	B-MED
programme	B-MED
for	O
patients	B-MED
with	O
ischemic	B-MED
cardiomyopathy	I-MED
undergoing	O
coronary	B-MED
artery	I-MED
bypass	I-MED
grafting	I-MED
:	O
what	O
benefits	B-MED
does	O
it	O
derive	O
?	O
Standardization	B-MED
of	O
stem	B-MED
cell	I-MED
therapy	I-MED
requires	O
application	O
of	O
appropriate	O
methods	B-MED
to	O
evaluate	B-MED
safety	B-MED
and	I-MED
efficac	I-MED
y	O
,	O
including	O
long	B-MED
-	I-MED
term	I-MED
pharmacovigilance	B-MED
.	O
To	O
accomplish	O
this	O
objective	B-MED
,	O
a	O
long	B-MED
-	I-MED
term	I-MED
registry	B-MED
programme	I-MED
was	O
installed	O
.	O
We	O
analysed	O
150	O
patients	B-MED
with	O
ischemic	B-MED
cardiomyopathy	I-MED
,	O
who	O
received	B-MED
intramyocardial	B-MED
CD133	B-MED
+	I-MED
bone	I-MED
marrow	I-MED
mononuclear	I-MED
stem	I-MED
cell	I-MED
treatment	B-MED
combined	B-MED
with	O
coronary	B-MED
artery	I-MED
bypass	I-MED
grafting	I-MED
(	O
CABG	B-MED
)	O
or	O
CABG	B-MED
alone	B-MED
.	O
The	O
mortality	B-MED
rate	I-MED
,	O
major	B-MED
adverse	B-MED
cerebral	I-MED
and	O
cardiac	B-MED
events	I-MED
,	O
and	O
functional	O
outcome	O
parameters	O
were	O
evaluated	B-MED
for	O
the	O
time	B-MED
period	I-MED
up	O
to	O
14	O
years	O
follow	B-MED
-	I-MED
up	I-MED
.	O
As	O
a	O
result	O
,	O
we	O
have	O
stratified	B-MED
the	O
patient	B-MED
population	B-MED
(	O
96	O
patients	B-MED
)	O
into	O
responders	B-MED
and	O
non	B-MED
-	I-MED
responders	I-MED
.	O
Furthermore	O
,	O
the	O
analysis	B-MED
of	O
relevant	B-MED
predictors	B-MED
of	O
good	B-MED
response	I-MED
to	O
CD133	B-MED
+	I-MED
bone	I-MED
marrow	I-MED
mononuclear	I-MED
stem	I-MED
cell	I-MED
treatment	B-MED
was	O
performed	B-MED
.	O
Several	B-MED
positive	O
tendencies	O
related	O
to	O
stem	B-MED
cells	I-MED
transplantation	I-MED
were	O
demonstrated	O
.	O
First	O
,	O
no	B-MED
significant	I-MED
difference	B-MED
in	O
major	B-MED
adverse	B-MED
cardiovascular	I-MED
and	O
cerebral	B-MED
events	I-MED
was	O
observed	B-MED
between	O
stem	B-MED
cell	I-MED
and	O
control	B-MED
group	I-MED
up	O
to	O
14	O
years	O
follow	B-MED
-	I-MED
up	I-MED
.	O
Second	O
,	O
an	O
improvement	B-MED
of	O
left	B-MED
ventricle	I-MED
ejection	I-MED
fraction	I-MED
(	O
LVEF	B-MED
)	O
in	O
stem	B-MED
cell	I-MED
group	B-MED
retained	B-MED
for	O
5	O
years	O
in	O
contrast	B-MED
with	O
CABG	B-MED
-	O
only	B-MED
group	B-MED
,	O
where	O
no	O
significant	O
changes	O
in	O
LVEF	B-MED
after	O
2	O
years	O
were	O
observed	O
.	O
In	O
addition	O
,	O
LVEF	B-MED
under	O
30	O
%	O
and	O
left	B-MED
ventricle	I-MED
end	I-MED
diastolic	I-MED
diameter	I-MED
above	O
60	O
mm	O
were	O
independent	O
predictors	B-MED
of	O
functional	B-MED
response	O
to	O
CD133	B-MED
+	I-MED
cell	I-MED
therapy	B-MED
.	O
Participants	B-MED
with	O
overt	B-MED
heart	I-MED
failure	I-MED
benefit	B-MED
most	B-MED
from	O
CABG	B-MED
combined	B-MED
with	O
intramyocardial	B-MED
injection	B-MED
of	O
CD133	B-MED
+	I-MED
bone	I-MED
marrow	I-MED
mononuclear	I-MED
cell	I-MED
within	O
the	O
group	B-MED
.	O
An	O
improvement	B-MED
LVEF	B-MED
in	O
stem	B-MED
cell	I-MED
group	B-MED
remained	O
for	O
5	O
years	O
in	O
contrast	B-MED
with	O
the	O
CABG	B-MED
-	O
only	B-MED
group	B-MED
.	O
The	O
patients	B-MED
,	O
in	O
whom	O
the	O
improvement	B-MED
of	O
both	O
LVEF	B-MED
and	O
LVED	B-MED
was	O
observed	B-MED
,	O
have	O
benefited	O
by	O
increased	B-MED
life	B-MED
expectancy	I-MED
.	O
Tetrabromobisphenol	B-MED
A	I-MED
activates	B-MED
the	O
hepatic	B-MED
interferon	B-MED
pathway	I-MED
in	O
rats	B-MED
Tetrabromobisphenol	B-MED
A	I-MED
(	O
TBBPA	B-MED
)	O
is	O
a	O
widely	O
used	O
flame	B-MED
retardant	I-MED
in	O
printed	B-MED
circuit	I-MED
boards	I-MED
,	O
paper	B-MED
,	O
and	O
textiles	B-MED
.	O
In	O
a	O
two	B-MED
-	I-MED
year	I-MED
study	B-MED
,	O
TBBPA	B-MED
showed	O
evidence	O
of	O
uterine	B-MED
tumors	I-MED
in	O
female	B-MED
Wistar	B-MED
-	I-MED
Han	I-MED
rats	I-MED
and	O
liver	B-MED
and	O
colon	B-MED
tumors	I-MED
in	O
B6C3F1	B-MED
mice	I-MED
.	O
In	O
order	O
to	O
gain	O
further	O
insight	O
into	O
early	O
gene	B-MED
and	O
pathway	B-MED
changes	O
leading	O
to	O
cancer	B-MED
,	O
we	O
exposed	O
female	B-MED
Wistar	B-MED
Han	I-MED
rats	I-MED
to	O
TBBPA	B-MED
at	O
0	O
,	O
25	O
,	O
250	O
,	O
or	O
1000mg	O
/	O
kg	O
(	O
oral	B-MED
gavage	I-MED
in	O
corn	B-MED
oil	I-MED
,	O
5×/	O
week	B-MED
)	O
for	O
13	O
weeks	B-MED
.	O
Because	O
at	O
the	O
end	O
of	O
the	O
TBBPA	B-MED
exposure	B-MED
period	O
,	O
there	O
were	O
no	O
treatment	O
-	O
related	O
effects	O
on	O
body	B-MED
weights	I-MED
,	O
liver	B-MED
or	O
uterus	B-MED
lesions	I-MED
,	O
and	O
liver	B-MED
and	O
uterine	B-MED
organ	I-MED
weights	B-MED
were	O
within	O
10	O
%	O
of	O
controls	B-MED
,	O
only	O
the	O
high	O
dose	B-MED
animals	B-MED
were	O
analyzed	B-MED
.	O
Analysis	B-MED
of	O
the	O
hepatic	B-MED
and	O
uterine	B-MED
transcriptomes	B-MED
showed	O
TBBPA	B-MED
-induced	O
changes	O
primarily	O
in	O
the	O
liver	B-MED
(	O
1000mg	O
/	O
kg	O
)	O
,	O
with	O
159	O
transcripts	B-MED
corresponding	O
to	O
132	O
genes	B-MED
differentially	O
expressed	B-MED
compared	O
to	O
controls	B-MED
(	O
FDR=0.05	O
)	O
.	O
Pathway	B-MED
analysis	I-MED
showed	O
activation	B-MED
of	O
interferon	B-MED
(	O
IFN	B-MED
)	O
and	O
metabolic	B-MED
networks	I-MED
.	O
TBBPA	B-MED
induced	O
few	O
molecular	O
changes	O
in	O
the	O
uterus	B-MED
.	O
Activation	B-MED
of	O
the	O
interferon	B-MED
pathway	I-MED
in	O
the	O
liver	B-MED
occurred	O
after	O
13	B-MED
-	I-MED
weeks	I-MED
of	O
TBBPA	B-MED
exposure	B-MED
,	O
and	O
with	O
longer	O
term	O
TBBPA	B-MED
exposure	B-MED
this	O
may	O
lead	O
to	O
immunomodulatory	B-MED
changes	B-MED
that	O
contribute	O
to	O
carcinogenic	B-MED
processes	I-MED
.	O
Boston	B-MED
Keratoprosthesis	I-MED
Type	I-MED
1	I-MED
:	O
A	O
Randomized	B-MED
Controlled	I-MED
Trial	I-MED
of	O
Fresh	B-MED
versus	O
Frozen	B-MED
Corneal	B-MED
Donor	I-MED
Carriers	I-MED
with	O
Long	B-MED
-	I-MED
Term	I-MED
Follow	B-MED
-	I-MED
up	I-MED
To	O
compare	B-MED
the	O
long	B-MED
-	I-MED
term	I-MED
clinical	B-MED
outcomes	I-MED
of	O
fresh	B-MED
versus	O
frozen	B-MED
corneal	B-MED
graft	I-MED
carriers	I-MED
for	O
the	O
Boston	B-MED
Keratoprosthesis	I-MED
type	I-MED
1	I-MED
(	O
B	B-MED
-	I-MED
KPro	I-MED
)	O
.	O
Prospective	O
,	O
single	O
-	O
center	O
,	O
nonblinded	B-MED
,	O
randomized	B-MED
controlled	I-MED
trial	I-MED
.	I-MED
All	O
participants	B-MED
were	O
followed	O
through	O
the	O
initial	B-MED
study	B-MED
protocol	I-MED
of	O
24	O
months	B-MED
and	O
were	O
approached	O
to	O
enter	O
an	O
extension	B-MED
phase	B-MED
,	O
with	O
continuing	O
follow	B-MED
-	I-MED
up	I-MED
visits	I-MED
to	O
60	O
months	B-MED
.	O
All	O
patients	B-MED
undergoing	O
B	B-MED
-	I-MED
KPro	I-MED
surgery	I-MED
between	O
October	O
2008	O
and	O
December	O
2009	O
by	O
a	O
single	O
experienced	B-MED
surgeon	I-MED
at	O
the	O
Centre	O
Hospitalier	B-MED
de	I-MED
l'Université	I-MED
de	I-MED
Montréal	I-MED
using	O
an	O
allograft	B-MED
carrier	I-MED
were	O
considered	O
.	O
Patients	B-MED
were	O
excluded	B-MED
if	O
they	O
had	O
previously	B-MED
undergone	O
B	B-MED
-	I-MED
KPro	I-MED
implantation	B-MED
.	O
Participants	B-MED
were	O
randomized	B-MED
individually	O
to	O
receive	B-MED
a	O
B	B-MED
-	I-MED
KPro	I-MED
using	O
a	O
frozen	B-MED
or	O
a	O
fresh	B-MED
corneal	B-MED
graft	I-MED
carrier	I-MED
on	O
the	O
basis	O
of	O
tissue	B-MED
availability	B-MED
on	O
the	O
day	B-MED
of	O
surgery	B-MED
,	O
as	O
determined	O
by	O
the	O
local	O
eye	B-MED
bank	I-MED
.	O
The	O
primary	O
outcome	B-MED
measure	I-MED
was	O
device	B-MED
retention	I-MED
at	O
24	O
and	O
60	O
months	B-MED
.	O
Secondary	O
outcome	O
measures	O
included	O
surgical	B-MED
feasibility	I-MED
,	O
visual	B-MED
acuity	I-MED
(	O
VA	B-MED
)	O
,	O
and	O
complications	B-MED
.	O
Thirty	O
-	O
seven	O
eyes	B-MED
of	O
37	O
patients	B-MED
were	O
enrolled	O
in	O
the	O
initial	B-MED
study	B-MED
protocol	I-MED
,	O
with	O
19	O
eyes	B-MED
randomized	B-MED
to	O
fresh	B-MED
and	O
18	O
to	O
frozen	B-MED
carrier	B-MED
grafts	I-MED
.	O
Thirty	O
-	O
six	O
eyes	B-MED
were	O
followed	O
through	O
to	O
24	O
months	B-MED
,	O
with	O
1	O
lost	O
to	O
follow	B-MED
-	I-MED
up	I-MED
.	O
Of	O
these	O
,	O
26	O
were	O
enrolled	O
in	O
the	O
extension	B-MED
(	O
11	O
eyes	B-MED
with	O
a	O
frozen	B-MED
and	O
15	O
eyes	B-MED
with	O
a	O
fresh	B-MED
carrier	B-MED
graft	I-MED
)	O
.	O
There	O
were	O
no	B-MED
differences	I-MED
in	O
the	O
baseline	B-MED
characteristics	B-MED
of	O
patients	B-MED
enrolled	O
in	O
the	O
extension	B-MED
phase	B-MED
versus	O
those	O
who	O
were	O
not	O
.	O
At	O
60	O
months	B-MED
,	O
median	O
corrected	O
distance	O
VA	B-MED
)	O
in	O
the	O
fresh	B-MED
group	I-MED
had	O
improved	B-MED
to	O
20/150	O
from	O
a	O
baseline	B-MED
of	O
counting	O
fingers	O
,	O
whereas	O
the	O
frozen	B-MED
group	I-MED
improved	B-MED
to	O
20/400	O
from	O
a	O
baseline	B-MED
of	O
hand	O
motions	O
.	O
Device	B-MED
retention	I-MED
was	O
100	O
%	O
at	O
24	O
months	B-MED
and	O
96	O
%	O
at	O
60	O
months	B-MED
.	O
There	O
were	O
no	O
significant	O
differences	B-MED
in	O
the	O
rate	B-MED
of	O
complications	B-MED
between	O
groups	B-MED
.	O
Fresh	B-MED
and	O
frozen	B-MED
corneal	B-MED
donors	I-MED
offer	O
similar	O
clinical	B-MED
outcomes	I-MED
when	O
used	O
as	O
carriers	B-MED
for	O
the	O
B	B-MED
-	I-MED
KPro	I-MED
,	O
with	O
no	O
significant	O
differences	B-MED
in	O
device	B-MED
retention	I-MED
,	O
visual	B-MED
rehabilitation	I-MED
,	O
or	O
rates	B-MED
of	O
complications	B-MED
at	O
24	O
or	O
60	O
months	B-MED
.	O
Spatio	B-MED
-	I-MED
Temporal	I-MED
Distribution	I-MED
of	O
Bark	B-MED
and	O
Ambrosia	B-MED
Beetles	B-MED
in	O
a	O
Brazilian	B-MED
Tropical	B-MED
Dry	I-MED
Forest	I-MED
Bark	B-MED
and	O
the	O
ambrosia	B-MED
beetles	B-MED
dig	O
into	O
host	B-MED
plants	I-MED
and	O
live	O
most	O
of	O
their	O
lives	O
in	O
concealed	O
tunnels	B-MED
.	O
We	O
assessed	B-MED
beetle	B-MED
community	B-MED
dynamics	B-MED
in	O
tropical	B-MED
dry	I-MED
forest	I-MED
sites	B-MED
in	O
early	B-MED
,	O
intermediate	B-MED
,	O
and	O
late	B-MED
successional	B-MED
stages	I-MED
,	O
evaluating	O
the	O
influence	O
of	O
resource	B-MED
availability	B-MED
and	O
seasonal	B-MED
variations	I-MED
in	O
guild	B-MED
structure	I-MED
.	O
We	O
collected	B-MED
a	O
total	O
of	O
763	O
beetles	B-MED
from	O
23	O
species	B-MED
,	O
including	O
14	O
bark	B-MED
beetle	B-MED
species	B-MED
,	O
and	O
9	O
ambrosia	B-MED
beetle	B-MED
species	B-MED
.	O
Local	B-MED
richness	B-MED
of	O
bark	B-MED
and	O
ambrosia	B-MED
beetles	B-MED
was	O
estimated	O
at	O
31	O
species	B-MED
.	O
Bark	B-MED
and	O
ambrosia	B-MED
composition	B-MED
was	O
similar	O
over	O
the	O
successional	B-MED
stages	I-MED
gradient	B-MED
,	O
and	O
beta	B-MED
diversity	I-MED
among	O
sites	B-MED
was	O
primarily	O
determined	O
by	O
species	B-MED
turnover	O
,	O
mainly	O
in	O
the	O
bark	B-MED
beetle	B-MED
community	B-MED
.	O
Bark	B-MED
beetle	B-MED
richness	B-MED
and	O
abundance	B-MED
were	O
higher	O
at	O
intermediate	B-MED
stages	I-MED
;	O
availability	B-MED
of	I-MED
wood	B-MED
was	O
the	O
main	O
spatial	B-MED
mechanism	I-MED
.	O
Climate	B-MED
factors	B-MED
were	O
effectively	O
non	B-MED
-	I-MED
seasonal	I-MED
.	O
Ambrosia	B-MED
beetles	B-MED
were	O
not	O
influenced	O
by	O
successional	B-MED
stages	I-MED
,	O
however	O
the	O
increase	B-MED
in	O
wood	B-MED
resulted	O
in	O
increased	B-MED
abundance	B-MED
.	O
We	O
found	O
higher	O
richness	B-MED
at	O
the	O
end	O
of	O
the	O
dry	B-MED
and	O
wet	B-MED
seasons	I-MED
,	O
and	O
abundance	B-MED
increased	B-MED
with	O
air	B-MED
moisture	B-MED
and	O
decreased	O
with	O
higher	O
temperatures	B-MED
and	O
greater	O
rainfall	B-MED
.	O
In	O
summary	O
,	O
bark	B-MED
beetle	B-MED
species	B-MED
accumulation	B-MED
was	O
higher	O
at	O
sites	B-MED
with	O
better	O
wood	B-MED
production	B-MED
,	O
while	O
the	O
needs	O
of	O
fungi	B-MED
(	O
host	B-MED
and	O
air	B-MED
moisture	B-MED
)	O
,	O
resulted	O
in	O
a	O
favorable	O
conditions	B-MED
for	O
species	B-MED
accumulation	B-MED
of	O
ambrosia	B-MED
.	O
The	O
overall	O
biological	B-MED
pattern	B-MED
among	O
guilds	O
differed	O
from	O
tropical	B-MED
rain	I-MED
forests	I-MED
,	O
showing	O
patterns	O
similar	O
to	O
dry	B-MED
forest	I-MED
areas	I-MED
.	O
Combined	B-MED
exposures	B-MED
of	O
whole	B-MED
-	I-MED
body	I-MED
vibration	I-MED
and	O
awkward	B-MED
posture	I-MED
:	O
a	O
cross	B-MED
sectional	I-MED
investigation	I-MED
among	O
occupational	B-MED
drivers	B-MED
by	O
means	O
of	O
simultaneous	B-MED
field	B-MED
measurements	I-MED
Multifactorial	B-MED
workloads	B-MED
such	O
as	O
whole	B-MED
-	I-MED
body	I-MED
vibration	I-MED
(	O
WBV	B-MED
)	O
,	O
awkward	B-MED
posture	I-MED
and	O
heavy	O
lifting	B-MED
are	O
potential	B-MED
predictors	B-MED
for	O
low	B-MED
back	I-MED
pain	I-MED
(	O
LBP	B-MED
)	O
.	O
In	O
this	O
study	B-MED
,	O
we	O
investigate	B-MED
the	O
association	B-MED
between	O
LBP	B-MED
and	O
these	O
exposures	B-MED
among	O
102	O
professional	B-MED
drivers	B-MED
.	O
The	O
combined	B-MED
exposures	B-MED
of	O
WBV	B-MED
and	O
posture	O
are	O
measured	B-MED
at	O
different	B-MED
workplaces	B-MED
.	O
Health	B-MED
and	O
personal	O
data	B-MED
as	O
well	O
as	O
information	B-MED
about	O
lifting	B-MED
tasks	B-MED
are	O
collected	B-MED
by	O
a	O
questionnaire	B-MED
.	O
The	O
daily	B-MED
vibration	B-MED
exposure	I-MED
value	B-MED
(	O
odds	B-MED
ratio	I-MED
1.69	O
)	O
and	O
an	O
index	B-MED
for	O
awkward	B-MED
posture	I-MED
(	O
odds	B-MED
ratio	I-MED
1.63	O
)	O
show	O
significant	B-MED
association	B-MED
with	O
the	O
occurence	B-MED
of	O
LBP	B-MED
.	O
Awkward	B-MED
posture	I-MED
and	O
heavy	O
lifting	B-MED
appear	B-MED
to	O
be	O
more	O
strongly	O
associated	B-MED
with	I-MED
sick	B-MED
leave	I-MED
than	O
WBV	B-MED
exposure	B-MED
.	O
Furthermore	O
,	O
a	O
combination	B-MED
of	O
the	O
measurement	B-MED
results	B-MED
of	O
WBV	B-MED
and	O
awkward	B-MED
posture	I-MED
into	O
one	O
quantity	B-MED
also	O
shows	O
significant	B-MED
correlation	B-MED
to	O
LBP	B-MED
.	O
The	O
combined	B-MED
exposure	B-MED
of	O
WBV	B-MED
and	O
awkward	B-MED
posture	I-MED
can	O
be	O
described	B-MED
in	O
terms	O
of	O
the	O
daily	B-MED
vibration	B-MED
exposure	I-MED
and	O
the	O
index	B-MED
for	O
awkward	B-MED
posture	I-MED
.	O
This	O
facilitates	O
work	B-MED
place	I-MED
assessments	B-MED
and	O
future	B-MED
research	B-MED
in	O
this	O
area	B-MED
.	O
Practitioner	O
Summary	O
:	O
For	O
the	O
first	O
time	O
,	O
quantitative	B-MED
measures	B-MED
combining	O
whole	B-MED
-	I-MED
body	I-MED
vibration	I-MED
and	O
awkward	B-MED
posture	I-MED
exposures	B-MED
have	O
shown	O
to	O
correlate	B-MED
with	O
the	O
occurrence	B-MED
of	O
low	B-MED
back	I-MED
pain	I-MED
significantly	O
.	O
This	O
validates	O
the	O
proposed	O
quantities	B-MED
and	O
measurement	B-MED
methods	B-MED
,	O
which	O
facilitate	O
workplace	B-MED
assessments	B-MED
and	O
assist	B-MED
in	O
the	O
design	B-MED
of	O
further	B-MED
studies	B-MED
which	O
are	O
necessary	O
to	O
establish	B-MED
a	O
causal	B-MED
exposure	I-MED
-	O
response	B-MED
relationship	B-MED
.	O
Spontaneous	B-MED
activity	I-MED
is	O
correlated	B-MED
with	O
coding	B-MED
density	B-MED
in	O
primary	B-MED
auditory	I-MED
cortex	I-MED
Sensory	B-MED
neurons	I-MED
across	O
sensory	B-MED
modalities	I-MED
and	O
specific	O
processing	B-MED
areas	O
have	O
diverse	O
levels	O
of	O
spontaneous	B-MED
firing	I-MED
rates	I-MED
(	O
SFRs	B-MED
)	O
in	O
the	O
absence	O
of	O
sensory	B-MED
stimuli	I-MED
.	O
However	O
,	O
the	O
functional	B-MED
significance	B-MED
of	O
this	O
spontaneous	B-MED
activity	I-MED
is	O
not	O
well	O
-	O
understood	O
.	O
Previous	O
studies	B-MED
in	O
the	O
auditory	B-MED
system	I-MED
have	O
demonstrated	O
that	O
different	O
levels	O
of	O
spontaneous	B-MED
activity	I-MED
are	O
correlated	B-MED
with	O
a	O
variety	O
of	O
physiological	B-MED
and	O
anatomic	B-MED
properties	O
,	O
suggesting	O
that	O
neurons	B-MED
with	O
differing	O
SFRs	B-MED
make	O
unique	O
contributions	O
to	O
the	O
encoding	B-MED
of	O
auditory	B-MED
stimuli	I-MED
.	O
Additionally	O
,	O
altered	O
SFRs	B-MED
are	O
a	O
correlate	O
of	O
tinnitus	B-MED
,	O
arising	O
in	O
several	O
auditory	B-MED
areas	I-MED
after	O
exposure	O
to	O
ototoxic	B-MED
substances	B-MED
and	O
noise	B-MED
trauma	B-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
recorded	B-MED
single	I-MED
-	I-MED
unit	I-MED
activity	I-MED
from	O
primary	B-MED
auditory	I-MED
cortex	I-MED
of	O
awake	O
marmoset	B-MED
monkeys	B-MED
while	O
delivering	O
wide	B-MED
-	I-MED
band	I-MED
random	I-MED
-	I-MED
spectrum	I-MED
stimuli	I-MED
and	O
white	B-MED
Gaussian	I-MED
noise	I-MED
(	O
WGN	B-MED
)	O
to	O
examine	O
any	O
divergences	B-MED
in	O
stimulus	B-MED
encoding	B-MED
properties	O
across	O
SFR	O
classes	O
.	O
We	O
found	O
that	O
higher	O
levels	O
of	O
spontaneous	B-MED
activity	I-MED
were	O
associated	O
with	O
both	O
higher	O
levels	O
of	O
activation	B-MED
relative	O
to	O
suppression	B-MED
across	O
a	O
variety	O
of	O
wide	B-MED
-	I-MED
band	I-MED
stimuli	I-MED
and	O
higher	O
driven	O
rates	O
in	O
response	B-MED
to	O
WGN	B-MED
.	O
Moreover	O
,	O
response	B-MED
latencies	I-MED
to	O
WGN	B-MED
were	O
negatively	O
correlated	B-MED
with	O
the	O
level	O
of	O
activation	B-MED
in	O
response	B-MED
to	O
both	O
stimulus	B-MED
types	O
.	O
These	O
findings	O
are	O
consistent	O
with	O
a	O
novel	O
view	O
of	O
the	O
role	O
spontaneous	B-MED
spiking	I-MED
may	O
play	O
during	O
normal	O
stimulus	B-MED
processing	B-MED
in	O
primary	B-MED
auditory	I-MED
cortex	I-MED
and	O
how	O
it	O
may	O
malfunction	B-MED
in	O
cases	O
of	O
tinnitus	B-MED
.	O
Expression	B-MED
of	O
caspase	B-MED
3	I-MED
in	O
ovarian	B-MED
follicle	I-MED
cells	B-MED
of	O
the	O
lizard	B-MED
Podarcis	B-MED
sicula	I-MED
In	O
this	O
study	O
,	O
our	O
aim	O
was	O
to	O
determine	O
whether	O
caspase	B-MED
3	I-MED
plays	O
a	O
role	O
,	O
during	O
previtellogenesis	B-MED
,	O
in	O
the	O
ovarian	B-MED
follicular	B-MED
epithelium	I-MED
of	O
the	O
lizard	B-MED
Podarcis	B-MED
sicula	I-MED
.	O
We	O
investigated	O
the	O
presence	O
and	O
localization	B-MED
of	O
proform	O
and	O
active	O
caspase	B-MED
3	I-MED
by	O
enzyme	B-MED
assay	I-MED
,	O
Western	B-MED
blotting	I-MED
and	O
immunocytochemistry	B-MED
.	O
In	O
parallel	O
,	O
a	O
fragment	B-MED
of	O
caspase	B-MED
3	I-MED
was	O
cloned	B-MED
for	O
the	O
first	O
time	O
in	O
this	O
species	B-MED
,	O
sequenced	B-MED
and	O
used	O
for	O
in	B-MED
situ	I-MED
hybridization	I-MED
to	O
localize	B-MED
messengers	B-MED
and	O
analysed	O
by	O
a	O
phylogenetic	B-MED
survey	I-MED
to	O
shed	O
light	O
on	O
its	O
homology	B-MED
with	O
reptilian	B-MED
caspases	B-MED
.	O
Results	O
demonstrated	O
that	O
:	O
(	O
1	O
)	O
the	O
follicle	B-MED
cells	B-MED
expressed	B-MED
a	O
caspase	B-MED
of	O
the	O
3/7	O
group	O
and	O
the	O
mRNA	B-MED
for	O
caspase	B-MED
3	I-MED
was	O
transcribed	B-MED
in	O
the	O
stem	B-MED
phase	I-MED
and	O
was	O
completely	O
translated	B-MED
during	O
cell	B-MED
differentiation	I-MED
;	O
(	O
2	O
)	O
the	O
proform	B-MED
protein	I-MED
was	O
stored	O
during	O
the	O
differentiated	B-MED
(	I-MED
nurse	I-MED
)	I-MED
stage	I-MED
and	O
activated	B-MED
at	O
the	O
end	O
of	O
previtellogenesis	B-MED
provoking	O
the	O
degeneration	B-MED
of	I-MED
cells	I-MED
;	O
(	O
3	O
)	O
the	O
predicted	O
protein	B-MED
sequence	I-MED
,	O
although	O
partial	O
,	O
had	O
a	O
strong	O
similarity	O
with	O
the	O
known	O
reptilian	B-MED
caspases	B-MED
3	I-MED
.	O
The	O
epithelial	B-MED
cells	I-MED
of	O
the	O
ovarian	B-MED
follicle	I-MED
,	O
therefore	O
,	O
do	O
not	O
employ	O
caspase	B-MED
3	I-MED
during	O
the	O
nurse	B-MED
stage	I-MED
but	O
,	O
instead	O
,	O
prepare	O
for	O
apoptosis	B-MED
long	O
before	O
the	O
process	O
actually	O
begins	O
.	O
The	O
relevance	O
of	O
this	O
strategy	O
is	O
discussed	O
.	O
Incident	B-MED
fracture	B-MED
associated	B-MED
with	I-MED
increased	B-MED
risk	B-MED
of	O
mortality	B-MED
even	O
after	O
adjusting	O
for	O
frailty	B-MED
status	B-MED
in	O
elderly	B-MED
Japanese	B-MED
men	B-MED
:	O
the	O
Fujiwara	B-MED
-	I-MED
kyo	I-MED
Osteoporosis	I-MED
Risk	I-MED
in	I-MED
Men	I-MED
(	I-MED
FORMEN	I-MED
)	I-MED
Cohort	I-MED
Study	I-MED
Frail	B-MED
elderly	B-MED
individuals	B-MED
have	O
elevated	B-MED
risks	B-MED
of	O
both	O
fracture	B-MED
and	O
mortality	B-MED
.	O
We	O
found	O
that	O
incident	B-MED
fractures	B-MED
were	O
associated	B-MED
with	I-MED
an	O
increased	B-MED
risk	B-MED
of	O
death	B-MED
even	O
after	O
adjusting	O
for	O
pre	B-MED
-	I-MED
fracture	I-MED
frailty	B-MED
status	B-MED
as	O
represented	O
by	O
physical	B-MED
performance	I-MED
tests	I-MED
and	O
laboratory	B-MED
tests	I-MED
for	O
common	O
geriatric	B-MED
diseases	B-MED
in	O
community	B-MED
-	I-MED
dwelling	I-MED
elderly	B-MED
Japanese	B-MED
men	B-MED
.	O
While	O
fractures	B-MED
reportedly	O
increase	B-MED
the	O
risk	B-MED
of	O
mortality	B-MED
,	O
frailty	B-MED
may	O
complicate	B-MED
this	O
association	B-MED
,	O
generating	O
a	O
false	B-MED
-	I-MED
positive	I-MED
result	I-MED
.	O
We	O
evaluated	B-MED
this	O
association	B-MED
after	O
adjusting	O
for	O
pre	B-MED
-	I-MED
fracture	I-MED
levels	B-MED
of	O
frailty	B-MED
.	O
We	O
examined	B-MED
1998	O
community	B-MED
-	I-MED
dwelling	I-MED
ambulatory	B-MED
men	B-MED
aged	B-MED
≥65	O
years	B-MED
at	O
baseline	B-MED
in	O
the	O
Fujiwara	B-MED
-	I-MED
kyo	I-MED
Osteoporosis	I-MED
Risk	I-MED
in	I-MED
Men	I-MED
Study	I-MED
for	O
frailty	B-MED
status	B-MED
as	O
represented	O
by	O
activities	B-MED
of	I-MED
daily	I-MED
living	I-MED
(	O
ADL	B-MED
)	O
,	O
physical	B-MED
performance	I-MED
tests	I-MED
(	O
grip	B-MED
strength	I-MED
,	O
one	B-MED
-	I-MED
foot	I-MED
standing	I-MED
balance	I-MED
with	I-MED
eyes	I-MED
open	I-MED
,	O
timed	B-MED
10	I-MED
-	I-MED
m	I-MED
walk	I-MED
)	O
,	O
and	O
laboratory	B-MED
sera	I-MED
tests	I-MED
sera	B-MED
.	O
Participants	B-MED
were	O
then	O
followed	O
for	O
5	O
years	B-MED
for	O
incident	B-MED
clinical	B-MED
fractures	B-MED
and	O
death	B-MED
.	O
Effects	B-MED
of	I-MED
incident	B-MED
fracture	B-MED
on	O
death	B-MED
were	O
determined	O
by	O
Cox	B-MED
proportional	I-MED
hazards	I-MED
model	I-MED
with	O
the	O
first	O
fracture	B-MED
during	O
follow	B-MED
-	I-MED
up	I-MED
as	O
a	O
time	B-MED
-	I-MED
dependent	I-MED
predictor	I-MED
and	O
with	O
frailty	B-MED
status	I-MED
indices	I-MED
as	O
covariates	B-MED
.	O
We	O
identified	B-MED
111	O
fractures	B-MED
in	O
99	O
men	B-MED
and	O
138	O
deaths	B-MED
during	O
the	O
follow	B-MED
-	I-MED
up	I-MED
period	B-MED
(	O
median	B-MED
follow	B-MED
-	I-MED
up	I-MED
,	O
4.5	O
years	B-MED
)	O
.	O
Participants	B-MED
with	O
incident	B-MED
fractures	B-MED
did	O
not	B-MED
have	I-MED
significantly	I-MED
worse	I-MED
frailty	B-MED
statuses	B-MED
,	O
but	O
did	O
show	O
a	O
significantly	B-MED
higher	B-MED
cumulative	B-MED
mortality	B-MED
rate	I-MED
than	O
those	O
without	O
fractures	B-MED
(	O
p	O
=	O
0.0047	O
)	O
.	O
Age	B-MED
-	I-MED
adjusted	I-MED
hazard	B-MED
ratio	I-MED
(	O
HR	B-MED
)	O
of	O
death	B-MED
for	O
incident	B-MED
fracture	B-MED
was	O
3.57	O
(	O
95	O
%	O
confidence	B-MED
interval	I-MED
:	O
2.05	O
,	O
6.24	O
)	O
.	O
When	O
adjusted	O
for	O
physical	B-MED
performance	I-MED
,	O
this	O
decreased	B-MED
to	O
2.77	O
(	O
1.51	O
,	O
5.06	O
)	O
,	O
but	O
remained	O
significant	B-MED
.	O
The	O
HR	B-MED
showed	O
no	B-MED
significant	I-MED
change	I-MED
when	O
adjusted	O
for	O
laboratory	B-MED
test	I-MED
results	I-MED
(	O
3.96	O
(	O
2.26	O
,	O
6.94	O
)	O
)	O
.	O
Exclusion	B-MED
of	O
deaths	B-MED
within	O
the	O
first	O
24	O
months	B-MED
of	O
follow	B-MED
-	I-MED
up	I-MED
did	O
not	B-MED
alter	I-MED
these	O
results	B-MED
.	O
Incident	B-MED
clinical	B-MED
fracture	B-MED
was	O
associated	B-MED
with	I-MED
an	O
elevated	B-MED
risk	B-MED
of	O
death	B-MED
independently	B-MED
of	O
pre	B-MED
-	I-MED
fracture	I-MED
levels	B-MED
of	O
frailty	B-MED
in	O
community	B-MED
-	I-MED
dwelling	I-MED
elderly	B-MED
men	B-MED
.	O
Management	B-MED
of	O
tachyarrhythmia	B-MED
during	O
pregnancy	B-MED
Maternal	B-MED
tachyarrhythmia	B-MED
is	O
a	O
common	B-MED
complication	B-MED
during	O
pregnancy	B-MED
due	O
to	O
hormonal	B-MED
changes	I-MED
that	O
enhance	B-MED
pre	B-MED
-	I-MED
existing	I-MED
arrhythmias	B-MED
or	O
induce	B-MED
new	O
arrhythmias	B-MED
in	O
the	O
presence	B-MED
of	O
congenital	B-MED
heart	I-MED
defects	I-MED
in	O
pregnant	B-MED
females	I-MED
.	O
Presence	B-MED
of	O
tachyarrhythmia	B-MED
during	O
pregnancy	B-MED
poses	O
risk	B-MED
to	O
the	O
mother	B-MED
and	O
fetus	B-MED
,	O
calling	B-MED
for	O
proper	B-MED
treatment	I-MED
with	O
medications	B-MED
.	O
Use	O
of	O
antiarrhythmic	B-MED
drugs	I-MED
in	O
cases	O
of	O
maternal	B-MED
tachyarrhythmia	B-MED
must	O
give	O
due	O
consideration	B-MED
of	O
potential	B-MED
teratogenic	B-MED
side	I-MED
effects	I-MED
.	O
Utilization	B-MED
of	O
antiarrhythmic	B-MED
drugs	I-MED
during	O
pregnancy	B-MED
has	O
been	O
well	O
studied	B-MED
;	O
some	O
result	B-MED
in	O
minimal	B-MED
fetal	B-MED
harm	B-MED
or	O
none	O
at	O
all	O
.	O
New	O
techniques	B-MED
,	O
such	O
as	O
cardiac	B-MED
ablation	I-MED
,	O
have	O
also	O
been	O
implemented	B-MED
with	O
minimal	B-MED
or	O
no	O
radiation	B-MED
exposure	I-MED
to	O
the	O
fetus	B-MED
or	O
mother	B-MED
.	O
Pregnant	B-MED
women	I-MED
with	O
tachyarrhythmia	B-MED
have	O
been	O
successfully	B-MED
treated	B-MED
with	O
little	B-MED
to	O
no	O
impact	B-MED
on	O
the	O
developing	B-MED
fetus	I-MED
as	O
result	B-MED
of	O
increasing	B-MED
experience	B-MED
with	O
antiarrhythmic	B-MED
drugs	I-MED
and	O
progress	B-MED
of	O
new	O
procedural	B-MED
techniques	B-MED
.	O
Assessment	B-MED
of	O
demographic	B-MED
and	O
pathoanatomic	B-MED
risk	I-MED
factors	I-MED
in	O
recurrent	B-MED
patellofemoral	B-MED
instability	B-MED
The	O
WARPS	B-MED
/	I-MED
STAID	I-MED
classification	I-MED
employs	O
clinical	B-MED
assessment	B-MED
of	O
presenting	O
features	B-MED
and	O
anatomic	B-MED
characteristics	B-MED
to	O
identify	O
two	O
distinct	O
subsets	B-MED
of	O
patients	B-MED
within	O
the	O
patellofemoral	B-MED
instability	I-MED
population	B-MED
.	O
The	O
purpose	B-MED
of	I-MED
this	I-MED
study	I-MED
was	O
to	O
further	O
define	O
the	O
specific	O
demographics	B-MED
and	O
the	O
prevalence	B-MED
of	O
risky	B-MED
pathoanatomies	B-MED
in	O
patients	B-MED
classified	O
as	O
either	O
WARPS	B-MED
or	O
STAID	B-MED
presenting	O
with	O
recurrent	B-MED
patellofemoral	B-MED
instability	B-MED
.	O
A	O
secondary	O
purpose	O
was	O
to	O
further	O
validate	O
the	O
WARPS	B-MED
/	I-MED
STAID	I-MED
classification	I-MED
with	O
the	O
Banff	B-MED
Patella	I-MED
Instability	I-MED
Instrument	I-MED
(	O
BPII	B-MED
)	O
,	O
the	O
Marx	B-MED
activity	I-MED
scale	I-MED
and	O
the	O
Patellar	B-MED
Instability	B-MED
Severity	I-MED
Score	I-MED
(	O
ISS	B-MED
)	O
.	O
A	O
convenience	O
sample	O
of	O
50	O
patients	B-MED
with	O
recurrent	B-MED
patellofemoral	B-MED
instability	B-MED
,	O
including	O
25	O
WARPS	B-MED
and	O
25	O
STAID	B-MED
subtype	I-MED
patients	B-MED
,	O
were	O
assessed	B-MED
.	O
Clinical	B-MED
data	I-MED
were	O
collected	O
including	O
assessment	B-MED
of	O
demographic	B-MED
risk	B-MED
factors	I-MED
(	O
sex	B-MED
,	O
BMI	B-MED
,	O
bilaterality	B-MED
of	O
symptoms	B-MED
,	O
affected	B-MED
limb	B-MED
side	I-MED
and	O
age	B-MED
at	O
first	O
dislocation	B-MED
)	O
and	O
pathoanatomic	B-MED
risk	I-MED
factors	I-MED
(	O
TT	B-MED
-	I-MED
TG	I-MED
distance	I-MED
,	O
patella	B-MED
height	B-MED
,	O
patellar	O
tilt	O
,	O
grade	B-MED
of	O
trochlear	B-MED
dysplasia	I-MED
,	O
Beighton	B-MED
score	I-MED
and	O
rotational	B-MED
abnormalities	I-MED
of	O
the	O
tibia	B-MED
or	O
femur	B-MED
)	O
.	O
Patients	B-MED
completed	O
the	O
BPII	B-MED
and	O
the	O
Marx	B-MED
activity	I-MED
scale	I-MED
.	O
The	O
ISS	B-MED
was	O
calculated	B-MED
from	O
the	O
clinical	B-MED
assessment	I-MED
data	I-MED
.	O
Patients	B-MED
were	O
stratified	O
into	O
the	O
WARPS	B-MED
or	O
STAID	B-MED
subtypes	I-MED
for	O
comparative	B-MED
analysis	I-MED
.	O
An	O
independent	O
t	B-MED
test	I-MED
was	O
used	O
to	O
compare	O
demographics	B-MED
,	O
the	O
pathoanatomic	B-MED
risk	I-MED
factors	I-MED
and	O
subjective	O
measures	O
between	O
the	O
groups	B-MED
.	O
Convergent	B-MED
validity	I-MED
was	O
tested	O
with	O
a	O
Pearson	B-MED
r	I-MED
correlation	I-MED
coefficient	I-MED
between	O
the	O
WARPS	B-MED
/	I-MED
STAID	I-MED
and	O
ISS	B-MED
scores	I-MED
.	O
Demographic	B-MED
risk	I-MED
factors	I-MED
statistically	O
associated	B-MED
with	I-MED
a	O
WARPS	B-MED
subtype	I-MED
included	O
female	B-MED
sex	I-MED
,	O
age	B-MED
at	O
first	O
dislocation	B-MED
and	O
bilaterality	B-MED
.	O
Pathoanatomic	B-MED
risk	I-MED
factors	I-MED
statistically	O
associated	B-MED
with	I-MED
a	O
WARPS	B-MED
subtype	I-MED
included	O
trochlear	B-MED
dysplasia	I-MED
,	O
TT	B-MED
-	I-MED
TG	I-MED
distance	I-MED
,	O
generalized	O
ligamentous	B-MED
laxity	I-MED
,	O
patellar	O
tilt	O
and	O
rotational	B-MED
abnormalities	I-MED
.	O
The	O
independent	O
t	B-MED
test	I-MED
revealed	O
a	O
significant	O
difference	O
between	O
the	O
ISS	B-MED
scores	O
:	O
WARPS	B-MED
subtype	I-MED
(	O
M	O
=	O
4.4	O
,	O
SD	O
=	O
1.1	O
)	O
and	O
STAID	B-MED
subtype	I-MED
(	O
M	O
=	O
2.5	O
,	O
SD	O
=	O
1.5	O
)	O
;	O
t(48	O
)	O
=	O
5.2	O
,	O
p	O
<	O
0.001	O
.	O
The	O
relationship	B-MED
between	O
the	O
WARPS	B-MED
/	I-MED
STAID	I-MED
and	O
the	O
ISS	B-MED
scores	I-MED
,	O
measured	O
using	O
a	O
Pearson	B-MED
r	I-MED
correlation	I-MED
coefficient	I-MED
,	O
demonstrated	O
a	O
strong	O
relationship	B-MED
:	O
r	O
=	O
-0.61	O
,	O
n	O
=	O
50	O
,	O
p	O
<	O
0.001	O
.	O
This	O
study	B-MED
has	O
demonstrated	O
statistically	B-MED
significant	I-MED
evidence	B-MED
that	O
certain	O
demographics	B-MED
and	O
pathoanatomies	B-MED
are	O
more	O
prevalent	O
in	O
each	O
of	O
the	O
WARPS	B-MED
and	O
STAID	B-MED
patellofemoral	B-MED
instability	B-MED
subtypes	B-MED
.	O
There	O
was	O
no	O
difference	O
in	O
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
life	I-MED
or	O
activity	B-MED
level	I-MED
between	O
the	O
subtypes	B-MED
.	O
The	O
WARPS	B-MED
/	I-MED
STAID	I-MED
score	I-MED
demonstrated	O
convergent	B-MED
validity	I-MED
to	O
the	O
ISS	B-MED
and	O
divergent	B-MED
validity	I-MED
to	O
the	O
BPII	B-MED
score	I-MED
and	O
the	O
Marx	B-MED
activity	I-MED
scale	I-MED
.	O
This	O
study	B-MED
has	O
further	O
validated	O
both	O
the	O
WARPS	B-MED
/	I-MED
STAID	I-MED
classification	I-MED
and	O
the	O
ISS	B-MED
of	O
patients	B-MED
that	O
present	O
with	O
recurrent	B-MED
patellofemoral	B-MED
instability	B-MED
.	O
III	O
.	O
Complications	B-MED
and	O
Near	O
-	O
Miss	O
Events	B-MED
After	O
Hepatectomy	B-MED
for	O
Living	B-MED
-	I-MED
Related	I-MED
Liver	I-MED
Donation	I-MED
:	O
An	O
Italian	B-MED
Single	B-MED
Center	I-MED
Report	B-MED
of	O
One	O
Hundred	O
Cases	B-MED
BACKGROUND	O
In	O
healthy	B-MED
individuals	B-MED
,	O
such	O
as	O
liver	B-MED
living	I-MED
donors	I-MED
,	O
potential	O
complications	B-MED
may	O
occur	O
during	O
surgery	B-MED
.	O
Reporting	O
such	O
complications	B-MED
and	O
near	O
-	O
miss	O
events	O
is	O
mandatory	O
to	O
improve	O
living	B-MED
donor	I-MED
management	B-MED
and	O
safety	B-MED
.	O
MATERIAL	O
AND	O
METHODS	O
This	O
retrospective	B-MED
study	I-MED
was	O
performed	O
on	O
a	O
prospective	O
database	B-MED
with	O
the	O
aim	O
of	O
providing	O
a	O
brief	O
analysis	B-MED
of	O
the	O
perioperative	B-MED
,	O
medium	B-MED
-	I-MED
term	I-MED
,	O
and	O
long	B-MED
-	I-MED
term	I-MED
complications	B-MED
,	O
and	O
the	O
near	O
-	O
miss	O
events	B-MED
in	O
a	O
single	B-MED
center	I-MED
series	O
of	O
100	O
consecutive	O
liver	B-MED
resections	I-MED
for	O
adult	B-MED
-to-	O
adult	B-MED
living	B-MED
-	I-MED
donor	I-MED
liver	B-MED
transplantation	I-MED
.	O
RESULTS	O
Only	O
23.3	O
%	O
of	O
potential	O
living	B-MED
donors	I-MED
underwent	O
surgery	B-MED
.	O
No	B-MED
living	B-MED
donor	I-MED
mortality	B-MED
was	O
reported	O
;	O
29	O
patients	B-MED
(	O
29	O
%	O
)	O
experienced	O
at	O
least	O
one	O
complication	B-MED
.	O
Five	O
patients	B-MED
developed	O
mild	B-MED
long	B-MED
-	I-MED
term	I-MED
dysfunction	B-MED
;	O
two	O
aborted	O
hepatectomies	B-MED
,	O
and	O
there	O
were	O
two	O
near	O
-	O
miss	O
events	B-MED
reported	O
.	O
CONCLUSIONS	O
A	O
strategy	B-MED
for	O
an	O
accurate	O
assessment	B-MED
of	O
living	B-MED
donor	I-MED
complications	B-MED
and	O
strict	O
selection	B-MED
criterion	O
can	O
not	O
be	O
overemphasized	O
,	O
as	O
well	O
as	O
the	O
need	O
to	O
continuously	O
update	O
center	B-MED
patient	B-MED
outcome	I-MED
reports	B-MED
.	O
Production	B-MED
of	O
Laccase	B-MED
by	O
Cochliobolus	B-MED
sp	I-MED
.	I-MED
Isolated	B-MED
from	O
Plastic	B-MED
Dumped	B-MED
Soils	I-MED
and	O
Their	O
Ability	B-MED
to	O
Degrade	B-MED
Low	B-MED
Molecular	I-MED
Weight	I-MED
PVC	I-MED
One	O
of	O
the	O
utmost	O
man	B-MED
-	I-MED
made	I-MED
problems	I-MED
faced	O
today	O
has	O
been	O
the	O
ever	B-MED
-	O
increasing	B-MED
plastic	B-MED
waste	B-MED
filling	B-MED
the	O
world	O
.	O
It	O
accounts	O
for	O
an	O
estimated	O
20	O
-	O
30	O
%	O
(	O
by	O
volume	O
)	O
of	O
municipal	B-MED
solid	I-MED
waste	I-MED
in	O
landfill	B-MED
sites	I-MED
worldwide	O
.	O
Research	O
on	O
plastic	B-MED
biodegradation	B-MED
has	O
been	O
steadily	O
growing	O
over	O
the	O
past	O
four	O
decades	O
.	O
Several	O
fungi	B-MED
have	O
been	O
identified	O
that	O
produce	O
enzymes	B-MED
capable	O
of	O
plastic	B-MED
degradation	B-MED
in	O
various	O
laboratory	B-MED
conditions	I-MED
.	O
This	O
paper	O
presents	O
a	O
study	O
that	O
determined	O
the	O
ability	B-MED
of	O
fungi	B-MED
to	O
degrade	B-MED
low	B-MED
molecular	I-MED
weight	I-MED
polyvinyl	I-MED
chloride	I-MED
(	O
PVC	B-MED
)	O
by	O
the	O
enzyme	B-MED
laccase	I-MED
.	O
We	O
have	O
isolated	B-MED
a	O
fungal	B-MED
species	B-MED
,	O
Cochliobolus	B-MED
sp	I-MED
.	I-MED
,	O
from	O
plastic	B-MED
dumped	B-MED
soils	I-MED
and	O
they	O
were	O
cultured	B-MED
on	O
Czapek	B-MED
Dox	I-MED
Agar	I-MED
slants	I-MED
at	O
30	O
°	O
C	O
.	O
The	O
effectiveness	B-MED
of	O
this	O
fungal	B-MED
species	B-MED
on	O
the	O
degradation	B-MED
of	O
commercial	O
low	B-MED
molecular	I-MED
weight	I-MED
polyvinyl	I-MED
chloride	I-MED
(	O
PVC	B-MED
)	O
was	O
studied	O
under	O
laboratory	B-MED
conditions	I-MED
.	O
Significant	O
differences	O
were	O
observed	O
from	O
the	O
FTIR	B-MED
,	O
GC	B-MED
-	I-MED
MS	I-MED
,	O
and	O
SEM	B-MED
results	O
in	O
between	O
control	B-MED
and	O
Cochliobolus	B-MED
sp	I-MED
.	I-MED
treated	O
PVC	B-MED
.	O
Empty	B-MED
Capsids	B-MED
and	O
Macrophage	B-MED
Inhibition	B-MED
/	O
Depletion	B-MED
Increase	B-MED
rAAV	B-MED
Transgene	B-MED
Expression	B-MED
in	O
Joints	B-MED
of	O
Both	O
Healthy	B-MED
and	O
Arthritic	B-MED
Mice	B-MED
Gene	B-MED
therapy	I-MED
has	O
potential	B-MED
to	O
treat	B-MED
rheumatic	B-MED
diseases	I-MED
;	O
however	O
,	O
the	O
presence	B-MED
of	O
macrophages	B-MED
in	O
the	O
joint	B-MED
might	O
hamper	O
adeno	B-MED
-	I-MED
associated	I-MED
viral	I-MED
vector	B-MED
-mediated	O
gene	B-MED
delivery	I-MED
.	O
Here	O
we	O
demonstrate	O
that	O
in	O
arthritic	B-MED
,	O
but	O
also	O
in	O
healthy	B-MED
,	O
mice	B-MED
administration	B-MED
of	I-MED
agents	I-MED
that	O
influence	B-MED
macrophage	B-MED
activity	B-MED
/	O
number	B-MED
and/or	O
addition	B-MED
of	O
empty	B-MED
decoy	B-MED
capsids	I-MED
substantially	O
improve	B-MED
the	O
efficacy	B-MED
of	O
recombinant	B-MED
adeno	B-MED
-	I-MED
associated	I-MED
viral	I-MED
vector	B-MED
5	O
transgene	B-MED
expression	B-MED
in	O
the	O
joint	B-MED
.	O
Pretreatment	B-MED
with	O
triamcinolone	B-MED
or	O
clodronate	B-MED
liposomes	B-MED
improved	B-MED
luciferase	B-MED
expression	B-MED
over	O
a	O
period	B-MED
of	O
4	O
weeks	B-MED
.	O
Similar	B-MED
results	B-MED
were	O
seen	O
when	O
empty	B-MED
decoy	B-MED
capsids	I-MED
were	O
added	B-MED
to	O
full	B-MED
genome	B-MED
containing	O
capsids	B-MED
in	O
a	O
5:1	O
ratio	B-MED
.	O
In	O
a	O
study	B-MED
to	O
assess	B-MED
the	O
duration	B-MED
of	O
expression	B-MED
as	O
well	O
as	O
to	O
investigate	B-MED
the	O
combination	B-MED
of	O
these	O
two	O
approaches	B-MED
,	O
we	O
observed	B-MED
a	O
synergistic	B-MED
enhancement	B-MED
of	O
gene	B-MED
expression	I-MED
,	O
sustained	B-MED
for	O
at	O
least	O
12	O
weeks	B-MED
.	O
The	O
enhancement	B-MED
of	O
gene	B-MED
expression	I-MED
was	O
independent	O
of	O
the	O
route	B-MED
of	I-MED
administration	I-MED
of	O
triamcinolone	B-MED
(	O
intra	B-MED
-	I-MED
articular	I-MED
or	O
intramuscular	B-MED
)	O
.	O
In	O
healthy	B-MED
mice	B-MED
it	O
was	O
demonstrated	O
that	O
the	O
combination	B-MED
improved	B-MED
expression	B-MED
of	O
the	O
transgene	B-MED
significantly	O
,	O
in	O
a	O
serotype	B-MED
independent	O
manner	O
.	O
These	O
data	B-MED
have	O
implications	O
for	O
future	O
applications	O
of	O
gene	B-MED
therapy	I-MED
to	O
the	O
joint	B-MED
and	O
for	O
other	O
tissues	B-MED
with	O
an	O
abundance	B-MED
of	O
macrophages	B-MED
.	O
Thymosin	B-MED
β4	I-MED
:	O
Roles	O
in	O
Development	B-MED
,	O
Repair	B-MED
,	O
and	O
Engineering	B-MED
of	O
the	O
Cardiovascular	B-MED
System	I-MED
The	O
burden	O
of	O
cardiovascular	B-MED
disease	I-MED
is	O
a	O
growing	O
worldwide	O
issue	O
that	O
demands	O
attention	O
.	O
While	O
many	O
clinical	B-MED
trials	I-MED
are	O
ongoing	O
to	O
test	B-MED
therapies	B-MED
for	O
treating	B-MED
the	O
heart	B-MED
after	O
myocardial	B-MED
infarction	I-MED
(	O
MI	B-MED
)	O
and	O
heart	B-MED
failure	I-MED
,	O
there	O
are	O
few	O
options	O
doctors	B-MED
able	O
to	O
currently	O
give	O
patients	B-MED
to	O
repair	B-MED
the	I-MED
heart	I-MED
.	O
This	O
eventually	O
leads	O
to	O
decreased	O
ventricular	B-MED
contractility	I-MED
and	O
increased	O
systemic	B-MED
disease	I-MED
,	O
including	O
vascular	B-MED
disorders	I-MED
that	O
could	O
result	O
in	O
stroke	B-MED
.	O
Small	O
peptides	B-MED
such	O
as	O
thymosin	B-MED
β4	I-MED
(	O
Tβ4	B-MED
)	O
are	O
upregulated	O
in	O
the	O
cardiovascular	B-MED
niche	B-MED
during	O
fetal	B-MED
development	I-MED
and	O
after	O
injuries	B-MED
such	O
as	O
MI	B-MED
,	O
providing	O
increased	O
neovasculogenesis	B-MED
and	O
paracrine	B-MED
signals	I-MED
for	O
endogenous	B-MED
endogenous	B-MED
stem	I-MED
cell	I-MED
recruitment	O
to	O
aid	O
in	O
wound	B-MED
repair	I-MED
.	O
New	O
research	B-MED
is	O
looking	O
into	O
the	O
effects	O
of	O
in	B-MED
vivo	I-MED
administration	B-MED
of	O
Tβ4	B-MED
through	O
injections	B-MED
and	O
coatings	B-MED
on	O
implants	B-MED
,	O
as	O
well	O
as	O
its	O
effect	O
on	O
cell	B-MED
differentiation	I-MED
.	O
Results	O
so	O
far	O
demonstrate	O
Tβ4	B-MED
administration	B-MED
leads	O
to	O
robust	O
increases	O
in	O
angiogenesis	B-MED
and	O
wound	B-MED
healing	I-MED
in	O
the	O
heart	B-MED
after	O
MI	B-MED
and	O
the	O
brain	B-MED
after	O
stroke	B-MED
,	O
and	O
can	O
differentiate	O
adult	B-MED
stem	I-MED
cells	I-MED
toward	O
the	O
cardiac	B-MED
lineage	B-MED
for	O
implantation	B-MED
to	O
the	O
heart	B-MED
to	O
increase	O
contractility	B-MED
and	O
survival	B-MED
.	O
Future	O
work	O
,	O
some	O
of	O
which	O
is	O
currently	O
in	O
clinical	B-MED
trials	I-MED
,	O
will	O
demonstrate	O
the	O
in	B-MED
vivo	I-MED
effect	B-MED
of	O
these	O
therapies	B-MED
on	O
human	B-MED
patients	B-MED
,	O
with	O
the	O
goal	B-MED
of	O
helping	O
the	O
millions	O
of	O
people	B-MED
worldwide	O
affected	O
by	O
cardiovascular	B-MED
disease	I-MED
.	O
Involvement	O
of	O
apoptotic	B-MED
pathways	I-MED
in	O
docosahexaenoic	B-MED
acid	I-MED
-induced	O
benefit	O
in	O
prostate	B-MED
cancer	I-MED
:	O
Pathway	O
-	O
focused	O
gene	B-MED
expression	I-MED
analysis	I-MED
using	O
RT(2	B-MED
)	I-MED
Profile	I-MED
PCR	I-MED
Array	I-MED
System	I-MED
Present	O
study	O
aimed	O
to	O
better	O
understand	O
the	O
potential	O
apoptotic	B-MED
pathways	I-MED
that	O
involved	O
in	O
docosahexaenoic	B-MED
acid	I-MED
DHA	B-MED
(	O
DHA)-induced	O
apoptosis	B-MED
of	O
prostate	B-MED
cancer	I-MED
cells	B-MED
.	O
Human	B-MED
prostate	B-MED
cancer	I-MED
DU145	B-MED
cells	I-MED
were	O
treated	O
with	O
different	O
concentrations	O
of	O
fish	B-MED
oil	I-MED
,	O
omega-3	B-MED
PUFA	I-MED
(	O
DHA	B-MED
,	O
and	O
Eicosapentaenoic	B-MED
acid	I-MED
,	O
EPA	B-MED
)	O
,	O
or	O
omega-6	B-MED
PUFA	I-MED
(	O
Arachidonic	B-MED
acid	I-MED
,	O
AA	B-MED
)	O
.	O
Cell	B-MED
viability	I-MED
and	O
apoptosis	B-MED
were	O
evaluated	O
by	O
MTT	B-MED
assay	I-MED
and	O
Hoechst	B-MED
staining	I-MED
.	O
Pathway	O
-	O
focused	O
gene	B-MED
expression	I-MED
profiling	I-MED
of	O
DU145	B-MED
cells	I-MED
was	O
analyzed	O
with	O
the	O
RT(2	O
)	O
Profile	O
PCR	O
Array	O
System	O
.	O
The	O
results	O
were	O
verified	O
by	O
real	B-MED
time	I-MED
quantitative	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
(	O
RT	B-MED
-	I-MED
qPCR	I-MED
)	O
.	O
AA	B-MED
exposure	O
showed	O
no	O
obvious	O
effect	O
on	O
viability	B-MED
of	O
DU145	B-MED
cells	I-MED
.	O
However	O
,	O
exposure	O
with	O
fish	B-MED
oil	I-MED
,	O
EPA	B-MED
,	O
or	O
DHA	B-MED
for	O
24	O
h	O
significantly	O
affected	O
cell	B-MED
viability	I-MED
.	O
The	O
growth	B-MED
inhibition	I-MED
of	O
DHA	B-MED
was	O
more	O
pronounced	O
than	O
that	O
of	O
EPA	B-MED
and	O
showed	O
a	O
time	O
-	O
dependent	O
increase	O
.	O
DHA	B-MED
exposure	O
caused	O
typical	O
apoptotic	B-MED
characteristics	O
.	O
Ten	O
genes	B-MED
were	O
more	O
expressed	O
,	O
while	O
5	O
genes	B-MED
were	O
less	O
expressed	O
following	O
DHA	B-MED
exposure	O
.	O
RT	B-MED
-	I-MED
qPCR	I-MED
confirmed	O
the	O
time	O
dependent	O
effect	O
of	O
DHA	B-MED
on	O
the	O
expression	O
of	O
these	O
differentially	O
expressed	O
genes	B-MED
.	O
KEGG	O
pathway	O
analysis	O
showed	O
that	O
DHA	B-MED
may	O
induce	O
the	O
apoptosis	B-MED
of	O
cancer	B-MED
cells	I-MED
preferentially	O
through	O
mediating	O
P53	B-MED
,	O
MAPK	B-MED
,	O
TNF	B-MED
,	O
PI3K	B-MED
/	I-MED
AKT	I-MED
,	O
and	O
NF	B-MED
-	I-MED
κB	I-MED
signaling	I-MED
pathways	I-MED
.	O
Our	O
study	O
demonstrated	O
the	O
beneficial	O
action	O
of	O
DHA	B-MED
on	O
human	B-MED
prostate	B-MED
carcinoma	I-MED
cell	B-MED
line	I-MED
DU145	I-MED
.	O
The	O
pro	O
-	O
apoptotic	O
effect	O
of	O
DHA	B-MED
on	O
DU145	B-MED
cells	I-MED
may	O
involve	O
mediation	O
various	O
pathways	B-MED
,	O
especially	O
P53	B-MED
,	O
MAPK	B-MED
,	O
TNF	B-MED
,	O
PI3K	B-MED
/	I-MED
AKT	I-MED
,	O
and	O
NF	B-MED
-	I-MED
κB	I-MED
signaling	I-MED
pathways	I-MED
.	O
Molecular	B-MED
mechanisms	I-MED
of	O
DHA	B-MED
on	O
apoptosis	B-MED
of	O
cancer	B-MED
cells	I-MED
still	O
need	O
to	O
be	O
further	O
clarified	O
.	O
New	B-MED
Diterpenoids	B-MED
from	O
Clerodendranthus	B-MED
spicatus	I-MED
Two	O
new	B-MED
diterpenoids	B-MED
,	O
neoorthosiphonones	B-MED
B	I-MED
and	O
C	B-MED
(	O
1	B-MED
and	O
2	B-MED
)	O
,	O
and	O
one	O
known	O
diterpenoid	B-MED
,	O
were	O
isolated	B-MED
from	O
the	O
aerial	B-MED
parts	I-MED
of	O
Clerodendranthus	B-MED
spicatus	I-MED
.	O
Their	O
structures	B-MED
including	O
absolute	B-MED
configurations	B-MED
were	O
determined	B-MED
by	I-MED
comprehensive	O
spectroscopic	B-MED
analyses	I-MED
and	O
X	B-MED
-	I-MED
ray	I-MED
crystallographic	I-MED
methods	I-MED
.	O
No	O
compound	B-MED
was	O
found	O
to	O
inhibit	B-MED
fibronectin	B-MED
production	B-MED
at	O
the	O
concentration	B-MED
of	O
20	O
μM.	O
The	O
Impact	B-MED
of	I-MED
Diabetes	B-MED
on	O
the	O
Risk	B-MED
of	O
Prostate	B-MED
Cancer	I-MED
Development	B-MED
according	O
to	O
Body	B-MED
Mass	I-MED
Index	I-MED
:	O
A	O
10	O
-	O
year	O
Nationwide	O
Cohort	B-MED
Study	I-MED
Purpose	O
:	O
We	O
examined	O
the	O
association	O
between	O
obesity	B-MED
and	O
prostate	B-MED
cancer	I-MED
both	O
with	O
and	O
without	B-MED
diabetic	B-MED
patients	B-MED
included	O
in	O
the	O
analysis	O
using	O
nationally	O
representative	O
data	B-MED
of	O
the	O
Korean	B-MED
population	I-MED
from	O
the	O
National	B-MED
Health	I-MED
Insurance	I-MED
System	I-MED
(	O
NHIS	B-MED
)	O
.	O
Materials	O
and	O
Methods	O
:	O
Of	O
the	O
424,712	O
participants	B-MED
who	O
underwent	O
health	B-MED
examinations	I-MED
in	O
2002	O
-	O
2008	O
,	O
139,519	O
men	B-MED
≥40	I-MED
years	I-MED
old	I-MED
and	O
without	B-MED
prostate	B-MED
cancer	I-MED
were	O
followed	O
from	O
the	O
beginning	O
of	O
2002	O
to	O
the	O
end	O
of	O
2012	O
.	O
Multivariate	B-MED
adjusted	I-MED
Cox	B-MED
regression	I-MED
analysis	I-MED
was	O
conducted	O
to	O
examine	O
the	O
hazard	B-MED
ratio	I-MED
(	O
HR	B-MED
)	O
and	O
95	O
%	O
confidence	B-MED
interval	I-MED
(	O
CI	B-MED
)	O
for	O
the	O
association	O
between	O
prostate	B-MED
cancer	I-MED
and	O
body	B-MED
mass	I-MED
index	I-MED
(	O
BMI	B-MED
)	O
both	O
with	O
and	O
without	B-MED
diabetes	B-MED
.	O
Results	O
:	O
The	O
HR	B-MED
for	O
prostate	B-MED
cancer	I-MED
according	O
to	O
the	O
existence	O
of	O
diabetes	B-MED
was	O
stratified	B-MED
by	O
BMI	B-MED
in	O
both	O
age	B-MED
-	O
and	O
multivariable	B-MED
-	I-MED
adjusted	I-MED
models	I-MED
.	O
In	O
the	O
population	B-MED
without	B-MED
diabetes	B-MED
,	O
the	O
HR	B-MED
for	O
prostate	B-MED
cancer	I-MED
significantly	B-MED
increased	I-MED
as	O
BMI	B-MED
increased	O
beyond	O
the	O
reference	O
range	O
in	O
a	O
model	B-MED
adjusted	I-MED
for	I-MED
age	I-MED
and	I-MED
multiple	I-MED
variables	I-MED
;	O
however	O
,	O
the	O
increase	O
in	O
the	O
HR	B-MED
was	O
small	O
.	O
In	O
the	O
population	B-MED
with	O
diabetes	B-MED
,	O
the	O
HR	B-MED
for	O
prostate	B-MED
cancer	I-MED
significantly	B-MED
increased	I-MED
as	O
BMI	B-MED
increased	O
from	O
<	O
18.5	O
kg	O
/	O
m(2	O
)	O
to	O
within	O
the	O
reference	O
range	O
(	O
18.5	O
to	O
22.9	O
)	O
in	O
the	O
multivariable	B-MED
-	I-MED
adjusted	I-MED
model	I-MED
.	O
In	O
addition	O
,	O
a	O
marked	B-MED
decrease	I-MED
in	O
HR	B-MED
in	O
the	O
population	B-MED
with	O
BMI	B-MED
of	O
<	O
18.5	O
kg	O
/	O
m(2	O
)	O
was	O
seen	O
compared	O
to	O
the	O
reference	O
or	O
higher	O
BMI	B-MED
population	B-MED
.	O
Conclusion	O
:	O
This	O
population	B-MED
-based	O
study	O
shows	O
the	O
evidence	O
of	O
association	O
between	O
obesity	B-MED
and	O
development	B-MED
of	O
prostate	B-MED
cancer	I-MED
,	O
and	O
the	O
risk	B-MED
increases	I-MED
vary	O
according	O
to	O
the	O
change	O
of	O
BMI	B-MED
category	O
and	O
the	O
existence	O
of	O
diabetes	B-MED
.	O
Endoscopic	B-MED
endonasal	B-MED
surgery	B-MED
for	O
remission	B-MED
of	O
Cushing	B-MED
's	I-MED
Disease	I-MED
caused	O
by	O
ectopic	B-MED
intracavernous	B-MED
macroadenoma	B-MED
:	O
case	B-MED
report	I-MED
and	O
literature	B-MED
review	I-MED
Complete	O
surgical	B-MED
resection	I-MED
of	O
an	O
ACTH	B-MED
-	I-MED
secreting	I-MED
pituitary	I-MED
adenoma	I-MED
is	O
the	O
gold	B-MED
standard	I-MED
of	O
treatment	B-MED
of	O
Cushing	B-MED
's	I-MED
Disease	I-MED
.	O
Ectopic	B-MED
location	B-MED
of	O
these	O
adenomas	B-MED
is	O
an	O
extremely	O
rare	B-MED
condition	O
that	O
may	O
compromise	O
the	O
diagnosis	B-MED
and	O
surgical	B-MED
success	B-MED
.	O
We	O
present	O
the	O
first	O
case	O
of	O
an	O
ectopic	B-MED
intracavernous	B-MED
ACTH	B-MED
-	I-MED
secreting	I-MED
macroadenoma	I-MED
totally	O
resected	O
with	O
endoscopic	B-MED
endonasal	B-MED
surgery	B-MED
(	O
EES	B-MED
)	O
.	O
A	O
36	O
year	O
old	O
female	B-MED
presented	O
with	O
Cushing	B-MED
syndrome	I-MED
.	O
Increased	B-MED
ACTH	B-MED
,	O
serum	B-MED
cortisol	I-MED
and	O
free	B-MED
urine	I-MED
cortisol	I-MED
levels	B-MED
were	O
identified	O
,	O
however	O
the	O
pituitary	B-MED
MRI	I-MED
failed	O
to	O
reveal	O
a	O
pituitary	B-MED
tumor	I-MED
;	O
instead	O
,	O
a	O
parasellar	B-MED
lesion	I-MED
in	O
the	O
left	O
cavernous	B-MED
sinus	I-MED
(	O
CS	B-MED
)	O
was	O
noticed	O
.	O
Inferior	B-MED
petrosal	I-MED
sinus	I-MED
sampling	I-MED
demonstrated	O
a	O
significant	O
central	B-MED
-to-	O
peripheral	B-MED
and	O
lateralized	O
left	O
-	O
sided	O
ACTH	B-MED
gradient	O
.	O
The	O
patient	B-MED
underwent	O
EES	B-MED
.	O
No	B-MED
tumor	I-MED
was	O
found	O
in	O
the	O
sella	B-MED
,	O
however	O
,	O
the	O
left	O
CS	B-MED
was	O
widely	O
explored	O
and	O
a	O
tumor	B-MED
was	O
found	O
lateral	B-MED
to	O
the	O
paraclival	O
segment	O
of	O
the	O
carotid	B-MED
artery	I-MED
.	O
There	O
were	O
no	B-MED
complications	B-MED
following	O
EES	B-MED
.	O
Pathology	B-MED
confirmed	O
the	O
diagnosis	B-MED
of	O
an	O
ACTH	B-MED
-	I-MED
secreting	I-MED
adenoma	I-MED
.	O
During	O
the	O
immediately	O
postoperative	B-MED
course	O
serum	B-MED
cortisol	I-MED
levels	B-MED
dropped	O
below	O
5	O
mcg	O
/	O
dl	O
.	O
Postoperative	B-MED
MRI	B-MED
demonstrated	O
complete	O
tumor	B-MED
resection	I-MED
.	O
At	O
20	O
months	O
follow	B-MED
-	I-MED
up	I-MED
,	O
the	O
patient	B-MED
remains	O
in	O
clinical	B-MED
and	O
biochemical	B-MED
remission	B-MED
of	O
Cushing	B-MED
's	I-MED
Disease	I-MED
.	O
Only	O
12	O
cases	O
of	O
ectopic	B-MED
intracavernous	B-MED
ACTH	B-MED
-	I-MED
secreting	I-MED
adenomas	I-MED
have	O
been	O
reported	O
to	O
date	O
and	O
all	O
were	O
microadenomas	B-MED
.	O
The	O
presence	O
of	O
an	O
ectopic	B-MED
ACTH	B-MED
-	I-MED
secreting	I-MED
macroadenoma	I-MED
in	O
the	O
CS	B-MED
represents	O
a	O
surgical	B-MED
challenge	O
.	O
EES	B-MED
is	O
the	O
ideal	O
approach	O
for	O
complete	O
resection	B-MED
of	O
ectopic	B-MED
intracavernous	B-MED
adenomas	B-MED
allowing	O
for	O
a	O
wide	O
exploration	B-MED
of	O
the	O
CS	B-MED
with	O
no	B-MED
surgical	B-MED
complications	B-MED
.	O
Highly	O
fluorescent	B-MED
gold	B-MED
nanoclusters	B-MED
stabilized	O
by	O
food	B-MED
proteins	I-MED
:	O
From	O
preparation	O
to	O
application	O
in	O
detection	B-MED
of	O
food	B-MED
contaminants	B-MED
and	O
bioactive	B-MED
nutrients	I-MED
Applications	O
of	O
nanotechnology	B-MED
in	O
food	B-MED
have	O
rapidly	O
increased	O
in	O
the	O
past	O
decades	O
.	O
Ultra	B-MED
-	I-MED
small	I-MED
gold	I-MED
nanoclusters	I-MED
(	O
Au	B-MED
NCs	I-MED
)	O
,	O
composed	O
of	O
several	O
to	O
roughly	O
a	O
hundred	O
atoms	O
,	O
represent	O
a	O
kind	O
of	O
novel	O
nanomaterials	B-MED
.	O
The	O
Au	B-MED
NCs	I-MED
directed	O
by	O
food	B-MED
proteins	I-MED
have	O
drawn	O
considerable	O
research	O
attention	O
due	O
to	O
their	O
environmentally	B-MED
friendly	I-MED
preparation	I-MED
,	O
strong	O
fluorescence	B-MED
,	O
excellent	O
photo	B-MED
-	I-MED
stability	I-MED
and	O
favorable	O
biocompatibility	B-MED
.	O
These	O
interesting	O
protein	B-MED
-	I-MED
Au	I-MED
hybrids	I-MED
have	O
opened	O
up	O
a	O
new	O
area	O
at	O
the	O
nano	B-MED
-	I-MED
bio	I-MED
-	I-MED
food	I-MED
interface	I-MED
,	O
not	O
only	O
did	O
they	O
provide	O
the	O
missing	O
link	O
between	O
single	B-MED
metal	I-MED
atoms	I-MED
and	O
plasmonic	B-MED
metal	B-MED
nanoparticles	I-MED
,	O
but	O
also	O
developed	O
the	O
hybrid	B-MED
system	I-MED
between	O
biomacromolecule	B-MED
and	O
inorganic	B-MED
ions	B-MED
.	O
In	O
this	O
review	O
,	O
we	O
highlighted	O
the	O
synthesis	B-MED
strategies	O
and	O
optical	B-MED
properties	I-MED
of	O
the	O
Au	B-MED
NCs	I-MED
stabilized	O
by	O
typical	O
food	B-MED
proteins	I-MED
as	O
well	O
as	O
their	O
applications	O
in	O
detection	B-MED
of	O
food	B-MED
contaminants	B-MED
or	O
bioactive	B-MED
nutrients	I-MED
.	O
In	O
addition	O
,	O
we	O
discussed	O
current	O
challenges	O
and	O
future	O
development	O
in	O
food	B-MED
proteins	I-MED
directed	O
gold	B-MED
nanoclusters	I-MED
for	O
size	O
-	O
controlled	O
synthesis	B-MED
and	O
multifunctional	O
applications	O
.	O
CXCL14	B-MED
-	O
CXCR4	B-MED
and	O
CXCL12	B-MED
-	O
CXCR4	B-MED
Axes	O
May	O
Play	O
Important	O
Roles	O
in	O
the	O
Unique	O
Invasion	B-MED
Process	B-MED
of	O
Endometrioid	B-MED
Carcinoma	I-MED
With	O
MELF	B-MED
-	I-MED
Pattern	I-MED
Myoinvasion	B-MED
The	O
term	O
"	O
MELF	B-MED
-	I-MED
pattern	I-MED
myometrial	B-MED
invasion	B-MED
"	O
(	O
MELF	B-MED
pattern	I-MED
)	O
denotes	O
an	O
unusual	B-MED
morphology	B-MED
of	O
myometrial	B-MED
invasion	B-MED
in	O
endometrioid	B-MED
carcinomas	I-MED
,	O
and	O
is	O
associated	B-MED
with	I-MED
frequent	O
lymphovascular	B-MED
invasion	I-MED
and	O
lymph	B-MED
node	I-MED
metastasis	I-MED
.	O
In	O
this	O
study	O
,	O
tumor	B-MED
cells	I-MED
were	O
directly	O
collected	B-MED
from	O
a	O
MELF	B-MED
pattern	I-MED
site	O
,	O
using	O
laser	B-MED
microdissection	I-MED
.	O
Comprehensive	B-MED
microarray	B-MED
analysis	I-MED
of	O
the	O
genes	B-MED
was	O
conducted	O
,	O
and	O
based	O
on	O
the	O
results	O
,	O
expression	B-MED
of	O
a	O
metastasis	B-MED
progression	I-MED
gene	I-MED
,	I-MED
CXCR4	I-MED
,	O
and	O
its	O
ligands	B-MED
CXCL14	B-MED
and	O
CXCL12	B-MED
,	O
was	O
further	O
investigated	B-MED
.	O
In	B-MED
vitro	I-MED
studies	I-MED
of	O
endometrioid	B-MED
carcinoma	I-MED
cell	B-MED
lines	I-MED
revealed	O
elevated	B-MED
invasion	B-MED
activity	B-MED
in	O
a	O
manner	O
dependent	O
on	O
the	O
CXCL14	B-MED
-	O
CXCR4	B-MED
or	O
CXCL12	B-MED
-	O
CXCR4	B-MED
axis	O
.	O
Immunohistochemical	B-MED
analysis	I-MED
of	O
93	O
(	O
MELF	B-MED
group	I-MED
,	O
46	O
;	O
non	B-MED
-	I-MED
MELF	I-MED
group	I-MED
,	O
47	O
)	O
cases	O
illustrated	O
CXCR4	B-MED
was	O
expressed	B-MED
in	O
all	O
endometrioid	B-MED
carcinomas	I-MED
,	O
while	O
based	O
on	O
CXCL14	B-MED
and	O
CXCL12	B-MED
expression	B-MED
score	B-MED
,	O
high	B-MED
proportions	I-MED
of	O
cells	B-MED
were	O
positive	B-MED
at	O
the	O
sites	B-MED
of	O
the	O
MELF	B-MED
pattern	I-MED
(	O
P<0.01	O
)	O
.	O
There	O
was	O
no	B-MED
significant	I-MED
difference	I-MED
in	O
progression	B-MED
-	I-MED
free	I-MED
survival	I-MED
or	O
overall	B-MED
survival	I-MED
between	O
MELF	B-MED
group	I-MED
and	O
non	B-MED
-	I-MED
MELF	I-MED
group	I-MED
by	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
analysis	I-MED
.	O
These	O
findings	O
suggest	O
a	O
possibility	O
that	O
cells	B-MED
at	O
the	O
sites	B-MED
of	O
MELF	B-MED
pattern	I-MED
had	O
acquired	O
increased	B-MED
invasiveness	B-MED
through	O
the	O
function	B-MED
of	O
the	O
CXCL14	B-MED
-	O
CXCR4	B-MED
and	O
CXCL12	B-MED
-	O
CXCR4	B-MED
axes	O
.	O
Systems	B-MED
Toxicology	B-MED
:	O
Real	O
World	B-MED
Applications	B-MED
and	O
Opportunities	B-MED
Systems	B-MED
Toxicology	B-MED
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	B-MED
biological	I-MED
effects	I-MED
of	O
xenobiotics	B-MED
are	O
characterized	B-MED
from	O
empirical	B-MED
end	B-MED
points	I-MED
to	O
describing	O
modes	B-MED
of	O
action	B-MED
as	O
adverse	B-MED
outcome	B-MED
pathways	B-MED
and	O
perturbed	B-MED
networks	I-MED
.	O
Toward	O
this	O
aim	O
,	O
Systems	B-MED
Toxicology	B-MED
entails	O
the	O
integration	B-MED
of	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
toxicity	B-MED
data	B-MED
with	O
computational	B-MED
modeling	I-MED
.	O
This	O
evolving	O
approach	B-MED
depends	O
critically	O
on	O
data	B-MED
reliability	B-MED
and	O
relevance	B-MED
,	O
which	O
in	O
turn	O
depends	O
on	O
the	O
quality	B-MED
of	O
experimental	B-MED
models	I-MED
and	O
bioanalysis	B-MED
techniques	I-MED
used	O
to	O
generate	O
toxicological	B-MED
data	B-MED
.	O
Systems	B-MED
Toxicology	B-MED
involves	O
the	O
use	O
of	O
large	O
-	O
scale	O
data	B-MED
streams	I-MED
(	O
"	O
big	O
data	B-MED
"	O
)	O
,	O
such	O
as	O
those	O
derived	O
from	O
omics	B-MED
measurements	I-MED
that	O
require	O
computational	B-MED
means	O
for	O
obtaining	O
informative	B-MED
results	B-MED
.	O
Thus	O
,	O
integrative	B-MED
analysis	I-MED
of	O
multiple	B-MED
molecular	B-MED
measurements	I-MED
,	O
particularly	O
acquired	O
by	O
omics	B-MED
strategies	I-MED
,	O
is	O
a	O
key	O
approach	B-MED
in	O
Systems	B-MED
Toxicology	B-MED
.	O
In	O
recent	O
years	O
,	O
there	O
have	O
been	O
significant	O
advances	O
centered	O
on	O
in	B-MED
vitro	I-MED
test	O
systems	O
and	O
bioanalytical	B-MED
strategies	I-MED
,	O
yet	O
a	O
frontier	O
challenge	O
concerns	O
linking	B-MED
observed	O
network	B-MED
perturbations	B-MED
to	O
phenotypes	B-MED
,	O
which	O
will	O
require	O
understanding	O
pathways	B-MED
and	O
networks	B-MED
that	O
give	O
rise	O
to	O
adverse	B-MED
responses	I-MED
.	O
This	O
summary	B-MED
perspective	O
from	O
a	O
2016	O
Systems	B-MED
Toxicology	B-MED
meeting	B-MED
,	O
an	O
international	B-MED
conference	I-MED
held	O
in	O
the	O
Alps	B-MED
of	O
Switzerland	B-MED
,	O
describes	O
the	O
limitations	B-MED
and	O
opportunities	B-MED
of	O
selected	O
emerging	O
applications	B-MED
in	O
this	O
rapidly	O
advancing	O
field	O
.	O
Systems	B-MED
Toxicology	B-MED
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	B-MED
biological	I-MED
effects	I-MED
of	O
xenobiotics	B-MED
are	O
characterized	B-MED
,	O
from	O
empirical	B-MED
end	B-MED
points	I-MED
to	O
pathways	B-MED
of	O
toxicity	B-MED
.	O
This	O
requires	O
the	O
integration	B-MED
of	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
data	B-MED
with	O
computational	B-MED
modeling	I-MED
.	O
Test	O
systems	O
and	O
bioanalytical	B-MED
technologies	I-MED
have	O
made	O
significant	O
advances	O
,	O
but	O
ensuring	O
data	B-MED
reliability	B-MED
and	O
relevance	B-MED
is	O
an	O
ongoing	O
concern	O
.	O
The	O
major	O
challenge	O
facing	O
the	O
new	O
pathway	B-MED
approach	B-MED
is	O
determining	O
how	O
to	O
link	B-MED
observed	O
network	B-MED
perturbations	B-MED
to	O
phenotypic	B-MED
toxicity	B-MED
.	O
Mobile	B-MED
phone	I-MED
use	B-MED
,	O
behavioural	B-MED
problems	I-MED
and	O
concentration	B-MED
capacity	B-MED
in	O
adolescents	B-MED
:	O
A	O
prospective	B-MED
study	I-MED
The	O
aim	O
of	O
this	O
study	B-MED
is	O
to	O
prospectively	O
investigate	B-MED
whether	O
exposure	B-MED
to	I-MED
radiofrequency	B-MED
electromagnetic	I-MED
fields	I-MED
(	O
RF	B-MED
-	I-MED
EMF	I-MED
)	O
emitted	O
by	O
mobile	B-MED
phones	I-MED
and	O
other	O
wireless	B-MED
communication	I-MED
devices	I-MED
is	O
related	O
to	O
behavioural	B-MED
problems	I-MED
or	O
concentration	B-MED
capacity	B-MED
in	O
adolescents	B-MED
.	O
The	O
HERMES	B-MED
(	O
Health	B-MED
Effects	B-MED
Related	B-MED
to	O
Mobile	B-MED
phonE	I-MED
use	O
in	O
adolescentS	B-MED
)	O
study	O
sample	B-MED
consisted	O
of	O
439	O
Swiss	B-MED
adolescents	B-MED
aged	B-MED
12	O
-	O
17	O
years	B-MED
.	O
Behavioural	B-MED
problems	I-MED
were	O
assessed	B-MED
using	O
the	O
Strengths	B-MED
and	I-MED
Difficulties	I-MED
Questionnaire	I-MED
(	O
SDQ	B-MED
)	O
,	O
concentration	B-MED
capacity	B-MED
of	O
the	O
adolescents	B-MED
was	O
measured	B-MED
by	O
means	O
of	O
a	O
standardized	B-MED
computerized	I-MED
cognitive	I-MED
test	I-MED
named	O
FAKT	B-MED
.	O
Cross	B-MED
-	I-MED
sectional	I-MED
and	O
longitudinal	B-MED
(	O
1year	B-MED
of	O
follow	B-MED
-	I-MED
up	I-MED
)	O
analyses	B-MED
were	O
performed	B-MED
to	O
investigate	B-MED
possible	O
associations	B-MED
between	O
behavioural	B-MED
problems	I-MED
and	O
concentration	B-MED
capacity	B-MED
and	O
different	B-MED
exposure	B-MED
measures	B-MED
:	O
self	B-MED
-	I-MED
reported	I-MED
and	O
operator	B-MED
-recorded	O
wireless	B-MED
communication	I-MED
device	I-MED
use	O
,	O
cumulative	B-MED
RF	B-MED
-	I-MED
EMF	I-MED
brain	B-MED
and	O
whole	B-MED
body	I-MED
dose	O
and	O
measured	B-MED
personal	O
RF	B-MED
-	I-MED
EMF	I-MED
exposure	B-MED
.	O
In	O
the	O
cross	B-MED
-	I-MED
sectional	I-MED
analyses	I-MED
behavioural	B-MED
problems	I-MED
were	O
associated	B-MED
with	I-MED
several	O
self	B-MED
-	I-MED
reported	I-MED
wireless	B-MED
device	I-MED
use	B-MED
measures	B-MED
but	O
not	O
operator	B-MED
-recorded	O
mobile	B-MED
phone	I-MED
use	B-MED
measures	B-MED
,	O
concentration	B-MED
capacity	B-MED
was	O
associated	B-MED
with	I-MED
several	O
self	B-MED
-	I-MED
reported	I-MED
and	O
operator	B-MED
-recorded	O
exposures	B-MED
.	O
The	O
longitudinal	B-MED
analyses	I-MED
point	O
towards	O
absence	B-MED
of	O
associations	B-MED
.	O
The	O
lack	B-MED
of	O
consistent	B-MED
exposure	B-MED
-response	O
patterns	B-MED
in	O
the	O
longitudinal	B-MED
analyses	I-MED
suggests	O
that	O
behavioural	B-MED
problems	I-MED
and	O
concentration	B-MED
capacity	B-MED
are	O
not	O
affected	B-MED
by	O
the	O
use	O
of	O
wireless	B-MED
communication	I-MED
devices	I-MED
or	O
RF	B-MED
-	I-MED
EMF	I-MED
exposure	B-MED
.	O
Information	B-MED
bias	B-MED
and	O
reverse	O
causality	O
are	O
likely	O
explanations	B-MED
for	O
the	O
observed	O
cross	B-MED
-	I-MED
sectional	I-MED
findings	I-MED
.	O
Temporal	O
upregulation	B-MED
of	O
host	B-MED
surface	I-MED
receptors	I-MED
provides	O
a	O
window	O
of	O
opportunity	O
for	O
bacterial	B-MED
adhesion	I-MED
and	O
disease	B-MED
Host	B-MED
surface	I-MED
receptors	I-MED
provide	O
bacteria	B-MED
with	O
a	O
foothold	O
from	O
which	O
to	O
attach	B-MED
,	O
colonize	O
and	O
,	O
in	O
some	O
cases	O
,	O
invade	O
tissue	B-MED
and	O
elicit	O
human	B-MED
disease	B-MED
.	O
In	O
this	O
review	O
,	O
we	O
discuss	O
several	O
key	O
host	B-MED
receptors	I-MED
and	O
cognate	B-MED
adhesins	I-MED
that	O
function	O
in	O
bacterial	B-MED
pathogenesis	B-MED
.	O
In	O
particular	O
,	O
we	O
examine	O
the	O
elevated	B-MED
expression	B-MED
of	O
host	B-MED
surface	I-MED
receptors	I-MED
such	O
as	O
CEACAM-1	B-MED
,	O
CEACAM-6	B-MED
,	O
ICAM-1	B-MED
and	O
PAFR	B-MED
in	O
response	B-MED
to	I-MED
specific	I-MED
stimuli	I-MED
.	O
We	O
explore	O
how	O
upregulated	B-MED
receptors	I-MED
,	O
in	O
turn	O
,	O
expose	O
the	O
host	B-MED
to	O
a	O
range	O
of	O
bacterial	B-MED
infections	I-MED
in	O
the	O
respiratory	B-MED
tract	I-MED
.	O
It	O
is	O
apparent	O
that	O
exploitation	O
of	O
receptor	B-MED
induction	B-MED
for	O
bacterial	B-MED
adherence	I-MED
is	O
not	O
unique	O
to	O
one	O
body	B-MED
system	I-MED
,	O
but	O
is	O
also	O
observed	O
in	O
the	O
central	B-MED
nervous	I-MED
,	O
gastrointestinal	B-MED
and	O
urogenital	B-MED
systems	I-MED
.	O
Prokaryotic	B-MED
pathogens	B-MED
which	O
utilize	O
this	O
mechanism	O
for	O
their	O
infectivity	B-MED
include	O
Streptococcus	B-MED
pneumoniae	I-MED
,	O
Haemophilus	B-MED
influenzae	I-MED
,	O
Neisseria	B-MED
meningitidis	I-MED
and	O
Escherichia	B-MED
coli	I-MED
.	O
A	O
number	O
of	O
approaches	O
have	O
been	O
used	O
,	O
in	O
both	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
experimental	I-MED
models	I-MED
,	O
to	O
inhibit	O
bacterial	B-MED
attachment	I-MED
to	O
temporally	O
expressed	B-MED
host	B-MED
receptors	I-MED
.	O
Some	O
of	O
these	O
novel	O
strategies	O
may	O
advance	O
future	O
targeted	B-MED
interventions	B-MED
for	O
the	O
prevention	B-MED
and	O
treatment	B-MED
of	O
bacterial	B-MED
disease	I-MED
.	O
Pre	B-MED
-	I-MED
hypertension	I-MED
,	O
pre	B-MED
-	I-MED
diabetes	I-MED
or	O
both	O
:	O
which	O
is	O
best	O
at	O
predicting	B-MED
cardiovascular	B-MED
events	I-MED
in	O
the	O
long	B-MED
term	I-MED
?	O
The	O
present	O
study	B-MED
aimed	O
to	O
assess	O
the	O
value	O
of	O
pre	B-MED
-	I-MED
diabetes	I-MED
and	O
pre	B-MED
-	I-MED
hypertension	I-MED
in	O
predicting	B-MED
cardiovascular	B-MED
events	I-MED
.	O
A	O
population	B-MED
-based	O
,	O
cross	B-MED
-	I-MED
sectional	I-MED
survey	I-MED
was	O
conducted	O
,	O
representing	O
a	O
large	O
sample	O
of	O
the	O
general	O
Iranian	B-MED
population	B-MED
aged	O
35	O
years	B-MED
and	O
older	O
from	O
the	O
Isfahan	B-MED
Province	I-MED
and	O
determined	O
using	O
a	O
random	B-MED
,	I-MED
multistage	I-MED
cluster	I-MED
-	I-MED
sampling	I-MED
10	O
-	O
year	O
cohort	B-MED
.	O
The	O
five	O
end	O
points	O
considered	O
as	O
study	B-MED
outcome	I-MED
were	O
unstable	B-MED
angina	I-MED
(	O
UA	B-MED
)	O
,	O
acute	B-MED
occurrence	B-MED
of	O
myocardial	B-MED
infarction	I-MED
(	O
MI	B-MED
)	O
,	O
sudden	B-MED
cardiac	I-MED
death	I-MED
(	O
SCD	B-MED
)	O
,	O
brain	B-MED
stroke	I-MED
and	O
cardiovascular	B-MED
disease	I-MED
(	O
CVD	B-MED
)	O
.	O
Of	O
the	O
6323	O
subjects	O
scheduled	O
for	O
assessment	B-MED
of	O
diabetes	B-MED
state	I-MED
617	O
were	O
diabetics	B-MED
and	O
712	O
were	O
pre	B-MED
-	I-MED
diabetic	I-MED
.	O
In	O
addition	O
,	O
of	O
these	O
subjects	O
,	O
1754	O
had	O
hypertension	B-MED
and	O
2500	O
had	O
pre	B-MED
-	I-MED
hypertension	I-MED
.	O
Analysing	O
only	O
pre	B-MED
-	I-MED
hypertension	I-MED
,	O
pre	B-MED
-	I-MED
diabetes	I-MED
and	O
its	O
combination	O
and	O
adjusted	O
for	O
gender	B-MED
and	O
age	O
variables	O
,	O
pre	B-MED
-	I-MED
hypertension	I-MED
and	O
pre	B-MED
-	I-MED
diabetes	I-MED
status	O
together	O
,	O
could	O
only	O
effectively	O
predict	O
occurrence	B-MED
of	O
MI	B-MED
(	O
hazard	B-MED
ratio	I-MED
HR	B-MED
(	O
HR)=3.21	O
,	O
95	O
%	O
confidence	B-MED
interval	I-MED
(	O
CI	B-MED
):	O
1.06	O
-	O
9.76	O
,	O
P=0.04	O
)	O
.	O
In	O
the	O
same	O
COX	B-MED
regression	I-MED
models	I-MED
,	O
pre	B-MED
-	I-MED
hypertension	I-MED
status	O
could	O
predict	O
UA	B-MED
and	O
CVD	B-MED
occurrence	B-MED
(	O
HR	B-MED
=	O
2.94	O
,	O
95	O
%	O
CI	B-MED
:	O
1.68	O
-	O
5.14	O
,	O
P<0.001	O
and	O
HR	B-MED
=	O
1.74	O
,	O
95	O
%	O
CI	B-MED
:	O
1.23	O
-	O
2.47	O
,	O
P=0.002	O
,	O
respectively	O
)	O
.	O
However	O
,	O
pre	B-MED
-	I-MED
diabetes	I-MED
status	O
could	O
not	O
predict	O
any	O
of	O
these	O
events	O
after	O
adjustment	O
for	O
gender	B-MED
and	O
age	B-MED
.	O
Our	O
data	B-MED
provide	O
valuable	O
evidence	B-MED
of	O
the	O
triggering	O
role	O
of	O
pre	B-MED
-	I-MED
hypertension	I-MED
and	O
pre	B-MED
-	I-MED
diabetes	I-MED
together	O
,	O
on	O
appearance	B-MED
and	O
progression	B-MED
of	O
MI	B-MED
even	O
in	O
healthy	B-MED
individuals	I-MED
and	O
the	O
significant	O
predicting	B-MED
value	O
of	O
pre	B-MED
-	I-MED
hypertension	I-MED
on	O
the	O
occurrence	B-MED
of	O
UA	B-MED
and	O
CVD	B-MED
.	O
In	O
this	O
regard	O
,	O
the	O
value	O
of	O
pre	B-MED
-	I-MED
hypertension	I-MED
and	O
pre	B-MED
-	I-MED
diabetes	I-MED
together	O
,	O
and	O
the	O
pre	B-MED
-	I-MED
hypertension	I-MED
state	O
alone	O
,	O
are	O
clearly	O
superior	O
to	O
pre	B-MED
-	I-MED
diabetes	I-MED
state	O
alone	O
in	O
predicting	B-MED
cardiovascular	B-MED
events	I-MED
.	O
Breakthrough	B-MED
viridans	B-MED
streptococcal	I-MED
bacteremia	I-MED
in	O
allogeneic	B-MED
hematopoietic	I-MED
stem	I-MED
cell	I-MED
transplant	I-MED
recipients	B-MED
receiving	B-MED
levofloxacin	B-MED
prophylaxis	B-MED
in	O
a	O
Japanese	B-MED
hospital	B-MED
Breakthrough	B-MED
viridans	B-MED
streptococcal	I-MED
bacteremia	I-MED
(	O
VSB	B-MED
)	O
in	O
patients	B-MED
with	O
hematological	B-MED
malignancy	I-MED
receiving	B-MED
levofloxacin	B-MED
prophylaxis	B-MED
is	O
a	O
major	B-MED
blood	B-MED
stream	I-MED
infection	I-MED
(	O
BSI	B-MED
)	O
occurring	B-MED
during	B-MED
febrile	B-MED
neutropenia	I-MED
.	O
However	O
,	O
clinical	B-MED
data	I-MED
focused	B-MED
on	O
VSB	B-MED
in	O
allogeneic	B-MED
hematopoietic	I-MED
stem	I-MED
cell	I-MED
transplant	I-MED
(	O
allo	B-MED
-	I-MED
HSCT	I-MED
)	O
recipients	B-MED
are	O
lacking	B-MED
.	O
The	O
medical	B-MED
records	I-MED
of	O
allo	B-MED
-	I-MED
HSCT	I-MED
recipients	B-MED
who	O
received	B-MED
oral	B-MED
levofloxacin	B-MED
prophylaxis	B-MED
between	O
January	O
2011	O
and	O
August	O
2013	O
at	O
Toranomon	B-MED
Hospital	I-MED
were	O
reviewed	B-MED
to	O
evaluate	B-MED
breakthrough	B-MED
VSB	B-MED
.	O
Stored	O
viridans	B-MED
streptococcal	I-MED
(	O
VGS	B-MED
)	O
species	B-MED
were	O
identified	B-MED
by	O
using	B-MED
sodA	B-MED
gene	I-MED
sequencing	B-MED
,	O
and	O
were	O
assessed	B-MED
for	O
drug	B-MED
susceptibility	I-MED
.	O
Among	O
the	O
184	O
allo	B-MED
-	I-MED
HSCT	I-MED
recipients	B-MED
on	O
levofloxacin	B-MED
prophylaxis	B-MED
,	O
28	O
(	O
15.2	O
%	O
)	O
experienced	O
breakthrough	B-MED
VSB	B-MED
.	O
All	O
of	O
the	O
28	O
recipients	B-MED
with	O
VSB	B-MED
were	O
treated	B-MED
with	O
a	O
cefepime	B-MED
-	O
based	B-MED
or	O
piperacillin	B-MED
/	I-MED
tazobactam	I-MED
-	O
based	B-MED
regimen	B-MED
.	O
The	O
susceptibility	B-MED
rates	B-MED
of	O
the	O
VGS	B-MED
strains	B-MED
for	O
levofloxacin	B-MED
,	O
cefepime	B-MED
,	O
piperacillin	B-MED
/	I-MED
tazobactam	I-MED
,	O
meropenem	B-MED
,	O
and	O
vancomycin	B-MED
were	O
0	O
%	O
,	O
95	O
%	O
,	O
100	O
%	O
,	O
100	O
%	O
,	O
and	O
100	O
%	O
,	O
respectively	O
.	O
Both	O
the	O
MIC50	B-MED
(	O
minimum	B-MED
inhibitory	I-MED
concentration	I-MED
)	O
and	O
the	O
MIC90	B-MED
of	O
ceftazidim	B-MED
(	O
0.5	O
μg	O
/	O
mL	O
and	O
2	O
μg	O
/	O
mL	O
,	O
respectively	O
)	O
were	O
higher	B-MED
than	O
the	O
MIC90	B-MED
of	O
all	O
the	O
other	O
anti	B-MED
-	I-MED
pseudomonal	I-MED
beta	I-MED
-	I-MED
lactams	I-MED
(	O
APBLs	B-MED
)	O
.	O
Only	O
1	O
VGS	B-MED
strain	B-MED
had	O
a	O
penicillin	B-MED
MIC	B-MED
≥	O
2	O
μg	O
/	O
mL	O
by	O
the	O
Etest	B-MED
(	O
3.6	O
%	O
)	O
.	O
There	O
were	O
no	B-MED
cases	B-MED
with	O
acute	B-MED
respiratory	I-MED
distress	I-MED
syndrome	I-MED
(	O
ARDS	B-MED
)	O
that	O
was	O
associated	B-MED
with	I-MED
VSB	B-MED
,	O
although	O
the	O
rate	B-MED
of	O
viridans	B-MED
group	I-MED
streptococcal	I-MED
shock	I-MED
syndrome	I-MED
was	O
high	B-MED
(	O
26	O
%	O
)	O
.	O
The	O
crude	O
30	B-MED
-	I-MED
day	I-MED
mortality	B-MED
rate	I-MED
in	O
the	O
VSB	B-MED
group	B-MED
(	O
10.7	O
%	O
)	O
did	O
not	B-MED
differ	B-MED
significantly	B-MED
from	O
that	O
in	O
the	O
BSI	B-MED
without	B-MED
VSB	B-MED
group	B-MED
(	O
9.3	O
%	O
)	O
or	O
non	B-MED
-	O
BSI	B-MED
group	B-MED
(	O
7.0	O
%	O
)	O
(	O
P	O
=	O
0.77	O
)	O
.	O
Also	O
,	O
VSB	B-MED
was	O
not	B-MED
a	O
risk	B-MED
factor	I-MED
for	O
all	O
-	O
cause	O
mortality	B-MED
up	O
to	O
60	B-MED
days	I-MED
following	B-MED
allo	B-MED
-	I-MED
HSCT	I-MED
(	O
P	O
=	O
0.43	O
)	O
.	O
APBL	B-MED
with	O
increased	B-MED
anti	B-MED
-	I-MED
VGS	I-MED
activity	I-MED
(	O
APBL	B-MED
-	I-MED
VA	I-MED
)	O
monotherapy	B-MED
would	O
typically	O
be	O
optimal	B-MED
for	O
treating	B-MED
the	O
VGS	B-MED
strains	B-MED
in	O
this	O
setting	O
.	O
Indication	O
of	O
adding	O
an	O
empiric	O
anti	B-MED
-	I-MED
gram	I-MED
-	I-MED
positive	I-MED
agent	I-MED
to	O
APBL	B-MED
-	I-MED
VA	I-MED
for	O
treating	B-MED
VSB	B-MED
should	O
depend	O
on	O
local	B-MED
factors	B-MED
,	O
such	O
as	O
the	O
susceptibility	B-MED
results	B-MED
.	O
In	O
addition	O
,	O
breakthrough	B-MED
VSB	B-MED
is	O
probably	O
not	B-MED
a	O
major	B-MED
cause	B-MED
of	I-MED
death	I-MED
in	O
allo	B-MED
-	I-MED
HSCT	I-MED
settings	O
,	O
where	O
beta	B-MED
-	I-MED
lactam	I-MED
non	B-MED
-	I-MED
susceptible	I-MED
VGS	I-MED
and	O
the	O
ARDS	B-MED
are	O
rare	B-MED
.	O
Exercise	B-MED
increases	B-MED
lactoferrin	B-MED
,	O
but	O
decreases	B-MED
lysozyme	B-MED
in	O
salivary	B-MED
granulocytes	B-MED
Intracellular	B-MED
lactoferrin	I-MED
(	O
Lac	B-MED
)	O
and	O
lysozyme	B-MED
(	O
Lys	B-MED
)	O
content	O
play	O
an	O
important	O
role	O
in	O
regulating	O
inflammation	B-MED
and	O
promoting	B-MED
host	B-MED
protection	I-MED
.	O
While	O
exercise	B-MED
has	O
demonstrated	O
an	O
increase	B-MED
in	O
Lac	B-MED
and	O
Lys	B-MED
concentration	B-MED
in	O
exocrine	B-MED
solutions	I-MED
,	O
little	O
is	O
known	O
regarding	O
intracellular	B-MED
concentration	I-MED
changes	I-MED
in	O
response	O
to	O
exercise	B-MED
.	O
To	O
quantify	B-MED
intracellular	O
Lac	B-MED
and	O
Lys	B-MED
concentration	B-MED
before	O
and	O
after	O
exercise	B-MED
in	O
salivary	B-MED
CD45(+)CD15(+	B-MED
)	I-MED
cells	I-MED
.	O
11	O
males	B-MED
(	O
20.3	O
±	O
0.8	O
years	B-MED
,	O
57.2	O
±	O
7.6	O
mL	O
/	O
kg	O
/	O
min	O
V̇O2pk	B-MED
,	O
11.1	O
±	O
3.9	O
%	O
body	B-MED
fat	I-MED
)	O
ran	B-MED
for	O
45	O
min	B-MED
at	O
75	O
%	O
of	O
VO2pk	B-MED
.	O
12	O
mL	O
of	O
stimulated	B-MED
saliva	I-MED
were	O
collected	B-MED
pre	B-MED
and	O
immediately	O
post	B-MED
exercise	I-MED
.	O
Saliva	B-MED
was	O
filtered	O
through	O
a	O
30-µm	O
filter	O
before	O
analysis	O
of	O
leukocytes	B-MED
(	O
CD45(+	B-MED
)	I-MED
)	O
and	O
granulocytes	B-MED
(	O
CD45(+)CD15(+	B-MED
)	I-MED
)	O
using	O
flow	B-MED
cytometry	I-MED
.	O
Median	B-MED
fluorescent	I-MED
intensity	I-MED
(	O
MFI	B-MED
)	O
of	O
Lac	B-MED
increased	B-MED
from	O
pre	B-MED
(	O
64,268	O
±	O
46,036	O
MFI	B-MED
)	O
to	O
post	B-MED
(	O
117,134	O
±	O
88,115	O
MFI	B-MED
)	O
exercise	B-MED
(	O
p	O
<	O
0.05	O
)	O
.	O
Lys	B-MED
MFI	B-MED
decreased	B-MED
with	O
exercise	B-MED
(	O
pre	B-MED
:	O
16,933	O
±	O
8249	O
;	O
post	B-MED
:	O
11,616	O
±	O
6875	O
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Acute	B-MED
running	I-MED
resulted	O
in	O
an	O
increased	B-MED
Lac	B-MED
concentration	B-MED
which	O
could	O
lead	O
to	O
a	O
decrease	B-MED
in	O
inflammation	B-MED
,	O
adding	O
further	O
evidence	O
of	O
the	O
anti	B-MED
-	I-MED
inflammatory	I-MED
effects	I-MED
of	O
exercise	B-MED
.	O
Conversely	O
,	O
the	O
exercise	B-MED
-associated	O
decrease	B-MED
of	O
intracellular	B-MED
Lys	I-MED
content	O
could	O
be	O
the	O
cause	B-MED
of	O
increased	B-MED
Lys	B-MED
in	O
exocrine	B-MED
solutions	I-MED
.	O
Functional	B-MED
Result	I-MED
After	O
Cochlear	B-MED
Implantation	I-MED
in	O
Children	B-MED
and	O
Adults	B-MED
With	O
Single	B-MED
-	I-MED
sided	I-MED
Deafness	I-MED
Patients	B-MED
with	O
single	B-MED
-	I-MED
sided	I-MED
deafness	I-MED
(	O
SSD	B-MED
)	O
suffer	O
from	O
reduced	B-MED
binaural	B-MED
hearing	I-MED
(	O
i.e.	O
,	O
sound	B-MED
localization	I-MED
and	O
speech	B-MED
in	O
noise	B-MED
discrimination	I-MED
)	O
.	O
Cochlear	B-MED
implantation	I-MED
has	O
recently	O
been	O
introduced	O
for	O
patients	B-MED
with	O
SSD	B-MED
,	O
as	O
an	O
alternative	B-MED
to	O
hearing	B-MED
devices	I-MED
that	O
employ	O
contralateral	B-MED
routing	O
of	O
the	O
signal	B-MED
.	O
Application	B-MED
to	O
children	B-MED
has	O
also	O
been	O
started	O
.	O
We	O
retrospectively	B-MED
analyze	O
a	O
case	O
series	O
of	O
4	O
children	B-MED
and	O
17	O
adults	B-MED
with	O
SSD	B-MED
,	O
treated	B-MED
with	I-MED
cochlear	B-MED
implantation	I-MED
.	O
The	O
outcome	B-MED
of	O
adult	B-MED
patients	B-MED
was	O
compared	O
with	O
a	O
control	B-MED
group	I-MED
of	O
27	O
patients	B-MED
with	O
bilateral	B-MED
profound	I-MED
hearing	I-MED
loss	I-MED
using	O
a	O
cochlear	B-MED
implant	I-MED
.	O
During	O
12	O
months	O
,	O
the	O
mean	B-MED
speech	B-MED
recognition	I-MED
score	B-MED
increased	O
from	O
30	O
to	O
41	O
%	O
for	O
monosyllabic	B-MED
monosyllabic	B-MED
words	I-MED
in	O
adults	B-MED
,	O
and	O
from	O
58	O
to	O
89	O
%	O
for	O
multisyllabic	B-MED
numbers	O
.	O
The	O
cochlear	B-MED
implant	I-MED
(	O
CI	B-MED
)	O
improved	B-MED
hearing	I-MED
in	O
noise	B-MED
in	O
all	O
SSD	B-MED
patients	B-MED
,	O
as	O
was	O
demonstrated	O
by	O
a	O
significant	O
improvement	B-MED
of	O
the	O
speech	B-MED
reception	I-MED
threshold	I-MED
in	O
different	O
speech	O
and	O
noise	O
configurations	O
.	O
Sound	B-MED
localization	I-MED
-correlated	O
angle	B-MED
detection	I-MED
error	I-MED
improved	B-MED
with	O
CI	B-MED
use	O
at	O
every	O
time	O
point	O
.	O
The	O
maximum	O
word	B-MED
recognition	I-MED
score	B-MED
for	O
monosyllabic	B-MED
monosyllabic	B-MED
words	I-MED
in	O
quiet	O
correlated	O
with	O
the	O
logarithm	B-MED
of	O
the	O
duration	B-MED
of	I-MED
deafness	I-MED
deafness	B-MED
;	O
improvement	B-MED
of	O
the	O
speech	B-MED
reception	I-MED
threshold	I-MED
and	O
RMS	B-MED
angle	I-MED
detection	I-MED
error	I-MED
by	O
the	O
CI	B-MED
did	O
not	O
.	O
All	O
SSD	B-MED
patients	B-MED
benefitted	O
from	O
the	O
CI	B-MED
in	O
different	O
hearing	B-MED
situations	B-MED
.	O
Patients	B-MED
with	O
SSD	B-MED
for	O
a	O
long	O
period	O
can	O
improve	B-MED
after	O
cochlear	B-MED
implantation	I-MED
.	O
Host	B-MED
plant	I-MED
affects	O
the	O
sexual	B-MED
attractiveness	I-MED
of	O
the	O
female	B-MED
white	B-MED
-	I-MED
spotted	I-MED
longicorn	I-MED
beetle	I-MED
,	O
Anoplophora	B-MED
malasiaca	I-MED
Anoplophora	B-MED
malasiaca	I-MED
(	O
Coleoptera	B-MED
:	O
Cerambycidae	B-MED
)	O
is	O
a	O
serious	O
pest	O
that	O
destroys	O
various	O
landscape	B-MED
and	O
crop	B-MED
trees	B-MED
in	O
Japan	B-MED
.	O
We	O
evaluated	O
the	O
precopulatory	B-MED
responses	B-MED
of	O
three	O
different	O
A.	B-MED
malasiaca	I-MED
populations	B-MED
collected	O
from	O
mandarin	B-MED
orange	I-MED
,	O
willow	B-MED
and	O
blueberry	B-MED
trees	I-MED
.	O
Most	O
of	O
the	O
males	B-MED
accepted	O
mates	O
from	O
within	O
the	O
same	O
host	B-MED
plant	I-MED
population	B-MED
as	O
well	O
as	O
females	B-MED
from	O
the	O
willow	B-MED
and	O
blueberry	B-MED
populations	B-MED
.	O
However	O
,	O
significant	O
number	O
of	O
males	B-MED
from	O
the	O
blueberry	B-MED
and	O
willow	B-MED
populations	B-MED
rejected	O
females	B-MED
from	O
the	O
mandarin	B-MED
orange	I-MED
population	B-MED
immediately	O
after	O
touching	O
them	O
with	O
their	O
antennae	B-MED
.	O
Because	O
all	O
three	O
of	O
the	O
female	B-MED
populations	B-MED
produced	O
contact	O
sex	B-MED
pheromones	I-MED
on	O
their	O
elytra	B-MED
,	O
the	O
females	B-MED
of	O
the	O
mandarin	B-MED
orange	I-MED
population	B-MED
were	O
predicted	O
to	O
possess	O
extra	O
chemicals	B-MED
that	O
repelled	O
the	O
males	B-MED
of	O
the	O
other	O
two	O
populations	B-MED
.	O
β	B-MED
-	I-MED
Elemene	I-MED
was	O
identified	O
as	O
a	O
key	O
component	O
that	O
was	O
only	O
found	O
in	O
mandarin	B-MED
orange	I-MED
-fed	O
females	B-MED
and	O
induced	O
a	O
rejection	B-MED
response	B-MED
in	O
willow	B-MED
-fed	O
males	B-MED
.	O
Our	O
results	O
represent	O
the	O
first	O
example	O
of	O
a	O
female	B-MED
-acquired	O
repellent	B-MED
against	O
conspecific	O
males	B-MED
of	O
different	O
host	B-MED
plant	I-MED
populations	B-MED
,	O
indicating	O
that	O
the	O
host	B-MED
plant	I-MED
greatly	O
affects	O
the	O
female	B-MED
's	I-MED
sexual	B-MED
attractiveness	I-MED
.	O
The	O
four	O
-	O
component	O
aureocin	B-MED
A70	I-MED
as	O
a	O
promising	B-MED
agent	I-MED
for	O
food	B-MED
biopreservation	I-MED
Aureocin	B-MED
A70	I-MED
is	O
the	O
only	O
four	O
-	O
component	O
bacteriocin	B-MED
described	O
to	O
date	O
.	O
As	O
it	O
inhibits	B-MED
the	I-MED
growth	I-MED
of	O
a	O
wide	O
range	O
of	O
Gram	B-MED
-	I-MED
positive	I-MED
bacteria	I-MED
,	O
including	O
Listeria	B-MED
monocytogenes	I-MED
strains	B-MED
isolated	O
from	O
food	B-MED
,	O
its	O
potential	O
for	O
improving	O
food	B-MED
safety	I-MED
was	O
investigated	O
in	O
this	O
study	O
.	O
Aureocin	B-MED
A70	I-MED
(	O
10,240AU	O
/	O
mL	O
)	O
proved	O
to	O
be	O
bactericidal	B-MED
,	O
but	O
not	O
extensively	O
lytic	B-MED
,	O
against	O
listerial	B-MED
strains	B-MED
.	O
The	O
antibacterial	B-MED
activity	I-MED
of	O
aureocin	B-MED
A70	I-MED
(	O
16AU	O
/	O
mL	O
)	O
was	O
then	O
tested	O
in	O
UHT	B-MED
-	I-MED
treated	I-MED
skimmed	B-MED
milk	I-MED
inoculated	B-MED
with	O
the	O
food	B-MED
-associated	O
L.	B-MED
monocytogenes	I-MED
L12	I-MED
strain	I-MED
(	O
4	O
-	O
log	O
CFU	O
/	O
mL	O
)	O
during	O
storage	B-MED
at	O
4	O
°	O
C	O
for	O
one	O
week	O
.	O
Aureocin	B-MED
A70	I-MED
caused	O
a	O
time	O
-	O
dependent	O
reduction	B-MED
in	O
the	O
listerial	B-MED
viable	B-MED
cell	I-MED
counts	I-MED
(	O
5.51	O
-	O
log	O
units	O
)	O
up	O
to	O
7days	O
of	O
incubation	B-MED
.	O
Aureocin	B-MED
A70	I-MED
was	O
neither	O
toxic	B-MED
to	O
the	O
Vero	B-MED
and	O
the	O
L-929	B-MED
cell	I-MED
lines	I-MED
nor	O
exhibited	O
a	O
hemolytic	B-MED
activity	I-MED
against	O
sheep	B-MED
red	B-MED
blood	I-MED
cells	I-MED
.	O
Aureocin	B-MED
A70	I-MED
proved	O
to	O
be	O
completely	O
stable	O
for	O
one	O
month	O
at	O
25	O
°	O
C	O
,	O
16weeks	O
at	O
4	O
°	O
C	O
and	O
20weeks	O
at	O
-20	O
°	O
C	O
.	O
Aureocin	B-MED
A70	I-MED
exhibited	O
a	O
time	O
-	O
dependent	O
susceptibility	B-MED
to	O
simulated	B-MED
gastric	B-MED
juice	I-MED
and	O
bile	B-MED
salts	I-MED
mimicking	O
gastrointestinal	B-MED
conditions	I-MED
.	O
The	O
entrapment	B-MED
of	O
aureocin	B-MED
A70	I-MED
in	O
an	O
alginate	B-MED
/	O
gelatin	B-MED
matrix	I-MED
revealed	O
that	O
this	O
bacteriocin	B-MED
can	O
be	O
released	O
from	O
this	O
matrix	O
.	O
Moreover	O
,	O
it	O
remained	O
adsorbed	O
to	O
and	O
active	O
on	O
a	O
low	B-MED
-	I-MED
density	I-MED
polyethylene	I-MED
plastic	I-MED
surface	O
suggesting	O
that	O
aureocin	B-MED
A70	I-MED
may	O
be	O
employed	O
in	O
bioactive	B-MED
packaging	B-MED
to	O
control	B-MED
the	I-MED
growth	I-MED
of	O
undesirable	O
bacteria	B-MED
.	O
Taken	O
together	O
these	O
results	O
suggest	O
that	O
aureocin	B-MED
A70	I-MED
is	O
a	O
promising	B-MED
alternative	I-MED
to	O
be	O
used	O
in	O
food	B-MED
applications	I-MED
.	O
Lightweight	O
Open	B-MED
-	I-MED
Cell	I-MED
Scaffolds	I-MED
from	O
Sea	B-MED
Urchin	I-MED
Spines	B-MED
with	O
Superior	O
Material	B-MED
Properties	B-MED
for	O
Bone	B-MED
Defect	I-MED
Repair	I-MED
Sea	B-MED
urchin	I-MED
spines	B-MED
(	O
Heterocentrotus	B-MED
mammillatus	I-MED
)	O
,	O
with	O
a	O
hierarchical	O
open	B-MED
-	I-MED
cell	I-MED
structure	I-MED
similar	O
to	O
that	O
of	O
human	B-MED
trabecular	B-MED
bone	I-MED
and	O
superior	O
mechanical	B-MED
property	I-MED
(	O
compressive	B-MED
strength	I-MED
∼43.4	O
MPa	O
)	O
suitable	B-MED
for	O
machining	B-MED
to	O
shape	B-MED
,	O
were	O
explored	O
for	O
potential	B-MED
applications	B-MED
of	O
bone	B-MED
defect	I-MED
repair	I-MED
.	O
Finite	B-MED
element	I-MED
analyses	I-MED
reveal	O
that	O
the	O
compressive	O
stress	B-MED
concentrates	B-MED
along	O
the	O
dense	B-MED
growth	B-MED
rings	I-MED
and	O
dissipates	B-MED
through	O
strut	O
structures	B-MED
of	I-MED
the	I-MED
stereoms	I-MED
,	O
indicating	O
that	O
the	O
exquisite	O
mesostructures	B-MED
play	O
an	O
important	B-MED
role	O
in	O
high	O
strength	B-MED
-to-	O
weight	B-MED
ratios	B-MED
.	O
The	O
fracture	B-MED
strength	B-MED
of	O
magnesium	B-MED
-	O
substituted	B-MED
tricalcium	I-MED
phosphate	I-MED
(	B-MED
β	I-MED
-	I-MED
TCMP	I-MED
)	I-MED
scaffolds	I-MED
produced	O
by	O
hydrothermal	B-MED
conversion	B-MED
of	O
urchin	B-MED
spines	B-MED
is	O
about	O
9.3	O
MPa	O
,	O
comparable	B-MED
to	O
that	O
of	O
human	B-MED
trabecular	B-MED
bone	I-MED
.	O
New	O
bone	B-MED
forms	B-MED
along	O
outer	O
surfaces	B-MED
of	O
β	B-MED
-	I-MED
TCMP	I-MED
scaffolds	I-MED
after	O
implantation	B-MED
in	O
rabbit	B-MED
femoral	B-MED
defects	I-MED
for	O
one	O
month	B-MED
and	O
grows	B-MED
into	O
the	O
majority	O
of	O
the	O
inner	O
open	B-MED
-	I-MED
cell	I-MED
spaces	I-MED
postoperation	B-MED
in	O
three	O
month	B-MED
s	O
,	O
showing	O
tight	B-MED
interface	I-MED
between	O
the	O
scaffold	B-MED
and	O
regenerative	B-MED
bone	I-MED
tissue	I-MED
.	O
Fusion	B-MED
of	O
beagle	B-MED
lumbar	B-MED
facet	I-MED
joints	I-MED
using	O
a	O
Ti-6Al-4V	B-MED
cage	I-MED
and	O
β	B-MED
-	I-MED
TCMP	I-MED
scaffold	I-MED
can	O
be	O
completed	B-MED
within	O
seven	O
months	B-MED
with	O
obvious	O
biodegradation	B-MED
of	O
the	O
β	B-MED
-	I-MED
TCMP	I-MED
scaffold	I-MED
,	O
which	O
is	O
nearly	O
completely	B-MED
degraded	B-MED
and	O
replaced	B-MED
by	I-MED
newly	O
formed	B-MED
bone	B-MED
ten	O
months	B-MED
after	O
implantation	B-MED
.	O
Thus	O
,	O
sea	B-MED
urchin	I-MED
spines	B-MED
suitable	O
for	O
machining	B-MED
to	O
shape	B-MED
have	O
advantages	O
for	O
production	O
of	O
biodegradable	B-MED
artificial	B-MED
grafts	I-MED
for	O
bone	B-MED
defect	I-MED
repair	I-MED
.	O
Management	B-MED
of	O
skin	B-MED
and	I-MED
soft	I-MED
-	I-MED
tissue	I-MED
infections	I-MED
at	O
a	O
community	O
teaching	B-MED
hospital	I-MED
using	O
a	O
severity	B-MED
-	I-MED
of	I-MED
-	I-MED
illness	I-MED
tool	I-MED
Skin	B-MED
and	I-MED
soft	I-MED
-	I-MED
tissue	I-MED
infections	I-MED
(	O
SSTIs	B-MED
)	O
encompass	O
a	O
diverse	B-MED
range	B-MED
of	O
infections	B-MED
of	O
varying	O
severity	B-MED
.	O
The	O
Clinical	B-MED
Resource	I-MED
Efficiency	I-MED
Support	I-MED
Team	I-MED
(	I-MED
CREST	I-MED
)	I-MED
scoring	I-MED
system	I-MED
stratifies	B-MED
patients	B-MED
into	O
four	O
classes	B-MED
(	O
I	O
=	O
least	O
severe	B-MED
to	O
IV	O
=	O
most	O
severe	B-MED
)	O
based	O
on	O
the	O
Standardized	B-MED
Early	I-MED
Warning	I-MED
Score	I-MED
(	O
SEWS	B-MED
)	O
.	O
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
apply	O
CREST	B-MED
to	O
hospitalized	B-MED
patients	I-MED
with	O
SSTIs	B-MED
in	O
order	O
to	O
quantify	O
disease	B-MED
severity	I-MED
and	O
evaluate	B-MED
appropriateness	O
of	O
antibiotic	B-MED
management	O
.	O
This	O
was	O
a	O
retrospective	B-MED
,	O
hypothesis	B-MED
-generating	O
,	O
single	O
-	O
centre	O
evaluation	B-MED
of	O
hospitalized	B-MED
patients	I-MED
with	O
SSTIs	B-MED
admitted	B-MED
in	O
2011	O
.	O
Based	O
on	O
CREST	B-MED
classification	O
,	O
the	O
empirical	B-MED
antimicrobial	B-MED
choices	O
were	O
categorized	B-MED
as	O
appropriate	O
,	O
over	B-MED
-	I-MED
treatment	I-MED
or	O
under	B-MED
-	I-MED
treatment	I-MED
.	O
A	O
total	O
of	O
369	O
patients	B-MED
were	O
screened	O
and	O
200	O
met	O
the	O
inclusion	B-MED
criteria	I-MED
.	O
The	O
majority	O
of	O
patients	B-MED
were	O
classified	B-MED
as	O
either	O
CREST	B-MED
class	B-MED
I	I-MED
(	O
n	O
=	O
68	O
)	O
or	O
class	B-MED
I	I-MED
I	O
(	O
n	O
=	O
102	O
)	O
.	O
Over	B-MED
-	I-MED
treatment	I-MED
was	O
more	O
common	O
in	O
the	O
less	O
severe	B-MED
classes	B-MED
(	O
88	O
%	O
and	O
32	O
%	O
in	O
class	B-MED
I	I-MED
and	O
class	B-MED
II	I-MED
,	O
respectively	O
;	O
P	O
<	O
0.05	O
)	O
.	O
Sixty	O
-	O
three	O
percent	B-MED
of	O
class	B-MED
I	I-MED
(	O
n	O
=	O
43	O
)	O
were	O
over	B-MED
-	I-MED
treated	I-MED
due	O
to	O
both	O
the	O
use	O
of	O
intravenous	B-MED
antibiotic	B-MED
s	O
when	O
oral	B-MED
therapy	I-MED
was	O
sufficient	O
and	O
use	O
of	O
unnecessarily	O
broad	B-MED
-	I-MED
spectrum	I-MED
antibiotics	I-MED
.	O
In	O
contrast	O
,	O
25	O
%	O
(	O
n	O
=	O
26	O
)	O
of	O
class	B-MED
II	I-MED
were	O
over	B-MED
-	I-MED
treated	I-MED
due	O
to	O
use	O
of	O
unnecessarily	O
broad	B-MED
-	I-MED
spectrum	I-MED
antibiotics	I-MED
.	O
Overall	O
clinical	B-MED
failure	I-MED
rates	O
remained	O
low	O
with	O
only	O
1	O
%	O
,	O
4	O
%	O
and	O
17	O
%	O
of	O
patients	B-MED
unable	O
to	O
achieve	O
initial	O
response	B-MED
in	O
class	B-MED
II	I-MED
,	O
class	B-MED
III	I-MED
and	O
class	B-MED
IV	I-MED
.	O
Retrospective	B-MED
application	B-MED
of	O
CREST	B-MED
identified	O
opportunities	O
to	O
improve	O
the	O
management	B-MED
of	O
SSTIs	B-MED
.	O
CREST	B-MED
can	O
be	O
of	O
great	O
value	O
in	O
discriminating	O
less-	O
severe	B-MED
SSTIs	B-MED
,	O
which	O
can	O
be	O
treated	B-MED
on	O
an	O
outpatient	B-MED
basis	O
.	O
Fingerprint	B-MED
-based	O
background	B-MED
checks	I-MED
for	O
personal	B-MED
care	I-MED
workers	I-MED
:	O
Stakeholder	B-MED
views	B-MED
of	O
policy	B-MED
criteria	B-MED
Decision	B-MED
makers	I-MED
face	O
difficult	O
choices	O
when	O
tasked	O
with	O
identifying	O
and	O
implementing	B-MED
appropriate	O
mechanisms	B-MED
for	O
protecting	B-MED
the	O
elderly	B-MED
and	O
other	O
vulnerable	B-MED
adults	I-MED
from	O
abuse	B-MED
.	O
A	O
pilot	B-MED
project	I-MED
involving	O
fingerprint	B-MED
-based	O
criminal	B-MED
history	O
background	B-MED
checks	I-MED
for	O
personal	B-MED
care	I-MED
workers	I-MED
in	O
Michigan	B-MED
has	O
supplied	O
an	O
opportunity	B-MED
to	O
examine	O
one	O
such	O
mechanism	B-MED
.	O
In	O
conjunction	B-MED
with	O
the	O
pilot	B-MED
project	I-MED
,	O
we	O
have	O
conducted	O
a	O
stakeholder	B-MED
analysis	B-MED
with	O
the	O
aim	O
of	O
informing	O
decision	B-MED
makers	I-MED
about	O
stakeholder	B-MED
perceptions	B-MED
of	O
standard	B-MED
policy	B-MED
criteria	B-MED
like	O
effectiveness	B-MED
,	O
efficiency	B-MED
,	O
and	O
equity	B-MED
.	O
We	O
employed	O
focus	B-MED
groups	I-MED
and	O
a	O
web	B-MED
-	I-MED
based	I-MED
survey	I-MED
to	O
collect	B-MED
data	B-MED
from	O
stakeholders	B-MED
.	O
While	O
stakeholders	B-MED
generally	O
see	O
fingerprint	B-MED
-based	O
background	B-MED
checks	I-MED
for	O
personal	B-MED
care	I-MED
workers	I-MED
as	O
potentially	O
effective	B-MED
and	O
as	O
a	O
net	B-MED
benefit	I-MED
,	O
they	O
also	O
point	O
to	O
a	O
variety	O
of	O
contingencies	B-MED
.	O
They	O
also	O
recognize	O
difficulties	B-MED
and	O
constraints	B-MED
for	O
government	B-MED
involvement	B-MED
.	O
This	O
preliminary	B-MED
analysis	I-MED
provides	O
solid	O
foundational	B-MED
information	I-MED
for	O
decision	B-MED
makers	I-MED
and	O
for	O
more	O
extensive	O
benefit	B-MED
-	I-MED
cost	I-MED
analysis	I-MED
.	O
Longitudinal	B-MED
study	I-MED
of	O
bovine	B-MED
rotavirus	B-MED
group	I-MED
A	I-MED
in	O
newborn	B-MED
calves	B-MED
from	O
vaccinated	B-MED
and	O
unvaccinated	B-MED
dairy	B-MED
herds	I-MED
Reports	O
of	O
rotavirus	B-MED
excretion	B-MED
in	O
calves	B-MED
usually	O
result	O
from	O
cross	B-MED
-	I-MED
sectional	I-MED
studies	I-MED
,	O
and	O
in	O
face	O
of	O
the	O
conflicting	O
results	O
regarding	O
protection	B-MED
of	O
calves	B-MED
born	B-MED
to	O
vaccinated	B-MED
dams	B-MED
against	O
diarrhea	B-MED
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
rotavirus	B-MED
excretion	B-MED
in	O
dairy	B-MED
calves	I-MED
born	O
to	O
vaccinated	B-MED
or	O
unvaccinated	B-MED
dams	B-MED
,	O
to	O
identify	O
the	O
genotypes	B-MED
of	O
bovine	B-MED
rotavirus	B-MED
group	I-MED
A	I-MED
(	O
RVA	B-MED
)	O
strains	B-MED
isolated	O
from	O
these	O
animals	B-MED
as	O
well	O
as	O
to	O
investigate	O
characteristics	O
of	O
the	O
disease	B-MED
in	O
naturally	B-MED
occurring	B-MED
circumstances	O
throughout	O
the	O
first	B-MED
month	I-MED
of	I-MED
life	I-MED
.	O
Five	O
hundred	O
fifty	O
-	O
two	O
fecal	B-MED
samples	I-MED
were	O
taken	O
from	O
56	O
calves	B-MED
,	O
28	O
from	O
each	O
farm	B-MED
and	O
,	O
in	O
the	O
vaccinated	B-MED
herd	B-MED
,	O
11/281	O
samples	B-MED
(	O
3.91	O
%	O
)	O
taken	O
from	O
six	O
different	O
calves	B-MED
tested	B-MED
positive	I-MED
for	O
RVA	B-MED
while	O
in	O
the	O
unvaccinated	B-MED
herd	O
,	O
3/271	O
samples	B-MED
(	O
1.11	O
%	O
)	O
taken	O
from	O
3	O
different	O
calves	B-MED
tested	B-MED
positive	I-MED
.	O
The	O
genotyping	B-MED
of	O
the	O
VP7	B-MED
genes	I-MED
showed	O
91.2	O
%	O
nucleotide	B-MED
sequence	I-MED
identity	O
to	O
G6	B-MED
genotype	I-MED
(	O
NCDV	B-MED
strain	I-MED
)	O
,	O
and	O
for	O
the	O
VP4	B-MED
gene	I-MED
,	O
strains	B-MED
from	O
the	O
vaccinated	B-MED
herd	O
were	O
96.6	O
%	O
related	O
to	O
B223	B-MED
strain	I-MED
,	O
while	O
strains	B-MED
from	O
the	O
unvaccinated	B-MED
herd	B-MED
were	O
88	O
%	O
related	O
to	O
P[5	B-MED
]	I-MED
genotype	I-MED
(	O
UK	B-MED
strain	I-MED
)	O
.	O
Genotypes	B-MED
found	O
in	O
this	O
study	O
were	O
G6P[11	B-MED
]	I-MED
in	O
the	O
vaccinated	B-MED
herd	B-MED
and	O
G6P[5	B-MED
]	I-MED
in	O
the	O
unvaccinated	B-MED
herd	B-MED
.	O
All	O
calves	B-MED
infected	B-MED
with	O
rotavirus	B-MED
presented	O
an	O
episode	O
of	O
diarrhea	B-MED
in	O
the	O
first	O
month	O
of	O
life	O
,	O
and	O
the	O
discrepancy	O
between	O
the	O
genotypes	B-MED
found	O
in	O
the	O
commercial	B-MED
vaccine	I-MED
(	O
G6P[1	B-MED
]	I-MED
and	O
G10P[11	B-MED
]	I-MED
)	O
and	O
the	O
rotavirus	B-MED
strains	B-MED
circulating	O
in	O
both	O
vaccinated	B-MED
and	O
unvaccinated	B-MED
herds	B-MED
show	O
the	O
importance	O
of	O
keeping	O
constant	B-MED
surveillance	B-MED
in	O
order	O
to	O
avoid	O
potential	B-MED
causes	B-MED
of	O
vaccination	B-MED
failure	B-MED
.	O
A	O
Tobramycin	B-MED
Vector	I-MED
Enhances	B-MED
Synergy	B-MED
and	O
Efficacy	B-MED
of	O
Efflux	B-MED
Pump	I-MED
Inhibitors	I-MED
against	B-MED
Multidrug	B-MED
-	I-MED
Resistant	I-MED
Gram	B-MED
-	I-MED
Negative	I-MED
Bacteria	I-MED
Drug	B-MED
efflux	I-MED
mechanisms	B-MED
interact	B-MED
synergistically	B-MED
with	O
the	O
outer	B-MED
membrane	I-MED
permeability	B-MED
barrier	B-MED
of	O
Gram	B-MED
-	I-MED
negative	I-MED
bacteria	I-MED
,	O
leading	B-MED
to	O
intrinsic	B-MED
resistance	B-MED
that	O
presents	O
a	O
major	B-MED
challenge	B-MED
for	O
antibiotic	B-MED
drug	B-MED
development	I-MED
.	O
Efflux	B-MED
pump	I-MED
inhibitors	I-MED
(	O
EPIs	B-MED
)	O
which	O
block	B-MED
the	O
efflux	B-MED
of	O
antibiotics	B-MED
synergize	B-MED
antibiotics	B-MED
,	O
but	O
the	O
clinical	B-MED
development	I-MED
of	O
EPI	B-MED
/	O
antibiotic	B-MED
combination	B-MED
therapy	I-MED
to	O
treat	B-MED
multidrug	B-MED
-	I-MED
resistant	I-MED
(	O
MDR	B-MED
)	O
Gram	B-MED
-	I-MED
negative	I-MED
infections	I-MED
has	O
been	O
challenging	B-MED
.	O
This	O
is	O
in	O
part	O
caused	B-MED
by	O
the	O
inefficiency	B-MED
of	O
current	B-MED
EPIs	B-MED
to	O
penetrate	B-MED
the	O
outer	B-MED
membrane	I-MED
and	O
resist	B-MED
efflux	B-MED
.	O
We	O
demonstrate	O
that	O
conjugation	B-MED
of	O
a	O
tobramycin	B-MED
(	O
TOB	B-MED
)	O
vector	O
to	O
EPIs	B-MED
like	O
NMP	B-MED
,	O
paroxetine	B-MED
,	O
or	O
DBP	B-MED
enhances	B-MED
synergy	B-MED
and	O
efficacy	B-MED
of	O
EPIs	B-MED
in	O
combination	B-MED
with	O
tetracycline	B-MED
antibiotics	I-MED
against	O
MDR	B-MED
Gram	B-MED
-	I-MED
negative	I-MED
bacteria	I-MED
including	O
Pseudomonas	B-MED
aeruginosa	I-MED
.	O
Besides	O
potentiating	B-MED
tetracycline	B-MED
antibiotics	I-MED
,	O
TOB	B-MED
-	O
EPI	B-MED
conjugates	B-MED
can	O
also	O
suppress	B-MED
resistance	B-MED
development	B-MED
to	O
the	O
tetracycline	B-MED
antibiotic	I-MED
minocycline	B-MED
,	O
thereby	O
providing	B-MED
a	O
strategy	B-MED
to	O
develop	B-MED
more	O
effective	B-MED
adjuvants	B-MED
to	O
rescue	O
tetracycline	B-MED
antibiotics	I-MED
from	O
resistance	B-MED
in	O
MDR	B-MED
Gram	B-MED
-	I-MED
negative	I-MED
bacteria	I-MED
.	O
The	O
use	B-MED
of	I-MED
neonatal	B-MED
extracorporeal	B-MED
life	I-MED
support	I-MED
in	O
pediatric	B-MED
cardiac	B-MED
intensive	I-MED
care	I-MED
unit	I-MED
The	O
aim	O
of	O
the	O
study	O
is	O
to	O
evaluate	B-MED
extracorporeal	B-MED
life	I-MED
support	I-MED
system	I-MED
(	O
ECLS	B-MED
)	O
employed	O
in	O
neonates	B-MED
in	O
pediatric	B-MED
cardiac	B-MED
intensive	I-MED
care	I-MED
unit	I-MED
.	O
Twenty	O
-	O
five	O
neonates	B-MED
that	O
required	O
ECLS	B-MED
in	O
between	O
November	O
2010	O
and	O
November	O
2015	O
were	O
evaluated	B-MED
.	O
The	O
median	B-MED
age	B-MED
was	O
12	O
days	B-MED
(	O
range	B-MED
3	O
-	O
28	O
days	B-MED
)	O
and	O
the	O
median	B-MED
body	B-MED
weight	I-MED
was	O
3	O
kg	O
(	O
range	B-MED
2.5	O
-	O
5	O
kg	O
)	O
.	O
Venoarterial	B-MED
ECLS	B-MED
was	O
performed	B-MED
in	O
all	O
of	O
the	O
cases	O
.	O
Ascendan	B-MED
aorta	I-MED
-	O
right	B-MED
atrial	I-MED
cannulation	B-MED
in	O
22	O
patients	B-MED
and	O
neck	B-MED
cannulation	B-MED
in	O
three	O
patients	B-MED
were	O
performed	B-MED
.	O
The	O
reason	O
for	O
ECLS	B-MED
was	O
E	B-MED
-	I-MED
CPR	I-MED
in	O
two	O
patients	B-MED
,	O
inability	B-MED
to	I-MED
wean	I-MED
from	O
cardiopulmonary	B-MED
bypass	I-MED
(	O
CPB	B-MED
)	O
in	O
seven	O
patients	B-MED
,	O
respiratory	B-MED
insufficiency	I-MED
and	O
hypoxia	B-MED
in	O
nine	O
patients	B-MED
,	O
low	B-MED
cardiac	I-MED
output	I-MED
(	O
LCOS	B-MED
)	O
in	O
seven	O
patients	B-MED
.	O
Median	B-MED
duration	B-MED
of	O
ECLS	B-MED
was	O
four	O
days	B-MED
(	O
range	B-MED
1	O
-	O
15	O
)	O
.	O
Hemorrhagic	B-MED
complications	B-MED
developed	O
in	O
15	O
,	O
renal	B-MED
complications	I-MED
in	O
13	O
,	O
pulmonary	B-MED
complications	I-MED
in	O
12	O
,	O
infectious	B-MED
complications	B-MED
in	O
11	O
,	O
neurologic	B-MED
complications	I-MED
in	O
three	O
and	O
mechanical	B-MED
complications	I-MED
in	O
two	O
of	O
the	O
patients	B-MED
.	O
Weaning	B-MED
was	O
successful	B-MED
in	O
15	O
of	O
the	O
patients	B-MED
.	O
Eleven	O
patients	B-MED
were	O
successfully	B-MED
discharged	B-MED
.	O
ECLS	B-MED
is	O
an	O
important	B-MED
treatment	B-MED
option	I-MED
that	O
is	O
performed	B-MED
successfully	B-MED
in	O
many	O
centers	B-MED
around	O
the	O
world	B-MED
to	O
maintain	B-MED
life	B-MED
support	I-MED
in	O
patients	B-MED
unresponsive	B-MED
to	I-MED
medical	I-MED
treatment	I-MED
.	O
The	O
utilization	B-MED
of	O
this	O
modality	B-MED
especially	O
in	O
newborns	B-MED
with	O
congenital	B-MED
heart	I-MED
disease	I-MED
should	O
be	O
taken	O
into	O
consideration	O
.	O
Anti	B-MED
-	I-MED
Inflammatory	I-MED
Properties	I-MED
of	O
Menthol	B-MED
and	O
Menthone	B-MED
in	O
Schistosoma	B-MED
mansoni	I-MED
Infection	I-MED
Schistosomiasis	B-MED
is	O
a	O
parasitic	B-MED
disease	I-MED
caused	O
by	O
several	O
species	B-MED
of	O
trematode	B-MED
worms	I-MED
and	O
it	O
is	O
believed	O
that	O
more	O
than	O
261	O
million	O
people	B-MED
are	O
affected	B-MED
worldwide	O
.	O
New	O
drug	B-MED
development	I-MED
has	O
become	O
essential	B-MED
because	O
there	O
is	O
a	O
risk	O
of	O
the	O
parasite	B-MED
becoming	O
resistant	B-MED
to	O
Praziquantel	B-MED
,	O
the	O
only	O
drug	B-MED
available	O
for	O
this	O
infection	B-MED
.	O
This	O
study	B-MED
evaluated	B-MED
parasitological	B-MED
,	O
immunological	B-MED
and	O
histological	B-MED
parameters	B-MED
in	O
mice	B-MED
infected	B-MED
with	O
Schistosoma	B-MED
mansoni	I-MED
and	O
treated	B-MED
with	I-MED
an	O
herbal	B-MED
commercial	I-MED
medicine	I-MED
.	O
This	O
drug	B-MED
consists	O
of	O
menthol	B-MED
(	O
30	O
-	O
55	O
%	O
)	O
and	O
menthone	B-MED
(	O
14	O
-	O
32	O
%	O
)	O
.	O
A	O
60	O
day	O
treatment	B-MED
regimen	I-MED
with	O
the	O
herbal	B-MED
medicine	I-MED
decreased	B-MED
the	O
number	O
of	O
S.	B-MED
mansoni	I-MED
eggs	B-MED
in	O
the	O
feces	B-MED
,	O
liver	B-MED
,	O
and	O
intestine	B-MED
and	O
reduced	B-MED
the	O
number	O
of	O
hepatic	B-MED
granulomas	I-MED
.	O
We	O
observed	B-MED
a	O
reduction	B-MED
of	O
84	O
%	O
in	O
blood	B-MED
eosinophilia	I-MED
and	O
a	O
decrease	B-MED
in	O
the	O
IL-4	B-MED
and	O
IL-10	B-MED
blood	B-MED
levels	I-MED
after	O
treatment	B-MED
.	O
Therefore	O
,	O
we	O
propose	O
that	O
schistosomiasis	B-MED
treatment	B-MED
with	O
this	O
herbal	B-MED
medicine	I-MED
for	O
60	O
days	O
has	O
an	O
immunomodulatory	B-MED
and	O
anti	B-MED
-	I-MED
inflammatory	I-MED
action	I-MED
in	O
this	O
animal	B-MED
model	I-MED
for	O
schistosomiasis	B-MED
thus	O
contributing	B-MED
to	O
the	O
decrease	B-MED
in	O
physio	O
pathological	B-MED
effects	B-MED
caused	O
by	O
S.	B-MED
mansoni	I-MED
infection	I-MED
.	O
Histopathology	B-MED
of	O
the	O
filum	B-MED
terminale	I-MED
in	O
children	B-MED
with	O
and	O
without	B-MED
tethered	B-MED
cord	I-MED
syndrome	I-MED
with	O
attention	O
to	O
the	O
elastic	B-MED
tissue	I-MED
within	O
the	O
filum	B-MED
To	O
compare	B-MED
histologically	B-MED
transected	B-MED
fila	B-MED
from	O
pediatric	B-MED
patients	B-MED
with	O
tethered	B-MED
cord	I-MED
syndrome	I-MED
(	O
TCS	B-MED
)	O
,	O
with	O
and	O
without	B-MED
a	O
low	B-MED
conus	B-MED
,	O
with	O
controls	O
,	O
focusing	O
on	O
collagenous	B-MED
and	O
elastic	B-MED
tissue	I-MED
.	O
Thirty	O
fila	B-MED
from	O
patients	B-MED
with	O
TCS	B-MED
,	O
including	O
5	O
where	O
minimal	B-MED
cautery	B-MED
was	O
used	O
prior	O
to	O
filum	B-MED
section	B-MED
,	O
were	O
compared	B-MED
with	O
fila	B-MED
from	O
27	O
pediatric	B-MED
cadavers	B-MED
without	B-MED
TCS	B-MED
(	O
controls	B-MED
)	O
.	O
Sections	B-MED
of	O
fila	B-MED
were	O
stained	B-MED
with	O
H&E	B-MED
,	O
Masson	B-MED
trichrome	I-MED
and	O
Verhoeff	B-MED
von	I-MED
Gieson	I-MED
elastic	I-MED
stains	I-MED
,	O
and	O
7	O
with	O
Gordon	B-MED
and	I-MED
Sweet	I-MED
's	I-MED
reticulin	I-MED
stain	I-MED
.	O
Fila	B-MED
from	O
controls	B-MED
showed	O
loose	B-MED
fibrous	B-MED
connective	I-MED
tissue	I-MED
(	O
FCT	B-MED
)	O
with	O
thin	B-MED
and	O
evenly	B-MED
dispersed	I-MED
elastic	B-MED
fibers	I-MED
(	O
EFs	B-MED
)	O
.	O
Reticulin	B-MED
fibers	I-MED
(	O
RFs	B-MED
)	O
were	O
seen	O
in	O
blood	B-MED
vessel	I-MED
walls	I-MED
and	O
nerve	B-MED
twigs	O
.	O
Fat	B-MED
was	O
identified	B-MED
microscopically	B-MED
in	O
2	O
fila	B-MED
.	O
All	O
fila	B-MED
from	O
patients	B-MED
with	O
TCS	B-MED
had	O
dense	B-MED
FCT	I-MED
.	O
The	O
EFs	B-MED
were	O
in	O
normal	B-MED
numbers	O
in	O
17	O
,	O
and	O
focally	B-MED
or	O
diffusely	B-MED
decreased	B-MED
in	O
13	O
.	O
All	O
25	O
patients	B-MED
where	O
the	O
fila	B-MED
were	O
cauterized	B-MED
during	O
resection	B-MED
had	O
thick	B-MED
and	O
coiled	B-MED
EFs	B-MED
.	O
Coiling	B-MED
was	O
not	O
seen	O
when	O
minimal	B-MED
cautery	B-MED
was	O
applied	O
.	O
RFs	B-MED
were	O
seen	O
in	O
blood	B-MED
vessel	I-MED
walls	I-MED
and	O
nerve	O
twigs	O
.	O
Fat	B-MED
was	O
identified	B-MED
in	O
19	O
patients	B-MED
.	O
Findings	B-MED
were	O
similar	B-MED
,	O
whether	O
the	O
conus	B-MED
termination	O
was	O
normal	B-MED
or	O
low	B-MED
.	O
The	O
fila	B-MED
of	O
all	O
patients	B-MED
with	O
TCS	B-MED
,	O
whether	O
or	O
not	O
the	O
conus	B-MED
was	O
low	B-MED
,	O
showed	O
abnormal	B-MED
FCT	B-MED
.	O
EFs	B-MED
were	O
decreased	B-MED
in	O
48	O
%	O
of	O
patients	B-MED
;	O
however	O
,	O
there	O
were	O
thick	B-MED
and	O
coiled	B-MED
EFs	B-MED
in	O
all	O
patients	B-MED
.	O
Coiling	B-MED
of	O
EFs	B-MED
,	O
initially	O
thought	O
to	O
be	O
an	O
abnormality	B-MED
in	O
patients	B-MED
,	O
is	O
considered	O
most	O
likely	O
to	O
be	O
a	O
result	B-MED
of	O
cautery	B-MED
(	O
i.e.	O
,	O
artifactual	B-MED
/	O
iatrogenic	B-MED
coiling	B-MED
)	O
.	O
Genetic	B-MED
diversity	I-MED
of	O
Taenia	B-MED
saginata	I-MED
(	O
Cestoda	B-MED
:	O
Cyclophyllidea	B-MED
)	O
from	O
Lao	B-MED
People	I-MED
's	I-MED
Democratic	I-MED
Republic	I-MED
and	O
northeastern	B-MED
Thailand	B-MED
based	O
on	O
mitochondrial	B-MED
DNA	I-MED
Taenia	B-MED
saginata	I-MED
is	O
a	O
tapeworm	B-MED
found	O
in	O
cattle	B-MED
worldwide	O
.	O
Analysis	B-MED
of	O
genetic	B-MED
diversity	I-MED
in	O
different	O
geographical	B-MED
populations	I-MED
of	O
T.	B-MED
saginata	I-MED
not	O
only	O
helps	O
to	O
understand	O
the	O
origin	B-MED
,	O
transmission	B-MED
and	O
spread	B-MED
of	O
this	O
organism	B-MED
,	O
but	O
also	O
to	O
evaluate	O
the	O
selection	O
pressures	O
acting	O
on	O
T.	B-MED
saginata	I-MED
and	O
how	O
it	O
is	O
responding	O
to	O
them	O
.	O
However	O
,	O
there	O
are	O
few	O
reports	O
of	O
the	O
genetic	B-MED
variability	I-MED
of	O
T.	B-MED
saginata	I-MED
populations	I-MED
in	O
different	O
regions	B-MED
of	O
the	O
world	B-MED
,	O
including	O
Lao	B-MED
PDR	I-MED
and	O
Thailand	B-MED
.	O
We	O
report	O
the	O
genetic	B-MED
diversity	I-MED
of	O
T.	B-MED
saginata	I-MED
populations	I-MED
in	O
Lao	B-MED
PDR	I-MED
and	O
northeastern	B-MED
Thailand	B-MED
together	O
with	O
sequences	B-MED
of	O
T.	B-MED
saginata	I-MED
from	O
other	O
countries	B-MED
deposited	O
in	O
GenBank	B-MED
.	O
Mitochondrial	B-MED
cox1	I-MED
sequence	B-MED
analysis	I-MED
revealed	O
that	O
15	O
and	O
8	O
haplotypes	B-MED
were	O
identified	O
in	O
30	O
and	O
21	O
T.	B-MED
saginata	I-MED
isolates	O
from	O
Lao	B-MED
PDR	I-MED
and	O
northeastern	B-MED
Thailand	B-MED
,	O
respectively	O
.	O
Fifty	O
-	O
three	O
haplotypes	B-MED
were	O
identified	O
from	O
98	O
sequences	B-MED
.	O
Phylogenetic	B-MED
tree	I-MED
and	O
haplotype	B-MED
network	I-MED
analyses	I-MED
revealed	O
that	O
global	B-MED
isolates	O
of	O
T.	B-MED
saginata	I-MED
were	O
genetically	O
divided	O
into	O
five	O
groups	B-MED
(	O
A	B-MED
,	O
B	B-MED
,	O
C1	B-MED
,	O
C2	B-MED
and	O
D	B-MED
)	O
.	O
Taenia	B-MED
saginata	I-MED
isolates	O
from	O
Lao	B-MED
PDR	I-MED
and	O
northeastern	B-MED
Thailand	B-MED
belonged	O
to	O
either	O
Group	B-MED
A	I-MED
B	B-MED
or	O
B.	O
Taenia	B-MED
saginata	I-MED
from	O
western	B-MED
Thailand	B-MED
clustered	O
in	O
groups	B-MED
C1	I-MED
,	O
C2	B-MED
and	O
D	B-MED
,	O
and	O
populations	B-MED
from	O
the	O
northeast	B-MED
and	O
western	B-MED
Thailand	B-MED
were	O
found	O
to	O
be	O
genetically	O
distinct	O
.	O
Taenia	B-MED
saginata	I-MED
isolates	O
in	O
Lao	B-MED
PDR	I-MED
and	O
Thailand	B-MED
were	O
also	O
found	O
to	O
be	O
genetically	B-MED
diverse	I-MED
but	O
the	O
degree	O
of	O
genetic	B-MED
differentiation	I-MED
was	O
low	O
.	O
Taenia	B-MED
saginata	I-MED
populations	I-MED
from	O
Lao	B-MED
PDR	I-MED
and	O
northeastern	B-MED
Thailand	B-MED
are	O
genetically	O
distinct	O
from	O
the	O
population	B-MED
in	O
western	B-MED
Thailand	B-MED
and	O
it	O
is	O
proposed	O
that	O
T.	B-MED
saginata	I-MED
has	O
been	O
dispersed	O
by	O
different	O
transmission	B-MED
routes	I-MED
in	O
Southeast	B-MED
Asia	I-MED
.	O
Application	B-MED
of	O
BRAF	B-MED
V600E	I-MED
mutation	B-MED
-	O
specific	B-MED
immunohistochemistry	B-MED
in	O
diagnosis	B-MED
of	O
gastrointestinal	B-MED
stromal	I-MED
tumors	I-MED
To	O
evaluate	B-MED
the	O
utility	O
of	O
BRAF	B-MED
V600E	I-MED
allele	B-MED
-	O
specific	B-MED
antibody	B-MED
in	O
the	O
diagnosis	B-MED
of	O
gastrointestinal	B-MED
stromal	I-MED
tumors	I-MED
(	O
GISTs	B-MED
)	O
.	O
BRAF	B-MED
V600E	I-MED
mutation	B-MED
-	O
specific	B-MED
immunohistochemistry	B-MED
and	O
BRAF	B-MED
sequencing	B-MED
were	O
performed	O
in	O
24	O
consecutive	B-MED
GISTs	B-MED
,	O
including	O
14	O
cases	B-MED
of	O
KIT	B-MED
or	O
PDGFRA	B-MED
mutations	I-MED
and	O
10	O
cases	B-MED
of	O
KIT	B-MED
/	O
PDGFRA	B-MED
wild	I-MED
GISTs	B-MED
.	O
GISTs	B-MED
of	O
11	O
men	B-MED
and	O
13	O
women	B-MED
with	O
a	O
mean	B-MED
age	B-MED
54	O
years(range	O
29	O
-	O
75	O
years	O
)	O
were	O
included	O
with	O
tumors	B-MED
arising	O
from	O
stomach	B-MED
(	O
16	O
cases	B-MED
)	O
,	O
small	B-MED
bowel	I-MED
(	O
7	O
cases	B-MED
)	O
,	O
and	O
peritoneal	B-MED
cavity	I-MED
(	O
1	O
case	B-MED
)	O
.	O
Strong	B-MED
and	O
diffuse	B-MED
cytoplasmic	B-MED
BRAF	B-MED
staining	B-MED
was	O
noted	B-MED
in	O
4	O
of	O
24	O
cases	B-MED
(	O
17	O
%	O
)	O
,	O
while	O
1	O
of	O
24	O
cases	B-MED
(	O
4	O
%	O
)	O
showed	O
weak	B-MED
staining	B-MED
,	O
and	O
19	O
of	O
24	O
cases	B-MED
(	O
79	O
%	O
)	O
had	O
no	B-MED
staining	B-MED
.	O
The	O
four	O
cases	B-MED
with	O
strong	B-MED
BRAF	B-MED
immunostain	B-MED
were	O
confirmed	B-MED
to	O
have	O
BRAF	B-MED
mutations	I-MED
,	O
including	O
3	O
cases	B-MED
in	O
the	O
stomach	B-MED
and	O
1	O
case	B-MED
in	O
the	O
small	B-MED
intestine	I-MED
.	O
All	O
tumors	B-MED
showed	O
spindle	B-MED
cell	I-MED
morphology	B-MED
.	O
Only	O
one	O
case	B-MED
had	O
progressive	B-MED
disease	I-MED
.	O
No	B-MED
BRAF	B-MED
mutations	I-MED
were	O
detected	B-MED
in	O
cases	B-MED
with	O
weak	B-MED
or	O
negative	B-MED
BRAF	B-MED
immunostain	B-MED
.	O
BRAF	B-MED
V600E	I-MED
mutation	B-MED
-	O
specific	B-MED
immunohistochemistry	B-MED
is	O
a	O
highly	B-MED
sensitive	I-MED
and	O
specific	B-MED
marker	B-MED
for	O
detecting	B-MED
BRAF	B-MED
-	I-MED
mutated	I-MED
GISTs	B-MED
.	O
Measurement	B-MED
of	O
fidgeting	B-MED
in	O
patients	B-MED
with	O
anorexia	B-MED
nervosa	I-MED
using	O
a	O
novel	O
shoe	B-MED
-based	O
monitor	B-MED
To	O
objectively	O
assess	O
seated	B-MED
non	B-MED
-	I-MED
exercise	I-MED
physical	I-MED
activity	I-MED
in	O
patients	B-MED
with	O
anorexia	B-MED
nervosa	I-MED
(	O
AN	B-MED
)	O
relative	O
to	O
healthy	B-MED
controls	I-MED
(	O
HCs	B-MED
)	O
and	O
examine	O
the	O
associations	B-MED
between	O
this	O
physical	B-MED
activity	I-MED
,	O
eating	B-MED
disorder	I-MED
pathology	B-MED
,	O
and	O
levels	B-MED
of	O
anxiety	B-MED
and	O
depression	B-MED
.	O
Eleven	O
inpatients	B-MED
with	O
AN	B-MED
and	O
10	O
HCs	B-MED
wore	O
a	O
shoe	B-MED
-based	O
accelerometer	B-MED
(	O
SmartShoe	B-MED
)	O
at	O
three	O
time	B-MED
points	I-MED
:	O
a	O
)	O
while	B-MED
eating	I-MED
lunch	I-MED
,	O
b	O
)	O
filling	B-MED
out	I-MED
questionnaires	I-MED
,	O
and	O
c	O
)	O
watching	B-MED
television	I-MED
for	I-MED
1h	I-MED
.	O
Across	O
all	O
three	O
tasks	B-MED
,	O
patients	B-MED
with	O
AN	B-MED
were	O
significantly	O
more	B-MED
active	I-MED
than	O
HCs	B-MED
,	O
thereby	O
engaging	O
in	O
a	O
greater	B-MED
degree	I-MED
of	O
restless	B-MED
or	O
fidgeting	B-MED
behavior	B-MED
.	O
Degree	B-MED
of	O
physical	B-MED
activity	I-MED
was	O
positively	B-MED
correlated	I-MED
with	O
eating	B-MED
disorder	I-MED
psychopathology	B-MED
in	O
the	O
sample	O
with	O
AN	B-MED
,	O
and	O
a	O
trend	O
towards	O
a	O
positive	B-MED
association	I-MED
between	O
physical	B-MED
activity	I-MED
and	O
levels	B-MED
of	O
depression	B-MED
and	O
anxiety	B-MED
was	O
also	O
found	O
in	O
this	O
sample	O
.	O
Among	O
individuals	B-MED
with	O
AN	B-MED
,	O
physical	B-MED
activity	I-MED
was	O
not	B-MED
significantly	O
correlated	B-MED
with	O
BMI	B-MED
,	O
duration	B-MED
of	I-MED
illness	I-MED
,	O
or	O
number	B-MED
of	I-MED
days	I-MED
since	O
hospital	B-MED
admission	I-MED
.	O
Use	O
of	O
a	O
minimally	B-MED
invasive	I-MED
,	O
shoe	B-MED
-based	O
monitor	B-MED
revealed	O
patients	B-MED
with	O
AN	B-MED
engaged	O
in	O
a	O
greater	B-MED
degree	I-MED
of	O
fidgeting	B-MED
relative	O
to	O
HCs	B-MED
during	O
quiet	O
,	O
seated	B-MED
tasks	B-MED
and	O
this	O
heightened	O
activity	B-MED
was	O
related	O
to	O
measures	B-MED
of	O
pathology	B-MED
.	O
Non	B-MED
-	I-MED
exercise	I-MED
physical	I-MED
activity	I-MED
,	O
including	O
fidgeting	B-MED
,	O
may	O
warrant	O
further	O
clinical	B-MED
attention	O
in	O
this	O
patient	B-MED
population	I-MED
.	O
Linking	O
phenological	B-MED
events	I-MED
in	O
migratory	B-MED
passerines	I-MED
with	O
a	O
changing	B-MED
climate	I-MED
:	O
50	O
years	B-MED
in	O
the	O
Laurel	B-MED
Highlands	I-MED
of	I-MED
Pennsylvania	I-MED
Advanced	B-MED
timing	I-MED
of	O
both	O
seasonal	B-MED
migration	O
and	O
reproduction	B-MED
in	O
birds	B-MED
has	O
been	O
strongly	O
associated	B-MED
with	I-MED
a	O
warming	B-MED
climate	I-MED
for	O
many	O
bird	B-MED
species	B-MED
.	O
Phenological	B-MED
responses	I-MED
to	O
climate	B-MED
linking	O
these	O
stages	B-MED
may	O
ultimately	O
impact	B-MED
fitness	B-MED
.	O
We	O
analyzed	B-MED
five	O
decades	B-MED
of	O
banding	B-MED
data	I-MED
from	O
17	O
migratory	B-MED
bird	I-MED
species	B-MED
to	O
investigate	O
1	O
)	O
how	O
spring	B-MED
arrival	B-MED
related	O
to	O
timing	B-MED
of	O
breeding	B-MED
,	O
2	O
)	O
if	O
the	O
interval	B-MED
between	O
arrival	B-MED
and	O
breeding	B-MED
has	O
changed	O
with	O
increasing	B-MED
spring	B-MED
temperatures	B-MED
,	O
and	O
3	O
)	O
whether	O
arrival	B-MED
timing	B-MED
or	O
breeding	B-MED
timing	B-MED
best	O
predicted	O
local	B-MED
productivity	I-MED
.	O
Four	O
of	O
17	O
species	B-MED
,	O
all	O
mid-	B-MED
to	I-MED
long	I-MED
-	I-MED
distance	I-MED
migrants	I-MED
,	O
hatched	B-MED
young	O
earlier	O
in	O
years	B-MED
when	O
migrants	B-MED
arrived	B-MED
earlier	B-MED
to	O
the	O
breeding	B-MED
grounds	I-MED
(	O
~1:1	O
day	B-MED
advancement	I-MED
)	O
.	O
The	O
interval	B-MED
between	O
arrival	B-MED
on	O
breeding	B-MED
grounds	I-MED
and	O
appearance	B-MED
of	O
juveniles	B-MED
shortened	B-MED
with	O
warmer	O
spring	B-MED
temperatures	B-MED
for	O
12	O
species	B-MED
(	O
1	O
-	O
6	O
days	B-MED
for	O
every	O
1	O
°	O
C	O
increase	B-MED
)	O
and	O
over	O
time	O
for	O
seven	O
species	B-MED
(	O
1	O
-	O
8	O
days	O
per	O
decade	B-MED
)	O
,	O
suggesting	O
that	O
some	O
migratory	B-MED
passerines	I-MED
adapt	O
to	O
climate	B-MED
change	I-MED
by	O
laying	B-MED
more	B-MED
quickly	I-MED
after	O
arrival	B-MED
or	O
reducing	B-MED
the	O
time	B-MED
from	O
laying	B-MED
to	O
fledging	O
.	O
We	O
found	O
more	O
support	O
for	O
the	O
former	B-MED
,	O
that	O
the	O
rate	B-MED
of	O
reproductive	B-MED
advancement	I-MED
was	O
higher	B-MED
than	O
that	O
for	O
arrival	B-MED
in	O
warm	B-MED
years	I-MED
.	O
Timing	B-MED
of	O
spring	B-MED
arrival	B-MED
and	O
breeding	B-MED
were	O
both	O
poor	B-MED
predictors	B-MED
of	O
avian	B-MED
productivity	B-MED
for	O
most	O
migrants	B-MED
analyzed	B-MED
.	O
Nevertheless	O
,	O
we	O
found	O
evidence	B-MED
that	O
fitness	B-MED
benefits	O
may	O
occur	O
from	O
shifts	B-MED
to	O
earlier	O
spring	B-MED
arrival	B-MED
for	O
the	O
multi	B-MED
-	I-MED
brooded	I-MED
Song	I-MED
Sparrow	I-MED
.	O
Our	O
results	B-MED
uniquely	O
demonstrate	O
that	O
co	O
-	O
occurring	O
avian	B-MED
species	B-MED
are	O
phenologically	B-MED
plastic	I-MED
in	O
their	O
response	B-MED
to	O
climate	B-MED
change	I-MED
on	O
their	O
breeding	B-MED
grounds	I-MED
.	O
If	O
migrants	B-MED
continue	O
to	O
show	O
a	O
weaker	B-MED
response	B-MED
to	O
temperatures	B-MED
during	O
migration	O
than	O
breeding	B-MED
,	O
and	O
the	O
window	B-MED
between	O
arrival	B-MED
and	O
optimal	B-MED
breeding	I-MED
shortens	B-MED
further	O
,	O
biological	O
constraints	O
to	O
plasticity	B-MED
may	O
limit	O
the	O
ability	B-MED
of	O
species	B-MED
to	O
adapt	O
successfully	O
to	O
future	B-MED
warming	I-MED
.	O
Prevalence	B-MED
of	O
Self	B-MED
-	I-MED
Reported	I-MED
Prescription	B-MED
Drug	I-MED
Use	B-MED
in	O
a	O
National	B-MED
Sample	B-MED
U.S	B-MED
of	O
U.S.	O
Drivers	B-MED
Drug	B-MED
-involved	O
driving	B-MED
has	O
become	O
an	O
increasing	B-MED
concern	B-MED
.	O
Although	O
the	O
focus	O
has	O
been	O
on	O
illegal	B-MED
drugs	I-MED
,	O
there	O
is	O
evidence	B-MED
that	O
prescribed	B-MED
medications	I-MED
can	O
impair	B-MED
driving	I-MED
ability	I-MED
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	B-MED
the	O
self	B-MED
-	I-MED
reported	I-MED
prevalence	B-MED
of	O
prescription	B-MED
drug	I-MED
use	B-MED
,	O
including	O
medical	B-MED
and	O
nonmedical	B-MED
use	B-MED
,	O
among	O
a	O
nationally	B-MED
representative	B-MED
sample	B-MED
of	O
drivers	B-MED
and	O
to	O
report	O
related	O
driver	B-MED
characteristics	B-MED
.	O
As	O
part	O
of	O
the	O
2013	O
-	O
2014	O
National	B-MED
Roadside	I-MED
Survey	I-MED
,	O
drivers	B-MED
from	O
60	O
sites	O
were	O
randomly	B-MED
recruited	O
and	O
asked	O
to	O
complete	B-MED
a	O
survey	B-MED
on	O
prescription	B-MED
drug	I-MED
use	B-MED
.	O
Almost	O
20	O
%	O
of	O
drivers	B-MED
reported	O
using	O
a	O
prescription	B-MED
drug	I-MED
within	O
the	O
past	B-MED
2	O
days	B-MED
,	O
with	O
the	O
most	O
common	B-MED
drug	I-MED
class	I-MED
being	O
sedatives	B-MED
(	O
8.0	O
%	O
)	O
,	O
followed	O
by	O
antidepressants	B-MED
(	O
7.7	O
%	O
)	O
,	O
narcotics	B-MED
(	O
7.5	O
%	O
)	O
,	O
and	O
stimulants	B-MED
(	O
3.9	O
%	O
)	O
.	O
Drivers	B-MED
who	O
reported	O
prescription	B-MED
drug	I-MED
use	B-MED
were	O
significantly	O
more	O
likely	O
to	O
be	O
female	B-MED
,	O
older	B-MED
,	O
non	B-MED
-	I-MED
Hispanic	I-MED
White	I-MED
,	O
and	O
report	O
disability	B-MED
.	O
Three	O
of	O
four	O
drivers	B-MED
who	O
reported	O
medication	B-MED
use	B-MED
(	O
78.2	O
%	O
)	O
said	O
the	O
drug	B-MED
was	O
prescribed	B-MED
for	O
their	O
use	B-MED
;	O
the	O
odds	O
of	O
using	O
without	O
a	O
prescription	B-MED
were	O
significantly	B-MED
higher	I-MED
for	O
males	B-MED
,	O
Black	B-MED
/	I-MED
African	I-MED
American	I-MED
,	O
and	O
Hispanic	B-MED
drivers	B-MED
,	O
and	O
lower	O
for	O
older	B-MED
drivers	B-MED
.	O
Among	O
those	O
with	O
a	O
prescription	B-MED
,	O
taking	O
more	O
than	O
prescribed	B-MED
was	O
most	O
common	O
for	O
narcotics	B-MED
(	O
6.8	O
%	O
)	O
,	O
followed	O
by	O
sedatives	B-MED
(	O
4.8	O
%	O
)	O
,	O
stimulants	B-MED
(	O
3.8	O
%	O
)	O
,	O
and	O
antidepressants	B-MED
(	O
1.5	O
%	O
)	O
.	O
These	O
findings	B-MED
help	O
to	O
identify	O
drivers	B-MED
using	O
potentially	B-MED
impairing	I-MED
prescription	B-MED
drugs	I-MED
,	O
both	O
medically	B-MED
and	O
nonmedically	B-MED
,	O
and	O
may	O
inform	O
the	O
targeting	B-MED
of	O
interventions	B-MED
to	O
reduce	O
impaired	B-MED
driving	I-MED
related	O
to	O
medications	B-MED
.	O
Molecular	B-MED
detection	B-MED
of	O
infection	B-MED
homogeneity	B-MED
and	O
impact	B-MED
of	O
miltefosine	B-MED
treatment	B-MED
in	O
a	O
Syrian	B-MED
golden	I-MED
hamster	I-MED
model	O
of	O
Leishmania	B-MED
donovani	I-MED
and	O
L.	B-MED
infantum	I-MED
visceral	B-MED
leishmaniasis	I-MED
Control	B-MED
of	O
visceral	B-MED
leishmaniasis	I-MED
caused	O
by	O
Leishmania	B-MED
infantum	I-MED
and	O
Leishmania	B-MED
donovani	I-MED
primarily	O
relies	O
on	O
chemotherapy	B-MED
using	O
an	O
increasingly	O
compromised	B-MED
repertoire	O
of	O
antileishmanial	B-MED
compounds	I-MED
.	O
For	O
evaluation	B-MED
of	O
novel	B-MED
drugs	B-MED
,	O
the	O
Syrian	B-MED
golden	I-MED
hamster	I-MED
is	O
considered	O
as	O
a	O
clinically	B-MED
relevant	B-MED
laboratory	B-MED
model	I-MED
.	O
In	O
this	O
study	B-MED
,	O
two	O
molecular	B-MED
parasite	I-MED
detection	I-MED
assays	I-MED
were	O
developed	O
targeting	B-MED
cathepsin	B-MED
-	I-MED
like	I-MED
cysteine	I-MED
protease	I-MED
B	I-MED
(	O
CPB	B-MED
)	O
DNA	B-MED
and	O
18S	O
rRNA	B-MED
to	O
achieve	O
absolute	B-MED
amastigote	B-MED
quantification	B-MED
in	O
the	O
major	O
target	B-MED
organs	B-MED
liver	B-MED
and	O
spleen	B-MED
.	O
Both	O
quantitative	B-MED
PCR	I-MED
(	B-MED
qPCR	I-MED
)	I-MED
techniques	I-MED
showed	O
excellent	O
agreement	O
with	O
a	O
strong	O
correlation	B-MED
with	O
the	O
conventional	O
microscopic	B-MED
reading	I-MED
of	O
Giemsa	B-MED
-	I-MED
stained	I-MED
tissue	B-MED
smears	B-MED
.	O
Using	O
multiple	B-MED
single	B-MED
tissue	B-MED
pieces	I-MED
and	O
all	O
three	O
detection	B-MED
methods	B-MED
,	O
we	O
confirmed	O
homogeneity	B-MED
of	O
infection	B-MED
in	O
liver	B-MED
and	O
spleen	B-MED
and	O
the	O
robustness	B-MED
of	O
extrapolating	O
whole	B-MED
organ	I-MED
burdens	I-MED
from	O
a	O
small	B-MED
single	B-MED
tissue	B-MED
piece	I-MED
.	O
Comparison	B-MED
of	O
pre	B-MED
-	O
and	O
post	B-MED
-	I-MED
treatment	I-MED
burdens	B-MED
in	O
infected	B-MED
hamsters	B-MED
using	O
the	O
three	O
detection	B-MED
methods	B-MED
consistently	O
revealed	B-MED
a	O
stronger	O
parasite	B-MED
reduction	B-MED
in	O
the	O
spleen	B-MED
compared	B-MED
to	O
the	O
liver	B-MED
,	O
indicating	O
an	O
organ	B-MED
-	O
dependent	B-MED
clearance	B-MED
efficacy	B-MED
for	O
miltefosine	B-MED
.	O
In	O
conclusion	B-MED
,	O
this	O
study	B-MED
in	O
the	O
hamster	B-MED
demonstrated	O
high	B-MED
homogeneity	B-MED
of	O
infection	B-MED
in	O
liver	B-MED
and	O
spleen	B-MED
and	O
advocates	O
the	O
use	O
of	O
molecular	B-MED
detection	B-MED
methods	B-MED
for	O
assessment	B-MED
of	O
low	B-MED
(	O
post	B-MED
-	I-MED
treatment	I-MED
)	O
tissue	B-MED
burdens	B-MED
.	O
Doxifluridine	B-MED
-	O
conjugated	B-MED
2	B-MED
-	I-MED
5A	I-MED
analog	B-MED
shows	O
strong	B-MED
RNase	B-MED
L	I-MED
activation	B-MED
ability	B-MED
and	O
tumor	B-MED
suppressive	I-MED
effect	B-MED
RNase	B-MED
L	I-MED
is	O
activated	B-MED
by	O
2',5'-oligoadenylates	B-MED
(	O
2	B-MED
-	I-MED
5A	I-MED
)	O
at	O
subnanomolar	B-MED
levels	B-MED
to	O
cleave	B-MED
single	B-MED
-	I-MED
stranded	I-MED
RNA	I-MED
.	O
We	O
previously	O
reported	B-MED
the	O
hypothesis	B-MED
that	O
the	O
introduction	B-MED
of	O
an	O
8	B-MED
-	I-MED
methyladenosine	I-MED
residue	O
at	O
the	O
2'-	O
terminus	B-MED
of	O
the	O
2	B-MED
-	I-MED
5A	I-MED
tetramer	I-MED
shifts	B-MED
the	O
2	B-MED
-	I-MED
5A	I-MED
binding	B-MED
site	I-MED
of	O
RNase	B-MED
L	I-MED
L.	O
In	O
this	O
study	B-MED
,	O
we	O
synthesized	B-MED
various	O
5'-	O
modified	B-MED
2	B-MED
-	I-MED
5A	I-MED
analog	B-MED
s	O
with	O
8	B-MED
-	I-MED
methyladenosine	I-MED
at	O
the	O
2'-	O
terminus	B-MED
.	O
The	O
doxifluridine	B-MED
-	O
conjugated	B-MED
8	B-MED
-	I-MED
methyladenosine	I-MED
-	O
substituted	B-MED
2	B-MED
-	I-MED
5A	I-MED
analog	B-MED
was	O
significantly	B-MED
more	I-MED
effective	B-MED
as	O
an	O
activator	B-MED
of	O
RNase	B-MED
L	I-MED
than	O
the	O
parent	B-MED
5'-	O
monophophorylated	B-MED
2	B-MED
-	I-MED
5A	I-MED
tetramer	I-MED
and	O
showed	O
a	O
tumor	B-MED
suppressive	I-MED
effect	B-MED
against	B-MED
human	B-MED
cervical	B-MED
cancer	I-MED
cells	B-MED
.	O
The	O
Business	B-MED
of	O
Health	B-MED
Physics	I-MED
-	O
Jobs	B-MED
In	O
A	O
Changing	B-MED
Market	I-MED
The	O
health	B-MED
physics	I-MED
profession	B-MED
was	O
born	O
abruptly	O
when	O
once	O
rare	O
and	O
precious	O
radioactive	B-MED
materials	I-MED
became	O
commonplace	B-MED
.	O
The	O
technological	B-MED
advancements	I-MED
that	O
triggered	O
an	O
industrial	B-MED
complex	I-MED
and	O
ended	O
World	B-MED
War	I-MED
II	I-MED
demanded	O
radiation	B-MED
safety	I-MED
on	O
an	O
unprecedented	B-MED
scale	I-MED
.	O
Until	O
then	O
,	O
protective	B-MED
measures	I-MED
against	I-MED
radiation	I-MED
were	O
largely	O
absent	O
in	O
laboratories	B-MED
.	O
Over	O
the	O
subsequent	O
decades	O
,	O
health	B-MED
physicists	I-MED
began	O
protecting	B-MED
people	I-MED
and	O
the	O
environment	B-MED
in	O
a	O
wide	O
range	O
of	O
settings	O
including	O
medical	B-MED
,	O
research	B-MED
,	O
and	O
industrial	B-MED
.	O
The	O
use	B-MED
of	I-MED
radioactive	I-MED
materials	I-MED
and	O
radiation	B-MED
-	I-MED
generating	I-MED
devices	I-MED
is	O
prevalent	B-MED
today	I-MED
.	O
Radiation	B-MED
doses	I-MED
occur	O
continuously	O
including	O
during	O
airline	B-MED
flights	I-MED
,	O
in	O
our	O
homes	O
,	O
during	O
medical	B-MED
procedures	I-MED
,	O
and	O
in	O
energy	O
production	O
.	O
Radiation	B-MED
is	O
integral	B-MED
to	I-MED
numerous	I-MED
applications	I-MED
including	O
those	O
in	O
medicine	B-MED
,	O
dentistry	B-MED
,	O
manufacturing	B-MED
,	O
construction	O
,	O
scientific	B-MED
research	I-MED
,	O
nuclear	B-MED
electric	I-MED
power	I-MED
generation	I-MED
,	O
and	O
oil	B-MED
and	I-MED
gas	I-MED
exploration	I-MED
.	O
Activities	O
that	O
were	O
once	O
groundbreaking	O
have	O
now	O
become	O
routine	B-MED
and	O
scripted	B-MED
.	O
At	O
higher	B-MED
doses	I-MED
,	O
health	B-MED
effects	I-MED
are	O
understood	B-MED
and	I-MED
avoided	I-MED
.	O
Instruments	B-MED
for	I-MED
the	I-MED
detection	I-MED
and	I-MED
measurement	I-MED
of	I-MED
radiation	I-MED
are	O
at	O
times	O
smarter	O
than	O
their	O
users	O
.	O
Ironically	O
,	O
the	O
same	O
health	B-MED
physics	I-MED
community	O
that	O
has	O
been	O
successful	O
in	O
demonstrating	O
that	O
exposures	B-MED
to	I-MED
radiation	I-MED
and	O
to	O
radioactive	B-MED
materials	I-MED
can	O
be	O
effectively	B-MED
managed	I-MED
is	O
shrinking	O
at	O
an	O
increasingly	O
rapid	B-MED
rate	I-MED
.	O
This	O
paper	O
highlights	O
the	O
creation	B-MED
of	O
past	O
and	O
current	O
jobs	B-MED
,	O
predicts	O
the	O
future	O
opportunities	B-MED
in	I-MED
the	I-MED
profession	I-MED
,	O
and	O
makes	O
recommendations	B-MED
necessary	O
to	O
protect	O
the	O
disappearing	B-MED
specialties	I-MED
.	O
Annexin	B-MED
A1	I-MED
restores	O
Aβ1	B-MED
-	I-MED
42	I-MED
-induced	O
blood	B-MED
-	I-MED
brain	I-MED
barrier	I-MED
disruption	I-MED
through	O
the	O
inhibition	B-MED
of	O
RhoA	B-MED
-	I-MED
ROCK	I-MED
signaling	I-MED
pathway	I-MED
The	O
blood	B-MED
-	I-MED
brain	I-MED
barrier	I-MED
(	O
BBB	B-MED
)	O
is	O
composed	O
of	O
brain	B-MED
capillary	I-MED
endothelial	B-MED
cells	I-MED
and	O
has	O
an	O
important	O
role	O
in	O
maintaining	O
homeostasis	B-MED
of	O
the	O
brain	B-MED
separating	O
the	O
blood	B-MED
from	O
the	O
parenchyma	B-MED
of	O
the	O
central	B-MED
nervous	I-MED
system	I-MED
(	O
CNS	B-MED
)	O
.	O
It	O
is	O
widely	O
known	O
that	O
disruption	B-MED
of	I-MED
the	I-MED
BBB	I-MED
occurs	O
in	O
various	O
neurodegenerative	B-MED
diseases	I-MED
,	O
including	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
(	O
AD	B-MED
)	O
.	O
Annexin	B-MED
A1	I-MED
(	O
ANXA1	B-MED
)	O
,	O
an	O
anti	B-MED
-	I-MED
inflammatory	I-MED
messenger	I-MED
,	O
is	O
expressed	B-MED
in	O
brain	B-MED
endothelial	I-MED
cells	I-MED
and	O
regulates	O
the	O
BBB	B-MED
integrity	O
.	O
However	O
,	O
its	O
role	O
and	O
mechanism	B-MED
for	O
protecting	O
BBB	B-MED
in	O
AD	B-MED
have	O
not	O
been	O
identified	O
.	O
We	O
found	O
that	O
β	B-MED
-	I-MED
Amyloid	I-MED
1	I-MED
-	I-MED
42	I-MED
Aβ42	B-MED
(	O
Aβ42)-induced	O
BBB	B-MED
disruption	I-MED
was	O
rescued	O
by	O
human	B-MED
recombinant	I-MED
ANXA1	I-MED
(	O
hrANXA1	B-MED
)	O
in	O
the	O
murine	B-MED
brain	B-MED
endothelial	I-MED
cell	I-MED
line	I-MED
bEnd.3	I-MED
.	I-MED
Also	O
,	O
ANXA1	B-MED
was	O
decreased	O
in	O
the	O
bEnd.3	B-MED
cells	I-MED
,	O
the	O
capillaries	B-MED
of	O
5XFAD	B-MED
mice	I-MED
,	O
and	O
the	O
human	B-MED
serum	I-MED
of	O
patients	B-MED
with	O
AD	B-MED
.	O
To	O
find	O
out	O
the	O
mechanism	B-MED
by	O
which	O
ANXA1	B-MED
recovers	O
the	O
BBB	B-MED
integrity	O
in	O
AD	B-MED
,	O
the	O
RhoA	B-MED
-	I-MED
ROCK	I-MED
signaling	I-MED
pathway	I-MED
was	O
examined	O
in	O
both	O
Aβ42	B-MED
-treated	O
bEnd.3	B-MED
cells	I-MED
and	O
the	O
capillaries	B-MED
of	O
5XFAD	B-MED
mice	I-MED
as	O
RhoA	B-MED
was	O
activated	B-MED
in	O
both	O
cases	O
.	O
RhoA	B-MED
inhibitors	I-MED
alleviated	O
Aβ42	B-MED
-induced	O
BBB	B-MED
disruption	I-MED
and	O
constitutively	O
overexpressed	B-MED
RhoA	B-MED
-	I-MED
GTP	I-MED
(	O
active	O
form	O
of	O
RhoA	B-MED
)	O
attenuated	O
the	O
protective	O
effect	O
of	O
ANXA1	B-MED
.	O
When	O
pericytes	B-MED
were	O
cocultured	B-MED
with	O
bEnd.3	B-MED
cells	I-MED
,	O
Aβ42	B-MED
-induced	O
RhoA	B-MED
activation	I-MED
of	O
bEnd.3	B-MED
cells	I-MED
was	O
inhibited	B-MED
by	O
the	O
secretion	B-MED
of	O
ANXA1	B-MED
from	O
pericytes	B-MED
.	O
Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
ANXA1	B-MED
restores	O
Aβ42	B-MED
-induced	O
BBB	B-MED
disruption	I-MED
through	O
inhibition	B-MED
of	O
RhoA	B-MED
-	I-MED
ROCK	I-MED
signaling	I-MED
pathway	I-MED
and	O
we	O
propose	O
ANXA1	B-MED
as	O
a	O
therapeutic	B-MED
reagent	I-MED
,	O
protecting	O
against	O
the	O
breakdown	B-MED
of	I-MED
the	I-MED
BBB	I-MED
in	O
AD	B-MED
.	O
Results	B-MED
of	O
a	O
Multicenter	B-MED
,	O
Randomized	B-MED
,	O
Controlled	B-MED
Trial	I-MED
of	O
a	O
Hydrogen	B-MED
Peroxide	I-MED
-based	O
Kit	B-MED
versus	O
a	O
Benzoyl	B-MED
Peroxide	I-MED
-based	O
Kit	B-MED
in	O
Mild	B-MED
-	I-MED
to	I-MED
-	I-MED
moderate	I-MED
Acne	B-MED
Objective	O
:	O
To	O
evaluate	B-MED
the	O
efficacy	B-MED
and	O
tolerability	B-MED
of	O
a	O
novel	O
hydrogen	B-MED
peroxide	I-MED
-based	O
regimen	B-MED
versus	O
a	O
benzoyl	B-MED
peroxide	I-MED
-based	O
regimen	B-MED
in	O
mild	B-MED
-	I-MED
to	I-MED
-	I-MED
moderate	I-MED
acne	B-MED
.	O
Methods	B-MED
:	O
In	O
this	O
eight-	O
week	B-MED
multicenter	B-MED
study	I-MED
,	O
patients	B-MED
were	O
randomized	B-MED
to	O
either	O
a	O
hydrogen	B-MED
peroxide	I-MED
-based	O
or	O
a	O
benzoyl	B-MED
peroxide	I-MED
-based	O
regimen	B-MED
.The	O
primary	B-MED
outcome	I-MED
measure	I-MED
of	O
clinical	B-MED
response	I-MED
was	O
assessed	B-MED
using	O
the	O
Global	B-MED
Acne	I-MED
Grading	I-MED
System	I-MED
(	O
GAGS	B-MED
)	O
at	O
baseline	B-MED
,	O
four	O
weeks	B-MED
,	O
and	O
eight	O
weeks	B-MED
.	O
At	O
Week	B-MED
8	O
,	O
a	O
patient	B-MED
self	B-MED
-	I-MED
satisfaction	I-MED
questionnaire	I-MED
was	O
administered	B-MED
.	O
Investigators	B-MED
were	O
also	O
queried	B-MED
at	O
that	O
time	O
regarding	O
assessment	B-MED
of	O
tolerability	B-MED
and	O
cosmetic	B-MED
acceptability	B-MED
.	O
Tolerability	B-MED
was	O
also	O
measured	B-MED
at	O
each	O
visit	B-MED
.	O
Results	O
:	O
Both	O
treatment	B-MED
regimens	I-MED
were	O
associated	B-MED
with	I-MED
improvement	B-MED
of	O
GAGS	B-MED
score	I-MED
at	O
Week	B-MED
8	O
compared	B-MED
to	O
baseline	B-MED
(	O
p<0.0001	O
)	O
.	O
GAGS	B-MED
score	I-MED
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
regimens	B-MED
over	O
the	O
same	O
period	B-MED
(	O
p=0.7765	O
)	O
.	O
No	B-MED
significant	I-MED
adverse	I-MED
events	I-MED
were	O
reported	B-MED
or	O
observed	B-MED
in	O
either	O
treatment	B-MED
arm	I-MED
.	O
Both	O
patients	B-MED
and	O
investigators	B-MED
found	O
both	O
regimens	B-MED
to	O
be	O
similarly	O
effective	B-MED
and	O
cosmetically	B-MED
acceptable	B-MED
.	O
Conclusion	O
:	O
A	O
novel	O
hydrogen	B-MED
peroxide	I-MED
-based	O
regimen	B-MED
was	O
shown	O
to	O
be	O
comparable	B-MED
in	O
efficacy	B-MED
,	O
safety	B-MED
,	O
and	O
cosmetic	B-MED
acceptability	B-MED
to	O
a	O
benzoyl	B-MED
peroxide	I-MED
-based	O
regimen	B-MED
in	O
the	O
treatment	B-MED
of	O
mild	B-MED
-	I-MED
to	I-MED
-	I-MED
moderate	I-MED
acne	B-MED
.	O
Active	B-MED
diffusion	B-MED
and	O
microtubule	B-MED
-	I-MED
based	I-MED
transport	I-MED
oppose	O
myosin	B-MED
forces	B-MED
to	O
position	B-MED
organelles	B-MED
in	O
cells	B-MED
Even	O
distribution	B-MED
of	O
peroxisomes	B-MED
(	O
POs	B-MED
)	O
and	O
lipid	B-MED
droplets	I-MED
(	O
LDs	B-MED
)	O
is	O
critical	O
to	O
their	O
role	B-MED
in	O
lipid	B-MED
and	O
reactive	B-MED
oxygen	I-MED
species	I-MED
homeostasis	B-MED
.	O
How	O
even	O
distribution	B-MED
is	O
achieved	O
remains	O
elusive	O
,	O
but	O
diffusive	B-MED
motion	I-MED
and	O
directed	O
motility	B-MED
may	O
play	O
a	O
role	B-MED
.	O
Here	O
we	O
show	O
that	O
in	O
the	O
fungus	B-MED
Ustilago	B-MED
maydis	I-MED
~95	O
%	O
of	O
POs	B-MED
and	O
LDs	B-MED
undergo	O
diffusive	B-MED
motions	I-MED
.	O
These	O
movements	B-MED
require	O
ATP	B-MED
and	O
involve	O
bidirectional	B-MED
early	O
endosome	B-MED
motility	B-MED
,	O
indicating	O
that	O
microtubule	B-MED
-	O
associated	B-MED
membrane	B-MED
trafficking	B-MED
enhances	B-MED
diffusion	B-MED
of	O
organelles	B-MED
.	O
When	O
early	O
endosome	B-MED
transport	I-MED
is	O
abolished	O
,	O
POs	B-MED
and	O
LDs	B-MED
drift	O
slowly	O
towards	O
the	O
growing	B-MED
cell	I-MED
end	I-MED
.	O
This	O
pole	B-MED
-	I-MED
ward	I-MED
drift	I-MED
is	O
facilitated	O
by	O
anterograde	B-MED
delivery	I-MED
of	O
secretory	B-MED
cargo	I-MED
to	O
the	O
cell	B-MED
tip	I-MED
by	O
myosin-5	B-MED
.	O
Modelling	B-MED
reveals	O
that	O
microtubule	B-MED
-	I-MED
based	I-MED
directed	I-MED
transport	I-MED
and	O
active	B-MED
diffusion	B-MED
support	O
distribution	B-MED
,	O
mobility	B-MED
and	O
mixing	O
of	O
POs	B-MED
.	O
In	O
mammalian	B-MED
COS-7	B-MED
cells	I-MED
,	O
microtubules	B-MED
and	O
F	B-MED
-	I-MED
actin	I-MED
also	O
counteract	O
each	O
other	O
to	O
distribute	B-MED
POs	B-MED
.	O
This	O
highlights	O
the	O
importance	O
of	O
opposing	O
cytoskeletal	B-MED
forces	B-MED
in	O
organelle	B-MED
positioning	B-MED
in	O
eukaryotes	B-MED
.	O
Polysaccharide	B-MED
-	O
Specific	B-MED
Memory	B-MED
B	I-MED
Cells	I-MED
Predict	O
Protection	B-MED
against	O
Experimental	B-MED
Human	B-MED
Pneumococcal	B-MED
Carriage	B-MED
We	O
have	O
previously	B-MED
demonstrated	O
that	O
experimental	B-MED
pneumococcal	B-MED
carriage	B-MED
enhances	B-MED
immunity	B-MED
and	O
protects	B-MED
healthy	B-MED
adults	B-MED
against	B-MED
carriage	B-MED
reacquisition	B-MED
after	O
rechallenge	B-MED
with	O
a	O
homologous	B-MED
strain	B-MED
.	O
To	O
investigate	O
the	O
role	O
of	O
naturally	B-MED
acquired	B-MED
pneumococcal	B-MED
protein	I-MED
and	O
polysaccharide	B-MED
PS	B-MED
(	O
PS)-	O
specific	B-MED
immunity	B-MED
in	O
protection	B-MED
against	B-MED
carriage	B-MED
acquisition	B-MED
using	O
a	O
heterologous	B-MED
challenge	I-MED
model	O
.	O
We	O
identified	O
healthy	B-MED
volunteers	I-MED
that	O
were	O
naturally	B-MED
colonized	B-MED
with	O
pneumococcus	B-MED
and	O
,	O
after	O
clearance	B-MED
of	O
their	O
natural	B-MED
carriage	B-MED
episode	B-MED
,	O
challenged	O
them	O
with	O
a	O
heterologous	B-MED
6B	B-MED
strain	I-MED
.	O
In	O
another	O
cohort	B-MED
of	O
volunteers	B-MED
we	O
assessed	O
6BPS	B-MED
-	O
specific	B-MED
,	O
PspA	B-MED
-	O
specific	B-MED
,	O
and	O
PspC	B-MED
-	O
specific	B-MED
IgG	B-MED
and	O
IgA	B-MED
plasma	B-MED
and	O
memory	B-MED
B	I-MED
-	I-MED
cell	I-MED
populations	I-MED
before	B-MED
and	O
7	O
,	O
14	O
,	O
and	O
35	O
days	O
after	B-MED
experimental	B-MED
pneumococcal	B-MED
inoculation	B-MED
.	O
Heterologous	B-MED
challenge	I-MED
with	O
6B	B-MED
resulted	O
in	O
50	O
%	O
carriage	B-MED
among	O
volunteers	B-MED
with	O
previous	B-MED
natural	B-MED
pneumococcal	B-MED
carriage	B-MED
.	O
Protection	B-MED
from	O
carriage	B-MED
was	O
associated	B-MED
with	I-MED
a	O
high	B-MED
number	O
of	O
circulating	B-MED
6BPS	B-MED
IgG	B-MED
-	O
secreting	B-MED
memory	B-MED
B	I-MED
cells	I-MED
at	O
baseline	B-MED
.	O
There	O
were	O
no	O
associations	B-MED
between	O
protection	B-MED
from	O
carriage	B-MED
and	O
baseline	B-MED
levels	B-MED
of	O
6BPS	B-MED
IgG	B-MED
in	O
serum	B-MED
or	O
nasal	B-MED
wash	I-MED
,	O
PspA	B-MED
-	O
specific	B-MED
,	O
or	O
PspC	B-MED
-	O
specific	B-MED
memory	B-MED
B	I-MED
cells	I-MED
or	O
plasma	B-MED
cells	I-MED
.	O
In	O
volunteers	B-MED
who	O
did	O
not	B-MED
develop	I-MED
carriage	B-MED
,	O
the	O
number	O
of	O
circulating	B-MED
6BPS	B-MED
memory	B-MED
B	I-MED
cells	I-MED
decreased	B-MED
and	O
the	O
number	O
of	O
6BPS	B-MED
plasma	B-MED
cells	I-MED
increased	B-MED
postinoculation	B-MED
.	O
Our	O
data	O
indicate	O
that	O
naturally	B-MED
acquired	B-MED
PS	B-MED
-	O
specific	B-MED
memory	B-MED
B	I-MED
cells	I-MED
,	O
but	O
not	B-MED
levels	I-MED
of	O
circulating	B-MED
IgG	B-MED
at	O
time	O
of	O
pneumococcal	B-MED
exposure	B-MED
,	O
are	O
associated	B-MED
with	I-MED
protection	B-MED
against	B-MED
carriage	B-MED
acquisition	B-MED
.	O
Selection	B-MED
of	O
a	O
marker	B-MED
gene	I-MED
to	O
construct	O
a	O
reference	B-MED
library	I-MED
for	O
wetland	B-MED
plants	B-MED
,	O
and	O
the	O
application	O
of	O
metabarcoding	B-MED
to	O
analyze	B-MED
the	O
diet	B-MED
of	O
wintering	B-MED
herbivorous	B-MED
waterbirds	B-MED
Food	B-MED
availability	B-MED
and	O
diet	B-MED
selection	B-MED
are	O
important	O
factors	B-MED
influencing	B-MED
the	O
abundance	B-MED
and	O
distribution	B-MED
of	O
wild	B-MED
waterbirds	B-MED
.	O
In	O
order	O
to	O
better	O
understand	O
changes	B-MED
in	O
waterbird	B-MED
population	B-MED
,	O
it	O
is	O
essential	O
to	O
figure	O
out	O
what	O
they	O
feed	B-MED
on	I-MED
.	O
However	O
,	O
analyzing	B-MED
their	O
diet	B-MED
could	O
be	O
difficult	B-MED
and	O
inefficient	B-MED
using	O
traditional	O
methods	B-MED
such	O
as	O
microhistologic	B-MED
observation	I-MED
.	O
Here	O
,	O
we	O
addressed	O
this	O
gap	O
of	O
knowledge	O
by	O
investigating	O
the	O
diet	B-MED
of	O
greater	B-MED
white	I-MED
-	I-MED
fronted	I-MED
goose	I-MED
Anser	I-MED
albifrons	I-MED
and	O
bean	B-MED
goose	I-MED
Anser	I-MED
fabalis	I-MED
,	O
which	O
are	O
obligate	B-MED
herbivores	I-MED
wintering	B-MED
in	O
China	B-MED
,	O
mostly	O
in	O
the	O
Middle	B-MED
and	O
Lower	B-MED
Yangtze	I-MED
River	I-MED
floodplain	I-MED
.	O
First	O
,	O
we	O
selected	B-MED
a	O
suitable	B-MED
and	O
high	O
-	O
resolution	O
marker	B-MED
gene	I-MED
for	O
wetland	B-MED
plants	B-MED
that	O
these	O
geese	B-MED
would	O
consume	O
during	O
the	O
wintering	B-MED
period	I-MED
.	O
Eight	O
candidate	B-MED
genes	I-MED
were	O
included	O
:	O
rbcL	B-MED
,	O
rpoC1	B-MED
,	O
rpoB	B-MED
,	O
matK	B-MED
,	O
trnH	B-MED
-	I-MED
psbA	I-MED
,	O
trnL	B-MED
(	O
UAA	B-MED
)	O
,	O
atpF	B-MED
-	I-MED
atpH	I-MED
,	O
and	O
psbK	B-MED
-	I-MED
psbI	I-MED
psbI.	O
The	O
selection	B-MED
was	O
performed	O
via	O
analysis	B-MED
of	O
representative	B-MED
sequences	B-MED
from	O
NCBI	B-MED
and	O
comparison	B-MED
of	O
amplification	B-MED
efficiency	B-MED
and	O
resolution	O
power	O
of	O
plant	B-MED
samples	B-MED
collected	O
from	O
the	O
wintering	B-MED
area	I-MED
.	O
The	O
trnL	B-MED
gene	I-MED
was	O
chosen	O
at	O
last	O
with	O
c	B-MED
/	I-MED
h	I-MED
primers	I-MED
,	O
and	O
a	O
local	B-MED
plant	B-MED
reference	B-MED
library	I-MED
was	O
constructed	B-MED
with	O
this	O
gene	B-MED
.	O
Then	O
,	O
utilizing	O
DNA	B-MED
metabarcoding	I-MED
,	O
we	O
discovered	B-MED
15	O
food	B-MED
items	I-MED
in	O
total	O
from	O
the	O
feces	B-MED
of	O
these	O
birds	B-MED
.	O
Of	O
the	O
15	O
unique	O
dietary	B-MED
sequences	B-MED
,	O
10	O
could	O
be	O
identified	O
at	O
specie	B-MED
level	B-MED
.	O
As	O
for	O
greater	B-MED
white	I-MED
-	I-MED
fronted	I-MED
goose	I-MED
,	O
73	O
%	O
of	O
sequences	B-MED
belonged	O
to	O
Poaceae	B-MED
spp	I-MED
.	I-MED
,	O
and	O
26	O
%	O
belonged	O
to	O
Carex	B-MED
spp	I-MED
.	O
In	O
contrast	O
,	O
almost	O
all	O
sequences	B-MED
of	O
bean	B-MED
goose	I-MED
belonged	O
to	O
Carex	B-MED
spp	I-MED
.	O
(	O
99	O
%	O
)	O
.	O
Using	O
the	O
same	O
samples	B-MED
,	O
microhistology	B-MED
provided	O
consistent	B-MED
food	B-MED
composition	I-MED
with	O
metabarcoding	B-MED
results	B-MED
for	O
greater	B-MED
white	I-MED
-	I-MED
fronted	I-MED
goose	I-MED
,	O
while	O
13	O
%	O
of	O
Poaceae	B-MED
was	O
recovered	O
for	O
bean	B-MED
goose	I-MED
.	O
In	O
addition	O
,	O
two	O
other	O
taxa	B-MED
were	O
discovered	B-MED
only	O
through	O
microhistologic	B-MED
analysis	I-MED
.	O
Although	O
most	O
of	O
the	O
identified	O
taxa	B-MED
matched	B-MED
relatively	O
well	O
between	O
the	O
two	O
methods	B-MED
,	O
DNA	B-MED
metabarcoding	I-MED
gave	O
taxonomically	B-MED
more	O
detailed	B-MED
information	I-MED
.	O
Discrepancies	B-MED
were	O
likely	O
due	O
to	O
biased	B-MED
PCR	B-MED
amplification	B-MED
in	O
metabarcoding	B-MED
,	O
low	O
discriminating	B-MED
power	B-MED
of	O
current	O
marker	B-MED
genes	I-MED
for	O
monocots	B-MED
,	O
and	O
biases	B-MED
in	O
microhistologic	B-MED
analysis	I-MED
.	O
The	O
diet	B-MED
differences	B-MED
between	O
two	O
geese	B-MED
species	B-MED
might	O
indicate	O
deeper	O
ecological	B-MED
significance	B-MED
beyond	O
the	O
scope	O
of	O
this	O
study	B-MED
.	O
We	O
concluded	O
that	O
DNA	B-MED
metabarcoding	I-MED
provides	O
new	O
perspectives	B-MED
for	O
studies	B-MED
of	O
herbivorous	B-MED
waterbird	B-MED
diets	B-MED
and	O
inter	B-MED
-	I-MED
specific	I-MED
interactions	I-MED
,	O
as	O
well	O
as	O
new	O
possibilities	O
to	O
investigate	B-MED
interactions	B-MED
between	O
herbivores	B-MED
and	O
plants	B-MED
.	O
In	O
addition	O
,	O
microhistologic	B-MED
analysis	I-MED
should	O
be	O
used	O
together	O
with	O
metabarcoding	B-MED
methods	I-MED
to	O
integrate	O
this	O
information	B-MED
.	O
Gender	B-MED
and	O
Direction	B-MED
of	O
Effect	B-MED
of	O
Alcohol	B-MED
Problems	I-MED
and	O
Internalizing	B-MED
Symptoms	I-MED
in	O
a	O
Longitudinal	B-MED
Sample	I-MED
of	O
College	B-MED
Students	I-MED
Alcohol	B-MED
problems	I-MED
and	O
internalizing	B-MED
symptoms	I-MED
are	O
consistently	O
found	O
to	O
be	O
associated	B-MED
but	O
how	O
they	O
relate	B-MED
to	O
each	O
other	O
is	O
unclear	B-MED
.	O
The	O
present	O
study	B-MED
aimed	O
to	O
address	O
limitations	B-MED
in	O
the	O
literature	B-MED
of	O
comorbidity	B-MED
of	O
alcohol	B-MED
problems	I-MED
and	O
internalizing	B-MED
symptoms	I-MED
by	O
investigating	B-MED
the	O
direction	B-MED
of	O
effect	B-MED
between	O
the	O
phenotypes	B-MED
and	O
possible	O
gender	B-MED
differences	I-MED
in	O
college	B-MED
students	I-MED
.	O
We	O
utilized	O
data	B-MED
from	O
a	O
large	O
longitudinal	B-MED
study	I-MED
of	O
college	B-MED
students	I-MED
from	O
the	O
United	B-MED
States	I-MED
(	O
N	O
=	O
2607	O
)	O
.	O
Three	O
waves	O
of	O
questionnaire	B-MED
-	I-MED
based	I-MED
data	B-MED
were	O
collected	O
over	O
the	O
first	O
two	O
years	B-MED
of	O
college	B-MED
(	O
in	O
2011	O
-	O
2013	O
)	O
.	O
Cross	B-MED
-	I-MED
lagged	I-MED
models	I-MED
were	O
applied	O
to	O
examine	O
the	O
possible	O
direction	B-MED
of	O
effect	B-MED
of	O
internalizing	B-MED
symptoms	I-MED
and	O
alcohol	B-MED
problems	I-MED
.	O
Possible	O
effects	B-MED
of	O
gender	B-MED
were	O
investigated	B-MED
using	O
multigroup	B-MED
modeling	I-MED
.	O
There	O
were	O
significant	B-MED
correlations	B-MED
between	O
alcohol	B-MED
problems	I-MED
and	O
internalizing	B-MED
symptoms	I-MED
.	O
A	O
direction	B-MED
of	O
effect	B-MED
was	O
found	O
between	O
alcohol	B-MED
problems	I-MED
and	O
internalizing	B-MED
symptoms	I-MED
but	O
differed	O
between	O
genders	B-MED
.	O
A	O
unidirectional	O
relationship	B-MED
varying	O
with	O
age	B-MED
was	O
identified	O
for	O
males	B-MED
where	O
alcohol	B-MED
problems	I-MED
initially	O
predicted	B-MED
internalizing	B-MED
symptoms	I-MED
followed	O
by	O
internalizing	B-MED
symptoms	I-MED
predicting	O
alcohol	B-MED
problems	I-MED
.	O
For	O
females	B-MED
,	O
a	O
unidirectional	O
relationship	B-MED
existed	O
wherein	O
alcohol	B-MED
problems	I-MED
predicted	O
internalizing	B-MED
symptoms	I-MED
.	O
Conclusions	O
/	O
Importance	O
:	O
We	O
conclude	O
that	O
the	O
relationship	B-MED
between	O
alcohol	B-MED
problems	I-MED
and	O
internalizing	B-MED
symptoms	I-MED
is	O
complex	B-MED
and	O
differ	O
between	O
genders	B-MED
.	O
In	O
males	B-MED
,	O
both	O
phenotypes	B-MED
are	O
predictive	B-MED
of	O
each	O
other	O
,	O
while	O
in	O
females	B-MED
the	O
relationship	B-MED
is	O
driven	O
by	O
alcohol	B-MED
problems	I-MED
.	O
Importantly	O
,	O
our	O
study	B-MED
examines	O
a	O
population	B-MED
-	I-MED
based	I-MED
sample	I-MED
,	O
revealing	O
that	O
the	O
observed	O
relationships	B-MED
between	O
alcohol	B-MED
problems	I-MED
and	O
internalizing	B-MED
symptoms	I-MED
are	O
not	O
limited	O
to	O
individuals	B-MED
with	O
clinically	B-MED
diagnosed	I-MED
mental	B-MED
health	I-MED
or	O
substance	B-MED
use	I-MED
problems	I-MED
.	O
The	O
added	B-MED
value	B-MED
of	O
cardiac	B-MED
index	I-MED
and	O
pulse	B-MED
pressure	I-MED
variation	B-MED
monitoring	B-MED
to	O
mean	B-MED
arterial	I-MED
pressure	I-MED
-	O
guided	B-MED
volume	I-MED
therapy	I-MED
in	O
moderate	B-MED
-	I-MED
risk	I-MED
abdominal	I-MED
surgery	I-MED
(	O
COGUIDE	B-MED
):	O
a	O
pragmatic	B-MED
multicentre	B-MED
randomised	B-MED
controlled	I-MED
trial	I-MED
There	O
is	O
disagreement	B-MED
regarding	O
the	O
benefits	B-MED
of	O
goal	B-MED
-	I-MED
directed	I-MED
therapy	I-MED
in	O
moderate	B-MED
-	I-MED
risk	I-MED
abdominal	I-MED
surgery	I-MED
.	O
Therefore	O
,	O
we	O
tested	B-MED
the	O
hypothesis	B-MED
that	O
the	O
addition	B-MED
of	O
non	B-MED
-	I-MED
invasive	I-MED
cardiac	B-MED
index	I-MED
and	O
pulse	B-MED
pressure	I-MED
variation	B-MED
monitoring	B-MED
to	O
mean	B-MED
arterial	I-MED
pressure	I-MED
-based	O
goal	B-MED
-	I-MED
directed	I-MED
therapy	I-MED
would	O
reduce	B-MED
the	O
incidence	B-MED
of	O
postoperative	B-MED
complications	I-MED
in	O
patients	B-MED
having	O
moderate	B-MED
-	I-MED
risk	I-MED
abdominal	I-MED
surgery	I-MED
.	O
In	O
this	O
pragmatic	B-MED
multicentre	B-MED
randomised	B-MED
controlled	I-MED
trial	I-MED
,	O
we	O
randomly	B-MED
allocated	I-MED
244	O
patients	B-MED
by	O
envelope	B-MED
drawing	I-MED
in	O
a	O
1:1	O
fashion	O
,	O
stratified	B-MED
per	O
centre	O
.	O
All	O
patients	B-MED
had	O
mean	B-MED
arterial	I-MED
pressure	I-MED
,	O
cardiac	B-MED
index	I-MED
and	O
pulse	B-MED
pressure	I-MED
variation	B-MED
measured	B-MED
continuously	B-MED
.	O
In	O
one	O
group	B-MED
,	O
healthcare	B-MED
professionals	I-MED
were	O
blinded	B-MED
to	O
cardiac	B-MED
index	I-MED
and	O
pulse	B-MED
pressure	I-MED
variation	B-MED
values	B-MED
and	O
were	O
asked	O
to	O
guide	O
haemodynamic	B-MED
therapy	I-MED
only	O
based	O
on	O
mean	B-MED
arterial	I-MED
pressure	I-MED
(	O
control	B-MED
group	I-MED
)	O
.	O
In	O
the	O
second	O
group	B-MED
,	O
cardiac	B-MED
index	I-MED
and	O
pulse	B-MED
pressure	I-MED
variation	B-MED
values	B-MED
were	O
displayed	B-MED
and	O
kept	O
within	O
target	B-MED
ranges	B-MED
following	O
a	O
pre	B-MED
-	I-MED
defined	I-MED
algorithm	I-MED
(	O
CI	B-MED
-	I-MED
PPV	I-MED
group	I-MED
)	O
.	O
The	O
primary	B-MED
endpoint	I-MED
was	O
the	O
incidence	B-MED
of	O
postoperative	B-MED
complications	I-MED
within	B-MED
30	I-MED
days	I-MED
.	O
One	O
hundred	O
and	O
seventy	O
-	O
five	O
patients	B-MED
were	O
eligible	B-MED
for	O
final	B-MED
analysis	B-MED
.	O
Overall	B-MED
complication	B-MED
rates	I-MED
were	O
similar	O
(	O
42/94	O
(	O
44.7	O
%	O
)	O
vs.	O
38/81	O
(	O
46.9	O
%	O
)	O
in	O
the	O
control	B-MED
and	O
CI	B-MED
-	I-MED
PPV	I-MED
groups	I-MED
,	O
respectively	O
;	O
p	O
=	O
0.95	O
)	O
.	O
The	O
CI	B-MED
-	I-MED
PPV	I-MED
group	I-MED
had	O
lower	B-MED
mean	B-MED
(	O
SD	B-MED
)	O
pulse	B-MED
pressure	I-MED
variation	B-MED
values	B-MED
(	O
9.5	O
(	O
2.0)%	O
vs.	O
11.9	O
(	O
4.6)%	O
;	O
p	O
=	O
0.003	O
)	O
and	O
higher	B-MED
mean	B-MED
(	O
SD	B-MED
)	O
cardiac	B-MED
indices	I-MED
(	O
2.76	O
(	O
0.62	O
)	O
l	O
min(-1	O
)	O
.m(-2	O
)	O
vs.	O
2.53	O
(	O
0.66	O
)	O
l	O
min(-1	O
)	O
.m(-2	O
)	O
;	O
p	O
=	O
0.004	O
)	O
than	O
the	O
control	B-MED
group	I-MED
.	O
In	O
moderate	B-MED
-	I-MED
risk	I-MED
abdominal	I-MED
surgery	I-MED
,	O
we	O
observed	B-MED
no	O
additional	B-MED
value	I-MED
of	O
cardiac	B-MED
index	I-MED
and	O
pulse	B-MED
pressure	I-MED
variation	B-MED
-	O
guided	B-MED
haemodynamic	I-MED
therapy	I-MED
to	O
mean	B-MED
arterial	I-MED
pressure	I-MED
-	O
guided	B-MED
volume	I-MED
therapy	I-MED
with	O
regard	O
to	O
postoperative	B-MED
complications	I-MED
.	O
Effects	B-MED
of	I-MED
argan	B-MED
oil	I-MED
on	O
the	O
mitochondrial	B-MED
function	I-MED
,	O
antioxidant	B-MED
system	I-MED
and	O
the	O
activity	B-MED
of	O
NADPH	B-MED
-	O
generating	B-MED
enzymes	B-MED
in	O
acrylamide	B-MED
treated	B-MED
rat	B-MED
brain	B-MED
Argan	B-MED
oil	I-MED
(	O
AO	B-MED
)	O
is	O
rich	O
in	O
minor	O
compounds	B-MED
such	O
as	O
polyphenols	B-MED
and	O
tocopherols	B-MED
which	O
are	O
powerful	O
antioxidants	B-MED
.	O
Acrylamide	B-MED
(	O
ACR	B-MED
)	O
has	O
been	O
classified	B-MED
as	O
a	O
neurotoxic	B-MED
agent	I-MED
in	O
animals	B-MED
and	O
humans	B-MED
.	O
Mitochondrial	B-MED
oxidative	B-MED
stress	I-MED
and	O
dysfunction	B-MED
is	O
one	O
of	O
the	O
most	O
probable	B-MED
molecular	B-MED
mechanisms	I-MED
of	O
neurodegenerative	B-MED
diseases	I-MED
.	O
Female	B-MED
Sprague	B-MED
Dawley	I-MED
rats	I-MED
were	O
exposed	B-MED
to	I-MED
ACR	B-MED
(	O
50mg	O
/	O
kg	O
i.p	O
.	O
three	O
times	O
a	O
week	O
)	O
,	O
AO	B-MED
(	O
6ml	O
/	O
kg	O
,	O
o.p	O
,	O
per	O
day	O
)	O
or	O
together	O
for	O
30days	O
.	O
The	O
activities	B-MED
of	O
cytosolic	B-MED
enzymes	B-MED
such	O
as	O
xanthine	B-MED
oxidase	I-MED
(	O
XO	B-MED
)	O
,	O
glucose	B-MED
6	I-MED
-	I-MED
phosphate	I-MED
dehydrogenase	I-MED
(	O
G6PDH	B-MED
)	O
,	O
glutathione	B-MED
-	I-MED
S	I-MED
-	I-MED
transferase	I-MED
(	O
GST	B-MED
)	O
,	O
mitochondrial	B-MED
oxidative	B-MED
stress	I-MED
,	O
oxidative	B-MED
phosphorylation	I-MED
(	O
OXPHOS	B-MED
)	O
and	O
tricarboxylic	B-MED
acid	I-MED
cycle	I-MED
(	O
TCA	B-MED
)	O
enzymes	B-MED
,	O
mitochondrial	B-MED
metabolic	B-MED
function	I-MED
,	O
adenosine	B-MED
triphosphate	I-MED
(	O
ATP	B-MED
)	O
level	B-MED
and	O
acetylcholinesterase	B-MED
(	I-MED
AChE	I-MED
)	I-MED
activity	I-MED
were	O
assessed	B-MED
in	O
rat	B-MED
brain	B-MED
.	O
Cytosolic	B-MED
and	O
mitochondrial	B-MED
antioxidant	B-MED
enzymes	I-MED
were	O
significantly	B-MED
diminished	B-MED
in	O
the	O
brains	B-MED
of	O
rats	B-MED
treated	B-MED
with	I-MED
ACR	B-MED
compared	B-MED
to	O
those	O
in	O
control	B-MED
.	O
Besides	O
,	O
ACR	B-MED
treatment	B-MED
resulted	B-MED
in	O
a	O
significant	B-MED
reduction	B-MED
in	O
brain	B-MED
ATP	B-MED
level	B-MED
,	O
mitochondrial	B-MED
metabolic	B-MED
function	I-MED
,	O
OXPHOS	B-MED
and	O
TCA	B-MED
enzymes	B-MED
.	O
Administration	B-MED
of	O
AO	B-MED
restored	O
both	O
the	O
cytosolic	B-MED
and	O
mitochondrial	B-MED
oxidative	B-MED
stress	I-MED
by	O
normalizing	B-MED
nicotinamide	B-MED
adenine	I-MED
dinucleotide	I-MED
phosphate	I-MED
(	O
NADPH	B-MED
)	O
generating	B-MED
enzymes	B-MED
.	O
In	O
addition	O
,	O
improved	B-MED
mitochondrial	B-MED
function	I-MED
primarily	O
enhancing	B-MED
nicotinamide	B-MED
adenine	I-MED
dinucleotide	I-MED
(	O
NADH	B-MED
)	O
generated	B-MED
enzymes	B-MED
activities	I-MED
and	O
ATP	B-MED
level	B-MED
in	O
the	O
mitochondria	B-MED
.	O
The	O
reason	B-MED
for	O
AO	B-MED
's	I-MED
obvious	O
beneficial	B-MED
effects	I-MED
in	O
this	O
study	B-MED
may	O
be	O
due	O
to	O
synergistic	B-MED
effects	I-MED
of	O
its	O
different	B-MED
bioactive	B-MED
compounds	I-MED
which	O
is	O
especially	O
effective	B-MED
on	O
mitochondria	B-MED
.	O
Modulation	B-MED
of	O
the	O
brain	B-MED
mitochondrial	B-MED
functions	I-MED
and	O
antioxidant	B-MED
systems	I-MED
by	O
AO	B-MED
may	O
lead	O
to	O
the	O
development	B-MED
of	O
new	O
mitochondria	B-MED
-	O
targeted	B-MED
antioxidants	B-MED
in	O
the	O
future	B-MED
.	O
The	O
effects	B-MED
of	I-MED
captopril	B-MED
on	O
lipopolysaccharide	B-MED
induced	B-MED
learning	B-MED
and	O
memory	B-MED
impairments	I-MED
and	O
the	O
brain	B-MED
cytokine	B-MED
levels	B-MED
and	O
oxidative	B-MED
damage	B-MED
in	O
rats	B-MED
Renin	B-MED
-	I-MED
angiotensin	I-MED
system	I-MED
has	O
a	O
role	O
in	O
inflammation	B-MED
and	O
also	O
involves	O
in	O
learning	B-MED
and	O
memory	B-MED
.	O
In	O
the	O
present	O
study	O
,	O
the	O
effects	B-MED
of	I-MED
captopril	B-MED
on	O
lipopolysaccharide	B-MED
(	O
LPS	B-MED
)	O
induced	B-MED
learning	B-MED
and	O
memory	B-MED
impairments	I-MED
,	O
hippocampal	B-MED
cytokine	B-MED
levels	B-MED
and	O
brain	B-MED
tissues	I-MED
oxidative	B-MED
damage	B-MED
was	O
investigated	B-MED
.	O
The	O
rats	B-MED
were	O
divided	O
and	O
treated	O
:	O
[	O
1	O
]	O
saline	B-MED
(	O
Control	B-MED
)	O
,	O
[	O
2	O
]	O
LPS	B-MED
(	O
1mg	O
/	O
kg	O
)	O
,	O
[	O
3	O
-	O
5	O
]	O
10	O
,	O
50	O
or	O
100mg	O
/	O
kg	O
captopril	B-MED
30min	O
before	O
LPS	B-MED
.	O
The	O
treatment	B-MED
was	O
started	O
since	O
six	O
days	B-MED
before	O
the	O
behavioral	B-MED
experiments	I-MED
and	O
continued	O
during	O
the	O
behavioral	B-MED
tests	I-MED
(	O
LPS	B-MED
injection	B-MED
two	O
h	O
before	O
each	O
behavioral	B-MED
experiment	I-MED
)	O
.	O
Administration	B-MED
of	O
LPS	B-MED
prolonged	B-MED
the	O
escape	O
latency	B-MED
and	O
traveled	O
path	O
to	O
find	O
the	O
platform	O
in	O
Morris	B-MED
water	I-MED
maze	I-MED
(	I-MED
MWM	I-MED
)	I-MED
test	I-MED
(	O
P<0.01	O
-	O
P<0.001	O
)	O
while	O
,	O
shortened	O
the	O
latency	B-MED
to	O
enter	O
the	O
dark	B-MED
compartment	I-MED
in	O
passive	B-MED
avoidance	I-MED
(	O
PA	B-MED
)	O
test	B-MED
(	O
P<0.001	O
)	O
.	O
Pretreatment	B-MED
by	O
all	O
doses	B-MED
of	O
captopril	B-MED
improved	B-MED
performances	B-MED
of	O
the	O
rats	B-MED
in	O
MWM	B-MED
(	O
P<0.05	O
-	O
P<0.001	O
)	O
and	O
also	O
prolonged	B-MED
the	O
latency	B-MED
to	O
enter	O
the	O
dark	B-MED
in	O
PA	B-MED
test	B-MED
(	O
P<0.001	O
)	O
.	O
LPS	B-MED
also	O
increased	B-MED
IL-6	B-MED
,	O
TNF	B-MED
-	I-MED
α	I-MED
,	O
malondialdehyde	B-MED
(	O
MDA	B-MED
)	O
and	O
nitric	B-MED
oxide	I-MED
(	O
NO	B-MED
)	O
metabolites	B-MED
in	O
the	O
hippocampal	B-MED
tissues	B-MED
(	O
P<0.05	O
-	O
P<0.001	O
)	O
which	O
were	O
prevented	B-MED
by	O
captopril	B-MED
(	O
P<0.05	O
-	O
P<0.001	O
)	O
.	O
The	O
thiol	B-MED
,	O
superoxide	B-MED
dismutase	I-MED
(	O
SOD	B-MED
)	O
and	O
catalase	B-MED
(	O
CAT	B-MED
)	O
in	O
the	O
hippocampus	B-MED
of	O
LPS	B-MED
group	B-MED
were	O
lower	O
than	O
the	O
control	B-MED
(	O
P<0.001	O
)	O
while	O
,	O
they	O
were	O
enhanced	B-MED
when	O
the	O
aniamls	B-MED
were	O
pretreated	B-MED
by	O
captopril	B-MED
(	O
P<0.01	O
-	O
P<0.001	O
)	O
.	O
The	O
results	O
of	O
present	O
study	O
showed	O
that	O
captopril	B-MED
improved	B-MED
the	O
LPS	B-MED
-	O
induced	B-MED
learning	B-MED
and	O
memory	B-MED
impairments	I-MED
in	O
rats	B-MED
which	O
were	O
accompanied	O
with	O
attenuating	B-MED
hippocampal	B-MED
cytokine	B-MED
levels	B-MED
and	O
improving	B-MED
the	O
brain	B-MED
tissues	I-MED
oxidative	B-MED
damage	B-MED
criteria	B-MED
.	O
NF	B-MED
-	I-MED
κB	I-MED
Links	O
TLR2	B-MED
and	O
PAR1	B-MED
to	O
Soluble	B-MED
Immunomodulator	B-MED
Factor	I-MED
Secretion	B-MED
in	O
Human	B-MED
Platelets	B-MED
The	O
primary	B-MED
toll	B-MED
-	I-MED
like	I-MED
receptor	I-MED
TLR	B-MED
(	O
TLR)-mediated	O
immune	B-MED
cell	I-MED
response	I-MED
pathway	I-MED
common	O
for	O
all	O
TLRs	B-MED
is	O
MyD88	B-MED
-dependent	O
activation	B-MED
of	O
NF	B-MED
-	I-MED
κB	I-MED
,	O
a	O
seminal	B-MED
transcription	B-MED
factor	I-MED
for	O
many	O
chemokines	B-MED
and	O
cytokines	B-MED
.	O
Remarkably	O
,	O
anucleate	B-MED
platelets	I-MED
express	O
the	O
NF	B-MED
-	I-MED
κB	I-MED
machinery	O
,	O
whose	O
role	O
in	O
platelets	B-MED
remains	O
poorly	O
understood	O
.	O
Here	O
,	O
we	O
investigated	B-MED
the	O
contribution	B-MED
of	O
NF	B-MED
-	I-MED
κB	I-MED
in	O
the	O
release	B-MED
of	O
cytokines	B-MED
and	O
serotonin	B-MED
by	O
human	B-MED
platelets	B-MED
,	O
following	B-MED
selective	O
stimulation	O
of	O
TLR2	B-MED
and	O
protease	B-MED
activated	I-MED
receptor	I-MED
1	I-MED
(	O
PAR1	B-MED
)	O
,	O
a	O
classical	O
and	O
non	O
-	O
classical	O
pattern	B-MED
-	I-MED
recognition	I-MED
receptor	I-MED
,	O
respectively	O
,	O
able	O
to	O
participate	O
to	O
the	O
innate	B-MED
immune	I-MED
system	I-MED
.	O
We	O
discovered	O
that	O
platelet	B-MED
PAR1	B-MED
activation	B-MED
drives	O
the	O
process	O
of	O
NF	B-MED
-	I-MED
κB	I-MED
phosphorylation	B-MED
,	O
in	O
contrast	O
to	O
TLR2	B-MED
activation	B-MED
,	O
which	O
induces	B-MED
a	O
slower	O
phosphorylation	B-MED
process	I-MED
.	O
Conversely	O
,	O
platelet	B-MED
PAR1	B-MED
and	O
TLR2	B-MED
activation	B-MED
induces	B-MED
similar	O
ERK1/2	B-MED
,	O
p38	B-MED
,	O
and	O
AKT	B-MED
phosphorylation	B-MED
.	O
Moreover	O
,	O
we	O
found	O
that	O
engagement	O
of	O
platelet	B-MED
TLR2	B-MED
with	O
its	O
ligand	B-MED
,	O
Pam3CSK4	B-MED
,	O
significantly	B-MED
increases	I-MED
the	O
release	B-MED
of	O
sCD62P	B-MED
,	O
RANTES	B-MED
,	O
and	O
sCD40L	B-MED
;	O
this	O
effect	B-MED
was	O
attenuated	B-MED
by	I-MED
incubating	B-MED
platelets	B-MED
with	O
a	O
blocking	B-MED
anti	B-MED
-	I-MED
TLR2	I-MED
antibody	I-MED
.	O
This	O
effect	B-MED
appeared	I-MED
selective	O
since	O
no	O
modulation	B-MED
of	O
serotonin	B-MED
secretion	I-MED
was	O
observed	B-MED
following	B-MED
platelet	B-MED
TLR2	B-MED
activation	B-MED
.	O
Platelet	B-MED
release	B-MED
of	O
sCD62P	B-MED
,	O
RANTES	B-MED
,	O
and	O
sCD40L	B-MED
following	B-MED
TLR2	B-MED
or	O
PAR1	B-MED
triggering	O
was	O
abolished	O
in	O
the	O
presence	B-MED
of	O
the	O
NF	B-MED
-	I-MED
κB	I-MED
inhibitor	B-MED
Bay11	B-MED
-	I-MED
7082	I-MED
,	O
while	O
serotonin	B-MED
release	I-MED
following	B-MED
PAR1	B-MED
activation	B-MED
was	O
significantly	B-MED
decreased	I-MED
.	O
These	O
new	B-MED
findings	B-MED
support	O
the	O
concept	O
that	O
NF	B-MED
-	I-MED
κB	I-MED
is	O
an	O
important	O
player	O
in	O
platelet	B-MED
immunoregulations	B-MED
and	O
functions	B-MED
.	O
Efficacy	O
of	O
pegylated	B-MED
liposomal	I-MED
etoposide	I-MED
nanoparticles	I-MED
on	O
breast	B-MED
cancer	I-MED
cell	I-MED
lines	I-MED
This	O
study	O
aimed	O
to	O
investigate	O
the	O
efficacy	B-MED
of	I-MED
pegylated	B-MED
liposomal	I-MED
etoposide	I-MED
nanoparticles	I-MED
(	O
NPs	O
)	O
against	O
T-47D	B-MED
and	O
MCF-7	B-MED
breast	I-MED
cancer	I-MED
cell	I-MED
lines	I-MED
.	O
Pegylated	B-MED
liposomal	I-MED
etoposide	I-MED
NPs	I-MED
were	O
prepared	O
by	O
reverse	B-MED
phase	I-MED
evaporation	I-MED
method	I-MED
.	O
The	O
size	B-MED
,	O
size	B-MED
distribution	I-MED
,	O
and	O
zeta	B-MED
potential	I-MED
of	O
the	O
NPs	B-MED
was	O
measured	O
by	O
a	O
Zetasizer	B-MED
instrument	I-MED
.	O
The	O
cytotoxicity	B-MED
of	O
NPs	B-MED
was	O
inspected	O
by	O
methyl	B-MED
thiazol	I-MED
tetrazolium	I-MED
assay	I-MED
.	O
The	O
release	B-MED
pattern	I-MED
of	I-MED
the	I-MED
drug	I-MED
from	I-MED
the	I-MED
vesicles	I-MED
was	O
studied	O
by	O
the	O
dialysis	B-MED
method	I-MED
.	O
Drug	B-MED
loading	I-MED
and	O
encapsulation	B-MED
efficiency	I-MED
(	O
EE	B-MED
)	O
were	O
also	O
measured	O
.	O
The	O
mean	B-MED
size	I-MED
,	O
size	B-MED
distribution	I-MED
,	O
and	O
zeta	B-MED
potential	I-MED
of	O
pegylated	B-MED
liposomal	I-MED
etoposide	I-MED
NPs	I-MED
were	O
491	O
±	O
15.5	O
nm	O
,	O
0.504	O
±	O
0.14	O
,	O
and	O
-35.8	O
±	O
2.5	O
mV	O
,	O
respectively	O
.	O
Drug	B-MED
loading	I-MED
and	O
EE	B-MED
were	O
10.3	O
±	O
1.6	O
%	O
and	O
99.1	O
±	O
2.8	O
%	O
,	O
respectively	O
.	O
The	O
etoposide	B-MED
release	I-MED
in	I-MED
the	I-MED
formulation	I-MED
was	O
estimated	O
at	O
about	O
3.48	O
%	O
after	O
48	O
h.	O
The	O
cytotoxicity	B-MED
effect	I-MED
of	O
etoposide	B-MED
NPs	I-MED
on	O
T-47D	B-MED
and	O
MCF-7	B-MED
cell	I-MED
lines	I-MED
of	I-MED
breast	I-MED
cancer	I-MED
showed	O
higher	O
antitumor	B-MED
activity	I-MED
as	O
compared	O
with	O
those	O
of	O
the	O
free	B-MED
drug	I-MED
.	O
Liposome	B-MED
-	I-MED
based	I-MED
NPs	I-MED
may	O
hold	O
great	O
potential	O
as	O
a	O
drug	B-MED
delivery	I-MED
system	I-MED
.	O
Hybrid	B-MED
automata	I-MED
models	I-MED
of	O
cardiac	B-MED
ventricular	I-MED
electrophysiology	B-MED
for	O
real	B-MED
-	I-MED
time	I-MED
computational	B-MED
applications	I-MED
Virtual	O
heart	B-MED
models	I-MED
have	O
been	O
proposed	O
for	O
closed	B-MED
loop	I-MED
validation	B-MED
of	O
safety	B-MED
-	O
critical	B-MED
embedded	O
medical	B-MED
devices	I-MED
,	O
such	O
as	O
pacemakers	B-MED
.	O
These	O
models	B-MED
must	O
react	O
in	O
real	B-MED
-	I-MED
time	I-MED
to	O
off	O
-	O
the	O
-	O
shelf	O
medical	B-MED
devices	I-MED
.	O
Real	B-MED
-	I-MED
time	I-MED
performance	B-MED
can	O
be	O
obtained	B-MED
by	O
implementing	O
models	B-MED
in	O
computer	B-MED
hardware	I-MED
,	O
and	O
methods	B-MED
of	O
compiling	O
classes	O
of	O
Hybrid	B-MED
Automata	I-MED
(	O
HA	B-MED
)	O
onto	O
FPGA	B-MED
have	O
been	O
developed	O
.	O
Models	B-MED
of	O
ventricular	B-MED
cardiac	I-MED
cell	I-MED
electrophysiology	B-MED
have	O
been	O
described	B-MED
using	O
HA	B-MED
which	O
capture	B-MED
the	O
complex	O
nonlinear	O
behavior	B-MED
of	O
biological	B-MED
systems	I-MED
.	O
However	O
,	O
many	O
models	B-MED
that	O
have	O
been	O
used	O
for	O
closed	B-MED
-	I-MED
loop	I-MED
validation	B-MED
of	O
pacemakers	B-MED
are	O
highly	O
abstract	B-MED
and	O
do	O
not	O
capture	B-MED
important	B-MED
characteristics	B-MED
of	O
the	O
dynamic	B-MED
rate	B-MED
response	I-MED
.	O
We	O
developed	O
a	O
new	O
HA	B-MED
model	I-MED
of	O
cardiac	B-MED
cells	I-MED
which	O
captures	B-MED
dynamic	B-MED
behavior	B-MED
and	O
we	O
implemented	O
the	O
model	B-MED
in	O
hardware	B-MED
.	O
This	O
potentially	B-MED
enables	O
modeling	B-MED
the	O
heart	B-MED
with	O
over	O
1	O
million	B-MED
dynamic	B-MED
cells	B-MED
,	O
making	O
the	O
approach	O
ideal	B-MED
for	O
closed	B-MED
loop	I-MED
testing	B-MED
of	O
medical	B-MED
devices	I-MED
.	O
Methylation	B-MED
dynamics	B-MED
during	O
folliculogenesis	B-MED
and	O
early	B-MED
embryo	B-MED
development	I-MED
in	O
sheep	B-MED
Genome	B-MED
-wide	O
DNA	B-MED
methylation	I-MED
reprogramming	O
occurs	O
during	O
mammalian	B-MED
gametogenesis	B-MED
and	O
early	B-MED
embryogenesis	B-MED
.	O
Post	B-MED
-	O
fertilization	B-MED
demethylation	B-MED
of	O
paternal	B-MED
and	O
maternal	B-MED
genomes	B-MED
is	O
considered	O
to	O
occur	O
by	O
an	O
active	O
and	O
passive	O
mechanism	O
respectively	O
,	O
in	O
most	O
mammals	B-MED
but	O
sheep	B-MED
;	O
in	O
this	O
species	O
no	O
loss	O
of	O
methylation	B-MED
was	O
observed	O
in	O
either	O
pronucleus	B-MED
.	O
Post	B-MED
-	O
fertilization	B-MED
reprogramming	O
relies	O
on	O
methylating	B-MED
and	O
demethylating	B-MED
enzymes	I-MED
and	O
co	O
-	O
factors	O
that	O
are	O
stored	O
during	O
oocyte	B-MED
growth	I-MED
,	O
concurrently	O
with	O
the	O
re	B-MED
-	I-MED
methylation	I-MED
of	O
the	O
oocyte	B-MED
itself	O
.	O
The	O
crucial	O
remodelling	O
of	O
the	O
oocyte	B-MED
epigenetic	O
baggage	O
often	O
overlaps	O
with	O
potential	O
interfering	O
events	O
such	O
as	O
exposure	O
to	O
assisted	O
reproduction	B-MED
technologies	I-MED
or	O
environmental	B-MED
changes	I-MED
.	O
Here	O
,	O
we	O
report	O
a	O
temporal	O
analysis	O
of	O
methylation	B-MED
dynamics	B-MED
during	O
folliculogenesis	B-MED
and	O
early	B-MED
embryo	B-MED
development	I-MED
in	O
sheep	B-MED
.	O
We	O
characterized	O
global	O
DNA	B-MED
methylation	I-MED
and	O
hydroxymethylation	B-MED
by	O
immunofluorescence	B-MED
and	O
relatively	O
quantified	O
the	O
expression	B-MED
of	O
the	O
enzymes	B-MED
and	O
co	O
-	O
factors	O
mainly	O
responsible	O
for	O
their	O
remodelling	O
(	O
DNA	B-MED
methyltransferases	I-MED
(	O
DNMTs	B-MED
)	O
,	O
ten	B-MED
-	I-MED
eleven	I-MED
translocation	I-MED
(	I-MED
TET	I-MED
)	I-MED
proteins	I-MED
and	O
methyl	B-MED
-	I-MED
CpG	I-MED
-	I-MED
binding	I-MED
domain	I-MED
(	O
MBD	B-MED
)	O
proteins	B-MED
)	O
.	O
Our	O
results	O
illustrate	O
for	O
the	O
first	O
time	O
the	O
patterns	O
of	O
hydroxymethylation	B-MED
during	O
oocyte	B-MED
growth	I-MED
.	O
We	O
observed	O
different	O
patterns	O
of	O
methylation	B-MED
and	O
hydroxymethylation	B-MED
between	O
the	O
two	O
parental	B-MED
pronuclei	I-MED
,	O
suggesting	O
that	O
male	B-MED
pronucleus	I-MED
undergoes	O
active	O
demethylation	B-MED
also	O
in	O
sheep	B-MED
.	O
Finally	O
,	O
we	O
describe	O
gene	B-MED
-specific	O
accumulation	O
dynamics	B-MED
for	O
methylating	B-MED
and	O
demethylating	B-MED
enzymes	I-MED
during	O
oocyte	B-MED
growth	I-MED
and	O
observe	O
patterns	O
of	O
expression	B-MED
associated	O
with	O
developmental	B-MED
competence	B-MED
in	O
a	O
differential	O
model	O
of	O
oocyte	B-MED
potential	O
.	O
Our	O
work	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
methylation	B-MED
dynamics	B-MED
during	O
folliculogenesis	B-MED
and	O
early	B-MED
embryo	B-MED
development	I-MED
and	O
improves	O
the	O
overall	O
picture	O
of	O
early	B-MED
rearrangements	O
that	O
will	O
originate	O
the	O
embryo	B-MED
epigenome	B-MED
.	O
Effects	B-MED
of	I-MED
Cerium	B-MED
and	O
Titanium	B-MED
Oxide	I-MED
Nanoparticles	B-MED
in	O
Soil	B-MED
on	O
the	O
Nutrient	B-MED
Composition	B-MED
of	O
Barley	B-MED
(	O
Hordeum	B-MED
vulgare	I-MED
L	I-MED
.	O
)	O
Kernels	B-MED
The	O
implications	B-MED
of	O
metal	B-MED
nanoparticles	I-MED
(	O
MeNPs	B-MED
)	I-MED
are	O
still	O
unknown	B-MED
for	O
many	B-MED
food	B-MED
crops	I-MED
.	O
The	O
purpose	B-MED
of	O
this	O
study	B-MED
was	O
to	O
evaluate	O
the	O
effects	B-MED
of	I-MED
cerium	B-MED
oxide	I-MED
(	O
nCeO₂	B-MED
)	O
and	O
titanium	B-MED
oxide	I-MED
(	O
nTiO₂	B-MED
)	O
nanoparticles	B-MED
in	O
soil	B-MED
at	O
0	O
,	O
500	O
and	O
1000	O
mg·kg(-1	O
)	O
on	O
the	O
nutritional	B-MED
parameters	I-MED
of	O
barley	B-MED
(	O
Hordeum	B-MED
vulgare	I-MED
L.	I-MED
)	O
kernels	B-MED
.	O
Mineral	B-MED
nutrients	I-MED
,	O
amylose	B-MED
,	O
β	B-MED
-	I-MED
glucans	I-MED
,	O
amino	B-MED
acid	I-MED
and	O
crude	B-MED
protein	I-MED
(	O
CP	B-MED
)	O
concentrations	B-MED
were	I-MED
measured	I-MED
in	O
kernels	B-MED
.	O
Whole	B-MED
flour	B-MED
samples	O
were	O
analyzed	O
by	O
ICP	B-MED
-	I-MED
AES	I-MED
/	I-MED
MS	I-MED
,	O
HPLC	B-MED
and	O
Elemental	B-MED
CHNS	I-MED
Analyzer	I-MED
.	O
Results	O
showed	O
that	O
Ce	B-MED
and	O
Ti	B-MED
accumulation	B-MED
under	O
MeNPs	B-MED
treatments	B-MED
did	O
not	O
differ	O
from	O
the	O
control	B-MED
treatment	I-MED
.	O
However	O
,	O
nCeO₂	B-MED
and	O
nTiO₂	B-MED
had	O
an	O
impact	B-MED
on	O
composition	B-MED
and	O
nutritional	B-MED
quality	I-MED
of	O
barley	B-MED
kernels	B-MED
in	O
contrasting	B-MED
ways	I-MED
.	O
Both	O
MeNPs	B-MED
left	O
β	B-MED
-	I-MED
glucans	I-MED
unaffected	B-MED
but	O
reduced	O
amylose	B-MED
content	O
by	O
approximately	O
21	O
%	O
.	O
Most	O
amino	B-MED
acids	I-MED
and	O
CP	B-MED
increased	B-MED
.	O
Among	O
amino	B-MED
acids	I-MED
,	O
lysine	B-MED
followed	O
by	O
proline	B-MED
saw	O
the	O
largest	B-MED
increase	I-MED
(	O
51	O
%	O
and	O
37	O
%	O
,	O
respectively	O
)	O
.	O
Potassium	B-MED
and	O
S	B-MED
were	O
both	O
negatively	B-MED
impacted	I-MED
by	O
MeNPs	B-MED
,	O
while	O
B	O
was	O
only	O
affected	B-MED
by	O
500	O
mg	O
nCeO₂	B-MED
·	O
kg(-1	O
)	O
.	O
On	O
the	O
contrary	O
Zn	B-MED
and	O
Mn	B-MED
concentrations	I-MED
were	O
improved	O
by	O
500	O
mg	O
nTiO₂	B-MED
·	O
kg(-1	O
)	O
,	O
and	O
Ca	O
by	O
both	O
nTiO₂	B-MED
treatments	B-MED
.	O
Generally	O
,	O
our	O
findings	O
demonstrated	B-MED
that	O
kernels	B-MED
are	O
negatively	B-MED
affected	I-MED
by	O
nCeO₂	B-MED
while	O
nTiO₂	B-MED
can	O
potentially	O
have	O
beneficial	B-MED
effects	I-MED
.	O
However	O
,	O
both	O
MeNPs	B-MED
have	O
the	O
potential	O
to	O
negatively	B-MED
impact	I-MED
malt	B-MED
and	O
feed	B-MED
production	I-MED
.	O
International	B-MED
validation	B-MED
of	O
a	O
urinary	B-MED
biomarker	B-MED
panel	B-MED
for	O
identification	O
of	O
active	B-MED
lupus	B-MED
nephritis	I-MED
in	O
children	B-MED
Conventional	O
markers	B-MED
of	O
juvenile	B-MED
-	I-MED
onset	I-MED
systemic	I-MED
lupus	I-MED
erythematosus	I-MED
(	O
JSLE	B-MED
)	O
disease	B-MED
activity	I-MED
fail	O
to	O
adequately	O
identify	O
lupus	B-MED
nephritis	I-MED
(	O
LN	B-MED
)	O
.	O
While	O
individual	O
novel	B-MED
urine	B-MED
biomarkers	B-MED
are	O
good	O
at	O
detecting	B-MED
LN	B-MED
flares	B-MED
,	O
biomarker	B-MED
panels	B-MED
may	O
improve	O
diagnostic	B-MED
accuracy	I-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
assess	B-MED
the	O
performance	O
of	O
a	O
biomarker	B-MED
panel	B-MED
to	O
identify	O
active	B-MED
LN	B-MED
in	O
two	O
international	B-MED
JSLE	B-MED
cohorts	B-MED
.	O
Novel	O
urinary	B-MED
biomarkers	B-MED
,	O
namely	O
vascular	B-MED
cell	I-MED
adhesion	I-MED
molecule-1	I-MED
(	O
VCAM-1	B-MED
)	O
,	O
monocyte	B-MED
chemoattractant	I-MED
protein	I-MED
1	I-MED
(	O
MCP-1	B-MED
)	O
,	O
lipocalin	B-MED
-	I-MED
like	I-MED
prostaglandin	I-MED
D	I-MED
synthase	I-MED
(	O
LPGDS	B-MED
)	O
,	O
transferrin	B-MED
(	O
TF	B-MED
)	O
,	O
ceruloplasmin	B-MED
,	O
alpha-1	B-MED
-	I-MED
acid	I-MED
glycoprotein	I-MED
(	O
AGP	B-MED
)	O
and	O
neutrophil	B-MED
gelatinase	I-MED
-	I-MED
associated	I-MED
lipocalin	I-MED
(	O
NGAL	B-MED
)	O
,	O
were	O
quantified	B-MED
in	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
that	O
included	O
participants	B-MED
of	O
the	O
UK	B-MED
JSLE	B-MED
Cohort	B-MED
Study	I-MED
(	O
Cohort	B-MED
1	I-MED
)	O
and	O
validated	O
within	O
the	O
Einstein	B-MED
Lupus	I-MED
Cohort	B-MED
(	O
Cohort	B-MED
2	I-MED
)	O
.	O
Binary	B-MED
logistic	B-MED
regression	I-MED
modelling	I-MED
and	O
receiver	B-MED
operating	I-MED
characteristic	I-MED
curve	B-MED
analysis	I-MED
[	O
area	B-MED
under	I-MED
the	I-MED
curve	I-MED
(	O
AUC	B-MED
)	O
]	O
were	O
used	O
to	O
identify	O
and	O
assess	B-MED
combinations	B-MED
of	O
biomarkers	B-MED
for	O
diagnostic	B-MED
accuracy	I-MED
.	O
A	O
total	O
of	O
91	O
JSLE	B-MED
patients	B-MED
were	O
recruited	O
across	O
both	O
cohorts	B-MED
,	O
of	O
whom	O
31	O
(	O
34	O
%	O
)	O
had	O
active	B-MED
LN	B-MED
and	O
60	O
(	O
66	O
%	O
)	O
had	O
no	O
LN	B-MED
.	O
Urinary	B-MED
AGP	B-MED
,	O
ceruloplasmin	B-MED
,	O
VCAM-1	B-MED
,	O
MCP-1	B-MED
and	O
LPGDS	B-MED
levels	B-MED
were	O
significantly	B-MED
higher	I-MED
in	O
those	O
patients	B-MED
with	O
active	B-MED
LN	B-MED
than	O
in	O
non	B-MED
-	O
LN	B-MED
patients	B-MED
[	O
all	O
corrected	O
p	O
values	O
(	O
p	O
c	O
)	O
<	O
0.05	O
]	O
across	O
both	O
cohorts	B-MED
.	O
Urinary	B-MED
TF	B-MED
also	O
differed	O
between	O
patient	B-MED
groups	O
in	O
Cohort	B-MED
2	I-MED
(	O
p	O
c	O
=	O
0.001	O
)	O
.	O
Within	O
Cohort	B-MED
1	I-MED
,	O
the	O
optimal	B-MED
biomarker	B-MED
panel	B-MED
included	O
AGP	B-MED
,	O
ceruloplasmin	B-MED
,	O
LPGDS	B-MED
and	O
TF	B-MED
(	O
AUC	B-MED
0.920	O
for	O
active	B-MED
LN	B-MED
identification	O
)	O
.	O
These	O
results	O
were	O
validated	O
in	O
Cohort	B-MED
2	I-MED
,	O
with	O
the	O
same	O
markers	B-MED
resulting	O
in	O
the	O
optimal	B-MED
urine	B-MED
biomarker	B-MED
panel	B-MED
(	O
AUC	B-MED
0.991	O
)	O
.	O
In	O
two	O
international	B-MED
JSLE	B-MED
cohorts	B-MED
,	O
urinary	B-MED
AGP	B-MED
,	O
ceruloplasmin	B-MED
,	O
LPGDS	B-MED
and	O
TF	B-MED
demonstrate	O
an	O
'	O
excellent	O
'	O
ability	O
for	O
accurately	O
identifying	O
active	B-MED
LN	B-MED
in	O
children	B-MED
.	O
Conditional	B-MED
reprogramming	I-MED
and	O
long	B-MED
-	I-MED
term	I-MED
expansion	B-MED
of	O
normal	B-MED
and	O
tumor	B-MED
cells	I-MED
from	O
human	B-MED
biospecimens	B-MED
Historically	O
,	O
it	O
has	O
been	O
difficult	O
to	O
propagate	B-MED
cells	B-MED
in	B-MED
vitro	I-MED
that	O
are	O
derived	O
directly	O
from	O
human	B-MED
tumors	B-MED
or	O
healthy	B-MED
tissue	I-MED
.	O
However	O
,	O
in	B-MED
vitro	I-MED
preclinical	B-MED
models	I-MED
are	O
essential	O
tools	O
for	O
both	O
the	O
study	B-MED
of	I-MED
basic	I-MED
cancer	I-MED
biology	I-MED
and	O
the	O
promotion	O
of	O
translational	B-MED
research	I-MED
,	O
including	O
drug	B-MED
discovery	I-MED
and	O
drug	B-MED
target	I-MED
identification	I-MED
.	O
This	O
protocol	B-MED
describes	O
conditional	B-MED
reprogramming	I-MED
(	O
CR	B-MED
)	O
,	O
which	O
involves	O
coculture	B-MED
of	O
irradiated	O
mouse	B-MED
fibroblast	B-MED
feeder	I-MED
cells	I-MED
with	O
normal	B-MED
and	O
tumor	B-MED
human	B-MED
epithelial	B-MED
cells	I-MED
in	O
the	O
presence	O
of	O
a	O
Rho	B-MED
kinase	I-MED
inhibitor	B-MED
(	O
Y-27632	B-MED
)	O
.	O
CR	B-MED
cells	B-MED
can	O
be	O
used	O
for	O
various	O
applications	O
,	O
including	O
regenerative	B-MED
medicine	I-MED
,	O
drug	B-MED
sensitivity	I-MED
testing	I-MED
,	O
gene	B-MED
expression	I-MED
profiling	I-MED
and	O
xenograft	B-MED
studies	I-MED
.	O
The	O
method	B-MED
requires	O
a	O
pathologist	B-MED
to	O
differentiate	O
healthy	B-MED
tissue	I-MED
from	O
tumor	B-MED
tissue	I-MED
,	O
and	O
basic	B-MED
tissue	I-MED
culture	I-MED
skills	O
.	O
The	O
protocol	B-MED
can	O
be	O
used	O
with	O
cells	B-MED
derived	O
from	O
both	O
fresh	B-MED
and	O
cryopreserved	B-MED
tissue	I-MED
samples	I-MED
.	O
As	O
approximately	O
1	O
million	O
cells	B-MED
can	O
be	O
generated	B-MED
in	O
7	O
d	O
,	O
the	O
technique	B-MED
is	O
directly	O
applicable	O
to	O
diagnostic	B-MED
and	O
predictive	B-MED
medicine	B-MED
.	O
Moreover	O
,	O
the	O
epithelial	B-MED
cells	I-MED
can	O
be	O
propagated	B-MED
indefinitely	O
in	B-MED
vitro	I-MED
,	O
yet	O
retain	O
the	O
capacity	B-MED
to	O
become	O
fully	O
differentiated	B-MED
when	O
placed	O
into	O
conditions	B-MED
that	O
mimic	O
their	O
natural	B-MED
environment	I-MED
.	O
The	O
Indications	B-MED
for	O
Laparoscopic	B-MED
Pancreatectomy	I-MED
Laparoscopic	B-MED
pancreatectomy	I-MED
is	O
not	O
yet	O
established	O
as	O
a	O
routine	B-MED
procedure	I-MED
everywhere	O
in	O
Germany	B-MED
or	O
in	O
other	O
countries	B-MED
.	O
Few	O
data	B-MED
are	O
available	O
on	O
its	O
short-	B-MED
and	I-MED
long	I-MED
-	I-MED
term	I-MED
outcomes	I-MED
.	O
From	O
2008	O
onward	O
,	O
a	O
working	B-MED
group	I-MED
initiated	O
by	O
10	O
centers	B-MED
and	O
currently	O
comprising	O
34	O
centers	B-MED
has	O
gathered	O
data	B-MED
on	O
all	O
cases	B-MED
of	O
laparoscopic	B-MED
pancreatectomy	I-MED
.	O
Procedures	B-MED
in	O
which	O
laparoscopy	B-MED
was	O
converted	O
to	O
open	B-MED
surgery	I-MED
are	O
also	O
included	O
.	O
The	O
registry	B-MED
now	O
contains	O
550	O
data	B-MED
sets	O
representing	O
267	O
cases	B-MED
of	O
benign	B-MED
disease	I-MED
,	O
244	O
malignancies	B-MED
,	O
and	O
39	O
borderline	B-MED
tumors	I-MED
.	O
The	O
most	O
common	O
procedure	B-MED
was	O
laparoscopic	B-MED
left	I-MED
pancreatectomy	I-MED
,	O
followed	O
by	O
resection	B-MED
of	O
the	O
head	B-MED
of	I-MED
the	I-MED
pancreas	I-MED
and	O
tumor	B-MED
enucleation	B-MED
.	O
The	O
most	O
common	O
intraoperative	B-MED
complication	I-MED
was	O
hemorrhage	B-MED
,	O
with	O
a	O
frequency	O
of	O
3	O
%	O
.	O
The	O
rate	B-MED
of	O
conversion	B-MED
to	O
open	B-MED
surgery	I-MED
was	O
35	O
%	O
;	O
if	O
minilaparotomies	B-MED
are	O
excluded	O
,	O
the	O
conversion	B-MED
rate	B-MED
was	O
only	O
16	O
%	O
.	O
39	O
%	O
of	O
patients	B-MED
developed	O
a	O
pancreatic	B-MED
fistula	I-MED
after	O
surgery	B-MED
(	O
usually	O
grade	O
A	O
or	O
B	O
,	O
with	O
1.5	O
%	O
grade	O
C	O
)	O
and	O
3	O
%	O
underwent	O
reoperation	B-MED
because	O
of	O
postoperative	B-MED
hemorrhage	I-MED
.	O
The	O
procedure	B-MED
-	I-MED
related	I-MED
mortality	I-MED
was	O
1.3	O
%	O
.	O
91	O
%	O
of	O
the	O
patients	B-MED
reported	O
only	O
very	O
mild	O
postoperative	B-MED
pain	I-MED
.	O
6.7	O
%	O
newly	O
developed	O
diabetes	B-MED
mellitus	I-MED
after	O
the	O
procedure	B-MED
.	O
The	O
patient	B-MED
cohort	B-MED
in	O
the	O
registry	B-MED
consists	O
of	O
persons	B-MED
who	O
were	O
selected	O
to	O
undergo	O
laparoscopic	B-MED
pancreatectomy	I-MED
by	O
the	O
participating	O
hospital	B-MED
teams	B-MED
,	O
and	O
the	O
data	B-MED
are	O
thus	O
inherently	O
affected	O
by	O
selection	B-MED
bias	I-MED
.	O
The	O
operative	B-MED
procedures	I-MED
that	O
they	O
underwent	O
reflect	O
the	O
current	O
practice	O
of	O
laparoscopic	B-MED
pancreatectomy	I-MED
in	O
Germany	B-MED
.	O
The	O
complication	B-MED
rates	B-MED
are	O
similar	O
to	O
those	O
of	O
open	B-MED
surgery	I-MED
.	O
Selection	B-MED
bias	I-MED
can	O
be	O
avoided	O
only	O
by	O
a	O
randomized	B-MED
trial	I-MED
.	O
Traumatic	B-MED
Brain	I-MED
Injury	I-MED
and	O
Depression	B-MED
in	O
a	O
Community	B-MED
-	O
Based	B-MED
Sample	O
:	O
A	O
Cohort	B-MED
Study	I-MED
Across	O
the	O
Adult	B-MED
Life	B-MED
Span	I-MED
To	O
determine	O
whether	O
self	O
-	O
reported	O
traumatic	B-MED
brain	I-MED
injuries	I-MED
(	O
TBIs	B-MED
)	O
are	O
associated	B-MED
with	I-MED
"	O
cases	B-MED
"	O
of	O
clinically	B-MED
significant	I-MED
depression	B-MED
in	O
the	O
general	B-MED
community	I-MED
.	O
To	O
examine	O
interactions	B-MED
between	O
variables	B-MED
previously	O
linked	O
to	O
depression	B-MED
after	O
a	O
TBI	B-MED
.	O
Population	B-MED
-based	O
community	B-MED
study	B-MED
(	O
Canberra	B-MED
and	O
Queanbeyan	B-MED
,	O
Australia	B-MED
)	O
.	O
Three	B-MED
age	B-MED
cohorts	I-MED
:	O
young	B-MED
,	O
middle	B-MED
-	I-MED
aged	I-MED
,	O
and	O
older	B-MED
adults	B-MED
(	O
aged	B-MED
20	O
-	O
24	O
,	O
40	O
-	O
44	O
,	O
and	O
60	B-MED
-	I-MED
64	I-MED
years	I-MED
at	O
baseline	B-MED
)	O
randomly	B-MED
selected	B-MED
from	O
the	O
electoral	O
roll	O
and	O
followed	B-MED
across	O
3	O
waves	O
(	O
4	O
years	B-MED
apart	I-MED
)	O
.	O
A	O
total	O
of	O
7397	O
,	O
6621	O
,	O
and	O
6042	O
people	B-MED
provided	O
their	O
TBI	B-MED
history	O
in	O
waves	O
1	O
to	O
3	O
.	O
Lifetime	B-MED
(	O
TBIlifetime	O
:	O
sustained	B-MED
at	O
any	O
time	B-MED
since	B-MED
birth	B-MED
)	O
,	O
recent	B-MED
(	O
TBIrecent	O
:	O
in	O
the	O
preceding	B-MED
4	O
years	B-MED
)	O
,	O
and	O
multiple	B-MED
(	O
TBImultiple	O
:	O
more	O
than	O
1	O
)	O
TBIs	B-MED
,	O
current	B-MED
depression	B-MED
,	O
and	O
known	O
risk	B-MED
factors	I-MED
for	O
depression	B-MED
(	O
age	B-MED
,	O
sex	B-MED
,	O
marital	B-MED
/	O
employment	B-MED
status	I-MED
,	O
prior	B-MED
history	I-MED
of	O
depression	B-MED
,	O
medical	B-MED
conditions	I-MED
,	O
recent	O
life	B-MED
events	I-MED
,	O
alcohol	B-MED
consumption	I-MED
,	O
social	B-MED
support	I-MED
,	O
physical	B-MED
activity	I-MED
)	O
.	O
Generalized	O
estimating	O
equations	B-MED
demonstrated	O
a	O
significant	O
association	B-MED
between	O
sustaining	O
a	O
TBI	B-MED
and	O
experiencing	O
clinically	B-MED
significant	I-MED
depression	B-MED
(	O
cases	B-MED
)	O
,	O
even	O
after	O
controlling	B-MED
for	O
multiple	B-MED
demographic	B-MED
and	O
health	B-MED
/	O
lifestyle	B-MED
factors	B-MED
.	O
There	O
is	O
an	O
enduring	O
association	B-MED
between	O
depression	B-MED
and	O
TBI	B-MED
,	O
suggesting	O
that	O
,	O
following	O
a	O
TBI	B-MED
,	O
individuals	B-MED
should	O
be	O
monitored	B-MED
and	O
supported	O
to	O
optimize	O
their	O
long	B-MED
-	I-MED
term	I-MED
psychological	B-MED
health	I-MED
.	O
Fine	B-MED
structure	I-MED
of	O
the	O
anterior	B-MED
median	I-MED
eyes	I-MED
of	O
the	O
funnel	B-MED
-	O
web	B-MED
spider	I-MED
Agelena	B-MED
labyrinthica	I-MED
(	O
Araneae	B-MED
:	O
Agelenidae	B-MED
)	O
Only	O
few	O
electron	B-MED
microscopic	I-MED
studies	I-MED
exist	O
on	O
the	O
structure	B-MED
of	O
the	O
main	O
eyes	B-MED
(	O
anterior	B-MED
median	I-MED
eyes	I-MED
,	O
AME	B-MED
)	O
of	O
web	B-MED
spiders	I-MED
.	O
The	O
present	O
paper	O
provides	O
details	O
on	O
the	O
anatomy	B-MED
of	O
the	O
AME	B-MED
in	O
the	O
funnel	O
-	O
web	O
spider	B-MED
Agelena	B-MED
labyrinthica	I-MED
.	O
The	O
retina	B-MED
consists	O
of	O
two	O
separate	O
regions	B-MED
with	O
differently	O
arranged	O
photoreceptor	B-MED
cells	I-MED
.	O
Its	O
central	B-MED
part	I-MED
has	O
sensory	B-MED
cells	I-MED
with	O
rhabdomeres	B-MED
on	O
2	O
,	O
3	O
,	O
or	O
4	O
sides	O
,	O
whereas	O
those	O
of	O
the	O
ventral	B-MED
retina	B-MED
have	O
only	O
two	O
rhabdomeres	B-MED
on	O
opposite	O
sides	O
.	O
In	O
addition	O
,	O
the	O
rhabdomeres	B-MED
of	O
the	O
ventral	B-MED
retina	B-MED
are	O
arranged	O
in	O
a	O
specific	O
way	O
:	O
Whereas	O
in	O
the	O
most	O
ventral	B-MED
part	O
they	O
form	O
long	B-MED
tangential	I-MED
rows	I-MED
,	O
those	O
towards	O
the	O
center	B-MED
are	O
detached	O
and	O
are	O
arranged	O
radially	O
.	O
All	O
sensory	B-MED
cells	I-MED
are	O
wrapped	O
by	O
unpigmented	B-MED
pigment	B-MED
cell	I-MED
processes	B-MED
.	O
In	O
agelenid	B-MED
spiders	B-MED
the	O
axons	B-MED
of	O
the	O
sensory	B-MED
cells	I-MED
exit	O
from	O
the	O
middle	O
of	O
the	O
cell	B-MED
body	I-MED
;	O
their	O
fine	B-MED
structure	I-MED
and	O
course	O
through	O
the	O
eye	B-MED
cup	I-MED
is	O
described	O
in	O
detail	O
.	O
In	O
the	O
central	B-MED
part	I-MED
of	O
the	O
retina	B-MED
efferent	O
nerve	B-MED
fibres	I-MED
were	O
found	O
forming	O
synapses	B-MED
along	O
the	O
distal	B-MED
region	I-MED
of	O
the	O
receptor	B-MED
cells	I-MED
.	O
A	O
muscle	B-MED
is	O
attached	O
laterally	O
to	O
each	O
eye	B-MED
cup	I-MED
that	O
allows	O
mainly	O
rotational	B-MED
movements	B-MED
of	O
the	O
eyes	B-MED
.	O
The	O
optical	B-MED
performance	I-MED
(	O
image	B-MED
resolution	I-MED
)	O
of	O
these	O
main	O
eyes	B-MED
with	O
relatively	O
few	O
visual	B-MED
cells	I-MED
is	O
discussed	O
.	O
Involvement	B-MED
Of	O
Vascular	B-MED
Aldosterone	B-MED
Synthase	I-MED
In	O
Phosphate	B-MED
-	O
Induced	B-MED
Osteogenic	B-MED
Transformation	I-MED
Of	O
Vascular	B-MED
Smooth	B-MED
Muscle	I-MED
Cells	I-MED
Vascular	B-MED
calcification	I-MED
resulting	O
from	O
hyperphosphatemia	B-MED
is	O
a	O
major	O
determinant	O
of	O
mortality	B-MED
in	O
chronic	B-MED
kidney	I-MED
disease	I-MED
(	O
CKD	B-MED
)	O
.	O
Vascular	B-MED
calcification	I-MED
is	O
driven	O
by	O
aldosterone	B-MED
-sensitive	O
osteogenic	B-MED
transformation	I-MED
of	O
vascular	B-MED
smooth	B-MED
muscle	I-MED
cells	I-MED
(	O
VSMCs	B-MED
)	O
.	O
We	O
show	O
that	O
even	O
in	O
absence	B-MED
of	O
exogenous	B-MED
aldosterone	B-MED
,	O
silencing	B-MED
and	O
pharmacological	B-MED
inhibition	I-MED
(	O
spironolactone	B-MED
,	O
eplerenone	B-MED
)	O
of	O
the	O
mineralocorticoid	B-MED
receptor	I-MED
(	O
MR	B-MED
)	O
ameliorated	O
phosphate	B-MED
-	O
induced	B-MED
osteo-	B-MED
/	O
chondrogenic	B-MED
transformation	I-MED
of	O
primary	B-MED
human	B-MED
aortic	B-MED
smooth	B-MED
muscle	I-MED
cells	I-MED
(	O
HAoSMCs	B-MED
)	O
.	O
High	O
phosphate	B-MED
concentrations	B-MED
up	B-MED
-	I-MED
regulated	I-MED
aldosterone	B-MED
synthase	I-MED
(	O
CYP11B2	B-MED
)	O
expression	B-MED
in	O
HAoSMCs	B-MED
.	O
Silencing	B-MED
and	O
deficiency	B-MED
of	O
CYP11B2	B-MED
in	O
VSMCs	B-MED
ameliorated	O
phosphate	B-MED
-	O
induced	B-MED
osteogenic	B-MED
reprogramming	I-MED
and	O
calcification	B-MED
.	O
Phosphate	B-MED
treatment	B-MED
was	O
followed	O
by	O
nuclear	B-MED
export	I-MED
of	O
APEX1	B-MED
,	O
a	O
CYP11B2	B-MED
transcriptional	B-MED
repressor	I-MED
.	O
APEX1	B-MED
silencing	B-MED
up	B-MED
-	I-MED
regulated	I-MED
CYP11B2	B-MED
expression	B-MED
and	O
stimulated	O
osteo-	B-MED
/	O
chondrogenic	B-MED
transformation	I-MED
.	O
APEX1	B-MED
overexpression	B-MED
blunted	O
the	O
phosphate	B-MED
-	O
induced	B-MED
osteo-	B-MED
/	O
chondrogenic	B-MED
transformation	I-MED
and	O
calcification	B-MED
of	O
HAoSMCs	B-MED
.	O
Cyp11b2	B-MED
expression	B-MED
was	O
higher	O
in	O
aortic	B-MED
tissue	B-MED
of	O
hyperphosphatemic	B-MED
klotho	B-MED
-	I-MED
hypomorphic	I-MED
(	I-MED
kl	I-MED
/	I-MED
kl	I-MED
)	I-MED
mice	I-MED
than	O
in	O
wild	B-MED
-	I-MED
type	I-MED
mice	B-MED
.	O
In	O
adrenalectomized	B-MED
kl	I-MED
/	I-MED
kl	I-MED
mice	I-MED
,	O
spironolactone	B-MED
treatment	B-MED
still	O
significantly	O
ameliorated	O
aortic	B-MED
osteoinductive	B-MED
reprogramming	I-MED
.	O
Our	O
findings	B-MED
suggest	O
that	O
VSMCs	B-MED
express	O
aldosterone	B-MED
synthase	I-MED
,	O
which	O
is	O
up	B-MED
-	I-MED
regulated	I-MED
by	O
phosphate	B-MED
-	O
induced	B-MED
disruption	B-MED
of	O
APEX1	B-MED
-dependent	O
gene	B-MED
suppression	I-MED
.	O
Vascular	B-MED
CYP11B2	B-MED
may	O
contribute	O
to	O
stimulation	O
of	O
VSMCs	B-MED
osteo-	B-MED
/	O
chondrogenic	B-MED
transformation	I-MED
during	O
hyperphosphatemia	B-MED
.	O
Automated	B-MED
characterization	B-MED
and	O
counting	B-MED
of	O
Ki-67	B-MED
protein	I-MED
for	O
breast	B-MED
cancer	I-MED
prognosis	B-MED
:	O
A	O
quantitative	B-MED
immunohistochemistry	B-MED
approach	B-MED
Ki-67	B-MED
protein	I-MED
expression	B-MED
plays	O
an	O
important	O
role	O
in	O
predicting	O
the	O
proliferative	B-MED
status	I-MED
of	O
tumour	B-MED
cell	I-MED
s	O
and	O
deciding	O
the	O
future	B-MED
course	B-MED
of	O
therapy	B-MED
in	O
breast	B-MED
cancer	I-MED
.	O
Immunohistochemical	B-MED
(	I-MED
IHC	I-MED
)	I-MED
determination	I-MED
of	O
Ki-67	B-MED
score	I-MED
or	O
labelling	B-MED
index	I-MED
,	O
by	O
estimating	O
the	O
fraction	B-MED
of	I-MED
Ki67	B-MED
positively	B-MED
stained	B-MED
tumour	B-MED
cells	I-MED
,	O
is	O
the	O
most	O
widely	O
practiced	O
method	B-MED
to	O
assess	B-MED
tumour	B-MED
proliferation	B-MED
(	O
Dowsett	O
et	O
al	O
.	O
2011	O
)	O
.	O
Accurate	B-MED
manual	B-MED
counting	I-MED
of	O
these	O
cells	B-MED
(	O
specifically	B-MED
nuclei	B-MED
)	O
due	O
to	O
complex	B-MED
and	O
dense	B-MED
distribution	B-MED
of	O
cells	B-MED
,	O
therefore	O
,	O
becomes	O
critical	B-MED
and	O
presents	B-MED
a	O
major	B-MED
challenge	O
to	O
pathologists	B-MED
.	O
In	O
this	O
paper	O
,	O
we	O
suggest	O
a	O
hybrid	B-MED
clustering	I-MED
algorithm	I-MED
to	O
quantify	B-MED
the	O
proliferative	B-MED
index	I-MED
of	O
breast	B-MED
cancer	I-MED
cells	I-MED
based	O
on	O
automated	B-MED
counting	I-MED
of	O
Ki-67	B-MED
nuclei	B-MED
.	O
The	O
proposed	O
methodology	B-MED
initially	B-MED
pre	B-MED
-	I-MED
processes	I-MED
the	O
IHC	B-MED
images	B-MED
of	O
Ki-67	B-MED
stained	B-MED
slides	B-MED
of	O
breast	B-MED
cancer	I-MED
.	O
The	O
RGB	O
images	O
are	O
converted	O
to	O
grey	B-MED
,	O
L*a*b	O
*	O
,	O
HSI	O
,	O
YCbCr	O
,	O
YIQ	O
and	O
XYZ	O
colour	B-MED
space	I-MED
.	O
All	O
the	O
stained	B-MED
cells	B-MED
are	O
then	O
characterized	B-MED
by	O
two	B-MED
stage	I-MED
segmentation	I-MED
process	I-MED
.	O
Fuzzy	B-MED
C	I-MED
-	I-MED
means	I-MED
quantifies	B-MED
all	O
the	O
stained	B-MED
cells	B-MED
as	O
one	O
cluster	B-MED
.	O
The	O
blue	B-MED
channel	B-MED
of	O
the	O
first	B-MED
stage	I-MED
output	B-MED
is	O
given	O
as	O
input	O
to	O
k	B-MED
-	I-MED
means	I-MED
algorithm	I-MED
,	O
which	O
provides	O
separate	B-MED
cluster	B-MED
for	O
Ki-67	B-MED
positive	B-MED
and	I-MED
negative	I-MED
cells	B-MED
.	O
The	O
count	B-MED
of	O
positive	B-MED
and	I-MED
negative	I-MED
nuclei	B-MED
is	O
used	O
to	O
calculate	B-MED
the	O
F	B-MED
-	I-MED
measure	I-MED
for	O
each	O
colour	B-MED
space	I-MED
.	O
A	O
comparative	B-MED
study	I-MED
of	O
our	O
work	O
with	O
the	O
expert	B-MED
opinion	I-MED
is	O
studied	O
to	O
evaluate	O
the	O
error	B-MED
rate	B-MED
.	O
The	O
positive	B-MED
and	I-MED
negative	I-MED
nuclei	B-MED
detection	B-MED
results	B-MED
for	O
all	O
colour	B-MED
space	I-MED
s	O
are	O
compared	B-MED
with	O
the	O
ground	O
truth	O
for	O
validation	O
and	O
F	B-MED
-	I-MED
measure	I-MED
is	O
calculated	B-MED
.	O
The	O
F	B-MED
-	I-MED
measure	I-MED
for	O
L*a*b	O
*	O
colour	B-MED
space	I-MED
(	O
0.8847	O
)	O
provides	O
the	O
best	O
statistical	B-MED
result	B-MED
as	O
compared	B-MED
to	O
grey	B-MED
,	O
HSI	O
,	O
YCbCr	O
,	O
YIQ	O
and	O
XYZ	O
colour	B-MED
space	I-MED
.	O
Further	O
,	O
a	O
study	B-MED
is	O
carried	O
out	O
to	O
count	B-MED
nuclei	B-MED
manually	B-MED
and	O
automatically	B-MED
from	O
the	O
proposed	O
algorithm	B-MED
with	O
an	O
average	B-MED
error	B-MED
rate	B-MED
of	O
6.84	O
%	O
which	O
is	O
significant	B-MED
.	O
The	O
study	B-MED
provides	O
an	O
automated	B-MED
count	B-MED
of	O
positive	B-MED
and	I-MED
negative	I-MED
nuclei	B-MED
using	O
L*a*b	O
*	O
colour	B-MED
space	I-MED
and	O
hybrid	B-MED
segmentation	I-MED
technique	I-MED
.	O
Computerized	B-MED
evaluation	I-MED
of	O
proliferation	B-MED
index	I-MED
can	O
aid	O
pathologist	B-MED
in	O
assessing	O
breast	B-MED
cancer	I-MED
severity	B-MED
.	O
The	O
proposed	O
methodology	B-MED
,	O
further	O
,	O
has	O
the	O
potential	B-MED
advantage	O
of	O
saving	O
time	O
and	O
assisting	B-MED
in	O
decision	O
making	O
over	O
the	O
present	O
manual	B-MED
procedure	I-MED
and	O
could	O
evolve	O
as	O
an	O
assistive	O
pathological	B-MED
decision	B-MED
support	I-MED
system	I-MED
.	O
Datasets	B-MED
for	O
the	O
validation	B-MED
of	O
the	O
"	O
in	B-MED
vivo	I-MED
"	O
siRNA	B-MED
-	O
silencing	B-MED
of	O
CD40	B-MED
and	O
for	O
the	O
detection	B-MED
of	O
new	O
markers	B-MED
of	O
atherosclerosis	B-MED
progression	B-MED
in	O
ApoE	B-MED
-	O
deficient	B-MED
mice	B-MED
Data	B-MED
presented	O
in	O
this	O
Data	B-MED
in	O
Brief	O
article	O
correspond	O
to	O
the	O
article	O
"	O
in	B-MED
vivo	I-MED
"	O
silencing	B-MED
of	O
CD40	B-MED
reduces	O
progression	B-MED
of	O
experimental	B-MED
atherogenesis	B-MED
through	O
a	O
NFκB	B-MED
/	O
miR-125b	B-MED
axis	O
and	O
reveals	O
new	O
potential	B-MED
mediators	B-MED
in	O
the	O
pathogenesis	B-MED
of	O
atherosclerosis	B-MED
"	O
(	O
M.	B-MED
Hueso	I-MED
,	O
L.	B-MED
De	I-MED
Ramon	I-MED
,	O
E.	B-MED
Navarro	I-MED
,	O
E.	B-MED
Ripoll	I-MED
,	O
J.M.	B-MED
Cruzado	I-MED
,	O
J.M.	B-MED
Grinyo	I-MED
,	O
J.	B-MED
Torras	I-MED
,	O
2016	O
)	O
[	O
1	O
]	O
.	O
Here	O
,	O
we	O
describe	O
the	O
validation	B-MED
of	O
the	O
silencing	B-MED
of	O
CD40	B-MED
expression	B-MED
with	O
a	O
specific	O
siRNA	B-MED
in	O
ApoE(-/-	B-MED
)	I-MED
mouse	B-MED
aortas	B-MED
,	O
and	O
its	O
systemic	O
effects	O
on	O
splenic	B-MED
lymphocytic	B-MED
subpopulations	I-MED
as	O
well	O
as	O
on	O
the	O
infiltration	B-MED
of	O
aortic	B-MED
intima	I-MED
by	O
F4/80(+	B-MED
)	I-MED
,	O
galectin-3(+	B-MED
)	I-MED
macrophages	I-MED
or	O
by	O
NF	B-MED
-	I-MED
κB(+	I-MED
)	I-MED
cells	I-MED
.	O
We	O
also	O
show	O
the	O
output	O
of	O
a	O
Gene	B-MED
Ontology	I-MED
and	O
TLDA	B-MED
analysis	I-MED
which	O
allowed	O
the	O
detection	B-MED
of	O
potential	B-MED
mediators	B-MED
of	O
atherosclerosis	B-MED
progression	B-MED
.	O
We	O
provide	O
the	O
scientific	O
community	O
with	O
a	O
set	O
of	O
genes	B-MED
whose	O
expression	B-MED
is	O
increased	B-MED
during	O
atherosclerosis	B-MED
progression	B-MED
but	O
downregulated	B-MED
upon	O
CD40	B-MED
silencing	B-MED
.	O
Impact	B-MED
sports	I-MED
and	O
bone	B-MED
fractures	I-MED
among	O
adolescents	B-MED
The	O
objective	O
of	O
the	O
present	O
study	B-MED
was	O
to	O
investigate	B-MED
the	O
effects	B-MED
of	I-MED
different	B-MED
sports	B-MED
on	O
stress	B-MED
fractures	I-MED
among	O
adolescents	B-MED
during	O
a	O
9-	O
month	B-MED
follow	B-MED
-	I-MED
up	I-MED
period	B-MED
.	O
The	O
sample	B-MED
was	O
composed	O
of	O
184	O
adolescents	B-MED
divided	O
into	O
three	O
groups	B-MED
(	O
impact	B-MED
sports	I-MED
[	O
n	O
=	O
102	O
]	O
;	O
swimming	B-MED
[	O
n	O
=	O
35	O
]	O
;	O
non	B-MED
-	I-MED
sports	I-MED
[	O
n	O
=	O
47	O
]	O
)	O
.	O
The	O
occurrence	B-MED
of	O
stress	B-MED
fracture	I-MED
was	O
reported	O
by	O
participants	B-MED
and	O
coaches	B-MED
.	O
As	O
potential	O
confounders	B-MED
we	O
considered	O
age	B-MED
,	O
sex	B-MED
,	O
resistance	B-MED
training	I-MED
,	O
body	B-MED
composition	I-MED
variables	B-MED
and	O
age	B-MED
at	O
peak	B-MED
of	O
height	B-MED
velocity	I-MED
.	O
There	O
were	O
13	O
adolescents	B-MED
who	O
reported	O
fractures	B-MED
during	O
the	O
9-	O
month	B-MED
period	B-MED
.	O
Bone	B-MED
mineral	I-MED
density	I-MED
values	B-MED
were	O
higher	O
in	O
adolescents	B-MED
engaged	O
in	O
impact	B-MED
sports	I-MED
(	O
P	B-MED
-	I-MED
value	I-MED
=	O
0.002	O
)	O
.	O
Independently	O
of	O
confounders	B-MED
,	O
the	O
risk	B-MED
of	O
stress	B-MED
fracture	I-MED
was	O
lower	O
in	O
adolescents	B-MED
engaged	O
in	O
impact	B-MED
sports	I-MED
than	O
in	O
non	B-MED
-	I-MED
active	I-MED
adolescents	I-MED
(	O
hazard	B-MED
ratio	I-MED
[	O
HR	B-MED
]	O
=	O
0.23	O
[	O
95	O
%	O
confidence	B-MED
interval	I-MED
(	O
CI	B-MED
)	O
=	O
0.05	O
to	O
0.98	O
]	O
)	O
,	O
while	O
swimming	B-MED
practice	B-MED
was	O
not	O
associated	O
to	O
lower	O
risk	B-MED
of	O
fracture	B-MED
(	O
HR	B-MED
=	O
0.49	O
[	O
95	O
%	O
CI	B-MED
=	O
0.09	O
to	O
2.55	O
]	O
)	O
.	O
In	O
conclusion	O
,	O
the	O
findings	B-MED
from	O
this	O
study	B-MED
indicate	O
the	O
importance	O
of	O
sports	B-MED
participation	B-MED
among	O
adolescents	B-MED
in	O
the	O
reduction	B-MED
of	O
stress	B-MED
fracture	I-MED
risk	B-MED
,	O
especially	O
with	O
impact	B-MED
sports	I-MED
.	O
More	O
importantly	O
,	O
these	O
results	B-MED
could	O
be	O
relevant	B-MED
for	O
recognising	O
adolescents	B-MED
in	O
danger	O
of	O
not	O
reaching	O
their	O
potential	O
for	O
peak	B-MED
bone	B-MED
mass	I-MED
and	O
later	O
an	O
increased	B-MED
risk	B-MED
of	O
fractures	B-MED
.	O
A	O
missense	B-MED
variant	B-MED
,	O
rs373863828	B-MED
-	I-MED
A	I-MED
(	I-MED
p.	I-MED
Arg457Gln	I-MED
)	I-MED
,	I-MED
of	I-MED
CREBRF	I-MED
and	O
body	B-MED
mass	I-MED
index	I-MED
in	O
Oceanic	B-MED
populations	I-MED
It	O
has	O
been	O
suggested	O
that	O
a	O
'	O
thrifty	O
'	O
genotype	B-MED
hypothesis	B-MED
can	O
account	O
for	O
high	B-MED
prevalence	I-MED
of	O
obesity	B-MED
in	O
the	O
island	B-MED
populations	B-MED
of	O
Oceania	B-MED
.	O
A	O
recent	O
genome	B-MED
-	I-MED
wide	I-MED
association	I-MED
study	I-MED
revealed	O
that	O
a	O
missense	B-MED
variant	B-MED
,	O
rs373863828	B-MED
-	I-MED
A	I-MED
(	I-MED
p.	I-MED
Arg457Gln	I-MED
)	I-MED
,	I-MED
of	I-MED
the	I-MED
CREBRF	I-MED
gene	I-MED
(	O
encoding	O
CREB3	B-MED
regulatory	I-MED
factor	I-MED
)	O
was	O
associated	B-MED
with	I-MED
an	O
excessive	B-MED
increase	B-MED
in	O
body	B-MED
mass	I-MED
index	I-MED
(	O
BMI	B-MED
)	O
in	O
Samoans	B-MED
.	O
In	O
the	O
present	O
study	O
,	O
the	O
association	O
of	O
rs373863828	B-MED
-	I-MED
A	I-MED
with	O
an	O
increase	B-MED
in	O
BMI	B-MED
was	O
examined	B-MED
in	O
four	O
Austronesian	B-MED
AN	B-MED
(	O
AN)-	O
speaking	B-MED
populations	B-MED
in	O
Oceania	B-MED
.	O
We	O
found	O
that	O
rs373863828	B-MED
-	I-MED
A	I-MED
was	O
frequently	O
observed	O
(	O
frequency	O
of	O
0.15	O
)	O
in	O
Tongans	B-MED
(	O
Polynesians	B-MED
)	O
,	O
and	O
was	O
strongly	O
associated	B-MED
with	I-MED
higher	O
BMI	B-MED
(	O
P=6.1	O
×	O
10(-4	O
)	O
)	O
.	O
A	O
single	O
copy	O
of	O
the	O
rs373863828	B-MED
-	I-MED
A	I-MED
allele	B-MED
increased	B-MED
BMI	B-MED
by	O
3.09	O
kg	O
m(-2	O
)	O
after	O
adjustment	O
of	O
age	B-MED
and	O
sex	B-MED
.	O
No	B-MED
significant	I-MED
association	B-MED
was	O
detected	B-MED
in	O
the	O
other	O
three	O
AN	B-MED
-	O
speaking	B-MED
populations	B-MED
(	O
Melanesians	B-MED
and	O
Micronesians	B-MED
)	O
living	B-MED
in	O
Solomon	B-MED
Islands	I-MED
.	O
This	O
was	O
probably	O
due	O
to	O
the	O
low	B-MED
allele	B-MED
frequency	I-MED
(	O
0.02	O
-	O
0.06	O
)	O
of	O
rs373863828	B-MED
-	I-MED
A	I-MED
as	O
well	O
as	O
small	O
sample	B-MED
size	I-MED
.	O
The	O
rs373863828	B-MED
-	I-MED
A	I-MED
allele	B-MED
was	O
not	O
found	O
in	O
both	O
AN	B-MED
-	O
speaking	B-MED
and	O
non-	O
AN	B-MED
-	O
speaking	B-MED
Melanesians	B-MED
living	O
in	O
Papua	B-MED
New	I-MED
Guinea	I-MED
.	O
Our	O
results	O
suggest	O
that	O
rs373863828	B-MED
-	I-MED
A	I-MED
of	I-MED
CREBRF	I-MED
,	O
a	O
promising	O
thrifty	O
variant	B-MED
,	O
arose	O
in	O
recent	O
ancestors	B-MED
of	O
AN	B-MED
-	O
speaking	B-MED
Polynesians	B-MED
.Journal	O
of	O
Human	O
Genetics	O
advance	O
online	O
publication	O
,	O
13	O
April	O
2017	O
;	O
doi:10.1038	O
/	O
jhg.2017.44	O
.	O
Associations	B-MED
between	O
major	B-MED
life	I-MED
events	I-MED
and	O
adherence	B-MED
,	O
glycemic	B-MED
control	I-MED
,	I-MED
and	O
psychosocial	B-MED
characteristics	I-MED
in	O
teens	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
This	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
assessed	B-MED
the	O
type	O
of	O
major	B-MED
life	I-MED
events	I-MED
occurring	O
in	O
a	O
contemporary	O
sample	O
of	O
teens	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
and	O
the	O
association	B-MED
between	O
event	B-MED
frequency	I-MED
and	O
demographic	B-MED
,	O
diabetes	B-MED
management	I-MED
,	O
and	O
psychosocial	B-MED
characteristics	I-MED
.	O
Parents	B-MED
of	O
178	O
teens	B-MED
completed	O
the	O
Life	B-MED
Events	I-MED
Checklist	B-MED
to	O
report	O
major	O
events	B-MED
teens	B-MED
had	O
experienced	B-MED
in	O
the	O
last	O
year	B-MED
:	O
42	O
%	O
experienced	B-MED
0	O
to	O
1	O
event	B-MED
(	O
n	O
=	O
75	O
)	O
,	O
32	O
%	O
experienced	B-MED
2	O
to	O
3	O
events	B-MED
(	O
n	O
=	O
57	O
)	O
,	O
and	O
26	O
%	O
experienced	B-MED
4	O
+	O
events	B-MED
(	O
n	O
=	O
46	O
)	O
.	O
Teens	B-MED
and	O
parents	B-MED
completed	O
validated	O
measures	B-MED
of	O
treatment	B-MED
adherence	I-MED
,	O
diabetes	B-MED
-specific	O
self	B-MED
-	I-MED
efficacy	I-MED
,	O
quality	B-MED
of	I-MED
life	I-MED
,	O
and	O
diabetes	B-MED
-specific	O
family	B-MED
conflict	I-MED
.	O
Parent	B-MED
-	I-MED
youth	I-MED
interview	I-MED
and	O
chart	B-MED
review	I-MED
provided	O
demographics	B-MED
and	O
diabetes	B-MED
management	I-MED
data	O
.	O
Mean	O
number	O
of	O
events	B-MED
/	O
teen	B-MED
was	O
2.6	O
±	O
2.7	O
(	O
range	O
=	O
0	O
-	O
15	O
)	O
.	O
The	O
most	O
common	O
events	B-MED
were	O
"	O
Hospitalization	B-MED
of	O
a	O
family	B-MED
member	I-MED
"	O
(	O
24	O
%	O
)	O
,	O
"	O
Getting	B-MED
a	I-MED
bad	I-MED
report	I-MED
card	I-MED
"	O
(	O
20	O
%	O
)	O
,	O
"	O
Serious	O
arguments	B-MED
between	O
parents	B-MED
"	O
(	O
19	O
%	O
)	O
,	O
and	O
"	O
Serious	B-MED
illness	I-MED
/	O
injury	B-MED
in	O
a	O
family	B-MED
member	I-MED
"	O
(	O
19	O
%	O
)	O
.	O
Compared	O
with	O
teens	B-MED
experiencing	O
0	O
to	O
1	O
event	B-MED
,	O
teens	B-MED
experiencing	O
4	O
+	O
events	B-MED
were	O
less	O
likely	O
to	O
have	O
married	O
parents	B-MED
(	O
P	O
=	O
.01	O
)	O
and	O
a	O
parent	B-MED
with	O
a	O
college	B-MED
degree	I-MED
(	O
P	O
=	O
.006	O
)	O
.	O
Teen	B-MED
s	O
with	O
4	O
+	O
events	B-MED
had	O
significantly	O
poorer	O
adherence	B-MED
(	O
P	O
=	O
.002	O
teen	B-MED
,	O
P	O
=	O
.02	O
parent	B-MED
)	O
,	O
lower	O
self	B-MED
-	I-MED
efficacy	I-MED
(	O
P	O
=	O
.03	O
teen	B-MED
,	O
P	O
<	O
.0001	O
parent	B-MED
)	O
,	O
poorer	O
quality	B-MED
of	I-MED
life	I-MED
(	O
P	O
<	O
.0001	O
teen	B-MED
,	O
P	O
<	O
.0001	O
parent	B-MED
)	O
,	O
and	O
more	O
conflict	B-MED
(	O
P	O
=	O
.006	O
teen	B-MED
,	O
P	O
=	O
.02	O
parent	B-MED
)	O
than	O
teens	B-MED
with	O
fewer	O
events	B-MED
.	O
In	O
a	O
multivariate	B-MED
model	I-MED
(	O
R	O
(	O
2	O
)	O
=	O
0.21	O
,	O
P	O
<	O
.0001	O
)	O
controlling	O
for	O
demographic	B-MED
and	O
diabetes	B-MED
management	I-MED
characteristics	O
,	O
fewer	O
events	B-MED
was	O
associated	O
with	O
lower	O
A1c	B-MED
(	O
P	O
=	O
.0009	O
)	O
.	O
Occurrence	O
of	O
more	O
major	B-MED
life	I-MED
events	I-MED
was	O
associated	B-MED
with	I-MED
poorer	O
diabetes	B-MED
care	I-MED
and	O
A1c	B-MED
and	O
more	O
negative	O
psychosocial	B-MED
qualities	I-MED
in	O
teens	B-MED
with	O
type	B-MED
1	I-MED
diabetes	I-MED
.	O
20S	B-MED
immunoproteasomes	I-MED
remove	O
formaldehyde	B-MED
-	O
damaged	B-MED
cytoplasmic	B-MED
proteins	I-MED
suppressing	B-MED
caspase	B-MED
-	I-MED
independent	I-MED
cell	I-MED
death	I-MED
Immunoproteasomes	B-MED
are	O
known	O
for	O
their	O
involvement	B-MED
in	O
antigen	B-MED
presentation	I-MED
.	O
However	O
,	O
their	O
broad	B-MED
tissue	B-MED
presence	B-MED
and	O
other	O
evidence	B-MED
are	O
indicative	B-MED
of	I-MED
nonimmune	B-MED
functions	I-MED
.	O
We	O
examined	O
a	O
role	O
for	O
immunoproteasomes	B-MED
in	O
cellular	B-MED
responses	I-MED
to	O
the	O
endogenous	B-MED
and	O
environmental	B-MED
carcinogen	I-MED
formaldehyde	B-MED
(	O
FA	B-MED
)	O
that	O
binds	O
to	O
cytosolic	B-MED
and	O
nuclear	B-MED
proteins	I-MED
producing	O
proteotoxic	B-MED
stress	I-MED
and	O
genotoxic	B-MED
DNA	B-MED
-	O
histone	B-MED
crosslinks	B-MED
.	O
We	O
found	O
that	O
immunoproteasomes	B-MED
were	O
important	B-MED
for	O
suppression	B-MED
of	O
a	O
caspase	B-MED
-	I-MED
independent	I-MED
cell	I-MED
death	I-MED
and	O
the	O
long	B-MED
-	I-MED
term	I-MED
survival	B-MED
of	O
FA	B-MED
-	I-MED
treated	I-MED
cells	I-MED
.	O
All	O
major	O
genotoxic	B-MED
responses	B-MED
to	O
FA	B-MED
,	O
including	O
replication	B-MED
inhibition	I-MED
and	O
activation	B-MED
of	O
the	O
transcription	B-MED
factor	I-MED
p53	I-MED
and	O
the	O
apical	B-MED
ATM	B-MED
and	O
ATR	B-MED
kinases	I-MED
,	O
were	O
unaffected	B-MED
by	O
immunoproteasome	B-MED
inactivity	B-MED
.	O
Immunoproteasome	O
inhibition	B-MED
enhanced	B-MED
activation	B-MED
of	O
the	O
cytosolic	B-MED
protein	B-MED
damage	B-MED
sensor	B-MED
HSF1	I-MED
,	O
elevated	B-MED
levels	I-MED
of	O
K48	B-MED
-	I-MED
polyubiquitinated	I-MED
cytoplasmic	B-MED
proteins	I-MED
and	O
increased	B-MED
depletion	B-MED
of	O
unconjugated	B-MED
ubiquitin	B-MED
.	O
We	O
further	O
found	O
that	O
FA	B-MED
induced	B-MED
the	O
disassembly	B-MED
of	O
26S	B-MED
immunoproteasomes	I-MED
,	O
but	O
not	O
standard	O
26S	B-MED
proteasomes	I-MED
,	O
releasing	O
the	O
20S	B-MED
catalytic	I-MED
immunoproteasome	I-MED
.	O
FA	B-MED
-	I-MED
treated	I-MED
cells	I-MED
also	O
had	O
higher	B-MED
amounts	I-MED
of	O
small	O
activators	B-MED
PA28αβ	I-MED
and	O
PA28γ	B-MED
bound	O
to	O
20S	B-MED
particles	I-MED
.	O
Our	O
findings	O
highlight	O
the	O
significance	B-MED
of	O
nonnuclear	B-MED
damage	I-MED
in	O
FA	B-MED
injury	O
and	O
reveal	O
a	O
major	O
role	O
for	O
immunoproteasomes	B-MED
in	O
elimination	O
of	O
FA	B-MED
-	I-MED
damaged	I-MED
cytoplasmic	B-MED
proteins	I-MED
through	O
ubiquitin	B-MED
-	O
independent	B-MED
proteolysis	B-MED
.	O
A	O
peptide	B-MED
from	O
human	B-MED
β	I-MED
thymosin	I-MED
as	O
a	O
platform	O
for	O
the	O
development	O
of	O
new	O
anti	B-MED
-	I-MED
biofilm	I-MED
anti	B-MED
-	I-MED
biofilm	I-MED
agents	I-MED
for	O
Staphylococcus	B-MED
spp	I-MED
.	I-MED
and	O
Pseudomonas	B-MED
aeruginosa	I-MED
Conventional	O
antibiotics	B-MED
might	O
fail	O
in	O
the	O
treatment	O
of	O
biofilm	B-MED
-associated	O
infections	B-MED
causing	O
infection	B-MED
recurrence	B-MED
and	O
chronicity	B-MED
.	O
The	O
search	O
for	O
antimicrobial	B-MED
peptides	I-MED
has	O
been	O
performed	O
with	O
the	O
aim	O
to	O
discover	B-MED
novel	O
anti	B-MED
-	I-MED
infective	I-MED
agents	I-MED
active	B-MED
on	O
pathogens	B-MED
in	O
both	O
planktonic	B-MED
and	O
biofilm	B-MED
associated	O
forms	O
.	O
The	O
fragment	B-MED
9	O
-	O
19	O
of	O
human	B-MED
thymosin	I-MED
β4	I-MED
was	O
studied	B-MED
through	O
1	O
μs	O
MD	B-MED
simulation	I-MED
.	O
Two	O
main	O
conformations	B-MED
of	I-MED
the	I-MED
peptide	I-MED
were	O
detected	O
,	O
both	O
constituted	O
by	O
a	O
central	B-MED
hydrophobic	I-MED
core	I-MED
and	O
by	O
the	O
presence	O
of	O
peripheral	B-MED
charged	O
residues	B-MED
suggesting	O
a	O
possible	O
mechanism	O
of	O
interaction	B-MED
with	O
two	O
models	B-MED
of	O
biological	B-MED
membranes	I-MED
,	O
related	O
to	O
eukaryotic	B-MED
or	O
bacterial	B-MED
membrane	I-MED
respectively	O
.	O
In	O
addition	O
,	O
the	O
peptide	B-MED
was	O
chemically	O
synthesized	O
and	O
its	O
antimicrobial	B-MED
activity	I-MED
was	O
tested	O
in	B-MED
vitro	I-MED
against	O
planktonic	B-MED
and	O
biofilm	B-MED
form	O
of	O
a	O
group	B-MED
of	O
reference	O
strains	B-MED
of	O
Staphylococcus	B-MED
spp	I-MED
.	I-MED
and	O
one	O
P.	B-MED
aeruginosa	I-MED
strain	B-MED
.	O
The	O
human	B-MED
thymosin	I-MED
β4	I-MED
fragment	B-MED
EIEKFDKSKLK	B-MED
showed	O
antibacterial	B-MED
activity	I-MED
against	O
staphylococcal	B-MED
strains	B-MED
and	O
Pseudomonas	B-MED
aeruginosa	I-MED
ATCC	O
15442	O
at	O
concentrations	B-MED
from	O
12.5	O
to	O
6.2	O
mg	O
/	O
ml	O
and	O
inhibited	O
biofilm	B-MED
formation	I-MED
at	O
sub	B-MED
-	I-MED
inhibitory	I-MED
concentrations	I-MED
(	O
3.1	O
-	O
0.75	O
mg	O
/	O
ml	O
)	O
.	O
The	O
activity	B-MED
of	O
the	O
fragment	B-MED
in	O
inhibiting	O
biofilm	B-MED
formation	I-MED
,	O
could	O
be	O
due	O
to	O
the	O
conformations	B-MED
highlighted	O
by	O
the	O
MD	B-MED
simulations	I-MED
,	O
suggesting	O
its	O
interaction	B-MED
with	O
the	O
bacterial	B-MED
membrane	I-MED
.	O
Human	B-MED
thymosin	I-MED
β4	I-MED
fragment	B-MED
can	O
be	O
considered	O
a	O
promising	O
lead	B-MED
compound	I-MED
to	O
develop	O
novel	O
synthetic	O
or	O
recombinant	B-MED
derivatives	I-MED
with	O
improved	O
pharmaceutical	B-MED
potential	O
.	O
The	O
clinical	B-MED
and	O
economic	B-MED
burden	B-MED
of	O
significant	B-MED
bleeding	B-MED
during	B-MED
lung	B-MED
resection	I-MED
surgery	I-MED
:	O
A	O
retrospective	B-MED
matched	I-MED
cohort	I-MED
analysis	I-MED
of	O
real	B-MED
-	O
world	B-MED
data	B-MED
The	O
objective	B-MED
of	O
this	O
retrospective	B-MED
study	I-MED
was	O
to	O
quantify	B-MED
the	O
clinical	B-MED
and	O
economic	B-MED
burden	B-MED
of	O
significant	B-MED
bleeding	B-MED
in	O
lung	B-MED
resection	I-MED
surgery	I-MED
in	O
the	O
US	B-MED
.	O
This	O
study	B-MED
utilized	B-MED
2009	O
-	O
2012	O
data	B-MED
from	O
the	O
Premier	B-MED
Perspective	I-MED
Database(TM	I-MED
)	I-MED
.	O
Adult	B-MED
patients	B-MED
with	O
primary	B-MED
pulmonary	I-MED
lobectomy	I-MED
or	O
segmentectomy	B-MED
procedures	I-MED
were	O
categorized	B-MED
by	O
the	O
surgical	B-MED
approach	I-MED
(	O
VATS	B-MED
vs	O
open	B-MED
)	O
and	O
primary	B-MED
diagnosis	I-MED
(	O
primary	B-MED
or	O
metastatic	B-MED
lung	I-MED
cancer	I-MED
vs	O
non	B-MED
-	I-MED
lung	I-MED
cancer	I-MED
)	O
.	O
Patients	B-MED
requiring	O
≥3	O
units	B-MED
of	O
blood	B-MED
products	I-MED
with	O
at	B-MED
least	I-MED
1	O
unit	B-MED
of	O
PRBCs	B-MED
:	O
"	O
significant	B-MED
bleeding	B-MED
"	O
cohort	B-MED
;	O
those	O
requiring	O
<3	O
units	B-MED
:	O
"	O
non	B-MED
-	I-MED
significant	I-MED
bleeding	B-MED
"	O
cohort	B-MED
;	O
and	O
those	O
not	O
requiring	O
blood	B-MED
products	I-MED
:	O
"	O
no	B-MED
bleeding	B-MED
"	O
cohort	B-MED
.	O
A	O
matched	O
cohort	B-MED
analysis	I-MED
was	O
performed	B-MED
between	O
the	O
"	O
significant	B-MED
bleeding	B-MED
"	O
and	O
the	O
"	O
no	B-MED
bleeding	B-MED
cohort	B-MED
"	O
using	O
matching	B-MED
variables	I-MED
:	O
hospital	B-MED
,	O
lung	B-MED
cancer	I-MED
diagnosis	I-MED
,	O
year	B-MED
of	I-MED
surgery	I-MED
,	O
APR	B-MED
-	I-MED
DRG	I-MED
severity	I-MED
score	I-MED
,	O
procedure	B-MED
type	I-MED
and	O
approach	B-MED
,	O
age	B-MED
,	O
and	O
gender	B-MED
.	O
The	O
"	O
All	B-MED
-	O
patient	B-MED
"	O
cohort	B-MED
comprised	O
21,429	O
patients	B-MED
:	O
213	O
"	O
significant	B-MED
bleeding	B-MED
"	O
;	O
2,780	O
"	O
non	B-MED
-	I-MED
significant	I-MED
bleeding	B-MED
"	O
;	O
and	O
18,436	O
"	O
no	B-MED
bleeding	B-MED
"	O
.	O
Overall	B-MED
incidence	B-MED
of	O
significant	B-MED
chest	B-MED
bleeding	B-MED
was	O
0.99	O
%	O
.	O
Patients	B-MED
from	O
"	O
significant	B-MED
bleeding	B-MED
"	O
cohort	B-MED
and	O
"	O
non	B-MED
-	I-MED
significant	I-MED
bleeding	B-MED
"	O
cohort	B-MED
had	O
2.5	O
days	B-MED
and	O
2	O
days	B-MED
(	O
p	O
<	O
0.0001	O
)	O
longer	B-MED
length	B-MED
of	I-MED
stay	I-MED
in	O
the	O
hospital	B-MED
compared	B-MED
to	O
those	O
in	O
the	O
"	O
no	B-MED
bleeding	B-MED
"	O
cohort	B-MED
,	O
respectively	O
.	O
Overall	B-MED
,	O
hospital	B-MED
costs	I-MED
for	O
"	O
significant	B-MED
bleeding	B-MED
"	O
cohort	B-MED
were	O
higher	B-MED
than	O
"	O
no	B-MED
bleeding	B-MED
"	O
cohort	B-MED
for	O
those	O
who	O
were	O
covered	B-MED
under	O
Medicare	B-MED
(	O
$	O
59,871	O
vs	O
$	O
23,641	O
)	O
,	O
were	O
≥76	O
years	B-MED
of	I-MED
age	I-MED
(	O
$	O
64,010	O
vs	O
$	O
24,243	O
)	O
,	O
had	O
greater	B-MED
severity	B-MED
of	I-MED
illness	I-MED
(	O
$	O
97,813	O
vs	O
$	O
51,871	O
)	O
and	O
underwent	O
open	O
segmentectomy	B-MED
(	O
$	O
74,220	O
vs	O
$	O
21,903	O
)	O
.	O
Hospital	B-MED
costs	I-MED
for	O
"	O
significant	B-MED
bleeding	B-MED
"	O
cohort	B-MED
and	O
"	O
non	B-MED
-	I-MED
significant	I-MED
bleeding	B-MED
"	O
were	O
significantly	B-MED
higher	B-MED
(	O
$	O
11,589	O
and	O
$	O
5,280	O
,	O
respectively	O
,	O
p	O
<	O
0.0001	O
)	O
than	O
no	B-MED
bleeding	B-MED
cohort	B-MED
.	O
Although	O
significant	B-MED
bleeding	B-MED
during	B-MED
lung	B-MED
resection	I-MED
surgery	I-MED
is	O
rare	B-MED
,	O
patients	B-MED
with	O
such	O
complication	B-MED
could	O
stay	B-MED
longer	B-MED
at	O
the	O
hospital	B-MED
and	O
cost	B-MED
an	O
average	O
of	O
$	O
13,103	O
more	O
than	O
those	O
without	O
.	O
Directing	B-MED
traffic	I-MED
on	I-MED
DNA	I-MED
-How	O
transcription	B-MED
factors	I-MED
relieve	B-MED
or	O
induce	B-MED
transcriptional	B-MED
interference	I-MED
Transcriptional	B-MED
interference	I-MED
(	O
TI	B-MED
)	O
is	O
increasingly	O
recognized	O
as	O
a	O
widespread	B-MED
mechanism	O
of	O
gene	B-MED
control	I-MED
,	O
particularly	O
given	O
the	O
pervasive	B-MED
nature	I-MED
of	O
transcription	B-MED
,	O
both	O
sense	B-MED
and	O
antisense	B-MED
,	O
across	O
all	O
kingdoms	B-MED
of	O
life	O
.	O
Here	O
,	O
we	O
discuss	O
how	O
transcription	B-MED
factor	I-MED
binding	B-MED
kinetics	I-MED
strongly	O
influence	B-MED
the	O
ability	B-MED
of	O
a	O
transcription	B-MED
factor	I-MED
to	O
relieve	B-MED
or	O
induce	B-MED
TI	B-MED
.	O
The	O
Association	B-MED
between	O
C9orf72	B-MED
Repeats	B-MED
and	O
Risk	B-MED
of	O
Alzheimer	B-MED
's	I-MED
Disease	I-MED
and	O
Amyotrophic	B-MED
Lateral	I-MED
Sclerosis	I-MED
:	O
A	O
Meta	B-MED
-	I-MED
Analysis	I-MED
C9orf72	B-MED
is	O
the	O
most	O
common	O
genetic	B-MED
cause	B-MED
of	O
amyotrophic	B-MED
lateral	I-MED
sclerosis	I-MED
(	O
ALS	B-MED
)	O
and	O
frontotemporal	B-MED
dementia	I-MED
(	O
FTD	B-MED
)	O
in	O
Caucasian	B-MED
populations	I-MED
.	O
However	O
,	O
the	O
relationship	B-MED
between	O
C9orf72	B-MED
repeats	B-MED
and	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
(	O
AD	B-MED
)	O
was	O
not	B-MED
clear	I-MED
.	O
Additionally	O
,	O
there	O
were	O
few	O
articles	B-MED
assessing	B-MED
C9orf72	B-MED
in	O
other	O
ethnicities	B-MED
with	O
ALS	B-MED
.	O
In	O
this	O
meta	B-MED
-	I-MED
analysis	I-MED
,	O
we	O
aimed	O
to	O
investigate	B-MED
the	O
relationship	B-MED
between	O
C9orf72	B-MED
repeat	B-MED
expansions	I-MED
(	O
≥30	O
repeats	B-MED
)	O
and	O
intermediate	B-MED
repeat	B-MED
copies	I-MED
(	O
20	O
-	O
29	O
repeats	B-MED
)	O
and	O
AD	B-MED
or	O
ALS	B-MED
.	O
The	O
results	B-MED
suggested	O
positive	B-MED
correlations	B-MED
between	O
C9orf72	B-MED
repeat	B-MED
expansions	I-MED
and	O
the	O
risk	B-MED
of	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
(	O
OR	B-MED
=	O
6.36	O
,	O
95	O
%	O
CI	B-MED
=	O
3.13	O
-	O
12.92	O
,	O
and	O
p	B-MED
<	O
0.00001	O
)	O
,	O
while	O
intermediate	B-MED
repeat	B-MED
copies	I-MED
of	O
C9orf72	B-MED
gene	I-MED
were	O
not	O
associated	B-MED
with	I-MED
the	O
risk	B-MED
of	O
the	O
disease	B-MED
.	O
C9orf72	B-MED
repeat	B-MED
expansions	I-MED
were	O
positively	B-MED
correlated	B-MED
with	O
the	O
risk	B-MED
of	O
familial	B-MED
and	O
sporadic	B-MED
ALS	I-MED
(	O
OR	B-MED
=	O
293.25	O
,	O
95	O
%	O
CI	B-MED
=	O
148.17	O
-	O
580.38	O
,	O
and	O
p	B-MED
<	O
0.00001	O
;	O
OR	B-MED
=	O
35.57	O
,	O
95	O
%	O
CI	B-MED
=	O
19.61	O
-	O
64.51	O
,	O
and	O
p	B-MED
<	O
0.00001	O
)	O
.	O
There	O
was	O
a	O
positive	B-MED
correlation	B-MED
between	O
the	O
gene	B-MED
variations	I-MED
and	O
ALS	B-MED
risk	B-MED
among	O
Caucasians	B-MED
and	O
Asians	B-MED
(	O
OR	B-MED
=	O
57.56	O
,	O
95	O
%	O
CI	B-MED
=	O
36.73	O
-	O
90.22	O
,	O
and	O
p	B-MED
<	O
0.00001	O
;	O
OR	B-MED
=	O
6.35	O
,	O
95	O
%	O
CI	B-MED
=	O
1.39	O
-	O
29.02	O
,	O
and	O
p	B-MED
=	O
0.02	O
)	O
.	O
Obstructive	B-MED
Acute	B-MED
Pancreatitis	I-MED
Secondary	O
to	O
PEG	B-MED
Tube	I-MED
Migration	B-MED
Percutaneous	B-MED
gastrostomy	I-MED
is	O
a	O
well	O
-	O
established	O
method	B-MED
of	O
providing	O
enteral	B-MED
nutrition	I-MED
to	O
patients	B-MED
incapable	B-MED
of	O
oral	B-MED
intake	I-MED
,	O
or	O
for	O
whom	O
oral	B-MED
intake	I-MED
is	O
insufficient	B-MED
to	O
meet	O
metabolic	B-MED
needs	B-MED
.	O
In	O
comparison	O
to	O
total	B-MED
parenteral	I-MED
nutrition	I-MED
,	O
enteral	B-MED
feeding	I-MED
is	O
advantageous	O
in	O
that	O
it	O
helps	O
maintain	O
gut	B-MED
mucosal	B-MED
integrity	B-MED
,	O
which	O
decreases	O
the	O
risk	B-MED
of	O
bacterial	B-MED
translocation	I-MED
through	O
the	O
gastrointestinal	B-MED
tract	I-MED
.	O
Complications	B-MED
include	O
bleeding	B-MED
,	O
aspiration	B-MED
,	O
internal	B-MED
organ	I-MED
injury	I-MED
,	O
perforation	B-MED
,	O
periostomal	B-MED
leaks	I-MED
,	O
tube	B-MED
dislodgement	I-MED
,	O
and	O
occlusion	B-MED
.	O
Acute	B-MED
pancreatitis	I-MED
secondary	O
to	O
percutaneous	B-MED
gastrostomy	I-MED
tube	I-MED
migration	B-MED
is	O
rare	O
.	O
We	O
present	O
a	O
patient	B-MED
with	O
acute	B-MED
obstructive	B-MED
pancreatitis	B-MED
secondary	O
to	O
percutaneous	B-MED
gastrostomy	I-MED
tube	I-MED
migration	B-MED
.	O
Nosocomial	B-MED
pneumonia	I-MED
caused	O
by	O
methicillin	B-MED
-	I-MED
resistant	I-MED
Staphylococcus	I-MED
aureus	I-MED
treated	B-MED
with	I-MED
linezolid	B-MED
or	O
vancomycin	B-MED
:	O
A	O
secondary	O
economic	B-MED
analysis	I-MED
of	O
resource	B-MED
use	I-MED
from	O
a	O
Spanish	B-MED
perspective	B-MED
Adopting	O
a	O
unique	O
Spanish	B-MED
perspective	B-MED
,	O
this	O
study	B-MED
aims	O
to	O
assess	O
healthcare	B-MED
resource	I-MED
utilization	I-MED
(	O
HCRU	B-MED
)	O
and	O
the	O
costs	B-MED
of	O
treating	B-MED
nosocomial	B-MED
pneumonia	I-MED
(	O
NP	B-MED
)	O
produced	O
by	O
methicillin	B-MED
-	I-MED
resistant	I-MED
Staphylococcus	I-MED
aureus	I-MED
(	O
MRSA	B-MED
)	O
in	O
hospitalized	B-MED
adults	I-MED
using	O
linezolid	B-MED
or	O
vancomycin	B-MED
.	O
An	O
evaluation	O
is	O
also	O
made	O
of	O
the	O
renal	B-MED
failure	I-MED
rate	B-MED
and	O
related	O
economic	B-MED
outcomes	I-MED
between	O
study	B-MED
groups	I-MED
.	O
An	O
economic	O
post	B-MED
hoc	I-MED
evaluation	I-MED
of	O
a	O
randomized	B-MED
,	O
double	B-MED
-	I-MED
blind	I-MED
,	O
multicenter	B-MED
phase	I-MED
4	I-MED
study	I-MED
was	O
carried	O
out	O
.	O
Nosocomial	B-MED
pneumonia	I-MED
due	O
to	O
MRSA	B-MED
in	O
hospitalized	B-MED
adults	I-MED
.	O
The	O
modified	B-MED
intent	I-MED
to	I-MED
treat	I-MED
(	O
mITT	B-MED
)	O
population	B-MED
comprised	O
224	O
linezolid	B-MED
-	O
and	O
224	O
vancomycin	B-MED
-	O
treated	B-MED
patients	B-MED
.	O
Costs	B-MED
and	O
HCRU	B-MED
were	O
evaluated	O
between	O
patients	B-MED
administered	B-MED
either	O
linezolid	B-MED
or	O
vancomycin	B-MED
,	O
and	O
between	O
patients	B-MED
who	O
developed	O
renal	B-MED
failure	I-MED
and	O
those	O
who	O
did	O
not	O
.	O
Analysis	O
of	O
HCRU	B-MED
outcomes	B-MED
and	O
costs	B-MED
.	O
Total	O
costs	B-MED
were	O
similar	O
between	O
the	O
linezolid	B-MED
-	O
(	O
€	O
17,782±€9,615	O
)	O
and	O
vancomycin	B-MED
-	O
treated	B-MED
patients	B-MED
(	O
€	O
17,423±€9,460	O
)	O
(	O
P=.69	O
)	O
.	O
The	O
renal	B-MED
failure	I-MED
rate	B-MED
was	O
significantly	O
lower	O
in	O
the	O
linezolid	B-MED
-	O
treated	B-MED
patients	B-MED
(	O
4	O
%	O
vs.	O
15	O
%	O
;	O
P<.001	O
)	O
.	O
The	O
total	O
costs	B-MED
tended	O
to	O
be	O
higher	O
in	O
patients	B-MED
who	O
developed	O
renal	B-MED
failure	I-MED
(	O
€	O
19,626±€10,840	O
vs.	O
€	O
17,388±€9,369	O
;	O
P=.14	O
)	O
.	O
Among	O
the	O
patients	B-MED
who	O
developed	O
renal	B-MED
failure	I-MED
,	O
HCRU	B-MED
(	O
days	B-MED
on	O
mechanical	B-MED
ventilation	I-MED
:	O
13.2±10.7	O
vs.	O
7.6±3.6	O
days	B-MED
;	O
P=.21	O
;	O
ICU	B-MED
stay	I-MED
:	O
14.4±10.5	O
vs.	O
9.9±6.6	O
days	B-MED
;	O
P=.30	O
;	O
hospital	B-MED
stay	I-MED
:	O
19.5±9.5	O
vs.	O
16.1±11.0	O
days	B-MED
;	O
P=.26	O
)	O
and	O
cost	B-MED
(	O
€	O
17,219±€8,792	O
vs.	O
€	O
20,263±€11,350	O
;	O
P=.51	O
)	O
tended	O
to	O
be	O
lower	O
in	O
the	O
linezolid	B-MED
-	O
vs.	O
vancomycin	B-MED
-	O
treated	B-MED
patients	B-MED
.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
costs	B-MED
per	O
patient	B-MED
-	O
day	B-MED
between	O
cohorts	B-MED
after	O
correcting	O
for	O
mortality	B-MED
(	O
€	O
1000	O
vs.	O
€	O
1,010	O
;	O
P=.98	O
)	O
.	O
From	O
a	O
Spanish	B-MED
perspective	B-MED
,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
total	O
costs	B-MED
between	O
the	O
linezolid	B-MED
and	O
vancomycin	B-MED
pneumonia	B-MED
cohorts	B-MED
.	O
The	O
drug	B-MED
cost	I-MED
corresponding	O
to	O
linezolid	B-MED
was	O
partially	O
offset	B-MED
by	O
fewer	O
renal	B-MED
failure	I-MED
adverse	B-MED
events	I-MED
.	O
Peptide	B-MED
-Mediated	O
Interference	B-MED
of	O
PB2	B-MED
-	O
eIF4G1	B-MED
Interaction	B-MED
Inhibits	B-MED
Influenza	B-MED
A	I-MED
Viruses	I-MED
'	O
Replication	B-MED
in	B-MED
Vitro	I-MED
and	O
in	B-MED
Vivo	I-MED
Influenza	B-MED
viruses	I-MED
are	O
obligate	B-MED
parasites	I-MED
that	O
hijack	B-MED
the	I-MED
host	I-MED
cellular	I-MED
system	I-MED
.	O
Previous	O
results	O
have	O
shown	O
that	O
the	O
influenza	B-MED
virus	I-MED
PB2	I-MED
subunit	O
confers	O
a	O
dependence	O
of	O
host	B-MED
eukaryotic	I-MED
translation	I-MED
initiation	I-MED
factor	I-MED
4	I-MED
-	I-MED
γ	I-MED
1	I-MED
(	O
eIF4G1	B-MED
)	O
for	O
viral	B-MED
mRNA	I-MED
translation	I-MED
.	O
Here	O
,	O
we	O
demonstrated	O
that	O
peptide	B-MED
-mediated	O
interference	B-MED
of	O
the	O
PB2	B-MED
-	O
eIF4G1	B-MED
interaction	B-MED
inhibited	B-MED
virus	B-MED
replication	I-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
Remarkably	O
,	O
intranasal	B-MED
administration	I-MED
of	O
the	O
peptide	B-MED
provided	O
100	O
%	O
protection	B-MED
against	O
lethal	B-MED
challenges	B-MED
of	O
influenza	B-MED
A	I-MED
viruses	I-MED
in	O
BALB	B-MED
/	I-MED
c	I-MED
mice	I-MED
,	O
including	O
H1N1	B-MED
,	O
H5N1	B-MED
,	O
and	O
H7N9	B-MED
influenza	I-MED
virus	I-MED
subtypes	I-MED
.	O
Mapping	B-MED
of	O
the	O
PB2	B-MED
protein	I-MED
indicated	O
that	O
the	O
eIF4G1	B-MED
binding	B-MED
sites	I-MED
resided	O
within	O
the	O
PB2	B-MED
cap	I-MED
-	O
binding	B-MED
domain	I-MED
.	O
Virtual	B-MED
docking	I-MED
analysis	I-MED
suggested	O
that	O
the	O
inhibitory	B-MED
peptide	B-MED
associated	B-MED
with	I-MED
the	O
conserved	O
amino	B-MED
acid	I-MED
residues	I-MED
that	O
were	O
essential	O
to	O
PB2	B-MED
cap	B-MED
-	I-MED
binding	I-MED
activity	I-MED
.	O
Overall	O
,	O
our	O
results	O
identified	O
the	O
PB2	B-MED
-	O
eIF4G1	B-MED
interactive	B-MED
site	I-MED
as	O
a	O
druggable	B-MED
target	O
for	O
influenza	B-MED
therapeutics	B-MED
.	O
Development	B-MED
of	O
chrysin	B-MED
loaded	O
poloxamer	B-MED
micelles	O
and	O
toxicity	B-MED
evaluation	B-MED
in	O
fish	B-MED
embryos	B-MED
Poloxamer	B-MED
micelles	B-MED
micelles	B-MED
promise	O
safety	B-MED
and	O
efficacy	B-MED
for	O
many	O
water	B-MED
insoluble	B-MED
drugs	B-MED
.	O
Chrysin	B-MED
has	O
been	O
reported	O
to	O
have	O
anticancer	B-MED
,	O
anti	B-MED
-	I-MED
inflammatory	I-MED
,	O
antioxidant	B-MED
,	O
and	O
anti	B-MED
-	I-MED
aromatase	I-MED
activities	I-MED
but	O
its	O
water	B-MED
insoluble	B-MED
properties	B-MED
limit	O
its	O
pharmaceutical	B-MED
application	I-MED
.	O
In	O
the	O
present	O
study	O
,	O
chrysin	B-MED
loaded	O
poloxamer	B-MED
micelles	B-MED
were	O
developed	O
.	O
Two	O
types	O
of	O
poloxamers	B-MED
,	O
Pluronic	B-MED
F-68	I-MED
and	O
Pluronic	B-MED
F-127	I-MED
were	O
compared	O
.	O
It	O
was	O
found	O
that	O
chrysin	B-MED
loaded	O
Pluronic	B-MED
F-68	I-MED
micelles	B-MED
(	O
CS	B-MED
-	I-MED
P68	I-MED
)	O
and	O
chrysin	B-MED
loaded	O
Pluronic	B-MED
F-127	I-MED
micelles	B-MED
(	O
CS	B-MED
-	I-MED
P127	I-MED
)	O
obviously	O
increase	B-MED
the	O
aqueous	B-MED
solubility	B-MED
of	O
chrysin	B-MED
.	O
The	O
results	B-MED
also	O
indicated	O
that	O
the	O
type	O
of	O
polymer	B-MED
and	O
ratio	O
of	O
drug	B-MED
to	O
polymer	B-MED
affected	O
size	B-MED
and	O
desirable	O
characteristics	B-MED
of	O
the	O
micelles	B-MED
.	O
The	O
micelle	B-MED
system	I-MED
of	O
CS	B-MED
-	I-MED
P68	I-MED
and	O
CS	B-MED
-	I-MED
P127	I-MED
formed	O
at	O
drug	B-MED
to	O
polymer	B-MED
ratios	B-MED
of	O
1:4	O
and	O
1:2	O
,	O
respectively	O
,	O
was	O
found	O
to	O
be	O
the	O
most	O
suitable	O
monodispersed	O
system	O
with	O
a	O
nanosize	B-MED
-	I-MED
range	I-MED
diameter	I-MED
.	O
The	O
in	B-MED
vivo	I-MED
study	I-MED
in	O
zebrafish	B-MED
eggs	B-MED
indicates	O
that	O
the	O
toxicity	B-MED
of	O
CS	B-MED
-	I-MED
P68	I-MED
and	O
CS	B-MED
-	I-MED
P127	I-MED
is	O
a	O
dose	B-MED
response	I-MED
.	O
CS	B-MED
-	I-MED
P68	I-MED
and	O
CS	B-MED
-	I-MED
P127	I-MED
at	O
a	O
drug	B-MED
dose	I-MED
of	O
10	O
ng	O
/	O
mL	O
or	O
less	B-MED
is	O
safe	O
for	O
zebrafish	B-MED
embryo	B-MED
growth	B-MED
.	O
The	O
results	O
of	O
this	O
study	B-MED
indicate	O
enhanced	B-MED
water	B-MED
solubility	I-MED
of	O
chrysin	B-MED
.	O
Chrysin	B-MED
loaded	O
poloxamer	B-MED
micelles	B-MED
are	O
promising	O
for	O
further	O
use	O
in	O
in	B-MED
vivo	I-MED
studies	I-MED
in	O
mammalian	B-MED
animals	B-MED
and	O
humans	B-MED
.	O
Spermatocytic	B-MED
Tumor	I-MED
With	O
Sarcoma	B-MED
:	O
A	O
Rare	B-MED
Testicular	B-MED
Neoplasm	I-MED
Spermatocytic	B-MED
tumor	I-MED
,	O
formerly	O
known	O
as	O
spermatocytic	B-MED
seminoma	I-MED
,	O
is	O
an	O
uncommon	B-MED
testicular	B-MED
neoplasm	I-MED
which	O
is	O
a	O
distinct	O
clinicopathologic	B-MED
entity	I-MED
from	O
classic	O
seminoma	B-MED
.	O
These	O
tumors	B-MED
are	O
not	O
associated	O
with	O
germ	B-MED
cell	I-MED
neoplasia	I-MED
in	O
situ	O
,	O
other	O
germ	B-MED
cell	I-MED
tumors	I-MED
,	O
or	O
isochromosome	B-MED
12p	I-MED
.	O
Although	O
typically	O
,	O
these	O
tumors	B-MED
have	O
an	O
excellent	B-MED
prognosis	B-MED
occasional	B-MED
cases	I-MED
are	O
associated	B-MED
with	I-MED
sarcoma	B-MED
and	O
have	O
a	O
very	B-MED
poor	I-MED
prognosis	I-MED
.	O
We	O
present	O
a	O
case	B-MED
of	O
spermatocytic	B-MED
tumor	I-MED
with	O
sarcoma	B-MED
showing	O
a	O
chondrosarcomatous	B-MED
component	I-MED
,	O
discuss	O
the	O
pathologic	B-MED
findings	I-MED
and	O
differential	B-MED
diagnosis	I-MED
and	O
provide	O
follow	B-MED
-	I-MED
up	I-MED
information	B-MED
.	O
Signature	B-MED
of	O
an	O
aggregation	B-MED
-	O
prone	B-MED
conformation	O
of	O
tau	B-MED
The	O
self	B-MED
-	I-MED
assembly	I-MED
of	O
the	O
microtubule	B-MED
associated	B-MED
tau	B-MED
protein	I-MED
into	O
fibrillar	B-MED
cell	I-MED
inclusions	I-MED
is	O
linked	B-MED
to	O
a	O
number	B-MED
of	O
devastating	O
neurodegenerative	B-MED
disorders	I-MED
collectively	O
known	O
as	O
tauopathies	B-MED
.	O
The	O
mechanism	B-MED
by	O
which	O
tau	B-MED
self	B-MED
-	I-MED
assembles	I-MED
into	O
pathological	B-MED
entities	B-MED
is	O
a	O
matter	O
of	O
much	O
debate	B-MED
,	O
largely	B-MED
due	B-MED
to	I-MED
the	O
lack	O
of	O
direct	B-MED
experimental	B-MED
insights	B-MED
into	O
the	O
earliest	B-MED
stages	I-MED
of	O
aggregation	B-MED
.	O
We	O
present	O
pulsed	B-MED
double	I-MED
electron	I-MED
-	I-MED
electron	I-MED
resonance	I-MED
measurements	B-MED
of	O
two	O
key	O
fibril	B-MED
-	O
forming	B-MED
regions	B-MED
of	O
tau	B-MED
,	O
PHF6	B-MED
and	O
PHF6	B-MED
*	I-MED
,	O
in	O
transient	B-MED
as	O
aggregation	B-MED
happens	O
.	O
By	O
monitoring	O
the	O
end	B-MED
-	I-MED
to	I-MED
-	I-MED
end	I-MED
distance	I-MED
distribution	B-MED
of	O
these	O
segments	O
as	O
a	O
function	B-MED
of	O
aggregation	B-MED
time	B-MED
,	O
we	O
show	O
that	O
the	O
PHF6	B-MED
(	I-MED
(	I-MED
*	I-MED
)	I-MED
)	I-MED
regions	B-MED
dramatically	O
extend	B-MED
to	O
distances	B-MED
commensurate	B-MED
with	O
extended	B-MED
β	B-MED
-	I-MED
strand	I-MED
structures	I-MED
within	O
the	O
earliest	B-MED
stages	I-MED
of	O
aggregation	B-MED
,	O
well	O
before	O
fibril	B-MED
formation	B-MED
.	O
Combined	B-MED
with	O
simulations	B-MED
,	O
our	O
experiments	B-MED
show	O
that	O
the	O
extended	B-MED
β	B-MED
-	I-MED
strand	I-MED
conformational	I-MED
state	B-MED
of	O
PHF6	B-MED
(	I-MED
(	I-MED
*	I-MED
)	I-MED
)	I-MED
is	O
readily	O
populated	O
under	O
aggregating	B-MED
conditions	B-MED
,	O
constituting	O
a	O
defining	O
signature	B-MED
of	O
aggregation	B-MED
-	O
prone	B-MED
tau	B-MED
,	O
and	O
as	O
such	O
,	O
a	O
possible	O
target	B-MED
for	O
therapeutic	B-MED
interventions	I-MED
.	O
Natural	B-MED
competence	B-MED
for	O
transformation	B-MED
While	O
most	O
molecular	B-MED
biologists	I-MED
are	O
familiar	O
with	O
the	O
artificial	B-MED
transformation	B-MED
of	I-MED
bacteria	I-MED
in	O
the	O
context	B-MED
of	O
laboratory	B-MED
cloning	B-MED
experiments	B-MED
,	O
natural	B-MED
competence	B-MED
for	O
transformation	B-MED
refers	O
to	O
a	O
specific	B-MED
physiological	B-MED
state	B-MED
in	O
which	O
prokaryotes	B-MED
are	O
able	O
to	O
take	O
up	O
genetic	B-MED
material	I-MED
from	O
their	O
surroundings	B-MED
.	O
Occasionally	O
,	O
such	O
absorbed	B-MED
DNA	B-MED
is	O
recombined	B-MED
into	O
the	O
organism	B-MED
's	I-MED
own	O
genome	B-MED
,	O
resulting	O
in	O
natural	B-MED
transformation	B-MED
(	O
Figure	O
1	O
)	O
.	O
As	O
a	O
consequence	B-MED
,	O
natural	B-MED
competence	B-MED
for	O
transformation	B-MED
is	O
considered	O
a	O
primary	B-MED
mode	B-MED
of	O
horizontal	B-MED
gene	I-MED
transfer	I-MED
(	O
HGT	B-MED
)	O
in	O
prokaryotes	B-MED
,	O
together	O
with	O
conjugation	B-MED
(	O
direct	B-MED
cell	B-MED
to	O
cell	B-MED
transfer	B-MED
of	O
DNA	B-MED
via	O
a	O
specialized	B-MED
conjugal	B-MED
pilus	I-MED
)	O
and	O
phage	B-MED
transduction	B-MED
(	O
DNA	B-MED
transfer	B-MED
mediated	O
by	O
viruses	B-MED
)	O
.	O
HGT	B-MED
plays	O
a	O
major	O
role	O
in	O
bacterial	B-MED
evolution	B-MED
,	O
and	O
past	B-MED
research	B-MED
has	O
demonstrated	O
that	O
HGT	B-MED
,	O
including	O
natural	B-MED
competence	B-MED
for	O
transformation	B-MED
,	O
contributes	B-MED
to	O
the	O
emergence	O
of	O
pathogens	B-MED
and	O
the	O
spread	B-MED
of	O
virulence	B-MED
factors	I-MED
.	O
Indeed	O
,	O
Frederick	O
Griffith	O
discovered	O
natural	B-MED
competence	B-MED
for	O
transformation	B-MED
in	O
1928	O
while	O
he	O
was	O
investigating	B-MED
the	O
exchange	B-MED
of	O
pathogenic	B-MED
traits	B-MED
in	O
pneumococci	B-MED
.	O
Due	O
to	O
the	O
increase	B-MED
in	O
the	O
abundance	B-MED
and	O
spread	B-MED
of	O
multidrug	B-MED
-	I-MED
resistant	I-MED
microbes	I-MED
,	O
research	B-MED
on	O
HGT	B-MED
is	O
even	O
more	O
important	O
today	O
than	O
ever	O
before	O
.	O
Trans	B-MED
-	I-MED
oral	I-MED
fine	B-MED
needle	I-MED
aspiration	I-MED
cytology	I-MED
in	O
cervical	B-MED
(	I-MED
C1	I-MED
and	I-MED
C2	I-MED
)	I-MED
vertebral	I-MED
lesions	B-MED
:	O
a	O
novel	O
diagnostic	B-MED
approach	I-MED
Fine	B-MED
needle	I-MED
aspiration	I-MED
(	I-MED
FNA	I-MED
)	I-MED
cytology	I-MED
is	O
a	O
relatively	O
non	B-MED
-	I-MED
invasive	I-MED
method	O
for	O
diagnosing	B-MED
both	O
superficial	B-MED
and	O
deep	B-MED
-	I-MED
seated	I-MED
neoplastic	I-MED
and	O
non	B-MED
-	I-MED
neoplastic	I-MED
lesions	I-MED
.	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
diagnostic	B-MED
utility	I-MED
of	O
trans	B-MED
-	I-MED
oral	I-MED
FNA	B-MED
in	O
cervical	B-MED
(	I-MED
C1	I-MED
and	I-MED
C2	I-MED
)	I-MED
vertebral	I-MED
and	O
paravertebral	B-MED
lesions	B-MED
.	O
Eighteen	O
FNA	B-MED
cases	O
of	O
cervical	B-MED
vertebral	I-MED
and	O
paravertebral	B-MED
lesions	B-MED
performed	O
by	O
a	O
trans	B-MED
-	I-MED
oral	I-MED
route	I-MED
without	O
any	O
image	B-MED
-	I-MED
guidance	I-MED
between	O
1995	O
and	O
2014	O
were	O
retrieved	O
from	O
the	O
archives	O
of	O
the	O
cytology	B-MED
department	B-MED
at	O
PGIMER	B-MED
,	O
Chandigarh	B-MED
and	O
reviewed	O
.	O
Out	O
of	O
18	O
cases	O
,	O
a	O
definite	O
diagnosis	B-MED
was	O
given	O
in	O
15	O
cases	O
(	O
83.3	O
%	O
)	O
.	O
The	O
commonest	O
diagnosis	B-MED
seen	O
was	O
granulomatous	B-MED
inflammation	I-MED
consistent	O
with	O
tuberculosis	B-MED
(	O
33.3	O
%	O
)	O
.	O
Trans	B-MED
-	I-MED
oral	I-MED
FNA	B-MED
is	O
a	O
quick	O
,	O
inexpensive	O
and	O
relatively	O
safe	O
outpatient	B-MED
procedure	I-MED
for	O
sampling	O
C1	B-MED
and	I-MED
C2	I-MED
vertebral	I-MED
and	O
paravertebral	B-MED
lesions	B-MED
,	O
which	O
are	O
clinically	B-MED
and	O
radiologically	B-MED
difficult	O
to	O
approach	O
.	O
It	O
helps	O
in	O
the	O
early	B-MED
diagnosis	I-MED
and	O
management	B-MED
of	I-MED
these	I-MED
patients	I-MED
.	O
Three	B-MED
-	I-MED
Dimensional	I-MED
HyCoSy	B-MED
With	O
Perfluoropropane	B-MED
-	I-MED
Albumin	I-MED
Microspheres	I-MED
as	O
Contrast	B-MED
Agents	I-MED
and	O
Normal	O
Saline	B-MED
Injections	B-MED
Into	O
the	O
Pelvic	B-MED
Cavity	I-MED
for	O
Morphological	B-MED
Assessment	B-MED
of	O
the	O
Fallopian	B-MED
Tube	I-MED
in	O
Infertile	B-MED
Women	B-MED
To	O
apply	O
the	O
three	B-MED
-	I-MED
dimensional	I-MED
(	O
3D	B-MED
)	O
hysterosalpingo	B-MED
-	I-MED
contrast	I-MED
sonography	I-MED
(	O
HyCoSy	B-MED
)	O
with	O
perfluoropropane	B-MED
-	I-MED
albumin	I-MED
microspheres	I-MED
as	O
contrast	B-MED
agents	I-MED
and	O
normal	O
saline	B-MED
injections	B-MED
into	O
the	O
pelvic	B-MED
cavity	I-MED
for	O
assessment	B-MED
of	I-MED
the	I-MED
tubal	I-MED
patency	I-MED
and	O
adhesions	B-MED
of	I-MED
fimbrial	I-MED
parts	I-MED
.	O
Fifty	O
-	O
five	O
infertile	B-MED
female	B-MED
patients	B-MED
were	O
recruited	O
to	O
undergo	O
3D	B-MED
HyCoSy	B-MED
with	O
normal	O
saline	B-MED
injected	B-MED
into	O
the	O
pelvic	B-MED
cavity	I-MED
,	O
in	O
which	O
the	O
tubal	O
patency	O
was	O
observed	O
by	O
visualizing	O
the	O
spillage	O
of	O
contrast	B-MED
agents	I-MED
from	O
the	O
fimbriae	B-MED
,	O
and	O
the	O
fimbrial	B-MED
adhesion	I-MED
was	O
confirmed	O
by	O
the	O
finger	B-MED
-	I-MED
like	I-MED
projections	I-MED
of	O
the	O
fimbriae	B-MED
and	O
their	O
floating	B-MED
and	O
moving	B-MED
status	I-MED
.	O
Of	O
the	O
55	O
patients	B-MED
,	O
bilateral	B-MED
tubal	I-MED
patency	I-MED
was	O
observed	O
in	O
44	O
(	O
80.0	O
%	O
)	O
,	O
unilateral	B-MED
tubal	I-MED
patency	I-MED
and	O
the	O
other	O
partial	B-MED
occlusion	I-MED
in	O
7	O
(	O
12.7	O
%	O
)	O
,	O
unilateral	B-MED
partial	B-MED
occlusion	I-MED
and	O
the	O
other	O
complete	B-MED
occlusion	I-MED
in	O
3	O
(	O
5.4	O
%	O
)	O
,	O
and	O
bilateral	B-MED
complete	B-MED
occlusion	I-MED
in	O
1	O
(	O
1.8	O
%	O
)	O
.	O
The	O
fimbrial	B-MED
parts	I-MED
were	O
observed	O
in	O
105	O
fallopian	B-MED
tubes	I-MED
,	O
among	O
which	O
101	O
were	O
seen	O
with	O
the	O
finger	B-MED
-	I-MED
like	I-MED
fimbriae	B-MED
floated	B-MED
and	O
moved	B-MED
in	O
the	O
pelvic	B-MED
cavity	I-MED
,	O
whereas	O
4	O
tubes	O
were	O
not	O
because	O
of	O
adhesion	B-MED
to	O
the	O
pelvic	B-MED
cavity	I-MED
(	O
n	O
=	O
3	O
)	O
or	O
the	O
ovary	B-MED
and	O
intestine	B-MED
(	O
n	O
=	O
1	O
)	O
.	O
More	O
than	O
three	O
visible	O
,	O
quite	O
long	O
,	O
and	O
distributed	O
evenly	O
finger	B-MED
-	I-MED
like	I-MED
projection	I-MED
s	O
were	O
present	O
for	O
the	O
patent	B-MED
fimbrial	B-MED
parts	I-MED
;	O
however	O
,	O
fewer	B-MED
,	O
flat	B-MED
,	O
and	O
not	O
evenly	O
distributed	O
finger	B-MED
-	I-MED
like	I-MED
projection	I-MED
s	O
were	O
present	O
for	O
the	O
adhesive	B-MED
tubes	I-MED
.	O
No	O
serious	O
complications	B-MED
occurred	O
during	O
or	O
after	O
this	O
procedure	B-MED
.	O
Combination	B-MED
of	O
3D	B-MED
HyCoSy	B-MED
with	O
normal	O
saline	B-MED
injected	B-MED
into	O
the	O
pelvic	B-MED
cavity	I-MED
may	O
be	O
a	O
feasible	O
and	O
safe	O
procedure	B-MED
to	O
assess	O
tubal	O
patency	O
and	O
adhesions	B-MED
of	I-MED
the	I-MED
fimbrial	I-MED
parts	I-MED
.	O
Microbiomes	B-MED
of	O
Muricea	B-MED
californica	I-MED
and	O
M.	B-MED
fruticosa	I-MED
:	O
Comparative	B-MED
Analyses	I-MED
of	O
Two	O
Co	O
-	O
occurring	O
Eastern	B-MED
Pacific	I-MED
Octocorals	B-MED
Octocorals	B-MED
are	O
sources	O
of	O
novel	O
but	O
understudied	B-MED
microbial	B-MED
diversity	B-MED
.	O
Conversely	O
,	O
scleractinian	B-MED
or	O
reef	B-MED
-	I-MED
building	I-MED
coral	I-MED
microbiomes	I-MED
have	O
been	O
heavily	O
examined	B-MED
in	O
light	O
of	O
the	O
threats	B-MED
of	O
climate	B-MED
change	I-MED
.	O
Muricea	B-MED
californica	I-MED
and	O
Muricea	B-MED
fruticosa	I-MED
are	O
two	O
co	B-MED
-	I-MED
occurring	I-MED
species	I-MED
of	O
gorgonian	B-MED
octocoral	I-MED
abundantly	B-MED
found	I-MED
in	O
the	O
kelp	B-MED
forests	B-MED
of	O
southern	B-MED
California	I-MED
,	O
and	O
thus	O
provide	O
an	O
excellent	B-MED
basis	I-MED
to	O
determine	O
if	O
octocoral	B-MED
microbiomes	B-MED
are	O
host	B-MED
specific	B-MED
.	O
Using	O
Illumina	B-MED
MiSeq	I-MED
amplicon	I-MED
sequencing	I-MED
and	O
replicate	B-MED
samples	I-MED
,	O
we	O
evaluated	O
the	O
microbiomes	B-MED
collected	O
from	O
multiple	B-MED
colonies	I-MED
of	O
both	O
species	B-MED
of	O
Muricea	B-MED
to	O
measure	B-MED
both	O
inter-	B-MED
and	O
intra	B-MED
-	I-MED
colony	I-MED
microbiome	B-MED
variabilities	B-MED
.	O
In	O
addition	O
,	O
microbiomes	B-MED
from	O
overlying	O
sea	B-MED
water	I-MED
and	O
nearby	O
zoanthids	B-MED
(	O
another	O
benthic	B-MED
invertebrate	I-MED
)	O
were	O
also	O
included	O
in	O
the	O
analysis	B-MED
to	O
evaluate	O
whether	O
bacterial	B-MED
taxa	I-MED
specifically	O
associate	B-MED
with	I-MED
octocorals	B-MED
.	O
This	O
is	O
also	O
the	O
first	B-MED
report	I-MED
of	O
microbiomes	B-MED
from	O
these	O
species	B-MED
of	O
Muricea	B-MED
.	O
We	O
show	O
that	O
microbiomes	B-MED
isolated	B-MED
from	O
each	O
sample	B-MED
type	I-MED
are	O
distinct	B-MED
,	O
and	O
specifically	O
,	O
that	O
octocoral	B-MED
species	B-MED
type	B-MED
had	O
the	O
greatest	O
effect	O
on	O
predicting	B-MED
the	O
composition	B-MED
of	O
the	O
Muricea	B-MED
microbiome	B-MED
.	O
Bacterial	B-MED
taxa	I-MED
contributing	O
to	O
compositional	B-MED
differences	I-MED
include	O
distinct	B-MED
strains	B-MED
of	O
Mycoplasma	B-MED
associated	B-MED
with	I-MED
either	O
M.	B-MED
californica	I-MED
or	O
M.	B-MED
fruticosa	I-MED
,	O
an	O
abundance	B-MED
of	O
Spirochaetes	B-MED
observed	B-MED
on	O
M.	B-MED
californica	I-MED
,	O
and	O
a	O
greater	B-MED
diversity	B-MED
of	O
γ	B-MED
-	I-MED
Proteobacteria	I-MED
associated	B-MED
with	I-MED
M.	B-MED
fruticosa	I-MED
.	O
Many	O
of	O
the	O
bacterial	B-MED
taxa	I-MED
contributing	O
to	O
these	O
differences	B-MED
are	O
known	O
for	O
their	O
presence	B-MED
in	O
photosymbiont	B-MED
-	I-MED
containing	I-MED
invertebrate	I-MED
microbiomes	B-MED
.	O
Bioinformatic	B-MED
Analysis	B-MED
of	O
Codon	B-MED
Usage	B-MED
and	O
Phylogenetic	B-MED
Relationships	I-MED
in	O
Different	O
Genotypes	B-MED
of	O
the	O
Hepatitis	B-MED
C	I-MED
Virus	I-MED
The	O
hepatitis	B-MED
C	I-MED
virus	I-MED
(	O
HCV	B-MED
)	O
has	O
six	O
major	O
genotypes	B-MED
.	O
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
phylogenetically	B-MED
investigate	I-MED
the	O
differences	O
between	O
the	O
genotypes	B-MED
of	O
HCV	B-MED
,	O
and	O
to	O
determine	O
the	O
types	O
of	O
amino	B-MED
acid	I-MED
codon	B-MED
usage	B-MED
in	O
the	O
structure	B-MED
of	I-MED
the	I-MED
virus	I-MED
in	O
order	O
to	O
discover	O
new	O
methods	O
for	O
treatment	B-MED
regimes	I-MED
.	O
The	O
codon	B-MED
usage	B-MED
of	O
the	O
six	O
genotypes	B-MED
of	O
the	O
HCV	B-MED
nucleotide	B-MED
sequence	I-MED
was	O
investigated	B-MED
through	O
the	O
online	O
application	O
available	O
on	O
the	O
website	B-MED
Gene	I-MED
Infinity	I-MED
.	O
Also	O
,	O
phylogenetic	B-MED
analysis	I-MED
and	O
the	O
evolutionary	B-MED
relationship	I-MED
of	O
HCV	B-MED
genotypes	B-MED
were	O
analyzed	B-MED
with	O
MEGA	B-MED
7	I-MED
software	I-MED
.	O
The	O
six	O
genotypes	B-MED
of	O
HCV	B-MED
were	O
divided	O
into	O
two	O
groups	B-MED
based	O
on	O
their	O
codon	B-MED
usage	B-MED
properties	B-MED
.	O
In	O
the	O
first	O
group	B-MED
,	O
genotypes	B-MED
1	I-MED
and	I-MED
5	I-MED
(	O
74.02	O
%	O
)	O
,	O
and	O
in	O
the	O
second	O
group	B-MED
,	O
genotypes	B-MED
2	I-MED
and	I-MED
6	I-MED
(	O
72.43	O
%	O
)	O
were	O
shown	O
to	O
have	O
the	O
most	O
similarity	B-MED
in	O
terms	O
of	O
codon	B-MED
usage	B-MED
.	O
Unlike	O
the	O
results	O
with	O
respect	O
to	O
determining	O
the	O
similarity	B-MED
of	O
codon	B-MED
usage	B-MED
,	O
the	O
phylogenetic	B-MED
analysis	I-MED
showed	O
the	O
closest	O
resemblance	B-MED
and	O
correlation	B-MED
between	O
genotypes	B-MED
1	I-MED
and	I-MED
4	I-MED
.	O
The	O
results	O
also	O
showed	O
that	O
HCV	B-MED
has	O
a	O
GC	B-MED
(	O
guanine	B-MED
guanine	B-MED
-	I-MED
cytosine	I-MED
cytosine	B-MED
)	O
abundant	O
genome	B-MED
structure	I-MED
and	O
prefers	O
codons	B-MED
with	O
GC	O
for	O
translation	B-MED
.	O
Genotypes	B-MED
1	I-MED
and	I-MED
4	I-MED
demonstrated	O
remarkable	O
similarity	B-MED
in	O
terms	O
of	O
genome	B-MED
sequences	I-MED
and	O
proteins	B-MED
,	O
but	O
surprisingly	O
,	O
in	O
terms	O
of	O
the	O
preferred	O
codons	B-MED
for	O
gene	B-MED
expression	I-MED
,	O
they	O
showed	O
the	O
greatest	O
difference	O
.	O
More	O
studies	B-MED
are	O
therefore	O
needed	O
to	O
confirm	O
the	O
results	O
and	O
select	O
the	O
best	O
approach	B-MED
for	O
treatment	B-MED
of	O
these	O
genotypes	B-MED
based	O
on	O
their	O
codon	B-MED
usage	B-MED
properties	B-MED
.	O
Expression	B-MED
and	O
methylation	B-MED
in	O
posttraumatic	B-MED
stress	I-MED
disorder	I-MED
and	O
resilience	B-MED
;	O
evidence	B-MED
of	O
a	O
role	B-MED
for	O
odorant	B-MED
receptors	I-MED
Post	B-MED
-	I-MED
traumatic	I-MED
stress	I-MED
disorder	I-MED
(	O
PTSD	B-MED
)	O
is	O
a	O
common	O
and	O
potentially	B-MED
disabling	B-MED
disorder	I-MED
that	O
develops	O
in	O
1/5	O
to	O
1/3	O
of	O
people	B-MED
exposed	B-MED
to	I-MED
severe	B-MED
trauma	B-MED
.	O
Twin	B-MED
studies	I-MED
indicate	O
that	O
genetic	B-MED
factors	B-MED
account	O
for	O
at	O
least	O
one	O
third	O
of	O
the	O
variance	B-MED
in	O
the	O
risk	O
for	O
developing	O
PTSD	B-MED
,	O
however	O
,	O
the	O
specific	B-MED
role	B-MED
for	O
genetic	B-MED
factors	B-MED
in	O
the	O
pathogenesis	B-MED
of	O
PTSD	B-MED
is	O
not	O
well	O
understood	O
.	O
We	O
studied	O
genome	B-MED
-	I-MED
wide	I-MED
gene	B-MED
expression	I-MED
and	O
DNA	B-MED
methylation	I-MED
profiles	B-MED
in	O
12	O
participants	B-MED
with	O
PTSD	B-MED
and	O
12	O
participants	B-MED
who	O
were	O
resilient	B-MED
to	O
similar	O
severity	B-MED
trauma	B-MED
exposure	B-MED
.	O
Close	O
to	O
4000	O
genes	B-MED
were	O
differentially	B-MED
expressed	B-MED
with	O
adjusted	B-MED
p<0.05	O
,	O
fold	B-MED
-	I-MED
change	I-MED
>	O
2	O
,	O
with	O
all	O
but	O
3	O
upregulated	B-MED
with	O
PTSD	B-MED
.	O
Eight	O
odorant	B-MED
/	I-MED
olfactory	I-MED
receptor	I-MED
related	O
genes	B-MED
were	O
up	B-MED
-	I-MED
regulated	I-MED
with	O
PTSD	B-MED
as	O
well	O
as	O
genes	B-MED
related	O
to	O
immune	B-MED
activation	I-MED
,	O
the	O
Gamma	B-MED
-	I-MED
Aminobutyric	I-MED
Acid	I-MED
A	I-MED
(	I-MED
GABAA	I-MED
)	I-MED
receptor	I-MED
,	O
and	O
vitamin	B-MED
D	I-MED
synthesis	I-MED
.	O
No	O
differences	O
with	O
adjusted	B-MED
significance	B-MED
for	O
DNA	B-MED
methylation	I-MED
were	O
found	O
.	O
We	O
conclude	O
that	O
increased	B-MED
gene	B-MED
expression	I-MED
may	O
play	O
an	O
important	B-MED
role	B-MED
in	O
PTSD	B-MED
and	O
this	O
expression	B-MED
may	O
not	O
be	O
a	O
consequence	B-MED
of	I-MED
DNA	B-MED
methylation	I-MED
.	O
The	O
role	B-MED
of	O
odorant	B-MED
receptor	I-MED
expression	B-MED
warrants	O
independent	B-MED
replication	B-MED
.	O
An	O
Inhibitory	B-MED
Septum	B-MED
to	O
Lateral	B-MED
Hypothalamus	I-MED
Circuit	B-MED
That	O
Suppresses	B-MED
Feeding	B-MED
Feeding	B-MED
behavior	I-MED
is	O
orchestrated	B-MED
by	O
neural	B-MED
circuits	I-MED
primarily	O
residing	O
in	O
the	O
hypothalamus	B-MED
and	O
hindbrain	B-MED
.	O
However	O
,	O
the	O
relative	B-MED
influence	B-MED
of	O
cognitive	B-MED
and	O
emotional	B-MED
brain	B-MED
circuits	I-MED
to	O
the	O
feeding	B-MED
circuitry	B-MED
in	O
the	O
hypothalamus	B-MED
and	O
hindbrain	B-MED
remains	O
unclear	B-MED
.	O
Here	O
,	O
using	B-MED
the	O
cell	B-MED
-	I-MED
type	I-MED
selectivity	O
of	O
genetic	B-MED
methods	I-MED
,	O
circuit	B-MED
mapping	I-MED
,	O
and	O
behavior	B-MED
assays	B-MED
,	O
we	O
sought	O
to	O
decipher	O
neural	B-MED
circuits	I-MED
emanating	O
from	O
the	O
septal	B-MED
nucleus	I-MED
to	O
the	O
lateral	B-MED
hypothalamus	I-MED
(	O
LH	B-MED
)	O
that	O
contribute	O
to	O
neural	B-MED
regulation	I-MED
of	O
food	B-MED
intake	I-MED
in	O
mice	B-MED
.	O
We	O
found	O
that	O
chemogenetic	B-MED
and	O
optogenetic	B-MED
activation	B-MED
of	O
septal	B-MED
vesicular	B-MED
GABA	I-MED
transporter	I-MED
vGAT	B-MED
(	O
vGAT)-	O
containing	B-MED
neurons	B-MED
or	O
their	O
projections	O
in	O
the	O
LH	B-MED
reduced	B-MED
food	B-MED
intake	I-MED
in	O
mice	B-MED
.	O
Consistently	O
,	O
chemogenetic	B-MED
inhibition	B-MED
of	O
septal	B-MED
vGAT	B-MED
neurons	B-MED
increased	B-MED
food	B-MED
intake	I-MED
.	O
Furthermore	O
,	O
we	O
investigated	B-MED
a	O
previously	O
unknown	B-MED
neural	B-MED
circuit	I-MED
originating	B-MED
from	O
septal	B-MED
vGAT	B-MED
neurons	B-MED
to	O
a	O
subset	B-MED
of	O
vGAT	B-MED
neurons	B-MED
in	O
the	O
LH	B-MED
,	O
an	O
area	B-MED
involved	B-MED
in	O
homeostatic	B-MED
and	O
hedonic	B-MED
control	B-MED
of	O
energy	B-MED
states	I-MED
.	O
Collectively	O
,	O
our	O
data	B-MED
reveal	B-MED
an	O
inhibitory	B-MED
septohypothalamic	B-MED
feeding	B-MED
circuit	I-MED
that	O
might	O
serve	O
as	O
a	O
therapeutic	B-MED
target	B-MED
for	O
the	O
treatment	B-MED
of	O
eating	B-MED
disorders	I-MED
such	O
as	O
anorexia	B-MED
nervosa	I-MED
.	O
Our	O
results	O
demonstrate	O
that	O
top	O
-	O
down	O
projections	O
from	O
the	O
septum	B-MED
to	O
the	O
hypothalamus	B-MED
control	B-MED
food	B-MED
intake	I-MED
negatively	B-MED
.	O
Given	O
the	O
known	O
role	O
for	O
both	O
of	O
these	O
brain	B-MED
regions	I-MED
in	O
the	O
control	B-MED
of	O
feeding	B-MED
and	O
emotion	B-MED
-	O
related	B-MED
behaviors	B-MED
,	O
these	O
findings	B-MED
reveal	B-MED
previously	O
unknown	B-MED
neural	B-MED
circuitry	I-MED
that	O
is	O
likely	O
implicated	O
in	O
emotional	B-MED
aspects	I-MED
of	O
food	B-MED
intake	I-MED
and	O
provide	B-MED
new	O
insights	B-MED
into	O
the	O
development	B-MED
of	O
therapeutic	B-MED
targets	B-MED
for	O
the	O
treatment	B-MED
of	O
eating	B-MED
disorders	I-MED
.	O
A	O
Practical	B-MED
Guide	I-MED
to	O
Forensic	B-MED
Nursing	I-MED
:	O
Incorporating	B-MED
forensic	B-MED
principles	B-MED
into	O
nursing	B-MED
practice	I-MED
Amar	B-MED
Angela	I-MED
F	I-MED
and	O
Sekula	B-MED
L	I-MED
Kathleen	I-MED
A	O
Practical	B-MED
Guide	I-MED
to	O
Forensic	B-MED
Nursing	I-MED
:	O
Incorporating	O
forensic	B-MED
principles	B-MED
into	O
nursing	B-MED
practice	I-MED
392pp	O
US$	O
59.95	O
Sigma	O
Theta	O
Tau	O
International	O
Honor	O
Society	O
of	O
Nursing	O
9781940446349	O
1940446341	O
[	O
Formula	O
:	O
see	O
text	O
George	B-MED
Bernard	I-MED
Shaw	I-MED
described	O
Britons	B-MED
and	O
Americans	B-MED
as	O
'	O
divided	B-MED
by	O
a	O
common	B-MED
language	I-MED
'	O
,	O
and	O
that	O
is	O
made	O
very	O
clear	O
in	O
this	O
fascinating	B-MED
publication	I-MED
that	O
describes	O
in	O
depth	O
the	O
roles	B-MED
and	I-MED
responsibilities	I-MED
of	O
forensic	B-MED
nurses	I-MED
in	O
the	O
US	B-MED
.	O
Soymilk	B-MED
residue	B-MED
(	O
okara	B-MED
)	O
as	O
a	O
natural	B-MED
immobilization	B-MED
carrier	I-MED
for	O
Lactobacillus	B-MED
plantarum	I-MED
cells	B-MED
enhances	B-MED
soymilk	B-MED
fermentation	B-MED
,	O
glucosidic	B-MED
isoflavone	I-MED
bioconversion	B-MED
,	O
and	O
cell	B-MED
survival	I-MED
under	O
simulated	B-MED
gastric	I-MED
and	O
intestinal	B-MED
conditions	B-MED
Cell	B-MED
immobilization	I-MED
is	O
an	O
alternative	B-MED
to	O
microencapsulation	B-MED
for	O
the	O
maintenance	O
of	O
cells	B-MED
in	O
a	O
liquid	B-MED
medium	B-MED
.	O
However	O
,	O
artificial	B-MED
immobilization	B-MED
carriers	I-MED
are	O
expensive	O
and	O
pose	O
a	O
high	O
safety	B-MED
risk	B-MED
.	O
Okara	B-MED
,	O
a	O
food	B-MED
-	I-MED
grade	I-MED
byproduct	B-MED
from	O
soymilk	B-MED
production	B-MED
,	O
is	O
rich	O
in	O
prebiotics	B-MED
.	O
Lactobacilli	B-MED
could	O
provide	O
health	B-MED
enhancing	B-MED
effects	B-MED
to	O
the	O
host	B-MED
.	O
This	O
study	B-MED
aimed	O
to	O
evaluate	O
the	O
potential	O
of	O
okara	B-MED
as	O
a	O
natural	O
immobilizer	O
for	O
L.	B-MED
plantarum	I-MED
70810	I-MED
cells	I-MED
.	O
The	O
study	O
also	O
aimed	O
to	O
evaluate	O
the	O
effects	O
of	O
okara	B-MED
-	I-MED
immobilized	I-MED
L.	B-MED
plantarum	I-MED
70810	I-MED
cells	I-MED
(	O
IL	B-MED
)	O
on	O
soymilk	B-MED
fermentation	B-MED
,	O
glucosidic	B-MED
isoflavone	I-MED
bioconversion	B-MED
,	O
and	O
cell	B-MED
resistance	B-MED
to	O
simulated	B-MED
gastric	I-MED
and	O
intestinal	B-MED
stresses	B-MED
.	O
Scanning	B-MED
electron	I-MED
microscopy	I-MED
(	O
SEM	B-MED
)	O
was	O
used	O
to	O
show	O
cells	B-MED
adherence	B-MED
to	O
the	O
surface	B-MED
of	O
okara	B-MED
.	O
Lactic	B-MED
acid	I-MED
,	O
acetic	B-MED
acid	I-MED
and	O
isoflavone	B-MED
analyses	B-MED
in	O
unfermented	O
and	O
fermented	B-MED
soymilk	B-MED
were	O
performed	B-MED
by	O
HPLC	B-MED
with	I-MED
UV	I-MED
detection	I-MED
.	O
Viability	B-MED
and	O
growth	O
kinetics	O
of	O
immobilized	B-MED
and	O
free	B-MED
L.	I-MED
plantarum	I-MED
70810	I-MED
cells	I-MED
(	O
FL	B-MED
)	O
were	O
followed	O
during	O
soymilk	B-MED
fermentation	B-MED
.	O
Moreover	O
,	O
changes	B-MED
in	O
pH	B-MED
,	O
titrable	B-MED
acidity	I-MED
and	O
viscosity	B-MED
were	O
measured	B-MED
by	O
conventional	B-MED
methods	I-MED
.	O
For	O
in	B-MED
vitro	I-MED
testing	B-MED
of	O
simulated	O
gastrointestinal	B-MED
resistance	B-MED
,	O
fermented	B-MED
soymilk	B-MED
was	O
inoculated	B-MED
with	O
FL	B-MED
or	O
IL	B-MED
and	O
an	O
aliquot	B-MED
incubated	B-MED
into	O
acidic	B-MED
MRS	I-MED
broth	I-MED
which	O
was	O
conveniently	O
prepared	O
to	O
simulate	O
gastric	B-MED
,	O
pancreatic	B-MED
juices	I-MED
and	O
bile	B-MED
salts	I-MED
.	O
Survival	O
to	O
simulated	B-MED
gastric	I-MED
and	O
intestinal	B-MED
stresses	B-MED
was	O
evaluated	O
by	O
plate	B-MED
count	I-MED
of	I-MED
colony	I-MED
forming	I-MED
units	I-MED
on	O
MRS	B-MED
agar	I-MED
.	O
SEM	B-MED
revealed	O
that	O
the	O
lactobacilli	B-MED
cells	B-MED
attached	B-MED
and	O
bound	O
to	O
the	O
surface	B-MED
of	O
okara	B-MED
.	O
Compared	B-MED
with	O
FL	B-MED
,	O
IL	B-MED
exhibited	O
a	O
significantly	O
higher	B-MED
specific	B-MED
growth	B-MED
rate	I-MED
,	O
shorter	B-MED
lag	B-MED
phase	I-MED
of	O
growth	B-MED
,	O
higher	O
productions	O
of	O
lactic	B-MED
and	O
acetic	B-MED
acids	I-MED
,	O
a	O
faster	B-MED
decrease	B-MED
in	O
pH	B-MED
and	O
increase	B-MED
in	O
titrable	B-MED
acidity	I-MED
,	O
and	O
a	O
higher	B-MED
soymilk	B-MED
viscosity	B-MED
.	O
Similarly	O
,	O
IL	B-MED
in	O
soymilk	B-MED
showed	O
higher	O
productions	O
of	O
daizein	B-MED
and	O
genistein	B-MED
compared	B-MED
with	O
the	O
control	B-MED
.	O
Compared	B-MED
with	O
FL	B-MED
,	O
IL	B-MED
showed	O
reinforced	O
resistance	O
to	O
simulatedgastric	B-MED
and	O
intestinal	B-MED
stresses	B-MED
in	B-MED
vitro	I-MED
that	O
included	O
low	B-MED
pH	I-MED
,	O
low	B-MED
pH	I-MED
plus	I-MED
pepsin	B-MED
,	O
pancreatin	B-MED
,	O
and	O
bile	B-MED
salt	I-MED
.	O
Our	O
results	B-MED
indicate	O
that	O
okara	B-MED
is	O
a	O
new	O
potential	O
immobilization	B-MED
carrier	I-MED
to	O
enhance	B-MED
the	O
growth	B-MED
and	O
glucosidic	B-MED
isoflavone	I-MED
bioconversion	B-MED
activities	B-MED
of	O
L.	B-MED
plantarum	I-MED
in	O
soymilk	B-MED
and	O
improve	B-MED
cell	B-MED
survivability	I-MED
following	O
simulated	B-MED
gastric	I-MED
and	O
intestinal	B-MED
conditions	B-MED
.	O
Systematic	B-MED
mapping	I-MED
of	O
functional	B-MED
enhancer	B-MED
-	O
promoter	B-MED
connections	B-MED
with	O
CRISPR	B-MED
CRISPR	B-MED
interference	I-MED
Gene	B-MED
expression	I-MED
in	O
mammals	B-MED
is	O
regulated	B-MED
by	O
noncoding	B-MED
elements	I-MED
that	O
can	O
affect	O
physiology	B-MED
and	O
disease	B-MED
,	O
yet	O
the	O
functions	B-MED
and	O
target	B-MED
genes	I-MED
of	O
most	O
noncoding	B-MED
elements	I-MED
remain	O
unknown	B-MED
.	O
We	O
present	O
a	O
high	B-MED
-	I-MED
throughput	I-MED
approach	I-MED
that	O
uses	O
clustered	B-MED
regularly	I-MED
interspaced	I-MED
short	I-MED
palindromic	I-MED
repeats	I-MED
clustered	B-MED
regularly	I-MED
interspaced	I-MED
short	I-MED
palindromic	I-MED
repeats	I-MED
(	I-MED
CRISPR	I-MED
)	I-MED
interference	I-MED
CRISPR	B-MED
(	O
CRISPRi	B-MED
)	O
to	O
discover	O
regulatory	B-MED
elements	I-MED
and	O
identify	O
their	O
target	B-MED
genes	I-MED
.	O
We	O
assess	B-MED
>	O
1	O
megabase	B-MED
of	O
sequence	B-MED
in	O
the	O
vicinity	O
of	O
two	O
essential	O
transcription	B-MED
factors	I-MED
,	O
MYC	B-MED
and	O
GATA1	B-MED
,	O
and	O
identify	O
nine	O
distal	B-MED
enhancers	B-MED
that	O
control	B-MED
gene	B-MED
expression	I-MED
and	O
cellular	B-MED
proliferation	I-MED
.	O
Quantitative	B-MED
features	B-MED
of	O
chromatin	B-MED
state	B-MED
and	O
chromosome	B-MED
conformation	B-MED
distinguish	O
the	O
seven	O
enhancers	B-MED
that	O
regulate	O
MYC	B-MED
from	O
other	O
elements	B-MED
that	O
do	O
not	O
,	O
suggesting	O
a	O
strategy	B-MED
for	O
predicting	O
enhancer	B-MED
-	O
promoter	B-MED
connectivity	B-MED
.	O
This	O
CRISPRi	B-MED
-based	O
approach	B-MED
can	O
be	O
applied	O
to	O
dissect	B-MED
transcriptional	B-MED
networks	I-MED
and	O
interpret	B-MED
the	O
contributions	B-MED
of	O
noncoding	B-MED
genetic	I-MED
variation	I-MED
to	O
human	B-MED
disease	B-MED
.	O
Epidemiological	B-MED
patterns	B-MED
of	O
bovine	B-MED
besnoitiosis	B-MED
in	O
an	O
endemic	B-MED
beef	B-MED
cattle	I-MED
herd	B-MED
reared	B-MED
under	O
extensive	O
conditions	O
Bovine	B-MED
besnoitiosis	B-MED
is	O
a	O
parasitic	B-MED
disease	I-MED
caused	O
by	O
the	O
protozoan	B-MED
Besnoitia	B-MED
besnoiti	I-MED
.	O
Described	O
many	O
decades	O
ago	O
,	O
recent	O
epidemiological	B-MED
studies	I-MED
reveal	O
its	O
important	O
spread	O
within	O
Europe	B-MED
in	O
the	O
last	O
years	B-MED
.	O
To	O
date	O
,	O
many	O
epidemiological	B-MED
aspects	B-MED
related	O
to	O
life	O
cycle	O
,	O
routes	O
of	O
transmission	B-MED
,	O
incidence	B-MED
rates	I-MED
and	O
associated	O
risk	B-MED
factors	I-MED
are	O
lacking	B-MED
;	O
hence	O
,	O
the	O
establishment	O
of	O
appropriate	B-MED
disease	I-MED
control	I-MED
programmes	B-MED
poses	O
an	O
important	O
challenge	O
.	O
Thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	B-MED
was	O
to	O
determine	O
the	O
epidemiological	B-MED
pattern	B-MED
of	O
the	O
disease	B-MED
in	O
an	O
endemic	B-MED
herd	B-MED
reared	B-MED
under	O
extensive	O
conditions	O
(	O
Spanish	B-MED
Pyrenees	B-MED
)	O
by	O
identifying	O
main	O
factors	O
associated	B-MED
with	I-MED
infection	B-MED
and	O
clinical	B-MED
disease	I-MED
dynamics	B-MED
.	O
The	O
study	B-MED
population	I-MED
consisted	O
of	O
276	O
Brown	B-MED
Swiss	I-MED
and	O
Pirenaica	B-MED
adult	B-MED
animals	I-MED
and	O
145	O
calves	B-MED
born	B-MED
and	O
weaned	B-MED
at	O
the	O
farm	B-MED
during	O
the	O
study	B-MED
.	O
Three	O
sampling	B-MED
time	B-MED
frames	I-MED
were	O
used	O
:	O
January	O
2010	O
,	O
September	O
2010	O
and	O
February	O
2011	O
,	O
which	O
allowed	O
us	O
to	O
differentiate	O
two	O
periods	B-MED
designated	O
as	O
mountain	B-MED
and	O
valley	B-MED
periods	B-MED
.	O
The	O
data	B-MED
related	O
to	O
animals	B-MED
(	O
breed	B-MED
,	O
sex	B-MED
and	O
age	B-MED
)	O
and	O
herd	B-MED
management	B-MED
(	O
animal	B-MED
grouping	I-MED
and	O
time	B-MED
in	O
housing	B-MED
)	O
were	O
recorded	O
.	O
The	O
data	B-MED
collection	I-MED
methodology	B-MED
was	O
mainly	O
based	O
on	O
clinical	B-MED
examinations	I-MED
and	O
defining	O
the	O
serological	B-MED
status	B-MED
against	O
bovine	B-MED
besnoitiosis	B-MED
by	O
the	O
immunofluorescent	B-MED
antibody	I-MED
testing	I-MED
of	O
blood	B-MED
samples	I-MED
.	O
The	O
total	O
prevalence	B-MED
among	O
adult	B-MED
animals	I-MED
was	O
38.34	O
%	O
(	O
CI	B-MED
95	O
%	O
:	O
34.53	O
-	O
42.07	O
)	O
,	O
with	O
18.54	O
%	O
of	O
seropositive	B-MED
animals	B-MED
showing	O
clinical	O
signs	O
.	O
In	O
regard	O
to	O
the	O
cumulative	B-MED
incidence	I-MED
,	O
34.57	O
%	O
of	O
new	B-MED
infections	B-MED
were	O
detected	B-MED
during	O
the	O
mountain	B-MED
period	B-MED
,	O
in	O
contrast	O
to	O
the	O
24.59	O
%	O
observed	O
in	O
the	O
valley	B-MED
period	B-MED
.	O
The	O
incidence	B-MED
density	I-MED
was	O
0.058	O
and	O
0.061	O
new	B-MED
infections	B-MED
per	O
animal	B-MED
-	O
month	B-MED
for	O
the	O
mountain	B-MED
and	O
valley	B-MED
periods	B-MED
,	O
respectively	O
.	O
According	O
to	O
the	O
seroepidemiological	B-MED
study	I-MED
,	O
the	O
seroconversion	B-MED
probability	B-MED
of	O
B.	B-MED
besnoiti	I-MED
infection	B-MED
was	O
directly	O
associated	B-MED
with	I-MED
the	O
number	B-MED
of	O
seropositive	B-MED
cows	B-MED
with	O
whom	O
an	O
animal	B-MED
had	O
been	O
stabled	O
as	O
well	O
as	O
the	O
housing	B-MED
period	B-MED
duration	B-MED
,	O
supporting	O
horizontal	B-MED
transmission	I-MED
by	O
close	O
contact	O
as	O
one	O
of	O
the	O
most	O
important	O
methods	O
of	O
disease	B-MED
spread	B-MED
.	O
In	O
addition	O
,	O
the	O
risk	B-MED
of	O
developing	O
the	O
clinical	B-MED
course	I-MED
increased	B-MED
with	O
age	B-MED
,	O
and	O
the	O
presence	B-MED
of	O
clinical	B-MED
signs	I-MED
was	O
related	O
to	O
higher	B-MED
antibody	B-MED
responses	I-MED
.	O
Among	O
calves	B-MED
(	O
from	O
3.1	O
to	O
7.1	O
months	B-MED
old	B-MED
)	O
sampled	O
once	O
at	O
weaning	B-MED
,	O
the	O
total	O
seroprevalence	B-MED
was	O
15.17	O
%	O
(	O
CI	B-MED
95	O
%	O
:	O
9.36	O
-	O
21.04	O
)	O
,	O
and	O
the	O
chronic	B-MED
stage	B-MED
was	O
observed	O
in	O
three	O
animals	B-MED
,	O
supporting	O
the	O
ability	O
of	O
B.	B-MED
besnoiti	I-MED
to	O
infect	B-MED
and	O
even	O
cause	B-MED
disease	B-MED
in	O
animals	B-MED
less	O
than	O
6	O
months	B-MED
old	B-MED
.	O
Finally	O
,	O
the	O
risk	B-MED
of	O
calf	B-MED
seroconversion	B-MED
was	O
positively	O
related	O
to	O
the	O
serological	B-MED
status	B-MED
of	O
the	O
cows	B-MED
,	O
suggesting	O
postnatal	B-MED
transmission	B-MED
between	O
dams	B-MED
and	O
offspring	B-MED
by	O
contact	O
during	O
the	O
suckling	B-MED
period	B-MED
.	O
Barriers	B-MED
to	O
access	B-MED
and	I-MED
uptake	I-MED
of	O
antiretroviral	B-MED
therapy	I-MED
among	O
HIV	B-MED
-	I-MED
positive	I-MED
men	B-MED
who	I-MED
have	I-MED
sex	I-MED
with	I-MED
men	I-MED
in	O
Hanoi	B-MED
,	O
Vietnam	B-MED
:	O
from	O
HIV	B-MED
testing	I-MED
to	O
treatment	B-MED
Little	O
is	O
known	O
about	O
the	O
experiences	B-MED
of	O
Vietnamese	B-MED
men	B-MED
who	I-MED
have	I-MED
sex	I-MED
with	I-MED
men	I-MED
in	O
accessing	B-MED
HIV	B-MED
testing	I-MED
and	O
treatment	B-MED
.	O
We	O
aimed	O
to	O
explore	O
barriers	B-MED
to	O
access	B-MED
and	I-MED
uptake	I-MED
of	O
antiretroviral	B-MED
therapy	I-MED
(	O
ART	B-MED
)	O
among	O
HIV	B-MED
-	I-MED
positive	I-MED
men	B-MED
who	I-MED
have	I-MED
sex	I-MED
with	I-MED
men	I-MED
in	O
Hanoi	B-MED
.	O
During	O
2015	O
,	O
we	O
conducted	O
qualitative	B-MED
interviews	B-MED
with	O
35	O
participants	B-MED
recruited	O
using	O
snowball	B-MED
sampling	I-MED
based	O
on	O
previous	O
research	B-MED
and	O
social	B-MED
networks	I-MED
.	O
Key	O
individual	O
impediments	O
to	O
ART	B-MED
uptake	O
included	O
inadequate	B-MED
preparation	B-MED
for	O
a	O
positive	B-MED
diagnosis	B-MED
and	O
the	O
dual	O
stigmatisation	B-MED
of	O
homosexuality	B-MED
and	O
HIV	B-MED
and	O
its	O
consequences	B-MED
,	O
leading	O
to	O
fear	B-MED
of	O
disclosure	B-MED
of	O
HIV	B-MED
status	I-MED
.	O
Health	B-MED
system	I-MED
barriers	B-MED
included	O
lack	O
of	O
clarity	O
and	O
consistency	B-MED
about	O
how	O
to	O
register	O
for	O
and	O
access	B-MED
ART	B-MED
,	O
failure	O
to	O
protect	O
patient	B-MED
confidentiality	B-MED
and	O
a	O
reticence	O
by	O
providers	B-MED
to	O
discuss	O
sexual	B-MED
identity	I-MED
and	O
same	B-MED
-	I-MED
sex	I-MED
issues	I-MED
.	O
Results	O
suggest	O
fundamental	O
problems	O
in	O
the	O
way	O
HIV	B-MED
testing	I-MED
is	O
currently	O
delivered	O
in	O
Hanoi	B-MED
,	O
including	O
a	O
lack	O
of	O
client	O
-	O
centred	O
counselling	B-MED
,	O
peer	B-MED
support	I-MED
and	O
clear	B-MED
referral	I-MED
pathways	O
.	O
Overcoming	O
these	O
barriers	B-MED
will	O
require	O
educating	O
men	B-MED
who	I-MED
have	I-MED
sex	I-MED
with	I-MED
men	I-MED
about	O
the	O
benefits	B-MED
of	O
routine	B-MED
testing	I-MED
,	O
improving	B-MED
access	B-MED
to	O
quality	O
diagnostic	B-MED
services	I-MED
and	O
building	O
a	O
safe	O
,	O
confidential	B-MED
treatment	B-MED
environment	B-MED
for	O
HIV	B-MED
-	I-MED
positive	I-MED
men	B-MED
to	O
access	B-MED
,	O
receive	B-MED
and	I-MED
remain	I-MED
in	I-MED
care	I-MED
.	O
Costing	B-MED
'	O
healthy	B-MED
'	I-MED
food	I-MED
baskets	I-MED
in	O
Australia	B-MED
-	O
a	O
systematic	B-MED
review	I-MED
of	O
food	B-MED
price	B-MED
and	O
affordability	B-MED
monitoring	B-MED
tools	I-MED
,	O
protocols	B-MED
and	O
methods	B-MED
To	O
undertake	O
a	O
systematic	B-MED
review	I-MED
to	O
determine	O
similarities	B-MED
and	O
differences	B-MED
in	O
metrics	B-MED
and	O
results	B-MED
between	O
recently	B-MED
and/or	O
currently	B-MED
used	O
tools	B-MED
,	O
protocols	B-MED
and	O
methods	B-MED
for	O
monitoring	B-MED
Australian	B-MED
healthy	B-MED
food	I-MED
prices	B-MED
and	O
affordability	B-MED
.	O
Electronic	B-MED
databases	I-MED
of	O
peer	B-MED
-	I-MED
reviewed	I-MED
literature	I-MED
and	O
online	B-MED
grey	I-MED
literature	I-MED
were	O
systematically	B-MED
searched	B-MED
using	O
the	O
PRISMA	B-MED
approach	O
for	O
articles	B-MED
and	O
reports	B-MED
relating	O
to	O
healthy	B-MED
food	I-MED
and	O
diet	B-MED
price	I-MED
assessment	I-MED
tools	I-MED
,	O
protocols	B-MED
,	O
methods	B-MED
and	O
results	B-MED
that	O
utilised	O
retail	B-MED
pricing	I-MED
.	O
National	B-MED
,	O
state	B-MED
,	O
regional	B-MED
and	O
local	B-MED
areas	I-MED
of	O
Australia	B-MED
from	O
1995	O
to	O
2015	O
.	O
Assessment	B-MED
tools	I-MED
,	O
protocols	B-MED
and	O
methods	B-MED
to	O
measure	B-MED
the	O
price	B-MED
of	O
'	B-MED
healthy	I-MED
'	I-MED
foods	I-MED
and	O
diets	B-MED
.	O
The	O
search	O
identified	B-MED
fifty	O
-	O
nine	O
discrete	O
surveys	B-MED
of	O
'	O
healthy	B-MED
'	I-MED
food	I-MED
pricing	B-MED
incorporating	O
six	O
major	O
food	B-MED
pricing	I-MED
tools	I-MED
(	O
those	O
used	O
in	O
multiple	B-MED
areas	I-MED
and	O
time	B-MED
periods	I-MED
)	O
and	O
five	O
minor	B-MED
food	B-MED
pricing	I-MED
tools	I-MED
(	O
those	O
used	O
in	O
a	O
single	B-MED
survey	I-MED
area	I-MED
or	O
time	B-MED
period	I-MED
)	O
.	O
Analysis	B-MED
demonstrated	O
methodological	B-MED
differences	B-MED
regarding	O
:	O
included	B-MED
foods	B-MED
;	O
reference	B-MED
households	I-MED
;	O
use	O
of	O
availability	B-MED
and/or	O
quality	B-MED
measures	I-MED
;	O
household	B-MED
income	I-MED
sources	B-MED
;	O
store	B-MED
sampling	B-MED
methods	I-MED
;	O
data	B-MED
collection	I-MED
protocols	B-MED
;	O
analysis	B-MED
methods	I-MED
;	O
and	O
results	B-MED
.	O
'	O
Healthy	B-MED
'	I-MED
food	I-MED
price	B-MED
assessment	B-MED
methods	B-MED
used	O
in	O
Australia	B-MED
lack	B-MED
comparability	B-MED
across	O
all	O
metrics	B-MED
and	O
most	O
do	O
not	O
fully	O
align	O
with	O
a	O
'	O
healthy	B-MED
'	I-MED
diet	I-MED
as	O
recommended	B-MED
by	O
the	O
current	O
Australian	B-MED
Dietary	I-MED
Guidelines	I-MED
.	O
None	O
have	O
been	O
applied	O
nationally	O
.	O
Assessment	B-MED
of	O
the	O
price	B-MED
,	O
price	B-MED
differential	I-MED
and	O
affordability	B-MED
of	O
healthy	B-MED
(	O
recommended	B-MED
)	O
and	O
current	B-MED
(	B-MED
unhealthy	I-MED
)	I-MED
diets	I-MED
would	O
provide	B-MED
more	O
robust	B-MED
and	O
meaningful	O
data	B-MED
to	O
inform	O
health	B-MED
and	I-MED
fiscal	I-MED
policy	I-MED
in	O
Australia	B-MED
.	O
The	O
INFORMAS	B-MED
'	O
optimal	B-MED
'	O
approach	O
provides	O
a	O
potential	B-MED
framework	O
for	O
development	B-MED
of	O
these	O
methods	B-MED
.	O
Gut	B-MED
microbiome	I-MED
alterations	B-MED
in	O
patients	B-MED
with	O
stage	B-MED
4	I-MED
hepatitis	B-MED
C	I-MED
Hepatitis	B-MED
C	I-MED
virus	I-MED
(	O
HCV	B-MED
)	O
causes	O
debilitating	O
liver	B-MED
diseases	I-MED
,	O
which	O
may	O
progress	O
to	O
cirrhosis	B-MED
and	O
cancer	B-MED
,	O
and	O
claims	O
500,000	O
annual	O
lives	O
worldwide	B-MED
.	O
While	O
HCV	B-MED
epidemiology	B-MED
,	O
pathophysiology	B-MED
,	O
and	O
therapy	B-MED
are	O
being	O
deeply	O
studied	O
,	O
rare	O
attention	O
is	O
given	O
to	O
reciprocal	B-MED
interactions	I-MED
between	O
HCV	B-MED
infection	I-MED
,	O
HCV	B-MED
-induced	O
chronic	B-MED
liver	I-MED
diseases	I-MED
,	O
and	O
the	O
human	B-MED
gut	B-MED
microbiome	I-MED
.	O
As	O
Egypt	B-MED
has	O
the	O
world	B-MED
's	I-MED
highest	B-MED
prevalence	I-MED
of	O
HCV	B-MED
infections	I-MED
,	O
we	O
launched	O
this	O
study	B-MED
to	O
monitor	O
differences	O
in	O
the	O
gut	B-MED
microbial	I-MED
community	I-MED
composition	B-MED
of	O
Egyptian	B-MED
HCV	B-MED
patients	B-MED
that	O
may	O
affect	O
,	O
or	O
result	O
from	O
,	O
the	O
patients	B-MED
'	O
liver	B-MED
state	B-MED
.	O
To	O
this	O
end	O
,	O
we	O
analyzed	O
stool	B-MED
samples	I-MED
from	O
six	O
stage	B-MED
4	I-MED
-	O
HCV	B-MED
patients	B-MED
and	O
eight	O
healthy	B-MED
individuals	I-MED
by	O
high	B-MED
-	I-MED
throughput	I-MED
16S	B-MED
rRNA	I-MED
gene	I-MED
sequencing	I-MED
using	O
Illumina	B-MED
MiSeq	I-MED
.	O
Overall	O
,	O
the	O
alpha	B-MED
-	I-MED
diversity	I-MED
of	O
the	O
healthy	B-MED
persons	I-MED
'	I-MED
gut	B-MED
microbiomes	I-MED
was	O
higher	B-MED
than	O
those	O
of	O
the	O
HCV	B-MED
patients	B-MED
.	O
Whereas	O
members	O
of	O
phylum	B-MED
Bacteroidetes	I-MED
were	O
more	O
abundant	O
in	O
HCV	B-MED
patients	B-MED
,	O
healthy	B-MED
individuals	I-MED
had	O
higher	B-MED
abundance	B-MED
of	O
Firmicutes	B-MED
,	O
Proteobacteria	B-MED
,	O
and	O
Actinobacteria	B-MED
.	O
Genus	B-MED
-level	O
analysis	B-MED
showed	O
differential	O
abundance	B-MED
of	O
Prevotella	B-MED
and	O
Faecalibacterium	B-MED
(	O
higher	B-MED
in	O
HCV	B-MED
patients	B-MED
)	O
vs.	O
Ruminococcus	B-MED
and	O
Clostridium	B-MED
(	O
healthy	B-MED
group	I-MED
)	O
,	O
indicating	O
that	O
the	O
higher	B-MED
abundance	B-MED
of	O
Bacteroidetes	B-MED
in	O
HCV	B-MED
patients	B-MED
is	O
most	O
likely	O
due	O
to	O
Prevotella	B-MED
overabundance	B-MED
.	O
The	O
probiotic	B-MED
genus	I-MED
,	O
Bifidobacterium	B-MED
,	O
was	O
only	O
observed	O
in	O
the	O
microbiotas	B-MED
of	O
healthy	B-MED
individuals	I-MED
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	B-MED
provides	O
a	O
first	O
overview	O
of	O
major	O
phyla	B-MED
and	O
genera	B-MED
differentiating	O
stage	B-MED
4	I-MED
-	O
HCV	B-MED
patients	B-MED
from	O
healthy	B-MED
individuals	I-MED
and	O
suggests	O
possible	O
microbiome	B-MED
remodeling	O
in	O
chronic	B-MED
hepatitis	I-MED
C	I-MED
,	O
possibly	O
shaped	O
by	O
bacterial	B-MED
translocation	I-MED
as	O
well	O
as	O
the	O
liver	B-MED
's	I-MED
impaired	B-MED
role	I-MED
in	O
digestion	B-MED
and	O
protein	B-MED
synthesis	I-MED
.	O
Future	O
studies	O
will	O
investigate	O
the	O
microbiome	B-MED
composition	B-MED
and	O
functional	O
capabilities	B-MED
in	O
more	O
patients	B-MED
while	O
tracing	O
some	O
potential	O
biomarker	B-MED
taxa	O
(	O
e.g.	O
,	O
Prevotella	B-MED
,	O
Faecalibacterium	B-MED
vs.	O
Bifidobacterium	B-MED
)	O
.	O
Untypeable	B-MED
hepatitis	B-MED
C	I-MED
virus	I-MED
subtypes	B-MED
in	O
Pakistan	B-MED
:	O
A	O
neglected	O
section	O
Diagnostically	B-MED
untypeable	B-MED
subtypes	B-MED
contribute	O
a	O
considerable	O
percent	O
of	O
hepatitis	B-MED
C	I-MED
virus	I-MED
(	O
HCV	B-MED
)	O
subtypes	B-MED
in	O
Pakistan	B-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
chronically	B-MED
infected	I-MED
HCV	B-MED
patients	B-MED
with	O
known	O
viremia	B-MED
were	O
subjected	O
to	O
HCV	B-MED
genotyping	B-MED
.	O
Among	O
the	O
total	O
retrieved	O
samples	B-MED
,	O
92.7	O
%	O
(	O
64/69	O
)	O
were	O
found	O
typeable	B-MED
while	O
7.24	O
%	O
(	O
5/69	O
)	O
were	O
diagnostically	B-MED
untypeable	B-MED
.	O
In	O
conclusion	B-MED
,	O
the	O
presence	O
of	O
large	O
number	O
of	O
untypeable	B-MED
HCV	B-MED
subtypes	B-MED
emphasizes	O
the	O
need	O
of	O
an	O
updated	O
type	B-MED
-	O
specific	B-MED
genotyping	B-MED
assay	B-MED
and	O
consideration	O
of	O
primers	B-MED
for	O
proportionally	O
rare	B-MED
subtypes	B-MED
to	O
minimize	B-MED
the	O
number	O
of	O
untypeable	B-MED
HCV	B-MED
subtypes	B-MED
.	O
Testing	O
the	O
Ret	B-MED
and	O
Sema3d	B-MED
genetic	B-MED
interaction	I-MED
in	O
mouse	B-MED
enteric	B-MED
nervous	I-MED
system	I-MED
development	I-MED
For	O
most	O
multigenic	B-MED
disorders	I-MED
,	O
clinical	B-MED
manifestation	I-MED
(	O
penetrance	B-MED
)	O
and	O
presentation	B-MED
(	O
expressivity	B-MED
)	O
are	O
likely	O
to	O
be	O
an	O
outcome	B-MED
of	O
genetic	B-MED
interaction	I-MED
between	O
multiple	O
susceptibility	B-MED
genes	I-MED
.	O
Here	O
,	O
using	O
gene	B-MED
knockouts	I-MED
in	O
mice	B-MED
we	O
evaluated	O
genetic	B-MED
interaction	I-MED
between	O
loss	O
of	O
Ret	B-MED
and	O
loss	O
of	O
Sema3d	B-MED
,	O
two	O
Hirschsprung	B-MED
disease	I-MED
susceptibility	B-MED
genes	I-MED
.	O
We	O
intercrossed	O
Ret	B-MED
and	O
Sema3d	B-MED
double	O
null	O
heterozygotes	O
to	O
generate	B-MED
mice	I-MED
with	O
the	O
nine	O
possible	O
genotypes	B-MED
and	O
assessed	B-MED
survival	I-MED
by	O
counting	B-MED
various	I-MED
genotypes	I-MED
,	O
myenteric	B-MED
plexus	I-MED
presence	O
by	O
acetylcholinesterase	B-MED
staining	I-MED
and	O
embryonic	B-MED
day	I-MED
12.5	I-MED
(	O
E12.5	B-MED
)	O
intestine	B-MED
transcriptome	I-MED
by	O
RNA	B-MED
-	I-MED
sequencing	I-MED
.	O
Survival	B-MED
rates	I-MED
of	O
Ret	B-MED
wildtype	B-MED
,	O
null	O
heterozygote	O
and	O
null	O
homozygote	O
mice	B-MED
at	O
E12.5	B-MED
,	O
birth	B-MED
and	O
weaning	B-MED
were	O
not	O
influenced	O
by	O
the	O
genotypes	B-MED
at	O
Sema3d	B-MED
locus	B-MED
and	O
vice	O
-	O
versa	O
.	O
Loss	O
of	O
myenteric	B-MED
plexus	I-MED
was	O
observed	O
only	O
in	O
all	O
Ret	B-MED
null	O
homozygotes	O
,	O
irrespective	O
of	O
the	O
genotypes	B-MED
at	O
Sema3d	B-MED
locus	B-MED
,	O
and	O
Sema3d	B-MED
null	O
heterozygote	B-MED
and	O
homozygote	B-MED
mice	I-MED
had	O
normal	O
intestinal	B-MED
innervation	I-MED
.	O
As	O
compared	O
to	O
wildtype	B-MED
mice	I-MED
intestinal	I-MED
gene	B-MED
expression	I-MED
,	O
loss	O
of	O
Ret	B-MED
in	O
null	O
homozygotes	O
led	O
to	O
differential	O
expression	B-MED
of	I-MED
∼300	I-MED
genes	I-MED
,	I-MED
whereas	O
loss	O
of	O
Sema3d	B-MED
in	O
null	O
homozygotes	O
had	O
no	O
major	O
consequence	O
and	O
there	O
was	O
no	B-MED
evidence	I-MED
supporting	O
major	O
interaction	B-MED
between	I-MED
the	I-MED
two	I-MED
genes	I-MED
influencing	O
intestine	B-MED
transcriptome	I-MED
.	O
Overall	O
,	O
given	O
the	O
null	B-MED
alleles	I-MED
and	O
phenotypic	B-MED
assays	I-MED
used	O
,	O
we	O
did	O
not	B-MED
find	I-MED
evidence	I-MED
for	O
genetic	B-MED
interaction	I-MED
between	O
Ret	B-MED
and	O
Sema3d	B-MED
affecting	O
survival	O
,	O
presence	O
of	O
myenteric	B-MED
plexus	I-MED
or	O
intestine	B-MED
transcriptome	I-MED
.	O
A	O
quasi	B-MED
-	I-MED
experimental	I-MED
study	I-MED
of	O
a	O
reminiscence	B-MED
program	I-MED
focused	O
on	O
autobiographical	B-MED
memory	I-MED
in	O
institutionalized	O
older	B-MED
adults	I-MED
with	O
cognitive	B-MED
impairment	I-MED
Working	O
with	O
past	B-MED
memories	I-MED
through	O
reminiscence	B-MED
interventions	I-MED
has	O
been	O
practiced	O
for	O
several	B-MED
decades	I-MED
with	O
successful	O
outcomes	B-MED
on	O
mental	B-MED
health	I-MED
in	O
older	B-MED
adults	I-MED
.	O
Few	O
studies	B-MED
however	O
have	O
focused	O
on	O
autobiographical	B-MED
memory	I-MED
recall	B-MED
in	O
older	B-MED
individuals	I-MED
with	O
cognitive	B-MED
impairment	I-MED
.	O
This	O
study	B-MED
aims	O
to	O
analyze	O
the	O
impact	O
of	O
an	O
individual	B-MED
reminiscence	B-MED
program	I-MED
in	O
a	O
group	O
of	O
older	B-MED
persons	I-MED
with	O
cognitive	B-MED
decline	I-MED
living	O
in	O
nursing	B-MED
homes	I-MED
on	O
the	O
dimensions	O
of	O
cognition	B-MED
,	O
autobiographical	B-MED
memory	I-MED
,	O
mood	B-MED
,	O
behavior	B-MED
and	O
anxiety	B-MED
.	O
A	O
two	O
-	O
group	O
pre	B-MED
-	I-MED
test	I-MED
and	I-MED
post	I-MED
-	I-MED
test	I-MED
design	I-MED
with	O
single	B-MED
blinded	I-MED
assessment	I-MED
was	O
conducted	O
.	O
Forty	O
-	O
one	O
participants	B-MED
were	O
randomized	O
to	O
an	O
experimental	B-MED
group	I-MED
(	O
n=20	O
)	O
and	O
a	O
control	B-MED
group	I-MED
(	O
n=21	O
)	O
.	O
The	O
first	O
group	O
attended	O
five	O
weekly	O
individual	B-MED
reminiscence	B-MED
sessions	B-MED
.	O
Changes	O
in	O
the	O
outcome	B-MED
measures	I-MED
were	O
examined	B-MED
for	O
cognition	B-MED
(	O
Montreal	B-MED
Cognitive	I-MED
Assessment	I-MED
;	O
Autobiographical	B-MED
Memory	I-MED
Test	I-MED
)	O
,	O
behavior	B-MED
(	O
Alzheimer	B-MED
Disease	I-MED
Assessment	I-MED
Subscale	I-MED
Non	I-MED
-	I-MED
Cog	I-MED
)	O
and	O
emotional	B-MED
status	I-MED
(	O
Cornell	B-MED
Scale	I-MED
for	I-MED
Depression	I-MED
in	O
Dementia	B-MED
;	O
Geriatric	B-MED
Depression	I-MED
Scale	I-MED
,	O
and	O
Geriatric	B-MED
Anxiety	I-MED
Inventory	I-MED
)	O
.	O
Participants	B-MED
attending	O
reminiscence	B-MED
sessions	I-MED
exhibited	O
better	O
outcomes	B-MED
compared	O
to	O
the	O
control	B-MED
group	I-MED
in	O
cognition	B-MED
,	O
anxiety	B-MED
and	O
depression	B-MED
(	O
p<0.001	O
)	O
,	O
and	O
presented	O
a	O
higher	O
number	O
of	O
retrieved	B-MED
autobiographical	B-MED
events	I-MED
,	O
specificity	O
of	O
evoked	O
memories	B-MED
and	O
positive	O
valence	O
of	O
events	B-MED
(	O
p<0.001	O
)	O
,	O
and	O
also	O
presented	O
lower	O
latency	O
time	O
for	O
recalling	B-MED
events	B-MED
,	O
and	O
lower	O
negative	O
recalled	B-MED
events	B-MED
(	O
p<0.01	O
)	O
.	O
This	O
study	O
supports	O
the	O
potential	O
value	O
of	O
reminiscence	B-MED
therapy	I-MED
in	O
improving	O
the	O
recall	B-MED
of	O
autobiographical	B-MED
memory	I-MED
.	O
Reminiscence	B-MED
therapy	I-MED
can	O
be	O
helpful	O
to	O
maintain	O
or	O
improve	O
cognitive	B-MED
function	I-MED
,	O
decrease	O
anxiety	B-MED
and	O
manage	O
depressive	B-MED
symptoms	I-MED
and	O
altered	B-MED
behavior	I-MED
,	O
but	O
further	O
investigation	O
is	O
needed	O
to	O
clarify	O
long	O
-	O
term	O
effects	O
.	O
An	O
approach	O
for	O
liposome	B-MED
immobilization	B-MED
using	O
sterically	B-MED
stabilized	I-MED
micelles	B-MED
(	O
SSMs	B-MED
)	O
as	O
a	O
precursor	B-MED
for	O
bio	B-MED
-	I-MED
layer	I-MED
interferometry	I-MED
-	O
based	B-MED
interaction	B-MED
studies	B-MED
Non	B-MED
-	I-MED
fluidic	I-MED
bio	B-MED
-	I-MED
layer	I-MED
interferometry	I-MED
(	O
BLI	B-MED
)	O
has	O
rapidly	B-MED
become	O
a	O
standard	B-MED
tool	O
for	O
monitoring	B-MED
almost	O
all	O
biomolecular	B-MED
interactions	B-MED
in	O
a	O
label	B-MED
-	I-MED
free	I-MED
,	O
real	B-MED
-	I-MED
time	I-MED
and	O
high	B-MED
-	I-MED
throughput	I-MED
manner	O
.	O
High	B-MED
-	O
efficiency	B-MED
screening	B-MED
methods	I-MED
which	O
measure	B-MED
the	O
kinetics	B-MED
of	O
liposomes	B-MED
with	O
a	O
variety	B-MED
of	O
compounds	B-MED
require	O
the	O
immobilization	B-MED
of	O
liposomes	B-MED
.	O
In	O
this	O
work	O
,	O
a	O
method	B-MED
is	O
described	B-MED
for	O
immobilizing	B-MED
liposomes	B-MED
for	O
interaction	B-MED
studies	B-MED
,	O
based	B-MED
on	O
the	O
biophysical	B-MED
principles	I-MED
of	O
this	O
biosensor	B-MED
platform	B-MED
.	O
The	O
immobilization	B-MED
approach	O
includes	B-MED
the	O
loading	B-MED
of	O
DSPE	B-MED
-	I-MED
PEG(2000	I-MED
)	I-MED
-	O
biotin	B-MED
containing	O
sterically	B-MED
stabilized	I-MED
micelles	B-MED
(	O
SSMs	B-MED
)	O
which	O
are	O
restructured	B-MED
in	O
a	O
buffer	B-MED
change	I-MED
step	O
,	O
resulting	B-MED
in	I-MED
an	O
accessible	O
substrate	B-MED
for	O
liposome	B-MED
immobilization	B-MED
.	O
Liposomes	B-MED
in	O
a	O
concentration	B-MED
of	O
5mM	O
of	O
varying	O
composition	B-MED
and	O
fluidity	B-MED
were	O
immobilized	B-MED
on	O
the	O
sensor	B-MED
surface	B-MED
by	O
inserting	O
the	O
hydrophobic	B-MED
residues	B-MED
of	O
the	O
former	B-MED
loaded	O
SSMs	B-MED
.	O
This	O
proof	O
of	O
principle	O
was	O
carried	O
out	O
using	O
Cytochrome	B-MED
C	I-MED
as	O
a	O
membrane	B-MED
-	I-MED
interacting	I-MED
model	O
protein	B-MED
.	O
The	O
binding	B-MED
of	O
Cytochrome	B-MED
C	I-MED
to	O
the	O
immobilized	B-MED
liposomes	B-MED
was	O
demonstrated	O
,	O
and	O
the	O
derived	O
kinetic	B-MED
and	O
affinity	B-MED
constants	B-MED
were	O
similar	B-MED
to	O
values	B-MED
given	O
in	O
the	O
literature	B-MED
.	O
In	O
order	O
to	O
obtain	O
a	O
detailed	B-MED
understanding	B-MED
of	O
this	O
surface	B-MED
,	O
and	O
to	O
show	O
the	O
integrity	B-MED
of	O
the	O
liposomes	B-MED
,	O
confocal	B-MED
fluorescence	I-MED
microscopy	I-MED
was	O
used	O
.	O
Images	O
of	O
immobilized	B-MED
liposomes	B-MED
containing	B-MED
calcein	B-MED
in	O
the	O
aqueous	B-MED
core	B-MED
indicated	B-MED
intact	B-MED
vesicles	B-MED
.	O
A	O
combination	B-MED
of	O
this	O
simple	O
liposome	B-MED
immobilization	B-MED
approach	O
,	O
the	O
possibility	O
of	O
automation	B-MED
on	O
BLI	B-MED
systems	B-MED
with	O
high	B-MED
throughput	I-MED
within	O
an	O
acceptable	B-MED
timescale	O
and	O
excellent	B-MED
reproducibility	B-MED
makes	O
this	O
assay	B-MED
suitable	B-MED
for	O
basic	O
research	B-MED
as	O
well	O
as	O
for	O
industrial	B-MED
and	O
regulatory	B-MED
applications	I-MED
.	O
Preventing	O
Youth	B-MED
Internalizing	B-MED
Symptoms	I-MED
Through	O
the	O
Familias	B-MED
Unidas	I-MED
Intervention	B-MED
:	O
Examining	O
Variation	B-MED
in	O
Response	B-MED
Prevention	B-MED
programs	I-MED
that	O
strengthen	O
parenting	B-MED
and	O
family	B-MED
functioning	I-MED
have	O
been	O
found	O
to	O
reduce	B-MED
poor	B-MED
behavioral	I-MED
outcomes	O
in	O
adolescents	B-MED
,	O
including	O
substance	B-MED
use	I-MED
,	O
HIV	B-MED
risk	I-MED
,	O
externalizing	O
and	O
internalizing	B-MED
problems	I-MED
.	O
However	O
,	O
there	O
is	O
evidence	O
that	O
not	O
all	O
youth	B-MED
benefit	O
similarly	O
from	O
these	O
programs	B-MED
.	O
Familias	B-MED
Unidas	I-MED
is	O
a	O
family	B-MED
-	I-MED
focused	I-MED
intervention	I-MED
designed	O
to	O
prevent	O
substance	B-MED
use	I-MED
and	O
sexual	B-MED
risk	I-MED
among	O
Hispanic	B-MED
youth	B-MED
and	O
has	O
recently	O
demonstrated	O
unanticipated	O
reductions	B-MED
in	O
internalizing	B-MED
symptoms	I-MED
for	O
some	O
youth	B-MED
.	O
This	O
paper	O
examines	O
variation	O
in	O
intervention	B-MED
response	O
for	O
internalizing	B-MED
symptoms	I-MED
using	O
individual	B-MED
-	I-MED
level	I-MED
data	I-MED
pooled	O
across	O
four	O
distinct	O
Familias	B-MED
Unidas	I-MED
trials	B-MED
:	O
(	O
1	O
)	O
266	O
eighth	B-MED
grade	I-MED
students	B-MED
recruited	O
from	O
the	O
general	O
school	B-MED
population	I-MED
;	O
(	O
2	O
)	O
160	O
ninth	B-MED
grade	I-MED
students	B-MED
from	O
the	O
general	O
school	B-MED
population	I-MED
;	O
(	O
3	O
)	O
213	O
adolescents	B-MED
with	O
conduct	B-MED
,	O
aggression	B-MED
,	O
and/or	O
attention	B-MED
problems	I-MED
;	O
and	O
(	O
4	O
)	O
242	O
adolescents	B-MED
with	O
a	O
delinquency	B-MED
history	O
.	O
Causal	B-MED
inference	I-MED
growth	I-MED
mixture	I-MED
modeling	I-MED
suggests	O
a	O
three-	O
class	B-MED
model	B-MED
.	O
The	O
two	O
largest	O
classes	B-MED
represent	O
youth	B-MED
with	O
low	B-MED
(	O
60	O
%	O
)	O
and	O
medium	B-MED
(	O
27	O
%	O
)	O
internalizing	B-MED
symptoms	I-MED
at	O
baseline	B-MED
,	O
and	O
both	O
intervention	B-MED
and	O
control	B-MED
participants	B-MED
show	O
reductions	B-MED
in	O
internalizing	B-MED
symptoms	I-MED
.	O
The	O
third	O
class	B-MED
(	O
13	O
%	O
)	O
represents	O
youth	B-MED
with	O
high	B-MED
levels	B-MED
of	O
baseline	B-MED
internalizing	B-MED
symptoms	I-MED
who	O
remain	O
at	O
steady	B-MED
levels	B-MED
of	O
internalizing	B-MED
symptoms	I-MED
when	O
exposed	B-MED
to	I-MED
the	O
intervention	B-MED
,	O
but	O
who	O
experience	O
an	O
increase	O
in	O
symptoms	B-MED
under	O
the	O
control	B-MED
condition	I-MED
.	O
Female	B-MED
gender	I-MED
,	O
low	B-MED
baseline	B-MED
levels	B-MED
of	O
parent	B-MED
-	O
adolescent	B-MED
communication	B-MED
,	O
and	O
older	B-MED
age	I-MED
were	O
associated	O
with	O
membership	O
in	O
the	O
high	B-MED
-	I-MED
risk	I-MED
class	B-MED
.	O
These	O
synthesis	O
analyses	O
involving	O
a	O
large	O
sample	O
of	O
youth	B-MED
with	O
varying	O
initial	B-MED
risk	I-MED
levels	I-MED
represent	O
a	O
further	O
step	O
toward	O
strengthening	O
our	O
knowledge	O
of	O
preventive	B-MED
intervention	I-MED
response	B-MED
and	O
improving	O
preventive	B-MED
interventions	I-MED
.	O
The	O
Impact	O
of	O
Deployment	B-MED
on	O
Parental	B-MED
,	O
Family	B-MED
and	O
Child	B-MED
Adjustment	B-MED
in	O
Military	B-MED
Families	I-MED
Since	O
9/11	O
,	O
military	B-MED
service	I-MED
in	O
the	O
United	B-MED
States	I-MED
has	O
been	O
characterized	O
by	O
wartime	B-MED
deployments	B-MED
and	O
reintegration	O
challenges	O
that	O
contribute	O
to	O
a	O
context	O
of	O
stress	B-MED
for	O
military	B-MED
families	I-MED
.	O
Research	B-MED
indicates	O
the	O
negative	B-MED
impact	I-MED
of	O
wartime	O
deployment	B-MED
on	O
the	O
well	B-MED
being	I-MED
of	O
service	B-MED
members	B-MED
,	O
military	B-MED
spouses	B-MED
,	O
and	O
children	B-MED
.	O
Yet	O
,	O
few	O
studies	O
have	O
considered	O
how	O
parental	B-MED
deployments	B-MED
may	O
affect	O
adjustment	B-MED
in	O
young	B-MED
children	I-MED
and	O
their	O
families	B-MED
.	O
Using	O
deployment	B-MED
deployment	B-MED
records	I-MED
and	O
parent	B-MED
-	O
reported	B-MED
measures	O
from	O
primary	O
caregiving	B-MED
(	O
N	O
=	O
680	O
)	O
and	O
military	B-MED
(	O
n	O
=	O
310	O
)	O
parents	B-MED
,	O
we	O
examined	O
the	O
influence	O
of	O
deployment	B-MED
on	O
adjustment	B-MED
in	O
military	B-MED
families	I-MED
with	O
children	B-MED
ages	O
0	O
-	O
10	O
years	O
.	O
Greater	O
deployment	B-MED
exposure	O
was	O
related	O
to	O
impaired	B-MED
family	B-MED
functioning	I-MED
and	O
marital	B-MED
instability	B-MED
.	O
Parental	B-MED
depressive	B-MED
and	O
posttraumatic	B-MED
stress	I-MED
symptoms	I-MED
were	O
associated	B-MED
with	I-MED
impairments	B-MED
in	O
social	B-MED
emotional	B-MED
adjustment	B-MED
in	O
young	B-MED
children	I-MED
,	O
increased	O
anxiety	B-MED
in	O
early	O
childhood	B-MED
,	O
and	O
adjustment	B-MED
problems	O
in	O
school	B-MED
-	I-MED
age	I-MED
children	I-MED
.	O
Conversely	O
,	O
parental	B-MED
sensitivity	B-MED
was	O
associated	B-MED
with	I-MED
improved	O
social	B-MED
and	O
emotional	B-MED
outcomes	I-MED
across	O
childhood	B-MED
.	O
These	O
findings	B-MED
provide	O
guidance	O
to	O
developing	O
preventive	B-MED
approaches	O
for	O
military	B-MED
families	I-MED
with	O
young	O
children	B-MED
.	O
Multivariate	B-MED
Imaging	B-MED
Genetics	B-MED
Study	I-MED
of	O
MRI	B-MED
Gray	B-MED
Matter	I-MED
Volume	B-MED
and	O
SNPs	B-MED
Reveals	O
Biological	B-MED
Pathways	B-MED
Correlated	B-MED
with	O
Brain	B-MED
Structural	B-MED
Differences	B-MED
in	O
Attention	B-MED
Deficit	I-MED
Hyperactivity	I-MED
Disorder	I-MED
Attention	B-MED
deficit	I-MED
hyperactivity	I-MED
disorder	I-MED
(	O
ADHD	B-MED
)	O
is	O
a	O
prevalent	B-MED
neurodevelopmental	B-MED
disorder	I-MED
affecting	B-MED
children	B-MED
,	O
adolescents	B-MED
,	O
and	O
adults	B-MED
.	O
Its	O
etiology	B-MED
is	O
not	O
well	O
understood	O
,	O
but	O
it	O
is	O
increasingly	O
believed	O
to	O
result	B-MED
from	O
diverse	B-MED
pathophysiologies	B-MED
that	O
affect	B-MED
the	O
structure	B-MED
and	O
function	B-MED
of	O
specific	B-MED
brain	B-MED
circuits	I-MED
.	O
Although	O
one	O
of	O
the	O
best	O
-	O
studied	O
neurobiological	B-MED
abnormalities	I-MED
in	O
ADHD	B-MED
is	O
reduced	B-MED
fronto	B-MED
-	I-MED
striatal	I-MED
-	I-MED
cerebellar	I-MED
gray	I-MED
matter	I-MED
(	O
GM	B-MED
)	O
volume	B-MED
,	O
its	O
specific	O
genetic	B-MED
correlates	B-MED
are	O
largely	O
unknown	B-MED
.	O
In	O
this	O
study	B-MED
,	O
T1	B-MED
-	I-MED
weighted	I-MED
MR	I-MED
images	I-MED
of	I-MED
brain	I-MED
structure	I-MED
were	O
collected	O
from	O
198	O
adolescents	B-MED
(	O
63	O
ADHD	B-MED
-	O
diagnosed	B-MED
)	O
.	O
A	O
multivariate	B-MED
parallel	I-MED
independent	I-MED
component	I-MED
analysis	I-MED
(	O
Para	B-MED
-	I-MED
ICA	I-MED
)	O
technique	B-MED
-identified	O
imaging	B-MED
genetic	B-MED
relationships	B-MED
between	O
regional	B-MED
GM	B-MED
volume	B-MED
and	O
single	B-MED
nucleotide	I-MED
polymorphism	I-MED
data	B-MED
.	O
Para	B-MED
-	I-MED
ICA	I-MED
analyses	I-MED
extracted	O
14	O
components	O
from	O
genetic	B-MED
data	I-MED
and	O
9	O
from	O
MR	B-MED
data	B-MED
.	O
An	O
iterative	B-MED
cross	I-MED
-	I-MED
validation	I-MED
using	O
randomly	O
chosen	O
subsamples	O
indicated	O
acceptable	O
stability	B-MED
of	O
these	O
ICA	B-MED
solutions	B-MED
.	O
A	O
series	O
of	O
partial	B-MED
correlation	I-MED
analyses	I-MED
controlling	B-MED
for	O
age	B-MED
,	O
sex	B-MED
,	O
and	O
ethnicity	B-MED
revealed	O
two	O
genotype	B-MED
-	I-MED
phenotype	I-MED
component	B-MED
pairs	B-MED
significantly	O
differed	O
between	O
ADHD	B-MED
and	O
non	B-MED
-	I-MED
ADHD	I-MED
groups	B-MED
,	O
after	O
a	O
Bonferroni	B-MED
correction	I-MED
for	O
multiple	B-MED
comparisons	B-MED
.	O
The	O
brain	B-MED
phenotype	B-MED
component	B-MED
not	O
only	O
included	O
structures	B-MED
frequently	O
found	O
to	O
have	O
abnormally	B-MED
low	I-MED
volume	B-MED
in	O
previous	O
ADHD	B-MED
studies	B-MED
but	O
was	O
also	O
significantly	O
associated	B-MED
with	I-MED
ADHD	B-MED
differences	O
in	O
symptom	B-MED
severity	I-MED
and	O
performance	B-MED
on	O
cognitive	B-MED
tests	I-MED
frequently	O
found	O
to	O
be	O
impaired	O
in	O
patients	B-MED
diagnosed	B-MED
with	O
the	O
disorder	B-MED
.	O
Pathway	B-MED
analysis	I-MED
of	O
the	O
genotype	B-MED
component	B-MED
identified	O
several	O
different	O
biological	B-MED
pathways	B-MED
linked	O
to	O
these	O
structural	B-MED
abnormalities	B-MED
in	O
ADHD	B-MED
.	O
Some	O
of	O
these	O
pathways	B-MED
implicate	O
well	O
-	O
known	O
dopaminergic	B-MED
neurotransmission	I-MED
and	O
neurodevelopment	B-MED
hypothesized	B-MED
to	O
be	O
abnormal	B-MED
in	O
ADHD	B-MED
.	O
Other	O
more	O
recently	O
implicated	O
pathways	B-MED
included	O
glutamatergic	B-MED
and	O
GABA	B-MED
-	I-MED
eric	I-MED
physiological	I-MED
systems	I-MED
;	O
others	O
might	O
reflect	O
sources	O
of	O
shared	O
liability	O
to	O
disturbances	O
commonly	O
found	O
in	O
ADHD	B-MED
,	O
such	O
as	O
sleep	B-MED
abnormalities	I-MED
.	O
Heart	B-MED
rate	I-MED
variability	B-MED
:	O
Pre	B-MED
-	I-MED
deployment	I-MED
predictor	B-MED
of	O
post	B-MED
-	I-MED
deployment	I-MED
PTSD	B-MED
symptoms	B-MED
Heart	B-MED
rate	I-MED
variability	B-MED
is	O
a	O
physiological	O
measure	O
associated	O
with	O
autonomic	B-MED
nervous	I-MED
system	I-MED
activity	B-MED
.	O
This	O
study	B-MED
hypothesized	O
that	O
lower	O
pre	B-MED
-	I-MED
deployment	I-MED
HRV	B-MED
would	O
be	O
associated	O
with	O
higher	O
post	B-MED
-	I-MED
deployment	I-MED
post	B-MED
-	I-MED
traumatic	I-MED
stress	I-MED
disorder	I-MED
(	O
PTSD	B-MED
)	O
symptoms	B-MED
.	O
Three	O
-	O
hundred	O
-	O
forty	O
-	O
three	O
Army	B-MED
National	I-MED
Guard	I-MED
soldiers	I-MED
enrolled	O
in	O
the	O
Warriors	B-MED
Achieving	I-MED
Resilience	I-MED
(	I-MED
WAR	I-MED
)	I-MED
study	I-MED
were	O
analyzed	O
.	O
The	O
primary	O
outcome	B-MED
was	O
PTSD	B-MED
symptom	B-MED
severity	B-MED
using	O
the	O
PTSD	B-MED
Checklist	B-MED
-	O
Military	B-MED
version	B-MED
(	O
PCL	B-MED
)	O
measured	O
at	O
baseline	B-MED
,	O
3-	O
and	O
12-	O
month	B-MED
post	B-MED
-	I-MED
deployment	I-MED
.	O
Heart	B-MED
rate	I-MED
variability	B-MED
predictor	B-MED
variables	B-MED
included	O
:	O
high	B-MED
frequency	I-MED
power	I-MED
(	O
HF	B-MED
)	O
and	O
standard	B-MED
deviation	I-MED
of	O
the	O
normal	O
cardiac	B-MED
inter	I-MED
-	I-MED
beat	I-MED
interval	B-MED
(	O
SDNN	B-MED
)	O
.	O
Generalized	O
linear	B-MED
mixed	I-MED
models	I-MED
revealed	O
that	O
the	O
pre	B-MED
-	I-MED
deployment	I-MED
PCL	B-MED
*	O
ln(HF	B-MED
)	I-MED
interaction	I-MED
term	O
was	O
significant	O
(	O
p<0.0001	O
)	O
.	O
Pre	B-MED
-	I-MED
deployment	I-MED
SDNN	B-MED
was	O
not	O
a	O
significant	O
predictor	B-MED
of	O
post	B-MED
-	I-MED
deployment	I-MED
PCL	B-MED
.	O
Covariates	B-MED
included	O
age	B-MED
,	O
pre	B-MED
-	I-MED
deployment	I-MED
PCL	B-MED
,	O
race	B-MED
/	O
ethnicity	B-MED
,	O
marital	B-MED
status	I-MED
,	O
tobacco	B-MED
use	I-MED
,	O
childhood	B-MED
abuse	I-MED
,	O
pre	B-MED
-	I-MED
deployment	I-MED
traumatic	B-MED
brain	I-MED
injury	I-MED
,	O
and	O
previous	O
combat	B-MED
zone	I-MED
deployment	B-MED
.	O
Pre	B-MED
-	I-MED
deployment	I-MED
heart	B-MED
rate	I-MED
variability	B-MED
predicts	O
post	B-MED
-	I-MED
deployment	I-MED
PTSD	B-MED
symptoms	B-MED
in	O
the	O
context	O
of	O
higher	O
pre	B-MED
-	I-MED
deployment	I-MED
PCL	B-MED
scores	B-MED
.	O
Prescription	B-MED
of	O
opioids	B-MED
for	O
breathlessness	B-MED
in	O
end	B-MED
-	I-MED
stage	I-MED
COPD	B-MED
:	O
a	O
national	O
population	B-MED
-	I-MED
based	I-MED
study	I-MED
Low	B-MED
-	I-MED
dose	I-MED
opioids	B-MED
can	O
relieve	B-MED
breathlessness	B-MED
but	O
may	O
be	O
underused	O
in	O
late	B-MED
-	I-MED
stage	I-MED
COPD	B-MED
due	O
to	O
fear	B-MED
of	O
complications	B-MED
,	O
contributing	O
to	O
poor	O
symptom	B-MED
control	I-MED
.	O
We	O
aimed	O
to	O
study	B-MED
the	O
period	B-MED
prevalence	O
and	O
indications	B-MED
of	O
opioids	B-MED
actually	O
prescribed	B-MED
in	O
people	B-MED
with	O
end	B-MED
-	I-MED
stage	I-MED
COPD	B-MED
.	O
The	O
study	B-MED
was	O
a	O
longitudinal	B-MED
,	O
population	B-MED
-	I-MED
based	I-MED
study	I-MED
of	O
patients	B-MED
starting	O
long	B-MED
-	I-MED
term	I-MED
oxygen	I-MED
therapy	I-MED
(	O
LTOT	B-MED
)	O
for	O
COPD	B-MED
between	O
October	O
1	O
,	O
2005	O
and	O
June	O
30	O
,	O
2009	O
in	O
Sweden	B-MED
.	O
A	O
random	O
sample	O
(	O
n=2,000	O
)	O
of	O
their	O
dispensed	B-MED
opioid	B-MED
prescriptions	B-MED
was	O
obtained	O
from	O
the	O
national	B-MED
Prescribed	I-MED
Drugs	I-MED
Register	I-MED
from	O
91	O
days	B-MED
before	O
starting	O
LTOT	B-MED
until	O
the	O
first	O
of	O
LTOT	B-MED
withdrawal	B-MED
,	O
death	B-MED
,	O
or	O
study	B-MED
end	I-MED
(	O
December	O
31	O
,	O
2009	O
)	O
.	O
We	O
analyzed	O
medication	O
type	O
,	O
dispensed	B-MED
quantity	I-MED
,	O
date	B-MED
of	I-MED
dispensing	I-MED
,	O
and	O
indications	B-MED
categorized	O
as	O
pain	B-MED
,	O
breathlessness	B-MED
,	O
other	O
,	O
or	O
unknown	O
.	O
In	O
total	O
,	O
2,249	O
COPD	B-MED
patients	B-MED
(	O
59	O
%	O
women	B-MED
)	O
were	O
included	O
.	O
During	O
a	O
median	O
follow	B-MED
-	I-MED
up	I-MED
of	O
1.1	O
(	O
interquartile	B-MED
range	I-MED
0.6	O
-	O
2.0	O
)	O
years	B-MED
,	O
1,034	O
patients	B-MED
(	O
46	O
%	O
)	O
were	O
dispensed	B-MED
≥1	O
opioid	B-MED
prescription	B-MED
(	O
N=13,722	O
prescriptions	B-MED
)	O
.	O
The	O
most	O
frequently	O
prescribed	B-MED
opioids	B-MED
were	O
tramadol	B-MED
(	O
23	O
%	O
)	O
,	O
oxycodone	B-MED
(	O
23	O
%	O
)	O
,	O
morphine	B-MED
(	O
16	O
%	O
)	O
,	O
and	O
codeine	B-MED
(	O
16	O
%	O
)	O
.	O
Average	O
dispensed	B-MED
quantity	I-MED
was	O
9.3	O
(	O
interquartile	B-MED
range	I-MED
3.7	O
-	O
16.7	O
)	O
defined	O
daily	B-MED
doses	I-MED
per	O
prescription	B-MED
.	O
In	O
the	O
random	O
sample	B-MED
,	O
the	O
most	O
commonly	O
stated	O
indication	B-MED
was	O
pain	B-MED
(	O
97	O
%	O
)	O
,	O
with	O
only	O
2	O
%	O
for	O
breathlessness	B-MED
and	O
1	O
%	O
for	O
other	O
reasons	O
.	O
Despite	O
evidence	O
that	O
supported	O
the	O
use	O
of	O
opioids	B-MED
for	O
the	O
relief	B-MED
of	O
breathlessness	B-MED
predating	O
this	O
study	B-MED
,	O
opioids	B-MED
are	O
rarely	O
prescribed	B-MED
to	O
relieve	B-MED
breathlessness	B-MED
in	O
oxygen	B-MED
-	I-MED
dependent	I-MED
COPD	B-MED
,	O
potentially	O
contributing	O
to	O
less	O
-	O
than	O
-	O
optimal	O
symptom	B-MED
control	I-MED
.	O
This	O
study	B-MED
creates	O
a	O
baseline	B-MED
against	O
which	O
to	O
compare	O
future	O
changes	O
in	O
morphine	B-MED
prescribing	O
in	O
this	O
setting	O
.	O
Pathways	B-MED
and	O
Genes	B-MED
Associated	B-MED
with	I-MED
Immune	B-MED
Dysfunction	B-MED
in	O
Sheep	B-MED
Paratuberculosis	B-MED
Multibacillary	B-MED
and	O
paucibacillary	B-MED
paratuberculosis	B-MED
are	O
both	O
caused	O
by	O
Mycobacterium	B-MED
avium	I-MED
subspecies	I-MED
paratuberculosis	I-MED
.	O
Multibacillary	B-MED
lesions	B-MED
are	O
composed	O
largely	O
of	O
infected	B-MED
epithelioid	B-MED
macrophages	I-MED
and	O
paucibacillary	B-MED
lesions	B-MED
contain	O
T	B-MED
cells	I-MED
but	O
few	O
bacteria	B-MED
.	O
Multibacillary	B-MED
disease	B-MED
is	O
similar	O
to	O
human	O
lepromatous	B-MED
leprosy	I-MED
,	O
with	O
variable	O
/	O
high	O
levels	O
of	O
antibody	B-MED
and	O
a	O
dysfunctional	B-MED
immune	B-MED
response	I-MED
.	O
Animals	B-MED
with	O
paucibacillary	B-MED
disease	B-MED
have	O
high	O
cell	B-MED
-	I-MED
mediated	I-MED
immunity	I-MED
and	O
variable	B-MED
levels	I-MED
of	O
antibody	B-MED
.	O
This	O
study	O
aims	O
to	O
characterize	O
the	O
immunological	B-MED
dysfunction	I-MED
using	O
TruSeq	B-MED
analysis	B-MED
of	O
the	O
ileocaecal	B-MED
lymph	B-MED
node	I-MED
that	O
drains	O
disease	B-MED
lesions	B-MED
.	O
Immune	B-MED
dysfunction	B-MED
is	O
highlighted	O
by	O
repression	B-MED
of	O
TCR	B-MED
/	O
CD3	B-MED
genes	I-MED
,	O
T	B-MED
cell	I-MED
co	I-MED
-	I-MED
receptors	I-MED
/	O
co	B-MED
-	I-MED
stimulators	I-MED
,	O
T	B-MED
cell	I-MED
activation	I-MED
and	O
signal	B-MED
-	I-MED
transduction	I-MED
genes	B-MED
.	O
Inflammation	B-MED
was	O
an	O
acute	B-MED
phase	I-MED
response	I-MED
and	O
chronic	B-MED
inflammation	I-MED
,	O
with	O
little	O
evidence	O
of	O
acute	B-MED
inflammation	I-MED
.	O
The	O
high	O
levels	O
of	O
immunoglobulin	B-MED
and	O
plasma	B-MED
cell	I-MED
transcripts	B-MED
is	O
consistent	O
with	O
the	O
anti	B-MED
-	I-MED
MAP	I-MED
antibody	I-MED
responses	I-MED
in	O
paratuberculosis	B-MED
sheep	B-MED
.	O
Also	O
notable	O
was	O
the	O
overwhelming	O
reduction	B-MED
in	O
mast	B-MED
cell	I-MED
transcripts	B-MED
,	O
potentially	O
affecting	B-MED
DC	B-MED
activation	I-MED
of	I-MED
the	I-MED
immune	I-MED
response	I-MED
.	O
This	O
study	O
also	O
shows	O
that	O
there	O
were	O
no	O
fundamental	O
differences	O
in	O
the	O
gene	B-MED
expression	I-MED
patterns	O
in	O
multibacillary	B-MED
and	O
paucibacillary	B-MED
disease	B-MED
,	O
no	O
shift	O
in	O
T	B-MED
cell	I-MED
genes	B-MED
from	O
Th1	B-MED
to	O
Th2	B-MED
pattern	O
but	O
rather	O
an	O
incremental	B-MED
decline	O
into	O
immune	B-MED
dysfunction	B-MED
leading	O
to	O
multibacillary	B-MED
pathology	B-MED
.	O
Acute	B-MED
sensitivity	B-MED
of	O
the	O
vernal	B-MED
pool	I-MED
fairy	I-MED
shrimp	I-MED
,	O
Branchinecta	B-MED
lynchi	I-MED
(	O
Anostraca	B-MED
;	O
Branchinectidae	B-MED
)	O
,	O
and	O
surrogate	B-MED
species	B-MED
to	O
10	O
chemicals	B-MED
Vernal	B-MED
pool	I-MED
fairy	I-MED
shrimp	I-MED
,	O
Branchinecta	B-MED
lynchi	I-MED
,	O
(	O
Branchiopoda	B-MED
;	O
Anostraca	B-MED
)	O
and	O
other	O
fairy	B-MED
shrimp	I-MED
species	B-MED
have	O
been	O
listed	O
as	O
threatened	B-MED
or	O
endangered	B-MED
under	O
the	O
US	O
Endangered	O
Species	O
Act	O
.	O
Because	O
few	O
data	B-MED
exist	O
about	O
the	O
sensitivity	B-MED
of	O
Branchinecta	B-MED
spp	B-MED
.	I-MED
to	O
toxic	B-MED
effects	I-MED
of	O
contaminants	B-MED
,	O
it	O
is	O
difficult	O
to	O
determine	O
whether	O
they	O
are	O
adequately	B-MED
protected	I-MED
by	O
water	B-MED
quality	I-MED
criteria	B-MED
.	O
A	O
series	O
of	O
acute	B-MED
(	I-MED
24	I-MED
-	I-MED
h	I-MED
)	I-MED
lethality	I-MED
/	I-MED
immobilization	I-MED
tests	I-MED
was	O
conducted	O
with	O
3	O
species	B-MED
of	O
fairy	B-MED
shrimp	I-MED
(	O
B.	B-MED
lynchi	I-MED
,	O
Branchinecta	B-MED
lindahli	I-MED
,	O
and	O
Thamnocephalus	B-MED
platyurus	I-MED
)	O
and	O
10	O
chemicals	B-MED
with	O
varying	O
modes	O
of	O
toxic	B-MED
action	I-MED
:	O
ammonia	B-MED
,	O
potassium	B-MED
,	O
chloride	B-MED
,	O
sulfate	B-MED
,	O
chromium(VI	B-MED
)	I-MED
,	O
copper	B-MED
,	O
nickel	B-MED
,	O
zinc	B-MED
,	O
alachlor	B-MED
,	O
and	O
metolachlor	B-MED
.	O
The	O
same	O
chemicals	B-MED
were	O
tested	O
in	O
48-	O
h	B-MED
tests	B-MED
with	O
other	O
branchiopods	B-MED
(	O
the	O
cladocerans	B-MED
Daphnia	B-MED
magna	I-MED
and	O
Ceriodaphnia	B-MED
dubia	I-MED
)	O
and	O
an	O
amphipod	B-MED
(	O
Hyalella	B-MED
azteca	I-MED
)	O
,	O
and	O
in	O
96-	O
h	B-MED
tests	B-MED
with	O
snails	B-MED
(	O
Physa	B-MED
gyrina	I-MED
and	O
Lymnaea	B-MED
stagnalis	I-MED
)	O
.	O
Median	O
effect	B-MED
concentrations	I-MED
(	O
EC50s	B-MED
)	O
for	O
B.	B-MED
lynchi	I-MED
were	O
strongly	O
correlated	B-MED
(	O
r(2	O
)	O
=	O
0.975	O
)	O
with	O
EC50s	B-MED
for	O
the	O
commercially	O
available	O
fairy	B-MED
shrimp	I-MED
species	B-MED
T.	B-MED
platyurus	I-MED
for	O
most	O
chemicals	B-MED
tested	O
.	O
Comparison	B-MED
of	O
EC50s	B-MED
for	O
fairy	B-MED
shrimp	I-MED
and	O
EC50s	B-MED
for	O
invertebrate	B-MED
taxa	I-MED
tested	O
concurrently	O
and	O
with	O
other	O
published	O
toxicity	B-MED
data	B-MED
indicated	O
that	O
fairy	B-MED
shrimp	I-MED
were	O
relatively	O
sensitive	B-MED
to	O
potassium	B-MED
and	O
several	O
trace	B-MED
metals	I-MED
compared	B-MED
with	O
other	O
invertebrate	B-MED
taxa	I-MED
,	O
although	O
cladocerans	B-MED
,	O
amphipods	B-MED
,	O
and	O
mussels	B-MED
had	O
similar	O
broad	O
toxicant	B-MED
sensitivity	B-MED
.	O
Interspecies	B-MED
correlation	I-MED
estimation	I-MED
models	I-MED
for	O
predicting	O
toxicity	B-MED
to	O
fairy	B-MED
shrimp	I-MED
from	O
surrogate	B-MED
species	B-MED
indicated	O
that	O
models	B-MED
with	O
cladocerans	B-MED
and	O
freshwater	B-MED
mussels	I-MED
as	O
surrogates	B-MED
produced	O
the	O
best	O
predictions	O
of	O
the	O
sensitivity	B-MED
of	O
fairy	B-MED
shrimp	I-MED
to	O
contaminants	B-MED
.	O
The	O
results	O
of	O
these	O
studies	B-MED
indicate	O
that	O
fairy	B-MED
shrimp	I-MED
are	O
relatively	O
sensitive	B-MED
to	O
a	O
range	O
of	O
toxicants	B-MED
,	O
but	O
Endangered	O
Species	O
Act	O
-listed	O
fairy	B-MED
shrimp	I-MED
of	O
the	O
genus	B-MED
Branchinecta	I-MED
were	O
not	O
consistently	O
more	O
sensitive	B-MED
than	O
other	O
fairy	B-MED
shrimp	I-MED
taxa	I-MED
.	O
Environ	O
Toxicol	O
Chem	O
2016;9999:1	O
-	O
10	O
.	O
Published	O
2016	O
Wiley	O
Periodicals	O
Inc.	O
on	O
behalf	O
of	O
SETAC	O
.	O
This	O
article	O
is	O
a	O
US	O
government	O
work	O
and	O
,	O
as	O
such	O
,	O
is	O
in	O
the	O
public	O
domain	O
in	O
the	O
United	O
States	O
of	O
America	O
.	O
Barriers	B-MED
and	O
facilitators	B-MED
to	O
smoking	B-MED
cessation	I-MED
in	O
a	O
cancer	B-MED
context	B-MED
:	O
A	O
qualitative	B-MED
study	I-MED
of	O
patient	B-MED
,	O
family	B-MED
and	O
professional	B-MED
views	B-MED
Continued	B-MED
smoking	B-MED
after	O
cancer	B-MED
adversely	B-MED
affects	I-MED
quality	B-MED
of	I-MED
life	I-MED
and	O
survival	B-MED
,	O
but	O
one	O
fifth	O
of	O
cancer	B-MED
survivors	B-MED
still	O
smoke	B-MED
.	O
Despite	O
its	O
demands	O
,	O
cancer	B-MED
presents	O
an	O
opportunity	O
for	O
positive	B-MED
behaviour	B-MED
change	I-MED
.	O
Smoking	B-MED
often	O
occurs	O
in	O
social	B-MED
groups	I-MED
,	O
therefore	O
interventions	B-MED
which	O
target	B-MED
families	B-MED
and	O
individuals	B-MED
may	O
be	O
more	O
successful	B-MED
.	O
This	O
qualitative	B-MED
study	I-MED
explored	O
patients	B-MED
,	O
family	B-MED
members	I-MED
and	O
health	B-MED
professionals	I-MED
'	O
views	B-MED
and	O
experiences	B-MED
of	O
smoking	B-MED
and	O
smoking	B-MED
cessation	I-MED
after	O
cancer	B-MED
,	O
in	O
order	O
to	O
inform	O
future	O
interventions	B-MED
.	O
In	B-MED
-	I-MED
depth	I-MED
qualitative	I-MED
interviews	I-MED
(	O
n	O
=	O
67	O
)	O
with	O
29	O
patients	B-MED
,	O
14	O
family	B-MED
members	I-MED
and	O
24	O
health	B-MED
professionals	I-MED
.	O
Data	B-MED
were	O
analysed	O
using	O
the	O
'	B-MED
Framework	I-MED
'	I-MED
method	I-MED
.	O
Few	O
patient	B-MED
s	O
and	O
family	B-MED
members	I-MED
had	O
used	O
National	B-MED
Health	I-MED
Service	I-MED
(	O
NHS	B-MED
)	O
smoking	B-MED
cessation	I-MED
services	B-MED
and	O
more	O
than	O
half	O
still	O
smoked	B-MED
.	O
Most	O
recalled	O
little	O
'	O
smoking	B-MED
-related	O
'	O
discussion	B-MED
with	O
clinicians	B-MED
but	O
were	O
receptive	O
to	O
talking	O
openly	O
.	O
Clinicians	B-MED
revealed	O
several	O
barriers	B-MED
to	O
discussion	B-MED
.	O
Participants	B-MED
'	O
continued	B-MED
smoking	B-MED
was	O
explained	O
by	O
the	O
stress	B-MED
of	O
diagnosis	B-MED
;	O
desire	O
to	O
maintain	O
personal	B-MED
control	B-MED
;	O
and	O
lack	B-MED
of	O
connection	O
between	O
smoking	B-MED
,	O
cancer	B-MED
and	O
health	B-MED
.	O
A	O
range	O
of	O
barriers	B-MED
to	O
smoking	B-MED
cessation	I-MED
exist	O
for	O
patients	B-MED
and	O
family	B-MED
members	I-MED
.	O
These	O
are	O
insufficiently	B-MED
assessed	B-MED
and	O
considered	O
by	O
clinicians	B-MED
.	O
Interventions	B-MED
must	O
be	O
more	O
effectively	O
integrated	O
into	O
routine	O
practice	O
.	O
Total	O
Fluorescence	B-MED
Fingerprinting	B-MED
of	O
Pesticides	B-MED
:	O
A	O
Reliable	O
Approach	O
for	O
Continuous	B-MED
Monitoring	B-MED
of	I-MED
Soils	I-MED
and	I-MED
Waters	I-MED
The	O
present	O
work	O
relates	O
to	O
the	O
creation	B-MED
/	O
extension	B-MED
of	O
a	O
database	B-MED
of	O
Total	B-MED
Excitation	I-MED
-	I-MED
Emission	I-MED
and	I-MED
Total	I-MED
Synchronous	I-MED
Fluorescence	I-MED
Matrices	I-MED
(	O
TEEMs	B-MED
and	I-MED
TSFMs	I-MED
)	O
along	O
with	O
optimal	B-MED
Synchronous	I-MED
Fluorescence	I-MED
Spectra	I-MED
(	O
SFS	B-MED
)	O
to	O
fingerprint	B-MED
pesticides	B-MED
widely	O
used	O
in	O
Morocco	B-MED
.	O
This	O
spectrometric	B-MED
multi	I-MED
-	I-MED
component	I-MED
fingerprinting	I-MED
may	O
permit	O
the	O
direct	O
detection	B-MED
of	I-MED
pesticides	I-MED
persisting	B-MED
in	I-MED
soil	I-MED
or	O
water	B-MED
.	O
The	O
objective	O
of	O
the	O
current	O
investigation	O
is	O
to	O
detect	B-MED
four	I-MED
pesticide	I-MED
remains	O
in	O
agricultural	B-MED
soils	I-MED
by	O
applying	O
the	O
spectrometric	B-MED
fingerprinting	I-MED
results	O
.	O
They	O
are	O
the	O
commercial	O
:	O
i	O
)	O
insecticide	B-MED
Axlera	I-MED
5	I-MED
G	I-MED
(	O
carbamate	B-MED
)	O
,	O
ii	O
)	O
fungicide	B-MED
Orsalis	I-MED
5	I-MED
%	I-MED
SC	I-MED
(	O
triazole	B-MED
)	O
,	O
iii	O
)	O
insecticide	B-MED
Force	I-MED
0,5	I-MED
G	I-MED
(	O
pyrethrinoid	B-MED
)	O
and	O
iv	O
)	O
insecticide	B-MED
Proclaim	I-MED
05	I-MED
SG	I-MED
(	O
non	O
-	O
assigned	O
)	O
.	O
The	O
agricultural	B-MED
plantations	I-MED
monitored	I-MED
are	O
located	O
in	O
the	O
great	B-MED
agricultural	I-MED
Doukkala	I-MED
region	I-MED
at	O
the	O
western	B-MED
Atlantic	I-MED
side	I-MED
of	O
Morocco	B-MED
,	O
where	O
these	O
chemicals	B-MED
are	O
in	O
large	O
sale	O
and	O
use	O
.	O
Aurantimonas	B-MED
endophytica	I-MED
sp	I-MED
.	I-MED
nov	I-MED
.	I-MED
,	O
a	O
novel	O
endophytic	B-MED
bacterium	I-MED
isolated	O
from	O
roots	B-MED
of	O
Anabasis	B-MED
elatior	I-MED
(	I-MED
C.	I-MED
A.	I-MED
Mey	I-MED
.	I-MED
)	I-MED
Schischk	I-MED
An	O
orange	B-MED
-	I-MED
coloured	I-MED
,	O
aerobic	B-MED
,	O
motile	B-MED
and	O
short	B-MED
-	I-MED
rods	I-MED
bacterial	I-MED
strain	I-MED
,	O
designated	O
EGI	B-MED
6500337	I-MED
T	I-MED
,	O
was	O
isolated	O
from	O
the	O
surface	O
-	O
sterilized	O
root	B-MED
of	O
a	O
halophyte	B-MED
Anabasis	B-MED
elatior	I-MED
(	I-MED
C.	I-MED
A.	I-MED
Mey	I-MED
.	I-MED
)	I-MED
Schischk	I-MED
collected	O
from	O
Urumqi	B-MED
,	O
Xinjiang	B-MED
province	I-MED
,	O
north	B-MED
-	I-MED
west	I-MED
China	I-MED
.	O
Growth	B-MED
occurred	O
at	O
5	O
-	O
35	O
°	O
C	O
(	O
optimum	O
30	O
°	O
C	O
)	O
,	O
at	O
pH	B-MED
6.0	O
-	O
9.0	O
(	O
optimum	O
pH	B-MED
7.0	O
)	O
,	O
and	O
in	O
the	O
presence	O
of	O
0	O
-	O
6	O
%	O
NaCl	B-MED
(	O
w	O
/	O
v	O
)	O
(	O
optimum	O
0	O
-	O
1	O
%	O
)	O
.	O
Phylogenetic	B-MED
tree	I-MED
based	O
on	O
16S	B-MED
rRNA	I-MED
gene	B-MED
sequences	I-MED
indicated	O
that	O
strain	B-MED
EGI	I-MED
6500337	I-MED
T	I-MED
formed	O
a	O
distinct	O
lineage	O
in	O
the	O
cluster	O
that	O
comprised	O
the	O
genera	B-MED
Aurantimonas	I-MED
and	O
Aureimonas	B-MED
in	O
the	O
family	B-MED
Aurantimonadaceae	I-MED
.	O
The	O
16S	B-MED
rRNA	I-MED
gene	B-MED
sequence	I-MED
of	O
strain	B-MED
EGI	I-MED
6500337	I-MED
T	I-MED
shared	O
the	O
highest	O
similarities	O
to	O
those	O
of	O
Aurantimonas	B-MED
coralicida	I-MED
DSM	I-MED
14790	I-MED
T	I-MED
(	O
97.15	O
%	O
)	O
and	O
Aurantimonas	B-MED
manganoxydans	I-MED
DSM	I-MED
21871	I-MED
T	I-MED
(	O
97.15	O
%	O
)	O
.	O
Strain	B-MED
EGI	I-MED
6500337	I-MED
T	I-MED
contained	O
Q-10	B-MED
as	O
the	O
dominant	O
isoprenoid	B-MED
quinone	I-MED
.	O
The	O
major	O
cellular	O
fatty	B-MED
acids	I-MED
were	O
C18:1	B-MED
7c	I-MED
(	O
66.4	O
%	O
)	O
and	O
C19:0	B-MED
8c	I-MED
cyclo	I-MED
(	O
23.3	O
%	O
)	O
.	O
The	O
polar	O
lipid	B-MED
profile	I-MED
of	O
strain	B-MED
EGI	I-MED
6500337	I-MED
T	I-MED
contained	O
diphosphatidylglycerol	B-MED
,	O
phosphatidylglycerol	B-MED
,	O
phosphatidylcholine	B-MED
,	O
phosphatidylethanolamine	B-MED
as	O
major	O
components	O
,	O
similarly	O
to	O
the	O
members	O
of	O
the	O
genus	B-MED
Aurantimonas	I-MED
.	O
The	O
DNA	B-MED
G+C	B-MED
content	I-MED
of	O
strain	B-MED
EGI	I-MED
6500337	I-MED
T	I-MED
was	O
66.8	O
mol%	O
.	O
The	O
DNA	B-MED
-	O
DNA	B-MED
relatedness	O
between	O
strain	B-MED
EGI	I-MED
6500337	I-MED
T	I-MED
and	O
Aurantimonas	B-MED
coralicida	I-MED
DSM	I-MED
14790	I-MED
T	I-MED
was	O
24.7	O
±	O
2.9	O
%	O
.	O
On	O
the	O
basis	O
of	O
the	O
phylogenetic	B-MED
analysis	I-MED
,	O
chemotaxonomic	B-MED
data	I-MED
and	O
phenotypic	B-MED
characteristics	I-MED
,	O
strain	B-MED
EGI	I-MED
6500337	I-MED
T	I-MED
represents	O
a	O
novel	O
species	O
of	O
the	O
genus	B-MED
Aurantimonas	I-MED
,	O
for	O
which	O
the	O
name	O
Aurantimonas	B-MED
endophytica	I-MED
sp	I-MED
.	I-MED
nov	I-MED
.	I-MED
is	O
proposed	O
.	O
The	O
type	O
strain	B-MED
is	O
EGI	B-MED
6500337	I-MED
T	I-MED
(=	O
KCTC	B-MED
52296	I-MED
T	I-MED
=	O
CPCC	B-MED
100904	I-MED
T	I-MED
)	O
.	O
Is	O
the	O
inactivation	B-MED
of	O
dentin	B-MED
proteases	B-MED
by	O
crosslinkers	B-MED
reversible	B-MED
?	O
Inactivation	B-MED
of	O
dentin	B-MED
proteases	B-MED
by	O
crosslinkers	B-MED
has	O
been	O
suggested	B-MED
as	O
a	O
way	O
to	O
prevent	B-MED
the	O
degradation	B-MED
of	O
dentin	B-MED
collagen	B-MED
in	O
the	O
hybrid	B-MED
layer	B-MED
.	O
However	O
,	O
it	O
is	O
not	B-MED
known	I-MED
if	O
the	O
inhibition	B-MED
is	O
reversible	B-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
evaluate	B-MED
the	O
inactivation	B-MED
effect	B-MED
of	O
various	O
crosslinkers	B-MED
on	O
dentin	B-MED
protease	B-MED
activity	B-MED
over	O
a	O
period	B-MED
of	O
6	O
months	O
.	O
Demineralized	B-MED
dentin	I-MED
beams	I-MED
(	O
1×2×6	O
mm	O
,	O
n=10	O
/	O
group	O
)	O
were	O
treated	B-MED
with	I-MED
(	O
1	O
)	O
1	O
%	O
glutaraldehyde	B-MED
(	O
GA1	B-MED
)	O
,	O
(	O
2	O
)	O
5	O
%	O
glutaraldehyde	B-MED
(	O
GA5	B-MED
)	O
,	O
(	O
3	O
)	O
1	O
%	O
grape	B-MED
seed	I-MED
extract	I-MED
(	O
GS1	B-MED
)	O
,	O
(	O
4	O
)	O
5	O
%	O
grape	B-MED
seed	I-MED
extract	I-MED
(	O
GS5	B-MED
)	O
,	O
(	O
5	O
)	O
10	O
%	O
sumac	B-MED
berry	I-MED
extract	I-MED
(	O
S	B-MED
)	O
,	O
(	O
6	O
)	O
20μM	B-MED
curcumin	I-MED
(	O
CR20	B-MED
)	O
,	O
and	O
(	O
7	O
)	O
200μM	O
curcumin	B-MED
(	O
CR200	B-MED
)	O
for	O
5min	O
.	O
Untreated	B-MED
beams	B-MED
served	O
as	O
control	B-MED
.	O
The	O
beams	B-MED
were	O
incubated	B-MED
up	O
to	O
6	O
months	O
and	O
incubation	B-MED
media	I-MED
were	O
used	O
to	O
analyze	B-MED
solubilized	B-MED
telopeptide	B-MED
(	O
ICTP	B-MED
and	O
CTX	B-MED
)	O
fragments	B-MED
as	O
indicators	B-MED
of	O
MMP	B-MED
-	O
and	O
cathepsin	B-MED
K	I-MED
-mediated	O
degradation	B-MED
after	O
1	O
,	O
3	O
and	O
6	O
months	O
of	O
incubation	B-MED
.	O
The	O
relative	B-MED
MMP	B-MED
activity	B-MED
of	O
dentin	B-MED
beams	I-MED
was	O
tested	O
using	O
a	O
generic	B-MED
MMP	B-MED
assay	B-MED
.	O
Data	B-MED
were	O
analyzed	B-MED
using	O
repeated	B-MED
-	I-MED
measures	I-MED
ANOVA	B-MED
,	O
α=0.05	O
.	O
All	O
treated	B-MED
groups	B-MED
showed	O
significant	B-MED
decrease	B-MED
in	O
CTX	B-MED
release	O
(	O
32.2	O
-	O
469.5pg	O
/	O
mg	O
dentin	B-MED
)	O
and	O
ICTP	B-MED
(	O
1.8	O
-	O
47.6ng	O
/	O
mg	O
dentin	B-MED
)	O
fragments	B-MED
during	O
the	O
first	O
month	O
of	O
incubation	B-MED
compared	B-MED
to	O
control	B-MED
(	O
1159pg	O
/	O
mg	O
and	O
72.9ng	O
/	O
mg	O
dentin	B-MED
,	O
respectively	O
)	O
.	O
GA5	B-MED
,	O
GS5	B-MED
and	O
CR200	B-MED
maintained	B-MED
their	O
inhibitory	B-MED
effect	B-MED
during	O
6	O
-	O
month	O
incubation	B-MED
.	O
The	O
results	B-MED
were	O
confirmed	O
by	O
dry	B-MED
mass	I-MED
loss	I-MED
and	O
relative	B-MED
MMP	B-MED
activity	B-MED
following	O
6	O
months	O
.	O
The	O
results	B-MED
of	O
this	O
study	B-MED
indicate	O
that	O
the	O
long	B-MED
-	I-MED
term	I-MED
effect	I-MED
is	O
both	O
crosslinker	B-MED
and	O
dose	B-MED
dependent	I-MED
.	O
The	O
Corneal	B-MED
Epithelial	I-MED
Barrier	B-MED
and	O
Its	O
Developmental	B-MED
Role	O
in	O
Isolating	B-MED
Corneal	B-MED
Epithelial	I-MED
and	O
Conjunctival	B-MED
Cells	I-MED
From	O
One	O
Another	O
During	O
development	B-MED
,	O
the	O
corneal	B-MED
epithelium	I-MED
(	O
CE	B-MED
)	O
and	O
the	O
conjunctiva	B-MED
are	O
derived	O
from	O
the	O
surface	B-MED
ectoderm	I-MED
.	O
Here	O
we	O
have	O
examined	B-MED
how	O
,	O
during	O
development	B-MED
,	O
the	O
cells	B-MED
of	O
these	O
two	O
issues	O
become	O
isolated	B-MED
from	O
each	O
other	O
.	O
Epithelia	B-MED
from	O
the	O
anterior	B-MED
eyes	I-MED
of	O
chicken	B-MED
embryos	I-MED
were	O
labeled	B-MED
with	O
the	O
fluorescent	B-MED
,	O
lipophilic	B-MED
dye	I-MED
,	O
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine	B-MED
perchlorate	I-MED
(	O
DiI	B-MED
)	O
.	O
DiI	B-MED
was	O
placed	O
on	O
the	O
epithelial	B-MED
surface	I-MED
of	O
the	O
developing	O
anterior	B-MED
eye	I-MED
and	O
its	O
diffusion	B-MED
was	O
monitored	O
by	O
fluorescence	B-MED
microscopy	I-MED
.	O
Concomitant	O
morphologic	B-MED
changes	B-MED
in	O
the	O
surface	B-MED
cells	I-MED
of	I-MED
these	I-MED
epithelial	I-MED
were	O
examined	B-MED
by	O
scanning	B-MED
electron	I-MED
microscopy	I-MED
.	O
Immunofluorescence	B-MED
was	O
used	O
to	O
analyze	O
the	O
expression	B-MED
of	O
cytokeratin	B-MED
K3	I-MED
,	O
ZO-1	B-MED
,	O
N	B-MED
-	I-MED
cadherin	I-MED
and	O
Connexin-43	B-MED
and	O
the	O
function	B-MED
of	O
gap	B-MED
junctions	I-MED
was	O
analyzed	B-MED
using	O
a	O
cut	B-MED
-	I-MED
loading	I-MED
with	O
the	O
fluorescent	B-MED
dye	I-MED
rhodamine	B-MED
-	I-MED
dextran	I-MED
.	O
Prior	O
to	O
embryonic	B-MED
day	B-MED
8	O
(	O
E	B-MED
8)	O
,	O
DiI	B-MED
placed	O
on	O
the	O
surface	B-MED
of	O
the	O
CE	B-MED
spreads	B-MED
throughout	O
all	O
the	O
epithelial	B-MED
cells	I-MED
of	O
the	O
anterior	B-MED
eye	I-MED
.	O
When	O
older	B-MED
eyes	I-MED
were	O
similarly	O
labeled	B-MED
,	O
dye	B-MED
diffusion	B-MED
was	O
restricted	B-MED
to	O
the	O
CE	B-MED
.	O
Similarly	O
,	O
diffusion	B-MED
of	O
DiI	B-MED
placed	O
on	O
the	O
conjunctival	B-MED
surface	B-MED
after	O
E	B-MED
8	O
was	O
restricted	B-MED
to	O
the	O
conjunctiva	B-MED
.	O
Scanning	B-MED
electron	I-MED
microscopy	I-MED
showed	O
that	O
developmentally	B-MED
(	O
1	O
)	O
physical	B-MED
separations	I-MED
progressively	B-MED
form	O
between	O
the	O
cells	B-MED
of	O
the	O
CE	B-MED
and	O
those	O
of	O
the	O
conjunctiva	B-MED
,	O
and	O
(	O
2	O
)	O
by	O
E	B-MED
8	O
these	O
separations	B-MED
form	O
a	O
ring	B-MED
that	O
completely	O
encompasses	O
the	O
cornea	B-MED
.	O
The	O
functional	B-MED
restriction	B-MED
of	O
gap	B-MED
junctions	I-MED
between	O
these	O
tissues	B-MED
did	O
not	O
occur	B-MED
until	O
E	B-MED
14	O
.	O
During	O
ocular	B-MED
development	I-MED
,	O
a	O
barrier	B-MED
to	O
the	O
diffusion	B-MED
of	O
DiI	B-MED
forms	O
between	O
the	O
contiguous	B-MED
CE	B-MED
and	O
conjunctiva	B-MED
prior	O
to	O
the	O
differential	B-MED
expression	B-MED
of	O
gap	B-MED
junctions	I-MED
within	O
these	O
tissues	B-MED
.	O
Body	B-MED
burden	I-MED
of	O
heavy	B-MED
metals	I-MED
among	O
HIV	B-MED
high	B-MED
risk	I-MED
population	I-MED
in	O
USA	B-MED
HIV	B-MED
high	B-MED
risk	I-MED
population	I-MED
may	O
face	O
not	O
only	O
the	O
threat	B-MED
of	O
HIV	B-MED
infection	I-MED
but	O
also	O
a	O
higher	B-MED
chance	B-MED
of	O
exposure	B-MED
to	I-MED
environmental	I-MED
contaminants	I-MED
.	O
However	O
,	O
no	O
previous	O
studies	B-MED
have	O
examined	B-MED
the	O
body	B-MED
burden	I-MED
of	O
environmental	B-MED
pollutants	I-MED
including	O
heavy	B-MED
metals	I-MED
among	O
HIV	B-MED
high	B-MED
risk	I-MED
populations	I-MED
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
investigate	O
whether	O
adults	B-MED
aged	I-MED
20	O
-	O
59	O
years	O
old	O
at	O
high	B-MED
risk	I-MED
of	I-MED
HIV	B-MED
infection	I-MED
have	O
higher	B-MED
blood	B-MED
levels	I-MED
of	I-MED
heavy	I-MED
metals	I-MED
compared	B-MED
to	O
those	O
with	O
low	B-MED
risk	I-MED
of	O
HIV	B-MED
infection	I-MED
in	O
United	B-MED
States	I-MED
.	O
We	O
used	O
the	O
National	B-MED
Health	I-MED
and	I-MED
Nutrition	I-MED
Examination	I-MED
Survey	I-MED
(	O
NHANES	B-MED
)	O
1999	O
-	O
2010	O
to	O
compare	B-MED
exposures	B-MED
to	I-MED
heavy	B-MED
metals	I-MED
including	O
cadmium	B-MED
,	O
lead	B-MED
,	O
and	O
total	O
mercury	B-MED
by	O
HIV	B-MED
risk	B-MED
status	I-MED
.	O
The	O
results	B-MED
showed	O
that	O
people	B-MED
at	O
high	B-MED
risk	I-MED
of	I-MED
HIV	B-MED
had	O
higher	B-MED
blood	B-MED
concentrations	I-MED
of	O
all	O
heavy	B-MED
metals	I-MED
compared	B-MED
to	O
their	O
counterparts	O
with	O
lower	B-MED
HIV	B-MED
risks	I-MED
.	O
In	O
multivariate	B-MED
linear	I-MED
regression	I-MED
models	B-MED
,	O
HIV	B-MED
risk	I-MED
status	O
was	O
significantly	O
associated	B-MED
with	I-MED
increased	B-MED
blood	B-MED
cadmium	I-MED
,	O
lead	B-MED
,	O
and	O
total	B-MED
mercury	I-MED
after	O
adjusting	B-MED
for	O
age	B-MED
,	O
sex	B-MED
,	O
race	B-MED
,	O
education	B-MED
,	O
and	O
poverty	B-MED
income	B-MED
ratio	B-MED
.	O
Our	O
study	B-MED
suggests	O
that	O
people	B-MED
at	O
high	B-MED
risk	I-MED
of	I-MED
HIV	B-MED
have	O
significantly	O
higher	B-MED
body	B-MED
burden	I-MED
of	O
heavy	B-MED
metals	I-MED
including	O
cadmium	B-MED
,	O
lead	B-MED
,	O
and	O
mercury	B-MED
compared	B-MED
to	O
those	O
with	O
low	B-MED
risk	I-MED
of	O
HIV	B-MED
.	O
Further	O
longitudinal	B-MED
study	I-MED
collecting	O
more	B-MED
pollutants	B-MED
are	O
warranted	B-MED
to	O
determine	O
the	O
potential	B-MED
health	B-MED
effects	B-MED
of	O
these	O
elevated	B-MED
pollutants	B-MED
on	O
both	O
HIV	B-MED
-	I-MED
infected	I-MED
and	O
HIV	B-MED
high	B-MED
-	I-MED
risk	I-MED
populations	I-MED
.	O
Double	B-MED
-	I-MED
Network	I-MED
Hydrogel	I-MED
with	O
Tunable	B-MED
Mechanical	B-MED
Performance	I-MED
and	O
Biocompatibility	B-MED
for	O
the	O
Fabrication	B-MED
of	O
Stem	B-MED
Cells	I-MED
-	O
Encapsulated	B-MED
Fibers	I-MED
and	O
3D	B-MED
Assemble	I-MED
Fabrication	B-MED
of	O
cell	B-MED
-	O
encapsulated	B-MED
fibers	I-MED
could	O
greatly	O
contribute	B-MED
to	O
tissue	B-MED
engineering	I-MED
and	O
regenerative	B-MED
medicine	I-MED
.	O
However	O
,	O
existing	B-MED
methods	B-MED
suffered	O
from	O
not	O
only	O
unavoidability	B-MED
of	O
cell	B-MED
damaging	I-MED
conditions	B-MED
and/or	O
sophisticated	B-MED
equipment	I-MED
,	O
but	O
also	O
unavailability	B-MED
of	O
proper	O
materials	B-MED
to	O
satisfy	O
both	O
mechanical	B-MED
and	O
biological	B-MED
expectations	B-MED
.	O
In	O
this	O
work	B-MED
,	O
a	O
simple	B-MED
method	B-MED
is	O
proposed	B-MED
to	O
prepare	B-MED
cell	B-MED
-	O
encapsulated	B-MED
fibers	I-MED
with	O
tunable	B-MED
mechanical	B-MED
strength	I-MED
and	O
stretching	B-MED
behavior	I-MED
as	O
well	O
as	O
diameter	B-MED
and	O
microstructure	B-MED
.	O
The	O
hydrogel	B-MED
fibers	B-MED
are	O
made	O
from	O
optimal	B-MED
combination	B-MED
of	O
alginate	B-MED
and	O
poly(N	B-MED
-	I-MED
iso	I-MED
-	I-MED
propylacrylamide)-poly(ethylene	I-MED
glycol	I-MED
)	I-MED
,	O
characteristics	O
of	O
double	B-MED
-	I-MED
network	I-MED
hydrogel	I-MED
,	O
with	O
enough	O
stiffness	B-MED
and	O
flexibility	B-MED
to	O
create	B-MED
a	O
variety	B-MED
of	O
three	B-MED
dimensional	I-MED
structures	I-MED
like	O
parallel	B-MED
helical	I-MED
and	O
different	B-MED
knots	B-MED
without	I-MED
crack	I-MED
.	O
Furthermore	O
,	O
such	O
hydrogel	B-MED
fibers	B-MED
exhibit	O
better	B-MED
compatibility	B-MED
as	O
indicated	B-MED
by	O
the	O
viability	B-MED
,	O
proliferation	B-MED
and	O
expression	B-MED
of	O
pluripotency	B-MED
markers	B-MED
of	O
embryonic	B-MED
stem	I-MED
cells	I-MED
encapsulated	B-MED
after	O
4	B-MED
-	I-MED
day	I-MED
culture	B-MED
.	O
The	O
double	B-MED
-	I-MED
network	I-MED
hydrogel	I-MED
possesses	B-MED
specific	B-MED
quick	B-MED
responses	B-MED
to	O
either	O
of	O
alginate	B-MED
lyase	I-MED
,	O
EDTA	B-MED
or	O
lower	O
environmental	B-MED
temperature	I-MED
which	O
facilitate	O
the	O
optional	O
degradation	B-MED
of	O
fibers	B-MED
or	O
fibrous	B-MED
assemblies	I-MED
to	O
release	O
the	O
cells	B-MED
encapsulated	B-MED
for	O
subsequent	B-MED
assay	B-MED
or	O
treatment	B-MED
.	O
Mimiviruses	B-MED
and	O
the	O
Human	B-MED
Interferon	B-MED
System	B-MED
:	O
Viral	B-MED
Evasion	I-MED
of	O
Classical	B-MED
Antiviral	B-MED
Activities	I-MED
,	O
But	O
Inhibition	B-MED
By	O
a	O
Novel	O
Interferon	B-MED
-	I-MED
β	I-MED
Regulated	B-MED
Immunomodulatory	B-MED
Pathway	B-MED
In	O
this	O
review	B-MED
we	O
discuss	O
the	O
role	B-MED
of	O
mimiviruses	B-MED
as	O
potential	B-MED
human	B-MED
pathogens	B-MED
focusing	O
on	O
clinical	B-MED
and	O
evolutionary	B-MED
evidence	B-MED
.	O
We	O
also	O
propose	B-MED
a	O
novel	O
antiviral	B-MED
immunomodulatory	B-MED
pathway	B-MED
controlled	B-MED
by	O
interferon	B-MED
-	I-MED
β	I-MED
(	O
IFN	B-MED
-	I-MED
β	I-MED
)	O
and	O
mediated	O
by	O
immune	B-MED
-	I-MED
responsive	I-MED
gene	I-MED
1	I-MED
(	O
IRG1	B-MED
)	O
and	O
itaconic	B-MED
acid	I-MED
,	O
its	O
product	B-MED
.	O
Acanthamoeba	B-MED
polyphaga	I-MED
Mimivirus	I-MED
(	O
APMV	B-MED
)	O
was	O
isolated	B-MED
from	O
amoebae	B-MED
in	O
a	O
hospital	B-MED
while	O
investigating	B-MED
a	O
pneumonia	B-MED
outbreak	B-MED
.	O
Mimivirus	B-MED
ubiquity	B-MED
and	O
role	B-MED
as	O
protist	B-MED
pathogens	B-MED
are	O
well	O
understood	O
,	O
and	O
its	O
putative	B-MED
status	B-MED
as	O
a	O
human	B-MED
pathogen	B-MED
has	O
been	O
gaining	B-MED
strength	B-MED
as	O
more	O
evidence	B-MED
is	O
being	O
found	O
.	O
The	O
study	B-MED
of	O
APMV	B-MED
and	O
human	B-MED
cells	B-MED
interaction	B-MED
revealed	O
that	O
the	O
virus	B-MED
is	O
able	O
to	O
evade	B-MED
the	O
IFN	B-MED
system	B-MED
by	O
inhibiting	B-MED
the	O
regulation	B-MED
of	O
interferon	B-MED
-stimulated	O
genes	B-MED
,	O
suggesting	O
that	O
the	O
virus	B-MED
and	O
humans	B-MED
have	O
had	O
host	B-MED
-	I-MED
pathogen	I-MED
interactions	I-MED
.	O
It	O
also	O
has	O
shown	O
that	O
the	O
virus	B-MED
is	O
capable	B-MED
of	O
growing	O
on	O
IFN	B-MED
-	I-MED
α2	I-MED
,	O
but	O
not	O
on	O
IFN	B-MED
-	I-MED
β	I-MED
-	O
treated	B-MED
cells	B-MED
,	O
hinting	O
at	O
an	O
exclusive	B-MED
IFN	B-MED
-	I-MED
β	I-MED
antiviral	B-MED
pathway	B-MED
.	O
Our	O
hypothesis	B-MED
based	B-MED
on	O
preliminary	B-MED
data	I-MED
and	O
published	B-MED
articles	I-MED
is	O
that	O
IFN	B-MED
-	I-MED
β	I-MED
preferentially	B-MED
upregulates	B-MED
IRG1	B-MED
in	I-MED
human	I-MED
macrophagic	B-MED
cells	I-MED
,	O
which	O
in	O
turn	O
produces	O
itaconic	B-MED
acid	I-MED
.	O
This	O
metabolite	B-MED
links	O
metabolism	B-MED
to	O
antiviral	B-MED
activity	I-MED
by	O
inactivating	B-MED
the	O
virus	B-MED
,	O
in	O
a	O
novel	O
immunomodulatory	B-MED
pathway	B-MED
relevant	B-MED
for	O
APMV	B-MED
infections	B-MED
and	O
probably	O
to	O
other	O
infectious	B-MED
diseases	I-MED
as	O
well	O
.	O
Optimization	O
of	O
Early	B-MED
Response	B-MED
Monitoring	I-MED
and	O
Prediction	O
of	O
Cancer	B-MED
Antiangiogenesis	B-MED
Therapy	I-MED
via	O
Noninvasive	B-MED
PET	B-MED
Molecular	I-MED
Imaging	I-MED
Strategies	O
of	O
Multifactorial	B-MED
Bioparameters	B-MED
Objective	O
:	O
Antiangiogenesis	B-MED
therapy	I-MED
(	O
AAT	B-MED
)	O
has	O
provided	O
substantial	O
benefits	O
regarding	O
improved	O
outcomes	O
and	O
survival	B-MED
for	O
suitable	O
patients	B-MED
in	O
clinical	B-MED
settings	I-MED
.	O
Therefore	O
,	O
the	O
early	B-MED
definition	O
of	O
therapeutic	B-MED
effects	I-MED
is	O
urgently	O
needed	O
to	O
guide	O
cancer	B-MED
AAT	B-MED
.	O
We	O
aimed	O
to	O
optimize	O
the	O
early	B-MED
response	B-MED
monitoring	I-MED
and	O
prediction	O
of	O
AAT	B-MED
efficacy	B-MED
,	O
as	O
indicated	O
by	O
the	O
multi	O
-	O
targeted	O
anti	B-MED
-	I-MED
angiogenic	I-MED
drug	I-MED
sunitinib	B-MED
in	O
U87MG	B-MED
tumors	I-MED
,	O
using	O
noninvasive	B-MED
positron	B-MED
emission	I-MED
computed	I-MED
tomography	I-MED
(	I-MED
PET	I-MED
)	I-MED
molecular	I-MED
imaging	I-MED
strategies	O
of	O
multifactorial	B-MED
bioparameters	B-MED
.	O
Methods	O
:	O
U87MG	B-MED
tumor	I-MED
mice	B-MED
were	O
treated	O
via	O
intragastric	B-MED
injections	B-MED
of	O
sunitinib	B-MED
(	O
80	O
mg	O
/	O
kg	O
)	O
or	O
vehicle	B-MED
for	O
7	O
consecutive	O
days	O
.	O
Longitudinal	B-MED
MicroPET	B-MED
/	I-MED
CT	I-MED
scans	I-MED
with	O
(	B-MED
18)F	I-MED
-	I-MED
FDG	I-MED
,	O
(	B-MED
18)F	I-MED
-	I-MED
FMISO	I-MED
,	I-MED
(	B-MED
18)F	I-MED
-	I-MED
ML-10	I-MED
and	O
(	B-MED
18)F	I-MED
-	I-MED
Alfatide	I-MED
II	I-MED
were	O
acquired	O
to	O
quantitatively	O
measure	O
metabolism	B-MED
,	O
hypoxia	B-MED
,	O
apoptosis	B-MED
and	O
angiogenesis	B-MED
on	O
days	O
0	O
,	O
1	O
,	O
3	O
,	O
7	O
and	O
13	O
following	O
therapy	B-MED
initiation	O
.	O
Tumor	B-MED
tissues	I-MED
from	O
a	O
dedicated	O
group	O
of	O
mice	B-MED
were	O
collected	O
for	O
immunohistochemical	B-MED
(	O
IHC	B-MED
)	O
analysis	O
of	O
key	O
biomarkers	B-MED
(	O
Glut-1	B-MED
,	O
CA	B-MED
-	I-MED
IX	I-MED
,	O
TUNEL	B-MED
,	O
ανβ3	B-MED
and	O
CD31	B-MED
)	O
at	O
the	O
time	O
points	O
of	O
PET	B-MED
imaging	I-MED
.	O
The	O
tumor	B-MED
sizes	I-MED
and	O
mouse	B-MED
weights	B-MED
were	O
measured	O
throughout	O
the	O
study	O
.	O
The	O
tumor	B-MED
uptake	B-MED
(	O
ID%/gmax	O
)	O
,	O
the	O
ratios	O
of	O
the	O
tumor	B-MED
/	O
muscle	B-MED
(	O
T	B-MED
/	O
M	B-MED
)	O
for	O
each	O
probe	O
,	O
and	O
the	O
tumor	B-MED
growth	I-MED
ratios	B-MED
(	O
TGR	B-MED
)	O
were	O
calculated	O
and	O
used	O
for	O
statistical	B-MED
analyses	I-MED
of	O
the	O
differences	O
and	O
correlations	O
.	O
Results	O
:	O
Sunitinib	B-MED
successfully	O
inhibited	O
U87MG	B-MED
tumor	I-MED
growth	I-MED
with	O
significant	O
differences	O
in	O
the	O
tumor	B-MED
size	I-MED
from	O
day	O
9	O
after	O
sunitinib	B-MED
treatment	B-MED
compared	O
with	O
the	O
control	B-MED
group	I-MED
(	O
P	O
<	O
0.01	O
)	O
.	O
The	O
uptakes	B-MED
of	O
(	B-MED
18)F	I-MED
-	I-MED
FMISO	I-MED
(	O
reduced	O
hypoxia	B-MED
)	O
,	O
(	B-MED
18)F	I-MED
-	I-MED
ML-10	I-MED
(	O
increased	O
apoptosis	B-MED
)	O
and	O
(	B-MED
18)F	I-MED
-	I-MED
Alfatide	I-MED
II	I-MED
(	O
decreased	O
angiogenesis	B-MED
)	O
in	O
the	O
tumor	B-MED
lesions	B-MED
significantly	O
changed	O
during	O
the	O
early	B-MED
early	B-MED
stage	I-MED
(	O
days	O
1	O
to	O
3	O
)	O
of	O
sunitinib	B-MED
treatment	B-MED
;	O
however	O
,	O
the	O
uptake	B-MED
of	O
(	B-MED
18)F	I-MED
-	I-MED
FDG	I-MED
(	O
increased	O
glucose	B-MED
metabolism	I-MED
)	O
was	O
significantly	O
different	O
during	O
the	O
late	B-MED
stage	I-MED
.	O
The	O
PET	B-MED
imaging	I-MED
data	O
of	O
each	O
probe	O
were	O
all	O
confirmed	O
via	O
ex	B-MED
vivo	I-MED
IHC	B-MED
of	O
the	O
relevant	O
biomarkers	B-MED
.	O
Notably	O
,	O
the	O
PET	B-MED
imaging	I-MED
of	O
(	B-MED
18)F	I-MED
-	I-MED
Alfatide	I-MED
II	I-MED
and	O
(	B-MED
18)F	I-MED
-	I-MED
FMISO	I-MED
was	O
significantly	O
correlated	O
(	O
all	O
P	O
<	O
0.05	O
)	O
with	O
TGR	B-MED
,	O
whereas	O
the	O
imaging	O
of	O
(	B-MED
18)F	I-MED
-	I-MED
FDG	I-MED
and	O
(	B-MED
18)F	I-MED
-	I-MED
ML-10	I-MED
was	O
not	O
significantly	O
correlated	O
with	O
TGR	B-MED
.	O
Conclusion	O
:	O
Based	O
on	O
the	O
tumor	B-MED
uptake	B-MED
of	O
the	O
PET	B-MED
probes	O
and	O
their	O
correlations	O
with	O
MVD	B-MED
and	O
TGR	B-MED
,	O
(	B-MED
18)F	I-MED
-	I-MED
Alfatide	I-MED
II	I-MED
PET	B-MED
may	O
not	O
only	O
monitor	O
the	O
early	B-MED
response	B-MED
but	O
also	O
precisely	O
predict	O
the	O
therapeutic	B-MED
efficacy	I-MED
of	O
the	O
multi	O
-	O
targeted	O
,	O
anti	B-MED
-	I-MED
angiogenic	I-MED
drug	I-MED
sunitinib	B-MED
in	O
U87MG	B-MED
tumors	I-MED
.	O
In	O
conclusion	O
,	O
it	O
is	O
feasible	O
to	O
optimize	O
the	O
early	B-MED
response	B-MED
monitoring	I-MED
and	O
efficacy	B-MED
prediction	O
of	O
cancer	B-MED
AAT	B-MED
using	O
noninvasive	B-MED
PET	B-MED
molecular	I-MED
imaging	I-MED
strategies	O
of	O
multifactorial	B-MED
bioparameters	B-MED
,	O
such	O
as	O
angiogenesis	B-MED
imaging	B-MED
with	O
(	B-MED
18)F	I-MED
-	I-MED
Alfatide	I-MED
II	I-MED
,	O
which	O
represents	O
an	O
RGD	B-MED
-based	O
probe	O
.	O
Allergen	B-MED
Valency	B-MED
,	O
Dose	B-MED
,	O
and	O
FcεRI	B-MED
Occupancy	B-MED
Set	O
Thresholds	B-MED
for	O
Secretory	B-MED
Responses	I-MED
to	O
Pen	B-MED
a	I-MED
1	I-MED
and	O
Motivate	O
Design	B-MED
of	O
Hypoallergens	B-MED
Ag	B-MED
-mediated	O
crosslinking	B-MED
of	O
IgE	B-MED
-	O
FcεRI	B-MED
complexes	B-MED
activates	O
mast	B-MED
cells	I-MED
and	O
basophils	B-MED
,	O
initiating	O
the	O
allergic	B-MED
response	I-MED
.	O
Of	O
34	O
donors	O
recruited	O
having	O
self	B-MED
-	I-MED
reported	I-MED
shrimp	B-MED
allergy	I-MED
,	O
only	O
35	O
%	O
had	O
significant	O
levels	O
of	O
shrimp	B-MED
-	I-MED
specific	I-MED
IgE	I-MED
in	O
serum	B-MED
and	O
measurable	O
basophil	B-MED
secretory	B-MED
responses	B-MED
to	O
rPen	B-MED
a	I-MED
1	I-MED
(	O
shrimp	B-MED
tropomyosin	B-MED
)	O
.	O
We	O
report	O
that	O
degranulation	O
is	O
linked	O
to	O
the	O
number	O
of	O
FcεRI	B-MED
occupied	O
with	O
allergen	B-MED
-	I-MED
specific	I-MED
IgE	I-MED
,	O
as	O
well	O
as	O
the	O
dose	B-MED
and	O
valency	B-MED
of	O
Pen	B-MED
a	I-MED
1	I-MED
.	O
Using	O
clustered	B-MED
regularly	I-MED
interspaced	I-MED
palindromic	I-MED
repeat	I-MED
-	I-MED
based	I-MED
gene	I-MED
editing	I-MED
,	O
human	O
RBL(rαKO	O
)	O
cells	O
were	O
created	O
that	O
exclusively	O
express	O
the	O
human	O
FcεRIα	B-MED
subunit	O
.	O
Pen	B-MED
a	I-MED
1	I-MED
-	O
specific	B-MED
IgE	I-MED
was	O
affinity	O
purified	O
from	O
shrimp	B-MED
-	O
positive	B-MED
plasma	B-MED
.	O
Cells	O
primed	O
with	O
a	O
range	O
of	O
Pen	B-MED
a	I-MED
1	I-MED
-	O
specific	B-MED
IgE	I-MED
and	O
challenged	O
with	O
Pen	B-MED
a	I-MED
1	I-MED
showed	O
a	O
bell	O
-	O
shaped	O
dose	B-MED
response	B-MED
for	I-MED
secretion	I-MED
,	O
with	O
optimal	O
Pen	B-MED
a	I-MED
1	I-MED
doses	B-MED
of	O
0.1	O
-	O
10	O
ng	O
/	O
ml	O
.	O
Mathematical	B-MED
modeling	I-MED
provided	O
estimates	O
of	O
receptor	B-MED
aggregation	I-MED
kinetics	B-MED
based	O
on	O
FcεRI	B-MED
occupancy	O
with	O
IgE	B-MED
and	O
allergen	B-MED
dose	B-MED
.	O
Maximal	O
degranulation	O
was	O
elicited	O
when	O
∼2700	O
I	O
gE	B-MED
-	O
FcεRI	B-MED
complexes	B-MED
were	O
occupied	O
with	O
specific	B-MED
IgE	I-MED
and	O
challenged	O
with	O
Pen	B-MED
a	I-MED
1	I-MED
(	O
IgE	B-MED
epitope	B-MED
valency	B-MED
of	O
≥8	O
)	O
,	O
although	O
measurable	O
responses	O
were	O
achieved	O
when	O
only	O
a	O
few	O
hundred	O
FcεRI	B-MED
were	O
occupied	O
.	O
Prolonged	O
periods	O
of	O
pepsin	B-MED
-mediated	O
Pen	B-MED
a	I-MED
1	I-MED
proteolysis	B-MED
,	O
which	O
simulates	O
gastric	B-MED
digestion	B-MED
,	O
were	O
required	O
to	O
diminish	O
secretory	B-MED
responses	I-MED
.	O
Recombinant	B-MED
fragments	I-MED
(	O
60	O
-	O
79	O
aa	O
)	O
,	O
which	O
together	O
span	O
the	O
entire	O
length	O
of	O
tropomyosin	B-MED
,	O
were	O
weak	O
secretagogues	O
.	O
These	O
fragments	O
have	O
reduced	O
dimerization	B-MED
capacity	B-MED
,	O
compete	O
with	O
intact	O
Pen	B-MED
a	I-MED
1	I-MED
for	O
binding	O
to	O
IgE	B-MED
-	O
FcεRI	B-MED
complexes	B-MED
,	O
and	O
represent	O
a	O
starting	O
point	O
for	O
the	O
design	O
of	O
promising	O
hypoallergens	B-MED
for	O
immunotherapy	B-MED
.	O
Identification	B-MED
of	O
a	O
group	B-MED
of	O
XTHs	B-MED
genes	B-MED
responding	O
to	O
heavy	B-MED
metal	I-MED
mercury	B-MED
,	O
salinity	B-MED
and	I-MED
drought	I-MED
stresses	I-MED
in	O
Medicago	B-MED
truncatula	I-MED
Xyloglucan	B-MED
endotransglucosylase	I-MED
/	I-MED
hydrolases	I-MED
(	O
XTH	B-MED
)	O
are	O
one	O
of	O
the	O
key	O
enzymes	B-MED
regulating	B-MED
cell	B-MED
wall	I-MED
construction	I-MED
,	O
extension	B-MED
and	O
metabolism	B-MED
.	O
In	O
the	O
study	B-MED
,	O
44	O
XTH	B-MED
protein	I-MED
genes	B-MED
from	O
Medicago	B-MED
truncatula	I-MED
genome	B-MED
were	O
identified	O
using	O
bioinformatics	B-MED
,	O
microarray	B-MED
and	O
RT	B-MED
-	I-MED
PCR	I-MED
.	O
Each	O
XTH	B-MED
was	O
showed	O
to	O
possess	O
a	O
highly	B-MED
conserved	I-MED
domain	I-MED
(	O
(	O
D	O
/	O
N)-E-(I	O
/	O
L	O
/	O
F	O
/	O
V)-D-(F	O
/	O
I	O
/	O
L)-E-(F	O
/	O
L)-L	O
-	O
G	O
)	O
,	O
and	O
most	O
of	O
XTHs	B-MED
possess	O
four	O
Cys	B-MED
in	O
the	O
C	B-MED
terminal	I-MED
region	I-MED
,	O
which	O
suggests	O
the	O
potential	B-MED
for	O
generating	O
disulfide	B-MED
bonds	I-MED
.	O
Based	O
on	O
the	O
XTH	B-MED
protein	B-MED
sequences	I-MED
,	O
these	O
XTHs	B-MED
can	O
be	O
classified	O
into	O
three	O
major	O
families	B-MED
and	O
each	O
family	B-MED
can	O
be	O
subdivided	O
into	O
more	O
groups	B-MED
.	O
Examination	O
of	O
the	O
genomic	B-MED
location	I-MED
of	O
XTH	B-MED
genes	I-MED
on	O
M.	B-MED
truncatula	I-MED
chromosomes	B-MED
showed	O
that	O
the	O
evolutional	B-MED
expansion	I-MED
of	O
the	O
genes	B-MED
was	O
possibly	O
attributed	O
to	O
localized	B-MED
gene	B-MED
duplications	I-MED
.	O
To	O
investigate	O
the	O
possible	O
involvement	B-MED
of	O
the	O
XTHs	B-MED
responding	O
to	O
heavy	B-MED
metals	I-MED
and	O
other	O
abiotic	B-MED
stresses	I-MED
,	O
the	O
XTH	B-MED
genes	I-MED
were	O
exposed	O
to	O
heavy	B-MED
metal	I-MED
(	O
Hg	B-MED
or	O
Cu	B-MED
)	O
,	O
salt	B-MED
and	I-MED
drought	I-MED
stresses	I-MED
.	O
There	O
were	O
28	O
,	O
21	O
and	O
21	O
MtXTH	B-MED
genes	I-MED
found	O
to	O
respond	O
to	O
HgCl2	B-MED
,	O
salt	B-MED
and	I-MED
drought	I-MED
stresses	I-MED
,	O
respectively	O
,	O
but	O
their	O
expression	B-MED
were	O
different	O
under	O
the	O
stresses	B-MED
.	O
Some	O
of	O
the	O
XTH	B-MED
genes	I-MED
were	O
well	O
confirmed	O
by	O
quantitative	B-MED
RT	B-MED
-	I-MED
PCR	I-MED
(	O
qRT	B-MED
-	I-MED
PCR	I-MED
)	O
.	O
We	O
further	O
specified	B-MED
expression	B-MED
of	O
a	O
XTH	B-MED
gene	I-MED
Medtr4g128580	B-MED
(	O
MtXTH3	B-MED
)	O
under	O
different	O
environmental	B-MED
stresses	I-MED
,	O
and	O
showed	O
that	O
MtXTH3	B-MED
was	O
induced	O
by	O
Hg	B-MED
exposure	B-MED
.	O
These	O
results	B-MED
indicated	O
that	O
a	O
group	B-MED
of	O
MtXTHs	B-MED
could	O
be	O
differentially	O
expressed	B-MED
under	O
the	O
environmental	B-MED
stresses	I-MED
.	O
Functional	B-MED
analyses	I-MED
of	O
OcRhS1	B-MED
and	O
OcUER1	B-MED
involved	O
in	O
UDP	B-MED
-	I-MED
L	I-MED
-	I-MED
rhamnose	I-MED
biosynthesis	B-MED
in	O
Ornithogalum	B-MED
caudatum	I-MED
UDP	B-MED
-	I-MED
L	I-MED
-	I-MED
rhamnose	I-MED
(	O
UDP	B-MED
-	I-MED
Rha	I-MED
)	O
is	O
an	O
important	O
sugar	B-MED
donor	I-MED
for	O
the	O
synthesis	B-MED
of	O
rhamnose	B-MED
-containing	O
compounds	B-MED
in	O
plants	B-MED
.	O
However	O
,	O
only	O
a	O
few	O
enzymes	B-MED
and	O
their	O
encoding	B-MED
genes	B-MED
involved	O
in	O
UDP	B-MED
-	I-MED
Rha	I-MED
biosynthesis	B-MED
are	O
available	O
in	O
plants	B-MED
.	O
Here	O
,	O
two	O
genes	B-MED
encoding	B-MED
rhamnose	B-MED
synthase	I-MED
(	O
RhS	B-MED
)	O
and	O
bi	B-MED
-	I-MED
functional	I-MED
UDP-4	B-MED
-	I-MED
keto-6	I-MED
-	I-MED
deoxy	I-MED
-	I-MED
D	I-MED
-	I-MED
glucose	I-MED
(	O
UDP-4K6DG	B-MED
)	O
3	B-MED
,	I-MED
5	I-MED
-	I-MED
epimerase	I-MED
/	I-MED
UDP-4	I-MED
-	I-MED
keto	I-MED
-	I-MED
L	I-MED
-	I-MED
rhamnose	I-MED
(	O
UDP-4KR	B-MED
)	O
4	B-MED
-	I-MED
keto	I-MED
-	I-MED
reductase	I-MED
(	O
UER	B-MED
)	O
were	O
isolated	O
from	O
Ornithogalum	B-MED
caudatum	I-MED
based	O
on	O
the	O
RNA	B-MED
-	O
Seq	B-MED
data	I-MED
.	O
The	O
OcRhS1	B-MED
gene	I-MED
has	O
an	O
ORF	B-MED
(	O
open	B-MED
reading	I-MED
frame	I-MED
)	O
of	O
2019	O
bp	O
encoding	B-MED
a	O
tri	B-MED
-	I-MED
functional	I-MED
RhS	I-MED
enzyme	I-MED
.	O
In	B-MED
vitro	I-MED
enzymatic	B-MED
assays	I-MED
revealed	B-MED
OcRhS1	B-MED
can	O
really	O
convert	O
UDP	B-MED
-	I-MED
D	I-MED
-	I-MED
glucose	I-MED
(	O
UDP	B-MED
-	I-MED
Glc	I-MED
)	O
into	O
UDP	B-MED
-	I-MED
Rha	I-MED
via	O
three	O
consecutive	B-MED
reactions	B-MED
.	O
Biochemical	B-MED
evidences	B-MED
indicated	O
that	O
the	O
recombinant	B-MED
OcRhS1	I-MED
was	O
active	O
in	O
the	O
pH	O
range	O
of	O
5	O
-	O
11	O
and	O
over	O
the	O
temperature	B-MED
range	I-MED
of	O
0	O
-	O
60	O
°	O
C	O
.	O
The	O
Km	B-MED
value	B-MED
of	O
OcRhS1	B-MED
for	O
UDP	B-MED
-	I-MED
Glc	I-MED
was	O
determined	O
to	O
be	O
1.52	O
×	O
10(-4	O
)	O
M.	O
OcRhS1	B-MED
is	O
a	O
multi	B-MED
-	I-MED
domain	I-MED
protein	I-MED
with	O
two	O
sets	O
of	O
cofactor	B-MED
-	I-MED
binding	I-MED
motifs	I-MED
.	O
The	O
cofactors	B-MED
dependent	O
properties	O
of	O
OcRhS1	B-MED
were	O
thus	O
characterized	O
in	O
this	O
research	B-MED
.	O
Moreover	O
,	O
the	O
N	B-MED
-	I-MED
terminal	I-MED
portion	I-MED
of	I-MED
OcRhS1	I-MED
(	O
OcRhS1	B-MED
-	I-MED
N	I-MED
)	O
was	O
observed	O
to	O
metabolize	B-MED
UDP	B-MED
-	I-MED
Glc	I-MED
to	O
form	O
intermediate	O
UDP-4K6DG	B-MED
.	O
OcUER1	B-MED
contains	O
an	O
ORF	B-MED
of	O
906	O
bp	O
encoding	B-MED
a	O
polypeptide	B-MED
of	O
301	O
aa	B-MED
.	O
OcUER1	B-MED
shared	O
high	O
similarity	O
with	O
the	O
carboxy	B-MED
-	I-MED
terminal	I-MED
domain	I-MED
of	I-MED
OcRhS1	I-MED
(	O
OcRhS1	B-MED
-	I-MED
C	I-MED
)	O
,	O
suggesting	O
its	O
intrinsic	O
ability	O
of	O
converting	O
UDP-4K6DG	B-MED
into	O
UDP	B-MED
-	I-MED
Rha	I-MED
.	O
It	O
was	O
thus	O
reasonably	O
inferred	O
that	O
UDP	B-MED
-	I-MED
Glc	I-MED
could	O
be	O
bio	B-MED
-	I-MED
transformed	I-MED
into	O
UDP	B-MED
-	I-MED
Rha	I-MED
under	O
the	O
collaborating	O
action	O
of	O
OcRhS1	B-MED
-	I-MED
N	I-MED
and	O
OcUER1	B-MED
.	O
The	O
subsequently	O
biochemical	B-MED
assay	I-MED
verified	O
this	O
notion	O
.	O
Importantly	O
,	O
expression	B-MED
profiles	I-MED
of	O
OcRhS1	B-MED
and	O
OcUER1	B-MED
revealed	B-MED
their	O
possible	O
involvement	O
in	O
the	O
biosynthesis	B-MED
of	O
rhamnose	B-MED
-containing	O
polysaccharides	B-MED
in	O
O.	B-MED
caudatum	I-MED
.	O
Iodine	B-MED
Storage	I-MED
and	O
Metabolism	B-MED
of	O
Mild	B-MED
to	I-MED
Moderate	I-MED
Iodine	B-MED
-	I-MED
Deficient	I-MED
Pregnant	B-MED
Rats	B-MED
Severe	B-MED
iodine	I-MED
deficiency	I-MED
during	B-MED
pregnancy	I-MED
results	I-MED
in	O
neurodevelopmental	B-MED
disorders	I-MED
in	O
children	B-MED
,	O
while	O
the	O
consequences	B-MED
of	I-MED
mild	B-MED
to	I-MED
moderate	I-MED
iodine	I-MED
deficiency	I-MED
(	O
MMID	B-MED
)	O
are	O
uncertain	B-MED
.	O
The	O
concentration	B-MED
of	I-MED
iodine	I-MED
in	O
the	O
thyroid	B-MED
is	O
the	O
most	O
accurate	O
indicator	O
of	O
iodine	B-MED
nutrition	I-MED
.	O
This	O
study	O
aimed	O
to	O
evaluate	O
whether	O
the	O
iodine	B-MED
stores	I-MED
in	O
the	O
thyroid	B-MED
cover	I-MED
the	O
needs	O
of	O
the	O
mother	B-MED
and	I-MED
the	I-MED
fetus	I-MED
in	O
iodine	B-MED
-	O
sufficient	B-MED
and	O
MMID	B-MED
conditions	O
by	O
inductively	B-MED
coupled	I-MED
plasma	I-MED
-	I-MED
mass	I-MED
spectrometry	I-MED
.	O
One	O
hundred	O
four	O
-	O
week	O
-	O
old	O
female	B-MED
Wistar	I-MED
rats	I-MED
were	O
randomly	O
divided	O
into	O
MMID	B-MED
(	O
low	B-MED
iodine	I-MED
intake	I-MED
[	O
L	O
]	O
)	O
and	O
normal	B-MED
(	O
normal	B-MED
iodine	I-MED
intake	I-MED
[	O
N	O
]	O
)	O
groups	B-MED
.	O
The	O
rats	B-MED
were	O
fed	B-MED
for	I-MED
the	I-MED
next	I-MED
three	I-MED
months	I-MED
,	O
and	O
after	B-MED
pregnancy	I-MED
they	O
were	O
further	O
divided	B-MED
into	I-MED
two	I-MED
subgroups	I-MED
,	O
respectively	O
:	O
low	B-MED
iodine	I-MED
pregnancy	B-MED
(	O
LP	B-MED
)	O
and	O
low	B-MED
iodine	I-MED
pregnancy	B-MED
with	O
iodine	B-MED
supplement	I-MED
(	O
LP+	B-MED
)	O
,	O
and	O
normal	B-MED
iodine	I-MED
intake	I-MED
pregnancy	B-MED
(	O
NP	B-MED
)	O
and	O
normal	B-MED
iodine	I-MED
intake	I-MED
pregnancy	B-MED
with	O
iodine	B-MED
supplement	I-MED
(	O
NP+	B-MED
)	O
.	O
The	O
iodine	B-MED
intake	I-MED
of	O
pregnant	B-MED
rats	B-MED
in	O
the	O
NP+	B-MED
and	O
LP+	B-MED
groups	I-MED
was	O
twice	O
as	O
much	O
as	O
in	O
the	O
NP	B-MED
and	O
LP	B-MED
groups	I-MED
.	O
The	O
rats	B-MED
were	O
sacrificed	O
on	O
gestational	B-MED
day	I-MED
15	O
and	O
postnatal	B-MED
day	I-MED
7	O
.	O
The	O
iodine	B-MED
concentration	I-MED
in	O
the	O
thyroid	B-MED
of	O
the	O
maternal	B-MED
and	O
newborn	B-MED
rats	B-MED
,	O
maternal	B-MED
serum	I-MED
,	O
placenta	B-MED
,	O
and	O
amniotic	B-MED
fluid	I-MED
were	O
determined	O
by	O
inductively	B-MED
coupled	I-MED
plasma	I-MED
-	I-MED
mass	I-MED
spectrometry	I-MED
.	O
The	O
concentration	B-MED
of	I-MED
iodine	I-MED
in	O
the	O
thyroid	B-MED
of	O
the	O
N	B-MED
group	I-MED
was	O
significantly	B-MED
higher	I-MED
than	O
that	O
in	O
the	O
L	B-MED
group	I-MED
before	B-MED
pregnancy	I-MED
.	O
The	O
concentration	B-MED
of	I-MED
iodine	I-MED
in	O
the	O
maternal	B-MED
thyroids	I-MED
of	O
the	O
LP	B-MED
group	I-MED
decreased	O
during	B-MED
pregnancy	I-MED
,	O
whereas	O
that	O
of	O
the	O
NP	B-MED
group	I-MED
did	O
not	O
change	O
significantly	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
iodine	B-MED
concentration	I-MED
in	O
the	O
thyroid	B-MED
of	O
mothers	B-MED
and	O
offspring	B-MED
between	O
the	O
NP	B-MED
and	O
NP+	B-MED
groups	I-MED
,	O
but	O
it	O
was	O
significant	O
between	O
LP	B-MED
and	O
LP+	B-MED
groups	I-MED
.	O
The	O
concentration	B-MED
of	I-MED
iodine	I-MED
in	O
amniotic	B-MED
fluid	I-MED
was	O
significantly	O
different	O
between	O
the	O
four	O
groups	B-MED
.	O
There	O
is	O
sufficient	O
iodine	B-MED
storage	I-MED
in	O
the	O
thyroid	B-MED
of	O
maternal	B-MED
rats	B-MED
with	O
normal	B-MED
iodine	I-MED
intake	I-MED
during	B-MED
pregnancy	I-MED
,	O
and	O
there	O
is	O
no	O
need	O
for	O
iodine	B-MED
supplementation	I-MED
.	O
However	O
,	O
iodine	B-MED
stores	I-MED
are	O
insufficient	O
in	O
rats	B-MED
with	O
MMID	B-MED
.	O
Iodine	B-MED
supplementation	I-MED
can	O
increase	O
the	O
iodine	B-MED
concentration	I-MED
in	O
the	O
thyroid	B-MED
of	O
maternal	B-MED
rats	B-MED
with	O
MMID	B-MED
and	O
their	O
offspring	B-MED
,	O
as	O
well	O
as	O
in	O
the	O
amniotic	B-MED
fluid	I-MED
during	B-MED
pregnancy	I-MED
.	O
Methods	B-MED
to	O
Study	B-MED
Autophagy	B-MED
in	O
Zebrafish	B-MED
Autophagy	B-MED
(	O
cellular	B-MED
self	I-MED
-	I-MED
eating	I-MED
)	O
is	O
a	O
highly	O
regulated	O
degradation	B-MED
process	I-MED
of	O
the	O
eukaryotic	B-MED
cell	I-MED
during	O
which	O
parts	O
of	O
the	O
cytoplasm	B-MED
are	O
delivered	B-MED
into	O
,	O
and	O
broken	B-MED
down	I-MED
within	O
,	O
the	O
lysosomal	B-MED
compartment	I-MED
.	O
The	O
process	O
serves	O
as	O
a	O
main	O
route	O
for	O
the	O
elimination	B-MED
of	O
superfluous	O
and	O
damaged	O
cellular	B-MED
constituents	I-MED
,	O
thereby	O
mediating	O
macromolecular	B-MED
and	O
organellar	B-MED
turnover	I-MED
.	O
In	O
addition	O
to	O
maintaining	O
cellular	B-MED
homeostasis	I-MED
,	O
autophagy	B-MED
is	O
involved	O
in	O
various	O
other	O
cellular	B-MED
and	O
developmental	B-MED
processes	I-MED
by	O
degrading	B-MED
specific	O
regulatory	B-MED
proteins	I-MED
,	O
and	O
contributing	O
to	O
the	O
clearance	O
of	O
intracellular	B-MED
pathogens	B-MED
.	O
The	O
physiological	B-MED
roles	I-MED
and	O
pathological	B-MED
involvement	O
of	O
autophagy	B-MED
can	O
be	O
effectively	O
studied	O
in	O
divergent	O
eukaryotic	B-MED
model	B-MED
systems	I-MED
ranging	O
from	O
yeast	B-MED
to	O
mice	B-MED
.	O
Such	O
a	O
tractable	O
animal	B-MED
model	I-MED
applied	O
only	O
recently	O
for	O
autophagy	B-MED
researchis	O
the	O
zebrafish	B-MED
Danio	B-MED
rerio	I-MED
,	O
which	O
also	O
facilitates	O
the	O
analysis	B-MED
of	O
more	O
specific	O
biological	B-MED
processes	I-MED
such	O
as	O
tissue	B-MED
regeneration	I-MED
.	O
In	O
this	O
chapter	O
,	O
we	O
overview	O
the	O
main	O
methods	B-MED
and	I-MED
tools	I-MED
that	O
are	O
used	O
to	O
monitor	O
autophagic	B-MED
structures	I-MED
and	O
to	O
assay	B-MED
autophagic	B-MED
responses	I-MED
in	O
this	O
vertebrate	B-MED
organism	I-MED
.	O
We	O
place	O
emphasis	O
on	O
genetic	B-MED
(	I-MED
functional	I-MED
)	I-MED
approaches	I-MED
applied	O
for	O
exploring	O
novel	O
cellular	B-MED
and	O
developmental	B-MED
roles	I-MED
of	O
the	O
autophagic	B-MED
process	I-MED
.	O
Prostate	B-MED
external	I-MED
beam	I-MED
radiotherapy	I-MED
combined	B-MED
with	O
high	B-MED
-	I-MED
dose	I-MED
-	I-MED
rate	I-MED
brachytherapy	I-MED
:	O
dose	B-MED
-	O
volume	B-MED
parameters	B-MED
from	O
deformably	B-MED
-	I-MED
registered	I-MED
plans	I-MED
correlate	B-MED
with	O
late	B-MED
gastrointestinal	B-MED
complications	I-MED
Derivation	B-MED
of	O
dose	B-MED
-	O
volume	B-MED
correlated	B-MED
with	O
toxicity	B-MED
for	O
multi	B-MED
-	I-MED
modal	I-MED
treatments	I-MED
can	O
be	O
difficult	B-MED
due	O
to	O
the	O
perceived	O
need	O
for	O
voxel	B-MED
-	I-MED
by	I-MED
-	I-MED
voxel	I-MED
dose	I-MED
accumulation	I-MED
.	O
With	O
data	B-MED
available	O
for	O
a	O
single	B-MED
-	O
institution	B-MED
cohort	B-MED
with	O
long	B-MED
follow	B-MED
-	I-MED
up	I-MED
,	O
an	O
investigation	B-MED
was	O
undertaken	O
into	O
rectal	B-MED
dose	B-MED
-	O
volume	B-MED
effects	B-MED
for	O
gastrointestinal	B-MED
toxicities	I-MED
after	O
deformably	O
-	O
registering	O
each	O
phase	B-MED
of	O
a	O
combined	B-MED
external	B-MED
beam	I-MED
radiotherapy	I-MED
EBRT	B-MED
(	O
EBRT)/	O
high	B-MED
-	I-MED
dose	I-MED
-	I-MED
rate	I-MED
(	I-MED
HDR	I-MED
)	I-MED
brachytherapy	I-MED
prostate	B-MED
treatment	I-MED
.	O
One	O
hundred	O
and	O
eighteen	O
patients	B-MED
received	O
EBRT	B-MED
in	O
23	O
fractions	B-MED
of	O
2	O
Gy	B-MED
and	O
HDR	B-MED
(	O
TG43	B-MED
algorithm	I-MED
)	O
in	O
3	O
fractions	B-MED
of	O
6.5	O
Gy	B-MED
.	O
Results	B-MED
for	O
the	O
Late	B-MED
Effects	I-MED
of	I-MED
Normal	I-MED
Tissues	I-MED
-	I-MED
Subjective	I-MED
,	I-MED
Objective	I-MED
,	I-MED
Management	I-MED
and	I-MED
Analytic	I-MED
toxicity	I-MED
assessments	I-MED
were	O
available	O
with	O
a	O
median	B-MED
follow	B-MED
-	I-MED
up	I-MED
of	O
72	O
months	B-MED
.	O
The	O
HDR	B-MED
CT	B-MED
was	O
deformably	O
-	O
registered	O
to	O
the	O
EBRT	B-MED
CT	B-MED
.	O
Doses	B-MED
were	O
corrected	B-MED
for	O
dose	B-MED
fractionation	I-MED
.	O
Rectum	B-MED
dose	B-MED
-	I-MED
volume	I-MED
histogram	I-MED
(	O
DVH	B-MED
)	O
parameters	B-MED
were	O
calculated	B-MED
in	O
two	O
ways	O
.	O
(	O
1	O
)	O
Distribution	B-MED
-	I-MED
adding	I-MED
:	O
parameters	B-MED
were	O
calculated	B-MED
after	O
the	O
EBRT	B-MED
dose	B-MED
distribution	B-MED
was	O
3D	O
-	O
summed	O
with	O
the	O
registered	O
HDR	B-MED
dose	B-MED
distribution	B-MED
.	O
(	O
2	O
)	O
Parameter	B-MED
-	I-MED
adding	I-MED
:	O
the	O
EBRT	B-MED
DVH	B-MED
parameters	B-MED
were	O
added	B-MED
to	O
HDR	B-MED
DVH	B-MED
parameters	B-MED
.	O
Logistic	B-MED
regressions	I-MED
and	O
Mann	B-MED
-	I-MED
Whitney	I-MED
U	I-MED
-	I-MED
tests	I-MED
were	O
used	O
to	O
correlate	B-MED
parameters	B-MED
with	O
late	B-MED
peak	B-MED
toxicity	B-MED
(	O
dichotomised	B-MED
at	O
grade	B-MED
1	O
or	O
2	O
)	O
.	O
The	O
48	O
-	O
80	O
,	O
40	O
-	O
63	O
and	O
49	O
-	O
55	O
Gy	B-MED
dose	B-MED
regions	B-MED
from	O
distribution	B-MED
-	I-MED
adding	I-MED
were	O
significantly	B-MED
correlated	B-MED
with	O
rectal	B-MED
bleeding	I-MED
,	O
urgency	B-MED
/	O
tenesmus	B-MED
and	O
stool	B-MED
frequency	I-MED
respectively	O
.	O
Additionally	B-MED
,	O
urgency	B-MED
/	O
tenesmus	B-MED
and	O
anorectal	B-MED
pain	I-MED
were	O
associated	B-MED
with	I-MED
the	O
25	O
-	O
26	O
Gy	B-MED
and	O
44	O
-	O
48	O
Gy	B-MED
dose	B-MED
regions	B-MED
from	O
distribution	B-MED
-	I-MED
adding	I-MED
respectively	O
.	O
Parameter	B-MED
-	I-MED
adding	I-MED
also	O
indicated	O
the	O
low	B-MED
-	O
mid	B-MED
dose	B-MED
region	B-MED
was	O
significantly	B-MED
correlated	B-MED
with	O
stool	B-MED
frequency	I-MED
and	O
proctitis	B-MED
.	O
This	O
study	B-MED
confirms	B-MED
significant	B-MED
dose	B-MED
-	I-MED
histogram	I-MED
effects	B-MED
for	O
gastrointestinal	B-MED
toxicities	I-MED
after	O
including	B-MED
deformable	B-MED
registration	I-MED
to	O
combine	B-MED
phases	B-MED
of	O
EBRT	B-MED
/	O
HDR	B-MED
prostate	B-MED
cancer	I-MED
treatment	B-MED
.	O
The	O
findings	B-MED
from	O
distribution	B-MED
-	I-MED
adding	I-MED
were	O
in	O
most	O
cases	B-MED
consistent	B-MED
with	I-MED
those	O
from	O
parameter	B-MED
-	I-MED
adding	I-MED
.	O
The	O
mid	B-MED
-	O
high	B-MED
dose	B-MED
range	B-MED
and	O
near	B-MED
maximum	B-MED
doses	B-MED
were	O
important	B-MED
for	O
rectal	B-MED
bleeding	I-MED
.	O
The	O
distribution	B-MED
-	I-MED
adding	I-MED
mid	B-MED
-	O
high	B-MED
dose	B-MED
range	B-MED
was	O
also	O
important	B-MED
for	O
stool	B-MED
frequency	I-MED
and	O
urgency	B-MED
/	O
tenesmus	B-MED
.	O
We	O
encourage	O
additional	B-MED
studies	B-MED
in	O
a	O
variety	B-MED
of	O
institutions	B-MED
using	O
a	O
variety	B-MED
of	O
dose	B-MED
accumulation	I-MED
methods	I-MED
with	O
appropriate	O
inter	B-MED
-	I-MED
fraction	I-MED
motion	I-MED
management	I-MED
.	O
NCT	O
NCT00193856	O
.	O
Retrospectively	O
registered	O
12	O
September	O
2005	O
.	O
Utilization	B-MED
Pattern	B-MED
and	O
Drug	B-MED
Use	I-MED
of	O
Traditional	B-MED
Chinese	I-MED
Medicine	I-MED
Chinese	B-MED
,	O
Western	B-MED
Medicine	I-MED
,	O
and	O
Integrated	B-MED
Chinese	I-MED
-	I-MED
Western	I-MED
Medicine	I-MED
Treatments	B-MED
for	O
Allergic	B-MED
Rhinitis	I-MED
Under	O
the	O
National	B-MED
Health	I-MED
Insurance	I-MED
Program	I-MED
in	O
Taiwan	B-MED
Patients	B-MED
in	O
Taiwan	B-MED
with	O
allergic	B-MED
rhinitis	I-MED
seek	O
not	O
only	O
Western	B-MED
medicine	I-MED
treatment	B-MED
but	O
also	O
Traditional	B-MED
Chinese	I-MED
Medicine	I-MED
treatment	B-MED
or	O
integrated	B-MED
Chinese	I-MED
-	I-MED
Western	I-MED
medicine	I-MED
treatment	B-MED
.	O
Various	O
studies	O
have	O
conducted	O
pairwise	B-MED
comparison	I-MED
on	O
Traditional	B-MED
Chinese	I-MED
Medicine	I-MED
,	O
Western	B-MED
medicine	I-MED
,	O
and	O
integrated	B-MED
Chinese	I-MED
-	I-MED
Western	I-MED
medicine	I-MED
treatments	B-MED
.	O
However	O
,	O
none	O
conducted	O
simultaneous	B-MED
analysis	B-MED
of	O
the	O
three	O
treatments	B-MED
.	O
This	O
study	O
analyzed	B-MED
patients	B-MED
with	O
allergic	B-MED
rhinitis	I-MED
receiving	O
the	O
three	O
treatments	B-MED
to	O
identify	O
differences	O
in	O
demographic	B-MED
characteristic	B-MED
and	O
medical	B-MED
use	B-MED
and	O
thereby	O
to	O
determine	O
drug	B-MED
use	I-MED
patterns	I-MED
of	O
different	O
treatments	B-MED
.	O
The	O
National	B-MED
Health	I-MED
Insurance	I-MED
Research	I-MED
Database	I-MED
was	O
the	O
data	B-MED
source	I-MED
,	O
and	O
included	O
patients	B-MED
were	O
those	O
diagnosed	B-MED
with	O
allergic	B-MED
rhinitis	I-MED
(	O
International	B-MED
Classification	I-MED
of	I-MED
Diseases	I-MED
,	I-MED
Ninth	I-MED
Revision	I-MED
,	O
Clinical	B-MED
Modification	I-MED
codes	I-MED
470	I-MED
-	I-MED
478	I-MED
)	O
.	O
Chi	B-MED
-	I-MED
square	I-MED
test	I-MED
and	O
Tukey	B-MED
studentized	I-MED
range	I-MED
(	I-MED
honest	I-MED
significant	I-MED
difference	I-MED
)	I-MED
test	I-MED
were	O
conducted	O
to	O
investigate	B-MED
the	O
differences	O
among	O
the	O
three	O
treatments	B-MED
.	O
Visit	B-MED
frequency	I-MED
for	O
allergic	B-MED
rhinitis	I-MED
treatment	B-MED
was	O
higher	O
in	O
female	B-MED
than	O
male	B-MED
patients	B-MED
,	O
regardless	O
of	O
treatment	B-MED
with	O
Traditional	B-MED
Chinese	I-MED
Medicine	I-MED
,	O
Western	B-MED
medicine	I-MED
,	O
or	O
integrated	B-MED
Chinese	I-MED
-	I-MED
Western	I-MED
medicine	I-MED
.	O
Persons	B-MED
aged	O
0	O
-	O
19	O
years	O
ranked	O
the	O
highest	B-MED
in	O
proportion	B-MED
of	O
visits	B-MED
for	O
allergic	B-MED
rhinitis	I-MED
.	O
Traditional	B-MED
Chinese	I-MED
Medicine	I-MED
treatment	B-MED
had	O
more	O
medical	B-MED
items	O
per	O
person	B-MED
-	I-MED
time	I-MED
and	O
daily	B-MED
drug	B-MED
cost	I-MED
per	O
person	B-MED
-	I-MED
time	I-MED
and	O
had	O
the	O
lowest	B-MED
total	B-MED
expenditure	B-MED
per	O
person	B-MED
-	I-MED
time	I-MED
.	O
In	O
contrast	O
,	O
Western	B-MED
medicine	I-MED
had	O
the	O
lowest	B-MED
daily	B-MED
drug	B-MED
cost	I-MED
per	O
person	B-MED
-	I-MED
time	I-MED
and	O
the	O
highest	B-MED
total	B-MED
expenditure	B-MED
per	O
person	B-MED
-	I-MED
time	I-MED
.	O
The	O
total	B-MED
expenditure	B-MED
per	O
person	B-MED
-	I-MED
time	I-MED
,	O
daily	B-MED
drug	B-MED
cost	I-MED
per	O
person	B-MED
-	I-MED
time	I-MED
,	O
and	O
medical	B-MED
items	B-MED
per	O
person	B-MED
-	I-MED
time	I-MED
of	O
integrated	B-MED
Chinese	I-MED
-	I-MED
Western	I-MED
medicine	I-MED
treatment	B-MED
lay	O
between	O
those	O
seen	O
with	O
Traditional	B-MED
Chinese	I-MED
Medicine	I-MED
and	O
Western	B-MED
medicine	I-MED
treatments	B-MED
.	O
Although	O
only	O
6.82	O
%	O
of	O
patients	B-MED
with	O
allergic	B-MED
rhinitis	I-MED
chose	O
integrated	B-MED
Chinese	I-MED
-	I-MED
Western	I-MED
medicine	I-MED
treatment	B-MED
,	O
the	O
visit	B-MED
frequency	I-MED
per	O
person	O
-	O
year	O
of	O
integrated	B-MED
Chinese	I-MED
-	I-MED
Western	I-MED
medicine	I-MED
ranked	O
highest	B-MED
.	O
In	O
addition	O
,	O
multiple	B-MED
-	I-MED
composition	I-MED
medicines	B-MED
were	O
used	O
more	O
frequently	B-MED
than	O
single	B-MED
-	I-MED
composition	I-MED
medicines	B-MED
,	O
and	O
mar	B-MED
huang	I-MED
(	O
Ephedra	B-MED
sinica	I-MED
Stapf	I-MED
)	O
was	O
seldom	O
used	O
to	O
decrease	B-MED
the	O
risk	B-MED
of	I-MED
combining	O
medications	B-MED
.	O
5	B-MED
-	I-MED
Bromo-2	I-MED
-	I-MED
aryl	I-MED
benzimidazole	I-MED
derivatives	I-MED
as	O
non	B-MED
-	I-MED
cytotoxic	I-MED
potential	B-MED
dual	O
inhibitors	B-MED
of	O
α	B-MED
-	I-MED
glucosidase	I-MED
and	O
urease	B-MED
enzymes	I-MED
On	O
the	O
basis	O
of	O
previous	O
report	B-MED
on	O
promising	O
α	B-MED
-	I-MED
glucosidase	I-MED
inhibitory	B-MED
activity	I-MED
of	O
5	B-MED
-	I-MED
bromo-2	I-MED
-	I-MED
aryl	I-MED
benzimidazole	I-MED
derivatives	I-MED
,	O
these	O
derivatives	O
were	O
further	O
screened	B-MED
for	O
urease	B-MED
inhibitory	B-MED
and	O
cytotoxicity	B-MED
activity	I-MED
in	O
order	O
to	O
get	O
more	B-MED
potent	I-MED
and	O
non	B-MED
-	I-MED
cytotoxic	I-MED
potential	B-MED
dual	O
inhibitor	B-MED
for	O
the	O
patients	B-MED
suffering	O
from	O
diabetes	B-MED
as	O
well	O
as	O
peptic	B-MED
ulcer	I-MED
.	O
In	O
this	O
study	B-MED
,	O
all	O
compounds	B-MED
showed	O
varying	O
degree	B-MED
of	I-MED
potency	I-MED
in	O
the	O
range	O
of	O
(	O
IC50	B-MED
=	O
8.15±0.03	O
-	O
354.67±0.19μM	O
)	O
as	O
compared	O
to	O
standard	B-MED
thiourea	B-MED
(	O
IC50	B-MED
=	O
21.25±0.15μM	O
)	O
.	O
It	O
is	O
worth	O
mentioning	O
that	O
derivatives	B-MED
7	I-MED
(	O
IC50	B-MED
=	O
12.07±0.05μM	O
)	O
,	O
8	B-MED
(	O
IC50	B-MED
=	O
10.57±0.12μM	O
)	O
,	O
11	B-MED
(	O
IC50	B-MED
=	O
13.76±0.02μM	O
)	O
,	O
14	B-MED
(	O
IC50	B-MED
=	O
15.70±0.12μM	O
)	O
and	O
22	B-MED
(	O
IC50	B-MED
=	O
8.15±0.03μM	O
)	O
were	O
found	O
to	O
be	O
more	O
potent	B-MED
inhibitors	I-MED
than	O
standard	B-MED
.	O
All	O
compounds	B-MED
were	O
also	O
evaluated	O
for	O
cytotoxicity	B-MED
towards	O
3T3	B-MED
mouse	B-MED
fibroblast	I-MED
cell	I-MED
line	I-MED
and	O
found	O
to	O
be	O
completely	O
non	B-MED
-	I-MED
toxic	I-MED
.	O
Previously	O
benzimidazole	B-MED
1	I-MED
-	I-MED
25	I-MED
were	O
also	O
showed	O
α	B-MED
-	I-MED
glucosidase	I-MED
inhibitory	B-MED
potential	I-MED
.	O
In	B-MED
silico	I-MED
studies	B-MED
were	O
performed	O
on	O
the	O
lead	B-MED
molecules	I-MED
i.e.	O
2	B-MED
,	O
7	B-MED
,	O
8	B-MED
,	O
11	B-MED
,	O
14	B-MED
,	O
and	O
22	B-MED
,	O
in	O
order	O
to	O
rationalize	O
the	O
binding	B-MED
interaction	I-MED
of	O
compounds	B-MED
with	O
the	O
active	B-MED
site	I-MED
of	O
urease	B-MED
enzyme	I-MED
.	O
Radiologic	B-MED
assessment	I-MED
of	O
quality	O
of	O
root	B-MED
canal	I-MED
fillings	I-MED
and	O
periapical	B-MED
status	I-MED
in	O
an	O
Austrian	B-MED
subpopulation	B-MED
-	O
An	O
observational	B-MED
study	I-MED
Progress	B-MED
in	O
endodontic	B-MED
techniques	I-MED
and	O
methodological	O
advances	O
have	O
altered	O
root	B-MED
canal	I-MED
therapy	I-MED
over	O
the	O
last	O
decades	O
.	O
These	O
techniques	O
and	O
methods	O
need	O
periodical	B-MED
documentation	B-MED
.	O
This	O
observational	B-MED
study	I-MED
determined	O
the	O
current	O
prevalence	B-MED
of	O
endodontic	B-MED
treatments	I-MED
,	I-MED
and	O
investigated	B-MED
the	O
relationship	O
of	O
various	O
factors	O
with	O
the	O
periapical	B-MED
status	I-MED
in	O
a	O
Lower	O
Austrian	B-MED
subpopulation	B-MED
.	O
One	O
thousand	O
orthopantomograms	B-MED
of	O
first	O
-	O
time	O
university	B-MED
adult	O
patients	B-MED
radiographed	B-MED
at	O
an	O
outpatient	B-MED
clinic	I-MED
were	O
evaluated	B-MED
.	O
For	O
each	O
tooth	B-MED
,	O
the	O
presence	B-MED
of	O
periradicular	B-MED
pathosis	I-MED
and/or	O
endodontic	B-MED
treatment	I-MED
was	O
recorded	O
,	O
as	O
was	O
the	O
quality	O
of	O
(	O
post-	O
)	O
endodontic	B-MED
treatment	I-MED
(	O
homogeneity	B-MED
and	O
length	O
of	O
root	B-MED
canal	I-MED
fillings	I-MED
;	O
preparation	B-MED
failures	I-MED
;	O
posts	B-MED
/	O
screws	B-MED
;	O
apicoectomies	B-MED
;	O
coronal	B-MED
restorations	I-MED
)	O
.	O
Two	O
evaluators	B-MED
,	O
blinded	B-MED
to	O
each	O
other	O
,	O
scored	B-MED
all	O
teeth	B-MED
.	O
In	O
cases	O
of	O
disagreement	O
,	O
they	O
joined	O
for	O
a	O
consensus	O
score	B-MED
.	O
In	O
all	O
,	O
22,586	O
teeth	B-MED
were	I-MED
counted	I-MED
.	O
Of	O
these	O
,	O
2,907	O
teeth	B-MED
(	O
12.9	O
%	O
)	O
had	O
periapical	B-MED
pathosis	I-MED
,	O
while	O
2,504	O
teeth	B-MED
had	O
undergone	O
root	B-MED
canal	I-MED
treatment	I-MED
.	O
Of	O
the	O
endodontically	B-MED
treated	I-MED
teeth	I-MED
,	O
52	O
%	O
showed	O
no	O
radiographic	B-MED
signs	O
of	O
apical	B-MED
periodontitis	I-MED
,	O
while	O
44.9	O
%	O
had	O
overt	O
apical	B-MED
lesions	I-MED
,	O
and	O
3,1	O
%	O
revealed	O
widened	B-MED
periodontal	I-MED
ligament	I-MED
space	I-MED
.	O
The	O
majority	O
of	O
the	O
root	B-MED
canal	I-MED
fillings	I-MED
was	O
inhomogeneous	O
(	O
70.4	O
%	O
)	O
;	O
75.4	O
%	O
were	O
rated	O
too	O
short	O
,	O
and	O
3.8	O
%	O
too	O
long	O
.	O
The	O
presence	B-MED
of	O
apical	B-MED
pathosis	B-MED
was	O
significantly	B-MED
correlated	I-MED
(	O
odds	B-MED
ratio	I-MED
(	O
OR	B-MED
)	O
2.556	O
[	O
confidence	B-MED
interval	I-MED
(	O
CI	B-MED
)	O
2.076	O
-	O
3.146	O
]	O
;	O
P<0.0001	O
)	O
with	O
poor	O
root	B-MED
canal	I-MED
fillings	I-MED
(	O
length	O
and	O
homogeneity	B-MED
)	O
.	O
Posts	B-MED
or	O
screws	B-MED
positively	O
affected	O
periapical	B-MED
status	I-MED
(	O
OR	B-MED
1.853	O
[	O
CI	O
1.219	O
-	O
2.819	O
]	O
;	O
P	O
=	O
0.004	O
)	O
,	O
but	O
endodontically	B-MED
treated	I-MED
posterior	I-MED
teeth	I-MED
were	O
infrequently	O
restored	B-MED
(	O
posts	B-MED
,	O
7.5	O
%	O
;	O
screws	B-MED
,	O
2.7	O
%	O
)	O
.	O
Best	O
results	O
were	O
found	O
for	O
teeth	B-MED
with	O
both	O
appropriate	O
endodontic	B-MED
treatment	I-MED
and	O
adequate	O
coronal	B-MED
restoration	I-MED
.	O
A	O
high	B-MED
prevalence	I-MED
of	O
periradicular	B-MED
radiolucencies	I-MED
was	O
observed	O
with	O
root	B-MED
canal	I-MED
filled	I-MED
teeth	I-MED
,	O
along	O
with	O
high	O
numbers	O
of	O
unmet	O
treatment	B-MED
needs	O
.	O
Periapical	B-MED
health	B-MED
was	O
associated	B-MED
with	I-MED
adequate	O
root	B-MED
canal	I-MED
obturation	I-MED
and	O
high	O
-	O
grade	O
postendodontic	B-MED
restorations	I-MED
,	O
and	O
quality	O
regarding	O
these	O
latter	O
aspects	O
is	O
considered	O
mandatory	O
to	O
promote	O
periapical	B-MED
health	B-MED
.	O
Molecular	B-MED
simulation	I-MED
study	B-MED
on	O
concentration	B-MED
effects	B-MED
of	I-MED
rofecoxib	B-MED
with	O
POPC	B-MED
bilayer	B-MED
The	O
interactions	B-MED
between	O
rofecoxib	B-MED
and	O
POPC	B-MED
(	B-MED
1	I-MED
-	I-MED
palmitoyl-2	I-MED
-	I-MED
oleoyl	I-MED
-	I-MED
sn	I-MED
-	I-MED
glycero-3	I-MED
-	I-MED
phosphocholine	I-MED
)	I-MED
bilayer	B-MED
were	O
studied	B-MED
using	B-MED
all	B-MED
-	I-MED
atom	I-MED
molecular	I-MED
dynamics	I-MED
simulation	I-MED
method	B-MED
.	O
Four	O
POPC	B-MED
bilayer	B-MED
systems	B-MED
with	O
different	B-MED
number	B-MED
of	O
rofecoxib	B-MED
molecules	B-MED
were	O
constructed	B-MED
to	O
simulate	B-MED
different	B-MED
drug	B-MED
concentration	B-MED
.	O
The	O
free	B-MED
energy	I-MED
of	O
rofecoxib	B-MED
passing	B-MED
across	O
pure	B-MED
POPC	B-MED
bilayer	B-MED
has	O
two	O
minima	B-MED
(	O
at	O
z	O
∼1.2	O
nm	O
or	O
1.6	O
nm	O
)	O
.	O
As	O
for	O
the	O
high	B-MED
concentration	B-MED
model	B-MED
,	O
the	O
minimum	B-MED
of	O
the	O
free	B-MED
energy	I-MED
profile	O
slightly	O
shifts	O
to	O
the	O
bilayer	B-MED
center	B-MED
.	O
Moreover	O
,	O
the	O
energy	B-MED
change	I-MED
from	O
bulk	B-MED
water	I-MED
to	O
POPC	B-MED
bilayer	B-MED
increases	B-MED
while	O
the	O
central	B-MED
barrier	B-MED
to	O
cross	B-MED
the	O
hydrophobic	B-MED
core	I-MED
of	O
bilayer	B-MED
slightly	B-MED
decreases	B-MED
,	O
suggesting	B-MED
that	O
increasing	B-MED
drug	B-MED
concentration	B-MED
makes	O
it	O
favorable	B-MED
for	O
rofecoxib	B-MED
to	O
partition	B-MED
into	O
the	O
bilayer	B-MED
and	O
easier	O
to	O
pass	B-MED
across	O
bialyer	B-MED
center	B-MED
.	O
Energy	B-MED
analysis	B-MED
show	O
that	O
the	O
stabilization	B-MED
between	O
the	O
selected	B-MED
rofecoxib	B-MED
and	O
other	O
pre	B-MED
-	I-MED
inserted	I-MED
rofecoxib	B-MED
molecule	B-MED
is	O
mainly	O
due	O
to	O
van	B-MED
der	I-MED
Waals	I-MED
interaction	I-MED
energy	B-MED
.	O
The	O
predicted	B-MED
permeability	B-MED
of	O
rofecoxib	B-MED
in	O
high	B-MED
concentration	B-MED
model	B-MED
slightly	O
weakens	B-MED
as	O
compared	B-MED
with	O
low	B-MED
concentration	B-MED
model	B-MED
.	O
MicroRNA	B-MED
101b	I-MED
Is	O
Downregulated	B-MED
in	O
the	O
Prefrontal	B-MED
Cortex	I-MED
of	O
a	O
Genetic	B-MED
Model	I-MED
of	O
Depression	B-MED
and	O
Targets	B-MED
the	O
Glutamate	B-MED
Transporter	I-MED
SLC1A1	B-MED
(	O
EAAT3	B-MED
)	O
in	B-MED
Vitro	I-MED
MicroRNAs	B-MED
(	O
miRNAs	B-MED
)	O
are	O
small	B-MED
regulatory	B-MED
molecules	B-MED
that	O
cause	O
translational	B-MED
repression	I-MED
by	O
base	B-MED
pairing	I-MED
with	I-MED
target	I-MED
mRNAs	I-MED
.	O
Cumulative	B-MED
evidence	B-MED
suggests	O
that	O
changes	B-MED
in	O
miRNA	B-MED
expression	B-MED
may	O
in	O
part	O
underlie	O
the	O
pathophysiology	B-MED
and	O
treatment	B-MED
of	O
neuropsychiatric	B-MED
disorders	I-MED
,	O
including	O
major	B-MED
depressive	I-MED
disorder	I-MED
(	O
MDD	B-MED
)	O
.	O
A	O
miRNA	B-MED
expression	B-MED
assay	B-MED
that	O
can	O
simultaneously	B-MED
detect	O
423	O
rat	O
miRNAs	B-MED
(	O
miRBase	O
v.17	O
)	O
was	O
used	O
to	O
profile	B-MED
the	O
prefrontal	B-MED
cortex	I-MED
(	O
PFC	B-MED
)	O
of	O
a	O
genetic	B-MED
rat	I-MED
model	I-MED
of	O
MDD	B-MED
(	O
the	O
Flinders	B-MED
Sensitive	I-MED
Line	I-MED
[	O
FSL	B-MED
]	O
)	O
and	O
the	O
controls	B-MED
,	O
the	O
Flinders	B-MED
Resistant	I-MED
Line	I-MED
(	O
FRL	B-MED
)	O
.	O
Gene	B-MED
expression	I-MED
data	B-MED
from	O
the	O
PFC	B-MED
of	O
FSL	B-MED
/	O
FRL	B-MED
animals	B-MED
(	O
GEO	O
accession	O
no	O
.	O
GSE20388	O
)	O
were	O
used	O
to	O
guide	O
mRNA	B-MED
target	B-MED
selection	B-MED
.	O
Luciferase	B-MED
reporter	I-MED
assays	I-MED
were	O
used	O
to	O
verify	B-MED
miRNA	B-MED
targets	B-MED
in	B-MED
vitro	I-MED
.	O
We	O
identified	B-MED
23	O
miRNAs	B-MED
that	O
were	O
downregulated	B-MED
in	O
the	O
PFC	B-MED
of	O
the	O
FSL	B-MED
model	I-MED
compared	B-MED
with	O
controls	B-MED
.	O
Interestingly	O
,	O
one	O
of	O
the	O
identified	B-MED
miRNAs	B-MED
(	O
miR-101b	B-MED
)	O
is	O
highly	O
conserved	B-MED
between	O
rat	B-MED
and	O
human	B-MED
and	O
was	O
recently	O
found	O
to	O
be	O
downregulated	B-MED
in	O
the	O
PFC	B-MED
of	O
depressed	B-MED
suicide	B-MED
subjects	B-MED
.	O
Using	O
a	O
combination	B-MED
of	O
in	B-MED
silico	I-MED
and	O
in	B-MED
vitro	I-MED
analyses	B-MED
,	O
we	O
found	O
that	O
miR-101b	B-MED
targets	B-MED
the	O
neuronal	B-MED
glutamate	B-MED
transporter	I-MED
SLC1A1	B-MED
(	O
also	O
known	O
as	O
EAAC1	B-MED
or	O
EAAT3	B-MED
)	O
.	O
Accordingly	O
,	O
both	O
mRNA	B-MED
and	O
protein	B-MED
levels	I-MED
of	O
SLC1A1	B-MED
were	O
found	O
to	O
be	O
upregulated	B-MED
in	O
the	O
PFC	B-MED
of	O
the	O
FSL	B-MED
model	I-MED
.	O
Besides	O
providing	O
a	O
list	O
of	O
novel	O
miRNAs	B-MED
associated	B-MED
with	I-MED
depression	B-MED
-	I-MED
like	I-MED
states	I-MED
,	O
this	O
preclinical	B-MED
study	I-MED
replicated	B-MED
the	O
human	B-MED
association	B-MED
of	O
miR-101	B-MED
with	O
depression	B-MED
.	O
In	O
addition	O
,	O
since	O
one	O
of	O
the	O
targets	B-MED
of	O
miR-101b	B-MED
appears	O
to	O
be	O
a	O
glutamate	B-MED
transporter	I-MED
,	O
our	O
preclinical	B-MED
data	B-MED
support	O
the	O
hypothesis	B-MED
of	O
a	O
glutamatergic	B-MED
dysregulation	B-MED
being	O
implicated	O
in	O
the	O
etiology	B-MED
of	O
depression	B-MED
.	O
A	O
randomized	B-MED
trial	I-MED
of	O
TLR-2	B-MED
agonist	B-MED
CADI-05	B-MED
targeting	B-MED
desmocollin-3	B-MED
for	O
advanced	B-MED
non	B-MED
-	I-MED
small	I-MED
-	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
Randomized	B-MED
controlled	I-MED
trial	I-MED
to	O
evaluate	B-MED
synergy	B-MED
between	O
taxane	B-MED
plus	O
platinum	B-MED
chemotherapy	B-MED
and	O
CADI-05	B-MED
,	O
a	O
Toll	B-MED
like	I-MED
receptor-2	I-MED
agonist	B-MED
targeting	B-MED
desmocollin-3	B-MED
as	O
a	O
first	B-MED
-	I-MED
line	I-MED
therapy	I-MED
in	O
advanced	B-MED
non	B-MED
-	I-MED
small	I-MED
-	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
(	O
NSCLC	B-MED
)	O
.	O
Patients	B-MED
with	O
advanced	B-MED
NSCLC	B-MED
(	O
stage	O
IIIB	O
or	O
IV	O
)	O
were	O
randomized	B-MED
to	O
cisplatin	B-MED
-	I-MED
paclitaxel	I-MED
(	O
chemotherapy	B-MED
group	B-MED
,	O
N	O
=	O
112	O
)	O
or	O
cisplatin	B-MED
-	I-MED
paclitaxel	I-MED
plus	O
CADI-05	B-MED
(	O
chemoimmunotherapy	B-MED
group	B-MED
,	O
N	O
=	O
109	O
)	O
.	O
CADI-05	B-MED
was	O
administered	B-MED
a	O
week	B-MED
before	O
chemotherapy	B-MED
and	O
on	O
days	B-MED
8	O
and	O
15	O
of	O
each	O
cycle	B-MED
and	O
every	O
month	B-MED
subsequently	O
for	O
12	O
months	B-MED
or	O
disease	B-MED
progression	I-MED
.	O
Overall	B-MED
survival	I-MED
was	O
compared	O
using	O
a	O
log	B-MED
-	I-MED
rank	I-MED
test	I-MED
.	O
Computed	B-MED
tomography	I-MED
was	O
carried	O
out	O
at	O
baseline	B-MED
,	O
end	O
of	O
two	O
cycles	B-MED
and	O
four	O
cycles	B-MED
.	O
Response	B-MED
rate	I-MED
was	O
evaluated	B-MED
using	O
Response	B-MED
Evaluation	I-MED
Criteria	I-MED
in	I-MED
Solid	I-MED
Tumors	I-MED
criteria	B-MED
by	O
an	O
independent	B-MED
radiologist	I-MED
.	O
As	O
per	O
intention	B-MED
-	I-MED
to	I-MED
-	I-MED
treat	I-MED
analysis	I-MED
,	O
no	O
survival	B-MED
benefit	B-MED
was	O
observed	O
between	O
two	O
groups	B-MED
[	O
208	O
versus	O
196	O
days	B-MED
;	O
hazard	B-MED
ratio	I-MED
,	O
0.86	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
(	O
CI	O
)	O
0.63	O
-	O
1.19	O
;	O
P	O
=	O
0.3804	O
]	O
.	O
In	O
a	O
subgroup	B-MED
analysis	I-MED
,	O
improvement	B-MED
in	O
median	B-MED
survival	I-MED
by	O
127	O
days	B-MED
was	O
observed	O
in	O
squamous	B-MED
NSCC	I-MED
with	O
chemoimmunotherapy	B-MED
(	O
hazard	B-MED
ratio	I-MED
,	O
0.55	O
;	O
95	O
%	O
CI	O
0.32	O
-	O
0.95	O
;	O
P	O
=	O
0.046	O
)	O
.	O
In	O
patients	B-MED
receiving	O
planned	O
four	O
cycles	B-MED
of	O
chemotherapy	B-MED
,	O
there	O
was	O
improved	B-MED
median	B-MED
overall	B-MED
survival	I-MED
by	O
66	O
days	B-MED
(	O
299	O
versus	O
233	O
days	B-MED
;	O
hazard	B-MED
ratio	I-MED
,	O
0.64	O
;	O
95	O
%	O
CI	O
0.41	O
to	O
0.98	O
;	O
P	O
=	O
0.04	O
)	O
in	O
the	O
chemoimmunotherapy	B-MED
group	B-MED
compared	O
with	O
the	O
chemotherapy	B-MED
group	B-MED
.	O
This	O
was	O
associated	B-MED
with	I-MED
the	O
improved	B-MED
survival	B-MED
by	O
17.48	O
%	O
at	O
the	O
end	O
of	O
1	O
year	B-MED
,	O
in	O
the	O
chemoimmunotherapy	B-MED
group	B-MED
.	O
Systemic	B-MED
adverse	I-MED
events	I-MED
were	O
identical	B-MED
in	O
both	O
the	O
group	B-MED
s.	O
There	O
was	O
no	O
survival	B-MED
benefit	B-MED
with	O
the	O
addition	B-MED
of	O
CADI-05	B-MED
to	O
the	O
combination	B-MED
of	O
cisplatin	B-MED
-	I-MED
paclitaxel	I-MED
in	O
patients	B-MED
with	O
advanced	B-MED
NSCLC	B-MED
;	O
however	O
,	O
the	O
squamous	B-MED
cell	I-MED
subset	I-MED
did	O
demonstrate	O
a	O
survival	B-MED
advantage	O
.	O
High	B-MED
-	I-MED
Intensity	I-MED
Intermittent	I-MED
Training	I-MED
Positively	B-MED
Affects	B-MED
Aerobic	B-MED
and	O
Anaerobic	B-MED
Performance	I-MED
in	O
Judo	B-MED
Athletes	B-MED
Independently	O
of	O
Exercise	B-MED
Mode	I-MED
The	O
present	O
study	O
investigated	O
the	O
effects	B-MED
of	O
high	B-MED
-	I-MED
intensity	I-MED
intermittent	I-MED
training	I-MED
(	O
HIIT	B-MED
)	O
on	O
lower	B-MED
-	O
and	O
upper	B-MED
-	I-MED
body	I-MED
graded	B-MED
exercise	I-MED
and	O
high	B-MED
-	I-MED
intensity	I-MED
intermittent	I-MED
exercise	I-MED
(	O
HIIE	B-MED
,	O
four	O
Wingate	O
bouts	O
)	O
performance	B-MED
,	O
and	O
on	O
physiological	B-MED
and	O
muscle	B-MED
damage	I-MED
markers	B-MED
responses	I-MED
in	O
judo	B-MED
athletes	B-MED
.	O
Thirty	O
-	O
five	O
subjects	B-MED
were	O
randomly	B-MED
allocated	I-MED
to	O
a	O
control	B-MED
group	I-MED
(	O
n	O
=	O
8)	O
or	O
to	O
one	O
of	O
the	O
following	O
HIIT	B-MED
groups	B-MED
(	O
n	O
=	O
9	O
for	O
each	O
)	O
and	O
tested	B-MED
pre-	I-MED
and	I-MED
post	I-MED
-four	O
weeks	O
(	O
2	O
training	O
d·wk(-1	O
)	O
):	O
(	O
1	O
)	O
lower	B-MED
-	I-MED
body	I-MED
cycle	B-MED
-	I-MED
ergometer	I-MED
;	O
(	O
2	O
)	O
upper	O
-	O
body	O
cycle	B-MED
-	I-MED
ergometer	I-MED
;	O
(	O
3	O
)	O
uchi	B-MED
-	I-MED
komi	I-MED
(	O
judo	B-MED
technique	I-MED
entrance	I-MED
)	O
.	O
All	O
HIIT	B-MED
were	O
constituted	O
by	O
two	O
blocks	O
of	O
10	O
sets	O
of	O
20	O
s	O
of	O
all	O
out	O
effort	O
interspersed	O
by	O
10	O
s	O
set	O
intervals	O
and	O
5	O
-	O
min	O
between	O
blocks	O
.	O
For	O
the	O
upper	B-MED
-	I-MED
body	I-MED
group	B-MED
there	O
was	O
an	O
increase	B-MED
in	O
maximal	B-MED
aerobic	I-MED
power	I-MED
in	O
graded	O
upper	B-MED
-	I-MED
body	I-MED
exercise	B-MED
test	I-MED
(	O
12.3	O
%	O
)	O
.	O
The	O
lower	B-MED
-	I-MED
body	I-MED
group	B-MED
increased	B-MED
power	B-MED
at	O
onset	B-MED
blood	I-MED
lactate	I-MED
in	O
graded	O
upper	B-MED
-	I-MED
body	I-MED
exercise	B-MED
test	I-MED
(	O
22.1	O
%	O
)	O
.	O
The	O
uchi	B-MED
-	I-MED
komi	I-MED
group	I-MED
increased	B-MED
peak	O
power	O
in	O
upper	B-MED
-	O
(	O
16.7	O
%	O
)	O
and	O
lower	B-MED
-	I-MED
body	I-MED
(	O
8.5	O
%	O
)	O
,	O
while	O
the	O
lower	B-MED
-	I-MED
body	I-MED
group	O
increased	B-MED
lower	B-MED
-	I-MED
body	I-MED
mean	O
power	O
(	O
14.2	O
%	O
)	O
during	O
the	O
HIIE	B-MED
.	O
There	O
was	O
a	O
decrease	B-MED
in	O
the	O
delta	B-MED
blood	I-MED
lactate	I-MED
for	O
the	O
uchi	B-MED
-	I-MED
komi	I-MED
training	I-MED
group	B-MED
and	O
in	O
the	O
third	O
and	O
fourth	O
bouts	O
for	O
the	O
upper	B-MED
-	I-MED
body	I-MED
training	B-MED
group	B-MED
.	O
Training	B-MED
induced	O
testosterone	B-MED
-	I-MED
cortisol	I-MED
ratio	B-MED
increased	B-MED
in	O
the	O
lower	B-MED
-	I-MED
body	I-MED
HIIE	B-MED
for	O
the	O
lower	B-MED
-	I-MED
body	I-MED
(	O
14.9	O
%	O
)	O
and	O
uchi	B-MED
-	I-MED
komi	I-MED
(	I-MED
61.4	I-MED
%	I-MED
)	I-MED
training	I-MED
groups	B-MED
.	O
Thus	O
,	O
short	B-MED
-	I-MED
duration	I-MED
low	O
-	O
volume	O
HIIT	B-MED
added	O
to	O
regular	B-MED
judo	I-MED
training	I-MED
was	O
able	O
to	O
increase	B-MED
upper	B-MED
-	I-MED
body	I-MED
aerobic	B-MED
power	I-MED
,	O
lower	B-MED
-	O
and	O
upper	B-MED
-	I-MED
body	I-MED
HIIE	B-MED
performance	B-MED
.	O
What	O
can	O
the	O
Canadians	B-MED
and	O
Americans	B-MED
learn	B-MED
from	O
each	O
other	O
's	O
health	B-MED
care	I-MED
systems	I-MED
?	O
Numerous	O
papers	B-MED
have	O
been	O
written	O
comparing	B-MED
the	O
Canadian	B-MED
and	O
US	B-MED
healthcare	B-MED
systems	I-MED
,	O
and	O
a	O
number	O
of	O
health	B-MED
policy	I-MED
experts	B-MED
have	O
recommended	B-MED
that	O
the	O
Americans	B-MED
implement	B-MED
their	O
single	B-MED
-	I-MED
payer	I-MED
system	I-MED
to	O
save	O
12	O
-	O
20	O
%	O
of	O
its	O
healthcare	B-MED
expenditures	I-MED
.	O
This	O
paper	B-MED
is	O
different	O
in	O
that	O
it	O
assumes	O
that	O
neither	O
country	B-MED
will	O
undertake	O
a	O
significant	B-MED
philosophic	B-MED
or	O
structural	B-MED
change	B-MED
in	O
their	O
healthcare	B-MED
system	I-MED
,	O
but	O
there	O
are	O
lessons	O
to	O
be	O
learned	B-MED
that	O
are	O
inherent	O
in	O
one	O
that	O
could	O
be	O
a	O
major	O
breakthrough	B-MED
for	O
the	O
other	O
.	O
Following	O
the	O
model	B-MED
in	O
Canada	B-MED
and	O
in	O
Western	B-MED
Europe	I-MED
,	O
the	O
USA	B-MED
could	O
implement	B-MED
universal	B-MED
health	B-MED
insurance	I-MED
so	O
that	O
the	O
32.0	O
million	O
(	O
2015	O
)	O
Americans	B-MED
still	O
uninsured	B-MED
would	O
have	O
at	O
least	O
minimal	B-MED
coverage	B-MED
when	O
incurring	O
medical	B-MED
expenditures	I-MED
.	O
Also	O
,	O
the	O
USA	B-MED
could	O
use	O
smart	B-MED
cards	I-MED
to	O
evaluate	B-MED
eligibility	I-MED
and	O
to	O
process	B-MED
health	B-MED
insurance	I-MED
claims	I-MED
;	O
these	O
changes	O
resulting	B-MED
in	I-MED
an	O
estimated	B-MED
15	O
%	O
reduction	B-MED
in	O
US	B-MED
health	B-MED
expenditures	I-MED
without	O
adversely	O
effecting	B-MED
access	B-MED
or	O
quality	B-MED
of	I-MED
care	I-MED
.	O
Such	O
a	O
strategy	O
would	O
result	B-MED
in	O
the	O
eventual	O
loss	B-MED
of	O
2.5	O
million	O
white	B-MED
-	I-MED
collar	I-MED
jobs	I-MED
at	O
hospitals	B-MED
,	O
physician	B-MED
offices	I-MED
and	O
insurance	B-MED
companies	I-MED
,	O
a	O
long	B-MED
-	I-MED
term	I-MED
economic	B-MED
gain	B-MED
.	O
Only	O
a	O
few	O
would	O
agree	O
with	O
the	O
statement	O
that	O
Canada	B-MED
already	O
functions	B-MED
with	O
a	O
multi	B-MED
-	I-MED
payer	I-MED
reimbursement	B-MED
system	I-MED
as	O
evidenced	O
by	O
(	O
1	O
)	O
a	O
federal	B-MED
-	O
provincial	B-MED
,	O
tax	B-MED
-	O
supported	B-MED
plan	B-MED
,	O
administered	O
by	O
each	O
of	O
the	O
provinces	B-MED
,	O
providing	O
universal	B-MED
coverage	I-MED
for	O
hospital	B-MED
and	O
physician	B-MED
services	I-MED
and	O
(	O
2	O
)	O
roughly	O
60	O
%	O
of	O
its	O
residents	B-MED
receiving	O
employer	B-MED
-	I-MED
paid	I-MED
health	B-MED
insurance	I-MED
benefits	B-MED
,	O
underwritten	O
primarily	O
by	O
investor	O
-	O
owned	O
plans	O
,	O
that	O
are	O
less	O
than	O
effective	B-MED
to	O
reimburse	B-MED
for	O
pharmaceuticals	B-MED
,	O
dental	B-MED
and	O
other	O
healthcare	B-MED
services	I-MED
.	O
What	O
could	O
be	O
learned	O
from	O
the	O
USA	B-MED
and	O
particularly	O
from	O
Western	B-MED
European	I-MED
countries	I-MED
is	O
possibly	O
implementing	B-MED
an	O
approach	O
,	O
whereby	O
at	O
least	O
upper	B-MED
-	I-MED
income	I-MED
Canadians	B-MED
could	O
opt	O
out	O
of	O
their	O
federal	B-MED
-	O
provincial	B-MED
plan	B-MED
and	O
purchase	O
private	B-MED
insurance	B-MED
coverage	I-MED
-	O
being	O
eligible	O
for	O
far	O
more	O
comprehensive	O
"	O
private	O
"	O
benefits	O
for	O
hospital	B-MED
,	O
physician	B-MED
,	O
pharmaceutical	B-MED
,	O
dental	B-MED
and	O
other	O
healthcare	B-MED
services	I-MED
.	O
Aside	O
from	O
generating	O
billions	O
of	O
additional	O
needed	O
revenues	B-MED
from	O
the	O
private	B-MED
sector	I-MED
,	O
it	O
could	O
(	O
1	O
)	O
help	O
eliminate	B-MED
long	O
waits	O
for	O
non	O
-	O
emergent	O
physicians	O
'	O
care	O
by	O
appointing	O
newly	O
minted	O
specialists	B-MED
to	O
their	O
medical	B-MED
staffs	I-MED
;	O
(	O
2	O
)	O
offer	O
prompt	B-MED
admissions	B-MED
for	O
elective	B-MED
cases	I-MED
to	O
"	O
private	B-MED
"	O
wings	B-MED
of	I-MED
hospitals	I-MED
;	O
(	O
3	O
)	O
increase	B-MED
available	O
funding	B-MED
for	O
what	O
is	O
currently	B-MED
an	O
undercapitalized	B-MED
system	B-MED
;	O
(	O
4	O
)	O
enhance	B-MED
the	O
system	O
's	O
sluggish	B-MED
operations	B-MED
;	O
and	O
(	O
5	O
)	O
encourage	O
more	O
competition	B-MED
among	O
various	O
providers	O
.	O
Although	O
such	O
a	O
two	B-MED
-	I-MED
tier	I-MED
approach	I-MED
,	O
such	O
as	O
available	O
in	O
the	O
USA	B-MED
and	O
elsewhere	O
,	O
is	O
politically	O
dead	O
on	O
arrival	O
in	O
Canada	B-MED
today	O
,	O
private	B-MED
insurance	I-MED
being	O
already	O
legal	B-MED
and	O
commonly	O
available	O
there	O
.	O
Interestingly	O
,	O
this	O
recommended	B-MED
solution	O
is	O
utilized	O
in	O
most	O
western	B-MED
European	I-MED
countries	I-MED
where	O
there	O
is	O
a	O
higher	O
percentagea	B-MED
than	O
in	O
Canada	B-MED
of	O
public	B-MED
(	O
versus	O
private	O
)	O
funding	B-MED
of	O
their	O
total	O
health	B-MED
expenditures	I-MED
.	O
Because	O
of	O
various	O
vested	O
interests	O
,	O
attempts	B-MED
to	O
implement	B-MED
any	O
of	O
the	O
aforementioned	O
proposals	O
will	O
undoubtedly	O
result	B-MED
in	O
considerable	O
political	B-MED
rancor	B-MED
.	O
There	O
is	O
greater	O
likelihood	O
,	O
however	O
,	O
that	O
the	O
Canadians	B-MED
because	O
their	O
need	O
to	O
be	O
more	O
effective	B-MED
and	O
efficient	B-MED
in	O
their	O
delivery	B-MED
of	I-MED
care	I-MED
,	O
and	O
their	O
overall	O
long	B-MED
-	I-MED
term	I-MED
fiscal	B-MED
outlook	O
will	O
agree	B-MED
to	O
the	O
further	O
privatization	B-MED
of	O
their	O
healthcare	B-MED
system	I-MED
before	O
the	O
Americans	B-MED
will	O
mandate	O
universal	O
access	O
,	O
use	O
the	O
smart	B-MED
card	I-MED
to	O
process	O
insurance	B-MED
eligibility	I-MED
and	O
claims	O
or	O
will	O
impose	O
price	O
controls	B-MED
on	O
high	O
-	O
tech	O
services	O
and	O
on	O
pharmaceuticals	B-MED
.	O
Copyright	O
©	O
2016	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
Multi	B-MED
-	I-MED
component	I-MED
model	I-MED
of	O
intramural	B-MED
hematoma	I-MED
A	O
novel	O
multi	B-MED
-	I-MED
component	I-MED
model	I-MED
is	O
introduced	O
for	O
studying	B-MED
interaction	B-MED
between	O
blood	B-MED
flow	I-MED
and	O
deforming	B-MED
aortic	B-MED
wall	I-MED
with	O
intramural	B-MED
hematoma	I-MED
(	O
IMH	B-MED
)	O
.	O
The	O
aortic	B-MED
wall	I-MED
is	O
simulated	B-MED
by	O
a	O
composite	B-MED
structure	I-MED
submodel	I-MED
representing	O
material	B-MED
properties	I-MED
of	O
the	O
three	O
main	O
wall	B-MED
layers	I-MED
.	O
The	O
IMH	B-MED
is	O
described	O
by	O
a	O
poroelasticity	B-MED
submodel	I-MED
which	O
takes	O
into	O
account	O
both	O
the	O
pressure	B-MED
inside	O
hematoma	B-MED
and	O
its	O
deformation	B-MED
.	O
The	O
submodel	B-MED
of	O
the	O
hematoma	B-MED
is	O
fully	O
coupled	O
with	O
the	O
aortic	B-MED
submodel	I-MED
as	O
well	O
as	O
with	O
the	O
submodel	B-MED
of	O
the	O
pulsatile	B-MED
blood	I-MED
flow	I-MED
.	O
Model	B-MED
simulations	I-MED
are	O
used	O
to	O
investigate	B-MED
the	O
relation	O
between	O
the	O
peak	O
wall	O
stress	O
,	O
hematoma	B-MED
thickness	O
and	O
permeability	B-MED
in	O
patients	B-MED
of	O
different	O
age	B-MED
.	O
The	O
results	O
indicate	O
that	O
an	O
increase	O
in	O
hematoma	B-MED
thickness	O
leads	O
to	O
larger	O
wall	B-MED
stress	I-MED
,	O
which	O
is	O
in	O
agreement	O
with	O
clinical	B-MED
data	I-MED
.	O
Further	O
simulations	B-MED
demonstrate	O
that	O
a	O
hematoma	B-MED
with	O
smaller	O
permeability	B-MED
results	O
in	O
larger	O
wall	B-MED
stress	I-MED
,	O
suggesting	O
that	O
blood	B-MED
coagulation	I-MED
in	O
hematoma	B-MED
might	O
increase	O
its	O
mechanical	B-MED
stability	I-MED
.	O
This	O
is	O
in	O
agreement	O
with	O
previous	O
experimental	B-MED
observations	B-MED
of	O
coagulation	B-MED
having	O
a	O
beneficial	B-MED
effect	I-MED
on	O
the	O
condition	O
of	O
a	O
patient	B-MED
with	O
the	O
IMH	B-MED
.	O
Discovery	B-MED
of	O
Orally	B-MED
Efficacious	B-MED
Phosphoinositide-3	B-MED
-	I-MED
Kinase	I-MED
delta	I-MED
Inhibitors	B-MED
with	O
Improved	B-MED
Metabolic	B-MED
Stability	B-MED
Aberrant	B-MED
signaling	I-MED
of	O
phosphoinositide-3	B-MED
-	I-MED
kinase	I-MED
delta	I-MED
(	O
PI3K	B-MED
-	I-MED
delta	I-MED
)	O
has	O
been	O
implicated	O
in	O
numerous	O
pathologies	B-MED
including	O
hematological	B-MED
malignancies	I-MED
and	O
rheumatoid	B-MED
arthritis	I-MED
.	O
Described	O
in	O
this	O
manuscript	O
is	O
the	O
discovery	B-MED
,	O
optimization	B-MED
and	O
in	B-MED
vivo	I-MED
evaluation	B-MED
of	O
a	O
novel	O
series	O
of	O
pyridine	B-MED
-	I-MED
containing	I-MED
PI3K	B-MED
-	I-MED
delta	I-MED
inhibitors	B-MED
.	O
This	O
work	O
led	O
to	O
the	O
discovery	B-MED
of	O
35	B-MED
,	O
a	O
highly	O
selective	O
inhibitor	B-MED
of	O
PI3K	B-MED
-	I-MED
delta	I-MED
which	O
displays	O
an	O
excellent	O
pharmacokinetic	B-MED
profile	I-MED
and	O
is	O
efficacious	B-MED
in	O
a	O
rodent	B-MED
model	I-MED
of	O
rheumatoid	B-MED
arthritis	I-MED
.	O
Novel	B-MED
Observations	B-MED
in	O
11	O
Heteroresistant	B-MED
Vancomycin	B-MED
-	I-MED
Intermediate	I-MED
Methicillin	B-MED
-	I-MED
Resistant	I-MED
Staphylococcus	I-MED
aureus	I-MED
Strains	I-MED
from	O
South	B-MED
India	I-MED
We	O
report	O
here	O
the	O
draft	O
genome	B-MED
sequences	I-MED
of	O
11	O
heteroresistant	B-MED
vancomycin	B-MED
-	I-MED
intermediate	I-MED
Staphylococcus	I-MED
aureus	I-MED
(	I-MED
hVISA	I-MED
)	I-MED
strains	I-MED
from	O
bloodstream	B-MED
infection	I-MED
.	O
All	O
strains	B-MED
harbor	O
mutations	B-MED
in	O
vraSR	B-MED
,	O
graSR	B-MED
,	O
walKR	B-MED
,	O
and/or	O
tcaRAB	B-MED
and	O
are	O
often	O
implicated	O
as	O
the	O
frequently	O
mutated	B-MED
candidate	O
genes	B-MED
in	O
hVISA	B-MED
phenotypes	B-MED
.	O
Obesogenic	B-MED
eating	B-MED
behaviors	I-MED
mediate	O
the	O
relationships	B-MED
between	O
psychological	B-MED
problems	I-MED
and	O
BMI	B-MED
in	O
children	B-MED
To	O
examine	O
the	O
association	B-MED
between	O
psychological	B-MED
problems	I-MED
and	O
weight	B-MED
status	B-MED
in	O
children	B-MED
aged	B-MED
3.5	O
to	O
4	O
years	B-MED
and	O
test	O
whether	O
obesogenic	B-MED
eating	B-MED
behaviors	I-MED
mediate	O
this	O
relationship	B-MED
.	O
This	O
study	O
is	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
secondary	I-MED
analysis	I-MED
of	O
data	B-MED
from	O
first	B-MED
-	I-MED
time	I-MED
mothers	I-MED
(	O
N	O
=	O
194	O
)	O
in	O
the	O
control	O
arm	O
of	O
the	O
NOURISH	B-MED
randomized	I-MED
controlled	I-MED
trial	I-MED
.	O
At	O
child	B-MED
child	B-MED
age	O
3.5	O
to	O
4	O
years	O
,	O
maternal	B-MED
-reported	O
child	B-MED
eating	B-MED
behaviors	I-MED
and	O
psychological	B-MED
problems	I-MED
were	O
collected	O
via	O
valid	O
tools	O
,	O
and	O
child	B-MED
weight	B-MED
and	O
height	B-MED
data	B-MED
were	I-MED
collected	I-MED
by	O
trained	O
study	O
staff	B-MED
.	O
Pearson	B-MED
's	I-MED
correlations	I-MED
and	O
linear	B-MED
regressions	I-MED
examined	O
associations	B-MED
between	O
eating	B-MED
behaviors	I-MED
,	O
psychological	B-MED
problems	I-MED
,	O
and	O
BMI	B-MED
z	B-MED
score	I-MED
.	O
Multiple	B-MED
mediation	I-MED
models	I-MED
were	O
tested	B-MED
by	O
assessing	O
indirect	B-MED
effects	B-MED
of	O
psychological	B-MED
problems	I-MED
on	O
BMI	B-MED
z	B-MED
score	I-MED
via	O
obesogenic	B-MED
eating	B-MED
behaviors	I-MED
.	O
Peer	B-MED
problems	B-MED
were	O
associated	B-MED
with	I-MED
both	O
higher	B-MED
food	B-MED
responsiveness	B-MED
and	O
emotional	B-MED
overeating	I-MED
and	O
directly	B-MED
with	O
higher	B-MED
BMI	B-MED
z	B-MED
score	I-MED
.	O
This	O
relationship	B-MED
was	O
partially	O
mediated	O
by	O
emotional	B-MED
overeating	I-MED
.	O
Both	O
emotional	B-MED
overeating	I-MED
and	O
food	B-MED
responsiveness	B-MED
fully	O
mediated	O
the	O
association	B-MED
between	O
emotional	B-MED
problems	I-MED
and	O
BMI	B-MED
z	B-MED
score	I-MED
,	O
and	O
food	B-MED
responsiveness	B-MED
fully	O
mediated	O
the	O
association	B-MED
between	O
conduct	B-MED
problems	I-MED
and	O
BMI	B-MED
z	B-MED
score	I-MED
.	O
The	O
findings	O
suggest	O
that	O
children	B-MED
with	O
psychological	B-MED
problems	I-MED
may	O
also	O
display	O
obesogenic	B-MED
eating	B-MED
behaviors	I-MED
,	O
which	O
may	O
result	O
in	O
higher	B-MED
BMI	B-MED
.	O
This	O
needs	O
to	O
be	O
considered	O
in	O
the	O
clinical	B-MED
management	I-MED
of	O
both	O
pediatric	B-MED
overweight	B-MED
/	O
obesity	B-MED
and	O
psychological	B-MED
problems	I-MED
.	O
Anti	B-MED
-	I-MED
tumor	I-MED
activity	I-MED
of	O
SL4	B-MED
against	O
breast	B-MED
cancer	I-MED
cells	I-MED
:	O
induction	B-MED
of	O
G2	B-MED
/	I-MED
M	I-MED
arrest	I-MED
through	O
modulation	B-MED
of	O
the	O
MAPK	B-MED
-dependent	O
p21	B-MED
signaling	B-MED
pathway	I-MED
SL4	B-MED
,	O
a	O
chalcone	B-MED
-based	O
compound	B-MED
,	O
has	O
been	O
shown	O
to	O
retard	B-MED
tumor	B-MED
invasion	I-MED
and	O
angiogenesis	B-MED
by	O
suppressing	B-MED
HIF1	B-MED
activity	B-MED
and	O
to	O
induce	B-MED
apoptosis	B-MED
by	O
promoting	B-MED
ROS	B-MED
release	B-MED
.	O
Here	O
,	O
we	O
report	B-MED
that	O
SL4	B-MED
is	O
able	O
to	O
inhibit	B-MED
the	O
proliferation	B-MED
of	O
different	B-MED
types	B-MED
of	O
breast	B-MED
cancer	I-MED
cell	I-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
by	O
inducing	B-MED
G2	B-MED
/	I-MED
M	I-MED
cell	I-MED
cycle	I-MED
arrest	I-MED
.	O
Our	O
results	B-MED
showed	O
that	O
SL4	B-MED
exhibited	B-MED
strong	B-MED
anti	B-MED
-	I-MED
proliferative	I-MED
activity	B-MED
in	O
several	O
human	B-MED
breast	B-MED
cancer	I-MED
cell	B-MED
lines	I-MED
,	O
with	O
IC50	B-MED
values	I-MED
lower	B-MED
than	O
1.3	O
μM.	O
Further	O
studies	B-MED
indicated	B-MED
that	O
SL4	B-MED
induced	B-MED
G2	B-MED
/	I-MED
M	I-MED
arrest	I-MED
in	O
these	O
cell	B-MED
lines	I-MED
.	O
Mechanistically	B-MED
,	O
SL4	B-MED
reduces	B-MED
the	O
expression	B-MED
of	O
cyclin	B-MED
A2	I-MED
and	O
cdc25C	B-MED
and	O
decreases	B-MED
the	O
activity	B-MED
of	O
the	O
cdc2	B-MED
/	O
cyclin	B-MED
B1	I-MED
complex	B-MED
.	O
Notably	O
,	O
SL4	B-MED
treatment	B-MED
resulted	B-MED
in	I-MED
an	O
obvious	O
increase	B-MED
in	O
p21	B-MED
mRNA	B-MED
and	O
protein	B-MED
levels	B-MED
through	O
activation	B-MED
of	O
MAPK	B-MED
signaling	I-MED
pathways	I-MED
,	O
but	O
not	O
the	O
TGF	B-MED
-	I-MED
β	I-MED
pathway	I-MED
.	O
SP600125	B-MED
and	O
PD98059	B-MED
,	O
specific	O
inhibitors	B-MED
of	O
JNK	B-MED
kinase	I-MED
and	O
ERK	B-MED
kinase	I-MED
,	O
significantly	B-MED
blocked	B-MED
the	O
SL4	B-MED
-	O
induced	B-MED
G2	B-MED
/	I-MED
M	I-MED
phase	I-MED
arrest	I-MED
and	O
upregulation	B-MED
of	O
p21	B-MED
.	O
Furthermore	O
,	O
SL4	B-MED
suppressed	B-MED
the	O
growth	B-MED
of	O
established	B-MED
breast	B-MED
tumors	I-MED
in	O
nude	B-MED
mice	I-MED
through	O
upregulation	B-MED
of	O
p21	B-MED
and	O
downregulation	B-MED
of	O
cdc25C	B-MED
,	O
and	O
displayed	B-MED
a	O
good	O
safety	B-MED
profile	B-MED
.	O
Taken	O
together	O
,	O
these	O
findings	B-MED
demonstrate	B-MED
the	O
potential	B-MED
value	B-MED
of	O
SL4	B-MED
as	O
a	O
novel	O
multi	B-MED
-	I-MED
target	I-MED
anti	I-MED
-	I-MED
tumor	I-MED
drug	I-MED
candidate	I-MED
.	O
The	B-MED
Daniel	I-MED
K.	I-MED
Inouye	I-MED
College	I-MED
of	I-MED
Pharmacy	I-MED
Scripts	I-MED
:	O
Poha	B-MED
Berry	I-MED
(	O
Physalis	B-MED
peruviana	I-MED
)	O
with	O
Potential	B-MED
Anti	B-MED
-	I-MED
inflammatory	I-MED
and	O
Cancer	B-MED
Prevention	I-MED
Activities	B-MED
The	B-MED
Daniel	I-MED
K.	I-MED
Inouye	I-MED
College	I-MED
of	I-MED
Pharmacy	I-MED
,	O
during	O
a	O
historic	B-MED
event	I-MED
in	O
Spring	B-MED
2016	O
,	O
graduated	B-MED
the	O
first	O
two	O
students	B-MED
in	O
the	O
Pacific	B-MED
region	I-MED
to	O
earn	O
a	O
PhD	B-MED
in	O
pharmaceutical	B-MED
sciences	I-MED
at	O
the	O
University	B-MED
of	I-MED
Hawai'i	I-MED
at	O
Hilo	B-MED
.	O
The	O
college	B-MED
offers	O
PhD	B-MED
programs	B-MED
in	O
these	O
five	O
disciplines	B-MED
:	O
Cancer	B-MED
Biology	I-MED
,	O
Medicinal	B-MED
Chemistry	I-MED
,	O
Pharmaceutics	B-MED
,	O
Pharmacognosy	B-MED
,	O
and	O
Pharmacology	B-MED
.	O
One	O
of	O
the	O
Pharmacognosy	B-MED
dissertations	B-MED
focused	O
on	O
plant	B-MED
-	I-MED
derived	I-MED
natural	B-MED
products	I-MED
with	O
potential	B-MED
anti	B-MED
-	I-MED
inflammatory	I-MED
and	O
cancer	B-MED
chemopreventive	B-MED
activities	B-MED
.	O
Physalis	B-MED
peruviana	I-MED
(	O
Pp	B-MED
)	O
L.	O
originated	O
in	O
tropical	O
South	B-MED
America	I-MED
.	O
It	O
has	O
become	O
naturalized	B-MED
and	O
is	O
found	O
readily	O
on	O
the	O
Island	B-MED
of	I-MED
Hawai'i	I-MED
.	O
The	O
edible	B-MED
fruits	B-MED
are	O
commonly	O
known	O
as	O
cape	B-MED
gooseberry	I-MED
or	O
poha	B-MED
in	O
Hawai'i	B-MED
.	O
In	O
part	O
of	O
our	O
study	O
,	O
three	O
new	O
withanolides	B-MED
,	O
physaperuvin	B-MED
G	I-MED
(	O
1	O
)	O
,	O
physaperuvins	B-MED
I	I-MED
-	I-MED
J	I-MED
(	O
2	O
-	O
3	O
)	O
,	O
along	O
with	O
four	O
known	O
withanolides	B-MED
,	O
namely	O
,	O
4β	B-MED
-	I-MED
hydroxywithanolide	I-MED
E	I-MED
(	O
4	O
)	O
,	O
withaperuvin	B-MED
C	I-MED
(	O
5	O
)	O
,	O
and	O
physalactone	B-MED
(	O
6	O
)	O
,	O
coagulin	B-MED
(	O
7	O
)	O
were	O
isolated	B-MED
from	O
the	O
aerial	B-MED
parts	I-MED
of	O
P.	B-MED
peruviana	I-MED
.	O
In	O
addition	O
,	O
two	O
known	O
compounds	B-MED
,	O
phyperunolide	B-MED
F	I-MED
(	O
8)	O
,	O
and	O
withanolide	B-MED
S	I-MED
(	O
9	O
)	O
,	O
were	O
isolated	B-MED
and	O
identified	O
from	O
the	O
poha	B-MED
berry	I-MED
fruits	I-MED
.	O
The	O
structures	B-MED
and	O
absolute	B-MED
stereochemistry	I-MED
of	O
new	O
compounds	O
from	O
poha	B-MED
were	O
elucidated	O
by	O
several	O
spectroscopy	B-MED
methods	I-MED
:	O
Nuclear	B-MED
Magnetic	I-MED
Resonance	I-MED
(	I-MED
NMR	I-MED
)	I-MED
spectroscopy	I-MED
,	O
X	B-MED
-	I-MED
ray	I-MED
diffraction	I-MED
,	O
and	O
mass	B-MED
spectrometry	I-MED
analyses	B-MED
.	O
All	O
isolated	B-MED
poha	B-MED
compounds	B-MED
(	O
aerial	B-MED
parts	I-MED
and	O
fruits	B-MED
)	O
were	O
evaluated	O
for	O
their	O
anti	B-MED
-	I-MED
inflammatory	I-MED
activity	I-MED
with	O
lipopolysaccharide	B-MED
LPS	B-MED
(	O
LPS)-activated	O
murine	B-MED
macrophage	B-MED
RAW	I-MED
264.7	I-MED
cells	I-MED
,	O
and	O
tumor	B-MED
necrosis	I-MED
factor	I-MED
alpha	I-MED
(	O
TNF	B-MED
-	I-MED
α	I-MED
α)-activated	O
nuclear	B-MED
factor	I-MED
-	I-MED
kappa	I-MED
B	I-MED
(	O
NF	B-MED
-	I-MED
κB	I-MED
)	O
with	O
transfected	O
human	B-MED
embryonic	I-MED
kidney	I-MED
cells	I-MED
293	I-MED
.	O
Most	O
of	O
the	O
isolated	B-MED
natural	B-MED
compounds	I-MED
showed	O
activity	B-MED
with	O
these	O
assays	B-MED
.	O
Additional	O
studies	O
were	O
performed	O
with	O
models	B-MED
of	O
colon	B-MED
cancer	I-MED
.	O
Specifically	O
,	O
4β	B-MED
-	I-MED
hydroxywithanolide	I-MED
E	I-MED
(	O
4HWE	B-MED
)	O
inhibited	B-MED
the	O
growth	B-MED
of	O
colon	B-MED
cancer	I-MED
monolayer	B-MED
and	O
spheroid	B-MED
cultures	B-MED
.	O
The	O
compound	B-MED
induced	B-MED
cell	B-MED
cycle	I-MED
arrest	I-MED
at	O
low	B-MED
concentrations	I-MED
and	O
apoptosis	B-MED
at	O
higher	B-MED
concentrations	I-MED
.	O
These	O
data	B-MED
suggest	O
the	O
ingestion	B-MED
of	O
poha	B-MED
berries	I-MED
may	O
have	O
some	O
effect	O
on	O
the	O
prevalence	O
of	O
colon	B-MED
cancer	I-MED
.	O
Additionally	O
,	O
poha	B-MED
isolates	B-MED
compounds	I-MED
were	O
evaluated	O
for	O
their	O
growth	B-MED
inhibitory	I-MED
effects	I-MED
with	O
U251MG	B-MED
glioblastoma	I-MED
and	O
MDA	B-MED
-	I-MED
MB-231	I-MED
breast	I-MED
cancer	I-MED
cells	I-MED
that	O
harbor	O
aberrantly	O
-	O
active	O
signal	B-MED
transducer	I-MED
and	I-MED
activation	I-MED
of	I-MED
transcription	I-MED
3	I-MED
(	I-MED
STAT3	I-MED
)	I-MED
,	O
compared	O
to	O
normal	O
NIH-3T3	B-MED
mouse	I-MED
fibroblasts	I-MED
.	O
This	O
work	O
has	O
led	O
to	O
the	O
filing	O
of	O
three	O
provisional	B-MED
patents	I-MED
with	O
the	O
University	B-MED
of	I-MED
Hawai'i	I-MED
Office	I-MED
of	I-MED
Technology	I-MED
Transfer	I-MED
and	I-MED
Economic	I-MED
Development	I-MED
.	O
Metabolite	B-MED
mapping	B-MED
by	O
consecutive	O
nanostructure	B-MED
and	O
silver	B-MED
-	I-MED
assisted	I-MED
mass	I-MED
spectrometry	I-MED
imaging	I-MED
on	O
tissue	B-MED
sections	I-MED
Nanostructure	B-MED
-	I-MED
based	I-MED
mass	I-MED
spectrometry	I-MED
imaging	I-MED
(	O
MSI	B-MED
)	O
is	O
a	O
promising	O
technology	O
for	O
molecular	B-MED
imaging	I-MED
of	O
small	B-MED
molecules	I-MED
,	O
without	O
the	O
complex	O
chemical	O
background	O
typically	O
encountered	O
in	O
matrix	B-MED
-	I-MED
assisted	I-MED
molecular	I-MED
imaging	I-MED
approaches	O
.	O
Here	O
,	O
we	O
have	O
enhanced	O
these	O
surfaces	B-MED
with	O
silver	B-MED
(	O
Ag	B-MED
)	O
to	O
provide	O
a	O
second	O
tier	O
of	O
MSI	B-MED
data	I-MED
from	O
a	O
single	O
sample	O
.	O
MSI	B-MED
data	I-MED
was	O
acquired	O
through	O
the	O
application	B-MED
of	O
laser	B-MED
desorption	I-MED
/	I-MED
ionization	I-MED
mass	I-MED
spectrometry	I-MED
to	O
biological	B-MED
samples	I-MED
imprinted	O
onto	O
desorption	B-MED
/	I-MED
ionization	I-MED
on	I-MED
silicon	I-MED
(	O
DIOS	B-MED
)	O
substrates	B-MED
.	O
Following	O
initial	O
analysis	B-MED
,	O
ultra	B-MED
-	I-MED
thin	I-MED
Ag	I-MED
layers	I-MED
were	O
overlaid	O
onto	O
the	O
followed	O
by	O
MSI	B-MED
analysis	I-MED
(	O
Ag	B-MED
-	I-MED
DIOS	I-MED
MSI	I-MED
)	O
.	O
This	O
approach	O
was	O
first	O
demonstrated	O
for	O
fingermark	O
small	B-MED
molecules	I-MED
including	O
environmental	B-MED
contaminants	B-MED
and	O
sebum	B-MED
components	O
.	O
Subsequently	O
,	O
this	O
bimodal	O
method	O
was	O
translated	O
to	O
lipids	B-MED
and	O
metabolites	B-MED
in	O
fore	B-MED
-	I-MED
stomach	I-MED
sections	I-MED
from	O
a	O
6	B-MED
-	I-MED
bromoisatin	I-MED
chemopreventative	B-MED
murine	B-MED
mouse	I-MED
model	I-MED
.	O
DIOS	B-MED
MSI	I-MED
allowed	O
mapping	B-MED
of	O
common	O
ions	B-MED
in	O
fingermarks	O
as	O
well	O
as	O
6	B-MED
-	I-MED
bromoisatin	I-MED
metabolites	B-MED
and	O
lipids	B-MED
in	O
murine	B-MED
fore	I-MED
-	I-MED
stomach	I-MED
.	O
Furthermore	O
,	O
DIOS	B-MED
MSI	I-MED
was	O
complemented	O
by	O
the	O
Ag	B-MED
-	I-MED
DIOS	I-MED
MSI	I-MED
of	O
Ag	B-MED
-	I-MED
adductable	I-MED
lipids	I-MED
such	O
as	O
wax	B-MED
esters	I-MED
in	O
fingermarks	O
and	O
cholesterol	B-MED
in	O
murine	B-MED
fore	I-MED
-	I-MED
stomach	I-MED
.	O
Gastrointestinal	B-MED
acid	I-MED
condensation	B-MED
products	B-MED
of	O
6	B-MED
-	I-MED
bromoisatin	I-MED
,	O
such	O
as	O
the	O
6,6'-dibromoindirubin	B-MED
mapped	O
herein	O
,	O
are	O
very	O
challenging	O
to	O
isolate	B-MED
and	O
characterize	B-MED
.	O
By	O
re	O
-	O
analyzing	O
the	O
same	O
tissue	B-MED
imprints	O
,	O
this	O
metabolite	B-MED
was	O
readily	O
detected	O
by	O
DIOS	B-MED
,	O
placed	O
in	O
a	O
tissue	B-MED
-	I-MED
specific	I-MED
spatial	I-MED
context	I-MED
,	O
and	O
subsequently	O
overlaid	O
with	O
additional	O
lipid	B-MED
distributions	I-MED
acquired	O
using	O
Ag	B-MED
-	I-MED
DIOS	I-MED
MSI	I-MED
.	O
The	O
ability	O
to	O
place	O
metabolite	B-MED
and	O
lipid	B-MED
classes	O
in	O
a	O
tissue	B-MED
-	I-MED
specific	I-MED
context	O
makes	O
this	O
novel	O
method	O
suited	O
to	O
MSI	B-MED
analyses	I-MED
where	O
the	O
collection	O
of	O
additional	O
information	O
from	O
the	O
same	O
sample	O
maximises	O
resource	O
use	O
,	O
and	O
also	O
maximises	O
the	O
number	O
of	O
annotated	O
small	B-MED
molecules	I-MED
,	O
in	O
particular	O
for	O
metabolites	B-MED
that	O
are	O
typically	O
undetectable	B-MED
with	O
traditional	O
platforms	O
.	O
Copyright	O
©	O
2017	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O
Targeting	B-MED
accuracy	B-MED
of	O
single	B-MED
-	I-MED
isocenter	I-MED
intensity	B-MED
-	I-MED
modulated	I-MED
radiosurgery	B-MED
for	O
multiple	O
lesions	B-MED
To	O
investigate	B-MED
the	O
targeting	B-MED
accuracy	B-MED
of	O
intensity	B-MED
-	I-MED
modulated	I-MED
SRS	B-MED
(	O
IMRS	B-MED
)	O
plans	B-MED
designed	O
to	O
simultaneously	O
treat	O
multiple	O
brain	B-MED
metastases	B-MED
with	O
a	O
single	B-MED
isocenter	I-MED
.	O
A	O
home	B-MED
-	I-MED
made	I-MED
acrylic	I-MED
phantom	B-MED
able	O
to	O
support	O
a	O
film	B-MED
(	O
EBT3	B-MED
)	O
in	O
its	O
coronal	B-MED
plane	I-MED
was	O
used	O
.	O
The	O
phantom	B-MED
was	O
CT	B-MED
scanned	I-MED
and	O
three	O
coplanar	O
small	O
targets	B-MED
(	O
a	O
central	B-MED
and	O
two	O
peripheral	B-MED
)	O
were	O
outlined	O
in	O
the	O
Eclipse	B-MED
system	I-MED
.	O
Peripheral	B-MED
targets	B-MED
were	O
6	O
cm	O
apart	O
from	O
the	O
central	B-MED
one	O
.	O
A	O
reference	O
IMRS	B-MED
plan	B-MED
was	O
designed	O
to	O
simultaneously	O
treat	O
the	O
three	O
targets	B-MED
,	O
but	O
only	O
a	O
single	B-MED
isocenter	I-MED
located	O
at	O
the	O
center	O
of	O
the	O
central	B-MED
target	B-MED
was	O
used	O
.	O
After	O
positioning	B-MED
the	O
phantom	B-MED
on	O
the	O
linac	B-MED
using	O
the	O
room	B-MED
lasers	B-MED
,	O
a	O
CBCT	B-MED
scan	I-MED
was	O
acquired	O
and	O
the	O
reference	O
plan	B-MED
were	O
mapped	B-MED
on	O
it	O
,	O
by	O
placing	O
the	O
planned	O
isocenter	B-MED
at	O
the	O
intersection	B-MED
of	O
the	O
landmarks	O
used	O
in	O
the	O
film	B-MED
showing	O
the	O
linac	B-MED
isocenter	B-MED
.	O
The	O
mapped	B-MED
plan	B-MED
was	O
then	O
recalculated	B-MED
and	O
delivered	B-MED
.	O
The	O
film	B-MED
dose	B-MED
distribution	I-MED
was	O
derived	O
using	O
a	O
cloud	B-MED
computing	I-MED
application	I-MED
(	O
www.radiochromic.com	B-MED
)	O
that	O
uses	O
a	O
triple	O
-	O
channel	O
dosimetry	B-MED
algorithm	B-MED
.	O
Comparison	O
of	O
dose	B-MED
distributions	I-MED
using	O
the	O
gamma	B-MED
index	I-MED
(	O
5%/1	O
mm	O
)	O
were	O
performed	O
over	O
a	O
5	O
×	O
5	O
cm(2	O
)	O
region	O
centered	O
over	O
each	O
target	B-MED
.	O
2D	B-MED
shifts	I-MED
required	O
to	O
get	O
the	O
best	O
gamma	B-MED
passing	O
rates	O
on	O
the	O
peripheral	B-MED
target	B-MED
regions	O
were	O
compared	O
with	O
the	O
reported	O
ones	O
for	O
the	O
central	B-MED
target	B-MED
.	O
The	O
experiment	B-MED
was	O
repeated	O
ten	O
times	O
in	O
different	O
sessions	B-MED
.	O
Average	O
2D	B-MED
shifts	I-MED
required	O
to	O
achieve	O
optimal	O
gamma	B-MED
passing	O
rates	O
(	O
99	O
%	O
,	O
97	O
%	O
,	O
99	O
%	O
)	O
were	O
0.7	O
mm	O
(	O
SD	O
:	O
0.3	O
mm	O
)	O
,	O
0.8	O
mm	O
(	O
SD	O
:	O
0.4	O
mm	O
)	O
and	O
0.8	O
mm	O
(	O
SD	O
:	O
0.3	O
mm	O
)	O
,	O
for	O
the	O
central	B-MED
and	O
the	O
two	O
peripheral	B-MED
targets	B-MED
,	O
respectively	O
.	O
No	O
statistical	O
differences	O
(	O
p	O
>	O
0.05	O
)	O
were	O
found	O
for	O
targeting	B-MED
accuracy	B-MED
between	O
the	O
central	B-MED
and	O
the	O
two	O
peripheral	B-MED
targets	B-MED
.	O
The	O
study	B-MED
revealed	O
a	O
targeting	B-MED
accuracy	B-MED
within	O
1	O
mm	O
for	O
off-	O
isocenter	B-MED
targets	B-MED
within	O
6	O
cm	O
of	O
the	O
linac	B-MED
isocenter	B-MED
,	O
when	O
a	O
single	B-MED
-	I-MED
isocenter	I-MED
IMRS	B-MED
plan	B-MED
is	O
designed	O
.	O
Maternal	B-MED
vitamin	B-MED
D	I-MED
levels	B-MED
and	O
the	O
risk	B-MED
of	O
perinatal	B-MED
death	I-MED
To	O
determine	O
the	O
association	B-MED
between	O
maternal	B-MED
vitamin	B-MED
D	I-MED
levels	B-MED
and	O
perinatal	B-MED
death	I-MED
.	O
A	O
retrospective	B-MED
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
of	O
all	O
non	O
-	O
anomalous	O
,	O
singleton	B-MED
births	B-MED
(	O
≥24	O
weeks	B-MED
)	O
with	O
perinatal	B-MED
death	I-MED
compared	O
to	O
a	O
matched	O
control	B-MED
group	I-MED
.	O
Only	O
pregnancies	B-MED
with	O
a	O
recorded	O
vitamin	B-MED
D	I-MED
level	B-MED
at	O
booking	O
(	O
8	O
-	O
19	O
weeks	B-MED
gestation	B-MED
)	O
were	O
included	O
for	O
analysis	B-MED
.	O
Maternal	B-MED
vitamin	B-MED
D	I-MED
levels	B-MED
were	O
categorized	O
into	O
normal	B-MED
,	O
deficient	B-MED
and	O
insufficient	B-MED
cohorts	B-MED
and	O
variables	B-MED
compared	O
between	O
the	O
three	O
groups	B-MED
.	O
There	O
were	O
31	O
perinatal	B-MED
deaths	I-MED
which	O
were	O
compared	O
to	O
111	O
controls	B-MED
.	O
Median	O
vitamin	B-MED
D	I-MED
levels	B-MED
were	O
lower	O
in	O
the	O
perinatal	B-MED
death	I-MED
cohort	B-MED
compared	O
to	O
the	O
control	B-MED
group	I-MED
(	O
55	O
nmol	O
/	O
L	O
versus	O
64	O
nmol	O
/	O
L	O
,	O
p	O
=	O
0.43	O
)	O
.	O
There	O
was	O
no	O
significant	O
increase	O
in	O
deaths	B-MED
between	O
the	O
normal	B-MED
and	O
deficient	B-MED
(	O
p	O
=	O
0.33	O
)	O
or	O
insufficient	B-MED
(	O
p	O
=	O
0.09	O
)	O
groups	B-MED
.	O
Low	O
maternal	B-MED
vitamin	B-MED
D	I-MED
levels	B-MED
at	O
booking	O
were	O
not	O
associated	B-MED
with	I-MED
an	O
increased	O
risk	B-MED
of	O
perinatal	B-MED
demise	I-MED
.	O
Post	O
-	O
synthetic	O
conversion	B-MED
of	O
5	B-MED
-	I-MED
pivaloyloxymethyluridine	I-MED
present	B-MED
in	O
a	O
support	O
-	O
bound	O
RNA	B-MED
oligomer	B-MED
into	O
biologically	B-MED
relevant	B-MED
derivatives	B-MED
of	O
5	B-MED
-	I-MED
methyluridine	I-MED
A	O
post	O
-	O
synthetic	O
reaction	B-MED
of	O
5	B-MED
-	I-MED
pivaloyloxymethyluridine	I-MED
(	O
present	B-MED
in	O
a	O
support	O
-	O
bound	O
RNA	B-MED
oligomer	B-MED
)	O
with	O
various	O
nucleophilic	B-MED
reagents	I-MED
furnished	O
efficiently	O
the	O
corresponding	O
products	B-MED
bearing	O
one	O
aof	O
the	O
tRNA	B-MED
wobble	I-MED
5	B-MED
-	I-MED
methyluridines	I-MED
(	O
mnm(5)U	B-MED
,	O
cmnm(5)U	B-MED
,	O
τm(5)U	B-MED
,	O
nm(5)U	B-MED
,	O
inm(5)U	B-MED
or	O
cnm(5)U	B-MED
)	O
.	O
The	O
syntheses	B-MED
of	O
oligoribonucleotides	B-MED
modified	B-MED
with	O
inm(5)U	B-MED
and	O
cnm(5)U	B-MED
are	O
reported	O
for	O
the	O
first	O
time	O
.	O
DT	B-MED
MRI	I-MED
microstructural	B-MED
cortical	B-MED
lesion	B-MED
damage	B-MED
does	O
not	O
explain	O
cognitive	B-MED
impairment	I-MED
in	O
MS	B-MED
We	O
combined	O
double	B-MED
inversion	I-MED
recovery	I-MED
(	O
DIR	B-MED
)	O
and	O
diffusion	B-MED
tensor	I-MED
(	I-MED
DT	I-MED
)	I-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
(	I-MED
MRI	I-MED
)	I-MED
to	O
quantify	B-MED
the	O
severity	B-MED
of	O
cortical	B-MED
lesion	B-MED
(	O
CL	B-MED
)	O
microstructural	B-MED
tissue	B-MED
abnormalities	B-MED
in	O
a	O
large	B-MED
cohort	B-MED
of	O
relapse	B-MED
-	O
onset	B-MED
multiple	B-MED
sclerosis	I-MED
(	O
MS	B-MED
)	O
patients	B-MED
and	O
its	O
contribution	B-MED
to	O
cognitive	B-MED
dysfunction	I-MED
.	O
DIR	B-MED
,	O
DT	B-MED
,	O
dual	B-MED
-	I-MED
echo	I-MED
,	O
and	O
three	B-MED
-	I-MED
dimensional	I-MED
(	O
3D	B-MED
)	O
T1	B-MED
-	I-MED
weighted	I-MED
scans	I-MED
were	O
acquired	O
from	O
149	O
MS	B-MED
patients	B-MED
and	O
40	O
controls	B-MED
.	O
Cognitively	B-MED
impaired	I-MED
(	O
CI	B-MED
)	O
patients	B-MED
had	O
⩾2	O
abnormal	B-MED
neuropsychological	B-MED
tests	I-MED
.	O
Diffusivity	B-MED
values	I-MED
in	O
CLs	B-MED
,	O
cortex	B-MED
,	O
white	B-MED
matter	I-MED
(	I-MED
WM	I-MED
)	I-MED
lesions	I-MED
,	O
and	O
normal	B-MED
-	I-MED
appearing	I-MED
(	I-MED
NA	I-MED
)	I-MED
WM	I-MED
were	O
assessed	B-MED
.	O
Predictors	B-MED
of	O
cognitive	B-MED
impairment	I-MED
were	O
identified	B-MED
using	O
a	O
random	B-MED
forest	I-MED
analysis	I-MED
.	O
Compared	O
to	O
controls	B-MED
,	O
MS	B-MED
patients	B-MED
had	O
lower	B-MED
normalized	B-MED
brain	I-MED
volume	I-MED
(	O
NBV	B-MED
)	O
,	O
gray	B-MED
matter	I-MED
volume	I-MED
(	O
GMV	B-MED
)	O
,	O
WM	B-MED
volume	I-MED
,	O
lower	B-MED
fractional	B-MED
anisotropy	I-MED
(	O
FA	B-MED
)	O
,	O
and	O
higher	B-MED
mean	B-MED
diffusivity	I-MED
in	O
cortex	B-MED
and	O
normal	B-MED
-	I-MED
appearing	I-MED
white	I-MED
matter	I-MED
(	O
NAWM	B-MED
)	O
.	O
A	O
total	O
of	O
44	O
(	O
29.5	O
%	O
)	O
patients	B-MED
were	O
CI	B-MED
.	O
Compared	O
to	O
cognitively	B-MED
preserved	I-MED
(	O
CP	B-MED
)	O
,	O
CI	B-MED
patients	B-MED
had	O
higher	B-MED
T2	B-MED
WM	I-MED
lesion	I-MED
volume	I-MED
(	O
LV	B-MED
)	O
,	O
lower	B-MED
NBV	B-MED
and	O
GMV	B-MED
,	O
and	O
more	O
severe	B-MED
diffusivity	B-MED
abnormalities	B-MED
in	O
WM	B-MED
lesions	I-MED
,	O
cortex	B-MED
,	O
and	O
NAWM	B-MED
.	O
CL	B-MED
measures	B-MED
did	O
not	B-MED
differ	I-MED
between	O
CI	B-MED
and	O
CP	B-MED
patients	I-MED
.	O
Cortex	B-MED
FA	B-MED
,	O
age	B-MED
,	O
disease	B-MED
duration	I-MED
,	O
T2	B-MED
WM	I-MED
LV	I-MED
,	O
and	O
GMV	B-MED
best	O
predicted	O
MS	B-MED
-related	O
cognitive	B-MED
impairment	I-MED
(	O
C	O
-	O
statistic	O
=	O
0.88	O
)	O
.	O
"	O
Diffuse	B-MED
"	O
GM	B-MED
and	O
NAWM	B-MED
damage	B-MED
and	O
WM	B-MED
lesions	I-MED
,	O
rather	O
than	O
intrinsic	B-MED
CL	B-MED
damage	B-MED
,	O
contribute	O
to	O
cognitive	B-MED
impairment	I-MED
in	O
MS	B-MED
.	O
Post	B-MED
endodontic	B-MED
pain	I-MED
following	O
single	O
-	O
visit	O
root	B-MED
canal	I-MED
preparation	I-MED
with	O
rotary	B-MED
vs	O
reciprocating	B-MED
instruments	I-MED
:	O
a	O
meta	B-MED
-	I-MED
analysis	I-MED
of	O
randomized	B-MED
clinical	I-MED
trials	I-MED
In	O
endodontic	B-MED
therapy	I-MED
,	O
continuous	O
rotary	B-MED
instrumentation	I-MED
reduced	O
debris	B-MED
compared	O
to	O
reciprocal	B-MED
instrumentation	I-MED
,	O
which	O
might	O
affect	O
the	O
incidence	B-MED
of	O
post	B-MED
-	I-MED
endodontic	I-MED
pain	I-MED
(	O
PP	B-MED
)	O
.	O
The	O
aim	O
of	O
our	O
study	B-MED
was	O
to	O
assess	O
whether	O
PP	B-MED
incidence	B-MED
and	O
levels	O
were	O
influenced	O
by	O
the	O
choice	O
of	O
rotary	B-MED
or	O
reciprocal	B-MED
instruments	I-MED
.	O
In	O
this	O
meta	B-MED
-	I-MED
analysis	I-MED
the	O
Pubmed	B-MED
and	O
EM	B-MED
databases	I-MED
were	O
searched	O
for	O
prospective	O
clinical	B-MED
randomized	I-MED
trials	I-MED
published	O
before	O
April	O
20	O
,	O
2016	O
,	O
using	O
combinations	O
of	O
the	O
keywords	O
:	O
root	B-MED
canal	I-MED
preparation	I-MED
/	O
instrumentation	B-MED
/	O
treatment	B-MED
/	O
therapy	B-MED
;	O
post	B-MED
-	I-MED
operative	I-MED
/	O
endodontic	B-MED
pain	I-MED
;	O
reciprocal	B-MED
and	O
rotary	B-MED
instruments	I-MED
.	O
Three	O
studies	B-MED
were	O
included	O
,	O
involving	O
a	O
total	O
of	O
1,317	O
patients	B-MED
,	O
659	O
treated	O
with	O
reciprocating	B-MED
instruments	I-MED
and	O
658	O
treated	O
with	O
rotary	B-MED
instruments	I-MED
.	O
PP	B-MED
was	O
reported	O
in	O
139	O
patients	B-MED
in	O
the	O
reciprocating	B-MED
group	I-MED
and	O
172	O
in	O
the	O
rotary	B-MED
group	I-MED
.	O
The	O
PP	B-MED
incidence	B-MED
odds	O
ratio	O
was	O
1.27	O
with	O
95	O
%	O
confidence	B-MED
interval	I-MED
(	O
CI	B-MED
)	O
(	O
0.25	O
,	O
6.52	O
)	O
favoring	O
rotary	B-MED
instruments	I-MED
.	O
The	O
mild	B-MED
,	O
moderate	B-MED
and	O
severe	B-MED
PP	B-MED
levels	O
odds	O
ratios	O
were	O
0.31	O
(	O
0.11	O
,	O
0.84	O
)	O
,	O
2.24	O
(	O
0.66	O
,	O
7.59	O
)	O
and	O
11.71	O
(	O
0.63	O
,	O
218.15	O
)	O
,	O
respectively	O
.	O
No	O
evidence	O
of	O
publication	O
bias	O
was	O
found	O
.	O
Rotary	B-MED
instrument	I-MED
choice	O
in	O
endodontic	B-MED
therapy	I-MED
is	O
associated	B-MED
with	I-MED
a	O
lower	O
incidence	B-MED
of	O
PP	B-MED
than	O
reciprocating	B-MED
instruments	I-MED
,	O
while	O
reciprocating	B-MED
instruments	I-MED
are	O
associated	B-MED
with	I-MED
less	O
mild	O
PP	B-MED
incidence	B-MED
.	O
Efficacy	B-MED
of	O
Intravenous	B-MED
Chlorothiazide	B-MED
for	O
Refractory	B-MED
Acute	B-MED
Decompensated	I-MED
Heart	I-MED
Failure	I-MED
Unresponsive	B-MED
to	O
Adjunct	B-MED
Metolazone	B-MED
To	O
assess	O
the	O
efficacy	B-MED
of	O
intravenous	B-MED
chlorothiazide	B-MED
in	O
patients	B-MED
with	O
acute	B-MED
decompensated	I-MED
heart	I-MED
failure	I-MED
(	O
ADHF	B-MED
)	O
who	O
were	O
determined	O
to	O
be	O
loop	B-MED
diuretic	I-MED
resistant	B-MED
and	O
refractory	B-MED
to	O
metolazone	B-MED
.	O
Retrospective	B-MED
cohort	I-MED
study	I-MED
with	O
patients	B-MED
serving	O
as	O
their	O
own	O
controls	B-MED
.	O
Large	B-MED
,	O
academic	B-MED
,	O
tertiary	B-MED
care	I-MED
hospital	I-MED
.	O
Forty	O
-	O
five	O
patients	B-MED
with	O
ADHF	B-MED
who	O
had	O
an	O
inadequate	B-MED
response	B-MED
to	O
high	B-MED
-	I-MED
dose	I-MED
loop	B-MED
diuretics	I-MED
and	O
then	O
received	O
at	O
least	O
one	O
dose	B-MED
of	O
oral	B-MED
metolazone	B-MED
5	O
mg	O
or	O
greater	B-MED
(	O
metolazone	B-MED
index	B-MED
dose	I-MED
)	O
followed	O
by	O
at	O
least	O
one	O
dose	B-MED
of	O
intravenous	B-MED
chlorothiazide	B-MED
500	O
mg	O
(	O
chlorothiazide	B-MED
index	B-MED
dose	I-MED
)	O
if	O
the	O
response	O
to	O
metolazone	B-MED
was	O
considered	O
inadequate	B-MED
,	O
according	O
to	O
the	O
institutional	B-MED
protocol	I-MED
,	O
between	O
February	O
4	O
,	O
2013	O
,	O
and	O
February	O
28	O
,	O
2015	O
,	O
were	O
included	O
.	O
If	O
multiple	O
doses	B-MED
of	O
metolazone	B-MED
were	O
administered	B-MED
,	O
the	O
last	O
dose	B-MED
given	O
before	O
the	O
chlorothiazide	B-MED
index	B-MED
dose	I-MED
was	O
considered	O
the	O
index	B-MED
dose	I-MED
;	O
the	O
metolazone	B-MED
index	B-MED
dose	I-MED
had	O
to	O
have	O
been	O
administered	B-MED
more	O
than	O
2	O
hours	B-MED
before	O
the	O
chlorothiazide	B-MED
index	B-MED
dose	I-MED
.	O
Data	B-MED
for	O
a	O
total	O
of	O
90	O
diuretic	B-MED
doses	B-MED
(	O
45	O
metolazone	B-MED
,	O
45	O
chlorothiazide	B-MED
)	O
were	O
included	O
in	O
the	O
analysis	B-MED
.	O
The	O
median	O
dose	B-MED
of	O
loop	B-MED
diuretic	I-MED
in	O
intravenous	B-MED
furosemide	B-MED
equivalents	O
given	O
over	O
the	O
24-	O
hour	B-MED
period	B-MED
before	O
the	O
metolazone	B-MED
index	B-MED
dose	I-MED
was	O
400	O
mg	O
.	O
The	O
average	O
length	O
of	O
stay	B-MED
was	O
34.7	O
days	B-MED
,	O
and	O
in	B-MED
-	I-MED
hospital	I-MED
mortality	I-MED
was	O
35.6	O
%	O
(	O
16/45	O
patients	B-MED
)	O
.	O
The	O
primary	O
end	B-MED
point	I-MED
of	O
a	O
net	B-MED
-	I-MED
negative	I-MED
urine	B-MED
output	I-MED
of	O
500	O
ml	O
or	O
greater	O
during	O
the	O
12	O
hours	B-MED
after	O
the	O
index	B-MED
dose	I-MED
occurred	O
in	O
42.2	O
%	O
(	O
19/45	O
patients	B-MED
)	O
and	O
35.5	O
%	O
(	O
16/45	O
patients	B-MED
)	O
for	O
the	O
chlorothiazide	B-MED
and	O
metolazone	B-MED
doses	B-MED
,	O
respectively	O
(	O
p=0.581	O
)	O
.	O
The	O
median	O
12-	O
hour	B-MED
urine	B-MED
output	I-MED
following	O
administration	B-MED
of	O
metolazone	B-MED
was	O
810	O
ml	O
(	O
interquartile	B-MED
range	I-MED
[	O
IQR	B-MED
]	O
866	O
ml	O
)	O
versus	O
1075	O
ml	O
(	O
IQR	B-MED
940	O
ml	O
)	O
following	O
administration	B-MED
of	O
chlorothiazide	B-MED
(	O
p=0.363	O
)	O
.	O
Compared	B-MED
with	O
metolazone	B-MED
,	O
the	O
chlorothiazide	B-MED
doses	B-MED
did	O
not	O
result	O
in	O
an	O
increase	B-MED
in	O
urine	B-MED
output	I-MED
of	O
at	O
least	O
500	O
ml	O
during	O
the	O
12	O
hours	B-MED
following	O
the	O
dose	B-MED
relative	O
to	O
the	O
12	O
hours	B-MED
before	O
the	O
dose	B-MED
(	O
31.1	O
%	O
vs	O
22.2	O
%	O
,	O
p=0.754	O
)	O
.	O
No	O
significant	O
difference	O
in	O
achievement	O
of	O
net	B-MED
-	I-MED
negative	I-MED
urine	B-MED
output	I-MED
of	O
500	O
ml	O
or	O
greater	O
during	O
the	O
12	O
hours	B-MED
following	O
the	O
chlorothiazide	B-MED
or	O
metolazone	B-MED
dose	B-MED
was	O
noted	O
(	O
42.2	O
%	O
for	O
chlorothiazide	B-MED
vs	O
35.5	O
%	O
for	O
metolazone	B-MED
,	O
p=0.581	O
)	O
.	O
The	O
addition	O
of	O
intravenous	B-MED
chlorothiazide	B-MED
did	O
not	O
result	O
in	O
improved	B-MED
diuresis	B-MED
in	O
patients	B-MED
with	O
ADHF	B-MED
determined	O
to	O
be	O
refractory	B-MED
to	O
loop	B-MED
diuretic	I-MED
s	O
and	O
adjunctive	B-MED
oral	B-MED
metolazone	B-MED
.	O
Fine	O
structure	O
of	O
interleukin	B-MED
18	I-MED
(	I-MED
IL-18	I-MED
)	I-MED
receptor	I-MED
-	O
immunoreactive	B-MED
neurons	B-MED
in	O
the	O
retrosplenial	B-MED
cortex	I-MED
and	O
its	O
changes	O
in	O
IL18	B-MED
knockout	B-MED
mice	I-MED
Interleukin	B-MED
18	I-MED
(	O
IL-18	B-MED
)	O
participates	O
in	O
the	O
inflammatory	B-MED
immune	B-MED
response	I-MED
immune	B-MED
response	I-MED
of	O
lymphocytes	B-MED
.	O
Delay	B-MED
in	I-MED
learning	I-MED
or	I-MED
memory	I-MED
are	O
common	O
in	O
the	O
IL-18	B-MED
knockout	B-MED
mouse	I-MED
.	O
Many	O
IL-18	B-MED
-	O
immunoreactive	B-MED
neurons	B-MED
are	O
found	O
in	O
the	O
retrosplenial	B-MED
cortex	I-MED
(	O
RSC	B-MED
)	O
and	O
the	O
subiculum	B-MED
.	O
These	O
neurons	B-MED
also	O
contain	O
the	O
IL-18	B-MED
receptor	I-MED
.	O
We	O
determined	O
the	O
location	O
and	O
the	O
ultrastructure	B-MED
of	O
the	O
IL-18	B-MED
receptor	I-MED
-	O
immunoreactive	B-MED
neurons	B-MED
in	O
the	O
RSC	B-MED
and	O
observed	O
changes	O
in	O
the	O
IL-18	B-MED
receptor	I-MED
-	O
immunoreactive	B-MED
neurons	B-MED
of	O
the	O
IL-18	B-MED
knockout	B-MED
mouse	I-MED
.	O
The	O
IL-18	B-MED
receptor	I-MED
-	O
immunoreactive	B-MED
neurons	B-MED
were	O
found	O
specifically	O
in	O
layer	B-MED
V	I-MED
of	I-MED
the	I-MED
granular	I-MED
RSC	I-MED
.	O
They	O
were	O
medium	O
-	O
sized	O
neurons	B-MED
with	O
a	O
light	O
oval	B-MED
nucleus	I-MED
and	O
had	O
little	O
cytoplasm	B-MED
with	O
many	O
free	B-MED
ribosomes	I-MED
,	O
rough	O
endoplasmic	B-MED
reticulum	I-MED
and	O
many	O
mitochondria	B-MED
,	O
but	O
no	O
Nissl	B-MED
bodies	I-MED
.	O
The	O
number	O
of	O
axosomatic	B-MED
terminals	I-MED
was	O
about	O
six	O
per	O
section	O
.	O
The	O
IL-18	B-MED
receptor	I-MED
-	O
immunoreactive	B-MED
neurons	B-MED
were	O
not	O
found	O
in	O
the	O
RSC	B-MED
in	O
the	O
IL-18	B-MED
knockout	B-MED
mouse	I-MED
at	O
5	O
or	O
9	O
weeks	O
of	O
age	O
.	O
However	O
,	O
many	O
small	B-MED
electron	I-MED
-	I-MED
dense	I-MED
neurons	B-MED
were	O
found	O
in	O
layer	B-MED
V	I-MED
V.	O
Both	O
the	O
nucleus	B-MED
and	O
cytoplasm	B-MED
were	O
electron	B-MED
-	I-MED
dense	I-MED
,	O
but	O
not	O
necrotic	O
.	O
The	O
mitochondria	B-MED
and	O
rough	B-MED
endoplasmic	I-MED
reticulum	I-MED
were	O
swollen	B-MED
.	O
The	O
IL-18	B-MED
receptor	I-MED
-	O
immunoreactive	B-MED
neurons	B-MED
were	O
presumed	O
to	O
be	O
degenerating	B-MED
.	O
The	O
degeneration	B-MED
of	O
the	O
IL18	B-MED
-	I-MED
receptor	I-MED
-	O
immunoreactive	B-MED
neurons	B-MED
in	O
the	O
RSC	B-MED
may	O
cause	O
the	O
abnormal	B-MED
behaviors	I-MED
of	O
the	O
IL-18	B-MED
knockout	B-MED
mice	I-MED
.	O
Problem	B-MED
-	I-MED
based	I-MED
learning	I-MED
using	O
patient	B-MED
patient	B-MED
-simulated	I-MED
videos	I-MED
showing	O
daily	B-MED
life	B-MED
for	O
a	O
comprehensive	B-MED
clinical	B-MED
approach	B-MED
We	O
examined	O
whether	O
problem	B-MED
-	I-MED
based	I-MED
learning	I-MED
tutorials	B-MED
using	O
patient	B-MED
patient	B-MED
-simulated	I-MED
videos	I-MED
showing	O
daily	B-MED
life	B-MED
are	O
more	O
practical	O
for	O
clinical	B-MED
learning	B-MED
,	O
compared	O
with	O
traditional	O
paper	B-MED
-	I-MED
based	I-MED
problem	I-MED
-	I-MED
based	I-MED
learning	I-MED
,	O
for	O
the	O
consideration	O
rate	B-MED
of	I-MED
psychosocial	I-MED
issues	I-MED
and	O
the	O
recall	B-MED
rate	I-MED
for	O
experienced	B-MED
learning	I-MED
.	O
Twenty	O
-	O
two	O
groups	B-MED
with	O
120	O
fifth-	O
year	B-MED
students	B-MED
were	O
each	O
assigned	O
paper	B-MED
-	I-MED
based	I-MED
problem	I-MED
-	I-MED
based	I-MED
learning	I-MED
and	O
video	B-MED
video	B-MED
-based	I-MED
problem	I-MED
-	I-MED
based	I-MED
learning	I-MED
using	O
patient	B-MED
patient	B-MED
-simulated	I-MED
videos	I-MED
.	O
We	O
compared	O
target	B-MED
achievement	B-MED
rates	I-MED
in	O
questionnaires	B-MED
using	O
the	O
Wilcoxon	B-MED
signed	I-MED
-	I-MED
rank	I-MED
test	I-MED
and	O
discussion	B-MED
contents	B-MED
diversity	B-MED
using	O
the	O
Mann	B-MED
-	I-MED
Whitney	I-MED
U	I-MED
test	I-MED
.	O
A	O
follow	B-MED
-	I-MED
up	I-MED
survey	B-MED
used	O
a	O
chi	B-MED
-	I-MED
square	I-MED
test	I-MED
to	O
measure	O
students	B-MED
'	O
recall	O
of	O
cases	O
in	O
three	O
categories	B-MED
:	O
video	B-MED
,	O
paper	B-MED
,	O
and	O
non	B-MED
-	I-MED
experienced	I-MED
.	O
Video	B-MED
Video	B-MED
-based	I-MED
problem	I-MED
-	I-MED
based	I-MED
learning	I-MED
displayed	O
significantly	O
higher	O
achievement	B-MED
rates	I-MED
for	O
imagining	O
authentic	B-MED
patients	I-MED
(	O
p=0.001	O
)	O
,	O
incorporating	O
a	O
comprehensive	B-MED
approach	B-MED
including	O
psychosocial	B-MED
aspects	I-MED
(	O
p<0.001	O
)	O
,	O
and	O
satisfaction	O
with	O
sessions	B-MED
(	O
p=0.001	O
)	O
.	O
No	B-MED
significant	I-MED
differences	I-MED
existed	O
in	O
the	O
discussion	B-MED
contents	B-MED
diversity	B-MED
regarding	O
the	O
International	B-MED
Classification	I-MED
of	I-MED
Primary	I-MED
Care	I-MED
Second	I-MED
Edition	I-MED
codes	I-MED
and	I-MED
chapter	I-MED
types	I-MED
or	O
in	O
the	O
rate	B-MED
of	I-MED
psychological	I-MED
codes	I-MED
.	O
In	O
a	O
follow	B-MED
-	I-MED
up	I-MED
survey	B-MED
comparing	O
video	B-MED
and	O
paper	B-MED
groups	B-MED
to	O
non	B-MED
-	I-MED
experienced	I-MED
groups	I-MED
,	O
the	O
rates	B-MED
were	O
higher	O
for	O
video	B-MED
(	O
χ(2)=24.319	O
,	O
p<0.001	O
)	O
and	O
paper	B-MED
(	O
χ(2)=11.134	O
,	O
p=0.001	O
)	O
.	O
Although	O
the	O
video	B-MED
rate	B-MED
tended	O
to	O
be	O
higher	O
than	O
the	O
paper	B-MED
rate	B-MED
,	O
no	B-MED
significant	I-MED
difference	I-MED
was	O
found	O
between	O
the	O
two	O
.	O
Patient	B-MED
Patient	B-MED
-simulated	I-MED
videos	I-MED
showing	O
daily	B-MED
life	B-MED
facilitate	O
imagining	O
true	O
patients	B-MED
and	O
support	O
a	O
comprehensive	B-MED
approach	B-MED
that	O
fosters	B-MED
better	O
memory	B-MED
.	O
The	O
clinical	B-MED
patient	B-MED
patient	B-MED
-simulated	I-MED
video	I-MED
method	B-MED
is	O
more	O
practical	O
and	O
clinical	B-MED
problem	B-MED
-	I-MED
based	I-MED
tutorials	I-MED
can	O
be	O
implemented	O
if	O
we	O
create	O
patient	B-MED
patient	B-MED
-simulated	I-MED
videos	I-MED
for	O
each	O
symptom	B-MED
as	O
teaching	B-MED
materials	I-MED
.	O
Antiviral	B-MED
activities	I-MED
of	O
selected	O
antimalarials	B-MED
against	B-MED
dengue	B-MED
virus	I-MED
type	I-MED
2	I-MED
and	O
Zika	B-MED
virus	I-MED
In	O
a	O
previous	B-MED
study	B-MED
,	I-MED
twelve	O
antimalarial	B-MED
compounds	I-MED
,	O
amodiaquine	B-MED
(	O
AQ	B-MED
)	O
and	O
derivatives	B-MED
,	O
were	O
shown	O
to	O
have	O
potent	B-MED
anti	B-MED
-	I-MED
dengue	I-MED
viral	I-MED
(	I-MED
DENV	I-MED
)	I-MED
activity	I-MED
by	O
using	O
the	O
stable	B-MED
DENV2	B-MED
Renilla	B-MED
luciferase	I-MED
reporter	B-MED
replicon	B-MED
expressing	B-MED
BHK-21	B-MED
cells	I-MED
,	O
infectivity	B-MED
(	O
plaque	B-MED
)	O
,	O
and	O
the	O
qRT	B-MED
-	I-MED
PCR	I-MED
assays	I-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
performed	B-MED
molecular	B-MED
modeling	I-MED
on	O
these	O
compounds	B-MED
to	O
determine	O
their	O
stereo	B-MED
-	I-MED
electronic	I-MED
properties	I-MED
required	O
for	O
optimal	B-MED
antiviral	B-MED
activity	I-MED
.	O
Based	O
on	O
the	O
similarity	B-MED
of	O
calculated	O
stereo	B-MED
-	I-MED
electronic	I-MED
profiles	I-MED
,	O
specifically	O
the	O
electrostatic	B-MED
potential	I-MED
profiles	I-MED
of	O
the	O
compounds	B-MED
,	O
and	O
in	B-MED
silico	I-MED
screening	I-MED
of	O
related	O
compounds	B-MED
from	O
literature	B-MED
,	O
we	O
identified	B-MED
three	O
additional	B-MED
compounds	B-MED
,	O
Quinacrine	B-MED
(	O
QC	B-MED
)	O
,	O
Mefloquine	B-MED
(	O
MQ	B-MED
)	O
,	O
and	O
GSK369796	B-MED
.	O
Analysis	O
of	O
their	O
antiviral	B-MED
activities	I-MED
indicated	O
that	O
all	O
three	B-MED
compounds	I-MED
have	O
high	B-MED
anti	B-MED
-	I-MED
DENV	I-MED
activity	I-MED
in	O
the	O
DENV2	B-MED
replicon	B-MED
expressing	B-MED
cells	B-MED
with	O
EC50	B-MED
values	I-MED
of	O
5.30	O
±	O
1.31	O
μM	O
(	O
QC	B-MED
)	O
,	O
3.22	O
±	O
0.37	O
μM	O
(	O
MQ	B-MED
)	O
,	O
and	O
5.06	O
±	O
0.86	O
μM	O
(	O
GSK369796	B-MED
)	O
.	O
The	O
infectivity	B-MED
assays	I-MED
revealed	B-MED
the	O
EC50	B-MED
values	I-MED
of	O
7.09	O
±	O
1.67	O
μM	O
(	O
QC	B-MED
)	O
,	O
4.36	O
±	O
0.31	O
μM	O
(	O
MQ	B-MED
)	O
and	O
3.03	O
±	O
0.35	O
μM	O
(	O
GSK369796	B-MED
)	O
.	O
The	O
mode	B-MED
of	I-MED
action	I-MED
of	O
these	O
compounds	B-MED
is	O
through	B-MED
inhibition	B-MED
of	O
autophagy	B-MED
,	O
thereby	O
affecting	B-MED
DENV2	B-MED
replication	B-MED
.	O
Moreover	O
,	O
these	O
compounds	B-MED
also	O
showed	O
antiviral	B-MED
activity	I-MED
against	B-MED
the	O
rapidly	O
emerging	O
Zika	B-MED
virus	I-MED
(	O
ZIKV	B-MED
)	O
with	O
EC50	B-MED
values	I-MED
of	O
2.27	O
±	O
0.14	O
μM	O
(	O
QC	B-MED
)	O
,	O
3.95	O
±	O
0.21	O
μM	O
(	O
MQ	B-MED
)	O
,	O
and	O
2.57	O
±	O
0.09	O
μM	O
(	O
GSK369796	B-MED
)	O
.	O
Sub	B-MED
-	I-MED
lethal	I-MED
effects	I-MED
of	O
dietary	B-MED
neonicotinoid	B-MED
insecticide	I-MED
exposure	B-MED
on	O
honey	B-MED
bee	I-MED
queen	I-MED
fecundity	B-MED
and	O
colony	B-MED
development	B-MED
Many	O
factors	B-MED
can	O
negatively	B-MED
affect	O
honey	B-MED
bee	I-MED
(	O
Apis	B-MED
mellifera	I-MED
L.	I-MED
)	O
health	B-MED
including	O
the	O
pervasive	B-MED
use	O
of	O
systemic	B-MED
neonicotinoid	B-MED
insecticides	I-MED
.	O
Through	O
direct	O
consumption	B-MED
of	O
contaminated	B-MED
nectar	B-MED
and	O
pollen	B-MED
from	O
treated	B-MED
plants	B-MED
,	O
neonicotinoids	B-MED
can	O
affect	O
foraging	B-MED
,	O
learning	B-MED
,	O
and	O
memory	B-MED
in	O
worker	B-MED
bees	I-MED
.	O
Less	O
well	O
studied	O
are	O
the	O
potential	O
effects	O
of	O
neonicotinoids	B-MED
on	O
queen	B-MED
bees	I-MED
,	O
which	O
may	O
be	O
exposed	O
indirectly	O
through	O
trophallaxis	B-MED
,	O
or	O
food	B-MED
-	O
sharing	B-MED
.	O
To	O
assess	B-MED
effects	O
on	O
queen	B-MED
productivity	B-MED
,	O
small	B-MED
colonies	B-MED
of	O
different	O
sizes	B-MED
(	O
1500	O
,	O
3000	O
,	O
and	O
7000	O
bees	B-MED
)	O
were	O
fed	B-MED
imidacloprid	B-MED
(	O
0	O
,	O
10	O
,	O
20	O
,	O
50	O
,	O
and	O
100	O
ppb	O
)	O
in	O
syrup	B-MED
for	O
three	O
weeks	B-MED
.	O
We	O
found	O
adverse	B-MED
effects	I-MED
of	O
imidacloprid	B-MED
on	O
queens	B-MED
(	O
egg	B-MED
-	I-MED
laying	I-MED
and	O
locomotor	B-MED
activity	I-MED
)	O
,	O
worker	B-MED
bees	I-MED
(	O
foraging	B-MED
and	O
hygienic	B-MED
activities	B-MED
)	O
,	O
and	O
colony	B-MED
development	B-MED
(	O
brood	B-MED
production	O
and	O
pollen	B-MED
stores	O
)	O
in	O
all	O
treated	B-MED
colonies	B-MED
.	O
Some	O
effects	O
were	O
less	B-MED
evident	O
as	O
colony	B-MED
size	B-MED
increased	B-MED
,	O
suggesting	O
that	O
larger	B-MED
colony	B-MED
populations	B-MED
may	O
act	O
as	O
a	O
buffer	O
to	O
pesticide	B-MED
exposure	I-MED
.	O
This	O
study	B-MED
is	O
the	O
first	O
to	O
show	O
adverse	B-MED
effects	I-MED
of	O
imidacloprid	B-MED
on	O
queen	B-MED
bee	I-MED
fecundity	B-MED
and	O
behavior	B-MED
and	O
improves	B-MED
our	O
understanding	B-MED
of	O
how	O
neonicotinoids	B-MED
may	O
impair	B-MED
short	O
-	O
term	O
colony	B-MED
functioning	B-MED
.	O
These	O
data	B-MED
indicate	O
that	O
risk	B-MED
-	I-MED
mitigation	I-MED
efforts	I-MED
should	O
focus	O
on	O
reducing	B-MED
neonicotinoid	B-MED
exposure	B-MED
in	O
the	O
early	B-MED
spring	I-MED
when	O
colonies	B-MED
are	O
smallest	B-MED
and	O
queens	B-MED
are	O
most	O
vulnerable	B-MED
to	O
exposure	B-MED
.	O
Keeping	O
the	O
Spirits	O
Up	O
:	O
The	O
Effect	B-MED
of	O
Teachers	B-MED
'	I-MED
and	O
Parents	B-MED
'	I-MED
Emotional	B-MED
Support	I-MED
on	O
Children	B-MED
's	I-MED
Working	B-MED
Memory	I-MED
Performance	B-MED
Working	B-MED
memory	I-MED
,	O
used	O
to	O
temporarily	B-MED
store	I-MED
and	O
mentally	O
manipulate	O
information	B-MED
,	O
is	O
important	O
for	O
children	B-MED
's	I-MED
learning	B-MED
.	O
It	O
is	O
therefore	O
valuable	O
to	O
understand	O
which	O
(	O
contextual	O
)	O
factors	B-MED
promote	B-MED
or	O
hinder	B-MED
working	B-MED
memory	I-MED
performance	B-MED
.	O
Recent	O
research	B-MED
shows	O
positive	B-MED
associations	B-MED
between	O
positive	B-MED
parent	B-MED
-	I-MED
child	I-MED
and	O
teacher	B-MED
-	I-MED
student	I-MED
interactions	I-MED
and	O
working	B-MED
memory	I-MED
performance	B-MED
and	O
development	B-MED
.	O
However	O
,	O
no	O
study	B-MED
has	O
yet	O
experimentally	B-MED
investigated	I-MED
how	O
parents	B-MED
and	O
teachers	B-MED
affect	O
working	B-MED
memory	I-MED
performance	B-MED
.	O
Based	O
on	O
attachment	B-MED
theory	I-MED
,	O
the	O
current	O
study	B-MED
investigated	B-MED
the	O
role	O
of	O
parent	B-MED
and	O
teacher	B-MED
emotional	B-MED
support	I-MED
in	O
promoting	B-MED
working	B-MED
memory	I-MED
performance	B-MED
by	O
buffering	O
the	O
negative	B-MED
effect	B-MED
of	O
social	B-MED
stress	I-MED
.	O
Questionnaires	B-MED
and	O
an	O
experimental	B-MED
session	I-MED
were	O
completed	O
by	O
170	O
children	B-MED
from	O
grade	O
1	O
to	O
2	O
(	O
Mage	O
=	O
7	O
years	B-MED
6	O
months	B-MED
,	O
SD	O
=	O
7	O
months	B-MED
)	O
.	O
Questionnaires	B-MED
were	O
used	O
to	O
assess	O
children	B-MED
's	I-MED
perceptions	B-MED
of	O
the	O
teacher	B-MED
-	I-MED
student	I-MED
and	O
parent	B-MED
-	I-MED
child	I-MED
relationship	I-MED
.	O
During	O
an	O
experimental	B-MED
session	I-MED
,	O
working	B-MED
memory	I-MED
was	O
measured	O
with	O
the	O
Corsi	B-MED
task	I-MED
backward	I-MED
(	O
Milner	O
,	O
1971	O
)	O
in	O
a	O
pre-	B-MED
and	O
post	B-MED
-	I-MED
test	I-MED
design	I-MED
.	O
In	O
-	O
between	O
the	O
tests	B-MED
stress	B-MED
was	O
induced	B-MED
in	O
the	O
children	B-MED
using	O
the	O
Cyberball	B-MED
paradigm	I-MED
(	O
Williams	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O
Emotional	B-MED
support	I-MED
was	O
manipulated	B-MED
(	O
between	O
-	O
subjects	O
)	O
through	O
an	O
audio	B-MED
message	B-MED
(	O
either	O
a	O
weather	B-MED
report	B-MED
,	O
a	O
supportive	B-MED
message	B-MED
of	O
a	O
stranger	B-MED
,	O
a	O
supportive	B-MED
message	B-MED
of	O
a	O
parent	B-MED
,	O
or	O
a	O
supportive	B-MED
message	B-MED
of	O
a	O
teacher	B-MED
)	O
.	O
Results	B-MED
of	O
repeated	B-MED
measures	I-MED
ANOVA	B-MED
showed	O
no	O
clear	O
effect	B-MED
of	O
the	O
stress	B-MED
induction	B-MED
.	O
Nevertheless	O
,	O
an	O
effect	B-MED
of	O
parent	B-MED
and	O
teacher	B-MED
support	B-MED
was	O
found	O
and	O
depended	O
on	O
the	O
quality	B-MED
of	O
the	O
parent	B-MED
-	I-MED
child	I-MED
relationship	I-MED
.	O
When	O
children	B-MED
had	O
a	O
positive	B-MED
relationship	B-MED
with	O
their	O
parent	B-MED
,	O
support	B-MED
of	O
parents	B-MED
and	O
teachers	B-MED
had	O
little	O
effect	B-MED
on	O
working	B-MED
memory	I-MED
performance	B-MED
.	O
When	O
children	B-MED
had	O
a	O
negative	B-MED
relationship	B-MED
with	O
their	O
parent	B-MED
,	O
a	O
supportive	B-MED
message	B-MED
of	O
that	O
parent	B-MED
decreased	O
working	B-MED
memory	I-MED
performance	B-MED
,	O
while	O
a	O
supportive	B-MED
message	B-MED
from	O
the	O
teacher	B-MED
increased	O
performance	B-MED
.	O
In	O
sum	O
,	O
the	O
current	O
study	B-MED
suggests	O
that	O
parents	B-MED
and	O
teachers	B-MED
can	O
support	B-MED
working	B-MED
memory	I-MED
performance	B-MED
by	O
being	O
supportive	B-MED
for	O
the	O
child	B-MED
.	O
Teacher	B-MED
support	B-MED
is	O
most	O
effective	B-MED
when	O
the	O
child	B-MED
has	O
a	O
negative	B-MED
relationship	B-MED
with	O
the	O
parent	B-MED
.	O
These	O
insights	O
can	O
give	O
direction	O
to	O
specific	O
measures	O
aimed	O
at	O
preventing	B-MED
and	O
resolving	B-MED
working	B-MED
memory	I-MED
problems	B-MED
and	O
related	O
issues	B-MED
.	O
Lignans	B-MED
from	O
the	O
fruits	B-MED
of	O
Schisandra	B-MED
chinensis	I-MED
(	I-MED
Turcz	I-MED
.	I-MED
)	I-MED
Baill	I-MED
inhibit	B-MED
proprotein	B-MED
convertase	I-MED
subtilisin	I-MED
/	I-MED
kexin	I-MED
type	I-MED
9	I-MED
expression	B-MED
Bioactivity	B-MED
-	I-MED
guided	I-MED
fractionation	I-MED
of	O
the	O
fruits	B-MED
of	O
Schisandra	B-MED
chinensis	I-MED
,	O
using	O
the	O
proprotein	B-MED
convertase	I-MED
subtilisin	I-MED
-	I-MED
kexin	I-MED
type	I-MED
9	I-MED
(	O
PCSK9	B-MED
)	O
mRNA	B-MED
expression	I-MED
screening	B-MED
assay	I-MED
,	O
led	O
to	O
isolation	B-MED
of	O
two	B-MED
previously	B-MED
unknown	I-MED
lignans	B-MED
,	O
14	B-MED
-	I-MED
tigloylschinlignan	I-MED
D	I-MED
and	O
rel-(7R	B-MED
,	I-MED
8R	I-MED
,	I-MED
7'R	I-MED
,	I-MED
8'R)-manglisin	I-MED
E	I-MED
,	O
along	O
with	O
28	O
known	O
compounds	O
.	O
All	O
structures	B-MED
were	O
established	B-MED
by	O
NMR	B-MED
spectroscopic	I-MED
data	B-MED
as	O
well	O
as	O
CD	B-MED
and	O
MS	B-MED
analysis	B-MED
.	O
All	O
isolates	O
were	O
tested	B-MED
for	O
their	O
inhibitory	B-MED
activities	B-MED
on	O
the	O
mRNA	B-MED
expression	I-MED
of	O
PCSK9	B-MED
.	O
Of	O
the	O
tested	B-MED
compounds	O
,	O
four	B-MED
of	O
the	O
compounds	O
rel-(7R	B-MED
,	I-MED
8R	I-MED
,	I-MED
7'R	I-MED
,	I-MED
8'R)-manglisin	I-MED
E	I-MED
,	O
(	B-MED
-)-schisandrin	I-MED
C	I-MED
,	O
schinlignan	B-MED
D	I-MED
,	O
and	O
(	B-MED
+	I-MED
)	I-MED
-schisandrol	I-MED
B	I-MED
potently	O
inhibited	B-MED
PCSK9	B-MED
mRNA	B-MED
expression	I-MED
with	O
IC50	B-MED
values	O
of	O
3.15	O
,	O
3.85	O
,	O
0.36	O
,	O
and	O
1.10	O
μM	O
,	O
respectively	O
.	O
Furthermore	O
,	O
schinlignan	O
D	O
and	O
(	B-MED
+	I-MED
)	I-MED
-schisandrol	I-MED
B	I-MED
were	O
found	O
to	O
suppress	B-MED
PCSK9	B-MED
protein	B-MED
expressions	I-MED
and	O
schinlignan	B-MED
D	I-MED
deemed	O
to	O
increase	O
low	B-MED
density	I-MED
lipoprotein	I-MED
receptor	I-MED
expression	B-MED
.	O
Histopathological	B-MED
Evaluation	B-MED
of	O
the	O
Effectiveness	B-MED
of	O
Glycyrrhizic	B-MED
Acid	I-MED
as	O
a	O
Radioprotector	B-MED
Against	O
the	O
Development	B-MED
of	O
Radiation	B-MED
-	I-MED
Induced	I-MED
Lung	I-MED
Fibrosis	I-MED
Radiotherapy	B-MED
of	O
the	O
thorax	B-MED
often	O
causes	O
lung	B-MED
inflammation	I-MED
leading	O
to	O
fibrosis	B-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
whether	O
the	O
use	O
of	O
glycyrrhizic	B-MED
acid	I-MED
(	O
GLA	B-MED
)	O
could	O
improve	O
the	O
development	B-MED
of	O
lung	B-MED
fibrosis	I-MED
in	O
irradiated	B-MED
animals	B-MED
.	O
Wistar	B-MED
rats	I-MED
were	O
divided	O
into	O
four	O
groups	B-MED
.	O
Group	B-MED
A	I-MED
rats	B-MED
received	O
thoracic	B-MED
irradiation	I-MED
.	O
Rats	B-MED
in	O
group	B-MED
B	I-MED
received	O
GLA	B-MED
and	O
irradiation	B-MED
.	O
Group	B-MED
C	I-MED
received	O
GLA	B-MED
and	O
no	O
irradiation	B-MED
.	O
Group	B-MED
D	I-MED
received	O
no	O
GLA	B-MED
and	O
irradiation	B-MED
.	O
GLA	B-MED
was	O
administered	B-MED
at	O
a	O
dose	B-MED
of	O
4	O
mg	O
/	O
kg	O
body	B-MED
weight	I-MED
using	O
an	O
intraperitoneal	B-MED
injection	I-MED
one	O
hour	O
before	O
thoracic	B-MED
irradiation	I-MED
.	O
Radiation	B-MED
therapy	I-MED
was	O
delivered	O
on	O
a	O
Cobalt-60	B-MED
unit	O
using	O
a	O
single	O
fraction	O
of	O
16	O
Gy	O
.	O
The	O
animals	B-MED
were	O
sacrificed	O
at	O
32	O
weeks	O
following	O
thoracic	B-MED
irradiation	I-MED
.	O
The	O
lungs	B-MED
were	O
dissected	B-MED
and	O
blind	O
histopathological	B-MED
evaluation	B-MED
was	O
performed	O
.	O
Histopathologically	B-MED
,	O
a	O
decrease	B-MED
(	O
statistically	O
not	O
significant	O
)	O
in	O
the	O
thickening	B-MED
of	O
alveolar	B-MED
or	O
bronchial	B-MED
wall	I-MED
,	O
formation	O
of	O
fibrous	B-MED
bands	I-MED
,	O
and	O
superimposed	O
collagen	B-MED
were	O
noted	O
in	O
the	O
animals	B-MED
in	O
group	B-MED
B	I-MED
as	O
compared	O
to	O
the	O
animals	B-MED
in	O
group	B-MED
A	I-MED
A.	O
In	O
this	O
experimental	B-MED
study	I-MED
,	O
administration	B-MED
of	O
GLA	B-MED
one	O
hour	O
before	O
thoracic	B-MED
irradiation	I-MED
may	O
be	O
a	O
protective	B-MED
agent	I-MED
against	O
radiation	B-MED
-	I-MED
induced	I-MED
fibrosis	I-MED
in	O
animals	B-MED
and	O
this	O
model	B-MED
could	O
be	O
used	O
in	O
future	O
studies	O
.	O
Botulinum	B-MED
Toxin	I-MED
Use	O
in	O
Refractory	B-MED
Pain	I-MED
and	O
Other	O
Symptoms	B-MED
in	O
Parkinsonism	B-MED
Parkinson	B-MED
's	I-MED
disease	I-MED
(	O
PD	B-MED
)	O
and	O
other	O
parkinsonian	B-MED
syndromes	I-MED
are	O
chronic	B-MED
,	O
progressive	B-MED
neurodegenerative	B-MED
diseases	I-MED
.	O
With	O
advancing	O
disease	B-MED
,	O
both	O
motor	B-MED
and	O
non	B-MED
-	I-MED
motor	I-MED
symptoms	I-MED
represent	O
a	O
considerable	O
burden	B-MED
and	O
symptom	B-MED
relief	B-MED
and	O
quality	B-MED
of	I-MED
life	I-MED
improvement	B-MED
become	O
the	O
main	O
goal	B-MED
of	O
treatment	B-MED
.	O
Botulinum	B-MED
toxins	I-MED
(	O
BTX	B-MED
)	O
are	O
an	O
effective	B-MED
treatment	B-MED
modality	B-MED
for	O
many	O
neurological	B-MED
conditions	I-MED
.	O
To	O
understand	O
the	O
potential	B-MED
usefulness	B-MED
of	O
BTX	B-MED
in	O
this	O
population	B-MED
,	O
we	O
performed	B-MED
a	O
retrospective	B-MED
chart	B-MED
review	I-MED
of	O
all	O
patients	B-MED
with	O
a	O
clinical	B-MED
diagnosis	I-MED
of	O
idiopathic	B-MED
PD	I-MED
and	O
atypical	B-MED
parkinsonism	I-MED
who	O
received	O
treatment	B-MED
with	O
BTX	B-MED
injections	I-MED
in	O
our	O
center	B-MED
from	O
1995	O
to	O
2014	O
for	O
a	O
variety	O
of	O
symptoms	B-MED
.	O
Response	B-MED
to	O
BTX	B-MED
was	O
assessed	B-MED
using	O
a	O
subjective	B-MED
Clinical	I-MED
Global	I-MED
Impression	I-MED
.	O
Records	B-MED
of	O
160	O
patients	B-MED
were	O
reviewed	B-MED
.	O
Probable	O
idiopathic	B-MED
PD	I-MED
was	O
the	O
diagnosis	B-MED
in	O
117	O
patients	B-MED
(	O
73.1	O
%	O
)	O
.	O
The	O
main	O
indication	B-MED
for	O
BTX	B-MED
treatment	B-MED
was	O
pain	B-MED
(	O
50.6	O
%	O
of	O
cases	O
)	O
.	O
Other	O
indications	B-MED
were	O
the	O
treatment	B-MED
of	O
functional	B-MED
impairment	I-MED
resulting	B-MED
from	O
dystonia	B-MED
(	O
26.25	O
%	O
)	O
,	O
sialorrhea	B-MED
(	O
18.75	O
%	O
)	O
,	O
freezing	B-MED
of	I-MED
gait	I-MED
,	O
and	O
camptocormia	B-MED
.	O
Considering	O
pain	B-MED
as	O
indication	B-MED
,	O
81	O
%	O
of	O
all	O
patients	B-MED
with	O
PD	B-MED
reported	B-MED
benefits	B-MED
after	O
the	O
first	O
BTX	B-MED
injections	I-MED
.	O
This	O
benefit	B-MED
was	O
maintained	B-MED
after	O
the	O
last	B-MED
recorded	I-MED
visit	I-MED
without	O
significant	O
difference	B-MED
in	O
outcome	B-MED
compared	B-MED
with	O
the	O
first	O
injection	B-MED
(	O
p=0.067	O
)	O
.	O
Similar	O
results	B-MED
were	O
observed	O
in	O
patients	B-MED
with	O
atypical	B-MED
parkinsonism	I-MED
.	O
Our	O
results	B-MED
confirm	O
the	O
safety	O
and	O
efficacy	B-MED
of	O
different	B-MED
uses	B-MED
of	O
BTX	B-MED
in	O
the	O
symptomatic	B-MED
treatment	B-MED
of	O
patients	B-MED
with	O
parkinsonism	B-MED
even	O
in	O
advanced	B-MED
stages	B-MED
of	O
the	O
disease	B-MED
,	O
and	O
suggest	B-MED
BTX	B-MED
treatment	B-MED
could	O
have	O
a	O
safe	O
and	O
useful	O
role	B-MED
in	O
the	O
treatment	B-MED
of	O
pain	B-MED
in	O
this	O
population	B-MED
.	O
Sedation	B-MED
of	O
Patients	B-MED
With	O
Disorders	B-MED
of	I-MED
Consciousness	I-MED
During	O
Neuroimaging	B-MED
:	O
Effects	O
on	O
Resting	B-MED
State	I-MED
Functional	I-MED
Brain	I-MED
Connectivity	I-MED
To	O
reduce	O
head	B-MED
movement	I-MED
during	O
resting	B-MED
state	I-MED
functional	I-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
,	O
post	B-MED
-	I-MED
coma	I-MED
patients	B-MED
with	O
disorders	B-MED
of	I-MED
consciousness	I-MED
(	O
DOC	B-MED
)	O
are	O
frequently	O
sedated	B-MED
with	O
propofol	B-MED
.	O
However	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
this	O
sedation	B-MED
on	O
the	O
brain	B-MED
connectivity	I-MED
patterns	I-MED
in	O
the	O
damaged	B-MED
brain	I-MED
essential	O
for	O
differential	B-MED
diagnosis	I-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
aimed	O
to	O
assess	B-MED
these	O
effects	O
.	O
Using	O
resting	B-MED
state	I-MED
functional	I-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
3	O
T	O
data	O
obtained	O
over	O
several	O
years	O
of	O
scanning	B-MED
patients	B-MED
for	O
diagnostic	B-MED
and	O
research	B-MED
purposes	B-MED
,	O
we	O
employed	O
a	O
seed	O
-	O
based	O
approach	O
to	O
examine	O
resting	B-MED
state	I-MED
connectivity	I-MED
in	O
higher	O
-	O
order	O
(	O
default	O
mode	O
,	O
bilateral	B-MED
external	B-MED
control	I-MED
,	O
and	O
salience	O
)	O
and	O
lower	O
-	O
order	O
(	O
auditory	B-MED
,	O
sensorimotor	B-MED
,	O
and	O
visual	B-MED
)	O
resting	B-MED
state	I-MED
networks	I-MED
and	O
connectivity	B-MED
with	O
the	O
thalamus	B-MED
,	O
in	O
20	O
healthy	B-MED
unsedated	B-MED
controls	B-MED
,	O
8	O
unsedated	B-MED
patients	B-MED
with	O
DOC	B-MED
,	O
and	O
8	O
patients	B-MED
with	O
DOC	B-MED
sedated	B-MED
with	O
propofol	B-MED
.	O
The	O
DOC	B-MED
groups	O
were	O
matched	O
for	O
age	B-MED
at	I-MED
onset	I-MED
,	O
etiology	B-MED
,	O
time	B-MED
spent	I-MED
in	O
DOC	B-MED
,	O
diagnosis	B-MED
,	O
standardized	B-MED
behavioral	I-MED
assessment	I-MED
scores	I-MED
,	O
movement	B-MED
intensities	B-MED
,	O
and	O
pattern	O
of	O
structural	B-MED
brain	I-MED
injury	I-MED
(	O
as	O
assessed	O
with	O
T1	B-MED
-	I-MED
based	I-MED
voxel	I-MED
-	I-MED
based	I-MED
morphometry	I-MED
)	O
.	O
DOC	B-MED
were	O
associated	B-MED
with	I-MED
severely	O
impaired	O
resting	B-MED
state	I-MED
network	I-MED
connectivity	I-MED
in	O
all	O
but	O
the	O
visual	B-MED
network	B-MED
.	O
Thalamic	B-MED
connectivity	B-MED
to	O
higher	O
-	O
order	O
network	O
regions	O
was	O
also	O
reduced	B-MED
.	O
Propofol	B-MED
administration	B-MED
to	O
patients	B-MED
was	O
associated	B-MED
with	I-MED
minor	O
further	O
decreases	B-MED
in	O
thalamic	B-MED
and	O
insular	B-MED
connectivity	B-MED
.	O
Our	O
findings	B-MED
indicate	O
that	O
connectivity	B-MED
decreases	B-MED
associated	B-MED
with	I-MED
propofol	B-MED
sedation	B-MED
,	O
involving	O
the	O
thalamus	B-MED
and	O
insula	B-MED
,	O
are	O
relatively	O
small	O
compared	O
with	O
those	O
already	O
caused	O
by	O
DOC	B-MED
-associated	O
structural	B-MED
brain	I-MED
injury	I-MED
.	O
Nonetheless	O
,	O
given	O
the	O
known	O
importance	O
of	O
the	O
thalamus	B-MED
in	O
brain	B-MED
arousal	I-MED
,	O
its	O
disruption	B-MED
could	O
well	O
reflect	O
the	O
diminished	B-MED
movement	B-MED
obtained	O
in	O
these	O
patients	B-MED
.	O
However	O
,	O
more	O
research	B-MED
is	O
needed	O
on	O
this	O
topic	O
to	O
fully	O
address	O
the	O
research	B-MED
question	I-MED
.	O
Bxb1	B-MED
phage	I-MED
recombinase	B-MED
assists	O
genome	B-MED
engineering	I-MED
in	O
Drosophila	B-MED
melanogaster	I-MED
Rapid	B-MED
and	O
reliable	B-MED
genome	B-MED
modifications	I-MED
provide	O
the	O
basis	O
for	O
detailed	O
in	B-MED
vivo	I-MED
functional	B-MED
analysis	I-MED
of	O
any	O
genomic	B-MED
entity	I-MED
(	O
gene	B-MED
,	O
regulatory	B-MED
DNA	I-MED
,	O
non	B-MED
-	I-MED
coding	I-MED
RNA	I-MED
,	O
etc	O
)	O
.	O
With	O
the	O
advent	O
of	O
CRISPR	B-MED
/	O
Cas9	B-MED
genome	I-MED
editing	I-MED
technology	I-MED
,	O
manipulation	B-MED
of	O
a	O
particular	O
genomic	B-MED
locus	I-MED
has	O
become	O
a	O
routine	O
undertaking	O
in	O
variety	O
of	O
model	B-MED
organisms	I-MED
,	O
including	O
the	O
fruit	B-MED
fly	I-MED
Drosophila	I-MED
melanogaster	I-MED
.	O
To	O
further	O
diversify	O
the	O
available	O
tools	O
for	O
genome	B-MED
engineering	I-MED
,	O
we	O
successfully	O
harnessed	O
the	O
phage	B-MED
recombinase	B-MED
Bxb1	I-MED
to	O
perform	O
recombinase	O
-	O
mediated	O
cassette	O
exchange	O
(	O
RMCE	O
)	O
in	O
D.	B-MED
melanogaster	I-MED
.	O
We	O
demonstrate	O
that	O
Bxb1	B-MED
possesses	O
highly	O
efficient	O
recombinase	B-MED
activity	I-MED
and	O
could	O
be	O
used	O
alone	O
or	O
in	O
conjunction	O
with	O
other	O
currently	O
available	O
recombinases	B-MED
for	O
creating	O
platforms	O
for	O
cassette	O
exchange	O
of	O
targeted	B-MED
loci	I-MED
.	O
Apixaban	B-MED
5	O
mg	O
Twice	B-MED
Daily	B-MED
and	O
Clinical	B-MED
Outcomes	B-MED
in	O
Patients	B-MED
With	O
Atrial	B-MED
Fibrillation	I-MED
and	O
Advanced	B-MED
Age	B-MED
,	O
Low	B-MED
Body	B-MED
Weight	I-MED
,	O
or	O
High	B-MED
Creatinine	B-MED
:	O
A	O
Secondary	B-MED
Analysis	I-MED
of	O
a	O
Randomized	B-MED
Clinical	I-MED
Trial	I-MED
In	O
the	O
Apixaban	B-MED
for	O
Reduction	B-MED
of	O
Stroke	B-MED
and	O
Other	O
Thromboembolic	B-MED
Complications	I-MED
in	O
Atrial	B-MED
Fibrillation	I-MED
(	O
ARISTOTLE	B-MED
)	O
trial	B-MED
,	O
the	O
standard	O
dose	B-MED
of	O
apixaban	B-MED
was	O
5	O
mg	O
twice	B-MED
daily	B-MED
;	O
patients	B-MED
with	O
at	O
least	O
2	O
dose	B-MED
-	O
reduction	B-MED
criteria-80	O
years	B-MED
or	O
older	O
,	O
weight	B-MED
60	O
kg	O
or	O
less	O
,	O
and	O
creatinine	B-MED
level	I-MED
level	B-MED
1.5	O
mg	O
/	O
dL	O
or	O
higher	O
-	O
received	O
a	O
reduced	B-MED
dose	B-MED
of	O
apixaban	B-MED
of	O
2.5	O
mg	O
twice	B-MED
daily	B-MED
.	O
Little	O
is	O
known	O
about	O
patients	B-MED
with	O
1	O
dose	B-MED
-	O
reduction	B-MED
criterion	O
who	O
received	O
the	O
5	O
mg	O
twice	B-MED
daily	B-MED
dose	B-MED
of	O
apixaban	B-MED
.	O
To	O
determine	O
the	O
frequency	B-MED
of	O
1	O
dose	B-MED
-	O
reduction	B-MED
criterion	O
and	O
whether	O
the	O
effects	B-MED
of	I-MED
the	O
5	O
mg	O
twice	B-MED
daily	B-MED
dose	B-MED
of	O
apixaban	B-MED
on	O
stroke	B-MED
or	O
systemic	B-MED
embolism	I-MED
and	O
bleeding	B-MED
varied	O
among	O
patients	B-MED
with	O
1	O
or	O
no	O
dose	B-MED
-	O
reduction	B-MED
criteria	O
.	O
Among	O
18	O
201	O
patients	B-MED
in	O
the	O
ARISTOTLE	B-MED
trial	I-MED
,	O
17	O
322	O
were	O
included	O
in	O
this	O
analysis	B-MED
.	O
Annualized	O
event	O
rates	O
of	O
stroke	B-MED
or	O
systemic	B-MED
embolism	I-MED
and	O
major	O
bleeding	B-MED
and	O
hazard	B-MED
ratios	I-MED
(	O
HRs	B-MED
)	O
and	O
95	O
%	O
CIs	B-MED
were	O
evaluated	B-MED
.	O
Interactions	B-MED
between	O
the	O
effects	B-MED
of	I-MED
apixaban	B-MED
vs	O
warfarin	B-MED
and	O
the	O
presence	O
of	O
1	O
or	O
no	O
dose	B-MED
-	O
reduction	B-MED
criteria	O
were	O
assessed	B-MED
.	O
The	O
first	O
patient	B-MED
was	O
enrolled	O
in	O
the	O
ARISTOTLE	B-MED
trial	I-MED
on	O
December	O
19	O
,	O
2006	O
,	O
and	O
follow	B-MED
-	I-MED
up	I-MED
was	O
completed	O
on	O
January	O
30	O
,	O
2011	O
.	O
Data	B-MED
were	O
analyzed	O
from	O
January	O
2015	O
to	O
May	O
30	O
,	O
2016	O
.	O
Analysis	B-MED
of	O
major	O
bleeding	B-MED
included	O
events	O
during	O
study	B-MED
drug	B-MED
treatment	I-MED
.	O
Analysis	B-MED
of	O
stroke	B-MED
or	O
systemic	B-MED
embolism	I-MED
was	O
based	O
on	O
intention	B-MED
to	O
treat	B-MED
.	O
Of	O
the	O
patients	B-MED
with	O
1	O
or	O
no	O
dose	B-MED
-	O
reduction	B-MED
criteria	O
assigned	O
to	O
receive	O
the	O
5	O
mg	O
twice	B-MED
daily	B-MED
dose	B-MED
of	O
apixaban	B-MED
or	O
warfarin	B-MED
,	O
3966	O
had	O
1	O
dose	B-MED
-	O
reduction	B-MED
criterion	O
;	O
these	O
patients	B-MED
had	O
higher	O
rates	O
of	O
stroke	B-MED
or	O
systemic	B-MED
embolism	I-MED
(	O
HR	B-MED
,	O
1.47	O
;	O
95	O
%	O
CI	B-MED
,	O
1.20	O
-	O
1.81	O
)	O
and	O
major	O
bleeding	B-MED
(	O
HR	B-MED
,	O
1.89	O
;	O
95	O
%	O
CI	B-MED
,	O
1.62	O
-	O
2.20	O
)	O
compared	O
with	O
those	O
with	O
no	O
dose	B-MED
-	O
reduction	B-MED
criteria	O
(	O
n	O
=	O
13	O
356	O
)	O
.	O
The	O
benefit	B-MED
of	O
the	O
5	O
mg	O
twice	B-MED
daily	B-MED
dose	B-MED
of	O
apixaban	B-MED
(	O
n	O
=	O
8665	O
)	O
compared	O
with	O
warfarin	B-MED
(	O
n	O
=	O
8657	O
)	O
on	O
stroke	B-MED
or	O
systemic	B-MED
embolism	I-MED
in	O
patients	B-MED
with	O
1	O
dose	B-MED
-	O
reduction	B-MED
criterion	O
(	O
HR	B-MED
,	O
0.94	O
;	O
95	O
%	O
CI	B-MED
,	O
0.66	O
-	O
1.32	O
)	O
and	O
no	O
dose	B-MED
-	O
reduction	B-MED
criterion	O
(	O
HR	B-MED
,	O
0.77	O
;	O
95	O
%	O
CI	B-MED
,	O
0.62	O
-	O
0.97	O
)	O
were	O
similar	O
(	O
P	O
for	O
interaction	O
=	O
.36	O
)	O
.	O
Similarly	O
,	O
the	O
benefit	B-MED
of	O
5	O
mg	O
twice	B-MED
daily	B-MED
dose	B-MED
of	O
apixaban	B-MED
compared	O
with	O
warfarin	B-MED
on	O
major	O
bleeding	B-MED
in	O
patients	B-MED
with	O
1	O
dose	B-MED
-	O
reduction	B-MED
criterion	O
(	O
HR	B-MED
,	O
0.68	O
;	O
95	O
%	O
CI	B-MED
,	O
0.53	O
-	O
0.87	O
)	O
and	O
no	O
dose	B-MED
-	O
reduction	B-MED
criterion	O
(	O
HR	B-MED
,	O
0.72	O
;	O
95	O
%	O
CI	B-MED
,	O
0.60	O
-	O
0.86	O
)	O
were	O
similar	O
(	O
P	O
for	O
interaction	O
=	O
.71	O
)	O
.	O
Similar	O
patterns	O
were	O
seen	O
for	O
each	O
dose	B-MED
-	O
reduction	B-MED
criterion	O
and	O
across	O
the	O
spectrum	O
of	O
age	B-MED
,	O
body	B-MED
weight	I-MED
,	O
creatinine	B-MED
level	I-MED
level	B-MED
,	O
and	O
creatinine	B-MED
clearance	B-MED
.	O
Patients	B-MED
with	O
atrial	B-MED
fibrillation	I-MED
and	O
isolated	O
advanced	O
age	B-MED
,	O
low	O
body	B-MED
weight	I-MED
,	O
or	O
renal	B-MED
dysfunction	I-MED
have	O
a	O
higher	O
risk	B-MED
of	O
stroke	B-MED
or	O
systemic	B-MED
embolism	I-MED
and	O
major	O
bleeding	B-MED
but	O
show	O
consistent	O
benefits	B-MED
with	O
the	O
5	O
mg	O
twice	B-MED
daily	B-MED
dose	B-MED
of	O
apixaban	B-MED
vs	O
warfarin	B-MED
compared	O
with	O
patients	B-MED
without	O
these	O
characteristics	O
.	O
The	O
5	O
mg	O
twice	B-MED
daily	B-MED
dose	B-MED
of	O
apixaban	B-MED
is	O
safe	O
,	O
efficacious	O
,	O
and	O
appropriate	O
for	O
patients	B-MED
with	O
only	O
1	O
dose	B-MED
-	O
reduction	B-MED
criterion	O
.	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT00412984	O
.	O
Prospective	O
Evaluation	B-MED
of	O
Opioid	B-MED
Consumption	I-MED
After	O
Distal	B-MED
Radius	I-MED
Fracture	I-MED
Repair	B-MED
Surgery	I-MED
Pain	B-MED
management	I-MED
and	O
opioid	B-MED
consumption	I-MED
after	O
distal	B-MED
radius	I-MED
fracture	I-MED
(	O
DRF	B-MED
)	O
open	B-MED
reduction	I-MED
and	I-MED
internal	I-MED
fixation	I-MED
(	I-MED
ORIF	I-MED
)	I-MED
are	O
highly	O
variable	O
and	O
poorly	O
understood	O
.	O
To	O
optimize	B-MED
postoperative	B-MED
opioid	B-MED
dosage	B-MED
and	O
better	O
understand	O
opioid	B-MED
consumption	I-MED
patterns	O
after	O
DRF	B-MED
-	O
ORIF	B-MED
,	O
we	O
conducted	O
a	O
prospective	B-MED
study	I-MED
with	O
the	O
hypothesis	B-MED
that	O
opioid	B-MED
consumption	I-MED
would	O
increase	B-MED
with	O
worsening	B-MED
fracture	B-MED
classification	B-MED
and	O
various	O
patient	B-MED
demographics	I-MED
.	O
All	O
patients	B-MED
who	O
underwent	O
DRF	B-MED
-	O
ORIF	B-MED
were	O
consecutively	O
enrolled	O
over	O
a	O
6	B-MED
-	I-MED
month	I-MED
period	I-MED
.	O
Information	O
collected	O
included	O
patient	B-MED
demographics	I-MED
,	O
fracture	B-MED
type	I-MED
,	O
anesthesia	B-MED
type	I-MED
,	O
amount	B-MED
and	O
type	B-MED
of	O
opioid	B-MED
prescribed	B-MED
,	O
number	B-MED
of	O
pills	B-MED
taken	B-MED
,	O
reason	B-MED
for	O
stopping	B-MED
,	O
and	O
adverse	B-MED
events	I-MED
.	O
Statistical	B-MED
analysis	I-MED
was	O
performed	O
.	O
Ninety	O
-	O
eight	O
patients	B-MED
(	O
79	O
female	B-MED
,	O
19	O
male	B-MED
)	O
were	O
eligible	O
for	O
the	O
study	O
.	O
Mean	O
age	O
was	O
58	O
years	O
.	O
Of	O
the	O
98	O
patients	B-MED
,	O
45	O
received	O
general	B-MED
anesthesia	I-MED
,	O
and	O
53	O
received	O
regional	B-MED
anesthesia	I-MED
with	O
a	O
single	O
-	O
shot	O
peripheral	B-MED
nerve	I-MED
block	I-MED
.	O
Mean	O
opioid	B-MED
consumption	I-MED
(	O
morphine	B-MED
equivalence	B-MED
)	O
over	O
a	O
mean	O
of	O
4.8	O
postoperative	B-MED
days	I-MED
(	O
range	O
,	O
0	O
-	O
16	O
days	O
)	O
was	O
58.5	O
mg	O
(	O
range	O
,	O
0	O
-	O
280	O
mg	O
)	O
.	O
There	O
were	O
no	B-MED
significant	I-MED
differences	O
in	O
opioid	B-MED
consumption	I-MED
between	O
the	O
general	B-MED
and	O
regional	B-MED
anesthesia	I-MED
groups	O
.	O
Mean	O
opioid	B-MED
consumption	I-MED
for	O
the	O
3	O
fracture	B-MED
-	I-MED
type	I-MED
groups	O
(	O
AO	B-MED
/	I-MED
OTA	I-MED
[	I-MED
Arbeitsgemeinschaft	I-MED
für	I-MED
Osteosynthesefragen	I-MED
/	I-MED
Orthopaedic	I-MED
Trauma	I-MED
Association	I-MED
]	I-MED
classification	I-MED
)	O
was	O
57.7	O
mg	O
(	O
class	B-MED
A	I-MED
)	O
,	O
60.3	O
mg	O
(	O
class	B-MED
B	I-MED
)	O
,	O
and	O
62.0	O
mg	O
(	O
class	B-MED
C	I-MED
)	O
.	O
Demographic	B-MED
analysis	I-MED
revealed	O
an	O
inverse	B-MED
relationship	B-MED
between	O
age	B-MED
and	O
opioid	B-MED
use	I-MED
.	O
Similarly	O
,	O
there	O
was	O
a	O
trend	O
toward	O
more	O
opioid	B-MED
consumption	I-MED
among	O
self	B-MED
-	I-MED
pay	I-MED
and	O
Medicaid	B-MED
patients	B-MED
.	O
Opioid	B-MED
consumption	I-MED
after	O
DRF	B-MED
-	O
ORIF	B-MED
was	O
equivalent	B-MED
for	O
general	B-MED
and	O
regional	B-MED
anesthesia	I-MED
.	O
A	O
significant	O
relationship	B-MED
was	O
found	O
between	O
increasing	B-MED
age	I-MED
and	O
decreasing	B-MED
opioid	B-MED
consumption	I-MED
.	O
Worsening	B-MED
fracture	B-MED
classification	I-MED
and	O
self	B-MED
-	I-MED
payment	I-MED
/	O
Medicaid	B-MED
payment	I-MED
trended	O
toward	O
increasing	B-MED
opioid	B-MED
consumption	I-MED
.	O
Mean	O
overall	O
opioid	B-MED
consumption	I-MED
(	O
morphine	B-MED
equivalence	B-MED
)	O
was	O
58.5	O
mg	O
,	O
or	O
14.6	O
pills	B-MED
of	O
oxycodone	B-MED
/	I-MED
acetaminophen	I-MED
5/325	O
mg	O
.	O
Surgeons	B-MED
should	O
take	O
these	O
findings	O
into	O
account	O
when	O
optimizing	B-MED
opioid	B-MED
prescribing	O
after	O
DRF	B-MED
repair	B-MED
.	O
Delineation	O
of	O
B	B-MED
-	I-MED
cell	I-MED
Epitopes	B-MED
of	O
Salmonella	B-MED
enterica	I-MED
serovar	I-MED
Typhi	I-MED
Hemolysin	B-MED
E	I-MED
:	O
Potential	B-MED
antibody	B-MED
therapeutic	B-MED
target	B-MED
Hemolysin	B-MED
E	I-MED
(	O
HlyE	B-MED
)	O
is	O
an	O
immunogenic	B-MED
novel	B-MED
pore	B-MED
-forming	O
toxin	B-MED
involved	O
in	O
the	O
pathogenesis	B-MED
of	O
typhoid	B-MED
fever	I-MED
.	O
Thus	O
,	O
mapping	B-MED
of	O
B	B-MED
-	I-MED
cell	I-MED
epitopes	B-MED
of	O
Salmonella	B-MED
enterica	I-MED
serovar	I-MED
Typhi	I-MED
(	O
S.	B-MED
Typhi	I-MED
)	O
is	O
critical	B-MED
to	O
identify	O
key	O
immunogenic	B-MED
regions	I-MED
HlyE	B-MED
of	O
HlyE.	O
A	O
random	O
20	O
-	O
mer	O
peptide	B-MED
library	I-MED
was	O
used	O
for	O
biopanning	O
with	O
enriched	O
anti	B-MED
-	I-MED
HlyE	I-MED
polyclonal	I-MED
antibodies	I-MED
from	O
typhoid	B-MED
patient	B-MED
sera	B-MED
.	O
Bioinformatic	B-MED
tools	B-MED
were	O
used	O
to	O
refine	O
,	O
analyze	B-MED
and	O
map	B-MED
the	O
enriched	O
peptide	B-MED
sequences	I-MED
against	O
the	O
protein	B-MED
to	O
identify	O
the	O
epitopes	B-MED
.	O
The	O
analysis	B-MED
identified	O
both	O
linear	B-MED
and	O
conformational	B-MED
epitopes	B-MED
on	O
the	O
HlyE	B-MED
protein	I-MED
.	O
The	O
predicted	B-MED
linear	B-MED
GAAAGIVAG	B-MED
and	O
conformational	B-MED
epitope	B-MED
PYSQESVLSADSQNQK	B-MED
were	O
further	O
validated	O
against	O
the	O
pooled	O
sera	B-MED
.	O
The	O
identified	O
epitopes	B-MED
were	O
then	O
used	O
to	O
isolate	B-MED
epitope	B-MED
specific	O
monoclonal	B-MED
antibodies	I-MED
by	O
antibody	B-MED
phage	B-MED
display	I-MED
.	O
Monoclonal	B-MED
scFv	I-MED
antibodies	B-MED
were	O
enriched	O
for	O
both	O
linear	B-MED
and	O
conformational	B-MED
epitopes	B-MED
.	O
Molecular	B-MED
docking	I-MED
was	O
performed	O
to	O
elucidate	O
the	O
antigen	B-MED
-	I-MED
antibody	I-MED
interaction	I-MED
of	O
the	O
monoclonal	B-MED
antibodies	I-MED
against	O
the	O
epitopes	B-MED
on	O
the	O
HlyE	B-MED
monomer	B-MED
and	O
oligomer	B-MED
structure	I-MED
.	O
An	O
in	O
-	O
depth	O
view	O
of	O
the	O
mechanistic	O
and	O
positional	B-MED
characteristics	B-MED
of	O
the	O
antibodies	B-MED
and	O
epitope	B-MED
for	O
HlyE	B-MED
was	O
successfully	O
accomplished	O
by	O
a	O
combination	B-MED
of	O
phage	B-MED
display	I-MED
and	O
bioinformatic	B-MED
analysis	B-MED
.	O
The	O
predicted	B-MED
function	B-MED
and	O
structure	B-MED
of	O
the	O
antibodies	B-MED
highlights	O
the	O
possibility	O
of	O
utilizing	O
the	O
antibodies	B-MED
as	O
neutralizing	B-MED
agents	I-MED
for	O
typhoid	B-MED
fever	I-MED
.	O
Approximate	B-MED
Bayesian	B-MED
computation	I-MED
for	O
estimating	B-MED
number	B-MED
concentrations	I-MED
of	O
monodisperse	B-MED
nanoparticles	B-MED
in	O
suspension	B-MED
by	O
optical	B-MED
microscopy	I-MED
We	O
present	B-MED
an	O
approximate	B-MED
Bayesian	B-MED
computation	I-MED
scheme	B-MED
for	O
estimating	B-MED
number	B-MED
concentrations	I-MED
of	O
monodisperse	B-MED
diffusing	B-MED
nanoparticles	B-MED
in	O
suspension	B-MED
by	O
optical	B-MED
particle	I-MED
tracking	I-MED
microscopy	I-MED
.	O
The	O
method	B-MED
is	O
based	B-MED
on	O
the	O
probability	B-MED
distribution	I-MED
of	O
the	O
time	B-MED
spent	B-MED
by	O
a	O
particle	B-MED
inside	B-MED
a	O
detection	B-MED
region	B-MED
.	O
We	O
validate	O
the	O
method	B-MED
on	O
suspensions	B-MED
of	O
well	B-MED
-	I-MED
controlled	I-MED
reference	B-MED
particles	B-MED
.	O
We	O
illustrate	O
its	O
usefulness	B-MED
with	O
an	O
application	B-MED
in	O
gene	B-MED
therapy	I-MED
,	O
applying	B-MED
the	O
method	B-MED
to	O
estimate	B-MED
number	B-MED
concentrations	I-MED
of	O
plasmid	B-MED
DNA	B-MED
molecules	I-MED
and	O
the	O
average	B-MED
number	I-MED
of	O
DNA	B-MED
molecules	I-MED
complexed	B-MED
with	O
liposomal	B-MED
drug	B-MED
delivery	I-MED
particles	B-MED
.	O
On	O
the	O
Relation	B-MED
between	O
Face	B-MED
and	O
Object	B-MED
Recognition	I-MED
in	O
Developmental	B-MED
Prosopagnosia	I-MED
:	O
No	O
Dissociation	B-MED
but	O
a	O
Systematic	B-MED
Association	B-MED
There	O
is	O
an	O
ongoing	O
debate	B-MED
about	O
whether	O
face	B-MED
recognition	I-MED
and	O
object	B-MED
recognition	I-MED
constitute	O
separate	B-MED
domains	B-MED
.	O
Clarification	B-MED
of	O
this	O
issue	B-MED
can	O
have	O
important	B-MED
theoretical	B-MED
implications	B-MED
as	O
face	B-MED
recognition	I-MED
is	O
often	O
used	O
as	O
a	O
prime	O
example	B-MED
of	O
domain	B-MED
-	O
specificity	B-MED
in	O
mind	B-MED
and	O
brain	B-MED
.	O
An	O
important	B-MED
source	B-MED
of	O
input	B-MED
to	O
this	O
debate	B-MED
comes	O
from	O
studies	O
of	O
individuals	B-MED
with	O
developmental	B-MED
prosopagnosia	I-MED
,	O
suggesting	B-MED
that	O
face	B-MED
recognition	I-MED
can	O
be	O
selectively	B-MED
impaired	I-MED
.	O
We	O
put	O
the	O
selectivity	B-MED
hypothesis	B-MED
to	O
test	B-MED
by	O
assessing	O
the	O
performance	B-MED
of	O
10	O
individuals	B-MED
with	O
developmental	B-MED
prosopagnosia	I-MED
on	O
demanding	O
tests	O
of	O
visual	B-MED
object	I-MED
processing	I-MED
involving	B-MED
both	O
regular	B-MED
and	O
degraded	B-MED
drawings	B-MED
.	O
None	O
of	O
the	O
individuals	B-MED
exhibited	O
a	O
clear	O
dissociation	B-MED
between	O
face	B-MED
and	O
object	B-MED
recognition	I-MED
,	O
and	O
as	O
a	O
group	B-MED
they	O
were	O
significantly	B-MED
more	O
affected	B-MED
by	O
degradation	B-MED
of	O
objects	B-MED
than	O
control	B-MED
participants	B-MED
.	O
Importantly	O
,	O
we	O
also	O
find	O
positive	B-MED
correlations	B-MED
between	O
the	O
severity	B-MED
of	O
the	O
face	B-MED
recognition	I-MED
impairment	B-MED
and	O
the	O
degree	B-MED
of	O
impaired	B-MED
performance	B-MED
with	O
degraded	B-MED
objects	B-MED
.	O
This	O
suggests	O
that	O
the	O
face	B-MED
and	O
object	B-MED
deficits	B-MED
are	O
systematically	O
related	B-MED
rather	O
than	O
coincidental	B-MED
.	O
We	O
conclude	O
that	O
at	O
present	O
,	O
there	O
is	O
no	O
strong	O
evidence	B-MED
in	O
the	O
literature	B-MED
on	O
developmental	B-MED
prosopagnosia	I-MED
supporting	O
domain	B-MED
-	O
specific	B-MED
accounts	O
of	O
face	B-MED
recognition	I-MED
.	O
Exploring	O
the	O
genetic	B-MED
variability	B-MED
in	O
water	B-MED
use	B-MED
efficiency	B-MED
:	O
Evaluation	O
of	O
inter	B-MED
and	O
intra	B-MED
cultivar	I-MED
genetic	B-MED
diversity	I-MED
in	O
grapevines	B-MED
Genetic	B-MED
improvement	B-MED
of	O
crop	B-MED
Water	B-MED
Use	B-MED
Efficiency	B-MED
(	O
WUE	B-MED
)	O
is	O
a	O
general	O
goal	B-MED
because	O
the	O
increasing	B-MED
water	B-MED
scarcity	B-MED
and	O
the	O
trend	O
to	O
a	O
more	O
sustainable	B-MED
agriculture	B-MED
.	O
For	O
grapevines	B-MED
,	O
this	O
subject	B-MED
is	O
relevant	B-MED
and	O
need	O
an	O
urgent	O
response	O
because	O
their	O
wide	O
distribution	B-MED
in	O
semi	B-MED
-	I-MED
arid	I-MED
areas	B-MED
.	O
New	O
cultivars	B-MED
are	O
difficult	B-MED
to	O
introduce	B-MED
in	O
viticulture	B-MED
due	O
to	O
the	O
narrow	O
dependency	O
of	O
consumer	B-MED
appreciation	B-MED
often	O
linked	O
to	O
a	O
certain	O
particular	O
wine	B-MED
taste	B-MED
.	O
Clones	B-MED
of	O
reputed	O
cultivars	B-MED
would	O
presumably	O
be	O
more	O
accepted	B-MED
but	O
little	O
is	O
known	O
on	O
the	O
intra	B-MED
-	I-MED
cultivar	I-MED
genetic	B-MED
variability	B-MED
of	O
the	O
WUE	B-MED
.	O
The	O
present	O
work	O
compares	B-MED
,	O
on	O
the	O
basis	O
of	O
two	O
field	B-MED
assays	O
,	O
the	O
variability	B-MED
of	O
intrinsic	O
water	B-MED
use	B-MED
efficiency	B-MED
(	O
WUEi	B-MED
)	O
in	O
a	O
large	O
collection	B-MED
of	O
cultivars	B-MED
in	O
contrast	B-MED
with	O
a	O
collection	B-MED
of	O
clones	B-MED
of	O
Tempranillo	B-MED
cultivar	I-MED
.	O
The	O
results	B-MED
show	O
that	O
clonal	B-MED
variability	B-MED
of	O
WUEi	B-MED
was	O
around	B-MED
80	O
%	O
of	O
the	O
inter	B-MED
-	I-MED
cultivar	I-MED
,	O
thus	O
providing	O
a	O
first	O
assessment	B-MED
on	O
the	O
opportunity	O
for	O
clonal	B-MED
selection	B-MED
by	O
WUE	B-MED
.	O
Plotting	O
the	O
WUEi	B-MED
data	B-MED
against	O
stem	B-MED
water	B-MED
potential	B-MED
or	O
stomatal	B-MED
conductance	I-MED
it	O
was	O
possible	B-MED
to	O
identify	B-MED
cultivars	B-MED
and	O
clones	B-MED
out	O
of	O
the	O
confidence	B-MED
intervals	I-MED
of	O
this	O
linear	B-MED
regression	I-MED
thus	O
with	O
significantly	B-MED
higher	I-MED
and	O
lower	B-MED
WUEi	B-MED
values	B-MED
.	O
The	O
present	O
results	B-MED
contribute	B-MED
to	O
open	O
the	O
expectative	O
for	O
a	O
genetic	B-MED
improvement	B-MED
of	O
grapevine	B-MED
WUE	B-MED
.	O
Types	O
of	O
internal	B-MED
facilitation	I-MED
activities	B-MED
in	O
hospitals	B-MED
implementing	B-MED
evidence	I-MED
-	I-MED
based	I-MED
interventions	I-MED
Implementation	B-MED
models	B-MED
,	O
frameworks	B-MED
,	O
and	O
theories	B-MED
recognize	O
the	O
importance	O
of	O
activities	B-MED
that	O
facilitate	O
implementation	B-MED
success	B-MED
.	O
However	O
,	O
little	O
is	O
known	O
about	O
internal	B-MED
facilitation	I-MED
activities	B-MED
that	O
hospital	B-MED
personnel	I-MED
engage	B-MED
in	O
during	O
implementation	B-MED
efforts	I-MED
.	O
The	O
aim	O
of	O
the	O
study	B-MED
was	O
to	O
examine	O
internal	B-MED
facilitation	I-MED
activities	B-MED
at	O
10	O
critical	B-MED
access	I-MED
hospitals	I-MED
in	O
rural	B-MED
Iowa	I-MED
during	O
their	O
implementation	B-MED
of	O
TeamSTEPPS	B-MED
,	O
a	O
patient	B-MED
safety	I-MED
intervention	B-MED
,	O
and	O
to	O
identify	O
characteristics	B-MED
that	O
distinguish	O
different	O
types	O
of	O
facilitation	B-MED
activities	B-MED
.	O
We	O
followed	O
10	O
critical	B-MED
access	I-MED
hospitals	I-MED
for	O
2	O
years	B-MED
after	O
the	O
onset	B-MED
of	I-MED
implementation	B-MED
,	O
conducting	O
quarterly	B-MED
interviews	B-MED
with	O
key	B-MED
informants	I-MED
.	O
On	O
the	O
basis	O
of	O
the	O
transcripts	B-MED
from	O
the	O
first	O
two	O
quarters	B-MED
,	O
a	O
coding	B-MED
template	I-MED
was	O
developed	O
using	O
inductive	B-MED
analyses	I-MED
.	O
The	O
template	B-MED
was	O
then	O
applied	O
deductively	B-MED
to	O
code	O
all	O
interview	B-MED
transcripts	B-MED
.	O
Using	O
comparative	B-MED
analysis	I-MED
,	O
we	O
examined	O
the	O
characteristics	B-MED
that	O
distinguish	O
between	O
the	O
facilitation	B-MED
types	O
.	O
We	O
identified	O
four	O
types	O
of	O
facilitation	B-MED
activities	B-MED
-	O
Leadership	B-MED
,	O
Buy	O
-	O
in	O
,	O
Customization	B-MED
,	O
and	O
Accountability	B-MED
.	O
Individuals	B-MED
and	O
teams	B-MED
engaged	B-MED
in	O
different	O
types	O
of	O
facilitation	B-MED
activities	B-MED
,	O
both	O
in	O
a	O
planned	O
and	O
an	O
ad	B-MED
hoc	I-MED
manner	I-MED
.	O
These	O
activities	B-MED
targeted	O
at	O
both	O
people	B-MED
and	O
practices	B-MED
and	O
exhibited	O
varying	O
temporal	B-MED
patterns	I-MED
(	O
start	B-MED
and	O
peak	B-MED
time	I-MED
)	O
.	O
There	O
are	O
four	O
types	O
of	O
facilitation	B-MED
activities	B-MED
that	O
hospitals	B-MED
engage	B-MED
in	O
while	O
implementing	B-MED
evidence	B-MED
-	I-MED
based	I-MED
practices	I-MED
,	O
offering	O
a	O
parsimonious	B-MED
way	O
to	O
characterize	O
facilitation	B-MED
activities	B-MED
.	O
New	O
theoretical	B-MED
and	O
empirical	B-MED
research	B-MED
opportunities	I-MED
are	O
discussed	O
.	O
Understanding	O
the	O
types	O
of	O
facilitation	B-MED
activities	B-MED
and	O
their	O
distinguishing	O
characteristics	B-MED
can	O
assist	O
managers	B-MED
in	O
planning	B-MED
and	O
executing	B-MED
implementations	B-MED
of	O
evidence	B-MED
-	I-MED
based	I-MED
interventions	I-MED
.	O
Effect	B-MED
of	I-MED
an	O
immunomodulatory	B-MED
regimen	I-MED
for	O
cancer	B-MED
prevention	I-MED
:	O
A	O
case	B-MED
report	I-MED
In	O
the	O
present	B-MED
case	B-MED
study	I-MED
,	O
an	O
immunomodulatory	B-MED
regimen	I-MED
for	O
cancer	B-MED
prevention	I-MED
is	O
reported	B-MED
.	O
A	O
patient	B-MED
with	O
an	O
abnormally	B-MED
high	I-MED
level	B-MED
of	O
the	O
tumor	B-MED
markers	I-MED
,	O
carbohydrate	B-MED
antigen-724	I-MED
(	O
CA724	B-MED
)	O
,	O
CA19	B-MED
-	I-MED
9	I-MED
and	O
carcinoembryonic	B-MED
antigen	I-MED
(	O
CEA	B-MED
)	O
,	O
although	O
without	B-MED
any	O
detectable	B-MED
tumor	B-MED
,	O
was	O
treated	B-MED
with	I-MED
an	O
immunomodulatory	B-MED
therapy	I-MED
featuring	O
an	O
infusion	B-MED
of	O
cytokine	B-MED
-	I-MED
induced	I-MED
autologous	I-MED
killer	I-MED
cells	I-MED
(	O
CIKs	B-MED
)	O
at	O
the	O
request	B-MED
of	O
the	O
patient	B-MED
.	O
Following	O
the	O
therapy	B-MED
,	O
the	O
three	O
tumor	B-MED
markers	I-MED
rapidly	B-MED
decreased	B-MED
to	O
below	O
the	O
normal	B-MED
reference	I-MED
level	I-MED
,	O
although	O
there	O
still	O
were	O
slight	B-MED
fluctuations	B-MED
within	O
a	O
narrow	B-MED
range	B-MED
frequently	B-MED
.	O
The	O
patient	B-MED
was	O
monitored	B-MED
for	O
21	O
months	B-MED
to	O
the	O
present	B-MED
day	B-MED
and	O
no	B-MED
abnormality	I-MED
was	O
observed	B-MED
.	O
The	O
results	B-MED
indicated	O
that	O
this	O
therapy	B-MED
may	O
be	O
applied	O
as	O
a	O
novel	B-MED
strategy	O
that	O
is	O
effective	B-MED
and	O
reliable	B-MED
for	O
cancer	B-MED
prevention	I-MED
.	O
As	O
there	O
is	O
no	O
promising	O
regimen	B-MED
for	O
the	O
prevention	B-MED
of	I-MED
malignancies	I-MED
to	O
date	O
,	O
such	O
a	O
treatment	B-MED
may	O
become	O
a	O
major	B-MED
cancer	B-MED
prophylactic	B-MED
regimen	I-MED
,	O
particularly	O
for	O
patients	B-MED
who	O
are	O
at	O
a	O
high	B-MED
risk	I-MED
of	I-MED
cancer	B-MED
.	O
Incidence	B-MED
of	O
Diabetes	B-MED
Mellitus	I-MED
and	O
Obesity	B-MED
and	O
the	O
Overlap	B-MED
of	O
Comorbidities	B-MED
in	O
HIV+	B-MED
Hispanics	B-MED
Initiating	B-MED
Antiretroviral	B-MED
Therapy	I-MED
Cardiovascular	B-MED
disease	I-MED
(	O
CVD	B-MED
)	O
is	O
a	O
leading	O
health	B-MED
threat	B-MED
for	O
HIV+	B-MED
patients	B-MED
on	O
antiretroviral	B-MED
therapy	I-MED
(	O
ART	B-MED
)	O
;	O
cardiometabolic	B-MED
comorbidities	B-MED
are	O
key	O
predictors	B-MED
of	I-MED
risk	I-MED
.	O
Data	B-MED
are	O
limited	O
on	O
incidence	B-MED
of	O
metabolic	B-MED
comorbidities	B-MED
in	O
HIV+	B-MED
individuals	B-MED
initiating	B-MED
ART	B-MED
in	O
low	B-MED
and	O
middle	B-MED
income	I-MED
countries	B-MED
(	O
LMICs	B-MED
)	O
,	O
particularly	B-MED
for	O
Hispanics	B-MED
.	O
We	O
examined	B-MED
incidence	B-MED
of	O
diabetes	B-MED
and	O
obesity	B-MED
in	O
a	O
prospective	B-MED
cohort	I-MED
of	O
those	O
initiating	B-MED
ART	B-MED
in	O
the	O
Dominican	B-MED
Republic	I-MED
.	O
Participants	B-MED
≥18	O
years	B-MED
,	O
initiating	B-MED
ART	B-MED
<	O
90	O
days	B-MED
prior	O
to	O
study	B-MED
enrollment	B-MED
,	O
were	O
examined	B-MED
for	O
incidence	B-MED
of	O
impaired	B-MED
fasting	I-MED
glucose	I-MED
(	O
IFG	B-MED
)	O
,	O
diabetes	B-MED
mellitus	I-MED
(	O
DM	B-MED
)	O
,	O
overweight	B-MED
,	I-MED
and	I-MED
obesity	I-MED
.	O
Fasting	B-MED
plasma	I-MED
glucose	I-MED
(	O
FPG	B-MED
)	O
100	O
-	O
125mg	O
/	O
dl	O
defined	O
IFG	B-MED
;	O
FPG	B-MED
≥126	O
mg	O
/	O
dl	O
,	O
diagnosis	B-MED
per	O
medical	B-MED
record	I-MED
,	O
or	O
use	O
of	O
hypoglycemic	B-MED
medication	I-MED
defined	O
DM	B-MED
.	O
Overweight	B-MED
and	I-MED
obesity	I-MED
were	O
BMI	B-MED
25	O
-	O
30	O
and	O
≥30kg	O
/	O
m2	O
,	O
respectively	O
.	O
Dyslipidemia	B-MED
was	O
total	B-MED
cholesterol	I-MED
≥240mg	O
/	O
dl	O
or	O
use	B-MED
of	I-MED
lipid	B-MED
-	I-MED
lowering	I-MED
medication	I-MED
.	O
Framingham	B-MED
risk	I-MED
equation	I-MED
was	O
used	B-MED
to	O
determine	B-MED
ten	B-MED
-	I-MED
year	I-MED
CVD	B-MED
risk	B-MED
at	O
the	O
end	B-MED
of	I-MED
observation	I-MED
.	O
Of	O
153	O
initiating	B-MED
ART	B-MED
,	O
8	O
(	O
6	O
%	O
)	O
had	O
DM	B-MED
and	O
23	O
(	O
16	O
%	O
)	O
had	O
IFG	B-MED
at	O
baseline	B-MED
,	O
6	O
developed	O
DM	B-MED
(	O
28/1000	O
person	B-MED
-	O
years	B-MED
follow	B-MED
up	I-MED
[	O
PYFU	B-MED
]	O
)	O
and	O
46	O
developed	O
IFG	B-MED
(	O
329/1000	O
PYFU	B-MED
)	O
.	O
At	O
baseline	B-MED
,	O
24	O
(	O
18	O
%	O
)	O
were	O
obese	B-MED
and	O
36	O
(	O
27	O
%	O
)	O
were	O
overweight	B-MED
,	O
15	O
became	O
obese	B-MED
(	O
69/1000	O
PYFU	B-MED
)	O
and	O
22	O
became	O
overweight	B-MED
(	O
163/1000	O
PYFU	B-MED
)	O
.	O
Median	B-MED
observation	B-MED
periods	B-MED
for	O
the	O
diabetes	B-MED
and	O
obesity	B-MED
analyses	B-MED
were	O
23.5	O
months	B-MED
and	O
24.3	O
months	B-MED
,	O
respectively	O
.	O
Increased	B-MED
CVD	B-MED
risk	B-MED
(	O
≥10	O
%	O
10	B-MED
-	I-MED
year	I-MED
Framingham	I-MED
risk	I-MED
score	I-MED
)	O
was	O
present	B-MED
for	O
13	O
%	O
of	O
the	O
cohort	B-MED
;	O
79	O
%	O
of	O
the	O
cohort	B-MED
had	O
≥1	O
cardiometabolic	B-MED
comorbidity	I-MED
,	O
48	O
%	O
had	O
≥2	O
,	O
and	O
13	O
%	O
had	O
all	O
three	O
.	O
In	O
this	O
Hispanic	B-MED
cohort	B-MED
in	O
an	O
LMIC	B-MED
,	O
incidences	B-MED
of	O
IFG	B-MED
/	O
DM	B-MED
and	O
overweight	B-MED
/	O
obesity	B-MED
were	O
similar	B-MED
to	O
or	O
higher	B-MED
than	I-MED
that	O
found	B-MED
in	O
high	B-MED
income	I-MED
countries	B-MED
,	O
and	O
cardiometabolic	B-MED
disorders	I-MED
affected	B-MED
three	O
-	O
quarters	O
of	O
those	O
initiating	B-MED
ART	B-MED
.	O
Care	B-MED
models	I-MED
incorporating	O
cardiovascular	B-MED
risk	I-MED
reduction	B-MED
into	O
HIV	B-MED
treatment	B-MED
programs	I-MED
are	O
needed	B-MED
to	O
prevent	B-MED
CVD	B-MED
-	O
associated	B-MED
mortality	B-MED
in	O
this	O
vulnerable	B-MED
population	I-MED
.	O
Intraspinal	B-MED
meningioma	I-MED
with	O
malignant	B-MED
transformation	I-MED
and	O
distant	B-MED
metastasis	I-MED
Meningioma	B-MED
is	O
typically	O
considered	O
to	O
be	O
a	O
benign	B-MED
tumor	I-MED
.	O
Malignant	B-MED
transformation	I-MED
and	O
metastasis	B-MED
of	O
meningiomas	B-MED
are	O
rare	B-MED
.	O
Moreover	O
,	O
most	O
meningiomas	B-MED
are	O
intracranial	B-MED
,	O
and	O
there	O
are	O
few	O
reports	B-MED
on	O
intraspinal	B-MED
meningiomas	I-MED
.	O
This	O
report	B-MED
aimed	O
to	O
describe	O
the	O
clinical	B-MED
features	I-MED
and	O
pathological	B-MED
findings	B-MED
of	O
a	O
case	B-MED
of	O
malignant	B-MED
transformation	I-MED
and	O
distant	B-MED
metastasis	I-MED
of	O
intraspinal	B-MED
meningioma	I-MED
,	O
with	O
a	O
review	B-MED
of	I-MED
the	O
literature	B-MED
.	O
A	O
44	O
-	O
year	O
-	O
old	O
man	B-MED
with	O
a	O
bilateral	B-MED
lower	B-MED
limb	I-MED
paresis	I-MED
was	O
diagnosed	B-MED
with	O
an	O
intradural	B-MED
extramedullary	I-MED
tumor	I-MED
of	I-MED
the	I-MED
thoracic	I-MED
spine	I-MED
.	O
Primary	B-MED
tumor	B-MED
resection	I-MED
was	O
performed	B-MED
,	O
and	O
the	O
histological	B-MED
findings	I-MED
revealed	O
atypical	B-MED
meningioma	I-MED
.	O
The	O
meningioma	B-MED
recurred	B-MED
2	O
years	B-MED
after	O
the	O
primary	B-MED
surgery	B-MED
,	O
and	O
a	O
second	B-MED
resection	B-MED
was	O
performed	B-MED
,	O
but	O
only	O
partial	B-MED
resection	B-MED
was	O
possible	O
because	O
of	O
decreased	B-MED
motor	B-MED
evoked	I-MED
potential	I-MED
.	O
At	O
age	B-MED
48	O
,	O
the	O
patient	B-MED
's	I-MED
lower	B-MED
limb	I-MED
weakness	I-MED
returned	B-MED
,	O
and	O
a	O
third	B-MED
resection	B-MED
was	O
performed	B-MED
,	O
and	O
the	O
histological	B-MED
finding	I-MED
remained	O
atypical	B-MED
meningioma	I-MED
.	O
At	O
age	B-MED
54	O
,	O
the	O
tumor	B-MED
increased	B-MED
and	O
stereotactic	B-MED
irradiation	I-MED
was	O
performed	B-MED
.	O
At	O
age	B-MED
60	O
,	O
the	O
patient	B-MED
was	O
diagnosed	B-MED
with	O
metastatic	B-MED
tumors	I-MED
of	O
the	O
rib	B-MED
,	O
lumbar	B-MED
vertebra	I-MED
,	O
cervical	B-MED
spine	I-MED
,	O
and	O
sacrum	B-MED
.	O
Biopsy	B-MED
of	O
the	O
rib	B-MED
metastatic	B-MED
tumor	I-MED
was	O
performed	B-MED
,	O
and	O
the	O
histological	B-MED
findings	I-MED
revealed	O
anaplastic	B-MED
meningioma	I-MED
.	O
This	O
case	B-MED
is	O
the	O
first	O
report	B-MED
of	O
an	O
intraspinal	B-MED
meningioma	I-MED
that	O
transformed	B-MED
from	O
atypical	B-MED
to	O
anaplastic	B-MED
meningioma	I-MED
with	O
distant	B-MED
hematogenous	I-MED
metastasis	I-MED
hematogenous	B-MED
.	O
Surgical	B-MED
Guidance	B-MED
via	O
Multiplexed	B-MED
Molecular	I-MED
Imaging	I-MED
of	O
Fresh	O
Tissues	B-MED
Labeled	B-MED
with	O
SERS	B-MED
-Coded	O
Nanoparticles	B-MED
The	O
imaging	B-MED
of	O
dysregulated	O
cell	B-MED
-	I-MED
surface	I-MED
receptors	I-MED
(	O
or	O
biomarkers	B-MED
)	I-MED
is	O
a	O
potential	O
means	O
of	O
identifying	O
the	O
presence	B-MED
of	O
cancer	B-MED
with	O
high	O
sensitivity	B-MED
and	O
specificity	B-MED
.	O
However	O
,	O
due	O
to	O
heterogeneities	B-MED
in	O
the	O
expression	B-MED
of	I-MED
protein	I-MED
biomarkers	B-MED
in	O
tumors	B-MED
,	O
molecular	B-MED
imaging	I-MED
technologies	B-MED
should	O
ideally	O
be	O
capable	O
of	O
visualizing	O
a	O
multiplexed	B-MED
panel	I-MED
of	O
cancer	B-MED
biomarkers	I-MED
.	O
Recently	O
,	O
surface	B-MED
-	I-MED
enhanced	I-MED
Raman	I-MED
-	I-MED
scattering	I-MED
(	O
SERS	B-MED
)	O
nanoparticles	B-MED
(	O
NPs	B-MED
)	O
have	O
attracted	O
wide	O
interest	O
due	O
to	O
their	O
potential	O
for	O
sensitive	B-MED
and	O
multiplexed	B-MED
biomarker	I-MED
detection	B-MED
.	O
In	O
this	O
review	B-MED
,	O
we	O
focus	O
on	O
the	O
most	O
recent	O
advances	O
in	O
tumor	B-MED
imaging	B-MED
using	O
SERS	B-MED
-coded	O
NPs	B-MED
.	O
A	O
brief	O
introduction	O
of	O
the	O
structure	B-MED
and	O
optical	B-MED
properties	I-MED
of	O
SERS	B-MED
NPs	B-MED
is	O
provided	O
,	O
followed	O
by	O
a	O
detailed	O
discussion	O
of	O
key	O
imaging	B-MED
issues	O
such	O
as	O
the	O
administration	B-MED
of	O
NPs	B-MED
in	O
tissue	B-MED
(	O
topical	B-MED
versus	O
systemic	B-MED
)	O
,	O
the	O
optical	B-MED
configuration	I-MED
and	O
imaging	B-MED
approach	O
of	O
Raman	B-MED
imaging	I-MED
systems	I-MED
,	O
spectral	B-MED
demultiplexing	I-MED
methods	I-MED
for	O
quantifying	B-MED
NP	B-MED
concentrations	B-MED
,	O
and	O
the	O
disambiguation	B-MED
of	O
specific	B-MED
vs.	O
nonspecific	B-MED
sources	O
of	O
contrast	O
through	O
ratiometric	B-MED
imaging	I-MED
of	O
targeted	B-MED
and	O
untargeted	B-MED
(	O
control	B-MED
)	O
NP	B-MED
pairs	O
.	O
Finally	O
,	O
future	O
challenges	O
and	O
directions	O
are	O
briefly	O
outlined	O
.	O
Food	B-MED
security	I-MED
and	O
the	O
nutritional	B-MED
status	I-MED
of	O
children	B-MED
in	O
foster	B-MED
care	I-MED
:	O
new	O
horizons	O
in	O
the	O
protection	O
of	O
a	O
fragile	O
population	O
The	O
nutritional	B-MED
status	I-MED
of	O
foster	B-MED
children	I-MED
,	O
the	O
quality	B-MED
of	O
daily	B-MED
menus	I-MED
in	O
group	B-MED
homes	I-MED
and	O
the	O
Food	B-MED
Security	I-MED
inside	O
these	O
organizations	B-MED
have	O
been	O
poorly	O
studied	O
and	O
this	O
study	B-MED
means	O
to	O
investigate	O
them	O
.	O
A	O
sample	O
of	O
125	O
children	B-MED
,	O
ranging	O
in	O
age	O
from	O
0	O
-	O
17	O
years	O
,	O
among	O
seven	O
group	B-MED
homes	I-MED
(	O
group	B-MED
A	I-MED
)	O
was	O
compared	O
with	O
121	O
children	B-MED
of	O
the	O
general	B-MED
population	I-MED
we	O
(	O
group	B-MED
B	I-MED
)	O
.	O
To	O
evaluate	O
nutritional	B-MED
status	I-MED
,	O
BMI	B-MED
percentiles	I-MED
were	O
used	O
.	O
Mean	B-MED
percentiles	B-MED
of	O
both	O
groups	B-MED
were	O
compared	O
through	O
statistical	B-MED
analysis	I-MED
.	O
Both	O
nutritional	B-MED
and	O
caloric	B-MED
daily	I-MED
distributions	I-MED
in	O
each	O
organization	B-MED
were	O
obtained	O
using	O
the	O
24	O
-	O
hour	O
recall	B-MED
method	I-MED
.	O
A	O
specific	O
questionnaire	B-MED
was	O
administered	O
to	O
evaluate	O
Food	B-MED
Security	I-MED
.	O
From	O
the	O
analysis	B-MED
of	O
mean	B-MED
BMI	B-MED
-for-	O
age	B-MED
(	O
or	O
height	O
-	O
for	O
-	O
length	O
)	O
percentiles	B-MED
,	O
did	O
not	O
observe	O
statistically	O
significant	O
differences	B-MED
between	O
group	B-MED
A	I-MED
and	O
group	B-MED
B	I-MED
B.	O
The	O
average	B-MED
daily	B-MED
nutrient	B-MED
and	O
calorie	B-MED
distribution	I-MED
in	O
group	B-MED
homes	I-MED
proves	O
to	O
be	O
nearly	B-MED
optimal	I-MED
with	O
the	O
exception	O
of	O
a	O
slight	O
excess	B-MED
in	O
proteins	B-MED
and	O
a	O
slight	O
deficiency	B-MED
in	O
PUFAs	B-MED
.	O
Moreover	O
,	O
a	O
low	B-MED
intake	I-MED
of	O
iron	B-MED
and	O
calcium	B-MED
was	O
revealed	O
.	O
All	O
organizations	B-MED
obtained	O
a	O
"	O
High	B-MED
Food	I-MED
Security	I-MED
"	O
profile	O
.	O
Nutritional	B-MED
conditions	I-MED
of	O
foster	B-MED
children	I-MED
are	O
no	O
worse	O
than	O
that	O
of	O
children	B-MED
of	O
the	O
general	B-MED
population	I-MED
.	O
Foster	B-MED
care	I-MED
provides	O
the	O
necessary	B-MED
conditions	I-MED
to	O
support	O
their	O
growth	B-MED
.	O
Expert	B-MED
position	B-MED
paper	I-MED
on	O
prolonged	B-MED
dual	B-MED
antiplatelet	I-MED
therapy	I-MED
in	O
secondary	B-MED
prevention	I-MED
following	O
myocardial	B-MED
infarction	I-MED
The	O
protective	B-MED
effect	I-MED
of	O
dual	B-MED
antiplatelet	I-MED
therapy	I-MED
(	O
DAPT	B-MED
)	O
following	O
acute	B-MED
coronary	I-MED
syndrome	I-MED
is	O
undisputed	O
,	O
but	O
its	O
duration	B-MED
is	O
subject	O
of	O
debate	B-MED
.	O
Several	O
studies	B-MED
show	O
that	O
prolonged	B-MED
therapy	B-MED
provides	O
a	O
clinical	B-MED
benefit	B-MED
in	O
patients	B-MED
following	O
acute	B-MED
coronary	I-MED
syndrome	I-MED
.	O
The	O
aim	O
of	O
this	O
position	B-MED
paper	I-MED
authored	O
by	O
Austrian	B-MED
experts	B-MED
is	O
to	O
outline	O
the	O
current	B-MED
evidence	B-MED
and	O
provide	O
an	O
overview	O
of	O
recent	O
studies	B-MED
.	O
It	O
is	O
also	O
intended	O
to	O
serve	O
as	O
a	O
practical	B-MED
guide	I-MED
to	O
identify	O
those	O
patients	B-MED
who	O
may	O
benefit	B-MED
from	O
prolonged	B-MED
DAPT	B-MED
.	O
CXCR4	B-MED
(	O
CD184	B-MED
)	O
expression	B-MED
on	O
stem	B-MED
cell	I-MED
harvest	I-MED
and	O
CD34(+	B-MED
)	I-MED
cells	B-MED
post	B-MED
-	I-MED
transplant	I-MED
CXCR4	B-MED
is	O
a	O
receptor	B-MED
for	O
stromal	B-MED
-	I-MED
derived	I-MED
factor-1	I-MED
(	O
SDF-1	B-MED
)	O
,	O
a	O
molecule	B-MED
that	O
has	O
a	O
chemotactic	B-MED
activity	B-MED
for	O
lymphocytes	B-MED
and	O
is	O
important	O
in	O
homing	B-MED
of	O
hematopoietic	B-MED
stem	I-MED
cells	I-MED
to	O
their	O
adult	B-MED
marrow	I-MED
.	O
We	O
evaluated	B-MED
the	O
CXCR4	B-MED
(	O
CD184	B-MED
)	O
expression	B-MED
in	O
the	O
harvest	B-MED
cells	I-MED
and	O
in	O
the	O
post	B-MED
-	I-MED
transplant	I-MED
bone	B-MED
marrow	I-MED
(	O
BM	B-MED
)	O
and	O
its	O
relation	B-MED
to	O
engraftment	B-MED
,	O
as	O
determined	O
by	O
the	O
consensus	B-MED
criteria	I-MED
and	O
chimerism	B-MED
.	O
This	O
is	O
a	O
prospective	B-MED
study	I-MED
which	O
included	O
30	O
patients	B-MED
undergoing	O
hematopoietic	B-MED
stem	I-MED
cell	I-MED
transplantation	I-MED
;	O
15	O
patients	B-MED
received	B-MED
autograft	B-MED
and	O
15	O
patients	B-MED
received	B-MED
allograft	B-MED
on	O
dates	O
between	O
January	O
2012	O
and	O
May	O
2014	O
.	O
We	O
assessed	B-MED
CD184	B-MED
(	O
CXCR4	B-MED
)	O
using	O
flow	B-MED
cytometry	I-MED
in	O
the	O
harvest	B-MED
cells	I-MED
together	O
with	O
post	B-MED
-	I-MED
transplant	I-MED
BM	B-MED
assessment	B-MED
on	O
Day	O
28	O
and	O
Day	O
90	O
for	O
complete	B-MED
morphologic	B-MED
,	O
molecular	B-MED
studies	I-MED
,	O
and	O
detection	B-MED
of	O
CD184	B-MED
expression	B-MED
on	O
CD34(+	B-MED
)	I-MED
cells	B-MED
with	O
chimerism	B-MED
studies	O
on	O
total	B-MED
peripheral	B-MED
blood	I-MED
mononuclear	I-MED
cells	I-MED
.	O
Diagnoses	B-MED
of	O
the	O
enrolled	O
patients	B-MED
were	O
as	O
follows	O
:	O
seven	O
(	O
24.1	O
%	O
)	O
with	O
acute	B-MED
myeloid	I-MED
leukemia	I-MED
,	O
eight	O
(	O
27.6	O
%	O
)	O
with	O
multiple	B-MED
myeloma	I-MED
,	O
four	O
(	O
13.8	O
%	O
)	O
with	O
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
,	O
three	O
(	O
10.3	O
%	O
)	O
with	O
non	B-MED
-	I-MED
Hodgkin	I-MED
lymphoma	I-MED
,	O
two	O
(	O
6.9	O
%	O
)	O
with	O
myelodysplastic	B-MED
syndromes	I-MED
,	O
two	O
(	O
6.9	O
%	O
)	O
with	O
aplastic	B-MED
anemia	I-MED
,	O
two	O
(	O
6.9	O
%	O
)	O
with	O
chronic	B-MED
myeloid	I-MED
leukemia	I-MED
,	O
one	O
(	O
3.4	O
%	O
)	O
with	O
Hodgkin	B-MED
lymphoma	I-MED
,	O
and	O
one	O
(	O
3.4	O
%	O
)	O
with	O
plasmacytomas	B-MED
.	O
One	O
patient	B-MED
died	B-MED
and	O
was	O
excluded	B-MED
from	O
the	O
study	B-MED
because	O
there	O
were	O
not	O
enough	O
data	O
about	O
engraftment	B-MED
.	O
There	O
was	O
no	B-MED
statistical	B-MED
significance	I-MED
between	O
the	O
level	B-MED
of	O
CD184	B-MED
in	O
stem	B-MED
cell	I-MED
harvest	I-MED
and	O
the	O
prediction	B-MED
of	O
successful	B-MED
engraftment	B-MED
(	O
p>0.05	O
)	O
as	O
well	O
as	O
in	O
Day	O
28	O
BM	B-MED
sample	I-MED
(	O
p>0.05	O
)	O
,	O
whereas	O
there	O
was	O
a	O
statistical	B-MED
significance	I-MED
between	O
the	O
level	B-MED
of	O
CD184	B-MED
in	O
Day	O
90	O
BM	B-MED
sample	I-MED
and	O
the	O
occurrence	B-MED
of	O
successful	B-MED
engraftment	B-MED
(	O
p=0.002	O
)	O
.	O
SDF-1	B-MED
/	O
CXCR4	B-MED
axis	O
plays	O
a	O
crucial	O
role	O
in	O
engraftment	B-MED
;	O
however	O
,	O
more	O
studies	O
are	O
warranted	O
to	O
assess	B-MED
their	O
expression	B-MED
post	B-MED
-	I-MED
transplant	I-MED
.	O
Evaluating	O
the	O
ligand	O
(	O
chemokine	B-MED
,	O
SDF-1	B-MED
)	O
or	O
its	O
receptor	B-MED
(	O
CXCR4	B-MED
)	O
may	O
serve	O
as	O
potential	B-MED
surrogate	B-MED
markers	I-MED
for	O
assessment	B-MED
of	O
engraftment	B-MED
.	O
Characterizing	B-MED
sexual	B-MED
function	I-MED
in	O
patients	B-MED
with	O
generalized	B-MED
anxiety	I-MED
disorder	I-MED
:	O
a	O
pooled	B-MED
analysis	I-MED
of	O
three	O
vilazodone	B-MED
studies	B-MED
Vilazodone	B-MED
has	O
been	O
shown	O
to	O
reduce	B-MED
core	B-MED
symptoms	I-MED
of	O
generalized	B-MED
anxiety	I-MED
disorder	I-MED
(	O
GAD	B-MED
)	O
in	O
three	O
randomized	B-MED
,	O
double	B-MED
-	I-MED
blind	I-MED
,	O
placebo	B-MED
-	I-MED
controlled	I-MED
trials	I-MED
.	O
Since	O
sexual	B-MED
dysfunction	I-MED
(	O
SD	B-MED
)	O
is	O
not	O
well	O
characterized	O
in	O
GAD	B-MED
,	O
a	O
post	B-MED
hoc	I-MED
analysis	I-MED
of	O
these	O
trials	B-MED
was	O
conducted	O
to	O
evaluate	B-MED
the	O
effects	B-MED
of	I-MED
vilazodone	B-MED
on	O
sexual	B-MED
functioning	I-MED
in	O
GAD	B-MED
patients	B-MED
.	O
Data	B-MED
were	O
pooled	B-MED
from	O
one	O
fixed	B-MED
-	I-MED
dose	I-MED
trial	I-MED
of	O
vilazodone	B-MED
20	O
and	O
40	O
mg	B-MED
/	I-MED
day	I-MED
(	O
NCT01629966	B-MED
)	O
and	O
two	O
flexible	B-MED
-	I-MED
dose	I-MED
studies	I-MED
of	O
vilazodone	B-MED
20	O
-	O
40	O
mg	B-MED
/	I-MED
day	I-MED
(	O
NCT01766401	B-MED
,	O
NCT01844115	B-MED
)	O
in	O
adults	B-MED
with	O
GAD	B-MED
.	O
Sexual	B-MED
functioning	I-MED
was	O
assessed	B-MED
using	O
the	O
Changes	B-MED
in	I-MED
Sexual	I-MED
Functioning	I-MED
Questionnaire	I-MED
(	O
CSFQ	B-MED
)	O
.	O
Outcomes	B-MED
included	O
mean	B-MED
change	I-MED
from	I-MED
baseline	I-MED
to	I-MED
end	I-MED
of	I-MED
treatment	I-MED
(	O
EOT	B-MED
)	O
in	O
CSFQ	B-MED
total	I-MED
score	I-MED
and	O
percentage	B-MED
of	O
patients	B-MED
shifting	B-MED
from	O
SD	B-MED
at	O
baseline	B-MED
(	O
CSFQ	B-MED
total	I-MED
score	I-MED
≤47	O
for	O
males	B-MED
,	O
≤41	O
for	O
females	B-MED
)	O
to	O
normal	B-MED
functioning	I-MED
at	O
EOT	B-MED
.	O
Treatment	B-MED
-	I-MED
emergent	I-MED
adverse	I-MED
events	I-MED
related	O
to	O
sexual	B-MED
functioning	I-MED
were	O
also	O
analyzed	B-MED
.	O
A	O
total	B-MED
of	O
1,373	O
patients	B-MED
were	O
included	O
in	O
the	O
analyses	B-MED
.	O
SD	B-MED
at	O
baseline	B-MED
was	O
more	O
common	O
in	O
females	B-MED
(	O
placebo	B-MED
,	O
46.4	O
%	O
;	O
vilazodone	B-MED
,	O
49	O
%	O
)	O
than	O
in	O
males	B-MED
(	O
placebo	B-MED
,	O
35.1	O
%	O
;	O
vilazodone	B-MED
,	O
40.9	O
%	O
)	O
.	O
CSFQ	B-MED
total	I-MED
score	I-MED
improvement	B-MED
was	O
found	O
in	O
both	O
females	B-MED
(	O
placebo	B-MED
,	O
+1.2	O
;	O
vilazodone	B-MED
,	O
+1.6	O
)	O
and	O
males	B-MED
(	O
placebo	B-MED
,	O
+2.1	O
;	O
vilazodone	B-MED
,	O
+1.0	O
)	O
,	O
with	O
no	B-MED
statistically	I-MED
significant	I-MED
differences	I-MED
between	O
treatment	B-MED
groups	B-MED
.	O
The	O
percentage	B-MED
of	O
patients	B-MED
who	O
shifted	B-MED
from	O
SD	B-MED
at	O
baseline	B-MED
to	O
normal	B-MED
sexual	B-MED
functioning	I-MED
at	O
EOT	B-MED
was	O
higher	O
in	O
males	B-MED
(	O
placebo	B-MED
,	O
40.6	O
%	O
;	O
vilazodone	B-MED
,	O
35.7	O
%	O
)	O
than	O
in	O
females	B-MED
(	O
placebo	B-MED
,	O
24.9	O
%	O
;	O
vilazodone	B-MED
,	O
34.9	O
%	O
)	O
;	O
no	B-MED
statistical	I-MED
testing	I-MED
was	O
performed	O
.	O
Except	O
for	O
erectile	B-MED
dysfunction	I-MED
and	O
delayed	B-MED
ejaculation	I-MED
in	O
vilazodone	B-MED
-	O
treated	B-MED
males	B-MED
(	O
2.4	O
%	O
and	O
2.1	O
%	O
,	O
respectively	O
)	O
,	O
no	B-MED
treatment	I-MED
-	I-MED
emergent	I-MED
adverse	I-MED
events	I-MED
related	O
to	O
sexual	B-MED
functioning	I-MED
occurred	B-MED
in	O
≥2	O
%	O
of	O
patients	B-MED
in	O
either	O
treatment	B-MED
group	B-MED
.	O
Approximately	B-MED
35%-50	O
%	O
of	O
patients	B-MED
in	O
the	O
vilazodone	B-MED
GAD	B-MED
studies	B-MED
had	O
SD	B-MED
at	O
baseline	B-MED
.	O
Vilazodone	B-MED
and	O
placebo	B-MED
had	O
similar	O
effects	B-MED
on	O
CSFQ	B-MED
outcomes	B-MED
in	O
both	O
females	B-MED
and	O
males	B-MED
,	O
indicating	O
a	O
limited	B-MED
adverse	B-MED
impact	I-MED
on	O
sexual	B-MED
functioning	I-MED
with	O
vilazodone	B-MED
.	O
Simultaneously	B-MED
Targeting	B-MED
Myofibroblast	B-MED
Contractility	I-MED
and	O
Extracellular	B-MED
Matrix	I-MED
Cross	B-MED
-	I-MED
Linking	I-MED
as	O
a	O
Therapeutic	B-MED
Concept	I-MED
in	O
Airway	B-MED
Fibrosis	B-MED
Fibrosis	B-MED
after	O
solid	B-MED
organ	I-MED
transplantation	I-MED
is	O
considered	O
an	O
irreversible	B-MED
process	B-MED
and	O
remains	O
the	O
major	B-MED
cause	O
of	O
graft	B-MED
dysfunction	I-MED
and	O
death	B-MED
with	O
limited	B-MED
therapies	B-MED
.	O
This	O
remodeling	B-MED
is	O
characterized	B-MED
by	O
aberrant	B-MED
accumulation	B-MED
of	O
contractile	B-MED
myofibroblasts	I-MED
that	O
deposit	B-MED
excessive	B-MED
extracellular	B-MED
matrix	I-MED
(	O
ECM	B-MED
)	O
and	O
increase	B-MED
tissue	B-MED
stiffness	I-MED
.	O
Studies	B-MED
demonstrate	O
,	O
however	O
,	O
that	O
a	O
stiff	B-MED
ECM	B-MED
itself	O
promotes	B-MED
fibroblast	B-MED
-to-	O
myofibroblast	B-MED
differentiation	B-MED
,	O
stimulating	B-MED
further	O
ECM	B-MED
production	B-MED
.	O
This	O
creates	O
a	O
positive	B-MED
feedback	I-MED
loop	I-MED
that	O
perpetuates	B-MED
fibrosis	B-MED
.	O
We	O
hypothesized	B-MED
that	O
simultaneously	B-MED
targeting	B-MED
myofibroblast	B-MED
contractility	I-MED
with	O
relaxin	B-MED
and	O
ECM	B-MED
stiffness	B-MED
with	O
lysyl	B-MED
oxidase	I-MED
inhibitors	B-MED
could	O
break	O
the	O
feedback	B-MED
loop	I-MED
,	O
reversing	B-MED
established	B-MED
fibrosis	B-MED
.	O
To	O
test	B-MED
this	O
,	O
we	O
used	O
the	O
orthotopic	B-MED
tracheal	I-MED
transplantation	I-MED
(	O
OTT	B-MED
)	O
mouse	B-MED
model	I-MED
,	O
which	O
develops	O
robust	B-MED
fibrotic	B-MED
airway	B-MED
remodeling	B-MED
.	O
Mice	B-MED
with	O
established	B-MED
fibrosis	B-MED
were	O
treated	B-MED
with	O
saline	B-MED
,	O
mono-	B-MED
,	O
or	O
combination	B-MED
therapies	I-MED
.	O
Although	O
monotherapies	B-MED
had	O
no	B-MED
effect	I-MED
,	O
combining	B-MED
these	I-MED
agents	I-MED
decreased	B-MED
collagen	B-MED
deposition	B-MED
and	O
promoted	B-MED
re	B-MED
-	I-MED
epithelialization	I-MED
of	O
remodeled	B-MED
airways	I-MED
.	O
Relaxin	B-MED
inhibited	B-MED
myofibroblast	B-MED
differentiation	B-MED
and	O
contraction	B-MED
in	O
a	O
matrix	B-MED
-	O
stiffness	B-MED
-	O
dependent	B-MED
manner	O
through	O
prostaglandin	B-MED
E2	I-MED
(	O
PGE2	B-MED
)	O
.	O
Furthermore	O
,	O
the	O
effect	B-MED
of	O
combination	B-MED
therapy	I-MED
was	O
lost	O
in	O
PGE2	B-MED
receptor	I-MED
knockout	B-MED
and	O
PGE2	B-MED
-	O
inhibited	B-MED
OTT	B-MED
mice	B-MED
.	O
This	O
study	B-MED
revealed	B-MED
the	O
important	O
synergistic	B-MED
roles	B-MED
of	O
cellular	B-MED
contractility	I-MED
and	O
tissue	B-MED
stiffness	I-MED
in	O
the	O
maintenance	B-MED
of	O
fibrotic	B-MED
tissue	B-MED
and	O
suggests	O
a	O
new	O
therapeutic	B-MED
principle	B-MED
for	O
fibrosis	B-MED
.	O
Skeletal	B-MED
muscle	I-MED
metabolic	O
adaptations	B-MED
to	O
endurance	B-MED
exercise	B-MED
training	I-MED
are	O
attainable	B-MED
in	O
mice	B-MED
with	O
simvastatin	B-MED
treatment	B-MED
We	O
tested	O
the	O
hypothesis	B-MED
that	O
a	O
6	O
-	O
week	O
regimen	B-MED
of	O
simvastatin	B-MED
would	O
attenuate	B-MED
skeletal	B-MED
muscle	I-MED
adaptation	B-MED
to	O
low	B-MED
-	I-MED
intensity	I-MED
exercise	I-MED
.	O
Male	B-MED
C57BL/6J	B-MED
wildtype	I-MED
mice	I-MED
were	O
subjected	O
to	O
6	O
-	O
weeks	O
of	O
voluntary	B-MED
wheel	I-MED
running	I-MED
or	O
normal	O
cage	B-MED
activities	B-MED
with	O
or	O
without	O
simvastatin	B-MED
treatment	B-MED
(	O
20	O
mg	O
/	O
kg	O
/	O
d	O
,	O
n	O
=	O
7	O
-	O
8	O
per	O
group	O
)	O
.	O
Adaptations	B-MED
in	O
in	B-MED
vivo	I-MED
fatigue	B-MED
resistance	B-MED
were	O
determined	O
by	O
a	O
treadmill	B-MED
running	I-MED
test	I-MED
,	O
and	O
by	O
ankle	B-MED
plantarflexor	I-MED
contractile	B-MED
assessment	O
.	O
The	O
tibialis	B-MED
anterior	I-MED
,	O
gastrocnemius	B-MED
,	O
and	O
plantaris	B-MED
muscles	I-MED
were	O
evaluated	B-MED
for	O
exercised	B-MED
-induced	O
mitochondrial	B-MED
adaptations	B-MED
(	O
i.e.	O
,	O
biogenesis	B-MED
,	O
function	B-MED
,	O
autophagy	B-MED
)	O
.	O
There	O
was	O
no	B-MED
difference	I-MED
in	O
weekly	O
wheel	B-MED
running	I-MED
distance	I-MED
between	O
control	O
and	O
simvastatin	B-MED
-	O
treated	B-MED
mice	B-MED
(	O
P	O
=	O
0.51	O
)	O
.	O
Trained	B-MED
mice	B-MED
had	O
greater	O
treadmill	B-MED
running	I-MED
distance	B-MED
(	O
296	O
%	O
,	O
P<0.001	O
)	O
,	O
and	O
ankle	B-MED
plantarflexor	I-MED
contractile	B-MED
fatigue	B-MED
resistance	B-MED
(	O
9	O
%	O
,	O
P<0.05	O
)	O
compared	O
to	O
sedentary	O
mice	B-MED
,	O
independent	O
of	O
simvastatin	B-MED
treatment	B-MED
.	O
At	O
the	O
cellular	B-MED
level	I-MED
,	O
trained	B-MED
mice	B-MED
had	O
greater	O
mitochondrial	B-MED
biogenesis	I-MED
(	O
e.g.	O
,	O
~2	O
-	O
fold	O
greater	O
PGC1α	B-MED
expression	B-MED
,	O
P<0.05	O
)	O
and	O
mitochondrial	B-MED
content	O
(	O
e.g.	O
,	O
25	O
%	O
greater	O
citrate	B-MED
synthase	I-MED
activity	B-MED
,	O
P<0.05	O
)	O
,	O
independent	O
of	O
simvastatin	B-MED
treatment	B-MED
.	O
Mitochondrial	B-MED
autophagy	B-MED
-related	O
protein	B-MED
contents	O
were	O
greater	O
in	O
trained	B-MED
mice	B-MED
(	O
e.g.	O
,	O
40	O
%	O
greater	O
Bnip3	B-MED
,	O
P<0.05	O
)	O
,	O
independent	O
of	O
simvastatin	B-MED
treatment	B-MED
.	O
However	O
,	O
Drp1	B-MED
,	O
a	O
marker	B-MED
of	O
mitochondrial	B-MED
fission	I-MED
,	O
was	O
less	O
in	O
simvastatin	B-MED
treated	B-MED
mice	B-MED
,	O
independent	O
of	O
exercise	B-MED
training	I-MED
,	O
and	O
there	O
was	O
a	O
significant	O
interaction	B-MED
between	O
training	B-MED
and	O
statin	O
treatment	B-MED
(	O
P<0.022	O
)	O
for	O
LC3	B-MED
-	I-MED
II	I-MED
protein	I-MED
content	B-MED
,	O
a	O
marker	B-MED
of	O
autophagy	B-MED
flux	O
.	O
These	O
data	O
indicate	O
that	O
whole	B-MED
body	I-MED
and	O
skeletal	B-MED
muscle	I-MED
adaptations	B-MED
to	O
endurance	B-MED
exercise	B-MED
training	I-MED
are	O
attainable	B-MED
with	O
simvastatin	B-MED
treatment	B-MED
,	O
but	O
simvastatin	B-MED
may	O
have	O
side	B-MED
effects	I-MED
on	O
muscle	B-MED
mitochondrial	B-MED
maintenance	O
via	O
autophagy	B-MED
,	O
which	O
could	O
have	O
long	B-MED
-	I-MED
term	I-MED
implications	O
on	O
muscle	B-MED
health	B-MED
.	O
Delayed	B-MED
Recognition	B-MED
of	O
Deterioration	B-MED
of	O
Patients	B-MED
in	O
General	B-MED
Wards	I-MED
Is	O
Mostly	O
Caused	O
by	O
Human	B-MED
Related	O
Monitoring	B-MED
Failures	B-MED
:	O
A	O
Root	B-MED
Cause	I-MED
Analysis	I-MED
of	O
Unplanned	O
ICU	B-MED
Admissions	I-MED
An	O
unplanned	O
ICU	B-MED
admission	I-MED
of	O
an	O
inpatient	B-MED
is	O
a	O
serious	B-MED
adverse	I-MED
event	I-MED
(	O
SAE	B-MED
)	O
.	O
So	O
far	O
,	O
no	O
in	O
depth	O
-	O
study	O
has	O
been	O
performed	O
to	O
systematically	O
analyse	O
the	O
root	B-MED
causes	I-MED
of	O
unplanned	O
ICU	B-MED
-	I-MED
admissions	I-MED
.	O
The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
healthcare	B-MED
worker	I-MED
-	O
,	O
organisational	B-MED
-	O
,	O
technical	B-MED
,	O
-	O
disease	B-MED
-	O
and	O
patient	B-MED
-	O
related	O
causes	O
that	O
contribute	O
to	O
acute	O
unplanned	O
ICU	B-MED
admissions	I-MED
from	O
general	B-MED
wards	I-MED
using	O
a	O
Root	B-MED
-	I-MED
Cause	I-MED
Analysis	I-MED
Tool	I-MED
called	O
PRISMA	B-MED
-	I-MED
medical	I-MED
.	O
Although	O
a	O
Track	B-MED
and	I-MED
Trigger	I-MED
System	I-MED
(	I-MED
MEWS	I-MED
)	I-MED
was	O
introduced	O
in	O
our	O
hospital	B-MED
a	O
few	O
years	O
ago	O
,	O
it	O
was	O
implemented	O
without	O
a	O
clear	O
protocol	B-MED
.	O
Therefore	O
,	O
the	O
secondary	O
aim	O
was	O
to	O
assess	O
the	O
adherence	O
to	O
a	O
Track	B-MED
and	I-MED
Trigger	I-MED
system	I-MED
to	O
identify	O
deterioration	B-MED
on	O
general	B-MED
hospital	I-MED
wards	I-MED
in	O
patients	B-MED
eventually	O
transferred	O
to	O
the	O
ICU	B-MED
.	O
Retrospective	B-MED
observational	I-MED
study	I-MED
in	O
49	O
consecutive	O
adult	O
patients	B-MED
acutely	O
admitted	B-MED
to	O
the	O
Intensive	B-MED
Care	I-MED
Unit	I-MED
from	O
a	O
general	B-MED
nursing	I-MED
ward	I-MED
.	O
1	O
.	O
PRISMA	B-MED
-	I-MED
analysis	I-MED
on	O
root	B-MED
causes	I-MED
of	O
unplanned	O
ICU	B-MED
admissions	I-MED
2	O
.	O
Assessment	O
of	O
protocol	B-MED
adherence	O
to	O
the	O
early	B-MED
warning	I-MED
score	I-MED
system	I-MED
.	O
Out	O
of	O
49	O
cases	O
,	O
156	O
root	B-MED
causes	I-MED
were	O
identified	O
.	O
The	O
most	O
frequent	O
root	B-MED
causes	I-MED
were	O
healthcare	B-MED
worker	I-MED
related	O
(	O
46	O
%	O
)	O
,	O
which	O
were	O
mainly	O
failures	B-MED
in	O
monitoring	B-MED
the	O
patient	B-MED
.	O
They	O
were	O
followed	O
by	O
disease	B-MED
-related	O
(	O
45	O
%	O
)	O
,	O
patient	B-MED
-related	O
causes	O
(	O
7	O
,	O
5	O
%	O
)	O
,	O
and	O
organisational	B-MED
root	B-MED
causes	I-MED
(	O
3	O
%	O
)	O
.	O
In	O
only	O
40	O
%	O
of	O
the	O
patients	B-MED
vital	B-MED
parameters	I-MED
were	O
monitored	O
as	O
was	O
instructed	O
by	O
the	O
doctor	B-MED
.	O
477	O
vital	B-MED
parameter	I-MED
sets	O
were	O
found	O
in	O
the	O
48	O
hours	O
before	O
ICU	B-MED
admission	I-MED
,	O
in	O
only	O
1	O
%	O
a	O
correct	O
MEWS	B-MED
was	O
explicitly	O
documented	B-MED
in	O
the	O
record	O
.	O
This	O
in	B-MED
-	I-MED
depth	I-MED
analysis	I-MED
demonstrates	O
that	O
almost	O
half	O
of	O
the	O
unplanned	O
ICU	B-MED
admissions	I-MED
from	O
the	O
general	B-MED
ward	I-MED
had	O
healthcare	B-MED
worker	I-MED
related	O
root	B-MED
causes	I-MED
,	O
mostly	O
due	O
to	O
monitoring	B-MED
failures	B-MED
in	O
clinically	B-MED
deteriorating	I-MED
patients	B-MED
.	O
In	O
order	O
to	O
reduce	O
unplanned	O
ICU	B-MED
admissions	I-MED
,	O
improving	O
the	O
monitoring	B-MED
of	O
patients	B-MED
is	O
therefore	O
warranted	O
.	O
Comparisons	B-MED
of	O
Safety	B-MED
and	O
Clinical	B-MED
Outcomes	B-MED
Between	O
Multiple	B-MED
-	I-MED
level	I-MED
and	O
Single	B-MED
-	I-MED
level	I-MED
Cervical	I-MED
Disk	I-MED
Replacement	I-MED
for	O
Cervical	B-MED
Spondylosis	I-MED
:	O
A	O
Systematic	B-MED
Review	I-MED
and	O
Meta	B-MED
-	I-MED
analysis	I-MED
This	O
is	O
a	O
systematic	B-MED
review	I-MED
and	O
meta	B-MED
-	I-MED
analysis	I-MED
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	B-MED
the	O
efficacy	B-MED
and	O
safety	B-MED
of	O
multiple	B-MED
-	I-MED
level	I-MED
cervical	I-MED
disk	I-MED
replacement	I-MED
(	O
CDR	B-MED
)	O
over	O
single	B-MED
-	I-MED
level	I-MED
CDR	I-MED
for	O
the	O
treatment	B-MED
of	O
cervical	B-MED
spondylosis	I-MED
.	O
Some	O
authors	O
advocate	O
for	O
the	O
multiple	B-MED
-	I-MED
level	I-MED
CDR	I-MED
instead	O
of	O
anterior	B-MED
decompression	B-MED
and	O
fusion	B-MED
in	O
cervical	B-MED
multiple	I-MED
-	I-MED
level	I-MED
spondylosis	I-MED
.	O
However	O
,	O
whether	O
the	O
efficacy	B-MED
and	O
safety	B-MED
of	O
multi	B-MED
-	I-MED
level	I-MED
CDR	I-MED
are	O
as	O
favorable	O
as	O
that	O
of	O
single	B-MED
-	I-MED
level	I-MED
CDR	I-MED
remains	O
controversial	O
.	O
MEDLINE	B-MED
,	O
EMBASE	B-MED
,	O
and	O
Cochrane	B-MED
library	I-MED
databases	I-MED
were	O
searched	O
up	O
to	O
November	O
2015	O
for	O
controlled	B-MED
studies	I-MED
that	O
compared	B-MED
the	O
clinical	B-MED
outcomes	B-MED
of	O
single	B-MED
-	I-MED
level	I-MED
and	O
multiple	B-MED
-	I-MED
level	I-MED
CDR	I-MED
for	O
the	O
treatment	B-MED
of	O
cervical	B-MED
spondylosis	I-MED
.	O
The	O
following	O
outcomes	B-MED
were	O
extracted	O
and	O
analyzed	B-MED
:	O
prevalence	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
and	O
reoperation	B-MED
,	O
preoperative	B-MED
and	O
postoperative	B-MED
Neck	B-MED
Disability	I-MED
Index	I-MED
scores	I-MED
,	O
preoperative	B-MED
and	O
postoperative	B-MED
Visual	B-MED
Analog	I-MED
Scale	I-MED
scores	I-MED
,	O
and	O
success	B-MED
rate	B-MED
using	O
the	O
Odom	B-MED
grading	I-MED
system	I-MED
.	O
Ten	O
studies	B-MED
involving	O
1402	O
patients	B-MED
were	O
included	O
:	O
including	O
3	O
randomized	B-MED
controlled	I-MED
trials	I-MED
,	O
5	O
prospective	B-MED
studies	I-MED
,	O
and	O
3	O
retrospective	B-MED
studies	I-MED
.	O
No	O
significant	O
differences	O
between	O
single	B-MED
-	I-MED
level	I-MED
and	O
multiple	B-MED
-	I-MED
level	I-MED
groups	O
were	O
found	O
in	O
terms	O
of	O
the	O
prevalence	B-MED
of	O
heterotopic	B-MED
ossification	I-MED
and	O
reoperation	B-MED
rate	B-MED
,	O
Neck	B-MED
Disability	I-MED
Index	I-MED
score	I-MED
,	O
Visual	B-MED
Analog	I-MED
Scale	I-MED
score	I-MED
,	O
and	O
success	B-MED
rate	B-MED
using	O
the	O
Odom	B-MED
grading	I-MED
system	I-MED
.	O
On	O
the	O
basis	O
of	O
this	O
meta	B-MED
-	I-MED
analysis	I-MED
,	O
clinical	B-MED
outcomes	B-MED
of	O
multiple	B-MED
-	I-MED
level	I-MED
CDR	I-MED
are	O
similar	O
to	O
those	O
of	O
single	B-MED
-	I-MED
level	I-MED
CDR	I-MED
for	O
cervical	B-MED
spondylosis	I-MED
,	O
which	O
suggests	O
the	O
multiple	B-MED
-	I-MED
level	I-MED
CDR	I-MED
is	O
as	O
effective	B-MED
and	O
safe	B-MED
as	O
the	O
single	B-MED
-	I-MED
level	I-MED
CDR	I-MED
.	O
Nonetheless	O
,	O
more	O
well	O
-	O
designed	O
studies	B-MED
are	O
needed	O
for	O
further	O
evaluation	B-MED
.	O
Open	B-MED
-	I-MED
label	I-MED
,	I-MED
multicentre	I-MED
safety	I-MED
study	I-MED
of	O
vemurafenib	B-MED
in	O
3219	O
patients	B-MED
with	O
BRAF(V600	B-MED
)	I-MED
mutation	I-MED
-	O
positive	B-MED
metastatic	B-MED
melanoma	I-MED
:	O
2	O
-	O
year	O
follow	B-MED
-	I-MED
up	I-MED
data	B-MED
and	O
long	B-MED
-	I-MED
term	I-MED
responders	B-MED
'	I-MED
analysis	I-MED
The	O
orally	B-MED
available	O
BRAF	B-MED
kinase	I-MED
inhibitor	I-MED
vemurafenib	B-MED
is	O
an	O
effective	B-MED
and	O
tolerable	B-MED
treatment	B-MED
option	I-MED
for	O
patients	B-MED
with	O
metastatic	B-MED
melanoma	I-MED
harbouring	O
BRAF(V600	B-MED
)	I-MED
mutations	I-MED
.	O
We	O
assessed	B-MED
the	O
safety	B-MED
of	O
vemurafenib	B-MED
in	O
a	O
large	B-MED
population	B-MED
of	O
patients	B-MED
with	O
few	O
alternative	B-MED
treatment	B-MED
options	I-MED
;	O
we	O
report	O
updated	O
2	O
-	O
year	O
safety	B-MED
.	O
This	O
was	O
an	O
open	B-MED
-	I-MED
label	I-MED
,	I-MED
multicentre	I-MED
study	I-MED
of	O
vemurafenib	B-MED
(	O
960	O
mg	O
bid	O
)	O
in	O
patients	B-MED
with	O
previously	O
treated	B-MED
or	O
untreated	B-MED
BRAF	B-MED
mutation	I-MED
-	O
positive	B-MED
metastatic	B-MED
melanoma	I-MED
(	O
cobas	B-MED
(	I-MED
®	I-MED
)	I-MED
4800	I-MED
BRAF	B-MED
V600	I-MED
Mutation	I-MED
Test	I-MED
)	O
.	O
The	O
primary	B-MED
end	B-MED
-	I-MED
point	I-MED
was	O
safety	B-MED
;	O
efficacy	O
end	B-MED
-	I-MED
points	I-MED
were	O
secondary	B-MED
.	O
An	O
exploratory	B-MED
analysis	I-MED
was	O
performed	O
to	O
assess	B-MED
safety	B-MED
outcomes	B-MED
in	O
patients	B-MED
with	O
long	B-MED
duration	B-MED
of	I-MED
response	I-MED
(	O
DOR	B-MED
)	O
(	O
≥12	O
or	O
≥24	O
months	B-MED
)	O
.	O
After	O
a	O
median	B-MED
follow	B-MED
-	I-MED
up	I-MED
of	O
32.2	O
months	B-MED
(	O
95	O
%	O
CI	O
,	O
31.1	O
-	O
33.2	O
months	B-MED
)	O
,	O
3079/3219	O
patients	B-MED
(	O
96	O
%	O
)	O
had	O
discontinued	B-MED
treatment	I-MED
.	O
Adverse	B-MED
events	I-MED
(	O
AEs	B-MED
)	O
were	O
largely	O
consistent	B-MED
with	I-MED
previous	O
reports	O
;	O
the	O
most	O
common	O
all	O
-	O
grade	O
treatment	B-MED
-related	O
AEs	B-MED
were	O
arthralgia	B-MED
(	O
37	O
%	O
)	O
,	O
alopecia	B-MED
(	O
25	O
%	O
)	O
and	O
hyperkeratosis	B-MED
(	O
23	O
%	O
)	O
;	O
the	O
most	O
common	O
grade	O
3/4	O
treatment	B-MED
-related	O
AEs	B-MED
were	O
squamous	B-MED
cell	I-MED
carcinoma	I-MED
of	I-MED
the	I-MED
skin	I-MED
(	O
8	O
%	O
)	O
and	O
keratoacanthoma	B-MED
(	O
8	O
%	O
)	O
.	O
In	O
the	O
exploratory	B-MED
analysis	I-MED
,	O
patients	B-MED
with	O
DOR	B-MED
≥12	O
months	B-MED
(	O
n	O
=	O
287	O
)	O
or	O
≥24	O
months	B-MED
(	O
n	O
=	O
133	O
)	O
were	O
more	O
likely	O
to	O
experience	O
grade	O
3/4	O
AEs	B-MED
than	O
the	O
overall	B-MED
population	B-MED
.	O
No	O
new	O
specific	B-MED
safety	B-MED
signals	I-MED
were	O
observed	O
with	O
longer	O
vemurafenib	B-MED
vemurafenib	B-MED
exposure	I-MED
.	O
After	O
2	O
years	O
'	O
follow	B-MED
-	I-MED
up	I-MED
,	O
safety	B-MED
was	O
maintained	O
in	O
this	O
large	B-MED
group	I-MED
of	O
patients	B-MED
with	O
BRAF(V600	B-MED
)	I-MED
mutation	I-MED
-	O
positive	B-MED
metastatic	B-MED
melanoma	I-MED
who	O
are	O
more	O
representative	O
of	O
routine	O
clinical	B-MED
practice	I-MED
than	O
typical	O
clinical	B-MED
trial	I-MED
populations	B-MED
.	O
These	O
data	O
suggest	O
that	O
long	B-MED
-	I-MED
term	I-MED
vemurafenib	B-MED
treatment	B-MED
is	O
effective	B-MED
and	O
tolerable	B-MED
without	O
the	O
development	O
of	O
new	O
safety	B-MED
signals	I-MED
.	O
Attenuation	B-MED
of	O
High	B-MED
Glucose	I-MED
-	O
Induced	B-MED
Rat	B-MED
Cardiomyocyte	B-MED
Apoptosis	B-MED
by	O
Exendin-4	B-MED
via	O
Intervention	B-MED
of	O
HO-1	B-MED
/	O
Nrf-2	B-MED
and	O
the	O
PI3K	B-MED
/	I-MED
AKT	I-MED
Signaling	I-MED
Pathway	I-MED
Exendin-4	B-MED
,	O
a	O
glucagon	B-MED
-	I-MED
like	I-MED
peptide-1	I-MED
receptor	I-MED
agonist	I-MED
,	O
demonstrated	O
cytoprotective	B-MED
actions	I-MED
beyond	O
glycemic	B-MED
control	I-MED
in	O
recent	O
studies	O
.	O
The	O
aims	B-MED
of	O
the	O
present	O
study	B-MED
were	O
to	O
investigate	B-MED
the	O
effects	B-MED
of	I-MED
exendin-4	B-MED
on	O
high	B-MED
glucose	I-MED
HG	B-MED
(	O
HG)-	O
induced	B-MED
cardiomyocyte	B-MED
apoptosis	B-MED
and	O
the	O
possible	O
mechanisms	B-MED
.	O
Rat	B-MED
cardiomyocytes	B-MED
were	O
divided	O
into	O
3	O
groups	B-MED
:	O
normal	B-MED
glucose	I-MED
group	B-MED
(	O
NG	B-MED
group	B-MED
)	O
,	O
HG	B-MED
group	B-MED
and	O
HG	B-MED
+	O
exendin-4	B-MED
group	B-MED
(	O
HG	B-MED
+	O
Ex	B-MED
Group	B-MED
)	O
.	O
Cardiomyocyte	B-MED
apoptosis	B-MED
was	O
evaluated	O
by	O
double	B-MED
-	I-MED
staining	I-MED
with	O
annexin	B-MED
V	I-MED
-	I-MED
fluorescein	I-MED
isothiocyanate	I-MED
FITC	B-MED
(	O
FITC)/	O
propidium	B-MED
iodide	I-MED
(	O
PI	B-MED
)	O
and	O
flow	B-MED
cytometry	I-MED
.	O
Intracellular	B-MED
reactive	B-MED
oxygen	I-MED
species	I-MED
(	I-MED
ROS	I-MED
)	I-MED
production	B-MED
was	O
detected	B-MED
by	O
2’,7’-dichlorodihydrofluorescein	B-MED
diacetate	I-MED
(	O
DCHF	B-MED
-	I-MED
DA	I-MED
)	O
incubation	B-MED
and	O
fluorescence	B-MED
microscopy	I-MED
.	O
LY294002	B-MED
(	O
LY	B-MED
)	O
,	O
a	O
phosphoinositide	B-MED
3	I-MED
-	I-MED
kinase	I-MED
(	O
PI3	B-MED
K	I-MED
)	O
pathway	B-MED
inhibitor	B-MED
,	O
was	O
added	O
to	O
the	O
medium	B-MED
of	O
the	O
HG	B-MED
+	O
Ex	B-MED
+	O
LY	B-MED
Group	B-MED
for	O
further	O
western	B-MED
blot	I-MED
analysis	I-MED
.	O
The	O
proteins	B-MED
analyzed	B-MED
involved	O
oxidative	B-MED
stress	I-MED
-	O
associated	B-MED
proteins	I-MED
,	O
heme	B-MED
oxygenase-1	I-MED
(	O
HO-1	B-MED
)	O
and	O
nuclear	B-MED
factor	I-MED
E2	I-MED
-	I-MED
related	I-MED
factor	I-MED
2	I-MED
(	O
Nrf-2	B-MED
)	O
,	O
and	O
apoptosis	B-MED
-	O
associated	B-MED
proteins	I-MED
,	O
caspase-3	B-MED
,	O
Bax	B-MED
/	I-MED
B	I-MED
-	I-MED
cell	I-MED
lymphoma	I-MED
2	I-MED
(	O
Bcl-2	B-MED
)	O
and	O
p	B-MED
-	I-MED
AKT	I-MED
/	O
AKT	B-MED
.	O
HG	B-MED
treatment	B-MED
induced	B-MED
cardiomyocyte	B-MED
apoptosis	B-MED
(	O
P	O
=	O
0.00	O
)	O
and	O
clearly	O
upregulated	B-MED
ROS	B-MED
production	B-MED
(	O
P	O
=	O
0.00	O
)	O
;	O
exendin-4	B-MED
co	B-MED
-	I-MED
incubation	I-MED
also	O
ameliorated	O
cardiomyocyte	B-MED
apoptosis	B-MED
(	O
P	O
=	O
0.004	O
)	O
and	O
decreased	B-MED
ROS	B-MED
(	O
P	O
=	O
0.00	O
)	O
level	B-MED
significantly	B-MED
.	O
HO-1	B-MED
and	O
Nrf-2	B-MED
protein	B-MED
expression	I-MED
levels	B-MED
decreased	B-MED
significantly	B-MED
in	O
the	O
HG	B-MED
group	B-MED
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
the	O
levels	B-MED
were	O
elevated	B-MED
by	O
exendin-4	B-MED
intervention	B-MED
(	O
P	O
<	O
0.05	O
)	O
.	O
Furthermore	O
,	O
exendin-4	B-MED
attenuated	B-MED
HG	B-MED
-	O
induced	B-MED
higher	O
protein	B-MED
expression	I-MED
,	O
including	O
cleaved	O
caspase-3	B-MED
and	O
Bax	B-MED
,	O
increased	B-MED
the	O
expression	B-MED
of	O
Bcl-2	B-MED
protein	I-MED
(	O
P	O
<	O
0.05	O
)	O
.	O
However	O
,	O
these	O
impacts	B-MED
of	O
exendin-4	B-MED
were	O
counteracted	O
significantly	B-MED
by	O
co	B-MED
-	I-MED
incubation	I-MED
with	O
LY294002	B-MED
.	O
In	O
addition	O
,	O
exendin-4	B-MED
ameliorated	O
HG	B-MED
-	O
induced	B-MED
p	B-MED
-	I-MED
AKT	I-MED
/	O
AKT	B-MED
lower	B-MED
expression	I-MED
,	O
and	O
this	O
impact	B-MED
was	O
also	O
suppressed	B-MED
by	O
LY294002	B-MED
.	O
Exendin-4	B-MED
ameliorates	O
HG	B-MED
-	O
induced	B-MED
cardiomyocyte	B-MED
apoptosis	B-MED
,	O
and	O
the	O
mechanisms	B-MED
may	O
involve	O
anti	B-MED
-	I-MED
oxidative	I-MED
stress	I-MED
via	O
the	O
HO-1	B-MED
/	O
Nrf-2	B-MED
system	O
,	O
as	O
well	O
as	O
intervention	B-MED
of	O
the	O
PI3K	B-MED
/	I-MED
AKT	I-MED
signaling	I-MED
pathway	I-MED
.	O
Pre	B-MED
-	I-MED
existing	I-MED
renal	B-MED
lesions	B-MED
revealed	O
after	O
renal	B-MED
trauma	B-MED
,	O
Difficulties	O
in	O
diagnosis	B-MED
and	O
accountability	B-MED
:	O
About	O
14	O
cases	B-MED
Pre	B-MED
-	I-MED
existing	I-MED
renal	B-MED
lesions	B-MED
(	O
PERL	B-MED
)	O
may	O
interfere	O
with	O
the	O
patho	B-MED
-	I-MED
physiology	I-MED
of	O
trauma	B-MED
,	O
alter	O
the	O
radiographic	B-MED
imaging	I-MED
and	O
influence	B-MED
the	O
therapeutic	B-MED
approach	O
.	O
The	O
aims	B-MED
of	O
this	O
study	B-MED
were	O
to	O
record	O
the	O
PERL	B-MED
found	O
incidentally	O
during	O
blunt	B-MED
renal	B-MED
trauma	B-MED
,	O
to	O
specify	O
the	O
place	O
for	O
effective	O
conservative	B-MED
management	I-MED
and	O
to	O
determin	O
the	O
estimated	O
partial	B-MED
permanent	I-MED
disability	I-MED
(	O
PPD	B-MED
)	O
.	O
The	O
medical	B-MED
records	I-MED
of	O
14	O
patients	B-MED
with	O
PERL	B-MED
and	O
blunt	B-MED
renal	B-MED
trauma	B-MED
were	O
reviewed	O
.	O
In	O
each	O
patient	B-MED
,	O
pre	B-MED
-	I-MED
existing	I-MED
renal	B-MED
abnormalities	O
,	O
clinical	B-MED
symptoms	B-MED
,	O
CT	B-MED
scan	I-MED
study	B-MED
findings	B-MED
,	O
associated	O
injuries	B-MED
,	O
therapeutic	B-MED
approach	O
,	O
the	O
accountability	B-MED
criteria	O
and	O
the	O
estimated	O
PPD	B-MED
were	O
recorded	O
.	O
There	O
were	O
11	O
men	B-MED
and	O
3	O
women	B-MED
with	O
a	O
mean	B-MED
age	B-MED
of	O
35,6	O
years	B-MED
(	O
range	O
19	O
-	O
66	O
years	B-MED
)	O
.	O
Renal	B-MED
trauma	B-MED
was	O
due	O
to	O
a	O
traffic	B-MED
accident	I-MED
in	O
8	O
patients	B-MED
.	O
Renal	B-MED
damage	O
appeared	O
to	O
be	O
disproportionate	O
to	O
the	O
severity	B-MED
of	O
the	O
trauma	B-MED
(	O
minor	O
trauma	B-MED
)	O
.	O
They	O
had	O
a	O
lower	O
rate	O
of	O
associated	O
trauma	B-MED
to	O
other	O
abdominal	B-MED
organs	I-MED
(	O
four	O
patients	B-MED
only	O
)	O
.	O
Urinary	B-MED
stones	I-MED
were	O
present	O
in	O
5	O
patients	B-MED
,	O
pelvi	B-MED
-	I-MED
ureteric	I-MED
junction	I-MED
obstruction	I-MED
in	O
3	O
,	O
horseshoe	B-MED
kidny	I-MED
in	O
3	O
,	O
ectopic	B-MED
kidney	I-MED
in	O
2	O
and	O
upper	O
urinary	B-MED
tract	I-MED
carcinoma	I-MED
in	O
one	O
case	O
.	O
Early	O
nephrectomy	B-MED
was	O
required	O
in	O
three	O
cases	B-MED
for	O
hemodynamic	B-MED
instability	I-MED
.	O
Ureteral	B-MED
stenting	I-MED
was	O
indicated	O
in	O
3	O
cases	B-MED
.	O
Six	O
patients	B-MED
were	O
operated	B-MED
later	O
because	O
of	O
their	O
underlying	O
renal	B-MED
pathology	B-MED
.	O
A	O
conservative	B-MED
treatment	I-MED
was	O
possible	O
only	O
in	O
7	O
of	O
cases	B-MED
.	O
The	O
PPD	B-MED
related	O
to	O
renal	B-MED
trauma	B-MED
varide	O
from	O
0	O
to	O
13	O
%	O
in	O
all	O
cases	B-MED
.	O
PERL	B-MED
may	O
complicate	O
a	O
negligible	O
renal	B-MED
trauma	B-MED
while	O
in	O
some	O
cases	B-MED
they	O
may	O
be	O
of	O
vital	O
importance	O
for	O
the	O
patient	B-MED
's	I-MED
final	O
outcome	O
.	O
The	O
imaging	O
findings	B-MED
are	O
crucial	O
but	O
may	O
be	O
confusing	O
.	O
The	O
therapeutic	B-MED
approach	O
is	O
,	O
to	O
a	O
large	O
extent	O
,	O
dependent	O
on	O
the	O
type	O
of	O
PERL	B-MED
and	O
the	O
severity	B-MED
of	O
damage	B-MED
,	O
and	O
is	O
often	O
conservative	O
in	O
the	O
hemo	B-MED
-	I-MED
dynamically	I-MED
stable	I-MED
patient	B-MED
.	O
Accountability	B-MED
link	O
may	O
be	O
difficult	O
to	O
establish	O
and	O
the	O
PPD	B-MED
depends	O
on	O
the	O
PERL	B-MED
and	O
the	O
renal	B-MED
injuries	I-MED
severity	B-MED
.	O
We	O
have	O
no	O
involvement	O
with	O
funding	O
in	O
this	O
case	O
.	O
Ethical	O
approval	O
:	O
Not	O
required	O
Conflicts	O
of	O
interest	O
:	O
None	O
.	O
GH32	B-MED
family	I-MED
activity	B-MED
:	O
a	O
topological	B-MED
approach	O
through	O
protein	B-MED
contact	I-MED
networks	I-MED
The	O
application	O
of	O
Protein	B-MED
Contact	I-MED
Networks	I-MED
methodology	I-MED
allowed	O
to	O
highlight	O
a	O
novel	O
response	O
of	O
border	B-MED
region	I-MED
between	O
the	O
two	O
domains	B-MED
to	I-MED
substrate	I-MED
binding	I-MED
.	O
Glycoside	B-MED
hydrolases	I-MED
(	O
GH	B-MED
)	O
are	O
enzymes	B-MED
that	O
mainly	O
hydrolyze	B-MED
the	O
glycosidic	B-MED
bond	I-MED
between	O
two	O
carbohydrates	B-MED
or	O
a	O
carbohydrate	B-MED
and	O
a	O
non	B-MED
-	I-MED
carbohydrate	I-MED
moiety	I-MED
.	O
These	O
enzymes	B-MED
are	O
involved	O
in	O
many	O
fundamental	O
and	O
diverse	O
biological	B-MED
processes	I-MED
in	O
plants	B-MED
.	O
We	O
have	O
focused	O
on	O
the	O
GH32	B-MED
family	I-MED
,	O
including	O
enzymes	B-MED
very	O
similar	O
in	O
both	O
sequence	B-MED
and	O
structure	B-MED
,	O
each	O
having	O
however	O
clear	O
specificities	O
of	O
substrate	B-MED
preferences	B-MED
and	O
kinetic	B-MED
properties	I-MED
.	O
Structural	B-MED
and	O
topological	B-MED
differences	O
among	O
proteins	B-MED
of	O
the	O
GH32	B-MED
family	I-MED
have	O
been	O
here	O
identified	O
by	O
means	O
of	O
an	O
emerging	O
approach	O
(	O
Protein	B-MED
Contact	I-MED
network	I-MED
,	O
PCN	B-MED
)	O
based	O
on	O
the	O
formalization	O
of	O
3D	B-MED
structures	I-MED
as	O
contact	B-MED
networks	I-MED
among	O
amino	B-MED
-	I-MED
acid	I-MED
residues	I-MED
.	O
The	O
PCN	B-MED
approach	O
proved	O
successful	O
in	O
both	O
reconstructing	O
the	O
already	O
known	O
functional	B-MED
domains	B-MED
and	O
in	O
identifying	O
the	O
structural	B-MED
counterpart	O
of	O
the	O
properties	O
of	O
GH32	B-MED
enzymes	I-MED
,	O
which	O
remain	O
uncertain	O
,	O
like	O
their	O
allosteric	B-MED
character	O
.	O
The	O
main	O
outcome	O
of	O
the	O
study	O
was	O
the	O
discovery	O
of	O
the	O
activation	B-MED
upon	O
binding	B-MED
of	I-MED
the	I-MED
border	I-MED
(	I-MED
cleft	I-MED
)	I-MED
region	I-MED
between	O
the	O
two	O
domains	B-MED
.	O
This	O
reveals	O
the	O
allosteric	B-MED
nature	O
of	O
the	O
enzymatic	B-MED
activity	I-MED
for	O
all	O
the	O
analyzed	O
forms	O
in	O
the	O
GH32	B-MED
family	I-MED
,	O
a	O
character	O
yet	O
to	O
be	O
highlighted	O
in	O
biochemical	B-MED
studies	I-MED
.	O
Furthermore	O
,	O
we	O
have	O
been	O
able	O
to	O
recognize	O
a	O
topological	B-MED
signature	I-MED
(	O
graph	O
energy	O
)	O
of	O
the	O
different	O
affinity	B-MED
of	O
the	O
enzymes	B-MED
towards	O
small	O
and	O
large	O
substrates	B-MED
.	O
Molecular	B-MED
subtyping	I-MED
of	O
Treponema	B-MED
pallidum	I-MED
and	O
associated	B-MED
factors	I-MED
of	O
serofast	B-MED
status	B-MED
in	O
early	B-MED
syphilis	I-MED
patients	B-MED
:	O
Identified	B-MED
novel	O
genotype	B-MED
and	O
cytokine	B-MED
marker	B-MED
Serofast	B-MED
,	O
a	O
persistent	B-MED
nontreponemal	B-MED
serological	I-MED
response	B-MED
observed	B-MED
in	O
early	B-MED
syphilis	I-MED
patients	B-MED
after	O
conventional	B-MED
treatment	I-MED
,	O
remains	O
a	O
concern	B-MED
of	O
clinicians	B-MED
and	O
syphilis	B-MED
patients	B-MED
.	O
No	O
consensus	O
has	O
been	O
established	O
,	O
however	O
,	O
that	O
defines	O
an	O
effective	B-MED
treatment	B-MED
strategy	I-MED
and	O
clarifies	B-MED
the	O
pathogenesis	B-MED
.	O
In	O
this	O
study	B-MED
,	O
517	O
patients	B-MED
with	O
early	B-MED
syphilis	I-MED
were	O
enrolled	B-MED
and	O
treated	B-MED
.	O
Twelve	O
months	B-MED
after	O
treatment	B-MED
,	O
79.3	O
%	O
(	O
410/517	O
)	O
of	O
patients	B-MED
achieved	O
serological	B-MED
cure	B-MED
,	O
20.1	O
%	O
(	O
104/517	O
)	O
were	O
serofast	B-MED
,	O
and	O
0.6	O
%	O
(	O
3/517	O
)	O
were	O
serological	B-MED
failures	B-MED
.	O
Multivariate	B-MED
analysis	I-MED
demonstrated	O
that	O
older	B-MED
age	I-MED
(	O
>	O
40	O
years	B-MED
)	O
and	O
lower	O
baseline	B-MED
RPR	B-MED
titer	I-MED
(	O
≤	O
1:8	O
)	O
were	O
associated	B-MED
with	I-MED
serofast	B-MED
status	B-MED
.	O
We	O
also	O
identified	O
21	O
T.	B-MED
pallidum	I-MED
molecular	B-MED
subtypes	I-MED
among	O
early	B-MED
syphilis	I-MED
patients	B-MED
and	O
detected	O
a	O
new	O
subtype	B-MED
,	I-MED
14i	I-MED
/	I-MED
a	I-MED
a.	O
We	O
found	O
that	O
the	O
proportion	O
of	O
14i	B-MED
/	I-MED
a	I-MED
type	I-MED
in	O
serofast	B-MED
patients	B-MED
was	O
significantly	O
higher	O
than	O
that	O
in	O
patients	B-MED
with	O
serological	B-MED
cure	B-MED
,	O
predicting	O
an	O
increasing	B-MED
risk	B-MED
of	O
serofast	B-MED
status	B-MED
status	B-MED
.	O
Levels	B-MED
of	O
chemerin	B-MED
were	O
higher	B-MED
in	O
the	O
serum	B-MED
of	O
serofast	B-MED
cases	O
than	O
serological	B-MED
cure	B-MED
cases	O
,	O
potentially	O
indicating	O
a	O
novel	O
cytokine	B-MED
marker	B-MED
for	O
serofast	B-MED
in	O
early	B-MED
syphilis	I-MED
patients	B-MED
after	O
therapy	B-MED
.	O
We	O
hope	O
that	O
these	O
results	B-MED
contribute	B-MED
to	O
improve	B-MED
guidelines	B-MED
for	O
the	O
management	B-MED
of	O
syphilis	B-MED
patients	B-MED
who	O
experience	O
serofast	B-MED
.	O
Discovery	B-MED
of	O
<	B-MED
i	I-MED
>	I-MED
Neopanorpa	I-MED
chillcotti</i	I-MED
>	I-MED
Byers	I-MED
(	O
Mecoptera	B-MED
:	O
Panorpidae	B-MED
)	O
from	O
Tibet	B-MED
,	O
China	B-MED
,	O
with	O
discussion	O
of	O
its	O
generic	B-MED
status	I-MED
Neopanorpa	B-MED
chillcotti	I-MED
Byers	I-MED
,	O
1971	O
was	O
originally	O
described	O
from	O
Kathmandu	B-MED
in	O
Nepal	B-MED
and	O
is	O
now	O
found	O
to	O
be	O
distributed	O
in	O
Gyirong	B-MED
,	O
Tibet	B-MED
in	O
China	B-MED
.	O
The	O
species	O
is	O
redescribed	O
and	O
illustrated	O
based	O
on	O
new	B-MED
material	I-MED
from	O
China	B-MED
and	O
Nepal	B-MED
.	O
The	O
generic	B-MED
status	I-MED
of	O
this	O
species	B-MED
is	O
briefly	O
discussed	B-MED
.	O
The	O
prognostic	B-MED
value	I-MED
of	O
extranodal	B-MED
extension	I-MED
in	O
human	B-MED
papillomavirus	I-MED
-associated	O
oropharyngeal	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
Extranodal	B-MED
(	I-MED
or	I-MED
extracapsular	I-MED
)	I-MED
extension	I-MED
(	O
ENE	B-MED
)	O
is	O
an	O
adverse	B-MED
prognostic	I-MED
factor	I-MED
in	O
patients	B-MED
with	O
head	B-MED
and	I-MED
neck	I-MED
cancers	I-MED
who	O
undergo	O
primary	B-MED
surgery	I-MED
.	O
However	O
,	O
the	O
significance	O
of	O
ENE	B-MED
in	O
human	B-MED
papillomavirus	I-MED
(	I-MED
HPV)-positive	I-MED
oropharyngeal	I-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
(	I-MED
OPSCC	I-MED
)	I-MED
is	O
not	O
well	O
established	O
,	O
and	O
single	B-MED
-	I-MED
institution	I-MED
studies	B-MED
have	O
not	B-MED
established	I-MED
that	O
ENE	B-MED
predicts	B-MED
inferior	B-MED
outcome	B-MED
.	O
The	O
authors	O
investigated	O
the	O
prognostic	B-MED
value	I-MED
of	O
ENE	B-MED
in	O
HPV	B-MED
-	O
positive	B-MED
patients	B-MED
who	O
underwent	O
primary	B-MED
surgery	I-MED
and	O
whether	O
adjuvant	B-MED
chemoradiation	I-MED
improved	O
overall	B-MED
survival	I-MED
(	O
OS	B-MED
)	O
compared	B-MED
with	O
radiation	B-MED
alone	I-MED
in	O
ENE	B-MED
-	O
positive	B-MED
patients	B-MED
.	O
Patients	B-MED
who	O
underwent	O
primary	B-MED
surgery	I-MED
for	O
pathologic	B-MED
T1	I-MED
(	O
pT1	B-MED
)	O
through	O
pT4	B-MED
tumors	I-MED
,	O
pathologic	B-MED
N1	I-MED
(	O
pN1	B-MED
)	O
through	O
pN3	B-MED
lymph	I-MED
node	I-MED
status	B-MED
,	O
HPV	B-MED
-	I-MED
positive	I-MED
OPSCC	I-MED
were	O
identified	B-MED
in	O
the	O
National	B-MED
Cancer	I-MED
Data	I-MED
Base	I-MED
from	O
2010	O
through	O
2012	O
.	O
Features	B-MED
associated	B-MED
with	I-MED
ENE	B-MED
were	O
analyzed	B-MED
.	O
Univariable	B-MED
and	I-MED
multivariable	I-MED
Cox	I-MED
regression	I-MED
analyses	I-MED
identified	B-MED
predictors	B-MED
of	O
OS	B-MED
.	O
The	O
effect	B-MED
of	O
adjuvant	B-MED
treatment	I-MED
on	O
OS	B-MED
in	O
ENE	B-MED
-	O
positive	B-MED
cohort	B-MED
was	O
also	O
evaluated	B-MED
.	O
In	O
total	O
,	O
1043	O
patients	B-MED
met	O
inclusion	B-MED
criteria	I-MED
,	O
among	O
whom	O
43.5	O
%	O
were	O
ENE	B-MED
-	O
positive	B-MED
.	O
Of	O
the	O
ENE	B-MED
-	O
positive	B-MED
patients	B-MED
who	O
had	O
treatment	B-MED
details	O
available	O
,	O
72	O
%	O
received	B-MED
concurrent	B-MED
chemoradiotherapy	I-MED
,	O
16	O
%	O
received	B-MED
radiotherapy	B-MED
,	O
and	O
12	O
%	O
received	B-MED
no	B-MED
adjuvant	B-MED
treatment	I-MED
.	O
After	O
a	O
median	B-MED
follow	B-MED
-	I-MED
up	I-MED
of	O
28.4	O
months	B-MED
,	O
ENE	B-MED
was	O
associated	B-MED
with	I-MED
worse	B-MED
3-	O
year	B-MED
OS	B-MED
(	O
89.3	O
%	O
vs	O
93.6	O
%	O
;	O
P	O
=	O
.01	O
)	O
.	O
On	O
multivariable	B-MED
analysis	I-MED
that	O
included	B-MED
involved	O
lymph	B-MED
nodes	I-MED
,	O
only	O
ENE	B-MED
,	O
lymphovascular	B-MED
invasion	I-MED
,	O
pT3	B-MED
/	I-MED
pT4	I-MED
tumors	I-MED
,	O
and	O
Charlson	B-MED
-	I-MED
Deyo	I-MED
score	I-MED
were	O
associated	B-MED
with	I-MED
worse	B-MED
OS	B-MED
.	O
Among	O
ENE	B-MED
-	O
positive	B-MED
patients	B-MED
,	O
there	O
was	O
no	B-MED
difference	I-MED
in	O
3-	O
year	B-MED
OS	B-MED
between	O
those	O
who	O
received	B-MED
adjuvant	B-MED
concurrent	I-MED
chemoradiotherapy	I-MED
versus	O
radiotherapy	B-MED
alone	I-MED
(	O
89.6	O
%	O
vs	O
89.3	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.55	O
)	O
.	O
Propensity	B-MED
score	I-MED
-	O
matched	B-MED
comparison	I-MED
revealed	B-MED
similar	O
results	B-MED
.	O
ENE	B-MED
is	O
associated	B-MED
with	I-MED
inferior	B-MED
OS	B-MED
in	O
patients	B-MED
with	O
HPV	B-MED
-	I-MED
positive	I-MED
OPSCC	I-MED
.	O
However	O
,	O
OS	B-MED
was	O
not	B-MED
better	I-MED
with	O
adjuvant	B-MED
chemoradiotherapy	I-MED
compared	B-MED
with	O
radiotherapy	B-MED
alone	I-MED
in	O
ENE	B-MED
-	O
positive	B-MED
patients	B-MED
.	O
The	O
current	B-MED
findings	I-MED
support	I-MED
the	O
need	O
for	O
prospective	B-MED
studies	I-MED
of	O
adjuvant	B-MED
chemoradiation	I-MED
in	O
HPV	B-MED
-	O
positive	B-MED
patients	B-MED
with	O
ENE	B-MED
.	O
Cancer	O
2017	O
.	O
©	O
2017	O
American	O
Cancer	O
Society	O
.	O
Chemosensitivity	B-MED
,	O
Cardiovascular	B-MED
Risk	I-MED
,	O
and	O
the	O
Ventilatory	B-MED
Response	I-MED
to	O
Exercise	B-MED
in	O
COPD	B-MED
COPD	B-MED
is	O
associated	O
with	O
elevated	B-MED
cardiovascular	B-MED
risk	I-MED
and	O
a	O
potentiated	B-MED
ventilatory	B-MED
response	I-MED
to	O
exercise	B-MED
.	O
Enhanced	O
carotid	B-MED
chemoreceptor	B-MED
(	O
CC	B-MED
)	O
activity	B-MED
/	O
sensitivity	B-MED
sensitivity	B-MED
is	O
present	O
in	O
other	O
clinical	B-MED
conditions	I-MED
,	O
has	O
been	O
shown	O
to	O
contribute	O
to	O
sympathetic	B-MED
vasoconstrictor	B-MED
outflow	I-MED
,	O
and	O
is	O
predictive	B-MED
of	O
mortality	B-MED
.	O
CC	B-MED
activity	B-MED
/	O
sensitivity	B-MED
,	O
and	O
the	O
resulting	O
functional	B-MED
significance	B-MED
,	O
has	O
not	B-MED
been	I-MED
well	I-MED
examined	I-MED
in	O
COPD	B-MED
.	O
We	O
hypothesized	O
that	O
CC	B-MED
activity	B-MED
/	O
sensitivity	B-MED
would	O
be	O
elevated	B-MED
in	O
COPD	B-MED
,	O
and	O
related	O
to	O
increased	B-MED
pulse	B-MED
wave	I-MED
velocity	I-MED
(	O
a	O
marker	B-MED
of	O
CV	B-MED
risk	I-MED
)	O
and	O
the	O
ventilatory	B-MED
response	I-MED
to	O
exercise	B-MED
.	O
30	O
COPD	B-MED
patients	B-MED
and	O
10	O
healthy	B-MED
age	O
-	O
matched	O
controls	B-MED
were	O
examined	B-MED
.	O
Participants	B-MED
performed	O
baseline	B-MED
cardiopulmonary	B-MED
exercise	I-MED
and	O
pulmonary	B-MED
function	I-MED
testing	I-MED
.	O
CC	B-MED
activity	B-MED
was	O
later	O
evaluated	B-MED
by	O
the	O
drop	B-MED
in	I-MED
ventilation	B-MED
with	O
breathing	B-MED
100	O
%	O
O2	B-MED
,	O
and	O
CC	B-MED
sensitivity	B-MED
was	O
then	O
assessed	O
by	O
the	O
ventilatory	B-MED
response	I-MED
to	I-MED
hypoxia	I-MED
(	O
ΔVE	O
/	O
ΔS	O
pO2	B-MED
)	O
.	O
Peripheral	B-MED
arterial	B-MED
stiffness	I-MED
was	O
subsequently	O
evaluated	B-MED
by	O
measurement	B-MED
of	O
pulse	B-MED
wave	I-MED
velocity	I-MED
(	O
PWV	B-MED
)	O
using	O
applanation	B-MED
tonometry	I-MED
while	O
the	O
subjects	O
were	O
breathing	B-MED
room	B-MED
air	I-MED
,	O
and	O
then	O
following	O
chemoreceptor	B-MED
inhibition	B-MED
by	O
breathing	B-MED
100	B-MED
%	I-MED
O2	B-MED
for	O
2	O
minutes	O
.	O
CC	B-MED
activity	B-MED
,	O
CC	B-MED
sensitivity	B-MED
,	O
PWV	B-MED
and	O
the	O
ventilatory	B-MED
response	I-MED
to	O
exercise	B-MED
were	O
all	O
increased	O
in	O
COPD	B-MED
relative	O
to	O
controls	B-MED
.	O
CC	B-MED
sensitivity	B-MED
was	O
related	O
to	O
PWV	B-MED
;	O
however	O
,	O
neither	O
CC	B-MED
activity	B-MED
nor	O
CC	B-MED
sensitivity	B-MED
was	O
related	O
to	O
the	O
ventilatory	B-MED
response	I-MED
to	O
exercise	B-MED
in	O
COPD	B-MED
.	O
CC	B-MED
inhibition	O
by	O
breathing	B-MED
100	B-MED
%	I-MED
O2	B-MED
normalized	O
PWV	B-MED
in	O
COPD	B-MED
,	O
while	O
no	B-MED
effect	I-MED
was	O
observed	O
in	O
controls	B-MED
.	O
CC	B-MED
activity	B-MED
and	O
sensitivity	B-MED
are	O
elevated	B-MED
in	O
COPD	B-MED
,	O
and	O
appear	O
related	O
to	O
cardiovascular	B-MED
risk	I-MED
;	O
however	O
,	O
CC	B-MED
activity	B-MED
/	O
sensitivity	B-MED
does	O
not	O
contribute	O
to	O
the	O
potentiated	B-MED
ventilatory	B-MED
response	I-MED
to	O
exercise	B-MED
.	O
Salvage	B-MED
Therapy	I-MED
with	O
Ceftolozane	B-MED
-	I-MED
Tazobactam	I-MED
for	O
Multidrug	B-MED
-	I-MED
Resistant	I-MED
Pseudomonas	I-MED
aeruginosa	I-MED
Infections	B-MED
Infections	B-MED
caused	O
by	O
multidrug	B-MED
-	I-MED
resistant	I-MED
Pseudomonas	I-MED
aeruginosa	I-MED
(	O
MDRPA	B-MED
)	O
present	O
a	O
major	O
problem	O
for	O
therapeutic	B-MED
management	I-MED
.	O
We	O
report	O
here	O
our	O
experience	O
with	O
12	O
patients	B-MED
with	O
a	O
severe	O
MDRPA	B-MED
infection	B-MED
(	O
6	O
of	O
which	O
were	O
pneumonia	B-MED
)	O
who	O
received	O
salvage	B-MED
therapy	I-MED
with	O
ceftolozane	B-MED
-	I-MED
tazobactam	I-MED
after	O
inappropriate	O
empirical	B-MED
treatment	I-MED
and/or	O
suboptimal	B-MED
targeted	O
treatment	B-MED
.	O
Although	O
10	O
of	O
the	O
12	O
patients	B-MED
(	O
83.3	O
%	O
)	O
experienced	O
septic	B-MED
shock	I-MED
,	O
only	O
3	O
patients	B-MED
(	O
25	O
%	O
)	O
died	B-MED
during	O
the	O
follow	B-MED
-	I-MED
up	I-MED
period	O
.	O
Microbiological	B-MED
cure	B-MED
in	O
7	O
patients	B-MED
(	O
58.3	O
%	O
)	O
was	O
observed	O
.	O
Assessing	B-MED
nitrous	B-MED
oxide	I-MED
effect	B-MED
using	O
electroencephalographically	B-MED
-based	O
depth	B-MED
of	I-MED
anesthesia	I-MED
measures	B-MED
cortical	B-MED
state	B-MED
and	O
cortical	B-MED
input	B-MED
Existing	O
electroencephalography	B-MED
(	O
EEG	B-MED
)	O
based	O
depth	B-MED
of	I-MED
anesthesia	I-MED
monitors	B-MED
can	O
not	O
reliably	O
track	O
sedative	B-MED
or	O
anesthetic	B-MED
states	B-MED
during	O
n	B-MED
-	I-MED
methyl	I-MED
-	I-MED
D	I-MED
-	I-MED
aspartate	I-MED
(	I-MED
NMDA	I-MED
)	I-MED
receptor	I-MED
antagonist	I-MED
based	O
anesthesia	B-MED
with	O
ketamine	B-MED
or	O
nitrous	B-MED
oxide	I-MED
(	O
N2O	B-MED
)	O
.	O
Here	O
,	O
a	O
physiologically	B-MED
-motivated	O
depth	B-MED
of	I-MED
anesthesia	I-MED
monitoring	B-MED
algorithm	B-MED
based	O
on	O
autoregressive	B-MED
-	I-MED
moving	I-MED
-	I-MED
average	I-MED
(	I-MED
ARMA	I-MED
)	I-MED
modeling	I-MED
and	O
derivative	O
measures	O
of	O
interest	O
,	O
Cortical	B-MED
State	B-MED
(	O
CS	B-MED
)	O
and	O
Cortical	B-MED
Input	B-MED
(	O
CI	B-MED
)	O
,	O
is	O
retrospectively	B-MED
applied	O
in	O
an	O
exploratory	B-MED
manner	O
to	O
the	O
NMDA	B-MED
receptor	I-MED
antagonist	I-MED
N2O	B-MED
,	O
an	O
adjuvant	B-MED
anesthetic	I-MED
gas	I-MED
used	O
in	O
clinical	B-MED
practice	I-MED
.	O
Composite	B-MED
Cortical	I-MED
State	I-MED
(	O
CCS	B-MED
)	O
and	O
Composite	B-MED
Cortical	I-MED
State	I-MED
distance	I-MED
(	O
CCSd	B-MED
)	O
,	O
two	O
new	O
modifications	B-MED
of	O
CS	B-MED
,	O
along	O
with	O
CS	B-MED
and	O
CI	B-MED
were	O
evaluated	B-MED
on	O
electroencephalographic	B-MED
(	O
EEG	B-MED
)	O
data	B-MED
of	O
healthy	B-MED
control	I-MED
individuals	I-MED
undergoing	O
N2O	B-MED
inhalation	B-MED
up	O
to	O
equilibrated	B-MED
peak	B-MED
gas	I-MED
concentrations	I-MED
of	O
20	O
,	O
40	O
or	O
60	O
%	O
N2O	B-MED
/	O
O2	B-MED
.	O
In	O
particular	O
,	O
CCSd	B-MED
has	O
been	O
devised	O
to	O
vary	O
consistently	O
for	O
increasing	B-MED
levels	B-MED
of	O
anesthetic	B-MED
concentration	I-MED
independent	B-MED
of	I-MED
the	O
anesthetic	B-MED
's	I-MED
microscopic	B-MED
mode	B-MED
of	I-MED
action	I-MED
for	O
both	O
N2O	B-MED
and	O
propofol	B-MED
.	O
The	O
strongest	O
effects	B-MED
were	O
observed	O
for	O
the	O
60	O
%	O
peak	B-MED
gas	I-MED
concentration	I-MED
group	B-MED
.	O
For	O
the	O
50	O
-	O
60	O
%	O
peak	B-MED
gas	I-MED
levels	I-MED
,	O
individuals	B-MED
showed	O
statistically	B-MED
significant	I-MED
reductions	B-MED
in	O
responsiveness	B-MED
compared	B-MED
to	O
rest	B-MED
,	O
and	O
across	O
the	O
group	B-MED
CS	B-MED
and	O
CCS	B-MED
increased	B-MED
by	O
39	O
and	O
42	O
%	O
,	O
respectively	O
,	O
while	O
CCSd	B-MED
was	O
found	O
to	O
decrease	B-MED
by	O
398	O
%	O
.	O
On	O
the	O
other	O
hand	O
a	O
clear	O
conclusion	B-MED
regarding	O
the	O
changes	O
in	O
CI	B-MED
could	O
not	O
be	O
reached	O
.	O
These	O
results	B-MED
indicate	O
that	O
,	O
contrary	B-MED
to	O
previous	O
depth	B-MED
of	I-MED
anesthesia	I-MED
monitoring	B-MED
measures	B-MED
,	O
the	O
CS	B-MED
,	O
CCS	B-MED
,	O
and	O
especially	O
CCSd	B-MED
measures	B-MED
derived	B-MED
from	O
frontal	B-MED
EEG	B-MED
are	O
potentially	B-MED
useful	O
for	O
differentiating	O
gas	B-MED
concentration	I-MED
and	O
responsiveness	B-MED
levels	I-MED
in	O
people	B-MED
N2O	B-MED
under	O
N2O.	O
On	O
the	O
other	O
hand	O
,	O
determining	O
the	O
utility	B-MED
of	O
CI	B-MED
in	O
this	O
regard	O
will	O
require	O
larger	B-MED
sample	B-MED
sizes	I-MED
and	O
potentially	B-MED
higher	B-MED
gas	B-MED
concentrations	I-MED
.	O
Future	O
work	O
will	O
assess	B-MED
the	O
sensitivity	B-MED
of	O
CS	B-MED
-based	O
and	O
CI	B-MED
measures	B-MED
to	O
other	O
anesthetics	B-MED
and	O
their	O
utility	B-MED
in	O
a	O
clinical	B-MED
environment	B-MED
.	O
Systemic	B-MED
matrix	I-MED
metalloproteinase-8	I-MED
response	B-MED
in	O
chronic	B-MED
tonsillitis	I-MED
The	O
development	B-MED
of	O
several	O
life	O
-	O
long	O
diseases	B-MED
,	O
such	O
as	O
coronary	B-MED
heart	I-MED
disease	I-MED
,	O
is	O
affected	O
by	O
low	B-MED
-	I-MED
grade	I-MED
systemic	B-MED
inflammation	B-MED
.	O
Data	B-MED
on	O
the	O
potential	B-MED
long	B-MED
-	I-MED
term	I-MED
health	B-MED
effects	B-MED
of	O
chronic	B-MED
tonsillitis	I-MED
are	O
limited	O
.	O
Many	O
inflammatory	B-MED
conditions	B-MED
present	O
with	O
enhanced	O
systemic	B-MED
matrix	I-MED
metalloproteinase	I-MED
(	B-MED
MMP)-8	I-MED
response	B-MED
.	O
In	O
head	B-MED
and	I-MED
neck	I-MED
cancer	I-MED
,	O
high	B-MED
plasma	B-MED
level	B-MED
of	O
tissue	B-MED
inhibitor	I-MED
of	I-MED
metalloproteinase	I-MED
(	B-MED
TIMP)-1	I-MED
predicts	B-MED
poor	B-MED
prognosis	I-MED
.	O
We	O
analyzed	O
S	B-MED
-	I-MED
MMP-8	I-MED
with	O
immunofluorometric	B-MED
assay	I-MED
and	O
S	B-MED
-	I-MED
TIMP-1	I-MED
with	O
an	O
immunosorbent	B-MED
assay	I-MED
in	O
175	O
consecutive	B-MED
patients	B-MED
undergoing	O
tonsillectomy	B-MED
for	O
benign	B-MED
tonsillar	I-MED
disease	I-MED
,	O
and	O
in	O
33	O
control	B-MED
patients	B-MED
with	O
tonsillar	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
.	O
Tonsillar	B-MED
human	B-MED
papillomavirus	I-MED
(	O
HPV	B-MED
)	O
status	O
was	O
determined	O
by	O
PCR	B-MED
.	O
In	O
patients	B-MED
with	O
benign	B-MED
tonsillar	I-MED
disease	I-MED
,	O
chronic	B-MED
tonsillitis	I-MED
without	O
hypertrophy	B-MED
was	O
associated	B-MED
with	I-MED
enhanced	O
systemic	B-MED
MMP-8	I-MED
response	B-MED
.	O
Compared	O
to	O
patients	B-MED
with	O
benign	B-MED
tonsillar	I-MED
disease	I-MED
,	O
patients	B-MED
with	O
tonsillar	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
had	O
significantly	B-MED
higher	I-MED
concentrations	B-MED
of	O
S	B-MED
-	I-MED
MMP-8	I-MED
and	O
S	B-MED
-	I-MED
TIMP-1	I-MED
.	O
Neither	O
S	B-MED
-	I-MED
MMP-8	I-MED
nor	O
S	B-MED
-	I-MED
TIMP-1	I-MED
correlated	O
with	O
tonsillar	B-MED
HPV	B-MED
positivity	B-MED
.	O
Accurate	B-MED
Lungs	B-MED
Segmentation	B-MED
on	O
CT	B-MED
Chest	B-MED
Images	B-MED
by	O
Adaptive	B-MED
Appearance	I-MED
-	I-MED
Guided	I-MED
Shape	I-MED
Modeling	I-MED
To	O
accurately	B-MED
segment	B-MED
pathological	B-MED
and	O
healthy	B-MED
lungs	B-MED
for	O
reliable	B-MED
computer	B-MED
-	I-MED
aided	I-MED
disease	I-MED
diagnostics	I-MED
,	O
a	O
stack	B-MED
of	O
chest	B-MED
CT	B-MED
scans	B-MED
is	O
modeled	B-MED
as	O
a	O
sample	O
of	O
a	O
spatially	B-MED
inhomogeneous	I-MED
joint	B-MED
3D	I-MED
Markov	I-MED
-	I-MED
Gibbs	I-MED
random	I-MED
field	I-MED
(	O
MGRF	B-MED
)	O
of	O
voxel	B-MED
-	I-MED
wise	I-MED
lung	B-MED
and	O
chest	B-MED
CT	B-MED
image	B-MED
signals	B-MED
(	O
intensities	B-MED
)	O
.	O
The	O
proposed	B-MED
learnable	O
MGRF	B-MED
integrates	B-MED
two	O
visual	B-MED
appearance	B-MED
sub	B-MED
-	I-MED
models	I-MED
with	O
an	O
adaptive	O
lung	B-MED
shape	O
submodel	B-MED
.	O
The	O
first	O
-	O
order	O
appearance	B-MED
submodel	B-MED
accounts	O
for	O
both	O
the	O
original	B-MED
CT	B-MED
image	B-MED
and	O
its	O
Gaussian	B-MED
scale	I-MED
space	I-MED
(	I-MED
GSS	I-MED
)	I-MED
filtered	I-MED
version	I-MED
to	O
specify	O
local	O
and	O
global	O
signal	B-MED
properties	O
,	O
respectively	O
.	O
Each	O
empirical	B-MED
marginal	B-MED
probability	B-MED
distribution	I-MED
of	O
signals	B-MED
is	O
closely	O
approximated	O
with	O
a	O
linear	B-MED
combination	I-MED
of	I-MED
discrete	I-MED
Gaussians	I-MED
(	O
LCDG	B-MED
)	O
,	O
containing	O
two	O
positive	B-MED
dominant	I-MED
and	I-MED
multiple	I-MED
sign	I-MED
-	I-MED
alternate	I-MED
subordinate	I-MED
DGs	I-MED
.	O
The	O
approximation	O
is	O
separated	O
into	O
two	O
LCDGs	B-MED
to	O
describe	O
individually	O
the	O
lungs	B-MED
and	O
their	O
background	O
,	O
i.e.	O
,	O
all	O
other	O
chest	B-MED
tissues	B-MED
.	O
The	O
second	O
-	O
order	O
appearance	B-MED
submodel	B-MED
quantifies	B-MED
conditional	B-MED
pairwise	B-MED
intensity	B-MED
dependencies	B-MED
in	O
the	O
nearest	O
voxel	O
26	O
-	O
neighborhood	O
in	O
both	O
the	O
original	B-MED
and	O
GSS	B-MED
-	I-MED
filtered	I-MED
images	B-MED
.	O
The	O
shape	O
submodel	B-MED
is	O
built	O
for	O
a	O
set	O
of	O
training	B-MED
data	I-MED
and	O
is	O
adapted	O
during	O
segmentation	B-MED
using	O
both	O
the	O
lung	B-MED
and	O
chest	B-MED
appearances	B-MED
.	O
The	O
accuracy	B-MED
of	O
the	O
proposed	B-MED
segmentation	B-MED
framework	O
is	O
quantitatively	B-MED
assessed	B-MED
using	O
two	O
public	O
databases	B-MED
(	O
ISBI	B-MED
VESSEL12	I-MED
challenge	I-MED
and	O
MICCAI	B-MED
LOLA11	I-MED
challenge	I-MED
)	O
and	O
our	O
own	O
database	B-MED
with	O
,	O
respectively	O
,	O
20	O
,	O
55	O
,	O
and	O
30	O
CT	B-MED
images	B-MED
of	O
various	O
lung	B-MED
pathologies	B-MED
acquired	O
with	O
different	O
scanners	B-MED
and	O
protocols	B-MED
.	O
Quantitative	B-MED
assessment	B-MED
of	O
our	O
framework	O
in	O
terms	O
of	O
Dice	B-MED
similarity	I-MED
coefficients	I-MED
,	O
95	B-MED
-	I-MED
percentile	I-MED
bidirectional	I-MED
Hausdorff	I-MED
distances	I-MED
,	O
and	O
percentage	B-MED
volume	I-MED
differences	I-MED
confirms	O
the	O
high	O
accuracy	B-MED
of	O
our	O
model	B-MED
on	O
both	O
our	O
database	B-MED
(	O
98.4±1.0	O
%	O
,	O
2.2±1.0	O
mm	O
,	O
0.42±0.10	O
%	O
)	O
and	O
the	O
VESSEL12	B-MED
database	I-MED
(	O
99.0±0.5	O
%	O
,	O
2.1±1.6	O
mm	O
,	O
0.39±0.20	O
%	O
)	O
,	O
respectively	O
.	O
Similarly	O
,	O
the	O
accuracy	B-MED
accuracy	B-MED
of	O
our	O
approach	B-MED
is	O
further	O
verified	B-MED
via	O
a	O
blind	B-MED
evaluation	B-MED
by	O
the	O
organizers	O
of	O
the	O
LOLA11	B-MED
competition	B-MED
,	O
where	O
an	O
average	B-MED
overlap	O
of	O
98.0	O
%	O
with	O
the	O
expert	O
's	O
segmentation	B-MED
is	O
yielded	O
on	O
all	O
55	O
subjects	O
with	O
our	O
framework	O
being	O
ranked	O
first	O
among	O
all	O
the	O
state	B-MED
-	I-MED
of	I-MED
-	I-MED
the	I-MED
-	I-MED
art	I-MED
techniques	B-MED
compared	B-MED
.	O
HERG1	B-MED
potassium	B-MED
channel	I-MED
expression	B-MED
in	O
potentially	B-MED
malignant	B-MED
disorders	I-MED
of	O
the	O
oral	B-MED
mucosa	I-MED
and	O
prognostic	B-MED
relevance	B-MED
in	O
oral	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
HERG1	B-MED
potassium	B-MED
channel	I-MED
plays	O
a	O
critical	B-MED
role	B-MED
in	O
the	O
cell	B-MED
proliferation	I-MED
.	O
HERG1	B-MED
protein	I-MED
expression	B-MED
was	O
analyzed	B-MED
by	O
immunohistochemistry	B-MED
(	O
IHC	B-MED
)	O
in	O
62	O
patients	B-MED
with	O
oral	B-MED
leukoplakias	I-MED
and	O
100	O
patients	B-MED
with	O
oral	B-MED
squamous	I-MED
cell	I-MED
carcinomas	I-MED
(	O
OSCC	B-MED
)	O
.	O
HERG1	B-MED
mRNA	B-MED
levels	B-MED
were	O
assessed	B-MED
by	O
real	B-MED
-	I-MED
time	I-MED
reverse	I-MED
transcriptase	I-MED
-	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
(	O
RT	B-MED
-	I-MED
PCR	I-MED
)	O
in	O
22	O
patients	B-MED
with	O
primary	B-MED
head	B-MED
and	I-MED
neck	I-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
(	O
HNSCC	B-MED
)	O
.	O
Statistically	B-MED
significant	I-MED
associations	B-MED
were	O
found	O
between	O
HERG1	B-MED
expression	B-MED
and	O
tobacco	B-MED
consumption	I-MED
,	O
disease	B-MED
stage	I-MED
,	O
tumor	B-MED
differentiation	B-MED
,	O
tumor	B-MED
recurrence	I-MED
,	O
and	O
reduced	B-MED
survival	B-MED
.	O
There	O
was	O
no	B-MED
association	B-MED
between	O
HERG1	B-MED
expression	B-MED
and	O
the	O
risk	B-MED
of	O
progression	B-MED
from	O
oral	B-MED
leukoplakia	I-MED
to	O
OSCC	B-MED
.	O
In	O
addition	O
,	O
a	O
high	B-MED
proportion	B-MED
of	O
tumors	B-MED
(	O
80	O
%	O
)	O
showed	O
increased	B-MED
HERG1	B-MED
mRNA	B-MED
levels	B-MED
compared	B-MED
to	O
normal	B-MED
mucosa	I-MED
from	O
nononcologic	B-MED
patients	I-MED
.	O
Aberrant	B-MED
HERG1	B-MED
expression	B-MED
increases	B-MED
as	O
oral	O
tumorigenesis	B-MED
progresses	I-MED
from	O
oral	B-MED
hyperplasia	I-MED
to	O
OSCC	B-MED
.	O
Increased	B-MED
HERG1	B-MED
mRNA	B-MED
levels	B-MED
were	O
also	O
frequently	O
detected	B-MED
in	O
OSCC	B-MED
and	O
other	O
HNSCC	B-MED
subsites	B-MED
.	O
HERG1	B-MED
expression	B-MED
emerges	O
as	O
a	O
clinically	B-MED
relevant	B-MED
feature	B-MED
during	O
tumor	B-MED
progression	I-MED
and	O
a	O
potential	B-MED
poor	B-MED
prognostic	B-MED
biomarker	B-MED
for	O
OSCC	B-MED
.	O
©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Head	O
Neck	O
38	O
:	O
1708	O
-	O
1716	O
,	O
2016	O
.	O
Spatio	B-MED
-	I-MED
Temporal	I-MED
History	I-MED
of	O
HIV-1	B-MED
CRF35_AD	I-MED
in	O
Afghanistan	B-MED
and	O
Iran	B-MED
HIV-1	B-MED
Circulating	I-MED
Recombinant	I-MED
Form	I-MED
35_AD	I-MED
(	O
CRF35_AD	B-MED
)	O
has	O
an	O
important	O
position	O
in	O
the	O
epidemiological	B-MED
profile	B-MED
of	O
Afghanistan	B-MED
and	O
Iran	B-MED
.	O
Despite	O
the	O
presence	O
of	O
this	O
clade	B-MED
in	O
Afghanistan	B-MED
and	O
Iran	B-MED
for	O
over	O
a	O
decade	O
,	O
our	O
understanding	O
of	O
its	O
origin	O
and	O
dissemination	B-MED
patterns	O
is	O
limited	O
.	O
In	O
this	O
study	O
,	O
we	O
performed	O
a	O
Bayesian	B-MED
phylogeographic	I-MED
analysis	I-MED
to	O
reconstruct	O
the	O
spatio	B-MED
-	I-MED
temporal	I-MED
dispersion	I-MED
pattern	I-MED
of	O
this	O
clade	B-MED
using	O
eligible	O
CRF35_AD	B-MED
gag	B-MED
and	I-MED
pol	I-MED
sequences	I-MED
available	O
in	O
the	O
Los	B-MED
Alamos	I-MED
HIV	B-MED
database	I-MED
(	O
432	O
sequences	B-MED
available	O
from	O
Iran	B-MED
,	O
16	O
sequences	B-MED
available	O
from	O
Afghanistan	B-MED
,	O
and	O
a	O
single	O
CRF35_AD	B-MED
-like	O
pol	B-MED
sequence	I-MED
available	O
from	O
USA	B-MED
)	O
.	O
Bayesian	B-MED
Markov	I-MED
Chain	I-MED
Monte	I-MED
Carlo	I-MED
algorithm	I-MED
was	O
implemented	O
in	O
BEAST	B-MED
v1.8.1	I-MED
.	O
Between	O
-	O
country	O
dispersion	O
rates	O
were	O
tested	O
with	O
Bayesian	B-MED
stochastic	I-MED
search	I-MED
variable	I-MED
selection	I-MED
method	I-MED
and	O
were	O
considered	O
significant	O
where	O
Bayes	B-MED
factor	I-MED
values	I-MED
were	O
greater	O
than	O
three	O
.	O
The	O
findings	O
suggested	O
that	O
CRF35_AD	B-MED
sequences	B-MED
were	O
genetically	O
similar	O
to	O
parental	B-MED
sequences	I-MED
from	O
Kenya	B-MED
and	O
Uganda	B-MED
,	O
and	O
to	O
a	O
set	O
of	O
subtype	B-MED
A1	I-MED
sequences	B-MED
available	O
from	O
Afghan	B-MED
refugees	B-MED
living	O
in	O
Pakistan	B-MED
.	O
Our	O
results	O
also	O
showed	O
that	O
across	O
all	O
phylogenies	B-MED
,	O
Afghan	B-MED
and	O
Iranian	B-MED
CRF35_AD	B-MED
sequences	B-MED
formed	O
a	O
monophyletic	B-MED
cluster	I-MED
(	O
posterior	O
clade	O
credibility	O
>	O
0.7	O
)	O
.	O
The	O
divergence	O
date	O
of	O
this	O
cluster	B-MED
was	O
estimated	O
to	O
be	O
between	O
1990	O
and	O
1992	O
.	O
Within	O
this	O
cluster	B-MED
,	O
a	O
bidirectional	B-MED
dispersion	B-MED
of	O
the	O
virus	B-MED
was	O
observed	O
across	O
Afghanistan	B-MED
and	O
Iran	B-MED
.	O
We	O
could	O
not	O
clearly	O
identify	O
if	O
Afghanistan	B-MED
or	O
Iran	B-MED
first	O
established	O
or	O
received	O
this	O
epidemic	B-MED
,	O
as	O
the	O
root	O
location	O
of	O
this	O
cluster	B-MED
could	O
not	O
be	O
robustly	O
estimated	O
.	O
Three	O
CRF35_AD	B-MED
sequences	B-MED
from	O
Afghan	B-MED
refugees	B-MED
living	B-MED
in	I-MED
Pakistan	B-MED
nested	O
among	O
Afghan	B-MED
and	O
Iranian	B-MED
CRF35_AD	B-MED
branches	O
.	O
However	O
,	O
the	O
CRF35_AD	B-MED
-like	O
sequence	B-MED
available	O
from	O
USA	B-MED
diverged	O
independently	O
from	O
Kenyan	B-MED
subtype	B-MED
A1	I-MED
sequences	B-MED
,	O
suggesting	O
it	O
not	O
to	O
be	O
a	O
true	O
CRF35_AD	B-MED
lineage	O
.	O
Potential	B-MED
factors	B-MED
contributing	O
to	O
viral	B-MED
exchange	O
between	O
Afghanistan	B-MED
and	O
Iran	B-MED
could	O
be	O
injection	O
drug	O
networks	O
and	O
mass	B-MED
migration	I-MED
of	O
Afghan	B-MED
refugees	B-MED
and	O
labours	B-MED
to	O
Iran	B-MED
,	O
which	O
calls	O
for	O
extensive	B-MED
preventive	B-MED
efforts	O
.	O
The	O
ErbB3	B-MED
receptor	I-MED
tyrosine	I-MED
kinase	I-MED
negatively	O
regulates	B-MED
Paneth	B-MED
cells	I-MED
by	O
PI3	B-MED
K	I-MED
-	O
dependent	B-MED
suppression	B-MED
of	O
Atoh1	B-MED
Paneth	B-MED
cells	I-MED
(	O
PCs	B-MED
)	O
,	O
a	O
secretory	B-MED
population	I-MED
located	O
at	O
the	O
base	O
of	O
the	O
intestinal	B-MED
crypt	I-MED
,	O
support	O
the	O
intestinal	B-MED
stem	B-MED
cells	I-MED
(	O
ISC	B-MED
)	O
with	O
growth	B-MED
factors	I-MED
and	O
participate	O
in	O
innate	B-MED
immunity	I-MED
by	O
releasing	O
antimicrobial	B-MED
peptides	I-MED
,	O
including	O
lysozyme	B-MED
and	O
defensins	B-MED
.	O
PC	B-MED
dysfunction	B-MED
is	O
associated	O
with	O
disorders	B-MED
such	O
as	O
Crohn	B-MED
's	I-MED
disease	I-MED
and	O
necrotizing	B-MED
enterocolitis	I-MED
,	O
but	O
the	O
specific	O
pathways	B-MED
regulating	B-MED
PC	B-MED
development	B-MED
and	O
function	B-MED
are	O
not	O
fully	O
understood	O
.	O
Here	O
we	O
tested	O
the	O
role	O
of	O
the	O
neuregulin	B-MED
receptor	I-MED
ErbB3	I-MED
in	O
control	O
of	O
PC	B-MED
differentiation	B-MED
and	O
the	O
ISC	B-MED
niche	I-MED
.	O
Intestinal	B-MED
epithelial	B-MED
ErbB3	B-MED
knockout	B-MED
caused	O
precocious	B-MED
appearance	B-MED
of	O
PCs	B-MED
as	O
early	O
as	O
postnatal	B-MED
day	B-MED
7	I-MED
,	O
and	O
substantially	O
increased	B-MED
the	O
number	O
of	O
mature	B-MED
PCs	B-MED
in	O
adult	B-MED
mouse	I-MED
ileum	B-MED
.	O
ErbB3	B-MED
loss	O
had	O
no	O
effect	O
on	O
other	O
secretory	B-MED
lineages	I-MED
,	O
but	O
increased	B-MED
expression	B-MED
of	O
the	O
ISC	B-MED
marker	O
Lgr5	B-MED
.	O
ErbB3	B-MED
-null	O
intestines	B-MED
had	O
elevated	O
levels	O
of	O
the	O
Atoh1	B-MED
transcription	B-MED
factor	I-MED
,	O
which	O
is	O
required	O
for	O
secretory	O
fate	O
determination	O
,	O
while	O
Atoh1(+	B-MED
)	I-MED
cells	B-MED
had	O
reduced	O
ErbB3	B-MED
,	O
suggesting	O
reciprocal	B-MED
negative	B-MED
regulation	B-MED
.	O
ErbB3	B-MED
-null	O
intestinal	B-MED
progenitor	I-MED
cells	I-MED
showed	O
reduced	B-MED
activation	B-MED
of	O
the	O
PI3K	B-MED
-	I-MED
Akt	I-MED
and	O
ERK	B-MED
MAPK	I-MED
pathways	I-MED
.	O
Inhibiting	O
these	O
pathways	B-MED
in	O
HT29	B-MED
cells	I-MED
increased	B-MED
levels	O
of	O
ATOH1	B-MED
and	O
the	O
PC	B-MED
marker	O
LYZ	B-MED
.	O
Conversely	O
,	O
ErbB3	B-MED
activation	O
suppressed	B-MED
LYZ	B-MED
and	O
ATOH1	B-MED
in	O
a	O
PI3	B-MED
K	I-MED
-	O
dependent	B-MED
manner	O
.	O
Expansion	O
of	O
the	O
PC	B-MED
compartment	O
in	O
ErbB3	B-MED
-null	O
intestines	B-MED
was	O
accompanied	O
with	O
elevated	O
ER	B-MED
stress	I-MED
and	O
inflammation	B-MED
markers	B-MED
,	O
raising	O
the	O
possibility	O
that	O
negative	B-MED
regulation	B-MED
of	O
PCs	B-MED
by	O
ErbB3	B-MED
is	O
necessary	O
to	O
maintain	O
homeostasis	B-MED
.	O
Taken	O
together	O
,	O
our	O
data	B-MED
suggest	O
that	O
ErbB3	B-MED
restricts	O
PC	B-MED
numbers	O
through	O
PI3	B-MED
K	I-MED
-mediated	O
suppression	B-MED
of	O
Atoh1	B-MED
levels	O
leading	O
to	O
inhibition	O
of	O
PC	B-MED
differentiation	B-MED
,	O
with	O
important	O
implications	O
for	O
regulation	B-MED
of	O
the	O
ISC	B-MED
niche	I-MED
.	O
On	B-MED
-	I-MED
Site	I-MED
Fertility	B-MED
Preservation	I-MED
Services	I-MED
for	O
Adolescents	B-MED
and	O
Young	B-MED
Adults	I-MED
in	O
a	O
Comprehensive	B-MED
Cancer	I-MED
Center	I-MED
Adolescents	B-MED
and	O
young	B-MED
adults	I-MED
(	O
AYAs	B-MED
)	O
receiving	O
cancer	B-MED
treatments	I-MED
that	O
may	O
impair	B-MED
fertility	I-MED
should	O
receive	O
counseling	B-MED
about	O
risk	B-MED
of	I-MED
infertility	I-MED
and	O
options	O
for	O
fertility	B-MED
preservation	I-MED
(	O
FP	B-MED
)	O
before	O
treatment	B-MED
and/or	O
during	O
survivorship	B-MED
.	O
Our	O
objective	B-MED
was	O
to	O
define	O
the	O
AYA	B-MED
patient	B-MED
population	B-MED
referred	O
to	O
an	O
on	B-MED
-	I-MED
site	I-MED
fertility	I-MED
consultation	I-MED
service	I-MED
within	O
a	O
comprehensive	B-MED
cancer	I-MED
center	I-MED
and	O
determine	O
factors	B-MED
associated	O
with	O
patients	B-MED
proceeding	O
with	O
FP	B-MED
treatment	I-MED
.	O
We	O
conducted	O
a	O
retrospective	B-MED
chart	I-MED
review	I-MED
of	O
AYA	B-MED
women	B-MED
who	O
completed	O
a	O
consultation	B-MED
at	O
the	O
MD	B-MED
Anderson	I-MED
Fertility	I-MED
Preservation	I-MED
and	I-MED
Family	I-MED
Building	I-MED
Service	I-MED
during	O
the	O
first	O
year	O
of	O
service	B-MED
.	O
Records	B-MED
of	O
154	O
referred	O
AYA	B-MED
patients	B-MED
were	O
reviewed	B-MED
for	O
age	B-MED
,	O
ethnicity	B-MED
,	O
cancer	B-MED
type	I-MED
gravidity	B-MED
and	O
parity	B-MED
,	O
survivorship	B-MED
status	B-MED
,	O
and	O
decision	O
to	O
pursue	O
FP	B-MED
treatment	I-MED
.	O
Patients	B-MED
(	O
mean	O
age	O
29.7	O
)	O
were	O
Caucasian	B-MED
(	O
55	O
%	O
)	O
,	O
Hispanic	B-MED
(	O
23	O
%	O
)	O
,	O
and	O
African	B-MED
American	I-MED
(	O
10	O
%	O
)	O
.	O
The	O
majority	O
of	O
women	B-MED
(	O
67	O
%	O
)	O
were	O
seen	O
for	O
FP	B-MED
before	O
cancer	B-MED
treatment	I-MED
and	O
the	O
remaining	O
sought	O
options	B-MED
for	O
family	B-MED
building	I-MED
while	O
in	O
survivorship	B-MED
.	O
The	O
most	O
common	O
cancer	B-MED
types	I-MED
were	O
hematologic	B-MED
(	O
29	O
%	O
)	O
,	O
breast	B-MED
(	O
25	O
%	O
)	O
,	O
and	O
gynecologic	B-MED
(	O
23	O
%	O
)	O
.	O
Patients	B-MED
referred	O
to	O
an	O
on	B-MED
-	I-MED
site	I-MED
fertility	I-MED
consultation	I-MED
service	I-MED
were	O
medically	O
and	O
ethnically	B-MED
diverse	B-MED
.	O
Interest	O
in	O
fertility	B-MED
counseling	I-MED
and	O
treatment	B-MED
was	O
apparent	O
in	O
both	O
survivorship	B-MED
pre-	B-MED
and	I-MED
postcancer	I-MED
treatment	I-MED
.	O
Although	O
the	O
referral	B-MED
group	B-MED
was	O
ethnically	B-MED
diverse	B-MED
,	O
Caucasian	B-MED
women	B-MED
were	O
most	O
likely	O
to	O
pursue	O
FP	B-MED
treatment	I-MED
compared	O
to	O
women	B-MED
of	O
other	O
ethnicities	B-MED
.	O
Comparison	B-MED
of	O
electrospun	B-MED
and	O
solvent	B-MED
cast	I-MED
polylactic	B-MED
acid	I-MED
PLA	B-MED
(	O
PLA)/	O
poly(vinyl	B-MED
alcohol	I-MED
)	I-MED
(	O
PVA	B-MED
)	O
inserts	B-MED
as	O
potential	O
ocular	B-MED
drug	B-MED
delivery	I-MED
vehicles	I-MED
The	O
purpose	O
of	O
this	O
work	O
was	O
to	O
develop	O
,	O
characterize	O
and	O
compare	O
electrospun	B-MED
nanofiber	I-MED
inserts	B-MED
(	O
ENIs	B-MED
)	O
and	O
solvent	B-MED
cast	I-MED
polymeric	B-MED
inserts	B-MED
(	O
SCIs	B-MED
)	O
for	O
ocular	B-MED
drug	B-MED
delivery	I-MED
.	O
ENI	B-MED
and	O
SCI	B-MED
of	O
1	O
%	O
,	O
5	O
%	O
and	O
10	O
%	O
w	O
/	O
w	O
dexamethasone	B-MED
were	O
fabricated	B-MED
using	O
a	O
blend	B-MED
of	O
poly	B-MED
-	I-MED
lactic	I-MED
acid	I-MED
(	O
PLA	B-MED
)	O
and	O
poly	B-MED
-	I-MED
vinyl	I-MED
alcohol	I-MED
(	O
PVA	B-MED
)	O
.	O
Inserts	B-MED
were	O
characterized	O
for	O
morphology	B-MED
,	O
thickness	B-MED
,	O
pH	B-MED
,	O
drug	B-MED
content	I-MED
,	O
drug	B-MED
crystallinity	I-MED
,	O
in	B-MED
vitro	I-MED
drug	B-MED
release	I-MED
,	O
sterility	B-MED
,	O
dimethylformamide	B-MED
(	O
DMF	B-MED
)	O
and	O
chloroform	B-MED
content	B-MED
,	O
and	O
cytotoxicity	B-MED
.	O
The	O
thickness	B-MED
of	O
1	O
%	O
,	O
5	O
%	O
,	O
and	O
10	O
%	O
dexamethasone	B-MED
-loaded	O
ENIs	B-MED
were	O
found	O
to	O
be	O
50μm	O
,	O
62.5μm	O
,	O
and	O
93.3μm	O
,	O
respectively	O
,	O
with	O
good	O
folding	B-MED
endurance	I-MED
.	O
SCIs	B-MED
were	O
brittle	B-MED
,	O
with	O
thickness	B-MED
values	O
>	O
200μm	O
.	O
Drug	B-MED
release	I-MED
rates	B-MED
from	O
1	O
%	O
,	O
5	O
%	O
and	O
10	O
%	O
ENIs	B-MED
were	O
found	O
to	O
be	O
0.62μg	O
/	O
h	O
,	O
1.46μg	O
/	O
h	O
,	O
and	O
2.30μg	O
/	O
h	O
,	O
respectively	O
,	O
while	O
those	O
from	O
SCIs	B-MED
were	O
erratic	O
.	O
DMF	B-MED
content	B-MED
in	O
ENIs	B-MED
and	O
SCIs	B-MED
were	O
0.007	O
%	O
w	O
/	O
w	O
and	O
0.123	O
%	O
w	O
/	O
w	O
,	O
respectively	O
,	O
while	O
chloroform	B-MED
was	O
not	B-MED
detected	I-MED
.	O
No	B-MED
cytotoxicity	B-MED
was	O
observed	O
from	O
ENIs	B-MED
in	O
cultured	B-MED
bovine	B-MED
corneal	B-MED
endothelial	I-MED
cells	I-MED
for	O
up	O
to	O
24h	O
.	O
We	O
conclude	O
that	O
ENIs	B-MED
are	O
better	O
than	O
SCIs	B-MED
and	O
could	O
be	O
utilized	O
as	O
a	O
potential	O
delivery	B-MED
system	I-MED
for	O
treating	B-MED
anterior	B-MED
segment	I-MED
ocular	B-MED
diseases	I-MED
.	O
Repetitive	B-MED
transcranial	I-MED
magnetic	I-MED
stimulation	I-MED
improves	O
cognitive	B-MED
function	I-MED
of	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
patients	B-MED
Repetitive	B-MED
transcranial	I-MED
magnetic	I-MED
stimulation	I-MED
(	O
rTMS	B-MED
)	O
acts	O
as	O
a	O
kind	O
of	O
widely	O
-	O
applied	O
and	O
non	O
-	O
invasive	O
method	O
in	O
the	O
intervention	B-MED
of	O
some	O
neurological	B-MED
disorders	I-MED
.	O
This	O
prospective	B-MED
,	O
randomized	B-MED
,	O
double	B-MED
-	I-MED
blind	I-MED
,	O
placebo	B-MED
-	I-MED
controlled	I-MED
trial	I-MED
investigates	B-MED
the	O
effect	O
of	O
rTMS	B-MED
on	O
30	O
cases	B-MED
of	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
(	O
AD	B-MED
)	O
participants	B-MED
,	O
who	O
were	O
classified	O
into	O
mild	B-MED
and	O
moderate	B-MED
groups	B-MED
.	O
Neuropsychological	B-MED
tests	I-MED
were	O
carried	O
out	O
using	O
the	O
AD	B-MED
Assessment	I-MED
Scale	I-MED
-	O
cognitive	B-MED
subscale	I-MED
(	O
ADAS	B-MED
-	O
cog	B-MED
)	O
,	O
Mini	B-MED
-	I-MED
Mental	I-MED
State	I-MED
Examination	I-MED
(	O
MMSE	B-MED
)	O
,	O
Montreal	B-MED
Cognitive	I-MED
Assessment	I-MED
(	O
MoCA	B-MED
)	O
,	O
and	O
World	B-MED
Health	I-MED
Organization	I-MED
University	I-MED
of	I-MED
California	I-MED
-	I-MED
Los	I-MED
Angeles	I-MED
,	I-MED
Auditory	I-MED
Verbal	I-MED
Learning	I-MED
Test	I-MED
(	O
WHO	B-MED
-	I-MED
UCLA	I-MED
AVLT	I-MED
)	O
before	O
,	O
immediately	O
after	O
,	O
and	O
6	O
weeks	B-MED
after	O
the	O
intervention	B-MED
.	O
In	O
this	O
work	O
,	O
data	B-MED
from	O
30	O
AD	B-MED
patients	B-MED
revealed	O
that	O
there	O
was	O
no	O
obvious	O
interaction	B-MED
effect	I-MED
of	O
time	O
-	O
by	O
-	O
group	O
.	O
The	O
ADAS	B-MED
-	O
cog	B-MED
,	O
MMSE	B-MED
and	O
WHO	B-MED
-	I-MED
UCLA	I-MED
AVLT	I-MED
score	B-MED
in	O
the	O
rTMS	B-MED
group	B-MED
was	O
significantly	O
improved	O
compared	B-MED
with	O
baselines	B-MED
at	O
6	O
weeks	B-MED
after	O
treatment	B-MED
(	O
all	O
p<0.05	O
)	O
.	O
Meanwhile	O
,	O
MoCA	B-MED
scores	B-MED
were	O
also	O
obviously	O
ameliorated	B-MED
in	O
the	O
mild	B-MED
AD	B-MED
patients	B-MED
with	O
rTMS	B-MED
.	O
Besides	O
,	O
subgroup	B-MED
analysis	I-MED
showed	O
that	O
the	O
effect	O
of	O
rTMS	B-MED
on	O
the	O
memory	B-MED
and	O
language	B-MED
of	O
mild	B-MED
AD	B-MED
patients	B-MED
was	O
superior	O
to	O
those	O
of	O
moderate	B-MED
AD	B-MED
patients	B-MED
.	O
In	O
conclusion	O
,	O
our	O
findings	B-MED
suggested	O
that	O
repetitive	B-MED
transcranial	I-MED
magnetic	I-MED
stimulation	I-MED
improves	O
cognitive	B-MED
function	I-MED
,	O
memory	B-MED
and	O
language	B-MED
level	B-MED
of	O
AD	B-MED
patients	B-MED
,	O
especially	O
in	O
the	O
mild	B-MED
stage	B-MED
of	O
AD	B-MED
.	O
Thus	O
,	O
rTMS	B-MED
can	O
be	O
recommended	O
as	O
a	O
promising	O
adjuvant	B-MED
therapy	I-MED
combined	O
with	O
cholinesterase	B-MED
inhibitors	I-MED
at	O
the	O
mild	B-MED
stage	B-MED
of	O
AD	B-MED
patients	B-MED
.	O
Emergency	B-MED
general	I-MED
surgery	I-MED
specific	B-MED
frailty	I-MED
index	I-MED
:	O
A	O
validation	B-MED
study	I-MED
Assessment	B-MED
of	O
operative	B-MED
risk	I-MED
in	O
geriatric	B-MED
patients	I-MED
undergoing	O
emergency	B-MED
general	I-MED
surgery	I-MED
(	O
EGS	B-MED
)	O
is	O
challenging	O
.	O
Frailty	B-MED
is	O
an	O
established	O
measure	B-MED
for	O
risk	B-MED
assessment	I-MED
in	O
surgical	B-MED
cases	I-MED
.	O
The	O
aim	O
of	O
our	O
study	B-MED
was	O
to	O
validate	B-MED
a	O
modified	O
15	O
variable	B-MED
emergency	B-MED
general	I-MED
surgery	I-MED
specific	I-MED
frailty	I-MED
index	I-MED
(	O
EGSFI	B-MED
)	O
.	O
We	O
prospectively	O
collected	B-MED
geriatric	B-MED
(	O
age	B-MED
>	I-MED
65	I-MED
)	O
emergency	B-MED
general	I-MED
surgery	I-MED
patients	B-MED
for	O
1-	O
year	B-MED
.	O
Post	B-MED
-	I-MED
operative	I-MED
complications	I-MED
were	O
collected	B-MED
.	O
Frailty	B-MED
Index	I-MED
was	O
calculated	B-MED
for	O
200	O
patients	B-MED
based	O
on	O
their	O
pre	B-MED
-	I-MED
admission	I-MED
condition	B-MED
using	O
50-	O
variable	B-MED
modified	O
Rockwood	B-MED
Frailty	I-MED
Index	I-MED
(	O
FI	B-MED
)	O
.	O
EGSFI	B-MED
was	O
developed	O
based	O
on	O
the	O
regression	B-MED
model	I-MED
for	O
complications	B-MED
and	O
the	O
most	O
significant	O
factors	O
in	O
the	O
FI	B-MED
.	O
ROC	B-MED
curve	I-MED
analysis	I-MED
was	O
performed	O
to	O
determine	O
cutoff	B-MED
for	O
frail	B-MED
status	B-MED
.	O
We	O
validated	B-MED
our	O
results	B-MED
using	O
60	O
patients	B-MED
for	O
predicting	B-MED
complications	B-MED
.	O
A	O
total	O
of	O
260	O
patients	B-MED
(	O
200	O
developing	O
,	O
60	O
Validation	B-MED
)	O
were	O
enrolled	B-MED
in	O
this	O
study	B-MED
.	O
Mean	B-MED
age	I-MED
was	O
71	O
±	O
11	O
years	B-MED
,	O
and	O
33	O
%	O
developed	O
complications	B-MED
.	O
Most	O
common	B-MED
complications	B-MED
were	O
pneumonia	B-MED
(	O
12	O
%	O
)	O
,	O
UTI	B-MED
(	O
9	O
%	O
)	O
,	O
and	O
wound	B-MED
infection	I-MED
(	O
7	O
%	O
)	O
.	O
Univariate	B-MED
analysis	I-MED
identified	O
15	O
variables	B-MED
significantly	O
associated	B-MED
with	I-MED
complications	B-MED
that	O
were	O
used	O
to	O
develop	O
the	O
EGSFI	B-MED
.	O
A	O
cutoff	B-MED
frailty	B-MED
score	I-MED
of	O
0.325	O
was	O
identified	O
using	O
ROC	B-MED
curve	I-MED
analysis	I-MED
for	O
frail	B-MED
status	B-MED
.Sixty-	O
patients	B-MED
(	O
frail	B-MED
:	O
18	O
,	O
non	B-MED
-	I-MED
frail	I-MED
:	O
42	O
)	O
were	O
enrolled	B-MED
in	O
the	O
validation	B-MED
cohort	B-MED
.	O
Frail	B-MED
patients	B-MED
were	O
more	O
likely	O
to	O
have	O
post	B-MED
-	I-MED
operative	I-MED
complications	I-MED
(	O
47	O
%	O
vs.	O
20	O
%	O
,	O
p	O
<	O
0.001	O
)	O
compared	O
to	O
nonfrail	B-MED
patients	I-MED
.	O
Frail	B-MED
status	B-MED
based	O
on	O
EGSFI	B-MED
was	O
a	O
significant	B-MED
predictor	I-MED
of	O
post	B-MED
-	I-MED
operative	I-MED
complications	I-MED
(	O
OR	B-MED
=	O
7.3	O
,	O
95	O
%	O
CI	B-MED
=	O
1.7	O
-	O
19.8	O
;	O
p=0.006	O
)	O
.	O
Age	B-MED
was	O
not	O
associated	B-MED
with	I-MED
postoperative	B-MED
complications	I-MED
(	O
OR	B-MED
=	O
0.99	O
,	O
95	O
%	O
CI	B-MED
=	O
0.92	O
-1.06	O
;	O
p=0.86	O
)	O
.	O
The	O
15-	O
variable	B-MED
validated	B-MED
EGSFI	B-MED
is	O
a	O
simple	O
and	O
reliable	O
bedside	B-MED
tool	I-MED
to	O
determine	O
the	O
frailty	B-MED
status	I-MED
of	O
patients	B-MED
undergoing	O
emergency	B-MED
general	I-MED
surgery	I-MED
.	O
Frail	B-MED
status	B-MED
as	O
determined	O
by	O
Abstract	O
the	O
EGSFI	B-MED
is	O
an	O
independent	B-MED
predictor	I-MED
of	O
post	B-MED
-	I-MED
operative	I-MED
complications	I-MED
and	O
mortality	B-MED
in	O
geriatric	B-MED
emergency	B-MED
general	I-MED
surgery	I-MED
patients	B-MED
.	O
Level	O
II	O
,	O
Prognostic	B-MED
Studies	I-MED
-	O
Investigating	B-MED
the	O
Effect	B-MED
of	O
a	O
Patient	B-MED
Characteristic	I-MED
on	O
the	O
Outcome	B-MED
of	I-MED
Disease	I-MED
.	O
Basic	B-MED
science	I-MED
and	O
pathogenesis	B-MED
of	O
ageing	B-MED
with	O
HIV	B-MED
:	O
potential	O
mechanisms	B-MED
and	O
biomarkers	B-MED
:	O
The	O
increased	O
prevalence	B-MED
of	O
age	B-MED
-related	O
comorbidities	B-MED
and	O
mortality	B-MED
is	O
worrisome	B-MED
in	O
ageing	B-MED
HIV	B-MED
-	I-MED
infected	I-MED
patients	B-MED
.	O
Here	O
,	O
we	O
aim	B-MED
to	O
analyse	B-MED
the	O
different	O
ageing	B-MED
mechanisms	B-MED
with	O
regard	O
to	O
HIV	B-MED
infection	I-MED
.	O
Ageing	B-MED
results	O
from	O
the	O
time	B-MED
-	O
dependent	B-MED
accumulation	B-MED
of	O
random	O
cellular	B-MED
damage	I-MED
.	O
Epigenetic	B-MED
modifications	I-MED
and	O
mitochondrial	B-MED
DNA	I-MED
haplogroups	B-MED
modulate	B-MED
ageing	B-MED
.	O
In	O
antiretroviral	B-MED
treatment	I-MED
-controlled	O
patients	B-MED
,	O
epigenetic	B-MED
clock	I-MED
appears	O
to	O
be	O
advanced	O
,	O
and	O
some	O
haplogroups	B-MED
are	O
associated	O
with	O
HIV	B-MED
infection	I-MED
severity	B-MED
.	O
Telomere	B-MED
shortening	I-MED
is	O
enhanced	O
in	O
HIV	B-MED
-	I-MED
infected	I-MED
patients	B-MED
because	O
of	O
HIV	B-MED
and	O
some	O
nucleoside	B-MED
analogue	I-MED
reverse	B-MED
transcriptase	I-MED
inhibitors	I-MED
.	O
Mitochondria	B-MED
-related	O
oxidative	B-MED
stress	I-MED
and	O
mitochondrial	B-MED
DNA	I-MED
mutations	B-MED
are	O
increased	O
during	O
ageing	B-MED
and	O
also	O
by	O
some	O
nucleoside	B-MED
analogue	I-MED
reverse	B-MED
transcriptase	I-MED
inhibitors	I-MED
.	O
Overall	O
,	O
increased	O
inflammation	B-MED
or	O
'	O
inflammageing	B-MED
'	O
is	O
a	O
major	O
driver	O
of	O
ageing	B-MED
and	O
could	O
result	O
from	O
cell	B-MED
senescence	I-MED
with	O
secreted	O
proinflammatory	B-MED
mediators	I-MED
,	O
altered	O
gut	B-MED
microbiota	I-MED
,	O
and	O
coinfections	B-MED
.	O
In	O
HIV	B-MED
-	I-MED
infected	I-MED
patients	B-MED
,	O
the	O
level	B-MED
of	O
inflammation	B-MED
and	O
innate	B-MED
immunity	I-MED
activation	B-MED
is	O
enhanced	O
and	O
related	O
to	O
most	O
comorbidities	B-MED
and	O
to	O
mortality	B-MED
.	O
This	O
status	O
could	O
result	O
,	O
in	O
addition	O
to	O
age	B-MED
,	O
from	O
the	O
virus	B-MED
itself	O
or	O
viral	B-MED
protein	I-MED
released	O
from	O
reservoirs	B-MED
,	O
from	O
HIV	B-MED
-enhanced	O
gut	B-MED
permeability	B-MED
and	O
dysbiosis	B-MED
,	O
from	O
antiretroviral	B-MED
treatment	I-MED
,	O
from	O
frequent	O
cytomegalovirus	B-MED
and	O
hepatitis	B-MED
C	I-MED
virus	I-MED
coinfections	B-MED
,	O
and	O
also	O
from	O
personal	O
and	O
environmental	B-MED
factors	I-MED
,	O
as	O
central	O
fat	B-MED
accumulation	I-MED
or	O
smoking	B-MED
.	O
Adaptive	B-MED
immune	I-MED
activation	B-MED
and	O
immunosenescence	B-MED
are	O
associated	O
with	O
comorbidities	B-MED
and	O
mortality	B-MED
in	O
the	O
general	B-MED
population	I-MED
but	O
are	O
less	O
predictive	B-MED
in	O
HIV	B-MED
-	I-MED
infected	I-MED
patients	B-MED
.	O
Biomarkers	B-MED
to	O
evaluate	B-MED
ageing	B-MED
in	O
HIV	B-MED
-	I-MED
infected	I-MED
patients	B-MED
are	O
required	O
.	O
Numerous	O
systemic	B-MED
or	O
cellular	B-MED
inflammatory	I-MED
,	O
immune	B-MED
activation	B-MED
,	O
oxidative	B-MED
stress	I-MED
,	O
or	O
senescence	O
markers	B-MED
can	O
be	O
tested	B-MED
in	O
serum	B-MED
or	O
peripheral	B-MED
blood	I-MED
mononuclear	I-MED
cells	I-MED
.	O
The	O
novel	O
European	B-MED
Study	B-MED
to	O
Establish	O
Biomarkers	B-MED
of	O
Human	B-MED
Ageing	I-MED
MARK	I-MED
-	I-MED
AGE	I-MED
algorithm	I-MED
,	O
evaluating	B-MED
the	O
biological	B-MED
age	B-MED
,	O
is	O
currently	O
assessed	O
in	O
HIV	B-MED
-	I-MED
infected	I-MED
patients	B-MED
and	O
reveals	O
an	O
advanced	O
biological	B-MED
age	B-MED
.	O
Some	O
enhanced	O
inflammatory	B-MED
or	O
innate	B-MED
immune	I-MED
activation	B-MED
markers	B-MED
are	O
interesting	O
but	O
still	O
not	O
validated	O
for	O
the	O
patient	B-MED
's	I-MED
follow	B-MED
-	I-MED
up	I-MED
.	O
To	O
be	O
able	O
to	O
assess	O
patients	B-MED
'	O
biological	B-MED
age	B-MED
is	O
an	O
important	O
objective	O
to	O
improve	O
their	O
healthspan	B-MED
.	O
Extended	B-MED
release	I-MED
of	O
flurbiprofen	B-MED
from	O
tromethamine	B-MED
-	O
buffered	B-MED
HPMC	B-MED
hydrophilic	B-MED
matrix	B-MED
tablets	I-MED
The	O
pH	B-MED
-	O
dependent	B-MED
solubility	B-MED
of	O
a	O
drug	B-MED
can	O
lead	O
to	O
pH	B-MED
-	O
dependent	B-MED
drug	B-MED
release	I-MED
from	O
hydrophilic	B-MED
matrix	B-MED
tablets	I-MED
.	O
Adding	O
buffer	B-MED
salts	I-MED
to	O
the	O
formulation	B-MED
to	O
attempt	B-MED
to	O
mitigate	B-MED
this	O
can	O
impair	B-MED
matrix	B-MED
hydration	I-MED
and	O
negatively	B-MED
impact	B-MED
drug	B-MED
release	I-MED
.	O
An	O
evaluation	B-MED
of	O
the	O
buffering	B-MED
of	O
hydrophilic	B-MED
matrix	B-MED
tablets	I-MED
containing	O
a	O
pH	B-MED
-	O
dependent	B-MED
solubility	B-MED
weak	B-MED
acid	I-MED
drug	I-MED
(	O
flurbiprofen	B-MED
)	O
,	O
identified	B-MED
as	O
possessing	B-MED
a	O
deleterious	B-MED
effect	I-MED
on	O
hydroxypropyl	B-MED
methylcellulose	I-MED
(	O
HPMC	B-MED
)	O
solubility	B-MED
,	O
swelling	B-MED
and	O
gelation	B-MED
,	O
with	O
respect	O
to	O
drug	B-MED
dissolution	I-MED
and	O
the	O
characteristics	B-MED
of	O
the	O
hydrophilic	B-MED
matrix	B-MED
gel	I-MED
layer	I-MED
in	O
the	O
presence	B-MED
of	O
tromethamine	B-MED
as	O
a	O
buffer	B-MED
was	O
undertaken	O
.	O
The	O
inclusion	B-MED
of	O
tromethamine	B-MED
as	O
an	O
alkalizing	B-MED
agent	I-MED
afforded	O
pH	B-MED
-	O
independent	B-MED
flurbiprofen	B-MED
release	B-MED
from	O
matrices	B-MED
based	O
on	O
both	O
HPMC	B-MED
2910	I-MED
(	I-MED
E	I-MED
series	I-MED
)	I-MED
and	O
2208	B-MED
(	I-MED
K	I-MED
series	I-MED
)	I-MED
,	O
while	O
concomitantly	B-MED
decreasing	B-MED
the	O
apparent	O
critical	B-MED
effect	I-MED
on	O
dissolution	B-MED
mediated	B-MED
by	O
this	O
drug	B-MED
with	O
respect	O
to	O
the	O
early	O
pseudo	B-MED
-	I-MED
gel	I-MED
layer	I-MED
formation	I-MED
and	O
functionality	B-MED
.	O
Drug	B-MED
release	I-MED
profiles	I-MED
were	O
unaffected	B-MED
by	O
matrix	B-MED
pH	B-MED
-	I-MED
changes	I-MED
resulting	O
from	O
loss	B-MED
of	O
tromethamine	B-MED
over	B-MED
time	I-MED
,	O
suggesting	O
that	O
HPMC	B-MED
inhibited	B-MED
precipitation	B-MED
of	O
drug	B-MED
from	O
supersaturated	B-MED
solution	I-MED
in	O
the	O
hydrated	B-MED
matrix	I-MED
.	O
We	O
propose	O
that	O
facilitation	B-MED
of	O
diffusion	B-MED
-	I-MED
based	I-MED
release	B-MED
of	O
potentially	O
deleterious	B-MED
drugs	I-MED
in	O
hydrophilic	B-MED
matrices	B-MED
may	O
be	O
achieved	O
through	O
judicious	O
selection	O
of	O
a	O
buffering	B-MED
species	I-MED
.	O
Custom	O
ocular	B-MED
prosthesis	I-MED
in	O
rehabilitation	B-MED
of	O
a	O
child	B-MED
operated	O
for	O
retinoblastoma	B-MED
A	O
maxillofacial	B-MED
prosthodontist	I-MED
forms	O
an	O
important	B-MED
link	O
in	O
the	O
interdisciplinary	O
management	B-MED
of	I-MED
a	I-MED
patient	I-MED
with	O
anopthalmosis	B-MED
.	O
Prosthetic	B-MED
management	I-MED
of	O
an	O
anopthalmic	B-MED
defect	I-MED
aims	O
to	O
deliver	O
a	O
well	O
-	O
fitting	O
ocular	B-MED
prosthesis	I-MED
that	O
can	O
mimic	O
the	O
original	O
eye	B-MED
as	O
closely	O
as	O
possible	O
,	O
and	O
thus	O
restoring	O
the	O
patient	B-MED
's	I-MED
self	B-MED
-	I-MED
confidence	I-MED
and	O
thereby	O
rehabilitating	B-MED
them	O
in	O
the	O
society	B-MED
.	O
The	O
fabrication	B-MED
of	O
a	O
custom	O
ocular	B-MED
prosthesis	I-MED
is	O
a	O
demanding	O
art	O
.	O
This	O
case	B-MED
report	I-MED
presents	O
a	O
simplified	O
technique	B-MED
for	O
the	O
fabrication	B-MED
of	O
a	O
custom	O
ocular	B-MED
prosthesis	I-MED
for	O
a	O
child	B-MED
who	O
had	O
lost	B-MED
his	O
eye	B-MED
to	O
enucleation	B-MED
following	O
retinoblastoma	B-MED
.	O
Early	O
and	O
effective	O
rehabilitation	B-MED
of	O
the	O
defect	O
goes	O
a	O
long	O
way	O
in	O
restoring	O
the	O
self	B-MED
-	I-MED
image	I-MED
of	O
a	O
child	B-MED
in	O
its	O
early	O
character	O
building	O
age	O
.	O
Defining	O
categories	B-MED
of	O
actionability	B-MED
for	O
secondary	B-MED
findings	B-MED
in	O
next	B-MED
-	I-MED
generation	I-MED
sequencing	I-MED
Next	B-MED
-	I-MED
generation	I-MED
sequencing	I-MED
is	O
increasingly	O
used	O
in	O
clinical	B-MED
practice	I-MED
for	O
the	O
diagnosis	B-MED
of	O
Mendelian	B-MED
diseases	I-MED
.	O
Because	O
of	O
the	O
high	O
likelihood	O
of	O
secondary	B-MED
findings	B-MED
associated	O
with	O
this	O
technique	B-MED
,	O
the	O
process	O
of	O
informing	B-MED
patients	I-MED
is	O
beset	O
with	O
new	O
challenges	O
.	O
One	O
of	O
them	O
is	O
regarding	O
the	O
type	O
of	O
secondary	B-MED
findings	B-MED
that	O
ought	O
to	O
be	O
disclosed	O
to	O
patients	B-MED
.	O
The	O
aim	O
of	O
this	O
research	B-MED
is	O
to	O
propose	O
a	O
practical	O
implementation	B-MED
of	O
the	O
notion	O
of	O
actionability	B-MED
,	O
a	O
common	O
criteria	O
justifying	O
the	O
disclosure	B-MED
of	O
secondary	B-MED
findings	B-MED
but	O
whose	O
interpretation	B-MED
varies	O
greatly	O
among	O
professionals	B-MED
.	O
We	O
distinguish	O
three	O
types	O
of	O
actionability	B-MED
corresponding	O
to	O
(	O
1	O
)	O
well	O
-	O
established	O
medical	B-MED
actions	B-MED
,	O
(	O
2	O
)	O
patient	B-MED
-initiated	O
health	B-MED
-	I-MED
related	I-MED
actions	I-MED
and	O
(	O
3	O
)	O
life	B-MED
-	I-MED
plan	I-MED
decisions	I-MED
.	O
We	O
argue	O
that	O
actionability	B-MED
depends	O
on	O
the	O
characteristics	O
of	O
the	O
mutation	B-MED
or	O
gene	B-MED
and	O
on	O
the	O
values	O
of	O
patients	B-MED
.	O
In	O
discussing	O
the	O
return	O
of	O
secondary	B-MED
findings	B-MED
,	O
it	O
is	O
important	O
that	O
the	O
physician	B-MED
tries	O
to	O
get	O
an	O
impression	B-MED
of	O
the	O
specific	O
situation	O
and	O
values	O
of	O
patients	B-MED
.	O
Regarding	O
variants	B-MED
of	O
uncertain	O
clinical	B-MED
significance	I-MED
in	O
actionable	O
genes	B-MED
,	O
we	O
found	O
that	O
different	O
understandings	O
of	O
autonomy	B-MED
lead	O
to	O
different	O
conclusions	B-MED
and	O
that	O
,	O
for	O
some	O
of	O
them	O
,	O
it	O
may	O
be	O
legitimate	O
to	O
refrain	O
from	O
returning	O
uncertain	O
information	B-MED
.	O
Mapping	B-MED
circulating	B-MED
serum	B-MED
miRNAs	B-MED
to	O
their	O
immune	B-MED
-	O
related	B-MED
target	B-MED
mRNAs	B-MED
Evidence	B-MED
suggests	B-MED
that	O
circulating	B-MED
serum	B-MED
microRNAs	B-MED
(	O
miRNAs	B-MED
)	O
might	O
preferentially	O
target	B-MED
immune	B-MED
-	O
related	B-MED
mRNAs	B-MED
.	O
If	O
this	O
were	O
the	O
case	O
,	O
we	O
hypothesized	O
that	O
immune	B-MED
-	O
related	B-MED
mRNAs	B-MED
would	O
have	O
more	O
predicted	B-MED
serum	B-MED
miRNA	B-MED
binding	I-MED
sites	B-MED
than	O
other	O
mRNAs	B-MED
and	O
,	O
reciprocally	B-MED
,	O
that	O
serum	B-MED
miRNAs	B-MED
would	O
have	O
more	O
immune	B-MED
-	O
related	B-MED
mRNA	B-MED
targets	B-MED
than	O
non	B-MED
-	O
serum	B-MED
miRNAs	B-MED
.	O
We	O
developed	B-MED
a	O
consensus	O
target	B-MED
predictor	O
using	O
the	O
random	B-MED
forest	I-MED
framework	I-MED
and	O
calculated	B-MED
the	O
number	O
of	O
predicted	B-MED
miRNA	B-MED
-	O
mRNA	B-MED
interactions	B-MED
in	O
various	O
subsets	B-MED
of	O
miRNAs	B-MED
(	O
serum	B-MED
,	O
non	B-MED
-	O
serum	B-MED
)	O
and	O
mRNAs	B-MED
(	O
immune	B-MED
related	B-MED
,	O
nonimmune	B-MED
related	I-MED
)	O
.	O
Immune	B-MED
-	O
related	B-MED
mRNAs	B-MED
were	O
predicted	B-MED
to	O
be	O
targeted	B-MED
by	O
serum	B-MED
miRNA	B-MED
more	O
than	O
other	O
mRNAs	B-MED
.	O
Moreover	O
,	O
serum	B-MED
miRNAs	B-MED
were	O
predicted	B-MED
to	O
target	B-MED
many	O
more	O
immune	B-MED
-	O
related	B-MED
mRNA	B-MED
targets	B-MED
than	O
non	B-MED
-	O
serum	B-MED
miRNAs	B-MED
;	O
however	O
,	O
these	O
two	O
biases	B-MED
in	O
immune	B-MED
-	O
related	B-MED
mRNAs	B-MED
and	O
serum	B-MED
miRNAs	B-MED
appear	O
to	O
be	O
completely	B-MED
independent	B-MED
.	O
Immune	B-MED
-	O
related	B-MED
mRNAs	B-MED
have	O
more	O
miRNA	B-MED
binding	I-MED
sites	B-MED
in	O
general	O
,	O
not	O
just	O
for	O
serum	B-MED
miRNAs	B-MED
;	O
likewise	O
,	O
serum	B-MED
miRNAs	B-MED
target	B-MED
many	O
more	O
mRNAs	B-MED
than	O
non	B-MED
-	O
serum	B-MED
miRNAs	B-MED
overall	O
,	O
regardless	B-MED
of	O
whether	O
they	O
are	O
immune	B-MED
related	B-MED
or	O
not	O
.	O
Nevertheless	O
,	O
these	O
two	O
independent	B-MED
phenomena	B-MED
result	B-MED
in	O
a	O
significantly	O
larger	O
number	O
of	O
predicted	B-MED
serum	B-MED
miRNA	B-MED
-	O
immune	B-MED
mRNA	B-MED
interactions	B-MED
than	O
would	O
be	O
expected	O
by	O
chance	O
.	O
Outcomes	B-MED
of	O
chest	B-MED
wall	I-MED
resections	I-MED
in	O
pediatric	B-MED
sarcoma	B-MED
patients	B-MED
Chest	B-MED
wall	I-MED
tumors	I-MED
in	O
pediatric	B-MED
patients	B-MED
are	O
rare	O
.	O
This	O
study	B-MED
evaluates	O
outcomes	B-MED
in	O
pediatric	B-MED
patients	B-MED
who	O
have	O
undergone	O
chest	B-MED
wall	I-MED
resections	I-MED
secondary	O
to	O
sarcomas	B-MED
.	O
A	O
retrospective	B-MED
review	I-MED
was	O
performed	O
for	O
patients	B-MED
<	O
19years	O
old	O
who	O
underwent	O
chest	B-MED
wall	I-MED
resections	I-MED
for	O
sarcoma	B-MED
1999	O
-	O
2014	O
at	O
the	O
University	B-MED
of	I-MED
Texas	I-MED
MD	I-MED
Anderson	I-MED
Cancer	I-MED
Center	I-MED
.	O
Of	O
44	O
patients	B-MED
,	O
Ewing	B-MED
's	I-MED
sarcoma	I-MED
(	O
n=18	O
)	O
and	O
osteosarcoma	B-MED
(	O
n=16	O
)	O
were	O
most	O
common	O
.	O
Other	O
sarcomas	B-MED
included	O
synovial	B-MED
sarcoma	I-MED
,	O
chondrosarcoma	B-MED
,	O
and	O
rhabdomyosarcoma	B-MED
.	O
Gore	B-MED
-	I-MED
Tex	I-MED
®	O
or	O
a	O
Marlex	B-MED
™	I-MED
mesh	I-MED
and	O
methyl	B-MED
methacrylate	I-MED
sandwich	I-MED
was	O
used	O
in	O
22	O
patients	B-MED
,	O
and	O
9	O
children	B-MED
did	O
not	B-MED
require	I-MED
reconstruction	I-MED
.	O
Twenty	O
-	O
four	O
(	O
54.5	O
%	O
)	O
patients	B-MED
had	O
normal	B-MED
activity	B-MED
,	O
3	O
(	O
6.8	O
%	O
)	O
had	O
occasional	B-MED
discomfort	I-MED
,	O
2	O
(	O
4.5	O
%	O
)	O
had	O
pain	B-MED
impairing	I-MED
function	I-MED
,	O
7	O
(	O
15.9	O
%	O
)	O
required	O
medication	B-MED
or	O
physical	B-MED
therapy	I-MED
for	O
impairment	B-MED
,	O
and	O
8	O
(	O
18.2	O
%	O
)	O
needed	O
additional	O
surgery	B-MED
.	O
Five	O
children	B-MED
(	O
11.4	O
%	O
)	O
developed	O
scoliosis	B-MED
,	O
and	O
all	O
of	O
these	O
patients	B-MED
had	O
posterior	B-MED
rib	B-MED
tumors	I-MED
.	O
Median	B-MED
overall	I-MED
survival	I-MED
for	O
the	O
entire	B-MED
cohort	I-MED
was	O
41.9±11.82	O
months	B-MED
.	O
Histology	B-MED
(	O
p=0.003	O
)	O
,	O
location	B-MED
of	O
tumor	B-MED
on	O
the	O
ribs	B-MED
(	O
p=0.007	O
)	O
,	O
and	O
surgical	B-MED
margins	I-MED
(	O
p=0.011	O
)	O
were	O
significantly	B-MED
associated	I-MED
with	I-MED
overall	B-MED
survival	I-MED
.	O
Tumors	B-MED
on	O
the	O
middle	O
and	O
posterior	B-MED
(	O
p=0.003	O
)	O
portions	O
of	O
the	O
ribs	B-MED
had	O
a	O
lower	O
chance	O
of	O
death	B-MED
.	O
Scoliosis	B-MED
is	O
more	O
common	O
in	O
posterior	B-MED
rib	B-MED
resections	I-MED
.	O
Histology	B-MED
,	O
location	B-MED
of	O
the	O
tumor	B-MED
,	O
and	O
surgical	B-MED
margins	I-MED
impact	O
survival	B-MED
,	O
but	O
,	O
type	O
of	O
reconstruction	O
does	O
not	O
.	O
III	O
.	O
Treatment	B-MED
Study	I-MED
.	O
Nationwide	B-MED
reduction	B-MED
in	O
the	O
number	O
of	O
corneal	B-MED
transplantations	I-MED
for	O
keratoconus	B-MED
following	O
the	O
implementation	B-MED
of	O
cross	B-MED
-	I-MED
linking	I-MED
Keratoconus	B-MED
is	O
characterized	O
by	O
corneal	B-MED
ectasia	I-MED
and	O
irregular	B-MED
astigmatism	I-MED
,	O
which	O
can	O
lead	O
to	O
diminished	B-MED
vision	I-MED
and	O
corneal	B-MED
scarring	I-MED
.	O
Approximately	O
10	O
-	O
20	O
%	O
of	O
patients	B-MED
with	O
keratoconus	B-MED
eventually	O
require	O
a	O
corneal	B-MED
transplant	I-MED
.	O
Corneal	B-MED
cross	I-MED
-	I-MED
linking	I-MED
(	O
CXL	B-MED
)	O
is	O
a	O
relatively	O
new	O
treatment	B-MED
that	O
may	O
help	O
prevent	O
the	O
need	O
for	O
corneal	B-MED
transplantation	I-MED
.	O
Here	O
,	O
we	O
investigated	B-MED
whether	O
the	O
introduction	B-MED
of	O
CXL	B-MED
has	O
reduced	O
the	O
number	O
of	O
corneal	B-MED
transplants	I-MED
performed	B-MED
annually	B-MED
.	O
Data	B-MED
regarding	O
the	O
transplantation	B-MED
procedures	I-MED
performed	B-MED
in	O
patients	B-MED
under	O
the	O
age	B-MED
of	O
50	O
years	B-MED
were	O
extracted	O
from	O
the	O
Dutch	B-MED
National	I-MED
Organ	I-MED
Transplant	I-MED
Registry	I-MED
.	O
The	O
number	O
of	O
corneal	B-MED
transplants	I-MED
performed	B-MED
prior	O
to	O
(	O
i.e.	O
in	O
2005	O
through	O
2007	O
)	O
and	O
following	O
the	O
introduction	B-MED
of	O
CXL	B-MED
(	O
i.e.	O
in	O
2012	O
through	O
2014	O
)	O
were	O
compared	B-MED
.	O
Furthermore	O
,	O
a	O
trend	B-MED
analysis	I-MED
on	O
annual	B-MED
keratoplasties	B-MED
over	O
time	O
was	O
performed	B-MED
.	O
Approximately	O
25	O
%	O
fewer	O
corneal	B-MED
transplants	I-MED
were	O
performed	B-MED
in	O
the	O
3-	O
year	B-MED
period	O
following	O
the	O
introduction	B-MED
of	O
CXL	B-MED
compared	B-MED
to	O
the	O
3-	O
year	B-MED
period	O
prior	O
to	O
the	O
introduction	B-MED
of	O
CXL	B-MED
(	O
201	O
versus	O
269	O
transplants	B-MED
,	O
respectively	O
;	O
p	O
=	O
0.005	O
)	O
.	O
Age	B-MED
,	O
gender	B-MED
and	O
visual	B-MED
acuity	I-MED
were	O
similar	O
between	O
the	O
patient	B-MED
groups	O
in	O
the	O
two	O
time	B-MED
periods	I-MED
.	O
Trend	B-MED
analysis	I-MED
also	O
demonstrated	O
a	O
significant	O
decrease	B-MED
in	O
the	O
amount	O
of	O
corneal	B-MED
transplants	I-MED
(	O
p	O
=	O
0.001	O
)	O
.	O
Significantly	O
fewer	O
corneal	B-MED
transplants	I-MED
were	O
performed	O
for	O
treating	O
keratoconus	B-MED
following	O
the	O
nationwide	B-MED
introduction	B-MED
of	O
CXL	B-MED
.	O
This	O
reduction	B-MED
suggests	O
that	O
corneal	B-MED
cross	I-MED
-	I-MED
linking	I-MED
can	O
significantly	O
reduce	B-MED
the	O
need	O
for	O
corneal	B-MED
transplantation	I-MED
.	O
First	B-MED
and	O
second	B-MED
generation	B-MED
DESs	B-MED
reduce	B-MED
diabetes	B-MED
adverse	B-MED
effect	I-MED
on	O
mortality	B-MED
and	O
re	B-MED
-	I-MED
intervention	I-MED
in	O
multivessel	B-MED
coronary	B-MED
disease	I-MED
:	O
9-	O
Year	B-MED
analysis	B-MED
Diabetes	B-MED
portends	B-MED
an	O
increased	B-MED
risk	B-MED
of	O
adverse	B-MED
early	B-MED
and	O
late	B-MED
outcomes	B-MED
in	O
patients	B-MED
undergoing	O
PCI	B-MED
.	O
In	O
this	O
study	B-MED
,	O
we	O
aimed	O
to	O
investigate	B-MED
if	O
the	O
adverse	B-MED
effect	I-MED
of	O
diabetes	B-MED
mellitus	I-MED
(	O
DM	B-MED
)	O
on	O
early	B-MED
and	O
late	B-MED
PCI	B-MED
outcomes	B-MED
is	O
reduced	B-MED
with	O
drug	B-MED
-	I-MED
eluting	I-MED
(	O
DES	B-MED
)	O
compared	O
to	O
bare	B-MED
-	I-MED
metal	I-MED
(	I-MED
BMS	I-MED
)	I-MED
stents	I-MED
.	O
We	O
reviewed	B-MED
the	O
Mount	B-MED
Sinai	I-MED
Beth	I-MED
Israel	I-MED
Hospital	I-MED
first	B-MED
PCI	B-MED
experience	O
for	O
multivessel	B-MED
coronary	B-MED
artery	I-MED
disease	I-MED
(	O
CAD	B-MED
,	O
1998	O
-	O
2009	O
)	O
.	O
Patients	B-MED
were	O
excluded	B-MED
if	O
they	O
had	O
single	B-MED
-	I-MED
vessel	I-MED
CAD	I-MED
,	O
emergency	B-MED
,	O
no	B-MED
stent	B-MED
,	O
prior	B-MED
bypass	B-MED
graft	I-MED
or	O
myocardial	B-MED
infarction	I-MED
<	O
24h	O
.	O
Diabetes	B-MED
-	O
effect	B-MED
was	O
derived	O
from	O
9-	O
year	B-MED
all	O
-	O
cause	O
mortality	B-MED
and	O
re	B-MED
-	I-MED
intervention	I-MED
risk	B-MED
-	I-MED
adjusted	I-MED
hazard	I-MED
ratios	I-MED
[	O
AHR	B-MED
(	O
95	O
%	O
confidence	B-MED
intervals	I-MED
)	O
]	O
for	O
DES	B-MED
(	O
N=2679	O
;	O
48	O
%	O
three	B-MED
-	I-MED
vessel	I-MED
;	O
39	O
%	O
DM	B-MED
)	O
and	O
BMS	B-MED
(	O
N=2651	O
;	O
40	O
%	O
three	B-MED
-	I-MED
vessel	I-MED
;	O
33	O
%	O
DM	B-MED
)	O
and	O
then	O
stratified	O
based	O
on	O
stent	B-MED
(	O
DES	B-MED
/	O
BMS	B-MED
)	O
and	O
vessel	B-MED
disease	I-MED
(	O
two	B-MED
/	O
three	B-MED
)	O
.	O
Diabetes	B-MED
-	O
effect	B-MED
on	O
mortality	B-MED
was	O
lower	B-MED
for	O
DES	B-MED
(	O
AHRDM	B-MED
/	I-MED
NoDM	I-MED
=	O
1.41	O
[	O
1.14	O
-	O
1.74	O
]	O
)	O
versus	O
BMS	B-MED
(	O
AHRDM	B-MED
/	I-MED
NoDM	I-MED
=	O
1.71	O
[	O
1.50	O
-	O
2.01	O
]	O
)	O
,	O
but	O
this	O
was	O
predominantly	B-MED
driven	O
by	O
two	B-MED
-	I-MED
vessel	I-MED
patients	B-MED
.	O
This	O
diabetes	B-MED
effect	B-MED
was	O
similar	O
for	O
first	B-MED
(	O
DES1	B-MED
:	O
AHRDM	B-MED
/	I-MED
NoDM	I-MED
=	O
1.43	O
[	O
1.14	O
-	O
1.79	O
]	O
)	O
and	O
second	B-MED
(	O
DES2	B-MED
:	O
AHRDM	B-MED
/	I-MED
NoDM	I-MED
=	O
1.53	O
[	O
0.77	O
-	O
3.07	O
]	O
)	O
generation	B-MED
DES	B-MED
.	O
Re	B-MED
-	I-MED
intervention	I-MED
comparisons	B-MED
were	O
similarly	O
increased	B-MED
by	O
diabetes	B-MED
in	O
all	O
sub	B-MED
-	I-MED
cohorts	I-MED
.	O
Our	O
analysis	B-MED
of	O
a	O
large	O
real	O
-	O
world	O
PCI	B-MED
series	O
indicates	O
that	O
diabetes	B-MED
is	O
associated	B-MED
with	I-MED
worse	B-MED
9-	O
year	B-MED
mortality	B-MED
irrespective	B-MED
of	O
stent	B-MED
type	B-MED
,	O
albeit	O
this	O
is	O
mitigated	O
to	O
varying	O
degrees	O
with	O
DES	B-MED
,	O
particularly	O
in	O
DES2	B-MED
and	O
in	O
case	O
of	O
2	B-MED
-	I-MED
vessel	I-MED
disease	I-MED
.	O
A	O
complementary	B-MED
stent	B-MED
-	O
effect	B-MED
analysis	B-MED
confirmed	B-MED
DES	B-MED
-to-	O
BMS	B-MED
and	O
DES2	B-MED
-to-	O
DES1	B-MED
superiority	B-MED
in	O
both	O
diabetics	B-MED
and	O
non	B-MED
-	I-MED
diabetics	I-MED
.	O
Molar	B-MED
loss	I-MED
and	O
powder	B-MED
diet	I-MED
leads	O
to	O
memory	B-MED
deficit	I-MED
and	O
modifies	O
the	O
mRNA	B-MED
expression	I-MED
of	O
brain	B-MED
-	I-MED
derived	I-MED
neurotrophic	I-MED
factor	I-MED
in	O
the	O
hippocampus	B-MED
of	O
adult	B-MED
mice	B-MED
It	O
is	O
known	O
that	O
tooth	B-MED
loss	I-MED
is	O
known	O
to	O
be	O
a	O
risk	B-MED
factor	I-MED
for	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
and	O
soft	B-MED
diet	I-MED
feeding	B-MED
induces	O
memory	B-MED
impairment	I-MED
.	O
Recent	O
studies	O
have	O
shown	O
that	O
brain	B-MED
-	I-MED
derived	I-MED
neurotrophic	I-MED
factor	I-MED
(	O
BDNF	B-MED
)	O
is	O
associated	B-MED
with	I-MED
tooth	B-MED
loss	I-MED
or	O
soft	B-MED
diet	I-MED
in	O
young	O
animal	B-MED
model	I-MED
,	O
and	O
that	O
BDNF	B-MED
expression	B-MED
is	O
decreased	O
in	O
patients	B-MED
with	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
.	O
However	O
,	O
single	O
or	O
combined	O
effect	B-MED
of	I-MED
tooth	B-MED
loss	I-MED
and/or	O
soft	B-MED
diet	I-MED
on	O
brain	B-MED
function	I-MED
has	O
not	O
fully	O
understood	O
.	O
Here	O
we	O
examined	O
the	O
effect	B-MED
of	I-MED
molar	B-MED
loss	I-MED
and	O
powder	B-MED
diet	I-MED
on	O
memory	B-MED
ability	I-MED
and	O
the	O
expression	B-MED
of	O
BDNF	B-MED
mRNA	I-MED
in	O
the	O
hippocampus	B-MED
of	O
adult	B-MED
C57BL/6J	B-MED
mice	I-MED
.	O
Twenty	O
eight	O
-	O
weeks	O
-	O
old	O
C57BL/6J	B-MED
mice	I-MED
were	O
divided	O
into	O
intact	O
molar	O
group	O
and	O
extracted	O
molar	O
group	O
.	O
They	O
were	O
randomly	B-MED
divided	O
into	O
the	O
I	O
/	O
S	O
group	O
(	O
Intact	O
upper	B-MED
molar	I-MED
teeth	I-MED
/	O
Solid	B-MED
diet	I-MED
feeding	B-MED
)	O
,	O
the	O
E	O
/	O
S	O
group	O
(	O
Extracted	B-MED
upper	B-MED
molar	I-MED
teeth	I-MED
/	O
Solid	B-MED
diet	I-MED
feeding	B-MED
)	O
,	O
the	O
I	O
/	O
P	O
group	O
(	O
Intact	O
upper	B-MED
molar	I-MED
teeth	I-MED
/	O
Powder	B-MED
diet	I-MED
feeding	B-MED
)	O
,	O
and	O
the	O
E	O
/	O
P	O
group	O
(	O
Extracted	O
upper	B-MED
molar	I-MED
teeth	I-MED
/	O
Powder	B-MED
diet	I-MED
feeding	B-MED
)	O
.	O
The	O
observation	O
periods	O
were	O
4	O
and	O
16	O
-	O
week	O
.	O
To	O
analyze	B-MED
the	O
memory	B-MED
ability	I-MED
,	O
the	O
step	O
-	O
through	O
passive	B-MED
avoidance	I-MED
test	O
was	O
conducted	O
.	O
BDNF	B-MED
-	I-MED
related	I-MED
mRNA	I-MED
in	O
the	O
hippocampus	B-MED
was	O
analyzed	B-MED
by	O
real	B-MED
-	I-MED
time	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
(	O
RT	B-MED
-	I-MED
PCR	I-MED
)	O
.	O
At	O
4	O
weeks	O
later	O
,	O
we	O
performed	O
memory	B-MED
test	I-MED
and	O
isolated	O
brains	B-MED
to	O
analyze	B-MED
.	O
There	O
were	O
no	B-MED
differences	I-MED
in	O
memory	B-MED
function	I-MED
and	O
BDNF	B-MED
mRNA	I-MED
level	O
between	O
these	O
four	O
groups	O
.	O
However	O
,	O
at	O
16	O
weeks	O
later	O
,	O
E	O
/	O
S	O
and	O
E	O
/	O
P	O
group	O
showed	O
memory	B-MED
impairment	I-MED
,	O
and	O
decreased	O
level	O
of	O
BDNF	B-MED
mRNA	I-MED
.	O
Whereas	O
,	O
the	O
powder	B-MED
diet	I-MED
had	O
no	B-MED
effect	I-MED
on	O
memory	B-MED
function	I-MED
and	O
BDNF	B-MED
mRNA	I-MED
level	O
even	O
at	O
16	O
weeks	O
later	O
.	O
These	O
results	O
suggest	O
that	O
the	O
effect	B-MED
of	I-MED
molar	B-MED
loss	I-MED
and	O
powder	B-MED
diet	I-MED
on	O
memory	B-MED
function	I-MED
and	O
BDNF	B-MED
mRNA	I-MED
levels	O
were	O
different	O
,	O
molar	B-MED
loss	I-MED
may	O
have	O
a	O
greater	O
long	B-MED
-	I-MED
term	I-MED
effect	I-MED
on	O
memory	B-MED
ability	I-MED
than	O
powder	B-MED
diet	I-MED
does	O
.	O
Associations	O
of	O
NEUROD2	B-MED
polymorphisms	B-MED
and	O
change	B-MED
of	O
cognitive	B-MED
dysfunctions	I-MED
in	O
schizophrenia	B-MED
and	O
schizoaffective	B-MED
disorder	I-MED
after	O
eight	O
weeks	B-MED
of	O
antipsychotic	B-MED
treatment	B-MED
NEUROD2	B-MED
is	O
a	O
neurospecific	B-MED
helix	I-MED
-	I-MED
loop	I-MED
-	I-MED
helix	I-MED
transcription	B-MED
factor	I-MED
which	O
has	O
an	O
impact	B-MED
on	O
the	O
regulation	B-MED
of	O
glutamatergic	B-MED
and	O
GABAergic	B-MED
genes	B-MED
.	O
We	O
investigated	B-MED
an	O
association	O
of	O
NEUROD2	B-MED
with	O
neurocognitive	B-MED
dysfunctions	I-MED
in	O
schizophrenia	B-MED
and	O
schizoaffective	B-MED
disorder	I-MED
patients	B-MED
before	O
and	O
during	O
treatment	B-MED
with	O
different	O
second	B-MED
-	I-MED
generation	I-MED
antipsychotics	I-MED
.	O
Patients	B-MED
were	O
genotyped	B-MED
for	O
four	O
different	O
polymorphisms	B-MED
of	O
the	O
NEUROD2	B-MED
gene	B-MED
(	O
(	O
rs9889354(A	B-MED
/	I-MED
G	I-MED
)	O
,	O
rs1877032(C	B-MED
/	I-MED
T	I-MED
)	I-MED
,	O
rs12453682(C	B-MED
/	I-MED
T	I-MED
)	I-MED
and	O
rs11078918(C	B-MED
/	I-MED
G	I-MED
)	I-MED
)	O
.	O
Cognitive	B-MED
function	I-MED
was	O
assessed	B-MED
at	O
baseline	B-MED
and	O
week	B-MED
8	O
.	O
Results	B-MED
of	O
individual	O
neuropsychological	B-MED
tests	I-MED
were	O
assigned	O
to	O
six	O
cognitive	B-MED
domains	I-MED
(	B-MED
reaction	I-MED
time	I-MED
and	O
quality	B-MED
;	O
executive	B-MED
function	I-MED
;	O
working	B-MED
,	O
verbal	B-MED
and	O
visual	B-MED
memory	I-MED
)	O
and	O
a	O
general	O
cognitive	B-MED
index	B-MED
.	O
167	O
patients	B-MED
were	O
included	O
in	O
the	O
study	B-MED
.	O
The	O
NEUROD2	B-MED
exonic	B-MED
polymorphism	I-MED
rs11078918	I-MED
showed	O
significant	O
associations	O
with	O
verbal	B-MED
memory	I-MED
and	O
executive	B-MED
functions	I-MED
,	O
whereas	O
the	O
NEUROD2	B-MED
polymorphism	B-MED
rs12453682	I-MED
was	O
significantly	O
associated	O
with	O
working	B-MED
and	O
verbal	B-MED
memory	I-MED
,	O
executive	B-MED
functions	I-MED
and	O
with	O
a	O
cognitive	B-MED
index	B-MED
.	O
Significant	O
associations	O
were	O
found	O
at	O
baseline	B-MED
and	O
after	O
eight	O
weeks	B-MED
.	O
Moreover	O
,	O
significant	O
associations	O
between	O
the	O
change	B-MED
in	O
neuropsychological	B-MED
test	I-MED
results	B-MED
during	O
antipsychotic	B-MED
treatment	B-MED
and	O
the	O
NEUROD2	B-MED
polymorphisms	B-MED
rs11078918	B-MED
and	O
rs12453682	B-MED
were	O
observed	O
.	O
Our	O
findings	O
suggest	O
that	O
the	O
NEUROD2	B-MED
gene	I-MED
could	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	B-MED
of	O
neurocognitive	B-MED
dysfunctions	I-MED
as	O
well	O
as	O
in	O
the	O
change	B-MED
of	O
cognitive	B-MED
symptoms	I-MED
under	O
antipsychotic	B-MED
treatment	B-MED
in	O
schizophrenia	B-MED
and	O
schizoaffective	B-MED
disorder	I-MED
.	O
It	O
takes	O
biking	O
to	O
learn	B-MED
:	O
Physical	B-MED
activity	I-MED
improves	B-MED
learning	B-MED
a	O
second	B-MED
language	I-MED
Recent	O
studies	B-MED
have	O
shown	O
that	O
concurrent	B-MED
physical	B-MED
activity	I-MED
enhances	B-MED
learning	B-MED
a	O
completely	O
unfamiliar	O
L2	B-MED
vocabulary	B-MED
as	O
compared	O
to	O
learning	B-MED
it	O
in	O
a	O
static	B-MED
condition	B-MED
.	O
In	O
this	O
paper	O
we	O
report	O
a	O
study	B-MED
whose	O
aim	O
is	O
twofold	O
:	O
to	O
test	O
for	O
possible	B-MED
positive	B-MED
effects	B-MED
of	I-MED
physical	B-MED
activity	I-MED
when	O
L2	B-MED
learning	B-MED
has	O
already	O
reached	O
some	O
level	B-MED
of	O
proficiency	B-MED
,	O
and	O
to	O
test	O
whether	O
the	O
assumed	O
better	B-MED
performance	B-MED
when	O
engaged	O
in	O
physical	B-MED
activity	I-MED
is	O
limited	O
to	O
the	O
linguistic	B-MED
level	B-MED
probed	O
at	O
training	B-MED
(	O
i.e.	O
L2	B-MED
vocabulary	B-MED
tested	B-MED
by	O
means	O
of	O
a	O
Word	B-MED
-	I-MED
Picture	I-MED
Verification	I-MED
task	I-MED
)	O
,	O
or	O
whether	O
it	O
extends	O
also	O
to	O
the	O
sentence	B-MED
level	B-MED
(	O
which	O
was	O
tested	B-MED
by	O
means	O
of	O
a	O
Sentence	B-MED
Semantic	I-MED
Judgment	I-MED
Task	I-MED
)	O
.	O
The	O
results	O
show	O
that	O
Chinese	B-MED
speakers	I-MED
with	O
basic	B-MED
knowledge	I-MED
of	O
English	B-MED
benefited	B-MED
from	O
physical	B-MED
activity	I-MED
while	O
learning	B-MED
a	O
set	O
of	O
new	O
words	B-MED
.	O
Furthermore	O
,	O
their	O
better	B-MED
performance	B-MED
emerged	O
also	O
at	O
the	O
sentential	B-MED
level	B-MED
,	I-MED
as	O
shown	O
by	O
their	O
performance	B-MED
in	O
a	O
Semantic	B-MED
Judgment	I-MED
task	I-MED
.	O
Finally	O
,	O
an	O
interesting	O
temporal	O
asymmetry	O
between	O
the	O
lexical	B-MED
and	O
the	O
sentential	B-MED
level	B-MED
emerges	O
,	O
with	O
the	O
difference	O
between	O
the	O
experimental	B-MED
and	O
control	B-MED
group	I-MED
emerging	O
from	O
the	O
1st	O
testing	B-MED
session	I-MED
at	O
the	O
lexical	B-MED
level	B-MED
but	O
after	O
several	O
weeks	O
at	O
the	O
sentential	B-MED
level	B-MED
.	O
Functional	O
Characterization	O
of	O
Pneumocystis	B-MED
carinii	I-MED
Inositol	B-MED
Transporter	I-MED
1	I-MED
Fungi	B-MED
in	O
the	O
genus	B-MED
Pneumocystis	I-MED
live	O
in	O
the	O
lungs	B-MED
of	O
mammals	B-MED
,	O
where	O
they	O
can	O
cause	O
a	O
fatal	B-MED
pneumonia	B-MED
(	O
PCP	B-MED
[	O
Pneumocystis	B-MED
pneumonia	I-MED
]	O
)	O
in	O
hosts	B-MED
with	O
compromised	O
immune	B-MED
systems	I-MED
.	O
The	O
absence	O
of	O
a	O
continuous	O
in	B-MED
vitro	I-MED
culture	B-MED
system	I-MED
for	O
any	O
species	B-MED
of	O
Pneumocystis	B-MED
has	O
led	O
to	O
limited	O
understanding	O
of	O
these	O
fungi	B-MED
,	O
especially	O
for	O
the	O
discovery	B-MED
of	O
new	O
therapies	B-MED
.	O
We	O
recently	O
reported	O
that	O
Pneumocystis	B-MED
carinii	I-MED
,	O
Pneumocystis	B-MED
murina	I-MED
,	O
and	O
most	O
significantly	O
,	O
Pneumocystis	B-MED
jirovecii	I-MED
lack	O
both	O
enzymes	B-MED
necessary	O
for	O
myo	B-MED
-	I-MED
inositol	I-MED
biosynthesis	I-MED
but	O
contain	O
genes	B-MED
with	I-MED
homologies	I-MED
to	O
fungal	B-MED
myo	B-MED
-	I-MED
inositol	I-MED
transporters	B-MED
.	O
Since	O
myo	B-MED
-	I-MED
inositol	I-MED
is	O
essential	O
for	O
eukaryotic	B-MED
viability	B-MED
,	O
the	O
primary	O
transporter	B-MED
,	O
ITR1	B-MED
,	O
was	O
functionally	B-MED
and	O
structurally	B-MED
characterized	O
in	O
P.	B-MED
carinii	I-MED
The	O
predicted	O
structure	B-MED
of	O
P.	B-MED
carinii	I-MED
ITR1	B-MED
(	O
PcITR1	B-MED
)	O
contained	O
12	O
transmembrane	B-MED
alpha	B-MED
-	I-MED
helices	I-MED
with	O
intracellular	B-MED
C	B-MED
and	O
N	B-MED
termini	I-MED
,	O
consistent	O
with	O
other	O
inositol	B-MED
transporters	B-MED
.	O
The	O
apparent	O
Km	O
was	O
0.94	O
±	O
0.08	O
(	O
mean	O
±	O
standard	O
deviation	O
)	O
,	O
suggesting	O
that	O
myo	B-MED
-	I-MED
inositol	I-MED
transport	I-MED
in	O
P.	B-MED
carinii	I-MED
is	O
likely	O
through	O
a	O
low	O
-	O
affinity	O
,	O
highly	O
selective	O
transport	B-MED
system	I-MED
,	O
as	O
no	O
other	O
sugars	B-MED
or	O
inositol	B-MED
stereoisomers	B-MED
were	O
significant	O
competitive	B-MED
inhibitors	B-MED
.	O
Glucose	B-MED
transport	I-MED
was	O
shown	O
to	O
use	O
a	O
different	O
transport	B-MED
system	O
.	O
The	O
myo	B-MED
-	I-MED
inositol	I-MED
transport	I-MED
was	O
distinct	O
from	O
mammalian	B-MED
transporters	B-MED
,	O
as	O
it	O
was	O
not	O
sodium	B-MED
dependent	I-MED
and	O
was	O
cytochalasin	B-MED
B	I-MED
resistant	B-MED
.	O
Inositol	B-MED
transport	I-MED
in	O
these	O
fungi	B-MED
offers	O
an	O
attractive	B-MED
new	O
drug	B-MED
target	B-MED
because	O
of	O
the	O
reliance	O
of	O
the	O
fungi	B-MED
on	O
its	O
transport	B-MED
,	O
clear	O
differences	O
between	O
the	O
mammalian	B-MED
and	O
fungal	B-MED
transporters	B-MED
,	O
and	O
the	O
ability	O
of	O
the	O
host	B-MED
to	O
both	O
synthesize	O
and	O
transport	B-MED
this	O
critical	B-MED
nutrient	B-MED
,	O
predicting	O
low	B-MED
toxicity	B-MED
of	O
potential	B-MED
inhibitors	B-MED
to	O
the	O
fungal	B-MED
transporter	B-MED
.	O
myo	B-MED
-	I-MED
Inositol	I-MED
is	O
a	O
sugarlike	B-MED
nutrient	B-MED
that	O
is	O
essential	B-MED
for	O
life	B-MED
in	O
most	O
organisms	B-MED
.	O
Humans	B-MED
and	O
microbes	B-MED
alike	O
can	O
obtain	O
it	O
by	O
making	O
it	O
,	O
which	O
involves	O
only	O
2	O
enzymes	B-MED
,	O
by	O
taking	O
it	O
from	O
the	O
environment	B-MED
by	O
a	O
transport	B-MED
process	I-MED
,	O
or	O
by	O
recycling	O
it	O
from	O
other	O
cellular	B-MED
constituents	B-MED
.	O
Inspection	O
of	O
the	O
genomes	B-MED
of	O
the	O
pathogenic	B-MED
fungi	I-MED
of	O
the	O
genus	B-MED
Pneumocystis	I-MED
showed	O
that	O
these	O
pneumonia	B-MED
-	O
causing	B-MED
parasites	B-MED
could	O
not	O
make	O
myo	B-MED
-	I-MED
inositol	I-MED
,	O
as	O
they	O
lacked	O
the	O
2	O
enzymes	B-MED
.	O
Instead	O
,	O
we	O
found	O
evidence	O
of	O
inositol	B-MED
transporters	B-MED
,	O
which	O
would	O
import	O
the	O
sugar	B-MED
from	O
the	O
lungs	B-MED
where	O
the	O
fungi	B-MED
reside	O
.	O
In	O
the	O
present	O
report	O
,	O
we	O
characterized	O
the	O
transport	B-MED
of	O
myo	B-MED
-	I-MED
inositol	I-MED
in	O
the	O
fungus	B-MED
and	O
found	O
that	O
the	O
transporter	B-MED
was	O
highly	O
selective	O
for	O
myo	B-MED
-	I-MED
inositol	I-MED
and	O
did	O
not	O
transport	B-MED
any	O
other	O
molecules	B-MED
.	O
The	O
transport	B-MED
was	O
distinct	O
from	O
that	O
in	O
mammalian	B-MED
cells	I-MED
,	O
and	O
since	O
mammals	B-MED
can	O
both	O
make	O
and	O
transport	B-MED
myo	B-MED
-	I-MED
inositol	I-MED
,	O
while	O
Pneumocystis	B-MED
fungi	I-MED
must	O
transport	B-MED
it	O
,	O
this	O
process	O
offers	O
a	O
potential	B-MED
new	O
drug	B-MED
target	B-MED
.	O
Enhancing	O
Comparative	B-MED
Effectiveness	I-MED
Research	I-MED
With	O
Automated	B-MED
Pediatric	B-MED
Pneumonia	B-MED
Detection	B-MED
in	O
a	O
Multi	B-MED
-	I-MED
Institutional	I-MED
Clinical	B-MED
Repository	B-MED
:	O
A	O
PHIS	B-MED
+	O
Pilot	B-MED
Study	I-MED
Community	B-MED
-	I-MED
acquired	I-MED
pneumonia	I-MED
is	O
a	O
leading	O
cause	O
of	O
pediatric	B-MED
morbidity	B-MED
.	O
Administrative	B-MED
data	B-MED
are	O
often	O
used	O
to	O
conduct	O
comparative	B-MED
effectiveness	I-MED
research	I-MED
(	O
CER	B-MED
)	O
with	O
sufficient	O
sample	B-MED
sizes	I-MED
to	O
enhance	O
detection	B-MED
of	O
important	B-MED
outcomes	B-MED
.	O
However	O
,	O
such	O
studies	O
are	O
prone	O
to	O
misclassification	B-MED
errors	I-MED
because	O
of	O
the	O
variable	B-MED
accuracy	B-MED
of	O
discharge	B-MED
diagnosis	I-MED
codes	B-MED
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
an	O
automated	B-MED
,	O
scalable	B-MED
,	O
and	O
accurate	B-MED
method	B-MED
to	O
determine	B-MED
the	O
presence	B-MED
or	O
absence	B-MED
of	O
pneumonia	B-MED
in	O
children	B-MED
using	O
chest	B-MED
imaging	I-MED
reports	B-MED
.	O
The	O
multi	B-MED
-	I-MED
institutional	I-MED
PHIS	B-MED
+	O
clinical	B-MED
repository	B-MED
was	O
developed	O
to	O
support	O
pediatric	B-MED
CER	B-MED
by	O
expanding	O
an	O
administrative	B-MED
database	B-MED
of	O
children	B-MED
's	I-MED
hospitals	I-MED
with	O
detailed	O
clinical	B-MED
data	B-MED
.	O
To	O
develop	O
a	O
scalable	B-MED
approach	O
to	O
find	B-MED
patients	B-MED
with	O
bacterial	B-MED
pneumonia	I-MED
more	O
accurately	O
,	O
we	O
developed	O
a	O
Natural	B-MED
Language	I-MED
Processing	I-MED
(	O
NLP	B-MED
)	O
application	B-MED
to	O
extract	O
relevant	B-MED
information	B-MED
from	O
chest	B-MED
diagnostic	I-MED
imaging	I-MED
reports	B-MED
.	O
Domain	B-MED
experts	B-MED
established	B-MED
a	O
reference	B-MED
standard	I-MED
by	O
manually	B-MED
annotating	B-MED
282	O
reports	B-MED
to	O
train	O
and	O
then	O
test	O
the	O
NLP	B-MED
application	B-MED
.	O
Findings	O
of	O
pleural	B-MED
effusion	I-MED
,	O
pulmonary	B-MED
infiltrate	I-MED
,	O
and	O
pneumonia	B-MED
were	O
automatically	B-MED
extracted	O
from	O
the	O
reports	B-MED
and	O
then	O
used	O
to	O
automatically	B-MED
classify	B-MED
whether	O
a	O
report	B-MED
was	O
consistent	B-MED
with	I-MED
bacterial	B-MED
pneumonia	I-MED
.	O
Compared	B-MED
with	O
the	O
annotated	O
diagnostic	B-MED
imaging	I-MED
reports	B-MED
reference	B-MED
standard	I-MED
,	O
the	O
most	O
accurate	B-MED
implementation	B-MED
of	O
machine	B-MED
learning	I-MED
algorithms	B-MED
in	O
our	O
NLP	B-MED
application	B-MED
allowed	O
extracting	O
relevant	B-MED
findings	B-MED
with	O
a	O
sensitivity	B-MED
of	O
.939	O
and	O
a	O
positive	B-MED
predictive	B-MED
value	I-MED
of	O
.925	O
.	O
It	O
allowed	O
classifying	B-MED
reports	B-MED
with	O
a	O
sensitivity	B-MED
of	O
.71	O
,	O
a	O
positive	B-MED
predictive	B-MED
value	I-MED
of	O
.86	O
,	O
and	O
a	O
specificity	B-MED
of	O
.962	O
.	O
When	O
compared	B-MED
with	O
each	O
of	O
the	O
domain	B-MED
experts	B-MED
manually	B-MED
annotating	B-MED
these	O
reports	B-MED
,	O
the	O
NLP	B-MED
application	B-MED
allowed	O
for	O
significantly	B-MED
higher	I-MED
sensitivity	B-MED
(	O
.71	O
vs	O
.527	O
)	O
and	O
similar	O
positive	B-MED
predictive	B-MED
value	I-MED
and	O
specificity	B-MED
.	O
NLP	B-MED
-based	O
pneumonia	B-MED
information	B-MED
extraction	O
of	O
pediatric	B-MED
diagnostic	B-MED
imaging	I-MED
reports	B-MED
performed	B-MED
better	O
than	O
domain	B-MED
experts	B-MED
in	O
this	O
pilot	B-MED
study	I-MED
.	O
NLP	B-MED
is	O
an	O
efficient	O
method	O
to	O
extract	O
information	B-MED
from	O
a	O
large	O
collection	B-MED
of	O
imaging	B-MED
reports	I-MED
to	O
facilitate	O
CER	B-MED
.	O
Bacteria	B-MED
and	O
Hoverflies	B-MED
(	O
Diptera	B-MED
:	O
Syrphidae	B-MED
)	O
in	O
Tree	B-MED
Hollows	I-MED
From	O
the	O
Iberian	B-MED
Mediterranean	I-MED
Forest	I-MED
Saproxylic	B-MED
insect	I-MED
communities	I-MED
inhabiting	B-MED
tree	B-MED
hollows	I-MED
in	O
Mediterranean	B-MED
forests	I-MED
depend	O
on	O
a	O
combination	O
of	O
physical	B-MED
characteristics	I-MED
and	O
interactions	B-MED
occurring	O
between	O
community	B-MED
member	I-MED
species	I-MED
.	O
Despite	O
the	O
need	O
to	O
preserve	O
these	O
organisms	B-MED
,	O
little	O
is	O
known	O
about	O
their	O
interrelationships	B-MED
,	O
in	O
particular	O
those	O
relationships	B-MED
between	O
saproxylic	B-MED
insects	I-MED
and	O
microbiota	B-MED
occurring	O
in	O
these	O
microhabitats	B-MED
.	O
In	O
tree	B-MED
hollows	I-MED
of	O
Quercus	B-MED
rotundifolia	I-MED
Lamark	I-MED
that	O
hold	B-MED
water	I-MED
and	O
contain	O
dead	B-MED
leaves	I-MED
,	O
abundant	B-MED
microbial	I-MED
populations	I-MED
can	O
be	O
found	O
.	O
Developing	O
on	O
them	O
are	O
the	O
larvae	B-MED
of	O
Mallota	B-MED
dusmeti	I-MED
Andréu	O
,	O
1926	O
(	O
Diptera	B-MED
:	O
Syrphidae	B-MED
)	O
,	O
a	O
vulnerable	B-MED
species	I-MED
(	O
IUCN	B-MED
category	I-MED
:	O
Marcos	B-MED
-	I-MED
García	I-MED
and	O
Quinto	B-MED
2011	O
)	O
.	O
This	O
study	O
provides	O
the	O
first	O
data	O
on	O
the	O
microbiota	B-MED
living	B-MED
inside	I-MED
the	O
gut	B-MED
of	O
the	O
larvae	B-MED
of	O
M.	B-MED
dusmeti	I-MED
,	O
as	O
well	O
as	O
the	O
microbiota	B-MED
in	O
the	O
hollow	B-MED
where	O
these	O
larvae	B-MED
develop	B-MED
.	O
Bacteria	B-MED
were	O
identified	O
by	O
amplification	B-MED
and	I-MED
partial	I-MED
sequencing	I-MED
of	O
the	O
V1	B-MED
-	I-MED
V3	I-MED
regions	I-MED
and	O
the	O
complete	O
nucleotide	B-MED
sequence	I-MED
of	O
16S	B-MED
rRNA	I-MED
genes	I-MED
.	O
We	O
found	O
eight	O
species	B-MED
of	I-MED
bacteria	I-MED
living	B-MED
in	I-MED
tree	B-MED
hollows	I-MED
and	O
three	O
species	B-MED
in	B-MED
the	I-MED
gut	I-MED
of	O
M.	B-MED
dusmeti	I-MED
larvae	B-MED
:	O
Bacillus	B-MED
cereus	I-MED
,	O
Bacillus	B-MED
toyonensis	I-MED
,	O
and	O
Lysinibacillus	B-MED
sphaericus	I-MED
The	O
filter	B-MED
-	I-MED
feeding	I-MED
mechanism	I-MED
characteristic	I-MED
of	O
M.	B-MED
dusmeti	I-MED
larvae	B-MED
is	O
selective	O
in	O
enabling	O
ingestion	B-MED
of	O
bacteria	B-MED
only	O
above	O
2.1	O
µm	O
in	O
diameter	O
.	O
Predictors	B-MED
of	O
neurologic	B-MED
and	O
nonneurologic	B-MED
death	I-MED
in	O
patients	B-MED
with	O
brain	B-MED
metastasis	I-MED
initially	O
treated	B-MED
with	O
upfront	B-MED
stereotactic	I-MED
radiosurgery	I-MED
without	O
whole	B-MED
-	I-MED
brain	I-MED
radiation	I-MED
therapy	I-MED
In	O
this	O
study	B-MED
we	O
attempted	O
to	O
discern	O
the	O
factors	B-MED
predictive	B-MED
of	O
neurologic	B-MED
death	I-MED
in	O
patients	B-MED
with	O
brain	B-MED
metastasis	I-MED
treated	B-MED
with	O
upfront	B-MED
stereotactic	I-MED
radiosurgery	I-MED
(	O
SRS	B-MED
)	O
without	O
whole	B-MED
brain	I-MED
radiation	I-MED
therapy	I-MED
(	O
WBRT	B-MED
)	O
while	O
accounting	O
for	O
the	O
competing	B-MED
risk	I-MED
of	O
nonneurologic	B-MED
death	I-MED
.	O
We	O
performed	O
a	O
retrospective	B-MED
single	B-MED
-	I-MED
institution	I-MED
analysis	B-MED
of	O
patients	B-MED
with	O
brain	B-MED
metastasis	I-MED
treated	B-MED
with	O
upfront	O
SRS	B-MED
without	O
WBRT	B-MED
.	O
Competing	B-MED
risks	I-MED
analysis	I-MED
was	O
performed	O
to	O
estimate	O
the	O
subdistribution	O
hazard	B-MED
ratios	I-MED
(	O
HRs	B-MED
)	O
for	O
neurologic	B-MED
and	O
nonneurologic	B-MED
death	I-MED
for	O
predictor	B-MED
variables	O
of	O
interest	O
.	O
Of	O
738	O
patients	B-MED
treated	B-MED
with	O
upfront	B-MED
SRS	I-MED
alone	O
,	O
neurologic	B-MED
death	I-MED
occurred	O
in	O
226	O
(	O
30.6	O
%	O
)	O
,	O
while	O
nonneurologic	B-MED
death	I-MED
occurred	O
in	O
309	O
(	O
41.9	O
%	O
)	O
.	O
Multivariate	B-MED
competing	I-MED
risks	I-MED
analysis	I-MED
identified	O
an	O
increased	B-MED
hazard	B-MED
of	O
neurologic	B-MED
death	I-MED
associated	O
with	O
diagnosis	B-MED
-	I-MED
specific	I-MED
graded	I-MED
prognostic	I-MED
assessment	I-MED
(	O
DS	B-MED
-	I-MED
GPA	I-MED
)	O
≤	O
2	O
(	O
P	O
=	O
.005	O
)	O
,	O
melanoma	B-MED
histology	B-MED
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
increased	B-MED
number	O
of	O
brain	B-MED
metastases	I-MED
(	O
P<.001	O
)	O
,	O
while	O
there	O
was	O
a	O
decreased	B-MED
hazard	B-MED
associated	O
with	O
higher	O
SRS	B-MED
dose	B-MED
(	O
P	O
=	O
.004	O
)	O
.	O
Targeted	B-MED
agents	I-MED
were	O
associated	O
with	O
a	O
decreased	B-MED
HR	B-MED
of	O
neurologic	B-MED
death	I-MED
in	O
the	O
first	O
1.5	O
years	B-MED
(	O
P	O
=	O
.04	O
)	O
but	O
not	O
afterwards	O
.	O
An	O
increased	B-MED
hazard	B-MED
of	O
nonneurologic	B-MED
death	I-MED
was	O
seen	O
with	O
increasing	O
age	B-MED
(	O
P	O
=	O
.03	O
)	O
,	O
nonmelanoma	B-MED
histology	I-MED
(	O
P<.001	O
)	O
,	O
presence	O
of	O
extracranial	B-MED
disease	I-MED
(	O
P<.001	O
)	O
,	O
and	O
progressive	B-MED
systemic	B-MED
disease	I-MED
(	O
P	O
=	O
.004	O
)	O
.	O
Melanoma	B-MED
,	O
DS	B-MED
-	I-MED
GPA	I-MED
,	O
number	B-MED
of	O
brain	B-MED
metastases	I-MED
,	O
and	O
SRS	B-MED
dose	B-MED
are	O
predictive	B-MED
of	O
neurologic	B-MED
death	I-MED
,	O
while	O
age	B-MED
,	O
nonmelanoma	B-MED
histology	I-MED
,	O
and	O
more	O
advanced	O
systemic	B-MED
disease	I-MED
are	O
predictive	B-MED
of	O
nonneurologic	B-MED
death	I-MED
.	O
Targeted	B-MED
agents	I-MED
appear	O
to	O
delay	B-MED
neurologic	B-MED
death	I-MED
.	O
Factors	B-MED
affecting	B-MED
the	O
formation	B-MED
of	O
nitrogenous	B-MED
disinfection	I-MED
by	B-MED
-	I-MED
products	I-MED
during	O
chlorination	B-MED
of	O
aspartic	B-MED
acid	I-MED
in	O
drinking	B-MED
water	I-MED
The	O
formation	B-MED
of	O
emerging	O
nitrogenous	B-MED
disinfection	I-MED
by	B-MED
-	I-MED
products	I-MED
(	O
N	B-MED
-	I-MED
DBPs	I-MED
)	O
from	O
the	O
chlorination	B-MED
of	O
aspartic	B-MED
acid	I-MED
(	O
Asp	B-MED
)	O
was	O
investigated	B-MED
.	O
The	O
yield	O
of	O
dichloroacetonitrile	B-MED
(	O
DCAN	B-MED
)	O
was	O
higher	O
than	O
other	O
N	B-MED
-	I-MED
DBPs	I-MED
,	O
such	O
as	O
dichloroacetamide	B-MED
(	O
DCAcAm	B-MED
)	O
and	O
chloropicrin	B-MED
(	O
TCNM	B-MED
)	O
during	O
the	O
chlorination	B-MED
of	O
Asp	B-MED
.	O
The	O
formation	B-MED
of	O
DCAN	B-MED
,	O
DCAcAm	B-MED
,	O
and	O
TCNM	B-MED
all	O
showed	O
a	O
trend	O
of	O
first	O
increasing	B-MED
and	O
then	O
decreasing	B-MED
during	O
the	O
chlorination	B-MED
of	O
Asp	B-MED
with	O
increasing	B-MED
contact	B-MED
time	I-MED
.	O
The	O
dosage	B-MED
of	O
chlorine	B-MED
had	O
an	O
impact	O
on	O
the	O
formation	B-MED
of	O
DCAN	B-MED
,	O
DCAcAm	B-MED
,	O
and	O
TCNM	B-MED
.	O
The	O
highest	O
yields	B-MED
of	O
DCAN	B-MED
and	O
DCAcAm	B-MED
appeared	O
when	O
the	O
Cl2	B-MED
/	O
Asp	B-MED
molar	B-MED
ratio	I-MED
was	O
about	O
20	O
,	O
the	O
yield	B-MED
of	O
TCNM	B-MED
increased	B-MED
with	O
increasing	B-MED
the	O
Cl2	B-MED
/	O
Asp	B-MED
molar	B-MED
ratio	I-MED
from	O
5	O
to	O
30	O
and	O
TCNM	B-MED
was	O
not	O
produced	O
when	O
the	O
ratio	B-MED
was	O
less	O
than	O
5	O
.	O
Cyanogen	B-MED
chloride	I-MED
(	O
CNCl	B-MED
)	O
was	O
detected	O
when	O
the	O
Cl2	B-MED
/	O
Asp	B-MED
molar	B-MED
ratio	I-MED
was	O
lower	O
than	O
5	O
.	O
N	B-MED
-	I-MED
DBPs	I-MED
formation	B-MED
pH	B-MED
was	O
influenced	O
by	O
pH.	O
DCAN	B-MED
formation	B-MED
increased	B-MED
with	O
increasing	B-MED
pH	B-MED
from	O
5	O
to	O
6	O
and	O
then	O
decreased	B-MED
with	O
increasing	B-MED
pH	B-MED
from	O
6	O
to	O
9	O
,	O
but	O
DCAcAm	B-MED
and	O
TCNM	B-MED
increased	B-MED
with	O
increasing	B-MED
pH	B-MED
from	O
5	O
to	O
8	O
and	O
then	O
decreased	B-MED
.	O
Higher	O
temperatures	B-MED
reduced	B-MED
the	O
formation	B-MED
of	O
DCAN	B-MED
and	O
DCAcAm	B-MED
,	O
but	O
increased	B-MED
TCNM	B-MED
formation	B-MED
.	O
DCAN	B-MED
and	O
DCAcAm	B-MED
formation	B-MED
decreased	B-MED
,	O
and	O
relatively	O
stable	B-MED
TCNM	B-MED
formation	B-MED
increased	B-MED
,	O
with	O
increasing	B-MED
free	O
chlorine	B-MED
contact	B-MED
time	I-MED
during	O
chloramination	B-MED
.	O
N	B-MED
-	I-MED
nitrosodimethylamine	I-MED
(	O
NDMA	B-MED
)	O
was	O
produced	O
during	O
chloramination	B-MED
of	O
Asp	B-MED
and	O
increased	B-MED
with	O
prolonged	B-MED
chloramination	B-MED
contact	B-MED
time	I-MED
.	O
The	O
presence	O
of	O
bromide	B-MED
ions	I-MED
enhanced	B-MED
the	O
yields	B-MED
of	O
haloacetonitriles	B-MED
and	O
shifted	O
N	B-MED
-	I-MED
DBPs	I-MED
to	O
more	O
brominated	B-MED
species	I-MED
.	O
Does	O
Intrawound	B-MED
Vancomycin	I-MED
Application	B-MED
During	O
Spine	B-MED
Surgery	I-MED
Create	O
Vancomycin	B-MED
-	I-MED
Resistant	I-MED
Organism	B-MED
?	O
Surgical	B-MED
site	I-MED
infection	I-MED
(	O
SSI	B-MED
)	O
following	O
spine	B-MED
surgery	I-MED
is	O
a	O
morbid	B-MED
and	O
expensive	B-MED
complication	I-MED
.	O
The	O
use	O
of	O
intrawound	B-MED
vancomycin	I-MED
is	O
emerging	O
as	O
a	O
solution	O
to	O
reduce	O
SSI	B-MED
.	O
The	O
development	O
of	O
vancomycin	B-MED
-	I-MED
resistant	I-MED
pathogens	B-MED
is	O
an	O
understandable	O
concern	O
.	O
To	O
determine	O
the	O
occurrence	B-MED
of	O
vancomycin	B-MED
-	I-MED
resistant	I-MED
SSI	B-MED
in	O
patients	B-MED
with	O
and	O
without	O
use	O
of	O
intrawound	B-MED
vancomycin	I-MED
.	O
Patients	B-MED
Patients	B-MED
undergoing	O
elective	O
spine	B-MED
surgery	I-MED
were	O
dichotomized	B-MED
based	O
on	O
whether	O
intrawound	B-MED
vancomycin	I-MED
was	O
applied	O
.	O
Outcome	O
was	O
occurrence	B-MED
of	O
SSI	B-MED
requiring	O
return	O
to	O
the	O
operating	B-MED
room	I-MED
within	O
postoperative	B-MED
90	I-MED
days	I-MED
.	O
The	O
intrawound	B-MED
culture	I-MED
and	O
vancomycin	B-MED
minimal	B-MED
inhibitory	I-MED
concentrations	I-MED
(	O
MIC	B-MED
)	O
were	O
reviewed	O
.	O
Analyses	O
were	O
conducted	O
to	O
compare	O
the	O
pathogen	B-MED
profile	I-MED
and	O
MIC	B-MED
for	O
vancomycin	B-MED
in	O
patients	B-MED
who	O
received	O
vancomycin	B-MED
and	O
those	O
who	O
did	O
not	O
.	O
Of	O
the	O
total	O
2802	O
patients	B-MED
,	O
43	O
%	O
(	O
n	O
=	O
1215	O
)	O
had	O
intrawound	B-MED
vancomycin	I-MED
application	O
during	B-MED
the	I-MED
index	I-MED
surgery	I-MED
.	O
The	O
use	O
of	O
vancomycin	B-MED
was	O
associated	O
with	O
significantly	B-MED
lower	I-MED
deep	O
SSI	B-MED
rates	B-MED
(	O
1.6	O
%	O
[	O
n	O
=	O
20	O
]	O
vs	O
2.5	O
%	O
[	O
n	O
=	O
40	O
]	O
,	O
P	O
=	O
.02	O
)	O
.	O
The	O
occurrence	B-MED
of	O
Staphylococcus	B-MED
aureus	I-MED
SSI	B-MED
was	O
significantly	B-MED
lower	I-MED
in	O
the	O
patients	B-MED
who	O
had	O
application	B-MED
of	O
intrawound	B-MED
vancomycin	I-MED
(	O
32	O
%	O
vs	O
65	O
%	O
,	O
P	O
=	O
.003	O
)	O
.	O
None	O
of	O
the	O
patients	B-MED
who	O
had	O
application	B-MED
of	O
intrawound	B-MED
vancomycin	I-MED
powder	I-MED
,	O
and	O
subsequently	O
developed	O
an	O
S	B-MED
aureus	I-MED
SSI	B-MED
,	O
demonstrated	O
pathogens	B-MED
with	O
resistance	B-MED
to	I-MED
vancomycin	I-MED
.	O
All	O
patients	B-MED
had	O
MIC	B-MED
<	O
2	O
μg	O
/	O
mL	O
,	O
the	O
vancomycin	B-MED
susceptibility	O
threshold	O
.	O
The	O
occurrence	B-MED
of	O
gram	B-MED
-	I-MED
negative	I-MED
SSI	B-MED
(	O
28	O
%	O
vs	O
7	O
%	O
)	O
and	O
culture	B-MED
negative	I-MED
fluid	I-MED
collection	I-MED
(	O
16	O
%	O
vs	O
5	O
%	O
)	O
was	O
higher	B-MED
in	O
the	O
vancomycin	B-MED
cohort	B-MED
.	O
The	O
use	O
of	O
intrawound	B-MED
vancomycin	I-MED
during	O
the	O
index	O
spine	B-MED
surgery	I-MED
was	O
protective	O
against	O
SSI	B-MED
following	O
spine	B-MED
surgery	I-MED
.	O
The	O
application	B-MED
of	O
intrawound	B-MED
vancomycin	I-MED
during	B-MED
index	I-MED
surgery	I-MED
does	O
not	O
appear	O
to	O
create	O
vancomycin	B-MED
-	I-MED
resistant	I-MED
organisms	B-MED
in	O
the	O
event	O
of	O
an	O
SSI	B-MED
.	O
Optimal	B-MED
Duration	B-MED
of	O
Coronary	B-MED
Ligation	I-MED
and	O
Reperfusion	B-MED
for	O
Reperfusion	B-MED
Injury	I-MED
Study	B-MED
in	O
a	O
Rat	B-MED
Model	B-MED
Reperfusion	B-MED
injury	I-MED
(	O
RI	B-MED
)	O
has	O
an	O
important	B-MED
impact	B-MED
on	O
the	O
clinical	B-MED
prognosis	B-MED
for	O
patients	B-MED
with	O
acute	B-MED
myocardial	I-MED
injury	I-MED
who	O
had	O
their	O
coronary	B-MED
blood	B-MED
flow	I-MED
reestablished	B-MED
.	O
However	O
,	O
no	O
studies	B-MED
to	O
date	O
have	O
investigated	B-MED
the	O
timeframe	B-MED
of	O
coronary	B-MED
occlusion	I-MED
and	O
reperfusion	B-MED
effects	B-MED
on	O
RI	B-MED
.	O
A	O
total	O
of	O
100	O
rats	B-MED
were	O
divided	O
into	O
4	O
groups	B-MED
based	O
on	O
the	O
coronary	B-MED
ligation	I-MED
period	B-MED
:	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
180	O
min	O
,	O
and	O
each	O
group	B-MED
was	O
further	O
divided	O
into	O
5	O
subgroups	B-MED
with	O
different	B-MED
reperfusion	B-MED
periods	B-MED
:	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
180	O
min	O
.	O
R0	O
was	O
the	O
baseline	B-MED
of	O
each	O
subgroup	B-MED
.	O
All	O
animals	B-MED
received	O
the	O
same	O
protocols	B-MED
for	O
designed	B-MED
ligation	B-MED
and	O
reperfusion	B-MED
periods	B-MED
.	O
Evans	B-MED
blue	I-MED
and	O
2,3,5	B-MED
-	I-MED
triphenyltetrazolium	I-MED
chloride	I-MED
were	O
used	O
to	O
distinguish	O
different	B-MED
myocardial	B-MED
injury	I-MED
areas	B-MED
:	O
area	B-MED
at	B-MED
risk	I-MED
(	O
AAR	B-MED
)	O
and	O
myocardial	B-MED
necrosis	I-MED
.	O
The	O
differences	B-MED
of	O
the	O
ratios	B-MED
of	O
the	O
necrotic	B-MED
area	B-MED
to	O
AAR	B-MED
between	O
each	O
subgroup	B-MED
and	O
baseline	B-MED
were	O
further	O
averaged	B-MED
to	O
calculate	B-MED
an	O
overall	B-MED
value	B-MED
of	O
each	O
heart	B-MED
.	O
The	O
relative	O
RI	B-MED
percentages	B-MED
showed	O
significant	B-MED
differences	B-MED
(	O
0.8	O
±	O
2.3	O
%	O
,	O
4.9	O
±	O
3.3	O
%	O
,	O
10.8	O
±	O
3.1	O
%	O
,	O
and	O
20.3	O
±	O
3.6	O
%	O
respectively	O
,	O
p	O
<	O
0.001	O
)	O
at	O
different	B-MED
time	B-MED
points	I-MED
of	O
reperfusion	B-MED
but	O
not	O
at	O
different	B-MED
time	B-MED
points	I-MED
of	O
ligation	B-MED
(	O
p	O
=	O
0.593	O
)	O
.	O
The	O
effects	B-MED
of	O
different	B-MED
time	B-MED
courses	I-MED
in	O
RI	B-MED
showed	O
that	O
the	O
L120R180	O
group	B-MED
(	O
43.4	O
±	O
2.3	O
%	O
)	O
had	O
the	O
highest	B-MED
RI	B-MED
difference	B-MED
with	O
the	O
baseline	B-MED
group	B-MED
.	O
Maximal	B-MED
RI	B-MED
occurred	O
at	O
the	O
timeframe	B-MED
of	O
L120R180	O
in	O
our	O
animal	B-MED
model	I-MED
.	O
This	O
result	B-MED
may	O
be	O
utilized	O
to	O
assess	B-MED
the	O
substantial	O
benefits	B-MED
of	O
RI	B-MED
therapies	I-MED
in	O
an	O
experimental	B-MED
rat	I-MED
model	I-MED
setting	O
.	O
Investigating	B-MED
Effects	B-MED
of	I-MED
Acidic	B-MED
pH	I-MED
on	O
Proliferation	B-MED
,	O
Invasion	B-MED
and	O
Drug	B-MED
-	O
Induced	B-MED
Apoptosis	B-MED
in	O
Lymphoblastic	B-MED
Leukemia	I-MED
Some	O
studies	O
have	O
shown	O
that	O
extracellular	B-MED
pH	B-MED
in	O
tumors	B-MED
,	O
which	O
results	O
in	O
tumor	B-MED
progression	I-MED
,	O
is	O
less	O
than	O
that	O
in	O
normal	B-MED
tissues	B-MED
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
the	O
effects	B-MED
of	I-MED
extracellular	B-MED
acidic	B-MED
pH	I-MED
on	O
proliferation	B-MED
,	O
invasion	B-MED
,	O
and	O
drug	B-MED
-	O
induced	B-MED
apoptosis	B-MED
in	O
acute	B-MED
lymphoblastic	I-MED
cells	I-MED
.	O
The	O
cells	B-MED
were	O
cultured	O
in	O
different	B-MED
pH	B-MED
(	O
pH	B-MED
6.6	O
and	O
pH	B-MED
7.4	O
)	O
for	O
12	O
days	B-MED
.	O
Cell	B-MED
proliferation	I-MED
was	O
assessed	B-MED
by	O
MTT	B-MED
assay	I-MED
and	O
cell	B-MED
invasion	I-MED
was	O
assayed	O
by	O
invasion	B-MED
assay	I-MED
and	O
gene	B-MED
expression	I-MED
analysis	I-MED
of	O
MMP-9	B-MED
.	O
Drug	B-MED
-	O
induced	B-MED
apoptosis	B-MED
was	O
evaluated	O
after	O
exposure	B-MED
to	I-MED
doxorubicin	B-MED
for	O
24	O
hours	O
by	O
annexin	B-MED
V	I-MED
/	O
PI	B-MED
staining	B-MED
and	O
gene	B-MED
expression	I-MED
analysis	I-MED
of	O
BAX	B-MED
pro	I-MED
-	I-MED
apoptotic	I-MED
protein	I-MED
.	O
The	O
results	O
indicated	O
the	O
enhanced	O
growth	B-MED
and	O
invasion	B-MED
of	O
leukemic	B-MED
cells	B-MED
at	O
pH	B-MED
6.6	O
(	O
P	O
≤	O
0.05	O
)	O
.	O
Furthermore	O
,	O
the	O
cells	B-MED
at	O
pH	B-MED
6.6	O
were	O
resistant	B-MED
to	O
apoptosis	B-MED
by	O
doxorubicin	B-MED
(	O
P	O
≤	O
0.05	O
)	O
.	O
It	O
can	O
be	O
concluded	O
that	O
acidic	B-MED
pH	I-MED
increases	B-MED
the	O
proliferation	B-MED
,	O
invasion	B-MED
and	O
reduces	B-MED
the	O
drug	B-MED
-	O
induced	B-MED
apoptosis	B-MED
in	O
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
.	O
Extracellular	B-MED
acidity	B-MED
can	O
influence	O
the	O
behavior	O
of	O
leukemic	B-MED
cells	B-MED
and	O
therefore	O
,	O
the	O
manipulation	B-MED
of	O
extracellular	B-MED
liquid	I-MED
can	O
be	O
selected	O
as	O
a	O
therapeutic	B-MED
strategy	I-MED
for	O
leukemia	B-MED
,	O
especially	O
for	O
acute	B-MED
lymphoblastic	I-MED
leukemia	I-MED
.	O
Breast	B-MED
Cancer	I-MED
Detection	B-MED
Rate	I-MED
,	O
Incidence	B-MED
,	O
Prevalence	B-MED
and	O
Interval	B-MED
Cancer	B-MED
-related	O
Mammography	B-MED
Screening	I-MED
Times	B-MED
among	O
Thai	B-MED
Women	B-MED
A	O
recent	O
guideline	B-MED
by	O
the	O
American	B-MED
Cancer	I-MED
Society	I-MED
recommended	O
that	O
mammography	B-MED
(	O
MMG	B-MED
)	O
should	O
be	O
done	O
for	O
women	B-MED
starting	O
in	O
their	O
mid-40s	O
.	O
In	O
Thailand	B-MED
,	O
information	O
on	O
opportunistic	B-MED
mammography	I-MED
screening	I-MED
is	O
limited	B-MED
and	O
data	B-MED
on	O
the	O
total	O
incidence	B-MED
of	O
breast	B-MED
cancer	I-MED
are	O
also	O
lacking	O
.	O
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
estimate	B-MED
the	O
breast	B-MED
cancer	I-MED
detection	B-MED
,	O
incident	B-MED
and	O
prevalence	B-MED
rates	I-MED
among	O
Thai	B-MED
women	B-MED
.	O
We	O
retrospectively	O
reviewed	O
the	O
opportunistic	B-MED
mammography	I-MED
screening	I-MED
of	O
normal	O
women	B-MED
between	O
30	O
and	O
80	O
years	B-MED
who	O
underwent	O
the	O
procedure	B-MED
between	O
2001	O
and	O
2010	O
.	O
All	O
cases	O
were	O
followed	O
until	O
2012	O
.	O
The	O
detection	B-MED
rate	I-MED
was	O
calculated	O
for	O
the	O
whole	O
period	O
of	O
observation	B-MED
using	O
'	O
number	B-MED
of	O
women	B-MED
with	O
positive	B-MED
findings	I-MED
'	O
divided	O
by	O
'	O
total	B-MED
number	I-MED
of	O
women	B-MED
screened	B-MED
'	O
.	O
The	O
incidence	B-MED
rate	I-MED
was	O
calculated	B-MED
only	O
at	O
the	O
first	O
MMG	B-MED
while	O
the	O
subsequence	O
rate	O
was	O
calculated	O
based	O
on	O
all	O
new	O
cases	O
detected	B-MED
at	O
each	O
subsequent	O
MMG	B-MED
.	O
Among	O
the	O
47,430	O
women	B-MED
,	O
there	O
were	O
152,091	O
MMGs	B-MED
or	O
approximately	O
3.2	O
occasions	O
per	O
person	B-MED
(	O
range	O
,	O
1	O
-	O
10	O
)	O
.	O
The	O
average	O
duration	B-MED
of	O
the	O
interval	B-MED
between	O
each	O
subsequence	O
visit	O
was	O
1.8	O
years	B-MED
.	O
Overall	O
,	O
breast	B-MED
cancer	I-MED
was	O
detected	B-MED
in	O
543	O
women	B-MED
,	O
with	O
a	O
detection	B-MED
rate	I-MED
of	O
10.3	O
per	O
1,000	O
persons	B-MED
.	O
The	O
prevalence	B-MED
rate	I-MED
of	O
breast	B-MED
cancer	I-MED
at	O
the	O
first	O
visit	O
was	O
5.78	O
per	O
1,000	O
person	B-MED
s.	O
The	O
incidence	B-MED
or	O
new	O
cases	O
detected	B-MED
at	O
any	O
follow	O
-	O
up	O
visit	O
was	O
10.4	O
per	O
1,000	O
person	B-MED
s.	O
The	O
overall	O
interval	B-MED
cancer	O
was	O
0.91	O
per	O
1,000	O
women	B-MED
,	O
mainly	O
detected	B-MED
before	O
their	O
second	O
and	O
third	O
MMG	B-MED
,	O
with	O
a	O
rate	O
of	O
0.0.47	O
and	O
0.76	O
per	O
1,000	O
women	B-MED
.	O
Opportunistic	B-MED
mammography	I-MED
screening	I-MED
in	O
Thailand	B-MED
detected	B-MED
10	O
cases	O
of	O
breast	B-MED
cancer	I-MED
from	O
each	O
1,000	O
women	B-MED
.	O
This	O
paper	O
indicated	O
a	O
high	O
rate	O
of	O
cancer	B-MED
detection	I-MED
during	O
a	O
two	O
year	O
interval	B-MED
,	O
hence	O
,	O
a	O
screening	B-MED
mammogram	I-MED
should	O
be	O
performed	O
more	O
often	O
.	O
Gestational	B-MED
age	I-MED
specific	O
stillbirth	B-MED
risk	B-MED
among	O
Indigenous	B-MED
and	O
non	B-MED
-	O
Indigenous	B-MED
women	B-MED
in	O
Queensland	B-MED
,	O
Australia	B-MED
:	O
a	O
population	B-MED
based	I-MED
study	I-MED
In	O
Australia	B-MED
,	O
significant	O
disparity	O
persists	O
in	O
stillbirth	B-MED
rates	B-MED
between	O
Aboriginal	B-MED
and	O
Torres	B-MED
Strait	I-MED
Islander	I-MED
(	O
Indigenous	B-MED
Australian	I-MED
)	O
and	O
non	B-MED
-	O
Indigenous	B-MED
women	B-MED
.	O
Diabetes	B-MED
,	O
hypertension	B-MED
,	O
antepartum	B-MED
haemorrhage	I-MED
and	O
small	B-MED
-	I-MED
for	I-MED
-	I-MED
gestational	I-MED
age	I-MED
(	O
SGA	B-MED
)	O
have	O
been	O
identified	B-MED
as	O
important	B-MED
contributors	O
to	O
higher	O
rates	B-MED
among	O
Indigenous	B-MED
women	B-MED
.	O
The	O
objective	O
of	O
this	O
study	B-MED
was	O
to	O
examine	O
gestational	B-MED
age	I-MED
specific	O
risk	B-MED
of	O
stillbirth	B-MED
associated	B-MED
with	I-MED
these	O
conditions	B-MED
among	O
Indigenous	B-MED
and	O
non	B-MED
-	O
Indigenous	B-MED
women	B-MED
.	O
Retrospective	B-MED
population	B-MED
-	I-MED
based	I-MED
study	I-MED
of	O
all	O
singleton	B-MED
births	B-MED
of	O
at	O
least	O
20	O
weeks	B-MED
gestation	B-MED
or	O
at	O
least	O
400	O
grams	B-MED
birthweight	B-MED
in	O
Queensland	B-MED
between	O
July	B-MED
2005	O
and	O
December	B-MED
2011	O
using	O
data	B-MED
from	O
the	O
Queensland	B-MED
Perinatal	B-MED
Data	B-MED
Collection	I-MED
,	O
which	O
is	O
a	O
routinely	B-MED
-	I-MED
maintained	I-MED
database	I-MED
that	O
collects	O
data	B-MED
on	O
all	O
births	B-MED
in	O
Queensland	B-MED
.	O
Multivariate	B-MED
logistic	I-MED
regression	I-MED
was	O
used	O
to	O
calculate	O
adjusted	B-MED
odds	I-MED
ratios	I-MED
(	O
aOR	B-MED
)	O
and	O
95	O
%	O
confidence	B-MED
intervals	I-MED
,	O
adjusting	O
for	O
maternal	B-MED
demographic	B-MED
and	O
pregnancy	B-MED
factors	I-MED
.	O
Of	O
360987	O
births	B-MED
analysed	B-MED
,	O
20273	O
(	O
5.6	O
%	O
)	O
were	O
to	O
Indigenous	B-MED
women	B-MED
and	O
340714	O
(	O
94.4	O
%	O
)	O
were	O
to	O
non	B-MED
-	O
Indigenous	B-MED
women	B-MED
.	O
Stillbirth	B-MED
rates	B-MED
were	O
7.9	O
(	O
95	O
%	O
CI	B-MED
6.8	O
-	O
9.2	O
)	O
and	O
4.1	O
(	O
95	O
%	O
CI	B-MED
3.9	O
-	O
4.3	O
)	O
per	O
1000	O
births	B-MED
,	O
respectively	O
.	O
For	O
both	O
Indigenous	B-MED
and	O
non	B-MED
-	O
Indigenous	B-MED
women	B-MED
across	O
most	O
gestational	B-MED
age	B-MED
groups	I-MED
,	O
antepartum	B-MED
haemorrhage	I-MED
,	O
SGA	B-MED
,	O
pre	B-MED
-	I-MED
existing	I-MED
diabetes	I-MED
and	O
pre	B-MED
-	I-MED
existing	I-MED
hypertension	I-MED
were	O
associated	B-MED
with	I-MED
increased	B-MED
risk	B-MED
of	O
stillbirth	B-MED
.	O
There	O
were	O
mixed	O
results	O
for	O
pre	B-MED
-	I-MED
eclampsia	I-MED
and	O
eclampsia	B-MED
and	O
a	O
consistently	O
raised	O
risk	B-MED
of	O
stillbirth	B-MED
was	O
not	O
seen	O
for	O
gestational	B-MED
diabetes	I-MED
.	O
This	O
study	B-MED
highlights	O
gestational	B-MED
age	I-MED
specific	O
stillbirth	B-MED
risk	B-MED
for	O
Indigenous	B-MED
and	O
non	B-MED
-	O
Indigenous	B-MED
women	B-MED
;	O
and	O
disparity	O
in	O
risk	B-MED
at	O
term	B-MED
gestations	I-MED
.	O
Improving	O
access	O
to	O
and	O
utilisation	O
of	O
appropriate	B-MED
and	O
responsive	B-MED
healthcare	B-MED
may	O
help	O
to	O
address	O
disparities	O
in	O
stillbirth	B-MED
risk	B-MED
for	O
Indigenous	B-MED
women	B-MED
.	O
Doxorubicin	B-MED
Has	O
Dose	B-MED
-	I-MED
Dependent	I-MED
Toxicity	B-MED
on	O
Mouse	B-MED
Ovarian	B-MED
Follicle	I-MED
Development	B-MED
,	O
Hormone	B-MED
Secretion	I-MED
,	O
and	O
Oocyte	B-MED
Maturation	I-MED
Doxorubicin	B-MED
(	O
DOX	B-MED
)	O
,	O
one	O
of	O
the	O
most	O
commonly	B-MED
used	O
anticancer	B-MED
medications	I-MED
,	O
has	O
been	O
reported	O
to	O
affect	O
fertility	B-MED
by	O
damaging	B-MED
ovarian	B-MED
follicles	I-MED
;	O
however	O
,	O
the	O
dose	B-MED
-	I-MED
dependent	I-MED
toxicity	B-MED
of	O
DOX	B-MED
on	O
the	O
dynamic	B-MED
follicle	B-MED
development	B-MED
and	O
oocyte	B-MED
maturation	I-MED
has	O
not	O
been	O
well	O
-	O
defined	O
.	O
Our	O
objective	B-MED
is	O
to	O
determine	O
the	O
effects	B-MED
of	I-MED
human	B-MED
-	O
relevant	B-MED
exposure	B-MED
levels	B-MED
of	O
DOX	B-MED
on	O
follicular	B-MED
functions	B-MED
across	O
developmental	B-MED
time	B-MED
.	O
In	B-MED
vitro	I-MED
cultured	B-MED
multilayered	B-MED
secondary	I-MED
mouse	I-MED
follicles	I-MED
were	O
treated	B-MED
with	O
DOX	B-MED
at	O
0	O
,	O
2	O
,	O
20	O
,	O
100	O
,	O
and	O
200	O
nM	O
for	O
24	O
h	O
,	O
and	O
follicle	B-MED
development	B-MED
,	O
hormone	B-MED
secretion	I-MED
,	O
and	O
oocyte	B-MED
maturation	I-MED
were	O
analyzed	O
.	O
DOX	B-MED
caused	O
dose	B-MED
-	I-MED
dependent	I-MED
toxicity	B-MED
on	O
follicle	B-MED
growth	I-MED
,	O
survival	B-MED
,	O
and	O
secretion	B-MED
of	O
17β	B-MED
-	I-MED
estradiol	I-MED
(	O
E2	B-MED
)	O
.	O
At	O
200	O
nM	O
,	O
DOX	B-MED
induced	B-MED
DNA	B-MED
damage	I-MED
and	O
apoptosis	B-MED
in	O
follicle	B-MED
somatic	B-MED
cells	I-MED
first	O
and	O
then	O
in	O
oocytes	B-MED
,	O
which	O
was	O
correlated	O
with	O
the	O
uptake	B-MED
of	O
DOX	B-MED
first	O
to	O
the	O
somatic	B-MED
cells	I-MED
followed	O
by	O
germ	B-MED
cells	I-MED
.	O
Follicles	B-MED
treated	B-MED
with	O
DOX	B-MED
at	O
0	O
,	O
2	O
,	O
and	O
20	O
nM	O
showed	O
similar	O
oocyte	B-MED
metaphase	B-MED
II	I-MED
(	O
MII	B-MED
)	O
percentages	B-MED
after	O
in	B-MED
vitro	I-MED
oocyte	B-MED
maturation	I-MED
;	O
however	O
,	O
20	O
nM	O
DOX	B-MED
significantly	O
increased	B-MED
the	O
number	O
of	O
MII	B-MED
oocytes	B-MED
with	O
abnormal	B-MED
spindle	B-MED
morphology	B-MED
and	O
chromosome	B-MED
misalignment	B-MED
.	O
In	O
an	O
effort	O
to	O
harmonize	O
the	O
in	B-MED
vitro	I-MED
study	I-MED
to	O
in	B-MED
vivo	I-MED
treatment	B-MED
,	O
dose	B-MED
-	I-MED
dependent	I-MED
toxicity	B-MED
on	O
oocyte	B-MED
meiotic	I-MED
maturation	I-MED
was	O
found	O
in	O
16	O
-	O
day	O
-	O
old	O
CD-1	B-MED
mice	I-MED
treated	B-MED
with	O
DOX	B-MED
at	O
0	O
,	O
0.4	O
,	O
2	O
,	O
and	O
10	O
mg	O
/	O
kg	O
,	O
consistent	B-MED
with	I-MED
the	O
in	B-MED
vitro	I-MED
oocyte	B-MED
maturation	I-MED
outcomes	B-MED
.	O
Our	O
study	B-MED
demonstrates	O
that	O
DOX	B-MED
has	O
dose	B-MED
-	I-MED
dependent	I-MED
toxicity	B-MED
on	O
ovarian	B-MED
follicle	I-MED
development	B-MED
,	O
hormone	B-MED
secretion	I-MED
,	O
and	O
oocyte	B-MED
maturation	I-MED
,	O
which	O
are	O
three	O
key	O
factors	B-MED
to	O
support	O
the	O
female	B-MED
reproductive	I-MED
and	O
endocrine	B-MED
functions	I-MED
.	O
Angiotensin	B-MED
-	I-MED
converting	I-MED
enzyme	I-MED
insertion	I-MED
/	I-MED
deletion	I-MED
polymorphism	I-MED
association	B-MED
with	I-MED
obesity	B-MED
and	O
some	O
related	O
disorders	B-MED
in	O
Egyptian	B-MED
females	B-MED
:	O
a	O
case	B-MED
-	I-MED
control	I-MED
observational	I-MED
study	I-MED
According	O
to	O
the	O
WHO	B-MED
report	B-MED
in	O
2015	O
,	O
obesity	B-MED
is	O
the	O
fifth	O
leading	O
cause	B-MED
of	I-MED
death	I-MED
worldwide	B-MED
,	O
and	O
the	O
prevalence	B-MED
of	O
Egyptian	B-MED
female	B-MED
obesity	B-MED
is	O
37.5	O
%	O
.	O
Since	O
obesity	B-MED
is	O
highly	O
influenced	B-MED
by	O
genetics	B-MED
,	O
and	O
adipose	B-MED
tissue	I-MED
renin	B-MED
-	I-MED
angiotensin	I-MED
system	I-MED
is	O
over	B-MED
-	I-MED
activated	I-MED
in	O
obesity	B-MED
,	O
the	O
effect	B-MED
of	I-MED
angiotensin	B-MED
-	I-MED
converting	I-MED
enzyme	I-MED
(	I-MED
ACE	I-MED
)	I-MED
insertion	I-MED
/	I-MED
deletion	I-MED
(	I-MED
I	I-MED
/	I-MED
D	I-MED
)	I-MED
polymorphism	I-MED
on	O
obesity	B-MED
and	O
related	O
disorders	B-MED
was	O
studied	O
in	O
several	O
populations	B-MED
,	O
because	O
of	O
its	O
effect	B-MED
on	O
ACE	B-MED
activity	I-MED
.	O
Our	O
objective	B-MED
was	O
to	O
study	B-MED
the	O
association	B-MED
of	O
ACE	B-MED
I	I-MED
/	I-MED
D	I-MED
polymorphism	I-MED
with	O
obesity	B-MED
and	O
certain	O
related	O
disorders	B-MED
,	O
namely	O
hypertension	B-MED
,	O
insulin	B-MED
resistance	I-MED
and	O
metabolic	B-MED
syndrome	I-MED
,	O
in	O
Egyptian	B-MED
females	B-MED
.	O
Eighty	B-MED
female	B-MED
volunteers	B-MED
were	O
recruited	O
,	O
blood	B-MED
pressure	I-MED
and	O
body	B-MED
measurements	I-MED
were	O
recorded	B-MED
and	O
a	O
fasting	B-MED
blood	B-MED
sample	I-MED
was	O
obtained	O
for	O
the	O
quantitation	B-MED
of	O
glucose	B-MED
,	O
lipid	B-MED
profile	I-MED
,	O
insulin	B-MED
,	I-MED
leptin	B-MED
and	O
identification	B-MED
of	O
ACE	B-MED
I	I-MED
/	I-MED
D	I-MED
polymorphs	I-MED
.	O
Subjects	B-MED
were	O
grouped	O
based	O
on	O
hypertension	B-MED
and	O
obesity	B-MED
states	I-MED
.	O
Comparisons	B-MED
of	O
continuous	B-MED
parameters	B-MED
were	O
made	O
with	O
independent	B-MED
sample	B-MED
t	I-MED
-	I-MED
test	I-MED
between	O
two	O
groups	B-MED
.	O
The	O
frequencies	B-MED
of	O
ACE	B-MED
genotypes	B-MED
and	O
alleles	B-MED
,	O
and	O
the	O
association	B-MED
between	O
gene	B-MED
polymorphism	I-MED
and	O
metabolic	B-MED
parameters	B-MED
were	O
assessed	B-MED
using	O
chi	B-MED
-	I-MED
square	I-MED
or	O
Fisher	B-MED
's	I-MED
exact	I-MED
test	I-MED
.	O
Genotype	B-MED
frequencies	B-MED
were	O
in	O
Hardy	B-MED
-	I-MED
Weinberg	I-MED
equilibrium	I-MED
for	O
all	O
groups	B-MED
.	O
Genotype	B-MED
distribution	B-MED
did	O
not	O
differ	O
significantly	O
between	O
controls	B-MED
and	O
cases	B-MED
of	O
all	O
the	O
studied	O
disorders	B-MED
.	O
Although	O
DD	B-MED
carriers	I-MED
had	O
apparently	O
higher	B-MED
parameters	B-MED
of	O
blood	B-MED
pressure	I-MED
,	O
lipid	B-MED
profile	I-MED
and	O
insulin	B-MED
resistance	I-MED
,	O
only	O
diastolic	B-MED
blood	I-MED
pressure	I-MED
was	O
almost	O
significant	B-MED
(	O
p	O
=	O
0.057	O
)	O
.	O
I	B-MED
-	I-MED
carriers	I-MED
were	O
significantly	O
less	O
susceptible	B-MED
to	O
hypertension	B-MED
than	O
DD	B-MED
carriers	I-MED
having	O
normal	B-MED
waist	B-MED
/	I-MED
hip	I-MED
ratio	I-MED
(	O
p	O
=	O
0.007	O
,	O
OR	B-MED
=	O
17.29	O
,	O
CI	B-MED
=	O
1.81	O
-	O
164.96	O
)	O
and	O
normal	B-MED
conicity	B-MED
index	I-MED
(	O
p	O
=	O
0.024	O
,	O
OR	B-MED
=	O
7.00	O
,	O
CI	B-MED
=	O
1.36	O
-	O
35.93	O
)	O
.	O
In	O
DD	B-MED
genotype	I-MED
carriers	I-MED
,	O
a	O
significant	B-MED
association	B-MED
was	O
found	O
between	O
insulin	B-MED
resistance	I-MED
and	O
high	B-MED
body	I-MED
mass	I-MED
index	I-MED
(	O
p	O
=	O
0.004	O
,	O
OR	B-MED
=	O
8.89	O
,	O
CI	B-MED
=	O
1.94	O
-	O
40.71	O
)	O
,	O
waist	B-MED
circumference	I-MED
(	O
p	O
=	O
0.003	O
,	O
OR	B-MED
=	O
9.63	O
,	O
CI	B-MED
=	O
2.14	O
-	O
43.36	O
)	O
and	O
waist	B-MED
/	I-MED
height	I-MED
ratio	I-MED
(	O
p	O
=	O
0.034	O
,	O
OR	B-MED
=	O
6.86	O
,	O
CI	B-MED
=	O
1.25	O
-	O
37.61	O
)	O
,	O
although	O
the	O
variations	B-MED
in	O
percentages	B-MED
between	O
DD	B-MED
and	O
I	B-MED
-	I-MED
carriers	I-MED
were	O
not	O
high	O
enough	O
to	O
conclude	O
an	O
effect	B-MED
of	I-MED
ACE	B-MED
I	I-MED
/	I-MED
D	I-MED
on	O
such	O
an	O
association	B-MED
.	O
In	O
this	O
sample	B-MED
of	O
Egyptian	B-MED
females	B-MED
,	O
ACE	B-MED
I	I-MED
/	I-MED
D	I-MED
polymorphism	I-MED
was	O
not	B-MED
significantly	I-MED
associated	B-MED
with	I-MED
obesity	B-MED
nor	O
with	O
any	O
of	O
its	O
related	O
disorders	B-MED
studied	O
.	O
The	O
I	B-MED
allele	I-MED
seemed	O
protective	O
against	O
hypertension	B-MED
in	O
subjects	B-MED
with	O
normal	B-MED
,	O
not	O
high	O
,	O
waist	B-MED
/	I-MED
hip	I-MED
ratio	I-MED
and	O
conicity	B-MED
index	I-MED
compared	O
to	O
DD	B-MED
genotype	I-MED
carriers	I-MED
.	O
Influence	B-MED
of	O
yeast	B-MED
and	O
lactic	B-MED
acid	I-MED
bacterium	I-MED
on	O
the	O
constituent	B-MED
profile	B-MED
of	O
soy	B-MED
sauce	I-MED
during	B-MED
fermentation	B-MED
Soy	B-MED
sauce	I-MED
is	O
a	O
Japanese	B-MED
traditional	B-MED
seasoning	B-MED
composed	B-MED
of	O
various	B-MED
constituents	B-MED
that	O
are	O
produced	B-MED
by	O
various	O
microbes	B-MED
during	B-MED
a	O
long	B-MED
-	I-MED
term	I-MED
fermentation	B-MED
process	I-MED
.	O
Due	B-MED
to	I-MED
the	O
complexity	B-MED
of	O
the	O
process	B-MED
,	O
the	O
investigation	B-MED
of	O
the	O
constituent	B-MED
profile	B-MED
during	B-MED
fermentation	B-MED
is	O
difficult	B-MED
.	O
Metabolomics	B-MED
,	O
the	O
comprehensive	B-MED
study	B-MED
of	O
low	B-MED
molecular	B-MED
weight	I-MED
compounds	B-MED
in	O
biological	B-MED
samples	B-MED
,	O
is	O
thought	O
to	O
be	O
a	O
promising	O
strategy	O
for	O
deep	O
understanding	B-MED
of	O
the	O
constituent	B-MED
contribution	B-MED
to	O
food	B-MED
flavor	I-MED
characteristics	B-MED
.	O
Therefore	O
,	O
metabolomics	B-MED
is	O
suitable	B-MED
for	O
the	O
analysis	B-MED
of	O
soy	B-MED
sauce	I-MED
fermentation	B-MED
.	O
Unfortunately	O
,	O
only	O
few	O
and	O
unrefined	O
studies	B-MED
of	O
soy	B-MED
sauce	I-MED
fermentation	B-MED
using	B-MED
metabolomics	B-MED
approach	B-MED
have	O
been	O
reported	B-MED
.	O
Therefore	O
,	O
we	O
investigated	B-MED
changes	B-MED
in	O
low	B-MED
molecular	B-MED
weight	I-MED
hydrophilic	B-MED
and	O
volatile	B-MED
compounds	I-MED
of	O
soy	B-MED
sauce	I-MED
using	O
gas	B-MED
chromatography	I-MED
/	I-MED
mass	I-MED
spectrometry	I-MED
(	O
GC	B-MED
/	I-MED
MS	I-MED
MS)-	O
based	B-MED
non	B-MED
-	I-MED
targeted	I-MED
metabolic	B-MED
profiling	I-MED
.	O
The	O
data	B-MED
were	O
analyzed	B-MED
by	O
statistical	B-MED
analysis	I-MED
to	O
evaluate	O
influences	B-MED
of	O
yeast	B-MED
and	O
lactic	B-MED
acid	I-MED
bacterium	I-MED
on	O
the	O
constituent	B-MED
profile	B-MED
.	O
Consequently	O
,	O
our	O
results	B-MED
suggested	B-MED
a	O
novel	B-MED
finding	B-MED
that	O
lactic	B-MED
acid	I-MED
bacterium	I-MED
affected	B-MED
the	O
production	B-MED
of	O
several	B-MED
constituents	B-MED
such	O
as	O
cyclotene	B-MED
,	O
furfural	B-MED
,	O
furfuryl	B-MED
alcohol	I-MED
and	O
methional	B-MED
in	O
the	O
soy	B-MED
sauce	I-MED
fermentation	B-MED
process	I-MED
.	O
Fyn	B-MED
regulates	O
multipolar	B-MED
-	O
bipolar	B-MED
transition	B-MED
and	O
neurite	B-MED
morphogenesis	I-MED
of	O
migrating	B-MED
neurons	I-MED
in	O
the	O
developing	B-MED
neocortex	I-MED
Fyn	B-MED
is	O
a	O
non	B-MED
-	I-MED
receptor	I-MED
protein	B-MED
tyrosine	I-MED
kinase	I-MED
that	O
belongs	O
to	O
Src	B-MED
family	I-MED
kinases	I-MED
.	O
Fyn	B-MED
plays	O
a	O
critical	O
role	O
in	O
neuronal	B-MED
migration	I-MED
,	O
but	O
the	O
mechanism	B-MED
remains	O
unclear	B-MED
.	O
Here	O
,	O
we	O
reported	O
that	O
suppression	B-MED
of	O
Fyn	B-MED
expression	B-MED
in	O
mouse	B-MED
cerebral	I-MED
cortex	I-MED
led	O
to	O
migration	B-MED
defects	I-MED
of	O
both	O
early	B-MED
-	I-MED
born	I-MED
and	O
late	B-MED
-	I-MED
born	I-MED
neurons	B-MED
.	O
Morphological	B-MED
analysis	B-MED
showed	O
that	O
loss	O
of	O
Fyn	B-MED
function	O
impaired	O
multipolar	B-MED
-	O
bipolar	B-MED
transition	B-MED
of	O
newly	O
generated	B-MED
neurons	B-MED
and	O
neurite	B-MED
formation	I-MED
in	O
the	O
early	O
phase	B-MED
of	O
migration	B-MED
.	O
Moreover	O
,	O
Fyn	B-MED
inhibition	B-MED
increased	O
the	O
length	O
of	O
leading	B-MED
process	I-MED
and	O
decreased	O
the	O
branching	B-MED
number	O
of	O
the	O
migrating	B-MED
cortical	I-MED
neurons	I-MED
.	O
Together	O
,	O
these	O
results	O
indicate	O
that	O
Fyn	B-MED
controls	B-MED
neuronal	B-MED
migration	I-MED
by	O
regulating	B-MED
the	O
cytoskeletal	B-MED
dynamics	B-MED
and	O
multipolar	B-MED
-	O
bipolar	B-MED
transition	B-MED
of	O
newly	B-MED
generated	B-MED
neurons	B-MED
during	O
cortical	B-MED
development	I-MED
.	O
Fluorescence	B-MED
hyperspectral	I-MED
imaging	I-MED
(	O
fHSI	B-MED
)	O
using	O
a	O
spectrally	B-MED
resolved	B-MED
detector	B-MED
array	I-MED
The	O
ability	O
to	O
resolve	B-MED
multiple	B-MED
fluorescent	B-MED
emissions	I-MED
from	O
different	B-MED
biological	B-MED
targets	B-MED
in	O
video	B-MED
rate	I-MED
applications	I-MED
,	O
such	O
as	O
endoscopy	B-MED
and	O
intraoperative	B-MED
imaging	I-MED
,	O
has	O
traditionally	O
been	O
limited	B-MED
by	O
the	O
use	O
of	O
filter	B-MED
-	I-MED
based	I-MED
imaging	B-MED
systems	I-MED
.	I-MED
Hyperspectral	B-MED
imaging	I-MED
(	O
HSI	B-MED
)	O
facilitates	O
the	O
detection	B-MED
of	O
both	O
spatial	B-MED
and	O
spectral	B-MED
information	B-MED
in	O
a	O
single	B-MED
data	I-MED
acquisition	I-MED
,	O
however	O
,	O
instrumentation	B-MED
for	O
HSI	B-MED
is	O
typically	O
complex	B-MED
,	O
bulky	B-MED
and	O
expensive	B-MED
.	O
We	O
sought	O
to	O
overcome	B-MED
these	O
limitations	B-MED
using	O
a	O
novel	B-MED
robust	B-MED
and	O
low	B-MED
cost	I-MED
HSI	B-MED
camera	B-MED
based	O
on	O
a	O
spectrally	B-MED
resolved	I-MED
detector	I-MED
array	I-MED
(	O
SRDA	B-MED
)	O
.	O
We	O
integrated	B-MED
this	O
HSI	B-MED
camera	B-MED
into	O
a	O
wide	B-MED
-	I-MED
field	I-MED
reflectance	B-MED
-	I-MED
based	I-MED
imaging	B-MED
system	I-MED
operating	B-MED
in	O
the	O
near	B-MED
-	I-MED
infrared	I-MED
range	B-MED
to	O
assess	B-MED
the	O
suitability	O
for	O
in	B-MED
vivo	I-MED
imaging	I-MED
of	O
exogenous	B-MED
fluorescent	B-MED
contrast	I-MED
agents	I-MED
.	O
Using	O
this	O
fluorescence	B-MED
HSI	I-MED
(	O
fHSI	B-MED
)	O
system	B-MED
,	O
we	O
were	O
able	O
to	O
accurately	B-MED
resolve	B-MED
the	O
presence	B-MED
and	O
concentration	B-MED
of	O
at	O
least	O
7	O
fluorescent	B-MED
dyes	I-MED
in	O
solution	B-MED
.	O
We	O
also	O
demonstrate	O
high	B-MED
spectral	B-MED
unmixing	I-MED
precision	B-MED
,	O
signal	B-MED
linearity	B-MED
with	O
dye	B-MED
concentration	B-MED
and	O
at	O
depth	B-MED
in	O
tissue	B-MED
mimicking	B-MED
phantoms	B-MED
,	O
and	O
delineate	B-MED
4	O
fluorescent	B-MED
dyes	I-MED
in	B-MED
vivo	I-MED
.	O
Our	O
approach	O
,	O
including	B-MED
statistical	B-MED
background	B-MED
removal	O
,	O
could	O
be	O
directly	B-MED
generalised	B-MED
to	O
broader	B-MED
spectral	I-MED
ranges	B-MED
,	O
for	O
example	O
,	O
to	O
resolve	B-MED
tissue	B-MED
reflectance	B-MED
or	O
autofluorescence	B-MED
and	O
in	O
future	B-MED
be	O
tailored	O
to	O
video	B-MED
rate	I-MED
applications	I-MED
requiring	O
snapshot	O
HSI	B-MED
data	B-MED
acquisition	I-MED
.	O
Ventricular	B-MED
pacing	I-MED
site	B-MED
separation	I-MED
by	O
cardiac	B-MED
computed	B-MED
tomography	I-MED
:	O
validation	B-MED
for	O
the	O
prediction	B-MED
of	O
clinical	B-MED
response	I-MED
to	O
cardiac	B-MED
resynchronization	I-MED
therapy	I-MED
Cardiac	B-MED
Resynchronization	I-MED
Therapy	I-MED
(	O
CRT	B-MED
)	O
fails	O
to	O
provide	B-MED
benefit	B-MED
in	O
up	O
to	O
one	O
-	O
third	O
of	O
patients	B-MED
.	O
Maximizing	O
the	O
geographic	B-MED
separation	I-MED
of	O
right	B-MED
and	O
left	B-MED
ventricular	B-MED
pacing	I-MED
lead	B-MED
sites	I-MED
has	O
been	O
suggested	B-MED
as	O
one	O
way	O
to	O
improve	B-MED
response	B-MED
.	O
Cardiac	B-MED
CT	I-MED
provides	B-MED
an	O
opportunity	B-MED
to	O
explore	O
3	B-MED
-	I-MED
dimensional	I-MED
inter	B-MED
-	I-MED
lead	I-MED
distance	I-MED
(	O
ILD	B-MED
)	O
measures	B-MED
for	O
the	O
prediction	B-MED
of	O
CRT	B-MED
response	B-MED
.	O
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
investigate	B-MED
associations	B-MED
between	O
standardized	B-MED
measures	B-MED
of	O
ILD	B-MED
by	O
cardiac	B-MED
CT	I-MED
and	O
echocardiographic	B-MED
response	B-MED
to	O
CRT	B-MED
.	O
Forty	O
-	O
two	O
consecutive	B-MED
patients	B-MED
undergoing	O
CRT	B-MED
had	O
serial	O
clinical	B-MED
and	O
echocardiographic	B-MED
evaluations	B-MED
performed	B-MED
in	B-MED
addition	I-MED
to	I-MED
a	O
post	B-MED
-	I-MED
procedural	I-MED
cardiac	B-MED
-gated	O
CT	B-MED
with	O
blinded	B-MED
measurement	B-MED
of	O
direct	B-MED
and	O
circumferential	B-MED
(	O
via	O
the	O
myocardium	B-MED
)	O
ILD	B-MED
measures	B-MED
.	O
Clinical	B-MED
response	I-MED
to	O
CRT	B-MED
,	O
the	O
primary	B-MED
clinical	I-MED
outcome	I-MED
,	O
was	O
defined	O
as	O
a	O
≥15	O
%	O
reduction	B-MED
in	O
LVESV	B-MED
using	O
echocardiography	B-MED
at	O
6	O
-	O
months	O
.	O
The	O
mean	B-MED
age	I-MED
and	O
ejection	B-MED
fraction	I-MED
was	O
63.6	O
±	O
8.9	O
years	O
and	O
25.2	O
±	O
7.8	O
%	O
,	O
respectively	O
.	O
The	O
primary	B-MED
outcome	I-MED
occurred	B-MED
in	O
35	O
of	O
42	O
patients	B-MED
(	O
83	O
%	O
)	O
.	O
Both	O
direct	B-MED
and	O
circumferential	B-MED
CT	B-MED
-based	O
ILD	B-MED
measures	B-MED
were	O
associated	B-MED
with	I-MED
the	O
primary	B-MED
outcome	I-MED
by	O
univariate	B-MED
analysis	I-MED
.	O
Receiver	B-MED
Operator	I-MED
Characteristic	I-MED
analysis	B-MED
identified	O
Circumferential	B-MED
ILD	B-MED
to	O
have	O
the	O
strongest	O
predictive	B-MED
accuracy	B-MED
(	O
AUC	O
0.78	O
)	O
.	O
Inter-	B-MED
and	O
intra	B-MED
-	I-MED
observer	I-MED
reproducibility	B-MED
of	O
CT	B-MED
-derived	O
ILD	B-MED
measures	B-MED
was	O
excellent	B-MED
.	O
Circumferential	B-MED
ILD	B-MED
measures	B-MED
on	O
cardiac	B-MED
CT	I-MED
are	O
predictive	B-MED
of	O
clinical	B-MED
response	I-MED
to	O
CRT	B-MED
.	O
Incorporation	B-MED
of	O
these	O
measures	B-MED
into	O
the	O
selection	B-MED
of	O
optimal	B-MED
pacing	B-MED
targets	B-MED
,	O
particularly	O
from	O
pre	B-MED
-	I-MED
procedural	I-MED
CT	B-MED
coronary	B-MED
vein	I-MED
imaging	B-MED
may	O
be	O
of	O
therapeutic	B-MED
benefit	B-MED
and	O
warrants	O
further	O
investigation	B-MED
.	O
No	O
free	B-MED
bed	I-MED
with	O
ventilator	B-MED
:	O
experience	O
of	O
a	O
public	B-MED
health	I-MED
specialist	I-MED
While	O
the	O
author	B-MED
was	O
dealing	O
with	O
a	O
poor	B-MED
elderly	B-MED
father	I-MED
struggling	O
to	O
shift	O
his	O
gravely	B-MED
injured	I-MED
young	B-MED
son	B-MED
to	O
a	O
government	B-MED
hospital	I-MED
due	O
to	O
the	O
high	O
cost	O
of	O
intensive	B-MED
care	I-MED
,	O
her	O
friends	B-MED
across	O
the	O
globe	B-MED
were	O
discussing	O
euthanasia	B-MED
in	O
the	O
social	B-MED
media	I-MED
.	O
While	O
marginalised	B-MED
groups	B-MED
of	I-MED
people	I-MED
are	O
struggling	O
to	O
access	B-MED
care	B-MED
in	O
India	B-MED
,	O
friends	B-MED
who	O
have	O
moved	O
to	O
developed	B-MED
parts	I-MED
of	I-MED
the	I-MED
world	I-MED
were	O
discussing	O
one	O
's	O
choice	B-MED
to	O
live	B-MED
or	O
die	B-MED
!	O
The	O
poor	B-MED
father	B-MED
,	O
after	O
battling	B-MED
to	O
save	B-MED
his	O
son	B-MED
and	O
reaching	O
out	O
to	O
many	O
people	B-MED
for	O
help	B-MED
,	O
could	O
not	O
save	B-MED
him	O
.	O
Early	B-MED
treatment	I-MED
might	O
have	O
helped	B-MED
the	O
young	B-MED
boy	B-MED
.	O
The	O
incident	B-MED
left	O
the	O
author	B-MED
thinking	O
about	O
how	O
the	O
poor	B-MED
are	O
denied	B-MED
care	B-MED
simply	O
because	O
they	O
can	O
not	O
afford	O
it	O
.	O
Others	O
debate	B-MED
when	O
to	O
pull	B-MED
the	I-MED
plug	I-MED
on	O
the	O
patient	B-MED
.	O
…	O
How	O
many	O
families	B-MED
can	O
afford	O
such	O
care	B-MED
in	O
India	B-MED
?	O
When	O
nearly	O
71	O
%	O
of	O
the	O
people	B-MED
are	O
paying	B-MED
out	I-MED
of	I-MED
pocket	I-MED
for	O
healthcare	B-MED
and	O
16	O
%	O
are	O
pushed	O
below	B-MED
the	I-MED
poverty	I-MED
line	I-MED
every	B-MED
year	I-MED
,	O
can	O
we	O
even	O
think	B-MED
of	O
universal	B-MED
health	I-MED
coverage	I-MED
health	B-MED
?	O
It	O
just	O
sounds	O
like	O
a	O
fancy	B-MED
term	I-MED
to	O
be	O
used	O
at	O
conferences	B-MED
and	I-MED
meetings	I-MED
because	O
the	O
ground	B-MED
reality	I-MED
is	O
completely	B-MED
different	I-MED
.	O
Development	B-MED
of	O
a	O
liquid	B-MED
chromatography	I-MED
-	I-MED
tandem	I-MED
mass	I-MED
spectrometry	I-MED
method	B-MED
for	O
quantitative	B-MED
analysis	I-MED
of	O
trace	B-MED
d	B-MED
-	I-MED
amino	I-MED
acids	I-MED
d	B-MED
-	I-MED
Amino	I-MED
acids	I-MED
have	O
recently	B-MED
attracted	O
much	O
attention	B-MED
in	O
various	O
research	B-MED
fields	I-MED
including	B-MED
medical	B-MED
,	O
clinical	B-MED
and	O
food	B-MED
industry	I-MED
due	O
to	O
their	O
important	B-MED
biological	B-MED
functions	I-MED
that	O
differ	O
from	O
l	B-MED
-	I-MED
amino	I-MED
acid	I-MED
.	O
Most	O
chiral	B-MED
amino	B-MED
acid	I-MED
separation	B-MED
techniques	B-MED
require	B-MED
complicated	B-MED
derivatization	B-MED
procedures	B-MED
in	O
order	O
to	O
achieve	O
the	O
desirable	B-MED
chromatographic	B-MED
behavior	O
and	O
detectability	B-MED
.	O
Thus	O
,	O
the	O
aim	B-MED
of	O
this	O
research	B-MED
is	O
to	O
develop	B-MED
a	O
highly	B-MED
sensitive	I-MED
analytical	B-MED
method	I-MED
for	O
the	O
enantioseparation	B-MED
of	O
chiral	B-MED
amino	B-MED
acids	I-MED
without	O
any	O
derivatization	B-MED
process	B-MED
using	O
liquid	B-MED
chromatography	I-MED
-	I-MED
tandem	I-MED
mass	I-MED
spectrometry	I-MED
(	O
LC	B-MED
-	I-MED
MS	I-MED
/	I-MED
MS	I-MED
)	O
.	O
By	O
optimizing	B-MED
MS	B-MED
/	I-MED
MS	I-MED
parameters	B-MED
,	O
we	O
established	B-MED
a	O
quantification	B-MED
method	B-MED
that	O
allowed	O
the	O
simultaneous	B-MED
analysis	B-MED
of	O
18	O
d	B-MED
-	I-MED
amino	I-MED
acids	I-MED
with	O
high	B-MED
sensitivity	I-MED
and	O
reproducibility	B-MED
.	O
Additionally	O
,	O
we	O
applied	B-MED
the	O
method	B-MED
to	O
food	B-MED
sample	I-MED
(	O
vinegar	B-MED
)	O
for	O
the	O
validation	B-MED
,	O
and	O
successfully	O
quantified	B-MED
trace	B-MED
levels	I-MED
of	O
d	B-MED
-	I-MED
amino	I-MED
acids	I-MED
in	O
samples	B-MED
.	O
These	O
results	B-MED
demonstrated	O
the	O
applicability	B-MED
and	O
feasibility	B-MED
of	O
the	O
LC	B-MED
-	I-MED
MS	I-MED
/	I-MED
MS	I-MED
method	B-MED
as	O
a	O
novel	B-MED
,	O
effective	B-MED
tool	O
for	O
d	B-MED
-	I-MED
amino	I-MED
acid	I-MED
measurement	B-MED
in	O
various	O
biological	B-MED
samples	I-MED
.	O
Targeting	B-MED
HIF2	B-MED
in	O
Clear	B-MED
Cell	I-MED
Renal	I-MED
Cell	I-MED
Carcinoma	I-MED
Inactivation	O
of	O
the	O
von	B-MED
Hippel	I-MED
-	I-MED
Lindau	I-MED
tumor	I-MED
-	I-MED
suppressor	I-MED
protein	I-MED
(	O
pVHL	B-MED
)	O
is	O
the	O
signature	B-MED
"	I-MED
truncal	I-MED
"	I-MED
event	I-MED
in	O
clear	B-MED
cell	I-MED
renal	I-MED
cell	I-MED
carcinoma	I-MED
,	O
which	O
is	O
the	O
most	O
common	O
form	O
of	O
kidney	B-MED
cancer	I-MED
.	O
pVHL	B-MED
is	O
part	O
of	O
a	O
ubiquitin	B-MED
ligase	I-MED
the	O
targets	B-MED
the	O
α	B-MED
subunit	I-MED
of	O
the	O
hypoxia	B-MED
-	I-MED
inducible	I-MED
factor	I-MED
(	I-MED
HIF	I-MED
)	I-MED
transcription	I-MED
factor	I-MED
for	O
destruction	B-MED
when	O
oxygen	O
is	O
available	O
.	O
Preclinical	B-MED
studies	B-MED
strongly	O
suggest	O
that	O
deregulation	B-MED
of	O
HIF	B-MED
,	O
and	O
particularly	O
HIF2	B-MED
,	O
drives	O
pVHL	B-MED
-defective	O
renal	B-MED
carcinogenesis	I-MED
.	O
Although	O
HIF2α	B-MED
was	O
classically	O
considered	O
undruggable	B-MED
,	O
structural	O
and	O
chemical	O
work	O
by	O
Rick	B-MED
Bruick	I-MED
and	O
Kevin	B-MED
Gardner	I-MED
at	O
University	B-MED
of	I-MED
Texas	I-MED
Southwestern	I-MED
laid	O
the	O
foundation	O
for	O
the	O
development	O
of	O
small	B-MED
molecule	I-MED
direct	O
HIF2α	B-MED
antagonists	I-MED
(	O
PT2385	B-MED
and	O
the	O
related	O
tool	O
compound	O
PT2399	B-MED
)	O
by	O
Peloton	B-MED
Therapeutics	I-MED
that	O
block	B-MED
the	O
dimerization	B-MED
of	O
HIF2α	B-MED
with	O
its	O
partner	O
protein	B-MED
ARNT1	I-MED
.	O
These	O
compounds	O
inhibit	B-MED
clear	I-MED
cell	I-MED
renal	I-MED
cell	I-MED
carcinoma	I-MED
growth	I-MED
in	O
preclinical	B-MED
models	I-MED
,	O
and	O
PT2385	B-MED
has	O
now	O
entered	O
the	O
clinic	B-MED
.	O
Nonetheless	O
,	O
the	O
availability	O
of	O
such	B-MED
compounds	I-MED
,	O
together	O
with	O
clustered	B-MED
regularly	I-MED
interspaced	I-MED
short	I-MED
palindromic	I-MED
repeat	I-MED
CRISPR	B-MED
(	O
CRISPR)-based	O
gene	B-MED
editing	I-MED
approaches	I-MED
,	O
has	O
revealed	O
a	O
previously	O
unappreciated	B-MED
heterogeneity	I-MED
among	O
clear	B-MED
cell	I-MED
renal	I-MED
carcinomas	I-MED
and	O
patient	B-MED
-derived	O
xenografts	B-MED
with	O
respect	O
to	O
HIF2	B-MED
dependence	O
,	O
suggesting	O
that	O
predictive	B-MED
biomarkers	I-MED
will	O
be	O
needed	O
to	O
optimize	B-MED
the	O
use	O
of	O
such	B-MED
agents	I-MED
in	O
the	O
clinic	B-MED
.	O
Autologous	B-MED
vs	O
Irradiated	B-MED
Homologous	I-MED
Costal	I-MED
Cartilage	I-MED
as	O
Graft	B-MED
Material	I-MED
in	O
Rhinoplasty	B-MED
Studies	O
comparing	O
surgical	O
results	O
of	O
rhinoplasty	B-MED
using	O
autologous	B-MED
costal	I-MED
cartilage	I-MED
(	O
ACC	B-MED
)	O
and	O
irradiated	B-MED
homologous	I-MED
costal	I-MED
cartilage	I-MED
(	O
IHCC	B-MED
)	O
are	O
rare	O
.	O
To	O
compare	O
the	O
clinical	B-MED
results	I-MED
of	O
major	O
augmentation	B-MED
rhinoplasty	I-MED
using	O
ACC	B-MED
vs	O
IHCC	B-MED
and	O
analyze	O
the	O
histologic	B-MED
properties	I-MED
of	O
both	O
types	O
of	O
cartilage	B-MED
.	O
A	O
retrospective	B-MED
clinical	I-MED
study	I-MED
was	O
conducted	O
among	O
patients	B-MED
who	O
had	O
undergone	O
rhinoseptoplasty	B-MED
using	O
ACC	B-MED
or	O
IHCC	B-MED
from	O
January	O
1	O
,	O
2009	O
,	O
to	O
December	O
31	O
,	O
2014	O
.	O
Patients	B-MED
were	O
followed	B-MED
up	I-MED
for	O
more	O
than	O
1	O
year	O
after	O
surgery	B-MED
and	O
the	O
histologic	B-MED
characteristics	I-MED
of	O
ACC	B-MED
and	O
IHCC	B-MED
were	O
compared	B-MED
.	O
The	O
details	O
of	O
the	O
surgical	B-MED
procedures	I-MED
and	O
complications	B-MED
,	O
including	O
warping	B-MED
,	O
infection	B-MED
,	O
resorption	B-MED
,	O
and/or	O
donor	B-MED
-	I-MED
site	I-MED
morbidity	B-MED
,	O
were	O
evaluated	B-MED
by	O
reviewing	O
medical	B-MED
records	I-MED
and	O
facial	B-MED
photographs	I-MED
.	O
Patients	B-MED
'	O
subjective	B-MED
satisfaction	B-MED
with	O
aesthetic	B-MED
and	O
functional	B-MED
results	B-MED
was	O
evaluated	B-MED
using	O
a	O
questionnaire	B-MED
.	O
The	O
details	O
of	O
the	O
surgical	B-MED
procedures	I-MED
and	O
complications	B-MED
,	O
including	O
warping	B-MED
,	O
infection	B-MED
,	O
resorption	B-MED
,	O
and/or	O
donor	B-MED
-	I-MED
site	I-MED
morbidity	B-MED
;	O
patients	B-MED
'	O
subjective	B-MED
satisfaction	B-MED
with	O
aesthetic	B-MED
and	O
functional	B-MED
results	B-MED
'	O
objective	B-MED
evaluation	B-MED
of	O
surgical	B-MED
outcomes	B-MED
,	O
including	O
symmetry	B-MED
,	O
dorsal	B-MED
height	B-MED
,	O
dorsal	B-MED
length	B-MED
,	O
dorsal	B-MED
width	B-MED
,	O
tip	B-MED
projection	I-MED
,	O
tip	B-MED
rotation	I-MED
,	O
tip	B-MED
width	I-MED
,	O
and	O
overall	B-MED
result	B-MED
;	O
and	O
histologic	B-MED
structures	B-MED
.	O
Objective	B-MED
evaluation	B-MED
of	O
surgical	B-MED
outcomes	B-MED
was	O
graded	O
using	O
the	O
Objective	B-MED
Rhinoplasty	B-MED
Outcome	B-MED
Score	I-MED
,	O
which	O
assessed	O
symmetry	B-MED
,	O
dorsal	B-MED
height	B-MED
,	O
dorsal	B-MED
length	B-MED
,	O
dorsal	B-MED
width	B-MED
,	O
tip	B-MED
projection	I-MED
,	O
tip	B-MED
rotation	I-MED
,	O
tip	B-MED
width	I-MED
,	O
and	O
overall	B-MED
result	B-MED
.	O
Histologic	B-MED
structures	I-MED
were	O
evaluated	B-MED
using	O
hematoxylin	B-MED
and	I-MED
eosin	I-MED
,	O
Masson	B-MED
trichrome	I-MED
,	O
Alcian	B-MED
blue	I-MED
,	O
and	O
Verhoeff	B-MED
elastic	I-MED
stains	I-MED
.	O
A	O
total	O
of	O
63	O
patients	B-MED
(	O
27	O
males	B-MED
and	O
36	O
females	B-MED
;	O
mean	O
[	O
SD	O
]	O
age	O
,	O
30.6	O
[	O
9.5	O
]	O
years	O
)	O
had	O
rhinoseptoplasty	B-MED
using	O
ACC	B-MED
and	O
20	O
(	O
9	O
males	B-MED
and	O
11	O
females	B-MED
;	O
mean	O
[	O
SD	O
]	O
age	O
,	O
35.4	O
[	O
15.4	O
]	O
years	O
)	O
had	O
rhinoseptoplasty	B-MED
using	O
IHCC	B-MED
.	O
Among	O
observed	B-MED
complications	B-MED
,	O
only	O
notable	B-MED
resorption	B-MED
occurred	B-MED
more	O
frequently	B-MED
in	O
patients	B-MED
using	O
IHCC	B-MED
(	O
6	O
[	O
30	O
%	O
]	O
)	O
than	O
with	O
ACC	B-MED
(	O
2	O
[	O
3	O
%	O
]	O
)	O
(	O
P	O
=	O
.002	O
)	O
.	O
In	O
subjective	B-MED
evaluations	B-MED
of	O
aesthetic	B-MED
satisfaction	B-MED
,	O
patients	B-MED
who	O
received	B-MED
ACC	B-MED
showed	O
significantly	B-MED
greater	B-MED
satisfaction	B-MED
(	O
37	O
of	O
51	O
patients	B-MED
[	O
73	O
%	O
]	O
were	O
very	B-MED
satisfied	I-MED
)	O
than	O
did	O
those	O
who	O
received	B-MED
IHCC	B-MED
(	O
6	O
of	O
20	O
[	O
30	O
%	O
]	O
)	O
(	O
P	O
=	O
.001	O
)	O
.	O
However	O
,	O
there	O
was	O
no	O
between	O
-	O
group	O
difference	O
in	O
subjective	B-MED
functional	B-MED
outcomes	B-MED
:	O
4	O
of	O
51	O
patients	B-MED
receiving	B-MED
ACC	B-MED
(	O
8	O
%	O
)	O
and	O
5	O
of	O
20	O
receiving	B-MED
IHCC	B-MED
(	O
25	O
%	O
)	O
were	O
satisfied	B-MED
(	O
P	O
=	O
.50	O
)	O
and	O
45	O
of	O
51	O
receiving	B-MED
ACC	B-MED
(	O
88	O
%	O
)	O
and	O
15	O
of	O
20	O
receiving	B-MED
IHCC	B-MED
(	O
75	O
%	O
)	O
were	O
very	B-MED
satisfied	I-MED
(	O
P	O
=	O
.15	O
)	O
.	O
Regarding	O
objective	B-MED
aesthetic	B-MED
outcomes	B-MED
,	O
all	O
scores	B-MED
for	O
both	O
ACC	B-MED
and	O
IHCC	B-MED
were	O
more	O
than	O
3.1	O
(	O
between	O
good	B-MED
and	O
excellent	B-MED
)	O
.	O
Histologic	B-MED
analyses	I-MED
showed	O
larger	B-MED
,	O
more	O
evenly	O
distributed	O
,	O
uniform	B-MED
chondrocytes	B-MED
and	O
more	O
collagens	B-MED
and	O
proteoglycan	B-MED
contents	B-MED
in	O
ACC	B-MED
than	O
in	O
IHCC	B-MED
.	O
Compared	B-MED
with	O
patients	B-MED
receiving	B-MED
IHCC	B-MED
,	O
those	O
receiving	B-MED
ACC	B-MED
for	O
rhinoseptoplasty	B-MED
showed	O
superior	B-MED
aesthetic	B-MED
satisfaction	B-MED
;	O
ACC	B-MED
also	O
had	O
less	B-MED
frequent	B-MED
notable	B-MED
resorption	B-MED
.	O
Autologous	B-MED
costal	I-MED
cartilage	I-MED
also	O
had	O
better	B-MED
histologic	B-MED
properties	I-MED
than	O
IHCC	B-MED
did	O
,	O
suggesting	O
it	O
as	O
an	O
ideal	B-MED
graft	B-MED
material	I-MED
with	O
less	B-MED
chance	B-MED
of	O
long	B-MED
-	I-MED
term	I-MED
resorption	B-MED
.	O
3	O
.	O
Impact	B-MED
of	O
Strategically	O
Located	O
White	B-MED
Matter	I-MED
Hyperintensities	I-MED
on	O
Cognition	B-MED
in	O
Memory	B-MED
Clinic	I-MED
Patients	B-MED
with	O
Small	B-MED
Vessel	I-MED
Disease	I-MED
Studies	O
on	O
the	O
impact	B-MED
of	O
small	B-MED
vessel	I-MED
disease	I-MED
(	O
SVD	B-MED
)	O
on	O
cognition	B-MED
generally	O
focus	B-MED
on	O
white	B-MED
matter	I-MED
hyperintensity	I-MED
(	O
WMH	B-MED
)	O
volume	B-MED
.	O
The	O
extent	B-MED
to	O
which	O
WMH	B-MED
location	B-MED
relates	B-MED
to	O
cognitive	B-MED
performance	I-MED
has	O
received	B-MED
less	B-MED
attention	B-MED
,	O
but	O
is	O
likely	O
to	O
be	O
functionally	B-MED
important	B-MED
.	O
We	O
examined	O
the	O
relation	B-MED
between	O
WMH	B-MED
location	B-MED
and	O
cognition	B-MED
in	O
a	O
memory	B-MED
clinic	I-MED
cohort	B-MED
of	O
patients	B-MED
with	O
sporadic	B-MED
SVD	B-MED
.	O
A	O
total	O
of	O
167	O
patients	B-MED
with	O
SVD	B-MED
were	O
recruited	O
from	O
memory	B-MED
clinics	I-MED
.	O
Assumption	B-MED
-	I-MED
free	I-MED
region	I-MED
of	I-MED
interest	I-MED
-	I-MED
based	I-MED
analyses	I-MED
based	B-MED
on	O
major	O
white	B-MED
matter	I-MED
tracts	B-MED
and	O
voxel	B-MED
-	O
wise	B-MED
analyses	B-MED
were	O
used	B-MED
to	O
determine	O
the	O
association	B-MED
between	O
WMH	B-MED
location	B-MED
and	O
executive	B-MED
functioning	I-MED
,	O
visuomotor	B-MED
speed	I-MED
and	O
memory	B-MED
.	O
Region	B-MED
of	I-MED
interest	I-MED
-	I-MED
based	I-MED
analyses	I-MED
showed	O
that	O
WMHs	B-MED
located	B-MED
particularly	O
within	B-MED
the	O
anterior	B-MED
thalamic	I-MED
radiation	I-MED
and	O
forceps	B-MED
minor	I-MED
were	O
inversely	B-MED
associated	B-MED
with	I-MED
both	O
executive	B-MED
functioning	I-MED
and	O
visuomotor	B-MED
speed	I-MED
,	O
independent	B-MED
of	I-MED
total	B-MED
WMH	B-MED
volume	B-MED
.	O
Memory	B-MED
was	O
significantly	O
associated	B-MED
with	I-MED
WMH	B-MED
volume	B-MED
in	O
the	O
forceps	B-MED
minor	I-MED
,	O
independent	B-MED
of	I-MED
total	B-MED
WMH	B-MED
volume	B-MED
.	O
An	O
independent	B-MED
assumption	I-MED
-	I-MED
free	I-MED
voxel	I-MED
-	I-MED
wise	I-MED
analysis	I-MED
identified	B-MED
strategic	O
voxels	B-MED
in	O
these	O
same	B-MED
tracts	B-MED
.	O
Region	B-MED
of	I-MED
interest	I-MED
-	I-MED
based	I-MED
analyses	I-MED
showed	O
that	O
WMH	B-MED
volume	B-MED
within	B-MED
the	O
anterior	B-MED
thalamic	I-MED
radiation	I-MED
explained	O
6.8	O
%	O
of	O
variance	B-MED
in	O
executive	B-MED
functioning	I-MED
,	O
compared	B-MED
to	O
3.9	O
%	O
for	O
total	B-MED
WMH	B-MED
volume	B-MED
;	O
WMH	B-MED
volume	B-MED
within	B-MED
the	O
forceps	B-MED
minor	I-MED
explained	O
4.6	O
%	O
of	O
variance	B-MED
in	O
visuomotor	B-MED
speed	I-MED
and	O
4.2	O
%	O
of	O
variance	B-MED
in	O
memory	B-MED
,	O
compared	B-MED
to	O
1.8	O
%	O
and	O
1.3	O
%	O
respectively	O
for	O
total	B-MED
WMH	B-MED
volume	B-MED
.	O
Our	O
findings	B-MED
identify	B-MED
the	O
anterior	B-MED
thalamic	I-MED
radiation	I-MED
and	O
forceps	B-MED
minor	I-MED
as	O
strategic	O
white	B-MED
matter	I-MED
tracts	B-MED
in	O
which	O
WMHs	B-MED
are	O
most	O
strongly	O
associated	B-MED
with	I-MED
cognitive	B-MED
impairment	I-MED
in	O
memory	B-MED
clinic	I-MED
patients	B-MED
with	O
SVD	B-MED
.	O
WMH	B-MED
volumes	B-MED
in	O
individual	O
tracts	B-MED
explained	O
more	O
variance	B-MED
in	O
cognition	B-MED
than	O
total	B-MED
WMH	B-MED
burden	O
,	O
emphasizing	O
the	O
importance	B-MED
of	O
lesion	B-MED
location	I-MED
when	O
addressing	O
the	O
functional	B-MED
consequences	B-MED
of	I-MED
WMHs	B-MED
.	O
Healthcare	B-MED
usage	B-MED
and	O
economic	B-MED
impact	I-MED
of	O
non	B-MED
-	I-MED
treated	I-MED
obesity	B-MED
in	O
Italy	B-MED
:	O
findings	B-MED
from	O
a	O
retrospective	B-MED
administrative	B-MED
and	O
clinical	B-MED
database	I-MED
analysis	B-MED
Investigate	B-MED
the	O
prevalence	B-MED
of	O
obesity	B-MED
in	O
Italy	B-MED
and	O
examine	O
its	O
resource	B-MED
consumption	B-MED
and	O
economic	B-MED
impact	I-MED
on	O
the	O
Italian	B-MED
national	B-MED
healthcare	I-MED
system	I-MED
(	O
NHS	B-MED
)	O
.	O
Retrospective	B-MED
,	O
observational	B-MED
and	O
real	B-MED
-	I-MED
life	I-MED
study	I-MED
.	O
Data	B-MED
from	O
three	O
health	B-MED
units	I-MED
from	O
Northern	B-MED
(	O
Bergamo	B-MED
,	O
Lombardy	B-MED
)	O
,	O
Central	B-MED
(	O
Grosseto	B-MED
,	O
Tuscany	B-MED
)	O
and	O
Southern	B-MED
(	O
Naples	B-MED
,	O
Campania	B-MED
)	O
Italy	B-MED
.	O
All	O
patients	B-MED
aged	B-MED
≥18	B-MED
years	I-MED
with	O
at	O
least	O
one	O
recorded	O
body	B-MED
mass	I-MED
index	I-MED
(	O
BMI	B-MED
)	O
measurement	B-MED
between	O
1	O
January	O
2009	O
and	O
31	O
December	O
2012	O
were	O
included	O
.	O
Information	B-MED
retrieved	O
from	O
the	O
databases	B-MED
included	O
primary	B-MED
care	I-MED
data	I-MED
,	O
medical	B-MED
prescriptions	I-MED
,	O
specialist	B-MED
consultations	I-MED
and	O
hospital	B-MED
discharge	I-MED
records	I-MED
from	O
2009	O
-	O
2013	O
.	O
Costs	B-MED
associated	B-MED
with	I-MED
these	O
data	B-MED
were	O
also	O
calculated	B-MED
.	O
Data	B-MED
are	O
presented	O
for	O
two	O
time	B-MED
periods	I-MED
(	O
1	B-MED
year	I-MED
after	O
BMI	B-MED
measurement	B-MED
and	O
study	O
end	O
)	O
.	O
Primary	B-MED
-to	O
estimate	B-MED
health	B-MED
resources	I-MED
consumption	B-MED
and	O
the	O
associated	O
economic	B-MED
impact	I-MED
on	O
the	O
Italian	B-MED
NHS	B-MED
.	O
Secondary	B-MED
-the	O
prevalence	B-MED
and	O
characteristics	B-MED
of	O
subjects	B-MED
by	O
BMI	B-MED
category	B-MED
.	O
20	O
159	O
adult	B-MED
subjects	B-MED
with	O
at	O
least	O
one	O
documented	B-MED
BMI	I-MED
measurement	B-MED
.	O
Subjects	B-MED
with	O
BMI	B-MED
≥30	O
kg	O
/	O
m(2	O
)	O
were	O
defined	O
as	O
obese	B-MED
.	O
The	O
prevalence	B-MED
of	O
obesity	B-MED
was	O
22.2	O
%	O
(	O
N=4471	O
)	O
and	O
increased	B-MED
with	O
age	B-MED
.	O
At	O
the	O
1	B-MED
-	I-MED
year	I-MED
observation	B-MED
period	B-MED
,	O
obese	B-MED
subjects	B-MED
who	O
did	O
not	O
receive	O
treatment	B-MED
for	O
their	O
obesity	B-MED
experienced	O
longer	B-MED
durations	I-MED
of	O
hospitalisation	B-MED
(	O
median	O
length	O
:	O
5	B-MED
days	I-MED
vs	O
3	B-MED
days	I-MED
)	O
,	O
used	O
more	O
prescription	B-MED
drugs	I-MED
(	O
75.0	O
%	O
vs	O
57.7	O
%	O
)	O
,	O
required	O
more	O
specialised	B-MED
outpatient	B-MED
healthcare	B-MED
(	O
mean	B-MED
number	I-MED
:	O
5.3	O
vs	O
4.4	O
)	O
and	O
were	O
associated	B-MED
with	I-MED
greater	B-MED
costs	I-MED
,	O
primarily	O
owing	O
to	O
prescription	B-MED
drugs	I-MED
and	O
hospital	B-MED
admissions	I-MED
(	O
mean	B-MED
annual	I-MED
cost	I-MED
per	O
year	B-MED
per	O
patient	B-MED
:	O
€	O
460.6	O
vs	O
€	O
288.0	O
for	O
drug	B-MED
prescriptions	I-MED
,	O
€	O
422.7	O
vs	O
€	O
279.2	O
for	O
hospitalisations	B-MED
and	O
€	O
283.2	O
vs	O
€	O
251.7	O
for	O
outpatient	B-MED
care	I-MED
)	O
,	O
compared	O
with	O
normal	B-MED
weight	I-MED
subjects	B-MED
.	O
Similar	O
findings	B-MED
were	O
observed	O
for	O
the	O
period	B-MED
up	O
to	O
data	B-MED
cut	O
-	O
off	O
(	O
mean	O
follow	B-MED
-	I-MED
up	I-MED
of	O
2.7	O
years	O
)	O
.	O
Untreated	B-MED
obesity	B-MED
has	O
a	O
significant	O
economic	B-MED
impact	I-MED
on	O
the	O
Italian	B-MED
healthcare	B-MED
system	I-MED
,	O
highlighting	O
the	O
need	O
to	O
raise	O
awareness	B-MED
and	O
proactively	O
treat	B-MED
obese	O
subjects	B-MED
.	O
Endpoints	B-MED
for	O
screening	B-MED
thyroid	B-MED
cancer	I-MED
in	O
the	O
Republic	B-MED
of	I-MED
Korea	I-MED
:	O
thyroid	B-MED
specialists	B-MED
'	O
perspectives	B-MED
Cancer	B-MED
screening	I-MED
is	O
aimed	O
primarily	O
at	O
reducing	B-MED
deaths	B-MED
from	O
the	O
specific	O
cancer	B-MED
.	O
Thyroid	B-MED
-	I-MED
specific	I-MED
cancer	I-MED
mortality	B-MED
may	O
be	O
the	O
most	O
ambitious	O
endpoint	B-MED
for	O
obtaining	O
estimates	B-MED
of	O
screening	B-MED
effect	B-MED
.	O
Numerous	B-MED
observations	B-MED
have	O
accumulated	B-MED
over	O
the	O
years	O
,	O
indicating	O
that	O
thyroid	B-MED
cancer	I-MED
mortality	B-MED
endpoint	B-MED
has	O
been	O
difficult	B-MED
to	O
study	O
and	O
is	O
confounded	O
by	O
population	B-MED
heterogeneity	I-MED
,	O
provision	B-MED
of	O
randomization	B-MED
,	O
and	O
requirement	B-MED
of	O
large	O
cohorts	B-MED
with	O
sufficiently	O
long	B-MED
follow	I-MED
-	I-MED
up	I-MED
due	O
to	O
the	O
excellent	B-MED
prognosis	B-MED
of	I-MED
the	I-MED
cancer	I-MED
.	O
Accordingly	O
,	O
it	O
may	O
be	O
important	B-MED
to	O
reconsider	O
how	O
to	O
best	O
measure	O
thyroid	B-MED
cancer	I-MED
screening	B-MED
efficacy	B-MED
.	O
Recommendations	B-MED
against	O
thyroid	B-MED
cancer	I-MED
screening	B-MED
should	O
be	O
based	O
upon	O
trials	O
designed	O
to	O
evaluate	O
its	O
effectiveness	B-MED
not	O
only	O
in	O
significant	B-MED
reduction	I-MED
in	O
cancer	B-MED
mortality	B-MED
,	O
but	O
also	O
of	O
other	O
distinct	O
endpoint	B-MED
s.	O
It	O
is	O
desirable	O
to	O
evaluate	O
derivative	O
endpoints	B-MED
that	O
can	O
reliably	O
predict	O
reductions	B-MED
in	I-MED
mortality	I-MED
.	O
The	O
term	O
"	O
derivative	O
"	O
means	O
a	O
variable	O
that	O
is	O
related	O
to	O
the	O
true	O
endpoint	B-MED
and	O
is	O
likely	O
to	O
be	O
observable	O
before	O
the	O
primary	O
endpoint	B-MED
.	O
Derivative	O
endpoints	B-MED
may	O
include	O
thyroid	B-MED
cancer	I-MED
incidence	B-MED
,	O
the	O
proportion	B-MED
of	O
early	B-MED
-	I-MED
stage	I-MED
tumors	B-MED
detected	B-MED
,	O
more	O
treatable	B-MED
stage	I-MED
,	O
the	O
identification	B-MED
of	O
small	B-MED
tumors	I-MED
(	O
to	O
maintain	O
in	O
observation	O
)	O
,	O
decrease	B-MED
in	I-MED
the	I-MED
number	I-MED
of	I-MED
people	I-MED
who	O
develop	O
metastatic	B-MED
disease	I-MED
,	O
the	O
increased	B-MED
chance	O
of	O
lesser	O
extent	O
surgery	B-MED
,	O
and	O
the	O
application	O
of	O
minimally	B-MED
invasive	I-MED
approaches	I-MED
,	O
as	O
well	O
as	O
no	O
need	O
for	O
lifelong	B-MED
thyroid	B-MED
replacement	I-MED
therapy	I-MED
,	O
a	O
consistent	B-MED
follow	B-MED
-	I-MED
up	I-MED
,	O
low	B-MED
-	I-MED
dose	I-MED
or	O
no	O
RAI	B-MED
administration	I-MED
and	O
risk	B-MED
factor	I-MED
assessments	I-MED
where	O
case	B-MED
findings	I-MED
should	O
be	O
continuous	B-MED
.	O
The	O
Korean	B-MED
Korean	B-MED
guidelines	I-MED
for	O
thyroid	B-MED
cancer	I-MED
national	B-MED
-	I-MED
level	I-MED
screening	B-MED
were	O
published	O
by	O
a	O
relevant	O
group	O
of	O
multidisciplinary	B-MED
thyroid	I-MED
experts	I-MED
.	O
It	O
was	O
concluded	O
that	O
the	O
evidence	B-MED
is	I-MED
insufficient	I-MED
to	O
balance	O
the	O
benefits	B-MED
and	O
harms	O
of	O
thyroid	B-MED
cancer	I-MED
screening	B-MED
.	O
However	O
,	O
the	O
paper	O
seems	O
to	O
raise	O
the	O
necessary	O
investments	O
in	O
future	O
research	B-MED
and	O
demand	O
a	O
complete	B-MED
analysis	B-MED
for	O
derivative	O
endpoints	B-MED
,	O
and	O
offer	O
screening	B-MED
participants	B-MED
with	O
complete	O
information	B-MED
necessary	O
to	B-MED
make	I-MED
decisions	I-MED
that	O
will	O
provide	O
them	O
with	O
the	O
most	O
value	O
when	O
a	O
small	O
thyroid	B-MED
cancer	I-MED
is	O
screen-	O
identified	B-MED
.	O
The	O
nurse	B-MED
-	I-MED
patient	I-MED
communication	I-MED
:	O
voices	O
from	O
nursing	B-MED
students	I-MED
Effective	B-MED
communication	I-MED
skills	I-MED
have	O
been	O
found	O
to	O
be	O
one	O
of	O
the	O
pivotal	B-MED
factors	I-MED
in	O
building	O
positive	B-MED
interpersonal	I-MED
relationships	I-MED
.	O
Little	O
is	O
known	O
about	O
nursing	B-MED
undergraduates	I-MED
'	O
perspectives	B-MED
on	O
communicating	B-MED
with	O
patients	B-MED
.	O
This	O
study	B-MED
aimed	O
to	O
explore	O
nursing	B-MED
students	I-MED
'	I-MED
perspectives	B-MED
and	O
experiences	B-MED
of	O
nurse	B-MED
-	I-MED
patient	I-MED
communication	I-MED
in	O
their	O
clinical	B-MED
placement	B-MED
.	O
The	O
participants	B-MED
included	O
21	O
second	B-MED
-	I-MED
year	I-MED
undergraduates	I-MED
and	O
21	O
first	B-MED
-	I-MED
year	I-MED
master	I-MED
's	I-MED
students	I-MED
.	O
Interviews	B-MED
were	O
conducted	O
in	O
Cantonese	B-MED
and	O
then	O
transcribed	O
in	O
Chinese	B-MED
and	O
translated	O
into	O
English	B-MED
.	O
A	O
content	B-MED
analysis	I-MED
approach	B-MED
was	O
adopted	O
to	O
analyze	O
the	O
data	B-MED
.	O
Five	O
themes	B-MED
emerged	O
from	O
the	O
interview	B-MED
data	I-MED
.	O
'	O
The	O
necessity	O
of	O
nurse	B-MED
-	I-MED
patient	I-MED
communication	I-MED
'	O
reveals	B-MED
why	O
the	O
students	B-MED
valued	O
nurse	B-MED
-	I-MED
patient	I-MED
communication	I-MED
.	O
'	O
The	O
conversation	B-MED
contents	I-MED
'	O
describes	O
the	O
content	B-MED
of	I-MED
the	I-MED
conversations	I-MED
that	O
students	B-MED
typically	O
had	O
with	O
patients	B-MED
.	O
The	O
third	O
theme	B-MED
is	O
'	O
self	B-MED
-	I-MED
reflection	I-MED
on	O
the	O
nurse	B-MED
-	I-MED
patient	I-MED
communication	I-MED
'	O
.	O
The	O
last	O
two	O
themes	B-MED
,	O
'	O
the	O
communication	B-MED
pattern	I-MED
in	I-MED
different	I-MED
hospital	B-MED
settings	I-MED
'	O
and	O
'	O
the	O
obstacles	O
impeding	O
nurse	B-MED
-	I-MED
patient	I-MED
communication	I-MED
'	O
,	O
are	O
about	O
the	O
students	B-MED
'	I-MED
communication	B-MED
styles	I-MED
in	O
different	O
hospitals	B-MED
and	O
the	O
barriers	O
they	O
encounter	B-MED
.	O
To	O
improve	B-MED
students	B-MED
'	I-MED
communication	B-MED
skills	I-MED
,	O
educators	B-MED
and	O
clinical	B-MED
staff	I-MED
should	O
listen	O
to	O
students	B-MED
,	O
enhance	B-MED
students	B-MED
'	I-MED
reflective	B-MED
skills	I-MED
and	O
strengthen	O
their	O
confidence	B-MED
.	O
Through	O
understanding	B-MED
students	B-MED
'	I-MED
difficulties	B-MED
in	O
the	O
nurse	B-MED
-	I-MED
patient	I-MED
communication	I-MED
experience	B-MED
and	O
the	O
skills	B-MED
that	O
they	O
lack	O
,	O
educators	B-MED
can	O
provide	O
them	O
with	O
helpful	O
recommendations	B-MED
to	O
improve	B-MED
their	O
communication	B-MED
skills	I-MED
in	O
clinical	B-MED
practice	I-MED
.	O
The	O
results	O
of	O
this	O
study	B-MED
reveal	B-MED
that	O
students	B-MED
'	I-MED
nurse	B-MED
-	I-MED
patient	I-MED
communication	I-MED
skills	B-MED
need	O
to	O
be	O
improved	B-MED
.	O
Accounting	B-MED
for	O
linkage	B-MED
disequilibrium	I-MED
in	O
genome	B-MED
scans	I-MED
for	O
selection	B-MED
without	B-MED
individual	B-MED
genotypes	B-MED
:	O
The	O
local	B-MED
score	I-MED
approach	I-MED
Detecting	B-MED
genomic	I-MED
footprints	I-MED
of	O
selection	B-MED
is	O
an	O
important	O
step	O
in	O
the	O
understanding	O
of	O
evolution	B-MED
.	O
Accounting	O
for	O
linkage	B-MED
disequilibrium	I-MED
in	O
genome	B-MED
scans	I-MED
increases	O
detection	B-MED
power	B-MED
,	O
but	O
haplotype	B-MED
-based	O
methods	O
require	O
individual	B-MED
genotypes	B-MED
and	O
are	O
not	O
applicable	O
on	O
pool	B-MED
-	I-MED
sequenced	I-MED
samples	I-MED
.	O
We	O
propose	O
to	O
take	O
advantage	O
of	O
the	O
local	B-MED
score	I-MED
approach	I-MED
to	O
account	O
for	O
linkage	B-MED
disequilibrium	I-MED
in	O
genome	B-MED
scans	I-MED
for	O
selection	B-MED
,	O
cumulating	B-MED
(	O
possibly	O
small	O
)	O
signals	B-MED
from	O
single	O
markers	B-MED
over	O
a	O
genomic	B-MED
segment	I-MED
,	O
to	O
clearly	O
pinpoint	O
a	O
selection	B-MED
signal	B-MED
.	O
Using	O
computer	B-MED
simulations	I-MED
,	O
we	O
demonstrate	O
that	O
this	O
approach	O
detects	B-MED
selection	B-MED
with	O
higher	O
power	O
than	O
several	O
state	B-MED
-	I-MED
of	I-MED
-	I-MED
the	I-MED
-	I-MED
art	I-MED
single	B-MED
-	I-MED
marker	I-MED
,	O
windowing	O
or	O
haplotype	B-MED
-based	O
approaches	O
.	O
We	O
illustrate	O
this	O
on	O
two	O
benchmark	B-MED
data	B-MED
sets	I-MED
including	O
individual	B-MED
genotypes	B-MED
,	O
for	O
which	O
we	O
obtain	O
similar	O
results	O
with	O
the	O
local	B-MED
score	I-MED
and	O
one	O
haplotype	B-MED
-based	O
approach	O
.	O
Finally	O
,	O
we	O
apply	O
the	O
local	B-MED
score	I-MED
approach	I-MED
to	O
Pool	B-MED
-	I-MED
Seq	I-MED
data	I-MED
obtained	O
from	O
a	O
divergent	B-MED
selection	B-MED
experiment	B-MED
on	O
behaviour	B-MED
in	O
quail	B-MED
and	O
obtain	O
precise	O
and	O
biologically	B-MED
coherent	B-MED
selection	B-MED
signals	B-MED
:	O
while	O
competing	O
methods	O
fail	O
to	O
highlight	O
any	O
clear	O
selection	B-MED
signature	O
,	O
our	O
method	O
detects	B-MED
several	O
regions	O
involving	O
genes	B-MED
known	O
to	O
act	O
on	O
social	B-MED
responsiveness	B-MED
or	O
autistic	B-MED
traits	I-MED
.	O
Although	O
we	O
focus	O
here	O
on	O
the	O
detection	B-MED
of	O
positive	B-MED
selection	B-MED
from	O
multiple	B-MED
population	I-MED
data	I-MED
,	O
the	O
local	B-MED
score	I-MED
approach	I-MED
is	O
general	O
and	O
can	O
be	O
applied	O
to	O
other	O
genome	B-MED
scans	I-MED
for	O
selection	B-MED
or	O
other	O
genomewide	B-MED
analyses	I-MED
such	O
as	O
GWAS	B-MED
.	O
Right	B-MED
Ventricular	I-MED
Response	B-MED
During	B-MED
Exercise	B-MED
in	O
Patients	B-MED
with	O
Chronic	B-MED
Obstructive	I-MED
Pulmonary	I-MED
Disease	I-MED
Right	B-MED
ventricular	I-MED
(	O
RV	B-MED
)	O
pump	B-MED
function	I-MED
is	O
of	O
essential	B-MED
clinical	B-MED
and	O
prognostic	B-MED
importance	B-MED
in	O
a	O
variety	B-MED
of	O
heart	B-MED
and	O
lung	B-MED
diseases	I-MED
.	O
While	O
the	O
evaluation	B-MED
of	O
RV	B-MED
performance	B-MED
at	O
rest	B-MED
has	O
been	O
implemented	O
in	O
the	O
clinical	B-MED
setting	I-MED
,	O
it	O
is	O
unknown	O
whether	O
this	O
assessment	B-MED
during	B-MED
exercise	B-MED
may	O
provide	O
additional	B-MED
benefit	B-MED
.	O
With	O
this	O
aim	B-MED
,	O
we	O
evaluated	B-MED
the	O
exercise	B-MED
-	O
induced	B-MED
pulmonary	B-MED
arterial	I-MED
systolic	I-MED
pressure	I-MED
(	O
PASP	B-MED
)	O
increase	B-MED
during	B-MED
exercise	B-MED
in	O
patients	B-MED
with	O
severe	B-MED
chronic	B-MED
obstructive	I-MED
pulmonary	I-MED
disease	I-MED
(	O
COPD	B-MED
)	O
as	O
an	O
expression	O
of	O
RV	B-MED
contractile	B-MED
reserve	I-MED
.	O
Cardiopulmonary	B-MED
exercise	I-MED
testing	I-MED
(	O
CPET	B-MED
)	O
with	O
synchronic	B-MED
echocardiography	I-MED
was	O
performed	B-MED
in	O
81	O
patients	B-MED
.	O
Patients	B-MED
were	O
classified	B-MED
into	O
two	O
groups	B-MED
according	O
to	O
an	O
exercise	B-MED
-	O
induced	B-MED
PASP	B-MED
increase	B-MED
above	O
30mmHg	O
(	O
High	B-MED
PSAP	B-MED
)	O
or	O
below	O
30mmHg	O
(	O
Low	B-MED
PSAP	B-MED
)	O
during	B-MED
maximal	B-MED
exercise	B-MED
.	O
Patients	B-MED
were	O
then	O
followed	B-MED
for	O
three	O
years	B-MED
.	O
Sixteen	O
patients	B-MED
(	O
20	O
%	O
)	O
had	O
low	B-MED
PSAP	B-MED
and	O
65	O
(	O
80	O
%	O
)	O
showed	O
high	B-MED
PSAP	B-MED
.	O
These	O
were	O
not	B-MED
significant	I-MED
clinical	B-MED
and	O
functional	B-MED
differences	B-MED
.	O
Low	B-MED
PSAP	B-MED
was	O
associated	B-MED
with	I-MED
a	O
significantly	B-MED
lower	I-MED
peak	B-MED
VO2	B-MED
(	O
mean	B-MED
(	O
SD	B-MED
)	O
,	O
35	O
(	O
2	O
)	O
%	O
predicted	B-MED
)	O
compared	B-MED
to	O
high	B-MED
PSAP	B-MED
response	B-MED
(	O
peak	B-MED
VO2	B-MED
45	O
(	O
3	O
)	O
%	O
predicted	B-MED
)	O
,	O
p=0.045	O
.	O
Factors	B-MED
associated	B-MED
with	I-MED
mortality	B-MED
were	O
age	B-MED
and	O
exercise	B-MED
-	O
induced	B-MED
PASP	B-MED
.	O
Seventeen	O
patients	B-MED
died	O
during	B-MED
the	O
three	O
years	B-MED
of	O
follow	B-MED
-	I-MED
up	I-MED
(	O
7	O
(	O
39	O
%	O
)	O
in	O
the	O
low	B-MED
PSAP	B-MED
group	B-MED
and	O
only	O
10	O
(	O
1	O
%	O
)	O
in	O
the	O
high	B-MED
PSAP	B-MED
group	B-MED
,	O
p=0.041	O
)	O
.	O
Cardiopulmonary	B-MED
exercise	I-MED
testing	I-MED
with	O
a	O
synchronic	B-MED
echocardiography	I-MED
may	O
be	O
a	O
useful	O
tool	O
for	O
the	O
assessment	B-MED
of	O
RV	B-MED
contractile	B-MED
reserve	I-MED
in	O
severe	B-MED
COPD	B-MED
patients	B-MED
.	O
Exercise	B-MED
-	O
induced	B-MED
PSAP	B-MED
emerges	O
as	O
a	O
possible	O
prognostic	B-MED
factor	I-MED
in	O
these	O
patients	B-MED
.	O
Clinicopathological	B-MED
and	O
Immunohistochemical	B-MED
Characteristics	O
of	O
Verruciform	B-MED
Xanthoma	I-MED
of	O
the	O
Lower	B-MED
Gingiva	I-MED
:	O
A	O
Case	B-MED
Report	I-MED
Verruciform	B-MED
xanthoma	I-MED
(	O
VX	B-MED
)	O
is	O
a	O
rare	O
benign	B-MED
lesion	I-MED
and	O
mainly	O
effects	O
the	O
oral	B-MED
mucosa	I-MED
.	O
This	O
slow	B-MED
-	I-MED
growing	I-MED
asymptomatic	B-MED
lesion	B-MED
typically	O
develops	O
along	O
the	O
gingival	B-MED
margin	I-MED
of	O
the	O
masticatory	B-MED
mucosa	B-MED
,	O
followed	O
by	O
the	O
hard	B-MED
palate	I-MED
,	O
tongue	B-MED
,	O
buccal	B-MED
mucosa	I-MED
,	O
floor	B-MED
of	I-MED
the	I-MED
mouth	I-MED
,	O
alveolar	B-MED
mucosa	I-MED
,	O
soft	B-MED
palate	I-MED
and	O
junction	B-MED
between	O
the	O
hard	B-MED
and	O
soft	B-MED
palate	I-MED
.	O
Moreover	O
,	O
this	O
lesion	B-MED
can	O
also	O
affect	O
the	O
skin	B-MED
and	O
genital	B-MED
organs	I-MED
.	O
Clinically	B-MED
,	O
VX	B-MED
generally	O
presents	O
a	O
sessile	B-MED
or	O
pedunculated	B-MED
appearance	I-MED
,	O
forming	O
a	O
papule	B-MED
or	O
single	B-MED
plaque	I-MED
with	O
verrucous	B-MED
or	O
papillomatous	B-MED
mucosal	B-MED
growth	B-MED
.	O
The	O
colour	B-MED
(	O
white	B-MED
,	O
pink	B-MED
,	O
grey	B-MED
,	O
or	O
yellow	B-MED
)	O
depends	O
on	O
the	O
thickness	B-MED
of	O
the	O
overlying	O
epidermis	B-MED
.	O
In	O
fact	O
,	O
the	O
clinical	B-MED
findings	B-MED
of	O
VX	B-MED
are	O
similar	O
to	O
those	O
of	O
verrucous	B-MED
carcinoma	I-MED
and	O
other	O
benign	B-MED
tumours	I-MED
,	O
such	O
as	O
squamous	B-MED
papilloma	I-MED
,	O
verruca	B-MED
vulgaris	I-MED
and	O
mucosal	B-MED
fibroma	I-MED
.	O
For	O
this	O
reason	O
,	O
clinical	B-MED
and	O
histopathological	B-MED
examinations	B-MED
are	O
essential	O
for	O
accurate	B-MED
differential	I-MED
diagnosis	I-MED
.	O
Histologically	B-MED
,	O
VX	B-MED
is	O
characterized	O
by	O
parakeratosis	B-MED
,	O
rete	B-MED
ridges	I-MED
of	O
uniform	O
depth	O
and	O
the	O
accumulation	B-MED
of	O
foam	B-MED
cells	I-MED
,	O
which	O
are	O
also	O
called	O
"	O
xanthoma	B-MED
cells	I-MED
"	O
.	O
Here	O
,	O
we	O
describe	O
the	O
clinicopathological	B-MED
and	O
immunohistochemical	B-MED
findings	B-MED
of	O
a	O
VX	B-MED
located	O
on	O
the	O
lower	B-MED
gingiva	I-MED
of	O
a	O
64	O
-	O
year	O
-	O
old	O
male	B-MED
patient	I-MED
.	O
The	O
Urokinase	B-MED
/	O
Urokinase	B-MED
Receptor	I-MED
System	O
in	O
Mast	B-MED
Cells	I-MED
:	O
Effects	B-MED
of	O
its	O
Functional	B-MED
Interaction	B-MED
with	O
fMLF	B-MED
Receptors	I-MED
Mast	B-MED
cell	I-MED
and	O
basophils	B-MED
express	B-MED
the	O
high	B-MED
affinity	I-MED
receptor	I-MED
for	O
IgE	B-MED
(	O
FcɛRI	B-MED
)	O
and	O
are	O
primary	B-MED
effector	I-MED
cells	I-MED
of	O
allergic	B-MED
disorders	I-MED
.	O
The	O
urokinase	B-MED
uPA	B-MED
(	O
uPA)-mediated	O
plasminogen	B-MED
activation	I-MED
system	I-MED
is	O
involved	O
in	O
physiological	B-MED
and	O
pathological	B-MED
events	I-MED
based	O
on	O
cell	B-MED
migration	I-MED
and	O
tissue	B-MED
remodelling	I-MED
,	O
such	O
as	O
inflammation	B-MED
,	O
wound	B-MED
healing	I-MED
,	O
angiogenesis	B-MED
and	O
metastasis	B-MED
.	O
uPA	B-MED
is	O
a	O
serine	B-MED
protease	I-MED
that	O
binds	O
uPAR	B-MED
,	O
a	O
high	B-MED
affinity	I-MED
glycosyl	I-MED
-	I-MED
phosphatidyl	I-MED
-	I-MED
inositol	I-MED
(	I-MED
GPI)-anchored	I-MED
receptor	B-MED
.	O
uPAR	B-MED
focuses	O
uPA	B-MED
activity	B-MED
at	O
the	O
cell	B-MED
surface	I-MED
and	O
activates	B-MED
intracellular	I-MED
signaling	I-MED
through	O
lateral	O
interactions	B-MED
with	O
integrins	B-MED
,	O
receptor	B-MED
tyrosine	I-MED
kinases	I-MED
and	O
the	O
G	B-MED
-	I-MED
protein	I-MED
-	I-MED
coupled	I-MED
family	I-MED
of	O
fMLF	B-MED
chemotaxis	I-MED
receptors	I-MED
(	O
FPRs	B-MED
)	O
.	O
We	O
investigated	B-MED
the	O
expression	B-MED
of	O
the	O
uPA	B-MED
-	O
uPAR	B-MED
system	O
and	O
its	O
functional	B-MED
interaction	B-MED
with	O
FPRs	B-MED
in	O
human	B-MED
mast	B-MED
cells	I-MED
(	O
MCs	B-MED
)	O
.	O
Differently	O
from	O
basophils	B-MED
,	O
MCs	B-MED
produced	O
uPA	B-MED
that	O
was	O
able	O
to	O
induce	O
their	O
chemotaxis	B-MED
.	O
Indeed	O
,	O
MCs	B-MED
also	O
expressed	O
uPAR	B-MED
,	O
both	O
in	O
the	O
intact	O
and	O
in	O
a	O
cleaved	O
form	O
(	O
DII	B-MED
-	I-MED
DIII	I-MED
-	I-MED
uPAR	I-MED
)	O
that	O
can	O
expose	O
,	O
at	O
the	O
N	O
-	O
terminus	O
,	O
the	O
SRSRY	B-MED
sequence	I-MED
,	O
able	O
to	O
interact	O
with	O
FPRs	B-MED
and	O
to	O
mediate	O
cell	B-MED
chemotaxis	I-MED
.	O
MCs	B-MED
also	O
expressed	O
mRNAs	B-MED
for	O
FPRs	B-MED
that	O
were	O
functionally	O
active	O
;	O
indeed	O
,	O
uPA	B-MED
and	O
a	O
soluble	B-MED
peptide	I-MED
(	O
uPAR84	B-MED
-	I-MED
95	I-MED
)	O
,	O
containing	O
the	O
SRSRY	B-MED
chemotactic	I-MED
sequence	I-MED
of	O
uPAR	B-MED
and	O
able	O
to	O
interact	O
with	O
FPRs	B-MED
,	O
were	O
able	O
to	O
induce	O
MCs	B-MED
chemotaxis	B-MED
.	O
Thus	O
,	O
uPA	B-MED
is	O
a	O
potent	O
chemoattractant	B-MED
for	O
MCs	B-MED
acting	O
through	O
the	O
exposure	B-MED
of	O
the	O
chemotactic	B-MED
epitope	B-MED
of	O
uPAR	B-MED
,	O
that	O
is	O
an	O
endogenous	B-MED
ligand	B-MED
for	O
FPRs	B-MED
.	O
The	O
same	O
mechanism	B-MED
could	O
be	O
involved	O
in	O
VEGF	B-MED
-	I-MED
A	I-MED
secretion	B-MED
by	O
human	B-MED
MCs	B-MED
,	O
also	O
induced	B-MED
by	O
uPA	B-MED
and	O
uPAR84	B-MED
-	I-MED
95	I-MED
stimulation	B-MED
.	I-MED
Yersinia	B-MED
ruckeri	I-MED
Isolates	B-MED
Recovered	B-MED
from	I-MED
Diseased	B-MED
Atlantic	B-MED
Salmon	I-MED
(	O
Salmo	B-MED
salar	I-MED
)	O
in	O
Scotland	B-MED
Are	O
More	O
Diverse	O
than	O
Those	O
from	O
Rainbow	B-MED
Trout	I-MED
(	O
Oncorhynchus	B-MED
mykiss	I-MED
)	O
and	O
Represent	B-MED
Distinct	O
Subpopulations	B-MED
Yersinia	B-MED
ruckeri	I-MED
is	O
the	O
etiological	B-MED
agent	I-MED
of	O
enteric	B-MED
redmouth	I-MED
(	O
ERM	B-MED
)	O
disease	B-MED
of	O
farmed	O
salmonids	B-MED
.	O
Enteric	B-MED
redmouth	I-MED
disease	I-MED
is	O
traditionally	O
associated	B-MED
with	I-MED
rainbow	B-MED
trout	I-MED
(	O
Oncorhynchus	B-MED
mykiss	I-MED
,	O
Walbaum	B-MED
)	O
,	O
but	O
its	O
incidence	B-MED
in	O
Atlantic	B-MED
salmon	I-MED
(	O
Salmo	B-MED
salar	I-MED
)	O
is	O
increasing	B-MED
.	O
Yersinia	B-MED
ruckeri	I-MED
isolates	B-MED
recovered	B-MED
from	I-MED
diseased	B-MED
Atlantic	B-MED
salmon	I-MED
have	O
been	O
poorly	B-MED
characterized	I-MED
,	O
and	O
very	O
little	O
is	O
known	O
about	O
the	O
relationship	B-MED
of	O
the	O
isolates	B-MED
associated	B-MED
with	I-MED
these	O
two	O
species	B-MED
.	O
Phenotypic	B-MED
approaches	O
were	O
used	O
to	O
characterize	O
109	O
Y.	B-MED
ruckeri	I-MED
isolates	B-MED
recovered	O
over	O
a	O
14	O
-	O
year	O
period	O
from	O
infected	B-MED
Atlantic	B-MED
salmon	I-MED
in	O
Scotland	B-MED
;	O
26	O
isolates	B-MED
from	O
infected	B-MED
rainbow	B-MED
trout	I-MED
were	O
also	O
characterized	B-MED
.	O
Biotyping	B-MED
,	O
serotyping	B-MED
,	O
and	O
comparison	B-MED
of	O
outer	B-MED
membrane	I-MED
protein	B-MED
profiles	I-MED
identified	O
19	O
Y.	B-MED
ruckeri	I-MED
clones	B-MED
associated	B-MED
with	I-MED
Atlantic	B-MED
salmon	I-MED
but	O
only	O
five	O
associated	B-MED
with	I-MED
rainbow	B-MED
trout	I-MED
;	O
none	O
of	O
the	O
Atlantic	B-MED
salmon	I-MED
clones	B-MED
occurred	O
in	O
rainbow	B-MED
trout	I-MED
and	O
vice	O
versa	O
These	O
findings	B-MED
suggest	O
that	O
distinct	O
subpopulations	B-MED
of	O
Y.	B-MED
ruckeri	I-MED
are	O
associated	B-MED
with	I-MED
each	O
species	B-MED
.	O
A	O
new	O
O	B-MED
serotype	I-MED
(	O
designated	O
O8	O
)	O
was	O
identified	O
in	O
56	B-MED
biotype	I-MED
1	I-MED
Atlantic	B-MED
salmon	I-MED
isolates	B-MED
and	O
was	O
the	O
most	O
common	O
serotype	B-MED
identified	O
from	O
2006	O
to	O
2011	O
and	O
in	O
2014	O
,	O
suggesting	O
an	O
increased	B-MED
prevalence	I-MED
during	O
the	O
time	O
period	O
sampled	O
.	O
Rainbow	B-MED
trout	I-MED
isolates	B-MED
were	O
represented	B-MED
almost	O
exclusively	O
by	O
the	O
same	O
biotype	B-MED
2	I-MED
,	O
serotype	B-MED
O1	I-MED
clone	O
that	O
has	O
been	O
responsible	O
for	O
the	O
majority	O
of	O
ERM	B-MED
outbreaks	O
in	O
this	O
species	B-MED
within	O
the	O
United	B-MED
Kingdom	I-MED
since	O
the	O
1980s	O
.	O
However	O
,	O
the	O
identification	O
of	O
two	O
biotype	B-MED
2	I-MED
,	O
serotype	B-MED
O8	I-MED
isolates	B-MED
in	O
rainbow	B-MED
trout	I-MED
suggests	O
that	O
vaccines	B-MED
containing	O
serotypes	B-MED
O1	I-MED
and	I-MED
O8	I-MED
should	O
be	O
evaluated	O
in	O
both	O
rainbow	B-MED
trout	I-MED
and	O
Atlantic	B-MED
salmon	I-MED
for	O
application	O
in	O
Scotland	B-MED
.	O
Vaccination	B-MED
plays	O
an	O
important	O
role	O
in	O
protecting	O
Atlantic	B-MED
salmon	I-MED
against	O
the	O
bacterial	B-MED
pathogen	O
Yersinia	B-MED
ruckeri	I-MED
,	O
but	O
,	O
in	O
recent	O
years	O
,	O
there	O
has	O
been	O
an	O
increasing	B-MED
incidence	B-MED
of	O
vaccine	B-MED
breakdown	O
in	O
salmon	B-MED
.	O
This	O
is	O
largely	O
because	O
current	O
vaccines	B-MED
are	O
aimed	O
at	O
rainbow	B-MED
trout	I-MED
and	O
are	O
based	O
on	O
serotypes	B-MED
specific	O
for	O
this	O
species	B-MED
.	O
A	O
wider	O
range	O
of	O
serotypes	B-MED
is	O
responsible	O
for	O
infection	B-MED
in	O
Atlantic	B-MED
salmon	I-MED
,	O
but	O
very	O
little	O
is	O
known	O
about	O
the	O
diversity	O
of	O
these	O
strains	B-MED
and	O
their	O
relationships	B-MED
to	O
those	O
recovered	B-MED
from	I-MED
rainbow	B-MED
trout	I-MED
.	O
In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
Y.	B-MED
ruckeri	I-MED
isolates	B-MED
recovered	B-MED
from	I-MED
diseased	B-MED
Atlantic	B-MED
salmon	I-MED
in	O
Scotland	B-MED
are	O
more	O
diverse	O
than	O
those	O
from	O
rainbow	B-MED
trout	I-MED
;	O
furthermore	O
,	O
isolates	B-MED
from	O
the	O
two	O
species	B-MED
represent	B-MED
distinct	O
subpopulations	B-MED
.	O
In	O
addition	O
,	O
a	O
new	O
O	B-MED
serotype	I-MED
was	O
identified	O
that	O
is	O
responsible	O
for	O
a	O
significant	B-MED
proportion	B-MED
of	O
the	O
disease	B-MED
in	O
Atlantic	B-MED
salmon	I-MED
.	O
Our	O
findings	B-MED
are	O
likely	O
to	O
have	O
important	O
implications	O
for	O
the	O
development	B-MED
of	I-MED
improved	I-MED
vaccines	I-MED
against	O
Y.	B-MED
ruckeri	I-MED
.	O
Assessment	O
of	O
groundwater	B-MED
vulnerability	B-MED
in	O
the	O
Daule	B-MED
aquifer	I-MED
,	O
Ecuador	B-MED
,	O
using	O
the	O
susceptibility	B-MED
index	I-MED
method	I-MED
The	O
Guayas	B-MED
region	I-MED
in	O
Ecuador	B-MED
is	O
economically	O
very	O
important	O
,	O
producing	O
68	O
%	O
of	O
the	O
national	B-MED
crops	I-MED
.	O
The	O
main	O
agricultural	B-MED
activities	I-MED
threaten	O
the	O
groundwater	B-MED
therein	O
with	O
nitrate	B-MED
contamination	B-MED
given	O
the	O
large	O
fertiliser	B-MED
and	O
water	B-MED
needs	B-MED
.	O
The	O
present	O
work	O
tests	O
the	O
applicability	O
of	O
the	O
susceptibility	B-MED
index	I-MED
assessment	I-MED
method	I-MED
in	O
evaluating	O
the	O
impact	O
of	O
agricultural	B-MED
activities	I-MED
on	O
groundwater	B-MED
quality	B-MED
,	O
using	O
as	O
a	O
case	O
study	O
an	O
aquifer	B-MED
of	O
the	O
Guayas	B-MED
river	B-MED
basin	I-MED
in	O
Ecuador	B-MED
.	O
The	O
index	O
adapts	O
four	O
parameters	O
of	O
the	O
DRASTIC	B-MED
method	I-MED
and	O
incorporated	O
a	O
new	O
land	B-MED
use	I-MED
parameter	O
.	O
Results	O
show	O
that	O
the	O
areas	B-MED
highly	B-MED
vulnerable	B-MED
to	O
contamination	B-MED
are	O
located	O
in	O
irrigation	B-MED
perimeters	B-MED
of	O
dominant	O
paddy	B-MED
fields	I-MED
associated	O
with	O
the	O
high	O
recharge	O
rates	O
in	O
the	O
alluvial	B-MED
deposits	I-MED
.	O
Respectively	O
,	O
moderately	B-MED
vulnerable	B-MED
and	O
low	B-MED
-	O
vulnerability	B-MED
areas	B-MED
correspond	O
to	O
aquatic	B-MED
environments	I-MED
and	O
forests	B-MED
,	O
semi	B-MED
-	I-MED
natural	I-MED
zones	I-MED
and	O
water	B-MED
bodies	I-MED
.	O
One	O
of	O
the	O
main	O
contributions	O
of	O
the	O
Daule	B-MED
aquifer	I-MED
vulnerability	B-MED
is	O
likely	O
its	O
wide	B-MED
,	O
flat	B-MED
topography	I-MED
.	O
A	O
great	O
part	O
of	O
the	O
aquifer	B-MED
is	O
at	O
high	B-MED
risk	I-MED
of	I-MED
contamination	I-MED
by	O
nitrates	B-MED
if	O
a	O
code	O
of	O
good	B-MED
agricultural	B-MED
practices	I-MED
is	O
not	O
applied	O
.	O
Therefore	O
the	O
implementation	O
of	O
a	O
monitoring	B-MED
network	I-MED
to	I-MED
control	I-MED
the	O
nitrates	B-MED
concentrations	B-MED
is	O
the	O
first	O
step	O
to	O
assure	O
groundwater	B-MED
quality	B-MED
for	O
drinking	B-MED
purposes	B-MED
.	O
Assessing	B-MED
the	O
physiological	B-MED
relevance	B-MED
of	O
alternate	O
architectures	B-MED
of	O
the	O
p7	B-MED
protein	I-MED
of	O
hepatitis	B-MED
C	I-MED
virus	I-MED
in	O
different	O
environments	B-MED
The	O
viroporin	B-MED
p7	B-MED
of	O
the	O
hepatitis	B-MED
C	I-MED
virus	I-MED
forms	O
multimeric	B-MED
channels	I-MED
eligible	O
for	O
ion	B-MED
transport	I-MED
across	O
the	O
endoplasmic	B-MED
reticulum	I-MED
membrane	I-MED
.	O
Currently	O
the	O
subject	B-MED
of	O
many	O
studies	B-MED
and	O
discussion	O
,	O
the	O
molecular	B-MED
assembly	I-MED
of	O
the	O
ion	B-MED
channel	I-MED
and	O
the	O
structural	B-MED
characteristics	B-MED
of	O
the	O
p7	B-MED
monomer	B-MED
are	O
not	O
yet	O
fully	O
understood	O
.	O
Structural	B-MED
investigation	B-MED
of	O
p7	B-MED
has	O
been	O
carried	O
out	O
only	O
in	O
detergent	B-MED
environments	B-MED
,	O
making	O
the	O
interpretation	O
of	O
the	O
experimental	O
results	O
somewhat	O
questionable	O
.	O
Here	O
,	O
we	O
analyze	B-MED
by	O
means	O
of	O
molecular	B-MED
dynamics	I-MED
simulations	I-MED
the	O
structure	B-MED
of	O
the	O
p7	B-MED
monomer	B-MED
as	O
a	O
function	O
of	O
its	O
sequence	B-MED
,	O
initial	O
conformation	B-MED
and	O
environment	B-MED
.	O
We	O
investigate	O
the	O
conductance	B-MED
properties	O
of	O
three	O
models	B-MED
of	O
a	O
hexameric	B-MED
p7	B-MED
ion	B-MED
channel	I-MED
by	O
examining	O
ion	B-MED
translocation	I-MED
in	O
a	O
pure	O
lipid	B-MED
bilayer	I-MED
.	O
It	O
is	O
noteworthy	O
that	O
although	O
none	O
of	O
the	O
models	B-MED
reflects	O
the	O
experimentally	O
observed	O
trend	O
to	O
conduct	O
preferentially	O
cations	B-MED
,	O
we	O
were	O
able	O
to	O
identify	O
the	O
position	B-MED
and	O
orientation	B-MED
of	O
titratable	O
acidic	B-MED
or	I-MED
basic	I-MED
residues	I-MED
playing	O
a	O
crucial	O
role	O
in	O
ion	B-MED
selectivity	B-MED
and	O
in	O
the	O
overall	O
conductance	B-MED
of	O
the	O
channel	B-MED
.	O
In	O
addition	O
,	O
too	O
compact	O
a	O
packing	B-MED
of	O
the	O
monomers	B-MED
leads	O
to	O
channel	B-MED
collapse	B-MED
rather	O
than	O
formation	O
of	O
a	O
reasonable	O
pore	B-MED
,	O
amenable	O
to	O
ion	B-MED
translocation	I-MED
.	O
The	O
present	O
findings	O
are	O
envisioned	O
to	O
help	O
assess	O
the	O
physiological	B-MED
relevance	B-MED
of	O
p7	B-MED
ion	B-MED
channel	I-MED
models	B-MED
consisting	O
of	O
multimeric	B-MED
structures	I-MED
obtained	O
in	O
non	O
-	O
native	O
environments	B-MED
.	O
Locating	O
the	O
Seventh	B-MED
Cervical	I-MED
Spinous	I-MED
Process	I-MED
:	O
Development	O
and	O
Validation	O
of	O
a	O
Multivariate	B-MED
Model	I-MED
Using	O
Palpation	B-MED
and	O
Personal	B-MED
Information	I-MED
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
validate	O
a	O
multivariate	B-MED
prediction	I-MED
model	I-MED
,	O
guided	O
by	O
palpation	B-MED
and	O
personal	B-MED
information	I-MED
,	O
for	O
locating	O
the	O
seventh	B-MED
cervical	I-MED
spinous	I-MED
process	I-MED
(	O
C7SP	B-MED
)	O
.	O
A	O
single	B-MED
-	I-MED
blinded	I-MED
,	I-MED
cross	I-MED
-	I-MED
sectional	I-MED
study	I-MED
at	O
a	O
primary	B-MED
to	I-MED
tertiary	I-MED
health	I-MED
care	I-MED
center	I-MED
was	O
conducted	O
for	O
model	B-MED
development	I-MED
and	O
temporal	B-MED
validation	I-MED
.	O
One	O
-	O
hundred	O
sixty	O
participants	B-MED
were	O
prospectively	O
included	O
for	O
model	B-MED
development	I-MED
(	O
n	O
=	O
80	O
)	O
and	O
time	B-MED
-	I-MED
split	I-MED
validation	I-MED
stages	I-MED
(	O
n	O
=	O
80	O
)	O
.	O
The	O
C7SP	B-MED
was	O
located	O
using	O
the	O
thorax	B-MED
-	I-MED
rib	I-MED
static	I-MED
method	I-MED
(	O
TRSM	B-MED
)	O
.	O
Participants	B-MED
underwent	O
chest	B-MED
radiography	I-MED
for	O
assessment	O
of	O
the	O
inner	B-MED
body	B-MED
structure	I-MED
located	O
with	O
TRSM	B-MED
and	O
using	O
radio	B-MED
-	I-MED
opaque	I-MED
markers	I-MED
placed	O
over	O
the	O
skin	B-MED
.	O
Age	B-MED
,	O
sex	B-MED
,	O
height	B-MED
,	O
body	B-MED
mass	I-MED
,	O
body	B-MED
mass	I-MED
index	I-MED
,	O
and	O
vertex	B-MED
-	I-MED
marker	I-MED
distanc	I-MED
e	O
(	O
DV	B-MED
-	I-MED
M	I-MED
)	O
were	O
used	O
to	O
predict	O
the	O
distance	B-MED
from	O
the	O
C7SP	B-MED
to	O
the	O
vertex	B-MED
(	O
DV	B-MED
-	I-MED
C7	I-MED
)	O
.	O
Multivariate	B-MED
linear	I-MED
regression	I-MED
modeling	I-MED
,	O
limits	O
of	O
agreement	O
plot	O
,	O
histogram	B-MED
of	I-MED
residues	I-MED
,	O
receiver	B-MED
operating	I-MED
characteristic	I-MED
curves	I-MED
,	O
and	O
confusion	B-MED
tables	I-MED
were	O
analyzed	O
.	O
The	O
multivariate	B-MED
linear	I-MED
prediction	I-MED
model	I-MED
for	O
DV	B-MED
-	I-MED
C7	I-MED
(	O
in	O
centimeters	O
)	O
was	O
DV	B-MED
-	I-MED
C7	I-MED
=	O
0.986DV	O
-	O
M	O
+	O
0.018(mass	O
)	O
+	O
0.014(age	O
)	O
-	O
1.008	O
.	O
Receiver	B-MED
operating	I-MED
characteristic	I-MED
curves	I-MED
had	O
better	O
discrimination	O
of	O
DV	B-MED
-	I-MED
C7	I-MED
(	O
area	O
under	O
the	O
curve	O
=	O
0.661	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
=	O
0.541	O
-	O
0.782	O
;	O
P	O
=	O
.015	O
)	O
than	O
DV	B-MED
-	I-MED
M	I-MED
(	O
area	O
under	O
the	O
curve	O
=	O
0.480	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
=	O
0.345	O
-	O
0.614	O
;	O
P	O
=	O
.761	O
)	O
,	O
with	O
respective	O
cutoff	O
points	O
at	O
23.40	O
cm	O
(	O
sensitivity	B-MED
=	O
41	O
%	O
,	O
specificity	B-MED
=	O
63	O
%	O
)	O
and	O
24.75	O
cm	O
(	O
sensitivity	B-MED
=	O
69	O
%	O
,	O
specificity	B-MED
=	O
52	O
%	O
)	O
.	O
The	O
C7SP	B-MED
was	O
correctly	O
located	O
more	O
often	O
when	O
using	O
predicted	O
DV	B-MED
-	I-MED
C7	I-MED
in	O
the	O
validation	O
sample	O
than	O
when	O
using	O
the	O
TRSM	B-MED
in	O
the	O
development	O
sample	O
:	O
n	O
=	O
53	O
(	O
66	O
%	O
)	O
vs	O
n	O
=	O
32	O
(	O
40	O
%	O
)	O
,	O
P	O
<	O
.001	O
.	O
Better	O
accuracy	O
was	O
obtained	O
when	O
locating	O
the	O
C7SP	B-MED
by	O
use	O
of	O
a	O
multivariate	B-MED
model	I-MED
that	O
incorporates	O
palpation	B-MED
and	O
personal	B-MED
information	I-MED
.	O
Effects	O
of	O
morphology	B-MED
and	O
surface	B-MED
hydroxyl	I-MED
on	O
the	O
toxicity	B-MED
of	O
BiOCl	B-MED
in	O
human	B-MED
HaCaT	B-MED
cells	I-MED
Recently	O
,	O
bismuth	B-MED
oxychloride	I-MED
nanomaterials	B-MED
(	O
BiOCls	B-MED
)	O
are	O
showing	O
great	O
promise	O
in	O
pollutant	B-MED
removal	B-MED
.	O
Residues	B-MED
from	O
these	O
environmental	B-MED
remediations	I-MED
are	O
potential	O
hazardous	B-MED
materials	I-MED
.	O
Unfortunately	O
,	O
human	B-MED
health	B-MED
risks	I-MED
of	O
BiOCls	B-MED
are	O
still	O
unexplored	O
widely	O
.	O
In	O
the	O
present	O
study	B-MED
,	O
we	O
focused	O
on	O
the	O
influence	O
of	O
physicochemical	B-MED
properties	I-MED
on	O
the	O
cytotoxicity	B-MED
of	O
BiOCls	B-MED
toward	O
a	O
human	B-MED
skin	B-MED
derived	O
cell	B-MED
line	I-MED
(	O
HaCaT	B-MED
)	O
.	O
Results	O
showed	O
that	O
morphology	B-MED
and	O
surface	B-MED
hydroxyl	I-MED
both	O
had	O
a	O
profound	O
effect	O
on	O
the	O
toxicity	B-MED
of	O
BiOCls	B-MED
.	O
Microsphere	B-MED
-	I-MED
shaped	I-MED
BiOCl	B-MED
caused	O
less	O
toxicity	B-MED
than	O
nanosheet	B-MED
-	I-MED
shaped	I-MED
BiOCl	B-MED
because	O
of	O
weaker	B-MED
particle	I-MED
-	I-MED
membrane	I-MED
interactions	I-MED
,	O
while	O
the	O
presence	O
of	O
surface	B-MED
hydroxyl	I-MED
on	O
microsphere	B-MED
-	I-MED
shaped	I-MED
BiOCl	B-MED
significantly	O
raised	O
the	O
toxicity	B-MED
owing	O
to	O
the	O
increased	O
interaction	B-MED
with	O
cell	B-MED
membrane	I-MED
.	O
Both	O
microsphere	B-MED
-	I-MED
shaped	I-MED
BiOCl	B-MED
with	O
surface	B-MED
hydroxyl	I-MED
and	O
nanosheet	B-MED
-	I-MED
shaped	I-MED
BiOCl	B-MED
caused	O
significant	O
cell	B-MED
membrane	I-MED
damage	B-MED
(	O
PI	B-MED
PI	B-MED
uptake	I-MED
and	O
LDH	B-MED
LDH	B-MED
release	I-MED
)	O
,	O
however	O
,	O
based	O
on	O
the	O
different	O
mechanism	B-MED
.	O
The	O
former	O
may	O
be	O
a	O
predominant	O
"	B-MED
chemical	I-MED
"	I-MED
mechanism	I-MED
involved	O
an	O
oxidative	B-MED
stress	I-MED
paradigm	I-MED
,	O
as	O
manifested	O
by	O
elevated	O
ROS	B-MED
and	O
depleted	O
GSH	B-MED
,	O
while	O
the	O
latter	O
is	O
mainly	O
due	O
to	O
a	O
direct	O
"	O
physical	B-MED
"	O
damage	B-MED
to	O
cell	B-MED
membrane	I-MED
.	O
Both	O
"	O
physical	B-MED
"	O
and	O
"	B-MED
chemical	I-MED
"	I-MED
response	I-MED
led	O
to	O
cell	B-MED
death	I-MED
.	O
Furthermore	O
,	O
a	O
set	O
of	O
experiments	B-MED
including	O
MMP	B-MED
collapse	O
,	O
cell	B-MED
cycle	I-MED
arrest	I-MED
,	O
and	O
apoptosis	B-MED
/	O
necrosis	B-MED
were	O
conducted	O
to	O
propose	O
a	O
scenario	O
for	O
toxicological	B-MED
aspects	I-MED
of	O
BiOCls	B-MED
.	O
Data	B-MED
presented	O
here	O
would	O
help	O
to	O
enable	O
the	O
rational	B-MED
design	I-MED
of	O
BiOCls	B-MED
for	O
either	O
reducing	O
their	O
unintended	B-MED
consequences	I-MED
or	O
increasing	O
their	O
application	B-MED
potentials	I-MED
.	O
Binding	B-MED
of	O
DEAD	B-MED
-	I-MED
box	I-MED
helicase	I-MED
Dhh1	B-MED
to	O
the	O
5'UTR	B-MED
of	O
ASH1	B-MED
mRNA	B-MED
represses	B-MED
localized	O
translation	B-MED
of	O
ASH1	B-MED
in	O
yeast	B-MED
cells	B-MED
Local	B-MED
translation	I-MED
of	O
specific	B-MED
mRNAs	B-MED
is	O
regulated	B-MED
by	O
dynamic	O
changes	O
in	O
their	O
subcellular	B-MED
localization	B-MED
,	O
and	O
these	O
changes	B-MED
are	O
due	O
to	O
complex	B-MED
mechanisms	B-MED
controlling	B-MED
cytoplasmic	B-MED
mRNA	B-MED
transport	I-MED
.	O
The	O
budding	B-MED
yeast	I-MED
Saccharomyces	B-MED
cerevisiae	I-MED
is	O
well	O
suited	O
to	O
studying	O
these	O
mechanisms	B-MED
because	O
many	O
of	O
its	O
transcripts	B-MED
are	O
transported	B-MED
from	O
the	O
mother	B-MED
cell	I-MED
to	O
the	O
budding	B-MED
daughter	B-MED
cell	I-MED
.	O
Here	O
,	O
we	O
investigated	B-MED
the	O
translational	B-MED
control	I-MED
of	O
ASH1	B-MED
mRNA	B-MED
after	O
transport	B-MED
and	O
localization	B-MED
.	O
We	O
show	O
that	O
although	O
ASH1	B-MED
ASH1	B-MED
transcripts	B-MED
were	O
translated	B-MED
after	O
they	O
reached	O
the	O
bud	B-MED
-	I-MED
tip	I-MED
,	O
some	O
mRNAs	B-MED
were	O
bound	O
by	O
the	O
RNA	B-MED
-	I-MED
binding	I-MED
protein	I-MED
Puf6	B-MED
and	O
were	O
non	B-MED
-	I-MED
polysomal	I-MED
.	O
We	O
also	O
found	O
that	O
the	O
DEAD	B-MED
-	I-MED
box	I-MED
helicase	I-MED
Dhh1	B-MED
complexed	B-MED
with	O
the	O
untranslated	B-MED
ASH1	B-MED
mRNA	B-MED
and	O
Puf6	B-MED
.	O
Loss	O
of	O
Dhh1	B-MED
affected	O
local	B-MED
translation	I-MED
of	O
ASH1	B-MED
mRNA	B-MED
and	O
resulted	O
in	O
delocalization	B-MED
of	O
ASH1	B-MED
transcript	B-MED
in	O
the	O
bud	B-MED
.	O
Forcibly	O
shifting	O
the	O
non	B-MED
-	I-MED
polysomal	I-MED
ASH1	B-MED
mRNA	B-MED
into	O
polysomes	B-MED
was	O
associated	O
with	O
Dhh1	B-MED
dissociation	B-MED
.	O
We	O
further	O
demonstrated	O
that	O
Dhh1	B-MED
is	O
not	O
recruited	O
to	O
ASH1	B-MED
mRNA	B-MED
co	B-MED
-	I-MED
transcriptionally	I-MED
,	O
suggesting	B-MED
that	O
it	O
could	O
bind	O
to	O
ASH1	B-MED
mRNA	B-MED
within	O
the	O
cytoplasm	B-MED
.	O
Of	O
note	O
,	O
Dhh1	B-MED
bound	O
to	O
the	O
5	B-MED
UTR	I-MED
of	O
ASH1	B-MED
mRNA	B-MED
and	O
inhibited	B-MED
its	O
translation	B-MED
in	B-MED
vitro	I-MED
.	O
These	O
results	O
suggest	B-MED
that	O
after	O
localization	B-MED
to	O
the	O
bud	B-MED
tip	I-MED
,	I-MED
a	O
portion	B-MED
of	O
the	O
localized	B-MED
ASH1	B-MED
mRNA	B-MED
becomes	O
translationally	B-MED
inactive	B-MED
,	O
because	O
of	O
binding	B-MED
of	O
Dhh1	B-MED
and	O
Puf6	B-MED
to	O
the	O
5	B-MED
'	I-MED
and	I-MED
3	I-MED
'	I-MED
UTRs	I-MED
of	O
ASH1	B-MED
mRNA	B-MED
.	O
Antigen	B-MED
Masking	B-MED
During	O
Fixation	B-MED
and	O
Embedding	B-MED
,	O
Dissected	B-MED
Antigen	B-MED
masking	B-MED
in	O
routinely	O
processed	B-MED
tissue	B-MED
is	O
a	O
poorly	O
understood	O
process	O
caused	O
by	O
multiple	B-MED
factors	B-MED
.	O
We	O
sought	O
to	O
dissect	B-MED
the	O
effect	O
on	O
antigenicity	B-MED
of	O
each	O
step	B-MED
of	O
processing	B-MED
by	O
using	O
frozen	B-MED
sections	I-MED
as	O
proxies	B-MED
of	O
the	O
whole	B-MED
tissue	I-MED
.	O
An	O
equivalent	O
extent	O
of	O
antigen	B-MED
masking	B-MED
occurs	O
across	O
variable	O
fixation	B-MED
times	B-MED
at	O
room	B-MED
temperature	I-MED
.	O
Most	O
antigens	B-MED
benefit	O
from	O
longer	O
fixation	B-MED
times	B-MED
(	O
>	O
24	O
hr	O
)	O
for	O
optimal	O
detection	B-MED
after	O
antigen	B-MED
retrieval	B-MED
(	O
AR	B-MED
;	O
for	O
example	O
,	O
Ki-67	B-MED
,	O
bcl-2	B-MED
,	O
ER	B-MED
)	O
.	O
The	O
transfer	B-MED
to	O
a	O
graded	B-MED
alcohol	I-MED
series	B-MED
results	O
in	O
an	O
enhanced	O
staining	B-MED
effect	I-MED
,	O
reproduced	O
by	O
treating	B-MED
the	O
sections	B-MED
with	O
detergents	B-MED
,	O
possibly	O
because	O
of	O
a	O
better	O
access	O
of	O
the	O
polymeric	B-MED
immunohistochemical	B-MED
detection	B-MED
system	B-MED
to	O
tissue	B-MED
structures	B-MED
.	O
A	O
second	O
round	O
of	O
masking	B-MED
occurs	O
upon	O
entering	O
the	O
clearing	B-MED
agent	I-MED
,	O
mostly	O
at	O
the	O
paraffin	B-MED
embedding	B-MED
step	B-MED
.	O
This	O
may	O
depend	O
on	O
the	O
non	B-MED
-	I-MED
freezable	I-MED
water	B-MED
removal	B-MED
.	O
AR	B-MED
fully	O
reverses	O
the	O
masking	B-MED
due	O
both	O
to	O
the	O
fixation	B-MED
time	B-MED
and	O
the	O
paraffin	B-MED
embedding	B-MED
.	O
AR	B-MED
itself	O
destroys	B-MED
some	O
epitopes	B-MED
which	O
do	O
not	O
survive	O
routine	B-MED
processing	B-MED
.	O
Processed	B-MED
frozen	B-MED
sections	I-MED
are	O
a	O
tool	O
to	O
investigate	B-MED
fixation	B-MED
and	O
processing	B-MED
requirements	B-MED
for	O
antigens	B-MED
in	O
routine	B-MED
specimens	B-MED
.	O
Visualization	B-MED
for	O
Understanding	O
Uncertainty	B-MED
in	O
Activation	B-MED
Volumes	B-MED
for	O
Deep	B-MED
Brain	I-MED
Stimulation	I-MED
We	O
have	O
created	O
the	O
Neurostimulation	B-MED
Uncertainty	I-MED
Viewer	I-MED
(	I-MED
nuView	I-MED
or	I-MED
νView	I-MED
)	I-MED
tool	I-MED
for	O
exploring	O
data	B-MED
arising	O
from	O
deep	B-MED
brain	I-MED
stimulation	I-MED
(	O
DBS	B-MED
)	O
.	O
Simulated	B-MED
volume	B-MED
of	I-MED
tissue	I-MED
activated	I-MED
(	O
VTA	B-MED
)	O
,	O
using	O
clinical	B-MED
electrode	I-MED
placements	I-MED
,	O
are	O
recorded	B-MED
along	O
with	O
patient	B-MED
outcomes	B-MED
in	O
the	O
Unified	B-MED
Parkinson	I-MED
's	I-MED
disease	I-MED
rating	I-MED
scale	I-MED
(	O
UPDRS	B-MED
)	O
.	O
The	O
data	B-MED
is	O
volumetric	B-MED
and	O
sparse	B-MED
,	O
with	O
multi	B-MED
-	I-MED
value	I-MED
patient	B-MED
results	B-MED
for	O
each	O
activated	B-MED
voxel	B-MED
in	O
the	O
simulation	B-MED
.	O
νView	B-MED
provides	O
a	O
collection	B-MED
of	O
visual	B-MED
methods	I-MED
to	O
explore	O
the	O
activated	B-MED
tissue	B-MED
to	O
enhance	O
understanding	O
of	O
electrode	B-MED
usage	B-MED
for	O
improved	O
therapy	B-MED
with	O
DBS	B-MED
.	O
PCVMZM	B-MED
:	O
Using	O
the	O
Probabilistic	B-MED
Classification	I-MED
Vector	I-MED
Machines	I-MED
Model	I-MED
Combined	I-MED
with	I-MED
a	I-MED
Zernike	I-MED
Moments	I-MED
Descriptor	O
to	O
Predict	B-MED
Protein	B-MED
-	I-MED
Protein	I-MED
Interactions	I-MED
from	O
Protein	B-MED
Sequences	I-MED
Protein	B-MED
-	I-MED
protein	I-MED
interactions	I-MED
(	O
PPIs	B-MED
)	O
are	O
essential	O
for	O
most	O
living	B-MED
organisms	I-MED
'	O
process	O
.	O
Thus	O
,	O
detecting	O
PPIs	B-MED
is	O
extremely	O
important	O
to	O
understand	O
the	O
molecular	B-MED
mechanisms	B-MED
of	O
biological	B-MED
systems	I-MED
.	O
Although	O
many	O
PPIs	B-MED
data	O
have	O
been	O
generated	O
by	O
high	B-MED
-	I-MED
throughput	I-MED
technologies	I-MED
for	O
a	O
variety	O
of	O
organisms	B-MED
,	O
the	O
whole	O
interatom	O
is	O
still	O
far	O
from	O
complete	O
.	O
In	O
addition	O
,	O
the	O
high	B-MED
-	I-MED
throughput	I-MED
technologies	I-MED
for	O
detecting	O
PPIs	B-MED
has	O
some	O
unavoidable	B-MED
defects	I-MED
,	O
including	O
time	B-MED
consumption	I-MED
,	O
high	O
cost	B-MED
,	O
and	O
high	O
error	B-MED
rate	I-MED
.	O
In	O
recent	O
years	O
,	O
with	O
the	O
development	O
of	O
machine	B-MED
learning	I-MED
,	O
computational	B-MED
methods	I-MED
have	O
been	O
broadly	O
used	O
to	O
predict	O
PPIs	B-MED
,	O
and	O
can	O
achieve	O
good	O
prediction	B-MED
rate	O
.	O
In	O
this	O
paper	O
,	O
we	O
present	O
here	O
PCVMZM	B-MED
,	O
a	O
computational	B-MED
method	I-MED
based	O
on	O
a	O
Probabilistic	B-MED
Classification	I-MED
Vector	I-MED
Machines	I-MED
(	I-MED
PCVM	I-MED
)	I-MED
model	I-MED
and	O
Zernike	B-MED
moments	I-MED
(	I-MED
ZM	I-MED
)	I-MED
descriptor	I-MED
for	O
predicting	B-MED
the	O
PPIs	B-MED
from	O
protein	B-MED
amino	B-MED
acids	I-MED
sequences	I-MED
.	O
Specifically	O
,	O
a	O
Zernike	B-MED
moments	I-MED
(	I-MED
ZM	I-MED
)	I-MED
descriptor	I-MED
is	O
used	O
to	O
extract	O
protein	B-MED
evolutionary	O
information	B-MED
from	O
Position	B-MED
-	I-MED
Specific	I-MED
Scoring	I-MED
Matrix	I-MED
(	O
PSSM	B-MED
)	O
generated	O
by	O
Position	B-MED
-	I-MED
Specific	I-MED
Iterated	I-MED
Basic	I-MED
Local	I-MED
Alignment	I-MED
Search	I-MED
Tool	I-MED
(	I-MED
PSI	I-MED
-	I-MED
BLAST	I-MED
)	I-MED
.	O
Then	O
,	O
PCVM	B-MED
classifier	I-MED
is	O
used	O
to	O
infer	O
the	O
interactions	B-MED
among	O
protein	B-MED
.	O
When	O
performed	O
on	O
PPIs	B-MED
datasets	O
of	O
Yeast	B-MED
and	O
H.	B-MED
Pylori	I-MED
,	O
the	O
proposed	O
method	O
can	O
achieve	O
the	O
average	O
prediction	B-MED
accuracy	B-MED
of	O
94.48	O
%	O
and	O
91.25	O
%	O
,	O
respectively	O
.	O
In	O
order	O
to	O
further	O
evaluate	O
the	O
performance	O
of	O
the	O
proposed	O
method	O
,	O
the	O
state	B-MED
-	I-MED
of	I-MED
-	I-MED
the	I-MED
-	I-MED
art	I-MED
support	B-MED
vector	I-MED
machines	I-MED
(	O
SVM	B-MED
)	I-MED
classifier	I-MED
is	O
used	O
and	O
compares	O
with	O
the	O
PCVM	B-MED
model	I-MED
.	O
Experimental	B-MED
results	I-MED
on	O
the	O
Yeast	B-MED
dataset	O
show	O
that	O
the	O
performance	O
of	O
PCVM	B-MED
classifier	I-MED
is	O
better	O
than	O
that	O
of	O
SVM	B-MED
classifier	I-MED
.	O
The	O
experimental	B-MED
results	I-MED
indicate	O
that	O
our	O
proposed	O
method	O
is	O
robust	O
,	O
powerful	O
and	O
feasible	O
,	O
which	O
can	O
be	O
used	O
as	O
a	O
helpful	O
tool	O
for	O
proteomics	B-MED
research	I-MED
.	O
Abundance	B-MED
and	O
Characterization	B-MED
of	O
Perfect	O
Microsatellites	B-MED
on	O
the	O
Cattle	B-MED
Y	B-MED
Chromosome	I-MED
Microsatellites	B-MED
or	O
simple	B-MED
sequence	I-MED
repeats	I-MED
(	O
SSRs	B-MED
)	O
are	O
found	O
in	O
most	O
organisms	B-MED
and	O
play	O
an	O
important	O
role	O
in	O
genomic	B-MED
organization	I-MED
and	O
function	B-MED
.	O
To	O
characterize	B-MED
the	O
abundance	B-MED
of	O
SSRs	B-MED
(	O
1	O
-	O
6	O
base	B-MED
-	I-MED
pairs	I-MED
[	O
bp	B-MED
]	O
)	O
on	O
the	O
cattle	B-MED
Y	B-MED
chromsome	I-MED
,	O
the	O
relative	O
frequency	B-MED
and	O
density	B-MED
of	O
perfect	O
or	O
uninterrupted	O
SSRs	B-MED
based	O
on	O
the	O
published	O
Y	B-MED
chromosome	I-MED
sequence	B-MED
were	O
examined	B-MED
.	O
A	O
total	O
of	O
17,273	O
perfect	O
SSRs	B-MED
were	O
found	O
,	O
with	O
total	O
length	B-MED
of	O
324.78	O
kb	O
,	O
indicating	O
that	O
approximately	O
0.75	O
%	O
of	O
the	O
cattle	B-MED
Y	B-MED
chromosome	I-MED
sequence	B-MED
(	O
43.30	O
Mb	O
)	O
comprises	O
perfect	O
SSRs	B-MED
,	O
with	O
an	O
average	O
length	B-MED
of	O
18.80	O
bp	B-MED
.	O
The	O
relative	O
frequency	B-MED
and	O
density	B-MED
were	O
398.92	O
loci	O
/	O
Mb	O
and	O
7500.62	O
bp	B-MED
/Mb	O
,	O
respectively	O
.	O
The	O
proportions	O
of	O
the	O
six	O
classes	O
of	O
perfect	O
SSRs	B-MED
were	O
highly	O
variable	O
on	O
the	O
cattle	B-MED
Y	B-MED
chromosome	I-MED
.	O
Mononucleotide	B-MED
repeats	I-MED
had	O
a	O
total	O
number	O
of	O
8073	O
(	O
46.74	O
%	O
)	O
and	O
an	O
average	O
length	B-MED
of	O
15.45	O
bp	B-MED
,	O
and	O
were	O
the	O
most	O
abundant	O
SSRs	B-MED
class	O
,	O
while	O
the	O
percentages	O
of	O
di-	B-MED
,	O
tetra-	B-MED
,	O
tri-	B-MED
,	O
penta-	B-MED
,	O
and	O
hexa	B-MED
-	I-MED
nucleotide	I-MED
repeats	I-MED
were	O
22.86	O
%	O
,	O
11.98	O
%	O
,	O
11.58	O
%	O
,	O
6.65	O
%	O
,	O
and	O
0.19	O
%	O
,	O
respectively	O
.	O
Different	O
classes	O
of	O
SSRs	B-MED
varied	O
in	O
their	O
repeat	O
number	O
,	O
with	O
the	O
highest	O
being	O
42	O
for	O
dinucleotides	B-MED
.	O
Results	O
reveal	O
that	O
repeat	O
categories	O
A	B-MED
,	O
AC	B-MED
,	O
AT	B-MED
,	O
AAC	B-MED
,	O
AGC	B-MED
,	O
GTTT	B-MED
,	O
CTTT	B-MED
,	O
ATTT	B-MED
,	O
and	O
AACTG	B-MED
predominate	O
on	O
the	O
Y	B-MED
chromosome	I-MED
.	O
This	O
study	B-MED
provides	O
insight	O
into	O
the	O
organization	O
of	O
cattle	B-MED
Y	B-MED
chromosome	I-MED
repetitive	O
DNA	B-MED
,	O
as	O
well	O
as	O
information	O
useful	O
for	O
developing	O
more	O
polymorphic	B-MED
cattle	B-MED
Y	B-MED
-	I-MED
chromosome	I-MED
-specific	O
SSRs	B-MED
.	O
Burden	B-MED
of	O
cervical	B-MED
cancer	I-MED
and	O
role	O
of	O
screening	B-MED
in	O
India	B-MED
Cervical	B-MED
cancer	I-MED
is	O
a	O
major	O
cause	O
of	O
cancer	B-MED
mortality	I-MED
in	O
women	B-MED
and	O
more	O
than	O
a	O
quarter	B-MED
of	O
its	O
global	B-MED
burden	B-MED
is	O
contributed	B-MED
by	O
developing	B-MED
countries	I-MED
.	O
In	O
India	B-MED
,	O
in	O
spite	O
of	O
alarmingly	O
high	O
figures	O
,	O
there	O
is	O
no	O
nationwide	O
government	B-MED
-	I-MED
sponsored	I-MED
screening	I-MED
program	I-MED
.	O
This	O
study	B-MED
was	O
conducted	B-MED
to	O
assess	B-MED
the	O
burden	B-MED
of	O
cervical	B-MED
cancer	I-MED
in	O
India	B-MED
and	O
review	B-MED
the	O
performance	B-MED
characteristics	B-MED
of	O
available	O
cervical	B-MED
cancer	I-MED
screening	B-MED
tools	O
,	O
so	O
as	O
to	O
provide	B-MED
evidence	B-MED
-based	O
recommendations	B-MED
for	O
application	O
of	O
most	O
practically	O
suited	O
screening	B-MED
test	I-MED
to	O
be	O
used	O
in	O
resource	B-MED
-poor	O
field	O
settings	O
.	O
MEDLINE	B-MED
and	O
Web	B-MED
of	I-MED
Science	I-MED
electronic	I-MED
database	I-MED
were	O
searched	B-MED
from	O
January	B-MED
1990	O
to	O
December	B-MED
2015	O
,	O
using	O
the	O
keywords	B-MED
such	O
as	O
"	O
cervical	B-MED
cancer	I-MED
"	O
,	O
"	O
screening	B-MED
"	O
,	O
"	O
early	B-MED
detection	I-MED
"	O
,	O
"	O
cervical	B-MED
cytology	I-MED
"	O
and	O
"	O
visual	B-MED
inspection	I-MED
"	O
,	O
and	O
their	O
corresponding	O
MeSH	B-MED
terms	I-MED
in	O
combination	B-MED
with	O
Boolean	B-MED
operators	I-MED
"	O
OR	O
,	O
AND	O
.	O
"	O
Two	O
authors	B-MED
independently	O
selected	B-MED
studies	B-MED
that	O
are	O
published	B-MED
in	O
English	B-MED
and	O
conducted	B-MED
in	O
India	B-MED
.	O
A	O
total	B-MED
of	O
11	O
studies	B-MED
were	O
found	B-MED
to	O
be	O
relevant	B-MED
and	O
eligible	B-MED
to	O
be	O
included	B-MED
in	O
the	O
present	B-MED
study	B-MED
.	O
In	O
India	B-MED
,	O
cervical	B-MED
cancer	I-MED
contributes	B-MED
to	O
approximately	B-MED
6	O
-	O
29	O
%	O
of	O
all	O
cancers	B-MED
in	O
women	B-MED
.	O
The	O
age	B-MED
-	I-MED
adjusted	I-MED
incidence	I-MED
rate	I-MED
of	O
cervical	B-MED
cancer	I-MED
varies	O
widely	O
among	O
registries	B-MED
;	O
highest	B-MED
is	O
23.07/100,000	O
in	O
Mizoram	B-MED
state	I-MED
and	O
the	O
lowest	B-MED
is	O
4.91/100,000	O
in	O
Dibrugarh	B-MED
district	I-MED
.	O
The	O
pooled	O
estimates	B-MED
of	O
sensitivity	B-MED
and	O
specificity	B-MED
of	O
visual	B-MED
inspection	I-MED
with	I-MED
acetic	I-MED
acid	I-MED
(	O
VIA	B-MED
)	O
,	O
magnified	B-MED
VIA	I-MED
,	O
visual	B-MED
inspection	I-MED
with	I-MED
Lugol	I-MED
's	I-MED
iodine	I-MED
(	O
VILI	B-MED
)	O
,	O
cytology	B-MED
(	O
Pap	B-MED
smear	I-MED
)	O
,	O
and	O
human	B-MED
papillomavirus	I-MED
DNA	I-MED
were	O
found	O
to	O
be	O
67.65	O
%	O
and	O
84.32	O
%	O
,	O
65.36	O
%	O
and	O
85.76	O
%	O
,	O
78.27	O
%	O
and	O
87.10	O
%	O
,	O
62.11	O
%	O
and	O
93.51	O
%	O
,	O
and	O
77.81	O
%	O
and	O
91.54	O
%	O
,	O
respectively	O
.	O
In	O
developing	B-MED
countries	I-MED
because	O
of	O
lack	B-MED
of	O
necessary	O
infrastructure	B-MED
and	O
quality	B-MED
control	I-MED
,	O
high	B-MED
-	I-MED
quality	I-MED
cytology	B-MED
screening	I-MED
may	O
not	O
be	O
feasible	O
for	O
wide	O
-	O
scale	O
implementation	B-MED
.	O
Hence	O
,	O
cervical	B-MED
cancer	I-MED
screening	B-MED
program	B-MED
based	O
on	O
visual	B-MED
screening	I-MED
test	I-MED
such	O
as	O
VIA	B-MED
/	O
VILI	B-MED
should	O
be	O
adopted	O
as	O
an	O
integral	O
part	O
of	O
primary	O
health	B-MED
-	I-MED
care	I-MED
setup	I-MED
in	O
resource	B-MED
-	O
poor	B-MED
countries	B-MED
like	O
India	B-MED
.	O
Catastrophic	B-MED
health	B-MED
expenditure	I-MED
:	O
a	O
comparative	B-MED
analysis	I-MED
of	O
empty	B-MED
-	I-MED
nest	I-MED
and	O
non	B-MED
-	I-MED
empty	I-MED
-	I-MED
nest	I-MED
households	B-MED
with	O
seniors	B-MED
in	O
Shandong	B-MED
,	I-MED
China	I-MED
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
compare	B-MED
the	O
catastrophic	B-MED
health	B-MED
expenditure	I-MED
(	O
CHE	B-MED
)	O
prevalence	B-MED
and	O
its	O
determinants	B-MED
between	O
empty	B-MED
-	I-MED
nest	I-MED
and	O
non	B-MED
-	I-MED
empty	I-MED
-	I-MED
nest	I-MED
elderly	B-MED
households	B-MED
.	O
Shandong	B-MED
province	I-MED
of	I-MED
China	I-MED
.	O
A	O
total	B-MED
of	O
2761	O
elderly	B-MED
households	B-MED
are	O
included	B-MED
in	O
the	O
analysis	B-MED
.	O
CHE	B-MED
incidence	B-MED
among	O
elderly	B-MED
households	B-MED
was	O
44.9	O
%	O
.	O
The	O
CHE	B-MED
incidence	B-MED
of	O
empty	B-MED
-	I-MED
nest	I-MED
singles	B-MED
(	O
59.3	O
%	O
,	O
p=0.000	O
,	O
OR=3.19	O
)	O
and	O
empty	B-MED
-	I-MED
nest	I-MED
couples	B-MED
(	O
52.9	O
%	O
,	O
p=0.000	O
,	O
OR=2.45	O
)	O
are	O
both	O
statistically	B-MED
higher	B-MED
than	O
that	O
of	O
non	B-MED
-	I-MED
empty	I-MED
-	I-MED
nest	I-MED
elderly	B-MED
households	B-MED
(	O
31.4	O
%	O
)	O
.	O
An	O
inverse	B-MED
association	I-MED
was	O
observed	B-MED
between	O
CHE	B-MED
incidence	B-MED
and	O
income	B-MED
level	I-MED
in	O
all	O
elderly	B-MED
household	B-MED
types	B-MED
.	O
Factors	B-MED
including	B-MED
1	O
or	O
more	O
household	B-MED
elderly	B-MED
members	I-MED
with	O
non	B-MED
-	I-MED
communicable	I-MED
chronic	I-MED
diseases	I-MED
in	O
the	O
past	O
6	O
months	O
,	O
1	O
or	O
more	O
elderly	B-MED
household	B-MED
members	I-MED
being	O
hospitalised	B-MED
in	O
the	O
past	B-MED
year	I-MED
and	O
lower	B-MED
household	B-MED
income	B-MED
,	O
are	O
significant	B-MED
risk	B-MED
factors	I-MED
for	O
CHE	B-MED
in	O
all	O
3	O
household	B-MED
types	B-MED
(	O
p<0.05	O
)	O
.	O
Health	B-MED
insurance	I-MED
status	B-MED
was	O
found	O
to	O
be	O
a	O
significant	B-MED
determinant	B-MED
of	O
CHE	B-MED
among	O
empty	B-MED
-	I-MED
nest	I-MED
singles	B-MED
and	O
non	B-MED
-	I-MED
empty	I-MED
-	I-MED
nest	I-MED
households	B-MED
(	O
p<0.05	O
)	O
.	O
CHE	B-MED
incidence	B-MED
among	O
elderly	B-MED
households	B-MED
is	O
high	B-MED
in	O
China	B-MED
.	O
Empty	B-MED
-	I-MED
nest	I-MED
households	B-MED
are	O
at	O
higher	B-MED
risk	B-MED
for	O
CHE	B-MED
than	O
non	B-MED
-	I-MED
empty	I-MED
-	I-MED
nest	I-MED
households	B-MED
.	O
Based	O
on	O
these	O
findings	B-MED
,	O
we	O
suggest	B-MED
that	O
special	B-MED
insurance	B-MED
be	O
developed	O
to	O
broaden	B-MED
the	O
coverage	B-MED
of	O
health	B-MED
services	I-MED
and	O
heighten	B-MED
the	O
reimbursement	B-MED
rate	I-MED
for	O
empty	B-MED
-	I-MED
nest	I-MED
elderly	B-MED
in	O
the	O
existing	O
health	B-MED
insurance	I-MED
schemes	B-MED
.	O
Financial	B-MED
and	O
social	B-MED
protection	I-MED
interventions	B-MED
are	O
also	O
essential	B-MED
for	O
identifie	B-MED
d	O
at	B-MED
-	I-MED
risk	I-MED
subgroups	B-MED
among	O
different	O
types	O
of	O
elderly	B-MED
households	B-MED
.	O
Permanence	B-MED
can	O
be	O
Defended	B-MED
In	O
donation	B-MED
after	O
the	O
circulatory	B-MED
-	I-MED
respiratory	I-MED
determination	I-MED
of	I-MED
death	I-MED
(	O
DCDD	B-MED
)	O
,	O
the	O
dead	B-MED
donor	B-MED
rule	B-MED
requires	B-MED
that	O
the	O
donor	B-MED
be	O
dead	B-MED
before	B-MED
organ	B-MED
procurement	I-MED
can	O
proceed	O
.	O
Under	O
the	O
relevant	B-MED
limb	I-MED
of	O
the	O
Uniform	B-MED
Determination	I-MED
of	I-MED
Death	I-MED
Act	I-MED
1981	I-MED
(	I-MED
USA	I-MED
)	I-MED
,	O
a	O
person	B-MED
is	O
dead	B-MED
when	O
the	O
cessation	B-MED
of	O
circulatory	B-MED
-	I-MED
respiratory	I-MED
function	I-MED
is	O
'	O
irreversible	B-MED
'	O
.	O
Critics	B-MED
of	O
current	B-MED
practice	B-MED
in	O
DCDD	B-MED
have	O
argued	B-MED
that	O
the	O
donor	B-MED
is	O
not	O
dead	B-MED
at	O
the	O
time	B-MED
organs	B-MED
are	O
procured	B-MED
,	O
and	O
so	O
the	O
procurement	B-MED
of	I-MED
organs	I-MED
from	O
these	O
donors	B-MED
violates	O
the	O
dead	B-MED
donor	B-MED
rule	B-MED
.	O
We	O
offer	B-MED
a	O
new	B-MED
argument	B-MED
here	O
in	O
defence	B-MED
of	O
current	B-MED
DCDD	B-MED
practice	B-MED
,	O
and	O
,	O
in	O
particular	O
,	O
of	O
the	O
interpretation	B-MED
of	O
the	O
requirement	B-MED
of	O
'	O
irreversibility	B-MED
'	O
as	O
permanence	B-MED
.	O
Total	O
colectomy	B-MED
for	O
colon	B-MED
perforation	I-MED
after	O
kayexalate	B-MED
administration	B-MED
:	O
a	O
case	O
report	O
and	O
literature	B-MED
review	I-MED
of	O
a	O
rare	B-MED
complication	B-MED
Kayexalate	B-MED
is	O
an	O
ion	B-MED
exchange	I-MED
resin	I-MED
that	O
is	O
commonly	O
used	O
to	O
acutely	O
treat	B-MED
patients	B-MED
with	O
hyperkalemia	B-MED
.	O
Bowel	B-MED
ulceration	I-MED
and	O
necrosis	B-MED
is	O
a	O
rare	B-MED
and	O
uncommonly	O
recognized	O
complication	B-MED
of	O
kayexalate	B-MED
administration	B-MED
.	O
More	O
often	O
,	O
concomitant	B-MED
administration	B-MED
with	O
sorbitol	B-MED
is	O
reported	O
to	O
damage	B-MED
the	O
bowel	B-MED
;	O
however	O
,	O
there	O
are	O
reports	O
of	O
kayexalate	B-MED
administration	B-MED
causing	O
bowel	B-MED
necrosis	I-MED
without	O
sorbitol	B-MED
.	O
We	O
present	O
a	O
case	O
of	O
a	O
critically	B-MED
ill	I-MED
patient	B-MED
who	O
underwent	O
total	O
colectomy	B-MED
for	O
colonic	B-MED
necrosis	I-MED
secondary	O
to	O
oral	B-MED
kayexalate	B-MED
administration	B-MED
that	O
was	O
not	O
recognized	O
until	O
late	O
in	O
the	O
pathologic	B-MED
process	I-MED
.	O
We	O
also	O
review	B-MED
the	I-MED
literature	I-MED
to	O
further	O
investigate	O
this	O
progression	B-MED
.	O
The	O
binding	B-MED
orientations	B-MED
of	O
structurally	B-MED
-related	O
ligands	B-MED
can	O
differ	B-MED
;	O
A	O
cautionary	O
note	O
Crystal	B-MED
structures	I-MED
can	O
identify	O
ligand	B-MED
-	I-MED
receptor	I-MED
interactions	I-MED
and	O
assist	O
the	O
development	O
of	O
novel	O
therapeutics	B-MED
,	O
but	O
experimental	B-MED
challenges	O
sometimes	O
necessitate	O
the	O
use	O
of	O
homologous	B-MED
proteins	I-MED
.	O
Tropisetron	B-MED
is	O
an	O
orthosteric	B-MED
ligand	I-MED
at	O
both	O
5	B-MED
-	I-MED
HT3	I-MED
and	O
α7	B-MED
nACh	I-MED
receptors	I-MED
and	O
its	O
binding	B-MED
orientation	B-MED
has	O
been	O
determined	O
in	O
the	O
structural	B-MED
homologue	I-MED
AChBP	B-MED
(	O
pdbid	O
:	O
2WNC	O
)	O
.	O
Co	B-MED
-	I-MED
crystallisation	I-MED
with	O
a	O
structurally	B-MED
-related	O
ligand	B-MED
,	O
granisetron	B-MED
,	O
reveals	O
an	O
almost	O
identical	B-MED
orientation	B-MED
(	O
pdbid	O
;	O
2YME	O
)	O
.	O
However	O
,	O
there	O
is	O
a	O
>	O
1000	O
-	O
fold	O
difference	B-MED
in	O
the	O
affinity	B-MED
of	O
tropisetron	B-MED
at	O
5	B-MED
-	I-MED
HT3	I-MED
versus	O
α7	B-MED
nACh	I-MED
receptors	I-MED
,	O
and	O
α7	B-MED
nACh	I-MED
receptors	I-MED
do	O
not	B-MED
bind	B-MED
granisetron	B-MED
.	O
These	O
striking	O
pharmacological	B-MED
differences	B-MED
prompt	O
questions	O
about	O
which	O
receptor	B-MED
the	O
crystal	B-MED
structures	I-MED
most	O
closely	O
represent	O
and	O
whether	O
the	O
ligand	B-MED
orientations	B-MED
are	O
correct	O
.	O
Here	O
we	O
probe	O
the	O
binding	B-MED
orientation	B-MED
of	O
tropisetron	B-MED
and	O
granisetron	B-MED
at	O
5	B-MED
-	I-MED
HT3	I-MED
receptors	I-MED
by	O
in	B-MED
silico	I-MED
modelling	B-MED
and	O
docking	B-MED
,	O
radioligand	B-MED
binding	I-MED
on	O
cysteine	B-MED
-	O
substituted	B-MED
5	B-MED
-	I-MED
HT3	I-MED
receptor	I-MED
mutants	B-MED
transiently	O
expressed	B-MED
in	O
HEK	B-MED
293	I-MED
cells	I-MED
,	O
and	O
synthetic	B-MED
modification	I-MED
of	O
the	O
ligands	B-MED
.	O
For	O
15	O
of	O
the	O
23	O
cysteine	B-MED
substitutions	B-MED
,	O
the	O
effects	B-MED
on	O
tropisetron	B-MED
and	O
granisetron	B-MED
were	O
different	O
.	O
Structure	B-MED
-	I-MED
activity	I-MED
relationships	I-MED
on	O
synthesised	O
derivatives	O
of	O
both	O
ligands	B-MED
were	O
also	O
consistent	O
with	O
different	O
orientations	B-MED
,	O
revealing	B-MED
that	O
contrary	O
to	O
the	O
crystallographic	B-MED
evidence	B-MED
from	O
AChBP	B-MED
,	O
the	O
two	O
ligands	B-MED
adopt	O
different	B-MED
orientations	B-MED
in	O
the	O
5	B-MED
-	I-MED
HT3	I-MED
receptor	I-MED
binding	B-MED
site	I-MED
.	O
Our	O
results	O
show	O
that	O
even	O
quite	O
structurally	B-MED
similar	O
molecules	B-MED
can	O
adopt	O
different	O
orientations	B-MED
in	O
the	O
same	O
binding	B-MED
site	I-MED
,	O
and	O
that	O
caution	O
may	O
be	O
needed	O
when	O
using	O
homologous	B-MED
proteins	I-MED
to	O
predict	O
ligand	B-MED
binding	I-MED
.	O
Recessive	B-MED
mutations	I-MED
in	O
MSTO1	B-MED
cause	O
mitochondrial	B-MED
dynamics	I-MED
impairment	B-MED
,	O
leading	O
to	O
myopathy	B-MED
and	O
ataxia	B-MED
We	O
report	O
here	O
the	O
first	O
families	B-MED
carrying	O
recessive	O
variants	B-MED
in	O
the	O
MSTO1	B-MED
gene	I-MED
:	O
compound	B-MED
heterozygous	I-MED
mutations	B-MED
mutations	B-MED
were	O
identified	B-MED
in	O
two	O
sisters	B-MED
and	O
in	O
an	O
unrelated	B-MED
singleton	B-MED
case	O
,	O
who	O
presented	B-MED
a	O
multisystem	O
complex	B-MED
phenotype	B-MED
mainly	O
characterized	B-MED
by	O
myopathy	B-MED
and	O
cerebellar	B-MED
ataxia	I-MED
.	O
Human	B-MED
MSTO1	I-MED
is	O
a	O
poorly	O
studied	O
protein	O
,	O
suggested	B-MED
to	O
have	O
mitochondrial	B-MED
localization	I-MED
and	O
to	O
regulate	B-MED
morphology	B-MED
and	O
distribution	B-MED
of	I-MED
mitochondria	I-MED
.	O
As	O
for	O
other	O
mutations	B-MED
affecting	B-MED
genes	B-MED
involved	O
in	O
mitochondrial	B-MED
dynamics	I-MED
,	O
no	O
biochemical	B-MED
defects	B-MED
typical	O
of	O
mitochondrial	B-MED
disorders	I-MED
were	O
reported	B-MED
.	O
Studies	O
in	O
patients	B-MED
'	O
fibroblasts	B-MED
revealed	B-MED
that	O
MSTO1	B-MED
protein	I-MED
levels	B-MED
were	O
strongly	O
reduced	B-MED
,	O
the	O
mitochondrial	B-MED
network	I-MED
was	I-MED
fragmented	I-MED
and	O
the	O
fusion	B-MED
events	O
among	O
mitochondria	B-MED
were	O
decreased	B-MED
,	O
confirming	O
the	O
deleterious	B-MED
effect	I-MED
of	O
the	O
identified	B-MED
variants	B-MED
and	O
the	O
role	O
of	O
MSTO1	B-MED
in	O
modulating	B-MED
mitochondrial	B-MED
dynamics	I-MED
.	O
We	O
also	O
found	O
that	O
MSTO1	O
is	O
mainly	O
a	O
cytosolic	B-MED
protein	I-MED
.	O
These	O
findings	O
indicate	O
recessive	B-MED
mutations	I-MED
in	O
MSTO1	B-MED
as	O
a	O
new	O
cause	O
for	O
inherited	B-MED
neuromuscular	B-MED
disorders	I-MED
with	O
multisystem	O
features	O
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
Safety	B-MED
Precautions	I-MED
and	O
Operating	B-MED
Procedures	I-MED
in	O
an	O
(	O
A	O
)	O
BSL-4	B-MED
Laboratory	B-MED
:	O
1	O
.	O
Biosafety	B-MED
Level	I-MED
4	I-MED
Suit	B-MED
Laboratory	I-MED
Suite	B-MED
Entry	I-MED
and	I-MED
Exit	I-MED
Procedures	I-MED
Biosafety	B-MED
level	I-MED
4	I-MED
(	O
BSL-4	B-MED
)	O
suit	B-MED
laboratories	I-MED
are	O
specifically	O
designed	B-MED
to	O
study	B-MED
high	B-MED
-	I-MED
consequence	I-MED
pathogens	I-MED
for	O
which	O
neither	O
infection	B-MED
prophylaxes	B-MED
nor	O
treatment	B-MED
options	O
exist	O
.	O
The	O
hallmarks	O
of	O
these	O
laboratories	B-MED
are	O
:	O
custom	B-MED
-	I-MED
designed	I-MED
airtight	B-MED
doors	I-MED
,	O
dedicated	O
supply	B-MED
and	O
exhaust	B-MED
airflow	I-MED
systems	I-MED
,	O
a	O
negative	B-MED
-	I-MED
pressure	I-MED
environment	I-MED
,	O
and	O
mandatory	O
use	O
of	O
positive	B-MED
-	I-MED
pressure	I-MED
(	I-MED
"	I-MED
space	I-MED
"	I-MED
)	I-MED
suits	I-MED
.	O
The	O
risk	O
for	O
laboratory	B-MED
specialists	B-MED
working	O
with	O
highly	O
pathogenic	B-MED
agents	I-MED
is	O
minimized	O
through	O
rigorous	O
training	B-MED
and	O
adherence	O
to	O
stringent	O
safety	B-MED
protocols	I-MED
and	O
standard	B-MED
operating	I-MED
procedures	I-MED
.	O
Researchers	B-MED
perform	O
the	O
majority	B-MED
of	O
their	O
work	B-MED
in	O
BSL-2	B-MED
laboratories	B-MED
and	O
switch	O
to	O
BSL-4	B-MED
suit	B-MED
laboratories	I-MED
when	O
work	O
with	O
a	O
high	B-MED
-	I-MED
consequence	I-MED
pathogen	I-MED
is	O
required	O
.	O
Collaborators	B-MED
and	O
scientists	B-MED
considering	O
BSL-4	B-MED
projects	B-MED
should	O
be	O
aware	O
of	O
the	O
challenges	B-MED
associated	B-MED
with	I-MED
BSL-4	B-MED
research	B-MED
both	O
in	O
terms	O
of	O
experimental	B-MED
technical	B-MED
limitations	B-MED
in	O
BSL-4	B-MED
laboratory	B-MED
space	B-MED
and	O
the	O
increased	B-MED
duration	B-MED
of	O
such	O
experiments	B-MED
.	O
Tasks	O
such	O
as	O
entering	B-MED
and	O
exiting	B-MED
the	O
BSL-4	B-MED
suit	B-MED
laboratories	I-MED
are	O
considerably	O
more	O
complex	B-MED
and	O
time	B-MED
-	I-MED
consuming	I-MED
compared	B-MED
to	O
BSL-2	B-MED
and	O
BSL-3	B-MED
laboratories	B-MED
.	O
The	O
focus	O
of	O
this	O
particular	O
article	B-MED
is	O
to	O
address	B-MED
basic	O
biosafety	B-MED
concerns	B-MED
and	O
describe	O
the	O
entrance	B-MED
and	I-MED
exit	I-MED
procedures	I-MED
for	O
the	O
BSL-4	B-MED
laboratory	B-MED
at	O
the	O
NIH	B-MED
/	O
NIAID	B-MED
Integrated	B-MED
Research	I-MED
Facility	I-MED
at	O
Fort	O
Detrick	O
.	O
Such	O
procedures	B-MED
include	O
checking	O
external	O
systems	O
that	O
support	O
the	O
BSL-4	B-MED
laboratory	B-MED
,	O
and	O
inspecting	O
and	O
donning	O
positive	B-MED
-	I-MED
pressure	I-MED
suits	I-MED
,	O
entering	O
the	O
laboratory	B-MED
,	O
moving	O
through	O
air	B-MED
pressure	I-MED
-	O
resistant	B-MED
doors	B-MED
,	O
and	O
connecting	O
to	O
air	B-MED
-	I-MED
supply	I-MED
hoses	I-MED
.	O
We	O
will	O
also	O
discuss	O
moving	B-MED
within	O
and	O
exiting	B-MED
the	O
BSL-4	B-MED
suit	B-MED
laboratories	I-MED
,	O
including	O
using	O
the	O
chemical	B-MED
shower	B-MED
and	O
removing	B-MED
and	O
storing	B-MED
positive	B-MED
-	I-MED
pressure	I-MED
suits	I-MED
.	O
Timing	B-MED
of	O
False	O
Ring	B-MED
Formation	I-MED
in	O
Pinus	B-MED
halepensis	I-MED
and	O
Arbutus	B-MED
unedo	I-MED
in	O
Southern	B-MED
Italy	B-MED
:	O
Outlook	B-MED
from	O
an	O
Analysis	B-MED
of	O
Xylogenesis	B-MED
and	O
Tree	B-MED
-	I-MED
Ring	I-MED
Chronologies	B-MED
Mediterranean	B-MED
tree	B-MED
rings	I-MED
are	O
characterized	B-MED
by	O
intra	B-MED
-	I-MED
annual	I-MED
density	I-MED
fluctuations	I-MED
(	O
IADFs	B-MED
)	O
due	O
to	O
partly	O
climate	B-MED
-	I-MED
driven	I-MED
cambial	B-MED
activity	I-MED
.	O
IADFs	B-MED
are	O
used	O
as	O
structural	B-MED
signals	B-MED
to	O
gain	O
information	B-MED
on	O
relations	B-MED
between	B-MED
environmental	B-MED
conditions	B-MED
and	O
eco	B-MED
-	I-MED
physiological	I-MED
processes	B-MED
during	B-MED
xylogenesis	B-MED
,	O
with	O
intra	B-MED
-	I-MED
annual	I-MED
resolution	B-MED
.	O
To	O
reach	O
an	O
unbiased	B-MED
synchronization	B-MED
of	O
the	O
IADF	B-MED
position	B-MED
within	O
tree	B-MED
rings	B-MED
and	O
seasonal	B-MED
fluctuations	B-MED
in	O
environmental	B-MED
conditions	B-MED
,	O
it	O
is	O
necessary	O
to	O
know	O
the	O
timing	B-MED
of	O
cambial	B-MED
activity	I-MED
and	O
wood	B-MED
formation	B-MED
,	O
which	O
are	O
species-	B-MED
and	O
site	B-MED
-	I-MED
specific	I-MED
processes	B-MED
.	O
We	O
applied	B-MED
the	O
microcoring	B-MED
technique	I-MED
to	O
analyze	B-MED
xylogenesis	B-MED
in	O
Pinus	B-MED
halepensis	I-MED
and	O
Arbutus	B-MED
unedo	I-MED
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
attempt	B-MED
to	O
study	B-MED
xylogenesis	B-MED
in	O
a	O
hardwood	B-MED
species	B-MED
forming	O
frequent	B-MED
IADFs	B-MED
.	O
Both	O
species	B-MED
co	B-MED
-	I-MED
occur	I-MED
at	O
a	O
site	B-MED
in	O
southern	B-MED
Italy	B-MED
characterized	B-MED
by	O
a	O
Mediterranean	B-MED
climate	B-MED
.	O
To	O
facilitate	O
tree	B-MED
-	I-MED
ring	I-MED
dating	I-MED
and	O
identification	B-MED
of	O
IADFs	B-MED
,	O
we	O
performed	B-MED
traditional	B-MED
dendroecological	B-MED
analysis	B-MED
.	O
We	O
analyzed	B-MED
xylogenesis	B-MED
during	B-MED
summer	B-MED
,	O
which	O
is	O
considered	B-MED
a	O
constraint	B-MED
for	O
xylogenesis	B-MED
and	O
a	O
trigger	O
for	O
IADF	B-MED
formation	B-MED
.	O
We	O
followed	O
the	O
different	B-MED
phases	B-MED
of	O
cell	B-MED
development	I-MED
in	O
the	O
current	B-MED
wood	B-MED
increment	B-MED
with	O
the	O
aim	O
of	O
evaluating	O
whether	O
and	O
which	O
type	O
of	O
IADFs	B-MED
were	O
formed	B-MED
.	O
We	O
additionally	O
analyzed	B-MED
the	O
same	O
phases	B-MED
again	O
in	O
September	B-MED
and	O
in	O
winter	B-MED
to	O
verify	B-MED
the	O
possible	B-MED
formation	B-MED
of	O
IADFs	B-MED
in	O
fall	B-MED
and	O
whether	O
cell	B-MED
production	B-MED
and	O
differentiation	B-MED
was	O
completed	B-MED
by	O
the	O
end	O
of	O
the	O
calendar	B-MED
year	I-MED
.	O
Both	O
species	B-MED
formed	B-MED
the	O
same	O
type	O
of	O
IADFs	B-MED
(	O
earlywood	B-MED
-like	O
cells	B-MED
within	O
latewood	B-MED
)	O
,	O
due	O
to	O
temporary	B-MED
growth	B-MED
restoration	B-MED
triggered	B-MED
by	I-MED
rain	B-MED
events	B-MED
during	B-MED
the	O
period	B-MED
of	O
summer	B-MED
drought	B-MED
.	O
At	O
the	O
end	O
of	O
the	O
calendar	B-MED
year	I-MED
,	O
no	O
cells	B-MED
in	O
the	O
phases	B-MED
of	O
enlargement	B-MED
and	O
secondary	B-MED
cell	I-MED
wall	I-MED
deposition	B-MED
occurred	B-MED
.	O
A.	B-MED
unedo	I-MED
was	O
more	O
sensitive	B-MED
than	O
P.	B-MED
halepensis	I-MED
because	O
IADF	B-MED
s	O
were	O
formed	B-MED
earlier	B-MED
in	O
the	O
season	B-MED
and	O
were	O
more	O
frequent	B-MED
in	O
the	O
tree	B-MED
-	I-MED
ring	I-MED
series	O
.	O
The	O
dendro	B-MED
-	I-MED
anatomical	I-MED
approach	O
,	O
combining	O
analysis	B-MED
of	O
tree	B-MED
-	I-MED
ring	I-MED
series	O
and	O
of	O
xylogenesis	B-MED
,	O
helped	O
to	O
detect	B-MED
the	O
period	B-MED
of	O
IADF	B-MED
formation	B-MED
in	O
the	O
two	O
species	B-MED
.	O
Results	B-MED
are	O
discussed	O
in	O
functional	B-MED
terms	B-MED
,	O
highlighting	O
the	O
environmental	B-MED
conditions	B-MED
triggering	B-MED
IADFs	B-MED
,	O
and	O
also	O
in	O
methodological	B-MED
terms	B-MED
,	O
evaluating	O
the	O
applicability	B-MED
of	O
xylogenesis	B-MED
analysis	B-MED
in	O
Mediterranean	B-MED
woods	B-MED
,	O
especially	O
when	O
the	O
formation	B-MED
of	O
IADFs	B-MED
is	O
not	O
uniform	B-MED
around	O
the	O
stem	B-MED
.	O
High	O
tacrolimus	B-MED
blood	B-MED
concentrations	I-MED
early	O
after	O
lung	B-MED
transplantation	I-MED
and	O
the	O
risk	B-MED
of	O
kidney	B-MED
injury	I-MED
Lung	B-MED
transplant	B-MED
recipients	I-MED
often	O
develop	O
acute	B-MED
kidney	I-MED
injury	I-MED
(	O
AKI	B-MED
)	O
evolving	O
into	O
chronic	B-MED
kidney	I-MED
disease	I-MED
(	O
CKD	B-MED
)	O
.	O
The	O
immunosuppressant	B-MED
tacrolimus	B-MED
might	O
be	O
associated	B-MED
with	I-MED
the	O
emergence	O
of	O
AKI	B-MED
.	O
We	O
analyzed	O
the	O
development	B-MED
and	O
recovery	B-MED
of	O
kidney	B-MED
injury	I-MED
after	O
lung	B-MED
transplantation	I-MED
and	O
related	O
AKI	B-MED
to	O
whole	B-MED
-	I-MED
blood	I-MED
tacrolimus	B-MED
trough	B-MED
concentrations	I-MED
and	O
other	O
factors	O
causing	O
kidney	B-MED
injury	I-MED
.	O
We	O
retrospectively	B-MED
studied	I-MED
kidney	B-MED
injury	I-MED
in	O
186	O
lung	B-MED
-	I-MED
transplantation	I-MED
patients	B-MED
at	O
the	O
UMC	B-MED
Utrecht	I-MED
between	O
2001	O
and	O
2011	O
.	O
Kidney	B-MED
function	I-MED
and	O
whole	B-MED
-	I-MED
blood	I-MED
tacrolimus	B-MED
trough	B-MED
concentrations	I-MED
were	O
determined	O
from	O
day	B-MED
1	O
to	O
14	O
and	O
at	O
1	O
,	O
3	O
,	O
6	O
,	O
and	O
12	O
months	B-MED
postoperative	B-MED
.	O
Systemic	B-MED
inflammatory	I-MED
response	I-MED
syndrome	I-MED
(	O
SIRS	B-MED
)	O
,	O
septic	B-MED
shock	I-MED
,	O
and	O
nephrotoxic	B-MED
medications	B-MED
were	O
evaluated	O
as	O
covariates	B-MED
for	O
AKI	B-MED
.	O
We	O
analyzed	O
liver	B-MED
injury	I-MED
and	O
drug	B-MED
-	I-MED
drug	I-MED
interactions	I-MED
.	O
AKI	B-MED
was	O
present	B-MED
in	O
85	O
(	O
46	O
%	O
)	O
patients	B-MED
.	O
Tacrolimus	B-MED
concentrations	B-MED
were	O
supra	B-MED
-	I-MED
therapeutic	I-MED
in	O
135	O
of	O
186	O
patients	B-MED
(	O
73	O
%	O
)	O
.	O
AKI	B-MED
in	O
the	O
first	O
week	B-MED
after	O
transplantation	B-MED
was	O
related	O
to	O
supra	B-MED
-	I-MED
therapeutic	I-MED
tacrolimus	B-MED
concentrations	B-MED
(	O
OR	B-MED
1.55	O
;	O
95	O
%	O
CI	B-MED
1.06	O
-	O
2.27	O
)	O
,	O
≥3	O
other	O
nephrotoxic	B-MED
drugs	I-MED
(	O
OR	B-MED
1.96	O
;	O
95	O
%	O
CI	B-MED
1.02	O
-	O
3.77	O
)	O
,	O
infection	B-MED
(	O
OR	B-MED
2.48	O
;	O
95	O
%	O
CI	B-MED
1.31	O
-	O
4.70	O
)	O
,	O
and	O
cystic	B-MED
fibrosis	I-MED
(	O
OR	B-MED
2.17	O
;	O
95	O
%	O
CI	B-MED
1.16	O
-	O
4.06	O
)	O
.	O
Recovery	B-MED
rate	I-MED
of	O
AKI	B-MED
was	O
lower	O
than	O
expected	O
(	O
19	O
%	O
)	O
,	O
and	O
the	O
cumulative	O
incidence	B-MED
of	O
severe	O
CKD	B-MED
at	O
1	O
year	B-MED
was	O
15	O
%	O
.	O
After	O
lung	B-MED
transplantation	I-MED
,	O
AKI	B-MED
is	O
common	O
and	O
often	O
evolves	O
into	O
severe	B-MED
CKD	B-MED
,	O
which	O
is	O
a	O
known	O
cause	O
of	O
morbidity	B-MED
and	O
mortality	B-MED
.	O
Supra	B-MED
-	I-MED
therapeutic	I-MED
whole	B-MED
-	I-MED
blood	I-MED
tacrolimus	B-MED
trough	B-MED
concentrations	I-MED
are	O
related	O
to	O
the	O
early	O
onset	O
of	O
AKI	B-MED
.	O
Conscientious	B-MED
targeting	B-MED
tacrolimus	B-MED
blood	B-MED
concentrations	I-MED
might	O
be	O
vital	B-MED
in	O
the	O
early	B-MED
phase	I-MED
after	O
lung	B-MED
transplantation	I-MED
.	O
What	O
is	O
known	O
about	O
this	O
subject	O
?	O
•	O
Lung	B-MED
transplant	B-MED
recipients	I-MED
often	O
develop	O
acute	B-MED
kidney	I-MED
injury	I-MED
evolving	O
into	O
chronic	B-MED
kidney	I-MED
disease	I-MED
increasing	O
both	O
morbidity	B-MED
and	O
mortality	B-MED
.	O
•	O
To	O
date	O
,	O
the	O
pathophysiology	B-MED
of	O
kidney	B-MED
injury	I-MED
after	O
lung	B-MED
transplantation	I-MED
has	O
not	O
been	O
fully	O
elucidated	O
.	O
•	O
The	O
immunosuppressant	B-MED
tacrolimus	B-MED
is	O
difficult	O
to	O
dose	B-MED
,	O
especially	O
in	O
the	O
unstable	B-MED
clinical	B-MED
setting	I-MED
,	O
and	O
is	O
nephrotoxic	B-MED
.	O
•	O
For	O
the	O
first	O
time	O
,	O
supra	B-MED
-	I-MED
therapeutic	I-MED
whole	B-MED
-	I-MED
blood	I-MED
tacrolimus	B-MED
trough	B-MED
concentrations	I-MED
are	O
related	O
to	O
the	O
emergence	O
of	O
acute	B-MED
kidney	I-MED
injury	I-MED
in	O
the	O
first	O
days	B-MED
after	O
lung	B-MED
transplantation	I-MED
.	O
•	O
Supra	B-MED
-	I-MED
therapeutic	I-MED
whole	B-MED
-	I-MED
blood	I-MED
tacrolimus	B-MED
trough	B-MED
concentrations	I-MED
often	O
occur	O
early	O
after	O
lung	B-MED
transplantation	I-MED
.	O
•	O
AKI	B-MED
after	O
lung	B-MED
transplantation	I-MED
shows	O
low	B-MED
recovery	B-MED
rates	B-MED
.	O
Real	B-MED
-	I-MED
time	I-MED
monitoring	B-MED
of	O
vesicle	B-MED
pH	B-MED
in	O
an	O
endocytic	B-MED
pathway	B-MED
using	O
an	O
EGF	B-MED
-	O
conjugated	B-MED
two	I-MED
-	I-MED
photon	I-MED
probe	I-MED
Herein	O
,	O
we	O
developed	O
a	O
ratiometric	B-MED
two	I-MED
-	I-MED
photon	I-MED
probe	I-MED
(	O
BHS3	B-MED
-	O
EGF	B-MED
)	O
,	O
derived	O
from	O
a	O
pH	B-MED
sensitive	B-MED
dye	O
and	O
epidermal	B-MED
growth	I-MED
factor	I-MED
(	O
EGF	B-MED
)	O
,	O
for	O
real	B-MED
-	I-MED
time	I-MED
monitoring	B-MED
and	O
quantitative	B-MED
analysis	B-MED
of	O
acidic	B-MED
luminal	I-MED
pH	B-MED
values	B-MED
during	O
endocytic	B-MED
pathway	B-MED
activity	I-MED
.	O
Two	B-MED
-	I-MED
photon	I-MED
microscopy	I-MED
imaging	I-MED
with	O
BHS3	B-MED
-	O
EGF	B-MED
allows	O
the	O
quantitative	B-MED
analysis	B-MED
of	O
pH	B-MED
distributions	B-MED
of	O
single	O
vesicles	B-MED
and	O
their	O
dynamics	B-MED
in	O
receptor	B-MED
-	I-MED
mediated	I-MED
endocytosis	I-MED
in	O
real	B-MED
-	I-MED
time	I-MED
.	O
Ecohydrological	B-MED
modeling	I-MED
and	O
environmental	B-MED
flow	B-MED
regime	B-MED
in	O
the	O
Formoso	B-MED
River	I-MED
,	O
Minas	B-MED
Gerais	I-MED
State	I-MED
,	O
Brazil	B-MED
This	O
paper	B-MED
aimed	O
at	O
determining	B-MED
the	O
environmental	B-MED
flow	B-MED
regime	O
in	O
a	O
1	B-MED
km	I-MED
stretch	B-MED
of	O
the	O
Formoso	B-MED
River	I-MED
,	O
MG	B-MED
,	O
using	O
River2D	B-MED
model	I-MED
.	O
To	O
carry	O
out	O
the	O
ecohydrological	B-MED
modeling	I-MED
,	O
the	O
following	B-MED
information	B-MED
was	O
used	O
:	O
bathymetry	B-MED
,	O
physical	B-MED
and	O
hydraulic	B-MED
features	B-MED
,	O
and	O
the	O
Habitat	B-MED
Suitability	B-MED
Index	I-MED
for	O
species	B-MED
of	O
the	O
Hypostomus	B-MED
auroguttatus	I-MED
.	O
In	O
the	O
River2D	B-MED
,	O
the	O
Weighted	B-MED
Usable	B-MED
Areas	B-MED
were	O
determined	B-MED
from	O
the	O
average	B-MED
long	B-MED
-	I-MED
term	I-MED
streamflows	B-MED
with	O
percentage	B-MED
from	O
10	O
%	O
to	O
100	O
%	O
.	O
Those	O
streamflows	B-MED
were	O
simulated	O
for	O
the	O
later	B-MED
construction	B-MED
of	O
optimization	B-MED
matrices	B-MED
that	O
maximize	B-MED
the	O
habitat	B-MED
area	B-MED
throughout	B-MED
the	O
year	B-MED
.	O
For	O
H.	B-MED
auroguttatus	I-MED
Juvenile	B-MED
,	O
higher	B-MED
values	B-MED
of	O
Weighted	B-MED
Usable	B-MED
Area	B-MED
were	O
associated	B-MED
with	I-MED
the	O
percentage	B-MED
of	O
60	O
%	O
and	O
70	O
%	O
of	O
the	O
average	B-MED
long	B-MED
-	I-MED
term	I-MED
streamflows	B-MED
in	O
October	B-MED
and	O
September	B-MED
,	O
respectively	O
.	O
For	O
H.	B-MED
auroguttatus	I-MED
Adult	B-MED
,	O
the	O
highest	B-MED
value	B-MED
of	O
Weighted	B-MED
Usable	B-MED
Usable	B-MED
Area	B-MED
was	O
associated	B-MED
with	I-MED
the	O
percentage	B-MED
of	O
100	O
%	O
of	O
the	O
average	B-MED
long	B-MED
-	I-MED
term	I-MED
streamflow	B-MED
in	O
September	B-MED
.	O
The	O
environmental	B-MED
flows	B-MED
found	B-MED
for	O
this	O
stretch	B-MED
of	O
the	O
Formoso	B-MED
River	I-MED
varied	B-MED
over	B-MED
the	O
year	B-MED
.	O
The	O
lowest	B-MED
environmental	B-MED
flow	B-MED
was	O
observed	B-MED
in	O
December	B-MED
(	O
2.85	O
m3	O
s-1	O
)	O
,	O
while	O
the	O
highest	B-MED
was	O
observed	B-MED
in	O
May	B-MED
(	O
4.13	O
m3	O
s-1	O
)	O
.	O
This	O
paper	B-MED
shows	O
the	O
importance	B-MED
of	O
ecohydrological	B-MED
studies	I-MED
in	O
forming	B-MED
a	O
basis	B-MED
for	O
water	B-MED
resources	I-MED
management	B-MED
actions	B-MED
.	O
Thyroid	B-MED
cancer	I-MED
burden	B-MED
in	O
Central	B-MED
and	O
South	B-MED
America	I-MED
Incidence	B-MED
of	O
thyroid	B-MED
cancer	I-MED
(	O
TC	B-MED
)	O
is	O
rapidly	B-MED
increasing	B-MED
worldwide	B-MED
,	O
but	O
little	O
is	O
known	O
about	O
the	O
TC	B-MED
burden	B-MED
in	O
Central	B-MED
and	O
South	B-MED
America	I-MED
(	O
CSA	B-MED
)	O
.	O
We	O
describe	O
the	O
geographic	B-MED
patterns	I-MED
and	O
trends	B-MED
of	O
TC	B-MED
by	O
sex	B-MED
in	O
CSA	B-MED
.	O
We	O
obtained	O
regional	B-MED
-	O
and	O
national	B-MED
-	I-MED
level	I-MED
incidence	B-MED
data	B-MED
from	O
48	O
population	B-MED
-	I-MED
based	I-MED
cancer	I-MED
registries	I-MED
in	O
13	O
countries	B-MED
and	O
nationwide	O
cancer	B-MED
deaths	I-MED
from	O
the	O
WHO	B-MED
mortality	B-MED
database	B-MED
for	O
18	O
countries	B-MED
.	O
We	O
estimated	O
world	B-MED
population	O
age	B-MED
-	I-MED
standardized	I-MED
incidence	I-MED
rates	I-MED
(	O
ASRs	B-MED
)	O
and	O
age	B-MED
-	I-MED
standardized	I-MED
mortality	I-MED
rates	I-MED
(	O
ASMRs	B-MED
)	O
per	O
100,000	O
person	B-MED
-	O
years	B-MED
.	O
We	O
calculated	O
ASRs	B-MED
by	O
histological	B-MED
subtype	I-MED
.	O
We	O
estimated	B-MED
the	I-MED
annual	I-MED
percentage	I-MED
change	I-MED
(	O
EAPC	B-MED
)	O
to	O
describe	O
time	B-MED
trends	I-MED
.	O
Between	O
CSA	B-MED
countries	B-MED
,	O
TC	B-MED
incidence	B-MED
and	O
mortality	B-MED
rates	I-MED
varied	O
from	O
8	O
-	O
fold	O
to	O
12	O
-	O
fold	O
and	O
from	O
2	O
-	O
fold	O
to	O
5	O
-	O
fold	O
,	O
respectively	O
.	O
In	O
2003	O
-	O
2007	O
,	O
the	O
highest	B-MED
TC	B-MED
ASRs	B-MED
in	O
females	B-MED
and	O
males	B-MED
were	O
in	O
Ecuador	B-MED
(	O
16.0	O
and	O
3.5	O
,	O
respectively	O
)	O
,	O
Brazil	B-MED
(	O
14.4	O
and	O
3.4	O
)	O
,	O
Costa	B-MED
Rica	I-MED
(	O
12.6	O
and	O
2.1	O
)	O
and	O
Colombia	B-MED
(	O
10.7	O
and	O
2.5	O
)	O
.	O
The	O
highest	B-MED
ASMRs	B-MED
were	O
in	O
Ecuador	B-MED
,	O
Colombia	B-MED
,	O
Mexico	B-MED
,	O
Peru	B-MED
and	O
Panama	B-MED
(	O
0.68	O
-	O
0.91	O
in	O
females	B-MED
and	O
0.41	O
-	O
0.48	O
in	O
males	B-MED
)	O
.	O
Papillary	B-MED
TC	I-MED
was	O
the	O
most	O
commonly	O
diagnosed	B-MED
histological	B-MED
subtype	I-MED
,	O
following	O
the	O
same	O
incidence	B-MED
pattern	I-MED
as	O
overall	O
TC	B-MED
.	O
In	O
Argentinean	B-MED
,	O
Brazilian	B-MED
,	O
Chilean	B-MED
and	O
Costa	B-MED
Rican	I-MED
females	B-MED
TC	B-MED
incidence	B-MED
increased	B-MED
by	O
2.2	O
-	O
17.9	O
%	O
annually	B-MED
,	O
and	O
papillary	B-MED
TC	I-MED
increased	B-MED
by	O
9.1	O
-	O
15.0	O
%	O
annually	B-MED
,	O
while	O
mortality	B-MED
remained	O
stable	B-MED
between	O
1997	O
and	O
2008	O
.	O
In	O
males	B-MED
,	O
trends	B-MED
in	O
TC	B-MED
were	O
stable	B-MED
.	O
TC	B-MED
occurred	B-MED
more	O
frequently	B-MED
in	O
females	B-MED
than	O
in	O
males	B-MED
.	O
The	O
overall	B-MED
high	B-MED
incidence	B-MED
and	O
low	B-MED
mortality	B-MED
of	O
TC	B-MED
suggest	B-MED
identification	O
of	O
subclinical	B-MED
disease	I-MED
due	O
to	O
improved	B-MED
detection	B-MED
methods	I-MED
.	O
Three	B-MED
-	I-MED
dimensional	I-MED
constructive	I-MED
interference	I-MED
in	I-MED
steady	I-MED
-	I-MED
state	I-MED
(	I-MED
3D	I-MED
-	I-MED
CISS	I-MED
)	I-MED
sequences	I-MED
and	O
Phase	B-MED
-	I-MED
contrast	I-MED
MRI	I-MED
of	O
arrested	B-MED
hydrocephalus	I-MED
to	O
evaluate	O
role	O
of	O
three	B-MED
-	I-MED
dimensional	I-MED
constructive	I-MED
interference	I-MED
in	I-MED
steady	I-MED
-	I-MED
state	I-MED
(	I-MED
3D	I-MED
-	I-MED
CISS	I-MED
)	I-MED
sequences	I-MED
and	O
phase	B-MED
-	I-MED
contrast	I-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
(	O
PC	B-MED
-	I-MED
MRI	I-MED
)	O
in	O
patients	B-MED
with	O
arrested	B-MED
hydrocephalus	I-MED
.	O
Prospective	B-MED
study	I-MED
was	O
conducted	O
on	O
20	O
patients	B-MED
with	O
arrested	B-MED
hydrocephalus	I-MED
.	O
All	O
patients	B-MED
underwent	O
PC	B-MED
-	I-MED
MRI	I-MED
and	O
3D	B-MED
-	I-MED
CISS	I-MED
for	O
assessment	B-MED
of	O
the	O
aqueduct	B-MED
.	O
Axial	B-MED
(	O
through	B-MED
-	I-MED
plane	I-MED
)	O
,	O
sagittal	B-MED
(	O
in	B-MED
-	I-MED
plane	I-MED
)	O
PC	B-MED
-	I-MED
MRI	I-MED
and	O
sagittal	B-MED
3D	B-MED
-	I-MED
CISS	I-MED
were	O
applied	O
to	O
assess	B-MED
the	O
cerebral	B-MED
aqueduct	I-MED
and	O
the	O
spontaneous	B-MED
third	B-MED
ventriculostomy	I-MED
if	O
present	O
.	O
Aqueductal	B-MED
patency	B-MED
was	O
graded	B-MED
using	O
3D	B-MED
-	I-MED
CISS	I-MED
and	O
PC	B-MED
-	I-MED
MRI	I-MED
.	O
Quantitative	B-MED
analysis	I-MED
of	O
flow	O
through	O
the	O
aqueduct	B-MED
was	O
done	O
using	O
PC	B-MED
-	I-MED
MRI	I-MED
.	O
The	O
causes	O
of	O
obstruction	B-MED
were	O
aqueductal	B-MED
obstruction	B-MED
in	O
75	O
%	O
(	O
n=15	O
)	O
,	O
3rd	O
ventricular	B-MED
obstruction	I-MED
in	O
5	O
%	O
(	O
n=1	O
)	O
and	O
4th	O
ventricular	B-MED
obstruction	I-MED
in	O
20	O
%	O
(	O
n=4	O
)	O
.	O
The	O
cause	O
of	O
arrest	B-MED
of	O
hydrocephalus	B-MED
was	O
spontaneous	B-MED
third	B-MED
ventriculostomy	I-MED
in	O
65	O
%	O
(	O
n=13	O
)	O
,	O
endoscopic	B-MED
third	I-MED
ventriculostomy	I-MED
in	O
10	O
%	O
(	O
n=2	O
)	O
,	O
ventriculo	B-MED
-	I-MED
peritoneal	I-MED
shunt	I-MED
in	O
5	O
%	O
(	O
n=1	O
)	O
and	O
no	O
cause	O
could	O
be	O
detected	B-MED
in	O
20	O
%	O
of	O
patients	B-MED
(	O
n=4	O
)	O
.	O
There	O
is	O
a	O
positive	B-MED
correlation	B-MED
(	O
r=	O
0.80	O
)	O
and	O
moderate	B-MED
agreement	B-MED
(	O
κ=	O
0.509	O
)	O
of	O
grading	B-MED
with	O
PC	B-MED
-	I-MED
MRI	I-MED
and	O
3D	B-MED
-	I-MED
CISS	I-MED
sequences	I-MED
.	O
The	O
mean	B-MED
peak	I-MED
systolic	I-MED
velocity	I-MED
of	O
CSF	B-MED
was	O
1.86	O
±	O
2.48	O
cm	O
/	O
sec	O
,	O
the	O
stroke	B-MED
volume	I-MED
was	O
6.43	O
±	O
13.81μl	O
/	O
cycle	O
,	O
and	O
the	O
mean	B-MED
flow	I-MED
was	O
0.21	O
±	O
0.32	O
ml	O
/	O
min	O
.	O
We	O
concluded	O
that	O
3D	B-MED
-	I-MED
CISS	I-MED
and	O
PC	B-MED
-	I-MED
MRI	I-MED
are	O
non	B-MED
-	I-MED
invasive	I-MED
sequences	O
for	O
diagnosis	B-MED
of	O
the	O
level	O
and	O
cause	B-MED
of	O
arrested	B-MED
hydrocephalus	I-MED
.	O
Total	B-MED
Energy	I-MED
Expenditure	I-MED
in	O
Obese	B-MED
Kuwaiti	B-MED
Primary	I-MED
School	I-MED
Children	B-MED
Assessed	B-MED
by	O
the	O
Doubly	B-MED
-	I-MED
Labeled	I-MED
Water	I-MED
Technique	I-MED
The	O
aim	O
of	O
this	O
pilot	B-MED
study	I-MED
was	O
to	O
assess	B-MED
body	O
composition	O
and	O
total	B-MED
energy	I-MED
expenditure	I-MED
(	O
TEE	B-MED
)	O
in	O
35	O
obese	B-MED
7	O
-	O
9	O
years	B-MED
old	O
Kuwaiti	B-MED
children	B-MED
(	O
18	O
girls	B-MED
and	O
17	O
boys	B-MED
)	O
.	O
Total	B-MED
body	I-MED
water	I-MED
(	O
TBW	B-MED
)	O
and	O
TEE	B-MED
were	O
assessed	B-MED
by	O
doubly	B-MED
-	I-MED
labeled	I-MED
water	I-MED
technique	I-MED
.	O
TBW	B-MED
was	O
derived	O
from	O
the	O
intercept	B-MED
of	O
the	O
elimination	B-MED
rate	I-MED
of	O
deuterium	B-MED
and	O
TEE	B-MED
from	O
the	O
difference	B-MED
in	O
elimination	B-MED
rates	I-MED
of	O
(	B-MED
18)O	I-MED
and	O
deuterium	B-MED
.	O
TBW	B-MED
was	O
used	O
to	O
estimate	B-MED
fat	B-MED
-	I-MED
free	I-MED
mass	I-MED
(	O
FFM	B-MED
)	O
,	O
using	O
hydration	B-MED
factors	B-MED
for	O
different	O
ages	B-MED
and	O
gender	B-MED
.	O
Fat	B-MED
mass	I-MED
(	O
FM	B-MED
)	O
was	O
calculated	B-MED
as	O
the	O
difference	B-MED
between	O
body	B-MED
weight	I-MED
and	O
FFM	B-MED
.	O
Body	B-MED
weight	I-MED
was	O
not	O
statistically	B-MED
different	I-MED
but	O
TBW	B-MED
was	O
significantly	B-MED
higher	I-MED
(	O
p	O
=	O
0.018	O
)	O
in	O
boys	B-MED
(	O
44.9	O
%	O
±	O
3.3	O
%	O
)	O
than	O
girls	B-MED
(	O
42.4	O
%	O
±	O
3.0	O
%	O
)	O
,	O
while	O
girls	B-MED
had	O
significantly	B-MED
higher	I-MED
estimated	B-MED
FM	B-MED
(	O
45.2	O
±	O
3.9	O
weight	O
%	O
versus	O
41.6	O
%	O
±	O
4.3	O
%	O
;	O
p	O
=	O
0.014	O
)	O
.	O
TEE	B-MED
was	O
significantly	B-MED
higher	I-MED
in	O
boys	B-MED
(	O
2395	O
±	O
349	O
kcal	O
/	O
day	O
)	O
compared	O
with	O
girls	B-MED
(	O
1978	O
±	O
169	O
kcal	O
/	O
day	O
)	O
;	O
p	O
=	O
0.001	O
.	O
Estimated	B-MED
physical	B-MED
activity	I-MED
level	I-MED
(	O
PAL	B-MED
)	O
was	O
significantly	B-MED
higher	I-MED
in	O
boys	B-MED
;	O
1.61	O
±	O
0.167	O
versus	O
1.51	O
±	O
0.870	O
;	O
p	O
=	O
0.034	O
.	O
Our	O
results	B-MED
provide	O
the	O
first	O
dataset	B-MED
of	O
TEE	B-MED
in	O
7	O
-	O
9	O
years	B-MED
old	O
obese	B-MED
Kuwaiti	B-MED
children	B-MED
and	O
highlight	O
important	O
gender	B-MED
differences	I-MED
to	O
be	O
considered	O
during	O
the	O
development	O
of	O
school	B-MED
based	I-MED
interventions	I-MED
targeted	O
to	O
combat	O
childhood	B-MED
obesity	I-MED
.	O
Oxidative	B-MED
stress	I-MED
and	O
immunosenescence	B-MED
in	O
spleen	B-MED
of	O
obese	B-MED
mice	I-MED
can	O
be	O
reversed	O
by	O
2	B-MED
-	I-MED
hydroxyoleic	I-MED
acid	I-MED
We	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
obesity	B-MED
on	O
oxidative	B-MED
stress	I-MED
and	O
leukocyte	B-MED
function	B-MED
in	O
spleen	B-MED
of	O
mice	B-MED
,	O
and	O
to	O
assess	O
whether	O
supplementation	B-MED
with	O
2	B-MED
-	I-MED
hydroxyoleic	I-MED
acid	I-MED
(	O
2	B-MED
-	I-MED
OHOA	I-MED
)	O
or	O
n-3	B-MED
polyunsaturated	I-MED
fatty	I-MED
acids	I-MED
(	O
PUFA	B-MED
)	O
could	O
reverse	O
those	O
effects	O
.	O
Female	B-MED
ICR	B-MED
/	I-MED
CD1	I-MED
mice	I-MED
(	O
8	O
weeks	B-MED
old	O
,	O
n	O
=	O
24	O
)	O
received	O
an	O
obesogenic	B-MED
diet	I-MED
(	O
22	O
%	O
fat	B-MED
for	O
4	O
weeks	B-MED
and	O
60	O
%	O
fat	B-MED
for	O
14	O
weeks	B-MED
)	O
.	O
After	O
6	O
weeks	B-MED
,	O
mice	B-MED
were	O
split	O
in	O
three	O
groups	B-MED
(	O
n	O
=	O
8/	O
group	B-MED
):	O
no	B-MED
supplementation	I-MED
,	O
2	B-MED
-	I-MED
OHOA	I-MED
supplementation	I-MED
(	O
1500	O
mg	O
kg(-1	O
)	O
)	O
and	O
n-3	B-MED
PUFA	I-MED
supplementation	I-MED
(	O
EPA	B-MED
+	O
DHA	B-MED
,	O
3000	O
mg	O
kg(-1	O
)	O
diet	O
)	O
.	O
Eight	O
mice	B-MED
were	O
fed	O
standard	O
diet	B-MED
for	O
the	O
whole	O
duration	B-MED
of	O
the	O
study	B-MED
(	O
control	B-MED
group	I-MED
)	O
.	O
At	O
the	O
end	O
of	O
the	O
experiment	B-MED
,	O
the	O
following	O
variables	B-MED
were	O
assessed	B-MED
in	O
spleens	B-MED
:	O
levels	B-MED
of	O
reduced	B-MED
(	O
GSH	B-MED
)	O
and	O
oxidized	B-MED
(	I-MED
GSSG	I-MED
)	I-MED
glutathione	I-MED
,	O
GSH	B-MED
/	O
GSSG	B-MED
,	O
xanthine	B-MED
oxidase	I-MED
(	I-MED
XO	I-MED
)	I-MED
activity	I-MED
,	O
lipid	B-MED
peroxidation	I-MED
,	O
lymphocyte	B-MED
chemotaxis	I-MED
,	O
natural	B-MED
killer	I-MED
(	I-MED
NK	I-MED
)	I-MED
activity	I-MED
and	O
mitogen	B-MED
(	O
ConA	B-MED
LPS	B-MED
and	O
LPS)-induced	O
lymphocyte	B-MED
proliferation	I-MED
.	O
Obese	B-MED
animals	B-MED
presented	O
higher	B-MED
GSSG	B-MED
levels	B-MED
(	O
P	O
=	O
0.003	O
)	O
,	O
GSSG	B-MED
/	O
GSH	B-MED
ratio	B-MED
(	O
P	O
=	O
0.013	O
)	O
,	O
lipid	B-MED
peroxidation	I-MED
(	O
P	O
=	O
0.004	O
)	O
,	O
XO	B-MED
activity	I-MED
(	O
P	O
=	O
0.015	O
)	O
and	O
lymphocyte	B-MED
chemotaxis	I-MED
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
lower	O
NK	B-MED
activity	I-MED
(	O
P	O
=	O
0.003	O
)	O
and	O
proliferation	B-MED
in	O
response	O
to	O
ConA	B-MED
(	O
P	O
<	O
0.001	O
)	O
than	O
controls	B-MED
.	O
2	B-MED
-	I-MED
OHOA	I-MED
reversed	O
totally	O
or	O
partially	O
most	O
of	O
the	O
changes	B-MED
(	O
body	B-MED
weight	I-MED
,	O
fat	O
content	O
,	O
GSSG	B-MED
levels	B-MED
,	O
GSH	B-MED
/	O
GSSG	B-MED
,	O
lipid	B-MED
peroxidation	I-MED
,	O
chemotaxis	B-MED
and	O
proliferation	B-MED
,	O
all	O
P	O
<	O
0.05	O
)	O
,	O
while	O
n-3	B-MED
PUFA	I-MED
reversed	O
the	O
increase	B-MED
in	O
XO	B-MED
activity	I-MED
(	O
P	O
=	O
0.032	O
)	O
.	O
In	O
conclusion	O
,	O
2	B-MED
-	I-MED
OHOA	I-MED
,	O
and	O
to	O
a	O
lesser	O
extent	O
n-3	B-MED
PUFA	I-MED
,	O
could	O
ameliorate	O
the	O
oxidative	B-MED
stress	I-MED
and	O
alteration	B-MED
of	O
leukocyte	B-MED
function	B-MED
in	O
spleen	B-MED
of	O
obese	B-MED
mice	I-MED
.	O
Our	O
findings	B-MED
support	O
a	O
link	O
between	O
obesity	B-MED
and	O
immunosenescence	B-MED
and	O
suggest	O
a	O
potential	O
therapeutic	B-MED
tool	I-MED
for	O
obesity	B-MED
-related	O
immune	B-MED
dysfunction	I-MED
.	O
This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
All	O
rights	O
reserved	O
.	O
Prolyl-4	B-MED
-	I-MED
hydroxylase	I-MED
2	I-MED
and	O
3	B-MED
coregulate	O
murine	B-MED
erythropoietin	B-MED
in	O
brain	B-MED
pericytes	B-MED
A	O
classic	O
response	B-MED
to	O
systemic	B-MED
hypoxia	B-MED
is	O
the	O
increased	B-MED
production	B-MED
of	I-MED
red	I-MED
blood	I-MED
cells	I-MED
due	O
to	O
hypoxia	B-MED
-	I-MED
inducible	I-MED
factor	I-MED
HIF	B-MED
(	O
HIF)-mediated	O
induction	B-MED
of	O
erythropoietin	B-MED
(	O
EPO	B-MED
)	O
.	O
EPO	B-MED
is	O
a	O
glycoprotein	B-MED
hormone	I-MED
that	O
is	O
essential	O
for	O
normal	B-MED
erythropoiesis	I-MED
and	O
is	O
predominantly	O
synthesized	O
by	O
peritubular	B-MED
renal	B-MED
interstitial	I-MED
fibroblast	I-MED
-	I-MED
like	I-MED
cells	I-MED
,	O
which	O
express	O
cellular	B-MED
markers	I-MED
characteristic	O
of	O
neuronal	B-MED
cells	I-MED
and	O
pericytes	B-MED
.	O
To	O
investigate	B-MED
whether	O
the	O
ability	O
to	O
synthesize	O
EPO	B-MED
is	O
a	O
general	O
functional	B-MED
feature	B-MED
of	O
pericytes	B-MED
,	O
we	O
used	O
conditional	O
gene	B-MED
targeting	I-MED
to	O
examine	O
the	O
von	B-MED
Hippel	I-MED
-	I-MED
Lindau	I-MED
/	O
prolyl-4	B-MED
-	I-MED
hydroxylase	I-MED
domain	I-MED
(	I-MED
PHD)/HIF	I-MED
axis	O
in	O
cell	B-MED
-	O
expressing	B-MED
neural	B-MED
glial	I-MED
antigen	I-MED
2	I-MED
,	O
a	O
known	O
molecular	B-MED
marker	I-MED
of	O
pericytes	B-MED
in	O
multiple	B-MED
organs	I-MED
.	O
We	O
found	O
that	O
pericytes	B-MED
in	O
the	O
brain	B-MED
synthesized	O
EPO	B-MED
in	O
mice	B-MED
with	O
genetic	B-MED
HIF	B-MED
activation	B-MED
and	O
were	O
capable	O
of	O
responding	O
to	O
systemic	B-MED
hypoxia	B-MED
with	O
the	O
induction	B-MED
of	O
Epo	B-MED
.	O
Using	O
high	B-MED
-	I-MED
resolution	I-MED
multiplex	O
in	B-MED
situ	I-MED
hybridization	I-MED
,	O
we	O
determined	O
that	O
brain	B-MED
pericytes	B-MED
represent	O
an	O
important	O
cellular	B-MED
source	I-MED
of	O
Epo	B-MED
in	O
the	O
hypoxic	B-MED
brain	B-MED
(	O
up	O
to	O
70	O
%	O
of	O
all	O
Epo	B-MED
-	O
expressing	B-MED
cells	B-MED
)	O
.	O
We	O
furthermore	O
determined	O
that	O
Epo	B-MED
transcription	B-MED
in	O
brain	B-MED
pericytes	B-MED
was	O
HIF-2	B-MED
dependent	O
and	O
cocontrolled	O
by	O
PHD2	B-MED
and	O
PHD3	B-MED
,	O
oxygen	B-MED
-	O
and	O
2	B-MED
-	I-MED
oxoglutarate	I-MED
-dependent	O
prolyl-4	B-MED
-	I-MED
hydroxylases	I-MED
that	O
regulate	O
HIF	B-MED
activity	B-MED
.	O
In	O
summary	O
,	O
our	O
studies	O
provide	O
experimental	B-MED
evidence	B-MED
that	O
pericytes	B-MED
in	O
the	O
brain	B-MED
have	O
the	O
ability	O
to	O
function	O
as	O
oxygen	B-MED
sensors	I-MED
and	O
respond	O
to	O
hypoxia	B-MED
with	O
EPO	B-MED
synthesis	O
.	O
Our	O
findings	B-MED
furthermore	O
suggest	O
that	O
the	O
ability	O
to	O
synthesize	O
EPO	B-MED
may	O
represent	O
a	O
functional	B-MED
feature	B-MED
of	O
pericytes	B-MED
in	O
the	O
brain	B-MED
and	O
kidney	B-MED
.	O
Vaginal	B-MED
Infections	I-MED
of	O
Albanian	B-MED
women	B-MED
Infected	B-MED
with	O
HPV	B-MED
and	O
their	O
impact	O
in	O
intraepithelial	B-MED
cervical	I-MED
lesions	I-MED
evidenced	O
by	O
Pap	B-MED
test	I-MED
Cervical	B-MED
cytology	I-MED
is	O
the	O
best	O
single	O
method	O
for	O
large	O
screening	B-MED
of	O
the	O
population	O
in	O
identifying	O
precancerous	B-MED
lesions	I-MED
of	O
the	O
uterine	B-MED
cervix	I-MED
.	O
To	O
estimate	O
the	O
frequency	O
of	O
human	B-MED
papillomavirus	I-MED
(	I-MED
HPV	I-MED
)	I-MED
positivity	I-MED
in	O
a	O
group	O
of	O
Albanian	B-MED
women	B-MED
,	O
the	O
prevalence	B-MED
of	O
vaginal	B-MED
coinfections	I-MED
,	O
and	O
the	O
relationship	O
of	O
coinfections	B-MED
with	O
HPV	B-MED
,	O
as	O
well	O
as	O
their	O
role	O
in	O
metaplasia	B-MED
or	O
cervical	B-MED
intraepithelial	I-MED
lesions	I-MED
(	O
CIN	B-MED
)	O
.	O
In	O
this	O
retrospective	B-MED
study	I-MED
,	O
2075	O
vaginal	B-MED
smears	I-MED
were	O
examined	O
.	O
The	O
Papanicolaou	B-MED
stain	I-MED
was	O
used	O
for	O
all	O
slides	O
.	O
The	O
New	B-MED
Bethesda	I-MED
System	I-MED
2001	O
was	O
used	O
for	O
the	O
interpretations	B-MED
of	I-MED
the	I-MED
smears	I-MED
.	O
Data	O
analysis	O
was	O
completed	O
using	O
the	O
Statistical	B-MED
Package	I-MED
for	I-MED
the	I-MED
Social	I-MED
Sciences	I-MED
version	I-MED
19.0	O
.	O
Prevalence	B-MED
of	O
HPV	B-MED
positivity	I-MED
was	O
43.9	O
%	O
with	O
an	O
average	O
age	O
of	O
35.48	O
±	O
9.27	O
years	O
.	O
Candida	B-MED
coinfection	I-MED
resulted	O
in	O
57.8	O
%	O
of	O
HPV	B-MED
positive	I-MED
women	B-MED
with	O
a	O
significant	O
relationship	O
between	O
them	O
.	O
Gardnerella	B-MED
coinfection	I-MED
resulted	O
in	O
36	O
(	O
23	O
%	O
)	O
,	O
mixed	B-MED
flora	I-MED
in	O
34	O
(	O
8	O
%	O
)	O
,	O
and	O
Trichomonas	B-MED
vaginalis	I-MED
in	O
50	O
%	O
of	O
HPV	B-MED
positive	I-MED
woman	B-MED
.	O
Among	O
the	O
women	B-MED
with	O
positive	B-MED
HPV	I-MED
,	O
19	O
%	O
had	O
CIN	B-MED
,	O
8	O
%	O
had	O
metaplasia	B-MED
,	O
and	O
1	O
%	O
had	O
metaplasia	B-MED
and	O
CIN	B-MED
;	O
9	O
%	O
of	O
the	O
women	B-MED
with	O
HPV	B-MED
had	O
CIN1	B-MED
and	O
one	O
of	O
the	O
coinfections	B-MED
.	O
There	O
is	O
a	O
strong	O
relationship	O
between	O
CIN1	B-MED
and	O
HPV	B-MED
positivity	I-MED
as	O
well	O
as	O
between	O
CIN1	B-MED
and	O
coinfections	B-MED
.	O
HPV	B-MED
infection	I-MED
is	O
a	O
major	O
factor	O
contributing	O
to	O
metaplasia	B-MED
,	O
and	O
bacterial	B-MED
coinfections	I-MED
in	O
HPV	B-MED
positive	I-MED
women	B-MED
have	O
a	O
statistically	B-MED
significant	I-MED
impact	O
in	O
the	O
development	O
of	O
metaplasia	B-MED
.	O
Beneficial	B-MED
effects	B-MED
of	O
dark	B-MED
chocolate	I-MED
on	O
exercise	B-MED
capacity	B-MED
in	O
sedentary	B-MED
subjects	B-MED
:	O
underlying	O
mechanisms	B-MED
.	O
A	O
double	B-MED
blind	I-MED
,	O
randomized	B-MED
,	O
placebo	B-MED
controlled	I-MED
trial	B-MED
In	O
heart	B-MED
failure	I-MED
patients	B-MED
the	O
consumption	B-MED
of	O
(	B-MED
-)-epicatechin	I-MED
(	O
(	B-MED
-)-Epi	I-MED
-)-Epi)-rich	O
cocoa	B-MED
can	O
restore	O
skeletal	B-MED
muscle	I-MED
(	O
SkM	B-MED
)	O
mitochondrial	B-MED
structure	B-MED
and	O
decrease	B-MED
biomarkers	B-MED
of	O
oxidative	B-MED
stress	I-MED
.	O
However	O
,	O
nothing	O
is	O
known	O
about	O
its	O
effects	B-MED
on	O
exercise	B-MED
capacity	B-MED
and	O
underlying	O
mechanisms	B-MED
in	O
normal	B-MED
,	O
sedentary	B-MED
subjects	B-MED
.	O
Twenty	O
normal	B-MED
,	O
sedentary	B-MED
subjects	B-MED
(	O
∼50	O
years	B-MED
old	I-MED
)	O
were	O
randomized	B-MED
to	O
placebo	B-MED
or	O
dark	B-MED
chocolate	I-MED
(	O
DC	B-MED
)	O
groups	B-MED
and	O
consumed	B-MED
20	O
g	O
of	O
the	O
products	O
for	O
3	O
months	B-MED
.	O
Subjects	B-MED
underwent	O
before	O
and	O
after	O
treatment	B-MED
,	O
bicycle	B-MED
ergometry	I-MED
to	O
assess	B-MED
VO2	B-MED
max	I-MED
and	O
work	B-MED
,	O
SkM	B-MED
biopsy	I-MED
to	O
assess	B-MED
changes	O
in	O
mitochondrial	B-MED
density	B-MED
,	O
function	B-MED
and	O
oxidative	B-MED
stress	I-MED
and	O
blood	B-MED
sampling	I-MED
to	O
assess	B-MED
metabolic	B-MED
endpoints	B-MED
.	O
Seventeen	O
subjects	B-MED
completed	O
the	O
trial	B-MED
.	O
In	O
the	O
DC	B-MED
group	O
(	O
n	O
=	O
9	O
)	O
,	O
VO2	B-MED
max	I-MED
increased	B-MED
(	O
17	O
%	O
increase	B-MED
,	O
p	O
=	O
0.056	O
)	O
as	O
well	O
as	O
maximum	O
work	B-MED
(	O
watts	B-MED
)	O
achieved	O
(	O
p	O
=	O
0.026	O
)	O
with	O
no	O
changes	O
with	O
placebo	B-MED
(	O
n	O
=	O
8)	O
.	O
The	O
DC	B-MED
group	O
evidenced	O
increases	B-MED
in	O
HDL	B-MED
levels	O
(	O
p	O
=	O
0.005	O
)	O
and	O
decreased	B-MED
triglycerides	B-MED
(	O
p	O
=	O
0.07	O
)	O
.	O
With	O
DC	B-MED
,	O
SkM	B-MED
evidenced	O
significant	B-MED
increases	B-MED
in	O
protein	B-MED
levels	O
for	O
LKB1	B-MED
,	O
AMPK	B-MED
and	O
PGC1α	B-MED
and	O
in	O
their	O
active	B-MED
forms	O
(	O
phosphorylated	B-MED
AMPK	B-MED
and	O
LKB1	B-MED
)	O
as	O
well	O
as	O
in	O
citrate	B-MED
synthase	I-MED
activity	I-MED
while	O
no	O
changes	O
were	O
observed	O
in	O
mitochondrial	B-MED
density	B-MED
.	O
With	O
DC	B-MED
,	O
significant	B-MED
increases	B-MED
in	O
SkM	B-MED
reduced	O
glutathione	B-MED
levels	O
and	O
decreases	B-MED
in	O
protein	B-MED
carbonylation	I-MED
were	O
observed	O
.	O
Improvements	O
in	O
maximum	O
work	B-MED
achieved	O
and	O
VO2	B-MED
max	I-MED
may	O
be	O
due	O
to	O
DC	B-MED
activation	B-MED
of	O
upstream	O
control	O
systems	O
and	O
enhancement	O
of	O
SkM	B-MED
mitochondria	B-MED
efficiency	B-MED
.	O
Larger	O
clinical	B-MED
studies	I-MED
are	O
warranted	O
to	O
confirm	O
these	O
observations	B-MED
.	O
Medication	B-MED
Reconciliation	I-MED
During	O
Hospitalization	B-MED
and	O
in	O
Hospital	B-MED
-	I-MED
Home	I-MED
Interface	I-MED
:	O
An	O
Observational	B-MED
Retrospective	I-MED
Study	I-MED
Medication	B-MED
errors	I-MED
are	O
one	O
of	O
the	O
leading	O
causes	O
of	O
patient	B-MED
harms	I-MED
.	O
Medication	B-MED
reconciliation	I-MED
is	O
a	O
fundamental	O
process	O
that	O
to	O
be	O
effective	O
,	O
it	O
should	O
be	O
embraced	O
during	O
each	O
single	O
care	B-MED
transition	I-MED
.	O
Our	O
objectives	O
were	O
to	O
investigate	B-MED
current	O
medication	B-MED
reconciliation	I-MED
practices	O
in	O
the	O
2	O
Fondazione	B-MED
Toscana	I-MED
Gabriele	I-MED
Monasterio	I-MED
hospitals	I-MED
and	O
comprehensively	O
assess	B-MED
the	I-MED
quality	I-MED
of	O
medication	B-MED
reconciliation	I-MED
practices	O
between	O
inpatient	B-MED
and	O
outpatient	B-MED
care	B-MED
by	O
analyzing	B-MED
the	O
medication	B-MED
patterns	I-MED
6	O
months	B-MED
before	O
admission	B-MED
,	O
during	O
hospitalization	B-MED
,	O
and	O
9	O
months	B-MED
after	O
discharge	B-MED
for	O
a	O
selected	O
group	O
of	O
patients	B-MED
with	O
cardiovascular	B-MED
diseases	I-MED
.	O
A	O
retrospective	B-MED
observational	I-MED
study	I-MED
was	O
conducted	O
in	O
the	O
Cardiothoracic	B-MED
Department	I-MED
of	O
the	O
Fondazione	B-MED
Toscana	I-MED
Gabriele	I-MED
Monasterio	I-MED
hospitals	I-MED
.	O
Medication	B-MED
history	I-MED
was	O
reviewed	B-MED
for	O
all	O
the	O
patients	B-MED
admitted	B-MED
from	O
and	O
discharged	B-MED
to	O
the	O
community	B-MED
,	O
from	O
January	O
to	O
March	O
2013	O
.	O
Patients	B-MED
were	O
excluded	O
if	O
they	O
had	O
less	O
than	O
4	O
drugs	B-MED
or	O
less	O
than	O
2	O
drugs	B-MED
for	O
cardiovascular	B-MED
system	I-MED
in	O
their	O
prescription	B-MED
list	I-MED
at	O
admission	B-MED
or	O
if	O
they	O
died	B-MED
during	O
follow	B-MED
-	I-MED
up	I-MED
.	O
We	O
selected	O
714	O
patients	B-MED
,	O
and	O
we	O
obtained	O
the	O
clinical	B-MED
charts	I-MED
and	O
all	O
drug	B-MED
prescriptions	I-MED
collected	O
during	O
patients	B-MED
'	O
hospitalization	B-MED
by	O
the	O
electronic	B-MED
clinical	I-MED
recording	I-MED
system	I-MED
.	O
We	O
also	O
analyzed	B-MED
the	O
list	B-MED
of	I-MED
prescriptions	I-MED
of	O
this	O
sample	O
of	O
patients	B-MED
,	O
from	O
6	O
months	B-MED
before	O
admission	B-MED
to	O
9	O
months	B-MED
after	O
discharge	B-MED
,	O
extracted	O
from	O
the	O
regional	B-MED
prescription	I-MED
registry	I-MED
.	O
In	O
the	O
resulting	O
sample	O
,	O
prescriptions	B-MED
were	O
analyzed	B-MED
to	O
assess	O
unintentional	B-MED
discrepancies	B-MED
.	O
The	O
study	B-MED
included	O
298	O
patients	B-MED
(	O
mean	O
age	B-MED
,	O
71.2	O
years	B-MED
)	O
,	O
according	O
to	O
the	O
inclusion	B-MED
and	I-MED
exclusion	I-MED
criteria	I-MED
.	O
Among	O
14,573	O
prescriptions	B-MED
analyzed	B-MED
,	O
we	O
found	O
4363	O
discrepancies	B-MED
(	O
14.6	O
discrepancies	B-MED
per	O
patient	B-MED
)	O
.	O
Among	O
these	O
discrepancies	B-MED
,	O
1310	O
were	O
classified	O
as	O
unintentional	B-MED
(	O
4.4	O
discrepancies	B-MED
per	O
patient	B-MED
)	O
.	O
Among	O
unintentional	B-MED
discrepancies	B-MED
,	O
only	O
63	O
(	O
4.8	O
%	O
)	O
took	O
place	O
during	O
hospitalization	B-MED
.	O
Although	O
at	O
the	O
hospital	B-MED
-	I-MED
home	I-MED
interface	I-MED
,	O
33.1	O
%	O
of	O
unintentional	B-MED
discrepancies	B-MED
were	O
detected	O
through	O
the	O
comparison	B-MED
between	O
the	O
patients	B-MED
'	O
declared	O
therapy	B-MED
and	O
the	O
previous	O
medication	B-MED
consumption	I-MED
and	O
62.1	O
%	O
were	O
identified	O
in	O
the	O
comparison	B-MED
between	O
the	O
prescription	B-MED
at	O
the	O
discharge	B-MED
and	O
the	O
following	O
medication	B-MED
pattern	I-MED
at	O
home	B-MED
.	O
Medication	B-MED
errors	I-MED
have	O
important	O
implications	O
for	O
patient	B-MED
safety	I-MED
,	O
and	O
their	O
identification	O
is	O
a	O
main	O
target	O
for	O
improving	O
clinical	B-MED
practice	I-MED
.	O
The	O
comparison	B-MED
between	O
the	O
medication	B-MED
patterns	I-MED
acquired	O
through	O
the	O
regional	B-MED
prescription	I-MED
registry	I-MED
before	O
and	O
after	O
hospitalization	B-MED
outlined	O
critical	O
touchpoint	O
in	O
the	O
current	O
medication	B-MED
reconciliation	I-MED
process	O
,	O
calling	O
for	O
the	O
definition	O
of	O
shared	O
medication	B-MED
reconciliation	I-MED
standards	O
between	O
hospitals	B-MED
and	O
primary	B-MED
care	I-MED
services	I-MED
to	O
minimize	O
medication	B-MED
discrepancies	I-MED
and	O
enhance	O
patient	B-MED
safety	I-MED
.	O
PI3	B-MED
K	I-MED
/	O
Akt	B-MED
pathway	B-MED
:	O
a	O
potential	O
therapeutic	B-MED
target	B-MED
for	O
chronic	B-MED
pain	I-MED
Chronic	B-MED
pain	I-MED
is	O
among	O
the	O
most	O
disabling	B-MED
and	O
costly	O
disorders	B-MED
,	O
with	O
prevalence	B-MED
ranging	B-MED
from	O
10	O
%	O
to	O
55	O
%	O
.	O
However	O
,	O
current	O
therapeutic	B-MED
strategies	O
for	O
chronic	B-MED
pain	I-MED
are	O
unsatisfactory	B-MED
due	O
to	O
our	O
poor	B-MED
understanding	B-MED
of	O
its	O
mechanisms	B-MED
.	O
Thus	O
,	O
novel	O
therapeutic	B-MED
targets	B-MED
need	O
to	O
be	O
found	O
in	O
order	O
to	O
improve	B-MED
these	O
patients	B-MED
'	I-MED
quality	B-MED
of	I-MED
life	I-MED
.	O
PI3	B-MED
K	I-MED
and	O
its	O
downstream	B-MED
Akt	B-MED
are	O
widely	O
expressed	B-MED
in	O
the	O
spinal	B-MED
cord	I-MED
,	O
particularly	O
in	O
the	O
laminae	B-MED
I	I-MED
-	I-MED
IV	I-MED
of	O
the	O
dorsal	B-MED
horn	I-MED
,	O
where	O
nociceptive	B-MED
C	I-MED
and	O
Aδ	B-MED
fibers	I-MED
of	O
primary	B-MED
afferents	B-MED
principally	O
terminate	B-MED
.	O
Recent	O
studies	B-MED
have	O
demonstrated	O
their	O
critical	B-MED
roles	B-MED
in	O
the	O
development	B-MED
and	O
maintenance	B-MED
of	O
chronic	B-MED
pain	I-MED
.	O
In	O
this	O
review	B-MED
,	O
we	O
summarized	O
the	O
roles	B-MED
and	O
mechanisms	B-MED
of	O
PI3	B-MED
K	I-MED
/	O
Akt	B-MED
pathway	B-MED
in	O
the	O
progression	B-MED
of	O
chronic	B-MED
pain	I-MED
through	O
sciatic	B-MED
nerve	I-MED
injury	I-MED
,	O
diabetic	B-MED
neuropathy	I-MED
,	O
spinal	B-MED
cord	I-MED
injury	I-MED
,	O
bone	B-MED
cancer	I-MED
,	O
opioid	B-MED
tolerance	I-MED
,	O
or	O
opioid	B-MED
-	O
induced	B-MED
hyperalgesia	B-MED
.	O
Improved	B-MED
protocol	B-MED
for	O
the	O
isolation	B-MED
of	O
naïve	O
follicular	B-MED
dendritic	I-MED
cells	I-MED
Follicular	B-MED
dendritic	I-MED
cells	I-MED
(	O
FDCs	B-MED
)	O
in	O
lymphoid	B-MED
organs	I-MED
play	O
an	O
important	O
role	B-MED
in	O
the	O
humoral	B-MED
immune	I-MED
response	I-MED
.	O
However	O
,	O
because	O
the	O
isolation	B-MED
of	O
FDCs	B-MED
is	O
difficult	B-MED
due	O
to	O
their	O
very	O
small	B-MED
population	B-MED
size	I-MED
and	O
fragility	B-MED
under	O
mechanical	B-MED
and	O
chemical	B-MED
stresses	I-MED
,	O
the	O
genetic	B-MED
and	O
biochemical	B-MED
characteristics	B-MED
of	O
FDCs	B-MED
remain	O
unclear	B-MED
.	O
Previously	O
,	O
we	O
identified	O
FDCs	B-MED
as	O
ICAM-1(+	B-MED
)	I-MED
cells	B-MED
in	O
the	O
CD45	B-MED
(	B-MED
-	I-MED
)	I-MED
non	B-MED
-	I-MED
hematopoietic	I-MED
cell	I-MED
fraction	I-MED
from	O
naïve	O
mouse	B-MED
spleen	I-MED
after	O
cell	B-MED
separation	I-MED
by	O
means	O
of	O
digestion	O
with	O
a	O
combination	B-MED
of	O
enzymes	B-MED
.	O
In	O
the	O
present	O
study	O
,	O
using	O
a	O
new	B-MED
combination	B-MED
of	O
enzymes	B-MED
,	O
we	O
found	O
that	O
FDCs	B-MED
are	O
highly	O
enriched	O
in	O
the	O
CD45	B-MED
(	B-MED
-	I-MED
)	I-MED
ICAM-1(+	B-MED
)	I-MED
CD21	B-MED
/	O
35(+	B-MED
)	I-MED
cell	B-MED
fraction	I-MED
.	O
CD45	B-MED
(	B-MED
-	I-MED
)	I-MED
ICAM-1(+	B-MED
)	I-MED
CD21	B-MED
/	O
35(+	B-MED
)	I-MED
cells	B-MED
in	O
the	O
mouse	B-MED
spleen	I-MED
retained	O
an	O
antigen	B-MED
administered	O
in	B-MED
vivo	I-MED
for	O
more	O
than	O
7	O
days	B-MED
.	O
Moreover	O
,	O
CD45	B-MED
(	B-MED
-	I-MED
)	I-MED
ICAM-1(+	B-MED
)	I-MED
CD21	B-MED
/	O
35(+	B-MED
)	I-MED
cells	B-MED
isolated	B-MED
from	O
the	O
spleen	B-MED
of	I-MED
mice	I-MED
administered	O
with	O
a	O
cognate	B-MED
antigen	I-MED
enhanced	B-MED
the	O
survival	B-MED
and	O
proliferation	B-MED
of	O
antigen	B-MED
-	I-MED
specific	I-MED
B	I-MED
cells	I-MED
in	B-MED
vitro	I-MED
.	O
Our	O
improved	B-MED
protocol	B-MED
for	O
the	O
isolation	B-MED
of	O
naïve	O
FDCs	B-MED
will	O
be	O
useful	O
for	O
the	O
analysis	B-MED
of	O
FDCs	B-MED
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
.	O
Psychometric	B-MED
properties	B-MED
of	O
the	O
Japanese	B-MED
version	B-MED
of	O
short	B-MED
forms	I-MED
of	O
the	O
Pain	B-MED
Catastrophizing	I-MED
Scale	I-MED
in	O
participants	B-MED
with	O
musculoskeletal	B-MED
pain	I-MED
:	O
A	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
The	O
Pain	B-MED
Catastrophizing	I-MED
Scale	I-MED
(	O
PCS	B-MED
)	O
is	O
a	O
commonly	O
used	O
as	O
measure	B-MED
of	O
pain	B-MED
catastrophizing	I-MED
.	O
The	O
scale	B-MED
comprises	O
13	O
items	B-MED
related	O
to	O
magnification	B-MED
,	O
rumination	B-MED
,	O
and	O
helplessness	B-MED
.	O
To	O
facilitate	O
quick	O
screening	B-MED
and	O
to	O
reduce	B-MED
participant	B-MED
's	I-MED
burden	B-MED
,	O
the	O
four-	O
item	B-MED
and	O
six-	O
item	B-MED
short	B-MED
forms	I-MED
of	O
the	O
English	B-MED
version	B-MED
of	O
the	O
PCS	B-MED
were	O
developed	O
.	O
The	O
purpose	O
of	O
the	O
present	O
study	B-MED
was	O
to	O
evaluate	B-MED
the	O
psychometric	B-MED
properties	B-MED
of	O
a	O
Japanese	B-MED
version	B-MED
of	O
the	O
short	B-MED
forms	I-MED
of	O
PCS	B-MED
using	O
a	O
contemporary	O
approach	B-MED
called	O
Rasch	B-MED
analysis	I-MED
.	O
A	O
total	O
of	O
216	O
patients	B-MED
with	O
musculoskeletal	B-MED
disorders	I-MED
were	O
recruited	O
in	O
this	O
study	B-MED
.	O
Participants	B-MED
completed	O
study	B-MED
measures	B-MED
,	O
which	O
included	O
the	O
pain	B-MED
intensity	I-MED
,	O
the	O
Pain	B-MED
Catastrophizing	I-MED
Scale	I-MED
(	O
PCS	B-MED
)	O
,	O
and	O
the	O
Tampa	B-MED
Scale	I-MED
of	I-MED
Kinesiophobia	I-MED
(	O
TSK	B-MED
)	O
.	O
Furthermore	O
,	O
the	O
four-	O
item	B-MED
(	O
items	B-MED
3	O
,	O
6	O
,	O
8	O
,	O
and	O
11	O
)	O
and	O
six-	O
item	B-MED
(	O
items	B-MED
4	O
,	O
5	O
,	O
6	O
,	O
10	O
,	O
11	O
,	O
and	O
13	O
)	O
short	B-MED
forms	I-MED
of	O
the	O
Japanese	B-MED
version	B-MED
of	O
PCS	B-MED
were	O
measured	O
.	O
We	O
used	O
Rasch	B-MED
analysis	I-MED
to	O
analyze	B-MED
the	O
psychometric	B-MED
properties	B-MED
of	O
the	O
original	O
,	O
four-	O
item	B-MED
,	O
and	O
six-	O
item	B-MED
short	B-MED
forms	I-MED
of	O
PCS	B-MED
.	O
Rasch	B-MED
analysis	I-MED
showed	O
that	O
both	O
short	B-MED
forms	I-MED
of	O
PCS	B-MED
had	O
acceptable	O
internal	O
consistency	B-MED
,	O
unidimensionality	B-MED
,	O
and	O
no	O
notable	O
DIF	O
and	O
were	O
functional	B-MED
on	O
the	O
category	B-MED
rating	I-MED
scale	I-MED
.	O
However	O
,	O
four-	O
item	B-MED
short	B-MED
form	I-MED
of	O
PCS	B-MED
had	O
two	O
misfit	O
items	B-MED
.	O
Six-	O
item	B-MED
short	B-MED
form	I-MED
of	O
PCS	B-MED
has	O
acceptable	O
psychometric	B-MED
properties	B-MED
and	O
is	O
suitable	O
for	O
use	O
in	O
participants	B-MED
with	O
musculoskeletal	B-MED
pain	I-MED
.	O
Thus	O
,	O
six-	O
item	B-MED
can	O
be	O
used	O
as	O
brief	O
instruments	B-MED
to	O
evaluate	B-MED
pain	B-MED
catastrophizing	I-MED
.	O
Using	O
language	B-MED
for	O
social	B-MED
interaction	I-MED
:	O
Communication	B-MED
mechanisms	O
promote	O
recovery	O
from	O
chronic	B-MED
non	B-MED
-	I-MED
fluent	I-MED
aphasia	I-MED
Clinical	B-MED
research	I-MED
highlights	O
the	O
importance	O
of	O
massed	B-MED
practice	I-MED
in	O
the	O
rehabilitation	B-MED
of	O
chronic	B-MED
post	B-MED
-	I-MED
stroke	I-MED
aphasia	B-MED
.	O
However	O
,	O
while	O
necessary	O
,	O
massed	B-MED
practice	I-MED
may	O
not	O
be	O
sufficient	O
for	O
ensuring	O
progress	B-MED
in	O
speech	B-MED
-	I-MED
language	I-MED
therapy	I-MED
.	O
Motivated	O
by	O
recent	O
advances	O
in	O
neuroscience	B-MED
,	O
it	O
has	O
been	O
claimed	O
that	O
using	O
language	B-MED
as	O
a	O
tool	O
for	O
communication	B-MED
and	O
social	B-MED
interaction	I-MED
leads	O
to	O
synergistic	B-MED
effects	I-MED
in	O
left	B-MED
perisylvian	I-MED
eloquent	I-MED
areas	I-MED
.	O
Here	O
,	O
we	O
conducted	O
a	O
crossover	O
randomized	O
controlled	O
trial	O
to	O
determine	O
the	O
influence	O
of	O
communicative	B-MED
language	B-MED
function	I-MED
on	O
the	O
outcome	B-MED
of	O
intensive	B-MED
aphasia	I-MED
therapy	I-MED
.	O
Eighteen	O
individuals	B-MED
with	O
left	B-MED
-	I-MED
hemisphere	I-MED
lesions	I-MED
and	O
chronic	B-MED
non	B-MED
-	I-MED
fluent	I-MED
aphasia	I-MED
each	O
received	O
two	O
types	O
of	O
training	B-MED
in	O
counterbalanced	B-MED
order	I-MED
:	O
(	O
i	O
)	O
Intensive	B-MED
Language	I-MED
-	I-MED
Action	I-MED
Therapy	I-MED
(	O
ILAT	B-MED
,	O
an	O
extended	O
form	O
of	O
Constraint	B-MED
-	I-MED
Induced	I-MED
Aphasia	I-MED
Therapy	I-MED
)	O
embedding	O
verbal	B-MED
utterances	I-MED
in	O
the	O
context	O
of	O
communication	B-MED
and	O
social	B-MED
interaction	I-MED
,	O
and	O
(	O
ii	O
)	O
Naming	B-MED
Therapy	I-MED
focusing	O
on	O
speech	B-MED
production	I-MED
per	I-MED
se	I-MED
.	O
Both	O
types	O
of	O
training	B-MED
were	O
delivered	O
with	O
the	O
same	O
high	O
intensity	O
(	O
3.5	O
h	O
per	O
session	O
)	O
and	O
duration	B-MED
(	O
six	O
consecutive	O
working	O
days	B-MED
)	O
,	O
with	O
therapy	B-MED
materials	B-MED
and	O
number	B-MED
of	I-MED
utterances	I-MED
matched	O
between	O
treatment	B-MED
groups	I-MED
.	O
A	O
standardized	O
aphasia	B-MED
test	B-MED
battery	I-MED
revealed	O
significantly	O
improved	O
language	B-MED
performance	B-MED
with	O
ILAT	B-MED
,	O
independent	O
of	O
when	O
this	O
method	B-MED
was	O
administered	O
.	O
In	O
contrast	O
,	O
Naming	B-MED
Therapy	I-MED
tended	O
to	O
benefit	O
language	B-MED
performance	O
only	O
when	O
given	O
at	O
the	O
onset	O
of	O
the	O
treatment	B-MED
,	O
but	O
not	O
when	O
applied	O
after	O
previous	O
intensive	O
training	B-MED
.	O
The	O
current	O
results	O
challenge	O
the	O
notion	O
that	O
massed	B-MED
practice	I-MED
alone	O
promotes	O
recovery	O
from	O
chronic	B-MED
post	B-MED
-	I-MED
stroke	I-MED
aphasia	B-MED
.	O
Instead	O
,	O
our	O
results	O
demonstrate	O
that	O
using	O
language	B-MED
for	O
communication	B-MED
and	O
social	B-MED
interaction	I-MED
increases	O
the	O
efficacy	O
of	O
intensive	B-MED
aphasia	I-MED
therapy	I-MED
.	O
A	O
neuronal	B-MED
PI(3,4,5)P3	B-MED
-dependent	O
program	B-MED
of	O
oligodendrocyte	B-MED
precursor	B-MED
recruitment	B-MED
and	O
myelination	B-MED
The	O
molecular	B-MED
trigger	I-MED
of	O
CNS	B-MED
myelination	B-MED
is	O
unknown	B-MED
.	O
By	O
targeting	B-MED
Pten	B-MED
in	O
cerebellar	B-MED
granule	I-MED
cells	I-MED
and	O
activating	B-MED
the	O
AKT1	B-MED
-	O
mTOR	B-MED
pathway	B-MED
,	O
we	O
increased	B-MED
the	O
caliber	O
of	O
normally	B-MED
unmyelinated	B-MED
axons	I-MED
and	O
the	O
expression	B-MED
of	O
numerous	B-MED
genes	B-MED
encoding	B-MED
regulatory	B-MED
proteins	I-MED
.	O
This	O
led	O
to	O
the	O
expansion	B-MED
of	O
genetically	B-MED
wild	I-MED
-	I-MED
type	I-MED
oligodendrocyte	B-MED
progenitor	B-MED
cells	I-MED
,	O
oligodendrocyte	B-MED
differentiation	B-MED
and	O
de	B-MED
novo	I-MED
myelination	B-MED
of	O
parallel	B-MED
fibers	I-MED
.	O
Thus	O
,	O
a	O
neuronal	B-MED
program	B-MED
dependent	O
on	O
the	O
phosphoinositide	B-MED
PI(3,4,5)P3	B-MED
is	O
sufficient	O
to	O
trigger	B-MED
all	O
steps	B-MED
of	O
myelination	B-MED
.	O
Increased	O
RhoA	B-MED
Activity	B-MED
Predicts	O
Worse	B-MED
Overall	B-MED
Survival	I-MED
in	O
Patients	B-MED
Undergoing	O
Surgical	B-MED
Resection	I-MED
for	O
Lauren	B-MED
Diffuse	B-MED
-	I-MED
Type	I-MED
Gastric	I-MED
Adenocarcinoma	I-MED
Several	O
studies	O
have	O
reported	O
a	O
high	O
rate	O
of	O
RHOA	B-MED
mutations	B-MED
in	O
the	O
Lauren	B-MED
diffuse	B-MED
-	I-MED
type	I-MED
gastric	I-MED
adenocarcinoma	I-MED
(	O
GA	B-MED
)	O
but	O
not	O
in	O
intestinal	B-MED
-	I-MED
type	I-MED
GA	I-MED
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
RhoA	B-MED
activity	B-MED
is	O
prognostic	B-MED
for	O
overall	B-MED
survival	I-MED
(	O
OS	B-MED
)	O
in	O
patients	B-MED
with	O
resectable	O
GA	B-MED
.	O
Retrospective	B-MED
review	I-MED
was	O
performed	O
on	O
a	O
prospective	O
database	O
of	O
GA	B-MED
patients	B-MED
who	O
underwent	O
potentially	O
curative	B-MED
resection	I-MED
between	O
2003	O
and	O
2012	O
at	O
a	O
single	B-MED
institution	I-MED
.	O
Tissue	B-MED
microarrays	B-MED
were	O
constructed	O
from	O
surgical	B-MED
specimens	I-MED
and	O
analyzed	O
for	O
phosphorylated	B-MED
RhoA	B-MED
,	O
a	O
marker	B-MED
of	O
inactive	O
RhoA	B-MED
signaling	B-MED
.	O
OS	B-MED
was	O
estimated	O
by	O
the	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
method	I-MED
,	O
and	O
multivariate	B-MED
analysis	I-MED
was	O
performed	O
by	O
Cox	B-MED
proportional	I-MED
hazards	I-MED
regression	I-MED
modeling	I-MED
.	O
One	O
hundred	O
thirty	O
-	O
six	O
patients	B-MED
with	O
diffuse	B-MED
-	I-MED
type	I-MED
GA	I-MED
and	O
129	O
patients	B-MED
with	O
intestinal	B-MED
-	I-MED
type	I-MED
GA	I-MED
were	O
examined	O
.	O
Compared	O
to	O
intestinal	B-MED
-	I-MED
type	I-MED
GA	I-MED
,	O
diffuse	B-MED
-	I-MED
type	I-MED
GA	I-MED
tumors	B-MED
were	O
significantly	O
associated	B-MED
with	I-MED
increased	O
tumor	B-MED
size	I-MED
and	O
advanced	B-MED
tumor	I-MED
,	I-MED
node	I-MED
,	I-MED
metastasis	I-MED
(	I-MED
TNM	I-MED
)	I-MED
classification	I-MED
system	I-MED
stage	I-MED
.	O
In	O
patients	B-MED
with	O
diffuse	B-MED
-	I-MED
type	I-MED
GA	I-MED
,	O
high	O
RhoA	B-MED
activity	B-MED
was	O
associated	B-MED
with	I-MED
significantly	O
worse	B-MED
OS	B-MED
when	O
compared	O
to	O
low	O
RhoA	B-MED
activity	B-MED
(	O
5	O
-	O
year	O
OS	B-MED
52.5	O
vs.	O
81.0	O
%	O
,	O
p	O
=	O
0.017	O
)	O
.	O
This	O
difference	O
in	O
OS	B-MED
was	O
not	O
observed	O
in	O
patients	B-MED
with	O
intestinal	B-MED
-	I-MED
type	I-MED
GA	I-MED
(	O
5	O
-	O
year	O
OS	B-MED
83.9	O
vs.	O
81.6	O
%	O
,	O
p	O
=	O
0.766	O
)	O
.	O
On	O
multivariate	B-MED
analysis	I-MED
of	O
diffuse	B-MED
-	I-MED
type	I-MED
GA	I-MED
patients	B-MED
,	O
high	O
RhoA	B-MED
activity	B-MED
was	O
an	O
independent	O
negative	O
prognostic	B-MED
factor	I-MED
for	O
OS	B-MED
(	O
hazard	B-MED
ratio	I-MED
2.38	O
,	O
95	O
%	O
confidence	B-MED
interval	I-MED
1.07	O
-	O
5.28	O
)	O
.	O
Increased	O
RhoA	B-MED
activity	B-MED
is	O
predictive	O
of	O
worse	B-MED
OS	B-MED
in	O
patients	B-MED
with	O
diffuse	B-MED
-	I-MED
type	I-MED
GA	I-MED
who	O
undergo	O
potentially	O
curative	B-MED
surgical	I-MED
resection	I-MED
.	O
Along	O
with	O
findings	O
from	O
genomic	B-MED
studies	I-MED
,	O
these	O
results	O
suggest	O
RhoA	B-MED
may	O
be	O
a	O
novel	O
therapeutic	B-MED
target	B-MED
in	O
diffuse	B-MED
-	I-MED
type	I-MED
GA	I-MED
.	O
Evaluation	B-MED
of	O
response	O
from	O
axitinib	B-MED
per	O
Response	B-MED
Evaluation	I-MED
Criteria	I-MED
in	I-MED
Solid	I-MED
Tumors	I-MED
versus	O
Choi	B-MED
criteria	I-MED
in	O
previously	O
treated	B-MED
patients	B-MED
with	O
metastatic	B-MED
renal	I-MED
cell	I-MED
carcinoma	I-MED
Axitinib	B-MED
,	O
a	O
selective	O
and	O
potent	O
tyrosine	B-MED
kinase	I-MED
inhibitor	I-MED
of	O
vascular	B-MED
endothelial	I-MED
growth	I-MED
factor	I-MED
receptors	I-MED
,	O
was	O
available	O
to	O
patients	B-MED
from	O
Canada	B-MED
and	O
Australia	B-MED
,	O
prior	O
to	O
regulatory	O
approval	B-MED
of	O
axitinib	B-MED
in	O
these	O
countries	B-MED
,	O
for	O
treatment	B-MED
of	O
clear	B-MED
-	I-MED
cell	I-MED
metastatic	I-MED
renal	I-MED
cell	I-MED
carcinoma	I-MED
(	O
mRCC	B-MED
)	O
after	O
failure	O
of	O
one	O
prior	O
systemic	O
regimen	B-MED
.	O
This	O
single	B-MED
-	I-MED
arm	I-MED
,	O
open	B-MED
-	I-MED
label	I-MED
study	I-MED
of	O
axitinib	B-MED
evaluated	O
the	O
efficacy	B-MED
,	O
safety	B-MED
,	O
and	O
quality	B-MED
of	I-MED
life	I-MED
(	O
QoL	B-MED
)	O
in	O
patients	B-MED
with	O
mRCC	B-MED
whose	O
disease	B-MED
progressed	B-MED
after	O
one	O
prior	O
systemic	O
first	B-MED
-	I-MED
line	I-MED
regimen	I-MED
.	O
Primary	O
objective	O
was	O
objective	O
response	B-MED
rate	I-MED
evaluated	B-MED
per	O
Response	B-MED
Evaluation	I-MED
Criteria	I-MED
in	I-MED
Solid	I-MED
Tumors	I-MED
(	O
RECIST	B-MED
)	O
and	O
Choi	B-MED
criteria	I-MED
.	O
Progression	B-MED
-	I-MED
free	I-MED
survival	I-MED
,	O
overall	B-MED
survival	I-MED
,	O
safety	B-MED
,	O
and	O
QoL	B-MED
were	O
secondary	O
end	O
points	O
.	O
Due	O
to	O
the	O
small	O
study	B-MED
size	O
,	O
analyses	O
comprised	O
of	O
descriptive	O
statistics	B-MED
.	O
Fifteen	O
patients	B-MED
were	O
recruited	O
,	O
five	O
from	O
Canada	B-MED
and	O
ten	O
from	O
Australia	B-MED
,	O
over	O
a	O
limited	O
recruitment	O
period	O
.	O
Thirteen	O
patients	B-MED
received	O
sunitinib	B-MED
as	O
prior	O
therapy	B-MED
.	O
All	O
patients	B-MED
had	O
clear	B-MED
-	I-MED
cell	I-MED
carcinoma	I-MED
,	O
eleven	O
had	O
prior	O
nephrectomy	B-MED
.	O
Liver	B-MED
,	O
lung	B-MED
,	O
and	O
lymph	B-MED
nodes	I-MED
were	O
the	O
most	O
frequent	O
sites	O
of	O
metastases	B-MED
;	O
one	O
patient	B-MED
had	O
brain	B-MED
metastasis	I-MED
.	O
Median	B-MED
time	O
on	O
axitinib	B-MED
was	O
118.0	O
days	B-MED
(	O
range	B-MED
:	O
3.5	O
-	O
645.0	O
days	B-MED
)	O
;	O
estimated	O
survival	B-MED
probability	O
at	O
12	O
months	B-MED
was	O
57.8	O
%	O
.	O
Two	O
(	O
13.3	O
%	O
)	O
patients	B-MED
had	O
objective	O
responses	B-MED
per	O
RECIST	B-MED
versus	O
nine	O
(	O
60.0	O
%	O
)	O
per	O
Choi	B-MED
criteria	I-MED
.	O
Six	O
patients	B-MED
had	O
progressive	B-MED
disease	B-MED
based	O
on	O
RECIST	B-MED
versus	O
three	O
per	O
Choi	B-MED
criteria	I-MED
.	O
Nine	O
(	O
60.0	O
%	O
)	O
events	O
of	O
progression	B-MED
or	O
death	B-MED
occurred	O
by	O
the	O
end	O
of	O
study	B-MED
,	O
and	O
three	O
patients	B-MED
continued	O
to	O
receive	O
the	O
study	B-MED
drug	B-MED
.	O
Fatigue	B-MED
(	O
33	O
%	O
)	O
and	O
diarrhea	B-MED
(	O
20	O
%	O
)	O
were	O
the	O
most	O
common	O
grade	O
≥3	O
all	O
-	O
causality	O
,	O
treatment	B-MED
-emergent	O
adverse	B-MED
events	I-MED
.	O
The	O
mean	B-MED
change	O
in	O
European	B-MED
Quality	B-MED
of	I-MED
Life	I-MED
-	O
5	O
Dimensions	O
score	B-MED
from	O
baseline	B-MED
to	O
end	O
of	O
treatment	B-MED
was	O
-0.0837	O
.	O
The	O
small	O
number	O
of	O
patients	B-MED
and	O
lack	O
of	O
a	O
comparator	O
arm	O
limit	O
the	O
ability	O
to	O
draw	O
definitive	B-MED
conclusions	B-MED
;	O
however	O
,	O
safety	B-MED
and	O
efficacy	B-MED
profiles	O
of	O
axitinib	B-MED
were	O
consistent	O
with	O
reports	O
from	O
previous	O
studies	B-MED
in	O
patients	B-MED
with	O
mRCC	B-MED
,	O
and	O
patients	B-MED
QoL	B-MED
generally	O
maintained	O
QoL.	O
The	O
sizeable	O
difference	O
observed	O
in	O
objective	O
response	B-MED
rate	I-MED
by	O
RECIST	B-MED
versus	O
Choi	B-MED
criteria	I-MED
merits	O
further	O
research	B-MED
.	O
Musculoskeletal	B-MED
pain	I-MED
profile	B-MED
of	O
obese	B-MED
individuals	B-MED
attending	B-MED
a	O
multidisciplinary	B-MED
weight	I-MED
management	I-MED
service	I-MED
Obesity	B-MED
is	O
associated	B-MED
with	I-MED
numerous	B-MED
chronic	B-MED
diseases	I-MED
,	O
including	B-MED
musculoskeletal	B-MED
(	I-MED
MSK	I-MED
)	I-MED
pain	I-MED
,	O
which	O
impacts	B-MED
on	O
quality	B-MED
of	I-MED
life	I-MED
(	O
QoL	B-MED
)	O
.	O
There	O
is	O
,	O
however	O
,	O
limited	O
research	O
providing	O
a	O
comprehensive	B-MED
MSK	B-MED
pain	I-MED
profile	B-MED
of	O
an	O
obese	B-MED
cohort	B-MED
.	O
This	O
retrospective	B-MED
study	I-MED
utilized	O
a	O
patient	B-MED
database	B-MED
at	O
a	O
national	B-MED
weight	I-MED
management	I-MED
service	I-MED
(	O
WMS	B-MED
)	O
.	O
Following	O
ethical	B-MED
approval	B-MED
,	O
anonymized	B-MED
patient	B-MED
data	I-MED
were	O
statistically	B-MED
analyzed	I-MED
to	O
develop	O
a	O
pain	B-MED
profile	B-MED
,	O
investigate	B-MED
relationships	B-MED
between	O
pain	B-MED
,	O
sleep	B-MED
,	O
and	O
function	B-MED
,	O
and	O
explore	O
variables	B-MED
associated	B-MED
with	I-MED
having	O
low	B-MED
back	I-MED
pain	I-MED
(	O
LBP	B-MED
)	O
and	O
knee	B-MED
pain	I-MED
.	O
Overall	O
,	O
915	O
individuals	B-MED
attended	O
the	O
WMS	B-MED
from	O
January	O
2011	O
to	O
September	O
2015	O
[	O
male	B-MED
,	O
35	O
%	O
(	O
n=318	O
;	O
CI	B-MED
=	O
32	O
-	O
38	O
)	O
;	O
female	B-MED
,	O
65	O
%	O
(	O
n=597	O
;	O
CI	B-MED
=	O
62	O
-	O
68	O
)	O
;	O
mean	B-MED
age	B-MED
44.6	O
]	O
.	O
Mean	B-MED
BMI	B-MED
was	O
50.7	O
kg	O
/	O
m2	O
[	O
Class	O
III	O
obese	B-MED
(	O
BMI	B-MED
≥40	O
kg	O
/	O
m2	O
)	O
,	O
92	O
%	O
(	O
n=835	O
;	O
CI	B-MED
=	O
91	O
-	O
94	O
)	O
]	O
.	O
Approximately	B-MED
91	O
%	O
reported	O
MSK	B-MED
pain	I-MED
:	O
LBP	B-MED
,	O
69	O
%	O
(	O
n=539	O
;	O
CI	B-MED
=	O
65-	O
72	O
)	O
[	O
mean	B-MED
NRS	O
7.4	O
]	O
;	O
knee	B-MED
pain	I-MED
,	O
58	O
%	O
(	O
n=447	O
;	O
CI	B-MED
=	O
55	O
-	O
61	O
)	O
[	O
mean	B-MED
NRS	O
6.8	O
]	O
.	O
Class	O
III	O
obese	B-MED
and	O
multi	B-MED
-	I-MED
site	I-MED
pain	B-MED
patients	B-MED
had	O
lower	B-MED
QoL	B-MED
and	O
physical	B-MED
activity	I-MED
levels	B-MED
,	O
reduced	B-MED
sleep	B-MED
,	O
and	O
poorer	B-MED
physical	B-MED
function	I-MED
than	O
less	B-MED
obese	B-MED
patients	B-MED
and	O
those	O
without	B-MED
pain	B-MED
(	O
p<0.05	O
)	O
.	O
Relationships	B-MED
were	O
found	O
between	O
demographic	B-MED
,	O
pain	B-MED
,	O
self	B-MED
-	I-MED
report	I-MED
,	O
psychological	B-MED
,	O
and	O
functional	B-MED
measures	B-MED
(	O
p<0.05	O
)	O
.	O
Patients	B-MED
who	O
slept	B-MED
fewer	I-MED
hours	I-MED
and	O
had	O
poorer	B-MED
functional	B-MED
outcomes	I-MED
were	O
more	O
likely	O
to	O
have	O
LBP	B-MED
;	O
patients	B-MED
who	O
were	O
divorced	B-MED
,	O
had	O
lower	B-MED
QoL	B-MED
,	O
and	O
more	O
frequent	B-MED
nocturia	B-MED
were	O
more	O
likely	O
to	O
have	O
knee	B-MED
pain	I-MED
(	O
p<0.05	O
)	O
.	O
Multi	B-MED
-	I-MED
site	I-MED
MSK	B-MED
pain	I-MED
is	O
prevalent	B-MED
and	O
severe	B-MED
in	O
obese	B-MED
patients	B-MED
and	O
is	O
negatively	B-MED
associated	B-MED
with	I-MED
most	O
self	O
-	O
report	O
and	O
functional	B-MED
outcomes	I-MED
.	O
This	O
high	O
prevalence	B-MED
suggests	O
pain	B-MED
management	I-MED
strategies	O
must	O
be	O
considered	O
when	O
treating	B-MED
obesity	B-MED
.	O
Chasing	O
ghosts	O
:	O
allopolyploid	O
origin	O
of	O
Oxyria	B-MED
sinensis	I-MED
(	O
Polygonaceae	B-MED
)	O
from	O
its	O
only	O
diploid	B-MED
congener	B-MED
and	O
an	O
unknown	O
ancestor	B-MED
Reconstructing	O
the	O
origin	B-MED
of	O
a	O
polyploid	B-MED
species	B-MED
is	O
particularly	O
challenging	O
when	O
an	O
ancestor	B-MED
has	O
become	O
extinct	B-MED
.	O
Under	O
such	O
circumstances	O
,	O
the	O
extinct	B-MED
donor	O
of	O
a	O
genome	B-MED
found	O
in	O
the	O
polyploid	B-MED
may	O
be	O
treated	O
as	O
a	O
'	O
ghost	O
'	O
species	B-MED
in	O
that	O
its	O
prior	O
existence	B-MED
is	O
recognized	O
through	O
the	O
presence	B-MED
of	O
its	O
genome	B-MED
in	O
the	O
polyploid	B-MED
.	O
In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
polyploid	B-MED
origin	B-MED
of	O
Oxyria	B-MED
sinensis	I-MED
(	O
2n	O
=	O
40	O
)	O
for	O
which	O
only	O
one	O
congeneric	B-MED
species	B-MED
is	O
known	O
,	O
that	O
is	O
diploid	B-MED
O.	B-MED
digyna	I-MED
(	O
2n	O
=	O
14	O
)	O
.	O
Genomic	B-MED
in	I-MED
situ	I-MED
hybridization	I-MED
(	O
GISH	B-MED
)	O
,	O
transcriptome	B-MED
,	O
phylogenetic	B-MED
and	O
demographic	B-MED
analyses	I-MED
,	O
and	O
ecological	B-MED
niche	I-MED
modelling	I-MED
were	O
conducted	O
for	O
this	O
purpose	O
.	O
GISH	B-MED
revealed	O
that	O
O.	B-MED
sinensis	I-MED
comprised	O
14	O
chromosomes	B-MED
from	O
O.	B-MED
digyna	I-MED
and	O
26	O
chromosomes	B-MED
from	O
an	O
unknown	O
ancestor	B-MED
.	O
Transcriptome	B-MED
analysis	I-MED
indicated	O
that	O
following	O
divergence	B-MED
from	O
O.	B-MED
digyna	I-MED
,	O
involving	O
genome	B-MED
duplication	I-MED
around	O
12	O
million	O
years	O
ago	O
(	O
Ma	O
)	O
,	O
a	O
second	O
genome	B-MED
duplication	I-MED
occurred	O
approximately	O
6	O
Ma	O
to	O
give	O
rise	O
to	O
O.	B-MED
sinensis	I-MED
.	O
Oxyria	B-MED
sinensis	I-MED
was	O
shown	O
to	O
contain	O
homologous	B-MED
gene	I-MED
sequences	I-MED
divergent	B-MED
from	O
those	O
present	O
in	O
O.	B-MED
digyna	I-MED
in	O
addition	O
to	O
a	O
set	O
that	O
clustered	B-MED
with	O
those	O
in	O
O.	B-MED
digyna	I-MED
.	O
Coalescent	B-MED
simulations	I-MED
indicated	O
that	O
O.	B-MED
sinensis	I-MED
expanded	O
its	O
distribution	B-MED
approximately	O
6	O
-	O
7	O
Ma	O
,	O
possibly	O
following	O
the	O
second	O
polyploidization	B-MED
event	I-MED
,	O
whereas	O
O.	B-MED
digyna	I-MED
expanded	O
its	O
range	O
much	O
later	O
.	O
It	O
was	O
also	O
indicated	O
that	O
the	O
distributions	B-MED
of	O
both	O
species	B-MED
contracted	B-MED
and	I-MED
re	I-MED
-	I-MED
expanded	I-MED
during	O
the	O
Pleistocene	B-MED
climatic	I-MED
oscillations	I-MED
.	O
Ecological	B-MED
niche	I-MED
modelling	I-MED
similarly	O
suggested	O
that	O
both	O
species	B-MED
experienced	O
changes	O
in	O
their	O
distributional	B-MED
ranges	O
in	O
response	O
to	O
Quaternary	B-MED
climatic	I-MED
changes	I-MED
.	O
The	O
extinction	B-MED
of	O
the	O
unknown	O
'	O
ghost	O
'	O
tetraploid	B-MED
species	B-MED
implicated	O
in	O
the	O
origin	B-MED
of	O
O.	B-MED
sinensis	I-MED
could	O
have	O
resulted	O
from	O
superior	O
adaptation	B-MED
of	O
O.	B-MED
sinensis	I-MED
to	O
repeated	B-MED
climatic	I-MED
changes	I-MED
in	O
the	O
region	O
where	O
it	O
now	O
occurs	O
.	O
Synthesis	B-MED
,	O
characterization	B-MED
and	O
drug	B-MED
loading	B-MED
property	B-MED
of	O
Monomethoxy	B-MED
-	I-MED
Poly(ethylene	I-MED
glycol)-Poly(ε	I-MED
-	I-MED
caprolactone)-Poly(D	I-MED
,	I-MED
L	I-MED
-	I-MED
lactide	I-MED
)	I-MED
(	I-MED
MPEG	I-MED
-	I-MED
PCLA	I-MED
)	I-MED
copolymers	I-MED
Amphiphilic	B-MED
block	I-MED
copolymers	I-MED
have	O
attracted	O
a	O
great	O
deal	O
of	O
attention	O
in	O
drug	B-MED
delivery	I-MED
systems	I-MED
.	O
In	O
this	O
work	O
,	O
a	O
series	O
of	O
monomethoxy	B-MED
-	I-MED
poly	I-MED
(	I-MED
ethylene	I-MED
glycol)-poly	I-MED
(	I-MED
ε	I-MED
-	I-MED
caprolactone	I-MED
-	I-MED
co	I-MED
-	I-MED
D	I-MED
,	I-MED
L	I-MED
-	I-MED
lactide	I-MED
)	I-MED
(	I-MED
MPEG	I-MED
-	I-MED
PCLA	I-MED
)	I-MED
copolymers	I-MED
with	O
variable	O
composition	B-MED
of	O
poly	B-MED
(	I-MED
ε	I-MED
-	I-MED
caprolactone	I-MED
)	I-MED
(	O
PCL	B-MED
)	O
and	O
poly	B-MED
(	I-MED
D	I-MED
,	I-MED
L	I-MED
-	I-MED
lactide	I-MED
)	I-MED
(	O
PDLLA	B-MED
)	O
were	O
prepared	O
via	O
ring	B-MED
-	I-MED
opening	I-MED
copolymerization	I-MED
of	O
ε	B-MED
-	I-MED
CL	I-MED
and	O
D	B-MED
,	I-MED
L	I-MED
-	I-MED
LA	I-MED
in	O
the	O
presence	O
of	O
MPEG	B-MED
and	O
stannous	B-MED
octoate	I-MED
.	O
The	O
structure	B-MED
and	O
molecular	B-MED
weight	I-MED
were	O
characterized	B-MED
by	O
nuclear	B-MED
magnetic	I-MED
resonance	I-MED
(	O
NMR	B-MED
)	O
and	O
gel	B-MED
permeation	I-MED
chromatography	I-MED
(	O
GPC	B-MED
)	O
.	O
The	O
crystallinity	B-MED
,	O
hydrophilicity	B-MED
,	O
thermal	B-MED
stability	B-MED
and	O
hydrolytic	B-MED
degradation	B-MED
behavior	I-MED
were	O
investigated	O
in	O
detail	O
,	O
respectively	O
.	O
The	O
results	O
showed	O
that	O
the	O
prepared	O
amphiphilic	B-MED
MPEG	I-MED
-	I-MED
PCLA	I-MED
copolymers	I-MED
have	O
adjustable	O
properties	B-MED
by	O
altering	O
the	O
composition	B-MED
of	O
PCLA	B-MED
,	O
which	O
make	O
it	O
convenient	O
for	O
clinical	B-MED
applications	I-MED
.	O
Besides	O
,	O
the	O
drug	B-MED
loading	B-MED
properties	B-MED
were	O
also	O
studied	O
.	O
Docetaxel	B-MED
(	O
DTX	B-MED
)	O
could	O
be	O
entrapped	O
in	O
MPEG	B-MED
-	I-MED
PCLA	I-MED
micelles	B-MED
with	O
high	B-MED
loading	B-MED
capacity	B-MED
and	O
encapsulation	B-MED
efficiency	B-MED
.	O
And	O
all	O
lyophilized	B-MED
DTX	B-MED
-loaded	O
MPEG	B-MED
-	I-MED
PCLA	I-MED
micelles	B-MED
except	O
MPEG	B-MED
-	I-MED
PCL	I-MED
micelles	B-MED
were	O
readily	O
re	B-MED
-	I-MED
dissolved	I-MED
in	O
normal	B-MED
saline	I-MED
at	O
25	O
°	O
C	O
.	O
In	O
addition	O
,	O
DTX	B-MED
-loaded	O
MPEG	B-MED
-	I-MED
PCLA	I-MED
micelles	B-MED
showed	O
a	O
slightly	O
enhanced	B-MED
antitumor	B-MED
activity	B-MED
compared	O
with	O
free	O
DTX	B-MED
.	O
Furthermore	O
,	O
DTX	B-MED
micelles	B-MED
exhibited	O
a	O
slower	B-MED
and	O
sustained	B-MED
release	B-MED
behavior	B-MED
in	B-MED
vitro	I-MED
,	O
and	O
higher	B-MED
DTX	B-MED
concentration	B-MED
and	O
longer	O
retention	B-MED
time	I-MED
in	B-MED
vivo	I-MED
.	O
The	O
results	O
suggested	O
that	O
the	O
MPEG	B-MED
-	I-MED
PCLA	I-MED
copolymer	I-MED
with	O
the	O
adjustable	O
ratio	B-MED
of	O
PCL	B-MED
to	O
PDLLA	B-MED
may	O
be	O
a	O
promising	O
drug	B-MED
delivery	I-MED
carrier	I-MED
for	O
DTX	B-MED
.	O
Multiparametric	B-MED
estimation	I-MED
of	O
brain	B-MED
hemodynamics	I-MED
with	O
MR	B-MED
fingerprinting	I-MED
ASL	I-MED
Assessment	B-MED
of	O
brain	B-MED
hemodynamics	I-MED
without	O
exogenous	B-MED
contrast	B-MED
agents	I-MED
is	O
of	O
increasing	B-MED
importance	B-MED
in	O
clinical	B-MED
applications	I-MED
.	O
This	O
study	O
aims	O
to	O
develop	O
an	O
MR	B-MED
perfusion	I-MED
technique	I-MED
that	O
can	O
provide	O
noncontrast	B-MED
and	O
multiparametric	B-MED
estimation	I-MED
of	O
hemodynamic	B-MED
markers	B-MED
.	O
We	O
devised	O
an	O
arterial	B-MED
spin	I-MED
labeling	I-MED
(	O
ASL	B-MED
)	O
method	O
based	O
on	O
the	O
principle	O
of	O
MR	B-MED
fingerprinting	I-MED
(	O
MRF	B-MED
)	O
,	O
referred	B-MED
to	O
as	O
MRF	B-MED
-	I-MED
ASL	I-MED
.	O
By	O
taking	O
advantage	O
of	O
the	O
rich	O
information	B-MED
contained	O
in	O
MRF	B-MED
sequence	I-MED
,	O
up	O
to	O
seven	O
hemodynamic	B-MED
parameters	B-MED
can	O
be	O
estimated	B-MED
concomitantly	B-MED
.	O
Feasibility	B-MED
demonstration	I-MED
,	O
flip	B-MED
angle	I-MED
optimization	B-MED
,	O
comparison	B-MED
with	O
Look	B-MED
-	I-MED
Locker	I-MED
ASL	I-MED
,	O
reproducibility	B-MED
test	I-MED
,	O
sensitivity	B-MED
to	O
hypercapnia	B-MED
challenge	I-MED
,	O
and	O
initial	O
clinical	B-MED
application	I-MED
in	O
an	O
intracranial	B-MED
steno	I-MED
-	I-MED
occlusive	I-MED
process	I-MED
,	O
Moyamoya	B-MED
disease	I-MED
,	O
were	O
performed	B-MED
to	O
evaluate	O
this	O
technique	B-MED
.	O
Magnetic	B-MED
resonance	I-MED
fingerprinting	I-MED
ASL	I-MED
provided	B-MED
estimation	O
of	O
up	O
to	O
seven	O
parameters	B-MED
,	O
including	O
B1	B-MED
+	I-MED
,	O
tissue	B-MED
T1	B-MED
,	O
cerebral	B-MED
blood	I-MED
flow	I-MED
(	O
CBF	B-MED
)	O
,	O
tissue	B-MED
bolus	B-MED
arrival	I-MED
time	I-MED
(	O
BAT	B-MED
)	O
,	O
pass	O
-	O
through	O
arterial	B-MED
BAT	B-MED
,	O
pass	O
-	O
through	O
blood	B-MED
volume	I-MED
,	O
and	O
pass	O
-	O
through	O
blood	B-MED
travel	I-MED
time	I-MED
.	O
Coefficients	B-MED
of	O
variation	B-MED
of	O
the	O
estimated	B-MED
parameters	B-MED
ranged	O
from	O
0.2	O
to	O
9.6	O
%	O
.	O
Hypercapnia	B-MED
resulted	O
in	O
an	O
increase	B-MED
in	O
CBF	B-MED
by	O
57.7	O
%	O
,	O
and	O
a	O
decrease	B-MED
in	O
BAT	B-MED
by	O
13.7	O
and	O
24.8	O
%	O
in	O
tissue	B-MED
and	O
vessels	B-MED
,	O
respectively	O
.	O
Patients	B-MED
with	O
Moyamoya	B-MED
disease	I-MED
showed	O
diminished	B-MED
CBF	B-MED
and	O
lengthened	B-MED
BAT	B-MED
that	O
could	B-MED
not	I-MED
be	I-MED
detected	I-MED
with	O
regular	B-MED
ASL	B-MED
.	O
Magnetic	B-MED
resonance	I-MED
fingerprinting	I-MED
ASL	I-MED
is	O
a	O
promising	O
technique	B-MED
for	O
noncontrast	B-MED
,	O
multiparametric	B-MED
perfusion	B-MED
assessment	I-MED
.	O
Magn	O
Reson	O
Med	O
,	O
2016	O
.	O
©	O
2016	O
International	B-MED
Society	I-MED
for	I-MED
Magnetic	I-MED
Resonance	I-MED
in	I-MED
Medicine	I-MED
.	O
Uridine	B-MED
stimulate	O
laxative	B-MED
effect	B-MED
in	O
the	O
loperamide	B-MED
-	O
induced	B-MED
constipation	B-MED
of	O
SD	B-MED
rats	I-MED
through	O
regulation	B-MED
of	O
the	O
mAChRs	B-MED
signaling	B-MED
pathway	I-MED
and	O
mucin	B-MED
secretion	B-MED
Uridine	B-MED
(	O
Urd	B-MED
)	O
,	O
which	O
has	O
been	O
reported	B-MED
as	O
a	O
major	B-MED
component	O
of	O
RNA	B-MED
,	O
plays	O
an	O
important	B-MED
role	B-MED
in	O
various	O
biological	B-MED
process	I-MED
including	O
neuroprotection	B-MED
,	O
biochemical	B-MED
modulation	I-MED
and	O
glycolysis	B-MED
,	O
although	O
its	O
role	B-MED
in	O
constipation	B-MED
has	O
yet	O
to	O
be	O
established	B-MED
.	O
Therefore	O
,	O
in	O
this	O
study	B-MED
,	O
we	O
investigated	B-MED
the	O
laxative	B-MED
effects	B-MED
of	O
Urd	B-MED
on	O
chronic	B-MED
constipation	B-MED
.	O
The	O
constipation	B-MED
phenotypes	B-MED
and	O
their	O
related	O
mechanisms	B-MED
were	O
investigated	B-MED
in	O
the	O
transverse	B-MED
colons	I-MED
of	O
SD	B-MED
rats	I-MED
with	O
loperamide	B-MED
Lop	B-MED
(	O
Lop)-	O
induced	B-MED
constipation	B-MED
after	O
treatment	B-MED
with	O
100	O
mg	O
/	O
kg	O
of	O
Urd	B-MED
.	O
The	O
number	B-MED
,	O
weight	B-MED
and	O
water	B-MED
contents	B-MED
of	O
stools	B-MED
were	O
significantly	B-MED
higher	B-MED
in	O
the	O
Lop	B-MED
+	O
Urd	B-MED
treated	B-MED
group	B-MED
than	O
the	O
Lop	B-MED
+	O
Vehicle	B-MED
treated	B-MED
group	B-MED
,	O
while	O
food	B-MED
intake	I-MED
and	O
water	B-MED
consumption	I-MED
of	O
the	O
same	O
group	B-MED
were	O
maintained	O
at	O
a	O
constant	B-MED
level	B-MED
.	O
The	O
thickness	B-MED
of	O
the	O
mucosa	B-MED
layer	I-MED
,	O
muscle	B-MED
and	O
flat	B-MED
luminal	I-MED
surface	I-MED
,	O
as	O
well	O
as	O
the	O
number	B-MED
of	O
goblet	B-MED
cells	I-MED
,	O
paneth	B-MED
cells	I-MED
and	O
lipid	B-MED
droplets	I-MED
were	O
enhanced	B-MED
in	O
the	O
Lop	B-MED
+	O
Urd	B-MED
treated	B-MED
group	B-MED
.	O
Furthermore	O
,	O
the	O
expression	B-MED
of	O
the	O
muscarinic	B-MED
acetylcholine	I-MED
receptors	I-MED
M2	I-MED
and	O
M3	B-MED
(	O
mAChR	B-MED
M2	I-MED
and	O
M3	B-MED
)	O
at	O
the	O
transcriptional	B-MED
and	O
translational	B-MED
level	B-MED
was	O
recovered	B-MED
in	O
the	O
Lop	B-MED
+	O
Urd	B-MED
treated	B-MED
group	B-MED
,	O
while	O
some	O
markers	B-MED
such	O
as	O
Gα	B-MED
and	O
inositol	B-MED
triphosphate	I-MED
(	O
IP3	B-MED
)	O
in	O
their	O
downstream	B-MED
signaling	B-MED
pathway	I-MED
were	O
completely	O
recovered	B-MED
by	O
Urd	B-MED
treatment	B-MED
.	O
Moreover	O
,	O
the	O
ability	O
for	O
mucin	B-MED
secretion	B-MED
and	O
the	O
expression	B-MED
of	O
membrane	B-MED
water	I-MED
channel	I-MED
(	O
aquaporine	B-MED
8	I-MED
,	O
AQP8	B-MED
)	O
were	O
increased	B-MED
significantly	B-MED
in	O
the	O
Lop	B-MED
+	O
Urd	B-MED
treated	B-MED
group	B-MED
compared	B-MED
with	O
Lop	B-MED
+	O
Vehicle	B-MED
treated	B-MED
group	B-MED
.	O
Finally	O
,	O
the	O
activity	B-MED
of	O
Urd	B-MED
was	O
confirmed	O
in	O
primary	B-MED
smooth	I-MED
muscle	I-MED
of	O
rat	B-MED
intestine	B-MED
cells	I-MED
(	O
pRISMC	B-MED
)	O
based	O
on	O
Gα	B-MED
expression	B-MED
and	O
IP3	B-MED
concentration	B-MED
.	O
The	O
results	B-MED
of	O
the	O
present	O
study	B-MED
provide	O
the	O
first	O
strong	B-MED
evidence	B-MED
that	O
Urd	B-MED
can	O
be	O
considered	O
an	O
important	B-MED
candidate	O
for	O
improving	B-MED
chronic	B-MED
constipation	B-MED
induced	B-MED
by	O
Lop	B-MED
treatment	B-MED
in	O
animal	B-MED
models	I-MED
.	O
Intravitreal	B-MED
chemotherapy	B-MED
in	O
the	O
management	B-MED
of	O
vitreous	B-MED
disease	I-MED
in	O
retinoblastoma	B-MED
To	O
evaluate	O
the	O
therapeutic	B-MED
outcome	I-MED
of	O
intravitreal	B-MED
melphalan	B-MED
injection	B-MED
in	O
the	O
management	B-MED
of	O
vitreous	B-MED
disease	I-MED
in	O
patients	B-MED
with	O
retinoblastoma	B-MED
.	O
We	O
particularly	O
aimed	O
to	O
assess	O
whether	O
higher	B-MED
melphalan	B-MED
dose	B-MED
with	O
lower	B-MED
number	B-MED
of	O
injections	B-MED
was	O
more	O
effective	B-MED
and	O
associated	B-MED
with	I-MED
fewer	B-MED
side	B-MED
effects	I-MED
.	O
This	O
retrospective	B-MED
,	O
interventional	B-MED
,	O
noncomparative	B-MED
,	O
and	O
nonrandomized	B-MED
study	I-MED
included	O
39	O
eyes	B-MED
of	O
37	O
patients	B-MED
.	O
Vitreous	B-MED
seeds	I-MED
were	O
classified	B-MED
as	O
dust	B-MED
,	O
sphere	B-MED
,	O
and	O
cloud	B-MED
types	I-MED
.	O
Intravitreal	B-MED
injections	B-MED
were	O
performed	B-MED
through	B-MED
pars	B-MED
plana	I-MED
free	O
of	O
any	O
visible	B-MED
tumor	B-MED
using	B-MED
30	B-MED
-	I-MED
G	I-MED
needle	I-MED
.	O
Response	B-MED
of	I-MED
the	I-MED
seeds	I-MED
(	O
disappearance	B-MED
,	O
conversion	B-MED
into	O
inactive	B-MED
debris	I-MED
,	O
or	O
progression	B-MED
)	O
and	O
enucleation	B-MED
rate	B-MED
were	O
determined	O
as	O
outcome	B-MED
measures	B-MED
.	O
All	O
patients	B-MED
previously	O
received	B-MED
systemic	B-MED
or	O
intra	B-MED
-	I-MED
arterial	I-MED
chemotherapy	I-MED
.	O
Vitreous	B-MED
seeding	I-MED
was	O
primary	B-MED
in	O
54	O
%	O
of	O
eyes	B-MED
and	O
secondary	B-MED
in	O
46	O
%	O
of	O
eyes	B-MED
.	O
Vitreous	B-MED
seeds	I-MED
were	O
classified	B-MED
as	O
dust	B-MED
in	O
9	O
(	O
23.1	O
%	O
)	O
eyes	B-MED
,	O
sphere	B-MED
in	O
24	O
(	O
61.5	O
%	O
)	O
eyes	B-MED
,	O
and	O
cloud	B-MED
in	O
6	O
(	O
15.4	O
%	O
)	O
eyes	B-MED
.	O
Melphalan	B-MED
dose	B-MED
varied	O
between	O
20	O
and	O
40	O
µg	O
and	O
20	O
(	O
51.3	O
%	O
)	O
eyes	B-MED
received	B-MED
>	O
30	O
µg	O
.	O
The	O
total	B-MED
number	I-MED
of	O
injections	B-MED
was	O
70	O
(	O
range	O
1	O
-	O
5	O
,	O
mean	B-MED
1.8	O
per	O
eye	B-MED
)	O
.	O
Various	B-MED
types	B-MED
of	O
regression	B-MED
were	O
obtained	B-MED
in	O
27	O
(	O
69.2	O
%	O
)	O
eyes	B-MED
.	O
Sphere	B-MED
-	I-MED
type	I-MED
seeds	I-MED
were	O
the	O
most	B-MED
responsive	B-MED
to	O
melphalan	B-MED
.	O
Nonresponse	B-MED
and	O
disease	B-MED
progression	I-MED
were	O
noted	B-MED
in	O
12	O
(	O
30.8	O
%	O
)	O
eyes	B-MED
.	O
After	O
a	O
mean	B-MED
follow	B-MED
-	I-MED
up	I-MED
of	O
11.8	O
months	B-MED
,	O
17	O
(	O
44	O
%	O
)	O
eyes	B-MED
were	O
enucleated	B-MED
.	O
Vitreous	B-MED
hemorrhage	I-MED
(	O
18	O
%	O
)	O
and	O
retinal	B-MED
pigment	I-MED
epithelial	I-MED
alterations	B-MED
(	O
8	O
%	O
)	O
were	O
the	O
most	B-MED
common	B-MED
side	B-MED
effects	I-MED
.	O
Intravitreal	B-MED
melphalan	B-MED
at	O
30	O
-	O
40	O
µg	O
in	O
1	O
or	O
2	O
injections	B-MED
proved	O
effective	B-MED
in	O
69.2	O
%	O
of	O
eyes	B-MED
with	O
vitreous	B-MED
disease	I-MED
.	O
Development	B-MED
and	O
initial	B-MED
validation	B-MED
of	O
the	O
Respirator	B-MED
Comfort	B-MED
,	O
Wearing	B-MED
Experience	I-MED
,	O
and	O
Function	B-MED
Instrument	B-MED
[	O
R	B-MED
-	I-MED
COMFI	I-MED
Filtering	B-MED
face	I-MED
-	I-MED
piece	I-MED
respirators	I-MED
(	O
FFRs	B-MED
)	O
are	O
worn	O
to	O
protect	B-MED
health	B-MED
care	I-MED
personnel	I-MED
from	O
airborne	B-MED
particles	I-MED
;	O
however	O
,	O
clinical	B-MED
studies	I-MED
have	O
demonstrated	O
that	O
FFR	B-MED
adherence	B-MED
is	O
relatively	O
low	B-MED
in	O
some	O
settings	O
,	O
in	O
part	B-MED
,	O
due	O
to	O
discomfort	B-MED
and	O
intolerance	B-MED
.	O
The	O
objective	B-MED
of	O
this	O
study	B-MED
was	O
to	O
develop	O
and	O
initially	B-MED
evaluate	B-MED
the	O
psychometric	B-MED
properties	I-MED
of	O
an	O
instrument	B-MED
designed	B-MED
to	O
measure	B-MED
the	O
comfort	B-MED
and	O
tolerability	B-MED
of	O
FFRs	B-MED
.	O
Instrument	B-MED
items	O
were	O
developed	O
through	O
literature	B-MED
reviews	I-MED
,	O
focus	B-MED
groups	I-MED
,	O
and	O
several	B-MED
iterations	B-MED
of	O
ranking	B-MED
and	O
refining	O
by	O
experts	B-MED
.	O
Psychometric	B-MED
evaluation	I-MED
of	O
the	O
instrument	B-MED
was	O
conducted	O
using	O
Rasch	B-MED
partial	I-MED
credit	I-MED
model	I-MED
(	O
PCM	B-MED
)	O
analysis	B-MED
.	O
Pivot	B-MED
anchoring	I-MED
was	O
used	O
to	O
specify	O
the	O
threshold	B-MED
defining	O
item	O
difficulty	B-MED
;	O
in	O
our	O
analyses	B-MED
,	O
this	O
was	O
the	O
point	B-MED
that	O
participants	B-MED
moved	O
from	O
possessing	B-MED
none	O
of	O
the	O
trait	B-MED
to	O
some	O
of	O
the	O
trait	B-MED
.	O
The	O
final	B-MED
instrument	B-MED
was	O
completed	B-MED
by	O
165	O
health	B-MED
care	I-MED
personnel	I-MED
from	O
3	O
Veterans	B-MED
Health	B-MED
Administration	I-MED
facilities	I-MED
,	O
and	O
data	B-MED
were	O
analyzed	B-MED
using	O
Rasch	B-MED
PCM	I-MED
.	O
Seven	O
items	O
were	O
removed	B-MED
because	O
they	O
:	O
(	O
1	O
)	O
violated	B-MED
the	I-MED
assumption	I-MED
of	I-MED
independence	I-MED
;	O
(	O
2	O
)	O
were	O
mis	B-MED
-	I-MED
fitting	I-MED
;	O
and/or	O
(	O
3	O
)	O
were	O
deemed	O
not	B-MED
relevant	I-MED
.	O
Category	B-MED
function	B-MED
analysis	B-MED
demonstrated	O
that	O
all	O
categories	B-MED
progressed	B-MED
monotonically	B-MED
.	O
Principal	B-MED
components	I-MED
analysis	I-MED
demonstrated	O
the	O
existence	B-MED
of	O
three	O
subscales	B-MED
(	O
Discomfort	B-MED
,	O
General	O
Wearing	B-MED
Experience	I-MED
,	O
and	O
Function	B-MED
)	O
.	O
Final	B-MED
reliability	B-MED
analyses	B-MED
showed	O
that	O
the	O
scale	B-MED
had	O
moderate	B-MED
to	O
high	B-MED
person	I-MED
reliability	I-MED
and	O
high	O
item	O
reliability	B-MED
.	O
The	O
final	O
instrument	B-MED
contained	B-MED
21	O
items	O
.	O
Until	O
now	O
,	O
to	O
our	O
knowledge	B-MED
no	O
instrument	B-MED
with	O
evidence	B-MED
supporting	O
its	O
reliability	B-MED
and	I-MED
validity	I-MED
to	O
assess	B-MED
discomfort	B-MED
and	O
tolerance	B-MED
of	O
FFRs	B-MED
among	O
health	B-MED
care	I-MED
personnel	I-MED
has	O
been	O
published	B-MED
.	O
A	O
21	O
-	O
item	O
psychometrically	B-MED
sound	I-MED
measure	I-MED
of	O
comfort	B-MED
and	O
tolerability	B-MED
of	O
FFRs	B-MED
,	O
Respirator	B-MED
Comfort	B-MED
,	O
Wearing	B-MED
Experience	I-MED
,	O
and	O
Function	B-MED
Instrument	B-MED
(	O
R	B-MED
-	I-MED
COMFI	I-MED
)	O
,	O
was	O
developed	O
.	O
The	O
significance	B-MED
of	O
developing	O
such	O
an	O
instrument	B-MED
is	O
that	O
it	O
will	O
help	O
identify	O
respirators	B-MED
that	O
are	O
likely	O
to	O
have	O
better	O
adherence	B-MED
in	O
practice	B-MED
settings	O
.	O
The	O
R	B-MED
-	I-MED
COMFI	I-MED
may	O
be	O
used	O
within	B-MED
and	O
beyond	O
the	O
VA	B-MED
healthcare	I-MED
system	I-MED
as	O
a	O
psychometrically	B-MED
sound	I-MED
instrument	I-MED
to	O
evaluate	B-MED
the	O
comfort	B-MED
and	O
tolerability	B-MED
of	O
respirators	B-MED
,	O
including	O
developmental	B-MED
prototypes	O
.	O
Radiosensitization	B-MED
of	O
non	B-MED
-	I-MED
small	I-MED
-	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
cells	B-MED
and	O
xenografts	B-MED
by	O
the	O
interactive	B-MED
effects	I-MED
of	O
pemetrexed	B-MED
and	O
methoxyamine	B-MED
The	O
anti	B-MED
-	I-MED
folate	I-MED
pemetrexed	B-MED
is	O
a	O
radiosensitizer	B-MED
.	O
In	O
pre	B-MED
-	I-MED
clinical	I-MED
models	I-MED
,	O
pemetrexed	B-MED
is	O
more	O
effective	B-MED
along	O
with	O
the	O
base	B-MED
-	I-MED
excision	I-MED
-	I-MED
repair	I-MED
inhibitor	B-MED
methoxyamine	B-MED
.	O
We	O
tested	B-MED
whether	O
methoxyamine	B-MED
enhances	B-MED
pemetrexed	B-MED
-mediated	O
radiosensitization	B-MED
of	O
lung	B-MED
adenocarcinoma	I-MED
cells	O
and	O
xenografts	B-MED
.	O
A549	B-MED
and	O
H1299	B-MED
cells	I-MED
were	O
evaluated	O
for	O
cell	B-MED
cycle	I-MED
distribution	B-MED
by	O
flow	B-MED
cytometry	I-MED
,	O
radiosensitization	B-MED
by	O
clonogenic	B-MED
assay	I-MED
,	O
and	O
DNA	B-MED
repair	I-MED
by	O
neutral	B-MED
comet	I-MED
assay	I-MED
and	O
repair	B-MED
protein	I-MED
activation	B-MED
.	O
H460	B-MED
cells	I-MED
were	O
included	O
in	O
some	O
studies	O
.	O
Xenografts	B-MED
in	O
nude	B-MED
mice	I-MED
received	B-MED
drug	I-MED
(	O
s	O
)	O
and/or	O
radiation	B-MED
,	O
and	O
tumor	B-MED
growth	I-MED
was	O
monitored	O
by	O
caliper	B-MED
and	O
in	B-MED
vivo	I-MED
toxicity	B-MED
by	O
animal	B-MED
weight	I-MED
.	O
Exposure	B-MED
to	I-MED
pemetrexed	B-MED
/	O
methoxyamine	B-MED
for	O
24	O
(	O
H1299	B-MED
,	O
H460	B-MED
A549	B-MED
)	O
or	O
48	O
(	O
A549)hours	O
before	O
irradiation	B-MED
resulted	O
in	O
accumulation	B-MED
of	O
cells	B-MED
near	O
the	O
radiosensitive	B-MED
G1	I-MED
/	I-MED
S	I-MED
border	I-MED
;	O
dose	B-MED
-	O
enhancement	B-MED
factors	B-MED
of	O
1.62±0.19	O
,	O
1.97±0.25	O
,	O
and	O
1.67±0.30	O
,	O
respectively	O
;	O
reduction	O
of	O
mean	O
inactivation	B-MED
dose	B-MED
by	O
32	O
%	O
,	O
30	O
%	O
,	O
and	O
46	O
%	O
,	O
respectively	O
;	O
and	O
significant	O
reductions	O
of	O
SF2	O
and	O
SF4	O
(	O
p<0.05	O
)	O
.	O
Radiosensitization	B-MED
was	O
associated	O
with	O
rapid	O
DNA	B-MED
double	I-MED
-	I-MED
strand	I-MED
-	I-MED
break	I-MED
rejoining	I-MED
and	O
increased	O
levels	O
of	O
DNA	B-MED
-	I-MED
PKcs	I-MED
.	O
Both	O
tumor	B-MED
-	I-MED
growth	I-MED
rate	B-MED
and	O
tumor	B-MED
-	I-MED
growth	I-MED
delay	B-MED
were	O
significantly	O
improved	O
by	O
adding	O
methoxyamine	B-MED
to	O
pemetrexed	B-MED
pre	B-MED
-	I-MED
irradiation	I-MED
(	O
p<0.0001	O
)	O
;	O
no	O
mice	B-MED
lost	O
weight	O
during	O
treatment	B-MED
.	O
Addition	O
of	O
methoxyamine	B-MED
to	O
pemetrexed	B-MED
and	O
fractionated	O
radiotherapy	O
may	O
improve	O
outcome	O
for	O
patients	B-MED
with	O
locally	O
advanced	O
non	B-MED
-	I-MED
squamous	I-MED
non	I-MED
-	I-MED
small	I-MED
-	I-MED
cell	I-MED
lung	I-MED
cancer	I-MED
.	O
Isolation	B-MED
of	I-MED
Cells	I-MED
Specialized	B-MED
in	O
Anticancer	B-MED
Alkaloid	B-MED
Metabolism	I-MED
by	O
Fluorescence	B-MED
-	I-MED
Activated	I-MED
Cell	I-MED
Sorting	I-MED
Plant	B-MED
specialized	B-MED
metabolism	B-MED
often	O
presents	O
a	O
complex	B-MED
cell	B-MED
-	O
specific	B-MED
compartmentation	B-MED
essential	O
to	O
accomplish	O
the	O
biosynthesis	B-MED
of	O
valuable	O
plant	B-MED
natural	B-MED
products	I-MED
.	O
Hence	O
,	O
the	O
disclosure	O
and	O
potential	O
manipulation	B-MED
of	O
such	O
pathways	B-MED
may	O
depend	O
on	O
the	O
capacity	O
to	O
isolate	B-MED
and	O
characterize	B-MED
specific	B-MED
cell	B-MED
types	I-MED
.	O
Catharanthus	B-MED
roseus	I-MED
is	O
the	O
source	O
of	O
several	O
medicinal	B-MED
terpenoid	B-MED
indole	I-MED
alkaloids	I-MED
,	O
including	O
the	O
low	O
-	O
level	O
anticancer	B-MED
vinblastine	B-MED
and	O
vincristine	B-MED
,	O
for	O
which	O
the	O
late	O
biosynthetic	B-MED
steps	I-MED
occur	O
in	O
specialized	B-MED
mesophyll	B-MED
cells	I-MED
called	O
idioblasts	B-MED
.	O
Here	O
,	O
the	O
optical	B-MED
,	O
fluorescence	B-MED
,	O
and	O
alkaloid	B-MED
-	O
accumulating	B-MED
properties	O
of	O
C.	B-MED
roseus	I-MED
leaf	B-MED
idioblasts	B-MED
are	O
characterized	B-MED
,	O
and	O
a	O
methodology	B-MED
for	O
the	O
isolation	B-MED
of	O
idioblast	B-MED
protoplasts	B-MED
by	O
fluorescence	B-MED
-	I-MED
activated	I-MED
cell	I-MED
sorting	I-MED
is	O
established	O
,	O
taking	O
advantage	O
of	O
the	O
distinctive	O
autofluorescence	B-MED
of	O
these	O
cells	B-MED
.	O
This	O
achievement	O
represents	O
a	O
crucial	O
step	O
for	O
the	O
development	O
of	O
differential	O
omic	B-MED
strategies	I-MED
leading	O
to	O
the	O
identification	B-MED
of	O
candidate	B-MED
genes	I-MED
putatively	O
involved	O
in	O
the	O
biosynthesis	B-MED
,	O
pathway	B-MED
regulation	B-MED
,	O
and	O
transmembrane	B-MED
transport	I-MED
leading	O
to	O
the	O
anticancer	B-MED
alkaloids	B-MED
from	O
C.	B-MED
roseus	I-MED
.	O
Transforming	B-MED
Growth	I-MED
Factor	I-MED
Beta	I-MED
1	I-MED
(	O
TGF	B-MED
-	I-MED
β1	I-MED
)	O
in	O
Thyroid	B-MED
Cancer	I-MED
Patients	B-MED
:	O
a	O
View	O
from	O
the	O
Peripheral	B-MED
Blood	I-MED
Transforming	B-MED
growth	I-MED
factor	I-MED
beta	I-MED
(	O
TGF	B-MED
-	I-MED
β	I-MED
)	O
plays	O
an	O
important	O
role	O
in	O
many	O
pathophysiological	B-MED
conditions	B-MED
,	O
including	O
cancer	B-MED
.	O
The	O
level	B-MED
of	O
TGF	B-MED
-	I-MED
β	I-MED
in	O
patients	B-MED
with	O
differentiated	B-MED
thyroid	I-MED
cancer	I-MED
(	O
DTC	B-MED
)	O
has	O
not	O
been	O
examined	B-MED
so	O
far	O
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
measure	O
TGF	B-MED
-	I-MED
β	I-MED
concentration	B-MED
in	O
serum	B-MED
samples	I-MED
and	O
in	O
PHA	B-MED
-	O
stimulated	B-MED
whole	B-MED
blood	I-MED
culture	B-MED
in	B-MED
vitro	I-MED
and	O
to	O
analyze	B-MED
possible	O
associations	O
of	O
TGF	B-MED
-	I-MED
β1	I-MED
levels	B-MED
with	O
leukocyte	B-MED
,	O
lymphocyte	B-MED
and	O
platelets	B-MED
counts	B-MED
,	O
the	O
histological	B-MED
type	O
of	O
thyroid	B-MED
cancer	I-MED
,	O
and	O
stage	B-MED
of	I-MED
disease	I-MED
.	O
TGF	B-MED
-	I-MED
β1	I-MED
was	O
measured	O
in	O
22	O
DTC	B-MED
patients	B-MED
and	O
20	O
healthy	B-MED
controls	B-MED
using	O
the	O
duoSet	B-MED
ELISA	I-MED
Development	I-MED
kit	I-MED
for	O
human	B-MED
TGF	I-MED
-	I-MED
β1	I-MED
.	O
The	O
concentration	B-MED
of	O
TGF	B-MED
-	I-MED
β1	I-MED
in	O
serum	B-MED
samples	I-MED
from	O
both	O
groups	B-MED
correlated	O
positively	O
with	O
the	O
platelet	B-MED
counts	B-MED
.	O
There	O
was	O
no	O
statistically	B-MED
significant	I-MED
difference	O
in	O
the	O
serum	B-MED
concentrations	I-MED
of	O
TGF	B-MED
-	I-MED
β1	I-MED
between	O
DTC	B-MED
patients	B-MED
and	O
control	B-MED
subjects	I-MED
,	O
but	O
PHA	B-MED
stimulated	B-MED
whole	B-MED
blood	I-MED
cultures	B-MED
of	O
DTC	B-MED
patients	B-MED
produced	O
less	O
TGF	B-MED
-	I-MED
β1	I-MED
than	O
those	O
from	O
controls	B-MED
.	O
Additional	O
studies	B-MED
are	O
needed	O
to	O
determine	O
the	O
significance	B-MED
of	O
these	O
in	B-MED
vitro	I-MED
findings	B-MED
.	O
Reduced	B-MED
Chest	I-MED
and	O
Abdominal	B-MED
Wall	I-MED
Mobility	B-MED
and	O
Their	O
Relationship	B-MED
to	O
Lung	B-MED
Function	I-MED
,	O
Respiratory	B-MED
Muscle	B-MED
Strength	I-MED
,	O
and	O
Exercise	B-MED
Tolerance	I-MED
in	O
Subjects	B-MED
With	O
COPD	B-MED
Advanced	O
air	B-MED
-	I-MED
flow	I-MED
limitation	B-MED
in	O
patients	B-MED
with	O
COPD	B-MED
leads	O
to	O
a	O
reduction	B-MED
in	O
vital	B-MED
capacity	I-MED
,	O
respiratory	B-MED
muscle	B-MED
strength	I-MED
,	O
and	O
exercise	B-MED
capacity	I-MED
.	O
However	O
,	O
its	O
impact	O
on	O
chest	B-MED
and	O
abdominal	B-MED
wall	I-MED
mobility	B-MED
is	O
unknown	B-MED
.	O
This	O
study	O
aimed	O
to	O
ascertain	O
the	O
prevalence	B-MED
of	O
patients	B-MED
with	O
COPD	B-MED
with	O
reduced	B-MED
chest	I-MED
and	O
abdominal	B-MED
wall	I-MED
mobility	B-MED
and	O
to	O
investigate	B-MED
the	O
effect	B-MED
of	O
reduced	B-MED
chest	I-MED
and	O
abdominal	B-MED
wall	I-MED
mobility	B-MED
on	O
pulmonary	B-MED
function	I-MED
,	O
respiratory	B-MED
muscle	B-MED
strength	I-MED
,	O
and	O
exercise	B-MED
capacity	I-MED
.	O
In	O
51	O
elderly	B-MED
male	B-MED
subjects	B-MED
with	O
COPD	B-MED
,	O
chest	B-MED
and	O
abdominal	B-MED
wall	I-MED
mobility	B-MED
,	O
FVC	B-MED
,	O
FEV1	B-MED
,	O
FEV1	B-MED
/	I-MED
FVC	I-MED
,	O
maximal	B-MED
inspiratory	I-MED
pressure	I-MED
(	O
PImax	B-MED
)	O
,	O
maximal	B-MED
expiratory	I-MED
pressure	I-MED
(	O
PEmax	B-MED
)	O
,	O
and	O
the	O
6	B-MED
-	I-MED
min	I-MED
walk	I-MED
distance	I-MED
(	O
6MWD	B-MED
)	O
were	O
assessed	B-MED
.	O
Chest	B-MED
and	O
abdominal	B-MED
wall	I-MED
mobility	B-MED
were	O
measured	B-MED
using	O
the	O
breathing	B-MED
movement	B-MED
scale	I-MED
(	O
0	O
-	O
8)	O
at	O
the	O
3	O
regions	B-MED
(	O
upper	B-MED
chest	I-MED
,	O
lower	B-MED
chest	I-MED
,	O
and	O
abdomen	B-MED
)	O
.	O
Reduced	B-MED
mobility	I-MED
was	O
defined	O
as	O
a	O
value	B-MED
lower	B-MED
than	O
the	O
lower	B-MED
limit	I-MED
of	I-MED
the	I-MED
normal	I-MED
scale	I-MED
.	O
The	O
unpaired	B-MED
t	I-MED
test	I-MED
,	O
Mann	B-MED
-	I-MED
Whitney	I-MED
test	I-MED
,	O
and	O
multiple	B-MED
regression	I-MED
analysis	I-MED
were	O
performed	B-MED
.	O
The	O
percentages	B-MED
of	O
subjects	B-MED
with	O
reduced	B-MED
mobility	I-MED
were	O
78	O
%	O
for	O
the	O
upper	B-MED
chest	I-MED
,	O
76	O
%	O
for	O
the	O
lower	B-MED
chest	I-MED
,	O
and	O
53	O
%	O
for	O
the	O
abdomen	B-MED
.	O
The	O
subjects	B-MED
with	O
reduced	B-MED
mobility	I-MED
had	O
significantly	B-MED
low	I-MED
FVC	B-MED
,	O
FEV1	B-MED
,	O
and	O
6MWD	B-MED
in	O
each	O
region	B-MED
and	O
significantly	B-MED
low	I-MED
FEV1	B-MED
/	I-MED
FVC	I-MED
,	O
PImax	B-MED
,	O
and	O
PEmax	B-MED
in	O
the	O
abdominal	B-MED
region	I-MED
compared	B-MED
with	O
those	O
with	O
nonreduced	O
mobility	B-MED
.	O
FVC	B-MED
and	O
6MWD	B-MED
were	O
independently	O
associated	B-MED
with	I-MED
the	O
scale	B-MED
values	I-MED
in	O
each	O
region	B-MED
and	O
with	O
the	O
abdominal	B-MED
scale	B-MED
value	I-MED
,	O
respectively	O
.	O
The	O
majority	O
of	O
subjects	B-MED
with	O
COPD	B-MED
had	O
reduced	B-MED
chest	I-MED
and	O
abdominal	B-MED
wall	I-MED
mobility	B-MED
,	O
which	O
was	O
independently	O
associated	B-MED
with	I-MED
FVC	B-MED
.	O
Even	O
though	O
abdominal	B-MED
wall	I-MED
mobility	B-MED
was	O
relatively	O
preserved	O
compared	B-MED
with	O
chest	B-MED
wall	I-MED
mobility	B-MED
,	O
it	O
was	O
also	O
independently	O
associated	B-MED
with	I-MED
6MWD	B-MED
.	O
Successful	B-MED
Restoration	I-MED
of	O
Severely	O
Mutilated	B-MED
Primary	B-MED
Incisors	I-MED
Using	O
a	O
Novel	O
Method	O
to	O
Retain	O
Zirconia	B-MED
Crowns	B-MED
-	O
Two	B-MED
Year	I-MED
Results	B-MED
This	O
manuscript	B-MED
describes	O
a	O
simple	O
reliable	B-MED
technique	I-MED
for	O
restoring	B-MED
severely	O
mutilated	B-MED
primary	B-MED
anterior	I-MED
teeth	I-MED
.	O
A	O
rigid	O
glass	B-MED
ionomer	I-MED
post	I-MED
is	O
created	O
over	O
which	O
zirconia	B-MED
crowns	B-MED
can	O
be	O
fitted	O
to	O
achieve	O
a	O
long	B-MED
-	I-MED
term	I-MED
stable	O
esthetic	B-MED
restoration	B-MED
for	O
primary	B-MED
anterior	I-MED
teeth	I-MED
.	O
Children	B-MED
aged	O
2	O
-	O
5	O
years	B-MED
with	O
two	O
up	O
to	O
six	O
extensively	O
decayed	B-MED
upper	B-MED
primary	I-MED
incisors	I-MED
were	O
included	O
.	O
Fuji	B-MED
IX	I-MED
was	O
condensed	O
into	O
an	O
intracanal	B-MED
space	I-MED
created	O
to	O
a	O
depth	B-MED
of	O
3	O
mm	O
,	O
to	O
provide	O
a	O
core	B-MED
which	O
also	O
extended	O
3	O
mm	O
supragingivally	B-MED
.	O
Crown	B-MED
preparations	I-MED
were	O
completed	O
upon	O
these	O
cores	B-MED
.	O
Zirconia	B-MED
crowns	B-MED
(	O
Nusmile	B-MED
,	O
Houston	B-MED
Texas	I-MED
USA	B-MED
)	O
were	O
fitted	B-MED
and	O
cemented	B-MED
over	O
the	O
prepared	O
cores	B-MED
.	O
All	O
patients	B-MED
were	O
recalled	B-MED
at	O
regular	B-MED
intervals	I-MED
.	O
Twenty	O
-	O
three	O
healthy	O
children	B-MED
with	O
86	O
restorations	B-MED
participated	O
in	O
the	O
study	B-MED
.	O
The	O
overall	B-MED
survival	I-MED
of	O
the	O
restorations	B-MED
was	O
95.3	O
%	O
after	O
12	O
months	B-MED
and	O
80.2	O
%	O
after	O
24	O
months	B-MED
.	O
According	O
to	O
Kaplan	B-MED
-	I-MED
Meier	I-MED
survival	I-MED
analysis	I-MED
,	O
the	O
median	B-MED
survival	I-MED
time	I-MED
was	O
not	O
reached	O
while	O
the	O
estimated	O
mean	B-MED
survival	I-MED
time	I-MED
was	O
22.9	O
months	B-MED
.	O
This	O
newly	O
described	O
clinical	B-MED
technique	I-MED
is	O
simple	O
and	O
reliable	B-MED
to	O
use	O
for	O
restoration	B-MED
of	O
extensively	O
decayed	B-MED
primary	B-MED
incisors	I-MED
.	O
Use	O
of	O
zirconia	B-MED
crowns	B-MED
retained	O
using	O
this	O
technique	B-MED
offers	O
superior	B-MED
esthetic	I-MED
,	O
durable	O
restorations	B-MED
with	O
remarkable	O
gingival	B-MED
response	I-MED
up	O
to	O
24	O
months	B-MED
.	O
Efficacy	B-MED
of	O
42	O
Pharmacologic	B-MED
Cotreatment	B-MED
Strategies	O
Added	O
to	O
Antipsychotic	B-MED
Monotherapy	B-MED
in	O
Schizophrenia	B-MED
:	O
Systematic	O
Overview	O
and	O
Quality	B-MED
Appraisal	O
of	O
the	O
Meta	B-MED
-	I-MED
analytic	I-MED
Evidence	B-MED
Limited	O
treatment	B-MED
responses	B-MED
in	O
schizophrenia	B-MED
prompted	O
the	O
testing	O
of	O
combining	O
an	O
antipsychotic	B-MED
drug	I-MED
treatment	B-MED
with	O
a	O
second	O
psychotropic	B-MED
medication	B-MED
.	O
A	O
comprehensive	O
evaluation	B-MED
of	O
the	O
efficacy	B-MED
of	O
multiple	O
medication	B-MED
combinations	B-MED
is	O
missing	O
.	O
To	O
summarize	O
and	O
compare	O
the	O
meta	B-MED
-	I-MED
analytically	I-MED
determined	O
efficacy	B-MED
of	O
pharmacologic	B-MED
combination	B-MED
strategies	O
of	O
antipsychotic	B-MED
drugs	I-MED
in	O
adults	B-MED
with	O
schizophrenia	B-MED
.	O
Systematic	O
search	O
of	O
PubMed	B-MED
and	O
PsycInfo	B-MED
until	O
May	O
13	O
,	O
2016	O
.	O
Meta	B-MED
-	I-MED
analyses	I-MED
of	O
randomized	B-MED
clinical	I-MED
trials	I-MED
comparing	O
the	O
efficacy	B-MED
of	O
antipsychotic	B-MED
drugs	I-MED
combined	O
with	O
other	O
antipsychotic	B-MED
or	O
nonantipsychotic	B-MED
medications	I-MED
vs	O
placebos	B-MED
or	O
antipsychotic	B-MED
monotherapy	B-MED
among	O
adults	B-MED
with	O
schizophrenia	B-MED
.	O
Independent	O
reviewers	B-MED
extracted	O
the	O
data	B-MED
and	O
assessed	O
the	O
quality	B-MED
of	O
the	O
methods	B-MED
of	O
the	O
included	O
meta	B-MED
-	I-MED
analyses	I-MED
using	O
A	O
Measurement	B-MED
Tool	I-MED
to	I-MED
Assess	I-MED
Systematic	I-MED
Reviews	I-MED
(	O
AMSTAR	B-MED
)	O
,	O
adding	O
6	O
new	O
items	O
to	O
rate	O
their	O
quality	B-MED
.	O
Effect	B-MED
sizes	I-MED
,	O
expressed	O
as	O
standardized	B-MED
mean	I-MED
difference	I-MED
/Hedges	O
g	O
or	O
risk	B-MED
ratio	I-MED
,	O
were	O
compared	O
separately	O
for	O
combinations	B-MED
with	O
any	O
antipsychotic	B-MED
drug	I-MED
and	O
for	O
combinations	B-MED
with	O
clozapine	B-MED
.	O
The	O
primary	O
outcome	O
was	O
total	O
symptom	B-MED
reduction	B-MED
.	O
Secondary	O
outcomes	O
included	O
positive	B-MED
and	O
negative	B-MED
symptoms	B-MED
,	O
treatment	B-MED
recommendations	I-MED
by	O
authors	O
,	O
study	O
-	O
defined	O
inefficacies	B-MED
,	O
cognitive	B-MED
and	O
depressive	B-MED
symptoms	I-MED
,	O
discontinuation	B-MED
of	O
treatment	B-MED
because	O
of	O
any	O
cause	O
,	O
and	O
inefficacies	B-MED
or	O
intolerabilities	O
.	O
Of	O
3397	O
publications	O
,	O
29	O
meta	B-MED
-	I-MED
analyses	I-MED
testing	O
42	O
combination	B-MED
strategies	O
in	O
381	O
individual	B-MED
trials	O
and	O
among	O
19	O
833	O
participants	B-MED
were	O
included	O
.	O
For	O
total	O
symptom	B-MED
reductions	B-MED
,	O
32	O
strategies	O
that	O
augmented	O
any	O
antipsychotic	B-MED
drug	I-MED
and	O
5	O
strategies	O
that	O
augmented	O
clozapine	B-MED
were	O
examined	O
.	O
Fourteen	O
combination	B-MED
treatments	B-MED
outperformed	O
controls	O
(	O
standard	B-MED
mean	I-MED
difference	I-MED
/Hedges	O
g	O
,	O
-1.27	O
[	O
95	O
%	O
CI	B-MED
,	O
-2.35	O
to	O
-0.19	O
]	O
to	O
-0.23	O
[	O
95	O
%	O
CI	B-MED
,	O
-0.44	O
to	O
-0.02	O
]	O
;	O
P	O
=	O
.05	O
)	O
.	O
No	O
combination	B-MED
strategies	O
with	O
clozapine	B-MED
outperformed	O
controls	O
.	O
The	O
quality	B-MED
of	O
the	O
methods	B-MED
of	O
the	O
meta	B-MED
-	I-MED
analyses	I-MED
was	O
generally	O
high	B-MED
(	O
mean	B-MED
score	I-MED
,	O
9	O
of	O
a	O
maximum	B-MED
score	I-MED
of	O
11	O
)	O
but	O
the	O
quality	B-MED
of	O
the	O
meta	B-MED
-	I-MED
analyzed	I-MED
studies	I-MED
was	O
low	B-MED
(	O
mean	B-MED
score	I-MED
,	O
2.8	O
of	O
a	O
maximum	B-MED
score	I-MED
of	O
8)	O
.	O
Treatment	B-MED
recommendations	I-MED
correlated	O
with	O
the	O
effect	B-MED
size	I-MED
(	O
correlation	B-MED
coefficient	I-MED
,	O
0.22	O
;	O
95	O
%	O
CI	B-MED
,	O
0.35	O
-	O
0.10	O
;	O
P	O
<	O
.001	O
)	O
,	O
yet	O
effect	B-MED
sizes	I-MED
were	O
inversely	O
correlated	O
with	O
study	O
quality	B-MED
(	O
correlation	B-MED
coefficient	I-MED
,	O
-0.06	O
;	O
95	O
%	O
CI	B-MED
,	O
0.01	O
to	O
-0.12	O
;	O
P	O
=	O
.02	O
)	O
.	O
Meta	B-MED
-	I-MED
analyses	I-MED
of	O
21	O
interventions	O
fully	O
or	O
partially	O
recommended	O
their	O
use	O
,	O
with	O
recommendations	B-MED
being	O
positively	B-MED
correlated	O
with	O
the	O
effect	B-MED
sizes	I-MED
of	O
the	O
pooled	O
intervention	O
.	O
However	O
,	O
the	O
effect	B-MED
sizes	I-MED
were	O
inversely	O
correlated	O
with	O
meta	B-MED
-	I-MED
analyzed	I-MED
study	I-MED
quality	B-MED
,	O
reducing	B-MED
confidence	B-MED
in	O
these	O
recommendations	B-MED
.	O
Higher	B-MED
-	O
quality	B-MED
trials	O
and	O
patient	B-MED
-based	O
meta	B-MED
-	I-MED
analyses	I-MED
are	O
needed	O
to	O
determine	O
whether	O
subpopulations	B-MED
might	O
benefit	O
from	O
combination	B-MED
treatment	B-MED
,	O
as	O
no	O
single	O
strategy	O
can	O
be	O
recommended	O
for	O
patients	B-MED
with	O
schizophrenia	B-MED
based	O
on	O
the	O
current	O
meta	B-MED
-	I-MED
analytic	I-MED
literature	B-MED
.	O
High	O
throughput	O
resistance	B-MED
profiling	B-MED
of	O
Plasmodium	B-MED
falciparum	I-MED
Plasmodium	B-MED
falciparum	I-MED
infections	I-MED
based	O
on	O
custom	B-MED
dual	I-MED
indexing	I-MED
and	O
Illumina	B-MED
next	I-MED
generation	I-MED
sequencing	I-MED
-	I-MED
technology	I-MED
Genetic	B-MED
polymorphisms	I-MED
in	O
P.	B-MED
falciparum	I-MED
can	O
be	O
used	O
to	O
indicate	O
the	O
parasite	B-MED
's	I-MED
susceptibility	B-MED
to	O
antimalarial	B-MED
drugs	I-MED
as	O
well	O
as	O
its	O
geographical	B-MED
origin	I-MED
.	O
Both	O
of	O
these	O
factors	O
are	O
key	O
to	O
monitoring	B-MED
development	B-MED
and	O
spread	B-MED
of	O
antimalarial	B-MED
antimalarial	B-MED
drug	I-MED
resistance	I-MED
.	O
In	O
this	O
study	O
,	O
we	O
combine	O
multiplex	B-MED
PCR	I-MED
,	O
custom	B-MED
designed	I-MED
dual	I-MED
indexing	I-MED
and	O
Miseq	B-MED
sequencing	B-MED
for	O
high	O
throughput	O
SNP	B-MED
-	O
profiling	B-MED
of	O
457	O
malaria	B-MED
infections	B-MED
from	O
Guinea	B-MED
-	I-MED
Bissau	I-MED
,	O
at	O
the	O
cost	B-MED
of	O
10	O
USD	O
per	O
sample	O
.	O
By	O
amplifying	B-MED
and	O
sequencing	B-MED
15	O
genetic	B-MED
fragments	B-MED
,	O
we	O
cover	O
20	O
resistance	B-MED
-conferring	O
SNPs	B-MED
occurring	O
in	O
pfcrt	B-MED
,	O
pfmdr1	B-MED
,	O
pfdhfr	B-MED
,	O
pfdhps	B-MED
,	O
as	O
well	O
as	O
the	O
entire	O
length	B-MED
of	O
pfK13	B-MED
,	O
and	O
the	O
mitochondrial	B-MED
barcode	B-MED
for	O
parasite	B-MED
origin	B-MED
.	O
SNPs	B-MED
of	O
interest	O
were	O
sequenced	O
with	O
an	O
average	B-MED
depth	O
of	O
2,043	O
reads	O
,	O
and	O
bases	O
were	O
called	O
for	O
the	O
various	O
SNP	B-MED
-	O
positions	B-MED
with	O
a	O
p	O
-	O
value	O
below	O
0.05	O
,	O
for	O
89.8	O
-	O
100	O
%	O
of	O
samples	O
.	O
The	O
SNP	B-MED
data	O
indicates	O
that	O
artemisinin	B-MED
artemisinin	B-MED
resistance	I-MED
-conferring	O
SNPs	B-MED
in	O
pfK13	B-MED
are	O
absent	B-MED
from	O
the	O
studied	O
area	O
of	O
Guinea	B-MED
-	I-MED
Bissau	I-MED
,	O
while	O
the	O
pfmdr1	B-MED
86	O
N	O
allele	O
is	O
found	O
at	O
a	O
high	O
prevalence	B-MED
.	O
The	O
mitochondrial	B-MED
barcodes	B-MED
are	O
unanimous	O
and	O
accommodate	O
a	O
West	B-MED
African	I-MED
West	B-MED
African	I-MED
origin	I-MED
of	O
the	O
parasites	B-MED
.	O
With	O
this	O
method	B-MED
,	O
very	O
reliable	B-MED
high	O
throughput	O
surveillance	B-MED
of	O
antimalarial	B-MED
antimalarial	B-MED
drug	I-MED
resistance	I-MED
becomes	O
more	O
affordable	O
than	O
ever	O
before	O
.	O
Interleukin-21	B-MED
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	B-MED
and	O
severity	O
of	O
type	B-MED
I	I-MED
autoimmune	I-MED
hepatitis	I-MED
Recently	O
,	O
the	O
number	O
of	O
follicular	B-MED
helper	B-MED
T	I-MED
(	I-MED
Tfh	I-MED
)	I-MED
cells	I-MED
expressing	O
interleukin	B-MED
(	I-MED
IL)-21	I-MED
was	O
found	O
to	O
increase	O
in	O
peripheral	B-MED
blood	I-MED
of	O
human	B-MED
and	O
murine	B-MED
models	B-MED
of	O
autoimmune	B-MED
hepatitis	I-MED
(	O
AIH	B-MED
)	O
.	O
IL-21	B-MED
,	O
the	O
most	O
recently	O
discovered	O
member	O
of	O
the	O
type	B-MED
-	I-MED
I	I-MED
cytokine	I-MED
family	I-MED
,	O
exerts	O
various	O
effects	O
on	O
the	O
immune	B-MED
system	I-MED
,	O
including	O
B	B-MED
cell	I-MED
activation	I-MED
,	O
plasma	B-MED
cell	I-MED
differentiation	I-MED
,	O
and	O
immunoglobulin	B-MED
production	I-MED
.	O
We	O
aimed	O
to	O
assess	O
the	O
relationship	O
of	O
serum	B-MED
IL-21	B-MED
levels	B-MED
in	O
patients	B-MED
with	O
type	B-MED
I	I-MED
AIH	I-MED
with	O
clinical	B-MED
and	O
laboratory	B-MED
parameters	B-MED
and	O
histology	B-MED
.	O
Ninety	O
-	O
two	O
Japanese	B-MED
patients	B-MED
with	O
liver	B-MED
disease	I-MED
(	O
22	O
AIH	B-MED
,	O
20	O
primary	B-MED
biliary	I-MED
cholangitis	I-MED
,	O
19	O
drug	B-MED
-	I-MED
induced	I-MED
liver	I-MED
injury	I-MED
,	O
8	O
acute	B-MED
hepatitis	I-MED
B	I-MED
,	O
8	O
chronic	B-MED
hepatitis	I-MED
C	I-MED
,	O
10	O
non	B-MED
-	I-MED
alcoholic	I-MED
steatohepatitis	I-MED
,	O
5	O
viral	B-MED
hepatitis	I-MED
)	O
and	O
10	O
healthy	B-MED
volunteers	I-MED
were	O
recruited	O
.	O
Serum	B-MED
IL-21	B-MED
levels	B-MED
were	O
detected	O
by	O
enzyme	B-MED
-	I-MED
linked	I-MED
immunosorbent	I-MED
assay	I-MED
.	O
Real	B-MED
-	I-MED
time	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
measured	O
mRNA	B-MED
levels	B-MED
of	O
Bcl-6	B-MED
,	O
IL-21	B-MED
,	O
and	O
CXCR5	B-MED
(	O
Tfh	B-MED
-	I-MED
related	I-MED
factors	I-MED
)	O
in	O
peripheral	B-MED
mononuclear	B-MED
cells	I-MED
.	O
Mean	O
age	O
at	O
diagnosis	B-MED
of	O
AIH	B-MED
was	O
58.6	O
years	O
,	O
male	B-MED
-	I-MED
to	I-MED
-	I-MED
female	I-MED
ratio	I-MED
was	O
4:18	O
,	O
18.2	O
%	O
of	O
participants	O
had	O
cirrhosis	B-MED
,	O
and	O
22.7	O
%	O
had	O
severe	B-MED
disease	B-MED
.	O
IL-21	B-MED
levels	B-MED
were	O
significantly	O
increased	B-MED
in	O
the	O
serum	B-MED
of	O
patients	B-MED
with	O
AIH	B-MED
compared	O
to	O
those	O
with	O
other	B-MED
liver	I-MED
diseases	I-MED
and	O
controls	B-MED
(	O
p	O
<	O
0.0001	O
)	O
.	O
Particularly	O
,	O
serum	B-MED
IL-21	B-MED
levels	B-MED
were	O
significantly	O
increased	B-MED
in	O
severe	B-MED
AIH	B-MED
cases	O
compared	O
to	O
non	O
-	O
severe	O
cases	O
(	O
p	O
<	O
0.05	O
)	O
.	O
Serum	B-MED
IL-21	B-MED
levels	B-MED
correlated	O
positively	O
with	O
total	O
serum	B-MED
bilirubin	B-MED
levels	I-MED
(	O
r	O
=	O
0.46	O
,	O
p	O
<	O
0.05	O
)	O
,	O
grading	B-MED
of	I-MED
necroinflammatory	I-MED
activity	I-MED
(	O
r	O
=	O
0.68	O
,	O
p	O
<	O
0.005	O
)	O
and	O
negatively	O
with	O
serum	B-MED
albumin	I-MED
levels	I-MED
in	O
patients	B-MED
with	O
AIH	B-MED
(	O
r	O
=	O
-0.49	O
,	O
p	O
<	O
0.05	O
)	O
.	O
In	O
patients	B-MED
with	O
biochemical	B-MED
remission	B-MED
of	O
AIH	B-MED
,	O
serum	B-MED
IL-21	B-MED
levels	B-MED
remained	O
elevated	B-MED
and	O
correlated	B-MED
positively	B-MED
with	O
serum	B-MED
IgG	I-MED
levels	I-MED
(	O
r	O
=	O
0.84	O
,	O
p	O
<	O
0.01	O
)	O
.	O
Expression	B-MED
of	O
Tfh	B-MED
-	I-MED
related	I-MED
factors	I-MED
,	O
such	O
as	O
Bcl-6	B-MED
and	O
IL-21	B-MED
,	O
in	O
peripheral	B-MED
blood	I-MED
mononuclear	I-MED
cells	I-MED
of	O
patients	B-MED
with	O
AIH	B-MED
was	O
significantly	O
higher	B-MED
than	O
that	O
in	O
healthy	B-MED
volunteers	I-MED
.	O
IL-21	B-MED
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-MED
and	O
severity	O
of	O
AIH	B-MED
,	O
and	O
may	O
present	O
a	O
promising	O
target	O
for	O
AIH	B-MED
therapy	B-MED
.	O
Caribbean	B-MED
massive	B-MED
corals	I-MED
not	B-MED
recovering	I-MED
from	I-MED
repeated	O
thermal	B-MED
stress	I-MED
events	B-MED
during	O
2005	O
-	O
2013	O
Massive	B-MED
coral	I-MED
bleaching	B-MED
events	B-MED
associated	O
with	O
high	O
sea	B-MED
surface	B-MED
temperatures	B-MED
are	O
forecast	O
to	O
become	O
more	O
frequent	B-MED
and	O
severe	B-MED
in	O
the	O
future	O
due	O
to	O
climate	B-MED
change	I-MED
.	O
Monitoring	B-MED
colony	B-MED
recovery	B-MED
from	O
bleaching	B-MED
disturbances	O
over	O
multiyear	B-MED
time	I-MED
frames	I-MED
is	O
important	O
for	O
improving	O
predictions	O
of	O
future	O
coral	B-MED
community	B-MED
changes	B-MED
.	O
However	O
,	O
there	O
are	O
currently	O
few	O
multiyear	B-MED
studies	I-MED
describing	O
long	B-MED
-	I-MED
term	I-MED
outcomes	B-MED
for	O
coral	B-MED
colonies	B-MED
following	O
acute	B-MED
bleaching	I-MED
events	B-MED
.	O
We	O
recorded	O
colony	B-MED
pigmentation	B-MED
and	O
size	B-MED
for	O
bleached	B-MED
and	O
unbleached	B-MED
groups	I-MED
of	O
co	O
-	O
located	O
conspecifics	O
of	O
three	O
major	O
reef	B-MED
-	I-MED
building	I-MED
scleractinian	I-MED
corals	B-MED
(	O
Orbicella	B-MED
franksi	I-MED
,	O
Siderastrea	B-MED
siderea	I-MED
,	O
and	O
Stephanocoenia	B-MED
michelini	I-MED
;	O
n	O
=	O
198	O
total	O
)	O
in	O
Bocas	B-MED
del	I-MED
Toro	I-MED
,	O
Panama	B-MED
,	O
during	O
the	O
major	O
2005	O
bleaching	B-MED
event	B-MED
and	O
then	O
monitored	B-MED
pigmentation	B-MED
status	B-MED
and	O
changes	O
live	B-MED
tissue	I-MED
colony	B-MED
size	B-MED
for	O
8	O
years	B-MED
(	O
2005	O
-	O
2013	O
)	O
.	O
Corals	B-MED
that	O
were	O
bleached	B-MED
in	O
2005	O
demonstrated	O
markedly	O
different	O
response	O
trajectories	O
compared	O
to	O
unbleached	O
colony	B-MED
groups	B-MED
,	O
with	O
extensive	O
live	B-MED
tissue	I-MED
loss	B-MED
for	O
bleached	B-MED
corals	B-MED
of	O
all	O
species	B-MED
following	O
bleaching	B-MED
,	O
with	O
mean	O
live	B-MED
tissue	I-MED
losses	B-MED
per	O
colony	B-MED
9	O
months	B-MED
postbleaching	B-MED
of	O
26.2	O
%	O
(	O
±5.4	O
SE	O
)	O
for	O
O.	B-MED
franksi	I-MED
,	O
35.7	O
%	O
(	O
±4.7	O
SE	O
)	O
for	O
S.	B-MED
michelini	I-MED
,	O
and	O
11.2	O
%	O
(	O
±3.9	O
SE	O
)	O
for	O
S.	B-MED
siderea	I-MED
.	O
Two	O
species	B-MED
,	O
O.	B-MED
franksi	I-MED
and	O
S.	B-MED
michelini	I-MED
,	O
later	O
recovered	O
to	O
net	O
positive	B-MED
growth	B-MED
,	O
which	O
continued	O
until	O
a	O
second	O
thermal	B-MED
stress	I-MED
event	B-MED
in	O
2010	O
.	O
Following	O
this	O
event	B-MED
,	O
all	O
species	B-MED
again	O
lost	B-MED
tissue	B-MED
,	O
with	O
previously	O
unbleached	O
colony	B-MED
species	B-MED
groups	B-MED
experiencing	O
greater	O
declines	O
than	O
conspecific	O
sample	O
groups	B-MED
,	O
which	O
were	O
previously	O
bleached	B-MED
,	O
indicating	O
a	O
possible	O
positive	O
acclimative	B-MED
response	I-MED
.	O
However	O
,	O
despite	O
this	O
beneficial	O
effect	O
for	O
previously	O
bleached	B-MED
corals	B-MED
,	O
all	O
groups	B-MED
experienced	O
substantial	O
net	O
tissue	B-MED
loss	B-MED
between	O
2005	O
and	O
2013	O
,	O
indicating	O
that	O
many	O
important	O
Caribbean	B-MED
reef	B-MED
-	I-MED
building	I-MED
corals	I-MED
will	O
likely	O
suffer	O
continued	O
tissue	B-MED
loss	B-MED
and	O
may	O
be	O
unable	O
to	O
maintain	O
current	O
benthic	B-MED
coverage	I-MED
when	O
faced	O
with	O
future	O
thermal	B-MED
stress	I-MED
forecast	O
for	O
the	O
region	B-MED
,	O
even	O
with	O
potential	O
benefits	O
from	O
bleaching	B-MED
-related	O
acclimation	B-MED
.	O
Enhanced	O
Performance	B-MED
of	O
Colorimetric	B-MED
Biosensing	B-MED
on	O
Paper	B-MED
Microfluidic	B-MED
Platforms	I-MED
Through	O
Chemical	B-MED
Modification	I-MED
and	O
Incorporation	B-MED
of	O
Nanoparticles	B-MED
This	O
chapter	O
describes	O
two	O
different	O
methodologies	B-MED
used	O
to	O
improve	O
the	O
analytical	B-MED
performance	I-MED
of	O
colorimetric	B-MED
paper	B-MED
-based	O
biosensors	B-MED
.	O
Microfluidic	B-MED
paper	I-MED
-	I-MED
based	I-MED
analytical	I-MED
devices	I-MED
(	O
μPADs	B-MED
)	O
have	O
been	O
produced	O
by	O
a	O
stamping	B-MED
process	I-MED
and	O
CO2	B-MED
laser	B-MED
ablation	I-MED
and	O
modified	B-MED
,	O
respectively	O
,	O
through	O
an	O
oxidation	B-MED
step	B-MED
and	O
incorporation	O
of	O
silica	B-MED
nanoparticles	B-MED
on	O
the	O
paper	B-MED
structure	I-MED
.	O
Both	O
methods	B-MED
are	O
employed	O
in	O
order	O
to	O
overcome	O
the	O
largest	O
problem	B-MED
associated	B-MED
with	I-MED
colorimetric	B-MED
detection	I-MED
,	O
the	O
heterogeneity	B-MED
of	O
the	O
color	B-MED
distribution	B-MED
in	O
the	O
detection	B-MED
zones	I-MED
.	O
The	O
modification	B-MED
steps	B-MED
are	O
necessary	O
to	O
improve	O
the	O
interaction	B-MED
between	O
the	O
paper	B-MED
surface	B-MED
and	O
the	O
selected	O
enzymes	B-MED
.	O
The	O
enhanced	O
performance	B-MED
has	O
ensured	O
reliability	B-MED
for	O
quantitative	B-MED
analysis	B-MED
of	O
clinically	B-MED
relevant	O
compounds	B-MED
.	O
Scoparone	B-MED
Inhibits	O
LPS	B-MED
-	O
Simulated	B-MED
Inflammatory	B-MED
Response	I-MED
by	O
Suppressing	B-MED
IRF3	B-MED
and	O
ERK	B-MED
in	O
BV-2	B-MED
Microglial	I-MED
Cells	I-MED
Microglia	B-MED
activation	B-MED
and	O
the	O
release	O
of	O
various	O
inflammatory	B-MED
cytokines	B-MED
are	O
largely	O
related	O
to	O
neurological	B-MED
diseases	I-MED
,	O
including	O
Parkinson	B-MED
's	I-MED
,	O
Alzheimer	B-MED
's	I-MED
,	O
and	O
other	B-MED
brain	B-MED
diseases	I-MED
.	O
The	O
suppression	O
of	O
microglial	B-MED
cells	I-MED
using	O
natural	B-MED
bioactive	B-MED
compounds	I-MED
has	O
become	O
increasingly	B-MED
important	B-MED
for	O
brain	B-MED
therapy	I-MED
owing	O
to	O
the	O
expected	O
beneficial	B-MED
effect	I-MED
of	O
lower	B-MED
toxicity	B-MED
.	O
Scoparone	B-MED
(	O
6,7	B-MED
-	I-MED
dimethoxycoumarin	I-MED
)	O
,	O
a	O
major	O
bioactive	B-MED
compound	I-MED
found	B-MED
in	O
various	O
plant	B-MED
parts	I-MED
,	O
including	O
the	O
inner	O
shell	B-MED
of	O
chestnut	B-MED
(	O
Castanea	B-MED
crenata	I-MED
)	O
,	O
was	O
evaluated	O
on	O
lipopolysaccharide	B-MED
LPS	B-MED
(	O
LPS)-	O
activated	B-MED
BV-2	B-MED
microglia	I-MED
cells	I-MED
.	O
The	O
results	B-MED
indicated	B-MED
that	O
scoparone	B-MED
suppresses	B-MED
the	O
LPS	B-MED
-	O
stimulated	B-MED
increase	B-MED
of	O
neuroinflammatory	B-MED
responses	I-MED
and	O
inhibited	B-MED
the	O
pro	B-MED
-	I-MED
inflammatory	I-MED
cytokine	B-MED
production	O
in	O
the	O
BV-2	B-MED
microglial	I-MED
cells	I-MED
.	O
A	O
mechanistic	B-MED
study	I-MED
showed	O
that	O
scoparone	B-MED
specifically	O
inhibited	B-MED
the	O
LPS	B-MED
-	O
stimulated	B-MED
activation	B-MED
via	O
a	O
major	O
regulation	B-MED
of	O
IRF-3	B-MED
and	O
a	O
regulation	B-MED
of	O
ERK	B-MED
,	O
whereby	O
the	O
phosphorylation	B-MED
in	O
the	O
BV-2	B-MED
microglial	I-MED
cells	I-MED
is	O
blocked	B-MED
.	O
These	O
data	B-MED
suggest	B-MED
that	O
scoparone	B-MED
has	O
anti	B-MED
-	I-MED
neuroinflammatory	I-MED
effects	I-MED
in	O
LPS	B-MED
-	O
activated	B-MED
BV-2	B-MED
microglial	I-MED
cells	I-MED
,	O
and	O
could	O
possibly	O
be	O
used	B-MED
in	O
the	O
development	B-MED
of	O
novel	B-MED
drugs	B-MED
for	O
the	O
prevention	B-MED
and	O
treatment	B-MED
of	O
neuroinflammatory	B-MED
diseases	I-MED
.	O
Intra	B-MED
-	I-MED
articular	I-MED
corticosteroids	B-MED
versus	O
intra	B-MED
-	I-MED
articular	I-MED
corticosteroids	B-MED
plus	B-MED
methotrexate	B-MED
in	O
oligoarticular	B-MED
juvenile	I-MED
idiopathic	I-MED
arthritis	I-MED
:	O
a	O
multicentre	B-MED
,	O
prospective	B-MED
,	O
randomised	B-MED
,	O
open	B-MED
-	I-MED
label	I-MED
trial	I-MED
Little	O
evidence	O
-	O
based	O
information	O
is	O
available	O
to	O
guide	B-MED
the	O
treatment	B-MED
of	O
oligoarticular	B-MED
juvenile	I-MED
idiopathic	I-MED
arthritis	I-MED
.	O
We	O
aimed	O
to	O
investigate	B-MED
whether	O
oral	B-MED
methotrexate	I-MED
increases	B-MED
the	O
efficacy	B-MED
of	O
intra	B-MED
-	I-MED
articular	I-MED
corticosteroid	I-MED
therapy	I-MED
.	O
We	O
did	O
this	O
prospective	B-MED
,	O
open	B-MED
-	I-MED
label	I-MED
,	O
randomised	B-MED
trial	I-MED
at	O
ten	O
hospitals	B-MED
in	O
Italy	B-MED
.	O
Using	O
a	O
concealed	B-MED
computer	B-MED
-	I-MED
generated	I-MED
list	I-MED
,	O
children	B-MED
younger	B-MED
than	I-MED
18	O
years	B-MED
with	O
oligoarticular	B-MED
-	O
onset	B-MED
disease	I-MED
were	O
randomly	B-MED
assigned	B-MED
(	O
1:1	O
)	O
to	O
intra	B-MED
-	I-MED
articular	I-MED
corticosteroids	B-MED
alone	B-MED
or	O
in	B-MED
combination	I-MED
with	I-MED
oral	B-MED
methotrexate	I-MED
(	O
15	O
mg	O
/	O
m(2	O
)	O
;	O
maximum	B-MED
20	O
mg	O
)	O
.	O
Corticosteroids	B-MED
used	O
were	O
triamcinolone	B-MED
hexacetonide	I-MED
(	O
shoulder	B-MED
,	O
elbow	B-MED
,	O
wrist	B-MED
,	O
knee	B-MED
,	O
and	O
tibiotalar	B-MED
joints	I-MED
)	O
or	O
methylprednisolone	B-MED
acetate	I-MED
(	O
ie	O
,	O
subtalar	B-MED
and	O
tarsal	B-MED
joints	I-MED
)	O
.	O
We	O
did	O
not	O
mask	O
patients	B-MED
or	O
investigators	B-MED
to	O
treatment	B-MED
assignments	B-MED
.	O
Our	O
primary	B-MED
outcome	I-MED
was	O
the	O
proportion	B-MED
of	O
patients	B-MED
in	O
the	O
intention	B-MED
-	I-MED
to	I-MED
-	I-MED
treat	I-MED
population	B-MED
who	O
had	O
remission	B-MED
of	O
arthritis	B-MED
in	O
all	O
injected	B-MED
joints	B-MED
at	O
12	O
months	B-MED
.	O
This	O
trial	B-MED
is	O
registered	B-MED
with	O
European	B-MED
Union	I-MED
Clinical	I-MED
Trials	I-MED
Register	I-MED
,	O
EudraCT	B-MED
number	I-MED
2008	O
-	O
006741	O
-	O
70	O
.	O
Between	O
July	B-MED
7	O
,	O
2009	O
,	O
and	O
March	B-MED
31	O
,	O
2013	O
,	O
we	O
screened	B-MED
226	O
participants	B-MED
and	O
randomly	B-MED
assigned	B-MED
102	O
to	O
intra	B-MED
-	I-MED
articular	I-MED
corticosteroids	B-MED
alone	B-MED
and	O
105	O
to	O
intra	B-MED
-	I-MED
articular	I-MED
corticosteroids	B-MED
plus	B-MED
methotrexate	B-MED
.	O
33	O
(	O
32	O
%	O
)	O
patients	B-MED
assigned	B-MED
to	O
intra	B-MED
-	I-MED
articular	I-MED
corticosteroids	B-MED
alone	B-MED
and	O
39	O
(	O
37	O
%	O
)	O
assigned	B-MED
to	O
intra	B-MED
-	I-MED
articular	I-MED
corticosteroids	B-MED
and	O
methotrexate	B-MED
therapy	B-MED
had	O
remission	B-MED
of	O
arthritis	B-MED
in	O
all	O
injected	B-MED
joints	B-MED
(	O
p=0·48	O
)	O
.	O
Adverse	B-MED
events	I-MED
were	O
recorded	O
for	O
20	O
(	O
17	O
%	O
)	O
patients	B-MED
who	O
received	O
methotrexate	B-MED
,	O
which	O
led	O
to	O
permanent	B-MED
treatment	B-MED
discontinuation	B-MED
in	O
two	O
patients	B-MED
(	O
one	O
due	O
to	O
increased	B-MED
liver	I-MED
transaminases	I-MED
and	O
one	O
due	O
to	O
gastrointestinal	B-MED
discomfort	I-MED
)	O
.	O
No	B-MED
patient	B-MED
had	O
a	O
serious	B-MED
adverse	B-MED
event	I-MED
.	O
Concomitant	B-MED
administration	I-MED
of	O
methotrexate	B-MED
did	O
not	O
augment	B-MED
the	O
effectiveness	B-MED
of	O
intra	B-MED
-	I-MED
articular	I-MED
corticosteroid	I-MED
therapy	I-MED
.	O
Future	B-MED
studies	I-MED
are	O
needed	O
to	O
define	O
the	O
optimal	B-MED
therapeutic	B-MED
strategies	I-MED
for	O
oligoarticular	B-MED
juvenile	I-MED
idiopathic	I-MED
arthritis	I-MED
.	O
Italian	B-MED
Agency	I-MED
of	I-MED
Drug	I-MED
Evaluation	I-MED
.	O
Human	B-MED
Umbilical	B-MED
Cord	I-MED
Blood	I-MED
-	O
Derived	B-MED
Neural	B-MED
Stem	I-MED
Cell	I-MED
Line	I-MED
as	O
a	O
Screening	B-MED
Model	B-MED
for	O
Toxicity	B-MED
The	O
aim	B-MED
was	O
to	O
investigate	B-MED
whether	O
a	O
human	B-MED
neural	B-MED
stem	I-MED
cell	I-MED
(	O
NSC	B-MED
)	O
line	B-MED
derived	B-MED
from	O
human	B-MED
umbilical	B-MED
cord	I-MED
blood	I-MED
(	O
hUCB	B-MED
)	O
can	O
be	O
used	O
for	O
toxicity	B-MED
study	B-MED
.	O
Toxicity	B-MED
of	O
both	O
neurotoxic	B-MED
environmental	B-MED
xenobiotics	B-MED
,	O
methyl	B-MED
mercury	I-MED
chloride	I-MED
(	O
CH3HgCl	B-MED
)	O
,	O
lead	B-MED
acetate	I-MED
(	O
CH3COOPb	B-MED
)	O
,	O
and	O
chlorpyrifos	B-MED
(	O
CP	B-MED
)	O
,	O
and	O
non	B-MED
-	I-MED
neurotoxic	I-MED
insecticide	B-MED
,	O
dichlorvos	B-MED
,	O
as	O
well	O
as	O
non	B-MED
-	I-MED
neurotoxic	I-MED
drugs	B-MED
,	O
theophylline	B-MED
and	O
acetaminophen	B-MED
were	O
assessed	B-MED
.	O
Additionally	O
,	O
differentiation	B-MED
of	O
neuronal	B-MED
and	O
glial	B-MED
cell	I-MED
lines	I-MED
derived	B-MED
from	O
hUCB	B-MED
was	O
elucidated	O
.	O
It	O
was	O
observed	B-MED
that	O
CH3HgCl	B-MED
was	O
more	O
toxic	B-MED
to	O
human	B-MED
NSCs	B-MED
in	O
comparison	B-MED
to	O
CH3COOPb	B-MED
and	O
CP	B-MED
.	O
The	O
minimum	B-MED
inhibitory	I-MED
concentration	I-MED
(	I-MED
MIC	I-MED
)	I-MED
value	I-MED
against	O
NSCs	B-MED
was	O
3	O
,	O
10	O
,	O
and	O
300	O
mg	O
/	O
L	O
,	O
in	O
each	O
staining	B-MED
process	I-MED
,	O
acridine	B-MED
orange	I-MED
/	O
ethidium	B-MED
bromide	I-MED
(	O
AO	B-MED
/	O
EB	B-MED
)	O
staining	B-MED
,	O
3-(4,5	B-MED
-	I-MED
dimethylthiazol-2	I-MED
-	I-MED
yl)2,5	I-MED
-	I-MED
diphenyl	I-MED
tetrazolium	I-MED
bromide	I-MED
(	O
MTT	B-MED
)	O
assay	B-MED
,	O
and	O
Hoechst	B-MED
staining	I-MED
,	O
for	O
CH3HgCl	B-MED
,	O
CP	B-MED
,	O
and	O
CH3COOPb	B-MED
,	O
respectively	O
.	O
CH3HgCl	B-MED
had	O
the	O
LC25	B-MED
value	B-MED
as	O
10.0	O
,	O
14.4	O
,	O
and	O
12.7	O
mg	O
/	O
L	O
,	O
by	O
staining	B-MED
method	I-MED
mentioned	O
in	O
succession	O
.	O
CP	B-MED
had	O
the	O
LC25	B-MED
value	B-MED
as	O
21.9	O
,	O
23.7	O
,	O
and	O
18.4	O
mg	O
/	O
L	O
;	O
similarly	O
,	O
CH3COOPb	B-MED
had	O
LC25	B-MED
values	B-MED
,	O
successively	O
as	O
616.9	O
,	O
719.2	O
,	O
and	O
890.3	O
mg	O
/	O
L.	O
LC50	B-MED
values	B-MED
ranged	B-MED
from	O
18.2	O
to	O
21.7	O
mg	O
/	O
L	O
for	O
CH3HgCl	B-MED
,	O
56.4	O
to	O
60.2	O
mg	O
/	O
L	O
for	O
CP	B-MED
,	O
and	O
1000	O
to	O
1460.1	O
for	O
CH3COOPb	B-MED
.	O
Theophylline	B-MED
,	O
acetaminophen	B-MED
,	O
and	O
dichlorvos	B-MED
had	O
no	O
impact	B-MED
on	O
the	O
viability	B-MED
of	O
NSCs	B-MED
.	O
This	O
work	O
justified	O
that	O
hUCB	B-MED
-	O
NSC	B-MED
model	B-MED
can	O
be	O
used	O
for	O
toxicity	B-MED
study	B-MED
.	O
An	O
Automated	B-MED
,	O
Pharmacist	B-MED
-Driven	O
Initiative	B-MED
Improves	B-MED
Quality	B-MED
of	I-MED
Care	I-MED
for	O
Staphylococcus	B-MED
aureus	I-MED
Bacteremia	I-MED
Infectious	B-MED
diseases	I-MED
(	O
ID	B-MED
)	O
consultation	B-MED
and	O
antimicrobial	B-MED
stewardship	I-MED
intervention	I-MED
have	O
been	O
shown	O
to	O
improve	B-MED
the	O
management	B-MED
of	O
Staphylococcus	B-MED
aureus	I-MED
bacteremia	I-MED
(	O
SAB	B-MED
)	O
.	O
As	O
the	O
workload	B-MED
of	O
antimicrobial	B-MED
stewardship	I-MED
programs	I-MED
(	O
ASPs	B-MED
)	O
continues	O
to	O
increase	O
,	O
ASPs	B-MED
must	O
find	O
a	O
way	O
to	O
maximize	O
the	O
efficiency	B-MED
of	I-MED
the	I-MED
program	I-MED
while	O
optimizing	O
patient	B-MED
outcomes	B-MED
.	O
The	O
objective	O
of	O
this	O
study	B-MED
was	O
to	O
evaluate	B-MED
the	O
impact	B-MED
of	O
incorporating	O
health	B-MED
informatics	I-MED
into	O
the	O
management	B-MED
of	O
SAB	B-MED
via	O
a	O
pharmacist	B-MED
-driven	O
initiative	B-MED
.	O
Retrospective	B-MED
,	O
single	O
-	O
center	O
quasi	B-MED
-	I-MED
experimental	I-MED
study	B-MED
of	O
hospitalized	B-MED
patients	I-MED
with	O
SAB	B-MED
.	O
During	O
the	O
intervention	B-MED
period	B-MED
,	O
pharmacists	B-MED
were	O
alerted	O
to	O
patients	B-MED
with	O
SAB	B-MED
via	O
a	O
patient	B-MED
scoring	B-MED
tool	I-MED
integrated	O
into	O
the	O
electronic	B-MED
medical	I-MED
record	I-MED
.	O
Pharmacists	B-MED
utilized	O
the	O
scoring	B-MED
tool	I-MED
and	O
the	O
institution	B-MED
's	I-MED
evidence	B-MED
-	I-MED
based	I-MED
practice	I-MED
guideline	B-MED
to	O
make	O
standardized	B-MED
recommendations	I-MED
to	O
promote	O
adherence	B-MED
to	O
SAB	B-MED
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
care	I-MED
measures	B-MED
and	O
encourage	O
ID	B-MED
consultation	B-MED
.	O
The	O
primary	B-MED
outcome	B-MED
was	O
overall	O
compliance	B-MED
along	O
with	O
adherence	B-MED
to	O
individual	B-MED
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
care	I-MED
components	B-MED
.	O
Secondary	B-MED
clinical	O
outcomes	B-MED
were	O
also	O
analyzed	B-MED
.	O
84	O
patients	B-MED
were	O
identified	O
for	O
study	B-MED
inclusion	B-MED
,	O
45	O
in	O
the	O
pre-	O
intervention	B-MED
and	O
39	O
in	O
the	O
intervention	B-MED
group	B-MED
.	O
As	O
a	O
whole	O
,	O
all	O
four	O
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
care	I-MED
components	B-MED
for	O
the	O
management	B-MED
of	O
SAB	B-MED
were	O
significantly	B-MED
more	O
frequently	O
adhered	O
to	O
in	O
the	O
intervention	B-MED
group	B-MED
(	O
68.9	O
%	O
vs.	O
92.3	O
%	O
;	O
P=0.008	O
)	O
.	O
The	O
incidence	B-MED
of	O
ID	B-MED
consult	B-MED
improved	B-MED
significantly	B-MED
by	O
almost	O
20	O
%	O
in	O
the	O
intervention	B-MED
group	B-MED
(	O
75.6	O
%	O
vs.	O
94.9	O
%	O
,	O
P=0.015	O
)	O
.	O
No	O
statistically	B-MED
significant	I-MED
differences	B-MED
in	O
duration	O
of	O
bacteremia	B-MED
,	O
length	B-MED
-	I-MED
of	I-MED
-	I-MED
stay	I-MED
,	O
infection	B-MED
-related	O
length	B-MED
-	I-MED
of	I-MED
-	I-MED
stay	I-MED
,	O
or	O
readmission	B-MED
were	O
observed	O
between	O
the	O
groups	B-MED
.	O
The	O
incidence	B-MED
of	O
all	O
-	O
cause	O
mortality	B-MED
was	O
6	O
-	O
fold	O
higher	O
in	O
the	O
pre-	O
intervention	B-MED
group	B-MED
compared	O
to	O
the	O
intervention	B-MED
group	B-MED
(	O
15.6	O
%	O
vs.	O
2.6	O
%	O
,	O
P=0.063	O
)	O
.	O
An	O
automated	B-MED
,	O
pharmacist	B-MED
-driven	O
intervention	B-MED
for	O
the	O
management	B-MED
of	O
patients	B-MED
with	O
SAB	B-MED
demonstrated	O
a	O
significant	B-MED
improvement	B-MED
in	O
patients	B-MED
receiving	O
an	O
ID	B-MED
consult	B-MED
,	O
targeted	B-MED
antimicrobial	B-MED
therapy	I-MED
,	O
and	O
adherence	B-MED
to	O
all	O
SAB	B-MED
quality	B-MED
-	I-MED
of	I-MED
-	I-MED
care	I-MED
measures	B-MED
.	O
As	O
antimicrobial	B-MED
stewardship	I-MED
becomes	O
a	O
mandatory	B-MED
aspect	O
of	O
healthcare	B-MED
in	O
all	O
hospitals	B-MED
in	O
the	O
U.S.	B-MED
,	O
ASPs	B-MED
will	O
be	O
forced	B-MED
to	O
find	B-MED
ways	O
to	O
provide	O
more	O
efficient	B-MED
,	O
impactful	B-MED
,	O
disease	B-MED
state	O
-	O
based	O
patient	B-MED
care	I-MED
.	O
Our	O
study	B-MED
provides	O
the	O
framework	O
for	O
and	O
data	B-MED
to	O
support	O
this	O
intervention	B-MED
in	O
one	O
of	O
the	O
most	O
clinically	B-MED
important	I-MED
infectious	B-MED
diseases	I-MED
.	O
Expressing	B-MED
sexuality	B-MED
in	O
nursing	B-MED
homes	I-MED
.	O
The	O
experience	B-MED
of	O
older	B-MED
women	I-MED
:	O
A	O
qualitative	B-MED
study	I-MED
In	O
nursing	B-MED
homes	I-MED
,	O
a	O
number	O
of	O
barriers	B-MED
to	O
the	O
expression	B-MED
of	O
sexuality	B-MED
exist	B-MED
,	O
such	O
as	O
the	O
lack	B-MED
of	I-MED
privacy	I-MED
,	O
certain	O
attitudes	B-MED
on	O
behalf	O
of	O
the	O
staff	B-MED
and	O
the	O
family	B-MED
,	O
the	O
lack	O
of	O
a	O
sexual	B-MED
partner	I-MED
,	O
and	O
physical	B-MED
limitations	I-MED
.	O
The	O
aim	O
of	O
this	O
study	B-MED
was	O
to	O
describe	O
the	O
lived	B-MED
experience	I-MED
of	O
sexuality	B-MED
in	O
elderly	B-MED
Spanish	I-MED
women	I-MED
residing	O
in	O
nursing	B-MED
homes	I-MED
.	O
A	O
qualitative	B-MED
phenomenological	I-MED
approach	I-MED
was	O
followed	O
.	O
Data	B-MED
were	O
collected	B-MED
over	O
an	O
18-	O
month	B-MED
period	I-MED
between	O
2013	O
and	O
2015	O
.	O
Purposeful	O
sampling	B-MED
was	O
conducted	O
with	O
Spanish	B-MED
residents	I-MED
in	O
nursing	B-MED
homes	I-MED
in	O
Madrid	B-MED
.	O
Data	B-MED
were	O
collected	O
using	O
unstructured	B-MED
and	I-MED
semi	I-MED
-	I-MED
structured	I-MED
interviews	I-MED
.	O
The	O
data	B-MED
were	O
analyzed	B-MED
using	O
thematic	B-MED
analysis	I-MED
.	O
Twenty	O
female	B-MED
residents	B-MED
participated	O
.	O
Three	O
main	O
themes	B-MED
emerged	O
from	O
the	O
data	B-MED
:	O
a	O
)	O
expressing	B-MED
sexuality	B-MED
,	O
b	O
)	O
sexuality	B-MED
as	O
a	O
duty	B-MED
and	O
c	O
)	O
respecting	O
vows	B-MED
.	O
Female	B-MED
residents	B-MED
reported	O
key	O
elements	O
influencing	O
how	O
they	O
manage	B-MED
their	O
sexuality	B-MED
in	O
Nursing	B-MED
Homes	I-MED
.	O
These	O
results	O
serve	O
to	O
improve	O
our	O
understanding	O
regarding	O
the	O
expression	B-MED
of	O
sexuality	B-MED
in	O
older	B-MED
female	I-MED
nursing	B-MED
home	I-MED
residents	B-MED
.	O
Epigenetic	B-MED
Editing	I-MED
of	O
Ascl1	B-MED
Gene	I-MED
in	O
Neural	B-MED
Stem	I-MED
Cells	I-MED
by	O
Optogenetics	B-MED
Enzymes	B-MED
involved	O
in	O
epigenetic	B-MED
processes	I-MED
such	O
as	O
methyltransferases	B-MED
or	O
demethylases	B-MED
are	O
becoming	O
highly	B-MED
utilized	B-MED
for	O
their	O
persistent	B-MED
DNA	I-MED
or	O
histone	B-MED
modifying	I-MED
efficacy	B-MED
.	O
Herein	O
,	O
we	O
have	O
developed	O
an	O
optogenetic	B-MED
toolbox	B-MED
fused	O
to	O
the	O
catalytic	B-MED
domain	I-MED
(	O
CD	B-MED
)	O
of	O
DNA	B-MED
-	I-MED
methyltransferase3A	I-MED
(	O
DNMT3A	B-MED
-	O
CD	B-MED
)	O
or	O
Ten	B-MED
-	I-MED
Eleven	I-MED
Dioxygenase-1	I-MED
(	O
TET1	B-MED
-	O
CD	B-MED
)	O
for	O
loci	B-MED
-	O
specific	B-MED
alteration	B-MED
of	O
the	O
methylation	B-MED
state	B-MED
at	O
the	O
promoter	B-MED
of	O
Ascl1	B-MED
(	O
Mash1	B-MED
)	O
,	O
a	O
candidate	B-MED
proneuron	I-MED
gene	I-MED
.	O
Optogenetical	B-MED
protein	I-MED
pairs	I-MED
,	O
CRY2	B-MED
linked	O
to	O
DNMT3A	B-MED
-	O
CD	B-MED
or	O
TET1	B-MED
-	O
CD	B-MED
and	O
CIB1	B-MED
fused	B-MED
to	O
a	O
Transcription	B-MED
Activator	I-MED
-	I-MED
Like	I-MED
Element	I-MED
(	O
TALE	B-MED
)	O
locating	O
an	O
Ascl1	B-MED
promoter	B-MED
region	I-MED
,	O
were	O
designed	O
for	O
site	B-MED
specific	I-MED
epigenetic	B-MED
editing	I-MED
.	O
A	O
differentially	B-MED
methylated	B-MED
region	I-MED
at	O
the	O
Ascl1	B-MED
promoter	B-MED
,	O
isolated	B-MED
from	O
murine	B-MED
dorsal	B-MED
root	I-MED
ganglion	I-MED
(	O
hypermethylated	B-MED
)	O
and	O
striated	B-MED
cells	B-MED
(	O
hypomethylated	B-MED
)	O
,	O
was	O
targeted	B-MED
with	O
these	O
optogenetic	B-MED
-	I-MED
epigenetic	I-MED
constructs	I-MED
.	O
Optimized	O
blue	B-MED
-	I-MED
light	I-MED
illumination	B-MED
triggered	B-MED
the	O
co	B-MED
-	I-MED
localization	I-MED
of	O
TALE	B-MED
constructs	I-MED
with	O
DNMT3A	B-MED
-	O
CD	B-MED
or	O
TET1	B-MED
-	O
CD	B-MED
fusion	B-MED
proteins	I-MED
at	O
the	O
targeted	B-MED
site	I-MED
of	O
the	O
Ascl1	B-MED
promoter	B-MED
.	O
We	O
found	O
that	O
this	O
spatiotemporal	B-MED
association	O
of	O
the	O
fusion	B-MED
proteins	I-MED
selectively	O
alters	B-MED
the	O
methylation	B-MED
state	B-MED
and	O
also	O
regulates	B-MED
gene	B-MED
activity	I-MED
.	O
This	O
proof	O
of	O
concept	B-MED
developed	O
herein	O
holds	O
immense	B-MED
promise	B-MED
for	O
the	O
ability	O
to	O
regulate	B-MED
gene	B-MED
activity	I-MED
via	O
epigenetic	B-MED
modulation	I-MED
with	O
spatiotemporal	B-MED
precision	B-MED
.	O
Modulation	B-MED
of	O
IL-6	B-MED
induced	B-MED
RANKL	B-MED
expression	B-MED
in	O
arthritic	B-MED
synovium	B-MED
by	O
a	O
transcription	B-MED
factor	I-MED
SOX5	I-MED
Receptor	B-MED
activator	I-MED
of	I-MED
nuclear	I-MED
factor	I-MED
κB	I-MED
ligand	I-MED
(	O
RANKL	B-MED
)	O
is	O
critically	B-MED
involved	O
in	O
bone	B-MED
erosion	I-MED
of	O
rheumatoid	B-MED
arthritis	I-MED
(	O
RA	B-MED
)	O
.	O
We	O
previously	B-MED
reported	O
association	O
between	O
younger	B-MED
age	I-MED
at	O
onset	O
of	O
RA	B-MED
and	O
a	O
RANKL	B-MED
promoter	O
SNP	B-MED
that	O
conferred	O
an	O
elevated	B-MED
promoter	O
activity	O
via	O
binding	B-MED
to	O
a	O
transcription	B-MED
factor	I-MED
SOX5	I-MED
.	O
Here	O
we	O
study	B-MED
the	O
regulation	B-MED
of	O
SOX5	B-MED
levels	O
in	O
relation	O
to	O
RANKL	B-MED
expression	B-MED
in	O
RA	B-MED
synovial	B-MED
fibroblasts	B-MED
(	O
SF	B-MED
)	O
and	O
the	O
development	B-MED
of	O
bone	B-MED
erosion	I-MED
in	O
the	O
collagen	B-MED
-	I-MED
induced	I-MED
arthritis	I-MED
(	O
CIA	B-MED
)	O
mouse	B-MED
.	O
Our	O
data	B-MED
indicated	B-MED
SOX5	B-MED
levels	O
were	O
higher	O
in	O
synovium	B-MED
and	O
synovial	B-MED
fluid	I-MED
from	O
RA	B-MED
compared	B-MED
to	O
osteoarthritis	B-MED
patients	B-MED
.	O
Pro	B-MED
-	I-MED
inflammatory	I-MED
cytokines	B-MED
upregulated	B-MED
SOX5	B-MED
and	O
RANKL	B-MED
expression	B-MED
in	O
both	O
primary	O
RA	B-MED
SF	B-MED
and	O
the	O
rheumatoid	O
synovial	O
fibroblast	B-MED
cell	I-MED
line	I-MED
MH7A	B-MED
,	O
MH7A.	O
Overexpression	B-MED
of	O
SOX5	B-MED
resulted	B-MED
in	O
significantly	B-MED
increased	I-MED
RANKL	B-MED
levels	O
,	O
while	O
knockdown	B-MED
of	O
SOX5	B-MED
resulted	B-MED
in	O
diminished	B-MED
IL-6	B-MED
mediated	O
RANKL	B-MED
upregulation	B-MED
in	O
MH7A	B-MED
cells	I-MED
.	O
Chromatin	B-MED
immunoprecipitation	I-MED
(	O
ChIP	B-MED
)	O
showed	O
approximately	B-MED
3	O
-	O
fold	O
enrichment	O
of	O
RANKL	B-MED
-	I-MED
specific	I-MED
DNA	I-MED
in	O
anti	B-MED
-	I-MED
SOX5	I-MED
immunoprecipitate	I-MED
in	O
IL-6	B-MED
treated	B-MED
MH7A	B-MED
cells	I-MED
as	O
compared	B-MED
to	O
untreated	B-MED
cells	I-MED
.	O
Locally	O
silencing	B-MED
SOX5	B-MED
gene	I-MED
significantly	B-MED
diminished	I-MED
RANKL	B-MED
positive	B-MED
cells	B-MED
and	O
bone	B-MED
erosion	I-MED
in	O
CIA	B-MED
mice	B-MED
.	O
These	O
findings	B-MED
suggest	B-MED
SOX5	B-MED
is	O
an	O
important	O
regulator	B-MED
of	O
IL-6	B-MED
-	O
induced	B-MED
RANKL	B-MED
expression	B-MED
in	O
RA	B-MED
SF	B-MED
.	O
Transfemoral	B-MED
aortic	I-MED
valve	I-MED
implantation	I-MED
with	O
the	O
repositionable	B-MED
Lotus	I-MED
valve	I-MED
for	O
treatment	B-MED
of	O
patients	B-MED
with	O
symptomatic	B-MED
severe	B-MED
aortic	B-MED
stenosis	I-MED
:	O
results	B-MED
from	O
a	O
single	B-MED
-	I-MED
centre	I-MED
experience	I-MED
The	O
aim	O
of	O
the	O
study	B-MED
was	O
to	O
evaluate	B-MED
the	O
procedural	O
and	O
30-	O
day	B-MED
results	B-MED
for	O
the	O
repositionable	B-MED
Lotus	I-MED
valve	I-MED
in	O
patients	B-MED
undergoing	O
transfemoral	B-MED
aortic	I-MED
valve	I-MED
implantation	I-MED
in	O
a	O
single	B-MED
-	I-MED
centre	I-MED
experience	I-MED
.	O
We	O
prospectively	O
enrolled	O
110	O
patients	B-MED
with	O
severe	B-MED
symptomatic	B-MED
aortic	B-MED
stenosis	I-MED
(	O
NCT02162069	B-MED
)	O
.	O
All	O
procedures	B-MED
were	O
performed	O
without	O
general	B-MED
anaesthesia	I-MED
by	O
the	O
transfemoral	B-MED
approach	I-MED
.	O
Patients	B-MED
were	O
followed	O
for	O
30	O
days	B-MED
.	O
Patients	B-MED
received	B-MED
the	O
23	O
mm	O
(	O
n=20	O
)	O
,	O
25	O
mm	O
(	O
n=43	O
)	O
or	O
27	O
mm	O
(	O
n=47	O
)	O
Lotus	B-MED
device	I-MED
.	O
Mean	B-MED
oversizing	I-MED
in	O
relation	O
to	O
annulus	B-MED
or	O
left	B-MED
ventricular	I-MED
outflow	I-MED
tract	I-MED
(	O
LVOT	B-MED
)	O
did	O
not	O
differ	O
among	O
groups	B-MED
.	O
There	O
was	O
no	B-MED
residual	I-MED
moderate	B-MED
or	O
severe	B-MED
aortic	B-MED
regurgitation	I-MED
.	O
The	O
rate	B-MED
of	I-MED
mild	I-MED
aortic	I-MED
regurgitation	I-MED
aortic	B-MED
regurgitation	I-MED
was	O
low	O
at	O
9.1	O
%	O
.	O
There	O
was	O
no	O
valve	B-MED
embolisation	B-MED
,	O
no	O
need	O
for	O
a	O
second	B-MED
valve	B-MED
and	O
no	B-MED
conversion	I-MED
to	O
surgery	B-MED
.	O
The	O
need	O
for	O
a	O
new	O
pacemaker	B-MED
implantation	I-MED
due	O
to	O
complete	B-MED
(	O
third	B-MED
degree	I-MED
)	O
or	O
type	B-MED
II	I-MED
(	I-MED
Mobitz	I-MED
)	I-MED
second	I-MED
degree	I-MED
atrioventricular	I-MED
block	I-MED
was	O
24.1	O
%	O
,	O
excluding	O
patients	B-MED
with	O
previously	O
implanted	B-MED
devices	I-MED
.	O
Within	O
30	O
days	B-MED
the	O
rates	B-MED
of	O
all	B-MED
-	I-MED
cause	I-MED
mortalit	I-MED
y	O
and	O
stroke	B-MED
were	O
low	B-MED
.	O
In	O
patients	B-MED
with	O
severe	B-MED
aortic	B-MED
stenosis	I-MED
,	O
transfemoral	B-MED
TAVI	I-MED
with	O
the	O
repositionable	B-MED
Lotus	I-MED
valve	I-MED
was	O
associated	B-MED
with	I-MED
a	O
high	B-MED
rate	B-MED
of	O
device	B-MED
success	B-MED
,	O
no	O
moderate	B-MED
or	O
severe	B-MED
residual	B-MED
aortic	B-MED
regurgitation	I-MED
,	O
low	B-MED
rates	B-MED
of	O
major	B-MED
vascular	B-MED
complications	I-MED
and	O
mortality	B-MED
within	O
30	O
days	B-MED
.	O
Association	B-MED
between	O
XRCC1	B-MED
and	O
ERCC1	B-MED
single	B-MED
-	I-MED
nucleotide	I-MED
polymorphisms	I-MED
and	O
the	O
efficacy	B-MED
of	O
concurrent	B-MED
radiochemotherapy	I-MED
in	O
patients	B-MED
with	O
esophageal	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	B-MED
the	O
association	B-MED
between	O
single	B-MED
-	I-MED
nucleotide	I-MED
polymorphisms	I-MED
(	O
SNPs	B-MED
)	O
in	O
X	B-MED
-	I-MED
ray	I-MED
repair	I-MED
cross	I-MED
-	I-MED
complementing	I-MED
1	I-MED
-	I-MED
399	I-MED
(	O
XRCC1	B-MED
-	I-MED
399	I-MED
)	O
or	O
excision	B-MED
repair	I-MED
cross	I-MED
-	I-MED
complementation	I-MED
group	I-MED
1	I-MED
-	I-MED
118	I-MED
(	O
ERCC1	B-MED
-	I-MED
118	I-MED
)	O
and	O
the	O
short	B-MED
-	I-MED
term	I-MED
efficacy	B-MED
of	O
radiochemotherapy	B-MED
,	O
tumor	B-MED
metastasis	I-MED
and	O
relapse	B-MED
,	O
as	O
well	O
as	O
the	O
survival	B-MED
time	I-MED
in	O
patients	B-MED
with	O
esophageal	B-MED
squamous	I-MED
cell	I-MED
carcinoma	I-MED
(	O
ESCC	B-MED
)	O
.	O
TaqMan	B-MED
probe	I-MED
-	I-MED
based	I-MED
quantitative	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
(	O
qPCR	B-MED
)	O
was	O
conducted	O
to	O
examine	B-MED
the	O
levels	B-MED
of	O
XRCC1	B-MED
-	I-MED
399	I-MED
and	O
ERCC1	B-MED
-	I-MED
118	I-MED
SNPs	B-MED
in	O
the	O
peripheral	B-MED
blood	I-MED
of	O
50	O
patients	B-MED
with	O
pathologically	B-MED
confirmed	B-MED
ESCC	B-MED
.	O
In	O
addition	O
,	O
the	O
associations	B-MED
between	O
different	B-MED
genotypes	B-MED
and	O
short	B-MED
-	I-MED
term	I-MED
therapeutic	B-MED
efficacy	I-MED
[	O
the	O
complete	B-MED
remission	I-MED
(	O
CR	B-MED
)	O
rate	B-MED
]	O
,	O
tumor	B-MED
metastasis	I-MED
and	O
relapse	B-MED
,	O
as	O
well	O
as	O
the	O
survival	B-MED
time	I-MED
following	O
concurrent	B-MED
radiochemotherapy	I-MED
,	O
were	O
determined	B-MED
.	O
A	O
total	O
of	O
50	O
ESCC	B-MED
patients	B-MED
who	O
received	O
concurrent	B-MED
radiochemotherapy	I-MED
were	O
enrolled	O
.	O
It	O
was	O
found	O
that	O
the	O
short	B-MED
-	I-MED
term	I-MED
therapeutic	B-MED
efficacy	I-MED
(	O
CR	B-MED
rate	B-MED
)	O
was	O
higher	O
in	O
the	O
group	B-MED
of	O
patients	B-MED
carrying	O
the	O
homozygous	B-MED
mutation	I-MED
of	O
XRCC1	B-MED
-	I-MED
399	I-MED
(	O
A	B-MED
/	O
A	B-MED
genotype	B-MED
)	O
than	O
in	O
the	O
group	B-MED
of	O
patients	B-MED
without	O
the	O
XRCC1	B-MED
-	I-MED
399	I-MED
mutation	B-MED
(	O
G	B-MED
/	O
G	B-MED
genotype	B-MED
)	O
.	O
In	O
addition	O
,	O
the	O
CR	B-MED
rate	B-MED
was	O
significantly	B-MED
increased	I-MED
in	O
patients	B-MED
carrying	O
one	O
or	O
two	O
ERCC1	B-MED
-	I-MED
118	I-MED
C	O
alleles	B-MED
(	O
C	B-MED
/	O
C	B-MED
or	O
C	B-MED
/	O
T	B-MED
genotype	B-MED
)	O
compared	B-MED
with	O
patients	B-MED
lacking	O
the	O
C	B-MED
allele	B-MED
(	O
T	B-MED
/	O
T	B-MED
genotype	B-MED
)	O
.	O
The	O
differences	O
were	O
statistically	B-MED
significant	I-MED
(	O
A	B-MED
/	O
A	B-MED
vs.	O
G	B-MED
/	O
G	B-MED
,	O
P=0.014	O
;	O
T	B-MED
T	B-MED
vs.	O
C	B-MED
/	O
T	B-MED
+	O
C	B-MED
/	O
C	B-MED
,	O
P=0.040	O
)	O
.	O
During	O
the	O
follow	B-MED
-	I-MED
up	I-MED
period	I-MED
,	O
the	O
group	B-MED
of	O
patients	B-MED
carrying	O
the	O
homozygous	B-MED
mutation	I-MED
of	O
XRCC1	B-MED
-	I-MED
399	I-MED
(	O
A	B-MED
/	O
A	B-MED
genotype	B-MED
)	O
exhibited	O
a	O
markedly	B-MED
reduced	I-MED
risk	B-MED
of	O
metastasis	B-MED
and	O
relapse	B-MED
compared	B-MED
with	O
the	O
group	B-MED
of	O
patients	B-MED
carrying	O
non	O
-	O
mutated	O
XRCC1	B-MED
-	I-MED
399	I-MED
(	O
G	B-MED
/	O
G	B-MED
genotype	B-MED
;	O
P=0.031	O
)	O
.	O
By	O
contrast	O
,	O
ERCC1	B-MED
-	I-MED
118	I-MED
SNP	B-MED
was	O
not	O
associated	B-MED
with	I-MED
the	O
risk	B-MED
of	O
metastasis	B-MED
and	O
recurrence	B-MED
(	O
P>0.05	O
)	O
.	O
The	O
combined	O
results	O
of	O
univariate	B-MED
and	O
multivariate	B-MED
Cox	I-MED
regression	I-MED
analysis	I-MED
showed	O
that	O
the	O
SNP	B-MED
in	O
ERCC1	B-MED
-	I-MED
118	I-MED
was	O
closely	O
associated	B-MED
with	I-MED
survival	B-MED
time	I-MED
.	O
The	O
mean	B-MED
survival	I-MED
time	I-MED
was	O
significantly	B-MED
prolonged	B-MED
in	O
patients	B-MED
carrying	O
1	O
or	O
2	O
C	B-MED
alleles	B-MED
(	O
C	B-MED
/	O
C	B-MED
or	O
C	B-MED
/	O
T	B-MED
genotype	B-MED
)	O
compared	B-MED
with	O
patients	B-MED
lacking	O
the	O
C	B-MED
allele	B-MED
(	O
T	B-MED
/	O
T	B-MED
genotype	B-MED
)	O
[	O
T	B-MED
/	O
T	B-MED
vs.	O
C	B-MED
/	O
C	B-MED
,	O
HR	B-MED
=	O
12.96	O
,	O
95	O
%	O
confidence	B-MED
interval	I-MED
CI	B-MED
(	O
CI)=3.08	O
-	O
54.61	O
,	O
P<0.001	O
;	O
T	B-MED
T	B-MED
vs.	O
C	B-MED
/	O
T	B-MED
+	O
C	B-MED
/	O
C	B-MED
,	O
HR	B-MED
=	O
11.71	O
,	O
95	O
%	O
CI	B-MED
=	O
3.06	O
-	O
44.83	O
,	O
P<0.001	O
]	O
.	O
However	O
,	O
XRCC1	B-MED
-	I-MED
399	I-MED
SNP	B-MED
had	O
no	B-MED
effect	I-MED
on	O
survival	B-MED
time	I-MED
(	O
P>0.05	O
)	O
.	O
XRCCl-399	B-MED
SNP	B-MED
was	O
associated	B-MED
with	I-MED
the	O
short	B-MED
-	I-MED
term	I-MED
therapeutic	B-MED
efficacy	I-MED
(	O
the	O
CR	B-MED
rate	B-MED
)	O
and	O
tumor	B-MED
metastasis	I-MED
/	O
relapse	B-MED
in	O
ESCC	B-MED
patients	B-MED
who	O
received	O
the	O
docetaxel	B-MED
plus	I-MED
cisplatin	I-MED
(	I-MED
TP	I-MED
)	I-MED
regimen	I-MED
-based	O
concurrent	B-MED
radiochemotherapy	I-MED
.	O
By	O
contrast	O
,	O
ERCC1	B-MED
-	I-MED
118	I-MED
SNP	B-MED
was	O
significantly	B-MED
associated	B-MED
with	I-MED
the	O
short	B-MED
-	I-MED
term	I-MED
therapeutic	B-MED
efficacy	I-MED
(	O
the	O
CR	B-MED
rate	B-MED
)	O
and	O
survival	B-MED
time	I-MED
in	O
ESCC	B-MED
patients	B-MED
who	O
received	O
TP	B-MED
regimen	I-MED
-based	O
concurrent	B-MED
radiochemotherapy	I-MED
.	O
Eliminating	O
Cancer	B-MED
Stem	I-MED
Cells	I-MED
in	O
CML	B-MED
with	O
Combination	O
Transcriptional	B-MED
Therapy	B-MED
Leukemia	B-MED
stem	B-MED
cells	I-MED
(	O
LSCs	B-MED
)	O
are	O
resistant	O
to	O
current	O
therapies	B-MED
used	O
to	O
treat	O
chronic	B-MED
myeloid	I-MED
leukemia	I-MED
(	O
CML	B-MED
)	O
.	O
Abraham	O
et	O
al	O
.	O
(	O
2016	O
)	O
have	O
identified	O
a	O
molecular	B-MED
network	I-MED
critical	B-MED
for	O
CML	B-MED
LSC	B-MED
survival	B-MED
and	O
propose	O
that	O
simultaneously	O
targeting	O
two	O
of	O
their	O
major	O
transcriptional	B-MED
regulators	I-MED
,	O
p53	B-MED
and	O
c	B-MED
-	I-MED
Myc	I-MED
,	O
may	O
facilitate	O
their	O
eradication	B-MED
.	O
Family	B-MED
close	B-MED
but	O
friends	B-MED
closer	B-MED
:	O
exploring	O
social	B-MED
support	I-MED
and	O
resilience	B-MED
in	O
older	B-MED
spousal	B-MED
dementia	B-MED
carers	B-MED
Spousal	B-MED
dementia	B-MED
carers	B-MED
have	O
unique	O
support	B-MED
needs	B-MED
;	O
they	O
are	O
likely	O
to	O
disengage	B-MED
from	O
their	O
existing	B-MED
social	B-MED
networks	I-MED
as	O
they	O
need	O
to	O
devote	O
more	O
time	B-MED
to	O
caring	B-MED
as	O
the	O
disease	B-MED
progresses	I-MED
.	O
Previously	O
we	O
showed	O
that	O
support	B-MED
resources	B-MED
can	O
facilitate	O
resilience	B-MED
in	O
carers	B-MED
,	O
but	O
the	O
relationship	B-MED
is	O
complex	B-MED
and	O
varies	O
by	O
relationship	B-MED
type	I-MED
.	O
The	O
current	O
paper	O
aims	O
to	O
explore	O
social	B-MED
support	I-MED
as	O
a	O
key	O
component	O
of	O
resilience	B-MED
to	O
identify	O
the	O
availability	B-MED
,	O
function	B-MED
and	O
perceived	B-MED
functional	I-MED
aspects	I-MED
of	O
support	B-MED
provided	O
to	O
older	B-MED
spousal	B-MED
dementia	B-MED
carers	B-MED
.	O
We	O
conducted	O
23	O
in	B-MED
-	I-MED
depth	I-MED
qualitative	I-MED
interviews	I-MED
with	O
spousal	B-MED
carers	B-MED
from	O
two	O
carer	B-MED
support	B-MED
groups	I-MED
and	O
a	O
care	O
home	O
in	O
North	B-MED
West	I-MED
England	I-MED
.	O
Family	B-MED
and	O
friends	B-MED
served	O
a	O
wide	O
range	O
of	O
functions	B-MED
but	O
were	O
equally	O
available	O
to	O
resilient	B-MED
and	O
non	B-MED
-	I-MED
resilient	I-MED
participants	I-MED
.	O
Family	B-MED
support	I-MED
was	O
perceived	B-MED
as	O
unhelpful	O
if	O
it	O
created	B-MED
feelings	B-MED
of	O
over	B-MED
-	I-MED
dependence	I-MED
.	O
Participants	B-MED
were	O
less	O
likely	O
to	O
resist	B-MED
involvement	I-MED
of	O
grandchildren	B-MED
due	O
to	O
their	O
relatively	O
narrow	B-MED
and	I-MED
low	I-MED
-	I-MED
level	I-MED
support	I-MED
functions	I-MED
.	O
Friend	B-MED
support	B-MED
was	O
perceived	B-MED
as	O
most	O
helpful	B-MED
when	O
it	O
derived	O
from	O
those	O
in	O
similar	O
circumstances	B-MED
.	O
Neighbours	B-MED
played	O
a	O
functionally	O
unique	O
role	O
of	O
crisis	B-MED
management	I-MED
.	O
These	O
perceptions	B-MED
may	O
moderate	B-MED
the	O
effect	B-MED
of	O
support	B-MED
on	O
resilience	B-MED
.	O
Family	B-MED
and	O
friend	B-MED
support	B-MED
is	O
not	O
always	O
sufficient	B-MED
to	O
facilitate	O
resilience	B-MED
.	O
Support	B-MED
functions	I-MED
facilitate	O
resilience	B-MED
only	O
if	O
they	O
are	O
perceived	B-MED
to	O
match	O
need	B-MED
.	O
Implications	B-MED
of	O
these	O
findings	B-MED
are	O
discussed	O
.	O
Pupillary	B-MED
response	I-MED
abnormalities	B-MED
in	O
depressive	B-MED
disorders	I-MED
Depressive	B-MED
disorders	I-MED
lack	B-MED
objective	B-MED
physiological	B-MED
measurements	B-MED
to	O
characterize	B-MED
the	O
affected	B-MED
population	I-MED
and	O
facilitate	O
study	B-MED
of	O
relevant	B-MED
mechanisms	B-MED
.	O
The	O
melanopsin	B-MED
-	O
mediated	B-MED
light	B-MED
signaling	I-MED
pathway	I-MED
may	O
contribute	O
to	O
seasonal	B-MED
variation	I-MED
and	O
can	O
be	O
measured	B-MED
non	O
-	O
invasively	O
by	O
pupillometry	B-MED
.	O
We	O
prospectively	B-MED
studied	I-MED
changes	O
in	O
melanopsin	B-MED
-	O
mediated	B-MED
pupillary	B-MED
constriction	I-MED
in	O
19	O
participants	B-MED
with	O
major	B-MED
depressive	I-MED
disorder	I-MED
(	O
MDD	B-MED
)	O
and	O
10	O
control	B-MED
across	O
the	O
summer	B-MED
and	I-MED
winter	I-MED
solstices	I-MED
.	O
The	O
melanopsin	B-MED
-	O
mediated	B-MED
response	I-MED
,	O
as	O
measured	B-MED
by	O
the	O
pupil	B-MED
's	I-MED
sustained	I-MED
constriction	I-MED
six	O
s	O
after	O
a	O
high	B-MED
intensity	I-MED
blue	B-MED
light	I-MED
stimulus	B-MED
,	O
was	O
marginally	O
attenuated	B-MED
in	O
those	O
with	O
MDD	B-MED
relative	O
to	O
controls	B-MED
(	O
p	B-MED
=	O
0.071	O
)	O
.	O
The	O
participants	B-MED
with	O
MDD	B-MED
unexpectedly	O
showed	O
a	O
significantly	B-MED
reduced	B-MED
transient	B-MED
pupillary	B-MED
response	I-MED
to	O
low	B-MED
intensity	I-MED
red	B-MED
(	O
p	B-MED
=	O
0.011	O
)	O
and	O
blue	B-MED
light	I-MED
(	O
p	B-MED
=	O
0.013	O
)	O
,	O
but	O
not	O
high	B-MED
intensity	I-MED
red	B-MED
and	O
blue	B-MED
light	I-MED
.	O
Sustained	O
pupillary	B-MED
constriction	I-MED
in	O
response	B-MED
to	O
high	B-MED
intensity	I-MED
blue	B-MED
light	I-MED
was	O
more	O
pronounced	O
with	O
increasing	B-MED
daylight	B-MED
hours	B-MED
(	O
p	B-MED
=	O
0.037	O
)	O
and	O
was	O
more	O
strongly	O
related	O
to	O
objectively	B-MED
measured	B-MED
versus	O
estimated	B-MED
light	B-MED
exposure	I-MED
.	O
Melanopsin	B-MED
-	O
mediated	B-MED
impairments	B-MED
in	O
pupil	B-MED
response	I-MED
may	O
serve	O
as	O
a	O
biological	B-MED
marker	I-MED
for	O
vulnerability	B-MED
to	O
depression	B-MED
in	O
low	B-MED
light	I-MED
conditions	B-MED
.	O
Assessment	B-MED
of	O
these	O
and	O
other	O
responses	B-MED
to	O
light	B-MED
stimuli	B-MED
,	O
such	O
as	O
response	B-MED
to	O
low	B-MED
intensity	I-MED
light	I-MED
,	O
may	O
be	O
useful	O
for	O
the	O
study	B-MED
of	O
the	O
neurobiology	B-MED
of	O
MDD	B-MED
and	O
related	O
mood	B-MED
disorders	I-MED
.	O
Prostate	B-MED
-	I-MED
specific	I-MED
antigen	I-MED
increase	B-MED
during	O
dutasteride	B-MED
to	O
indicate	O
the	O
need	O
for	O
prostate	B-MED
biopsy	I-MED
:	O
influence	O
of	O
prostatic	B-MED
inflammation	I-MED
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	B-MED
the	O
significance	O
of	O
an	O
increase	B-MED
in	O
total	B-MED
prostate	I-MED
-	I-MED
specific	I-MED
antigen	I-MED
(	I-MED
PSA	I-MED
)	I-MED
serum	I-MED
levels	I-MED
despite	O
dutasteride	B-MED
treatment	B-MED
as	O
a	O
predictor	B-MED
of	O
prostate	B-MED
cancer	I-MED
(	O
PC	B-MED
)	O
at	O
biopsy	B-MED
.	O
We	O
focused	O
our	O
attention	O
on	O
the	O
rate	B-MED
of	O
the	O
first	O
PSA	B-MED
PSA	B-MED
increase	B-MED
and	O
on	O
the	O
influence	O
of	O
prostatic	B-MED
inflammation	I-MED
.	O
From	O
2011	O
to	O
2016	O
,	O
365	O
men	B-MED
with	O
a	O
previous	O
negative	O
prostate	B-MED
biopsy	I-MED
and	O
persistent	O
elevated	B-MED
PSA	B-MED
PSA	B-MED
levels	I-MED
received	O
dutasteride	B-MED
treatment	B-MED
.	O
The	O
population	B-MED
was	O
followed	O
for	O
a	O
range	O
of	O
12	O
-	O
48	O
months	O
.	O
One	O
hundred	O
twelve	O
cases	O
with	O
a	O
confirmed	O
PSA	B-MED
increase	B-MED
>	O
0.5	O
ng	O
/	O
ml	O
over	O
the	O
nadir	O
value	O
during	O
the	O
follow	B-MED
-	I-MED
up	I-MED
were	O
included	O
in	O
Group	O
A	O
and	O
underwent	O
a	O
new	O
prostate	B-MED
biopsy	I-MED
.	O
In	O
Group	O
A	O
,	O
the	O
PSA	B-MED
increase	B-MED
was	O
associated	B-MED
with	I-MED
PC	B-MED
at	O
the	O
re	B-MED
-	I-MED
biopsy	I-MED
in	O
66	O
%	O
of	O
cases	O
.	O
The	O
percentage	O
of	O
PSA	B-MED
reduction	I-MED
after	O
6	O
months	O
of	O
treatment	B-MED
was	O
not	O
a	O
significant	O
indicator	B-MED
of	O
the	O
risk	O
for	O
PC	B-MED
.	O
The	O
distribution	O
of	O
inflammatory	B-MED
infiltrates	I-MED
significantly	O
(	O
p<00.01	O
)	O
varied	O
from	O
positive	O
to	O
negative	O
prostate	B-MED
biopsies	I-MED
.	O
The	O
relative	O
risk	O
for	O
PC	B-MED
at	O
biopsy	B-MED
significantly	O
increase	B-MED
d	O
according	O
to	O
PSA	B-MED
PSA	B-MED
level	I-MED
during	O
dutasteride	B-MED
.	O
Treatment	B-MED
with	O
dutasteride	B-MED
can	O
help	O
to	O
analyze	B-MED
PSA	B-MED
kinetic	B-MED
.	O
A	O
persistent	O
prostatic	B-MED
inflammation	I-MED
is	O
a	O
factor	O
able	O
to	O
reduce	O
the	O
performance	O
of	O
PSA	B-MED
kinetic	B-MED
during	O
dutasteride	B-MED
treatment	B-MED
.	O
Polymorphisms	B-MED
in	O
Inflammatory	B-MED
Mediator	B-MED
Genes	I-MED
and	O
Risk	B-MED
of	O
Preeclampsia	B-MED
in	O
Taiyuan	B-MED
,	O
China	B-MED
Excessive	B-MED
maternal	B-MED
inflammatory	B-MED
response	I-MED
is	O
involved	O
in	O
the	O
pathogenesis	B-MED
of	O
preeclampsia	B-MED
.	O
Few	O
epidemiologic	B-MED
studies	I-MED
have	O
investigated	B-MED
the	O
associations	B-MED
between	O
genetic	B-MED
variations	I-MED
in	O
the	O
inflammatory	B-MED
mediator	B-MED
genes	I-MED
and	O
preeclampsia	B-MED
risk	B-MED
,	O
and	O
these	O
studies	B-MED
have	O
reached	O
inconsistent	O
results	O
.	O
We	O
examined	O
31	O
single	B-MED
-	I-MED
nucleotide	I-MED
polymorphisms	I-MED
in	O
IL-1A	B-MED
,	O
IL-1B	B-MED
,	O
IL-1R1	B-MED
,	O
IL-2RA	B-MED
,	O
IL-5RA	B-MED
,	O
IL-6	B-MED
,	O
IL-6R	B-MED
,	O
TNFSF11	B-MED
,	O
TNFRSF11A	B-MED
,	O
IL-28RA	B-MED
,	O
IRAK4	B-MED
,	O
and	O
KIT	B-MED
genes	I-MED
and	O
the	O
risk	B-MED
of	O
preeclampsia	B-MED
and	O
its	O
clinical	B-MED
subtypes	B-MED
in	O
a	O
nested	B-MED
case	I-MED
-	I-MED
control	I-MED
study	I-MED
including	O
203	O
preeclampsia	B-MED
cases	B-MED
and	O
233	O
controls	B-MED
.	O
We	O
found	O
that	O
IL-1R1	B-MED
,	O
IL-5RA	B-MED
,	O
IL-6R	B-MED
,	O
and	O
TNFSF11	B-MED
were	O
associated	B-MED
with	I-MED
the	O
risk	B-MED
of	O
preeclampsia	B-MED
.	O
Although	O
the	O
significant	B-MED
associations	B-MED
observed	O
for	O
preeclampsia	B-MED
overall	B-MED
were	O
mainly	O
seen	O
for	O
late	B-MED
-	I-MED
onset	I-MED
preeclampsia	B-MED
and	O
severe	B-MED
preeclampsia	B-MED
,	O
IL-6R	B-MED
(	O
rs2229238	B-MED
)	O
and	O
TNFSF11	B-MED
(	O
rs9525643	B-MED
)	O
polymorphisms	B-MED
were	O
associated	B-MED
with	I-MED
the	O
risk	B-MED
of	O
early	O
-	O
onset	O
preeclampsia	B-MED
.	O
TNFSF11	B-MED
(	O
rs2200287	B-MED
and	O
rs2148072	B-MED
)	O
polymorphisms	B-MED
were	O
associated	B-MED
with	I-MED
risk	B-MED
of	O
mild	O
preeclampsia	B-MED
.	O
Our	O
study	B-MED
provided	O
the	O
first	O
evidence	B-MED
that	O
genetic	B-MED
variations	I-MED
in	O
inflammatory	B-MED
mediator	B-MED
genes	I-MED
IL-1R1	B-MED
,	O
IL-6R	B-MED
,	O
TNFSF11	B-MED
,	O
and	O
IL-5RA	B-MED
were	O
associated	B-MED
with	I-MED
preeclampsia	B-MED
risk	B-MED
,	O
and	O
the	O
risk	B-MED
varied	O
by	O
preeclampsia	B-MED
subtypes	B-MED
.	O
The	O
effects	B-MED
of	I-MED
gestational	B-MED
use	B-MED
of	I-MED
antidepressants	B-MED
and	O
antipsychotics	B-MED
on	O
neonatal	B-MED
outcomes	B-MED
for	O
women	B-MED
with	O
severe	B-MED
mental	B-MED
illness	I-MED
Psychotropic	B-MED
medication	I-MED
use	B-MED
occurs	B-MED
in	O
8	O
%	O
of	O
pregnancies	B-MED
,	O
with	O
rates	B-MED
increasing	B-MED
,	O
and	O
often	B-MED
multiple	B-MED
medications	B-MED
prescribed	B-MED
.	O
This	O
study	B-MED
aims	O
to	O
determine	O
if	O
the	O
use	B-MED
of	I-MED
psychotropic	B-MED
medication	I-MED
,	O
in	O
a	O
cohort	B-MED
of	O
women	B-MED
with	O
severe	B-MED
mental	B-MED
illness	I-MED
,	O
increases	B-MED
rates	B-MED
of	O
special	B-MED
care	I-MED
nursery	I-MED
admission	B-MED
and	O
reports	B-MED
differences	B-MED
between	O
antidepressant	B-MED
and	O
antipsychotic	B-MED
medication	I-MED
use	B-MED
either	O
alone	B-MED
or	O
in	O
combination	B-MED
.	O
A	O
retrospective	B-MED
database	I-MED
analysis	I-MED
from	I-MED
a	I-MED
cohort	I-MED
with	O
severe	B-MED
mental	B-MED
illness	I-MED
in	O
pregnancy	B-MED
identified	B-MED
268	O
pregnant	B-MED
women	I-MED
who	O
were	O
grouped	B-MED
according	O
to	O
medication	B-MED
type	B-MED
.	O
Demographic	B-MED
,	O
obstetric	B-MED
and	O
neonatal	B-MED
variables	B-MED
were	O
analysed	B-MED
using	B-MED
t	B-MED
-	I-MED
tests	I-MED
,	O
χ(2	O
)	O
,	O
analysis	B-MED
of	O
variance	B-MED
and	O
logistic	B-MED
regression	I-MED
analysis	I-MED
for	O
special	B-MED
care	I-MED
nursery	I-MED
admission	B-MED
.	O
The	O
medication	B-MED
groups	I-MED
consisted	O
of	O
:	O
women	B-MED
taking	B-MED
no	I-MED
psychotropic	I-MED
medications	I-MED
(	O
n	O
=	O
67	O
)	O
;	O
those	B-MED
taking	I-MED
antipsychotics	I-MED
(	O
n	O
=	O
87	O
)	O
;	O
those	B-MED
taking	I-MED
antidepressants	I-MED
(	O
n	O
=	O
55	O
)	O
;	O
those	B-MED
taking	I-MED
and	I-MED
a	I-MED
combination	I-MED
of	I-MED
antidepressants	I-MED
/	I-MED
antipsychotics	I-MED
(	O
n	O
=	O
59	O
)	O
.	O
Rates	B-MED
of	O
special	B-MED
care	I-MED
nursery	I-MED
admission	B-MED
in	O
women	B-MED
who	O
took	O
psychotropic	B-MED
medication	I-MED
(	O
41.3	O
%	O
)	O
were	O
elevated	O
compared	B-MED
to	O
those	B-MED
who	I-MED
did	I-MED
not	I-MED
(	O
26.9	O
%	O
)	O
(	O
P	O
=	O
0.035	O
)	O
,	O
and	O
were	O
significantly	B-MED
raised	B-MED
when	O
compared	B-MED
to	O
the	O
general	B-MED
population	I-MED
(	O
P	O
<	O
0.000	O
)	O
.	O
No	B-MED
significant	I-MED
difference	I-MED
occurred	O
between	O
the	O
medication	B-MED
groups	I-MED
.	O
A	O
significant	B-MED
adjusted	O
odds	B-MED
ratio	I-MED
of	O
2.79	O
(	O
95	O
%	O
CI	O
1.286	O
-	O
6.049	O
)	O
was	O
found	B-MED
for	O
special	B-MED
care	I-MED
nursery	I-MED
and	O
psychiatric	B-MED
admission	I-MED
during	B-MED
pregnancy	B-MED
but	O
not	O
for	O
psychotropic	B-MED
medication	I-MED
.	O
Rates	B-MED
of	O
special	B-MED
care	I-MED
nursery	I-MED
admission	B-MED
are	O
elevated	O
in	O
neonates	B-MED
of	O
women	B-MED
with	O
severe	B-MED
mental	B-MED
illness	I-MED
taking	O
psychotropic	B-MED
medication	I-MED
,	O
but	O
were	O
not	O
different	O
for	O
monotherapy	B-MED
or	O
polytherapy	B-MED
when	O
prescribing	B-MED
antidepressants	B-MED
or	O
antipsychotic	B-MED
medication	I-MED
.	O
Additional	O
vulnerability	B-MED
occurs	B-MED
in	O
the	O
neonates	B-MED
of	O
women	B-MED
with	O
a	O
mental	B-MED
illness	I-MED
and	O
paediatric	B-MED
presence	O
at	O
delivery	B-MED
is	O
recommended	B-MED
.	O
A	O
Randomized	B-MED
,	O
Head	B-MED
-	I-MED
to	I-MED
-	I-MED
Head	I-MED
Study	B-MED
of	O
Virtual	B-MED
Reality	I-MED
Exposure	I-MED
Therapy	I-MED
for	O
Posttraumatic	B-MED
Stress	I-MED
Disorder	I-MED
Virtual	B-MED
reality	I-MED
exposure	I-MED
therapy	I-MED
(	O
VRET	B-MED
)	O
is	O
one	O
of	O
the	O
few	O
interventions	B-MED
supported	B-MED
by	O
randomized	B-MED
controlled	I-MED
trials	I-MED
for	O
the	O
treatment	B-MED
of	O
combat	B-MED
-	I-MED
related	I-MED
posttraumatic	I-MED
stress	I-MED
disorder	I-MED
(	O
PTSD	B-MED
)	O
in	O
active	B-MED
duty	I-MED
service	I-MED
members	B-MED
.	O
A	O
comparative	B-MED
effectiveness	I-MED
study	I-MED
was	O
conducted	O
to	O
determine	O
if	O
virtual	B-MED
reality	I-MED
technology	B-MED
itself	O
improved	B-MED
outcomes	B-MED
,	O
or	O
if	O
similar	B-MED
results	B-MED
could	O
be	O
achieved	B-MED
with	O
a	O
control	B-MED
exposure	I-MED
therapy	I-MED
(	O
CET	B-MED
)	O
condition	B-MED
.	O
Service	B-MED
members	B-MED
with	O
combat	B-MED
-	I-MED
related	I-MED
PTSD	I-MED
were	O
randomly	B-MED
selected	B-MED
to	O
receive	B-MED
nine	O
weeks	B-MED
of	O
VRET	B-MED
or	O
CET	B-MED
.	O
Assessors	B-MED
,	O
but	O
not	O
therapists	B-MED
,	O
were	O
blinded	B-MED
.	O
PTSD	B-MED
symptom	B-MED
improvement	B-MED
was	O
assessed	B-MED
one	O
week	B-MED
and	O
3	O
months	B-MED
after	O
the	O
conclusion	B-MED
of	O
treatment	B-MED
using	O
the	O
clinician	B-MED
-	I-MED
administered	I-MED
PTSD	I-MED
scale	I-MED
(	O
CAPS	B-MED
)	O
.	O
A	O
small	B-MED
crossover	O
component	O
was	O
included	B-MED
.	O
Results	B-MED
demonstrated	O
that	O
PTSD	B-MED
symptoms	B-MED
improved	B-MED
with	O
both	O
treatments	B-MED
,	O
but	O
there	O
were	O
no	O
statistically	B-MED
significant	I-MED
differences	B-MED
between	O
groups	B-MED
.	O
Dropout	B-MED
rates	B-MED
were	O
higher	B-MED
in	O
VRET	B-MED
.	O
Of	O
those	O
who	O
received	B-MED
VRET	B-MED
,	O
13/42	O
(	O
31	O
%	O
)	O
showed	O
>	O
30	O
%	O
improvement	B-MED
on	O
the	O
CAPS	B-MED
,	O
versus	O
16/43	O
(	O
37	O
%	O
)	O
who	O
received	B-MED
CET	B-MED
.	O
Three	O
months	B-MED
after	O
treatment	B-MED
,	O
>	O
30	O
%	O
improvement	B-MED
was	O
seen	O
in	O
10/33	O
(	O
30	O
%	O
)	O
of	O
VRET	B-MED
participants	B-MED
and	O
12/33	O
(	O
36	O
%	O
)	O
in	O
CET	B-MED
.	O
Participants	B-MED
who	O
crossed	B-MED
over	I-MED
(	O
n	O
=	O
11	O
)	O
showed	O
no	O
statistically	B-MED
significant	I-MED
improvements	B-MED
in	O
a	O
second	B-MED
round	O
of	O
treatment	B-MED
,	O
regardless	B-MED
of	O
condition	B-MED
.	O
This	O
study	B-MED
supported	B-MED
the	O
utility	B-MED
of	O
exposure	B-MED
therapy	I-MED
for	O
PTSD	B-MED
,	O
but	O
did	O
not	O
support	B-MED
additional	B-MED
benefit	B-MED
by	O
the	O
inclusion	B-MED
of	O
virtual	B-MED
reality	I-MED
.	O
Identifying	O
the	O
presence	B-MED
of	O
Parkinson	B-MED
's	I-MED
disease	I-MED
using	O
low	B-MED
-	I-MED
frequency	I-MED
fluctuations	B-MED
in	O
BOLD	B-MED
signals	I-MED
Parkinson	B-MED
's	I-MED
disease	I-MED
(	O
PD	B-MED
)	O
is	O
a	O
chronic	B-MED
,	O
progressive	B-MED
,	O
and	O
degenerative	B-MED
neurological	B-MED
disorder	I-MED
that	O
is	O
characterized	B-MED
by	O
the	O
degeneration	B-MED
of	O
dopamine	B-MED
neurons	I-MED
in	O
the	O
substantia	B-MED
nigra	I-MED
and	O
the	O
formation	B-MED
of	O
intracellular	B-MED
Lewy	B-MED
inclusion	I-MED
bodies	I-MED
.	O
Resting	B-MED
-	I-MED
state	I-MED
functional	I-MED
magnetic	I-MED
resonance	I-MED
imaging	I-MED
(	O
RS	B-MED
-	I-MED
fMRI	I-MED
)	O
has	O
demonstrated	O
evidence	B-MED
of	O
changes	O
in	O
metabolic	B-MED
patterns	B-MED
in	O
individuals	B-MED
with	O
PD	B-MED
.	O
The	O
purpose	B-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	O
whether	O
the	O
presence	B-MED
of	O
PD	B-MED
could	O
be	O
"	O
predicted	B-MED
"	O
based	O
on	O
resting	O
fluctuations	B-MED
in	O
the	O
blood	B-MED
oxygenation	I-MED
level	I-MED
dependent	I-MED
signal	I-MED
.	O
We	O
utilized	O
RS	B-MED
-	I-MED
fMRI	I-MED
to	O
measure	O
the	O
amplitude	B-MED
of	O
low	B-MED
-	I-MED
frequency	I-MED
fluctuation	B-MED
(	O
ALFF	B-MED
)	O
and	O
the	O
fractional	O
ALFF	B-MED
(	O
fALFF	B-MED
)	O
in	O
51	O
patients	B-MED
with	O
PD	B-MED
and	O
50	O
age	B-MED
-	O
and	O
sex	B-MED
-matched	O
healthy	B-MED
controls	I-MED
.	O
Compared	O
with	O
the	O
healthy	B-MED
controls	I-MED
,	O
the	O
individuals	B-MED
with	O
PD	B-MED
exhibited	O
altered	O
ALFFs	B-MED
in	O
the	O
bilateral	B-MED
lingual	B-MED
gyrus	I-MED
and	O
left	B-MED
putamen	I-MED
and	O
an	O
altered	O
fALFF	B-MED
in	O
the	O
right	B-MED
cerebellum	I-MED
posterior	I-MED
lobe	I-MED
.	O
Support	B-MED
vector	I-MED
machines	I-MED
(	O
SVMs	B-MED
)	O
,	O
which	O
comprise	O
a	O
supervised	O
pattern	B-MED
recognition	I-MED
method	B-MED
that	O
enables	O
predictions	B-MED
at	O
the	O
individual	B-MED
level	B-MED
,	O
were	O
trained	O
to	O
separate	O
individuals	B-MED
with	O
PD	B-MED
from	O
healthy	B-MED
controls	I-MED
based	O
on	O
the	O
ALFF	B-MED
and	O
fALFF	B-MED
.	O
Using	O
the	O
leave	O
-	O
one	O
-	O
out	O
cross	B-MED
-	I-MED
validation	I-MED
method	I-MED
to	O
analyze	B-MED
our	O
sample	B-MED
,	O
we	O
reliably	O
distinguished	O
the	O
participants	B-MED
with	O
PD	B-MED
from	O
the	O
controls	B-MED
with	O
92	O
%	O
sensitivity	B-MED
and	O
87	O
%	O
specificity	B-MED
.	O
Overall	O
,	O
these	O
findings	B-MED
suggest	O
that	O
the	O
SVM	B-MED
-	O
neuroimaging	B-MED
approach	O
may	O
be	O
of	O
particular	O
clinical	B-MED
value	O
because	O
it	O
enables	O
the	O
accurate	O
identification	O
of	O
PD	B-MED
at	O
the	O
individual	B-MED
level	B-MED
.	O
RS	B-MED
-	I-MED
fMRI	I-MED
should	O
be	O
considered	O
for	O
development	B-MED
as	O
a	O
biomarker	B-MED
and	O
an	O
analytical	O
tool	O
for	O
the	O
evaluation	B-MED
of	O
PD	B-MED
.	O
Common	B-MED
Laboratory	B-MED
Parameters	B-MED
for	O
Differentiating	B-MED
Between	O
Community	B-MED
-	I-MED
Acquired	I-MED
and	O
Healthcare	B-MED
-	I-MED
Associated	I-MED
Pneumonia	I-MED
The	O
correct	B-MED
diagnosis	B-MED
of	O
healthcare	B-MED
-	I-MED
associated	I-MED
pneumonia	I-MED
(	O
HCAP	B-MED
)	O
as	O
opposed	O
to	O
community	B-MED
-	I-MED
acquired	I-MED
pneumonia	I-MED
is	O
essential	B-MED
for	O
the	O
selection	B-MED
of	O
a	O
correct	B-MED
empirical	B-MED
antimicrobial	B-MED
approach	O
,	O
reserving	O
the	O
broad	B-MED
-	I-MED
spectrum	I-MED
or	O
highly	B-MED
potent	I-MED
antimicrobial	B-MED
therapies	I-MED
for	O
resistant	B-MED
strains	B-MED
most	O
commonly	O
present	O
in	O
HCAP	B-MED
,	O
whereas	O
treating	B-MED
the	O
less	O
resistant	B-MED
strains	B-MED
,	O
most	O
commonly	O
associated	B-MED
with	I-MED
community	B-MED
and	O
long	B-MED
-	I-MED
term	I-MED
care	I-MED
facility	I-MED
-	O
acquired	B-MED
infections	I-MED
,	O
with	O
a	O
more	O
targeted	B-MED
empirical	B-MED
approach	I-MED
.	O
The	O
standard	B-MED
approach	I-MED
today	B-MED
is	O
to	O
differentiate	B-MED
between	O
the	O
two	O
based	O
on	O
the	O
medical	B-MED
history	I-MED
of	O
the	O
past	B-MED
90	O
days	B-MED
prior	O
to	O
admission	B-MED
.	O
Measurable	B-MED
,	O
quantitative	B-MED
assessment	B-MED
may	O
be	O
able	O
to	O
assist	B-MED
in	O
this	O
decision	B-MED
.	O
The	O
objective	O
of	O
this	O
study	O
is	O
to	O
find	O
a	O
measurable	B-MED
method	B-MED
of	O
differentiating	B-MED
between	O
community	B-MED
-	I-MED
acquired	I-MED
and	O
healthcare	B-MED
-	I-MED
associated	I-MED
pneumonias	I-MED
.	O
The	O
records	B-MED
of	O
126	O
patients	B-MED
admitted	B-MED
with	O
a	O
diagnosis	B-MED
of	O
pneumonia	B-MED
were	O
divided	O
into	O
two	O
groups	B-MED
based	O
on	O
the	O
probable	O
cause	B-MED
of	I-MED
their	I-MED
disease	I-MED
,	O
in	O
accordance	O
with	O
common	B-MED
practice	I-MED
.	O
The	O
routine	B-MED
laboratory	B-MED
work	I-MED
taken	O
upon	O
admittance	B-MED
was	O
analyzed	B-MED
using	O
logistical	B-MED
regression	I-MED
and	O
Student	B-MED
's	I-MED
t	I-MED
-	I-MED
test	I-MED
.	O
We	O
have	O
found	O
that	O
the	O
red	B-MED
blood	I-MED
cell	I-MED
distribution	I-MED
width	I-MED
and	O
the	O
neutrophil	B-MED
neutrophil	B-MED
-to-	I-MED
lymphocyte	I-MED
ratio	I-MED
lymphocyte	B-MED
,	O
both	O
routine	B-MED
parameters	I-MED
obtained	O
in	O
a	O
simple	O
blood	B-MED
count	I-MED
,	O
can	O
each	O
assist	B-MED
in	O
differentiating	B-MED
between	O
community	B-MED
-	I-MED
acquired	I-MED
and	O
healthcare	B-MED
-	I-MED
associated	I-MED
pneumonias	I-MED
.	O
We	O
have	O
found	O
two	O
statistically	B-MED
significant	I-MED
parameters	I-MED
that	O
may	O
be	O
used	O
as	O
adjuncts	O
to	O
the	O
medical	B-MED
history	I-MED
,	O
chest	B-MED
radiography	I-MED
and	O
other	B-MED
parameters	I-MED
in	O
forming	O
an	O
immediate	B-MED
clinical	B-MED
impression	I-MED
of	O
a	O
patient	B-MED
presenting	O
with	O
pneumonia	B-MED
.	O
Long	B-MED
Noncoding	I-MED
RNAs	I-MED
in	O
Cardiovascular	B-MED
Pathology	I-MED
,	O
Diagnosis	B-MED
,	O
and	O
Therapy	B-MED
Vast	O
parts	O
of	O
mammalian	B-MED
genomes	B-MED
encode	B-MED
for	O
transcripts	B-MED
that	O
are	O
not	O
further	O
translated	B-MED
into	I-MED
proteins	I-MED
.	O
The	O
purpose	B-MED
of	O
the	O
majority	B-MED
of	O
such	O
noncoding	B-MED
ribonucleic	I-MED
acids	I-MED
(	B-MED
RNAs	I-MED
)	I-MED
remained	O
paradoxical	B-MED
for	O
a	O
long	O
time	O
.	O
However	O
,	O
a	O
growing	B-MED
body	O
of	O
evidence	B-MED
demonstrates	B-MED
that	O
long	B-MED
noncoding	I-MED
RNAs	I-MED
are	O
dynamically	B-MED
expressed	B-MED
in	O
different	B-MED
cell	B-MED
types	I-MED
,	O
diseases	B-MED
,	O
or	O
developmental	B-MED
stages	I-MED
to	O
execute	B-MED
a	O
wide	B-MED
variety	I-MED
of	O
regulatory	B-MED
roles	I-MED
at	O
virtually	B-MED
every	O
step	B-MED
of	O
gene	B-MED
expression	I-MED
and	O
translation	B-MED
.	O
Indeed	O
,	O
long	B-MED
noncoding	I-MED
RNAs	I-MED
influence	B-MED
gene	B-MED
expression	I-MED
via	O
epigenetic	B-MED
modulations	I-MED
,	O
through	O
regulating	B-MED
alternative	B-MED
splicing	I-MED
,	O
or	O
by	O
acting	O
as	O
molecular	B-MED
sponges	I-MED
.	O
The	O
abundance	B-MED
of	O
long	B-MED
noncoding	I-MED
RNAs	I-MED
in	O
the	O
cardiovascular	B-MED
system	I-MED
indicates	O
that	O
they	O
may	O
be	O
part	O
of	O
a	O
complex	B-MED
regulatory	B-MED
network	I-MED
governing	B-MED
physiology	B-MED
and	O
pathology	B-MED
of	O
the	O
heart	B-MED
.	O
In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
multifaceted	B-MED
functions	B-MED
of	O
long	B-MED
noncoding	I-MED
RNAs	I-MED
and	O
highlight	O
the	O
current	B-MED
literature	I-MED
with	O
an	O
emphasis	O
on	O
cardiac	B-MED
development	I-MED
and	O
disease	B-MED
.	O
Furthermore	B-MED
,	O
as	O
the	O
enormous	B-MED
spectrum	O
of	O
long	B-MED
noncoding	I-MED
RNAs	I-MED
potentially	B-MED
opens	O
up	O
new	O
avenues	B-MED
for	O
diagnosis	B-MED
and	O
prevention	B-MED
of	O
heart	B-MED
failure	I-MED
,	O
we	O
ultimately	O
evaluate	O
the	O
futuristic	B-MED
prospects	I-MED
of	O
long	B-MED
noncoding	I-MED
RNAs	I-MED
as	O
biomarkers	B-MED
,	O
and	O
therapeutic	B-MED
targets	B-MED
for	O
the	O
treatment	B-MED
of	O
cardiovascular	B-MED
disorders	I-MED
,	O
as	O
well	O
.	O
Measuring	B-MED
nonlinear	B-MED
signal	B-MED
combination	B-MED
using	O
EEG	B-MED
Relatively	B-MED
little	O
is	O
known	O
about	O
the	O
processes	B-MED
,	O
both	O
linear	B-MED
and	O
nonlinear	B-MED
,	O
by	O
which	O
signals	B-MED
are	O
combined	B-MED
beyond	O
V1	B-MED
.	O
By	O
presenting	O
two	O
stimulus	B-MED
components	B-MED
simultaneously	B-MED
,	O
flickering	B-MED
at	O
different	B-MED
temporal	B-MED
frequencies	I-MED
(	O
frequency	B-MED
tagging	B-MED
)	O
while	O
measuring	B-MED
steady	B-MED
-	I-MED
state	I-MED
visual	B-MED
evoked	I-MED
potentials	I-MED
,	O
we	O
can	O
assess	B-MED
responses	B-MED
to	O
the	O
individual	O
components	B-MED
,	O
including	O
direct	B-MED
measurements	B-MED
of	O
suppression	B-MED
on	O
each	O
other	O
,	O
and	O
various	O
nonlinear	B-MED
responses	B-MED
to	O
their	O
combination	B-MED
found	O
at	O
intermodulation	B-MED
frequencies	B-MED
.	O
The	O
result	B-MED
is	O
a	O
rather	O
rich	O
dataset	B-MED
of	O
frequencies	B-MED
at	O
which	O
responses	B-MED
can	O
be	O
found	O
.	O
We	O
presented	O
pairs	B-MED
of	O
sinusoidal	B-MED
gratings	I-MED
at	O
different	B-MED
temporal	B-MED
frequencies	I-MED
,	O
forming	O
plaid	B-MED
patterns	I-MED
that	O
were	O
"	O
coherent	B-MED
"	O
(	O
looking	B-MED
like	I-MED
a	I-MED
checkerboar	I-MED
d	O
)	O
and	O
"	O
noncoherent	B-MED
"	O
(	O
looking	O
like	O
a	O
pair	B-MED
of	O
transparently	B-MED
overlaid	B-MED
gratings	I-MED
)	O
,	O
and	O
found	O
clear	O
intermodulation	B-MED
responses	B-MED
to	O
compound	B-MED
stimuli	B-MED
,	O
indicating	O
nonlinear	B-MED
summation	B-MED
.	O
This	O
might	O
have	O
been	O
attributed	O
to	O
cross	B-MED
-	I-MED
orientation	I-MED
suppression	B-MED
except	O
that	O
the	O
pattern	B-MED
of	O
intermodulation	B-MED
responses	B-MED
differed	B-MED
for	O
coherent	B-MED
and	O
noncoherent	B-MED
patterns	B-MED
,	O
whereas	O
the	O
effects	B-MED
of	I-MED
suppression	B-MED
(	O
measured	O
at	O
the	O
component	B-MED
frequencies	B-MED
)	O
did	O
not	O
.	O
A	O
two	B-MED
-	I-MED
stage	I-MED
model	I-MED
of	O
nonlinear	B-MED
summation	B-MED
involving	O
conjunction	B-MED
detection	B-MED
with	O
a	O
logical	B-MED
AND	B-MED
gate	I-MED
described	O
the	O
data	B-MED
well	O
,	O
capturing	O
the	O
difference	B-MED
between	O
coherent	B-MED
and	O
noncoherent	B-MED
plaids	B-MED
over	O
a	O
wide	O
array	B-MED
of	O
possible	B-MED
response	B-MED
frequencies	I-MED
.	O
Multistimulus	B-MED
frequency	B-MED
-tagged	O
EEG	B-MED
in	O
combination	B-MED
with	O
computational	B-MED
modeling	I-MED
may	O
be	O
a	O
very	O
valuable	O
tool	O
in	O
studying	O
the	O
conjunction	B-MED
of	O
these	O
signals	B-MED
.	O
In	O
the	O
current	O
study	B-MED
the	O
results	B-MED
suggest	O
a	O
second	B-MED
-	I-MED
order	I-MED
mechanism	I-MED
responding	O
selectively	B-MED
to	O
coherent	B-MED
plaid	B-MED
patterns	I-MED
.	O
C-5a	B-MED
-	I-MED
substituted	I-MED
validamine	I-MED
type	I-MED
glycosidase	B-MED
inhibitors	I-MED
A	O
series	O
of	O
N	B-MED
-	I-MED
alkyl	I-MED
derivatives	I-MED
of	O
the	O
D	B-MED
-	I-MED
galactosidase	I-MED
inhibitor	B-MED
1,4	B-MED
-	I-MED
di	I-MED
-	I-MED
epi	I-MED
-	I-MED
validamine	I-MED
featuring	O
lipophilic	B-MED
substituents	B-MED
at	I-MED
position	I-MED
C-5a	I-MED
was	O
prepared	O
and	O
screened	B-MED
for	O
their	O
glycosidase	B-MED
inhibitory	B-MED
properties	I-MED
.	O
Products	B-MED
turned	O
out	O
selective	O
for	O
β	B-MED
-	I-MED
galactosidases	I-MED
as	O
well	O
as	O
β	B-MED
-	I-MED
glucosidases	I-MED
.	O
Therapeutic	B-MED
applications	I-MED
of	O
CRISPR	B-MED
RNA	B-MED
-	I-MED
guided	I-MED
genome	B-MED
editing	I-MED
The	O
rapid	O
development	O
of	O
programmable	B-MED
nuclease	I-MED
-based	O
genome	B-MED
editing	I-MED
technologies	B-MED
has	O
enabled	O
targeted	B-MED
gene	B-MED
disruption	B-MED
and	O
correction	B-MED
both	O
in	B-MED
vitro	I-MED
and	O
in	B-MED
vivo	I-MED
This	O
revolution	O
opens	O
up	O
the	O
possibility	O
of	O
precise	O
genome	B-MED
editing	I-MED
at	O
target	B-MED
genomic	B-MED
sites	I-MED
to	O
modulate	O
gene	B-MED
function	I-MED
in	O
animals	B-MED
and	O
plants	B-MED
.	O
Among	O
several	O
programmable	B-MED
nucleases	I-MED
,	O
the	O
type	B-MED
II	I-MED
clustered	I-MED
regularly	I-MED
interspaced	I-MED
short	I-MED
palindromic	I-MED
repeats	I-MED
CRISPR	B-MED
(	O
CRISPR)-	O
CRISPR	B-MED
-	I-MED
associated	I-MED
nuclease	I-MED
9	I-MED
(	I-MED
Cas9	I-MED
)	I-MED
system	I-MED
has	O
progressed	O
remarkably	O
in	O
recent	O
years	O
,	O
leading	O
to	O
its	O
widespread	O
use	O
in	O
research	B-MED
,	O
medicine	B-MED
and	O
biotechnology	B-MED
.	O
In	O
particular	O
,	O
CRISPR	B-MED
-	I-MED
Cas9	I-MED
shows	O
highly	O
efficient	O
gene	B-MED
editing	I-MED
activity	O
for	O
therapeutic	B-MED
purposes	I-MED
in	O
systems	O
ranging	O
from	O
patient	B-MED
stem	B-MED
cells	I-MED
to	O
animal	B-MED
models	I-MED
.	O
However	O
,	O
the	O
development	O
of	O
therapeutic	B-MED
approaches	I-MED
and	O
delivery	B-MED
methods	I-MED
remains	O
a	O
great	O
challenge	O
for	O
biomedical	B-MED
applications	B-MED
.	O
Herein	O
,	O
we	O
review	O
therapeutic	B-MED
applications	I-MED
that	O
use	O
the	O
CRISPR	B-MED
-	I-MED
Cas9	I-MED
system	I-MED
and	O
discuss	O
the	O
possibilities	O
and	O
challenges	O
ahead	O
.	O
Non	O
-	O
specific	O
transient	O
mutualism	B-MED
between	O
the	O
plant	B-MED
parasitic	I-MED
nematode	I-MED
,	O
Bursaphelenchus	B-MED
xylophilus	I-MED
,	O
and	O
the	O
opportunistic	O
bacterium	B-MED
Serratia	B-MED
quinivorans	I-MED
BXF1	I-MED
,	O
a	O
plant	B-MED
-	I-MED
growth	I-MED
promoting	O
pine	B-MED
endophyte	B-MED
with	O
antagonistic	B-MED
effects	B-MED
The	O
aim	O
of	O
this	O
study	B-MED
is	O
to	O
understand	O
the	O
biological	O
role	O
of	O
Serratia	B-MED
quinivorans	I-MED
BXF1	I-MED
,	O
a	O
bacterium	B-MED
commonly	O
found	O
associated	O
with	O
Bursaphelenchus	B-MED
xylophilus	I-MED
,	O
the	O
plant	B-MED
parasitic	I-MED
nematode	I-MED
responsible	O
for	O
pine	B-MED
wilt	B-MED
disease	I-MED
.	O
Therefore	O
,	O
we	O
studied	O
strain	B-MED
BXF1	I-MED
effect	O
in	O
pine	B-MED
wilt	B-MED
disease	I-MED
.	O
We	O
found	O
that	O
strain	B-MED
BXF1	I-MED
promoted	O
in	B-MED
vitro	I-MED
nematode	B-MED
reproduction	B-MED
.	O
Moreover	O
,	O
the	O
presence	O
of	O
bacteria	B-MED
led	O
to	O
the	O
absence	O
of	O
nematode	B-MED
chitinase	B-MED
gene	I-MED
(	I-MED
Bxcht-1	I-MED
)	I-MED
expression	B-MED
,	O
suggesting	O
an	O
effect	O
for	O
bacterial	B-MED
chitinase	B-MED
in	O
nematode	B-MED
reproduction	B-MED
.	O
Nevertheless	O
,	O
strain	B-MED
BXF1	I-MED
was	O
unable	O
to	O
colonize	B-MED
the	O
nematode	B-MED
interior	O
,	O
bind	O
to	O
its	O
cuticle	B-MED
with	O
high	O
affinity	O
or	O
protect	O
the	O
nematode	B-MED
from	O
xenobiotic	B-MED
stress	B-MED
.	O
Interestingly	O
,	O
strain	B-MED
BXF1	I-MED
was	O
able	O
to	O
promote	O
tomato	B-MED
and	O
pine	B-MED
plant	B-MED
-	I-MED
growth	I-MED
,	O
as	O
well	O
as	O
to	O
colonize	B-MED
its	O
interior	O
,	O
thus	O
,	O
acting	O
like	O
a	O
plant	B-MED
-	I-MED
growth	I-MED
promoting	O
endophyte	B-MED
.	O
Consequently	O
,	O
strain	B-MED
BXF1	I-MED
failed	O
to	O
induce	O
wilting	B-MED
symptoms	I-MED
when	O
inoculated	O
in	O
pine	B-MED
shoot	B-MED
artificial	B-MED
incisions	I-MED
.	O
This	O
bacterium	B-MED
also	O
presented	O
strong	O
antagonistic	B-MED
activities	B-MED
against	O
fungi	B-MED
and	O
bacteria	B-MED
isolated	O
from	O
Pinus	B-MED
pinaster	I-MED
.	O
Our	O
results	O
suggest	O
that	O
B.	B-MED
xylophilus	I-MED
does	O
not	O
possess	O
a	O
strict	O
symbiotic	B-MED
community	I-MED
capable	O
of	O
inducing	O
pine	B-MED
wilt	B-MED
disease	I-MED
symptoms	B-MED
as	O
previously	O
hypothesized	O
.	O
We	O
show	O
that	O
bacteria	B-MED
like	O
BXF1	B-MED
,	O
which	O
possess	O
plant	B-MED
-	I-MED
growth	I-MED
promoting	O
and	O
antagonistic	B-MED
effects	B-MED
,	O
may	O
be	O
opportunistically	O
associated	O
with	O
B.	B-MED
xylophilus	I-MED
,	O
possibly	O
acquired	O
from	O
the	O
bacterial	B-MED
endophytic	B-MED
community	I-MED
of	O
the	O
host	B-MED
pine	B-MED
.	O
Atypical	O
microglial	B-MED
response	B-MED
to	O
biodiesel	B-MED
exhaust	I-MED
in	O
healthy	B-MED
and	O
hypertensive	B-MED
rats	B-MED
Accumulating	O
evidence	B-MED
suggests	B-MED
a	O
deleterious	B-MED
role	B-MED
for	O
urban	B-MED
air	B-MED
pollution	I-MED
in	O
central	B-MED
nervous	I-MED
system	I-MED
(	I-MED
CNS	I-MED
)	I-MED
diseases	I-MED
and	O
neurodevelopmental	B-MED
disorders	I-MED
.	O
Microglia	B-MED
,	O
the	O
resident	O
innate	B-MED
immune	B-MED
cells	I-MED
and	O
sentinels	B-MED
in	O
the	O
brain	B-MED
,	O
are	O
a	O
common	B-MED
source	B-MED
of	O
neuroinflammation	B-MED
and	O
are	O
implicated	O
in	O
air	B-MED
pollution	I-MED
-	O
induced	B-MED
CNS	B-MED
effects	I-MED
.	O
While	O
renewable	B-MED
energy	I-MED
,	O
such	O
as	O
soy	B-MED
-	I-MED
based	I-MED
biofuel	I-MED
,	O
is	O
of	O
increasing	B-MED
public	B-MED
interest	B-MED
,	O
there	O
is	O
little	B-MED
information	B-MED
on	O
how	O
soy	B-MED
biofuel	I-MED
may	O
affect	B-MED
the	O
brain	B-MED
,	O
especially	O
in	O
people	B-MED
with	O
preexisting	B-MED
disease	I-MED
conditions	I-MED
.	O
To	O
address	O
this	O
,	O
male	B-MED
spontaneously	B-MED
hypertensive	I-MED
rats	I-MED
(	O
SHR	B-MED
)	O
and	O
normotensive	B-MED
Wistar	B-MED
Kyoto	I-MED
(	I-MED
WKY	I-MED
)	I-MED
rats	I-MED
were	O
exposed	B-MED
to	I-MED
100	B-MED
%	I-MED
Soy	I-MED
-	I-MED
based	I-MED
Biodiesel	I-MED
Exhaust	I-MED
(	O
100SBDE	B-MED
;	O
0	O
,	O
50	O
,	O
150	O
and	O
500μg	O
/	O
m(3	O
)	O
)	O
by	O
inhalation	B-MED
,	O
4h/	O
day	B-MED
for	O
4	O
weeks	B-MED
(	O
5	O
days	B-MED
/	O
week	B-MED
)	O
.	O
Ionized	B-MED
calcium	I-MED
-	I-MED
binding	I-MED
adapter	I-MED
molecule-1	I-MED
(	O
IBA-1	B-MED
)	O
staining	B-MED
of	O
microglia	B-MED
in	O
the	O
substantia	B-MED
nigra	I-MED
revealed	B-MED
significant	B-MED
changes	B-MED
in	O
morphology	B-MED
with	O
100SBDE	B-MED
exposure	B-MED
in	O
rats	B-MED
from	O
both	B-MED
genotypes	B-MED
,	O
where	O
SHR	B-MED
were	O
less	B-MED
sensitive	B-MED
.	O
Aconitase	B-MED
activity	I-MED
was	O
inhibited	B-MED
in	O
the	O
frontal	B-MED
cortex	I-MED
and	O
cerebellum	B-MED
of	O
WKY	B-MED
rats	I-MED
exposed	B-MED
to	I-MED
100SBDE	B-MED
.	O
No	B-MED
consistent	B-MED
changes	B-MED
occurred	B-MED
in	O
pro	B-MED
-	I-MED
inflammatory	I-MED
cytokine	B-MED
expression	B-MED
,	O
nitrated	B-MED
protein	I-MED
,	O
or	O
arginase1	B-MED
expression	B-MED
in	O
brain	B-MED
regions	I-MED
from	O
either	O
rat	B-MED
strain	I-MED
exposed	B-MED
to	I-MED
100SBDE	B-MED
.	O
However	O
,	O
while	O
IBA-1	B-MED
mRNA	B-MED
expression	I-MED
was	O
not	B-MED
modified	B-MED
,	O
CX3CR1	B-MED
mRNA	B-MED
expression	I-MED
was	O
lower	B-MED
in	O
the	O
striatum	B-MED
of	O
100SBDE	B-MED
exposed	B-MED
rats	I-MED
regardless	B-MED
of	O
genotype	B-MED
,	O
suggesting	B-MED
a	O
downregulation	B-MED
of	O
the	O
fractalkine	B-MED
receptor	I-MED
on	O
microglia	B-MED
in	O
this	O
brain	B-MED
region	I-MED
.	O
Together	O
,	O
these	O
data	B-MED
indicate	B-MED
that	O
while	O
microglia	B-MED
are	O
detecting	B-MED
and	O
responding	B-MED
to	O
100SBDE	B-MED
exposure	B-MED
with	O
changes	B-MED
in	O
morphology	B-MED
,	O
there	O
is	O
reduced	B-MED
expression	B-MED
of	O
CX3CR1	B-MED
regardless	B-MED
of	O
genetic	B-MED
background	I-MED
and	O
the	O
activation	B-MED
response	B-MED
is	O
atypical	B-MED
without	O
traditional	B-MED
inflammatory	B-MED
markers	I-MED
of	O
M1	B-MED
or	O
M2	B-MED
activation	B-MED
in	O
the	O
brain	B-MED
.	O
Identification	B-MED
and	O
characterization	B-MED
of	O
Dichelobacter	B-MED
nodosus	I-MED
serogroup	B-MED
H	I-MED
from	O
ovine	B-MED
footrot	B-MED
in	O
India	B-MED
A	O
total	O
of	O
56	O
foot	B-MED
swabs	I-MED
were	O
collected	O
from	O
inter	B-MED
digital	I-MED
spaces	I-MED
of	O
sheep	B-MED
with	O
footrot	B-MED
lesions	B-MED
were	O
screened	B-MED
for	O
16	O
rRNA	B-MED
of	O
Dichelobacter	B-MED
nodosus	I-MED
by	O
PCR	B-MED
.	O
Out	O
of	O
the	O
56	O
samples	B-MED
,	O
38(67.85	O
%	O
)	O
were	O
found	O
to	O
be	O
positive	B-MED
.	O
All	O
the	O
positive	B-MED
samples	B-MED
were	O
subjected	O
to	O
multiplex	B-MED
PCR	I-MED
targeting	B-MED
fimA	I-MED
gene	I-MED
for	O
identification	B-MED
of	O
serogroups	B-MED
of	O
D.	B-MED
nodosus	I-MED
.	O
Serogroup	B-MED
H	I-MED
was	O
found	O
along	O
with	O
serogroup	B-MED
B	I-MED
in	O
12	O
(	O
55.26	O
%	O
)	O
samples	B-MED
and	O
with	O
serogroup	B-MED
I	I-MED
in	O
8	O
(	O
22.2	O
%	O
)	O
samples	B-MED
.	O
The	O
serogroup	B-MED
H	I-MED
was	O
identified	B-MED
for	O
the	O
first	O
time	O
from	O
the	O
Indian	B-MED
subcontinent	I-MED
.	O
The	O
phylogenetic	B-MED
analysis	I-MED
of	O
the	O
present	O
sequence	B-MED
with	O
the	O
available	O
serogroup	B-MED
H	I-MED
sequences	B-MED
of	O
GenBank	B-MED
revealed	O
to	O
be	O
in	O
close	O
association	O
with	O
the	O
serotype	B-MED
H1	I-MED
.	O
The	O
Role	O
of	O
the	O
Iron	B-MED
Stain	I-MED
in	O
Assessing	B-MED
Intracranial	B-MED
Hemorrhage	I-MED
The	O
timing	B-MED
of	O
the	O
breakdown	O
of	O
red	B-MED
blood	I-MED
cells	I-MED
and	O
organization	B-MED
of	O
hemorrhage	B-MED
has	O
significance	B-MED
in	O
the	O
catabolism	B-MED
of	O
heme	B-MED
and	O
the	O
processing	B-MED
of	O
iron	B-MED
,	O
but	O
also	O
has	O
a	O
practical	O
application	B-MED
in	O
terms	O
of	O
assigning	B-MED
,	O
or	O
attempting	B-MED
to	O
assign	B-MED
,	O
a	O
time	B-MED
course	I-MED
with	O
respect	O
to	O
traumatic	B-MED
events	B-MED
(	O
e.g.	O
contusions	B-MED
and	O
hemorrhages	B-MED
)	O
.	O
Attempts	B-MED
to	O
date	B-MED
contusions	I-MED
,	O
however	O
,	O
have	O
generally	O
been	O
unsuccessful	B-MED
by	O
macroscopic	B-MED
observation	I-MED
,	O
whereas	O
the	O
microscopic	B-MED
observations	I-MED
provide	O
broad	O
data	B-MED
but	O
are	O
also	O
anatomically	B-MED
imprecise	B-MED
as	O
a	O
function	B-MED
of	O
time	B-MED
.	O
Intracranial	B-MED
lesions	I-MED
are	O
of	O
particular	O
significance	B-MED
with	O
respect	O
to	O
the	O
timing	B-MED
of	O
organizing	B-MED
hemorrhage	B-MED
given	O
the	O
acute	B-MED
,	O
and	O
often	O
life	B-MED
-	I-MED
threatening	I-MED
nature	B-MED
of	O
the	O
hemorrhages	B-MED
,	O
and	O
the	O
medicolegal	B-MED
investigation	I-MED
into	O
potential	B-MED
crimes	B-MED
.	O
Of	O
concern	O
is	O
that	O
the	O
Prussian	B-MED
Blue	I-MED
reaction	I-MED
for	O
iron	B-MED
,	O
a	O
relatively	O
straightforward	O
histochemical	B-MED
reaction	B-MED
that	O
has	O
been	O
in	O
use	O
for	O
over	O
150	O
years	B-MED
,	O
is	O
sometimes	O
suggested	O
as	O
a	O
diagnostic	B-MED
test	I-MED
for	O
chronicity	B-MED
.	O
Therefore	O
,	O
this	O
study	B-MED
examined	B-MED
the	O
utility	O
of	O
the	O
Prussian	B-MED
Blue	I-MED
iron	I-MED
stain	I-MED
in	O
living	B-MED
patients	I-MED
with	O
intracranial	B-MED
hemorrhages	I-MED
and	O
well	O
-	O
defined	O
symptom	B-MED
onset	I-MED
,	O
to	O
test	O
whether	O
the	O
presence	B-MED
of	O
Prussian	B-MED
Blue	I-MED
reactivity	B-MED
could	O
be	O
correlated	B-MED
with	O
chronicity	B-MED
.	O
It	O
was	O
found	B-MED
that	O
out	O
of	O
12	O
cases	B-MED
with	O
intracranial	B-MED
hemorrhage	I-MED
,	O
eight	O
cases	B-MED
showed	O
at	O
least	O
focal	B-MED
iron	I-MED
reactivity	B-MED
.	O
The	O
duration	B-MED
from	O
symptom	B-MED
onset	I-MED
to	O
surgery	B-MED
in	O
those	O
eight	O
cases	B-MED
ranged	B-MED
from	O
<	O
24	O
hours	B-MED
to	O
more	O
than	O
3	O
days	B-MED
.	O
Of	O
those	O
cases	B-MED
with	O
no	B-MED
iron	I-MED
reactivity	I-MED
,	O
the	O
duration	B-MED
from	O
symptom	B-MED
onset	I-MED
to	O
surgery	B-MED
ranged	O
from	O
<	O
24	O
hours	B-MED
to	O
six	O
days	B-MED
.	O
In	O
conclusion	O
,	O
the	O
Prussian	B-MED
Blue	I-MED
reaction	I-MED
was	O
unreliable	B-MED
as	O
an	O
indicator	B-MED
of	O
timing	B-MED
in	O
intracranial	B-MED
hemorrhage	I-MED
.	O
The	O
use	O
of	O
the	O
Prussian	B-MED
blue	I-MED
reaction	I-MED
as	O
an	O
independent	B-MED
indicator	I-MED
of	O
chronicity	B-MED
is	O
therefore	O
not	O
valid	B-MED
and	O
can	O
be	O
misleading	O
.	O
Caution	O
is	O
indicated	B-MED
when	O
employing	O
iron	B-MED
staining	I-MED
for	O
timing	B-MED
purposes	O
,	O
as	O
its	O
only	O
use	O
is	O
to	O
highlight	O
,	O
as	O
opposed	O
to	O
identify	O
,	O
pre	B-MED
-	I-MED
existing	I-MED
lesions	B-MED
.	O
With	O
respect	O
to	O
brain	B-MED
lesions	I-MED
,	O
the	O
Prussian	B-MED
blue	I-MED
reaction	I-MED
should	O
not	O
be	O
used	O
in	O
place	O
of	O
the	O
clinical	B-MED
timing	B-MED
of	O
the	O
neurologic	B-MED
decline	I-MED
,	O
or	O
clinical	B-MED
data	I-MED
that	O
is	O
otherwise	O
more	O
accurate	B-MED
and	O
less	O
susceptible	B-MED
to	O
false	B-MED
positive	I-MED
results	I-MED
.	O
Gambling	B-MED
disorders	I-MED
,	O
gambling	B-MED
type	O
preferences	O
,	O
and	O
psychiatric	B-MED
comorbidity	B-MED
among	O
the	O
Thai	B-MED
general	I-MED
population	I-MED
:	O
Results	O
of	O
the	O
2013	O
National	B-MED
Mental	I-MED
Health	I-MED
Survey	I-MED
Background	O
and	O
aims	O
To	O
estimate	O
the	O
prevalence	B-MED
of	O
problem	B-MED
and	O
pathological	B-MED
gambling	I-MED
,	O
gender	B-MED
and	O
age	B-MED
-	I-MED
group	I-MED
differences	O
in	O
gambling	B-MED
types	I-MED
,	O
and	O
comorbidities	B-MED
with	O
other	O
psychiatric	B-MED
disorders	I-MED
among	O
the	O
Thai	B-MED
general	I-MED
population	I-MED
.	O
Methods	O
Analysis	O
was	O
conducted	O
on	O
4,727	O
participants	B-MED
of	O
Thailand	B-MED
's	I-MED
2013	O
National	B-MED
Mental	I-MED
Health	I-MED
Survey	I-MED
,	O
a	O
multistage	B-MED
stratified	I-MED
cluster	I-MED
survey	I-MED
,	O
using	O
the	O
Composite	B-MED
International	I-MED
Diagnostic	I-MED
Interview	I-MED
.	O
Diagnoses	B-MED
of	O
problem	B-MED
and	O
pathological	B-MED
gambling	I-MED
and	O
other	O
psychiatric	B-MED
disorders	I-MED
were	O
based	O
on	O
the	O
DSM	B-MED
-	I-MED
IV	I-MED
-	I-MED
TR	I-MED
criteria	I-MED
with	O
the	O
following	O
additional	O
criteria	B-MED
for	O
gamblers	B-MED
:	O
more	O
than	O
10	O
lifetime	B-MED
gambling	O
episodes	O
and	O
a	O
single	B-MED
year	I-MED
loss	I-MED
of	O
at	O
least	O
365	O
USD	B-MED
from	O
gambling	B-MED
.	O
Results	O
The	O
estimated	O
lifetime	B-MED
prevalence	B-MED
rates	I-MED
of	O
pathological	B-MED
and	O
problem	B-MED
gambling	I-MED
were	O
0.90	O
%	O
[	O
95	O
%	O
confidence	B-MED
interval	I-MED
(	O
CI	B-MED
):	O
0.51	O
-	O
1.29	O
]	O
and	O
1.14	O
%	O
(	O
95	O
%	O
CI	B-MED
:	O
0.58	O
-	O
1.70	O
)	O
,	O
respectively	O
.	O
The	O
most	O
popular	O
type	O
of	O
gambling	B-MED
was	O
playing	B-MED
lotteries	I-MED
[	O
69.5	O
%	O
,	O
standard	B-MED
error	I-MED
(	O
SE	B-MED
)	O
=	O
1.9	O
]	O
,	O
the	O
prevalence	B-MED
of	O
which	O
was	O
significantly	O
higher	O
among	O
females	B-MED
and	O
older	B-MED
age	I-MED
groups	I-MED
.	O
The	O
most	O
common	O
psychiatric	B-MED
disorders	I-MED
seen	O
among	O
pathological	B-MED
gamblers	I-MED
were	O
alcohol	B-MED
abuse	I-MED
(	O
57.4	O
%	O
)	O
,	O
nicotine	B-MED
dependence	I-MED
(	O
49.5	O
%	O
)	O
,	O
and	O
any	O
drug	B-MED
use	I-MED
disorder	I-MED
(	O
16.2	O
%	O
)	O
.	O
Pathological	B-MED
gambling	I-MED
was	O
highly	O
prevalent	O
among	O
those	O
who	O
ever	O
experienced	O
major	B-MED
depressive	I-MED
episodes	I-MED
(	O
5.5	O
%	O
)	O
,	O
any	O
drug	B-MED
dependence	I-MED
(	O
5.1	O
%	O
)	O
,	O
and	O
intermittent	B-MED
explosive	I-MED
disorder	I-MED
(	O
4.8	O
%	O
)	O
.	O
The	O
association	O
between	O
pathological	B-MED
gambling	I-MED
was	O
strongest	O
with	O
a	O
history	O
of	O
major	B-MED
depressive	I-MED
episode	I-MED
[	O
adjusted	B-MED
odds	I-MED
ratio	I-MED
(	O
AOR	B-MED
)	O
=	O
10.4	O
,	O
95	O
%	O
CI	B-MED
:	O
2.80	O
-	O
38.4	O
]	O
.	O
Conclusion	O
The	O
study	O
confirms	O
the	O
recognition	B-MED
of	O
gambling	B-MED
disorders	I-MED
as	O
a	O
public	B-MED
health	I-MED
concern	O
in	O
Thailand	B-MED
and	O
suggests	O
a	O
need	O
for	O
culturally	B-MED
specific	O
preventive	B-MED
measures	O
for	O
pathological	B-MED
gamblers	I-MED
and	O
those	O
with	O
a	O
history	O
of	O
substance	B-MED
use	I-MED
disorders	I-MED
or	O
major	B-MED
depression	I-MED
.	O
Glucose	B-MED
metabolism	I-MED
-	O
weighted	B-MED
imaging	I-MED
with	O
chemical	B-MED
exchange	I-MED
-	I-MED
sensitive	I-MED
MRI	I-MED
of	O
2	B-MED
-	I-MED
deoxyglucose	I-MED
(	O
2DG	B-MED
)	O
in	O
brain	B-MED
:	O
Sensitivity	B-MED
and	O
biological	B-MED
sources	B-MED
Recent	B-MED
proof	I-MED
-	I-MED
of	I-MED
-	I-MED
principle	I-MED
studies	I-MED
have	O
demonstrated	O
the	O
feasibility	O
of	O
measuring	O
the	O
uptake	B-MED
and	O
metabolism	B-MED
of	O
non	O
-	O
labeled	O
2	B-MED
-	I-MED
deoxy	I-MED
-	I-MED
D	I-MED
-	I-MED
glucose	I-MED
(	O
2DG	B-MED
)	O
by	O
a	O
chemical	B-MED
exchange	I-MED
-	I-MED
sensitive	I-MED
spin	I-MED
-	I-MED
lock	I-MED
(	I-MED
CESL	I-MED
)	I-MED
MRI	I-MED
approach	I-MED
.	O
In	O
order	O
to	O
gain	O
better	O
understanding	O
of	O
this	O
new	O
approach	O
,	O
we	O
performed	O
dynamic	B-MED
in	B-MED
vivo	I-MED
CESL	B-MED
MRI	I-MED
on	O
healthy	B-MED
rat	B-MED
brains	B-MED
with	O
an	O
intravenous	B-MED
injection	I-MED
of	O
2DG	B-MED
under	O
various	O
conditions	O
at	O
9.4T.	O
For	O
three	O
2DG	B-MED
doses	B-MED
of	O
0.25	O
,	O
0.5	O
and	O
1g	O
/	O
kg	O
,	O
we	O
found	O
that	O
2DG	B-MED
-	O
CESL	B-MED
signals	B-MED
increased	B-MED
linearly	O
with	O
injection	B-MED
dose	B-MED
at	O
the	O
initial	O
(	O
<	O
20min	O
)	O
but	O
not	O
the	O
later	O
period	O
(	O
>	O
40min	O
)	O
suggesting	O
time	O
-	O
dependent	O
differential	O
weightings	O
of	O
2DG	B-MED
transport	B-MED
and	O
metabolism	B-MED
.	O
Remaining	O
2DG	B-MED
-	O
CESL	B-MED
studies	O
were	O
performed	O
with	O
0.25g	O
/	O
kg	O
2DG	B-MED
.	O
Since	O
a	O
higher	B-MED
isoflurane	B-MED
level	B-MED
reduces	B-MED
glucose	B-MED
metabolism	I-MED
and	O
increases	B-MED
blood	B-MED
flow	I-MED
,	O
2DG	B-MED
-	O
CESL	B-MED
was	O
measured	B-MED
under	O
0.5	O
%	O
,	O
1.5	O
%	O
and	O
2.2	O
%	O
isoflurane	B-MED
.	O
The	O
2DG	B-MED
-	O
CESL	B-MED
signal	B-MED
was	O
reduced	B-MED
at	O
higher	B-MED
isoflurane	B-MED
levels	O
correlating	O
well	O
with	O
the	O
2DG	B-MED
phosphorylation	B-MED
in	O
the	O
intracellular	B-MED
space	I-MED
.	O
To	O
detect	O
regional	B-MED
heterogeneities	I-MED
of	O
glucose	B-MED
metabolism	I-MED
,	O
2DG	B-MED
-	O
CESL	B-MED
with	O
0.33×0.33×1.50mm(3	O
)	O
resolution	O
was	O
obtained	O
,	O
which	O
indeed	O
showed	O
a	O
higher	B-MED
response	O
in	O
the	O
cortex	B-MED
compared	O
to	O
the	O
corpus	B-MED
callosum	I-MED
.	O
Lastly	O
,	O
unlike	O
CESL	B-MED
MRI	I-MED
with	O
the	O
injection	B-MED
of	O
non	B-MED
-	I-MED
transportable	I-MED
mannitol	I-MED
,	O
the	O
2DG	B-MED
-	O
CESL	B-MED
response	O
decreased	B-MED
with	O
an	O
increased	B-MED
spin	B-MED
-	I-MED
lock	I-MED
pulse	I-MED
power	I-MED
confirming	O
that	O
2DG	B-MED
-	O
CESL	B-MED
is	O
dominated	O
by	O
chemical	B-MED
exchange	B-MED
processes	B-MED
in	O
the	O
extravascular	B-MED
space	I-MED
.	O
Taken	O
together	O
,	O
our	O
results	O
showed	O
that	O
2DG	B-MED
-	O
CESL	B-MED
MRI	I-MED
signals	B-MED
mainly	O
indicate	O
glucose	B-MED
transport	I-MED
and	O
metabolism	B-MED
and	O
may	O
be	O
a	O
useful	O
biomarker	B-MED
for	O
metabolic	B-MED
studies	B-MED
of	O
normal	B-MED
and	O
diseased	B-MED
brains	B-MED
.	O
Robust	B-MED
DLPP	B-MED
With	O
Nongreedy	B-MED
ℓ₁$-Norm	I-MED
Minimization	I-MED
and	O
Maximization	B-MED
Recently	O
,	O
discriminant	B-MED
locality	I-MED
preserving	I-MED
projection	I-MED
based	I-MED
on	I-MED
L1	I-MED
-	I-MED
norm	I-MED
(	O
DLPP	B-MED
-	I-MED
L1	I-MED
)	O
was	O
developed	O
for	O
robust	B-MED
subspace	B-MED
learning	I-MED
and	O
image	B-MED
classification	B-MED
.	O
It	O
obtains	O
projection	B-MED
vectors	B-MED
by	O
greedy	B-MED
strategy	I-MED
,	O
i.e.	O
,	O
all	O
projection	B-MED
vectors	B-MED
are	O
optimized	O
individually	O
through	O
maximizing	B-MED
the	O
objective	B-MED
function	B-MED
.	O
Thus	O
,	O
the	O
obtained	O
solution	B-MED
does	O
not	O
necessarily	O
best	O
optimize	O
the	O
corresponding	O
trace	B-MED
ratio	I-MED
optimization	I-MED
algorithm	I-MED
,	O
which	O
is	O
the	O
essential	O
objective	B-MED
function	B-MED
for	O
general	O
dimensionality	B-MED
reduction	I-MED
.	O
It	O
results	O
in	O
insufficient	O
recognition	B-MED
accuracy	B-MED
.	O
To	O
tackle	O
this	O
problem	O
,	O
we	O
propose	O
a	O
nongreedy	B-MED
algorithm	I-MED
to	O
solve	O
the	O
trace	B-MED
ratio	I-MED
formula	I-MED
of	O
DLPP	B-MED
-	I-MED
L1	I-MED
,	O
and	O
analyze	O
its	O
convergence	B-MED
.	O
Experimental	O
results	O
on	O
three	O
databases	B-MED
illustrate	O
the	O
effectiveness	O
of	O
our	O
proposed	O
algorithm	B-MED
.	O
Developmental	B-MED
Hypoxia	B-MED
Has	O
Negligible	B-MED
Effects	B-MED
on	O
Long	B-MED
-	I-MED
Term	I-MED
Hypoxia	B-MED
Tolerance	B-MED
and	O
Aerobic	B-MED
Metabolism	I-MED
of	O
Atlantic	B-MED
Salmon	I-MED
(	O
Salmo	B-MED
salar	I-MED
)	O
Exposure	B-MED
to	I-MED
developmental	B-MED
hypoxia	B-MED
can	O
have	O
long	B-MED
-	I-MED
term	I-MED
impacts	B-MED
on	O
the	O
physiological	B-MED
performance	B-MED
of	O
fish	B-MED
because	O
of	O
irreversible	B-MED
plasticity	B-MED
.	O
Wild	B-MED
and	O
captive	B-MED
-	I-MED
reared	I-MED
Atlantic	B-MED
salmon	I-MED
(	O
Salmo	B-MED
salar	I-MED
)	O
can	O
be	O
exposed	B-MED
to	I-MED
hypoxic	B-MED
conditions	B-MED
during	O
development	B-MED
and	O
continue	B-MED
to	O
experience	O
fluctuating	B-MED
oxygen	B-MED
levels	B-MED
as	O
juveniles	B-MED
and	O
adults	B-MED
.	O
Here	O
,	O
we	O
examine	B-MED
whether	O
developmental	B-MED
hypoxia	B-MED
impacts	B-MED
subsequent	B-MED
hypoxia	B-MED
tolerance	B-MED
and	O
aerobic	B-MED
performance	B-MED
of	O
Atlantic	B-MED
salmon	I-MED
.	O
Individuals	B-MED
at	O
8	O
°	O
C	O
were	O
exposed	B-MED
to	I-MED
50	O
%	O
(	O
hypoxia	B-MED
)	O
or	O
100	O
%	O
(	O
normoxia	B-MED
)	O
dissolved	B-MED
oxygen	I-MED
(	I-MED
DO	I-MED
)	I-MED
saturation	I-MED
(	O
as	O
percent	O
of	O
air	B-MED
saturation	I-MED
)	O
from	O
fertilization	B-MED
for	O
∼100	O
d	O
(	O
800	O
degree	O
days	O
)	O
and	O
then	O
raised	B-MED
in	O
normoxic	B-MED
conditions	B-MED
for	O
a	O
further	O
15	O
mo	O
.	O
At	O
18	O
mo	O
after	O
fertilization	B-MED
,	O
aerobic	B-MED
scope	B-MED
was	O
calculated	B-MED
in	O
normoxia	B-MED
(	O
100	O
%	O
DO	B-MED
)	O
and	O
acute	B-MED
(	O
18	O
h	O
)	O
hypoxia	B-MED
(	O
50	O
%	O
DO	B-MED
)	O
from	O
the	O
difference	B-MED
between	O
the	O
minimum	B-MED
and	O
maximum	B-MED
oxygen	B-MED
consumption	I-MED
rates	B-MED
(	O
[	O
Formula	O
:	O
see	O
text	O
]	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
respectively	O
)	O
at	O
10	O
°	O
C	O
.	O
Hypoxia	B-MED
tolerance	B-MED
was	O
determined	B-MED
as	O
the	O
DO	B-MED
at	O
which	O
loss	B-MED
of	I-MED
equilibrium	I-MED
(	O
LOE	B-MED
)	O
occurred	B-MED
in	O
a	O
constantly	O
decreasing	B-MED
DO	B-MED
environment	O
.	O
There	O
was	O
no	B-MED
difference	I-MED
in	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
or	O
aerobic	B-MED
scope	B-MED
between	O
fish	B-MED
raised	B-MED
in	O
hypoxia	B-MED
or	O
normoxia	B-MED
.	O
There	O
was	O
some	O
evidence	B-MED
that	O
hypoxia	B-MED
tolerance	B-MED
was	O
lower	B-MED
(	O
higher	O
DO	B-MED
at	O
LOE	B-MED
)	O
in	O
hypoxia	B-MED
-	O
raised	B-MED
fish	B-MED
compared	O
with	O
those	O
raised	B-MED
in	O
normoxia	B-MED
,	O
but	O
the	O
magnitude	B-MED
of	O
the	O
effect	B-MED
was	O
small	B-MED
(	O
12.52	O
%	O
DO	B-MED
vs.	O
11.73	O
%	O
DO	B-MED
at	O
LOE	B-MED
)	O
.	O
Acute	B-MED
hypoxia	B-MED
significantly	O
reduced	B-MED
aerobic	B-MED
scope	B-MED
by	O
reducing	B-MED
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
while	O
[	O
Formula	O
:	O
see	O
text	O
]	O
remained	O
unchanged	B-MED
.	O
Interestingly	O
,	O
acute	B-MED
hypoxia	B-MED
uncovered	O
individual	B-MED
-level	O
relationships	B-MED
between	O
DO	B-MED
at	O
LOE	B-MED
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
and	O
aerobic	B-MED
scope	B-MED
.	O
We	O
discuss	O
our	O
findings	B-MED
in	O
the	O
context	O
of	O
developmental	B-MED
trajectories	O
and	O
the	O
role	O
of	O
aerobic	B-MED
performance	B-MED
in	O
hypoxia	B-MED
tolerance	B-MED
.	O
2,8	B-MED
-	I-MED
Dihydroxyadenine	I-MED
Nephropathy	B-MED
Identified	O
as	O
Cause	B-MED
of	O
End	B-MED
-	I-MED
Stage	I-MED
Renal	I-MED
Disease	I-MED
After	O
Renal	B-MED
Transplant	I-MED
Adenine	B-MED
phosphoribosyltransferase	I-MED
Adenine	B-MED
phosphoribosyltransferase	I-MED
deficiency	I-MED
is	O
a	O
rare	O
autosomal	B-MED
recessive	I-MED
disorder	I-MED
of	O
uric	B-MED
acid	I-MED
metabolism	B-MED
that	O
leads	O
to	O
formation	B-MED
and	O
excretion	B-MED
of	O
2,8	B-MED
-	I-MED
dihydroxyadenine	I-MED
into	O
urine	B-MED
.	O
The	O
low	O
solubility	B-MED
of	O
2,8	B-MED
-	I-MED
dihydroxyadenine	I-MED
results	O
in	O
precipitation	B-MED
and	O
formation	B-MED
of	O
urinary	B-MED
crystals	I-MED
and	O
renal	B-MED
stones	I-MED
.	O
Patients	B-MED
with	O
this	O
disorder	B-MED
usually	O
have	O
recurrent	B-MED
nephrolithiasis	I-MED
and	O
can	O
develop	O
nephropathy	B-MED
secondary	I-MED
to	O
crystal	B-MED
precipitation	B-MED
in	O
the	O
renal	B-MED
parenchyma	I-MED
.	O
The	O
disease	B-MED
is	O
most	O
often	O
underdiagnosed	B-MED
and	O
can	O
recur	B-MED
in	O
renal	B-MED
transplant	I-MED
,	O
causing	B-MED
graft	B-MED
failure	I-MED
.	O
Lack	O
of	O
specific	O
clinical	B-MED
manifestations	B-MED
,	O
chemical	B-MED
and	O
radiologic	B-MED
features	I-MED
identical	O
to	O
those	O
shown	O
with	O
uric	B-MED
acid	I-MED
uric	B-MED
acid	I-MED
stones	I-MED
,	O
and	O
lack	B-MED
of	I-MED
awareness	I-MED
among	O
clinicians	B-MED
are	O
among	O
the	O
causes	B-MED
for	O
the	O
underdiagnoses	B-MED
of	O
this	O
treatable	B-MED
disease	B-MED
.	O
Allopurinol	B-MED
,	O
a	O
xanthine	B-MED
dehydrogenase	I-MED
inhibitor	B-MED
,	O
is	O
the	O
mainstay	O
of	O
treatment	B-MED
,	O
supported	O
by	O
high	O
fluid	B-MED
intake	I-MED
and	O
dietary	B-MED
modifications	I-MED
.	O
The	O
possibility	O
of	O
adenine	B-MED
phosphoribosyl	I-MED
transferase	I-MED
adenine	B-MED
phosphoribosyl	I-MED
transferase	I-MED
deficiency	I-MED
should	O
be	O
considered	O
in	O
all	O
cases	O
of	O
urolithiasis	B-MED
in	O
children	B-MED
,	O
patients	B-MED
with	O
recurrent	B-MED
urolithiasis	I-MED
,	O
and	O
patients	B-MED
with	O
urolithiasis	B-MED
associated	B-MED
with	I-MED
renal	B-MED
failure	I-MED
of	O
unknown	O
cause	B-MED
,	O
including	O
patients	B-MED
with	O
end	B-MED
-	I-MED
stage	I-MED
renal	I-MED
disease	I-MED
and	O
renal	B-MED
transplant	I-MED
recipients	I-MED
.	O
Here	O
,	O
we	O
report	O
a	O
case	O
of	O
a	O
41	O
-	O
year	O
-	O
old	O
female	B-MED
patient	I-MED
who	O
had	O
a	O
late	B-MED
diagnosis	I-MED
of	O
2,8	B-MED
-	I-MED
dihydroxyadenine	I-MED
nephropathy	B-MED
-induced	O
end	B-MED
-	I-MED
stage	I-MED
renal	I-MED
disease	I-MED
,	O
made	O
on	O
the	O
native	B-MED
nephrectomy	B-MED
that	O
accompanied	O
the	O
renal	B-MED
transplant	I-MED
,	O
and	O
who	O
had	O
a	O
timely	O
intervention	O
that	O
prevented	B-MED
recurrence	B-MED
in	O
the	O
graft	B-MED
.	O
Diabetes	B-MED
and	O
breast	B-MED
cancer	I-MED
mortality	B-MED
in	O
Black	B-MED
women	I-MED
Breast	B-MED
cancer	I-MED
mortality	B-MED
is	O
higher	O
in	O
Black	B-MED
women	I-MED
than	O
in	O
White	B-MED
women	I-MED
.	O
The	O
prevalence	B-MED
of	O
type	B-MED
2	I-MED
diabetes	I-MED
mellitus	I-MED
is	O
also	O
higher	O
,	O
yet	O
data	B-MED
on	O
whether	O
diabetes	B-MED
affects	B-MED
breast	B-MED
cancer	I-MED
mortality	B-MED
in	O
this	O
population	B-MED
are	O
lacking	B-MED
.	O
We	O
investigated	B-MED
the	O
relation	O
of	O
diabetes	B-MED
at	O
the	O
time	O
of	O
breast	B-MED
cancer	I-MED
diagnosis	B-MED
to	O
breast	B-MED
cancer	I-MED
mortality	B-MED
in	O
the	O
Black	B-MED
Women	I-MED
's	I-MED
Health	B-MED
Study	B-MED
,	O
a	O
prospective	B-MED
cohort	I-MED
study	I-MED
.	O
1,621	O
Black	B-MED
women	I-MED
with	O
invasive	B-MED
breast	B-MED
cancer	I-MED
diagnosed	B-MED
in	O
1995	O
-	O
2013	O
were	O
followed	B-MED
by	I-MED
mailed	O
questionnaires	B-MED
and	O
searches	O
of	O
the	O
National	B-MED
Death	I-MED
Index	I-MED
.	O
Multivariable	B-MED
Cox	I-MED
regression	I-MED
analysis	I-MED
was	O
used	O
to	O
compute	O
hazard	B-MED
ratios	I-MED
(	O
HRs	B-MED
)	O
for	O
diabetes	B-MED
in	O
relation	O
to	O
breast	B-MED
cancer	I-MED
mortality	B-MED
and	O
all	O
-	O
cause	O
mortality	B-MED
,	O
with	O
adjustment	O
for	O
age	B-MED
,	O
stage	B-MED
,	O
treatment	B-MED
modality	I-MED
,	O
estrogen	B-MED
receptor	I-MED
(	O
ER	B-MED
)	O
status	B-MED
,	O
and	O
body	B-MED
mass	I-MED
index	I-MED
.	O
There	O
were	O
368	O
deaths	B-MED
during	O
follow	B-MED
-	I-MED
up	I-MED
,	O
of	O
which	O
273	O
were	O
due	O
to	O
breast	B-MED
cancer	I-MED
.	O
Breast	B-MED
cancer	I-MED
mortality	B-MED
was	O
significantly	B-MED
increased	I-MED
in	O
women	B-MED
who	O
had	O
been	O
diagnosed	B-MED
with	O
diabetes	B-MED
at	O
least	O
5	O
years	O
before	O
breast	B-MED
cancer	I-MED
occurrence	B-MED
,	O
HR	B-MED
1.86	O
(	O
95	O
%	O
CI	O
1.20	O
-	O
2.89	O
)	O
,	O
with	O
elevations	B-MED
observed	B-MED
for	O
both	O
ER+	B-MED
and	O
ER-	B-MED
breast	B-MED
cancer	I-MED
.	O
All	O
-	O
cause	O
mortality	B-MED
was	O
also	O
higher	O
in	O
diabetics	B-MED
,	O
with	O
HRs	B-MED
of	O
1.54	O
(	O
95	O
%	O
CI	O
1.12	O
-	O
2.07	O
)	O
overall	B-MED
and	O
2.26	O
(	O
95	O
%	O
CI	O
1.62	O
-	O
3.15	O
)	O
for	O
≥5	O
-	O
year	O
duration	O
of	O
diabetes	B-MED
relative	B-MED
to	O
non	B-MED
-	I-MED
diabetics	I-MED
.	O
Our	O
results	B-MED
present	B-MED
the	O
first	O
solid	O
evidence	B-MED
of	O
a	O
positive	B-MED
association	O
of	O
type	B-MED
2	I-MED
diabetes	I-MED
with	O
breast	B-MED
cancer	I-MED
mortality	B-MED
in	O
Black	B-MED
women	I-MED
.	O
Given	O
the	O
higher	O
prevalence	B-MED
and	O
earlier	B-MED
onset	I-MED
of	O
type	B-MED
2	I-MED
diabetes	I-MED
in	O
Black	B-MED
women	I-MED
,	O
it	O
is	O
likely	O
that	O
diabetes	B-MED
contributes	B-MED
to	O
racial	B-MED
disparities	B-MED
in	O
breast	B-MED
cancer	I-MED
mortality	B-MED
.	O
Matrix	B-MED
solid	I-MED
-	I-MED
phase	I-MED
dispersion	I-MED
combined	O
to	O
liquid	B-MED
chromatography	I-MED
-	I-MED
tandem	I-MED
mass	I-MED
spectrometry	I-MED
for	O
the	O
determination	B-MED
of	O
paraben	B-MED
preservatives	B-MED
in	O
mollusks	B-MED
A	O
method	B-MED
for	I-MED
the	I-MED
extraction	I-MED
and	O
determination	B-MED
of	O
seven	O
parabens	B-MED
,	O
esters	B-MED
of	O
4	B-MED
-	I-MED
hydroxybenzoic	I-MED
acid	I-MED
,	O
widely	O
used	O
as	O
preservatives	B-MED
in	O
personal	B-MED
care	I-MED
products	I-MED
,	O
pharmaceuticals	B-MED
,	O
etc	O
.	O
,	O
and	O
two	O
chlorinated	B-MED
derivatives	I-MED
(	O
mono-	B-MED
and	O
di	B-MED
-	I-MED
chloro	I-MED
methyl	I-MED
paraben	I-MED
)	O
from	O
mollusk	B-MED
samples	B-MED
was	O
developed	O
by	O
combining	O
matrix	B-MED
solid	I-MED
-	I-MED
phase	I-MED
dispersion	I-MED
(	O
MSPD	B-MED
)	O
and	O
liquid	B-MED
chromatography	I-MED
-	I-MED
tandem	I-MED
mass	I-MED
spectrometry	I-MED
.	O
MSPD	B-MED
parameters	I-MED
,	O
such	O
as	O
solvent	B-MED
,	O
solid	B-MED
support	I-MED
and	O
clean	B-MED
-	I-MED
up	I-MED
sorbent	I-MED
,	O
were	O
optimized	B-MED
.	O
Besides	O
,	O
since	O
blank	O
problems	O
were	O
observed	O
for	O
some	O
parabens	B-MED
,	O
these	O
were	O
investigated	B-MED
and	O
blanks	O
were	O
tackled	O
by	O
precleaning	B-MED
all	O
sorbents	B-MED
prior	O
to	O
use	O
.	O
Under	O
final	O
conditions	O
,	O
0.5	O
g	O
of	O
freeze	B-MED
-	I-MED
dried	I-MED
mollusk	B-MED
were	O
dispersed	B-MED
with	O
1.2	O
g	O
of	O
silica	B-MED
and	O
packed	B-MED
into	O
a	O
cartridge	B-MED
containing	O
3	O
g	O
of	O
C18	B-MED
,	O
as	O
on	O
-	O
line	O
clean	B-MED
-	I-MED
up	I-MED
sorbent	I-MED
.	O
This	O
cartridge	B-MED
was	O
eluted	O
with	O
10mL	O
of	O
acetonitrile	B-MED
,	O
evaporated	B-MED
and	O
reconstituted	B-MED
in	O
methanol	B-MED
for	O
analysis	B-MED
.	O
In	O
the	O
validation	B-MED
stage	O
,	O
successful	O
linearity	O
(	O
R(2)>0.999	O
)	O
,	O
recoveries	B-MED
(	O
between	O
71	O
and	O
117	O
%	O
for	O
most	O
analytes	B-MED
)	O
,	O
precision	B-MED
(	O
RSD	O
lower	O
than	O
21	O
%	O
)	O
and	O
limits	B-MED
of	I-MED
detection	I-MED
and	O
quantification	B-MED
(	O
LOD	B-MED
and	O
LOQ	B-MED
,	O
lower	O
than	O
0.4	O
and	O
1.4ngg(-1	O
)	O
dry	B-MED
weight	I-MED
respectively	O
)	O
levels	B-MED
were	O
achieved	O
.	O
Finally	O
,	O
the	O
new	O
methodology	B-MED
was	O
applied	O
to	O
mussel	B-MED
,	O
clam	B-MED
and	O
cockle	B-MED
samples	B-MED
.	O
Methyl	B-MED
paraben	I-MED
was	O
above	O
the	O
LOQ	B-MED
in	O
five	O
of	O
the	O
six	O
samples	B-MED
(	O
not	O
found	O
in	O
one	O
clam	B-MED
sample	B-MED
)	O
at	O
concentrations	B-MED
up	O
to	O
7ngg(-1	O
)	O
dry	B-MED
weight	I-MED
.	O
Ethyl	B-MED
paraben	I-MED
was	O
found	O
above	O
the	O
LOQ	B-MED
in	O
mussel	B-MED
and	O
cockle	B-MED
samples	B-MED
at	O
a	O
concentration	B-MED
level	I-MED
around	O
0.3ngg(-1	O
)	O
.	O
n	B-MED
-	I-MED
Propyl	I-MED
paraben	I-MED
was	O
only	O
above	O
the	O
LOQ	B-MED
in	O
one	O
mussel	B-MED
sample	B-MED
.	O
Evidence	O
for	O
instructions	B-MED
-based	O
updating	O
of	O
task	B-MED
-	I-MED
set	I-MED
representations	I-MED
:	O
the	O
informed	B-MED
fadeout	B-MED
effect	I-MED
The	O
cognitive	B-MED
system	I-MED
can	O
be	O
updated	O
rapidly	O
and	O
efficiently	O
to	O
maximize	O
performance	B-MED
in	O
cognitive	B-MED
tasks	I-MED
.	O
This	O
paper	O
used	O
a	O
task	B-MED
-	O
switching	B-MED
task	B-MED
to	O
explore	O
updating	O
at	O
the	O
level	B-MED
of	O
the	O
plausible	O
task	B-MED
-sets	O
held	O
for	O
future	O
performance	B-MED
.	O
Previous	O
research	B-MED
suggested	O
a	O
"	O
fadeout	B-MED
effect	I-MED
"	O
,	O
performance	B-MED
improvement	B-MED
when	O
moving	O
from	O
task	B-MED
-	O
switching	B-MED
context	O
to	O
single	B-MED
-	I-MED
task	I-MED
context	O
,	O
yet	O
this	O
effect	O
could	O
reflect	O
passive	B-MED
learning	B-MED
rather	O
than	O
intentional	B-MED
control	B-MED
.	O
In	O
a	O
novel	O
"	O
informed	B-MED
fadeout	B-MED
paradigm	B-MED
"	O
,	O
one	O
of	O
two	O
tasks	B-MED
was	O
canceled	O
for	O
a	O
certain	O
number	O
of	O
trials	B-MED
and	O
participants	B-MED
were	O
informed	B-MED
or	O
uninformed	B-MED
regarding	O
task	B-MED
cancelation	B-MED
.	O
The	O
"	O
informed	B-MED
fadeout	B-MED
effect	I-MED
"	O
indicates	O
better	O
performance	B-MED
in	O
the	O
informed	B-MED
than	O
uninformed	B-MED
fadeout	B-MED
after	O
one	O
informed	B-MED
trial	B-MED
had	O
been	O
executed	B-MED
.	O
However	O
,	O
the	O
results	O
regarding	O
the	O
first	O
trial	B-MED
were	O
inconclusive	O
.	O
Possible	O
underlying	O
mechanisms	B-MED
are	O
discussed	O
.	O
Structural	B-MED
Insights	B-MED
into	O
5	B-MED
-	I-MED
HT1A	I-MED
/	O
D4	B-MED
Selectivity	B-MED
of	O
WAY-100635	B-MED
Analogues	B-MED
:	O
Molecular	B-MED
Modeling	I-MED
,	O
Synthesis	B-MED
,	O
and	O
in	B-MED
Vitro	I-MED
Binding	B-MED
The	O
resurgence	O
of	O
interest	O
in	O
5	B-MED
-	I-MED
HT1A	I-MED
receptors	I-MED
as	O
a	O
therapeutic	B-MED
target	B-MED
requires	O
the	O
existence	O
of	O
highly	O
selective	B-MED
5	B-MED
-	I-MED
HT1A	I-MED
ligands	B-MED
.	O
To	O
date	O
,	O
WAY-100635	B-MED
has	O
been	O
the	O
prototypical	B-MED
antagonist	I-MED
of	O
these	O
receptors	B-MED
.	O
However	O
,	O
this	O
compound	B-MED
also	O
has	O
significant	O
affinity	B-MED
for	O
and	O
activity	O
at	O
D4	B-MED
dopamine	I-MED
receptors	I-MED
.	O
In	O
this	O
context	O
,	O
this	O
work	O
was	O
aimed	O
at	O
better	O
understanding	O
the	O
5	B-MED
-	I-MED
HT1A	I-MED
/	O
D4	B-MED
selectivity	B-MED
of	O
WAY-100635	B-MED
and	O
analogues	B-MED
from	O
a	O
structural	B-MED
point	O
of	O
view	O
.	O
In	B-MED
silico	I-MED
investigations	B-MED
revealed	O
two	O
key	O
interactions	B-MED
for	O
the	O
5	B-MED
-	I-MED
HT1A	I-MED
/	O
D4	B-MED
selectivity	B-MED
of	O
WAY-100635	B-MED
and	O
analogues	B-MED
.	O
First	O
,	O
a	O
hydrogen	B-MED
bond	I-MED
only	O
found	O
with	O
the	O
Ser	B-MED
7.36	I-MED
of	O
D4	B-MED
receptor	I-MED
appeared	O
to	O
be	O
the	O
key	O
for	O
a	O
higher	O
D4	B-MED
affinity	B-MED
for	O
newly	O
synthesized	B-MED
aza	B-MED
analogues	B-MED
.	O
The	O
role	O
of	O
Ser	B-MED
7.36	I-MED
was	O
confirmed	O
as	O
the	O
affinity	B-MED
of	O
aza	B-MED
analogues	B-MED
for	O
the	O
mutant	B-MED
D4	B-MED
receptor	I-MED
S7.36A	I-MED
was	O
reduced	O
.	O
Then	O
,	O
the	O
formation	O
of	O
another	O
hydrogen	B-MED
bond	I-MED
with	O
the	O
conserved	O
Ser	B-MED
5.42	I-MED
residue	I-MED
appeared	O
to	O
be	O
also	O
critical	O
for	O
D4	B-MED
binding	B-MED
.	O
Heteroprotein	B-MED
Complex	B-MED
Formation	O
of	O
Bovine	B-MED
Lactoferrin	I-MED
and	O
Pea	B-MED
Protein	I-MED
Isolate	B-MED
:	O
A	O
Multiscale	O
Structural	O
Analysis	O
Associative	B-MED
electrostatic	B-MED
interactions	I-MED
between	O
two	O
oppositely	B-MED
charged	B-MED
globular	B-MED
proteins	I-MED
,	O
lactoferrin	B-MED
(	O
LF	B-MED
)	O
and	O
pea	B-MED
protein	I-MED
isolate	B-MED
(	O
PPI	B-MED
)	O
,	O
the	O
latter	O
being	O
a	O
mixture	B-MED
of	O
vicilin	B-MED
,	O
legumin	B-MED
,	O
and	O
convicilin	B-MED
,	O
was	O
studied	B-MED
with	O
a	O
specific	B-MED
PPI	B-MED
/	O
LF	B-MED
molar	B-MED
ratio	I-MED
at	O
room	B-MED
temperature	I-MED
.	O
Structural	B-MED
aspects	B-MED
of	O
the	O
electrostatic	B-MED
complexes	B-MED
probed	O
at	O
different	B-MED
length	B-MED
scales	B-MED
were	O
investigated	B-MED
as	O
a	O
function	B-MED
of	O
pH	B-MED
by	O
means	O
of	O
different	B-MED
complementary	B-MED
techniques	I-MED
,	O
namely	O
,	O
with	O
dynamic	B-MED
light	I-MED
scattering	I-MED
,	O
small	B-MED
-	I-MED
angle	I-MED
X	I-MED
-	I-MED
ray	I-MED
scattering	I-MED
(	O
SAXS	B-MED
)	O
,	O
turbidity	B-MED
measurements	I-MED
,	O
and	O
atomic	B-MED
force	I-MED
microscopy	I-MED
(	O
AFM	B-MED
)	O
.	O
Irrespective	O
of	O
the	O
applied	O
techniques	B-MED
,	O
the	O
results	B-MED
consistently	B-MED
displayed	B-MED
that	O
complexation	B-MED
between	O
LF	B-MED
and	O
PPI	B-MED
did	O
occur	B-MED
.	O
In	O
an	O
optimum	B-MED
narrow	B-MED
range	B-MED
of	O
pH	B-MED
5.0	O
-	O
5.8	O
,	O
a	O
viscous	B-MED
liquid	B-MED
phase	B-MED
of	O
complex	B-MED
coacervate	B-MED
was	O
obtained	B-MED
upon	O
mild	O
centrifugation	B-MED
of	O
the	O
turbid	B-MED
LF	B-MED
-	O
PPI	B-MED
mixture	B-MED
with	O
a	O
maximum	B-MED
Rh	O
,	O
turbidity	B-MED
and	O
the	O
ζ	B-MED
-	I-MED
potential	I-MED
being	O
close	O
to	O
zero	O
observed	B-MED
at	O
pH	B-MED
5.4	O
.	O
In	O
particular	O
,	O
the	O
SAXS	B-MED
data	B-MED
demonstrated	O
that	O
the	O
coacervates	B-MED
were	O
densely	B-MED
assembled	B-MED
with	O
a	O
roughly	B-MED
spherical	B-MED
size	B-MED
distribution	B-MED
exhibiting	O
a	O
maximum	B-MED
extension	B-MED
of	O
∼80	O
nm	O
at	O
pH	B-MED
5.4	O
.	O
Equally	O
,	O
AFM	B-MED
image	B-MED
analysis	I-MED
showed	O
size	B-MED
distributions	B-MED
containing	B-MED
most	O
frequent	B-MED
cluster	B-MED
sizes	B-MED
around	O
40	O
-	O
80	O
nm	O
with	O
spherical	B-MED
to	O
elliptical	B-MED
shapes	I-MED
(	O
axis	O
aspect	O
ratio	O
≤	O
2	O
)	O
as	O
well	O
as	O
less	O
frequent	B-MED
elongated	O
to	O
chainlike	B-MED
structures	B-MED
.	O
The	O
most	O
frequently	B-MED
observed	B-MED
compact	O
complexes	B-MED
,	O
we	O
identify	O
as	O
mainly	O
leading	O
to	O
LF	B-MED
-	O
PPI	B-MED
coacervation	B-MED
,	O
whereas	O
for	O
the	O
less	O
frequent	B-MED
chain	B-MED
-	I-MED
like	I-MED
aggregates	I-MED
,	O
we	O
hypothesize	O
that	O
additionally	O
PPI	B-MED
-	O
PPI	B-MED
facilitated	O
complexes	B-MED
exist	O
.	O
Genomic	B-MED
analysis	I-MED
of	O
nontypeable	B-MED
pneumococci	I-MED
causing	O
invasive	B-MED
pneumococcal	I-MED
disease	I-MED
in	O
South	B-MED
Africa	I-MED
,	O
2003	O
-	O
2013	O
The	O
capsular	B-MED
polysaccharide	I-MED
is	O
the	O
principal	O
virulence	B-MED
factor	I-MED
of	O
Streptococcus	B-MED
pneumoniae	I-MED
and	O
a	O
target	B-MED
for	O
current	O
pneumococcal	B-MED
vaccines	I-MED
.	O
However	O
,	O
some	O
pathogenic	B-MED
pneumococci	B-MED
are	O
serologically	B-MED
nontypeable	I-MED
[	O
nontypeable	B-MED
pneumococci	I-MED
(	O
NTPn	B-MED
)	O
]	O
.	O
Due	O
to	O
their	O
relative	O
rarity	B-MED
,	O
NTPn	B-MED
are	O
poorly	O
characterized	B-MED
,	O
and	O
,	O
as	O
such	O
,	O
limited	O
data	B-MED
exist	O
which	O
describe	O
these	O
organisms	B-MED
.	O
We	O
aimed	O
to	O
describe	O
disease	B-MED
and	O
genotypically	B-MED
characterize	B-MED
NTPn	B-MED
causing	O
invasive	B-MED
pneumococcal	I-MED
disease	I-MED
in	O
South	B-MED
Africa	I-MED
.	O
Isolates	B-MED
were	O
detected	O
through	O
national	O
,	O
laboratory	B-MED
-	O
based	B-MED
surveillance	B-MED
for	O
invasive	B-MED
pneumococcal	I-MED
disease	I-MED
in	O
South	B-MED
Africa	I-MED
and	O
characterized	B-MED
by	O
whole	O
genome	B-MED
analysis	I-MED
.	O
We	O
predicted	O
ancestral	B-MED
serotypes	B-MED
(	O
serotypes	B-MED
from	O
which	O
NTPn	B-MED
may	O
have	O
originated	O
)	O
for	O
Group	B-MED
I	I-MED
NTPn	B-MED
using	O
multilocus	B-MED
sequence	I-MED
typing	I-MED
and	O
capsular	B-MED
region	I-MED
sequence	B-MED
analyses	I-MED
.	O
Antimicrobial	B-MED
resistance	I-MED
patterns	B-MED
and	O
mutations	B-MED
potentially	B-MED
causing	O
nontypeability	B-MED
were	O
identified	B-MED
.	O
From	O
2003	O
-	O
2013	O
,	O
39	O
(	O
0.1	O
%	O
,	O
39/32,824	O
)	O
NTPn	B-MED
were	O
reported	O
.	O
Twenty	B-MED
-	I-MED
two	I-MED
(	O
56	O
%	O
)	O
had	O
partial	B-MED
capsular	B-MED
genes	I-MED
(	O
Group	B-MED
I	I-MED
)	O
and	O
17	O
(	O
44	O
%	O
)	O
had	O
complete	B-MED
capsular	B-MED
deletion	I-MED
of	O
which	O
15	O
had	O
replacement	B-MED
by	O
other	O
genes	B-MED
(	O
Group	B-MED
II	I-MED
)	O
.	O
Seventy	B-MED
-	I-MED
nine	I-MED
percent	B-MED
(	O
31/39	O
)	O
of	O
our	O
NTPn	B-MED
isolates	B-MED
were	O
derived	O
from	O
encapsulated	B-MED
S.	B-MED
pneumoniae	I-MED
.	O
Ancestral	O
serotypes	B-MED
1	O
(	O
27	O
%	O
,	O
6/22	O
)	O
and	O
8	O
(	O
14	O
%	O
,	O
3/22	O
)	O
were	O
most	O
prevalent	O
,	O
and	O
59	O
%	O
(	O
13/22	O
)	O
of	O
ancestral	B-MED
serotypes	B-MED
were	O
serotypes	B-MED
included	O
in	O
the	O
13	B-MED
-	I-MED
valent	I-MED
pneumococcal	I-MED
conjugate	I-MED
vaccine	I-MED
.	O
We	O
identified	O
a	O
variety	O
of	O
mutations	B-MED
within	O
the	O
capsular	B-MED
region	I-MED
of	O
Group	B-MED
I	I-MED
NTPn	B-MED
,	O
some	O
of	O
which	O
may	O
be	O
responsible	O
for	O
the	O
nontypeable	B-MED
phenotype	B-MED
.	O
Nonsusceptibility	B-MED
to	O
tetracycline	B-MED
and	O
erythromycin	B-MED
was	O
higher	O
in	O
NTPn	B-MED
than	O
encapsulated	B-MED
S.	B-MED
pneumoniae	I-MED
.	O
NTPn	B-MED
are	O
currently	O
a	O
rare	O
cause	O
of	O
invasive	B-MED
pneumococcal	I-MED
disease	I-MED
in	O
South	B-MED
Africa	I-MED
and	O
represent	O
a	O
genetically	O
diverse	O
collection	O
of	O
isolates	O
.	O
Engagement	O
of	O
cellular	B-MED
prion	I-MED
protein	I-MED
with	O
the	O
co	B-MED
-	I-MED
chaperone	I-MED
Hsp70	B-MED
Hsp70	B-MED
/	I-MED
90	I-MED
organizing	I-MED
protein	I-MED
90	B-MED
regulates	O
the	O
proliferation	B-MED
of	O
glioblastoma	B-MED
glioblastoma	B-MED
stem	I-MED
-	I-MED
like	I-MED
cells	I-MED
Glioblastoma	B-MED
(	O
GBM	B-MED
)	O
,	O
a	O
highly	O
aggressive	O
brain	B-MED
tumor	I-MED
,	O
contains	O
a	O
subpopulation	O
of	O
glioblastoma	B-MED
glioblastoma	B-MED
stem	I-MED
-	I-MED
like	I-MED
cells	I-MED
(	O
GSCs	B-MED
)	O
that	O
play	O
roles	O
in	O
tumor	B-MED
maintenance	B-MED
,	O
invasion	B-MED
,	O
and	O
therapeutic	B-MED
resistance	I-MED
.	O
GSCs	B-MED
are	O
therefore	O
a	O
promising	O
target	B-MED
for	O
GBM	B-MED
treatment	B-MED
.	O
Our	O
group	O
identified	O
the	O
cellular	B-MED
prion	I-MED
protein	I-MED
(	O
PrP(C	B-MED
)	I-MED
)	O
and	O
its	O
partner	O
,	O
the	O
co	B-MED
-	I-MED
chaperone	I-MED
Hsp70	B-MED
Hsp70	B-MED
/	I-MED
90	I-MED
organizing	I-MED
protein	I-MED
90	B-MED
(	O
HOP	B-MED
)	O
,	O
as	O
potential	O
target	B-MED
candidates	O
due	O
to	O
their	O
role	O
in	O
GBM	B-MED
tumorigenesis	B-MED
and	O
in	O
neural	B-MED
stem	I-MED
cell	I-MED
maintenance	O
.	O
GSCs	B-MED
expressing	O
different	O
levels	O
of	O
PrP(C	B-MED
)	I-MED
were	O
cultured	B-MED
as	O
neurospheres	B-MED
with	O
growth	B-MED
factors	I-MED
,	O
and	O
characterized	O
with	O
stem	B-MED
cells	I-MED
markers	B-MED
and	O
adhesion	B-MED
molecules	I-MED
markers	I-MED
through	O
immunofluorescence	B-MED
and	O
flow	B-MED
cytometry	I-MED
.	O
We	O
than	O
evaluated	O
GSC	B-MED
self	B-MED
-	I-MED
renewal	I-MED
and	O
proliferation	B-MED
by	O
clonal	B-MED
density	I-MED
assays	I-MED
and	O
BrdU	B-MED
BrdU	B-MED
incorporation	I-MED
,	O
respectively	O
,	O
in	O
front	O
of	O
recombinant	O
HOP	B-MED
treatment	B-MED
,	O
combined	O
or	O
not	O
with	O
a	O
HOP	B-MED
peptide	B-MED
which	O
mimics	O
the	O
PrP(C	B-MED
)	I-MED
binding	B-MED
site	I-MED
.	O
Stable	O
silencing	B-MED
of	O
HOP	B-MED
was	O
also	O
performed	O
in	O
parental	O
and/or	O
PrP(C	B-MED
)	I-MED
-depleted	O
cell	B-MED
populations	I-MED
,	O
and	O
proliferation	B-MED
in	B-MED
vitro	I-MED
and	O
tumor	B-MED
growth	I-MED
in	B-MED
vivo	I-MED
were	O
evaluated	O
.	O
Migration	B-MED
assays	I-MED
were	O
performed	O
on	O
laminin-1	B-MED
laminin-1	B-MED
pre	I-MED
-	I-MED
coated	I-MED
glass	I-MED
.	O
We	O
observed	O
that	O
,	O
when	O
GBM	B-MED
cells	B-MED
are	O
cultured	B-MED
as	O
neurospheres	B-MED
,	O
they	O
express	O
specific	O
stemness	B-MED
markers	I-MED
such	O
as	O
CD133	B-MED
,	O
CD15	B-MED
,	O
Oct4	B-MED
,	O
and	O
SOX2	B-MED
;	O
PrP(C	B-MED
)	I-MED
is	O
upregulated	O
compared	O
to	O
monolayer	B-MED
culture	I-MED
and	O
co	O
-	O
localizes	O
with	O
CD133	B-MED
.	O
PrP(C	B-MED
)	I-MED
silencing	B-MED
downregulates	O
the	O
expression	B-MED
of	I-MED
molecules	I-MED
associated	O
with	O
cancer	B-MED
stem	I-MED
cells	I-MED
,	O
upregulates	O
markers	B-MED
of	O
cell	B-MED
differentiation	I-MED
and	O
affects	O
GSC	B-MED
self	B-MED
-	I-MED
renewal	I-MED
,	O
pointing	O
to	O
a	O
pivotal	O
role	O
for	O
PrP(C	B-MED
)	I-MED
in	O
the	O
maintenance	O
of	O
GSCs	B-MED
.	O
Exogenous	O
HOP	B-MED
treatment	B-MED
increases	O
proliferation	B-MED
and	O
self	B-MED
-	I-MED
renewal	I-MED
of	O
GSCs	B-MED
in	O
a	O
PrP(C	B-MED
)	I-MED
-dependent	O
manner	O
while	O
HOP	B-MED
knockdown	O
disturbs	O
the	O
proliferation	B-MED
process	I-MED
.	O
In	B-MED
vivo	I-MED
,	O
PrP(C	B-MED
)	I-MED
and/or	O
HOP	B-MED
knockdown	O
potently	O
inhibits	B-MED
the	O
growth	B-MED
of	O
subcutaneously	O
implanted	O
glioblastoma	B-MED
cells	B-MED
.	O
In	O
addition	O
,	O
disruption	O
of	O
the	O
PrP(C	B-MED
)	I-MED
PrP(C	B-MED
)	I-MED
-	I-MED
HOP	I-MED
complex	I-MED
HOP	B-MED
by	O
a	O
HOP	B-MED
peptide	B-MED
,	O
which	O
mimics	O
the	O
PrP(C	B-MED
)	I-MED
binding	B-MED
site	I-MED
,	O
affects	O
GSC	B-MED
self	B-MED
-	I-MED
renewal	I-MED
and	O
proliferation	B-MED
indicating	O
that	O
the	O
HOP	B-MED
HOP	B-MED
-	I-MED
PrP(C	I-MED
)	I-MED
complex	I-MED
PrP(C	B-MED
)	I-MED
is	O
required	O
for	O
GSC	B-MED
stemness	B-MED
.	O
Furthermore	O
,	O
PrP(C	B-MED
)	I-MED
-depleted	O
GSCs	B-MED
downregulate	O
cell	B-MED
adhesion	B-MED
-	I-MED
related	I-MED
proteins	I-MED
and	O
impair	O
cell	B-MED
migration	I-MED
indicating	O
a	O
putative	O
role	O
for	O
PrP(C	B-MED
)	I-MED
in	O
the	O
cell	B-MED
surface	I-MED
stability	I-MED
of	O
cell	B-MED
adhesion	I-MED
molecules	I-MED
and	O
GBM	B-MED
cell	O
invasiveness	B-MED
,	O
respectively	O
.	O
In	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
the	O
modulation	O
of	O
HOP	B-MED
-	O
PrP(C	B-MED
)	I-MED
engagement	O
or	O
the	O
decrease	O
of	O
PrP(C	B-MED
)	I-MED
and	O
HOP	B-MED
expression	B-MED
may	O
represent	O
a	O
potential	O
therapeutic	B-MED
intervention	I-MED
in	O
GBM	B-MED
,	O
regulating	O
glioblastoma	B-MED
glioblastoma	B-MED
stem	I-MED
-	I-MED
like	I-MED
cell	I-MED
self	B-MED
-	I-MED
renewal	I-MED
,	O
proliferation	B-MED
,	O
and	O
migration	B-MED
.	O
Mildly	B-MED
raised	B-MED
tricuspid	B-MED
regurgitant	I-MED
velocity	I-MED
2.5	O
-	O
3.0	O
m	O
/	O
s	O
in	O
pregnant	B-MED
women	I-MED
with	O
sickle	B-MED
cell	I-MED
disease	I-MED
is	O
not	O
associated	B-MED
with	I-MED
poor	B-MED
obstetric	B-MED
outcome	B-MED
-	O
An	O
observational	B-MED
cross	I-MED
-	I-MED
sectional	I-MED
study	I-MED
Pulmonary	B-MED
hypertension	I-MED
is	O
associated	B-MED
with	I-MED
36	O
%	O
mortality	B-MED
in	O
pregnancy	B-MED
,	O
and	O
6	O
-	O
10	O
%	O
of	O
patients	B-MED
with	O
sickle	B-MED
cell	I-MED
disease	I-MED
have	O
pulmonary	B-MED
hypertension	I-MED
.	O
Tricuspid	B-MED
regurgitant	I-MED
velocity	I-MED
≥2.5	O
m	O
/	O
s	O
on	O
echocardiography	B-MED
is	O
a	O
well	O
validated	O
means	O
of	O
screening	B-MED
for	O
pulmonary	B-MED
hypertension	I-MED
in	O
the	O
non	B-MED
-	I-MED
pregnant	I-MED
population	B-MED
.	O
This	O
is	O
a	O
pilot	B-MED
study	I-MED
to	O
determine	O
if	O
this	O
is	O
a	O
useful	O
non	B-MED
-	I-MED
invasive	I-MED
screening	B-MED
test	I-MED
for	O
pulmonary	B-MED
hypertension	I-MED
in	O
pregnancy	B-MED
,	O
and	O
whether	O
raised	O
tricuspid	B-MED
regurgitant	I-MED
velocity	I-MED
≥2.5	O
m	O
/	O
s	O
was	O
associated	B-MED
with	I-MED
poor	B-MED
outcomes	B-MED
.	O
This	O
is	O
a	O
cross	B-MED
-	I-MED
sectional	I-MED
study	I-MED
over	O
a	O
five	O
-	O
year	O
period	O
in	O
a	O
tertiary	B-MED
referral	I-MED
centre	I-MED
with	O
a	O
specialised	O
multidisciplinary	B-MED
clinic	I-MED
for	O
pregnant	B-MED
women	I-MED
with	O
sickle	B-MED
cell	I-MED
disease	I-MED
.	O
Women	B-MED
with	O
sickle	B-MED
cell	I-MED
disease	I-MED
,	O
no	O
prior	O
pulmonary	B-MED
hypertension	I-MED
and	O
singleton	B-MED
pregnancies	B-MED
who	O
had	O
echocardiography	B-MED
with	O
a	O
measurable	O
tricuspid	B-MED
regurgitant	I-MED
velocity	I-MED
in	O
pregnancy	B-MED
were	O
included	O
.	O
There	O
were	O
34	O
pregnancies	B-MED
,	O
of	O
which	O
eight	O
had	O
tricuspid	B-MED
regurgitant	I-MED
velocity	I-MED
≥2.5	O
m	O
/	O
s.	O
There	O
were	O
no	B-MED
significant	I-MED
differences	O
in	O
their	O
characteristics	B-MED
,	O
sickle	B-MED
cell	I-MED
-related	O
complications	B-MED
or	O
medical	B-MED
co	B-MED
-	I-MED
morbidities	I-MED
.	O
The	O
women	B-MED
with	O
tricuspid	B-MED
regurgitant	I-MED
velocity	I-MED
≥2.5	O
m	O
/	O
s	O
had	O
similar	O
obstetric	B-MED
and	O
perinatal	B-MED
outcomes	B-MED
as	O
those	O
with	O
a	O
tricuspid	B-MED
regurgitant	I-MED
velocity	I-MED
<	O
2.5	O
m	O
/	O
s.	O
Abiraterone	B-MED
-	O
induced	B-MED
rhabdomyolysis	B-MED
resulting	O
in	O
acute	B-MED
kidney	I-MED
injury	I-MED
:	O
A	O
case	B-MED
report	I-MED
and	O
review	B-MED
of	I-MED
the	I-MED
literature	I-MED
Abiraterone	B-MED
,	O
a	O
CYP17	B-MED
inhibitor	I-MED
,	O
blocks	O
androgen	B-MED
biosynthesis	I-MED
in	O
multiple	O
tissue	B-MED
types	O
.	O
In	O
combination	O
with	O
prednisone	B-MED
,	O
it	O
is	O
approved	O
as	O
a	O
first	B-MED
-	I-MED
line	I-MED
treatment	I-MED
for	O
metastatic	B-MED
castration	B-MED
-	I-MED
resistant	I-MED
prostate	I-MED
cancer	I-MED
.	O
We	O
present	O
a	O
case	B-MED
of	O
rhabdomyolysis	B-MED
associated	O
with	O
abiraterone	B-MED
therapy	B-MED
resulting	O
in	O
acute	B-MED
on	O
chronic	B-MED
kidney	B-MED
injury	I-MED
in	O
a	O
patient	B-MED
with	O
metastatic	B-MED
castration	B-MED
-	I-MED
resistant	I-MED
prostate	I-MED
cancer	I-MED
.	O
Strict	O
monitoring	B-MED
should	O
be	O
employed	O
in	O
patients	B-MED
started	O
on	O
abiraterone	B-MED
who	O
have	O
additional	O
risk	B-MED
factors	I-MED
for	O
developing	O
rhabdomyolysis	B-MED
.	O
Reassembly	B-MED
of	I-MED
Excitable	I-MED
Domains	I-MED
after	O
CNS	B-MED
Axon	B-MED
Regeneration	I-MED
Action	B-MED
potential	I-MED
initiation	I-MED
and	O
propagation	B-MED
in	O
myelinated	B-MED
axons	I-MED
require	O
ion	B-MED
channel	I-MED
clustering	I-MED
at	O
axon	B-MED
initial	I-MED
segments	I-MED
(	B-MED
AIS	I-MED
)	O
and	O
nodes	B-MED
of	I-MED
Ranvier	I-MED
.	O
Disruption	B-MED
of	O
these	O
domains	O
after	O
injury	B-MED
impairs	B-MED
nervous	B-MED
system	I-MED
function	I-MED
.	O
Traditionally	O
,	O
injured	B-MED
CNS	B-MED
axons	B-MED
are	O
considered	O
refractory	B-MED
to	O
regeneration	B-MED
,	O
but	O
some	O
recent	O
approaches	O
challenge	O
this	O
view	O
by	O
showing	O
robust	B-MED
long	B-MED
-	I-MED
distance	I-MED
regeneration	B-MED
.	O
However	O
,	O
whether	O
these	O
approaches	O
allow	O
remyelination	B-MED
and	O
promote	O
the	O
reestablishment	B-MED
of	O
AIS	B-MED
and	O
nodes	B-MED
of	I-MED
Ranvier	I-MED
is	O
unknown	B-MED
.	O
Using	O
mouse	B-MED
optic	B-MED
nerve	I-MED
crush	B-MED
as	O
a	O
model	B-MED
for	O
CNS	B-MED
traumatic	B-MED
injury	I-MED
,	O
we	O
performed	O
a	O
detailed	O
analysis	B-MED
of	O
AIS	B-MED
and	O
node	B-MED
disruption	B-MED
after	O
nerve	B-MED
crush	I-MED
.	O
We	O
found	O
significant	O
disruption	B-MED
of	O
AIS	B-MED
and	O
loss	B-MED
of	O
nodes	B-MED
within	O
days	O
of	O
the	O
crush	B-MED
,	O
and	O
complete	O
loss	B-MED
of	O
nodes	B-MED
1	O
week	O
after	O
injury	B-MED
.	O
Genetic	B-MED
deletion	I-MED
of	O
the	O
tumor	B-MED
suppressor	I-MED
phosphatase	I-MED
and	I-MED
tensin	I-MED
homolog	I-MED
(	O
Pten	B-MED
)	O
in	O
retinal	B-MED
ganglion	I-MED
cells	I-MED
(	O
RGCs	B-MED
)	O
,	O
coupled	O
with	O
stimulation	B-MED
of	O
RGCs	B-MED
by	O
inflammation	B-MED
and	O
cAMP	B-MED
,	O
dramatically	O
enhanced	O
regeneration	B-MED
.	O
With	O
this	O
treatmen	B-MED
t	O
,	O
we	O
found	O
significant	O
reestablishment	B-MED
of	O
RGC	B-MED
AIS	B-MED
,	O
remyelination	B-MED
,	O
and	O
even	O
reassembly	B-MED
of	O
nodes	B-MED
in	O
regions	B-MED
proximal	I-MED
,	O
within	B-MED
,	O
and	O
distal	B-MED
to	O
the	O
crush	B-MED
site	B-MED
.	O
Remyelination	B-MED
began	O
near	B-MED
the	I-MED
retina	I-MED
,	O
progressed	B-MED
distally	B-MED
,	O
and	O
was	O
confirmed	O
by	O
electron	B-MED
microscopy	I-MED
.	O
Although	O
axons	B-MED
grew	B-MED
rapidly	B-MED
,	O
remyelination	B-MED
and	O
nodal	B-MED
ion	I-MED
channel	I-MED
clustering	I-MED
was	O
much	O
slower	B-MED
.	O
Finally	O
,	O
genetic	B-MED
deletion	I-MED
of	O
ankyrinG	B-MED
from	O
RGCs	B-MED
to	O
block	B-MED
AIS	B-MED
reassembly	B-MED
did	O
not	O
affect	O
axon	B-MED
regeneration	I-MED
,	O
indicating	O
that	O
preservation	O
of	O
neuronal	B-MED
polarity	I-MED
is	O
not	B-MED
required	I-MED
for	O
axon	B-MED
regeneration	I-MED
.	O
Together	O
,	O
our	O
results	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
regenerating	B-MED
CNS	B-MED
axons	B-MED
can	O
be	O
remyelinated	B-MED
and	O
reassemble	B-MED
new	O
AIS	B-MED
and	O
nodes	B-MED
of	I-MED
Ranvier	I-MED
.	O
We	O
show	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
regenerated	B-MED
CNS	B-MED
axons	B-MED
have	O
the	O
capacity	B-MED
to	O
both	O
remyelinate	B-MED
and	O
reassemble	B-MED
the	O
axon	B-MED
initial	I-MED
segments	I-MED
and	O
nodes	B-MED
of	I-MED
Ranvier	I-MED
necessary	O
for	O
rapid	B-MED
and	O
efficient	B-MED
action	B-MED
potential	I-MED
propagation	I-MED
.	O
Unconventional	B-MED
Protein	B-MED
Secretion	I-MED
in	O
Plants	B-MED
Unconventional	B-MED
protein	B-MED
secretion	I-MED
(	O
UPS	B-MED
)	O
describes	B-MED
secretion	B-MED
pathways	I-MED
that	O
bypass	O
one	O
or	O
several	B-MED
of	O
the	O
canonical	B-MED
secretion	B-MED
pit	O
-	O
stops	O
on	O
the	O
way	O
to	O
the	O
plasma	B-MED
membrane	I-MED
,	O
and/or	O
involve	B-MED
the	O
secretion	B-MED
of	O
leaderless	O
proteins	B-MED
.	O
So	O
far	O
,	O
alternatives	B-MED
to	O
conventional	B-MED
secretion	B-MED
were	O
primarily	B-MED
observed	B-MED
and	O
studied	B-MED
in	O
yeast	B-MED
and	O
animal	B-MED
cells	I-MED
.	O
The	O
sessile	B-MED
lifestyle	O
of	O
plants	B-MED
brings	O
with	O
it	O
unique	B-MED
restraints	O
on	O
how	O
they	O
adapt	B-MED
to	I-MED
adverse	I-MED
conditions	I-MED
and	O
environmental	B-MED
challenges	I-MED
.	O
Recently	O
,	O
attention	B-MED
towards	O
unconventional	B-MED
secretion	B-MED
pathways	I-MED
in	O
plant	B-MED
cells	I-MED
has	O
substantially	O
increased	O
,	O
with	O
the	O
large	O
number	O
of	O
leaderless	O
proteins	B-MED
identified	B-MED
through	O
proteomic	B-MED
studies	I-MED
.	O
While	O
UPS	B-MED
pathways	B-MED
in	O
plants	B-MED
are	O
certainly	O
not	O
yet	O
exhaustively	O
researched	O
,	O
an	O
emerging	O
notion	O
is	O
that	O
induction	B-MED
of	O
UPS	B-MED
pathways	B-MED
is	O
correlated	B-MED
with	O
pathogenesis	B-MED
and	O
stress	B-MED
responses	I-MED
.	O
Given	O
the	O
multitude	O
UPS	B-MED
events	O
observed	O
,	O
comprehensively	B-MED
organizing	B-MED
the	O
routes	O
proteins	B-MED
take	O
to	O
the	O
apoplast	B-MED
in	O
defined	O
UPS	B-MED
categories	O
is	O
challenging	O
.	O
With	O
the	O
establishment	B-MED
of	O
a	O
larger	O
collection	B-MED
of	O
studied	O
plant	B-MED
proteins	I-MED
taking	O
these	O
UPS	B-MED
pathways	B-MED
,	O
a	O
clearer	O
picture	O
of	O
endomembrane	B-MED
trafficking	B-MED
as	O
a	O
whole	O
will	O
emerge	O
.	O
There	O
are	O
several	B-MED
novel	B-MED
enabling	B-MED
technologies	B-MED
,	O
such	O
as	O
vesicle	B-MED
proteomics	B-MED
and	O
chemical	B-MED
genomics	B-MED
,	O
with	O
great	O
potential	B-MED
for	O
dissecting	B-MED
secretion	B-MED
pathways	I-MED
,	O
providing	B-MED
information	B-MED
about	O
the	O
cargo	O
that	O
travels	O
along	O
them	O
and	O
the	O
conditions	O
that	O
induce	B-MED
them	O
.	O
Isolation	B-MED
and	O
characterization	B-MED
of	O
Burkholderia	B-MED
sp	I-MED
.	I-MED
strain	I-MED
CCA53	I-MED
exhibiting	O
ligninolytic	B-MED
potential	B-MED
Microbial	B-MED
degradation	B-MED
of	O
lignin	B-MED
releases	O
fermentable	B-MED
sugars	I-MED
,	O
effective	B-MED
utilization	B-MED
of	O
which	O
could	O
support	O
biofuel	B-MED
production	B-MED
from	O
lignocellulosic	B-MED
biomass	B-MED
.	O
In	O
the	O
present	O
study	B-MED
,	O
a	O
lignin	B-MED
-	I-MED
degrading	I-MED
bacterium	B-MED
was	O
isolated	B-MED
from	O
leaf	B-MED
soil	B-MED
and	O
identified	O
as	O
Burkholderia	B-MED
sp	I-MED
.	I-MED
based	O
on	O
16S	B-MED
rRNA	I-MED
gene	B-MED
sequencing	I-MED
.	O
This	O
strain	B-MED
was	O
named	O
CCA53	B-MED
,	O
and	O
its	O
lignin	B-MED
-	I-MED
degrading	I-MED
capability	B-MED
was	O
assessed	B-MED
by	O
observing	O
its	O
growth	B-MED
on	O
medium	B-MED
containing	O
alkali	B-MED
lignin	I-MED
or	O
lignin	B-MED
-associated	O
aromatic	B-MED
monomers	I-MED
as	O
the	O
sole	O
carbon	B-MED
source	B-MED
.	O
Alkali	B-MED
lignin	I-MED
and	O
at	O
least	O
eight	O
lignin	B-MED
-associated	O
aromatic	B-MED
monomers	I-MED
supported	O
growth	B-MED
of	O
this	O
strain	B-MED
,	O
and	O
the	O
most	O
effective	B-MED
utilization	B-MED
was	O
observed	O
for	O
p	B-MED
-	I-MED
hydroxybenzene	I-MED
monomers	I-MED
.	O
These	O
findings	B-MED
indicate	O
that	O
Burkholderia	B-MED
sp	I-MED
.	I-MED
strain	I-MED
CCA53	I-MED
has	O
fragmentary	B-MED
activity	I-MED
for	O
lignin	B-MED
degradation	I-MED
.	O
KMAP	B-MED
-	I-MED
O	I-MED
framework	I-MED
for	O
care	B-MED
management	I-MED
research	B-MED
of	O
patients	B-MED
with	O
type	B-MED
2	I-MED
diabetes	I-MED
To	O
review	B-MED
impacts	B-MED
of	O
interventions	B-MED
involving	O
self	B-MED
-	I-MED
management	I-MED
education	I-MED
,	O
health	B-MED
coaching	I-MED
,	O
and	O
motivational	B-MED
interviewing	I-MED
for	O
type	B-MED
2	I-MED
diabetes	I-MED
.	O
A	O
thorough	O
review	B-MED
of	O
the	O
scientific	B-MED
literature	I-MED
on	O
diabetes	B-MED
care	B-MED
and	I-MED
management	I-MED
was	O
executed	O
by	O
a	O
research	B-MED
team	B-MED
.	O
This	O
article	B-MED
summarizes	O
important	O
findings	B-MED
in	O
regard	O
to	O
the	O
validity	B-MED
of	O
developing	B-MED
a	O
comprehensive	B-MED
behavioral	B-MED
system	I-MED
as	O
a	O
framework	B-MED
for	O
empirical	B-MED
investigation	B-MED
.	O
The	O
behavioral	B-MED
system	I-MED
framework	B-MED
consists	O
of	O
patients	B-MED
'	O
knowledge	B-MED
(	O
K	B-MED
)	O
,	O
motivation	B-MED
(	O
M	B-MED
)	O
,	O
attitude	B-MED
(	O
A	B-MED
)	O
,	O
and	O
practice	B-MED
(	O
P	B-MED
)	O
as	O
predictor	B-MED
variables	B-MED
for	O
diabetes	B-MED
care	B-MED
outcomes	I-MED
(	O
O	B-MED
)	O
.	O
Care	B-MED
management	I-MED
strategies	O
or	O
health	B-MED
education	I-MED
programs	I-MED
serve	O
as	O
the	O
intervention	B-MED
variable	B-MED
that	O
directly	O
influences	B-MED
K	B-MED
,	O
M	B-MED
,	O
A	B-MED
,	O
and	O
P	B-MED
and	O
then	O
indirectly	O
affects	O
the	O
variability	B-MED
in	O
patient	B-MED
care	B-MED
outcomes	I-MED
of	O
patients	B-MED
with	O
type	B-MED
2	I-MED
diabetes	I-MED
.	O
This	O
review	B-MED
contributes	O
to	O
the	O
understanding	O
of	O
the	O
KMAP	B-MED
-	I-MED
O	I-MED
framework	I-MED
and	O
how	O
it	O
can	O
guide	B-MED
the	O
care	B-MED
management	I-MED
of	O
patients	B-MED
with	O
type	B-MED
2	I-MED
diabetes	I-MED
.	O
It	O
will	O
allow	O
the	O
tailoring	O
of	O
interventions	B-MED
to	O
be	O
more	O
effective	O
through	O
knowledge	B-MED
enhancement	B-MED
,	O
increased	B-MED
motivation	I-MED
,	O
attitudinal	B-MED
changes	B-MED
,	O
and	O
improved	B-MED
preventive	B-MED
practice	I-MED
to	O
reduce	B-MED
the	O
progression	B-MED
of	O
type	B-MED
2	I-MED
diabetes	I-MED
and	O
comorbidities	B-MED
.	O
Furthermore	O
,	O
the	O
use	B-MED
of	I-MED
health	B-MED
information	I-MED
technology	I-MED
for	O
enhancing	B-MED
changes	B-MED
in	O
KMAP	B-MED
and	O
communications	B-MED
is	O
advocated	O
in	O
health	B-MED
promotion	I-MED
and	O
development	B-MED
.	O
SNAI1	B-MED
promotes	B-MED
the	O
development	B-MED
of	O
HCC	B-MED
through	O
the	O
enhancement	B-MED
of	O
proliferation	B-MED
and	O
inhibition	B-MED
of	I-MED
apoptosis	I-MED
SNAI1	B-MED
,	O
a	O
zinc	B-MED
-	I-MED
finger	I-MED
transcription	I-MED
factor	I-MED
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
induction	B-MED
of	O
epithelial	B-MED
-	I-MED
mesenchymal	I-MED
transition	I-MED
(	O
EMT	B-MED
)	O
in	O
various	O
cancers	B-MED
.	O
However	O
,	O
the	O
possible	O
functions	O
of	O
SNAI1	B-MED
in	O
the	O
proliferation	B-MED
and	O
apoptosis	B-MED
of	O
hepatocellular	B-MED
carcinoma	I-MED
have	O
not	O
been	O
clearly	O
identified	O
.	O
In	O
this	O
study	B-MED
,	O
we	O
investigated	O
the	O
effects	B-MED
and	O
mechanisms	B-MED
of	O
SNAI1	B-MED
in	O
the	O
proliferation	B-MED
and	O
apoptosis	B-MED
of	O
hepatocellular	B-MED
carcinoma	I-MED
using	O
clinical	B-MED
samples	B-MED
and	O
cell	B-MED
lines	I-MED
.	O
We	O
found	O
that	O
SNAI1	B-MED
is	O
highly	O
expressed	B-MED
in	O
the	O
tissues	B-MED
of	O
liver	B-MED
cancer	I-MED
compared	O
with	O
adjacent	O
nontumor	B-MED
tissues	I-MED
.	O
SNAI1	B-MED
is	O
also	O
highly	O
expressed	B-MED
in	O
the	O
hepatoma	B-MED
cell	I-MED
lines	I-MED
HepG2	I-MED
,	O
SMMC-7721	B-MED
,	O
and	O
BEL-7402	B-MED
compared	O
with	O
the	O
human	B-MED
normal	I-MED
liver	I-MED
cell	I-MED
line	I-MED
L02	I-MED
.	O
We	O
also	O
observed	O
that	O
SNAI1	B-MED
expression	B-MED
was	O
correlated	O
with	O
distal	B-MED
metastasis	I-MED
,	O
incomplete	O
tumor	B-MED
capsule	I-MED
formation	I-MED
,	O
and	O
histological	B-MED
differentiation	I-MED
in	O
hepatocellular	B-MED
carcinoma	I-MED
(	O
HCC	B-MED
)	O
.	O
Moreover	O
,	O
we	O
demonstrated	O
that	O
knockdown	B-MED
of	O
SNAI1	B-MED
via	O
lentiviral	B-MED
vectors	B-MED
of	O
RNAi	B-MED
against	O
SNAI	B-MED
inhibited	O
cell	B-MED
proliferation	I-MED
by	O
inducing	O
G1	B-MED
arrest	I-MED
,	O
which	O
was	O
accompanied	O
by	O
the	O
downregulation	B-MED
of	O
cyclin	B-MED
D1	I-MED
but	O
not	O
that	O
of	O
cyclin	B-MED
A	I-MED
A.	O
In	O
addition	O
,	O
knockdown	B-MED
of	O
SNAI1	B-MED
promoted	B-MED
apoptosis	B-MED
by	O
decreasing	O
the	O
expression	B-MED
of	O
Bcl-2	B-MED
.	O
In	O
conclusion	O
,	O
our	O
findings	O
revealed	O
that	O
SNAI1	B-MED
is	O
involved	O
in	O
the	O
development	B-MED
of	O
hepatocellular	B-MED
carcinoma	I-MED
via	O
regulating	B-MED
the	I-MED
growth	I-MED
and	O
apoptosis	B-MED
of	O
tumor	B-MED
cells	I-MED
.	O
Proliferation	B-MED
-enhancing	O
effects	B-MED
of	I-MED
gastrodin	B-MED
on	O
RSC96	B-MED
Schwann	I-MED
cells	I-MED
by	O
regulating	B-MED
ERK1	B-MED
/	O
2	B-MED
and	O
PI3	B-MED
K	I-MED
signaling	B-MED
pathways	I-MED
The	O
proliferation	B-MED
and	O
migration	B-MED
of	O
Schwann	B-MED
cells	I-MED
(	O
SCs	B-MED
)	O
are	O
essential	O
in	O
the	O
process	B-MED
of	O
peripheral	B-MED
nerve	I-MED
repair	I-MED
.	O
A	O
large	O
amount	O
of	O
studies	O
focused	O
on	O
the	O
promotion	B-MED
of	O
the	O
growth	B-MED
of	O
SCs	B-MED
for	O
cell	B-MED
based	I-MED
therapy	I-MED
.	O
Gastrodin	B-MED
(	O
GAS	B-MED
)	O
,	O
the	O
main	O
constituent	O
of	O
a	O
Chinese	B-MED
traditional	I-MED
herbal	B-MED
medicine	I-MED
named	O
Gastrodia	B-MED
elata	I-MED
Blume	I-MED
,	O
has	O
been	O
reported	B-MED
to	O
be	O
associated	B-MED
with	I-MED
neuroprotective	B-MED
properties	I-MED
.	O
Besides	O
,	O
GAS	B-MED
activated	B-MED
MAPK	B-MED
and	O
PI3	B-MED
K	I-MED
signaling	B-MED
pathways	I-MED
which	O
are	O
often	O
involved	O
in	O
growth	B-MED
of	O
nerve	B-MED
cells	I-MED
were	O
also	O
reported	B-MED
.	O
Based	O
on	O
the	O
hypothesis	B-MED
that	O
GAS	B-MED
may	O
have	O
an	O
effect	O
on	O
SCs	B-MED
growth	B-MED
,	O
we	O
studied	O
the	O
effect	B-MED
of	I-MED
GAS	B-MED
on	O
rat	B-MED
RSC96	B-MED
Schwann	I-MED
cells	I-MED
(	O
SCs	B-MED
)	O
and	O
further	O
explored	O
the	O
underlying	O
mechanism	B-MED
.	O
Various	O
concentration	B-MED
of	O
GAS	B-MED
(	O
0μM	O
,	O
50μM	O
,	O
100μM	O
,	O
and	O
200μM	O
)	O
was	O
used	O
for	O
treatment	B-MED
of	O
RSC96	B-MED
SCs	I-MED
,	O
with	O
the	O
cell	B-MED
proliferation	I-MED
and	O
gene	B-MED
expression	I-MED
of	O
several	O
neurotrophic	B-MED
factors	I-MED
to	O
be	O
detected	O
.	O
Regulation	B-MED
of	I-MED
MAPK	B-MED
and	O
PI3	B-MED
K	I-MED
signaling	B-MED
pathways	I-MED
were	O
assayed	O
by	O
detecting	O
phosphorylation	B-MED
of	O
ERK1	B-MED
/	O
2	B-MED
and	O
Akt	B-MED
.	O
The	O
results	O
showed	O
that	O
GAS	B-MED
could	O
effectively	O
promote	B-MED
proliferation	B-MED
of	O
RSC96	B-MED
SCs	I-MED
in	O
a	O
dose	B-MED
-	O
and	O
time	B-MED
-dependent	O
manner	O
.	O
The	O
best	O
performance	O
was	O
obtained	O
at	O
the	O
concentration	B-MED
of	O
200μM.	O
Exploration	B-MED
of	O
the	O
underlying	O
mechanism	B-MED
showed	O
that	O
GAS	B-MED
probably	O
affects	O
SCs	B-MED
metabolism	B-MED
through	O
inhibiting	B-MED
ERK1	B-MED
/	O
2	B-MED
phosphorylation	B-MED
and	O
activating	B-MED
Akt	B-MED
phosphorylation	B-MED
in	O
RSC96	B-MED
SCs	I-MED
.	O
This	O
study	O
may	O
provide	O
reference	O
for	O
its	O
application	O
in	O
treatment	B-MED
of	O
peripheral	B-MED
nerve	I-MED
injuries	I-MED
.	O
Technical	O
note	O
:	O
A	O
preliminary	B-MED
comparative	B-MED
study	I-MED
between	O
classical	B-MED
and	O
interventional	B-MED
radiological	I-MED
approaches	I-MED
for	O
multi	B-MED
-	I-MED
phase	I-MED
post	B-MED
-	I-MED
mortem	I-MED
CT	I-MED
angiography	B-MED
Multi	B-MED
-	I-MED
phase	I-MED
post	B-MED
-	I-MED
mortem	I-MED
computed	I-MED
tomography	I-MED
angiography	I-MED
(	O
MPMCTA	B-MED
)	O
is	O
a	O
new	B-MED
diagnostic	B-MED
tool	I-MED
,	O
used	O
in	O
forensic	B-MED
pathology	I-MED
.	O
On	O
the	O
one	O
hand	O
,	O
this	O
technique	B-MED
allows	O
a	O
better	O
and	O
direct	B-MED
visualization	I-MED
of	O
vascular	B-MED
and	O
solid	B-MED
organ	I-MED
lesions	B-MED
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
invasiveness	B-MED
of	O
the	O
procedure	B-MED
-which	O
requires	O
surgical	B-MED
denudation	I-MED
(	O
inguinal	B-MED
and/or	O
cervical	B-MED
)	O
and	O
the	O
insertion	B-MED
of	O
surgical	B-MED
cannulas	I-MED
-leads	O
to	O
many	O
relatives	B-MED
refusing	B-MED
scientific	B-MED
autopsies	I-MED
.	O
Our	O
hypothesis	B-MED
states	O
that	O
a	O
minimally	B-MED
-	I-MED
invasive	I-MED
procedure	I-MED
combining	O
interventional	B-MED
radiological	I-MED
techniques	I-MED
with	O
MPMCTA	B-MED
(	O
replacement	B-MED
of	O
surgical	B-MED
cannulas	I-MED
by	O
radiological	B-MED
catheters	I-MED
)	O
will	O
improve	B-MED
the	O
approval	B-MED
rate	B-MED
of	O
scientific	B-MED
autopsies	I-MED
by	O
families	B-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
evaluate	O
the	O
feasibility	B-MED
of	O
the	O
minimally	B-MED
-	I-MED
invasive	I-MED
MPMCTA	B-MED
approach	O
and	O
to	O
compare	B-MED
its	O
performance	B-MED
to	O
the	O
current	B-MED
reference	B-MED
-	I-MED
standard	I-MED
(	O
the	O
conventional	O
approach	O
)	O
.	O
We	O
included	O
consecutively	B-MED
16	O
corpses	B-MED
divided	O
in	O
two	O
groups	B-MED
according	O
to	O
the	O
contrast	B-MED
enhancement	B-MED
approach	O
:	O
radiological	B-MED
catheters	I-MED
(	O
n=8	O
)	O
,	O
and	O
surgical	B-MED
cannulas	I-MED
(	O
n=8	O
)	O
.	O
Corpses	B-MED
were	O
chosen	O
and	O
assigned	O
randomly	O
from	O
our	O
local	O
data	B-MED
.	O
The	O
quality	B-MED
of	O
the	O
imaging	B-MED
procedure	I-MED
was	O
compared	B-MED
according	O
to	O
four	O
items	O
:	O
global	B-MED
vascular	I-MED
opacification	B-MED
,	O
cerebral	B-MED
venous	I-MED
opacification	I-MED
,	O
and	O
lower	B-MED
limbs	I-MED
opacification	B-MED
(	O
arterial	B-MED
and	O
venous	B-MED
)	O
.	O
A	O
minimally	B-MED
-	I-MED
invasive	I-MED
approach	I-MED
for	O
scientific	B-MED
autopsies	I-MED
is	O
feasible	O
through	O
a	O
radiological	B-MED
catheter	I-MED
.	O
Vascular	B-MED
opacification	B-MED
was	O
optimal	B-MED
in	O
8	O
out	O
of	O
8	O
cases	O
and	O
was	O
no	O
less	O
effective	B-MED
than	O
the	O
control	B-MED
reference	I-MED
group	I-MED
using	O
surgical	B-MED
cannula	I-MED
incision	B-MED
associated	B-MED
with	I-MED
their	O
non	B-MED
-	I-MED
occlusive	I-MED
aspects	I-MED
.	O
Design	B-MED
,	O
synthesis	B-MED
,	O
molecular	B-MED
docking	I-MED
,	O
anti	B-MED
-	I-MED
Proteus	I-MED
mirabilis	I-MED
and	O
urease	B-MED
inhibition	B-MED
of	O
new	O
fluoroquinolone	B-MED
carboxylic	I-MED
acid	I-MED
derivatives	I-MED
New	O
hydroxamic	B-MED
acid	I-MED
,	O
hydrazide	B-MED
and	O
amide	B-MED
derivatives	I-MED
of	O
ciprofloxacin	B-MED
in	O
addition	O
to	O
their	O
analogues	B-MED
of	O
levofloxacin	B-MED
were	O
prepared	O
and	O
identified	O
by	O
different	O
spectroscopic	B-MED
techniques	I-MED
.	O
Some	O
of	O
the	O
prepared	O
compounds	B-MED
revealed	O
good	O
activity	B-MED
against	O
the	O
urease	B-MED
splitting	O
bacteria	B-MED
,	O
Proteus	B-MED
mirabilis	I-MED
.	O
The	O
urease	B-MED
inhibitory	B-MED
activity	I-MED
was	O
investigated	O
using	O
indophenol	B-MED
method	I-MED
.	O
Most	O
of	O
the	O
tested	B-MED
compounds	B-MED
showed	O
better	O
activity	B-MED
than	O
the	O
reference	O
acetohydroxamic	B-MED
acid	I-MED
(	O
AHA	B-MED
)	O
.	O
The	O
ciprofloxacin	B-MED
hydrazide	I-MED
derivative	I-MED
3a	I-MED
and	O
levofloxacin	B-MED
hydroxamic	I-MED
acid	I-MED
7	I-MED
experienced	O
the	O
highest	O
activity	B-MED
(	O
IC50	B-MED
=	O
1.22μM	O
and	O
2.20μM	O
,	O
respectively	O
)	O
.	O
Molecular	B-MED
docking	I-MED
study	I-MED
revealed	O
high	O
spontaneous	O
binding	B-MED
ability	I-MED
of	O
the	O
tested	B-MED
compounds	B-MED
to	O
the	O
active	B-MED
site	I-MED
of	O
urease	B-MED
.	O
Transcriptional	B-MED
enhancement	I-MED
of	O
Smn	B-MED
levels	B-MED
in	O
motoneurons	B-MED
is	O
crucial	O
for	O
proper	O
axon	B-MED
morphology	B-MED
in	O
zebrafish	B-MED
An	O
unresolved	O
mystery	O
in	O
the	O
field	O
of	O
spinal	B-MED
muscular	I-MED
atrophy	I-MED
(	O
SMA	B-MED
)	O
is	O
why	O
a	O
reduction	O
of	O
the	O
ubiquitously	O
expressed	O
Smn	B-MED
protein	I-MED
causes	O
defects	B-MED
mostly	O
in	O
motoneurons	B-MED
.	O
We	O
addressed	O
the	O
possibility	O
that	O
this	O
restricted	O
vulnerability	O
stems	O
from	O
elevated	O
Smn	B-MED
expression	I-MED
in	O
motoneurons	B-MED
.	O
To	O
explore	O
this	O
,	O
we	O
established	O
an	O
ex	B-MED
vivo	I-MED
zebrafish	I-MED
culture	I-MED
system	I-MED
zebrafish	B-MED
of	O
GFP	B-MED
-	O
marked	B-MED
motoneurons	B-MED
to	O
quantitatively	O
measure	O
Smn	B-MED
protein	I-MED
and	O
smn	B-MED
mRNA	I-MED
levels	B-MED
as	O
well	O
as	O
promoter	O
activity	O
in	O
motoneurons	B-MED
versus	O
other	O
cell	B-MED
types	O
.	O
Importantly	O
,	O
we	O
uncovered	O
that	O
Smn	B-MED
levels	I-MED
are	O
elevated	O
in	O
motoneurons	B-MED
by	O
means	O
of	O
transcriptional	B-MED
activation	I-MED
.	O
In	O
addition	O
,	O
we	O
identified	O
the	O
ETS	B-MED
family	I-MED
transcription	I-MED
factor	I-MED
Etv5b	I-MED
to	O
be	O
responsible	O
for	O
increased	O
smn	B-MED
transcription	I-MED
in	O
motoneurons	B-MED
.	O
Moreover	O
,	O
we	O
established	O
that	O
the	O
additional	O
supply	O
of	O
Smn	B-MED
protein	I-MED
in	O
motoneurons	B-MED
is	O
necessary	O
for	O
proper	O
axonogenesis	B-MED
in	O
a	O
cell	B-MED
-	I-MED
autonomous	I-MED
manner	I-MED
.	O
These	O
findings	B-MED
demonstrate	O
the	O
reliance	O
of	O
motoneurons	B-MED
on	O
more	O
Smn	B-MED
,	O
thereby	O
adding	O
a	O
novel	O
piece	O
of	O
evidence	B-MED
for	O
their	O
increased	B-MED
vulnerability	B-MED
under	O
SMA	B-MED
conditions	I-MED
.	O
The	O
ABBA	B-MED
study	I-MED
-	O
approach	O
bias	O
modification	O
in	O
bulimia	B-MED
nervosa	I-MED
and	O
binge	B-MED
eating	I-MED
disorder	I-MED
:	O
study	O
protocol	O
for	O
a	O
randomised	B-MED
controlled	I-MED
trial	I-MED
The	O
core	O
symptoms	B-MED
of	O
bulimia	B-MED
nervosa	I-MED
(	O
BN	B-MED
)	O
and	O
binge	B-MED
eating	I-MED
disorder	I-MED
(	O
BED	B-MED
)	O
are	O
recurrent	B-MED
episodes	I-MED
of	I-MED
binge	I-MED
eating	I-MED
.	O
Despite	O
negative	B-MED
psychological	I-MED
and	O
physical	B-MED
consequences	I-MED
,	O
BN	B-MED
/	I-MED
BED	I-MED
patients	B-MED
show	O
uncontrollable	O
approach	O
tendencies	B-MED
towards	I-MED
food	I-MED
.	O
This	O
cognitive	B-MED
bias	I-MED
occurs	O
at	O
an	O
early	O
stage	O
of	O
information	B-MED
processing	I-MED
.	O
Cognitive	B-MED
bias	I-MED
modification	I-MED
(	O
CBM	B-MED
)	O
directly	O
targets	O
such	O
biases	B-MED
and	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
treating	B-MED
several	O
mental	B-MED
disorders	I-MED
.	O
In	O
alcohol	B-MED
addiction	I-MED
,	O
automatic	O
action	O
tendencies	O
towards	O
alcohol	B-MED
cues	I-MED
and	O
relapse	B-MED
rates	B-MED
were	O
successfully	O
reduced	O
by	O
a	O
specific	O
form	O
of	O
CBM	B-MED
,	O
termed	O
approach	O
bias	B-MED
modification	I-MED
.	O
Based	O
on	O
these	O
findings	O
and	O
data	B-MED
from	O
a	O
proof	B-MED
-	I-MED
of	I-MED
-	I-MED
concept	I-MED
study	I-MED
in	O
people	B-MED
with	O
high	O
levels	O
of	O
food	B-MED
craving	I-MED
,	O
CBM	B-MED
is	O
considered	O
a	O
promising	O
new	O
treatment	B-MED
approach	I-MED
for	O
BN	B-MED
/	I-MED
BED	I-MED
.	O
Given	O
the	O
similarities	O
between	O
BN	B-MED
/	I-MED
BED	I-MED
and	O
addictive	B-MED
disorders	I-MED
,	O
the	O
rationale	B-MED
for	O
using	O
approach	O
bias	B-MED
modification	I-MED
appears	O
to	O
be	O
particularly	O
strong	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
examine	O
whether	O
,	O
compared	O
to	O
a	O
sham	B-MED
training	I-MED
,	O
computerised	O
approach	O
bias	B-MED
modification	I-MED
(	O
10	O
sessions	O
)	O
can	O
reduce	O
binge	B-MED
-	I-MED
eating	I-MED
episodes	I-MED
in	O
BN	B-MED
/	I-MED
BED	I-MED
patients	B-MED
from	O
pre	B-MED
-	I-MED
treatment	I-MED
to	O
follow	O
-	O
up	O
.	O
Additionally	O
,	O
we	O
will	O
investigate	O
whether	O
this	O
CBM	B-MED
programme	O
also	O
reduces	O
global	B-MED
eating	B-MED
disorder	I-MED
psychopathology	I-MED
,	O
trait	B-MED
and	O
cue	B-MED
-	I-MED
elicited	I-MED
food	I-MED
craving	I-MED
,	O
food	B-MED
intake	I-MED
as	O
well	O
as	O
approach	O
and	O
attentional	B-MED
bias	I-MED
towards	O
visual	B-MED
food	I-MED
cues	I-MED
.	O
Treatment	B-MED
acceptance	I-MED
will	O
be	O
determined	O
by	O
attrition	B-MED
rates	I-MED
and	O
responses	B-MED
on	O
a	O
feedback	O
form	O
.	O
This	O
is	O
a	O
double	B-MED
-	I-MED
blind	I-MED
,	O
randomised	B-MED
,	O
placebo	B-MED
-	I-MED
controlled	I-MED
,	O
parallel	B-MED
-	I-MED
group	I-MED
superiority	I-MED
trial	I-MED
with	O
two	O
parallel	O
arms	O
.	O
A	O
total	O
of	O
54	O
BN	B-MED
/	I-MED
BED	I-MED
patients	B-MED
will	O
be	O
recruited	O
.	O
Approach	O
bias	B-MED
towards	I-MED
food	I-MED
will	O
be	O
retrained	O
by	O
a	O
computer	O
task	O
adopting	O
an	O
implicit	B-MED
learning	I-MED
paradigm	I-MED
.	O
Patients	B-MED
in	O
the	O
control	O
condition	O
(	O
sham	B-MED
)	O
will	O
conduct	O
a	O
similar	B-MED
task	I-MED
but	O
will	O
not	O
be	O
trained	O
to	O
avoid	O
food	B-MED
cues	I-MED
.	O
Methods	O
against	O
bias	B-MED
include	O
public	B-MED
registration	I-MED
,	O
randomisation	B-MED
by	O
a	O
central	B-MED
study	I-MED
office	I-MED
,	O
standardisation	B-MED
of	I-MED
the	I-MED
treatments	I-MED
and	O
blinding	B-MED
of	I-MED
assessors	I-MED
.	O
Furthermore	O
,	O
the	O
session	O
number	O
and	O
duration	O
will	O
be	O
equivalent	O
in	O
the	O
two	O
conditions	O
.	O
This	O
is	O
the	O
first	O
registered	O
randomised	B-MED
controlled	I-MED
trial	I-MED
of	O
approach	O
bias	B-MED
modification	I-MED
in	O
a	O
clinical	B-MED
BN	I-MED
/	I-MED
BED	I-MED
sample	I-MED
.	O
Results	O
from	O
this	O
study	O
will	O
provide	O
an	O
indication	O
of	O
the	O
efficacy	O
of	O
approach	O
bias	B-MED
modification	I-MED
training	O
for	O
BN	B-MED
/	I-MED
BED	I-MED
and	O
the	O
potential	O
mechanisms	O
of	O
action	O
underlying	O
this	O
treatment	B-MED
.	O
DRKS00010231	O
(	O
retrospectively	O
registered	O
on	O
24	O
March	O
2016	O
;	O
first	O
version	O
)	O
.	O
The	O
neural	B-MED
legacy	B-MED
of	O
a	O
single	O
concussion	B-MED
It	O
has	O
been	O
hypothesized	B-MED
that	O
concussions	B-MED
impart	B-MED
lasting	B-MED
brain	B-MED
damage	I-MED
,	O
even	O
after	O
a	O
patient	B-MED
has	O
ostensibly	O
recovered	B-MED
.	O
This	O
hypothesis	B-MED
is	O
based	O
largely	B-MED
upon	O
neuropathological	B-MED
studies	B-MED
in	O
deceased	B-MED
athletes	B-MED
,	O
however	O
,	O
leaving	O
open	O
the	O
question	O
of	O
whether	O
it	O
can	O
be	O
detected	B-MED
in	B-MED
vivo	I-MED
.	O
We	O
measured	B-MED
neural	B-MED
responses	B-MED
to	O
speech	B-MED
in	O
collegiate	B-MED
student	I-MED
-	O
athletes	B-MED
with	O
a	O
history	B-MED
of	O
a	O
single	O
concussion	B-MED
from	O
which	O
they	O
had	O
recovered	B-MED
.	O
These	O
student	B-MED
-	O
athletes	B-MED
had	O
weaker	B-MED
responses	B-MED
to	O
speech	B-MED
than	O
age	B-MED
-	O
and	O
position	B-MED
-	O
matched	B-MED
peers	B-MED
.	O
This	O
group	B-MED
difference	B-MED
suggests	B-MED
that	O
concussions	B-MED
engender	B-MED
small	B-MED
,	O
but	O
detectable	B-MED
,	O
changes	B-MED
in	O
brain	B-MED
function	I-MED
prior	B-MED
to	O
the	O
emergence	B-MED
of	O
frank	B-MED
behavioral	B-MED
indications	I-MED
.	O
Learned	B-MED
helplessness	I-MED
at	O
fifty	O
:	O
Insights	B-MED
from	O
neuroscience	B-MED
Learned	B-MED
helplessness	I-MED
,	O
the	O
failure	B-MED
to	O
escape	B-MED
shock	B-MED
induced	B-MED
by	O
uncontrollable	O
aversive	B-MED
events	I-MED
,	O
was	O
discovered	O
half	O
a	O
century	O
ago	O
.	O
Seligman	B-MED
and	I-MED
Maier	I-MED
(	O
1967	O
)	O
theorized	B-MED
that	O
animals	B-MED
learned	B-MED
that	O
outcomes	B-MED
were	O
independent	B-MED
of	I-MED
their	O
responses	B-MED
-that	O
nothing	O
they	O
did	O
mattered	O
-	O
and	O
that	O
this	O
learning	B-MED
undermined	O
trying	O
to	O
escape	B-MED
.	O
The	O
mechanism	O
of	O
learned	B-MED
helplessness	I-MED
is	O
now	O
very	O
well	B-MED
-	I-MED
charted	I-MED
biologically	I-MED
,	O
and	O
the	O
original	O
theory	B-MED
got	O
it	O
backward	O
.	O
Passivity	B-MED
in	O
response	B-MED
to	O
shock	B-MED
is	O
not	O
learned	B-MED
.	O
It	O
is	O
the	O
default	O
,	O
unlearned	O
response	B-MED
to	O
prolonged	B-MED
aversive	B-MED
events	I-MED
and	O
it	O
is	O
mediated	O
by	O
the	O
serotonergic	B-MED
activity	I-MED
of	O
the	O
dorsal	B-MED
raphe	I-MED
nucleus	I-MED
,	O
which	O
in	O
turn	O
inhibits	B-MED
escape	B-MED
.	O
This	O
passivity	B-MED
can	O
be	O
overcome	O
by	O
learning	B-MED
control	B-MED
,	O
with	O
the	O
activity	O
of	O
the	O
medial	B-MED
prefrontal	I-MED
cortex	I-MED
,	O
which	O
subserves	O
the	O
detection	B-MED
of	O
control	B-MED
leading	O
to	O
the	O
automatic	B-MED
inhibition	B-MED
of	O
the	O
dorsal	B-MED
raphe	I-MED
nucleus	I-MED
.	O
So	O
animals	B-MED
learn	B-MED
that	O
they	O
can	O
control	B-MED
aversive	B-MED
events	I-MED
,	O
but	O
the	O
passive	B-MED
failure	B-MED
to	O
learn	B-MED
to	O
escape	B-MED
is	O
an	O
unlearned	O
reaction	B-MED
to	O
prolonged	B-MED
aversive	B-MED
stimulation	I-MED
.	O
In	O
addition	O
,	O
alterations	B-MED
of	O
the	O
ventromedial	B-MED
prefrontal	I-MED
cortex	I-MED
-	O
dorsal	B-MED
raphe	I-MED
pathway	B-MED
can	O
come	O
to	O
subserve	O
the	O
expectation	B-MED
of	O
control	B-MED
.	O
We	O
speculate	O
that	O
default	O
passivity	B-MED
and	O
the	O
compensating	B-MED
detection	B-MED
and	O
expectation	B-MED
of	O
control	B-MED
may	O
have	O
substantial	O
implications	O
for	O
how	O
to	O
treat	B-MED
depression	B-MED
.	O
(	O
PsycINFO	O
Database	O
Record	O
Intra	B-MED
-	I-MED
articular	I-MED
implantation	B-MED
of	O
collagen	B-MED
scaffold	B-MED
carriers	B-MED
is	O
safe	B-MED
in	O
both	O
native	B-MED
and	O
arthrofibrotic	B-MED
rabbit	B-MED
knee	B-MED
joints	I-MED
Sustained	B-MED
intra	B-MED
-	I-MED
articular	I-MED
delivery	B-MED
of	I-MED
pharmacological	I-MED
agents	I-MED
is	O
an	O
attractive	B-MED
modality	B-MED
but	O
requires	O
use	B-MED
of	O
a	O
safe	B-MED
carrier	B-MED
that	O
would	O
not	O
induce	B-MED
cartilage	B-MED
damage	I-MED
or	O
fibrosis	B-MED
.	O
Collagen	B-MED
scaffolds	B-MED
are	O
widely	O
available	B-MED
and	O
could	O
be	O
used	O
intra	B-MED
-	I-MED
articularly	I-MED
,	O
but	O
no	O
investigation	B-MED
has	O
looked	O
at	O
the	O
safety	B-MED
of	O
collagen	B-MED
scaffolds	B-MED
within	O
synovial	B-MED
joints	I-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
was	O
to	O
determine	B-MED
the	O
safety	B-MED
of	O
collagen	B-MED
scaffold	B-MED
implantation	B-MED
in	O
a	O
validated	B-MED
in	B-MED
vivo	I-MED
animal	B-MED
model	O
of	O
knee	B-MED
arthrofibrosis	I-MED
.	O
A	O
total	O
of	O
96	O
rabbits	B-MED
were	O
randomly	B-MED
and	O
equally	B-MED
assigned	B-MED
to	O
four	O
different	B-MED
groups	B-MED
:	O
arthrotomy	B-MED
alone	O
;	O
arthrotomy	B-MED
and	O
collagen	B-MED
scaffold	B-MED
placement	B-MED
;	O
contracture	B-MED
surgery	B-MED
;	O
and	O
contracture	B-MED
surgery	B-MED
and	O
collagen	B-MED
scaffold	B-MED
placement	B-MED
.	O
Animals	B-MED
were	O
killed	B-MED
in	O
equal	B-MED
numbers	O
at	O
72	O
hours	B-MED
,	O
two	O
weeks	B-MED
,	O
eight	O
weeks	B-MED
,	O
and	O
24	O
weeks	B-MED
.	O
Joint	B-MED
contracture	I-MED
was	O
measured	B-MED
,	O
and	O
cartilage	B-MED
and	O
synovial	B-MED
samples	B-MED
underwent	O
histological	B-MED
analysis	I-MED
.	O
Animals	B-MED
that	O
underwent	O
arthrotomy	B-MED
had	O
equivalent	B-MED
joint	B-MED
contractures	I-MED
regardless	O
of	O
scaffold	B-MED
implantation	B-MED
(	O
-13.9	O
°	O
versus	O
-10.9	O
°	O
,	O
equivalence	O
limit	O
15	O
°	O
)	O
.	O
Animals	B-MED
that	O
underwent	O
surgery	B-MED
to	O
induce	B-MED
contracture	B-MED
did	O
not	O
demonstrate	O
equivalent	B-MED
joint	B-MED
contracture	I-MED
joint	B-MED
contracture	I-MED
s	I-MED
with	O
(	O
41.8	O
°	O
)	O
or	O
without	O
(	O
53.9	O
°	O
)	O
collagen	B-MED
scaffold	B-MED
implantation	B-MED
.	O
Chondral	B-MED
damage	B-MED
damage	B-MED
occurred	B-MED
in	O
similar	O
rates	B-MED
with	O
(	O
11	O
of	O
48	O
)	O
and	O
without	O
(	O
nine	O
of	O
48	O
)	O
scaffold	B-MED
implantation	B-MED
.	O
No	O
significant	B-MED
difference	I-MED
in	O
synovitis	B-MED
was	O
noted	O
between	O
groups	B-MED
.	O
Absorption	B-MED
of	O
the	O
collagen	B-MED
scaffold	B-MED
occurred	B-MED
within	O
eight	O
weeks	B-MED
in	O
all	O
animals	B-MED
CONCLUSION	O
:	O
Our	O
data	B-MED
suggest	O
that	O
intra	B-MED
-	I-MED
articular	I-MED
implantation	B-MED
of	O
a	O
collagen	B-MED
sponge	B-MED
does	O
not	O
induce	B-MED
synovitis	B-MED
or	O
cartilage	B-MED
damage	I-MED
.	O
Implantation	B-MED
in	O
a	O
native	B-MED
joint	B-MED
does	O
not	O
seem	O
to	O
induce	B-MED
contracture	B-MED
.	O
Implantation	B-MED
of	O
the	O
collagen	B-MED
sponge	B-MED
in	O
a	O
rabbit	B-MED
knee	O
model	O
of	O
contracture	B-MED
may	O
decrease	B-MED
the	O
severity	B-MED
of	O
the	O
contracture	B-MED
.Cite	O
this	O
article	O
:	O
J.	O
A.	O
Walker	O
,	O
T.	O
J.	O
Ewald	O
,	O
E.	O
Lewallen	O
,	O
A.	O
Van	O
Wijnen	O
,	O
A.	O
D.	O
Hanssen	O
,	O
B.	O
F.	O
Morrey	O
,	O
M.	O
E.	O
Morrey	O
,	O
M.	O
P.	O
Abdel	O
,	O
J.	O
Sanchez	O
-	O
Sotelo	O
.	O
Intra	O
-	O
articular	O
implantation	O
of	O
collagen	O
scaffold	O
carriers	O
is	O
safe	O
in	O
both	O
native	O
and	O
arthrofibrotic	O
rabbit	O
knee	O
joints	O
.	O
Bone	O
Joint	O
Res	O
2016;6:162	O
-	O
171	O
.	O
DOI	O
:	O
10.1302/2046	O
-	O
3758.63.BJR-2016	O
-	O
0193	O
.	O
Masters	B-MED
Athletes	I-MED
:	O
Exemplars	O
of	O
Successful	B-MED
Aging	I-MED
?	O
Global	B-MED
population	I-MED
aging	B-MED
has	O
raised	B-MED
academic	I-MED
interest	I-MED
in	O
successful	B-MED
aging	I-MED
to	O
a	O
public	B-MED
policy	I-MED
priority	O
.	O
Currently	O
there	O
is	O
no	O
consensus	B-MED
regarding	O
the	O
definition	O
of	O
successful	B-MED
aging	I-MED
.	O
However	O
,	O
a	O
synthesis	O
of	O
research	O
shows	O
successful	B-MED
aging	I-MED
can	O
be	O
defined	O
as	O
a	O
late	B-MED
-	I-MED
life	I-MED
process	I-MED
of	I-MED
change	I-MED
characterized	O
by	O
high	B-MED
physical	I-MED
,	O
psychological	B-MED
,	O
cognitive	B-MED
,	O
and	O
social	B-MED
functioning	I-MED
.	O
Masters	B-MED
athletes	I-MED
systematically	B-MED
train	I-MED
for	O
,	O
and	O
compete	B-MED
in	I-MED
,	O
organized	B-MED
forms	I-MED
of	I-MED
team	I-MED
and	O
individual	B-MED
sport	I-MED
specifically	O
designed	O
for	O
older	B-MED
adults	I-MED
.	O
Masters	B-MED
athletes	I-MED
are	O
often	O
proposed	O
as	O
exemplars	O
of	O
successful	B-MED
aging	I-MED
.	O
However	O
,	O
their	O
aging	B-MED
status	I-MED
has	O
never	O
been	O
examined	O
using	O
a	O
comprehensive	B-MED
multidimensional	B-MED
successful	B-MED
aging	I-MED
definition	O
.	O
Here	O
,	O
we	O
examine	O
the	O
successful	B-MED
aging	I-MED
literature	I-MED
,	O
propose	O
a	O
successful	B-MED
aging	I-MED
definition	O
based	O
on	O
this	O
literature	B-MED
,	O
present	O
evidence	O
which	O
suggests	O
masters	B-MED
athletes	I-MED
could	O
be	O
considered	O
exemplars	O
of	O
successful	B-MED
aging	I-MED
according	O
to	O
the	O
proposed	O
definition	O
,	O
and	O
list	O
future	O
experimental	B-MED
research	I-MED
directions	O
.	O
Synovial	B-MED
sarcoma	I-MED
of	O
the	O
hypopharynx	B-MED
in	O
a	O
pediatric	B-MED
patient	B-MED
:	O
Case	B-MED
report	I-MED
Synovial	B-MED
sarcoma	I-MED
(	O
SS	B-MED
)	O
is	O
uncommon	O
high	O
grade	O
soft	B-MED
tissue	I-MED
sarcoma	B-MED
,	O
accounting	O
for	O
less	O
than	O
10	O
%	O
of	O
all	O
head	B-MED
and	I-MED
neck	I-MED
sarcomas	I-MED
.	O
Also	O
,	O
about	O
10	O
%	O
of	O
SS	B-MED
occur	O
within	O
the	O
Head	B-MED
&	O
Neck	B-MED
.	O
In	O
the	O
pediatric	B-MED
population	B-MED
,	O
SS	B-MED
is	O
an	O
extremely	O
rare	B-MED
head	B-MED
&	I-MED
neck	I-MED
malignancy	I-MED
.	O
We	O
present	O
a	O
case	O
of	O
sixteen	O
years	O
old	O
boy	B-MED
diagnosed	B-MED
with	O
SS	B-MED
situated	O
of	O
the	O
hypopharynx	B-MED
treated	B-MED
by	I-MED
surgical	B-MED
excision	I-MED
and	O
post	B-MED
operative	I-MED
radio	B-MED
-	O
chemotherapy	B-MED
.	O
This	O
anatomical	B-MED
location	I-MED
brings	O
additional	O
functional	B-MED
challenges	B-MED
(	O
swallowing	B-MED
,	O
phonation	B-MED
,	O
respiration	B-MED
)	O
,	O
especially	O
in	O
the	O
pediatric	B-MED
population	B-MED
.	O
Pre	B-MED
-	I-MED
operative	I-MED
and	O
even	O
post	B-MED
-	I-MED
operative	I-MED
histopathological	B-MED
diagnosis	B-MED
of	O
SS	B-MED
remains	O
difficult	O
.	O
Optimal	B-MED
treatment	B-MED
of	O
Head	B-MED
&	O
Neck	B-MED
SS	B-MED
has	O
to	O
balance	O
functional	B-MED
and	O
oncologic	B-MED
aspects	B-MED
.	O
SS	B-MED
is	O
an	O
extremely	O
rare	B-MED
head	B-MED
&	I-MED
neck	I-MED
malignancy	I-MED
in	O
pediatric	B-MED
population	B-MED
.	O
It	O
has	O
multifaceted	B-MED
challenges	B-MED
including	O
pre	O
and	O
post	B-MED
-	I-MED
operative	I-MED
histopathological	B-MED
diagnosis	B-MED
and	O
optimal	B-MED
modality	B-MED
of	O
treatment	B-MED
.	O
Clinical	B-MED
judgment	I-MED
,	O
especially	O
in	O
the	O
pediatric	B-MED
population	B-MED
,	O
needs	O
to	O
balance	O
tumor	B-MED
free	I-MED
margins	I-MED
and	O
organ	B-MED
preservation	I-MED
in	O
head	B-MED
and	O
neck	B-MED
region	B-MED
.	O
Urticarial	B-MED
exanthema	B-MED
due	O
to	O
hepatitis	B-MED
B	I-MED
in	O
a	O
pregnant	B-MED
woman	I-MED
,	O
mimicking	O
a	O
polymorphic	B-MED
eruption	I-MED
of	O
pregnancy	B-MED
Hepatitis	B-MED
B	I-MED
virus	I-MED
(	I-MED
HBV	I-MED
)	I-MED
infection	I-MED
in	I-MED
pregnant	I-MED
women	I-MED
is	O
very	O
rare	O
in	O
western	B-MED
countries	I-MED
,	O
thus	O
,	O
cutaneous	B-MED
manifestation	B-MED
of	I-MED
HBV	B-MED
infection	I-MED
may	O
be	O
confused	O
with	O
a	O
dermatosis	B-MED
specific	O
of	O
pregnancy	B-MED
.	O
We	O
report	O
a	O
39	O
-	O
year	O
-	O
old	O
woman	B-MED
who	O
presented	O
in	O
her	O
20th	O
week	O
of	O
pregnancy	B-MED
with	O
a	O
pruritic	B-MED
rash	I-MED
,	O
which	O
consisted	O
of	O
generalized	O
erythematous	B-MED
plaques	I-MED
,	O
some	O
of	O
them	O
with	O
a	O
purple	B-MED
centre	I-MED
.	O
Serology	B-MED
testing	I-MED
showed	O
acute	B-MED
HBV	I-MED
infection	I-MED
,	O
and	O
a	O
biopsy	B-MED
revealed	O
a	O
superficial	B-MED
and	O
interstitial	B-MED
perivascular	I-MED
inflammatory	I-MED
infiltrate	I-MED
of	O
lymphocytes	B-MED
and	O
eosinophils	B-MED
.	O
A	O
diagnosis	B-MED
of	O
exanthema	B-MED
due	O
to	O
acute	B-MED
hepatitis	I-MED
B	I-MED
infection	I-MED
was	O
established	O
.	O
The	O
patient	B-MED
delivered	B-MED
a	O
clinically	B-MED
healthy	I-MED
boy	I-MED
,	O
who	O
was	O
given	O
the	O
first	B-MED
dose	I-MED
of	O
the	O
HBV	B-MED
vaccine	I-MED
and	O
intravenous	B-MED
specific	I-MED
immunoglobulin	I-MED
,	O
followed	O
by	O
the	O
second	B-MED
dose	I-MED
2	O
months	O
later	O
,	O
and	O
did	O
not	O
get	O
infected	B-MED
with	O
HBV	B-MED
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
describing	O
HBV	B-MED
exanthema	B-MED
in	O
a	O
pregnant	B-MED
woman	I-MED
,	O
which	O
led	O
to	O
early	O
action	O
for	O
the	O
newborn	B-MED
,	O
avoiding	O
vertical	B-MED
transmission	I-MED
and	O
its	O
high	O
prevalence	O
of	O
cirrhosis	B-MED
and	O
hepatocellular	B-MED
carcinoma	I-MED
.	O
Functional	B-MED
Impairment	B-MED
in	O
Children	B-MED
With	O
Externalizing	B-MED
Behavior	I-MED
Disorders	I-MED
:	O
Psychometric	B-MED
Properties	B-MED
of	O
the	O
Weiss	B-MED
Functional	I-MED
Impairment	I-MED
Rating	I-MED
Scale	I-MED
-	I-MED
Parent	I-MED
Report	I-MED
in	O
a	O
German	B-MED
Clinical	B-MED
Sample	I-MED
To	O
examine	O
the	O
psychometric	B-MED
properties	B-MED
of	O
a	O
German	B-MED
adaptation	O
of	O
the	O
Weiss	B-MED
Functional	I-MED
Impairment	I-MED
Rating	I-MED
Scale	I-MED
-	I-MED
Parent	I-MED
Report	I-MED
(	O
WFIRS	B-MED
-	I-MED
P	I-MED
)	O
in	O
a	O
clinical	B-MED
sample	I-MED
of	O
children	B-MED
(	O
4	O
-	O
12	O
years	B-MED
)	O
with	O
externalizing	B-MED
behavior	I-MED
disorders	I-MED
.	O
Data	B-MED
were	O
collected	B-MED
within	O
two	O
clinical	B-MED
trials	I-MED
(	O
N	O
=	O
264	O
)	O
.	O
Factorial	B-MED
validity	I-MED
,	O
reliability	B-MED
,	O
and	O
divergent	B-MED
validity	I-MED
from	O
symptoms	B-MED
of	O
ADHD	B-MED
and	O
oppositional	B-MED
defiant	I-MED
disorder	I-MED
(	O
ODD	B-MED
)	O
were	O
assessed	B-MED
.	O
Confirmatory	B-MED
factor	I-MED
analyses	I-MED
revealed	B-MED
that	O
a	O
bifactor	B-MED
model	I-MED
consistent	B-MED
with	I-MED
the	O
theoretical	B-MED
assumption	I-MED
of	O
a	O
general	B-MED
construct	I-MED
of	O
impairment	B-MED
(	O
total	O
scale	O
)	O
and	O
additional	B-MED
specific	B-MED
factors	I-MED
(	O
subscales	O
)	O
provided	O
satisfactory	B-MED
data	B-MED
fit	I-MED
.	O
Model	B-MED
-based	O
reliability	B-MED
estimates	B-MED
showed	O
that	O
both	O
the	O
general	B-MED
construct	I-MED
and	O
specific	B-MED
factors	I-MED
accounted	O
for	O
item	O
variance	B-MED
.	O
Internal	O
consistencies	B-MED
were	O
>	O
.70	O
,	O
part	O
-	O
whole	O
corrected	O
item	O
-	O
scale	O
correlations	B-MED
mostly	O
>	O
.30	O
.	O
Correlations	B-MED
between	O
the	O
WFIRS	B-MED
-	I-MED
P	I-MED
Scales	I-MED
and	O
ADHD	B-MED
and	O
ODD	B-MED
symptoms	B-MED
were	O
low	B-MED
to	O
moderate	B-MED
.	O
The	O
results	B-MED
support	O
the	O
factorial	B-MED
validity	I-MED
,	O
reliability	B-MED
,	O
and	O
divergent	B-MED
validity	I-MED
of	O
the	O
WFIRS	B-MED
-	I-MED
P	I-MED
P.	O
Xylan	B-MED
-	I-MED
based	I-MED
temperature	B-MED
/	O
pH	B-MED
sensitive	B-MED
hydrogels	B-MED
for	O
drug	B-MED
controlled	I-MED
release	I-MED
Xylan	B-MED
-	I-MED
based	I-MED
temperature	B-MED
/	O
pH	B-MED
sensitive	B-MED
hydrogels	B-MED
were	O
prepared	O
by	O
the	O
crosslinking	B-MED
copolymerization	I-MED
of	O
xylan	B-MED
with	O
N	B-MED
-	I-MED
isopropylacrylamide	I-MED
(	O
NIPAm	B-MED
)	O
and	O
acrylic	B-MED
acid	I-MED
(	O
AA	B-MED
)	O
using	O
N	B-MED
,	I-MED
Ń-methylenebis	I-MED
-	I-MED
acrylamide	I-MED
(	O
MBA	B-MED
)	O
as	O
a	O
cross	B-MED
-	I-MED
linker	I-MED
and	O
2,2	B-MED
-	I-MED
dimethoxy-2	I-MED
-	I-MED
phenylacetophenone	I-MED
as	O
a	O
photoinitiator	B-MED
via	O
ultraviolet	B-MED
irradiation	I-MED
.	O
The	O
influence	B-MED
of	O
the	O
NIPAm	B-MED
,	O
AA	B-MED
and	O
MBA	B-MED
amount	O
on	O
properties	O
of	O
xylan	B-MED
-	I-MED
based	I-MED
hydrogels	B-MED
was	O
discussed	O
.	O
The	O
morphology	B-MED
and	O
interactions	B-MED
of	O
hydrogels	B-MED
were	O
characterized	B-MED
by	O
SEM	B-MED
and	O
FTIR	B-MED
.	O
The	O
lower	B-MED
critical	I-MED
solution	I-MED
temperature	I-MED
(	O
LCST	B-MED
)	O
of	O
hydrogels	B-MED
was	O
investigated	B-MED
by	O
DSC	B-MED
.	O
The	O
results	B-MED
indicated	O
that	O
the	O
LCST	B-MED
of	O
hydrogels	B-MED
emerged	O
at	O
around	O
34	O
°	O
C	O
and	O
increased	O
with	O
increasing	O
the	O
AA	B-MED
content	O
.	O
The	O
drug	B-MED
encapsulation	B-MED
efficiency	B-MED
of	O
as	O
-	O
prepared	O
hydrogels	B-MED
reached	O
to	O
97.60	O
%	O
and	O
the	O
cumulative	B-MED
release	B-MED
rate	B-MED
of	O
acetylsalicylic	B-MED
acid	I-MED
was	O
90.12	O
%	O
and	O
26.35	O
%	O
in	O
the	O
intestinal	B-MED
and	O
gastric	B-MED
fluid	I-MED
,	O
respectively	O
.	O
Xylan	B-MED
-	I-MED
based	I-MED
hydrogels	B-MED
were	O
proved	O
to	O
be	O
biocompatible	B-MED
with	O
NIH3T3	B-MED
cell	I-MED
by	O
MTT	B-MED
assay	I-MED
and	O
showed	O
the	O
promising	O
application	O
as	O
drug	B-MED
carriers	I-MED
for	O
the	O
intestinal	B-MED
-	O
targeted	B-MED
oral	B-MED
drug	I-MED
delivery	I-MED
.	O
The	O
Benefits	B-MED
of	O
Combination	B-MED
Therapy	I-MED
with	O
Esomeprazole	B-MED
and	O
Rebamipide	B-MED
in	O
Symptom	B-MED
Improvement	B-MED
in	O
Reflux	B-MED
Esophagitis	I-MED
:	O
An	O
International	B-MED
Multicenter	B-MED
Study	I-MED
To	O
investigate	B-MED
the	O
effects	B-MED
of	O
esomeprazole	B-MED
and	O
rebamipide	B-MED
combination	B-MED
therapy	I-MED
on	O
symptomatic	B-MED
improvement	B-MED
in	O
patients	B-MED
with	O
reflux	B-MED
esophagitis	I-MED
.	O
A	O
total	O
of	O
501	O
patients	B-MED
with	O
reflux	B-MED
esophagitis	I-MED
were	O
randomized	B-MED
into	O
one	O
of	O
the	O
following	O
two	O
treatment	B-MED
regimens	I-MED
:	O
40	O
mg	O
esomeprazole	B-MED
plus	O
300	O
mg	O
rebamipide	B-MED
daily	B-MED
(	O
combination	B-MED
therapy	I-MED
group	B-MED
)	O
or	O
40	O
mg	O
esomeprazole	B-MED
daily	B-MED
(	O
monotherapy	B-MED
group	B-MED
)	O
.	O
We	O
used	O
a	O
symptom	B-MED
questionnaire	B-MED
that	O
evaluated	B-MED
heartburn	B-MED
,	O
acid	B-MED
regurgitation	I-MED
,	O
and	O
four	O
upper	B-MED
gastrointestinal	I-MED
symptoms	I-MED
.	O
The	O
primary	O
efficacy	B-MED
end	O
point	O
was	O
the	O
mean	O
decrease	B-MED
in	O
the	O
total	O
symptom	B-MED
score	I-MED
.	O
The	O
mean	O
decreases	B-MED
in	O
the	O
total	O
symptom	B-MED
score	I-MED
at	O
4	O
weeks	B-MED
were	O
estimated	O
to	O
be	O
-18.1±13.8	O
in	O
the	O
combination	B-MED
therapy	I-MED
group	B-MED
and	O
-15.1±11.9	O
in	O
the	O
monotherapy	B-MED
group	B-MED
(	O
p=0.011	O
)	O
.	O
Changes	O
in	O
reflux	B-MED
symptom	B-MED
s	O
from	O
baseline	B-MED
after	O
4	O
weeks	B-MED
of	O
treatment	B-MED
were	O
-8.4±6.6	O
in	O
the	O
combination	B-MED
therapy	I-MED
group	B-MED
and	O
-6.8±5.9	O
in	O
the	O
monotherapy	B-MED
group	B-MED
(	O
p=0.009	O
)	O
.	O
Over	O
a	O
4-	O
week	B-MED
treatment	B-MED
course	O
,	O
esomeprazole	B-MED
and	O
rebamipide	B-MED
combination	B-MED
therapy	I-MED
was	O
more	O
effective	B-MED
in	O
decreasing	B-MED
the	O
symptoms	B-MED
of	O
reflux	B-MED
esophagitis	I-MED
than	O
esomeprazole	B-MED
monotherapy	B-MED
.	O
Association	B-MED
of	O
Radiomics	O
and	O
Metabolic	B-MED
Tumor	B-MED
Volumes	I-MED
in	O
Radiation	B-MED
Treatment	I-MED
of	O
Glioblastoma	B-MED
Multiforme	I-MED
To	O
build	O
a	O
framework	O
for	O
investigation	B-MED
of	O
the	O
associations	B-MED
between	O
imaging	B-MED
,	O
clinical	B-MED
target	I-MED
volumes	I-MED
(	O
CTVs	B-MED
)	O
,	O
and	O
metabolic	B-MED
tumor	B-MED
volumes	I-MED
(	O
MTVs	B-MED
)	O
features	B-MED
for	O
better	O
understanding	O
of	O
the	O
underlying	O
information	B-MED
in	O
the	O
CTVs	B-MED
and	O
dependencies	O
between	O
these	O
volumes	B-MED
.	O
High	B-MED
-	I-MED
throughput	I-MED
extraction	I-MED
of	O
imaging	B-MED
and	O
metabolomic	B-MED
quantitative	B-MED
features	B-MED
from	O
magnetic	B-MED
resonance	I-MED
imaging	I-MED
(	O
MRI	B-MED
)	O
and	O
magnetic	B-MED
resonance	I-MED
spectroscopic	I-MED
imaging	I-MED
of	O
glioblastoma	B-MED
multiforme	I-MED
(	O
GBM	B-MED
)	O
results	O
in	O
tens	O
of	O
variables	O
per	O
patient	B-MED
.	O
In	O
radiation	B-MED
therapy	I-MED
of	O
GBM	B-MED
the	O
relevant	B-MED
metabolic	B-MED
tumor	B-MED
volumes	I-MED
(	O
MTVs	B-MED
)	O
are	O
related	O
to	O
aberrant	B-MED
levels	B-MED
of	O
N	B-MED
-	I-MED
acetyl	I-MED
aspartate	I-MED
(	O
NAA	B-MED
)	O
and	O
choline	B-MED
(	O
Cho	B-MED
)	O
.	O
The	O
corresponding	O
clinical	B-MED
target	I-MED
volumes	I-MED
(	O
CTVs	B-MED
)	O
for	O
radiation	B-MED
therapy	I-MED
are	O
based	O
on	O
contrast	B-MED
-	I-MED
enhanced	I-MED
T1	I-MED
-	I-MED
weighted	I-MED
(	O
CE	B-MED
-	I-MED
T1w	I-MED
)	O
and	O
T2	B-MED
-	I-MED
weighted	I-MED
(	I-MED
T2w)/fluid	I-MED
-	I-MED
attenuated	I-MED
inversion	I-MED
recovery	I-MED
MRI	I-MED
.	O
Necrotic	B-MED
portions	I-MED
,	O
enhancing	B-MED
lesion	I-MED
,	O
and	O
edema	B-MED
were	O
manually	O
contoured	O
on	O
CE	B-MED
-	I-MED
T1w	I-MED
/	O
T2w	B-MED
images	I-MED
for	O
17	O
GBM	B-MED
patients	B-MED
.	O
Clinical	B-MED
target	I-MED
volumes	I-MED
and	O
MTVs	B-MED
for	O
NAA	B-MED
(	O
MTVNAA	B-MED
)	O
and	O
Cho	B-MED
(	O
MTVCho	B-MED
)	O
were	O
constructed	O
.	O
Imaging	B-MED
and	O
metabolic	B-MED
features	I-MED
related	O
to	O
size	B-MED
,	O
shape	B-MED
,	O
and	O
signal	B-MED
intensities	I-MED
of	O
the	O
volumes	B-MED
were	O
extracted	O
.	O
Tumors	B-MED
were	O
also	O
scored	O
categorically	O
for	O
10	O
semantic	B-MED
imaging	B-MED
traits	I-MED
by	O
a	O
neuroradiologist	B-MED
.	O
All	O
features	B-MED
were	O
investigated	B-MED
for	O
redundancy	B-MED
.	O
Two	B-MED
-	I-MED
way	I-MED
correlations	I-MED
between	O
imaging	B-MED
and	O
CTVs	B-MED
/	O
MTVs	B-MED
features	O
were	O
visualized	O
as	O
heatmaps	B-MED
.	O
Associations	B-MED
between	O
MTVNAA	B-MED
and	O
MTVCho	B-MED
and	O
imaging	B-MED
features	I-MED
were	O
studied	O
using	O
Spearman	B-MED
correlation	I-MED
.	O
Forty	O
-	O
eight	O
imaging	B-MED
features	I-MED
were	O
extracted	O
per	O
patient	B-MED
.	O
Half	B-MED
of	O
the	O
imaging	B-MED
traits	I-MED
were	O
replaced	B-MED
with	O
automatically	O
extracted	O
continuous	B-MED
variables	I-MED
.	O
Twenty	O
features	B-MED
were	O
extracted	O
from	O
CTVs	B-MED
and	O
MTVs	B-MED
.	O
A	O
series	O
of	O
semantic	B-MED
imaging	B-MED
traits	I-MED
were	O
replaced	B-MED
with	O
automatically	O
extracted	O
continuous	B-MED
variables	I-MED
.	O
There	O
were	O
multiple	O
(	O
22	O
)	O
significant	O
correlations	B-MED
of	O
imaging	B-MED
measures	I-MED
with	O
CTVs	B-MED
/	O
MTVNAA	B-MED
,	O
whereas	O
there	O
were	O
only	O
6	O
with	O
CTVs	B-MED
/	O
MTVCho	B-MED
.	O
A	O
framework	O
for	O
investigation	O
of	O
codependencies	O
between	O
MRI	B-MED
and	O
magnetic	B-MED
resonance	I-MED
spectroscopic	I-MED
imaging	I-MED
radiomic	O
features	B-MED
and	O
CTVs	B-MED
/	O
MTVs	B-MED
has	O
been	O
established	O
.	O
The	O
MTV	B-MED
for	O
NAA	B-MED
was	O
found	O
to	O
be	O
closely	O
associated	B-MED
with	I-MED
MRI	B-MED
volumes	B-MED
,	O
whereas	O
very	O
few	O
imaging	B-MED
features	I-MED
were	O
related	O
to	O
MTVCho	B-MED
,	O
indicating	O
that	O
Cho	B-MED
provides	O
additional	B-MED
information	I-MED
to	O
imaging	B-MED
.	O
Cyclic	B-MED
thrombocytopenia	I-MED
synchronizing	B-MED
with	O
the	O
menstrual	B-MED
cycle	I-MED
showing	O
periodic	B-MED
phases	B-MED
of	O
thrombocytopenia	B-MED
and	O
rebound	B-MED
thrombocytosis	B-MED
A	O
37-	O
year	B-MED
-old	O
woman	B-MED
was	O
admitted	B-MED
to	O
our	O
hospital	B-MED
for	O
purpura	B-MED
involving	O
the	O
extremities	B-MED
and	O
thrombocytopenia	B-MED
.	O
Prednisolone	B-MED
(	O
PSL	B-MED
)	O
was	O
administered	B-MED
based	O
on	O
a	O
diagnosis	B-MED
of	O
idiopathic	B-MED
thrombocytopenic	I-MED
purpura	I-MED
(	O
ITP	B-MED
)	O
,	O
but	O
was	O
not	B-MED
effective	I-MED
for	O
maintaining	B-MED
her	O
platelet	B-MED
count	I-MED
within	O
the	O
normal	B-MED
range	I-MED
,	O
which	O
showed	O
cyclic	B-MED
fluctuation	I-MED
corresponding	O
to	O
the	O
menstrual	B-MED
cycle	I-MED
.	O
Therefore	O
,	O
we	O
discontinued	B-MED
PSL	B-MED
,	O
and	O
cyclic	B-MED
thrombocytopenia	I-MED
(	O
CTP	B-MED
)	O
was	O
diagnosed	B-MED
.	O
CTP	B-MED
is	O
a	O
rare	B-MED
disease	I-MED
which	O
is	O
usually	O
treated	B-MED
as	O
ITP	B-MED
but	O
with	O
no	B-MED
response	I-MED
.	O
Although	O
the	O
exact	O
cause	B-MED
of	O
CTP	B-MED
is	O
uncertain	B-MED
,	O
in	O
our	O
case	B-MED
,	O
a	O
hormonal	B-MED
mechanism	I-MED
may	O
be	O
responsible	O
for	O
fluctuating	B-MED
platelet	B-MED
count	I-MED
.	O
LAMP-2	B-MED
mediates	O
oxidative	B-MED
stress	I-MED
-dependent	O
cell	B-MED
death	I-MED
in	O
Zn(2	B-MED
+	I-MED
)	I-MED
-	O
treated	B-MED
lung	B-MED
epithelium	B-MED
cells	I-MED
Zinc	B-MED
is	O
an	O
essential	O
element	B-MED
for	O
the	O
biological	B-MED
system	I-MED
.	O
However	O
,	O
excessive	O
exogenous	B-MED
Zn(2	B-MED
+	I-MED
)	I-MED
would	O
disrupt	O
cellular	B-MED
Zn(2	I-MED
+	I-MED
)	I-MED
homeostasis	I-MED
and	O
cause	B-MED
toxicity	I-MED
.	O
In	O
particular	O
,	O
Zinc	B-MED
salts	I-MED
or	O
ZnO	B-MED
nanoparticles	B-MED
exposure	O
could	O
induce	O
respiratory	B-MED
injury	I-MED
.	O
Although	O
previous	O
studies	O
have	O
indicated	O
that	O
organelle	B-MED
damage	B-MED
(	O
including	O
mitochondria	B-MED
or	O
lysosomes	B-MED
)	O
and	O
reactive	B-MED
oxygen	I-MED
species	I-MED
(	O
ROS	B-MED
)	O
production	O
are	O
involved	O
in	O
Zn(2	B-MED
+	I-MED
)	I-MED
-induced	O
toxicity	B-MED
,	O
the	O
interplay	O
between	O
mitochondria	B-MED
/	O
lysosomes	B-MED
damage	B-MED
and	O
ROS	B-MED
production	O
is	O
obscure	O
.	O
Herein	O
,	O
we	O
demonstrated	O
that	O
Zn(2	B-MED
+	I-MED
)	I-MED
could	O
induce	O
deglycosylation	B-MED
of	O
lysosome	B-MED
-	I-MED
associated	I-MED
membrane	I-MED
protein	I-MED
1	I-MED
and	O
2	B-MED
(	O
LAMP-1	B-MED
and	O
LAMP-2	B-MED
)	O
,	O
which	O
primarily	O
locate	O
in	O
late	O
endosomes	B-MED
/	O
lysosomes	B-MED
,	O
in	O
A549	B-MED
lung	I-MED
epithelium	I-MED
cells	I-MED
.	O
Intriguingly	O
,	O
LAMP-2	B-MED
knockdown	B-MED
further	O
aggravated	B-MED
Zn(2	B-MED
+	I-MED
)	I-MED
-mediated	O
ROS	B-MED
production	O
and	O
cell	B-MED
death	I-MED
,	O
indicating	O
LAMP-2	B-MED
(	O
not	O
LAMP-1	B-MED
)	O
was	O
involved	O
in	O
Zn(2	B-MED
+	I-MED
)	I-MED
-induced	O
toxicity	B-MED
.	O
Our	O
results	O
provide	O
a	O
new	O
insight	O
that	O
LAMP-2	B-MED
contributes	O
to	O
the	O
ROS	B-MED
clearance	O
and	O
cell	B-MED
death	I-MED
induced	O
by	O
Zn(2	B-MED
+	I-MED
)	I-MED
treatment	B-MED
,	O
which	O
would	O
help	O
us	O
to	O
get	O
a	O
better	O
understanding	O
of	O
Zn(2	B-MED
+	I-MED
)	I-MED
-induced	O
toxicity	B-MED
in	O
respiratory	B-MED
system	I-MED
.	O
Impact	B-MED
of	O
an	O
Educational	B-MED
Intervention	I-MED
to	O
Improve	B-MED
Antibiotic	B-MED
Prescribing	B-MED
for	O
Nurse	B-MED
Practitioners	I-MED
in	O
a	O
Pediatric	B-MED
Urgent	B-MED
Care	I-MED
Center	I-MED
Up	O
to	O
21	O
%	O
of	O
pediatric	B-MED
visits	I-MED
result	O
in	O
an	O
antibiotic	B-MED
prescription	B-MED
,	O
and	O
a	O
large	O
portion	O
of	O
these	O
are	O
unnecessary	O
.	O
To	O
determine	O
if	O
educational	B-MED
sessions	I-MED
would	O
reduce	B-MED
inappropriate	B-MED
antibiotic	B-MED
use	B-MED
.	O
Intervention	B-MED
study	I-MED
evaluating	B-MED
antibiotic	B-MED
prescribing	B-MED
following	O
educational	B-MED
sessions	I-MED
for	O
urinary	B-MED
tract	I-MED
infection	I-MED
,	O
skin	B-MED
and	O
soft	B-MED
tissue	I-MED
infection	I-MED
,	O
pharyngitis	B-MED
,	O
upper	B-MED
respiratory	I-MED
tract	I-MED
infection	I-MED
,	O
acute	B-MED
otitis	I-MED
media	I-MED
,	O
and	O
acute	B-MED
bacterial	I-MED
sinusitis	I-MED
.	O
A	O
total	O
of	O
26	O
out	O
of	O
43	O
(	O
60	O
%	O
)	O
nurse	B-MED
practitioners	I-MED
in	O
4	O
urgent	B-MED
care	I-MED
centers	I-MED
were	O
enrolled	B-MED
in	O
the	O
study	B-MED
.	O
The	O
rate	B-MED
of	O
inappropriate	B-MED
antibiotic	B-MED
use	B-MED
among	O
all	O
conditions	O
was	O
10	O
%	O
before	O
and	O
8	O
%	O
after	O
the	O
intervention	B-MED
(	O
p	O
=	O
.02	O
)	O
.	O
A	O
decrease	B-MED
in	O
inappropriate	B-MED
antibiotic	B-MED
prescribing	B-MED
was	O
seen	O
after	O
the	O
educational	B-MED
session	I-MED
(	O
p	O
<	O
.01	O
)	O
.	O
The	O
most	O
common	O
reasons	O
for	O
inappropriate	B-MED
antibiotic	B-MED
prescribing	B-MED
were	O
too	O
broad	O
(	O
41	O
%	O
)	O
,	O
wrong	B-MED
dosage	I-MED
(	O
22	O
%	O
)	O
,	O
and	O
not	B-MED
indicated	I-MED
(	O
17	O
%	O
)	O
.	O
Educational	B-MED
sessions	I-MED
led	O
to	O
improvement	B-MED
in	O
overall	O
inappropriate	B-MED
antibiotic	B-MED
use	B-MED
.	O
Additional	O
stewardship	B-MED
interventions	B-MED
are	O
needed	O
to	O
further	O
reduce	B-MED
unnecessary	O
antibiotic	B-MED
use	B-MED
.	O
Optical	B-MED
tweezers	I-MED
studies	B-MED
of	O
transcription	B-MED
by	O
eukaryotic	B-MED
RNA	B-MED
polymerases	I-MED
Transcription	B-MED
is	O
the	O
first	B-MED
step	I-MED
in	O
the	O
expression	B-MED
of	O
genetic	B-MED
information	B-MED
and	O
it	O
is	O
carried	B-MED
out	O
by	O
large	O
macromolecular	B-MED
enzymes	B-MED
called	O
RNA	B-MED
polymerases	I-MED
.	O
Transcription	B-MED
has	O
been	O
studied	B-MED
for	O
many	O
years	O
and	O
with	O
a	O
myriad	B-MED
of	O
experimental	B-MED
techniques	B-MED
,	O
ranging	B-MED
from	O
bulk	O
studies	B-MED
to	O
high	B-MED
-	I-MED
resolution	I-MED
transcript	I-MED
sequencing	I-MED
.	O
In	O
this	O
review	B-MED
,	O
we	O
emphasise	O
the	O
advantages	O
of	O
using	O
single	B-MED
-	I-MED
molecule	I-MED
techniques	B-MED
,	O
particularly	O
optical	B-MED
tweezers	I-MED
,	O
to	O
study	B-MED
transcription	B-MED
dynamics	B-MED
.	O
We	O
give	O
an	O
overview	B-MED
of	O
the	O
latest	O
results	B-MED
in	O
the	O
single	B-MED
-	I-MED
molecule	I-MED
transcription	B-MED
field	B-MED
,	O
focusing	O
on	O
transcription	B-MED
by	O
eukaryotic	B-MED
RNA	B-MED
polymerases	I-MED
.	O
Finally	O
,	O
we	O
evaluate	O
recent	O
quantitative	B-MED
models	B-MED
that	O
describe	B-MED
the	O
biophysics	B-MED
of	O
RNA	B-MED
polymerase	I-MED
translocation	B-MED
and	O
backtracking	O
dynamics	B-MED
.	O
Comparison	B-MED
of	O
Esophageal	B-MED
,	O
Rectal	B-MED
,	O
and	O
Gastrointestinal	B-MED
Temperatures	B-MED
During	O
Passive	B-MED
Rest	I-MED
After	O
Exercise	B-MED
in	O
The	O
Heat	B-MED
:	O
The	O
Influence	B-MED
of	O
Hydration	B-MED
It	O
is	O
unknown	O
how	O
valid	O
esophageal	B-MED
,	O
rectal	B-MED
,	O
and	O
gastrointestinal	B-MED
temperatures	B-MED
(	O
TES	B-MED
,	O
TRE	B-MED
,	O
and	O
TGI	B-MED
)	O
compare	O
after	O
exercise	B-MED
-	I-MED
induced	I-MED
hyperthermia	B-MED
in	O
various	O
hydration	B-MED
states	I-MED
.	O
The	O
purpose	O
of	O
this	O
study	B-MED
was	O
to	O
examine	O
the	O
differences	O
between	O
TES	B-MED
,	O
TRE	B-MED
,	O
and	O
TGI	B-MED
during	O
passive	B-MED
rest	I-MED
following	O
exercise	B-MED
-	I-MED
induced	I-MED
hyperthermia	B-MED
under	O
two	O
different	O
hydration	B-MED
states	I-MED
:	O
euhydrated	B-MED
(	O
EU	B-MED
)	O
and	O
hypohydrated	B-MED
(	O
HY	B-MED
)	O
.	O
Randomized	B-MED
-	I-MED
crossover	I-MED
design	I-MED
.	O
Controlled	B-MED
laboratory	B-MED
setting	I-MED
.	O
Nine	O
recreationally	B-MED
active	B-MED
male	B-MED
participants	B-MED
(	O
mean±	O
SD	B-MED
;	O
age	B-MED
,	O
24±4	O
;	O
height	B-MED
,	O
177.3±9.9	O
cm	O
;	O
body	B-MED
mass	I-MED
,	O
76.7±11.6	O
kg	O
;	O
body	B-MED
fat	I-MED
,	O
14.7±5.8	O
%	O
)	O
.	O
Participants	B-MED
completed	O
two	O
trials	B-MED
(	O
EU	B-MED
and	O
HY	B-MED
)	O
consisting	O
of	O
a	O
bout	B-MED
of	O
treadmill	B-MED
exercise	I-MED
(	O
a	O
10	O
minute	O
walk	O
ranging	B-MED
4.8	O
-	O
7.2km·hr(-1	O
)	O
at	O
a	O
5	O
%	O
grade	B-MED
followed	O
by	O
a	O
20	O
minute	B-MED
jog	B-MED
ranging	B-MED
8.0	O
-	O
12.1km·hr(-1	O
)	O
at	O
a	O
1	O
%	O
grade	O
)	O
in	O
a	O
hot	B-MED
environment	I-MED
(	O
ambient	B-MED
temperature	I-MED
,	O
39.3±1.0	O
°	O
C	O
;	O
relative	B-MED
humidity	I-MED
,	O
37.6±6.0	O
%	O
;	O
wet	B-MED
bulb	I-MED
globe	I-MED
temperature	I-MED
,	O
31.3±1.5	O
°	O
C	O
)	O
followed	O
by	O
passive	B-MED
rest	I-MED
.	O
Root	B-MED
mean	I-MED
squared	I-MED
difference	I-MED
(	O
RMSD	B-MED
)	O
was	O
used	O
to	O
compare	O
the	O
variance	B-MED
of	O
temperature	B-MED
readings	I-MED
at	O
corresponding	O
time	B-MED
points	I-MED
for	O
TRE	B-MED
vs	O
TGI	B-MED
,	O
TRE	B-MED
vs	O
TES	B-MED
,	O
and	O
TGI	B-MED
vs	O
TES	B-MED
in	O
EU	B-MED
and	O
HY	B-MED
.	O
RMSD	B-MED
values	O
were	O
compared	O
using	O
three	B-MED
-	I-MED
way	I-MED
repeated	I-MED
measures	I-MED
ANOVA	I-MED
.	O
Post	O
hoc	O
analysis	B-MED
of	O
significant	O
main	O
effects	B-MED
was	O
done	O
using	O
Tukey	B-MED
's	I-MED
HSD	I-MED
with	O
significance	O
set	O
at	O
p<0.05	O
.	O
RMSD	B-MED
values	I-MED
(	O
°	O
C	O
)	O
for	O
all	O
device	B-MED
comparisons	B-MED
were	O
significantly	B-MED
different	O
in	O
EU	B-MED
(	O
TRE	B-MED
-	O
TGI	B-MED
,	O
0.11±0.12	O
;	O
TRE	B-MED
-	O
TES	B-MED
,	O
1.58±1.01	O
;	O
TGI	B-MED
-	O
TES	B-MED
,	O
2.04±1.19	O
)	O
than	O
HY	B-MED
(	O
TRE	B-MED
-	O
TGI	B-MED
,	O
0.22±0.28	O
;	O
TRE	B-MED
-	O
TES	B-MED
,	O
1.27±0.61	O
;	O
TGI	B-MED
-	O
TES	B-MED
,	O
1.16±0.76	O
)	O
(	O
p<0.01	O
)	O
.	O
Across	O
the	O
45-	O
minute	B-MED
bout	B-MED
of	O
passive	B-MED
rest	I-MED
,	O
there	O
were	O
no	O
differences	O
in	O
TRE	B-MED
,	O
TGI	B-MED
and	O
TES	B-MED
between	O
EU	B-MED
and	O
HY	B-MED
trials	B-MED
(	O
p=0.468	O
)	O
.	O
During	O
passive	B-MED
rest	I-MED
after	O
exercise	B-MED
in	O
the	O
heat	B-MED
,	O
TRE	B-MED
and	O
TGI	B-MED
were	O
in	O
good	O
agreement	O
when	O
tracking	O
body	B-MED
temperature	I-MED
,	O
with	O
a	O
better	O
agreement	O
appearing	O
in	O
those	O
maintaining	O
a	O
state	O
of	O
euhydration	B-MED
versus	O
those	O
who	O
became	O
hypohydrated	B-MED
during	O
exercise	B-MED
;	O
however	O
,	O
this	O
small	O
difference	O
does	O
not	O
appear	O
to	O
be	O
of	O
clinical	B-MED
significance	I-MED
.	O
Liquid	B-MED
chromatography	I-MED
-	I-MED
mass	I-MED
spectrometry	I-MED
-based	O
quantitative	B-MED
proteomics	I-MED
analysis	I-MED
proteomics	B-MED
reveals	O
chondroprotective	B-MED
effects	I-MED
of	O
astragaloside	B-MED
IV	I-MED
in	O
interleukin-1β	B-MED
-	O
induced	B-MED
SW1353	B-MED
chondrocyte	I-MED
-	I-MED
like	I-MED
cells	I-MED
Chondrocyte	B-MED
apoptosis	B-MED
played	O
a	O
key	O
role	O
on	O
the	O
progression	B-MED
of	O
Osteoarthritis	B-MED
(	O
OA	B-MED
)	O
.	O
Safe	O
and	O
effective	O
drugs	B-MED
are	O
urgently	O
needed	O
for	O
the	O
treatment	B-MED
of	O
OA	B-MED
.	O
Previous	O
study	B-MED
reported	O
that	O
Astragaloside	B-MED
IV	I-MED
(	O
ASG	B-MED
-	I-MED
IV	I-MED
)	O
had	O
exerted	O
a	O
protective	B-MED
effect	I-MED
against	O
articular	B-MED
cartilage	I-MED
degeneration	I-MED
by	O
promoting	O
rapid	O
proliferation	B-MED
of	O
chondrocyte	B-MED
.	O
Therefore	O
,	O
the	O
aim	O
of	O
our	O
study	B-MED
is	O
to	O
explore	O
the	O
effects	B-MED
and	O
mechanisms	B-MED
of	O
ASG	B-MED
-	I-MED
IV	I-MED
in	O
chondrocyte	B-MED
apoptosis	B-MED
.	O
Isobaric	B-MED
Tags	I-MED
For	I-MED
Relative	I-MED
And	I-MED
Absolute	I-MED
Quantitation	I-MED
(	I-MED
iTRAQ)-based	I-MED
quantitative	I-MED
proteomics	I-MED
proteomics	B-MED
was	O
used	O
to	O
quantitatively	O
detect	B-MED
and	O
map	B-MED
proteins	B-MED
in	O
SW1353	B-MED
chondrocyte	I-MED
-	I-MED
like	I-MED
cells	I-MED
pre	B-MED
-	I-MED
treated	I-MED
with	O
ASG	B-MED
-	I-MED
IV	I-MED
or	O
interleukin-1β	B-MED
(	O
IL-1β	B-MED
)	O
or	O
ASG	B-MED
-	I-MED
IV	I-MED
+	O
IL-1β	B-MED
.	O
The	O
iTRAQ	B-MED
-	I-MED
labeled	I-MED
peptides	I-MED
were	O
fractionated	B-MED
by	O
high	B-MED
-	I-MED
accuracy	I-MED
liquid	I-MED
chromatography	I-MED
-	I-MED
mass	I-MED
spectrometry	I-MED
(	O
LC	B-MED
-	I-MED
MS	I-MED
)	O
.	O
Cell	B-MED
apoptosis	I-MED
and	O
differentially	B-MED
expressed	I-MED
proteins	I-MED
was	O
detected	B-MED
by	O
flow	B-MED
cytometry	I-MED
(	O
FCM	B-MED
)	O
,	O
quantitative	B-MED
real	I-MED
-	I-MED
time	I-MED
polymerase	I-MED
chain	I-MED
reaction	I-MED
(	O
qRT	B-MED
-	I-MED
PCR	I-MED
)	O
,	O
and	O
western	B-MED
blotting	I-MED
,	O
respectively	O
.	O
The	O
apoptosis	B-MED
of	O
the	O
IL-1β	B-MED
-	O
induced	B-MED
SW1353	B-MED
cells	I-MED
treated	B-MED
with	O
ASG	B-MED
-	I-MED
IV	I-MED
was	O
greatly	O
inhibited	B-MED
.	O
Bioinformatics	B-MED
Bioinformatics	B-MED
analysis	I-MED
revealed	O
that	O
gamma	B-MED
actin	I-MED
1	I-MED
(	O
ACTG1	B-MED
)	O
and	O
Yes	B-MED
Associated	I-MED
Protein	I-MED
1	I-MED
(	O
YAP1	B-MED
)	O
,	O
participating	O
in	O
the	O
Hippo	B-MED
signaling	I-MED
pathway	I-MED
and	O
Vitronectin	B-MED
(	O
VTN	B-MED
)	O
and	O
Collagen	B-MED
Type	I-MED
I	I-MED
Alpha	I-MED
1	I-MED
Chain	I-MED
(	O
COL1A1	B-MED
)	O
,	O
involving	O
in	O
the	O
extracellular	B-MED
matrix	I-MED
(	I-MED
ECM)-receptor	I-MED
interaction	I-MED
signaling	I-MED
pathway	I-MED
,	O
were	O
all	O
significantly	O
up	B-MED
-	I-MED
regulated	I-MED
in	O
the	O
IL-1β	B-MED
-	O
induced	B-MED
SW1353	B-MED
cells	I-MED
after	O
treatment	B-MED
with	O
ASG	B-MED
-	I-MED
IV	I-MED
.	O
The	O
qRT	B-MED
-	I-MED
PCR	I-MED
and	O
Western	B-MED
blotting	I-MED
results	O
confirmed	O
the	O
up	B-MED
-	I-MED
regulation	I-MED
of	O
these	O
four	O
genes	B-MED
.	O
ASG	B-MED
-	I-MED
IV	I-MED
played	O
a	O
positive	B-MED
role	I-MED
in	O
human	B-MED
osteoarthritic	B-MED
chondrocyte	I-MED
apoptosis	I-MED
chondrocyte	B-MED
,	O
possibly	O
through	O
modulation	B-MED
of	O
the	O
Hippo	B-MED
signaling	I-MED
pathway	I-MED
by	O
up	B-MED
-	I-MED
regulating	I-MED
YAP1	B-MED
and	O
ACTG1	B-MED
expression	B-MED
,	O
and	O
also	O
by	O
up	B-MED
-	I-MED
regulating	I-MED
VTN	B-MED
and	O
COL1A1	B-MED
,	O
which	O
are	O
involved	O
in	O
the	O
ECM	B-MED
-	I-MED
receptor	I-MED
interaction	I-MED
pathway	I-MED
.	O
Taken	O
together	O
,	O
all	O
the	O
results	O
suggested	O
that	O
ASG	B-MED
-	I-MED
IV	I-MED
had	O
a	O
novel	O
therapeutic	B-MED
potential	B-MED
for	O
the	O
treatment	B-MED
of	O
OA	B-MED
.	O
Intratympanic	B-MED
steroid	I-MED
delivery	I-MED
steroid	B-MED
by	O
an	O
indwelling	B-MED
catheter	I-MED
in	O
refractory	B-MED
severe	I-MED
sudden	I-MED
sensorineural	I-MED
hearing	I-MED
loss	I-MED
Many	O
studies	O
over	O
the	O
last	O
decade	B-MED
showed	O
favorable	O
outcomes	B-MED
with	O
intratympanic	B-MED
(	O
IT	B-MED
)	O
steroid	B-MED
steroid	B-MED
treatment	I-MED
,	O
alone	O
as	O
salvage	B-MED
treatment	I-MED
or	O
in	O
combination	O
with	O
conventional	O
systemic	B-MED
therapy	I-MED
(	O
ST	B-MED
)	O
.	O
However	O
,	O
in	O
severe	O
to	O
profound	O
sensorineural	B-MED
hearing	I-MED
loss	I-MED
resistant	B-MED
to	O
ST	B-MED
,	O
the	O
optimal	O
infusion	B-MED
mode	I-MED
,	O
the	O
type	B-MED
and	O
concentration	B-MED
of	O
the	O
solution	B-MED
,	O
the	O
preferable	O
drug	B-MED
,	O
its	O
total	B-MED
amount	I-MED
,	O
and	O
the	O
duration	B-MED
and	O
fractionation	B-MED
of	O
the	O
treatment	B-MED
are	O
still	O
debated	O
.	O
Aim	O
of	O
the	O
study	O
was	O
to	O
investigate	B-MED
the	O
feasibility	O
and	O
the	O
outcomes	B-MED
of	O
a	O
direct	B-MED
and	I-MED
constant	I-MED
IT	I-MED
delivery	I-MED
of	O
dexamethasone	B-MED
(	O
DEX	B-MED
)	O
by	O
means	O
of	O
a	O
new	O
indwelling	B-MED
catheter	I-MED
.	O
A	O
prospective	B-MED
case	I-MED
-	I-MED
control	I-MED
study	I-MED
in	O
a	O
tertiary	B-MED
referral	I-MED
university	I-MED
hospital	I-MED
.	O
Ninety	O
-	O
nine	O
subjects	B-MED
treated	B-MED
with	O
ST	B-MED
only	O
and	O
28	O
with	O
additional	O
IT	B-MED
DEX	B-MED
have	O
been	O
included	O
in	O
the	O
study	O
.	O
A	O
4	B-MED
Fr	I-MED
catheter	I-MED
inserted	B-MED
in	O
a	O
sub	B-MED
-	I-MED
annular	I-MED
fashion	I-MED
with	O
a	O
minimal	O
postero	B-MED
-	I-MED
inferior	I-MED
tympanotomy	B-MED
through	O
and	O
endocanalar	B-MED
approach	I-MED
under	O
local	B-MED
anesthesia	I-MED
.	O
DEX	B-MED
4mg	O
/	O
ml	O
delivered	O
daily	O
,	O
up	O
to	O
7	O
days	B-MED
.	O
Daily	O
bone	B-MED
and	I-MED
air	I-MED
-	I-MED
conducted	I-MED
pure	I-MED
tone	I-MED
and	O
speech	B-MED
audiometry	I-MED
were	O
performed	O
with	O
a	O
follow	O
-	O
up	O
at	O
1	O
,	O
3	O
,	O
6	O
months	B-MED
after	O
treatment	B-MED
.	O
Twenty	O
-	O
one	O
out	O
of	O
28	O
patients	B-MED
(	O
75	O
%	O
)	O
refractory	B-MED
to	O
ST	B-MED
gained	O
on	O
average	O
24.0dB±20.5dB	O
HL	B-MED
after	O
IT	B-MED
-	O
DEX	B-MED
,	O
compared	O
to	O
35.4	O
%	O
(	O
average	O
6.7dB±16.6dB	O
HL	B-MED
)	O
of	O
those	O
receiving	O
only	O
medical	O
ST	B-MED
(	O
p<0.001	O
)	O
.	O
No	O
significant	O
side	B-MED
effects	I-MED
were	O
noted	O
.	O
In	O
severe	O
to	O
profound	O
sudden	B-MED
deafness	I-MED
refractory	B-MED
to	O
conventional	O
ST	B-MED
,	O
the	O
daily	O
perfusion	B-MED
of	O
4mg	O
/	O
ml	O
DEX	B-MED
through	O
an	O
intratympanic	B-MED
catheter	B-MED
is	O
an	O
easy	O
,	O
well	O
accepted	O
procedure	O
that	O
enables	O
patients	B-MED
to	O
receive	O
a	O
drug	B-MED
in	O
the	O
middle	B-MED
ear	I-MED
in	O
a	O
repeatable	B-MED
or	O
sustained	B-MED
form	I-MED
,	O
with	O
minimal	O
discomfort	B-MED
and	I-MED
a	I-MED
partial	I-MED
rescue	I-MED
(	O
67.86	O
%	O
)	O
and	O
a	O
speech	B-MED
recognition	I-MED
gain	O
of	O
39	O
%	O
.	O
Development	B-MED
and	O
Validation	B-MED
of	O
a	O
New	O
Reliable	O
Method	B-MED
for	O
the	O
Diagnosis	B-MED
of	O
Avian	B-MED
Botulism	B-MED
Liver	B-MED
is	O
a	O
reliable	O
matrix	B-MED
for	O
laboratory	B-MED
confirmation	B-MED
of	I-MED
avian	B-MED
botulism	B-MED
using	O
real	B-MED
-	I-MED
time	I-MED
PCR	I-MED
.	O
Here	O
,	O
we	O
developed	B-MED
,	O
optimized	B-MED
,	O
and	O
validated	B-MED
the	O
analytical	B-MED
steps	B-MED
preceding	B-MED
PCR	B-MED
to	O
maximize	O
the	O
detection	B-MED
of	O
Clostridium	B-MED
botulinum	I-MED
group	I-MED
III	I-MED
in	O
avian	B-MED
liver	B-MED
.	O
These	O
pre	B-MED
-	O
PCR	B-MED
steps	B-MED
included	O
enrichment	B-MED
incubation	B-MED
of	O
the	O
whole	O
liver	B-MED
(	O
maximum	O
25	O
g	O
)	O
at	O
37	B-MED
°	I-MED
C	I-MED
for	O
at	O
least	O
24	O
h	B-MED
in	O
an	O
anaerobic	B-MED
chamber	I-MED
and	O
DNA	B-MED
extraction	I-MED
using	O
an	O
enzymatic	B-MED
digestion	I-MED
step	O
followed	O
by	O
a	O
DNA	B-MED
purification	I-MED
step	O
.	O
Conditions	O
of	O
sample	B-MED
storage	B-MED
before	O
analysis	B-MED
appear	O
to	O
have	O
a	O
strong	O
effect	B-MED
on	O
the	O
detection	B-MED
of	O
group	B-MED
III	I-MED
C.	I-MED
botulinum	I-MED
strains	I-MED
and	O
our	O
results	B-MED
recommend	O
storage	B-MED
at	O
temperatures	B-MED
below	O
-18	O
°	O
C	O
.	O
Short	B-MED
-	I-MED
term	I-MED
storage	B-MED
at	O
5	O
°	O
C	O
is	O
possible	O
for	O
up	O
to	O
24	O
h	B-MED
,	O
but	O
a	O
decrease	B-MED
in	O
sensitivity	B-MED
was	O
observed	O
at	O
48	O
h	B-MED
of	O
storage	B-MED
at	O
this	O
temperature	B-MED
.	O
Analysis	B-MED
of	O
whole	O
livers	B-MED
(	O
maximum	O
25	O
g	O
)	O
is	O
required	O
and	O
pooling	B-MED
samples	B-MED
before	O
enrichment	B-MED
culturing	I-MED
must	O
be	O
avoided	O
.	O
Pooling	B-MED
is	O
however	O
possible	O
before	O
or	O
after	O
DNA	B-MED
extraction	I-MED
under	O
certain	O
conditions	O
.	O
Whole	O
livers	B-MED
should	O
be	O
10	O
-	O
fold	O
diluted	O
in	O
enrichment	B-MED
medium	I-MED
and	O
homogenized	O
using	O
a	O
Pulsifier	B-MED
®	I-MED
blender	I-MED
(	O
Microgen	O
,	O
Surrey	B-MED
,	O
UK	B-MED
)	O
instead	O
of	O
a	O
conventional	O
paddle	B-MED
blender	I-MED
.	O
Spiked	B-MED
liver	I-MED
samples	B-MED
showed	O
a	O
limit	O
of	O
detection	B-MED
of	O
5	O
spores	B-MED
/g	O
liver	B-MED
for	O
types	B-MED
C	I-MED
and	O
D	B-MED
and	O
250	O
spores	B-MED
/g	O
for	O
type	B-MED
E	I-MED
E.	O
Using	O
the	O
method	B-MED
developed	B-MED
here	O
,	O
the	O
analysis	B-MED
of	O
268	O
samples	B-MED
from	O
73	O
suspected	O
outbreaks	B-MED
showed	O
100	O
%	O
specificity	B-MED
and	O
95.35	O
%	O
sensitivity	B-MED
compared	B-MED
with	O
other	O
PCR	B-MED
-based	O
methods	B-MED
considered	O
as	O
reference	O
.	O
The	O
mosaic	B-MED
type	I-MED
C	I-MED
/	O
D	B-MED
was	O
the	O
most	O
common	O
neurotoxin	B-MED
type	O
found	O
in	O
examined	O
samples	B-MED
,	O
which	O
included	O
both	O
wild	B-MED
and	O
domestic	B-MED
birds	I-MED
.	O
Comparison	B-MED
of	O
Leishmania	B-MED
typing	B-MED
results	B-MED
obtained	B-MED
from	O
16	O
European	B-MED
clinical	B-MED
laboratories	I-MED
in	O
2014	O
Leishmaniasis	B-MED
is	O
endemic	B-MED
in	O
southern	B-MED
Europe	I-MED
,	O
and	O
in	O
other	O
European	B-MED
countries	B-MED
cases	B-MED
are	O
diagnosed	B-MED
in	O
travellers	B-MED
who	O
have	O
visited	O
affected	B-MED
areas	I-MED
both	O
within	B-MED
the	O
continent	B-MED
and	O
beyond	O
.	O
Prompt	B-MED
and	O
accurate	B-MED
diagnosis	B-MED
poses	O
a	O
challenge	O
in	O
clinical	B-MED
practice	I-MED
in	O
Europe	B-MED
.	O
Different	B-MED
methods	B-MED
exist	B-MED
for	O
identification	B-MED
of	O
the	O
infecting	B-MED
Leishmania	B-MED
species	B-MED
.	O
Sixteen	O
clinical	B-MED
laboratories	I-MED
in	O
10	O
European	B-MED
countries	B-MED
,	O
plus	O
Israel	B-MED
and	O
Turkey	B-MED
,	O
conducted	O
a	O
study	B-MED
to	O
assess	O
their	O
genotyping	B-MED
performance	B-MED
.	O
DNA	B-MED
from	O
21	O
promastigote	B-MED
cultures	I-MED
of	O
13	O
species	B-MED
was	O
analysed	B-MED
blindly	B-MED
by	O
the	O
routinely	B-MED
used	O
typing	B-MED
method	B-MED
.	O
Five	O
different	B-MED
molecular	B-MED
targets	I-MED
were	O
used	O
,	O
which	O
were	O
analysed	B-MED
with	O
PCR	B-MED
-	I-MED
based	I-MED
methods	B-MED
.	O
Different	B-MED
levels	B-MED
of	O
identification	B-MED
were	O
achieved	B-MED
,	O
and	O
either	O
the	O
Leishmania	B-MED
subgenus	B-MED
,	O
species	B-MED
complex	O
,	O
or	O
actual	O
species	B-MED
were	O
reported	B-MED
.	O
The	O
overall	B-MED
error	B-MED
rate	B-MED
of	O
strains	B-MED
placed	O
in	O
the	O
wrong	B-MED
complex	O
or	O
species	B-MED
was	O
8.5	O
%	O
.	O
Various	O
reasons	B-MED
for	O
incorrect	B-MED
typing	B-MED
were	O
identified	B-MED
.	O
The	O
study	B-MED
shows	O
there	O
is	O
considerable	B-MED
room	O
for	O
improvement	B-MED
and	O
standardisation	B-MED
of	O
Leishmania	B-MED
typing	B-MED
.	O
The	O
use	O
of	O
well	O
validated	B-MED
standard	B-MED
operating	I-MED
procedures	I-MED
is	O
recommended	B-MED
,	O
covering	O
testing	B-MED
,	O
interpretation	B-MED
,	O
and	O
reporting	B-MED
guidelines	B-MED
.	O
Application	O
of	O
the	O
internal	B-MED
transcribed	B-MED
spacer	B-MED
1	I-MED
of	O
the	O
rDNA	B-MED
array	B-MED
should	O
be	O
restricted	B-MED
to	O
Old	B-MED
World	I-MED
samples	B-MED
,	O
while	O
the	O
heat	B-MED
-	I-MED
shock	I-MED
protein	I-MED
70	I-MED
gene	I-MED
and	O
the	O
mini	B-MED
-	I-MED
exon	I-MED
can	O
be	O
applied	B-MED
globally	B-MED
.	O
Anterolateral	B-MED
entorhinal	B-MED
cortex	I-MED
volume	B-MED
predicted	O
by	O
altered	O
intra	B-MED
-	I-MED
item	I-MED
configural	I-MED
processing	I-MED
Recent	O
functional	O
imaging	B-MED
studies	I-MED
have	O
proposed	O
that	O
the	O
human	B-MED
entorhinal	B-MED
cortex	I-MED
is	O
subdivided	O
into	O
functionally	O
distinct	O
anterolateral	B-MED
(	O
alERC	B-MED
)	O
and	O
posteromedial	B-MED
(	O
pmERC	B-MED
)	O
subregions	B-MED
.	O
The	O
alERC	B-MED
overlaps	O
with	O
regions	O
that	O
are	O
affected	O
earliest	O
by	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
pathology	B-MED
,	O
yet	O
its	O
cognitive	B-MED
function	I-MED
remains	O
poorly	O
understood	O
.	O
Previous	O
human	B-MED
fMRI	B-MED
studies	I-MED
have	O
focused	O
on	O
its	O
role	O
in	O
object	B-MED
memory	B-MED
,	O
but	O
rodent	B-MED
studies	B-MED
on	O
the	O
putatively	O
homologous	O
lateral	O
entorhinal	B-MED
cortex	I-MED
suggest	O
that	O
it	O
also	O
plays	O
an	O
important	O
role	O
in	O
representing	O
spatial	B-MED
properties	I-MED
of	O
objects	B-MED
.	O
In	O
order	O
to	O
investigate	O
the	O
cognitive	B-MED
effects	I-MED
of	O
human	B-MED
alERC	B-MED
volume	B-MED
differences	O
,	O
we	O
developed	O
an	O
eyetracking	O
-	O
based	O
task	O
to	O
evaluate	B-MED
intra	B-MED
-	I-MED
item	I-MED
configural	I-MED
processing	I-MED
(	O
i.e.	O
,	O
processing	B-MED
the	O
arrangement	B-MED
of	O
an	O
object	B-MED
's	I-MED
features	O
)	O
,	O
and	O
used	O
manual	B-MED
segmentation	I-MED
based	O
on	O
a	O
recently-	O
developed	B-MED
protocol	I-MED
to	O
delineate	O
the	O
alERC	B-MED
/	O
pmERC	B-MED
as	O
well	O
as	O
other	O
medial	B-MED
temporal	I-MED
lobe	I-MED
(	O
MTL	B-MED
)	O
subregions	B-MED
.	O
In	O
a	O
group	O
of	O
older	O
adult	B-MED
men	B-MED
and	O
women	B-MED
at	O
varying	O
stages	B-MED
of	O
brain	B-MED
atrophy	I-MED
and	O
cognitive	B-MED
decline	I-MED
,	O
we	O
found	O
that	O
intra	B-MED
-	I-MED
item	I-MED
configural	I-MED
processing	I-MED
-	O
regardless	O
of	O
an	O
object	B-MED
's	I-MED
novelty	O
-	O
was	O
strongly	O
predicted	O
by	O
alERC	B-MED
volume	B-MED
,	O
but	O
not	O
by	O
the	O
volume	B-MED
of	O
any	O
other	O
MTL	B-MED
subregion	I-MED
.	O
These	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
the	O
human	B-MED
alERC	B-MED
plays	O
a	O
role	O
in	O
supporting	O
a	O
distinct	O
aspect	O
of	O
object	B-MED
processing	B-MED
,	O
namely	O
attending	O
to	O
the	O
arrangement	B-MED
of	O
an	O
object	B-MED
's	I-MED
component	O
features	O
.	O
SIGNIFICANCE	O
STATEMENT	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
pathology	B-MED
appears	O
earliest	O
in	O
brain	B-MED
regions	I-MED
that	O
overlap	O
with	O
the	O
anterolateral	B-MED
entorhinal	B-MED
cortex	I-MED
(	O
alERC	B-MED
)	O
.	O
However	O
,	O
the	O
cognitive	B-MED
role	I-MED
of	O
the	O
alERC	B-MED
is	O
poorly	O
understood	O
.	O
Previous	O
human	B-MED
studies	I-MED
treat	B-MED
the	O
alERC	B-MED
as	O
an	O
extension	O
of	O
the	O
neighboring	O
perirhinal	B-MED
cortex	I-MED
,	O
supporting	O
object	B-MED
memory	B-MED
.	O
Animal	B-MED
studies	I-MED
suggest	O
that	O
the	O
alERC	B-MED
may	O
support	O
the	O
spatial	B-MED
properties	I-MED
of	O
objects	B-MED
.	O
In	O
a	O
group	O
of	O
older	O
adult	B-MED
humans	B-MED
at	O
the	O
earliest	B-MED
stages	I-MED
of	O
cognitive	B-MED
decline	I-MED
,	O
we	O
show	O
that	O
alERC	B-MED
volume	B-MED
selectively	O
predicted	O
configural	B-MED
processing	I-MED
(	O
attention	B-MED
to	O
the	O
spatial	B-MED
arrangement	I-MED
of	O
an	O
object	B-MED
's	I-MED
parts	O
)	O
.	O
This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
a	O
cognitive	B-MED
role	I-MED
related	O
to	O
alERC	B-MED
volume	B-MED
in	O
humans	B-MED
.	O
This	O
task	O
can	O
be	O
adapted	O
to	O
serve	O
as	O
an	O
early	B-MED
detection	I-MED
method	I-MED
for	O
Alzheimer	B-MED
's	I-MED
disease	I-MED
pathology	B-MED
.	O
Hounsfield	B-MED
unit	I-MED
recovery	B-MED
in	O
clinical	B-MED
cone	B-MED
beam	I-MED
CT	I-MED
images	B-MED
of	O
the	O
thorax	B-MED
acquired	O
for	O
image	B-MED
guided	I-MED
radiation	I-MED
therapy	I-MED
A	O
comprehensive	B-MED
artefact	B-MED
correction	B-MED
method	B-MED
for	O
clinical	B-MED
cone	B-MED
beam	I-MED
CT	I-MED
(	O
CBCT	B-MED
)	O
images	B-MED
acquired	O
for	O
image	B-MED
guided	I-MED
radiation	I-MED
therapy	I-MED
(	O
IGRT	B-MED
)	O
on	O
a	O
commercial	O
system	O
is	O
presented	O
.	O
The	O
method	B-MED
is	O
demonstrated	O
to	O
reduce	B-MED
artefacts	B-MED
and	O
recover	B-MED
CT	B-MED
-like	O
Hounsfield	B-MED
units	I-MED
(	O
HU	B-MED
)	O
in	O
reconstructed	B-MED
CBCT	B-MED
images	B-MED
of	O
five	O
lung	B-MED
cancer	I-MED
patients	B-MED
.	O
Projection	B-MED
image	I-MED
based	O
artefact	B-MED
corrections	B-MED
of	O
image	B-MED
lag	I-MED
,	O
detector	B-MED
scatter	I-MED
,	O
body	B-MED
scatter	I-MED
and	O
beam	B-MED
hardening	I-MED
are	O
described	O
and	O
applied	O
to	O
CBCT	B-MED
images	B-MED
of	O
five	O
lung	B-MED
cancer	I-MED
patients	B-MED
.	O
Image	B-MED
quality	I-MED
is	O
evaluated	B-MED
through	O
visual	B-MED
appearance	B-MED
of	O
the	O
reconstructed	B-MED
images	B-MED
,	O
HU	B-MED
-correspondence	O
with	O
the	O
planning	O
CT	B-MED
images	B-MED
,	O
and	O
total	B-MED
volume	I-MED
HU	B-MED
error	B-MED
.	O
Artefacts	B-MED
are	O
reduced	B-MED
and	O
CT	B-MED
-like	O
HUs	B-MED
are	O
recovered	B-MED
in	O
the	O
artefact	B-MED
corrected	B-MED
CBCT	B-MED
images	B-MED
.	O
Visual	B-MED
inspection	I-MED
confirms	B-MED
that	O
artefacts	B-MED
are	O
indeed	O
suppressed	B-MED
by	O
the	O
proposed	O
method	B-MED
,	O
and	O
the	O
HU	B-MED
root	B-MED
mean	I-MED
square	I-MED
difference	B-MED
between	O
reconstructed	B-MED
CBCTs	B-MED
and	O
the	O
reference	B-MED
CT	B-MED
images	B-MED
are	O
reduced	B-MED
by	O
31	O
%	O
when	O
using	O
the	O
artefact	B-MED
corrections	B-MED
compared	B-MED
to	O
the	O
standard	B-MED
clinical	B-MED
CBCT	B-MED
reconstruction	B-MED
.	O
A	O
versatile	O
artefact	B-MED
correction	B-MED
method	B-MED
for	O
clinical	B-MED
CBCT	B-MED
images	B-MED
acquired	O
for	O
IGRT	B-MED
has	O
been	O
developed	O
.	O
HU	B-MED
values	B-MED
are	O
recovered	B-MED
in	O
the	O
corrected	B-MED
CBCT	B-MED
images	B-MED
.	O
The	O
proposed	O
method	B-MED
relies	O
on	O
post	B-MED
processing	I-MED
of	O
clinical	B-MED
projection	B-MED
images	I-MED
,	O
and	O
does	O
not	O
require	O
patient	B-MED
specific	B-MED
optimisation	B-MED
.	O
It	O
is	O
thus	O
a	O
powerful	O
tool	B-MED
for	O
image	B-MED
quality	B-MED
improvement	B-MED
of	O
large	B-MED
numbers	B-MED
of	O
CBCT	B-MED
images	B-MED
.	O
The	O
effects	B-MED
of	I-MED
clinical	B-MED
supervision	I-MED
on	O
supervisees	B-MED
and	O
patients	B-MED
in	O
cognitive	B-MED
-	I-MED
behavioral	I-MED
therapy	I-MED
:	O
a	O
study	B-MED
protocol	I-MED
for	O
a	O
systematic	B-MED
review	I-MED
Clinical	B-MED
supervision	I-MED
by	O
a	O
senior	B-MED
therapist	I-MED
is	O
a	O
very	O
common	O
practice	B-MED
in	O
psychotherapist	B-MED
training	B-MED
and	O
psychiatric	B-MED
care	I-MED
settings	O
.	O
Though	O
clinical	B-MED
supervision	I-MED
is	O
advocated	O
by	O
most	O
educational	B-MED
and	I-MED
governing	I-MED
institutions	I-MED
,	O
the	O
effects	O
of	O
clinical	B-MED
supervision	I-MED
on	O
the	O
supervisees	B-MED
'	O
competence	B-MED
,	O
e.g.	O
,	O
attitudes	B-MED
,	O
behaviors	B-MED
,	O
and	O
skills	B-MED
,	O
as	O
well	O
as	O
on	O
treatment	B-MED
outcomes	I-MED
and	O
other	O
patient	B-MED
variables	O
are	O
debated	O
and	O
largely	O
unknown	O
.	O
Evidence	B-MED
-	I-MED
based	I-MED
practice	I-MED
is	O
advocated	O
in	O
clinical	B-MED
settings	I-MED
but	O
has	O
not	O
yet	O
been	O
fully	O
implemented	O
in	O
educational	O
or	O
clinical	O
training	O
settings	O
.	O
The	O
aim	O
of	O
this	O
systematic	B-MED
review	I-MED
is	O
to	O
synthesize	O
and	O
present	O
the	O
empirical	B-MED
literature	I-MED
regarding	O
effects	O
of	O
clinical	B-MED
supervision	I-MED
in	O
cognitive	B-MED
-	I-MED
behavioral	I-MED
therapy	I-MED
.	O
This	O
study	O
will	O
include	O
a	O
systematic	B-MED
review	I-MED
of	O
the	O
literature	B-MED
to	O
identify	O
studies	O
that	O
have	O
empirically	O
investigated	O
the	O
effects	O
of	O
supervision	O
on	O
supervised	B-MED
psychotherapists	I-MED
and/or	O
the	O
supervisees	O
'	O
patients	B-MED
.	O
A	O
comprehensive	O
search	O
strategy	O
will	O
be	O
conducted	O
to	O
identify	O
published	O
controlled	O
studies	O
indexed	B-MED
in	O
the	O
MEDLINE	B-MED
,	O
EMBASE	B-MED
,	O
PsycINFO	B-MED
,	O
and	O
Cochrane	B-MED
Library	I-MED
databases	I-MED
.	O
Data	B-MED
on	O
supervision	O
outcomes	O
in	O
both	O
psychotherapists	B-MED
and	O
their	O
patients	B-MED
will	O
be	O
extracted	O
,	O
synthesized	O
,	O
and	O
reported	B-MED
.	O
Risk	O
of	O
bias	O
and	O
quality	O
of	O
the	O
included	O
studies	O
will	O
be	O
assessed	O
systematically	O
.	O
This	O
systematic	B-MED
review	I-MED
will	O
rigorously	O
follow	O
established	O
guidelines	B-MED
for	O
systematic	B-MED
reviews	I-MED
in	O
order	O
to	O
summarize	O
and	O
present	O
the	O
evidence	O
base	O
for	O
clinical	B-MED
supervision	I-MED
in	O
cognitive	B-MED
-	I-MED
behavioral	I-MED
therapy	I-MED
and	O
may	O
aid	O
further	O
research	B-MED
and	O
discussion	O
in	O
this	O
area	O
.	O
PROSPERO	O
CRD42016046834	O
.	O
The	O
genome	B-MED
-scale	O
DNA	B-MED
-	I-MED
binding	I-MED
profile	B-MED
of	O
BarR	B-MED
,	O
a	O
β	B-MED
-	I-MED
alanine	I-MED
responsive	B-MED
transcription	B-MED
factor	I-MED
in	O
the	O
archaeon	B-MED
Sulfolobus	B-MED
acidocaldarius	I-MED
The	O
Leucine	B-MED
-	I-MED
responsive	I-MED
Regulatory	I-MED
Protein	I-MED
(	O
Lrp	B-MED
)	O
family	B-MED
is	O
a	O
widespread	O
family	B-MED
of	O
regulatory	B-MED
transcription	I-MED
factors	I-MED
in	O
prokaryotes	B-MED
.	O
BarR	B-MED
is	O
an	O
Lrp	B-MED
-like	O
transcription	B-MED
factor	I-MED
in	O
the	O
model	O
archaeon	B-MED
Sulfolobus	B-MED
acidocaldarius	I-MED
that	O
activates	B-MED
the	O
expression	B-MED
of	O
a	O
β	B-MED
-	I-MED
alanine	I-MED
aminotransferase	I-MED
gene	I-MED
,	O
which	O
is	O
involved	O
in	O
β	B-MED
-	I-MED
alanine	I-MED
degradation	I-MED
.	O
In	O
contrast	O
to	O
classical	O
Lrp	B-MED
-like	O
transcription	B-MED
factors	I-MED
,	O
BarR	B-MED
is	O
not	B-MED
responsive	I-MED
to	O
any	O
of	O
the	O
α	B-MED
-	I-MED
amino	I-MED
acids	I-MED
but	O
interacts	O
specifically	O
with	O
β	B-MED
-	I-MED
alanine	I-MED
.	O
Besides	O
the	O
juxtaposed	O
β	B-MED
-	I-MED
alanine	I-MED
aminotransferase	I-MED
gene	I-MED
,	O
other	O
regulatory	O
targets	O
of	O
BarR	B-MED
have	O
not	O
yet	O
been	O
identified	O
although	O
β	B-MED
-	I-MED
alanine	I-MED
is	O
the	O
precursor	B-MED
of	O
coenzyme	B-MED
A	I-MED
and	O
thus	O
an	O
important	O
central	O
metabolite	B-MED
.	O
The	O
aim	B-MED
of	O
this	O
study	B-MED
is	O
to	O
extend	O
the	O
knowledge	O
of	O
the	O
DNA	B-MED
-	I-MED
binding	I-MED
characteristics	B-MED
of	O
BarR	B-MED
and	O
of	O
its	O
corresponding	O
regulon	B-MED
from	O
a	O
local	B-MED
to	O
a	O
genome	B-MED
-wide	O
perspective	O
.	O
We	O
characterized	O
the	O
genome	B-MED
-	I-MED
wide	I-MED
binding	I-MED
profile	I-MED
of	O
BarR	B-MED
using	O
chromatin	B-MED
immunoprecipation	I-MED
combined	O
with	O
high	B-MED
-	I-MED
throughput	I-MED
sequencing	I-MED
(	O
ChIP	B-MED
-	I-MED
seq	I-MED
)	O
.	O
This	O
revealed	O
21	O
genomic	B-MED
binding	B-MED
loci	B-MED
.	O
High	O
-	O
enrichment	O
binding	B-MED
regions	I-MED
were	O
validated	O
to	O
interact	O
with	O
purified	O
BarR	B-MED
protein	I-MED
in	B-MED
vitro	I-MED
using	O
electrophoretic	B-MED
mobility	I-MED
shift	I-MED
assays	I-MED
and	O
almost	O
all	O
targets	O
were	O
also	O
shown	O
to	O
harbour	O
a	O
conserved	B-MED
semi	B-MED
-	I-MED
palindromic	I-MED
binding	B-MED
motif	I-MED
.	O
Only	O
a	O
small	O
subset	O
of	O
enriched	O
genomic	B-MED
sites	I-MED
are	O
located	O
in	O
intergenic	B-MED
regions	I-MED
at	O
a	O
relative	O
short	O
distance	O
to	O
a	O
promoter	B-MED
,	O
and	O
qRT	B-MED
-	I-MED
PCR	I-MED
analysis	I-MED
demonstrated	O
that	O
only	O
one	O
additional	O
operon	B-MED
is	O
under	O
activation	B-MED
of	O
BarR	B-MED
,	O
namely	O
the	O
glutamine	B-MED
synthase	I-MED
operon	I-MED
.	O
The	O
latter	O
is	O
also	O
a	O
target	O
of	O
other	O
Lrp	B-MED
-like	O
transcription	B-MED
factors	I-MED
.	O
Detailed	O
inspection	O
of	O
the	O
BarR	B-MED
ChIP	B-MED
-	I-MED
seq	I-MED
profile	I-MED
at	O
the	O
β	B-MED
-	I-MED
alanine	I-MED
aminotransferase	I-MED
promoter	I-MED
region	I-MED
in	O
combination	B-MED
with	O
binding	B-MED
motif	I-MED
predictions	O
indicate	O
that	O
the	O
operator	B-MED
structure	I-MED
is	O
more	O
complicated	B-MED
than	O
previously	O
anticipated	O
,	O
consisting	O
of	O
multiple	B-MED
(	I-MED
major	I-MED
and	I-MED
auxiliary	I-MED
)	I-MED
operators	I-MED
.	O
BarR	B-MED
has	O
a	O
limited	B-MED
regulon	B-MED
,	O
and	O
includes	O
also	O
glutamine	B-MED
synthase	I-MED
genes	I-MED
besides	O
the	O
previously	O
characterized	O
β	B-MED
-	I-MED
alanine	I-MED
aminotransferase	I-MED
.	O
Regulation	B-MED
of	O
glutamine	B-MED
synthase	I-MED
is	O
suggestive	O
of	O
a	O
link	O
between	O
β	B-MED
-	I-MED
alanine	I-MED
and	O
α	B-MED
-	I-MED
amino	I-MED
acid	I-MED
metabolism	I-MED
in	O
S.	B-MED
acidocaldarius	I-MED
.	O
Furthermore	O
,	O
this	O
work	O
reveals	O
that	O
the	O
BarR	B-MED
regulon	B-MED
overlaps	O
with	O
that	O
of	O
other	O
Lrp	B-MED
-like	O
regulators	B-MED
.	O
Air	B-MED
Pollutant	I-MED
Exposure	B-MED
Within	O
a	O
Few	O
Days	O
of	O
Delivery	B-MED
and	O
Placental	B-MED
Abruption	I-MED
in	O
Japan	B-MED
Placental	B-MED
abruption	I-MED
is	O
an	O
emergency	B-MED
obstetric	I-MED
complication	I-MED
.	O
Although	O
the	O
etiology	B-MED
of	O
abruption	B-MED
is	O
not	O
fully	O
understood	O
,	O
acute	B-MED
stimuli	B-MED
,	O
such	O
as	O
ischemia	B-MED
and/or	O
inflammation	B-MED
,	O
are	O
associated	B-MED
with	I-MED
rupture	B-MED
of	I-MED
the	I-MED
decidual	I-MED
artery	I-MED
,	O
resulting	O
in	O
placental	B-MED
separation	I-MED
.	O
Ischemia	B-MED
and	O
inflammation	B-MED
are	O
acute	B-MED
biologic	B-MED
effects	B-MED
of	O
air	B-MED
pollution	I-MED
.	O
Using	O
a	O
case	B-MED
-	I-MED
crossover	I-MED
design	I-MED
,	O
we	O
tested	O
the	O
hypothesis	B-MED
that	O
a	O
short	B-MED
-	I-MED
term	I-MED
increase	B-MED
in	O
exposure	B-MED
to	O
air	B-MED
pollutants	I-MED
is	O
a	O
potential	B-MED
trigger	B-MED
of	O
placental	B-MED
abruption	I-MED
.	O
We	O
received	O
data	B-MED
for	O
western	B-MED
Japan	I-MED
(	O
Kyushu	B-MED
-	I-MED
Okinawa	I-MED
Districts	I-MED
)	O
from	O
the	O
Japan	B-MED
Perinatal	I-MED
Registry	I-MED
Network	I-MED
database	I-MED
.	O
From	O
2005	O
to	O
2010	O
,	O
821	O
singleton	B-MED
pregnant	B-MED
women	I-MED
with	O
placental	B-MED
abruption	I-MED
were	O
identified	O
.	O
We	O
assigned	O
daily	B-MED
concentrations	B-MED
of	O
air	B-MED
pollutants	I-MED
,	O
including	O
nitrogen	B-MED
dioxide	I-MED
(	O
NO2	B-MED
)	O
,	O
suspended	B-MED
particulate	I-MED
matter	I-MED
,	O
ozone	B-MED
,	O
and	O
sulfur	B-MED
dioxide	I-MED
(	O
SO2	B-MED
)	O
,	O
from	O
the	O
nearest	O
monitoring	B-MED
station	I-MED
to	O
the	O
respective	O
delivery	B-MED
hospital	B-MED
of	O
each	O
woman	B-MED
.	O
Because	O
information	B-MED
on	O
the	O
onset	B-MED
day	I-MED
of	O
abruption	B-MED
was	O
not	O
obtained	O
,	O
we	O
assumed	O
the	O
case	B-MED
day	O
to	O
be	O
1	O
day	B-MED
before	O
the	O
day	B-MED
of	O
delivery	B-MED
.	O
Exposure	B-MED
to	O
NO2	B-MED
at	O
2	O
days	O
'	O
lag	O
was	O
associated	B-MED
with	I-MED
placental	B-MED
abruption	I-MED
(	O
temperature	B-MED
adjusted	O
odds	B-MED
ratio	I-MED
per	O
10	O
ppb	O
increase	B-MED
=	O
1.4	O
;	O
95	O
%	O
confidence	B-MED
interval	I-MED
=	O
1.1	O
,	O
1.8	O
)	O
.	O
The	O
association	B-MED
patterns	O
were	O
similar	O
,	O
when	O
we	O
restricted	O
to	O
participants	B-MED
who	O
delivered	B-MED
by	O
emergency	B-MED
cesarean	I-MED
(	O
1.4	O
,	O
1.1	O
,	O
1.9	O
)	O
,	O
or	O
who	O
delivered	B-MED
after	O
35	B-MED
weeks	I-MED
of	I-MED
gestation	I-MED
(	O
1.4	O
,	O
1.0	O
,	O
2.0	O
)	O
.	O
There	O
was	O
no	B-MED
association	I-MED
with	O
suspended	B-MED
particulate	I-MED
matter	I-MED
,	O
ozone	B-MED
,	O
or	O
SO2	B-MED
.	O
We	O
observed	O
an	O
association	B-MED
between	O
NO2	B-MED
exposure	B-MED
at	O
2	O
days	B-MED
before	O
the	O
day	B-MED
of	O
delivery	B-MED
and	O
placental	B-MED
abruption	I-MED
in	O
pregnant	B-MED
Japanese	I-MED
women	I-MED
.	O
Individual	B-MED
Leg	B-MED
Muscle	I-MED
Contributions	B-MED
to	O
the	O
Cost	O
of	O
Walking	B-MED
:	O
Effects	B-MED
of	O
Age	B-MED
and	O
Walking	B-MED
Speed	I-MED
This	O
study	B-MED
examined	B-MED
the	O
contributions	B-MED
of	O
individual	B-MED
muscles	B-MED
to	O
changes	O
in	O
energetic	O
cost	B-MED
of	I-MED
transport	I-MED
(	O
COT	B-MED
)	O
over	O
seven	O
walking	B-MED
speeds	I-MED
,	O
and	O
compared	O
results	O
between	O
healthy	B-MED
young	I-MED
and	O
elderly	B-MED
subjects	I-MED
.	O
Twenty	O
six	O
participants	B-MED
(	O
13	O
young	B-MED
aged	I-MED
18	O
-	O
30	O
;	O
13	O
old	B-MED
aged	I-MED
70	O
-	O
80	O
)	O
were	O
recruited	O
.	O
COT	B-MED
(	O
O2	O
/	O
kg	O
body	O
mass	O
/	O
km	O
)	O
was	O
calculated	O
by	O
standardizing	O
the	O
mean	B-MED
oxygen	I-MED
consumption	I-MED
recorded	O
during	O
steady	B-MED
state	I-MED
walking	I-MED
.	O
Electromyography	B-MED
signals	B-MED
from	O
10	O
leg	B-MED
muscles	I-MED
were	O
used	O
to	O
calculate	O
the	O
cumulative	B-MED
activity	I-MED
required	I-MED
to	I-MED
traverse	I-MED
a	I-MED
unit	I-MED
of	I-MED
distance	I-MED
(	O
CMAPD	B-MED
)	O
for	O
each	O
muscle	B-MED
at	O
each	O
speed	B-MED
.	O
In	O
the	O
old	B-MED
group	I-MED
CMAPD	B-MED
was	O
correlated	B-MED
with	O
COT	B-MED
,	O
presented	O
higher	O
and	O
more	O
variable	O
values	O
,	O
and	O
showed	O
greater	O
increases	O
around	O
optimal	B-MED
speed	I-MED
for	O
all	O
studied	O
muscles	B-MED
.	O
Soleus	B-MED
CMAPD	B-MED
was	O
independent	O
of	O
speed	B-MED
in	O
the	O
young	B-MED
group	I-MED
,	O
but	O
this	O
was	O
not	O
evident	O
with	O
aging	B-MED
.	O
Greater	B-MED
energy	I-MED
cost	I-MED
of	O
walking	B-MED
in	O
older	B-MED
individuals	B-MED
seems	O
to	O
be	O
attributable	O
to	O
increased	O
energy	B-MED
cost	I-MED
of	O
all	O
lower	B-MED
limb	I-MED
muscles	I-MED
.	O
Emergence	B-MED
of	O
family	B-MED
medicine	I-MED
in	O
Ethiopia	B-MED
[	O
corrected	O
]	O
:	O
an	O
international	B-MED
collaborative	B-MED
education	B-MED
model	I-MED
Family	B-MED
Medicine	I-MED
(	O
FM	B-MED
)	O
is	O
a	O
new	O
specialty	B-MED
in	O
Ethiopia	B-MED
.	O
The	O
first	B-MED
seven	I-MED
family	I-MED
physicians	I-MED
graduated	B-MED
in	O
February	B-MED
2016	O
from	O
the	O
inaugural	O
residency	B-MED
programme	B-MED
at	O
Addis	B-MED
Ababa	I-MED
University	I-MED
.	O
Cooperation	B-MED
amongst	O
Ethiopian	B-MED
and	O
expatriate	B-MED
decision	B-MED
-	I-MED
makers	I-MED
and	O
physicians	B-MED
was	O
needed	O
to	O
begin	B-MED
the	O
programme	B-MED
.	O
Intentional	B-MED
replacement	B-MED
of	O
expatriates	B-MED
with	O
Ethiopian	B-MED
family	B-MED
physicians	I-MED
has	O
begun	B-MED
.	O
Barriers	B-MED
include	O
lack	B-MED
of	I-MED
understanding	B-MED
of	O
FM	B-MED
and	O
the	O
human	B-MED
and	O
financial	B-MED
resources	I-MED
needed	O
for	O
scaling	B-MED
up	I-MED
the	O
programme	B-MED
.	O
Regular	B-MED
programme	B-MED
review	B-MED
with	O
resident	B-MED
physician	I-MED
involvement	B-MED
has	O
allowed	O
the	O
FM	B-MED
training	B-MED
programme	I-MED
to	O
adapt	B-MED
and	O
fit	B-MED
the	O
Ethiopian	B-MED
context	B-MED
.	O
Further	O
successes	B-MED
will	O
result	B-MED
from	O
ongoing	O
support	B-MED
and	O
advocacy	B-MED
from	O
the	O
Federal	B-MED
Ministry	I-MED
of	I-MED
Health	I-MED
and	O
other	O
Ethiopian	B-MED
,	O
African	B-MED
,	O
and	O
international	B-MED
international	B-MED
primary	I-MED
care	I-MED
organisations	I-MED
.	O
Classification	B-MED
of	O
Edible	B-MED
Oils	I-MED
Based	O
on	O
ATR	B-MED
-	I-MED
FTIR	I-MED
Spectral	B-MED
Information	I-MED
During	O
a	O
Long	B-MED
Heating	I-MED
Treatment	I-MED
Identification	B-MED
of	O
oil	B-MED
type	B-MED
and	O
its	O
QC	B-MED
are	O
important	O
concerns	O
in	O
food	B-MED
food	B-MED
control	I-MED
laboratories	I-MED
.	O
Classifying	B-MED
edible	B-MED
oils	I-MED
that	O
have	O
not	O
been	O
used	O
(	O
i.e.	O
,	O
unheated	B-MED
)	O
with	O
the	O
aid	O
of	O
vibrational	B-MED
spectroscopy	I-MED
has	O
previously	O
been	O
reported	O
.	O
However	O
,	O
the	O
classification	B-MED
of	O
used	O
(	O
i.e.	O
,	O
heat	B-MED
-	I-MED
treated	I-MED
)	O
oils	B-MED
needs	O
special	O
attention	O
.	O
The	O
effect	B-MED
of	O
long	B-MED
heating	I-MED
times	I-MED
on	O
the	O
classification	B-MED
of	O
four	O
kinds	O
of	O
edible	B-MED
oils	I-MED
(	O
canola	B-MED
,	O
corn	B-MED
,	O
frying	B-MED
,	O
and	O
sunflower	B-MED
)	O
based	O
on	O
attenuated	B-MED
total	I-MED
reflectance	I-MED
(	I-MED
ATR)-FTIR	I-MED
spectra	I-MED
was	O
surveyed	B-MED
.	O
The	O
sampling	B-MED
was	O
done	O
on	O
the	O
oils	B-MED
during	O
a	O
36	O
h	O
heating	B-MED
process	I-MED
(	O
at	O
170	O
°	O
C	O
)	O
.	O
The	O
ATR	B-MED
-	I-MED
FTIR	I-MED
spectra	I-MED
of	O
the	O
samples	B-MED
were	O
collected	B-MED
in	O
the	O
range	O
of	O
4000	O
-	O
550	O
cm-1	O
.	O
Interval	B-MED
extended	I-MED
canonical	I-MED
variates	I-MED
analysis	I-MED
(	O
ECVA	B-MED
)	O
,	O
as	O
a	O
variable	B-MED
selection	I-MED
and	O
classification	B-MED
tool	O
,	O
was	O
used	O
to	O
determine	O
the	O
best	O
intervals	B-MED
during	O
the	O
heating	B-MED
procedure	I-MED
for	O
classification	B-MED
.	O
Principal	B-MED
component	I-MED
analysis	I-MED
discriminate	B-MED
analysis	I-MED
,	O
partial	B-MED
least	I-MED
-	I-MED
squares	I-MED
discriminate	I-MED
analysis	I-MED
,	O
and	O
ECVA	B-MED
were	O
performed	O
on	O
the	O
selected	O
intervals	B-MED
and	O
on	O
the	O
total	B-MED
heating	I-MED
time	I-MED
.	O
The	O
effect	O
of	O
autoscaling	B-MED
and	O
mean	B-MED
-	I-MED
centering	I-MED
,	O
as	O
data	B-MED
preprocessing	I-MED
methods	I-MED
,	O
was	O
also	O
investigated	B-MED
.	O
The	O
ECVA	B-MED
method	I-MED
resulted	O
in	O
the	O
best	O
performances	O
for	O
classification	B-MED
,	O
with	O
a	O
94	O
%	O
cross	B-MED
-	I-MED
validated	I-MED
nonerror	I-MED
rate	I-MED
(	O
one	O
misclassification	O
)	O
for	O
the	O
heating	B-MED
process	I-MED
times	B-MED
of	O
24	O
-	O
27	O
and	O
33	O
-	O
36	O
h.	O
Reflections	B-MED
on	O
Hip	B-MED
Fracture	I-MED
Recovery	I-MED
From	O
Older	B-MED
Adults	I-MED
Enrolled	O
in	O
a	O
Clinical	B-MED
Trial	I-MED
This	O
study	B-MED
describes	O
patients	B-MED
'	I-MED
perspectives	B-MED
on	O
recovery	B-MED
during	O
participation	B-MED
in	O
a	O
randomized	B-MED
controlled	I-MED
trial	I-MED
that	O
tested	B-MED
a	O
postoperative	B-MED
hip	B-MED
fracture	I-MED
management	B-MED
program	I-MED
(	O
B4	B-MED
Clinic	I-MED
)	O
,	O
compared	B-MED
with	O
usual	B-MED
care	I-MED
,	O
on	O
mobility	B-MED
.	O
Semistructured	B-MED
qualitative	B-MED
interviews	B-MED
were	O
conducted	O
with	O
50	O
older	B-MED
adults	I-MED
with	O
hip	B-MED
fracture	I-MED
(	O
from	O
both	O
groups	B-MED
)	O
twice	O
over	O
12	O
months	O
.	O
A	O
total	B-MED
of	O
32	O
women	B-MED
(	O
64	O
%	O
)	O
and	O
18	O
men	B-MED
(	O
36	O
%	O
)	O
participated	B-MED
in	O
the	O
study	B-MED
with	O
a	O
mean	B-MED
age	B-MED
at	O
baseline	B-MED
of	O
82	O
(	O
range	B-MED
=	O
65	O
-	O
98	O
)	O
years	O
.	O
A	O
total	B-MED
of	O
40	O
participants	B-MED
reported	B-MED
recovery	B-MED
goals	B-MED
at	O
some	O
point	O
during	O
their	O
recovery	B-MED
from	O
hip	B-MED
fracture	I-MED
but	O
only	O
18	O
participants	B-MED
realized	B-MED
their	O
goals	B-MED
within	O
12	O
months	O
.	O
Recovering	B-MED
mobility	B-MED
,	O
returning	B-MED
to	O
prefracture	B-MED
activities	I-MED
,	O
and	O
obtaining	B-MED
stable	B-MED
health	B-MED
were	O
the	O
most	B-MED
commonly	B-MED
reported	B-MED
goals	B-MED
.	O
Participants	B-MED
described	O
good	B-MED
social	B-MED
support	I-MED
,	O
access	B-MED
to	O
physiotherapy	B-MED
,	O
and	O
positive	B-MED
perspective	B-MED
as	O
most	B-MED
important	B-MED
to	O
recovery	B-MED
.	O
These	O
factors	B-MED
were	O
influenced	B-MED
by	O
participants	B-MED
'	O
knowledge	B-MED
,	O
resources	B-MED
,	O
and	O
monthly	O
contact	B-MED
with	O
study	B-MED
staff	B-MED
(	O
perceived	B-MED
as	O
a	O
form	O
of	O
social	B-MED
support	I-MED
)	O
.	O
The	O
most	B-MED
frequently	B-MED
reported	B-MED
barriers	B-MED
to	O
participants	B-MED
'	O
recovery	B-MED
were	O
the	O
onset	B-MED
of	I-MED
complications	B-MED
,	O
pain	B-MED
,	O
and	O
limited	B-MED
access	I-MED
to	O
physiotherapy	B-MED
.	O
Potential	B-MED
implications	B-MED
of	O
these	O
findings	B-MED
include	B-MED
design	B-MED
and	O
modification	B-MED
of	O
new	O
or	O
preexisting	B-MED
fracture	B-MED
programs	B-MED
,	O
prioritizing	B-MED
patient	B-MED
engagement	I-MED
and	O
enhanced	B-MED
knowledge	B-MED
for	O
future	B-MED
clinical	B-MED
research	I-MED
in	O
hip	B-MED
fracture	I-MED
recovery	I-MED
.	O
The	O
influence	B-MED
of	O
slope	B-MED
on	O
Spartium	B-MED
junceum	I-MED
root	B-MED
system	I-MED
:	O
morphological	B-MED
,	O
anatomical	B-MED
and	O
biomechanical	B-MED
adaptation	B-MED
Root	B-MED
systems	I-MED
have	O
a	O
pivotal	O
role	B-MED
in	O
plant	B-MED
anchorage	B-MED
and	O
their	O
mechanical	B-MED
interactions	I-MED
with	O
the	O
soil	B-MED
may	O
contribute	O
to	O
soil	B-MED
reinforcement	B-MED
and	O
stabilization	B-MED
of	O
slide	B-MED
-	I-MED
prone	I-MED
slopes	I-MED
.	O
In	O
order	O
to	O
understand	O
the	O
responses	B-MED
of	O
root	B-MED
system	I-MED
to	O
mechanical	B-MED
stress	I-MED
induced	B-MED
by	O
slope	B-MED
,	O
samples	B-MED
of	O
Spartium	B-MED
junceum	I-MED
L.	I-MED
,	O
growing	B-MED
in	O
slope	B-MED
and	O
in	O
plane	B-MED
natural	B-MED
conditions	I-MED
,	O
were	O
compared	O
in	O
their	O
morphology	B-MED
,	O
biomechanical	B-MED
properties	I-MED
and	O
anatomical	B-MED
features	I-MED
.	O
Soils	B-MED
sampled	B-MED
in	O
slope	B-MED
and	O
plane	B-MED
revealed	O
similar	O
characteristics	B-MED
,	O
with	O
the	O
exception	B-MED
of	O
organic	B-MED
matter	I-MED
content	B-MED
and	O
penetrometer	B-MED
resistance	I-MED
,	O
both	O
higher	O
in	O
slope	B-MED
.	O
Slope	B-MED
significantly	O
influenced	B-MED
root	B-MED
morphology	B-MED
and	O
in	O
particular	O
the	O
distribution	B-MED
of	O
lateral	B-MED
roots	B-MED
along	O
the	O
soil	B-MED
depth	B-MED
.	O
Indeed	O
,	O
first	B-MED
-	I-MED
order	I-MED
lateral	B-MED
roots	B-MED
of	O
plants	B-MED
growing	B-MED
on	O
slope	B-MED
condition	B-MED
showed	O
an	O
asymmetric	B-MED
distribution	B-MED
between	O
up-	B-MED
and	O
down	B-MED
-	I-MED
slope	I-MED
.	O
Contrarily	O
,	O
this	O
asymmetric	B-MED
distribution	B-MED
was	O
not	O
observed	O
in	O
plants	B-MED
growing	B-MED
in	O
plane	B-MED
.	O
The	O
tensile	B-MED
strength	I-MED
was	O
higher	O
in	O
lateral	B-MED
roots	B-MED
growing	B-MED
up	B-MED
-	I-MED
slope	I-MED
and	O
in	O
plane	B-MED
conditions	B-MED
than	O
in	O
those	O
growing	B-MED
down	B-MED
-	I-MED
slope	I-MED
.	O
Anatomical	B-MED
investigations	I-MED
revealed	O
that	O
,	O
while	O
roots	B-MED
grown	O
up	B-MED
-	I-MED
slope	I-MED
had	O
higher	O
area	B-MED
covered	O
by	O
xylem	B-MED
fibers	I-MED
,	O
the	O
ratio	B-MED
of	O
xylem	B-MED
and	O
phloem	B-MED
fibers	I-MED
to	O
root	B-MED
diameter	B-MED
did	O
not	O
differ	O
among	O
the	O
three	O
conditions	B-MED
,	O
as	O
also	O
,	O
no	B-MED
differences	I-MED
were	O
found	O
for	O
xylem	B-MED
fiber	I-MED
cell	B-MED
wall	I-MED
thickness	B-MED
.	O
Roots	B-MED
growing	B-MED
up	B-MED
-	I-MED
slope	I-MED
were	O
the	O
main	O
contributors	O
to	O
anchorage	B-MED
properties	B-MED
,	O
which	O
included	O
higher	O
strength	B-MED
and	O
higher	O
number	O
of	O
fibers	B-MED
in	O
the	O
xylematic	B-MED
tissues	B-MED
.	O
Results	O
suggested	O
that	O
a	O
combination	O
of	O
root	B-MED
-	O
specific	B-MED
morphological	B-MED
,	O
anatomical	B-MED
and	O
biomechanical	B-MED
traits	B-MED
,	O
determines	O
anchorage	B-MED
functions	B-MED
in	O
slope	B-MED
conditions	B-MED
.	O
The	O
Longitudinal	B-MED
Effects	B-MED
of	I-MED
Parenting	B-MED
on	O
Adaptive	B-MED
Behavior	I-MED
in	O
Children	B-MED
with	O
Fragile	B-MED
X	I-MED
Syndrome	I-MED
Several	O
studies	B-MED
have	O
reported	O
declines	B-MED
in	O
adaptive	B-MED
behavior	I-MED
amongst	O
children	B-MED
with	O
fragile	B-MED
X	I-MED
syndrome	I-MED
(	O
FXS	B-MED
)	O
starting	O
in	O
middle	B-MED
childhood	B-MED
.	O
We	O
examined	B-MED
the	O
effects	B-MED
of	I-MED
maternal	B-MED
responsivity	B-MED
on	O
adaptive	B-MED
behavior	I-MED
in	O
55	O
children	B-MED
with	O
FXS	B-MED
visited	O
5	O
-	O
6	O
times	O
in	O
their	O
homes	B-MED
from	O
early	O
through	O
middle	B-MED
childhood	B-MED
.	O
Our	O
analyses	B-MED
indicated	O
that	O
sustained	B-MED
maternal	B-MED
responsivity	B-MED
had	O
a	O
significant	B-MED
positive	B-MED
impact	I-MED
on	O
the	O
trajectories	B-MED
of	O
communication	B-MED
and	O
to	O
a	O
lesser	O
extent	O
other	O
adaptive	B-MED
behavior	I-MED
domains	B-MED
through	O
middle	B-MED
childhood	B-MED
with	O
many	O
effects	B-MED
remaining	O
significant	B-MED
after	O
controlling	B-MED
for	O
autism	B-MED
symptoms	I-MED
and	O
developmental	B-MED
level	I-MED
.	O
For	O
children	B-MED
who	O
showed	O
declines	B-MED
in	O
adaptive	B-MED
behavior	I-MED
during	O
middle	B-MED
childhood	B-MED
,	O
sustained	B-MED
high	B-MED
levels	I-MED
of	O
maternal	B-MED
responsivity	B-MED
minimized	B-MED
the	O
amount	O
of	O
decline	B-MED
observed	B-MED
in	O
the	O
communication	B-MED
,	O
socialization	B-MED
,	O
and	O
daily	B-MED
living	I-MED
domains	I-MED
.	O
Prevalence	B-MED
and	O
correlates	B-MED
of	O
antibiotic	B-MED
sharing	B-MED
in	O
the	O
Philippines	B-MED
:	O
antibiotic	B-MED
misconceptions	B-MED
and	O
community	B-MED
-	O
level	B-MED
access	O
to	O
non	B-MED
-	I-MED
medical	I-MED
sources	B-MED
of	O
antibiotics	B-MED
To	O
identify	O
sociodemographic	B-MED
,	O
knowledge	B-MED
and	O
attitudinal	B-MED
correlates	B-MED
to	O
antibiotic	B-MED
sharing	B-MED
among	O
a	O
community	B-MED
-	I-MED
based	I-MED
sample	I-MED
of	O
adults	B-MED
(	O
age	O
18	O
and	O
older	O
)	O
in	O
a	O
low	B-MED
-	I-MED
income	I-MED
setting	I-MED
of	O
the	O
Philippines	B-MED
and	O
to	O
explore	O
community	B-MED
-	O
level	B-MED
data	B-MED
on	O
informal	B-MED
antibiotic	B-MED
distribution	B-MED
in	O
roadside	B-MED
stands	I-MED
(	O
i.e.	O
,	O
sari	B-MED
-	I-MED
sari	I-MED
stands	I-MED
)	O
.	O
Participants	B-MED
(	O
n	O
=	O
307	O
)	O
completed	B-MED
self	B-MED
-	I-MED
administered	I-MED
surveys	B-MED
.	O
Correlates	B-MED
to	O
antibiotic	B-MED
sharing	B-MED
were	O
assessed	B-MED
using	O
logistic	B-MED
regression	I-MED
with	O
Firth	B-MED
's	I-MED
bias	I-MED
-	I-MED
adjusted	I-MED
estimate	I-MED
s.	O
Study	O
staff	B-MED
also	O
visited	O
106	O
roadside	B-MED
stands	I-MED
and	O
collected	B-MED
data	I-MED
on	O
availability	B-MED
and	O
characteristics	O
of	O
antibiotics	B-MED
in	O
the	O
stands	B-MED
.	O
78	O
%	O
had	O
shared	B-MED
antibiotics	B-MED
in	O
their	O
lifetime	B-MED
,	O
most	O
often	B-MED
with	O
family	B-MED
members	I-MED
.	O
In	O
multivariable	B-MED
analysis	I-MED
,	O
agreement	B-MED
with	O
the	O
belief	B-MED
that	O
it	O
is	O
safe	O
to	O
prematurely	B-MED
stop	B-MED
an	O
antibiotic	B-MED
course	B-MED
(	O
OR	B-MED
:	O
2.8	O
,	O
CI	O
:	O
1.3	O
-	O
5.8	O
)	O
and	O
concerns	B-MED
about	O
antibiotic	B-MED
side	I-MED
effects	I-MED
(	O
OR	B-MED
:	O
2.1	O
,	O
CI	O
:	O
1.1	O
-	O
4.4	O
)	O
were	O
significantly	O
associated	B-MED
with	I-MED
increased	B-MED
odds	O
of	O
reported	O
antibiotic	B-MED
sharing	B-MED
.	O
Antibiotic	B-MED
sharing	B-MED
was	O
not	O
associated	B-MED
with	I-MED
sociodemographic	B-MED
characteristics	I-MED
or	O
antibiotic	B-MED
knowledge	B-MED
.	O
Antibiotics	B-MED
were	O
widely	O
available	B-MED
in	O
60	O
%	O
of	O
sampled	O
sari	B-MED
-	I-MED
sari	I-MED
stands	I-MED
,	O
in	O
which	O
59	O
%	O
of	O
antibiotics	B-MED
were	O
missing	B-MED
expiration	I-MED
dates	I-MED
.	O
Amoxicillin	B-MED
and	O
cephalexin	B-MED
were	O
the	O
most	O
commonly	B-MED
available	B-MED
antibiotics	B-MED
for	O
sale	O
at	O
the	O
stands	B-MED
(	O
60	O
%	O
and	O
21	O
%	O
,	O
respectively	O
)	O
.	O
Antibiotic	B-MED
sharing	B-MED
was	O
common	B-MED
and	O
was	O
associated	B-MED
with	I-MED
misconceptions	B-MED
about	O
proper	O
antibiotic	B-MED
use	O
.	O
Antibiotics	B-MED
were	O
widely	O
available	B-MED
in	O
sari	B-MED
-	I-MED
sari	I-MED
stands	I-MED
,	O
and	O
usually	O
without	B-MED
expiration	B-MED
information	I-MED
.	O
This	O
study	O
suggests	O
that	O
multipronged	O
and	O
locally	O
tailored	O
approaches	O
to	O
curbing	B-MED
informal	B-MED
antibiotic	B-MED
access	O
are	O
needed	O
in	O
the	O
Philippines	B-MED
and	O
similar	O
Southeast	B-MED
-	I-MED
Asian	I-MED
countries	I-MED
.	O
Historical	B-MED
Environment	B-MED
Is	O
Reflected	O
in	O
Modern	B-MED
Population	I-MED
Genetics	I-MED
and	O
Biogeography	B-MED
of	O
an	O
Island	B-MED
Endemic	B-MED
Lizard	B-MED
(	O
Xantusia	B-MED
riversiana	I-MED
reticulata	I-MED
)	O
The	O
restricted	B-MED
distribution	I-MED
and	O
isolation	B-MED
of	O
island	B-MED
endemics	B-MED
often	O
produces	O
unique	O
genetic	B-MED
and	O
phenotypic	B-MED
diversity	B-MED
of	O
conservation	B-MED
interest	O
to	O
management	B-MED
agencies	B-MED
.	O
However	O
,	O
these	O
isolated	B-MED
species	B-MED
,	O
especially	O
those	O
with	O
sensitive	B-MED
life	B-MED
history	I-MED
traits	B-MED
,	O
are	O
at	O
high	B-MED
risk	I-MED
for	O
the	O
adverse	B-MED
effects	I-MED
of	O
genetic	B-MED
drift	I-MED
and	O
habitat	B-MED
degradation	B-MED
by	O
non	B-MED
-	I-MED
native	I-MED
wildlife	I-MED
.	O
Here	O
,	O
we	O
study	B-MED
the	O
population	B-MED
genetic	B-MED
diversity	I-MED
,	O
structure	B-MED
,	O
and	O
stability	B-MED
of	O
a	O
classic	O
"	O
island	B-MED
giant	I-MED
"	O
(	O
Xantusia	B-MED
riversiana	I-MED
,	O
the	O
Island	B-MED
Night	I-MED
Lizard	I-MED
)	O
on	O
San	B-MED
Clemente	I-MED
Island	I-MED
,	O
California	B-MED
following	O
the	O
removal	B-MED
of	O
feral	B-MED
goats	I-MED
.	O
Using	O
DNA	B-MED
microsatellites	B-MED
,	O
we	O
found	O
that	O
this	O
population	B-MED
is	O
reasonably	O
genetically	B-MED
robust	B-MED
despite	O
historical	B-MED
grazing	B-MED
,	O
with	O
similar	O
effective	O
population	B-MED
sizes	I-MED
and	O
genetic	B-MED
diversity	I-MED
metrics	O
across	O
all	O
sampling	B-MED
locations	B-MED
irrespective	O
of	O
habitat	B-MED
type	O
and	O
degree	B-MED
of	I-MED
degradation	I-MED
.	O
However	O
,	O
we	O
also	O
found	O
strong	O
site	B-MED
-	I-MED
specific	I-MED
patterns	B-MED
of	O
genetic	B-MED
variation	I-MED
and	O
low	O
genetic	B-MED
diversity	I-MED
compared	O
to	O
mainland	B-MED
congeners	I-MED
,	O
warranting	O
continued	O
special	O
management	B-MED
as	O
an	O
island	B-MED
endemic	B-MED
.	O
We	O
identify	O
both	O
high	B-MED
and	O
low	B-MED
elevation	B-MED
areas	I-MED
that	O
remain	O
valuable	O
repositories	B-MED
of	O
genetic	B-MED
diversity	I-MED
and	O
provide	O
a	O
case	B-MED
study	I-MED
for	O
other	O
low	B-MED
-	I-MED
dispersal	I-MED
coastal	B-MED
organisms	B-MED
in	O
the	O
face	O
of	O
future	B-MED
climate	B-MED
change	I-MED
.	O
Design	B-MED
,	O
synthesis	B-MED
and	O
anti	B-MED
-	I-MED
tumor	I-MED
activity	I-MED
study	B-MED
of	O
novel	O
histone	B-MED
deacetylase	I-MED
inhibitors	I-MED
containing	O
isatin	B-MED
-based	O
caps	B-MED
and	O
o	B-MED
-	I-MED
phenylenediamine	I-MED
-based	O
zinc	B-MED
binding	I-MED
groups	I-MED
As	O
a	O
hot	O
topic	O
of	O
epigenetic	B-MED
studies	I-MED
,	O
histone	B-MED
deacetylases	I-MED
(	O
HDACs	B-MED
)	O
are	O
related	O
to	O
lots	O
of	O
diseases	B-MED
,	O
especially	O
cancer	B-MED
.	O
Further	O
researches	B-MED
indicated	O
that	O
different	B-MED
HDAC	B-MED
isoforms	I-MED
played	O
various	O
roles	B-MED
in	O
a	O
wide	O
range	O
of	O
tumor	B-MED
types	I-MED
.	O
Herein	O
a	O
novel	O
series	B-MED
of	O
HDAC	B-MED
inhibitors	I-MED
with	O
isatin	B-MED
-based	O
caps	B-MED
and	O
o	B-MED
-	I-MED
phenylenediamine	I-MED
-based	O
zinc	B-MED
binding	I-MED
groups	I-MED
have	O
been	O
designed	B-MED
and	O
synthesized	B-MED
through	B-MED
scaffold	B-MED
hopping	I-MED
strategy	I-MED
.	O
Among	O
these	O
compounds	B-MED
,	O
the	O
most	O
potent	O
compound	B-MED
9n	I-MED
exhibited	O
similar	O
if	O
not	O
better	B-MED
HDAC	B-MED
inhibition	B-MED
and	O
antiproliferative	B-MED
activities	I-MED
against	O
multiple	B-MED
tumor	B-MED
cell	I-MED
lines	I-MED
compared	B-MED
with	O
the	O
positive	B-MED
control	I-MED
entinostat	B-MED
(	O
MS-275	B-MED
)	O
.	O
Additionally	O
,	O
compared	B-MED
with	O
MS-275	B-MED
(	O
IC50	B-MED
values	B-MED
for	O
HDAC1	B-MED
,	O
2	B-MED
and	O
3	B-MED
were	O
0.163	O
,	O
0.396	O
and	O
0.605µM	O
,	O
respectively	O
)	O
,	O
compound	B-MED
9n	I-MED
with	O
IC50	B-MED
values	B-MED
of	O
0.032	O
,	O
0.256	O
and	O
0.311µM	O
for	O
HDAC1	B-MED
,	O
2	B-MED
and	O
3	B-MED
respectively	O
,	O
showed	O
a	O
moderate	O
HDAC1	B-MED
selectivity	B-MED
.	O
The	O
underlying	O
inflammatory	B-MED
chronic	I-MED
disease	I-MED
influences	B-MED
infliximab	B-MED
pharmacokinetics	B-MED
Infliximab	B-MED
is	O
an	O
anti	B-MED
-	I-MED
tumor	I-MED
necrosis	I-MED
factor	I-MED
monoclonal	B-MED
antibody	I-MED
approved	O
in	O
chronic	B-MED
inflammatory	I-MED
diseases	I-MED
such	O
as	O
rheumatoid	B-MED
arthritis	I-MED
(	O
RA	B-MED
)	O
,	O
psoriatic	B-MED
arthritis	I-MED
(	O
PsA	B-MED
)	O
,	O
ankylosing	B-MED
spondylitis	I-MED
(	O
AS	B-MED
)	O
,	O
Crohn	B-MED
's	I-MED
disease	I-MED
(	O
CD	B-MED
)	O
and	O
ulcerative	B-MED
colitis	I-MED
(	O
UC	B-MED
)	O
.	O
Infliximab	B-MED
pharmacokinetics	B-MED
is	O
variable	O
between	O
patients	B-MED
,	O
but	O
influence	B-MED
of	O
the	O
underlying	B-MED
disease	I-MED
was	O
never	O
assessed	B-MED
.	O
This	O
study	O
aimed	O
at	O
assessing	O
this	O
influence	B-MED
using	O
a	O
cohort	B-MED
of	O
patients	B-MED
monitored	I-MED
in	O
a	O
single	O
center	O
and	O
with	O
the	O
same	O
assay	B-MED
.	O
Infliximab	B-MED
trough	O
concentrations	B-MED
were	O
determined	B-MED
on	O
samples	B-MED
collected	I-MED
between	O
weeks	O
0	O
and	O
22	O
after	O
treatment	B-MED
initiation	B-MED
in	O
218	O
patients	B-MED
treated	B-MED
for	O
RA	B-MED
,	O
PsA	B-MED
,	O
AS	B-MED
,	O
CD	B-MED
or	O
UC	B-MED
.	O
Infliximab	B-MED
pharmacokinetics	B-MED
was	O
analyzed	B-MED
by	O
a	O
one	O
-	O
compartment	O
population	B-MED
model	O
with	O
first	O
-	O
order	O
elimination	B-MED
rate	B-MED
constant	I-MED
.	O
In	O
AS	B-MED
patients	B-MED
,	O
volume	B-MED
of	I-MED
distribution	I-MED
(	O
V	B-MED
)	O
and	O
elimination	B-MED
clearance	B-MED
(	O
CL	B-MED
)	O
were	O
5.4	O
L	O
and	O
0.24	O
L	O
/	O
day	O
,	O
respectively	O
.	O
In	O
CD	B-MED
and	O
UC	B-MED
patients	B-MED
,	O
V	O
was	O
49	O
%	O
and	O
52	O
%	O
higher	O
than	O
in	O
AS	B-MED
,	O
respectively	O
,	O
and	O
CL	B-MED
was	O
47	O
%	O
and	O
60	O
%	O
higher	O
than	O
in	O
AS	B-MED
,	O
respectively	O
.	O
In	O
RA	B-MED
patients	B-MED
,	O
CL	B-MED
was	O
49	O
%	O
higher	O
than	O
in	O
AS	B-MED
patients	B-MED
.	O
Simulations	B-MED
showed	O
that	O
without	O
methotrexate	B-MED
,	O
a	O
3	O
mg	O
/	O
kg	O
dosing	B-MED
regimen	B-MED
would	O
lead	O
only	O
16	O
%	O
of	O
RA	B-MED
patients	B-MED
to	O
reach	O
the	O
target	B-MED
concentration	B-MED
(	O
2.5	O
mg	O
/	O
L	O
)	O
at	O
week	O
22	O
,	O
whereas	O
target	B-MED
concentrations	B-MED
would	O
be	O
reached	O
in	O
approximately	B-MED
half	O
of	O
RA	B-MED
patients	B-MED
cotreated	B-MED
with	O
methotrexate	B-MED
,	O
as	O
well	O
as	O
half	O
of	O
CD	B-MED
(	O
3.5	O
mg	O
/	O
L	O
)	O
and	O
UC	B-MED
(	O
3.7	O
mg	O
/	O
L	O
)	O
patients	B-MED
.	O
The	O
suboptimality	O
of	O
approved	O
dosing	B-MED
regimens	B-MED
supports	O
the	O
development	B-MED
of	O
dosing	B-MED
optimization	B-MED
based	O
on	O
concentration	B-MED
measurements	I-MED
.	O
Synthesis	B-MED
of	O
1,2	B-MED
-	I-MED
Dioxetanes	I-MED
as	O
Thermochemiluminescent	B-MED
Labels	I-MED
for	O
Ultrasensitive	B-MED
Bioassays	I-MED
:	O
Rational	B-MED
Prediction	I-MED
of	O
Olefin	B-MED
Photooxygenation	B-MED
Outcome	B-MED
by	O
Using	O
a	O
Chemometric	B-MED
Approach	I-MED
Great	O
interest	O
in	O
new	O
thermochemiluminescent	B-MED
(	I-MED
TCL	I-MED
)	I-MED
molecules	I-MED
,	O
for	O
example	O
,	O
in	O
bioanalytical	B-MED
assays	I-MED
,	O
has	O
prompted	O
the	O
design	B-MED
and	O
synthesis	B-MED
of	O
a	O
small	O
library	B-MED
of	O
more	O
than	O
30	O
olefins	B-MED
to	O
be	O
subjected	O
to	O
photooxygenation	B-MED
,	O
with	O
the	O
aim	O
of	O
obtaining	O
new	O
1,2	B-MED
-	I-MED
dioxetane	I-MED
-	I-MED
based	I-MED
TCL	B-MED
labels	I-MED
with	O
optimized	B-MED
properties	I-MED
.	O
Fluorine	B-MED
atoms	O
on	O
the	O
acridan	B-MED
system	O
remarkably	O
stabilize	O
1,2	B-MED
-	I-MED
dioxetanes	I-MED
when	O
they	O
are	O
located	O
in	O
the	O
3-	B-MED
and/or	I-MED
6	I-MED
-	I-MED
position	I-MED
(	O
4	O
h	O
and	O
4	O
i	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
2,7	B-MED
-	I-MED
difluorinated	I-MED
acridan	I-MED
dioxetane	I-MED
(	O
4	O
j	O
)	O
showed	O
a	O
significantly	O
enhanced	O
fluorescence	B-MED
quantum	I-MED
yield	I-MED
with	O
respect	O
to	O
the	O
unsubstituted	B-MED
dioxetane	I-MED
(	O
4	O
a	O
)	O
.	O
Some	O
of	O
the	O
synthesized	B-MED
olefins	B-MED
did	O
not	O
undergo	O
singlet	B-MED
oxygen	I-MED
addition	I-MED
and	O
a	O
rationale	B-MED
was	O
sought	O
to	O
ease	O
the	O
photooxygenation	B-MED
step	O
,	O
leading	O
to	O
the	O
TCL	B-MED
dioxetanes	I-MED
.	O
A	O
chemometric	B-MED
approach	I-MED
has	O
been	O
adopted	O
to	O
exploit	O
principal	B-MED
component	I-MED
analysis	I-MED
and	O
linear	B-MED
discriminant	I-MED
analysis	I-MED
of	O
the	O
structural	B-MED
and	O
electronic	B-MED
molecular	I-MED
descriptors	I-MED
obtained	O
by	O
DFT	B-MED
optimizations	I-MED
of	O
olefins	B-MED
3	O
.	O
This	O
approach	B-MED
allows	O
the	O
steric	B-MED
and	I-MED
electronic	I-MED
parameters	I-MED
that	O
govern	O
dioxetane	B-MED
formation	B-MED
to	O
be	O
revealed	B-MED
.	O
Development	B-MED
of	O
the	O
pediatric	B-MED
quality	I-MED
of	I-MED
life	I-MED
inventory	I-MED
neurofibromatosis	B-MED
type	I-MED
1	I-MED
module	B-MED
items	B-MED
for	O
children	B-MED
,	O
adolescents	B-MED
and	O
young	B-MED
adults	I-MED
:	O
qualitative	B-MED
methods	I-MED
Health	B-MED
-	I-MED
related	I-MED
quality	I-MED
of	I-MED
life	I-MED
(	O
HRQOL	B-MED
)	O
is	O
arguably	O
one	O
of	O
the	O
most	O
important	B-MED
measures	B-MED
in	O
evaluating	B-MED
effectiveness	B-MED
of	O
clinical	B-MED
treatments	I-MED
.	O
At	O
present	O
,	O
there	O
is	O
no	O
disease	B-MED
-	O
specific	B-MED
outcome	B-MED
measure	I-MED
to	O
assess	B-MED
the	O
HRQOL	B-MED
of	O
children	B-MED
,	O
adolescents	B-MED
and	O
young	B-MED
adults	I-MED
with	O
Neurofibromatosis	B-MED
Type	I-MED
1	I-MED
(	O
NF1	B-MED
)	O
.	O
This	O
study	B-MED
aimed	O
to	O
develop	O
the	O
items	B-MED
and	O
support	O
the	O
content	B-MED
validity	I-MED
for	O
the	O
Pediatric	B-MED
Quality	I-MED
of	I-MED
Life	I-MED
Inventory	I-MED
™	I-MED
(	O
PedsQL	B-MED
™	I-MED
)	O
NF1	B-MED
Module	B-MED
for	O
children	B-MED
,	O
adolescents	B-MED
and	O
young	B-MED
adults	I-MED
.	O
The	O
iterative	B-MED
process	B-MED
included	O
multiphase	B-MED
qualitative	I-MED
methods	I-MED
including	O
a	O
literature	B-MED
review	I-MED
,	O
survey	B-MED
of	O
expert	B-MED
opinions	I-MED
,	O
semi	B-MED
-	I-MED
structured	I-MED
interviews	I-MED
,	O
cognitive	B-MED
interviews	B-MED
and	O
pilot	B-MED
testing	I-MED
.	O
Fifteen	O
domains	B-MED
were	O
derived	O
from	O
the	O
qualitative	B-MED
methods	I-MED
,	O
with	O
content	B-MED
saturation	O
achieved	O
,	O
resulting	O
in	O
115	O
items	B-MED
.	O
The	O
domains	B-MED
include	O
skin	B-MED
,	O
pain	B-MED
,	O
pain	B-MED
impact	B-MED
,	O
pain	B-MED
management	I-MED
,	O
cognitive	B-MED
functioning	I-MED
,	O
speech	B-MED
,	O
fine	B-MED
motor	I-MED
,	O
balance	B-MED
,	O
vision	B-MED
,	O
perceived	B-MED
physical	B-MED
appearance	I-MED
,	O
communication	B-MED
,	O
worry	B-MED
,	O
treatment	B-MED
,	O
medicines	B-MED
and	O
gastrointestinal	B-MED
symptoms	I-MED
.	O
This	O
study	O
is	O
limited	B-MED
because	O
all	O
participants	B-MED
are	O
recruited	O
from	O
a	O
single	B-MED
-	O
site	B-MED
.	O
Qualitative	B-MED
methods	I-MED
support	O
the	O
content	B-MED
validity	I-MED
for	O
the	O
PedsQL	B-MED
™	I-MED
NF1	B-MED
Module	B-MED
for	O
children	B-MED
,	O
adolescents	B-MED
and	O
young	B-MED
adults	I-MED
.	O
The	O
PedsQL	B-MED
™	I-MED
NF1	B-MED
Module	B-MED
is	O
now	O
undergoing	O
national	B-MED
multisite	I-MED
field	I-MED
testing	I-MED
for	O
the	O
psychometric	B-MED
validation	B-MED
of	O
the	O
instrument	B-MED
development	B-MED
.	O
